6	TEFLARO.xml:S1:4:1	6	CD	O	O
.	TEFLARO.xml:S1:5:1	.	.	O	O

ADVERSE	TEFLARO.xml:S1:7:7	advers	JJ	O	O
REACTIONS	TEFLARO.xml:S1:15:9	reaction	NNP	O	O

The	TEFLARO.xml:S1:28:3	the	DT	O	O
following	TEFLARO.xml:S1:32:9	follow	VBG	O	O
serious	TEFLARO.xml:S1:42:7	seriou	JJ	O	O
adverse	TEFLARO.xml:S1:50:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:58:9	reaction	NNS	O	O
are	TEFLARO.xml:S1:68:3	are	VBP	O	O
described	TEFLARO.xml:S1:72:9	describ	VBN	O	O
in	TEFLARO.xml:S1:82:2	in	IN	O	O
greater	TEFLARO.xml:S1:85:7	greater	JJR	O	O
detail	TEFLARO.xml:S1:93:6	detail	NN	O	O
in	TEFLARO.xml:S1:100:2	in	IN	O	O
the	TEFLARO.xml:S1:103:3	the	DT	O	O
Warnings	TEFLARO.xml:S1:107:8	warn	NNP	O	O
and	TEFLARO.xml:S1:116:3	and	CC	O	O
Precautions	TEFLARO.xml:S1:120:11	precaut	NNP	O	O
section	TEFLARO.xml:S1:132:7	section	NN	O	O

Hypersensitivity	TEFLARO.xml:S1:147:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TEFLARO.xml:S1:164:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	TEFLARO.xml:S1:174:1	[	NNP	O	O
see	TEFLARO.xml:S1:175:3	see	VBP	O	O
Warnings	TEFLARO.xml:S1:179:8	warn	NNP	O	O
and	TEFLARO.xml:S1:188:3	and	CC	O	O
Precautions	TEFLARO.xml:S1:192:11	precaut	NNP	O	O
(	TEFLARO.xml:S1:204:1	(	(	O	O
5.1	TEFLARO.xml:S1:207:3	5.1	CD	O	O
)]	TEFLARO.xml:S1:212:2	)]	NN	O	O

Clostridium	TEFLARO.xml:S1:222:11	clostridium	NN	B-AdverseReaction	B-AdverseReaction
difficile	TEFLARO.xml:S1:234:9	difficil	NN	I-AdverseReaction	I-AdverseReaction
-	TEFLARO.xml:S1:244:1	-	:	I-AdverseReaction	I-AdverseReaction
Associated	TEFLARO.xml:S1:245:10	associ	VBN	I-AdverseReaction	I-AdverseReaction
diarrhea	TEFLARO.xml:S1:256:8	diarrhea	JJ	I-AdverseReaction	I-AdverseReaction
[	TEFLARO.xml:S1:265:1	[	NNP	O	O
see	TEFLARO.xml:S1:266:3	see	VBP	O	O
Warnings	TEFLARO.xml:S1:270:8	warn	NNP	O	O
and	TEFLARO.xml:S1:279:3	and	CC	O	O
Precautions	TEFLARO.xml:S1:283:11	precaut	NNP	O	O
(	TEFLARO.xml:S1:295:1	(	(	O	O
5.2	TEFLARO.xml:S1:298:3	5.2	CD	O	O
)]	TEFLARO.xml:S1:303:2	)]	NN	O	O

Direct	TEFLARO.xml:S1:312:6	direct	JJ	B-AdverseReaction	O
Coombs	TEFLARO.xml:S1:319:6	coomb	NNP	I-AdverseReaction	O
Test	TEFLARO.xml:S1:327:4	test	NNP	I-AdverseReaction	O
Seroconversion	TEFLARO.xml:S1:332:14	seroconvers	NNP	I-AdverseReaction	O
[	TEFLARO.xml:S1:347:1	[	NNP	O	O
see	TEFLARO.xml:S1:348:3	see	VBP	O	O
Warnings	TEFLARO.xml:S1:352:8	warn	NNP	O	O
and	TEFLARO.xml:S1:361:3	and	CC	O	O
Precautions	TEFLARO.xml:S1:365:11	precaut	NNP	O	O
(	TEFLARO.xml:S1:377:1	(	(	O	O
5.3	TEFLARO.xml:S1:380:3	5.3	CD	O	O
)]	TEFLARO.xml:S1:385:2	)]	NN	O	O

EXCERPT	TEFLARO.xml:S1:396:7	excerpt	NN	O	O
:	TEFLARO.xml:S1:403:1	:	:	O	O
The	TEFLARO.xml:S1:407:3	the	DT	O	O
most	TEFLARO.xml:S1:411:4	most	RBS	O	O
common	TEFLARO.xml:S1:416:6	common	JJ	O	O
adverse	TEFLARO.xml:S1:423:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:431:9	reaction	NNS	O	O
occurring	TEFLARO.xml:S1:441:9	occur	VBG	O	O
in	TEFLARO.xml:S1:451:2	in	IN	O	O
2	TEFLARO.xml:S1:455:1	2	CD	O	O
of	TEFLARO.xml:S1:459:2	of	IN	O	O
patients	TEFLARO.xml:S1:462:8	patient	NNS	O	O
are	TEFLARO.xml:S1:471:3	are	VBP	O	O
diarrhea	TEFLARO.xml:S1:475:8	diarrhea	JJ	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:483:1	,	,	O	O
nausea	TEFLARO.xml:S1:485:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:491:1	,	,	O	O
and	TEFLARO.xml:S1:493:3	and	CC	O	O
rash	TEFLARO.xml:S1:497:4	rash	NN	B-AdverseReaction	B-AdverseReaction
.	TEFLARO.xml:S1:501:1	.	.	O	O

(	TEFLARO.xml:S1:503:1	(	(	O	O
6.1	TEFLARO.xml:S1:506:3	6.1	CD	O	O
)	TEFLARO.xml:S1:511:1	)	)	O	O

To	TEFLARO.xml:S1:519:2	To	TO	O	O

report	TEFLARO.xml:S1:522:6	report	NN	O	O
SUSPECTED	TEFLARO.xml:S1:529:9	suspect	NNP	O	O
ADVERSE	TEFLARO.xml:S1:539:7	advers	NNP	O	O
REACTIONS	TEFLARO.xml:S1:547:9	reaction	NNP	O	O
,	TEFLARO.xml:S1:556:1	,	,	O	O
contact	TEFLARO.xml:S1:558:7	contact	NN	O	O
Forest	TEFLARO.xml:S1:566:6	forest	NNP	O	O
Laboratories	TEFLARO.xml:S1:573:12	laboratori	NNPS	O	O
,	TEFLARO.xml:S1:585:1	,	,	O	O
LLC	TEFLARO.xml:S1:587:3	llc	NNP	O	O
,	TEFLARO.xml:S1:590:1	,	,	O	O
at	TEFLARO.xml:S1:592:2	at	IN	O	O
1	TEFLARO.xml:S1:595:1	1	CD	O	O
-	TEFLARO.xml:S1:596:1	-	:	O	O
800	TEFLARO.xml:S1:597:3	800	CD	O	O
-	TEFLARO.xml:S1:600:1	-	:	O	O
678	TEFLARO.xml:S1:601:3	678	CD	O	O
-	TEFLARO.xml:S1:604:1	-	:	O	O
1605	TEFLARO.xml:S1:605:4	1605	CD	O	O
or	TEFLARO.xml:S1:610:2	or	CC	O	O
FDA	TEFLARO.xml:S1:613:3	fda	NNP	O	O
at	TEFLARO.xml:S1:617:2	at	IN	O	O
1	TEFLARO.xml:S1:620:1	1	CD	O	O
-	TEFLARO.xml:S1:621:1	-	:	O	O
800	TEFLARO.xml:S1:622:3	800	CD	O	O
-	TEFLARO.xml:S1:625:1	-	:	O	O
FDA	TEFLARO.xml:S1:626:3	fda	NNP	O	O
-	TEFLARO.xml:S1:629:1	-	:	O	O
1088	TEFLARO.xml:S1:630:4	1088	CD	O	O
or	TEFLARO.xml:S1:635:2	or	CC	O	O
www	TEFLARO.xml:S1:641:3	www	VB	O	O
.	TEFLARO.xml:S1:644:1	.	.	O	O
fda	TEFLARO.xml:S1:645:3	fda	NN	O	O
.	TEFLARO.xml:S1:648:1	.	.	O	O
gov	TEFLARO.xml:S1:649:3	gov	JJ	O	O
medwatch	TEFLARO.xml:S1:653:8	medwatch	NN	O	O
.	TEFLARO.xml:S1:665:1	.	.	O	O

6.1	TEFLARO.xml:S1:677:3	6.1	CD	O	O

Clinical	TEFLARO.xml:S1:681:8	clinic	JJ	O	O
Trials	TEFLARO.xml:S1:690:6	trial	NNS	O	O
Experience	TEFLARO.xml:S1:697:10	experi	NN	O	O

Because	TEFLARO.xml:S1:711:7	becaus	IN	O	O
clinical	TEFLARO.xml:S1:719:8	clinic	JJ	O	O
trials	TEFLARO.xml:S1:728:6	trial	NNS	O	O
are	TEFLARO.xml:S1:735:3	are	VBP	O	O
conducted	TEFLARO.xml:S1:739:9	conduct	VBN	O	O
under	TEFLARO.xml:S1:749:5	under	IN	O	O
widely	TEFLARO.xml:S1:755:6	wide	RB	O	O
varying	TEFLARO.xml:S1:762:7	vari	VBG	O	O
conditions	TEFLARO.xml:S1:770:10	condit	NNS	O	O
,	TEFLARO.xml:S1:780:1	,	,	O	O
adverse	TEFLARO.xml:S1:782:7	advers	JJ	O	O
reaction	TEFLARO.xml:S1:790:8	reaction	NN	O	O
rates	TEFLARO.xml:S1:799:5	rate	NNS	O	O
observed	TEFLARO.xml:S1:805:8	observ	VBD	O	O
in	TEFLARO.xml:S1:814:2	in	IN	O	O
clinical	TEFLARO.xml:S1:817:8	clinic	JJ	O	O
trials	TEFLARO.xml:S1:826:6	trial	NNS	O	O
of	TEFLARO.xml:S1:833:2	of	IN	O	O
a	TEFLARO.xml:S1:836:1	a	DT	O	O
drug	TEFLARO.xml:S1:838:4	drug	NN	O	O
cannot	TEFLARO.xml:S1:843:6	cannot	NN	O	O
be	TEFLARO.xml:S1:850:2	be	VB	O	O
compared	TEFLARO.xml:S1:853:8	compar	VBN	O	O
directly	TEFLARO.xml:S1:862:8	directli	RB	O	O
to	TEFLARO.xml:S1:871:2	to	TO	O	O
rates	TEFLARO.xml:S1:874:5	rate	NNS	O	O
from	TEFLARO.xml:S1:880:4	from	IN	O	O
clinical	TEFLARO.xml:S1:885:8	clinic	JJ	O	O
trials	TEFLARO.xml:S1:894:6	trial	NNS	O	O
of	TEFLARO.xml:S1:901:2	of	IN	O	O
another	TEFLARO.xml:S1:904:7	anoth	DT	O	O
drug	TEFLARO.xml:S1:912:4	drug	NN	O	O
and	TEFLARO.xml:S1:917:3	and	CC	O	O
may	TEFLARO.xml:S1:921:3	may	MD	O	O
not	TEFLARO.xml:S1:925:3	not	RB	O	O
reflect	TEFLARO.xml:S1:929:7	reflect	VB	O	O
rates	TEFLARO.xml:S1:937:5	rate	NNS	O	O
observed	TEFLARO.xml:S1:943:8	observ	VBN	O	O
in	TEFLARO.xml:S1:952:2	in	IN	O	O
practice	TEFLARO.xml:S1:955:8	practic	NN	O	O
.	TEFLARO.xml:S1:963:1	.	.	O	O

Teflaro	TEFLARO.xml:S1:969:7	teflaro	NN	O	O
was	TEFLARO.xml:S1:977:3	wa	VBD	O	O
evaluated	TEFLARO.xml:S1:981:9	evalu	VBN	O	O
in	TEFLARO.xml:S1:991:2	in	IN	O	O
four	TEFLARO.xml:S1:994:4	four	CD	O	O
controlled	TEFLARO.xml:S1:999:10	control	VBD	O	O
comparative	TEFLARO.xml:S1:1010:11	compar	JJ	O	O
Phase	TEFLARO.xml:S1:1022:5	phase	NNP	O	O
3	TEFLARO.xml:S1:1028:1	3	CD	O	O
clinical	TEFLARO.xml:S1:1030:8	clinic	JJ	O	O
trials	TEFLARO.xml:S1:1039:6	trial	NNS	O	O
(	TEFLARO.xml:S1:1046:1	(	(	O	O
two	TEFLARO.xml:S1:1047:3	two	CD	O	O
in	TEFLARO.xml:S1:1051:2	in	IN	O	O
ABSSSI	TEFLARO.xml:S1:1054:6	absssi	NNP	O	O
and	TEFLARO.xml:S1:1061:3	and	CC	O	O
two	TEFLARO.xml:S1:1065:3	two	CD	O	O
in	TEFLARO.xml:S1:1069:2	in	IN	O	O
CABP	TEFLARO.xml:S1:1072:4	cabp	NNP	O	O
)	TEFLARO.xml:S1:1076:1	)	)	O	O
which	TEFLARO.xml:S1:1078:5	which	WDT	O	O
included	TEFLARO.xml:S1:1084:8	includ	VBD	O	O
1300	TEFLARO.xml:S1:1093:4	1300	CD	O	O
adult	TEFLARO.xml:S1:1098:5	adult	NN	O	O
patients	TEFLARO.xml:S1:1104:8	patient	NNS	O	O
treated	TEFLARO.xml:S1:1113:7	treat	VBN	O	O
with	TEFLARO.xml:S1:1121:4	with	IN	O	O
Teflaro	TEFLARO.xml:S1:1126:7	teflaro	NNP	O	O
(	TEFLARO.xml:S1:1134:1	(	(	O	O
600	TEFLARO.xml:S1:1135:3	600	CD	O	O
mg	TEFLARO.xml:S1:1139:2	mg	NN	O	O
administered	TEFLARO.xml:S1:1142:12	administ	VBN	O	O
by	TEFLARO.xml:S1:1155:2	by	IN	O	O
IV	TEFLARO.xml:S1:1158:2	IV	NNP	O	O
over	TEFLARO.xml:S1:1161:4	over	IN	O	O
1	TEFLARO.xml:S1:1166:1	1	CD	O	O
hour	TEFLARO.xml:S1:1168:4	hour	NN	O	O
every	TEFLARO.xml:S1:1173:5	everi	DT	O	O
12	TEFLARO.xml:S1:1179:2	12	CD	O	O
h	TEFLARO.xml:S1:1181:1	h	NN	O	O
)	TEFLARO.xml:S1:1182:1	)	)	O	O
and	TEFLARO.xml:S1:1184:3	and	CC	O	O
1297	TEFLARO.xml:S1:1188:4	1297	CD	O	O
patients	TEFLARO.xml:S1:1193:8	patient	NNS	O	O
treated	TEFLARO.xml:S1:1202:7	treat	VBN	O	O
with	TEFLARO.xml:S1:1210:4	with	IN	O	O
comparator	TEFLARO.xml:S1:1215:10	compar	NN	O	O
(	TEFLARO.xml:S1:1226:1	(	(	O	O
vancomycin	TEFLARO.xml:S1:1227:10	vancomycin	JJ	O	O
plus	TEFLARO.xml:S1:1238:4	plu	CC	O	O
aztreonam	TEFLARO.xml:S1:1243:9	aztreonam	JJ	O	O
or	TEFLARO.xml:S1:1253:2	or	CC	O	O
ceftriaxone	TEFLARO.xml:S1:1256:11	ceftriaxon	NN	O	O
)	TEFLARO.xml:S1:1267:1	)	)	O	O
for	TEFLARO.xml:S1:1269:3	for	IN	O	O
a	TEFLARO.xml:S1:1273:1	a	DT	O	O
treatment	TEFLARO.xml:S1:1275:9	treatment	NN	O	O
period	TEFLARO.xml:S1:1285:6	period	NN	O	O
up	TEFLARO.xml:S1:1292:2	up	IN	O	O
to	TEFLARO.xml:S1:1295:2	to	TO	O	O
21	TEFLARO.xml:S1:1298:2	21	CD	O	O
days	TEFLARO.xml:S1:1301:4	day	NNS	O	O
.	TEFLARO.xml:S1:1305:1	.	.	O	O

The	TEFLARO.xml:S1:1307:3	the	DT	O	O
median	TEFLARO.xml:S1:1311:6	median	JJ	O	O
age	TEFLARO.xml:S1:1318:3	age	NN	O	O
of	TEFLARO.xml:S1:1322:2	of	IN	O	O
patients	TEFLARO.xml:S1:1325:8	patient	NNS	O	O
treated	TEFLARO.xml:S1:1334:7	treat	VBN	O	O
with	TEFLARO.xml:S1:1342:4	with	IN	O	O
Teflaro	TEFLARO.xml:S1:1347:7	teflaro	NNP	O	O
was	TEFLARO.xml:S1:1355:3	wa	VBD	O	O
54	TEFLARO.xml:S1:1359:2	54	CD	O	O
years	TEFLARO.xml:S1:1362:5	year	NNS	O	O
,	TEFLARO.xml:S1:1367:1	,	,	O	O
ranging	TEFLARO.xml:S1:1369:7	rang	VBG	O	O
between	TEFLARO.xml:S1:1377:7	between	IN	O	O
18	TEFLARO.xml:S1:1385:2	18	CD	O	O
and	TEFLARO.xml:S1:1388:3	and	CC	O	O
99	TEFLARO.xml:S1:1392:2	99	CD	O	O
years	TEFLARO.xml:S1:1395:5	year	NNS	O	O
old	TEFLARO.xml:S1:1401:3	old	JJ	O	O
.	TEFLARO.xml:S1:1404:1	.	.	O	O

Patients	TEFLARO.xml:S1:1406:8	patient	NNS	O	O
treated	TEFLARO.xml:S1:1415:7	treat	VBN	O	O
with	TEFLARO.xml:S1:1423:4	with	IN	O	O
Teflaro	TEFLARO.xml:S1:1428:7	teflaro	NNP	O	O
were	TEFLARO.xml:S1:1436:4	were	VBD	O	O
predominantly	TEFLARO.xml:S1:1441:13	predominantli	RB	O	O
male	TEFLARO.xml:S1:1455:4	male	JJ	O	O
(	TEFLARO.xml:S1:1460:1	(	(	O	O
63%	TEFLARO.xml:S1:1461:3	63%	CD	O	O
)	TEFLARO.xml:S1:1464:1	)	)	O	O
and	TEFLARO.xml:S1:1466:3	and	CC	O	O
Caucasian	TEFLARO.xml:S1:1470:9	caucasian	NNP	O	O
(	TEFLARO.xml:S1:1480:1	(	(	O	O
82%	TEFLARO.xml:S1:1481:3	82%	CD	O	O
)	TEFLARO.xml:S1:1484:1	)	)	O	O
.	TEFLARO.xml:S1:1485:1	.	.	O	O

Serious	TEFLARO.xml:S1:1495:7	seriou	JJ	O	O
Adverse	TEFLARO.xml:S1:1503:7	advers	NNP	O	O
Reactions	TEFLARO.xml:S1:1511:9	reaction	NNP	O	O
and	TEFLARO.xml:S1:1521:3	and	CC	O	O
Adverse	TEFLARO.xml:S1:1525:7	advers	NNP	O	O
Reactions	TEFLARO.xml:S1:1533:9	reaction	NNP	O	O
Leading	TEFLARO.xml:S1:1543:7	lead	NNP	O	O
to	TEFLARO.xml:S1:1551:2	to	TO	O	O
Discontinuation	TEFLARO.xml:S1:1554:15	discontinu	NNP	O	O

In	TEFLARO.xml:S1:1576:2	In	IN	O	O
the	TEFLARO.xml:S1:1579:3	the	DT	O	O
four	TEFLARO.xml:S1:1583:4	four	CD	O	O
pooled	TEFLARO.xml:S1:1588:6	pool	VBD	O	O
Phase	TEFLARO.xml:S1:1595:5	phase	NNP	O	O
3	TEFLARO.xml:S1:1601:1	3	CD	O	O
clinical	TEFLARO.xml:S1:1603:8	clinic	JJ	O	O
trials	TEFLARO.xml:S1:1612:6	trial	NNS	O	O
,	TEFLARO.xml:S1:1618:1	,	,	O	O
serious	TEFLARO.xml:S1:1620:7	seriou	JJ	O	O
adverse	TEFLARO.xml:S1:1628:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:1636:9	reaction	NNS	O	O
(	TEFLARO.xml:S1:1646:1	(	(	O	O
SARs	TEFLARO.xml:S1:1647:4	sar	NNP	O	O
)	TEFLARO.xml:S1:1651:1	)	)	O	O
occurred	TEFLARO.xml:S1:1653:8	occur	VBD	O	O
in	TEFLARO.xml:S1:1662:2	in	IN	O	O
98	TEFLARO.xml:S1:1665:2	98	CD	O	O
1300	TEFLARO.xml:S1:1668:4	1300	CD	O	O
(	TEFLARO.xml:S1:1673:1	(	(	O	O
7.5%	TEFLARO.xml:S1:1674:4	7.5%	CD	O	O
)	TEFLARO.xml:S1:1678:1	)	)	O	O
of	TEFLARO.xml:S1:1680:2	of	IN	O	O
patients	TEFLARO.xml:S1:1683:8	patient	NNS	O	O
receiving	TEFLARO.xml:S1:1692:9	receiv	VBG	O	O
Teflaro	TEFLARO.xml:S1:1702:7	teflaro	NNP	O	O
and	TEFLARO.xml:S1:1710:3	and	CC	O	O
100	TEFLARO.xml:S1:1714:3	100	CD	O	O
1297	TEFLARO.xml:S1:1718:4	1297	CD	O	O
(	TEFLARO.xml:S1:1723:1	(	(	O	O
7.7%	TEFLARO.xml:S1:1724:4	7.7%	CD	O	O
)	TEFLARO.xml:S1:1728:1	)	)	O	O
of	TEFLARO.xml:S1:1730:2	of	IN	O	O
patients	TEFLARO.xml:S1:1733:8	patient	NNS	O	O
receiving	TEFLARO.xml:S1:1742:9	receiv	VBG	O	O
comparator	TEFLARO.xml:S1:1752:10	compar	NN	O	O
drugs	TEFLARO.xml:S1:1763:5	drug	NNS	O	O
.	TEFLARO.xml:S1:1768:1	.	.	O	O

Treatment	TEFLARO.xml:S1:1770:9	treatment	JJ	O	O
discontinuation	TEFLARO.xml:S1:1780:15	discontinu	NN	O	O
due	TEFLARO.xml:S1:1796:3	due	JJ	O	O
to	TEFLARO.xml:S1:1800:2	to	TO	O	O
adverse	TEFLARO.xml:S1:1803:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:1811:9	reaction	NNS	O	O
occurred	TEFLARO.xml:S1:1821:8	occur	VBD	O	O
in	TEFLARO.xml:S1:1830:2	in	IN	O	O
35	TEFLARO.xml:S1:1833:2	35	CD	O	O
1300	TEFLARO.xml:S1:1836:4	1300	CD	O	O
(	TEFLARO.xml:S1:1841:1	(	(	O	O
2.7%	TEFLARO.xml:S1:1842:4	2.7%	CD	O	O
)	TEFLARO.xml:S1:1846:1	)	)	O	O
of	TEFLARO.xml:S1:1848:2	of	IN	O	O
patients	TEFLARO.xml:S1:1851:8	patient	NNS	O	O
receiving	TEFLARO.xml:S1:1860:9	receiv	VBG	O	O
Teflaro	TEFLARO.xml:S1:1870:7	teflaro	NNP	O	O
and	TEFLARO.xml:S1:1878:3	and	CC	O	O
48	TEFLARO.xml:S1:1882:2	48	CD	O	O
1297	TEFLARO.xml:S1:1885:4	1297	CD	O	O
(	TEFLARO.xml:S1:1890:1	(	(	O	O
3.7%	TEFLARO.xml:S1:1891:4	3.7%	CD	O	O
)	TEFLARO.xml:S1:1895:1	)	)	O	O
of	TEFLARO.xml:S1:1897:2	of	IN	O	O
patients	TEFLARO.xml:S1:1900:8	patient	NNS	O	O
receiving	TEFLARO.xml:S1:1909:9	receiv	VBG	O	O
comparator	TEFLARO.xml:S1:1919:10	compar	NN	O	O
drugs	TEFLARO.xml:S1:1930:5	drug	NNS	O	O
with	TEFLARO.xml:S1:1936:4	with	IN	O	O
the	TEFLARO.xml:S1:1941:3	the	DT	O	O
most	TEFLARO.xml:S1:1945:4	most	RBS	O	O
common	TEFLARO.xml:S1:1950:6	common	JJ	O	O
adverse	TEFLARO.xml:S1:1957:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:1965:9	reaction	NNS	O	O
leading	TEFLARO.xml:S1:1975:7	lead	VBG	O	O
to	TEFLARO.xml:S1:1983:2	to	TO	O	O
discontinuation	TEFLARO.xml:S1:1986:15	discontinu	VB	O	O
being	TEFLARO.xml:S1:2002:5	be	VBG	O	O
hypersensitivity	TEFLARO.xml:S1:2008:16	hypersensit	NN	B-AdverseReaction	O
for	TEFLARO.xml:S1:2025:3	for	IN	O	O
both	TEFLARO.xml:S1:2029:4	both	DT	O	O
treatment	TEFLARO.xml:S1:2034:9	treatment	NN	O	O
groups	TEFLARO.xml:S1:2044:6	group	NNS	O	O
at	TEFLARO.xml:S1:2051:2	at	IN	O	O
a	TEFLARO.xml:S1:2054:1	a	DT	O	O
rate	TEFLARO.xml:S1:2056:4	rate	NN	O	O
of	TEFLARO.xml:S1:2061:2	of	IN	O	O
0.3%	TEFLARO.xml:S1:2064:4	0.3%	CD	O	O
in	TEFLARO.xml:S1:2069:2	in	IN	O	O
the	TEFLARO.xml:S1:2072:3	the	DT	O	O
Teflaro	TEFLARO.xml:S1:2076:7	teflaro	NNP	O	O
group	TEFLARO.xml:S1:2084:5	group	NN	O	O
and	TEFLARO.xml:S1:2090:3	and	CC	O	O
0.5%	TEFLARO.xml:S1:2094:4	0.5%	CD	O	O
in	TEFLARO.xml:S1:2099:2	in	IN	O	O
comparator	TEFLARO.xml:S1:2102:10	compar	NN	O	O
group	TEFLARO.xml:S1:2113:5	group	NN	O	O
.	TEFLARO.xml:S1:2118:1	.	.	O	O

Most	TEFLARO.xml:S1:2128:4	most	JJS	O	O
Common	TEFLARO.xml:S1:2133:6	common	JJ	O	O
Adverse	TEFLARO.xml:S1:2140:7	advers	JJ	O	O
Reactions	TEFLARO.xml:S1:2148:9	reaction	NNS	O	O

No	TEFLARO.xml:S1:2164:2	No	DT	O	O
adverse	TEFLARO.xml:S1:2167:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:2175:9	reaction	NNS	O	O
occurred	TEFLARO.xml:S1:2185:8	occur	VBD	O	O
in	TEFLARO.xml:S1:2194:2	in	IN	O	O
greater	TEFLARO.xml:S1:2197:7	greater	JJR	O	O
than	TEFLARO.xml:S1:2205:4	than	IN	O	O
5%	TEFLARO.xml:S1:2210:2	5%	CD	O	O
of	TEFLARO.xml:S1:2213:2	of	IN	O	O
patients	TEFLARO.xml:S1:2216:8	patient	NNS	O	O
receiving	TEFLARO.xml:S1:2225:9	receiv	VBG	O	O
Teflaro	TEFLARO.xml:S1:2235:7	teflaro	NNP	O	O
.	TEFLARO.xml:S1:2242:1	.	.	O	O

The	TEFLARO.xml:S1:2244:3	the	DT	O	O
most	TEFLARO.xml:S1:2248:4	most	RBS	O	O
common	TEFLARO.xml:S1:2253:6	common	JJ	O	O
adverse	TEFLARO.xml:S1:2260:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:2268:9	reaction	NNS	O	O
occurring	TEFLARO.xml:S1:2278:9	occur	VBG	O	O
in	TEFLARO.xml:S1:2288:2	in	IN	O	O
2%	TEFLARO.xml:S1:2293:2	2%	CD	O	O
of	TEFLARO.xml:S1:2296:2	of	IN	O	O
patients	TEFLARO.xml:S1:2299:8	patient	NNS	O	O
receiving	TEFLARO.xml:S1:2308:9	receiv	VBG	O	O
Teflaro	TEFLARO.xml:S1:2318:7	teflaro	NNP	O	O
in	TEFLARO.xml:S1:2326:2	in	IN	O	O
the	TEFLARO.xml:S1:2329:3	the	DT	O	O
pooled	TEFLARO.xml:S1:2333:6	pool	JJ	O	O
phase	TEFLARO.xml:S1:2340:5	phase	NN	O	O
3	TEFLARO.xml:S1:2346:1	3	CD	O	O
clinical	TEFLARO.xml:S1:2348:8	clinic	JJ	O	O
trials	TEFLARO.xml:S1:2357:6	trial	NNS	O	O
were	TEFLARO.xml:S1:2364:4	were	VBD	O	O
diarrhea	TEFLARO.xml:S1:2369:8	diarrhea	JJ	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:2377:1	,	,	O	O
nausea	TEFLARO.xml:S1:2379:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:2385:1	,	,	O	O
and	TEFLARO.xml:S1:2387:3	and	CC	O	O
rash	TEFLARO.xml:S1:2391:4	rash	NN	B-AdverseReaction	B-AdverseReaction
.	TEFLARO.xml:S1:2395:1	.	.	O	O

Table	TEFLARO.xml:S1:2403:5	tabl	JJ	O	O
4	TEFLARO.xml:S1:2409:1	4	CD	O	O
lists	TEFLARO.xml:S1:2412:5	list	NNS	O	O
adverse	TEFLARO.xml:S1:2418:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:2426:9	reaction	NNS	O	O
occurring	TEFLARO.xml:S1:2436:9	occur	VBG	O	O
in	TEFLARO.xml:S1:2446:2	in	IN	O	O
2%	TEFLARO.xml:S1:2452:2	2%	CD	O	O
of	TEFLARO.xml:S1:2455:2	of	IN	O	O
patients	TEFLARO.xml:S1:2458:8	patient	NNS	O	O
receiving	TEFLARO.xml:S1:2467:9	receiv	VBG	O	O
Teflaro	TEFLARO.xml:S1:2477:7	teflaro	NNP	O	O
in	TEFLARO.xml:S1:2485:2	in	IN	O	O
the	TEFLARO.xml:S1:2488:3	the	DT	O	O
pooled	TEFLARO.xml:S1:2492:6	pool	JJ	O	O
Phase	TEFLARO.xml:S1:2499:5	phase	NNP	O	O
3	TEFLARO.xml:S1:2505:1	3	CD	O	O
clinical	TEFLARO.xml:S1:2507:8	clinic	JJ	O	O
trials	TEFLARO.xml:S1:2516:6	trial	NNS	O	O
.	TEFLARO.xml:S1:2522:1	.	.	O	O

Table	TEFLARO.xml:S1:2528:5	tabl	JJ	O	O
4	TEFLARO.xml:S1:2534:1	4	CD	O	O
:	TEFLARO.xml:S1:2535:1	:	:	O	O
Adverse	TEFLARO.xml:S1:2537:7	advers	JJ	O	O
Reactions	TEFLARO.xml:S1:2545:9	reaction	NNS	O	O
Occurring	TEFLARO.xml:S1:2555:9	occur	VBG	O	O
in	TEFLARO.xml:S1:2565:2	in	IN	O	O
2%	TEFLARO.xml:S1:2571:2	2%	CD	O	O
of	TEFLARO.xml:S1:2574:2	of	IN	O	O
Patients	TEFLARO.xml:S1:2577:8	patient	NNS	O	O
Receiving	TEFLARO.xml:S1:2586:9	receiv	VBG	O	O
Teflaro	TEFLARO.xml:S1:2596:7	teflaro	NNP	O	O
in	TEFLARO.xml:S1:2604:2	in	IN	O	O
the	TEFLARO.xml:S1:2607:3	the	DT	O	O
Pooled	TEFLARO.xml:S1:2611:6	pool	NNP	O	O
Phase	TEFLARO.xml:S1:2618:5	phase	NNP	O	O
3	TEFLARO.xml:S1:2624:1	3	CD	O	O
Clinical	TEFLARO.xml:S1:2626:8	clinic	NNP	O	O
Trials	TEFLARO.xml:S1:2635:6	trial	NNS	O	O

a	TEFLARO.xml:S1:2645:1	a	DT	O	O
Comparators	TEFLARO.xml:S1:2647:11	compar	NNP	O	O
included	TEFLARO.xml:S1:2659:8	includ	VBD	O	O
vancomycin	TEFLARO.xml:S1:2668:10	vancomycin	JJ	O	O
1	TEFLARO.xml:S1:2679:1	1	CD	O	O
gram	TEFLARO.xml:S1:2681:4	gram	NN	O	O
IV	TEFLARO.xml:S1:2686:2	IV	NNP	O	O
every	TEFLARO.xml:S1:2689:5	everi	DT	O	O
12	TEFLARO.xml:S1:2695:2	12	CD	O	O
h	TEFLARO.xml:S1:2697:1	h	NN	O	O
plus	TEFLARO.xml:S1:2699:4	plu	CC	O	O
aztreonam	TEFLARO.xml:S1:2704:9	aztreonam	JJ	O	O
1	TEFLARO.xml:S1:2714:1	1	CD	O	O
gram	TEFLARO.xml:S1:2716:4	gram	NN	O	O
IV	TEFLARO.xml:S1:2721:2	IV	NNP	O	O
every	TEFLARO.xml:S1:2724:5	everi	DT	O	O
12	TEFLARO.xml:S1:2730:2	12	CD	O	O
h	TEFLARO.xml:S1:2732:1	h	NN	O	O
in	TEFLARO.xml:S1:2734:2	in	IN	O	O
the	TEFLARO.xml:S1:2737:3	the	DT	O	O
Phase	TEFLARO.xml:S1:2741:5	phase	NNP	O	O
3	TEFLARO.xml:S1:2747:1	3	CD	O	O
ABSSSI	TEFLARO.xml:S1:2749:6	absssi	NNP	O	O
trials	TEFLARO.xml:S1:2756:6	trial	NNS	O	O
,	TEFLARO.xml:S1:2762:1	,	,	O	O
and	TEFLARO.xml:S1:2764:3	and	CC	O	O
ceftriaxone	TEFLARO.xml:S1:2768:11	ceftriaxon	NN	O	O
1	TEFLARO.xml:S1:2780:1	1	CD	O	O
gram	TEFLARO.xml:S1:2782:4	gram	NN	O	O
IV	TEFLARO.xml:S1:2787:2	IV	NNP	O	O
every	TEFLARO.xml:S1:2790:5	everi	DT	O	O
24	TEFLARO.xml:S1:2796:2	24	CD	O	O
h	TEFLARO.xml:S1:2798:1	h	NN	O	O
in	TEFLARO.xml:S1:2800:2	in	IN	O	O
the	TEFLARO.xml:S1:2803:3	the	DT	O	O
Phase	TEFLARO.xml:S1:2807:5	phase	NNP	O	O
3	TEFLARO.xml:S1:2813:1	3	CD	O	O
CABP	TEFLARO.xml:S1:2815:4	cabp	NNP	O	O
trials	TEFLARO.xml:S1:2820:6	trial	NNS	O	O
.	TEFLARO.xml:S1:2826:1	.	.	O	O

Adverse	TEFLARO.xml:S1:2838:7	advers	NN	O	O

Reactions	TEFLARO.xml:S1:2846:9	reaction	NNS	O	O
Pooled	TEFLARO.xml:S1:2882:6	pool	VBD	O	O
Phase	TEFLARO.xml:S1:2889:5	phase	NNP	O	O
3	TEFLARO.xml:S1:2895:1	3	CD	O	O
Clinical	TEFLARO.xml:S1:2897:8	clinic	NNP	O	O
Trials	TEFLARO.xml:S1:2906:6	trial	NNP	O	O
(	TEFLARO.xml:S1:2916:1	(	(	O	O
four	TEFLARO.xml:S1:2917:4	four	CD	O	O
trials	TEFLARO.xml:S1:2922:6	trial	NNS	O	O
,	TEFLARO.xml:S1:2928:1	,	,	O	O
two	TEFLARO.xml:S1:2930:3	two	CD	O	O
in	TEFLARO.xml:S1:2934:2	in	IN	O	O
ABSSSI	TEFLARO.xml:S1:2937:6	absssi	NNP	O	O
and	TEFLARO.xml:S1:2944:3	and	CC	O	O
two	TEFLARO.xml:S1:2948:3	two	CD	O	O
in	TEFLARO.xml:S1:2952:2	in	IN	O	O
CABP	TEFLARO.xml:S1:2955:4	cabp	NNP	O	O
)	TEFLARO.xml:S1:2959:1	)	)	O	O

Teflaro	TEFLARO.xml:S1:2969:7	teflaro	NNP	O	O
(	TEFLARO.xml:S1:2980:1	(	(	O	O
N	TEFLARO.xml:S1:2981:1	N	NNP	O	O
1300	TEFLARO.xml:S1:2983:4	1300	CD	O	O
)	TEFLARO.xml:S1:2987:1	)	)	O	O
Pooled	TEFLARO.xml:S1:3013:6	pool	VBD	O	O
Comparators	TEFLARO.xml:S1:3020:11	compar	NNS	O	O
a	TEFLARO.xml:S1:3037:1	a	DT	O	O
(	TEFLARO.xml:S1:3044:1	(	(	O	O
N	TEFLARO.xml:S1:3045:1	N	NNP	O	O
1297	TEFLARO.xml:S1:3047:4	1297	CD	O	O
)	TEFLARO.xml:S1:3051:1	)	)	O	O

Gastrointestinal	TEFLARO.xml:S1:3061:16	gastrointestin	JJ	O	O
Disorders	TEFLARO.xml:S1:3078:9	disord	NNS	O	O

Diarrhea	TEFLARO.xml:S1:3106:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
5	TEFLARO.xml:S1:3150:1	5	CD	O	O
3	TEFLARO.xml:S1:3180:1	3	CD	O	O

Nausea	TEFLARO.xml:S1:3213:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
4	TEFLARO.xml:S1:3257:1	4	CD	O	O
4	TEFLARO.xml:S1:3287:1	4	CD	O	O

Constipation	TEFLARO.xml:S1:3320:12	constip	NN	B-AdverseReaction	B-AdverseReaction
2	TEFLARO.xml:S1:3364:1	2	CD	O	O
2	TEFLARO.xml:S1:3394:1	2	CD	O	O

Vomiting	TEFLARO.xml:S1:3427:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
2	TEFLARO.xml:S1:3471:1	2	CD	O	O
2	TEFLARO.xml:S1:3501:1	2	CD	O	O

Laboratory	TEFLARO.xml:S1:3536:10	laboratori	NN	O	O
Investigations	TEFLARO.xml:S1:3547:14	investig	NNS	O	O

Increased	TEFLARO.xml:S1:3581:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
transaminases	TEFLARO.xml:S1:3591:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
2%	TEFLARO.xml:S1:3625:2	2%	CD	O	O
3	TEFLARO.xml:S1:3655:1	3	CD	O	O

Metabolism	TEFLARO.xml:S1:3690:10	metabol	NN	O	O
and	TEFLARO.xml:S1:3701:3	and	CC	O	O
Nutrition	TEFLARO.xml:S1:3705:9	nutrit	NN	O	O
disorders	TEFLARO.xml:S1:3715:9	disord	NNS	O	O

Hypokalemia	TEFLARO.xml:S1:3735:11	hypokalemia	NNP	B-AdverseReaction	B-AdverseReaction
2	TEFLARO.xml:S1:3779:1	2	CD	O	O
3	TEFLARO.xml:S1:3809:1	3	CD	O	O

Skin	TEFLARO.xml:S1:3844:4	skin	NNP	O	O
and	TEFLARO.xml:S1:3849:3	and	CC	O	O
Subcutaneous	TEFLARO.xml:S1:3853:12	subcutan	NNP	O	O
Tissue	TEFLARO.xml:S1:3866:6	tissu	NNP	O	O
Disorders	TEFLARO.xml:S1:3873:9	disord	NNP	O	O

Rash	TEFLARO.xml:S1:3889:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
3%	TEFLARO.xml:S1:3933:2	3%	CD	O	O
2%	TEFLARO.xml:S1:3963:2	2%	CD	O	O

Vascular	TEFLARO.xml:S1:3998:8	vascular	JJ	O	O
Disorders	TEFLARO.xml:S1:4007:9	disord	NNS	O	O

Phlebitis	TEFLARO.xml:S1:4043:9	phlebiti	NN	B-AdverseReaction	B-AdverseReaction
2%	TEFLARO.xml:S1:4087:2	2%	CD	O	O
1%	TEFLARO.xml:S1:4117:2	1%	CD	O	O

Other	TEFLARO.xml:S1:4162:5	other	JJ	O	O
Adverse	TEFLARO.xml:S1:4168:7	advers	NNP	O	O
Reactions	TEFLARO.xml:S1:4176:9	reaction	NNP	O	O
Observed	TEFLARO.xml:S1:4186:8	observ	NNP	O	O
During	TEFLARO.xml:S1:4195:6	dure	IN	O	O
Clinical	TEFLARO.xml:S1:4202:8	clinic	JJ	O	O
Trials	TEFLARO.xml:S1:4211:6	trial	NNS	O	O
of	TEFLARO.xml:S1:4218:2	of	IN	O	O
Teflaro	TEFLARO.xml:S1:4221:7	teflaro	NNP	O	O

Following	TEFLARO.xml:S1:4235:9	follow	VBG	O	O

is	TEFLARO.xml:S1:4245:2	is	VBZ	O	O
a	TEFLARO.xml:S1:4248:1	a	DT	O	O
list	TEFLARO.xml:S1:4250:4	list	NN	O	O
of	TEFLARO.xml:S1:4255:2	of	IN	O	O
additional	TEFLARO.xml:S1:4258:10	addit	JJ	O	O
adverse	TEFLARO.xml:S1:4269:7	advers	JJ	O	O
reactions	TEFLARO.xml:S1:4277:9	reaction	NNS	O	O
reported	TEFLARO.xml:S1:4287:8	report	VBN	O	O
by	TEFLARO.xml:S1:4296:2	by	IN	O	O
the	TEFLARO.xml:S1:4299:3	the	DT	O	O
1740	TEFLARO.xml:S1:4303:4	1740	CD	O	O
patients	TEFLARO.xml:S1:4308:8	patient	NNS	O	O
who	TEFLARO.xml:S1:4317:3	who	WP	O	O
received	TEFLARO.xml:S1:4321:8	receiv	VBD	O	O
Teflaro	TEFLARO.xml:S1:4330:7	teflaro	NNP	O	O
in	TEFLARO.xml:S1:4338:2	in	IN	O	O
any	TEFLARO.xml:S1:4341:3	ani	DT	O	O
clinical	TEFLARO.xml:S1:4345:8	clinic	JJ	O	O
trial	TEFLARO.xml:S1:4354:5	trial	NN	O	O
with	TEFLARO.xml:S1:4360:4	with	IN	O	O
incidences	TEFLARO.xml:S1:4365:10	incid	NNS	O	O
less	TEFLARO.xml:S1:4376:4	less	JJR	O	O
than	TEFLARO.xml:S1:4381:4	than	IN	O	O
2%	TEFLARO.xml:S1:4386:2	2%	CD	O	O
.	TEFLARO.xml:S1:4388:1	.	.	O	O

Blood	TEFLARO.xml:S1:4396:5	blood	NN	O	O
and	TEFLARO.xml:S1:4402:3	and	CC	O	O
lymphatic	TEFLARO.xml:S1:4406:9	lymphat	JJ	O	O
system	TEFLARO.xml:S1:4416:6	system	NN	O	O
disorders	TEFLARO.xml:S1:4423:9	disord	NNS	O	O
-	TEFLARO.xml:S1:4434:1	-	:	O	O
Anemia	TEFLARO.xml:S1:4436:6	anemia	NNP	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:4442:1	,	,	O	O
Eosinophilia	TEFLARO.xml:S1:4444:12	eosinophilia	NNP	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:4456:1	,	,	O	O
Neutropenia	TEFLARO.xml:S1:4458:11	neutropenia	NNP	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:4469:1	,	,	O	O
Thrombocytopenia	TEFLARO.xml:S1:4471:16	thrombocytopenia	NNP	B-AdverseReaction	B-AdverseReaction

Cardiac	TEFLARO.xml:S1:4494:7	cardiac	NNP	O	O
disorders	TEFLARO.xml:S1:4502:9	disord	NNS	O	O
-	TEFLARO.xml:S1:4513:1	-	:	O	O
Bradycardia	TEFLARO.xml:S1:4515:11	bradycardia	NNP	B-AdverseReaction	O
,	TEFLARO.xml:S1:4526:1	,	,	O	O
Palpitations	TEFLARO.xml:S1:4528:12	palpit	NNP	B-AdverseReaction	O

Gastrointestinal	TEFLARO.xml:S1:4547:16	gastrointestin	NNP	O	O
disorders	TEFLARO.xml:S1:4564:9	disord	NNS	O	O
-	TEFLARO.xml:S1:4575:1	-	:	O	O
Abdominal	TEFLARO.xml:S1:4577:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	TEFLARO.xml:S1:4587:4	pain	NN	I-AdverseReaction	I-AdverseReaction

General	TEFLARO.xml:S1:4598:7	gener	NNP	O	O
disorders	TEFLARO.xml:S1:4606:9	disord	NNS	O	O
and	TEFLARO.xml:S1:4616:3	and	CC	O	O
administration	TEFLARO.xml:S1:4620:14	administr	NN	O	O
site	TEFLARO.xml:S1:4635:4	site	NN	O	O
conditions	TEFLARO.xml:S1:4640:10	condit	NNS	O	O
-	TEFLARO.xml:S1:4652:1	-	:	O	O
Pyrexia	TEFLARO.xml:S1:4654:7	pyrexia	NN	B-AdverseReaction	O

Hepatobiliary	TEFLARO.xml:S1:4668:13	hepatobiliari	JJ	O	O
disorders	TEFLARO.xml:S1:4682:9	disord	NNS	O	O
-	TEFLARO.xml:S1:4692:1	-	:	O	O
Hepatitis	TEFLARO.xml:S1:4695:9	hepat	NN	B-AdverseReaction	B-AdverseReaction

Immune	TEFLARO.xml:S1:4711:6	immun	NNP	O	O
system	TEFLARO.xml:S1:4718:6	system	NN	O	O
disorders	TEFLARO.xml:S1:4725:9	disord	NNS	O	O
-	TEFLARO.xml:S1:4736:1	-	:	O	O
Hypersensitivity	TEFLARO.xml:S1:4738:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:4754:1	,	,	O	O
Anaphylaxis	TEFLARO.xml:S1:4756:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction

Infections	TEFLARO.xml:S1:4774:10	infect	NNS	O	O
and	TEFLARO.xml:S1:4785:3	and	CC	O	O
infestations	TEFLARO.xml:S1:4789:12	infest	NNS	O	O
-	TEFLARO.xml:S1:4803:1	-	:	O	O
Clostridium	TEFLARO.xml:S1:4806:11	clostridium	NN	B-AdverseReaction	O
difficile	TEFLARO.xml:S1:4818:9	difficil	NN	I-AdverseReaction	O
colitis	TEFLARO.xml:S1:4829:7	coliti	NN	I-AdverseReaction	O

Metabolism	TEFLARO.xml:S1:4843:10	metabol	NN	O	O
and	TEFLARO.xml:S1:4854:3	and	CC	O	O
nutrition	TEFLARO.xml:S1:4858:9	nutrit	NN	O	O
disorders	TEFLARO.xml:S1:4868:9	disord	NNS	O	O
-	TEFLARO.xml:S1:4879:1	-	:	O	O
Hyperglycemia	TEFLARO.xml:S1:4881:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:4894:1	,	,	O	O
Hyperkalemia	TEFLARO.xml:S1:4896:12	hyperkalemia	NNP	B-AdverseReaction	B-AdverseReaction

Nervous	TEFLARO.xml:S1:4915:7	nervou	JJ	O	O
system	TEFLARO.xml:S1:4923:6	system	NN	O	O
disorders	TEFLARO.xml:S1:4930:9	disord	NNS	O	O
-	TEFLARO.xml:S1:4941:1	-	:	O	O
Dizziness	TEFLARO.xml:S1:4943:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	TEFLARO.xml:S1:4952:1	,	,	O	O
Convulsion	TEFLARO.xml:S1:4954:10	convuls	NN	B-AdverseReaction	B-AdverseReaction

Renal	TEFLARO.xml:S1:4971:5	renal	NNP	O	O
and	TEFLARO.xml:S1:4977:3	and	CC	O	O
urinary	TEFLARO.xml:S1:4981:7	urinari	JJ	O	O
disorders	TEFLARO.xml:S1:4989:9	disord	NNS	O	O
-	TEFLARO.xml:S1:5000:1	-	:	O	O
Renal	TEFLARO.xml:S1:5002:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	TEFLARO.xml:S1:5008:7	failur	NN	I-AdverseReaction	I-AdverseReaction

Skin	TEFLARO.xml:S1:5022:4	skin	NNP	O	O
and	TEFLARO.xml:S1:5027:3	and	CC	O	O
subcutaneous	TEFLARO.xml:S1:5031:12	subcutan	JJ	O	O
tissue	TEFLARO.xml:S1:5044:6	tissu	NN	O	O
disorders	TEFLARO.xml:S1:5051:9	disord	NNS	O	O
-	TEFLARO.xml:S1:5062:1	-	:	O	O
Urticaria	TEFLARO.xml:S1:5064:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction

6.2	TEFLARO.xml:S1:5080:3	6.2	CD	O	O
Postmarketing	TEFLARO.xml:S1:5084:13	postmarket	VBG	O	O
Experience	TEFLARO.xml:S1:5098:10	experi	NN	O	O

The	TEFLARO.xml:S1:5112:3	the	DT	O	O
following	TEFLARO.xml:S1:5116:9	follow	JJ	O	O
adverse	TEFLARO.xml:S1:5126:7	advers	JJ	O	O
reaction	TEFLARO.xml:S1:5134:8	reaction	NN	O	O
has	TEFLARO.xml:S1:5143:3	ha	VBZ	O	O
been	TEFLARO.xml:S1:5147:4	been	VBN	O	O
identified	TEFLARO.xml:S1:5152:10	identifi	VBN	O	O
during	TEFLARO.xml:S1:5163:6	dure	IN	O	O
postapproval	TEFLARO.xml:S1:5170:12	postapprov	JJ	O	O
use	TEFLARO.xml:S1:5183:3	use	NN	O	O
of	TEFLARO.xml:S1:5187:2	of	IN	O	O
Teflaro	TEFLARO.xml:S1:5190:7	teflaro	NNP	O	O
.	TEFLARO.xml:S1:5197:1	.	.	O	O

Because	TEFLARO.xml:S1:5199:7	becaus	IN	O	O
this	TEFLARO.xml:S1:5207:4	thi	DT	O	O
adverse	TEFLARO.xml:S1:5212:7	advers	JJ	O	O
reaction	TEFLARO.xml:S1:5220:8	reaction	NN	O	O
was	TEFLARO.xml:S1:5229:3	wa	VBD	O	O
reported	TEFLARO.xml:S1:5233:8	report	VBN	O	O
voluntarily	TEFLARO.xml:S1:5242:11	voluntarili	RB	O	O
from	TEFLARO.xml:S1:5254:4	from	IN	O	O
a	TEFLARO.xml:S1:5259:1	a	DT	O	O
population	TEFLARO.xml:S1:5261:10	popul	NN	O	O
of	TEFLARO.xml:S1:5272:2	of	IN	O	O
uncertain	TEFLARO.xml:S1:5275:9	uncertain	JJ	O	O
size	TEFLARO.xml:S1:5285:4	size	NN	O	O
,	TEFLARO.xml:S1:5289:1	,	,	O	O
it	TEFLARO.xml:S1:5291:2	it	PRP	O	O
is	TEFLARO.xml:S1:5294:2	is	VBZ	O	O
not	TEFLARO.xml:S1:5297:3	not	RB	O	O
possible	TEFLARO.xml:S1:5301:8	possibl	JJ	O	O
to	TEFLARO.xml:S1:5310:2	to	TO	O	O
estimate	TEFLARO.xml:S1:5313:8	estim	VB	O	O
its	TEFLARO.xml:S1:5322:3	it	PRP$	O	O
frequency	TEFLARO.xml:S1:5326:9	frequenc	NN	O	O
or	TEFLARO.xml:S1:5336:2	or	CC	O	O
establish	TEFLARO.xml:S1:5339:9	establish	VB	O	O
a	TEFLARO.xml:S1:5349:1	a	DT	O	O
causal	TEFLARO.xml:S1:5351:6	causal	NN	O	O
relationship	TEFLARO.xml:S1:5358:12	relationship	NN	O	O
to	TEFLARO.xml:S1:5371:2	to	TO	O	O
drug	TEFLARO.xml:S1:5374:4	drug	NN	O	O
exposure	TEFLARO.xml:S1:5379:8	exposur	NN	O	O
.	TEFLARO.xml:S1:5387:1	.	.	O	O

Blood	TEFLARO.xml:S1:5395:5	blood	NN	O	O
and	TEFLARO.xml:S1:5401:3	and	CC	O	O
lymphatic	TEFLARO.xml:S1:5405:9	lymphat	JJ	O	O
system	TEFLARO.xml:S1:5415:6	system	NN	O	O
disorders	TEFLARO.xml:S1:5422:9	disord	NNS	O	O
:	TEFLARO.xml:S1:5433:1	:	:	O	O
Agranulocytosis	TEFLARO.xml:S1:5435:15	agranulocytosi	NNP	B-AdverseReaction	B-AdverseReaction
.	TEFLARO.xml:S1:5450:1	.	.	O	O
5	TEFLARO.xml:S2:4:1	5	CD	O	O
.	TEFLARO.xml:S2:5:1	.	.	O	O

WARNINGS	TEFLARO.xml:S2:7:8	warn	NNP	O	O
AND	TEFLARO.xml:S2:16:3	and	NNP	O	O
PRECAUTIONS	TEFLARO.xml:S2:20:11	precaut	NNP	O	O

EXCERPT	TEFLARO.xml:S2:38:7	excerpt	NN	O	O
:	TEFLARO.xml:S2:45:1	:	:	O	O
Serious	TEFLARO.xml:S2:53:7	seriou	JJ	O	O
hypersensitivity	TEFLARO.xml:S2:61:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
(	TEFLARO.xml:S2:78:1	(	(	O	O
anaphylactic	TEFLARO.xml:S2:79:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
)	TEFLARO.xml:S2:91:1	)	)	O	O
reactions	TEFLARO.xml:S2:93:9	reaction	NNS	I-AdverseReaction	O
have	TEFLARO.xml:S2:103:4	have	VBP	O	O
been	TEFLARO.xml:S2:108:4	been	VBN	O	O
reported	TEFLARO.xml:S2:113:8	report	VBN	O	O
with	TEFLARO.xml:S2:122:4	with	IN	O	O
beta	TEFLARO.xml:S2:127:4	beta	NN	O	O
-	TEFLARO.xml:S2:131:1	-	:	O	O
lactam	TEFLARO.xml:S2:132:6	lactam	JJ	O	O
antibacterial	TEFLARO.xml:S2:139:13	antibacteri	JJ	O	O
drugs	TEFLARO.xml:S2:153:5	drug	NNS	O	O
,	TEFLARO.xml:S2:158:1	,	,	O	O
including	TEFLARO.xml:S2:160:9	includ	VBG	O	O
Teflaro	TEFLARO.xml:S2:170:7	teflaro	NNP	O	O
.	TEFLARO.xml:S2:177:1	.	.	O	O

If	TEFLARO.xml:S2:179:2	If	IN	O	O
a	TEFLARO.xml:S2:182:1	a	DT	O	O
hypersensitivity	TEFLARO.xml:S2:184:16	hypersensit	NN	O	O
reaction	TEFLARO.xml:S2:201:8	reaction	NN	O	O
occurs	TEFLARO.xml:S2:210:6	occur	VBZ	O	O
,	TEFLARO.xml:S2:216:1	,	,	O	O
discontinue	TEFLARO.xml:S2:218:11	discontinu	VB	O	O
Teflaro	TEFLARO.xml:S2:230:7	teflaro	NNP	O	O
.	TEFLARO.xml:S2:237:1	.	.	O	O

(	TEFLARO.xml:S2:239:1	(	(	O	O
5.1	TEFLARO.xml:S2:242:3	5.1	CD	O	O
)	TEFLARO.xml:S2:247:1	)	)	O	O

Clostridium	TEFLARO.xml:S2:255:11	clostridium	NN	B-AdverseReaction	B-AdverseReaction
difficile	TEFLARO.xml:S2:267:9	difficil	NN	I-AdverseReaction	I-AdverseReaction
-	TEFLARO.xml:S2:277:1	-	:	I-AdverseReaction	I-AdverseReaction
associated	TEFLARO.xml:S2:278:10	associ	VBN	I-AdverseReaction	I-AdverseReaction
diarrhea	TEFLARO.xml:S2:289:8	diarrhea	NN	I-AdverseReaction	I-AdverseReaction
(	TEFLARO.xml:S2:298:1	(	(	O	O
CDAD	TEFLARO.xml:S2:299:4	cdad	NNP	B-AdverseReaction	B-AdverseReaction
)	TEFLARO.xml:S2:303:1	)	)	O	O
has	TEFLARO.xml:S2:305:3	ha	VBZ	O	O
been	TEFLARO.xml:S2:309:4	been	VBN	O	O
reported	TEFLARO.xml:S2:314:8	report	VBN	O	O
with	TEFLARO.xml:S2:323:4	with	IN	O	O
nearly	TEFLARO.xml:S2:328:6	nearli	RB	O	O
all	TEFLARO.xml:S2:335:3	all	DT	O	O
systemic	TEFLARO.xml:S2:339:8	system	JJ	O	O
antibacterial	TEFLARO.xml:S2:348:13	antibacteri	JJ	O	O
agents	TEFLARO.xml:S2:362:6	agent	NNS	O	O
,	TEFLARO.xml:S2:368:1	,	,	O	O
including	TEFLARO.xml:S2:370:9	includ	VBG	O	O
Teflaro	TEFLARO.xml:S2:380:7	teflaro	NNP	O	O
.	TEFLARO.xml:S2:387:1	.	.	O	O

Evaluate	TEFLARO.xml:S2:389:8	evalu	VB	O	O
if	TEFLARO.xml:S2:398:2	if	IN	O	O
diarrhea	TEFLARO.xml:S2:401:8	diarrhea	JJ	O	O
occurs	TEFLARO.xml:S2:410:6	occur	NNS	O	O
.	TEFLARO.xml:S2:416:1	.	.	O	O

(	TEFLARO.xml:S2:418:1	(	(	O	O
5.2	TEFLARO.xml:S2:421:3	5.2	CD	O	O
)	TEFLARO.xml:S2:426:1	)	)	O	O

Direct	TEFLARO.xml:S2:433:6	direct	JJ	B-AdverseReaction	O
Coombs	TEFLARO.xml:S2:440:6	coomb	NNP	I-AdverseReaction	O
test	TEFLARO.xml:S2:448:4	test	NN	I-AdverseReaction	O
seroconversion	TEFLARO.xml:S2:453:14	seroconvers	NN	I-AdverseReaction	O
has	TEFLARO.xml:S2:468:3	ha	VBZ	O	O
been	TEFLARO.xml:S2:472:4	been	VBN	O	O
reported	TEFLARO.xml:S2:477:8	report	VBN	O	O
with	TEFLARO.xml:S2:486:4	with	IN	O	O
Teflaro	TEFLARO.xml:S2:491:7	teflaro	NNP	O	O
.	TEFLARO.xml:S2:498:1	.	.	O	O

If	TEFLARO.xml:S2:500:2	If	IN	O	O
anemia	TEFLARO.xml:S2:503:6	anemia	JJ	O	O
develops	TEFLARO.xml:S2:510:8	develop	NNS	O	O
during	TEFLARO.xml:S2:519:6	dure	IN	O	O
or	TEFLARO.xml:S2:526:2	or	CC	O	O
after	TEFLARO.xml:S2:529:5	after	IN	O	O
therapy	TEFLARO.xml:S2:535:7	therapi	NN	O	O
,	TEFLARO.xml:S2:542:1	,	,	O	O
a	TEFLARO.xml:S2:544:1	a	DT	O	O
diagnostic	TEFLARO.xml:S2:546:10	diagnost	JJ	O	O
workup	TEFLARO.xml:S2:557:6	workup	NN	O	O
for	TEFLARO.xml:S2:564:3	for	IN	O	O
drug	TEFLARO.xml:S2:568:4	drug	NN	O	O
-	TEFLARO.xml:S2:572:1	-	:	O	O
induced	TEFLARO.xml:S2:573:7	induc	VBN	O	O
hemolytic	TEFLARO.xml:S2:581:9	hemolyt	JJ	O	O
anemia	TEFLARO.xml:S2:591:6	anemia	NN	O	O
should	TEFLARO.xml:S2:598:6	should	MD	O	O
be	TEFLARO.xml:S2:605:2	be	VB	O	O
performed	TEFLARO.xml:S2:608:9	perform	VBN	O	O
and	TEFLARO.xml:S2:618:3	and	CC	O	O
consideration	TEFLARO.xml:S2:622:13	consider	NN	O	O
given	TEFLARO.xml:S2:636:5	given	VBN	O	O
to	TEFLARO.xml:S2:642:2	to	TO	O	O
discontinuation	TEFLARO.xml:S2:645:15	discontinu	NN	O	O
of	TEFLARO.xml:S2:661:2	of	IN	O	O
Teflaro	TEFLARO.xml:S2:664:7	teflaro	NNP	O	O
.	TEFLARO.xml:S2:671:1	.	.	O	O

(	TEFLARO.xml:S2:673:1	(	(	O	O
5.3	TEFLARO.xml:S2:676:3	5.3	CD	O	O
)	TEFLARO.xml:S2:681:1	)	)	O	O

5.1	TEFLARO.xml:S2:695:3	5.1	CD	O	O

Hypersensitivity	TEFLARO.xml:S2:699:16	hypersensit	NN	O	O

Reactions	TEFLARO.xml:S2:716:9	reaction	NNS	O	O

Serious	TEFLARO.xml:S2:731:7	seriou	JJ	O	O
and	TEFLARO.xml:S2:739:3	and	CC	O	O
occasionally	TEFLARO.xml:S2:743:12	occasion	RB	O	O
fatal	TEFLARO.xml:S2:756:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
hypersensitivity	TEFLARO.xml:S2:762:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
(	TEFLARO.xml:S2:779:1	(	(	O	O
anaphylactic	TEFLARO.xml:S2:780:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
)	TEFLARO.xml:S2:792:1	)	)	O	O
reactions	TEFLARO.xml:S2:794:9	reaction	NNS	I-AdverseReaction	O
and	TEFLARO.xml:S2:804:3	and	CC	O	O
serious	TEFLARO.xml:S2:808:7	seriou	JJ	O	O
skin	TEFLARO.xml:S2:816:4	skin	NN	B-AdverseReaction	B-AdverseReaction
reactions	TEFLARO.xml:S2:821:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
have	TEFLARO.xml:S2:831:4	have	VBP	O	O
been	TEFLARO.xml:S2:836:4	been	VBN	O	O
reported	TEFLARO.xml:S2:841:8	report	VBN	O	O
in	TEFLARO.xml:S2:850:2	in	IN	O	O
patients	TEFLARO.xml:S2:853:8	patient	NNS	O	O
receiving	TEFLARO.xml:S2:862:9	receiv	VBG	O	O
beta	TEFLARO.xml:S2:872:4	beta	SYM	O	O
-	TEFLARO.xml:S2:876:1	-	:	O	O
lactam	TEFLARO.xml:S2:877:6	lactam	JJ	O	O
antibacterial	TEFLARO.xml:S2:884:13	antibacteri	JJ	O	O
drugs	TEFLARO.xml:S2:898:5	drug	NNS	O	O
.	TEFLARO.xml:S2:903:1	.	.	O	O

Before	TEFLARO.xml:S2:905:6	befor	IN	O	O
therapy	TEFLARO.xml:S2:912:7	therapi	NN	O	O
with	TEFLARO.xml:S2:920:4	with	IN	O	O
Teflaro	TEFLARO.xml:S2:925:7	teflaro	NNP	O	O
is	TEFLARO.xml:S2:933:2	is	VBZ	O	O
instituted	TEFLARO.xml:S2:936:10	institut	VBN	O	O
,	TEFLARO.xml:S2:946:1	,	,	O	O
careful	TEFLARO.xml:S2:948:7	care	JJ	O	O
inquiry	TEFLARO.xml:S2:956:7	inquiri	NN	O	O
about	TEFLARO.xml:S2:964:5	about	IN	O	O
previous	TEFLARO.xml:S2:970:8	previou	JJ	O	O
hypersensitivity	TEFLARO.xml:S2:979:16	hypersensit	NN	O	O
reactions	TEFLARO.xml:S2:996:9	reaction	NNS	O	O
to	TEFLARO.xml:S2:1006:2	to	TO	O	O
other	TEFLARO.xml:S2:1009:5	other	JJ	O	O
cephalosporins	TEFLARO.xml:S2:1015:14	cephalosporin	NNS	O	O
,	TEFLARO.xml:S2:1029:1	,	,	O	O
penicillins	TEFLARO.xml:S2:1031:11	penicillin	NNS	O	O
,	TEFLARO.xml:S2:1042:1	,	,	O	O
or	TEFLARO.xml:S2:1044:2	or	CC	O	O
carbapenems	TEFLARO.xml:S2:1047:11	carbapenem	NNS	O	O
should	TEFLARO.xml:S2:1059:6	should	MD	O	O
be	TEFLARO.xml:S2:1066:2	be	VB	O	O
made	TEFLARO.xml:S2:1069:4	made	VBN	O	O
.	TEFLARO.xml:S2:1073:1	.	.	O	O

Maintain	TEFLARO.xml:S2:1075:8	maintain	NNP	O	O
clinical	TEFLARO.xml:S2:1084:8	clinic	JJ	O	O
supervision	TEFLARO.xml:S2:1093:11	supervis	NN	O	O
if	TEFLARO.xml:S2:1105:2	if	IN	O	O
this	TEFLARO.xml:S2:1108:4	thi	DT	O	O
product	TEFLARO.xml:S2:1113:7	product	NN	O	O
is	TEFLARO.xml:S2:1121:2	is	VBZ	O	O
to	TEFLARO.xml:S2:1124:2	to	TO	O	O
be	TEFLARO.xml:S2:1127:2	be	VB	O	O
given	TEFLARO.xml:S2:1130:5	given	VBN	O	O
to	TEFLARO.xml:S2:1136:2	to	TO	O	O
a	TEFLARO.xml:S2:1139:1	a	DT	O	O
penicillin	TEFLARO.xml:S2:1141:10	penicillin	NN	O	O
-	TEFLARO.xml:S2:1151:1	-	:	O	O
or	TEFLARO.xml:S2:1153:2	or	CC	O	O
other	TEFLARO.xml:S2:1156:5	other	JJ	O	O
beta	TEFLARO.xml:S2:1162:4	beta	NN	O	O
-	TEFLARO.xml:S2:1166:1	-	:	O	O
lactam	TEFLARO.xml:S2:1167:6	lactam	NN	O	O
-	TEFLARO.xml:S2:1173:1	-	:	O	O
allergic	TEFLARO.xml:S2:1174:8	allerg	JJ	O	O
patient	TEFLARO.xml:S2:1183:7	patient	NN	O	O
,	TEFLARO.xml:S2:1190:1	,	,	O	O
because	TEFLARO.xml:S2:1192:7	becaus	IN	O	O
cross	TEFLARO.xml:S2:1200:5	cross	JJ	O	O
sensitivity	TEFLARO.xml:S2:1206:11	sensit	NN	O	O
among	TEFLARO.xml:S2:1218:5	among	IN	O	O
beta	TEFLARO.xml:S2:1224:4	beta	JJ	O	O
-	TEFLARO.xml:S2:1228:1	-	:	O	O
lactam	TEFLARO.xml:S2:1229:6	lactam	JJ	O	O
antibacterial	TEFLARO.xml:S2:1236:13	antibacteri	JJ	O	O
agents	TEFLARO.xml:S2:1250:6	agent	NNS	O	O
has	TEFLARO.xml:S2:1257:3	ha	VBZ	O	O
been	TEFLARO.xml:S2:1261:4	been	VBN	O	O
clearly	TEFLARO.xml:S2:1266:7	clearli	RB	O	O
established	TEFLARO.xml:S2:1274:11	establish	VBN	O	O
.	TEFLARO.xml:S2:1285:1	.	.	O	O

If	TEFLARO.xml:S2:1291:2	If	IN	O	O
an	TEFLARO.xml:S2:1294:2	an	DT	O	O
allergic	TEFLARO.xml:S2:1297:8	allerg	JJ	O	O
reaction	TEFLARO.xml:S2:1306:8	reaction	NN	O	O
to	TEFLARO.xml:S2:1315:2	to	TO	O	O
Teflaro	TEFLARO.xml:S2:1318:7	teflaro	NNP	O	O
occurs	TEFLARO.xml:S2:1326:6	occur	NNS	O	O
,	TEFLARO.xml:S2:1332:1	,	,	O	O
discontinue	TEFLARO.xml:S2:1334:11	discontinu	VBP	O	O
Teflaro	TEFLARO.xml:S2:1346:7	teflaro	NNP	O	O
and	TEFLARO.xml:S2:1354:3	and	CC	O	O
institute	TEFLARO.xml:S2:1358:9	institut	JJ	O	O
appropriate	TEFLARO.xml:S2:1368:11	appropri	JJ	O	O
treatment	TEFLARO.xml:S2:1380:9	treatment	NN	O	O
and	TEFLARO.xml:S2:1390:3	and	CC	O	O
supportive	TEFLARO.xml:S2:1394:10	support	JJ	O	O
measures	TEFLARO.xml:S2:1405:8	measur	NNS	O	O
.	TEFLARO.xml:S2:1413:1	.	.	O	O

5.2	TEFLARO.xml:S2:1422:3	5.2	CD	O	O
Clostridium	TEFLARO.xml:S2:1426:11	clostridium	NNP	O	O
difficile	TEFLARO.xml:S2:1438:9	difficil	NN	O	O
-	TEFLARO.xml:S2:1447:1	-	:	O	O
Associated	TEFLARO.xml:S2:1448:10	associ	VBN	O	O
Diarrhea	TEFLARO.xml:S2:1459:8	diarrhea	NNP	O	O

Clostridium	TEFLARO.xml:S2:1474:11	clostridium	NN	B-AdverseReaction	B-AdverseReaction
difficile	TEFLARO.xml:S2:1486:9	difficil	NN	I-AdverseReaction	I-AdverseReaction
-	TEFLARO.xml:S2:1497:1	-	:	I-AdverseReaction	I-AdverseReaction
associated	TEFLARO.xml:S2:1498:10	associ	VBN	I-AdverseReaction	I-AdverseReaction
diarrhea	TEFLARO.xml:S2:1509:8	diarrhea	NN	I-AdverseReaction	I-AdverseReaction
(	TEFLARO.xml:S2:1518:1	(	(	O	O
CDAD	TEFLARO.xml:S2:1519:4	cdad	NNP	B-AdverseReaction	B-AdverseReaction
)	TEFLARO.xml:S2:1523:1	)	)	O	O
has	TEFLARO.xml:S2:1525:3	ha	VBZ	O	O
been	TEFLARO.xml:S2:1529:4	been	VBN	O	O
reported	TEFLARO.xml:S2:1534:8	report	VBN	O	O
for	TEFLARO.xml:S2:1543:3	for	IN	O	O
nearly	TEFLARO.xml:S2:1547:6	nearli	RB	O	O
all	TEFLARO.xml:S2:1554:3	all	DT	O	O
systemic	TEFLARO.xml:S2:1558:8	system	JJ	O	O
antibacterial	TEFLARO.xml:S2:1567:13	antibacteri	JJ	O	O
agents	TEFLARO.xml:S2:1581:6	agent	NNS	O	O
,	TEFLARO.xml:S2:1587:1	,	,	O	O
including	TEFLARO.xml:S2:1589:9	includ	VBG	O	O
Teflaro	TEFLARO.xml:S2:1599:7	teflaro	NNP	O	O
,	TEFLARO.xml:S2:1606:1	,	,	O	O
and	TEFLARO.xml:S2:1608:3	and	CC	O	O
may	TEFLARO.xml:S2:1612:3	may	MD	O	O
range	TEFLARO.xml:S2:1616:5	rang	VB	O	O
in	TEFLARO.xml:S2:1622:2	in	IN	O	O
severity	TEFLARO.xml:S2:1625:8	sever	NN	O	O
from	TEFLARO.xml:S2:1634:4	from	IN	O	O
mild	TEFLARO.xml:S2:1639:4	mild	JJ	O	O
diarrhea	TEFLARO.xml:S2:1644:8	diarrhea	NN	B-AdverseReaction	O
to	TEFLARO.xml:S2:1653:2	to	TO	O	O
fatal	TEFLARO.xml:S2:1656:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
colitis	TEFLARO.xml:S2:1662:7	coliti	NN	B-AdverseReaction	B-AdverseReaction
.	TEFLARO.xml:S2:1669:1	.	.	O	O

Treatment	TEFLARO.xml:S2:1675:9	treatment	NN	O	O
with	TEFLARO.xml:S2:1685:4	with	IN	O	O
antibacterial	TEFLARO.xml:S2:1690:13	antibacteri	JJ	O	O
agents	TEFLARO.xml:S2:1704:6	agent	NNS	O	O
alters	TEFLARO.xml:S2:1711:6	alter	VBZ	O	O
the	TEFLARO.xml:S2:1718:3	the	DT	O	O
normal	TEFLARO.xml:S2:1722:6	normal	JJ	O	O
flora	TEFLARO.xml:S2:1729:5	flora	NN	O	O
of	TEFLARO.xml:S2:1735:2	of	IN	O	O
the	TEFLARO.xml:S2:1738:3	the	DT	O	O
colon	TEFLARO.xml:S2:1742:5	colon	NN	O	O
and	TEFLARO.xml:S2:1748:3	and	CC	O	O
may	TEFLARO.xml:S2:1752:3	may	MD	O	O
permit	TEFLARO.xml:S2:1756:6	permit	VB	O	O
overgrowth	TEFLARO.xml:S2:1763:10	overgrowth	NN	O	O
of	TEFLARO.xml:S2:1774:2	of	IN	O	O
C.	TEFLARO.xml:S2:1777:2	C.	NNP	O	O
difficile	TEFLARO.xml:S2:1780:9	difficil	NN	O	O
.	TEFLARO.xml:S2:1791:1	.	.	O	O

C.	TEFLARO.xml:S2:1798:2	C.	NNP	O	O
difficile	TEFLARO.xml:S2:1801:9	difficil	NN	O	O
produces	TEFLARO.xml:S2:1812:8	produc	VBZ	O	O
toxins	TEFLARO.xml:S2:1821:6	toxin	VBZ	O	O
A	TEFLARO.xml:S2:1828:1	A	NNP	O	O
and	TEFLARO.xml:S2:1830:3	and	CC	O	O
B	TEFLARO.xml:S2:1834:1	B	NNP	O	O
which	TEFLARO.xml:S2:1836:5	which	WDT	O	O
contribute	TEFLARO.xml:S2:1842:10	contribut	VBP	O	O
to	TEFLARO.xml:S2:1853:2	to	TO	O	O
the	TEFLARO.xml:S2:1856:3	the	DT	O	O
development	TEFLARO.xml:S2:1860:11	develop	NN	O	O
of	TEFLARO.xml:S2:1872:2	of	IN	O	O
CDAD	TEFLARO.xml:S2:1875:4	cdad	NNP	O	O
.	TEFLARO.xml:S2:1879:1	.	.	O	O

Hypertoxin	TEFLARO.xml:S2:1881:10	hypertoxin	NNP	O	O
-	TEFLARO.xml:S2:1891:1	-	:	O	O
producing	TEFLARO.xml:S2:1892:9	produc	VBG	O	O
strains	TEFLARO.xml:S2:1902:7	strain	NNS	O	O
of	TEFLARO.xml:S2:1910:2	of	IN	O	O
C.	TEFLARO.xml:S2:1913:2	C.	NNP	O	O
difficile	TEFLARO.xml:S2:1916:9	difficil	NN	O	O
cause	TEFLARO.xml:S2:1927:5	caus	NN	O	O
increased	TEFLARO.xml:S2:1933:9	increas	VBD	O	O
morbidity	TEFLARO.xml:S2:1943:9	morbid	NN	O	O
and	TEFLARO.xml:S2:1953:3	and	CC	O	O
mortality	TEFLARO.xml:S2:1957:9	mortal	NN	O	O
,	TEFLARO.xml:S2:1966:1	,	,	O	O
as	TEFLARO.xml:S2:1968:2	as	IN	O	O
these	TEFLARO.xml:S2:1971:5	these	DT	O	O
infections	TEFLARO.xml:S2:1977:10	infect	NNS	O	O
can	TEFLARO.xml:S2:1988:3	can	MD	O	O
be	TEFLARO.xml:S2:1992:2	be	VB	O	O
refractory	TEFLARO.xml:S2:1995:10	refractori	JJ	O	O
to	TEFLARO.xml:S2:2006:2	to	TO	O	O
antimicrobial	TEFLARO.xml:S2:2009:13	antimicrobi	JJ	O	O
therapy	TEFLARO.xml:S2:2023:7	therapi	NN	O	O
and	TEFLARO.xml:S2:2031:3	and	CC	O	O
may	TEFLARO.xml:S2:2035:3	may	MD	O	O
require	TEFLARO.xml:S2:2039:7	requir	VB	O	O
colectomy	TEFLARO.xml:S2:2047:9	colectomi	NN	O	O
.	TEFLARO.xml:S2:2056:1	.	.	O	O

CDAD	TEFLARO.xml:S2:2058:4	cdad	NNP	O	O
must	TEFLARO.xml:S2:2063:4	must	MD	O	O
be	TEFLARO.xml:S2:2068:2	be	VB	O	O
considered	TEFLARO.xml:S2:2071:10	consid	VBN	O	O
in	TEFLARO.xml:S2:2082:2	in	IN	O	O
all	TEFLARO.xml:S2:2085:3	all	DT	O	O
patients	TEFLARO.xml:S2:2089:8	patient	NNS	O	O
who	TEFLARO.xml:S2:2098:3	who	WP	O	O
present	TEFLARO.xml:S2:2102:7	present	VBP	O	O
with	TEFLARO.xml:S2:2110:4	with	IN	O	O
diarrhea	TEFLARO.xml:S2:2115:8	diarrhea	NN	O	O
following	TEFLARO.xml:S2:2124:9	follow	VBG	O	O
antibiotic	TEFLARO.xml:S2:2134:10	antibiot	JJ	O	O
use	TEFLARO.xml:S2:2145:3	use	NN	O	O
.	TEFLARO.xml:S2:2148:1	.	.	O	O

Careful	TEFLARO.xml:S2:2150:7	care	JJ	O	O
medical	TEFLARO.xml:S2:2158:7	medic	JJ	O	O
history	TEFLARO.xml:S2:2166:7	histori	NN	O	O
is	TEFLARO.xml:S2:2174:2	is	VBZ	O	O
necessary	TEFLARO.xml:S2:2177:9	necessari	JJ	O	O
because	TEFLARO.xml:S2:2187:7	becaus	IN	O	O
CDAD	TEFLARO.xml:S2:2195:4	cdad	NNP	O	O
has	TEFLARO.xml:S2:2200:3	ha	VBZ	O	O
been	TEFLARO.xml:S2:2204:4	been	VBN	O	O
reported	TEFLARO.xml:S2:2209:8	report	VBN	O	O
to	TEFLARO.xml:S2:2218:2	to	TO	O	O
occur	TEFLARO.xml:S2:2221:5	occur	VB	O	O
more	TEFLARO.xml:S2:2227:4	more	JJR	O	O
than	TEFLARO.xml:S2:2232:4	than	IN	O	O
2	TEFLARO.xml:S2:2237:1	2	CD	O	O
months	TEFLARO.xml:S2:2239:6	month	NNS	O	O
after	TEFLARO.xml:S2:2246:5	after	IN	O	O
the	TEFLARO.xml:S2:2252:3	the	DT	O	O
administration	TEFLARO.xml:S2:2256:14	administr	NN	O	O
of	TEFLARO.xml:S2:2271:2	of	IN	O	O
antibacterial	TEFLARO.xml:S2:2274:13	antibacteri	JJ	O	O
agents	TEFLARO.xml:S2:2288:6	agent	NNS	O	O
.	TEFLARO.xml:S2:2294:1	.	.	O	O

If	TEFLARO.xml:S2:2300:2	If	IN	O	O
CDAD	TEFLARO.xml:S2:2303:4	cdad	NNP	O	O
is	TEFLARO.xml:S2:2308:2	is	VBZ	O	O
suspected	TEFLARO.xml:S2:2311:9	suspect	VBN	O	O
or	TEFLARO.xml:S2:2321:2	or	CC	O	O
confirmed	TEFLARO.xml:S2:2324:9	confirm	VBN	O	O
,	TEFLARO.xml:S2:2333:1	,	,	O	O
antibacterials	TEFLARO.xml:S2:2335:14	antibacteri	NNS	O	O
not	TEFLARO.xml:S2:2350:3	not	RB	O	O
directed	TEFLARO.xml:S2:2354:8	direct	VBN	O	O
against	TEFLARO.xml:S2:2363:7	against	IN	O	O
C.	TEFLARO.xml:S2:2371:2	C.	NNP	O	O
difficile	TEFLARO.xml:S2:2374:9	difficil	NN	O	O
should	TEFLARO.xml:S2:2385:6	should	MD	O	O
be	TEFLARO.xml:S2:2392:2	be	VB	O	O
discontinued	TEFLARO.xml:S2:2395:12	discontinu	VBN	O	O
,	TEFLARO.xml:S2:2407:1	,	,	O	O
if	TEFLARO.xml:S2:2409:2	if	IN	O	O
possible	TEFLARO.xml:S2:2412:8	possibl	JJ	O	O
.	TEFLARO.xml:S2:2420:1	.	.	O	O

Appropriate	TEFLARO.xml:S2:2422:11	appropri	NNP	O	O
fluid	TEFLARO.xml:S2:2434:5	fluid	NN	O	O
and	TEFLARO.xml:S2:2440:3	and	CC	O	O
electrolyte	TEFLARO.xml:S2:2444:11	electrolyt	JJ	O	O
management	TEFLARO.xml:S2:2456:10	manag	NN	O	O
,	TEFLARO.xml:S2:2466:1	,	,	O	O
protein	TEFLARO.xml:S2:2468:7	protein	NN	O	O
supplementation	TEFLARO.xml:S2:2476:15	supplement	NN	O	O
,	TEFLARO.xml:S2:2491:1	,	,	O	O
antibiotic	TEFLARO.xml:S2:2493:10	antibiot	JJ	O	O
treatment	TEFLARO.xml:S2:2504:9	treatment	NN	O	O
of	TEFLARO.xml:S2:2514:2	of	IN	O	O
C.	TEFLARO.xml:S2:2517:2	C.	NNP	O	O
difficile	TEFLARO.xml:S2:2520:9	difficil	NN	O	O
,	TEFLARO.xml:S2:2531:1	,	,	O	O
and	TEFLARO.xml:S2:2533:3	and	CC	O	O
surgical	TEFLARO.xml:S2:2537:8	surgic	JJ	O	O
evaluation	TEFLARO.xml:S2:2546:10	evalu	NN	O	O
should	TEFLARO.xml:S2:2557:6	should	MD	O	O
be	TEFLARO.xml:S2:2564:2	be	VB	O	O
instituted	TEFLARO.xml:S2:2567:10	institut	VBN	O	O
as	TEFLARO.xml:S2:2578:2	as	IN	O	O
clinically	TEFLARO.xml:S2:2581:10	clinic	RB	O	O
indicated	TEFLARO.xml:S2:2592:9	indic	JJ	O	O
[	TEFLARO.xml:S2:2602:1	[	NNP	O	O
see	TEFLARO.xml:S2:2603:3	see	VBP	O	O
Adverse	TEFLARO.xml:S2:2607:7	advers	JJ	O	O
Reactions	TEFLARO.xml:S2:2615:9	reaction	NNP	O	O
(	TEFLARO.xml:S2:2625:1	(	(	O	O
6.1	TEFLARO.xml:S2:2628:3	6.1	CD	O	O
)]	TEFLARO.xml:S2:2633:2	)]	NN	O	O
.	TEFLARO.xml:S2:2635:1	.	.	O	O

5.3	TEFLARO.xml:S2:2646:3	5.3	CD	O	O
Direct	TEFLARO.xml:S2:2650:6	direct	JJ	O	O
Coombs	TEFLARO.xml:S2:2657:6	coomb	NNP	O	O
Test	TEFLARO.xml:S2:2665:4	test	NNP	O	O
Seroconversion	TEFLARO.xml:S2:2670:14	seroconvers	NN	O	O

Seroconversion	TEFLARO.xml:S2:2690:14	seroconvers	NN	B-AdverseReaction	O
from	TEFLARO.xml:S2:2705:4	from	IN	I-AdverseReaction	O
a	TEFLARO.xml:S2:2710:1	a	DT	I-AdverseReaction	O
negative	TEFLARO.xml:S2:2712:8	neg	JJ	I-AdverseReaction	O
to	TEFLARO.xml:S2:2721:2	to	TO	I-AdverseReaction	O
a	TEFLARO.xml:S2:2724:1	a	DT	I-AdverseReaction	O
positive	TEFLARO.xml:S2:2726:8	posit	JJ	I-AdverseReaction	O
direct	TEFLARO.xml:S2:2735:6	direct	JJ	I-AdverseReaction	O
Coombs	TEFLARO.xml:S2:2742:6	coomb	NNP	I-AdverseReaction	O
test	TEFLARO.xml:S2:2750:4	test	NN	I-AdverseReaction	O
result	TEFLARO.xml:S2:2755:6	result	NN	I-AdverseReaction	O
occurred	TEFLARO.xml:S2:2762:8	occur	VBD	O	O
in	TEFLARO.xml:S2:2771:2	in	IN	O	O
120	TEFLARO.xml:S2:2774:3	120	CD	O	O
1114	TEFLARO.xml:S2:2778:4	1114	CD	O	O
(	TEFLARO.xml:S2:2783:1	(	(	O	O
10.8%	TEFLARO.xml:S2:2784:5	10.8%	CD	O	O
)	TEFLARO.xml:S2:2789:1	)	)	O	O
of	TEFLARO.xml:S2:2791:2	of	IN	O	O
patients	TEFLARO.xml:S2:2794:8	patient	NNS	O	O
receiving	TEFLARO.xml:S2:2803:9	receiv	VBG	O	O
Teflaro	TEFLARO.xml:S2:2813:7	teflaro	NNP	O	O
and	TEFLARO.xml:S2:2821:3	and	CC	O	O
49	TEFLARO.xml:S2:2825:2	49	CD	O	O
1116	TEFLARO.xml:S2:2828:4	1116	CD	O	O
(	TEFLARO.xml:S2:2833:1	(	(	O	O
4.4%	TEFLARO.xml:S2:2834:4	4.4%	CD	O	O
)	TEFLARO.xml:S2:2838:1	)	)	O	O
of	TEFLARO.xml:S2:2840:2	of	IN	O	O
patients	TEFLARO.xml:S2:2843:8	patient	NNS	O	O
receiving	TEFLARO.xml:S2:2852:9	receiv	VBG	O	O
comparator	TEFLARO.xml:S2:2862:10	compar	NN	O	O
drugs	TEFLARO.xml:S2:2873:5	drug	NNS	O	O
in	TEFLARO.xml:S2:2879:2	in	IN	O	O
the	TEFLARO.xml:S2:2882:3	the	DT	O	O
four	TEFLARO.xml:S2:2886:4	four	CD	O	O
pooled	TEFLARO.xml:S2:2891:6	pool	VBD	O	O
Phase	TEFLARO.xml:S2:2898:5	phase	NNP	O	O
3	TEFLARO.xml:S2:2904:1	3	CD	O	O
trials	TEFLARO.xml:S2:2906:6	trial	NNS	O	O
.	TEFLARO.xml:S2:2912:1	.	.	O	O

In	TEFLARO.xml:S2:2918:2	In	IN	O	O
the	TEFLARO.xml:S2:2921:3	the	DT	O	O
pooled	TEFLARO.xml:S2:2925:6	pool	JJ	O	O
Phase	TEFLARO.xml:S2:2932:5	phase	NNP	O	O
3	TEFLARO.xml:S2:2938:1	3	CD	O	O
CABP	TEFLARO.xml:S2:2940:4	cabp	NNP	O	O
trials	TEFLARO.xml:S2:2945:6	trial	NNS	O	O
,	TEFLARO.xml:S2:2951:1	,	,	O	O
51	TEFLARO.xml:S2:2953:2	51	CD	O	O
520	TEFLARO.xml:S2:2956:3	520	CD	O	O
(	TEFLARO.xml:S2:2960:1	(	(	O	O
9.8%	TEFLARO.xml:S2:2961:4	9.8%	CD	O	O
)	TEFLARO.xml:S2:2965:1	)	)	O	O
of	TEFLARO.xml:S2:2967:2	of	IN	O	O
Teflaro	TEFLARO.xml:S2:2970:7	teflaro	NNP	O	O
-	TEFLARO.xml:S2:2977:1	-	:	O	O
treated	TEFLARO.xml:S2:2978:7	treat	VBD	O	O
patients	TEFLARO.xml:S2:2986:8	patient	NNS	O	O
compared	TEFLARO.xml:S2:2995:8	compar	VBN	O	O
to	TEFLARO.xml:S2:3004:2	to	TO	O	O
24	TEFLARO.xml:S2:3007:2	24	CD	O	O
534	TEFLARO.xml:S2:3010:3	534	CD	O	O
(	TEFLARO.xml:S2:3014:1	(	(	O	O
4.5%	TEFLARO.xml:S2:3015:4	4.5%	CD	O	O
)	TEFLARO.xml:S2:3019:1	)	)	O	O
of	TEFLARO.xml:S2:3021:2	of	IN	O	O
ceftriaxone	TEFLARO.xml:S2:3024:11	ceftriaxon	NN	O	O
-	TEFLARO.xml:S2:3035:1	-	:	O	O
treated	TEFLARO.xml:S2:3036:7	treat	JJ	O	O
patients	TEFLARO.xml:S2:3044:8	patient	NNS	O	O
seroconverted	TEFLARO.xml:S2:3053:13	seroconvert	VBN	B-AdverseReaction	O
from	TEFLARO.xml:S2:3067:4	from	IN	I-AdverseReaction	O
a	TEFLARO.xml:S2:3072:1	a	DT	I-AdverseReaction	O
negative	TEFLARO.xml:S2:3074:8	neg	JJ	I-AdverseReaction	O
to	TEFLARO.xml:S2:3083:2	to	TO	I-AdverseReaction	O
a	TEFLARO.xml:S2:3086:1	a	DT	I-AdverseReaction	O
positive	TEFLARO.xml:S2:3088:8	posit	JJ	I-AdverseReaction	O
direct	TEFLARO.xml:S2:3097:6	direct	JJ	I-AdverseReaction	O
Coombs	TEFLARO.xml:S2:3104:6	coomb	NNP	I-AdverseReaction	O
test	TEFLARO.xml:S2:3112:4	test	NN	I-AdverseReaction	O
result	TEFLARO.xml:S2:3117:6	result	NN	I-AdverseReaction	O
.	TEFLARO.xml:S2:3123:1	.	.	O	O

No	TEFLARO.xml:S2:3125:2	No	DT	O	O
adverse	TEFLARO.xml:S2:3128:7	advers	JJ	O	O
reactions	TEFLARO.xml:S2:3136:9	reaction	NNS	O	O
representing	TEFLARO.xml:S2:3146:12	repres	VBG	O	O
hemolytic	TEFLARO.xml:S2:3159:9	hemolyt	JJ	B-AdverseReaction	B-AdverseReaction
anemia	TEFLARO.xml:S2:3169:6	anemia	NN	I-AdverseReaction	I-AdverseReaction
were	TEFLARO.xml:S2:3176:4	were	VBD	O	O
reported	TEFLARO.xml:S2:3181:8	report	VBN	O	O
in	TEFLARO.xml:S2:3190:2	in	IN	O	O
any	TEFLARO.xml:S2:3193:3	ani	DT	O	O
treatment	TEFLARO.xml:S2:3197:9	treatment	NN	O	O
group	TEFLARO.xml:S2:3207:5	group	NN	O	O
.	TEFLARO.xml:S2:3212:1	.	.	O	O

If	TEFLARO.xml:S2:3218:2	If	IN	O	O
anemia	TEFLARO.xml:S2:3221:6	anemia	JJ	O	O
develops	TEFLARO.xml:S2:3228:8	develop	NNS	O	O
during	TEFLARO.xml:S2:3237:6	dure	IN	O	O
or	TEFLARO.xml:S2:3244:2	or	CC	O	O
after	TEFLARO.xml:S2:3247:5	after	IN	O	O
treatment	TEFLARO.xml:S2:3253:9	treatment	NN	O	O
with	TEFLARO.xml:S2:3263:4	with	IN	O	O
Teflaro	TEFLARO.xml:S2:3268:7	teflaro	NNP	O	O
,	TEFLARO.xml:S2:3275:1	,	,	O	O
drug	TEFLARO.xml:S2:3277:4	drug	NN	O	O
-	TEFLARO.xml:S2:3281:1	-	:	O	O
induced	TEFLARO.xml:S2:3282:7	induc	VBN	O	O
hemolytic	TEFLARO.xml:S2:3290:9	hemolyt	JJ	O	O
anemia	TEFLARO.xml:S2:3300:6	anemia	NN	O	O
should	TEFLARO.xml:S2:3307:6	should	MD	O	O
be	TEFLARO.xml:S2:3314:2	be	VB	O	O
considered	TEFLARO.xml:S2:3317:10	consid	VBN	O	O
.	TEFLARO.xml:S2:3327:1	.	.	O	O

Diagnostic	TEFLARO.xml:S2:3329:10	diagnost	JJ	O	O
studies	TEFLARO.xml:S2:3340:7	studi	NNS	O	O
including	TEFLARO.xml:S2:3348:9	includ	VBG	O	O
a	TEFLARO.xml:S2:3358:1	a	DT	O	O
direct	TEFLARO.xml:S2:3360:6	direct	JJ	O	O
Coombs	TEFLARO.xml:S2:3367:6	coomb	NNP	O	O
test	TEFLARO.xml:S2:3375:4	test	NN	O	O
,	TEFLARO.xml:S2:3379:1	,	,	O	O
should	TEFLARO.xml:S2:3381:6	should	MD	O	O
be	TEFLARO.xml:S2:3388:2	be	VB	O	O
performed	TEFLARO.xml:S2:3391:9	perform	VBN	O	O
.	TEFLARO.xml:S2:3400:1	.	.	O	O

If	TEFLARO.xml:S2:3402:2	If	IN	O	O
drug	TEFLARO.xml:S2:3405:4	drug	NN	O	O
-	TEFLARO.xml:S2:3409:1	-	:	O	O
induced	TEFLARO.xml:S2:3410:7	induc	VBN	O	O
hemolytic	TEFLARO.xml:S2:3418:9	hemolyt	JJ	O	O
anemia	TEFLARO.xml:S2:3428:6	anemia	NN	O	O
is	TEFLARO.xml:S2:3435:2	is	VBZ	O	O
suspected	TEFLARO.xml:S2:3438:9	suspect	VBN	O	O
,	TEFLARO.xml:S2:3447:1	,	,	O	O
discontinuation	TEFLARO.xml:S2:3449:15	discontinu	NN	O	O
of	TEFLARO.xml:S2:3465:2	of	IN	O	O
Teflaro	TEFLARO.xml:S2:3468:7	teflaro	NNP	O	O
should	TEFLARO.xml:S2:3476:6	should	MD	O	O
be	TEFLARO.xml:S2:3483:2	be	VB	O	O
considered	TEFLARO.xml:S2:3486:10	consid	VBN	O	O
and	TEFLARO.xml:S2:3497:3	and	CC	O	O
supportive	TEFLARO.xml:S2:3501:10	support	JJ	O	O
care	TEFLARO.xml:S2:3512:4	care	NN	O	O
should	TEFLARO.xml:S2:3517:6	should	MD	O	O
be	TEFLARO.xml:S2:3524:2	be	VB	O	O
administered	TEFLARO.xml:S2:3527:12	administ	VBN	O	O
to	TEFLARO.xml:S2:3540:2	to	TO	O	O
the	TEFLARO.xml:S2:3543:3	the	DT	O	O
patient	TEFLARO.xml:S2:3547:7	patient	NN	O	O
(	TEFLARO.xml:S2:3555:1	(	(	O	O
i	TEFLARO.xml:S2:3556:1	i	JJ	O	O
.	TEFLARO.xml:S2:3557:1	.	.	O	O
e	TEFLARO.xml:S2:3558:1	e	NN	O	O
.	TEFLARO.xml:S2:3559:1	.	.	O	O

transfusion	TEFLARO.xml:S2:3561:11	transfus	NN	O	O
)	TEFLARO.xml:S2:3572:1	)	)	O	O
if	TEFLARO.xml:S2:3574:2	if	IN	O	O
clinically	TEFLARO.xml:S2:3577:10	clinic	RB	O	O
indicated	TEFLARO.xml:S2:3588:9	indic	VBN	O	O
.	TEFLARO.xml:S2:3597:1	.	.	O	O

5.4	TEFLARO.xml:S2:3606:3	5.4	CD	O	O
Development	TEFLARO.xml:S2:3610:11	develop	NNP	O	O
of	TEFLARO.xml:S2:3622:2	of	IN	O	O
Drug	TEFLARO.xml:S2:3625:4	drug	NNP	O	O
-	TEFLARO.xml:S2:3629:1	-	:	O	O
Resistant	TEFLARO.xml:S2:3630:9	resist	JJ	O	O
Bacteria	TEFLARO.xml:S2:3640:8	bacteria	NNS	O	O

Prescribing	TEFLARO.xml:S2:3654:11	prescrib	VBG	O	O
Teflaro	TEFLARO.xml:S2:3666:7	teflaro	NNP	O	O
in	TEFLARO.xml:S2:3674:2	in	IN	O	O
the	TEFLARO.xml:S2:3677:3	the	DT	O	O
absence	TEFLARO.xml:S2:3681:7	absenc	NN	O	O
of	TEFLARO.xml:S2:3689:2	of	IN	O	O
a	TEFLARO.xml:S2:3692:1	a	DT	O	O
proven	TEFLARO.xml:S2:3694:6	proven	NN	O	O
or	TEFLARO.xml:S2:3701:2	or	CC	O	O
strongly	TEFLARO.xml:S2:3704:8	strongli	RB	O	O
suspected	TEFLARO.xml:S2:3713:9	suspect	VBN	O	O
bacterial	TEFLARO.xml:S2:3723:9	bacteri	JJ	O	O
infection	TEFLARO.xml:S2:3733:9	infect	NN	O	O
is	TEFLARO.xml:S2:3743:2	is	VBZ	O	O
unlikely	TEFLARO.xml:S2:3746:8	unlik	JJ	O	O
to	TEFLARO.xml:S2:3755:2	to	TO	O	O
provide	TEFLARO.xml:S2:3758:7	provid	VB	O	O
benefit	TEFLARO.xml:S2:3766:7	benefit	NN	O	O
to	TEFLARO.xml:S2:3774:2	to	TO	O	O
the	TEFLARO.xml:S2:3777:3	the	DT	O	O
patient	TEFLARO.xml:S2:3781:7	patient	NN	O	O
and	TEFLARO.xml:S2:3789:3	and	CC	O	O
increases	TEFLARO.xml:S2:3793:9	increas	VBZ	O	O
the	TEFLARO.xml:S2:3803:3	the	DT	O	O
risk	TEFLARO.xml:S2:3807:4	risk	NN	O	O
of	TEFLARO.xml:S2:3812:2	of	IN	O	O
the	TEFLARO.xml:S2:3815:3	the	DT	O	O
development	TEFLARO.xml:S2:3819:11	develop	NN	O	O
of	TEFLARO.xml:S2:3831:2	of	IN	O	O
drug	TEFLARO.xml:S2:3834:4	drug	NN	O	O
-	TEFLARO.xml:S2:3838:1	-	:	O	O
resistant	TEFLARO.xml:S2:3839:9	resist	JJ	O	O
bacteria	TEFLARO.xml:S2:3849:8	bacteria	NNS	O	O
.	TEFLARO.xml:S2:3857:1	.	.	O	O
6	TIVICAY.xml:S1:4:1	6	CD	O	O
ADVERSE	TIVICAY.xml:S1:6:7	advers	JJ	O	O
REACTIONS	TIVICAY.xml:S1:14:9	reaction	NN	O	O

The	TIVICAY.xml:S1:27:3	the	DT	O	O
following	TIVICAY.xml:S1:31:9	follow	JJ	O	O
adverse	TIVICAY.xml:S1:41:7	advers	JJ	O	O
drug	TIVICAY.xml:S1:49:4	drug	NN	O	O
reactions	TIVICAY.xml:S1:54:9	reaction	NNS	O	O
(	TIVICAY.xml:S1:64:1	(	(	O	O
adverse	TIVICAY.xml:S1:65:7	advers	JJ	O	O
events	TIVICAY.xml:S1:73:6	event	NNS	O	O
assessed	TIVICAY.xml:S1:80:8	assess	VBD	O	O
as	TIVICAY.xml:S1:89:2	as	IN	O	O
causally	TIVICAY.xml:S1:92:8	causal	RB	O	O
related	TIVICAY.xml:S1:101:7	relat	VBN	O	O
by	TIVICAY.xml:S1:109:2	by	IN	O	O
the	TIVICAY.xml:S1:112:3	the	DT	O	O
investigator	TIVICAY.xml:S1:116:12	investig	NN	O	O
or	TIVICAY.xml:S1:129:2	or	CC	O	O
ADRs	TIVICAY.xml:S1:132:4	adr	NNP	O	O
)	TIVICAY.xml:S1:136:1	)	)	O	O
are	TIVICAY.xml:S1:138:3	are	VBP	O	O
discussed	TIVICAY.xml:S1:142:9	discuss	VBN	O	O
in	TIVICAY.xml:S1:152:2	in	IN	O	O
other	TIVICAY.xml:S1:155:5	other	JJ	O	O
sections	TIVICAY.xml:S1:161:8	section	NNS	O	O
of	TIVICAY.xml:S1:170:2	of	IN	O	O
the	TIVICAY.xml:S1:173:3	the	DT	O	O
labeling	TIVICAY.xml:S1:177:8	label	NN	O	O
:	TIVICAY.xml:S1:185:1	:	:	O	O

Hypersensitivity	TIVICAY.xml:S1:196:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	TIVICAY.xml:S1:213:9	reaction	NNS	O	I-AdverseReaction
[	TIVICAY.xml:S1:223:1	[	VBP	O	O
see	TIVICAY.xml:S1:224:3	see	VBP	O	O
Warnings	TIVICAY.xml:S1:228:8	warn	NNS	O	O
and	TIVICAY.xml:S1:237:3	and	CC	O	O
Precautions	TIVICAY.xml:S1:241:11	precaut	NNP	O	O
(	TIVICAY.xml:S1:253:1	(	(	O	O
5.1	TIVICAY.xml:S1:254:3	5.1	CD	O	O
)]	TIVICAY.xml:S1:257:2	)]	NN	O	O
.	TIVICAY.xml:S1:260:1	.	.	O	O

Effects	TIVICAY.xml:S1:269:7	effect	NNS	O	O
on	TIVICAY.xml:S1:277:2	on	IN	O	O
serum	TIVICAY.xml:S1:280:5	serum	NN	O	O
liver	TIVICAY.xml:S1:286:5	liver	NN	O	O
biochemistries	TIVICAY.xml:S1:292:14	biochemistri	NNS	O	O
in	TIVICAY.xml:S1:307:2	in	IN	O	O
patients	TIVICAY.xml:S1:310:8	patient	NNS	O	O
with	TIVICAY.xml:S1:319:4	with	IN	O	O
hepatitis	TIVICAY.xml:S1:324:9	hepat	NN	O	O
B	TIVICAY.xml:S1:334:1	B	NNP	O	O
or	TIVICAY.xml:S1:336:2	or	CC	O	O
C	TIVICAY.xml:S1:339:1	C	NNP	O	O
co	TIVICAY.xml:S1:341:2	co	SYM	O	O
-	TIVICAY.xml:S1:343:1	-	:	O	O
infection	TIVICAY.xml:S1:344:9	infect	NN	O	O
[	TIVICAY.xml:S1:354:1	[	FW	O	O
see	TIVICAY.xml:S1:355:3	see	VBP	O	O
Warnings	TIVICAY.xml:S1:359:8	warn	NNS	O	O
and	TIVICAY.xml:S1:368:3	and	CC	O	O
Precautions	TIVICAY.xml:S1:372:11	precaut	NNP	O	O
(	TIVICAY.xml:S1:384:1	(	(	O	O
5.2	TIVICAY.xml:S1:385:3	5.2	CD	O	O
)]	TIVICAY.xml:S1:388:2	)]	NN	O	O
.	TIVICAY.xml:S1:391:1	.	.	O	O

Fat	TIVICAY.xml:S1:400:3	fat	NNP	B-AdverseReaction	B-AdverseReaction
Redistribution	TIVICAY.xml:S1:404:14	redistribut	NNP	I-AdverseReaction	I-AdverseReaction
[	TIVICAY.xml:S1:419:1	[	NNP	O	O
see	TIVICAY.xml:S1:420:3	see	VBP	O	O
Warnings	TIVICAY.xml:S1:424:8	warn	NNP	O	O
and	TIVICAY.xml:S1:433:3	and	CC	O	O
Precautions	TIVICAY.xml:S1:437:11	precaut	NNP	O	O
(	TIVICAY.xml:S1:449:1	(	(	O	O
5.3	TIVICAY.xml:S1:450:3	5.3	CD	O	O
)]	TIVICAY.xml:S1:453:2	)]	NN	O	O
.	TIVICAY.xml:S1:456:1	.	.	O	O

Immune	TIVICAY.xml:S1:465:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
Reconstitution	TIVICAY.xml:S1:472:14	reconstitut	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	TIVICAY.xml:S1:487:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
[	TIVICAY.xml:S1:496:1	[	NNP	O	O
see	TIVICAY.xml:S1:497:3	see	VBP	O	O
Warnings	TIVICAY.xml:S1:501:8	warn	NNP	O	O
and	TIVICAY.xml:S1:510:3	and	CC	O	O
Precautions	TIVICAY.xml:S1:514:11	precaut	NNP	O	O
(	TIVICAY.xml:S1:526:1	(	(	O	O
5.4	TIVICAY.xml:S1:527:3	5.4	CD	O	O
)]	TIVICAY.xml:S1:530:2	)]	NN	O	O
.	TIVICAY.xml:S1:533:1	.	.	O	O

Because	TIVICAY.xml:S1:540:7	becaus	IN	O	O
clinical	TIVICAY.xml:S1:548:8	clinic	JJ	O	O
trials	TIVICAY.xml:S1:557:6	trial	NNS	O	O
are	TIVICAY.xml:S1:564:3	are	VBP	O	O
conducted	TIVICAY.xml:S1:568:9	conduct	VBN	O	O
under	TIVICAY.xml:S1:578:5	under	IN	O	O
widely	TIVICAY.xml:S1:584:6	wide	RB	O	O
varying	TIVICAY.xml:S1:591:7	vari	VBG	O	O
conditions	TIVICAY.xml:S1:599:10	condit	NNS	O	O
,	TIVICAY.xml:S1:609:1	,	,	O	O
adverse	TIVICAY.xml:S1:611:7	advers	JJ	O	O
reaction	TIVICAY.xml:S1:619:8	reaction	NN	O	O
rates	TIVICAY.xml:S1:628:5	rate	NNS	O	O
observed	TIVICAY.xml:S1:634:8	observ	VBD	O	O
in	TIVICAY.xml:S1:643:2	in	IN	O	O
the	TIVICAY.xml:S1:646:3	the	DT	O	O
clinical	TIVICAY.xml:S1:650:8	clinic	JJ	O	O
trials	TIVICAY.xml:S1:659:6	trial	NNS	O	O
of	TIVICAY.xml:S1:666:2	of	IN	O	O
a	TIVICAY.xml:S1:669:1	a	DT	O	O
drug	TIVICAY.xml:S1:671:4	drug	NN	O	O
cannot	TIVICAY.xml:S1:676:6	cannot	NN	O	O
be	TIVICAY.xml:S1:683:2	be	VB	O	O
directly	TIVICAY.xml:S1:686:8	directli	RB	O	O
compared	TIVICAY.xml:S1:695:8	compar	VBN	O	O
with	TIVICAY.xml:S1:704:4	with	IN	O	O
rates	TIVICAY.xml:S1:709:5	rate	NNS	O	O
in	TIVICAY.xml:S1:715:2	in	IN	O	O
the	TIVICAY.xml:S1:718:3	the	DT	O	O
clinical	TIVICAY.xml:S1:722:8	clinic	JJ	O	O
trials	TIVICAY.xml:S1:731:6	trial	NNS	O	O
of	TIVICAY.xml:S1:738:2	of	IN	O	O
another	TIVICAY.xml:S1:741:7	anoth	DT	O	O
drug	TIVICAY.xml:S1:749:4	drug	NN	O	O
and	TIVICAY.xml:S1:754:3	and	CC	O	O
may	TIVICAY.xml:S1:758:3	may	MD	O	O
not	TIVICAY.xml:S1:762:3	not	RB	O	O
reflect	TIVICAY.xml:S1:766:7	reflect	VB	O	O
the	TIVICAY.xml:S1:774:3	the	DT	O	O
rates	TIVICAY.xml:S1:778:5	rate	NNS	O	O
observed	TIVICAY.xml:S1:784:8	observ	VBD	O	O
in	TIVICAY.xml:S1:793:2	in	IN	O	O
practice	TIVICAY.xml:S1:796:8	practic	NN	O	O
.	TIVICAY.xml:S1:804:1	.	.	O	O

EXCERPT	TIVICAY.xml:S1:812:7	excerpt	NN	O	O

:	TIVICAY.xml:S1:819:1	:	:	O	O
The	TIVICAY.xml:S1:823:3	the	DT	O	O
most	TIVICAY.xml:S1:827:4	most	RBS	O	O
common	TIVICAY.xml:S1:832:6	common	JJ	O	O
adverse	TIVICAY.xml:S1:839:7	advers	JJ	O	O
reactions	TIVICAY.xml:S1:847:9	reaction	NNS	O	O
of	TIVICAY.xml:S1:857:2	of	IN	O	O
moderate	TIVICAY.xml:S1:860:8	moder	JJ	O	O
to	TIVICAY.xml:S1:869:2	to	TO	O	O
severe	TIVICAY.xml:S1:872:6	sever	JJ	O	O
intensity	TIVICAY.xml:S1:879:9	intens	NN	O	O
and	TIVICAY.xml:S1:889:3	and	CC	O	O
incidence	TIVICAY.xml:S1:893:9	incid	NN	O	O
at	TIVICAY.xml:S1:903:2	at	IN	O	O
least	TIVICAY.xml:S1:906:5	least	JJS	O	O
2%	TIVICAY.xml:S1:912:2	2%	CD	O	O
(	TIVICAY.xml:S1:915:1	(	(	O	O
in	TIVICAY.xml:S1:916:2	in	IN	O	O
those	TIVICAY.xml:S1:919:5	those	DT	O	O
receiving	TIVICAY.xml:S1:925:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S1:935:7	tivicay	NNP	O	O
in	TIVICAY.xml:S1:943:2	in	IN	O	O
any	TIVICAY.xml:S1:946:3	ani	DT	O	O
one	TIVICAY.xml:S1:950:3	one	CD	O	O
adult	TIVICAY.xml:S1:954:5	adult	NN	O	O
trial	TIVICAY.xml:S1:960:5	trial	NN	O	O
)	TIVICAY.xml:S1:965:1	)	)	O	O
are	TIVICAY.xml:S1:967:3	are	VBP	O	O
insomnia	TIVICAY.xml:S1:971:8	insomnia	JJ	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S1:979:1	,	,	O	O
fatigue	TIVICAY.xml:S1:981:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S1:988:1	,	,	O	O
and	TIVICAY.xml:S1:990:3	and	CC	O	O
headache	TIVICAY.xml:S1:994:8	headach	NN	B-AdverseReaction	B-AdverseReaction
.	TIVICAY.xml:S1:1002:1	.	.	O	O

(	TIVICAY.xml:S1:1004:1	(	(	O	O
6.1	TIVICAY.xml:S1:1007:3	6.1	CD	O	O
)	TIVICAY.xml:S1:1012:1	)	)	O	O

To	TIVICAY.xml:S1:1020:2	To	TO	O	O
report	TIVICAY.xml:S1:1023:6	report	VB	O	O
SUSPECTED	TIVICAY.xml:S1:1030:9	suspect	NNP	O	O
ADVERSE	TIVICAY.xml:S1:1040:7	advers	NNP	O	O
REACTIONS	TIVICAY.xml:S1:1048:9	reaction	NNP	O	O
,	TIVICAY.xml:S1:1057:1	,	,	O	O
contact	TIVICAY.xml:S1:1059:7	contact	NN	O	O
ViiV	TIVICAY.xml:S1:1067:4	viiv	NNP	O	O
Healthcare	TIVICAY.xml:S1:1072:10	healthcar	NNP	O	O
at	TIVICAY.xml:S1:1083:2	at	IN	O	O
1	TIVICAY.xml:S1:1086:1	1	CD	O	O
-	TIVICAY.xml:S1:1087:1	-	:	O	O
877	TIVICAY.xml:S1:1088:3	877	CD	O	O
-	TIVICAY.xml:S1:1091:1	-	:	O	O
844	TIVICAY.xml:S1:1092:3	844	CD	O	O
-	TIVICAY.xml:S1:1095:1	-	:	O	O
8872	TIVICAY.xml:S1:1096:4	8872	CD	O	O
or	TIVICAY.xml:S1:1101:2	or	CC	O	O
FDA	TIVICAY.xml:S1:1104:3	fda	NNP	O	O
at	TIVICAY.xml:S1:1108:2	at	IN	O	O
1	TIVICAY.xml:S1:1111:1	1	CD	O	O
-	TIVICAY.xml:S1:1112:1	-	:	O	O
800	TIVICAY.xml:S1:1113:3	800	CD	O	O
-	TIVICAY.xml:S1:1116:1	-	:	O	O
FDA	TIVICAY.xml:S1:1117:3	fda	NNP	O	O
-	TIVICAY.xml:S1:1120:1	-	:	O	O
1088	TIVICAY.xml:S1:1121:4	1088	CD	O	O
or	TIVICAY.xml:S1:1126:2	or	CC	O	O
www	TIVICAY.xml:S1:1130:3	www	VB	O	O
.	TIVICAY.xml:S1:1133:1	.	.	O	O
fda	TIVICAY.xml:S1:1134:3	fda	NN	O	O
.	TIVICAY.xml:S1:1137:1	.	.	O	O
gov	TIVICAY.xml:S1:1138:3	gov	NN	O	O
medwatch	TIVICAY.xml:S1:1142:8	medwatch	NN	O	O

6.1	TIVICAY.xml:S1:1163:3	6.1	CD	O	O

Clinical	TIVICAY.xml:S1:1167:8	clinic	JJ	O	O
Trials	TIVICAY.xml:S1:1176:6	trial	NNS	O	O
Experience	TIVICAY.xml:S1:1183:10	experi	NN	O	O
in	TIVICAY.xml:S1:1194:2	in	IN	O	O
Adult	TIVICAY.xml:S1:1197:5	adult	NNP	O	O
Subjects	TIVICAY.xml:S1:1203:8	subject	NNS	O	O

Treatment	TIVICAY.xml:S1:1217:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:1228:1	-	:	O	O
emergent	TIVICAY.xml:S1:1231:8	emerg	JJ	O	O
Adverse	TIVICAY.xml:S1:1240:7	advers	JJ	O	O
Drug	TIVICAY.xml:S1:1248:4	drug	NNP	O	O
Reactions	TIVICAY.xml:S1:1253:9	reaction	NNP	O	O
(	TIVICAY.xml:S1:1263:1	(	(	O	O
ADRs	TIVICAY.xml:S1:1264:4	adr	NNP	O	O
)	TIVICAY.xml:S1:1268:1	)	)	O	O

Treatment	TIVICAY.xml:S1:1278:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:1287:1	-	:	O	O
naive	TIVICAY.xml:S1:1288:5	naiv	JJ	O	O
Subjects	TIVICAY.xml:S1:1294:8	subject	NNS	O	O
:	TIVICAY.xml:S1:1304:1	:	:	O	O
The	TIVICAY.xml:S1:1306:3	the	DT	O	O
safety	TIVICAY.xml:S1:1310:6	safeti	NN	O	O
assessment	TIVICAY.xml:S1:1317:10	assess	NN	O	O
of	TIVICAY.xml:S1:1328:2	of	IN	O	O
TIVICAY	TIVICAY.xml:S1:1331:7	tivicay	NNP	O	O
in	TIVICAY.xml:S1:1339:2	in	IN	O	O
HIV	TIVICAY.xml:S1:1342:3	hiv	NNP	O	O
-	TIVICAY.xml:S1:1345:1	-	:	O	O
1	TIVICAY.xml:S1:1346:1	1	CD	O	O
-	TIVICAY.xml:S1:1347:1	-	:	O	O
infected	TIVICAY.xml:S1:1348:8	infect	VBN	O	O
treatment	TIVICAY.xml:S1:1357:9	treatment	NN	O	O
-	TIVICAY.xml:S1:1366:1	-	:	O	O
naive	TIVICAY.xml:S1:1367:5	naiv	JJ	O	O
subjects	TIVICAY.xml:S1:1373:8	subject	NNS	O	O
is	TIVICAY.xml:S1:1382:2	is	VBZ	O	O
based	TIVICAY.xml:S1:1385:5	base	VBN	O	O
on	TIVICAY.xml:S1:1391:2	on	IN	O	O
the	TIVICAY.xml:S1:1394:3	the	DT	O	O
analyses	TIVICAY.xml:S1:1398:8	analys	NNS	O	O
of	TIVICAY.xml:S1:1407:2	of	IN	O	O
96	TIVICAY.xml:S1:1410:2	96	CD	O	O
-	TIVICAY.xml:S1:1412:1	-	:	O	O
week	TIVICAY.xml:S1:1413:4	week	NN	O	O
data	TIVICAY.xml:S1:1418:4	data	NNS	O	O
from	TIVICAY.xml:S1:1423:4	from	IN	O	O
2	TIVICAY.xml:S1:1428:1	2	CD	O	O
international	TIVICAY.xml:S1:1430:13	intern	JJ	O	O
,	TIVICAY.xml:S1:1443:1	,	,	O	O
multicenter	TIVICAY.xml:S1:1445:11	multicent	NN	O	O
,	TIVICAY.xml:S1:1456:1	,	,	O	O
double	TIVICAY.xml:S1:1458:6	doubl	JJ	O	O
-	TIVICAY.xml:S1:1464:1	-	:	O	O
blind	TIVICAY.xml:S1:1465:5	blind	NN	O	O
trials	TIVICAY.xml:S1:1471:6	trial	NNS	O	O
,	TIVICAY.xml:S1:1477:1	,	,	O	O
SPRING	TIVICAY.xml:S1:1479:6	spring	NNP	O	O
-	TIVICAY.xml:S1:1485:1	-	:	O	O
2	TIVICAY.xml:S1:1486:1	2	CD	O	O
(	TIVICAY.xml:S1:1488:1	(	(	O	O
ING113086	TIVICAY.xml:S1:1489:9	ing113086	NNP	O	O
)	TIVICAY.xml:S1:1498:1	)	)	O	O
and	TIVICAY.xml:S1:1500:3	and	CC	O	O
SINGLE	TIVICAY.xml:S1:1504:6	singl	NNP	O	O
(	TIVICAY.xml:S1:1511:1	(	(	O	O
ING114467	TIVICAY.xml:S1:1512:9	ing114467	NNP	O	O
)	TIVICAY.xml:S1:1521:1	)	)	O	O
and	TIVICAY.xml:S1:1523:3	and	CC	O	O
48	TIVICAY.xml:S1:1527:2	48	CD	O	O
-	TIVICAY.xml:S1:1529:1	-	:	O	O
week	TIVICAY.xml:S1:1530:4	week	NN	O	O
data	TIVICAY.xml:S1:1535:4	data	NNS	O	O
from	TIVICAY.xml:S1:1540:4	from	IN	O	O
the	TIVICAY.xml:S1:1545:3	the	DT	O	O
international	TIVICAY.xml:S1:1549:13	intern	JJ	O	O
,	TIVICAY.xml:S1:1562:1	,	,	O	O
multicenter	TIVICAY.xml:S1:1564:11	multicent	NN	O	O
,	TIVICAY.xml:S1:1575:1	,	,	O	O
open	TIVICAY.xml:S1:1577:4	open	JJ	O	O
-	TIVICAY.xml:S1:1581:1	-	:	O	O
label	TIVICAY.xml:S1:1582:5	label	NN	O	O
FLAMINGO	TIVICAY.xml:S1:1588:8	flamingo	NNP	O	O
(	TIVICAY.xml:S1:1597:1	(	(	O	O
ING114915	TIVICAY.xml:S1:1598:9	ing114915	NNP	O	O
)	TIVICAY.xml:S1:1607:1	)	)	O	O
trial	TIVICAY.xml:S1:1609:5	trial	NN	O	O
.	TIVICAY.xml:S1:1614:1	.	.	O	O

In	TIVICAY.xml:S1:1620:2	In	IN	O	O
SPRING	TIVICAY.xml:S1:1623:6	spring	NNP	O	O
-	TIVICAY.xml:S1:1629:1	-	:	O	O
2	TIVICAY.xml:S1:1630:1	2	CD	O	O
,	TIVICAY.xml:S1:1631:1	,	,	O	O
822	TIVICAY.xml:S1:1633:3	822	CD	O	O
subjects	TIVICAY.xml:S1:1637:8	subject	NNS	O	O
were	TIVICAY.xml:S1:1646:4	were	VBD	O	O
randomized	TIVICAY.xml:S1:1651:10	random	VBN	O	O
and	TIVICAY.xml:S1:1662:3	and	CC	O	O
received	TIVICAY.xml:S1:1666:8	receiv	VBN	O	O
at	TIVICAY.xml:S1:1675:2	at	IN	O	O
least	TIVICAY.xml:S1:1678:5	least	JJS	O	O
1	TIVICAY.xml:S1:1684:1	1	CD	O	O
dose	TIVICAY.xml:S1:1686:4	dose	NN	O	O
of	TIVICAY.xml:S1:1691:2	of	IN	O	O
either	TIVICAY.xml:S1:1694:6	either	DT	O	O
TIVICAY	TIVICAY.xml:S1:1701:7	tivicay	NNP	O	O
50	TIVICAY.xml:S1:1709:2	50	CD	O	O
mg	TIVICAY.xml:S1:1712:2	mg	NN	O	O
once	TIVICAY.xml:S1:1715:4	onc	RB	O	O
daily	TIVICAY.xml:S1:1720:5	daili	JJ	O	O
or	TIVICAY.xml:S1:1726:2	or	CC	O	O
raltegravir	TIVICAY.xml:S1:1729:11	raltegravir	JJ	O	O
400	TIVICAY.xml:S1:1741:3	400	CD	O	O
mg	TIVICAY.xml:S1:1745:2	mg	JJ	O	O
twice	TIVICAY.xml:S1:1748:5	twice	RB	O	O
daily	TIVICAY.xml:S1:1754:5	daili	RB	O	O
,	TIVICAY.xml:S1:1759:1	,	,	O	O
both	TIVICAY.xml:S1:1761:4	both	DT	O	O
in	TIVICAY.xml:S1:1766:2	in	IN	O	O
combination	TIVICAY.xml:S1:1769:11	combin	NN	O	O
with	TIVICAY.xml:S1:1781:4	with	IN	O	O
fixed	TIVICAY.xml:S1:1786:5	fix	JJ	O	O
-	TIVICAY.xml:S1:1791:1	-	:	O	O
dose	TIVICAY.xml:S1:1792:4	dose	JJ	O	O
dual	TIVICAY.xml:S1:1797:4	dual	JJ	O	O
nucleoside	TIVICAY.xml:S1:1802:10	nucleosid	JJ	O	O
reverse	TIVICAY.xml:S1:1813:7	revers	NN	O	O
transcriptase	TIVICAY.xml:S1:1821:13	transcriptas	NN	O	O
inhibitor	TIVICAY.xml:S1:1835:9	inhibitor	NN	O	O
(	TIVICAY.xml:S1:1845:1	(	(	O	O
NRTI	TIVICAY.xml:S1:1846:4	nrti	NNP	O	O
)	TIVICAY.xml:S1:1850:1	)	)	O	O
treatment	TIVICAY.xml:S1:1852:9	treatment	NN	O	O
(	TIVICAY.xml:S1:1862:1	(	(	O	O
either	TIVICAY.xml:S1:1863:6	either	CC	O	O
abacavir	TIVICAY.xml:S1:1870:8	abacavir	VB	O	O
sulfate	TIVICAY.xml:S1:1879:7	sulfat	NN	O	O
and	TIVICAY.xml:S1:1887:3	and	CC	O	O
lamivudine	TIVICAY.xml:S1:1891:10	lamivudin	NN	O	O
[	TIVICAY.xml:S1:1902:1	[	NN	O	O
EPZICOM	TIVICAY.xml:S1:1903:7	epzicom	NNP	O	O
(	TIVICAY.xml:S1:1912:1	(	(	O	O
r	TIVICAY.xml:S1:1913:1	r	NN	O	O
)	TIVICAY.xml:S1:1914:1	)	)	O	O
]	TIVICAY.xml:S1:1917:1	]	NN	O	O
or	TIVICAY.xml:S1:1919:2	or	CC	O	O
emtricitabine	TIVICAY.xml:S1:1922:13	emtricitabin	VB	O	O
tenofovir	TIVICAY.xml:S1:1936:9	tenofovir	JJ	O	O
[	TIVICAY.xml:S1:1946:1	[	NNP	O	O
TRUVADA	TIVICAY.xml:S1:1947:7	truvada	NNP	O	O
(	TIVICAY.xml:S1:1956:1	(	(	O	O
r	TIVICAY.xml:S1:1957:1	r	NN	O	O
)	TIVICAY.xml:S1:1958:1	)	)	O	O
])	TIVICAY.xml:S1:1961:2	])	NN	O	O
.	TIVICAY.xml:S1:1963:1	.	.	O	O

There	TIVICAY.xml:S1:1965:5	there	EX	O	O
were	TIVICAY.xml:S1:1971:4	were	VBD	O	O
808	TIVICAY.xml:S1:1976:3	808	CD	O	O
subjects	TIVICAY.xml:S1:1980:8	subject	NNS	O	O
included	TIVICAY.xml:S1:1989:8	includ	VBN	O	O
in	TIVICAY.xml:S1:1998:2	in	IN	O	O
the	TIVICAY.xml:S1:2001:3	the	DT	O	O
efficacy	TIVICAY.xml:S1:2005:8	efficaci	NN	O	O
and	TIVICAY.xml:S1:2014:3	and	CC	O	O
safety	TIVICAY.xml:S1:2018:6	safeti	NN	O	O
analyses	TIVICAY.xml:S1:2025:8	analys	NNS	O	O
.	TIVICAY.xml:S1:2033:1	.	.	O	O

Through	TIVICAY.xml:S1:2035:7	through	IN	O	O
96	TIVICAY.xml:S1:2043:2	96	CD	O	O
weeks	TIVICAY.xml:S1:2046:5	week	NNS	O	O
,	TIVICAY.xml:S1:2051:1	,	,	O	O
the	TIVICAY.xml:S1:2053:3	the	DT	O	O
rate	TIVICAY.xml:S1:2057:4	rate	NN	O	O
of	TIVICAY.xml:S1:2062:2	of	IN	O	O
adverse	TIVICAY.xml:S1:2065:7	advers	JJ	O	O
events	TIVICAY.xml:S1:2073:6	event	NNS	O	O
leading	TIVICAY.xml:S1:2080:7	lead	VBG	O	O
to	TIVICAY.xml:S1:2088:2	to	TO	O	O
discontinuation	TIVICAY.xml:S1:2091:15	discontinu	NN	O	O
was	TIVICAY.xml:S1:2107:3	wa	VBD	O	O
2%	TIVICAY.xml:S1:2111:2	2%	CD	O	O
in	TIVICAY.xml:S1:2114:2	in	IN	O	O
both	TIVICAY.xml:S1:2117:4	both	DT	O	O
treatment	TIVICAY.xml:S1:2122:9	treatment	NN	O	O
arms	TIVICAY.xml:S1:2132:4	arm	NNS	O	O
.	TIVICAY.xml:S1:2136:1	.	.	O	O

In	TIVICAY.xml:S1:2142:2	In	IN	O	O
SINGLE	TIVICAY.xml:S1:2145:6	singl	NNP	O	O
,	TIVICAY.xml:S1:2151:1	,	,	O	O
833	TIVICAY.xml:S1:2153:3	833	CD	O	O
subjects	TIVICAY.xml:S1:2157:8	subject	NNS	O	O
were	TIVICAY.xml:S1:2166:4	were	VBD	O	O
randomized	TIVICAY.xml:S1:2171:10	random	VBN	O	O
and	TIVICAY.xml:S1:2182:3	and	CC	O	O
received	TIVICAY.xml:S1:2186:8	receiv	VBN	O	O
at	TIVICAY.xml:S1:2195:2	at	IN	O	O
least	TIVICAY.xml:S1:2198:5	least	JJS	O	O
1	TIVICAY.xml:S1:2204:1	1	CD	O	O
dose	TIVICAY.xml:S1:2206:4	dose	NN	O	O
of	TIVICAY.xml:S1:2211:2	of	IN	O	O
either	TIVICAY.xml:S1:2214:6	either	DT	O	O
TIVICAY	TIVICAY.xml:S1:2221:7	tivicay	NNP	O	O
50	TIVICAY.xml:S1:2229:2	50	CD	O	O
mg	TIVICAY.xml:S1:2232:2	mg	NN	O	O
with	TIVICAY.xml:S1:2235:4	with	IN	O	O
fixed	TIVICAY.xml:S1:2240:5	fix	JJ	O	O
-	TIVICAY.xml:S1:2245:1	-	:	O	O
dose	TIVICAY.xml:S1:2246:4	dose	NN	O	O
abacavir	TIVICAY.xml:S1:2251:8	abacavir	JJ	O	O
sulfate	TIVICAY.xml:S1:2260:7	sulfat	NN	O	O
and	TIVICAY.xml:S1:2268:3	and	CC	O	O
lamivudine	TIVICAY.xml:S1:2272:10	lamivudin	NN	O	O
(	TIVICAY.xml:S1:2283:1	(	(	O	O
EPZICOM	TIVICAY.xml:S1:2284:7	epzicom	NNP	O	O
)	TIVICAY.xml:S1:2291:1	)	)	O	O
once	TIVICAY.xml:S1:2293:4	onc	RB	O	O
daily	TIVICAY.xml:S1:2298:5	daili	JJ	O	O
or	TIVICAY.xml:S1:2304:2	or	CC	O	O
fixed	TIVICAY.xml:S1:2307:5	fix	VBN	O	O
-	TIVICAY.xml:S1:2312:1	-	:	O	O
dose	TIVICAY.xml:S1:2313:4	dose	NN	O	O
efavirenz	TIVICAY.xml:S1:2318:9	efavirenz	JJ	O	O
emtricitabine	TIVICAY.xml:S1:2328:13	emtricitabin	NN	O	O
tenofovir	TIVICAY.xml:S1:2342:9	tenofovir	NN	O	O
(	TIVICAY.xml:S1:2352:1	(	(	O	O
ATRIPLA	TIVICAY.xml:S1:2353:7	atripla	NNP	O	O
(	TIVICAY.xml:S1:2362:1	(	(	O	O
r	TIVICAY.xml:S1:2363:1	r	NN	O	O
)	TIVICAY.xml:S1:2364:1	)	)	O	O
)	TIVICAY.xml:S1:2367:1	)	)	O	O
once	TIVICAY.xml:S1:2369:4	onc	RB	O	O
daily	TIVICAY.xml:S1:2374:5	daili	JJ	O	O
.	TIVICAY.xml:S1:2379:1	.	.	O	O

Through	TIVICAY.xml:S1:2381:7	through	IN	O	O
96	TIVICAY.xml:S1:2389:2	96	CD	O	O
weeks	TIVICAY.xml:S1:2392:5	week	NNS	O	O
,	TIVICAY.xml:S1:2397:1	,	,	O	O
the	TIVICAY.xml:S1:2399:3	the	DT	O	O
rates	TIVICAY.xml:S1:2403:5	rate	NNS	O	O
of	TIVICAY.xml:S1:2409:2	of	IN	O	O
adverse	TIVICAY.xml:S1:2412:7	advers	JJ	O	O
events	TIVICAY.xml:S1:2420:6	event	NNS	O	O
leading	TIVICAY.xml:S1:2427:7	lead	VBG	O	O
to	TIVICAY.xml:S1:2435:2	to	TO	O	O
discontinuation	TIVICAY.xml:S1:2438:15	discontinu	NN	O	O
were	TIVICAY.xml:S1:2454:4	were	VBD	O	O
3%	TIVICAY.xml:S1:2459:2	3%	CD	O	O
in	TIVICAY.xml:S1:2462:2	in	IN	O	O
subjects	TIVICAY.xml:S1:2465:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:2474:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S1:2484:7	tivicay	NNP	O	O
50	TIVICAY.xml:S1:2492:2	50	CD	O	O
mg	TIVICAY.xml:S1:2495:2	mg	NN	O	O
once	TIVICAY.xml:S1:2498:4	onc	RB	O	O
daily	TIVICAY.xml:S1:2503:5	daili	JJ	O	O
EPZICOM	TIVICAY.xml:S1:2511:7	epzicom	NNP	O	O
and	TIVICAY.xml:S1:2519:3	and	CC	O	O
12%	TIVICAY.xml:S1:2523:3	12%	CD	O	O
in	TIVICAY.xml:S1:2527:2	in	IN	O	O
subjects	TIVICAY.xml:S1:2530:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:2539:9	receiv	VBG	O	O
ATRIPLA	TIVICAY.xml:S1:2549:7	atripla	NNP	O	O
once	TIVICAY.xml:S1:2557:4	onc	RB	O	O
daily	TIVICAY.xml:S1:2562:5	daili	RB	O	O
.	TIVICAY.xml:S1:2567:1	.	.	O	O

Treatment	TIVICAY.xml:S1:2573:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:2582:1	-	:	O	O
emergent	TIVICAY.xml:S1:2583:8	emerg	NN	O	O
ADRs	TIVICAY.xml:S1:2592:4	adr	NNP	O	O
of	TIVICAY.xml:S1:2597:2	of	IN	O	O
moderate	TIVICAY.xml:S1:2600:8	moder	JJ	O	O
to	TIVICAY.xml:S1:2609:2	to	TO	O	O
severe	TIVICAY.xml:S1:2612:6	sever	JJ	O	O
intensity	TIVICAY.xml:S1:2619:9	intens	NN	O	O
observed	TIVICAY.xml:S1:2629:8	observ	VBN	O	O
in	TIVICAY.xml:S1:2638:2	in	IN	O	O
at	TIVICAY.xml:S1:2641:2	at	IN	O	O
least	TIVICAY.xml:S1:2644:5	least	JJS	O	O
2%	TIVICAY.xml:S1:2650:2	2%	CD	O	O
of	TIVICAY.xml:S1:2653:2	of	IN	O	O
subjects	TIVICAY.xml:S1:2656:8	subject	NNS	O	O
in	TIVICAY.xml:S1:2665:2	in	IN	O	O
either	TIVICAY.xml:S1:2668:6	either	DT	O	O
treatment	TIVICAY.xml:S1:2675:9	treatment	NN	O	O
arm	TIVICAY.xml:S1:2685:3	arm	NN	O	O
in	TIVICAY.xml:S1:2689:2	in	IN	O	O
SPRING	TIVICAY.xml:S1:2692:6	spring	NN	O	O
-	TIVICAY.xml:S1:2698:1	-	:	O	O
2	TIVICAY.xml:S1:2699:1	2	CD	O	O
and	TIVICAY.xml:S1:2701:3	and	CC	O	O
SINGLE	TIVICAY.xml:S1:2705:6	singl	NNP	O	O
trials	TIVICAY.xml:S1:2712:6	trial	NNS	O	O
are	TIVICAY.xml:S1:2719:3	are	VBP	O	O
provided	TIVICAY.xml:S1:2723:8	provid	VBN	O	O
in	TIVICAY.xml:S1:2732:2	in	IN	O	O
Table	TIVICAY.xml:S1:2735:5	tabl	JJ	O	O
2	TIVICAY.xml:S1:2741:1	2	CD	O	O
.	TIVICAY.xml:S1:2742:1	.	.	O	O

Side	TIVICAY.xml:S1:2744:4	side	NNP	O	O
-	TIVICAY.xml:S1:2748:1	-	:	O	O
by	TIVICAY.xml:S1:2749:2	by	IN	O	O
-	TIVICAY.xml:S1:2751:1	-	:	O	O
side	TIVICAY.xml:S1:2752:4	side	NN	O	O
tabulation	TIVICAY.xml:S1:2757:10	tabul	NN	O	O
is	TIVICAY.xml:S1:2768:2	is	VBZ	O	O
to	TIVICAY.xml:S1:2771:2	to	TO	O	O
simplify	TIVICAY.xml:S1:2774:8	simplifi	VB	O	O
presentation	TIVICAY.xml:S1:2783:12	present	NN	O	O
;	TIVICAY.xml:S1:2795:1	;	:	O	O
direct	TIVICAY.xml:S1:2797:6	direct	JJ	O	O
comparisons	TIVICAY.xml:S1:2804:11	comparison	NNS	O	O
across	TIVICAY.xml:S1:2816:6	across	IN	O	O
trials	TIVICAY.xml:S1:2823:6	trial	NNS	O	O
should	TIVICAY.xml:S1:2830:6	should	MD	O	O
not	TIVICAY.xml:S1:2837:3	not	RB	O	O
be	TIVICAY.xml:S1:2841:2	be	VB	O	O
made	TIVICAY.xml:S1:2844:4	made	VBN	O	O
due	TIVICAY.xml:S1:2849:3	due	JJ	O	O
to	TIVICAY.xml:S1:2853:2	to	TO	O	O
differing	TIVICAY.xml:S1:2856:9	differ	VBG	O	O
trial	TIVICAY.xml:S1:2866:5	trial	NN	O	O
designs	TIVICAY.xml:S1:2872:7	design	NNS	O	O
.	TIVICAY.xml:S1:2879:1	.	.	O	O

Table	TIVICAY.xml:S1:2885:5	tabl	JJ	O	O
2	TIVICAY.xml:S1:2891:1	2	CD	O	O
.	TIVICAY.xml:S1:2892:1	.	.	O	O

Treatment	TIVICAY.xml:S1:2894:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:2903:1	-	:	O	O
emergent	TIVICAY.xml:S1:2904:8	emerg	JJ	O	O
Adverse	TIVICAY.xml:S1:2913:7	advers	JJ	O	O
Drug	TIVICAY.xml:S1:2921:4	drug	NNP	O	O
Reactions	TIVICAY.xml:S1:2926:9	reaction	NNP	O	O
of	TIVICAY.xml:S1:2936:2	of	IN	O	O
at	TIVICAY.xml:S1:2939:2	at	IN	O	O
Least	TIVICAY.xml:S1:2942:5	least	NNP	O	O
Moderate	TIVICAY.xml:S1:2948:8	moder	NNP	O	O
Intensity	TIVICAY.xml:S1:2957:9	intens	NNP	O	O
(	TIVICAY.xml:S1:2967:1	(	(	O	O
Grades	TIVICAY.xml:S1:2968:6	grade	NNP	O	O
2	TIVICAY.xml:S1:2975:1	2	CD	O	O
to	TIVICAY.xml:S1:2977:2	to	TO	O	O
4	TIVICAY.xml:S1:2980:1	4	CD	O	O
)	TIVICAY.xml:S1:2981:1	)	)	O	O
and	TIVICAY.xml:S1:2983:3	and	CC	O	O
at	TIVICAY.xml:S1:2987:2	at	IN	O	O
Least	TIVICAY.xml:S1:2990:5	least	JJS	O	O
2%	TIVICAY.xml:S1:2996:2	2%	CD	O	O
Frequency	TIVICAY.xml:S1:2999:9	frequenc	NNP	O	O
in	TIVICAY.xml:S1:3009:2	in	IN	O	O
Treatment	TIVICAY.xml:S1:3012:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:3021:1	-	:	O	O
naive	TIVICAY.xml:S1:3022:5	naiv	JJ	O	O
Subjects	TIVICAY.xml:S1:3028:8	subject	NNS	O	O
in	TIVICAY.xml:S1:3037:2	in	IN	O	O
SPRING	TIVICAY.xml:S1:3040:6	spring	NNP	O	O
-	TIVICAY.xml:S1:3046:1	-	:	O	O
2	TIVICAY.xml:S1:3047:1	2	CD	O	O
and	TIVICAY.xml:S1:3049:3	and	CC	O	O
SINGLE	TIVICAY.xml:S1:3053:6	singl	NNP	O	O
Trials	TIVICAY.xml:S1:3060:6	trial	NNP	O	O
(	TIVICAY.xml:S1:3067:1	(	(	O	O
Week	TIVICAY.xml:S1:3068:4	week	NNP	O	O
96	TIVICAY.xml:S1:3073:2	96	CD	O	O
Analysis	TIVICAY.xml:S1:3076:8	analysi	NN	O	O
)	TIVICAY.xml:S1:3084:1	)	)	O	O

System	TIVICAY.xml:S1:3089:6	system	NNP	O	O
Organ	TIVICAY.xml:S1:3096:5	organ	NNP	O	O
Class	TIVICAY.xml:S1:3102:5	class	NNP	O	O
Preferred	TIVICAY.xml:S1:3109:9	prefer	NNP	O	O
Term	TIVICAY.xml:S1:3119:4	term	NNP	O	O
SPRING	TIVICAY.xml:S1:3127:6	spring	NNP	O	O
-	TIVICAY.xml:S1:3133:1	-	:	O	O
2	TIVICAY.xml:S1:3134:1	2	CD	O	O
SINGLE	TIVICAY.xml:S1:3150:6	singl	NN	O	O

TIVICAY	TIVICAY.xml:S1:3173:7	tivicay	$	O	O
50	TIVICAY.xml:S1:3181:2	50	CD	O	O
mg	TIVICAY.xml:S1:3184:2	mg	NN	O	O
Once	TIVICAY.xml:S1:3187:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:3192:5	daili	NNP	O	O
2	TIVICAY.xml:S1:3200:1	2	CD	O	O
NRTIs	TIVICAY.xml:S1:3202:5	nrti	NNP	O	O
(	TIVICAY.xml:S1:3208:1	(	(	O	O
n	TIVICAY.xml:S1:3209:1	n	JJ	O	O
403	TIVICAY.xml:S1:3213:3	403	CD	O	O
)	TIVICAY.xml:S1:3216:1	)	)	O	O
Raltegravir	TIVICAY.xml:S1:3221:11	raltegravir	NNP	O	O
400	TIVICAY.xml:S1:3234:3	400	CD	O	O
mg	TIVICAY.xml:S1:3238:2	mg	NN	O	O
Twice	TIVICAY.xml:S1:3241:5	twice	NNP	O	O
Daily	TIVICAY.xml:S1:3247:5	daili	NNP	O	O
2	TIVICAY.xml:S1:3255:1	2	CD	O	O
NRTIs	TIVICAY.xml:S1:3257:5	nrti	NNP	O	O
(	TIVICAY.xml:S1:3262:1	(	(	O	O
n	TIVICAY.xml:S1:3263:1	n	JJ	O	O
405	TIVICAY.xml:S1:3267:3	405	CD	O	O
)	TIVICAY.xml:S1:3270:1	)	)	O	O
TIVICAY	TIVICAY.xml:S1:3275:7	tivicay	$	O	O
50	TIVICAY.xml:S1:3283:2	50	CD	O	O
mg	TIVICAY.xml:S1:3286:2	mg	NN	O	O
EPZICOM	TIVICAY.xml:S1:3291:7	epzicom	NNP	O	O
Once	TIVICAY.xml:S1:3299:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:3304:5	daili	NNP	O	O
(	TIVICAY.xml:S1:3309:1	(	(	O	O
n	TIVICAY.xml:S1:3310:1	n	JJ	O	O
414	TIVICAY.xml:S1:3314:3	414	CD	O	O
)	TIVICAY.xml:S1:3317:1	)	)	O	O
ATRIPLA	TIVICAY.xml:S1:3322:7	atripla	NNP	O	O
Once	TIVICAY.xml:S1:3330:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:3335:5	daili	NNP	O	O
(	TIVICAY.xml:S1:3340:1	(	(	O	O
n	TIVICAY.xml:S1:3341:1	n	JJ	O	O
419	TIVICAY.xml:S1:3345:3	419	CD	O	O
)	TIVICAY.xml:S1:3348:1	)	)	O	O

Psychiatric	TIVICAY.xml:S1:3356:11	psychiatr	JJ	O	O

Insomnia	TIVICAY.xml:S1:3469:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
1%	TIVICAY.xml:S1:3495:2	1%	CD	O	O
1%	TIVICAY.xml:S1:3518:2	1%	CD	O	O
3%	TIVICAY.xml:S1:3537:2	3%	CD	O	O
2%	TIVICAY.xml:S1:3562:2	2%	CD	O	O

Depression	TIVICAY.xml:S1:3582:10	depress	NNP	B-AdverseReaction	B-AdverseReaction
1%	TIVICAY.xml:S1:3608:2	1%	CD	O	O
1%	TIVICAY.xml:S1:3631:2	1%	CD	O	O
1%	TIVICAY.xml:S1:3650:2	1%	CD	O	O
2%	TIVICAY.xml:S1:3675:2	2%	CD	O	O

Abnormal	TIVICAY.xml:S1:3695:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
dreams	TIVICAY.xml:S1:3704:6	dream	VBZ	I-AdverseReaction	I-AdverseReaction
1%	TIVICAY.xml:S1:3721:2	1%	CD	O	O
1%	TIVICAY.xml:S1:3744:2	1%	CD	O	O
1%	TIVICAY.xml:S1:3764:2	1%	CD	O	O
2%	TIVICAY.xml:S1:3788:2	2%	CD	O	O

Nervous	TIVICAY.xml:S1:3808:7	nervou	JJ	O	O
System	TIVICAY.xml:S1:3816:6	system	NN	O	O

Dizziness	TIVICAY.xml:S1:3921:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
1%	TIVICAY.xml:S1:3947:2	1%	CD	O	O
1%	TIVICAY.xml:S1:3970:2	1%	CD	O	O
1%	TIVICAY.xml:S1:3990:2	1%	CD	O	O
5%	TIVICAY.xml:S1:4014:2	5%	CD	O	O

Headache	TIVICAY.xml:S1:4034:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
1%	TIVICAY.xml:S1:4060:2	1%	CD	O	O
1%	TIVICAY.xml:S1:4083:2	1%	CD	O	O
2%	TIVICAY.xml:S1:4102:2	2%	CD	O	O
2%	TIVICAY.xml:S1:4127:2	2%	CD	O	O

Gastrointestinal	TIVICAY.xml:S1:4147:16	gastrointestin	JJ	O	O

Nausea	TIVICAY.xml:S1:4260:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
1%	TIVICAY.xml:S1:4285:2	1%	CD	O	O
1%	TIVICAY.xml:S1:4308:2	1%	CD	O	O
1%	TIVICAY.xml:S1:4329:2	1%	CD	O	O
3%	TIVICAY.xml:S1:4353:2	3%	CD	O	O

Diarrhea	TIVICAY.xml:S1:4373:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
1%	TIVICAY.xml:S1:4399:2	1%	CD	O	O
1%	TIVICAY.xml:S1:4422:2	1%	CD	O	O
1%	TIVICAY.xml:S1:4442:2	1%	CD	O	O
2%	TIVICAY.xml:S1:4466:2	2%	CD	O	O

Skin	TIVICAY.xml:S1:4486:4	skin	NNP	O	O
and	TIVICAY.xml:S1:4491:3	and	CC	O	O
Subcutaneous	TIVICAY.xml:S1:4495:12	subcutan	NNP	O	O
Tissue	TIVICAY.xml:S1:4508:6	tissu	NNP	O	O

Rasha	TIVICAY.xml:S1:4606:5	rasha	NNP	B-AdverseReaction	B-AdverseReaction
0	TIVICAY.xml:S1:4631:1	0	CD	O	O
1%	TIVICAY.xml:S1:4655:2	1%	CD	O	O
1%	TIVICAY.xml:S1:4675:2	1%	CD	O	O
6%	TIVICAY.xml:S1:4699:2	6%	CD	O	O

General	TIVICAY.xml:S1:4719:7	gener	NNP	O	O
Disorders	TIVICAY.xml:S1:4727:9	disord	NNP	O	O

Fatigue	TIVICAY.xml:S1:4832:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
1%	TIVICAY.xml:S1:4858:2	1%	CD	O	O
1%	TIVICAY.xml:S1:4881:2	1%	CD	O	O
2%	TIVICAY.xml:S1:4900:2	2%	CD	O	O
2%	TIVICAY.xml:S1:4925:2	2%	CD	O	O

Ear	TIVICAY.xml:S1:4945:3	ear	NN	O	O
and	TIVICAY.xml:S1:4949:3	and	CC	O	O
Labyrinth	TIVICAY.xml:S1:4953:9	labyrinth	NNP	O	O

Vertigo	TIVICAY.xml:S1:5058:7	vertigo	NNP	B-AdverseReaction	B-AdverseReaction
0	TIVICAY.xml:S1:5083:1	0	CD	O	O
1%	TIVICAY.xml:S1:5107:2	1%	CD	O	O
0	TIVICAY.xml:S1:5126:1	0	CD	O	O
2%	TIVICAY.xml:S1:5151:2	2%	CD	O	O

a	TIVICAY.xml:S1:5182:1	a	DT	O	O
Includes	TIVICAY.xml:S1:5185:8	includ	NNP	O	O
pooled	TIVICAY.xml:S1:5194:6	pool	VBD	O	O
terms	TIVICAY.xml:S1:5201:5	term	NNS	O	O
:	TIVICAY.xml:S1:5206:1	:	:	O	O
rash	TIVICAY.xml:S1:5208:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S1:5212:1	,	,	O	O
rash	TIVICAY.xml:S1:5214:4	rash	NN	B-AdverseReaction	B-AdverseReaction
generalized	TIVICAY.xml:S1:5219:11	gener	VBD	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S1:5230:1	,	,	O	O
rash	TIVICAY.xml:S1:5232:4	rash	NN	B-AdverseReaction	B-AdverseReaction
macular	TIVICAY.xml:S1:5237:7	macular	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S1:5244:1	,	,	O	O
rash	TIVICAY.xml:S1:5246:4	rash	NN	B-AdverseReaction	B-AdverseReaction
maculo	TIVICAY.xml:S1:5251:6	maculo	SYM	I-AdverseReaction	I-AdverseReaction
-	TIVICAY.xml:S1:5257:1	-	:	I-AdverseReaction	I-AdverseReaction
papular	TIVICAY.xml:S1:5258:7	papular	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S1:5265:1	,	,	O	O
rash	TIVICAY.xml:S1:5267:4	rash	NN	B-AdverseReaction	B-AdverseReaction
pruritic	TIVICAY.xml:S1:5272:8	prurit	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S1:5280:1	,	,	O	O
and	TIVICAY.xml:S1:5282:3	and	CC	O	O
drug	TIVICAY.xml:S1:5286:4	drug	NN	B-AdverseReaction	O
eruption	TIVICAY.xml:S1:5291:8	erupt	NN	I-AdverseReaction	O
.	TIVICAY.xml:S1:5299:1	.	.	O	O

In	TIVICAY.xml:S1:5305:2	In	IN	O	O

addition	TIVICAY.xml:S1:5308:8	addit	NN	O	O
,	TIVICAY.xml:S1:5316:1	,	,	O	O
Grade	TIVICAY.xml:S1:5318:5	grade	NNP	O	O
1	TIVICAY.xml:S1:5324:1	1	CD	O	O
insomnia	TIVICAY.xml:S1:5326:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
was	TIVICAY.xml:S1:5335:3	wa	VBD	O	O
reported	TIVICAY.xml:S1:5339:8	report	VBN	O	O
by	TIVICAY.xml:S1:5348:2	by	IN	O	O
1%	TIVICAY.xml:S1:5351:2	1%	CD	O	O
and	TIVICAY.xml:S1:5354:3	and	CC	O	O
less	TIVICAY.xml:S1:5358:4	less	JJR	O	O
than	TIVICAY.xml:S1:5363:4	than	IN	O	O
1%	TIVICAY.xml:S1:5368:2	1%	CD	O	O
of	TIVICAY.xml:S1:5371:2	of	IN	O	O
subjects	TIVICAY.xml:S1:5374:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:5383:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S1:5393:7	tivicay	NNP	O	O
and	TIVICAY.xml:S1:5401:3	and	CC	O	O
raltegravir	TIVICAY.xml:S1:5405:11	raltegravir	NN	O	O
,	TIVICAY.xml:S1:5416:1	,	,	O	O
respectively	TIVICAY.xml:S1:5418:12	respect	RB	O	O
,	TIVICAY.xml:S1:5430:1	,	,	O	O
in	TIVICAY.xml:S1:5432:2	in	IN	O	O
SPRING	TIVICAY.xml:S1:5435:6	spring	NNP	O	O
-	TIVICAY.xml:S1:5441:1	-	:	O	O
2	TIVICAY.xml:S1:5442:1	2	CD	O	O
;	TIVICAY.xml:S1:5443:1	;	:	O	O
whereas	TIVICAY.xml:S1:5445:7	wherea	NNS	O	O
in	TIVICAY.xml:S1:5453:2	in	IN	O	O
SINGLE	TIVICAY.xml:S1:5456:6	singl	NNP	O	O
the	TIVICAY.xml:S1:5463:3	the	DT	O	O
rates	TIVICAY.xml:S1:5467:5	rate	NNS	O	O
were	TIVICAY.xml:S1:5473:4	were	VBD	O	O
7%	TIVICAY.xml:S1:5478:2	7%	CD	O	O
and	TIVICAY.xml:S1:5481:3	and	CC	O	O
4%	TIVICAY.xml:S1:5485:2	4%	CD	O	O
for	TIVICAY.xml:S1:5488:3	for	IN	O	O
TIVICAY	TIVICAY.xml:S1:5492:7	tivicay	NNP	O	O
and	TIVICAY.xml:S1:5500:3	and	CC	O	O
ATRIPLA	TIVICAY.xml:S1:5504:7	atripla	NNP	O	O
,	TIVICAY.xml:S1:5511:1	,	,	O	O
respectively	TIVICAY.xml:S1:5513:12	respect	RB	O	O
.	TIVICAY.xml:S1:5525:1	.	.	O	O

These	TIVICAY.xml:S1:5527:5	these	DT	O	O
events	TIVICAY.xml:S1:5533:6	event	NNS	O	O
were	TIVICAY.xml:S1:5540:4	were	VBD	O	O
not	TIVICAY.xml:S1:5545:3	not	RB	O	O
treatment	TIVICAY.xml:S1:5549:9	treatment	NN	O	O
limiting	TIVICAY.xml:S1:5559:8	limit	NN	O	O
.	TIVICAY.xml:S1:5567:1	.	.	O	O

In	TIVICAY.xml:S1:5573:2	In	IN	O	O
a	TIVICAY.xml:S1:5576:1	a	DT	O	O
multicenter	TIVICAY.xml:S1:5578:11	multicent	NN	O	O
,	TIVICAY.xml:S1:5589:1	,	,	O	O
open	TIVICAY.xml:S1:5591:4	open	JJ	O	O
-	TIVICAY.xml:S1:5595:1	-	:	O	O
label	TIVICAY.xml:S1:5596:5	label	NN	O	O
trial	TIVICAY.xml:S1:5602:5	trial	NN	O	O
(	TIVICAY.xml:S1:5608:1	(	(	O	O
FLAMINGO	TIVICAY.xml:S1:5609:8	flamingo	NNP	O	O
)	TIVICAY.xml:S1:5617:1	)	)	O	O
,	TIVICAY.xml:S1:5618:1	,	,	O	O
243	TIVICAY.xml:S1:5620:3	243	CD	O	O
subjects	TIVICAY.xml:S1:5624:8	subject	NNS	O	O
received	TIVICAY.xml:S1:5633:8	receiv	VBD	O	O
TIVICAY	TIVICAY.xml:S1:5642:7	tivicay	NNP	O	O
50	TIVICAY.xml:S1:5650:2	50	CD	O	O
mg	TIVICAY.xml:S1:5653:2	mg	NN	O	O
once	TIVICAY.xml:S1:5656:4	onc	RB	O	O
daily	TIVICAY.xml:S1:5661:5	daili	JJ	O	O
versus	TIVICAY.xml:S1:5667:6	versu	NN	O	O
242	TIVICAY.xml:S1:5674:3	242	CD	O	O
subjects	TIVICAY.xml:S1:5678:8	subject	NNS	O	O
who	TIVICAY.xml:S1:5687:3	who	WP	O	O
received	TIVICAY.xml:S1:5691:8	receiv	VBD	O	O
darunavir	TIVICAY.xml:S1:5700:9	darunavir	RB	O	O
800	TIVICAY.xml:S1:5710:3	800	CD	O	O
mg	TIVICAY.xml:S1:5714:2	mg	NNS	O	O
ritonavir	TIVICAY.xml:S1:5717:9	ritonavir	VBP	O	O
100	TIVICAY.xml:S1:5727:3	100	CD	O	O
mg	TIVICAY.xml:S1:5731:2	mg	NNS	O	O
once	TIVICAY.xml:S1:5734:4	onc	RB	O	O
daily	TIVICAY.xml:S1:5739:5	daili	RB	O	O
,	TIVICAY.xml:S1:5744:1	,	,	O	O
both	TIVICAY.xml:S1:5746:4	both	DT	O	O
in	TIVICAY.xml:S1:5751:2	in	IN	O	O
combination	TIVICAY.xml:S1:5754:11	combin	NN	O	O
with	TIVICAY.xml:S1:5766:4	with	IN	O	O
investigator	TIVICAY.xml:S1:5771:12	investig	NN	O	O
-	TIVICAY.xml:S1:5783:1	-	:	O	O
selected	TIVICAY.xml:S1:5784:8	select	VBN	O	O
NRTI	TIVICAY.xml:S1:5793:4	nrti	NNP	O	O
background	TIVICAY.xml:S1:5798:10	background	IN	O	O
regimen	TIVICAY.xml:S1:5809:7	regimen	NNS	O	O
(	TIVICAY.xml:S1:5817:1	(	(	O	O
either	TIVICAY.xml:S1:5818:6	either	CC	O	O
EPZICOM	TIVICAY.xml:S1:5825:7	epzicom	NNP	O	O
or	TIVICAY.xml:S1:5833:2	or	CC	O	O
TRUVADA	TIVICAY.xml:S1:5836:7	truvada	NNP	O	O
)	TIVICAY.xml:S1:5843:1	)	)	O	O
.	TIVICAY.xml:S1:5844:1	.	.	O	O

There	TIVICAY.xml:S1:5846:5	there	EX	O	O
were	TIVICAY.xml:S1:5852:4	were	VBD	O	O
484	TIVICAY.xml:S1:5857:3	484	CD	O	O
subjects	TIVICAY.xml:S1:5861:8	subject	NNS	O	O
included	TIVICAY.xml:S1:5870:8	includ	VBN	O	O
in	TIVICAY.xml:S1:5879:2	in	IN	O	O
the	TIVICAY.xml:S1:5882:3	the	DT	O	O
efficacy	TIVICAY.xml:S1:5886:8	efficaci	NN	O	O
and	TIVICAY.xml:S1:5895:3	and	CC	O	O
safety	TIVICAY.xml:S1:5899:6	safeti	NN	O	O
analyses	TIVICAY.xml:S1:5906:8	analys	NNS	O	O
.	TIVICAY.xml:S1:5914:1	.	.	O	O

Through	TIVICAY.xml:S1:5916:7	through	IN	O	O
48	TIVICAY.xml:S1:5924:2	48	CD	O	O
weeks	TIVICAY.xml:S1:5927:5	week	NNS	O	O
,	TIVICAY.xml:S1:5932:1	,	,	O	O
the	TIVICAY.xml:S1:5934:3	the	DT	O	O
rates	TIVICAY.xml:S1:5938:5	rate	NNS	O	O
of	TIVICAY.xml:S1:5944:2	of	IN	O	O
adverse	TIVICAY.xml:S1:5947:7	advers	JJ	O	O
events	TIVICAY.xml:S1:5955:6	event	NNS	O	O
leading	TIVICAY.xml:S1:5962:7	lead	VBG	O	O
to	TIVICAY.xml:S1:5970:2	to	TO	O	O
discontinuation	TIVICAY.xml:S1:5973:15	discontinu	NN	O	O
were	TIVICAY.xml:S1:5989:4	were	VBD	O	O
2%	TIVICAY.xml:S1:5994:2	2%	CD	O	O
in	TIVICAY.xml:S1:5997:2	in	IN	O	O
subjects	TIVICAY.xml:S1:6000:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:6009:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S1:6019:7	tivicay	NNP	O	O
and	TIVICAY.xml:S1:6027:3	and	CC	O	O
4%	TIVICAY.xml:S1:6031:2	4%	CD	O	O
in	TIVICAY.xml:S1:6034:2	in	IN	O	O
subjects	TIVICAY.xml:S1:6037:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:6046:9	receiv	VBG	O	O
darunavir	TIVICAY.xml:S1:6056:9	darunavir	NN	O	O
ritonavir	TIVICAY.xml:S1:6066:9	ritonavir	NN	O	O
.	TIVICAY.xml:S1:6075:1	.	.	O	O

The	TIVICAY.xml:S1:6077:3	the	DT	O	O
ADRs	TIVICAY.xml:S1:6081:4	adr	NNP	O	O
observed	TIVICAY.xml:S1:6086:8	observ	VBN	O	O
in	TIVICAY.xml:S1:6095:2	in	IN	O	O
FLAMINGO	TIVICAY.xml:S1:6098:8	flamingo	NNP	O	O
were	TIVICAY.xml:S1:6107:4	were	VBD	O	O
generally	TIVICAY.xml:S1:6112:9	gener	RB	O	O
consistent	TIVICAY.xml:S1:6122:10	consist	JJ	O	O
with	TIVICAY.xml:S1:6133:4	with	IN	O	O
those	TIVICAY.xml:S1:6138:5	those	DT	O	O
seen	TIVICAY.xml:S1:6144:4	seen	VBN	O	O
in	TIVICAY.xml:S1:6149:2	in	IN	O	O
SPRING	TIVICAY.xml:S1:6152:6	spring	NNP	O	O
-	TIVICAY.xml:S1:6158:1	-	:	O	O
2	TIVICAY.xml:S1:6159:1	2	CD	O	O
and	TIVICAY.xml:S1:6161:3	and	CC	O	O
SINGLE	TIVICAY.xml:S1:6165:6	singl	NNP	O	O
.	TIVICAY.xml:S1:6171:1	.	.	O	O

Treatment	TIVICAY.xml:S1:6179:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:6188:1	-	:	O	O
experienced	TIVICAY.xml:S1:6189:11	experienc	VBD	O	O
,	TIVICAY.xml:S1:6200:1	,	,	O	O
Integrase	TIVICAY.xml:S1:6202:9	integras	NNP	O	O
Strand	TIVICAY.xml:S1:6212:6	strand	NNP	O	O
Transfer	TIVICAY.xml:S1:6219:8	transfer	NNP	O	O
Inhibitor	TIVICAY.xml:S1:6228:9	inhibitor	NNP	O	O
-	TIVICAY.xml:S1:6237:1	-	:	O	O
naive	TIVICAY.xml:S1:6238:5	naiv	JJ	O	O
Subjects	TIVICAY.xml:S1:6244:8	subject	NNS	O	O
:	TIVICAY.xml:S1:6254:1	:	:	O	O
In	TIVICAY.xml:S1:6256:2	In	IN	O	O
an	TIVICAY.xml:S1:6259:2	an	DT	O	O
international	TIVICAY.xml:S1:6262:13	intern	JJ	O	O
,	TIVICAY.xml:S1:6275:1	,	,	O	O
multicenter	TIVICAY.xml:S1:6277:11	multicent	NN	O	O
,	TIVICAY.xml:S1:6288:1	,	,	O	O
double	TIVICAY.xml:S1:6290:6	doubl	JJ	O	O
-	TIVICAY.xml:S1:6296:1	-	:	O	O
blind	TIVICAY.xml:S1:6297:5	blind	NN	O	O
trial	TIVICAY.xml:S1:6303:5	trial	NN	O	O
(	TIVICAY.xml:S1:6309:1	(	(	O	O
ING111762	TIVICAY.xml:S1:6310:9	ing111762	NNP	O	O
,	TIVICAY.xml:S1:6319:1	,	,	O	O
SAILING	TIVICAY.xml:S1:6321:7	sail	NNP	O	O
)	TIVICAY.xml:S1:6328:1	)	)	O	O
,	TIVICAY.xml:S1:6329:1	,	,	O	O
719	TIVICAY.xml:S1:6331:3	719	CD	O	O
HIV	TIVICAY.xml:S1:6335:3	hiv	NNP	O	O
-	TIVICAY.xml:S1:6338:1	-	:	O	O
1	TIVICAY.xml:S1:6339:1	1	CD	O	O
-	TIVICAY.xml:S1:6340:1	-	:	O	O
infected	TIVICAY.xml:S1:6341:8	infect	VBN	O	O
,	TIVICAY.xml:S1:6349:1	,	,	O	O
antiretroviral	TIVICAY.xml:S1:6351:14	antiretrovir	JJ	O	O
treatment	TIVICAY.xml:S1:6366:9	treatment	NN	O	O
-	TIVICAY.xml:S1:6375:1	-	:	O	O
experienced	TIVICAY.xml:S1:6376:11	experienc	JJ	O	O
adults	TIVICAY.xml:S1:6388:6	adult	NNS	O	O
were	TIVICAY.xml:S1:6395:4	were	VBD	O	O
randomized	TIVICAY.xml:S1:6400:10	random	VBN	O	O
and	TIVICAY.xml:S1:6411:3	and	CC	O	O
received	TIVICAY.xml:S1:6415:8	receiv	VBN	O	O
either	TIVICAY.xml:S1:6424:6	either	RB	O	O
TIVICAY	TIVICAY.xml:S1:6431:7	tivicay	NNP	O	O
50	TIVICAY.xml:S1:6439:2	50	CD	O	O
mg	TIVICAY.xml:S1:6442:2	mg	NN	O	O
once	TIVICAY.xml:S1:6445:4	onc	RB	O	O
daily	TIVICAY.xml:S1:6450:5	daili	JJ	O	O
or	TIVICAY.xml:S1:6456:2	or	CC	O	O
raltegravir	TIVICAY.xml:S1:6459:11	raltegravir	JJ	O	O
400	TIVICAY.xml:S1:6471:3	400	CD	O	O
mg	TIVICAY.xml:S1:6475:2	mg	JJ	O	O
twice	TIVICAY.xml:S1:6478:5	twice	RB	O	O
daily	TIVICAY.xml:S1:6484:5	daili	RB	O	O
with	TIVICAY.xml:S1:6490:4	with	IN	O	O
investigator	TIVICAY.xml:S1:6495:12	investig	NN	O	O
-	TIVICAY.xml:S1:6507:1	-	:	O	O
selected	TIVICAY.xml:S1:6508:8	select	VBN	O	O
background	TIVICAY.xml:S1:6517:10	background	IN	O	O
regimen	TIVICAY.xml:S1:6528:7	regimen	NNS	O	O
consisting	TIVICAY.xml:S1:6536:10	consist	VBG	O	O
of	TIVICAY.xml:S1:6547:2	of	IN	O	O
up	TIVICAY.xml:S1:6550:2	up	IN	O	O
to	TIVICAY.xml:S1:6553:2	to	TO	O	O
2	TIVICAY.xml:S1:6556:1	2	CD	O	O
agents	TIVICAY.xml:S1:6558:6	agent	NNS	O	O
,	TIVICAY.xml:S1:6564:1	,	,	O	O
including	TIVICAY.xml:S1:6566:9	includ	VBG	O	O
at	TIVICAY.xml:S1:6576:2	at	IN	O	O
least	TIVICAY.xml:S1:6579:5	least	JJS	O	O
one	TIVICAY.xml:S1:6585:3	one	CD	O	O
fully	TIVICAY.xml:S1:6589:5	fulli	RB	O	O
active	TIVICAY.xml:S1:6595:6	activ	JJ	O	O
agent	TIVICAY.xml:S1:6602:5	agent	NN	O	O
.	TIVICAY.xml:S1:6607:1	.	.	O	O

At	TIVICAY.xml:S1:6609:2	At	IN	O	O
48	TIVICAY.xml:S1:6612:2	48	CD	O	O
weeks	TIVICAY.xml:S1:6615:5	week	NNS	O	O
,	TIVICAY.xml:S1:6620:1	,	,	O	O
the	TIVICAY.xml:S1:6622:3	the	DT	O	O
rates	TIVICAY.xml:S1:6626:5	rate	NNS	O	O
of	TIVICAY.xml:S1:6632:2	of	IN	O	O
adverse	TIVICAY.xml:S1:6635:7	advers	JJ	O	O
events	TIVICAY.xml:S1:6643:6	event	NNS	O	O
leading	TIVICAY.xml:S1:6650:7	lead	VBG	O	O
to	TIVICAY.xml:S1:6658:2	to	TO	O	O
discontinuation	TIVICAY.xml:S1:6661:15	discontinu	NN	O	O
were	TIVICAY.xml:S1:6677:4	were	VBD	O	O
3%	TIVICAY.xml:S1:6682:2	3%	CD	O	O
in	TIVICAY.xml:S1:6685:2	in	IN	O	O
subjects	TIVICAY.xml:S1:6688:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:6697:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S1:6707:7	tivicay	NNP	O	O
50	TIVICAY.xml:S1:6715:2	50	CD	O	O
mg	TIVICAY.xml:S1:6718:2	mg	NN	O	O
once	TIVICAY.xml:S1:6721:4	onc	RB	O	O
daily	TIVICAY.xml:S1:6726:5	daili	JJ	O	O
background	TIVICAY.xml:S1:6734:10	background	IN	O	O
regimen	TIVICAY.xml:S1:6745:7	regimen	NNS	O	O
and	TIVICAY.xml:S1:6753:3	and	CC	O	O
4%	TIVICAY.xml:S1:6757:2	4%	CD	O	O
in	TIVICAY.xml:S1:6760:2	in	IN	O	O
subjects	TIVICAY.xml:S1:6763:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:6772:9	receiv	VBG	O	O
raltegravir	TIVICAY.xml:S1:6782:11	raltegravir	NN	O	O
400	TIVICAY.xml:S1:6794:3	400	CD	O	O
mg	TIVICAY.xml:S1:6798:2	mg	NN	O	O
twice	TIVICAY.xml:S1:6801:5	twice	RB	O	O
daily	TIVICAY.xml:S1:6807:5	daili	RB	O	O
background	TIVICAY.xml:S1:6815:10	background	IN	O	O
regimen	TIVICAY.xml:S1:6826:7	regimen	NNS	O	O
.	TIVICAY.xml:S1:6833:1	.	.	O	O

The	TIVICAY.xml:S1:6839:3	the	DT	O	O
only	TIVICAY.xml:S1:6843:4	onli	JJ	O	O
treatment	TIVICAY.xml:S1:6848:9	treatment	NN	O	O
-	TIVICAY.xml:S1:6857:1	-	:	O	O
emergent	TIVICAY.xml:S1:6858:8	emerg	NN	O	O
ADR	TIVICAY.xml:S1:6867:3	adr	NNP	O	O
of	TIVICAY.xml:S1:6871:2	of	IN	O	O
moderate	TIVICAY.xml:S1:6874:8	moder	JJ	O	O
to	TIVICAY.xml:S1:6883:2	to	TO	O	O
severe	TIVICAY.xml:S1:6886:6	sever	JJ	O	O
intensity	TIVICAY.xml:S1:6893:9	intens	NN	O	O
with	TIVICAY.xml:S1:6903:4	with	IN	O	O
at	TIVICAY.xml:S1:6908:2	at	IN	O	O
least	TIVICAY.xml:S1:6911:5	least	JJS	O	O
2%	TIVICAY.xml:S1:6917:2	2%	CD	O	O
frequency	TIVICAY.xml:S1:6920:9	frequenc	NN	O	O
in	TIVICAY.xml:S1:6930:2	in	IN	O	O
either	TIVICAY.xml:S1:6933:6	either	DT	O	O
treatment	TIVICAY.xml:S1:6940:9	treatment	NN	O	O
group	TIVICAY.xml:S1:6950:5	group	NN	O	O
was	TIVICAY.xml:S1:6956:3	wa	VBD	O	O
diarrhea	TIVICAY.xml:S1:6960:8	diarrhea	RB	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S1:6968:1	,	,	O	O
2%	TIVICAY.xml:S1:6970:2	2%	CD	O	O
(	TIVICAY.xml:S1:6973:1	(	(	O	O
6	TIVICAY.xml:S1:6974:1	6	CD	O	O
of	TIVICAY.xml:S1:6976:2	of	IN	O	O
354	TIVICAY.xml:S1:6979:3	354	CD	O	O
)	TIVICAY.xml:S1:6982:1	)	)	O	O
in	TIVICAY.xml:S1:6984:2	in	IN	O	O
subjects	TIVICAY.xml:S1:6987:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:6996:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S1:7006:7	tivicay	NNP	O	O
50	TIVICAY.xml:S1:7014:2	50	CD	O	O
mg	TIVICAY.xml:S1:7017:2	mg	NN	O	O
once	TIVICAY.xml:S1:7020:4	onc	RB	O	O
daily	TIVICAY.xml:S1:7025:5	daili	JJ	O	O
background	TIVICAY.xml:S1:7033:10	background	IN	O	O
regimen	TIVICAY.xml:S1:7044:7	regimen	NNS	O	O
and	TIVICAY.xml:S1:7052:3	and	CC	O	O
1%	TIVICAY.xml:S1:7056:2	1%	CD	O	O
(	TIVICAY.xml:S1:7059:1	(	(	O	O
5	TIVICAY.xml:S1:7060:1	5	CD	O	O
of	TIVICAY.xml:S1:7062:2	of	IN	O	O
361	TIVICAY.xml:S1:7065:3	361	CD	O	O
)	TIVICAY.xml:S1:7068:1	)	)	O	O
in	TIVICAY.xml:S1:7070:2	in	IN	O	O
subjects	TIVICAY.xml:S1:7073:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:7082:9	receiv	VBG	O	O
raltegravir	TIVICAY.xml:S1:7092:11	raltegravir	NN	O	O
400	TIVICAY.xml:S1:7104:3	400	CD	O	O
mg	TIVICAY.xml:S1:7108:2	mg	NN	O	O
twice	TIVICAY.xml:S1:7111:5	twice	RB	O	O
daily	TIVICAY.xml:S1:7117:5	daili	RB	O	O
background	TIVICAY.xml:S1:7125:10	background	IN	O	O
regimen	TIVICAY.xml:S1:7136:7	regimen	NNS	O	O
.	TIVICAY.xml:S1:7143:1	.	.	O	O

Treatment	TIVICAY.xml:S1:7151:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:7160:1	-	:	O	O
experienced	TIVICAY.xml:S1:7161:11	experienc	VBD	O	O
,	TIVICAY.xml:S1:7172:1	,	,	O	O
Integrase	TIVICAY.xml:S1:7174:9	integras	NNP	O	O
Strand	TIVICAY.xml:S1:7184:6	strand	NNP	O	O
Transfer	TIVICAY.xml:S1:7191:8	transfer	NNP	O	O
Inhibitor	TIVICAY.xml:S1:7200:9	inhibitor	NNP	O	O
-	TIVICAY.xml:S1:7209:1	-	:	O	O
experienced	TIVICAY.xml:S1:7210:11	experienc	JJ	O	O
Subjects	TIVICAY.xml:S1:7222:8	subject	NNS	O	O
:	TIVICAY.xml:S1:7232:1	:	:	O	O
In	TIVICAY.xml:S1:7234:2	In	IN	O	O
a	TIVICAY.xml:S1:7237:1	a	DT	O	O
multicenter	TIVICAY.xml:S1:7239:11	multicent	NN	O	O
,	TIVICAY.xml:S1:7250:1	,	,	O	O
open	TIVICAY.xml:S1:7252:4	open	JJ	O	O
-	TIVICAY.xml:S1:7256:1	-	:	O	O
label	TIVICAY.xml:S1:7257:5	label	NN	O	O
,	TIVICAY.xml:S1:7262:1	,	,	O	O
single	TIVICAY.xml:S1:7264:6	singl	JJ	O	O
-	TIVICAY.xml:S1:7270:1	-	:	O	O
arm	TIVICAY.xml:S1:7271:3	arm	NN	O	O
trial	TIVICAY.xml:S1:7275:5	trial	NN	O	O
(	TIVICAY.xml:S1:7281:1	(	(	O	O
ING112574	TIVICAY.xml:S1:7282:9	ing112574	NNP	O	O
,	TIVICAY.xml:S1:7291:1	,	,	O	O
VIKING	TIVICAY.xml:S1:7293:6	vike	NNP	O	O
-	TIVICAY.xml:S1:7299:1	-	:	O	O
3	TIVICAY.xml:S1:7300:1	3	CD	O	O
)	TIVICAY.xml:S1:7301:1	)	)	O	O
,	TIVICAY.xml:S1:7302:1	,	,	O	O
183	TIVICAY.xml:S1:7304:3	183	CD	O	O
HIV	TIVICAY.xml:S1:7308:3	hiv	NNP	O	O
-	TIVICAY.xml:S1:7311:1	-	:	O	O
1	TIVICAY.xml:S1:7312:1	1	CD	O	O
-	TIVICAY.xml:S1:7313:1	-	:	O	O
infected	TIVICAY.xml:S1:7314:8	infect	VBN	O	O
,	TIVICAY.xml:S1:7322:1	,	,	O	O
antiretroviral	TIVICAY.xml:S1:7324:14	antiretrovir	JJ	O	O
treatment	TIVICAY.xml:S1:7339:9	treatment	NN	O	O
-	TIVICAY.xml:S1:7348:1	-	:	O	O
experienced	TIVICAY.xml:S1:7349:11	experienc	JJ	O	O
adults	TIVICAY.xml:S1:7361:6	adult	NNS	O	O
with	TIVICAY.xml:S1:7368:4	with	IN	O	O
virological	TIVICAY.xml:S1:7373:11	virolog	JJ	O	O
failure	TIVICAY.xml:S1:7385:7	failur	NN	O	O
and	TIVICAY.xml:S1:7393:3	and	CC	O	O
current	TIVICAY.xml:S1:7397:7	current	JJ	O	O
or	TIVICAY.xml:S1:7405:2	or	CC	O	O
historical	TIVICAY.xml:S1:7408:10	histor	JJ	O	O
evidence	TIVICAY.xml:S1:7419:8	evid	NN	O	O
of	TIVICAY.xml:S1:7428:2	of	IN	O	O
raltegravir	TIVICAY.xml:S1:7431:11	raltegravir	NN	O	O
and	TIVICAY.xml:S1:7443:3	and	CC	O	O
or	TIVICAY.xml:S1:7447:2	or	CC	O	O
elvitegravir	TIVICAY.xml:S1:7450:12	elvitegravir	VB	O	O
resistance	TIVICAY.xml:S1:7463:10	resist	NN	O	O
received	TIVICAY.xml:S1:7474:8	receiv	VBD	O	O
TIVICAY	TIVICAY.xml:S1:7483:7	tivicay	NNP	O	O
50	TIVICAY.xml:S1:7491:2	50	CD	O	O
mg	TIVICAY.xml:S1:7494:2	mg	NN	O	O
twice	TIVICAY.xml:S1:7497:5	twice	RB	O	O
daily	TIVICAY.xml:S1:7503:5	daili	RB	O	O
with	TIVICAY.xml:S1:7509:4	with	IN	O	O
the	TIVICAY.xml:S1:7514:3	the	DT	O	O
current	TIVICAY.xml:S1:7518:7	current	JJ	O	O
failing	TIVICAY.xml:S1:7526:7	fail	NN	O	O
background	TIVICAY.xml:S1:7534:10	background	NN	O	O
regimen	TIVICAY.xml:S1:7545:7	regimen	NNS	O	O
for	TIVICAY.xml:S1:7553:3	for	IN	O	O
7	TIVICAY.xml:S1:7557:1	7	CD	O	O
days	TIVICAY.xml:S1:7559:4	day	NNS	O	O
and	TIVICAY.xml:S1:7564:3	and	CC	O	O
with	TIVICAY.xml:S1:7568:4	with	IN	O	O
optimized	TIVICAY.xml:S1:7573:9	optim	JJ	O	O
background	TIVICAY.xml:S1:7583:10	background	NN	O	O
therapy	TIVICAY.xml:S1:7594:7	therapi	NN	O	O
from	TIVICAY.xml:S1:7602:4	from	IN	O	O
Day	TIVICAY.xml:S1:7607:3	day	NNP	O	O
8	TIVICAY.xml:S1:7611:1	8	CD	O	O
.	TIVICAY.xml:S1:7612:1	.	.	O	O

The	TIVICAY.xml:S1:7614:3	the	DT	O	O
rate	TIVICAY.xml:S1:7618:4	rate	NN	O	O
of	TIVICAY.xml:S1:7623:2	of	IN	O	O
adverse	TIVICAY.xml:S1:7626:7	advers	JJ	O	O
events	TIVICAY.xml:S1:7634:6	event	NNS	O	O
leading	TIVICAY.xml:S1:7641:7	lead	VBG	O	O
to	TIVICAY.xml:S1:7649:2	to	TO	O	O
discontinuation	TIVICAY.xml:S1:7652:15	discontinu	NN	O	O
was	TIVICAY.xml:S1:7668:3	wa	VBD	O	O
4%	TIVICAY.xml:S1:7672:2	4%	CD	O	O
of	TIVICAY.xml:S1:7675:2	of	IN	O	O
subjects	TIVICAY.xml:S1:7678:8	subject	NNS	O	O
at	TIVICAY.xml:S1:7687:2	at	IN	O	O
Week	TIVICAY.xml:S1:7690:4	week	NNP	O	O
48	TIVICAY.xml:S1:7695:2	48	CD	O	O
.	TIVICAY.xml:S1:7697:1	.	.	O	O

Treatment	TIVICAY.xml:S1:7703:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:7712:1	-	:	O	O
emergent	TIVICAY.xml:S1:7713:8	emerg	NN	O	O
ADRs	TIVICAY.xml:S1:7722:4	adr	NNP	O	O
in	TIVICAY.xml:S1:7727:2	in	IN	O	O
VIKING	TIVICAY.xml:S1:7730:6	vike	NNP	O	O
-	TIVICAY.xml:S1:7736:1	-	:	O	O
3	TIVICAY.xml:S1:7737:1	3	CD	O	O
were	TIVICAY.xml:S1:7739:4	were	VBD	O	O
generally	TIVICAY.xml:S1:7744:9	gener	RB	O	O
similar	TIVICAY.xml:S1:7754:7	similar	JJ	O	O
compared	TIVICAY.xml:S1:7762:8	compar	VBN	O	O
with	TIVICAY.xml:S1:7771:4	with	IN	O	O
observations	TIVICAY.xml:S1:7776:12	observ	NNS	O	O
with	TIVICAY.xml:S1:7789:4	with	IN	O	O
the	TIVICAY.xml:S1:7794:3	the	DT	O	O
50	TIVICAY.xml:S1:7798:2	50	CD	O	O
-	TIVICAY.xml:S1:7800:1	-	:	O	O
mg	TIVICAY.xml:S1:7801:2	mg	NN	O	O
once	TIVICAY.xml:S1:7804:4	onc	RB	O	O
-	TIVICAY.xml:S1:7808:1	-	:	O	O
daily	TIVICAY.xml:S1:7809:5	daili	JJ	O	O
dose	TIVICAY.xml:S1:7815:4	dose	NN	O	O
in	TIVICAY.xml:S1:7820:2	in	IN	O	O
adult	TIVICAY.xml:S1:7823:5	adult	NN	O	O
Phase	TIVICAY.xml:S1:7829:5	phase	NNP	O	O
3	TIVICAY.xml:S1:7835:1	3	CD	O	O
trials	TIVICAY.xml:S1:7837:6	trial	NNS	O	O
.	TIVICAY.xml:S1:7843:1	.	.	O	O

Less	TIVICAY.xml:S1:7851:4	less	NNP	O	O
Common	TIVICAY.xml:S1:7856:6	common	NNP	O	O
Adverse	TIVICAY.xml:S1:7863:7	advers	NNP	O	O
Reactions	TIVICAY.xml:S1:7871:9	reaction	NNP	O	O
Observed	TIVICAY.xml:S1:7881:8	observ	NNP	O	O
in	TIVICAY.xml:S1:7890:2	in	IN	O	O
Treatment	TIVICAY.xml:S1:7893:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:7902:1	-	:	O	O
naive	TIVICAY.xml:S1:7903:5	naiv	JJ	O	O
and	TIVICAY.xml:S1:7909:3	and	CC	O	O
Treatment	TIVICAY.xml:S1:7913:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:7922:1	-	:	O	O
experienced	TIVICAY.xml:S1:7923:11	experienc	VBD	O	O
Trials	TIVICAY.xml:S1:7935:6	trial	NNS	O	O

The	TIVICAY.xml:S1:7948:3	the	DT	O	O
following	TIVICAY.xml:S1:7952:9	follow	JJ	O	O
ADRs	TIVICAY.xml:S1:7962:4	adr	NNP	O	O
occurred	TIVICAY.xml:S1:7967:8	occur	VBD	O	O
in	TIVICAY.xml:S1:7976:2	in	IN	O	O
less	TIVICAY.xml:S1:7979:4	less	JJR	O	O
than	TIVICAY.xml:S1:7984:4	than	IN	O	O
2%	TIVICAY.xml:S1:7989:2	2%	CD	O	O
of	TIVICAY.xml:S1:7992:2	of	IN	O	O
treatment	TIVICAY.xml:S1:7995:9	treatment	NN	O	O
-	TIVICAY.xml:S1:8004:1	-	:	O	O
naive	TIVICAY.xml:S1:8005:5	naiv	JJ	O	O
or	TIVICAY.xml:S1:8011:2	or	CC	O	O
treatment	TIVICAY.xml:S1:8014:9	treatment	NN	O	O
-	TIVICAY.xml:S1:8023:1	-	:	O	O
experienced	TIVICAY.xml:S1:8024:11	experienc	JJ	O	O
subjects	TIVICAY.xml:S1:8036:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:8045:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S1:8055:7	tivicay	NNP	O	O
in	TIVICAY.xml:S1:8063:2	in	IN	O	O
a	TIVICAY.xml:S1:8066:1	a	DT	O	O
combination	TIVICAY.xml:S1:8068:11	combin	NN	O	O
regimen	TIVICAY.xml:S1:8080:7	regimen	NNS	O	O
in	TIVICAY.xml:S1:8088:2	in	IN	O	O
any	TIVICAY.xml:S1:8091:3	ani	DT	O	O
one	TIVICAY.xml:S1:8095:3	one	CD	O	O
trial	TIVICAY.xml:S1:8099:5	trial	NN	O	O
.	TIVICAY.xml:S1:8104:1	.	.	O	O

These	TIVICAY.xml:S1:8106:5	these	DT	O	O
events	TIVICAY.xml:S1:8112:6	event	NNS	O	O
have	TIVICAY.xml:S1:8119:4	have	VBP	O	O
been	TIVICAY.xml:S1:8124:4	been	VBN	O	O
included	TIVICAY.xml:S1:8129:8	includ	VBN	O	O
because	TIVICAY.xml:S1:8138:7	becaus	IN	O	O
of	TIVICAY.xml:S1:8146:2	of	IN	O	O
their	TIVICAY.xml:S1:8149:5	their	PRP$	O	O
seriousness	TIVICAY.xml:S1:8155:11	serious	NN	O	O
and	TIVICAY.xml:S1:8167:3	and	CC	O	O
assessment	TIVICAY.xml:S1:8171:10	assess	NN	O	O
of	TIVICAY.xml:S1:8182:2	of	IN	O	O
potential	TIVICAY.xml:S1:8185:9	potenti	JJ	O	O
causal	TIVICAY.xml:S1:8195:6	causal	NN	O	O
relationship	TIVICAY.xml:S1:8202:12	relationship	NN	O	O
.	TIVICAY.xml:S1:8214:1	.	.	O	O

Gastrointestinal	TIVICAY.xml:S1:8222:16	gastrointestin	JJ	O	O
Disorders	TIVICAY.xml:S1:8239:9	disord	NNS	O	O
:	TIVICAY.xml:S1:8248:1	:	:	O	O
Abdominal	TIVICAY.xml:S1:8251:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	TIVICAY.xml:S1:8261:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S1:8265:1	,	,	O	O
abdominal	TIVICAY.xml:S1:8267:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	TIVICAY.xml:S1:8277:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S1:8287:1	,	,	O	O
flatulence	TIVICAY.xml:S1:8289:10	flatul	NN	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S1:8299:1	,	,	O	O
upper	TIVICAY.xml:S1:8301:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
abdominal	TIVICAY.xml:S1:8307:9	abdomin	JJ	I-AdverseReaction	I-AdverseReaction
pain	TIVICAY.xml:S1:8317:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S1:8321:1	,	,	O	O
vomiting	TIVICAY.xml:S1:8323:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
.	TIVICAY.xml:S1:8331:1	.	.	O	O

Hepatobiliary	TIVICAY.xml:S1:8339:13	hepatobiliari	JJ	O	O
Disorders	TIVICAY.xml:S1:8353:9	disord	NNS	O	O
:	TIVICAY.xml:S1:8362:1	:	:	O	O
Hepatitis	TIVICAY.xml:S1:8365:9	hepat	NN	B-AdverseReaction	B-AdverseReaction
.	TIVICAY.xml:S1:8374:1	.	.	O	O

Musculoskeletal	TIVICAY.xml:S1:8382:15	musculoskelet	JJ	O	O
Disorders	TIVICAY.xml:S1:8398:9	disord	NNS	O	O
:	TIVICAY.xml:S1:8407:1	:	:	O	O
Myositis	TIVICAY.xml:S1:8410:8	myositi	NN	B-AdverseReaction	B-AdverseReaction
.	TIVICAY.xml:S1:8418:1	.	.	O	O

Psychiatric	TIVICAY.xml:S1:8426:11	psychiatr	JJ	O	O
Disorders	TIVICAY.xml:S1:8438:9	disord	NNS	O	O
:	TIVICAY.xml:S1:8447:1	:	:	O	O
Suicidal	TIVICAY.xml:S1:8450:8	suicid	NNP	B-AdverseReaction	B-AdverseReaction
ideation	TIVICAY.xml:S1:8459:8	ideat	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S1:8467:1	,	,	O	O
attempt	TIVICAY.xml:S1:8469:7	attempt	NN	I-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S1:8476:1	,	,	O	O
behavior	TIVICAY.xml:S1:8478:8	behavior	NN	I-AdverseReaction	O
,	TIVICAY.xml:S1:8486:1	,	,	O	O
or	TIVICAY.xml:S1:8488:2	or	CC	O	O
completion	TIVICAY.xml:S1:8491:10	complet	NN	I-AdverseReaction	O
.	TIVICAY.xml:S1:8501:1	.	.	O	O

These	TIVICAY.xml:S1:8503:5	these	DT	O	O
events	TIVICAY.xml:S1:8509:6	event	NNS	O	O
were	TIVICAY.xml:S1:8516:4	were	VBD	O	O
observed	TIVICAY.xml:S1:8521:8	observ	VBN	O	O
primarily	TIVICAY.xml:S1:8530:9	primarili	RB	O	O
in	TIVICAY.xml:S1:8540:2	in	IN	O	O
subjects	TIVICAY.xml:S1:8543:8	subject	NNS	O	O
with	TIVICAY.xml:S1:8552:4	with	IN	O	O
a	TIVICAY.xml:S1:8557:1	a	DT	O	O
pre	TIVICAY.xml:S1:8559:3	pre	NN	O	O
-	TIVICAY.xml:S1:8562:1	-	:	O	O
existing	TIVICAY.xml:S1:8563:8	exist	VBG	O	O
history	TIVICAY.xml:S1:8572:7	histori	NN	O	O
of	TIVICAY.xml:S1:8580:2	of	IN	O	O
depression	TIVICAY.xml:S1:8583:10	depress	NN	O	O
or	TIVICAY.xml:S1:8594:2	or	CC	O	O
other	TIVICAY.xml:S1:8597:5	other	JJ	O	O
psychiatric	TIVICAY.xml:S1:8603:11	psychiatr	JJ	O	O
illness	TIVICAY.xml:S1:8615:7	ill	NN	O	O
.	TIVICAY.xml:S1:8622:1	.	.	O	O

Renal	TIVICAY.xml:S1:8630:5	renal	NNP	O	O
and	TIVICAY.xml:S1:8636:3	and	CC	O	O
Urinary	TIVICAY.xml:S1:8640:7	urinari	JJ	O	O
Disorders	TIVICAY.xml:S1:8648:9	disord	NNS	O	O
:	TIVICAY.xml:S1:8659:1	:	:	O	O
Renal	TIVICAY.xml:S1:8661:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
impairment	TIVICAY.xml:S1:8667:10	impair	NN	I-AdverseReaction	I-AdverseReaction
.	TIVICAY.xml:S1:8677:1	.	.	O	O

Skin	TIVICAY.xml:S1:8685:4	skin	NNP	O	O
and	TIVICAY.xml:S1:8690:3	and	CC	O	O
Subcutaneous	TIVICAY.xml:S1:8694:12	subcutan	NNP	O	O
Tissue	TIVICAY.xml:S1:8707:6	tissu	NNP	O	O
Disorders	TIVICAY.xml:S1:8714:9	disord	NNP	O	O
:	TIVICAY.xml:S1:8723:1	:	:	O	O
Pruritus	TIVICAY.xml:S1:8726:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
.	TIVICAY.xml:S1:8734:1	.	.	O	O

Laboratory	TIVICAY.xml:S1:8742:10	laboratori	NN	O	O
Abnormalities	TIVICAY.xml:S1:8753:13	abnorm	NNS	O	O

Treatment	TIVICAY.xml:S1:8775:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:8784:1	-	:	O	O
naive	TIVICAY.xml:S1:8785:5	naiv	JJ	O	O
Subjects	TIVICAY.xml:S1:8791:8	subject	NNS	O	O
:	TIVICAY.xml:S1:8801:1	:	:	O	O
Selected	TIVICAY.xml:S1:8803:8	select	VBN	O	O
laboratory	TIVICAY.xml:S1:8812:10	laboratori	NN	O	O
abnormalities	TIVICAY.xml:S1:8823:13	abnorm	NNS	O	O
(	TIVICAY.xml:S1:8837:1	(	(	O	O
Grades	TIVICAY.xml:S1:8838:6	grade	NNP	O	O
2	TIVICAY.xml:S1:8845:1	2	CD	O	O
to	TIVICAY.xml:S1:8847:2	to	TO	O	O
4	TIVICAY.xml:S1:8850:1	4	CD	O	O
)	TIVICAY.xml:S1:8851:1	)	)	O	O
with	TIVICAY.xml:S1:8853:4	with	IN	O	O
a	TIVICAY.xml:S1:8858:1	a	DT	O	O
worsening	TIVICAY.xml:S1:8860:9	worsen	VBG	O	O
grade	TIVICAY.xml:S1:8870:5	grade	NN	O	O
from	TIVICAY.xml:S1:8876:4	from	IN	O	O
baseline	TIVICAY.xml:S1:8881:8	baselin	NN	O	O
and	TIVICAY.xml:S1:8890:3	and	CC	O	O
representing	TIVICAY.xml:S1:8894:12	repres	VBG	O	O
the	TIVICAY.xml:S1:8907:3	the	DT	O	O
worst	TIVICAY.xml:S1:8911:5	worst	JJS	O	O
-	TIVICAY.xml:S1:8916:1	-	:	O	O
grade	TIVICAY.xml:S1:8917:5	grade	NN	O	O
toxicity	TIVICAY.xml:S1:8923:8	toxic	NN	O	O
in	TIVICAY.xml:S1:8932:2	in	IN	O	O
at	TIVICAY.xml:S1:8935:2	at	IN	O	O
least	TIVICAY.xml:S1:8938:5	least	JJS	O	O
2%	TIVICAY.xml:S1:8944:2	2%	CD	O	O
of	TIVICAY.xml:S1:8947:2	of	IN	O	O
subjects	TIVICAY.xml:S1:8950:8	subject	NNS	O	O
are	TIVICAY.xml:S1:8959:3	are	VBP	O	O
presented	TIVICAY.xml:S1:8963:9	present	VBN	O	O
in	TIVICAY.xml:S1:8973:2	in	IN	O	O
Table	TIVICAY.xml:S1:8976:5	tabl	JJ	O	O
3	TIVICAY.xml:S1:8982:1	3	CD	O	O
.	TIVICAY.xml:S1:8983:1	.	.	O	O

The	TIVICAY.xml:S1:8985:3	the	DT	O	O
mean	TIVICAY.xml:S1:8989:4	mean	JJ	O	O
change	TIVICAY.xml:S1:8994:6	chang	NN	O	O
from	TIVICAY.xml:S1:9001:4	from	IN	O	O
baseline	TIVICAY.xml:S1:9006:8	baselin	NN	O	O
observed	TIVICAY.xml:S1:9015:8	observ	VBN	O	O
for	TIVICAY.xml:S1:9024:3	for	IN	O	O
selected	TIVICAY.xml:S1:9028:8	select	VBN	O	O
lipid	TIVICAY.xml:S1:9037:5	lipid	JJ	O	O
values	TIVICAY.xml:S1:9043:6	valu	NNS	O	O
is	TIVICAY.xml:S1:9050:2	is	VBZ	O	O
presented	TIVICAY.xml:S1:9053:9	present	VBN	O	O
in	TIVICAY.xml:S1:9063:2	in	IN	O	O
Table	TIVICAY.xml:S1:9066:5	tabl	JJ	O	O
4	TIVICAY.xml:S1:9072:1	4	CD	O	O
.	TIVICAY.xml:S1:9073:1	.	.	O	O

Side	TIVICAY.xml:S1:9075:4	side	NNP	O	O
-	TIVICAY.xml:S1:9079:1	-	:	O	O
by	TIVICAY.xml:S1:9080:2	by	IN	O	O
-	TIVICAY.xml:S1:9082:1	-	:	O	O
side	TIVICAY.xml:S1:9083:4	side	NN	O	O
tabulation	TIVICAY.xml:S1:9088:10	tabul	NN	O	O
is	TIVICAY.xml:S1:9099:2	is	VBZ	O	O
to	TIVICAY.xml:S1:9102:2	to	TO	O	O
simplify	TIVICAY.xml:S1:9105:8	simplifi	VB	O	O
presentation	TIVICAY.xml:S1:9114:12	present	NN	O	O
;	TIVICAY.xml:S1:9126:1	;	:	O	O
direct	TIVICAY.xml:S1:9128:6	direct	JJ	O	O
comparisons	TIVICAY.xml:S1:9135:11	comparison	NNS	O	O
across	TIVICAY.xml:S1:9147:6	across	IN	O	O
trials	TIVICAY.xml:S1:9154:6	trial	NNS	O	O
should	TIVICAY.xml:S1:9161:6	should	MD	O	O
not	TIVICAY.xml:S1:9168:3	not	RB	O	O
be	TIVICAY.xml:S1:9172:2	be	VB	O	O
made	TIVICAY.xml:S1:9175:4	made	VBN	O	O
due	TIVICAY.xml:S1:9180:3	due	JJ	O	O
to	TIVICAY.xml:S1:9184:2	to	TO	O	O
differing	TIVICAY.xml:S1:9187:9	differ	VBG	O	O
trial	TIVICAY.xml:S1:9197:5	trial	NN	O	O
designs	TIVICAY.xml:S1:9203:7	design	NNS	O	O
.	TIVICAY.xml:S1:9210:1	.	.	O	O

Table	TIVICAY.xml:S1:9216:5	tabl	JJ	O	O
3	TIVICAY.xml:S1:9222:1	3	CD	O	O
.	TIVICAY.xml:S1:9223:1	.	.	O	O

Selected	TIVICAY.xml:S1:9225:8	select	VBN	O	O
Laboratory	TIVICAY.xml:S1:9234:10	laboratori	JJ	O	O
Abnormalities	TIVICAY.xml:S1:9245:13	abnorm	NNP	O	O
(	TIVICAY.xml:S1:9259:1	(	(	O	O
Grades	TIVICAY.xml:S1:9260:6	grade	NNP	O	O
2	TIVICAY.xml:S1:9267:1	2	CD	O	O
to	TIVICAY.xml:S1:9269:2	to	TO	O	O
4	TIVICAY.xml:S1:9272:1	4	CD	O	O
)	TIVICAY.xml:S1:9273:1	)	)	O	O
in	TIVICAY.xml:S1:9275:2	in	IN	O	O
Treatment	TIVICAY.xml:S1:9278:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:9287:1	-	:	O	O
naive	TIVICAY.xml:S1:9288:5	naiv	JJ	O	O
Subjects	TIVICAY.xml:S1:9294:8	subject	NNS	O	O
in	TIVICAY.xml:S1:9303:2	in	IN	O	O
SPRING	TIVICAY.xml:S1:9306:6	spring	NNP	O	O
-	TIVICAY.xml:S1:9312:1	-	:	O	O
2	TIVICAY.xml:S1:9313:1	2	CD	O	O
and	TIVICAY.xml:S1:9315:3	and	CC	O	O
SINGLE	TIVICAY.xml:S1:9319:6	singl	NNP	O	O
Trials	TIVICAY.xml:S1:9326:6	trial	NNP	O	O
(	TIVICAY.xml:S1:9333:1	(	(	O	O
Week	TIVICAY.xml:S1:9334:4	week	NNP	O	O
96	TIVICAY.xml:S1:9339:2	96	CD	O	O
Analysis	TIVICAY.xml:S1:9342:8	analysi	NN	O	O
)	TIVICAY.xml:S1:9350:1	)	)	O	O

Laboratory	TIVICAY.xml:S1:9355:10	laboratori	NN	O	O
Parameter	TIVICAY.xml:S1:9366:9	paramet	NNP	O	O
Preferred	TIVICAY.xml:S1:9377:9	prefer	NNP	O	O
Term	TIVICAY.xml:S1:9387:4	term	NNP	O	O
SPRING	TIVICAY.xml:S1:9395:6	spring	NNP	O	O
-	TIVICAY.xml:S1:9401:1	-	:	O	O
2	TIVICAY.xml:S1:9402:1	2	CD	O	O
SINGLE	TIVICAY.xml:S1:9417:6	singl	NN	O	O

TIVICAY	TIVICAY.xml:S1:9442:7	tivicay	$	O	O
50	TIVICAY.xml:S1:9450:2	50	CD	O	O
mg	TIVICAY.xml:S1:9453:2	mg	NN	O	O
Once	TIVICAY.xml:S1:9456:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:9461:5	daili	NNP	O	O
2	TIVICAY.xml:S1:9470:1	2	CD	O	O
NRTIs	TIVICAY.xml:S1:9472:5	nrti	NNP	O	O
(	TIVICAY.xml:S1:9479:1	(	(	O	O
n	TIVICAY.xml:S1:9480:1	n	JJ	O	O
403	TIVICAY.xml:S1:9484:3	403	CD	O	O
)	TIVICAY.xml:S1:9487:1	)	)	O	O
Raltegravir	TIVICAY.xml:S1:9492:11	raltegravir	NNP	O	O
400	TIVICAY.xml:S1:9505:3	400	CD	O	O
mg	TIVICAY.xml:S1:9509:2	mg	NN	O	O
Twice	TIVICAY.xml:S1:9512:5	twice	NNP	O	O
Daily	TIVICAY.xml:S1:9518:5	daili	NNP	O	O
2	TIVICAY.xml:S1:9526:1	2	CD	O	O
NRTIs	TIVICAY.xml:S1:9528:5	nrti	NNP	O	O
(	TIVICAY.xml:S1:9535:1	(	(	O	O
n	TIVICAY.xml:S1:9536:1	n	JJ	O	O
405	TIVICAY.xml:S1:9540:3	405	CD	O	O
)	TIVICAY.xml:S1:9543:1	)	)	O	O
TIVICAY	TIVICAY.xml:S1:9548:7	tivicay	$	O	O
50	TIVICAY.xml:S1:9556:2	50	CD	O	O
mg	TIVICAY.xml:S1:9559:2	mg	NN	O	O
EPZICOM	TIVICAY.xml:S1:9564:7	epzicom	NNP	O	O
Once	TIVICAY.xml:S1:9572:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:9577:5	daili	NNP	O	O
(	TIVICAY.xml:S1:9584:1	(	(	O	O
n	TIVICAY.xml:S1:9585:1	n	JJ	O	O
414	TIVICAY.xml:S1:9589:3	414	CD	O	O
)	TIVICAY.xml:S1:9592:1	)	)	O	O
ATRIPLA	TIVICAY.xml:S1:9597:7	atripla	NNP	O	O
Once	TIVICAY.xml:S1:9606:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:9611:5	daili	NNP	O	O
(	TIVICAY.xml:S1:9618:1	(	(	O	O
n	TIVICAY.xml:S1:9619:1	n	JJ	O	O
419	TIVICAY.xml:S1:9623:3	419	CD	O	O
)	TIVICAY.xml:S1:9626:1	)	)	O	O

ALT	TIVICAY.xml:S1:9634:3	alt	NN	O	O

4%	TIVICAY.xml:S1:9773:2	4%	CD	O	O
4%	TIVICAY.xml:S1:9795:2	4%	CD	O	O
2%	TIVICAY.xml:S1:9817:2	2%	CD	O	O
5%	TIVICAY.xml:S1:9844:2	5%	CD	O	O

2%	TIVICAY.xml:S1:9886:2	2%	CD	O	O
2%	TIVICAY.xml:S1:9908:2	2%	CD	O	O
1%	TIVICAY.xml:S1:9931:2	1%	CD	O	O
1%	TIVICAY.xml:S1:9958:2	1%	CD	O	O

AST	TIVICAY.xml:S1:9973:3	ast	NN	O	O

5%	TIVICAY.xml:S1:10112:2	5%	CD	O	O
3%	TIVICAY.xml:S1:10134:2	3%	CD	O	O
3%	TIVICAY.xml:S1:10156:2	3%	CD	O	O
3%	TIVICAY.xml:S1:10183:2	3%	CD	O	O

3%	TIVICAY.xml:S1:10225:2	3%	CD	O	O
2%	TIVICAY.xml:S1:10247:2	2%	CD	O	O
1%	TIVICAY.xml:S1:10270:2	1%	CD	O	O
3%	TIVICAY.xml:S1:10296:2	3%	CD	O	O

3%	TIVICAY.xml:S1:10451:2	3%	CD	O	O

2%	TIVICAY.xml:S1:10473:2	2%	CD	O	O
1%	TIVICAY.xml:S1:10496:2	1%	CD	O	O
0	TIVICAY.xml:S1:10522:1	0	CD	O	O

1%	TIVICAY.xml:S1:10565:2	1%	CD	O	O
1%	TIVICAY.xml:S1:10587:2	1%	CD	O	O
1%	TIVICAY.xml:S1:10609:2	1%	CD	O	O
0	TIVICAY.xml:S1:10635:1	0	CD	O	O

Creatine	TIVICAY.xml:S1:10651:8	creatin	NNP	O	O
kinase	TIVICAY.xml:S1:10660:6	kinas	NN	O	O

2%	TIVICAY.xml:S1:10790:2	2%	CD	O	O
5%	TIVICAY.xml:S1:10812:2	5%	CD	O	O
4%	TIVICAY.xml:S1:10834:2	4%	CD	O	O
1%	TIVICAY.xml:S1:10861:2	1%	CD	O	O

7%	TIVICAY.xml:S1:10903:2	7%	CD	O	O
4%	TIVICAY.xml:S1:10925:2	4%	CD	O	O
5%	TIVICAY.xml:S1:10947:2	5%	CD	O	O
7%	TIVICAY.xml:S1:10974:2	7%	CD	O	O

Hyperglycemia	TIVICAY.xml:S1:10990:13	hyperglycemia	NN	B-AdverseReaction	O

6%	TIVICAY.xml:S1:11129:2	6%	CD	O	O
6%	TIVICAY.xml:S1:11151:2	6%	CD	O	O
7%	TIVICAY.xml:S1:11173:2	7%	CD	O	O
5%	TIVICAY.xml:S1:11200:2	5%	CD	O	O

1%	TIVICAY.xml:S1:11243:2	1%	CD	O	O
2%	TIVICAY.xml:S1:11264:2	2%	CD	O	O
2%	TIVICAY.xml:S1:11286:2	2%	CD	O	O
1%	TIVICAY.xml:S1:11314:2	1%	CD	O	O

Lipase	TIVICAY.xml:S1:11329:6	lipas	NN	O	O

7%	TIVICAY.xml:S1:11468:2	7%	CD	O	O
7%	TIVICAY.xml:S1:11490:2	7%	CD	O	O
9%	TIVICAY.xml:S1:11512:2	9%	CD	O	O
9%	TIVICAY.xml:S1:11539:2	9%	CD	O	O

2%	TIVICAY.xml:S1:11581:2	2%	CD	O	O
5%	TIVICAY.xml:S1:11603:2	5%	CD	O	O
4%	TIVICAY.xml:S1:11625:2	4%	CD	O	O
3%	TIVICAY.xml:S1:11652:2	3%	CD	O	O

Total	TIVICAY.xml:S1:11668:5	total	JJ	O	O
neutrophils	TIVICAY.xml:S1:11674:11	neutrophil	NNS	O	O

4%	TIVICAY.xml:S1:11807:2	4%	CD	O	O
3%	TIVICAY.xml:S1:11829:2	3%	CD	O	O
3%	TIVICAY.xml:S1:11851:2	3%	CD	O	O
5%	TIVICAY.xml:S1:11878:2	5%	CD	O	O

2%	TIVICAY.xml:S1:11920:2	2%	CD	O	O
2%	TIVICAY.xml:S1:11942:2	2%	CD	O	O
2%	TIVICAY.xml:S1:11964:2	2%	CD	O	O
3%	TIVICAY.xml:S1:11991:2	3%	CD	O	O

ULN	TIVICAY.xml:S1:12016:3	uln	NNP	O	O
Upper	TIVICAY.xml:S1:12022:5	upper	NNP	O	O
limit	TIVICAY.xml:S1:12028:5	limit	NN	O	O
of	TIVICAY.xml:S1:12034:2	of	IN	O	O
normal	TIVICAY.xml:S1:12037:6	normal	JJ	O	O
.	TIVICAY.xml:S1:12043:1	.	.	O	O

Table	TIVICAY.xml:S1:12049:5	tabl	NN	O	O

4	TIVICAY.xml:S1:12055:1	4	CD	O	O
.	TIVICAY.xml:S1:12056:1	.	.	O	O

Mean	TIVICAY.xml:S1:12058:4	mean	JJ	O	O
Change	TIVICAY.xml:S1:12063:6	chang	NNP	O	O
from	TIVICAY.xml:S1:12070:4	from	IN	O	O
Baseline	TIVICAY.xml:S1:12075:8	baselin	NNP	O	O
in	TIVICAY.xml:S1:12084:2	in	IN	O	I-AdverseReaction
Fasted	TIVICAY.xml:S1:12087:6	fast	NNP	O	I-AdverseReaction
Lipid	TIVICAY.xml:S1:12094:5	lipid	NNP	O	O
Values	TIVICAY.xml:S1:12100:6	valu	NNP	O	O
in	TIVICAY.xml:S1:12107:2	in	IN	O	O
Treatment	TIVICAY.xml:S1:12110:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:12119:1	-	:	O	O
naive	TIVICAY.xml:S1:12120:5	naiv	JJ	O	O
Subjects	TIVICAY.xml:S1:12126:8	subject	NNS	O	O
in	TIVICAY.xml:S1:12135:2	in	IN	O	O
SPRING	TIVICAY.xml:S1:12138:6	spring	NNP	O	O
-	TIVICAY.xml:S1:12144:1	-	:	O	O
2	TIVICAY.xml:S1:12145:1	2	CD	O	O
and	TIVICAY.xml:S1:12147:3	and	CC	O	O
SINGLE	TIVICAY.xml:S1:12151:6	singl	NNP	O	O
Trials	TIVICAY.xml:S1:12158:6	trial	NNP	O	O
(	TIVICAY.xml:S1:12165:1	(	(	O	O
Week	TIVICAY.xml:S1:12166:4	week	NNP	O	O
96	TIVICAY.xml:S1:12171:2	96	CD	O	O
Analysisa	TIVICAY.xml:S1:12174:9	analysisa	NNP	O	O
)	TIVICAY.xml:S1:12183:1	)	)	O	O

Laboratory	TIVICAY.xml:S1:12188:10	laboratori	NN	O	O
Parameter	TIVICAY.xml:S1:12199:9	paramet	NNP	O	O
Preferred	TIVICAY.xml:S1:12210:9	prefer	NNP	O	O
Term	TIVICAY.xml:S1:12220:4	term	NNP	O	O
SPRING	TIVICAY.xml:S1:12228:6	spring	NNP	O	O
-	TIVICAY.xml:S1:12234:1	-	:	O	O
2	TIVICAY.xml:S1:12235:1	2	CD	O	O
SINGLE	TIVICAY.xml:S1:12253:6	singl	NN	O	O

TIVICAY	TIVICAY.xml:S1:12283:7	tivicay	$	O	O
50	TIVICAY.xml:S1:12291:2	50	CD	O	O
mg	TIVICAY.xml:S1:12294:2	mg	NN	O	O
Once	TIVICAY.xml:S1:12297:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:12302:5	daili	NNP	O	O
2	TIVICAY.xml:S1:12310:1	2	CD	O	O
NRTIs	TIVICAY.xml:S1:12312:5	nrti	NNP	O	O
(	TIVICAY.xml:S1:12319:1	(	(	O	O
n	TIVICAY.xml:S1:12320:1	n	JJ	O	O
403	TIVICAY.xml:S1:12324:3	403	CD	O	O
)	TIVICAY.xml:S1:12327:1	)	)	O	O
Raltegravir	TIVICAY.xml:S1:12332:11	raltegravir	NNP	O	O
400	TIVICAY.xml:S1:12344:3	400	CD	O	O
mg	TIVICAY.xml:S1:12348:2	mg	NN	O	O
Twice	TIVICAY.xml:S1:12351:5	twice	NNP	O	O
Daily	TIVICAY.xml:S1:12357:5	daili	NNP	O	O
2	TIVICAY.xml:S1:12365:1	2	CD	O	O
NRTIs	TIVICAY.xml:S1:12367:5	nrti	NNP	O	O
(	TIVICAY.xml:S1:12374:1	(	(	O	O
n	TIVICAY.xml:S1:12375:1	n	JJ	O	O
405	TIVICAY.xml:S1:12379:3	405	CD	O	O
)	TIVICAY.xml:S1:12382:1	)	)	O	O
TIVICAY	TIVICAY.xml:S1:12387:7	tivicay	$	O	O
50	TIVICAY.xml:S1:12395:2	50	CD	O	O
mg	TIVICAY.xml:S1:12398:2	mg	NN	O	O
EPZICOM	TIVICAY.xml:S1:12403:7	epzicom	NNP	O	O
Once	TIVICAY.xml:S1:12411:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:12416:5	daili	NNP	O	O
(	TIVICAY.xml:S1:12423:1	(	(	O	O
n	TIVICAY.xml:S1:12424:1	n	JJ	O	O
414	TIVICAY.xml:S1:12428:3	414	CD	O	O
)	TIVICAY.xml:S1:12431:1	)	)	O	O
ATRIPLA	TIVICAY.xml:S1:12436:7	atripla	NNP	O	O
Once	TIVICAY.xml:S1:12445:4	onc	NNP	O	O
Daily	TIVICAY.xml:S1:12450:5	daili	NNP	O	O
(	TIVICAY.xml:S1:12457:1	(	(	O	O
n	TIVICAY.xml:S1:12458:1	n	JJ	O	O
419	TIVICAY.xml:S1:12462:3	419	CD	O	O
)	TIVICAY.xml:S1:12465:1	)	)	O	O

Cholesterol	TIVICAY.xml:S1:12473:11	cholesterol	NNP	O	O
(	TIVICAY.xml:S1:12485:1	(	(	O	O
mg	TIVICAY.xml:S1:12486:2	mg	FW	O	O
dL	TIVICAY.xml:S1:12489:2	dL	NN	O	O
)	TIVICAY.xml:S1:12491:1	)	)	O	O
8.1	TIVICAY.xml:S1:12496:3	8.1	CD	O	O
10.1	TIVICAY.xml:S1:12521:4	10.1	CD	O	O
23.2	TIVICAY.xml:S1:12548:4	23.2	CD	O	O
28.0	TIVICAY.xml:S1:12574:4	28.0	CD	O	O

HDL	TIVICAY.xml:S1:12590:3	hdl	NNP	O	O
cholesterol	TIVICAY.xml:S1:12594:11	cholesterol	NN	O	O
(	TIVICAY.xml:S1:12606:1	(	(	O	O
mg	TIVICAY.xml:S1:12607:2	mg	JJ	O	O
dL	TIVICAY.xml:S1:12610:2	dL	NN	O	O
)	TIVICAY.xml:S1:12612:1	)	)	O	O
2.0	TIVICAY.xml:S1:12617:3	2.0	CD	O	O
2.3	TIVICAY.xml:S1:12642:3	2.3	CD	O	O
5.2	TIVICAY.xml:S1:12669:3	5.2	CD	O	O
7.4	TIVICAY.xml:S1:12695:3	7.4	CD	O	O

LDL	TIVICAY.xml:S1:12711:3	ldl	NNP	O	O
cholesterol	TIVICAY.xml:S1:12715:11	cholesterol	NN	O	O
(	TIVICAY.xml:S1:12727:1	(	(	O	O
mg	TIVICAY.xml:S1:12728:2	mg	JJ	O	O
dL	TIVICAY.xml:S1:12731:2	dL	NN	O	O
)	TIVICAY.xml:S1:12733:1	)	)	O	O
5.1	TIVICAY.xml:S1:12738:3	5.1	CD	O	O
6.1	TIVICAY.xml:S1:12763:3	6.1	CD	O	O
14.5	TIVICAY.xml:S1:12790:4	14.5	CD	O	O
18.0	TIVICAY.xml:S1:12816:4	18.0	CD	O	O

Triglycerides	TIVICAY.xml:S1:12832:13	triglycerid	NNP	O	O
(	TIVICAY.xml:S1:12846:1	(	(	O	O
mg	TIVICAY.xml:S1:12847:2	mg	FW	O	O
dL	TIVICAY.xml:S1:12850:2	dL	NN	O	O
)	TIVICAY.xml:S1:12852:1	)	)	O	O
6.7	TIVICAY.xml:S1:12857:3	6.7	CD	O	O
6.6	TIVICAY.xml:S1:12882:3	6.6	CD	O	O
17.2	TIVICAY.xml:S1:12909:4	17.2	CD	O	O
17.4	TIVICAY.xml:S1:12935:4	17.4	CD	O	O

a	TIVICAY.xml:S1:12962:1	a	DT	O	O
Subjects	TIVICAY.xml:S1:12965:8	subject	NNS	O	O
on	TIVICAY.xml:S1:12974:2	on	IN	O	O
lipid	TIVICAY.xml:S1:12977:5	lipid	JJ	O	O
-	TIVICAY.xml:S1:12982:1	-	:	O	O
lowering	TIVICAY.xml:S1:12983:8	lower	VBG	O	O
agents	TIVICAY.xml:S1:12992:6	agent	NNS	O	O
at	TIVICAY.xml:S1:12999:2	at	IN	O	O
baseline	TIVICAY.xml:S1:13002:8	baselin	NN	O	O
were	TIVICAY.xml:S1:13011:4	were	VBD	O	O
excluded	TIVICAY.xml:S1:13016:8	exclud	VBN	O	O
from	TIVICAY.xml:S1:13025:4	from	IN	O	O
these	TIVICAY.xml:S1:13030:5	these	DT	O	O
analyses	TIVICAY.xml:S1:13036:8	analys	NNS	O	O
(	TIVICAY.xml:S1:13045:1	(	(	O	O
19	TIVICAY.xml:S1:13046:2	19	CD	O	O
subjects	TIVICAY.xml:S1:13049:8	subject	NNS	O	O
in	TIVICAY.xml:S1:13058:2	in	IN	O	O
each	TIVICAY.xml:S1:13061:4	each	DT	O	O
arm	TIVICAY.xml:S1:13066:3	arm	NN	O	O
in	TIVICAY.xml:S1:13070:2	in	IN	O	O
SPRING	TIVICAY.xml:S1:13073:6	spring	NN	O	O
-	TIVICAY.xml:S1:13079:1	-	:	O	O
2	TIVICAY.xml:S1:13080:1	2	CD	O	O
,	TIVICAY.xml:S1:13081:1	,	,	O	O
and	TIVICAY.xml:S1:13083:3	and	CC	O	O
in	TIVICAY.xml:S1:13087:2	in	IN	O	O
SINGLE	TIVICAY.xml:S1:13090:6	singl	NNP	O	O
:	TIVICAY.xml:S1:13096:1	:	:	O	O
TIVICAY	TIVICAY.xml:S1:13098:7	tivicay	NNP	O	O
n	TIVICAY.xml:S1:13106:1	n	CC	O	O
30	TIVICAY.xml:S1:13110:2	30	CD	O	O
and	TIVICAY.xml:S1:13113:3	and	CC	O	O
ATRIPLA	TIVICAY.xml:S1:13117:7	atripla	NNP	O	O
n	TIVICAY.xml:S1:13125:1	n	RB	O	O
27	TIVICAY.xml:S1:13129:2	27	CD	O	O
)	TIVICAY.xml:S1:13131:1	)	)	O	O
.	TIVICAY.xml:S1:13132:1	.	.	O	O

Seventy	TIVICAY.xml:S1:13134:7	seventi	NNP	O	O
-	TIVICAY.xml:S1:13141:1	-	:	O	O
seven	TIVICAY.xml:S1:13142:5	seven	CD	O	O
subjects	TIVICAY.xml:S1:13148:8	subject	NNS	O	O
initiated	TIVICAY.xml:S1:13157:9	initi	VBD	O	O
a	TIVICAY.xml:S1:13167:1	a	DT	O	O
lipid	TIVICAY.xml:S1:13169:5	lipid	JJ	O	O
-	TIVICAY.xml:S1:13174:1	-	:	O	O
lowering	TIVICAY.xml:S1:13175:8	lower	VBG	O	O
agent	TIVICAY.xml:S1:13184:5	agent	NN	O	O
post	TIVICAY.xml:S1:13190:4	post	NN	O	O
-	TIVICAY.xml:S1:13194:1	-	:	O	O
baseline	TIVICAY.xml:S1:13195:8	baselin	NN	O	O
;	TIVICAY.xml:S1:13203:1	;	:	O	O
their	TIVICAY.xml:S1:13205:5	their	PRP$	O	O
last	TIVICAY.xml:S1:13211:4	last	JJ	O	O
fasted	TIVICAY.xml:S1:13216:6	fast	VBN	O	O
on	TIVICAY.xml:S1:13223:2	on	IN	O	O
-	TIVICAY.xml:S1:13225:1	-	:	O	O
treatment	TIVICAY.xml:S1:13226:9	treatment	NN	O	O
values	TIVICAY.xml:S1:13236:6	valu	NNS	O	O
(	TIVICAY.xml:S1:13243:1	(	(	O	O
prior	TIVICAY.xml:S1:13244:5	prior	RB	O	O
to	TIVICAY.xml:S1:13250:2	to	TO	O	O
starting	TIVICAY.xml:S1:13253:8	start	VBG	O	O
the	TIVICAY.xml:S1:13262:3	the	DT	O	O
agent	TIVICAY.xml:S1:13266:5	agent	NN	O	O
)	TIVICAY.xml:S1:13271:1	)	)	O	O
were	TIVICAY.xml:S1:13273:4	were	VBD	O	O
used	TIVICAY.xml:S1:13278:4	use	VBN	O	O
regardless	TIVICAY.xml:S1:13283:10	regardless	RB	O	O
if	TIVICAY.xml:S1:13294:2	if	IN	O	O
they	TIVICAY.xml:S1:13297:4	they	PRP	O	O
discontinued	TIVICAY.xml:S1:13302:12	discontinu	VBD	O	O
the	TIVICAY.xml:S1:13315:3	the	DT	O	O
agent	TIVICAY.xml:S1:13319:5	agent	NN	O	O
(	TIVICAY.xml:S1:13325:1	(	(	O	O
SPRING	TIVICAY.xml:S1:13326:6	spring	NNP	O	O
-	TIVICAY.xml:S1:13332:1	-	:	O	O
2	TIVICAY.xml:S1:13333:1	2	CD	O	O
:	TIVICAY.xml:S1:13334:1	:	:	O	O
TIVICAY	TIVICAY.xml:S1:13336:7	tivicay	NNP	O	O
n	TIVICAY.xml:S1:13344:1	n	RB	O	O
9	TIVICAY.xml:S1:13348:1	9	CD	O	O
,	TIVICAY.xml:S1:13349:1	,	,	O	O
raltegravir	TIVICAY.xml:S1:13351:11	raltegravir	NN	O	O
n	TIVICAY.xml:S1:13363:1	n	RB	O	O
13	TIVICAY.xml:S1:13367:2	13	CD	O	O
;	TIVICAY.xml:S1:13369:1	;	:	O	O
SINGLE	TIVICAY.xml:S1:13371:6	singl	NNP	O	O
:	TIVICAY.xml:S1:13377:1	:	:	O	O
TIVICAY	TIVICAY.xml:S1:13379:7	tivicay	NNP	O	O
n	TIVICAY.xml:S1:13387:1	n	CC	O	O
25	TIVICAY.xml:S1:13391:2	25	CD	O	O
and	TIVICAY.xml:S1:13394:3	and	CC	O	O
ATRIPLA	TIVICAY.xml:S1:13398:7	atripla	NNP	O	O
:	TIVICAY.xml:S1:13405:1	:	:	O	O
n	TIVICAY.xml:S1:13407:1	n	RB	O	O
30	TIVICAY.xml:S1:13411:2	30	CD	O	O
)	TIVICAY.xml:S1:13413:1	)	)	O	O
.	TIVICAY.xml:S1:13414:1	.	.	O	O

Laboratory	TIVICAY.xml:S1:13420:10	laboratori	NN	O	O

abnormalities	TIVICAY.xml:S1:13431:13	abnorm	NNS	O	O
observed	TIVICAY.xml:S1:13445:8	observ	VBN	O	O
in	TIVICAY.xml:S1:13454:2	in	IN	O	O
the	TIVICAY.xml:S1:13457:3	the	DT	O	O
FLAMINGO	TIVICAY.xml:S1:13461:8	flamingo	NNP	O	O
trial	TIVICAY.xml:S1:13470:5	trial	NN	O	O
were	TIVICAY.xml:S1:13476:4	were	VBD	O	O
generally	TIVICAY.xml:S1:13481:9	gener	RB	O	O
consistent	TIVICAY.xml:S1:13491:10	consist	JJ	O	O
with	TIVICAY.xml:S1:13502:4	with	IN	O	O
observations	TIVICAY.xml:S1:13507:12	observ	NNS	O	O
in	TIVICAY.xml:S1:13520:2	in	IN	O	O
SPRING	TIVICAY.xml:S1:13523:6	spring	NNP	O	O
-	TIVICAY.xml:S1:13529:1	-	:	O	O
2	TIVICAY.xml:S1:13530:1	2	CD	O	O
and	TIVICAY.xml:S1:13532:3	and	CC	O	O
SINGLE	TIVICAY.xml:S1:13536:6	singl	NNP	O	O
.	TIVICAY.xml:S1:13542:1	.	.	O	O

Treatment	TIVICAY.xml:S1:13550:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:13559:1	-	:	O	O
experienced	TIVICAY.xml:S1:13560:11	experienc	VBD	O	O
,	TIVICAY.xml:S1:13571:1	,	,	O	O
Integrase	TIVICAY.xml:S1:13573:9	integras	NNP	O	O
Strand	TIVICAY.xml:S1:13583:6	strand	NNP	O	O
Transfer	TIVICAY.xml:S1:13590:8	transfer	NNP	O	O
Inhibitor	TIVICAY.xml:S1:13599:9	inhibitor	NNP	O	O
-	TIVICAY.xml:S1:13608:1	-	:	O	O
naive	TIVICAY.xml:S1:13609:5	naiv	JJ	O	O
Subjects	TIVICAY.xml:S1:13615:8	subject	NNS	O	O
:	TIVICAY.xml:S1:13625:1	:	:	O	O
Laboratory	TIVICAY.xml:S1:13627:10	laboratori	NN	O	O
abnormalities	TIVICAY.xml:S1:13638:13	abnorm	NNS	O	O
observed	TIVICAY.xml:S1:13652:8	observ	VBN	O	O
in	TIVICAY.xml:S1:13661:2	in	IN	O	O
SAILING	TIVICAY.xml:S1:13664:7	sail	NN	O	O
were	TIVICAY.xml:S1:13672:4	were	VBD	O	O
generally	TIVICAY.xml:S1:13677:9	gener	RB	O	O
similar	TIVICAY.xml:S1:13687:7	similar	JJ	O	O
compared	TIVICAY.xml:S1:13695:8	compar	VBN	O	O
with	TIVICAY.xml:S1:13704:4	with	IN	O	O
observations	TIVICAY.xml:S1:13709:12	observ	NNS	O	O
seen	TIVICAY.xml:S1:13722:4	seen	VBN	O	O
in	TIVICAY.xml:S1:13727:2	in	IN	O	O
the	TIVICAY.xml:S1:13730:3	the	DT	O	O
treatment	TIVICAY.xml:S1:13734:9	treatment	NN	O	O
-	TIVICAY.xml:S1:13743:1	-	:	O	O
naive	TIVICAY.xml:S1:13744:5	naiv	JJ	O	O
(	TIVICAY.xml:S1:13750:1	(	(	O	O
SPRING	TIVICAY.xml:S1:13751:6	spring	NNP	O	O
-	TIVICAY.xml:S1:13757:1	-	:	O	O
2	TIVICAY.xml:S1:13758:1	2	CD	O	O
and	TIVICAY.xml:S1:13760:3	and	CC	O	O
SINGLE	TIVICAY.xml:S1:13764:6	singl	NNP	O	O
)	TIVICAY.xml:S1:13770:1	)	)	O	O
trials	TIVICAY.xml:S1:13772:6	trial	NNS	O	O
.	TIVICAY.xml:S1:13778:1	.	.	O	O

Treatment	TIVICAY.xml:S1:13786:9	treatment	NNP	O	O
-	TIVICAY.xml:S1:13795:1	-	:	O	O
experienced	TIVICAY.xml:S1:13796:11	experienc	VBD	O	O
,	TIVICAY.xml:S1:13807:1	,	,	O	O
Integrase	TIVICAY.xml:S1:13809:9	integras	NNP	O	O
Strand	TIVICAY.xml:S1:13819:6	strand	NNP	O	O
Transfer	TIVICAY.xml:S1:13826:8	transfer	NNP	O	O
Inhibitor	TIVICAY.xml:S1:13835:9	inhibitor	NNP	O	O
-	TIVICAY.xml:S1:13844:1	-	:	O	O
experienced	TIVICAY.xml:S1:13845:11	experienc	JJ	O	O
Subjects	TIVICAY.xml:S1:13857:8	subject	NNS	O	O
:	TIVICAY.xml:S1:13867:1	:	:	O	O
The	TIVICAY.xml:S1:13869:3	the	DT	O	O
most	TIVICAY.xml:S1:13873:4	most	RBS	O	O
common	TIVICAY.xml:S1:13878:6	common	JJ	O	O
treatment	TIVICAY.xml:S1:13885:9	treatment	NN	O	O
-	TIVICAY.xml:S1:13894:1	-	:	O	O
emergent	TIVICAY.xml:S1:13895:8	emerg	JJ	O	O
laboratory	TIVICAY.xml:S1:13904:10	laboratori	NN	O	O
abnormalities	TIVICAY.xml:S1:13915:13	abnorm	NNS	O	O
(	TIVICAY.xml:S1:13929:1	(	(	O	O
greater	TIVICAY.xml:S1:13930:7	greater	JJR	O	O
than	TIVICAY.xml:S1:13938:4	than	IN	O	O
5%	TIVICAY.xml:S1:13943:2	5%	CD	O	O
for	TIVICAY.xml:S1:13946:3	for	IN	O	O
Grades	TIVICAY.xml:S1:13950:6	grade	NNP	O	O
2	TIVICAY.xml:S1:13957:1	2	CD	O	O
to	TIVICAY.xml:S1:13959:2	to	TO	O	O
4	TIVICAY.xml:S1:13962:1	4	CD	O	O
combined	TIVICAY.xml:S1:13964:8	combin	VBN	O	O
)	TIVICAY.xml:S1:13972:1	)	)	O	O
observed	TIVICAY.xml:S1:13974:8	observ	VBN	O	O
in	TIVICAY.xml:S1:13983:2	in	IN	O	O
VIKING	TIVICAY.xml:S1:13986:6	vike	NNP	O	O
-	TIVICAY.xml:S1:13992:1	-	:	O	O
3	TIVICAY.xml:S1:13993:1	3	CD	O	O
at	TIVICAY.xml:S1:13995:2	at	IN	O	O
Week	TIVICAY.xml:S1:13998:4	week	JJ	O	O
48	TIVICAY.xml:S1:14003:2	48	CD	O	O
were	TIVICAY.xml:S1:14006:4	were	VBD	O	O
elevated	TIVICAY.xml:S1:14011:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
ALT	TIVICAY.xml:S1:14020:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
(	TIVICAY.xml:S1:14024:1	(	(	O	O
9%	TIVICAY.xml:S1:14025:2	9%	CD	O	O
)	TIVICAY.xml:S1:14027:1	)	)	O	O
,	TIVICAY.xml:S1:14028:1	,	,	O	O
AST	TIVICAY.xml:S1:14030:3	ast	NNP	O	O
(	TIVICAY.xml:S1:14034:1	(	(	O	O
8%	TIVICAY.xml:S1:14035:2	8%	CD	O	O
)	TIVICAY.xml:S1:14037:1	)	)	O	O
,	TIVICAY.xml:S1:14038:1	,	,	O	O
cholesterol	TIVICAY.xml:S1:14040:11	cholesterol	NN	I-AdverseReaction	B-AdverseReaction
(	TIVICAY.xml:S1:14052:1	(	(	O	O
10%	TIVICAY.xml:S1:14053:3	10%	CD	O	O
)	TIVICAY.xml:S1:14056:1	)	)	O	O
,	TIVICAY.xml:S1:14057:1	,	,	O	O
creatine	TIVICAY.xml:S1:14059:8	creatin	JJ	I-AdverseReaction	B-AdverseReaction
kinase	TIVICAY.xml:S1:14068:6	kinas	NN	I-AdverseReaction	I-AdverseReaction
(	TIVICAY.xml:S1:14075:1	(	(	O	O
6%	TIVICAY.xml:S1:14076:2	6%	CD	O	O
)	TIVICAY.xml:S1:14078:1	)	)	O	O
,	TIVICAY.xml:S1:14079:1	,	,	O	O
hyperglycemia	TIVICAY.xml:S1:14081:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
(	TIVICAY.xml:S1:14095:1	(	(	O	O
14%	TIVICAY.xml:S1:14096:3	14%	CD	O	O
)	TIVICAY.xml:S1:14099:1	)	)	O	O
,	TIVICAY.xml:S1:14100:1	,	,	O	O
and	TIVICAY.xml:S1:14102:3	and	CC	O	O
lipase	TIVICAY.xml:S1:14106:6	lipas	NN	I-AdverseReaction	O
(	TIVICAY.xml:S1:14113:1	(	(	O	O
10%	TIVICAY.xml:S1:14114:3	10%	CD	O	O
)	TIVICAY.xml:S1:14117:1	)	)	O	O
.	TIVICAY.xml:S1:14118:1	.	.	O	O

Two	TIVICAY.xml:S1:14120:3	two	CD	O	O
percent	TIVICAY.xml:S1:14124:7	percent	NN	O	O
(	TIVICAY.xml:S1:14132:1	(	(	O	O
4	TIVICAY.xml:S1:14133:1	4	CD	O	O
of	TIVICAY.xml:S1:14135:2	of	IN	O	O
183	TIVICAY.xml:S1:14138:3	183	CD	O	O
)	TIVICAY.xml:S1:14141:1	)	)	O	O
of	TIVICAY.xml:S1:14143:2	of	IN	O	O
subjects	TIVICAY.xml:S1:14146:8	subject	NNS	O	O
had	TIVICAY.xml:S1:14155:3	had	VBD	O	O
a	TIVICAY.xml:S1:14159:1	a	DT	O	O
Grade	TIVICAY.xml:S1:14161:5	grade	NNP	O	O
3	TIVICAY.xml:S1:14167:1	3	CD	O	O
to	TIVICAY.xml:S1:14169:2	to	TO	O	O
4	TIVICAY.xml:S1:14172:1	4	CD	O	O
treatment	TIVICAY.xml:S1:14174:9	treatment	NN	O	O
-	TIVICAY.xml:S1:14183:1	-	:	O	O
emergent	TIVICAY.xml:S1:14184:8	emerg	NN	O	O
hematology	TIVICAY.xml:S1:14193:10	hematolog	NN	O	O
laboratory	TIVICAY.xml:S1:14204:10	laboratori	NN	O	O
abnormality	TIVICAY.xml:S1:14215:11	abnorm	NN	O	O
,	TIVICAY.xml:S1:14226:1	,	,	O	O
with	TIVICAY.xml:S1:14228:4	with	IN	O	O
neutropenia	TIVICAY.xml:S1:14233:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
(	TIVICAY.xml:S1:14245:1	(	(	O	O
2%	TIVICAY.xml:S1:14246:2	2%	CD	O	O
[	TIVICAY.xml:S1:14249:1	[	RB	O	O
3	TIVICAY.xml:S1:14250:1	3	CD	O	O
of	TIVICAY.xml:S1:14252:2	of	IN	O	O
183	TIVICAY.xml:S1:14255:3	183	CD	O	O
])	TIVICAY.xml:S1:14258:2	])	NNS	O	O
being	TIVICAY.xml:S1:14261:5	be	VBG	O	O
the	TIVICAY.xml:S1:14267:3	the	DT	O	O
most	TIVICAY.xml:S1:14271:4	most	RBS	O	O
frequently	TIVICAY.xml:S1:14276:10	frequent	RB	O	O
reported	TIVICAY.xml:S1:14287:8	report	VBN	O	O
.	TIVICAY.xml:S1:14295:1	.	.	O	O

Hepatitis	TIVICAY.xml:S1:14303:9	hepat	NN	O	O
B	TIVICAY.xml:S1:14313:1	B	NNP	O	O
and	TIVICAY.xml:S1:14315:3	and	CC	O	O
or	TIVICAY.xml:S1:14319:2	or	CC	O	O
Hepatitis	TIVICAY.xml:S1:14322:9	hepat	NNP	O	O
C	TIVICAY.xml:S1:14332:1	C	NNP	O	O
Virus	TIVICAY.xml:S1:14334:5	viru	NNP	O	O
Co	TIVICAY.xml:S1:14340:2	Co	NNP	O	O
-	TIVICAY.xml:S1:14342:1	-	:	O	O
infection	TIVICAY.xml:S1:14343:9	infect	NN	O	O
:	TIVICAY.xml:S1:14354:1	:	:	O	O
In	TIVICAY.xml:S1:14356:2	In	IN	O	O
Phase	TIVICAY.xml:S1:14359:5	phase	NNP	O	O
3	TIVICAY.xml:S1:14365:1	3	CD	O	O
trials	TIVICAY.xml:S1:14367:6	trial	NNS	O	O
,	TIVICAY.xml:S1:14373:1	,	,	O	O
subjects	TIVICAY.xml:S1:14375:8	subject	NNS	O	O
with	TIVICAY.xml:S1:14384:4	with	IN	O	O
hepatitis	TIVICAY.xml:S1:14389:9	hepat	NN	O	O
B	TIVICAY.xml:S1:14399:1	B	NNP	O	O
and	TIVICAY.xml:S1:14401:3	and	CC	O	O
or	TIVICAY.xml:S1:14405:2	or	CC	O	O
C	TIVICAY.xml:S1:14408:1	C	NNP	O	O
virus	TIVICAY.xml:S1:14410:5	viru	VBP	O	O
co	TIVICAY.xml:S1:14416:2	co	SYM	O	O
-	TIVICAY.xml:S1:14418:1	-	:	O	O
infection	TIVICAY.xml:S1:14419:9	infect	NN	O	O
were	TIVICAY.xml:S1:14429:4	were	VBD	O	O
permitted	TIVICAY.xml:S1:14434:9	permit	VBN	O	O
to	TIVICAY.xml:S1:14444:2	to	TO	O	O
enroll	TIVICAY.xml:S1:14447:6	enrol	VB	O	O
provided	TIVICAY.xml:S1:14454:8	provid	VBN	O	O
that	TIVICAY.xml:S1:14463:4	that	IN	O	O
baseline	TIVICAY.xml:S1:14468:8	baselin	NN	O	O
liver	TIVICAY.xml:S1:14477:5	liver	RB	O	O
chemistry	TIVICAY.xml:S1:14483:9	chemistri	NN	O	O
tests	TIVICAY.xml:S1:14493:5	test	NNS	O	O
did	TIVICAY.xml:S1:14499:3	did	VBD	O	O
not	TIVICAY.xml:S1:14503:3	not	RB	O	O
exceed	TIVICAY.xml:S1:14507:6	exceed	VB	O	O
5	TIVICAY.xml:S1:14514:1	5	CD	O	O
times	TIVICAY.xml:S1:14516:5	time	NNS	O	O
the	TIVICAY.xml:S1:14522:3	the	DT	O	O
upper	TIVICAY.xml:S1:14526:5	upper	JJ	O	O
limit	TIVICAY.xml:S1:14532:5	limit	NN	O	O
of	TIVICAY.xml:S1:14538:2	of	IN	O	O
normal	TIVICAY.xml:S1:14541:6	normal	JJ	O	O
.	TIVICAY.xml:S1:14547:1	.	.	O	O

Overall	TIVICAY.xml:S1:14549:7	overal	JJ	O	O
,	TIVICAY.xml:S1:14556:1	,	,	O	O
the	TIVICAY.xml:S1:14558:3	the	DT	O	O
safety	TIVICAY.xml:S1:14562:6	safeti	NN	O	O
profile	TIVICAY.xml:S1:14569:7	profil	NN	O	O
in	TIVICAY.xml:S1:14577:2	in	IN	O	O
subjects	TIVICAY.xml:S1:14580:8	subject	NNS	O	O
with	TIVICAY.xml:S1:14589:4	with	IN	O	O
hepatitis	TIVICAY.xml:S1:14594:9	hepat	NN	O	O
B	TIVICAY.xml:S1:14604:1	B	NNP	O	O
and	TIVICAY.xml:S1:14606:3	and	CC	O	O
or	TIVICAY.xml:S1:14610:2	or	CC	O	O
C	TIVICAY.xml:S1:14613:1	C	NNP	O	O
virus	TIVICAY.xml:S1:14615:5	viru	VBP	O	O
co	TIVICAY.xml:S1:14621:2	co	SYM	O	O
-	TIVICAY.xml:S1:14623:1	-	:	O	O
infection	TIVICAY.xml:S1:14624:9	infect	NN	O	O
was	TIVICAY.xml:S1:14634:3	wa	VBD	O	O
similar	TIVICAY.xml:S1:14638:7	similar	JJ	O	O
to	TIVICAY.xml:S1:14646:2	to	TO	O	O
that	TIVICAY.xml:S1:14649:4	that	DT	O	O
observed	TIVICAY.xml:S1:14654:8	observ	VBN	O	O
in	TIVICAY.xml:S1:14663:2	in	IN	O	O
subjects	TIVICAY.xml:S1:14666:8	subject	NNS	O	O
without	TIVICAY.xml:S1:14675:7	without	IN	O	O
hepatitis	TIVICAY.xml:S1:14683:9	hepat	NN	O	O
B	TIVICAY.xml:S1:14693:1	B	NNP	O	O
or	TIVICAY.xml:S1:14695:2	or	CC	O	O
C	TIVICAY.xml:S1:14698:1	C	NNP	O	O
co	TIVICAY.xml:S1:14700:2	co	SYM	O	O
-	TIVICAY.xml:S1:14702:1	-	:	O	O
infection	TIVICAY.xml:S1:14703:9	infect	NN	O	O
,	TIVICAY.xml:S1:14712:1	,	,	O	O
although	TIVICAY.xml:S1:14714:8	although	IN	O	O
the	TIVICAY.xml:S1:14723:3	the	DT	O	O
rates	TIVICAY.xml:S1:14727:5	rate	NNS	O	O
of	TIVICAY.xml:S1:14733:2	of	IN	O	O
AST	TIVICAY.xml:S1:14736:3	ast	NNP	B-AdverseReaction	O
and	TIVICAY.xml:S1:14740:3	and	CC	O	O
ALT	TIVICAY.xml:S1:14744:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
abnormalities	TIVICAY.xml:S1:14748:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
were	TIVICAY.xml:S1:14762:4	were	VBD	O	O
higher	TIVICAY.xml:S1:14767:6	higher	JJR	O	O
in	TIVICAY.xml:S1:14774:2	in	IN	O	O
the	TIVICAY.xml:S1:14777:3	the	DT	O	O
subgroup	TIVICAY.xml:S1:14781:8	subgroup	NN	O	O
with	TIVICAY.xml:S1:14790:4	with	IN	O	O
hepatitis	TIVICAY.xml:S1:14795:9	hepat	NN	O	O
B	TIVICAY.xml:S1:14805:1	B	NNP	O	O
and	TIVICAY.xml:S1:14807:3	and	CC	O	O
or	TIVICAY.xml:S1:14811:2	or	CC	O	O
C	TIVICAY.xml:S1:14814:1	C	NNP	O	O
virus	TIVICAY.xml:S1:14816:5	viru	VBP	O	O
co	TIVICAY.xml:S1:14822:2	co	SYM	O	O
-	TIVICAY.xml:S1:14824:1	-	:	O	O
infection	TIVICAY.xml:S1:14825:9	infect	NN	O	O
for	TIVICAY.xml:S1:14835:3	for	IN	O	O
all	TIVICAY.xml:S1:14839:3	all	DT	O	O
treatment	TIVICAY.xml:S1:14843:9	treatment	NN	O	O
groups	TIVICAY.xml:S1:14853:6	group	NNS	O	O
.	TIVICAY.xml:S1:14859:1	.	.	O	O

Grades	TIVICAY.xml:S1:14861:6	grade	NNS	O	O
2	TIVICAY.xml:S1:14868:1	2	CD	O	O
to	TIVICAY.xml:S1:14870:2	to	TO	O	O
4	TIVICAY.xml:S1:14873:1	4	CD	O	O
ALT	TIVICAY.xml:S1:14875:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
abnormalities	TIVICAY.xml:S1:14879:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
in	TIVICAY.xml:S1:14893:2	in	IN	O	O
hepatitis	TIVICAY.xml:S1:14896:9	hepat	NN	O	O
B	TIVICAY.xml:S1:14906:1	B	NNP	O	O
and	TIVICAY.xml:S1:14908:3	and	CC	O	O
or	TIVICAY.xml:S1:14912:2	or	CC	O	O
C	TIVICAY.xml:S1:14915:1	C	NNP	O	O
co	TIVICAY.xml:S1:14917:2	co	SYM	O	O
-	TIVICAY.xml:S1:14919:1	-	:	O	O
infected	TIVICAY.xml:S1:14920:8	infect	VBN	O	O
compared	TIVICAY.xml:S1:14929:8	compar	VBN	O	O
with	TIVICAY.xml:S1:14938:4	with	IN	O	O
HIV	TIVICAY.xml:S1:14943:3	hiv	NNP	O	O
mono	TIVICAY.xml:S1:14947:4	mono	FW	O	O
-	TIVICAY.xml:S1:14951:1	-	:	O	O
infected	TIVICAY.xml:S1:14952:8	infect	JJ	O	O
subjects	TIVICAY.xml:S1:14961:8	subject	NNS	O	O
receiving	TIVICAY.xml:S1:14970:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S1:14980:7	tivicay	NNP	O	O
were	TIVICAY.xml:S1:14988:4	were	VBD	O	O
observed	TIVICAY.xml:S1:14993:8	observ	VBN	O	O
in	TIVICAY.xml:S1:15002:2	in	IN	O	O
18%	TIVICAY.xml:S1:15005:3	18%	CD	O	O
vs	TIVICAY.xml:S1:15009:2	vs	NN	O	O
.	TIVICAY.xml:S1:15011:1	.	.	O	O

3%	TIVICAY.xml:S1:15013:2	3%	CD	O	O
with	TIVICAY.xml:S1:15016:4	with	IN	O	O
the	TIVICAY.xml:S1:15021:3	the	DT	O	O
50	TIVICAY.xml:S1:15025:2	50	CD	O	O
-	TIVICAY.xml:S1:15027:1	-	:	O	O
mg	TIVICAY.xml:S1:15028:2	mg	NN	O	O
once	TIVICAY.xml:S1:15031:4	onc	RB	O	O
-	TIVICAY.xml:S1:15035:1	-	:	O	O
daily	TIVICAY.xml:S1:15036:5	daili	JJ	O	O
dose	TIVICAY.xml:S1:15042:4	dose	NN	O	O
and	TIVICAY.xml:S1:15047:3	and	CC	O	O
13%	TIVICAY.xml:S1:15051:3	13%	CD	O	O
vs	TIVICAY.xml:S1:15055:2	vs	NN	O	O
.	TIVICAY.xml:S1:15057:1	.	.	O	O

8%	TIVICAY.xml:S1:15059:2	8%	CD	O	O
with	TIVICAY.xml:S1:15062:4	with	IN	O	O
the	TIVICAY.xml:S1:15067:3	the	DT	O	O
50	TIVICAY.xml:S1:15071:2	50	CD	O	O
-	TIVICAY.xml:S1:15073:1	-	:	O	O
mg	TIVICAY.xml:S1:15074:2	mg	NN	O	O
twice	TIVICAY.xml:S1:15077:5	twice	RB	O	O
-	TIVICAY.xml:S1:15082:1	-	:	O	O
daily	TIVICAY.xml:S1:15083:5	daili	JJ	O	O
dose	TIVICAY.xml:S1:15089:4	dose	NN	O	O
.	TIVICAY.xml:S1:15093:1	.	.	O	O

Liver	TIVICAY.xml:S1:15095:5	liver	NNP	B-AdverseReaction	O
chemistry	TIVICAY.xml:S1:15101:9	chemistri	NN	I-AdverseReaction	O
elevations	TIVICAY.xml:S1:15111:10	elev	NNS	I-AdverseReaction	O
consistent	TIVICAY.xml:S1:15122:10	consist	VBP	O	O
with	TIVICAY.xml:S1:15133:4	with	IN	O	O
immune	TIVICAY.xml:S1:15138:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
reconstitution	TIVICAY.xml:S1:15145:14	reconstitut	NN	I-AdverseReaction	I-AdverseReaction
syndrome	TIVICAY.xml:S1:15160:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
were	TIVICAY.xml:S1:15169:4	were	VBD	O	O
observed	TIVICAY.xml:S1:15174:8	observ	VBN	O	O
in	TIVICAY.xml:S1:15183:2	in	IN	O	O
some	TIVICAY.xml:S1:15186:4	some	DT	O	O
subjects	TIVICAY.xml:S1:15191:8	subject	NNS	O	O
with	TIVICAY.xml:S1:15200:4	with	IN	O	O
hepatitis	TIVICAY.xml:S1:15205:9	hepat	NN	O	O
B	TIVICAY.xml:S1:15215:1	B	NNP	O	O
and	TIVICAY.xml:S1:15217:3	and	CC	O	O
or	TIVICAY.xml:S1:15221:2	or	CC	O	O
C	TIVICAY.xml:S1:15224:1	C	NNP	O	O
at	TIVICAY.xml:S1:15226:2	at	IN	O	O
the	TIVICAY.xml:S1:15229:3	the	DT	O	O
start	TIVICAY.xml:S1:15233:5	start	NN	O	O
of	TIVICAY.xml:S1:15239:2	of	IN	O	O
therapy	TIVICAY.xml:S1:15242:7	therapi	NN	O	O
with	TIVICAY.xml:S1:15250:4	with	IN	O	O
TIVICAY	TIVICAY.xml:S1:15255:7	tivicay	NNP	O	O
,	TIVICAY.xml:S1:15262:1	,	,	O	O
particularly	TIVICAY.xml:S1:15264:12	particularli	RB	O	O
in	TIVICAY.xml:S1:15277:2	in	IN	O	O
the	TIVICAY.xml:S1:15280:3	the	DT	O	O
setting	TIVICAY.xml:S1:15284:7	set	NN	O	O
where	TIVICAY.xml:S1:15292:5	where	WRB	O	O
anti	TIVICAY.xml:S1:15298:4	anti	SYM	O	O
-	TIVICAY.xml:S1:15302:1	-	:	O	O
hepatitis	TIVICAY.xml:S1:15303:9	hepat	NN	O	O
therapy	TIVICAY.xml:S1:15313:7	therapi	NN	O	O
was	TIVICAY.xml:S1:15321:3	wa	VBD	O	O
withdrawn	TIVICAY.xml:S1:15325:9	withdrawn	VBN	O	O
[	TIVICAY.xml:S1:15336:1	[	NNP	O	O
see	TIVICAY.xml:S1:15337:3	see	VBP	O	O
Warnings	TIVICAY.xml:S1:15341:8	warn	NNP	O	O
and	TIVICAY.xml:S1:15350:3	and	CC	O	O
Precautions	TIVICAY.xml:S1:15354:11	precaut	NNP	O	O
(	TIVICAY.xml:S1:15366:1	(	(	O	O
5.2	TIVICAY.xml:S1:15367:3	5.2	CD	O	O
)]	TIVICAY.xml:S1:15370:2	)]	NN	O	O
.	TIVICAY.xml:S1:15374:1	.	.	O	O

Changes	TIVICAY.xml:S1:15382:7	chang	NNS	O	O
in	TIVICAY.xml:S1:15390:2	in	IN	O	O
Serum	TIVICAY.xml:S1:15393:5	serum	NNP	O	O
Creatinine	TIVICAY.xml:S1:15399:10	creatinin	NNP	O	O

Dolutegravir	TIVICAY.xml:S1:15416:12	dolutegravir	NNP	O	O
has	TIVICAY.xml:S1:15429:3	ha	VBZ	O	O
been	TIVICAY.xml:S1:15433:4	been	VBN	O	O
shown	TIVICAY.xml:S1:15438:5	shown	VBN	O	O
to	TIVICAY.xml:S1:15444:2	to	TO	O	O
increase	TIVICAY.xml:S1:15447:8	increas	VB	B-AdverseReaction	B-AdverseReaction
serum	TIVICAY.xml:S1:15456:5	serum	JJ	I-AdverseReaction	I-AdverseReaction
creatinine	TIVICAY.xml:S1:15462:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
due	TIVICAY.xml:S1:15473:3	due	JJ	O	O
to	TIVICAY.xml:S1:15477:2	to	TO	O	O
inhibition	TIVICAY.xml:S1:15480:10	inhibit	NN	O	O
of	TIVICAY.xml:S1:15491:2	of	IN	O	O
tubular	TIVICAY.xml:S1:15494:7	tubular	JJ	O	O
secretion	TIVICAY.xml:S1:15502:9	secret	NN	O	O
of	TIVICAY.xml:S1:15512:2	of	IN	O	O
creatinine	TIVICAY.xml:S1:15515:10	creatinin	NN	O	O
without	TIVICAY.xml:S1:15526:7	without	IN	O	O
affecting	TIVICAY.xml:S1:15534:9	affect	VBG	O	O
renal	TIVICAY.xml:S1:15544:5	renal	JJ	O	O
glomerular	TIVICAY.xml:S1:15550:10	glomerular	JJ	O	O
function	TIVICAY.xml:S1:15561:8	function	NN	O	O
[	TIVICAY.xml:S1:15571:1	[	NNP	O	O
see	TIVICAY.xml:S1:15572:3	see	VBP	O	O
Clinical	TIVICAY.xml:S1:15576:8	clinic	JJ	O	O
Pharmacology	TIVICAY.xml:S1:15585:12	pharmacolog	NNP	O	O
(	TIVICAY.xml:S1:15598:1	(	(	O	O
12.2	TIVICAY.xml:S1:15599:4	12.2	CD	O	O
)]	TIVICAY.xml:S1:15603:2	)]	NN	O	O
.	TIVICAY.xml:S1:15607:1	.	.	O	O

Increases	TIVICAY.xml:S1:15609:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	TIVICAY.xml:S1:15619:2	in	IN	I-AdverseReaction	I-AdverseReaction
serum	TIVICAY.xml:S1:15622:5	serum	JJ	I-AdverseReaction	I-AdverseReaction
creatinine	TIVICAY.xml:S1:15628:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
occurred	TIVICAY.xml:S1:15639:8	occur	VBD	O	O
within	TIVICAY.xml:S1:15648:6	within	IN	O	O
the	TIVICAY.xml:S1:15655:3	the	DT	O	O
first	TIVICAY.xml:S1:15659:5	first	JJ	O	O
4	TIVICAY.xml:S1:15665:1	4	CD	O	O
weeks	TIVICAY.xml:S1:15667:5	week	NNS	O	O
of	TIVICAY.xml:S1:15673:2	of	IN	O	O
treatment	TIVICAY.xml:S1:15676:9	treatment	NN	O	O
and	TIVICAY.xml:S1:15686:3	and	CC	O	O
remained	TIVICAY.xml:S1:15690:8	remain	VBD	O	O
stable	TIVICAY.xml:S1:15699:6	stabl	JJ	O	O
through	TIVICAY.xml:S1:15706:7	through	IN	O	O
48	TIVICAY.xml:S1:15714:2	48	CD	O	O
to	TIVICAY.xml:S1:15717:2	to	TO	O	O
96	TIVICAY.xml:S1:15720:2	96	CD	O	O
weeks	TIVICAY.xml:S1:15723:5	week	NNS	O	O
.	TIVICAY.xml:S1:15728:1	.	.	O	O

In	TIVICAY.xml:S1:15730:2	In	IN	O	O
treatment	TIVICAY.xml:S1:15733:9	treatment	NN	O	O
-	TIVICAY.xml:S1:15742:1	-	:	O	O
naive	TIVICAY.xml:S1:15743:5	naiv	JJ	O	O
subjects	TIVICAY.xml:S1:15749:8	subject	NNS	O	O
,	TIVICAY.xml:S1:15757:1	,	,	O	O
a	TIVICAY.xml:S1:15759:1	a	DT	O	O
mean	TIVICAY.xml:S1:15761:4	mean	JJ	O	O
change	TIVICAY.xml:S1:15766:6	chang	NN	O	O
from	TIVICAY.xml:S1:15773:4	from	IN	O	O
baseline	TIVICAY.xml:S1:15778:8	baselin	NN	O	O
of	TIVICAY.xml:S1:15787:2	of	IN	O	O
0.15	TIVICAY.xml:S1:15790:4	0.15	CD	O	O
mg	TIVICAY.xml:S1:15795:2	mg	NNS	O	O
per	TIVICAY.xml:S1:15798:3	per	IN	O	O
dL	TIVICAY.xml:S1:15802:2	dL	NN	O	O
(	TIVICAY.xml:S1:15805:1	(	(	O	O
range	TIVICAY.xml:S1:15806:5	rang	NN	O	O
:	TIVICAY.xml:S1:15811:1	:	:	O	O
-	TIVICAY.xml:S1:15813:1	-	:	O	O
0.32	TIVICAY.xml:S1:15814:4	0.32	CD	O	O
mg	TIVICAY.xml:S1:15819:2	mg	NN	O	O
per	TIVICAY.xml:S1:15822:3	per	IN	O	O
dL	TIVICAY.xml:S1:15826:2	dL	NN	O	O
to	TIVICAY.xml:S1:15829:2	to	TO	O	O
0.65	TIVICAY.xml:S1:15832:4	0.65	CD	O	O
mg	TIVICAY.xml:S1:15837:2	mg	NNS	O	O
per	TIVICAY.xml:S1:15840:3	per	IN	O	O
dL	TIVICAY.xml:S1:15844:2	dL	NN	O	O
)	TIVICAY.xml:S1:15846:1	)	)	O	O
was	TIVICAY.xml:S1:15848:3	wa	VBD	O	O
observed	TIVICAY.xml:S1:15852:8	observ	VBN	O	O
after	TIVICAY.xml:S1:15861:5	after	IN	O	O
96	TIVICAY.xml:S1:15867:2	96	CD	O	O
weeks	TIVICAY.xml:S1:15870:5	week	NNS	O	O
of	TIVICAY.xml:S1:15876:2	of	IN	O	O
treatment	TIVICAY.xml:S1:15879:9	treatment	NN	O	O
.	TIVICAY.xml:S1:15888:1	.	.	O	O

Creatinine	TIVICAY.xml:S1:15890:10	creatinin	NN	B-AdverseReaction	B-AdverseReaction
increases	TIVICAY.xml:S1:15901:9	increas	NNS	I-AdverseReaction	I-AdverseReaction
were	TIVICAY.xml:S1:15911:4	were	VBD	O	O
comparable	TIVICAY.xml:S1:15916:10	compar	JJ	O	O
by	TIVICAY.xml:S1:15927:2	by	IN	O	O
background	TIVICAY.xml:S1:15930:10	background	NN	O	O
NRTIs	TIVICAY.xml:S1:15941:5	nrti	NNP	O	O
and	TIVICAY.xml:S1:15947:3	and	CC	O	O
were	TIVICAY.xml:S1:15951:4	were	VBD	O	O
similar	TIVICAY.xml:S1:15956:7	similar	JJ	O	O
in	TIVICAY.xml:S1:15964:2	in	IN	O	O
treatment	TIVICAY.xml:S1:15967:9	treatment	NN	O	O
-	TIVICAY.xml:S1:15976:1	-	:	O	O
experienced	TIVICAY.xml:S1:15977:11	experienc	JJ	O	O
subjects	TIVICAY.xml:S1:15989:8	subject	NNS	O	O
.	TIVICAY.xml:S1:15997:1	.	.	O	O

6.2	TIVICAY.xml:S1:16005:3	6.2	CD	O	O
Clinical	TIVICAY.xml:S1:16009:8	clinic	JJ	O	O
Trials	TIVICAY.xml:S1:16018:6	trial	NNS	O	O
Experience	TIVICAY.xml:S1:16025:10	experi	NN	O	O
in	TIVICAY.xml:S1:16036:2	in	IN	O	O
Pediatric	TIVICAY.xml:S1:16039:9	pediatr	NNP	O	O
Subjects	TIVICAY.xml:S1:16049:8	subject	NNS	O	O

IMPAACT	TIVICAY.xml:S1:16061:7	impaact	NNP	O	O
P1093	TIVICAY.xml:S1:16069:5	p1093	NNP	O	O
is	TIVICAY.xml:S1:16075:2	is	VBZ	O	O
an	TIVICAY.xml:S1:16078:2	an	DT	O	O
ongoing	TIVICAY.xml:S1:16081:7	ongo	JJ	O	O
multicenter	TIVICAY.xml:S1:16089:11	multicent	NN	O	O
,	TIVICAY.xml:S1:16100:1	,	,	O	O
open	TIVICAY.xml:S1:16102:4	open	JJ	O	O
-	TIVICAY.xml:S1:16106:1	-	:	O	O
label	TIVICAY.xml:S1:16107:5	label	NN	O	O
,	TIVICAY.xml:S1:16112:1	,	,	O	O
non	TIVICAY.xml:S1:16114:3	non	SYM	O	O
-	TIVICAY.xml:S1:16117:1	-	:	O	O
comparative	TIVICAY.xml:S1:16118:11	compar	JJ	O	O
trial	TIVICAY.xml:S1:16130:5	trial	NN	O	O
of	TIVICAY.xml:S1:16136:2	of	IN	O	O
approximately	TIVICAY.xml:S1:16139:13	approxim	RB	O	O
160	TIVICAY.xml:S1:16153:3	160	CD	O	O
HIV	TIVICAY.xml:S1:16157:3	hiv	NNP	O	O
-	TIVICAY.xml:S1:16160:1	-	:	O	O
1	TIVICAY.xml:S1:16161:1	1	CD	O	O
-	TIVICAY.xml:S1:16162:1	-	:	O	O
infected	TIVICAY.xml:S1:16163:8	infect	VBN	O	O
pediatric	TIVICAY.xml:S1:16172:9	pediatr	JJ	O	O
subjects	TIVICAY.xml:S1:16182:8	subject	NNS	O	O
aged	TIVICAY.xml:S1:16191:4	age	VBD	O	O
6	TIVICAY.xml:S1:16196:1	6	CD	O	O
weeks	TIVICAY.xml:S1:16198:5	week	NNS	O	O
to	TIVICAY.xml:S1:16204:2	to	TO	O	O
less	TIVICAY.xml:S1:16207:4	less	JJR	O	O
than	TIVICAY.xml:S1:16212:4	than	IN	O	O
18	TIVICAY.xml:S1:16217:2	18	CD	O	O
years	TIVICAY.xml:S1:16220:5	year	NNS	O	O
,	TIVICAY.xml:S1:16225:1	,	,	O	O
of	TIVICAY.xml:S1:16227:2	of	IN	O	O
which	TIVICAY.xml:S1:16230:5	which	WDT	O	O
23	TIVICAY.xml:S1:16236:2	23	CD	O	O
treatment	TIVICAY.xml:S1:16239:9	treatment	NN	O	O
-	TIVICAY.xml:S1:16248:1	-	:	O	O
experienced	TIVICAY.xml:S1:16249:11	experienc	VBN	O	O
,	TIVICAY.xml:S1:16260:1	,	,	O	O
INSTI	TIVICAY.xml:S1:16262:5	insti	NNP	O	O
-	TIVICAY.xml:S1:16267:1	-	:	O	O
naive	TIVICAY.xml:S1:16268:5	naiv	JJ	O	O
subjects	TIVICAY.xml:S1:16274:8	subject	NNS	O	O
aged	TIVICAY.xml:S1:16283:4	age	VBD	O	O
12	TIVICAY.xml:S1:16288:2	12	CD	O	O
to	TIVICAY.xml:S1:16291:2	to	TO	O	O
less	TIVICAY.xml:S1:16294:4	less	JJR	O	O
than	TIVICAY.xml:S1:16299:4	than	IN	O	O
18	TIVICAY.xml:S1:16304:2	18	CD	O	O
years	TIVICAY.xml:S1:16307:5	year	NNS	O	O
were	TIVICAY.xml:S1:16313:4	were	VBD	O	O
enrolled	TIVICAY.xml:S1:16318:8	enrol	VBN	O	O
[	TIVICAY.xml:S1:16328:1	[	NNS	O	O
see	TIVICAY.xml:S1:16329:3	see	VBP	O	O
Use	TIVICAY.xml:S1:16333:3	use	NNP	O	O
in	TIVICAY.xml:S1:16337:2	in	IN	O	O
Specific	TIVICAY.xml:S1:16340:8	specif	NNP	O	O
Populations	TIVICAY.xml:S1:16349:11	popul	NNP	O	O
(	TIVICAY.xml:S1:16361:1	(	(	O	O
8.4	TIVICAY.xml:S1:16362:3	8.4	CD	O	O
)	TIVICAY.xml:S1:16365:1	)	)	O	O
,	TIVICAY.xml:S1:16366:1	,	,	O	O
Clinical	TIVICAY.xml:S1:16368:8	clinic	JJ	O	O
Studies	TIVICAY.xml:S1:16377:7	studi	NNP	O	O
(	TIVICAY.xml:S1:16385:1	(	(	O	O
14.2	TIVICAY.xml:S1:16386:4	14.2	CD	O	O
)]	TIVICAY.xml:S1:16390:2	)]	NN	O	O
.	TIVICAY.xml:S1:16392:1	.	.	O	O

The	TIVICAY.xml:S1:16400:3	the	DT	O	O
adverse	TIVICAY.xml:S1:16404:7	advers	JJ	O	O
reaction	TIVICAY.xml:S1:16412:8	reaction	NN	O	O
profile	TIVICAY.xml:S1:16421:7	profil	NN	O	O
was	TIVICAY.xml:S1:16429:3	wa	VBD	O	O
similar	TIVICAY.xml:S1:16433:7	similar	JJ	O	O
to	TIVICAY.xml:S1:16441:2	to	TO	O	O
that	TIVICAY.xml:S1:16444:4	that	DT	O	O
for	TIVICAY.xml:S1:16449:3	for	IN	O	O
adults	TIVICAY.xml:S1:16453:6	adult	NNS	O	O
.	TIVICAY.xml:S1:16459:1	.	.	O	O

Grade	TIVICAY.xml:S1:16461:5	grade	$	O	O
2	TIVICAY.xml:S1:16467:1	2	CD	O	O
ADRs	TIVICAY.xml:S1:16469:4	adr	NNP	O	O
reported	TIVICAY.xml:S1:16474:8	report	VBD	O	O
in	TIVICAY.xml:S1:16483:2	in	IN	O	O
at	TIVICAY.xml:S1:16486:2	at	IN	O	O
least	TIVICAY.xml:S1:16489:5	least	JJS	O	O
1	TIVICAY.xml:S1:16495:1	1	CD	O	O
subject	TIVICAY.xml:S1:16497:7	subject	JJ	O	O
were	TIVICAY.xml:S1:16505:4	were	VBD	O	O
rash	TIVICAY.xml:S1:16510:4	rash	NN	B-AdverseReaction	B-AdverseReaction
(	TIVICAY.xml:S1:16515:1	(	(	O	O
n	TIVICAY.xml:S1:16516:1	n	JJ	O	O
1	TIVICAY.xml:S1:16520:1	1	CD	O	O
)	TIVICAY.xml:S1:16521:1	)	)	O	O
,	TIVICAY.xml:S1:16522:1	,	,	O	O
abdominal	TIVICAY.xml:S1:16524:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TIVICAY.xml:S1:16534:4	pain	NN	I-AdverseReaction	I-AdverseReaction
(	TIVICAY.xml:S1:16539:1	(	(	O	O
n	TIVICAY.xml:S1:16540:1	n	JJ	O	O
1	TIVICAY.xml:S1:16544:1	1	CD	O	O
)	TIVICAY.xml:S1:16545:1	)	)	O	O
,	TIVICAY.xml:S1:16546:1	,	,	O	O
and	TIVICAY.xml:S1:16548:3	and	CC	O	O
diarrhea	TIVICAY.xml:S1:16552:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
(	TIVICAY.xml:S1:16561:1	(	(	O	O
n	TIVICAY.xml:S1:16562:1	n	JJ	O	O
1	TIVICAY.xml:S1:16566:1	1	CD	O	O
)	TIVICAY.xml:S1:16567:1	)	)	O	O
.	TIVICAY.xml:S1:16568:1	.	.	O	O

No	TIVICAY.xml:S1:16570:2	No	DT	O	O
Grade	TIVICAY.xml:S1:16573:5	grade	NNP	O	O
3	TIVICAY.xml:S1:16579:1	3	CD	O	O
or	TIVICAY.xml:S1:16581:2	or	CC	O	O
4	TIVICAY.xml:S1:16584:1	4	CD	O	O
ADRs	TIVICAY.xml:S1:16586:4	adr	NNS	O	O
were	TIVICAY.xml:S1:16591:4	were	VBD	O	O
reported	TIVICAY.xml:S1:16596:8	report	VBN	O	O
.	TIVICAY.xml:S1:16604:1	.	.	O	O

The	TIVICAY.xml:S1:16606:3	the	DT	O	O
Grade	TIVICAY.xml:S1:16610:5	grade	NNP	O	O
3	TIVICAY.xml:S1:16616:1	3	CD	O	O
laboratory	TIVICAY.xml:S1:16618:10	laboratori	NN	O	O
abnormalities	TIVICAY.xml:S1:16629:13	abnorm	NNS	O	O
were	TIVICAY.xml:S1:16643:4	were	VBD	O	O
elevated	TIVICAY.xml:S1:16648:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
total	TIVICAY.xml:S1:16657:5	total	JJ	I-AdverseReaction	I-AdverseReaction
bilirubin	TIVICAY.xml:S1:16663:9	bilirubin	NN	I-AdverseReaction	I-AdverseReaction
and	TIVICAY.xml:S1:16673:3	and	CC	O	O
lipase	TIVICAY.xml:S1:16677:6	lipas	NN	I-AdverseReaction	O
reported	TIVICAY.xml:S1:16684:8	report	VBN	O	O
in	TIVICAY.xml:S1:16693:2	in	IN	O	O
1	TIVICAY.xml:S1:16696:1	1	CD	O	O
subject	TIVICAY.xml:S1:16698:7	subject	JJ	O	O
each	TIVICAY.xml:S1:16706:4	each	DT	O	O
.	TIVICAY.xml:S1:16710:1	.	.	O	O

No	TIVICAY.xml:S1:16712:2	No	DT	O	O
Grade	TIVICAY.xml:S1:16715:5	grade	NNP	O	O
4	TIVICAY.xml:S1:16721:1	4	CD	O	O
laboratory	TIVICAY.xml:S1:16723:10	laboratori	NN	O	O
abnormalities	TIVICAY.xml:S1:16734:13	abnorm	NNS	O	O
were	TIVICAY.xml:S1:16748:4	were	VBD	O	O
reported	TIVICAY.xml:S1:16753:8	report	VBN	O	O
.	TIVICAY.xml:S1:16761:1	.	.	O	O

The	TIVICAY.xml:S1:16763:3	the	DT	O	O
changes	TIVICAY.xml:S1:16767:7	chang	NNS	O	O
in	TIVICAY.xml:S1:16775:2	in	IN	O	O
mean	TIVICAY.xml:S1:16778:4	mean	JJ	O	O
serum	TIVICAY.xml:S1:16783:5	serum	NN	O	O
creatinine	TIVICAY.xml:S1:16789:10	creatinin	NN	O	O
were	TIVICAY.xml:S1:16800:4	were	VBD	O	O
similar	TIVICAY.xml:S1:16805:7	similar	JJ	O	O
to	TIVICAY.xml:S1:16813:2	to	TO	O	O
those	TIVICAY.xml:S1:16816:5	those	DT	O	O
observed	TIVICAY.xml:S1:16822:8	observ	VBN	O	O
in	TIVICAY.xml:S1:16831:2	in	IN	O	O
adults	TIVICAY.xml:S1:16834:6	adult	NNS	O	O
.	TIVICAY.xml:S1:16840:1	.	.	O	O
5	TIVICAY.xml:S2:4:1	5	CD	O	O
WARNINGS	TIVICAY.xml:S2:6:8	warn	NNP	O	O
AND	TIVICAY.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	TIVICAY.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	TIVICAY.xml:S2:37:7	excerpt	NN	O	O
:	TIVICAY.xml:S2:44:1	:	:	O	O
Hypersensitivity	TIVICAY.xml:S2:54:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	TIVICAY.xml:S2:71:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
characterized	TIVICAY.xml:S2:81:13	character	VBN	O	O
by	TIVICAY.xml:S2:95:2	by	IN	O	O
rash	TIVICAY.xml:S2:98:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S2:102:1	,	,	O	O
constitutional	TIVICAY.xml:S2:104:14	constitut	JJ	O	O
findings	TIVICAY.xml:S2:119:8	find	NNS	O	O
,	TIVICAY.xml:S2:127:1	,	,	O	O
and	TIVICAY.xml:S2:129:3	and	CC	O	O
sometimes	TIVICAY.xml:S2:133:9	sometim	RB	O	O
organ	TIVICAY.xml:S2:143:5	organ	JJ	B-AdverseReaction	B-AdverseReaction
dysfunction	TIVICAY.xml:S2:149:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:160:1	,	,	O	O
including	TIVICAY.xml:S2:162:9	includ	VBG	O	O
liver	TIVICAY.xml:S2:172:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
injury	TIVICAY.xml:S2:178:6	injuri	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:184:1	,	,	O	O
have	TIVICAY.xml:S2:186:4	have	VBP	O	O
been	TIVICAY.xml:S2:191:4	been	VBN	O	O
reported	TIVICAY.xml:S2:196:8	report	VBN	O	O
.	TIVICAY.xml:S2:204:1	.	.	O	O

Discontinue	TIVICAY.xml:S2:206:11	discontinu	NNP	O	O
TIVICAY	TIVICAY.xml:S2:218:7	tivicay	NNP	O	O
and	TIVICAY.xml:S2:226:3	and	CC	O	O
other	TIVICAY.xml:S2:230:5	other	JJ	O	O
suspect	TIVICAY.xml:S2:236:7	suspect	JJ	O	O
agents	TIVICAY.xml:S2:244:6	agent	NNS	O	O
immediately	TIVICAY.xml:S2:251:11	immedi	RB	O	O
if	TIVICAY.xml:S2:263:2	if	IN	O	O
signs	TIVICAY.xml:S2:266:5	sign	NNS	O	O
or	TIVICAY.xml:S2:272:2	or	CC	O	O
symptoms	TIVICAY.xml:S2:275:8	symptom	NNS	O	O
of	TIVICAY.xml:S2:284:2	of	IN	O	O
hypersensitivity	TIVICAY.xml:S2:287:16	hypersensit	NN	O	O
reactions	TIVICAY.xml:S2:304:9	reaction	NNS	O	O
develop	TIVICAY.xml:S2:314:7	develop	VBP	O	O
,	TIVICAY.xml:S2:321:1	,	,	O	O
as	TIVICAY.xml:S2:323:2	as	IN	O	O
a	TIVICAY.xml:S2:326:1	a	DT	O	O
delay	TIVICAY.xml:S2:328:5	delay	NN	O	O
in	TIVICAY.xml:S2:334:2	in	IN	O	O
stopping	TIVICAY.xml:S2:337:8	stop	VBG	O	O
treatment	TIVICAY.xml:S2:346:9	treatment	NN	O	O
may	TIVICAY.xml:S2:356:3	may	MD	O	O
result	TIVICAY.xml:S2:360:6	result	VB	O	O
in	TIVICAY.xml:S2:367:2	in	IN	O	O
a	TIVICAY.xml:S2:370:1	a	DT	O	O
life	TIVICAY.xml:S2:372:4	life	NN	O	O
-	TIVICAY.xml:S2:376:1	-	:	O	O
threatening	TIVICAY.xml:S2:377:11	threaten	JJ	O	O
reaction	TIVICAY.xml:S2:389:8	reaction	NN	O	O
.	TIVICAY.xml:S2:397:1	.	.	O	O

(	TIVICAY.xml:S2:399:1	(	(	O	O
5.1	TIVICAY.xml:S2:402:3	5.1	CD	O	O
)	TIVICAY.xml:S2:407:1	)	)	O	O

Patients	TIVICAY.xml:S2:416:8	patient	NNS	O	O
with	TIVICAY.xml:S2:425:4	with	IN	O	O
underlying	TIVICAY.xml:S2:430:10	underli	JJ	O	O
hepatitis	TIVICAY.xml:S2:441:9	hepat	NN	O	O
B	TIVICAY.xml:S2:451:1	B	NNP	O	O
or	TIVICAY.xml:S2:453:2	or	CC	O	O
C	TIVICAY.xml:S2:456:1	C	NNP	O	O
may	TIVICAY.xml:S2:458:3	may	MD	O	O
be	TIVICAY.xml:S2:462:2	be	VB	O	O
at	TIVICAY.xml:S2:465:2	at	IN	O	O
increased	TIVICAY.xml:S2:468:9	increas	VBN	O	O
risk	TIVICAY.xml:S2:478:4	risk	NN	O	O
for	TIVICAY.xml:S2:483:3	for	IN	O	O
worsening	TIVICAY.xml:S2:487:9	worsen	VBG	O	O
or	TIVICAY.xml:S2:497:2	or	CC	O	O
development	TIVICAY.xml:S2:500:11	develop	NN	O	O
of	TIVICAY.xml:S2:512:2	of	IN	O	O
transaminase	TIVICAY.xml:S2:515:12	transaminas	NN	B-AdverseReaction	O
elevations	TIVICAY.xml:S2:528:10	elev	NNS	I-AdverseReaction	O
with	TIVICAY.xml:S2:539:4	with	IN	O	O
use	TIVICAY.xml:S2:544:3	use	NN	O	O
of	TIVICAY.xml:S2:548:2	of	IN	O	O
TIVICAY	TIVICAY.xml:S2:551:7	tivicay	NNP	O	O
.	TIVICAY.xml:S2:558:1	.	.	O	O

Appropriate	TIVICAY.xml:S2:560:11	appropri	NNP	O	O
laboratory	TIVICAY.xml:S2:572:10	laboratori	NN	O	O
testing	TIVICAY.xml:S2:583:7	test	VBG	O	O
prior	TIVICAY.xml:S2:591:5	prior	RB	O	O
to	TIVICAY.xml:S2:597:2	to	TO	O	O
initiating	TIVICAY.xml:S2:600:10	initi	VBG	O	O
therapy	TIVICAY.xml:S2:611:7	therapi	NN	O	O
and	TIVICAY.xml:S2:619:3	and	CC	O	O
monitoring	TIVICAY.xml:S2:623:10	monitor	NN	O	O
for	TIVICAY.xml:S2:634:3	for	IN	O	O
hepatotoxicity	TIVICAY.xml:S2:638:14	hepatotox	NN	O	O
during	TIVICAY.xml:S2:653:6	dure	IN	O	O
therapy	TIVICAY.xml:S2:660:7	therapi	NN	O	O
with	TIVICAY.xml:S2:668:4	with	IN	O	O
TIVICAY	TIVICAY.xml:S2:673:7	tivicay	NNP	O	O
is	TIVICAY.xml:S2:681:2	is	VBZ	O	O
recommended	TIVICAY.xml:S2:684:11	recommend	VBN	O	O
in	TIVICAY.xml:S2:696:2	in	IN	O	O
patients	TIVICAY.xml:S2:699:8	patient	NNS	O	O
with	TIVICAY.xml:S2:708:4	with	IN	O	O
underlying	TIVICAY.xml:S2:713:10	underli	JJ	O	O
hepatic	TIVICAY.xml:S2:724:7	hepat	JJ	O	O
disease	TIVICAY.xml:S2:732:7	diseas	NN	O	O
such	TIVICAY.xml:S2:740:4	such	JJ	O	O
as	TIVICAY.xml:S2:745:2	as	IN	O	O
hepatitis	TIVICAY.xml:S2:748:9	hepat	NN	O	O
B	TIVICAY.xml:S2:758:1	B	NNP	O	O
or	TIVICAY.xml:S2:760:2	or	CC	O	O
C.	TIVICAY.xml:S2:763:2	C.	NNP	O	O

(	TIVICAY.xml:S2:766:1	(	(	O	O
5.2	TIVICAY.xml:S2:769:3	5.2	CD	O	O
)	TIVICAY.xml:S2:774:1	)	)	O	O

Redistribution	TIVICAY.xml:S2:783:14	redistribut	NNP	B-AdverseReaction	O
accumulation	TIVICAY.xml:S2:798:12	accumul	NN	B-AdverseReaction	O
of	TIVICAY.xml:S2:811:2	of	IN	I-AdverseReaction	O
body	TIVICAY.xml:S2:814:4	bodi	NN	I-AdverseReaction	O
fat	TIVICAY.xml:S2:819:3	fat	JJ	I-AdverseReaction	O
and	TIVICAY.xml:S2:823:3	and	CC	O	O
immune	TIVICAY.xml:S2:827:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
reconstitution	TIVICAY.xml:S2:834:14	reconstitut	NN	I-AdverseReaction	I-AdverseReaction
syndrome	TIVICAY.xml:S2:849:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
have	TIVICAY.xml:S2:858:4	have	VBP	O	O
been	TIVICAY.xml:S2:863:4	been	VBN	O	O
reported	TIVICAY.xml:S2:868:8	report	VBN	O	O
in	TIVICAY.xml:S2:877:2	in	IN	O	O
patients	TIVICAY.xml:S2:880:8	patient	NNS	O	O
treated	TIVICAY.xml:S2:889:7	treat	VBN	O	O
with	TIVICAY.xml:S2:897:4	with	IN	O	O
combination	TIVICAY.xml:S2:902:11	combin	NN	O	O
antiretroviral	TIVICAY.xml:S2:914:14	antiretrovir	JJ	O	O
therapy	TIVICAY.xml:S2:929:7	therapi	NN	O	O
.	TIVICAY.xml:S2:936:1	.	.	O	O

(	TIVICAY.xml:S2:938:1	(	(	O	O
5.3	TIVICAY.xml:S2:941:3	5.3	CD	O	O
,	TIVICAY.xml:S2:946:1	,	,	O	O
5.4	TIVICAY.xml:S2:949:3	5.4	CD	O	O
)	TIVICAY.xml:S2:954:1	)	)	O	O

5.1	TIVICAY.xml:S2:968:3	5.1	CD	O	O

Hypersensitivity	TIVICAY.xml:S2:972:16	hypersensit	NN	O	O

Reactions	TIVICAY.xml:S2:989:9	reaction	NNS	O	O

Hypersensitivity	TIVICAY.xml:S2:1004:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	TIVICAY.xml:S2:1021:9	reaction	NNS	O	I-AdverseReaction
have	TIVICAY.xml:S2:1031:4	have	VBP	O	O
been	TIVICAY.xml:S2:1036:4	been	VBN	O	O
reported	TIVICAY.xml:S2:1041:8	report	VBN	O	O
and	TIVICAY.xml:S2:1050:3	and	CC	O	O
were	TIVICAY.xml:S2:1054:4	were	VBD	O	O
characterized	TIVICAY.xml:S2:1059:13	character	VBN	O	O
by	TIVICAY.xml:S2:1073:2	by	IN	O	O
rash	TIVICAY.xml:S2:1076:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S2:1080:1	,	,	O	O
constitutional	TIVICAY.xml:S2:1082:14	constitut	JJ	O	O
findings	TIVICAY.xml:S2:1097:8	find	NNS	O	O
,	TIVICAY.xml:S2:1105:1	,	,	O	O
and	TIVICAY.xml:S2:1107:3	and	CC	O	O
sometimes	TIVICAY.xml:S2:1111:9	sometim	RB	O	O
organ	TIVICAY.xml:S2:1121:5	organ	JJ	B-AdverseReaction	B-AdverseReaction
dysfunction	TIVICAY.xml:S2:1127:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:1138:1	,	,	O	O
including	TIVICAY.xml:S2:1140:9	includ	VBG	O	O
liver	TIVICAY.xml:S2:1150:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
injury	TIVICAY.xml:S2:1156:6	injuri	NN	I-AdverseReaction	I-AdverseReaction
.	TIVICAY.xml:S2:1162:1	.	.	O	O

The	TIVICAY.xml:S2:1164:3	the	DT	O	O
events	TIVICAY.xml:S2:1168:6	event	NNS	O	O
were	TIVICAY.xml:S2:1175:4	were	VBD	O	O
reported	TIVICAY.xml:S2:1180:8	report	VBN	O	O
in	TIVICAY.xml:S2:1189:2	in	IN	O	O
less	TIVICAY.xml:S2:1192:4	less	JJR	O	O
than	TIVICAY.xml:S2:1197:4	than	IN	O	O
1%	TIVICAY.xml:S2:1202:2	1%	CD	O	O
of	TIVICAY.xml:S2:1205:2	of	IN	O	O
subjects	TIVICAY.xml:S2:1208:8	subject	NNS	O	O
receiving	TIVICAY.xml:S2:1217:9	receiv	VBG	O	O
TIVICAY	TIVICAY.xml:S2:1227:7	tivicay	NNP	O	O
in	TIVICAY.xml:S2:1235:2	in	IN	O	O
Phase	TIVICAY.xml:S2:1238:5	phase	NNP	O	O
3	TIVICAY.xml:S2:1244:1	3	CD	O	O
clinical	TIVICAY.xml:S2:1246:8	clinic	JJ	O	O
trials	TIVICAY.xml:S2:1255:6	trial	NNS	O	O
.	TIVICAY.xml:S2:1261:1	.	.	O	O

Discontinue	TIVICAY.xml:S2:1263:11	discontinu	NNP	O	O
TIVICAY	TIVICAY.xml:S2:1275:7	tivicay	NNP	O	O
and	TIVICAY.xml:S2:1283:3	and	CC	O	O
other	TIVICAY.xml:S2:1287:5	other	JJ	O	O
suspect	TIVICAY.xml:S2:1293:7	suspect	JJ	O	O
agents	TIVICAY.xml:S2:1301:6	agent	NNS	O	O
immediately	TIVICAY.xml:S2:1308:11	immedi	RB	O	O
if	TIVICAY.xml:S2:1320:2	if	IN	O	O
signs	TIVICAY.xml:S2:1323:5	sign	NNS	O	O
or	TIVICAY.xml:S2:1329:2	or	CC	O	O
symptoms	TIVICAY.xml:S2:1332:8	symptom	NNS	O	O
of	TIVICAY.xml:S2:1341:2	of	IN	O	O
hypersensitivity	TIVICAY.xml:S2:1344:16	hypersensit	NN	O	O
reactions	TIVICAY.xml:S2:1361:9	reaction	NNS	O	O
develop	TIVICAY.xml:S2:1371:7	develop	VBP	O	O
(	TIVICAY.xml:S2:1379:1	(	(	O	O
including	TIVICAY.xml:S2:1380:9	includ	VBG	O	O
,	TIVICAY.xml:S2:1389:1	,	,	O	O
but	TIVICAY.xml:S2:1391:3	but	CC	O	O
not	TIVICAY.xml:S2:1395:3	not	RB	O	O
limited	TIVICAY.xml:S2:1399:7	limit	JJ	O	O
to	TIVICAY.xml:S2:1407:2	to	TO	O	O
,	TIVICAY.xml:S2:1409:1	,	,	O	O
severe	TIVICAY.xml:S2:1411:6	sever	JJ	O	O
rash	TIVICAY.xml:S2:1418:4	rash	NN	O	O
or	TIVICAY.xml:S2:1423:2	or	CC	O	O
rash	TIVICAY.xml:S2:1426:4	rash	NN	O	B-AdverseReaction
accompanied	TIVICAY.xml:S2:1431:11	accompani	VBN	O	O
by	TIVICAY.xml:S2:1443:2	by	IN	O	O
fever	TIVICAY.xml:S2:1446:5	fever	NN	O	O
,	TIVICAY.xml:S2:1451:1	,	,	O	O
general	TIVICAY.xml:S2:1453:7	gener	JJ	O	O
malaise	TIVICAY.xml:S2:1461:7	malais	NN	O	O
,	TIVICAY.xml:S2:1468:1	,	,	O	O
fatigue	TIVICAY.xml:S2:1470:7	fatigu	NN	O	B-AdverseReaction
,	TIVICAY.xml:S2:1477:1	,	,	O	O
muscle	TIVICAY.xml:S2:1479:6	muscl	NN	O	O
or	TIVICAY.xml:S2:1486:2	or	CC	O	O
joint	TIVICAY.xml:S2:1489:5	joint	JJ	O	O
aches	TIVICAY.xml:S2:1495:5	ach	NNS	O	O
,	TIVICAY.xml:S2:1500:1	,	,	O	O
blisters	TIVICAY.xml:S2:1502:8	blister	NNS	O	O
or	TIVICAY.xml:S2:1511:2	or	CC	O	O
peeling	TIVICAY.xml:S2:1514:7	peel	NN	O	O
of	TIVICAY.xml:S2:1522:2	of	IN	O	O
the	TIVICAY.xml:S2:1525:3	the	DT	O	O
skin	TIVICAY.xml:S2:1529:4	skin	NN	O	O
,	TIVICAY.xml:S2:1533:1	,	,	O	O
oral	TIVICAY.xml:S2:1535:4	oral	JJ	O	O
blisters	TIVICAY.xml:S2:1540:8	blister	NNS	O	O
or	TIVICAY.xml:S2:1549:2	or	CC	O	O
lesions	TIVICAY.xml:S2:1552:7	lesion	NNS	O	O
,	TIVICAY.xml:S2:1559:1	,	,	O	O
conjunctivitis	TIVICAY.xml:S2:1561:14	conjunct	NN	O	O
,	TIVICAY.xml:S2:1575:1	,	,	O	O
facial	TIVICAY.xml:S2:1577:6	facial	JJ	O	B-AdverseReaction
edema	TIVICAY.xml:S2:1584:5	edema	NN	O	I-AdverseReaction
,	TIVICAY.xml:S2:1589:1	,	,	O	O
hepatitis	TIVICAY.xml:S2:1591:9	hepat	NN	O	B-AdverseReaction
,	TIVICAY.xml:S2:1600:1	,	,	O	O
eosinophilia	TIVICAY.xml:S2:1602:12	eosinophilia	NN	O	B-AdverseReaction
,	TIVICAY.xml:S2:1614:1	,	,	O	O
angioedema	TIVICAY.xml:S2:1616:10	angioedema	NN	O	B-AdverseReaction
,	TIVICAY.xml:S2:1626:1	,	,	O	O
difficulty	TIVICAY.xml:S2:1628:10	difficulti	NN	O	B-AdverseReaction
breathing	TIVICAY.xml:S2:1639:9	breath	NN	O	I-AdverseReaction
)	TIVICAY.xml:S2:1648:1	)	)	O	O
.	TIVICAY.xml:S2:1649:1	.	.	O	O

Clinical	TIVICAY.xml:S2:1651:8	clinic	JJ	O	O
status	TIVICAY.xml:S2:1660:6	statu	NN	O	O
,	TIVICAY.xml:S2:1666:1	,	,	O	O
including	TIVICAY.xml:S2:1668:9	includ	VBG	O	O
liver	TIVICAY.xml:S2:1678:5	liver	NN	O	O
aminotransferases	TIVICAY.xml:S2:1684:17	aminotransferas	NNS	O	O
,	TIVICAY.xml:S2:1701:1	,	,	O	O
should	TIVICAY.xml:S2:1703:6	should	MD	O	O
be	TIVICAY.xml:S2:1710:2	be	VB	O	O
monitored	TIVICAY.xml:S2:1713:9	monitor	VBN	O	O
and	TIVICAY.xml:S2:1723:3	and	CC	O	O
appropriate	TIVICAY.xml:S2:1727:11	appropri	JJ	O	O
therapy	TIVICAY.xml:S2:1739:7	therapi	NN	O	O
initiated	TIVICAY.xml:S2:1747:9	initi	VBN	O	O
.	TIVICAY.xml:S2:1756:1	.	.	O	O

Delay	TIVICAY.xml:S2:1758:5	delay	NN	O	O
in	TIVICAY.xml:S2:1764:2	in	IN	O	O
stopping	TIVICAY.xml:S2:1767:8	stop	VBG	O	O
treatment	TIVICAY.xml:S2:1776:9	treatment	NN	O	O
with	TIVICAY.xml:S2:1786:4	with	IN	O	O
TIVICAY	TIVICAY.xml:S2:1791:7	tivicay	NNP	O	O
or	TIVICAY.xml:S2:1799:2	or	CC	O	O
other	TIVICAY.xml:S2:1802:5	other	JJ	O	O
suspect	TIVICAY.xml:S2:1808:7	suspect	JJ	O	O
agents	TIVICAY.xml:S2:1816:6	agent	NNS	O	O
after	TIVICAY.xml:S2:1823:5	after	IN	O	O
the	TIVICAY.xml:S2:1829:3	the	DT	O	O
onset	TIVICAY.xml:S2:1833:5	onset	NN	O	O
of	TIVICAY.xml:S2:1839:2	of	IN	O	O
hypersensitivity	TIVICAY.xml:S2:1842:16	hypersensit	NN	O	B-AdverseReaction
may	TIVICAY.xml:S2:1859:3	may	MD	O	O
result	TIVICAY.xml:S2:1863:6	result	VB	O	O
in	TIVICAY.xml:S2:1870:2	in	IN	O	O
a	TIVICAY.xml:S2:1873:1	a	DT	O	O
life	TIVICAY.xml:S2:1875:4	life	NN	O	O
-	TIVICAY.xml:S2:1879:1	-	:	O	O
threatening	TIVICAY.xml:S2:1880:11	threaten	JJ	O	O
reaction	TIVICAY.xml:S2:1892:8	reaction	NN	O	O
.	TIVICAY.xml:S2:1900:1	.	.	O	O

TIVICAY	TIVICAY.xml:S2:1902:7	tivicay	NNP	O	O
is	TIVICAY.xml:S2:1910:2	is	VBZ	O	O
contraindicated	TIVICAY.xml:S2:1913:15	contraind	VBN	O	O
in	TIVICAY.xml:S2:1929:2	in	IN	O	O
patients	TIVICAY.xml:S2:1932:8	patient	NNS	O	O
who	TIVICAY.xml:S2:1941:3	who	WP	O	O
have	TIVICAY.xml:S2:1945:4	have	VBP	O	O
experienced	TIVICAY.xml:S2:1950:11	experienc	VBN	O	O
a	TIVICAY.xml:S2:1962:1	a	DT	O	O
previous	TIVICAY.xml:S2:1964:8	previou	JJ	O	O
hypersensitivity	TIVICAY.xml:S2:1973:16	hypersensit	NN	O	O
reaction	TIVICAY.xml:S2:1990:8	reaction	NN	O	O
to	TIVICAY.xml:S2:1999:2	to	TO	O	O
dolutegravir	TIVICAY.xml:S2:2002:12	dolutegravir	VB	O	O
.	TIVICAY.xml:S2:2014:1	.	.	O	O

5.2	TIVICAY.xml:S2:2023:3	5.2	CD	O	O
Effects	TIVICAY.xml:S2:2027:7	effect	NNS	O	O
on	TIVICAY.xml:S2:2035:2	on	IN	O	O
Serum	TIVICAY.xml:S2:2038:5	serum	NNP	O	O
Liver	TIVICAY.xml:S2:2044:5	liver	NNP	O	O
Biochemistries	TIVICAY.xml:S2:2050:14	biochemistri	NNP	O	O
in	TIVICAY.xml:S2:2065:2	in	IN	O	O
Patients	TIVICAY.xml:S2:2068:8	patient	NNP	O	O
with	TIVICAY.xml:S2:2077:4	with	IN	O	O
Hepatitis	TIVICAY.xml:S2:2082:9	hepat	NNP	O	O
B	TIVICAY.xml:S2:2092:1	B	NNP	O	O
or	TIVICAY.xml:S2:2094:2	or	CC	O	O
C	TIVICAY.xml:S2:2097:1	C	NNP	O	O
Co	TIVICAY.xml:S2:2099:2	Co	NNP	O	O
-	TIVICAY.xml:S2:2101:1	-	:	O	O
infection	TIVICAY.xml:S2:2102:9	infect	NN	O	O

Patients	TIVICAY.xml:S2:2117:8	patient	NNS	O	O
with	TIVICAY.xml:S2:2126:4	with	IN	O	O
underlying	TIVICAY.xml:S2:2131:10	underli	JJ	O	O
hepatitis	TIVICAY.xml:S2:2142:9	hepat	NN	O	O
B	TIVICAY.xml:S2:2152:1	B	NNP	O	O
or	TIVICAY.xml:S2:2154:2	or	CC	O	O
C	TIVICAY.xml:S2:2157:1	C	NNP	O	O
may	TIVICAY.xml:S2:2159:3	may	MD	O	O
be	TIVICAY.xml:S2:2163:2	be	VB	O	O
at	TIVICAY.xml:S2:2166:2	at	IN	O	O
increased	TIVICAY.xml:S2:2169:9	increas	VBN	O	O
risk	TIVICAY.xml:S2:2179:4	risk	NN	O	O
for	TIVICAY.xml:S2:2184:3	for	IN	O	O
worsening	TIVICAY.xml:S2:2188:9	worsen	VBG	O	O
or	TIVICAY.xml:S2:2198:2	or	CC	O	O
development	TIVICAY.xml:S2:2201:11	develop	NN	O	O
of	TIVICAY.xml:S2:2213:2	of	IN	O	O
transaminase	TIVICAY.xml:S2:2216:12	transaminas	NN	B-AdverseReaction	O
elevations	TIVICAY.xml:S2:2229:10	elev	NNS	I-AdverseReaction	O
with	TIVICAY.xml:S2:2240:4	with	IN	O	O
use	TIVICAY.xml:S2:2245:3	use	NN	O	O
of	TIVICAY.xml:S2:2249:2	of	IN	O	O
TIVICAY	TIVICAY.xml:S2:2252:7	tivicay	NNP	O	O
[	TIVICAY.xml:S2:2260:1	[	NNP	O	O
see	TIVICAY.xml:S2:2261:3	see	VBP	O	O
Adverse	TIVICAY.xml:S2:2265:7	advers	JJ	O	O
Reactions	TIVICAY.xml:S2:2273:9	reaction	NNP	O	O
(	TIVICAY.xml:S2:2283:1	(	(	O	O
6.1	TIVICAY.xml:S2:2284:3	6.1	CD	O	O
)]	TIVICAY.xml:S2:2287:2	)]	NN	O	O
.	TIVICAY.xml:S2:2291:1	.	.	O	O

In	TIVICAY.xml:S2:2293:2	In	IN	O	O
some	TIVICAY.xml:S2:2296:4	some	DT	O	O
cases	TIVICAY.xml:S2:2301:5	case	NNS	O	O
the	TIVICAY.xml:S2:2307:3	the	DT	O	O
elevations	TIVICAY.xml:S2:2311:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	TIVICAY.xml:S2:2322:2	in	IN	I-AdverseReaction	I-AdverseReaction
transaminases	TIVICAY.xml:S2:2325:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
were	TIVICAY.xml:S2:2339:4	were	VBD	O	O
consistent	TIVICAY.xml:S2:2344:10	consist	JJ	O	O
with	TIVICAY.xml:S2:2355:4	with	IN	O	O
immune	TIVICAY.xml:S2:2360:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
reconstitution	TIVICAY.xml:S2:2367:14	reconstitut	NN	I-AdverseReaction	I-AdverseReaction
syndrome	TIVICAY.xml:S2:2382:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
or	TIVICAY.xml:S2:2391:2	or	CC	O	O
hepatitis	TIVICAY.xml:S2:2394:9	hepat	NN	B-AdverseReaction	O
B	TIVICAY.xml:S2:2404:1	B	NNP	I-AdverseReaction	O
reactivation	TIVICAY.xml:S2:2406:12	reactiv	NN	I-AdverseReaction	O
particularly	TIVICAY.xml:S2:2419:12	particularli	RB	O	O
in	TIVICAY.xml:S2:2432:2	in	IN	O	O
the	TIVICAY.xml:S2:2435:3	the	DT	O	O
setting	TIVICAY.xml:S2:2439:7	set	NN	O	O
where	TIVICAY.xml:S2:2447:5	where	WRB	O	O
anti	TIVICAY.xml:S2:2453:4	anti	SYM	O	O
-	TIVICAY.xml:S2:2457:1	-	:	O	O
hepatitis	TIVICAY.xml:S2:2458:9	hepat	NN	O	O
therapy	TIVICAY.xml:S2:2468:7	therapi	NN	O	O
was	TIVICAY.xml:S2:2476:3	wa	VBD	O	O
withdrawn	TIVICAY.xml:S2:2480:9	withdrawn	VBN	O	O
.	TIVICAY.xml:S2:2489:1	.	.	O	O

Appropriate	TIVICAY.xml:S2:2491:11	appropri	NNP	O	O
laboratory	TIVICAY.xml:S2:2503:10	laboratori	NN	O	O
testing	TIVICAY.xml:S2:2514:7	test	VBG	O	O
prior	TIVICAY.xml:S2:2522:5	prior	RB	O	O
to	TIVICAY.xml:S2:2528:2	to	TO	O	O
initiating	TIVICAY.xml:S2:2531:10	initi	VBG	O	O
therapy	TIVICAY.xml:S2:2542:7	therapi	NN	O	O
and	TIVICAY.xml:S2:2550:3	and	CC	O	O
monitoring	TIVICAY.xml:S2:2554:10	monitor	NN	O	O
for	TIVICAY.xml:S2:2565:3	for	IN	O	O
hepatotoxicity	TIVICAY.xml:S2:2569:14	hepatotox	NN	O	O
during	TIVICAY.xml:S2:2584:6	dure	IN	O	O
therapy	TIVICAY.xml:S2:2591:7	therapi	NN	O	O
with	TIVICAY.xml:S2:2599:4	with	IN	O	O
TIVICAY	TIVICAY.xml:S2:2604:7	tivicay	NNP	O	O
are	TIVICAY.xml:S2:2612:3	are	VBP	O	O
recommended	TIVICAY.xml:S2:2616:11	recommend	VBN	O	O
in	TIVICAY.xml:S2:2628:2	in	IN	O	O
patients	TIVICAY.xml:S2:2631:8	patient	NNS	O	O
with	TIVICAY.xml:S2:2640:4	with	IN	O	O
underlying	TIVICAY.xml:S2:2645:10	underli	JJ	O	O
hepatic	TIVICAY.xml:S2:2656:7	hepat	JJ	O	O
disease	TIVICAY.xml:S2:2664:7	diseas	NN	O	O
such	TIVICAY.xml:S2:2672:4	such	JJ	O	O
as	TIVICAY.xml:S2:2677:2	as	IN	O	O
hepatitis	TIVICAY.xml:S2:2680:9	hepat	NN	O	O
B	TIVICAY.xml:S2:2690:1	B	NNP	O	O
or	TIVICAY.xml:S2:2692:2	or	CC	O	O
C.	TIVICAY.xml:S2:2695:2	C.	NNP	O	O

5.3	TIVICAY.xml:S2:2705:3	5.3	CD	O	O
Fat	TIVICAY.xml:S2:2709:3	fat	NNP	O	O
Redistribution	TIVICAY.xml:S2:2713:14	redistribut	NNP	O	O

Redistribution	TIVICAY.xml:S2:2733:14	redistribut	NNP	B-AdverseReaction	B-AdverseReaction
accumulation	TIVICAY.xml:S2:2748:12	accumul	NN	B-AdverseReaction	B-AdverseReaction
of	TIVICAY.xml:S2:2761:2	of	IN	I-AdverseReaction	I-AdverseReaction
body	TIVICAY.xml:S2:2764:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
fat	TIVICAY.xml:S2:2769:3	fat	JJ	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:2772:1	,	,	O	O
including	TIVICAY.xml:S2:2774:9	includ	VBG	O	O
central	TIVICAY.xml:S2:2784:7	central	JJ	B-AdverseReaction	B-AdverseReaction
obesity	TIVICAY.xml:S2:2792:7	obes	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:2799:1	,	,	O	O
dorsocervical	TIVICAY.xml:S2:2801:13	dorsocerv	JJ	B-AdverseReaction	B-AdverseReaction
fat	TIVICAY.xml:S2:2815:3	fat	NN	I-AdverseReaction	I-AdverseReaction
enlargement	TIVICAY.xml:S2:2819:11	enlarg	NN	I-AdverseReaction	I-AdverseReaction
(	TIVICAY.xml:S2:2831:1	(	(	O	O
buffalo	TIVICAY.xml:S2:2832:7	buffalo	JJ	B-AdverseReaction	B-AdverseReaction
hump	TIVICAY.xml:S2:2840:4	hump	NN	I-AdverseReaction	I-AdverseReaction
)	TIVICAY.xml:S2:2844:1	)	)	O	O
,	TIVICAY.xml:S2:2845:1	,	,	O	O
peripheral	TIVICAY.xml:S2:2847:10	peripher	JJ	I-AdverseReaction	B-AdverseReaction
wasting	TIVICAY.xml:S2:2858:7	wast	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:2865:1	,	,	O	O
facial	TIVICAY.xml:S2:2867:6	facial	JJ	B-AdverseReaction	B-AdverseReaction
wasting	TIVICAY.xml:S2:2874:7	wast	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:2881:1	,	,	O	O
breast	TIVICAY.xml:S2:2883:6	breast	NN	B-AdverseReaction	B-AdverseReaction
enlargement	TIVICAY.xml:S2:2890:11	enlarg	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:2901:1	,	,	O	O
and	TIVICAY.xml:S2:2903:3	and	CC	O	O
"	TIVICAY.xml:S2:2907:1	"	NNP	O	O
cushingoid	TIVICAY.xml:S2:2908:10	cushingoid	VBP	B-AdverseReaction	B-AdverseReaction
appearance	TIVICAY.xml:S2:2919:10	appear	NN	I-AdverseReaction	I-AdverseReaction
"	TIVICAY.xml:S2:2929:1	"	NNS	O	O
have	TIVICAY.xml:S2:2931:4	have	VBP	O	O
been	TIVICAY.xml:S2:2936:4	been	VBN	O	O
observed	TIVICAY.xml:S2:2941:8	observ	VBN	O	O
in	TIVICAY.xml:S2:2950:2	in	IN	O	O
patients	TIVICAY.xml:S2:2953:8	patient	NNS	O	O
receiving	TIVICAY.xml:S2:2962:9	receiv	VBG	O	O
antiretroviral	TIVICAY.xml:S2:2972:14	antiretrovir	JJ	O	O
therapy	TIVICAY.xml:S2:2987:7	therapi	NN	O	O
.	TIVICAY.xml:S2:2994:1	.	.	O	O

The	TIVICAY.xml:S2:2996:3	the	DT	O	O
mechanism	TIVICAY.xml:S2:3000:9	mechan	NN	O	O
and	TIVICAY.xml:S2:3010:3	and	CC	O	O
long	TIVICAY.xml:S2:3014:4	long	JJ	O	O
-	TIVICAY.xml:S2:3018:1	-	:	O	O
term	TIVICAY.xml:S2:3019:4	term	NN	O	O
consequences	TIVICAY.xml:S2:3024:12	consequ	NNS	O	O
of	TIVICAY.xml:S2:3037:2	of	IN	O	O
these	TIVICAY.xml:S2:3040:5	these	DT	O	O
events	TIVICAY.xml:S2:3046:6	event	NNS	O	O
are	TIVICAY.xml:S2:3053:3	are	VBP	O	O
currently	TIVICAY.xml:S2:3057:9	current	RB	O	O
unknown	TIVICAY.xml:S2:3067:7	unknown	JJ	O	O
.	TIVICAY.xml:S2:3074:1	.	.	O	O

A	TIVICAY.xml:S2:3076:1	A	DT	O	O
causal	TIVICAY.xml:S2:3078:6	causal	NN	O	O
relationship	TIVICAY.xml:S2:3085:12	relationship	NN	O	O
has	TIVICAY.xml:S2:3098:3	ha	VBZ	O	O
not	TIVICAY.xml:S2:3102:3	not	RB	O	O
been	TIVICAY.xml:S2:3106:4	been	VBN	O	O
established	TIVICAY.xml:S2:3111:11	establish	VBN	O	O
.	TIVICAY.xml:S2:3122:1	.	.	O	O

5.4	TIVICAY.xml:S2:3131:3	5.4	CD	O	O
Immune	TIVICAY.xml:S2:3135:6	immun	NNP	O	O
Reconstitution	TIVICAY.xml:S2:3142:14	reconstitut	NNP	O	O
Syndrome	TIVICAY.xml:S2:3157:8	syndrom	NNP	O	O

Immune	TIVICAY.xml:S2:3171:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
reconstitution	TIVICAY.xml:S2:3178:14	reconstitut	NN	I-AdverseReaction	I-AdverseReaction
syndrome	TIVICAY.xml:S2:3193:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
has	TIVICAY.xml:S2:3202:3	ha	VBZ	O	O
been	TIVICAY.xml:S2:3206:4	been	VBN	O	O
reported	TIVICAY.xml:S2:3211:8	report	VBN	O	O
in	TIVICAY.xml:S2:3220:2	in	IN	O	O
patients	TIVICAY.xml:S2:3223:8	patient	NNS	O	O
treated	TIVICAY.xml:S2:3232:7	treat	VBN	O	O
with	TIVICAY.xml:S2:3240:4	with	IN	O	O
combination	TIVICAY.xml:S2:3245:11	combin	NN	O	O
antiretroviral	TIVICAY.xml:S2:3257:14	antiretrovir	JJ	O	O
therapy	TIVICAY.xml:S2:3272:7	therapi	NN	O	O
,	TIVICAY.xml:S2:3279:1	,	,	O	O
including	TIVICAY.xml:S2:3281:9	includ	VBG	O	O
TIVICAY	TIVICAY.xml:S2:3291:7	tivicay	NNP	O	O
.	TIVICAY.xml:S2:3298:1	.	.	O	O

During	TIVICAY.xml:S2:3300:6	dure	IN	O	O
the	TIVICAY.xml:S2:3307:3	the	DT	O	O
initial	TIVICAY.xml:S2:3311:7	initi	JJ	O	O
phase	TIVICAY.xml:S2:3319:5	phase	NN	O	O
of	TIVICAY.xml:S2:3325:2	of	IN	O	O
combination	TIVICAY.xml:S2:3328:11	combin	NN	O	O
antiretroviral	TIVICAY.xml:S2:3340:14	antiretrovir	JJ	O	O
treatment	TIVICAY.xml:S2:3355:9	treatment	NN	O	O
,	TIVICAY.xml:S2:3364:1	,	,	O	O
patients	TIVICAY.xml:S2:3366:8	patient	NNS	O	O
whose	TIVICAY.xml:S2:3375:5	whose	WP$	O	O
immune	TIVICAY.xml:S2:3381:6	immun	JJ	O	O
systems	TIVICAY.xml:S2:3388:7	system	NNS	O	O
respond	TIVICAY.xml:S2:3396:7	respond	NN	O	O
may	TIVICAY.xml:S2:3404:3	may	MD	O	O
develop	TIVICAY.xml:S2:3408:7	develop	VB	O	O
an	TIVICAY.xml:S2:3416:2	an	DT	O	O
inflammatory	TIVICAY.xml:S2:3419:12	inflammatori	JJ	B-AdverseReaction	B-AdverseReaction
response	TIVICAY.xml:S2:3432:8	respons	NN	I-AdverseReaction	I-AdverseReaction
to	TIVICAY.xml:S2:3441:2	to	TO	O	O
indolent	TIVICAY.xml:S2:3444:8	indol	NN	O	O
or	TIVICAY.xml:S2:3453:2	or	CC	O	O
residual	TIVICAY.xml:S2:3456:8	residu	JJ	B-AdverseReaction	O
opportunistic	TIVICAY.xml:S2:3465:13	opportunist	JJ	I-AdverseReaction	B-AdverseReaction
infections	TIVICAY.xml:S2:3479:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
(	TIVICAY.xml:S2:3490:1	(	(	O	O
such	TIVICAY.xml:S2:3491:4	such	JJ	O	O
as	TIVICAY.xml:S2:3496:2	as	IN	O	O
Mycobacterium	TIVICAY.xml:S2:3499:13	mycobacterium	NNP	B-AdverseReaction	B-AdverseReaction
avium	TIVICAY.xml:S2:3513:5	avium	NN	I-AdverseReaction	I-AdverseReaction
infection	TIVICAY.xml:S2:3520:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	TIVICAY.xml:S2:3529:1	,	,	O	O
cytomegalovirus	TIVICAY.xml:S2:3531:15	cytomegaloviru	NN	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S2:3546:1	,	,	O	O
Pneumocystis	TIVICAY.xml:S2:3548:12	pneumocysti	NNP	B-AdverseReaction	B-AdverseReaction
jirovecii	TIVICAY.xml:S2:3561:9	jirovecii	NN	I-AdverseReaction	I-AdverseReaction
pneumonia	TIVICAY.xml:S2:3572:9	pneumonia	NN	I-AdverseReaction	I-AdverseReaction
[	TIVICAY.xml:S2:3582:1	[	NNP	O	O
PCP	TIVICAY.xml:S2:3583:3	pcp	NNP	B-AdverseReaction	O
]	TIVICAY.xml:S2:3586:1	]	NNP	O	O
,	TIVICAY.xml:S2:3587:1	,	,	O	O
or	TIVICAY.xml:S2:3589:2	or	CC	O	O
tuberculosis	TIVICAY.xml:S2:3592:12	tuberculosi	NN	B-AdverseReaction	B-AdverseReaction
)	TIVICAY.xml:S2:3604:1	)	)	O	O
,	TIVICAY.xml:S2:3605:1	,	,	O	O
which	TIVICAY.xml:S2:3607:5	which	WDT	O	O
may	TIVICAY.xml:S2:3613:3	may	MD	O	O
necessitate	TIVICAY.xml:S2:3617:11	necessit	VB	O	O
further	TIVICAY.xml:S2:3629:7	further	JJ	O	O
evaluation	TIVICAY.xml:S2:3637:10	evalu	NN	O	O
and	TIVICAY.xml:S2:3648:3	and	CC	O	O
treatment	TIVICAY.xml:S2:3652:9	treatment	NN	O	O
.	TIVICAY.xml:S2:3661:1	.	.	O	O

Autoimmune	TIVICAY.xml:S2:3667:10	autoimmun	NNP	B-AdverseReaction	B-AdverseReaction
disorders	TIVICAY.xml:S2:3678:9	disord	NNS	I-AdverseReaction	I-AdverseReaction
(	TIVICAY.xml:S2:3688:1	(	(	O	O
such	TIVICAY.xml:S2:3689:4	such	JJ	O	O
as	TIVICAY.xml:S2:3694:2	as	IN	O	O
Graves	TIVICAY.xml:S2:3697:6	grave	NNS	B-AdverseReaction	O
disease	TIVICAY.xml:S2:3705:7	diseas	NN	I-AdverseReaction	O
,	TIVICAY.xml:S2:3712:1	,	,	O	O
polymyositis	TIVICAY.xml:S2:3714:12	polymyos	NN	B-AdverseReaction	B-AdverseReaction
,	TIVICAY.xml:S2:3726:1	,	,	O	O
and	TIVICAY.xml:S2:3728:3	and	CC	O	O
Guillain	TIVICAY.xml:S2:3732:8	guillain	NNP	B-AdverseReaction	B-AdverseReaction
-	TIVICAY.xml:S2:3740:1	-	:	I-AdverseReaction	I-AdverseReaction
Barre	TIVICAY.xml:S2:3741:5	barr	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	TIVICAY.xml:S2:3747:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
)	TIVICAY.xml:S2:3755:1	)	)	O	O
have	TIVICAY.xml:S2:3757:4	have	VBP	O	O
also	TIVICAY.xml:S2:3762:4	also	RB	O	O
been	TIVICAY.xml:S2:3767:4	been	VBN	O	O
reported	TIVICAY.xml:S2:3772:8	report	VBN	O	O
to	TIVICAY.xml:S2:3781:2	to	TO	O	O
occur	TIVICAY.xml:S2:3784:5	occur	VB	O	O
in	TIVICAY.xml:S2:3790:2	in	IN	O	O
the	TIVICAY.xml:S2:3793:3	the	DT	O	O
setting	TIVICAY.xml:S2:3797:7	set	NN	O	O
of	TIVICAY.xml:S2:3805:2	of	IN	O	O
immune	TIVICAY.xml:S2:3808:6	immun	JJ	O	O
reconstitution	TIVICAY.xml:S2:3815:14	reconstitut	NN	O	O
;	TIVICAY.xml:S2:3829:1	;	:	O	O
however	TIVICAY.xml:S2:3831:7	howev	RB	O	O
,	TIVICAY.xml:S2:3838:1	,	,	O	O
the	TIVICAY.xml:S2:3840:3	the	DT	O	O
time	TIVICAY.xml:S2:3844:4	time	NN	O	O
to	TIVICAY.xml:S2:3849:2	to	TO	O	O
onset	TIVICAY.xml:S2:3852:5	onset	VB	O	O
is	TIVICAY.xml:S2:3858:2	is	VBZ	O	O
more	TIVICAY.xml:S2:3861:4	more	RBR	O	O
variable	TIVICAY.xml:S2:3866:8	variabl	JJ	O	O
and	TIVICAY.xml:S2:3875:3	and	CC	O	O
can	TIVICAY.xml:S2:3879:3	can	MD	O	O
occur	TIVICAY.xml:S2:3883:5	occur	VB	O	O
many	TIVICAY.xml:S2:3889:4	mani	JJ	O	O
months	TIVICAY.xml:S2:3894:6	month	NNS	O	O
after	TIVICAY.xml:S2:3901:5	after	IN	O	O
initiation	TIVICAY.xml:S2:3907:10	initi	NN	O	O
of	TIVICAY.xml:S2:3918:2	of	IN	O	O
treatment	TIVICAY.xml:S2:3921:9	treatment	NN	O	O
.	TIVICAY.xml:S2:3930:1	.	.	O	O
6	TOVIAZ.xml:S1:4:1	6	CD	O	O
ADVERSE	TOVIAZ.xml:S1:6:7	advers	JJ	O	O
REACTIONS	TOVIAZ.xml:S1:14:9	reaction	NN	O	O

EXCERPT	TOVIAZ.xml:S1:27:7	excerpt	NN	O	O
:	TOVIAZ.xml:S1:34:1	:	:	O	O
The	TOVIAZ.xml:S1:38:3	the	DT	O	O
most	TOVIAZ.xml:S1:42:4	most	RBS	O	O
frequently	TOVIAZ.xml:S1:47:10	frequent	RB	O	O
reported	TOVIAZ.xml:S1:58:8	report	VBD	O	O
adverse	TOVIAZ.xml:S1:67:7	advers	JJ	O	O
events	TOVIAZ.xml:S1:75:6	event	NNS	O	O
(	TOVIAZ.xml:S1:82:1	(	(	O	O
4%	TOVIAZ.xml:S1:85:2	4%	CD	O	O
)	TOVIAZ.xml:S1:87:1	)	)	O	O
for	TOVIAZ.xml:S1:89:3	for	IN	O	O
Toviaz	TOVIAZ.xml:S1:93:6	toviaz	NNP	O	O
were	TOVIAZ.xml:S1:100:4	were	VBD	O	O
:	TOVIAZ.xml:S1:104:1	:	:	O	O
dry	TOVIAZ.xml:S1:106:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	TOVIAZ.xml:S1:110:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
(	TOVIAZ.xml:S1:116:1	(	(	O	O
placebo	TOVIAZ.xml:S1:117:7	placebo	NN	O	O
,	TOVIAZ.xml:S1:124:1	,	,	O	O
7%	TOVIAZ.xml:S1:126:2	7%	CD	O	O
;	TOVIAZ.xml:S1:128:1	;	:	O	O
Toviaz	TOVIAZ.xml:S1:130:6	toviaz	NNP	O	O
4	TOVIAZ.xml:S1:137:1	4	CD	O	O
mg	TOVIAZ.xml:S1:139:2	mg	NN	O	O
,	TOVIAZ.xml:S1:141:1	,	,	O	O
19%	TOVIAZ.xml:S1:143:3	19%	CD	O	O
;	TOVIAZ.xml:S1:146:1	;	:	O	O
Toviaz	TOVIAZ.xml:S1:148:6	toviaz	NNP	O	O
8	TOVIAZ.xml:S1:155:1	8	CD	O	O
mg	TOVIAZ.xml:S1:157:2	mg	NN	O	O
,	TOVIAZ.xml:S1:159:1	,	,	O	O
35%	TOVIAZ.xml:S1:161:3	35%	CD	O	O
)	TOVIAZ.xml:S1:164:1	)	)	O	O
and	TOVIAZ.xml:S1:166:3	and	CC	O	O
constipation	TOVIAZ.xml:S1:170:12	constip	NN	B-AdverseReaction	B-AdverseReaction
(	TOVIAZ.xml:S1:183:1	(	(	O	O
placebo	TOVIAZ.xml:S1:184:7	placebo	NN	O	O
,	TOVIAZ.xml:S1:191:1	,	,	O	O
2%	TOVIAZ.xml:S1:193:2	2%	CD	O	O
;	TOVIAZ.xml:S1:195:1	;	:	O	O
Toviaz	TOVIAZ.xml:S1:197:6	toviaz	NNP	O	O
4	TOVIAZ.xml:S1:204:1	4	CD	O	O
mg	TOVIAZ.xml:S1:206:2	mg	NN	O	O
,	TOVIAZ.xml:S1:208:1	,	,	O	O
4%	TOVIAZ.xml:S1:210:2	4%	CD	O	O
;	TOVIAZ.xml:S1:212:1	;	:	O	O
Toviaz	TOVIAZ.xml:S1:214:6	toviaz	NNP	O	O
8	TOVIAZ.xml:S1:221:1	8	CD	O	O
mg	TOVIAZ.xml:S1:223:2	mg	NN	O	O
,	TOVIAZ.xml:S1:225:1	,	,	O	O
6%	TOVIAZ.xml:S1:227:2	6%	CD	O	O
)	TOVIAZ.xml:S1:229:1	)	)	O	O
.	TOVIAZ.xml:S1:230:1	.	.	O	O

(	TOVIAZ.xml:S1:232:1	(	(	O	O
6	TOVIAZ.xml:S1:235:1	6	CD	O	O
)	TOVIAZ.xml:S1:238:1	)	)	O	O

To	TOVIAZ.xml:S1:246:2	To	TO	O	O
report	TOVIAZ.xml:S1:249:6	report	VB	O	O
SUSPECTED	TOVIAZ.xml:S1:256:9	suspect	NNP	O	O
ADVERSE	TOVIAZ.xml:S1:266:7	advers	NNP	O	O
REACTIONS	TOVIAZ.xml:S1:274:9	reaction	NNP	O	O
,	TOVIAZ.xml:S1:283:1	,	,	O	O
contact	TOVIAZ.xml:S1:285:7	contact	NN	O	O
Pfizer	TOVIAZ.xml:S1:293:6	pfizer	NNP	O	O
Inc	TOVIAZ.xml:S1:300:3	inc	NNP	O	O
at	TOVIAZ.xml:S1:304:2	at	IN	O	O
1	TOVIAZ.xml:S1:307:1	1	CD	O	O
-	TOVIAZ.xml:S1:308:1	-	:	O	O
800	TOVIAZ.xml:S1:309:3	800	CD	O	O
-	TOVIAZ.xml:S1:312:1	-	:	O	O
438	TOVIAZ.xml:S1:313:3	438	CD	O	O
-	TOVIAZ.xml:S1:316:1	-	:	O	O
1985	TOVIAZ.xml:S1:317:4	1985	CD	O	O
or	TOVIAZ.xml:S1:322:2	or	CC	O	O
FDA	TOVIAZ.xml:S1:325:3	fda	NNP	O	O
at	TOVIAZ.xml:S1:329:2	at	IN	O	O
1	TOVIAZ.xml:S1:332:1	1	CD	O	O
-	TOVIAZ.xml:S1:333:1	-	:	O	O
800	TOVIAZ.xml:S1:334:3	800	CD	O	O
-	TOVIAZ.xml:S1:337:1	-	:	O	O
FDA	TOVIAZ.xml:S1:338:3	fda	NNP	O	O
-	TOVIAZ.xml:S1:341:1	-	:	O	O
1088	TOVIAZ.xml:S1:342:4	1088	CD	O	O
or	TOVIAZ.xml:S1:347:2	or	CC	O	O
www	TOVIAZ.xml:S1:350:3	www	VB	O	O
.	TOVIAZ.xml:S1:353:1	.	.	O	O
fda	TOVIAZ.xml:S1:354:3	fda	NN	O	O
.	TOVIAZ.xml:S1:357:1	.	.	O	O
gov	TOVIAZ.xml:S1:358:3	gov	JJ	O	O
medwatch	TOVIAZ.xml:S1:362:8	medwatch	NN	O	O
.	TOVIAZ.xml:S1:370:1	.	.	O	O

6.1	TOVIAZ.xml:S1:382:3	6.1	CD	O	O

Clinical	TOVIAZ.xml:S1:386:8	clinic	JJ	O	O
Trials	TOVIAZ.xml:S1:395:6	trial	NNS	O	O
Experience	TOVIAZ.xml:S1:402:10	experi	NN	O	O

The	TOVIAZ.xml:S1:416:3	the	DT	O	O
safety	TOVIAZ.xml:S1:420:6	safeti	NN	O	O
of	TOVIAZ.xml:S1:427:2	of	IN	O	O
Toviaz	TOVIAZ.xml:S1:430:6	toviaz	NNP	O	O
was	TOVIAZ.xml:S1:437:3	wa	VBD	O	O
evaluated	TOVIAZ.xml:S1:441:9	evalu	VBN	O	O
in	TOVIAZ.xml:S1:451:2	in	IN	O	O
Phase	TOVIAZ.xml:S1:454:5	phase	NNP	O	O
2	TOVIAZ.xml:S1:460:1	2	CD	O	O
and	TOVIAZ.xml:S1:462:3	and	CC	O	O
3	TOVIAZ.xml:S1:466:1	3	CD	O	O
controlled	TOVIAZ.xml:S1:468:10	control	JJ	O	O
trials	TOVIAZ.xml:S1:479:6	trial	NNS	O	O
in	TOVIAZ.xml:S1:486:2	in	IN	O	O
a	TOVIAZ.xml:S1:489:1	a	DT	O	O
total	TOVIAZ.xml:S1:491:5	total	NN	O	O
of	TOVIAZ.xml:S1:497:2	of	IN	O	O
2859	TOVIAZ.xml:S1:500:4	2859	CD	O	O
patients	TOVIAZ.xml:S1:505:8	patient	NNS	O	O
with	TOVIAZ.xml:S1:514:4	with	IN	O	O
overactive	TOVIAZ.xml:S1:519:10	overact	JJ	O	O
bladder	TOVIAZ.xml:S1:530:7	bladder	NN	O	O
,	TOVIAZ.xml:S1:537:1	,	,	O	O
of	TOVIAZ.xml:S1:539:2	of	IN	O	O
which	TOVIAZ.xml:S1:542:5	which	WDT	O	O
2288	TOVIAZ.xml:S1:548:4	2288	CD	O	O
were	TOVIAZ.xml:S1:553:4	were	VBD	O	O
treated	TOVIAZ.xml:S1:558:7	treat	VBN	O	O
with	TOVIAZ.xml:S1:566:4	with	IN	O	O
fesoterodine	TOVIAZ.xml:S1:571:12	fesoterodin	NN	O	O
.	TOVIAZ.xml:S1:583:1	.	.	O	O

Of	TOVIAZ.xml:S1:585:2	Of	IN	O	O
this	TOVIAZ.xml:S1:588:4	thi	DT	O	O
total	TOVIAZ.xml:S1:593:5	total	NN	O	O
,	TOVIAZ.xml:S1:598:1	,	,	O	O
782	TOVIAZ.xml:S1:600:3	782	CD	O	O
received	TOVIAZ.xml:S1:604:8	receiv	VBD	O	O
Toviaz	TOVIAZ.xml:S1:613:6	toviaz	NNP	O	O
4	TOVIAZ.xml:S1:620:1	4	CD	O	O
mg	TOVIAZ.xml:S1:622:2	mg	NN	O	O
day	TOVIAZ.xml:S1:625:3	day	NN	O	O
,	TOVIAZ.xml:S1:628:1	,	,	O	O
and	TOVIAZ.xml:S1:630:3	and	CC	O	O
785	TOVIAZ.xml:S1:634:3	785	CD	O	O
received	TOVIAZ.xml:S1:638:8	receiv	VBD	O	O
Toviaz	TOVIAZ.xml:S1:647:6	toviaz	NNP	O	O
8	TOVIAZ.xml:S1:654:1	8	CD	O	O
mg	TOVIAZ.xml:S1:656:2	mg	NN	O	O
day	TOVIAZ.xml:S1:659:3	day	NN	O	O
in	TOVIAZ.xml:S1:663:2	in	IN	O	O
Phase	TOVIAZ.xml:S1:666:5	phase	NNP	O	O
2	TOVIAZ.xml:S1:672:1	2	CD	O	O
or	TOVIAZ.xml:S1:674:2	or	CC	O	O
3	TOVIAZ.xml:S1:677:1	3	CD	O	O
studies	TOVIAZ.xml:S1:679:7	studi	NNS	O	O
with	TOVIAZ.xml:S1:687:4	with	IN	O	O
treatment	TOVIAZ.xml:S1:692:9	treatment	NN	O	O
periods	TOVIAZ.xml:S1:702:7	period	NNS	O	O
of	TOVIAZ.xml:S1:710:2	of	IN	O	O
8	TOVIAZ.xml:S1:713:1	8	CD	O	O
or	TOVIAZ.xml:S1:715:2	or	CC	O	O
12	TOVIAZ.xml:S1:718:2	12	CD	O	O
weeks	TOVIAZ.xml:S1:721:5	week	NNS	O	O
.	TOVIAZ.xml:S1:726:1	.	.	O	O

Approximately	TOVIAZ.xml:S1:728:13	approxim	RB	O	O
80%	TOVIAZ.xml:S1:742:3	80%	CD	O	O
of	TOVIAZ.xml:S1:746:2	of	IN	O	O
these	TOVIAZ.xml:S1:749:5	these	DT	O	O
patients	TOVIAZ.xml:S1:755:8	patient	NNS	O	O
had	TOVIAZ.xml:S1:764:3	had	VBD	O	O
10	TOVIAZ.xml:S1:769:2	10	CD	O	O
weeks	TOVIAZ.xml:S1:772:5	week	NNS	O	O
exposure	TOVIAZ.xml:S1:778:8	exposur	NN	O	O
to	TOVIAZ.xml:S1:787:2	to	TO	O	O
Toviaz	TOVIAZ.xml:S1:790:6	toviaz	VB	O	O
in	TOVIAZ.xml:S1:797:2	in	IN	O	O
these	TOVIAZ.xml:S1:800:5	these	DT	O	O
trials	TOVIAZ.xml:S1:806:6	trial	NNS	O	O
.	TOVIAZ.xml:S1:812:1	.	.	O	O

A	TOVIAZ.xml:S1:818:1	A	DT	O	O
total	TOVIAZ.xml:S1:820:5	total	NN	O	O
of	TOVIAZ.xml:S1:826:2	of	IN	O	O
1964	TOVIAZ.xml:S1:829:4	1964	CD	O	O
patients	TOVIAZ.xml:S1:834:8	patient	NNS	O	O
participated	TOVIAZ.xml:S1:843:12	particip	VBN	O	O
in	TOVIAZ.xml:S1:856:2	in	IN	O	O
two	TOVIAZ.xml:S1:859:3	two	CD	O	O
12	TOVIAZ.xml:S1:863:2	12	CD	O	O
-	TOVIAZ.xml:S1:865:1	-	:	O	O
week	TOVIAZ.xml:S1:866:4	week	NN	O	O
,	TOVIAZ.xml:S1:870:1	,	,	O	O
Phase	TOVIAZ.xml:S1:872:5	phase	NNP	O	O
3	TOVIAZ.xml:S1:878:1	3	CD	O	O
efficacy	TOVIAZ.xml:S1:880:8	efficaci	NN	O	O
and	TOVIAZ.xml:S1:889:3	and	CC	O	O
safety	TOVIAZ.xml:S1:893:6	safeti	NN	O	O
studies	TOVIAZ.xml:S1:900:7	studi	NNS	O	O
and	TOVIAZ.xml:S1:908:3	and	CC	O	O
subsequent	TOVIAZ.xml:S1:912:10	subsequ	JJ	O	O
open	TOVIAZ.xml:S1:923:4	open	JJ	O	O
-	TOVIAZ.xml:S1:927:1	-	:	O	O
label	TOVIAZ.xml:S1:928:5	label	NN	O	O
extension	TOVIAZ.xml:S1:934:9	extens	NN	O	O
studies	TOVIAZ.xml:S1:944:7	studi	NNS	O	O
.	TOVIAZ.xml:S1:951:1	.	.	O	O

In	TOVIAZ.xml:S1:953:2	In	IN	O	O
these	TOVIAZ.xml:S1:956:5	these	DT	O	O
two	TOVIAZ.xml:S1:962:3	two	CD	O	O
studies	TOVIAZ.xml:S1:966:7	studi	NNS	O	O
combined	TOVIAZ.xml:S1:974:8	combin	VBN	O	O
,	TOVIAZ.xml:S1:982:1	,	,	O	O
554	TOVIAZ.xml:S1:984:3	554	CD	O	O
patients	TOVIAZ.xml:S1:988:8	patient	NNS	O	O
received	TOVIAZ.xml:S1:997:8	receiv	VBD	O	O
Toviaz	TOVIAZ.xml:S1:1006:6	toviaz	NNP	O	O
4	TOVIAZ.xml:S1:1013:1	4	CD	O	O
mg	TOVIAZ.xml:S1:1015:2	mg	NN	O	O
day	TOVIAZ.xml:S1:1018:3	day	NN	O	O
and	TOVIAZ.xml:S1:1022:3	and	CC	O	O
566	TOVIAZ.xml:S1:1026:3	566	CD	O	O
patients	TOVIAZ.xml:S1:1030:8	patient	NNS	O	O
received	TOVIAZ.xml:S1:1039:8	receiv	VBD	O	O
Toviaz	TOVIAZ.xml:S1:1048:6	toviaz	NNP	O	O
8	TOVIAZ.xml:S1:1055:1	8	CD	O	O
mg	TOVIAZ.xml:S1:1057:2	mg	NN	O	O
day	TOVIAZ.xml:S1:1060:3	day	NN	O	O
.	TOVIAZ.xml:S1:1063:1	.	.	O	O

In	TOVIAZ.xml:S1:1069:2	In	IN	O	O
Phase	TOVIAZ.xml:S1:1072:5	phase	NNP	O	O
2	TOVIAZ.xml:S1:1078:1	2	CD	O	O
and	TOVIAZ.xml:S1:1080:3	and	CC	O	O
3	TOVIAZ.xml:S1:1084:1	3	CD	O	O
placebo	TOVIAZ.xml:S1:1086:7	placebo	NN	O	O
-	TOVIAZ.xml:S1:1093:1	-	:	O	O
controlled	TOVIAZ.xml:S1:1094:10	control	VBN	O	O
trials	TOVIAZ.xml:S1:1105:6	trial	NNS	O	O
combined	TOVIAZ.xml:S1:1112:8	combin	VBN	O	O
,	TOVIAZ.xml:S1:1120:1	,	,	O	O
the	TOVIAZ.xml:S1:1122:3	the	DT	O	O
incidences	TOVIAZ.xml:S1:1126:10	incid	NNS	O	O
of	TOVIAZ.xml:S1:1137:2	of	IN	O	O
serious	TOVIAZ.xml:S1:1140:7	seriou	JJ	O	O
adverse	TOVIAZ.xml:S1:1148:7	advers	JJ	O	O
events	TOVIAZ.xml:S1:1156:6	event	NNS	O	O
in	TOVIAZ.xml:S1:1163:2	in	IN	O	O
patients	TOVIAZ.xml:S1:1166:8	patient	NNS	O	O
receiving	TOVIAZ.xml:S1:1175:9	receiv	VBG	O	O
placebo	TOVIAZ.xml:S1:1185:7	placebo	NN	O	O
,	TOVIAZ.xml:S1:1192:1	,	,	O	O
Toviaz	TOVIAZ.xml:S1:1194:6	toviaz	NNP	O	O
4	TOVIAZ.xml:S1:1201:1	4	CD	O	O
mg	TOVIAZ.xml:S1:1203:2	mg	NN	O	O
,	TOVIAZ.xml:S1:1205:1	,	,	O	O
and	TOVIAZ.xml:S1:1207:3	and	CC	O	O
Toviaz	TOVIAZ.xml:S1:1211:6	toviaz	NNP	O	O
8	TOVIAZ.xml:S1:1218:1	8	CD	O	O
mg	TOVIAZ.xml:S1:1220:2	mg	NN	O	O
were	TOVIAZ.xml:S1:1223:4	were	VBD	O	O
1.9%	TOVIAZ.xml:S1:1228:4	1.9%	CD	O	O
,	TOVIAZ.xml:S1:1232:1	,	,	O	O
3.5%	TOVIAZ.xml:S1:1234:4	3.5%	CD	O	O
,	TOVIAZ.xml:S1:1238:1	,	,	O	O
and	TOVIAZ.xml:S1:1240:3	and	CC	O	O
2.9%	TOVIAZ.xml:S1:1244:4	2.9%	CD	O	O
,	TOVIAZ.xml:S1:1248:1	,	,	O	O
respectively	TOVIAZ.xml:S1:1250:12	respect	RB	O	O
.	TOVIAZ.xml:S1:1262:1	.	.	O	O

All	TOVIAZ.xml:S1:1264:3	all	DT	O	O
serious	TOVIAZ.xml:S1:1268:7	seriou	JJ	O	O
adverse	TOVIAZ.xml:S1:1276:7	advers	JJ	O	O
events	TOVIAZ.xml:S1:1284:6	event	NNS	O	O
were	TOVIAZ.xml:S1:1291:4	were	VBD	O	O
judged	TOVIAZ.xml:S1:1296:6	judg	VBN	O	O
to	TOVIAZ.xml:S1:1303:2	to	TO	O	O
be	TOVIAZ.xml:S1:1306:2	be	VB	O	O
not	TOVIAZ.xml:S1:1309:3	not	RB	O	O
related	TOVIAZ.xml:S1:1313:7	relat	VBN	O	O
or	TOVIAZ.xml:S1:1321:2	or	CC	O	O
unlikely	TOVIAZ.xml:S1:1324:8	unlik	JJ	O	O
to	TOVIAZ.xml:S1:1333:2	to	TO	O	O
be	TOVIAZ.xml:S1:1336:2	be	VB	O	O
related	TOVIAZ.xml:S1:1339:7	relat	VBN	O	O
to	TOVIAZ.xml:S1:1347:2	to	TO	O	O
study	TOVIAZ.xml:S1:1350:5	studi	VB	O	O
medication	TOVIAZ.xml:S1:1356:10	medic	NN	O	O
by	TOVIAZ.xml:S1:1367:2	by	IN	O	O
the	TOVIAZ.xml:S1:1370:3	the	DT	O	O
investigator	TOVIAZ.xml:S1:1374:12	investig	NN	O	O
,	TOVIAZ.xml:S1:1386:1	,	,	O	O
except	TOVIAZ.xml:S1:1388:6	except	IN	O	O
for	TOVIAZ.xml:S1:1395:3	for	IN	O	O
four	TOVIAZ.xml:S1:1399:4	four	CD	O	O
patients	TOVIAZ.xml:S1:1404:8	patient	NNS	O	O
receiving	TOVIAZ.xml:S1:1413:9	receiv	VBG	O	O
Toviaz	TOVIAZ.xml:S1:1423:6	toviaz	NNP	O	O
who	TOVIAZ.xml:S1:1430:3	who	WP	O	O
reported	TOVIAZ.xml:S1:1434:8	report	VBD	O	O
one	TOVIAZ.xml:S1:1443:3	one	CD	O	O
serious	TOVIAZ.xml:S1:1447:7	seriou	JJ	O	O
adverse	TOVIAZ.xml:S1:1455:7	advers	JJ	O	O
event	TOVIAZ.xml:S1:1463:5	event	NN	O	O
each	TOVIAZ.xml:S1:1469:4	each	DT	O	O
:	TOVIAZ.xml:S1:1473:1	:	:	O	O
angina	TOVIAZ.xml:S1:1475:6	angina	NN	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S1:1481:1	,	,	O	O
chest	TOVIAZ.xml:S1:1483:5	chest	NN	B-AdverseReaction	B-AdverseReaction
pain	TOVIAZ.xml:S1:1489:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TOVIAZ.xml:S1:1493:1	,	,	O	O
gastroenteritis	TOVIAZ.xml:S1:1495:15	gastroenter	NN	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S1:1510:1	,	,	O	O
and	TOVIAZ.xml:S1:1512:3	and	CC	O	O
QT	TOVIAZ.xml:S1:1516:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
prolongation	TOVIAZ.xml:S1:1519:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
on	TOVIAZ.xml:S1:1532:2	on	IN	O	O
ECG	TOVIAZ.xml:S1:1535:3	ecg	NNP	O	O
.	TOVIAZ.xml:S1:1538:1	.	.	O	O

The	TOVIAZ.xml:S1:1544:3	the	DT	O	O
most	TOVIAZ.xml:S1:1548:4	most	RBS	O	O
commonly	TOVIAZ.xml:S1:1553:8	commonli	RB	O	O
reported	TOVIAZ.xml:S1:1562:8	report	VBD	O	O
adverse	TOVIAZ.xml:S1:1571:7	advers	JJ	O	O
event	TOVIAZ.xml:S1:1579:5	event	NN	O	O
in	TOVIAZ.xml:S1:1585:2	in	IN	O	O
patients	TOVIAZ.xml:S1:1588:8	patient	NNS	O	O
treated	TOVIAZ.xml:S1:1597:7	treat	VBN	O	O
with	TOVIAZ.xml:S1:1605:4	with	IN	O	O
Toviaz	TOVIAZ.xml:S1:1610:6	toviaz	NNP	O	O
was	TOVIAZ.xml:S1:1617:3	wa	VBD	O	O
dry	TOVIAZ.xml:S1:1621:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	TOVIAZ.xml:S1:1625:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
.	TOVIAZ.xml:S1:1630:1	.	.	O	O

The	TOVIAZ.xml:S1:1632:3	the	DT	O	O
incidence	TOVIAZ.xml:S1:1636:9	incid	NN	O	O
of	TOVIAZ.xml:S1:1646:2	of	IN	O	O
dry	TOVIAZ.xml:S1:1649:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	TOVIAZ.xml:S1:1653:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
was	TOVIAZ.xml:S1:1659:3	wa	VBD	O	O
higher	TOVIAZ.xml:S1:1663:6	higher	RBR	O	O
in	TOVIAZ.xml:S1:1670:2	in	IN	O	O
those	TOVIAZ.xml:S1:1673:5	those	DT	O	O
taking	TOVIAZ.xml:S1:1679:6	take	VBG	O	O
8	TOVIAZ.xml:S1:1686:1	8	CD	O	O
mg	TOVIAZ.xml:S1:1688:2	mg	JJ	O	O
day	TOVIAZ.xml:S1:1691:3	day	NN	O	O
(	TOVIAZ.xml:S1:1695:1	(	(	O	O
35%	TOVIAZ.xml:S1:1696:3	35%	CD	O	O
)	TOVIAZ.xml:S1:1699:1	)	)	O	O
and	TOVIAZ.xml:S1:1701:3	and	CC	O	O
in	TOVIAZ.xml:S1:1705:2	in	IN	O	O
those	TOVIAZ.xml:S1:1708:5	those	DT	O	O
taking	TOVIAZ.xml:S1:1714:6	take	VBG	O	O
4	TOVIAZ.xml:S1:1721:1	4	CD	O	O
mg	TOVIAZ.xml:S1:1723:2	mg	JJ	O	O
day	TOVIAZ.xml:S1:1726:3	day	NN	O	O
(	TOVIAZ.xml:S1:1730:1	(	(	O	O
19%	TOVIAZ.xml:S1:1731:3	19%	CD	O	O
)	TOVIAZ.xml:S1:1734:1	)	)	O	O
,	TOVIAZ.xml:S1:1735:1	,	,	O	O
as	TOVIAZ.xml:S1:1737:2	as	IN	O	O
compared	TOVIAZ.xml:S1:1740:8	compar	VBN	O	O
to	TOVIAZ.xml:S1:1749:2	to	TO	O	O
placebo	TOVIAZ.xml:S1:1752:7	placebo	VB	O	O
(	TOVIAZ.xml:S1:1760:1	(	(	O	O
7%	TOVIAZ.xml:S1:1761:2	7%	CD	O	O
)	TOVIAZ.xml:S1:1763:1	)	)	O	O
.	TOVIAZ.xml:S1:1764:1	.	.	O	O

Dry	TOVIAZ.xml:S1:1766:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
mouth	TOVIAZ.xml:S1:1770:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
led	TOVIAZ.xml:S1:1776:3	led	VBD	O	O
to	TOVIAZ.xml:S1:1780:2	to	TO	O	O
discontinuation	TOVIAZ.xml:S1:1783:15	discontinu	NN	O	O
in	TOVIAZ.xml:S1:1799:2	in	IN	O	O
0.4%	TOVIAZ.xml:S1:1802:4	0.4%	CD	O	O
,	TOVIAZ.xml:S1:1806:1	,	,	O	O
0.4%	TOVIAZ.xml:S1:1808:4	0.4%	CD	O	O
,	TOVIAZ.xml:S1:1812:1	,	,	O	O
and	TOVIAZ.xml:S1:1814:3	and	CC	O	O
0.8%	TOVIAZ.xml:S1:1818:4	0.8%	CD	O	O
of	TOVIAZ.xml:S1:1823:2	of	IN	O	O
patients	TOVIAZ.xml:S1:1826:8	patient	NNS	O	O
receiving	TOVIAZ.xml:S1:1835:9	receiv	VBG	O	O
placebo	TOVIAZ.xml:S1:1845:7	placebo	NN	O	O
,	TOVIAZ.xml:S1:1852:1	,	,	O	O
Toviaz	TOVIAZ.xml:S1:1854:6	toviaz	NNP	O	O
4	TOVIAZ.xml:S1:1861:1	4	CD	O	O
mg	TOVIAZ.xml:S1:1863:2	mg	NN	O	O
,	TOVIAZ.xml:S1:1865:1	,	,	O	O
and	TOVIAZ.xml:S1:1867:3	and	CC	O	O
Toviaz	TOVIAZ.xml:S1:1871:6	toviaz	NNP	O	O
8	TOVIAZ.xml:S1:1878:1	8	CD	O	O
mg	TOVIAZ.xml:S1:1880:2	mg	NN	O	O
,	TOVIAZ.xml:S1:1882:1	,	,	O	O
respectively	TOVIAZ.xml:S1:1884:12	respect	RB	O	O
.	TOVIAZ.xml:S1:1896:1	.	.	O	O

For	TOVIAZ.xml:S1:1898:3	for	IN	O	O
those	TOVIAZ.xml:S1:1902:5	those	DT	O	O
patients	TOVIAZ.xml:S1:1908:8	patient	NNS	O	O
who	TOVIAZ.xml:S1:1917:3	who	WP	O	O
reported	TOVIAZ.xml:S1:1921:8	report	VBD	O	O
dry	TOVIAZ.xml:S1:1930:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	TOVIAZ.xml:S1:1934:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
,	TOVIAZ.xml:S1:1939:1	,	,	O	O
most	TOVIAZ.xml:S1:1941:4	most	RBS	O	O
had	TOVIAZ.xml:S1:1946:3	had	VBD	O	O
their	TOVIAZ.xml:S1:1950:5	their	PRP$	O	O
first	TOVIAZ.xml:S1:1956:5	first	JJ	O	O
occurrence	TOVIAZ.xml:S1:1962:10	occurr	NN	O	O
of	TOVIAZ.xml:S1:1973:2	of	IN	O	O
the	TOVIAZ.xml:S1:1976:3	the	DT	O	O
event	TOVIAZ.xml:S1:1980:5	event	NN	O	O
within	TOVIAZ.xml:S1:1986:6	within	IN	O	O
the	TOVIAZ.xml:S1:1993:3	the	DT	O	O
first	TOVIAZ.xml:S1:1997:5	first	JJ	O	O
month	TOVIAZ.xml:S1:2003:5	month	NN	O	O
of	TOVIAZ.xml:S1:2009:2	of	IN	O	O
treatment	TOVIAZ.xml:S1:2012:9	treatment	NN	O	O
.	TOVIAZ.xml:S1:2021:1	.	.	O	O

The	TOVIAZ.xml:S1:2027:3	the	DT	O	O
second	TOVIAZ.xml:S1:2031:6	second	JJ	O	O
most	TOVIAZ.xml:S1:2038:4	most	RBS	O	O
commonly	TOVIAZ.xml:S1:2043:8	commonli	RB	O	O
reported	TOVIAZ.xml:S1:2052:8	report	VBD	O	O
adverse	TOVIAZ.xml:S1:2061:7	advers	JJ	O	O
event	TOVIAZ.xml:S1:2069:5	event	NN	O	O
was	TOVIAZ.xml:S1:2075:3	wa	VBD	O	O
constipation	TOVIAZ.xml:S1:2079:12	constip	NN	B-AdverseReaction	B-AdverseReaction
.	TOVIAZ.xml:S1:2091:1	.	.	O	O

The	TOVIAZ.xml:S1:2093:3	the	DT	O	O
incidence	TOVIAZ.xml:S1:2097:9	incid	NN	O	O
of	TOVIAZ.xml:S1:2107:2	of	IN	O	O
constipation	TOVIAZ.xml:S1:2110:12	constip	NN	B-AdverseReaction	B-AdverseReaction
was	TOVIAZ.xml:S1:2123:3	wa	VBD	O	O
2%	TOVIAZ.xml:S1:2127:2	2%	CD	O	O
in	TOVIAZ.xml:S1:2130:2	in	IN	O	O
those	TOVIAZ.xml:S1:2133:5	those	DT	O	O
taking	TOVIAZ.xml:S1:2139:6	take	VBG	O	O
placebo	TOVIAZ.xml:S1:2146:7	placebo	NN	O	O
,	TOVIAZ.xml:S1:2153:1	,	,	O	O
4%	TOVIAZ.xml:S1:2155:2	4%	CD	O	O
in	TOVIAZ.xml:S1:2158:2	in	IN	O	O
those	TOVIAZ.xml:S1:2161:5	those	DT	O	O
taking	TOVIAZ.xml:S1:2167:6	take	VBG	O	O
4	TOVIAZ.xml:S1:2174:1	4	CD	O	O
mg	TOVIAZ.xml:S1:2176:2	mg	JJ	O	O
day	TOVIAZ.xml:S1:2179:3	day	NN	O	O
,	TOVIAZ.xml:S1:2182:1	,	,	O	O
and	TOVIAZ.xml:S1:2184:3	and	CC	O	O
6%	TOVIAZ.xml:S1:2188:2	6%	CD	O	O
in	TOVIAZ.xml:S1:2191:2	in	IN	O	O
those	TOVIAZ.xml:S1:2194:5	those	DT	O	O
taking	TOVIAZ.xml:S1:2200:6	take	VBG	O	O
8	TOVIAZ.xml:S1:2207:1	8	CD	O	O
mg	TOVIAZ.xml:S1:2209:2	mg	JJ	O	O
day	TOVIAZ.xml:S1:2212:3	day	NN	O	O
.	TOVIAZ.xml:S1:2215:1	.	.	O	O

Table	TOVIAZ.xml:S1:2221:5	tabl	JJ	O	O
1	TOVIAZ.xml:S1:2227:1	1	CD	O	O
lists	TOVIAZ.xml:S1:2229:5	list	NNS	O	O
adverse	TOVIAZ.xml:S1:2235:7	advers	JJ	O	O
events	TOVIAZ.xml:S1:2243:6	event	NNS	O	O
,	TOVIAZ.xml:S1:2249:1	,	,	O	O
regardless	TOVIAZ.xml:S1:2251:10	regardless	RB	O	O
of	TOVIAZ.xml:S1:2262:2	of	IN	O	O
causality	TOVIAZ.xml:S1:2265:9	causal	NN	O	O
,	TOVIAZ.xml:S1:2274:1	,	,	O	O
that	TOVIAZ.xml:S1:2276:4	that	WDT	O	O
were	TOVIAZ.xml:S1:2281:4	were	VBD	O	O
reported	TOVIAZ.xml:S1:2286:8	report	VBN	O	O
in	TOVIAZ.xml:S1:2295:2	in	IN	O	O
the	TOVIAZ.xml:S1:2298:3	the	DT	O	O
combined	TOVIAZ.xml:S1:2302:8	combin	JJ	O	O
Phase	TOVIAZ.xml:S1:2311:5	phase	NNP	O	O
3	TOVIAZ.xml:S1:2317:1	3	CD	O	O
,	TOVIAZ.xml:S1:2318:1	,	,	O	O
randomized	TOVIAZ.xml:S1:2320:10	random	VBN	O	O
,	TOVIAZ.xml:S1:2330:1	,	,	O	O
placebo	TOVIAZ.xml:S1:2332:7	placebo	SYM	O	O
-	TOVIAZ.xml:S1:2339:1	-	:	O	O
controlled	TOVIAZ.xml:S1:2340:10	control	VBN	O	O
trials	TOVIAZ.xml:S1:2351:6	trial	NNS	O	O
at	TOVIAZ.xml:S1:2358:2	at	IN	O	O
an	TOVIAZ.xml:S1:2361:2	an	DT	O	O
incidence	TOVIAZ.xml:S1:2364:9	incid	NN	O	O
greater	TOVIAZ.xml:S1:2374:7	greater	JJR	O	O
than	TOVIAZ.xml:S1:2382:4	than	IN	O	O
placebo	TOVIAZ.xml:S1:2387:7	placebo	NN	O	O
and	TOVIAZ.xml:S1:2395:3	and	CC	O	O
in	TOVIAZ.xml:S1:2399:2	in	IN	O	O
1%	TOVIAZ.xml:S1:2402:2	1%	CD	O	O
or	TOVIAZ.xml:S1:2405:2	or	CC	O	O
more	TOVIAZ.xml:S1:2408:4	more	JJR	O	O
of	TOVIAZ.xml:S1:2413:2	of	IN	O	O
patients	TOVIAZ.xml:S1:2416:8	patient	NNS	O	O
treated	TOVIAZ.xml:S1:2425:7	treat	VBN	O	O
with	TOVIAZ.xml:S1:2433:4	with	IN	O	O
Toviaz	TOVIAZ.xml:S1:2438:6	toviaz	NNP	O	O
4	TOVIAZ.xml:S1:2445:1	4	CD	O	O
or	TOVIAZ.xml:S1:2447:2	or	CC	O	O
8	TOVIAZ.xml:S1:2450:1	8	CD	O	O
mg	TOVIAZ.xml:S1:2452:2	mg	NNS	O	O
once	TOVIAZ.xml:S1:2455:4	onc	RB	O	O
daily	TOVIAZ.xml:S1:2460:5	daili	RB	O	O
for	TOVIAZ.xml:S1:2466:3	for	IN	O	O
up	TOVIAZ.xml:S1:2470:2	up	IN	O	O
to	TOVIAZ.xml:S1:2473:2	to	TO	O	O
12	TOVIAZ.xml:S1:2476:2	12	CD	O	O
weeks	TOVIAZ.xml:S1:2479:5	week	NNS	O	O
.	TOVIAZ.xml:S1:2484:1	.	.	O	O

Table	TOVIAZ.xml:S1:2490:5	tabl	JJ	O	O
1	TOVIAZ.xml:S1:2496:1	1	CD	O	O
:	TOVIAZ.xml:S1:2497:1	:	:	O	O
Adverse	TOVIAZ.xml:S1:2499:7	advers	JJ	O	O
events	TOVIAZ.xml:S1:2507:6	event	NNS	O	O
with	TOVIAZ.xml:S1:2514:4	with	IN	O	O
an	TOVIAZ.xml:S1:2519:2	an	DT	O	O
incidence	TOVIAZ.xml:S1:2522:9	incid	NN	O	O
exceeding	TOVIAZ.xml:S1:2532:9	exceed	VBG	O	O
the	TOVIAZ.xml:S1:2542:3	the	DT	O	O
placebo	TOVIAZ.xml:S1:2546:7	placebo	NN	O	O
rate	TOVIAZ.xml:S1:2554:4	rate	NN	O	O
and	TOVIAZ.xml:S1:2559:3	and	CC	O	O
reported	TOVIAZ.xml:S1:2563:8	report	VBN	O	O
by	TOVIAZ.xml:S1:2572:2	by	IN	O	O
1%	TOVIAZ.xml:S1:2577:2	1%	CD	O	O
of	TOVIAZ.xml:S1:2580:2	of	IN	O	O
patients	TOVIAZ.xml:S1:2583:8	patient	NNS	O	O
from	TOVIAZ.xml:S1:2592:4	from	IN	O	O
double	TOVIAZ.xml:S1:2597:6	doubl	JJ	O	O
-	TOVIAZ.xml:S1:2603:1	-	:	O	O
blind	TOVIAZ.xml:S1:2604:5	blind	NN	O	O
,	TOVIAZ.xml:S1:2609:1	,	,	O	O
placebo	TOVIAZ.xml:S1:2611:7	placebo	SYM	O	O
-	TOVIAZ.xml:S1:2618:1	-	:	O	O
controlled	TOVIAZ.xml:S1:2619:10	control	VBN	O	O
Phase	TOVIAZ.xml:S1:2630:5	phase	NNP	O	O
3	TOVIAZ.xml:S1:2636:1	3	CD	O	O
trials	TOVIAZ.xml:S1:2638:6	trial	NNS	O	O
of	TOVIAZ.xml:S1:2645:2	of	IN	O	O
12	TOVIAZ.xml:S1:2648:2	12	CD	O	O
weeks	TOVIAZ.xml:S1:2651:5	week	NNS	O	O
treatment	TOVIAZ.xml:S1:2657:9	treatment	NN	O	O
duration	TOVIAZ.xml:S1:2667:8	durat	NN	O	O

System	TOVIAZ.xml:S1:2680:6	system	NNP	O	O
organ	TOVIAZ.xml:S1:2687:5	organ	JJ	O	O
class	TOVIAZ.xml:S1:2693:5	class	NN	O	O
Preferred	TOVIAZ.xml:S1:2699:9	prefer	NNP	O	O
term	TOVIAZ.xml:S1:2709:4	term	NN	O	O
Placebo	TOVIAZ.xml:S1:2741:7	placebo	NNP	O	O
N	TOVIAZ.xml:S1:2752:1	N	NNP	O	O
554	TOVIAZ.xml:S1:2754:3	554	CD	O	O
Toviaz	TOVIAZ.xml:S1:2768:6	toviaz	NNP	O	O
4	TOVIAZ.xml:S1:2778:1	4	CD	O	O
mg	TOVIAZ.xml:S1:2780:2	mg	NN	O	O
day	TOVIAZ.xml:S1:2783:3	day	NN	O	O
N	TOVIAZ.xml:S1:2790:1	N	NNP	O	O
554	TOVIAZ.xml:S1:2792:3	554	CD	O	O
Toviaz	TOVIAZ.xml:S1:2806:6	toviaz	NNP	O	O
8	TOVIAZ.xml:S1:2816:1	8	CD	O	O
mg	TOVIAZ.xml:S1:2818:2	mg	NN	O	O
day	TOVIAZ.xml:S1:2821:3	day	NN	O	O
N	TOVIAZ.xml:S1:2828:1	N	NNP	O	O
566	TOVIAZ.xml:S1:2830:3	566	CD	O	O

ALT	TOVIAZ.xml:S1:2848:3	alt	NN	O	O

alanine	TOVIAZ.xml:S1:2854:7	alanin	JJ	O	O
aminotransferase	TOVIAZ.xml:S1:2862:16	aminotransferas	NN	O	O
;	TOVIAZ.xml:S1:2878:1	;	:	O	O
GGT	TOVIAZ.xml:S1:2880:3	ggt	NNP	O	O
gamma	TOVIAZ.xml:S1:2886:5	gamma	NN	O	O
glutamyltransferase	TOVIAZ.xml:S1:2892:19	glutamyltransferas	NN	O	O

Gastrointestinal	TOVIAZ.xml:S1:2920:16	gastrointestin	JJ	O	O

disorders	TOVIAZ.xml:S1:2937:9	disord	NNS	O	O

Dry	TOVIAZ.xml:S1:3031:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
mouth	TOVIAZ.xml:S1:3035:5	mouth	VBD	I-AdverseReaction	I-AdverseReaction
7.0	TOVIAZ.xml:S1:3090:3	7.0	CD	O	O
18.8	TOVIAZ.xml:S1:3105:4	18.8	CD	O	O
34.6	TOVIAZ.xml:S1:3120:4	34.6	CD	O	O

Constipation	TOVIAZ.xml:S1:3140:12	constip	NN	B-AdverseReaction	B-AdverseReaction
2.0	TOVIAZ.xml:S1:3199:3	2.0	CD	O	O
4.2	TOVIAZ.xml:S1:3214:3	4.2	CD	O	O
6.0	TOVIAZ.xml:S1:3229:3	6.0	CD	O	O

Dyspepsia	TOVIAZ.xml:S1:3249:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
0.5	TOVIAZ.xml:S1:3308:3	0.5	CD	O	O
1.6	TOVIAZ.xml:S1:3323:3	1.6	CD	O	O
2.3	TOVIAZ.xml:S1:3338:3	2.3	CD	O	O

Nausea	TOVIAZ.xml:S1:3358:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
1.3	TOVIAZ.xml:S1:3417:3	1.3	CD	O	O
0.7	TOVIAZ.xml:S1:3432:3	0.7	CD	O	O
1.9	TOVIAZ.xml:S1:3447:3	1.9	CD	O	O

Abdominal	TOVIAZ.xml:S1:3467:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	TOVIAZ.xml:S1:3477:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	TOVIAZ.xml:S1:3482:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
0.5	TOVIAZ.xml:S1:3526:3	0.5	CD	O	O
1.1	TOVIAZ.xml:S1:3541:3	1.1	CD	O	O
0.5	TOVIAZ.xml:S1:3556:3	0.5	CD	O	O

Infections	TOVIAZ.xml:S1:3574:10	infect	NNS	O	O

Urinary	TOVIAZ.xml:S1:3685:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	TOVIAZ.xml:S1:3693:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	TOVIAZ.xml:S1:3699:9	infect	NN	I-AdverseReaction	I-AdverseReaction
3.1	TOVIAZ.xml:S1:3744:3	3.1	CD	O	O
3.2	TOVIAZ.xml:S1:3759:3	3.2	CD	O	O
4.2	TOVIAZ.xml:S1:3774:3	4.2	CD	O	O

Upper	TOVIAZ.xml:S1:3794:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	TOVIAZ.xml:S1:3800:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	TOVIAZ.xml:S1:3812:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	TOVIAZ.xml:S1:3818:9	infect	NN	I-AdverseReaction	I-AdverseReaction
2.2	TOVIAZ.xml:S1:3853:3	2.2	CD	O	O
2.5	TOVIAZ.xml:S1:3868:3	2.5	CD	O	O
1.8	TOVIAZ.xml:S1:3883:3	1.8	CD	O	O

Eye	TOVIAZ.xml:S1:3901:3	eye	NN	O	O
disorders	TOVIAZ.xml:S1:3905:9	disord	NNS	O	O

Dry	TOVIAZ.xml:S1:4012:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
eyes	TOVIAZ.xml:S1:4016:4	eye	VBD	I-AdverseReaction	I-AdverseReaction
0	TOVIAZ.xml:S1:4071:1	0	CD	O	O
1.4	TOVIAZ.xml:S1:4086:3	1.4	CD	O	O
3.7	TOVIAZ.xml:S1:4101:3	3.7	CD	O	O

Renal	TOVIAZ.xml:S1:4119:5	renal	NNP	O	O
and	TOVIAZ.xml:S1:4125:3	and	CC	O	O
urinary	TOVIAZ.xml:S1:4129:7	urinari	JJ	O	O
disorders	TOVIAZ.xml:S1:4137:9	disord	NNS	O	O

Dysuria	TOVIAZ.xml:S1:4230:7	dysuria	NNP	B-AdverseReaction	B-AdverseReaction
0.7	TOVIAZ.xml:S1:4289:3	0.7	CD	O	O
1.3	TOVIAZ.xml:S1:4304:3	1.3	CD	O	O
1.6	TOVIAZ.xml:S1:4319:3	1.6	CD	O	O

Urinary	TOVIAZ.xml:S1:4339:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	TOVIAZ.xml:S1:4347:9	retent	NN	I-AdverseReaction	I-AdverseReaction
0.2	TOVIAZ.xml:S1:4398:3	0.2	CD	O	O
1.1	TOVIAZ.xml:S1:4413:3	1.1	CD	O	O
1.4	TOVIAZ.xml:S1:4428:3	1.4	CD	O	O

Respiratory	TOVIAZ.xml:S1:4446:11	respiratori	NN	O	O
disorders	TOVIAZ.xml:S1:4458:9	disord	NNS	O	O

Cough	TOVIAZ.xml:S1:4557:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
0.5	TOVIAZ.xml:S1:4616:3	0.5	CD	O	O
1.6	TOVIAZ.xml:S1:4631:3	1.6	CD	O	O
0.9	TOVIAZ.xml:S1:4646:3	0.9	CD	O	O

Dry	TOVIAZ.xml:S1:4666:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
throat	TOVIAZ.xml:S1:4670:6	throat	NN	I-AdverseReaction	I-AdverseReaction
0.4	TOVIAZ.xml:S1:4725:3	0.4	CD	O	O
0.9	TOVIAZ.xml:S1:4740:3	0.9	CD	O	O
2.3	TOVIAZ.xml:S1:4755:3	2.3	CD	O	O

General	TOVIAZ.xml:S1:4773:7	gener	NNP	O	O
disorders	TOVIAZ.xml:S1:4781:9	disord	NNS	O	O

Edema	TOVIAZ.xml:S1:4884:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
peripheral	TOVIAZ.xml:S1:4890:10	peripher	JJ	I-AdverseReaction	I-AdverseReaction
0.7	TOVIAZ.xml:S1:4943:3	0.7	CD	O	O
0.7	TOVIAZ.xml:S1:4958:3	0.7	CD	O	O
1.2	TOVIAZ.xml:S1:4973:3	1.2	CD	O	O

Musculoskeletal	TOVIAZ.xml:S1:4991:15	musculoskelet	JJ	O	O
disorders	TOVIAZ.xml:S1:5007:9	disord	NNS	O	O

Back	TOVIAZ.xml:S1:5102:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	TOVIAZ.xml:S1:5107:4	pain	NN	I-AdverseReaction	I-AdverseReaction
0.4	TOVIAZ.xml:S1:5161:3	0.4	CD	O	O
2.0	TOVIAZ.xml:S1:5176:3	2.0	CD	O	O
0.9	TOVIAZ.xml:S1:5191:3	0.9	CD	O	O

Psychiatric	TOVIAZ.xml:S1:5209:11	psychiatr	JJ	O	O
disorders	TOVIAZ.xml:S1:5221:9	disord	NNS	O	O

Insomnia	TOVIAZ.xml:S1:5320:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
0.5	TOVIAZ.xml:S1:5379:3	0.5	CD	O	O
1.3	TOVIAZ.xml:S1:5394:3	1.3	CD	O	O
0.4	TOVIAZ.xml:S1:5409:3	0.4	CD	O	O

Investigations	TOVIAZ.xml:S1:5427:14	investig	NNS	O	O

ALT	TOVIAZ.xml:S1:5538:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
increased	TOVIAZ.xml:S1:5542:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
0.9	TOVIAZ.xml:S1:5597:3	0.9	CD	O	O
0.5	TOVIAZ.xml:S1:5612:3	0.5	CD	O	O
1.2	TOVIAZ.xml:S1:5627:3	1.2	CD	O	O

GGT	TOVIAZ.xml:S1:5647:3	ggt	NNP	B-AdverseReaction	B-AdverseReaction
increased	TOVIAZ.xml:S1:5651:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
0.4	TOVIAZ.xml:S1:5706:3	0.4	CD	O	O
0.4	TOVIAZ.xml:S1:5721:3	0.4	CD	O	O
1.2	TOVIAZ.xml:S1:5736:3	1.2	CD	O	O

Skin	TOVIAZ.xml:S1:5754:4	skin	NNP	O	O
disorders	TOVIAZ.xml:S1:5759:9	disord	NNS	O	O

Rash	TOVIAZ.xml:S1:5865:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
0.5	TOVIAZ.xml:S1:5924:3	0.5	CD	O	O
0.7	TOVIAZ.xml:S1:5939:3	0.7	CD	O	O
1.1	TOVIAZ.xml:S1:5954:3	1.1	CD	O	O

Patients	TOVIAZ.xml:S1:5980:8	patient	NNS	O	O
also	TOVIAZ.xml:S1:5989:4	also	RB	O	O
received	TOVIAZ.xml:S1:5994:8	receiv	VBD	O	O
Toviaz	TOVIAZ.xml:S1:6003:6	toviaz	NNP	O	O
for	TOVIAZ.xml:S1:6010:3	for	IN	O	O
up	TOVIAZ.xml:S1:6014:2	up	RB	O	O
to	TOVIAZ.xml:S1:6017:2	to	TO	O	O
three	TOVIAZ.xml:S1:6020:5	three	CD	O	O
years	TOVIAZ.xml:S1:6026:5	year	NNS	O	O
in	TOVIAZ.xml:S1:6032:2	in	IN	O	O
open	TOVIAZ.xml:S1:6035:4	open	JJ	O	O
-	TOVIAZ.xml:S1:6039:1	-	:	O	O
label	TOVIAZ.xml:S1:6040:5	label	NN	O	O
extension	TOVIAZ.xml:S1:6046:9	extens	NN	O	O
phases	TOVIAZ.xml:S1:6056:6	phase	NNS	O	O
of	TOVIAZ.xml:S1:6063:2	of	IN	O	O
one	TOVIAZ.xml:S1:6066:3	one	CD	O	O
Phase	TOVIAZ.xml:S1:6070:5	phase	NNP	O	O
2	TOVIAZ.xml:S1:6076:1	2	CD	O	O
and	TOVIAZ.xml:S1:6078:3	and	CC	O	O
two	TOVIAZ.xml:S1:6082:3	two	CD	O	O
Phase	TOVIAZ.xml:S1:6086:5	phase	NNP	O	O
3	TOVIAZ.xml:S1:6092:1	3	CD	O	O
controlled	TOVIAZ.xml:S1:6094:10	control	VBD	O	O
trials	TOVIAZ.xml:S1:6105:6	trial	NNS	O	O
.	TOVIAZ.xml:S1:6111:1	.	.	O	O

In	TOVIAZ.xml:S1:6113:2	In	IN	O	O
all	TOVIAZ.xml:S1:6116:3	all	DT	O	O
open	TOVIAZ.xml:S1:6120:4	open	JJ	O	O
-	TOVIAZ.xml:S1:6124:1	-	:	O	O
label	TOVIAZ.xml:S1:6125:5	label	NN	O	O
trials	TOVIAZ.xml:S1:6131:6	trial	NNS	O	O
combined	TOVIAZ.xml:S1:6138:8	combin	VBD	O	O
,	TOVIAZ.xml:S1:6146:1	,	,	O	O
857	TOVIAZ.xml:S1:6148:3	857	CD	O	O
,	TOVIAZ.xml:S1:6151:1	,	,	O	O
701	TOVIAZ.xml:S1:6153:3	701	CD	O	O
,	TOVIAZ.xml:S1:6156:1	,	,	O	O
529	TOVIAZ.xml:S1:6158:3	529	CD	O	O
,	TOVIAZ.xml:S1:6161:1	,	,	O	O
and	TOVIAZ.xml:S1:6163:3	and	CC	O	O
105	TOVIAZ.xml:S1:6167:3	105	CD	O	O
patients	TOVIAZ.xml:S1:6171:8	patient	NNS	O	O
received	TOVIAZ.xml:S1:6180:8	receiv	VBD	O	O
Toviaz	TOVIAZ.xml:S1:6189:6	toviaz	NNP	O	O
for	TOVIAZ.xml:S1:6196:3	for	IN	O	O
at	TOVIAZ.xml:S1:6200:2	at	IN	O	O
least	TOVIAZ.xml:S1:6203:5	least	JJS	O	O
6	TOVIAZ.xml:S1:6209:1	6	CD	O	O
months	TOVIAZ.xml:S1:6211:6	month	NNS	O	O
,	TOVIAZ.xml:S1:6217:1	,	,	O	O
1	TOVIAZ.xml:S1:6219:1	1	CD	O	O
year	TOVIAZ.xml:S1:6221:4	year	NN	O	O
,	TOVIAZ.xml:S1:6225:1	,	,	O	O
2	TOVIAZ.xml:S1:6227:1	2	CD	O	O
years	TOVIAZ.xml:S1:6229:5	year	NNS	O	O
,	TOVIAZ.xml:S1:6234:1	,	,	O	O
and	TOVIAZ.xml:S1:6236:3	and	CC	O	O
3	TOVIAZ.xml:S1:6240:1	3	CD	O	O
years	TOVIAZ.xml:S1:6242:5	year	NNS	O	O
,	TOVIAZ.xml:S1:6247:1	,	,	O	O
respectively	TOVIAZ.xml:S1:6249:12	respect	RB	O	O
.	TOVIAZ.xml:S1:6261:1	.	.	O	O

The	TOVIAZ.xml:S1:6263:3	the	DT	O	O
adverse	TOVIAZ.xml:S1:6267:7	advers	JJ	O	O
events	TOVIAZ.xml:S1:6275:6	event	NNS	O	O
observed	TOVIAZ.xml:S1:6282:8	observ	VBD	O	O
during	TOVIAZ.xml:S1:6291:6	dure	IN	O	O
long	TOVIAZ.xml:S1:6298:4	long	JJ	O	O
-	TOVIAZ.xml:S1:6302:1	-	:	O	O
term	TOVIAZ.xml:S1:6303:4	term	NN	O	O
,	TOVIAZ.xml:S1:6307:1	,	,	O	O
open	TOVIAZ.xml:S1:6309:4	open	JJ	O	O
-	TOVIAZ.xml:S1:6313:1	-	:	O	O
label	TOVIAZ.xml:S1:6314:5	label	NN	O	O
studies	TOVIAZ.xml:S1:6320:7	studi	NNS	O	O
were	TOVIAZ.xml:S1:6328:4	were	VBD	O	O
similar	TOVIAZ.xml:S1:6333:7	similar	JJ	O	O
to	TOVIAZ.xml:S1:6341:2	to	TO	O	O
those	TOVIAZ.xml:S1:6344:5	those	DT	O	O
observed	TOVIAZ.xml:S1:6350:8	observ	VBN	O	O
in	TOVIAZ.xml:S1:6359:2	in	IN	O	O
the	TOVIAZ.xml:S1:6362:3	the	DT	O	O
12	TOVIAZ.xml:S1:6366:2	12	CD	O	O
-	TOVIAZ.xml:S1:6368:1	-	:	O	O
week	TOVIAZ.xml:S1:6369:4	week	NN	O	O
,	TOVIAZ.xml:S1:6373:1	,	,	O	O
placebo	TOVIAZ.xml:S1:6375:7	placebo	SYM	O	O
-	TOVIAZ.xml:S1:6382:1	-	:	O	O
controlled	TOVIAZ.xml:S1:6383:10	control	VBN	O	O
studies	TOVIAZ.xml:S1:6394:7	studi	NNS	O	O
,	TOVIAZ.xml:S1:6401:1	,	,	O	O
and	TOVIAZ.xml:S1:6403:3	and	CC	O	O
included	TOVIAZ.xml:S1:6407:8	includ	VBD	O	O
dry	TOVIAZ.xml:S1:6416:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	TOVIAZ.xml:S1:6420:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
,	TOVIAZ.xml:S1:6425:1	,	,	O	O
constipation	TOVIAZ.xml:S1:6427:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S1:6439:1	,	,	O	O
dry	TOVIAZ.xml:S1:6441:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
eyes	TOVIAZ.xml:S1:6445:4	eye	NNS	I-AdverseReaction	I-AdverseReaction
,	TOVIAZ.xml:S1:6449:1	,	,	O	O
dyspepsia	TOVIAZ.xml:S1:6451:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S1:6460:1	,	,	O	O
and	TOVIAZ.xml:S1:6462:3	and	CC	O	O
abdominal	TOVIAZ.xml:S1:6466:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TOVIAZ.xml:S1:6476:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	TOVIAZ.xml:S1:6480:1	.	.	O	O

Similar	TOVIAZ.xml:S1:6482:7	similar	JJ	O	O
to	TOVIAZ.xml:S1:6490:2	to	TO	O	O
the	TOVIAZ.xml:S1:6493:3	the	DT	O	O
controlled	TOVIAZ.xml:S1:6497:10	control	VBN	O	O
studies	TOVIAZ.xml:S1:6508:7	studi	NNS	O	O
,	TOVIAZ.xml:S1:6515:1	,	,	O	O
most	TOVIAZ.xml:S1:6517:4	most	JJS	O	O
adverse	TOVIAZ.xml:S1:6522:7	advers	JJ	O	O
events	TOVIAZ.xml:S1:6530:6	event	NNS	O	O
of	TOVIAZ.xml:S1:6537:2	of	IN	O	O
dry	TOVIAZ.xml:S1:6540:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	TOVIAZ.xml:S1:6544:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
and	TOVIAZ.xml:S1:6550:3	and	CC	O	O
constipation	TOVIAZ.xml:S1:6554:12	constip	NN	B-AdverseReaction	B-AdverseReaction
were	TOVIAZ.xml:S1:6567:4	were	VBD	O	O
mild	TOVIAZ.xml:S1:6572:4	mild	JJ	O	O
to	TOVIAZ.xml:S1:6577:2	to	TO	O	O
moderate	TOVIAZ.xml:S1:6580:8	moder	VB	O	O
in	TOVIAZ.xml:S1:6589:2	in	IN	O	O
intensity	TOVIAZ.xml:S1:6592:9	intens	NN	O	O
.	TOVIAZ.xml:S1:6601:1	.	.	O	O

Serious	TOVIAZ.xml:S1:6603:7	seriou	JJ	O	O
adverse	TOVIAZ.xml:S1:6611:7	advers	JJ	O	O
events	TOVIAZ.xml:S1:6619:6	event	NNS	O	O
,	TOVIAZ.xml:S1:6625:1	,	,	O	O
judged	TOVIAZ.xml:S1:6627:6	judg	VBN	O	O
to	TOVIAZ.xml:S1:6634:2	to	TO	O	O
be	TOVIAZ.xml:S1:6637:2	be	VB	O	O
at	TOVIAZ.xml:S1:6640:2	at	IN	O	O
least	TOVIAZ.xml:S1:6643:5	least	JJS	O	O
possibly	TOVIAZ.xml:S1:6649:8	possibl	RB	O	O
related	TOVIAZ.xml:S1:6658:7	relat	VBN	O	O
to	TOVIAZ.xml:S1:6666:2	to	TO	O	O
study	TOVIAZ.xml:S1:6669:5	studi	VB	O	O
medication	TOVIAZ.xml:S1:6675:10	medic	NN	O	O
by	TOVIAZ.xml:S1:6686:2	by	IN	O	O
the	TOVIAZ.xml:S1:6689:3	the	DT	O	O
investigator	TOVIAZ.xml:S1:6693:12	investig	NN	O	O
and	TOVIAZ.xml:S1:6706:3	and	CC	O	O
reported	TOVIAZ.xml:S1:6710:8	report	VBD	O	O
more	TOVIAZ.xml:S1:6719:4	more	JJR	O	O
than	TOVIAZ.xml:S1:6724:4	than	IN	O	O
once	TOVIAZ.xml:S1:6729:4	onc	RB	O	O
during	TOVIAZ.xml:S1:6734:6	dure	IN	O	O
the	TOVIAZ.xml:S1:6741:3	the	DT	O	O
open	TOVIAZ.xml:S1:6745:4	open	JJ	O	O
-	TOVIAZ.xml:S1:6749:1	-	:	O	O
label	TOVIAZ.xml:S1:6750:5	label	NN	O	O
treatment	TOVIAZ.xml:S1:6756:9	treatment	NN	O	O
period	TOVIAZ.xml:S1:6766:6	period	NN	O	O
of	TOVIAZ.xml:S1:6773:2	of	IN	O	O
up	TOVIAZ.xml:S1:6776:2	up	IN	O	O
to	TOVIAZ.xml:S1:6779:2	to	TO	O	O
3	TOVIAZ.xml:S1:6782:1	3	CD	O	O
years	TOVIAZ.xml:S1:6784:5	year	NNS	O	O
,	TOVIAZ.xml:S1:6789:1	,	,	O	O
included	TOVIAZ.xml:S1:6791:8	includ	VBD	O	O
urinary	TOVIAZ.xml:S1:6800:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	TOVIAZ.xml:S1:6808:9	retent	NN	I-AdverseReaction	I-AdverseReaction
(	TOVIAZ.xml:S1:6818:1	(	(	O	O
3	TOVIAZ.xml:S1:6819:1	3	CD	O	O
cases	TOVIAZ.xml:S1:6821:5	case	NNS	O	O
)	TOVIAZ.xml:S1:6826:1	)	)	O	O
,	TOVIAZ.xml:S1:6827:1	,	,	O	O
diverticulitis	TOVIAZ.xml:S1:6829:14	diverticul	NN	B-AdverseReaction	B-AdverseReaction
(	TOVIAZ.xml:S1:6844:1	(	(	O	O
3	TOVIAZ.xml:S1:6845:1	3	CD	O	O
cases	TOVIAZ.xml:S1:6847:5	case	NNS	O	O
)	TOVIAZ.xml:S1:6852:1	)	)	O	O
,	TOVIAZ.xml:S1:6853:1	,	,	O	O
constipation	TOVIAZ.xml:S1:6855:12	constip	NN	B-AdverseReaction	B-AdverseReaction
(	TOVIAZ.xml:S1:6868:1	(	(	O	O
2	TOVIAZ.xml:S1:6869:1	2	CD	O	O
cases	TOVIAZ.xml:S1:6871:5	case	NNS	O	O
)	TOVIAZ.xml:S1:6876:1	)	)	O	O
,	TOVIAZ.xml:S1:6877:1	,	,	O	O
irritable	TOVIAZ.xml:S1:6879:9	irrit	JJ	B-AdverseReaction	B-AdverseReaction
bowel	TOVIAZ.xml:S1:6889:5	bowel	NN	I-AdverseReaction	I-AdverseReaction
syndrome	TOVIAZ.xml:S1:6895:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
(	TOVIAZ.xml:S1:6904:1	(	(	O	O
2	TOVIAZ.xml:S1:6905:1	2	CD	O	O
cases	TOVIAZ.xml:S1:6907:5	case	NNS	O	O
)	TOVIAZ.xml:S1:6912:1	)	)	O	O
,	TOVIAZ.xml:S1:6913:1	,	,	O	O
and	TOVIAZ.xml:S1:6915:3	and	CC	O	O
electrocardiogram	TOVIAZ.xml:S1:6919:17	electrocardiogram	RB	O	O
QT	TOVIAZ.xml:S1:6937:2	QT	NNP	B-AdverseReaction	O
corrected	TOVIAZ.xml:S1:6940:9	correct	VBD	I-AdverseReaction	O
interval	TOVIAZ.xml:S1:6950:8	interv	JJ	I-AdverseReaction	B-AdverseReaction
prolongation	TOVIAZ.xml:S1:6959:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
(	TOVIAZ.xml:S1:6972:1	(	(	O	O
2	TOVIAZ.xml:S1:6973:1	2	CD	O	O
cases	TOVIAZ.xml:S1:6975:5	case	NNS	O	O
)	TOVIAZ.xml:S1:6980:1	)	)	O	O
.	TOVIAZ.xml:S1:6981:1	.	.	O	O

6.2	TOVIAZ.xml:S1:6989:3	6.2	CD	O	O

Post	TOVIAZ.xml:S1:6993:4	post	NNP	O	O
-	TOVIAZ.xml:S1:6997:1	-	:	O	O
marketing	TOVIAZ.xml:S1:6998:9	market	NN	O	O
Experience	TOVIAZ.xml:S1:7008:10	experi	NN	O	O

The	TOVIAZ.xml:S1:7022:3	the	DT	O	O
following	TOVIAZ.xml:S1:7026:9	follow	JJ	O	O
events	TOVIAZ.xml:S1:7036:6	event	NNS	O	O
have	TOVIAZ.xml:S1:7043:4	have	VBP	O	O
been	TOVIAZ.xml:S1:7048:4	been	VBN	O	O
reported	TOVIAZ.xml:S1:7053:8	report	VBN	O	O
in	TOVIAZ.xml:S1:7062:2	in	IN	O	O
association	TOVIAZ.xml:S1:7065:11	associ	NN	O	O
with	TOVIAZ.xml:S1:7077:4	with	IN	O	O
fesoterodine	TOVIAZ.xml:S1:7082:12	fesoterodin	NN	O	O
use	TOVIAZ.xml:S1:7095:3	use	NN	O	O
in	TOVIAZ.xml:S1:7099:2	in	IN	O	O
worldwide	TOVIAZ.xml:S1:7102:9	worldwid	NN	O	O
post	TOVIAZ.xml:S1:7112:4	post	NN	O	O
-	TOVIAZ.xml:S1:7116:1	-	:	O	O
marketing	TOVIAZ.xml:S1:7117:9	market	NN	O	O
experience	TOVIAZ.xml:S1:7127:10	experi	NN	O	O
:	TOVIAZ.xml:S1:7137:1	:	:	O	O
Eye	TOVIAZ.xml:S1:7142:3	eye	NN	O	O
disorders	TOVIAZ.xml:S1:7146:9	disord	NNS	O	O
:	TOVIAZ.xml:S1:7155:1	:	:	O	O
Blurred	TOVIAZ.xml:S1:7160:7	blur	NNP	B-AdverseReaction	B-AdverseReaction
vision	TOVIAZ.xml:S1:7168:6	vision	NN	I-AdverseReaction	I-AdverseReaction
;	TOVIAZ.xml:S1:7174:1	;	:	O	O
Cardiac	TOVIAZ.xml:S1:7179:7	cardiac	NNP	O	O
disorders	TOVIAZ.xml:S1:7187:9	disord	NNS	O	O
:	TOVIAZ.xml:S1:7196:1	:	:	O	O
Palpitations	TOVIAZ.xml:S1:7201:12	palpit	NNS	B-AdverseReaction	B-AdverseReaction
;	TOVIAZ.xml:S1:7213:1	;	:	O	O
General	TOVIAZ.xml:S1:7218:7	gener	NNP	O	O
disorders	TOVIAZ.xml:S1:7226:9	disord	NNPS	O	O
and	TOVIAZ.xml:S1:7236:3	and	CC	O	O
administrative	TOVIAZ.xml:S1:7240:14	administr	JJ	O	O
site	TOVIAZ.xml:S1:7255:4	site	NN	O	O
conditions	TOVIAZ.xml:S1:7260:10	condit	NNS	O	O
:	TOVIAZ.xml:S1:7270:1	:	:	O	O
Hypersensitivity	TOVIAZ.xml:S1:7275:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	TOVIAZ.xml:S1:7292:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	TOVIAZ.xml:S1:7301:1	,	,	O	O
including	TOVIAZ.xml:S1:7303:9	includ	VBG	O	O
angioedema	TOVIAZ.xml:S1:7313:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
with	TOVIAZ.xml:S1:7324:4	with	IN	O	O
airway	TOVIAZ.xml:S1:7329:6	airway	JJ	B-AdverseReaction	O
obstruction	TOVIAZ.xml:S1:7336:11	obstruct	NN	I-AdverseReaction	O
,	TOVIAZ.xml:S1:7347:1	,	,	O	O
face	TOVIAZ.xml:S1:7349:4	face	NN	B-AdverseReaction	B-AdverseReaction
edema	TOVIAZ.xml:S1:7354:5	edema	NN	I-AdverseReaction	I-AdverseReaction
;	TOVIAZ.xml:S1:7359:1	;	:	O	O
Central	TOVIAZ.xml:S1:7364:7	central	NNP	O	O
nervous	TOVIAZ.xml:S1:7372:7	nervou	JJ	O	O
system	TOVIAZ.xml:S1:7380:6	system	NN	O	O
disorders	TOVIAZ.xml:S1:7387:9	disord	NNS	O	O
:	TOVIAZ.xml:S1:7396:1	:	:	O	O
Dizziness	TOVIAZ.xml:S1:7401:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S1:7410:1	,	,	O	O
headache	TOVIAZ.xml:S1:7412:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S1:7420:1	,	,	O	O
somnolence	TOVIAZ.xml:S1:7422:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
;	TOVIAZ.xml:S1:7432:1	;	:	O	O
Skin	TOVIAZ.xml:S1:7437:4	skin	NNP	O	O
and	TOVIAZ.xml:S1:7442:3	and	CC	O	O
subcutaneous	TOVIAZ.xml:S1:7446:12	subcutan	JJ	O	O
tissue	TOVIAZ.xml:S1:7459:6	tissu	NN	O	O
disorders	TOVIAZ.xml:S1:7466:9	disord	NNS	O	O
:	TOVIAZ.xml:S1:7477:1	:	:	O	O
Urticaria	TOVIAZ.xml:S1:7480:9	urticaria	NNP	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S1:7489:1	,	,	O	O
pruritus	TOVIAZ.xml:S1:7491:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction

Because	TOVIAZ.xml:S1:7504:7	becaus	IN	O	O
these	TOVIAZ.xml:S1:7512:5	these	DT	O	O
spontaneously	TOVIAZ.xml:S1:7518:13	spontan	RB	O	O
reported	TOVIAZ.xml:S1:7532:8	report	VBN	O	O
events	TOVIAZ.xml:S1:7541:6	event	NNS	O	O
are	TOVIAZ.xml:S1:7548:3	are	VBP	O	O
from	TOVIAZ.xml:S1:7552:4	from	IN	O	O
the	TOVIAZ.xml:S1:7557:3	the	DT	O	O
worldwide	TOVIAZ.xml:S1:7561:9	worldwid	NN	O	O
post	TOVIAZ.xml:S1:7571:4	post	NN	O	O
-	TOVIAZ.xml:S1:7575:1	-	:	O	O
marketing	TOVIAZ.xml:S1:7576:9	market	NN	O	O
experience	TOVIAZ.xml:S1:7586:10	experi	NN	O	O
,	TOVIAZ.xml:S1:7596:1	,	,	O	O
the	TOVIAZ.xml:S1:7598:3	the	DT	O	O
frequency	TOVIAZ.xml:S1:7602:9	frequenc	NN	O	O
of	TOVIAZ.xml:S1:7612:2	of	IN	O	O
events	TOVIAZ.xml:S1:7615:6	event	NNS	O	O
and	TOVIAZ.xml:S1:7622:3	and	CC	O	O
the	TOVIAZ.xml:S1:7626:3	the	DT	O	O
role	TOVIAZ.xml:S1:7630:4	role	NN	O	O
of	TOVIAZ.xml:S1:7635:2	of	IN	O	O
fesoterodine	TOVIAZ.xml:S1:7638:12	fesoterodin	NN	O	O
in	TOVIAZ.xml:S1:7651:2	in	IN	O	O
their	TOVIAZ.xml:S1:7654:5	their	PRP$	O	O
causation	TOVIAZ.xml:S1:7660:9	causat	NN	O	O
cannot	TOVIAZ.xml:S1:7670:6	cannot	NN	O	O
be	TOVIAZ.xml:S1:7677:2	be	VB	O	O
reliably	TOVIAZ.xml:S1:7680:8	reliabl	RB	O	O
determined	TOVIAZ.xml:S1:7689:10	determin	VBN	O	O
.	TOVIAZ.xml:S1:7699:1	.	.	O	O
5	TOVIAZ.xml:S2:4:1	5	CD	O	O
WARNINGS	TOVIAZ.xml:S2:6:8	warn	NNP	O	O
AND	TOVIAZ.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	TOVIAZ.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	TOVIAZ.xml:S2:37:7	excerpt	NN	O	O
:	TOVIAZ.xml:S2:44:1	:	:	O	O
Angioedema	TOVIAZ.xml:S2:54:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
of	TOVIAZ.xml:S2:65:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	TOVIAZ.xml:S2:68:3	the	DT	I-AdverseReaction	I-AdverseReaction
face	TOVIAZ.xml:S2:72:4	face	NN	I-AdverseReaction	I-AdverseReaction
,	TOVIAZ.xml:S2:76:1	,	,	O	O
lips	TOVIAZ.xml:S2:78:4	lip	NNS	I-AdverseReaction	O
,	TOVIAZ.xml:S2:82:1	,	,	O	O
tongue	TOVIAZ.xml:S2:84:6	tongu	NN	I-AdverseReaction	O
,	TOVIAZ.xml:S2:90:1	,	,	O	O
and	TOVIAZ.xml:S2:92:3	and	CC	O	O
or	TOVIAZ.xml:S2:96:2	or	CC	O	O
larynx	TOVIAZ.xml:S2:99:6	larynx	NN	I-AdverseReaction	O
has	TOVIAZ.xml:S2:106:3	ha	VBZ	O	O
been	TOVIAZ.xml:S2:110:4	been	VBN	O	O
reported	TOVIAZ.xml:S2:115:8	report	VBN	O	O
with	TOVIAZ.xml:S2:124:4	with	IN	O	O
fesoterodine	TOVIAZ.xml:S2:129:12	fesoterodin	NN	O	O
.	TOVIAZ.xml:S2:141:1	.	.	O	O

(	TOVIAZ.xml:S2:143:1	(	(	O	O
5.1	TOVIAZ.xml:S2:146:3	5.1	CD	O	O
)	TOVIAZ.xml:S2:151:1	)	)	O	O
.	TOVIAZ.xml:S2:152:1	.	.	O	O

Toviaz	TOVIAZ.xml:S2:161:6	toviaz	NNP	O	O
should	TOVIAZ.xml:S2:168:6	should	MD	O	O
be	TOVIAZ.xml:S2:175:2	be	VB	O	O
administered	TOVIAZ.xml:S2:178:12	administ	VBN	O	O
with	TOVIAZ.xml:S2:191:4	with	IN	O	O
caution	TOVIAZ.xml:S2:196:7	caution	NN	O	O
to	TOVIAZ.xml:S2:204:2	to	TO	O	O
patients	TOVIAZ.xml:S2:207:8	patient	NNS	O	O
with	TOVIAZ.xml:S2:216:4	with	IN	O	O
clinically	TOVIAZ.xml:S2:221:10	clinic	RB	O	O
significant	TOVIAZ.xml:S2:232:11	signific	JJ	O	O
bladder	TOVIAZ.xml:S2:244:7	bladder	NN	O	O
outlet	TOVIAZ.xml:S2:252:6	outlet	NN	O	O
obstruction	TOVIAZ.xml:S2:259:11	obstruct	NN	O	O
because	TOVIAZ.xml:S2:271:7	becaus	IN	O	O
of	TOVIAZ.xml:S2:279:2	of	IN	O	O
the	TOVIAZ.xml:S2:282:3	the	DT	O	O
risk	TOVIAZ.xml:S2:286:4	risk	NN	O	O
of	TOVIAZ.xml:S2:291:2	of	IN	O	O
urinary	TOVIAZ.xml:S2:294:7	urinari	JJ	O	B-AdverseReaction
retention	TOVIAZ.xml:S2:302:9	retent	NN	O	I-AdverseReaction
.	TOVIAZ.xml:S2:311:1	.	.	O	O

(	TOVIAZ.xml:S2:313:1	(	(	O	O
5.2	TOVIAZ.xml:S2:316:3	5.2	CD	O	O
)	TOVIAZ.xml:S2:321:1	)	)	O	O

Toviaz	TOVIAZ.xml:S2:330:6	toviaz	NNP	O	O
,	TOVIAZ.xml:S2:336:1	,	,	O	O
like	TOVIAZ.xml:S2:338:4	like	IN	O	O
other	TOVIAZ.xml:S2:343:5	other	JJ	O	O
antimuscarinic	TOVIAZ.xml:S2:349:14	antimuscarin	JJ	O	O
drugs	TOVIAZ.xml:S2:364:5	drug	NNS	O	O
,	TOVIAZ.xml:S2:369:1	,	,	O	O
should	TOVIAZ.xml:S2:371:6	should	MD	O	O
be	TOVIAZ.xml:S2:378:2	be	VB	O	O
used	TOVIAZ.xml:S2:381:4	use	VBN	O	O
with	TOVIAZ.xml:S2:386:4	with	IN	O	O
caution	TOVIAZ.xml:S2:391:7	caution	NN	O	O
in	TOVIAZ.xml:S2:399:2	in	IN	O	O
patients	TOVIAZ.xml:S2:402:8	patient	NNS	O	O
with	TOVIAZ.xml:S2:411:4	with	IN	O	O
decreased	TOVIAZ.xml:S2:416:9	decreas	JJ	O	B-AdverseReaction
gastrointestinal	TOVIAZ.xml:S2:426:16	gastrointestin	JJ	O	I-AdverseReaction
motility	TOVIAZ.xml:S2:443:8	motil	NN	O	I-AdverseReaction
,	TOVIAZ.xml:S2:451:1	,	,	O	O
such	TOVIAZ.xml:S2:453:4	such	JJ	O	O
as	TOVIAZ.xml:S2:458:2	as	IN	O	O
those	TOVIAZ.xml:S2:461:5	those	DT	O	O
with	TOVIAZ.xml:S2:467:4	with	IN	O	O
severe	TOVIAZ.xml:S2:472:6	sever	JJ	O	O
constipation	TOVIAZ.xml:S2:479:12	constip	NN	O	O
.	TOVIAZ.xml:S2:491:1	.	.	O	O

(	TOVIAZ.xml:S2:493:1	(	(	O	O
5.3	TOVIAZ.xml:S2:496:3	5.3	CD	O	O
)	TOVIAZ.xml:S2:501:1	)	)	O	O

Toviaz	TOVIAZ.xml:S2:510:6	toviaz	NNP	O	O
should	TOVIAZ.xml:S2:517:6	should	MD	O	O
be	TOVIAZ.xml:S2:524:2	be	VB	O	O
used	TOVIAZ.xml:S2:527:4	use	VBN	O	O
with	TOVIAZ.xml:S2:532:4	with	IN	O	O
caution	TOVIAZ.xml:S2:537:7	caution	NN	O	O
in	TOVIAZ.xml:S2:545:2	in	IN	O	O
patients	TOVIAZ.xml:S2:548:8	patient	NNS	O	O
being	TOVIAZ.xml:S2:557:5	be	VBG	O	O
treated	TOVIAZ.xml:S2:563:7	treat	VBN	O	O
for	TOVIAZ.xml:S2:571:3	for	IN	O	O
narrow	TOVIAZ.xml:S2:575:6	narrow	JJ	O	O
-	TOVIAZ.xml:S2:581:1	-	:	O	O
angle	TOVIAZ.xml:S2:582:5	angl	NN	O	O
glaucoma	TOVIAZ.xml:S2:588:8	glaucoma	NN	O	O
,	TOVIAZ.xml:S2:596:1	,	,	O	O
and	TOVIAZ.xml:S2:598:3	and	CC	O	O
only	TOVIAZ.xml:S2:602:4	onli	RB	O	O
where	TOVIAZ.xml:S2:607:5	where	WRB	O	O
the	TOVIAZ.xml:S2:613:3	the	DT	O	O
potential	TOVIAZ.xml:S2:617:9	potenti	JJ	O	O
benefits	TOVIAZ.xml:S2:627:8	benefit	NNS	O	O
outweigh	TOVIAZ.xml:S2:636:8	outweigh	VBP	O	O
the	TOVIAZ.xml:S2:645:3	the	DT	O	O
risks	TOVIAZ.xml:S2:649:5	risk	NNS	O	O
(	TOVIAZ.xml:S2:655:1	(	(	O	O
5.4	TOVIAZ.xml:S2:658:3	5.4	CD	O	O
)	TOVIAZ.xml:S2:663:1	)	)	O	O

Central	TOVIAZ.xml:S2:672:7	central	NNP	B-AdverseReaction	O
Nervous	TOVIAZ.xml:S2:680:7	nervou	NNP	I-AdverseReaction	O
System	TOVIAZ.xml:S2:688:6	system	NNP	I-AdverseReaction	O
Effects	TOVIAZ.xml:S2:695:7	effect	NNPS	I-AdverseReaction	O
:	TOVIAZ.xml:S2:702:1	:	:	O	O
Somnolence	TOVIAZ.xml:S2:704:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
has	TOVIAZ.xml:S2:715:3	ha	VBZ	O	O
been	TOVIAZ.xml:S2:719:4	been	VBN	O	O
reported	TOVIAZ.xml:S2:724:8	report	VBN	O	O
with	TOVIAZ.xml:S2:733:4	with	IN	O	O
Toviaz	TOVIAZ.xml:S2:738:6	toviaz	NNP	O	O
.	TOVIAZ.xml:S2:744:1	.	.	O	O

Advise	TOVIAZ.xml:S2:746:6	advis	NN	O	O
patients	TOVIAZ.xml:S2:753:8	patient	NNS	O	O
not	TOVIAZ.xml:S2:762:3	not	RB	O	O
to	TOVIAZ.xml:S2:766:2	to	TO	O	O
drive	TOVIAZ.xml:S2:769:5	drive	VB	O	O
or	TOVIAZ.xml:S2:775:2	or	CC	O	O
operate	TOVIAZ.xml:S2:778:7	oper	VB	O	O
heavy	TOVIAZ.xml:S2:786:5	heavi	JJ	O	O
machinery	TOVIAZ.xml:S2:792:9	machineri	NN	O	O
until	TOVIAZ.xml:S2:802:5	until	IN	O	O
they	TOVIAZ.xml:S2:808:4	they	PRP	O	O
know	TOVIAZ.xml:S2:813:4	know	VBP	O	O
how	TOVIAZ.xml:S2:818:3	how	WRB	O	O
Toviaz	TOVIAZ.xml:S2:822:6	toviaz	NNP	O	O
affects	TOVIAZ.xml:S2:829:7	affect	VBZ	O	O
them	TOVIAZ.xml:S2:837:4	them	PRP	O	O
(	TOVIAZ.xml:S2:842:1	(	(	O	O
5.5	TOVIAZ.xml:S2:845:3	5.5	CD	O	O
)	TOVIAZ.xml:S2:850:1	)	)	O	O

Toviaz	TOVIAZ.xml:S2:859:6	toviaz	NNP	O	O
should	TOVIAZ.xml:S2:866:6	should	MD	O	O
be	TOVIAZ.xml:S2:873:2	be	VB	O	O
used	TOVIAZ.xml:S2:876:4	use	VBN	O	O
with	TOVIAZ.xml:S2:881:4	with	IN	O	O
caution	TOVIAZ.xml:S2:886:7	caution	NN	O	O
in	TOVIAZ.xml:S2:894:2	in	IN	O	O
patients	TOVIAZ.xml:S2:897:8	patient	NNS	O	O
with	TOVIAZ.xml:S2:906:4	with	IN	O	O
myasthenia	TOVIAZ.xml:S2:911:10	myasthenia	JJ	O	O
gravis	TOVIAZ.xml:S2:922:6	gravi	NN	O	O
,	TOVIAZ.xml:S2:928:1	,	,	O	O
a	TOVIAZ.xml:S2:930:1	a	DT	O	O
disease	TOVIAZ.xml:S2:932:7	diseas	NN	O	O
characterized	TOVIAZ.xml:S2:940:13	character	VBN	O	O
by	TOVIAZ.xml:S2:954:2	by	IN	O	O
decreased	TOVIAZ.xml:S2:957:9	decreas	JJ	O	B-AdverseReaction
cholinergic	TOVIAZ.xml:S2:967:11	cholinerg	NN	O	I-AdverseReaction
activity	TOVIAZ.xml:S2:979:8	activ	NN	O	I-AdverseReaction
at	TOVIAZ.xml:S2:988:2	at	IN	O	O
the	TOVIAZ.xml:S2:991:3	the	DT	O	O
neuromuscular	TOVIAZ.xml:S2:995:13	neuromuscular	JJ	O	O
junction	TOVIAZ.xml:S2:1009:8	junction	NN	O	O
.	TOVIAZ.xml:S2:1017:1	.	.	O	O

(	TOVIAZ.xml:S2:1019:1	(	(	O	O
5.9	TOVIAZ.xml:S2:1022:3	5.9	CD	O	O
)	TOVIAZ.xml:S2:1027:1	)	)	O	O

5.1	TOVIAZ.xml:S2:1041:3	5.1	CD	O	O

Angioedema	TOVIAZ.xml:S2:1045:10	angioedema	NN	O	O

Angioedema	TOVIAZ.xml:S2:1061:10	angioedema	NN	B-AdverseReaction	O

of	TOVIAZ.xml:S2:1072:2	of	IN	I-AdverseReaction	O
the	TOVIAZ.xml:S2:1075:3	the	DT	I-AdverseReaction	O
face	TOVIAZ.xml:S2:1079:4	face	NN	I-AdverseReaction	O
,	TOVIAZ.xml:S2:1083:1	,	,	O	O
lips	TOVIAZ.xml:S2:1085:4	lip	NNS	I-AdverseReaction	O
,	TOVIAZ.xml:S2:1089:1	,	,	O	O
tongue	TOVIAZ.xml:S2:1091:6	tongu	NN	I-AdverseReaction	O
,	TOVIAZ.xml:S2:1097:1	,	,	O	O
and	TOVIAZ.xml:S2:1099:3	and	CC	O	O
or	TOVIAZ.xml:S2:1103:2	or	CC	O	O
larynx	TOVIAZ.xml:S2:1106:6	larynx	NN	I-AdverseReaction	O
has	TOVIAZ.xml:S2:1113:3	ha	VBZ	O	O
been	TOVIAZ.xml:S2:1117:4	been	VBN	O	O
reported	TOVIAZ.xml:S2:1122:8	report	VBN	O	O
with	TOVIAZ.xml:S2:1131:4	with	IN	O	O
fesoterodine	TOVIAZ.xml:S2:1136:12	fesoterodin	NN	O	O
.	TOVIAZ.xml:S2:1148:1	.	.	O	O

In	TOVIAZ.xml:S2:1150:2	In	IN	O	O
some	TOVIAZ.xml:S2:1153:4	some	DT	O	O
cases	TOVIAZ.xml:S2:1158:5	case	NNS	O	O
angioedema	TOVIAZ.xml:S2:1164:10	angioedema	VBP	O	O
occurred	TOVIAZ.xml:S2:1175:8	occur	VBN	O	O
after	TOVIAZ.xml:S2:1184:5	after	IN	O	O
the	TOVIAZ.xml:S2:1190:3	the	DT	O	O
first	TOVIAZ.xml:S2:1194:5	first	JJ	O	O
dose	TOVIAZ.xml:S2:1200:4	dose	NN	O	O
.	TOVIAZ.xml:S2:1204:1	.	.	O	O

Angioedema	TOVIAZ.xml:S2:1206:10	angioedema	NNP	B-AdverseReaction	B-AdverseReaction
associated	TOVIAZ.xml:S2:1217:10	associ	VBD	O	O
with	TOVIAZ.xml:S2:1228:4	with	IN	O	O
upper	TOVIAZ.xml:S2:1233:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
airway	TOVIAZ.xml:S2:1239:6	airway	NN	I-AdverseReaction	I-AdverseReaction
swelling	TOVIAZ.xml:S2:1246:8	swell	NN	I-AdverseReaction	I-AdverseReaction
may	TOVIAZ.xml:S2:1255:3	may	MD	O	O
be	TOVIAZ.xml:S2:1259:2	be	VB	O	O
life	TOVIAZ.xml:S2:1262:4	life	NN	O	O
-	TOVIAZ.xml:S2:1266:1	-	:	O	O
threatening	TOVIAZ.xml:S2:1267:11	threaten	NN	O	O
.	TOVIAZ.xml:S2:1278:1	.	.	O	O

If	TOVIAZ.xml:S2:1280:2	If	IN	O	O
involvement	TOVIAZ.xml:S2:1283:11	involv	NN	O	O
of	TOVIAZ.xml:S2:1295:2	of	IN	O	O
the	TOVIAZ.xml:S2:1298:3	the	DT	O	O
tongue	TOVIAZ.xml:S2:1302:6	tongu	NN	O	O
,	TOVIAZ.xml:S2:1308:1	,	,	O	O
hypopharynx	TOVIAZ.xml:S2:1310:11	hypopharynx	NN	O	O
,	TOVIAZ.xml:S2:1321:1	,	,	O	O
or	TOVIAZ.xml:S2:1323:2	or	CC	O	O
larynx	TOVIAZ.xml:S2:1326:6	larynx	NN	O	O
occurs	TOVIAZ.xml:S2:1333:6	occur	NNS	O	O
,	TOVIAZ.xml:S2:1339:1	,	,	O	O
fesoterodine	TOVIAZ.xml:S2:1341:12	fesoterodin	NN	O	O
should	TOVIAZ.xml:S2:1354:6	should	MD	O	O
be	TOVIAZ.xml:S2:1361:2	be	VB	O	O
promptly	TOVIAZ.xml:S2:1364:8	promptli	RB	O	O
discontinued	TOVIAZ.xml:S2:1373:12	discontinu	VBN	O	O
and	TOVIAZ.xml:S2:1386:3	and	CC	O	O
appropriate	TOVIAZ.xml:S2:1390:11	appropri	JJ	O	O
therapy	TOVIAZ.xml:S2:1402:7	therapi	NN	O	O
and	TOVIAZ.xml:S2:1410:3	and	CC	O	O
or	TOVIAZ.xml:S2:1414:2	or	CC	O	O
measures	TOVIAZ.xml:S2:1417:8	measur	NNS	O	O
to	TOVIAZ.xml:S2:1426:2	to	TO	O	O
ensure	TOVIAZ.xml:S2:1429:6	ensur	VB	O	O
a	TOVIAZ.xml:S2:1436:1	a	DT	O	O
patent	TOVIAZ.xml:S2:1438:6	patent	NN	O	O
airway	TOVIAZ.xml:S2:1445:6	airway	NN	O	O
should	TOVIAZ.xml:S2:1452:6	should	MD	O	O
be	TOVIAZ.xml:S2:1459:2	be	VB	O	O
promptly	TOVIAZ.xml:S2:1462:8	promptli	RB	O	O
provided	TOVIAZ.xml:S2:1471:8	provid	VBN	O	O
.	TOVIAZ.xml:S2:1479:1	.	.	O	O

5.2	TOVIAZ.xml:S2:1488:3	5.2	CD	O	O
Bladder	TOVIAZ.xml:S2:1492:7	bladder	NNP	O	O
Outlet	TOVIAZ.xml:S2:1500:6	outlet	NNP	O	O
Obstruction	TOVIAZ.xml:S2:1507:11	obstruct	NNP	O	O

Toviaz	TOVIAZ.xml:S2:1524:6	toviaz	NNP	O	O
should	TOVIAZ.xml:S2:1531:6	should	MD	O	O
be	TOVIAZ.xml:S2:1538:2	be	VB	O	O
administered	TOVIAZ.xml:S2:1541:12	administ	VBN	O	O
with	TOVIAZ.xml:S2:1554:4	with	IN	O	O
caution	TOVIAZ.xml:S2:1559:7	caution	NN	O	O
to	TOVIAZ.xml:S2:1567:2	to	TO	O	O
patients	TOVIAZ.xml:S2:1570:8	patient	NNS	O	O
with	TOVIAZ.xml:S2:1579:4	with	IN	O	O
clinically	TOVIAZ.xml:S2:1584:10	clinic	RB	O	O
significant	TOVIAZ.xml:S2:1595:11	signific	JJ	O	O
bladder	TOVIAZ.xml:S2:1607:7	bladder	NN	O	O
outlet	TOVIAZ.xml:S2:1615:6	outlet	NN	O	O
obstruction	TOVIAZ.xml:S2:1622:11	obstruct	NN	O	O
because	TOVIAZ.xml:S2:1634:7	becaus	IN	O	O
of	TOVIAZ.xml:S2:1642:2	of	IN	O	O
the	TOVIAZ.xml:S2:1645:3	the	DT	O	O
risk	TOVIAZ.xml:S2:1649:4	risk	NN	O	O
of	TOVIAZ.xml:S2:1654:2	of	IN	O	O
urinary	TOVIAZ.xml:S2:1657:7	urinari	JJ	O	B-AdverseReaction
retention	TOVIAZ.xml:S2:1665:9	retent	NN	O	I-AdverseReaction
[	TOVIAZ.xml:S2:1675:1	[	NNP	O	O
see	TOVIAZ.xml:S2:1677:3	see	VBP	O	O
Contraindications	TOVIAZ.xml:S2:1682:17	contraind	NNP	O	O
(	TOVIAZ.xml:S2:1700:1	(	(	O	O
4	TOVIAZ.xml:S2:1701:1	4	CD	O	O
)	TOVIAZ.xml:S2:1702:1	)	)	O	O
]	TOVIAZ.xml:S2:1707:1	]	NN	O	O
.	TOVIAZ.xml:S2:1708:1	.	.	O	O

5.3	TOVIAZ.xml:S2:1717:3	5.3	CD	O	O
Decreased	TOVIAZ.xml:S2:1721:9	decreas	VBD	O	O
Gastrointestinal	TOVIAZ.xml:S2:1731:16	gastrointestin	NNP	O	O
Motility	TOVIAZ.xml:S2:1748:8	motil	NNP	O	O

Toviaz	TOVIAZ.xml:S2:1762:6	toviaz	NNP	O	O
,	TOVIAZ.xml:S2:1768:1	,	,	O	O
like	TOVIAZ.xml:S2:1770:4	like	IN	O	O
other	TOVIAZ.xml:S2:1775:5	other	JJ	O	O
antimuscarinic	TOVIAZ.xml:S2:1781:14	antimuscarin	JJ	O	O
drugs	TOVIAZ.xml:S2:1796:5	drug	NNS	O	O
,	TOVIAZ.xml:S2:1801:1	,	,	O	O
should	TOVIAZ.xml:S2:1803:6	should	MD	O	O
be	TOVIAZ.xml:S2:1810:2	be	VB	O	O
used	TOVIAZ.xml:S2:1813:4	use	VBN	O	O
with	TOVIAZ.xml:S2:1818:4	with	IN	O	O
caution	TOVIAZ.xml:S2:1823:7	caution	NN	O	O
in	TOVIAZ.xml:S2:1831:2	in	IN	O	O
patients	TOVIAZ.xml:S2:1834:8	patient	NNS	O	O
with	TOVIAZ.xml:S2:1843:4	with	IN	O	O
decreased	TOVIAZ.xml:S2:1848:9	decreas	JJ	O	B-AdverseReaction
gastrointestinal	TOVIAZ.xml:S2:1858:16	gastrointestin	JJ	O	I-AdverseReaction
motility	TOVIAZ.xml:S2:1875:8	motil	NN	O	I-AdverseReaction
,	TOVIAZ.xml:S2:1883:1	,	,	O	O
such	TOVIAZ.xml:S2:1885:4	such	JJ	O	O
as	TOVIAZ.xml:S2:1890:2	as	IN	O	O
those	TOVIAZ.xml:S2:1893:5	those	DT	O	O
with	TOVIAZ.xml:S2:1899:4	with	IN	O	O
severe	TOVIAZ.xml:S2:1904:6	sever	JJ	O	O
constipation	TOVIAZ.xml:S2:1911:12	constip	NN	O	O
.	TOVIAZ.xml:S2:1923:1	.	.	O	O

5.4	TOVIAZ.xml:S2:1932:3	5.4	CD	O	O
Controlled	TOVIAZ.xml:S2:1936:10	control	VBN	O	O
Narrow	TOVIAZ.xml:S2:1947:6	narrow	NNP	O	O
-	TOVIAZ.xml:S2:1953:1	-	:	O	O
Angle	TOVIAZ.xml:S2:1954:5	angl	NNP	O	O
Glaucoma	TOVIAZ.xml:S2:1960:8	glaucoma	NNP	O	O

Toviaz	TOVIAZ.xml:S2:1974:6	toviaz	NNP	O	O
should	TOVIAZ.xml:S2:1981:6	should	MD	O	O
be	TOVIAZ.xml:S2:1988:2	be	VB	O	O
used	TOVIAZ.xml:S2:1991:4	use	VBN	O	O
with	TOVIAZ.xml:S2:1996:4	with	IN	O	O
caution	TOVIAZ.xml:S2:2001:7	caution	NN	O	O
in	TOVIAZ.xml:S2:2009:2	in	IN	O	O
patients	TOVIAZ.xml:S2:2012:8	patient	NNS	O	O
being	TOVIAZ.xml:S2:2021:5	be	VBG	O	O
treated	TOVIAZ.xml:S2:2027:7	treat	VBN	O	O
for	TOVIAZ.xml:S2:2035:3	for	IN	O	O
narrow	TOVIAZ.xml:S2:2039:6	narrow	JJ	O	O
-	TOVIAZ.xml:S2:2045:1	-	:	O	O
angle	TOVIAZ.xml:S2:2046:5	angl	NN	O	O
glaucoma	TOVIAZ.xml:S2:2052:8	glaucoma	NN	O	O
,	TOVIAZ.xml:S2:2060:1	,	,	O	O
and	TOVIAZ.xml:S2:2062:3	and	CC	O	O
only	TOVIAZ.xml:S2:2066:4	onli	RB	O	O
where	TOVIAZ.xml:S2:2071:5	where	WRB	O	O
the	TOVIAZ.xml:S2:2077:3	the	DT	O	O
potential	TOVIAZ.xml:S2:2081:9	potenti	JJ	O	O
benefits	TOVIAZ.xml:S2:2091:8	benefit	NNS	O	O
outweigh	TOVIAZ.xml:S2:2100:8	outweigh	VBP	O	O
the	TOVIAZ.xml:S2:2109:3	the	DT	O	O
risks	TOVIAZ.xml:S2:2113:5	risk	NNS	O	O
[	TOVIAZ.xml:S2:2119:1	[	NNP	O	O
see	TOVIAZ.xml:S2:2121:3	see	VBP	O	O
Contraindications	TOVIAZ.xml:S2:2126:17	contraind	NNP	O	O
(	TOVIAZ.xml:S2:2144:1	(	(	O	O
4	TOVIAZ.xml:S2:2145:1	4	CD	O	O
)	TOVIAZ.xml:S2:2146:1	)	)	O	O
]	TOVIAZ.xml:S2:2151:1	]	NN	O	O
.	TOVIAZ.xml:S2:2152:1	.	.	O	O

5.5	TOVIAZ.xml:S2:2161:3	5.5	CD	O	O
Central	TOVIAZ.xml:S2:2165:7	central	NNP	O	O
Nervous	TOVIAZ.xml:S2:2173:7	nervou	NNP	O	O
System	TOVIAZ.xml:S2:2181:6	system	NNP	O	O
Effects	TOVIAZ.xml:S2:2188:7	effect	NNS	O	O

Toviaz	TOVIAZ.xml:S2:2201:6	toviaz	NNP	O	O
is	TOVIAZ.xml:S2:2208:2	is	VBZ	O	O
associated	TOVIAZ.xml:S2:2211:10	associ	VBN	O	O
with	TOVIAZ.xml:S2:2222:4	with	IN	O	O
anticholinergic	TOVIAZ.xml:S2:2227:15	anticholinerg	JJ	B-AdverseReaction	O
central	TOVIAZ.xml:S2:2243:7	central	JJ	I-AdverseReaction	O
nervous	TOVIAZ.xml:S2:2251:7	nervou	JJ	I-AdverseReaction	O
sytem	TOVIAZ.xml:S2:2259:5	sytem	NN	I-AdverseReaction	O
(	TOVIAZ.xml:S2:2265:1	(	(	O	O
CNS	TOVIAZ.xml:S2:2266:3	cn	NNP	I-AdverseReaction	O
)	TOVIAZ.xml:S2:2269:1	)	)	O	O
effects	TOVIAZ.xml:S2:2271:7	effect	NNS	I-AdverseReaction	O
[	TOVIAZ.xml:S2:2279:1	[	VBP	O	O
see	TOVIAZ.xml:S2:2280:3	see	VB	O	O
Adverse	TOVIAZ.xml:S2:2285:7	advers	JJ	O	O
Reactions	TOVIAZ.xml:S2:2293:9	reaction	NNP	O	O
(	TOVIAZ.xml:S2:2303:1	(	(	O	O
6.2	TOVIAZ.xml:S2:2304:3	6.2	CD	O	O
)	TOVIAZ.xml:S2:2307:1	)	)	O	O
]	TOVIAZ.xml:S2:2310:1	]	NN	O	O
.	TOVIAZ.xml:S2:2311:1	.	.	O	O

A	TOVIAZ.xml:S2:2313:1	A	DT	O	O
variety	TOVIAZ.xml:S2:2315:7	varieti	NN	O	O
of	TOVIAZ.xml:S2:2323:2	of	IN	O	O
CNS	TOVIAZ.xml:S2:2326:3	cn	NNP	B-AdverseReaction	O
anticholinergic	TOVIAZ.xml:S2:2330:15	anticholinerg	JJ	I-AdverseReaction	O
effects	TOVIAZ.xml:S2:2346:7	effect	NNS	I-AdverseReaction	O
have	TOVIAZ.xml:S2:2354:4	have	VBP	O	O
been	TOVIAZ.xml:S2:2359:4	been	VBN	O	O
reported	TOVIAZ.xml:S2:2364:8	report	VBN	O	O
,	TOVIAZ.xml:S2:2372:1	,	,	O	O
including	TOVIAZ.xml:S2:2374:9	includ	VBG	O	O
headache	TOVIAZ.xml:S2:2384:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S2:2392:1	,	,	O	O
dizziness	TOVIAZ.xml:S2:2394:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	TOVIAZ.xml:S2:2403:1	,	,	O	O
and	TOVIAZ.xml:S2:2405:3	and	CC	O	O
somnolence	TOVIAZ.xml:S2:2409:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
.	TOVIAZ.xml:S2:2419:1	.	.	O	O

Patients	TOVIAZ.xml:S2:2421:8	patient	NNS	O	O
should	TOVIAZ.xml:S2:2430:6	should	MD	O	O
be	TOVIAZ.xml:S2:2437:2	be	VB	O	O
monitored	TOVIAZ.xml:S2:2440:9	monitor	VBN	O	O
for	TOVIAZ.xml:S2:2450:3	for	IN	O	O
signs	TOVIAZ.xml:S2:2454:5	sign	NNS	O	O
of	TOVIAZ.xml:S2:2460:2	of	IN	O	O
anticholinergic	TOVIAZ.xml:S2:2463:15	anticholinerg	JJ	O	O
CNS	TOVIAZ.xml:S2:2479:3	cn	NNP	O	O
effects	TOVIAZ.xml:S2:2483:7	effect	NNS	O	O
,	TOVIAZ.xml:S2:2490:1	,	,	O	O
particularly	TOVIAZ.xml:S2:2492:12	particularli	RB	O	O
after	TOVIAZ.xml:S2:2505:5	after	IN	O	O
beginning	TOVIAZ.xml:S2:2511:9	begin	VBG	O	O
treatment	TOVIAZ.xml:S2:2521:9	treatment	NN	O	O
or	TOVIAZ.xml:S2:2531:2	or	CC	O	O
increasing	TOVIAZ.xml:S2:2534:10	increas	VBG	O	O
the	TOVIAZ.xml:S2:2545:3	the	DT	O	O
dose	TOVIAZ.xml:S2:2549:4	dose	NN	O	O
.	TOVIAZ.xml:S2:2553:1	.	.	O	O

Advise	TOVIAZ.xml:S2:2555:6	advis	NN	O	O
patients	TOVIAZ.xml:S2:2562:8	patient	NNS	O	O
not	TOVIAZ.xml:S2:2571:3	not	RB	O	O
to	TOVIAZ.xml:S2:2575:2	to	TO	O	O
drive	TOVIAZ.xml:S2:2578:5	drive	VB	O	O
or	TOVIAZ.xml:S2:2584:2	or	CC	O	O
operate	TOVIAZ.xml:S2:2587:7	oper	VB	O	O
heavy	TOVIAZ.xml:S2:2595:5	heavi	JJ	O	O
machinery	TOVIAZ.xml:S2:2601:9	machineri	NN	O	O
until	TOVIAZ.xml:S2:2611:5	until	IN	O	O
they	TOVIAZ.xml:S2:2617:4	they	PRP	O	O
know	TOVIAZ.xml:S2:2622:4	know	VBP	O	O
how	TOVIAZ.xml:S2:2627:3	how	WRB	O	O
Toviaz	TOVIAZ.xml:S2:2631:6	toviaz	NNP	O	O
affects	TOVIAZ.xml:S2:2638:7	affect	VBZ	O	O
them	TOVIAZ.xml:S2:2646:4	them	PRP	O	O
.	TOVIAZ.xml:S2:2650:1	.	.	O	O

If	TOVIAZ.xml:S2:2652:2	If	IN	O	O
a	TOVIAZ.xml:S2:2655:1	a	DT	O	O
patient	TOVIAZ.xml:S2:2657:7	patient	NN	O	O
experiences	TOVIAZ.xml:S2:2665:11	experi	VBZ	O	O
anticholinergic	TOVIAZ.xml:S2:2677:15	anticholinerg	JJ	O	O
CNS	TOVIAZ.xml:S2:2693:3	cn	NNP	O	O
effects	TOVIAZ.xml:S2:2697:7	effect	NNS	O	O
,	TOVIAZ.xml:S2:2704:1	,	,	O	O
dose	TOVIAZ.xml:S2:2706:4	dose	JJ	O	O
reduction	TOVIAZ.xml:S2:2711:9	reduct	NN	O	O
or	TOVIAZ.xml:S2:2721:2	or	CC	O	O
drug	TOVIAZ.xml:S2:2724:4	drug	NN	O	O
discontinuation	TOVIAZ.xml:S2:2729:15	discontinu	NN	O	O
should	TOVIAZ.xml:S2:2745:6	should	MD	O	O
be	TOVIAZ.xml:S2:2752:2	be	VB	O	O
considered	TOVIAZ.xml:S2:2755:10	consid	VBN	O	O
.	TOVIAZ.xml:S2:2765:1	.	.	O	O

5.6	TOVIAZ.xml:S2:2774:3	5.6	CD	O	O
Hepatic	TOVIAZ.xml:S2:2778:7	hepat	JJ	O	O
Impairment	TOVIAZ.xml:S2:2786:10	impair	NN	O	O

Toviaz	TOVIAZ.xml:S2:2802:6	toviaz	NNP	O	O
has	TOVIAZ.xml:S2:2809:3	ha	VBZ	O	O
not	TOVIAZ.xml:S2:2813:3	not	RB	O	O
been	TOVIAZ.xml:S2:2817:4	been	VBN	O	O
studied	TOVIAZ.xml:S2:2822:7	studi	VBN	O	O
in	TOVIAZ.xml:S2:2830:2	in	IN	O	O
patients	TOVIAZ.xml:S2:2833:8	patient	NNS	O	O
with	TOVIAZ.xml:S2:2842:4	with	IN	O	O
severe	TOVIAZ.xml:S2:2847:6	sever	JJ	O	O
hepatic	TOVIAZ.xml:S2:2854:7	hepat	JJ	O	O
impairment	TOVIAZ.xml:S2:2862:10	impair	NN	O	O
and	TOVIAZ.xml:S2:2873:3	and	CC	O	O
therefore	TOVIAZ.xml:S2:2877:9	therefor	NN	O	O
is	TOVIAZ.xml:S2:2887:2	is	VBZ	O	O
not	TOVIAZ.xml:S2:2890:3	not	RB	O	O
recommended	TOVIAZ.xml:S2:2894:11	recommend	VBN	O	O
for	TOVIAZ.xml:S2:2906:3	for	IN	O	O
use	TOVIAZ.xml:S2:2910:3	use	NN	O	O
in	TOVIAZ.xml:S2:2914:2	in	IN	O	O
this	TOVIAZ.xml:S2:2917:4	thi	DT	O	O
patient	TOVIAZ.xml:S2:2922:7	patient	JJ	O	O
population	TOVIAZ.xml:S2:2930:10	popul	NN	O	O
[	TOVIAZ.xml:S2:2941:1	[	NNP	O	O
see	TOVIAZ.xml:S2:2943:3	see	VBP	O	O
Use	TOVIAZ.xml:S2:2948:3	use	NNP	O	O
in	TOVIAZ.xml:S2:2952:2	in	IN	O	O
Specific	TOVIAZ.xml:S2:2955:8	specif	NNP	O	O
Populations	TOVIAZ.xml:S2:2964:11	popul	NNP	O	O
(	TOVIAZ.xml:S2:2976:1	(	(	O	O
8.7	TOVIAZ.xml:S2:2977:3	8.7	CD	O	O
)	TOVIAZ.xml:S2:2980:1	)	)	O	O
and	TOVIAZ.xml:S2:2983:3	and	CC	O	O
Dosage	TOVIAZ.xml:S2:2988:6	dosag	NNP	O	O
and	TOVIAZ.xml:S2:2995:3	and	CC	O	O
Administration	TOVIAZ.xml:S2:2999:14	administr	NNP	O	O
(	TOVIAZ.xml:S2:3014:1	(	(	O	O
2	TOVIAZ.xml:S2:3015:1	2	CD	O	O
)	TOVIAZ.xml:S2:3016:1	)	)	O	O
]	TOVIAZ.xml:S2:3021:1	]	NN	O	O
.	TOVIAZ.xml:S2:3022:1	.	.	O	O

5.7	TOVIAZ.xml:S2:3031:3	5.7	CD	O	O
Renal	TOVIAZ.xml:S2:3035:5	renal	JJ	O	O
Impairment	TOVIAZ.xml:S2:3041:10	impair	NN	O	O

Doses	TOVIAZ.xml:S2:3057:5	dose	NNS	O	O
of	TOVIAZ.xml:S2:3063:2	of	IN	O	O
Toviaz	TOVIAZ.xml:S2:3066:6	toviaz	NNP	O	O
greater	TOVIAZ.xml:S2:3073:7	greater	JJR	O	O
than	TOVIAZ.xml:S2:3081:4	than	IN	O	O
4	TOVIAZ.xml:S2:3086:1	4	CD	O	O
mg	TOVIAZ.xml:S2:3088:2	mg	NNS	O	O
are	TOVIAZ.xml:S2:3091:3	are	VBP	O	O
not	TOVIAZ.xml:S2:3095:3	not	RB	O	O
recommended	TOVIAZ.xml:S2:3099:11	recommend	VBN	O	O
in	TOVIAZ.xml:S2:3111:2	in	IN	O	O
patients	TOVIAZ.xml:S2:3114:8	patient	NNS	O	O
with	TOVIAZ.xml:S2:3123:4	with	IN	O	O
severe	TOVIAZ.xml:S2:3128:6	sever	JJ	O	O
renal	TOVIAZ.xml:S2:3135:5	renal	JJ	O	O
impairment	TOVIAZ.xml:S2:3141:10	impair	NN	O	O
[	TOVIAZ.xml:S2:3152:1	[	NNP	O	O
see	TOVIAZ.xml:S2:3154:3	see	NN	O	O
Use	TOVIAZ.xml:S2:3159:3	use	NNP	O	O
In	TOVIAZ.xml:S2:3163:2	In	IN	O	O
Specific	TOVIAZ.xml:S2:3166:8	specif	NNP	O	O
Populations	TOVIAZ.xml:S2:3175:11	popul	NNP	O	O
(	TOVIAZ.xml:S2:3187:1	(	(	O	O
8.6	TOVIAZ.xml:S2:3188:3	8.6	CD	O	O
)	TOVIAZ.xml:S2:3191:1	)	)	O	O
and	TOVIAZ.xml:S2:3194:3	and	CC	O	O
Dosage	TOVIAZ.xml:S2:3199:6	dosag	NNP	O	O
and	TOVIAZ.xml:S2:3206:3	and	CC	O	O
Administration	TOVIAZ.xml:S2:3210:14	administr	NNP	O	O
(	TOVIAZ.xml:S2:3225:1	(	(	O	O
2	TOVIAZ.xml:S2:3226:1	2	CD	O	O
)	TOVIAZ.xml:S2:3227:1	)	)	O	O
]	TOVIAZ.xml:S2:3232:1	]	NN	O	O
.	TOVIAZ.xml:S2:3233:1	.	.	O	O

5.8	TOVIAZ.xml:S2:3242:3	5.8	CD	O	O
Concomitant	TOVIAZ.xml:S2:3246:11	concomit	JJ	O	O
Administration	TOVIAZ.xml:S2:3258:14	administr	NNP	O	O
with	TOVIAZ.xml:S2:3273:4	with	IN	O	O
CYP3A4	TOVIAZ.xml:S2:3278:6	cyp3a4	NNP	O	O
Inhibitors	TOVIAZ.xml:S2:3285:10	inhibitor	NNS	O	O

Doses	TOVIAZ.xml:S2:3309:5	dose	NNS	O	O
of	TOVIAZ.xml:S2:3315:2	of	IN	O	O
Toviaz	TOVIAZ.xml:S2:3318:6	toviaz	NNP	O	O
greater	TOVIAZ.xml:S2:3325:7	greater	JJR	O	O
than	TOVIAZ.xml:S2:3333:4	than	IN	O	O
4	TOVIAZ.xml:S2:3338:1	4	CD	O	O
mg	TOVIAZ.xml:S2:3340:2	mg	NNS	O	O
are	TOVIAZ.xml:S2:3343:3	are	VBP	O	O
not	TOVIAZ.xml:S2:3347:3	not	RB	O	O
recommended	TOVIAZ.xml:S2:3351:11	recommend	VBN	O	O
in	TOVIAZ.xml:S2:3363:2	in	IN	O	O
patients	TOVIAZ.xml:S2:3366:8	patient	NNS	O	O
taking	TOVIAZ.xml:S2:3375:6	take	VBG	O	O
a	TOVIAZ.xml:S2:3382:1	a	DT	O	O
potent	TOVIAZ.xml:S2:3384:6	potent	NN	O	O
CYP3A4	TOVIAZ.xml:S2:3391:6	cyp3a4	NNP	O	O
inhibitor	TOVIAZ.xml:S2:3398:9	inhibitor	NN	O	O
(	TOVIAZ.xml:S2:3408:1	(	(	O	O
e	TOVIAZ.xml:S2:3409:1	e	NN	O	O
.	TOVIAZ.xml:S2:3410:1	.	.	O	O
g	TOVIAZ.xml:S2:3411:1	g	NN	O	O
.	TOVIAZ.xml:S2:3412:1	.	.	O	O
,	TOVIAZ.xml:S2:3413:1	,	,	O	O
ketoconazole	TOVIAZ.xml:S2:3415:12	ketoconazol	NN	O	O
,	TOVIAZ.xml:S2:3427:1	,	,	O	O
itraconazole	TOVIAZ.xml:S2:3429:12	itraconazol	NN	O	O
,	TOVIAZ.xml:S2:3441:1	,	,	O	O
clarithromycin	TOVIAZ.xml:S2:3443:14	clarithromycin	NN	O	O
)	TOVIAZ.xml:S2:3457:1	)	)	O	O
.	TOVIAZ.xml:S2:3458:1	.	.	O	O

No	TOVIAZ.xml:S2:3468:2	No	DT	O	O
dosing	TOVIAZ.xml:S2:3471:6	dose	NN	O	O
adjustments	TOVIAZ.xml:S2:3478:11	adjust	NNS	O	O
are	TOVIAZ.xml:S2:3490:3	are	VBP	O	O
recommended	TOVIAZ.xml:S2:3494:11	recommend	VBN	O	O
in	TOVIAZ.xml:S2:3506:2	in	IN	O	O
the	TOVIAZ.xml:S2:3509:3	the	DT	O	O
presence	TOVIAZ.xml:S2:3513:8	presenc	NN	O	O
of	TOVIAZ.xml:S2:3522:2	of	IN	O	O
moderate	TOVIAZ.xml:S2:3525:8	moder	JJ	O	O
CYP3A4	TOVIAZ.xml:S2:3534:6	cyp3a4	NNP	O	O
inhibitors	TOVIAZ.xml:S2:3541:10	inhibitor	NNS	O	O
(	TOVIAZ.xml:S2:3552:1	(	(	O	O
e	TOVIAZ.xml:S2:3553:1	e	NN	O	O
.	TOVIAZ.xml:S2:3554:1	.	.	O	O
g	TOVIAZ.xml:S2:3555:1	g	NN	O	O
.	TOVIAZ.xml:S2:3556:1	.	.	O	O
,	TOVIAZ.xml:S2:3557:1	,	,	O	O
erythromycin	TOVIAZ.xml:S2:3559:12	erythromycin	NN	O	O
,	TOVIAZ.xml:S2:3571:1	,	,	O	O
fluconazole	TOVIAZ.xml:S2:3573:11	fluconazol	NN	O	B-AdverseReaction
,	TOVIAZ.xml:S2:3584:1	,	,	O	O
diltiazem	TOVIAZ.xml:S2:3586:9	diltiazem	NN	O	B-AdverseReaction
,	TOVIAZ.xml:S2:3595:1	,	,	O	O
verapamil	TOVIAZ.xml:S2:3597:9	verapamil	NN	O	O
and	TOVIAZ.xml:S2:3607:3	and	CC	O	O
grapefruit	TOVIAZ.xml:S2:3611:10	grapefruit	NN	O	O
juice	TOVIAZ.xml:S2:3622:5	juic	NN	O	O
)	TOVIAZ.xml:S2:3627:1	)	)	O	O
.	TOVIAZ.xml:S2:3628:1	.	.	O	O

While	TOVIAZ.xml:S2:3638:5	while	IN	O	O
the	TOVIAZ.xml:S2:3644:3	the	DT	O	O
effect	TOVIAZ.xml:S2:3648:6	effect	NN	O	O
of	TOVIAZ.xml:S2:3655:2	of	IN	O	O
weak	TOVIAZ.xml:S2:3658:4	weak	JJ	O	O
CYP3A4	TOVIAZ.xml:S2:3663:6	cyp3a4	NNP	O	O
inhibitors	TOVIAZ.xml:S2:3670:10	inhibitor	NNS	O	O
(	TOVIAZ.xml:S2:3681:1	(	(	O	O
e	TOVIAZ.xml:S2:3682:1	e	NN	O	O
.	TOVIAZ.xml:S2:3683:1	.	.	O	O
g	TOVIAZ.xml:S2:3684:1	g	NN	O	O
.	TOVIAZ.xml:S2:3685:1	.	.	O	O

cimetidine	TOVIAZ.xml:S2:3687:10	cimetidin	NN	O	O
)	TOVIAZ.xml:S2:3697:1	)	)	O	O
was	TOVIAZ.xml:S2:3699:3	wa	VBD	O	O
not	TOVIAZ.xml:S2:3703:3	not	RB	O	O
examined	TOVIAZ.xml:S2:3707:8	examin	VBN	O	O
by	TOVIAZ.xml:S2:3716:2	by	IN	O	O
clinical	TOVIAZ.xml:S2:3719:8	clinic	JJ	O	O
study	TOVIAZ.xml:S2:3728:5	studi	NN	O	O
,	TOVIAZ.xml:S2:3733:1	,	,	O	O
some	TOVIAZ.xml:S2:3735:4	some	DT	O	O
pharmacokinetic	TOVIAZ.xml:S2:3740:15	pharmacokinet	JJ	O	O
interaction	TOVIAZ.xml:S2:3756:11	interact	NN	O	O
is	TOVIAZ.xml:S2:3768:2	is	VBZ	O	O
expected	TOVIAZ.xml:S2:3771:8	expect	VBN	O	O
,	TOVIAZ.xml:S2:3779:1	,	,	O	O
albeit	TOVIAZ.xml:S2:3781:6	albeit	IN	O	O
less	TOVIAZ.xml:S2:3788:4	less	JJR	O	O
than	TOVIAZ.xml:S2:3793:4	than	IN	O	O
that	TOVIAZ.xml:S2:3798:4	that	DT	O	O
observed	TOVIAZ.xml:S2:3803:8	observ	VBD	O	O
with	TOVIAZ.xml:S2:3812:4	with	IN	O	O
moderate	TOVIAZ.xml:S2:3817:8	moder	JJ	O	O
CYP3A4	TOVIAZ.xml:S2:3826:6	cyp3a4	NNP	O	O
inhibitors	TOVIAZ.xml:S2:3833:10	inhibitor	NNS	O	O
[	TOVIAZ.xml:S2:3844:1	[	NNP	O	O
see	TOVIAZ.xml:S2:3846:3	see	VBP	O	O
Drug	TOVIAZ.xml:S2:3851:4	drug	NNP	O	O
Interactions	TOVIAZ.xml:S2:3856:12	interact	NNP	O	O
(	TOVIAZ.xml:S2:3869:1	(	(	O	O
7.2	TOVIAZ.xml:S2:3870:3	7.2	CD	O	O
)	TOVIAZ.xml:S2:3873:1	)	)	O	O
and	TOVIAZ.xml:S2:3876:3	and	CC	O	O
Dosage	TOVIAZ.xml:S2:3881:6	dosag	NNP	O	O
and	TOVIAZ.xml:S2:3888:3	and	CC	O	O
Administration	TOVIAZ.xml:S2:3892:14	administr	NNP	O	O
(	TOVIAZ.xml:S2:3907:1	(	(	O	O
2	TOVIAZ.xml:S2:3908:1	2	CD	O	O
)	TOVIAZ.xml:S2:3909:1	)	)	O	O
]	TOVIAZ.xml:S2:3913:1	]	NN	O	O
.	TOVIAZ.xml:S2:3914:1	.	.	O	O

5.9	TOVIAZ.xml:S2:3924:3	5.9	CD	O	O
Myasthenia	TOVIAZ.xml:S2:3928:10	myasthenia	NNP	O	O
Gravis	TOVIAZ.xml:S2:3939:6	gravi	NNP	O	O

Toviaz	TOVIAZ.xml:S2:3951:6	toviaz	NN	O	O

should	TOVIAZ.xml:S2:3958:6	should	MD	O	O
be	TOVIAZ.xml:S2:3965:2	be	VB	O	O
used	TOVIAZ.xml:S2:3968:4	use	VBN	O	O
with	TOVIAZ.xml:S2:3973:4	with	IN	O	O
caution	TOVIAZ.xml:S2:3978:7	caution	NN	O	O
in	TOVIAZ.xml:S2:3986:2	in	IN	O	O
patients	TOVIAZ.xml:S2:3989:8	patient	NNS	O	O
with	TOVIAZ.xml:S2:3998:4	with	IN	O	O
myasthenia	TOVIAZ.xml:S2:4003:10	myasthenia	JJ	O	O
gravis	TOVIAZ.xml:S2:4014:6	gravi	NN	O	O
,	TOVIAZ.xml:S2:4020:1	,	,	O	O
a	TOVIAZ.xml:S2:4022:1	a	DT	O	O
disease	TOVIAZ.xml:S2:4024:7	diseas	NN	O	O
characterized	TOVIAZ.xml:S2:4032:13	character	VBN	O	O
by	TOVIAZ.xml:S2:4046:2	by	IN	O	O
decreased	TOVIAZ.xml:S2:4049:9	decreas	JJ	O	B-AdverseReaction
cholinergic	TOVIAZ.xml:S2:4059:11	cholinerg	NN	O	I-AdverseReaction
activity	TOVIAZ.xml:S2:4071:8	activ	NN	O	I-AdverseReaction
at	TOVIAZ.xml:S2:4080:2	at	IN	O	O
the	TOVIAZ.xml:S2:4083:3	the	DT	O	O
neuromuscular	TOVIAZ.xml:S2:4087:13	neuromuscular	JJ	O	O
junction	TOVIAZ.xml:S2:4101:8	junction	NN	O	O
.	TOVIAZ.xml:S2:4109:1	.	.	O	O
6	TREANDA.xml:S1:4:1	6	CD	O	O
ADVERSE	TREANDA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	TREANDA.xml:S1:14:9	reaction	NN	O	O

The	TREANDA.xml:S1:27:3	the	DT	O	O
following	TREANDA.xml:S1:31:9	follow	VBG	O	O
serious	TREANDA.xml:S1:41:7	seriou	JJ	O	O
adverse	TREANDA.xml:S1:49:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:57:9	reaction	NNS	O	O
have	TREANDA.xml:S1:67:4	have	VBP	O	O
been	TREANDA.xml:S1:72:4	been	VBN	O	O
associated	TREANDA.xml:S1:77:10	associ	VBN	O	O
with	TREANDA.xml:S1:88:4	with	IN	O	O
TREANDA	TREANDA.xml:S1:93:7	treanda	NNP	O	O
in	TREANDA.xml:S1:101:2	in	IN	O	O
clinical	TREANDA.xml:S1:104:8	clinic	JJ	O	O
trials	TREANDA.xml:S1:113:6	trial	NNS	O	O
and	TREANDA.xml:S1:120:3	and	CC	O	O
are	TREANDA.xml:S1:124:3	are	VBP	O	O
discussed	TREANDA.xml:S1:128:9	discuss	VBN	O	O
in	TREANDA.xml:S1:138:2	in	IN	O	O
greater	TREANDA.xml:S1:141:7	greater	JJR	O	O
detail	TREANDA.xml:S1:149:6	detail	NN	O	O
in	TREANDA.xml:S1:156:2	in	IN	O	O
other	TREANDA.xml:S1:159:5	other	JJ	O	O
sections	TREANDA.xml:S1:165:8	section	NNS	O	O
of	TREANDA.xml:S1:174:2	of	IN	O	O
the	TREANDA.xml:S1:177:3	the	DT	O	O
label	TREANDA.xml:S1:181:5	label	NN	O	O
.	TREANDA.xml:S1:186:1	.	.	O	O

Myelosuppression	TREANDA.xml:S1:197:16	myelosuppress	NN	B-AdverseReaction	B-AdverseReaction
[	TREANDA.xml:S1:214:1	[	NNP	O	O
see	TREANDA.xml:S1:215:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:220:8	warn	NNP	O	O
and	TREANDA.xml:S1:229:3	and	CC	O	O
Precautions	TREANDA.xml:S1:233:11	precaut	NNP	O	O
(	TREANDA.xml:S1:246:1	(	(	O	O
5.1	TREANDA.xml:S1:249:3	5.1	CD	O	O
)]	TREANDA.xml:S1:254:2	)]	NN	O	O

Infections	TREANDA.xml:S1:265:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
[	TREANDA.xml:S1:276:1	[	VBP	O	O
see	TREANDA.xml:S1:277:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:282:8	warn	NNS	O	O
and	TREANDA.xml:S1:291:3	and	CC	O	O
Precautions	TREANDA.xml:S1:295:11	precaut	NNP	O	O
(	TREANDA.xml:S1:308:1	(	(	O	O
5.2	TREANDA.xml:S1:311:3	5.2	CD	O	O
)]	TREANDA.xml:S1:316:2	)]	NN	O	O

Anaphylaxis	TREANDA.xml:S1:327:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
and	TREANDA.xml:S1:339:3	and	CC	O	O
Infusion	TREANDA.xml:S1:343:8	infus	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TREANDA.xml:S1:352:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	TREANDA.xml:S1:362:1	[	NNP	O	O
see	TREANDA.xml:S1:363:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:368:8	warn	NNP	O	O
and	TREANDA.xml:S1:377:3	and	CC	O	O
Precautions	TREANDA.xml:S1:381:11	precaut	NNP	O	O
(	TREANDA.xml:S1:394:1	(	(	O	O
5.3	TREANDA.xml:S1:397:3	5.3	CD	O	O
)]	TREANDA.xml:S1:402:2	)]	NN	O	O

Tumor	TREANDA.xml:S1:413:5	tumor	NNP	B-AdverseReaction	B-AdverseReaction
Lysis	TREANDA.xml:S1:419:5	lysi	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	TREANDA.xml:S1:425:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
[	TREANDA.xml:S1:434:1	[	NNP	O	O
see	TREANDA.xml:S1:435:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:440:8	warn	NNP	O	O
and	TREANDA.xml:S1:449:3	and	CC	O	O
Precautions	TREANDA.xml:S1:453:11	precaut	NNP	O	O
(	TREANDA.xml:S1:466:1	(	(	O	O
5.4	TREANDA.xml:S1:469:3	5.4	CD	O	O
)]	TREANDA.xml:S1:474:2	)]	NN	O	O

Skin	TREANDA.xml:S1:485:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TREANDA.xml:S1:490:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	TREANDA.xml:S1:500:1	[	NNP	O	O
see	TREANDA.xml:S1:501:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:506:8	warn	NNP	O	O
and	TREANDA.xml:S1:515:3	and	CC	O	O
Precautions	TREANDA.xml:S1:519:11	precaut	NNP	O	O
(	TREANDA.xml:S1:532:1	(	(	O	O
5.5	TREANDA.xml:S1:535:3	5.5	CD	O	O
)]	TREANDA.xml:S1:540:2	)]	NN	O	O

Other	TREANDA.xml:S1:551:5	other	JJ	O	O
Malignancies	TREANDA.xml:S1:557:12	malign	NNPS	B-AdverseReaction	B-AdverseReaction
[	TREANDA.xml:S1:570:1	[	NNP	O	O
see	TREANDA.xml:S1:571:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:576:8	warn	NNP	O	O
and	TREANDA.xml:S1:585:3	and	CC	O	O
Precautions	TREANDA.xml:S1:589:11	precaut	NNP	O	O
(	TREANDA.xml:S1:602:1	(	(	O	O
5.6	TREANDA.xml:S1:605:3	5.6	CD	O	O
)]	TREANDA.xml:S1:610:2	)]	NN	O	O

Extravasation	TREANDA.xml:S1:621:13	extravas	NNP	B-AdverseReaction	B-AdverseReaction
injury	TREANDA.xml:S1:635:6	injuri	NN	I-AdverseReaction	I-AdverseReaction
[	TREANDA.xml:S1:642:1	[	NNP	O	O
see	TREANDA.xml:S1:643:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:648:8	warn	NNP	O	O
and	TREANDA.xml:S1:657:3	and	CC	O	O
Precautions	TREANDA.xml:S1:661:11	precaut	NNP	O	O
(	TREANDA.xml:S1:673:1	(	(	O	O
5.7	TREANDA.xml:S1:674:3	5.7	CD	O	O
)]	TREANDA.xml:S1:677:2	)]	NN	O	O

Most	TREANDA.xml:S1:702:4	most	JJS	O	O

common	TREANDA.xml:S1:707:6	common	JJ	O	O
non	TREANDA.xml:S1:714:3	non	SYM	O	O
-	TREANDA.xml:S1:717:1	-	:	O	O
hematologic	TREANDA.xml:S1:718:11	hematolog	JJ	O	O
adverse	TREANDA.xml:S1:730:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:738:9	reaction	NNS	O	O
for	TREANDA.xml:S1:748:3	for	IN	O	O
CLL	TREANDA.xml:S1:752:3	cll	NNP	O	O
(	TREANDA.xml:S1:756:1	(	(	O	O
frequency	TREANDA.xml:S1:757:9	frequenc	NN	O	O
15%	TREANDA.xml:S1:770:3	15%	CD	O	O
)	TREANDA.xml:S1:773:1	)	)	O	O
are	TREANDA.xml:S1:775:3	are	VBP	O	O
pyrexia	TREANDA.xml:S1:779:7	pyrexia	JJ	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:786:1	,	,	O	O
nausea	TREANDA.xml:S1:788:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:794:1	,	,	O	O
and	TREANDA.xml:S1:796:3	and	CC	O	O
vomiting	TREANDA.xml:S1:800:8	vomit	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S1:808:1	.	.	O	O

(	TREANDA.xml:S1:810:1	(	(	O	O
6.1	TREANDA.xml:S1:813:3	6.1	CD	O	O
)	TREANDA.xml:S1:818:1	)	)	O	O

Most	TREANDA.xml:S1:829:4	most	JJS	O	O
common	TREANDA.xml:S1:834:6	common	JJ	O	O
non	TREANDA.xml:S1:841:3	non	NN	O	O
-	TREANDA.xml:S1:844:1	-	:	O	O
hematologic	TREANDA.xml:S1:845:11	hematolog	JJ	O	O
adverse	TREANDA.xml:S1:857:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:865:9	reaction	NNS	O	O
for	TREANDA.xml:S1:875:3	for	IN	O	O
NHL	TREANDA.xml:S1:879:3	nhl	NNP	O	O
(	TREANDA.xml:S1:883:1	(	(	O	O
frequency	TREANDA.xml:S1:884:9	frequenc	NN	O	O
15%	TREANDA.xml:S1:897:3	15%	CD	O	O
)	TREANDA.xml:S1:900:1	)	)	O	O
are	TREANDA.xml:S1:902:3	are	VBP	O	O
nausea	TREANDA.xml:S1:906:6	nausea	JJ	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:912:1	,	,	O	O
fatigue	TREANDA.xml:S1:914:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:921:1	,	,	O	O
vomiting	TREANDA.xml:S1:923:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:931:1	,	,	O	O
diarrhea	TREANDA.xml:S1:933:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:941:1	,	,	O	O
pyrexia	TREANDA.xml:S1:943:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:950:1	,	,	O	O
constipation	TREANDA.xml:S1:952:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:964:1	,	,	O	O
anorexia	TREANDA.xml:S1:966:8	anorexia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:974:1	,	,	O	O
cough	TREANDA.xml:S1:976:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:981:1	,	,	O	O
headache	TREANDA.xml:S1:983:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:991:1	,	,	O	O
weight	TREANDA.xml:S1:993:6	weight	NN	B-AdverseReaction	B-AdverseReaction
decreased	TREANDA.xml:S1:1000:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:1009:1	,	,	O	O
dyspnea	TREANDA.xml:S1:1011:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:1018:1	,	,	O	O
rash	TREANDA.xml:S1:1020:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:1024:1	,	,	O	O
and	TREANDA.xml:S1:1026:3	and	CC	O	O
stomatitis	TREANDA.xml:S1:1030:10	stomat	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S1:1040:1	.	.	O	O

(	TREANDA.xml:S1:1042:1	(	(	O	O
6.1	TREANDA.xml:S1:1045:3	6.1	CD	O	O
)	TREANDA.xml:S1:1050:1	)	)	O	O

Most	TREANDA.xml:S1:1062:4	most	JJS	O	O
common	TREANDA.xml:S1:1067:6	common	JJ	O	O
hematologic	TREANDA.xml:S1:1074:11	hematolog	NN	B-AdverseReaction	O
abnormalities	TREANDA.xml:S1:1086:13	abnorm	NNS	I-AdverseReaction	O
for	TREANDA.xml:S1:1100:3	for	IN	O	O
both	TREANDA.xml:S1:1104:4	both	DT	O	O
indications	TREANDA.xml:S1:1109:11	indic	NNS	O	O
(	TREANDA.xml:S1:1121:1	(	(	O	O
frequency	TREANDA.xml:S1:1122:9	frequenc	NN	O	O
15%	TREANDA.xml:S1:1135:3	15%	CD	O	O
)	TREANDA.xml:S1:1138:1	)	)	O	O
are	TREANDA.xml:S1:1140:3	are	VBP	O	O
lymphopenia	TREANDA.xml:S1:1144:11	lymphopenia	JJ	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:1155:1	,	,	O	O
anemia	TREANDA.xml:S1:1157:6	anemia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:1163:1	,	,	O	O
leukopenia	TREANDA.xml:S1:1165:10	leukopenia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:1175:1	,	,	O	O
thrombocytopenia	TREANDA.xml:S1:1177:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:1193:1	,	,	O	O
and	TREANDA.xml:S1:1195:3	and	CC	O	O
neutropenia	TREANDA.xml:S1:1199:11	neutropenia	RB	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S1:1210:1	.	.	O	O

(	TREANDA.xml:S1:1212:1	(	(	O	O
6.1	TREANDA.xml:S1:1215:3	6.1	CD	O	O
)	TREANDA.xml:S1:1220:1	)	)	O	O

EXCERPT	TREANDA.xml:S1:1229:7	excerpt	NN	O	O
:	TREANDA.xml:S1:1236:1	:	:	O	O
To	TREANDA.xml:S1:1242:2	To	TO	O	O
report	TREANDA.xml:S1:1245:6	report	VB	O	O
SUSPECTED	TREANDA.xml:S1:1252:9	suspect	NNP	O	O
ADVERSE	TREANDA.xml:S1:1262:7	advers	NNP	O	O
REACTIONS	TREANDA.xml:S1:1270:9	reaction	NNP	O	O
,	TREANDA.xml:S1:1279:1	,	,	O	O
contact	TREANDA.xml:S1:1281:7	contact	NN	O	O
Teva	TREANDA.xml:S1:1289:4	teva	NNP	O	O
Pharmaceuticals	TREANDA.xml:S1:1294:15	pharmaceut	NNP	O	O
at	TREANDA.xml:S1:1310:2	at	IN	O	O
1	TREANDA.xml:S1:1313:1	1	CD	O	O
-	TREANDA.xml:S1:1314:1	-	:	O	O
800	TREANDA.xml:S1:1315:3	800	CD	O	O
-	TREANDA.xml:S1:1318:1	-	:	O	O
896	TREANDA.xml:S1:1319:3	896	CD	O	O
-	TREANDA.xml:S1:1322:1	-	:	O	O
5855	TREANDA.xml:S1:1323:4	5855	CD	O	O
or	TREANDA.xml:S1:1328:2	or	CC	O	O
FDA	TREANDA.xml:S1:1331:3	fda	NNP	O	O
at	TREANDA.xml:S1:1335:2	at	IN	O	O
1	TREANDA.xml:S1:1338:1	1	CD	O	O
-	TREANDA.xml:S1:1339:1	-	:	O	O
800	TREANDA.xml:S1:1340:3	800	CD	O	O
-	TREANDA.xml:S1:1343:1	-	:	O	O
FDA	TREANDA.xml:S1:1344:3	fda	NNP	O	O
-	TREANDA.xml:S1:1347:1	-	:	O	O
1088	TREANDA.xml:S1:1348:4	1088	CD	O	O
or	TREANDA.xml:S1:1353:2	or	CC	O	O
www	TREANDA.xml:S1:1359:3	www	VB	O	O
.	TREANDA.xml:S1:1362:1	.	.	O	O
fda	TREANDA.xml:S1:1363:3	fda	NN	O	O
.	TREANDA.xml:S1:1366:1	.	.	O	O
gov	TREANDA.xml:S1:1367:3	gov	JJ	O	O
medwatch	TREANDA.xml:S1:1371:8	medwatch	NN	O	O
.	TREANDA.xml:S1:1383:1	.	.	O	O

6.1	TREANDA.xml:S1:1395:3	6.1	CD	O	O

Clinical	TREANDA.xml:S1:1399:8	clinic	JJ	O	O

Trials	TREANDA.xml:S1:1408:6	trial	NNS	O	O
Experience	TREANDA.xml:S1:1415:10	experi	NN	O	O

Because	TREANDA.xml:S1:1429:7	becaus	IN	O	O
clinical	TREANDA.xml:S1:1437:8	clinic	JJ	O	O
trials	TREANDA.xml:S1:1446:6	trial	NNS	O	O
are	TREANDA.xml:S1:1453:3	are	VBP	O	O
conducted	TREANDA.xml:S1:1457:9	conduct	VBN	O	O
under	TREANDA.xml:S1:1467:5	under	IN	O	O
widely	TREANDA.xml:S1:1473:6	wide	RB	O	O
varying	TREANDA.xml:S1:1480:7	vari	VBG	O	O
conditions	TREANDA.xml:S1:1488:10	condit	NNS	O	O
,	TREANDA.xml:S1:1498:1	,	,	O	O
adverse	TREANDA.xml:S1:1500:7	advers	JJ	O	O
reaction	TREANDA.xml:S1:1508:8	reaction	NN	O	O
rates	TREANDA.xml:S1:1517:5	rate	NNS	O	O
observed	TREANDA.xml:S1:1523:8	observ	VBD	O	O
in	TREANDA.xml:S1:1532:2	in	IN	O	O
the	TREANDA.xml:S1:1535:3	the	DT	O	O
clinical	TREANDA.xml:S1:1539:8	clinic	JJ	O	O
trials	TREANDA.xml:S1:1548:6	trial	NNS	O	O
of	TREANDA.xml:S1:1555:2	of	IN	O	O
a	TREANDA.xml:S1:1558:1	a	DT	O	O
drug	TREANDA.xml:S1:1560:4	drug	NN	O	O
cannot	TREANDA.xml:S1:1565:6	cannot	NN	O	O
be	TREANDA.xml:S1:1572:2	be	VB	O	O
directly	TREANDA.xml:S1:1575:8	directli	RB	O	O
compared	TREANDA.xml:S1:1584:8	compar	VBN	O	O
to	TREANDA.xml:S1:1593:2	to	TO	O	O
rates	TREANDA.xml:S1:1596:5	rate	NNS	O	O
in	TREANDA.xml:S1:1602:2	in	IN	O	O
the	TREANDA.xml:S1:1605:3	the	DT	O	O
clinical	TREANDA.xml:S1:1609:8	clinic	JJ	O	O
trials	TREANDA.xml:S1:1618:6	trial	NNS	O	O
of	TREANDA.xml:S1:1625:2	of	IN	O	O
another	TREANDA.xml:S1:1628:7	anoth	DT	O	O
drug	TREANDA.xml:S1:1636:4	drug	NN	O	O
and	TREANDA.xml:S1:1641:3	and	CC	O	O
may	TREANDA.xml:S1:1645:3	may	MD	O	O
not	TREANDA.xml:S1:1649:3	not	RB	O	O
reflect	TREANDA.xml:S1:1653:7	reflect	VB	O	O
the	TREANDA.xml:S1:1661:3	the	DT	O	O
rates	TREANDA.xml:S1:1665:5	rate	NNS	O	O
observed	TREANDA.xml:S1:1671:8	observ	VBD	O	O
in	TREANDA.xml:S1:1680:2	in	IN	O	O
practice	TREANDA.xml:S1:1683:8	practic	NN	O	O
.	TREANDA.xml:S1:1691:1	.	.	O	O

Chronic	TREANDA.xml:S1:1699:7	chronic	NNP	O	O
Lymphocytic	TREANDA.xml:S1:1707:11	lymphocyt	NNP	O	O
Leukemia	TREANDA.xml:S1:1719:8	leukemia	NNP	O	O

The	TREANDA.xml:S1:1734:3	the	DT	O	O
data	TREANDA.xml:S1:1738:4	data	NNS	O	O
described	TREANDA.xml:S1:1743:9	describ	VBD	O	O
below	TREANDA.xml:S1:1753:5	below	IN	O	O
reflect	TREANDA.xml:S1:1759:7	reflect	NN	O	O
exposure	TREANDA.xml:S1:1767:8	exposur	NN	O	O
to	TREANDA.xml:S1:1776:2	to	TO	O	O
TREANDA	TREANDA.xml:S1:1779:7	treanda	NNP	O	O
in	TREANDA.xml:S1:1787:2	in	IN	O	O
153	TREANDA.xml:S1:1790:3	153	CD	O	O
patients	TREANDA.xml:S1:1794:8	patient	NNS	O	O
with	TREANDA.xml:S1:1803:4	with	IN	O	O
CLL	TREANDA.xml:S1:1808:3	cll	NNP	O	O
studied	TREANDA.xml:S1:1812:7	studi	VBD	O	O
in	TREANDA.xml:S1:1820:2	in	IN	O	O
an	TREANDA.xml:S1:1823:2	an	DT	O	O
active	TREANDA.xml:S1:1826:6	activ	JJ	O	O
-	TREANDA.xml:S1:1832:1	-	:	O	O
controlled	TREANDA.xml:S1:1833:10	control	VBN	O	O
,	TREANDA.xml:S1:1843:1	,	,	O	O
randomized	TREANDA.xml:S1:1845:10	random	VBN	O	O
trial	TREANDA.xml:S1:1856:5	trial	NN	O	O
.	TREANDA.xml:S1:1861:1	.	.	O	O

The	TREANDA.xml:S1:1864:3	the	DT	O	O
population	TREANDA.xml:S1:1868:10	popul	NN	O	O
was	TREANDA.xml:S1:1879:3	wa	VBD	O	O
45	TREANDA.xml:S1:1883:2	45	CD	O	O
-	TREANDA.xml:S1:1885:1	-	:	O	O
77	TREANDA.xml:S1:1886:2	77	CD	O	O
years	TREANDA.xml:S1:1889:5	year	NNS	O	O
of	TREANDA.xml:S1:1895:2	of	IN	O	O
age	TREANDA.xml:S1:1898:3	age	NN	O	O
,	TREANDA.xml:S1:1901:1	,	,	O	O
63%	TREANDA.xml:S1:1903:3	63%	CD	O	O
male	TREANDA.xml:S1:1907:4	male	NN	O	O
,	TREANDA.xml:S1:1911:1	,	,	O	O
100%	TREANDA.xml:S1:1913:4	100%	CD	O	O
white	TREANDA.xml:S1:1918:5	white	JJ	O	O
,	TREANDA.xml:S1:1923:1	,	,	O	O
and	TREANDA.xml:S1:1925:3	and	CC	O	O
were	TREANDA.xml:S1:1929:4	were	VBD	O	O
treatment	TREANDA.xml:S1:1934:9	treatment	NN	O	O
naive	TREANDA.xml:S1:1944:5	naiv	JJ	O	O
.	TREANDA.xml:S1:1949:1	.	.	O	O

All	TREANDA.xml:S1:1951:3	all	DT	O	O
patients	TREANDA.xml:S1:1955:8	patient	NNS	O	O
started	TREANDA.xml:S1:1964:7	start	VBD	O	O
the	TREANDA.xml:S1:1972:3	the	DT	O	O
study	TREANDA.xml:S1:1976:5	studi	NN	O	O
at	TREANDA.xml:S1:1982:2	at	IN	O	O
a	TREANDA.xml:S1:1985:1	a	DT	O	O
dose	TREANDA.xml:S1:1987:4	dose	NN	O	O
of	TREANDA.xml:S1:1992:2	of	IN	O	O
100	TREANDA.xml:S1:1995:3	100	CD	O	O
mg	TREANDA.xml:S1:1999:2	mg	NNS	O	O
m	TREANDA.xml:S1:2002:1	m	RB	O	O
2	TREANDA.xml:S1:2005:1	2	CD	O	O
intravenously	TREANDA.xml:S1:2008:13	intraven	RB	O	O
over	TREANDA.xml:S1:2022:4	over	IN	O	O
30	TREANDA.xml:S1:2027:2	30	CD	O	O
minutes	TREANDA.xml:S1:2030:7	minut	NNS	O	O
on	TREANDA.xml:S1:2038:2	on	IN	O	O
Days	TREANDA.xml:S1:2041:4	day	NNS	O	O
1	TREANDA.xml:S1:2046:1	1	CD	O	O
and	TREANDA.xml:S1:2048:3	and	CC	O	O
2	TREANDA.xml:S1:2052:1	2	CD	O	O
every	TREANDA.xml:S1:2054:5	everi	DT	O	O
28	TREANDA.xml:S1:2060:2	28	CD	O	O
days	TREANDA.xml:S1:2063:4	day	NNS	O	O
.	TREANDA.xml:S1:2067:1	.	.	O	O

Adverse	TREANDA.xml:S1:2074:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:2082:9	reaction	NNS	O	O
were	TREANDA.xml:S1:2092:4	were	VBD	O	O
reported	TREANDA.xml:S1:2097:8	report	VBN	O	O
according	TREANDA.xml:S1:2106:9	accord	VBG	O	O
to	TREANDA.xml:S1:2116:2	to	TO	O	O
NCI	TREANDA.xml:S1:2119:3	nci	NNP	O	O
CTC	TREANDA.xml:S1:2123:3	ctc	NNP	O	O
v	TREANDA.xml:S1:2127:1	v	NN	O	O
.	TREANDA.xml:S1:2128:1	.	.	O	O
2.0	TREANDA.xml:S1:2129:3	2.0	CD	O	O
.	TREANDA.xml:S1:2132:1	.	.	O	O

Non	TREANDA.xml:S1:2135:3	non	NNP	O	O
-	TREANDA.xml:S1:2138:1	-	:	O	O
hematologic	TREANDA.xml:S1:2139:11	hematolog	JJ	O	O
adverse	TREANDA.xml:S1:2151:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:2159:9	reaction	NNS	O	O
(	TREANDA.xml:S1:2169:1	(	(	O	O
any	TREANDA.xml:S1:2170:3	ani	DT	O	O
grade	TREANDA.xml:S1:2174:5	grade	NN	O	O
)	TREANDA.xml:S1:2179:1	)	)	O	O
in	TREANDA.xml:S1:2181:2	in	IN	O	O
the	TREANDA.xml:S1:2184:3	the	DT	O	O
TREANDA	TREANDA.xml:S1:2188:7	treanda	NNP	O	O
group	TREANDA.xml:S1:2196:5	group	NN	O	O
that	TREANDA.xml:S1:2202:4	that	WDT	O	O
occurred	TREANDA.xml:S1:2207:8	occur	VBD	O	O
with	TREANDA.xml:S1:2216:4	with	IN	O	O
a	TREANDA.xml:S1:2221:1	a	DT	O	O
frequency	TREANDA.xml:S1:2223:9	frequenc	NN	O	O
greater	TREANDA.xml:S1:2233:7	greater	JJR	O	O
than	TREANDA.xml:S1:2241:4	than	IN	O	O
15%	TREANDA.xml:S1:2246:3	15%	CD	O	O
were	TREANDA.xml:S1:2250:4	were	VBD	O	O
pyrexia	TREANDA.xml:S1:2255:7	pyrexia	NNS	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:2263:1	(	(	O	O
24%	TREANDA.xml:S1:2264:3	24%	CD	O	O
)	TREANDA.xml:S1:2267:1	)	)	O	O
,	TREANDA.xml:S1:2268:1	,	,	O	O
nausea	TREANDA.xml:S1:2270:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:2277:1	(	(	O	O
20%	TREANDA.xml:S1:2278:3	20%	CD	O	O
)	TREANDA.xml:S1:2281:1	)	)	O	O
,	TREANDA.xml:S1:2282:1	,	,	O	O
and	TREANDA.xml:S1:2284:3	and	CC	O	O
vomiting	TREANDA.xml:S1:2288:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:2297:1	(	(	O	O
16%	TREANDA.xml:S1:2298:3	16%	CD	O	O
)	TREANDA.xml:S1:2301:1	)	)	O	O
.	TREANDA.xml:S1:2302:1	.	.	O	O

Other	TREANDA.xml:S1:2310:5	other	JJ	O	O
adverse	TREANDA.xml:S1:2316:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:2324:9	reaction	NNS	O	O
seen	TREANDA.xml:S1:2334:4	seen	VBN	O	O
frequently	TREANDA.xml:S1:2339:10	frequent	RB	O	O
in	TREANDA.xml:S1:2350:2	in	IN	O	O
one	TREANDA.xml:S1:2353:3	one	CD	O	O
or	TREANDA.xml:S1:2357:2	or	CC	O	O
more	TREANDA.xml:S1:2360:4	more	JJR	O	O
studies	TREANDA.xml:S1:2365:7	studi	NNS	O	O
included	TREANDA.xml:S1:2373:8	includ	VBD	O	O
asthenia	TREANDA.xml:S1:2382:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:2390:1	,	,	O	O
fatigue	TREANDA.xml:S1:2392:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:2399:1	,	,	O	O
malaise	TREANDA.xml:S1:2401:7	malais	NN	B-AdverseReaction	O
,	TREANDA.xml:S1:2408:1	,	,	O	O
and	TREANDA.xml:S1:2410:3	and	CC	O	O
weakness	TREANDA.xml:S1:2414:8	weak	NN	B-AdverseReaction	O
;	TREANDA.xml:S1:2422:1	;	:	O	O
dry	TREANDA.xml:S1:2424:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	TREANDA.xml:S1:2428:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
;	TREANDA.xml:S1:2433:1	;	:	O	O
somnolence	TREANDA.xml:S1:2435:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
;	TREANDA.xml:S1:2445:1	;	:	O	O
cough	TREANDA.xml:S1:2447:5	cough	NN	B-AdverseReaction	B-AdverseReaction
;	TREANDA.xml:S1:2452:1	;	:	O	O
constipation	TREANDA.xml:S1:2454:12	constip	NN	B-AdverseReaction	B-AdverseReaction
;	TREANDA.xml:S1:2466:1	;	:	O	O
headache	TREANDA.xml:S1:2468:8	headach	NN	B-AdverseReaction	B-AdverseReaction
;	TREANDA.xml:S1:2476:1	;	:	O	O
mucosal	TREANDA.xml:S1:2478:7	mucos	CC	B-AdverseReaction	O
inflammation	TREANDA.xml:S1:2486:12	inflamm	NN	I-AdverseReaction	O
and	TREANDA.xml:S1:2499:3	and	CC	O	O
stomatitis	TREANDA.xml:S1:2503:10	stomat	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S1:2513:1	.	.	O	O

Worsening	TREANDA.xml:S1:2520:9	worsen	VBG	B-AdverseReaction	O
hypertension	TREANDA.xml:S1:2530:12	hypertens	NN	I-AdverseReaction	B-AdverseReaction
was	TREANDA.xml:S1:2543:3	wa	VBD	O	O
reported	TREANDA.xml:S1:2547:8	report	VBN	O	O
in	TREANDA.xml:S1:2556:2	in	IN	O	O
4	TREANDA.xml:S1:2559:1	4	CD	O	O
patients	TREANDA.xml:S1:2561:8	patient	NNS	O	O
treated	TREANDA.xml:S1:2570:7	treat	VBN	O	O
with	TREANDA.xml:S1:2578:4	with	IN	O	O
TREANDA	TREANDA.xml:S1:2583:7	treanda	NNP	O	O
in	TREANDA.xml:S1:2591:2	in	IN	O	O
the	TREANDA.xml:S1:2594:3	the	DT	O	O
CLL	TREANDA.xml:S1:2598:3	cll	NNP	O	O
trial	TREANDA.xml:S1:2602:5	trial	NN	O	O
and	TREANDA.xml:S1:2608:3	and	CC	O	O
in	TREANDA.xml:S1:2612:2	in	IN	O	O
none	TREANDA.xml:S1:2615:4	none	NN	O	O
treated	TREANDA.xml:S1:2620:7	treat	VBN	O	O
with	TREANDA.xml:S1:2628:4	with	IN	O	O
chlorambucil	TREANDA.xml:S1:2633:12	chlorambucil	NN	O	O
.	TREANDA.xml:S1:2645:1	.	.	O	O

Three	TREANDA.xml:S1:2648:5	three	CD	O	O
of	TREANDA.xml:S1:2654:2	of	IN	O	O
these	TREANDA.xml:S1:2657:5	these	DT	O	O
4	TREANDA.xml:S1:2663:1	4	CD	O	O
adverse	TREANDA.xml:S1:2665:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:2673:9	reaction	NNS	O	O
were	TREANDA.xml:S1:2683:4	were	VBD	O	O
described	TREANDA.xml:S1:2688:9	describ	VBN	O	O
as	TREANDA.xml:S1:2698:2	as	IN	O	O
a	TREANDA.xml:S1:2701:1	a	DT	O	O
hypertensive	TREANDA.xml:S1:2703:12	hypertens	JJ	B-AdverseReaction	O
crisis	TREANDA.xml:S1:2716:6	crisi	NN	I-AdverseReaction	O
and	TREANDA.xml:S1:2723:3	and	CC	O	O
were	TREANDA.xml:S1:2727:4	were	VBD	O	O
managed	TREANDA.xml:S1:2732:7	manag	VBN	O	O
with	TREANDA.xml:S1:2740:4	with	IN	O	O
oral	TREANDA.xml:S1:2745:4	oral	JJ	O	O
medications	TREANDA.xml:S1:2750:11	medic	NNS	O	O
and	TREANDA.xml:S1:2762:3	and	CC	O	O
resolved	TREANDA.xml:S1:2766:8	resolv	VBN	O	O
.	TREANDA.xml:S1:2774:1	.	.	O	O

The	TREANDA.xml:S1:2780:3	the	DT	O	O
most	TREANDA.xml:S1:2784:4	most	RBS	O	O
frequent	TREANDA.xml:S1:2789:8	frequent	JJ	O	O
adverse	TREANDA.xml:S1:2798:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:2806:9	reaction	NNS	O	O
leading	TREANDA.xml:S1:2816:7	lead	VBG	O	O
to	TREANDA.xml:S1:2824:2	to	TO	O	O
study	TREANDA.xml:S1:2827:5	studi	VB	O	O
withdrawal	TREANDA.xml:S1:2833:10	withdraw	NN	O	O
for	TREANDA.xml:S1:2844:3	for	IN	O	O
patients	TREANDA.xml:S1:2848:8	patient	NNS	O	O
receiving	TREANDA.xml:S1:2857:9	receiv	VBG	O	O
TREANDA	TREANDA.xml:S1:2867:7	treanda	NNP	O	O
were	TREANDA.xml:S1:2875:4	were	VBD	O	O
hypersensitivity	TREANDA.xml:S1:2880:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:2897:1	(	(	O	O
2%	TREANDA.xml:S1:2898:2	2%	CD	O	O
)	TREANDA.xml:S1:2900:1	)	)	O	O
and	TREANDA.xml:S1:2902:3	and	CC	O	O
pyrexia	TREANDA.xml:S1:2906:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:2914:1	(	(	O	O
1%	TREANDA.xml:S1:2915:2	1%	CD	O	O
)	TREANDA.xml:S1:2917:1	)	)	O	O
.	TREANDA.xml:S1:2918:1	.	.	O	O

Table	TREANDA.xml:S1:2924:5	tabl	JJ	O	O
1	TREANDA.xml:S1:2930:1	1	CD	O	O
contains	TREANDA.xml:S1:2932:8	contain	VBZ	O	O
the	TREANDA.xml:S1:2941:3	the	DT	O	O
treatment	TREANDA.xml:S1:2945:9	treatment	NN	O	O
emergent	TREANDA.xml:S1:2955:8	emerg	JJ	O	O
adverse	TREANDA.xml:S1:2964:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:2972:9	reaction	NNS	O	O
,	TREANDA.xml:S1:2981:1	,	,	O	O
regardless	TREANDA.xml:S1:2983:10	regardless	RB	O	O
of	TREANDA.xml:S1:2994:2	of	IN	O	O
attribution	TREANDA.xml:S1:2997:11	attribut	NN	O	O
,	TREANDA.xml:S1:3008:1	,	,	O	O
that	TREANDA.xml:S1:3010:4	that	WDT	O	O
were	TREANDA.xml:S1:3015:4	were	VBD	O	O
reported	TREANDA.xml:S1:3020:8	report	VBN	O	O
in	TREANDA.xml:S1:3029:2	in	IN	O	O
5%	TREANDA.xml:S1:3035:2	5%	CD	O	O
of	TREANDA.xml:S1:3038:2	of	IN	O	O
patients	TREANDA.xml:S1:3041:8	patient	NNS	O	O
in	TREANDA.xml:S1:3050:2	in	IN	O	O
either	TREANDA.xml:S1:3053:6	either	DT	O	O
treatment	TREANDA.xml:S1:3060:9	treatment	NN	O	O
group	TREANDA.xml:S1:3070:5	group	NN	O	O
in	TREANDA.xml:S1:3076:2	in	IN	O	O
the	TREANDA.xml:S1:3079:3	the	DT	O	O
randomized	TREANDA.xml:S1:3083:10	random	JJ	O	O
CLL	TREANDA.xml:S1:3094:3	cll	NNP	O	O
clinical	TREANDA.xml:S1:3098:8	clinic	JJ	O	O
study	TREANDA.xml:S1:3107:5	studi	NN	O	O
.	TREANDA.xml:S1:3112:1	.	.	O	O

Table	TREANDA.xml:S1:3118:5	tabl	JJ	O	O
1	TREANDA.xml:S1:3124:1	1	CD	O	O
:	TREANDA.xml:S1:3125:1	:	:	O	O
Non	TREANDA.xml:S1:3127:3	non	NNP	O	O
-	TREANDA.xml:S1:3130:1	-	:	O	O
Hematologic	TREANDA.xml:S1:3131:11	hematolog	NNP	O	O
Adverse	TREANDA.xml:S1:3143:7	advers	NNP	O	O
Reactions	TREANDA.xml:S1:3151:9	reaction	NNP	O	O
Occurring	TREANDA.xml:S1:3161:9	occur	NNP	O	O
in	TREANDA.xml:S1:3171:2	in	IN	O	O
Randomized	TREANDA.xml:S1:3174:10	random	NNP	O	O
CLL	TREANDA.xml:S1:3185:3	cll	NNP	O	O
Clinical	TREANDA.xml:S1:3189:8	clinic	NNP	O	O
Study	TREANDA.xml:S1:3198:5	studi	NNP	O	O
in	TREANDA.xml:S1:3204:2	in	IN	O	O
at	TREANDA.xml:S1:3207:2	at	IN	O	O
Least	TREANDA.xml:S1:3210:5	least	NNP	O	O
5%	TREANDA.xml:S1:3216:2	5%	CD	O	O
of	TREANDA.xml:S1:3219:2	of	IN	O	O
Patients	TREANDA.xml:S1:3222:8	patient	NNS	O	O

Number	TREANDA.xml:S1:3289:6	number	NNP	O	O
(	TREANDA.xml:S1:3296:1	(	(	O	O
)	TREANDA.xml:S1:3298:1	)	)	O	O
of	TREANDA.xml:S1:3300:2	of	IN	O	O
patients	TREANDA.xml:S1:3303:8	patient	NNS	O	O

TREANDA	TREANDA.xml:S1:3372:7	treanda	NNP	O	O
(	TREANDA.xml:S1:3379:1	(	(	O	O
N	TREANDA.xml:S1:3380:1	N	NNP	O	O
153	TREANDA.xml:S1:3382:3	153	CD	O	O
)	TREANDA.xml:S1:3385:1	)	)	O	O
Chlorambucil	TREANDA.xml:S1:3390:12	chlorambucil	NNP	O	O
(	TREANDA.xml:S1:3402:1	(	(	O	O
N	TREANDA.xml:S1:3403:1	N	NNP	O	O
143	TREANDA.xml:S1:3405:3	143	CD	O	O
)	TREANDA.xml:S1:3408:1	)	)	O	O

System	TREANDA.xml:S1:3416:6	system	NNP	O	O
organ	TREANDA.xml:S1:3423:5	organ	JJ	O	O
class	TREANDA.xml:S1:3429:5	class	NN	O	O
Preferred	TREANDA.xml:S1:3439:9	prefer	NNP	O	O
term	TREANDA.xml:S1:3449:4	term	NN	O	O
All	TREANDA.xml:S1:3470:3	all	NNP	O	O
Grades	TREANDA.xml:S1:3474:6	grade	NNP	O	O
Grade	TREANDA.xml:S1:3485:5	grade	NNP	O	O
3	TREANDA.xml:S1:3491:1	3	CD	O	O
4	TREANDA.xml:S1:3493:1	4	CD	O	O
All	TREANDA.xml:S1:3499:3	all	DT	O	O
Grades	TREANDA.xml:S1:3503:6	grade	NNP	O	O
Grade	TREANDA.xml:S1:3514:5	grade	NNP	O	O
3	TREANDA.xml:S1:3520:1	3	CD	O	O
4	TREANDA.xml:S1:3522:1	4	CD	O	O

Total	TREANDA.xml:S1:3531:5	total	JJ	O	O
number	TREANDA.xml:S1:3537:6	number	NN	O	O
of	TREANDA.xml:S1:3544:2	of	IN	O	O
patients	TREANDA.xml:S1:3547:8	patient	NNS	O	O
with	TREANDA.xml:S1:3556:4	with	IN	O	O
at	TREANDA.xml:S1:3561:2	at	IN	O	O
least	TREANDA.xml:S1:3564:5	least	JJS	O	O
1	TREANDA.xml:S1:3570:1	1	CD	O	O
adverse	TREANDA.xml:S1:3572:7	advers	JJ	O	O
reaction	TREANDA.xml:S1:3580:8	reaction	NN	O	O
121	TREANDA.xml:S1:3592:3	121	CD	O	O
(	TREANDA.xml:S1:3596:1	(	(	O	O
79	TREANDA.xml:S1:3597:2	79	CD	O	O
)	TREANDA.xml:S1:3599:1	)	)	O	O
52	TREANDA.xml:S1:3606:2	52	CD	O	O
(	TREANDA.xml:S1:3609:1	(	(	O	O
34	TREANDA.xml:S1:3610:2	34	CD	O	O
)	TREANDA.xml:S1:3612:1	)	)	O	O
96	TREANDA.xml:S1:3619:2	96	CD	O	O
(	TREANDA.xml:S1:3622:1	(	(	O	O
67	TREANDA.xml:S1:3623:2	67	CD	O	O
)	TREANDA.xml:S1:3625:1	)	)	O	O
25	TREANDA.xml:S1:3633:2	25	CD	O	O
(	TREANDA.xml:S1:3636:1	(	(	O	O
17	TREANDA.xml:S1:3637:2	17	CD	O	O
)	TREANDA.xml:S1:3639:1	)	)	O	O

Gastrointestinal	TREANDA.xml:S1:3649:16	gastrointestin	JJ	O	O
disorders	TREANDA.xml:S1:3666:9	disord	NNS	O	O

Nausea	TREANDA.xml:S1:3762:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
31	TREANDA.xml:S1:3814:2	31	CD	O	O
(	TREANDA.xml:S1:3817:1	(	(	O	O
20	TREANDA.xml:S1:3818:2	20	CD	O	O
)	TREANDA.xml:S1:3820:1	)	)	O	O
1	TREANDA.xml:S1:3828:1	1	CD	O	O
(	TREANDA.xml:S1:3830:1	(	(	O	O
1	TREANDA.xml:S1:3832:1	1	CD	O	O
)	TREANDA.xml:S1:3833:1	)	)	O	O
21	TREANDA.xml:S1:3841:2	21	CD	O	O
(	TREANDA.xml:S1:3844:1	(	(	O	O
15	TREANDA.xml:S1:3845:2	15	CD	O	O
)	TREANDA.xml:S1:3847:1	)	)	O	O
1	TREANDA.xml:S1:3855:1	1	CD	O	O
(	TREANDA.xml:S1:3857:1	(	(	O	O
1	TREANDA.xml:S1:3859:1	1	CD	O	O
)	TREANDA.xml:S1:3860:1	)	)	O	O

Vomiting	TREANDA.xml:S1:3873:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
24	TREANDA.xml:S1:3925:2	24	CD	O	O
(	TREANDA.xml:S1:3928:1	(	(	O	O
16	TREANDA.xml:S1:3929:2	16	CD	O	O
)	TREANDA.xml:S1:3931:1	)	)	O	O
1	TREANDA.xml:S1:3939:1	1	CD	O	O
(	TREANDA.xml:S1:3941:1	(	(	O	O
1	TREANDA.xml:S1:3943:1	1	CD	O	O
)	TREANDA.xml:S1:3944:1	)	)	O	O
9	TREANDA.xml:S1:3952:1	9	CD	O	O
(	TREANDA.xml:S1:3954:1	(	(	O	O
6	TREANDA.xml:S1:3955:1	6	CD	O	O
)	TREANDA.xml:S1:3956:1	)	)	O	O
0	TREANDA.xml:S1:3966:1	0	CD	O	O

Diarrhea	TREANDA.xml:S1:3984:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
14	TREANDA.xml:S1:4036:2	14	CD	O	O
(	TREANDA.xml:S1:4039:1	(	(	O	O
9	TREANDA.xml:S1:4040:1	9	CD	O	O
)	TREANDA.xml:S1:4041:1	)	)	O	O
2	TREANDA.xml:S1:4050:1	2	CD	O	O
(	TREANDA.xml:S1:4052:1	(	(	O	O
1	TREANDA.xml:S1:4053:1	1	CD	O	O
)	TREANDA.xml:S1:4054:1	)	)	O	O
5	TREANDA.xml:S1:4063:1	5	CD	O	O
(	TREANDA.xml:S1:4065:1	(	(	O	O
3	TREANDA.xml:S1:4066:1	3	CD	O	O
)	TREANDA.xml:S1:4067:1	)	)	O	O
0	TREANDA.xml:S1:4077:1	0	CD	O	O

General	TREANDA.xml:S1:4093:7	gener	NNP	O	O
disorders	TREANDA.xml:S1:4101:9	disord	NNS	O	O
and	TREANDA.xml:S1:4111:3	and	CC	O	O
administration	TREANDA.xml:S1:4115:14	administr	NN	O	O
site	TREANDA.xml:S1:4130:4	site	NN	O	O
conditions	TREANDA.xml:S1:4135:10	condit	NNS	O	O

Pyrexia	TREANDA.xml:S1:4208:7	pyrexia	$	B-AdverseReaction	B-AdverseReaction
36	TREANDA.xml:S1:4260:2	36	CD	O	O
(	TREANDA.xml:S1:4263:1	(	(	O	O
24	TREANDA.xml:S1:4264:2	24	CD	O	O
)	TREANDA.xml:S1:4266:1	)	)	O	O
6	TREANDA.xml:S1:4274:1	6	CD	O	O
(	TREANDA.xml:S1:4276:1	(	(	O	O
4	TREANDA.xml:S1:4277:1	4	CD	O	O
)	TREANDA.xml:S1:4278:1	)	)	O	O
8	TREANDA.xml:S1:4287:1	8	CD	O	O
(	TREANDA.xml:S1:4289:1	(	(	O	O
6	TREANDA.xml:S1:4290:1	6	CD	O	O
)	TREANDA.xml:S1:4291:1	)	)	O	O
2	TREANDA.xml:S1:4301:1	2	CD	O	O
(	TREANDA.xml:S1:4303:1	(	(	O	O
1	TREANDA.xml:S1:4304:1	1	CD	O	O
)	TREANDA.xml:S1:4305:1	)	)	O	O

Fatigue	TREANDA.xml:S1:4319:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
14	TREANDA.xml:S1:4371:2	14	CD	O	O
(	TREANDA.xml:S1:4374:1	(	(	O	O
9	TREANDA.xml:S1:4375:1	9	CD	O	O
)	TREANDA.xml:S1:4376:1	)	)	O	O
2	TREANDA.xml:S1:4385:1	2	CD	O	O
(	TREANDA.xml:S1:4387:1	(	(	O	O
1	TREANDA.xml:S1:4388:1	1	CD	O	O
)	TREANDA.xml:S1:4389:1	)	)	O	O
8	TREANDA.xml:S1:4398:1	8	CD	O	O
(	TREANDA.xml:S1:4400:1	(	(	O	O
6	TREANDA.xml:S1:4401:1	6	CD	O	O
)	TREANDA.xml:S1:4402:1	)	)	O	O
0	TREANDA.xml:S1:4412:1	0	CD	O	O

Asthenia	TREANDA.xml:S1:4430:8	asthenia	NNP	B-AdverseReaction	B-AdverseReaction
13	TREANDA.xml:S1:4482:2	13	CD	O	O
(	TREANDA.xml:S1:4485:1	(	(	O	O
8	TREANDA.xml:S1:4486:1	8	CD	O	O
)	TREANDA.xml:S1:4487:1	)	)	O	O
0	TREANDA.xml:S1:4496:1	0	CD	O	O
6	TREANDA.xml:S1:4509:1	6	CD	O	O
(	TREANDA.xml:S1:4511:1	(	(	O	O
4	TREANDA.xml:S1:4512:1	4	CD	O	O
)	TREANDA.xml:S1:4513:1	)	)	O	O
0	TREANDA.xml:S1:4523:1	0	CD	O	O

Chills	TREANDA.xml:S1:4541:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
9	TREANDA.xml:S1:4593:1	9	CD	O	O
(	TREANDA.xml:S1:4595:1	(	(	O	O
6	TREANDA.xml:S1:4596:1	6	CD	O	O
)	TREANDA.xml:S1:4597:1	)	)	O	O
0	TREANDA.xml:S1:4607:1	0	CD	O	O
1	TREANDA.xml:S1:4620:1	1	CD	O	O
(	TREANDA.xml:S1:4622:1	(	(	O	O
1	TREANDA.xml:S1:4624:1	1	CD	O	O
)	TREANDA.xml:S1:4625:1	)	)	O	O
0	TREANDA.xml:S1:4634:1	0	CD	O	O

Immune	TREANDA.xml:S1:4650:6	immun	NNP	O	O
system	TREANDA.xml:S1:4657:6	system	NN	O	O
disorders	TREANDA.xml:S1:4664:9	disord	NNS	O	O

Hypersensitivity	TREANDA.xml:S1:4763:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
7	TREANDA.xml:S1:4815:1	7	CD	O	O
(	TREANDA.xml:S1:4817:1	(	(	O	O
5	TREANDA.xml:S1:4818:1	5	CD	O	O
)	TREANDA.xml:S1:4819:1	)	)	O	O
2	TREANDA.xml:S1:4829:1	2	CD	O	O
(	TREANDA.xml:S1:4831:1	(	(	O	O
1	TREANDA.xml:S1:4832:1	1	CD	O	O
)	TREANDA.xml:S1:4833:1	)	)	O	O
3	TREANDA.xml:S1:4842:1	3	CD	O	O
(	TREANDA.xml:S1:4844:1	(	(	O	O
2	TREANDA.xml:S1:4845:1	2	CD	O	O
)	TREANDA.xml:S1:4846:1	)	)	O	O
0	TREANDA.xml:S1:4856:1	0	CD	O	O

Infections	TREANDA.xml:S1:4872:10	infect	NNS	O	O
and	TREANDA.xml:S1:4883:3	and	CC	O	O
infestations	TREANDA.xml:S1:4887:12	infest	NNS	O	O

Nasopharyngitis	TREANDA.xml:S1:4985:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
10	TREANDA.xml:S1:5037:2	10	CD	O	O
(	TREANDA.xml:S1:5040:1	(	(	O	O
7	TREANDA.xml:S1:5041:1	7	CD	O	O
)	TREANDA.xml:S1:5042:1	)	)	O	O
0	TREANDA.xml:S1:5051:1	0	CD	O	O
12	TREANDA.xml:S1:5064:2	12	CD	O	O
(	TREANDA.xml:S1:5067:1	(	(	O	O
8	TREANDA.xml:S1:5068:1	8	CD	O	O
)	TREANDA.xml:S1:5069:1	)	)	O	O
0	TREANDA.xml:S1:5078:1	0	CD	O	O

Infection	TREANDA.xml:S1:5096:9	infect	NN	B-AdverseReaction	B-AdverseReaction
9	TREANDA.xml:S1:5148:1	9	CD	O	O
(	TREANDA.xml:S1:5150:1	(	(	O	O
6	TREANDA.xml:S1:5151:1	6	CD	O	O
)	TREANDA.xml:S1:5152:1	)	)	O	O
3	TREANDA.xml:S1:5162:1	3	CD	O	O
(	TREANDA.xml:S1:5164:1	(	(	O	O
2	TREANDA.xml:S1:5165:1	2	CD	O	O
)	TREANDA.xml:S1:5166:1	)	)	O	O
1	TREANDA.xml:S1:5175:1	1	CD	O	O
(	TREANDA.xml:S1:5177:1	(	(	O	O
1	TREANDA.xml:S1:5179:1	1	CD	O	O
)	TREANDA.xml:S1:5180:1	)	)	O	O
1	TREANDA.xml:S1:5189:1	1	CD	O	O
(	TREANDA.xml:S1:5191:1	(	(	O	O
1	TREANDA.xml:S1:5193:1	1	CD	O	O
)	TREANDA.xml:S1:5194:1	)	)	O	O

Herpes	TREANDA.xml:S1:5207:6	herp	NNP	B-AdverseReaction	B-AdverseReaction
simplex	TREANDA.xml:S1:5214:7	simplex	VBD	I-AdverseReaction	I-AdverseReaction
5	TREANDA.xml:S1:5259:1	5	CD	O	O
(	TREANDA.xml:S1:5261:1	(	(	O	O
3	TREANDA.xml:S1:5262:1	3	CD	O	O
)	TREANDA.xml:S1:5263:1	)	)	O	O
0	TREANDA.xml:S1:5273:1	0	CD	O	O
7	TREANDA.xml:S1:5286:1	7	CD	O	O
(	TREANDA.xml:S1:5288:1	(	(	O	O
5	TREANDA.xml:S1:5289:1	5	CD	O	O
)	TREANDA.xml:S1:5290:1	)	)	O	O
0	TREANDA.xml:S1:5300:1	0	CD	O	O

Investigations	TREANDA.xml:S1:5316:14	investig	NNS	O	O

Weight	TREANDA.xml:S1:5429:6	weight	NNP	B-AdverseReaction	B-AdverseReaction
decreased	TREANDA.xml:S1:5436:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
11	TREANDA.xml:S1:5481:2	11	CD	O	O
(	TREANDA.xml:S1:5484:1	(	(	O	O
7	TREANDA.xml:S1:5485:1	7	CD	O	O
)	TREANDA.xml:S1:5486:1	)	)	O	O
0	TREANDA.xml:S1:5495:1	0	CD	O	O
5	TREANDA.xml:S1:5508:1	5	CD	O	O
(	TREANDA.xml:S1:5510:1	(	(	O	O
3	TREANDA.xml:S1:5511:1	3	CD	O	O
)	TREANDA.xml:S1:5512:1	)	)	O	O
0	TREANDA.xml:S1:5522:1	0	CD	O	O

Metabolism	TREANDA.xml:S1:5538:10	metabol	NN	O	O
and	TREANDA.xml:S1:5549:3	and	CC	O	O
nutrition	TREANDA.xml:S1:5553:9	nutrit	NN	O	O
disorders	TREANDA.xml:S1:5563:9	disord	NNS	O	O

Hyperuricemia	TREANDA.xml:S1:5651:13	hyperuricemia	$	B-AdverseReaction	B-AdverseReaction
11	TREANDA.xml:S1:5703:2	11	CD	O	O
(	TREANDA.xml:S1:5706:1	(	(	O	O
7	TREANDA.xml:S1:5707:1	7	CD	O	O
)	TREANDA.xml:S1:5708:1	)	)	O	O
3	TREANDA.xml:S1:5717:1	3	CD	O	O
(	TREANDA.xml:S1:5719:1	(	(	O	O
2	TREANDA.xml:S1:5720:1	2	CD	O	O
)	TREANDA.xml:S1:5721:1	)	)	O	O
2	TREANDA.xml:S1:5730:1	2	CD	O	O
(	TREANDA.xml:S1:5732:1	(	(	O	O
1	TREANDA.xml:S1:5733:1	1	CD	O	O
)	TREANDA.xml:S1:5734:1	)	)	O	O
0	TREANDA.xml:S1:5744:1	0	CD	O	O

Respiratory	TREANDA.xml:S1:5760:11	respiratori	NNP	O	O
,	TREANDA.xml:S1:5771:1	,	,	O	O
thoracic	TREANDA.xml:S1:5773:8	thorac	NN	O	O
and	TREANDA.xml:S1:5782:3	and	CC	O	O
mediastinal	TREANDA.xml:S1:5786:11	mediastin	JJ	O	O
disorders	TREANDA.xml:S1:5798:9	disord	NNS	O	O

Cough	TREANDA.xml:S1:5873:5	cough	IN	B-AdverseReaction	B-AdverseReaction
6	TREANDA.xml:S1:5925:1	6	CD	O	O
(	TREANDA.xml:S1:5927:1	(	(	O	O
4	TREANDA.xml:S1:5928:1	4	CD	O	O
)	TREANDA.xml:S1:5929:1	)	)	O	O
1	TREANDA.xml:S1:5939:1	1	CD	O	O
(	TREANDA.xml:S1:5941:1	(	(	O	O
1	TREANDA.xml:S1:5943:1	1	CD	O	O
)	TREANDA.xml:S1:5944:1	)	)	O	O
7	TREANDA.xml:S1:5952:1	7	CD	O	O
(	TREANDA.xml:S1:5954:1	(	(	O	O
5	TREANDA.xml:S1:5955:1	5	CD	O	O
)	TREANDA.xml:S1:5956:1	)	)	O	O
1	TREANDA.xml:S1:5966:1	1	CD	O	O
(	TREANDA.xml:S1:5968:1	(	(	O	O
1	TREANDA.xml:S1:5970:1	1	CD	O	O
)	TREANDA.xml:S1:5971:1	)	)	O	O

Skin	TREANDA.xml:S1:5982:4	skin	NNP	O	O
and	TREANDA.xml:S1:5987:3	and	CC	O	O
subcutaneous	TREANDA.xml:S1:5991:12	subcutan	JJ	O	O
tissue	TREANDA.xml:S1:6004:6	tissu	NN	O	O
disorders	TREANDA.xml:S1:6011:9	disord	NNS	O	O

Rash	TREANDA.xml:S1:6095:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
12	TREANDA.xml:S1:6147:2	12	CD	O	O
(	TREANDA.xml:S1:6150:1	(	(	O	O
8	TREANDA.xml:S1:6151:1	8	CD	O	O
)	TREANDA.xml:S1:6152:1	)	)	O	O
4	TREANDA.xml:S1:6161:1	4	CD	O	O
(	TREANDA.xml:S1:6163:1	(	(	O	O
3	TREANDA.xml:S1:6164:1	3	CD	O	O
)	TREANDA.xml:S1:6165:1	)	)	O	O
7	TREANDA.xml:S1:6174:1	7	CD	O	O
(	TREANDA.xml:S1:6176:1	(	(	O	O
5	TREANDA.xml:S1:6177:1	5	CD	O	O
)	TREANDA.xml:S1:6178:1	)	)	O	O
3	TREANDA.xml:S1:6188:1	3	CD	O	O
(	TREANDA.xml:S1:6190:1	(	(	O	O
2	TREANDA.xml:S1:6191:1	2	CD	O	O
)	TREANDA.xml:S1:6192:1	)	)	O	O

Pruritus	TREANDA.xml:S1:6206:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
8	TREANDA.xml:S1:6258:1	8	CD	O	O
(	TREANDA.xml:S1:6260:1	(	(	O	O
5	TREANDA.xml:S1:6261:1	5	CD	O	O
)	TREANDA.xml:S1:6262:1	)	)	O	O
0	TREANDA.xml:S1:6272:1	0	CD	O	O
2	TREANDA.xml:S1:6285:1	2	CD	O	O
(	TREANDA.xml:S1:6287:1	(	(	O	O
1	TREANDA.xml:S1:6288:1	1	CD	O	O
)	TREANDA.xml:S1:6289:1	)	)	O	O
0	TREANDA.xml:S1:6299:1	0	CD	O	O

The	TREANDA.xml:S1:6324:3	the	DT	O	O
Grade	TREANDA.xml:S1:6328:5	grade	NNP	O	O
3	TREANDA.xml:S1:6334:1	3	CD	O	O
and	TREANDA.xml:S1:6336:3	and	CC	O	O
4	TREANDA.xml:S1:6340:1	4	CD	O	O
hematology	TREANDA.xml:S1:6342:10	hematolog	NN	O	O
laboratory	TREANDA.xml:S1:6353:10	laboratori	JJ	O	O
test	TREANDA.xml:S1:6364:4	test	NN	O	O
values	TREANDA.xml:S1:6369:6	valu	NNS	O	O
by	TREANDA.xml:S1:6376:2	by	IN	O	O
treatment	TREANDA.xml:S1:6379:9	treatment	NN	O	O
group	TREANDA.xml:S1:6389:5	group	NN	O	O
in	TREANDA.xml:S1:6395:2	in	IN	O	O
the	TREANDA.xml:S1:6398:3	the	DT	O	O
randomized	TREANDA.xml:S1:6402:10	random	JJ	O	O
CLL	TREANDA.xml:S1:6413:3	cll	NNP	O	O
clinical	TREANDA.xml:S1:6417:8	clinic	NN	O	O
study	TREANDA.xml:S1:6426:5	studi	NN	O	O
are	TREANDA.xml:S1:6432:3	are	VBP	O	O
described	TREANDA.xml:S1:6436:9	describ	VBN	O	O
in	TREANDA.xml:S1:6446:2	in	IN	O	O
Table	TREANDA.xml:S1:6449:5	tabl	JJ	O	O
2	TREANDA.xml:S1:6455:1	2	CD	O	O
.	TREANDA.xml:S1:6456:1	.	.	O	O

These	TREANDA.xml:S1:6458:5	these	DT	O	O
findings	TREANDA.xml:S1:6464:8	find	NNS	O	O
confirm	TREANDA.xml:S1:6473:7	confirm	VBP	O	O
the	TREANDA.xml:S1:6481:3	the	DT	O	O
myelosuppressive	TREANDA.xml:S1:6485:16	myelosuppress	JJ	B-AdverseReaction	O
effects	TREANDA.xml:S1:6502:7	effect	NNS	I-AdverseReaction	O
seen	TREANDA.xml:S1:6510:4	seen	VBN	O	O
in	TREANDA.xml:S1:6515:2	in	IN	O	O
patients	TREANDA.xml:S1:6518:8	patient	NNS	O	O
treated	TREANDA.xml:S1:6527:7	treat	VBN	O	O
with	TREANDA.xml:S1:6535:4	with	IN	O	O
TREANDA	TREANDA.xml:S1:6540:7	treanda	NNP	O	O
.	TREANDA.xml:S1:6547:1	.	.	O	O

Red	TREANDA.xml:S1:6549:3	red	JJ	O	O
blood	TREANDA.xml:S1:6553:5	blood	NN	O	O
cell	TREANDA.xml:S1:6559:4	cell	NN	O	O
transfusions	TREANDA.xml:S1:6564:12	transfus	NNS	O	O
were	TREANDA.xml:S1:6577:4	were	VBD	O	O
administered	TREANDA.xml:S1:6582:12	administ	VBN	O	O
to	TREANDA.xml:S1:6595:2	to	TO	O	O
20%	TREANDA.xml:S1:6598:3	20%	CD	O	O
of	TREANDA.xml:S1:6602:2	of	IN	O	O
patients	TREANDA.xml:S1:6605:8	patient	NNS	O	O
receiving	TREANDA.xml:S1:6614:9	receiv	VBG	O	O
TREANDA	TREANDA.xml:S1:6624:7	treanda	NNP	O	O
compared	TREANDA.xml:S1:6632:8	compar	VBN	O	O
with	TREANDA.xml:S1:6641:4	with	IN	O	O
6%	TREANDA.xml:S1:6646:2	6%	CD	O	O
of	TREANDA.xml:S1:6649:2	of	IN	O	O
patients	TREANDA.xml:S1:6652:8	patient	NNS	O	O
receiving	TREANDA.xml:S1:6661:9	receiv	VBG	O	O
chlorambucil	TREANDA.xml:S1:6671:12	chlorambucil	NN	O	O
.	TREANDA.xml:S1:6683:1	.	.	O	O

Table	TREANDA.xml:S1:6689:5	tabl	NN	O	O

2	TREANDA.xml:S1:6695:1	2	CD	O	O
:	TREANDA.xml:S1:6696:1	:	:	O	O
Incidence	TREANDA.xml:S1:6699:9	incid	NN	O	O
of	TREANDA.xml:S1:6709:2	of	IN	O	O
Hematology	TREANDA.xml:S1:6712:10	hematolog	NNP	O	O
Laboratory	TREANDA.xml:S1:6723:10	laboratori	NNP	O	O
Abnormalities	TREANDA.xml:S1:6734:13	abnorm	NNP	O	O
in	TREANDA.xml:S1:6748:2	in	IN	O	O
Patients	TREANDA.xml:S1:6751:8	patient	NNPS	O	O
Who	TREANDA.xml:S1:6760:3	who	WP	O	O
Received	TREANDA.xml:S1:6764:8	receiv	VBD	O	O
TREANDA	TREANDA.xml:S1:6773:7	treanda	NNP	O	O
or	TREANDA.xml:S1:6781:2	or	CC	O	O
Chlorambucil	TREANDA.xml:S1:6784:12	chlorambucil	NNP	O	O
in	TREANDA.xml:S1:6797:2	in	IN	O	O
the	TREANDA.xml:S1:6800:3	the	DT	O	O
Randomized	TREANDA.xml:S1:6804:10	random	NNP	O	O
CLL	TREANDA.xml:S1:6815:3	cll	NNP	O	O
Clinical	TREANDA.xml:S1:6819:8	clinic	NNP	O	O
Study	TREANDA.xml:S1:6828:5	studi	NNP	O	O

TREANDA	TREANDA.xml:S1:6866:7	treanda	NNP	O	O
N	TREANDA.xml:S1:6874:1	N	NNP	O	O
150	TREANDA.xml:S1:6876:3	150	CD	O	O
ChlorambucilN	TREANDA.xml:S1:6883:13	chlorambuciln	NNP	O	O
141	TREANDA.xml:S1:6897:3	141	CD	O	O

Laboratory	TREANDA.xml:S1:6907:10	laboratori	NNP	O	O
Abnormality	TREANDA.xml:S1:6918:11	abnorm	NNP	O	O
All	TREANDA.xml:S1:6936:3	all	NNP	O	O
Gradesn	TREANDA.xml:S1:6940:7	gradesn	NNP	O	O
(	TREANDA.xml:S1:6948:1	(	(	O	O
)	TREANDA.xml:S1:6950:1	)	)	O	O
Grade	TREANDA.xml:S1:6955:5	grade	VBD	O	O
3	TREANDA.xml:S1:6961:1	3	CD	O	O
4	TREANDA.xml:S1:6963:1	4	CD	O	O
n	TREANDA.xml:S1:6964:1	n	NNS	O	O
(	TREANDA.xml:S1:6966:1	(	(	O	O
)	TREANDA.xml:S1:6968:1	)	)	O	O
All	TREANDA.xml:S1:6973:3	all	DT	O	O
Gradesn	TREANDA.xml:S1:6977:7	gradesn	NNP	O	O
(	TREANDA.xml:S1:6985:1	(	(	O	O
)	TREANDA.xml:S1:6987:1	)	)	O	O
Grade	TREANDA.xml:S1:6992:5	grade	VBD	O	O
3	TREANDA.xml:S1:6998:1	3	CD	O	O
4	TREANDA.xml:S1:7000:1	4	CD	O	O
n	TREANDA.xml:S1:7001:1	n	NNS	O	O
(	TREANDA.xml:S1:7003:1	(	(	O	O
)	TREANDA.xml:S1:7005:1	)	)	O	O

Hemoglobin	TREANDA.xml:S1:7013:10	hemoglobin	NNP	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:7024:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
134	TREANDA.xml:S1:7042:3	134	CD	O	O
(	TREANDA.xml:S1:7046:1	(	(	O	O
89	TREANDA.xml:S1:7047:2	89	CD	O	O
)	TREANDA.xml:S1:7049:1	)	)	O	O
20	TREANDA.xml:S1:7057:2	20	CD	O	O
(	TREANDA.xml:S1:7060:1	(	(	O	O
13	TREANDA.xml:S1:7061:2	13	CD	O	O
)	TREANDA.xml:S1:7063:1	)	)	O	O
115	TREANDA.xml:S1:7071:3	115	CD	O	O
(	TREANDA.xml:S1:7075:1	(	(	O	O
82	TREANDA.xml:S1:7076:2	82	CD	O	O
)	TREANDA.xml:S1:7078:1	)	)	O	O
12	TREANDA.xml:S1:7086:2	12	CD	O	O
(	TREANDA.xml:S1:7089:1	(	(	O	O
9	TREANDA.xml:S1:7090:1	9	CD	O	O
)	TREANDA.xml:S1:7091:1	)	)	O	O

Platelets	TREANDA.xml:S1:7103:9	platelet	NNS	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:7113:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
116	TREANDA.xml:S1:7132:3	116	CD	O	O
(	TREANDA.xml:S1:7136:1	(	(	O	O
77	TREANDA.xml:S1:7137:2	77	CD	O	O
)	TREANDA.xml:S1:7139:1	)	)	O	O
16	TREANDA.xml:S1:7147:2	16	CD	O	O
(	TREANDA.xml:S1:7150:1	(	(	O	O
11	TREANDA.xml:S1:7151:2	11	CD	O	O
)	TREANDA.xml:S1:7153:1	)	)	O	O
110	TREANDA.xml:S1:7161:3	110	CD	O	O
(	TREANDA.xml:S1:7165:1	(	(	O	O
78	TREANDA.xml:S1:7166:2	78	CD	O	O
)	TREANDA.xml:S1:7168:1	)	)	O	O
14	TREANDA.xml:S1:7176:2	14	CD	O	O
(	TREANDA.xml:S1:7179:1	(	(	O	O
10	TREANDA.xml:S1:7180:2	10	CD	O	O
)	TREANDA.xml:S1:7182:1	)	)	O	O

Leukocytes	TREANDA.xml:S1:7193:10	leukocyt	NNS	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:7204:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
92	TREANDA.xml:S1:7222:2	92	CD	O	O
(	TREANDA.xml:S1:7225:1	(	(	O	O
61	TREANDA.xml:S1:7226:2	61	CD	O	O
)	TREANDA.xml:S1:7228:1	)	)	O	O
42	TREANDA.xml:S1:7237:2	42	CD	O	O
(	TREANDA.xml:S1:7240:1	(	(	O	O
28	TREANDA.xml:S1:7241:2	28	CD	O	O
)	TREANDA.xml:S1:7243:1	)	)	O	O
26	TREANDA.xml:S1:7251:2	26	CD	O	O
(	TREANDA.xml:S1:7254:1	(	(	O	O
18	TREANDA.xml:S1:7255:2	18	CD	O	O
)	TREANDA.xml:S1:7257:1	)	)	O	O
4	TREANDA.xml:S1:7266:1	4	CD	O	O
(	TREANDA.xml:S1:7268:1	(	(	O	O
3	TREANDA.xml:S1:7269:1	3	CD	O	O
)	TREANDA.xml:S1:7270:1	)	)	O	O

Lymphocytes	TREANDA.xml:S1:7283:11	lymphocyt	NNS	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:7295:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
102	TREANDA.xml:S1:7312:3	102	CD	O	O
(	TREANDA.xml:S1:7316:1	(	(	O	O
68	TREANDA.xml:S1:7317:2	68	CD	O	O
)	TREANDA.xml:S1:7319:1	)	)	O	O
70	TREANDA.xml:S1:7327:2	70	CD	O	O
(	TREANDA.xml:S1:7330:1	(	(	O	O
47	TREANDA.xml:S1:7331:2	47	CD	O	O
)	TREANDA.xml:S1:7333:1	)	)	O	O
27	TREANDA.xml:S1:7341:2	27	CD	O	O
(	TREANDA.xml:S1:7344:1	(	(	O	O
19	TREANDA.xml:S1:7345:2	19	CD	O	O
)	TREANDA.xml:S1:7347:1	)	)	O	O
6	TREANDA.xml:S1:7356:1	6	CD	O	O
(	TREANDA.xml:S1:7358:1	(	(	O	O
4	TREANDA.xml:S1:7359:1	4	CD	O	O
)	TREANDA.xml:S1:7360:1	)	)	O	O

Neutrophils	TREANDA.xml:S1:7373:11	neutrophil	NNS	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:7385:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
113	TREANDA.xml:S1:7402:3	113	CD	O	O
(	TREANDA.xml:S1:7406:1	(	(	O	O
75	TREANDA.xml:S1:7407:2	75	CD	O	O
)	TREANDA.xml:S1:7409:1	)	)	O	O
65	TREANDA.xml:S1:7417:2	65	CD	O	O
(	TREANDA.xml:S1:7420:1	(	(	O	O
43	TREANDA.xml:S1:7421:2	43	CD	O	O
)	TREANDA.xml:S1:7423:1	)	)	O	O
86	TREANDA.xml:S1:7431:2	86	CD	O	O
(	TREANDA.xml:S1:7434:1	(	(	O	O
61	TREANDA.xml:S1:7435:2	61	CD	O	O
)	TREANDA.xml:S1:7437:1	)	)	O	O
30	TREANDA.xml:S1:7446:2	30	CD	O	O
(	TREANDA.xml:S1:7449:1	(	(	O	O
21	TREANDA.xml:S1:7450:2	21	CD	O	O
)	TREANDA.xml:S1:7452:1	)	)	O	O

In	TREANDA.xml:S1:7472:2	In	IN	O	O
the	TREANDA.xml:S1:7475:3	the	DT	O	O
CLL	TREANDA.xml:S1:7479:3	cll	NNP	O	O
trial	TREANDA.xml:S1:7483:5	trial	NN	O	O
,	TREANDA.xml:S1:7488:1	,	,	O	O
34%	TREANDA.xml:S1:7490:3	34%	CD	O	O
of	TREANDA.xml:S1:7494:2	of	IN	O	O
patients	TREANDA.xml:S1:7497:8	patient	NNS	O	O
had	TREANDA.xml:S1:7506:3	had	VBD	O	O
bilirubin	TREANDA.xml:S1:7510:9	bilirubin	JJ	B-AdverseReaction	B-AdverseReaction
elevations	TREANDA.xml:S1:7520:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:7530:1	,	,	O	O
some	TREANDA.xml:S1:7532:4	some	DT	O	O
without	TREANDA.xml:S1:7537:7	without	IN	O	O
associated	TREANDA.xml:S1:7545:10	associ	VBN	O	O
significant	TREANDA.xml:S1:7556:11	signific	JJ	O	O
elevations	TREANDA.xml:S1:7568:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	TREANDA.xml:S1:7579:2	in	IN	I-AdverseReaction	I-AdverseReaction
AST	TREANDA.xml:S1:7582:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
and	TREANDA.xml:S1:7586:3	and	CC	O	O
ALT	TREANDA.xml:S1:7590:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
.	TREANDA.xml:S1:7593:1	.	.	O	O

Grade	TREANDA.xml:S1:7596:5	grade	VB	O	O
3	TREANDA.xml:S1:7602:1	3	CD	O	O
or	TREANDA.xml:S1:7604:2	or	CC	O	O
4	TREANDA.xml:S1:7607:1	4	CD	O	O
increased	TREANDA.xml:S1:7609:9	increas	JJ	B-AdverseReaction	B-AdverseReaction
bilirubin	TREANDA.xml:S1:7619:9	bilirubin	NN	I-AdverseReaction	I-AdverseReaction
occurred	TREANDA.xml:S1:7629:8	occur	VBD	O	O
in	TREANDA.xml:S1:7638:2	in	IN	O	O
3%	TREANDA.xml:S1:7641:2	3%	CD	O	O
of	TREANDA.xml:S1:7644:2	of	IN	O	O
patients	TREANDA.xml:S1:7647:8	patient	NNS	O	O
.	TREANDA.xml:S1:7655:1	.	.	O	O

Increases	TREANDA.xml:S1:7658:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	TREANDA.xml:S1:7668:2	in	IN	I-AdverseReaction	I-AdverseReaction
AST	TREANDA.xml:S1:7671:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
and	TREANDA.xml:S1:7675:3	and	CC	O	O
ALT	TREANDA.xml:S1:7679:3	alt	NNP	I-AdverseReaction	O
of	TREANDA.xml:S1:7683:2	of	IN	O	O
Grade	TREANDA.xml:S1:7686:5	grade	NNP	O	O
3	TREANDA.xml:S1:7692:1	3	CD	O	O
or	TREANDA.xml:S1:7694:2	or	CC	O	O
4	TREANDA.xml:S1:7697:1	4	CD	O	O
were	TREANDA.xml:S1:7699:4	were	VBD	O	O
limited	TREANDA.xml:S1:7704:7	limit	VBN	O	O
to	TREANDA.xml:S1:7712:2	to	TO	O	O
1%	TREANDA.xml:S1:7715:2	1%	CD	O	O
and	TREANDA.xml:S1:7718:3	and	CC	O	O
3%	TREANDA.xml:S1:7722:2	3%	CD	O	O
of	TREANDA.xml:S1:7725:2	of	IN	O	O
patients	TREANDA.xml:S1:7728:8	patient	NNS	O	O
,	TREANDA.xml:S1:7736:1	,	,	O	O
respectively	TREANDA.xml:S1:7738:12	respect	RB	O	O
.	TREANDA.xml:S1:7750:1	.	.	O	O

Patients	TREANDA.xml:S1:7753:8	patient	NNS	O	O
treated	TREANDA.xml:S1:7762:7	treat	VBN	O	O
with	TREANDA.xml:S1:7770:4	with	IN	O	O
TREANDA	TREANDA.xml:S1:7775:7	treanda	NNP	O	O
may	TREANDA.xml:S1:7783:3	may	MD	O	O
also	TREANDA.xml:S1:7787:4	also	RB	O	O
have	TREANDA.xml:S1:7792:4	have	VB	O	O
changes	TREANDA.xml:S1:7797:7	chang	NNS	B-AdverseReaction	O
in	TREANDA.xml:S1:7805:2	in	IN	I-AdverseReaction	O
their	TREANDA.xml:S1:7808:5	their	PRP$	O	O
creatinine	TREANDA.xml:S1:7814:10	creatinin	NN	I-AdverseReaction	O
levels	TREANDA.xml:S1:7825:6	level	NNS	I-AdverseReaction	O
.	TREANDA.xml:S1:7831:1	.	.	O	O

If	TREANDA.xml:S1:7833:2	If	IN	O	O
abnormalities	TREANDA.xml:S1:7836:13	abnorm	NNS	O	O
are	TREANDA.xml:S1:7850:3	are	VBP	O	O
detected	TREANDA.xml:S1:7854:8	detect	VBN	O	O
,	TREANDA.xml:S1:7862:1	,	,	O	O
monitoring	TREANDA.xml:S1:7864:10	monitor	NN	O	O
of	TREANDA.xml:S1:7875:2	of	IN	O	O
these	TREANDA.xml:S1:7878:5	these	DT	O	O
parameters	TREANDA.xml:S1:7884:10	paramet	NNS	O	O
should	TREANDA.xml:S1:7895:6	should	MD	O	O
be	TREANDA.xml:S1:7902:2	be	VB	O	O
continued	TREANDA.xml:S1:7905:9	continu	VBN	O	O
to	TREANDA.xml:S1:7915:2	to	TO	O	O
ensure	TREANDA.xml:S1:7918:6	ensur	VB	O	O
that	TREANDA.xml:S1:7925:4	that	IN	O	O
further	TREANDA.xml:S1:7930:7	further	JJ	O	O
deterioration	TREANDA.xml:S1:7938:13	deterior	NN	O	O
does	TREANDA.xml:S1:7952:4	doe	VBZ	O	O
not	TREANDA.xml:S1:7957:3	not	RB	O	O
occur	TREANDA.xml:S1:7961:5	occur	VB	O	O
.	TREANDA.xml:S1:7966:1	.	.	O	O

Non	TREANDA.xml:S1:7974:3	non	NN	O	O

-	TREANDA.xml:S1:7977:1	-	:	O	O
Hodgkin	TREANDA.xml:S1:7978:7	hodgkin	NN	O	O
Lymphoma	TREANDA.xml:S1:7986:8	lymphoma	NNP	O	O

The	TREANDA.xml:S1:8001:3	the	DT	O	O
data	TREANDA.xml:S1:8005:4	data	NNS	O	O
described	TREANDA.xml:S1:8010:9	describ	VBD	O	O
below	TREANDA.xml:S1:8020:5	below	IN	O	O
reflect	TREANDA.xml:S1:8026:7	reflect	NN	O	O
exposure	TREANDA.xml:S1:8034:8	exposur	NN	O	O
to	TREANDA.xml:S1:8043:2	to	TO	O	O
TREANDA	TREANDA.xml:S1:8046:7	treanda	NNP	O	O
in	TREANDA.xml:S1:8054:2	in	IN	O	O
176	TREANDA.xml:S1:8057:3	176	CD	O	O
patients	TREANDA.xml:S1:8061:8	patient	NNS	O	O
with	TREANDA.xml:S1:8070:4	with	IN	O	O
indolent	TREANDA.xml:S1:8075:8	indol	NN	O	O
B	TREANDA.xml:S1:8084:1	B	NNP	O	O
-	TREANDA.xml:S1:8085:1	-	:	O	O
cell	TREANDA.xml:S1:8086:4	cell	NN	O	O
NHL	TREANDA.xml:S1:8091:3	nhl	NNP	O	O
treated	TREANDA.xml:S1:8095:7	treat	VBN	O	O
in	TREANDA.xml:S1:8103:2	in	IN	O	O
two	TREANDA.xml:S1:8106:3	two	CD	O	O
single	TREANDA.xml:S1:8110:6	singl	JJ	O	O
-	TREANDA.xml:S1:8116:1	-	:	O	O
arm	TREANDA.xml:S1:8117:3	arm	NN	O	O
studies	TREANDA.xml:S1:8121:7	studi	NNS	O	O
.	TREANDA.xml:S1:8128:1	.	.	O	O

The	TREANDA.xml:S1:8131:3	the	DT	O	O
population	TREANDA.xml:S1:8135:10	popul	NN	O	O
was	TREANDA.xml:S1:8146:3	wa	VBD	O	O
31	TREANDA.xml:S1:8150:2	31	CD	O	O
-	TREANDA.xml:S1:8152:1	-	:	O	O
84	TREANDA.xml:S1:8153:2	84	CD	O	O
years	TREANDA.xml:S1:8156:5	year	NNS	O	O
of	TREANDA.xml:S1:8162:2	of	IN	O	O
age	TREANDA.xml:S1:8165:3	age	NN	O	O
,	TREANDA.xml:S1:8168:1	,	,	O	O
60%	TREANDA.xml:S1:8170:3	60%	CD	O	O
male	TREANDA.xml:S1:8174:4	male	NN	O	O
,	TREANDA.xml:S1:8178:1	,	,	O	O
and	TREANDA.xml:S1:8180:3	and	CC	O	O
40%	TREANDA.xml:S1:8184:3	40%	CD	O	O
female	TREANDA.xml:S1:8188:6	femal	NN	O	O
.	TREANDA.xml:S1:8194:1	.	.	O	O

The	TREANDA.xml:S1:8197:3	the	DT	O	O
race	TREANDA.xml:S1:8201:4	race	NN	O	O
distribution	TREANDA.xml:S1:8206:12	distribut	NN	O	O
was	TREANDA.xml:S1:8219:3	wa	VBD	O	O
89%	TREANDA.xml:S1:8223:3	89%	CD	O	O
White	TREANDA.xml:S1:8227:5	white	NNP	O	O
,	TREANDA.xml:S1:8232:1	,	,	O	O
7%	TREANDA.xml:S1:8234:2	7%	CD	O	O
Black	TREANDA.xml:S1:8237:5	black	NNP	O	O
,	TREANDA.xml:S1:8242:1	,	,	O	O
3%	TREANDA.xml:S1:8244:2	3%	CD	O	O
Hispanic	TREANDA.xml:S1:8247:8	hispan	NNP	O	O
,	TREANDA.xml:S1:8255:1	,	,	O	O
1%	TREANDA.xml:S1:8257:2	1%	CD	O	O
other	TREANDA.xml:S1:8260:5	other	JJ	O	O
,	TREANDA.xml:S1:8265:1	,	,	O	O
and	TREANDA.xml:S1:8267:3	and	CC	O	O
1%	TREANDA.xml:S1:8272:2	1%	CD	O	O
Asian	TREANDA.xml:S1:8275:5	asian	JJ	O	O
.	TREANDA.xml:S1:8280:1	.	.	O	O

These	TREANDA.xml:S1:8282:5	these	DT	O	O
patients	TREANDA.xml:S1:8288:8	patient	NNS	O	O
received	TREANDA.xml:S1:8297:8	receiv	VBD	O	O
TREANDA	TREANDA.xml:S1:8306:7	treanda	NNP	O	O
at	TREANDA.xml:S1:8314:2	at	IN	O	O
a	TREANDA.xml:S1:8317:1	a	DT	O	O
dose	TREANDA.xml:S1:8319:4	dose	NN	O	O
of	TREANDA.xml:S1:8324:2	of	IN	O	O
120	TREANDA.xml:S1:8327:3	120	CD	O	O
mg	TREANDA.xml:S1:8331:2	mg	NNS	O	O
m	TREANDA.xml:S1:8334:1	m	RB	O	O
2	TREANDA.xml:S1:8337:1	2	CD	O	O
intravenously	TREANDA.xml:S1:8340:13	intraven	RB	O	O
on	TREANDA.xml:S1:8354:2	on	IN	O	O
Days	TREANDA.xml:S1:8357:4	day	NNS	O	O
1	TREANDA.xml:S1:8362:1	1	CD	O	O
and	TREANDA.xml:S1:8364:3	and	CC	O	O
2	TREANDA.xml:S1:8368:1	2	CD	O	O
for	TREANDA.xml:S1:8370:3	for	IN	O	O
up	TREANDA.xml:S1:8374:2	up	RB	O	O
to	TREANDA.xml:S1:8377:2	to	TO	O	O
eight	TREANDA.xml:S1:8380:5	eight	CD	O	O
21	TREANDA.xml:S1:8386:2	21	CD	O	O
-	TREANDA.xml:S1:8388:1	-	:	O	O
day	TREANDA.xml:S1:8389:3	day	NN	O	O
cycles	TREANDA.xml:S1:8393:6	cycl	NNS	O	O
.	TREANDA.xml:S1:8399:1	.	.	O	O

The	TREANDA.xml:S1:8405:3	the	DT	O	O
adverse	TREANDA.xml:S1:8409:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:8417:9	reaction	NNS	O	O
occurring	TREANDA.xml:S1:8427:9	occur	VBG	O	O
in	TREANDA.xml:S1:8437:2	in	IN	O	O
at	TREANDA.xml:S1:8440:2	at	IN	O	O
least	TREANDA.xml:S1:8443:5	least	JJS	O	O
5%	TREANDA.xml:S1:8449:2	5%	CD	O	O
of	TREANDA.xml:S1:8452:2	of	IN	O	O
the	TREANDA.xml:S1:8455:3	the	DT	O	O
NHL	TREANDA.xml:S1:8459:3	nhl	NNP	O	O
patients	TREANDA.xml:S1:8463:8	patient	NNS	O	O
,	TREANDA.xml:S1:8471:1	,	,	O	O
regardless	TREANDA.xml:S1:8473:10	regardless	RB	O	O
of	TREANDA.xml:S1:8484:2	of	IN	O	O
severity	TREANDA.xml:S1:8487:8	sever	NN	O	O
,	TREANDA.xml:S1:8495:1	,	,	O	O
are	TREANDA.xml:S1:8497:3	are	VBP	O	O
shown	TREANDA.xml:S1:8501:5	shown	VBN	O	O
in	TREANDA.xml:S1:8507:2	in	IN	O	O
Table	TREANDA.xml:S1:8510:5	tabl	JJ	O	O
3	TREANDA.xml:S1:8516:1	3	CD	O	O
.	TREANDA.xml:S1:8517:1	.	.	O	O

The	TREANDA.xml:S1:8519:3	the	DT	O	O
most	TREANDA.xml:S1:8523:4	most	RBS	O	O
common	TREANDA.xml:S1:8528:6	common	JJ	O	O
non	TREANDA.xml:S1:8535:3	non	JJ	O	O
-	TREANDA.xml:S1:8538:1	-	:	O	O
hematologic	TREANDA.xml:S1:8539:11	hematolog	JJ	O	O
adverse	TREANDA.xml:S1:8551:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:8559:9	reaction	NNS	O	O
(	TREANDA.xml:S1:8569:1	(	(	O	O
30%	TREANDA.xml:S1:8572:3	30%	CD	O	O
)	TREANDA.xml:S1:8575:1	)	)	O	O
were	TREANDA.xml:S1:8577:4	were	VBD	O	O
nausea	TREANDA.xml:S1:8582:6	nausea	JJ	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:8589:1	(	(	O	O
75%	TREANDA.xml:S1:8590:3	75%	CD	O	O
)	TREANDA.xml:S1:8593:1	)	)	O	O
,	TREANDA.xml:S1:8594:1	,	,	O	O
fatigue	TREANDA.xml:S1:8596:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:8604:1	(	(	O	O
57%	TREANDA.xml:S1:8605:3	57%	CD	O	O
)	TREANDA.xml:S1:8608:1	)	)	O	O
,	TREANDA.xml:S1:8609:1	,	,	O	O
vomiting	TREANDA.xml:S1:8611:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:8620:1	(	(	O	O
40%	TREANDA.xml:S1:8621:3	40%	CD	O	O
)	TREANDA.xml:S1:8624:1	)	)	O	O
,	TREANDA.xml:S1:8625:1	,	,	O	O
diarrhea	TREANDA.xml:S1:8627:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:8636:1	(	(	O	O
37%	TREANDA.xml:S1:8637:3	37%	CD	O	O
)	TREANDA.xml:S1:8640:1	)	)	O	O
and	TREANDA.xml:S1:8642:3	and	CC	O	O
pyrexia	TREANDA.xml:S1:8646:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:8654:1	(	(	O	O
34%	TREANDA.xml:S1:8655:3	34%	CD	O	O
)	TREANDA.xml:S1:8658:1	)	)	O	O
.	TREANDA.xml:S1:8659:1	.	.	O	O

The	TREANDA.xml:S1:8662:3	the	DT	O	O
most	TREANDA.xml:S1:8666:4	most	RBS	O	O
common	TREANDA.xml:S1:8671:6	common	JJ	O	O
non	TREANDA.xml:S1:8678:3	non	JJ	O	O
-	TREANDA.xml:S1:8681:1	-	:	O	O
hematologic	TREANDA.xml:S1:8682:11	hematolog	NN	O	O
Grade	TREANDA.xml:S1:8694:5	grade	VBD	O	O
3	TREANDA.xml:S1:8700:1	3	CD	O	O
or	TREANDA.xml:S1:8702:2	or	CC	O	O
4	TREANDA.xml:S1:8705:1	4	CD	O	O
adverse	TREANDA.xml:S1:8707:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:8715:9	reaction	NNS	O	O
(	TREANDA.xml:S1:8725:1	(	(	O	O
5%	TREANDA.xml:S1:8728:2	5%	CD	O	O
)	TREANDA.xml:S1:8730:1	)	)	O	O
were	TREANDA.xml:S1:8732:4	were	VBD	O	O
fatigue	TREANDA.xml:S1:8737:7	fatigu	JJ	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:8745:1	(	(	O	O
11%	TREANDA.xml:S1:8746:3	11%	CD	O	O
)	TREANDA.xml:S1:8749:1	)	)	O	O
,	TREANDA.xml:S1:8750:1	,	,	O	O
febrile	TREANDA.xml:S1:8752:7	febril	JJ	B-AdverseReaction	B-AdverseReaction
neutropenia	TREANDA.xml:S1:8760:11	neutropenia	NN	I-AdverseReaction	I-AdverseReaction
(	TREANDA.xml:S1:8772:1	(	(	O	O
6%	TREANDA.xml:S1:8773:2	6%	CD	O	O
)	TREANDA.xml:S1:8775:1	)	)	O	O
,	TREANDA.xml:S1:8776:1	,	,	O	O
and	TREANDA.xml:S1:8778:3	and	CC	O	O
pneumonia	TREANDA.xml:S1:8782:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:8791:1	,	,	O	O
hypokalemia	TREANDA.xml:S1:8793:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
and	TREANDA.xml:S1:8805:3	and	CC	O	O
dehydration	TREANDA.xml:S1:8809:11	dehydr	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:8820:1	,	,	O	O
each	TREANDA.xml:S1:8822:4	each	DT	O	O
reported	TREANDA.xml:S1:8827:8	report	VBN	O	O
in	TREANDA.xml:S1:8836:2	in	IN	O	O
5%	TREANDA.xml:S1:8839:2	5%	CD	O	O
of	TREANDA.xml:S1:8842:2	of	IN	O	O
patients	TREANDA.xml:S1:8845:8	patient	NNS	O	O
.	TREANDA.xml:S1:8853:1	.	.	O	O

Table	TREANDA.xml:S1:8859:5	tabl	JJ	O	O
3	TREANDA.xml:S1:8865:1	3	CD	O	O
:	TREANDA.xml:S1:8866:1	:	:	O	O
Non	TREANDA.xml:S1:8868:3	non	NNP	O	O
-	TREANDA.xml:S1:8871:1	-	:	O	O
Hematologic	TREANDA.xml:S1:8872:11	hematolog	NNP	O	O
Adverse	TREANDA.xml:S1:8884:7	advers	NNP	O	O
Reactions	TREANDA.xml:S1:8892:9	reaction	NNP	O	O
Occurring	TREANDA.xml:S1:8902:9	occur	NNP	O	O
in	TREANDA.xml:S1:8912:2	in	IN	O	O
at	TREANDA.xml:S1:8915:2	at	IN	O	O
Least	TREANDA.xml:S1:8918:5	least	NNP	O	O
5%	TREANDA.xml:S1:8924:2	5%	CD	O	O
of	TREANDA.xml:S1:8927:2	of	IN	O	O
NHL	TREANDA.xml:S1:8930:3	nhl	NNP	O	O
Patients	TREANDA.xml:S1:8934:8	patient	NNP	O	O
Treated	TREANDA.xml:S1:8943:7	treat	NNP	O	O
with	TREANDA.xml:S1:8951:4	with	IN	O	O
TREANDA	TREANDA.xml:S1:8956:7	treanda	NNP	O	O
by	TREANDA.xml:S1:8964:2	by	IN	O	O
System	TREANDA.xml:S1:8967:6	system	NNP	O	O
Organ	TREANDA.xml:S1:8974:5	organ	NNP	O	O
Class	TREANDA.xml:S1:8980:5	class	NNP	O	O
and	TREANDA.xml:S1:8986:3	and	CC	O	O
Preferred	TREANDA.xml:S1:8990:9	prefer	NNP	O	O
Term	TREANDA.xml:S1:9000:4	term	NNP	O	O
(	TREANDA.xml:S1:9005:1	(	(	O	O
N	TREANDA.xml:S1:9006:1	N	NNP	O	O
176	TREANDA.xml:S1:9008:3	176	CD	O	O
)	TREANDA.xml:S1:9011:1	)	)	O	O

System	TREANDA.xml:S1:9016:6	system	NNP	O	O
organ	TREANDA.xml:S1:9023:5	organ	JJ	O	O
class	TREANDA.xml:S1:9029:5	class	NN	O	O
Number	TREANDA.xml:S1:9086:6	number	NNP	O	O
(	TREANDA.xml:S1:9093:1	(	(	O	O
)	TREANDA.xml:S1:9095:1	)	)	O	O
of	TREANDA.xml:S1:9097:2	of	IN	O	O
patients	TREANDA.xml:S1:9100:8	patient	NNS	O	O

Preferred	TREANDA.xml:S1:9120:9	prefer	JJ	O	O
term	TREANDA.xml:S1:9130:4	term	NN	O	O
All	TREANDA.xml:S1:9186:3	all	NNP	O	O
Grades	TREANDA.xml:S1:9190:6	grade	NNP	O	O
Grade	TREANDA.xml:S1:9204:5	grade	NNP	O	O
3	TREANDA.xml:S1:9210:1	3	CD	O	O
4	TREANDA.xml:S1:9212:1	4	CD	O	O

Total	TREANDA.xml:S1:9224:5	total	JJ	O	O
number	TREANDA.xml:S1:9230:6	number	NN	O	O
of	TREANDA.xml:S1:9237:2	of	IN	O	O
patients	TREANDA.xml:S1:9240:8	patient	NNS	O	O
with	TREANDA.xml:S1:9249:4	with	IN	O	O
at	TREANDA.xml:S1:9254:2	at	IN	O	O
least	TREANDA.xml:S1:9257:5	least	JJS	O	O
1	TREANDA.xml:S1:9263:1	1	CD	O	O
adverse	TREANDA.xml:S1:9265:7	advers	JJ	O	O
reaction	TREANDA.xml:S1:9273:8	reaction	NN	O	O
176	TREANDA.xml:S1:9294:3	176	CD	O	O
(	TREANDA.xml:S1:9298:1	(	(	O	O
100	TREANDA.xml:S1:9299:3	100	CD	O	O
)	TREANDA.xml:S1:9302:1	)	)	O	O
94	TREANDA.xml:S1:9312:2	94	CD	O	O
(	TREANDA.xml:S1:9315:1	(	(	O	O
53	TREANDA.xml:S1:9316:2	53	CD	O	O
)	TREANDA.xml:S1:9318:1	)	)	O	O

Cardiac	TREANDA.xml:S1:9332:7	cardiac	JJ	O	O
disorders	TREANDA.xml:S1:9340:9	disord	NNS	O	O

Tachycardia	TREANDA.xml:S1:9409:11	tachycardia	NNP	B-AdverseReaction	B-AdverseReaction
13	TREANDA.xml:S1:9475:2	13	CD	O	O
(	TREANDA.xml:S1:9478:1	(	(	O	O
7	TREANDA.xml:S1:9479:1	7	CD	O	O
)	TREANDA.xml:S1:9480:1	)	)	O	O
0	TREANDA.xml:S1:9493:1	0	CD	O	O

Gastrointestinal	TREANDA.xml:S1:9513:16	gastrointestin	JJ	O	O
disorders	TREANDA.xml:S1:9530:9	disord	NNS	O	O

Nausea	TREANDA.xml:S1:9590:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
132	TREANDA.xml:S1:9656:3	132	CD	O	O
(	TREANDA.xml:S1:9660:1	(	(	O	O
75	TREANDA.xml:S1:9661:2	75	CD	O	O
)	TREANDA.xml:S1:9663:1	)	)	O	O
7	TREANDA.xml:S1:9674:1	7	CD	O	O
(	TREANDA.xml:S1:9676:1	(	(	O	O
4	TREANDA.xml:S1:9677:1	4	CD	O	O
)	TREANDA.xml:S1:9678:1	)	)	O	O

Vomiting	TREANDA.xml:S1:9698:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
71	TREANDA.xml:S1:9764:2	71	CD	O	O
(	TREANDA.xml:S1:9767:1	(	(	O	O
40	TREANDA.xml:S1:9768:2	40	CD	O	O
)	TREANDA.xml:S1:9770:1	)	)	O	O
5	TREANDA.xml:S1:9782:1	5	CD	O	O
(	TREANDA.xml:S1:9784:1	(	(	O	O
3	TREANDA.xml:S1:9785:1	3	CD	O	O
)	TREANDA.xml:S1:9786:1	)	)	O	O

Diarrhea	TREANDA.xml:S1:9806:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
65	TREANDA.xml:S1:9872:2	65	CD	O	O
(	TREANDA.xml:S1:9875:1	(	(	O	O
37	TREANDA.xml:S1:9876:2	37	CD	O	O
)	TREANDA.xml:S1:9878:1	)	)	O	O
6	TREANDA.xml:S1:9890:1	6	CD	O	O
(	TREANDA.xml:S1:9892:1	(	(	O	O
3	TREANDA.xml:S1:9893:1	3	CD	O	O
)	TREANDA.xml:S1:9894:1	)	)	O	O

Constipation	TREANDA.xml:S1:9914:12	constip	NN	B-AdverseReaction	B-AdverseReaction
51	TREANDA.xml:S1:9980:2	51	CD	O	O
(	TREANDA.xml:S1:9983:1	(	(	O	O
29	TREANDA.xml:S1:9984:2	29	CD	O	O
)	TREANDA.xml:S1:9986:1	)	)	O	O
1	TREANDA.xml:S1:9998:1	1	CD	O	O
(	TREANDA.xml:S1:10000:1	(	(	O	O
1	TREANDA.xml:S1:10002:1	1	CD	O	O
)	TREANDA.xml:S1:10003:1	)	)	O	O

Stomatitis	TREANDA.xml:S1:10022:10	stomat	NN	B-AdverseReaction	B-AdverseReaction
27	TREANDA.xml:S1:10088:2	27	CD	O	O
(	TREANDA.xml:S1:10091:1	(	(	O	O
15	TREANDA.xml:S1:10092:2	15	CD	O	O
)	TREANDA.xml:S1:10094:1	)	)	O	O
1	TREANDA.xml:S1:10106:1	1	CD	O	O
(	TREANDA.xml:S1:10108:1	(	(	O	O
1	TREANDA.xml:S1:10110:1	1	CD	O	O
)	TREANDA.xml:S1:10111:1	)	)	O	O

Abdominal	TREANDA.xml:S1:10130:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	TREANDA.xml:S1:10140:4	pain	NN	I-AdverseReaction	I-AdverseReaction
22	TREANDA.xml:S1:10196:2	22	CD	O	O
(	TREANDA.xml:S1:10199:1	(	(	O	O
13	TREANDA.xml:S1:10200:2	13	CD	O	O
)	TREANDA.xml:S1:10202:1	)	)	O	O
2	TREANDA.xml:S1:10214:1	2	CD	O	O
(	TREANDA.xml:S1:10216:1	(	(	O	O
1	TREANDA.xml:S1:10217:1	1	CD	O	O
)	TREANDA.xml:S1:10218:1	)	)	O	O

Dyspepsia	TREANDA.xml:S1:10238:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
20	TREANDA.xml:S1:10304:2	20	CD	O	O
(	TREANDA.xml:S1:10307:1	(	(	O	O
11	TREANDA.xml:S1:10308:2	11	CD	O	O
)	TREANDA.xml:S1:10310:1	)	)	O	O
0	TREANDA.xml:S1:10322:1	0	CD	O	O

Gastroesophageal	TREANDA.xml:S1:10346:16	gastroesophag	NNP	B-AdverseReaction	B-AdverseReaction
reflux	TREANDA.xml:S1:10363:6	reflux	VBZ	I-AdverseReaction	I-AdverseReaction
disease	TREANDA.xml:S1:10370:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
18	TREANDA.xml:S1:10412:2	18	CD	O	O
(	TREANDA.xml:S1:10415:1	(	(	O	O
10	TREANDA.xml:S1:10416:2	10	CD	O	O
)	TREANDA.xml:S1:10418:1	)	)	O	O
0	TREANDA.xml:S1:10430:1	0	CD	O	O

Dry	TREANDA.xml:S1:10454:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
mouth	TREANDA.xml:S1:10458:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
15	TREANDA.xml:S1:10520:2	15	CD	O	O
(	TREANDA.xml:S1:10523:1	(	(	O	O
9	TREANDA.xml:S1:10524:1	9	CD	O	O
)	TREANDA.xml:S1:10525:1	)	)	O	O
1	TREANDA.xml:S1:10538:1	1	CD	O	O
(	TREANDA.xml:S1:10540:1	(	(	O	O
1	TREANDA.xml:S1:10542:1	1	CD	O	O
)	TREANDA.xml:S1:10543:1	)	)	O	O

Abdominal	TREANDA.xml:S1:10562:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	TREANDA.xml:S1:10572:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	TREANDA.xml:S1:10577:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
8	TREANDA.xml:S1:10628:1	8	CD	O	O
(	TREANDA.xml:S1:10630:1	(	(	O	O
5	TREANDA.xml:S1:10631:1	5	CD	O	O
)	TREANDA.xml:S1:10632:1	)	)	O	O
0	TREANDA.xml:S1:10646:1	0	CD	O	O

Abdominal	TREANDA.xml:S1:10670:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
distension	TREANDA.xml:S1:10680:10	distens	NN	I-AdverseReaction	I-AdverseReaction
8	TREANDA.xml:S1:10736:1	8	CD	O	O
(	TREANDA.xml:S1:10738:1	(	(	O	O
5	TREANDA.xml:S1:10739:1	5	CD	O	O
)	TREANDA.xml:S1:10740:1	)	)	O	O
0	TREANDA.xml:S1:10754:1	0	CD	O	O

General	TREANDA.xml:S1:10774:7	gener	NNP	O	O
disorders	TREANDA.xml:S1:10782:9	disord	NNS	O	O
and	TREANDA.xml:S1:10792:3	and	CC	O	O
administration	TREANDA.xml:S1:10796:14	administr	NN	O	O
site	TREANDA.xml:S1:10811:4	site	NN	O	O
conditions	TREANDA.xml:S1:10816:10	condit	NNS	O	O

Fatigue	TREANDA.xml:S1:10851:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
101	TREANDA.xml:S1:10917:3	101	CD	O	O
(	TREANDA.xml:S1:10921:1	(	(	O	O
57	TREANDA.xml:S1:10922:2	57	CD	O	O
)	TREANDA.xml:S1:10924:1	)	)	O	O
19	TREANDA.xml:S1:10935:2	19	CD	O	O
(	TREANDA.xml:S1:10938:1	(	(	O	O
11	TREANDA.xml:S1:10939:2	11	CD	O	O
)	TREANDA.xml:S1:10941:1	)	)	O	O

Pyrexia	TREANDA.xml:S1:10959:7	pyrexia	$	B-AdverseReaction	B-AdverseReaction
59	TREANDA.xml:S1:11025:2	59	CD	O	O
(	TREANDA.xml:S1:11028:1	(	(	O	O
34	TREANDA.xml:S1:11029:2	34	CD	O	O
)	TREANDA.xml:S1:11031:1	)	)	O	O
3	TREANDA.xml:S1:11043:1	3	CD	O	O
(	TREANDA.xml:S1:11045:1	(	(	O	O
2	TREANDA.xml:S1:11046:1	2	CD	O	O
)	TREANDA.xml:S1:11047:1	)	)	O	O

Chills	TREANDA.xml:S1:11067:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
24	TREANDA.xml:S1:11133:2	24	CD	O	O
(	TREANDA.xml:S1:11136:1	(	(	O	O
14	TREANDA.xml:S1:11137:2	14	CD	O	O
)	TREANDA.xml:S1:11139:1	)	)	O	O
0	TREANDA.xml:S1:11151:1	0	CD	O	O

Edema	TREANDA.xml:S1:11175:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
peripheral	TREANDA.xml:S1:11181:10	peripher	JJ	I-AdverseReaction	I-AdverseReaction
23	TREANDA.xml:S1:11241:2	23	CD	O	O
(	TREANDA.xml:S1:11244:1	(	(	O	O
13	TREANDA.xml:S1:11245:2	13	CD	O	O
)	TREANDA.xml:S1:11247:1	)	)	O	O
1	TREANDA.xml:S1:11259:1	1	CD	O	O
(	TREANDA.xml:S1:11261:1	(	(	O	O
1	TREANDA.xml:S1:11263:1	1	CD	O	O
)	TREANDA.xml:S1:11264:1	)	)	O	O

Asthenia	TREANDA.xml:S1:11283:8	asthenia	NNP	B-AdverseReaction	B-AdverseReaction
19	TREANDA.xml:S1:11349:2	19	CD	O	O
(	TREANDA.xml:S1:11352:1	(	(	O	O
11	TREANDA.xml:S1:11353:2	11	CD	O	O
)	TREANDA.xml:S1:11355:1	)	)	O	O
4	TREANDA.xml:S1:11367:1	4	CD	O	O
(	TREANDA.xml:S1:11369:1	(	(	O	O
2	TREANDA.xml:S1:11370:1	2	CD	O	O
)	TREANDA.xml:S1:11371:1	)	)	O	O

Chest	TREANDA.xml:S1:11391:5	chest	NNP	B-AdverseReaction	B-AdverseReaction
pain	TREANDA.xml:S1:11397:4	pain	NN	I-AdverseReaction	I-AdverseReaction
11	TREANDA.xml:S1:11457:2	11	CD	O	O
(	TREANDA.xml:S1:11460:1	(	(	O	O
6	TREANDA.xml:S1:11461:1	6	CD	O	O
)	TREANDA.xml:S1:11462:1	)	)	O	O
1	TREANDA.xml:S1:11475:1	1	CD	O	O
(	TREANDA.xml:S1:11477:1	(	(	O	O
1	TREANDA.xml:S1:11479:1	1	CD	O	O
)	TREANDA.xml:S1:11480:1	)	)	O	O

Infusion	TREANDA.xml:S1:11499:8	infus	NNP	B-AdverseReaction	B-AdverseReaction
site	TREANDA.xml:S1:11508:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	TREANDA.xml:S1:11513:4	pain	NN	I-AdverseReaction	I-AdverseReaction
11	TREANDA.xml:S1:11565:2	11	CD	O	O
(	TREANDA.xml:S1:11568:1	(	(	O	O
6	TREANDA.xml:S1:11569:1	6	CD	O	O
)	TREANDA.xml:S1:11570:1	)	)	O	O
0	TREANDA.xml:S1:11583:1	0	CD	O	O

Pain	TREANDA.xml:S1:11607:4	pain	NN	B-AdverseReaction	B-AdverseReaction
10	TREANDA.xml:S1:11673:2	10	CD	O	O
(	TREANDA.xml:S1:11676:1	(	(	O	O
6	TREANDA.xml:S1:11677:1	6	CD	O	O
)	TREANDA.xml:S1:11678:1	)	)	O	O
0	TREANDA.xml:S1:11691:1	0	CD	O	O

Catheter	TREANDA.xml:S1:11715:8	cathet	NNP	B-AdverseReaction	B-AdverseReaction
site	TREANDA.xml:S1:11724:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	TREANDA.xml:S1:11729:4	pain	NN	I-AdverseReaction	I-AdverseReaction
8	TREANDA.xml:S1:11781:1	8	CD	O	O
(	TREANDA.xml:S1:11783:1	(	(	O	O
5	TREANDA.xml:S1:11784:1	5	CD	O	O
)	TREANDA.xml:S1:11785:1	)	)	O	O
0	TREANDA.xml:S1:11799:1	0	CD	O	O

Infections	TREANDA.xml:S1:11819:10	infect	NNS	O	O
and	TREANDA.xml:S1:11830:3	and	CC	O	O
infestations	TREANDA.xml:S1:11834:12	infest	NNS	O	O

Herpes	TREANDA.xml:S1:11896:6	herp	NNP	B-AdverseReaction	B-AdverseReaction
zoster	TREANDA.xml:S1:11903:6	zoster	NN	I-AdverseReaction	I-AdverseReaction
18	TREANDA.xml:S1:11962:2	18	CD	O	O
(	TREANDA.xml:S1:11965:1	(	(	O	O
10	TREANDA.xml:S1:11966:2	10	CD	O	O
)	TREANDA.xml:S1:11968:1	)	)	O	O
5	TREANDA.xml:S1:11980:1	5	CD	O	O
(	TREANDA.xml:S1:11982:1	(	(	O	O
3	TREANDA.xml:S1:11983:1	3	CD	O	O
)	TREANDA.xml:S1:11984:1	)	)	O	O

Upper	TREANDA.xml:S1:12004:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	TREANDA.xml:S1:12010:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	TREANDA.xml:S1:12022:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	TREANDA.xml:S1:12028:9	infect	NN	I-AdverseReaction	I-AdverseReaction
18	TREANDA.xml:S1:12070:2	18	CD	O	O
(	TREANDA.xml:S1:12073:1	(	(	O	O
10	TREANDA.xml:S1:12074:2	10	CD	O	O
)	TREANDA.xml:S1:12076:1	)	)	O	O
0	TREANDA.xml:S1:12088:1	0	CD	O	O

Urinary	TREANDA.xml:S1:12112:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	TREANDA.xml:S1:12120:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	TREANDA.xml:S1:12126:9	infect	NN	I-AdverseReaction	I-AdverseReaction
17	TREANDA.xml:S1:12178:2	17	CD	O	O
(	TREANDA.xml:S1:12181:1	(	(	O	O
10	TREANDA.xml:S1:12182:2	10	CD	O	O
)	TREANDA.xml:S1:12184:1	)	)	O	O
4	TREANDA.xml:S1:12196:1	4	CD	O	O
(	TREANDA.xml:S1:12198:1	(	(	O	O
2	TREANDA.xml:S1:12199:1	2	CD	O	O
)	TREANDA.xml:S1:12200:1	)	)	O	O

Sinusitis	TREANDA.xml:S1:12220:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
15	TREANDA.xml:S1:12286:2	15	CD	O	O
(	TREANDA.xml:S1:12289:1	(	(	O	O
9	TREANDA.xml:S1:12290:1	9	CD	O	O
)	TREANDA.xml:S1:12291:1	)	)	O	O
0	TREANDA.xml:S1:12304:1	0	CD	O	O

Pneumonia	TREANDA.xml:S1:12328:9	pneumonia	NNP	B-AdverseReaction	B-AdverseReaction
14	TREANDA.xml:S1:12394:2	14	CD	O	O
(	TREANDA.xml:S1:12397:1	(	(	O	O
8	TREANDA.xml:S1:12398:1	8	CD	O	O
)	TREANDA.xml:S1:12399:1	)	)	O	O
9	TREANDA.xml:S1:12412:1	9	CD	O	O
(	TREANDA.xml:S1:12414:1	(	(	O	O
5	TREANDA.xml:S1:12415:1	5	CD	O	O
)	TREANDA.xml:S1:12416:1	)	)	O	O

Febrile	TREANDA.xml:S1:12436:7	febril	NNP	B-AdverseReaction	B-AdverseReaction
neutropenia	TREANDA.xml:S1:12444:11	neutropenia	CC	I-AdverseReaction	I-AdverseReaction
11	TREANDA.xml:S1:12502:2	11	CD	O	O
(	TREANDA.xml:S1:12505:1	(	(	O	O
6	TREANDA.xml:S1:12506:1	6	CD	O	O
)	TREANDA.xml:S1:12507:1	)	)	O	O
11	TREANDA.xml:S1:12520:2	11	CD	O	O
(	TREANDA.xml:S1:12523:1	(	(	O	O
6	TREANDA.xml:S1:12524:1	6	CD	O	O
)	TREANDA.xml:S1:12525:1	)	)	O	O

Oral	TREANDA.xml:S1:12544:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
candidiasis	TREANDA.xml:S1:12549:11	candidiasi	NN	I-AdverseReaction	I-AdverseReaction
11	TREANDA.xml:S1:12610:2	11	CD	O	O
(	TREANDA.xml:S1:12613:1	(	(	O	O
6	TREANDA.xml:S1:12614:1	6	CD	O	O
)	TREANDA.xml:S1:12615:1	)	)	O	O
2	TREANDA.xml:S1:12628:1	2	CD	O	O
(	TREANDA.xml:S1:12630:1	(	(	O	O
1	TREANDA.xml:S1:12631:1	1	CD	O	O
)	TREANDA.xml:S1:12632:1	)	)	O	O

Nasopharyngitis	TREANDA.xml:S1:12652:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
11	TREANDA.xml:S1:12718:2	11	CD	O	O
(	TREANDA.xml:S1:12721:1	(	(	O	O
6	TREANDA.xml:S1:12722:1	6	CD	O	O
)	TREANDA.xml:S1:12723:1	)	)	O	O
0	TREANDA.xml:S1:12736:1	0	CD	O	O

Investigations	TREANDA.xml:S1:12756:14	investig	NNS	O	O

Weight	TREANDA.xml:S1:12833:6	weight	NNP	B-AdverseReaction	B-AdverseReaction
decreased	TREANDA.xml:S1:12840:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
31	TREANDA.xml:S1:12899:2	31	CD	O	O
(	TREANDA.xml:S1:12902:1	(	(	O	O
18	TREANDA.xml:S1:12903:2	18	CD	O	O
)	TREANDA.xml:S1:12905:1	)	)	O	O
3	TREANDA.xml:S1:12917:1	3	CD	O	O
(	TREANDA.xml:S1:12919:1	(	(	O	O
2	TREANDA.xml:S1:12920:1	2	CD	O	O
)	TREANDA.xml:S1:12921:1	)	)	O	O

Metabolism	TREANDA.xml:S1:12937:10	metabol	NN	O	O
and	TREANDA.xml:S1:12948:3	and	CC	O	O
nutrition	TREANDA.xml:S1:12952:9	nutrit	NN	O	O
disorders	TREANDA.xml:S1:12962:9	disord	NNS	O	O

Anorexia	TREANDA.xml:S1:13014:8	anorexia	$	B-AdverseReaction	B-AdverseReaction
40	TREANDA.xml:S1:13080:2	40	CD	O	O
(	TREANDA.xml:S1:13083:1	(	(	O	O
23	TREANDA.xml:S1:13084:2	23	CD	O	O
)	TREANDA.xml:S1:13086:1	)	)	O	O
3	TREANDA.xml:S1:13098:1	3	CD	O	O
(	TREANDA.xml:S1:13100:1	(	(	O	O
2	TREANDA.xml:S1:13101:1	2	CD	O	O
)	TREANDA.xml:S1:13102:1	)	)	O	O

Dehydration	TREANDA.xml:S1:13122:11	dehydr	NN	B-AdverseReaction	B-AdverseReaction
24	TREANDA.xml:S1:13188:2	24	CD	O	O
(	TREANDA.xml:S1:13191:1	(	(	O	O
14	TREANDA.xml:S1:13192:2	14	CD	O	O
)	TREANDA.xml:S1:13194:1	)	)	O	O
8	TREANDA.xml:S1:13206:1	8	CD	O	O
(	TREANDA.xml:S1:13208:1	(	(	O	O
5	TREANDA.xml:S1:13209:1	5	CD	O	O
)	TREANDA.xml:S1:13210:1	)	)	O	O

Decreased	TREANDA.xml:S1:13230:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	TREANDA.xml:S1:13240:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
22	TREANDA.xml:S1:13296:2	22	CD	O	O
(	TREANDA.xml:S1:13299:1	(	(	O	O
13	TREANDA.xml:S1:13300:2	13	CD	O	O
)	TREANDA.xml:S1:13302:1	)	)	O	O
1	TREANDA.xml:S1:13314:1	1	CD	O	O
(	TREANDA.xml:S1:13316:1	(	(	O	O
1	TREANDA.xml:S1:13318:1	1	CD	O	O
)	TREANDA.xml:S1:13319:1	)	)	O	O

Hypokalemia	TREANDA.xml:S1:13338:11	hypokalemia	$	B-AdverseReaction	B-AdverseReaction
15	TREANDA.xml:S1:13404:2	15	CD	O	O
(	TREANDA.xml:S1:13407:1	(	(	O	O
9	TREANDA.xml:S1:13408:1	9	CD	O	O
)	TREANDA.xml:S1:13409:1	)	)	O	O
9	TREANDA.xml:S1:13422:1	9	CD	O	O
(	TREANDA.xml:S1:13424:1	(	(	O	O
5	TREANDA.xml:S1:13425:1	5	CD	O	O
)	TREANDA.xml:S1:13426:1	)	)	O	O

Musculoskeletal	TREANDA.xml:S1:13442:15	musculoskelet	NNP	O	O
and	TREANDA.xml:S1:13458:3	and	CC	O	O
connective	TREANDA.xml:S1:13462:10	connect	JJ	O	O
tissue	TREANDA.xml:S1:13473:6	tissu	NN	O	O
disorders	TREANDA.xml:S1:13480:9	disord	NNS	O	O

Back	TREANDA.xml:S1:13519:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	TREANDA.xml:S1:13524:4	pain	NN	I-AdverseReaction	I-AdverseReaction
25	TREANDA.xml:S1:13585:2	25	CD	O	O
(	TREANDA.xml:S1:13588:1	(	(	O	O
14	TREANDA.xml:S1:13589:2	14	CD	O	O
)	TREANDA.xml:S1:13591:1	)	)	O	O
5	TREANDA.xml:S1:13603:1	5	CD	O	O
(	TREANDA.xml:S1:13605:1	(	(	O	O
3	TREANDA.xml:S1:13606:1	3	CD	O	O
)	TREANDA.xml:S1:13607:1	)	)	O	O

Arthralgia	TREANDA.xml:S1:13627:10	arthralgia	$	B-AdverseReaction	B-AdverseReaction
11	TREANDA.xml:S1:13693:2	11	CD	O	O
(	TREANDA.xml:S1:13696:1	(	(	O	O
6	TREANDA.xml:S1:13697:1	6	CD	O	O
)	TREANDA.xml:S1:13698:1	)	)	O	O
0	TREANDA.xml:S1:13711:1	0	CD	O	O

Pain	TREANDA.xml:S1:13735:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	TREANDA.xml:S1:13740:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	TREANDA.xml:S1:13743:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
8	TREANDA.xml:S1:13801:1	8	CD	O	O
(	TREANDA.xml:S1:13803:1	(	(	O	O
5	TREANDA.xml:S1:13804:1	5	CD	O	O
)	TREANDA.xml:S1:13805:1	)	)	O	O
2	TREANDA.xml:S1:13819:1	2	CD	O	O
(	TREANDA.xml:S1:13821:1	(	(	O	O
1	TREANDA.xml:S1:13822:1	1	CD	O	O
)	TREANDA.xml:S1:13823:1	)	)	O	O

Bone	TREANDA.xml:S1:13843:4	bone	NNP	B-AdverseReaction	B-AdverseReaction
pain	TREANDA.xml:S1:13848:4	pain	NN	I-AdverseReaction	I-AdverseReaction
8	TREANDA.xml:S1:13909:1	8	CD	O	O
(	TREANDA.xml:S1:13911:1	(	(	O	O
5	TREANDA.xml:S1:13912:1	5	CD	O	O
)	TREANDA.xml:S1:13913:1	)	)	O	O
0	TREANDA.xml:S1:13927:1	0	CD	O	O

Nervous	TREANDA.xml:S1:13947:7	nervou	JJ	O	O
system	TREANDA.xml:S1:13955:6	system	NN	O	O
disorders	TREANDA.xml:S1:13962:9	disord	NNS	O	O

Headache	TREANDA.xml:S1:14024:8	headach	$	B-AdverseReaction	B-AdverseReaction
36	TREANDA.xml:S1:14090:2	36	CD	O	O
(	TREANDA.xml:S1:14093:1	(	(	O	O
21	TREANDA.xml:S1:14094:2	21	CD	O	O
)	TREANDA.xml:S1:14096:1	)	)	O	O
0	TREANDA.xml:S1:14108:1	0	CD	O	O

Dizziness	TREANDA.xml:S1:14132:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
25	TREANDA.xml:S1:14198:2	25	CD	O	O
(	TREANDA.xml:S1:14201:1	(	(	O	O
14	TREANDA.xml:S1:14202:2	14	CD	O	O
)	TREANDA.xml:S1:14204:1	)	)	O	O
0	TREANDA.xml:S1:14216:1	0	CD	O	O

Dysgeusia	TREANDA.xml:S1:14240:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
13	TREANDA.xml:S1:14306:2	13	CD	O	O
(	TREANDA.xml:S1:14309:1	(	(	O	O
7	TREANDA.xml:S1:14310:1	7	CD	O	O
)	TREANDA.xml:S1:14311:1	)	)	O	O
0	TREANDA.xml:S1:14324:1	0	CD	O	O

Psychiatric	TREANDA.xml:S1:14344:11	psychiatr	JJ	O	O
disorders	TREANDA.xml:S1:14356:9	disord	NNS	O	O

Insomnia	TREANDA.xml:S1:14421:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
23	TREANDA.xml:S1:14487:2	23	CD	O	O
(	TREANDA.xml:S1:14490:1	(	(	O	O
13	TREANDA.xml:S1:14491:2	13	CD	O	O
)	TREANDA.xml:S1:14493:1	)	)	O	O
0	TREANDA.xml:S1:14505:1	0	CD	O	O

Anxiety	TREANDA.xml:S1:14529:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
14	TREANDA.xml:S1:14595:2	14	CD	O	O
(	TREANDA.xml:S1:14598:1	(	(	O	O
8	TREANDA.xml:S1:14599:1	8	CD	O	O
)	TREANDA.xml:S1:14600:1	)	)	O	O
1	TREANDA.xml:S1:14613:1	1	CD	O	O
(	TREANDA.xml:S1:14615:1	(	(	O	O
1	TREANDA.xml:S1:14617:1	1	CD	O	O
)	TREANDA.xml:S1:14618:1	)	)	O	O

Depression	TREANDA.xml:S1:14637:10	depress	NN	B-AdverseReaction	B-AdverseReaction
10	TREANDA.xml:S1:14703:2	10	CD	O	O
(	TREANDA.xml:S1:14706:1	(	(	O	O
6	TREANDA.xml:S1:14707:1	6	CD	O	O
)	TREANDA.xml:S1:14708:1	)	)	O	O
0	TREANDA.xml:S1:14721:1	0	CD	O	O

Respiratory	TREANDA.xml:S1:14741:11	respiratori	NNP	O	O
,	TREANDA.xml:S1:14752:1	,	,	O	O
thoracic	TREANDA.xml:S1:14754:8	thorac	NN	O	O
and	TREANDA.xml:S1:14763:3	and	CC	O	O
mediastinal	TREANDA.xml:S1:14767:11	mediastin	JJ	O	O
disorders	TREANDA.xml:S1:14779:9	disord	NNS	O	O

Cough	TREANDA.xml:S1:14818:5	cough	IN	B-AdverseReaction	B-AdverseReaction
38	TREANDA.xml:S1:14884:2	38	CD	O	O
(	TREANDA.xml:S1:14887:1	(	(	O	O
22	TREANDA.xml:S1:14888:2	22	CD	O	O
)	TREANDA.xml:S1:14890:1	)	)	O	O
1	TREANDA.xml:S1:14902:1	1	CD	O	O
(	TREANDA.xml:S1:14904:1	(	(	O	O
1	TREANDA.xml:S1:14906:1	1	CD	O	O
)	TREANDA.xml:S1:14907:1	)	)	O	O

Dyspnea	TREANDA.xml:S1:14926:7	dyspnea	NNP	B-AdverseReaction	B-AdverseReaction
28	TREANDA.xml:S1:14992:2	28	CD	O	O
(	TREANDA.xml:S1:14995:1	(	(	O	O
16	TREANDA.xml:S1:14996:2	16	CD	O	O
)	TREANDA.xml:S1:14998:1	)	)	O	O
3	TREANDA.xml:S1:15010:1	3	CD	O	O
(	TREANDA.xml:S1:15012:1	(	(	O	O
2	TREANDA.xml:S1:15013:1	2	CD	O	O
)	TREANDA.xml:S1:15014:1	)	)	O	O

Pharyngolaryngeal	TREANDA.xml:S1:15034:17	pharyngolaryng	NNP	B-AdverseReaction	B-AdverseReaction
pain	TREANDA.xml:S1:15052:4	pain	NN	I-AdverseReaction	I-AdverseReaction
14	TREANDA.xml:S1:15100:2	14	CD	O	O
(	TREANDA.xml:S1:15103:1	(	(	O	O
8	TREANDA.xml:S1:15104:1	8	CD	O	O
)	TREANDA.xml:S1:15105:1	)	)	O	O
1	TREANDA.xml:S1:15118:1	1	CD	O	O
(	TREANDA.xml:S1:15120:1	(	(	O	O
1	TREANDA.xml:S1:15122:1	1	CD	O	O
)	TREANDA.xml:S1:15123:1	)	)	O	O

Wheezing	TREANDA.xml:S1:15142:8	wheez	VBG	B-AdverseReaction	B-AdverseReaction
8	TREANDA.xml:S1:15208:1	8	CD	O	O
(	TREANDA.xml:S1:15210:1	(	(	O	O
5	TREANDA.xml:S1:15211:1	5	CD	O	O
)	TREANDA.xml:S1:15212:1	)	)	O	O
0	TREANDA.xml:S1:15226:1	0	CD	O	O

Nasal	TREANDA.xml:S1:15250:5	nasal	NNP	B-AdverseReaction	B-AdverseReaction
congestion	TREANDA.xml:S1:15256:10	congest	NN	I-AdverseReaction	I-AdverseReaction
8	TREANDA.xml:S1:15316:1	8	CD	O	O
(	TREANDA.xml:S1:15318:1	(	(	O	O
5	TREANDA.xml:S1:15319:1	5	CD	O	O
)	TREANDA.xml:S1:15320:1	)	)	O	O
0	TREANDA.xml:S1:15334:1	0	CD	O	O

Skin	TREANDA.xml:S1:15354:4	skin	NNP	O	O
and	TREANDA.xml:S1:15359:3	and	CC	O	O
subcutaneous	TREANDA.xml:S1:15363:12	subcutan	JJ	O	O
tissue	TREANDA.xml:S1:15376:6	tissu	NN	O	O
disorders	TREANDA.xml:S1:15383:9	disord	NNS	O	O

Rash	TREANDA.xml:S1:15431:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
28	TREANDA.xml:S1:15497:2	28	CD	O	O
(	TREANDA.xml:S1:15500:1	(	(	O	O
16	TREANDA.xml:S1:15501:2	16	CD	O	O
)	TREANDA.xml:S1:15503:1	)	)	O	O
1	TREANDA.xml:S1:15515:1	1	CD	O	O
(	TREANDA.xml:S1:15517:1	(	(	O	O
1	TREANDA.xml:S1:15519:1	1	CD	O	O
)	TREANDA.xml:S1:15520:1	)	)	O	O

Pruritus	TREANDA.xml:S1:15539:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
11	TREANDA.xml:S1:15605:2	11	CD	O	O
(	TREANDA.xml:S1:15608:1	(	(	O	O
6	TREANDA.xml:S1:15609:1	6	CD	O	O
)	TREANDA.xml:S1:15610:1	)	)	O	O
0	TREANDA.xml:S1:15623:1	0	CD	O	O

Dry	TREANDA.xml:S1:15647:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
skin	TREANDA.xml:S1:15651:4	skin	NN	I-AdverseReaction	I-AdverseReaction
9	TREANDA.xml:S1:15713:1	9	CD	O	O
(	TREANDA.xml:S1:15715:1	(	(	O	O
5	TREANDA.xml:S1:15716:1	5	CD	O	O
)	TREANDA.xml:S1:15717:1	)	)	O	O
0	TREANDA.xml:S1:15731:1	0	CD	O	O

Night	TREANDA.xml:S1:15755:5	night	NNP	B-AdverseReaction	B-AdverseReaction
sweats	TREANDA.xml:S1:15761:6	sweat	VBZ	I-AdverseReaction	I-AdverseReaction
9	TREANDA.xml:S1:15821:1	9	CD	O	O
(	TREANDA.xml:S1:15823:1	(	(	O	O
5	TREANDA.xml:S1:15824:1	5	CD	O	O
)	TREANDA.xml:S1:15825:1	)	)	O	O
0	TREANDA.xml:S1:15839:1	0	CD	O	O

Hyperhidrosis	TREANDA.xml:S1:15863:13	hyperhidrosi	NN	B-AdverseReaction	B-AdverseReaction
8	TREANDA.xml:S1:15929:1	8	CD	O	O
(	TREANDA.xml:S1:15931:1	(	(	O	O
5	TREANDA.xml:S1:15932:1	5	CD	O	O
)	TREANDA.xml:S1:15933:1	)	)	O	O
0	TREANDA.xml:S1:15947:1	0	CD	O	O

Vascular	TREANDA.xml:S1:15967:8	vascular	JJ	O	O
disorders	TREANDA.xml:S1:15976:9	disord	NNS	O	O

Hypotension	TREANDA.xml:S1:16044:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
10	TREANDA.xml:S1:16110:2	10	CD	O	O
(	TREANDA.xml:S1:16113:1	(	(	O	O
6	TREANDA.xml:S1:16114:1	6	CD	O	O
)	TREANDA.xml:S1:16115:1	)	)	O	O
2	TREANDA.xml:S1:16128:1	2	CD	O	O
(	TREANDA.xml:S1:16130:1	(	(	O	O
1	TREANDA.xml:S1:16131:1	1	CD	O	O
)	TREANDA.xml:S1:16132:1	)	)	O	O

Patients	TREANDA.xml:S1:16149:8	patient	NNS	O	O
may	TREANDA.xml:S1:16158:3	may	MD	O	O
have	TREANDA.xml:S1:16162:4	have	VB	O	O
reported	TREANDA.xml:S1:16167:8	report	VBN	O	O
more	TREANDA.xml:S1:16176:4	more	JJR	O	O
than	TREANDA.xml:S1:16181:4	than	IN	O	O
1	TREANDA.xml:S1:16186:1	1	CD	O	O
adverse	TREANDA.xml:S1:16188:7	advers	JJ	O	O
reaction	TREANDA.xml:S1:16196:8	reaction	NN	O	O
.	TREANDA.xml:S1:16204:1	.	.	O	O
NOTE	TREANDA.xml:S1:16205:4	note	NN	O	O
:	TREANDA.xml:S1:16209:1	:	:	O	O
Patients	TREANDA.xml:S1:16211:8	patient	NNS	O	O
counted	TREANDA.xml:S1:16220:7	count	VBN	O	O
only	TREANDA.xml:S1:16228:4	onli	RB	O	O
once	TREANDA.xml:S1:16233:4	onc	RB	O	O
in	TREANDA.xml:S1:16238:2	in	IN	O	O
each	TREANDA.xml:S1:16241:4	each	DT	O	O
preferred	TREANDA.xml:S1:16246:9	prefer	JJ	O	O
term	TREANDA.xml:S1:16256:4	term	NN	O	O
category	TREANDA.xml:S1:16261:8	categori	NN	O	O
and	TREANDA.xml:S1:16270:3	and	CC	O	O
once	TREANDA.xml:S1:16274:4	onc	RB	O	O
in	TREANDA.xml:S1:16279:2	in	IN	O	O
each	TREANDA.xml:S1:16282:4	each	DT	O	O
system	TREANDA.xml:S1:16287:6	system	NN	O	O
organ	TREANDA.xml:S1:16294:5	organ	JJ	O	O
class	TREANDA.xml:S1:16300:5	class	NN	O	O
category	TREANDA.xml:S1:16306:8	categori	NN	O	O
.	TREANDA.xml:S1:16314:1	.	.	O	O

Hematologic	TREANDA.xml:S1:16329:11	hematolog	NNP	B-AdverseReaction	B-AdverseReaction
toxicities	TREANDA.xml:S1:16341:10	toxic	NNS	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:16351:1	,	,	O	O
based	TREANDA.xml:S1:16353:5	base	VBN	O	O
on	TREANDA.xml:S1:16359:2	on	IN	O	O
laboratory	TREANDA.xml:S1:16362:10	laboratori	NN	O	O
values	TREANDA.xml:S1:16373:6	valu	NNS	O	O
and	TREANDA.xml:S1:16380:3	and	CC	O	O
CTC	TREANDA.xml:S1:16384:3	ctc	NNP	O	O
grade	TREANDA.xml:S1:16388:5	grade	NN	O	O
,	TREANDA.xml:S1:16393:1	,	,	O	O
in	TREANDA.xml:S1:16395:2	in	IN	O	O
NHL	TREANDA.xml:S1:16398:3	nhl	NNP	O	O
patients	TREANDA.xml:S1:16402:8	patient	NNS	O	O
treated	TREANDA.xml:S1:16411:7	treat	VBN	O	O
in	TREANDA.xml:S1:16419:2	in	IN	O	O
both	TREANDA.xml:S1:16422:4	both	DT	O	O
single	TREANDA.xml:S1:16427:6	singl	JJ	O	O
arm	TREANDA.xml:S1:16434:3	arm	NN	O	O
studies	TREANDA.xml:S1:16438:7	studi	NNS	O	O
combined	TREANDA.xml:S1:16446:8	combin	VBN	O	O
are	TREANDA.xml:S1:16455:3	are	VBP	O	O
described	TREANDA.xml:S1:16459:9	describ	VBN	O	O
in	TREANDA.xml:S1:16469:2	in	IN	O	O
Table	TREANDA.xml:S1:16472:5	tabl	JJ	O	O
4	TREANDA.xml:S1:16478:1	4	CD	O	O
.	TREANDA.xml:S1:16479:1	.	.	O	O

Clinically	TREANDA.xml:S1:16482:10	clinic	RB	O	O
important	TREANDA.xml:S1:16493:9	import	JJ	O	O
chemistry	TREANDA.xml:S1:16503:9	chemistri	NN	O	O
laboratory	TREANDA.xml:S1:16513:10	laboratori	NN	O	O
values	TREANDA.xml:S1:16524:6	valu	NNS	O	O
that	TREANDA.xml:S1:16531:4	that	WDT	O	O
were	TREANDA.xml:S1:16536:4	were	VBD	O	O
new	TREANDA.xml:S1:16541:3	new	JJ	O	O
or	TREANDA.xml:S1:16545:2	or	CC	O	O
worsened	TREANDA.xml:S1:16548:8	worsen	VBN	O	O
from	TREANDA.xml:S1:16557:4	from	IN	O	O
baseline	TREANDA.xml:S1:16562:8	baselin	NN	O	O
and	TREANDA.xml:S1:16571:3	and	CC	O	O
occurred	TREANDA.xml:S1:16575:8	occur	VBD	O	O
in	TREANDA.xml:S1:16584:2	in	IN	O	O
1%	TREANDA.xml:S1:16588:2	1%	CD	O	O
of	TREANDA.xml:S1:16591:2	of	IN	O	O
patients	TREANDA.xml:S1:16594:8	patient	NNS	O	O
at	TREANDA.xml:S1:16603:2	at	IN	O	O
Grade	TREANDA.xml:S1:16606:5	grade	NNP	O	O
3	TREANDA.xml:S1:16612:1	3	CD	O	O
or	TREANDA.xml:S1:16614:2	or	CC	O	O
4	TREANDA.xml:S1:16617:1	4	CD	O	O
,	TREANDA.xml:S1:16618:1	,	,	O	O
in	TREANDA.xml:S1:16621:2	in	IN	O	O
NHL	TREANDA.xml:S1:16624:3	nhl	NNP	O	O
patients	TREANDA.xml:S1:16628:8	patient	NNS	O	O
treated	TREANDA.xml:S1:16637:7	treat	VBN	O	O
in	TREANDA.xml:S1:16645:2	in	IN	O	O
both	TREANDA.xml:S1:16648:4	both	DT	O	O
single	TREANDA.xml:S1:16653:6	singl	JJ	O	O
arm	TREANDA.xml:S1:16660:3	arm	NN	O	O
studies	TREANDA.xml:S1:16664:7	studi	NNS	O	O
combined	TREANDA.xml:S1:16672:8	combin	VBN	O	O
were	TREANDA.xml:S1:16681:4	were	VBD	O	O
hyperglycemia	TREANDA.xml:S1:16686:13	hyperglycemia	NNS	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:16700:1	(	(	O	O
3%	TREANDA.xml:S1:16701:2	3%	CD	O	O
)	TREANDA.xml:S1:16703:1	)	)	O	O
,	TREANDA.xml:S1:16704:1	,	,	O	O
elevated	TREANDA.xml:S1:16706:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
creatinine	TREANDA.xml:S1:16715:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
(	TREANDA.xml:S1:16726:1	(	(	O	O
2%	TREANDA.xml:S1:16727:2	2%	CD	O	O
)	TREANDA.xml:S1:16729:1	)	)	O	O
,	TREANDA.xml:S1:16730:1	,	,	O	O
hyponatremia	TREANDA.xml:S1:16732:12	hyponatremia	NN	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:16745:1	(	(	O	O
2%	TREANDA.xml:S1:16746:2	2%	CD	O	O
)	TREANDA.xml:S1:16748:1	)	)	O	O
,	TREANDA.xml:S1:16749:1	,	,	O	O
and	TREANDA.xml:S1:16751:3	and	CC	O	O
hypocalcemia	TREANDA.xml:S1:16755:12	hypocalcemia	NN	B-AdverseReaction	B-AdverseReaction
(	TREANDA.xml:S1:16768:1	(	(	O	O
2%	TREANDA.xml:S1:16769:2	2%	CD	O	O
)	TREANDA.xml:S1:16771:1	)	)	O	O
.	TREANDA.xml:S1:16772:1	.	.	O	O

Table	TREANDA.xml:S1:16778:5	tabl	NN	O	O

4	TREANDA.xml:S1:16784:1	4	CD	O	O
:	TREANDA.xml:S1:16785:1	:	:	O	O
Incidence	TREANDA.xml:S1:16788:9	incid	NN	O	O
of	TREANDA.xml:S1:16798:2	of	IN	O	O
Hematology	TREANDA.xml:S1:16801:10	hematolog	NNP	O	O
Laboratory	TREANDA.xml:S1:16812:10	laboratori	NNP	O	O
Abnormalities	TREANDA.xml:S1:16823:13	abnorm	NNP	O	O
in	TREANDA.xml:S1:16837:2	in	IN	O	O
Patients	TREANDA.xml:S1:16840:8	patient	NNPS	O	O
Who	TREANDA.xml:S1:16849:3	who	WP	O	O
Received	TREANDA.xml:S1:16853:8	receiv	VBD	O	O
TREANDA	TREANDA.xml:S1:16862:7	treanda	NNP	O	O
in	TREANDA.xml:S1:16870:2	in	IN	O	O
the	TREANDA.xml:S1:16873:3	the	DT	O	O
NHL	TREANDA.xml:S1:16877:3	nhl	NNP	O	O
Studies	TREANDA.xml:S1:16881:7	studi	NNPS	O	O

Percent	TREANDA.xml:S1:16917:7	percent	NN	O	O
of	TREANDA.xml:S1:16925:2	of	IN	O	O
patients	TREANDA.xml:S1:16928:8	patient	NNS	O	O

Hematology	TREANDA.xml:S1:16943:10	hematolog	NNP	O	O
variable	TREANDA.xml:S1:16954:8	variabl	JJ	O	O
All	TREANDA.xml:S1:16968:3	all	NNP	O	O
Grades	TREANDA.xml:S1:16972:6	grade	NNP	O	O
Grades	TREANDA.xml:S1:16983:6	grade	NNP	O	O
3	TREANDA.xml:S1:16990:1	3	CD	O	O
4	TREANDA.xml:S1:16992:1	4	CD	O	O

Lymphocytes	TREANDA.xml:S1:17001:11	lymphocyt	NNS	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:17013:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
99	TREANDA.xml:S1:17026:2	99	CD	O	O
94	TREANDA.xml:S1:17041:2	94	CD	O	O

Leukocytes	TREANDA.xml:S1:17059:10	leukocyt	NNS	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:17070:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
94	TREANDA.xml:S1:17084:2	94	CD	O	O
56	TREANDA.xml:S1:17099:2	56	CD	O	O

Hemoglobin	TREANDA.xml:S1:17117:10	hemoglobin	NNP	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:17128:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
88	TREANDA.xml:S1:17142:2	88	CD	O	O
11	TREANDA.xml:S1:17157:2	11	CD	O	O

Neutrophils	TREANDA.xml:S1:17175:11	neutrophil	NNS	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:17187:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
86	TREANDA.xml:S1:17200:2	86	CD	O	O
60	TREANDA.xml:S1:17215:2	60	CD	O	O

Platelets	TREANDA.xml:S1:17233:9	platelet	NNS	B-AdverseReaction	B-AdverseReaction
Decreased	TREANDA.xml:S1:17243:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
86	TREANDA.xml:S1:17258:2	86	CD	O	O
25	TREANDA.xml:S1:17273:2	25	CD	O	O

In	TREANDA.xml:S1:17298:2	In	IN	O	O
both	TREANDA.xml:S1:17301:4	both	DT	O	O
studies	TREANDA.xml:S1:17306:7	studi	NNS	O	O
,	TREANDA.xml:S1:17313:1	,	,	O	O
serious	TREANDA.xml:S1:17315:7	seriou	JJ	O	O
adverse	TREANDA.xml:S1:17323:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:17331:9	reaction	NNS	O	O
,	TREANDA.xml:S1:17340:1	,	,	O	O
regardless	TREANDA.xml:S1:17342:10	regardless	RB	O	O
of	TREANDA.xml:S1:17353:2	of	IN	O	O
causality	TREANDA.xml:S1:17356:9	causal	NN	O	O
,	TREANDA.xml:S1:17365:1	,	,	O	O
were	TREANDA.xml:S1:17367:4	were	VBD	O	O
reported	TREANDA.xml:S1:17372:8	report	VBN	O	O
in	TREANDA.xml:S1:17381:2	in	IN	O	O
37%	TREANDA.xml:S1:17384:3	37%	CD	O	O
of	TREANDA.xml:S1:17388:2	of	IN	O	O
patients	TREANDA.xml:S1:17391:8	patient	NNS	O	O
receiving	TREANDA.xml:S1:17400:9	receiv	VBG	O	O
TREANDA	TREANDA.xml:S1:17410:7	treanda	NNP	O	O
.	TREANDA.xml:S1:17417:1	.	.	O	O

The	TREANDA.xml:S1:17420:3	the	DT	O	O
most	TREANDA.xml:S1:17424:4	most	RBS	O	O
common	TREANDA.xml:S1:17429:6	common	JJ	O	O
serious	TREANDA.xml:S1:17436:7	seriou	JJ	O	O
adverse	TREANDA.xml:S1:17444:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:17452:9	reaction	NNS	O	O
occurring	TREANDA.xml:S1:17462:9	occur	VBG	O	O
in	TREANDA.xml:S1:17472:2	in	IN	O	O
5%	TREANDA.xml:S1:17477:2	5%	CD	O	O
of	TREANDA.xml:S1:17480:2	of	IN	O	O
patients	TREANDA.xml:S1:17483:8	patient	NNS	O	O
were	TREANDA.xml:S1:17492:4	were	VBD	O	O
febrile	TREANDA.xml:S1:17497:7	febril	JJ	B-AdverseReaction	B-AdverseReaction
neutropenia	TREANDA.xml:S1:17505:11	neutropenia	NN	I-AdverseReaction	I-AdverseReaction
and	TREANDA.xml:S1:17517:3	and	CC	O	O
pneumonia	TREANDA.xml:S1:17521:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S1:17530:1	.	.	O	O

Other	TREANDA.xml:S1:17533:5	other	JJ	O	O
important	TREANDA.xml:S1:17539:9	import	JJ	O	O
serious	TREANDA.xml:S1:17549:7	seriou	JJ	O	O
adverse	TREANDA.xml:S1:17557:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:17565:9	reaction	NNS	O	O
reported	TREANDA.xml:S1:17575:8	report	VBN	O	O
in	TREANDA.xml:S1:17584:2	in	IN	O	O
clinical	TREANDA.xml:S1:17587:8	clinic	JJ	O	O
trials	TREANDA.xml:S1:17596:6	trial	NNS	O	O
and	TREANDA.xml:S1:17603:3	and	CC	O	O
or	TREANDA.xml:S1:17607:2	or	CC	O	O
postmarketing	TREANDA.xml:S1:17610:13	postmarket	VBG	O	O
experience	TREANDA.xml:S1:17624:10	experi	NN	O	O
were	TREANDA.xml:S1:17635:4	were	VBD	O	O
acute	TREANDA.xml:S1:17640:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
renal	TREANDA.xml:S1:17646:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	TREANDA.xml:S1:17652:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:17659:1	,	,	O	O
cardiac	TREANDA.xml:S1:17661:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
failure	TREANDA.xml:S1:17669:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:17676:1	,	,	O	O
hypersensitivity	TREANDA.xml:S1:17678:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:17694:1	,	,	O	O
skin	TREANDA.xml:S1:17696:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
reactions	TREANDA.xml:S1:17701:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:17710:1	,	,	O	O
pulmonary	TREANDA.xml:S1:17712:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
fibrosis	TREANDA.xml:S1:17722:8	fibrosi	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:17730:1	,	,	O	O
and	TREANDA.xml:S1:17732:3	and	CC	O	O
myelodysplastic	TREANDA.xml:S1:17736:15	myelodysplast	JJ	B-AdverseReaction	B-AdverseReaction
syndrome	TREANDA.xml:S1:17752:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
.	TREANDA.xml:S1:17760:1	.	.	O	O

Serious	TREANDA.xml:S1:17766:7	seriou	JJ	O	O

drug	TREANDA.xml:S1:17774:4	drug	NN	O	B-AdverseReaction
-	TREANDA.xml:S1:17778:1	-	:	O	I-AdverseReaction
related	TREANDA.xml:S1:17779:7	relat	JJ	O	I-AdverseReaction
adverse	TREANDA.xml:S1:17787:7	advers	JJ	O	I-AdverseReaction
reactions	TREANDA.xml:S1:17795:9	reaction	NNS	O	I-AdverseReaction
reported	TREANDA.xml:S1:17805:8	report	VBN	O	O
in	TREANDA.xml:S1:17814:2	in	IN	O	O
clinical	TREANDA.xml:S1:17817:8	clinic	JJ	O	O
trials	TREANDA.xml:S1:17826:6	trial	NNS	O	O
included	TREANDA.xml:S1:17833:8	includ	VBD	O	O
myelosuppression	TREANDA.xml:S1:17842:16	myelosuppress	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:17858:1	,	,	O	O
infection	TREANDA.xml:S1:17860:9	infect	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:17869:1	,	,	O	O
pneumonia	TREANDA.xml:S1:17871:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:17880:1	,	,	O	O
tumor	TREANDA.xml:S1:17882:5	tumor	NN	B-AdverseReaction	B-AdverseReaction
lysis	TREANDA.xml:S1:17888:5	lysi	NN	I-AdverseReaction	I-AdverseReaction
syndrome	TREANDA.xml:S1:17894:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
and	TREANDA.xml:S1:17903:3	and	CC	O	O
infusion	TREANDA.xml:S1:17907:8	infus	NN	B-AdverseReaction	B-AdverseReaction
reactions	TREANDA.xml:S1:17916:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
[	TREANDA.xml:S1:17927:1	[	VBP	O	O
see	TREANDA.xml:S1:17928:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:17933:8	warn	NNS	O	O
and	TREANDA.xml:S1:17942:3	and	CC	O	O
Precautions	TREANDA.xml:S1:17946:11	precaut	NNP	O	O
(	TREANDA.xml:S1:17959:1	(	(	O	O
5	TREANDA.xml:S1:17962:1	5	CD	O	O
)]	TREANDA.xml:S1:17965:2	)]	NN	O	O
.	TREANDA.xml:S1:17969:1	.	.	O	O

Adverse	TREANDA.xml:S1:17971:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:17979:9	reaction	NNS	O	O
occurring	TREANDA.xml:S1:17989:9	occur	VBG	O	O
less	TREANDA.xml:S1:17999:4	less	RBR	O	O
frequently	TREANDA.xml:S1:18004:10	frequent	RB	O	O
but	TREANDA.xml:S1:18015:3	but	CC	O	O
possibly	TREANDA.xml:S1:18019:8	possibl	RB	O	O
related	TREANDA.xml:S1:18028:7	relat	VBN	O	O
to	TREANDA.xml:S1:18036:2	to	TO	O	O
TREANDA	TREANDA.xml:S1:18039:7	treanda	NNP	O	O
treatment	TREANDA.xml:S1:18047:9	treatment	NN	O	O
were	TREANDA.xml:S1:18057:4	were	VBD	O	O
hemolysis	TREANDA.xml:S1:18062:9	hemolysi	NN	B-AdverseReaction	O
,	TREANDA.xml:S1:18071:1	,	,	O	O
dysgeusia	TREANDA.xml:S1:18073:9	dysgeusia	JJ	B-AdverseReaction	B-AdverseReaction
taste	TREANDA.xml:S1:18083:5	tast	NN	B-AdverseReaction	I-AdverseReaction
disorder	TREANDA.xml:S1:18089:8	disord	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:18097:1	,	,	O	O
atypical	TREANDA.xml:S1:18099:8	atyp	JJ	B-AdverseReaction	B-AdverseReaction
pneumonia	TREANDA.xml:S1:18108:9	pneumonia	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:18117:1	,	,	O	O
sepsis	TREANDA.xml:S1:18119:6	sepsi	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:18125:1	,	,	O	O
herpes	TREANDA.xml:S1:18127:6	herp	NNS	B-AdverseReaction	B-AdverseReaction
zoster	TREANDA.xml:S1:18134:6	zoster	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:18140:1	,	,	O	O
erythema	TREANDA.xml:S1:18142:8	erythema	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:18150:1	,	,	O	O
dermatitis	TREANDA.xml:S1:18152:10	dermat	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:18162:1	,	,	O	O
and	TREANDA.xml:S1:18164:3	and	CC	O	O
skin	TREANDA.xml:S1:18168:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
necrosis	TREANDA.xml:S1:18173:8	necrosi	NN	I-AdverseReaction	I-AdverseReaction
.	TREANDA.xml:S1:18181:1	.	.	O	O

6.2	TREANDA.xml:S1:18190:3	6.2	CD	O	O
Postmarketing	TREANDA.xml:S1:18194:13	postmarket	VBG	O	O
Experience	TREANDA.xml:S1:18208:10	experi	NN	O	O

The	TREANDA.xml:S1:18222:3	the	DT	O	O
following	TREANDA.xml:S1:18226:9	follow	JJ	O	O
adverse	TREANDA.xml:S1:18236:7	advers	JJ	O	O
reactions	TREANDA.xml:S1:18244:9	reaction	NNS	O	O
have	TREANDA.xml:S1:18254:4	have	VBP	O	O
been	TREANDA.xml:S1:18259:4	been	VBN	O	O
identified	TREANDA.xml:S1:18264:10	identifi	VBN	O	O
during	TREANDA.xml:S1:18275:6	dure	IN	O	O
post	TREANDA.xml:S1:18282:4	post	NN	O	O
-	TREANDA.xml:S1:18286:1	-	:	O	O
approval	TREANDA.xml:S1:18287:8	approv	NN	O	O
use	TREANDA.xml:S1:18296:3	use	NN	O	O
of	TREANDA.xml:S1:18300:2	of	IN	O	O
TREANDA	TREANDA.xml:S1:18303:7	treanda	NNP	O	O
.	TREANDA.xml:S1:18310:1	.	.	O	O

Because	TREANDA.xml:S1:18313:7	becaus	IN	O	O
these	TREANDA.xml:S1:18321:5	these	DT	O	O
reactions	TREANDA.xml:S1:18327:9	reaction	NNS	O	O
are	TREANDA.xml:S1:18337:3	are	VBP	O	O
reported	TREANDA.xml:S1:18341:8	report	VBN	O	O
voluntarily	TREANDA.xml:S1:18350:11	voluntarili	RB	O	O
from	TREANDA.xml:S1:18362:4	from	IN	O	O
a	TREANDA.xml:S1:18367:1	a	DT	O	O
population	TREANDA.xml:S1:18369:10	popul	NN	O	O
of	TREANDA.xml:S1:18380:2	of	IN	O	O
uncertain	TREANDA.xml:S1:18383:9	uncertain	JJ	O	O
size	TREANDA.xml:S1:18393:4	size	NN	O	O
,	TREANDA.xml:S1:18397:1	,	,	O	O
it	TREANDA.xml:S1:18399:2	it	PRP	O	O
is	TREANDA.xml:S1:18402:2	is	VBZ	O	O
not	TREANDA.xml:S1:18405:3	not	RB	O	O
always	TREANDA.xml:S1:18409:6	alway	RB	O	O
possible	TREANDA.xml:S1:18416:8	possibl	JJ	O	O
to	TREANDA.xml:S1:18425:2	to	TO	O	O
reliably	TREANDA.xml:S1:18428:8	reliabl	VB	O	O
estimate	TREANDA.xml:S1:18437:8	estim	VB	O	O
their	TREANDA.xml:S1:18446:5	their	PRP$	O	O
frequency	TREANDA.xml:S1:18452:9	frequenc	NN	O	O
or	TREANDA.xml:S1:18462:2	or	CC	O	O
establish	TREANDA.xml:S1:18465:9	establish	VB	O	O
a	TREANDA.xml:S1:18475:1	a	DT	O	O
causal	TREANDA.xml:S1:18477:6	causal	NN	O	O
relationship	TREANDA.xml:S1:18484:12	relationship	NN	O	O
to	TREANDA.xml:S1:18497:2	to	TO	O	O
drug	TREANDA.xml:S1:18500:4	drug	NN	O	O
exposure	TREANDA.xml:S1:18505:8	exposur	NN	O	O
:	TREANDA.xml:S1:18513:1	:	:	O	O
anaphylaxis	TREANDA.xml:S1:18515:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
;	TREANDA.xml:S1:18526:1	;	:	O	O
and	TREANDA.xml:S1:18528:3	and	CC	O	O
injection	TREANDA.xml:S1:18532:9	inject	NN	B-AdverseReaction	B-AdverseReaction
or	TREANDA.xml:S1:18542:2	or	CC	O	O
infusion	TREANDA.xml:S1:18545:8	infus	NN	B-AdverseReaction	B-AdverseReaction
site	TREANDA.xml:S1:18554:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	TREANDA.xml:S1:18559:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
including	TREANDA.xml:S1:18569:9	includ	VBG	O	O
phlebitis	TREANDA.xml:S1:18579:9	phlebiti	NN	I-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:18588:1	,	,	O	O
pruritus	TREANDA.xml:S1:18590:8	pruritu	NN	I-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S1:18598:1	,	,	O	O
irritation	TREANDA.xml:S1:18600:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:18610:1	,	,	O	O
pain	TREANDA.xml:S1:18612:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S1:18616:1	,	,	O	O
and	TREANDA.xml:S1:18618:3	and	CC	O	O
swelling	TREANDA.xml:S1:18622:8	swell	VBG	I-AdverseReaction	B-AdverseReaction
;	TREANDA.xml:S1:18630:1	;	:	O	O
pneumocystis	TREANDA.xml:S1:18632:12	pneumocysti	NN	B-AdverseReaction	O
jiroveci	TREANDA.xml:S1:18645:8	jiroveci	NN	I-AdverseReaction	O
pneumonia	TREANDA.xml:S1:18654:9	pneumonia	NN	I-AdverseReaction	O
and	TREANDA.xml:S1:18664:3	and	CC	O	O
pneumonitis	TREANDA.xml:S1:18668:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S1:18679:1	.	.	O	O

Skin	TREANDA.xml:S1:18685:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
reactions	TREANDA.xml:S1:18690:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
including	TREANDA.xml:S1:18700:9	includ	VBG	O	O
SJS	TREANDA.xml:S1:18710:3	sj	NNP	B-AdverseReaction	O
and	TREANDA.xml:S1:18714:3	and	CC	O	O
TEN	TREANDA.xml:S1:18718:3	ten	NNP	B-AdverseReaction	B-AdverseReaction
have	TREANDA.xml:S1:18722:4	have	VBP	O	O
occurred	TREANDA.xml:S1:18727:8	occur	VBN	O	O
when	TREANDA.xml:S1:18736:4	when	WRB	O	O
TREANDA	TREANDA.xml:S1:18741:7	treanda	NNP	O	O
was	TREANDA.xml:S1:18749:3	wa	VBD	O	O
administered	TREANDA.xml:S1:18753:12	administ	VBN	O	O
concomitantly	TREANDA.xml:S1:18766:13	concomitantli	RB	O	O
with	TREANDA.xml:S1:18780:4	with	IN	O	O
allopurinol	TREANDA.xml:S1:18785:11	allopurinol	NNS	O	O
and	TREANDA.xml:S1:18797:3	and	CC	O	O
other	TREANDA.xml:S1:18801:5	other	JJ	O	O
medications	TREANDA.xml:S1:18807:11	medic	NNS	O	O
known	TREANDA.xml:S1:18819:5	known	VBN	O	O
to	TREANDA.xml:S1:18825:2	to	TO	O	O
cause	TREANDA.xml:S1:18828:5	caus	VB	O	O
these	TREANDA.xml:S1:18834:5	these	DT	O	O
syndromes	TREANDA.xml:S1:18840:9	syndrom	NNS	O	O
.	TREANDA.xml:S1:18849:1	.	.	O	O

[	TREANDA.xml:S1:18854:1	[	NNS	O	O
see	TREANDA.xml:S1:18855:3	see	VBP	O	O
Warnings	TREANDA.xml:S1:18860:8	warn	NNS	O	O
and	TREANDA.xml:S1:18869:3	and	CC	O	O
Precautions	TREANDA.xml:S1:18873:11	precaut	NNP	O	O
(	TREANDA.xml:S1:18886:1	(	(	O	O
5.5	TREANDA.xml:S1:18889:3	5.5	CD	O	O
)]	TREANDA.xml:S1:18894:2	)]	RB	O	O
5	TREANDA.xml:S2:4:1	5	CD	O	O
WARNINGS	TREANDA.xml:S2:6:8	warn	NNP	O	O
AND	TREANDA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	TREANDA.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	TREANDA.xml:S2:37:7	excerpt	NN	O	O
:	TREANDA.xml:S2:44:1	:	:	O	O
Myelosuppression	TREANDA.xml:S2:54:16	myelosuppress	NN	B-AdverseReaction	O
:	TREANDA.xml:S2:70:1	:	:	O	O
Delay	TREANDA.xml:S2:73:5	delay	NN	O	O
or	TREANDA.xml:S2:79:2	or	CC	O	O
reduce	TREANDA.xml:S2:82:6	reduc	VB	O	O
dose	TREANDA.xml:S2:89:4	dose	NN	O	O
.	TREANDA.xml:S2:93:1	.	.	O	O

Restart	TREANDA.xml:S2:95:7	restart	NNP	O	O
treatment	TREANDA.xml:S2:103:9	treatment	NN	O	O
based	TREANDA.xml:S2:113:5	base	VBN	O	O
on	TREANDA.xml:S2:119:2	on	IN	O	O
ANC	TREANDA.xml:S2:122:3	anc	NNP	O	O
and	TREANDA.xml:S2:126:3	and	CC	O	O
platelet	TREANDA.xml:S2:130:8	platelet	NN	O	O
count	TREANDA.xml:S2:139:5	count	NN	O	O
recovery	TREANDA.xml:S2:145:8	recoveri	NN	O	O
.	TREANDA.xml:S2:153:1	.	.	O	O

(	TREANDA.xml:S2:155:1	(	(	O	O
2.2	TREANDA.xml:S2:158:3	2.2	CD	O	O
)	TREANDA.xml:S2:163:1	)	)	O	O
Complications	TREANDA.xml:S2:165:13	complic	NNS	O	O
of	TREANDA.xml:S2:179:2	of	IN	O	O
myelosuppression	TREANDA.xml:S2:182:16	myelosuppress	NN	B-AdverseReaction	O
may	TREANDA.xml:S2:199:3	may	MD	O	O
lead	TREANDA.xml:S2:203:4	lead	VB	O	O
to	TREANDA.xml:S2:208:2	to	TO	O	O
death	TREANDA.xml:S2:211:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S2:216:1	.	.	O	O

(	TREANDA.xml:S2:218:1	(	(	O	O
5.1	TREANDA.xml:S2:221:3	5.1	CD	O	O
)	TREANDA.xml:S2:226:1	)	)	O	O

Infections	TREANDA.xml:S2:235:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
:	TREANDA.xml:S2:245:1	:	:	O	O
Monitor	TREANDA.xml:S2:248:7	monitor	NNP	O	O
for	TREANDA.xml:S2:256:3	for	IN	O	O
fever	TREANDA.xml:S2:260:5	fever	NN	O	O
and	TREANDA.xml:S2:266:3	and	CC	O	O
other	TREANDA.xml:S2:270:5	other	JJ	O	O
signs	TREANDA.xml:S2:276:5	sign	NNS	O	O
of	TREANDA.xml:S2:282:2	of	IN	O	O
infection	TREANDA.xml:S2:285:9	infect	NN	O	O
and	TREANDA.xml:S2:295:3	and	CC	O	O
treat	TREANDA.xml:S2:299:5	treat	NN	O	O
promptly	TREANDA.xml:S2:305:8	promptli	RB	O	O
.	TREANDA.xml:S2:313:1	.	.	O	O

(	TREANDA.xml:S2:315:1	(	(	O	O
5.2	TREANDA.xml:S2:318:3	5.2	CD	O	O
)	TREANDA.xml:S2:323:1	)	)	O	O

Anaphylaxis	TREANDA.xml:S2:332:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
and	TREANDA.xml:S2:344:3	and	CC	O	O
Infusion	TREANDA.xml:S2:348:8	infus	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TREANDA.xml:S2:357:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
:	TREANDA.xml:S2:366:1	:	:	O	O
Severe	TREANDA.xml:S2:368:6	sever	NNP	O	O
and	TREANDA.xml:S2:375:3	and	CC	O	O
anaphylactic	TREANDA.xml:S2:379:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reactions	TREANDA.xml:S2:392:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
have	TREANDA.xml:S2:402:4	have	VBP	O	O
occurred	TREANDA.xml:S2:407:8	occur	VBN	O	O
;	TREANDA.xml:S2:415:1	;	:	O	O
monitor	TREANDA.xml:S2:417:7	monitor	NN	O	O
clinically	TREANDA.xml:S2:425:10	clinic	RB	O	O
and	TREANDA.xml:S2:436:3	and	CC	O	O
discontinue	TREANDA.xml:S2:440:11	discontinu	VB	O	O
TREANDA	TREANDA.xml:S2:452:7	treanda	NNP	O	O
.	TREANDA.xml:S2:459:1	.	.	O	O

Pre	TREANDA.xml:S2:461:3	pre	NNP	O	O
-	TREANDA.xml:S2:464:1	-	:	O	O
medicate	TREANDA.xml:S2:465:8	medic	NN	O	O
in	TREANDA.xml:S2:474:2	in	IN	O	O
subsequent	TREANDA.xml:S2:477:10	subsequ	JJ	O	O
cycles	TREANDA.xml:S2:488:6	cycl	NNS	O	O
for	TREANDA.xml:S2:495:3	for	IN	O	O
milder	TREANDA.xml:S2:499:6	milder	NN	O	O
reactions	TREANDA.xml:S2:506:9	reaction	NNS	O	O
.	TREANDA.xml:S2:515:1	.	.	O	O

(	TREANDA.xml:S2:517:1	(	(	O	O
5.3	TREANDA.xml:S2:520:3	5.3	CD	O	O
)	TREANDA.xml:S2:525:1	)	)	O	O

Tumor	TREANDA.xml:S2:534:5	tumor	NNP	B-AdverseReaction	B-AdverseReaction
Lysis	TREANDA.xml:S2:540:5	lysi	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	TREANDA.xml:S2:546:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
:	TREANDA.xml:S2:554:1	:	:	O	O
Acute	TREANDA.xml:S2:557:5	acut	NNP	B-AdverseReaction	B-AdverseReaction
renal	TREANDA.xml:S2:563:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	TREANDA.xml:S2:569:7	failur	NN	I-AdverseReaction	I-AdverseReaction
and	TREANDA.xml:S2:577:3	and	CC	O	O
death	TREANDA.xml:S2:581:5	death	NN	B-AdverseReaction	B-AdverseReaction
;	TREANDA.xml:S2:586:1	;	:	O	O
anticipate	TREANDA.xml:S2:588:10	anticip	NN	O	O
and	TREANDA.xml:S2:599:3	and	CC	O	O
use	TREANDA.xml:S2:603:3	use	VB	O	O
supportive	TREANDA.xml:S2:607:10	support	JJ	O	O
measures	TREANDA.xml:S2:618:8	measur	NNS	O	O
.	TREANDA.xml:S2:626:1	.	.	O	O

(	TREANDA.xml:S2:628:1	(	(	O	O
5.4	TREANDA.xml:S2:631:3	5.4	CD	O	O
)	TREANDA.xml:S2:636:1	)	)	O	O

Skin	TREANDA.xml:S2:645:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
Reactions	TREANDA.xml:S2:650:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
:	TREANDA.xml:S2:659:1	:	:	O	O
Discontinue	TREANDA.xml:S2:662:11	discontinu	NNP	O	O
for	TREANDA.xml:S2:674:3	for	IN	O	O
severe	TREANDA.xml:S2:678:6	sever	JJ	O	O
skin	TREANDA.xml:S2:685:4	skin	JJ	O	O
reactions	TREANDA.xml:S2:690:9	reaction	NNS	O	O
.	TREANDA.xml:S2:699:1	.	.	O	O

Cases	TREANDA.xml:S2:701:5	case	NNS	O	O
of	TREANDA.xml:S2:707:2	of	IN	O	O
SJS	TREANDA.xml:S2:710:3	sj	NNP	B-AdverseReaction	O
and	TREANDA.xml:S2:714:3	and	CC	O	O
TEN	TREANDA.xml:S2:718:3	ten	NNP	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:721:1	,	,	O	O
some	TREANDA.xml:S2:723:4	some	DT	O	O
fatal	TREANDA.xml:S2:728:5	fatal	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:733:1	,	,	O	O
have	TREANDA.xml:S2:735:4	have	VBP	O	O
been	TREANDA.xml:S2:740:4	been	VBN	O	O
reported	TREANDA.xml:S2:745:8	report	VBN	O	O
when	TREANDA.xml:S2:754:4	when	WRB	O	O
TREANDA	TREANDA.xml:S2:759:7	treanda	NNP	O	O
was	TREANDA.xml:S2:767:3	wa	VBD	O	O
administered	TREANDA.xml:S2:771:12	administ	VBN	O	O
concomitantly	TREANDA.xml:S2:784:13	concomitantli	RB	O	O
with	TREANDA.xml:S2:798:4	with	IN	O	O
allopurinol	TREANDA.xml:S2:803:11	allopurinol	NNS	O	O
and	TREANDA.xml:S2:815:3	and	CC	O	O
other	TREANDA.xml:S2:819:5	other	JJ	O	O
medications	TREANDA.xml:S2:825:11	medic	NNS	O	O
known	TREANDA.xml:S2:837:5	known	VBN	O	O
to	TREANDA.xml:S2:843:2	to	TO	O	O
cause	TREANDA.xml:S2:846:5	caus	VB	O	O
these	TREANDA.xml:S2:852:5	these	DT	O	O
syndromes	TREANDA.xml:S2:858:9	syndrom	NNS	O	O
.	TREANDA.xml:S2:867:1	.	.	O	O

(	TREANDA.xml:S2:869:1	(	(	O	O
5.5	TREANDA.xml:S2:872:3	5.5	CD	O	O
)	TREANDA.xml:S2:877:1	)	)	O	O

Other	TREANDA.xml:S2:886:5	other	JJ	O	O
Malignancies	TREANDA.xml:S2:892:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
:	TREANDA.xml:S2:904:1	:	:	O	O
Pre	TREANDA.xml:S2:906:3	pre	NNP	B-AdverseReaction	O
-	TREANDA.xml:S2:909:1	-	:	I-AdverseReaction	O
malignant	TREANDA.xml:S2:910:9	malign	NN	I-AdverseReaction	O
and	TREANDA.xml:S2:920:3	and	CC	O	O
malignant	TREANDA.xml:S2:924:9	malign	JJ	B-AdverseReaction	B-AdverseReaction
diseases	TREANDA.xml:S2:934:8	diseas	NNS	I-AdverseReaction	I-AdverseReaction
have	TREANDA.xml:S2:943:4	have	VBP	O	O
been	TREANDA.xml:S2:948:4	been	VBN	O	O
reported	TREANDA.xml:S2:953:8	report	VBN	O	O
.	TREANDA.xml:S2:961:1	.	.	O	O

(	TREANDA.xml:S2:963:1	(	(	O	O
5.6	TREANDA.xml:S2:966:3	5.6	CD	O	O
)	TREANDA.xml:S2:971:1	)	)	O	O

Extravasation	TREANDA.xml:S2:980:13	extravas	NN	B-AdverseReaction	O
:	TREANDA.xml:S2:993:1	:	:	O	O
Assure	TREANDA.xml:S2:995:6	assur	NN	O	B-AdverseReaction
good	TREANDA.xml:S2:1002:4	good	JJ	O	I-AdverseReaction
venous	TREANDA.xml:S2:1007:6	venou	JJ	O	I-AdverseReaction
access	TREANDA.xml:S2:1014:6	access	NN	O	I-AdverseReaction
and	TREANDA.xml:S2:1021:3	and	CC	O	O
monitor	TREANDA.xml:S2:1025:7	monitor	NN	O	O
infusion	TREANDA.xml:S2:1033:8	infus	NN	O	O
site	TREANDA.xml:S2:1042:4	site	NN	O	O
during	TREANDA.xml:S2:1047:6	dure	IN	O	O
and	TREANDA.xml:S2:1054:3	and	CC	O	O
after	TREANDA.xml:S2:1058:5	after	IN	O	O
administration	TREANDA.xml:S2:1064:14	administr	NN	O	O
.	TREANDA.xml:S2:1078:1	.	.	O	O

(	TREANDA.xml:S2:1080:1	(	(	O	O
5.7	TREANDA.xml:S2:1083:3	5.7	CD	O	O
)	TREANDA.xml:S2:1088:1	)	)	O	O

Embryo	TREANDA.xml:S2:1097:6	embryo	NNP	B-AdverseReaction	B-AdverseReaction
-	TREANDA.xml:S2:1103:1	-	:	I-AdverseReaction	I-AdverseReaction
fetal	TREANDA.xml:S2:1104:5	fetal	JJ	I-AdverseReaction	I-AdverseReaction
toxicity	TREANDA.xml:S2:1110:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
:	TREANDA.xml:S2:1118:1	:	:	O	O
Fetal	TREANDA.xml:S2:1121:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	TREANDA.xml:S2:1127:4	harm	NN	I-AdverseReaction	I-AdverseReaction
can	TREANDA.xml:S2:1132:3	can	MD	O	O
occur	TREANDA.xml:S2:1136:5	occur	VB	O	O
when	TREANDA.xml:S2:1142:4	when	WRB	O	O
administered	TREANDA.xml:S2:1147:12	administ	VBN	O	O
to	TREANDA.xml:S2:1160:2	to	TO	O	O
a	TREANDA.xml:S2:1163:1	a	DT	O	O
pregnant	TREANDA.xml:S2:1165:8	pregnant	JJ	O	O
woman	TREANDA.xml:S2:1174:5	woman	NN	O	O
.	TREANDA.xml:S2:1179:1	.	.	O	O

Women	TREANDA.xml:S2:1181:5	women	NNS	O	O
should	TREANDA.xml:S2:1187:6	should	MD	O	O
be	TREANDA.xml:S2:1194:2	be	VB	O	O
advised	TREANDA.xml:S2:1197:7	advis	VBN	O	O
to	TREANDA.xml:S2:1205:2	to	TO	O	O
avoid	TREANDA.xml:S2:1208:5	avoid	VB	O	O
becoming	TREANDA.xml:S2:1214:8	becom	VBG	O	O
pregnant	TREANDA.xml:S2:1223:8	pregnant	JJ	O	O
when	TREANDA.xml:S2:1232:4	when	WRB	O	O
receiving	TREANDA.xml:S2:1237:9	receiv	VBG	O	O
TREANDA	TREANDA.xml:S2:1247:7	treanda	NNP	O	O
.	TREANDA.xml:S2:1254:1	.	.	O	O

(	TREANDA.xml:S2:1256:1	(	(	O	O
5.8	TREANDA.xml:S2:1259:3	5.8	CD	O	O
,	TREANDA.xml:S2:1264:1	,	,	O	O
8.1	TREANDA.xml:S2:1267:3	8.1	CD	O	O
)	TREANDA.xml:S2:1272:1	)	)	O	O

5.1	TREANDA.xml:S2:1286:3	5.1	CD	O	O

Myelosuppression	TREANDA.xml:S2:1291:16	myelosuppress	NN	O	O

TREANDA	TREANDA.xml:S2:1313:7	treanda	NN	O	O

caused	TREANDA.xml:S2:1321:6	caus	VBN	O	O
severe	TREANDA.xml:S2:1328:6	sever	JJ	O	O
myelosuppression	TREANDA.xml:S2:1335:16	myelosuppress	NN	B-AdverseReaction	O
(	TREANDA.xml:S2:1352:1	(	(	O	O
Grade	TREANDA.xml:S2:1353:5	grade	NNP	O	O
3	TREANDA.xml:S2:1359:1	3	CD	O	O
-	TREANDA.xml:S2:1360:1	-	:	O	O
4	TREANDA.xml:S2:1361:1	4	CD	O	O
)	TREANDA.xml:S2:1362:1	)	)	O	O
in	TREANDA.xml:S2:1364:2	in	IN	O	O
98%	TREANDA.xml:S2:1367:3	98%	CD	O	O
of	TREANDA.xml:S2:1371:2	of	IN	O	O
patients	TREANDA.xml:S2:1374:8	patient	NNS	O	O
in	TREANDA.xml:S2:1383:2	in	IN	O	O
the	TREANDA.xml:S2:1386:3	the	DT	O	O
two	TREANDA.xml:S2:1390:3	two	CD	O	O
NHL	TREANDA.xml:S2:1394:3	nhl	NNP	O	O
studies	TREANDA.xml:S2:1398:7	studi	NNS	O	O
(	TREANDA.xml:S2:1406:1	(	(	O	O
see	TREANDA.xml:S2:1407:3	see	VB	O	O
Table	TREANDA.xml:S2:1411:5	tabl	NNP	O	O
4	TREANDA.xml:S2:1417:1	4	CD	O	O
)	TREANDA.xml:S2:1418:1	)	)	O	O
.	TREANDA.xml:S2:1419:1	.	.	O	O

Three	TREANDA.xml:S2:1421:5	three	CD	O	O
patients	TREANDA.xml:S2:1427:8	patient	NNS	O	O
(	TREANDA.xml:S2:1436:1	(	(	O	O
2%	TREANDA.xml:S2:1437:2	2%	CD	O	O
)	TREANDA.xml:S2:1439:1	)	)	O	O
died	TREANDA.xml:S2:1441:4	die	VBD	B-AdverseReaction	B-AdverseReaction
from	TREANDA.xml:S2:1446:4	from	IN	O	O
myelosuppression	TREANDA.xml:S2:1451:16	myelosuppress	NN	B-AdverseReaction	O
-	TREANDA.xml:S2:1467:1	-	:	I-AdverseReaction	O
related	TREANDA.xml:S2:1468:7	relat	JJ	I-AdverseReaction	O
adverse	TREANDA.xml:S2:1476:7	advers	JJ	I-AdverseReaction	O
reactions	TREANDA.xml:S2:1484:9	reaction	NNS	I-AdverseReaction	O
;	TREANDA.xml:S2:1493:1	;	:	O	O
one	TREANDA.xml:S2:1495:3	one	CD	O	O
each	TREANDA.xml:S2:1499:4	each	DT	O	O
from	TREANDA.xml:S2:1504:4	from	IN	O	O
neutropenic	TREANDA.xml:S2:1509:11	neutropen	JJ	B-AdverseReaction	B-AdverseReaction
sepsis	TREANDA.xml:S2:1521:6	sepsi	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S2:1527:1	,	,	O	O
diffuse	TREANDA.xml:S2:1529:7	diffus	IN	B-AdverseReaction	B-AdverseReaction
alveolar	TREANDA.xml:S2:1537:8	alveolar	JJ	I-AdverseReaction	I-AdverseReaction
hemorrhage	TREANDA.xml:S2:1546:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
with	TREANDA.xml:S2:1557:4	with	IN	O	O
Grade	TREANDA.xml:S2:1562:5	grade	NNP	O	O
3	TREANDA.xml:S2:1568:1	3	CD	O	O
thrombocytopenia	TREANDA.xml:S2:1570:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:1586:1	,	,	O	O
and	TREANDA.xml:S2:1588:3	and	CC	O	O
pneumonia	TREANDA.xml:S2:1592:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
from	TREANDA.xml:S2:1602:4	from	IN	O	O
an	TREANDA.xml:S2:1607:2	an	DT	O	O
opportunistic	TREANDA.xml:S2:1610:13	opportunist	JJ	B-AdverseReaction	O
infection	TREANDA.xml:S2:1624:9	infect	NN	I-AdverseReaction	O
(	TREANDA.xml:S2:1634:1	(	(	O	O
CMV	TREANDA.xml:S2:1635:3	cmv	NNP	I-AdverseReaction	O
)	TREANDA.xml:S2:1638:1	)	)	O	O
.	TREANDA.xml:S2:1639:1	.	.	O	O

In	TREANDA.xml:S2:1645:2	In	IN	O	O
the	TREANDA.xml:S2:1648:3	the	DT	O	O
event	TREANDA.xml:S2:1652:5	event	NN	O	O
of	TREANDA.xml:S2:1658:2	of	IN	O	O
treatment	TREANDA.xml:S2:1661:9	treatment	NN	O	O
-	TREANDA.xml:S2:1670:1	-	:	O	O
related	TREANDA.xml:S2:1671:7	relat	JJ	O	O
myelosuppression	TREANDA.xml:S2:1679:16	myelosuppress	NN	O	O
,	TREANDA.xml:S2:1695:1	,	,	O	O
monitor	TREANDA.xml:S2:1697:7	monitor	NN	O	O
leukocytes	TREANDA.xml:S2:1705:10	leukocyt	NNS	O	O
,	TREANDA.xml:S2:1715:1	,	,	O	O
platelets	TREANDA.xml:S2:1717:9	platelet	NNS	O	I-AdverseReaction
,	TREANDA.xml:S2:1726:1	,	,	O	O
hemoglobin	TREANDA.xml:S2:1728:10	hemoglobin	NN	O	B-AdverseReaction
(	TREANDA.xml:S2:1739:1	(	(	O	O
Hgb	TREANDA.xml:S2:1740:3	hgb	NNP	O	O
)	TREANDA.xml:S2:1743:1	)	)	O	O
,	TREANDA.xml:S2:1744:1	,	,	O	O
and	TREANDA.xml:S2:1746:3	and	CC	O	O
neutrophils	TREANDA.xml:S2:1750:11	neutrophil	NNS	O	I-AdverseReaction
frequently	TREANDA.xml:S2:1762:10	frequent	RB	O	O
.	TREANDA.xml:S2:1772:1	.	.	O	O

In	TREANDA.xml:S2:1774:2	In	IN	O	O
the	TREANDA.xml:S2:1777:3	the	DT	O	O
clinical	TREANDA.xml:S2:1781:8	clinic	JJ	O	O
trials	TREANDA.xml:S2:1790:6	trial	NNS	O	O
,	TREANDA.xml:S2:1796:1	,	,	O	O
blood	TREANDA.xml:S2:1798:5	blood	NN	O	O
counts	TREANDA.xml:S2:1804:6	count	NNS	O	O
were	TREANDA.xml:S2:1811:4	were	VBD	O	O
monitored	TREANDA.xml:S2:1816:9	monitor	VBN	O	O
every	TREANDA.xml:S2:1826:5	everi	DT	O	O
week	TREANDA.xml:S2:1832:4	week	NN	O	O
initially	TREANDA.xml:S2:1837:9	initi	RB	O	O
.	TREANDA.xml:S2:1846:1	.	.	O	O

Hematologic	TREANDA.xml:S2:1848:11	hematolog	NNP	O	B-AdverseReaction
nadirs	TREANDA.xml:S2:1860:6	nadir	NNS	O	I-AdverseReaction
were	TREANDA.xml:S2:1867:4	were	VBD	O	O
observed	TREANDA.xml:S2:1872:8	observ	VBN	O	O
predominantly	TREANDA.xml:S2:1881:13	predominantli	RB	O	O
in	TREANDA.xml:S2:1895:2	in	IN	O	O
the	TREANDA.xml:S2:1898:3	the	DT	O	O
third	TREANDA.xml:S2:1902:5	third	JJ	O	O
week	TREANDA.xml:S2:1908:4	week	NN	O	O
of	TREANDA.xml:S2:1913:2	of	IN	O	O
therapy	TREANDA.xml:S2:1916:7	therapi	NN	O	O
.	TREANDA.xml:S2:1923:1	.	.	O	O

Myelosuppression	TREANDA.xml:S2:1925:16	myelosuppress	NN	O	O
may	TREANDA.xml:S2:1942:3	may	MD	O	O
require	TREANDA.xml:S2:1946:7	requir	VB	O	O
dose	TREANDA.xml:S2:1954:4	dose	JJ	O	O
delays	TREANDA.xml:S2:1959:6	delay	NNS	O	O
and	TREANDA.xml:S2:1966:3	and	CC	O	O
or	TREANDA.xml:S2:1970:2	or	CC	O	O
subsequent	TREANDA.xml:S2:1973:10	subsequ	JJ	O	O
dose	TREANDA.xml:S2:1984:4	dose	NN	O	O
reductions	TREANDA.xml:S2:1989:10	reduct	NNS	O	O
if	TREANDA.xml:S2:2000:2	if	IN	O	O
recovery	TREANDA.xml:S2:2003:8	recoveri	NN	O	O
to	TREANDA.xml:S2:2012:2	to	TO	O	O
the	TREANDA.xml:S2:2015:3	the	DT	O	O
recommended	TREANDA.xml:S2:2019:11	recommend	VBN	O	O
values	TREANDA.xml:S2:2031:6	valu	NNS	O	O
has	TREANDA.xml:S2:2038:3	ha	VBZ	O	O
not	TREANDA.xml:S2:2042:3	not	RB	O	O
occurred	TREANDA.xml:S2:2046:8	occur	VBN	O	O
by	TREANDA.xml:S2:2055:2	by	IN	O	O
the	TREANDA.xml:S2:2058:3	the	DT	O	O
first	TREANDA.xml:S2:2062:5	first	JJ	O	O
day	TREANDA.xml:S2:2068:3	day	NN	O	O
of	TREANDA.xml:S2:2072:2	of	IN	O	O
the	TREANDA.xml:S2:2075:3	the	DT	O	O
next	TREANDA.xml:S2:2079:4	next	JJ	O	O
scheduled	TREANDA.xml:S2:2084:9	schedul	JJ	O	O
cycle	TREANDA.xml:S2:2094:5	cycl	NN	O	O
.	TREANDA.xml:S2:2099:1	.	.	O	O

Prior	TREANDA.xml:S2:2101:5	prior	RB	O	O
to	TREANDA.xml:S2:2107:2	to	TO	O	O
the	TREANDA.xml:S2:2110:3	the	DT	O	O
initiation	TREANDA.xml:S2:2114:10	initi	NN	O	O
of	TREANDA.xml:S2:2125:2	of	IN	O	O
the	TREANDA.xml:S2:2128:3	the	DT	O	O
next	TREANDA.xml:S2:2132:4	next	JJ	O	O
cycle	TREANDA.xml:S2:2137:5	cycl	NN	O	O
of	TREANDA.xml:S2:2143:2	of	IN	O	O
therapy	TREANDA.xml:S2:2146:7	therapi	NN	O	O
,	TREANDA.xml:S2:2153:1	,	,	O	O
the	TREANDA.xml:S2:2155:3	the	DT	O	O
ANC	TREANDA.xml:S2:2159:3	anc	NNP	O	O
should	TREANDA.xml:S2:2163:6	should	MD	O	O
be	TREANDA.xml:S2:2170:2	be	VB	O	O
1	TREANDA.xml:S2:2176:1	1	CD	O	O
x	TREANDA.xml:S2:2178:1	x	JJ	O	O
10	TREANDA.xml:S2:2180:2	10	CD	O	O
9	TREANDA.xml:S2:2184:1	9	CD	O	O
L	TREANDA.xml:S2:2188:1	L	NNP	O	O
and	TREANDA.xml:S2:2190:3	and	CC	O	O
the	TREANDA.xml:S2:2194:3	the	DT	O	O
platelet	TREANDA.xml:S2:2198:8	platelet	NN	O	O
count	TREANDA.xml:S2:2207:5	count	NN	O	O
should	TREANDA.xml:S2:2213:6	should	MD	O	O
be	TREANDA.xml:S2:2220:2	be	VB	O	O
75	TREANDA.xml:S2:2226:2	75	CD	O	O
x	TREANDA.xml:S2:2229:1	x	JJ	O	O
10	TREANDA.xml:S2:2231:2	10	CD	O	O
9	TREANDA.xml:S2:2235:1	9	CD	O	O
L.	TREANDA.xml:S2:2239:2	L.	NNP	O	O

[	TREANDA.xml:S2:2242:1	[	NNS	O	O
see	TREANDA.xml:S2:2243:3	see	VBP	O	O
Dosage	TREANDA.xml:S2:2248:6	dosag	NNP	O	O
and	TREANDA.xml:S2:2255:3	and	CC	O	O
Administration	TREANDA.xml:S2:2259:14	administr	NNP	O	O
(	TREANDA.xml:S2:2275:1	(	(	O	O
2.2	TREANDA.xml:S2:2278:3	2.2	CD	O	O
)	TREANDA.xml:S2:2283:1	)	)	O	O
and	TREANDA.xml:S2:2285:3	and	CC	O	O
(	TREANDA.xml:S2:2289:1	(	(	O	O
2.3	TREANDA.xml:S2:2292:3	2.3	CD	O	O
)]	TREANDA.xml:S2:2297:2	)]	NN	O	O

5.2	TREANDA.xml:S2:2309:3	5.2	CD	O	O
Infections	TREANDA.xml:S2:2314:10	infect	NNS	O	O

Infection	TREANDA.xml:S2:2330:9	infect	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:2339:1	,	,	O	O
including	TREANDA.xml:S2:2341:9	includ	VBG	O	O
pneumonia	TREANDA.xml:S2:2351:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:2360:1	,	,	O	O
sepsis	TREANDA.xml:S2:2362:6	sepsi	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:2368:1	,	,	O	O
septic	TREANDA.xml:S2:2370:6	septic	JJ	B-AdverseReaction	B-AdverseReaction
shock	TREANDA.xml:S2:2377:5	shock	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S2:2382:1	,	,	O	O
and	TREANDA.xml:S2:2384:3	and	CC	O	O
death	TREANDA.xml:S2:2388:5	death	NN	B-AdverseReaction	B-AdverseReaction
have	TREANDA.xml:S2:2394:4	have	VBP	O	O
occurred	TREANDA.xml:S2:2399:8	occur	VBN	O	O
in	TREANDA.xml:S2:2408:2	in	IN	O	O
adult	TREANDA.xml:S2:2411:5	adult	NN	O	O
and	TREANDA.xml:S2:2417:3	and	CC	O	O
pediatric	TREANDA.xml:S2:2421:9	pediatr	JJ	O	O
patients	TREANDA.xml:S2:2431:8	patient	NNS	O	O
in	TREANDA.xml:S2:2440:2	in	IN	O	O
clinical	TREANDA.xml:S2:2443:8	clinic	JJ	O	O
trials	TREANDA.xml:S2:2452:6	trial	NNS	O	O
and	TREANDA.xml:S2:2459:3	and	CC	O	O
in	TREANDA.xml:S2:2463:2	in	IN	O	O
postmarketing	TREANDA.xml:S2:2466:13	postmarket	VBG	O	O
reports	TREANDA.xml:S2:2480:7	report	NNS	O	O
.	TREANDA.xml:S2:2487:1	.	.	O	O

Patients	TREANDA.xml:S2:2489:8	patient	NNS	O	O
with	TREANDA.xml:S2:2498:4	with	IN	O	O
myelosuppression	TREANDA.xml:S2:2503:16	myelosuppress	NN	B-AdverseReaction	O
following	TREANDA.xml:S2:2520:9	follow	VBG	O	O
treatment	TREANDA.xml:S2:2530:9	treatment	NN	O	O
with	TREANDA.xml:S2:2540:4	with	IN	O	O
TREANDA	TREANDA.xml:S2:2545:7	treanda	NNP	O	O
are	TREANDA.xml:S2:2553:3	are	VBP	O	O
more	TREANDA.xml:S2:2557:4	more	RBR	O	O
susceptible	TREANDA.xml:S2:2562:11	suscept	JJ	O	O
to	TREANDA.xml:S2:2574:2	to	TO	O	O
infections	TREANDA.xml:S2:2577:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S2:2587:1	.	.	O	O

Advise	TREANDA.xml:S2:2589:6	advis	NN	O	O
patients	TREANDA.xml:S2:2596:8	patient	NNS	O	O
with	TREANDA.xml:S2:2605:4	with	IN	O	O
myelosuppression	TREANDA.xml:S2:2610:16	myelosuppress	NN	O	O
following	TREANDA.xml:S2:2627:9	follow	VBG	O	O
TREANDA	TREANDA.xml:S2:2637:7	treanda	NNP	O	O
treatment	TREANDA.xml:S2:2645:9	treatment	NN	O	O
to	TREANDA.xml:S2:2655:2	to	TO	O	O
contact	TREANDA.xml:S2:2658:7	contact	VB	O	O
a	TREANDA.xml:S2:2666:1	a	DT	O	O
physician	TREANDA.xml:S2:2668:9	physician	NN	O	O
if	TREANDA.xml:S2:2678:2	if	IN	O	O
they	TREANDA.xml:S2:2681:4	they	PRP	O	O
have	TREANDA.xml:S2:2686:4	have	VBP	O	O
symptoms	TREANDA.xml:S2:2691:8	symptom	NNS	O	O
or	TREANDA.xml:S2:2700:2	or	CC	O	O
signs	TREANDA.xml:S2:2703:5	sign	NNS	O	O
of	TREANDA.xml:S2:2709:2	of	IN	O	O
infection	TREANDA.xml:S2:2712:9	infect	NN	O	O
.	TREANDA.xml:S2:2721:1	.	.	O	O

5.3	TREANDA.xml:S2:2730:3	5.3	CD	O	O
Anaphylaxis	TREANDA.xml:S2:2735:11	anaphylaxi	NNP	O	O
and	TREANDA.xml:S2:2747:3	and	CC	O	O
Infusion	TREANDA.xml:S2:2751:8	infus	NNP	O	O
Reactions	TREANDA.xml:S2:2760:9	reaction	NNP	O	O

Infusion	TREANDA.xml:S2:2775:8	infus	NN	B-AdverseReaction	O
reactions	TREANDA.xml:S2:2784:9	reaction	NNS	I-AdverseReaction	O
to	TREANDA.xml:S2:2794:2	to	TO	O	O
TREANDA	TREANDA.xml:S2:2797:7	treanda	NNP	O	O
have	TREANDA.xml:S2:2805:4	have	VB	O	O
occurred	TREANDA.xml:S2:2810:8	occur	VBN	O	O
commonly	TREANDA.xml:S2:2819:8	commonli	RB	O	O
in	TREANDA.xml:S2:2828:2	in	IN	O	O
clinical	TREANDA.xml:S2:2831:8	clinic	JJ	O	O
trials	TREANDA.xml:S2:2840:6	trial	NNS	O	O
.	TREANDA.xml:S2:2846:1	.	.	O	O

Symptoms	TREANDA.xml:S2:2848:8	symptom	NNP	O	O
include	TREANDA.xml:S2:2857:7	includ	VBP	O	O
fever	TREANDA.xml:S2:2865:5	fever	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:2870:1	,	,	O	O
chills	TREANDA.xml:S2:2872:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:2878:1	,	,	O	O
pruritus	TREANDA.xml:S2:2880:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
and	TREANDA.xml:S2:2889:3	and	CC	O	O
rash	TREANDA.xml:S2:2893:4	rash	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S2:2897:1	.	.	O	O

In	TREANDA.xml:S2:2899:2	In	IN	O	O
rare	TREANDA.xml:S2:2902:4	rare	JJ	O	O
instances	TREANDA.xml:S2:2907:9	instanc	NNS	O	O
severe	TREANDA.xml:S2:2917:6	sever	JJ	O	O
anaphylactic	TREANDA.xml:S2:2924:12	anaphylact	JJ	B-AdverseReaction	O
and	TREANDA.xml:S2:2937:3	and	CC	O	O
anaphylactoid	TREANDA.xml:S2:2941:13	anaphylactoid	JJ	B-AdverseReaction	B-AdverseReaction
reactions	TREANDA.xml:S2:2955:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
have	TREANDA.xml:S2:2965:4	have	VBP	O	O
occurred	TREANDA.xml:S2:2970:8	occur	VBN	O	O
,	TREANDA.xml:S2:2978:1	,	,	O	O
particularly	TREANDA.xml:S2:2980:12	particularli	RB	O	O
in	TREANDA.xml:S2:2993:2	in	IN	O	O
the	TREANDA.xml:S2:2996:3	the	DT	O	O
second	TREANDA.xml:S2:3000:6	second	JJ	O	O
and	TREANDA.xml:S2:3007:3	and	CC	O	O
subsequent	TREANDA.xml:S2:3011:10	subsequ	JJ	O	O
cycles	TREANDA.xml:S2:3022:6	cycl	NNS	O	O
of	TREANDA.xml:S2:3029:2	of	IN	O	O
therapy	TREANDA.xml:S2:3032:7	therapi	NN	O	O
.	TREANDA.xml:S2:3039:1	.	.	O	O

Monitor	TREANDA.xml:S2:3041:7	monitor	NNP	O	O
clinically	TREANDA.xml:S2:3049:10	clinic	RB	O	O
and	TREANDA.xml:S2:3060:3	and	CC	O	O
discontinue	TREANDA.xml:S2:3064:11	discontinu	JJ	O	O
drug	TREANDA.xml:S2:3076:4	drug	NN	O	O
for	TREANDA.xml:S2:3081:3	for	IN	O	O
severe	TREANDA.xml:S2:3085:6	sever	JJ	O	O
reactions	TREANDA.xml:S2:3092:9	reaction	NNS	O	O
.	TREANDA.xml:S2:3101:1	.	.	O	O

Ask	TREANDA.xml:S2:3103:3	ask	NNP	O	O
patients	TREANDA.xml:S2:3107:8	patient	NNS	O	O
about	TREANDA.xml:S2:3116:5	about	IN	O	O
symptoms	TREANDA.xml:S2:3122:8	symptom	NNS	O	O
suggestive	TREANDA.xml:S2:3131:10	suggest	JJ	O	O
of	TREANDA.xml:S2:3142:2	of	IN	O	O
infusion	TREANDA.xml:S2:3145:8	infus	NN	O	O
reactions	TREANDA.xml:S2:3154:9	reaction	NNS	O	O
after	TREANDA.xml:S2:3164:5	after	IN	O	O
their	TREANDA.xml:S2:3170:5	their	PRP$	O	O
first	TREANDA.xml:S2:3176:5	first	JJ	O	O
cycle	TREANDA.xml:S2:3182:5	cycl	NN	O	O
of	TREANDA.xml:S2:3188:2	of	IN	O	O
therapy	TREANDA.xml:S2:3191:7	therapi	NN	O	O
.	TREANDA.xml:S2:3198:1	.	.	O	O

Patients	TREANDA.xml:S2:3200:8	patient	NNS	O	O
who	TREANDA.xml:S2:3209:3	who	WP	O	O
experience	TREANDA.xml:S2:3213:10	experi	VBP	O	O
Grade	TREANDA.xml:S2:3224:5	grade	NNP	O	O
3	TREANDA.xml:S2:3230:1	3	CD	O	O
or	TREANDA.xml:S2:3232:2	or	CC	O	O
worse	TREANDA.xml:S2:3235:5	wors	JJR	O	O
allergic	TREANDA.xml:S2:3241:8	allerg	JJ	O	O
-	TREANDA.xml:S2:3249:1	-	:	O	O
type	TREANDA.xml:S2:3250:4	type	NN	O	O
reactions	TREANDA.xml:S2:3255:9	reaction	NNS	O	O
should	TREANDA.xml:S2:3265:6	should	MD	O	O
not	TREANDA.xml:S2:3272:3	not	RB	O	O
be	TREANDA.xml:S2:3276:2	be	VB	O	O
rechallenged	TREANDA.xml:S2:3279:12	rechalleng	VBN	O	O
.	TREANDA.xml:S2:3291:1	.	.	O	O

Consider	TREANDA.xml:S2:3293:8	consid	VB	O	O
measures	TREANDA.xml:S2:3302:8	measur	NNS	O	O
to	TREANDA.xml:S2:3311:2	to	TO	O	O
prevent	TREANDA.xml:S2:3314:7	prevent	VB	O	O
severe	TREANDA.xml:S2:3322:6	sever	JJ	O	O
reactions	TREANDA.xml:S2:3329:9	reaction	NNS	O	O
,	TREANDA.xml:S2:3338:1	,	,	O	O
including	TREANDA.xml:S2:3340:9	includ	VBG	O	O
antihistamines	TREANDA.xml:S2:3350:14	antihistamin	NNS	O	O
,	TREANDA.xml:S2:3364:1	,	,	O	O
antipyretics	TREANDA.xml:S2:3366:12	antipyret	NNS	O	O
and	TREANDA.xml:S2:3379:3	and	CC	O	O
corticosteroids	TREANDA.xml:S2:3383:15	corticosteroid	NNS	O	O
in	TREANDA.xml:S2:3399:2	in	IN	O	O
subsequent	TREANDA.xml:S2:3402:10	subsequ	JJ	O	O
cycles	TREANDA.xml:S2:3413:6	cycl	NNS	O	O
in	TREANDA.xml:S2:3420:2	in	IN	O	O
patients	TREANDA.xml:S2:3423:8	patient	NNS	O	O
who	TREANDA.xml:S2:3432:3	who	WP	O	O
have	TREANDA.xml:S2:3436:4	have	VBP	O	O
experienced	TREANDA.xml:S2:3441:11	experienc	VBN	O	O
Grade	TREANDA.xml:S2:3453:5	grade	NNP	O	O
1	TREANDA.xml:S2:3459:1	1	CD	O	O
or	TREANDA.xml:S2:3461:2	or	CC	O	O
2	TREANDA.xml:S2:3464:1	2	CD	O	O
infusion	TREANDA.xml:S2:3466:8	infus	NN	O	O
reactions	TREANDA.xml:S2:3475:9	reaction	NNS	O	O
.	TREANDA.xml:S2:3484:1	.	.	O	O

Discontinue	TREANDA.xml:S2:3486:11	discontinu	NNP	O	O
TREANDA	TREANDA.xml:S2:3498:7	treanda	NNP	O	O
for	TREANDA.xml:S2:3506:3	for	IN	O	O
patients	TREANDA.xml:S2:3510:8	patient	NNS	O	O
with	TREANDA.xml:S2:3519:4	with	IN	O	O
Grade	TREANDA.xml:S2:3524:5	grade	NNP	O	O
4	TREANDA.xml:S2:3530:1	4	CD	O	O
infusion	TREANDA.xml:S2:3532:8	infus	NN	O	B-AdverseReaction
reactions	TREANDA.xml:S2:3541:9	reaction	NNS	O	I-AdverseReaction
.	TREANDA.xml:S2:3550:1	.	.	O	O

Consider	TREANDA.xml:S2:3552:8	consid	VB	O	O
discontinuation	TREANDA.xml:S2:3561:15	discontinu	NN	O	O
for	TREANDA.xml:S2:3577:3	for	IN	O	O
Grade	TREANDA.xml:S2:3581:5	grade	NNP	O	O
3	TREANDA.xml:S2:3587:1	3	CD	O	O
infusions	TREANDA.xml:S2:3589:9	infus	NNS	O	O
reactions	TREANDA.xml:S2:3599:9	reaction	NNS	O	O
as	TREANDA.xml:S2:3609:2	as	IN	O	O
clinically	TREANDA.xml:S2:3612:10	clinic	RB	O	O
appropriate	TREANDA.xml:S2:3623:11	appropri	JJ	O	O
considering	TREANDA.xml:S2:3635:11	consid	VBG	O	O
individual	TREANDA.xml:S2:3647:10	individu	JJ	O	O
benefits	TREANDA.xml:S2:3658:8	benefit	NNS	O	O
,	TREANDA.xml:S2:3666:1	,	,	O	O
risks	TREANDA.xml:S2:3668:5	risk	NNS	O	O
,	TREANDA.xml:S2:3673:1	,	,	O	O
and	TREANDA.xml:S2:3675:3	and	CC	O	O
supportive	TREANDA.xml:S2:3679:10	support	JJ	O	O
care	TREANDA.xml:S2:3690:4	care	NN	O	O
.	TREANDA.xml:S2:3694:1	.	.	O	O

5.4	TREANDA.xml:S2:3703:3	5.4	CD	O	O
Tumor	TREANDA.xml:S2:3708:5	tumor	NNP	O	O
Lysis	TREANDA.xml:S2:3714:5	lysi	NNP	O	O
Syndrome	TREANDA.xml:S2:3720:8	syndrom	NNP	O	O

Tumor	TREANDA.xml:S2:3734:5	tumor	NNP	B-AdverseReaction	O
lysis	TREANDA.xml:S2:3740:5	lysi	VBD	I-AdverseReaction	O
syndrome	TREANDA.xml:S2:3746:8	syndrom	RB	I-AdverseReaction	O
associated	TREANDA.xml:S2:3755:10	associ	VBN	O	O
with	TREANDA.xml:S2:3766:4	with	IN	O	O
TREANDA	TREANDA.xml:S2:3771:7	treanda	NNP	O	O
treatment	TREANDA.xml:S2:3779:9	treatment	NN	O	O
has	TREANDA.xml:S2:3789:3	ha	VBZ	O	O
occurred	TREANDA.xml:S2:3793:8	occur	VBN	O	O
in	TREANDA.xml:S2:3802:2	in	IN	O	O
patients	TREANDA.xml:S2:3805:8	patient	NNS	O	O
in	TREANDA.xml:S2:3814:2	in	IN	O	O
clinical	TREANDA.xml:S2:3817:8	clinic	JJ	O	O
trials	TREANDA.xml:S2:3826:6	trial	NNS	O	O
and	TREANDA.xml:S2:3833:3	and	CC	O	O
in	TREANDA.xml:S2:3837:2	in	IN	O	O
postmarketing	TREANDA.xml:S2:3840:13	postmarket	VBG	O	O
reports	TREANDA.xml:S2:3854:7	report	NNS	O	O
.	TREANDA.xml:S2:3861:1	.	.	O	O

The	TREANDA.xml:S2:3863:3	the	DT	O	O
onset	TREANDA.xml:S2:3867:5	onset	NN	O	O
tends	TREANDA.xml:S2:3873:5	tend	VBZ	O	O
to	TREANDA.xml:S2:3879:2	to	TO	O	O
be	TREANDA.xml:S2:3882:2	be	VB	O	O
within	TREANDA.xml:S2:3885:6	within	IN	O	O
the	TREANDA.xml:S2:3892:3	the	DT	O	O
first	TREANDA.xml:S2:3896:5	first	JJ	O	O
treatment	TREANDA.xml:S2:3902:9	treatment	NN	O	O
cycle	TREANDA.xml:S2:3912:5	cycl	NN	O	O
of	TREANDA.xml:S2:3918:2	of	IN	O	O
TREANDA	TREANDA.xml:S2:3921:7	treanda	NNP	O	O
and	TREANDA.xml:S2:3929:3	and	CC	O	O
,	TREANDA.xml:S2:3932:1	,	,	O	O
without	TREANDA.xml:S2:3934:7	without	IN	O	O
intervention	TREANDA.xml:S2:3942:12	intervent	NN	O	O
,	TREANDA.xml:S2:3954:1	,	,	O	O
may	TREANDA.xml:S2:3956:3	may	MD	O	O
lead	TREANDA.xml:S2:3960:4	lead	VB	O	O
to	TREANDA.xml:S2:3965:2	to	TO	O	O
acute	TREANDA.xml:S2:3968:5	acut	VB	B-AdverseReaction	B-AdverseReaction
renal	TREANDA.xml:S2:3974:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	TREANDA.xml:S2:3980:7	failur	NN	I-AdverseReaction	I-AdverseReaction
and	TREANDA.xml:S2:3988:3	and	CC	O	O
death	TREANDA.xml:S2:3992:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S2:3997:1	.	.	O	O

Preventive	TREANDA.xml:S2:3999:10	prevent	JJ	O	O
measures	TREANDA.xml:S2:4010:8	measur	NNS	O	O
include	TREANDA.xml:S2:4019:7	includ	VBP	O	O
vigorous	TREANDA.xml:S2:4027:8	vigor	JJ	O	O
hydration	TREANDA.xml:S2:4036:9	hydrat	NN	O	O
and	TREANDA.xml:S2:4046:3	and	CC	O	O
close	TREANDA.xml:S2:4050:5	close	JJ	O	O
monitoring	TREANDA.xml:S2:4056:10	monitor	NN	O	O
of	TREANDA.xml:S2:4067:2	of	IN	O	O
blood	TREANDA.xml:S2:4070:5	blood	NN	O	O
chemistry	TREANDA.xml:S2:4076:9	chemistri	NN	O	O
,	TREANDA.xml:S2:4085:1	,	,	O	O
particularly	TREANDA.xml:S2:4087:12	particularli	RB	O	O
potassium	TREANDA.xml:S2:4100:9	potassium	NN	O	O
and	TREANDA.xml:S2:4110:3	and	CC	O	O
uric	TREANDA.xml:S2:4114:4	uric	JJ	O	O
acid	TREANDA.xml:S2:4119:4	acid	NN	O	O
levels	TREANDA.xml:S2:4124:6	level	NNS	O	O
.	TREANDA.xml:S2:4130:1	.	.	O	O

Allopurinol	TREANDA.xml:S2:4132:11	allopurinol	NNP	O	O
has	TREANDA.xml:S2:4144:3	ha	VBZ	O	O
also	TREANDA.xml:S2:4148:4	also	RB	O	O
been	TREANDA.xml:S2:4153:4	been	VBN	O	O
used	TREANDA.xml:S2:4158:4	use	VBN	O	O
during	TREANDA.xml:S2:4163:6	dure	IN	O	O
the	TREANDA.xml:S2:4170:3	the	DT	O	O
beginning	TREANDA.xml:S2:4174:9	begin	NN	O	O
of	TREANDA.xml:S2:4184:2	of	IN	O	O
TREANDA	TREANDA.xml:S2:4187:7	treanda	NNP	O	O
therapy	TREANDA.xml:S2:4195:7	therapi	NN	O	O
.	TREANDA.xml:S2:4202:1	.	.	O	O

However	TREANDA.xml:S2:4204:7	howev	RB	O	O
,	TREANDA.xml:S2:4211:1	,	,	O	O
there	TREANDA.xml:S2:4213:5	there	EX	O	O
may	TREANDA.xml:S2:4219:3	may	MD	O	O
be	TREANDA.xml:S2:4223:2	be	VB	O	O
an	TREANDA.xml:S2:4226:2	an	DT	O	O
increased	TREANDA.xml:S2:4229:9	increas	VBN	O	O
risk	TREANDA.xml:S2:4239:4	risk	NN	O	O
of	TREANDA.xml:S2:4244:2	of	IN	O	O
severe	TREANDA.xml:S2:4247:6	sever	JJ	O	O
skin	TREANDA.xml:S2:4254:4	skin	NN	B-AdverseReaction	B-AdverseReaction
toxicity	TREANDA.xml:S2:4259:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
when	TREANDA.xml:S2:4268:4	when	WRB	O	O
TREANDA	TREANDA.xml:S2:4273:7	treanda	NNP	O	O
and	TREANDA.xml:S2:4281:3	and	CC	O	O
allopurinol	TREANDA.xml:S2:4285:11	allopurinol	NNS	O	O
are	TREANDA.xml:S2:4297:3	are	VBP	O	O
administered	TREANDA.xml:S2:4301:12	administ	VBN	O	O
concomitantly	TREANDA.xml:S2:4314:13	concomitantli	RB	O	O
[	TREANDA.xml:S2:4328:1	[	JJ	O	O
see	TREANDA.xml:S2:4329:3	see	VBP	O	O
Warnings	TREANDA.xml:S2:4334:8	warn	NNS	O	O
and	TREANDA.xml:S2:4343:3	and	CC	O	O
Precautions	TREANDA.xml:S2:4347:11	precaut	NNP	O	O
(	TREANDA.xml:S2:4360:1	(	(	O	O
5.5	TREANDA.xml:S2:4363:3	5.5	CD	O	O
)]	TREANDA.xml:S2:4368:2	)]	NN	O	O
.	TREANDA.xml:S2:4372:1	.	.	O	O

5.5	TREANDA.xml:S2:4381:3	5.5	CD	O	O
Skin	TREANDA.xml:S2:4386:4	skin	NNP	O	O
Reactions	TREANDA.xml:S2:4391:9	reaction	NNS	O	O

Skin	TREANDA.xml:S2:4406:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
reactions	TREANDA.xml:S2:4411:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
have	TREANDA.xml:S2:4421:4	have	VBP	O	O
been	TREANDA.xml:S2:4426:4	been	VBN	O	O
reported	TREANDA.xml:S2:4431:8	report	VBN	O	O
with	TREANDA.xml:S2:4440:4	with	IN	O	O
TREANDA	TREANDA.xml:S2:4445:7	treanda	NNP	O	O
treatment	TREANDA.xml:S2:4453:9	treatment	NN	O	O
in	TREANDA.xml:S2:4463:2	in	IN	O	O
clinical	TREANDA.xml:S2:4466:8	clinic	JJ	O	O
trials	TREANDA.xml:S2:4475:6	trial	NNS	O	O
and	TREANDA.xml:S2:4482:3	and	CC	O	O
postmarketing	TREANDA.xml:S2:4486:13	postmarket	VBG	O	O
safety	TREANDA.xml:S2:4500:6	safeti	NN	O	O
reports	TREANDA.xml:S2:4507:7	report	NNS	O	O
,	TREANDA.xml:S2:4514:1	,	,	O	O
including	TREANDA.xml:S2:4516:9	includ	VBG	O	O
rash	TREANDA.xml:S2:4526:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:4530:1	,	,	O	O
toxic	TREANDA.xml:S2:4532:5	toxic	JJ	B-AdverseReaction	B-AdverseReaction
skin	TREANDA.xml:S2:4538:4	skin	NN	I-AdverseReaction	I-AdverseReaction
reactions	TREANDA.xml:S2:4543:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
and	TREANDA.xml:S2:4553:3	and	CC	O	O
bullous	TREANDA.xml:S2:4557:7	bullou	JJ	B-AdverseReaction	B-AdverseReaction
exanthema	TREANDA.xml:S2:4565:9	exanthema	NN	I-AdverseReaction	I-AdverseReaction
.	TREANDA.xml:S2:4574:1	.	.	O	O

Some	TREANDA.xml:S2:4576:4	some	DT	O	O
events	TREANDA.xml:S2:4581:6	event	NNS	O	O
occurred	TREANDA.xml:S2:4588:8	occur	VBD	O	O
when	TREANDA.xml:S2:4597:4	when	WRB	O	O
TREANDA	TREANDA.xml:S2:4602:7	treanda	NNP	O	O
was	TREANDA.xml:S2:4610:3	wa	VBD	O	O
given	TREANDA.xml:S2:4614:5	given	VBN	O	O
in	TREANDA.xml:S2:4620:2	in	IN	O	O
combination	TREANDA.xml:S2:4623:11	combin	NN	O	O
with	TREANDA.xml:S2:4635:4	with	IN	O	O
other	TREANDA.xml:S2:4640:5	other	JJ	O	O
anticancer	TREANDA.xml:S2:4646:10	anticanc	NN	O	O
agents	TREANDA.xml:S2:4657:6	agent	NNS	O	O
.	TREANDA.xml:S2:4663:1	.	.	O	O

In	TREANDA.xml:S2:4669:2	In	IN	O	O
a	TREANDA.xml:S2:4672:1	a	DT	O	O
study	TREANDA.xml:S2:4674:5	studi	NN	O	O
of	TREANDA.xml:S2:4680:2	of	IN	O	O
TREANDA	TREANDA.xml:S2:4683:7	treanda	NNP	O	O
(	TREANDA.xml:S2:4691:1	(	(	O	O
90	TREANDA.xml:S2:4692:2	90	CD	O	O
mg	TREANDA.xml:S2:4695:2	mg	NN	O	O
m	TREANDA.xml:S2:4698:1	m	NN	O	O
2	TREANDA.xml:S2:4701:1	2	CD	O	O
)	TREANDA.xml:S2:4704:1	)	)	O	O
in	TREANDA.xml:S2:4706:2	in	IN	O	O
combination	TREANDA.xml:S2:4709:11	combin	NN	O	O
with	TREANDA.xml:S2:4721:4	with	IN	O	O
rituximab	TREANDA.xml:S2:4726:9	rituximab	NN	O	O
,	TREANDA.xml:S2:4735:1	,	,	O	O
one	TREANDA.xml:S2:4737:3	one	CD	O	O
case	TREANDA.xml:S2:4741:4	case	NN	O	O
of	TREANDA.xml:S2:4746:2	of	IN	O	O
toxic	TREANDA.xml:S2:4749:5	toxic	NN	B-AdverseReaction	O
epidermal	TREANDA.xml:S2:4755:9	epiderm	JJ	I-AdverseReaction	O
necrolysis	TREANDA.xml:S2:4765:10	necrolysi	NN	I-AdverseReaction	O
(	TREANDA.xml:S2:4776:1	(	(	O	O
TEN	TREANDA.xml:S2:4777:3	ten	NNP	B-AdverseReaction	B-AdverseReaction
)	TREANDA.xml:S2:4780:1	)	)	O	O
occurred	TREANDA.xml:S2:4782:8	occur	VBD	O	O
.	TREANDA.xml:S2:4790:1	.	.	O	O

TEN	TREANDA.xml:S2:4792:3	ten	NN	O	O
has	TREANDA.xml:S2:4796:3	ha	VBZ	O	O
been	TREANDA.xml:S2:4800:4	been	VBN	O	O
reported	TREANDA.xml:S2:4805:8	report	VBN	O	O
for	TREANDA.xml:S2:4814:3	for	IN	O	O
rituximab	TREANDA.xml:S2:4818:9	rituximab	NN	O	O
(	TREANDA.xml:S2:4828:1	(	(	O	O
see	TREANDA.xml:S2:4829:3	see	VB	O	O
rituximab	TREANDA.xml:S2:4833:9	rituximab	JJ	O	O
package	TREANDA.xml:S2:4843:7	packag	NN	O	O
insert	TREANDA.xml:S2:4851:6	insert	NN	O	O
)	TREANDA.xml:S2:4857:1	)	)	O	O
.	TREANDA.xml:S2:4858:1	.	.	O	O

Cases	TREANDA.xml:S2:4860:5	case	NNS	O	O
of	TREANDA.xml:S2:4866:2	of	IN	O	O
Stevens	TREANDA.xml:S2:4869:7	steven	NNP	B-AdverseReaction	B-AdverseReaction
-	TREANDA.xml:S2:4876:1	-	:	I-AdverseReaction	I-AdverseReaction
Johnson	TREANDA.xml:S2:4877:7	johnson	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	TREANDA.xml:S2:4885:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
(	TREANDA.xml:S2:4894:1	(	(	O	O
SJS	TREANDA.xml:S2:4895:3	sj	NNP	B-AdverseReaction	B-AdverseReaction
)	TREANDA.xml:S2:4898:1	)	)	O	O
and	TREANDA.xml:S2:4900:3	and	CC	O	O
TEN	TREANDA.xml:S2:4904:3	ten	NNP	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:4907:1	,	,	O	O
some	TREANDA.xml:S2:4909:4	some	DT	O	O
fatal	TREANDA.xml:S2:4914:5	fatal	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:4919:1	,	,	O	O
have	TREANDA.xml:S2:4921:4	have	VBP	O	O
been	TREANDA.xml:S2:4926:4	been	VBN	O	O
reported	TREANDA.xml:S2:4931:8	report	VBN	O	O
when	TREANDA.xml:S2:4940:4	when	WRB	O	O
TREANDA	TREANDA.xml:S2:4945:7	treanda	NNP	O	O
was	TREANDA.xml:S2:4953:3	wa	VBD	O	O
administered	TREANDA.xml:S2:4957:12	administ	VBN	O	O
concomitantly	TREANDA.xml:S2:4970:13	concomitantli	RB	O	O
with	TREANDA.xml:S2:4984:4	with	IN	O	O
allopurinol	TREANDA.xml:S2:4989:11	allopurinol	NNS	O	O
and	TREANDA.xml:S2:5001:3	and	CC	O	O
other	TREANDA.xml:S2:5005:5	other	JJ	O	O
medications	TREANDA.xml:S2:5011:11	medic	NNS	O	O
known	TREANDA.xml:S2:5023:5	known	VBN	O	O
to	TREANDA.xml:S2:5029:2	to	TO	O	O
cause	TREANDA.xml:S2:5032:5	caus	VB	O	O
these	TREANDA.xml:S2:5038:5	these	DT	O	O
syndromes	TREANDA.xml:S2:5044:9	syndrom	NNS	O	O
.	TREANDA.xml:S2:5053:1	.	.	O	O

The	TREANDA.xml:S2:5055:3	the	DT	O	O
relationship	TREANDA.xml:S2:5059:12	relationship	NN	O	O
to	TREANDA.xml:S2:5072:2	to	TO	O	O
TREANDA	TREANDA.xml:S2:5075:7	treanda	NNP	O	O
cannot	TREANDA.xml:S2:5083:6	cannot	NN	O	O
be	TREANDA.xml:S2:5090:2	be	VB	O	O
determined	TREANDA.xml:S2:5093:10	determin	VBN	O	O
.	TREANDA.xml:S2:5103:1	.	.	O	O

Where	TREANDA.xml:S2:5109:5	where	WRB	O	O
skin	TREANDA.xml:S2:5115:4	skin	JJ	B-AdverseReaction	O
reactions	TREANDA.xml:S2:5120:9	reaction	NNS	I-AdverseReaction	O
occur	TREANDA.xml:S2:5130:5	occur	VBP	O	O
,	TREANDA.xml:S2:5135:1	,	,	O	O
they	TREANDA.xml:S2:5137:4	they	PRP	O	O
may	TREANDA.xml:S2:5142:3	may	MD	O	O
be	TREANDA.xml:S2:5146:2	be	VB	O	O
progressive	TREANDA.xml:S2:5149:11	progress	JJ	O	O
and	TREANDA.xml:S2:5161:3	and	CC	O	O
increase	TREANDA.xml:S2:5165:8	increas	VB	O	O
in	TREANDA.xml:S2:5174:2	in	IN	O	O
severity	TREANDA.xml:S2:5177:8	sever	NN	O	O
with	TREANDA.xml:S2:5186:4	with	IN	O	O
further	TREANDA.xml:S2:5191:7	further	JJ	O	O
treatment	TREANDA.xml:S2:5199:9	treatment	NN	O	O
.	TREANDA.xml:S2:5208:1	.	.	O	O

Monitor	TREANDA.xml:S2:5210:7	monitor	NN	O	O
patients	TREANDA.xml:S2:5218:8	patient	NNS	O	O
with	TREANDA.xml:S2:5227:4	with	IN	O	O
skin	TREANDA.xml:S2:5232:4	skin	JJ	O	O
reactions	TREANDA.xml:S2:5237:9	reaction	NNS	O	O
closely	TREANDA.xml:S2:5247:7	close	RB	O	O
.	TREANDA.xml:S2:5254:1	.	.	O	O

If	TREANDA.xml:S2:5256:2	If	IN	O	O
skin	TREANDA.xml:S2:5259:4	skin	JJ	O	O
reactions	TREANDA.xml:S2:5264:9	reaction	NNS	O	O
are	TREANDA.xml:S2:5274:3	are	VBP	O	O
severe	TREANDA.xml:S2:5278:6	sever	JJ	O	O
or	TREANDA.xml:S2:5285:2	or	CC	O	O
progressive	TREANDA.xml:S2:5288:11	progress	JJ	O	O
,	TREANDA.xml:S2:5299:1	,	,	O	O
withhold	TREANDA.xml:S2:5301:8	withhold	VBD	O	O
or	TREANDA.xml:S2:5310:2	or	CC	O	O
discontinue	TREANDA.xml:S2:5313:11	discontinu	JJ	O	O
TREANDA	TREANDA.xml:S2:5325:7	treanda	NNP	O	O
.	TREANDA.xml:S2:5332:1	.	.	O	O

5.6	TREANDA.xml:S2:5341:3	5.6	CD	O	O
Other	TREANDA.xml:S2:5346:5	other	JJ	O	O
Malignancies	TREANDA.xml:S2:5352:12	malign	NNS	O	O

There	TREANDA.xml:S2:5370:5	there	EX	O	O
are	TREANDA.xml:S2:5376:3	are	VBP	O	O
reports	TREANDA.xml:S2:5380:7	report	NNS	O	O
of	TREANDA.xml:S2:5388:2	of	IN	O	O
pre	TREANDA.xml:S2:5391:3	pre	JJ	B-AdverseReaction	O
-	TREANDA.xml:S2:5394:1	-	:	I-AdverseReaction	O
malignant	TREANDA.xml:S2:5395:9	malign	NN	I-AdverseReaction	O
and	TREANDA.xml:S2:5405:3	and	CC	O	O
malignant	TREANDA.xml:S2:5409:9	malign	JJ	B-AdverseReaction	B-AdverseReaction
diseases	TREANDA.xml:S2:5419:8	diseas	NNS	I-AdverseReaction	I-AdverseReaction
that	TREANDA.xml:S2:5428:4	that	WDT	O	O
have	TREANDA.xml:S2:5433:4	have	VBP	O	O
developed	TREANDA.xml:S2:5438:9	develop	VBN	O	O
in	TREANDA.xml:S2:5448:2	in	IN	O	O
patients	TREANDA.xml:S2:5451:8	patient	NNS	O	O
who	TREANDA.xml:S2:5460:3	who	WP	O	O
have	TREANDA.xml:S2:5464:4	have	VBP	O	O
been	TREANDA.xml:S2:5469:4	been	VBN	O	O
treated	TREANDA.xml:S2:5474:7	treat	VBN	O	O
with	TREANDA.xml:S2:5482:4	with	IN	O	O
TREANDA	TREANDA.xml:S2:5487:7	treanda	NNP	O	O
,	TREANDA.xml:S2:5494:1	,	,	O	O
including	TREANDA.xml:S2:5496:9	includ	VBG	O	O
myelodysplastic	TREANDA.xml:S2:5506:15	myelodysplast	JJ	B-AdverseReaction	B-AdverseReaction
syndrome	TREANDA.xml:S2:5522:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S2:5530:1	,	,	O	O
myeloproliferative	TREANDA.xml:S2:5532:18	myeloprolif	JJ	B-AdverseReaction	B-AdverseReaction
disorders	TREANDA.xml:S2:5551:9	disord	NNS	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S2:5560:1	,	,	O	O
acute	TREANDA.xml:S2:5562:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
myeloid	TREANDA.xml:S2:5568:7	myeloid	NN	I-AdverseReaction	I-AdverseReaction
leukemia	TREANDA.xml:S2:5576:8	leukemia	NN	I-AdverseReaction	I-AdverseReaction
and	TREANDA.xml:S2:5585:3	and	CC	O	O
bronchial	TREANDA.xml:S2:5589:9	bronchial	JJ	B-AdverseReaction	B-AdverseReaction
carcinoma	TREANDA.xml:S2:5599:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
.	TREANDA.xml:S2:5608:1	.	.	O	O

The	TREANDA.xml:S2:5611:3	the	DT	O	O
association	TREANDA.xml:S2:5615:11	associ	NN	O	O
with	TREANDA.xml:S2:5627:4	with	IN	O	O
TREANDA	TREANDA.xml:S2:5632:7	treanda	NNP	O	O
therapy	TREANDA.xml:S2:5640:7	therapi	NN	O	O
has	TREANDA.xml:S2:5648:3	ha	VBZ	O	O
not	TREANDA.xml:S2:5652:3	not	RB	O	O
been	TREANDA.xml:S2:5656:4	been	VBN	O	O
determined	TREANDA.xml:S2:5661:10	determin	VBN	O	O
.	TREANDA.xml:S2:5671:1	.	.	O	O

5.7	TREANDA.xml:S2:5680:3	5.7	CD	O	O
Extravasation	TREANDA.xml:S2:5685:13	extravas	NNP	O	O
Injury	TREANDA.xml:S2:5699:6	injuri	NNP	O	O

TREANDA	TREANDA.xml:S2:5711:7	treanda	NNP	O	B-AdverseReaction
extravasations	TREANDA.xml:S2:5719:14	extravas	NNS	B-AdverseReaction	I-AdverseReaction
have	TREANDA.xml:S2:5734:4	have	VBP	O	O
been	TREANDA.xml:S2:5739:4	been	VBN	O	O
reported	TREANDA.xml:S2:5744:8	report	VBN	O	O
in	TREANDA.xml:S2:5753:2	in	IN	O	O
post	TREANDA.xml:S2:5756:4	post	NN	O	O
marketing	TREANDA.xml:S2:5761:9	market	NN	O	O
resulting	TREANDA.xml:S2:5771:9	result	VBG	O	O
in	TREANDA.xml:S2:5781:2	in	IN	O	O
hospitalizations	TREANDA.xml:S2:5784:16	hospit	NNS	O	O
from	TREANDA.xml:S2:5801:4	from	IN	O	O
erythema	TREANDA.xml:S2:5806:8	erythema	NN	B-AdverseReaction	B-AdverseReaction
,	TREANDA.xml:S2:5814:1	,	,	O	O
marked	TREANDA.xml:S2:5816:6	mark	VBD	O	B-AdverseReaction
swelling	TREANDA.xml:S2:5823:8	swell	NN	B-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S2:5831:1	,	,	O	O
and	TREANDA.xml:S2:5833:3	and	CC	O	O
pain	TREANDA.xml:S2:5837:4	pain	NN	B-AdverseReaction	B-AdverseReaction
.	TREANDA.xml:S2:5841:1	.	.	O	O

Assure	TREANDA.xml:S2:5843:6	assur	RB	O	O
good	TREANDA.xml:S2:5850:4	good	JJ	O	O
venous	TREANDA.xml:S2:5855:6	venou	JJ	O	O
access	TREANDA.xml:S2:5862:6	access	NN	O	O
prior	TREANDA.xml:S2:5869:5	prior	RB	O	O
to	TREANDA.xml:S2:5875:2	to	TO	O	O
starting	TREANDA.xml:S2:5878:8	start	VBG	O	O
TREANDA	TREANDA.xml:S2:5887:7	treanda	NNP	O	O
infusion	TREANDA.xml:S2:5895:8	infus	NN	O	O
and	TREANDA.xml:S2:5904:3	and	CC	O	O
monitor	TREANDA.xml:S2:5908:7	monitor	VB	O	O
the	TREANDA.xml:S2:5916:3	the	DT	O	O
intravenous	TREANDA.xml:S2:5920:11	intraven	JJ	O	O
infusion	TREANDA.xml:S2:5932:8	infus	NN	O	O
site	TREANDA.xml:S2:5941:4	site	NN	O	O
for	TREANDA.xml:S2:5946:3	for	IN	O	O
redness	TREANDA.xml:S2:5950:7	red	NN	O	O
,	TREANDA.xml:S2:5957:1	,	,	O	O
swelling	TREANDA.xml:S2:5959:8	swell	VBG	O	I-AdverseReaction
,	TREANDA.xml:S2:5967:1	,	,	O	O
pain	TREANDA.xml:S2:5969:4	pain	NN	O	B-AdverseReaction
,	TREANDA.xml:S2:5973:1	,	,	O	O
infection	TREANDA.xml:S2:5975:9	infect	NN	O	B-AdverseReaction
,	TREANDA.xml:S2:5984:1	,	,	O	O
and	TREANDA.xml:S2:5986:3	and	CC	O	O
necrosis	TREANDA.xml:S2:5990:8	necrosi	NN	O	O
during	TREANDA.xml:S2:5999:6	dure	IN	O	O
and	TREANDA.xml:S2:6006:3	and	CC	O	O
after	TREANDA.xml:S2:6010:5	after	IN	O	O
administration	TREANDA.xml:S2:6016:14	administr	NN	O	O
of	TREANDA.xml:S2:6031:2	of	IN	O	O
TREANDA	TREANDA.xml:S2:6034:7	treanda	NNP	O	O
.	TREANDA.xml:S2:6041:1	.	.	O	O

5.8	TREANDA.xml:S2:6050:3	5.8	CD	O	O
Embryo	TREANDA.xml:S2:6055:6	embryo	NNP	O	O
-	TREANDA.xml:S2:6061:1	-	:	O	O
fetal	TREANDA.xml:S2:6062:5	fetal	JJ	O	O
Toxicity	TREANDA.xml:S2:6068:8	toxic	NN	O	O

TREANDA	TREANDA.xml:S2:6082:7	treanda	NNP	O	O
can	TREANDA.xml:S2:6090:3	can	MD	O	O
cause	TREANDA.xml:S2:6094:5	caus	VB	O	O
fetal	TREANDA.xml:S2:6100:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	TREANDA.xml:S2:6106:4	harm	NN	I-AdverseReaction	I-AdverseReaction
when	TREANDA.xml:S2:6111:4	when	WRB	O	O
administered	TREANDA.xml:S2:6116:12	administ	VBN	O	O
to	TREANDA.xml:S2:6129:2	to	TO	O	O
a	TREANDA.xml:S2:6132:1	a	DT	O	O
pregnant	TREANDA.xml:S2:6134:8	pregnant	JJ	O	O
woman	TREANDA.xml:S2:6143:5	woman	NN	O	O
.	TREANDA.xml:S2:6148:1	.	.	O	O

Single	TREANDA.xml:S2:6151:6	singl	NNP	O	O
intraperitoneal	TREANDA.xml:S2:6158:15	intraperiton	NN	O	O
doses	TREANDA.xml:S2:6174:5	dose	NNS	O	O
of	TREANDA.xml:S2:6180:2	of	IN	O	O
bendamustine	TREANDA.xml:S2:6183:12	bendamustin	NN	O	O
in	TREANDA.xml:S2:6196:2	in	IN	O	O
mice	TREANDA.xml:S2:6199:4	mice	NN	O	O
and	TREANDA.xml:S2:6204:3	and	CC	O	O
rats	TREANDA.xml:S2:6208:4	rat	NNS	O	O
administered	TREANDA.xml:S2:6213:12	administ	VBD	O	O
during	TREANDA.xml:S2:6226:6	dure	IN	O	O
organogenesis	TREANDA.xml:S2:6233:13	organogenesi	NN	O	O
caused	TREANDA.xml:S2:6247:6	caus	VBD	O	O
an	TREANDA.xml:S2:6254:2	an	DT	O	O
increase	TREANDA.xml:S2:6257:8	increas	NN	B-AdverseReaction	O
in	TREANDA.xml:S2:6266:2	in	IN	I-AdverseReaction	O
resorptions	TREANDA.xml:S2:6269:11	resorpt	NNS	I-AdverseReaction	O
,	TREANDA.xml:S2:6280:1	,	,	O	O
skeletal	TREANDA.xml:S2:6282:8	skelet	JJ	B-AdverseReaction	O
and	TREANDA.xml:S2:6291:3	and	CC	O	O
visceral	TREANDA.xml:S2:6295:8	viscer	JJ	B-AdverseReaction	B-AdverseReaction
malformations	TREANDA.xml:S2:6304:13	malform	NNS	I-AdverseReaction	I-AdverseReaction
,	TREANDA.xml:S2:6317:1	,	,	O	O
and	TREANDA.xml:S2:6319:3	and	CC	O	O
decreased	TREANDA.xml:S2:6323:9	decreas	VBD	B-AdverseReaction	B-AdverseReaction
fetal	TREANDA.xml:S2:6333:5	fetal	JJ	I-AdverseReaction	I-AdverseReaction
body	TREANDA.xml:S2:6339:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
weights	TREANDA.xml:S2:6344:7	weight	NNS	I-AdverseReaction	I-AdverseReaction
.	TREANDA.xml:S2:6351:1	.	.	O	O

[	TREANDA.xml:S2:6353:1	[	NNS	O	O
see	TREANDA.xml:S2:6354:3	see	VBP	O	O
Use	TREANDA.xml:S2:6359:3	use	NNP	O	O
in	TREANDA.xml:S2:6363:2	in	IN	O	O
Specific	TREANDA.xml:S2:6366:8	specif	NNP	O	O
Populations	TREANDA.xml:S2:6375:11	popul	NNP	O	O
(	TREANDA.xml:S2:6388:1	(	(	O	O
8.1	TREANDA.xml:S2:6391:3	8.1	CD	O	O
)]	TREANDA.xml:S2:6396:2	)]	RB	O	O
6	TRULICITY.xml:S1:4:1	6	CD	O	O
ADVERSE	TRULICITY.xml:S1:6:7	advers	NNP	O	O
REACTIONS	TRULICITY.xml:S1:14:9	reaction	NNP	O	O

The	TRULICITY.xml:S1:27:3	the	DT	O	O
following	TRULICITY.xml:S1:31:9	follow	VBG	O	O
serious	TRULICITY.xml:S1:41:7	seriou	JJ	O	O
reactions	TRULICITY.xml:S1:49:9	reaction	NNS	O	O
are	TRULICITY.xml:S1:59:3	are	VBP	O	O
described	TRULICITY.xml:S1:63:9	describ	VBN	O	O
below	TRULICITY.xml:S1:73:5	below	IN	O	O
or	TRULICITY.xml:S1:79:2	or	CC	O	O
elsewhere	TRULICITY.xml:S1:82:9	elsewher	RB	O	O
in	TRULICITY.xml:S1:92:2	in	IN	O	O
the	TRULICITY.xml:S1:95:3	the	DT	O	O
prescribing	TRULICITY.xml:S1:99:11	prescrib	NN	O	O
information	TRULICITY.xml:S1:111:11	inform	NN	O	O
:	TRULICITY.xml:S1:122:1	:	:	O	O

Risk	TRULICITY.xml:S1:131:4	risk	NN	O	O
of	TRULICITY.xml:S1:136:2	of	IN	O	O
Thyroid	TRULICITY.xml:S1:139:7	thyroid	NNP	B-AdverseReaction	O
C	TRULICITY.xml:S1:147:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S1:148:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S1:149:4	cell	NN	I-AdverseReaction	O
Tumors	TRULICITY.xml:S1:154:6	tumor	NNPS	I-AdverseReaction	O
[	TRULICITY.xml:S1:161:1	[	NNP	O	O
see	TRULICITY.xml:S1:162:3	see	VBP	O	O
Warnings	TRULICITY.xml:S1:166:8	warn	NNP	O	O
and	TRULICITY.xml:S1:175:3	and	CC	O	O
Precautions	TRULICITY.xml:S1:179:11	precaut	NNP	O	O
(	TRULICITY.xml:S1:191:1	(	(	O	O
5.1	TRULICITY.xml:S1:194:3	5.1	CD	O	O
)]	TRULICITY.xml:S1:199:2	)]	NN	O	O

Pancreatitis	TRULICITY.xml:S1:208:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
[	TRULICITY.xml:S1:221:1	[	NNP	O	O
see	TRULICITY.xml:S1:222:3	see	VBP	O	O
Warnings	TRULICITY.xml:S1:226:8	warn	NNP	O	O
and	TRULICITY.xml:S1:235:3	and	CC	O	O
Precautions	TRULICITY.xml:S1:239:11	precaut	NNP	O	O
(	TRULICITY.xml:S1:251:1	(	(	O	O
5.2	TRULICITY.xml:S1:254:3	5.2	CD	O	O
)]	TRULICITY.xml:S1:259:2	)]	NN	O	O

Hypoglycemia	TRULICITY.xml:S1:268:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
with	TRULICITY.xml:S1:281:4	with	IN	O	O
Concomitant	TRULICITY.xml:S1:286:11	concomit	NNP	O	O
Use	TRULICITY.xml:S1:298:3	use	NNP	O	O
of	TRULICITY.xml:S1:302:2	of	IN	O	O
Insulin	TRULICITY.xml:S1:305:7	insulin	NNP	O	O
Secretagogues	TRULICITY.xml:S1:313:13	secretagogu	NNP	O	O
or	TRULICITY.xml:S1:327:2	or	CC	O	O
Insulin	TRULICITY.xml:S1:330:7	insulin	NNP	O	O
[	TRULICITY.xml:S1:338:1	[	NNP	O	O
see	TRULICITY.xml:S1:339:3	see	VBP	O	O
Warnings	TRULICITY.xml:S1:343:8	warn	NNP	O	O
and	TRULICITY.xml:S1:352:3	and	CC	O	O
Precautions	TRULICITY.xml:S1:356:11	precaut	NNP	O	O
(	TRULICITY.xml:S1:368:1	(	(	O	O
5.3	TRULICITY.xml:S1:371:3	5.3	CD	O	O
)]	TRULICITY.xml:S1:376:2	)]	NN	O	O

Hypersensitivity	TRULICITY.xml:S1:385:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	TRULICITY.xml:S1:402:9	reaction	NNS	O	I-AdverseReaction
[	TRULICITY.xml:S1:412:1	[	VBP	O	O
see	TRULICITY.xml:S1:413:3	see	VBP	O	O
Warnings	TRULICITY.xml:S1:417:8	warn	NNS	O	O
and	TRULICITY.xml:S1:426:3	and	CC	O	O
Precautions	TRULICITY.xml:S1:430:11	precaut	NNP	O	O
(	TRULICITY.xml:S1:442:1	(	(	O	O
5.4	TRULICITY.xml:S1:445:3	5.4	CD	O	O
)]	TRULICITY.xml:S1:450:2	)]	NN	O	O

Renal	TRULICITY.xml:S1:459:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
impairment	TRULICITY.xml:S1:465:10	impair	NN	I-AdverseReaction	I-AdverseReaction
[	TRULICITY.xml:S1:476:1	[	NNP	O	O
see	TRULICITY.xml:S1:477:3	see	VBP	O	O
Warnings	TRULICITY.xml:S1:481:8	warn	NNP	O	O
and	TRULICITY.xml:S1:490:3	and	CC	O	O
Precautions	TRULICITY.xml:S1:494:11	precaut	NNP	O	O
(	TRULICITY.xml:S1:506:1	(	(	O	O
5.5	TRULICITY.xml:S1:509:3	5.5	CD	O	O
)]	TRULICITY.xml:S1:514:2	)]	NN	O	O

Severe	TRULICITY.xml:S1:523:6	sever	JJ	O	O
Gastrointestinal	TRULICITY.xml:S1:530:16	gastrointestin	NNP	B-AdverseReaction	O
Disease	TRULICITY.xml:S1:547:7	diseas	NNP	I-AdverseReaction	O
[	TRULICITY.xml:S1:555:1	[	NNP	O	O
see	TRULICITY.xml:S1:556:3	see	VBP	O	O
Warnings	TRULICITY.xml:S1:560:8	warn	NNP	O	O
and	TRULICITY.xml:S1:569:3	and	CC	O	O
Precautions	TRULICITY.xml:S1:573:11	precaut	NNP	O	O
(	TRULICITY.xml:S1:585:1	(	(	O	O
5.6	TRULICITY.xml:S1:588:3	5.6	CD	O	O
)]	TRULICITY.xml:S1:593:2	)]	NN	O	O

EXCERPT	TRULICITY.xml:S1:604:7	excerpt	NN	O	O
:	TRULICITY.xml:S1:611:1	:	:	O	O
The	TRULICITY.xml:S1:615:3	the	DT	O	O
most	TRULICITY.xml:S1:619:4	most	RBS	O	O
common	TRULICITY.xml:S1:624:6	common	JJ	O	O
adverse	TRULICITY.xml:S1:631:7	advers	JJ	O	O
reactions	TRULICITY.xml:S1:639:9	reaction	NNS	O	O
,	TRULICITY.xml:S1:648:1	,	,	O	O
reported	TRULICITY.xml:S1:650:8	report	VBD	O	O
in	TRULICITY.xml:S1:659:2	in	IN	O	O
5%	TRULICITY.xml:S1:664:2	5%	CD	O	O
of	TRULICITY.xml:S1:667:2	of	IN	O	O
patients	TRULICITY.xml:S1:670:8	patient	NNS	O	O
treated	TRULICITY.xml:S1:679:7	treat	VBN	O	O
with	TRULICITY.xml:S1:687:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S1:692:9	trulic	NNP	O	O
are	TRULICITY.xml:S1:702:3	are	VBP	O	O
:	TRULICITY.xml:S1:705:1	:	:	O	O
nausea	TRULICITY.xml:S1:707:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:713:1	,	,	O	O
diarrhea	TRULICITY.xml:S1:715:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:723:1	,	,	O	O
vomiting	TRULICITY.xml:S1:725:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:733:1	,	,	O	O
abdominal	TRULICITY.xml:S1:735:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TRULICITY.xml:S1:745:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:749:1	,	,	O	O
and	TRULICITY.xml:S1:751:3	and	CC	O	O
decreased	TRULICITY.xml:S1:755:9	decreas	VBD	B-AdverseReaction	B-AdverseReaction
appetite	TRULICITY.xml:S1:765:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S1:774:1	(	(	O	O
6.1	TRULICITY.xml:S1:777:3	6.1	CD	O	O
)	TRULICITY.xml:S1:782:1	)	)	O	O
.	TRULICITY.xml:S1:783:1	.	.	O	O

To	TRULICITY.xml:S1:791:2	To	TO	O	O

report	TRULICITY.xml:S1:794:6	report	NN	O	O
SUSPECTED	TRULICITY.xml:S1:801:9	suspect	NNP	O	O
ADVERSE	TRULICITY.xml:S1:811:7	advers	NNP	O	O
REACTIONS	TRULICITY.xml:S1:819:9	reaction	NNP	O	O
,	TRULICITY.xml:S1:828:1	,	,	O	O
contact	TRULICITY.xml:S1:830:7	contact	NN	O	O
Eli	TRULICITY.xml:S1:838:3	eli	NNP	O	O
Lilly	TRULICITY.xml:S1:842:5	lilli	NNP	O	O
and	TRULICITY.xml:S1:848:3	and	CC	O	O
Company	TRULICITY.xml:S1:852:7	compani	NNP	O	O
at	TRULICITY.xml:S1:860:2	at	IN	O	O
1	TRULICITY.xml:S1:863:1	1	CD	O	O
-	TRULICITY.xml:S1:864:1	-	:	O	O
800	TRULICITY.xml:S1:865:3	800	CD	O	O
-	TRULICITY.xml:S1:868:1	-	:	O	O
LillyRx	TRULICITY.xml:S1:869:7	lillyrx	NNP	O	O
(	TRULICITY.xml:S1:877:1	(	(	O	O
1	TRULICITY.xml:S1:878:1	1	CD	O	O
-	TRULICITY.xml:S1:879:1	-	:	O	O
800	TRULICITY.xml:S1:880:3	800	CD	O	O
-	TRULICITY.xml:S1:883:1	-	:	O	O
545	TRULICITY.xml:S1:884:3	545	CD	O	O
-	TRULICITY.xml:S1:887:1	-	:	O	O
5979	TRULICITY.xml:S1:888:4	5979	CD	O	O
)	TRULICITY.xml:S1:892:1	)	)	O	O
or	TRULICITY.xml:S1:894:2	or	CC	O	O
FDA	TRULICITY.xml:S1:897:3	fda	NNP	O	O
at	TRULICITY.xml:S1:901:2	at	IN	O	O
1	TRULICITY.xml:S1:904:1	1	CD	O	O
-	TRULICITY.xml:S1:905:1	-	:	O	O
800	TRULICITY.xml:S1:906:3	800	CD	O	O
-	TRULICITY.xml:S1:909:1	-	:	O	O
FDA	TRULICITY.xml:S1:910:3	fda	NNP	O	O
-	TRULICITY.xml:S1:913:1	-	:	O	O
1088	TRULICITY.xml:S1:914:4	1088	CD	O	O
or	TRULICITY.xml:S1:919:2	or	CC	O	O
www	TRULICITY.xml:S1:922:3	www	VB	O	O
.	TRULICITY.xml:S1:925:1	.	.	O	O
fda	TRULICITY.xml:S1:926:3	fda	NN	O	O
.	TRULICITY.xml:S1:929:1	.	.	O	O
gov	TRULICITY.xml:S1:930:3	gov	JJ	O	O
medwatch	TRULICITY.xml:S1:934:8	medwatch	NN	O	O
.	TRULICITY.xml:S1:942:1	.	.	O	O

6.1	TRULICITY.xml:S1:954:3	6.1	CD	O	O

Clinical	TRULICITY.xml:S1:958:8	clinic	JJ	O	O
Studies	TRULICITY.xml:S1:967:7	studi	NNS	O	O
Experience	TRULICITY.xml:S1:975:10	experi	NN	O	O

Because	TRULICITY.xml:S1:989:7	becaus	IN	O	O
clinical	TRULICITY.xml:S1:997:8	clinic	JJ	O	O
studies	TRULICITY.xml:S1:1006:7	studi	NNS	O	O
are	TRULICITY.xml:S1:1014:3	are	VBP	O	O
conducted	TRULICITY.xml:S1:1018:9	conduct	VBN	O	O
under	TRULICITY.xml:S1:1028:5	under	IN	O	O
widely	TRULICITY.xml:S1:1034:6	wide	RB	O	O
varying	TRULICITY.xml:S1:1041:7	vari	VBG	O	O
conditions	TRULICITY.xml:S1:1049:10	condit	NNS	O	O
,	TRULICITY.xml:S1:1059:1	,	,	O	O
adverse	TRULICITY.xml:S1:1061:7	advers	JJ	O	O
reaction	TRULICITY.xml:S1:1069:8	reaction	NN	O	O
rates	TRULICITY.xml:S1:1078:5	rate	NNS	O	O
observed	TRULICITY.xml:S1:1084:8	observ	VBD	O	O
in	TRULICITY.xml:S1:1093:2	in	IN	O	O
the	TRULICITY.xml:S1:1096:3	the	DT	O	O
clinical	TRULICITY.xml:S1:1100:8	clinic	JJ	O	O
studies	TRULICITY.xml:S1:1109:7	studi	NNS	O	O
of	TRULICITY.xml:S1:1117:2	of	IN	O	O
a	TRULICITY.xml:S1:1120:1	a	DT	O	O
drug	TRULICITY.xml:S1:1122:4	drug	NN	O	O
cannot	TRULICITY.xml:S1:1127:6	cannot	NN	O	O
be	TRULICITY.xml:S1:1134:2	be	VB	O	O
directly	TRULICITY.xml:S1:1137:8	directli	RB	O	O
compared	TRULICITY.xml:S1:1146:8	compar	VBN	O	O
to	TRULICITY.xml:S1:1155:2	to	TO	O	O
rates	TRULICITY.xml:S1:1158:5	rate	NNS	O	O
in	TRULICITY.xml:S1:1164:2	in	IN	O	O
the	TRULICITY.xml:S1:1167:3	the	DT	O	O
clinical	TRULICITY.xml:S1:1171:8	clinic	JJ	O	O
studies	TRULICITY.xml:S1:1180:7	studi	NNS	O	O
of	TRULICITY.xml:S1:1188:2	of	IN	O	O
another	TRULICITY.xml:S1:1191:7	anoth	DT	O	O
drug	TRULICITY.xml:S1:1199:4	drug	NN	O	O
and	TRULICITY.xml:S1:1204:3	and	CC	O	O
may	TRULICITY.xml:S1:1208:3	may	MD	O	O
not	TRULICITY.xml:S1:1212:3	not	RB	O	O
reflect	TRULICITY.xml:S1:1216:7	reflect	VB	O	O
the	TRULICITY.xml:S1:1224:3	the	DT	O	O
rates	TRULICITY.xml:S1:1228:5	rate	NNS	O	O
observed	TRULICITY.xml:S1:1234:8	observ	VBD	O	O
in	TRULICITY.xml:S1:1243:2	in	IN	O	O
practice	TRULICITY.xml:S1:1246:8	practic	NN	O	O
.	TRULICITY.xml:S1:1254:1	.	.	O	O

Pool	TRULICITY.xml:S1:1264:4	pool	NN	O	O
of	TRULICITY.xml:S1:1269:2	of	IN	O	O
Placebo	TRULICITY.xml:S1:1272:7	placebo	NNP	O	O
-	TRULICITY.xml:S1:1279:1	-	:	O	O
controlled	TRULICITY.xml:S1:1280:10	control	VBD	O	O
Trials	TRULICITY.xml:S1:1291:6	trial	NNS	O	O

The	TRULICITY.xml:S1:1304:3	the	DT	O	O
data	TRULICITY.xml:S1:1308:4	data	NN	O	O
in	TRULICITY.xml:S1:1313:2	in	IN	O	O
Table	TRULICITY.xml:S1:1317:5	tabl	JJ	O	O
1	TRULICITY.xml:S1:1323:1	1	CD	O	O
are	TRULICITY.xml:S1:1326:3	are	VBP	O	O
derived	TRULICITY.xml:S1:1330:7	deriv	VBN	O	O
from	TRULICITY.xml:S1:1338:4	from	IN	O	O
the	TRULICITY.xml:S1:1343:3	the	DT	O	O
placebo	TRULICITY.xml:S1:1347:7	placebo	NN	O	O
-	TRULICITY.xml:S1:1354:1	-	:	O	O
controlled	TRULICITY.xml:S1:1355:10	control	VBN	O	O
trials	TRULICITY.xml:S1:1366:6	trial	NNS	O	O
[	TRULICITY.xml:S1:1374:1	[	VBD	O	O
see	TRULICITY.xml:S1:1375:3	see	VB	O	O
Clinical	TRULICITY.xml:S1:1379:8	clinic	JJ	O	O
Studies	TRULICITY.xml:S1:1388:7	studi	NNP	O	O
(	TRULICITY.xml:S1:1396:1	(	(	O	O
14	TRULICITY.xml:S1:1399:2	14	CD	O	O
)]	TRULICITY.xml:S1:1403:2	)]	NN	O	O
.	TRULICITY.xml:S1:1407:1	.	.	O	O

These	TRULICITY.xml:S1:1413:5	these	DT	O	O
data	TRULICITY.xml:S1:1419:4	data	NNS	O	O
reflect	TRULICITY.xml:S1:1424:7	reflect	VBP	O	O
exposure	TRULICITY.xml:S1:1432:8	exposur	NN	O	O
of	TRULICITY.xml:S1:1441:2	of	IN	O	O
1670	TRULICITY.xml:S1:1444:4	1670	CD	O	O
patients	TRULICITY.xml:S1:1449:8	patient	NNS	O	O
to	TRULICITY.xml:S1:1458:2	to	TO	O	O
TRULICITY	TRULICITY.xml:S1:1461:9	trulic	NNP	O	O
and	TRULICITY.xml:S1:1471:3	and	CC	O	O
a	TRULICITY.xml:S1:1475:1	a	DT	O	O
mean	TRULICITY.xml:S1:1477:4	mean	JJ	O	O
duration	TRULICITY.xml:S1:1482:8	durat	NN	O	O
of	TRULICITY.xml:S1:1491:2	of	IN	O	O
exposure	TRULICITY.xml:S1:1494:8	exposur	NN	O	O
to	TRULICITY.xml:S1:1503:2	to	TO	O	O
TRULICITY	TRULICITY.xml:S1:1506:9	trulic	NNP	O	O
of	TRULICITY.xml:S1:1516:2	of	IN	O	O
23.8	TRULICITY.xml:S1:1519:4	23.8	CD	O	O
weeks	TRULICITY.xml:S1:1524:5	week	NNS	O	O
.	TRULICITY.xml:S1:1529:1	.	.	O	O

Across	TRULICITY.xml:S1:1531:6	across	IN	O	O
the	TRULICITY.xml:S1:1538:3	the	DT	O	O
treatment	TRULICITY.xml:S1:1542:9	treatment	NN	O	O
arms	TRULICITY.xml:S1:1552:4	arm	NNS	O	O
,	TRULICITY.xml:S1:1556:1	,	,	O	O
the	TRULICITY.xml:S1:1558:3	the	DT	O	O
mean	TRULICITY.xml:S1:1562:4	mean	JJ	O	O
age	TRULICITY.xml:S1:1567:3	age	NN	O	O
of	TRULICITY.xml:S1:1571:2	of	IN	O	O
patients	TRULICITY.xml:S1:1574:8	patient	NNS	O	O
was	TRULICITY.xml:S1:1583:3	wa	VBD	O	O
56	TRULICITY.xml:S1:1587:2	56	CD	O	O
years	TRULICITY.xml:S1:1590:5	year	NNS	O	O
,	TRULICITY.xml:S1:1595:1	,	,	O	O
1%	TRULICITY.xml:S1:1597:2	1%	CD	O	O
were	TRULICITY.xml:S1:1600:4	were	VBD	O	O
75	TRULICITY.xml:S1:1605:2	75	CD	O	O
years	TRULICITY.xml:S1:1608:5	year	NNS	O	O
or	TRULICITY.xml:S1:1614:2	or	CC	O	O
older	TRULICITY.xml:S1:1617:5	older	JJR	O	O
and	TRULICITY.xml:S1:1623:3	and	CC	O	O
53%	TRULICITY.xml:S1:1627:3	53%	CD	O	O
were	TRULICITY.xml:S1:1631:4	were	VBD	O	O
male	TRULICITY.xml:S1:1636:4	male	NN	O	O
.	TRULICITY.xml:S1:1640:1	.	.	O	O

The	TRULICITY.xml:S1:1642:3	the	DT	O	O
population	TRULICITY.xml:S1:1646:10	popul	NN	O	O
in	TRULICITY.xml:S1:1657:2	in	IN	O	O
these	TRULICITY.xml:S1:1660:5	these	DT	O	O
studies	TRULICITY.xml:S1:1666:7	studi	NNS	O	O
was	TRULICITY.xml:S1:1674:3	wa	VBD	O	O
69%	TRULICITY.xml:S1:1678:3	69%	CD	O	O
White	TRULICITY.xml:S1:1682:5	white	NNP	O	O
,	TRULICITY.xml:S1:1687:1	,	,	O	O
7%	TRULICITY.xml:S1:1689:2	7%	CD	O	O
Black	TRULICITY.xml:S1:1692:5	black	NNP	O	O
or	TRULICITY.xml:S1:1698:2	or	CC	O	O
African	TRULICITY.xml:S1:1701:7	african	JJ	O	O
American	TRULICITY.xml:S1:1709:8	american	NNP	O	O
,	TRULICITY.xml:S1:1717:1	,	,	O	O
13%	TRULICITY.xml:S1:1719:3	13%	CD	O	O
Asian	TRULICITY.xml:S1:1723:5	asian	JJ	O	O
;	TRULICITY.xml:S1:1728:1	;	:	O	O
30%	TRULICITY.xml:S1:1730:3	30%	CD	O	O
were	TRULICITY.xml:S1:1734:4	were	VBD	O	O
of	TRULICITY.xml:S1:1739:2	of	IN	O	O
Hispanic	TRULICITY.xml:S1:1742:8	hispan	NNP	O	O
or	TRULICITY.xml:S1:1751:2	or	CC	O	O
Latino	TRULICITY.xml:S1:1754:6	latino	NNP	O	O
ethnicity	TRULICITY.xml:S1:1761:9	ethnic	NN	O	O
.	TRULICITY.xml:S1:1770:1	.	.	O	O

At	TRULICITY.xml:S1:1772:2	At	IN	O	O
baseline	TRULICITY.xml:S1:1775:8	baselin	NN	O	O
,	TRULICITY.xml:S1:1783:1	,	,	O	O
the	TRULICITY.xml:S1:1785:3	the	DT	O	O
population	TRULICITY.xml:S1:1789:10	popul	NN	O	O
had	TRULICITY.xml:S1:1800:3	had	VBD	O	O
diabetes	TRULICITY.xml:S1:1804:8	diabet	NNS	O	O
for	TRULICITY.xml:S1:1813:3	for	IN	O	O
an	TRULICITY.xml:S1:1817:2	an	DT	O	O
average	TRULICITY.xml:S1:1820:7	averag	NN	O	O
of	TRULICITY.xml:S1:1828:2	of	IN	O	O
8.0	TRULICITY.xml:S1:1831:3	8.0	CD	O	O
years	TRULICITY.xml:S1:1835:5	year	NNS	O	O
and	TRULICITY.xml:S1:1841:3	and	CC	O	O
had	TRULICITY.xml:S1:1845:3	had	VBD	O	O
a	TRULICITY.xml:S1:1849:1	a	DT	O	O
mean	TRULICITY.xml:S1:1851:4	mean	JJ	O	O
HbA1c	TRULICITY.xml:S1:1856:5	hba1c	NNP	O	O
of	TRULICITY.xml:S1:1862:2	of	IN	O	O
8.0%	TRULICITY.xml:S1:1865:4	8.0%	CD	O	O
.	TRULICITY.xml:S1:1869:1	.	.	O	O

At	TRULICITY.xml:S1:1871:2	At	IN	O	O
baseline	TRULICITY.xml:S1:1874:8	baselin	NN	O	O
,	TRULICITY.xml:S1:1882:1	,	,	O	O
2.5%	TRULICITY.xml:S1:1884:4	2.5%	CD	O	O
of	TRULICITY.xml:S1:1889:2	of	IN	O	O
the	TRULICITY.xml:S1:1892:3	the	DT	O	O
population	TRULICITY.xml:S1:1896:10	popul	NN	O	O
reported	TRULICITY.xml:S1:1907:8	report	VBD	O	O
retinopathy	TRULICITY.xml:S1:1916:11	retinopathi	JJ	O	O
.	TRULICITY.xml:S1:1927:1	.	.	O	O

Baseline	TRULICITY.xml:S1:1929:8	baselin	NNP	O	O
estimated	TRULICITY.xml:S1:1938:9	estim	VBD	O	O
renal	TRULICITY.xml:S1:1948:5	renal	JJ	O	O
function	TRULICITY.xml:S1:1954:8	function	NN	O	O
was	TRULICITY.xml:S1:1963:3	wa	VBD	O	O
normal	TRULICITY.xml:S1:1967:6	normal	JJ	O	O
or	TRULICITY.xml:S1:1974:2	or	CC	O	O
mildly	TRULICITY.xml:S1:1977:6	mildli	RB	O	O
impaired	TRULICITY.xml:S1:1984:8	impair	JJ	O	O
(	TRULICITY.xml:S1:1993:1	(	(	O	O
eGFR	TRULICITY.xml:S1:1994:4	egfr	JJ	O	O
60	TRULICITY.xml:S1:2001:2	60	CD	O	O
mL	TRULICITY.xml:S1:2003:2	mL	NN	O	O
min	TRULICITY.xml:S1:2006:3	min	NN	O	O
1.73	TRULICITY.xml:S1:2010:4	1.73	CD	O	O
m	TRULICITY.xml:S1:2015:1	m	NN	O	O
2	TRULICITY.xml:S1:2018:1	2	CD	O	O
)	TRULICITY.xml:S1:2021:1	)	)	O	O
in	TRULICITY.xml:S1:2023:2	in	IN	O	O
96.0%	TRULICITY.xml:S1:2026:5	96.0%	CD	O	O
of	TRULICITY.xml:S1:2032:2	of	IN	O	O
the	TRULICITY.xml:S1:2035:3	the	DT	O	O
pooled	TRULICITY.xml:S1:2039:6	pool	JJ	O	O
study	TRULICITY.xml:S1:2046:5	studi	NN	O	O
populations	TRULICITY.xml:S1:2052:11	popul	NNS	O	O
.	TRULICITY.xml:S1:2063:1	.	.	O	O

Table	TRULICITY.xml:S1:2069:5	tabl	JJ	O	O
1	TRULICITY.xml:S1:2075:1	1	CD	O	O
shows	TRULICITY.xml:S1:2077:5	show	NNS	O	O
common	TRULICITY.xml:S1:2083:6	common	JJ	O	O
adverse	TRULICITY.xml:S1:2090:7	advers	JJ	O	O
reactions	TRULICITY.xml:S1:2098:9	reaction	NNS	O	O
,	TRULICITY.xml:S1:2107:1	,	,	O	O
excluding	TRULICITY.xml:S1:2109:9	exclud	VBG	O	O
hypoglycemia	TRULICITY.xml:S1:2119:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:2131:1	,	,	O	O
associated	TRULICITY.xml:S1:2133:10	associ	VBN	O	O
with	TRULICITY.xml:S1:2144:4	with	IN	O	O
the	TRULICITY.xml:S1:2149:3	the	DT	O	O
use	TRULICITY.xml:S1:2153:3	use	NN	O	O
of	TRULICITY.xml:S1:2157:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S1:2160:9	trulic	NNP	O	O
in	TRULICITY.xml:S1:2170:2	in	IN	O	O
the	TRULICITY.xml:S1:2173:3	the	DT	O	O
pool	TRULICITY.xml:S1:2177:4	pool	NN	O	O
of	TRULICITY.xml:S1:2182:2	of	IN	O	O
placebo	TRULICITY.xml:S1:2185:7	placebo	NN	O	O
-	TRULICITY.xml:S1:2192:1	-	:	O	O
controlled	TRULICITY.xml:S1:2193:10	control	VBN	O	O
trials	TRULICITY.xml:S1:2204:6	trial	NNS	O	O
.	TRULICITY.xml:S1:2210:1	.	.	O	O

These	TRULICITY.xml:S1:2212:5	these	DT	O	O
adverse	TRULICITY.xml:S1:2218:7	advers	JJ	O	O
reactions	TRULICITY.xml:S1:2226:9	reaction	NNS	O	O
were	TRULICITY.xml:S1:2236:4	were	VBD	O	O
not	TRULICITY.xml:S1:2241:3	not	RB	O	O
present	TRULICITY.xml:S1:2245:7	present	JJ	O	O
at	TRULICITY.xml:S1:2253:2	at	IN	O	O
baseline	TRULICITY.xml:S1:2256:8	baselin	NN	O	O
,	TRULICITY.xml:S1:2264:1	,	,	O	O
occurred	TRULICITY.xml:S1:2266:8	occur	VBD	O	O
more	TRULICITY.xml:S1:2275:4	more	JJR	O	O
commonly	TRULICITY.xml:S1:2280:8	commonli	RB	O	O
on	TRULICITY.xml:S1:2289:2	on	IN	O	O
TRULICITY	TRULICITY.xml:S1:2292:9	trulic	NNP	O	O
than	TRULICITY.xml:S1:2302:4	than	IN	O	O
on	TRULICITY.xml:S1:2307:2	on	IN	O	O
placebo	TRULICITY.xml:S1:2310:7	placebo	NN	O	O
,	TRULICITY.xml:S1:2317:1	,	,	O	O
and	TRULICITY.xml:S1:2319:3	and	CC	O	O
occurred	TRULICITY.xml:S1:2323:8	occur	VBD	O	O
in	TRULICITY.xml:S1:2332:2	in	IN	O	O
at	TRULICITY.xml:S1:2335:2	at	IN	O	O
least	TRULICITY.xml:S1:2338:5	least	JJS	O	O
5%	TRULICITY.xml:S1:2344:2	5%	CD	O	O
of	TRULICITY.xml:S1:2347:2	of	IN	O	O
patients	TRULICITY.xml:S1:2350:8	patient	NNS	O	O
treated	TRULICITY.xml:S1:2359:7	treat	VBN	O	O
with	TRULICITY.xml:S1:2367:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S1:2372:9	trulic	NNP	O	O
.	TRULICITY.xml:S1:2381:1	.	.	O	O

Table	TRULICITY.xml:S1:2387:5	tabl	JJ	O	O
1	TRULICITY.xml:S1:2393:1	1	CD	O	O
:	TRULICITY.xml:S1:2394:1	:	:	O	O
Adverse	TRULICITY.xml:S1:2396:7	advers	JJ	O	O
Reactions	TRULICITY.xml:S1:2404:9	reaction	NNS	O	O
in	TRULICITY.xml:S1:2414:2	in	IN	O	O
Placebo	TRULICITY.xml:S1:2417:7	placebo	NNP	O	O
-	TRULICITY.xml:S1:2424:1	-	:	O	O
Controlled	TRULICITY.xml:S1:2425:10	control	VBN	O	O
Trials	TRULICITY.xml:S1:2436:6	trial	NNS	O	O
Reported	TRULICITY.xml:S1:2443:8	report	VBD	O	O
in	TRULICITY.xml:S1:2452:2	in	IN	O	O
5%	TRULICITY.xml:S1:2457:2	5%	CD	O	O
of	TRULICITY.xml:S1:2460:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S1:2463:9	trulic	NNP	O	O
-	TRULICITY.xml:S1:2472:1	-	:	O	O
Treated	TRULICITY.xml:S1:2473:7	treat	VBD	O	O
Patients	TRULICITY.xml:S1:2481:8	patient	NNS	O	O

a	TRULICITY.xml:S1:2493:1	a	DT	O	O
Includes	TRULICITY.xml:S1:2495:8	includ	NNP	O	O
diarrhea	TRULICITY.xml:S1:2504:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:2512:1	,	,	O	O
fecal	TRULICITY.xml:S1:2514:5	fecal	JJ	B-AdverseReaction	B-AdverseReaction
volume	TRULICITY.xml:S1:2520:6	volum	NN	I-AdverseReaction	I-AdverseReaction
increased	TRULICITY.xml:S1:2527:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:2536:1	,	,	O	O
frequent	TRULICITY.xml:S1:2538:8	frequent	JJ	B-AdverseReaction	O
bowel	TRULICITY.xml:S1:2547:5	bowel	NN	I-AdverseReaction	O
movements	TRULICITY.xml:S1:2553:9	movement	NNS	I-AdverseReaction	O
.	TRULICITY.xml:S1:2562:1	.	.	O	O

b	TRULICITY.xml:S1:2570:1	b	NN	O	O
Includes	TRULICITY.xml:S1:2572:8	includ	NNP	O	O
retching	TRULICITY.xml:S1:2581:8	retch	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:2589:1	,	,	O	O
vomiting	TRULICITY.xml:S1:2591:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:2599:1	,	,	O	O
vomiting	TRULICITY.xml:S1:2601:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
projectile	TRULICITY.xml:S1:2610:10	projectil	NN	I-AdverseReaction	I-AdverseReaction
.	TRULICITY.xml:S1:2620:1	.	.	O	O

c	TRULICITY.xml:S1:2628:1	c	SYM	O	O
Includes	TRULICITY.xml:S1:2630:8	includ	VBZ	O	O
abdominal	TRULICITY.xml:S1:2639:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	TRULICITY.xml:S1:2649:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:2659:1	,	,	O	O
abdominal	TRULICITY.xml:S1:2661:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TRULICITY.xml:S1:2671:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:2675:1	,	,	O	O
abdominal	TRULICITY.xml:S1:2677:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TRULICITY.xml:S1:2687:4	pain	NN	I-AdverseReaction	I-AdverseReaction
lower	TRULICITY.xml:S1:2692:5	lower	RBR	I-AdverseReaction	O
,	TRULICITY.xml:S1:2697:1	,	,	O	O
abdominal	TRULICITY.xml:S1:2699:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TRULICITY.xml:S1:2709:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	TRULICITY.xml:S1:2714:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:2719:1	,	,	O	O
abdominal	TRULICITY.xml:S1:2721:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
tenderness	TRULICITY.xml:S1:2731:10	tender	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:2741:1	,	,	O	O
gastrointestinal	TRULICITY.xml:S1:2743:16	gastrointestin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TRULICITY.xml:S1:2760:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	TRULICITY.xml:S1:2764:1	.	.	O	O

d	TRULICITY.xml:S1:2772:1	d	NN	O	O
Includes	TRULICITY.xml:S1:2774:8	includ	NNP	O	O
fatigue	TRULICITY.xml:S1:2783:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:2790:1	,	,	O	O
asthenia	TRULICITY.xml:S1:2792:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:2800:1	,	,	O	O
malaise	TRULICITY.xml:S1:2802:7	malais	NN	B-AdverseReaction	B-AdverseReaction
.	TRULICITY.xml:S1:2809:1	.	.	O	O

Note	TRULICITY.xml:S1:2819:4	note	NN	O	O
:	TRULICITY.xml:S1:2823:1	:	:	O	O
Percentages	TRULICITY.xml:S1:2825:11	percentag	NNS	O	O
reflect	TRULICITY.xml:S1:2837:7	reflect	VBP	O	O
the	TRULICITY.xml:S1:2845:3	the	DT	O	O
number	TRULICITY.xml:S1:2849:6	number	NN	O	O
of	TRULICITY.xml:S1:2856:2	of	IN	O	O
patients	TRULICITY.xml:S1:2859:8	patient	NNS	O	O
that	TRULICITY.xml:S1:2868:4	that	WDT	O	O
reported	TRULICITY.xml:S1:2873:8	report	VBD	O	O
at	TRULICITY.xml:S1:2882:2	at	IN	O	O
least	TRULICITY.xml:S1:2885:5	least	JJS	O	O
1	TRULICITY.xml:S1:2891:1	1	CD	O	O
treatment	TRULICITY.xml:S1:2893:9	treatment	NN	O	O
-	TRULICITY.xml:S1:2902:1	-	:	O	O
emergent	TRULICITY.xml:S1:2904:8	emerg	JJ	O	O
occurrence	TRULICITY.xml:S1:2913:10	occurr	NN	O	O
of	TRULICITY.xml:S1:2924:2	of	IN	O	O
the	TRULICITY.xml:S1:2927:3	the	DT	O	O
adverse	TRULICITY.xml:S1:2931:7	advers	JJ	O	O
reaction	TRULICITY.xml:S1:2939:8	reaction	NN	O	O
.	TRULICITY.xml:S1:2947:1	.	.	O	O

Adverse	TRULICITY.xml:S1:2959:7	advers	NN	O	O

Reaction	TRULICITY.xml:S1:2967:8	reaction	NN	O	O
Placebo	TRULICITY.xml:S1:2986:7	placebo	NNP	O	O
(	TRULICITY.xml:S1:2997:1	(	(	O	O
N	TRULICITY.xml:S1:2998:1	N	NNP	O	O
568	TRULICITY.xml:S1:3000:3	568	CD	O	O
)	TRULICITY.xml:S1:3003:1	)	)	O	O
Trulicity	TRULICITY.xml:S1:3015:9	trulic	NN	O	O
0.75	TRULICITY.xml:S1:3025:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:3030:2	mg	NN	O	O
(	TRULICITY.xml:S1:3036:1	(	(	O	O
N	TRULICITY.xml:S1:3037:1	N	NNP	O	O
836	TRULICITY.xml:S1:3039:3	836	CD	O	O
)	TRULICITY.xml:S1:3042:1	)	)	O	O
Trulicity	TRULICITY.xml:S1:3054:9	trulic	NN	O	O
1.5	TRULICITY.xml:S1:3064:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:3068:2	mg	NN	O	O
(	TRULICITY.xml:S1:3074:1	(	(	O	O
N	TRULICITY.xml:S1:3075:1	N	NNP	O	O
834	TRULICITY.xml:S1:3077:3	834	CD	O	O
)	TRULICITY.xml:S1:3080:1	)	)	O	O

Nausea	TRULICITY.xml:S1:3093:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
5.3	TRULICITY.xml:S1:3120:3	5.3	CD	O	O
12.4	TRULICITY.xml:S1:3147:4	12.4	CD	O	O
21.1	TRULICITY.xml:S1:3172:4	21.1	CD	O	O

Diarrhea	TRULICITY.xml:S1:3202:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
a	TRULICITY.xml:S1:3212:1	a	DT	O	O
6.7	TRULICITY.xml:S1:3229:3	6.7	CD	O	O
8.9	TRULICITY.xml:S1:3256:3	8.9	CD	O	O
12.6	TRULICITY.xml:S1:3281:4	12.6	CD	O	O

Vomiting	TRULICITY.xml:S1:3311:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
b	TRULICITY.xml:S1:3321:1	b	NN	O	I-AdverseReaction
2.3	TRULICITY.xml:S1:3338:3	2.3	CD	O	O
6.0	TRULICITY.xml:S1:3365:3	6.0	CD	O	O
12.7	TRULICITY.xml:S1:3390:4	12.7	CD	O	O

Abdominal	TRULICITY.xml:S1:3420:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
Pain	TRULICITY.xml:S1:3430:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
c	TRULICITY.xml:S1:3436:1	c	VBD	O	O
4.9	TRULICITY.xml:S1:3447:3	4.9	CD	O	O
6.5	TRULICITY.xml:S1:3474:3	6.5	CD	O	O
9.4	TRULICITY.xml:S1:3499:3	9.4	CD	O	O

Decreased	TRULICITY.xml:S1:3529:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
Appetite	TRULICITY.xml:S1:3539:8	appetit	NNP	I-AdverseReaction	I-AdverseReaction
1.6	TRULICITY.xml:S1:3556:3	1.6	CD	O	O
4.9	TRULICITY.xml:S1:3583:3	4.9	CD	O	O
8.6	TRULICITY.xml:S1:3608:3	8.6	CD	O	O

Dyspepsia	TRULICITY.xml:S1:3638:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
2.3	TRULICITY.xml:S1:3665:3	2.3	CD	O	O
4.1	TRULICITY.xml:S1:3692:3	4.1	CD	O	O
5.8	TRULICITY.xml:S1:3717:3	5.8	CD	O	O

Fatigue	TRULICITY.xml:S1:3747:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
d	TRULICITY.xml:S1:3756:1	d	VBD	O	O
2.6	TRULICITY.xml:S1:3774:3	2.6	CD	O	O
4.2	TRULICITY.xml:S1:3801:3	4.2	CD	O	O
5.6	TRULICITY.xml:S1:3826:3	5.6	CD	O	O

Gastrointestinal	TRULICITY.xml:S1:3869:16	gastrointestin	JJ	O	O
Adverse	TRULICITY.xml:S1:3886:7	advers	NNP	O	O
Reactions	TRULICITY.xml:S1:3894:9	reaction	NNP	O	O

In	TRULICITY.xml:S1:3910:2	In	IN	O	O

the	TRULICITY.xml:S1:3913:3	the	DT	O	O
pool	TRULICITY.xml:S1:3917:4	pool	NN	O	O
of	TRULICITY.xml:S1:3922:2	of	IN	O	O
placebo	TRULICITY.xml:S1:3925:7	placebo	NN	O	O
-	TRULICITY.xml:S1:3932:1	-	:	O	O
controlled	TRULICITY.xml:S1:3933:10	control	VBN	O	O
trials	TRULICITY.xml:S1:3944:6	trial	NNS	O	O
,	TRULICITY.xml:S1:3950:1	,	,	O	O
gastrointestinal	TRULICITY.xml:S1:3952:16	gastrointestin	JJ	B-AdverseReaction	O
adverse	TRULICITY.xml:S1:3969:7	advers	JJ	I-AdverseReaction	O
reactions	TRULICITY.xml:S1:3977:9	reaction	NNS	I-AdverseReaction	O
occurred	TRULICITY.xml:S1:3987:8	occur	VBD	O	O
more	TRULICITY.xml:S1:3996:4	more	RBR	O	O
frequently	TRULICITY.xml:S1:4001:10	frequent	RB	O	O
among	TRULICITY.xml:S1:4012:5	among	IN	O	O
patients	TRULICITY.xml:S1:4018:8	patient	NNS	O	O
receiving	TRULICITY.xml:S1:4027:9	receiv	VBG	O	O
TRULICITY	TRULICITY.xml:S1:4037:9	trulic	NNP	O	O
than	TRULICITY.xml:S1:4047:4	than	IN	O	O
placebo	TRULICITY.xml:S1:4052:7	placebo	NN	O	O
(	TRULICITY.xml:S1:4060:1	(	(	O	O
placebo	TRULICITY.xml:S1:4061:7	placebo	JJ	O	O
21.3%	TRULICITY.xml:S1:4069:5	21.3%	CD	O	O
,	TRULICITY.xml:S1:4074:1	,	,	O	O
0.75	TRULICITY.xml:S1:4076:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:4081:2	mg	NN	O	O
31.6%	TRULICITY.xml:S1:4084:5	31.6%	CD	O	O
,	TRULICITY.xml:S1:4089:1	,	,	O	O
1.5	TRULICITY.xml:S1:4091:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:4095:2	mg	NN	O	O
41.0%	TRULICITY.xml:S1:4098:5	41.0%	CD	O	O
)	TRULICITY.xml:S1:4103:1	)	)	O	O
.	TRULICITY.xml:S1:4104:1	.	.	O	O

More	TRULICITY.xml:S1:4106:4	more	JJR	O	O
patients	TRULICITY.xml:S1:4111:8	patient	NNS	O	O
receiving	TRULICITY.xml:S1:4120:9	receiv	VBG	O	O
TRULICITY	TRULICITY.xml:S1:4130:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:4140:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:4145:2	mg	NN	O	O
(	TRULICITY.xml:S1:4148:1	(	(	O	O
1.3%	TRULICITY.xml:S1:4149:4	1.3%	CD	O	O
)	TRULICITY.xml:S1:4153:1	)	)	O	O
and	TRULICITY.xml:S1:4155:3	and	CC	O	O
TRULICITY	TRULICITY.xml:S1:4159:9	trulic	$	O	O
1.5	TRULICITY.xml:S1:4169:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:4173:2	mg	NN	O	O
(	TRULICITY.xml:S1:4176:1	(	(	O	O
3.5%	TRULICITY.xml:S1:4177:4	3.5%	CD	O	O
)	TRULICITY.xml:S1:4181:1	)	)	O	O
discontinued	TRULICITY.xml:S1:4183:12	discontinu	VBN	O	O
treatment	TRULICITY.xml:S1:4196:9	treatment	NN	O	O
due	TRULICITY.xml:S1:4206:3	due	JJ	O	O
to	TRULICITY.xml:S1:4210:2	to	TO	O	O
gastrointestinal	TRULICITY.xml:S1:4213:16	gastrointestin	JJ	B-AdverseReaction	O
adverse	TRULICITY.xml:S1:4230:7	advers	JJ	I-AdverseReaction	O
reactions	TRULICITY.xml:S1:4238:9	reaction	NNS	I-AdverseReaction	O
than	TRULICITY.xml:S1:4248:4	than	IN	O	O
patients	TRULICITY.xml:S1:4253:8	patient	NNS	O	O
receiving	TRULICITY.xml:S1:4262:9	receiv	VBG	O	O
placebo	TRULICITY.xml:S1:4272:7	placebo	NN	O	O
(	TRULICITY.xml:S1:4280:1	(	(	O	O
0.2%	TRULICITY.xml:S1:4281:4	0.2%	CD	O	O
)	TRULICITY.xml:S1:4285:1	)	)	O	O
.	TRULICITY.xml:S1:4286:1	.	.	O	O

Investigators	TRULICITY.xml:S1:4288:13	investig	NNS	O	O
graded	TRULICITY.xml:S1:4302:6	grade	VBD	O	O
the	TRULICITY.xml:S1:4309:3	the	DT	O	O
severity	TRULICITY.xml:S1:4313:8	sever	NN	O	O
of	TRULICITY.xml:S1:4322:2	of	IN	O	O
gastrointestinal	TRULICITY.xml:S1:4325:16	gastrointestin	JJ	B-AdverseReaction	O
adverse	TRULICITY.xml:S1:4342:7	advers	JJ	I-AdverseReaction	O
reactions	TRULICITY.xml:S1:4350:9	reaction	NNS	I-AdverseReaction	O
occurring	TRULICITY.xml:S1:4360:9	occur	VBG	O	O
on	TRULICITY.xml:S1:4370:2	on	IN	O	O
0.75	TRULICITY.xml:S1:4373:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:4378:2	mg	NNS	O	O
and	TRULICITY.xml:S1:4381:3	and	CC	O	O
1.5	TRULICITY.xml:S1:4385:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:4389:2	mg	NN	O	O
of	TRULICITY.xml:S1:4392:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S1:4395:9	trulic	NNP	O	O
as	TRULICITY.xml:S1:4405:2	as	IN	O	O
"	TRULICITY.xml:S1:4408:1	"	NNP	O	O
mild	TRULICITY.xml:S1:4409:4	mild	VBP	O	O
"	TRULICITY.xml:S1:4413:1	"	NNP	O	O
in	TRULICITY.xml:S1:4415:2	in	IN	O	O
58%	TRULICITY.xml:S1:4418:3	58%	CD	O	O
and	TRULICITY.xml:S1:4422:3	and	CC	O	O
48%	TRULICITY.xml:S1:4426:3	48%	CD	O	O
of	TRULICITY.xml:S1:4430:2	of	IN	O	O
cases	TRULICITY.xml:S1:4433:5	case	NNS	O	O
,	TRULICITY.xml:S1:4438:1	,	,	O	O
respectively	TRULICITY.xml:S1:4440:12	respect	RB	O	O
,	TRULICITY.xml:S1:4452:1	,	,	O	O
"	TRULICITY.xml:S1:4454:1	"	JJ	O	O
moderate	TRULICITY.xml:S1:4455:8	moder	JJ	O	O
"	TRULICITY.xml:S1:4463:1	"	NN	O	O
in	TRULICITY.xml:S1:4465:2	in	IN	O	O
35%	TRULICITY.xml:S1:4468:3	35%	CD	O	O
and	TRULICITY.xml:S1:4472:3	and	CC	O	O
42%	TRULICITY.xml:S1:4476:3	42%	CD	O	O
of	TRULICITY.xml:S1:4480:2	of	IN	O	O
cases	TRULICITY.xml:S1:4483:5	case	NNS	O	O
,	TRULICITY.xml:S1:4488:1	,	,	O	O
respectively	TRULICITY.xml:S1:4490:12	respect	RB	O	O
,	TRULICITY.xml:S1:4502:1	,	,	O	O
or	TRULICITY.xml:S1:4504:2	or	CC	O	O
"	TRULICITY.xml:S1:4507:1	"	VB	O	O
severe	TRULICITY.xml:S1:4508:6	sever	JJ	O	O
"	TRULICITY.xml:S1:4514:1	"	NN	O	O
in	TRULICITY.xml:S1:4516:2	in	IN	O	O
7%	TRULICITY.xml:S1:4519:2	7%	CD	O	O
and	TRULICITY.xml:S1:4522:3	and	CC	O	O
11%	TRULICITY.xml:S1:4526:3	11%	CD	O	O
of	TRULICITY.xml:S1:4530:2	of	IN	O	O
cases	TRULICITY.xml:S1:4533:5	case	NNS	O	O
,	TRULICITY.xml:S1:4538:1	,	,	O	O
respectively	TRULICITY.xml:S1:4540:12	respect	RB	O	O
.	TRULICITY.xml:S1:4552:1	.	.	O	O

In	TRULICITY.xml:S1:4558:2	In	IN	O	O
addition	TRULICITY.xml:S1:4561:8	addit	NN	O	O
to	TRULICITY.xml:S1:4570:2	to	TO	O	O
the	TRULICITY.xml:S1:4573:3	the	DT	O	O
reactions	TRULICITY.xml:S1:4577:9	reaction	NNS	O	O
in	TRULICITY.xml:S1:4587:2	in	IN	O	O
Table	TRULICITY.xml:S1:4591:5	tabl	JJ	O	O
1	TRULICITY.xml:S1:4597:1	1	CD	O	O
,	TRULICITY.xml:S1:4600:1	,	,	O	O
the	TRULICITY.xml:S1:4602:3	the	DT	O	O
following	TRULICITY.xml:S1:4606:9	follow	JJ	O	O
adverse	TRULICITY.xml:S1:4616:7	advers	JJ	O	O
reactions	TRULICITY.xml:S1:4624:9	reaction	NNS	O	O
were	TRULICITY.xml:S1:4634:4	were	VBD	O	O
reported	TRULICITY.xml:S1:4639:8	report	VBN	O	O
more	TRULICITY.xml:S1:4648:4	more	RBR	O	O
frequently	TRULICITY.xml:S1:4653:10	frequent	RB	O	O
in	TRULICITY.xml:S1:4664:2	in	IN	O	O
TRULICITY	TRULICITY.xml:S1:4667:9	trulic	NNP	O	O
-	TRULICITY.xml:S1:4676:1	-	:	O	O
treated	TRULICITY.xml:S1:4677:7	treat	VBD	O	O
patients	TRULICITY.xml:S1:4685:8	patient	NNS	O	O
than	TRULICITY.xml:S1:4694:4	than	IN	O	O
placebo	TRULICITY.xml:S1:4699:7	placebo	NN	O	O
(	TRULICITY.xml:S1:4707:1	(	(	O	O
frequencies	TRULICITY.xml:S1:4708:11	frequenc	NNS	O	O
listed	TRULICITY.xml:S1:4720:6	list	VBN	O	O
,	TRULICITY.xml:S1:4726:1	,	,	O	O
respectively	TRULICITY.xml:S1:4728:12	respect	RB	O	O
,	TRULICITY.xml:S1:4740:1	,	,	O	O
as	TRULICITY.xml:S1:4742:2	as	IN	O	O
:	TRULICITY.xml:S1:4744:1	:	:	O	O
placebo	TRULICITY.xml:S1:4746:7	placebo	NN	O	O
;	TRULICITY.xml:S1:4753:1	;	:	O	O
0.75	TRULICITY.xml:S1:4755:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:4760:2	mg	NN	O	O
;	TRULICITY.xml:S1:4762:1	;	:	O	O
1.5	TRULICITY.xml:S1:4764:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:4768:2	mg	NN	O	O
)	TRULICITY.xml:S1:4770:1	)	)	O	O
:	TRULICITY.xml:S1:4771:1	:	:	O	O
constipation	TRULICITY.xml:S1:4773:12	constip	NN	B-AdverseReaction	B-AdverseReaction
(	TRULICITY.xml:S1:4786:1	(	(	O	O
0.7%	TRULICITY.xml:S1:4787:4	0.7%	CD	O	O
,	TRULICITY.xml:S1:4791:1	,	,	O	O
3.9%	TRULICITY.xml:S1:4793:4	3.9%	CD	O	O
,	TRULICITY.xml:S1:4797:1	,	,	O	O
3.7%	TRULICITY.xml:S1:4799:4	3.7%	CD	O	O
)	TRULICITY.xml:S1:4803:1	)	)	O	O
,	TRULICITY.xml:S1:4804:1	,	,	O	O
flatulence	TRULICITY.xml:S1:4806:10	flatul	NN	B-AdverseReaction	B-AdverseReaction
(	TRULICITY.xml:S1:4817:1	(	(	O	O
1.4%	TRULICITY.xml:S1:4818:4	1.4%	CD	O	O
,	TRULICITY.xml:S1:4822:1	,	,	O	O
1.4%	TRULICITY.xml:S1:4824:4	1.4%	CD	O	O
,	TRULICITY.xml:S1:4828:1	,	,	O	O
3.4%	TRULICITY.xml:S1:4830:4	3.4%	CD	O	O
)	TRULICITY.xml:S1:4834:1	)	)	O	O
,	TRULICITY.xml:S1:4835:1	,	,	O	O
abdominal	TRULICITY.xml:S1:4837:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
distension	TRULICITY.xml:S1:4847:10	distens	NN	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S1:4858:1	(	(	O	O
0.7%	TRULICITY.xml:S1:4859:4	0.7%	CD	O	O
,	TRULICITY.xml:S1:4863:1	,	,	O	O
2.9%	TRULICITY.xml:S1:4865:4	2.9%	CD	O	O
,	TRULICITY.xml:S1:4869:1	,	,	O	O
2.3%	TRULICITY.xml:S1:4871:4	2.3%	CD	O	O
)	TRULICITY.xml:S1:4875:1	)	)	O	O
,	TRULICITY.xml:S1:4876:1	,	,	O	O
gastroesophageal	TRULICITY.xml:S1:4878:16	gastroesophag	JJ	B-AdverseReaction	B-AdverseReaction
reflux	TRULICITY.xml:S1:4895:6	reflux	NN	I-AdverseReaction	I-AdverseReaction
disease	TRULICITY.xml:S1:4902:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S1:4910:1	(	(	O	O
0.5%	TRULICITY.xml:S1:4911:4	0.5%	CD	O	O
,	TRULICITY.xml:S1:4915:1	,	,	O	O
1.7%	TRULICITY.xml:S1:4917:4	1.7%	CD	O	O
,	TRULICITY.xml:S1:4921:1	,	,	O	O
2.0%	TRULICITY.xml:S1:4923:4	2.0%	CD	O	O
)	TRULICITY.xml:S1:4927:1	)	)	O	O
,	TRULICITY.xml:S1:4928:1	,	,	O	O
and	TRULICITY.xml:S1:4930:3	and	CC	O	O
eructation	TRULICITY.xml:S1:4934:10	eruct	NN	B-AdverseReaction	B-AdverseReaction
(	TRULICITY.xml:S1:4945:1	(	(	O	O
0.2%	TRULICITY.xml:S1:4946:4	0.2%	CD	O	O
,	TRULICITY.xml:S1:4950:1	,	,	O	O
0.6%	TRULICITY.xml:S1:4952:4	0.6%	CD	O	O
,	TRULICITY.xml:S1:4956:1	,	,	O	O
1.6%	TRULICITY.xml:S1:4958:4	1.6%	CD	O	O
)	TRULICITY.xml:S1:4962:1	)	)	O	O
.	TRULICITY.xml:S1:4963:1	.	.	O	O

Pool	TRULICITY.xml:S1:4973:4	pool	NN	O	O
of	TRULICITY.xml:S1:4978:2	of	IN	O	O
Placebo	TRULICITY.xml:S1:4981:7	placebo	NNP	O	O
-	TRULICITY.xml:S1:4988:1	-	:	O	O
and	TRULICITY.xml:S1:4990:3	and	CC	O	O
Active	TRULICITY.xml:S1:4994:6	activ	NNP	O	O
-	TRULICITY.xml:S1:5000:1	-	:	O	O
Controlled	TRULICITY.xml:S1:5001:10	control	VBD	O	O
Trials	TRULICITY.xml:S1:5012:6	trial	NNS	O	O

The	TRULICITY.xml:S1:5025:3	the	DT	O	O
occurrence	TRULICITY.xml:S1:5029:10	occurr	NN	O	O
of	TRULICITY.xml:S1:5040:2	of	IN	O	O
adverse	TRULICITY.xml:S1:5043:7	advers	JJ	O	O
reactions	TRULICITY.xml:S1:5051:9	reaction	NNS	O	O
was	TRULICITY.xml:S1:5061:3	wa	VBD	O	O
also	TRULICITY.xml:S1:5065:4	also	RB	O	O
evaluated	TRULICITY.xml:S1:5070:9	evalu	VBN	O	O
in	TRULICITY.xml:S1:5080:2	in	IN	O	O
a	TRULICITY.xml:S1:5083:1	a	DT	O	O
larger	TRULICITY.xml:S1:5085:6	larger	JJR	O	O
pool	TRULICITY.xml:S1:5092:4	pool	NN	O	O
of	TRULICITY.xml:S1:5097:2	of	IN	O	O
patients	TRULICITY.xml:S1:5100:8	patient	NNS	O	O
with	TRULICITY.xml:S1:5109:4	with	IN	O	O
type	TRULICITY.xml:S1:5114:4	type	JJ	O	O
2	TRULICITY.xml:S1:5119:1	2	CD	O	O
diabetes	TRULICITY.xml:S1:5121:8	diabet	NNS	O	O
participating	TRULICITY.xml:S1:5130:13	particip	VBG	O	O
in	TRULICITY.xml:S1:5144:2	in	IN	O	O
6	TRULICITY.xml:S1:5147:1	6	CD	O	O
placebo	TRULICITY.xml:S1:5149:7	placebo	NN	O	O
-	TRULICITY.xml:S1:5156:1	-	:	O	O
and	TRULICITY.xml:S1:5158:3	and	CC	O	O
active	TRULICITY.xml:S1:5162:6	activ	JJ	O	O
-	TRULICITY.xml:S1:5168:1	-	:	O	O
controlled	TRULICITY.xml:S1:5169:10	control	VBN	O	O
trials	TRULICITY.xml:S1:5180:6	trial	NNS	O	O
evaluating	TRULICITY.xml:S1:5187:10	evalu	VBG	O	O
the	TRULICITY.xml:S1:5198:3	the	DT	O	O
use	TRULICITY.xml:S1:5202:3	use	NN	O	O
of	TRULICITY.xml:S1:5206:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S1:5209:9	trulic	NNP	O	O
as	TRULICITY.xml:S1:5219:2	as	IN	O	O
monotherapy	TRULICITY.xml:S1:5222:11	monotherapi	NN	O	O
and	TRULICITY.xml:S1:5234:3	and	CC	O	O
add	TRULICITY.xml:S1:5238:3	add	VB	O	O
-	TRULICITY.xml:S1:5241:1	-	:	O	O
on	TRULICITY.xml:S1:5242:2	on	IN	O	O
therapy	TRULICITY.xml:S1:5245:7	therapi	NN	O	O
to	TRULICITY.xml:S1:5253:2	to	TO	O	O
oral	TRULICITY.xml:S1:5256:4	oral	JJ	O	O
medications	TRULICITY.xml:S1:5261:11	medic	NNS	O	O
or	TRULICITY.xml:S1:5273:2	or	CC	O	O
insulin	TRULICITY.xml:S1:5276:7	insulin	NN	O	O
.	TRULICITY.xml:S1:5283:1	.	.	O	O

[	TRULICITY.xml:S1:5286:1	[	NNS	O	O
see	TRULICITY.xml:S1:5287:3	see	VBP	O	O
Clinical	TRULICITY.xml:S1:5291:8	clinic	JJ	O	O
Studies	TRULICITY.xml:S1:5300:7	studi	NNP	O	O
(	TRULICITY.xml:S1:5308:1	(	(	O	O
14	TRULICITY.xml:S1:5311:2	14	CD	O	O
)]	TRULICITY.xml:S1:5315:2	)]	NN	O	O
.	TRULICITY.xml:S1:5319:1	.	.	O	O

In	TRULICITY.xml:S1:5321:2	In	IN	O	O
this	TRULICITY.xml:S1:5324:4	thi	DT	O	O
pool	TRULICITY.xml:S1:5329:4	pool	NN	O	O
,	TRULICITY.xml:S1:5333:1	,	,	O	O
a	TRULICITY.xml:S1:5335:1	a	DT	O	O
total	TRULICITY.xml:S1:5337:5	total	NN	O	O
of	TRULICITY.xml:S1:5343:2	of	IN	O	O
3342	TRULICITY.xml:S1:5346:4	3342	CD	O	O
patients	TRULICITY.xml:S1:5351:8	patient	NNS	O	O
with	TRULICITY.xml:S1:5360:4	with	IN	O	O
type	TRULICITY.xml:S1:5365:4	type	JJ	O	O
2	TRULICITY.xml:S1:5370:1	2	CD	O	O
diabetes	TRULICITY.xml:S1:5372:8	diabet	NNS	O	O
were	TRULICITY.xml:S1:5381:4	were	VBD	O	O
treated	TRULICITY.xml:S1:5386:7	treat	VBN	O	O
with	TRULICITY.xml:S1:5394:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S1:5399:9	trulic	NNP	O	O
for	TRULICITY.xml:S1:5409:3	for	IN	O	O
a	TRULICITY.xml:S1:5413:1	a	DT	O	O
mean	TRULICITY.xml:S1:5415:4	mean	JJ	O	O
duration	TRULICITY.xml:S1:5420:8	durat	NN	O	O
of	TRULICITY.xml:S1:5429:2	of	IN	O	O
52	TRULICITY.xml:S1:5432:2	52	CD	O	O
weeks	TRULICITY.xml:S1:5435:5	week	NNS	O	O
.	TRULICITY.xml:S1:5440:1	.	.	O	O

The	TRULICITY.xml:S1:5442:3	the	DT	O	O
mean	TRULICITY.xml:S1:5446:4	mean	JJ	O	O
age	TRULICITY.xml:S1:5451:3	age	NN	O	O
of	TRULICITY.xml:S1:5455:2	of	IN	O	O
patients	TRULICITY.xml:S1:5458:8	patient	NNS	O	O
was	TRULICITY.xml:S1:5467:3	wa	VBD	O	O
56	TRULICITY.xml:S1:5471:2	56	CD	O	O
years	TRULICITY.xml:S1:5474:5	year	NNS	O	O
,	TRULICITY.xml:S1:5479:1	,	,	O	O
2%	TRULICITY.xml:S1:5481:2	2%	CD	O	O
were	TRULICITY.xml:S1:5484:4	were	VBD	O	O
75	TRULICITY.xml:S1:5489:2	75	CD	O	O
years	TRULICITY.xml:S1:5492:5	year	NNS	O	O
or	TRULICITY.xml:S1:5498:2	or	CC	O	O
older	TRULICITY.xml:S1:5501:5	older	JJR	O	O
and	TRULICITY.xml:S1:5507:3	and	CC	O	O
51%	TRULICITY.xml:S1:5511:3	51%	CD	O	O
were	TRULICITY.xml:S1:5515:4	were	VBD	O	O
male	TRULICITY.xml:S1:5520:4	male	NN	O	O
.	TRULICITY.xml:S1:5524:1	.	.	O	O

The	TRULICITY.xml:S1:5526:3	the	DT	O	O
population	TRULICITY.xml:S1:5530:10	popul	NN	O	O
in	TRULICITY.xml:S1:5541:2	in	IN	O	O
these	TRULICITY.xml:S1:5544:5	these	DT	O	O
studies	TRULICITY.xml:S1:5550:7	studi	NNS	O	O
was	TRULICITY.xml:S1:5558:3	wa	VBD	O	O
71%	TRULICITY.xml:S1:5562:3	71%	CD	O	O
White	TRULICITY.xml:S1:5566:5	white	NNP	O	O
,	TRULICITY.xml:S1:5571:1	,	,	O	O
7%	TRULICITY.xml:S1:5573:2	7%	CD	O	O
Black	TRULICITY.xml:S1:5576:5	black	NNP	O	O
or	TRULICITY.xml:S1:5582:2	or	CC	O	O
African	TRULICITY.xml:S1:5585:7	african	JJ	O	O
American	TRULICITY.xml:S1:5593:8	american	NNP	O	O
,	TRULICITY.xml:S1:5601:1	,	,	O	O
11%	TRULICITY.xml:S1:5603:3	11%	CD	O	O
Asian	TRULICITY.xml:S1:5607:5	asian	JJ	O	O
;	TRULICITY.xml:S1:5612:1	;	:	O	O
32%	TRULICITY.xml:S1:5614:3	32%	CD	O	O
were	TRULICITY.xml:S1:5618:4	were	VBD	O	O
of	TRULICITY.xml:S1:5623:2	of	IN	O	O
Hispanic	TRULICITY.xml:S1:5626:8	hispan	NNP	O	O
or	TRULICITY.xml:S1:5635:2	or	CC	O	O
Latino	TRULICITY.xml:S1:5638:6	latino	NNP	O	O
ethnicity	TRULICITY.xml:S1:5645:9	ethnic	NN	O	O
.	TRULICITY.xml:S1:5654:1	.	.	O	O

At	TRULICITY.xml:S1:5656:2	At	IN	O	O
baseline	TRULICITY.xml:S1:5659:8	baselin	NN	O	O
,	TRULICITY.xml:S1:5667:1	,	,	O	O
the	TRULICITY.xml:S1:5669:3	the	DT	O	O
population	TRULICITY.xml:S1:5673:10	popul	NN	O	O
had	TRULICITY.xml:S1:5684:3	had	VBD	O	O
diabetes	TRULICITY.xml:S1:5688:8	diabet	NNS	O	O
for	TRULICITY.xml:S1:5697:3	for	IN	O	O
an	TRULICITY.xml:S1:5701:2	an	DT	O	O
average	TRULICITY.xml:S1:5704:7	averag	NN	O	O
of	TRULICITY.xml:S1:5712:2	of	IN	O	O
8.2	TRULICITY.xml:S1:5715:3	8.2	CD	O	O
years	TRULICITY.xml:S1:5719:5	year	NNS	O	O
and	TRULICITY.xml:S1:5725:3	and	CC	O	O
had	TRULICITY.xml:S1:5729:3	had	VBD	O	O
a	TRULICITY.xml:S1:5733:1	a	DT	O	O
mean	TRULICITY.xml:S1:5735:4	mean	JJ	O	O
HbA1c	TRULICITY.xml:S1:5740:5	hba1c	NNP	O	O
of	TRULICITY.xml:S1:5746:2	of	IN	O	O
7.6	TRULICITY.xml:S1:5749:3	7.6	CD	O	O
-	TRULICITY.xml:S1:5752:1	-	:	O	O
8.5%	TRULICITY.xml:S1:5753:4	8.5%	CD	O	O
.	TRULICITY.xml:S1:5757:1	.	.	O	O

At	TRULICITY.xml:S1:5759:2	At	IN	O	O
baseline	TRULICITY.xml:S1:5762:8	baselin	NN	O	O
,	TRULICITY.xml:S1:5770:1	,	,	O	O
5.2%	TRULICITY.xml:S1:5772:4	5.2%	CD	O	O
of	TRULICITY.xml:S1:5777:2	of	IN	O	O
the	TRULICITY.xml:S1:5780:3	the	DT	O	O
population	TRULICITY.xml:S1:5784:10	popul	NN	O	O
reported	TRULICITY.xml:S1:5795:8	report	VBD	O	O
retinopathy	TRULICITY.xml:S1:5804:11	retinopathi	JJ	O	O
.	TRULICITY.xml:S1:5815:1	.	.	O	O

Baseline	TRULICITY.xml:S1:5817:8	baselin	NNP	O	O
estimated	TRULICITY.xml:S1:5826:9	estim	VBD	O	O
renal	TRULICITY.xml:S1:5836:5	renal	JJ	O	O
function	TRULICITY.xml:S1:5842:8	function	NN	O	O
was	TRULICITY.xml:S1:5851:3	wa	VBD	O	O
normal	TRULICITY.xml:S1:5855:6	normal	JJ	O	O
or	TRULICITY.xml:S1:5862:2	or	CC	O	O
mildly	TRULICITY.xml:S1:5865:6	mildli	RB	O	O
impaired	TRULICITY.xml:S1:5872:8	impair	JJ	O	O
(	TRULICITY.xml:S1:5881:1	(	(	O	O
eGFR	TRULICITY.xml:S1:5882:4	egfr	JJ	O	O
60	TRULICITY.xml:S1:5889:2	60	CD	O	O
ml	TRULICITY.xml:S1:5892:2	ml	NN	O	O
min	TRULICITY.xml:S1:5895:3	min	NN	O	O
1.73	TRULICITY.xml:S1:5899:4	1.73	CD	O	O
m2	TRULICITY.xml:S1:5904:2	m2	NN	O	O
)	TRULICITY.xml:S1:5906:1	)	)	O	O
in	TRULICITY.xml:S1:5908:2	in	IN	O	O
95.7%	TRULICITY.xml:S1:5911:5	95.7%	CD	O	O
of	TRULICITY.xml:S1:5917:2	of	IN	O	O
the	TRULICITY.xml:S1:5920:3	the	DT	O	O
TRULICITY	TRULICITY.xml:S1:5924:9	trulic	NNP	O	O
population	TRULICITY.xml:S1:5934:10	popul	NN	O	O
.	TRULICITY.xml:S1:5944:1	.	.	O	O

In	TRULICITY.xml:S1:5950:2	In	IN	O	O
the	TRULICITY.xml:S1:5953:3	the	DT	O	O
pool	TRULICITY.xml:S1:5957:4	pool	NN	O	O
of	TRULICITY.xml:S1:5962:2	of	IN	O	O
placebo	TRULICITY.xml:S1:5965:7	placebo	NN	O	O
-	TRULICITY.xml:S1:5972:1	-	:	O	O
and	TRULICITY.xml:S1:5974:3	and	CC	O	O
active	TRULICITY.xml:S1:5978:6	activ	JJ	O	O
-	TRULICITY.xml:S1:5984:1	-	:	O	O
controlled	TRULICITY.xml:S1:5985:10	control	VBN	O	O
trials	TRULICITY.xml:S1:5996:6	trial	NNS	O	O
,	TRULICITY.xml:S1:6002:1	,	,	O	O
the	TRULICITY.xml:S1:6004:3	the	DT	O	O
types	TRULICITY.xml:S1:6008:5	type	NNS	O	O
and	TRULICITY.xml:S1:6014:3	and	CC	O	O
frequency	TRULICITY.xml:S1:6018:9	frequenc	NN	O	O
of	TRULICITY.xml:S1:6028:2	of	IN	O	O
common	TRULICITY.xml:S1:6031:6	common	JJ	O	O
adverse	TRULICITY.xml:S1:6038:7	advers	JJ	O	O
reactions	TRULICITY.xml:S1:6046:9	reaction	NNS	O	O
,	TRULICITY.xml:S1:6055:1	,	,	O	O
excluding	TRULICITY.xml:S1:6057:9	exclud	VBG	O	O
hypoglycemia	TRULICITY.xml:S1:6067:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S1:6079:1	,	,	O	O
were	TRULICITY.xml:S1:6081:4	were	VBD	O	O
similar	TRULICITY.xml:S1:6086:7	similar	JJ	O	O
to	TRULICITY.xml:S1:6094:2	to	TO	O	O
those	TRULICITY.xml:S1:6097:5	those	DT	O	O
listed	TRULICITY.xml:S1:6103:6	list	VBN	O	O
in	TRULICITY.xml:S1:6110:2	in	IN	O	O
Table	TRULICITY.xml:S1:6114:5	tabl	JJ	O	O
1	TRULICITY.xml:S1:6120:1	1	CD	O	O
.	TRULICITY.xml:S1:6123:1	.	.	O	O

Other	TRULICITY.xml:S1:6133:5	other	JJ	O	O
Adverse	TRULICITY.xml:S1:6139:7	advers	NNP	O	O
Reactions	TRULICITY.xml:S1:6147:9	reaction	NNP	O	O

Hypoglycemia	TRULICITY.xml:S1:6167:12	hypoglycemia	NN	O	O

Table	TRULICITY.xml:S1:6188:5	tabl	JJ	O	O
2	TRULICITY.xml:S1:6194:1	2	CD	O	O
summarizes	TRULICITY.xml:S1:6197:10	summar	VBZ	O	O
the	TRULICITY.xml:S1:6208:3	the	DT	O	O
incidence	TRULICITY.xml:S1:6212:9	incid	NN	O	O
of	TRULICITY.xml:S1:6222:2	of	IN	O	O
documented	TRULICITY.xml:S1:6225:10	document	VBN	O	O
symptomatic	TRULICITY.xml:S1:6236:11	symptomat	JJ	B-AdverseReaction	O
(	TRULICITY.xml:S1:6248:1	(	(	O	O
70	TRULICITY.xml:S1:6251:2	70	CD	O	O
mg	TRULICITY.xml:S1:6254:2	mg	NN	O	O
dL	TRULICITY.xml:S1:6257:2	dL	NN	O	O
glucose	TRULICITY.xml:S1:6260:7	glucos	VBP	O	O
threshold	TRULICITY.xml:S1:6268:9	threshold	NN	O	O
)	TRULICITY.xml:S1:6277:1	)	)	O	O
and	TRULICITY.xml:S1:6279:3	and	CC	O	O
severe	TRULICITY.xml:S1:6283:6	sever	JJ	O	O
hypoglycemia	TRULICITY.xml:S1:6290:12	hypoglycemia	NN	I-AdverseReaction	O
in	TRULICITY.xml:S1:6303:2	in	IN	O	O
the	TRULICITY.xml:S1:6306:3	the	DT	O	O
placebo	TRULICITY.xml:S1:6310:7	placebo	NN	O	O
-	TRULICITY.xml:S1:6317:1	-	:	O	O
controlled	TRULICITY.xml:S1:6318:10	control	VBN	O	O
clinical	TRULICITY.xml:S1:6329:8	clinic	JJ	O	O
studies	TRULICITY.xml:S1:6338:7	studi	NNS	O	O
.	TRULICITY.xml:S1:6345:1	.	.	O	O

Table	TRULICITY.xml:S1:6351:5	tabl	JJ	O	O
2	TRULICITY.xml:S1:6357:1	2	CD	O	O
:	TRULICITY.xml:S1:6358:1	:	:	O	O
Incidence	TRULICITY.xml:S1:6360:9	incid	NNP	O	O
(	TRULICITY.xml:S1:6370:1	(	(	O	O
)	TRULICITY.xml:S1:6372:1	)	)	O	O
of	TRULICITY.xml:S1:6374:2	of	IN	O	O
Documented	TRULICITY.xml:S1:6377:10	document	NNP	O	O
Symptomatic	TRULICITY.xml:S1:6388:11	symptomat	NNP	B-AdverseReaction	O
and	TRULICITY.xml:S1:6400:3	and	CC	O	O
Severe	TRULICITY.xml:S1:6404:6	sever	NNP	O	O
Hypoglycemia	TRULICITY.xml:S1:6411:12	hypoglycemia	NNP	I-AdverseReaction	O
Adverse	TRULICITY.xml:S1:6424:7	advers	NNP	O	O
Reactions	TRULICITY.xml:S1:6432:9	reaction	NNP	O	O
in	TRULICITY.xml:S1:6442:2	in	IN	O	O
Placebo	TRULICITY.xml:S1:6445:7	placebo	NNP	O	O
-	TRULICITY.xml:S1:6452:1	-	:	O	O
Controlled	TRULICITY.xml:S1:6453:10	control	VBD	O	O
Trials	TRULICITY.xml:S1:6464:6	trial	NNS	O	O

Placebo	TRULICITY.xml:S1:6502:7	placebo	NNP	O	O
TRULICITY	TRULICITY.xml:S1:6529:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:6539:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:6544:2	mg	NN	O	O
TRULICITY	TRULICITY.xml:S1:6556:9	trulic	NNP	O	O
1.5	TRULICITY.xml:S1:6566:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:6570:2	mg	NN	O	O

Add	TRULICITY.xml:S1:6586:3	add	NNP	O	O
-	TRULICITY.xml:S1:6589:1	-	:	O	O
on	TRULICITY.xml:S1:6590:2	on	IN	O	O
to	TRULICITY.xml:S1:6593:2	to	TO	O	O
Metformin	TRULICITY.xml:S1:6596:9	metformin	NNP	O	O

(	TRULICITY.xml:S1:6621:1	(	(	O	O
26	TRULICITY.xml:S1:6622:2	26	CD	O	O
weeks	TRULICITY.xml:S1:6625:5	week	NNS	O	O
)	TRULICITY.xml:S1:6630:1	)	)	O	O
N	TRULICITY.xml:S1:6643:1	N	VBP	O	O
177	TRULICITY.xml:S1:6645:3	177	CD	O	O
N	TRULICITY.xml:S1:6670:1	N	NNP	O	O
302	TRULICITY.xml:S1:6672:3	302	CD	O	O
N	TRULICITY.xml:S1:6697:1	N	NNP	O	O
304	TRULICITY.xml:S1:6699:3	304	CD	O	O

Documented	TRULICITY.xml:S1:6731:10	document	VBN	O	B-AdverseReaction
symptomatic	TRULICITY.xml:S1:6742:11	symptomat	JJ	O	I-AdverseReaction
1.1%	TRULICITY.xml:S1:6755:4	1.1%	CD	O	O
2.6%	TRULICITY.xml:S1:6782:4	2.6%	CD	O	O
5.6%	TRULICITY.xml:S1:6809:4	5.6%	CD	O	O

Severe	TRULICITY.xml:S1:6845:6	sever	RB	O	O
0	TRULICITY.xml:S1:6866:1	0	CD	O	O
0	TRULICITY.xml:S1:6893:1	0	CD	O	O
0	TRULICITY.xml:S1:6920:1	0	CD	O	O

Add	TRULICITY.xml:S1:6952:3	add	NNP	O	O
-	TRULICITY.xml:S1:6955:1	-	:	O	O
on	TRULICITY.xml:S1:6956:2	on	IN	O	O
to	TRULICITY.xml:S1:6959:2	to	TO	O	O
Metformin	TRULICITY.xml:S1:6962:9	metformin	NNP	O	O
Pioglitazone	TRULICITY.xml:S1:6974:12	pioglitazon	NNP	O	O

(	TRULICITY.xml:S1:7000:1	(	(	O	O
26	TRULICITY.xml:S1:7001:2	26	CD	O	O
weeks	TRULICITY.xml:S1:7004:5	week	NNS	O	O
)	TRULICITY.xml:S1:7009:1	)	)	O	O
N	TRULICITY.xml:S1:7022:1	N	VBP	O	O
141	TRULICITY.xml:S1:7024:3	141	CD	O	O
N	TRULICITY.xml:S1:7049:1	N	NNP	O	O
280	TRULICITY.xml:S1:7051:3	280	CD	O	O
N	TRULICITY.xml:S1:7076:1	N	NNP	O	O
279	TRULICITY.xml:S1:7078:3	279	CD	O	O

Documented	TRULICITY.xml:S1:7110:10	document	VBN	O	B-AdverseReaction
symptomatic	TRULICITY.xml:S1:7121:11	symptomat	JJ	O	I-AdverseReaction
1.4%	TRULICITY.xml:S1:7134:4	1.4%	CD	O	O
4.6%	TRULICITY.xml:S1:7161:4	4.6%	CD	O	O
5.0%	TRULICITY.xml:S1:7188:4	5.0%	CD	O	O

Severe	TRULICITY.xml:S1:7224:6	sever	RB	O	O
0	TRULICITY.xml:S1:7245:1	0	CD	O	O
0	TRULICITY.xml:S1:7272:1	0	CD	O	O
0	TRULICITY.xml:S1:7299:1	0	CD	O	O

Hypoglycemia	TRULICITY.xml:S1:7338:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
was	TRULICITY.xml:S1:7351:3	wa	VBD	O	O
more	TRULICITY.xml:S1:7355:4	more	RBR	O	O
frequent	TRULICITY.xml:S1:7360:8	frequent	JJ	O	O
when	TRULICITY.xml:S1:7369:4	when	WRB	O	O
TRULICITY	TRULICITY.xml:S1:7374:9	trulic	NNP	O	O
was	TRULICITY.xml:S1:7384:3	wa	VBD	O	O
used	TRULICITY.xml:S1:7388:4	use	VBN	O	O
in	TRULICITY.xml:S1:7393:2	in	IN	O	O
combination	TRULICITY.xml:S1:7396:11	combin	NN	O	O
with	TRULICITY.xml:S1:7408:4	with	IN	O	O
a	TRULICITY.xml:S1:7413:1	a	DT	O	O
sulfonylurea	TRULICITY.xml:S1:7415:12	sulfonylurea	NN	O	O
or	TRULICITY.xml:S1:7428:2	or	CC	O	O
insulin	TRULICITY.xml:S1:7431:7	insulin	NN	O	O
[	TRULICITY.xml:S1:7440:1	[	NNS	O	O
see	TRULICITY.xml:S1:7441:3	see	VBP	O	O
Warnings	TRULICITY.xml:S1:7445:8	warn	NNS	O	O
and	TRULICITY.xml:S1:7454:3	and	CC	O	O
Precautions	TRULICITY.xml:S1:7458:11	precaut	NNP	O	O
(	TRULICITY.xml:S1:7470:1	(	(	O	O
5.3	TRULICITY.xml:S1:7473:3	5.3	CD	O	O
)]	TRULICITY.xml:S1:7478:2	)]	NN	O	O
.	TRULICITY.xml:S1:7482:1	.	.	O	O

Documented	TRULICITY.xml:S1:7484:10	document	VBN	O	B-AdverseReaction
symptomatic	TRULICITY.xml:S1:7495:11	symptomat	JJ	B-AdverseReaction	I-AdverseReaction
hypoglycemia	TRULICITY.xml:S1:7507:12	hypoglycemia	NN	I-AdverseReaction	I-AdverseReaction
occurred	TRULICITY.xml:S1:7520:8	occur	VBD	O	O
in	TRULICITY.xml:S1:7529:2	in	IN	O	O
39%	TRULICITY.xml:S1:7532:3	39%	CD	O	O
and	TRULICITY.xml:S1:7536:3	and	CC	O	O
40%	TRULICITY.xml:S1:7540:3	40%	CD	O	O
of	TRULICITY.xml:S1:7544:2	of	IN	O	O
patients	TRULICITY.xml:S1:7547:8	patient	NNS	O	O
when	TRULICITY.xml:S1:7556:4	when	WRB	O	O
TRULICITY	TRULICITY.xml:S1:7561:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:7571:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:7576:2	mg	NN	O	O
and	TRULICITY.xml:S1:7579:3	and	CC	O	O
1.5	TRULICITY.xml:S1:7583:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:7587:2	mg	NN	O	O
,	TRULICITY.xml:S1:7589:1	,	,	O	O
respectively	TRULICITY.xml:S1:7591:12	respect	RB	O	O
,	TRULICITY.xml:S1:7603:1	,	,	O	O
was	TRULICITY.xml:S1:7605:3	wa	VBD	O	O
co	TRULICITY.xml:S1:7609:2	co	VBN	O	O
-	TRULICITY.xml:S1:7611:1	-	:	O	O
administered	TRULICITY.xml:S1:7612:12	administ	VBN	O	O
with	TRULICITY.xml:S1:7625:4	with	IN	O	O
a	TRULICITY.xml:S1:7630:1	a	DT	O	O
sulfonylurea	TRULICITY.xml:S1:7632:12	sulfonylurea	NN	O	O
.	TRULICITY.xml:S1:7644:1	.	.	O	O

Severe	TRULICITY.xml:S1:7646:6	sever	NNP	O	O
hypoglycemia	TRULICITY.xml:S1:7653:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
occurred	TRULICITY.xml:S1:7666:8	occur	VBD	O	O
in	TRULICITY.xml:S1:7675:2	in	IN	O	O
0%	TRULICITY.xml:S1:7678:2	0%	CD	O	O
and	TRULICITY.xml:S1:7681:3	and	CC	O	O
0.7%	TRULICITY.xml:S1:7685:4	0.7%	CD	O	O
of	TRULICITY.xml:S1:7690:2	of	IN	O	O
patients	TRULICITY.xml:S1:7693:8	patient	NNS	O	O
when	TRULICITY.xml:S1:7702:4	when	WRB	O	O
TRULICITY	TRULICITY.xml:S1:7707:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:7717:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:7722:2	mg	NN	O	O
and	TRULICITY.xml:S1:7725:3	and	CC	O	O
1.5	TRULICITY.xml:S1:7729:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:7733:2	mg	NN	O	O
,	TRULICITY.xml:S1:7735:1	,	,	O	O
respectively	TRULICITY.xml:S1:7737:12	respect	RB	O	O
,	TRULICITY.xml:S1:7749:1	,	,	O	O
was	TRULICITY.xml:S1:7751:3	wa	VBD	O	O
co	TRULICITY.xml:S1:7755:2	co	VBN	O	O
-	TRULICITY.xml:S1:7757:1	-	:	O	O
administered	TRULICITY.xml:S1:7758:12	administ	VBN	O	O
with	TRULICITY.xml:S1:7771:4	with	IN	O	O
a	TRULICITY.xml:S1:7776:1	a	DT	O	O
sulfonylurea	TRULICITY.xml:S1:7778:12	sulfonylurea	NN	O	O
.	TRULICITY.xml:S1:7790:1	.	.	O	O

Documented	TRULICITY.xml:S1:7792:10	document	VBN	O	B-AdverseReaction
symptomatic	TRULICITY.xml:S1:7803:11	symptomat	JJ	B-AdverseReaction	I-AdverseReaction
hypoglycemia	TRULICITY.xml:S1:7815:12	hypoglycemia	NN	I-AdverseReaction	I-AdverseReaction
occurred	TRULICITY.xml:S1:7828:8	occur	VBD	O	O
in	TRULICITY.xml:S1:7837:2	in	IN	O	O
85%	TRULICITY.xml:S1:7840:3	85%	CD	O	O
and	TRULICITY.xml:S1:7844:3	and	CC	O	O
80%	TRULICITY.xml:S1:7848:3	80%	CD	O	O
of	TRULICITY.xml:S1:7852:2	of	IN	O	O
patients	TRULICITY.xml:S1:7855:8	patient	NNS	O	O
when	TRULICITY.xml:S1:7864:4	when	WRB	O	O
TRULICITY	TRULICITY.xml:S1:7869:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:7879:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:7884:2	mg	NN	O	O
and	TRULICITY.xml:S1:7887:3	and	CC	O	O
1.5	TRULICITY.xml:S1:7891:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:7895:2	mg	NN	O	O
,	TRULICITY.xml:S1:7897:1	,	,	O	O
respectively	TRULICITY.xml:S1:7899:12	respect	RB	O	O
,	TRULICITY.xml:S1:7911:1	,	,	O	O
was	TRULICITY.xml:S1:7913:3	wa	VBD	O	O
co	TRULICITY.xml:S1:7917:2	co	VBN	O	O
-	TRULICITY.xml:S1:7919:1	-	:	O	O
administered	TRULICITY.xml:S1:7920:12	administ	VBN	O	O
with	TRULICITY.xml:S1:7933:4	with	IN	O	O
prandial	TRULICITY.xml:S1:7938:8	prandial	JJ	O	O
insulin	TRULICITY.xml:S1:7947:7	insulin	NN	O	O
.	TRULICITY.xml:S1:7954:1	.	.	O	O

Severe	TRULICITY.xml:S1:7956:6	sever	NNP	O	O
hypoglycemia	TRULICITY.xml:S1:7963:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
occurred	TRULICITY.xml:S1:7976:8	occur	VBD	O	O
in	TRULICITY.xml:S1:7985:2	in	IN	O	O
2.4%	TRULICITY.xml:S1:7988:4	2.4%	CD	O	O
and	TRULICITY.xml:S1:7993:3	and	CC	O	O
3.4%	TRULICITY.xml:S1:7997:4	3.4%	CD	O	O
of	TRULICITY.xml:S1:8002:2	of	IN	O	O
patients	TRULICITY.xml:S1:8005:8	patient	NNS	O	O
when	TRULICITY.xml:S1:8014:4	when	WRB	O	O
TRULICITY	TRULICITY.xml:S1:8019:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:8029:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:8034:2	mg	NN	O	O
and	TRULICITY.xml:S1:8037:3	and	CC	O	O
1.5	TRULICITY.xml:S1:8041:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:8045:2	mg	NN	O	O
,	TRULICITY.xml:S1:8047:1	,	,	O	O
respectively	TRULICITY.xml:S1:8049:12	respect	RB	O	O
,	TRULICITY.xml:S1:8061:1	,	,	O	O
was	TRULICITY.xml:S1:8063:3	wa	VBD	O	O
co	TRULICITY.xml:S1:8067:2	co	VBN	O	O
-	TRULICITY.xml:S1:8069:1	-	:	O	O
administered	TRULICITY.xml:S1:8070:12	administ	VBN	O	O
with	TRULICITY.xml:S1:8083:4	with	IN	O	O
prandial	TRULICITY.xml:S1:8088:8	prandial	JJ	O	O
insulin	TRULICITY.xml:S1:8097:7	insulin	NN	O	O
.	TRULICITY.xml:S1:8104:1	.	.	O	O

Heart	TRULICITY.xml:S1:8114:5	heart	NN	O	O

Rate	TRULICITY.xml:S1:8120:4	rate	NNP	O	B-AdverseReaction
Increase	TRULICITY.xml:S1:8125:8	increas	NNP	O	I-AdverseReaction
and	TRULICITY.xml:S1:8134:3	and	CC	O	O
Tachycardia	TRULICITY.xml:S1:8138:11	tachycardia	NNP	O	B-AdverseReaction
Related	TRULICITY.xml:S1:8150:7	relat	NNP	O	I-AdverseReaction
Adverse	TRULICITY.xml:S1:8158:7	advers	NNP	O	I-AdverseReaction
Reactions	TRULICITY.xml:S1:8166:9	reaction	NNP	O	I-AdverseReaction
.	TRULICITY.xml:S1:8175:1	.	.	O	O

TRULICITY	TRULICITY.xml:S1:8183:9	trulic	$	O	O
0.75	TRULICITY.xml:S1:8193:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:8198:2	mg	NN	O	O
and	TRULICITY.xml:S1:8201:3	and	CC	O	O
1.5	TRULICITY.xml:S1:8205:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:8209:2	mg	NN	O	O
resulted	TRULICITY.xml:S1:8212:8	result	VBD	O	O
in	TRULICITY.xml:S1:8221:2	in	IN	O	O
a	TRULICITY.xml:S1:8224:1	a	DT	O	O
mean	TRULICITY.xml:S1:8226:4	mean	JJ	O	O
increase	TRULICITY.xml:S1:8231:8	increas	NN	B-AdverseReaction	B-AdverseReaction
in	TRULICITY.xml:S1:8240:2	in	IN	I-AdverseReaction	I-AdverseReaction
heart	TRULICITY.xml:S1:8243:5	heart	NN	I-AdverseReaction	I-AdverseReaction
rate	TRULICITY.xml:S1:8249:4	rate	NN	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S1:8254:1	(	(	O	O
HR	TRULICITY.xml:S1:8255:2	HR	NNP	I-AdverseReaction	O
)	TRULICITY.xml:S1:8257:1	)	)	O	O
of	TRULICITY.xml:S1:8259:2	of	IN	O	O
2	TRULICITY.xml:S1:8262:1	2	CD	O	O
-	TRULICITY.xml:S1:8263:1	-	:	O	O
4	TRULICITY.xml:S1:8264:1	4	CD	O	O
beats	TRULICITY.xml:S1:8266:5	beat	NNS	O	O
per	TRULICITY.xml:S1:8272:3	per	IN	O	O
minute	TRULICITY.xml:S1:8276:6	minut	NN	O	O
(	TRULICITY.xml:S1:8283:1	(	(	O	O
bpm	TRULICITY.xml:S1:8284:3	bpm	NN	O	O
)	TRULICITY.xml:S1:8287:1	)	)	O	O
.	TRULICITY.xml:S1:8288:1	.	.	O	O

The	TRULICITY.xml:S1:8290:3	the	DT	O	O
long	TRULICITY.xml:S1:8294:4	long	JJ	O	O
-	TRULICITY.xml:S1:8298:1	-	:	O	O
term	TRULICITY.xml:S1:8299:4	term	NN	O	O
clinical	TRULICITY.xml:S1:8304:8	clinic	JJ	O	O
effects	TRULICITY.xml:S1:8313:7	effect	NNS	O	O
of	TRULICITY.xml:S1:8321:2	of	IN	O	O
the	TRULICITY.xml:S1:8324:3	the	DT	O	O
increase	TRULICITY.xml:S1:8328:8	increas	NN	B-AdverseReaction	O
in	TRULICITY.xml:S1:8337:2	in	IN	I-AdverseReaction	O
HR	TRULICITY.xml:S1:8340:2	HR	NNP	I-AdverseReaction	O
have	TRULICITY.xml:S1:8343:4	have	VBP	O	O
not	TRULICITY.xml:S1:8348:3	not	RB	O	O
been	TRULICITY.xml:S1:8352:4	been	VBN	O	O
established	TRULICITY.xml:S1:8357:11	establish	VBN	O	O
[	TRULICITY.xml:S1:8370:1	[	NNP	O	O
see	TRULICITY.xml:S1:8371:3	see	VBP	O	O
Warnings	TRULICITY.xml:S1:8375:8	warn	NNP	O	O
and	TRULICITY.xml:S1:8384:3	and	CC	O	O
Precautions	TRULICITY.xml:S1:8388:11	precaut	NNP	O	O
(	TRULICITY.xml:S1:8400:1	(	(	O	O
5.7	TRULICITY.xml:S1:8403:3	5.7	CD	O	O
)]	TRULICITY.xml:S1:8408:2	)]	NN	O	O
.	TRULICITY.xml:S1:8412:1	.	.	O	O

Adverse	TRULICITY.xml:S1:8418:7	advers	JJ	O	O
reactions	TRULICITY.xml:S1:8426:9	reaction	NNS	O	O
of	TRULICITY.xml:S1:8436:2	of	IN	O	O
sinus	TRULICITY.xml:S1:8439:5	sinu	JJ	B-AdverseReaction	B-AdverseReaction
tachycardia	TRULICITY.xml:S1:8445:11	tachycardia	NN	I-AdverseReaction	I-AdverseReaction
were	TRULICITY.xml:S1:8457:4	were	VBD	O	O
reported	TRULICITY.xml:S1:8462:8	report	VBN	O	O
more	TRULICITY.xml:S1:8471:4	more	RBR	O	O
frequently	TRULICITY.xml:S1:8476:10	frequent	RB	O	O
in	TRULICITY.xml:S1:8487:2	in	IN	O	O
patients	TRULICITY.xml:S1:8490:8	patient	NNS	O	O
exposed	TRULICITY.xml:S1:8499:7	expos	VBN	O	O
to	TRULICITY.xml:S1:8507:2	to	TO	O	O
TRULICITY	TRULICITY.xml:S1:8510:9	trulic	NNP	O	O
.	TRULICITY.xml:S1:8519:1	.	.	O	O

Sinus	TRULICITY.xml:S1:8521:5	sinu	NNP	B-AdverseReaction	B-AdverseReaction
tachycardia	TRULICITY.xml:S1:8527:11	tachycardia	NN	I-AdverseReaction	I-AdverseReaction
was	TRULICITY.xml:S1:8539:3	wa	VBD	O	O
reported	TRULICITY.xml:S1:8543:8	report	VBN	O	O
in	TRULICITY.xml:S1:8552:2	in	IN	O	O
3.0%	TRULICITY.xml:S1:8555:4	3.0%	CD	O	O
,	TRULICITY.xml:S1:8559:1	,	,	O	O
2.8%	TRULICITY.xml:S1:8561:4	2.8%	CD	O	O
,	TRULICITY.xml:S1:8565:1	,	,	O	O
and	TRULICITY.xml:S1:8567:3	and	CC	O	O
5.6%	TRULICITY.xml:S1:8571:4	5.6%	CD	O	O
of	TRULICITY.xml:S1:8576:2	of	IN	O	O
patient	TRULICITY.xml:S1:8579:7	patient	NN	O	O
treated	TRULICITY.xml:S1:8587:7	treat	VBN	O	O
with	TRULICITY.xml:S1:8595:4	with	IN	O	O
placebo	TRULICITY.xml:S1:8600:7	placebo	NN	O	O
,	TRULICITY.xml:S1:8607:1	,	,	O	O
TRULICITY	TRULICITY.xml:S1:8609:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:8619:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:8624:2	mg	NN	O	O
and	TRULICITY.xml:S1:8627:3	and	CC	O	O
TRULICITY	TRULICITY.xml:S1:8631:9	trulic	NNP	O	O
1.5	TRULICITY.xml:S1:8641:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:8645:2	mg	NN	O	O
,	TRULICITY.xml:S1:8647:1	,	,	O	O
respectively	TRULICITY.xml:S1:8649:12	respect	RB	O	O
.	TRULICITY.xml:S1:8661:1	.	.	O	O

Persistence	TRULICITY.xml:S1:8663:11	persist	NN	B-AdverseReaction	B-AdverseReaction
of	TRULICITY.xml:S1:8675:2	of	IN	I-AdverseReaction	I-AdverseReaction
sinus	TRULICITY.xml:S1:8678:5	sinu	JJ	I-AdverseReaction	I-AdverseReaction
tachycardia	TRULICITY.xml:S1:8684:11	tachycardia	NN	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S1:8696:1	(	(	O	O
reported	TRULICITY.xml:S1:8697:8	report	VBN	O	O
at	TRULICITY.xml:S1:8706:2	at	IN	O	O
more	TRULICITY.xml:S1:8709:4	more	JJR	O	O
than	TRULICITY.xml:S1:8714:4	than	IN	O	O
2	TRULICITY.xml:S1:8719:1	2	CD	O	O
visits	TRULICITY.xml:S1:8721:6	visit	NNS	O	O
)	TRULICITY.xml:S1:8727:1	)	)	O	O
was	TRULICITY.xml:S1:8729:3	wa	VBD	O	O
reported	TRULICITY.xml:S1:8733:8	report	VBN	O	O
in	TRULICITY.xml:S1:8742:2	in	IN	O	O
0.2%	TRULICITY.xml:S1:8745:4	0.2%	CD	O	O
,	TRULICITY.xml:S1:8749:1	,	,	O	O
0.4%	TRULICITY.xml:S1:8751:4	0.4%	CD	O	O
and	TRULICITY.xml:S1:8756:3	and	CC	O	O
1.6%	TRULICITY.xml:S1:8760:4	1.6%	CD	O	O
of	TRULICITY.xml:S1:8765:2	of	IN	O	O
patients	TRULICITY.xml:S1:8768:8	patient	NNS	O	O
treated	TRULICITY.xml:S1:8777:7	treat	VBN	O	O
with	TRULICITY.xml:S1:8785:4	with	IN	O	O
placebo	TRULICITY.xml:S1:8790:7	placebo	NN	O	O
,	TRULICITY.xml:S1:8797:1	,	,	O	O
TRULICITY	TRULICITY.xml:S1:8799:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:8809:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:8814:2	mg	NN	O	O
and	TRULICITY.xml:S1:8817:3	and	CC	O	O
TRULICITY	TRULICITY.xml:S1:8821:9	trulic	NNP	O	O
1.5	TRULICITY.xml:S1:8831:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:8835:2	mg	NN	O	O
,	TRULICITY.xml:S1:8837:1	,	,	O	O
respectively	TRULICITY.xml:S1:8839:12	respect	RB	O	O
.	TRULICITY.xml:S1:8851:1	.	.	O	O

Episodes	TRULICITY.xml:S1:8853:8	episod	NNS	O	B-AdverseReaction
of	TRULICITY.xml:S1:8862:2	of	IN	O	I-AdverseReaction
sinus	TRULICITY.xml:S1:8865:5	sinu	JJ	B-AdverseReaction	I-AdverseReaction
tachycardia	TRULICITY.xml:S1:8871:11	tachycardia	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:8882:1	,	,	O	O
associated	TRULICITY.xml:S1:8884:10	associ	VBN	O	O
with	TRULICITY.xml:S1:8895:4	with	IN	O	O
a	TRULICITY.xml:S1:8900:1	a	DT	O	O
concomitant	TRULICITY.xml:S1:8902:11	concomit	JJ	O	O
increase	TRULICITY.xml:S1:8914:8	increas	NN	B-AdverseReaction	O
from	TRULICITY.xml:S1:8923:4	from	IN	O	O
baseline	TRULICITY.xml:S1:8928:8	baselin	NN	O	O
in	TRULICITY.xml:S1:8937:2	in	IN	I-AdverseReaction	O
heart	TRULICITY.xml:S1:8940:5	heart	NN	I-AdverseReaction	O
rate	TRULICITY.xml:S1:8946:4	rate	NN	I-AdverseReaction	O
of	TRULICITY.xml:S1:8951:2	of	IN	O	O
15	TRULICITY.xml:S1:8956:2	15	CD	O	O
beats	TRULICITY.xml:S1:8959:5	beat	NNS	O	O
per	TRULICITY.xml:S1:8965:3	per	IN	O	O
minute	TRULICITY.xml:S1:8969:6	minut	NN	O	O
,	TRULICITY.xml:S1:8975:1	,	,	O	O
were	TRULICITY.xml:S1:8977:4	were	VBD	O	O
reported	TRULICITY.xml:S1:8982:8	report	VBN	O	O
in	TRULICITY.xml:S1:8991:2	in	IN	O	O
0.7%	TRULICITY.xml:S1:8994:4	0.7%	CD	O	O
,	TRULICITY.xml:S1:8998:1	,	,	O	O
1.3%	TRULICITY.xml:S1:9000:4	1.3%	CD	O	O
and	TRULICITY.xml:S1:9005:3	and	CC	O	O
2.2%	TRULICITY.xml:S1:9009:4	2.2%	CD	O	O
of	TRULICITY.xml:S1:9014:2	of	IN	O	O
patient	TRULICITY.xml:S1:9017:7	patient	NN	O	O
treated	TRULICITY.xml:S1:9025:7	treat	VBN	O	O
with	TRULICITY.xml:S1:9033:4	with	IN	O	O
placebo	TRULICITY.xml:S1:9038:7	placebo	NN	O	O
,	TRULICITY.xml:S1:9045:1	,	,	O	O
TRULICITY	TRULICITY.xml:S1:9047:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:9057:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:9062:2	mg	NN	O	O
and	TRULICITY.xml:S1:9065:3	and	CC	O	O
TRULICITY	TRULICITY.xml:S1:9069:9	trulic	NNP	O	O
1.5	TRULICITY.xml:S1:9079:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:9083:2	mg	NN	O	O
,	TRULICITY.xml:S1:9085:1	,	,	O	O
respectively	TRULICITY.xml:S1:9087:12	respect	RB	O	O
.	TRULICITY.xml:S1:9099:1	.	.	O	O

Immunogenicity	TRULICITY.xml:S1:9109:14	immunogen	NN	O	O

Across	TRULICITY.xml:S1:9130:6	across	IN	O	O
four	TRULICITY.xml:S1:9137:4	four	CD	O	O
Phase	TRULICITY.xml:S1:9142:5	phase	NN	O	O
2	TRULICITY.xml:S1:9148:1	2	CD	O	O
and	TRULICITY.xml:S1:9150:3	and	CC	O	O
five	TRULICITY.xml:S1:9154:4	five	CD	O	O
Phase	TRULICITY.xml:S1:9159:5	phase	NNP	O	O
3	TRULICITY.xml:S1:9165:1	3	CD	O	O
clinical	TRULICITY.xml:S1:9167:8	clinic	JJ	O	O
studies	TRULICITY.xml:S1:9176:7	studi	NNS	O	O
,	TRULICITY.xml:S1:9183:1	,	,	O	O
64	TRULICITY.xml:S1:9185:2	64	CD	O	O
(	TRULICITY.xml:S1:9188:1	(	(	O	O
1.6%	TRULICITY.xml:S1:9189:4	1.6%	CD	O	O
)	TRULICITY.xml:S1:9193:1	)	)	O	O
TRULICITY	TRULICITY.xml:S1:9195:9	trulic	NNP	O	O
treated	TRULICITY.xml:S1:9205:7	treat	VBD	O	O
patients	TRULICITY.xml:S1:9213:8	patient	NNS	O	O
developed	TRULICITY.xml:S1:9222:9	develop	VBD	O	O
anti	TRULICITY.xml:S1:9232:4	anti	JJ	O	O
-	TRULICITY.xml:S1:9236:1	-	:	O	O
drug	TRULICITY.xml:S1:9237:4	drug	NN	O	O
antibodies	TRULICITY.xml:S1:9242:10	antibodi	NNS	O	O
(	TRULICITY.xml:S1:9253:1	(	(	O	O
ADAs	TRULICITY.xml:S1:9254:4	ada	NNP	O	O
)	TRULICITY.xml:S1:9258:1	)	)	O	O
to	TRULICITY.xml:S1:9260:2	to	TO	O	O
the	TRULICITY.xml:S1:9263:3	the	DT	O	O
active	TRULICITY.xml:S1:9267:6	activ	JJ	O	O
ingredient	TRULICITY.xml:S1:9274:10	ingredi	NN	O	O
in	TRULICITY.xml:S1:9285:2	in	IN	O	O
TRULICITY	TRULICITY.xml:S1:9288:9	trulic	NNP	O	O
(	TRULICITY.xml:S1:9298:1	(	(	O	O
i	TRULICITY.xml:S1:9299:1	i	NN	O	O
.	TRULICITY.xml:S1:9300:1	.	.	O	O
e	TRULICITY.xml:S1:9301:1	e	NN	O	O
.	TRULICITY.xml:S1:9302:1	.	.	O	O
,	TRULICITY.xml:S1:9303:1	,	,	O	O
dulaglutide	TRULICITY.xml:S1:9305:11	dulaglutid	NN	O	O
)	TRULICITY.xml:S1:9316:1	)	)	O	O
.	TRULICITY.xml:S1:9317:1	.	.	O	O

Of	TRULICITY.xml:S1:9323:2	Of	IN	O	O
the	TRULICITY.xml:S1:9326:3	the	DT	O	O
64	TRULICITY.xml:S1:9330:2	64	CD	O	O
dulaglutide	TRULICITY.xml:S1:9333:11	dulaglutid	NN	O	O
-	TRULICITY.xml:S1:9344:1	-	:	O	O
treated	TRULICITY.xml:S1:9345:7	treat	JJ	O	O
patients	TRULICITY.xml:S1:9353:8	patient	NNS	O	O
that	TRULICITY.xml:S1:9362:4	that	WDT	O	O
developed	TRULICITY.xml:S1:9367:9	develop	VBD	O	O
dulaglutide	TRULICITY.xml:S1:9377:11	dulaglutid	VB	O	O
ADAs	TRULICITY.xml:S1:9389:4	ada	NNP	O	O
,	TRULICITY.xml:S1:9393:1	,	,	O	O
34	TRULICITY.xml:S1:9395:2	34	CD	O	O
patients	TRULICITY.xml:S1:9398:8	patient	NNS	O	O
(	TRULICITY.xml:S1:9407:1	(	(	O	O
0.9%	TRULICITY.xml:S1:9408:4	0.9%	CD	O	O
of	TRULICITY.xml:S1:9413:2	of	IN	O	O
the	TRULICITY.xml:S1:9416:3	the	DT	O	O
overall	TRULICITY.xml:S1:9420:7	overal	JJ	O	O
population	TRULICITY.xml:S1:9428:10	popul	NN	O	O
)	TRULICITY.xml:S1:9438:1	)	)	O	O
had	TRULICITY.xml:S1:9440:3	had	VBD	O	O
dulaglutide	TRULICITY.xml:S1:9444:11	dulaglutid	VBN	O	O
-	TRULICITY.xml:S1:9455:1	-	:	O	O
neutralizing	TRULICITY.xml:S1:9456:12	neutral	NN	O	O
antibodies	TRULICITY.xml:S1:9469:10	antibodi	NNS	O	O
,	TRULICITY.xml:S1:9479:1	,	,	O	O
and	TRULICITY.xml:S1:9481:3	and	CC	O	O
36	TRULICITY.xml:S1:9485:2	36	CD	O	O
patients	TRULICITY.xml:S1:9488:8	patient	NNS	O	O
(	TRULICITY.xml:S1:9497:1	(	(	O	O
0.9%	TRULICITY.xml:S1:9498:4	0.9%	CD	O	O
of	TRULICITY.xml:S1:9503:2	of	IN	O	O
the	TRULICITY.xml:S1:9506:3	the	DT	O	O
overall	TRULICITY.xml:S1:9510:7	overal	JJ	O	O
population	TRULICITY.xml:S1:9518:10	popul	NN	O	O
)	TRULICITY.xml:S1:9528:1	)	)	O	O
developed	TRULICITY.xml:S1:9530:9	develop	VBD	O	O
antibodies	TRULICITY.xml:S1:9540:10	antibodi	NNS	O	O
against	TRULICITY.xml:S1:9551:7	against	IN	O	O
native	TRULICITY.xml:S1:9559:6	nativ	JJ	O	O
GLP	TRULICITY.xml:S1:9566:3	glp	NNP	O	O
-	TRULICITY.xml:S1:9569:1	-	:	O	O
1	TRULICITY.xml:S1:9570:1	1	CD	O	O
.	TRULICITY.xml:S1:9571:1	.	.	O	O

The	TRULICITY.xml:S1:9577:3	the	DT	O	O
detection	TRULICITY.xml:S1:9581:9	detect	NN	O	O
of	TRULICITY.xml:S1:9591:2	of	IN	O	O
antibody	TRULICITY.xml:S1:9594:8	antibodi	NN	O	O
formation	TRULICITY.xml:S1:9603:9	format	NN	O	O
is	TRULICITY.xml:S1:9613:2	is	VBZ	O	O
highly	TRULICITY.xml:S1:9616:6	highli	RB	O	O
dependent	TRULICITY.xml:S1:9623:9	depend	JJ	O	O
on	TRULICITY.xml:S1:9633:2	on	IN	O	O
the	TRULICITY.xml:S1:9636:3	the	DT	O	O
sensitivity	TRULICITY.xml:S1:9640:11	sensit	NN	O	O
and	TRULICITY.xml:S1:9652:3	and	CC	O	O
specificity	TRULICITY.xml:S1:9656:11	specif	NN	O	O
of	TRULICITY.xml:S1:9668:2	of	IN	O	O
the	TRULICITY.xml:S1:9671:3	the	DT	O	O
assay	TRULICITY.xml:S1:9675:5	assay	NN	O	O
.	TRULICITY.xml:S1:9680:1	.	.	O	O

Additionally	TRULICITY.xml:S1:9682:12	addit	RB	O	O
,	TRULICITY.xml:S1:9694:1	,	,	O	O
the	TRULICITY.xml:S1:9696:3	the	DT	O	O
observed	TRULICITY.xml:S1:9700:8	observ	JJ	O	O
incidence	TRULICITY.xml:S1:9709:9	incid	NN	O	O
of	TRULICITY.xml:S1:9719:2	of	IN	O	O
antibody	TRULICITY.xml:S1:9722:8	antibodi	NN	O	O
(	TRULICITY.xml:S1:9731:1	(	(	O	O
including	TRULICITY.xml:S1:9732:9	includ	VBG	O	O
neutralizing	TRULICITY.xml:S1:9742:12	neutral	VBG	O	O
antibody	TRULICITY.xml:S1:9755:8	antibodi	NN	O	O
)	TRULICITY.xml:S1:9763:1	)	)	O	O
positivity	TRULICITY.xml:S1:9765:10	posit	NN	O	O
in	TRULICITY.xml:S1:9776:2	in	IN	O	O
an	TRULICITY.xml:S1:9779:2	an	DT	O	O
assay	TRULICITY.xml:S1:9782:5	assay	NN	O	O
may	TRULICITY.xml:S1:9788:3	may	MD	O	O
be	TRULICITY.xml:S1:9792:2	be	VB	O	O
influenced	TRULICITY.xml:S1:9795:10	influenc	VBN	O	O
by	TRULICITY.xml:S1:9806:2	by	IN	O	O
several	TRULICITY.xml:S1:9809:7	sever	JJ	O	O
factors	TRULICITY.xml:S1:9817:7	factor	NNS	O	O
including	TRULICITY.xml:S1:9825:9	includ	VBG	O	O
assay	TRULICITY.xml:S1:9835:5	assay	JJ	O	O
methodology	TRULICITY.xml:S1:9841:11	methodolog	NN	O	O
,	TRULICITY.xml:S1:9852:1	,	,	O	O
sample	TRULICITY.xml:S1:9854:6	sampl	NN	O	O
handling	TRULICITY.xml:S1:9861:8	handl	NN	O	O
,	TRULICITY.xml:S1:9869:1	,	,	O	O
timing	TRULICITY.xml:S1:9871:6	time	NN	O	O
of	TRULICITY.xml:S1:9878:2	of	IN	O	O
sample	TRULICITY.xml:S1:9881:6	sampl	JJ	O	O
collection	TRULICITY.xml:S1:9888:10	collect	NN	O	O
,	TRULICITY.xml:S1:9898:1	,	,	O	O
concomitant	TRULICITY.xml:S1:9900:11	concomit	JJ	O	O
medications	TRULICITY.xml:S1:9912:11	medic	NNS	O	O
,	TRULICITY.xml:S1:9923:1	,	,	O	O
and	TRULICITY.xml:S1:9925:3	and	CC	O	O
underlying	TRULICITY.xml:S1:9929:10	underli	JJ	O	O
disease	TRULICITY.xml:S1:9940:7	diseas	NN	O	O
.	TRULICITY.xml:S1:9947:1	.	.	O	O

For	TRULICITY.xml:S1:9949:3	for	IN	O	O
these	TRULICITY.xml:S1:9953:5	these	DT	O	O
reasons	TRULICITY.xml:S1:9959:7	reason	NNS	O	O
,	TRULICITY.xml:S1:9966:1	,	,	O	O
the	TRULICITY.xml:S1:9968:3	the	DT	O	O
incidence	TRULICITY.xml:S1:9972:9	incid	NN	O	O
of	TRULICITY.xml:S1:9982:2	of	IN	O	O
antibodies	TRULICITY.xml:S1:9985:10	antibodi	NNS	O	O
to	TRULICITY.xml:S1:9996:2	to	TO	O	O
dulaglutide	TRULICITY.xml:S1:9999:11	dulaglutid	VB	O	O
cannot	TRULICITY.xml:S1:10011:6	cannot	NN	O	O
be	TRULICITY.xml:S1:10018:2	be	VB	O	O
directly	TRULICITY.xml:S1:10021:8	directli	RB	O	O
compared	TRULICITY.xml:S1:10030:8	compar	VBN	O	O
with	TRULICITY.xml:S1:10039:4	with	IN	O	O
the	TRULICITY.xml:S1:10044:3	the	DT	O	O
incidence	TRULICITY.xml:S1:10048:9	incid	NN	O	O
of	TRULICITY.xml:S1:10058:2	of	IN	O	O
antibodies	TRULICITY.xml:S1:10061:10	antibodi	NNS	O	O
of	TRULICITY.xml:S1:10072:2	of	IN	O	O
other	TRULICITY.xml:S1:10075:5	other	JJ	O	O
products	TRULICITY.xml:S1:10081:8	product	NNS	O	O
.	TRULICITY.xml:S1:10089:1	.	.	O	O

Hypersensitivity	TRULICITY.xml:S1:10099:16	hypersensit	NN	O	O

Systemic	TRULICITY.xml:S1:10122:8	system	NNP	B-AdverseReaction	O
hypersensitivity	TRULICITY.xml:S1:10131:16	hypersensit	NN	I-AdverseReaction	O
adverse	TRULICITY.xml:S1:10148:7	advers	JJ	O	O
reactions	TRULICITY.xml:S1:10156:9	reaction	NNS	O	O
sometimes	TRULICITY.xml:S1:10166:9	sometim	RB	O	O
severe	TRULICITY.xml:S1:10176:6	sever	JJ	O	O
(	TRULICITY.xml:S1:10183:1	(	(	O	O
e	TRULICITY.xml:S1:10184:1	e	JJ	O	O
.	TRULICITY.xml:S1:10185:1	.	.	O	O
g	TRULICITY.xml:S1:10186:1	g	NN	O	O
.	TRULICITY.xml:S1:10187:1	.	.	O	O
,	TRULICITY.xml:S1:10188:1	,	,	O	O
severe	TRULICITY.xml:S1:10190:6	sever	JJ	O	O
urticaria	TRULICITY.xml:S1:10197:9	urticaria	NN	B-AdverseReaction	O
,	TRULICITY.xml:S1:10206:1	,	,	O	O
systemic	TRULICITY.xml:S1:10208:8	system	JJ	B-AdverseReaction	B-AdverseReaction
rash	TRULICITY.xml:S1:10217:4	rash	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:10221:1	,	,	O	O
facial	TRULICITY.xml:S1:10223:6	facial	JJ	B-AdverseReaction	B-AdverseReaction
edema	TRULICITY.xml:S1:10230:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:10235:1	,	,	O	O
lip	TRULICITY.xml:S1:10237:3	lip	FW	B-AdverseReaction	B-AdverseReaction
swelling	TRULICITY.xml:S1:10241:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
)	TRULICITY.xml:S1:10249:1	)	)	O	O
occurred	TRULICITY.xml:S1:10251:8	occur	VBD	O	O
in	TRULICITY.xml:S1:10260:2	in	IN	O	O
0.5%	TRULICITY.xml:S1:10263:4	0.5%	CD	O	O
of	TRULICITY.xml:S1:10268:2	of	IN	O	O
patients	TRULICITY.xml:S1:10271:8	patient	NNS	O	O
on	TRULICITY.xml:S1:10280:2	on	IN	O	O
TRULICITY	TRULICITY.xml:S1:10283:9	trulic	NNP	O	O
in	TRULICITY.xml:S1:10293:2	in	IN	O	O
the	TRULICITY.xml:S1:10296:3	the	DT	O	O
four	TRULICITY.xml:S1:10300:4	four	CD	O	O
Phase	TRULICITY.xml:S1:10305:5	phase	NNP	O	O
2	TRULICITY.xml:S1:10311:1	2	CD	O	O
and	TRULICITY.xml:S1:10313:3	and	CC	O	O
five	TRULICITY.xml:S1:10317:4	five	CD	O	O
Phase	TRULICITY.xml:S1:10322:5	phase	NNP	O	O
3	TRULICITY.xml:S1:10328:1	3	CD	O	O
studies	TRULICITY.xml:S1:10330:7	studi	NNS	O	O
.	TRULICITY.xml:S1:10337:1	.	.	O	O

Injection	TRULICITY.xml:S1:10347:9	inject	NNP	O	O
-	TRULICITY.xml:S1:10356:1	-	:	O	O
site	TRULICITY.xml:S1:10357:4	site	NN	O	O
Reactions	TRULICITY.xml:S1:10362:9	reaction	NNS	O	O

In	TRULICITY.xml:S1:10378:2	In	IN	O	O
the	TRULICITY.xml:S1:10381:3	the	DT	O	O
placebo	TRULICITY.xml:S1:10385:7	placebo	NN	O	O
-	TRULICITY.xml:S1:10392:1	-	:	O	O
controlled	TRULICITY.xml:S1:10393:10	control	JJ	O	O
studies	TRULICITY.xml:S1:10404:7	studi	NNS	O	O
,	TRULICITY.xml:S1:10411:1	,	,	O	O
injection	TRULICITY.xml:S1:10413:9	inject	NN	B-AdverseReaction	B-AdverseReaction
-	TRULICITY.xml:S1:10422:1	-	:	I-AdverseReaction	I-AdverseReaction
site	TRULICITY.xml:S1:10423:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	TRULICITY.xml:S1:10428:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S1:10438:1	(	(	O	O
e	TRULICITY.xml:S1:10439:1	e	NN	O	O
.	TRULICITY.xml:S1:10440:1	.	.	O	O
g	TRULICITY.xml:S1:10441:1	g	NN	O	O
.	TRULICITY.xml:S1:10442:1	.	.	O	O
,	TRULICITY.xml:S1:10443:1	,	,	O	O
injection	TRULICITY.xml:S1:10445:9	inject	NN	B-AdverseReaction	B-AdverseReaction
-	TRULICITY.xml:S1:10454:1	-	:	I-AdverseReaction	I-AdverseReaction
site	TRULICITY.xml:S1:10455:4	site	NN	I-AdverseReaction	I-AdverseReaction
rash	TRULICITY.xml:S1:10460:4	rash	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S1:10464:1	,	,	O	O
erythema	TRULICITY.xml:S1:10466:8	erythema	NN	I-AdverseReaction	B-AdverseReaction
)	TRULICITY.xml:S1:10474:1	)	)	O	O
were	TRULICITY.xml:S1:10476:4	were	VBD	O	O
reported	TRULICITY.xml:S1:10481:8	report	VBN	O	O
in	TRULICITY.xml:S1:10490:2	in	IN	O	O
0.5%	TRULICITY.xml:S1:10493:4	0.5%	CD	O	O
of	TRULICITY.xml:S1:10498:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S1:10501:9	trulic	NNP	O	O
-	TRULICITY.xml:S1:10510:1	-	:	O	O
treated	TRULICITY.xml:S1:10511:7	treat	VBD	O	O
patients	TRULICITY.xml:S1:10519:8	patient	NNS	O	O
and	TRULICITY.xml:S1:10528:3	and	CC	O	O
in	TRULICITY.xml:S1:10532:2	in	IN	O	O
0.0%	TRULICITY.xml:S1:10535:4	0.0%	CD	O	O
of	TRULICITY.xml:S1:10540:2	of	IN	O	O
placebo	TRULICITY.xml:S1:10543:7	placebo	NN	O	O
-	TRULICITY.xml:S1:10550:1	-	:	O	O
treated	TRULICITY.xml:S1:10551:7	treat	JJ	O	O
patients	TRULICITY.xml:S1:10559:8	patient	NNS	O	O
.	TRULICITY.xml:S1:10567:1	.	.	O	O

PR	TRULICITY.xml:S1:10577:2	PR	NNP	O	O
Interval	TRULICITY.xml:S1:10580:8	interv	NNP	O	O
Prolongation	TRULICITY.xml:S1:10589:12	prolong	NNP	O	O
and	TRULICITY.xml:S1:10602:3	and	CC	O	O
Adverse	TRULICITY.xml:S1:10606:7	advers	NNP	O	O
Reactions	TRULICITY.xml:S1:10614:9	reaction	NNP	O	O
of	TRULICITY.xml:S1:10624:2	of	IN	O	O
First	TRULICITY.xml:S1:10627:5	first	NNP	O	O
Degree	TRULICITY.xml:S1:10633:6	degre	NNP	O	O
Atrioventricular	TRULICITY.xml:S1:10640:16	atrioventricular	NNP	O	O
(	TRULICITY.xml:S1:10657:1	(	(	O	O
AV	TRULICITY.xml:S1:10658:2	AV	NNP	O	O
)	TRULICITY.xml:S1:10660:1	)	)	O	O
Block	TRULICITY.xml:S1:10662:5	block	NNP	O	O

A	TRULICITY.xml:S1:10674:1	A	DT	O	O
mean	TRULICITY.xml:S1:10676:4	mean	JJ	O	O
increase	TRULICITY.xml:S1:10681:8	increas	NN	B-AdverseReaction	O
from	TRULICITY.xml:S1:10690:4	from	IN	O	O
baseline	TRULICITY.xml:S1:10695:8	baselin	NN	O	O
in	TRULICITY.xml:S1:10704:2	in	IN	O	O
PR	TRULICITY.xml:S1:10707:2	PR	NNP	I-AdverseReaction	O
interval	TRULICITY.xml:S1:10710:8	interv	NN	I-AdverseReaction	O
of	TRULICITY.xml:S1:10719:2	of	IN	O	O
2	TRULICITY.xml:S1:10722:1	2	CD	O	O
-	TRULICITY.xml:S1:10723:1	-	:	O	O
3	TRULICITY.xml:S1:10724:1	3	CD	O	O
milliseconds	TRULICITY.xml:S1:10726:12	millisecond	NNS	O	O
was	TRULICITY.xml:S1:10739:3	wa	VBD	O	O
observed	TRULICITY.xml:S1:10743:8	observ	VBN	O	O
in	TRULICITY.xml:S1:10752:2	in	IN	O	O
TRULICITY	TRULICITY.xml:S1:10755:9	trulic	NNP	O	O
-	TRULICITY.xml:S1:10764:1	-	:	O	O
treated	TRULICITY.xml:S1:10765:7	treat	VBD	O	O
patients	TRULICITY.xml:S1:10773:8	patient	NNS	O	O
in	TRULICITY.xml:S1:10782:2	in	IN	O	O
contrast	TRULICITY.xml:S1:10785:8	contrast	NN	O	O
to	TRULICITY.xml:S1:10794:2	to	TO	O	O
a	TRULICITY.xml:S1:10797:1	a	DT	O	O
mean	TRULICITY.xml:S1:10799:4	mean	JJ	O	O
decrease	TRULICITY.xml:S1:10804:8	decreas	NN	O	O
of	TRULICITY.xml:S1:10813:2	of	IN	O	O
0.9	TRULICITY.xml:S1:10816:3	0.9	CD	O	O
millisecond	TRULICITY.xml:S1:10820:11	millisecond	NN	O	O
in	TRULICITY.xml:S1:10832:2	in	IN	O	O
placebo	TRULICITY.xml:S1:10835:7	placebo	NN	O	O
-	TRULICITY.xml:S1:10842:1	-	:	O	O
treated	TRULICITY.xml:S1:10843:7	treat	JJ	O	O
patients	TRULICITY.xml:S1:10851:8	patient	NNS	O	O
.	TRULICITY.xml:S1:10859:1	.	.	O	O

The	TRULICITY.xml:S1:10861:3	the	DT	O	O
adverse	TRULICITY.xml:S1:10865:7	advers	JJ	O	O
reaction	TRULICITY.xml:S1:10873:8	reaction	NN	O	O
of	TRULICITY.xml:S1:10882:2	of	IN	O	O
first	TRULICITY.xml:S1:10885:5	first	JJ	B-AdverseReaction	B-AdverseReaction
degree	TRULICITY.xml:S1:10891:6	degre	NN	I-AdverseReaction	I-AdverseReaction
AV	TRULICITY.xml:S1:10898:2	AV	NNP	I-AdverseReaction	I-AdverseReaction
block	TRULICITY.xml:S1:10901:5	block	NN	I-AdverseReaction	I-AdverseReaction
occurred	TRULICITY.xml:S1:10907:8	occur	VBD	O	O
more	TRULICITY.xml:S1:10916:4	more	RBR	O	O
frequently	TRULICITY.xml:S1:10921:10	frequent	RB	O	O
in	TRULICITY.xml:S1:10932:2	in	IN	O	O
patients	TRULICITY.xml:S1:10935:8	patient	NNS	O	O
treated	TRULICITY.xml:S1:10944:7	treat	VBN	O	O
with	TRULICITY.xml:S1:10952:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S1:10957:9	trulic	NNP	O	O
than	TRULICITY.xml:S1:10967:4	than	IN	O	O
placebo	TRULICITY.xml:S1:10972:7	placebo	NN	O	O
(	TRULICITY.xml:S1:10980:1	(	(	O	O
0.9%	TRULICITY.xml:S1:10981:4	0.9%	CD	O	O
,	TRULICITY.xml:S1:10985:1	,	,	O	O
1.7%	TRULICITY.xml:S1:10987:4	1.7%	CD	O	O
and	TRULICITY.xml:S1:10992:3	and	CC	O	O
2.3%	TRULICITY.xml:S1:10996:4	2.3%	CD	O	O
for	TRULICITY.xml:S1:11001:3	for	IN	O	O
placebo	TRULICITY.xml:S1:11005:7	placebo	NN	O	O
,	TRULICITY.xml:S1:11012:1	,	,	O	O
TRULICITY	TRULICITY.xml:S1:11014:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:11024:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:11029:2	mg	NN	O	O
and	TRULICITY.xml:S1:11032:3	and	CC	O	O
TRULICITY	TRULICITY.xml:S1:11036:9	trulic	NNP	O	O
1.5	TRULICITY.xml:S1:11046:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:11050:2	mg	NN	O	O
,	TRULICITY.xml:S1:11052:1	,	,	O	O
respectively	TRULICITY.xml:S1:11054:12	respect	RB	O	O
)	TRULICITY.xml:S1:11066:1	)	)	O	O
.	TRULICITY.xml:S1:11067:1	.	.	O	O

On	TRULICITY.xml:S1:11069:2	On	IN	O	O
electrocardiograms	TRULICITY.xml:S1:11072:18	electrocardiogram	NNS	O	O
,	TRULICITY.xml:S1:11090:1	,	,	O	O
a	TRULICITY.xml:S1:11092:1	a	DT	O	O
PR	TRULICITY.xml:S1:11094:2	PR	NNP	B-AdverseReaction	O
interval	TRULICITY.xml:S1:11097:8	interv	JJ	I-AdverseReaction	O
increase	TRULICITY.xml:S1:11106:8	increas	NN	I-AdverseReaction	O
to	TRULICITY.xml:S1:11115:2	to	TO	O	O
at	TRULICITY.xml:S1:11118:2	at	IN	O	O
least	TRULICITY.xml:S1:11121:5	least	JJS	O	O
220	TRULICITY.xml:S1:11127:3	220	CD	O	O
milliseconds	TRULICITY.xml:S1:11131:12	millisecond	NNS	O	O
was	TRULICITY.xml:S1:11144:3	wa	VBD	O	O
observed	TRULICITY.xml:S1:11148:8	observ	VBN	O	O
in	TRULICITY.xml:S1:11157:2	in	IN	O	O
0.7%	TRULICITY.xml:S1:11160:4	0.7%	CD	O	O
,	TRULICITY.xml:S1:11164:1	,	,	O	O
2.5%	TRULICITY.xml:S1:11166:4	2.5%	CD	O	O
and	TRULICITY.xml:S1:11171:3	and	CC	O	O
3.2%	TRULICITY.xml:S1:11175:4	3.2%	CD	O	O
of	TRULICITY.xml:S1:11180:2	of	IN	O	O
patients	TRULICITY.xml:S1:11183:8	patient	NNS	O	O
treated	TRULICITY.xml:S1:11192:7	treat	VBN	O	O
with	TRULICITY.xml:S1:11200:4	with	IN	O	O
placebo	TRULICITY.xml:S1:11205:7	placebo	NN	O	O
,	TRULICITY.xml:S1:11212:1	,	,	O	O
TRULICITY	TRULICITY.xml:S1:11214:9	trulic	NNP	O	O
0.75	TRULICITY.xml:S1:11224:4	0.75	CD	O	O
mg	TRULICITY.xml:S1:11229:2	mg	NN	O	O
and	TRULICITY.xml:S1:11232:3	and	CC	O	O
TRULICITY	TRULICITY.xml:S1:11236:9	trulic	NNP	O	O
1.5	TRULICITY.xml:S1:11246:3	1.5	CD	O	O
mg	TRULICITY.xml:S1:11250:2	mg	NN	O	O
,	TRULICITY.xml:S1:11252:1	,	,	O	O
respectively	TRULICITY.xml:S1:11254:12	respect	RB	O	O
.	TRULICITY.xml:S1:11266:1	.	.	O	O

Amylase	TRULICITY.xml:S1:11276:7	amylas	NNP	O	O
and	TRULICITY.xml:S1:11284:3	and	CC	O	O
Lipase	TRULICITY.xml:S1:11288:6	lipas	NNP	O	O
Increase	TRULICITY.xml:S1:11295:8	increas	NNP	O	O

Patients	TRULICITY.xml:S1:11310:8	patient	NNS	O	O
exposed	TRULICITY.xml:S1:11319:7	expos	VBD	O	O
to	TRULICITY.xml:S1:11327:2	to	TO	O	O
TRULICITY	TRULICITY.xml:S1:11330:9	trulic	NNP	O	O
had	TRULICITY.xml:S1:11340:3	had	VBD	O	O
mean	TRULICITY.xml:S1:11344:4	mean	VBN	O	O
increases	TRULICITY.xml:S1:11349:9	increas	NNS	B-AdverseReaction	O
from	TRULICITY.xml:S1:11359:4	from	IN	O	O
baseline	TRULICITY.xml:S1:11364:8	baselin	NN	O	O
in	TRULICITY.xml:S1:11373:2	in	IN	I-AdverseReaction	O
lipase	TRULICITY.xml:S1:11376:6	lipas	NN	I-AdverseReaction	O
and	TRULICITY.xml:S1:11383:3	and	CC	O	O
or	TRULICITY.xml:S1:11387:2	or	CC	O	O
pancreatic	TRULICITY.xml:S1:11390:10	pancreat	JJ	I-AdverseReaction	O
amylase	TRULICITY.xml:S1:11401:7	amylas	NN	I-AdverseReaction	O
of	TRULICITY.xml:S1:11409:2	of	IN	O	O
14%	TRULICITY.xml:S1:11412:3	14%	CD	O	O
to	TRULICITY.xml:S1:11416:2	to	TO	O	O
20%	TRULICITY.xml:S1:11419:3	20%	CD	O	O
,	TRULICITY.xml:S1:11422:1	,	,	O	O
while	TRULICITY.xml:S1:11424:5	while	IN	O	O
placebo	TRULICITY.xml:S1:11430:7	placebo	SYM	O	O
-	TRULICITY.xml:S1:11437:1	-	:	O	O
treated	TRULICITY.xml:S1:11438:7	treat	JJ	O	O
patients	TRULICITY.xml:S1:11446:8	patient	NNS	O	O
had	TRULICITY.xml:S1:11455:3	had	VBD	O	O
mean	TRULICITY.xml:S1:11459:4	mean	JJ	O	O
increases	TRULICITY.xml:S1:11464:9	increas	NNS	O	O
of	TRULICITY.xml:S1:11474:2	of	IN	O	O
up	TRULICITY.xml:S1:11477:2	up	IN	O	O
to	TRULICITY.xml:S1:11480:2	to	TO	O	O
3%	TRULICITY.xml:S1:11483:2	3%	CD	O	O
.	TRULICITY.xml:S1:11485:1	.	.	O	O
\n\n	TRULICITY.xml:S2:0:2	\n\n	VB	O	O
BOXED	TRULICITY.xml:S2:6:5	box	NNP	O	O
WARNING	TRULICITY.xml:S2:12:7	warn	NNP	O	O
:	TRULICITY.xml:S2:19:1	:	:	O	O
WARNING	TRULICITY.xml:S2:21:7	warn	NN	O	O
:	TRULICITY.xml:S2:28:1	:	:	O	O
RISK	TRULICITY.xml:S2:30:4	risk	NN	O	O
OF	TRULICITY.xml:S2:35:2	OF	IN	O	O
THYROID	TRULICITY.xml:S2:38:7	thyroid	NNP	B-AdverseReaction	O
C	TRULICITY.xml:S2:46:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:47:1	-	:	I-AdverseReaction	O
CELL	TRULICITY.xml:S2:48:4	cell	NN	I-AdverseReaction	O
TUMORS	TRULICITY.xml:S2:53:6	tumor	NNP	I-AdverseReaction	O
\n\n\n\n	TRULICITY.xml:S2:59:4	\n\n\n\n	VBD	O	O
WARNING	TRULICITY.xml:S2:65:7	warn	NN	O	O
:	TRULICITY.xml:S2:72:1	:	:	O	O
RISK	TRULICITY.xml:S2:74:4	risk	NN	O	O
OF	TRULICITY.xml:S2:79:2	OF	IN	O	O
THYROID	TRULICITY.xml:S2:82:7	thyroid	NNP	B-AdverseReaction	O
C	TRULICITY.xml:S2:90:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:91:1	-	:	I-AdverseReaction	O
CELL	TRULICITY.xml:S2:92:4	cell	NN	I-AdverseReaction	O
TUMORS	TRULICITY.xml:S2:97:6	tumor	NNP	I-AdverseReaction	O
\n\n\n\n	TRULICITY.xml:S2:103:4	\n\n\n\n	NNP	O	O
In	TRULICITY.xml:S2:114:2	In	IN	O	O
male	TRULICITY.xml:S2:117:4	male	NN	O	O
and	TRULICITY.xml:S2:122:3	and	CC	O	O
female	TRULICITY.xml:S2:126:6	femal	JJ	O	O
rats	TRULICITY.xml:S2:133:4	rat	NNS	O	O
,	TRULICITY.xml:S2:137:1	,	,	O	O
dulaglutide	TRULICITY.xml:S2:139:11	dulaglutid	JJ	O	O
causes	TRULICITY.xml:S2:151:6	caus	VBZ	O	O
a	TRULICITY.xml:S2:158:1	a	DT	O	O
dose	TRULICITY.xml:S2:160:4	dose	JJ	O	O
-	TRULICITY.xml:S2:164:1	-	:	O	O
related	TRULICITY.xml:S2:165:7	relat	JJ	O	O
and	TRULICITY.xml:S2:173:3	and	CC	O	O
treatment	TRULICITY.xml:S2:177:9	treatment	NN	O	O
-	TRULICITY.xml:S2:186:1	-	:	O	O
duration	TRULICITY.xml:S2:187:8	durat	NN	O	O
-	TRULICITY.xml:S2:195:1	-	:	O	O
dependent	TRULICITY.xml:S2:196:9	depend	JJ	O	O
increase	TRULICITY.xml:S2:206:8	increas	NN	O	O
in	TRULICITY.xml:S2:215:2	in	IN	O	O
the	TRULICITY.xml:S2:218:3	the	DT	O	O
incidence	TRULICITY.xml:S2:222:9	incid	NN	O	O
of	TRULICITY.xml:S2:232:2	of	IN	O	O
thyroid	TRULICITY.xml:S2:235:7	thyroid	JJ	B-AdverseReaction	O
C	TRULICITY.xml:S2:243:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:244:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S2:245:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S2:250:6	tumor	NNS	I-AdverseReaction	O
(	TRULICITY.xml:S2:257:1	(	(	O	O
adenomas	TRULICITY.xml:S2:258:8	adenoma	NN	I-AdverseReaction	O
and	TRULICITY.xml:S2:267:3	and	CC	O	O
carcinomas	TRULICITY.xml:S2:271:10	carcinoma	NN	I-AdverseReaction	B-AdverseReaction
)	TRULICITY.xml:S2:281:1	)	)	O	O
after	TRULICITY.xml:S2:283:5	after	IN	O	O
lifetime	TRULICITY.xml:S2:289:8	lifetim	NN	O	O
exposure	TRULICITY.xml:S2:298:8	exposur	NN	O	O
.	TRULICITY.xml:S2:306:1	.	.	O	O

It	TRULICITY.xml:S2:308:2	It	PRP	O	O
is	TRULICITY.xml:S2:311:2	is	VBZ	O	O
unknown	TRULICITY.xml:S2:314:7	unknown	JJ	O	O
whether	TRULICITY.xml:S2:322:7	whether	IN	O	O
TRULICITY	TRULICITY.xml:S2:330:9	trulic	NNP	O	O
causes	TRULICITY.xml:S2:340:6	caus	VBZ	O	O
thyroid	TRULICITY.xml:S2:347:7	thyroid	JJ	B-AdverseReaction	O
C	TRULICITY.xml:S2:355:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:356:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S2:357:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S2:362:6	tumor	NNS	I-AdverseReaction	O
,	TRULICITY.xml:S2:368:1	,	,	O	O
including	TRULICITY.xml:S2:370:9	includ	VBG	O	O
medullary	TRULICITY.xml:S2:380:9	medullari	JJ	B-AdverseReaction	B-AdverseReaction
thyroid	TRULICITY.xml:S2:390:7	thyroid	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TRULICITY.xml:S2:398:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S2:408:1	(	(	O	O
MTC	TRULICITY.xml:S2:409:3	mtc	NNP	B-AdverseReaction	O
)	TRULICITY.xml:S2:412:1	)	)	O	O
,	TRULICITY.xml:S2:413:1	,	,	O	O
in	TRULICITY.xml:S2:415:2	in	IN	O	O
humans	TRULICITY.xml:S2:418:6	human	NNS	O	O
as	TRULICITY.xml:S2:425:2	as	IN	O	O
human	TRULICITY.xml:S2:428:5	human	JJ	O	O
relevance	TRULICITY.xml:S2:434:9	relev	NN	O	O
of	TRULICITY.xml:S2:444:2	of	IN	O	O
dulaglutide	TRULICITY.xml:S2:447:11	dulaglutid	JJ	O	O
-	TRULICITY.xml:S2:458:1	-	:	O	O
induced	TRULICITY.xml:S2:459:7	induc	JJ	O	O
rodent	TRULICITY.xml:S2:467:6	rodent	NN	O	O
thyroid	TRULICITY.xml:S2:474:7	thyroid	NN	B-AdverseReaction	O
C	TRULICITY.xml:S2:482:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:483:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S2:484:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S2:489:6	tumor	NNS	I-AdverseReaction	O
has	TRULICITY.xml:S2:496:3	ha	VBZ	O	O
not	TRULICITY.xml:S2:500:3	not	RB	O	O
been	TRULICITY.xml:S2:504:4	been	VBN	O	O
determined	TRULICITY.xml:S2:509:10	determin	VBN	O	O
[	TRULICITY.xml:S2:520:1	[	NNP	O	O
see	TRULICITY.xml:S2:521:3	see	VBP	O	O
Warnings	TRULICITY.xml:S2:525:8	warn	NNP	O	O
and	TRULICITY.xml:S2:534:3	and	CC	O	O
Precautions	TRULICITY.xml:S2:538:11	precaut	NNP	O	O
(	TRULICITY.xml:S2:550:1	(	(	O	O
5.1	TRULICITY.xml:S2:551:3	5.1	CD	O	O
)	TRULICITY.xml:S2:554:1	)	)	O	O
,	TRULICITY.xml:S2:555:1	,	,	O	O
and	TRULICITY.xml:S2:557:3	and	CC	O	O
Nonclinical	TRULICITY.xml:S2:561:11	nonclin	NNP	O	O
Toxicology	TRULICITY.xml:S2:573:10	toxicolog	NNP	O	O
(	TRULICITY.xml:S2:584:1	(	(	O	O
13.1	TRULICITY.xml:S2:585:4	13.1	CD	O	O
)]	TRULICITY.xml:S2:589:2	)]	NN	O	O
.	TRULICITY.xml:S2:591:1	.	.	O	O

TRULICITY	TRULICITY.xml:S2:598:9	trulic	NNP	O	O
is	TRULICITY.xml:S2:608:2	is	VBZ	O	O
contraindicated	TRULICITY.xml:S2:611:15	contraind	VBN	O	O
in	TRULICITY.xml:S2:627:2	in	IN	O	O
patients	TRULICITY.xml:S2:630:8	patient	NNS	O	O
with	TRULICITY.xml:S2:639:4	with	IN	O	O
a	TRULICITY.xml:S2:644:1	a	DT	O	O
personal	TRULICITY.xml:S2:646:8	person	JJ	O	O
or	TRULICITY.xml:S2:655:2	or	CC	O	O
family	TRULICITY.xml:S2:658:6	famili	NN	O	O
history	TRULICITY.xml:S2:665:7	histori	NN	O	O
of	TRULICITY.xml:S2:673:2	of	IN	O	O
MTC	TRULICITY.xml:S2:676:3	mtc	NNP	O	O
and	TRULICITY.xml:S2:680:3	and	CC	O	O
in	TRULICITY.xml:S2:684:2	in	IN	O	O
patients	TRULICITY.xml:S2:687:8	patient	NNS	O	O
with	TRULICITY.xml:S2:696:4	with	IN	O	O
Multiple	TRULICITY.xml:S2:701:8	multipl	NNP	O	O
Endocrine	TRULICITY.xml:S2:710:9	endocrin	NNP	O	O
Neoplasia	TRULICITY.xml:S2:720:9	neoplasia	NNP	O	O
syndrome	TRULICITY.xml:S2:730:8	syndrom	VBD	O	O
type	TRULICITY.xml:S2:739:4	type	JJ	O	O
2	TRULICITY.xml:S2:744:1	2	CD	O	O
(	TRULICITY.xml:S2:746:1	(	(	O	O
MEN	TRULICITY.xml:S2:747:3	men	NNP	O	O
2	TRULICITY.xml:S2:751:1	2	CD	O	O
)	TRULICITY.xml:S2:752:1	)	)	O	O
.	TRULICITY.xml:S2:753:1	.	.	O	O

Counsel	TRULICITY.xml:S2:755:7	counsel	NNP	O	O
patients	TRULICITY.xml:S2:763:8	patient	NNS	O	O
regarding	TRULICITY.xml:S2:772:9	regard	VBG	O	O
the	TRULICITY.xml:S2:782:3	the	DT	O	O
potential	TRULICITY.xml:S2:786:9	potenti	JJ	O	O
risk	TRULICITY.xml:S2:796:4	risk	NN	O	O
of	TRULICITY.xml:S2:801:2	of	IN	O	O
MTC	TRULICITY.xml:S2:804:3	mtc	NNP	O	O
with	TRULICITY.xml:S2:808:4	with	IN	O	O
use	TRULICITY.xml:S2:813:3	use	NN	O	O
of	TRULICITY.xml:S2:817:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S2:820:9	trulic	NNP	O	O
and	TRULICITY.xml:S2:830:3	and	CC	O	O
inform	TRULICITY.xml:S2:834:6	inform	VB	O	O
them	TRULICITY.xml:S2:841:4	them	PRP	O	O
of	TRULICITY.xml:S2:846:2	of	IN	O	O
symptoms	TRULICITY.xml:S2:849:8	symptom	NNS	O	O
of	TRULICITY.xml:S2:858:2	of	IN	O	O
thyroid	TRULICITY.xml:S2:861:7	thyroid	JJ	O	O
tumors	TRULICITY.xml:S2:869:6	tumor	NNS	O	O
(	TRULICITY.xml:S2:876:1	(	(	O	O
e	TRULICITY.xml:S2:877:1	e	NN	O	O
.	TRULICITY.xml:S2:878:1	.	.	O	O
g	TRULICITY.xml:S2:879:1	g	NN	O	O
.	TRULICITY.xml:S2:880:1	.	.	O	O
,	TRULICITY.xml:S2:881:1	,	,	O	O
mass	TRULICITY.xml:S2:883:4	mass	NN	O	O
in	TRULICITY.xml:S2:888:2	in	IN	O	O
the	TRULICITY.xml:S2:891:3	the	DT	O	O
neck	TRULICITY.xml:S2:895:4	neck	NN	O	O
,	TRULICITY.xml:S2:899:1	,	,	O	O
dysphagia	TRULICITY.xml:S2:901:9	dysphagia	NN	O	B-AdverseReaction
,	TRULICITY.xml:S2:910:1	,	,	O	O
dyspnea	TRULICITY.xml:S2:912:7	dyspnea	NN	O	B-AdverseReaction
,	TRULICITY.xml:S2:919:1	,	,	O	O
persistent	TRULICITY.xml:S2:921:10	persist	JJ	O	O
hoarseness	TRULICITY.xml:S2:932:10	hoars	NN	O	O
)	TRULICITY.xml:S2:942:1	)	)	O	O
.	TRULICITY.xml:S2:943:1	.	.	O	O

Routine	TRULICITY.xml:S2:945:7	routin	JJ	O	O
monitoring	TRULICITY.xml:S2:953:10	monitor	NN	O	O
of	TRULICITY.xml:S2:964:2	of	IN	O	O
serum	TRULICITY.xml:S2:967:5	serum	JJ	O	O
calcitonin	TRULICITY.xml:S2:973:10	calcitonin	NN	O	O
or	TRULICITY.xml:S2:984:2	or	CC	O	O
using	TRULICITY.xml:S2:987:5	use	VBG	O	O
thyroid	TRULICITY.xml:S2:993:7	thyroid	JJ	O	O
ultrasound	TRULICITY.xml:S2:1001:10	ultrasound	NN	O	O
is	TRULICITY.xml:S2:1012:2	is	VBZ	O	O
of	TRULICITY.xml:S2:1015:2	of	IN	O	O
uncertain	TRULICITY.xml:S2:1018:9	uncertain	JJ	O	O
value	TRULICITY.xml:S2:1028:5	valu	NN	O	O
for	TRULICITY.xml:S2:1034:3	for	IN	O	O
early	TRULICITY.xml:S2:1038:5	earli	JJ	O	O
detection	TRULICITY.xml:S2:1044:9	detect	NN	O	O
of	TRULICITY.xml:S2:1054:2	of	IN	O	O
MTC	TRULICITY.xml:S2:1057:3	mtc	NNP	O	O
in	TRULICITY.xml:S2:1061:2	in	IN	O	O
patients	TRULICITY.xml:S2:1064:8	patient	NNS	O	O
treated	TRULICITY.xml:S2:1073:7	treat	VBN	O	O
with	TRULICITY.xml:S2:1081:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S2:1086:9	trulic	NNP	O	O
[	TRULICITY.xml:S2:1096:1	[	NNP	O	O
see	TRULICITY.xml:S2:1097:3	see	VBP	O	O
Contraindications	TRULICITY.xml:S2:1101:17	contraind	NNP	O	O
(	TRULICITY.xml:S2:1119:1	(	(	O	O
4.1	TRULICITY.xml:S2:1120:3	4.1	CD	O	O
)	TRULICITY.xml:S2:1123:1	)	)	O	O
and	TRULICITY.xml:S2:1125:3	and	CC	O	O
Warnings	TRULICITY.xml:S2:1129:8	warn	NNP	O	O
and	TRULICITY.xml:S2:1138:3	and	CC	O	O
Precautions	TRULICITY.xml:S2:1142:11	precaut	NNP	O	O
(	TRULICITY.xml:S2:1154:1	(	(	O	O
5.1	TRULICITY.xml:S2:1155:3	5.1	CD	O	O
)]	TRULICITY.xml:S2:1158:2	)]	NN	O	O
.	TRULICITY.xml:S2:1160:1	.	.	O	O

EXCERPT	TRULICITY.xml:S2:1169:7	excerpt	NN	O	O
:	TRULICITY.xml:S2:1176:1	:	:	O	O
WARNING	TRULICITY.xml:S2:1182:7	warn	NN	O	O
:	TRULICITY.xml:S2:1189:1	:	:	O	O
RISK	TRULICITY.xml:S2:1191:4	risk	NN	O	O
OF	TRULICITY.xml:S2:1196:2	OF	IN	O	O
THYROID	TRULICITY.xml:S2:1199:7	thyroid	NNP	B-AdverseReaction	O
C	TRULICITY.xml:S2:1207:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:1208:1	-	:	I-AdverseReaction	O
CELL	TRULICITY.xml:S2:1209:4	cell	NN	I-AdverseReaction	O
TUMORS	TRULICITY.xml:S2:1214:6	tumor	NNP	I-AdverseReaction	O
\n	TRULICITY.xml:S2:1222:1	\n	NNP	O	O
\n\n	TRULICITY.xml:S2:1224:2	\n\n	NNP	O	O
See	TRULICITY.xml:S2:1229:3	see	NNP	O	O
full	TRULICITY.xml:S2:1233:4	full	JJ	O	O
prescribing	TRULICITY.xml:S2:1238:11	prescrib	VBG	O	O
information	TRULICITY.xml:S2:1250:11	inform	NN	O	O
for	TRULICITY.xml:S2:1262:3	for	IN	O	O
complete	TRULICITY.xml:S2:1266:8	complet	JJ	O	O
boxed	TRULICITY.xml:S2:1275:5	box	JJ	O	O
warning	TRULICITY.xml:S2:1281:7	warn	NN	O	O
.	TRULICITY.xml:S2:1288:1	.	.	O	O

Dulaglutide	TRULICITY.xml:S2:1299:11	dulaglutid	NNP	O	O
causes	TRULICITY.xml:S2:1311:6	caus	VBZ	O	O
thyroid	TRULICITY.xml:S2:1318:7	thyroid	JJ	B-AdverseReaction	O
C	TRULICITY.xml:S2:1326:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:1327:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S2:1328:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S2:1333:6	tumor	NNS	I-AdverseReaction	O
in	TRULICITY.xml:S2:1340:2	in	IN	O	O
rats	TRULICITY.xml:S2:1343:4	rat	NNS	O	O
.	TRULICITY.xml:S2:1347:1	.	.	O	O

It	TRULICITY.xml:S2:1349:2	It	PRP	O	O
is	TRULICITY.xml:S2:1352:2	is	VBZ	O	O
unknown	TRULICITY.xml:S2:1355:7	unknown	JJ	O	O
whether	TRULICITY.xml:S2:1363:7	whether	IN	O	O
TRULICITY	TRULICITY.xml:S2:1371:9	trulic	NNP	O	O
causes	TRULICITY.xml:S2:1381:6	caus	VBZ	O	O
thyroid	TRULICITY.xml:S2:1388:7	thyroid	JJ	B-AdverseReaction	O
C	TRULICITY.xml:S2:1396:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:1397:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S2:1398:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S2:1403:6	tumor	NNS	I-AdverseReaction	O
,	TRULICITY.xml:S2:1409:1	,	,	O	O
including	TRULICITY.xml:S2:1411:9	includ	VBG	O	O
medullary	TRULICITY.xml:S2:1421:9	medullari	JJ	B-AdverseReaction	B-AdverseReaction
thyroid	TRULICITY.xml:S2:1431:7	thyroid	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TRULICITY.xml:S2:1439:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S2:1449:1	(	(	O	O
MTC	TRULICITY.xml:S2:1450:3	mtc	NNP	B-AdverseReaction	O
)	TRULICITY.xml:S2:1453:1	)	)	O	O
,	TRULICITY.xml:S2:1454:1	,	,	O	O
in	TRULICITY.xml:S2:1456:2	in	IN	O	O
humans	TRULICITY.xml:S2:1459:6	human	NNS	O	O
as	TRULICITY.xml:S2:1466:2	as	IN	O	O
the	TRULICITY.xml:S2:1469:3	the	DT	O	O
human	TRULICITY.xml:S2:1473:5	human	JJ	O	O
relevance	TRULICITY.xml:S2:1479:9	relev	NN	O	O
of	TRULICITY.xml:S2:1489:2	of	IN	O	O
dulaglutide	TRULICITY.xml:S2:1492:11	dulaglutid	JJ	O	O
-	TRULICITY.xml:S2:1503:1	-	:	O	O
induced	TRULICITY.xml:S2:1504:7	induc	JJ	O	O
rodent	TRULICITY.xml:S2:1512:6	rodent	NN	O	O
thyroid	TRULICITY.xml:S2:1519:7	thyroid	NN	B-AdverseReaction	O
C	TRULICITY.xml:S2:1527:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S2:1528:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S2:1529:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S2:1534:6	tumor	NNS	I-AdverseReaction	O
has	TRULICITY.xml:S2:1541:3	ha	VBZ	O	O
not	TRULICITY.xml:S2:1545:3	not	RB	O	O
been	TRULICITY.xml:S2:1549:4	been	VBN	O	O
determined	TRULICITY.xml:S2:1554:10	determin	VBN	O	O
(	TRULICITY.xml:S2:1565:1	(	(	O	O
5.1	TRULICITY.xml:S2:1566:3	5.1	CD	O	O
,	TRULICITY.xml:S2:1569:1	,	,	O	O
13.1	TRULICITY.xml:S2:1571:4	13.1	CD	O	O
)	TRULICITY.xml:S2:1575:1	)	)	O	O
.	TRULICITY.xml:S2:1576:1	.	.	O	O

TRULICITY	TRULICITY.xml:S2:1583:9	trulic	NNP	O	O
is	TRULICITY.xml:S2:1593:2	is	VBZ	O	O
contraindicated	TRULICITY.xml:S2:1596:15	contraind	VBN	O	O
in	TRULICITY.xml:S2:1612:2	in	IN	O	O
patients	TRULICITY.xml:S2:1615:8	patient	NNS	O	O
with	TRULICITY.xml:S2:1624:4	with	IN	O	O
a	TRULICITY.xml:S2:1629:1	a	DT	O	O
personal	TRULICITY.xml:S2:1631:8	person	JJ	O	O
or	TRULICITY.xml:S2:1640:2	or	CC	O	O
family	TRULICITY.xml:S2:1643:6	famili	NN	O	O
history	TRULICITY.xml:S2:1650:7	histori	NN	O	O
of	TRULICITY.xml:S2:1658:2	of	IN	O	O
MTC	TRULICITY.xml:S2:1661:3	mtc	NNP	O	O
and	TRULICITY.xml:S2:1665:3	and	CC	O	O
in	TRULICITY.xml:S2:1669:2	in	IN	O	O
patients	TRULICITY.xml:S2:1672:8	patient	NNS	O	O
with	TRULICITY.xml:S2:1681:4	with	IN	O	O
Multiple	TRULICITY.xml:S2:1686:8	multipl	NNP	O	O
Endocrine	TRULICITY.xml:S2:1695:9	endocrin	NNP	O	O
Neoplasia	TRULICITY.xml:S2:1705:9	neoplasia	NNP	O	O
syndrome	TRULICITY.xml:S2:1715:8	syndrom	VBD	O	O
type	TRULICITY.xml:S2:1724:4	type	JJ	O	O
2	TRULICITY.xml:S2:1729:1	2	CD	O	O
(	TRULICITY.xml:S2:1731:1	(	(	O	O
MEN	TRULICITY.xml:S2:1732:3	men	NNP	O	O
2	TRULICITY.xml:S2:1736:1	2	CD	O	O
)	TRULICITY.xml:S2:1737:1	)	)	O	O
.	TRULICITY.xml:S2:1738:1	.	.	O	O

Counsel	TRULICITY.xml:S2:1740:7	counsel	NNP	O	O
patients	TRULICITY.xml:S2:1748:8	patient	NNS	O	O
regarding	TRULICITY.xml:S2:1757:9	regard	VBG	O	O
the	TRULICITY.xml:S2:1767:3	the	DT	O	O
potential	TRULICITY.xml:S2:1771:9	potenti	JJ	O	O
risk	TRULICITY.xml:S2:1781:4	risk	NN	O	O
of	TRULICITY.xml:S2:1786:2	of	IN	O	O
MTC	TRULICITY.xml:S2:1789:3	mtc	NNP	O	O
and	TRULICITY.xml:S2:1793:3	and	CC	O	O
symptoms	TRULICITY.xml:S2:1797:8	symptom	NNS	O	O
of	TRULICITY.xml:S2:1806:2	of	IN	O	O
thyroid	TRULICITY.xml:S2:1809:7	thyroid	JJ	O	O
tumors	TRULICITY.xml:S2:1817:6	tumor	NNS	O	O
(	TRULICITY.xml:S2:1824:1	(	(	O	O
4.1	TRULICITY.xml:S2:1825:3	4.1	CD	O	O
,	TRULICITY.xml:S2:1828:1	,	,	O	O
5.1	TRULICITY.xml:S2:1830:3	5.1	CD	O	O
)	TRULICITY.xml:S2:1833:1	)	)	O	O
.	TRULICITY.xml:S2:1834:1	.	.	O	O
\n	TRULICITY.xml:S2:1836:1	\n	$	O	O
5	TRULICITY.xml:S3:4:1	5	CD	O	O
WARNINGS	TRULICITY.xml:S3:6:8	warn	NNP	O	O
AND	TRULICITY.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	TRULICITY.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	TRULICITY.xml:S3:37:7	excerpt	NN	O	O
:	TRULICITY.xml:S3:44:1	:	:	O	O
Thyroid	TRULICITY.xml:S3:53:7	thyroid	NNP	B-AdverseReaction	O
C	TRULICITY.xml:S3:61:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S3:62:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S3:63:4	cell	NN	I-AdverseReaction	O
Tumors	TRULICITY.xml:S3:68:6	tumor	NNS	I-AdverseReaction	O
:	TRULICITY.xml:S3:74:1	:	:	O	O
See	TRULICITY.xml:S3:76:3	see	VB	O	O
Boxed	TRULICITY.xml:S3:80:5	box	NNP	O	O
Warning	TRULICITY.xml:S3:86:7	warn	NNP	O	O
(	TRULICITY.xml:S3:94:1	(	(	O	O
5.1	TRULICITY.xml:S3:97:3	5.1	CD	O	O
)	TRULICITY.xml:S3:102:1	)	)	O	O
.	TRULICITY.xml:S3:103:1	.	.	O	O

Pancreatitis	TRULICITY.xml:S3:111:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
:	TRULICITY.xml:S3:123:1	:	:	O	O
Has	TRULICITY.xml:S3:125:3	ha	NNP	O	O
been	TRULICITY.xml:S3:129:4	been	VBN	O	O
reported	TRULICITY.xml:S3:134:8	report	VBN	O	O
in	TRULICITY.xml:S3:143:2	in	IN	O	O
clinical	TRULICITY.xml:S3:146:8	clinic	JJ	O	O
trials	TRULICITY.xml:S3:155:6	trial	NNS	O	O
.	TRULICITY.xml:S3:161:1	.	.	O	O

Discontinue	TRULICITY.xml:S3:163:11	discontinu	NNP	O	O
promptly	TRULICITY.xml:S3:175:8	promptli	RB	O	O
if	TRULICITY.xml:S3:184:2	if	IN	O	O
pancreatitis	TRULICITY.xml:S3:187:12	pancreat	NN	O	O
is	TRULICITY.xml:S3:200:2	is	VBZ	O	O
suspected	TRULICITY.xml:S3:203:9	suspect	VBN	O	O
.	TRULICITY.xml:S3:212:1	.	.	O	O

Do	TRULICITY.xml:S3:214:2	Do	NNP	O	O
not	TRULICITY.xml:S3:217:3	not	RB	O	O
restart	TRULICITY.xml:S3:221:7	restart	VB	O	O
if	TRULICITY.xml:S3:229:2	if	IN	O	O
pancreatitis	TRULICITY.xml:S3:232:12	pancreat	NN	O	O
is	TRULICITY.xml:S3:245:2	is	VBZ	O	O
confirmed	TRULICITY.xml:S3:248:9	confirm	VBN	O	O
.	TRULICITY.xml:S3:257:1	.	.	O	O

Consider	TRULICITY.xml:S3:259:8	consid	VB	O	O
other	TRULICITY.xml:S3:268:5	other	JJ	O	O
antidiabetic	TRULICITY.xml:S3:274:12	antidiabet	JJ	O	O
therapies	TRULICITY.xml:S3:287:9	therapi	NNS	O	O
in	TRULICITY.xml:S3:297:2	in	IN	O	O
patients	TRULICITY.xml:S3:300:8	patient	NNS	O	O
with	TRULICITY.xml:S3:309:4	with	IN	O	O
history	TRULICITY.xml:S3:314:7	histori	NN	O	O
of	TRULICITY.xml:S3:322:2	of	IN	O	O
pancreatitis	TRULICITY.xml:S3:325:12	pancreat	NN	O	O
(	TRULICITY.xml:S3:338:1	(	(	O	O
5.2	TRULICITY.xml:S3:341:3	5.2	CD	O	O
)	TRULICITY.xml:S3:346:1	)	)	O	O
.	TRULICITY.xml:S3:347:1	.	.	O	O

Hypoglycemia	TRULICITY.xml:S3:355:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
:	TRULICITY.xml:S3:367:1	:	:	O	O
When	TRULICITY.xml:S3:369:4	when	WRB	O	O
TRULICITY	TRULICITY.xml:S3:374:9	trulic	NNP	O	O
is	TRULICITY.xml:S3:384:2	is	VBZ	O	O
used	TRULICITY.xml:S3:387:4	use	VBN	O	O
with	TRULICITY.xml:S3:392:4	with	IN	O	O
an	TRULICITY.xml:S3:397:2	an	DT	O	O
insulin	TRULICITY.xml:S3:400:7	insulin	NN	O	O
secretagogue	TRULICITY.xml:S3:408:12	secretagogu	NN	O	O
(	TRULICITY.xml:S3:421:1	(	(	O	O
e	TRULICITY.xml:S3:422:1	e	NN	O	O
.	TRULICITY.xml:S3:423:1	.	.	O	O
g	TRULICITY.xml:S3:424:1	g	NN	O	O
.	TRULICITY.xml:S3:425:1	.	.	O	O
,	TRULICITY.xml:S3:426:1	,	,	O	O
a	TRULICITY.xml:S3:428:1	a	DT	O	O
sulfonylurea	TRULICITY.xml:S3:430:12	sulfonylurea	NN	O	O
)	TRULICITY.xml:S3:442:1	)	)	O	O
or	TRULICITY.xml:S3:444:2	or	CC	O	O
insulin	TRULICITY.xml:S3:447:7	insulin	NN	O	O
,	TRULICITY.xml:S3:454:1	,	,	O	O
consider	TRULICITY.xml:S3:456:8	consid	VB	O	O
lowering	TRULICITY.xml:S3:465:8	lower	VBG	O	O
the	TRULICITY.xml:S3:474:3	the	DT	O	O
dose	TRULICITY.xml:S3:478:4	dose	NN	O	O
of	TRULICITY.xml:S3:483:2	of	IN	O	O
the	TRULICITY.xml:S3:486:3	the	DT	O	O
sulfonylurea	TRULICITY.xml:S3:490:12	sulfonylurea	NN	O	O
or	TRULICITY.xml:S3:503:2	or	CC	O	O
insulin	TRULICITY.xml:S3:506:7	insulin	NN	O	O
to	TRULICITY.xml:S3:514:2	to	TO	O	O
reduce	TRULICITY.xml:S3:517:6	reduc	VB	O	O
the	TRULICITY.xml:S3:524:3	the	DT	O	O
risk	TRULICITY.xml:S3:528:4	risk	NN	O	O
of	TRULICITY.xml:S3:533:2	of	IN	O	O
hypoglycemia	TRULICITY.xml:S3:536:12	hypoglycemia	NN	O	B-AdverseReaction
(	TRULICITY.xml:S3:549:1	(	(	O	O
5.3	TRULICITY.xml:S3:552:3	5.3	CD	O	O
)	TRULICITY.xml:S3:557:1	)	)	O	O
.	TRULICITY.xml:S3:558:1	.	.	O	O

Hypersensitivity	TRULICITY.xml:S3:566:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TRULICITY.xml:S3:583:9	reaction	NNP	O	I-AdverseReaction
:	TRULICITY.xml:S3:592:1	:	:	O	O
Discontinue	TRULICITY.xml:S3:594:11	discontinu	NNP	O	O
TRULICITY	TRULICITY.xml:S3:606:9	trulic	NNP	O	O
if	TRULICITY.xml:S3:616:2	if	IN	O	O
suspected	TRULICITY.xml:S3:619:9	suspect	VBN	O	O
.	TRULICITY.xml:S3:628:1	.	.	O	O

Monitor	TRULICITY.xml:S3:630:7	monitor	NNP	O	O
and	TRULICITY.xml:S3:638:3	and	CC	O	O
treat	TRULICITY.xml:S3:642:5	treat	NN	O	O
promptly	TRULICITY.xml:S3:648:8	promptli	RB	O	O
per	TRULICITY.xml:S3:657:3	per	IN	O	O
standard	TRULICITY.xml:S3:661:8	standard	NN	O	O
of	TRULICITY.xml:S3:670:2	of	IN	O	O
care	TRULICITY.xml:S3:673:4	care	NN	O	O
until	TRULICITY.xml:S3:678:5	until	IN	O	O
signs	TRULICITY.xml:S3:684:5	sign	NNS	O	O
and	TRULICITY.xml:S3:690:3	and	CC	O	O
symptoms	TRULICITY.xml:S3:694:8	symptom	NNS	O	O
resolve	TRULICITY.xml:S3:703:7	resolv	VBP	O	O
(	TRULICITY.xml:S3:711:1	(	(	O	O
5.4	TRULICITY.xml:S3:714:3	5.4	CD	O	O
)	TRULICITY.xml:S3:719:1	)	)	O	O
.	TRULICITY.xml:S3:720:1	.	.	O	O

Renal	TRULICITY.xml:S3:728:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
Impairment	TRULICITY.xml:S3:734:10	impair	NN	I-AdverseReaction	I-AdverseReaction
:	TRULICITY.xml:S3:744:1	:	:	O	O
Monitor	TRULICITY.xml:S3:746:7	monitor	NNP	O	O
renal	TRULICITY.xml:S3:754:5	renal	JJ	O	O
function	TRULICITY.xml:S3:760:8	function	NN	O	O
in	TRULICITY.xml:S3:769:2	in	IN	O	O
patients	TRULICITY.xml:S3:772:8	patient	NNS	O	O
with	TRULICITY.xml:S3:781:4	with	IN	O	O
renal	TRULICITY.xml:S3:786:5	renal	JJ	O	O
impairment	TRULICITY.xml:S3:792:10	impair	NN	O	O
reporting	TRULICITY.xml:S3:803:9	report	NN	O	O
severe	TRULICITY.xml:S3:813:6	sever	JJ	O	O
adverse	TRULICITY.xml:S3:820:7	advers	JJ	O	O
gastrointestinal	TRULICITY.xml:S3:828:16	gastrointestin	JJ	O	O
reactions	TRULICITY.xml:S3:845:9	reaction	NNS	O	O
(	TRULICITY.xml:S3:855:1	(	(	O	O
5.5	TRULICITY.xml:S3:858:3	5.5	CD	O	O
)	TRULICITY.xml:S3:863:1	)	)	O	O
.	TRULICITY.xml:S3:864:1	.	.	O	O

Macrovascular	TRULICITY.xml:S3:872:13	macrovascular	JJ	O	O
outcomes	TRULICITY.xml:S3:886:8	outcom	NNS	O	O
:	TRULICITY.xml:S3:894:1	:	:	O	O
There	TRULICITY.xml:S3:896:5	there	EX	O	O
have	TRULICITY.xml:S3:902:4	have	VBP	O	O
been	TRULICITY.xml:S3:907:4	been	VBN	O	O
no	TRULICITY.xml:S3:912:2	no	DT	O	O
studies	TRULICITY.xml:S3:915:7	studi	NNS	O	O
establishing	TRULICITY.xml:S3:923:12	establish	VBG	O	O
conclusive	TRULICITY.xml:S3:936:10	conclus	JJ	O	O
evidence	TRULICITY.xml:S3:947:8	evid	NN	O	O
of	TRULICITY.xml:S3:956:2	of	IN	O	O
macrovascular	TRULICITY.xml:S3:959:13	macrovascular	JJ	O	O
risk	TRULICITY.xml:S3:973:4	risk	NN	O	O
reduction	TRULICITY.xml:S3:978:9	reduct	NN	O	O
with	TRULICITY.xml:S3:988:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S3:993:9	trulic	NNP	O	O
or	TRULICITY.xml:S3:1003:2	or	CC	O	O
any	TRULICITY.xml:S3:1006:3	ani	DT	O	O
other	TRULICITY.xml:S3:1010:5	other	JJ	O	O
antidiabetic	TRULICITY.xml:S3:1016:12	antidiabet	JJ	O	O
drug	TRULICITY.xml:S3:1029:4	drug	NN	O	O
(	TRULICITY.xml:S3:1034:1	(	(	O	O
5.7	TRULICITY.xml:S3:1037:3	5.7	CD	O	O
)	TRULICITY.xml:S3:1042:1	)	)	O	O
.	TRULICITY.xml:S3:1043:1	.	.	O	O

5.1	TRULICITY.xml:S3:1057:3	5.1	CD	O	O

Risk	TRULICITY.xml:S3:1061:4	risk	NN	O	O

of	TRULICITY.xml:S3:1066:2	of	IN	O	O
Thyroid	TRULICITY.xml:S3:1069:7	thyroid	NNP	O	O
C	TRULICITY.xml:S3:1077:1	C	NNP	O	O
-	TRULICITY.xml:S3:1078:1	-	:	O	O
cell	TRULICITY.xml:S3:1079:4	cell	NN	O	O
Tumors	TRULICITY.xml:S3:1084:6	tumor	NNS	O	O

In	TRULICITY.xml:S3:1099:2	In	IN	O	O
male	TRULICITY.xml:S3:1102:4	male	NN	O	O
and	TRULICITY.xml:S3:1107:3	and	CC	O	O
female	TRULICITY.xml:S3:1111:6	femal	JJ	O	O
rats	TRULICITY.xml:S3:1118:4	rat	NNS	O	O
,	TRULICITY.xml:S3:1122:1	,	,	O	O
dulaglutide	TRULICITY.xml:S3:1124:11	dulaglutid	JJ	O	O
causes	TRULICITY.xml:S3:1136:6	caus	VBZ	O	O
a	TRULICITY.xml:S3:1143:1	a	DT	O	O
dose	TRULICITY.xml:S3:1145:4	dose	JJ	O	O
-	TRULICITY.xml:S3:1149:1	-	:	O	O
related	TRULICITY.xml:S3:1150:7	relat	JJ	O	O
and	TRULICITY.xml:S3:1158:3	and	CC	O	O
treatment	TRULICITY.xml:S3:1162:9	treatment	NN	O	O
-	TRULICITY.xml:S3:1171:1	-	:	O	O
duration	TRULICITY.xml:S3:1172:8	durat	NN	O	O
-	TRULICITY.xml:S3:1180:1	-	:	O	O
dependent	TRULICITY.xml:S3:1181:9	depend	JJ	O	O
increase	TRULICITY.xml:S3:1191:8	increas	NN	O	O
in	TRULICITY.xml:S3:1200:2	in	IN	O	O
the	TRULICITY.xml:S3:1203:3	the	DT	O	O
incidence	TRULICITY.xml:S3:1207:9	incid	NN	O	O
of	TRULICITY.xml:S3:1217:2	of	IN	O	O
thyroid	TRULICITY.xml:S3:1220:7	thyroid	JJ	B-AdverseReaction	O
C	TRULICITY.xml:S3:1228:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S3:1229:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S3:1230:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S3:1235:6	tumor	NNS	I-AdverseReaction	O
(	TRULICITY.xml:S3:1242:1	(	(	O	O
adenomas	TRULICITY.xml:S3:1243:8	adenoma	NN	I-AdverseReaction	O
and	TRULICITY.xml:S3:1252:3	and	CC	O	O
carcinomas	TRULICITY.xml:S3:1256:10	carcinoma	NN	I-AdverseReaction	B-AdverseReaction
)	TRULICITY.xml:S3:1266:1	)	)	O	O
after	TRULICITY.xml:S3:1268:5	after	IN	O	O
lifetime	TRULICITY.xml:S3:1274:8	lifetim	NN	O	O
exposure	TRULICITY.xml:S3:1283:8	exposur	NN	O	O
[	TRULICITY.xml:S3:1292:1	[	NNP	O	O
see	TRULICITY.xml:S3:1293:3	see	VBP	O	O
Nonclinical	TRULICITY.xml:S3:1297:11	nonclin	JJ	O	O
Toxicology	TRULICITY.xml:S3:1309:10	toxicolog	NNP	O	O
(	TRULICITY.xml:S3:1320:1	(	(	O	O
13.1	TRULICITY.xml:S3:1323:4	13.1	CD	O	O
)]	TRULICITY.xml:S3:1329:2	)]	NN	O	O
.	TRULICITY.xml:S3:1333:1	.	.	O	O

Glucagon	TRULICITY.xml:S3:1335:8	glucagon	NNP	O	B-AdverseReaction
-	TRULICITY.xml:S3:1343:1	-	:	O	I-AdverseReaction
like	TRULICITY.xml:S3:1344:4	like	IN	O	I-AdverseReaction
peptide	TRULICITY.xml:S3:1349:7	peptid	NN	O	I-AdverseReaction
(	TRULICITY.xml:S3:1357:1	(	(	O	O
GLP	TRULICITY.xml:S3:1358:3	glp	NNP	O	O
-	TRULICITY.xml:S3:1361:1	-	:	O	O
1	TRULICITY.xml:S3:1362:1	1	CD	O	O
)	TRULICITY.xml:S3:1363:1	)	)	O	O
receptor	TRULICITY.xml:S3:1365:8	receptor	NN	O	O
agonists	TRULICITY.xml:S3:1374:8	agonist	NNS	O	O
have	TRULICITY.xml:S3:1383:4	have	VBP	O	O
induced	TRULICITY.xml:S3:1388:7	induc	VBN	O	O
thyroid	TRULICITY.xml:S3:1396:7	thyroid	JJ	B-AdverseReaction	O
C	TRULICITY.xml:S3:1404:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S3:1405:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S3:1406:4	cell	NN	I-AdverseReaction	O
adenomas	TRULICITY.xml:S3:1411:8	adenoma	NN	I-AdverseReaction	O
and	TRULICITY.xml:S3:1420:3	and	CC	O	O
carcinomas	TRULICITY.xml:S3:1424:10	carcinoma	NN	I-AdverseReaction	B-AdverseReaction
in	TRULICITY.xml:S3:1435:2	in	IN	O	I-AdverseReaction
mice	TRULICITY.xml:S3:1438:4	mice	NN	O	I-AdverseReaction
and	TRULICITY.xml:S3:1443:3	and	CC	O	O
rats	TRULICITY.xml:S3:1447:4	rat	NNS	O	O
at	TRULICITY.xml:S3:1452:2	at	IN	O	O
clinically	TRULICITY.xml:S3:1455:10	clinic	RB	O	O
relevant	TRULICITY.xml:S3:1466:8	relev	JJ	O	O
exposures	TRULICITY.xml:S3:1475:9	exposur	NNS	O	O
.	TRULICITY.xml:S3:1484:1	.	.	O	O

It	TRULICITY.xml:S3:1486:2	It	PRP	O	O
is	TRULICITY.xml:S3:1489:2	is	VBZ	O	O
unknown	TRULICITY.xml:S3:1492:7	unknown	JJ	O	O
whether	TRULICITY.xml:S3:1500:7	whether	IN	O	O
TRULICITY	TRULICITY.xml:S3:1508:9	trulic	NNP	O	O
will	TRULICITY.xml:S3:1518:4	will	MD	O	O
cause	TRULICITY.xml:S3:1523:5	caus	VB	O	O
thyroid	TRULICITY.xml:S3:1529:7	thyroid	JJ	B-AdverseReaction	O
C	TRULICITY.xml:S3:1537:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S3:1538:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S3:1539:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S3:1544:6	tumor	NNS	I-AdverseReaction	O
,	TRULICITY.xml:S3:1550:1	,	,	O	O
including	TRULICITY.xml:S3:1552:9	includ	VBG	O	O
medullary	TRULICITY.xml:S3:1562:9	medullari	JJ	B-AdverseReaction	B-AdverseReaction
thyroid	TRULICITY.xml:S3:1572:7	thyroid	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TRULICITY.xml:S3:1580:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
(	TRULICITY.xml:S3:1590:1	(	(	O	O
MTC	TRULICITY.xml:S3:1591:3	mtc	NNP	B-AdverseReaction	O
)	TRULICITY.xml:S3:1594:1	)	)	O	O
,	TRULICITY.xml:S3:1595:1	,	,	O	O
in	TRULICITY.xml:S3:1597:2	in	IN	O	O
humans	TRULICITY.xml:S3:1600:6	human	NNS	O	O
,	TRULICITY.xml:S3:1606:1	,	,	O	O
as	TRULICITY.xml:S3:1608:2	as	IN	O	O
the	TRULICITY.xml:S3:1611:3	the	DT	O	O
human	TRULICITY.xml:S3:1615:5	human	JJ	O	O
relevance	TRULICITY.xml:S3:1621:9	relev	NN	O	O
of	TRULICITY.xml:S3:1631:2	of	IN	O	O
dulaglutide	TRULICITY.xml:S3:1634:11	dulaglutid	JJ	O	O
-	TRULICITY.xml:S3:1645:1	-	:	O	O
induced	TRULICITY.xml:S3:1646:7	induc	JJ	O	O
rodent	TRULICITY.xml:S3:1654:6	rodent	NN	O	O
thyroid	TRULICITY.xml:S3:1661:7	thyroid	NN	B-AdverseReaction	O
C	TRULICITY.xml:S3:1669:1	C	NNP	I-AdverseReaction	O
-	TRULICITY.xml:S3:1670:1	-	:	I-AdverseReaction	O
cell	TRULICITY.xml:S3:1671:4	cell	NN	I-AdverseReaction	O
tumors	TRULICITY.xml:S3:1676:6	tumor	NNS	I-AdverseReaction	O
has	TRULICITY.xml:S3:1683:3	ha	VBZ	O	O
not	TRULICITY.xml:S3:1687:3	not	RB	O	O
been	TRULICITY.xml:S3:1691:4	been	VBN	O	O
determined	TRULICITY.xml:S3:1696:10	determin	VBN	O	O
.	TRULICITY.xml:S3:1706:1	.	.	O	O

One	TRULICITY.xml:S3:1715:3	one	CD	O	O
case	TRULICITY.xml:S3:1719:4	case	NN	O	O
of	TRULICITY.xml:S3:1724:2	of	IN	O	O
MTC	TRULICITY.xml:S3:1727:3	mtc	NNP	B-AdverseReaction	B-AdverseReaction
was	TRULICITY.xml:S3:1731:3	wa	VBD	O	O
reported	TRULICITY.xml:S3:1735:8	report	VBN	O	O
in	TRULICITY.xml:S3:1744:2	in	IN	O	O
a	TRULICITY.xml:S3:1747:1	a	DT	O	O
patient	TRULICITY.xml:S3:1749:7	patient	NN	O	O
treated	TRULICITY.xml:S3:1757:7	treat	VBN	O	O
with	TRULICITY.xml:S3:1765:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S3:1770:9	trulic	NNP	O	O
.	TRULICITY.xml:S3:1779:1	.	.	O	O

This	TRULICITY.xml:S3:1781:4	thi	DT	O	O
patient	TRULICITY.xml:S3:1786:7	patient	NN	O	O
had	TRULICITY.xml:S3:1794:3	had	VBD	O	O
pretreatment	TRULICITY.xml:S3:1798:12	pretreat	JJ	O	O
calcitonin	TRULICITY.xml:S3:1811:10	calcitonin	NN	O	O
levels	TRULICITY.xml:S3:1822:6	level	NNS	O	O
approximately	TRULICITY.xml:S3:1829:13	approxim	RB	O	O
8	TRULICITY.xml:S3:1843:1	8	CD	O	O
times	TRULICITY.xml:S3:1845:5	time	NNS	O	O
the	TRULICITY.xml:S3:1851:3	the	DT	O	O
upper	TRULICITY.xml:S3:1855:5	upper	JJ	O	O
limit	TRULICITY.xml:S3:1861:5	limit	NN	O	O
of	TRULICITY.xml:S3:1867:2	of	IN	O	O
normal	TRULICITY.xml:S3:1870:6	normal	JJ	O	O
(	TRULICITY.xml:S3:1877:1	(	(	O	O
ULN	TRULICITY.xml:S3:1878:3	uln	NNP	O	O
)	TRULICITY.xml:S3:1881:1	)	)	O	O
.	TRULICITY.xml:S3:1882:1	.	.	O	O

Cases	TRULICITY.xml:S3:1884:5	case	NNS	O	O
of	TRULICITY.xml:S3:1890:2	of	IN	O	O
MTC	TRULICITY.xml:S3:1893:3	mtc	NNP	B-AdverseReaction	O
in	TRULICITY.xml:S3:1897:2	in	IN	O	O
patients	TRULICITY.xml:S3:1900:8	patient	NNS	O	O
treated	TRULICITY.xml:S3:1909:7	treat	VBN	O	O
with	TRULICITY.xml:S3:1917:4	with	IN	O	O
liraglutide	TRULICITY.xml:S3:1922:11	liraglutid	NN	O	O
,	TRULICITY.xml:S3:1933:1	,	,	O	O
another	TRULICITY.xml:S3:1935:7	anoth	DT	O	O
GLP	TRULICITY.xml:S3:1943:3	glp	NNP	O	O
-	TRULICITY.xml:S3:1946:1	-	:	O	O
1	TRULICITY.xml:S3:1947:1	1	CD	O	O
receptor	TRULICITY.xml:S3:1949:8	receptor	NN	O	O
agonist	TRULICITY.xml:S3:1958:7	agonist	NN	O	O
,	TRULICITY.xml:S3:1965:1	,	,	O	O
have	TRULICITY.xml:S3:1967:4	have	VBP	O	O
been	TRULICITY.xml:S3:1972:4	been	VBN	O	O
reported	TRULICITY.xml:S3:1977:8	report	VBN	O	O
in	TRULICITY.xml:S3:1986:2	in	IN	O	O
the	TRULICITY.xml:S3:1989:3	the	DT	O	O
postmarketing	TRULICITY.xml:S3:1993:13	postmarket	JJ	O	O
period	TRULICITY.xml:S3:2007:6	period	NN	O	O
;	TRULICITY.xml:S3:2013:1	;	:	O	O
the	TRULICITY.xml:S3:2015:3	the	DT	O	O
data	TRULICITY.xml:S3:2019:4	data	NNS	O	O
in	TRULICITY.xml:S3:2024:2	in	IN	O	O
these	TRULICITY.xml:S3:2027:5	these	DT	O	O
reports	TRULICITY.xml:S3:2033:7	report	NNS	O	O
are	TRULICITY.xml:S3:2041:3	are	VBP	O	O
insufficient	TRULICITY.xml:S3:2045:12	insuffici	JJ	O	O
to	TRULICITY.xml:S3:2058:2	to	TO	O	O
establish	TRULICITY.xml:S3:2061:9	establish	VB	O	O
or	TRULICITY.xml:S3:2071:2	or	CC	O	O
exclude	TRULICITY.xml:S3:2074:7	exclud	VB	O	O
a	TRULICITY.xml:S3:2082:1	a	DT	O	O
causal	TRULICITY.xml:S3:2084:6	causal	NN	O	O
relationship	TRULICITY.xml:S3:2091:12	relationship	NN	O	O
between	TRULICITY.xml:S3:2104:7	between	IN	O	O
MTC	TRULICITY.xml:S3:2112:3	mtc	NNP	B-AdverseReaction	O
and	TRULICITY.xml:S3:2116:3	and	CC	O	O
GLP	TRULICITY.xml:S3:2120:3	glp	NNP	O	O
-	TRULICITY.xml:S3:2123:1	-	:	O	O
1	TRULICITY.xml:S3:2124:1	1	CD	O	O
receptor	TRULICITY.xml:S3:2126:8	receptor	NN	O	O
agonist	TRULICITY.xml:S3:2135:7	agonist	NN	O	O
use	TRULICITY.xml:S3:2143:3	use	NN	O	O
in	TRULICITY.xml:S3:2147:2	in	IN	O	O
humans	TRULICITY.xml:S3:2150:6	human	NNS	O	O
.	TRULICITY.xml:S3:2156:1	.	.	O	O

TRULICITY	TRULICITY.xml:S3:2165:9	trulic	NNP	O	O
is	TRULICITY.xml:S3:2175:2	is	VBZ	O	O
contraindicated	TRULICITY.xml:S3:2178:15	contraind	VBN	O	O
in	TRULICITY.xml:S3:2194:2	in	IN	O	O
patients	TRULICITY.xml:S3:2197:8	patient	NNS	O	O
with	TRULICITY.xml:S3:2206:4	with	IN	O	O
a	TRULICITY.xml:S3:2211:1	a	DT	O	O
personal	TRULICITY.xml:S3:2213:8	person	JJ	O	O
or	TRULICITY.xml:S3:2222:2	or	CC	O	O
family	TRULICITY.xml:S3:2225:6	famili	NN	O	O
history	TRULICITY.xml:S3:2232:7	histori	NN	O	O
of	TRULICITY.xml:S3:2240:2	of	IN	O	O
MTC	TRULICITY.xml:S3:2243:3	mtc	NNP	O	O
or	TRULICITY.xml:S3:2247:2	or	CC	O	O
in	TRULICITY.xml:S3:2250:2	in	IN	O	O
patients	TRULICITY.xml:S3:2253:8	patient	NNS	O	O
with	TRULICITY.xml:S3:2262:4	with	IN	O	O
MEN	TRULICITY.xml:S3:2267:3	men	NNP	O	O
2	TRULICITY.xml:S3:2271:1	2	CD	O	O
.	TRULICITY.xml:S3:2272:1	.	.	O	O

Counsel	TRULICITY.xml:S3:2274:7	counsel	NNP	O	O
patients	TRULICITY.xml:S3:2282:8	patient	NNS	O	O
regarding	TRULICITY.xml:S3:2291:9	regard	VBG	O	O
the	TRULICITY.xml:S3:2301:3	the	DT	O	O
potential	TRULICITY.xml:S3:2305:9	potenti	JJ	O	O
risk	TRULICITY.xml:S3:2315:4	risk	NN	O	O
for	TRULICITY.xml:S3:2320:3	for	IN	O	O
MTC	TRULICITY.xml:S3:2324:3	mtc	NNP	O	O
with	TRULICITY.xml:S3:2328:4	with	IN	O	O
the	TRULICITY.xml:S3:2333:3	the	DT	O	O
use	TRULICITY.xml:S3:2337:3	use	NN	O	O
of	TRULICITY.xml:S3:2341:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S3:2344:9	trulic	NNP	O	O
and	TRULICITY.xml:S3:2354:3	and	CC	O	O
inform	TRULICITY.xml:S3:2358:6	inform	VB	O	O
them	TRULICITY.xml:S3:2365:4	them	PRP	O	O
of	TRULICITY.xml:S3:2370:2	of	IN	O	O
symptoms	TRULICITY.xml:S3:2373:8	symptom	NNS	O	O
of	TRULICITY.xml:S3:2382:2	of	IN	O	O
thyroid	TRULICITY.xml:S3:2385:7	thyroid	JJ	O	O
tumors	TRULICITY.xml:S3:2393:6	tumor	NNS	O	O
(	TRULICITY.xml:S3:2400:1	(	(	O	O
e	TRULICITY.xml:S3:2401:1	e	NN	O	O
.	TRULICITY.xml:S3:2402:1	.	.	O	O
g	TRULICITY.xml:S3:2403:1	g	NN	O	O
.	TRULICITY.xml:S3:2404:1	.	.	O	O

a	TRULICITY.xml:S3:2406:1	a	DT	O	O
mass	TRULICITY.xml:S3:2408:4	mass	NN	O	O
in	TRULICITY.xml:S3:2413:2	in	IN	O	O
the	TRULICITY.xml:S3:2416:3	the	DT	O	O
neck	TRULICITY.xml:S3:2420:4	neck	NN	O	O
,	TRULICITY.xml:S3:2424:1	,	,	O	O
dysphagia	TRULICITY.xml:S3:2426:9	dysphagia	NN	O	B-AdverseReaction
,	TRULICITY.xml:S3:2435:1	,	,	O	O
dyspnea	TRULICITY.xml:S3:2437:7	dyspnea	NN	O	B-AdverseReaction
,	TRULICITY.xml:S3:2444:1	,	,	O	O
persistent	TRULICITY.xml:S3:2446:10	persist	JJ	O	O
hoarseness	TRULICITY.xml:S3:2457:10	hoars	NN	O	O
)	TRULICITY.xml:S3:2467:1	)	)	O	O
.	TRULICITY.xml:S3:2468:1	.	.	O	O

Routine	TRULICITY.xml:S3:2477:7	routin	JJ	O	O
monitoring	TRULICITY.xml:S3:2485:10	monitor	NN	O	O
of	TRULICITY.xml:S3:2496:2	of	IN	O	O
serum	TRULICITY.xml:S3:2499:5	serum	JJ	O	O
calcitonin	TRULICITY.xml:S3:2505:10	calcitonin	NN	O	O
or	TRULICITY.xml:S3:2516:2	or	CC	O	O
using	TRULICITY.xml:S3:2519:5	use	VBG	O	O
thyroid	TRULICITY.xml:S3:2525:7	thyroid	JJ	O	O
ultrasound	TRULICITY.xml:S3:2533:10	ultrasound	NN	O	O
is	TRULICITY.xml:S3:2544:2	is	VBZ	O	O
of	TRULICITY.xml:S3:2547:2	of	IN	O	O
uncertain	TRULICITY.xml:S3:2550:9	uncertain	JJ	O	O
value	TRULICITY.xml:S3:2560:5	valu	NN	O	O
for	TRULICITY.xml:S3:2566:3	for	IN	O	O
early	TRULICITY.xml:S3:2570:5	earli	JJ	O	O
detection	TRULICITY.xml:S3:2576:9	detect	NN	O	O
of	TRULICITY.xml:S3:2586:2	of	IN	O	O
MTC	TRULICITY.xml:S3:2589:3	mtc	NNP	O	O
in	TRULICITY.xml:S3:2593:2	in	IN	O	O
patients	TRULICITY.xml:S3:2596:8	patient	NNS	O	O
treated	TRULICITY.xml:S3:2605:7	treat	VBN	O	O
with	TRULICITY.xml:S3:2613:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S3:2618:9	trulic	NNP	O	O
.	TRULICITY.xml:S3:2627:1	.	.	O	O

Such	TRULICITY.xml:S3:2629:4	such	JJ	O	O
monitoring	TRULICITY.xml:S3:2634:10	monitor	NN	O	O
may	TRULICITY.xml:S3:2645:3	may	MD	O	O
increase	TRULICITY.xml:S3:2649:8	increas	VB	O	O
the	TRULICITY.xml:S3:2658:3	the	DT	O	O
risk	TRULICITY.xml:S3:2662:4	risk	NN	O	O
of	TRULICITY.xml:S3:2667:2	of	IN	O	O
unnecessary	TRULICITY.xml:S3:2670:11	unnecessari	JJ	O	O
procedures	TRULICITY.xml:S3:2682:10	procedur	NNS	O	O
,	TRULICITY.xml:S3:2692:1	,	,	O	O
due	TRULICITY.xml:S3:2694:3	due	JJ	O	O
to	TRULICITY.xml:S3:2698:2	to	TO	O	O
the	TRULICITY.xml:S3:2701:3	the	DT	O	O
low	TRULICITY.xml:S3:2705:3	low	JJ	O	O
test	TRULICITY.xml:S3:2709:4	test	NN	O	O
specificity	TRULICITY.xml:S3:2714:11	specif	NN	O	O
for	TRULICITY.xml:S3:2726:3	for	IN	O	O
serum	TRULICITY.xml:S3:2730:5	serum	NN	O	O
calcitonin	TRULICITY.xml:S3:2736:10	calcitonin	NN	O	O
and	TRULICITY.xml:S3:2747:3	and	CC	O	O
a	TRULICITY.xml:S3:2751:1	a	DT	O	O
high	TRULICITY.xml:S3:2753:4	high	JJ	O	O
background	TRULICITY.xml:S3:2758:10	background	NN	O	O
incidence	TRULICITY.xml:S3:2769:9	incid	NN	O	O
of	TRULICITY.xml:S3:2779:2	of	IN	O	O
thyroid	TRULICITY.xml:S3:2782:7	thyroid	JJ	O	O
disease	TRULICITY.xml:S3:2790:7	diseas	NN	O	O
.	TRULICITY.xml:S3:2797:1	.	.	O	O

Significantly	TRULICITY.xml:S3:2799:13	significantli	RB	O	O
elevated	TRULICITY.xml:S3:2813:8	elev	VBN	O	O
serum	TRULICITY.xml:S3:2822:5	serum	NN	O	O
calcitonin	TRULICITY.xml:S3:2828:10	calcitonin	NN	O	O
value	TRULICITY.xml:S3:2839:5	valu	NN	O	O
may	TRULICITY.xml:S3:2845:3	may	MD	O	O
indicate	TRULICITY.xml:S3:2849:8	indic	VB	O	O
MTC	TRULICITY.xml:S3:2858:3	mtc	NNP	O	O
and	TRULICITY.xml:S3:2862:3	and	CC	O	O
patients	TRULICITY.xml:S3:2866:8	patient	NNS	O	O
with	TRULICITY.xml:S3:2875:4	with	IN	O	O
MTC	TRULICITY.xml:S3:2880:3	mtc	NNP	O	O
usually	TRULICITY.xml:S3:2884:7	usual	RB	O	O
have	TRULICITY.xml:S3:2892:4	have	VBP	O	O
calcitonin	TRULICITY.xml:S3:2897:10	calcitonin	VBN	O	O
values	TRULICITY.xml:S3:2908:6	valu	NNS	O	O
50	TRULICITY.xml:S3:2916:2	50	CD	O	O
ng	TRULICITY.xml:S3:2919:2	ng	NNS	O	O
L.	TRULICITY.xml:S3:2922:2	L.	NNP	O	O

If	TRULICITY.xml:S3:2925:2	If	IN	O	O
serum	TRULICITY.xml:S3:2928:5	serum	JJ	O	O
calcitonin	TRULICITY.xml:S3:2934:10	calcitonin	NN	O	O
is	TRULICITY.xml:S3:2945:2	is	VBZ	O	O
measured	TRULICITY.xml:S3:2948:8	measur	VBN	O	O
and	TRULICITY.xml:S3:2957:3	and	CC	O	O
found	TRULICITY.xml:S3:2961:5	found	VBN	O	O
to	TRULICITY.xml:S3:2967:2	to	TO	O	O
be	TRULICITY.xml:S3:2970:2	be	VB	O	O
elevated	TRULICITY.xml:S3:2973:8	elev	VBN	O	O
,	TRULICITY.xml:S3:2981:1	,	,	O	O
the	TRULICITY.xml:S3:2983:3	the	DT	O	O
patient	TRULICITY.xml:S3:2987:7	patient	NN	O	O
should	TRULICITY.xml:S3:2995:6	should	MD	O	O
be	TRULICITY.xml:S3:3002:2	be	VB	O	O
further	TRULICITY.xml:S3:3005:7	further	RB	O	O
evaluated	TRULICITY.xml:S3:3013:9	evalu	VBN	O	O
.	TRULICITY.xml:S3:3022:1	.	.	O	O

Patients	TRULICITY.xml:S3:3024:8	patient	NNS	O	O
with	TRULICITY.xml:S3:3033:4	with	IN	O	O
thyroid	TRULICITY.xml:S3:3038:7	thyroid	JJ	O	O
nodules	TRULICITY.xml:S3:3046:7	nodul	NNS	O	O
noted	TRULICITY.xml:S3:3054:5	note	VBN	O	O
on	TRULICITY.xml:S3:3060:2	on	IN	O	O
physical	TRULICITY.xml:S3:3063:8	physic	JJ	O	O
examination	TRULICITY.xml:S3:3072:11	examin	NN	O	O
or	TRULICITY.xml:S3:3084:2	or	CC	O	O
neck	TRULICITY.xml:S3:3087:4	neck	NN	O	O
imaging	TRULICITY.xml:S3:3092:7	imag	NN	O	O
should	TRULICITY.xml:S3:3100:6	should	MD	O	O
also	TRULICITY.xml:S3:3107:4	also	RB	O	O
be	TRULICITY.xml:S3:3112:2	be	VB	O	O
further	TRULICITY.xml:S3:3115:7	further	RB	O	O
evaluated	TRULICITY.xml:S3:3123:9	evalu	VBN	O	O
.	TRULICITY.xml:S3:3132:1	.	.	O	O

5.2	TRULICITY.xml:S3:3141:3	5.2	CD	O	O
Pancreatitis	TRULICITY.xml:S3:3145:12	pancreat	NN	O	O

In	TRULICITY.xml:S3:3163:2	In	IN	O	O
Phase	TRULICITY.xml:S3:3166:5	phase	NNP	O	O
2	TRULICITY.xml:S3:3172:1	2	CD	O	O
and	TRULICITY.xml:S3:3174:3	and	CC	O	O
Phase	TRULICITY.xml:S3:3178:5	phase	NNP	O	O
3	TRULICITY.xml:S3:3184:1	3	CD	O	O
clinical	TRULICITY.xml:S3:3186:8	clinic	JJ	O	O
studies	TRULICITY.xml:S3:3195:7	studi	NNS	O	O
,	TRULICITY.xml:S3:3202:1	,	,	O	O
12	TRULICITY.xml:S3:3204:2	12	CD	O	O
(	TRULICITY.xml:S3:3207:1	(	(	O	O
3.4	TRULICITY.xml:S3:3208:3	3.4	CD	O	O
cases	TRULICITY.xml:S3:3212:5	case	NNS	O	O
per	TRULICITY.xml:S3:3218:3	per	IN	O	O
1000	TRULICITY.xml:S3:3222:4	1000	CD	O	O
patient	TRULICITY.xml:S3:3227:7	patient	NN	O	O
years	TRULICITY.xml:S3:3235:5	year	NNS	O	O
)	TRULICITY.xml:S3:3240:1	)	)	O	O
pancreatitis	TRULICITY.xml:S3:3242:12	pancreat	NN	B-AdverseReaction	O
related	TRULICITY.xml:S3:3255:7	relat	JJ	O	O
adverse	TRULICITY.xml:S3:3263:7	advers	JJ	O	O
reactions	TRULICITY.xml:S3:3271:9	reaction	NNS	O	O
were	TRULICITY.xml:S3:3281:4	were	VBD	O	O
reported	TRULICITY.xml:S3:3286:8	report	VBN	O	O
in	TRULICITY.xml:S3:3295:2	in	IN	O	O
patients	TRULICITY.xml:S3:3298:8	patient	NNS	O	O
exposed	TRULICITY.xml:S3:3307:7	expos	VBN	O	O
to	TRULICITY.xml:S3:3315:2	to	TO	O	O
TRULICITY	TRULICITY.xml:S3:3318:9	trulic	NNP	O	O
versus	TRULICITY.xml:S3:3328:6	versu	NN	O	O
3	TRULICITY.xml:S3:3335:1	3	CD	O	O
in	TRULICITY.xml:S3:3337:2	in	IN	O	O
non	TRULICITY.xml:S3:3340:3	non	JJ	O	O
-	TRULICITY.xml:S3:3343:1	-	:	O	O
incretin	TRULICITY.xml:S3:3344:8	incretin	NN	O	O
comparators	TRULICITY.xml:S3:3353:11	compar	NNS	O	O
(	TRULICITY.xml:S3:3365:1	(	(	O	O
2.7	TRULICITY.xml:S3:3366:3	2.7	CD	O	O
cases	TRULICITY.xml:S3:3370:5	case	NNS	O	O
per	TRULICITY.xml:S3:3376:3	per	IN	O	O
1000	TRULICITY.xml:S3:3380:4	1000	CD	O	O
patient	TRULICITY.xml:S3:3385:7	patient	NN	O	O
years	TRULICITY.xml:S3:3393:5	year	NNS	O	O
)	TRULICITY.xml:S3:3398:1	)	)	O	O
.	TRULICITY.xml:S3:3399:1	.	.	O	O

An	TRULICITY.xml:S3:3401:2	An	DT	O	O
analyses	TRULICITY.xml:S3:3404:8	analys	NNS	O	O
of	TRULICITY.xml:S3:3413:2	of	IN	O	O
adjudicated	TRULICITY.xml:S3:3416:11	adjud	JJ	O	O
events	TRULICITY.xml:S3:3428:6	event	NNS	O	O
revealed	TRULICITY.xml:S3:3435:8	reveal	VBD	O	O
5	TRULICITY.xml:S3:3444:1	5	CD	O	O
cases	TRULICITY.xml:S3:3446:5	case	NNS	O	O
of	TRULICITY.xml:S3:3452:2	of	IN	O	O
confirmed	TRULICITY.xml:S3:3455:9	confirm	JJ	O	B-AdverseReaction
pancreatitis	TRULICITY.xml:S3:3465:12	pancreat	NN	B-AdverseReaction	I-AdverseReaction
in	TRULICITY.xml:S3:3478:2	in	IN	O	O
patients	TRULICITY.xml:S3:3481:8	patient	NNS	O	O
exposed	TRULICITY.xml:S3:3490:7	expos	VBN	O	O
to	TRULICITY.xml:S3:3498:2	to	TO	O	O
TRULICITY	TRULICITY.xml:S3:3501:9	trulic	NNP	O	O
(	TRULICITY.xml:S3:3511:1	(	(	O	O
1.4	TRULICITY.xml:S3:3512:3	1.4	CD	O	O
cases	TRULICITY.xml:S3:3516:5	case	NNS	O	O
per	TRULICITY.xml:S3:3522:3	per	IN	O	O
1000	TRULICITY.xml:S3:3526:4	1000	CD	O	O
patient	TRULICITY.xml:S3:3531:7	patient	NN	O	O
years	TRULICITY.xml:S3:3539:5	year	NNS	O	O
)	TRULICITY.xml:S3:3544:1	)	)	O	O
versus	TRULICITY.xml:S3:3546:6	versu	VBP	O	O
1	TRULICITY.xml:S3:3553:1	1	CD	O	O
case	TRULICITY.xml:S3:3555:4	case	NN	O	O
in	TRULICITY.xml:S3:3560:2	in	IN	O	O
non	TRULICITY.xml:S3:3563:3	non	JJ	O	O
-	TRULICITY.xml:S3:3566:1	-	:	O	O
incretin	TRULICITY.xml:S3:3567:8	incretin	NN	O	O
comparators	TRULICITY.xml:S3:3576:11	compar	NNS	O	O
(	TRULICITY.xml:S3:3588:1	(	(	O	O
0.88	TRULICITY.xml:S3:3589:4	0.88	CD	O	O
cases	TRULICITY.xml:S3:3594:5	case	NNS	O	O
per	TRULICITY.xml:S3:3600:3	per	IN	O	O
1000	TRULICITY.xml:S3:3604:4	1000	CD	O	O
patient	TRULICITY.xml:S3:3609:7	patient	NN	O	O
years	TRULICITY.xml:S3:3617:5	year	NNS	O	O
)	TRULICITY.xml:S3:3622:1	)	)	O	O
.	TRULICITY.xml:S3:3623:1	.	.	O	O

After	TRULICITY.xml:S3:3629:5	after	IN	O	O
initiation	TRULICITY.xml:S3:3635:10	initi	NN	O	O
of	TRULICITY.xml:S3:3646:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S3:3649:9	trulic	NNP	O	O
,	TRULICITY.xml:S3:3658:1	,	,	O	O
observe	TRULICITY.xml:S3:3660:7	observ	NN	O	O
patients	TRULICITY.xml:S3:3668:8	patient	NNS	O	O
carefully	TRULICITY.xml:S3:3677:9	care	RB	O	O
for	TRULICITY.xml:S3:3687:3	for	IN	O	O
signs	TRULICITY.xml:S3:3691:5	sign	NNS	O	O
and	TRULICITY.xml:S3:3697:3	and	CC	O	O
symptoms	TRULICITY.xml:S3:3701:8	symptom	NNS	O	O
of	TRULICITY.xml:S3:3710:2	of	IN	O	O
pancreatitis	TRULICITY.xml:S3:3713:12	pancreat	NN	O	O
,	TRULICITY.xml:S3:3725:1	,	,	O	O
including	TRULICITY.xml:S3:3727:9	includ	VBG	O	O
persistent	TRULICITY.xml:S3:3737:10	persist	NN	O	O
severe	TRULICITY.xml:S3:3748:6	sever	JJ	O	O
abdominal	TRULICITY.xml:S3:3755:9	abdomin	JJ	O	O
pain	TRULICITY.xml:S3:3765:4	pain	NN	O	O
.	TRULICITY.xml:S3:3769:1	.	.	O	O

If	TRULICITY.xml:S3:3771:2	If	IN	O	O
pancreatitis	TRULICITY.xml:S3:3774:12	pancreat	NN	O	O
is	TRULICITY.xml:S3:3787:2	is	VBZ	O	O
suspected	TRULICITY.xml:S3:3790:9	suspect	VBN	O	O
,	TRULICITY.xml:S3:3799:1	,	,	O	O
promptly	TRULICITY.xml:S3:3801:8	promptli	RB	O	O
discontinue	TRULICITY.xml:S3:3810:11	discontinu	JJ	O	O
TRULICITY	TRULICITY.xml:S3:3822:9	trulic	NNP	O	O
.	TRULICITY.xml:S3:3831:1	.	.	O	O

If	TRULICITY.xml:S3:3833:2	If	IN	O	O
pancreatitis	TRULICITY.xml:S3:3836:12	pancreat	NN	O	O
is	TRULICITY.xml:S3:3849:2	is	VBZ	O	O
confirmed	TRULICITY.xml:S3:3852:9	confirm	VBN	O	O
,	TRULICITY.xml:S3:3861:1	,	,	O	O
TRULICITY	TRULICITY.xml:S3:3863:9	trulic	NNP	O	O
should	TRULICITY.xml:S3:3873:6	should	MD	O	O
not	TRULICITY.xml:S3:3880:3	not	RB	O	O
be	TRULICITY.xml:S3:3884:2	be	VB	O	O
restarted	TRULICITY.xml:S3:3887:9	restart	VBN	O	O
.	TRULICITY.xml:S3:3896:1	.	.	O	O

TRULICITY	TRULICITY.xml:S3:3898:9	trulic	NNP	O	O
has	TRULICITY.xml:S3:3908:3	ha	VBZ	O	O
not	TRULICITY.xml:S3:3912:3	not	RB	O	O
been	TRULICITY.xml:S3:3916:4	been	VBN	O	O
evaluated	TRULICITY.xml:S3:3921:9	evalu	VBN	O	O
in	TRULICITY.xml:S3:3931:2	in	IN	O	O
patients	TRULICITY.xml:S3:3934:8	patient	NNS	O	O
with	TRULICITY.xml:S3:3943:4	with	IN	O	O
a	TRULICITY.xml:S3:3948:1	a	DT	O	O
prior	TRULICITY.xml:S3:3950:5	prior	JJ	O	O
history	TRULICITY.xml:S3:3956:7	histori	NN	O	O
of	TRULICITY.xml:S3:3964:2	of	IN	O	O
pancreatitis	TRULICITY.xml:S3:3967:12	pancreat	NN	O	O
.	TRULICITY.xml:S3:3979:1	.	.	O	O

Consider	TRULICITY.xml:S3:3981:8	consid	VB	O	O
other	TRULICITY.xml:S3:3990:5	other	JJ	O	O
antidiabetic	TRULICITY.xml:S3:3996:12	antidiabet	JJ	O	O
therapies	TRULICITY.xml:S3:4009:9	therapi	NNS	O	O
in	TRULICITY.xml:S3:4019:2	in	IN	O	O
patients	TRULICITY.xml:S3:4022:8	patient	NNS	O	O
with	TRULICITY.xml:S3:4031:4	with	IN	O	O
a	TRULICITY.xml:S3:4036:1	a	DT	O	O
history	TRULICITY.xml:S3:4038:7	histori	NN	O	O
of	TRULICITY.xml:S3:4046:2	of	IN	O	O
pancreatitis	TRULICITY.xml:S3:4049:12	pancreat	NN	O	O
.	TRULICITY.xml:S3:4061:1	.	.	O	O

5.3	TRULICITY.xml:S3:4070:3	5.3	CD	O	O
Hypoglycemia	TRULICITY.xml:S3:4074:12	hypoglycemia	NNP	O	O
with	TRULICITY.xml:S3:4087:4	with	IN	O	O
Concomitant	TRULICITY.xml:S3:4092:11	concomit	NNP	O	O
Use	TRULICITY.xml:S3:4104:3	use	NNP	O	O
of	TRULICITY.xml:S3:4108:2	of	IN	O	O
Insulin	TRULICITY.xml:S3:4111:7	insulin	NNP	O	O
Secretagogues	TRULICITY.xml:S3:4119:13	secretagogu	NNP	O	O
or	TRULICITY.xml:S3:4133:2	or	CC	O	O
Insulin	TRULICITY.xml:S3:4136:7	insulin	NNP	O	O

The	TRULICITY.xml:S3:4149:3	the	DT	O	O
risk	TRULICITY.xml:S3:4153:4	risk	NN	O	O
of	TRULICITY.xml:S3:4158:2	of	IN	O	O
hypoglycemia	TRULICITY.xml:S3:4161:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
is	TRULICITY.xml:S3:4174:2	is	VBZ	O	O
increased	TRULICITY.xml:S3:4177:9	increas	VBN	O	O
when	TRULICITY.xml:S3:4187:4	when	WRB	O	O
TRULICITY	TRULICITY.xml:S3:4192:9	trulic	NNP	O	O
is	TRULICITY.xml:S3:4202:2	is	VBZ	O	O
used	TRULICITY.xml:S3:4205:4	use	VBN	O	O
in	TRULICITY.xml:S3:4210:2	in	IN	O	O
combination	TRULICITY.xml:S3:4213:11	combin	NN	O	O
with	TRULICITY.xml:S3:4225:4	with	IN	O	O
insulin	TRULICITY.xml:S3:4230:7	insulin	NN	O	O
secretagogues	TRULICITY.xml:S3:4238:13	secretagogu	NNS	O	O
(	TRULICITY.xml:S3:4252:1	(	(	O	O
e	TRULICITY.xml:S3:4253:1	e	NN	O	O
.	TRULICITY.xml:S3:4254:1	.	.	O	O
g	TRULICITY.xml:S3:4255:1	g	NN	O	O
.	TRULICITY.xml:S3:4256:1	.	.	O	O
,	TRULICITY.xml:S3:4257:1	,	,	O	O
sulfonylureas	TRULICITY.xml:S3:4259:13	sulfonylurea	JJ	O	O
)	TRULICITY.xml:S3:4272:1	)	)	O	O
or	TRULICITY.xml:S3:4274:2	or	CC	O	O
insulin	TRULICITY.xml:S3:4277:7	insulin	NN	O	O
.	TRULICITY.xml:S3:4284:1	.	.	O	O

Patients	TRULICITY.xml:S3:4286:8	patient	NNS	O	O
may	TRULICITY.xml:S3:4295:3	may	MD	O	O
require	TRULICITY.xml:S3:4299:7	requir	VB	O	O
a	TRULICITY.xml:S3:4307:1	a	DT	O	O
lower	TRULICITY.xml:S3:4309:5	lower	JJR	O	O
dose	TRULICITY.xml:S3:4315:4	dose	NN	O	O
of	TRULICITY.xml:S3:4320:2	of	IN	O	O
sulfonylurea	TRULICITY.xml:S3:4323:12	sulfonylurea	NN	O	O
or	TRULICITY.xml:S3:4336:2	or	CC	O	O
insulin	TRULICITY.xml:S3:4339:7	insulin	NN	O	O
to	TRULICITY.xml:S3:4347:2	to	TO	O	O
reduce	TRULICITY.xml:S3:4350:6	reduc	VB	O	O
the	TRULICITY.xml:S3:4357:3	the	DT	O	O
risk	TRULICITY.xml:S3:4361:4	risk	NN	O	O
of	TRULICITY.xml:S3:4366:2	of	IN	O	O
hypoglycemia	TRULICITY.xml:S3:4369:12	hypoglycemia	NN	O	B-AdverseReaction
in	TRULICITY.xml:S3:4382:2	in	IN	O	O
this	TRULICITY.xml:S3:4385:4	thi	DT	O	O
setting	TRULICITY.xml:S3:4390:7	set	NN	O	O
[	TRULICITY.xml:S3:4398:1	[	NNP	O	O
see	TRULICITY.xml:S3:4399:3	see	VBP	O	O
Adverse	TRULICITY.xml:S3:4403:7	advers	JJ	O	O
Reactions	TRULICITY.xml:S3:4411:9	reaction	NNP	O	O
(	TRULICITY.xml:S3:4421:1	(	(	O	O
6.1	TRULICITY.xml:S3:4424:3	6.1	CD	O	O
)]	TRULICITY.xml:S3:4429:2	)]	NN	O	O
.	TRULICITY.xml:S3:4433:1	.	.	O	O

5.4	TRULICITY.xml:S3:4442:3	5.4	CD	O	O
Hypersensitivity	TRULICITY.xml:S3:4446:16	hypersensit	NNP	O	O
Reactions	TRULICITY.xml:S3:4463:9	reaction	NNP	O	O

Systemic	TRULICITY.xml:S3:4478:8	system	NNP	B-AdverseReaction	B-AdverseReaction
hypersensitivity	TRULICITY.xml:S3:4487:16	hypersensit	NN	I-AdverseReaction	I-AdverseReaction
reactions	TRULICITY.xml:S3:4504:9	reaction	NNS	O	I-AdverseReaction
were	TRULICITY.xml:S3:4514:4	were	VBD	O	O
observed	TRULICITY.xml:S3:4519:8	observ	VBN	O	O
in	TRULICITY.xml:S3:4528:2	in	IN	O	O
patients	TRULICITY.xml:S3:4531:8	patient	NNS	O	O
receiving	TRULICITY.xml:S3:4540:9	receiv	VBG	O	O
TRULICITY	TRULICITY.xml:S3:4550:9	trulic	NNP	O	O
in	TRULICITY.xml:S3:4560:2	in	IN	O	O
clinical	TRULICITY.xml:S3:4563:8	clinic	JJ	O	O
trials	TRULICITY.xml:S3:4572:6	trial	NNS	O	O
[	TRULICITY.xml:S3:4579:1	[	VBP	O	O
see	TRULICITY.xml:S3:4580:3	see	VB	O	O
Adverse	TRULICITY.xml:S3:4584:7	advers	JJ	O	O
Reactions	TRULICITY.xml:S3:4592:9	reaction	NNP	O	O
(	TRULICITY.xml:S3:4602:1	(	(	O	O
6.1	TRULICITY.xml:S3:4605:3	6.1	CD	O	O
)]	TRULICITY.xml:S3:4610:2	)]	NN	O	O
.	TRULICITY.xml:S3:4612:1	.	.	O	O

If	TRULICITY.xml:S3:4615:2	If	IN	O	O
a	TRULICITY.xml:S3:4618:1	a	DT	O	O
hypersensitivity	TRULICITY.xml:S3:4620:16	hypersensit	NN	O	O
reaction	TRULICITY.xml:S3:4637:8	reaction	NN	O	O
occurs	TRULICITY.xml:S3:4646:6	occur	VBZ	O	O
,	TRULICITY.xml:S3:4652:1	,	,	O	O
the	TRULICITY.xml:S3:4654:3	the	DT	O	O
patient	TRULICITY.xml:S3:4658:7	patient	NN	O	O
should	TRULICITY.xml:S3:4666:6	should	MD	O	O
discontinue	TRULICITY.xml:S3:4673:11	discontinu	VB	O	O
TRULICITY	TRULICITY.xml:S3:4685:9	trulic	NNP	O	O
and	TRULICITY.xml:S3:4695:3	and	CC	O	O
promptly	TRULICITY.xml:S3:4699:8	promptli	RB	O	O
seek	TRULICITY.xml:S3:4708:4	seek	VB	O	O
medical	TRULICITY.xml:S3:4713:7	medic	JJ	O	O
advice	TRULICITY.xml:S3:4721:6	advic	NN	O	O
.	TRULICITY.xml:S3:4727:1	.	.	O	O

5.5	TRULICITY.xml:S3:4736:3	5.5	CD	O	O
Renal	TRULICITY.xml:S3:4740:5	renal	JJ	O	O
Impairment	TRULICITY.xml:S3:4746:10	impair	NN	O	O

In	TRULICITY.xml:S3:4762:2	In	IN	O	O
patients	TRULICITY.xml:S3:4765:8	patient	NNS	O	O
treated	TRULICITY.xml:S3:4774:7	treat	VBN	O	O
with	TRULICITY.xml:S3:4782:4	with	IN	O	O
GLP	TRULICITY.xml:S3:4787:3	glp	NNP	O	O
-	TRULICITY.xml:S3:4790:1	-	:	O	O
1	TRULICITY.xml:S3:4791:1	1	CD	O	O
receptor	TRULICITY.xml:S3:4793:8	receptor	NN	O	O
agonists	TRULICITY.xml:S3:4802:8	agonist	NNS	O	O
,	TRULICITY.xml:S3:4810:1	,	,	O	O
there	TRULICITY.xml:S3:4812:5	there	EX	O	O
have	TRULICITY.xml:S3:4818:4	have	VBP	O	O
been	TRULICITY.xml:S3:4823:4	been	VBN	O	O
postmarketing	TRULICITY.xml:S3:4828:13	postmarket	VBG	O	O
reports	TRULICITY.xml:S3:4842:7	report	NNS	O	O
of	TRULICITY.xml:S3:4850:2	of	IN	O	O
acute	TRULICITY.xml:S3:4853:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
renal	TRULICITY.xml:S3:4859:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	TRULICITY.xml:S3:4865:7	failur	NN	I-AdverseReaction	I-AdverseReaction
and	TRULICITY.xml:S3:4873:3	and	CC	O	O
worsening	TRULICITY.xml:S3:4877:9	worsen	NN	O	B-AdverseReaction
of	TRULICITY.xml:S3:4887:2	of	IN	O	I-AdverseReaction
chronic	TRULICITY.xml:S3:4890:7	chronic	JJ	B-AdverseReaction	I-AdverseReaction
renal	TRULICITY.xml:S3:4898:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	TRULICITY.xml:S3:4904:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	TRULICITY.xml:S3:4911:1	,	,	O	O
which	TRULICITY.xml:S3:4913:5	which	WDT	O	O
may	TRULICITY.xml:S3:4919:3	may	MD	O	O
sometimes	TRULICITY.xml:S3:4923:9	sometim	RB	O	O
require	TRULICITY.xml:S3:4933:7	requir	VB	O	O
hemodialysis	TRULICITY.xml:S3:4941:12	hemodialysi	NN	O	O
.	TRULICITY.xml:S3:4953:1	.	.	O	O

Some	TRULICITY.xml:S3:4955:4	some	DT	O	O
of	TRULICITY.xml:S3:4960:2	of	IN	O	O
these	TRULICITY.xml:S3:4963:5	these	DT	O	O
events	TRULICITY.xml:S3:4969:6	event	NNS	O	O
were	TRULICITY.xml:S3:4976:4	were	VBD	O	O
reported	TRULICITY.xml:S3:4981:8	report	VBN	O	O
in	TRULICITY.xml:S3:4990:2	in	IN	O	O
patients	TRULICITY.xml:S3:4993:8	patient	NNS	O	O
without	TRULICITY.xml:S3:5002:7	without	IN	O	O
known	TRULICITY.xml:S3:5010:5	known	VBN	O	O
underlying	TRULICITY.xml:S3:5016:10	underli	JJ	O	O
renal	TRULICITY.xml:S3:5027:5	renal	JJ	O	O
disease	TRULICITY.xml:S3:5033:7	diseas	NN	O	O
.	TRULICITY.xml:S3:5040:1	.	.	O	O

A	TRULICITY.xml:S3:5042:1	A	DT	O	O
majority	TRULICITY.xml:S3:5044:8	major	NN	O	O
of	TRULICITY.xml:S3:5053:2	of	IN	O	O
reported	TRULICITY.xml:S3:5056:8	report	JJ	O	O
events	TRULICITY.xml:S3:5065:6	event	NNS	O	O
occurred	TRULICITY.xml:S3:5072:8	occur	VBD	O	O
in	TRULICITY.xml:S3:5081:2	in	IN	O	O
patients	TRULICITY.xml:S3:5084:8	patient	NNS	O	O
who	TRULICITY.xml:S3:5093:3	who	WP	O	O
had	TRULICITY.xml:S3:5097:3	had	VBD	O	O
experienced	TRULICITY.xml:S3:5101:11	experienc	VBN	O	O
nausea	TRULICITY.xml:S3:5113:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S3:5119:1	,	,	O	O
vomiting	TRULICITY.xml:S3:5121:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S3:5129:1	,	,	O	O
diarrhea	TRULICITY.xml:S3:5131:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TRULICITY.xml:S3:5139:1	,	,	O	O
or	TRULICITY.xml:S3:5141:2	or	CC	O	O
dehydration	TRULICITY.xml:S3:5144:11	dehydr	NN	B-AdverseReaction	O
.	TRULICITY.xml:S3:5155:1	.	.	O	O

Because	TRULICITY.xml:S3:5157:7	becaus	IN	O	O
these	TRULICITY.xml:S3:5165:5	these	DT	O	O
reactions	TRULICITY.xml:S3:5171:9	reaction	NNS	O	O
may	TRULICITY.xml:S3:5181:3	may	MD	O	O
worsen	TRULICITY.xml:S3:5185:6	worsen	VB	O	O
renal	TRULICITY.xml:S3:5192:5	renal	JJ	O	O
function	TRULICITY.xml:S3:5198:8	function	NN	O	O
,	TRULICITY.xml:S3:5206:1	,	,	O	O
use	TRULICITY.xml:S3:5208:3	use	NN	O	O
caution	TRULICITY.xml:S3:5212:7	caution	NN	O	O
when	TRULICITY.xml:S3:5220:4	when	WRB	O	O
initiating	TRULICITY.xml:S3:5225:10	initi	NN	O	O
or	TRULICITY.xml:S3:5236:2	or	CC	O	O
escalating	TRULICITY.xml:S3:5239:10	escal	VBG	O	O
doses	TRULICITY.xml:S3:5250:5	dose	NNS	O	O
of	TRULICITY.xml:S3:5256:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S3:5259:9	trulic	NNP	O	O
in	TRULICITY.xml:S3:5269:2	in	IN	O	O
patients	TRULICITY.xml:S3:5272:8	patient	NNS	O	O
with	TRULICITY.xml:S3:5281:4	with	IN	O	O
renal	TRULICITY.xml:S3:5286:5	renal	JJ	O	O
impairment	TRULICITY.xml:S3:5292:10	impair	NN	O	O
.	TRULICITY.xml:S3:5302:1	.	.	O	O

Monitor	TRULICITY.xml:S3:5304:7	monitor	NNP	O	O
renal	TRULICITY.xml:S3:5312:5	renal	JJ	O	O
function	TRULICITY.xml:S3:5318:8	function	NN	O	O
in	TRULICITY.xml:S3:5327:2	in	IN	O	O
patients	TRULICITY.xml:S3:5330:8	patient	NNS	O	O
with	TRULICITY.xml:S3:5339:4	with	IN	O	O
renal	TRULICITY.xml:S3:5344:5	renal	JJ	O	O
impairment	TRULICITY.xml:S3:5350:10	impair	NN	O	O
reporting	TRULICITY.xml:S3:5361:9	report	NN	O	O
severe	TRULICITY.xml:S3:5371:6	sever	JJ	O	O
adverse	TRULICITY.xml:S3:5378:7	advers	JJ	O	O
gastrointestinal	TRULICITY.xml:S3:5386:16	gastrointestin	JJ	O	O
reactions	TRULICITY.xml:S3:5403:9	reaction	NNS	O	O
[	TRULICITY.xml:S3:5413:1	[	VBP	O	O
see	TRULICITY.xml:S3:5414:3	see	VBP	O	O
Dosage	TRULICITY.xml:S3:5418:6	dosag	NNP	O	O
and	TRULICITY.xml:S3:5425:3	and	CC	O	O
Administration	TRULICITY.xml:S3:5429:14	administr	NNP	O	O
(	TRULICITY.xml:S3:5444:1	(	(	O	O
2.3	TRULICITY.xml:S3:5447:3	2.3	CD	O	O
)	TRULICITY.xml:S3:5452:1	)	)	O	O
,	TRULICITY.xml:S3:5453:1	,	,	O	O
Use	TRULICITY.xml:S3:5455:3	use	NNP	O	O
in	TRULICITY.xml:S3:5459:2	in	IN	O	O
Specific	TRULICITY.xml:S3:5462:8	specif	NNP	O	O
Populations	TRULICITY.xml:S3:5471:11	popul	NNP	O	O
(	TRULICITY.xml:S3:5483:1	(	(	O	O
8.7	TRULICITY.xml:S3:5486:3	8.7	CD	O	O
)]	TRULICITY.xml:S3:5491:2	)]	NN	O	O
.	TRULICITY.xml:S3:5493:1	.	.	O	O

5.6	TRULICITY.xml:S3:5504:3	5.6	CD	O	O
Severe	TRULICITY.xml:S3:5508:6	sever	NNP	O	O
Gastrointestinal	TRULICITY.xml:S3:5515:16	gastrointestin	NNP	O	O
Disease	TRULICITY.xml:S3:5532:7	diseas	NNP	O	O

Use	TRULICITY.xml:S3:5545:3	use	NNP	O	O
of	TRULICITY.xml:S3:5549:2	of	IN	O	O
TRULICITY	TRULICITY.xml:S3:5552:9	trulic	NNP	O	O
may	TRULICITY.xml:S3:5562:3	may	MD	O	O
be	TRULICITY.xml:S3:5566:2	be	VB	O	O
associated	TRULICITY.xml:S3:5569:10	associ	VBN	O	O
with	TRULICITY.xml:S3:5580:4	with	IN	O	O
gastrointestinal	TRULICITY.xml:S3:5585:16	gastrointestin	JJ	B-AdverseReaction	O
adverse	TRULICITY.xml:S3:5602:7	advers	JJ	I-AdverseReaction	O
reactions	TRULICITY.xml:S3:5610:9	reaction	NNS	I-AdverseReaction	O
,	TRULICITY.xml:S3:5619:1	,	,	O	O
sometimes	TRULICITY.xml:S3:5621:9	sometim	RB	O	O
severe	TRULICITY.xml:S3:5631:6	sever	JJ	O	O
[	TRULICITY.xml:S3:5638:1	[	NNP	O	O
see	TRULICITY.xml:S3:5639:3	see	VBP	O	O
Adverse	TRULICITY.xml:S3:5643:7	advers	JJ	O	O
Reactions	TRULICITY.xml:S3:5651:9	reaction	NNP	O	O
(	TRULICITY.xml:S3:5661:1	(	(	O	O
6.1	TRULICITY.xml:S3:5664:3	6.1	CD	O	O
)]	TRULICITY.xml:S3:5669:2	)]	NN	O	O
.	TRULICITY.xml:S3:5673:1	.	.	O	O

TRULICITY	TRULICITY.xml:S3:5675:9	trulic	NNP	O	O
has	TRULICITY.xml:S3:5685:3	ha	VBZ	O	O
not	TRULICITY.xml:S3:5689:3	not	RB	O	O
been	TRULICITY.xml:S3:5693:4	been	VBN	O	O
studied	TRULICITY.xml:S3:5698:7	studi	VBN	O	O
in	TRULICITY.xml:S3:5706:2	in	IN	O	O
patients	TRULICITY.xml:S3:5709:8	patient	NNS	O	O
with	TRULICITY.xml:S3:5718:4	with	IN	O	O
severe	TRULICITY.xml:S3:5723:6	sever	JJ	O	O
gastrointestinal	TRULICITY.xml:S3:5730:16	gastrointestin	JJ	O	O
disease	TRULICITY.xml:S3:5747:7	diseas	NN	O	O
,	TRULICITY.xml:S3:5754:1	,	,	O	O
including	TRULICITY.xml:S3:5756:9	includ	VBG	O	O
severe	TRULICITY.xml:S3:5766:6	sever	JJ	O	O
gastroparesis	TRULICITY.xml:S3:5773:13	gastroparesi	NN	O	O
,	TRULICITY.xml:S3:5786:1	,	,	O	O
and	TRULICITY.xml:S3:5788:3	and	CC	O	O
is	TRULICITY.xml:S3:5792:2	is	VBZ	O	O
therefore	TRULICITY.xml:S3:5795:9	therefor	RB	O	O
not	TRULICITY.xml:S3:5805:3	not	RB	O	O
recommended	TRULICITY.xml:S3:5809:11	recommend	VBN	O	O
in	TRULICITY.xml:S3:5821:2	in	IN	O	O
these	TRULICITY.xml:S3:5824:5	these	DT	O	O
patients	TRULICITY.xml:S3:5830:8	patient	NNS	O	O
.	TRULICITY.xml:S3:5838:1	.	.	O	O

5.7	TRULICITY.xml:S3:5847:3	5.7	CD	O	O
Macrovascular	TRULICITY.xml:S3:5851:13	macrovascular	JJ	O	O
Outcomes	TRULICITY.xml:S3:5865:8	outcom	NNS	O	O

There	TRULICITY.xml:S3:5879:5	there	EX	O	O
have	TRULICITY.xml:S3:5885:4	have	VBP	O	O
been	TRULICITY.xml:S3:5890:4	been	VBN	O	O
no	TRULICITY.xml:S3:5895:2	no	DT	O	O
clinical	TRULICITY.xml:S3:5898:8	clinic	JJ	O	O
studies	TRULICITY.xml:S3:5907:7	studi	NNS	O	O
establishing	TRULICITY.xml:S3:5915:12	establish	VBG	O	O
conclusive	TRULICITY.xml:S3:5928:10	conclus	JJ	O	O
evidence	TRULICITY.xml:S3:5939:8	evid	NN	O	O
of	TRULICITY.xml:S3:5948:2	of	IN	O	O
macrovascular	TRULICITY.xml:S3:5951:13	macrovascular	JJ	O	O
risk	TRULICITY.xml:S3:5965:4	risk	NN	O	O
reduction	TRULICITY.xml:S3:5970:9	reduct	NN	O	O
with	TRULICITY.xml:S3:5980:4	with	IN	O	O
TRULICITY	TRULICITY.xml:S3:5985:9	trulic	NNP	O	O
or	TRULICITY.xml:S3:5995:2	or	CC	O	O
any	TRULICITY.xml:S3:5998:3	ani	DT	O	O
other	TRULICITY.xml:S3:6002:5	other	JJ	O	O
antidiabetic	TRULICITY.xml:S3:6008:12	antidiabet	JJ	O	O
drug	TRULICITY.xml:S3:6021:4	drug	NN	O	O
.	TRULICITY.xml:S3:6025:1	.	.	O	O
6	TUDORZA.xml:S1:4:1	6	CD	O	O
ADVERSE	TUDORZA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	TUDORZA.xml:S1:14:9	reaction	NN	O	O

The	TUDORZA.xml:S1:27:3	the	DT	O	O
following	TUDORZA.xml:S1:31:9	follow	JJ	O	O
adverse	TUDORZA.xml:S1:41:7	advers	JJ	O	O
reactions	TUDORZA.xml:S1:49:9	reaction	NNS	O	O
are	TUDORZA.xml:S1:59:3	are	VBP	O	O
described	TUDORZA.xml:S1:63:9	describ	VBN	O	O
in	TUDORZA.xml:S1:73:2	in	IN	O	O
greater	TUDORZA.xml:S1:76:7	greater	JJR	O	O
detail	TUDORZA.xml:S1:84:6	detail	NN	O	O
in	TUDORZA.xml:S1:91:2	in	IN	O	O
other	TUDORZA.xml:S1:94:5	other	JJ	O	O
sections	TUDORZA.xml:S1:100:8	section	NNS	O	O
:	TUDORZA.xml:S1:108:1	:	:	O	O

Paradoxical	TUDORZA.xml:S1:119:11	paradox	JJ	B-AdverseReaction	B-AdverseReaction
bronchospasm	TUDORZA.xml:S1:131:12	bronchospasm	NN	I-AdverseReaction	I-AdverseReaction
[	TUDORZA.xml:S1:144:1	[	NNP	O	O
see	TUDORZA.xml:S1:145:3	see	VBP	O	O
Warnings	TUDORZA.xml:S1:149:8	warn	NNP	O	O
and	TUDORZA.xml:S1:158:3	and	CC	O	O
Precautions	TUDORZA.xml:S1:162:11	precaut	NNP	O	O
(	TUDORZA.xml:S1:174:1	(	(	O	O
5.2	TUDORZA.xml:S1:175:3	5.2	CD	O	O
)]	TUDORZA.xml:S1:178:2	)]	NN	O	O

Worsening	TUDORZA.xml:S1:189:9	worsen	VBG	B-AdverseReaction	B-AdverseReaction
of	TUDORZA.xml:S1:199:2	of	IN	I-AdverseReaction	I-AdverseReaction
narrow	TUDORZA.xml:S1:202:6	narrow	JJ	I-AdverseReaction	I-AdverseReaction
-	TUDORZA.xml:S1:208:1	-	:	I-AdverseReaction	I-AdverseReaction
angle	TUDORZA.xml:S1:209:5	angl	NN	I-AdverseReaction	I-AdverseReaction
glaucoma	TUDORZA.xml:S1:215:8	glaucoma	NN	I-AdverseReaction	I-AdverseReaction
[	TUDORZA.xml:S1:224:1	[	NNP	O	O
see	TUDORZA.xml:S1:225:3	see	VBP	O	O
Warnings	TUDORZA.xml:S1:229:8	warn	NNP	O	O
and	TUDORZA.xml:S1:238:3	and	CC	O	O
Precautions	TUDORZA.xml:S1:242:11	precaut	NNP	O	O
(	TUDORZA.xml:S1:254:1	(	(	O	O
5.3	TUDORZA.xml:S1:255:3	5.3	CD	O	O
)]	TUDORZA.xml:S1:258:2	)]	NN	O	O

Worsening	TUDORZA.xml:S1:269:9	worsen	VBG	B-AdverseReaction	B-AdverseReaction
of	TUDORZA.xml:S1:279:2	of	IN	I-AdverseReaction	I-AdverseReaction
urinary	TUDORZA.xml:S1:282:7	urinari	JJ	I-AdverseReaction	I-AdverseReaction
retention	TUDORZA.xml:S1:290:9	retent	NN	I-AdverseReaction	I-AdverseReaction
[	TUDORZA.xml:S1:300:1	[	NNP	O	O
see	TUDORZA.xml:S1:301:3	see	VBP	O	O
Warnings	TUDORZA.xml:S1:305:8	warn	NNP	O	O
and	TUDORZA.xml:S1:314:3	and	CC	O	O
Precautions	TUDORZA.xml:S1:318:11	precaut	NNP	O	O
(	TUDORZA.xml:S1:330:1	(	(	O	O
5.4	TUDORZA.xml:S1:331:3	5.4	CD	O	O
)]	TUDORZA.xml:S1:334:2	)]	NN	O	O

Immediate	TUDORZA.xml:S1:345:9	immedi	NNP	B-AdverseReaction	O
Hypersensitivity	TUDORZA.xml:S1:355:16	hypersensit	NNP	I-AdverseReaction	B-AdverseReaction
Reactions	TUDORZA.xml:S1:372:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	TUDORZA.xml:S1:382:1	[	NNP	O	O
see	TUDORZA.xml:S1:384:3	see	VBP	O	O
Warnings	TUDORZA.xml:S1:388:8	warn	NNP	O	O
and	TUDORZA.xml:S1:397:3	and	CC	O	O
Precautions	TUDORZA.xml:S1:401:11	precaut	NNP	O	O
(	TUDORZA.xml:S1:413:1	(	(	O	O
5.5	TUDORZA.xml:S1:414:3	5.5	CD	O	O
)	TUDORZA.xml:S1:417:1	)	)	O	O
]	TUDORZA.xml:S1:419:1	]	NN	O	O

EXCERPT	TUDORZA.xml:S1:428:7	excerpt	NNS	O	O
:	TUDORZA.xml:S1:435:1	:	:	O	O
Most	TUDORZA.xml:S1:439:4	most	JJS	O	O
common	TUDORZA.xml:S1:444:6	common	JJ	O	O
adverse	TUDORZA.xml:S1:451:7	advers	JJ	O	O
reactions	TUDORZA.xml:S1:459:9	reaction	NNS	O	O
(	TUDORZA.xml:S1:469:1	(	(	O	O
3%	TUDORZA.xml:S1:472:2	3%	CD	O	O
incidence	TUDORZA.xml:S1:475:9	incid	NN	O	O
and	TUDORZA.xml:S1:485:3	and	CC	O	O
greater	TUDORZA.xml:S1:489:7	greater	JJR	O	O
than	TUDORZA.xml:S1:497:4	than	IN	O	O
placebo	TUDORZA.xml:S1:502:7	placebo	NN	O	O
)	TUDORZA.xml:S1:509:1	)	)	O	O
are	TUDORZA.xml:S1:511:3	are	VBP	O	O
headache	TUDORZA.xml:S1:515:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S1:523:1	,	,	O	O
nasopharyngitis	TUDORZA.xml:S1:525:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
and	TUDORZA.xml:S1:541:3	and	CC	O	O
cough	TUDORZA.xml:S1:545:5	cough	NN	B-AdverseReaction	B-AdverseReaction
.	TUDORZA.xml:S1:550:1	.	.	O	O

(	TUDORZA.xml:S1:552:1	(	(	O	O
6.1	TUDORZA.xml:S1:553:3	6.1	CD	O	O
)	TUDORZA.xml:S1:556:1	)	)	O	O

To	TUDORZA.xml:S1:564:2	To	TO	O	O

report	TUDORZA.xml:S1:567:6	report	NN	O	O
SUSPECTED	TUDORZA.xml:S1:574:9	suspect	NNP	O	O
ADVERSE	TUDORZA.xml:S1:584:7	advers	NNP	O	O
REACTIONS	TUDORZA.xml:S1:592:9	reaction	NNP	O	O
,	TUDORZA.xml:S1:601:1	,	,	O	O
Contact	TUDORZA.xml:S1:603:7	contact	NNP	O	O
AstraZeneca	TUDORZA.xml:S1:611:11	astrazeneca	NNP	O	O
at	TUDORZA.xml:S1:623:2	at	IN	O	O
1	TUDORZA.xml:S1:626:1	1	CD	O	O
-	TUDORZA.xml:S1:627:1	-	:	O	O
800	TUDORZA.xml:S1:628:3	800	CD	O	O
-	TUDORZA.xml:S1:631:1	-	:	O	O
236	TUDORZA.xml:S1:632:3	236	CD	O	O
-	TUDORZA.xml:S1:635:1	-	:	O	O
9933	TUDORZA.xml:S1:636:4	9933	CD	O	O
or	TUDORZA.xml:S1:641:2	or	CC	O	O
FDA	TUDORZA.xml:S1:644:3	fda	NNP	O	O
at	TUDORZA.xml:S1:648:2	at	IN	O	O
1	TUDORZA.xml:S1:651:1	1	CD	O	O
-	TUDORZA.xml:S1:652:1	-	:	O	O
800	TUDORZA.xml:S1:653:3	800	CD	O	O
-	TUDORZA.xml:S1:656:1	-	:	O	O
FDA	TUDORZA.xml:S1:657:3	fda	NNP	O	O
-	TUDORZA.xml:S1:660:1	-	:	O	O
1088	TUDORZA.xml:S1:661:4	1088	CD	O	O
or	TUDORZA.xml:S1:666:2	or	CC	O	O
www	TUDORZA.xml:S1:669:3	www	VB	O	O
.	TUDORZA.xml:S1:672:1	.	.	O	O
fda	TUDORZA.xml:S1:673:3	fda	NN	O	O
.	TUDORZA.xml:S1:676:1	.	.	O	O
gov	TUDORZA.xml:S1:677:3	gov	JJ	O	O
medwatch	TUDORZA.xml:S1:681:8	medwatch	NN	O	O
.	TUDORZA.xml:S1:689:1	.	.	O	O

6.1	TUDORZA.xml:S1:701:3	6.1	CD	O	O

Clinical	TUDORZA.xml:S1:705:8	clinic	JJ	O	O
Trials	TUDORZA.xml:S1:714:6	trial	NNS	O	O
Experience	TUDORZA.xml:S1:721:10	experi	NN	O	O

Because	TUDORZA.xml:S1:735:7	becaus	IN	O	O
clinical	TUDORZA.xml:S1:743:8	clinic	JJ	O	O
trials	TUDORZA.xml:S1:752:6	trial	NNS	O	O
are	TUDORZA.xml:S1:759:3	are	VBP	O	O
conducted	TUDORZA.xml:S1:763:9	conduct	VBN	O	O
under	TUDORZA.xml:S1:773:5	under	IN	O	O
widely	TUDORZA.xml:S1:779:6	wide	RB	O	O
varying	TUDORZA.xml:S1:786:7	vari	VBG	O	O
conditions	TUDORZA.xml:S1:794:10	condit	NNS	O	O
,	TUDORZA.xml:S1:804:1	,	,	O	O
adverse	TUDORZA.xml:S1:806:7	advers	JJ	O	O
reaction	TUDORZA.xml:S1:814:8	reaction	NN	O	O
rates	TUDORZA.xml:S1:823:5	rate	NNS	O	O
observed	TUDORZA.xml:S1:829:8	observ	VBD	O	O
in	TUDORZA.xml:S1:838:2	in	IN	O	O
the	TUDORZA.xml:S1:841:3	the	DT	O	O
clinical	TUDORZA.xml:S1:845:8	clinic	JJ	O	O
trials	TUDORZA.xml:S1:854:6	trial	NNS	O	O
of	TUDORZA.xml:S1:861:2	of	IN	O	O
a	TUDORZA.xml:S1:864:1	a	DT	O	O
drug	TUDORZA.xml:S1:866:4	drug	NN	O	O
cannot	TUDORZA.xml:S1:871:6	cannot	NN	O	O
be	TUDORZA.xml:S1:878:2	be	VB	O	O
directly	TUDORZA.xml:S1:881:8	directli	RB	O	O
compared	TUDORZA.xml:S1:890:8	compar	VBN	O	O
to	TUDORZA.xml:S1:899:2	to	TO	O	O
rates	TUDORZA.xml:S1:902:5	rate	NNS	O	O
in	TUDORZA.xml:S1:908:2	in	IN	O	O
the	TUDORZA.xml:S1:911:3	the	DT	O	O
clinical	TUDORZA.xml:S1:915:8	clinic	JJ	O	O
trials	TUDORZA.xml:S1:924:6	trial	NNS	O	O
of	TUDORZA.xml:S1:931:2	of	IN	O	O
another	TUDORZA.xml:S1:934:7	anoth	DT	O	O
drug	TUDORZA.xml:S1:942:4	drug	NN	O	O
and	TUDORZA.xml:S1:947:3	and	CC	O	O
may	TUDORZA.xml:S1:951:3	may	MD	O	O
not	TUDORZA.xml:S1:955:3	not	RB	O	O
reflect	TUDORZA.xml:S1:959:7	reflect	VB	O	O
the	TUDORZA.xml:S1:967:3	the	DT	O	O
rates	TUDORZA.xml:S1:971:5	rate	NNS	O	O
observed	TUDORZA.xml:S1:977:8	observ	VBD	O	O
in	TUDORZA.xml:S1:986:2	in	IN	O	O
practice	TUDORZA.xml:S1:989:8	practic	NN	O	O
.	TUDORZA.xml:S1:997:1	.	.	O	O

3	TUDORZA.xml:S1:1007:1	3	LS	O	O
-	TUDORZA.xml:S1:1008:1	-	:	O	O
Month	TUDORZA.xml:S1:1009:5	month	NN	O	O
and	TUDORZA.xml:S1:1015:3	and	CC	O	O
6	TUDORZA.xml:S1:1019:1	6	CD	O	O
-	TUDORZA.xml:S1:1020:1	-	:	O	O
Month	TUDORZA.xml:S1:1021:5	month	NN	O	O
Trials	TUDORZA.xml:S1:1027:6	trial	NNS	O	O

TUDORZA	TUDORZA.xml:S1:1040:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:1048:8	pressair	NNP	O	O
was	TUDORZA.xml:S1:1057:3	wa	VBD	O	O
studied	TUDORZA.xml:S1:1061:7	studi	VBN	O	O
in	TUDORZA.xml:S1:1069:2	in	IN	O	O
two	TUDORZA.xml:S1:1072:3	two	CD	O	O
3	TUDORZA.xml:S1:1076:1	3	CD	O	O
-	TUDORZA.xml:S1:1077:1	-	:	O	O
month	TUDORZA.xml:S1:1078:5	month	NN	O	O
(	TUDORZA.xml:S1:1084:1	(	(	O	O
Trials	TUDORZA.xml:S1:1085:6	trial	NNP	O	O
B	TUDORZA.xml:S1:1092:1	B	NNP	O	O
and	TUDORZA.xml:S1:1094:3	and	CC	O	O
C	TUDORZA.xml:S1:1098:1	C	NNP	O	O
)	TUDORZA.xml:S1:1099:1	)	)	O	O
and	TUDORZA.xml:S1:1101:3	and	CC	O	O
one	TUDORZA.xml:S1:1105:3	one	CD	O	O
6	TUDORZA.xml:S1:1109:1	6	CD	O	O
-	TUDORZA.xml:S1:1110:1	-	:	O	O
month	TUDORZA.xml:S1:1111:5	month	NN	O	O
(	TUDORZA.xml:S1:1117:1	(	(	O	O
Trial	TUDORZA.xml:S1:1118:5	trial	NNP	O	O
D	TUDORZA.xml:S1:1124:1	D	NNP	O	O
)	TUDORZA.xml:S1:1125:1	)	)	O	O
placebo	TUDORZA.xml:S1:1127:7	placebo	NN	O	O
-	TUDORZA.xml:S1:1134:1	-	:	O	O
controlled	TUDORZA.xml:S1:1135:10	control	VBN	O	O
trials	TUDORZA.xml:S1:1146:6	trial	NNS	O	O
in	TUDORZA.xml:S1:1153:2	in	IN	O	O
patients	TUDORZA.xml:S1:1156:8	patient	NNS	O	O
with	TUDORZA.xml:S1:1165:4	with	IN	O	O
COPD	TUDORZA.xml:S1:1170:4	copd	NNP	O	O
.	TUDORZA.xml:S1:1174:1	.	.	O	O

In	TUDORZA.xml:S1:1176:2	In	IN	O	O
these	TUDORZA.xml:S1:1179:5	these	DT	O	O
trials	TUDORZA.xml:S1:1185:6	trial	NNS	O	O
,	TUDORZA.xml:S1:1191:1	,	,	O	O
636	TUDORZA.xml:S1:1193:3	636	CD	O	O
patients	TUDORZA.xml:S1:1197:8	patient	NNS	O	O
were	TUDORZA.xml:S1:1206:4	were	VBD	O	O
treated	TUDORZA.xml:S1:1211:7	treat	VBN	O	O
with	TUDORZA.xml:S1:1219:4	with	IN	O	O
TUDORZA	TUDORZA.xml:S1:1224:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:1232:8	pressair	NNP	O	O
at	TUDORZA.xml:S1:1241:2	at	IN	O	O
the	TUDORZA.xml:S1:1244:3	the	DT	O	O
recommended	TUDORZA.xml:S1:1248:11	recommend	JJ	O	O
dose	TUDORZA.xml:S1:1260:4	dose	NN	O	O
of	TUDORZA.xml:S1:1265:2	of	IN	O	O
400	TUDORZA.xml:S1:1268:3	400	CD	O	O
mcg	TUDORZA.xml:S1:1272:3	mcg	JJ	O	O
twice	TUDORZA.xml:S1:1276:5	twice	RB	O	O
daily	TUDORZA.xml:S1:1282:5	daili	RB	O	O
.	TUDORZA.xml:S1:1287:1	.	.	O	O

The	TUDORZA.xml:S1:1293:3	the	DT	O	O
population	TUDORZA.xml:S1:1297:10	popul	NN	O	O
had	TUDORZA.xml:S1:1308:3	had	VBD	O	O
a	TUDORZA.xml:S1:1312:1	a	DT	O	O
mean	TUDORZA.xml:S1:1314:4	mean	JJ	O	O
age	TUDORZA.xml:S1:1319:3	age	NN	O	O
of	TUDORZA.xml:S1:1323:2	of	IN	O	O
64	TUDORZA.xml:S1:1326:2	64	CD	O	O
years	TUDORZA.xml:S1:1329:5	year	NNS	O	O
(	TUDORZA.xml:S1:1335:1	(	(	O	O
ranging	TUDORZA.xml:S1:1336:7	rang	VBG	O	O
from	TUDORZA.xml:S1:1344:4	from	IN	O	O
40	TUDORZA.xml:S1:1349:2	40	CD	O	O
to	TUDORZA.xml:S1:1352:2	to	TO	O	O
89	TUDORZA.xml:S1:1355:2	89	CD	O	O
years	TUDORZA.xml:S1:1358:5	year	NNS	O	O
)	TUDORZA.xml:S1:1363:1	)	)	O	O
,	TUDORZA.xml:S1:1364:1	,	,	O	O
with	TUDORZA.xml:S1:1366:4	with	IN	O	O
58%	TUDORZA.xml:S1:1371:3	58%	CD	O	O
males	TUDORZA.xml:S1:1375:5	male	NNS	O	O
,	TUDORZA.xml:S1:1380:1	,	,	O	O
94%	TUDORZA.xml:S1:1382:3	94%	CD	O	O
Caucasian	TUDORZA.xml:S1:1386:9	caucasian	JJ	O	O
,	TUDORZA.xml:S1:1395:1	,	,	O	O
and	TUDORZA.xml:S1:1397:3	and	CC	O	O
had	TUDORZA.xml:S1:1401:3	had	VBD	O	O
COPD	TUDORZA.xml:S1:1405:4	copd	NNP	O	O
with	TUDORZA.xml:S1:1410:4	with	IN	O	O
a	TUDORZA.xml:S1:1415:1	a	DT	O	O
mean	TUDORZA.xml:S1:1417:4	mean	JJ	O	O
pre	TUDORZA.xml:S1:1422:3	pre	NN	O	O
-	TUDORZA.xml:S1:1425:1	-	:	O	O
bronchodilator	TUDORZA.xml:S1:1426:14	bronchodil	NN	O	O
forced	TUDORZA.xml:S1:1441:6	forc	VBD	O	O
expiratory	TUDORZA.xml:S1:1448:10	expiratori	JJ	O	O
volume	TUDORZA.xml:S1:1459:6	volum	NN	O	O
in	TUDORZA.xml:S1:1466:2	in	IN	O	O
one	TUDORZA.xml:S1:1469:3	one	CD	O	O
second	TUDORZA.xml:S1:1473:6	second	NN	O	O
(	TUDORZA.xml:S1:1480:1	(	(	O	O
FEV1	TUDORZA.xml:S1:1481:4	fev1	NNP	O	O
)	TUDORZA.xml:S1:1485:1	)	)	O	O
percent	TUDORZA.xml:S1:1487:7	percent	NN	O	O
predicted	TUDORZA.xml:S1:1495:9	predict	VBD	O	O
of	TUDORZA.xml:S1:1505:2	of	IN	O	O
48%	TUDORZA.xml:S1:1508:3	48%	CD	O	O
.	TUDORZA.xml:S1:1511:1	.	.	O	O

Patients	TUDORZA.xml:S1:1513:8	patient	NNS	O	O
with	TUDORZA.xml:S1:1522:4	with	IN	O	O
unstable	TUDORZA.xml:S1:1527:8	unstabl	JJ	O	O
cardiac	TUDORZA.xml:S1:1536:7	cardiac	JJ	O	O
disease	TUDORZA.xml:S1:1544:7	diseas	NN	O	O
,	TUDORZA.xml:S1:1551:1	,	,	O	O
narrow	TUDORZA.xml:S1:1553:6	narrow	JJ	O	O
-	TUDORZA.xml:S1:1559:1	-	:	O	O
angle	TUDORZA.xml:S1:1560:5	angl	NN	O	O
glaucoma	TUDORZA.xml:S1:1566:8	glaucoma	NN	O	O
,	TUDORZA.xml:S1:1574:1	,	,	O	O
or	TUDORZA.xml:S1:1576:2	or	CC	O	O
symptomatic	TUDORZA.xml:S1:1579:11	symptomat	JJ	O	O
prostatic	TUDORZA.xml:S1:1591:9	prostat	JJ	O	O
hypertrophy	TUDORZA.xml:S1:1601:11	hypertrophi	NN	O	O
or	TUDORZA.xml:S1:1613:2	or	CC	O	O
bladder	TUDORZA.xml:S1:1616:7	bladder	NN	O	O
outlet	TUDORZA.xml:S1:1624:6	outlet	NN	O	O
obstruction	TUDORZA.xml:S1:1631:11	obstruct	NN	O	O
were	TUDORZA.xml:S1:1643:4	were	VBD	O	O
excluded	TUDORZA.xml:S1:1648:8	exclud	VBN	O	O
from	TUDORZA.xml:S1:1657:4	from	IN	O	O
these	TUDORZA.xml:S1:1662:5	these	DT	O	O
trials	TUDORZA.xml:S1:1668:6	trial	NNS	O	O
.	TUDORZA.xml:S1:1674:1	.	.	O	O

Table	TUDORZA.xml:S1:1680:5	tabl	JJ	O	O
1	TUDORZA.xml:S1:1686:1	1	CD	O	O
shows	TUDORZA.xml:S1:1687:5	show	VBZ	O	O
all	TUDORZA.xml:S1:1693:3	all	DT	O	O
adverse	TUDORZA.xml:S1:1697:7	advers	JJ	O	O
reactions	TUDORZA.xml:S1:1705:9	reaction	NNS	O	O
that	TUDORZA.xml:S1:1715:4	that	WDT	O	O
occurred	TUDORZA.xml:S1:1720:8	occur	VBD	O	O
with	TUDORZA.xml:S1:1729:4	with	IN	O	O
a	TUDORZA.xml:S1:1734:1	a	DT	O	O
frequency	TUDORZA.xml:S1:1736:9	frequenc	NN	O	O
of	TUDORZA.xml:S1:1746:2	of	IN	O	O
greater	TUDORZA.xml:S1:1749:7	greater	JJR	O	O
than	TUDORZA.xml:S1:1757:4	than	IN	O	O
or	TUDORZA.xml:S1:1762:2	or	CC	O	O
equal	TUDORZA.xml:S1:1765:5	equal	JJ	O	O
to	TUDORZA.xml:S1:1771:2	to	TO	O	O
1%	TUDORZA.xml:S1:1774:2	1%	CD	O	O
in	TUDORZA.xml:S1:1777:2	in	IN	O	O
the	TUDORZA.xml:S1:1780:3	the	DT	O	O
TUDORZA	TUDORZA.xml:S1:1784:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:1792:8	pressair	NNP	O	O
group	TUDORZA.xml:S1:1801:5	group	NN	O	O
in	TUDORZA.xml:S1:1807:2	in	IN	O	O
the	TUDORZA.xml:S1:1810:3	the	DT	O	O
two	TUDORZA.xml:S1:1814:3	two	CD	O	O
3	TUDORZA.xml:S1:1818:1	3	CD	O	O
-	TUDORZA.xml:S1:1819:1	-	:	O	O
month	TUDORZA.xml:S1:1820:5	month	NN	O	O
and	TUDORZA.xml:S1:1826:3	and	CC	O	O
one	TUDORZA.xml:S1:1830:3	one	CD	O	O
6	TUDORZA.xml:S1:1834:1	6	CD	O	O
-	TUDORZA.xml:S1:1835:1	-	:	O	O
month	TUDORZA.xml:S1:1836:5	month	NN	O	O
placebo	TUDORZA.xml:S1:1842:7	placebo	SYM	O	O
-	TUDORZA.xml:S1:1849:1	-	:	O	O
controlled	TUDORZA.xml:S1:1850:10	control	VBN	O	O
trials	TUDORZA.xml:S1:1861:6	trial	NNS	O	O
where	TUDORZA.xml:S1:1868:5	where	WRB	O	O
the	TUDORZA.xml:S1:1874:3	the	DT	O	O
rates	TUDORZA.xml:S1:1878:5	rate	NNS	O	O
in	TUDORZA.xml:S1:1884:2	in	IN	O	O
the	TUDORZA.xml:S1:1887:3	the	DT	O	O
TUDORZA	TUDORZA.xml:S1:1891:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:1899:8	pressair	NNP	O	O
group	TUDORZA.xml:S1:1908:5	group	NN	O	O
exceeded	TUDORZA.xml:S1:1914:8	exceed	VBD	O	O
placebo	TUDORZA.xml:S1:1923:7	placebo	NN	O	O
.	TUDORZA.xml:S1:1930:1	.	.	O	O

Table	TUDORZA.xml:S1:1936:5	tabl	JJ	O	O
1	TUDORZA.xml:S1:1942:1	1	CD	O	O
:	TUDORZA.xml:S1:1943:1	:	:	O	O
Adverse	TUDORZA.xml:S1:1945:7	advers	JJ	O	O
Reactions	TUDORZA.xml:S1:1953:9	reaction	NNP	O	O
(	TUDORZA.xml:S1:1963:1	(	(	O	O
Patients	TUDORZA.xml:S1:1966:8	patient	NNPS	O	O
)	TUDORZA.xml:S1:1974:1	)	)	O	O
in	TUDORZA.xml:S1:1976:2	in	IN	O	O
Placebo	TUDORZA.xml:S1:1979:7	placebo	NNP	O	O
-	TUDORZA.xml:S1:1986:1	-	:	O	O
Controlled	TUDORZA.xml:S1:1987:10	control	VBD	O	O
Clinical	TUDORZA.xml:S1:1998:8	clinic	JJ	O	O
Trials	TUDORZA.xml:S1:2007:6	trial	NNS	O	O

Treatment	TUDORZA.xml:S1:2055:9	treatment	NN	O	O

Adverse	TUDORZA.xml:S1:2106:7	advers	JJ	O	O
Reactions	TUDORZA.xml:S1:2114:9	reaction	NNP	O	O
TUDORZA	TUDORZA.xml:S1:2144:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:2152:8	pressair	NNP	O	O
Placebo	TUDORZA.xml:S1:2192:7	placebo	NNP	O	O

Preferred	TUDORZA.xml:S1:2215:9	prefer	JJ	O	O
Term	TUDORZA.xml:S1:2225:4	term	NNP	O	O
(	TUDORZA.xml:S1:2253:1	(	(	O	O
N	TUDORZA.xml:S1:2254:1	N	NNP	O	O
636	TUDORZA.xml:S1:2256:3	636	CD	O	O
)	TUDORZA.xml:S1:2259:1	)	)	O	O
(	TUDORZA.xml:S1:2301:1	(	(	O	O
N	TUDORZA.xml:S1:2302:1	N	NNP	O	O
640	TUDORZA.xml:S1:2304:3	640	CD	O	O
)	TUDORZA.xml:S1:2307:1	)	)	O	O

n	TUDORZA.xml:S1:2362:1	n	RB	O	O
(	TUDORZA.xml:S1:2364:1	(	(	O	O
)	TUDORZA.xml:S1:2366:1	)	)	O	O
n	TUDORZA.xml:S1:2410:1	n	FW	O	O
(	TUDORZA.xml:S1:2412:1	(	(	O	O
)	TUDORZA.xml:S1:2414:1	)	)	O	O

Headache	TUDORZA.xml:S1:2433:8	headach	$	B-AdverseReaction	B-AdverseReaction
42	TUDORZA.xml:S1:2471:2	42	CD	O	O
(	TUDORZA.xml:S1:2474:1	(	(	O	O
6.6	TUDORZA.xml:S1:2475:3	6.6	CD	O	O
)	TUDORZA.xml:S1:2478:1	)	)	O	O
32	TUDORZA.xml:S1:2519:2	32	CD	O	O
(	TUDORZA.xml:S1:2522:1	(	(	O	O
5.0	TUDORZA.xml:S1:2523:3	5.0	CD	O	O
)	TUDORZA.xml:S1:2526:1	)	)	O	O

Nasopharyngitis	TUDORZA.xml:S1:2542:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
35	TUDORZA.xml:S1:2580:2	35	CD	O	O
(	TUDORZA.xml:S1:2583:1	(	(	O	O
5.5	TUDORZA.xml:S1:2584:3	5.5	CD	O	O
)	TUDORZA.xml:S1:2587:1	)	)	O	O
25	TUDORZA.xml:S1:2628:2	25	CD	O	O
(	TUDORZA.xml:S1:2631:1	(	(	O	O
3.9	TUDORZA.xml:S1:2632:3	3.9	CD	O	O
)	TUDORZA.xml:S1:2635:1	)	)	O	O

Cough	TUDORZA.xml:S1:2651:5	cough	IN	B-AdverseReaction	B-AdverseReaction
19	TUDORZA.xml:S1:2689:2	19	CD	O	O
(	TUDORZA.xml:S1:2692:1	(	(	O	O
3.0	TUDORZA.xml:S1:2693:3	3.0	CD	O	O
)	TUDORZA.xml:S1:2696:1	)	)	O	O
14	TUDORZA.xml:S1:2737:2	14	CD	O	O
(	TUDORZA.xml:S1:2740:1	(	(	O	O
2.2	TUDORZA.xml:S1:2741:3	2.2	CD	O	O
)	TUDORZA.xml:S1:2744:1	)	)	O	O

Diarrhea	TUDORZA.xml:S1:2760:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
17	TUDORZA.xml:S1:2798:2	17	CD	O	O
(	TUDORZA.xml:S1:2801:1	(	(	O	O
2.7	TUDORZA.xml:S1:2802:3	2.7	CD	O	O
)	TUDORZA.xml:S1:2805:1	)	)	O	O
9	TUDORZA.xml:S1:2846:1	9	CD	O	O
(	TUDORZA.xml:S1:2848:1	(	(	O	O
1.4	TUDORZA.xml:S1:2849:3	1.4	CD	O	O
)	TUDORZA.xml:S1:2852:1	)	)	O	O

Sinusitis	TUDORZA.xml:S1:2869:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
11	TUDORZA.xml:S1:2907:2	11	CD	O	O
(	TUDORZA.xml:S1:2910:1	(	(	O	O
1.7	TUDORZA.xml:S1:2911:3	1.7	CD	O	O
)	TUDORZA.xml:S1:2914:1	)	)	O	O
5	TUDORZA.xml:S1:2955:1	5	CD	O	O
(	TUDORZA.xml:S1:2957:1	(	(	O	O
0.8	TUDORZA.xml:S1:2958:3	0.8	CD	O	O
)	TUDORZA.xml:S1:2961:1	)	)	O	O

Rhinitis	TUDORZA.xml:S1:2978:8	rhiniti	NN	B-AdverseReaction	B-AdverseReaction
10	TUDORZA.xml:S1:3016:2	10	CD	O	O
(	TUDORZA.xml:S1:3019:1	(	(	O	O
1.6	TUDORZA.xml:S1:3020:3	1.6	CD	O	O
)	TUDORZA.xml:S1:3023:1	)	)	O	O
8	TUDORZA.xml:S1:3064:1	8	CD	O	O
(	TUDORZA.xml:S1:3066:1	(	(	O	O
1.2	TUDORZA.xml:S1:3067:3	1.2	CD	O	O
)	TUDORZA.xml:S1:3070:1	)	)	O	O

Toothache	TUDORZA.xml:S1:3087:9	toothach	NN	B-AdverseReaction	B-AdverseReaction
7	TUDORZA.xml:S1:3125:1	7	CD	O	O
(	TUDORZA.xml:S1:3127:1	(	(	O	O
1.1	TUDORZA.xml:S1:3128:3	1.1	CD	O	O
)	TUDORZA.xml:S1:3131:1	)	)	O	O
5	TUDORZA.xml:S1:3173:1	5	CD	O	O
(	TUDORZA.xml:S1:3175:1	(	(	O	O
0.8	TUDORZA.xml:S1:3176:3	0.8	CD	O	O
)	TUDORZA.xml:S1:3179:1	)	)	O	O

Fall	TUDORZA.xml:S1:3196:4	fall	NN	B-AdverseReaction	B-AdverseReaction
7	TUDORZA.xml:S1:3234:1	7	CD	O	O
(	TUDORZA.xml:S1:3236:1	(	(	O	O
1.1	TUDORZA.xml:S1:3237:3	1.1	CD	O	O
)	TUDORZA.xml:S1:3240:1	)	)	O	O
3	TUDORZA.xml:S1:3282:1	3	CD	O	O
(	TUDORZA.xml:S1:3284:1	(	(	O	O
0.5	TUDORZA.xml:S1:3285:3	0.5	CD	O	O
)	TUDORZA.xml:S1:3288:1	)	)	O	O

Vomiting	TUDORZA.xml:S1:3305:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
7	TUDORZA.xml:S1:3343:1	7	CD	O	O
(	TUDORZA.xml:S1:3345:1	(	(	O	O
1.1	TUDORZA.xml:S1:3346:3	1.1	CD	O	O
)	TUDORZA.xml:S1:3349:1	)	)	O	O
3	TUDORZA.xml:S1:3391:1	3	CD	O	O
(	TUDORZA.xml:S1:3393:1	(	(	O	O
0.5	TUDORZA.xml:S1:3394:3	0.5	CD	O	O
)	TUDORZA.xml:S1:3397:1	)	)	O	O

In	TUDORZA.xml:S1:3421:2	In	IN	O	O
addition	TUDORZA.xml:S1:3424:8	addit	NN	O	O
,	TUDORZA.xml:S1:3432:1	,	,	O	O
among	TUDORZA.xml:S1:3434:5	among	IN	O	O
the	TUDORZA.xml:S1:3440:3	the	DT	O	O
adverse	TUDORZA.xml:S1:3444:7	advers	JJ	O	O
reactions	TUDORZA.xml:S1:3452:9	reaction	NNS	O	O
observed	TUDORZA.xml:S1:3462:8	observ	VBN	O	O
in	TUDORZA.xml:S1:3471:2	in	IN	O	O
the	TUDORZA.xml:S1:3474:3	the	DT	O	O
clinical	TUDORZA.xml:S1:3478:8	clinic	JJ	O	O
trials	TUDORZA.xml:S1:3487:6	trial	NNS	O	O
with	TUDORZA.xml:S1:3494:4	with	IN	O	O
an	TUDORZA.xml:S1:3499:2	an	DT	O	O
incidence	TUDORZA.xml:S1:3502:9	incid	NN	O	O
of	TUDORZA.xml:S1:3512:2	of	IN	O	O
less	TUDORZA.xml:S1:3515:4	less	JJR	O	O
than	TUDORZA.xml:S1:3520:4	than	IN	O	O
1%	TUDORZA.xml:S1:3525:2	1%	CD	O	O
were	TUDORZA.xml:S1:3528:4	were	VBD	O	O
diabetes	TUDORZA.xml:S1:3533:8	diabet	NNS	B-AdverseReaction	B-AdverseReaction
mellitus	TUDORZA.xml:S1:3542:8	mellitu	NNS	I-AdverseReaction	I-AdverseReaction
,	TUDORZA.xml:S1:3550:1	,	,	O	O
dry	TUDORZA.xml:S1:3552:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	TUDORZA.xml:S1:3556:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
,	TUDORZA.xml:S1:3561:1	,	,	O	O
1	TUDORZA.xml:S1:3563:1	1	CD	O	B-AdverseReaction
st	TUDORZA.xml:S1:3564:2	st	NN	O	I-AdverseReaction
degree	TUDORZA.xml:S1:3567:6	degre	NN	O	I-AdverseReaction
AV	TUDORZA.xml:S1:3574:2	AV	NNP	B-AdverseReaction	I-AdverseReaction
block	TUDORZA.xml:S1:3577:5	block	NN	I-AdverseReaction	I-AdverseReaction
,	TUDORZA.xml:S1:3582:1	,	,	O	O
osteoarthritis	TUDORZA.xml:S1:3584:14	osteoarthr	NN	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S1:3598:1	,	,	O	O
cardiac	TUDORZA.xml:S1:3600:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
failure	TUDORZA.xml:S1:3608:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	TUDORZA.xml:S1:3615:1	,	,	O	O
and	TUDORZA.xml:S1:3617:3	and	CC	O	O
cardio	TUDORZA.xml:S1:3621:6	cardio	SYM	B-AdverseReaction	B-AdverseReaction
-	TUDORZA.xml:S1:3627:1	-	:	I-AdverseReaction	I-AdverseReaction
respiratory	TUDORZA.xml:S1:3628:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
arrest	TUDORZA.xml:S1:3640:6	arrest	NN	I-AdverseReaction	I-AdverseReaction
.	TUDORZA.xml:S1:3646:1	.	.	O	O

Long	TUDORZA.xml:S1:3658:4	long	RB	O	O

-	TUDORZA.xml:S1:3662:1	-	:	O	O
term	TUDORZA.xml:S1:3663:4	term	NN	O	O
Safety	TUDORZA.xml:S1:3668:6	safeti	NNP	O	O
Trials	TUDORZA.xml:S1:3675:6	trial	NNP	O	O

TUDORZA	TUDORZA.xml:S1:3690:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:3698:8	pressair	NNP	O	O
was	TUDORZA.xml:S1:3707:3	wa	VBD	O	O
studied	TUDORZA.xml:S1:3711:7	studi	VBN	O	O
in	TUDORZA.xml:S1:3719:2	in	IN	O	O
three	TUDORZA.xml:S1:3722:5	three	CD	O	O
long	TUDORZA.xml:S1:3728:4	long	JJ	O	O
term	TUDORZA.xml:S1:3733:4	term	NN	O	O
safety	TUDORZA.xml:S1:3738:6	safeti	NN	O	O
trials	TUDORZA.xml:S1:3745:6	trial	NNS	O	O
,	TUDORZA.xml:S1:3751:1	,	,	O	O
two	TUDORZA.xml:S1:3753:3	two	CD	O	O
double	TUDORZA.xml:S1:3757:6	doubl	JJ	O	O
blind	TUDORZA.xml:S1:3764:5	blind	NN	O	O
and	TUDORZA.xml:S1:3770:3	and	CC	O	O
one	TUDORZA.xml:S1:3774:3	one	CD	O	O
open	TUDORZA.xml:S1:3778:4	open	JJ	O	O
label	TUDORZA.xml:S1:3783:5	label	NN	O	O
,	TUDORZA.xml:S1:3788:1	,	,	O	O
ranging	TUDORZA.xml:S1:3790:7	rang	VBG	O	O
from	TUDORZA.xml:S1:3798:4	from	IN	O	O
40	TUDORZA.xml:S1:3803:2	40	CD	O	O
to	TUDORZA.xml:S1:3806:2	to	TO	O	O
52	TUDORZA.xml:S1:3809:2	52	CD	O	O
weeks	TUDORZA.xml:S1:3812:5	week	NNS	O	O
in	TUDORZA.xml:S1:3818:2	in	IN	O	O
patients	TUDORZA.xml:S1:3821:8	patient	NNS	O	O
with	TUDORZA.xml:S1:3830:4	with	IN	O	O
moderate	TUDORZA.xml:S1:3835:8	moder	JJ	O	O
to	TUDORZA.xml:S1:3844:2	to	TO	O	O
severe	TUDORZA.xml:S1:3847:6	sever	VB	O	O
COPD	TUDORZA.xml:S1:3854:4	copd	NNP	O	O
.	TUDORZA.xml:S1:3858:1	.	.	O	O

Two	TUDORZA.xml:S1:3860:3	two	CD	O	O
of	TUDORZA.xml:S1:3864:2	of	IN	O	O
these	TUDORZA.xml:S1:3867:5	these	DT	O	O
trials	TUDORZA.xml:S1:3873:6	trial	NNS	O	O
were	TUDORZA.xml:S1:3880:4	were	VBD	O	O
extensions	TUDORZA.xml:S1:3885:10	extens	NNS	O	O
of	TUDORZA.xml:S1:3896:2	of	IN	O	O
the	TUDORZA.xml:S1:3899:3	the	DT	O	O
3	TUDORZA.xml:S1:3903:1	3	CD	O	O
-	TUDORZA.xml:S1:3904:1	-	:	O	O
month	TUDORZA.xml:S1:3905:5	month	NN	O	O
trials	TUDORZA.xml:S1:3911:6	trial	NNS	O	O
,	TUDORZA.xml:S1:3917:1	,	,	O	O
and	TUDORZA.xml:S1:3919:3	and	CC	O	O
one	TUDORZA.xml:S1:3923:3	one	CD	O	O
was	TUDORZA.xml:S1:3927:3	wa	VBD	O	O
a	TUDORZA.xml:S1:3931:1	a	DT	O	O
dedicated	TUDORZA.xml:S1:3933:9	dedic	VBN	O	O
long	TUDORZA.xml:S1:3943:4	long	JJ	O	O
term	TUDORZA.xml:S1:3948:4	term	NN	O	O
safety	TUDORZA.xml:S1:3953:6	safeti	NN	O	O
trial	TUDORZA.xml:S1:3960:5	trial	NN	O	O
.	TUDORZA.xml:S1:3965:1	.	.	O	O

In	TUDORZA.xml:S1:3967:2	In	IN	O	O
these	TUDORZA.xml:S1:3970:5	these	DT	O	O
trials	TUDORZA.xml:S1:3976:6	trial	NNS	O	O
,	TUDORZA.xml:S1:3982:1	,	,	O	O
891	TUDORZA.xml:S1:3984:3	891	CD	O	O
patients	TUDORZA.xml:S1:3988:8	patient	NNS	O	O
were	TUDORZA.xml:S1:3997:4	were	VBD	O	O
treated	TUDORZA.xml:S1:4002:7	treat	VBN	O	O
with	TUDORZA.xml:S1:4010:4	with	IN	O	O
TUDORZA	TUDORZA.xml:S1:4015:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:4023:8	pressair	NNP	O	O
at	TUDORZA.xml:S1:4032:2	at	IN	O	O
the	TUDORZA.xml:S1:4035:3	the	DT	O	O
recommended	TUDORZA.xml:S1:4039:11	recommend	JJ	O	O
dose	TUDORZA.xml:S1:4051:4	dose	NN	O	O
of	TUDORZA.xml:S1:4056:2	of	IN	O	O
400	TUDORZA.xml:S1:4059:3	400	CD	O	O
mcg	TUDORZA.xml:S1:4063:3	mcg	JJ	O	O
twice	TUDORZA.xml:S1:4067:5	twice	RB	O	O
daily	TUDORZA.xml:S1:4073:5	daili	RB	O	O
.	TUDORZA.xml:S1:4078:1	.	.	O	O

The	TUDORZA.xml:S1:4080:3	the	DT	O	O
demographic	TUDORZA.xml:S1:4084:11	demograph	JJ	O	O
and	TUDORZA.xml:S1:4096:3	and	CC	O	O
baseline	TUDORZA.xml:S1:4100:8	baselin	JJ	O	O
characteristics	TUDORZA.xml:S1:4109:15	characterist	NNS	O	O
of	TUDORZA.xml:S1:4125:2	of	IN	O	O
the	TUDORZA.xml:S1:4128:3	the	DT	O	O
long	TUDORZA.xml:S1:4132:4	long	JJ	O	O
term	TUDORZA.xml:S1:4137:4	term	NN	O	O
safety	TUDORZA.xml:S1:4142:6	safeti	NN	O	O
trials	TUDORZA.xml:S1:4149:6	trial	NNS	O	O
were	TUDORZA.xml:S1:4156:4	were	VBD	O	O
similar	TUDORZA.xml:S1:4161:7	similar	JJ	O	O
to	TUDORZA.xml:S1:4169:2	to	TO	O	O
those	TUDORZA.xml:S1:4172:5	those	DT	O	O
of	TUDORZA.xml:S1:4178:2	of	IN	O	O
the	TUDORZA.xml:S1:4181:3	the	DT	O	O
placebo	TUDORZA.xml:S1:4185:7	placebo	NN	O	O
-	TUDORZA.xml:S1:4192:1	-	:	O	O
controlled	TUDORZA.xml:S1:4193:10	control	VBN	O	O
trials	TUDORZA.xml:S1:4204:6	trial	NNS	O	O
.	TUDORZA.xml:S1:4210:1	.	.	O	O

The	TUDORZA.xml:S1:4212:3	the	DT	O	O
adverse	TUDORZA.xml:S1:4216:7	advers	JJ	O	O
events	TUDORZA.xml:S1:4224:6	event	NNS	O	O
reported	TUDORZA.xml:S1:4231:8	report	VBN	O	O
in	TUDORZA.xml:S1:4240:2	in	IN	O	O
the	TUDORZA.xml:S1:4243:3	the	DT	O	O
long	TUDORZA.xml:S1:4247:4	long	JJ	O	O
term	TUDORZA.xml:S1:4252:4	term	NN	O	O
safety	TUDORZA.xml:S1:4257:6	safeti	NN	O	O
trials	TUDORZA.xml:S1:4264:6	trial	NNS	O	O
were	TUDORZA.xml:S1:4271:4	were	VBD	O	O
similar	TUDORZA.xml:S1:4276:7	similar	JJ	O	O
to	TUDORZA.xml:S1:4284:2	to	TO	O	O
those	TUDORZA.xml:S1:4287:5	those	DT	O	O
occurring	TUDORZA.xml:S1:4293:9	occur	VBG	O	O
in	TUDORZA.xml:S1:4303:2	in	IN	O	O
the	TUDORZA.xml:S1:4306:3	the	DT	O	O
placebo	TUDORZA.xml:S1:4310:7	placebo	NN	O	O
-	TUDORZA.xml:S1:4317:1	-	:	O	O
controlled	TUDORZA.xml:S1:4318:10	control	VBN	O	O
trials	TUDORZA.xml:S1:4329:6	trial	NNS	O	O
of	TUDORZA.xml:S1:4336:2	of	IN	O	O
3	TUDORZA.xml:S1:4339:1	3	CD	O	O
to	TUDORZA.xml:S1:4341:2	to	TO	O	O
6	TUDORZA.xml:S1:4344:1	6	CD	O	O
months	TUDORZA.xml:S1:4346:6	month	NNS	O	O
.	TUDORZA.xml:S1:4352:1	.	.	O	O

No	TUDORZA.xml:S1:4354:2	No	DT	O	O
new	TUDORZA.xml:S1:4357:3	new	JJ	O	O
safety	TUDORZA.xml:S1:4361:6	safeti	NN	O	O
findings	TUDORZA.xml:S1:4368:8	find	NNS	O	O
were	TUDORZA.xml:S1:4377:4	were	VBD	O	O
reported	TUDORZA.xml:S1:4382:8	report	VBN	O	O
compared	TUDORZA.xml:S1:4391:8	compar	VBN	O	O
to	TUDORZA.xml:S1:4400:2	to	TO	O	O
the	TUDORZA.xml:S1:4403:3	the	DT	O	O
placebo	TUDORZA.xml:S1:4407:7	placebo	NN	O	O
controlled	TUDORZA.xml:S1:4415:10	control	VBD	O	O
trials	TUDORZA.xml:S1:4426:6	trial	NNS	O	O
.	TUDORZA.xml:S1:4432:1	.	.	O	O

6.2	TUDORZA.xml:S1:4440:3	6.2	CD	O	O
Postmarketing	TUDORZA.xml:S1:4444:13	postmarket	VBG	O	O
Experience	TUDORZA.xml:S1:4458:10	experi	NN	O	O

The	TUDORZA.xml:S1:4472:3	the	DT	O	O
following	TUDORZA.xml:S1:4476:9	follow	JJ	O	O
adverse	TUDORZA.xml:S1:4486:7	advers	JJ	O	O
reactions	TUDORZA.xml:S1:4494:9	reaction	NNS	O	O
have	TUDORZA.xml:S1:4504:4	have	VBP	O	O
been	TUDORZA.xml:S1:4509:4	been	VBN	O	O
identified	TUDORZA.xml:S1:4514:10	identifi	VBN	O	O
during	TUDORZA.xml:S1:4525:6	dure	IN	O	O
postapproval	TUDORZA.xml:S1:4532:12	postapprov	JJ	O	O
use	TUDORZA.xml:S1:4545:3	use	NN	O	O
of	TUDORZA.xml:S1:4549:2	of	IN	O	O
drug	TUDORZA.xml:S1:4552:4	drug	NN	O	O
TUDORZA	TUDORZA.xml:S1:4557:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:4565:8	pressair	NNP	O	O
.	TUDORZA.xml:S1:4573:1	.	.	O	O

Because	TUDORZA.xml:S1:4575:7	becaus	IN	O	O
these	TUDORZA.xml:S1:4583:5	these	DT	O	O
reactions	TUDORZA.xml:S1:4589:9	reaction	NNS	O	O
are	TUDORZA.xml:S1:4599:3	are	VBP	O	O
reported	TUDORZA.xml:S1:4603:8	report	VBN	O	O
voluntarily	TUDORZA.xml:S1:4612:11	voluntarili	RB	O	O
from	TUDORZA.xml:S1:4624:4	from	IN	O	O
a	TUDORZA.xml:S1:4629:1	a	DT	O	O
population	TUDORZA.xml:S1:4631:10	popul	NN	O	O
of	TUDORZA.xml:S1:4642:2	of	IN	O	O
uncertain	TUDORZA.xml:S1:4645:9	uncertain	JJ	O	O
size	TUDORZA.xml:S1:4655:4	size	NN	O	O
,	TUDORZA.xml:S1:4659:1	,	,	O	O
it	TUDORZA.xml:S1:4661:2	it	PRP	O	O
is	TUDORZA.xml:S1:4664:2	is	VBZ	O	O
not	TUDORZA.xml:S1:4667:3	not	RB	O	O
always	TUDORZA.xml:S1:4671:6	alway	RB	O	O
possible	TUDORZA.xml:S1:4678:8	possibl	JJ	O	O
to	TUDORZA.xml:S1:4687:2	to	TO	O	O
reliably	TUDORZA.xml:S1:4690:8	reliabl	VB	O	O
estimate	TUDORZA.xml:S1:4699:8	estim	VB	O	O
their	TUDORZA.xml:S1:4708:5	their	PRP$	O	O
frequency	TUDORZA.xml:S1:4714:9	frequenc	NN	O	O
or	TUDORZA.xml:S1:4724:2	or	CC	O	O
establish	TUDORZA.xml:S1:4727:9	establish	VB	O	O
a	TUDORZA.xml:S1:4737:1	a	DT	O	O
causal	TUDORZA.xml:S1:4739:6	causal	NN	O	O
relationship	TUDORZA.xml:S1:4746:12	relationship	NN	O	O
to	TUDORZA.xml:S1:4759:2	to	TO	O	O
drug	TUDORZA.xml:S1:4762:4	drug	NN	O	O
exposure	TUDORZA.xml:S1:4767:8	exposur	NN	O	O
.	TUDORZA.xml:S1:4775:1	.	.	O	O

In	TUDORZA.xml:S1:4781:2	In	IN	O	O
postmarketing	TUDORZA.xml:S1:4784:13	postmarket	VBG	O	O
experience	TUDORZA.xml:S1:4798:10	experi	NN	O	O
with	TUDORZA.xml:S1:4809:4	with	IN	O	O
TUDORZA	TUDORZA.xml:S1:4814:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S1:4822:8	pressair	NNP	O	O
,	TUDORZA.xml:S1:4830:1	,	,	O	O
immediate	TUDORZA.xml:S1:4832:9	immedi	JJ	B-AdverseReaction	B-AdverseReaction
hypersensitivity	TUDORZA.xml:S1:4842:16	hypersensit	NN	I-AdverseReaction	I-AdverseReaction
reactions	TUDORZA.xml:S1:4859:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	TUDORZA.xml:S1:4868:1	,	,	O	O
including	TUDORZA.xml:S1:4870:9	includ	VBG	O	O
anaphylaxis	TUDORZA.xml:S1:4880:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S1:4891:1	,	,	O	O
angioedema	TUDORZA.xml:S1:4893:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
(	TUDORZA.xml:S1:4904:1	(	(	O	O
including	TUDORZA.xml:S1:4905:9	includ	VBG	O	O
swelling	TUDORZA.xml:S1:4915:8	swell	NN	B-AdverseReaction	B-AdverseReaction
of	TUDORZA.xml:S1:4924:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	TUDORZA.xml:S1:4927:3	the	DT	I-AdverseReaction	I-AdverseReaction
lips	TUDORZA.xml:S1:4931:4	lip	NNS	I-AdverseReaction	I-AdverseReaction
,	TUDORZA.xml:S1:4935:1	,	,	O	O
tongue	TUDORZA.xml:S1:4937:6	tongu	NN	I-AdverseReaction	O
,	TUDORZA.xml:S1:4943:1	,	,	O	O
or	TUDORZA.xml:S1:4945:2	or	CC	O	O
throat	TUDORZA.xml:S1:4948:6	throat	NN	I-AdverseReaction	I-AdverseReaction
)	TUDORZA.xml:S1:4954:1	)	)	O	O
,	TUDORZA.xml:S1:4955:1	,	,	O	O
urticaria	TUDORZA.xml:S1:4957:9	urticaria	JJ	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S1:4966:1	,	,	O	O
rash	TUDORZA.xml:S1:4968:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S1:4972:1	,	,	O	O
bronchospasm	TUDORZA.xml:S1:4974:12	bronchospasm	NN	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S1:4986:1	,	,	O	O
or	TUDORZA.xml:S1:4988:2	or	CC	O	O
itching	TUDORZA.xml:S1:4991:7	itch	VBG	B-AdverseReaction	O
have	TUDORZA.xml:S1:4999:4	have	VBP	O	O
been	TUDORZA.xml:S1:5004:4	been	VBN	O	O
reported	TUDORZA.xml:S1:5009:8	report	VBN	O	O
.	TUDORZA.xml:S1:5017:1	.	.	O	O
5	TUDORZA.xml:S2:4:1	5	CD	O	O
WARNINGS	TUDORZA.xml:S2:6:8	warn	NNP	O	O
AND	TUDORZA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	TUDORZA.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	TUDORZA.xml:S2:35:7	excerpt	NNS	O	O
:	TUDORZA.xml:S2:42:1	:	:	O	O
Not	TUDORZA.xml:S2:52:3	not	RB	O	O
for	TUDORZA.xml:S2:56:3	for	IN	O	O
acute	TUDORZA.xml:S2:60:5	acut	JJ	O	O
use	TUDORZA.xml:S2:66:3	use	NN	O	O
:	TUDORZA.xml:S2:69:1	:	:	O	O
Not	TUDORZA.xml:S2:71:3	not	RB	O	O
for	TUDORZA.xml:S2:75:3	for	IN	O	O
use	TUDORZA.xml:S2:79:3	use	NN	O	O
as	TUDORZA.xml:S2:83:2	as	IN	O	O
a	TUDORZA.xml:S2:86:1	a	DT	O	O
rescue	TUDORZA.xml:S2:88:6	rescu	NN	O	O
medication	TUDORZA.xml:S2:95:10	medic	NN	O	O
.	TUDORZA.xml:S2:105:1	.	.	O	O

(	TUDORZA.xml:S2:107:1	(	(	O	O
5.1	TUDORZA.xml:S2:108:3	5.1	CD	O	O
)	TUDORZA.xml:S2:111:1	)	)	O	O

Paradoxical	TUDORZA.xml:S2:120:11	paradox	JJ	B-AdverseReaction	B-AdverseReaction
bronchospasm	TUDORZA.xml:S2:132:12	bronchospasm	NN	I-AdverseReaction	I-AdverseReaction
:	TUDORZA.xml:S2:144:1	:	:	O	O
Discontinue	TUDORZA.xml:S2:146:11	discontinu	NNP	O	O
TUDORZA	TUDORZA.xml:S2:158:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:166:8	pressair	NNP	O	O
and	TUDORZA.xml:S2:175:3	and	CC	O	O
consider	TUDORZA.xml:S2:179:8	consid	VB	O	O
other	TUDORZA.xml:S2:188:5	other	JJ	O	O
treatments	TUDORZA.xml:S2:194:10	treatment	NNS	O	O
if	TUDORZA.xml:S2:205:2	if	IN	O	O
paradoxical	TUDORZA.xml:S2:208:11	paradox	JJ	O	O
bronchospasm	TUDORZA.xml:S2:220:12	bronchospasm	NN	O	O
occurs	TUDORZA.xml:S2:233:6	occur	NNS	O	O
.	TUDORZA.xml:S2:239:1	.	.	O	O

(	TUDORZA.xml:S2:241:1	(	(	O	O
5.2	TUDORZA.xml:S2:242:3	5.2	CD	O	O
)	TUDORZA.xml:S2:245:1	)	)	O	O

Worsening	TUDORZA.xml:S2:254:9	worsen	VBG	B-AdverseReaction	B-AdverseReaction
of	TUDORZA.xml:S2:264:2	of	IN	I-AdverseReaction	I-AdverseReaction
narrow	TUDORZA.xml:S2:267:6	narrow	JJ	I-AdverseReaction	I-AdverseReaction
-	TUDORZA.xml:S2:273:1	-	:	I-AdverseReaction	I-AdverseReaction
angle	TUDORZA.xml:S2:274:5	angl	NN	I-AdverseReaction	I-AdverseReaction
glaucoma	TUDORZA.xml:S2:280:8	glaucoma	NN	I-AdverseReaction	I-AdverseReaction
may	TUDORZA.xml:S2:289:3	may	MD	O	O
occur	TUDORZA.xml:S2:293:5	occur	VB	O	O
.	TUDORZA.xml:S2:298:1	.	.	O	O

Use	TUDORZA.xml:S2:300:3	use	NN	O	O
with	TUDORZA.xml:S2:304:4	with	IN	O	O
caution	TUDORZA.xml:S2:309:7	caution	NN	O	O
in	TUDORZA.xml:S2:317:2	in	IN	O	O
patients	TUDORZA.xml:S2:320:8	patient	NNS	O	O
with	TUDORZA.xml:S2:329:4	with	IN	O	O
narrow	TUDORZA.xml:S2:334:6	narrow	JJ	O	O
-	TUDORZA.xml:S2:340:1	-	:	O	O
angle	TUDORZA.xml:S2:341:5	angl	NN	O	O
glaucoma	TUDORZA.xml:S2:347:8	glaucoma	NN	O	O
and	TUDORZA.xml:S2:356:3	and	CC	O	O
instruct	TUDORZA.xml:S2:360:8	instruct	NN	O	O
patients	TUDORZA.xml:S2:369:8	patient	NNS	O	O
to	TUDORZA.xml:S2:378:2	to	TO	O	O
consult	TUDORZA.xml:S2:381:7	consult	VB	O	O
a	TUDORZA.xml:S2:389:1	a	DT	O	O
physician	TUDORZA.xml:S2:391:9	physician	NN	O	O
immediately	TUDORZA.xml:S2:401:11	immedi	RB	O	O
if	TUDORZA.xml:S2:413:2	if	IN	O	O
this	TUDORZA.xml:S2:416:4	thi	DT	O	O
occurs	TUDORZA.xml:S2:421:6	occur	VBZ	O	O
.	TUDORZA.xml:S2:427:1	.	.	O	O

(	TUDORZA.xml:S2:429:1	(	(	O	O
5.3	TUDORZA.xml:S2:430:3	5.3	CD	O	O
)	TUDORZA.xml:S2:433:1	)	)	O	O

Worsening	TUDORZA.xml:S2:442:9	worsen	VBG	B-AdverseReaction	B-AdverseReaction
of	TUDORZA.xml:S2:452:2	of	IN	I-AdverseReaction	I-AdverseReaction
urinary	TUDORZA.xml:S2:455:7	urinari	JJ	I-AdverseReaction	I-AdverseReaction
retention	TUDORZA.xml:S2:463:9	retent	NN	I-AdverseReaction	I-AdverseReaction
may	TUDORZA.xml:S2:473:3	may	MD	O	O
occur	TUDORZA.xml:S2:477:5	occur	VB	O	O
.	TUDORZA.xml:S2:482:1	.	.	O	O

Use	TUDORZA.xml:S2:484:3	use	NN	O	O
with	TUDORZA.xml:S2:488:4	with	IN	O	O
caution	TUDORZA.xml:S2:493:7	caution	NN	O	O
in	TUDORZA.xml:S2:501:2	in	IN	O	O
patients	TUDORZA.xml:S2:504:8	patient	NNS	O	O
with	TUDORZA.xml:S2:513:4	with	IN	O	O
prostatic	TUDORZA.xml:S2:518:9	prostat	JJ	O	O
hyperplasia	TUDORZA.xml:S2:528:11	hyperplasia	NN	O	O
or	TUDORZA.xml:S2:540:2	or	CC	O	O
bladder	TUDORZA.xml:S2:543:7	bladder	NN	O	B-AdverseReaction
-	TUDORZA.xml:S2:550:1	-	:	O	I-AdverseReaction
neck	TUDORZA.xml:S2:551:4	neck	NN	O	I-AdverseReaction
obstruction	TUDORZA.xml:S2:556:11	obstruct	NN	O	I-AdverseReaction
and	TUDORZA.xml:S2:568:3	and	CC	O	O
instruct	TUDORZA.xml:S2:572:8	instruct	NN	O	O
patients	TUDORZA.xml:S2:581:8	patient	NNS	O	O
to	TUDORZA.xml:S2:590:2	to	TO	O	O
consult	TUDORZA.xml:S2:593:7	consult	VB	O	O
a	TUDORZA.xml:S2:601:1	a	DT	O	O
physician	TUDORZA.xml:S2:603:9	physician	NN	O	O
immediately	TUDORZA.xml:S2:613:11	immedi	RB	O	O
if	TUDORZA.xml:S2:625:2	if	IN	O	O
this	TUDORZA.xml:S2:628:4	thi	DT	O	O
occurs	TUDORZA.xml:S2:633:6	occur	VBZ	O	O
.	TUDORZA.xml:S2:639:1	.	.	O	O

(	TUDORZA.xml:S2:641:1	(	(	O	O
5.4	TUDORZA.xml:S2:642:3	5.4	CD	O	O
)	TUDORZA.xml:S2:645:1	)	)	O	O

Immediate	TUDORZA.xml:S2:654:9	immedi	NNP	O	O
hypersensitivity	TUDORZA.xml:S2:664:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	TUDORZA.xml:S2:681:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
:	TUDORZA.xml:S2:690:1	:	:	O	O
Discontinue	TUDORZA.xml:S2:692:11	discontinu	NNP	O	O
TUDORZA	TUDORZA.xml:S2:704:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:712:8	pressair	NNP	O	O
at	TUDORZA.xml:S2:721:2	at	IN	O	O
once	TUDORZA.xml:S2:724:4	onc	RB	O	O
and	TUDORZA.xml:S2:729:3	and	CC	O	O
consider	TUDORZA.xml:S2:733:8	consid	VB	O	O
alternatives	TUDORZA.xml:S2:742:12	altern	NNS	O	O
if	TUDORZA.xml:S2:755:2	if	IN	O	O
immediate	TUDORZA.xml:S2:758:9	immedi	JJ	O	O
hypersensitivity	TUDORZA.xml:S2:768:16	hypersensit	NN	O	O
reactions	TUDORZA.xml:S2:785:9	reaction	NNS	O	O
,	TUDORZA.xml:S2:794:1	,	,	O	O
including	TUDORZA.xml:S2:796:9	includ	VBG	O	O
angioedema	TUDORZA.xml:S2:806:10	angioedema	NN	O	B-AdverseReaction
,	TUDORZA.xml:S2:816:1	,	,	O	O
bronchospasm	TUDORZA.xml:S2:818:12	bronchospasm	NN	O	B-AdverseReaction
,	TUDORZA.xml:S2:830:1	,	,	O	O
or	TUDORZA.xml:S2:832:2	or	CC	O	O
anaphylaxis	TUDORZA.xml:S2:835:11	anaphylaxi	NN	O	B-AdverseReaction
,	TUDORZA.xml:S2:846:1	,	,	O	O
occur	TUDORZA.xml:S2:848:5	occur	NN	O	O
.	TUDORZA.xml:S2:853:1	.	.	O	O

Use	TUDORZA.xml:S2:855:3	use	NN	O	O
with	TUDORZA.xml:S2:859:4	with	IN	O	O
caution	TUDORZA.xml:S2:864:7	caution	NN	O	O
in	TUDORZA.xml:S2:872:2	in	IN	O	O
patients	TUDORZA.xml:S2:875:8	patient	NNS	O	O
with	TUDORZA.xml:S2:884:4	with	IN	O	O
severe	TUDORZA.xml:S2:889:6	sever	JJ	O	O
hypersensitivity	TUDORZA.xml:S2:896:16	hypersensit	NN	O	O
to	TUDORZA.xml:S2:913:2	to	TO	O	O
milk	TUDORZA.xml:S2:916:4	milk	VB	O	O
proteins	TUDORZA.xml:S2:921:8	protein	NNS	O	O
.	TUDORZA.xml:S2:929:1	.	.	O	O

(	TUDORZA.xml:S2:931:1	(	(	O	O
5.5	TUDORZA.xml:S2:932:3	5.5	CD	O	O
)	TUDORZA.xml:S2:935:1	)	)	O	O

5.1	TUDORZA.xml:S2:946:3	5.1	CD	O	O

Not	TUDORZA.xml:S2:950:3	not	RB	O	O
for	TUDORZA.xml:S2:954:3	for	IN	O	O
Acute	TUDORZA.xml:S2:958:5	acut	NNP	O	O
Use	TUDORZA.xml:S2:964:3	use	NNP	O	O

TUDORZA	TUDORZA.xml:S2:971:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:979:8	pressair	NNP	O	O
is	TUDORZA.xml:S2:988:2	is	VBZ	O	O
intended	TUDORZA.xml:S2:991:8	intend	VBN	O	O
as	TUDORZA.xml:S2:1000:2	as	IN	O	O
a	TUDORZA.xml:S2:1003:1	a	DT	O	O
twice	TUDORZA.xml:S2:1005:5	twice	JJ	O	O
-	TUDORZA.xml:S2:1010:1	-	:	O	O
daily	TUDORZA.xml:S2:1011:5	daili	JJ	O	O
maintenance	TUDORZA.xml:S2:1017:11	mainten	NN	O	O
treatment	TUDORZA.xml:S2:1029:9	treatment	NN	O	O
for	TUDORZA.xml:S2:1039:3	for	IN	O	O
COPD	TUDORZA.xml:S2:1043:4	copd	NNP	O	O
and	TUDORZA.xml:S2:1048:3	and	CC	O	O
is	TUDORZA.xml:S2:1052:2	is	VBZ	O	O
not	TUDORZA.xml:S2:1055:3	not	RB	O	O
indicated	TUDORZA.xml:S2:1059:9	indic	VBN	O	O
for	TUDORZA.xml:S2:1069:3	for	IN	O	O
the	TUDORZA.xml:S2:1073:3	the	DT	O	O
initial	TUDORZA.xml:S2:1077:7	initi	JJ	O	O
treatment	TUDORZA.xml:S2:1085:9	treatment	NN	O	O
of	TUDORZA.xml:S2:1095:2	of	IN	O	O
acute	TUDORZA.xml:S2:1098:5	acut	JJ	O	O
episodes	TUDORZA.xml:S2:1104:8	episod	NNS	O	O
of	TUDORZA.xml:S2:1113:2	of	IN	O	O
bronchospasm	TUDORZA.xml:S2:1116:12	bronchospasm	NN	O	O
(	TUDORZA.xml:S2:1129:1	(	(	O	O
i	TUDORZA.xml:S2:1130:1	i	JJ	O	O
.	TUDORZA.xml:S2:1131:1	.	.	O	O
e	TUDORZA.xml:S2:1132:1	e	NN	O	O
.	TUDORZA.xml:S2:1133:1	.	.	O	O
,	TUDORZA.xml:S2:1134:1	,	,	O	O
rescue	TUDORZA.xml:S2:1136:6	rescu	JJ	O	O
therapy	TUDORZA.xml:S2:1143:7	therapi	NN	O	O
)	TUDORZA.xml:S2:1150:1	)	)	O	O
.	TUDORZA.xml:S2:1151:1	.	.	O	O

5.2	TUDORZA.xml:S2:1159:3	5.2	CD	O	O
Paradoxical	TUDORZA.xml:S2:1163:11	paradox	JJ	O	O
Bronchospasm	TUDORZA.xml:S2:1175:12	bronchospasm	NNP	O	O

Inhaled	TUDORZA.xml:S2:1191:7	inhal	VBN	O	O
medicines	TUDORZA.xml:S2:1199:9	medicin	NNS	O	O
,	TUDORZA.xml:S2:1208:1	,	,	O	O
including	TUDORZA.xml:S2:1210:9	includ	VBG	O	O
TUDORZA	TUDORZA.xml:S2:1220:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:1228:8	pressair	NNP	O	O
,	TUDORZA.xml:S2:1236:1	,	,	O	O
may	TUDORZA.xml:S2:1238:3	may	MD	O	O
cause	TUDORZA.xml:S2:1242:5	caus	VB	O	O
paradoxical	TUDORZA.xml:S2:1248:11	paradox	JJ	B-AdverseReaction	B-AdverseReaction
bronchospasm	TUDORZA.xml:S2:1260:12	bronchospasm	NN	I-AdverseReaction	I-AdverseReaction
.	TUDORZA.xml:S2:1272:1	.	.	O	O

If	TUDORZA.xml:S2:1274:2	If	IN	O	O
this	TUDORZA.xml:S2:1277:4	thi	DT	O	O
occurs	TUDORZA.xml:S2:1282:6	occur	VBZ	O	O
,	TUDORZA.xml:S2:1288:1	,	,	O	O
treatment	TUDORZA.xml:S2:1290:9	treatment	NN	O	O
with	TUDORZA.xml:S2:1300:4	with	IN	O	O
TUDORZA	TUDORZA.xml:S2:1305:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:1313:8	pressair	NNP	O	O
should	TUDORZA.xml:S2:1322:6	should	MD	O	O
be	TUDORZA.xml:S2:1329:2	be	VB	O	O
stopped	TUDORZA.xml:S2:1332:7	stop	VBN	O	O
and	TUDORZA.xml:S2:1340:3	and	CC	O	O
other	TUDORZA.xml:S2:1344:5	other	JJ	O	O
treatments	TUDORZA.xml:S2:1350:10	treatment	NNS	O	O
considered	TUDORZA.xml:S2:1361:10	consid	VBN	O	O
.	TUDORZA.xml:S2:1371:1	.	.	O	O

5.3	TUDORZA.xml:S2:1379:3	5.3	CD	O	O
Worsening	TUDORZA.xml:S2:1383:9	worsen	NNP	O	O
of	TUDORZA.xml:S2:1393:2	of	IN	O	O
Narrow	TUDORZA.xml:S2:1396:6	narrow	NNP	O	O
-	TUDORZA.xml:S2:1402:1	-	:	O	O
Angle	TUDORZA.xml:S2:1403:5	angl	NNP	O	O
Glaucoma	TUDORZA.xml:S2:1409:8	glaucoma	NNP	O	O

TUDORZA	TUDORZA.xml:S2:1421:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:1429:8	pressair	NNP	O	O
should	TUDORZA.xml:S2:1438:6	should	MD	O	O
be	TUDORZA.xml:S2:1445:2	be	VB	O	O
used	TUDORZA.xml:S2:1448:4	use	VBN	O	O
with	TUDORZA.xml:S2:1453:4	with	IN	O	O
caution	TUDORZA.xml:S2:1458:7	caution	NN	O	O
in	TUDORZA.xml:S2:1466:2	in	IN	O	O
patients	TUDORZA.xml:S2:1469:8	patient	NNS	O	O
with	TUDORZA.xml:S2:1478:4	with	IN	O	O
narrow	TUDORZA.xml:S2:1483:6	narrow	JJ	O	O
-	TUDORZA.xml:S2:1489:1	-	:	O	O
angle	TUDORZA.xml:S2:1490:5	angl	NN	O	O
glaucoma	TUDORZA.xml:S2:1496:8	glaucoma	NN	O	O
.	TUDORZA.xml:S2:1504:1	.	.	O	O

Prescribers	TUDORZA.xml:S2:1506:11	prescrib	NNS	O	O
and	TUDORZA.xml:S2:1518:3	and	CC	O	O
patients	TUDORZA.xml:S2:1522:8	patient	NNS	O	O
should	TUDORZA.xml:S2:1531:6	should	MD	O	O
be	TUDORZA.xml:S2:1538:2	be	VB	O	O
alert	TUDORZA.xml:S2:1541:5	alert	JJ	O	O
for	TUDORZA.xml:S2:1547:3	for	IN	O	O
signs	TUDORZA.xml:S2:1551:5	sign	NNS	O	O
and	TUDORZA.xml:S2:1557:3	and	CC	O	O
symptoms	TUDORZA.xml:S2:1561:8	symptom	NNS	O	O
of	TUDORZA.xml:S2:1570:2	of	IN	O	O
acute	TUDORZA.xml:S2:1573:5	acut	NN	O	O
narrow	TUDORZA.xml:S2:1579:6	narrow	JJ	O	O
-	TUDORZA.xml:S2:1585:1	-	:	O	O
angle	TUDORZA.xml:S2:1586:5	angl	NN	O	O
glaucoma	TUDORZA.xml:S2:1592:8	glaucoma	NN	O	O
(	TUDORZA.xml:S2:1601:1	(	(	O	O
e	TUDORZA.xml:S2:1602:1	e	NN	O	O
.	TUDORZA.xml:S2:1603:1	.	.	O	O
g	TUDORZA.xml:S2:1604:1	g	NN	O	O
.	TUDORZA.xml:S2:1605:1	.	.	O	O
,	TUDORZA.xml:S2:1606:1	,	,	O	O
eye	TUDORZA.xml:S2:1608:3	eye	NN	O	B-AdverseReaction
pain	TUDORZA.xml:S2:1612:4	pain	NN	O	I-AdverseReaction
or	TUDORZA.xml:S2:1617:2	or	CC	O	O
discomfort	TUDORZA.xml:S2:1620:10	discomfort	NN	O	I-AdverseReaction
,	TUDORZA.xml:S2:1630:1	,	,	O	O
blurred	TUDORZA.xml:S2:1632:7	blur	VBN	O	B-AdverseReaction
vision	TUDORZA.xml:S2:1640:6	vision	NN	O	I-AdverseReaction
,	TUDORZA.xml:S2:1646:1	,	,	O	O
visual	TUDORZA.xml:S2:1648:6	visual	JJ	O	B-AdverseReaction
halos	TUDORZA.xml:S2:1655:5	halo	NN	O	I-AdverseReaction
or	TUDORZA.xml:S2:1661:2	or	CC	O	O
colored	TUDORZA.xml:S2:1664:7	color	VBN	O	O
images	TUDORZA.xml:S2:1672:6	imag	NNS	O	O
in	TUDORZA.xml:S2:1679:2	in	IN	O	O
association	TUDORZA.xml:S2:1682:11	associ	NN	O	O
with	TUDORZA.xml:S2:1694:4	with	IN	O	O
red	TUDORZA.xml:S2:1699:3	red	JJ	O	B-AdverseReaction
eyes	TUDORZA.xml:S2:1703:4	eye	NNS	O	I-AdverseReaction
from	TUDORZA.xml:S2:1708:4	from	IN	O	I-AdverseReaction
conjunctival	TUDORZA.xml:S2:1713:12	conjunctiv	JJ	O	I-AdverseReaction
congestion	TUDORZA.xml:S2:1726:10	congest	NN	O	I-AdverseReaction
and	TUDORZA.xml:S2:1737:3	and	CC	O	O
corneal	TUDORZA.xml:S2:1741:7	corneal	VB	O	B-AdverseReaction
edema	TUDORZA.xml:S2:1749:5	edema	NN	O	I-AdverseReaction
)	TUDORZA.xml:S2:1754:1	)	)	O	O
.	TUDORZA.xml:S2:1755:1	.	.	O	O

Instruct	TUDORZA.xml:S2:1757:8	instruct	NN	O	O
patients	TUDORZA.xml:S2:1766:8	patient	NNS	O	O
to	TUDORZA.xml:S2:1775:2	to	TO	O	O
consult	TUDORZA.xml:S2:1778:7	consult	VB	O	O
a	TUDORZA.xml:S2:1786:1	a	DT	O	O
physician	TUDORZA.xml:S2:1788:9	physician	JJ	O	O
immediately	TUDORZA.xml:S2:1798:11	immedi	RB	O	O
should	TUDORZA.xml:S2:1810:6	should	MD	O	O
any	TUDORZA.xml:S2:1817:3	ani	DT	O	O
of	TUDORZA.xml:S2:1821:2	of	IN	O	O
these	TUDORZA.xml:S2:1824:5	these	DT	O	O
signs	TUDORZA.xml:S2:1830:5	sign	NNS	O	O
or	TUDORZA.xml:S2:1836:2	or	CC	O	O
symptoms	TUDORZA.xml:S2:1839:8	symptom	NNS	O	O
develop	TUDORZA.xml:S2:1848:7	develop	VBP	O	O
.	TUDORZA.xml:S2:1855:1	.	.	O	O

5.4	TUDORZA.xml:S2:1863:3	5.4	CD	O	O
Worsening	TUDORZA.xml:S2:1867:9	worsen	NNP	O	O
of	TUDORZA.xml:S2:1877:2	of	IN	O	O
Urinary	TUDORZA.xml:S2:1880:7	urinari	NNP	O	O
Retention	TUDORZA.xml:S2:1888:9	retent	NNP	O	O

TUDORZA	TUDORZA.xml:S2:1901:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:1909:8	pressair	NNP	O	O
should	TUDORZA.xml:S2:1918:6	should	MD	O	O
be	TUDORZA.xml:S2:1925:2	be	VB	O	O
used	TUDORZA.xml:S2:1928:4	use	VBN	O	O
with	TUDORZA.xml:S2:1933:4	with	IN	O	O
caution	TUDORZA.xml:S2:1938:7	caution	NN	O	O
in	TUDORZA.xml:S2:1946:2	in	IN	O	O
patients	TUDORZA.xml:S2:1949:8	patient	NNS	O	O
with	TUDORZA.xml:S2:1958:4	with	IN	O	O
urinary	TUDORZA.xml:S2:1963:7	urinari	JJ	O	O
retention	TUDORZA.xml:S2:1971:9	retent	NN	O	O
.	TUDORZA.xml:S2:1980:1	.	.	O	O

Prescribers	TUDORZA.xml:S2:1982:11	prescrib	NNS	O	O
and	TUDORZA.xml:S2:1994:3	and	CC	O	O
patients	TUDORZA.xml:S2:1998:8	patient	NNS	O	O
should	TUDORZA.xml:S2:2007:6	should	MD	O	O
be	TUDORZA.xml:S2:2014:2	be	VB	O	O
alert	TUDORZA.xml:S2:2017:5	alert	JJ	O	O
for	TUDORZA.xml:S2:2023:3	for	IN	O	O
signs	TUDORZA.xml:S2:2027:5	sign	NNS	O	O
and	TUDORZA.xml:S2:2033:3	and	CC	O	O
symptoms	TUDORZA.xml:S2:2037:8	symptom	NNS	O	O
of	TUDORZA.xml:S2:2046:2	of	IN	O	O
prostatic	TUDORZA.xml:S2:2049:9	prostat	JJ	O	O
hyperplasia	TUDORZA.xml:S2:2059:11	hyperplasia	NN	O	O
or	TUDORZA.xml:S2:2071:2	or	CC	O	O
bladder	TUDORZA.xml:S2:2074:7	bladder	NN	O	B-AdverseReaction
-	TUDORZA.xml:S2:2081:1	-	:	O	I-AdverseReaction
neck	TUDORZA.xml:S2:2082:4	neck	NN	O	I-AdverseReaction
obstruction	TUDORZA.xml:S2:2087:11	obstruct	NN	O	I-AdverseReaction
(	TUDORZA.xml:S2:2099:1	(	(	O	O
e	TUDORZA.xml:S2:2100:1	e	NN	O	O
.	TUDORZA.xml:S2:2101:1	.	.	O	O
g	TUDORZA.xml:S2:2102:1	g	NN	O	O
.	TUDORZA.xml:S2:2103:1	.	.	O	O
,	TUDORZA.xml:S2:2104:1	,	,	O	O
difficulty	TUDORZA.xml:S2:2106:10	difficulti	NN	O	O
passing	TUDORZA.xml:S2:2117:7	pass	VBG	O	O
urine	TUDORZA.xml:S2:2125:5	urin	JJ	O	O
,	TUDORZA.xml:S2:2130:1	,	,	O	O
painful	TUDORZA.xml:S2:2132:7	pain	JJ	O	B-AdverseReaction
urination	TUDORZA.xml:S2:2140:9	urin	NN	O	I-AdverseReaction
)	TUDORZA.xml:S2:2149:1	)	)	O	O
.	TUDORZA.xml:S2:2150:1	.	.	O	O

Instruct	TUDORZA.xml:S2:2152:8	instruct	NN	O	O
patients	TUDORZA.xml:S2:2161:8	patient	NNS	O	O
to	TUDORZA.xml:S2:2170:2	to	TO	O	O
consult	TUDORZA.xml:S2:2173:7	consult	VB	O	O
a	TUDORZA.xml:S2:2181:1	a	DT	O	O
physician	TUDORZA.xml:S2:2183:9	physician	JJ	O	O
immediately	TUDORZA.xml:S2:2193:11	immedi	RB	O	O
should	TUDORZA.xml:S2:2205:6	should	MD	O	O
any	TUDORZA.xml:S2:2212:3	ani	DT	O	O
of	TUDORZA.xml:S2:2216:2	of	IN	O	O
these	TUDORZA.xml:S2:2219:5	these	DT	O	O
signs	TUDORZA.xml:S2:2225:5	sign	NNS	O	O
or	TUDORZA.xml:S2:2231:2	or	CC	O	O
symptoms	TUDORZA.xml:S2:2234:8	symptom	NNS	O	O
develop	TUDORZA.xml:S2:2243:7	develop	VBP	O	O
.	TUDORZA.xml:S2:2250:1	.	.	O	O

5.5	TUDORZA.xml:S2:2258:3	5.5	CD	O	O
Immediate	TUDORZA.xml:S2:2262:9	immedi	NNP	O	O
Hypersensitivity	TUDORZA.xml:S2:2272:16	hypersensit	NNP	O	O
Reactions	TUDORZA.xml:S2:2289:9	reaction	NNP	O	O

Immediate	TUDORZA.xml:S2:2302:9	immedi	NNP	B-AdverseReaction	O
hypersensitivity	TUDORZA.xml:S2:2312:16	hypersensit	NN	I-AdverseReaction	B-AdverseReaction
reactions	TUDORZA.xml:S2:2329:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	TUDORZA.xml:S2:2338:1	,	,	O	O
including	TUDORZA.xml:S2:2340:9	includ	VBG	O	O
anaphylaxis	TUDORZA.xml:S2:2350:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S2:2361:1	,	,	O	O
angioedema	TUDORZA.xml:S2:2363:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
(	TUDORZA.xml:S2:2374:1	(	(	O	O
including	TUDORZA.xml:S2:2375:9	includ	VBG	O	O
swelling	TUDORZA.xml:S2:2385:8	swell	NN	B-AdverseReaction	B-AdverseReaction
of	TUDORZA.xml:S2:2394:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	TUDORZA.xml:S2:2397:3	the	DT	I-AdverseReaction	I-AdverseReaction
lips	TUDORZA.xml:S2:2401:4	lip	NNS	I-AdverseReaction	I-AdverseReaction
,	TUDORZA.xml:S2:2405:1	,	,	O	O
tongue	TUDORZA.xml:S2:2407:6	tongu	NN	I-AdverseReaction	O
,	TUDORZA.xml:S2:2413:1	,	,	O	O
or	TUDORZA.xml:S2:2415:2	or	CC	O	O
throat	TUDORZA.xml:S2:2418:6	throat	NN	I-AdverseReaction	I-AdverseReaction
)	TUDORZA.xml:S2:2424:1	)	)	O	O
,	TUDORZA.xml:S2:2425:1	,	,	O	O
urticaria	TUDORZA.xml:S2:2427:9	urticaria	JJ	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S2:2436:1	,	,	O	O
rash	TUDORZA.xml:S2:2438:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S2:2442:1	,	,	O	O
bronchospasm	TUDORZA.xml:S2:2444:12	bronchospasm	NN	B-AdverseReaction	B-AdverseReaction
,	TUDORZA.xml:S2:2456:1	,	,	O	O
or	TUDORZA.xml:S2:2458:2	or	CC	O	O
itching	TUDORZA.xml:S2:2461:7	itch	NN	B-AdverseReaction	O
,	TUDORZA.xml:S2:2468:1	,	,	O	O
have	TUDORZA.xml:S2:2470:4	have	VBP	O	O
occurred	TUDORZA.xml:S2:2475:8	occur	VBN	O	O
after	TUDORZA.xml:S2:2484:5	after	IN	O	O
administration	TUDORZA.xml:S2:2490:14	administr	NN	O	O
of	TUDORZA.xml:S2:2505:2	of	IN	O	O
TUDORZA	TUDORZA.xml:S2:2508:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:2516:8	pressair	NNP	O	O
.	TUDORZA.xml:S2:2524:1	.	.	O	O

If	TUDORZA.xml:S2:2526:2	If	IN	O	O
such	TUDORZA.xml:S2:2529:4	such	PDT	O	O
a	TUDORZA.xml:S2:2534:1	a	DT	O	O
reaction	TUDORZA.xml:S2:2536:8	reaction	NN	O	O
occurs	TUDORZA.xml:S2:2545:6	occur	VBZ	O	O
,	TUDORZA.xml:S2:2551:1	,	,	O	O
therapy	TUDORZA.xml:S2:2553:7	therapi	NN	O	O
with	TUDORZA.xml:S2:2561:4	with	IN	O	O
TUDORZA	TUDORZA.xml:S2:2566:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:2574:8	pressair	NNP	O	O
should	TUDORZA.xml:S2:2583:6	should	MD	O	O
be	TUDORZA.xml:S2:2590:2	be	VB	O	O
stopped	TUDORZA.xml:S2:2593:7	stop	VBN	O	O
at	TUDORZA.xml:S2:2601:2	at	IN	O	O
once	TUDORZA.xml:S2:2604:4	onc	RB	O	O
and	TUDORZA.xml:S2:2609:3	and	CC	O	O
alternative	TUDORZA.xml:S2:2613:11	altern	JJ	O	O
treatments	TUDORZA.xml:S2:2625:10	treatment	NNS	O	O
should	TUDORZA.xml:S2:2636:6	should	MD	O	O
be	TUDORZA.xml:S2:2643:2	be	VB	O	O
considered	TUDORZA.xml:S2:2646:10	consid	VBN	O	O
.	TUDORZA.xml:S2:2656:1	.	.	O	O

Given	TUDORZA.xml:S2:2658:5	given	VBN	O	O
the	TUDORZA.xml:S2:2664:3	the	DT	O	O
similar	TUDORZA.xml:S2:2668:7	similar	JJ	O	O
structural	TUDORZA.xml:S2:2676:10	structur	JJ	O	O
formula	TUDORZA.xml:S2:2687:7	formula	NN	O	O
of	TUDORZA.xml:S2:2695:2	of	IN	O	O
atropine	TUDORZA.xml:S2:2698:8	atropin	NN	O	O
to	TUDORZA.xml:S2:2707:2	to	TO	O	O
aclidinium	TUDORZA.xml:S2:2710:10	aclidinium	VB	O	O
,	TUDORZA.xml:S2:2720:1	,	,	O	O
patients	TUDORZA.xml:S2:2722:8	patient	NNS	O	O
with	TUDORZA.xml:S2:2731:4	with	IN	O	O
a	TUDORZA.xml:S2:2736:1	a	DT	O	O
history	TUDORZA.xml:S2:2738:7	histori	NN	O	O
of	TUDORZA.xml:S2:2746:2	of	IN	O	O
hypersensitivity	TUDORZA.xml:S2:2749:16	hypersensit	NN	O	O
reactions	TUDORZA.xml:S2:2766:9	reaction	NNS	O	O
to	TUDORZA.xml:S2:2776:2	to	TO	O	O
atropine	TUDORZA.xml:S2:2779:8	atropin	VB	O	O
should	TUDORZA.xml:S2:2788:6	should	MD	O	O
be	TUDORZA.xml:S2:2795:2	be	VB	O	O
closely	TUDORZA.xml:S2:2798:7	close	RB	O	O
monitored	TUDORZA.xml:S2:2806:9	monitor	VBN	O	O
for	TUDORZA.xml:S2:2816:3	for	IN	O	O
similar	TUDORZA.xml:S2:2820:7	similar	JJ	O	O
hypersensitivity	TUDORZA.xml:S2:2828:16	hypersensit	NN	O	O
reactions	TUDORZA.xml:S2:2845:9	reaction	NNS	O	O
to	TUDORZA.xml:S2:2855:2	to	TO	O	O
TUDORZA	TUDORZA.xml:S2:2858:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:2866:8	pressair	NNP	O	O
.	TUDORZA.xml:S2:2874:1	.	.	O	O

In	TUDORZA.xml:S2:2876:2	In	IN	O	O
addition	TUDORZA.xml:S2:2879:8	addit	NN	O	O
,	TUDORZA.xml:S2:2887:1	,	,	O	O
TUDORZA	TUDORZA.xml:S2:2889:7	tudorza	NNP	O	O
PRESSAIR	TUDORZA.xml:S2:2897:8	pressair	NNP	O	O
should	TUDORZA.xml:S2:2906:6	should	MD	O	O
be	TUDORZA.xml:S2:2913:2	be	VB	O	O
used	TUDORZA.xml:S2:2916:4	use	VBN	O	O
with	TUDORZA.xml:S2:2921:4	with	IN	O	O
caution	TUDORZA.xml:S2:2926:7	caution	NN	O	O
in	TUDORZA.xml:S2:2934:2	in	IN	O	O
patients	TUDORZA.xml:S2:2937:8	patient	NNS	O	O
with	TUDORZA.xml:S2:2946:4	with	IN	O	O
severe	TUDORZA.xml:S2:2951:6	sever	JJ	O	O
hypersensitivity	TUDORZA.xml:S2:2958:16	hypersensit	NN	O	O
to	TUDORZA.xml:S2:2975:2	to	TO	O	O
milk	TUDORZA.xml:S2:2978:4	milk	VB	O	O
proteins	TUDORZA.xml:S2:2983:8	protein	NNS	O	O
.	TUDORZA.xml:S2:2991:1	.	.	O	O
6	ULESFIA.xml:S1:6:1	6	CD	O	O
ADVERSE	ULESFIA.xml:S1:20:7	advers	JJ	O	O
REACTIONS	ULESFIA.xml:S1:28:9	reaction	NN	O	O

EXCERPT	ULESFIA.xml:S1:43:7	excerpt	NNS	O	O
:	ULESFIA.xml:S1:50:1	:	:	O	O
Most	ULESFIA.xml:S1:54:4	most	JJS	O	O
common	ULESFIA.xml:S1:59:6	common	JJ	O	O
adverse	ULESFIA.xml:S1:66:7	advers	JJ	O	O
reactions	ULESFIA.xml:S1:74:9	reaction	NNS	O	O
(	ULESFIA.xml:S1:84:1	(	(	O	O
1%	ULESFIA.xml:S1:87:2	1%	CD	O	O
and	ULESFIA.xml:S1:90:3	and	CC	O	O
more	ULESFIA.xml:S1:94:4	more	JJR	O	O
common	ULESFIA.xml:S1:99:6	common	JJ	O	O
than	ULESFIA.xml:S1:106:4	than	IN	O	O
with	ULESFIA.xml:S1:111:4	with	IN	O	O
placebo	ULESFIA.xml:S1:116:7	placebo	NN	O	O
)	ULESFIA.xml:S1:123:1	)	)	O	O
:	ULESFIA.xml:S1:124:1	:	:	O	O
ocular	ULESFIA.xml:S1:126:6	ocular	JJ	B-AdverseReaction	B-AdverseReaction
irritation	ULESFIA.xml:S1:133:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S1:143:1	,	,	O	O
application	ULESFIA.xml:S1:145:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	ULESFIA.xml:S1:157:4	site	NN	I-AdverseReaction	I-AdverseReaction
irritation	ULESFIA.xml:S1:162:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S1:172:1	,	,	O	O
and	ULESFIA.xml:S1:174:3	and	CC	O	O
application	ULESFIA.xml:S1:178:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	ULESFIA.xml:S1:190:4	site	NN	I-AdverseReaction	I-AdverseReaction
anesthesia	ULESFIA.xml:S1:195:10	anesthesia	NN	I-AdverseReaction	I-AdverseReaction
and	ULESFIA.xml:S1:206:3	and	CC	O	O
hypoesthesia	ULESFIA.xml:S1:210:12	hypoesthesia	NN	I-AdverseReaction	O
.	ULESFIA.xml:S1:222:1	.	.	O	O

(	ULESFIA.xml:S1:224:1	(	(	O	O
6	ULESFIA.xml:S1:227:1	6	CD	O	O
)	ULESFIA.xml:S1:230:1	)	)	O	O

To	ULESFIA.xml:S1:238:2	To	TO	O	O
report	ULESFIA.xml:S1:241:6	report	VB	O	O
SUSPECTED	ULESFIA.xml:S1:248:9	suspect	NNP	O	O
ADVERSE	ULESFIA.xml:S1:258:7	advers	NNP	O	O
REACTIONS	ULESFIA.xml:S1:266:9	reaction	NNP	O	O
,	ULESFIA.xml:S1:275:1	,	,	O	O
contact	ULESFIA.xml:S1:277:7	contact	NN	O	O
Zylera	ULESFIA.xml:S1:285:6	zylera	NNP	O	O
Pharmaceuticals	ULESFIA.xml:S1:292:15	pharmaceut	NNP	O	O
,	ULESFIA.xml:S1:307:1	,	,	O	O
LLC	ULESFIA.xml:S1:309:3	llc	NNP	O	O
.	ULESFIA.xml:S1:312:1	.	.	O	O

at	ULESFIA.xml:S1:314:2	at	IN	O	O
1	ULESFIA.xml:S1:317:1	1	CD	O	O
-	ULESFIA.xml:S1:318:1	-	:	O	O
866	ULESFIA.xml:S1:319:3	866	CD	O	O
-	ULESFIA.xml:S1:322:1	-	:	O	O
416	ULESFIA.xml:S1:323:3	416	CD	O	O
-	ULESFIA.xml:S1:326:1	-	:	O	O
9637	ULESFIA.xml:S1:327:4	9637	CD	O	O
or	ULESFIA.xml:S1:332:2	or	CC	O	O
FDA	ULESFIA.xml:S1:335:3	fda	NNP	O	O
at	ULESFIA.xml:S1:339:2	at	IN	O	O
1	ULESFIA.xml:S1:342:1	1	CD	O	O
-	ULESFIA.xml:S1:343:1	-	:	O	O
800	ULESFIA.xml:S1:344:3	800	CD	O	O
-	ULESFIA.xml:S1:347:1	-	:	O	O
FDA	ULESFIA.xml:S1:348:3	fda	NNP	O	O
-	ULESFIA.xml:S1:351:1	-	:	O	O
1088	ULESFIA.xml:S1:352:4	1088	CD	O	O
or	ULESFIA.xml:S1:357:2	or	CC	O	O
www	ULESFIA.xml:S1:360:3	www	VB	O	O
.	ULESFIA.xml:S1:363:1	.	.	O	O
fda	ULESFIA.xml:S1:364:3	fda	NN	O	O
.	ULESFIA.xml:S1:367:1	.	.	O	O
gov	ULESFIA.xml:S1:368:3	gov	JJ	O	O
medwatch	ULESFIA.xml:S1:372:8	medwatch	NN	O	O
.	ULESFIA.xml:S1:380:1	.	.	O	O

6.1	ULESFIA.xml:S1:394:3	6.1	CD	O	O

Clinical	ULESFIA.xml:S1:410:8	clinic	JJ	O	O
Trials	ULESFIA.xml:S1:419:6	trial	NNS	O	O
Experience	ULESFIA.xml:S1:426:10	experi	NN	O	O

Because	ULESFIA.xml:S1:448:7	becaus	IN	O	O
clinical	ULESFIA.xml:S1:456:8	clinic	JJ	O	O
trials	ULESFIA.xml:S1:465:6	trial	NNS	O	O
are	ULESFIA.xml:S1:472:3	are	VBP	O	O
conducted	ULESFIA.xml:S1:476:9	conduct	VBN	O	O
under	ULESFIA.xml:S1:486:5	under	IN	O	O
widely	ULESFIA.xml:S1:492:6	wide	RB	O	O
varying	ULESFIA.xml:S1:499:7	vari	VBG	O	O
conditions	ULESFIA.xml:S1:507:10	condit	NNS	O	O
,	ULESFIA.xml:S1:517:1	,	,	O	O
adverse	ULESFIA.xml:S1:519:7	advers	JJ	O	O
reaction	ULESFIA.xml:S1:527:8	reaction	NN	O	O
rates	ULESFIA.xml:S1:536:5	rate	NNS	O	O
observed	ULESFIA.xml:S1:542:8	observ	VBD	O	O
in	ULESFIA.xml:S1:551:2	in	IN	O	O
the	ULESFIA.xml:S1:554:3	the	DT	O	O
clinical	ULESFIA.xml:S1:558:8	clinic	JJ	O	O
trials	ULESFIA.xml:S1:567:6	trial	NNS	O	O
of	ULESFIA.xml:S1:574:2	of	IN	O	O
a	ULESFIA.xml:S1:577:1	a	DT	O	O
drug	ULESFIA.xml:S1:579:4	drug	NN	O	O
cannot	ULESFIA.xml:S1:584:6	cannot	NN	O	O
be	ULESFIA.xml:S1:591:2	be	VB	O	O
directly	ULESFIA.xml:S1:594:8	directli	RB	O	O
compared	ULESFIA.xml:S1:603:8	compar	VBN	O	O
to	ULESFIA.xml:S1:612:2	to	TO	O	O
rates	ULESFIA.xml:S1:615:5	rate	NNS	O	O
in	ULESFIA.xml:S1:621:2	in	IN	O	O
the	ULESFIA.xml:S1:624:3	the	DT	O	O
clinical	ULESFIA.xml:S1:628:8	clinic	JJ	O	O
trials	ULESFIA.xml:S1:637:6	trial	NNS	O	O
of	ULESFIA.xml:S1:644:2	of	IN	O	O
another	ULESFIA.xml:S1:647:7	anoth	DT	O	O
drug	ULESFIA.xml:S1:655:4	drug	NN	O	O
and	ULESFIA.xml:S1:660:3	and	CC	O	O
may	ULESFIA.xml:S1:664:3	may	MD	O	O
not	ULESFIA.xml:S1:668:3	not	RB	O	O
reflect	ULESFIA.xml:S1:672:7	reflect	VB	O	O
the	ULESFIA.xml:S1:680:3	the	DT	O	O
rates	ULESFIA.xml:S1:684:5	rate	NNS	O	O
observed	ULESFIA.xml:S1:690:8	observ	VBD	O	O
in	ULESFIA.xml:S1:699:2	in	IN	O	O
clinical	ULESFIA.xml:S1:702:8	clinic	JJ	O	O
practice	ULESFIA.xml:S1:711:8	practic	NN	O	O
.	ULESFIA.xml:S1:719:1	.	.	O	O

The	ULESFIA.xml:S1:731:3	the	DT	O	O
rates	ULESFIA.xml:S1:735:5	rate	NNS	O	O
of	ULESFIA.xml:S1:741:2	of	IN	O	O
adverse	ULESFIA.xml:S1:744:7	advers	JJ	O	O
reactions	ULESFIA.xml:S1:752:9	reaction	NNS	O	O
below	ULESFIA.xml:S1:762:5	below	IN	O	O
were	ULESFIA.xml:S1:768:4	were	VBD	O	O
derived	ULESFIA.xml:S1:773:7	deriv	VBN	O	O
from	ULESFIA.xml:S1:781:4	from	IN	O	O
two	ULESFIA.xml:S1:786:3	two	CD	O	O
randomized	ULESFIA.xml:S1:790:10	random	NNS	O	O
,	ULESFIA.xml:S1:800:1	,	,	O	O
multi	ULESFIA.xml:S1:802:5	multi	SYM	O	O
-	ULESFIA.xml:S1:807:1	-	:	O	O
center	ULESFIA.xml:S1:808:6	center	NN	O	O
,	ULESFIA.xml:S1:814:1	,	,	O	O
vehicle	ULESFIA.xml:S1:816:7	vehicl	NN	O	O
-	ULESFIA.xml:S1:823:1	-	:	O	O
controlled	ULESFIA.xml:S1:824:10	control	VBN	O	O
clinical	ULESFIA.xml:S1:835:8	clinic	JJ	O	O
trials	ULESFIA.xml:S1:844:6	trial	NNS	O	O
and	ULESFIA.xml:S1:851:3	and	CC	O	O
one	ULESFIA.xml:S1:855:3	one	CD	O	O
open	ULESFIA.xml:S1:859:4	open	JJ	O	O
-	ULESFIA.xml:S1:863:1	-	:	O	O
label	ULESFIA.xml:S1:864:5	label	NN	O	O
study	ULESFIA.xml:S1:870:5	studi	NN	O	O
in	ULESFIA.xml:S1:876:2	in	IN	O	O
subjects	ULESFIA.xml:S1:879:8	subject	NNS	O	O
with	ULESFIA.xml:S1:888:4	with	IN	O	O
head	ULESFIA.xml:S1:893:4	head	NN	O	O
lice	ULESFIA.xml:S1:898:4	lice	NN	O	O
infestation	ULESFIA.xml:S1:903:11	infest	NN	O	O
.	ULESFIA.xml:S1:914:1	.	.	O	O

Skin	ULESFIA.xml:S1:926:4	skin	NNP	O	O
,	ULESFIA.xml:S1:930:1	,	,	O	O
scalp	ULESFIA.xml:S1:932:5	scalp	NN	O	O
,	ULESFIA.xml:S1:937:1	,	,	O	O
and	ULESFIA.xml:S1:939:3	and	CC	O	O
ocular	ULESFIA.xml:S1:943:6	ocular	JJ	O	B-AdverseReaction
irritation	ULESFIA.xml:S1:950:10	irrit	NN	O	I-AdverseReaction
were	ULESFIA.xml:S1:961:4	were	VBD	O	O
monitored	ULESFIA.xml:S1:966:9	monitor	VBN	O	O
in	ULESFIA.xml:S1:976:2	in	IN	O	O
the	ULESFIA.xml:S1:979:3	the	DT	O	O
clinical	ULESFIA.xml:S1:983:8	clinic	JJ	O	O
trials	ULESFIA.xml:S1:992:6	trial	NNS	O	O
.	ULESFIA.xml:S1:998:1	.	.	O	O

All	ULESFIA.xml:S1:1000:3	all	DT	O	O
subjects	ULESFIA.xml:S1:1004:8	subject	NNS	O	O
were	ULESFIA.xml:S1:1013:4	were	VBD	O	O
queried	ULESFIA.xml:S1:1018:7	queri	VBN	O	O
about	ULESFIA.xml:S1:1026:5	about	IN	O	O
the	ULESFIA.xml:S1:1032:3	the	DT	O	O
presence	ULESFIA.xml:S1:1036:8	presenc	NN	O	O
of	ULESFIA.xml:S1:1045:2	of	IN	O	O
skin	ULESFIA.xml:S1:1048:4	skin	NN	O	O
and	ULESFIA.xml:S1:1053:3	and	CC	O	O
scalp	ULESFIA.xml:S1:1057:5	scalp	NN	O	O
symptoms	ULESFIA.xml:S1:1063:8	symptom	NNS	O	O
;	ULESFIA.xml:S1:1071:1	;	:	O	O
the	ULESFIA.xml:S1:1073:3	the	DT	O	O
results	ULESFIA.xml:S1:1077:7	result	NNS	O	O
are	ULESFIA.xml:S1:1085:3	are	VBP	O	O
presented	ULESFIA.xml:S1:1089:9	present	VBN	O	O
in	ULESFIA.xml:S1:1099:2	in	IN	O	O
Table	ULESFIA.xml:S1:1102:5	tabl	JJ	O	O
2	ULESFIA.xml:S1:1108:1	2	CD	O	O
.	ULESFIA.xml:S1:1109:1	.	.	O	O

Table	ULESFIA.xml:S1:1127:5	tabl	NN	O	O

2	ULESFIA.xml:S1:1133:1	2	CD	O	O
:	ULESFIA.xml:S1:1134:1	:	:	O	O
Monitored	ULESFIA.xml:S1:1136:9	monitor	JJ	O	O
Adverse	ULESFIA.xml:S1:1146:7	advers	NNP	O	O
Reactions	ULESFIA.xml:S1:1154:9	reaction	NNP	O	O
-	ULESFIA.xml:S1:1164:1	-	:	O	O
Application	ULESFIA.xml:S1:1166:11	applic	NNP	O	O
Site	ULESFIA.xml:S1:1178:4	site	NNP	O	O
Symptoms	ULESFIA.xml:S1:1183:8	symptom	NNP	O	O

Event	ULESFIA.xml:S1:1194:5	event	NN	O	O
ULESFIA	ULESFIA.xml:S1:1211:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S1:1222:1	(	(	O	O
r	ULESFIA.xml:S1:1223:1	r	NN	O	O
)	ULESFIA.xml:S1:1224:1	)	)	O	O
Lotion	ULESFIA.xml:S1:1229:6	lotion	NN	O	O
Vehicle	ULESFIA.xml:S1:1237:7	vehicl	NNP	O	O

Application	ULESFIA.xml:S1:1257:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	ULESFIA.xml:S1:1269:4	site	NN	I-AdverseReaction	I-AdverseReaction
Irritation	ULESFIA.xml:S1:1274:10	irrit	NNP	I-AdverseReaction	I-AdverseReaction
2%	ULESFIA.xml:S1:1286:2	2%	CD	O	O
(	ULESFIA.xml:S1:1289:1	(	(	O	O
11	ULESFIA.xml:S1:1290:2	11	CD	O	O
478	ULESFIA.xml:S1:1293:3	478	CD	O	O
)	ULESFIA.xml:S1:1296:1	)	)	O	O
1%	ULESFIA.xml:S1:1303:2	1%	CD	O	O
(	ULESFIA.xml:S1:1306:1	(	(	O	O
2	ULESFIA.xml:S1:1307:1	2	CD	O	O
336	ULESFIA.xml:S1:1309:3	336	CD	O	O
)	ULESFIA.xml:S1:1312:1	)	)	O	O

Application	ULESFIA.xml:S1:1322:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	ULESFIA.xml:S1:1334:4	site	NN	I-AdverseReaction	I-AdverseReaction
anesthesia	ULESFIA.xml:S1:1339:10	anesthesia	NN	I-AdverseReaction	I-AdverseReaction
hypoesthesia	ULESFIA.xml:S1:1351:12	hypoesthesia	NN	I-AdverseReaction	I-AdverseReaction
2%	ULESFIA.xml:S1:1365:2	2%	CD	O	O
(	ULESFIA.xml:S1:1368:1	(	(	O	O
10	ULESFIA.xml:S1:1369:2	10	CD	O	O
478	ULESFIA.xml:S1:1372:3	478	CD	O	O
)	ULESFIA.xml:S1:1375:1	)	)	O	O
0%	ULESFIA.xml:S1:1382:2	0%	CD	O	O
(	ULESFIA.xml:S1:1385:1	(	(	O	O
0	ULESFIA.xml:S1:1386:1	0	CD	O	O
336	ULESFIA.xml:S1:1388:3	336	CD	O	O
)	ULESFIA.xml:S1:1391:1	)	)	O	O

Pain	ULESFIA.xml:S1:1401:4	pain	NN	B-AdverseReaction	B-AdverseReaction
1%	ULESFIA.xml:S1:1418:2	1%	CD	O	O
(	ULESFIA.xml:S1:1421:1	(	(	O	O
5	ULESFIA.xml:S1:1422:1	5	CD	O	O
478	ULESFIA.xml:S1:1424:3	478	CD	O	O
)	ULESFIA.xml:S1:1427:1	)	)	O	O
0%	ULESFIA.xml:S1:1435:2	0%	CD	O	O
(	ULESFIA.xml:S1:1438:1	(	(	O	O
1	ULESFIA.xml:S1:1439:1	1	CD	O	O
336	ULESFIA.xml:S1:1441:3	336	CD	O	O
)	ULESFIA.xml:S1:1444:1	)	)	O	O

The	ULESFIA.xml:S1:1469:3	the	DT	O	O
subset	ULESFIA.xml:S1:1473:6	subset	NN	O	O
of	ULESFIA.xml:S1:1480:2	of	IN	O	O
subjects	ULESFIA.xml:S1:1483:8	subject	NNS	O	O
who	ULESFIA.xml:S1:1492:3	who	WP	O	O
did	ULESFIA.xml:S1:1496:3	did	VBD	O	O
not	ULESFIA.xml:S1:1500:3	not	RB	O	O
have	ULESFIA.xml:S1:1504:4	have	VB	O	O
pruritus	ULESFIA.xml:S1:1509:8	pruritu	NN	O	B-AdverseReaction
,	ULESFIA.xml:S1:1517:1	,	,	O	O
erythema	ULESFIA.xml:S1:1519:8	erythema	NN	O	B-AdverseReaction
,	ULESFIA.xml:S1:1527:1	,	,	O	O
edema	ULESFIA.xml:S1:1529:5	edema	NN	O	B-AdverseReaction
or	ULESFIA.xml:S1:1535:2	or	CC	O	O
pyoderma	ULESFIA.xml:S1:1538:8	pyoderma	NN	O	O
of	ULESFIA.xml:S1:1547:2	of	IN	O	O
skin	ULESFIA.xml:S1:1550:4	skin	NN	O	O
and	ULESFIA.xml:S1:1555:3	and	CC	O	O
scalp	ULESFIA.xml:S1:1559:5	scalp	NN	O	O
,	ULESFIA.xml:S1:1564:1	,	,	O	O
or	ULESFIA.xml:S1:1566:2	or	CC	O	O
ocular	ULESFIA.xml:S1:1569:6	ocular	JJ	O	O
irritation	ULESFIA.xml:S1:1576:10	irrit	NN	O	O
prior	ULESFIA.xml:S1:1587:5	prior	RB	O	O
to	ULESFIA.xml:S1:1593:2	to	TO	O	O
treatment	ULESFIA.xml:S1:1596:9	treatment	NN	O	O
were	ULESFIA.xml:S1:1606:4	were	VBD	O	O
assessed	ULESFIA.xml:S1:1611:8	assess	VBN	O	O
for	ULESFIA.xml:S1:1620:3	for	IN	O	O
these	ULESFIA.xml:S1:1624:5	these	DT	O	O
signs	ULESFIA.xml:S1:1630:5	sign	NNS	O	O
and	ULESFIA.xml:S1:1636:3	and	CC	O	O
symptoms	ULESFIA.xml:S1:1640:8	symptom	NNS	O	O
after	ULESFIA.xml:S1:1649:5	after	IN	O	O
treatment	ULESFIA.xml:S1:1655:9	treatment	NN	O	O
;	ULESFIA.xml:S1:1664:1	;	:	O	O
the	ULESFIA.xml:S1:1666:3	the	DT	O	O
results	ULESFIA.xml:S1:1670:7	result	NNS	O	O
are	ULESFIA.xml:S1:1678:3	are	VBP	O	O
presented	ULESFIA.xml:S1:1682:9	present	VBN	O	O
in	ULESFIA.xml:S1:1692:2	in	IN	O	O
Table	ULESFIA.xml:S1:1695:5	tabl	JJ	O	O
3	ULESFIA.xml:S1:1701:1	3	CD	O	O
.	ULESFIA.xml:S1:1702:1	.	.	O	O

Table	ULESFIA.xml:S1:1718:5	tabl	NN	O	O

3	ULESFIA.xml:S1:1724:1	3	CD	O	O

:	ULESFIA.xml:S1:1725:1	:	:	O	O
Monitored	ULESFIA.xml:S1:1727:9	monitor	VBD	O	O
Adverse	ULESFIA.xml:S1:1737:7	advers	NNP	O	O
Reactions	ULESFIA.xml:S1:1745:9	reaction	NNP	O	O
-	ULESFIA.xml:S1:1755:1	-	:	O	O
Pruritus	ULESFIA.xml:S1:1757:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
,	ULESFIA.xml:S1:1765:1	,	,	O	O
Erythema	ULESFIA.xml:S1:1767:8	erythema	NNP	B-AdverseReaction	B-AdverseReaction
,	ULESFIA.xml:S1:1775:1	,	,	O	O
Pyoderma	ULESFIA.xml:S1:1777:8	pyoderma	NNP	B-AdverseReaction	O
and	ULESFIA.xml:S1:1786:3	and	CC	O	O
Ocular	ULESFIA.xml:S1:1790:6	ocular	NNP	B-AdverseReaction	O
Irritation	ULESFIA.xml:S1:1797:10	irrit	NNP	I-AdverseReaction	O
with	ULESFIA.xml:S1:1808:4	with	IN	O	O
Onset	ULESFIA.xml:S1:1813:5	onset	NNP	O	O
After	ULESFIA.xml:S1:1819:5	after	IN	O	O
Treatment	ULESFIA.xml:S1:1825:9	treatment	NNP	O	O

Signs	ULESFIA.xml:S1:1837:5	sign	NNS	O	O
Symptoms	ULESFIA.xml:S1:1843:8	symptom	NNP	O	O
ULESFIA	ULESFIA.xml:S1:1854:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S1:1865:1	(	(	O	O
r	ULESFIA.xml:S1:1866:1	r	NN	O	O
)	ULESFIA.xml:S1:1867:1	)	)	O	O
Lotion	ULESFIA.xml:S1:1872:6	lotion	NN	O	O
Vehicle	ULESFIA.xml:S1:1880:7	vehicl	NNP	O	O

Pruritus	ULESFIA.xml:S1:1900:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
12%	ULESFIA.xml:S1:1917:3	12%	CD	O	O
(	ULESFIA.xml:S1:1921:1	(	(	O	O
14	ULESFIA.xml:S1:1922:2	14	CD	O	O
116	ULESFIA.xml:S1:1925:3	116	CD	O	O
)	ULESFIA.xml:S1:1928:1	)	)	O	O
4%	ULESFIA.xml:S1:1934:2	4%	CD	O	O
(	ULESFIA.xml:S1:1937:1	(	(	O	O
3	ULESFIA.xml:S1:1938:1	3	CD	O	O
67	ULESFIA.xml:S1:1940:2	67	CD	O	O
)	ULESFIA.xml:S1:1942:1	)	)	O	O

Erythema	ULESFIA.xml:S1:1954:8	erythema	RB	B-AdverseReaction	B-AdverseReaction
10%	ULESFIA.xml:S1:1971:3	10%	CD	O	O
(	ULESFIA.xml:S1:1975:1	(	(	O	O
32	ULESFIA.xml:S1:1976:2	32	CD	O	O
309	ULESFIA.xml:S1:1979:3	309	CD	O	O
)	ULESFIA.xml:S1:1982:1	)	)	O	O
9%	ULESFIA.xml:S1:1988:2	9%	CD	O	O
(	ULESFIA.xml:S1:1991:1	(	(	O	O
19	ULESFIA.xml:S1:1992:2	19	CD	O	O
217	ULESFIA.xml:S1:1995:3	217	CD	O	O
)	ULESFIA.xml:S1:1998:1	)	)	O	O

Pyoderma	ULESFIA.xml:S1:2008:8	pyoderma	$	B-AdverseReaction	B-AdverseReaction
7%	ULESFIA.xml:S1:2025:2	7%	CD	O	O
(	ULESFIA.xml:S1:2028:1	(	(	O	O
22	ULESFIA.xml:S1:2029:2	22	CD	O	O
308	ULESFIA.xml:S1:2032:3	308	CD	O	O
)	ULESFIA.xml:S1:2035:1	)	)	O	O
4%	ULESFIA.xml:S1:2042:2	4%	CD	O	O
(	ULESFIA.xml:S1:2045:1	(	(	O	O
10	ULESFIA.xml:S1:2046:2	10	CD	O	O
230	ULESFIA.xml:S1:2049:3	230	CD	O	O
)	ULESFIA.xml:S1:2052:1	)	)	O	O

Ocular	ULESFIA.xml:S1:2062:6	ocular	JJ	B-AdverseReaction	B-AdverseReaction
irritation	ULESFIA.xml:S1:2069:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
6%	ULESFIA.xml:S1:2081:2	6%	CD	O	O
(	ULESFIA.xml:S1:2084:1	(	(	O	O
26	ULESFIA.xml:S1:2085:2	26	CD	O	O
428	ULESFIA.xml:S1:2088:3	428	CD	O	O
)	ULESFIA.xml:S1:2091:1	)	)	O	O
1%	ULESFIA.xml:S1:2098:2	1%	CD	O	O
(	ULESFIA.xml:S1:2101:1	(	(	O	O
3	ULESFIA.xml:S1:2102:1	3	CD	O	O
313	ULESFIA.xml:S1:2104:3	313	CD	O	O
)	ULESFIA.xml:S1:2107:1	)	)	O	O

Other	ULESFIA.xml:S1:2132:5	other	JJ	O	O
less	ULESFIA.xml:S1:2138:4	less	JJR	O	O
common	ULESFIA.xml:S1:2143:6	common	JJ	O	O
reactions	ULESFIA.xml:S1:2150:9	reaction	NNS	O	O
(	ULESFIA.xml:S1:2160:1	(	(	O	O
less	ULESFIA.xml:S1:2161:4	less	JJR	O	O
than	ULESFIA.xml:S1:2166:4	than	IN	O	O
1%	ULESFIA.xml:S1:2171:2	1%	CD	O	O
but	ULESFIA.xml:S1:2174:3	but	CC	O	O
more	ULESFIA.xml:S1:2178:4	more	JJR	O	O
than	ULESFIA.xml:S1:2183:4	than	IN	O	O
0.1%	ULESFIA.xml:S1:2188:4	0.1%	CD	O	O
)	ULESFIA.xml:S1:2192:1	)	)	O	O
were	ULESFIA.xml:S1:2194:4	were	VBD	O	O
,	ULESFIA.xml:S1:2198:1	,	,	O	O
in	ULESFIA.xml:S1:2200:2	in	IN	O	O
decreasing	ULESFIA.xml:S1:2203:10	decreas	VBG	O	O
order	ULESFIA.xml:S1:2214:5	order	NN	O	O
of	ULESFIA.xml:S1:2220:2	of	IN	O	O
incidence	ULESFIA.xml:S1:2223:9	incid	NN	O	O
:	ULESFIA.xml:S1:2232:1	:	:	O	O
application	ULESFIA.xml:S1:2234:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	ULESFIA.xml:S1:2246:4	site	NN	I-AdverseReaction	I-AdverseReaction
dryness	ULESFIA.xml:S1:2251:7	dryness	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S1:2258:1	,	,	O	O
application	ULESFIA.xml:S1:2260:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	ULESFIA.xml:S1:2272:4	site	NN	I-AdverseReaction	I-AdverseReaction
excoriation	ULESFIA.xml:S1:2277:11	excori	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S1:2288:1	,	,	O	O
paraesthesia	ULESFIA.xml:S1:2290:12	paraesthesia	NN	B-AdverseReaction	B-AdverseReaction
,	ULESFIA.xml:S1:2302:1	,	,	O	O
application	ULESFIA.xml:S1:2304:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	ULESFIA.xml:S1:2316:4	site	NN	I-AdverseReaction	I-AdverseReaction
dermatitis	ULESFIA.xml:S1:2321:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S1:2331:1	,	,	O	O
excoriation	ULESFIA.xml:S1:2333:11	excori	NN	B-AdverseReaction	B-AdverseReaction
,	ULESFIA.xml:S1:2344:1	,	,	O	O
thermal	ULESFIA.xml:S1:2346:7	thermal	JJ	B-AdverseReaction	B-AdverseReaction
burn	ULESFIA.xml:S1:2354:4	burn	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S1:2358:1	,	,	O	O
dandruff	ULESFIA.xml:S1:2360:8	dandruff	NN	B-AdverseReaction	B-AdverseReaction
,	ULESFIA.xml:S1:2368:1	,	,	O	O
erythema	ULESFIA.xml:S1:2370:8	erythema	NN	B-AdverseReaction	B-AdverseReaction
,	ULESFIA.xml:S1:2378:1	,	,	O	O
rash	ULESFIA.xml:S1:2380:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	ULESFIA.xml:S1:2384:1	,	,	O	O
and	ULESFIA.xml:S1:2386:3	and	CC	O	O
skin	ULESFIA.xml:S1:2390:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
exfoliation	ULESFIA.xml:S1:2395:11	exfoli	NN	I-AdverseReaction	I-AdverseReaction
.	ULESFIA.xml:S1:2406:1	.	.	O	O
5	ULESFIA.xml:S2:5:1	5	CD	O	O
WARNINGS	ULESFIA.xml:S2:17:8	warn	NNP	O	O
AND	ULESFIA.xml:S2:26:3	and	NNP	O	O
PRECAUTIONS	ULESFIA.xml:S2:30:11	precaut	NNP	O	O

EXCERPT	ULESFIA.xml:S2:50:7	excerpt	NN	O	O
:	ULESFIA.xml:S2:57:1	:	:	O	O
Neonatal	ULESFIA.xml:S2:65:8	neonat	JJ	B-AdverseReaction	B-AdverseReaction
toxicity	ULESFIA.xml:S2:74:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
:	ULESFIA.xml:S2:82:1	:	:	O	O
Risk	ULESFIA.xml:S2:84:4	risk	NN	O	O
of	ULESFIA.xml:S2:89:2	of	IN	O	O
gasping	ULESFIA.xml:S2:92:7	gasp	VBG	B-AdverseReaction	O
syndrome	ULESFIA.xml:S2:100:8	syndrom	JJ	I-AdverseReaction	O
if	ULESFIA.xml:S2:109:2	if	IN	O	O
benzyl	ULESFIA.xml:S2:112:6	benzyl	JJ	O	O
alcohol	ULESFIA.xml:S2:119:7	alcohol	NN	O	O
is	ULESFIA.xml:S2:127:2	is	VBZ	O	O
used	ULESFIA.xml:S2:130:4	use	VBN	O	O
in	ULESFIA.xml:S2:135:2	in	IN	O	O
neonates	ULESFIA.xml:S2:138:8	neonat	NNS	O	O
.	ULESFIA.xml:S2:146:1	.	.	O	O

(	ULESFIA.xml:S2:148:1	(	(	O	O
5.1	ULESFIA.xml:S2:151:3	5.1	CD	O	O
)	ULESFIA.xml:S2:156:1	)	)	O	O

Eye	ULESFIA.xml:S2:163:3	eye	JJ	B-AdverseReaction	B-AdverseReaction
irritation	ULESFIA.xml:S2:167:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
:	ULESFIA.xml:S2:177:1	:	:	O	O
Avoid	ULESFIA.xml:S2:179:5	avoid	NNP	O	O
eye	ULESFIA.xml:S2:185:3	eye	NN	O	O
exposure	ULESFIA.xml:S2:189:8	exposur	NN	O	O
.	ULESFIA.xml:S2:197:1	.	.	O	O

Flush	ULESFIA.xml:S2:199:5	flush	NNP	O	O
immediately	ULESFIA.xml:S2:205:11	immedi	RB	O	O
with	ULESFIA.xml:S2:217:4	with	IN	O	O
water	ULESFIA.xml:S2:222:5	water	NN	O	O
if	ULESFIA.xml:S2:228:2	if	IN	O	O
ULESFIA	ULESFIA.xml:S2:231:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S2:241:1	(	(	O	O
r	ULESFIA.xml:S2:242:1	r	NN	O	O
)	ULESFIA.xml:S2:243:1	)	)	O	O
Lotion	ULESFIA.xml:S2:248:6	lotion	NN	O	O
comes	ULESFIA.xml:S2:255:5	come	VBZ	O	O
into	ULESFIA.xml:S2:261:4	into	IN	O	O
contact	ULESFIA.xml:S2:266:7	contact	NN	O	O
with	ULESFIA.xml:S2:274:4	with	IN	O	O
eyes	ULESFIA.xml:S2:279:4	eye	NNS	O	O
.	ULESFIA.xml:S2:283:1	.	.	O	O

(	ULESFIA.xml:S2:285:1	(	(	O	O
5.2	ULESFIA.xml:S2:288:3	5.2	CD	O	O
)	ULESFIA.xml:S2:293:1	)	)	O	O

Contact	ULESFIA.xml:S2:300:7	contact	JJ	B-AdverseReaction	O
dermatitis	ULESFIA.xml:S2:308:10	dermat	NN	I-AdverseReaction	O
:	ULESFIA.xml:S2:318:1	:	:	O	O
May	ULESFIA.xml:S2:320:3	may	NNP	O	O
occur	ULESFIA.xml:S2:324:5	occur	VB	O	O
with	ULESFIA.xml:S2:330:4	with	IN	O	O
ULESFIA	ULESFIA.xml:S2:335:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S2:345:1	(	(	O	O
r	ULESFIA.xml:S2:346:1	r	NN	O	O
)	ULESFIA.xml:S2:347:1	)	)	O	O
Lotion	ULESFIA.xml:S2:352:6	lotion	NN	O	O
.	ULESFIA.xml:S2:358:1	.	.	O	O

(	ULESFIA.xml:S2:360:1	(	(	O	O
5.3	ULESFIA.xml:S2:363:3	5.3	CD	O	O
)	ULESFIA.xml:S2:368:1	)	)	O	O

Use	ULESFIA.xml:S2:375:3	use	NNP	O	O
in	ULESFIA.xml:S2:379:2	in	IN	O	O
children	ULESFIA.xml:S2:382:8	children	NNS	O	O
:	ULESFIA.xml:S2:390:1	:	:	O	O
ULESFIA	ULESFIA.xml:S2:392:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S2:402:1	(	(	O	O
r	ULESFIA.xml:S2:403:1	r	NN	O	O
)	ULESFIA.xml:S2:404:1	)	)	O	O
Lotion	ULESFIA.xml:S2:409:6	lotion	NN	O	O
should	ULESFIA.xml:S2:416:6	should	MD	O	O
only	ULESFIA.xml:S2:423:4	onli	RB	O	O
be	ULESFIA.xml:S2:428:2	be	VB	O	O
used	ULESFIA.xml:S2:431:4	use	VBN	O	O
on	ULESFIA.xml:S2:436:2	on	IN	O	O
children	ULESFIA.xml:S2:439:8	children	NNS	O	O
under	ULESFIA.xml:S2:448:5	under	IN	O	O
the	ULESFIA.xml:S2:454:3	the	DT	O	O
direct	ULESFIA.xml:S2:458:6	direct	JJ	O	O
supervision	ULESFIA.xml:S2:465:11	supervis	NN	O	O
of	ULESFIA.xml:S2:477:2	of	IN	O	O
an	ULESFIA.xml:S2:480:2	an	DT	O	O
adult	ULESFIA.xml:S2:483:5	adult	NN	O	O
.	ULESFIA.xml:S2:488:1	.	.	O	O

Keep	ULESFIA.xml:S2:490:4	keep	VB	O	O
out	ULESFIA.xml:S2:495:3	out	IN	O	O
of	ULESFIA.xml:S2:499:2	of	IN	O	O
reach	ULESFIA.xml:S2:502:5	reach	NN	O	O
of	ULESFIA.xml:S2:508:2	of	IN	O	O
children	ULESFIA.xml:S2:511:8	children	NNS	O	O
.	ULESFIA.xml:S2:519:1	.	.	O	O

(	ULESFIA.xml:S2:521:1	(	(	O	O
5.4	ULESFIA.xml:S2:524:3	5.4	CD	O	O
)	ULESFIA.xml:S2:529:1	)	)	O	O

5	ULESFIA.xml:S2:544:1	5	CD	O	O

.	ULESFIA.xml:S2:545:1	.	.	O	O

1	ULESFIA.xml:S2:549:1	1	CD	O	O

Neonatal	ULESFIA.xml:S2:561:8	neonat	JJ	O	O
Toxicity	ULESFIA.xml:S2:570:8	toxic	NN	O	O

Intravenous	ULESFIA.xml:S2:592:11	intraven	JJ	O	O
administration	ULESFIA.xml:S2:604:14	administr	NN	O	O
of	ULESFIA.xml:S2:619:2	of	IN	O	O
products	ULESFIA.xml:S2:622:8	product	NNS	O	O
containing	ULESFIA.xml:S2:631:10	contain	VBG	O	O
benzyl	ULESFIA.xml:S2:642:6	benzyl	NN	O	O
alcohol	ULESFIA.xml:S2:649:7	alcohol	NN	O	O
has	ULESFIA.xml:S2:657:3	ha	VBZ	O	O
been	ULESFIA.xml:S2:661:4	been	VBN	O	O
associated	ULESFIA.xml:S2:666:10	associ	VBN	O	O
with	ULESFIA.xml:S2:677:4	with	IN	O	O
neonatal	ULESFIA.xml:S2:682:8	neonat	JJ	B-AdverseReaction	O
gasping	ULESFIA.xml:S2:691:7	gasp	VBG	I-AdverseReaction	O
syndrome	ULESFIA.xml:S2:699:8	syndrom	JJ	I-AdverseReaction	O
consisting	ULESFIA.xml:S2:708:10	consist	NN	O	O
of	ULESFIA.xml:S2:719:2	of	IN	O	O
severe	ULESFIA.xml:S2:722:6	sever	JJ	O	O
metabolic	ULESFIA.xml:S2:729:9	metabol	JJ	B-AdverseReaction	O
acidosis	ULESFIA.xml:S2:739:8	acidosi	NN	I-AdverseReaction	O
,	ULESFIA.xml:S2:747:1	,	,	O	O
gasping	ULESFIA.xml:S2:749:7	gasp	VBG	B-AdverseReaction	B-AdverseReaction
respirations	ULESFIA.xml:S2:757:12	respir	NNS	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S2:769:1	,	,	O	O
progressive	ULESFIA.xml:S2:771:11	progress	JJ	B-AdverseReaction	B-AdverseReaction
hypotension	ULESFIA.xml:S2:783:11	hypotens	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S2:794:1	,	,	O	O
seizures	ULESFIA.xml:S2:796:8	seizur	NNS	B-AdverseReaction	B-AdverseReaction
,	ULESFIA.xml:S2:804:1	,	,	O	O
central	ULESFIA.xml:S2:806:7	central	JJ	B-AdverseReaction	B-AdverseReaction
nervous	ULESFIA.xml:S2:814:7	nervou	JJ	I-AdverseReaction	I-AdverseReaction
system	ULESFIA.xml:S2:822:6	system	NN	I-AdverseReaction	I-AdverseReaction
depression	ULESFIA.xml:S2:829:10	depress	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S2:839:1	,	,	O	O
intraventricular	ULESFIA.xml:S2:841:16	intraventricular	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	ULESFIA.xml:S2:858:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	ULESFIA.xml:S2:868:1	,	,	O	O
and	ULESFIA.xml:S2:870:3	and	CC	O	O
death	ULESFIA.xml:S2:874:5	death	NN	B-AdverseReaction	B-AdverseReaction
in	ULESFIA.xml:S2:880:2	in	IN	O	O
preterm	ULESFIA.xml:S2:883:7	preterm	NN	O	O
,	ULESFIA.xml:S2:890:1	,	,	O	O
low	ULESFIA.xml:S2:892:3	low	JJ	O	O
birth	ULESFIA.xml:S2:896:5	birth	NN	O	O
weight	ULESFIA.xml:S2:902:6	weight	NN	O	O
infants	ULESFIA.xml:S2:909:7	infant	NNS	O	O
.	ULESFIA.xml:S2:916:1	.	.	O	O

Neonates	ULESFIA.xml:S2:918:8	neonat	NNS	O	O
(	ULESFIA.xml:S2:927:1	(	(	O	O
i	ULESFIA.xml:S2:928:1	i	NN	O	O
.	ULESFIA.xml:S2:929:1	.	.	O	O
e	ULESFIA.xml:S2:930:1	e	NN	O	O
.	ULESFIA.xml:S2:931:1	.	.	O	O

patients	ULESFIA.xml:S2:933:8	patient	NNS	O	O
less	ULESFIA.xml:S2:942:4	less	JJR	O	O
than	ULESFIA.xml:S2:947:4	than	IN	O	O
1	ULESFIA.xml:S2:952:1	1	CD	O	O
month	ULESFIA.xml:S2:954:5	month	NN	O	O
of	ULESFIA.xml:S2:960:2	of	IN	O	O
age	ULESFIA.xml:S2:963:3	age	NN	O	O
or	ULESFIA.xml:S2:967:2	or	CC	O	O
preterm	ULESFIA.xml:S2:970:7	preterm	JJ	O	O
infants	ULESFIA.xml:S2:978:7	infant	NNS	O	O
with	ULESFIA.xml:S2:986:4	with	IN	O	O
a	ULESFIA.xml:S2:991:1	a	DT	O	O
corrected	ULESFIA.xml:S2:993:9	correct	VBN	O	O
age	ULESFIA.xml:S2:1003:3	age	NN	O	O
of	ULESFIA.xml:S2:1007:2	of	IN	O	O
less	ULESFIA.xml:S2:1010:4	less	JJR	O	O
than	ULESFIA.xml:S2:1015:4	than	IN	O	O
44	ULESFIA.xml:S2:1020:2	44	CD	O	O
weeks	ULESFIA.xml:S2:1023:5	week	NNS	O	O
)	ULESFIA.xml:S2:1028:1	)	)	O	O
could	ULESFIA.xml:S2:1030:5	could	MD	O	O
be	ULESFIA.xml:S2:1036:2	be	VB	O	O
at	ULESFIA.xml:S2:1039:2	at	IN	O	O
risk	ULESFIA.xml:S2:1042:4	risk	NN	O	O
for	ULESFIA.xml:S2:1047:3	for	IN	O	O
gasping	ULESFIA.xml:S2:1051:7	gasp	VBG	B-AdverseReaction	O
syndrome	ULESFIA.xml:S2:1059:8	syndrom	JJ	I-AdverseReaction	O
if	ULESFIA.xml:S2:1068:2	if	IN	O	O
treated	ULESFIA.xml:S2:1071:7	treat	VBN	O	O
with	ULESFIA.xml:S2:1079:4	with	IN	O	O
ULESFIA	ULESFIA.xml:S2:1084:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S2:1094:1	(	(	O	O
r	ULESFIA.xml:S2:1095:1	r	NN	O	O
)	ULESFIA.xml:S2:1096:1	)	)	O	O
Lotion	ULESFIA.xml:S2:1102:6	lotion	NNP	O	O
[	ULESFIA.xml:S2:1110:1	[	NNP	O	O
see	ULESFIA.xml:S2:1111:3	see	VBP	O	O
Use	ULESFIA.xml:S2:1119:3	use	NNP	O	O
in	ULESFIA.xml:S2:1123:2	in	IN	O	O
Specific	ULESFIA.xml:S2:1126:8	specif	NNP	O	O
Populations	ULESFIA.xml:S2:1135:11	popul	NNP	O	O
(	ULESFIA.xml:S2:1151:1	(	(	O	O
8.4	ULESFIA.xml:S2:1157:3	8.4	CD	O	O
)]	ULESFIA.xml:S2:1165:2	)]	NN	O	O
.	ULESFIA.xml:S2:1169:1	.	.	O	O

5.2	ULESFIA.xml:S2:1191:3	5.2	CD	O	O

Eye	ULESFIA.xml:S2:1205:3	eye	NNP	O	O
Irritation	ULESFIA.xml:S2:1209:10	irrit	NNP	O	O

Avoid	ULESFIA.xml:S2:1237:5	avoid	NNP	O	O
eye	ULESFIA.xml:S2:1243:3	eye	NN	O	O
exposure	ULESFIA.xml:S2:1247:8	exposur	NN	O	O
.	ULESFIA.xml:S2:1255:1	.	.	O	O

ULESFIA	ULESFIA.xml:S2:1257:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S2:1267:1	(	(	O	O
r	ULESFIA.xml:S2:1268:1	r	NN	O	O
)	ULESFIA.xml:S2:1269:1	)	)	O	O
Lotion	ULESFIA.xml:S2:1275:6	lotion	NN	O	O
may	ULESFIA.xml:S2:1282:3	may	MD	O	O
cause	ULESFIA.xml:S2:1286:5	caus	VB	O	O
eye	ULESFIA.xml:S2:1292:3	eye	NN	B-AdverseReaction	B-AdverseReaction
irritation	ULESFIA.xml:S2:1296:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
.	ULESFIA.xml:S2:1306:1	.	.	O	O

If	ULESFIA.xml:S2:1308:2	If	IN	O	O
ULESFIA	ULESFIA.xml:S2:1311:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S2:1321:1	(	(	O	O
r	ULESFIA.xml:S2:1322:1	r	NN	O	O
)	ULESFIA.xml:S2:1323:1	)	)	O	O
Lotion	ULESFIA.xml:S2:1329:6	lotion	NN	O	O
comes	ULESFIA.xml:S2:1336:5	come	VBZ	O	O
in	ULESFIA.xml:S2:1342:2	in	IN	O	O
contact	ULESFIA.xml:S2:1345:7	contact	NN	O	O
with	ULESFIA.xml:S2:1353:4	with	IN	O	O
the	ULESFIA.xml:S2:1358:3	the	DT	O	O
eyes	ULESFIA.xml:S2:1362:4	eye	NNS	O	O
,	ULESFIA.xml:S2:1366:1	,	,	O	O
flush	ULESFIA.xml:S2:1368:5	flush	VB	O	O
them	ULESFIA.xml:S2:1374:4	them	PRP	O	O
immediately	ULESFIA.xml:S2:1379:11	immedi	RB	O	O
with	ULESFIA.xml:S2:1391:4	with	IN	O	O
water	ULESFIA.xml:S2:1396:5	water	NN	O	O
.	ULESFIA.xml:S2:1401:1	.	.	O	O

If	ULESFIA.xml:S2:1403:2	If	IN	O	O
irritation	ULESFIA.xml:S2:1406:10	irrit	NN	O	O
persists	ULESFIA.xml:S2:1417:8	persist	NNS	O	O
,	ULESFIA.xml:S2:1425:1	,	,	O	O
consult	ULESFIA.xml:S2:1427:7	consult	NN	O	O
a	ULESFIA.xml:S2:1435:1	a	DT	O	O
physician	ULESFIA.xml:S2:1437:9	physician	NN	O	O
.	ULESFIA.xml:S2:1446:1	.	.	O	O

5	ULESFIA.xml:S2:1466:1	5	CD	O	O

.	ULESFIA.xml:S2:1467:1	.	.	O	O

3	ULESFIA.xml:S2:1471:1	3	CD	O	O
Contact	ULESFIA.xml:S2:1483:7	contact	NNP	O	O
Dermatitis	ULESFIA.xml:S2:1491:10	dermat	NNP	O	O

ULESFIA	ULESFIA.xml:S2:1515:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S2:1525:1	(	(	O	O
r	ULESFIA.xml:S2:1526:1	r	NN	O	O
)	ULESFIA.xml:S2:1527:1	)	)	O	O
Lotion	ULESFIA.xml:S2:1533:6	lotion	NN	O	O
may	ULESFIA.xml:S2:1540:3	may	MD	O	O
cause	ULESFIA.xml:S2:1544:5	caus	VB	O	O
allergic	ULESFIA.xml:S2:1550:8	allerg	NN	B-AdverseReaction	O
or	ULESFIA.xml:S2:1559:2	or	CC	O	O
irritant	ULESFIA.xml:S2:1562:8	irrit	JJ	B-AdverseReaction	O
dermatitis	ULESFIA.xml:S2:1571:10	dermat	NN	I-AdverseReaction	O
.	ULESFIA.xml:S2:1581:1	.	.	O	O

5.4	ULESFIA.xml:S2:1601:3	5.4	CD	O	O

Use	ULESFIA.xml:S2:1615:3	use	NNP	O	O
in	ULESFIA.xml:S2:1619:2	in	IN	O	O
Children	ULESFIA.xml:S2:1622:8	children	NNP	O	O

ULESFIA	ULESFIA.xml:S2:1648:7	ulesfia	NNP	O	O
(	ULESFIA.xml:S2:1658:1	(	(	O	O
r	ULESFIA.xml:S2:1659:1	r	NN	O	O
)	ULESFIA.xml:S2:1660:1	)	)	O	O
Lotion	ULESFIA.xml:S2:1666:6	lotion	NN	O	O
should	ULESFIA.xml:S2:1673:6	should	MD	O	O
only	ULESFIA.xml:S2:1680:4	onli	RB	O	O
be	ULESFIA.xml:S2:1685:2	be	VB	O	O
used	ULESFIA.xml:S2:1688:4	use	VBN	O	O
on	ULESFIA.xml:S2:1693:2	on	IN	O	O
children	ULESFIA.xml:S2:1696:8	children	NNS	O	O
(	ULESFIA.xml:S2:1705:1	(	(	O	O
6	ULESFIA.xml:S2:1706:1	6	CD	O	O
months	ULESFIA.xml:S2:1708:6	month	NNS	O	O
of	ULESFIA.xml:S2:1715:2	of	IN	O	O
age	ULESFIA.xml:S2:1718:3	age	NN	O	O
and	ULESFIA.xml:S2:1722:3	and	CC	O	O
older	ULESFIA.xml:S2:1726:5	older	JJR	O	O
)	ULESFIA.xml:S2:1731:1	)	)	O	O
under	ULESFIA.xml:S2:1733:5	under	IN	O	O
the	ULESFIA.xml:S2:1739:3	the	DT	O	O
direct	ULESFIA.xml:S2:1743:6	direct	JJ	O	O
supervision	ULESFIA.xml:S2:1750:11	supervis	NN	O	O
of	ULESFIA.xml:S2:1762:2	of	IN	O	O
an	ULESFIA.xml:S2:1765:2	an	DT	O	O
adult	ULESFIA.xml:S2:1768:5	adult	NN	O	O
.	ULESFIA.xml:S2:1773:1	.	.	O	O

Keep	ULESFIA.xml:S2:1775:4	keep	VB	O	O
out	ULESFIA.xml:S2:1780:3	out	IN	O	O
of	ULESFIA.xml:S2:1784:2	of	IN	O	O
reach	ULESFIA.xml:S2:1787:5	reach	NN	O	O
of	ULESFIA.xml:S2:1793:2	of	IN	O	O
children	ULESFIA.xml:S2:1796:8	children	NNS	O	O
.	ULESFIA.xml:S2:1804:1	.	.	O	O
6	ULORIC.xml:S1:4:1	6	CD	O	O
ADVERSE	ULORIC.xml:S1:6:7	advers	JJ	O	O
REACTIONS	ULORIC.xml:S1:14:9	reaction	NN	O	O

EXCERPT	ULORIC.xml:S1:27:7	excerpt	NN	O	O
:	ULORIC.xml:S1:34:1	:	:	O	O
Adverse	ULORIC.xml:S1:38:7	advers	JJ	O	O
reactions	ULORIC.xml:S1:46:9	reaction	NNS	O	O
occurring	ULORIC.xml:S1:56:9	occur	VBG	O	O
in	ULORIC.xml:S1:66:2	in	IN	O	O
at	ULORIC.xml:S1:69:2	at	IN	O	O
least	ULORIC.xml:S1:72:5	least	JJS	O	O
1%	ULORIC.xml:S1:78:2	1%	CD	O	O
of	ULORIC.xml:S1:81:2	of	IN	O	O
ULORIC	ULORIC.xml:S1:84:6	ulor	NNP	O	O
-	ULORIC.xml:S1:90:1	-	:	O	O
treated	ULORIC.xml:S1:91:7	treat	VBD	O	O
patients	ULORIC.xml:S1:99:8	patient	NNS	O	O
,	ULORIC.xml:S1:107:1	,	,	O	O
and	ULORIC.xml:S1:109:3	and	CC	O	O
at	ULORIC.xml:S1:113:2	at	IN	O	O
least	ULORIC.xml:S1:116:5	least	JJS	O	O
0.5%	ULORIC.xml:S1:122:4	0.5%	CD	O	O
greater	ULORIC.xml:S1:127:7	greater	JJR	O	O
than	ULORIC.xml:S1:135:4	than	IN	O	O
placebo	ULORIC.xml:S1:140:7	placebo	NN	O	O
,	ULORIC.xml:S1:147:1	,	,	O	O
are	ULORIC.xml:S1:149:3	are	VBP	O	O
liver	ULORIC.xml:S1:153:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
function	ULORIC.xml:S1:159:8	function	NN	I-AdverseReaction	I-AdverseReaction
abnormalities	ULORIC.xml:S1:168:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:181:1	,	,	O	O
nausea	ULORIC.xml:S1:183:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:189:1	,	,	O	O
arthralgia	ULORIC.xml:S1:191:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:201:1	,	,	O	O
and	ULORIC.xml:S1:203:3	and	CC	O	O
rash	ULORIC.xml:S1:207:4	rash	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:211:1	.	.	O	O

(	ULORIC.xml:S1:213:1	(	(	O	O
6.1	ULORIC.xml:S1:216:3	6.1	CD	O	O
)	ULORIC.xml:S1:221:1	)	)	O	O

To	ULORIC.xml:S1:239:2	To	TO	O	O

report	ULORIC.xml:S1:242:6	report	NN	O	O
SUSPECTED	ULORIC.xml:S1:249:9	suspect	NNP	O	O
ADVERSE	ULORIC.xml:S1:259:7	advers	NNP	O	O
REACTIONS	ULORIC.xml:S1:267:9	reaction	NNP	O	O
,	ULORIC.xml:S1:276:1	,	,	O	O
contact	ULORIC.xml:S1:278:7	contact	NN	O	O
Takeda	ULORIC.xml:S1:286:6	takeda	NNP	O	O
Pharmaceuticals	ULORIC.xml:S1:293:15	pharmaceut	NNP	O	O
at	ULORIC.xml:S1:309:2	at	IN	O	O
1	ULORIC.xml:S1:312:1	1	CD	O	O
-	ULORIC.xml:S1:313:1	-	:	O	O
877	ULORIC.xml:S1:314:3	877	CD	O	O
-	ULORIC.xml:S1:317:1	-	:	O	O
TAKEDA	ULORIC.xml:S1:318:6	takeda	NNP	O	O
-	ULORIC.xml:S1:324:1	-	:	O	O
7	ULORIC.xml:S1:325:1	7	CD	O	O
(	ULORIC.xml:S1:327:1	(	(	O	O
1	ULORIC.xml:S1:328:1	1	CD	O	O
-	ULORIC.xml:S1:329:1	-	:	O	O
877	ULORIC.xml:S1:330:3	877	CD	O	O
-	ULORIC.xml:S1:333:1	-	:	O	O
825	ULORIC.xml:S1:334:3	825	CD	O	O
-	ULORIC.xml:S1:337:1	-	:	O	O
3327	ULORIC.xml:S1:338:4	3327	CD	O	O
)	ULORIC.xml:S1:342:1	)	)	O	O
or	ULORIC.xml:S1:344:2	or	CC	O	O
FDA	ULORIC.xml:S1:347:3	fda	NNP	O	O
at	ULORIC.xml:S1:351:2	at	IN	O	O
1	ULORIC.xml:S1:354:1	1	CD	O	O
-	ULORIC.xml:S1:355:1	-	:	O	O
800	ULORIC.xml:S1:356:3	800	CD	O	O
-	ULORIC.xml:S1:359:1	-	:	O	O
FDA	ULORIC.xml:S1:360:3	fda	NNP	O	O
-	ULORIC.xml:S1:363:1	-	:	O	O
1088	ULORIC.xml:S1:364:4	1088	CD	O	O
or	ULORIC.xml:S1:369:2	or	CC	O	O
www	ULORIC.xml:S1:372:3	www	VB	O	O
.	ULORIC.xml:S1:375:1	.	.	O	O
fda	ULORIC.xml:S1:376:3	fda	NN	O	O
.	ULORIC.xml:S1:379:1	.	.	O	O
gov	ULORIC.xml:S1:380:3	gov	JJ	O	O
medwatch	ULORIC.xml:S1:384:8	medwatch	NN	O	O
.	ULORIC.xml:S1:392:1	.	.	O	O

6.1	ULORIC.xml:S1:404:3	6.1	CD	O	O

Clinical	ULORIC.xml:S1:408:8	clinic	JJ	O	O
Trials	ULORIC.xml:S1:417:6	trial	NNS	O	O
Experience	ULORIC.xml:S1:424:10	experi	NN	O	O

Because	ULORIC.xml:S1:438:7	becaus	IN	O	O
clinical	ULORIC.xml:S1:446:8	clinic	JJ	O	O
trials	ULORIC.xml:S1:455:6	trial	NNS	O	O
are	ULORIC.xml:S1:462:3	are	VBP	O	O
conducted	ULORIC.xml:S1:466:9	conduct	VBN	O	O
under	ULORIC.xml:S1:476:5	under	IN	O	O
widely	ULORIC.xml:S1:482:6	wide	RB	O	O
varying	ULORIC.xml:S1:489:7	vari	VBG	O	O
conditions	ULORIC.xml:S1:497:10	condit	NNS	O	O
,	ULORIC.xml:S1:507:1	,	,	O	O
adverse	ULORIC.xml:S1:509:7	advers	JJ	O	O
reaction	ULORIC.xml:S1:517:8	reaction	NN	O	O
rates	ULORIC.xml:S1:526:5	rate	NNS	O	O
observed	ULORIC.xml:S1:532:8	observ	VBD	O	O
in	ULORIC.xml:S1:541:2	in	IN	O	O
the	ULORIC.xml:S1:544:3	the	DT	O	O
clinical	ULORIC.xml:S1:548:8	clinic	JJ	O	O
trials	ULORIC.xml:S1:557:6	trial	NNS	O	O
of	ULORIC.xml:S1:564:2	of	IN	O	O
a	ULORIC.xml:S1:567:1	a	DT	O	O
drug	ULORIC.xml:S1:569:4	drug	NN	O	O
cannot	ULORIC.xml:S1:574:6	cannot	NN	O	O
be	ULORIC.xml:S1:581:2	be	VB	O	O
directly	ULORIC.xml:S1:584:8	directli	RB	O	O
compared	ULORIC.xml:S1:593:8	compar	VBN	O	O
to	ULORIC.xml:S1:602:2	to	TO	O	O
rates	ULORIC.xml:S1:605:5	rate	NNS	O	O
in	ULORIC.xml:S1:611:2	in	IN	O	O
the	ULORIC.xml:S1:614:3	the	DT	O	O
clinical	ULORIC.xml:S1:618:8	clinic	JJ	O	O
trials	ULORIC.xml:S1:627:6	trial	NNS	O	O
of	ULORIC.xml:S1:634:2	of	IN	O	O
another	ULORIC.xml:S1:637:7	anoth	DT	O	O
drug	ULORIC.xml:S1:645:4	drug	NN	O	O
and	ULORIC.xml:S1:650:3	and	CC	O	O
may	ULORIC.xml:S1:654:3	may	MD	O	O
not	ULORIC.xml:S1:658:3	not	RB	O	O
reflect	ULORIC.xml:S1:662:7	reflect	VB	O	O
the	ULORIC.xml:S1:670:3	the	DT	O	O
rates	ULORIC.xml:S1:674:5	rate	NNS	O	O
observed	ULORIC.xml:S1:680:8	observ	VBD	O	O
in	ULORIC.xml:S1:689:2	in	IN	O	O
practice	ULORIC.xml:S1:692:8	practic	NN	O	O
.	ULORIC.xml:S1:700:1	.	.	O	O

A	ULORIC.xml:S1:706:1	A	DT	O	O
total	ULORIC.xml:S1:708:5	total	NN	O	O
of	ULORIC.xml:S1:714:2	of	IN	O	O
2757	ULORIC.xml:S1:717:4	2757	CD	O	O
subjects	ULORIC.xml:S1:722:8	subject	NNS	O	O
with	ULORIC.xml:S1:731:4	with	IN	O	O
hyperuricemia	ULORIC.xml:S1:736:13	hyperuricemia	NN	O	O
and	ULORIC.xml:S1:750:3	and	CC	O	O
gout	ULORIC.xml:S1:754:4	gout	NN	O	O
were	ULORIC.xml:S1:759:4	were	VBD	O	O
treated	ULORIC.xml:S1:764:7	treat	VBN	O	O
with	ULORIC.xml:S1:772:4	with	IN	O	O
ULORIC	ULORIC.xml:S1:777:6	ulor	NNP	O	O
40	ULORIC.xml:S1:784:2	40	CD	O	O
mg	ULORIC.xml:S1:787:2	mg	NN	O	O
or	ULORIC.xml:S1:790:2	or	CC	O	O
80	ULORIC.xml:S1:793:2	80	CD	O	O
mg	ULORIC.xml:S1:796:2	mg	JJ	O	O
daily	ULORIC.xml:S1:799:5	daili	RB	O	O
in	ULORIC.xml:S1:805:2	in	IN	O	O
clinical	ULORIC.xml:S1:808:8	clinic	JJ	O	O
studies	ULORIC.xml:S1:817:7	studi	NNS	O	O
.	ULORIC.xml:S1:824:1	.	.	O	O

For	ULORIC.xml:S1:826:3	for	IN	O	O
ULORIC	ULORIC.xml:S1:830:6	ulor	NNP	O	O
40	ULORIC.xml:S1:837:2	40	CD	O	O
mg	ULORIC.xml:S1:840:2	mg	NN	O	O
,	ULORIC.xml:S1:842:1	,	,	O	O
559	ULORIC.xml:S1:844:3	559	CD	O	O
patients	ULORIC.xml:S1:848:8	patient	NNS	O	O
were	ULORIC.xml:S1:857:4	were	VBD	O	O
treated	ULORIC.xml:S1:862:7	treat	VBN	O	O
for	ULORIC.xml:S1:870:3	for	IN	O	O
6	ULORIC.xml:S1:876:1	6	CD	O	O
months	ULORIC.xml:S1:878:6	month	NNS	O	O
.	ULORIC.xml:S1:884:1	.	.	O	O

For	ULORIC.xml:S1:886:3	for	IN	O	O
ULORIC	ULORIC.xml:S1:890:6	ulor	NNP	O	O
80	ULORIC.xml:S1:897:2	80	CD	O	O
mg	ULORIC.xml:S1:900:2	mg	NN	O	O
,	ULORIC.xml:S1:902:1	,	,	O	O
1377	ULORIC.xml:S1:904:4	1377	CD	O	O
subjects	ULORIC.xml:S1:909:8	subject	NNS	O	O
were	ULORIC.xml:S1:918:4	were	VBD	O	O
treated	ULORIC.xml:S1:923:7	treat	VBN	O	O
for	ULORIC.xml:S1:931:3	for	IN	O	O
6	ULORIC.xml:S1:937:1	6	CD	O	O
months	ULORIC.xml:S1:939:6	month	NNS	O	O
,	ULORIC.xml:S1:945:1	,	,	O	O
674	ULORIC.xml:S1:947:3	674	CD	O	O
patients	ULORIC.xml:S1:951:8	patient	NNS	O	O
were	ULORIC.xml:S1:960:4	were	VBD	O	O
treated	ULORIC.xml:S1:965:7	treat	VBN	O	O
for	ULORIC.xml:S1:973:3	for	IN	O	O
1	ULORIC.xml:S1:979:1	1	CD	O	O
year	ULORIC.xml:S1:981:4	year	NN	O	O
and	ULORIC.xml:S1:986:3	and	CC	O	O
515	ULORIC.xml:S1:990:3	515	CD	O	O
patients	ULORIC.xml:S1:994:8	patient	NNS	O	O
were	ULORIC.xml:S1:1003:4	were	VBD	O	O
treated	ULORIC.xml:S1:1008:7	treat	VBN	O	O
for	ULORIC.xml:S1:1016:3	for	IN	O	O
2	ULORIC.xml:S1:1022:1	2	CD	O	O
years	ULORIC.xml:S1:1024:5	year	NNS	O	O
.	ULORIC.xml:S1:1029:1	.	.	O	O

Most	ULORIC.xml:S1:1037:4	most	JJS	O	O
Common	ULORIC.xml:S1:1042:6	common	JJ	O	O
Adverse	ULORIC.xml:S1:1049:7	advers	JJ	O	O
Reactions	ULORIC.xml:S1:1057:9	reaction	NNS	O	O

In	ULORIC.xml:S1:1073:2	In	IN	O	O
three	ULORIC.xml:S1:1076:5	three	CD	O	O
randomized	ULORIC.xml:S1:1082:10	random	NNS	O	O
,	ULORIC.xml:S1:1092:1	,	,	O	O
controlled	ULORIC.xml:S1:1094:10	control	VBD	O	O
clinical	ULORIC.xml:S1:1105:8	clinic	JJ	O	O
studies	ULORIC.xml:S1:1114:7	studi	NNS	O	O
(	ULORIC.xml:S1:1122:1	(	(	O	O
Studies	ULORIC.xml:S1:1123:7	studi	NNPS	O	O
1	ULORIC.xml:S1:1131:1	1	CD	O	O
,	ULORIC.xml:S1:1132:1	,	,	O	O
2	ULORIC.xml:S1:1134:1	2	CD	O	O
and	ULORIC.xml:S1:1136:3	and	CC	O	O
3	ULORIC.xml:S1:1140:1	3	CD	O	O
)	ULORIC.xml:S1:1141:1	)	)	O	O
,	ULORIC.xml:S1:1142:1	,	,	O	O
which	ULORIC.xml:S1:1144:5	which	WDT	O	O
were	ULORIC.xml:S1:1150:4	were	VBD	O	O
six	ULORIC.xml:S1:1155:3	six	CD	O	O
to	ULORIC.xml:S1:1159:2	to	TO	O	O
12	ULORIC.xml:S1:1162:2	12	CD	O	O
months	ULORIC.xml:S1:1165:6	month	NNS	O	O
in	ULORIC.xml:S1:1172:2	in	IN	O	O
duration	ULORIC.xml:S1:1175:8	durat	NN	O	O
,	ULORIC.xml:S1:1183:1	,	,	O	O
the	ULORIC.xml:S1:1185:3	the	DT	O	O
following	ULORIC.xml:S1:1189:9	follow	JJ	O	O
adverse	ULORIC.xml:S1:1199:7	advers	JJ	O	O
reactions	ULORIC.xml:S1:1207:9	reaction	NNS	O	O
were	ULORIC.xml:S1:1217:4	were	VBD	O	O
reported	ULORIC.xml:S1:1222:8	report	VBN	O	O
by	ULORIC.xml:S1:1231:2	by	IN	O	O
the	ULORIC.xml:S1:1234:3	the	DT	O	O
treating	ULORIC.xml:S1:1238:8	treat	VBG	O	O
physician	ULORIC.xml:S1:1247:9	physician	NN	O	O
as	ULORIC.xml:S1:1257:2	as	IN	O	O
related	ULORIC.xml:S1:1260:7	relat	VBN	O	O
to	ULORIC.xml:S1:1268:2	to	TO	O	O
study	ULORIC.xml:S1:1271:5	studi	VB	O	O
drug	ULORIC.xml:S1:1277:4	drug	NN	O	O
.	ULORIC.xml:S1:1281:1	.	.	O	O

Table	ULORIC.xml:S1:1283:5	tabl	JJ	O	O
1	ULORIC.xml:S1:1289:1	1	CD	O	O
summarizes	ULORIC.xml:S1:1291:10	summar	JJ	O	O
adverse	ULORIC.xml:S1:1302:7	advers	JJ	O	O
reactions	ULORIC.xml:S1:1310:9	reaction	NNS	O	O
reported	ULORIC.xml:S1:1320:8	report	VBN	O	O
at	ULORIC.xml:S1:1329:2	at	IN	O	O
a	ULORIC.xml:S1:1332:1	a	DT	O	O
rate	ULORIC.xml:S1:1334:4	rate	NN	O	O
of	ULORIC.xml:S1:1339:2	of	IN	O	O
at	ULORIC.xml:S1:1342:2	at	IN	O	O
least	ULORIC.xml:S1:1345:5	least	JJS	O	O
1%	ULORIC.xml:S1:1351:2	1%	CD	O	O
in	ULORIC.xml:S1:1354:2	in	IN	O	O
ULORIC	ULORIC.xml:S1:1357:6	ulor	NNP	O	O
treatment	ULORIC.xml:S1:1364:9	treatment	NN	O	O
groups	ULORIC.xml:S1:1374:6	group	NNS	O	O
and	ULORIC.xml:S1:1381:3	and	CC	O	O
at	ULORIC.xml:S1:1385:2	at	IN	O	O
least	ULORIC.xml:S1:1388:5	least	JJS	O	O
0.5%	ULORIC.xml:S1:1394:4	0.5%	CD	O	O
greater	ULORIC.xml:S1:1399:7	greater	JJR	O	O
than	ULORIC.xml:S1:1407:4	than	IN	O	O
placebo	ULORIC.xml:S1:1412:7	placebo	NN	O	O
.	ULORIC.xml:S1:1419:1	.	.	O	O

Table	ULORIC.xml:S1:1427:5	tabl	JJ	O	O
1	ULORIC.xml:S1:1433:1	1	CD	O	O
:	ULORIC.xml:S1:1434:1	:	:	O	O
Adverse	ULORIC.xml:S1:1436:7	advers	JJ	O	O
Reactions	ULORIC.xml:S1:1444:9	reaction	NNS	O	O
Occurring	ULORIC.xml:S1:1454:9	occur	VBG	O	O
in	ULORIC.xml:S1:1464:2	in	IN	O	O
1%	ULORIC.xml:S1:1469:2	1%	CD	O	O
of	ULORIC.xml:S1:1472:2	of	IN	O	O
ULORIC	ULORIC.xml:S1:1475:6	ulor	NNP	O	O
-	ULORIC.xml:S1:1481:1	-	:	O	O
Treated	ULORIC.xml:S1:1482:7	treat	VBD	O	O
Patients	ULORIC.xml:S1:1490:8	patient	NNS	O	O
and	ULORIC.xml:S1:1499:3	and	CC	O	O
at	ULORIC.xml:S1:1503:2	at	IN	O	O
Least	ULORIC.xml:S1:1506:5	least	JJS	O	O
0.5%	ULORIC.xml:S1:1512:4	0.5%	CD	O	O
Greater	ULORIC.xml:S1:1516:7	greater	NNP	O	O
than	ULORIC.xml:S1:1524:4	than	IN	O	O
Seen	ULORIC.xml:S1:1529:4	seen	NNP	O	O
in	ULORIC.xml:S1:1534:2	in	IN	O	O
Patients	ULORIC.xml:S1:1537:8	patient	NNP	O	O
Receiving	ULORIC.xml:S1:1546:9	receiv	NNP	O	O
Placebo	ULORIC.xml:S1:1556:7	placebo	NNP	O	O
in	ULORIC.xml:S1:1564:2	in	IN	O	O
Controlled	ULORIC.xml:S1:1567:10	control	NNP	O	O
Studies	ULORIC.xml:S1:1578:7	studi	NNS	O	O

Adverse	ULORIC.xml:S1:1592:7	advers	JJ	O	O
Reactions	ULORIC.xml:S1:1600:9	reaction	NNP	O	O
Placebo	ULORIC.xml:S1:1623:7	placebo	NNP	O	O
ULORIC	ULORIC.xml:S1:1654:6	ulor	NNP	O	O
allopurinolOf	ULORIC.xml:S1:1670:13	allopurinolof	VBD	O	O
the	ULORIC.xml:S1:1684:3	the	DT	O	O
subjects	ULORIC.xml:S1:1688:8	subject	NNS	O	O
who	ULORIC.xml:S1:1697:3	who	WP	O	O
received	ULORIC.xml:S1:1701:8	receiv	VBD	O	O
allopurinol	ULORIC.xml:S1:1710:11	allopurinol	RB	O	O
,	ULORIC.xml:S1:1721:1	,	,	O	O
10	ULORIC.xml:S1:1723:2	10	CD	O	O
received	ULORIC.xml:S1:1726:8	receiv	VBD	O	O
100	ULORIC.xml:S1:1735:3	100	CD	O	O
mg	ULORIC.xml:S1:1739:2	mg	NNS	O	O
,	ULORIC.xml:S1:1741:1	,	,	O	O
145	ULORIC.xml:S1:1743:3	145	CD	O	O
received	ULORIC.xml:S1:1747:8	receiv	VBD	O	O
200	ULORIC.xml:S1:1756:3	200	CD	O	O
mg	ULORIC.xml:S1:1760:2	mg	NN	O	O
,	ULORIC.xml:S1:1762:1	,	,	O	O
and	ULORIC.xml:S1:1764:3	and	CC	O	O
1122	ULORIC.xml:S1:1768:4	1122	CD	O	O
received	ULORIC.xml:S1:1773:8	receiv	VBD	O	O
300	ULORIC.xml:S1:1782:3	300	CD	O	O
mg	ULORIC.xml:S1:1786:2	mg	NN	O	O
,	ULORIC.xml:S1:1788:1	,	,	O	O
based	ULORIC.xml:S1:1790:5	base	VBN	O	O
on	ULORIC.xml:S1:1796:2	on	IN	O	O
level	ULORIC.xml:S1:1799:5	level	NN	O	O
of	ULORIC.xml:S1:1805:2	of	IN	O	O
renal	ULORIC.xml:S1:1808:5	renal	JJ	O	O
impairment	ULORIC.xml:S1:1814:10	impair	NN	O	O
.	ULORIC.xml:S1:1824:1	.	.	O	O

(	ULORIC.xml:S1:1832:1	(	(	O	O
N	ULORIC.xml:S1:1833:1	N	NNP	O	O
134	ULORIC.xml:S1:1835:3	134	CD	O	O
)	ULORIC.xml:S1:1838:1	)	)	O	O
40	ULORIC.xml:S1:1863:2	40	CD	O	O
mg	ULORIC.xml:S1:1866:2	mg	JJ	O	O
daily	ULORIC.xml:S1:1869:5	daili	JJ	O	O
(	ULORIC.xml:S1:1874:1	(	(	O	O
N	ULORIC.xml:S1:1875:1	N	NNP	O	O
757	ULORIC.xml:S1:1877:3	757	CD	O	O
)	ULORIC.xml:S1:1880:1	)	)	O	O
80	ULORIC.xml:S1:1894:2	80	CD	O	O
mg	ULORIC.xml:S1:1897:2	mg	JJ	O	O
daily	ULORIC.xml:S1:1900:5	daili	JJ	O	O
(	ULORIC.xml:S1:1905:1	(	(	O	O
N	ULORIC.xml:S1:1906:1	N	NNP	O	O
1279	ULORIC.xml:S1:1908:4	1279	CD	O	O
)	ULORIC.xml:S1:1912:1	)	)	O	O
(	ULORIC.xml:S1:1917:1	(	(	O	O
N	ULORIC.xml:S1:1918:1	N	NNP	O	O
1277	ULORIC.xml:S1:1920:4	1277	CD	O	O
)	ULORIC.xml:S1:1924:1	)	)	O	O

Liver	ULORIC.xml:S1:1936:5	liver	NNP	B-AdverseReaction	B-AdverseReaction
Function	ULORIC.xml:S1:1942:8	function	NNP	I-AdverseReaction	I-AdverseReaction
Abnormalities	ULORIC.xml:S1:1951:13	abnorm	NNP	I-AdverseReaction	I-AdverseReaction
0.7%	ULORIC.xml:S1:1968:4	0.7%	CD	O	O
6.6%	ULORIC.xml:S1:1999:4	6.6%	CD	O	O
4.6%	ULORIC.xml:S1:2015:4	4.6%	CD	O	O
4.2%	ULORIC.xml:S1:2031:4	4.2%	CD	O	O

Nausea	ULORIC.xml:S1:2051:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
0.7%	ULORIC.xml:S1:2082:4	0.7%	CD	O	O
1.1%	ULORIC.xml:S1:2113:4	1.1%	CD	O	O
1.3%	ULORIC.xml:S1:2129:4	1.3%	CD	O	O
0.8%	ULORIC.xml:S1:2145:4	0.8%	CD	O	O

Arthralgia	ULORIC.xml:S1:2165:10	arthralgia	NNP	B-AdverseReaction	B-AdverseReaction
0%	ULORIC.xml:S1:2197:2	0%	CD	O	O
1.1%	ULORIC.xml:S1:2227:4	1.1%	CD	O	O
0.7%	ULORIC.xml:S1:2243:4	0.7%	CD	O	O
0.7%	ULORIC.xml:S1:2259:4	0.7%	CD	O	O

Rash	ULORIC.xml:S1:2279:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
0.7%	ULORIC.xml:S1:2310:4	0.7%	CD	O	O
0.5%	ULORIC.xml:S1:2341:4	0.5%	CD	O	O
1.6%	ULORIC.xml:S1:2357:4	1.6%	CD	O	O
1.6%	ULORIC.xml:S1:2373:4	1.6%	CD	O	O

The	ULORIC.xml:S1:2402:3	the	DT	O	O
most	ULORIC.xml:S1:2406:4	most	RBS	O	O
common	ULORIC.xml:S1:2411:6	common	JJ	O	O
adverse	ULORIC.xml:S1:2418:7	advers	JJ	O	O
reaction	ULORIC.xml:S1:2426:8	reaction	NN	O	O
leading	ULORIC.xml:S1:2435:7	lead	VBG	O	O
to	ULORIC.xml:S1:2443:2	to	TO	O	O
discontinuation	ULORIC.xml:S1:2446:15	discontinu	NN	O	O
from	ULORIC.xml:S1:2462:4	from	IN	O	O
therapy	ULORIC.xml:S1:2467:7	therapi	NN	O	O
was	ULORIC.xml:S1:2475:3	wa	VBD	O	O
liver	ULORIC.xml:S1:2479:5	liver	JJ	B-AdverseReaction	O
function	ULORIC.xml:S1:2485:8	function	NN	I-AdverseReaction	O
abnormalities	ULORIC.xml:S1:2494:13	abnorm	NNS	I-AdverseReaction	O
in	ULORIC.xml:S1:2508:2	in	IN	O	O
1.8%	ULORIC.xml:S1:2511:4	1.8%	CD	O	O
of	ULORIC.xml:S1:2516:2	of	IN	O	O
ULORIC	ULORIC.xml:S1:2519:6	ulor	NNP	O	O
40	ULORIC.xml:S1:2526:2	40	CD	O	O
mg	ULORIC.xml:S1:2529:2	mg	NN	O	O
,	ULORIC.xml:S1:2531:1	,	,	O	O
1.2%	ULORIC.xml:S1:2533:4	1.2%	CD	O	O
of	ULORIC.xml:S1:2538:2	of	IN	O	O
ULORIC	ULORIC.xml:S1:2541:6	ulor	NNP	O	O
80	ULORIC.xml:S1:2548:2	80	CD	O	O
mg	ULORIC.xml:S1:2551:2	mg	NN	O	O
,	ULORIC.xml:S1:2553:1	,	,	O	O
and	ULORIC.xml:S1:2555:3	and	CC	O	O
in	ULORIC.xml:S1:2559:2	in	IN	O	O
0.9%	ULORIC.xml:S1:2562:4	0.9%	CD	O	O
of	ULORIC.xml:S1:2567:2	of	IN	O	O
allopurinol	ULORIC.xml:S1:2570:11	allopurinol	JJ	O	O
-	ULORIC.xml:S1:2581:1	-	:	O	O
treated	ULORIC.xml:S1:2582:7	treat	JJ	O	O
subjects	ULORIC.xml:S1:2590:8	subject	NNS	O	O
.	ULORIC.xml:S1:2598:1	.	.	O	O

In	ULORIC.xml:S1:2604:2	In	IN	O	O

addition	ULORIC.xml:S1:2607:8	addit	NN	O	O
to	ULORIC.xml:S1:2616:2	to	TO	O	O
the	ULORIC.xml:S1:2619:3	the	DT	O	O
adverse	ULORIC.xml:S1:2623:7	advers	JJ	O	O
reactions	ULORIC.xml:S1:2631:9	reaction	NNS	O	O
presented	ULORIC.xml:S1:2641:9	present	VBN	O	O
in	ULORIC.xml:S1:2651:2	in	IN	O	O
Table	ULORIC.xml:S1:2654:5	tabl	JJ	O	O
1	ULORIC.xml:S1:2660:1	1	CD	O	O
,	ULORIC.xml:S1:2661:1	,	,	O	O
dizziness	ULORIC.xml:S1:2663:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
was	ULORIC.xml:S1:2673:3	wa	VBD	O	O
reported	ULORIC.xml:S1:2677:8	report	VBN	O	O
in	ULORIC.xml:S1:2686:2	in	IN	O	O
more	ULORIC.xml:S1:2689:4	more	JJR	O	O
than	ULORIC.xml:S1:2694:4	than	IN	O	O
1%	ULORIC.xml:S1:2699:2	1%	CD	O	O
of	ULORIC.xml:S1:2702:2	of	IN	O	O
ULORIC	ULORIC.xml:S1:2705:6	ulor	NNP	O	O
-	ULORIC.xml:S1:2711:1	-	:	O	O
treated	ULORIC.xml:S1:2712:7	treat	JJ	O	O
subjects	ULORIC.xml:S1:2720:8	subject	NNS	O	O
although	ULORIC.xml:S1:2729:8	although	IN	O	O
not	ULORIC.xml:S1:2738:3	not	RB	O	O
at	ULORIC.xml:S1:2742:2	at	IN	O	O
a	ULORIC.xml:S1:2745:1	a	DT	O	O
rate	ULORIC.xml:S1:2747:4	rate	NN	O	O
more	ULORIC.xml:S1:2752:4	more	JJR	O	O
than	ULORIC.xml:S1:2757:4	than	IN	O	O
0.5%	ULORIC.xml:S1:2762:4	0.5%	CD	O	O
greater	ULORIC.xml:S1:2767:7	greater	JJR	O	O
than	ULORIC.xml:S1:2775:4	than	IN	O	O
placebo	ULORIC.xml:S1:2780:7	placebo	NN	O	O
.	ULORIC.xml:S1:2787:1	.	.	O	O

Less	ULORIC.xml:S1:2795:4	less	NNP	O	O
Common	ULORIC.xml:S1:2800:6	common	NNP	O	O
Adverse	ULORIC.xml:S1:2807:7	advers	NNP	O	O
Reactions	ULORIC.xml:S1:2815:9	reaction	NNP	O	O

In	ULORIC.xml:S1:2831:2	In	IN	O	O
Phase	ULORIC.xml:S1:2834:5	phase	NNP	O	O
2	ULORIC.xml:S1:2840:1	2	CD	O	O
and	ULORIC.xml:S1:2842:3	and	CC	O	O
3	ULORIC.xml:S1:2846:1	3	CD	O	O
clinical	ULORIC.xml:S1:2848:8	clinic	JJ	O	O
studies	ULORIC.xml:S1:2857:7	studi	NNS	O	O
the	ULORIC.xml:S1:2865:3	the	DT	O	O
following	ULORIC.xml:S1:2869:9	follow	JJ	O	O
adverse	ULORIC.xml:S1:2879:7	advers	JJ	O	O
reactions	ULORIC.xml:S1:2887:9	reaction	NNS	O	O
occurred	ULORIC.xml:S1:2897:8	occur	VBD	O	O
in	ULORIC.xml:S1:2906:2	in	IN	O	O
less	ULORIC.xml:S1:2909:4	less	JJR	O	O
than	ULORIC.xml:S1:2914:4	than	IN	O	O
1%	ULORIC.xml:S1:2919:2	1%	CD	O	O
of	ULORIC.xml:S1:2922:2	of	IN	O	O
subjects	ULORIC.xml:S1:2925:8	subject	NNS	O	O
and	ULORIC.xml:S1:2934:3	and	CC	O	O
in	ULORIC.xml:S1:2938:2	in	IN	O	O
more	ULORIC.xml:S1:2941:4	more	JJR	O	O
than	ULORIC.xml:S1:2946:4	than	IN	O	O
one	ULORIC.xml:S1:2951:3	one	CD	O	O
subject	ULORIC.xml:S1:2955:7	subject	NN	O	O
treated	ULORIC.xml:S1:2963:7	treat	VBN	O	O
with	ULORIC.xml:S1:2971:4	with	IN	O	O
doses	ULORIC.xml:S1:2976:5	dose	NNS	O	O
ranging	ULORIC.xml:S1:2982:7	rang	VBG	O	O
from	ULORIC.xml:S1:2990:4	from	IN	O	O
40	ULORIC.xml:S1:2995:2	40	CD	O	O
mg	ULORIC.xml:S1:2998:2	mg	NNS	O	O
to	ULORIC.xml:S1:3001:2	to	TO	O	O
240	ULORIC.xml:S1:3004:3	240	CD	O	O
mg	ULORIC.xml:S1:3008:2	mg	NN	O	O
of	ULORIC.xml:S1:3011:2	of	IN	O	O
ULORIC	ULORIC.xml:S1:3014:6	ulor	NNP	O	O
.	ULORIC.xml:S1:3020:1	.	.	O	O

This	ULORIC.xml:S1:3022:4	thi	DT	O	O
list	ULORIC.xml:S1:3027:4	list	NN	O	O
also	ULORIC.xml:S1:3032:4	also	RB	O	O
includes	ULORIC.xml:S1:3037:8	includ	VBZ	O	O
adverse	ULORIC.xml:S1:3046:7	advers	JJ	O	O
reactions	ULORIC.xml:S1:3054:9	reaction	NNS	O	O
(	ULORIC.xml:S1:3064:1	(	(	O	O
less	ULORIC.xml:S1:3065:4	less	JJR	O	O
than	ULORIC.xml:S1:3070:4	than	IN	O	O
1%	ULORIC.xml:S1:3075:2	1%	CD	O	O
of	ULORIC.xml:S1:3078:2	of	IN	O	O
subjects	ULORIC.xml:S1:3081:8	subject	NNS	O	O
)	ULORIC.xml:S1:3089:1	)	)	O	O
associated	ULORIC.xml:S1:3091:10	associ	VBN	O	O
with	ULORIC.xml:S1:3102:4	with	IN	O	O
organ	ULORIC.xml:S1:3107:5	organ	JJ	O	O
systems	ULORIC.xml:S1:3113:7	system	NNS	O	O
from	ULORIC.xml:S1:3121:4	from	IN	O	O
Warnings	ULORIC.xml:S1:3126:8	warn	NNP	O	O
and	ULORIC.xml:S1:3135:3	and	CC	O	O
Precautions	ULORIC.xml:S1:3139:11	precaut	NNP	O	O
.	ULORIC.xml:S1:3150:1	.	.	O	O

Blood	ULORIC.xml:S1:3158:5	blood	NN	O	O
and	ULORIC.xml:S1:3164:3	and	CC	O	O
Lymphatic	ULORIC.xml:S1:3168:9	lymphat	NNP	O	O
System	ULORIC.xml:S1:3178:6	system	NNP	O	O
Disorders	ULORIC.xml:S1:3185:9	disord	NNPS	O	O
:	ULORIC.xml:S1:3196:1	:	:	O	O
anemia	ULORIC.xml:S1:3198:6	anemia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3204:1	,	,	O	O
idiopathic	ULORIC.xml:S1:3206:10	idiopath	JJ	B-AdverseReaction	B-AdverseReaction
thrombocytopenic	ULORIC.xml:S1:3217:16	thrombocytopen	JJ	I-AdverseReaction	I-AdverseReaction
purpura	ULORIC.xml:S1:3234:7	purpura	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3241:1	,	,	O	O
leukocytosis	ULORIC.xml:S1:3243:12	leukocytosi	NN	B-AdverseReaction	B-AdverseReaction
leukopenia	ULORIC.xml:S1:3256:10	leukopenia	NN	B-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3266:1	,	,	O	O
neutropenia	ULORIC.xml:S1:3268:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3279:1	,	,	O	O
pancytopenia	ULORIC.xml:S1:3281:12	pancytopenia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3293:1	,	,	O	O
splenomegaly	ULORIC.xml:S1:3295:12	splenomegali	NN	B-AdverseReaction	O
,	ULORIC.xml:S1:3307:1	,	,	O	O
thrombocytopenia	ULORIC.xml:S1:3309:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:3325:1	.	.	O	O

Cardiac	ULORIC.xml:S1:3333:7	cardiac	JJ	O	O
Disorders	ULORIC.xml:S1:3341:9	disord	NNS	O	O
:	ULORIC.xml:S1:3352:1	:	:	O	O
angina	ULORIC.xml:S1:3354:6	angina	NN	B-AdverseReaction	B-AdverseReaction
pectoris	ULORIC.xml:S1:3361:8	pectori	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3369:1	,	,	O	O
atrial	ULORIC.xml:S1:3371:6	atrial	JJ	B-AdverseReaction	B-AdverseReaction
fibrillation	ULORIC.xml:S1:3378:12	fibril	NN	I-AdverseReaction	I-AdverseReaction
flutter	ULORIC.xml:S1:3391:7	flutter	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3398:1	,	,	O	O
cardiac	ULORIC.xml:S1:3400:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
murmur	ULORIC.xml:S1:3408:6	murmur	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3414:1	,	,	O	O
ECG	ULORIC.xml:S1:3416:3	ecg	NNP	B-AdverseReaction	B-AdverseReaction
abnormal	ULORIC.xml:S1:3420:8	abnorm	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3428:1	,	,	O	O
palpitations	ULORIC.xml:S1:3430:12	palpit	NNS	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3442:1	,	,	O	O
sinus	ULORIC.xml:S1:3444:5	sinu	NN	B-AdverseReaction	B-AdverseReaction
bradycardia	ULORIC.xml:S1:3450:11	bradycardia	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3461:1	,	,	O	O
tachycardia	ULORIC.xml:S1:3463:11	tachycardia	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:3474:1	.	.	O	O

Ear	ULORIC.xml:S1:3482:3	ear	NN	O	O
and	ULORIC.xml:S1:3486:3	and	CC	O	O
Labyrinth	ULORIC.xml:S1:3490:9	labyrinth	JJ	O	O
Disorders	ULORIC.xml:S1:3500:9	disord	NNS	O	O
:	ULORIC.xml:S1:3511:1	:	:	O	O
deafness	ULORIC.xml:S1:3513:8	deaf	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3521:1	,	,	O	O
tinnitus	ULORIC.xml:S1:3523:8	tinnitu	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3531:1	,	,	O	O
vertigo	ULORIC.xml:S1:3533:7	vertigo	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:3540:1	.	.	O	O

Eye	ULORIC.xml:S1:3548:3	eye	JJ	O	O
Disorders	ULORIC.xml:S1:3552:9	disord	NNS	O	O
:	ULORIC.xml:S1:3563:1	:	:	O	O
vision	ULORIC.xml:S1:3565:6	vision	NN	B-AdverseReaction	B-AdverseReaction
blurred	ULORIC.xml:S1:3572:7	blur	VBD	I-AdverseReaction	I-AdverseReaction
.	ULORIC.xml:S1:3579:1	.	.	O	O

Gastrointestinal	ULORIC.xml:S1:3587:16	gastrointestin	JJ	O	O
Disorders	ULORIC.xml:S1:3604:9	disord	NNS	O	O
:	ULORIC.xml:S1:3615:1	:	:	O	O
abdominal	ULORIC.xml:S1:3617:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
distention	ULORIC.xml:S1:3627:10	distent	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3637:1	,	,	O	O
abdominal	ULORIC.xml:S1:3639:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ULORIC.xml:S1:3649:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3653:1	,	,	O	O
constipation	ULORIC.xml:S1:3655:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3667:1	,	,	O	O
dry	ULORIC.xml:S1:3669:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	ULORIC.xml:S1:3673:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3678:1	,	,	O	O
dyspepsia	ULORIC.xml:S1:3680:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3689:1	,	,	O	O
flatulence	ULORIC.xml:S1:3691:10	flatul	NN	B-AdverseReaction	O
,	ULORIC.xml:S1:3701:1	,	,	O	O
frequent	ULORIC.xml:S1:3703:8	frequent	JJ	B-AdverseReaction	O
stools	ULORIC.xml:S1:3712:6	stool	NNS	I-AdverseReaction	O
,	ULORIC.xml:S1:3718:1	,	,	O	O
gastritis	ULORIC.xml:S1:3720:9	gastriti	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3729:1	,	,	O	O
gastroesophageal	ULORIC.xml:S1:3731:16	gastroesophag	JJ	B-AdverseReaction	B-AdverseReaction
reflux	ULORIC.xml:S1:3748:6	reflux	NN	I-AdverseReaction	I-AdverseReaction
disease	ULORIC.xml:S1:3755:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3762:1	,	,	O	O
gastrointestinal	ULORIC.xml:S1:3764:16	gastrointestin	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	ULORIC.xml:S1:3781:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3791:1	,	,	O	O
gingival	ULORIC.xml:S1:3793:8	gingiv	NN	B-AdverseReaction	B-AdverseReaction
pain	ULORIC.xml:S1:3802:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3806:1	,	,	O	O
haematemesis	ULORIC.xml:S1:3808:12	haematemesi	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3820:1	,	,	O	O
hyperchlorhydria	ULORIC.xml:S1:3822:16	hyperchlorhydria	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3838:1	,	,	O	O
hematochezia	ULORIC.xml:S1:3840:12	hematochezia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3852:1	,	,	O	O
mouth	ULORIC.xml:S1:3854:5	mouth	JJ	B-AdverseReaction	B-AdverseReaction
ulceration	ULORIC.xml:S1:3860:10	ulcer	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3870:1	,	,	O	O
pancreatitis	ULORIC.xml:S1:3872:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3884:1	,	,	O	O
peptic	ULORIC.xml:S1:3886:6	peptic	JJ	B-AdverseReaction	B-AdverseReaction
ulcer	ULORIC.xml:S1:3893:5	ulcer	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:3898:1	,	,	O	O
vomiting	ULORIC.xml:S1:3900:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:3908:1	.	.	O	O

General	ULORIC.xml:S1:3916:7	gener	NNP	O	O
Disorders	ULORIC.xml:S1:3924:9	disord	NNP	O	O
and	ULORIC.xml:S1:3934:3	and	CC	O	O
Administration	ULORIC.xml:S1:3938:14	administr	NNP	O	O
Site	ULORIC.xml:S1:3953:4	site	NNP	O	O
Conditions	ULORIC.xml:S1:3958:10	condit	NNS	O	O
:	ULORIC.xml:S1:3970:1	:	:	O	O
asthenia	ULORIC.xml:S1:3972:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:3980:1	,	,	O	O
chest	ULORIC.xml:S1:3982:5	chest	VBP	B-AdverseReaction	B-AdverseReaction
pain	ULORIC.xml:S1:3988:4	pain	NN	I-AdverseReaction	I-AdverseReaction
discomfort	ULORIC.xml:S1:3993:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4003:1	,	,	O	O
edema	ULORIC.xml:S1:4005:5	edema	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4010:1	,	,	O	O
fatigue	ULORIC.xml:S1:4012:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4019:1	,	,	O	O
feeling	ULORIC.xml:S1:4021:7	feel	VBG	B-AdverseReaction	B-AdverseReaction
abnormal	ULORIC.xml:S1:4029:8	abnorm	JJ	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4037:1	,	,	O	O
gait	ULORIC.xml:S1:4039:4	gait	JJ	B-AdverseReaction	B-AdverseReaction
disturbance	ULORIC.xml:S1:4044:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4055:1	,	,	O	O
influenza	ULORIC.xml:S1:4057:9	influenza	JJ	B-AdverseReaction	B-AdverseReaction
-	ULORIC.xml:S1:4066:1	-	:	I-AdverseReaction	I-AdverseReaction
like	ULORIC.xml:S1:4067:4	like	IN	I-AdverseReaction	I-AdverseReaction
symptoms	ULORIC.xml:S1:4072:8	symptom	NNS	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4080:1	,	,	O	O
mass	ULORIC.xml:S1:4082:4	mass	NN	B-AdverseReaction	O
,	ULORIC.xml:S1:4086:1	,	,	O	O
pain	ULORIC.xml:S1:4088:4	pain	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4092:1	,	,	O	O
thirst	ULORIC.xml:S1:4094:6	thirst	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:4100:1	.	.	O	O

Hepatobiliary	ULORIC.xml:S1:4108:13	hepatobiliari	JJ	O	O
Disorders	ULORIC.xml:S1:4122:9	disord	NNS	O	O
:	ULORIC.xml:S1:4133:1	:	:	O	O
cholelithiasis	ULORIC.xml:S1:4135:14	cholelithiasi	NN	B-AdverseReaction	B-AdverseReaction
cholecystitis	ULORIC.xml:S1:4150:13	cholecyst	NN	B-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4163:1	,	,	O	O
hepatic	ULORIC.xml:S1:4165:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
steatosis	ULORIC.xml:S1:4173:9	steatosi	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4182:1	,	,	O	O
hepatitis	ULORIC.xml:S1:4184:9	hepat	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4193:1	,	,	O	O
hepatomegaly	ULORIC.xml:S1:4195:12	hepatomegali	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:4207:1	.	.	O	O

Immune	ULORIC.xml:S1:4215:6	immun	NNP	O	O
System	ULORIC.xml:S1:4222:6	system	NNP	O	O
Disorder	ULORIC.xml:S1:4229:8	disord	NNP	O	O
:	ULORIC.xml:S1:4239:1	:	:	O	O
hypersensitivity	ULORIC.xml:S1:4241:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:4257:1	.	.	O	O

Infections	ULORIC.xml:S1:4265:10	infect	NNS	O	O
and	ULORIC.xml:S1:4276:3	and	CC	O	O
Infestations	ULORIC.xml:S1:4280:12	infest	NNS	O	O
:	ULORIC.xml:S1:4294:1	:	:	O	O
herpes	ULORIC.xml:S1:4296:6	herp	NNS	B-AdverseReaction	B-AdverseReaction
zoster	ULORIC.xml:S1:4303:6	zoster	NN	I-AdverseReaction	I-AdverseReaction
.	ULORIC.xml:S1:4309:1	.	.	O	O

Procedural	ULORIC.xml:S1:4317:10	procedur	JJ	O	O
Complications	ULORIC.xml:S1:4328:13	complic	NNS	O	O
:	ULORIC.xml:S1:4343:1	:	:	O	O
contusion	ULORIC.xml:S1:4345:9	contus	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:4354:1	.	.	O	O

Metabolism	ULORIC.xml:S1:4362:10	metabol	NN	O	O
and	ULORIC.xml:S1:4373:3	and	CC	O	O
Nutrition	ULORIC.xml:S1:4377:9	nutrit	NN	O	O
Disorders	ULORIC.xml:S1:4387:9	disord	NNS	O	O
:	ULORIC.xml:S1:4398:1	:	:	O	O
anorexia	ULORIC.xml:S1:4400:8	anorexia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4408:1	,	,	O	O
appetite	ULORIC.xml:S1:4410:8	appetit	RB	B-AdverseReaction	O
decreased	ULORIC.xml:S1:4419:9	decreas	VBN	I-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:4429:9	increas	VBN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4438:1	,	,	O	O
dehydration	ULORIC.xml:S1:4440:11	dehydr	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4451:1	,	,	O	O
diabetes	ULORIC.xml:S1:4453:8	diabet	VBZ	B-AdverseReaction	O
mellitus	ULORIC.xml:S1:4462:8	mellitu	NN	I-AdverseReaction	O
,	ULORIC.xml:S1:4470:1	,	,	O	O
hypercholesterolemia	ULORIC.xml:S1:4472:20	hypercholesterolemia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4492:1	,	,	O	O
hyperglycemia	ULORIC.xml:S1:4494:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4507:1	,	,	O	O
hyperlipidemia	ULORIC.xml:S1:4509:14	hyperlipidemia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4523:1	,	,	O	O
hypertriglyceridemia	ULORIC.xml:S1:4525:20	hypertriglyceridemia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4545:1	,	,	O	O
hypokalemia	ULORIC.xml:S1:4547:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4558:1	,	,	O	O
weight	ULORIC.xml:S1:4560:6	weight	NN	B-AdverseReaction	B-AdverseReaction
decreased	ULORIC.xml:S1:4567:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
increased	ULORIC.xml:S1:4577:9	increas	VBN	I-AdverseReaction	O
.	ULORIC.xml:S1:4586:1	.	.	O	O

Musculoskeletal	ULORIC.xml:S1:4594:15	musculoskelet	NNP	O	O
and	ULORIC.xml:S1:4610:3	and	CC	O	O
Connective	ULORIC.xml:S1:4614:10	connect	NNP	O	O
Tissue	ULORIC.xml:S1:4625:6	tissu	NNP	O	O
Disorders	ULORIC.xml:S1:4632:9	disord	NNP	O	O
:	ULORIC.xml:S1:4643:1	:	:	O	O
arthritis	ULORIC.xml:S1:4645:9	arthriti	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4654:1	,	,	O	O
joint	ULORIC.xml:S1:4656:5	joint	JJ	B-AdverseReaction	B-AdverseReaction
stiffness	ULORIC.xml:S1:4662:9	stiff	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4671:1	,	,	O	O
joint	ULORIC.xml:S1:4673:5	joint	JJ	B-AdverseReaction	B-AdverseReaction
swelling	ULORIC.xml:S1:4679:8	swell	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4687:1	,	,	O	O
muscle	ULORIC.xml:S1:4689:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
spasms	ULORIC.xml:S1:4696:6	spasm	NNS	I-AdverseReaction	I-AdverseReaction
twitching	ULORIC.xml:S1:4703:9	twitch	VBG	I-AdverseReaction	O
tightness	ULORIC.xml:S1:4713:9	tight	NN	I-AdverseReaction	O
weakness	ULORIC.xml:S1:4723:8	weak	NN	I-AdverseReaction	O
,	ULORIC.xml:S1:4731:1	,	,	O	O
musculoskeletal	ULORIC.xml:S1:4733:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	ULORIC.xml:S1:4749:4	pain	NN	I-AdverseReaction	I-AdverseReaction
stiffness	ULORIC.xml:S1:4754:9	stiff	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4763:1	,	,	O	O
myalgia	ULORIC.xml:S1:4765:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:4772:1	.	.	O	O

Nervous	ULORIC.xml:S1:4780:7	nervou	JJ	O	O
System	ULORIC.xml:S1:4788:6	system	NN	O	O
Disorders	ULORIC.xml:S1:4795:9	disord	NNS	O	O
:	ULORIC.xml:S1:4806:1	:	:	O	O
altered	ULORIC.xml:S1:4808:7	alter	VBN	B-AdverseReaction	B-AdverseReaction
taste	ULORIC.xml:S1:4816:5	tast	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4821:1	,	,	O	O
balance	ULORIC.xml:S1:4823:7	balanc	NN	B-AdverseReaction	B-AdverseReaction
disorder	ULORIC.xml:S1:4831:8	disord	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4839:1	,	,	O	O
cerebrovascular	ULORIC.xml:S1:4841:15	cerebrovascular	JJ	B-AdverseReaction	B-AdverseReaction
accident	ULORIC.xml:S1:4857:8	accid	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4865:1	,	,	O	O
Guillain	ULORIC.xml:S1:4867:8	guillain	NNP	B-AdverseReaction	B-AdverseReaction
-	ULORIC.xml:S1:4875:1	-	:	I-AdverseReaction	I-AdverseReaction
Barre	ULORIC.xml:S1:4876:5	barr	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	ULORIC.xml:S1:4882:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4890:1	,	,	O	O
headache	ULORIC.xml:S1:4892:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4900:1	,	,	O	O
hemiparesis	ULORIC.xml:S1:4902:11	hemiparesi	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4913:1	,	,	O	O
hypoesthesia	ULORIC.xml:S1:4915:12	hypoesthesia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4927:1	,	,	O	O
hyposmia	ULORIC.xml:S1:4929:8	hyposmia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4937:1	,	,	O	O
lacunar	ULORIC.xml:S1:4939:7	lacunar	JJ	B-AdverseReaction	O
infarction	ULORIC.xml:S1:4947:10	infarct	NN	I-AdverseReaction	O
,	ULORIC.xml:S1:4957:1	,	,	O	O
lethargy	ULORIC.xml:S1:4959:8	lethargi	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4967:1	,	,	O	O
mental	ULORIC.xml:S1:4969:6	mental	JJ	B-AdverseReaction	B-AdverseReaction
impairment	ULORIC.xml:S1:4976:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:4986:1	,	,	O	O
migraine	ULORIC.xml:S1:4988:8	migrain	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:4996:1	,	,	O	O
paresthesia	ULORIC.xml:S1:4998:11	paresthesia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5009:1	,	,	O	O
somnolence	ULORIC.xml:S1:5011:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5021:1	,	,	O	O
transient	ULORIC.xml:S1:5023:9	transient	JJ	B-AdverseReaction	B-AdverseReaction
ischemic	ULORIC.xml:S1:5033:8	ischem	JJ	I-AdverseReaction	I-AdverseReaction
attack	ULORIC.xml:S1:5042:6	attack	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5048:1	,	,	O	O
tremor	ULORIC.xml:S1:5050:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:5056:1	.	.	O	O

Psychiatric	ULORIC.xml:S1:5064:11	psychiatr	JJ	O	O
Disorders	ULORIC.xml:S1:5076:9	disord	NNS	O	O
:	ULORIC.xml:S1:5087:1	:	:	O	O
agitation	ULORIC.xml:S1:5089:9	agit	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5098:1	,	,	O	O
anxiety	ULORIC.xml:S1:5100:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5107:1	,	,	O	O
depression	ULORIC.xml:S1:5109:10	depress	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5119:1	,	,	O	O
insomnia	ULORIC.xml:S1:5121:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5129:1	,	,	O	O
irritability	ULORIC.xml:S1:5131:12	irrit	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5143:1	,	,	O	O
libido	ULORIC.xml:S1:5145:6	libido	NN	B-AdverseReaction	B-AdverseReaction
decreased	ULORIC.xml:S1:5152:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5161:1	,	,	O	O
nervousness	ULORIC.xml:S1:5163:11	nervous	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5174:1	,	,	O	O
panic	ULORIC.xml:S1:5176:5	panic	JJ	B-AdverseReaction	B-AdverseReaction
attack	ULORIC.xml:S1:5182:6	attack	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5188:1	,	,	O	O
personality	ULORIC.xml:S1:5190:11	person	NN	B-AdverseReaction	O
change	ULORIC.xml:S1:5202:6	chang	NN	I-AdverseReaction	O
.	ULORIC.xml:S1:5208:1	.	.	O	O

Renal	ULORIC.xml:S1:5216:5	renal	NNP	O	O
and	ULORIC.xml:S1:5222:3	and	CC	O	O
Urinary	ULORIC.xml:S1:5226:7	urinari	JJ	B-AdverseReaction	O
Disorders	ULORIC.xml:S1:5234:9	disord	NNS	O	O
:	ULORIC.xml:S1:5245:1	:	:	O	O
hematuria	ULORIC.xml:S1:5247:9	hematuria	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5256:1	,	,	O	O
nephrolithiasis	ULORIC.xml:S1:5258:15	nephrolithiasi	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5273:1	,	,	O	O
pollakiuria	ULORIC.xml:S1:5275:11	pollakiuria	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5286:1	,	,	O	O
proteinuria	ULORIC.xml:S1:5288:11	proteinuria	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5299:1	,	,	O	O
renal	ULORIC.xml:S1:5301:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	ULORIC.xml:S1:5307:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5314:1	,	,	O	O
renal	ULORIC.xml:S1:5316:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
insufficiency	ULORIC.xml:S1:5322:13	insuffici	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5335:1	,	,	O	O
urgency	ULORIC.xml:S1:5337:7	urgenc	NN	I-AdverseReaction	O
,	ULORIC.xml:S1:5344:1	,	,	O	O
incontinence	ULORIC.xml:S1:5346:12	incontin	NN	I-AdverseReaction	O
.	ULORIC.xml:S1:5358:1	.	.	O	O

Reproductive	ULORIC.xml:S1:5366:12	reproduct	JJ	O	O
System	ULORIC.xml:S1:5379:6	system	NNP	O	O
and	ULORIC.xml:S1:5386:3	and	CC	O	O
Breast	ULORIC.xml:S1:5390:6	breast	NNP	O	B-AdverseReaction
Changes	ULORIC.xml:S1:5397:7	chang	NNS	O	I-AdverseReaction
:	ULORIC.xml:S1:5406:1	:	:	O	O
breast	ULORIC.xml:S1:5408:6	breast	NN	B-AdverseReaction	B-AdverseReaction
pain	ULORIC.xml:S1:5415:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5419:1	,	,	O	O
erectile	ULORIC.xml:S1:5421:8	erectil	JJ	B-AdverseReaction	B-AdverseReaction
dysfunction	ULORIC.xml:S1:5430:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5441:1	,	,	O	O
gynecomastia	ULORIC.xml:S1:5443:12	gynecomastia	NN	B-AdverseReaction	O
.	ULORIC.xml:S1:5455:1	.	.	O	O

Respiratory	ULORIC.xml:S1:5463:11	respiratori	NNP	O	O
,	ULORIC.xml:S1:5474:1	,	,	O	O
Thoracic	ULORIC.xml:S1:5476:8	thorac	NNP	O	O
and	ULORIC.xml:S1:5485:3	and	CC	O	O
Mediastinal	ULORIC.xml:S1:5489:11	mediastin	NNP	O	O
Disorders	ULORIC.xml:S1:5501:9	disord	NNS	O	O
:	ULORIC.xml:S1:5512:1	:	:	O	O
bronchitis	ULORIC.xml:S1:5514:10	bronchiti	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5524:1	,	,	O	O
cough	ULORIC.xml:S1:5526:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5531:1	,	,	O	O
dyspnea	ULORIC.xml:S1:5533:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5540:1	,	,	O	O
epistaxis	ULORIC.xml:S1:5542:9	epistaxi	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5551:1	,	,	O	O
nasal	ULORIC.xml:S1:5553:5	nasal	JJ	B-AdverseReaction	B-AdverseReaction
dryness	ULORIC.xml:S1:5559:7	dryness	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5566:1	,	,	O	O
paranasal	ULORIC.xml:S1:5568:9	paranas	JJ	B-AdverseReaction	B-AdverseReaction
sinus	ULORIC.xml:S1:5578:5	sinu	NN	I-AdverseReaction	I-AdverseReaction
hypersecretion	ULORIC.xml:S1:5584:14	hypersecret	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5598:1	,	,	O	O
pharyngeal	ULORIC.xml:S1:5600:10	pharyng	NN	B-AdverseReaction	B-AdverseReaction
edema	ULORIC.xml:S1:5611:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5616:1	,	,	O	O
respiratory	ULORIC.xml:S1:5618:11	respiratori	JJ	B-AdverseReaction	B-AdverseReaction
tract	ULORIC.xml:S1:5630:5	tract	NN	I-AdverseReaction	I-AdverseReaction
congestion	ULORIC.xml:S1:5636:10	congest	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5646:1	,	,	O	O
sneezing	ULORIC.xml:S1:5648:8	sneez	VBG	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5656:1	,	,	O	O
throat	ULORIC.xml:S1:5658:6	throat	NN	B-AdverseReaction	B-AdverseReaction
irritation	ULORIC.xml:S1:5665:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5675:1	,	,	O	O
upper	ULORIC.xml:S1:5677:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	ULORIC.xml:S1:5683:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	ULORIC.xml:S1:5695:5	tract	JJ	I-AdverseReaction	I-AdverseReaction
infection	ULORIC.xml:S1:5701:9	infect	NN	I-AdverseReaction	I-AdverseReaction
.	ULORIC.xml:S1:5710:1	.	.	O	O

Skin	ULORIC.xml:S1:5718:4	skin	NNP	O	O
and	ULORIC.xml:S1:5723:3	and	CC	O	O
Subcutaneous	ULORIC.xml:S1:5727:12	subcutan	NNP	O	O
Tissue	ULORIC.xml:S1:5740:6	tissu	NNP	O	O
Disorders	ULORIC.xml:S1:5747:9	disord	NNP	O	O
:	ULORIC.xml:S1:5758:1	:	:	O	O
alopecia	ULORIC.xml:S1:5760:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5768:1	,	,	O	O
angio	ULORIC.xml:S1:5770:5	angio	SYM	B-AdverseReaction	B-AdverseReaction
-	ULORIC.xml:S1:5775:1	-	:	I-AdverseReaction	I-AdverseReaction
edema	ULORIC.xml:S1:5776:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5781:1	,	,	O	O
dermatitis	ULORIC.xml:S1:5783:10	dermat	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5793:1	,	,	O	O
dermographism	ULORIC.xml:S1:5795:13	dermograph	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5808:1	,	,	O	O
ecchymosis	ULORIC.xml:S1:5810:10	ecchymosi	NN	B-AdverseReaction	O
,	ULORIC.xml:S1:5820:1	,	,	O	O
eczema	ULORIC.xml:S1:5822:6	eczema	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5828:1	,	,	O	O
hair	ULORIC.xml:S1:5830:4	hair	NN	B-AdverseReaction	B-AdverseReaction
color	ULORIC.xml:S1:5835:5	color	NN	I-AdverseReaction	I-AdverseReaction
changes	ULORIC.xml:S1:5841:7	chang	NNS	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5848:1	,	,	O	O
hair	ULORIC.xml:S1:5850:4	hair	NN	B-AdverseReaction	B-AdverseReaction
growth	ULORIC.xml:S1:5855:6	growth	NN	I-AdverseReaction	I-AdverseReaction
abnormal	ULORIC.xml:S1:5862:8	abnorm	JJ	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5870:1	,	,	O	O
hyperhidrosis	ULORIC.xml:S1:5872:13	hyperhidrosi	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5887:1	,	,	O	O
peeling	ULORIC.xml:S1:5890:7	peel	VBG	B-AdverseReaction	B-AdverseReaction
skin	ULORIC.xml:S1:5898:4	skin	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:5902:1	,	,	O	O
petechiae	ULORIC.xml:S1:5904:9	petechia	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5913:1	,	,	O	O
photosensitivity	ULORIC.xml:S1:5915:16	photosensit	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5931:1	,	,	O	O
pruritus	ULORIC.xml:S1:5933:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:5941:1	,	,	O	O
purpura	ULORIC.xml:S1:5943:7	purpura	NN	B-AdverseReaction	O
,	ULORIC.xml:S1:5950:1	,	,	O	O
skin	ULORIC.xml:S1:5952:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
discoloration	ULORIC.xml:S1:5957:13	discolor	NN	I-AdverseReaction	I-AdverseReaction
altered	ULORIC.xml:S1:5971:7	alter	VBD	I-AdverseReaction	O
pigmentation	ULORIC.xml:S1:5979:12	pigment	NN	I-AdverseReaction	O
,	ULORIC.xml:S1:5991:1	,	,	O	O
skin	ULORIC.xml:S1:5993:4	skin	JJ	B-AdverseReaction	O
lesion	ULORIC.xml:S1:5998:6	lesion	NN	I-AdverseReaction	O
,	ULORIC.xml:S1:6004:1	,	,	O	O
skin	ULORIC.xml:S1:6006:4	skin	FW	B-AdverseReaction	O
odor	ULORIC.xml:S1:6011:4	odor	NN	I-AdverseReaction	O
abnormal	ULORIC.xml:S1:6016:8	abnorm	NN	I-AdverseReaction	O
,	ULORIC.xml:S1:6024:1	,	,	O	O
urticaria	ULORIC.xml:S1:6026:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:6035:1	.	.	O	O

Vascular	ULORIC.xml:S1:6043:8	vascular	JJ	O	O
Disorders	ULORIC.xml:S1:6052:9	disord	NNS	O	O
:	ULORIC.xml:S1:6063:1	:	:	O	O
flushing	ULORIC.xml:S1:6065:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:6073:1	,	,	O	O
hot	ULORIC.xml:S1:6075:3	hot	JJ	B-AdverseReaction	B-AdverseReaction
flush	ULORIC.xml:S1:6079:5	flush	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6084:1	,	,	O	O
hypertension	ULORIC.xml:S1:6086:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:6098:1	,	,	O	O
hypotension	ULORIC.xml:S1:6100:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:6111:1	.	.	O	O

Laboratory	ULORIC.xml:S1:6119:10	laboratori	NN	O	O
Parameters	ULORIC.xml:S1:6130:10	paramet	NNS	O	O
:	ULORIC.xml:S1:6140:1	:	:	O	O
activated	ULORIC.xml:S1:6143:9	activ	VBN	B-AdverseReaction	O
partial	ULORIC.xml:S1:6153:7	partial	JJ	I-AdverseReaction	O
thromboplastin	ULORIC.xml:S1:6161:14	thromboplastin	NN	I-AdverseReaction	O
time	ULORIC.xml:S1:6176:4	time	NN	I-AdverseReaction	O
prolonged	ULORIC.xml:S1:6181:9	prolong	VBN	I-AdverseReaction	O
,	ULORIC.xml:S1:6190:1	,	,	O	O
creatine	ULORIC.xml:S1:6192:8	creatin	NN	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6201:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6210:1	,	,	O	O
bicarbonate	ULORIC.xml:S1:6212:11	bicarbon	NN	B-AdverseReaction	B-AdverseReaction
decreased	ULORIC.xml:S1:6224:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6233:1	,	,	O	O
sodium	ULORIC.xml:S1:6235:6	sodium	NN	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6242:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6251:1	,	,	O	O
EEG	ULORIC.xml:S1:6253:3	eeg	NNP	B-AdverseReaction	B-AdverseReaction
abnormal	ULORIC.xml:S1:6257:8	abnorm	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6265:1	,	,	O	O
glucose	ULORIC.xml:S1:6267:7	glucos	NN	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6275:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6284:1	,	,	O	O
cholesterol	ULORIC.xml:S1:6286:11	cholesterol	NN	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6298:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6307:1	,	,	O	O
triglycerides	ULORIC.xml:S1:6309:13	triglycerid	NNS	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6323:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6332:1	,	,	O	O
amylase	ULORIC.xml:S1:6334:7	amylas	NN	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6342:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6351:1	,	,	O	O
potassium	ULORIC.xml:S1:6353:9	potassium	NN	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6363:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6372:1	,	,	O	O
TSH	ULORIC.xml:S1:6374:3	tsh	NNP	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6378:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6387:1	,	,	O	O
platelet	ULORIC.xml:S1:6389:8	platelet	NN	B-AdverseReaction	B-AdverseReaction
count	ULORIC.xml:S1:6398:5	count	NN	I-AdverseReaction	I-AdverseReaction
decreased	ULORIC.xml:S1:6404:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6413:1	,	,	O	O
hematocrit	ULORIC.xml:S1:6415:10	hematocrit	NN	B-AdverseReaction	B-AdverseReaction
decreased	ULORIC.xml:S1:6426:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6435:1	,	,	O	O
hemoglobin	ULORIC.xml:S1:6437:10	hemoglobin	NN	B-AdverseReaction	B-AdverseReaction
decreased	ULORIC.xml:S1:6448:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6457:1	,	,	O	O
MCV	ULORIC.xml:S1:6459:3	mcv	NNP	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6463:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6472:1	,	,	O	O
RBC	ULORIC.xml:S1:6474:3	rbc	NNP	B-AdverseReaction	B-AdverseReaction
decreased	ULORIC.xml:S1:6478:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6487:1	,	,	O	O
creatinine	ULORIC.xml:S1:6489:10	creatinin	NN	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6500:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6509:1	,	,	O	O
blood	ULORIC.xml:S1:6511:5	blood	NN	B-AdverseReaction	B-AdverseReaction
urea	ULORIC.xml:S1:6517:4	urea	NN	I-AdverseReaction	I-AdverseReaction
increased	ULORIC.xml:S1:6522:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6531:1	,	,	O	O
BUN	ULORIC.xml:S1:6533:3	bun	NNP	B-AdverseReaction	B-AdverseReaction
creatinine	ULORIC.xml:S1:6537:10	creatinin	VBP	I-AdverseReaction	I-AdverseReaction
ratio	ULORIC.xml:S1:6548:5	ratio	NN	I-AdverseReaction	I-AdverseReaction
increased	ULORIC.xml:S1:6554:9	increas	VBN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6563:1	,	,	O	O
creatine	ULORIC.xml:S1:6565:8	creatin	JJ	B-AdverseReaction	B-AdverseReaction
phosphokinase	ULORIC.xml:S1:6574:13	phosphokinas	NN	I-AdverseReaction	I-AdverseReaction
(	ULORIC.xml:S1:6588:1	(	(	O	O
CPK	ULORIC.xml:S1:6589:3	cpk	NNP	B-AdverseReaction	B-AdverseReaction
)	ULORIC.xml:S1:6592:1	)	)	O	O
increased	ULORIC.xml:S1:6594:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6603:1	,	,	O	O
alkaline	ULORIC.xml:S1:6605:8	alkalin	JJ	B-AdverseReaction	B-AdverseReaction
phosphatase	ULORIC.xml:S1:6614:11	phosphatas	NN	I-AdverseReaction	I-AdverseReaction
increased	ULORIC.xml:S1:6626:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6635:1	,	,	O	O
LDH	ULORIC.xml:S1:6637:3	ldh	NNP	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6641:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6650:1	,	,	O	O
PSA	ULORIC.xml:S1:6652:3	psa	NNP	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6656:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6665:1	,	,	O	O
urine	ULORIC.xml:S1:6667:5	urin	JJ	B-AdverseReaction	B-AdverseReaction
output	ULORIC.xml:S1:6673:6	output	NN	I-AdverseReaction	I-AdverseReaction
increased	ULORIC.xml:S1:6680:9	increas	VBD	I-AdverseReaction	B-AdverseReaction
decreased	ULORIC.xml:S1:6690:9	decreas	VBN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6699:1	,	,	O	O
lymphocyte	ULORIC.xml:S1:6701:10	lymphocyt	JJ	B-AdverseReaction	B-AdverseReaction
count	ULORIC.xml:S1:6712:5	count	NN	I-AdverseReaction	I-AdverseReaction
decreased	ULORIC.xml:S1:6718:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6727:1	,	,	O	O
neutrophil	ULORIC.xml:S1:6729:10	neutrophil	JJ	B-AdverseReaction	B-AdverseReaction
count	ULORIC.xml:S1:6740:5	count	NN	I-AdverseReaction	I-AdverseReaction
decreased	ULORIC.xml:S1:6746:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6755:1	,	,	O	O
WBC	ULORIC.xml:S1:6757:3	wbc	NNP	B-AdverseReaction	B-AdverseReaction
increased	ULORIC.xml:S1:6761:9	increas	VBD	I-AdverseReaction	B-AdverseReaction
decreased	ULORIC.xml:S1:6771:9	decreas	VBN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6780:1	,	,	O	O
coagulation	ULORIC.xml:S1:6782:11	coagul	NN	B-AdverseReaction	B-AdverseReaction
test	ULORIC.xml:S1:6794:4	test	NN	I-AdverseReaction	I-AdverseReaction
abnormal	ULORIC.xml:S1:6799:8	abnorm	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6807:1	,	,	O	O
low	ULORIC.xml:S1:6809:3	low	JJ	B-AdverseReaction	B-AdverseReaction
density	ULORIC.xml:S1:6813:7	densiti	NN	I-AdverseReaction	I-AdverseReaction
lipoprotein	ULORIC.xml:S1:6821:11	lipoprotein	NN	I-AdverseReaction	I-AdverseReaction
(	ULORIC.xml:S1:6833:1	(	(	O	O
LDL	ULORIC.xml:S1:6834:3	ldl	NNP	B-AdverseReaction	B-AdverseReaction
)	ULORIC.xml:S1:6837:1	)	)	O	O
increased	ULORIC.xml:S1:6839:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6848:1	,	,	O	O
prothrombin	ULORIC.xml:S1:6850:11	prothrombin	JJ	B-AdverseReaction	O
time	ULORIC.xml:S1:6862:4	time	NN	I-AdverseReaction	O
prolonged	ULORIC.xml:S1:6867:9	prolong	VBN	I-AdverseReaction	O
,	ULORIC.xml:S1:6876:1	,	,	O	O
urinary	ULORIC.xml:S1:6878:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
casts	ULORIC.xml:S1:6886:5	cast	NNS	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:6891:1	,	,	O	O
urine	ULORIC.xml:S1:6893:5	urin	JJ	B-AdverseReaction	O
positive	ULORIC.xml:S1:6899:8	posit	JJ	I-AdverseReaction	O
for	ULORIC.xml:S1:6908:3	for	IN	I-AdverseReaction	O
white	ULORIC.xml:S1:6912:5	white	JJ	I-AdverseReaction	O
blood	ULORIC.xml:S1:6918:5	blood	NN	I-AdverseReaction	O
cells	ULORIC.xml:S1:6924:5	cell	NNS	I-AdverseReaction	O
and	ULORIC.xml:S1:6930:3	and	CC	O	O
protein	ULORIC.xml:S1:6934:7	protein	NN	I-AdverseReaction	O
.	ULORIC.xml:S1:6941:1	.	.	O	O

Cardiovascular	ULORIC.xml:S1:6949:14	cardiovascular	JJ	O	O
Safety	ULORIC.xml:S1:6964:6	safeti	NN	O	O

Cardiovascular	ULORIC.xml:S1:6977:14	cardiovascular	JJ	B-AdverseReaction	O
events	ULORIC.xml:S1:6992:6	event	NNS	I-AdverseReaction	O
and	ULORIC.xml:S1:6999:3	and	CC	O	O
deaths	ULORIC.xml:S1:7003:6	death	NNS	B-AdverseReaction	B-AdverseReaction
were	ULORIC.xml:S1:7010:4	were	VBD	O	O
adjudicated	ULORIC.xml:S1:7015:11	adjud	VBN	O	O
to	ULORIC.xml:S1:7027:2	to	TO	O	O
one	ULORIC.xml:S1:7030:3	one	CD	O	O
of	ULORIC.xml:S1:7034:2	of	IN	O	O
the	ULORIC.xml:S1:7037:3	the	DT	O	O
pre	ULORIC.xml:S1:7041:3	pre	NN	O	O
-	ULORIC.xml:S1:7044:1	-	:	O	O
defined	ULORIC.xml:S1:7045:7	defin	JJ	O	O
endpoints	ULORIC.xml:S1:7053:9	endpoint	NNS	O	O
from	ULORIC.xml:S1:7063:4	from	IN	O	O
the	ULORIC.xml:S1:7068:3	the	DT	O	O
Anti	ULORIC.xml:S1:7072:4	anti	NNP	O	O
-	ULORIC.xml:S1:7076:1	-	:	O	O
Platelet	ULORIC.xml:S1:7077:8	platelet	NN	O	O
Trialists	ULORIC.xml:S1:7086:9	trialist	NNS	O	O
Collaborations	ULORIC.xml:S1:7097:14	collabor	NNP	O	O
(	ULORIC.xml:S1:7112:1	(	(	O	O
APTC	ULORIC.xml:S1:7113:4	aptc	NNP	O	O
)	ULORIC.xml:S1:7117:1	)	)	O	O
(	ULORIC.xml:S1:7119:1	(	(	O	O
cardiovascular	ULORIC.xml:S1:7120:14	cardiovascular	JJ	B-AdverseReaction	B-AdverseReaction
death	ULORIC.xml:S1:7135:5	death	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:7140:1	,	,	O	O
non	ULORIC.xml:S1:7142:3	non	SYM	O	O
-	ULORIC.xml:S1:7145:1	-	:	O	O
fatal	ULORIC.xml:S1:7146:5	fatal	JJ	O	O
myocardial	ULORIC.xml:S1:7152:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
infarction	ULORIC.xml:S1:7163:10	infarct	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:7173:1	,	,	O	O
and	ULORIC.xml:S1:7175:3	and	CC	O	O
non	ULORIC.xml:S1:7179:3	non	SYM	O	O
-	ULORIC.xml:S1:7182:1	-	:	O	O
fatal	ULORIC.xml:S1:7183:5	fatal	JJ	O	O
stroke	ULORIC.xml:S1:7189:6	stroke	NN	B-AdverseReaction	B-AdverseReaction
)	ULORIC.xml:S1:7195:1	)	)	O	O
in	ULORIC.xml:S1:7197:2	in	IN	O	O
the	ULORIC.xml:S1:7200:3	the	DT	O	O
randomized	ULORIC.xml:S1:7204:10	random	NN	O	O
controlled	ULORIC.xml:S1:7215:10	control	VBD	O	O
and	ULORIC.xml:S1:7226:3	and	CC	O	O
long	ULORIC.xml:S1:7230:4	long	JJ	O	O
-	ULORIC.xml:S1:7234:1	-	:	O	O
term	ULORIC.xml:S1:7235:4	term	NN	O	O
extension	ULORIC.xml:S1:7240:9	extens	NN	O	O
studies	ULORIC.xml:S1:7250:7	studi	NNS	O	O
.	ULORIC.xml:S1:7257:1	.	.	O	O

In	ULORIC.xml:S1:7259:2	In	IN	O	O
the	ULORIC.xml:S1:7262:3	the	DT	O	O
Phase	ULORIC.xml:S1:7266:5	phase	NNP	O	O
3	ULORIC.xml:S1:7272:1	3	CD	O	O
randomized	ULORIC.xml:S1:7274:10	random	VBD	O	O
controlled	ULORIC.xml:S1:7285:10	control	VBN	O	O
studies	ULORIC.xml:S1:7296:7	studi	NNS	O	O
,	ULORIC.xml:S1:7303:1	,	,	O	O
the	ULORIC.xml:S1:7305:3	the	DT	O	O
incidences	ULORIC.xml:S1:7309:10	incid	NNS	O	O
of	ULORIC.xml:S1:7320:2	of	IN	O	O
adjudicated	ULORIC.xml:S1:7323:11	adjud	JJ	O	O
APTC	ULORIC.xml:S1:7335:4	aptc	NNP	O	O
events	ULORIC.xml:S1:7340:6	event	NNS	O	O
per	ULORIC.xml:S1:7347:3	per	IN	O	O
100	ULORIC.xml:S1:7351:3	100	CD	O	O
patient	ULORIC.xml:S1:7355:7	patient	JJ	O	O
-	ULORIC.xml:S1:7362:1	-	:	O	O
years	ULORIC.xml:S1:7363:5	year	NNS	O	O
of	ULORIC.xml:S1:7369:2	of	IN	O	O
exposure	ULORIC.xml:S1:7372:8	exposur	NN	O	O
were	ULORIC.xml:S1:7381:4	were	VBD	O	O
:	ULORIC.xml:S1:7385:1	:	:	O	O
Placebo	ULORIC.xml:S1:7387:7	placebo	VB	O	O
0	ULORIC.xml:S1:7395:1	0	CD	O	O
(	ULORIC.xml:S1:7397:1	(	(	O	O
95%	ULORIC.xml:S1:7398:3	95%	CD	O	O
CI	ULORIC.xml:S1:7402:2	CI	NNP	O	O
0.00	ULORIC.xml:S1:7405:4	0.00	CD	O	O
-	ULORIC.xml:S1:7409:1	-	:	O	O
6.16	ULORIC.xml:S1:7410:4	6.16	CD	O	O
)	ULORIC.xml:S1:7414:1	)	)	O	O
,	ULORIC.xml:S1:7415:1	,	,	O	O
ULORIC	ULORIC.xml:S1:7417:6	ulor	NNP	O	O
40	ULORIC.xml:S1:7424:2	40	CD	O	O
mg	ULORIC.xml:S1:7427:2	mg	NN	O	O
0	ULORIC.xml:S1:7430:1	0	CD	O	O
(	ULORIC.xml:S1:7432:1	(	(	O	O
95%	ULORIC.xml:S1:7433:3	95%	CD	O	O
CI	ULORIC.xml:S1:7437:2	CI	NNP	O	O
0.00	ULORIC.xml:S1:7440:4	0.00	CD	O	O
-	ULORIC.xml:S1:7444:1	-	:	O	O
1.08	ULORIC.xml:S1:7445:4	1.08	CD	O	O
)	ULORIC.xml:S1:7449:1	)	)	O	O
,	ULORIC.xml:S1:7450:1	,	,	O	O
ULORIC	ULORIC.xml:S1:7452:6	ulor	NNP	O	O
80	ULORIC.xml:S1:7459:2	80	CD	O	O
mg	ULORIC.xml:S1:7462:2	mg	NN	O	O
1.09	ULORIC.xml:S1:7465:4	1.09	CD	O	O
(	ULORIC.xml:S1:7470:1	(	(	O	O
95%	ULORIC.xml:S1:7471:3	95%	CD	O	O
CI	ULORIC.xml:S1:7475:2	CI	NNP	O	O
0.44	ULORIC.xml:S1:7478:4	0.44	CD	O	O
-	ULORIC.xml:S1:7482:1	-	:	O	O
2.24	ULORIC.xml:S1:7483:4	2.24	CD	O	O
)	ULORIC.xml:S1:7487:1	)	)	O	O
,	ULORIC.xml:S1:7488:1	,	,	O	O
and	ULORIC.xml:S1:7490:3	and	CC	O	O
allopurinol	ULORIC.xml:S1:7494:11	allopurinol	RB	O	O
0.60	ULORIC.xml:S1:7506:4	0.60	CD	O	O
(	ULORIC.xml:S1:7511:1	(	(	O	O
95%	ULORIC.xml:S1:7512:3	95%	CD	O	O
CI	ULORIC.xml:S1:7516:2	CI	NNP	O	O
0.16	ULORIC.xml:S1:7519:4	0.16	CD	O	O
-	ULORIC.xml:S1:7523:1	-	:	O	O
1.53	ULORIC.xml:S1:7524:4	1.53	CD	O	O
)	ULORIC.xml:S1:7528:1	)	)	O	O
.	ULORIC.xml:S1:7529:1	.	.	O	O

In	ULORIC.xml:S1:7535:2	In	IN	O	O
the	ULORIC.xml:S1:7538:3	the	DT	O	O
long	ULORIC.xml:S1:7542:4	long	JJ	O	O
-	ULORIC.xml:S1:7546:1	-	:	O	O
term	ULORIC.xml:S1:7547:4	term	NN	O	O
extension	ULORIC.xml:S1:7552:9	extens	NN	O	O
studies	ULORIC.xml:S1:7562:7	studi	NNS	O	O
,	ULORIC.xml:S1:7569:1	,	,	O	O
the	ULORIC.xml:S1:7571:3	the	DT	O	O
incidences	ULORIC.xml:S1:7575:10	incid	NNS	O	O
of	ULORIC.xml:S1:7586:2	of	IN	O	O
adjudicated	ULORIC.xml:S1:7589:11	adjud	JJ	O	O
APTC	ULORIC.xml:S1:7601:4	aptc	NNP	O	O
events	ULORIC.xml:S1:7606:6	event	NNS	O	O
were	ULORIC.xml:S1:7613:4	were	VBD	O	O
:	ULORIC.xml:S1:7617:1	:	:	O	O
ULORIC	ULORIC.xml:S1:7619:6	ulor	JJ	O	O
80	ULORIC.xml:S1:7626:2	80	CD	O	O
mg	ULORIC.xml:S1:7629:2	mg	NN	O	O
0.97	ULORIC.xml:S1:7632:4	0.97	CD	O	O
(	ULORIC.xml:S1:7637:1	(	(	O	O
95%	ULORIC.xml:S1:7638:3	95%	CD	O	O
CI	ULORIC.xml:S1:7642:2	CI	NNP	O	O
0.57	ULORIC.xml:S1:7645:4	0.57	CD	O	O
-	ULORIC.xml:S1:7649:1	-	:	O	O
1.56	ULORIC.xml:S1:7650:4	1.56	CD	O	O
)	ULORIC.xml:S1:7654:1	)	)	O	O
,	ULORIC.xml:S1:7655:1	,	,	O	O
and	ULORIC.xml:S1:7657:3	and	CC	O	O
allopurinol	ULORIC.xml:S1:7661:11	allopurinol	RB	O	O
0.58	ULORIC.xml:S1:7673:4	0.58	CD	O	O
(	ULORIC.xml:S1:7678:1	(	(	O	O
95%	ULORIC.xml:S1:7679:3	95%	CD	O	O
CI	ULORIC.xml:S1:7683:2	CI	NNP	O	O
0.02	ULORIC.xml:S1:7686:4	0.02	CD	O	O
-	ULORIC.xml:S1:7690:1	-	:	O	O
3.24	ULORIC.xml:S1:7691:4	3.24	CD	O	O
)	ULORIC.xml:S1:7695:1	)	)	O	O
.	ULORIC.xml:S1:7696:1	.	.	O	O

Overall	ULORIC.xml:S1:7702:7	overal	JJ	O	O
,	ULORIC.xml:S1:7709:1	,	,	O	O
a	ULORIC.xml:S1:7711:1	a	DT	O	O
higher	ULORIC.xml:S1:7713:6	higher	JJR	O	O
rate	ULORIC.xml:S1:7720:4	rate	NN	O	O
of	ULORIC.xml:S1:7725:2	of	IN	O	O
APTC	ULORIC.xml:S1:7728:4	aptc	NNP	O	B-AdverseReaction
events	ULORIC.xml:S1:7733:6	event	NNS	O	I-AdverseReaction
was	ULORIC.xml:S1:7740:3	wa	VBD	O	O
observed	ULORIC.xml:S1:7744:8	observ	VBN	O	O
in	ULORIC.xml:S1:7753:2	in	IN	O	O
ULORIC	ULORIC.xml:S1:7756:6	ulor	NNP	O	O
than	ULORIC.xml:S1:7763:4	than	IN	O	O
in	ULORIC.xml:S1:7768:2	in	IN	O	O
allopurinol	ULORIC.xml:S1:7771:11	allopurinol	JJ	O	O
-	ULORIC.xml:S1:7782:1	-	:	O	O
treated	ULORIC.xml:S1:7783:7	treat	JJ	O	O
patients	ULORIC.xml:S1:7791:8	patient	NNS	O	O
.	ULORIC.xml:S1:7799:1	.	.	O	O

A	ULORIC.xml:S1:7801:1	A	DT	O	O
causal	ULORIC.xml:S1:7803:6	causal	NN	O	O
relationship	ULORIC.xml:S1:7810:12	relationship	NN	O	O
with	ULORIC.xml:S1:7823:4	with	IN	O	O
ULORIC	ULORIC.xml:S1:7828:6	ulor	NNP	O	O
has	ULORIC.xml:S1:7835:3	ha	VBZ	O	O
not	ULORIC.xml:S1:7839:3	not	RB	O	O
been	ULORIC.xml:S1:7843:4	been	VBN	O	O
established	ULORIC.xml:S1:7848:11	establish	VBN	O	O
.	ULORIC.xml:S1:7859:1	.	.	O	O

Monitor	ULORIC.xml:S1:7861:7	monitor	NNP	O	O
for	ULORIC.xml:S1:7869:3	for	IN	O	O
signs	ULORIC.xml:S1:7873:5	sign	NNS	O	O
and	ULORIC.xml:S1:7879:3	and	CC	O	O
symptoms	ULORIC.xml:S1:7883:8	symptom	NNS	O	O
of	ULORIC.xml:S1:7892:2	of	IN	O	O
MI	ULORIC.xml:S1:7895:2	MI	NNP	O	O
and	ULORIC.xml:S1:7898:3	and	CC	O	O
stroke	ULORIC.xml:S1:7902:6	stroke	NN	O	B-AdverseReaction
.	ULORIC.xml:S1:7908:1	.	.	O	O

6.2	ULORIC.xml:S1:7916:3	6.2	CD	O	O
Postmarketing	ULORIC.xml:S1:7920:13	postmarket	VBG	O	O
Experience	ULORIC.xml:S1:7934:10	experi	NN	O	O

Adverse	ULORIC.xml:S1:7948:7	advers	JJ	O	O
reactions	ULORIC.xml:S1:7956:9	reaction	NNS	O	O
have	ULORIC.xml:S1:7966:4	have	VBP	O	O
been	ULORIC.xml:S1:7971:4	been	VBN	O	O
identified	ULORIC.xml:S1:7976:10	identifi	VBN	O	O
during	ULORIC.xml:S1:7987:6	dure	IN	O	O
postapproval	ULORIC.xml:S1:7994:12	postapprov	JJ	O	O
use	ULORIC.xml:S1:8007:3	use	NN	O	O
of	ULORIC.xml:S1:8011:2	of	IN	O	O
ULORIC	ULORIC.xml:S1:8014:6	ulor	NNP	O	O
.	ULORIC.xml:S1:8020:1	.	.	O	O

Because	ULORIC.xml:S1:8022:7	becaus	IN	O	O
these	ULORIC.xml:S1:8030:5	these	DT	O	O
reactions	ULORIC.xml:S1:8036:9	reaction	NNS	O	O
are	ULORIC.xml:S1:8046:3	are	VBP	O	O
reported	ULORIC.xml:S1:8050:8	report	VBN	O	O
voluntarily	ULORIC.xml:S1:8059:11	voluntarili	RB	O	O
from	ULORIC.xml:S1:8071:4	from	IN	O	O
a	ULORIC.xml:S1:8076:1	a	DT	O	O
population	ULORIC.xml:S1:8078:10	popul	NN	O	O
of	ULORIC.xml:S1:8089:2	of	IN	O	O
uncertain	ULORIC.xml:S1:8092:9	uncertain	JJ	O	O
size	ULORIC.xml:S1:8102:4	size	NN	O	O
,	ULORIC.xml:S1:8106:1	,	,	O	O
it	ULORIC.xml:S1:8108:2	it	PRP	O	O
is	ULORIC.xml:S1:8111:2	is	VBZ	O	O
not	ULORIC.xml:S1:8114:3	not	RB	O	O
always	ULORIC.xml:S1:8118:6	alway	RB	O	O
possible	ULORIC.xml:S1:8125:8	possibl	JJ	O	O
to	ULORIC.xml:S1:8134:2	to	TO	O	O
reliably	ULORIC.xml:S1:8137:8	reliabl	VB	O	O
estimate	ULORIC.xml:S1:8146:8	estim	VB	O	O
their	ULORIC.xml:S1:8155:5	their	PRP$	O	O
frequency	ULORIC.xml:S1:8161:9	frequenc	NN	O	O
or	ULORIC.xml:S1:8171:2	or	CC	O	O
establish	ULORIC.xml:S1:8174:9	establish	VB	O	O
a	ULORIC.xml:S1:8184:1	a	DT	O	O
causal	ULORIC.xml:S1:8186:6	causal	NN	O	O
relationship	ULORIC.xml:S1:8193:12	relationship	NN	O	O
.	ULORIC.xml:S1:8205:1	.	.	O	O

Hepatobiliary	ULORIC.xml:S1:8213:13	hepatobiliari	JJ	O	O
Disorders	ULORIC.xml:S1:8227:9	disord	NNS	O	O
:	ULORIC.xml:S1:8236:1	:	:	O	O
hepatic	ULORIC.xml:S1:8239:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
failure	ULORIC.xml:S1:8247:7	failur	NN	I-AdverseReaction	I-AdverseReaction
(	ULORIC.xml:S1:8255:1	(	(	O	O
some	ULORIC.xml:S1:8256:4	some	DT	O	O
fatal	ULORIC.xml:S1:8261:5	fatal	NN	B-AdverseReaction	B-AdverseReaction
)	ULORIC.xml:S1:8266:1	)	)	O	O
,	ULORIC.xml:S1:8267:1	,	,	O	O
jaundice	ULORIC.xml:S1:8269:8	jaundic	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:8277:1	,	,	O	O
serious	ULORIC.xml:S1:8279:7	seriou	JJ	O	O
cases	ULORIC.xml:S1:8287:5	case	NNS	O	O
of	ULORIC.xml:S1:8293:2	of	IN	O	O
abnormal	ULORIC.xml:S1:8296:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
liver	ULORIC.xml:S1:8305:5	liver	NN	I-AdverseReaction	I-AdverseReaction
function	ULORIC.xml:S1:8311:8	function	NN	I-AdverseReaction	O
test	ULORIC.xml:S1:8320:4	test	NN	O	O
results	ULORIC.xml:S1:8325:7	result	NNS	O	O
,	ULORIC.xml:S1:8332:1	,	,	O	O
liver	ULORIC.xml:S1:8334:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
disorder	ULORIC.xml:S1:8340:8	disord	NN	I-AdverseReaction	I-AdverseReaction
.	ULORIC.xml:S1:8348:1	.	.	O	O

Immune	ULORIC.xml:S1:8356:6	immun	NNP	O	O
System	ULORIC.xml:S1:8363:6	system	NNP	O	O
Disorders	ULORIC.xml:S1:8370:9	disord	NNPS	O	O
:	ULORIC.xml:S1:8379:1	:	:	O	O
anaphylaxis	ULORIC.xml:S1:8382:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
,	ULORIC.xml:S1:8393:1	,	,	O	O
anaphylactic	ULORIC.xml:S1:8395:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reaction	ULORIC.xml:S1:8408:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
.	ULORIC.xml:S1:8416:1	.	.	O	O

Musculoskeletal	ULORIC.xml:S1:8424:15	musculoskelet	NNP	O	O
and	ULORIC.xml:S1:8440:3	and	CC	O	O
Connective	ULORIC.xml:S1:8444:10	connect	NNP	O	O
Tissue	ULORIC.xml:S1:8455:6	tissu	NNP	O	O
Disorders	ULORIC.xml:S1:8462:9	disord	NNP	O	O
:	ULORIC.xml:S1:8471:1	:	:	O	O
rhabdomyolysis	ULORIC.xml:S1:8474:14	rhabdomyolysi	NN	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S1:8488:1	.	.	O	O

Psychiatric	ULORIC.xml:S1:8496:11	psychiatr	JJ	O	O
Disorders	ULORIC.xml:S1:8508:9	disord	NNS	O	O
:	ULORIC.xml:S1:8517:1	:	:	O	O
psychotic	ULORIC.xml:S1:8520:9	psychot	JJ	B-AdverseReaction	B-AdverseReaction
behavior	ULORIC.xml:S1:8530:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
including	ULORIC.xml:S1:8539:9	includ	VBG	O	O
aggressive	ULORIC.xml:S1:8549:10	aggress	JJ	B-AdverseReaction	O
thoughts	ULORIC.xml:S1:8560:8	thought	NNS	I-AdverseReaction	O
.	ULORIC.xml:S1:8568:1	.	.	O	O

Renal	ULORIC.xml:S1:8576:5	renal	NNP	O	O
and	ULORIC.xml:S1:8582:3	and	CC	O	O
Urinary	ULORIC.xml:S1:8586:7	urinari	JJ	O	O
Disorders	ULORIC.xml:S1:8594:9	disord	NNS	O	O
:	ULORIC.xml:S1:8603:1	:	:	O	O
tubulointerstitial	ULORIC.xml:S1:8606:18	tubulointerstiti	JJ	B-AdverseReaction	B-AdverseReaction
nephritis	ULORIC.xml:S1:8625:9	nephriti	NN	I-AdverseReaction	I-AdverseReaction
.	ULORIC.xml:S1:8634:1	.	.	O	O

Skin	ULORIC.xml:S1:8642:4	skin	NNP	O	O
and	ULORIC.xml:S1:8647:3	and	CC	O	O
Subcutaneous	ULORIC.xml:S1:8651:12	subcutan	NNP	O	O
Tissue	ULORIC.xml:S1:8664:6	tissu	NNP	O	O
Disorders	ULORIC.xml:S1:8671:9	disord	NNP	O	O
:	ULORIC.xml:S1:8680:1	:	:	O	O
generalized	ULORIC.xml:S1:8683:11	gener	JJ	B-AdverseReaction	B-AdverseReaction
rash	ULORIC.xml:S1:8695:4	rash	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:8699:1	,	,	O	O
Stevens	ULORIC.xml:S1:8701:7	steven	NNP	B-AdverseReaction	B-AdverseReaction
Johnson	ULORIC.xml:S1:8709:7	johnson	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	ULORIC.xml:S1:8717:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S1:8725:1	,	,	O	O
hypersensitivity	ULORIC.xml:S1:8727:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
skin	ULORIC.xml:S1:8744:4	skin	NN	I-AdverseReaction	I-AdverseReaction
reactions	ULORIC.xml:S1:8749:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
.	ULORIC.xml:S1:8758:1	.	.	O	O
5	ULORIC.xml:S2:4:1	5	CD	O	O
WARNINGS	ULORIC.xml:S2:6:8	warn	NNP	O	O
AND	ULORIC.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	ULORIC.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	ULORIC.xml:S2:37:7	excerpt	NN	O	O
:	ULORIC.xml:S2:44:1	:	:	O	O
Gout	ULORIC.xml:S2:55:4	gout	NN	B-AdverseReaction	B-AdverseReaction
Flare	ULORIC.xml:S2:60:5	flare	NN	I-AdverseReaction	I-AdverseReaction
:	ULORIC.xml:S2:66:1	:	:	O	O
An	ULORIC.xml:S2:68:2	An	DT	O	O
increase	ULORIC.xml:S2:71:8	increas	NN	O	O
in	ULORIC.xml:S2:80:2	in	IN	O	O
gout	ULORIC.xml:S2:83:4	gout	NN	B-AdverseReaction	O
flares	ULORIC.xml:S2:88:6	flare	NNS	I-AdverseReaction	O
is	ULORIC.xml:S2:95:2	is	VBZ	O	O
frequently	ULORIC.xml:S2:98:10	frequent	RB	O	O
observed	ULORIC.xml:S2:109:8	observ	VBN	O	O
during	ULORIC.xml:S2:118:6	dure	IN	O	O
initiation	ULORIC.xml:S2:125:10	initi	NN	O	O
of	ULORIC.xml:S2:136:2	of	IN	O	O
anti	ULORIC.xml:S2:139:4	anti	JJ	O	O
-	ULORIC.xml:S2:143:1	-	:	O	O
hyperuricemic	ULORIC.xml:S2:144:13	hyperuricem	JJ	O	O
agents	ULORIC.xml:S2:158:6	agent	NNS	O	O
,	ULORIC.xml:S2:164:1	,	,	O	O
including	ULORIC.xml:S2:166:9	includ	VBG	O	O
ULORIC	ULORIC.xml:S2:176:6	ulor	NNP	O	O
.	ULORIC.xml:S2:182:1	.	.	O	O

If	ULORIC.xml:S2:184:2	If	IN	O	O
a	ULORIC.xml:S2:187:1	a	DT	O	O
gout	ULORIC.xml:S2:189:4	gout	NN	O	O
flare	ULORIC.xml:S2:194:5	flare	NN	O	O
occurs	ULORIC.xml:S2:200:6	occur	VBZ	O	O
during	ULORIC.xml:S2:207:6	dure	IN	O	O
treatment	ULORIC.xml:S2:214:9	treatment	NN	O	O
,	ULORIC.xml:S2:223:1	,	,	O	O
ULORIC	ULORIC.xml:S2:225:6	ulor	NNP	O	O
need	ULORIC.xml:S2:232:4	need	MD	O	O
not	ULORIC.xml:S2:237:3	not	RB	O	O
be	ULORIC.xml:S2:241:2	be	VB	O	O
discontinued	ULORIC.xml:S2:244:12	discontinu	VBN	O	O
.	ULORIC.xml:S2:256:1	.	.	O	O

Prophylactic	ULORIC.xml:S2:258:12	prophylact	JJ	O	O
therapy	ULORIC.xml:S2:271:7	therapi	NN	O	O
(	ULORIC.xml:S2:279:1	(	(	O	O
i	ULORIC.xml:S2:280:1	i	JJ	O	O
.	ULORIC.xml:S2:281:1	.	.	O	O
e	ULORIC.xml:S2:282:1	e	NN	O	O
.	ULORIC.xml:S2:283:1	.	.	O	O
,	ULORIC.xml:S2:284:1	,	,	O	O
non	ULORIC.xml:S2:286:3	non	JJ	O	O
-	ULORIC.xml:S2:289:1	-	:	O	O
steroidal	ULORIC.xml:S2:290:9	steroid	NN	O	O
anti	ULORIC.xml:S2:300:4	anti	SYM	O	O
-	ULORIC.xml:S2:304:1	-	:	O	O
inflammatory	ULORIC.xml:S2:305:12	inflammatori	JJ	O	O
drug	ULORIC.xml:S2:318:4	drug	NN	O	O
[	ULORIC.xml:S2:323:1	[	NNP	O	O
NSAID	ULORIC.xml:S2:324:5	nsaid	NNP	O	O
]	ULORIC.xml:S2:329:1	]	NNP	O	O
or	ULORIC.xml:S2:331:2	or	CC	O	O
colchicine	ULORIC.xml:S2:334:10	colchicin	VB	O	O
upon	ULORIC.xml:S2:345:4	upon	IN	O	O
initiation	ULORIC.xml:S2:350:10	initi	NN	O	O
of	ULORIC.xml:S2:361:2	of	IN	O	O
treatment	ULORIC.xml:S2:364:9	treatment	NN	O	O
)	ULORIC.xml:S2:373:1	)	)	O	O
may	ULORIC.xml:S2:375:3	may	MD	O	O
be	ULORIC.xml:S2:379:2	be	VB	O	O
beneficial	ULORIC.xml:S2:382:10	benefici	JJ	O	O
for	ULORIC.xml:S2:393:3	for	IN	O	O
up	ULORIC.xml:S2:397:2	up	IN	O	O
to	ULORIC.xml:S2:400:2	to	TO	O	O
six	ULORIC.xml:S2:403:3	six	CD	O	O
months	ULORIC.xml:S2:407:6	month	NNS	O	O
.	ULORIC.xml:S2:413:1	.	.	O	O

(	ULORIC.xml:S2:415:1	(	(	O	O
2.4	ULORIC.xml:S2:418:3	2.4	CD	O	O
,	ULORIC.xml:S2:423:1	,	,	O	O
5.1	ULORIC.xml:S2:426:3	5.1	CD	O	O
)	ULORIC.xml:S2:431:1	)	)	O	O

Cardiovascular	ULORIC.xml:S2:441:14	cardiovascular	JJ	B-AdverseReaction	B-AdverseReaction
Events	ULORIC.xml:S2:456:6	event	NNS	I-AdverseReaction	I-AdverseReaction
:	ULORIC.xml:S2:463:1	:	:	O	O
A	ULORIC.xml:S2:465:1	A	DT	O	O
higher	ULORIC.xml:S2:467:6	higher	JJR	O	O
rate	ULORIC.xml:S2:474:4	rate	NN	O	O
of	ULORIC.xml:S2:479:2	of	IN	O	O
cardiovascular	ULORIC.xml:S2:482:14	cardiovascular	JJ	B-AdverseReaction	B-AdverseReaction
thromboembolic	ULORIC.xml:S2:497:14	thromboembol	JJ	I-AdverseReaction	I-AdverseReaction
events	ULORIC.xml:S2:512:6	event	NNS	I-AdverseReaction	I-AdverseReaction
was	ULORIC.xml:S2:519:3	wa	VBD	O	O
observed	ULORIC.xml:S2:523:8	observ	VBN	O	O
in	ULORIC.xml:S2:532:2	in	IN	O	O
patients	ULORIC.xml:S2:535:8	patient	NNS	O	O
treated	ULORIC.xml:S2:544:7	treat	VBN	O	O
with	ULORIC.xml:S2:552:4	with	IN	O	O
ULORIC	ULORIC.xml:S2:557:6	ulor	NNP	O	O
than	ULORIC.xml:S2:564:4	than	IN	O	O
allopurinol	ULORIC.xml:S2:569:11	allopurinol	NN	O	O
in	ULORIC.xml:S2:581:2	in	IN	O	O
clinical	ULORIC.xml:S2:584:8	clinic	JJ	O	O
trials	ULORIC.xml:S2:593:6	trial	NNS	O	O
.	ULORIC.xml:S2:599:1	.	.	O	O

Monitor	ULORIC.xml:S2:601:7	monitor	NNP	O	O
for	ULORIC.xml:S2:609:3	for	IN	O	O
signs	ULORIC.xml:S2:613:5	sign	NNS	O	O
and	ULORIC.xml:S2:619:3	and	CC	O	O
symptoms	ULORIC.xml:S2:623:8	symptom	NNS	O	O
of	ULORIC.xml:S2:632:2	of	IN	O	O
MI	ULORIC.xml:S2:635:2	MI	NNP	O	O
and	ULORIC.xml:S2:638:3	and	CC	O	O
stroke	ULORIC.xml:S2:642:6	stroke	NN	O	B-AdverseReaction
.	ULORIC.xml:S2:648:1	.	.	O	O

(	ULORIC.xml:S2:650:1	(	(	O	O
5.2	ULORIC.xml:S2:653:3	5.2	CD	O	O
)	ULORIC.xml:S2:658:1	)	)	O	O

Hepatic	ULORIC.xml:S2:668:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
Effects	ULORIC.xml:S2:676:7	effect	NNS	I-AdverseReaction	I-AdverseReaction
:	ULORIC.xml:S2:683:1	:	:	O	O
Postmarketing	ULORIC.xml:S2:685:13	postmarket	VBG	O	O
reports	ULORIC.xml:S2:699:7	report	NNS	O	O
of	ULORIC.xml:S2:707:2	of	IN	O	O
hepatic	ULORIC.xml:S2:710:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
failure	ULORIC.xml:S2:718:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S2:725:1	,	,	O	O
sometimes	ULORIC.xml:S2:727:9	sometim	RB	O	O
fatal	ULORIC.xml:S2:737:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
.	ULORIC.xml:S2:742:1	.	.	O	O

Causality	ULORIC.xml:S2:744:9	causal	NNP	O	O
cannot	ULORIC.xml:S2:754:6	cannot	NN	O	O
be	ULORIC.xml:S2:761:2	be	VB	O	O
excluded	ULORIC.xml:S2:764:8	exclud	VBN	O	O
.	ULORIC.xml:S2:772:1	.	.	O	O

If	ULORIC.xml:S2:774:2	If	IN	O	O
liver	ULORIC.xml:S2:777:5	liver	JJ	O	O
injury	ULORIC.xml:S2:783:6	injuri	NN	O	O
is	ULORIC.xml:S2:790:2	is	VBZ	O	O
detected	ULORIC.xml:S2:793:8	detect	VBN	O	O
,	ULORIC.xml:S2:801:1	,	,	O	O
promptly	ULORIC.xml:S2:803:8	promptli	RB	O	O
interrupt	ULORIC.xml:S2:812:9	interrupt	JJ	O	O
ULORIC	ULORIC.xml:S2:822:6	ulor	NNP	O	O
and	ULORIC.xml:S2:829:3	and	CC	O	O
assess	ULORIC.xml:S2:833:6	assess	JJ	O	O
patient	ULORIC.xml:S2:840:7	patient	NN	O	O
for	ULORIC.xml:S2:848:3	for	IN	O	O
probable	ULORIC.xml:S2:852:8	probabl	JJ	O	O
cause	ULORIC.xml:S2:861:5	caus	NN	O	O
,	ULORIC.xml:S2:866:1	,	,	O	O
then	ULORIC.xml:S2:868:4	then	RB	O	O
treat	ULORIC.xml:S2:873:5	treat	NN	O	O
cause	ULORIC.xml:S2:879:5	caus	NN	O	O
if	ULORIC.xml:S2:885:2	if	IN	O	O
possible	ULORIC.xml:S2:888:8	possibl	JJ	O	O
,	ULORIC.xml:S2:896:1	,	,	O	O
to	ULORIC.xml:S2:898:2	to	TO	O	O
resolution	ULORIC.xml:S2:901:10	resolut	NN	O	O
or	ULORIC.xml:S2:912:2	or	CC	O	O
stabilization	ULORIC.xml:S2:915:13	stabil	NN	O	O
.	ULORIC.xml:S2:928:1	.	.	O	O

Do	ULORIC.xml:S2:930:2	Do	NNP	O	O
not	ULORIC.xml:S2:933:3	not	RB	O	O
restart	ULORIC.xml:S2:937:7	restart	VB	O	O
ULORIC	ULORIC.xml:S2:945:6	ulor	NNP	O	O
if	ULORIC.xml:S2:952:2	if	IN	O	O
liver	ULORIC.xml:S2:955:5	liver	JJ	O	O
injury	ULORIC.xml:S2:961:6	injuri	NN	O	O
is	ULORIC.xml:S2:968:2	is	VBZ	O	O
confirmed	ULORIC.xml:S2:971:9	confirm	VBN	O	O
and	ULORIC.xml:S2:981:3	and	CC	O	O
no	ULORIC.xml:S2:985:2	no	DT	O	O
alternate	ULORIC.xml:S2:988:9	altern	JJ	O	O
etiology	ULORIC.xml:S2:998:8	etiolog	NN	O	O
can	ULORIC.xml:S2:1007:3	can	MD	O	O
be	ULORIC.xml:S2:1011:2	be	VB	O	O
found	ULORIC.xml:S2:1014:5	found	VBN	O	O
.	ULORIC.xml:S2:1019:1	.	.	O	O

(	ULORIC.xml:S2:1021:1	(	(	O	O
5.3	ULORIC.xml:S2:1024:3	5.3	CD	O	O
)	ULORIC.xml:S2:1029:1	)	)	O	O

5.1	ULORIC.xml:S2:1043:3	5.1	CD	O	O

Gout	ULORIC.xml:S2:1047:4	gout	NN	O	O

Flare	ULORIC.xml:S2:1052:5	flare	NN	O	O

After	ULORIC.xml:S2:1063:5	after	IN	O	O
initiation	ULORIC.xml:S2:1069:10	initi	NN	O	O
of	ULORIC.xml:S2:1080:2	of	IN	O	O
ULORIC	ULORIC.xml:S2:1083:6	ulor	NNP	O	O
,	ULORIC.xml:S2:1089:1	,	,	O	O
an	ULORIC.xml:S2:1091:2	an	DT	O	O
increase	ULORIC.xml:S2:1094:8	increas	NN	O	O
in	ULORIC.xml:S2:1103:2	in	IN	O	O
gout	ULORIC.xml:S2:1106:4	gout	NN	B-AdverseReaction	O
flares	ULORIC.xml:S2:1111:6	flare	NNS	I-AdverseReaction	O
is	ULORIC.xml:S2:1118:2	is	VBZ	O	O
frequently	ULORIC.xml:S2:1121:10	frequent	RB	O	O
observed	ULORIC.xml:S2:1132:8	observ	VBN	O	O
.	ULORIC.xml:S2:1140:1	.	.	O	O

This	ULORIC.xml:S2:1142:4	thi	DT	O	O
increase	ULORIC.xml:S2:1147:8	increas	NN	O	O
is	ULORIC.xml:S2:1156:2	is	VBZ	O	O
due	ULORIC.xml:S2:1159:3	due	JJ	O	O
to	ULORIC.xml:S2:1163:2	to	TO	O	O
reduction	ULORIC.xml:S2:1166:9	reduct	NN	O	B-AdverseReaction
in	ULORIC.xml:S2:1176:2	in	IN	O	I-AdverseReaction
serum	ULORIC.xml:S2:1179:5	serum	NN	O	I-AdverseReaction
uric	ULORIC.xml:S2:1185:4	uric	JJ	O	I-AdverseReaction
acid	ULORIC.xml:S2:1190:4	acid	NN	O	I-AdverseReaction
levels	ULORIC.xml:S2:1195:6	level	NNS	O	I-AdverseReaction
,	ULORIC.xml:S2:1201:1	,	,	O	O
resulting	ULORIC.xml:S2:1203:9	result	VBG	O	O
in	ULORIC.xml:S2:1213:2	in	IN	O	O
mobilization	ULORIC.xml:S2:1216:12	mobil	NN	O	O
of	ULORIC.xml:S2:1229:2	of	IN	O	O
urate	ULORIC.xml:S2:1232:5	urat	NN	O	O
from	ULORIC.xml:S2:1238:4	from	IN	O	O
tissue	ULORIC.xml:S2:1243:6	tissu	NN	O	O
deposits	ULORIC.xml:S2:1250:8	deposit	NNS	O	O
.	ULORIC.xml:S2:1258:1	.	.	O	O

In	ULORIC.xml:S2:1264:2	In	IN	O	O
order	ULORIC.xml:S2:1267:5	order	NN	O	O
to	ULORIC.xml:S2:1273:2	to	TO	O	O
prevent	ULORIC.xml:S2:1276:7	prevent	VB	O	O
gout	ULORIC.xml:S2:1284:4	gout	NN	O	O
flares	ULORIC.xml:S2:1289:6	flare	NNS	O	O
when	ULORIC.xml:S2:1296:4	when	WRB	O	O
ULORIC	ULORIC.xml:S2:1301:6	ulor	NNP	O	O
is	ULORIC.xml:S2:1308:2	is	VBZ	O	O
initiated	ULORIC.xml:S2:1311:9	initi	VBN	O	O
,	ULORIC.xml:S2:1320:1	,	,	O	O
concurrent	ULORIC.xml:S2:1322:10	concurr	JJ	O	O
prophylactic	ULORIC.xml:S2:1333:12	prophylact	JJ	O	O
treatment	ULORIC.xml:S2:1346:9	treatment	NN	O	O
with	ULORIC.xml:S2:1356:4	with	IN	O	O
an	ULORIC.xml:S2:1361:2	an	DT	O	O
NSAID	ULORIC.xml:S2:1364:5	nsaid	NNP	O	O
or	ULORIC.xml:S2:1370:2	or	CC	O	O
colchicine	ULORIC.xml:S2:1373:10	colchicin	NN	O	O
is	ULORIC.xml:S2:1384:2	is	VBZ	O	O
recommended	ULORIC.xml:S2:1387:11	recommend	VBN	O	O
[	ULORIC.xml:S2:1399:1	[	JJ	O	O
see	ULORIC.xml:S2:1400:3	see	NN	O	O
Dosage	ULORIC.xml:S2:1405:6	dosag	NNP	O	O
and	ULORIC.xml:S2:1412:3	and	CC	O	O
Administration	ULORIC.xml:S2:1416:14	administr	NNP	O	O
(	ULORIC.xml:S2:1431:1	(	(	O	O
2.4	ULORIC.xml:S2:1432:3	2.4	CD	O	O
)	ULORIC.xml:S2:1435:1	)	)	O	O
]	ULORIC.xml:S2:1438:1	]	NN	O	O
.	ULORIC.xml:S2:1439:1	.	.	O	O

5.2	ULORIC.xml:S2:1450:3	5.2	CD	O	O
Cardiovascular	ULORIC.xml:S2:1454:14	cardiovascular	JJ	O	O
Events	ULORIC.xml:S2:1469:6	event	NNS	O	O

In	ULORIC.xml:S2:1481:2	In	IN	O	O
the	ULORIC.xml:S2:1484:3	the	DT	O	O
randomized	ULORIC.xml:S2:1488:10	random	NN	O	O
controlled	ULORIC.xml:S2:1499:10	control	VBD	O	O
studies	ULORIC.xml:S2:1510:7	studi	NNS	O	O
,	ULORIC.xml:S2:1517:1	,	,	O	O
there	ULORIC.xml:S2:1519:5	there	EX	O	O
was	ULORIC.xml:S2:1525:3	wa	VBD	O	O
a	ULORIC.xml:S2:1529:1	a	DT	O	O
higher	ULORIC.xml:S2:1531:6	higher	JJR	O	O
rate	ULORIC.xml:S2:1538:4	rate	NN	O	O
of	ULORIC.xml:S2:1543:2	of	IN	O	O
cardiovascular	ULORIC.xml:S2:1546:14	cardiovascular	JJ	B-AdverseReaction	B-AdverseReaction
thromboembolic	ULORIC.xml:S2:1561:14	thromboembol	JJ	I-AdverseReaction	I-AdverseReaction
events	ULORIC.xml:S2:1576:6	event	NNS	I-AdverseReaction	I-AdverseReaction
(	ULORIC.xml:S2:1583:1	(	(	O	O
cardiovascular	ULORIC.xml:S2:1584:14	cardiovascular	JJ	B-AdverseReaction	B-AdverseReaction
deaths	ULORIC.xml:S2:1599:6	death	NNS	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S2:1605:1	,	,	O	O
non	ULORIC.xml:S2:1607:3	non	SYM	O	O
-	ULORIC.xml:S2:1610:1	-	:	O	O
fatal	ULORIC.xml:S2:1611:5	fatal	JJ	O	O
myocardial	ULORIC.xml:S2:1617:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
infarctions	ULORIC.xml:S2:1628:11	infarct	NNS	I-AdverseReaction	I-AdverseReaction
,	ULORIC.xml:S2:1639:1	,	,	O	O
and	ULORIC.xml:S2:1641:3	and	CC	O	O
non	ULORIC.xml:S2:1645:3	non	SYM	O	O
-	ULORIC.xml:S2:1648:1	-	:	O	O
fatal	ULORIC.xml:S2:1649:5	fatal	JJ	O	O
strokes	ULORIC.xml:S2:1655:7	stroke	NNS	B-AdverseReaction	O
)	ULORIC.xml:S2:1662:1	)	)	O	O
in	ULORIC.xml:S2:1664:2	in	IN	O	O
patients	ULORIC.xml:S2:1667:8	patient	NNS	O	O
treated	ULORIC.xml:S2:1676:7	treat	VBN	O	O
with	ULORIC.xml:S2:1684:4	with	IN	O	O
ULORIC	ULORIC.xml:S2:1689:6	ulor	NNP	O	O
(	ULORIC.xml:S2:1696:1	(	(	O	O
0.74	ULORIC.xml:S2:1697:4	0.74	CD	O	O
per	ULORIC.xml:S2:1702:3	per	IN	O	O
100	ULORIC.xml:S2:1706:3	100	CD	O	O
P	ULORIC.xml:S2:1710:1	P	NNP	O	O
-	ULORIC.xml:S2:1711:1	-	:	O	O
Y	ULORIC.xml:S2:1712:1	Y	NNP	O	O
[	ULORIC.xml:S2:1714:1	[	VBZ	O	O
95%	ULORIC.xml:S2:1715:3	95%	CD	O	O
Confidence	ULORIC.xml:S2:1719:10	confid	NN	O	O
Interval	ULORIC.xml:S2:1730:8	interv	NNP	O	O
(	ULORIC.xml:S2:1739:1	(	(	O	O
CI	ULORIC.xml:S2:1740:2	CI	NNP	O	O
)	ULORIC.xml:S2:1742:1	)	)	O	O
0.36	ULORIC.xml:S2:1744:4	0.36	CD	O	O
-	ULORIC.xml:S2:1748:1	-	:	O	O
1.37	ULORIC.xml:S2:1749:4	1.37	CD	O	O
])	ULORIC.xml:S2:1753:2	])	NN	O	O
than	ULORIC.xml:S2:1756:4	than	IN	O	O
allopurinol	ULORIC.xml:S2:1761:11	allopurinol	NN	O	O
(	ULORIC.xml:S2:1773:1	(	(	O	O
0.60	ULORIC.xml:S2:1774:4	0.60	CD	O	O
per	ULORIC.xml:S2:1779:3	per	IN	O	O
100	ULORIC.xml:S2:1783:3	100	CD	O	O
P	ULORIC.xml:S2:1787:1	P	NNP	O	O
-	ULORIC.xml:S2:1788:1	-	:	O	O
Y	ULORIC.xml:S2:1789:1	Y	NNP	O	O
[	ULORIC.xml:S2:1791:1	[	VBZ	O	O
95%	ULORIC.xml:S2:1792:3	95%	CD	O	O
CI	ULORIC.xml:S2:1796:2	CI	NNP	O	O
0.16	ULORIC.xml:S2:1799:4	0.16	CD	O	O
-	ULORIC.xml:S2:1803:1	-	:	O	O
1.53	ULORIC.xml:S2:1804:4	1.53	CD	O	O
])	ULORIC.xml:S2:1808:2	])	JJ	O	O
[	ULORIC.xml:S2:1811:1	[	NNP	O	O
see	ULORIC.xml:S2:1812:3	see	VBP	O	O
Adverse	ULORIC.xml:S2:1817:7	advers	JJ	O	O
Reactions	ULORIC.xml:S2:1825:9	reaction	NNP	O	O
(	ULORIC.xml:S2:1835:1	(	(	O	O
6.1	ULORIC.xml:S2:1836:3	6.1	CD	O	O
)	ULORIC.xml:S2:1839:1	)	)	O	O
]	ULORIC.xml:S2:1842:1	]	NN	O	O
.	ULORIC.xml:S2:1845:1	.	.	O	O

A	ULORIC.xml:S2:1847:1	A	DT	O	O
causal	ULORIC.xml:S2:1849:6	causal	NN	O	O
relationship	ULORIC.xml:S2:1856:12	relationship	NN	O	O
with	ULORIC.xml:S2:1869:4	with	IN	O	O
ULORIC	ULORIC.xml:S2:1874:6	ulor	NNP	O	O
has	ULORIC.xml:S2:1881:3	ha	VBZ	O	O
not	ULORIC.xml:S2:1885:3	not	RB	O	O
been	ULORIC.xml:S2:1889:4	been	VBN	O	O
established	ULORIC.xml:S2:1894:11	establish	VBN	O	O
.	ULORIC.xml:S2:1905:1	.	.	O	O

Monitor	ULORIC.xml:S2:1907:7	monitor	NNP	O	O
for	ULORIC.xml:S2:1915:3	for	IN	O	O
signs	ULORIC.xml:S2:1919:5	sign	NNS	O	O
and	ULORIC.xml:S2:1925:3	and	CC	O	O
symptoms	ULORIC.xml:S2:1929:8	symptom	NNS	O	O
of	ULORIC.xml:S2:1938:2	of	IN	O	O
myocardial	ULORIC.xml:S2:1941:10	myocardi	JJ	O	O
infarction	ULORIC.xml:S2:1952:10	infarct	NN	O	O
(	ULORIC.xml:S2:1963:1	(	(	O	O
MI	ULORIC.xml:S2:1964:2	MI	NNP	O	O
)	ULORIC.xml:S2:1966:1	)	)	O	O
and	ULORIC.xml:S2:1968:3	and	CC	O	O
stroke	ULORIC.xml:S2:1972:6	stroke	NN	O	B-AdverseReaction
.	ULORIC.xml:S2:1978:1	.	.	O	O

5.3	ULORIC.xml:S2:1987:3	5.3	CD	O	O
Hepatic	ULORIC.xml:S2:1991:7	hepat	JJ	O	O
Effects	ULORIC.xml:S2:1999:7	effect	NNS	O	O

There	ULORIC.xml:S2:2013:5	there	EX	O	O
have	ULORIC.xml:S2:2019:4	have	VBP	O	O
been	ULORIC.xml:S2:2024:4	been	VBN	O	O
postmarketing	ULORIC.xml:S2:2029:13	postmarket	VBG	O	O
reports	ULORIC.xml:S2:2043:7	report	NNS	O	O
of	ULORIC.xml:S2:2051:2	of	IN	O	O
fatal	ULORIC.xml:S2:2054:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
and	ULORIC.xml:S2:2060:3	and	CC	O	O
non	ULORIC.xml:S2:2064:3	non	JJ	O	O
-	ULORIC.xml:S2:2067:1	-	:	O	O
fatal	ULORIC.xml:S2:2068:5	fatal	JJ	O	B-AdverseReaction
hepatic	ULORIC.xml:S2:2074:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
failure	ULORIC.xml:S2:2082:7	failur	NN	I-AdverseReaction	I-AdverseReaction
in	ULORIC.xml:S2:2090:2	in	IN	O	O
patients	ULORIC.xml:S2:2093:8	patient	NNS	O	O
taking	ULORIC.xml:S2:2102:6	take	VBG	O	O
ULORIC	ULORIC.xml:S2:2109:6	ulor	NNP	O	O
,	ULORIC.xml:S2:2115:1	,	,	O	O
although	ULORIC.xml:S2:2117:8	although	IN	O	O
the	ULORIC.xml:S2:2126:3	the	DT	O	O
reports	ULORIC.xml:S2:2130:7	report	NNS	O	O
contain	ULORIC.xml:S2:2138:7	contain	VBP	O	O
insufficient	ULORIC.xml:S2:2146:12	insuffici	JJ	O	O
information	ULORIC.xml:S2:2159:11	inform	NN	O	O
necessary	ULORIC.xml:S2:2171:9	necessari	JJ	O	O
to	ULORIC.xml:S2:2181:2	to	TO	O	O
establish	ULORIC.xml:S2:2184:9	establish	VB	O	O
the	ULORIC.xml:S2:2194:3	the	DT	O	O
probable	ULORIC.xml:S2:2198:8	probabl	JJ	O	O
cause	ULORIC.xml:S2:2207:5	caus	NN	O	O
.	ULORIC.xml:S2:2212:1	.	.	O	O

During	ULORIC.xml:S2:2214:6	dure	IN	O	O
randomized	ULORIC.xml:S2:2221:10	random	VBN	O	O
controlled	ULORIC.xml:S2:2232:10	control	JJ	O	O
studies	ULORIC.xml:S2:2243:7	studi	NNS	O	O
,	ULORIC.xml:S2:2250:1	,	,	O	O
transaminase	ULORIC.xml:S2:2252:12	transaminas	NN	B-AdverseReaction	B-AdverseReaction
elevations	ULORIC.xml:S2:2265:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
greater	ULORIC.xml:S2:2276:7	greater	JJR	O	O
than	ULORIC.xml:S2:2284:4	than	IN	O	O
three	ULORIC.xml:S2:2289:5	three	CD	O	O
times	ULORIC.xml:S2:2295:5	time	NNS	O	O
the	ULORIC.xml:S2:2301:3	the	DT	O	O
upper	ULORIC.xml:S2:2305:5	upper	JJ	O	O
limit	ULORIC.xml:S2:2311:5	limit	NN	O	O
of	ULORIC.xml:S2:2317:2	of	IN	O	O
normal	ULORIC.xml:S2:2320:6	normal	JJ	O	O
(	ULORIC.xml:S2:2327:1	(	(	O	O
ULN	ULORIC.xml:S2:2328:3	uln	NNP	O	O
)	ULORIC.xml:S2:2331:1	)	)	O	O
were	ULORIC.xml:S2:2333:4	were	VBD	O	O
observed	ULORIC.xml:S2:2338:8	observ	VBN	O	O
(	ULORIC.xml:S2:2347:1	(	(	O	O
AST	ULORIC.xml:S2:2348:3	ast	NNP	O	I-AdverseReaction
:	ULORIC.xml:S2:2351:1	:	:	O	O
2%	ULORIC.xml:S2:2353:2	2%	CD	O	O
,	ULORIC.xml:S2:2355:1	,	,	O	O
2%	ULORIC.xml:S2:2357:2	2%	CD	O	O
,	ULORIC.xml:S2:2359:1	,	,	O	O
and	ULORIC.xml:S2:2361:3	and	CC	O	O
ALT	ULORIC.xml:S2:2365:3	alt	NNP	O	I-AdverseReaction
:	ULORIC.xml:S2:2368:1	:	:	O	O
3%	ULORIC.xml:S2:2370:2	3%	CD	O	O
,	ULORIC.xml:S2:2372:1	,	,	O	O
2%	ULORIC.xml:S2:2374:2	2%	CD	O	O
in	ULORIC.xml:S2:2377:2	in	IN	O	O
ULORIC	ULORIC.xml:S2:2380:6	ulor	NNP	O	O
and	ULORIC.xml:S2:2387:3	and	CC	O	O
allopurinol	ULORIC.xml:S2:2391:11	allopurinol	SYM	O	O
-	ULORIC.xml:S2:2402:1	-	:	O	O
treated	ULORIC.xml:S2:2403:7	treat	JJ	O	O
patients	ULORIC.xml:S2:2411:8	patient	NNS	O	O
,	ULORIC.xml:S2:2419:1	,	,	O	O
respectively	ULORIC.xml:S2:2421:12	respect	RB	O	O
)	ULORIC.xml:S2:2433:1	)	)	O	O
.	ULORIC.xml:S2:2434:1	.	.	O	O

No	ULORIC.xml:S2:2436:2	No	DT	O	O
dose	ULORIC.xml:S2:2439:4	dose	JJ	O	O
-	ULORIC.xml:S2:2443:1	-	:	O	O
effect	ULORIC.xml:S2:2444:6	effect	NN	O	O
relationship	ULORIC.xml:S2:2451:12	relationship	NN	O	O
for	ULORIC.xml:S2:2464:3	for	IN	O	O
these	ULORIC.xml:S2:2468:5	these	DT	O	O
transaminase	ULORIC.xml:S2:2474:12	transaminas	JJ	O	O
elevations	ULORIC.xml:S2:2487:10	elev	NNS	O	O
was	ULORIC.xml:S2:2498:3	wa	VBD	O	O
noted	ULORIC.xml:S2:2502:5	note	VBN	O	O
[	ULORIC.xml:S2:2508:1	[	NNP	O	O
see	ULORIC.xml:S2:2509:3	see	VBP	O	O
Clinical	ULORIC.xml:S2:2520:8	clinic	JJ	O	O
Pharmacology	ULORIC.xml:S2:2529:12	pharmacolog	NNP	O	O
(	ULORIC.xml:S2:2542:1	(	(	O	O
12.3	ULORIC.xml:S2:2543:4	12.3	CD	O	O
)	ULORIC.xml:S2:2547:1	)	)	O	O
]	ULORIC.xml:S2:2551:1	]	NN	O	O
.	ULORIC.xml:S2:2557:1	.	.	O	O

Obtain	ULORIC.xml:S2:2566:6	obtain	VB	O	O
a	ULORIC.xml:S2:2573:1	a	DT	O	O
liver	ULORIC.xml:S2:2575:5	liver	JJ	O	O
test	ULORIC.xml:S2:2581:4	test	NN	O	O
panel	ULORIC.xml:S2:2586:5	panel	NN	O	O
(	ULORIC.xml:S2:2592:1	(	(	O	O
serum	ULORIC.xml:S2:2593:5	serum	JJ	O	O
alanine	ULORIC.xml:S2:2599:7	alanin	NN	O	O
aminotransferase	ULORIC.xml:S2:2607:16	aminotransferas	NN	O	O
[	ULORIC.xml:S2:2624:1	[	NNP	O	O
ALT	ULORIC.xml:S2:2625:3	alt	NNP	O	O
]	ULORIC.xml:S2:2628:1	]	NNP	O	O
,	ULORIC.xml:S2:2629:1	,	,	O	O
aspartate	ULORIC.xml:S2:2631:9	aspart	JJ	O	O
aminotransferase	ULORIC.xml:S2:2641:16	aminotransferas	NN	O	O
[	ULORIC.xml:S2:2658:1	[	NNP	O	O
AST	ULORIC.xml:S2:2659:3	ast	NNP	O	O
]	ULORIC.xml:S2:2662:1	]	NNP	O	O
,	ULORIC.xml:S2:2663:1	,	,	O	O
alkaline	ULORIC.xml:S2:2665:8	alkalin	JJ	O	O
phosphatase	ULORIC.xml:S2:2674:11	phosphatas	NN	O	O
,	ULORIC.xml:S2:2685:1	,	,	O	O
and	ULORIC.xml:S2:2687:3	and	CC	O	O
total	ULORIC.xml:S2:2691:5	total	JJ	O	O
bilirubin	ULORIC.xml:S2:2697:9	bilirubin	NN	O	O
)	ULORIC.xml:S2:2706:1	)	)	O	O
as	ULORIC.xml:S2:2708:2	as	IN	O	O
a	ULORIC.xml:S2:2711:1	a	DT	O	O
baseline	ULORIC.xml:S2:2713:8	baselin	NN	O	O
before	ULORIC.xml:S2:2722:6	befor	IN	O	O
initiating	ULORIC.xml:S2:2729:10	initi	VBG	O	O
ULORIC	ULORIC.xml:S2:2740:6	ulor	NNP	O	O
.	ULORIC.xml:S2:2746:1	.	.	O	O

Measure	ULORIC.xml:S2:2755:7	measur	NN	O	O
liver	ULORIC.xml:S2:2763:5	liver	NN	O	O
tests	ULORIC.xml:S2:2769:5	test	NNS	O	O
promptly	ULORIC.xml:S2:2775:8	promptli	RB	O	O
in	ULORIC.xml:S2:2784:2	in	IN	O	O
patients	ULORIC.xml:S2:2787:8	patient	NNS	O	O
who	ULORIC.xml:S2:2796:3	who	WP	O	O
report	ULORIC.xml:S2:2800:6	report	VBP	O	O
symptoms	ULORIC.xml:S2:2807:8	symptom	NNS	O	O
that	ULORIC.xml:S2:2816:4	that	WDT	O	O
may	ULORIC.xml:S2:2821:3	may	MD	O	O
indicate	ULORIC.xml:S2:2825:8	indic	VB	O	O
liver	ULORIC.xml:S2:2834:5	liver	JJ	O	O
injury	ULORIC.xml:S2:2840:6	injuri	NN	O	O
,	ULORIC.xml:S2:2846:1	,	,	O	O
including	ULORIC.xml:S2:2848:9	includ	VBG	O	O
fatigue	ULORIC.xml:S2:2858:7	fatigu	NN	O	O
,	ULORIC.xml:S2:2865:1	,	,	O	O
anorexia	ULORIC.xml:S2:2867:8	anorexia	NN	O	O
,	ULORIC.xml:S2:2875:1	,	,	O	O
right	ULORIC.xml:S2:2877:5	right	JJ	O	O
upper	ULORIC.xml:S2:2883:5	upper	JJ	O	O
abdominal	ULORIC.xml:S2:2889:9	abdomin	JJ	O	O
discomfort	ULORIC.xml:S2:2899:10	discomfort	NN	O	O
,	ULORIC.xml:S2:2909:1	,	,	O	O
dark	ULORIC.xml:S2:2911:4	dark	JJ	O	O
urine	ULORIC.xml:S2:2916:5	urin	NN	O	O
or	ULORIC.xml:S2:2922:2	or	CC	O	O
jaundice	ULORIC.xml:S2:2925:8	jaundic	NN	O	O
.	ULORIC.xml:S2:2933:1	.	.	O	O

In	ULORIC.xml:S2:2935:2	In	IN	O	O
this	ULORIC.xml:S2:2938:4	thi	DT	O	O
clinical	ULORIC.xml:S2:2943:8	clinic	JJ	O	O
context	ULORIC.xml:S2:2952:7	context	NN	O	O
,	ULORIC.xml:S2:2959:1	,	,	O	O
if	ULORIC.xml:S2:2961:2	if	IN	O	O
the	ULORIC.xml:S2:2964:3	the	DT	O	O
patient	ULORIC.xml:S2:2968:7	patient	NN	O	O
is	ULORIC.xml:S2:2976:2	is	VBZ	O	O
found	ULORIC.xml:S2:2979:5	found	VBN	O	O
to	ULORIC.xml:S2:2985:2	to	TO	O	O
have	ULORIC.xml:S2:2988:4	have	VB	O	O
abnormal	ULORIC.xml:S2:2993:8	abnorm	JJ	O	O
liver	ULORIC.xml:S2:3002:5	liver	NN	O	O
tests	ULORIC.xml:S2:3008:5	test	NNS	O	O
(	ULORIC.xml:S2:3014:1	(	(	O	O
ALT	ULORIC.xml:S2:3015:3	alt	NNP	O	I-AdverseReaction
greater	ULORIC.xml:S2:3019:7	greater	JJR	O	O
than	ULORIC.xml:S2:3027:4	than	IN	O	O
three	ULORIC.xml:S2:3032:5	three	CD	O	O
times	ULORIC.xml:S2:3038:5	time	NNS	O	O
the	ULORIC.xml:S2:3044:3	the	DT	O	O
upper	ULORIC.xml:S2:3048:5	upper	JJ	O	O
limit	ULORIC.xml:S2:3054:5	limit	NN	O	O
of	ULORIC.xml:S2:3060:2	of	IN	O	O
the	ULORIC.xml:S2:3063:3	the	DT	O	O
reference	ULORIC.xml:S2:3067:9	refer	NN	O	O
range	ULORIC.xml:S2:3077:5	rang	NN	O	O
)	ULORIC.xml:S2:3082:1	)	)	O	O
,	ULORIC.xml:S2:3083:1	,	,	O	O
ULORIC	ULORIC.xml:S2:3085:6	ulor	NNP	O	O
treatment	ULORIC.xml:S2:3092:9	treatment	NN	O	O
should	ULORIC.xml:S2:3102:6	should	MD	O	O
be	ULORIC.xml:S2:3109:2	be	VB	O	O
interrupted	ULORIC.xml:S2:3112:11	interrupt	VBN	O	O
and	ULORIC.xml:S2:3124:3	and	CC	O	O
investigation	ULORIC.xml:S2:3128:13	investig	NN	O	O
done	ULORIC.xml:S2:3142:4	done	VBN	O	O
to	ULORIC.xml:S2:3147:2	to	TO	O	O
establish	ULORIC.xml:S2:3150:9	establish	VB	O	O
the	ULORIC.xml:S2:3160:3	the	DT	O	O
probable	ULORIC.xml:S2:3164:8	probabl	JJ	O	O
cause	ULORIC.xml:S2:3173:5	caus	NN	O	O
.	ULORIC.xml:S2:3178:1	.	.	O	O

ULORIC	ULORIC.xml:S2:3180:6	ulor	NNP	O	O
should	ULORIC.xml:S2:3187:6	should	MD	O	O
not	ULORIC.xml:S2:3194:3	not	RB	O	O
be	ULORIC.xml:S2:3198:2	be	VB	O	O
restarted	ULORIC.xml:S2:3201:9	restart	VBN	O	O
in	ULORIC.xml:S2:3211:2	in	IN	O	O
these	ULORIC.xml:S2:3214:5	these	DT	O	O
patients	ULORIC.xml:S2:3220:8	patient	NNS	O	O
without	ULORIC.xml:S2:3229:7	without	IN	O	O
another	ULORIC.xml:S2:3237:7	anoth	DT	O	O
explanation	ULORIC.xml:S2:3245:11	explan	NN	O	O
for	ULORIC.xml:S2:3257:3	for	IN	O	O
the	ULORIC.xml:S2:3261:3	the	DT	O	O
liver	ULORIC.xml:S2:3265:5	liver	JJ	O	O
test	ULORIC.xml:S2:3271:4	test	NN	O	O
abnormalities	ULORIC.xml:S2:3276:13	abnorm	NNS	O	O
.	ULORIC.xml:S2:3289:1	.	.	O	O

Patients	ULORIC.xml:S2:3298:8	patient	NNS	O	O
who	ULORIC.xml:S2:3307:3	who	WP	O	O
have	ULORIC.xml:S2:3311:4	have	VBP	O	O
serum	ULORIC.xml:S2:3316:5	serum	VBN	O	O
ALT	ULORIC.xml:S2:3322:3	alt	NNP	O	O
greater	ULORIC.xml:S2:3326:7	greater	JJR	O	O
than	ULORIC.xml:S2:3334:4	than	IN	O	O
three	ULORIC.xml:S2:3339:5	three	CD	O	O
times	ULORIC.xml:S2:3345:5	time	NNS	O	O
the	ULORIC.xml:S2:3351:3	the	DT	O	O
reference	ULORIC.xml:S2:3355:9	refer	NN	O	O
range	ULORIC.xml:S2:3365:5	rang	NN	O	O
with	ULORIC.xml:S2:3371:4	with	IN	O	O
serum	ULORIC.xml:S2:3376:5	serum	JJ	O	O
total	ULORIC.xml:S2:3382:5	total	JJ	O	O
bilirubin	ULORIC.xml:S2:3388:9	bilirubin	NN	O	O
greater	ULORIC.xml:S2:3398:7	greater	JJR	O	O
than	ULORIC.xml:S2:3406:4	than	IN	O	O
two	ULORIC.xml:S2:3411:3	two	CD	O	O
times	ULORIC.xml:S2:3415:5	time	NNS	O	O
the	ULORIC.xml:S2:3421:3	the	DT	O	O
reference	ULORIC.xml:S2:3425:9	refer	NN	O	O
range	ULORIC.xml:S2:3435:5	rang	NN	O	O
without	ULORIC.xml:S2:3441:7	without	IN	O	O
alternative	ULORIC.xml:S2:3449:11	altern	JJ	O	O
etiologies	ULORIC.xml:S2:3461:10	etiolog	NNS	O	O
are	ULORIC.xml:S2:3472:3	are	VBP	O	O
at	ULORIC.xml:S2:3476:2	at	IN	O	O
risk	ULORIC.xml:S2:3479:4	risk	NN	O	O
for	ULORIC.xml:S2:3484:3	for	IN	O	O
severe	ULORIC.xml:S2:3488:6	sever	JJ	O	O
drug	ULORIC.xml:S2:3495:4	drug	NN	O	O
-	ULORIC.xml:S2:3499:1	-	:	O	O
induced	ULORIC.xml:S2:3500:7	induc	VBN	O	O
liver	ULORIC.xml:S2:3508:5	liver	JJ	O	O
injury	ULORIC.xml:S2:3514:6	injuri	NN	O	O
and	ULORIC.xml:S2:3521:3	and	CC	O	O
should	ULORIC.xml:S2:3525:6	should	MD	O	O
not	ULORIC.xml:S2:3532:3	not	RB	O	O
be	ULORIC.xml:S2:3536:2	be	VB	O	O
restarted	ULORIC.xml:S2:3539:9	restart	VBN	O	O
on	ULORIC.xml:S2:3549:2	on	IN	O	O
ULORIC	ULORIC.xml:S2:3552:6	ulor	NNP	O	O
.	ULORIC.xml:S2:3558:1	.	.	O	O

For	ULORIC.xml:S2:3560:3	for	IN	O	O
patients	ULORIC.xml:S2:3564:8	patient	NNS	O	O
with	ULORIC.xml:S2:3573:4	with	IN	O	O
lesser	ULORIC.xml:S2:3578:6	lesser	JJR	O	O
elevations	ULORIC.xml:S2:3585:10	elev	NNS	O	B-AdverseReaction
of	ULORIC.xml:S2:3596:2	of	IN	O	I-AdverseReaction
serum	ULORIC.xml:S2:3599:5	serum	NN	O	I-AdverseReaction
ALT	ULORIC.xml:S2:3605:3	alt	NNP	O	I-AdverseReaction
or	ULORIC.xml:S2:3609:2	or	CC	O	O
bilirubin	ULORIC.xml:S2:3612:9	bilirubin	NN	O	I-AdverseReaction
and	ULORIC.xml:S2:3622:3	and	CC	O	O
with	ULORIC.xml:S2:3626:4	with	IN	O	O
an	ULORIC.xml:S2:3631:2	an	DT	O	O
alternate	ULORIC.xml:S2:3634:9	altern	NN	O	O
probable	ULORIC.xml:S2:3644:8	probabl	JJ	O	O
cause	ULORIC.xml:S2:3653:5	caus	NN	O	O
,	ULORIC.xml:S2:3658:1	,	,	O	O
treatment	ULORIC.xml:S2:3660:9	treatment	NN	O	O
with	ULORIC.xml:S2:3670:4	with	IN	O	O
ULORIC	ULORIC.xml:S2:3675:6	ulor	NNP	O	O
can	ULORIC.xml:S2:3682:3	can	MD	O	O
be	ULORIC.xml:S2:3686:2	be	VB	O	O
used	ULORIC.xml:S2:3689:4	use	VBN	O	O
with	ULORIC.xml:S2:3694:4	with	IN	O	O
caution	ULORIC.xml:S2:3699:7	caution	NN	O	O
.	ULORIC.xml:S2:3706:1	.	.	O	O
6	VICTRELIS.xml:S1:4:1	6	CD	O	O
ADVERSE	VICTRELIS.xml:S1:6:7	advers	JJ	O	O
REACTIONS	VICTRELIS.xml:S1:14:9	reaction	NN	O	O

See	VICTRELIS.xml:S1:27:3	see	VB	O	O
the	VICTRELIS.xml:S1:31:3	the	DT	O	O
peginterferon	VICTRELIS.xml:S1:35:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:49:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:54:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:58:9	ribavirin	VB	O	O
prescribing	VICTRELIS.xml:S1:68:11	prescrib	VBG	O	O
information	VICTRELIS.xml:S1:80:11	inform	NN	O	O
for	VICTRELIS.xml:S1:92:3	for	IN	O	O
description	VICTRELIS.xml:S1:96:11	descript	NN	O	O
of	VICTRELIS.xml:S1:108:2	of	IN	O	O
adverse	VICTRELIS.xml:S1:111:7	advers	JJ	O	O
reactions	VICTRELIS.xml:S1:119:9	reaction	NNS	O	O
associated	VICTRELIS.xml:S1:129:10	associ	VBN	O	O
with	VICTRELIS.xml:S1:140:4	with	IN	O	O
their	VICTRELIS.xml:S1:145:5	their	PRP$	O	O
use	VICTRELIS.xml:S1:151:3	use	NN	O	O
.	VICTRELIS.xml:S1:154:1	.	.	O	O

EXCERPT	VICTRELIS.xml:S1:162:7	excerpt	NN	O	O
:	VICTRELIS.xml:S1:169:1	:	:	O	O
The	VICTRELIS.xml:S1:173:3	the	DT	O	O
most	VICTRELIS.xml:S1:177:4	most	RBS	O	O
commonly	VICTRELIS.xml:S1:182:8	commonli	RB	O	O
reported	VICTRELIS.xml:S1:191:8	report	VBD	O	O
adverse	VICTRELIS.xml:S1:200:7	advers	JJ	O	O
reactions	VICTRELIS.xml:S1:208:9	reaction	NNS	O	O
(	VICTRELIS.xml:S1:218:1	(	(	O	O
greater	VICTRELIS.xml:S1:219:7	greater	JJR	O	O
than	VICTRELIS.xml:S1:227:4	than	IN	O	O
35%	VICTRELIS.xml:S1:232:3	35%	CD	O	O
of	VICTRELIS.xml:S1:236:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:239:8	subject	NNS	O	O
)	VICTRELIS.xml:S1:247:1	)	)	O	O
in	VICTRELIS.xml:S1:249:2	in	IN	O	O
clinical	VICTRELIS.xml:S1:252:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S1:261:6	trial	NNS	O	O
in	VICTRELIS.xml:S1:268:2	in	IN	O	O
adult	VICTRELIS.xml:S1:271:5	adult	NN	O	O
subjects	VICTRELIS.xml:S1:277:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:286:9	receiv	VBG	O	O
the	VICTRELIS.xml:S1:296:3	the	DT	O	O
combination	VICTRELIS.xml:S1:300:11	combin	NN	O	O
of	VICTRELIS.xml:S1:312:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:315:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:325:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:330:9	pegintron	NNP	O	O
and	VICTRELIS.xml:S1:340:3	and	CC	O	O
REBETOL	VICTRELIS.xml:S1:344:7	rebetol	NNP	O	O
were	VICTRELIS.xml:S1:352:4	were	VBD	O	O
fatigue	VICTRELIS.xml:S1:357:7	fatigu	JJ	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:364:1	,	,	O	O
anemia	VICTRELIS.xml:S1:366:6	anemia	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:372:1	,	,	O	O
nausea	VICTRELIS.xml:S1:374:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:380:1	,	,	O	O
headache	VICTRELIS.xml:S1:382:8	headach	NN	B-AdverseReaction	B-AdverseReaction
and	VICTRELIS.xml:S1:391:3	and	CC	O	O
dysgeusia	VICTRELIS.xml:S1:395:9	dysgeusia	NN	B-AdverseReaction	B-AdverseReaction
.	VICTRELIS.xml:S1:404:1	.	.	O	O

(	VICTRELIS.xml:S1:406:1	(	(	O	O
6.1	VICTRELIS.xml:S1:409:3	6.1	CD	O	O
)	VICTRELIS.xml:S1:414:1	)	)	O	O

To	VICTRELIS.xml:S1:422:2	To	TO	O	O
report	VICTRELIS.xml:S1:425:6	report	VB	O	O
SUSPECTED	VICTRELIS.xml:S1:432:9	suspect	NNP	O	O
ADVERSE	VICTRELIS.xml:S1:442:7	advers	NNP	O	O
REACTIONS	VICTRELIS.xml:S1:450:9	reaction	NNP	O	O
,	VICTRELIS.xml:S1:459:1	,	,	O	O
contact	VICTRELIS.xml:S1:461:7	contact	NN	O	O
Merck	VICTRELIS.xml:S1:469:5	merck	NNP	O	O
Sharp	VICTRELIS.xml:S1:475:5	sharp	NNP	O	O
Dohme	VICTRELIS.xml:S1:483:5	dohm	NNP	O	O
Corp	VICTRELIS.xml:S1:489:4	corp	NNP	O	O
.	VICTRELIS.xml:S1:493:1	.	.	O	O
,	VICTRELIS.xml:S1:494:1	,	,	O	O
a	VICTRELIS.xml:S1:496:1	a	DT	O	O
subsidiary	VICTRELIS.xml:S1:498:10	subsidiari	NN	O	O
of	VICTRELIS.xml:S1:509:2	of	IN	O	O
Merck	VICTRELIS.xml:S1:512:5	merck	NNP	O	O
Co	VICTRELIS.xml:S1:520:2	Co	NNP	O	O
.	VICTRELIS.xml:S1:522:1	.	.	O	O
,	VICTRELIS.xml:S1:523:1	,	,	O	O
Inc	VICTRELIS.xml:S1:525:3	inc	NNP	O	O
.	VICTRELIS.xml:S1:528:1	.	.	O	O
,	VICTRELIS.xml:S1:529:1	,	,	O	O
at	VICTRELIS.xml:S1:531:2	at	IN	O	O
1	VICTRELIS.xml:S1:534:1	1	CD	O	O
-	VICTRELIS.xml:S1:535:1	-	:	O	O
877	VICTRELIS.xml:S1:536:3	877	CD	O	O
-	VICTRELIS.xml:S1:539:1	-	:	O	O
888	VICTRELIS.xml:S1:540:3	888	CD	O	O
-	VICTRELIS.xml:S1:543:1	-	:	O	O
4231	VICTRELIS.xml:S1:544:4	4231	CD	O	O
or	VICTRELIS.xml:S1:549:2	or	CC	O	O
FDA	VICTRELIS.xml:S1:552:3	fda	NNP	O	O
at	VICTRELIS.xml:S1:556:2	at	IN	O	O
1	VICTRELIS.xml:S1:559:1	1	CD	O	O
-	VICTRELIS.xml:S1:560:1	-	:	O	O
800	VICTRELIS.xml:S1:561:3	800	CD	O	O
-	VICTRELIS.xml:S1:564:1	-	:	O	O
FDA	VICTRELIS.xml:S1:565:3	fda	NNP	O	O
-	VICTRELIS.xml:S1:568:1	-	:	O	O
1088	VICTRELIS.xml:S1:569:4	1088	CD	O	O
or	VICTRELIS.xml:S1:574:2	or	CC	O	O
www	VICTRELIS.xml:S1:582:3	www	VB	O	O
.	VICTRELIS.xml:S1:585:1	.	.	O	O
fda	VICTRELIS.xml:S1:586:3	fda	NN	O	O
.	VICTRELIS.xml:S1:589:1	.	.	O	O
gov	VICTRELIS.xml:S1:590:3	gov	JJ	O	O
medwatch	VICTRELIS.xml:S1:594:8	medwatch	NN	O	O
.	VICTRELIS.xml:S1:604:1	.	.	O	O

6.1	VICTRELIS.xml:S1:616:3	6.1	CD	O	O

Clinical	VICTRELIS.xml:S1:620:8	clinic	JJ	O	O
Trials	VICTRELIS.xml:S1:629:6	trial	NNS	O	O
Experience	VICTRELIS.xml:S1:636:10	experi	NN	O	O

Because	VICTRELIS.xml:S1:650:7	becaus	IN	O	O
clinical	VICTRELIS.xml:S1:658:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S1:667:6	trial	NNS	O	O
are	VICTRELIS.xml:S1:674:3	are	VBP	O	O
conducted	VICTRELIS.xml:S1:678:9	conduct	VBN	O	O
under	VICTRELIS.xml:S1:688:5	under	IN	O	O
widely	VICTRELIS.xml:S1:694:6	wide	RB	O	O
varying	VICTRELIS.xml:S1:701:7	vari	VBG	O	O
conditions	VICTRELIS.xml:S1:709:10	condit	NNS	O	O
,	VICTRELIS.xml:S1:719:1	,	,	O	O
adverse	VICTRELIS.xml:S1:721:7	advers	JJ	O	O
reaction	VICTRELIS.xml:S1:729:8	reaction	NN	O	O
rates	VICTRELIS.xml:S1:738:5	rate	NNS	O	O
observed	VICTRELIS.xml:S1:744:8	observ	VBD	O	O
in	VICTRELIS.xml:S1:753:2	in	IN	O	O
clinical	VICTRELIS.xml:S1:756:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S1:765:6	trial	NNS	O	O
of	VICTRELIS.xml:S1:772:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:775:9	victr	NNP	O	O
cannot	VICTRELIS.xml:S1:785:6	cannot	NN	O	O
be	VICTRELIS.xml:S1:792:2	be	VB	O	O
directly	VICTRELIS.xml:S1:795:8	directli	RB	O	O
compared	VICTRELIS.xml:S1:804:8	compar	VBN	O	O
to	VICTRELIS.xml:S1:813:2	to	TO	O	O
rates	VICTRELIS.xml:S1:816:5	rate	NNS	O	O
in	VICTRELIS.xml:S1:822:2	in	IN	O	O
the	VICTRELIS.xml:S1:825:3	the	DT	O	O
clinical	VICTRELIS.xml:S1:829:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S1:838:6	trial	NNS	O	O
of	VICTRELIS.xml:S1:845:2	of	IN	O	O
another	VICTRELIS.xml:S1:848:7	anoth	DT	O	O
drug	VICTRELIS.xml:S1:856:4	drug	NN	O	O
and	VICTRELIS.xml:S1:861:3	and	CC	O	O
may	VICTRELIS.xml:S1:865:3	may	MD	O	O
not	VICTRELIS.xml:S1:869:3	not	RB	O	O
reflect	VICTRELIS.xml:S1:873:7	reflect	VB	O	O
the	VICTRELIS.xml:S1:881:3	the	DT	O	O
rates	VICTRELIS.xml:S1:885:5	rate	NNS	O	O
observed	VICTRELIS.xml:S1:891:8	observ	VBD	O	O
in	VICTRELIS.xml:S1:900:2	in	IN	O	O
practice	VICTRELIS.xml:S1:903:8	practic	NN	O	O
.	VICTRELIS.xml:S1:911:1	.	.	O	O

The	VICTRELIS.xml:S1:917:3	the	DT	O	O
following	VICTRELIS.xml:S1:921:9	follow	VBG	O	O
serious	VICTRELIS.xml:S1:931:7	seriou	JJ	O	O
and	VICTRELIS.xml:S1:939:3	and	CC	O	O
otherwise	VICTRELIS.xml:S1:943:9	otherwis	RB	O	O
important	VICTRELIS.xml:S1:953:9	import	JJ	O	O
adverse	VICTRELIS.xml:S1:963:7	advers	JJ	O	O
drug	VICTRELIS.xml:S1:971:4	drug	NN	O	O
reactions	VICTRELIS.xml:S1:976:9	reaction	NNS	O	O
(	VICTRELIS.xml:S1:986:1	(	(	O	O
ADRs	VICTRELIS.xml:S1:987:4	adr	NNP	O	O
)	VICTRELIS.xml:S1:991:1	)	)	O	O
are	VICTRELIS.xml:S1:993:3	are	VBP	O	O
discussed	VICTRELIS.xml:S1:997:9	discuss	VBN	O	O
in	VICTRELIS.xml:S1:1007:2	in	IN	O	O
detail	VICTRELIS.xml:S1:1010:6	detail	NN	O	O
in	VICTRELIS.xml:S1:1017:2	in	IN	O	O
another	VICTRELIS.xml:S1:1020:7	anoth	DT	O	O
section	VICTRELIS.xml:S1:1028:7	section	NN	O	O
of	VICTRELIS.xml:S1:1036:2	of	IN	O	O
the	VICTRELIS.xml:S1:1039:3	the	DT	O	O
labeling	VICTRELIS.xml:S1:1043:8	label	NN	O	O
:	VICTRELIS.xml:S1:1051:1	:	:	O	O

Anemia	VICTRELIS.xml:S1:1060:6	anemia	NNP	B-AdverseReaction	B-AdverseReaction
[	VICTRELIS.xml:S1:1067:1	[	NNP	O	O
see	VICTRELIS.xml:S1:1068:3	see	VBP	O	O
Warnings	VICTRELIS.xml:S1:1073:8	warn	NNP	O	O
and	VICTRELIS.xml:S1:1082:3	and	CC	O	O
Precautions	VICTRELIS.xml:S1:1086:11	precaut	NNP	O	O
(	VICTRELIS.xml:S1:1098:1	(	(	O	O
5.2	VICTRELIS.xml:S1:1099:3	5.2	CD	O	O
)	VICTRELIS.xml:S1:1102:1	)	)	O	O
]	VICTRELIS.xml:S1:1105:1	]	NN	O	O

Neutropenia	VICTRELIS.xml:S1:1113:11	neutropenia	NNP	B-AdverseReaction	B-AdverseReaction
[	VICTRELIS.xml:S1:1125:1	[	NNP	O	O
see	VICTRELIS.xml:S1:1126:3	see	VBP	O	O
Warnings	VICTRELIS.xml:S1:1131:8	warn	NNP	O	O
and	VICTRELIS.xml:S1:1140:3	and	CC	O	O
Precautions	VICTRELIS.xml:S1:1144:11	precaut	NNP	O	O
(	VICTRELIS.xml:S1:1156:1	(	(	O	O
5.3	VICTRELIS.xml:S1:1157:3	5.3	CD	O	O
)	VICTRELIS.xml:S1:1160:1	)	)	O	O
]	VICTRELIS.xml:S1:1163:1	]	NN	O	O

Pancytopenia	VICTRELIS.xml:S1:1171:12	pancytopenia	NNP	B-AdverseReaction	B-AdverseReaction
[	VICTRELIS.xml:S1:1184:1	[	NNP	O	O
see	VICTRELIS.xml:S1:1185:3	see	VBP	O	O
Warnings	VICTRELIS.xml:S1:1190:8	warn	NNP	O	O
and	VICTRELIS.xml:S1:1199:3	and	CC	O	O
Precautions	VICTRELIS.xml:S1:1203:11	precaut	NNP	O	O
(	VICTRELIS.xml:S1:1215:1	(	(	O	O
5.4	VICTRELIS.xml:S1:1216:3	5.4	CD	O	O
)	VICTRELIS.xml:S1:1219:1	)	)	O	O
]	VICTRELIS.xml:S1:1222:1	]	NN	O	O

Hypersensitivity	VICTRELIS.xml:S1:1230:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
[	VICTRELIS.xml:S1:1247:1	[	NNP	O	O
see	VICTRELIS.xml:S1:1248:3	see	VBP	O	O
Contraindications	VICTRELIS.xml:S1:1253:17	contraind	NNP	O	O
(	VICTRELIS.xml:S1:1271:1	(	(	O	O
4	VICTRELIS.xml:S1:1272:1	4	CD	O	O
)	VICTRELIS.xml:S1:1273:1	)	)	O	O
and	VICTRELIS.xml:S1:1276:3	and	CC	O	O
Warnings	VICTRELIS.xml:S1:1281:8	warn	NNP	O	O
and	VICTRELIS.xml:S1:1290:3	and	CC	O	O
Precautions	VICTRELIS.xml:S1:1294:11	precaut	NNP	O	O
(	VICTRELIS.xml:S1:1306:1	(	(	O	O
5.5	VICTRELIS.xml:S1:1307:3	5.5	CD	O	O
)	VICTRELIS.xml:S1:1310:1	)	)	O	O
]	VICTRELIS.xml:S1:1313:1	]	NN	O	O

The	VICTRELIS.xml:S1:1321:3	the	DT	O	O
most	VICTRELIS.xml:S1:1325:4	most	RBS	O	O
commonly	VICTRELIS.xml:S1:1330:8	commonli	RB	O	O
reported	VICTRELIS.xml:S1:1339:8	report	VBD	O	O
adverse	VICTRELIS.xml:S1:1348:7	advers	JJ	O	O
reactions	VICTRELIS.xml:S1:1356:9	reaction	NNS	O	O
(	VICTRELIS.xml:S1:1366:1	(	(	O	O
more	VICTRELIS.xml:S1:1367:4	more	JJR	O	O
than	VICTRELIS.xml:S1:1372:4	than	IN	O	O
35%	VICTRELIS.xml:S1:1377:3	35%	CD	O	O
of	VICTRELIS.xml:S1:1381:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:1384:8	subject	NNS	O	O
regardless	VICTRELIS.xml:S1:1393:10	regardless	RB	O	O
of	VICTRELIS.xml:S1:1404:2	of	IN	O	O
investigator	VICTRELIS.xml:S1:1407:12	investig	NN	O	O
's	VICTRELIS.xml:S1:1419:2	's	POS	O	O
causality	VICTRELIS.xml:S1:1422:9	causal	NN	O	O
assessment	VICTRELIS.xml:S1:1432:10	assess	NN	O	O
)	VICTRELIS.xml:S1:1442:1	)	)	O	O
in	VICTRELIS.xml:S1:1444:2	in	IN	O	O
adult	VICTRELIS.xml:S1:1447:5	adult	NN	O	O
subjects	VICTRELIS.xml:S1:1453:8	subject	NNS	O	O
were	VICTRELIS.xml:S1:1462:4	were	VBD	O	O
fatigue	VICTRELIS.xml:S1:1467:7	fatigu	JJ	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:1474:1	,	,	O	O
anemia	VICTRELIS.xml:S1:1476:6	anemia	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:1482:1	,	,	O	O
nausea	VICTRELIS.xml:S1:1484:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:1490:1	,	,	O	O
headache	VICTRELIS.xml:S1:1492:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:1500:1	,	,	O	O
and	VICTRELIS.xml:S1:1502:3	and	CC	O	O
dysgeusia	VICTRELIS.xml:S1:1506:9	dysgeusia	NN	B-AdverseReaction	B-AdverseReaction
when	VICTRELIS.xml:S1:1516:4	when	WRB	O	O
VICTRELIS	VICTRELIS.xml:S1:1521:9	victr	NNP	O	O
was	VICTRELIS.xml:S1:1531:3	wa	VBD	O	O
used	VICTRELIS.xml:S1:1535:4	use	VBN	O	O
in	VICTRELIS.xml:S1:1540:2	in	IN	O	O
combination	VICTRELIS.xml:S1:1543:11	combin	NN	O	O
with	VICTRELIS.xml:S1:1555:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:1560:9	pegintron	NNP	O	O
and	VICTRELIS.xml:S1:1570:3	and	CC	O	O
REBETOL	VICTRELIS.xml:S1:1574:7	rebetol	NNP	O	O
.	VICTRELIS.xml:S1:1581:1	.	.	O	O

The	VICTRELIS.xml:S1:1587:3	the	DT	O	O

safety	VICTRELIS.xml:S1:1591:6	safeti	NN	O	O
of	VICTRELIS.xml:S1:1598:2	of	IN	O	O
the	VICTRELIS.xml:S1:1601:3	the	DT	O	O
combination	VICTRELIS.xml:S1:1605:11	combin	NN	O	O
of	VICTRELIS.xml:S1:1617:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:1620:9	victr	NNP	O	O
800	VICTRELIS.xml:S1:1630:3	800	CD	O	O
mg	VICTRELIS.xml:S1:1634:2	mg	NN	O	O
three	VICTRELIS.xml:S1:1637:5	three	CD	O	O
times	VICTRELIS.xml:S1:1643:5	time	NNS	O	O
daily	VICTRELIS.xml:S1:1649:5	daili	RB	O	O
with	VICTRELIS.xml:S1:1655:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:1660:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:1670:7	rebetol	NNP	O	O
was	VICTRELIS.xml:S1:1678:3	wa	VBD	O	O
assessed	VICTRELIS.xml:S1:1682:8	assess	VBN	O	O
in	VICTRELIS.xml:S1:1691:2	in	IN	O	O
2095	VICTRELIS.xml:S1:1694:4	2095	CD	O	O
subjects	VICTRELIS.xml:S1:1699:8	subject	NNS	O	O
with	VICTRELIS.xml:S1:1708:4	with	IN	O	O
chronic	VICTRELIS.xml:S1:1713:7	chronic	JJ	O	O
hepatitis	VICTRELIS.xml:S1:1721:9	hepat	NN	O	O
C	VICTRELIS.xml:S1:1731:1	C	NNP	O	O
in	VICTRELIS.xml:S1:1733:2	in	IN	O	O
one	VICTRELIS.xml:S1:1736:3	one	CD	O	O
Phase	VICTRELIS.xml:S1:1740:5	phase	NNP	O	O
2	VICTRELIS.xml:S1:1746:1	2	CD	O	O
,	VICTRELIS.xml:S1:1747:1	,	,	O	O
open	VICTRELIS.xml:S1:1749:4	open	JJ	O	O
-	VICTRELIS.xml:S1:1753:1	-	:	O	O
label	VICTRELIS.xml:S1:1754:5	label	NN	O	O
trial	VICTRELIS.xml:S1:1760:5	trial	NN	O	O
and	VICTRELIS.xml:S1:1766:3	and	CC	O	O
two	VICTRELIS.xml:S1:1770:3	two	CD	O	O
Phase	VICTRELIS.xml:S1:1774:5	phase	NNP	O	O
3	VICTRELIS.xml:S1:1780:1	3	CD	O	O
,	VICTRELIS.xml:S1:1781:1	,	,	O	O
randomized	VICTRELIS.xml:S1:1783:10	random	VBN	O	O
,	VICTRELIS.xml:S1:1793:1	,	,	O	O
double	VICTRELIS.xml:S1:1795:6	doubl	JJ	O	O
-	VICTRELIS.xml:S1:1801:1	-	:	O	O
blind	VICTRELIS.xml:S1:1802:5	blind	NN	O	O
,	VICTRELIS.xml:S1:1807:1	,	,	O	O
placebo	VICTRELIS.xml:S1:1809:7	placebo	SYM	O	O
-	VICTRELIS.xml:S1:1816:1	-	:	O	O
controlled	VICTRELIS.xml:S1:1817:10	control	VBN	O	O
clinical	VICTRELIS.xml:S1:1828:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S1:1837:6	trial	NNS	O	O
.	VICTRELIS.xml:S1:1843:1	.	.	O	O

SPRINT	VICTRELIS.xml:S1:1845:6	sprint	NNP	O	O
-	VICTRELIS.xml:S1:1851:1	-	:	O	O
1	VICTRELIS.xml:S1:1852:1	1	CD	O	O
(	VICTRELIS.xml:S1:1854:1	(	(	O	O
subjects	VICTRELIS.xml:S1:1855:8	subject	NNS	O	O
who	VICTRELIS.xml:S1:1864:3	who	WP	O	O
were	VICTRELIS.xml:S1:1868:4	were	VBD	O	O
previously	VICTRELIS.xml:S1:1873:10	previous	RB	O	O
untreated	VICTRELIS.xml:S1:1884:9	untreat	VBN	O	O
)	VICTRELIS.xml:S1:1893:1	)	)	O	O
evaluated	VICTRELIS.xml:S1:1895:9	evalu	VBD	O	O
the	VICTRELIS.xml:S1:1905:3	the	DT	O	O
use	VICTRELIS.xml:S1:1909:3	use	NN	O	O
of	VICTRELIS.xml:S1:1913:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:1916:9	victr	NNP	O	O
in	VICTRELIS.xml:S1:1926:2	in	IN	O	O
combination	VICTRELIS.xml:S1:1929:11	combin	NN	O	O
with	VICTRELIS.xml:S1:1941:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:1946:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:1956:7	rebetol	NNP	O	O
with	VICTRELIS.xml:S1:1964:4	with	IN	O	O
or	VICTRELIS.xml:S1:1969:2	or	CC	O	O
without	VICTRELIS.xml:S1:1972:7	without	IN	O	O
a	VICTRELIS.xml:S1:1980:1	a	DT	O	O
four	VICTRELIS.xml:S1:1982:4	four	CD	O	O
-	VICTRELIS.xml:S1:1986:1	-	:	O	O
week	VICTRELIS.xml:S1:1987:4	week	NN	O	O
lead	VICTRELIS.xml:S1:1992:4	lead	JJ	O	O
-	VICTRELIS.xml:S1:1996:1	-	:	O	O
in	VICTRELIS.xml:S1:1997:2	in	IN	O	O
period	VICTRELIS.xml:S1:2000:6	period	NN	O	O
with	VICTRELIS.xml:S1:2007:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:2012:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:2022:7	rebetol	NNP	O	O
compared	VICTRELIS.xml:S1:2030:8	compar	VBN	O	O
to	VICTRELIS.xml:S1:2039:2	to	TO	O	O
PegIntron	VICTRELIS.xml:S1:2042:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:2052:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:2060:5	alon	RB	O	O
.	VICTRELIS.xml:S1:2065:1	.	.	O	O

SPRINT	VICTRELIS.xml:S1:2067:6	sprint	NNP	O	O
-	VICTRELIS.xml:S1:2073:1	-	:	O	O
2	VICTRELIS.xml:S1:2074:1	2	CD	O	O
(	VICTRELIS.xml:S1:2076:1	(	(	O	O
subjects	VICTRELIS.xml:S1:2077:8	subject	NNS	O	O
who	VICTRELIS.xml:S1:2086:3	who	WP	O	O
were	VICTRELIS.xml:S1:2090:4	were	VBD	O	O
previously	VICTRELIS.xml:S1:2095:10	previous	RB	O	O
untreated	VICTRELIS.xml:S1:2106:9	untreat	VBN	O	O
)	VICTRELIS.xml:S1:2115:1	)	)	O	O
and	VICTRELIS.xml:S1:2117:3	and	CC	O	O
RESPOND	VICTRELIS.xml:S1:2121:7	respond	NNP	O	O
-	VICTRELIS.xml:S1:2128:1	-	:	O	O
2	VICTRELIS.xml:S1:2129:1	2	CD	O	O
(	VICTRELIS.xml:S1:2131:1	(	(	O	O
subjects	VICTRELIS.xml:S1:2132:8	subject	NNS	O	O
who	VICTRELIS.xml:S1:2141:3	who	WP	O	O
had	VICTRELIS.xml:S1:2145:3	had	VBD	O	O
failed	VICTRELIS.xml:S1:2149:6	fail	VBN	O	O
previous	VICTRELIS.xml:S1:2156:8	previou	JJ	O	O
therapy	VICTRELIS.xml:S1:2165:7	therapi	NN	O	O
)	VICTRELIS.xml:S1:2172:1	)	)	O	O
evaluated	VICTRELIS.xml:S1:2174:9	evalu	VBD	O	O
the	VICTRELIS.xml:S1:2184:3	the	DT	O	O
use	VICTRELIS.xml:S1:2188:3	use	NN	O	O
of	VICTRELIS.xml:S1:2192:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:2195:9	victr	NNP	O	O
800	VICTRELIS.xml:S1:2205:3	800	CD	O	O
mg	VICTRELIS.xml:S1:2209:2	mg	NN	O	O
three	VICTRELIS.xml:S1:2212:5	three	CD	O	O
times	VICTRELIS.xml:S1:2218:5	time	NNS	O	O
daily	VICTRELIS.xml:S1:2224:5	daili	RB	O	O
in	VICTRELIS.xml:S1:2230:2	in	IN	O	O
combination	VICTRELIS.xml:S1:2233:11	combin	NN	O	O
with	VICTRELIS.xml:S1:2245:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:2250:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:2260:7	rebetol	NNP	O	O
with	VICTRELIS.xml:S1:2268:4	with	IN	O	O
a	VICTRELIS.xml:S1:2273:1	a	DT	O	O
four	VICTRELIS.xml:S1:2275:4	four	CD	O	O
-	VICTRELIS.xml:S1:2279:1	-	:	O	O
week	VICTRELIS.xml:S1:2280:4	week	NN	O	O
lead	VICTRELIS.xml:S1:2285:4	lead	JJ	O	O
-	VICTRELIS.xml:S1:2289:1	-	:	O	O
in	VICTRELIS.xml:S1:2290:2	in	IN	O	O
period	VICTRELIS.xml:S1:2293:6	period	NN	O	O
with	VICTRELIS.xml:S1:2300:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:2305:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:2315:7	rebetol	NNP	O	O
compared	VICTRELIS.xml:S1:2323:8	compar	VBN	O	O
to	VICTRELIS.xml:S1:2332:2	to	TO	O	O
PegIntron	VICTRELIS.xml:S1:2335:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:2345:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:2353:5	alon	RB	O	O
[	VICTRELIS.xml:S1:2360:1	[	VBD	O	O
see	VICTRELIS.xml:S1:2361:3	see	VB	O	O
Clinical	VICTRELIS.xml:S1:2366:8	clinic	JJ	O	O
Studies	VICTRELIS.xml:S1:2375:7	studi	NNP	O	O
(	VICTRELIS.xml:S1:2383:1	(	(	O	O
14	VICTRELIS.xml:S1:2384:2	14	CD	O	O
)	VICTRELIS.xml:S1:2386:1	)	)	O	O
]	VICTRELIS.xml:S1:2389:1	]	NN	O	O
.	VICTRELIS.xml:S1:2392:1	.	.	O	O

The	VICTRELIS.xml:S1:2394:3	the	DT	O	O
population	VICTRELIS.xml:S1:2398:10	popul	NN	O	O
studied	VICTRELIS.xml:S1:2409:7	studi	VBD	O	O
had	VICTRELIS.xml:S1:2417:3	had	VBD	O	O
a	VICTRELIS.xml:S1:2421:1	a	DT	O	O
mean	VICTRELIS.xml:S1:2423:4	mean	JJ	O	O
age	VICTRELIS.xml:S1:2428:3	age	NN	O	O
of	VICTRELIS.xml:S1:2432:2	of	IN	O	O
49	VICTRELIS.xml:S1:2435:2	49	CD	O	O
years	VICTRELIS.xml:S1:2438:5	year	NNS	O	O
(	VICTRELIS.xml:S1:2444:1	(	(	O	O
3%	VICTRELIS.xml:S1:2445:2	3%	CD	O	O
of	VICTRELIS.xml:S1:2448:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:2451:8	subject	NNS	O	O
were	VICTRELIS.xml:S1:2460:4	were	VBD	O	O
older	VICTRELIS.xml:S1:2465:5	older	JJR	O	O
than	VICTRELIS.xml:S1:2471:4	than	IN	O	O
65	VICTRELIS.xml:S1:2476:2	65	CD	O	O
years	VICTRELIS.xml:S1:2479:5	year	NNS	O	O
of	VICTRELIS.xml:S1:2485:2	of	IN	O	O
age	VICTRELIS.xml:S1:2488:3	age	NN	O	O
)	VICTRELIS.xml:S1:2491:1	)	)	O	O
,	VICTRELIS.xml:S1:2492:1	,	,	O	O
39%	VICTRELIS.xml:S1:2494:3	39%	CD	O	O
were	VICTRELIS.xml:S1:2498:4	were	VBD	O	O
female	VICTRELIS.xml:S1:2503:6	femal	JJ	O	O
,	VICTRELIS.xml:S1:2509:1	,	,	O	O
82%	VICTRELIS.xml:S1:2511:3	82%	CD	O	O
were	VICTRELIS.xml:S1:2515:4	were	VBD	O	O
white	VICTRELIS.xml:S1:2520:5	white	JJ	O	O
and	VICTRELIS.xml:S1:2526:3	and	CC	O	O
15%	VICTRELIS.xml:S1:2530:3	15%	CD	O	O
were	VICTRELIS.xml:S1:2534:4	were	VBD	O	O
black	VICTRELIS.xml:S1:2539:5	black	JJ	O	O
.	VICTRELIS.xml:S1:2544:1	.	.	O	O

During	VICTRELIS.xml:S1:2550:6	dure	IN	O	O
the	VICTRELIS.xml:S1:2557:3	the	DT	O	O
four	VICTRELIS.xml:S1:2561:4	four	CD	O	O
week	VICTRELIS.xml:S1:2566:4	week	NN	O	O
lead	VICTRELIS.xml:S1:2571:4	lead	SYM	O	O
-	VICTRELIS.xml:S1:2575:1	-	:	O	O
in	VICTRELIS.xml:S1:2576:2	in	IN	O	O
period	VICTRELIS.xml:S1:2579:6	period	NN	O	O
with	VICTRELIS.xml:S1:2586:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:2591:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:2601:7	rebetol	NNP	O	O
in	VICTRELIS.xml:S1:2609:2	in	IN	O	O
subjects	VICTRELIS.xml:S1:2612:8	subject	NNS	O	O
treated	VICTRELIS.xml:S1:2621:7	treat	VBN	O	O
with	VICTRELIS.xml:S1:2629:4	with	IN	O	O
the	VICTRELIS.xml:S1:2634:3	the	DT	O	O
combination	VICTRELIS.xml:S1:2638:11	combin	NN	O	O
of	VICTRELIS.xml:S1:2650:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:2653:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:2663:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:2668:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:2678:7	rebetol	NNP	O	O
,	VICTRELIS.xml:S1:2685:1	,	,	O	O
28	VICTRELIS.xml:S1:2687:2	28	CD	O	O
1263	VICTRELIS.xml:S1:2690:4	1263	CD	O	O
(	VICTRELIS.xml:S1:2695:1	(	(	O	O
2%	VICTRELIS.xml:S1:2696:2	2%	CD	O	O
)	VICTRELIS.xml:S1:2698:1	)	)	O	O
subjects	VICTRELIS.xml:S1:2700:8	subject	NNS	O	O
experienced	VICTRELIS.xml:S1:2709:11	experienc	VBD	O	O
adverse	VICTRELIS.xml:S1:2721:7	advers	JJ	O	O
reactions	VICTRELIS.xml:S1:2729:9	reaction	NNS	O	O
leading	VICTRELIS.xml:S1:2739:7	lead	VBG	O	O
to	VICTRELIS.xml:S1:2747:2	to	TO	O	O
discontinuation	VICTRELIS.xml:S1:2750:15	discontinu	NN	O	O
of	VICTRELIS.xml:S1:2766:2	of	IN	O	O
treatment	VICTRELIS.xml:S1:2769:9	treatment	NN	O	O
.	VICTRELIS.xml:S1:2778:1	.	.	O	O

During	VICTRELIS.xml:S1:2780:6	dure	IN	O	O
the	VICTRELIS.xml:S1:2787:3	the	DT	O	O
entire	VICTRELIS.xml:S1:2791:6	entir	JJ	O	O
course	VICTRELIS.xml:S1:2798:6	cours	NN	O	O
of	VICTRELIS.xml:S1:2805:2	of	IN	O	O
treatment	VICTRELIS.xml:S1:2808:9	treatment	NN	O	O
,	VICTRELIS.xml:S1:2817:1	,	,	O	O
the	VICTRELIS.xml:S1:2819:3	the	DT	O	O
proportion	VICTRELIS.xml:S1:2823:10	proport	NN	O	O
of	VICTRELIS.xml:S1:2834:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:2837:8	subject	NNS	O	O
who	VICTRELIS.xml:S1:2846:3	who	WP	O	O
discontinued	VICTRELIS.xml:S1:2850:12	discontinu	VBD	O	O
treatment	VICTRELIS.xml:S1:2863:9	treatment	NN	O	O
due	VICTRELIS.xml:S1:2873:3	due	JJ	O	O
to	VICTRELIS.xml:S1:2877:2	to	TO	O	O
adverse	VICTRELIS.xml:S1:2880:7	advers	JJ	O	O
reactions	VICTRELIS.xml:S1:2888:9	reaction	NNS	O	O
was	VICTRELIS.xml:S1:2898:3	wa	VBD	O	O
13%	VICTRELIS.xml:S1:2902:3	13%	CD	O	O
for	VICTRELIS.xml:S1:2906:3	for	IN	O	O
subjects	VICTRELIS.xml:S1:2910:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:2919:9	receiv	VBG	O	O
the	VICTRELIS.xml:S1:2929:3	the	DT	O	O
combination	VICTRELIS.xml:S1:2933:11	combin	NN	O	O
of	VICTRELIS.xml:S1:2945:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:2948:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:2958:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:2963:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:2973:7	rebetol	NNP	O	O
and	VICTRELIS.xml:S1:2981:3	and	CC	O	O
12%	VICTRELIS.xml:S1:2985:3	12%	CD	O	O
for	VICTRELIS.xml:S1:2989:3	for	IN	O	O
subjects	VICTRELIS.xml:S1:2993:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:3002:9	receiv	VBG	O	O
PegIntron	VICTRELIS.xml:S1:3012:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:3022:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:3030:5	alon	RB	O	O
.	VICTRELIS.xml:S1:3035:1	.	.	O	O

Events	VICTRELIS.xml:S1:3037:6	event	NNS	O	O
resulting	VICTRELIS.xml:S1:3044:9	result	VBG	O	O
in	VICTRELIS.xml:S1:3054:2	in	IN	O	O
discontinuation	VICTRELIS.xml:S1:3057:15	discontinu	NN	O	O
were	VICTRELIS.xml:S1:3073:4	were	VBD	O	O
similar	VICTRELIS.xml:S1:3078:7	similar	JJ	O	O
to	VICTRELIS.xml:S1:3086:2	to	TO	O	O
those	VICTRELIS.xml:S1:3089:5	those	DT	O	O
seen	VICTRELIS.xml:S1:3095:4	seen	VBN	O	O
in	VICTRELIS.xml:S1:3100:2	in	IN	O	O
previous	VICTRELIS.xml:S1:3103:8	previou	JJ	O	O
studies	VICTRELIS.xml:S1:3112:7	studi	NNS	O	O
with	VICTRELIS.xml:S1:3120:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:3125:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:3135:7	rebetol	NNP	O	O
.	VICTRELIS.xml:S1:3142:1	.	.	O	O

Only	VICTRELIS.xml:S1:3144:4	onli	RB	O	O
anemia	VICTRELIS.xml:S1:3149:6	anemia	NN	B-AdverseReaction	O
and	VICTRELIS.xml:S1:3156:3	and	CC	O	O
fatigue	VICTRELIS.xml:S1:3160:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
were	VICTRELIS.xml:S1:3168:4	were	VBD	O	O
reported	VICTRELIS.xml:S1:3173:8	report	VBN	O	O
as	VICTRELIS.xml:S1:3182:2	as	IN	O	O
events	VICTRELIS.xml:S1:3185:6	event	NNS	O	O
that	VICTRELIS.xml:S1:3192:4	that	WDT	O	O
led	VICTRELIS.xml:S1:3197:3	led	VBD	O	O
to	VICTRELIS.xml:S1:3201:2	to	TO	O	O
discontinuation	VICTRELIS.xml:S1:3204:15	discontinu	VB	O	O
in	VICTRELIS.xml:S1:3220:2	in	IN	O	O
more	VICTRELIS.xml:S1:3223:4	more	JJR	O	O
than	VICTRELIS.xml:S1:3228:4	than	IN	O	O
1%	VICTRELIS.xml:S1:3233:2	1%	CD	O	O
of	VICTRELIS.xml:S1:3236:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:3239:8	subject	NNS	O	O
in	VICTRELIS.xml:S1:3248:2	in	IN	O	O
any	VICTRELIS.xml:S1:3251:3	ani	DT	O	O
arm	VICTRELIS.xml:S1:3255:3	arm	NN	O	O
.	VICTRELIS.xml:S1:3258:1	.	.	O	O

Adverse	VICTRELIS.xml:S1:3264:7	advers	JJ	O	O
reactions	VICTRELIS.xml:S1:3272:9	reaction	NNS	O	O
that	VICTRELIS.xml:S1:3282:4	that	WDT	O	O
led	VICTRELIS.xml:S1:3287:3	led	VBD	O	O
to	VICTRELIS.xml:S1:3291:2	to	TO	O	O
dose	VICTRELIS.xml:S1:3294:4	dose	VB	O	O
modifications	VICTRELIS.xml:S1:3299:13	modif	NNS	O	O
of	VICTRELIS.xml:S1:3313:2	of	IN	O	O
any	VICTRELIS.xml:S1:3316:3	ani	DT	O	O
drug	VICTRELIS.xml:S1:3320:4	drug	NN	O	O
(	VICTRELIS.xml:S1:3325:1	(	(	O	O
primarily	VICTRELIS.xml:S1:3326:9	primarili	RB	O	O
PegIntron	VICTRELIS.xml:S1:3336:9	pegintron	NNP	O	O
and	VICTRELIS.xml:S1:3346:3	and	CC	O	O
REBETOL	VICTRELIS.xml:S1:3350:7	rebetol	NNP	O	O
)	VICTRELIS.xml:S1:3357:1	)	)	O	O
occurred	VICTRELIS.xml:S1:3359:8	occur	VBD	O	O
in	VICTRELIS.xml:S1:3368:2	in	IN	O	O
39%	VICTRELIS.xml:S1:3371:3	39%	CD	O	O
of	VICTRELIS.xml:S1:3375:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:3378:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:3387:9	receiv	VBG	O	O
the	VICTRELIS.xml:S1:3397:3	the	DT	O	O
combination	VICTRELIS.xml:S1:3401:11	combin	NN	O	O
of	VICTRELIS.xml:S1:3413:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:3416:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:3426:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:3431:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:3441:7	rebetol	NNP	O	O
compared	VICTRELIS.xml:S1:3449:8	compar	VBN	O	O
to	VICTRELIS.xml:S1:3458:2	to	TO	O	O
24%	VICTRELIS.xml:S1:3461:3	24%	CD	O	O
of	VICTRELIS.xml:S1:3465:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:3468:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:3477:9	receiv	VBG	O	O
PegIntron	VICTRELIS.xml:S1:3487:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:3497:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:3505:5	alon	RB	O	O
.	VICTRELIS.xml:S1:3510:1	.	.	O	O

The	VICTRELIS.xml:S1:3512:3	the	DT	O	O
most	VICTRELIS.xml:S1:3516:4	most	RBS	O	O
common	VICTRELIS.xml:S1:3521:6	common	JJ	O	O
reason	VICTRELIS.xml:S1:3528:6	reason	NN	O	O
for	VICTRELIS.xml:S1:3535:3	for	IN	O	O
dose	VICTRELIS.xml:S1:3539:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S1:3544:9	reduct	NN	O	O
was	VICTRELIS.xml:S1:3554:3	wa	VBD	O	O
anemia	VICTRELIS.xml:S1:3558:6	anemia	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:3564:1	,	,	O	O
which	VICTRELIS.xml:S1:3566:5	which	WDT	O	O
occurred	VICTRELIS.xml:S1:3572:8	occur	VBD	O	O
more	VICTRELIS.xml:S1:3581:4	more	RBR	O	O
frequently	VICTRELIS.xml:S1:3586:10	frequent	RB	O	O
in	VICTRELIS.xml:S1:3597:2	in	IN	O	O
subjects	VICTRELIS.xml:S1:3600:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:3609:9	receiv	VBG	O	O
the	VICTRELIS.xml:S1:3619:3	the	DT	O	O
combination	VICTRELIS.xml:S1:3623:11	combin	NN	O	O
of	VICTRELIS.xml:S1:3635:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:3638:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:3648:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:3653:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:3663:7	rebetol	NNP	O	O
than	VICTRELIS.xml:S1:3671:4	than	IN	O	O
in	VICTRELIS.xml:S1:3676:2	in	IN	O	O
subjects	VICTRELIS.xml:S1:3679:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:3688:9	receiv	VBG	O	O
PegIntron	VICTRELIS.xml:S1:3698:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:3708:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:3716:5	alon	RB	O	O
.	VICTRELIS.xml:S1:3721:1	.	.	O	O

Serious	VICTRELIS.xml:S1:3727:7	seriou	JJ	O	O
adverse	VICTRELIS.xml:S1:3735:7	advers	JJ	O	O
events	VICTRELIS.xml:S1:3743:6	event	NNS	O	O
were	VICTRELIS.xml:S1:3750:4	were	VBD	O	O
reported	VICTRELIS.xml:S1:3755:8	report	VBN	O	O
in	VICTRELIS.xml:S1:3764:2	in	IN	O	O
11%	VICTRELIS.xml:S1:3767:3	11%	CD	O	O
of	VICTRELIS.xml:S1:3771:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:3774:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:3783:9	receiv	VBG	O	O
the	VICTRELIS.xml:S1:3793:3	the	DT	O	O
combination	VICTRELIS.xml:S1:3797:11	combin	NN	O	O
of	VICTRELIS.xml:S1:3809:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:3812:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:3822:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:3827:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:3837:7	rebetol	NNP	O	O
and	VICTRELIS.xml:S1:3845:3	and	CC	O	O
in	VICTRELIS.xml:S1:3849:2	in	IN	O	O
8%	VICTRELIS.xml:S1:3852:2	8%	CD	O	O
of	VICTRELIS.xml:S1:3855:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:3858:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:3867:9	receiv	VBG	O	O
PegIntron	VICTRELIS.xml:S1:3877:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:3887:7	rebetol	NNP	O	O
.	VICTRELIS.xml:S1:3894:1	.	.	O	O

Adverse	VICTRELIS.xml:S1:3900:7	advers	JJ	O	O
events	VICTRELIS.xml:S1:3908:6	event	NNS	O	O
(	VICTRELIS.xml:S1:3915:1	(	(	O	O
regardless	VICTRELIS.xml:S1:3916:10	regardless	NN	O	O
of	VICTRELIS.xml:S1:3927:2	of	IN	O	O
investigator	VICTRELIS.xml:S1:3930:12	investig	NN	O	O
's	VICTRELIS.xml:S1:3942:2	's	POS	O	O
causality	VICTRELIS.xml:S1:3945:9	causal	NN	O	O
assessment	VICTRELIS.xml:S1:3955:10	assess	NN	O	O
)	VICTRELIS.xml:S1:3965:1	)	)	O	O
reported	VICTRELIS.xml:S1:3967:8	report	VBD	O	O
in	VICTRELIS.xml:S1:3976:2	in	IN	O	O
greater	VICTRELIS.xml:S1:3979:7	greater	JJR	O	O
than	VICTRELIS.xml:S1:3987:4	than	IN	O	O
or	VICTRELIS.xml:S1:3992:2	or	CC	O	O
equal	VICTRELIS.xml:S1:3995:5	equal	JJ	O	O
to	VICTRELIS.xml:S1:4001:2	to	TO	O	O
10%	VICTRELIS.xml:S1:4004:3	10%	CD	O	O
of	VICTRELIS.xml:S1:4008:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:4011:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:4020:9	receiv	VBG	O	O
the	VICTRELIS.xml:S1:4030:3	the	DT	O	O
combination	VICTRELIS.xml:S1:4034:11	combin	NN	O	O
of	VICTRELIS.xml:S1:4046:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:4049:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:4059:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:4064:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:4074:7	rebetol	NNP	O	O
and	VICTRELIS.xml:S1:4082:3	and	CC	O	O
reported	VICTRELIS.xml:S1:4086:8	report	VBD	O	O
at	VICTRELIS.xml:S1:4095:2	at	IN	O	O
a	VICTRELIS.xml:S1:4098:1	a	DT	O	O
rate	VICTRELIS.xml:S1:4100:4	rate	NN	O	O
of	VICTRELIS.xml:S1:4105:2	of	IN	O	O
greater	VICTRELIS.xml:S1:4108:7	greater	JJR	O	O
than	VICTRELIS.xml:S1:4116:4	than	IN	O	O
or	VICTRELIS.xml:S1:4121:2	or	CC	O	O
equal	VICTRELIS.xml:S1:4124:5	equal	JJ	O	O
to	VICTRELIS.xml:S1:4130:2	to	TO	O	O
5%	VICTRELIS.xml:S1:4133:2	5%	CD	O	O
than	VICTRELIS.xml:S1:4136:4	than	IN	O	O
PegIntron	VICTRELIS.xml:S1:4141:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:4151:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:4159:5	alon	RB	O	O
in	VICTRELIS.xml:S1:4165:2	in	IN	O	O
SPRINT	VICTRELIS.xml:S1:4168:6	sprint	NNP	O	O
-	VICTRELIS.xml:S1:4174:1	-	:	O	O
1	VICTRELIS.xml:S1:4175:1	1	CD	O	O
,	VICTRELIS.xml:S1:4176:1	,	,	O	O
SPRINT	VICTRELIS.xml:S1:4178:6	sprint	NNP	O	O
-	VICTRELIS.xml:S1:4184:1	-	:	O	O
2	VICTRELIS.xml:S1:4185:1	2	CD	O	O
,	VICTRELIS.xml:S1:4186:1	,	,	O	O
and	VICTRELIS.xml:S1:4188:3	and	CC	O	O
RESPOND	VICTRELIS.xml:S1:4192:7	respond	NNP	O	O
-	VICTRELIS.xml:S1:4199:1	-	:	O	O
2	VICTRELIS.xml:S1:4200:1	2	CD	O	O
are	VICTRELIS.xml:S1:4202:3	are	VBP	O	O
presented	VICTRELIS.xml:S1:4206:9	present	VBN	O	O
in	VICTRELIS.xml:S1:4216:2	in	IN	O	O
Table	VICTRELIS.xml:S1:4220:5	tabl	JJ	O	O
3	VICTRELIS.xml:S1:4226:1	3	CD	O	O
.	VICTRELIS.xml:S1:4229:1	.	.	O	O

Table	VICTRELIS.xml:S1:4235:5	tabl	JJ	O	O
3	VICTRELIS.xml:S1:4241:1	3	CD	O	O
Adverse	VICTRELIS.xml:S1:4243:7	advers	JJ	O	O
Events	VICTRELIS.xml:S1:4251:6	event	NNS	O	O
Reported	VICTRELIS.xml:S1:4258:8	report	VBN	O	O
in	VICTRELIS.xml:S1:4267:2	in	IN	O	O
10%	VICTRELIS.xml:S1:4272:3	10%	CD	O	O
of	VICTRELIS.xml:S1:4276:2	of	IN	O	O
Subjects	VICTRELIS.xml:S1:4279:8	subject	NNS	O	O
Receiving	VICTRELIS.xml:S1:4288:9	receiv	VBG	O	O
the	VICTRELIS.xml:S1:4298:3	the	DT	O	O
Combination	VICTRELIS.xml:S1:4302:11	combin	NN	O	O
of	VICTRELIS.xml:S1:4314:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:4317:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:4327:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:4332:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:4342:7	rebetol	NNP	O	O
and	VICTRELIS.xml:S1:4350:3	and	CC	O	O
Reported	VICTRELIS.xml:S1:4354:8	report	VBD	O	O
at	VICTRELIS.xml:S1:4363:2	at	IN	O	O
a	VICTRELIS.xml:S1:4366:1	a	DT	O	O
Rate	VICTRELIS.xml:S1:4368:4	rate	NNP	O	O
of	VICTRELIS.xml:S1:4373:2	of	IN	O	O
5%	VICTRELIS.xml:S1:4378:2	5%	CD	O	O
than	VICTRELIS.xml:S1:4381:4	than	IN	O	O
PegIntron	VICTRELIS.xml:S1:4386:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:4396:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:4404:5	alon	RB	O	O

Adverse	VICTRELIS.xml:S1:4412:7	advers	JJ	O	O
Events	VICTRELIS.xml:S1:4420:6	event	NNS	O	O
Previously	VICTRELIS.xml:S1:4438:10	previous	RB	O	O
Untreated	VICTRELIS.xml:S1:4449:9	untreat	VBN	O	O
(	VICTRELIS.xml:S1:4458:1	(	(	O	O
SPRINT	VICTRELIS.xml:S1:4459:6	sprint	NNP	O	O
-	VICTRELIS.xml:S1:4465:1	-	:	O	O
1	VICTRELIS.xml:S1:4466:1	1	CD	O	O
and	VICTRELIS.xml:S1:4468:3	and	CC	O	O
SPRINT	VICTRELIS.xml:S1:4472:6	sprint	NNP	O	O
-	VICTRELIS.xml:S1:4478:1	-	:	O	O
2	VICTRELIS.xml:S1:4479:1	2	CD	O	O
)	VICTRELIS.xml:S1:4480:1	)	)	O	O
Previous	VICTRELIS.xml:S1:4483:8	previou	NNP	O	O
Treatment	VICTRELIS.xml:S1:4492:9	treatment	NNP	O	O
Failures	VICTRELIS.xml:S1:4502:8	failur	NNP	O	O
(	VICTRELIS.xml:S1:4510:1	(	(	O	O
RESPOND	VICTRELIS.xml:S1:4511:7	respond	NNP	O	O
-	VICTRELIS.xml:S1:4518:1	-	:	O	O
2	VICTRELIS.xml:S1:4519:1	2	CD	O	O
)	VICTRELIS.xml:S1:4520:1	)	)	O	O

Percentage	VICTRELIS.xml:S1:4552:10	percentag	NN	O	O
of	VICTRELIS.xml:S1:4563:2	of	IN	O	O
Subjects	VICTRELIS.xml:S1:4566:8	subject	NNS	O	O
Reporting	VICTRELIS.xml:S1:4575:9	report	VBG	O	O
Adverse	VICTRELIS.xml:S1:4585:7	advers	JJ	O	O
Events	VICTRELIS.xml:S1:4593:6	event	NNS	O	O
Percentage	VICTRELIS.xml:S1:4601:10	percentag	NN	O	O
of	VICTRELIS.xml:S1:4612:2	of	IN	O	O
Subjects	VICTRELIS.xml:S1:4615:8	subject	NNS	O	O
Reporting	VICTRELIS.xml:S1:4624:9	report	VBG	O	O
Adverse	VICTRELIS.xml:S1:4634:7	advers	JJ	O	O
Events	VICTRELIS.xml:S1:4642:6	event	NNS	O	O

Body	VICTRELIS.xml:S1:4653:4	bodi	NN	O	O
System	VICTRELIS.xml:S1:4658:6	system	NNP	O	O
Organ	VICTRELIS.xml:S1:4665:5	organ	NNP	O	O
Class	VICTRELIS.xml:S1:4671:5	class	NNP	O	O
VICTRELIS	VICTRELIS.xml:S1:4679:9	victr	NNP	O	O
PegIntron	VICTRELIS.xml:S1:4691:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:4703:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S1:4710:1	(	(	O	O
n	VICTRELIS.xml:S1:4711:1	n	JJ	O	O
1225	VICTRELIS.xml:S1:4713:4	1225	CD	O	O
)	VICTRELIS.xml:S1:4717:1	)	)	O	O
PegIntron	VICTRELIS.xml:S1:4720:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:4732:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S1:4739:1	(	(	O	O
n	VICTRELIS.xml:S1:4740:1	n	JJ	O	O
467	VICTRELIS.xml:S1:4742:3	467	CD	O	O
)	VICTRELIS.xml:S1:4745:1	)	)	O	O
VICTRELIS	VICTRELIS.xml:S1:4748:9	victr	NNP	O	O
PegIntron	VICTRELIS.xml:S1:4760:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:4772:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S1:4779:1	(	(	O	O
n	VICTRELIS.xml:S1:4780:1	n	JJ	O	O
323	VICTRELIS.xml:S1:4782:3	323	CD	O	O
)	VICTRELIS.xml:S1:4785:1	)	)	O	O
PegIntron	VICTRELIS.xml:S1:4788:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:4800:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S1:4807:1	(	(	O	O
n	VICTRELIS.xml:S1:4808:1	n	JJ	O	O
80	VICTRELIS.xml:S1:4810:2	80	CD	O	O
)	VICTRELIS.xml:S1:4812:1	)	)	O	O

Median	VICTRELIS.xml:S1:4823:6	median	JJ	O	O

Exposure	VICTRELIS.xml:S1:4830:8	exposur	NN	O	O
(	VICTRELIS.xml:S1:4839:1	(	(	O	O
days	VICTRELIS.xml:S1:4840:4	day	NNS	O	O
)	VICTRELIS.xml:S1:4844:1	)	)	O	O
197	VICTRELIS.xml:S1:4857:3	197	CD	O	O
216	VICTRELIS.xml:S1:4878:3	216	CD	O	O
253	VICTRELIS.xml:S1:4899:3	253	CD	O	O
104	VICTRELIS.xml:S1:4920:3	104	CD	O	O

Blood	VICTRELIS.xml:S1:4938:5	blood	NN	O	O
and	VICTRELIS.xml:S1:4944:3	and	CC	O	O
Lymphatic	VICTRELIS.xml:S1:4948:9	lymphat	NNP	O	O
System	VICTRELIS.xml:S1:4958:6	system	NNP	O	O
Disorders	VICTRELIS.xml:S1:4965:9	disord	NNP	O	O

Anemia	VICTRELIS.xml:S1:4981:6	anemia	NNP	B-AdverseReaction	B-AdverseReaction
50	VICTRELIS.xml:S1:5015:2	50	CD	O	O
30	VICTRELIS.xml:S1:5036:2	30	CD	O	O
45	VICTRELIS.xml:S1:5057:2	45	CD	O	O
20	VICTRELIS.xml:S1:5078:2	20	CD	O	O

Neutropenia	VICTRELIS.xml:S1:5094:11	neutropenia	NNP	B-AdverseReaction	B-AdverseReaction
25	VICTRELIS.xml:S1:5128:2	25	CD	O	O
19	VICTRELIS.xml:S1:5149:2	19	CD	O	O
14	VICTRELIS.xml:S1:5170:2	14	CD	O	O
10	VICTRELIS.xml:S1:5191:2	10	CD	O	O

Gastrointestinal	VICTRELIS.xml:S1:5209:16	gastrointestin	JJ	O	O
Disorders	VICTRELIS.xml:S1:5226:9	disord	NNS	O	O

Nausea	VICTRELIS.xml:S1:5242:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
46	VICTRELIS.xml:S1:5276:2	46	CD	O	O
42	VICTRELIS.xml:S1:5297:2	42	CD	O	O
43	VICTRELIS.xml:S1:5318:2	43	CD	O	O
38	VICTRELIS.xml:S1:5339:2	38	CD	O	O

Dysgeusia	VICTRELIS.xml:S1:5355:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
35	VICTRELIS.xml:S1:5389:2	35	CD	O	O
16	VICTRELIS.xml:S1:5410:2	16	CD	O	O
44	VICTRELIS.xml:S1:5431:2	44	CD	O	O
11	VICTRELIS.xml:S1:5452:2	11	CD	O	O

Diarrhea	VICTRELIS.xml:S1:5468:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
25	VICTRELIS.xml:S1:5502:2	25	CD	O	O
22	VICTRELIS.xml:S1:5523:2	22	CD	O	O
24	VICTRELIS.xml:S1:5544:2	24	CD	O	O
16	VICTRELIS.xml:S1:5565:2	16	CD	O	O

Vomiting	VICTRELIS.xml:S1:5581:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
20	VICTRELIS.xml:S1:5615:2	20	CD	O	O
13	VICTRELIS.xml:S1:5636:2	13	CD	O	O
15	VICTRELIS.xml:S1:5657:2	15	CD	O	O
8	VICTRELIS.xml:S1:5679:1	8	CD	O	O

Dry	VICTRELIS.xml:S1:5694:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
Mouth	VICTRELIS.xml:S1:5698:5	mouth	NNP	I-AdverseReaction	I-AdverseReaction
11	VICTRELIS.xml:S1:5728:2	11	CD	O	O
10	VICTRELIS.xml:S1:5749:2	10	CD	O	O
15	VICTRELIS.xml:S1:5770:2	15	CD	O	O
9	VICTRELIS.xml:S1:5792:1	9	CD	O	O

General	VICTRELIS.xml:S1:5809:7	gener	NNP	O	O
Disorders	VICTRELIS.xml:S1:5817:9	disord	NNP	O	O
and	VICTRELIS.xml:S1:5827:3	and	CC	O	O
Administration	VICTRELIS.xml:S1:5831:14	administr	NNP	O	O
Site	VICTRELIS.xml:S1:5846:4	site	NNP	O	O
Conditions	VICTRELIS.xml:S1:5851:10	condit	NNS	O	O

Fatigue	VICTRELIS.xml:S1:5868:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
58	VICTRELIS.xml:S1:5902:2	58	CD	O	O
59	VICTRELIS.xml:S1:5923:2	59	CD	O	O
55	VICTRELIS.xml:S1:5944:2	55	CD	O	O
50	VICTRELIS.xml:S1:5965:2	50	CD	O	O

Chills	VICTRELIS.xml:S1:5981:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
34	VICTRELIS.xml:S1:6015:2	34	CD	O	O
29	VICTRELIS.xml:S1:6036:2	29	CD	O	O
33	VICTRELIS.xml:S1:6057:2	33	CD	O	O
30	VICTRELIS.xml:S1:6078:2	30	CD	O	O

Asthenia	VICTRELIS.xml:S1:6094:8	asthenia	NNP	B-AdverseReaction	B-AdverseReaction
15	VICTRELIS.xml:S1:6128:2	15	CD	O	O
18	VICTRELIS.xml:S1:6149:2	18	CD	O	O
21	VICTRELIS.xml:S1:6170:2	21	CD	O	O
16	VICTRELIS.xml:S1:6191:2	16	CD	O	O

Metabolism	VICTRELIS.xml:S1:6209:10	metabol	NN	O	O
and	VICTRELIS.xml:S1:6220:3	and	CC	O	O
Nutrition	VICTRELIS.xml:S1:6224:9	nutrit	NN	O	O
Disorders	VICTRELIS.xml:S1:6234:9	disord	NNS	O	O

Decreased	VICTRELIS.xml:S1:6250:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
Appetite	VICTRELIS.xml:S1:6260:8	appetit	NNP	I-AdverseReaction	I-AdverseReaction
25	VICTRELIS.xml:S1:6284:2	25	CD	O	O
24	VICTRELIS.xml:S1:6305:2	24	CD	O	O
26	VICTRELIS.xml:S1:6326:2	26	CD	O	O
16	VICTRELIS.xml:S1:6347:2	16	CD	O	O

Musculoskeletal	VICTRELIS.xml:S1:6365:15	musculoskelet	NNP	O	O
and	VICTRELIS.xml:S1:6381:3	and	CC	O	O
Connective	VICTRELIS.xml:S1:6385:10	connect	NNP	O	O
Tissue	VICTRELIS.xml:S1:6396:6	tissu	NNP	O	O
Disorders	VICTRELIS.xml:S1:6403:9	disord	NNP	O	O

Arthralgia	VICTRELIS.xml:S1:6419:10	arthralgia	NNP	B-AdverseReaction	B-AdverseReaction
19	VICTRELIS.xml:S1:6453:2	19	CD	O	O
19	VICTRELIS.xml:S1:6474:2	19	CD	O	O
23	VICTRELIS.xml:S1:6495:2	23	CD	O	O
16	VICTRELIS.xml:S1:6516:2	16	CD	O	O

Nervous	VICTRELIS.xml:S1:6534:7	nervou	JJ	O	O
System	VICTRELIS.xml:S1:6542:6	system	NNP	O	O
Disorders	VICTRELIS.xml:S1:6549:9	disord	NNP	O	O

Dizziness	VICTRELIS.xml:S1:6565:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
19	VICTRELIS.xml:S1:6599:2	19	CD	O	O
16	VICTRELIS.xml:S1:6620:2	16	CD	O	O
16	VICTRELIS.xml:S1:6641:2	16	CD	O	O
10	VICTRELIS.xml:S1:6662:2	10	CD	O	O

Psychiatric	VICTRELIS.xml:S1:6680:11	psychiatr	JJ	O	O
Disorders	VICTRELIS.xml:S1:6692:9	disord	NNS	O	O

Insomnia	VICTRELIS.xml:S1:6708:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
34	VICTRELIS.xml:S1:6742:2	34	CD	O	O
34	VICTRELIS.xml:S1:6763:2	34	CD	O	O
30	VICTRELIS.xml:S1:6784:2	30	CD	O	O
24	VICTRELIS.xml:S1:6805:2	24	CD	O	O

Irritability	VICTRELIS.xml:S1:6821:12	irrit	NNP	B-AdverseReaction	B-AdverseReaction
22	VICTRELIS.xml:S1:6855:2	22	CD	O	O
23	VICTRELIS.xml:S1:6876:2	23	CD	O	O
21	VICTRELIS.xml:S1:6897:2	21	CD	O	O
13	VICTRELIS.xml:S1:6918:2	13	CD	O	O

Respiratory	VICTRELIS.xml:S1:6936:11	respiratori	NNP	O	O
,	VICTRELIS.xml:S1:6947:1	,	,	O	O
Thoracic	VICTRELIS.xml:S1:6949:8	thorac	NNP	O	O
,	VICTRELIS.xml:S1:6957:1	,	,	O	O
and	VICTRELIS.xml:S1:6959:3	and	CC	O	O
Mediastinal	VICTRELIS.xml:S1:6963:11	mediastin	NNP	O	O
Disorders	VICTRELIS.xml:S1:6975:9	disord	NNP	O	O

Dyspnea	VICTRELIS.xml:S1:6991:7	dyspnea	NNP	B-AdverseReaction	B-AdverseReaction
Exertional	VICTRELIS.xml:S1:6999:10	exert	NNP	I-AdverseReaction	I-AdverseReaction
8	VICTRELIS.xml:S1:7026:1	8	CD	O	O
8	VICTRELIS.xml:S1:7047:1	8	CD	O	O
11	VICTRELIS.xml:S1:7067:2	11	CD	O	O
5	VICTRELIS.xml:S1:7089:1	5	CD	O	O

Skin	VICTRELIS.xml:S1:7106:4	skin	NNP	O	O
and	VICTRELIS.xml:S1:7111:3	and	CC	O	O
Subcutaneous	VICTRELIS.xml:S1:7115:12	subcutan	NNP	O	O
Tissue	VICTRELIS.xml:S1:7128:6	tissu	NNP	O	O
Disorders	VICTRELIS.xml:S1:7135:9	disord	NNP	O	O

Alopecia	VICTRELIS.xml:S1:7151:8	alopecia	NNP	B-AdverseReaction	B-AdverseReaction
27	VICTRELIS.xml:S1:7185:2	27	CD	O	O
27	VICTRELIS.xml:S1:7206:2	27	CD	O	O
22	VICTRELIS.xml:S1:7227:2	22	CD	O	O
16	VICTRELIS.xml:S1:7248:2	16	CD	O	O

Dry	VICTRELIS.xml:S1:7264:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
Skin	VICTRELIS.xml:S1:7268:4	skin	NNP	I-AdverseReaction	I-AdverseReaction
18	VICTRELIS.xml:S1:7298:2	18	CD	O	O
18	VICTRELIS.xml:S1:7319:2	18	CD	O	O
22	VICTRELIS.xml:S1:7340:2	22	CD	O	O
9	VICTRELIS.xml:S1:7362:1	9	CD	O	O

Rash	VICTRELIS.xml:S1:7377:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
17	VICTRELIS.xml:S1:7411:2	17	CD	O	O
19	VICTRELIS.xml:S1:7432:2	19	CD	O	O
16	VICTRELIS.xml:S1:7453:2	16	CD	O	O
6	VICTRELIS.xml:S1:7475:1	6	CD	O	O

Other	VICTRELIS.xml:S1:7504:5	other	JJ	O	O
Important	VICTRELIS.xml:S1:7510:9	import	NNP	O	O
Adverse	VICTRELIS.xml:S1:7520:7	advers	NNP	O	O
Reactions	VICTRELIS.xml:S1:7528:9	reaction	NNP	O	O
Reported	VICTRELIS.xml:S1:7538:8	report	VBD	O	O
in	VICTRELIS.xml:S1:7547:2	in	IN	O	O
Clinical	VICTRELIS.xml:S1:7550:8	clinic	JJ	O	O
Trials	VICTRELIS.xml:S1:7559:6	trial	NNS	O	O

Among	VICTRELIS.xml:S1:7572:5	among	IN	O	O

subjects	VICTRELIS.xml:S1:7578:8	subject	NNS	O	O
(	VICTRELIS.xml:S1:7587:1	(	(	O	O
previously	VICTRELIS.xml:S1:7588:10	previous	RB	O	O
untreated	VICTRELIS.xml:S1:7599:9	untreat	VBN	O	O
subjects	VICTRELIS.xml:S1:7609:8	subject	NNS	O	O
or	VICTRELIS.xml:S1:7618:2	or	CC	O	O
those	VICTRELIS.xml:S1:7621:5	those	DT	O	O
who	VICTRELIS.xml:S1:7627:3	who	WP	O	O
failed	VICTRELIS.xml:S1:7631:6	fail	VBD	O	O
previous	VICTRELIS.xml:S1:7638:8	previou	JJ	O	O
therapy	VICTRELIS.xml:S1:7647:7	therapi	NN	O	O
)	VICTRELIS.xml:S1:7654:1	)	)	O	O
who	VICTRELIS.xml:S1:7656:3	who	WP	O	O
received	VICTRELIS.xml:S1:7660:8	receiv	VBD	O	O
VICTRELIS	VICTRELIS.xml:S1:7669:9	victr	NNP	O	O
in	VICTRELIS.xml:S1:7679:2	in	IN	O	O
combination	VICTRELIS.xml:S1:7682:11	combin	NN	O	O
with	VICTRELIS.xml:S1:7694:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S1:7699:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:7713:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:7718:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:7722:9	ribavirin	NN	O	O
,	VICTRELIS.xml:S1:7731:1	,	,	O	O
the	VICTRELIS.xml:S1:7733:3	the	DT	O	O
following	VICTRELIS.xml:S1:7737:9	follow	JJ	O	O
adverse	VICTRELIS.xml:S1:7747:7	advers	JJ	O	O
drug	VICTRELIS.xml:S1:7755:4	drug	NN	O	O
reactions	VICTRELIS.xml:S1:7760:9	reaction	NNS	O	O
were	VICTRELIS.xml:S1:7770:4	were	VBD	O	O
reported	VICTRELIS.xml:S1:7775:8	report	VBN	O	O
.	VICTRELIS.xml:S1:7783:1	.	.	O	O

These	VICTRELIS.xml:S1:7785:5	these	DT	O	O
events	VICTRELIS.xml:S1:7791:6	event	NNS	O	O
are	VICTRELIS.xml:S1:7798:3	are	VBP	O	O
notable	VICTRELIS.xml:S1:7802:7	notabl	JJ	O	O
because	VICTRELIS.xml:S1:7810:7	becaus	IN	O	O
of	VICTRELIS.xml:S1:7818:2	of	IN	O	O
their	VICTRELIS.xml:S1:7821:5	their	PRP$	O	O
seriousness	VICTRELIS.xml:S1:7827:11	serious	NN	O	O
,	VICTRELIS.xml:S1:7838:1	,	,	O	O
severity	VICTRELIS.xml:S1:7840:8	sever	NN	O	O
,	VICTRELIS.xml:S1:7848:1	,	,	O	O
or	VICTRELIS.xml:S1:7850:2	or	CC	O	O
increased	VICTRELIS.xml:S1:7853:9	increas	JJ	O	O
frequency	VICTRELIS.xml:S1:7863:9	frequenc	NN	O	O
in	VICTRELIS.xml:S1:7873:2	in	IN	O	O
subjects	VICTRELIS.xml:S1:7876:8	subject	NNS	O	O
who	VICTRELIS.xml:S1:7885:3	who	WP	O	O
received	VICTRELIS.xml:S1:7889:8	receiv	VBD	O	O
VICTRELIS	VICTRELIS.xml:S1:7898:9	victr	NNP	O	O
in	VICTRELIS.xml:S1:7908:2	in	IN	O	O
combination	VICTRELIS.xml:S1:7911:11	combin	NN	O	O
with	VICTRELIS.xml:S1:7923:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S1:7928:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:7942:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:7947:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:7951:9	ribavirin	NN	O	O
compared	VICTRELIS.xml:S1:7961:8	compar	VBN	O	O
with	VICTRELIS.xml:S1:7970:4	with	IN	O	O
subjects	VICTRELIS.xml:S1:7975:8	subject	NNS	O	O
who	VICTRELIS.xml:S1:7984:3	who	WP	O	O
received	VICTRELIS.xml:S1:7988:8	receiv	VBD	O	O
only	VICTRELIS.xml:S1:7997:4	onli	RB	O	O
peginterferon	VICTRELIS.xml:S1:8002:13	peginterferon	JJ	O	O
alfa	VICTRELIS.xml:S1:8016:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:8021:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:8025:9	ribavirin	NN	O	O
.	VICTRELIS.xml:S1:8034:1	.	.	O	O

Gastrointestinal	VICTRELIS.xml:S1:8044:16	gastrointestin	JJ	O	O
Disorders	VICTRELIS.xml:S1:8061:9	disord	NNS	O	O

Dysgeusia	VICTRELIS.xml:S1:8077:9	dysgeusia	NNP	B-AdverseReaction	O
(	VICTRELIS.xml:S1:8087:1	(	(	O	O
alteration	VICTRELIS.xml:S1:8088:10	alter	NN	B-AdverseReaction	O
of	VICTRELIS.xml:S1:8099:2	of	IN	I-AdverseReaction	O
taste	VICTRELIS.xml:S1:8102:5	tast	NN	I-AdverseReaction	B-AdverseReaction
)	VICTRELIS.xml:S1:8107:1	)	)	O	O
was	VICTRELIS.xml:S1:8109:3	wa	VBD	O	O
an	VICTRELIS.xml:S1:8113:2	an	DT	O	O
adverse	VICTRELIS.xml:S1:8116:7	advers	JJ	O	O
event	VICTRELIS.xml:S1:8124:5	event	NN	O	O
reported	VICTRELIS.xml:S1:8130:8	report	VBD	O	O
at	VICTRELIS.xml:S1:8139:2	at	IN	O	O
an	VICTRELIS.xml:S1:8142:2	an	DT	O	O
increased	VICTRELIS.xml:S1:8145:9	increas	JJ	O	O
frequency	VICTRELIS.xml:S1:8155:9	frequenc	NN	O	O
in	VICTRELIS.xml:S1:8165:2	in	IN	O	O
subjects	VICTRELIS.xml:S1:8168:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:8177:9	receiv	VBG	O	O
VICTRELIS	VICTRELIS.xml:S1:8187:9	victr	NNP	O	O
in	VICTRELIS.xml:S1:8197:2	in	IN	O	O
combination	VICTRELIS.xml:S1:8200:11	combin	NN	O	O
with	VICTRELIS.xml:S1:8212:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S1:8217:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:8231:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:8236:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:8240:9	ribavirin	NN	O	O
compared	VICTRELIS.xml:S1:8250:8	compar	VBN	O	O
with	VICTRELIS.xml:S1:8259:4	with	IN	O	O
subjects	VICTRELIS.xml:S1:8264:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:8273:9	receiv	VBG	O	O
peginterferon	VICTRELIS.xml:S1:8283:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:8297:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:8302:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:8306:9	ribavirin	VB	O	O
alone	VICTRELIS.xml:S1:8316:5	alon	RB	O	O
(	VICTRELIS.xml:S1:8322:1	(	(	O	O
Table	VICTRELIS.xml:S1:8325:5	tabl	JJ	O	O
3	VICTRELIS.xml:S1:8331:1	3	CD	O	O
)	VICTRELIS.xml:S1:8334:1	)	)	O	O
.	VICTRELIS.xml:S1:8335:1	.	.	O	O

Adverse	VICTRELIS.xml:S1:8337:7	advers	JJ	O	O
events	VICTRELIS.xml:S1:8345:6	event	NNS	O	O
such	VICTRELIS.xml:S1:8352:4	such	JJ	O	O
as	VICTRELIS.xml:S1:8357:2	as	IN	O	O
dry	VICTRELIS.xml:S1:8360:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	VICTRELIS.xml:S1:8364:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
,	VICTRELIS.xml:S1:8369:1	,	,	O	O
nausea	VICTRELIS.xml:S1:8371:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:8377:1	,	,	O	O
vomiting	VICTRELIS.xml:S1:8379:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
and	VICTRELIS.xml:S1:8388:3	and	CC	O	O
diarrhea	VICTRELIS.xml:S1:8392:8	diarrhea	NNS	B-AdverseReaction	B-AdverseReaction
were	VICTRELIS.xml:S1:8401:4	were	VBD	O	O
also	VICTRELIS.xml:S1:8406:4	also	RB	O	O
reported	VICTRELIS.xml:S1:8411:8	report	VBN	O	O
at	VICTRELIS.xml:S1:8420:2	at	IN	O	O
an	VICTRELIS.xml:S1:8423:2	an	DT	O	O
increased	VICTRELIS.xml:S1:8426:9	increas	JJ	O	O
frequency	VICTRELIS.xml:S1:8436:9	frequenc	NN	O	O
in	VICTRELIS.xml:S1:8446:2	in	IN	O	O
subjects	VICTRELIS.xml:S1:8449:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:8458:9	receiv	VBG	O	O
VICTRELIS	VICTRELIS.xml:S1:8468:9	victr	NNP	O	O
in	VICTRELIS.xml:S1:8478:2	in	IN	O	O
combination	VICTRELIS.xml:S1:8481:11	combin	NN	O	O
with	VICTRELIS.xml:S1:8493:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S1:8498:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:8512:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:8517:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:8521:9	ribavirin	NN	O	O
.	VICTRELIS.xml:S1:8530:1	.	.	O	O

Laboratory	VICTRELIS.xml:S1:8540:10	laboratori	NN	O	O
Values	VICTRELIS.xml:S1:8551:6	valu	NNS	O	O

Changes	VICTRELIS.xml:S1:8564:7	chang	NNS	O	O
in	VICTRELIS.xml:S1:8572:2	in	IN	O	O
selected	VICTRELIS.xml:S1:8575:8	select	JJ	O	O
hematological	VICTRELIS.xml:S1:8584:13	hematolog	JJ	O	O
parameters	VICTRELIS.xml:S1:8598:10	paramet	NNS	O	O
during	VICTRELIS.xml:S1:8609:6	dure	IN	O	O
treatment	VICTRELIS.xml:S1:8616:9	treatment	NN	O	O
of	VICTRELIS.xml:S1:8626:2	of	IN	O	O
adult	VICTRELIS.xml:S1:8629:5	adult	NN	O	O
subjects	VICTRELIS.xml:S1:8635:8	subject	NNS	O	O
with	VICTRELIS.xml:S1:8644:4	with	IN	O	O
the	VICTRELIS.xml:S1:8649:3	the	DT	O	O
combination	VICTRELIS.xml:S1:8653:11	combin	NN	O	O
of	VICTRELIS.xml:S1:8665:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:8668:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:8678:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:8683:9	pegintron	NNP	O	O
and	VICTRELIS.xml:S1:8693:3	and	CC	O	O
REBETOL	VICTRELIS.xml:S1:8697:7	rebetol	NNP	O	O
are	VICTRELIS.xml:S1:8705:3	are	VBP	O	O
described	VICTRELIS.xml:S1:8709:9	describ	VBN	O	O
in	VICTRELIS.xml:S1:8719:2	in	IN	O	O
Table	VICTRELIS.xml:S1:8723:5	tabl	JJ	O	O
4	VICTRELIS.xml:S1:8729:1	4	CD	O	O
.	VICTRELIS.xml:S1:8730:1	.	.	O	O

Hemoglobin	VICTRELIS.xml:S1:8742:10	hemoglobin	NN	O	B-AdverseReaction

Decreases	VICTRELIS.xml:S1:8759:9	decreas	NNS	O	O
in	VICTRELIS.xml:S1:8769:2	in	IN	O	O
hemoglobin	VICTRELIS.xml:S1:8772:10	hemoglobin	NN	O	O
may	VICTRELIS.xml:S1:8783:3	may	MD	O	O
require	VICTRELIS.xml:S1:8787:7	requir	VB	O	O
a	VICTRELIS.xml:S1:8795:1	a	DT	O	O
decrease	VICTRELIS.xml:S1:8797:8	decreas	NN	O	O
in	VICTRELIS.xml:S1:8806:2	in	IN	O	O
dosage	VICTRELIS.xml:S1:8809:6	dosag	NN	O	O
or	VICTRELIS.xml:S1:8816:2	or	CC	O	O
discontinuation	VICTRELIS.xml:S1:8819:15	discontinu	NN	O	O
of	VICTRELIS.xml:S1:8835:2	of	IN	O	O
ribavirin	VICTRELIS.xml:S1:8838:9	ribavirin	NN	O	O
[	VICTRELIS.xml:S1:8849:1	[	NNP	O	O
see	VICTRELIS.xml:S1:8850:3	see	VBP	O	O
Warnings	VICTRELIS.xml:S1:8855:8	warn	NNP	O	O
and	VICTRELIS.xml:S1:8864:3	and	CC	O	O
Precautions	VICTRELIS.xml:S1:8868:11	precaut	NNP	O	O
(	VICTRELIS.xml:S1:8880:1	(	(	O	O
5.2	VICTRELIS.xml:S1:8881:3	5.2	CD	O	O
)	VICTRELIS.xml:S1:8884:1	)	)	O	O
and	VICTRELIS.xml:S1:8887:3	and	CC	O	O
Clinical	VICTRELIS.xml:S1:8892:8	clinic	JJ	O	O
Studies	VICTRELIS.xml:S1:8901:7	studi	NNP	O	O
(	VICTRELIS.xml:S1:8909:1	(	(	O	O
14	VICTRELIS.xml:S1:8910:2	14	CD	O	O
)	VICTRELIS.xml:S1:8912:1	)	)	O	O
]	VICTRELIS.xml:S1:8915:1	]	NN	O	O
[	VICTRELIS.xml:S1:8917:1	[	NNP	O	O
see	VICTRELIS.xml:S1:8918:3	see	VBP	O	O
prescribing	VICTRELIS.xml:S1:8922:11	prescrib	VBG	O	O
information	VICTRELIS.xml:S1:8934:11	inform	NN	O	O
for	VICTRELIS.xml:S1:8946:3	for	IN	O	O
ribavirin	VICTRELIS.xml:S1:8950:9	ribavirin	NN	O	O
]	VICTRELIS.xml:S1:8959:1	]	NN	O	O
.	VICTRELIS.xml:S1:8962:1	.	.	O	O

If	VICTRELIS.xml:S1:8964:2	If	IN	O	O
ribavirin	VICTRELIS.xml:S1:8967:9	ribavirin	VBN	O	O
is	VICTRELIS.xml:S1:8977:2	is	VBZ	O	O
permanently	VICTRELIS.xml:S1:8980:11	perman	RB	O	O
discontinued	VICTRELIS.xml:S1:8992:12	discontinu	VBN	O	O
,	VICTRELIS.xml:S1:9004:1	,	,	O	O
then	VICTRELIS.xml:S1:9006:4	then	RB	O	O
peginterferon	VICTRELIS.xml:S1:9011:13	peginterferon	VB	O	O
alfa	VICTRELIS.xml:S1:9025:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:9030:3	and	CC	O	O
VICTRELIS	VICTRELIS.xml:S1:9034:9	victr	NNP	O	O
must	VICTRELIS.xml:S1:9044:4	must	MD	O	O
also	VICTRELIS.xml:S1:9049:4	also	RB	O	O
be	VICTRELIS.xml:S1:9054:2	be	VB	O	O
discontinued	VICTRELIS.xml:S1:9057:12	discontinu	VBN	O	O
[	VICTRELIS.xml:S1:9071:1	[	NNP	O	O
see	VICTRELIS.xml:S1:9072:3	see	VBP	O	O
Dosage	VICTRELIS.xml:S1:9077:6	dosag	NNP	O	O
and	VICTRELIS.xml:S1:9084:3	and	CC	O	O
Administration	VICTRELIS.xml:S1:9088:14	administr	NNP	O	O
(	VICTRELIS.xml:S1:9103:1	(	(	O	O
2.3	VICTRELIS.xml:S1:9104:3	2.3	CD	O	O
)	VICTRELIS.xml:S1:9107:1	)	)	O	O
]	VICTRELIS.xml:S1:9110:1	]	NN	O	O
.	VICTRELIS.xml:S1:9113:1	.	.	O	O

Neutrophils	VICTRELIS.xml:S1:9123:11	neutrophil	NNS	O	B-AdverseReaction
and	VICTRELIS.xml:S1:9135:3	and	CC	O	O
Platelets	VICTRELIS.xml:S1:9139:9	platelet	NNS	O	O

The	VICTRELIS.xml:S1:9155:3	the	DT	O	O
proportion	VICTRELIS.xml:S1:9159:10	proport	NN	O	O
of	VICTRELIS.xml:S1:9170:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:9173:8	subject	NNS	O	O
with	VICTRELIS.xml:S1:9182:4	with	IN	O	O
decreased	VICTRELIS.xml:S1:9187:9	decreas	JJ	B-AdverseReaction	B-AdverseReaction
neutrophil	VICTRELIS.xml:S1:9197:10	neutrophil	NNS	I-AdverseReaction	I-AdverseReaction
and	VICTRELIS.xml:S1:9208:3	and	CC	O	O
platelet	VICTRELIS.xml:S1:9212:8	platelet	NN	I-AdverseReaction	B-AdverseReaction
counts	VICTRELIS.xml:S1:9221:6	count	NNS	I-AdverseReaction	I-AdverseReaction
was	VICTRELIS.xml:S1:9228:3	wa	VBD	O	O
higher	VICTRELIS.xml:S1:9232:6	higher	RBR	O	O
in	VICTRELIS.xml:S1:9239:2	in	IN	O	O
subjects	VICTRELIS.xml:S1:9242:8	subject	NNS	O	O
treated	VICTRELIS.xml:S1:9251:7	treat	VBN	O	O
with	VICTRELIS.xml:S1:9259:4	with	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:9264:9	victr	NNP	O	O
in	VICTRELIS.xml:S1:9274:2	in	IN	O	O
combination	VICTRELIS.xml:S1:9277:11	combin	NN	O	O
with	VICTRELIS.xml:S1:9289:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:9294:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:9304:7	rebetol	NNP	O	O
compared	VICTRELIS.xml:S1:9312:8	compar	VBN	O	O
to	VICTRELIS.xml:S1:9321:2	to	TO	O	O
subjects	VICTRELIS.xml:S1:9324:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:9333:9	receiv	VBG	O	O
PegIntron	VICTRELIS.xml:S1:9343:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:9353:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:9361:5	alon	RB	O	O
.	VICTRELIS.xml:S1:9366:1	.	.	O	O

Three	VICTRELIS.xml:S1:9368:5	three	CD	O	O
percent	VICTRELIS.xml:S1:9374:7	percent	NN	O	O
of	VICTRELIS.xml:S1:9382:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:9385:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:9394:9	receiv	VBG	O	O
the	VICTRELIS.xml:S1:9404:3	the	DT	O	O
combination	VICTRELIS.xml:S1:9408:11	combin	NN	O	O
of	VICTRELIS.xml:S1:9420:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:9423:9	victr	NNP	O	O
with	VICTRELIS.xml:S1:9433:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S1:9438:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:9448:7	rebetol	NNP	O	O
had	VICTRELIS.xml:S1:9456:3	had	VBD	O	O
platelet	VICTRELIS.xml:S1:9460:8	platelet	VBN	B-AdverseReaction	O
counts	VICTRELIS.xml:S1:9469:6	count	NNS	I-AdverseReaction	O
of	VICTRELIS.xml:S1:9476:2	of	IN	I-AdverseReaction	O
less	VICTRELIS.xml:S1:9479:4	less	JJR	I-AdverseReaction	O
than	VICTRELIS.xml:S1:9484:4	than	IN	I-AdverseReaction	O
50	VICTRELIS.xml:S1:9489:2	50	CD	I-AdverseReaction	O
10	VICTRELIS.xml:S1:9494:2	10	CD	I-AdverseReaction	O
9	VICTRELIS.xml:S1:9498:1	9	CD	I-AdverseReaction	O
per	VICTRELIS.xml:S1:9501:3	per	IN	I-AdverseReaction	O
L	VICTRELIS.xml:S1:9505:1	L	NNP	I-AdverseReaction	O
compared	VICTRELIS.xml:S1:9507:8	compar	VBN	O	O
to	VICTRELIS.xml:S1:9516:2	to	TO	O	O
1%	VICTRELIS.xml:S1:9519:2	1%	CD	O	O
of	VICTRELIS.xml:S1:9522:2	of	IN	O	O
subjects	VICTRELIS.xml:S1:9525:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S1:9534:9	receiv	VBG	O	O
PegIntron	VICTRELIS.xml:S1:9544:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:9554:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S1:9562:5	alon	RB	O	O
.	VICTRELIS.xml:S1:9567:1	.	.	O	O

Decreases	VICTRELIS.xml:S1:9569:9	decreas	NNS	O	B-AdverseReaction
in	VICTRELIS.xml:S1:9579:2	in	IN	O	I-AdverseReaction
neutrophils	VICTRELIS.xml:S1:9582:11	neutrophil	NNS	O	I-AdverseReaction
or	VICTRELIS.xml:S1:9594:2	or	CC	O	O
platelets	VICTRELIS.xml:S1:9597:9	platelet	NNS	O	O
may	VICTRELIS.xml:S1:9607:3	may	MD	O	O
require	VICTRELIS.xml:S1:9611:7	requir	VB	O	O
a	VICTRELIS.xml:S1:9619:1	a	DT	O	O
decrease	VICTRELIS.xml:S1:9621:8	decreas	NN	O	O
in	VICTRELIS.xml:S1:9630:2	in	IN	O	O
dosage	VICTRELIS.xml:S1:9633:6	dosag	NN	O	O
or	VICTRELIS.xml:S1:9640:2	or	CC	O	O
interruption	VICTRELIS.xml:S1:9643:12	interrupt	NN	O	O
of	VICTRELIS.xml:S1:9656:2	of	IN	O	O
peginterferon	VICTRELIS.xml:S1:9659:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:9673:4	alfa	NN	O	O
,	VICTRELIS.xml:S1:9677:1	,	,	O	O
or	VICTRELIS.xml:S1:9679:2	or	CC	O	O
discontinuation	VICTRELIS.xml:S1:9682:15	discontinu	NN	O	O
of	VICTRELIS.xml:S1:9698:2	of	IN	O	O
therapy	VICTRELIS.xml:S1:9701:7	therapi	NN	O	O
[	VICTRELIS.xml:S1:9710:1	[	NNP	O	O
see	VICTRELIS.xml:S1:9711:3	see	VBP	O	O
prescribing	VICTRELIS.xml:S1:9715:11	prescrib	VBG	O	O
information	VICTRELIS.xml:S1:9727:11	inform	NN	O	O
for	VICTRELIS.xml:S1:9739:3	for	IN	O	O
peginterferon	VICTRELIS.xml:S1:9743:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:9757:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:9762:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:9766:9	ribavirin	NN	O	O
]	VICTRELIS.xml:S1:9775:1	]	NN	O	O
.	VICTRELIS.xml:S1:9778:1	.	.	O	O

If	VICTRELIS.xml:S1:9780:2	If	IN	O	O
peginterferon	VICTRELIS.xml:S1:9783:13	peginterferon	VBN	O	O
alfa	VICTRELIS.xml:S1:9797:4	alfa	NN	O	O
is	VICTRELIS.xml:S1:9802:2	is	VBZ	O	O
permanently	VICTRELIS.xml:S1:9805:11	perman	RB	O	O
discontinued	VICTRELIS.xml:S1:9817:12	discontinu	VBN	O	O
,	VICTRELIS.xml:S1:9829:1	,	,	O	O
then	VICTRELIS.xml:S1:9831:4	then	RB	O	O
ribavirin	VICTRELIS.xml:S1:9836:9	ribavirin	NN	O	O
and	VICTRELIS.xml:S1:9846:3	and	CC	O	O
VICTRELIS	VICTRELIS.xml:S1:9850:9	victr	NNP	O	O
must	VICTRELIS.xml:S1:9860:4	must	MD	O	O
also	VICTRELIS.xml:S1:9865:4	also	RB	O	O
be	VICTRELIS.xml:S1:9870:2	be	VB	O	O
discontinued	VICTRELIS.xml:S1:9873:12	discontinu	VBN	O	O
[	VICTRELIS.xml:S1:9887:1	[	NNP	O	O
see	VICTRELIS.xml:S1:9888:3	see	VBP	O	O
Dosage	VICTRELIS.xml:S1:9893:6	dosag	NNP	O	O
and	VICTRELIS.xml:S1:9900:3	and	CC	O	O
Administration	VICTRELIS.xml:S1:9904:14	administr	NNP	O	O
(	VICTRELIS.xml:S1:9919:1	(	(	O	O
2.3	VICTRELIS.xml:S1:9920:3	2.3	CD	O	O
)	VICTRELIS.xml:S1:9923:1	)	)	O	O
]	VICTRELIS.xml:S1:9926:1	]	NN	O	O
.	VICTRELIS.xml:S1:9929:1	.	.	O	O

Table	VICTRELIS.xml:S1:9935:5	tabl	JJ	O	O
4	VICTRELIS.xml:S1:9941:1	4	CD	O	O
Selected	VICTRELIS.xml:S1:9943:8	select	NNP	O	O
Hematological	VICTRELIS.xml:S1:9952:13	hematolog	NNP	O	O
Parameters	VICTRELIS.xml:S1:9966:10	paramet	NNS	O	O

Previously	VICTRELIS.xml:S1:10005:10	previous	RB	O	O
Untreated	VICTRELIS.xml:S1:10016:9	untreat	VBN	O	O
(	VICTRELIS.xml:S1:10025:1	(	(	O	O
SPRINT	VICTRELIS.xml:S1:10026:6	sprint	NNP	O	O
-	VICTRELIS.xml:S1:10032:1	-	:	O	O
1	VICTRELIS.xml:S1:10033:1	1	CD	O	O
and	VICTRELIS.xml:S1:10035:3	and	CC	O	O
SPRINT	VICTRELIS.xml:S1:10039:6	sprint	NNP	O	O
-	VICTRELIS.xml:S1:10045:1	-	:	O	O
2	VICTRELIS.xml:S1:10046:1	2	CD	O	O
)	VICTRELIS.xml:S1:10047:1	)	)	O	O
Previous	VICTRELIS.xml:S1:10050:8	previou	NNP	O	O
Treatment	VICTRELIS.xml:S1:10059:9	treatment	NNP	O	O
Failures	VICTRELIS.xml:S1:10069:8	failur	NNP	O	O
(	VICTRELIS.xml:S1:10077:1	(	(	O	O
RESPOND	VICTRELIS.xml:S1:10078:7	respond	NNP	O	O
-	VICTRELIS.xml:S1:10085:1	-	:	O	O
2	VICTRELIS.xml:S1:10086:1	2	CD	O	O
)	VICTRELIS.xml:S1:10087:1	)	)	O	O

Percentage	VICTRELIS.xml:S1:10119:10	percentag	NN	O	O
of	VICTRELIS.xml:S1:10130:2	of	IN	O	O
Subjects	VICTRELIS.xml:S1:10133:8	subject	NNS	O	O
Reporting	VICTRELIS.xml:S1:10142:9	report	VBG	O	O
Selected	VICTRELIS.xml:S1:10152:8	select	NNP	O	O
Hematological	VICTRELIS.xml:S1:10161:13	hematolog	NNP	O	O
Parameters	VICTRELIS.xml:S1:10175:10	paramet	NNP	O	O
Percentage	VICTRELIS.xml:S1:10187:10	percentag	NNP	O	O
of	VICTRELIS.xml:S1:10198:2	of	IN	O	O
Subjects	VICTRELIS.xml:S1:10201:8	subject	NNP	O	O
Reporting	VICTRELIS.xml:S1:10210:9	report	NNP	O	O
Selected	VICTRELIS.xml:S1:10220:8	select	NNP	O	O
Hematological	VICTRELIS.xml:S1:10229:13	hematolog	NNP	O	O
Parameters	VICTRELIS.xml:S1:10243:10	paramet	NNS	O	O

Hematological	VICTRELIS.xml:S1:10258:13	hematolog	JJ	O	O
Parameters	VICTRELIS.xml:S1:10272:10	paramet	NNS	O	O
VICTRELIS	VICTRELIS.xml:S1:10284:9	victr	NNP	O	O
PegIntron	VICTRELIS.xml:S1:10296:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:10308:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S1:10315:1	(	(	O	O
n	VICTRELIS.xml:S1:10316:1	n	JJ	O	O
1225	VICTRELIS.xml:S1:10318:4	1225	CD	O	O
)	VICTRELIS.xml:S1:10322:1	)	)	O	O
PegIntron	VICTRELIS.xml:S1:10325:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:10337:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S1:10344:1	(	(	O	O
n	VICTRELIS.xml:S1:10345:1	n	JJ	O	O
467	VICTRELIS.xml:S1:10347:3	467	CD	O	O
)	VICTRELIS.xml:S1:10350:1	)	)	O	O
VICTRELIS	VICTRELIS.xml:S1:10353:9	victr	NNP	O	O
PegIntron	VICTRELIS.xml:S1:10365:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:10377:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S1:10384:1	(	(	O	O
n	VICTRELIS.xml:S1:10385:1	n	JJ	O	O
323	VICTRELIS.xml:S1:10387:3	323	CD	O	O
)	VICTRELIS.xml:S1:10390:1	)	)	O	O
PegIntron	VICTRELIS.xml:S1:10393:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S1:10405:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S1:10412:1	(	(	O	O
n	VICTRELIS.xml:S1:10413:1	n	JJ	O	O
80	VICTRELIS.xml:S1:10415:2	80	CD	O	O
)	VICTRELIS.xml:S1:10417:1	)	)	O	O

Hemoglobin	VICTRELIS.xml:S1:10428:10	hemoglobin	NN	B-AdverseReaction	B-AdverseReaction

(	VICTRELIS.xml:S1:10439:1	(	(	I-AdverseReaction	O
g	VICTRELIS.xml:S1:10440:1	g	VB	I-AdverseReaction	O
dL	VICTRELIS.xml:S1:10442:2	dL	NN	I-AdverseReaction	O
)	VICTRELIS.xml:S1:10444:1	)	)	I-AdverseReaction	O

10	VICTRELIS.xml:S1:10456:2	10	CD	I-AdverseReaction	O
49	VICTRELIS.xml:S1:10489:2	49	CD	O	O
29	VICTRELIS.xml:S1:10510:2	29	CD	O	O
49	VICTRELIS.xml:S1:10531:2	49	CD	O	O
25	VICTRELIS.xml:S1:10552:2	25	CD	O	O

8.5	VICTRELIS.xml:S1:10569:3	8.5	CD	I-AdverseReaction	O
6	VICTRELIS.xml:S1:10603:1	6	CD	O	O
3	VICTRELIS.xml:S1:10624:1	3	CD	O	O
10	VICTRELIS.xml:S1:10644:2	10	CD	O	O
1	VICTRELIS.xml:S1:10666:1	1	CD	O	O

Neutrophils	VICTRELIS.xml:S1:10683:11	neutrophil	NNP	B-AdverseReaction	B-AdverseReaction
(	VICTRELIS.xml:S1:10695:1	(	(	I-AdverseReaction	O
10	VICTRELIS.xml:S1:10698:2	10	CD	I-AdverseReaction	O
9	VICTRELIS.xml:S1:10702:1	9	CD	I-AdverseReaction	O
L	VICTRELIS.xml:S1:10706:1	L	NNP	I-AdverseReaction	O
)	VICTRELIS.xml:S1:10707:1	)	)	I-AdverseReaction	O

0.75	VICTRELIS.xml:S1:10716:4	0.75	CD	I-AdverseReaction	O
31	VICTRELIS.xml:S1:10749:2	31	CD	O	O
18	VICTRELIS.xml:S1:10770:2	18	CD	O	O
26	VICTRELIS.xml:S1:10791:2	26	CD	O	O
13	VICTRELIS.xml:S1:10812:2	13	CD	O	O

0.5	VICTRELIS.xml:S1:10829:3	0.5	CD	I-AdverseReaction	O
8	VICTRELIS.xml:S1:10863:1	8	CD	O	O
4	VICTRELIS.xml:S1:10884:1	4	CD	O	O
7	VICTRELIS.xml:S1:10905:1	7	CD	O	O
4	VICTRELIS.xml:S1:10926:1	4	CD	O	O

Platelets	VICTRELIS.xml:S1:10943:9	platelet	NNS	B-AdverseReaction	B-AdverseReaction
(	VICTRELIS.xml:S1:10953:1	(	(	I-AdverseReaction	O
10	VICTRELIS.xml:S1:10956:2	10	CD	I-AdverseReaction	O
9	VICTRELIS.xml:S1:10960:1	9	CD	I-AdverseReaction	O
L	VICTRELIS.xml:S1:10964:1	L	NNP	I-AdverseReaction	O
)	VICTRELIS.xml:S1:10965:1	)	)	I-AdverseReaction	O

50	VICTRELIS.xml:S1:10974:2	50	CD	I-AdverseReaction	O
3	VICTRELIS.xml:S1:11008:1	3	CD	O	O
1	VICTRELIS.xml:S1:11029:1	1	CD	O	O
4	VICTRELIS.xml:S1:11050:1	4	CD	O	O
0	VICTRELIS.xml:S1:11071:1	0	CD	O	O

25	VICTRELIS.xml:S1:11087:2	25	CD	I-AdverseReaction	O
1	VICTRELIS.xml:S1:11121:1	1	CD	O	O
0	VICTRELIS.xml:S1:11142:1	0	CD	O	O
0	VICTRELIS.xml:S1:11163:1	0	CD	O	O
0	VICTRELIS.xml:S1:11184:1	0	CD	O	O

6.2	VICTRELIS.xml:S1:11211:3	6.2	CD	O	O
Postmarketing	VICTRELIS.xml:S1:11215:13	postmarket	VBG	O	O
Experience	VICTRELIS.xml:S1:11229:10	experi	NN	O	O

The	VICTRELIS.xml:S1:11243:3	the	DT	O	O
following	VICTRELIS.xml:S1:11247:9	follow	JJ	O	O
adverse	VICTRELIS.xml:S1:11257:7	advers	JJ	O	O
reactions	VICTRELIS.xml:S1:11265:9	reaction	NNS	O	O
have	VICTRELIS.xml:S1:11275:4	have	VBP	O	O
been	VICTRELIS.xml:S1:11280:4	been	VBN	O	O
identified	VICTRELIS.xml:S1:11285:10	identifi	VBN	O	O
during	VICTRELIS.xml:S1:11296:6	dure	IN	O	O
post	VICTRELIS.xml:S1:11303:4	post	NN	O	O
-	VICTRELIS.xml:S1:11307:1	-	:	O	O
approval	VICTRELIS.xml:S1:11308:8	approv	NN	O	O
use	VICTRELIS.xml:S1:11317:3	use	NN	O	O
of	VICTRELIS.xml:S1:11321:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S1:11324:9	victr	NNP	O	O
in	VICTRELIS.xml:S1:11334:2	in	IN	O	O
combination	VICTRELIS.xml:S1:11337:11	combin	NN	O	O
with	VICTRELIS.xml:S1:11349:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S1:11354:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S1:11368:4	alfa	NN	O	O
and	VICTRELIS.xml:S1:11373:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S1:11377:9	ribavirin	NN	O	O
.	VICTRELIS.xml:S1:11386:1	.	.	O	O

Because	VICTRELIS.xml:S1:11388:7	becaus	IN	O	O
these	VICTRELIS.xml:S1:11396:5	these	DT	O	O
reactions	VICTRELIS.xml:S1:11402:9	reaction	NNS	O	O
are	VICTRELIS.xml:S1:11412:3	are	VBP	O	O
reported	VICTRELIS.xml:S1:11416:8	report	VBN	O	O
voluntarily	VICTRELIS.xml:S1:11425:11	voluntarili	RB	O	O
from	VICTRELIS.xml:S1:11437:4	from	IN	O	O
a	VICTRELIS.xml:S1:11442:1	a	DT	O	O
population	VICTRELIS.xml:S1:11444:10	popul	NN	O	O
of	VICTRELIS.xml:S1:11455:2	of	IN	O	O
uncertain	VICTRELIS.xml:S1:11458:9	uncertain	JJ	O	O
size	VICTRELIS.xml:S1:11468:4	size	NN	O	O
,	VICTRELIS.xml:S1:11472:1	,	,	O	O
it	VICTRELIS.xml:S1:11474:2	it	PRP	O	O
is	VICTRELIS.xml:S1:11477:2	is	VBZ	O	O
not	VICTRELIS.xml:S1:11480:3	not	RB	O	O
always	VICTRELIS.xml:S1:11484:6	alway	RB	O	O
possible	VICTRELIS.xml:S1:11491:8	possibl	JJ	O	O
to	VICTRELIS.xml:S1:11500:2	to	TO	O	O
reliably	VICTRELIS.xml:S1:11503:8	reliabl	VB	O	O
estimate	VICTRELIS.xml:S1:11512:8	estim	VB	O	O
their	VICTRELIS.xml:S1:11521:5	their	PRP$	O	O
frequency	VICTRELIS.xml:S1:11527:9	frequenc	NN	O	O
or	VICTRELIS.xml:S1:11537:2	or	CC	O	O
establish	VICTRELIS.xml:S1:11540:9	establish	VB	O	O
a	VICTRELIS.xml:S1:11550:1	a	DT	O	O
causal	VICTRELIS.xml:S1:11552:6	causal	NN	O	O
relationship	VICTRELIS.xml:S1:11559:12	relationship	NN	O	O
to	VICTRELIS.xml:S1:11572:2	to	TO	O	O
drug	VICTRELIS.xml:S1:11575:4	drug	NN	O	O
exposure	VICTRELIS.xml:S1:11580:8	exposur	NN	O	O
.	VICTRELIS.xml:S1:11588:1	.	.	O	O

Blood	VICTRELIS.xml:S1:11596:5	blood	NN	O	O
and	VICTRELIS.xml:S1:11602:3	and	CC	O	O
Lymphatic	VICTRELIS.xml:S1:11606:9	lymphat	NNP	O	O
System	VICTRELIS.xml:S1:11616:6	system	NNP	O	O
Disorders	VICTRELIS.xml:S1:11623:9	disord	NNPS	O	O
:	VICTRELIS.xml:S1:11632:1	:	:	O	O
agranulocytosis	VICTRELIS.xml:S1:11635:15	agranulocytosi	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:11650:1	,	,	O	O
pancytopenia	VICTRELIS.xml:S1:11652:12	pancytopenia	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:11666:1	,	,	O	O
thrombocytopenia	VICTRELIS.xml:S1:11669:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
[	VICTRELIS.xml:S1:11687:1	[	NNP	O	O
see	VICTRELIS.xml:S1:11688:3	see	VBP	O	O
Warnings	VICTRELIS.xml:S1:11693:8	warn	NNP	O	O
and	VICTRELIS.xml:S1:11702:3	and	CC	O	O
Precautions	VICTRELIS.xml:S1:11706:11	precaut	NNP	O	O
(	VICTRELIS.xml:S1:11718:1	(	(	O	O
5.4	VICTRELIS.xml:S1:11719:3	5.4	CD	O	O
)	VICTRELIS.xml:S1:11722:1	)	)	O	O
]	VICTRELIS.xml:S1:11725:1	]	NN	O	O

Gastrointestinal	VICTRELIS.xml:S1:11735:16	gastrointestin	JJ	O	O
Disorders	VICTRELIS.xml:S1:11752:9	disord	NNS	O	O
:	VICTRELIS.xml:S1:11761:1	:	:	O	O
mouth	VICTRELIS.xml:S1:11764:5	mouth	NN	B-AdverseReaction	B-AdverseReaction
ulceration	VICTRELIS.xml:S1:11770:10	ulcer	NN	I-AdverseReaction	I-AdverseReaction
,	VICTRELIS.xml:S1:11780:1	,	,	O	O
stomatitis	VICTRELIS.xml:S1:11782:10	stomat	NN	B-AdverseReaction	B-AdverseReaction

Infections	VICTRELIS.xml:S1:11799:10	infect	NNS	O	O
and	VICTRELIS.xml:S1:11810:3	and	CC	O	O
Infestations	VICTRELIS.xml:S1:11814:12	infest	NNS	O	O
:	VICTRELIS.xml:S1:11826:1	:	:	O	O
pneumonia	VICTRELIS.xml:S1:11829:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:11838:1	,	,	O	O
sepsis	VICTRELIS.xml:S1:11840:6	sepsi	NN	B-AdverseReaction	B-AdverseReaction

Skin	VICTRELIS.xml:S1:11853:4	skin	NNP	O	O
and	VICTRELIS.xml:S1:11858:3	and	CC	O	O
Subcutaneous	VICTRELIS.xml:S1:11862:12	subcutan	NNP	O	O
Tissue	VICTRELIS.xml:S1:11875:6	tissu	NNP	O	O
Disorders	VICTRELIS.xml:S1:11882:9	disord	NNP	O	O
:	VICTRELIS.xml:S1:11891:1	:	:	O	O
angioedema	VICTRELIS.xml:S1:11894:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S1:11904:1	,	,	O	O
urticaria	VICTRELIS.xml:S1:11906:9	urticaria	JJ	B-AdverseReaction	B-AdverseReaction
[	VICTRELIS.xml:S1:11917:1	[	NNP	O	O
see	VICTRELIS.xml:S1:11918:3	see	VBP	O	O
Warnings	VICTRELIS.xml:S1:11923:8	warn	NNP	O	O
and	VICTRELIS.xml:S1:11932:3	and	CC	O	O
Precautions	VICTRELIS.xml:S1:11936:11	precaut	NNP	O	O
(	VICTRELIS.xml:S1:11948:1	(	(	O	O
5.5	VICTRELIS.xml:S1:11949:3	5.5	CD	O	O
)	VICTRELIS.xml:S1:11952:1	)	)	O	O
]	VICTRELIS.xml:S1:11955:1	]	NN	O	O
;	VICTRELIS.xml:S1:11958:1	;	:	O	O
drug	VICTRELIS.xml:S1:11960:4	drug	NN	B-AdverseReaction	B-AdverseReaction
rash	VICTRELIS.xml:S1:11965:4	rash	NN	I-AdverseReaction	I-AdverseReaction
with	VICTRELIS.xml:S1:11970:4	with	IN	I-AdverseReaction	I-AdverseReaction
eosinophilia	VICTRELIS.xml:S1:11975:12	eosinophilia	NNS	I-AdverseReaction	I-AdverseReaction
and	VICTRELIS.xml:S1:11988:3	and	CC	I-AdverseReaction	I-AdverseReaction
systemic	VICTRELIS.xml:S1:11992:8	system	JJ	I-AdverseReaction	I-AdverseReaction
symptoms	VICTRELIS.xml:S1:12001:8	symptom	NNS	I-AdverseReaction	I-AdverseReaction
(	VICTRELIS.xml:S1:12010:1	(	(	O	O
DRESS	VICTRELIS.xml:S1:12011:5	dress	NNP	B-AdverseReaction	B-AdverseReaction
)	VICTRELIS.xml:S1:12016:1	)	)	O	O
syndrome	VICTRELIS.xml:S1:12018:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	VICTRELIS.xml:S1:12026:1	,	,	O	O
exfoliative	VICTRELIS.xml:S1:12028:11	exfoli	JJ	B-AdverseReaction	B-AdverseReaction
rash	VICTRELIS.xml:S1:12040:4	rash	NN	I-AdverseReaction	I-AdverseReaction
,	VICTRELIS.xml:S1:12044:1	,	,	O	O
exfoliative	VICTRELIS.xml:S1:12046:11	exfoli	JJ	B-AdverseReaction	B-AdverseReaction
dermatitis	VICTRELIS.xml:S1:12058:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
,	VICTRELIS.xml:S1:12068:1	,	,	O	O
Stevens	VICTRELIS.xml:S1:12070:7	steven	NNP	B-AdverseReaction	B-AdverseReaction
-	VICTRELIS.xml:S1:12077:1	-	:	I-AdverseReaction	I-AdverseReaction
Johnson	VICTRELIS.xml:S1:12078:7	johnson	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	VICTRELIS.xml:S1:12086:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	VICTRELIS.xml:S1:12094:1	,	,	O	O
toxic	VICTRELIS.xml:S1:12096:5	toxic	JJ	B-AdverseReaction	B-AdverseReaction
skin	VICTRELIS.xml:S1:12102:4	skin	NN	I-AdverseReaction	I-AdverseReaction
eruption	VICTRELIS.xml:S1:12107:8	erupt	NN	I-AdverseReaction	I-AdverseReaction
,	VICTRELIS.xml:S1:12115:1	,	,	O	O
toxicoderma	VICTRELIS.xml:S1:12117:11	toxicoderma	VBD	B-AdverseReaction	O
5	VICTRELIS.xml:S2:4:1	5	CD	O	O
WARNINGS	VICTRELIS.xml:S2:6:8	warn	NNP	O	O
AND	VICTRELIS.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	VICTRELIS.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	VICTRELIS.xml:S2:36:7	excerpt	NN	O	O
:	VICTRELIS.xml:S2:43:1	:	:	O	O
Use	VICTRELIS.xml:S2:48:3	use	NN	O	O
of	VICTRELIS.xml:S2:52:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:55:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:65:4	with	IN	O	O
Ribavirin	VICTRELIS.xml:S2:70:9	ribavirin	NNP	O	O
and	VICTRELIS.xml:S2:80:3	and	CC	O	O
Peginterferon	VICTRELIS.xml:S2:84:13	peginterferon	NNP	O	O
alfa	VICTRELIS.xml:S2:98:4	alfa	NN	O	O
:	VICTRELIS.xml:S2:102:1	:	:	O	O

Embryofetal	VICTRELIS.xml:S2:114:11	embryofet	JJ	B-AdverseReaction	B-AdverseReaction
Toxicity	VICTRELIS.xml:S2:126:8	toxic	NNP	I-AdverseReaction	I-AdverseReaction
(	VICTRELIS.xml:S2:135:1	(	(	O	O
Use	VICTRELIS.xml:S2:136:3	use	NNP	O	O
with	VICTRELIS.xml:S2:140:4	with	IN	O	O
Ribavirin	VICTRELIS.xml:S2:145:9	ribavirin	NNP	O	O
and	VICTRELIS.xml:S2:155:3	and	CC	O	O
Peginterferon	VICTRELIS.xml:S2:159:13	peginterferon	NNP	O	O
Alfa	VICTRELIS.xml:S2:173:4	alfa	NNP	O	O
)	VICTRELIS.xml:S2:177:1	)	)	O	O
:	VICTRELIS.xml:S2:178:1	:	:	O	O
Ribavirin	VICTRELIS.xml:S2:180:9	ribavirin	NN	O	O
may	VICTRELIS.xml:S2:190:3	may	MD	O	O
cause	VICTRELIS.xml:S2:194:5	caus	VB	O	O
birth	VICTRELIS.xml:S2:200:5	birth	NN	B-AdverseReaction	B-AdverseReaction
defects	VICTRELIS.xml:S2:206:7	defect	NNS	I-AdverseReaction	I-AdverseReaction
and	VICTRELIS.xml:S2:214:3	and	CC	O	O
fetal	VICTRELIS.xml:S2:218:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
death	VICTRELIS.xml:S2:224:5	death	NN	I-AdverseReaction	I-AdverseReaction
;	VICTRELIS.xml:S2:229:1	;	:	O	O
avoid	VICTRELIS.xml:S2:231:5	avoid	JJ	O	O
pregnancy	VICTRELIS.xml:S2:237:9	pregnanc	NN	O	O
in	VICTRELIS.xml:S2:247:2	in	IN	O	O
female	VICTRELIS.xml:S2:250:6	femal	JJ	O	O
patients	VICTRELIS.xml:S2:257:8	patient	NNS	O	O
and	VICTRELIS.xml:S2:266:3	and	CC	O	O
female	VICTRELIS.xml:S2:270:6	femal	JJ	O	O
partners	VICTRELIS.xml:S2:277:8	partner	NNS	O	O
of	VICTRELIS.xml:S2:286:2	of	IN	O	O
male	VICTRELIS.xml:S2:289:4	male	JJ	O	O
patients	VICTRELIS.xml:S2:294:8	patient	NNS	O	O
.	VICTRELIS.xml:S2:302:1	.	.	O	O

Patients	VICTRELIS.xml:S2:304:8	patient	NNS	O	O
must	VICTRELIS.xml:S2:313:4	must	MD	O	O
have	VICTRELIS.xml:S2:318:4	have	VB	O	O
a	VICTRELIS.xml:S2:323:1	a	DT	O	O
negative	VICTRELIS.xml:S2:325:8	neg	JJ	O	O
pregnancy	VICTRELIS.xml:S2:334:9	pregnanc	NN	O	O
test	VICTRELIS.xml:S2:344:4	test	NN	O	O
prior	VICTRELIS.xml:S2:349:5	prior	RB	O	O
to	VICTRELIS.xml:S2:355:2	to	TO	O	O
therapy	VICTRELIS.xml:S2:358:7	therapi	NN	O	O
;	VICTRELIS.xml:S2:365:1	;	:	O	O
use	VICTRELIS.xml:S2:367:3	use	VB	O	O
two	VICTRELIS.xml:S2:371:3	two	CD	O	O
or	VICTRELIS.xml:S2:375:2	or	CC	O	O
more	VICTRELIS.xml:S2:378:4	more	JJR	O	O
forms	VICTRELIS.xml:S2:383:5	form	NNS	O	O
of	VICTRELIS.xml:S2:389:2	of	IN	O	O
contraception	VICTRELIS.xml:S2:392:13	contracept	NN	O	O
,	VICTRELIS.xml:S2:405:1	,	,	O	O
and	VICTRELIS.xml:S2:407:3	and	CC	O	O
have	VICTRELIS.xml:S2:411:4	have	VBP	O	O
monthly	VICTRELIS.xml:S2:416:7	monthli	JJ	O	O
pregnancy	VICTRELIS.xml:S2:424:9	pregnanc	NN	O	O
tests	VICTRELIS.xml:S2:434:5	test	NNS	O	O
.	VICTRELIS.xml:S2:439:1	.	.	O	O

(	VICTRELIS.xml:S2:441:1	(	(	O	O
5.1	VICTRELIS.xml:S2:444:3	5.1	CD	O	O
)	VICTRELIS.xml:S2:449:1	)	)	O	O

Anemia	VICTRELIS.xml:S2:456:6	anemia	NNP	B-AdverseReaction	O
-	VICTRELIS.xml:S2:463:1	-	:	O	O
The	VICTRELIS.xml:S2:465:3	the	DT	O	O
addition	VICTRELIS.xml:S2:469:8	addit	NN	O	O
of	VICTRELIS.xml:S2:478:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:481:9	victr	NNP	O	O
to	VICTRELIS.xml:S2:491:2	to	TO	O	O
peginterferon	VICTRELIS.xml:S2:494:13	peginterferon	VB	O	O
alfa	VICTRELIS.xml:S2:508:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:513:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:517:9	ribavirin	NN	O	O
is	VICTRELIS.xml:S2:527:2	is	VBZ	O	O
associated	VICTRELIS.xml:S2:530:10	associ	VBN	O	O
with	VICTRELIS.xml:S2:541:4	with	IN	O	O
an	VICTRELIS.xml:S2:546:2	an	DT	O	O
additional	VICTRELIS.xml:S2:549:10	addit	JJ	O	O
decrease	VICTRELIS.xml:S2:560:8	decreas	NN	B-AdverseReaction	O
in	VICTRELIS.xml:S2:569:2	in	IN	I-AdverseReaction	O
hemoglobin	VICTRELIS.xml:S2:572:10	hemoglobin	JJ	I-AdverseReaction	O
concentrations	VICTRELIS.xml:S2:583:14	concentr	NNS	I-AdverseReaction	O
compared	VICTRELIS.xml:S2:598:8	compar	VBN	O	O
with	VICTRELIS.xml:S2:607:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S2:612:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:626:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:631:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:635:9	ribavirin	VB	O	O
alone	VICTRELIS.xml:S2:645:5	alon	RB	O	O
.	VICTRELIS.xml:S2:650:1	.	.	O	O

(	VICTRELIS.xml:S2:652:1	(	(	O	O
5.2	VICTRELIS.xml:S2:655:3	5.2	CD	O	O
)	VICTRELIS.xml:S2:660:1	)	)	O	O

Neutropenia	VICTRELIS.xml:S2:667:11	neutropenia	NNP	B-AdverseReaction	O
-	VICTRELIS.xml:S2:679:1	-	:	O	O
The	VICTRELIS.xml:S2:681:3	the	DT	O	O
addition	VICTRELIS.xml:S2:685:8	addit	NN	O	O
of	VICTRELIS.xml:S2:694:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:697:9	victr	NNP	O	O
to	VICTRELIS.xml:S2:707:2	to	TO	O	O
peginterferon	VICTRELIS.xml:S2:710:13	peginterferon	VB	O	O
alfa	VICTRELIS.xml:S2:724:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:729:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:733:9	ribavirin	NN	O	B-AdverseReaction
may	VICTRELIS.xml:S2:743:3	may	MD	O	O
result	VICTRELIS.xml:S2:747:6	result	VB	O	O
in	VICTRELIS.xml:S2:754:2	in	IN	O	O
worsening	VICTRELIS.xml:S2:757:9	worsen	NN	B-AdverseReaction	B-AdverseReaction
of	VICTRELIS.xml:S2:767:2	of	IN	I-AdverseReaction	I-AdverseReaction
neutropenia	VICTRELIS.xml:S2:770:11	neutropenia	NN	I-AdverseReaction	I-AdverseReaction
associated	VICTRELIS.xml:S2:782:10	associ	VBN	O	O
with	VICTRELIS.xml:S2:793:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S2:798:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:812:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:817:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:821:9	ribavirin	JJ	O	O
therapy	VICTRELIS.xml:S2:831:7	therapi	NN	O	O
alone	VICTRELIS.xml:S2:839:5	alon	RB	O	O
.	VICTRELIS.xml:S2:844:1	.	.	O	O

(	VICTRELIS.xml:S2:846:1	(	(	O	O
5.3	VICTRELIS.xml:S2:849:3	5.3	CD	O	O
)	VICTRELIS.xml:S2:854:1	)	)	O	O

Hypersensitivity	VICTRELIS.xml:S2:861:16	hypersensit	NNP	B-AdverseReaction	O
-	VICTRELIS.xml:S2:878:1	-	:	O	O
Serious	VICTRELIS.xml:S2:880:7	seriou	JJ	O	O
acute	VICTRELIS.xml:S2:888:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
hypersensitivity	VICTRELIS.xml:S2:894:16	hypersensit	NN	I-AdverseReaction	I-AdverseReaction
reactions	VICTRELIS.xml:S2:911:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	VICTRELIS.xml:S2:921:1	(	(	O	O
e	VICTRELIS.xml:S2:922:1	e	NN	O	O
.	VICTRELIS.xml:S2:923:1	.	.	O	O
g	VICTRELIS.xml:S2:924:1	g	NN	O	O
.	VICTRELIS.xml:S2:925:1	.	.	O	O
,	VICTRELIS.xml:S2:926:1	,	,	O	O
urticaria	VICTRELIS.xml:S2:928:9	urticaria	JJ	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S2:937:1	,	,	O	O
angioedema	VICTRELIS.xml:S2:939:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
)	VICTRELIS.xml:S2:949:1	)	)	O	O
have	VICTRELIS.xml:S2:951:4	have	VBP	O	O
been	VICTRELIS.xml:S2:956:4	been	VBN	O	O
observed	VICTRELIS.xml:S2:961:8	observ	VBN	O	O
during	VICTRELIS.xml:S2:970:6	dure	IN	O	O
combination	VICTRELIS.xml:S2:977:11	combin	NN	O	O
therapy	VICTRELIS.xml:S2:989:7	therapi	NN	O	O
with	VICTRELIS.xml:S2:997:4	with	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:1002:9	victr	NNP	O	O
,	VICTRELIS.xml:S2:1011:1	,	,	O	O
peginterferon	VICTRELIS.xml:S2:1013:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:1027:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:1032:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:1036:9	ribavirin	NN	O	O
.	VICTRELIS.xml:S2:1045:1	.	.	O	O

(	VICTRELIS.xml:S2:1047:1	(	(	O	O
5.5	VICTRELIS.xml:S2:1050:3	5.5	CD	O	O
)	VICTRELIS.xml:S2:1055:1	)	)	O	O

5.1	VICTRELIS.xml:S2:1069:3	5.1	CD	O	O

Embryofetal	VICTRELIS.xml:S2:1073:11	embryofet	NN	O	O

Toxicity	VICTRELIS.xml:S2:1085:8	toxic	NNP	O	O
(	VICTRELIS.xml:S2:1094:1	(	(	O	O
Use	VICTRELIS.xml:S2:1095:3	use	NNP	O	O
with	VICTRELIS.xml:S2:1099:4	with	IN	O	O
Ribavirin	VICTRELIS.xml:S2:1104:9	ribavirin	NNP	O	O
and	VICTRELIS.xml:S2:1114:3	and	CC	O	O
Peginterferon	VICTRELIS.xml:S2:1118:13	peginterferon	NNP	O	O
Alfa	VICTRELIS.xml:S2:1132:4	alfa	NNP	O	O
)	VICTRELIS.xml:S2:1136:1	)	)	O	O

Ribavirin	VICTRELIS.xml:S2:1143:9	ribavirin	NNP	O	O
may	VICTRELIS.xml:S2:1153:3	may	MD	O	O
cause	VICTRELIS.xml:S2:1157:5	caus	VB	O	O
birth	VICTRELIS.xml:S2:1163:5	birth	NN	B-AdverseReaction	B-AdverseReaction
defects	VICTRELIS.xml:S2:1169:7	defect	NNS	I-AdverseReaction	I-AdverseReaction
and	VICTRELIS.xml:S2:1177:3	and	CC	O	O
or	VICTRELIS.xml:S2:1181:2	or	CC	O	O
death	VICTRELIS.xml:S2:1184:5	death	NN	B-AdverseReaction	O
of	VICTRELIS.xml:S2:1190:2	of	IN	I-AdverseReaction	O
the	VICTRELIS.xml:S2:1193:3	the	DT	I-AdverseReaction	O
exposed	VICTRELIS.xml:S2:1197:7	expos	JJ	I-AdverseReaction	O
fetus	VICTRELIS.xml:S2:1205:5	fetu	NN	I-AdverseReaction	O
.	VICTRELIS.xml:S2:1210:1	.	.	O	O

Extreme	VICTRELIS.xml:S2:1212:7	extrem	NNP	O	O
care	VICTRELIS.xml:S2:1220:4	care	NN	O	O
must	VICTRELIS.xml:S2:1225:4	must	MD	O	O
be	VICTRELIS.xml:S2:1230:2	be	VB	O	O
taken	VICTRELIS.xml:S2:1233:5	taken	VBN	O	O
to	VICTRELIS.xml:S2:1239:2	to	TO	O	O
avoid	VICTRELIS.xml:S2:1242:5	avoid	VB	O	O
pregnancy	VICTRELIS.xml:S2:1248:9	pregnanc	NN	O	O
in	VICTRELIS.xml:S2:1258:2	in	IN	O	O
female	VICTRELIS.xml:S2:1261:6	femal	JJ	O	O
patients	VICTRELIS.xml:S2:1268:8	patient	NNS	O	O
and	VICTRELIS.xml:S2:1277:3	and	CC	O	O
in	VICTRELIS.xml:S2:1281:2	in	IN	O	O
female	VICTRELIS.xml:S2:1284:6	femal	JJ	O	O
partners	VICTRELIS.xml:S2:1291:8	partner	NNS	O	O
of	VICTRELIS.xml:S2:1300:2	of	IN	O	O
male	VICTRELIS.xml:S2:1303:4	male	JJ	O	O
patients	VICTRELIS.xml:S2:1308:8	patient	NNS	O	O
.	VICTRELIS.xml:S2:1316:1	.	.	O	O

Ribavirin	VICTRELIS.xml:S2:1318:9	ribavirin	NNP	O	O
therapy	VICTRELIS.xml:S2:1328:7	therapi	NN	O	O
should	VICTRELIS.xml:S2:1336:6	should	MD	O	O
not	VICTRELIS.xml:S2:1343:3	not	RB	O	O
be	VICTRELIS.xml:S2:1347:2	be	VB	O	O
started	VICTRELIS.xml:S2:1350:7	start	VBN	O	O
unless	VICTRELIS.xml:S2:1358:6	unless	IN	O	O
a	VICTRELIS.xml:S2:1365:1	a	DT	O	O
report	VICTRELIS.xml:S2:1367:6	report	NN	O	O
of	VICTRELIS.xml:S2:1374:2	of	IN	O	O
a	VICTRELIS.xml:S2:1377:1	a	DT	O	O
negative	VICTRELIS.xml:S2:1379:8	neg	JJ	O	O
pregnancy	VICTRELIS.xml:S2:1388:9	pregnanc	NN	O	O
test	VICTRELIS.xml:S2:1398:4	test	NN	O	O
has	VICTRELIS.xml:S2:1403:3	ha	VBZ	O	O
been	VICTRELIS.xml:S2:1407:4	been	VBN	O	O
obtained	VICTRELIS.xml:S2:1412:8	obtain	VBN	O	O
immediately	VICTRELIS.xml:S2:1421:11	immedi	RB	O	O
prior	VICTRELIS.xml:S2:1433:5	prior	JJ	O	O
to	VICTRELIS.xml:S2:1439:2	to	TO	O	O
initiation	VICTRELIS.xml:S2:1442:10	initi	NN	O	O
of	VICTRELIS.xml:S2:1453:2	of	IN	O	O
therapy	VICTRELIS.xml:S2:1456:7	therapi	NN	O	O
.	VICTRELIS.xml:S2:1463:1	.	.	O	O

Refer	VICTRELIS.xml:S2:1465:5	refer	NN	O	O
to	VICTRELIS.xml:S2:1471:2	to	TO	O	O
the	VICTRELIS.xml:S2:1474:3	the	DT	O	O
prescribing	VICTRELIS.xml:S2:1478:11	prescrib	NN	O	O
information	VICTRELIS.xml:S2:1490:11	inform	NN	O	O
for	VICTRELIS.xml:S2:1502:3	for	IN	O	O
ribavirin	VICTRELIS.xml:S2:1506:9	ribavirin	NN	O	O
for	VICTRELIS.xml:S2:1516:3	for	IN	O	O
additional	VICTRELIS.xml:S2:1520:10	addit	JJ	O	O
information	VICTRELIS.xml:S2:1531:11	inform	NN	O	O
.	VICTRELIS.xml:S2:1542:1	.	.	O	O

Women	VICTRELIS.xml:S2:1548:5	women	NNS	O	O
of	VICTRELIS.xml:S2:1554:2	of	IN	O	O
childbearing	VICTRELIS.xml:S2:1557:12	childbear	VBG	O	O
potential	VICTRELIS.xml:S2:1570:9	potenti	JJ	O	O
and	VICTRELIS.xml:S2:1580:3	and	CC	O	O
men	VICTRELIS.xml:S2:1584:3	men	NNS	O	O
must	VICTRELIS.xml:S2:1588:4	must	MD	O	O
use	VICTRELIS.xml:S2:1593:3	use	VB	O	O
at	VICTRELIS.xml:S2:1597:2	at	IN	O	O
least	VICTRELIS.xml:S2:1600:5	least	JJS	O	O
two	VICTRELIS.xml:S2:1606:3	two	CD	O	O
forms	VICTRELIS.xml:S2:1610:5	form	NNS	O	O
of	VICTRELIS.xml:S2:1616:2	of	IN	O	O
effective	VICTRELIS.xml:S2:1619:9	effect	JJ	O	O
contraception	VICTRELIS.xml:S2:1629:13	contracept	NN	O	O
during	VICTRELIS.xml:S2:1643:6	dure	IN	O	O
treatment	VICTRELIS.xml:S2:1650:9	treatment	NN	O	O
and	VICTRELIS.xml:S2:1660:3	and	CC	O	O
for	VICTRELIS.xml:S2:1664:3	for	IN	O	O
at	VICTRELIS.xml:S2:1668:2	at	IN	O	O
least	VICTRELIS.xml:S2:1671:5	least	JJS	O	O
6	VICTRELIS.xml:S2:1677:1	6	CD	O	O
months	VICTRELIS.xml:S2:1679:6	month	NNS	O	O
after	VICTRELIS.xml:S2:1686:5	after	IN	O	O
treatment	VICTRELIS.xml:S2:1692:9	treatment	NN	O	O
has	VICTRELIS.xml:S2:1702:3	ha	VBZ	O	O
concluded	VICTRELIS.xml:S2:1706:9	conclud	VBN	O	O
.	VICTRELIS.xml:S2:1715:1	.	.	O	O

One	VICTRELIS.xml:S2:1717:3	one	CD	O	O
of	VICTRELIS.xml:S2:1721:2	of	IN	O	O
these	VICTRELIS.xml:S2:1724:5	these	DT	O	O
forms	VICTRELIS.xml:S2:1730:5	form	NNS	O	O
of	VICTRELIS.xml:S2:1736:2	of	IN	O	O
contraception	VICTRELIS.xml:S2:1739:13	contracept	NN	O	O
can	VICTRELIS.xml:S2:1753:3	can	MD	O	O
be	VICTRELIS.xml:S2:1757:2	be	VB	O	O
a	VICTRELIS.xml:S2:1760:1	a	DT	O	O
combined	VICTRELIS.xml:S2:1762:8	combin	JJ	O	O
oral	VICTRELIS.xml:S2:1771:4	oral	JJ	O	O
contraceptive	VICTRELIS.xml:S2:1776:13	contracept	JJ	O	O
product	VICTRELIS.xml:S2:1790:7	product	NN	O	O
containing	VICTRELIS.xml:S2:1798:10	contain	VBG	O	O
at	VICTRELIS.xml:S2:1809:2	at	IN	O	O
least	VICTRELIS.xml:S2:1812:5	least	JJS	O	O
1	VICTRELIS.xml:S2:1818:1	1	CD	O	O
mg	VICTRELIS.xml:S2:1820:2	mg	NN	O	O
of	VICTRELIS.xml:S2:1823:2	of	IN	O	O
norethindrone	VICTRELIS.xml:S2:1826:13	norethindron	NN	O	O
.	VICTRELIS.xml:S2:1839:1	.	.	O	O

Oral	VICTRELIS.xml:S2:1841:4	oral	JJ	O	O
contraceptives	VICTRELIS.xml:S2:1846:14	contracept	NNS	O	O
containing	VICTRELIS.xml:S2:1861:10	contain	VBG	O	O
lower	VICTRELIS.xml:S2:1872:5	lower	JJR	O	O
doses	VICTRELIS.xml:S2:1878:5	dose	NNS	O	O
of	VICTRELIS.xml:S2:1884:2	of	IN	O	O
norethindrone	VICTRELIS.xml:S2:1887:13	norethindron	NN	O	O
and	VICTRELIS.xml:S2:1901:3	and	CC	O	O
other	VICTRELIS.xml:S2:1905:5	other	JJ	O	O
forms	VICTRELIS.xml:S2:1911:5	form	NNS	O	O
of	VICTRELIS.xml:S2:1917:2	of	IN	O	O
hormonal	VICTRELIS.xml:S2:1920:8	hormon	JJ	O	O
contraception	VICTRELIS.xml:S2:1929:13	contracept	NN	O	O
have	VICTRELIS.xml:S2:1943:4	have	VBP	O	O
not	VICTRELIS.xml:S2:1948:3	not	RB	O	O
been	VICTRELIS.xml:S2:1952:4	been	VBN	O	O
studied	VICTRELIS.xml:S2:1957:7	studi	VBN	O	O
or	VICTRELIS.xml:S2:1965:2	or	CC	O	O
are	VICTRELIS.xml:S2:1968:3	are	VBP	O	O
contraindicated	VICTRELIS.xml:S2:1972:15	contraind	VBN	O	O
.	VICTRELIS.xml:S2:1987:1	.	.	O	O

Routine	VICTRELIS.xml:S2:1989:7	routin	NNP	O	O
monthly	VICTRELIS.xml:S2:1997:7	monthli	JJ	O	O
pregnancy	VICTRELIS.xml:S2:2005:9	pregnanc	NN	O	O
tests	VICTRELIS.xml:S2:2015:5	test	NNS	O	O
must	VICTRELIS.xml:S2:2021:4	must	MD	O	O
be	VICTRELIS.xml:S2:2026:2	be	VB	O	O
performed	VICTRELIS.xml:S2:2029:9	perform	VBN	O	O
during	VICTRELIS.xml:S2:2039:6	dure	IN	O	O
this	VICTRELIS.xml:S2:2046:4	thi	DT	O	O
time	VICTRELIS.xml:S2:2051:4	time	NN	O	O
[	VICTRELIS.xml:S2:2056:1	[	VBZ	O	O
see	VICTRELIS.xml:S2:2057:3	see	VBP	O	O
Contraindications	VICTRELIS.xml:S2:2062:17	contraind	NNP	O	O
(	VICTRELIS.xml:S2:2080:1	(	(	O	O
4	VICTRELIS.xml:S2:2081:1	4	CD	O	O
)	VICTRELIS.xml:S2:2082:1	)	)	O	O
and	VICTRELIS.xml:S2:2085:3	and	CC	O	O
Drug	VICTRELIS.xml:S2:2090:4	drug	NNP	O	O
Interactions	VICTRELIS.xml:S2:2095:12	interact	NNP	O	O
(	VICTRELIS.xml:S2:2108:1	(	(	O	O
7	VICTRELIS.xml:S2:2109:1	7	CD	O	O
)	VICTRELIS.xml:S2:2110:1	)	)	O	O
]	VICTRELIS.xml:S2:2113:1	]	NN	O	O
.	VICTRELIS.xml:S2:2116:1	.	.	O	O

5.2	VICTRELIS.xml:S2:2125:3	5.2	CD	O	O
Anemia	VICTRELIS.xml:S2:2129:6	anemia	NNP	O	O
(	VICTRELIS.xml:S2:2136:1	(	(	O	O
Use	VICTRELIS.xml:S2:2137:3	use	NNP	O	O
with	VICTRELIS.xml:S2:2141:4	with	IN	O	O
Ribavirin	VICTRELIS.xml:S2:2146:9	ribavirin	NNP	O	O
and	VICTRELIS.xml:S2:2156:3	and	CC	O	O
Peginterferon	VICTRELIS.xml:S2:2160:13	peginterferon	NNP	O	O
Alfa	VICTRELIS.xml:S2:2174:4	alfa	NNP	O	O
)	VICTRELIS.xml:S2:2178:1	)	)	O	O

Anemia	VICTRELIS.xml:S2:2185:6	anemia	NNP	B-AdverseReaction	B-AdverseReaction
has	VICTRELIS.xml:S2:2192:3	ha	VBZ	O	O
been	VICTRELIS.xml:S2:2196:4	been	VBN	O	O
reported	VICTRELIS.xml:S2:2201:8	report	VBN	O	O
with	VICTRELIS.xml:S2:2210:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S2:2215:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:2229:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:2234:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:2238:9	ribavirin	NN	O	O
therapy	VICTRELIS.xml:S2:2248:7	therapi	NN	O	O
.	VICTRELIS.xml:S2:2255:1	.	.	O	O

The	VICTRELIS.xml:S2:2257:3	the	DT	O	O
addition	VICTRELIS.xml:S2:2261:8	addit	NN	O	O
of	VICTRELIS.xml:S2:2270:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:2273:9	victr	NNP	O	O
to	VICTRELIS.xml:S2:2283:2	to	TO	O	O
peginterferon	VICTRELIS.xml:S2:2286:13	peginterferon	VB	O	O
alfa	VICTRELIS.xml:S2:2300:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:2305:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:2309:9	ribavirin	NN	O	O
is	VICTRELIS.xml:S2:2319:2	is	VBZ	O	O
associated	VICTRELIS.xml:S2:2322:10	associ	VBN	O	O
with	VICTRELIS.xml:S2:2333:4	with	IN	O	O
an	VICTRELIS.xml:S2:2338:2	an	DT	O	O
additional	VICTRELIS.xml:S2:2341:10	addit	JJ	B-AdverseReaction	O
decrease	VICTRELIS.xml:S2:2352:8	decreas	NN	I-AdverseReaction	O
in	VICTRELIS.xml:S2:2361:2	in	IN	I-AdverseReaction	O
hemoglobin	VICTRELIS.xml:S2:2364:10	hemoglobin	JJ	I-AdverseReaction	O
concentrations	VICTRELIS.xml:S2:2375:14	concentr	NNS	I-AdverseReaction	O
.	VICTRELIS.xml:S2:2389:1	.	.	O	O

Complete	VICTRELIS.xml:S2:2391:8	complet	JJ	O	O
blood	VICTRELIS.xml:S2:2400:5	blood	NN	O	O
counts	VICTRELIS.xml:S2:2406:6	count	NNS	O	O
(	VICTRELIS.xml:S2:2413:1	(	(	O	O
with	VICTRELIS.xml:S2:2414:4	with	IN	O	O
white	VICTRELIS.xml:S2:2419:5	white	JJ	O	O
blood	VICTRELIS.xml:S2:2425:5	blood	NN	O	O
cell	VICTRELIS.xml:S2:2431:4	cell	NN	O	O
differential	VICTRELIS.xml:S2:2436:12	differenti	JJ	O	O
counts	VICTRELIS.xml:S2:2449:6	count	NNS	O	O
)	VICTRELIS.xml:S2:2455:1	)	)	O	O
should	VICTRELIS.xml:S2:2457:6	should	MD	O	O
be	VICTRELIS.xml:S2:2464:2	be	VB	O	O
obtained	VICTRELIS.xml:S2:2467:8	obtain	VBN	O	O
pretreatment	VICTRELIS.xml:S2:2476:12	pretreat	NN	O	O
,	VICTRELIS.xml:S2:2488:1	,	,	O	O
and	VICTRELIS.xml:S2:2490:3	and	CC	O	O
at	VICTRELIS.xml:S2:2494:2	at	IN	O	O
Treatment	VICTRELIS.xml:S2:2497:9	treatment	NNP	O	O
Weeks	VICTRELIS.xml:S2:2507:5	week	NNP	O	O
2	VICTRELIS.xml:S2:2513:1	2	CD	O	O
,	VICTRELIS.xml:S2:2514:1	,	,	O	O
4	VICTRELIS.xml:S2:2516:1	4	CD	O	O
,	VICTRELIS.xml:S2:2517:1	,	,	O	O
8	VICTRELIS.xml:S2:2519:1	8	CD	O	O
,	VICTRELIS.xml:S2:2520:1	,	,	O	O
and	VICTRELIS.xml:S2:2522:3	and	CC	O	O
12	VICTRELIS.xml:S2:2526:2	12	CD	O	O
,	VICTRELIS.xml:S2:2528:1	,	,	O	O
and	VICTRELIS.xml:S2:2530:3	and	CC	O	O
should	VICTRELIS.xml:S2:2534:6	should	MD	O	O
be	VICTRELIS.xml:S2:2541:2	be	VB	O	O
monitored	VICTRELIS.xml:S2:2544:9	monitor	VBN	O	O
closely	VICTRELIS.xml:S2:2554:7	close	RB	O	O
at	VICTRELIS.xml:S2:2562:2	at	IN	O	O
other	VICTRELIS.xml:S2:2565:5	other	JJ	O	O
time	VICTRELIS.xml:S2:2571:4	time	NN	O	O
points	VICTRELIS.xml:S2:2576:6	point	NNS	O	O
,	VICTRELIS.xml:S2:2582:1	,	,	O	O
as	VICTRELIS.xml:S2:2584:2	as	IN	O	O
clinically	VICTRELIS.xml:S2:2587:10	clinic	RB	O	O
appropriate	VICTRELIS.xml:S2:2598:11	appropri	JJ	O	O
.	VICTRELIS.xml:S2:2609:1	.	.	O	O

If	VICTRELIS.xml:S2:2611:2	If	IN	O	O
hemoglobin	VICTRELIS.xml:S2:2614:10	hemoglobin	VBN	O	O
is	VICTRELIS.xml:S2:2625:2	is	VBZ	O	O
less	VICTRELIS.xml:S2:2628:4	less	JJR	O	O
than	VICTRELIS.xml:S2:2633:4	than	IN	O	O
10	VICTRELIS.xml:S2:2638:2	10	CD	O	O
g	VICTRELIS.xml:S2:2641:1	g	JJ	O	O
per	VICTRELIS.xml:S2:2643:3	per	IN	O	O
dL	VICTRELIS.xml:S2:2647:2	dL	NN	O	O
,	VICTRELIS.xml:S2:2649:1	,	,	O	O
a	VICTRELIS.xml:S2:2651:1	a	DT	O	O
decrease	VICTRELIS.xml:S2:2653:8	decreas	NN	O	O
in	VICTRELIS.xml:S2:2662:2	in	IN	O	O
dosage	VICTRELIS.xml:S2:2665:6	dosag	NN	O	O
of	VICTRELIS.xml:S2:2672:2	of	IN	O	O
ribavirin	VICTRELIS.xml:S2:2675:9	ribavirin	NN	O	O
is	VICTRELIS.xml:S2:2685:2	is	VBZ	O	O
recommended	VICTRELIS.xml:S2:2688:11	recommend	VBN	O	O
;	VICTRELIS.xml:S2:2699:1	;	:	O	O
and	VICTRELIS.xml:S2:2701:3	and	CC	O	O
if	VICTRELIS.xml:S2:2705:2	if	IN	O	O
hemoglobin	VICTRELIS.xml:S2:2708:10	hemoglobin	VBN	O	O
is	VICTRELIS.xml:S2:2719:2	is	VBZ	O	O
less	VICTRELIS.xml:S2:2722:4	less	JJR	O	O
than	VICTRELIS.xml:S2:2727:4	than	IN	O	O
8.5	VICTRELIS.xml:S2:2732:3	8.5	CD	O	O
g	VICTRELIS.xml:S2:2736:1	g	JJ	O	O
per	VICTRELIS.xml:S2:2738:3	per	IN	O	O
dL	VICTRELIS.xml:S2:2742:2	dL	NN	O	O
,	VICTRELIS.xml:S2:2744:1	,	,	O	O
discontinuation	VICTRELIS.xml:S2:2746:15	discontinu	NN	O	O
of	VICTRELIS.xml:S2:2762:2	of	IN	O	O
ribavirin	VICTRELIS.xml:S2:2765:9	ribavirin	NN	O	O
is	VICTRELIS.xml:S2:2775:2	is	VBZ	O	O
recommended	VICTRELIS.xml:S2:2778:11	recommend	VBN	O	O
[	VICTRELIS.xml:S2:2790:1	[	JJ	O	O
see	VICTRELIS.xml:S2:2791:3	see	VBP	O	O
Adverse	VICTRELIS.xml:S2:2796:7	advers	JJ	O	O
Reactions	VICTRELIS.xml:S2:2804:9	reaction	NNP	O	O
(	VICTRELIS.xml:S2:2814:1	(	(	O	O
6.1	VICTRELIS.xml:S2:2815:3	6.1	CD	O	O
)	VICTRELIS.xml:S2:2818:1	)	)	O	O
and	VICTRELIS.xml:S2:2821:3	and	CC	O	O
Clinical	VICTRELIS.xml:S2:2826:8	clinic	JJ	O	O
Studies	VICTRELIS.xml:S2:2835:7	studi	NNP	O	O
(	VICTRELIS.xml:S2:2843:1	(	(	O	O
14	VICTRELIS.xml:S2:2844:2	14	CD	O	O
)	VICTRELIS.xml:S2:2846:1	)	)	O	O
]	VICTRELIS.xml:S2:2849:1	]	NN	O	O
.	VICTRELIS.xml:S2:2852:1	.	.	O	O

If	VICTRELIS.xml:S2:2854:2	If	IN	O	O
ribavirin	VICTRELIS.xml:S2:2857:9	ribavirin	VBN	O	O
is	VICTRELIS.xml:S2:2867:2	is	VBZ	O	O
permanently	VICTRELIS.xml:S2:2870:11	perman	RB	O	O
discontinued	VICTRELIS.xml:S2:2882:12	discontinu	VBN	O	O
for	VICTRELIS.xml:S2:2895:3	for	IN	O	O
management	VICTRELIS.xml:S2:2899:10	manag	NN	O	O
of	VICTRELIS.xml:S2:2910:2	of	IN	O	O
anemia	VICTRELIS.xml:S2:2913:6	anemia	NN	O	B-AdverseReaction
,	VICTRELIS.xml:S2:2919:1	,	,	O	O
then	VICTRELIS.xml:S2:2921:4	then	RB	O	O
peginterferon	VICTRELIS.xml:S2:2926:13	peginterferon	VB	O	O
alfa	VICTRELIS.xml:S2:2940:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:2945:3	and	CC	O	O
VICTRELIS	VICTRELIS.xml:S2:2949:9	victr	NNP	O	O
must	VICTRELIS.xml:S2:2959:4	must	MD	O	O
also	VICTRELIS.xml:S2:2964:4	also	RB	O	O
be	VICTRELIS.xml:S2:2969:2	be	VB	O	O
discontinued	VICTRELIS.xml:S2:2972:12	discontinu	VBN	O	O
[	VICTRELIS.xml:S2:2985:1	[	NNP	O	O
see	VICTRELIS.xml:S2:2986:3	see	VBP	O	O
Dosage	VICTRELIS.xml:S2:2991:6	dosag	NNP	O	O
and	VICTRELIS.xml:S2:2998:3	and	CC	O	O
Administration	VICTRELIS.xml:S2:3002:14	administr	NNP	O	O
(	VICTRELIS.xml:S2:3017:1	(	(	O	O
2.3	VICTRELIS.xml:S2:3018:3	2.3	CD	O	O
)	VICTRELIS.xml:S2:3021:1	)	)	O	O
]	VICTRELIS.xml:S2:3024:1	]	NN	O	O
.	VICTRELIS.xml:S2:3027:1	.	.	O	O

Refer	VICTRELIS.xml:S2:3033:5	refer	NN	O	O
to	VICTRELIS.xml:S2:3039:2	to	TO	O	O
the	VICTRELIS.xml:S2:3042:3	the	DT	O	O
prescribing	VICTRELIS.xml:S2:3046:11	prescrib	NN	O	O
information	VICTRELIS.xml:S2:3058:11	inform	NN	O	O
for	VICTRELIS.xml:S2:3070:3	for	IN	O	O
ribavirin	VICTRELIS.xml:S2:3074:9	ribavirin	NN	O	O
for	VICTRELIS.xml:S2:3084:3	for	IN	O	O
additional	VICTRELIS.xml:S2:3088:10	addit	JJ	O	O
information	VICTRELIS.xml:S2:3099:11	inform	NN	O	O
regarding	VICTRELIS.xml:S2:3111:9	regard	VBG	O	O
dose	VICTRELIS.xml:S2:3121:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:3126:9	reduct	NN	O	O
and	VICTRELIS.xml:S2:3136:3	and	CC	O	O
or	VICTRELIS.xml:S2:3140:2	or	CC	O	O
discontinuation	VICTRELIS.xml:S2:3143:15	discontinu	NN	O	O
.	VICTRELIS.xml:S2:3158:1	.	.	O	O

In	VICTRELIS.xml:S2:3164:2	In	IN	O	O
clinical	VICTRELIS.xml:S2:3167:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S2:3176:6	trial	NNS	O	O
with	VICTRELIS.xml:S2:3183:4	with	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:3188:9	victr	NNP	O	O
,	VICTRELIS.xml:S2:3197:1	,	,	O	O
the	VICTRELIS.xml:S2:3199:3	the	DT	O	O
proportion	VICTRELIS.xml:S2:3203:10	proport	NN	O	O
of	VICTRELIS.xml:S2:3214:2	of	IN	O	O
subjects	VICTRELIS.xml:S2:3217:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:3226:3	who	WP	O	O
experienced	VICTRELIS.xml:S2:3230:11	experienc	VBD	O	O
hemoglobin	VICTRELIS.xml:S2:3242:10	hemoglobin	NN	B-AdverseReaction	B-AdverseReaction
values	VICTRELIS.xml:S2:3253:6	valu	NNS	I-AdverseReaction	I-AdverseReaction
less	VICTRELIS.xml:S2:3260:4	less	RBR	I-AdverseReaction	I-AdverseReaction
than	VICTRELIS.xml:S2:3265:4	than	IN	I-AdverseReaction	O
10	VICTRELIS.xml:S2:3270:2	10	CD	I-AdverseReaction	O
g	VICTRELIS.xml:S2:3273:1	g	JJ	I-AdverseReaction	O
per	VICTRELIS.xml:S2:3275:3	per	IN	I-AdverseReaction	O
dL	VICTRELIS.xml:S2:3279:2	dL	NN	I-AdverseReaction	O
and	VICTRELIS.xml:S2:3282:3	and	CC	O	O
less	VICTRELIS.xml:S2:3286:4	less	JJR	I-AdverseReaction	O
than	VICTRELIS.xml:S2:3291:4	than	IN	I-AdverseReaction	O
8.5	VICTRELIS.xml:S2:3296:3	8.5	CD	I-AdverseReaction	O
g	VICTRELIS.xml:S2:3300:1	g	JJ	I-AdverseReaction	O
per	VICTRELIS.xml:S2:3302:3	per	IN	I-AdverseReaction	O
dL	VICTRELIS.xml:S2:3306:2	dL	NN	I-AdverseReaction	O
was	VICTRELIS.xml:S2:3309:3	wa	VBD	O	O
higher	VICTRELIS.xml:S2:3313:6	higher	RBR	O	O
in	VICTRELIS.xml:S2:3320:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:3323:8	subject	NNS	O	O
treated	VICTRELIS.xml:S2:3332:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:3340:4	with	IN	O	O
the	VICTRELIS.xml:S2:3345:3	the	DT	O	O
combination	VICTRELIS.xml:S2:3349:11	combin	NN	O	O
of	VICTRELIS.xml:S2:3361:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:3364:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:3374:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:3379:9	pegintron	NNP	O	O
(	VICTRELIS.xml:S2:3390:1	(	(	O	O
r	VICTRELIS.xml:S2:3391:1	r	NN	O	O
)	VICTRELIS.xml:S2:3392:1	)	)	O	O
REBETOL	VICTRELIS.xml:S2:3396:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S2:3405:1	(	(	O	O
r	VICTRELIS.xml:S2:3406:1	r	NN	O	O
)	VICTRELIS.xml:S2:3407:1	)	)	O	O
than	VICTRELIS.xml:S2:3410:4	than	IN	O	O
in	VICTRELIS.xml:S2:3415:2	in	IN	O	O
those	VICTRELIS.xml:S2:3418:5	those	DT	O	O
treated	VICTRELIS.xml:S2:3424:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:3432:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:3437:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:3447:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S2:3455:5	alon	RB	O	O
(	VICTRELIS.xml:S2:3461:1	(	(	O	O
see	VICTRELIS.xml:S2:3462:3	see	VB	O	O
Table	VICTRELIS.xml:S2:3467:5	tabl	NNP	O	O
4	VICTRELIS.xml:S2:3473:1	4	CD	O	O
)	VICTRELIS.xml:S2:3476:1	)	)	O	O
.	VICTRELIS.xml:S2:3477:1	.	.	O	O

With	VICTRELIS.xml:S2:3479:4	with	IN	O	O
the	VICTRELIS.xml:S2:3484:3	the	DT	O	O
interventions	VICTRELIS.xml:S2:3488:13	intervent	NNS	O	O
used	VICTRELIS.xml:S2:3502:4	use	VBN	O	O
for	VICTRELIS.xml:S2:3507:3	for	IN	O	O
anemia	VICTRELIS.xml:S2:3511:6	anemia	JJ	O	O
management	VICTRELIS.xml:S2:3518:10	manag	NN	O	O
in	VICTRELIS.xml:S2:3529:2	in	IN	O	O
the	VICTRELIS.xml:S2:3532:3	the	DT	O	O
clinical	VICTRELIS.xml:S2:3536:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S2:3545:6	trial	NNS	O	O
,	VICTRELIS.xml:S2:3551:1	,	,	O	O
the	VICTRELIS.xml:S2:3553:3	the	DT	O	O
average	VICTRELIS.xml:S2:3557:7	averag	JJ	O	O
additional	VICTRELIS.xml:S2:3565:10	addit	JJ	O	O
decrease	VICTRELIS.xml:S2:3576:8	decreas	NN	O	B-AdverseReaction
of	VICTRELIS.xml:S2:3585:2	of	IN	O	I-AdverseReaction
hemoglobin	VICTRELIS.xml:S2:3588:10	hemoglobin	NN	O	I-AdverseReaction
was	VICTRELIS.xml:S2:3599:3	wa	VBD	O	O
approximately	VICTRELIS.xml:S2:3603:13	approxim	RB	O	O
1	VICTRELIS.xml:S2:3617:1	1	CD	O	O
g	VICTRELIS.xml:S2:3619:1	g	NNS	O	O
per	VICTRELIS.xml:S2:3621:3	per	IN	O	O
dL	VICTRELIS.xml:S2:3625:2	dL	NN	O	O
.	VICTRELIS.xml:S2:3627:1	.	.	O	O

In	VICTRELIS.xml:S2:3633:2	In	IN	O	O
clinical	VICTRELIS.xml:S2:3636:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S2:3645:6	trial	NNS	O	O
,	VICTRELIS.xml:S2:3651:1	,	,	O	O
the	VICTRELIS.xml:S2:3653:3	the	DT	O	O
median	VICTRELIS.xml:S2:3657:6	median	JJ	O	O
time	VICTRELIS.xml:S2:3664:4	time	NN	O	O
to	VICTRELIS.xml:S2:3669:2	to	TO	O	O
onset	VICTRELIS.xml:S2:3672:5	onset	VB	O	O
of	VICTRELIS.xml:S2:3678:2	of	IN	O	O
hemoglobin	VICTRELIS.xml:S2:3681:10	hemoglobin	NN	B-AdverseReaction	O
less	VICTRELIS.xml:S2:3692:4	less	JJR	I-AdverseReaction	O
than	VICTRELIS.xml:S2:3697:4	than	IN	I-AdverseReaction	O
10	VICTRELIS.xml:S2:3702:2	10	CD	I-AdverseReaction	O
g	VICTRELIS.xml:S2:3705:1	g	JJ	I-AdverseReaction	O
per	VICTRELIS.xml:S2:3707:3	per	IN	I-AdverseReaction	O
dL	VICTRELIS.xml:S2:3711:2	dL	NN	I-AdverseReaction	O
from	VICTRELIS.xml:S2:3714:4	from	IN	O	O
the	VICTRELIS.xml:S2:3719:3	the	DT	O	O
initiation	VICTRELIS.xml:S2:3723:10	initi	NN	O	O
of	VICTRELIS.xml:S2:3734:2	of	IN	O	O
therapy	VICTRELIS.xml:S2:3737:7	therapi	NN	O	O
was	VICTRELIS.xml:S2:3745:3	wa	VBD	O	O
similar	VICTRELIS.xml:S2:3749:7	similar	JJ	O	O
among	VICTRELIS.xml:S2:3757:5	among	IN	O	O
subjects	VICTRELIS.xml:S2:3763:8	subject	NNS	O	O
treated	VICTRELIS.xml:S2:3772:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:3780:4	with	IN	O	O
the	VICTRELIS.xml:S2:3785:3	the	DT	O	O
combination	VICTRELIS.xml:S2:3789:11	combin	NN	O	O
of	VICTRELIS.xml:S2:3801:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:3804:9	victr	NNP	O	O
and	VICTRELIS.xml:S2:3814:3	and	CC	O	O
PegIntron	VICTRELIS.xml:S2:3818:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:3828:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S2:3836:1	(	(	O	O
71	VICTRELIS.xml:S2:3837:2	71	CD	O	O
days	VICTRELIS.xml:S2:3840:4	day	NNS	O	O
with	VICTRELIS.xml:S2:3845:4	with	IN	O	O
a	VICTRELIS.xml:S2:3850:1	a	DT	O	O
range	VICTRELIS.xml:S2:3852:5	rang	NN	O	O
of	VICTRELIS.xml:S2:3858:2	of	IN	O	O
15	VICTRELIS.xml:S2:3861:2	15	CD	O	O
-	VICTRELIS.xml:S2:3863:1	-	:	O	O
337	VICTRELIS.xml:S2:3864:3	337	CD	O	O
days	VICTRELIS.xml:S2:3868:4	day	NNS	O	O
)	VICTRELIS.xml:S2:3872:1	)	)	O	O
,	VICTRELIS.xml:S2:3873:1	,	,	O	O
compared	VICTRELIS.xml:S2:3875:8	compar	VBN	O	O
to	VICTRELIS.xml:S2:3884:2	to	TO	O	O
those	VICTRELIS.xml:S2:3887:5	those	DT	O	O
who	VICTRELIS.xml:S2:3893:3	who	WP	O	O
received	VICTRELIS.xml:S2:3897:8	receiv	VBD	O	O
PegIntron	VICTRELIS.xml:S2:3906:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:3916:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S2:3924:1	(	(	O	O
71	VICTRELIS.xml:S2:3925:2	71	CD	O	O
days	VICTRELIS.xml:S2:3928:4	day	NNS	O	O
with	VICTRELIS.xml:S2:3933:4	with	IN	O	O
a	VICTRELIS.xml:S2:3938:1	a	DT	O	O
range	VICTRELIS.xml:S2:3940:5	rang	NN	O	O
of	VICTRELIS.xml:S2:3946:2	of	IN	O	O
8	VICTRELIS.xml:S2:3949:1	8	CD	O	O
-	VICTRELIS.xml:S2:3950:1	-	:	O	O
337	VICTRELIS.xml:S2:3951:3	337	CD	O	O
days	VICTRELIS.xml:S2:3955:4	day	NNS	O	O
)	VICTRELIS.xml:S2:3959:1	)	)	O	O
.	VICTRELIS.xml:S2:3960:1	.	.	O	O

Certain	VICTRELIS.xml:S2:3962:7	certain	NNP	O	O
adverse	VICTRELIS.xml:S2:3970:7	advers	JJ	O	O
reactions	VICTRELIS.xml:S2:3978:9	reaction	NNS	O	O
consistent	VICTRELIS.xml:S2:3988:10	consist	VBP	O	O
with	VICTRELIS.xml:S2:3999:4	with	IN	O	O
symptoms	VICTRELIS.xml:S2:4004:8	symptom	NNS	O	O
of	VICTRELIS.xml:S2:4013:2	of	IN	O	O
anemia	VICTRELIS.xml:S2:4016:6	anemia	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S2:4022:1	,	,	O	O
such	VICTRELIS.xml:S2:4024:4	such	JJ	O	O
as	VICTRELIS.xml:S2:4029:2	as	IN	O	O
dyspnea	VICTRELIS.xml:S2:4032:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S2:4039:1	,	,	O	O
exertional	VICTRELIS.xml:S2:4041:10	exert	JJ	B-AdverseReaction	B-AdverseReaction
dyspnea	VICTRELIS.xml:S2:4052:7	dyspnea	NN	I-AdverseReaction	I-AdverseReaction
,	VICTRELIS.xml:S2:4059:1	,	,	O	O
dizziness	VICTRELIS.xml:S2:4061:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
and	VICTRELIS.xml:S2:4071:3	and	CC	O	O
syncope	VICTRELIS.xml:S2:4075:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
were	VICTRELIS.xml:S2:4083:4	were	VBD	O	O
reported	VICTRELIS.xml:S2:4088:8	report	VBN	O	O
more	VICTRELIS.xml:S2:4097:4	more	RBR	O	O
frequently	VICTRELIS.xml:S2:4102:10	frequent	RB	O	O
in	VICTRELIS.xml:S2:4113:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:4116:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:4125:3	who	WP	O	O
received	VICTRELIS.xml:S2:4129:8	receiv	VBD	O	O
the	VICTRELIS.xml:S2:4138:3	the	DT	O	O
combination	VICTRELIS.xml:S2:4142:11	combin	NN	O	O
of	VICTRELIS.xml:S2:4154:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:4157:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:4167:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:4172:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:4182:7	rebetol	NNP	O	O
than	VICTRELIS.xml:S2:4190:4	than	IN	O	O
in	VICTRELIS.xml:S2:4195:2	in	IN	O	O
those	VICTRELIS.xml:S2:4198:5	those	DT	O	O
treated	VICTRELIS.xml:S2:4204:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:4212:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:4217:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:4227:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S2:4235:5	alon	RB	O	O
[	VICTRELIS.xml:S2:4241:1	[	VBD	O	O
see	VICTRELIS.xml:S2:4242:3	see	JJ	O	O
Adverse	VICTRELIS.xml:S2:4247:7	advers	JJ	O	O
Reactions	VICTRELIS.xml:S2:4255:9	reaction	NNP	O	O
(	VICTRELIS.xml:S2:4265:1	(	(	O	O
6.1	VICTRELIS.xml:S2:4266:3	6.1	CD	O	O
)	VICTRELIS.xml:S2:4269:1	)	)	O	O
]	VICTRELIS.xml:S2:4272:1	]	NN	O	O
.	VICTRELIS.xml:S2:4273:1	.	.	O	O

In	VICTRELIS.xml:S2:4281:2	In	IN	O	O
clinical	VICTRELIS.xml:S2:4284:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S2:4293:6	trial	NNS	O	O
with	VICTRELIS.xml:S2:4300:4	with	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:4305:9	victr	NNP	O	O
,	VICTRELIS.xml:S2:4314:1	,	,	O	O
dose	VICTRELIS.xml:S2:4316:4	dose	JJ	O	O
modifications	VICTRELIS.xml:S2:4321:13	modif	NNS	O	O
(	VICTRELIS.xml:S2:4335:1	(	(	O	O
generally	VICTRELIS.xml:S2:4336:9	gener	RB	O	O
of	VICTRELIS.xml:S2:4346:2	of	IN	O	O
PegIntron	VICTRELIS.xml:S2:4349:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:4359:7	rebetol	NNP	O	O
)	VICTRELIS.xml:S2:4366:1	)	)	O	O
due	VICTRELIS.xml:S2:4368:3	due	JJ	O	O
to	VICTRELIS.xml:S2:4372:2	to	TO	O	O
anemia	VICTRELIS.xml:S2:4375:6	anemia	VB	B-AdverseReaction	O
occurred	VICTRELIS.xml:S2:4382:8	occur	JJ	O	O
twice	VICTRELIS.xml:S2:4391:5	twice	RB	O	O
as	VICTRELIS.xml:S2:4397:2	as	RB	O	O
often	VICTRELIS.xml:S2:4400:5	often	RB	O	O
in	VICTRELIS.xml:S2:4406:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:4409:8	subject	NNS	O	O
treated	VICTRELIS.xml:S2:4418:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:4426:4	with	IN	O	O
the	VICTRELIS.xml:S2:4431:3	the	DT	O	O
combination	VICTRELIS.xml:S2:4435:11	combin	NN	O	O
of	VICTRELIS.xml:S2:4447:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:4450:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:4460:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:4465:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:4475:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S2:4483:1	(	(	O	O
26%	VICTRELIS.xml:S2:4484:3	26%	CD	O	O
)	VICTRELIS.xml:S2:4487:1	)	)	O	O
compared	VICTRELIS.xml:S2:4489:8	compar	VBN	O	O
to	VICTRELIS.xml:S2:4498:2	to	TO	O	O
PegIntron	VICTRELIS.xml:S2:4501:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:4511:7	rebetol	NNP	O	O
(	VICTRELIS.xml:S2:4519:1	(	(	O	O
13%	VICTRELIS.xml:S2:4520:3	13%	CD	O	O
)	VICTRELIS.xml:S2:4523:1	)	)	O	O
.	VICTRELIS.xml:S2:4524:1	.	.	O	O

The	VICTRELIS.xml:S2:4526:3	the	DT	O	O
proportion	VICTRELIS.xml:S2:4530:10	proport	NN	O	O
of	VICTRELIS.xml:S2:4541:2	of	IN	O	O
subjects	VICTRELIS.xml:S2:4544:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:4553:3	who	WP	O	O
discontinued	VICTRELIS.xml:S2:4557:12	discontinu	VBD	O	O
study	VICTRELIS.xml:S2:4570:5	studi	JJ	O	O
drug	VICTRELIS.xml:S2:4576:4	drug	NN	O	O
due	VICTRELIS.xml:S2:4581:3	due	JJ	O	O
to	VICTRELIS.xml:S2:4585:2	to	TO	O	O
anemia	VICTRELIS.xml:S2:4588:6	anemia	VB	B-AdverseReaction	B-AdverseReaction
was	VICTRELIS.xml:S2:4595:3	wa	VBD	O	O
1%	VICTRELIS.xml:S2:4599:2	1%	CD	O	O
in	VICTRELIS.xml:S2:4602:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:4605:8	subject	NNS	O	O
treated	VICTRELIS.xml:S2:4614:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:4622:4	with	IN	O	O
the	VICTRELIS.xml:S2:4627:3	the	DT	O	O
combination	VICTRELIS.xml:S2:4631:11	combin	NN	O	O
of	VICTRELIS.xml:S2:4643:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:4646:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:4656:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:4661:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:4671:7	rebetol	NNP	O	O
and	VICTRELIS.xml:S2:4679:3	and	CC	O	O
1%	VICTRELIS.xml:S2:4683:2	1%	CD	O	O
in	VICTRELIS.xml:S2:4686:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:4689:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:4698:3	who	WP	O	O
received	VICTRELIS.xml:S2:4702:8	receiv	VBD	O	O
PegIntron	VICTRELIS.xml:S2:4711:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:4721:7	rebetol	NNP	O	O
.	VICTRELIS.xml:S2:4728:1	.	.	O	O

The	VICTRELIS.xml:S2:4730:3	the	DT	O	O
use	VICTRELIS.xml:S2:4734:3	use	NN	O	O
of	VICTRELIS.xml:S2:4738:2	of	IN	O	O
erythropoiesis	VICTRELIS.xml:S2:4741:14	erythropoiesi	NN	O	O
stimulating	VICTRELIS.xml:S2:4756:11	stimul	VBG	O	O
agents	VICTRELIS.xml:S2:4768:6	agent	NNS	O	O
(	VICTRELIS.xml:S2:4775:1	(	(	O	O
ESAs	VICTRELIS.xml:S2:4776:4	esa	NNP	O	O
)	VICTRELIS.xml:S2:4780:1	)	)	O	O
was	VICTRELIS.xml:S2:4782:3	wa	VBD	O	O
permitted	VICTRELIS.xml:S2:4786:9	permit	VBN	O	O
for	VICTRELIS.xml:S2:4796:3	for	IN	O	O
management	VICTRELIS.xml:S2:4800:10	manag	NN	O	O
of	VICTRELIS.xml:S2:4811:2	of	IN	O	O
anemia	VICTRELIS.xml:S2:4814:6	anemia	NN	O	O
,	VICTRELIS.xml:S2:4820:1	,	,	O	O
at	VICTRELIS.xml:S2:4822:2	at	IN	O	O
the	VICTRELIS.xml:S2:4825:3	the	DT	O	O
investigator	VICTRELIS.xml:S2:4829:12	investig	NN	O	O
's	VICTRELIS.xml:S2:4841:2	's	POS	O	O
discretion	VICTRELIS.xml:S2:4844:10	discret	NN	O	O
,	VICTRELIS.xml:S2:4854:1	,	,	O	O
with	VICTRELIS.xml:S2:4856:4	with	IN	O	O
or	VICTRELIS.xml:S2:4861:2	or	CC	O	O
without	VICTRELIS.xml:S2:4864:7	without	IN	O	O
ribavirin	VICTRELIS.xml:S2:4872:9	ribavirin	NNS	O	O
dose	VICTRELIS.xml:S2:4882:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:4887:9	reduct	NN	O	O
in	VICTRELIS.xml:S2:4897:2	in	IN	O	O
the	VICTRELIS.xml:S2:4900:3	the	DT	O	O
Phase	VICTRELIS.xml:S2:4904:5	phase	NNP	O	O
2	VICTRELIS.xml:S2:4910:1	2	CD	O	O
and	VICTRELIS.xml:S2:4912:3	and	CC	O	O
3	VICTRELIS.xml:S2:4916:1	3	CD	O	O
clinical	VICTRELIS.xml:S2:4918:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S2:4927:6	trial	NNS	O	O
.	VICTRELIS.xml:S2:4933:1	.	.	O	O

The	VICTRELIS.xml:S2:4935:3	the	DT	O	O
proportion	VICTRELIS.xml:S2:4939:10	proport	NN	O	O
of	VICTRELIS.xml:S2:4950:2	of	IN	O	O
subjects	VICTRELIS.xml:S2:4953:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:4962:3	who	WP	O	O
received	VICTRELIS.xml:S2:4966:8	receiv	VBD	O	O
an	VICTRELIS.xml:S2:4975:2	an	DT	O	O
ESA	VICTRELIS.xml:S2:4978:3	esa	NNP	O	O
was	VICTRELIS.xml:S2:4982:3	wa	VBD	O	O
43%	VICTRELIS.xml:S2:4986:3	43%	CD	O	O
in	VICTRELIS.xml:S2:4990:2	in	IN	O	O
those	VICTRELIS.xml:S2:4993:5	those	DT	O	O
treated	VICTRELIS.xml:S2:4999:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:5007:4	with	IN	O	O
the	VICTRELIS.xml:S2:5012:3	the	DT	O	O
combination	VICTRELIS.xml:S2:5016:11	combin	NN	O	O
of	VICTRELIS.xml:S2:5028:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:5031:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:5041:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:5046:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:5056:7	rebetol	NNP	O	O
compared	VICTRELIS.xml:S2:5064:8	compar	VBN	O	O
to	VICTRELIS.xml:S2:5073:2	to	TO	O	O
24%	VICTRELIS.xml:S2:5076:3	24%	CD	O	O
in	VICTRELIS.xml:S2:5080:2	in	IN	O	O
those	VICTRELIS.xml:S2:5083:5	those	DT	O	O
treated	VICTRELIS.xml:S2:5089:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:5097:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:5102:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:5112:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S2:5120:5	alon	RB	O	O
.	VICTRELIS.xml:S2:5125:1	.	.	O	O

The	VICTRELIS.xml:S2:5127:3	the	DT	O	O
proportion	VICTRELIS.xml:S2:5131:10	proport	NN	O	O
of	VICTRELIS.xml:S2:5142:2	of	IN	O	O
subjects	VICTRELIS.xml:S2:5145:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:5154:3	who	WP	O	O
received	VICTRELIS.xml:S2:5158:8	receiv	VBD	O	O
a	VICTRELIS.xml:S2:5167:1	a	DT	O	O
transfusion	VICTRELIS.xml:S2:5169:11	transfus	NN	O	O
for	VICTRELIS.xml:S2:5181:3	for	IN	O	O
the	VICTRELIS.xml:S2:5185:3	the	DT	O	O
management	VICTRELIS.xml:S2:5189:10	manag	NN	O	O
of	VICTRELIS.xml:S2:5200:2	of	IN	O	O
anemia	VICTRELIS.xml:S2:5203:6	anemia	NN	O	B-AdverseReaction
was	VICTRELIS.xml:S2:5210:3	wa	VBD	O	O
3%	VICTRELIS.xml:S2:5214:2	3%	CD	O	O
of	VICTRELIS.xml:S2:5217:2	of	IN	O	O
subjects	VICTRELIS.xml:S2:5220:8	subject	NNS	O	O
treated	VICTRELIS.xml:S2:5229:7	treat	VBN	O	O
with	VICTRELIS.xml:S2:5237:4	with	IN	O	O
the	VICTRELIS.xml:S2:5242:3	the	DT	O	O
combination	VICTRELIS.xml:S2:5246:11	combin	NN	O	O
of	VICTRELIS.xml:S2:5258:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:5261:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:5271:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:5276:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:5286:7	rebetol	NNP	O	O
compared	VICTRELIS.xml:S2:5294:8	compar	VBN	O	O
to	VICTRELIS.xml:S2:5303:2	to	TO	O	O
less	VICTRELIS.xml:S2:5306:4	less	JJR	O	O
than	VICTRELIS.xml:S2:5311:4	than	IN	O	O
1%	VICTRELIS.xml:S2:5316:2	1%	CD	O	O
in	VICTRELIS.xml:S2:5319:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:5322:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:5331:3	who	WP	O	O
received	VICTRELIS.xml:S2:5335:8	receiv	VBD	O	O
PegIntron	VICTRELIS.xml:S2:5344:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:5354:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S2:5362:5	alon	RB	O	O
.	VICTRELIS.xml:S2:5367:1	.	.	O	O

Thromboembolic	VICTRELIS.xml:S2:5373:14	thromboembol	JJ	O	B-AdverseReaction
events	VICTRELIS.xml:S2:5388:6	event	NNS	O	I-AdverseReaction
have	VICTRELIS.xml:S2:5395:4	have	VBP	O	O
been	VICTRELIS.xml:S2:5400:4	been	VBN	O	O
associated	VICTRELIS.xml:S2:5405:10	associ	VBN	O	O
with	VICTRELIS.xml:S2:5416:4	with	IN	O	O
ESA	VICTRELIS.xml:S2:5421:3	esa	NNP	O	O
use	VICTRELIS.xml:S2:5425:3	use	NN	O	O
in	VICTRELIS.xml:S2:5429:2	in	IN	O	O
other	VICTRELIS.xml:S2:5432:5	other	JJ	O	O
disease	VICTRELIS.xml:S2:5438:7	diseas	NN	O	O
states	VICTRELIS.xml:S2:5446:6	state	NNS	O	O
;	VICTRELIS.xml:S2:5452:1	;	:	O	O
and	VICTRELIS.xml:S2:5454:3	and	CC	O	O
have	VICTRELIS.xml:S2:5458:4	have	VBP	O	O
also	VICTRELIS.xml:S2:5463:4	also	RB	O	O
been	VICTRELIS.xml:S2:5468:4	been	VBN	O	O
reported	VICTRELIS.xml:S2:5473:8	report	VBN	O	O
with	VICTRELIS.xml:S2:5482:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S2:5487:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:5501:4	alfa	NN	O	O
use	VICTRELIS.xml:S2:5506:3	use	NN	O	O
in	VICTRELIS.xml:S2:5510:2	in	IN	O	O
hepatitis	VICTRELIS.xml:S2:5513:9	hepat	NN	O	O
C	VICTRELIS.xml:S2:5523:1	C	NNP	O	O
patients	VICTRELIS.xml:S2:5525:8	patient	NNS	O	O
.	VICTRELIS.xml:S2:5533:1	.	.	O	O

Thromboembolic	VICTRELIS.xml:S2:5535:14	thromboembol	JJ	B-AdverseReaction	B-AdverseReaction
events	VICTRELIS.xml:S2:5550:6	event	NNS	I-AdverseReaction	I-AdverseReaction
were	VICTRELIS.xml:S2:5557:4	were	VBD	O	O
reported	VICTRELIS.xml:S2:5562:8	report	VBN	O	O
in	VICTRELIS.xml:S2:5571:2	in	IN	O	O
clinical	VICTRELIS.xml:S2:5574:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S2:5583:6	trial	NNS	O	O
with	VICTRELIS.xml:S2:5590:4	with	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:5595:9	victr	NNP	O	O
among	VICTRELIS.xml:S2:5605:5	among	IN	O	O
subjects	VICTRELIS.xml:S2:5611:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S2:5620:9	receiv	VBG	O	O
the	VICTRELIS.xml:S2:5630:3	the	DT	O	O
combination	VICTRELIS.xml:S2:5634:11	combin	NN	O	O
of	VICTRELIS.xml:S2:5646:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:5649:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:5659:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:5664:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:5674:7	rebetol	NNP	O	O
,	VICTRELIS.xml:S2:5681:1	,	,	O	O
and	VICTRELIS.xml:S2:5683:3	and	CC	O	O
among	VICTRELIS.xml:S2:5687:5	among	IN	O	O
those	VICTRELIS.xml:S2:5693:5	those	DT	O	O
receiving	VICTRELIS.xml:S2:5699:9	receiv	VBG	O	O
PegIntron	VICTRELIS.xml:S2:5709:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:5719:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S2:5727:5	alon	RB	O	O
,	VICTRELIS.xml:S2:5732:1	,	,	O	O
regardless	VICTRELIS.xml:S2:5734:10	regardless	RB	O	O
of	VICTRELIS.xml:S2:5745:2	of	IN	O	O
ESA	VICTRELIS.xml:S2:5748:3	esa	NNP	O	O
use	VICTRELIS.xml:S2:5752:3	use	NN	O	O
.	VICTRELIS.xml:S2:5755:1	.	.	O	O

No	VICTRELIS.xml:S2:5757:2	No	DT	O	O
definite	VICTRELIS.xml:S2:5760:8	definit	JJ	O	O
causality	VICTRELIS.xml:S2:5769:9	causal	NN	O	O
assessment	VICTRELIS.xml:S2:5779:10	assess	NN	O	O
or	VICTRELIS.xml:S2:5790:2	or	CC	O	O
benefit	VICTRELIS.xml:S2:5793:7	benefit	NN	O	O
risk	VICTRELIS.xml:S2:5801:4	risk	NN	O	O
assessment	VICTRELIS.xml:S2:5806:10	assess	NN	O	O
could	VICTRELIS.xml:S2:5817:5	could	MD	O	O
be	VICTRELIS.xml:S2:5823:2	be	VB	O	O
made	VICTRELIS.xml:S2:5826:4	made	VBN	O	O
for	VICTRELIS.xml:S2:5831:3	for	IN	O	O
these	VICTRELIS.xml:S2:5835:5	these	DT	O	O
events	VICTRELIS.xml:S2:5841:6	event	NNS	O	O
due	VICTRELIS.xml:S2:5848:3	due	JJ	O	O
to	VICTRELIS.xml:S2:5852:2	to	TO	O	O
the	VICTRELIS.xml:S2:5855:3	the	DT	O	O
presence	VICTRELIS.xml:S2:5859:8	presenc	NN	O	O
of	VICTRELIS.xml:S2:5868:2	of	IN	O	O
confounding	VICTRELIS.xml:S2:5871:11	confound	VBG	O	O
factors	VICTRELIS.xml:S2:5883:7	factor	NNS	O	O
and	VICTRELIS.xml:S2:5891:3	and	CC	O	O
lack	VICTRELIS.xml:S2:5895:4	lack	NN	O	O
of	VICTRELIS.xml:S2:5900:2	of	IN	O	O
randomization	VICTRELIS.xml:S2:5903:13	random	NN	O	O
of	VICTRELIS.xml:S2:5917:2	of	IN	O	O
ESA	VICTRELIS.xml:S2:5920:3	esa	NNP	O	O
use	VICTRELIS.xml:S2:5924:3	use	NN	O	O
.	VICTRELIS.xml:S2:5927:1	.	.	O	O

A	VICTRELIS.xml:S2:5933:1	A	DT	O	O
randomized	VICTRELIS.xml:S2:5935:10	random	VBN	O	O
,	VICTRELIS.xml:S2:5945:1	,	,	O	O
parallel	VICTRELIS.xml:S2:5947:8	parallel	JJ	O	O
-	VICTRELIS.xml:S2:5955:1	-	:	O	O
arm	VICTRELIS.xml:S2:5956:3	arm	NN	O	O
,	VICTRELIS.xml:S2:5959:1	,	,	O	O
open	VICTRELIS.xml:S2:5961:4	open	JJ	O	O
-	VICTRELIS.xml:S2:5965:1	-	:	O	O
label	VICTRELIS.xml:S2:5966:5	label	NN	O	O
clinical	VICTRELIS.xml:S2:5972:8	clinic	JJ	O	O
trial	VICTRELIS.xml:S2:5981:5	trial	NN	O	O
was	VICTRELIS.xml:S2:5987:3	wa	VBD	O	O
conducted	VICTRELIS.xml:S2:5991:9	conduct	VBN	O	O
in	VICTRELIS.xml:S2:6001:2	in	IN	O	O
previously	VICTRELIS.xml:S2:6004:10	previous	RB	O	O
untreated	VICTRELIS.xml:S2:6015:9	untreat	JJ	O	O
CHC	VICTRELIS.xml:S2:6025:3	chc	NNP	O	O
subjects	VICTRELIS.xml:S2:6029:8	subject	NNS	O	O
with	VICTRELIS.xml:S2:6038:4	with	IN	O	O
genotype	VICTRELIS.xml:S2:6043:8	genotyp	JJ	O	O
1	VICTRELIS.xml:S2:6052:1	1	CD	O	O
infection	VICTRELIS.xml:S2:6054:9	infect	NN	O	O
to	VICTRELIS.xml:S2:6064:2	to	TO	O	O
compare	VICTRELIS.xml:S2:6067:7	compar	VB	O	O
use	VICTRELIS.xml:S2:6075:3	use	NN	O	O
of	VICTRELIS.xml:S2:6079:2	of	IN	O	O
an	VICTRELIS.xml:S2:6082:2	an	DT	O	O
ESA	VICTRELIS.xml:S2:6085:3	esa	NNP	O	O
versus	VICTRELIS.xml:S2:6089:6	versu	NN	O	O
ribavirin	VICTRELIS.xml:S2:6096:9	ribavirin	NN	O	O
dose	VICTRELIS.xml:S2:6106:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:6111:9	reduct	NN	O	O
for	VICTRELIS.xml:S2:6121:3	for	IN	O	O
initial	VICTRELIS.xml:S2:6125:7	initi	JJ	O	O
management	VICTRELIS.xml:S2:6133:10	manag	NN	O	O
of	VICTRELIS.xml:S2:6144:2	of	IN	O	O
anemia	VICTRELIS.xml:S2:6147:6	anemia	NN	O	O
during	VICTRELIS.xml:S2:6154:6	dure	IN	O	O
therapy	VICTRELIS.xml:S2:6161:7	therapi	NN	O	O
with	VICTRELIS.xml:S2:6169:4	with	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:6174:9	victr	NNP	O	O
in	VICTRELIS.xml:S2:6184:2	in	IN	O	O
combination	VICTRELIS.xml:S2:6187:11	combin	NN	O	O
with	VICTRELIS.xml:S2:6199:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S2:6204:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:6218:4	alfa	NN	O	O
-	VICTRELIS.xml:S2:6222:1	-	:	O	O
2	VICTRELIS.xml:S2:6223:1	2	CD	O	O
b	VICTRELIS.xml:S2:6224:1	b	NN	O	O
and	VICTRELIS.xml:S2:6226:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:6230:9	ribavirin	NN	O	O
.	VICTRELIS.xml:S2:6239:1	.	.	O	O

Similar	VICTRELIS.xml:S2:6241:7	similar	JJ	O	O
SVR	VICTRELIS.xml:S2:6249:3	svr	NNP	O	O
rates	VICTRELIS.xml:S2:6253:5	rate	NNS	O	O
were	VICTRELIS.xml:S2:6259:4	were	VBD	O	O
reported	VICTRELIS.xml:S2:6264:8	report	VBN	O	O
in	VICTRELIS.xml:S2:6273:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:6276:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:6285:3	who	WP	O	O
were	VICTRELIS.xml:S2:6289:4	were	VBD	O	O
randomized	VICTRELIS.xml:S2:6294:10	random	VBN	O	O
to	VICTRELIS.xml:S2:6305:2	to	TO	O	O
receive	VICTRELIS.xml:S2:6308:7	receiv	VB	O	O
ribavirin	VICTRELIS.xml:S2:6316:9	ribavirin	NN	O	O
dose	VICTRELIS.xml:S2:6326:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:6331:9	reduct	NN	O	O
compared	VICTRELIS.xml:S2:6341:8	compar	VBN	O	O
to	VICTRELIS.xml:S2:6350:2	to	TO	O	O
subjects	VICTRELIS.xml:S2:6353:8	subject	NNS	O	O
who	VICTRELIS.xml:S2:6362:3	who	WP	O	O
were	VICTRELIS.xml:S2:6366:4	were	VBD	O	O
randomized	VICTRELIS.xml:S2:6371:10	random	VBN	O	O
to	VICTRELIS.xml:S2:6382:2	to	TO	O	O
receive	VICTRELIS.xml:S2:6385:7	receiv	VB	O	O
an	VICTRELIS.xml:S2:6393:2	an	DT	O	O
ESA	VICTRELIS.xml:S2:6396:3	esa	NNP	O	O
.	VICTRELIS.xml:S2:6399:1	.	.	O	O

In	VICTRELIS.xml:S2:6401:2	In	IN	O	O
this	VICTRELIS.xml:S2:6404:4	thi	DT	O	O
trial	VICTRELIS.xml:S2:6409:5	trial	NN	O	O
,	VICTRELIS.xml:S2:6414:1	,	,	O	O
use	VICTRELIS.xml:S2:6416:3	use	NN	O	O
of	VICTRELIS.xml:S2:6420:2	of	IN	O	O
ESAs	VICTRELIS.xml:S2:6423:4	esa	NNP	O	O
was	VICTRELIS.xml:S2:6428:3	wa	VBD	O	O
associated	VICTRELIS.xml:S2:6432:10	associ	VBN	O	O
with	VICTRELIS.xml:S2:6443:4	with	IN	O	O
an	VICTRELIS.xml:S2:6448:2	an	DT	O	O
increased	VICTRELIS.xml:S2:6451:9	increas	VBN	O	O
risk	VICTRELIS.xml:S2:6461:4	risk	NN	O	O
of	VICTRELIS.xml:S2:6466:2	of	IN	O	O
thromboembolic	VICTRELIS.xml:S2:6469:14	thromboembol	JJ	O	B-AdverseReaction
events	VICTRELIS.xml:S2:6484:6	event	NNS	O	I-AdverseReaction
including	VICTRELIS.xml:S2:6491:9	includ	VBG	O	O
pulmonary	VICTRELIS.xml:S2:6501:9	pulmonari	JJ	O	B-AdverseReaction
embolism	VICTRELIS.xml:S2:6511:8	embol	NN	O	I-AdverseReaction
,	VICTRELIS.xml:S2:6519:1	,	,	O	O
acute	VICTRELIS.xml:S2:6521:5	acut	JJ	O	B-AdverseReaction
myocardial	VICTRELIS.xml:S2:6527:10	myocardi	JJ	O	I-AdverseReaction
infarction	VICTRELIS.xml:S2:6538:10	infarct	NN	O	I-AdverseReaction
,	VICTRELIS.xml:S2:6548:1	,	,	O	O
cerebrovascular	VICTRELIS.xml:S2:6550:15	cerebrovascular	JJ	O	B-AdverseReaction
accident	VICTRELIS.xml:S2:6566:8	accid	NN	O	I-AdverseReaction
,	VICTRELIS.xml:S2:6574:1	,	,	O	O
and	VICTRELIS.xml:S2:6576:3	and	CC	O	O
deep	VICTRELIS.xml:S2:6580:4	deep	JJ	O	B-AdverseReaction
vein	VICTRELIS.xml:S2:6585:4	vein	NN	O	I-AdverseReaction
thrombosis	VICTRELIS.xml:S2:6590:10	thrombosi	NN	O	I-AdverseReaction
compared	VICTRELIS.xml:S2:6601:8	compar	VBN	O	O
to	VICTRELIS.xml:S2:6610:2	to	TO	O	O
ribavirin	VICTRELIS.xml:S2:6613:9	ribavirin	VB	O	O
dose	VICTRELIS.xml:S2:6623:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:6628:9	reduct	NN	O	O
alone	VICTRELIS.xml:S2:6638:5	alon	RB	O	O
.	VICTRELIS.xml:S2:6643:1	.	.	O	O

The	VICTRELIS.xml:S2:6645:3	the	DT	O	O
treatment	VICTRELIS.xml:S2:6649:9	treatment	NN	O	O
discontinuation	VICTRELIS.xml:S2:6659:15	discontinu	NN	O	O
rate	VICTRELIS.xml:S2:6675:4	rate	NN	O	O
due	VICTRELIS.xml:S2:6680:3	due	JJ	O	O
to	VICTRELIS.xml:S2:6684:2	to	TO	O	O
anemia	VICTRELIS.xml:S2:6687:6	anemia	VB	B-AdverseReaction	B-AdverseReaction
was	VICTRELIS.xml:S2:6694:3	wa	VBD	O	O
similar	VICTRELIS.xml:S2:6698:7	similar	JJ	O	O
in	VICTRELIS.xml:S2:6706:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:6709:8	subject	NNS	O	O
randomized	VICTRELIS.xml:S2:6718:10	random	VBN	O	O
to	VICTRELIS.xml:S2:6729:2	to	TO	O	O
receive	VICTRELIS.xml:S2:6732:7	receiv	VB	O	O
ribavirin	VICTRELIS.xml:S2:6740:9	ribavirin	NN	O	O
dose	VICTRELIS.xml:S2:6750:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:6755:9	reduct	NN	O	O
compared	VICTRELIS.xml:S2:6765:8	compar	VBN	O	O
to	VICTRELIS.xml:S2:6774:2	to	TO	O	O
subjects	VICTRELIS.xml:S2:6777:8	subject	NNS	O	O
randomized	VICTRELIS.xml:S2:6786:10	random	VBN	O	O
to	VICTRELIS.xml:S2:6797:2	to	TO	O	O
receive	VICTRELIS.xml:S2:6800:7	receiv	VB	O	O
ESA	VICTRELIS.xml:S2:6808:3	esa	NNP	O	O
(	VICTRELIS.xml:S2:6812:1	(	(	O	O
2%	VICTRELIS.xml:S2:6813:2	2%	CD	O	O
in	VICTRELIS.xml:S2:6816:2	in	IN	O	O
each	VICTRELIS.xml:S2:6819:4	each	DT	O	O
group	VICTRELIS.xml:S2:6824:5	group	NN	O	O
)	VICTRELIS.xml:S2:6829:1	)	)	O	O
.	VICTRELIS.xml:S2:6830:1	.	.	O	O

The	VICTRELIS.xml:S2:6832:3	the	DT	O	O
transfusion	VICTRELIS.xml:S2:6836:11	transfus	NN	O	O
rate	VICTRELIS.xml:S2:6848:4	rate	NN	O	O
was	VICTRELIS.xml:S2:6853:3	wa	VBD	O	O
4%	VICTRELIS.xml:S2:6857:2	4%	CD	O	O
in	VICTRELIS.xml:S2:6860:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:6863:8	subject	NNS	O	O
randomized	VICTRELIS.xml:S2:6872:10	random	VBN	O	O
to	VICTRELIS.xml:S2:6883:2	to	TO	O	O
receive	VICTRELIS.xml:S2:6886:7	receiv	VB	O	O
ribavirin	VICTRELIS.xml:S2:6894:9	ribavirin	NN	O	O
dose	VICTRELIS.xml:S2:6904:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:6909:9	reduct	NN	O	O
and	VICTRELIS.xml:S2:6919:3	and	CC	O	O
2%	VICTRELIS.xml:S2:6923:2	2%	CD	O	O
in	VICTRELIS.xml:S2:6926:2	in	IN	O	O
subjects	VICTRELIS.xml:S2:6929:8	subject	NNS	O	O
randomized	VICTRELIS.xml:S2:6938:10	random	VBN	O	O
to	VICTRELIS.xml:S2:6949:2	to	TO	O	O
receive	VICTRELIS.xml:S2:6952:7	receiv	VB	O	O
ESA	VICTRELIS.xml:S2:6960:3	esa	NNP	O	O
.	VICTRELIS.xml:S2:6963:1	.	.	O	O

Ribavirin	VICTRELIS.xml:S2:6969:9	ribavirin	NNP	O	O
dose	VICTRELIS.xml:S2:6979:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:6984:9	reduct	NN	O	O
is	VICTRELIS.xml:S2:6994:2	is	VBZ	O	O
recommended	VICTRELIS.xml:S2:6997:11	recommend	VBN	O	O
for	VICTRELIS.xml:S2:7009:3	for	IN	O	O
the	VICTRELIS.xml:S2:7013:3	the	DT	O	O
initial	VICTRELIS.xml:S2:7017:7	initi	JJ	O	O
management	VICTRELIS.xml:S2:7025:10	manag	NN	O	O
of	VICTRELIS.xml:S2:7036:2	of	IN	O	O
anemia	VICTRELIS.xml:S2:7039:6	anemia	NN	O	O
.	VICTRELIS.xml:S2:7045:1	.	.	O	O

5.3	VICTRELIS.xml:S2:7054:3	5.3	CD	O	O
Neutropenia	VICTRELIS.xml:S2:7058:11	neutropenia	NNP	O	O
(	VICTRELIS.xml:S2:7070:1	(	(	O	O
Use	VICTRELIS.xml:S2:7071:3	use	NNP	O	O
with	VICTRELIS.xml:S2:7075:4	with	IN	O	O
Ribavirin	VICTRELIS.xml:S2:7080:9	ribavirin	NNP	O	O
and	VICTRELIS.xml:S2:7090:3	and	CC	O	O
Peginterferon	VICTRELIS.xml:S2:7094:13	peginterferon	NNP	O	O
Alfa	VICTRELIS.xml:S2:7108:4	alfa	NNP	O	O
)	VICTRELIS.xml:S2:7112:1	)	)	O	O

In	VICTRELIS.xml:S2:7119:2	In	IN	O	O
Phase	VICTRELIS.xml:S2:7122:5	phase	NNP	O	O
2	VICTRELIS.xml:S2:7128:1	2	CD	O	O
and	VICTRELIS.xml:S2:7130:3	and	CC	O	O
3	VICTRELIS.xml:S2:7134:1	3	CD	O	O
clinical	VICTRELIS.xml:S2:7136:8	clinic	JJ	O	O
trials	VICTRELIS.xml:S2:7145:6	trial	NNS	O	O
,	VICTRELIS.xml:S2:7151:1	,	,	O	O
seven	VICTRELIS.xml:S2:7153:5	seven	CD	O	O
percent	VICTRELIS.xml:S2:7159:7	percent	NN	O	O
of	VICTRELIS.xml:S2:7167:2	of	IN	O	O
subjects	VICTRELIS.xml:S2:7170:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S2:7179:9	receiv	VBG	O	O
the	VICTRELIS.xml:S2:7189:3	the	DT	O	O
combination	VICTRELIS.xml:S2:7193:11	combin	NN	O	O
of	VICTRELIS.xml:S2:7205:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:7208:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:7218:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:7223:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:7233:7	rebetol	NNP	O	O
had	VICTRELIS.xml:S2:7241:3	had	VBD	O	O
neutrophil	VICTRELIS.xml:S2:7245:10	neutrophil	JJ	B-AdverseReaction	O
counts	VICTRELIS.xml:S2:7256:6	count	NNS	I-AdverseReaction	O
of	VICTRELIS.xml:S2:7263:2	of	IN	I-AdverseReaction	O
less	VICTRELIS.xml:S2:7266:4	less	JJR	I-AdverseReaction	O
than	VICTRELIS.xml:S2:7271:4	than	IN	I-AdverseReaction	O
0.5	VICTRELIS.xml:S2:7276:3	0.5	CD	I-AdverseReaction	O
10	VICTRELIS.xml:S2:7282:2	10	CD	I-AdverseReaction	O
9	VICTRELIS.xml:S2:7286:1	9	CD	I-AdverseReaction	O
per	VICTRELIS.xml:S2:7289:3	per	IN	I-AdverseReaction	O
L	VICTRELIS.xml:S2:7293:1	L	NNP	I-AdverseReaction	O
compared	VICTRELIS.xml:S2:7295:8	compar	VBN	O	O
to	VICTRELIS.xml:S2:7304:2	to	TO	O	O
4%	VICTRELIS.xml:S2:7307:2	4%	CD	O	O
of	VICTRELIS.xml:S2:7310:2	of	IN	O	O
subjects	VICTRELIS.xml:S2:7313:8	subject	NNS	O	O
receiving	VICTRELIS.xml:S2:7322:9	receiv	VBG	O	O
PegIntron	VICTRELIS.xml:S2:7332:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:7342:7	rebetol	NNP	O	O
alone	VICTRELIS.xml:S2:7350:5	alon	RB	O	O
(	VICTRELIS.xml:S2:7356:1	(	(	O	O
see	VICTRELIS.xml:S2:7357:3	see	VB	O	O
Table	VICTRELIS.xml:S2:7362:5	tabl	NNP	O	O
4	VICTRELIS.xml:S2:7368:1	4	CD	O	O
)	VICTRELIS.xml:S2:7371:1	)	)	O	O
.	VICTRELIS.xml:S2:7372:1	.	.	O	O

Three	VICTRELIS.xml:S2:7374:5	three	CD	O	O
subjects	VICTRELIS.xml:S2:7380:8	subject	NNS	O	O
experienced	VICTRELIS.xml:S2:7389:11	experienc	VBD	O	O
severe	VICTRELIS.xml:S2:7401:6	sever	JJ	O	O
or	VICTRELIS.xml:S2:7408:2	or	CC	O	O
life	VICTRELIS.xml:S2:7411:4	life	NN	O	O
-	VICTRELIS.xml:S2:7415:1	-	:	O	O
threatening	VICTRELIS.xml:S2:7416:11	threaten	JJ	O	O
infections	VICTRELIS.xml:S2:7428:10	infect	NNS	B-AdverseReaction	O
associated	VICTRELIS.xml:S2:7439:10	associ	VBN	O	O
with	VICTRELIS.xml:S2:7450:4	with	IN	O	O
neutropenia	VICTRELIS.xml:S2:7455:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S2:7466:1	,	,	O	O
and	VICTRELIS.xml:S2:7468:3	and	CC	O	O
two	VICTRELIS.xml:S2:7472:3	two	CD	O	O
subjects	VICTRELIS.xml:S2:7476:8	subject	NNS	O	O
experienced	VICTRELIS.xml:S2:7485:11	experienc	VBD	O	O
life	VICTRELIS.xml:S2:7497:4	life	NN	O	O
-	VICTRELIS.xml:S2:7501:1	-	:	O	O
threatening	VICTRELIS.xml:S2:7502:11	threaten	VBG	O	O
neutropenia	VICTRELIS.xml:S2:7514:11	neutropenia	NN	B-AdverseReaction	O
while	VICTRELIS.xml:S2:7526:5	while	IN	O	O
receiving	VICTRELIS.xml:S2:7532:9	receiv	VBG	O	O
the	VICTRELIS.xml:S2:7542:3	the	DT	O	O
combination	VICTRELIS.xml:S2:7546:11	combin	NN	O	O
of	VICTRELIS.xml:S2:7558:2	of	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:7561:9	victr	NNP	O	O
with	VICTRELIS.xml:S2:7571:4	with	IN	O	O
PegIntron	VICTRELIS.xml:S2:7576:9	pegintron	NNP	O	O
REBETOL	VICTRELIS.xml:S2:7586:7	rebetol	NNP	O	O
.	VICTRELIS.xml:S2:7593:1	.	.	O	O

Complete	VICTRELIS.xml:S2:7595:8	complet	JJ	O	O
blood	VICTRELIS.xml:S2:7604:5	blood	NN	O	O
counts	VICTRELIS.xml:S2:7610:6	count	NNS	O	O
(	VICTRELIS.xml:S2:7617:1	(	(	O	O
with	VICTRELIS.xml:S2:7618:4	with	IN	O	O
white	VICTRELIS.xml:S2:7623:5	white	JJ	O	O
blood	VICTRELIS.xml:S2:7629:5	blood	NN	O	O
cell	VICTRELIS.xml:S2:7635:4	cell	NN	O	O
differential	VICTRELIS.xml:S2:7640:12	differenti	JJ	O	O
counts	VICTRELIS.xml:S2:7653:6	count	NNS	O	O
)	VICTRELIS.xml:S2:7659:1	)	)	O	O
should	VICTRELIS.xml:S2:7661:6	should	MD	O	O
be	VICTRELIS.xml:S2:7668:2	be	VB	O	O
obtained	VICTRELIS.xml:S2:7671:8	obtain	VBN	O	O
at	VICTRELIS.xml:S2:7680:2	at	IN	O	O
pretreatment	VICTRELIS.xml:S2:7683:12	pretreat	NN	O	O
,	VICTRELIS.xml:S2:7695:1	,	,	O	O
and	VICTRELIS.xml:S2:7697:3	and	CC	O	O
at	VICTRELIS.xml:S2:7701:2	at	IN	O	O
Treatment	VICTRELIS.xml:S2:7704:9	treatment	NNP	O	O
Weeks	VICTRELIS.xml:S2:7714:5	week	NNP	O	O
2	VICTRELIS.xml:S2:7720:1	2	CD	O	O
,	VICTRELIS.xml:S2:7721:1	,	,	O	O
4	VICTRELIS.xml:S2:7723:1	4	CD	O	O
,	VICTRELIS.xml:S2:7724:1	,	,	O	O
8	VICTRELIS.xml:S2:7726:1	8	CD	O	O
,	VICTRELIS.xml:S2:7727:1	,	,	O	O
and	VICTRELIS.xml:S2:7729:3	and	CC	O	O
12	VICTRELIS.xml:S2:7733:2	12	CD	O	O
,	VICTRELIS.xml:S2:7735:1	,	,	O	O
and	VICTRELIS.xml:S2:7737:3	and	CC	O	O
should	VICTRELIS.xml:S2:7741:6	should	MD	O	O
be	VICTRELIS.xml:S2:7748:2	be	VB	O	O
monitored	VICTRELIS.xml:S2:7751:9	monitor	VBN	O	O
closely	VICTRELIS.xml:S2:7761:7	close	RB	O	O
at	VICTRELIS.xml:S2:7769:2	at	IN	O	O
other	VICTRELIS.xml:S2:7772:5	other	JJ	O	O
time	VICTRELIS.xml:S2:7778:4	time	NN	O	O
points	VICTRELIS.xml:S2:7783:6	point	NNS	O	O
,	VICTRELIS.xml:S2:7789:1	,	,	O	O
as	VICTRELIS.xml:S2:7791:2	as	IN	O	O
clinically	VICTRELIS.xml:S2:7794:10	clinic	RB	O	O
appropriate	VICTRELIS.xml:S2:7805:11	appropri	JJ	O	O
.	VICTRELIS.xml:S2:7816:1	.	.	O	O

Decreases	VICTRELIS.xml:S2:7818:9	decreas	NNS	O	O
in	VICTRELIS.xml:S2:7828:2	in	IN	O	O
neutrophil	VICTRELIS.xml:S2:7831:10	neutrophil	JJ	O	O
counts	VICTRELIS.xml:S2:7842:6	count	NNS	O	O
may	VICTRELIS.xml:S2:7849:3	may	MD	O	O
require	VICTRELIS.xml:S2:7853:7	requir	VB	O	O
dose	VICTRELIS.xml:S2:7861:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:7866:9	reduct	NN	O	O
or	VICTRELIS.xml:S2:7876:2	or	CC	O	O
discontinuation	VICTRELIS.xml:S2:7879:15	discontinu	NN	O	O
of	VICTRELIS.xml:S2:7895:2	of	IN	O	O
peginterferon	VICTRELIS.xml:S2:7898:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:7912:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:7917:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:7921:9	ribavirin	NN	O	O
.	VICTRELIS.xml:S2:7930:1	.	.	O	O

If	VICTRELIS.xml:S2:7932:2	If	IN	O	O
peginterferon	VICTRELIS.xml:S2:7935:13	peginterferon	VBN	O	O
alfa	VICTRELIS.xml:S2:7949:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:7954:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:7958:9	ribavirin	NN	O	O
are	VICTRELIS.xml:S2:7968:3	are	VBP	O	O
permanently	VICTRELIS.xml:S2:7972:11	perman	RB	O	O
discontinued	VICTRELIS.xml:S2:7984:12	discontinu	VBN	O	O
,	VICTRELIS.xml:S2:7996:1	,	,	O	O
then	VICTRELIS.xml:S2:7998:4	then	RB	O	O
VICTRELIS	VICTRELIS.xml:S2:8003:9	victr	NNP	O	O
must	VICTRELIS.xml:S2:8013:4	must	MD	O	O
also	VICTRELIS.xml:S2:8018:4	also	RB	O	O
be	VICTRELIS.xml:S2:8023:2	be	VB	O	O
discontinued	VICTRELIS.xml:S2:8026:12	discontinu	VBN	O	O
[	VICTRELIS.xml:S2:8039:1	[	NNP	O	O
see	VICTRELIS.xml:S2:8040:3	see	VBP	O	O
Dosage	VICTRELIS.xml:S2:8045:6	dosag	NNP	O	O
and	VICTRELIS.xml:S2:8052:3	and	CC	O	O
Administration	VICTRELIS.xml:S2:8056:14	administr	NNP	O	O
(	VICTRELIS.xml:S2:8071:1	(	(	O	O
2.3	VICTRELIS.xml:S2:8072:3	2.3	CD	O	O
)	VICTRELIS.xml:S2:8075:1	)	)	O	O
]	VICTRELIS.xml:S2:8078:1	]	NN	O	O
.	VICTRELIS.xml:S2:8079:1	.	.	O	O

Refer	VICTRELIS.xml:S2:8087:5	refer	NN	O	O
to	VICTRELIS.xml:S2:8093:2	to	TO	O	O
the	VICTRELIS.xml:S2:8096:3	the	DT	O	O
prescribing	VICTRELIS.xml:S2:8100:11	prescrib	NN	O	O
information	VICTRELIS.xml:S2:8112:11	inform	NN	O	O
for	VICTRELIS.xml:S2:8124:3	for	IN	O	O
peginterferon	VICTRELIS.xml:S2:8128:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:8142:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:8147:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:8151:9	ribavirin	NN	O	O
for	VICTRELIS.xml:S2:8161:3	for	IN	O	O
additional	VICTRELIS.xml:S2:8165:10	addit	JJ	O	O
information	VICTRELIS.xml:S2:8176:11	inform	NN	O	O
regarding	VICTRELIS.xml:S2:8188:9	regard	VBG	O	O
dose	VICTRELIS.xml:S2:8198:4	dose	JJ	O	O
reduction	VICTRELIS.xml:S2:8203:9	reduct	NN	O	O
or	VICTRELIS.xml:S2:8213:2	or	CC	O	O
discontinuation	VICTRELIS.xml:S2:8216:15	discontinu	NN	O	O
.	VICTRELIS.xml:S2:8231:1	.	.	O	O

5.4	VICTRELIS.xml:S2:8240:3	5.4	CD	O	O
Pancytopenia	VICTRELIS.xml:S2:8244:12	pancytopenia	NNP	O	O
(	VICTRELIS.xml:S2:8257:1	(	(	O	O
Use	VICTRELIS.xml:S2:8258:3	use	NNP	O	O
with	VICTRELIS.xml:S2:8262:4	with	IN	O	O
Ribavirin	VICTRELIS.xml:S2:8267:9	ribavirin	NNP	O	O
and	VICTRELIS.xml:S2:8277:3	and	CC	O	O
Peginterferon	VICTRELIS.xml:S2:8281:13	peginterferon	NNP	O	O
Alfa	VICTRELIS.xml:S2:8295:4	alfa	NNP	O	O
)	VICTRELIS.xml:S2:8299:1	)	)	O	O

Serious	VICTRELIS.xml:S2:8307:7	seriou	JJ	O	O
cases	VICTRELIS.xml:S2:8315:5	case	NNS	O	O
of	VICTRELIS.xml:S2:8321:2	of	IN	O	O
pancytopenia	VICTRELIS.xml:S2:8324:12	pancytopenia	NN	B-AdverseReaction	B-AdverseReaction
have	VICTRELIS.xml:S2:8337:4	have	VBP	O	O
been	VICTRELIS.xml:S2:8342:4	been	VBN	O	O
reported	VICTRELIS.xml:S2:8347:8	report	VBN	O	O
postmarketing	VICTRELIS.xml:S2:8356:13	postmarket	VBG	O	O
in	VICTRELIS.xml:S2:8370:2	in	IN	O	O
patients	VICTRELIS.xml:S2:8373:8	patient	NNS	O	O
receiving	VICTRELIS.xml:S2:8382:9	receiv	VBG	O	O
VICTRELIS	VICTRELIS.xml:S2:8392:9	victr	NNP	O	O
in	VICTRELIS.xml:S2:8402:2	in	IN	O	O
combination	VICTRELIS.xml:S2:8405:11	combin	NN	O	O
with	VICTRELIS.xml:S2:8417:4	with	IN	O	O
peginterferon	VICTRELIS.xml:S2:8422:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:8436:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:8441:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:8445:9	ribavirin	NN	O	O
.	VICTRELIS.xml:S2:8454:1	.	.	O	O

Complete	VICTRELIS.xml:S2:8456:8	complet	JJ	O	O
blood	VICTRELIS.xml:S2:8465:5	blood	NN	O	O
counts	VICTRELIS.xml:S2:8471:6	count	NNS	O	O
(	VICTRELIS.xml:S2:8478:1	(	(	O	O
with	VICTRELIS.xml:S2:8479:4	with	IN	O	O
white	VICTRELIS.xml:S2:8484:5	white	JJ	O	O
blood	VICTRELIS.xml:S2:8490:5	blood	NN	O	O
cell	VICTRELIS.xml:S2:8496:4	cell	NN	O	O
differential	VICTRELIS.xml:S2:8501:12	differenti	JJ	O	O
counts	VICTRELIS.xml:S2:8514:6	count	NNS	O	O
)	VICTRELIS.xml:S2:8520:1	)	)	O	O
should	VICTRELIS.xml:S2:8522:6	should	MD	O	O
be	VICTRELIS.xml:S2:8529:2	be	VB	O	O
obtained	VICTRELIS.xml:S2:8532:8	obtain	VBN	O	O
at	VICTRELIS.xml:S2:8541:2	at	IN	O	O
pretreatment	VICTRELIS.xml:S2:8544:12	pretreat	NN	O	O
,	VICTRELIS.xml:S2:8556:1	,	,	O	O
and	VICTRELIS.xml:S2:8558:3	and	CC	O	O
at	VICTRELIS.xml:S2:8562:2	at	IN	O	O
Treatment	VICTRELIS.xml:S2:8565:9	treatment	NNP	O	O
Weeks	VICTRELIS.xml:S2:8575:5	week	NNP	O	O
2	VICTRELIS.xml:S2:8581:1	2	CD	O	O
,	VICTRELIS.xml:S2:8582:1	,	,	O	O
4	VICTRELIS.xml:S2:8584:1	4	CD	O	O
,	VICTRELIS.xml:S2:8585:1	,	,	O	O
8	VICTRELIS.xml:S2:8587:1	8	CD	O	O
,	VICTRELIS.xml:S2:8588:1	,	,	O	O
and	VICTRELIS.xml:S2:8590:3	and	CC	O	O
12	VICTRELIS.xml:S2:8594:2	12	CD	O	O
,	VICTRELIS.xml:S2:8596:1	,	,	O	O
and	VICTRELIS.xml:S2:8598:3	and	CC	O	O
should	VICTRELIS.xml:S2:8602:6	should	MD	O	O
be	VICTRELIS.xml:S2:8609:2	be	VB	O	O
monitored	VICTRELIS.xml:S2:8612:9	monitor	VBN	O	O
closely	VICTRELIS.xml:S2:8622:7	close	RB	O	O
at	VICTRELIS.xml:S2:8630:2	at	IN	O	O
other	VICTRELIS.xml:S2:8633:5	other	JJ	O	O
time	VICTRELIS.xml:S2:8639:4	time	NN	O	O
points	VICTRELIS.xml:S2:8644:6	point	NNS	O	O
,	VICTRELIS.xml:S2:8650:1	,	,	O	O
as	VICTRELIS.xml:S2:8652:2	as	IN	O	O
clinically	VICTRELIS.xml:S2:8655:10	clinic	RB	O	O
appropriate	VICTRELIS.xml:S2:8666:11	appropri	JJ	O	O
.	VICTRELIS.xml:S2:8677:1	.	.	O	O

Refer	VICTRELIS.xml:S2:8686:5	refer	NN	O	O
to	VICTRELIS.xml:S2:8692:2	to	TO	O	O
the	VICTRELIS.xml:S2:8695:3	the	DT	O	O
prescribing	VICTRELIS.xml:S2:8699:11	prescrib	NN	O	O
information	VICTRELIS.xml:S2:8711:11	inform	NN	O	O
for	VICTRELIS.xml:S2:8723:3	for	IN	O	O
ribavirin	VICTRELIS.xml:S2:8727:9	ribavirin	NN	O	O
and	VICTRELIS.xml:S2:8737:3	and	CC	O	O
peginterferon	VICTRELIS.xml:S2:8741:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:8755:4	alfa	NN	O	O
for	VICTRELIS.xml:S2:8760:3	for	IN	O	O
guidelines	VICTRELIS.xml:S2:8764:10	guidelin	NNS	O	O
for	VICTRELIS.xml:S2:8775:3	for	IN	O	O
discontinuation	VICTRELIS.xml:S2:8779:15	discontinu	NN	O	O
of	VICTRELIS.xml:S2:8795:2	of	IN	O	O
therapy	VICTRELIS.xml:S2:8798:7	therapi	NN	O	O
based	VICTRELIS.xml:S2:8806:5	base	VBN	O	O
on	VICTRELIS.xml:S2:8812:2	on	IN	O	O
laboratory	VICTRELIS.xml:S2:8815:10	laboratori	NN	O	O
parameters	VICTRELIS.xml:S2:8826:10	paramet	NNS	O	O
.	VICTRELIS.xml:S2:8836:1	.	.	O	O

5.5	VICTRELIS.xml:S2:8847:3	5.5	CD	O	O
Hypersensitivity	VICTRELIS.xml:S2:8851:16	hypersensit	NN	O	O

Serious	VICTRELIS.xml:S2:8873:7	seriou	JJ	O	O
acute	VICTRELIS.xml:S2:8881:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
hypersensitivity	VICTRELIS.xml:S2:8887:16	hypersensit	NN	I-AdverseReaction	I-AdverseReaction
reactions	VICTRELIS.xml:S2:8904:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	VICTRELIS.xml:S2:8914:1	(	(	O	O
e	VICTRELIS.xml:S2:8915:1	e	NN	O	O
.	VICTRELIS.xml:S2:8916:1	.	.	O	O
g	VICTRELIS.xml:S2:8917:1	g	NN	O	O
.	VICTRELIS.xml:S2:8918:1	.	.	O	O
,	VICTRELIS.xml:S2:8919:1	,	,	O	O
urticaria	VICTRELIS.xml:S2:8921:9	urticaria	JJ	B-AdverseReaction	B-AdverseReaction
,	VICTRELIS.xml:S2:8930:1	,	,	O	O
angioedema	VICTRELIS.xml:S2:8932:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
)	VICTRELIS.xml:S2:8942:1	)	)	O	O
have	VICTRELIS.xml:S2:8944:4	have	VBP	O	O
been	VICTRELIS.xml:S2:8949:4	been	VBN	O	O
observed	VICTRELIS.xml:S2:8954:8	observ	VBN	O	O
during	VICTRELIS.xml:S2:8963:6	dure	IN	O	O
combination	VICTRELIS.xml:S2:8970:11	combin	NN	O	O
therapy	VICTRELIS.xml:S2:8982:7	therapi	NN	O	O
with	VICTRELIS.xml:S2:8990:4	with	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:8995:9	victr	NNP	O	O
,	VICTRELIS.xml:S2:9004:1	,	,	O	O
peginterferon	VICTRELIS.xml:S2:9006:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:9020:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:9025:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:9029:9	ribavirin	NN	O	O
.	VICTRELIS.xml:S2:9038:1	.	.	O	O

If	VICTRELIS.xml:S2:9040:2	If	IN	O	O
such	VICTRELIS.xml:S2:9043:4	such	PDT	O	O
an	VICTRELIS.xml:S2:9048:2	an	DT	O	O
acute	VICTRELIS.xml:S2:9051:5	acut	JJ	O	O
reaction	VICTRELIS.xml:S2:9057:8	reaction	NN	O	O
occurs	VICTRELIS.xml:S2:9066:6	occur	VBZ	O	O
,	VICTRELIS.xml:S2:9072:1	,	,	O	O
combination	VICTRELIS.xml:S2:9074:11	combin	NN	O	O
therapy	VICTRELIS.xml:S2:9086:7	therapi	NN	O	O
should	VICTRELIS.xml:S2:9094:6	should	MD	O	O
be	VICTRELIS.xml:S2:9101:2	be	VB	O	O
discontinued	VICTRELIS.xml:S2:9104:12	discontinu	VBN	O	O
and	VICTRELIS.xml:S2:9117:3	and	CC	O	O
appropriate	VICTRELIS.xml:S2:9121:11	appropri	JJ	O	O
medical	VICTRELIS.xml:S2:9133:7	medic	JJ	O	O
therapy	VICTRELIS.xml:S2:9141:7	therapi	NN	O	O
immediately	VICTRELIS.xml:S2:9149:11	immedi	RB	O	O
instituted	VICTRELIS.xml:S2:9161:10	institut	VBD	O	O
[	VICTRELIS.xml:S2:9172:1	[	NNP	O	O
see	VICTRELIS.xml:S2:9173:3	see	VBP	O	O
Contraindications	VICTRELIS.xml:S2:9178:17	contraind	NNP	O	O
(	VICTRELIS.xml:S2:9196:1	(	(	O	O
4	VICTRELIS.xml:S2:9197:1	4	CD	O	O
)	VICTRELIS.xml:S2:9198:1	)	)	O	O
and	VICTRELIS.xml:S2:9201:3	and	CC	O	O
Adverse	VICTRELIS.xml:S2:9206:7	advers	JJ	O	O
Reactions	VICTRELIS.xml:S2:9214:9	reaction	NNP	O	O
(	VICTRELIS.xml:S2:9224:1	(	(	O	O
6.2	VICTRELIS.xml:S2:9225:3	6.2	CD	O	O
)	VICTRELIS.xml:S2:9228:1	)	)	O	O
]	VICTRELIS.xml:S2:9231:1	]	NN	O	O
.	VICTRELIS.xml:S2:9234:1	.	.	O	O

5.6	VICTRELIS.xml:S2:9243:3	5.6	CD	O	O
Drug	VICTRELIS.xml:S2:9247:4	drug	NNP	O	O
Interactions	VICTRELIS.xml:S2:9252:12	interact	NNS	O	O

See	VICTRELIS.xml:S2:9270:3	see	VB	O	O
Table	VICTRELIS.xml:S2:9275:5	tabl	JJ	O	O
2	VICTRELIS.xml:S2:9281:1	2	CD	O	O
for	VICTRELIS.xml:S2:9284:3	for	IN	O	O
a	VICTRELIS.xml:S2:9288:1	a	DT	O	O
listing	VICTRELIS.xml:S2:9290:7	list	NN	O	O
of	VICTRELIS.xml:S2:9298:2	of	IN	O	O
drugs	VICTRELIS.xml:S2:9301:5	drug	NNS	O	O
that	VICTRELIS.xml:S2:9307:4	that	WDT	O	O
are	VICTRELIS.xml:S2:9312:3	are	VBP	O	O
contraindicated	VICTRELIS.xml:S2:9316:15	contraind	VBN	O	O
for	VICTRELIS.xml:S2:9332:3	for	IN	O	O
use	VICTRELIS.xml:S2:9336:3	use	NN	O	O
with	VICTRELIS.xml:S2:9340:4	with	IN	O	O
VICTRELIS	VICTRELIS.xml:S2:9345:9	victr	NNP	O	O
due	VICTRELIS.xml:S2:9355:3	due	JJ	O	O
to	VICTRELIS.xml:S2:9359:2	to	TO	O	O
potentially	VICTRELIS.xml:S2:9362:11	potenti	RB	O	O
life	VICTRELIS.xml:S2:9374:4	life	NN	O	O
-	VICTRELIS.xml:S2:9378:1	-	:	O	O
threatening	VICTRELIS.xml:S2:9379:11	threaten	JJ	O	O
adverse	VICTRELIS.xml:S2:9391:7	advers	JJ	O	O
events	VICTRELIS.xml:S2:9399:6	event	NNS	O	O
,	VICTRELIS.xml:S2:9405:1	,	,	O	O
significant	VICTRELIS.xml:S2:9407:11	signific	JJ	O	O
drug	VICTRELIS.xml:S2:9419:4	drug	NN	O	O
interactions	VICTRELIS.xml:S2:9424:12	interact	NNS	O	O
or	VICTRELIS.xml:S2:9437:2	or	CC	O	O
loss	VICTRELIS.xml:S2:9440:4	loss	NN	O	B-AdverseReaction
of	VICTRELIS.xml:S2:9445:2	of	IN	O	I-AdverseReaction
virologic	VICTRELIS.xml:S2:9448:9	virolog	JJ	O	I-AdverseReaction
activity	VICTRELIS.xml:S2:9458:8	activ	NN	O	I-AdverseReaction
[	VICTRELIS.xml:S2:9467:1	[	NNP	O	O
see	VICTRELIS.xml:S2:9468:3	see	NN	O	O
Contraindications	VICTRELIS.xml:S2:9473:17	contraind	NNP	O	O
(	VICTRELIS.xml:S2:9491:1	(	(	O	O
4	VICTRELIS.xml:S2:9492:1	4	CD	O	O
)	VICTRELIS.xml:S2:9493:1	)	)	O	O
]	VICTRELIS.xml:S2:9496:1	]	NN	O	O
.	VICTRELIS.xml:S2:9497:1	.	.	O	O

Please	VICTRELIS.xml:S2:9500:6	pleas	NNP	O	O
refer	VICTRELIS.xml:S2:9507:5	refer	NN	O	O
to	VICTRELIS.xml:S2:9513:2	to	TO	O	O
Table	VICTRELIS.xml:S2:9517:5	tabl	VB	O	O
5	VICTRELIS.xml:S2:9523:1	5	CD	O	O
for	VICTRELIS.xml:S2:9526:3	for	IN	O	O
established	VICTRELIS.xml:S2:9530:11	establish	VBN	O	O
and	VICTRELIS.xml:S2:9542:3	and	CC	O	O
other	VICTRELIS.xml:S2:9546:5	other	JJ	O	O
potentially	VICTRELIS.xml:S2:9552:11	potenti	RB	O	O
significant	VICTRELIS.xml:S2:9564:11	signific	JJ	O	O
drug	VICTRELIS.xml:S2:9576:4	drug	NN	O	O
interactions	VICTRELIS.xml:S2:9581:12	interact	NNS	O	O
[	VICTRELIS.xml:S2:9594:1	[	VBP	O	O
see	VICTRELIS.xml:S2:9595:3	see	VBP	O	O
Drug	VICTRELIS.xml:S2:9600:4	drug	JJ	O	O
Interactions	VICTRELIS.xml:S2:9605:12	interact	NNP	O	O
(	VICTRELIS.xml:S2:9618:1	(	(	O	O
7.3	VICTRELIS.xml:S2:9619:3	7.3	CD	O	O
)	VICTRELIS.xml:S2:9622:1	)	)	O	O
]	VICTRELIS.xml:S2:9625:1	]	NN	O	O
.	VICTRELIS.xml:S2:9626:1	.	.	O	O

5.7	VICTRELIS.xml:S2:9637:3	5.7	CD	O	O
Laboratory	VICTRELIS.xml:S2:9641:10	laboratori	NN	O	O
Tests	VICTRELIS.xml:S2:9652:5	test	NNS	O	O

HCV	VICTRELIS.xml:S2:9663:3	hcv	NNP	O	O
-	VICTRELIS.xml:S2:9666:1	-	:	O	O
RNA	VICTRELIS.xml:S2:9667:3	rna	NN	O	O
levels	VICTRELIS.xml:S2:9671:6	level	NNS	O	O
should	VICTRELIS.xml:S2:9678:6	should	MD	O	O
be	VICTRELIS.xml:S2:9685:2	be	VB	O	O
monitored	VICTRELIS.xml:S2:9688:9	monitor	VBN	O	O
at	VICTRELIS.xml:S2:9698:2	at	IN	O	O
Treatment	VICTRELIS.xml:S2:9701:9	treatment	NNP	O	O
Weeks	VICTRELIS.xml:S2:9711:5	week	NNP	O	O
4	VICTRELIS.xml:S2:9717:1	4	CD	O	O
,	VICTRELIS.xml:S2:9718:1	,	,	O	O
8	VICTRELIS.xml:S2:9720:1	8	CD	O	O
,	VICTRELIS.xml:S2:9721:1	,	,	O	O
12	VICTRELIS.xml:S2:9723:2	12	CD	O	O
,	VICTRELIS.xml:S2:9725:1	,	,	O	O
and	VICTRELIS.xml:S2:9727:3	and	CC	O	O
24	VICTRELIS.xml:S2:9731:2	24	CD	O	O
,	VICTRELIS.xml:S2:9733:1	,	,	O	O
at	VICTRELIS.xml:S2:9735:2	at	IN	O	O
the	VICTRELIS.xml:S2:9738:3	the	DT	O	O
end	VICTRELIS.xml:S2:9742:3	end	NN	O	O
of	VICTRELIS.xml:S2:9746:2	of	IN	O	O
treatment	VICTRELIS.xml:S2:9749:9	treatment	NN	O	O
,	VICTRELIS.xml:S2:9758:1	,	,	O	O
during	VICTRELIS.xml:S2:9760:6	dure	IN	O	O
treatment	VICTRELIS.xml:S2:9767:9	treatment	NN	O	O
follow	VICTRELIS.xml:S2:9777:6	follow	SYM	O	O
-	VICTRELIS.xml:S2:9783:1	-	:	O	O
up	VICTRELIS.xml:S2:9784:2	up	RB	O	O
,	VICTRELIS.xml:S2:9786:1	,	,	O	O
and	VICTRELIS.xml:S2:9788:3	and	CC	O	O
for	VICTRELIS.xml:S2:9792:3	for	IN	O	O
other	VICTRELIS.xml:S2:9796:5	other	JJ	O	O
time	VICTRELIS.xml:S2:9802:4	time	NN	O	O
points	VICTRELIS.xml:S2:9807:6	point	NNS	O	O
as	VICTRELIS.xml:S2:9814:2	as	IN	O	O
clinically	VICTRELIS.xml:S2:9817:10	clinic	RB	O	O
indicated	VICTRELIS.xml:S2:9828:9	indic	VBN	O	O
.	VICTRELIS.xml:S2:9837:1	.	.	O	O

Use	VICTRELIS.xml:S2:9839:3	use	NNP	O	O
of	VICTRELIS.xml:S2:9843:2	of	IN	O	O
a	VICTRELIS.xml:S2:9846:1	a	DT	O	O
sensitive	VICTRELIS.xml:S2:9848:9	sensit	JJ	O	O
real	VICTRELIS.xml:S2:9858:4	real	JJ	O	O
-	VICTRELIS.xml:S2:9862:1	-	:	O	O
time	VICTRELIS.xml:S2:9863:4	time	NN	O	O
reverse	VICTRELIS.xml:S2:9868:7	revers	JJ	O	O
-	VICTRELIS.xml:S2:9875:1	-	:	O	O
transcription	VICTRELIS.xml:S2:9876:13	transcript	NN	O	O
polymerase	VICTRELIS.xml:S2:9890:10	polymeras	NN	O	O
chain	VICTRELIS.xml:S2:9901:5	chain	NN	O	O
reaction	VICTRELIS.xml:S2:9907:8	reaction	NN	O	O
(	VICTRELIS.xml:S2:9916:1	(	(	O	O
RT	VICTRELIS.xml:S2:9917:2	RT	NNP	O	O
-	VICTRELIS.xml:S2:9919:1	-	:	O	O
PCR	VICTRELIS.xml:S2:9920:3	pcr	NN	O	O
)	VICTRELIS.xml:S2:9923:1	)	)	O	O
assay	VICTRELIS.xml:S2:9925:5	assay	NN	O	O
for	VICTRELIS.xml:S2:9931:3	for	IN	O	O
monitoring	VICTRELIS.xml:S2:9935:10	monitor	VBG	O	O
HCV	VICTRELIS.xml:S2:9946:3	hcv	NNP	O	O
-	VICTRELIS.xml:S2:9949:1	-	:	O	O
RNA	VICTRELIS.xml:S2:9950:3	rna	NN	O	O
levels	VICTRELIS.xml:S2:9954:6	level	NNS	O	O
during	VICTRELIS.xml:S2:9961:6	dure	IN	O	O
treatment	VICTRELIS.xml:S2:9968:9	treatment	NN	O	O
is	VICTRELIS.xml:S2:9978:2	is	VBZ	O	O
recommended	VICTRELIS.xml:S2:9981:11	recommend	VBN	O	O
.	VICTRELIS.xml:S2:9992:1	.	.	O	O

The	VICTRELIS.xml:S2:9994:3	the	DT	O	O
assay	VICTRELIS.xml:S2:9998:5	assay	NN	O	O
should	VICTRELIS.xml:S2:10004:6	should	MD	O	O
have	VICTRELIS.xml:S2:10011:4	have	VB	O	O
a	VICTRELIS.xml:S2:10016:1	a	DT	O	O
lower	VICTRELIS.xml:S2:10018:5	lower	JJR	O	O
limit	VICTRELIS.xml:S2:10024:5	limit	NN	O	O
of	VICTRELIS.xml:S2:10030:2	of	IN	O	O
HCV	VICTRELIS.xml:S2:10033:3	hcv	NNP	O	O
-	VICTRELIS.xml:S2:10036:1	-	:	O	O
RNA	VICTRELIS.xml:S2:10037:3	rna	NNP	O	O
quantification	VICTRELIS.xml:S2:10041:14	quantif	NN	O	O
of	VICTRELIS.xml:S2:10056:2	of	IN	O	O
equal	VICTRELIS.xml:S2:10059:5	equal	JJ	O	O
to	VICTRELIS.xml:S2:10065:2	to	TO	O	O
or	VICTRELIS.xml:S2:10068:2	or	CC	O	O
less	VICTRELIS.xml:S2:10071:4	less	JJR	O	O
than	VICTRELIS.xml:S2:10076:4	than	IN	O	O
25	VICTRELIS.xml:S2:10081:2	25	CD	O	O
IU	VICTRELIS.xml:S2:10084:2	IU	NNP	O	O
per	VICTRELIS.xml:S2:10087:3	per	IN	O	O
mL	VICTRELIS.xml:S2:10091:2	mL	NN	O	O
,	VICTRELIS.xml:S2:10093:1	,	,	O	O
and	VICTRELIS.xml:S2:10095:3	and	CC	O	O
a	VICTRELIS.xml:S2:10099:1	a	DT	O	O
limit	VICTRELIS.xml:S2:10101:5	limit	NN	O	O
of	VICTRELIS.xml:S2:10107:2	of	IN	O	O
HCV	VICTRELIS.xml:S2:10110:3	hcv	NNP	O	O
-	VICTRELIS.xml:S2:10113:1	-	:	O	O
RNA	VICTRELIS.xml:S2:10114:3	rna	NNP	O	O
detection	VICTRELIS.xml:S2:10118:9	detect	NN	O	O
of	VICTRELIS.xml:S2:10128:2	of	IN	O	O
approximately	VICTRELIS.xml:S2:10131:13	approxim	RB	O	O
10	VICTRELIS.xml:S2:10145:2	10	CD	O	O
to	VICTRELIS.xml:S2:10148:2	to	TO	O	O
15	VICTRELIS.xml:S2:10151:2	15	CD	O	O
IU	VICTRELIS.xml:S2:10154:2	IU	NNP	O	O
per	VICTRELIS.xml:S2:10157:3	per	IN	O	O
mL	VICTRELIS.xml:S2:10161:2	mL	NN	O	O
.	VICTRELIS.xml:S2:10163:1	.	.	O	O

For	VICTRELIS.xml:S2:10165:3	for	IN	O	O
the	VICTRELIS.xml:S2:10169:3	the	DT	O	O
purposes	VICTRELIS.xml:S2:10173:8	purpos	NNS	O	O
of	VICTRELIS.xml:S2:10182:2	of	IN	O	O
assessing	VICTRELIS.xml:S2:10185:9	assess	VBG	O	O
Response	VICTRELIS.xml:S2:10195:8	respons	NNP	O	O
-	VICTRELIS.xml:S2:10203:1	-	:	O	O
Guided	VICTRELIS.xml:S2:10204:6	guid	VBD	O	O
Therapy	VICTRELIS.xml:S2:10211:7	therapi	NNP	O	O
milestones	VICTRELIS.xml:S2:10219:10	mileston	NNS	O	O
,	VICTRELIS.xml:S2:10229:1	,	,	O	O
a	VICTRELIS.xml:S2:10231:1	a	DT	O	O
confirmed	VICTRELIS.xml:S2:10233:9	confirm	JJ	O	O
"	VICTRELIS.xml:S2:10243:1	"	NN	O	O
detectable	VICTRELIS.xml:S2:10244:10	detect	NN	O	O
but	VICTRELIS.xml:S2:10255:3	but	CC	O	O
below	VICTRELIS.xml:S2:10259:5	below	IN	O	O
limit	VICTRELIS.xml:S2:10265:5	limit	NN	O	O
of	VICTRELIS.xml:S2:10271:2	of	IN	O	O
quantification	VICTRELIS.xml:S2:10274:14	quantif	NN	O	O
"	VICTRELIS.xml:S2:10288:1	"	NNP	O	O
HCV	VICTRELIS.xml:S2:10290:3	hcv	NNP	O	O
-	VICTRELIS.xml:S2:10293:1	-	:	O	O
RNA	VICTRELIS.xml:S2:10294:3	rna	NNP	O	O
result	VICTRELIS.xml:S2:10298:6	result	NN	O	O
should	VICTRELIS.xml:S2:10305:6	should	MD	O	O
not	VICTRELIS.xml:S2:10312:3	not	RB	O	O
be	VICTRELIS.xml:S2:10316:2	be	VB	O	O
considered	VICTRELIS.xml:S2:10319:10	consid	VBN	O	O
equivalent	VICTRELIS.xml:S2:10330:10	equival	JJ	O	O
to	VICTRELIS.xml:S2:10341:2	to	TO	O	O
an	VICTRELIS.xml:S2:10344:2	an	DT	O	O
"	VICTRELIS.xml:S2:10347:1	"	NN	O	O
undetectable	VICTRELIS.xml:S2:10348:12	undetect	JJ	O	O
"	VICTRELIS.xml:S2:10360:1	"	NN	O	O
HCV	VICTRELIS.xml:S2:10362:3	hcv	NNP	O	O
-	VICTRELIS.xml:S2:10365:1	-	:	O	O
RNA	VICTRELIS.xml:S2:10366:3	rna	NNP	O	O
result	VICTRELIS.xml:S2:10370:6	result	NN	O	O
(	VICTRELIS.xml:S2:10377:1	(	(	O	O
reported	VICTRELIS.xml:S2:10378:8	report	VBN	O	O
as	VICTRELIS.xml:S2:10387:2	as	IN	O	O
"	VICTRELIS.xml:S2:10390:1	"	NNP	O	O
Target	VICTRELIS.xml:S2:10391:6	target	NNP	O	O
Not	VICTRELIS.xml:S2:10398:3	not	RB	O	O
Detected	VICTRELIS.xml:S2:10402:8	detect	NNP	O	O
"	VICTRELIS.xml:S2:10410:1	"	NNP	O	O
or	VICTRELIS.xml:S2:10412:2	or	CC	O	O
"	VICTRELIS.xml:S2:10415:1	"	NNP	O	O
HCV	VICTRELIS.xml:S2:10416:3	hcv	NNP	O	O
-	VICTRELIS.xml:S2:10419:1	-	:	O	O
RNA	VICTRELIS.xml:S2:10420:3	rna	NNP	O	O
Not	VICTRELIS.xml:S2:10424:3	not	RB	O	O
Detected	VICTRELIS.xml:S2:10428:8	detect	NNP	O	O
"	VICTRELIS.xml:S2:10436:1	"	NNP	O	O
)	VICTRELIS.xml:S2:10437:1	)	)	O	O
.	VICTRELIS.xml:S2:10438:1	.	.	O	O

Complete	VICTRELIS.xml:S2:10444:8	complet	JJ	O	O
blood	VICTRELIS.xml:S2:10453:5	blood	NN	O	O
count	VICTRELIS.xml:S2:10459:5	count	NN	O	O
(	VICTRELIS.xml:S2:10465:1	(	(	O	O
with	VICTRELIS.xml:S2:10466:4	with	IN	O	O
white	VICTRELIS.xml:S2:10471:5	white	JJ	O	O
blood	VICTRELIS.xml:S2:10477:5	blood	NN	O	O
cell	VICTRELIS.xml:S2:10483:4	cell	NN	O	O
differential	VICTRELIS.xml:S2:10488:12	differenti	JJ	O	O
counts	VICTRELIS.xml:S2:10501:6	count	NNS	O	O
)	VICTRELIS.xml:S2:10507:1	)	)	O	O
should	VICTRELIS.xml:S2:10509:6	should	MD	O	O
be	VICTRELIS.xml:S2:10516:2	be	VB	O	O
obtained	VICTRELIS.xml:S2:10519:8	obtain	VBN	O	O
at	VICTRELIS.xml:S2:10528:2	at	IN	O	O
pretreatment	VICTRELIS.xml:S2:10531:12	pretreat	NN	O	O
,	VICTRELIS.xml:S2:10543:1	,	,	O	O
and	VICTRELIS.xml:S2:10545:3	and	CC	O	O
at	VICTRELIS.xml:S2:10549:2	at	IN	O	O
Treatment	VICTRELIS.xml:S2:10552:9	treatment	NNP	O	O
Weeks	VICTRELIS.xml:S2:10562:5	week	NNP	O	O
2	VICTRELIS.xml:S2:10568:1	2	CD	O	O
,	VICTRELIS.xml:S2:10569:1	,	,	O	O
4	VICTRELIS.xml:S2:10571:1	4	CD	O	O
,	VICTRELIS.xml:S2:10572:1	,	,	O	O
8	VICTRELIS.xml:S2:10574:1	8	CD	O	O
,	VICTRELIS.xml:S2:10575:1	,	,	O	O
and	VICTRELIS.xml:S2:10577:3	and	CC	O	O
12	VICTRELIS.xml:S2:10581:2	12	CD	O	O
,	VICTRELIS.xml:S2:10583:1	,	,	O	O
and	VICTRELIS.xml:S2:10585:3	and	CC	O	O
should	VICTRELIS.xml:S2:10589:6	should	MD	O	O
be	VICTRELIS.xml:S2:10596:2	be	VB	O	O
monitored	VICTRELIS.xml:S2:10599:9	monitor	VBN	O	O
closely	VICTRELIS.xml:S2:10609:7	close	RB	O	O
at	VICTRELIS.xml:S2:10617:2	at	IN	O	O
other	VICTRELIS.xml:S2:10620:5	other	JJ	O	O
time	VICTRELIS.xml:S2:10626:4	time	NN	O	O
points	VICTRELIS.xml:S2:10631:6	point	NNS	O	O
,	VICTRELIS.xml:S2:10637:1	,	,	O	O
as	VICTRELIS.xml:S2:10639:2	as	IN	O	O
clinically	VICTRELIS.xml:S2:10642:10	clinic	RB	O	O
appropriate	VICTRELIS.xml:S2:10653:11	appropri	JJ	O	O
.	VICTRELIS.xml:S2:10664:1	.	.	O	O

Refer	VICTRELIS.xml:S2:10671:5	refer	NN	O	O
to	VICTRELIS.xml:S2:10677:2	to	TO	O	O
the	VICTRELIS.xml:S2:10680:3	the	DT	O	O
prescribing	VICTRELIS.xml:S2:10684:11	prescrib	NN	O	O
information	VICTRELIS.xml:S2:10696:11	inform	NN	O	O
for	VICTRELIS.xml:S2:10708:3	for	IN	O	O
peginterferon	VICTRELIS.xml:S2:10712:13	peginterferon	NN	O	O
alfa	VICTRELIS.xml:S2:10726:4	alfa	NN	O	O
and	VICTRELIS.xml:S2:10731:3	and	CC	O	O
ribavirin	VICTRELIS.xml:S2:10735:9	ribavirin	NN	O	O
for	VICTRELIS.xml:S2:10745:3	for	IN	O	O
pre	VICTRELIS.xml:S2:10749:3	pre	JJ	O	O
-	VICTRELIS.xml:S2:10752:1	-	:	O	O
treatment	VICTRELIS.xml:S2:10753:9	treatment	NN	O	O
,	VICTRELIS.xml:S2:10762:1	,	,	O	O
on	VICTRELIS.xml:S2:10764:2	on	IN	O	O
-	VICTRELIS.xml:S2:10766:1	-	:	O	O
treatment	VICTRELIS.xml:S2:10767:9	treatment	NN	O	O
and	VICTRELIS.xml:S2:10777:3	and	CC	O	O
post	VICTRELIS.xml:S2:10781:4	post	NN	O	O
-	VICTRELIS.xml:S2:10785:1	-	:	O	O
treatment	VICTRELIS.xml:S2:10786:9	treatment	NN	O	O
laboratory	VICTRELIS.xml:S2:10796:10	laboratori	NN	O	O
testing	VICTRELIS.xml:S2:10807:7	test	VBG	O	O
recommendations	VICTRELIS.xml:S2:10815:15	recommend	NNS	O	O
including	VICTRELIS.xml:S2:10831:9	includ	VBG	O	O
hematology	VICTRELIS.xml:S2:10841:10	hematolog	NN	O	O
,	VICTRELIS.xml:S2:10851:1	,	,	O	O
biochemistry	VICTRELIS.xml:S2:10853:12	biochemistri	NN	O	O
(	VICTRELIS.xml:S2:10866:1	(	(	O	O
including	VICTRELIS.xml:S2:10867:9	includ	VBG	O	O
hepatic	VICTRELIS.xml:S2:10877:7	hepat	JJ	O	O
function	VICTRELIS.xml:S2:10885:8	function	NN	O	O
tests	VICTRELIS.xml:S2:10894:5	test	NNS	O	O
)	VICTRELIS.xml:S2:10899:1	)	)	O	O
,	VICTRELIS.xml:S2:10900:1	,	,	O	O
and	VICTRELIS.xml:S2:10902:3	and	CC	O	O
pregnancy	VICTRELIS.xml:S2:10906:9	pregnanc	NN	O	O
testing	VICTRELIS.xml:S2:10916:7	test	NN	O	O
requirements	VICTRELIS.xml:S2:10924:12	requir	NNS	O	O
.	VICTRELIS.xml:S2:10936:1	.	.	O	O
6	VIMIZIM.xml:S1:4:1	6	CD	O	O
ADVERSE	VIMIZIM.xml:S1:6:7	advers	JJ	O	O
REACTIONS	VIMIZIM.xml:S1:14:9	reaction	NN	O	O

Because	VIMIZIM.xml:S1:27:7	becaus	IN	O	O
clinical	VIMIZIM.xml:S1:35:8	clinic	JJ	O	O
trials	VIMIZIM.xml:S1:44:6	trial	NNS	O	O
are	VIMIZIM.xml:S1:51:3	are	VBP	O	O
conducted	VIMIZIM.xml:S1:55:9	conduct	VBN	O	O
under	VIMIZIM.xml:S1:65:5	under	IN	O	O
widely	VIMIZIM.xml:S1:71:6	wide	RB	O	O
varying	VIMIZIM.xml:S1:78:7	vari	VBG	O	O
conditions	VIMIZIM.xml:S1:86:10	condit	NNS	O	O
,	VIMIZIM.xml:S1:96:1	,	,	O	O
adverse	VIMIZIM.xml:S1:98:7	advers	JJ	O	O
reaction	VIMIZIM.xml:S1:106:8	reaction	NN	O	O
rates	VIMIZIM.xml:S1:115:5	rate	NNS	O	O
observed	VIMIZIM.xml:S1:121:8	observ	VBD	O	O
in	VIMIZIM.xml:S1:130:2	in	IN	O	O
the	VIMIZIM.xml:S1:133:3	the	DT	O	O
clinical	VIMIZIM.xml:S1:137:8	clinic	JJ	O	O
trials	VIMIZIM.xml:S1:146:6	trial	NNS	O	O
of	VIMIZIM.xml:S1:153:2	of	IN	O	O
a	VIMIZIM.xml:S1:156:1	a	DT	O	O
drug	VIMIZIM.xml:S1:158:4	drug	NN	O	O
cannot	VIMIZIM.xml:S1:163:6	cannot	NN	O	O
be	VIMIZIM.xml:S1:170:2	be	VB	O	O
directly	VIMIZIM.xml:S1:173:8	directli	RB	O	O
compared	VIMIZIM.xml:S1:182:8	compar	VBN	O	O
to	VIMIZIM.xml:S1:191:2	to	TO	O	O
rates	VIMIZIM.xml:S1:194:5	rate	NNS	O	O
in	VIMIZIM.xml:S1:200:2	in	IN	O	O
the	VIMIZIM.xml:S1:203:3	the	DT	O	O
clinical	VIMIZIM.xml:S1:207:8	clinic	JJ	O	O
trials	VIMIZIM.xml:S1:216:6	trial	NNS	O	O
of	VIMIZIM.xml:S1:223:2	of	IN	O	O
another	VIMIZIM.xml:S1:226:7	anoth	DT	O	O
drug	VIMIZIM.xml:S1:234:4	drug	NN	O	O
and	VIMIZIM.xml:S1:239:3	and	CC	O	O
may	VIMIZIM.xml:S1:243:3	may	MD	O	O
not	VIMIZIM.xml:S1:247:3	not	RB	O	O
reflect	VIMIZIM.xml:S1:251:7	reflect	VB	O	O
the	VIMIZIM.xml:S1:259:3	the	DT	O	O
rates	VIMIZIM.xml:S1:263:5	rate	NNS	O	O
observed	VIMIZIM.xml:S1:269:8	observ	VBD	O	O
in	VIMIZIM.xml:S1:278:2	in	IN	O	O
practice	VIMIZIM.xml:S1:281:8	practic	NN	O	O
.	VIMIZIM.xml:S1:289:1	.	.	O	O

The	VIMIZIM.xml:S1:295:3	the	DT	O	O
following	VIMIZIM.xml:S1:299:9	follow	VBG	O	O
serious	VIMIZIM.xml:S1:309:7	seriou	JJ	O	O
adverse	VIMIZIM.xml:S1:317:7	advers	JJ	O	O
reactions	VIMIZIM.xml:S1:325:9	reaction	NNS	O	O
are	VIMIZIM.xml:S1:335:3	are	VBP	O	O
described	VIMIZIM.xml:S1:339:9	describ	VBN	O	O
below	VIMIZIM.xml:S1:349:5	below	IN	O	O
and	VIMIZIM.xml:S1:355:3	and	CC	O	O
elsewhere	VIMIZIM.xml:S1:359:9	elsewher	RB	O	O
in	VIMIZIM.xml:S1:369:2	in	IN	O	O
the	VIMIZIM.xml:S1:372:3	the	DT	O	O
labeling	VIMIZIM.xml:S1:376:8	label	NN	O	O
:	VIMIZIM.xml:S1:384:1	:	:	O	O

.	VIMIZIM.xml:S1:390:1	.	.	O	O

Anaphylaxis	VIMIZIM.xml:S1:392:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
and	VIMIZIM.xml:S1:404:3	and	CC	O	O
hypersensitivity	VIMIZIM.xml:S1:408:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S1:425:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
[	VIMIZIM.xml:S1:436:1	[	VBP	O	O
see	VIMIZIM.xml:S1:441:3	see	VBP	O	O
Warnings	VIMIZIM.xml:S1:445:8	warn	NNS	O	O
and	VIMIZIM.xml:S1:454:3	and	CC	O	O
Precautions	VIMIZIM.xml:S1:458:11	precaut	NNP	O	O
(	VIMIZIM.xml:S1:470:1	(	(	O	O
5.1	VIMIZIM.xml:S1:473:3	5.1	CD	O	O
)]	VIMIZIM.xml:S1:478:2	)]	NN	O	O
.	VIMIZIM.xml:S1:480:1	.	.	O	O

The	VIMIZIM.xml:S1:488:3	the	DT	O	O
most	VIMIZIM.xml:S1:492:4	most	RBS	O	O
common	VIMIZIM.xml:S1:497:6	common	JJ	O	O
adverse	VIMIZIM.xml:S1:504:7	advers	JJ	O	O
reactions	VIMIZIM.xml:S1:512:9	reaction	NNS	O	O
(	VIMIZIM.xml:S1:522:1	(	(	O	O
10%	VIMIZIM.xml:S1:525:3	10%	CD	O	O
)	VIMIZIM.xml:S1:528:1	)	)	O	O
observed	VIMIZIM.xml:S1:530:8	observ	VBN	O	O
across	VIMIZIM.xml:S1:539:6	across	IN	O	O
pre	VIMIZIM.xml:S1:546:3	pre	NN	O	O
-	VIMIZIM.xml:S1:549:1	-	:	O	O
marketing	VIMIZIM.xml:S1:550:9	market	NN	O	O
clinical	VIMIZIM.xml:S1:560:8	clinic	JJ	O	O
trials	VIMIZIM.xml:S1:569:6	trial	NNS	O	O
were	VIMIZIM.xml:S1:576:4	were	VBD	O	O
similar	VIMIZIM.xml:S1:581:7	similar	JJ	O	O
in	VIMIZIM.xml:S1:589:2	in	IN	O	O
type	VIMIZIM.xml:S1:592:4	type	NN	O	O
and	VIMIZIM.xml:S1:597:3	and	CC	O	O
frequency	VIMIZIM.xml:S1:601:9	frequenc	NN	O	O
as	VIMIZIM.xml:S1:611:2	as	IN	O	O
those	VIMIZIM.xml:S1:614:5	those	DT	O	O
observed	VIMIZIM.xml:S1:620:8	observ	VBN	O	O
in	VIMIZIM.xml:S1:629:2	in	IN	O	O
the	VIMIZIM.xml:S1:632:3	the	DT	O	O
placebo	VIMIZIM.xml:S1:636:7	placebo	NN	O	O
-	VIMIZIM.xml:S1:643:1	-	:	O	O
controlled	VIMIZIM.xml:S1:644:10	control	VBN	O	O
trial	VIMIZIM.xml:S1:655:5	trial	NN	O	O
(	VIMIZIM.xml:S1:661:1	(	(	O	O
see	VIMIZIM.xml:S1:662:3	see	VB	O	O
Table1	VIMIZIM.xml:S1:666:6	table1	NNP	O	O
)	VIMIZIM.xml:S1:672:1	)	)	O	O
.	VIMIZIM.xml:S1:673:1	.	.	O	O

The	VIMIZIM.xml:S1:675:3	the	DT	O	O
acute	VIMIZIM.xml:S1:679:5	acut	JJ	O	O
reactions	VIMIZIM.xml:S1:685:9	reaction	NNS	O	O
requiring	VIMIZIM.xml:S1:695:9	requir	VBG	O	O
intervention	VIMIZIM.xml:S1:705:12	intervent	NN	O	O
were	VIMIZIM.xml:S1:718:4	were	VBD	O	O
managed	VIMIZIM.xml:S1:723:7	manag	VBN	O	O
by	VIMIZIM.xml:S1:731:2	by	IN	O	O
either	VIMIZIM.xml:S1:734:6	either	DT	O	O
temporarily	VIMIZIM.xml:S1:741:11	temporarili	RB	O	O
interrupting	VIMIZIM.xml:S1:753:12	interrupt	NN	O	O
or	VIMIZIM.xml:S1:766:2	or	CC	O	O
discontinuing	VIMIZIM.xml:S1:769:13	discontinu	VBG	O	O
infusion	VIMIZIM.xml:S1:783:8	infus	NN	O	O
,	VIMIZIM.xml:S1:791:1	,	,	O	O
and	VIMIZIM.xml:S1:793:3	and	CC	O	O
administering	VIMIZIM.xml:S1:797:13	administ	VBG	O	O
additional	VIMIZIM.xml:S1:811:10	addit	JJ	O	O
antihistamine	VIMIZIM.xml:S1:822:13	antihistamin	NN	O	O
,	VIMIZIM.xml:S1:835:1	,	,	O	O
antipyretics	VIMIZIM.xml:S1:837:12	antipyret	NNS	O	O
,	VIMIZIM.xml:S1:849:1	,	,	O	O
or	VIMIZIM.xml:S1:851:2	or	CC	O	O
corticosteroids	VIMIZIM.xml:S1:854:15	corticosteroid	NNS	O	O
.	VIMIZIM.xml:S1:869:1	.	.	O	O

EXCERPT	VIMIZIM.xml:S1:877:7	excerpt	NN	O	O
:	VIMIZIM.xml:S1:884:1	:	:	O	O
The	VIMIZIM.xml:S1:888:3	the	DT	O	O
most	VIMIZIM.xml:S1:892:4	most	RBS	O	O
common	VIMIZIM.xml:S1:897:6	common	JJ	O	O
adverse	VIMIZIM.xml:S1:904:7	advers	JJ	O	O
reactions	VIMIZIM.xml:S1:912:9	reaction	NNS	O	O
(	VIMIZIM.xml:S1:922:1	(	(	O	O
10%	VIMIZIM.xml:S1:925:3	10%	CD	O	O
in	VIMIZIM.xml:S1:929:2	in	IN	O	O
Vimizim	VIMIZIM.xml:S1:932:7	vimizim	NNP	O	O
patients	VIMIZIM.xml:S1:940:8	patient	NNS	O	O
and	VIMIZIM.xml:S1:949:3	and	CC	O	O
occurring	VIMIZIM.xml:S1:953:9	occur	VBG	O	O
at	VIMIZIM.xml:S1:963:2	at	IN	O	O
a	VIMIZIM.xml:S1:966:1	a	DT	O	O
higher	VIMIZIM.xml:S1:968:6	higher	JJR	O	O
incidence	VIMIZIM.xml:S1:975:9	incid	NN	O	O
than	VIMIZIM.xml:S1:985:4	than	IN	O	O
placebo	VIMIZIM.xml:S1:990:7	placebo	FW	O	O
-	VIMIZIM.xml:S1:997:1	-	:	O	O
treated	VIMIZIM.xml:S1:998:7	treat	JJ	O	O
patients	VIMIZIM.xml:S1:1006:8	patient	NNS	O	O
)	VIMIZIM.xml:S1:1014:1	)	)	O	O
were	VIMIZIM.xml:S1:1016:4	were	VBD	O	O
pyrexia	VIMIZIM.xml:S1:1021:7	pyrexia	JJ	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S1:1028:1	,	,	O	O
vomiting	VIMIZIM.xml:S1:1030:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S1:1038:1	,	,	O	O
headache	VIMIZIM.xml:S1:1040:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S1:1048:1	,	,	O	O
nausea	VIMIZIM.xml:S1:1050:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S1:1056:1	,	,	O	O
abdominal	VIMIZIM.xml:S1:1058:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	VIMIZIM.xml:S1:1068:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S1:1072:1	,	,	O	O
chills	VIMIZIM.xml:S1:1074:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S1:1080:1	,	,	O	O
and	VIMIZIM.xml:S1:1082:3	and	CC	O	O
fatigue	VIMIZIM.xml:S1:1086:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
(	VIMIZIM.xml:S1:1094:1	(	(	O	O
6.1	VIMIZIM.xml:S1:1097:3	6.1	CD	O	O
)	VIMIZIM.xml:S1:1102:1	)	)	O	O
.	VIMIZIM.xml:S1:1103:1	.	.	O	O

To	VIMIZIM.xml:S1:1111:2	To	TO	O	O
report	VIMIZIM.xml:S1:1114:6	report	VB	O	O
SUSPECTED	VIMIZIM.xml:S1:1121:9	suspect	NNP	O	O
ADVERSE	VIMIZIM.xml:S1:1131:7	advers	NNP	O	O
REACTIONS	VIMIZIM.xml:S1:1139:9	reaction	NNP	O	O
,	VIMIZIM.xml:S1:1148:1	,	,	O	O
contact	VIMIZIM.xml:S1:1150:7	contact	NN	O	O
BioMarin	VIMIZIM.xml:S1:1158:8	biomarin	NNP	O	O
at	VIMIZIM.xml:S1:1167:2	at	IN	O	O
1	VIMIZIM.xml:S1:1170:1	1	CD	O	O
-	VIMIZIM.xml:S1:1171:1	-	:	O	O
866	VIMIZIM.xml:S1:1172:3	866	CD	O	O
-	VIMIZIM.xml:S1:1175:1	-	:	O	O
906	VIMIZIM.xml:S1:1176:3	906	CD	O	O
-	VIMIZIM.xml:S1:1179:1	-	:	O	O
6100	VIMIZIM.xml:S1:1180:4	6100	CD	O	O
or	VIMIZIM.xml:S1:1185:2	or	CC	O	O
FDA	VIMIZIM.xml:S1:1188:3	fda	NNP	O	O
at	VIMIZIM.xml:S1:1192:2	at	IN	O	O
1	VIMIZIM.xml:S1:1195:1	1	CD	O	O
-	VIMIZIM.xml:S1:1196:1	-	:	O	O
800	VIMIZIM.xml:S1:1197:3	800	CD	O	O
-	VIMIZIM.xml:S1:1200:1	-	:	O	O
FDA	VIMIZIM.xml:S1:1201:3	fda	NNP	O	O
-	VIMIZIM.xml:S1:1204:1	-	:	O	O
1088	VIMIZIM.xml:S1:1205:4	1088	CD	O	O
or	VIMIZIM.xml:S1:1210:2	or	CC	O	O
www	VIMIZIM.xml:S1:1213:3	www	VB	O	O
.	VIMIZIM.xml:S1:1216:1	.	.	O	O
fda	VIMIZIM.xml:S1:1217:3	fda	NN	O	O
.	VIMIZIM.xml:S1:1220:1	.	.	O	O
gov	VIMIZIM.xml:S1:1221:3	gov	JJ	O	O
medwatch	VIMIZIM.xml:S1:1225:8	medwatch	NN	O	O
.	VIMIZIM.xml:S1:1233:1	.	.	O	O

6.1	VIMIZIM.xml:S1:1245:3	6.1	CD	O	O

Clinical	VIMIZIM.xml:S1:1249:8	clinic	JJ	O	O
Trials	VIMIZIM.xml:S1:1258:6	trial	NNS	O	O
Experience	VIMIZIM.xml:S1:1265:10	experi	NN	O	O

A	VIMIZIM.xml:S1:1279:1	A	DT	O	O
24	VIMIZIM.xml:S1:1281:2	24	CD	O	O
-	VIMIZIM.xml:S1:1283:1	-	:	O	O
week	VIMIZIM.xml:S1:1284:4	week	NN	O	O
,	VIMIZIM.xml:S1:1288:1	,	,	O	O
randomized	VIMIZIM.xml:S1:1290:10	random	VBN	O	O
,	VIMIZIM.xml:S1:1300:1	,	,	O	O
double	VIMIZIM.xml:S1:1302:6	doubl	JJ	O	O
-	VIMIZIM.xml:S1:1308:1	-	:	O	O
blind	VIMIZIM.xml:S1:1309:5	blind	NN	O	O
,	VIMIZIM.xml:S1:1314:1	,	,	O	O
placebo	VIMIZIM.xml:S1:1316:7	placebo	SYM	O	O
-	VIMIZIM.xml:S1:1323:1	-	:	O	O
controlled	VIMIZIM.xml:S1:1324:10	control	VBN	O	O
clinical	VIMIZIM.xml:S1:1335:8	clinic	JJ	O	O
trial	VIMIZIM.xml:S1:1344:5	trial	NN	O	O
of	VIMIZIM.xml:S1:1350:2	of	IN	O	O
Vimizim	VIMIZIM.xml:S1:1353:7	vimizim	NNP	O	O
was	VIMIZIM.xml:S1:1361:3	wa	VBD	O	O
conducted	VIMIZIM.xml:S1:1365:9	conduct	VBN	O	O
in	VIMIZIM.xml:S1:1375:2	in	IN	O	O
176	VIMIZIM.xml:S1:1378:3	176	CD	O	O
patients	VIMIZIM.xml:S1:1382:8	patient	NNS	O	O
with	VIMIZIM.xml:S1:1391:4	with	IN	O	O
MPS	VIMIZIM.xml:S1:1396:3	mp	NNP	O	O
IVA	VIMIZIM.xml:S1:1400:3	iva	NNP	O	O
,	VIMIZIM.xml:S1:1403:1	,	,	O	O
ages	VIMIZIM.xml:S1:1405:4	age	VBZ	O	O
5	VIMIZIM.xml:S1:1410:1	5	CD	O	O
to	VIMIZIM.xml:S1:1412:2	to	TO	O	O
57	VIMIZIM.xml:S1:1415:2	57	CD	O	O
years	VIMIZIM.xml:S1:1418:5	year	NNS	O	O
old	VIMIZIM.xml:S1:1424:3	old	JJ	O	O
.	VIMIZIM.xml:S1:1427:1	.	.	O	O

Approximately	VIMIZIM.xml:S1:1430:13	approxim	RB	O	O
half	VIMIZIM.xml:S1:1444:4	half	NN	O	O
of	VIMIZIM.xml:S1:1449:2	of	IN	O	O
the	VIMIZIM.xml:S1:1452:3	the	DT	O	O
patients	VIMIZIM.xml:S1:1456:8	patient	NNS	O	O
(	VIMIZIM.xml:S1:1465:1	(	(	O	O
49%	VIMIZIM.xml:S1:1466:3	49%	CD	O	O
)	VIMIZIM.xml:S1:1469:1	)	)	O	O
were	VIMIZIM.xml:S1:1471:4	were	VBD	O	O
male	VIMIZIM.xml:S1:1476:4	male	JJ	O	O
.	VIMIZIM.xml:S1:1480:1	.	.	O	O

Of	VIMIZIM.xml:S1:1483:2	Of	IN	O	O
the	VIMIZIM.xml:S1:1486:3	the	DT	O	O
176	VIMIZIM.xml:S1:1490:3	176	CD	O	O
patients	VIMIZIM.xml:S1:1494:8	patient	NNS	O	O
,	VIMIZIM.xml:S1:1502:1	,	,	O	O
65%	VIMIZIM.xml:S1:1504:3	65%	CD	O	O
were	VIMIZIM.xml:S1:1508:4	were	VBD	O	O
White	VIMIZIM.xml:S1:1513:5	white	NNP	O	O
,	VIMIZIM.xml:S1:1518:1	,	,	O	O
23%	VIMIZIM.xml:S1:1520:3	23%	CD	O	O
Asian	VIMIZIM.xml:S1:1524:5	asian	JJ	O	O
,	VIMIZIM.xml:S1:1529:1	,	,	O	O
3%	VIMIZIM.xml:S1:1531:2	3%	CD	O	O
Black	VIMIZIM.xml:S1:1534:5	black	NNP	O	O
,	VIMIZIM.xml:S1:1539:1	,	,	O	O
and	VIMIZIM.xml:S1:1541:3	and	CC	O	O
10%	VIMIZIM.xml:S1:1545:3	10%	CD	O	O
Other	VIMIZIM.xml:S1:1549:5	other	JJ	O	O
race	VIMIZIM.xml:S1:1555:4	race	NN	O	O
.	VIMIZIM.xml:S1:1559:1	.	.	O	O

The	VIMIZIM.xml:S1:1562:3	the	DT	O	O
majority	VIMIZIM.xml:S1:1566:8	major	NN	O	O
of	VIMIZIM.xml:S1:1575:2	of	IN	O	O
patients	VIMIZIM.xml:S1:1578:8	patient	NNS	O	O
(	VIMIZIM.xml:S1:1587:1	(	(	O	O
78%	VIMIZIM.xml:S1:1588:3	78%	CD	O	O
)	VIMIZIM.xml:S1:1591:1	)	)	O	O
were	VIMIZIM.xml:S1:1593:4	were	VBD	O	O
non	VIMIZIM.xml:S1:1598:3	non	JJ	O	O
-	VIMIZIM.xml:S1:1601:1	-	:	O	O
Hispanic	VIMIZIM.xml:S1:1602:8	hispan	NN	O	O
.	VIMIZIM.xml:S1:1610:1	.	.	O	O

Patients	VIMIZIM.xml:S1:1612:8	patient	NNS	O	O
were	VIMIZIM.xml:S1:1621:4	were	VBD	O	O
randomized	VIMIZIM.xml:S1:1626:10	random	VBN	O	O
to	VIMIZIM.xml:S1:1637:2	to	TO	O	O
three	VIMIZIM.xml:S1:1640:5	three	CD	O	O
treatment	VIMIZIM.xml:S1:1646:9	treatment	NN	O	O
groups	VIMIZIM.xml:S1:1656:6	group	NNS	O	O
:	VIMIZIM.xml:S1:1662:1	:	:	O	O
Vimizim	VIMIZIM.xml:S1:1665:7	vimizim	NNP	O	O
2	VIMIZIM.xml:S1:1673:1	2	CD	O	O
mg	VIMIZIM.xml:S1:1675:2	mg	NN	O	O
kg	VIMIZIM.xml:S1:1678:2	kg	NN	O	O
once	VIMIZIM.xml:S1:1681:4	onc	RB	O	O
per	VIMIZIM.xml:S1:1686:3	per	IN	O	O
week	VIMIZIM.xml:S1:1690:4	week	NN	O	O
(	VIMIZIM.xml:S1:1695:1	(	(	O	O
n	VIMIZIM.xml:S1:1696:1	n	JJ	O	O
58	VIMIZIM.xml:S1:1698:2	58	CD	O	O
)	VIMIZIM.xml:S1:1700:1	)	)	O	O
,	VIMIZIM.xml:S1:1701:1	,	,	O	O
Vimizim	VIMIZIM.xml:S1:1703:7	vimizim	NNP	O	O
2	VIMIZIM.xml:S1:1711:1	2	CD	O	O
mg	VIMIZIM.xml:S1:1713:2	mg	NN	O	O
kg	VIMIZIM.xml:S1:1716:2	kg	NN	O	O
once	VIMIZIM.xml:S1:1719:4	onc	RB	O	O
every	VIMIZIM.xml:S1:1724:5	everi	DT	O	O
other	VIMIZIM.xml:S1:1730:5	other	JJ	O	O
week	VIMIZIM.xml:S1:1736:4	week	NN	O	O
(	VIMIZIM.xml:S1:1741:1	(	(	O	O
n	VIMIZIM.xml:S1:1742:1	n	JJ	O	O
59	VIMIZIM.xml:S1:1744:2	59	CD	O	O
)	VIMIZIM.xml:S1:1746:1	)	)	O	O
,	VIMIZIM.xml:S1:1747:1	,	,	O	O
or	VIMIZIM.xml:S1:1749:2	or	CC	O	O
placebo	VIMIZIM.xml:S1:1752:7	placebo	NN	O	O
(	VIMIZIM.xml:S1:1760:1	(	(	O	O
n	VIMIZIM.xml:S1:1761:1	n	JJ	O	O
59	VIMIZIM.xml:S1:1763:2	59	CD	O	O
)	VIMIZIM.xml:S1:1765:1	)	)	O	O
.	VIMIZIM.xml:S1:1766:1	.	.	O	O

All	VIMIZIM.xml:S1:1769:3	all	DT	O	O
patients	VIMIZIM.xml:S1:1773:8	patient	NNS	O	O
were	VIMIZIM.xml:S1:1782:4	were	VBD	O	O
treated	VIMIZIM.xml:S1:1787:7	treat	VBN	O	O
with	VIMIZIM.xml:S1:1795:4	with	IN	O	O
antihistamines	VIMIZIM.xml:S1:1800:14	antihistamin	NNS	O	O
prior	VIMIZIM.xml:S1:1815:5	prior	RB	O	O
to	VIMIZIM.xml:S1:1821:2	to	TO	O	O
each	VIMIZIM.xml:S1:1824:4	each	DT	O	O
infusion	VIMIZIM.xml:S1:1829:8	infus	NN	O	O
.	VIMIZIM.xml:S1:1837:1	.	.	O	O

Table	VIMIZIM.xml:S1:1843:5	tabl	JJ	O	O
1	VIMIZIM.xml:S1:1849:1	1	CD	O	O
summarizes	VIMIZIM.xml:S1:1851:10	summar	VBZ	O	O
the	VIMIZIM.xml:S1:1862:3	the	DT	O	O
most	VIMIZIM.xml:S1:1866:4	most	RBS	O	O
common	VIMIZIM.xml:S1:1871:6	common	JJ	O	O
adverse	VIMIZIM.xml:S1:1878:7	advers	JJ	O	O
reactions	VIMIZIM.xml:S1:1886:9	reaction	NNS	O	O
that	VIMIZIM.xml:S1:1896:4	that	WDT	O	O
occurred	VIMIZIM.xml:S1:1901:8	occur	VBD	O	O
in	VIMIZIM.xml:S1:1910:2	in	IN	O	O
the	VIMIZIM.xml:S1:1913:3	the	DT	O	O
placebo	VIMIZIM.xml:S1:1917:7	placebo	NN	O	O
-	VIMIZIM.xml:S1:1924:1	-	:	O	O
controlled	VIMIZIM.xml:S1:1925:10	control	VBN	O	O
trial	VIMIZIM.xml:S1:1936:5	trial	NN	O	O
with	VIMIZIM.xml:S1:1942:4	with	IN	O	O
an	VIMIZIM.xml:S1:1947:2	an	DT	O	O
incidence	VIMIZIM.xml:S1:1950:9	incid	NN	O	O
of	VIMIZIM.xml:S1:1960:2	of	IN	O	O
10%	VIMIZIM.xml:S1:1966:3	10%	CD	O	O
in	VIMIZIM.xml:S1:1970:2	in	IN	O	O
patients	VIMIZIM.xml:S1:1973:8	patient	NNS	O	O
treated	VIMIZIM.xml:S1:1982:7	treat	VBN	O	O
with	VIMIZIM.xml:S1:1990:4	with	IN	O	O
Vimizim	VIMIZIM.xml:S1:1995:7	vimizim	NNP	O	O
2	VIMIZIM.xml:S1:2003:1	2	CD	O	O
mg	VIMIZIM.xml:S1:2005:2	mg	NN	O	O
kg	VIMIZIM.xml:S1:2008:2	kg	NN	O	O
once	VIMIZIM.xml:S1:2011:4	onc	RB	O	O
per	VIMIZIM.xml:S1:2016:3	per	IN	O	O
week	VIMIZIM.xml:S1:2020:4	week	NN	O	O
and	VIMIZIM.xml:S1:2025:3	and	CC	O	O
with	VIMIZIM.xml:S1:2029:4	with	IN	O	O
a	VIMIZIM.xml:S1:2034:1	a	DT	O	O
higher	VIMIZIM.xml:S1:2036:6	higher	JJR	O	O
incidence	VIMIZIM.xml:S1:2043:9	incid	NN	O	O
than	VIMIZIM.xml:S1:2053:4	than	IN	O	O
in	VIMIZIM.xml:S1:2058:2	in	IN	O	O
the	VIMIZIM.xml:S1:2061:3	the	DT	O	O
placebo	VIMIZIM.xml:S1:2065:7	placebo	NN	O	O
-	VIMIZIM.xml:S1:2072:1	-	:	O	O
treated	VIMIZIM.xml:S1:2073:7	treat	JJ	O	O
patients	VIMIZIM.xml:S1:2081:8	patient	NNS	O	O
.	VIMIZIM.xml:S1:2089:1	.	.	O	O

Table	VIMIZIM.xml:S1:2098:5	tabl	JJ	O	O
1	VIMIZIM.xml:S1:2104:1	1	CD	O	O
:	VIMIZIM.xml:S1:2105:1	:	:	O	O
Adverse	VIMIZIM.xml:S1:2107:7	advers	JJ	O	O
Reactions	VIMIZIM.xml:S1:2115:9	reaction	NNS	O	O
That	VIMIZIM.xml:S1:2125:4	that	WDT	O	O
Occurred	VIMIZIM.xml:S1:2130:8	occur	VBD	O	O
in	VIMIZIM.xml:S1:2139:2	in	IN	O	O
the	VIMIZIM.xml:S1:2142:3	the	DT	O	O
Placebo	VIMIZIM.xml:S1:2146:7	placebo	NNP	O	O
-	VIMIZIM.xml:S1:2153:1	-	:	O	O
Controlled	VIMIZIM.xml:S1:2154:10	control	VBD	O	O
Trial	VIMIZIM.xml:S1:2165:5	trial	JJ	O	O
in	VIMIZIM.xml:S1:2171:2	in	IN	O	O
At	VIMIZIM.xml:S1:2174:2	At	IN	O	O
Least	VIMIZIM.xml:S1:2177:5	least	NNP	O	O
10%	VIMIZIM.xml:S1:2183:3	10%	CD	O	O
of	VIMIZIM.xml:S1:2187:2	of	IN	O	O
Patients	VIMIZIM.xml:S1:2190:8	patient	NNS	O	O
in	VIMIZIM.xml:S1:2199:2	in	IN	O	O
the	VIMIZIM.xml:S1:2202:3	the	DT	O	O
Vimizim	VIMIZIM.xml:S1:2206:7	vimizim	NNP	O	O
2	VIMIZIM.xml:S1:2214:1	2	CD	O	O
mg	VIMIZIM.xml:S1:2216:2	mg	NN	O	O
kg	VIMIZIM.xml:S1:2219:2	kg	NN	O	O
Once	VIMIZIM.xml:S1:2222:4	onc	NNP	O	O
Per	VIMIZIM.xml:S1:2227:3	per	NNP	O	O
Week	VIMIZIM.xml:S1:2231:4	week	NNP	O	O
Group	VIMIZIM.xml:S1:2236:5	group	NNP	O	O
and	VIMIZIM.xml:S1:2242:3	and	CC	O	O
with	VIMIZIM.xml:S1:2246:4	with	IN	O	O
a	VIMIZIM.xml:S1:2251:1	a	DT	O	O
Higher	VIMIZIM.xml:S1:2253:6	higher	JJR	O	O
Incidence	VIMIZIM.xml:S1:2260:9	incid	NN	O	O
than	VIMIZIM.xml:S1:2270:4	than	IN	O	O
in	VIMIZIM.xml:S1:2275:2	in	IN	O	O
the	VIMIZIM.xml:S1:2278:3	the	DT	O	O
Placebo	VIMIZIM.xml:S1:2282:7	placebo	NNP	O	O
Group	VIMIZIM.xml:S1:2290:5	group	NNP	O	O

Adverse	VIMIZIM.xml:S1:2304:7	advers	JJ	O	O
Reaction	VIMIZIM.xml:S1:2312:8	reaction	NNP	O	O
Vimizim	VIMIZIM.xml:S1:2324:7	vimizim	NNP	O	O
2	VIMIZIM.xml:S1:2332:1	2	CD	O	O
mg	VIMIZIM.xml:S1:2334:2	mg	NN	O	O
kg	VIMIZIM.xml:S1:2337:2	kg	NN	O	O
once	VIMIZIM.xml:S1:2340:4	onc	RB	O	O
per	VIMIZIM.xml:S1:2345:3	per	IN	O	O
week	VIMIZIM.xml:S1:2349:4	week	NN	O	O
Placebo	VIMIZIM.xml:S1:2357:7	placebo	NN	O	O

N	VIMIZIM.xml:S1:2394:1	N	NNP	O	O
58	VIMIZIM.xml:S1:2397:2	58	CD	O	O
n	VIMIZIM.xml:S1:2399:1	n	NN	O	O
(	VIMIZIM.xml:S1:2401:1	(	(	O	O
)	VIMIZIM.xml:S1:2403:1	)	)	O	O
N	VIMIZIM.xml:S1:2411:1	N	NNP	O	O
59	VIMIZIM.xml:S1:2414:2	59	CD	O	O
n	VIMIZIM.xml:S1:2418:1	n	NN	O	O
(	VIMIZIM.xml:S1:2420:1	(	(	O	O
)	VIMIZIM.xml:S1:2422:1	)	)	O	O

Pyrexia	VIMIZIM.xml:S1:2431:7	pyrexia	$	B-AdverseReaction	B-AdverseReaction
19	VIMIZIM.xml:S1:2448:2	19	CD	O	O
(	VIMIZIM.xml:S1:2451:1	(	(	O	O
33%	VIMIZIM.xml:S1:2452:3	33%	CD	O	O
)	VIMIZIM.xml:S1:2455:1	)	)	O	O
8	VIMIZIM.xml:S1:2465:1	8	CD	O	O
(	VIMIZIM.xml:S1:2467:1	(	(	O	O
14%	VIMIZIM.xml:S1:2468:3	14%	CD	O	O
)	VIMIZIM.xml:S1:2471:1	)	)	O	O

Vomiting	VIMIZIM.xml:S1:2485:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
18	VIMIZIM.xml:S1:2502:2	18	CD	O	O
(	VIMIZIM.xml:S1:2505:1	(	(	O	O
31%	VIMIZIM.xml:S1:2506:3	31%	CD	O	O
)	VIMIZIM.xml:S1:2509:1	)	)	O	O
4	VIMIZIM.xml:S1:2519:1	4	CD	O	O
(	VIMIZIM.xml:S1:2521:1	(	(	O	O
7%	VIMIZIM.xml:S1:2522:2	7%	CD	O	O
)	VIMIZIM.xml:S1:2524:1	)	)	O	O

Headache	VIMIZIM.xml:S1:2539:8	headach	$	B-AdverseReaction	B-AdverseReaction
15	VIMIZIM.xml:S1:2556:2	15	CD	O	O
(	VIMIZIM.xml:S1:2559:1	(	(	O	O
26%	VIMIZIM.xml:S1:2560:3	26%	CD	O	O
)	VIMIZIM.xml:S1:2563:1	)	)	O	O
9	VIMIZIM.xml:S1:2573:1	9	CD	O	O
(	VIMIZIM.xml:S1:2575:1	(	(	O	O
15%	VIMIZIM.xml:S1:2576:3	15%	CD	O	O
)	VIMIZIM.xml:S1:2579:1	)	)	O	O

Nausea	VIMIZIM.xml:S1:2593:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
14	VIMIZIM.xml:S1:2610:2	14	CD	O	O
(	VIMIZIM.xml:S1:2613:1	(	(	O	O
24%	VIMIZIM.xml:S1:2614:3	24%	CD	O	O
)	VIMIZIM.xml:S1:2617:1	)	)	O	O
4	VIMIZIM.xml:S1:2627:1	4	CD	O	O
(	VIMIZIM.xml:S1:2629:1	(	(	O	O
7%	VIMIZIM.xml:S1:2630:2	7%	CD	O	O
)	VIMIZIM.xml:S1:2632:1	)	)	O	O

Abdominal	VIMIZIM.xml:S1:2647:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	VIMIZIM.xml:S1:2657:4	pain	NN	I-AdverseReaction	I-AdverseReaction
12	VIMIZIM.xml:S1:2665:2	12	CD	O	O
(	VIMIZIM.xml:S1:2668:1	(	(	O	O
21%	VIMIZIM.xml:S1:2669:3	21%	CD	O	O
)	VIMIZIM.xml:S1:2672:1	)	)	O	O
1	VIMIZIM.xml:S1:2682:1	1	CD	O	O
(	VIMIZIM.xml:S1:2684:1	(	(	O	O
1.7%	VIMIZIM.xml:S1:2685:4	1.7%	CD	O	O
)	VIMIZIM.xml:S1:2689:1	)	)	O	O

Chills	VIMIZIM.xml:S1:2702:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
6	VIMIZIM.xml:S1:2719:1	6	CD	O	O
(	VIMIZIM.xml:S1:2721:1	(	(	O	O
10.3%	VIMIZIM.xml:S1:2722:5	10.3%	CD	O	O
)	VIMIZIM.xml:S1:2727:1	)	)	O	O
1	VIMIZIM.xml:S1:2736:1	1	CD	O	O
(	VIMIZIM.xml:S1:2738:1	(	(	O	O
1.7%	VIMIZIM.xml:S1:2739:4	1.7%	CD	O	O
)	VIMIZIM.xml:S1:2743:1	)	)	O	O

Fatigue	VIMIZIM.xml:S1:2756:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
6	VIMIZIM.xml:S1:2773:1	6	CD	O	O
(	VIMIZIM.xml:S1:2775:1	(	(	O	O
10.3%	VIMIZIM.xml:S1:2776:5	10.3%	CD	O	O
)	VIMIZIM.xml:S1:2781:1	)	)	O	O
2	VIMIZIM.xml:S1:2790:1	2	CD	O	O
(	VIMIZIM.xml:S1:2792:1	(	(	O	O
3.4%	VIMIZIM.xml:S1:2793:4	3.4%	CD	O	O
)	VIMIZIM.xml:S1:2797:1	)	)	O	O

Extension	VIMIZIM.xml:S1:2819:9	extens	NN	O	O
Trial	VIMIZIM.xml:S1:2829:5	trial	NN	O	O

An	VIMIZIM.xml:S1:2841:2	An	DT	O	O

open	VIMIZIM.xml:S1:2844:4	open	JJ	O	O
-	VIMIZIM.xml:S1:2848:1	-	:	O	O
label	VIMIZIM.xml:S1:2849:5	label	NN	O	O
extension	VIMIZIM.xml:S1:2855:9	extens	NN	O	O
trial	VIMIZIM.xml:S1:2865:5	trial	NN	O	O
was	VIMIZIM.xml:S1:2871:3	wa	VBD	O	O
conducted	VIMIZIM.xml:S1:2875:9	conduct	VBN	O	O
in	VIMIZIM.xml:S1:2885:2	in	IN	O	O
173	VIMIZIM.xml:S1:2888:3	173	CD	O	O
patients	VIMIZIM.xml:S1:2892:8	patient	NNS	O	O
who	VIMIZIM.xml:S1:2901:3	who	WP	O	O
completed	VIMIZIM.xml:S1:2905:9	complet	VBD	O	O
the	VIMIZIM.xml:S1:2915:3	the	DT	O	O
placebo	VIMIZIM.xml:S1:2919:7	placebo	NN	O	O
-	VIMIZIM.xml:S1:2926:1	-	:	O	O
controlled	VIMIZIM.xml:S1:2927:10	control	VBN	O	O
trial	VIMIZIM.xml:S1:2938:5	trial	NN	O	O
[	VIMIZIM.xml:S1:2945:1	[	NN	O	O
see	VIMIZIM.xml:S1:2946:3	see	VB	O	O
Clinical	VIMIZIM.xml:S1:2950:8	clinic	JJ	O	O
Studies	VIMIZIM.xml:S1:2959:7	studi	NNP	O	O
(	VIMIZIM.xml:S1:2967:1	(	(	O	O
14	VIMIZIM.xml:S1:2970:2	14	CD	O	O
)]	VIMIZIM.xml:S1:2974:2	)]	NN	O	O
.	VIMIZIM.xml:S1:2978:1	.	.	O	O

No	VIMIZIM.xml:S1:2980:2	No	DT	O	O
new	VIMIZIM.xml:S1:2983:3	new	JJ	O	O
adverse	VIMIZIM.xml:S1:2987:7	advers	JJ	O	O
reactions	VIMIZIM.xml:S1:2995:9	reaction	NNS	O	O
were	VIMIZIM.xml:S1:3005:4	were	VBD	O	O
reported	VIMIZIM.xml:S1:3010:8	report	VBN	O	O
.	VIMIZIM.xml:S1:3018:1	.	.	O	O

6.2	VIMIZIM.xml:S1:3026:3	6.2	CD	O	O
Immunogenicity	VIMIZIM.xml:S1:3030:14	immunogen	NN	O	O

As	VIMIZIM.xml:S1:3048:2	As	IN	O	O
with	VIMIZIM.xml:S1:3051:4	with	IN	O	O
all	VIMIZIM.xml:S1:3056:3	all	DT	O	O
therapeutic	VIMIZIM.xml:S1:3060:11	therapeut	JJ	O	O
proteins	VIMIZIM.xml:S1:3072:8	protein	NNS	O	O
,	VIMIZIM.xml:S1:3080:1	,	,	O	O
there	VIMIZIM.xml:S1:3082:5	there	EX	O	O
is	VIMIZIM.xml:S1:3088:2	is	VBZ	O	O
potential	VIMIZIM.xml:S1:3091:9	potenti	JJ	O	O
for	VIMIZIM.xml:S1:3101:3	for	IN	O	O
immunogenicity	VIMIZIM.xml:S1:3105:14	immunogen	NN	O	O
.	VIMIZIM.xml:S1:3119:1	.	.	O	O

All	VIMIZIM.xml:S1:3121:3	all	DT	O	O
patients	VIMIZIM.xml:S1:3125:8	patient	NNS	O	O
treated	VIMIZIM.xml:S1:3134:7	treat	VBN	O	O
with	VIMIZIM.xml:S1:3142:4	with	IN	O	O
Vimizim	VIMIZIM.xml:S1:3147:7	vimizim	NNP	O	O
2	VIMIZIM.xml:S1:3155:1	2	CD	O	O
mg	VIMIZIM.xml:S1:3157:2	mg	NN	O	O
kg	VIMIZIM.xml:S1:3160:2	kg	NN	O	O
once	VIMIZIM.xml:S1:3163:4	onc	RB	O	O
per	VIMIZIM.xml:S1:3168:3	per	IN	O	O
week	VIMIZIM.xml:S1:3172:4	week	NN	O	O
in	VIMIZIM.xml:S1:3177:2	in	IN	O	O
the	VIMIZIM.xml:S1:3180:3	the	DT	O	O
placebo	VIMIZIM.xml:S1:3184:7	placebo	NN	O	O
-	VIMIZIM.xml:S1:3191:1	-	:	O	O
controlled	VIMIZIM.xml:S1:3192:10	control	VBN	O	O
trial	VIMIZIM.xml:S1:3203:5	trial	NN	O	O
developed	VIMIZIM.xml:S1:3209:9	develop	VBD	O	O
anti	VIMIZIM.xml:S1:3219:4	anti	JJ	O	O
-	VIMIZIM.xml:S1:3223:1	-	:	O	O
drug	VIMIZIM.xml:S1:3224:4	drug	NN	O	O
antibodies	VIMIZIM.xml:S1:3229:10	antibodi	NNS	O	O
by	VIMIZIM.xml:S1:3240:2	by	IN	O	O
Week	VIMIZIM.xml:S1:3243:4	week	JJ	O	O
4	VIMIZIM.xml:S1:3248:1	4	CD	O	O
.	VIMIZIM.xml:S1:3249:1	.	.	O	O

Anti	VIMIZIM.xml:S1:3251:4	anti	NNP	O	O
-	VIMIZIM.xml:S1:3255:1	-	:	O	O
drug	VIMIZIM.xml:S1:3256:4	drug	NN	O	O
antibody	VIMIZIM.xml:S1:3261:8	antibodi	NN	O	O
titers	VIMIZIM.xml:S1:3270:6	titer	NNS	O	O
were	VIMIZIM.xml:S1:3277:4	were	VBD	O	O
sustained	VIMIZIM.xml:S1:3282:9	sustain	VBN	O	O
or	VIMIZIM.xml:S1:3292:2	or	CC	O	O
increased	VIMIZIM.xml:S1:3295:9	increas	VBN	O	O
for	VIMIZIM.xml:S1:3305:3	for	IN	O	O
the	VIMIZIM.xml:S1:3309:3	the	DT	O	O
duration	VIMIZIM.xml:S1:3313:8	durat	NN	O	O
of	VIMIZIM.xml:S1:3322:2	of	IN	O	O
Vimizim	VIMIZIM.xml:S1:3325:7	vimizim	NNP	O	O
treatment	VIMIZIM.xml:S1:3333:9	treatment	NN	O	O
.	VIMIZIM.xml:S1:3342:1	.	.	O	O

Because	VIMIZIM.xml:S1:3344:7	becaus	IN	O	O
all	VIMIZIM.xml:S1:3352:3	all	DT	O	O
patients	VIMIZIM.xml:S1:3356:8	patient	NNS	O	O
developed	VIMIZIM.xml:S1:3365:9	develop	VBD	O	O
anti	VIMIZIM.xml:S1:3375:4	anti	JJ	O	O
-	VIMIZIM.xml:S1:3379:1	-	:	O	O
drug	VIMIZIM.xml:S1:3380:4	drug	NN	O	O
antibodies	VIMIZIM.xml:S1:3385:10	antibodi	NNS	O	O
,	VIMIZIM.xml:S1:3395:1	,	,	O	O
associations	VIMIZIM.xml:S1:3397:12	associ	NNS	O	O
between	VIMIZIM.xml:S1:3410:7	between	IN	O	O
antibody	VIMIZIM.xml:S1:3418:8	antibodi	NN	O	O
titers	VIMIZIM.xml:S1:3427:6	titer	NNS	O	O
and	VIMIZIM.xml:S1:3434:3	and	CC	O	O
reductions	VIMIZIM.xml:S1:3438:10	reduct	NNS	O	O
in	VIMIZIM.xml:S1:3449:2	in	IN	O	O
treatment	VIMIZIM.xml:S1:3452:9	treatment	NN	O	O
effect	VIMIZIM.xml:S1:3462:6	effect	NN	O	O
or	VIMIZIM.xml:S1:3469:2	or	CC	O	O
the	VIMIZIM.xml:S1:3472:3	the	DT	O	O
occurrence	VIMIZIM.xml:S1:3476:10	occurr	NN	O	O
of	VIMIZIM.xml:S1:3487:2	of	IN	O	O
anaphylaxis	VIMIZIM.xml:S1:3490:11	anaphylaxi	NN	O	O
or	VIMIZIM.xml:S1:3502:2	or	CC	O	O
other	VIMIZIM.xml:S1:3505:5	other	JJ	O	O
hypersensitivity	VIMIZIM.xml:S1:3511:16	hypersensit	NN	O	O
reactions	VIMIZIM.xml:S1:3528:9	reaction	NNS	O	O
could	VIMIZIM.xml:S1:3538:5	could	MD	O	O
not	VIMIZIM.xml:S1:3544:3	not	RB	O	O
be	VIMIZIM.xml:S1:3548:2	be	VB	O	O
determined	VIMIZIM.xml:S1:3551:10	determin	VBN	O	O
.	VIMIZIM.xml:S1:3561:1	.	.	O	O

All	VIMIZIM.xml:S1:3567:3	all	DT	O	O
patients	VIMIZIM.xml:S1:3571:8	patient	NNS	O	O
treated	VIMIZIM.xml:S1:3580:7	treat	VBN	O	O
with	VIMIZIM.xml:S1:3588:4	with	IN	O	O
Vimizim	VIMIZIM.xml:S1:3593:7	vimizim	NNP	O	O
2	VIMIZIM.xml:S1:3601:1	2	CD	O	O
mg	VIMIZIM.xml:S1:3603:2	mg	NN	O	O
kg	VIMIZIM.xml:S1:3606:2	kg	NN	O	O
once	VIMIZIM.xml:S1:3609:4	onc	RB	O	O
per	VIMIZIM.xml:S1:3614:3	per	IN	O	O
week	VIMIZIM.xml:S1:3618:4	week	NN	O	O
tested	VIMIZIM.xml:S1:3623:6	test	VBN	O	O
positive	VIMIZIM.xml:S1:3630:8	posit	JJ	O	O
for	VIMIZIM.xml:S1:3639:3	for	IN	O	O
neutralizing	VIMIZIM.xml:S1:3643:12	neutral	VBG	O	O
antibodies	VIMIZIM.xml:S1:3656:10	antibodi	NNS	O	O
capable	VIMIZIM.xml:S1:3667:7	capabl	JJ	O	O
of	VIMIZIM.xml:S1:3675:2	of	IN	O	O
inhibiting	VIMIZIM.xml:S1:3678:10	inhibit	VBG	O	O
the	VIMIZIM.xml:S1:3689:3	the	DT	O	O
drug	VIMIZIM.xml:S1:3693:4	drug	NN	O	O
from	VIMIZIM.xml:S1:3698:4	from	IN	O	O
binding	VIMIZIM.xml:S1:3703:7	bind	VBG	O	O
to	VIMIZIM.xml:S1:3711:2	to	TO	O	O
the	VIMIZIM.xml:S1:3714:3	the	DT	O	O
mannose	VIMIZIM.xml:S1:3718:7	mannos	JJ	O	O
-	VIMIZIM.xml:S1:3725:1	-	:	O	O
6	VIMIZIM.xml:S1:3726:1	6	CD	O	O
-	VIMIZIM.xml:S1:3727:1	-	:	O	O
phosphate	VIMIZIM.xml:S1:3728:9	phosphat	NN	O	O
receptor	VIMIZIM.xml:S1:3738:8	receptor	NN	O	O
at	VIMIZIM.xml:S1:3747:2	at	IN	O	O
least	VIMIZIM.xml:S1:3750:5	least	JJS	O	O
once	VIMIZIM.xml:S1:3756:4	onc	RB	O	O
during	VIMIZIM.xml:S1:3761:6	dure	IN	O	O
the	VIMIZIM.xml:S1:3768:3	the	DT	O	O
trial	VIMIZIM.xml:S1:3772:5	trial	NN	O	O
.	VIMIZIM.xml:S1:3777:1	.	.	O	O

Binding	VIMIZIM.xml:S1:3779:7	bind	VBG	O	O
to	VIMIZIM.xml:S1:3787:2	to	TO	O	O
this	VIMIZIM.xml:S1:3790:4	thi	DT	O	O
receptor	VIMIZIM.xml:S1:3795:8	receptor	NN	O	O
is	VIMIZIM.xml:S1:3804:2	is	VBZ	O	O
required	VIMIZIM.xml:S1:3807:8	requir	VBN	O	O
for	VIMIZIM.xml:S1:3816:3	for	IN	O	O
Vimizim	VIMIZIM.xml:S1:3820:7	vimizim	NNP	O	O
to	VIMIZIM.xml:S1:3828:2	to	TO	O	O
be	VIMIZIM.xml:S1:3831:2	be	VB	O	O
taken	VIMIZIM.xml:S1:3834:5	taken	VBN	O	O
into	VIMIZIM.xml:S1:3840:4	into	IN	O	O
cells	VIMIZIM.xml:S1:3845:5	cell	NNS	O	O
where	VIMIZIM.xml:S1:3851:5	where	WRB	O	O
it	VIMIZIM.xml:S1:3857:2	it	PRP	O	O
is	VIMIZIM.xml:S1:3860:2	is	VBZ	O	O
active	VIMIZIM.xml:S1:3863:6	activ	JJ	O	O
.	VIMIZIM.xml:S1:3869:1	.	.	O	O

Neutralizing	VIMIZIM.xml:S1:3872:12	neutral	VBG	O	O
antibody	VIMIZIM.xml:S1:3885:8	antibodi	NN	O	O
titers	VIMIZIM.xml:S1:3894:6	titer	NNS	O	O
were	VIMIZIM.xml:S1:3901:4	were	VBD	O	O
not	VIMIZIM.xml:S1:3906:3	not	RB	O	O
determined	VIMIZIM.xml:S1:3910:10	determin	VBN	O	O
in	VIMIZIM.xml:S1:3921:2	in	IN	O	O
the	VIMIZIM.xml:S1:3924:3	the	DT	O	O
patients	VIMIZIM.xml:S1:3928:8	patient	NNS	O	O
.	VIMIZIM.xml:S1:3936:1	.	.	O	O

Therefore	VIMIZIM.xml:S1:3939:9	therefor	RB	O	O
,	VIMIZIM.xml:S1:3948:1	,	,	O	O
the	VIMIZIM.xml:S1:3950:3	the	DT	O	O
possibility	VIMIZIM.xml:S1:3954:11	possibl	NN	O	O
of	VIMIZIM.xml:S1:3966:2	of	IN	O	O
an	VIMIZIM.xml:S1:3969:2	an	DT	O	O
association	VIMIZIM.xml:S1:3972:11	associ	NN	O	O
between	VIMIZIM.xml:S1:3984:7	between	IN	O	O
neutralizing	VIMIZIM.xml:S1:3992:12	neutral	VBG	O	O
antibody	VIMIZIM.xml:S1:4005:8	antibodi	NN	O	O
titer	VIMIZIM.xml:S1:4014:5	titer	NN	O	O
and	VIMIZIM.xml:S1:4020:3	and	CC	O	O
treatment	VIMIZIM.xml:S1:4024:9	treatment	NN	O	O
effect	VIMIZIM.xml:S1:4034:6	effect	NN	O	O
cannot	VIMIZIM.xml:S1:4041:6	cannot	NN	O	O
be	VIMIZIM.xml:S1:4048:2	be	VB	O	O
assessed	VIMIZIM.xml:S1:4051:8	assess	VBN	O	O
.	VIMIZIM.xml:S1:4059:1	.	.	O	O

Assessment	VIMIZIM.xml:S1:4065:10	assess	NN	O	O
of	VIMIZIM.xml:S1:4076:2	of	IN	O	O
the	VIMIZIM.xml:S1:4079:3	the	DT	O	O
incidence	VIMIZIM.xml:S1:4083:9	incid	NN	O	O
of	VIMIZIM.xml:S1:4093:2	of	IN	O	O
antibody	VIMIZIM.xml:S1:4096:8	antibodi	NN	O	O
formation	VIMIZIM.xml:S1:4105:9	format	NN	O	O
is	VIMIZIM.xml:S1:4115:2	is	VBZ	O	O
highly	VIMIZIM.xml:S1:4118:6	highli	RB	O	O
dependent	VIMIZIM.xml:S1:4125:9	depend	JJ	O	O
on	VIMIZIM.xml:S1:4135:2	on	IN	O	O
the	VIMIZIM.xml:S1:4138:3	the	DT	O	O
sensitivity	VIMIZIM.xml:S1:4142:11	sensit	NN	O	O
and	VIMIZIM.xml:S1:4154:3	and	CC	O	O
specificity	VIMIZIM.xml:S1:4158:11	specif	NN	O	O
of	VIMIZIM.xml:S1:4170:2	of	IN	O	O
the	VIMIZIM.xml:S1:4173:3	the	DT	O	O
assay	VIMIZIM.xml:S1:4177:5	assay	NN	O	O
.	VIMIZIM.xml:S1:4182:1	.	.	O	O

Additionally	VIMIZIM.xml:S1:4184:12	addit	RB	O	O
,	VIMIZIM.xml:S1:4196:1	,	,	O	O
the	VIMIZIM.xml:S1:4198:3	the	DT	O	O
observed	VIMIZIM.xml:S1:4202:8	observ	JJ	O	O
incidence	VIMIZIM.xml:S1:4211:9	incid	NN	O	O
of	VIMIZIM.xml:S1:4221:2	of	IN	O	O
antibody	VIMIZIM.xml:S1:4224:8	antibodi	NN	O	O
(	VIMIZIM.xml:S1:4233:1	(	(	O	O
including	VIMIZIM.xml:S1:4234:9	includ	VBG	O	O
neutralizing	VIMIZIM.xml:S1:4244:12	neutral	VBG	O	O
antibody	VIMIZIM.xml:S1:4257:8	antibodi	NN	O	O
)	VIMIZIM.xml:S1:4265:1	)	)	O	O
positivity	VIMIZIM.xml:S1:4267:10	posit	NN	O	O
in	VIMIZIM.xml:S1:4278:2	in	IN	O	O
an	VIMIZIM.xml:S1:4281:2	an	DT	O	O
assay	VIMIZIM.xml:S1:4284:5	assay	NN	O	O
may	VIMIZIM.xml:S1:4290:3	may	MD	O	O
be	VIMIZIM.xml:S1:4294:2	be	VB	O	O
influenced	VIMIZIM.xml:S1:4297:10	influenc	VBN	O	O
by	VIMIZIM.xml:S1:4308:2	by	IN	O	O
several	VIMIZIM.xml:S1:4311:7	sever	JJ	O	O
factors	VIMIZIM.xml:S1:4319:7	factor	NNS	O	O
including	VIMIZIM.xml:S1:4327:9	includ	VBG	O	O
assay	VIMIZIM.xml:S1:4337:5	assay	JJ	O	O
methodology	VIMIZIM.xml:S1:4343:11	methodolog	NN	O	O
,	VIMIZIM.xml:S1:4354:1	,	,	O	O
sample	VIMIZIM.xml:S1:4356:6	sampl	NN	O	O
handling	VIMIZIM.xml:S1:4363:8	handl	NN	O	O
,	VIMIZIM.xml:S1:4371:1	,	,	O	O
timing	VIMIZIM.xml:S1:4373:6	time	NN	O	O
of	VIMIZIM.xml:S1:4380:2	of	IN	O	O
sample	VIMIZIM.xml:S1:4383:6	sampl	JJ	O	O
collection	VIMIZIM.xml:S1:4390:10	collect	NN	O	O
,	VIMIZIM.xml:S1:4400:1	,	,	O	O
concomitant	VIMIZIM.xml:S1:4402:11	concomit	JJ	O	O
medications	VIMIZIM.xml:S1:4414:11	medic	NNS	O	O
,	VIMIZIM.xml:S1:4425:1	,	,	O	O
and	VIMIZIM.xml:S1:4427:3	and	CC	O	O
underlying	VIMIZIM.xml:S1:4431:10	underli	JJ	O	O
disease	VIMIZIM.xml:S1:4442:7	diseas	NN	O	O
.	VIMIZIM.xml:S1:4449:1	.	.	O	O

For	VIMIZIM.xml:S1:4451:3	for	IN	O	O
these	VIMIZIM.xml:S1:4455:5	these	DT	O	O
reasons	VIMIZIM.xml:S1:4461:7	reason	NNS	O	O
,	VIMIZIM.xml:S1:4468:1	,	,	O	O
comparison	VIMIZIM.xml:S1:4470:10	comparison	NN	O	O
of	VIMIZIM.xml:S1:4481:2	of	IN	O	O
the	VIMIZIM.xml:S1:4484:3	the	DT	O	O
incidence	VIMIZIM.xml:S1:4488:9	incid	NN	O	O
of	VIMIZIM.xml:S1:4498:2	of	IN	O	O
antibodies	VIMIZIM.xml:S1:4501:10	antibodi	NNS	O	O
to	VIMIZIM.xml:S1:4512:2	to	TO	O	O
Vimizim	VIMIZIM.xml:S1:4515:7	vimizim	VB	O	O
with	VIMIZIM.xml:S1:4523:4	with	IN	O	O
the	VIMIZIM.xml:S1:4528:3	the	DT	O	O
incidence	VIMIZIM.xml:S1:4532:9	incid	NN	O	O
of	VIMIZIM.xml:S1:4542:2	of	IN	O	O
antibodies	VIMIZIM.xml:S1:4545:10	antibodi	NNS	O	O
to	VIMIZIM.xml:S1:4556:2	to	TO	O	O
other	VIMIZIM.xml:S1:4559:5	other	JJ	O	O
products	VIMIZIM.xml:S1:4565:8	product	NNS	O	O
may	VIMIZIM.xml:S1:4574:3	may	MD	O	O
be	VIMIZIM.xml:S1:4578:2	be	VB	O	O
misleading	VIMIZIM.xml:S1:4581:10	mislead	VBG	O	O
.	VIMIZIM.xml:S1:4591:1	.	.	O	O
\n\n	VIMIZIM.xml:S2:0:2	\n\n	VB	O	O
BOXED	VIMIZIM.xml:S2:6:5	box	NNP	O	O
WARNING	VIMIZIM.xml:S2:12:7	warn	NNP	O	O
:	VIMIZIM.xml:S2:19:1	:	:	O	O
WARNING	VIMIZIM.xml:S2:21:7	warn	NN	O	O
:	VIMIZIM.xml:S2:28:1	:	:	O	O
RISK	VIMIZIM.xml:S2:30:4	risk	NN	O	O
OF	VIMIZIM.xml:S2:35:2	OF	IN	O	O
ANAPHYLAXIS	VIMIZIM.xml:S2:38:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
\n\n	VIMIZIM.xml:S2:49:2	\n\n	NNP	O	O
WARNING	VIMIZIM.xml:S2:55:7	warn	NN	O	O
:	VIMIZIM.xml:S2:62:1	:	:	O	O
RISK	VIMIZIM.xml:S2:64:4	risk	NN	O	O
OF	VIMIZIM.xml:S2:69:2	OF	IN	O	O
ANAPHYLAXIS	VIMIZIM.xml:S2:72:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
\n\n	VIMIZIM.xml:S2:85:2	\n\n	NNP	O	O
Life	VIMIZIM.xml:S2:91:4	life	NNP	O	O
-	VIMIZIM.xml:S2:95:1	-	:	O	O
threatening	VIMIZIM.xml:S2:96:11	threaten	VBG	O	O
anaphylactic	VIMIZIM.xml:S2:108:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S2:121:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
have	VIMIZIM.xml:S2:131:4	have	VBP	O	O
occurred	VIMIZIM.xml:S2:136:8	occur	VBN	O	O
in	VIMIZIM.xml:S2:145:2	in	IN	O	O
some	VIMIZIM.xml:S2:148:4	some	DT	O	O
patients	VIMIZIM.xml:S2:153:8	patient	NNS	O	O
during	VIMIZIM.xml:S2:162:6	dure	IN	O	O
Vimizim	VIMIZIM.xml:S2:169:7	vimizim	NNP	O	O
infusions	VIMIZIM.xml:S2:177:9	infus	NNS	O	O
.	VIMIZIM.xml:S2:186:1	.	.	O	O

Anaphylaxis	VIMIZIM.xml:S2:188:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:199:1	,	,	O	O
presenting	VIMIZIM.xml:S2:201:10	present	VBG	O	O
as	VIMIZIM.xml:S2:212:2	as	IN	O	O
cough	VIMIZIM.xml:S2:215:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:220:1	,	,	O	O
erythema	VIMIZIM.xml:S2:222:8	erythema	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:230:1	,	,	O	O
throat	VIMIZIM.xml:S2:232:6	throat	NN	B-AdverseReaction	B-AdverseReaction
tightness	VIMIZIM.xml:S2:239:9	tight	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S2:248:1	,	,	O	O
urticaria	VIMIZIM.xml:S2:250:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:259:1	,	,	O	O
flushing	VIMIZIM.xml:S2:261:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:269:1	,	,	O	O
cyanosis	VIMIZIM.xml:S2:271:8	cyanosi	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:279:1	,	,	O	O
hypotension	VIMIZIM.xml:S2:281:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:292:1	,	,	O	O
rash	VIMIZIM.xml:S2:294:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:298:1	,	,	O	O
dyspnea	VIMIZIM.xml:S2:300:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:307:1	,	,	O	O
chest	VIMIZIM.xml:S2:309:5	chest	NN	B-AdverseReaction	B-AdverseReaction
discomfort	VIMIZIM.xml:S2:315:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S2:325:1	,	,	O	O
and	VIMIZIM.xml:S2:327:3	and	CC	O	O
gastrointestinal	VIMIZIM.xml:S2:331:16	gastrointestin	JJ	B-AdverseReaction	O
symptoms	VIMIZIM.xml:S2:348:8	symptom	NNS	I-AdverseReaction	O
(	VIMIZIM.xml:S2:357:1	(	(	O	O
e	VIMIZIM.xml:S2:358:1	e	NN	O	O
.	VIMIZIM.xml:S2:359:1	.	.	O	O
g	VIMIZIM.xml:S2:360:1	g	NN	O	O
.	VIMIZIM.xml:S2:361:1	.	.	O	O
,	VIMIZIM.xml:S2:362:1	,	,	O	O
nausea	VIMIZIM.xml:S2:364:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:370:1	,	,	O	O
abdominal	VIMIZIM.xml:S2:372:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	VIMIZIM.xml:S2:382:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S2:386:1	,	,	O	O
retching	VIMIZIM.xml:S2:388:8	retch	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:396:1	,	,	O	O
and	VIMIZIM.xml:S2:398:3	and	CC	O	O
vomiting	VIMIZIM.xml:S2:402:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
)	VIMIZIM.xml:S2:410:1	)	)	O	O
in	VIMIZIM.xml:S2:412:2	in	IN	O	O
conjunction	VIMIZIM.xml:S2:415:11	conjunct	NN	O	O
with	VIMIZIM.xml:S2:427:4	with	IN	O	O
urticaria	VIMIZIM.xml:S2:432:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:441:1	,	,	O	O
have	VIMIZIM.xml:S2:443:4	have	VBP	O	O
been	VIMIZIM.xml:S2:448:4	been	VBN	O	O
reported	VIMIZIM.xml:S2:453:8	report	VBN	O	O
to	VIMIZIM.xml:S2:462:2	to	TO	O	O
occur	VIMIZIM.xml:S2:465:5	occur	VB	O	O
during	VIMIZIM.xml:S2:471:6	dure	IN	O	O
Vimizim	VIMIZIM.xml:S2:478:7	vimizim	NNP	O	O
infusions	VIMIZIM.xml:S2:486:9	infus	NNS	O	O
,	VIMIZIM.xml:S2:495:1	,	,	O	O
regardless	VIMIZIM.xml:S2:497:10	regardless	RB	O	O
of	VIMIZIM.xml:S2:508:2	of	IN	O	O
duration	VIMIZIM.xml:S2:511:8	durat	NN	O	O
of	VIMIZIM.xml:S2:520:2	of	IN	O	O
the	VIMIZIM.xml:S2:523:3	the	DT	O	O
course	VIMIZIM.xml:S2:527:6	cours	NN	O	O
of	VIMIZIM.xml:S2:534:2	of	IN	O	O
treatment	VIMIZIM.xml:S2:537:9	treatment	NN	O	O
.	VIMIZIM.xml:S2:546:1	.	.	O	O

Closely	VIMIZIM.xml:S2:548:7	close	RB	O	O
observe	VIMIZIM.xml:S2:556:7	observ	JJ	O	O
patients	VIMIZIM.xml:S2:564:8	patient	NNS	O	O
during	VIMIZIM.xml:S2:573:6	dure	IN	O	O
and	VIMIZIM.xml:S2:580:3	and	CC	O	O
after	VIMIZIM.xml:S2:584:5	after	IN	O	O
Vimizim	VIMIZIM.xml:S2:590:7	vimizim	NNP	O	O
administration	VIMIZIM.xml:S2:598:14	administr	NN	O	O
and	VIMIZIM.xml:S2:613:3	and	CC	O	O
be	VIMIZIM.xml:S2:617:2	be	VB	O	O
prepared	VIMIZIM.xml:S2:620:8	prepar	VBN	O	O
to	VIMIZIM.xml:S2:629:2	to	TO	O	O
manage	VIMIZIM.xml:S2:632:6	manag	VB	O	O
anaphylaxis	VIMIZIM.xml:S2:639:11	anaphylaxi	NN	O	O
.	VIMIZIM.xml:S2:650:1	.	.	O	O

Inform	VIMIZIM.xml:S2:652:6	inform	NNP	O	O
patients	VIMIZIM.xml:S2:659:8	patient	NNS	O	O
of	VIMIZIM.xml:S2:668:2	of	IN	O	O
the	VIMIZIM.xml:S2:671:3	the	DT	O	O
signs	VIMIZIM.xml:S2:675:5	sign	NNS	O	O
and	VIMIZIM.xml:S2:681:3	and	CC	O	O
symptoms	VIMIZIM.xml:S2:685:8	symptom	NNS	O	O
of	VIMIZIM.xml:S2:694:2	of	IN	O	O
anaphylaxis	VIMIZIM.xml:S2:697:11	anaphylaxi	NN	O	O
and	VIMIZIM.xml:S2:709:3	and	CC	O	O
have	VIMIZIM.xml:S2:713:4	have	VBP	O	O
them	VIMIZIM.xml:S2:718:4	them	PRP	O	O
seek	VIMIZIM.xml:S2:723:4	seek	VB	O	O
immediate	VIMIZIM.xml:S2:728:9	immedi	JJ	O	O
medical	VIMIZIM.xml:S2:738:7	medic	JJ	O	O
care	VIMIZIM.xml:S2:746:4	care	NN	O	O
should	VIMIZIM.xml:S2:751:6	should	MD	O	O
symptoms	VIMIZIM.xml:S2:758:8	symptom	VB	O	O
occur	VIMIZIM.xml:S2:767:5	occur	NN	O	O
.	VIMIZIM.xml:S2:772:1	.	.	O	O

Patients	VIMIZIM.xml:S2:775:8	patient	NNS	O	O
with	VIMIZIM.xml:S2:784:4	with	IN	O	O
acute	VIMIZIM.xml:S2:789:5	acut	JJ	O	O
respiratory	VIMIZIM.xml:S2:795:11	respiratori	NN	O	O
illness	VIMIZIM.xml:S2:807:7	ill	NN	O	O
may	VIMIZIM.xml:S2:815:3	may	MD	O	O
be	VIMIZIM.xml:S2:819:2	be	VB	O	O
at	VIMIZIM.xml:S2:822:2	at	IN	O	O
risk	VIMIZIM.xml:S2:825:4	risk	NN	O	O
of	VIMIZIM.xml:S2:830:2	of	IN	O	O
serious	VIMIZIM.xml:S2:833:7	seriou	JJ	O	O
acute	VIMIZIM.xml:S2:841:5	acut	JJ	O	B-AdverseReaction
exacerbation	VIMIZIM.xml:S2:847:12	exacerb	NN	O	I-AdverseReaction
of	VIMIZIM.xml:S2:860:2	of	IN	O	I-AdverseReaction
their	VIMIZIM.xml:S2:863:5	their	PRP$	O	O
respiratory	VIMIZIM.xml:S2:869:11	respiratori	NN	O	I-AdverseReaction
compromise	VIMIZIM.xml:S2:881:10	compromis	NN	O	I-AdverseReaction
due	VIMIZIM.xml:S2:892:3	due	JJ	O	O
to	VIMIZIM.xml:S2:896:2	to	TO	O	O
hypersensitivity	VIMIZIM.xml:S2:899:16	hypersensit	NN	O	B-AdverseReaction
reactions	VIMIZIM.xml:S2:916:9	reaction	NNS	O	I-AdverseReaction
,	VIMIZIM.xml:S2:925:1	,	,	O	O
and	VIMIZIM.xml:S2:927:3	and	CC	O	O
require	VIMIZIM.xml:S2:931:7	requir	VBP	O	O
additional	VIMIZIM.xml:S2:939:10	addit	JJ	O	O
monitoring	VIMIZIM.xml:S2:950:10	monitor	NN	O	O
[	VIMIZIM.xml:S2:963:1	[	NNP	O	O
see	VIMIZIM.xml:S2:964:3	see	VBP	O	O
Warnings	VIMIZIM.xml:S2:968:8	warn	NNP	O	O
and	VIMIZIM.xml:S2:977:3	and	CC	O	O
Precautions	VIMIZIM.xml:S2:981:11	precaut	NNP	O	O
(	VIMIZIM.xml:S2:993:1	(	(	O	O
5.1	VIMIZIM.xml:S2:996:3	5.1	CD	O	O
,	VIMIZIM.xml:S2:1001:1	,	,	O	O
5.2	VIMIZIM.xml:S2:1005:3	5.2	CD	O	O
)	VIMIZIM.xml:S2:1010:1	)	)	O	O
and	VIMIZIM.xml:S2:1012:3	and	CC	O	O
Adverse	VIMIZIM.xml:S2:1016:7	advers	JJ	O	O
Reactions	VIMIZIM.xml:S2:1024:9	reaction	NNP	O	O
(	VIMIZIM.xml:S2:1034:1	(	(	O	O
6	VIMIZIM.xml:S2:1037:1	6	CD	O	O
)]	VIMIZIM.xml:S2:1040:2	)]	NN	O	O
.	VIMIZIM.xml:S2:1044:1	.	.	O	O

EXCERPT	VIMIZIM.xml:S2:1054:7	excerpt	NN	O	O
:	VIMIZIM.xml:S2:1061:1	:	:	O	O
WARNING	VIMIZIM.xml:S2:1067:7	warn	NN	O	O
:	VIMIZIM.xml:S2:1074:1	:	:	O	O
RISK	VIMIZIM.xml:S2:1076:4	risk	NN	O	O
OF	VIMIZIM.xml:S2:1081:2	OF	IN	O	O
ANAPHYLAXIS	VIMIZIM.xml:S2:1084:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
\n\n\n\n	VIMIZIM.xml:S2:1097:4	\n\n\n\n	NNP	O	O
See	VIMIZIM.xml:S2:1106:3	see	NNP	O	O
full	VIMIZIM.xml:S2:1110:4	full	JJ	O	O
prescribing	VIMIZIM.xml:S2:1115:11	prescrib	VBG	O	O
information	VIMIZIM.xml:S2:1127:11	inform	NN	O	O
for	VIMIZIM.xml:S2:1139:3	for	IN	O	O
complete	VIMIZIM.xml:S2:1143:8	complet	JJ	O	O
boxed	VIMIZIM.xml:S2:1152:5	box	JJ	O	O
warning	VIMIZIM.xml:S2:1158:7	warn	NN	O	O
.	VIMIZIM.xml:S2:1169:1	.	.	O	O

Life	VIMIZIM.xml:S2:1177:4	life	NNP	O	O
-	VIMIZIM.xml:S2:1181:1	-	:	O	O
threatening	VIMIZIM.xml:S2:1182:11	threaten	VBG	O	O
anaphylactic	VIMIZIM.xml:S2:1194:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S2:1207:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
have	VIMIZIM.xml:S2:1217:4	have	VBP	O	O
occurred	VIMIZIM.xml:S2:1222:8	occur	VBN	O	O
in	VIMIZIM.xml:S2:1231:2	in	IN	O	O
some	VIMIZIM.xml:S2:1234:4	some	DT	O	O
patients	VIMIZIM.xml:S2:1239:8	patient	NNS	O	O
during	VIMIZIM.xml:S2:1248:6	dure	IN	O	O
Vimizim	VIMIZIM.xml:S2:1255:7	vimizim	NNP	O	O
infusions	VIMIZIM.xml:S2:1263:9	infus	NNS	O	O
.	VIMIZIM.xml:S2:1272:1	.	.	O	O

Anaphylaxis	VIMIZIM.xml:S2:1274:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1285:1	,	,	O	O
presenting	VIMIZIM.xml:S2:1287:10	present	VBG	O	O
as	VIMIZIM.xml:S2:1298:2	as	IN	O	O
cough	VIMIZIM.xml:S2:1301:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1306:1	,	,	O	O
erythema	VIMIZIM.xml:S2:1308:8	erythema	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1316:1	,	,	O	O
throat	VIMIZIM.xml:S2:1318:6	throat	NN	B-AdverseReaction	B-AdverseReaction
tightness	VIMIZIM.xml:S2:1325:9	tight	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S2:1334:1	,	,	O	O
urticaria	VIMIZIM.xml:S2:1336:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1345:1	,	,	O	O
flushing	VIMIZIM.xml:S2:1347:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1355:1	,	,	O	O
cyanosis	VIMIZIM.xml:S2:1357:8	cyanosi	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1365:1	,	,	O	O
hypotension	VIMIZIM.xml:S2:1367:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1378:1	,	,	O	O
rash	VIMIZIM.xml:S2:1380:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1384:1	,	,	O	O
dyspnea	VIMIZIM.xml:S2:1386:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1393:1	,	,	O	O
chest	VIMIZIM.xml:S2:1395:5	chest	NN	B-AdverseReaction	B-AdverseReaction
discomfort	VIMIZIM.xml:S2:1401:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S2:1411:1	,	,	O	O
and	VIMIZIM.xml:S2:1413:3	and	CC	O	O
gastrointestinal	VIMIZIM.xml:S2:1417:16	gastrointestin	JJ	B-AdverseReaction	O
symptoms	VIMIZIM.xml:S2:1434:8	symptom	NNS	I-AdverseReaction	O
in	VIMIZIM.xml:S2:1443:2	in	IN	O	O
conjunction	VIMIZIM.xml:S2:1446:11	conjunct	NN	O	O
with	VIMIZIM.xml:S2:1458:4	with	IN	O	O
urticaria	VIMIZIM.xml:S2:1463:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S2:1472:1	,	,	O	O
have	VIMIZIM.xml:S2:1474:4	have	VBP	O	O
been	VIMIZIM.xml:S2:1479:4	been	VBN	O	O
reported	VIMIZIM.xml:S2:1484:8	report	VBN	O	O
to	VIMIZIM.xml:S2:1493:2	to	TO	O	O
occur	VIMIZIM.xml:S2:1496:5	occur	VB	O	O
during	VIMIZIM.xml:S2:1502:6	dure	IN	O	O
infusions	VIMIZIM.xml:S2:1509:9	infus	NNS	O	O
,	VIMIZIM.xml:S2:1518:1	,	,	O	O
regardless	VIMIZIM.xml:S2:1520:10	regardless	RB	O	O
of	VIMIZIM.xml:S2:1531:2	of	IN	O	O
duration	VIMIZIM.xml:S2:1534:8	durat	NN	O	O
of	VIMIZIM.xml:S2:1543:2	of	IN	O	O
the	VIMIZIM.xml:S2:1546:3	the	DT	O	O
course	VIMIZIM.xml:S2:1550:6	cours	NN	O	O
of	VIMIZIM.xml:S2:1557:2	of	IN	O	O
treatment	VIMIZIM.xml:S2:1560:9	treatment	NN	O	O
.	VIMIZIM.xml:S2:1569:1	.	.	O	O

Closely	VIMIZIM.xml:S2:1571:7	close	RB	O	O
observe	VIMIZIM.xml:S2:1579:7	observ	JJ	O	O
patients	VIMIZIM.xml:S2:1587:8	patient	NNS	O	O
during	VIMIZIM.xml:S2:1596:6	dure	IN	O	O
and	VIMIZIM.xml:S2:1603:3	and	CC	O	O
after	VIMIZIM.xml:S2:1607:5	after	IN	O	O
Vimizim	VIMIZIM.xml:S2:1613:7	vimizim	NNP	O	O
administration	VIMIZIM.xml:S2:1621:14	administr	NN	O	O
and	VIMIZIM.xml:S2:1636:3	and	CC	O	O
be	VIMIZIM.xml:S2:1640:2	be	VB	O	O
prepared	VIMIZIM.xml:S2:1643:8	prepar	VBN	O	O
to	VIMIZIM.xml:S2:1652:2	to	TO	O	O
manage	VIMIZIM.xml:S2:1655:6	manag	VB	O	O
anaphylaxis	VIMIZIM.xml:S2:1662:11	anaphylaxi	NN	O	O
.	VIMIZIM.xml:S2:1673:1	.	.	O	O

Inform	VIMIZIM.xml:S2:1675:6	inform	NNP	O	O
patients	VIMIZIM.xml:S2:1682:8	patient	NNS	O	O
of	VIMIZIM.xml:S2:1691:2	of	IN	O	O
the	VIMIZIM.xml:S2:1694:3	the	DT	O	O
signs	VIMIZIM.xml:S2:1698:5	sign	NNS	O	O
and	VIMIZIM.xml:S2:1704:3	and	CC	O	O
symptoms	VIMIZIM.xml:S2:1708:8	symptom	NNS	O	O
of	VIMIZIM.xml:S2:1717:2	of	IN	O	O
anaphylaxis	VIMIZIM.xml:S2:1720:11	anaphylaxi	NN	O	O
and	VIMIZIM.xml:S2:1732:3	and	CC	O	O
have	VIMIZIM.xml:S2:1736:4	have	VBP	O	O
them	VIMIZIM.xml:S2:1741:4	them	PRP	O	O
seek	VIMIZIM.xml:S2:1746:4	seek	VB	O	O
immediate	VIMIZIM.xml:S2:1751:9	immedi	JJ	O	O
medical	VIMIZIM.xml:S2:1761:7	medic	JJ	O	O
care	VIMIZIM.xml:S2:1769:4	care	NN	O	O
should	VIMIZIM.xml:S2:1774:6	should	MD	O	O
symptoms	VIMIZIM.xml:S2:1781:8	symptom	VB	O	O
occur	VIMIZIM.xml:S2:1790:5	occur	NN	O	O
.	VIMIZIM.xml:S2:1795:1	.	.	O	O

Patients	VIMIZIM.xml:S2:1798:8	patient	NNS	O	O
with	VIMIZIM.xml:S2:1807:4	with	IN	O	O
acute	VIMIZIM.xml:S2:1812:5	acut	JJ	O	O
respiratory	VIMIZIM.xml:S2:1818:11	respiratori	NN	O	O
illness	VIMIZIM.xml:S2:1830:7	ill	NN	O	O
may	VIMIZIM.xml:S2:1838:3	may	MD	O	O
be	VIMIZIM.xml:S2:1842:2	be	VB	O	O
at	VIMIZIM.xml:S2:1845:2	at	IN	O	O
risk	VIMIZIM.xml:S2:1848:4	risk	NN	O	O
of	VIMIZIM.xml:S2:1853:2	of	IN	O	O
serious	VIMIZIM.xml:S2:1856:7	seriou	JJ	O	O
acute	VIMIZIM.xml:S2:1864:5	acut	JJ	O	B-AdverseReaction
exacerbation	VIMIZIM.xml:S2:1870:12	exacerb	NN	O	I-AdverseReaction
of	VIMIZIM.xml:S2:1883:2	of	IN	O	I-AdverseReaction
their	VIMIZIM.xml:S2:1886:5	their	PRP$	O	O
respiratory	VIMIZIM.xml:S2:1892:11	respiratori	NN	O	I-AdverseReaction
compromise	VIMIZIM.xml:S2:1904:10	compromis	NN	O	I-AdverseReaction
due	VIMIZIM.xml:S2:1915:3	due	JJ	O	O
to	VIMIZIM.xml:S2:1919:2	to	TO	O	O
hypersensitivity	VIMIZIM.xml:S2:1922:16	hypersensit	NN	O	B-AdverseReaction
reactions	VIMIZIM.xml:S2:1939:9	reaction	NNS	O	I-AdverseReaction
,	VIMIZIM.xml:S2:1948:1	,	,	O	O
and	VIMIZIM.xml:S2:1950:3	and	CC	O	O
require	VIMIZIM.xml:S2:1954:7	requir	VBP	O	O
additional	VIMIZIM.xml:S2:1962:10	addit	JJ	O	O
monitoring	VIMIZIM.xml:S2:1977:10	monitor	NN	O	O
(	VIMIZIM.xml:S2:1988:1	(	(	O	O
5.1	VIMIZIM.xml:S2:1995:3	5.1	CD	O	O
,	VIMIZIM.xml:S2:2004:1	,	,	O	O
5.2	VIMIZIM.xml:S2:2012:3	5.2	CD	O	O
,	VIMIZIM.xml:S2:2021:1	,	,	O	O
6	VIMIZIM.xml:S2:2029:1	6	CD	O	O
)	VIMIZIM.xml:S2:2036:1	)	)	O	O
.	VIMIZIM.xml:S2:2037:1	.	.	O	O
\n	VIMIZIM.xml:S2:2040:1	\n	$	O	O
5	VIMIZIM.xml:S3:4:1	5	CD	O	O
WARNINGS	VIMIZIM.xml:S3:6:8	warn	NNP	O	O
AND	VIMIZIM.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	VIMIZIM.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	VIMIZIM.xml:S3:36:7	excerpt	NN	O	O
:	VIMIZIM.xml:S3:43:1	:	:	O	O
.	VIMIZIM.xml:S3:47:1	.	.	O	O

Anaphylaxis	VIMIZIM.xml:S3:49:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
and	VIMIZIM.xml:S3:61:3	and	CC	O	O
Hypersensitivity	VIMIZIM.xml:S3:65:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	VIMIZIM.xml:S3:82:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
:	VIMIZIM.xml:S3:91:1	:	:	O	O
Life	VIMIZIM.xml:S3:93:4	life	NNP	O	O
-	VIMIZIM.xml:S3:97:1	-	:	O	O
threatening	VIMIZIM.xml:S3:98:11	threaten	VBG	O	O
anaphylaxis	VIMIZIM.xml:S3:110:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
and	VIMIZIM.xml:S3:122:3	and	CC	O	O
hypersensitivity	VIMIZIM.xml:S3:126:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S3:143:9	reaction	NNS	O	I-AdverseReaction
have	VIMIZIM.xml:S3:153:4	have	VBP	O	O
been	VIMIZIM.xml:S3:158:4	been	VBN	O	O
observed	VIMIZIM.xml:S3:163:8	observ	VBN	O	O
in	VIMIZIM.xml:S3:172:2	in	IN	O	O
some	VIMIZIM.xml:S3:175:4	some	DT	O	O
patients	VIMIZIM.xml:S3:180:8	patient	NNS	O	O
during	VIMIZIM.xml:S3:189:6	dure	IN	O	O
treatment	VIMIZIM.xml:S3:196:9	treatment	NN	O	O
with	VIMIZIM.xml:S3:206:4	with	IN	O	O
Vimizim	VIMIZIM.xml:S3:211:7	vimizim	NNP	O	O
.	VIMIZIM.xml:S3:218:1	.	.	O	O

If	VIMIZIM.xml:S3:220:2	If	IN	O	O
anaphylaxis	VIMIZIM.xml:S3:223:11	anaphylaxi	NNS	O	O
or	VIMIZIM.xml:S3:235:2	or	CC	O	O
severe	VIMIZIM.xml:S3:238:6	sever	JJ	O	O
hypersensitivity	VIMIZIM.xml:S3:245:16	hypersensit	NN	O	O
reactions	VIMIZIM.xml:S3:262:9	reaction	NNS	O	O
occur	VIMIZIM.xml:S3:272:5	occur	VBP	O	O
,	VIMIZIM.xml:S3:277:1	,	,	O	O
immediately	VIMIZIM.xml:S3:279:11	immedi	RB	O	O
stop	VIMIZIM.xml:S3:291:4	stop	VB	O	O
the	VIMIZIM.xml:S3:296:3	the	DT	O	O
infusion	VIMIZIM.xml:S3:300:8	infus	NN	O	O
and	VIMIZIM.xml:S3:309:3	and	CC	O	O
initiate	VIMIZIM.xml:S3:313:8	initi	VB	O	O
appropriate	VIMIZIM.xml:S3:322:11	appropri	JJ	O	O
medical	VIMIZIM.xml:S3:334:7	medic	JJ	O	O
treatment	VIMIZIM.xml:S3:342:9	treatment	NN	O	O
.	VIMIZIM.xml:S3:351:1	.	.	O	O

Pre	VIMIZIM.xml:S3:353:3	pre	NNP	O	O
-	VIMIZIM.xml:S3:356:1	-	:	O	O
treatment	VIMIZIM.xml:S3:357:9	treatment	NN	O	O
with	VIMIZIM.xml:S3:367:4	with	IN	O	O
antihistamines	VIMIZIM.xml:S3:372:14	antihistamin	NNS	O	O
with	VIMIZIM.xml:S3:387:4	with	IN	O	O
or	VIMIZIM.xml:S3:392:2	or	CC	O	O
without	VIMIZIM.xml:S3:395:7	without	IN	O	O
antipyretics	VIMIZIM.xml:S3:403:12	antipyret	NNS	O	O
is	VIMIZIM.xml:S3:416:2	is	VBZ	O	O
recommended	VIMIZIM.xml:S3:419:11	recommend	VBN	O	O
prior	VIMIZIM.xml:S3:431:5	prior	RB	O	O
to	VIMIZIM.xml:S3:437:2	to	TO	O	O
the	VIMIZIM.xml:S3:440:3	the	DT	O	O
start	VIMIZIM.xml:S3:444:5	start	NN	O	O
of	VIMIZIM.xml:S3:450:2	of	IN	O	O
infusion	VIMIZIM.xml:S3:453:8	infus	NN	O	O
(	VIMIZIM.xml:S3:462:1	(	(	O	O
5.1	VIMIZIM.xml:S3:465:3	5.1	CD	O	O
)	VIMIZIM.xml:S3:470:1	)	)	O	O
.	VIMIZIM.xml:S3:471:1	.	.	O	O

.	VIMIZIM.xml:S3:478:1	.	.	O	O

Risk	VIMIZIM.xml:S3:480:4	risk	NN	O	O
of	VIMIZIM.xml:S3:485:2	of	IN	O	O
Acute	VIMIZIM.xml:S3:488:5	acut	NNP	B-AdverseReaction	B-AdverseReaction
Respiratory	VIMIZIM.xml:S3:494:11	respiratori	NNP	I-AdverseReaction	I-AdverseReaction
Complications	VIMIZIM.xml:S3:506:13	complic	NNP	I-AdverseReaction	I-AdverseReaction
:	VIMIZIM.xml:S3:519:1	:	:	O	O
Patients	VIMIZIM.xml:S3:521:8	patient	NNS	O	O
with	VIMIZIM.xml:S3:530:4	with	IN	O	O
acute	VIMIZIM.xml:S3:535:5	acut	JJ	O	O
febrile	VIMIZIM.xml:S3:541:7	febril	NN	O	O
or	VIMIZIM.xml:S3:549:2	or	CC	O	O
respiratory	VIMIZIM.xml:S3:552:11	respiratori	NN	O	O
illness	VIMIZIM.xml:S3:564:7	ill	NN	O	O
may	VIMIZIM.xml:S3:572:3	may	MD	O	O
be	VIMIZIM.xml:S3:576:2	be	VB	O	O
at	VIMIZIM.xml:S3:579:2	at	IN	O	O
higher	VIMIZIM.xml:S3:582:6	higher	JJR	O	O
risk	VIMIZIM.xml:S3:589:4	risk	NN	O	O
of	VIMIZIM.xml:S3:594:2	of	IN	O	O
life	VIMIZIM.xml:S3:597:4	life	NN	O	O
-	VIMIZIM.xml:S3:601:1	-	:	O	O
threatening	VIMIZIM.xml:S3:602:11	threaten	VBG	O	O
complications	VIMIZIM.xml:S3:614:13	complic	NNS	O	O
from	VIMIZIM.xml:S3:628:4	from	IN	O	O
hypersensitivity	VIMIZIM.xml:S3:633:16	hypersensit	NN	B-AdverseReaction	O
reactions	VIMIZIM.xml:S3:650:9	reaction	NNS	I-AdverseReaction	O
.	VIMIZIM.xml:S3:659:1	.	.	O	O

Careful	VIMIZIM.xml:S3:661:7	care	JJ	O	O
consideration	VIMIZIM.xml:S3:669:13	consider	NN	O	O
should	VIMIZIM.xml:S3:683:6	should	MD	O	O
be	VIMIZIM.xml:S3:690:2	be	VB	O	O
given	VIMIZIM.xml:S3:693:5	given	VBN	O	O
to	VIMIZIM.xml:S3:699:2	to	TO	O	O
the	VIMIZIM.xml:S3:702:3	the	DT	O	O
patient	VIMIZIM.xml:S3:706:7	patient	NN	O	O
's	VIMIZIM.xml:S3:713:2	's	POS	O	O
clinical	VIMIZIM.xml:S3:716:8	clinic	JJ	O	O
status	VIMIZIM.xml:S3:725:6	statu	NN	O	O
prior	VIMIZIM.xml:S3:732:5	prior	RB	O	O
to	VIMIZIM.xml:S3:738:2	to	TO	O	O
administration	VIMIZIM.xml:S3:741:14	administr	NN	O	O
of	VIMIZIM.xml:S3:756:2	of	IN	O	O
Vimizim	VIMIZIM.xml:S3:759:7	vimizim	NNP	O	O
and	VIMIZIM.xml:S3:767:3	and	CC	O	O
consider	VIMIZIM.xml:S3:771:8	consid	VB	O	O
delaying	VIMIZIM.xml:S3:780:8	delay	VBG	O	O
the	VIMIZIM.xml:S3:789:3	the	DT	O	O
Vimizim	VIMIZIM.xml:S3:793:7	vimizim	NNP	O	O
infusion	VIMIZIM.xml:S3:801:8	infus	NN	O	O
(	VIMIZIM.xml:S3:810:1	(	(	O	O
5.2	VIMIZIM.xml:S3:813:3	5.2	CD	O	O
)	VIMIZIM.xml:S3:818:1	)	)	O	O
.	VIMIZIM.xml:S3:819:1	.	.	O	O

5.1	VIMIZIM.xml:S3:832:3	5.1	CD	O	O

Anaphylaxis	VIMIZIM.xml:S3:836:11	anaphylaxi	NNP	O	B-AdverseReaction
and	VIMIZIM.xml:S3:848:3	and	CC	O	O
Hypersensitivity	VIMIZIM.xml:S3:852:16	hypersensit	NNP	O	O
Reactions	VIMIZIM.xml:S3:869:9	reaction	NNP	O	O

Anaphylaxis	VIMIZIM.xml:S3:884:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
and	VIMIZIM.xml:S3:896:3	and	CC	O	O
hypersensitivity	VIMIZIM.xml:S3:900:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S3:917:9	reaction	NNS	O	I-AdverseReaction
have	VIMIZIM.xml:S3:927:4	have	VBP	O	O
been	VIMIZIM.xml:S3:932:4	been	VBN	O	O
reported	VIMIZIM.xml:S3:937:8	report	VBN	O	O
in	VIMIZIM.xml:S3:946:2	in	IN	O	O
patients	VIMIZIM.xml:S3:949:8	patient	NNS	O	O
treated	VIMIZIM.xml:S3:958:7	treat	VBN	O	O
with	VIMIZIM.xml:S3:966:4	with	IN	O	O
Vimizim	VIMIZIM.xml:S3:971:7	vimizim	NNP	O	O
.	VIMIZIM.xml:S3:978:1	.	.	O	O

In	VIMIZIM.xml:S3:980:2	In	IN	O	O
premarketing	VIMIZIM.xml:S3:983:12	premarket	VBG	O	O
clinical	VIMIZIM.xml:S3:996:8	clinic	JJ	O	O
trials	VIMIZIM.xml:S3:1005:6	trial	NNS	O	O
,	VIMIZIM.xml:S3:1011:1	,	,	O	O
18	VIMIZIM.xml:S3:1013:2	18	CD	O	O
of	VIMIZIM.xml:S3:1016:2	of	IN	O	O
235	VIMIZIM.xml:S3:1019:3	235	CD	O	O
(	VIMIZIM.xml:S3:1023:1	(	(	O	O
7.7%	VIMIZIM.xml:S3:1024:4	7.7%	CD	O	O
)	VIMIZIM.xml:S3:1028:1	)	)	O	O
patients	VIMIZIM.xml:S3:1030:8	patient	NNS	O	O
treated	VIMIZIM.xml:S3:1039:7	treat	VBN	O	O
with	VIMIZIM.xml:S3:1047:4	with	IN	O	O
Vimizim	VIMIZIM.xml:S3:1052:7	vimizim	NNP	O	O
experienced	VIMIZIM.xml:S3:1060:11	experienc	VBD	O	O
signs	VIMIZIM.xml:S3:1072:5	sign	NNS	O	O
and	VIMIZIM.xml:S3:1078:3	and	CC	O	O
symptoms	VIMIZIM.xml:S3:1082:8	symptom	NNS	O	O
consistent	VIMIZIM.xml:S3:1091:10	consist	JJ	O	O
with	VIMIZIM.xml:S3:1102:4	with	IN	O	O
anaphylaxis	VIMIZIM.xml:S3:1107:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
.	VIMIZIM.xml:S3:1118:1	.	.	O	O

These	VIMIZIM.xml:S3:1120:5	these	DT	O	O
18	VIMIZIM.xml:S3:1126:2	18	CD	O	O
patients	VIMIZIM.xml:S3:1129:8	patient	NNS	O	O
experienced	VIMIZIM.xml:S3:1138:11	experienc	VBD	O	O
26	VIMIZIM.xml:S3:1150:2	26	CD	O	O
anaphylactic	VIMIZIM.xml:S3:1153:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S3:1166:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
during	VIMIZIM.xml:S3:1176:6	dure	IN	O	O
infusion	VIMIZIM.xml:S3:1183:8	infus	NN	O	O
with	VIMIZIM.xml:S3:1192:4	with	IN	O	O
signs	VIMIZIM.xml:S3:1197:5	sign	NNS	O	O
and	VIMIZIM.xml:S3:1203:3	and	CC	O	O
symptoms	VIMIZIM.xml:S3:1207:8	symptom	NNS	O	O
including	VIMIZIM.xml:S3:1216:9	includ	VBG	O	O
cough	VIMIZIM.xml:S3:1226:5	cough	NN	B-AdverseReaction	O
,	VIMIZIM.xml:S3:1231:1	,	,	O	O
erythema	VIMIZIM.xml:S3:1233:8	erythema	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1241:1	,	,	O	O
throat	VIMIZIM.xml:S3:1243:6	throat	NN	B-AdverseReaction	B-AdverseReaction
tightness	VIMIZIM.xml:S3:1250:9	tight	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S3:1259:1	,	,	O	O
urticaria	VIMIZIM.xml:S3:1261:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1270:1	,	,	O	O
flushing	VIMIZIM.xml:S3:1272:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1280:1	,	,	O	O
cyanosis	VIMIZIM.xml:S3:1282:8	cyanosi	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1290:1	,	,	O	O
hypotension	VIMIZIM.xml:S3:1292:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1303:1	,	,	O	O
rash	VIMIZIM.xml:S3:1305:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1309:1	,	,	O	O
dyspnea	VIMIZIM.xml:S3:1311:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1318:1	,	,	O	O
chest	VIMIZIM.xml:S3:1320:5	chest	NN	B-AdverseReaction	B-AdverseReaction
discomfort	VIMIZIM.xml:S3:1326:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S3:1336:1	,	,	O	O
and	VIMIZIM.xml:S3:1338:3	and	CC	O	O
gastrointestinal	VIMIZIM.xml:S3:1342:16	gastrointestin	JJ	B-AdverseReaction	O
symptoms	VIMIZIM.xml:S3:1359:8	symptom	NNS	I-AdverseReaction	O
(	VIMIZIM.xml:S3:1368:1	(	(	O	O
e	VIMIZIM.xml:S3:1369:1	e	NN	O	O
.	VIMIZIM.xml:S3:1370:1	.	.	O	O
g	VIMIZIM.xml:S3:1371:1	g	NN	O	O
.	VIMIZIM.xml:S3:1372:1	.	.	O	O
,	VIMIZIM.xml:S3:1373:1	,	,	O	O
nausea	VIMIZIM.xml:S3:1375:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1381:1	,	,	O	O
abdominal	VIMIZIM.xml:S3:1383:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	VIMIZIM.xml:S3:1393:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S3:1397:1	,	,	O	O
retching	VIMIZIM.xml:S3:1399:8	retch	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:1407:1	,	,	O	O
and	VIMIZIM.xml:S3:1409:3	and	CC	O	O
vomiting	VIMIZIM.xml:S3:1413:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
)	VIMIZIM.xml:S3:1421:1	)	)	O	O
in	VIMIZIM.xml:S3:1423:2	in	IN	O	O
conjunction	VIMIZIM.xml:S3:1426:11	conjunct	NN	O	O
with	VIMIZIM.xml:S3:1438:4	with	IN	O	O
urticaria	VIMIZIM.xml:S3:1443:9	urticaria	NNS	B-AdverseReaction	O
.	VIMIZIM.xml:S3:1452:1	.	.	O	O

These	VIMIZIM.xml:S3:1454:5	these	DT	O	O
cases	VIMIZIM.xml:S3:1460:5	case	NNS	O	O
of	VIMIZIM.xml:S3:1466:2	of	IN	O	O
anaphylaxis	VIMIZIM.xml:S3:1469:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
occurred	VIMIZIM.xml:S3:1481:8	occur	VBD	O	O
as	VIMIZIM.xml:S3:1490:2	as	RB	O	O
early	VIMIZIM.xml:S3:1493:5	earli	RB	O	O
as	VIMIZIM.xml:S3:1499:2	as	IN	O	O
30	VIMIZIM.xml:S3:1502:2	30	CD	O	O
minutes	VIMIZIM.xml:S3:1505:7	minut	NNS	O	O
from	VIMIZIM.xml:S3:1513:4	from	IN	O	O
the	VIMIZIM.xml:S3:1518:3	the	DT	O	O
start	VIMIZIM.xml:S3:1522:5	start	NN	O	O
of	VIMIZIM.xml:S3:1528:2	of	IN	O	O
infusion	VIMIZIM.xml:S3:1531:8	infus	NN	O	O
and	VIMIZIM.xml:S3:1540:3	and	CC	O	O
up	VIMIZIM.xml:S3:1544:2	up	RB	O	O
to	VIMIZIM.xml:S3:1547:2	to	TO	O	O
three	VIMIZIM.xml:S3:1550:5	three	CD	O	O
hours	VIMIZIM.xml:S3:1556:5	hour	NNS	O	O
after	VIMIZIM.xml:S3:1562:5	after	IN	O	O
infusion	VIMIZIM.xml:S3:1568:8	infus	NN	O	O
.	VIMIZIM.xml:S3:1576:1	.	.	O	O

Anaphylaxis	VIMIZIM.xml:S3:1579:11	anaphylaxi	RB	B-AdverseReaction	B-AdverseReaction
occurred	VIMIZIM.xml:S3:1591:8	occur	VBD	O	O
as	VIMIZIM.xml:S3:1600:2	as	IN	O	O
late	VIMIZIM.xml:S3:1603:4	late	JJ	O	O
into	VIMIZIM.xml:S3:1608:4	into	IN	O	O
treatment	VIMIZIM.xml:S3:1613:9	treatment	NN	O	O
as	VIMIZIM.xml:S3:1623:2	as	IN	O	O
the	VIMIZIM.xml:S3:1626:3	the	DT	O	O
47	VIMIZIM.xml:S3:1630:2	47	CD	O	O
th	VIMIZIM.xml:S3:1634:2	th	JJ	O	O
infusion	VIMIZIM.xml:S3:1638:8	infus	NN	O	O
.	VIMIZIM.xml:S3:1646:1	.	.	O	O

In	VIMIZIM.xml:S3:1652:2	In	IN	O	O
clinical	VIMIZIM.xml:S3:1655:8	clinic	JJ	O	O
trials	VIMIZIM.xml:S3:1664:6	trial	NNS	O	O
with	VIMIZIM.xml:S3:1671:4	with	IN	O	O
Vimizim	VIMIZIM.xml:S3:1676:7	vimizim	NNP	O	O
,	VIMIZIM.xml:S3:1683:1	,	,	O	O
44	VIMIZIM.xml:S3:1685:2	44	CD	O	O
of	VIMIZIM.xml:S3:1688:2	of	IN	O	O
235	VIMIZIM.xml:S3:1691:3	235	CD	O	O
(	VIMIZIM.xml:S3:1695:1	(	(	O	O
18.7%	VIMIZIM.xml:S3:1696:5	18.7%	CD	O	O
)	VIMIZIM.xml:S3:1701:1	)	)	O	O
patients	VIMIZIM.xml:S3:1703:8	patient	NNS	O	O
experienced	VIMIZIM.xml:S3:1712:11	experienc	JJ	O	O
hypersensitivity	VIMIZIM.xml:S3:1724:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S3:1741:9	reaction	NNS	O	I-AdverseReaction
,	VIMIZIM.xml:S3:1750:1	,	,	O	O
including	VIMIZIM.xml:S3:1752:9	includ	VBG	O	O
anaphylaxis	VIMIZIM.xml:S3:1762:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
.	VIMIZIM.xml:S3:1773:1	.	.	O	O

Hypersensitivity	VIMIZIM.xml:S3:1775:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S3:1792:9	reaction	NNS	O	I-AdverseReaction
have	VIMIZIM.xml:S3:1802:4	have	VBP	O	O
occurred	VIMIZIM.xml:S3:1807:8	occur	VBN	O	O
as	VIMIZIM.xml:S3:1816:2	as	RB	O	O
early	VIMIZIM.xml:S3:1819:5	earli	RB	O	O
as	VIMIZIM.xml:S3:1825:2	as	IN	O	O
30	VIMIZIM.xml:S3:1828:2	30	CD	O	O
minutes	VIMIZIM.xml:S3:1831:7	minut	NNS	O	O
from	VIMIZIM.xml:S3:1839:4	from	IN	O	O
the	VIMIZIM.xml:S3:1844:3	the	DT	O	O
start	VIMIZIM.xml:S3:1848:5	start	NN	O	O
of	VIMIZIM.xml:S3:1854:2	of	IN	O	O
infusion	VIMIZIM.xml:S3:1857:8	infus	NN	O	O
but	VIMIZIM.xml:S3:1866:3	but	CC	O	O
as	VIMIZIM.xml:S3:1870:2	as	RB	O	O
late	VIMIZIM.xml:S3:1873:4	late	RB	O	O
as	VIMIZIM.xml:S3:1878:2	as	IN	O	O
six	VIMIZIM.xml:S3:1881:3	six	CD	O	O
days	VIMIZIM.xml:S3:1885:4	day	NNS	O	O
after	VIMIZIM.xml:S3:1890:5	after	IN	O	O
infusion	VIMIZIM.xml:S3:1896:8	infus	NN	O	O
.	VIMIZIM.xml:S3:1904:1	.	.	O	O

Frequent	VIMIZIM.xml:S3:1906:8	frequent	NNP	O	O
symptoms	VIMIZIM.xml:S3:1915:8	symptom	NNS	O	O
of	VIMIZIM.xml:S3:1924:2	of	IN	O	O
hypersensitivity	VIMIZIM.xml:S3:1927:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S3:1944:9	reaction	NNS	O	I-AdverseReaction
(	VIMIZIM.xml:S3:1954:1	(	(	O	O
occurring	VIMIZIM.xml:S3:1955:9	occur	VBG	O	O
in	VIMIZIM.xml:S3:1965:2	in	IN	O	O
more	VIMIZIM.xml:S3:1968:4	more	JJR	O	O
than	VIMIZIM.xml:S3:1973:4	than	IN	O	O
2	VIMIZIM.xml:S3:1978:1	2	CD	O	O
patients	VIMIZIM.xml:S3:1980:8	patient	NNS	O	O
)	VIMIZIM.xml:S3:1988:1	)	)	O	O
included	VIMIZIM.xml:S3:1990:8	includ	VBD	O	O
anaphylactic	VIMIZIM.xml:S3:1999:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VIMIZIM.xml:S3:2012:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S3:2021:1	,	,	O	O
urticaria	VIMIZIM.xml:S3:2023:9	urticaria	NNS	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:2032:1	,	,	O	O
peripheral	VIMIZIM.xml:S3:2034:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	VIMIZIM.xml:S3:2045:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	VIMIZIM.xml:S3:2050:1	,	,	O	O
cough	VIMIZIM.xml:S3:2052:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:2057:1	,	,	O	O
dyspnea	VIMIZIM.xml:S3:2059:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	VIMIZIM.xml:S3:2066:1	,	,	O	O
and	VIMIZIM.xml:S3:2068:3	and	CC	O	O
flushing	VIMIZIM.xml:S3:2072:8	flush	NN	B-AdverseReaction	B-AdverseReaction
.	VIMIZIM.xml:S3:2080:1	.	.	O	O

Due	VIMIZIM.xml:S3:2086:3	due	JJ	O	O
to	VIMIZIM.xml:S3:2090:2	to	TO	O	O
the	VIMIZIM.xml:S3:2093:3	the	DT	O	O
potential	VIMIZIM.xml:S3:2097:9	potenti	NN	O	O
for	VIMIZIM.xml:S3:2107:3	for	IN	O	O
anaphylaxis	VIMIZIM.xml:S3:2111:11	anaphylaxi	NN	O	B-AdverseReaction
,	VIMIZIM.xml:S3:2122:1	,	,	O	O
appropriate	VIMIZIM.xml:S3:2124:11	appropri	JJ	O	O
medical	VIMIZIM.xml:S3:2136:7	medic	JJ	O	O
support	VIMIZIM.xml:S3:2144:7	support	NN	O	O
should	VIMIZIM.xml:S3:2152:6	should	MD	O	O
be	VIMIZIM.xml:S3:2159:2	be	VB	O	O
readily	VIMIZIM.xml:S3:2162:7	readili	RB	O	O
available	VIMIZIM.xml:S3:2170:9	avail	JJ	O	O
when	VIMIZIM.xml:S3:2180:4	when	WRB	O	O
Vimizim	VIMIZIM.xml:S3:2185:7	vimizim	NNP	O	O
is	VIMIZIM.xml:S3:2193:2	is	VBZ	O	O
administered	VIMIZIM.xml:S3:2196:12	administ	VBN	O	O
.	VIMIZIM.xml:S3:2208:1	.	.	O	O

Observe	VIMIZIM.xml:S3:2210:7	observ	NN	O	O
patients	VIMIZIM.xml:S3:2218:8	patient	NNS	O	O
closely	VIMIZIM.xml:S3:2227:7	close	RB	O	O
for	VIMIZIM.xml:S3:2235:3	for	IN	O	O
an	VIMIZIM.xml:S3:2239:2	an	DT	O	O
appropriate	VIMIZIM.xml:S3:2242:11	appropri	JJ	O	O
period	VIMIZIM.xml:S3:2254:6	period	NN	O	O
of	VIMIZIM.xml:S3:2261:2	of	IN	O	O
time	VIMIZIM.xml:S3:2264:4	time	NN	O	O
after	VIMIZIM.xml:S3:2269:5	after	IN	O	O
administration	VIMIZIM.xml:S3:2275:14	administr	NN	O	O
of	VIMIZIM.xml:S3:2290:2	of	IN	O	O
Vimizim	VIMIZIM.xml:S3:2293:7	vimizim	NNP	O	O
,	VIMIZIM.xml:S3:2300:1	,	,	O	O
taking	VIMIZIM.xml:S3:2302:6	take	VBG	O	O
into	VIMIZIM.xml:S3:2309:4	into	IN	O	O
account	VIMIZIM.xml:S3:2314:7	account	NN	O	O
the	VIMIZIM.xml:S3:2322:3	the	DT	O	O
time	VIMIZIM.xml:S3:2326:4	time	NN	O	O
to	VIMIZIM.xml:S3:2331:2	to	TO	O	O
onset	VIMIZIM.xml:S3:2334:5	onset	VB	O	O
of	VIMIZIM.xml:S3:2340:2	of	IN	O	O
anaphylaxis	VIMIZIM.xml:S3:2343:11	anaphylaxi	NN	O	O
seen	VIMIZIM.xml:S3:2355:4	seen	VBN	O	O
in	VIMIZIM.xml:S3:2360:2	in	IN	O	O
premarketing	VIMIZIM.xml:S3:2363:12	premarket	VBG	O	O
clinical	VIMIZIM.xml:S3:2376:8	clinic	JJ	O	O
trials	VIMIZIM.xml:S3:2385:6	trial	NNS	O	O
.	VIMIZIM.xml:S3:2391:1	.	.	O	O

Inform	VIMIZIM.xml:S3:2393:6	inform	NNP	O	O
patients	VIMIZIM.xml:S3:2400:8	patient	NNS	O	O
of	VIMIZIM.xml:S3:2409:2	of	IN	O	O
the	VIMIZIM.xml:S3:2412:3	the	DT	O	O
signs	VIMIZIM.xml:S3:2416:5	sign	NNS	O	O
and	VIMIZIM.xml:S3:2422:3	and	CC	O	O
symptoms	VIMIZIM.xml:S3:2426:8	symptom	NNS	O	O
of	VIMIZIM.xml:S3:2435:2	of	IN	O	O
anaphylaxis	VIMIZIM.xml:S3:2438:11	anaphylaxi	NN	O	O
,	VIMIZIM.xml:S3:2449:1	,	,	O	O
and	VIMIZIM.xml:S3:2451:3	and	CC	O	O
instruct	VIMIZIM.xml:S3:2455:8	instruct	VB	O	O
them	VIMIZIM.xml:S3:2464:4	them	PRP	O	O
to	VIMIZIM.xml:S3:2469:2	to	TO	O	O
seek	VIMIZIM.xml:S3:2472:4	seek	VB	O	O
immediate	VIMIZIM.xml:S3:2477:9	immedi	JJ	O	O
medical	VIMIZIM.xml:S3:2487:7	medic	JJ	O	O
care	VIMIZIM.xml:S3:2495:4	care	NN	O	O
should	VIMIZIM.xml:S3:2500:6	should	MD	O	O
signs	VIMIZIM.xml:S3:2507:5	sign	NNS	O	O
and	VIMIZIM.xml:S3:2513:3	and	CC	O	O
symptoms	VIMIZIM.xml:S3:2517:8	symptom	NNS	O	O
occur	VIMIZIM.xml:S3:2526:5	occur	VBP	O	O
.	VIMIZIM.xml:S3:2531:1	.	.	O	O

Because	VIMIZIM.xml:S3:2538:7	becaus	IN	O	O
of	VIMIZIM.xml:S3:2546:2	of	IN	O	O
the	VIMIZIM.xml:S3:2549:3	the	DT	O	O
potential	VIMIZIM.xml:S3:2553:9	potenti	NN	O	O
for	VIMIZIM.xml:S3:2563:3	for	IN	O	O
hypersensitivity	VIMIZIM.xml:S3:2567:16	hypersensit	NN	O	O
reactions	VIMIZIM.xml:S3:2584:9	reaction	NNS	O	O
,	VIMIZIM.xml:S3:2593:1	,	,	O	O
administer	VIMIZIM.xml:S3:2595:10	administ	NN	O	O
antihistamines	VIMIZIM.xml:S3:2606:14	antihistamin	NNS	O	O
with	VIMIZIM.xml:S3:2621:4	with	IN	O	O
or	VIMIZIM.xml:S3:2626:2	or	CC	O	O
without	VIMIZIM.xml:S3:2629:7	without	IN	O	O
antipyretics	VIMIZIM.xml:S3:2637:12	antipyret	NNS	O	O
prior	VIMIZIM.xml:S3:2650:5	prior	RB	O	O
to	VIMIZIM.xml:S3:2656:2	to	TO	O	O
infusion	VIMIZIM.xml:S3:2659:8	infus	NN	O	O
.	VIMIZIM.xml:S3:2667:1	.	.	O	O

Management	VIMIZIM.xml:S3:2669:10	manag	NN	O	O
of	VIMIZIM.xml:S3:2680:2	of	IN	O	O
hypersensitivity	VIMIZIM.xml:S3:2683:16	hypersensit	NN	O	O
reactions	VIMIZIM.xml:S3:2700:9	reaction	NNS	O	O
should	VIMIZIM.xml:S3:2710:6	should	MD	O	O
be	VIMIZIM.xml:S3:2717:2	be	VB	O	O
based	VIMIZIM.xml:S3:2720:5	base	VBN	O	O
on	VIMIZIM.xml:S3:2726:2	on	IN	O	O
the	VIMIZIM.xml:S3:2729:3	the	DT	O	O
severity	VIMIZIM.xml:S3:2733:8	sever	NN	O	O
of	VIMIZIM.xml:S3:2742:2	of	IN	O	O
the	VIMIZIM.xml:S3:2745:3	the	DT	O	O
reaction	VIMIZIM.xml:S3:2749:8	reaction	NN	O	O
and	VIMIZIM.xml:S3:2758:3	and	CC	O	O
include	VIMIZIM.xml:S3:2762:7	includ	VBP	O	O
slowing	VIMIZIM.xml:S3:2770:7	slow	VBG	O	O
or	VIMIZIM.xml:S3:2778:2	or	CC	O	O
temporary	VIMIZIM.xml:S3:2781:9	temporari	JJ	O	O
interruption	VIMIZIM.xml:S3:2791:12	interrupt	NN	O	O
of	VIMIZIM.xml:S3:2804:2	of	IN	O	O
the	VIMIZIM.xml:S3:2807:3	the	DT	O	O
infusion	VIMIZIM.xml:S3:2811:8	infus	NN	O	O
and	VIMIZIM.xml:S3:2820:3	and	CC	O	O
or	VIMIZIM.xml:S3:2824:2	or	CC	O	O
administration	VIMIZIM.xml:S3:2827:14	administr	NN	O	O
of	VIMIZIM.xml:S3:2842:2	of	IN	O	O
additional	VIMIZIM.xml:S3:2845:10	addit	JJ	O	O
antihistamines	VIMIZIM.xml:S3:2856:14	antihistamin	NNS	O	O
,	VIMIZIM.xml:S3:2870:1	,	,	O	O
antipyretics	VIMIZIM.xml:S3:2872:12	antipyret	NNS	O	O
,	VIMIZIM.xml:S3:2884:1	,	,	O	O
and	VIMIZIM.xml:S3:2886:3	and	CC	O	O
or	VIMIZIM.xml:S3:2890:2	or	CC	O	O
corticosteroids	VIMIZIM.xml:S3:2893:15	corticosteroid	NNS	O	O
for	VIMIZIM.xml:S3:2909:3	for	IN	O	O
mild	VIMIZIM.xml:S3:2913:4	mild	JJ	O	O
reactions	VIMIZIM.xml:S3:2918:9	reaction	NNS	O	O
.	VIMIZIM.xml:S3:2927:1	.	.	O	O

However	VIMIZIM.xml:S3:2929:7	howev	RB	O	O
,	VIMIZIM.xml:S3:2936:1	,	,	O	O
if	VIMIZIM.xml:S3:2938:2	if	IN	O	O
severe	VIMIZIM.xml:S3:2941:6	sever	JJ	O	O
hypersensitivity	VIMIZIM.xml:S3:2948:16	hypersensit	NN	O	O
reactions	VIMIZIM.xml:S3:2965:9	reaction	NNS	O	O
occur	VIMIZIM.xml:S3:2975:5	occur	VBP	O	O
,	VIMIZIM.xml:S3:2980:1	,	,	O	O
immediately	VIMIZIM.xml:S3:2982:11	immedi	RB	O	O
stop	VIMIZIM.xml:S3:2994:4	stop	VB	O	O
the	VIMIZIM.xml:S3:2999:3	the	DT	O	O
infusion	VIMIZIM.xml:S3:3003:8	infus	NN	O	O
of	VIMIZIM.xml:S3:3012:2	of	IN	O	O
Vimizim	VIMIZIM.xml:S3:3015:7	vimizim	NNP	O	O
and	VIMIZIM.xml:S3:3023:3	and	CC	O	O
initiate	VIMIZIM.xml:S3:3027:8	initi	VB	O	O
appropriate	VIMIZIM.xml:S3:3036:11	appropri	JJ	O	O
treatment	VIMIZIM.xml:S3:3048:9	treatment	NN	O	O
.	VIMIZIM.xml:S3:3057:1	.	.	O	O

Consider	VIMIZIM.xml:S3:3063:8	consid	VB	O	O
the	VIMIZIM.xml:S3:3072:3	the	DT	O	O
risks	VIMIZIM.xml:S3:3076:5	risk	NNS	O	O
and	VIMIZIM.xml:S3:3082:3	and	CC	O	O
benefits	VIMIZIM.xml:S3:3086:8	benefit	NNS	O	O
of	VIMIZIM.xml:S3:3095:2	of	IN	O	O
re	VIMIZIM.xml:S3:3098:2	re	NN	O	O
-	VIMIZIM.xml:S3:3100:1	-	:	O	O
administering	VIMIZIM.xml:S3:3101:13	administ	VBG	O	O
Vimizim	VIMIZIM.xml:S3:3115:7	vimizim	NNP	O	O
following	VIMIZIM.xml:S3:3123:9	follow	VBG	O	O
a	VIMIZIM.xml:S3:3133:1	a	DT	O	O
severe	VIMIZIM.xml:S3:3135:6	sever	JJ	O	O
reaction	VIMIZIM.xml:S3:3142:8	reaction	NN	O	O
.	VIMIZIM.xml:S3:3150:1	.	.	O	O

5.2	VIMIZIM.xml:S3:3159:3	5.2	CD	O	O
Risk	VIMIZIM.xml:S3:3163:4	risk	NN	O	O
of	VIMIZIM.xml:S3:3168:2	of	IN	O	O
Acute	VIMIZIM.xml:S3:3171:5	acut	NNP	O	O
Respiratory	VIMIZIM.xml:S3:3177:11	respiratori	NNP	O	O
Complications	VIMIZIM.xml:S3:3189:13	complic	NNP	O	O

Patients	VIMIZIM.xml:S3:3208:8	patient	NNS	O	O
with	VIMIZIM.xml:S3:3217:4	with	IN	O	O
acute	VIMIZIM.xml:S3:3222:5	acut	JJ	O	O
febrile	VIMIZIM.xml:S3:3228:7	febril	NN	O	O
or	VIMIZIM.xml:S3:3236:2	or	CC	O	O
respiratory	VIMIZIM.xml:S3:3239:11	respiratori	NN	O	O
illness	VIMIZIM.xml:S3:3251:7	ill	NN	O	O
at	VIMIZIM.xml:S3:3259:2	at	IN	O	O
the	VIMIZIM.xml:S3:3262:3	the	DT	O	O
time	VIMIZIM.xml:S3:3266:4	time	NN	O	O
of	VIMIZIM.xml:S3:3271:2	of	IN	O	O
Vimizim	VIMIZIM.xml:S3:3274:7	vimizim	NNP	O	O
infusion	VIMIZIM.xml:S3:3282:8	infus	NN	O	O
may	VIMIZIM.xml:S3:3291:3	may	MD	O	O
be	VIMIZIM.xml:S3:3295:2	be	VB	O	O
at	VIMIZIM.xml:S3:3298:2	at	IN	O	O
higher	VIMIZIM.xml:S3:3301:6	higher	JJR	O	O
risk	VIMIZIM.xml:S3:3308:4	risk	NN	O	O
of	VIMIZIM.xml:S3:3313:2	of	IN	O	O
life	VIMIZIM.xml:S3:3316:4	life	NN	O	O
-	VIMIZIM.xml:S3:3320:1	-	:	O	O
threatening	VIMIZIM.xml:S3:3321:11	threaten	VBG	O	O
complications	VIMIZIM.xml:S3:3333:13	complic	NNS	O	O
from	VIMIZIM.xml:S3:3347:4	from	IN	O	O
hypersensitivity	VIMIZIM.xml:S3:3352:16	hypersensit	NN	B-AdverseReaction	O
reactions	VIMIZIM.xml:S3:3369:9	reaction	NNS	I-AdverseReaction	O
.	VIMIZIM.xml:S3:3378:1	.	.	O	O

Careful	VIMIZIM.xml:S3:3380:7	care	JJ	O	O
consideration	VIMIZIM.xml:S3:3388:13	consider	NN	O	O
should	VIMIZIM.xml:S3:3402:6	should	MD	O	O
be	VIMIZIM.xml:S3:3409:2	be	VB	O	O
given	VIMIZIM.xml:S3:3412:5	given	VBN	O	O
to	VIMIZIM.xml:S3:3418:2	to	TO	O	O
the	VIMIZIM.xml:S3:3421:3	the	DT	O	O
patient	VIMIZIM.xml:S3:3425:7	patient	NN	O	O
's	VIMIZIM.xml:S3:3432:2	's	POS	O	O
clinical	VIMIZIM.xml:S3:3435:8	clinic	JJ	O	O
status	VIMIZIM.xml:S3:3444:6	statu	NN	O	O
prior	VIMIZIM.xml:S3:3451:5	prior	RB	O	O
to	VIMIZIM.xml:S3:3457:2	to	TO	O	O
administration	VIMIZIM.xml:S3:3460:14	administr	NN	O	O
of	VIMIZIM.xml:S3:3475:2	of	IN	O	O
Vimizim	VIMIZIM.xml:S3:3478:7	vimizim	NNP	O	O
and	VIMIZIM.xml:S3:3486:3	and	CC	O	O
consider	VIMIZIM.xml:S3:3490:8	consid	VB	O	O
delaying	VIMIZIM.xml:S3:3499:8	delay	VBG	O	O
the	VIMIZIM.xml:S3:3508:3	the	DT	O	O
Vimizim	VIMIZIM.xml:S3:3512:7	vimizim	NNP	O	O
infusion	VIMIZIM.xml:S3:3520:8	infus	NN	O	O
.	VIMIZIM.xml:S3:3528:1	.	.	O	O

Sleep	VIMIZIM.xml:S3:3534:5	sleep	JJ	O	O
apnea	VIMIZIM.xml:S3:3540:5	apnea	NN	O	O
is	VIMIZIM.xml:S3:3546:2	is	VBZ	O	O
common	VIMIZIM.xml:S3:3549:6	common	JJ	O	O
in	VIMIZIM.xml:S3:3556:2	in	IN	O	O
MPS	VIMIZIM.xml:S3:3559:3	mp	NNP	O	O
IVA	VIMIZIM.xml:S3:3563:3	iva	NNP	O	O
patients	VIMIZIM.xml:S3:3567:8	patient	NNS	O	O
.	VIMIZIM.xml:S3:3575:1	.	.	O	O

Evaluation	VIMIZIM.xml:S3:3578:10	evalu	NN	O	O
of	VIMIZIM.xml:S3:3589:2	of	IN	O	O
airway	VIMIZIM.xml:S3:3592:6	airway	JJ	O	O
patency	VIMIZIM.xml:S3:3599:7	patenc	NN	O	O
should	VIMIZIM.xml:S3:3607:6	should	MD	O	O
be	VIMIZIM.xml:S3:3614:2	be	VB	O	O
considered	VIMIZIM.xml:S3:3617:10	consid	VBN	O	O
prior	VIMIZIM.xml:S3:3628:5	prior	JJ	O	O
to	VIMIZIM.xml:S3:3634:2	to	TO	O	O
initiation	VIMIZIM.xml:S3:3637:10	initi	NN	O	O
of	VIMIZIM.xml:S3:3648:2	of	IN	O	O
treatment	VIMIZIM.xml:S3:3651:9	treatment	NN	O	O
with	VIMIZIM.xml:S3:3661:4	with	IN	O	O
Vimizim	VIMIZIM.xml:S3:3666:7	vimizim	NNP	O	O
.	VIMIZIM.xml:S3:3673:1	.	.	O	O

Patients	VIMIZIM.xml:S3:3676:8	patient	NNS	O	O
using	VIMIZIM.xml:S3:3685:5	use	VBG	O	O
supplemental	VIMIZIM.xml:S3:3691:12	supplement	JJ	O	O
oxygen	VIMIZIM.xml:S3:3704:6	oxygen	NN	O	O
or	VIMIZIM.xml:S3:3711:2	or	CC	O	O
continuous	VIMIZIM.xml:S3:3714:10	continu	JJ	O	O
positive	VIMIZIM.xml:S3:3725:8	posit	JJ	O	O
airway	VIMIZIM.xml:S3:3734:6	airway	NN	O	O
pressure	VIMIZIM.xml:S3:3741:8	pressur	NN	O	O
(	VIMIZIM.xml:S3:3750:1	(	(	O	O
CPAP	VIMIZIM.xml:S3:3751:4	cpap	NNP	O	O
)	VIMIZIM.xml:S3:3755:1	)	)	O	O
during	VIMIZIM.xml:S3:3757:6	dure	IN	O	O
sleep	VIMIZIM.xml:S3:3764:5	sleep	NN	O	O
should	VIMIZIM.xml:S3:3770:6	should	MD	O	O
have	VIMIZIM.xml:S3:3777:4	have	VB	O	O
these	VIMIZIM.xml:S3:3782:5	these	DT	O	O
treatments	VIMIZIM.xml:S3:3788:10	treatment	NNS	O	O
readily	VIMIZIM.xml:S3:3799:7	readili	RB	O	O
available	VIMIZIM.xml:S3:3807:9	avail	JJ	O	O
during	VIMIZIM.xml:S3:3817:6	dure	IN	O	O
infusion	VIMIZIM.xml:S3:3824:8	infus	NN	O	O
in	VIMIZIM.xml:S3:3833:2	in	IN	O	O
the	VIMIZIM.xml:S3:3836:3	the	DT	O	O
event	VIMIZIM.xml:S3:3840:5	event	NN	O	O
of	VIMIZIM.xml:S3:3846:2	of	IN	O	O
an	VIMIZIM.xml:S3:3849:2	an	DT	O	O
acute	VIMIZIM.xml:S3:3852:5	acut	JJ	O	O
reaction	VIMIZIM.xml:S3:3858:8	reaction	NN	O	O
,	VIMIZIM.xml:S3:3866:1	,	,	O	O
or	VIMIZIM.xml:S3:3868:2	or	CC	O	O
extreme	VIMIZIM.xml:S3:3871:7	extrem	JJ	O	O
drowsiness	VIMIZIM.xml:S3:3879:10	drowsi	NN	O	O
sleep	VIMIZIM.xml:S3:3890:5	sleep	NN	O	O
induced	VIMIZIM.xml:S3:3896:7	induc	VBN	O	O
by	VIMIZIM.xml:S3:3904:2	by	IN	O	O
antihistamine	VIMIZIM.xml:S3:3907:13	antihistamin	NN	O	O
use	VIMIZIM.xml:S3:3921:3	use	NN	O	O
.	VIMIZIM.xml:S3:3924:1	.	.	O	O

5.3	VIMIZIM.xml:S3:3933:3	5.3	CD	O	O
Spinal	VIMIZIM.xml:S3:3937:6	spinal	NNP	O	O
or	VIMIZIM.xml:S3:3944:2	or	CC	O	O
Cervical	VIMIZIM.xml:S3:3947:8	cervic	NNP	O	O
Cord	VIMIZIM.xml:S3:3956:4	cord	NNP	O	O
Compression	VIMIZIM.xml:S3:3961:11	compress	NNP	O	O

Spinal	VIMIZIM.xml:S3:3978:6	spinal	NNP	O	O
or	VIMIZIM.xml:S3:3985:2	or	CC	O	O
cervical	VIMIZIM.xml:S3:3988:8	cervic	JJ	O	O
cord	VIMIZIM.xml:S3:3997:4	cord	NN	O	O
compression	VIMIZIM.xml:S3:4002:11	compress	NN	O	O
(	VIMIZIM.xml:S3:4014:1	(	(	O	O
SCC	VIMIZIM.xml:S3:4015:3	scc	NNP	O	O
)	VIMIZIM.xml:S3:4018:1	)	)	O	O
is	VIMIZIM.xml:S3:4020:2	is	VBZ	O	O
a	VIMIZIM.xml:S3:4023:1	a	DT	O	O
known	VIMIZIM.xml:S3:4025:5	known	JJ	O	O
and	VIMIZIM.xml:S3:4031:3	and	CC	O	O
serious	VIMIZIM.xml:S3:4035:7	seriou	JJ	O	O
complication	VIMIZIM.xml:S3:4043:12	complic	NN	O	O
of	VIMIZIM.xml:S3:4056:2	of	IN	O	O
MPS	VIMIZIM.xml:S3:4059:3	mp	NNP	O	O
IVA	VIMIZIM.xml:S3:4063:3	iva	NNP	O	O
and	VIMIZIM.xml:S3:4067:3	and	CC	O	O
may	VIMIZIM.xml:S3:4071:3	may	MD	O	O
occur	VIMIZIM.xml:S3:4075:5	occur	VB	O	O
as	VIMIZIM.xml:S3:4081:2	as	IN	O	O
part	VIMIZIM.xml:S3:4084:4	part	NN	O	O
of	VIMIZIM.xml:S3:4089:2	of	IN	O	O
the	VIMIZIM.xml:S3:4092:3	the	DT	O	O
natural	VIMIZIM.xml:S3:4096:7	natur	JJ	O	O
history	VIMIZIM.xml:S3:4104:7	histori	NN	O	O
of	VIMIZIM.xml:S3:4112:2	of	IN	O	O
the	VIMIZIM.xml:S3:4115:3	the	DT	O	O
disease	VIMIZIM.xml:S3:4119:7	diseas	NN	O	O
.	VIMIZIM.xml:S3:4126:1	.	.	O	O

In	VIMIZIM.xml:S3:4128:2	In	IN	O	O
clinical	VIMIZIM.xml:S3:4131:8	clinic	JJ	O	O
trials	VIMIZIM.xml:S3:4140:6	trial	NNS	O	O
,	VIMIZIM.xml:S3:4146:1	,	,	O	O
SCC	VIMIZIM.xml:S3:4148:3	scc	NNP	O	O
was	VIMIZIM.xml:S3:4152:3	wa	VBD	O	O
observed	VIMIZIM.xml:S3:4156:8	observ	VBN	O	O
both	VIMIZIM.xml:S3:4165:4	both	DT	O	O
in	VIMIZIM.xml:S3:4170:2	in	IN	O	O
patients	VIMIZIM.xml:S3:4173:8	patient	NNS	O	O
receiving	VIMIZIM.xml:S3:4182:9	receiv	VBG	O	O
Vimizim	VIMIZIM.xml:S3:4192:7	vimizim	NNP	O	O
and	VIMIZIM.xml:S3:4200:3	and	CC	O	O
patients	VIMIZIM.xml:S3:4204:8	patient	NNS	O	O
receiving	VIMIZIM.xml:S3:4213:9	receiv	VBG	O	O
placebo	VIMIZIM.xml:S3:4223:7	placebo	NN	O	O
.	VIMIZIM.xml:S3:4230:1	.	.	O	O

Patients	VIMIZIM.xml:S3:4233:8	patient	NNS	O	O
with	VIMIZIM.xml:S3:4242:4	with	IN	O	O
MPS	VIMIZIM.xml:S3:4247:3	mp	NNP	O	O
IVA	VIMIZIM.xml:S3:4251:3	iva	NNP	O	O
should	VIMIZIM.xml:S3:4255:6	should	MD	O	O
be	VIMIZIM.xml:S3:4262:2	be	VB	O	O
monitored	VIMIZIM.xml:S3:4265:9	monitor	VBN	O	O
for	VIMIZIM.xml:S3:4275:3	for	IN	O	O
signs	VIMIZIM.xml:S3:4279:5	sign	NNS	O	O
and	VIMIZIM.xml:S3:4285:3	and	CC	O	O
symptoms	VIMIZIM.xml:S3:4289:8	symptom	NNS	O	O
of	VIMIZIM.xml:S3:4298:2	of	IN	O	O
SCC	VIMIZIM.xml:S3:4301:3	scc	NNP	O	O
(	VIMIZIM.xml:S3:4305:1	(	(	O	O
including	VIMIZIM.xml:S3:4306:9	includ	VBG	O	O
back	VIMIZIM.xml:S3:4316:4	back	RB	O	B-AdverseReaction
pain	VIMIZIM.xml:S3:4321:4	pain	NN	O	I-AdverseReaction
,	VIMIZIM.xml:S3:4325:1	,	,	O	O
paralysis	VIMIZIM.xml:S3:4327:9	paralysi	NN	O	B-AdverseReaction
of	VIMIZIM.xml:S3:4337:2	of	IN	O	I-AdverseReaction
limbs	VIMIZIM.xml:S3:4340:5	limb	NNS	O	I-AdverseReaction
below	VIMIZIM.xml:S3:4346:5	below	IN	O	I-AdverseReaction
the	VIMIZIM.xml:S3:4352:3	the	DT	O	I-AdverseReaction
level	VIMIZIM.xml:S3:4356:5	level	NN	O	I-AdverseReaction
of	VIMIZIM.xml:S3:4362:2	of	IN	O	I-AdverseReaction
compression	VIMIZIM.xml:S3:4365:11	compress	NN	O	I-AdverseReaction
,	VIMIZIM.xml:S3:4376:1	,	,	O	O
urinary	VIMIZIM.xml:S3:4378:7	urinari	JJ	O	O
and	VIMIZIM.xml:S3:4386:3	and	CC	O	O
fecal	VIMIZIM.xml:S3:4390:5	fecal	JJ	O	B-AdverseReaction
incontinence	VIMIZIM.xml:S3:4396:12	incontin	NN	O	I-AdverseReaction
)	VIMIZIM.xml:S3:4408:1	)	)	O	O
and	VIMIZIM.xml:S3:4410:3	and	CC	O	O
given	VIMIZIM.xml:S3:4414:5	given	VBN	O	O
appropriate	VIMIZIM.xml:S3:4420:11	appropri	JJ	O	O
clinical	VIMIZIM.xml:S3:4432:8	clinic	JJ	O	O
care	VIMIZIM.xml:S3:4441:4	care	NN	O	O
.	VIMIZIM.xml:S3:4445:1	.	.	O	O
6	VIZAMYL.xml:S1:4:1	6	CD	O	O
ADVERSE	VIZAMYL.xml:S1:6:7	advers	JJ	O	O
REACTIONS	VIZAMYL.xml:S1:14:9	reaction	NN	O	O

EXCERPT	VIZAMYL.xml:S1:27:7	excerpt	NNS	O	O
:	VIZAMYL.xml:S1:34:1	:	:	O	O
Most	VIZAMYL.xml:S1:38:4	most	JJS	O	O
commonly	VIZAMYL.xml:S1:43:8	commonli	RB	O	O
reported	VIZAMYL.xml:S1:52:8	report	VBD	O	O
adverse	VIZAMYL.xml:S1:61:7	advers	JJ	O	O
reactions	VIZAMYL.xml:S1:69:9	reaction	NNS	O	O
were	VIZAMYL.xml:S1:79:4	were	VBD	O	O
flushing	VIZAMYL.xml:S1:84:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
(	VIZAMYL.xml:S1:93:1	(	(	O	O
2%	VIZAMYL.xml:S1:94:2	2%	CD	O	O
)	VIZAMYL.xml:S1:96:1	)	)	O	O
,	VIZAMYL.xml:S1:97:1	,	,	O	O
headache	VIZAMYL.xml:S1:99:8	headach	NN	B-AdverseReaction	B-AdverseReaction
(	VIZAMYL.xml:S1:108:1	(	(	O	O
1%	VIZAMYL.xml:S1:109:2	1%	CD	O	O
)	VIZAMYL.xml:S1:111:1	)	)	O	O
,	VIZAMYL.xml:S1:112:1	,	,	O	O
increased	VIZAMYL.xml:S1:114:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
blood	VIZAMYL.xml:S1:124:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	VIZAMYL.xml:S1:130:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
(	VIZAMYL.xml:S1:139:1	(	(	O	O
2%	VIZAMYL.xml:S1:140:2	2%	CD	O	O
)	VIZAMYL.xml:S1:142:1	)	)	O	O
,	VIZAMYL.xml:S1:143:1	,	,	O	O
nausea	VIZAMYL.xml:S1:145:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
(	VIZAMYL.xml:S1:152:1	(	(	O	O
1%	VIZAMYL.xml:S1:153:2	1%	CD	O	O
)	VIZAMYL.xml:S1:155:1	)	)	O	O
,	VIZAMYL.xml:S1:156:1	,	,	O	O
and	VIZAMYL.xml:S1:158:3	and	CC	O	O
dizziness	VIZAMYL.xml:S1:162:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
(	VIZAMYL.xml:S1:172:1	(	(	O	O
1%	VIZAMYL.xml:S1:173:2	1%	CD	O	O
)	VIZAMYL.xml:S1:175:1	)	)	O	O
.	VIZAMYL.xml:S1:176:1	.	.	O	O

To	VIZAMYL.xml:S1:184:2	To	TO	O	O
report	VIZAMYL.xml:S1:187:6	report	VB	O	O
SUSPECTED	VIZAMYL.xml:S1:194:9	suspect	NNP	O	O
ADVERSE	VIZAMYL.xml:S1:204:7	advers	NNP	O	O
REACTIONS	VIZAMYL.xml:S1:212:9	reaction	NNP	O	O
,	VIZAMYL.xml:S1:221:1	,	,	O	O
contact	VIZAMYL.xml:S1:223:7	contact	NN	O	O
GE	VIZAMYL.xml:S1:231:2	GE	NNP	O	O
Healthcare	VIZAMYL.xml:S1:234:10	healthcar	NNP	O	O
at	VIZAMYL.xml:S1:245:2	at	IN	O	O
1	VIZAMYL.xml:S1:248:1	1	CD	O	O
-	VIZAMYL.xml:S1:249:1	-	:	O	O
800	VIZAMYL.xml:S1:250:3	800	CD	O	O
-	VIZAMYL.xml:S1:253:1	-	:	O	O
654	VIZAMYL.xml:S1:254:3	654	CD	O	O
-	VIZAMYL.xml:S1:257:1	-	:	O	O
0118	VIZAMYL.xml:S1:258:4	0118	CD	O	O
or	VIZAMYL.xml:S1:263:2	or	CC	O	O
FDA	VIZAMYL.xml:S1:266:3	fda	NNP	O	O
at	VIZAMYL.xml:S1:270:2	at	IN	O	O
1	VIZAMYL.xml:S1:273:1	1	CD	O	O
-	VIZAMYL.xml:S1:274:1	-	:	O	O
800	VIZAMYL.xml:S1:275:3	800	CD	O	O
-	VIZAMYL.xml:S1:278:1	-	:	O	O
FDA	VIZAMYL.xml:S1:279:3	fda	NNP	O	O
-	VIZAMYL.xml:S1:282:1	-	:	O	O
1088	VIZAMYL.xml:S1:283:4	1088	CD	O	O
or	VIZAMYL.xml:S1:288:2	or	CC	O	O
www	VIZAMYL.xml:S1:291:3	www	VB	O	O
.	VIZAMYL.xml:S1:294:1	.	.	O	O
fda	VIZAMYL.xml:S1:295:3	fda	NN	O	O
.	VIZAMYL.xml:S1:298:1	.	.	O	O
gov	VIZAMYL.xml:S1:299:3	gov	JJ	O	O
medwatch	VIZAMYL.xml:S1:303:8	medwatch	NN	O	O
.	VIZAMYL.xml:S1:311:1	.	.	O	O

(	VIZAMYL.xml:S1:314:1	(	(	O	O
6	VIZAMYL.xml:S1:317:1	6	CD	O	O
)	VIZAMYL.xml:S1:320:1	)	)	O	O

6.1	VIZAMYL.xml:S1:330:3	6.1	CD	O	O

Clinical	VIZAMYL.xml:S1:334:8	clinic	JJ	O	O
Trials	VIZAMYL.xml:S1:343:6	trial	NNS	O	O
Experience	VIZAMYL.xml:S1:350:10	experi	NN	O	O

Clinical	VIZAMYL.xml:S1:364:8	clinic	JJ	O	O
trials	VIZAMYL.xml:S1:373:6	trial	NNS	O	O
are	VIZAMYL.xml:S1:380:3	are	VBP	O	O
conducted	VIZAMYL.xml:S1:384:9	conduct	VBN	O	O
under	VIZAMYL.xml:S1:394:5	under	IN	O	O
widely	VIZAMYL.xml:S1:400:6	wide	RB	O	O
varying	VIZAMYL.xml:S1:407:7	vari	VBG	O	O
conditions	VIZAMYL.xml:S1:415:10	condit	NNS	O	O
and	VIZAMYL.xml:S1:426:3	and	CC	O	O
adverse	VIZAMYL.xml:S1:430:7	advers	JJ	O	O
reaction	VIZAMYL.xml:S1:438:8	reaction	NN	O	O
rates	VIZAMYL.xml:S1:447:5	rate	NNS	O	O
observed	VIZAMYL.xml:S1:453:8	observ	VBD	O	O
in	VIZAMYL.xml:S1:462:2	in	IN	O	O
the	VIZAMYL.xml:S1:465:3	the	DT	O	O
clinical	VIZAMYL.xml:S1:469:8	clinic	JJ	O	O
trials	VIZAMYL.xml:S1:478:6	trial	NNS	O	O
of	VIZAMYL.xml:S1:485:2	of	IN	O	O
Vizamyl	VIZAMYL.xml:S1:488:7	vizamyl	NNP	O	O
cannot	VIZAMYL.xml:S1:496:6	cannot	NN	O	O
be	VIZAMYL.xml:S1:503:2	be	VB	O	O
directly	VIZAMYL.xml:S1:506:8	directli	RB	O	O
compared	VIZAMYL.xml:S1:515:8	compar	VBN	O	O
to	VIZAMYL.xml:S1:524:2	to	TO	O	O
rates	VIZAMYL.xml:S1:527:5	rate	NNS	O	O
in	VIZAMYL.xml:S1:533:2	in	IN	O	O
the	VIZAMYL.xml:S1:536:3	the	DT	O	O
clinical	VIZAMYL.xml:S1:540:8	clinic	JJ	O	O
trials	VIZAMYL.xml:S1:549:6	trial	NNS	O	O
of	VIZAMYL.xml:S1:556:2	of	IN	O	O
another	VIZAMYL.xml:S1:559:7	anoth	DT	O	O
drug	VIZAMYL.xml:S1:567:4	drug	NN	O	O
and	VIZAMYL.xml:S1:572:3	and	CC	O	O
may	VIZAMYL.xml:S1:576:3	may	MD	O	O
not	VIZAMYL.xml:S1:580:3	not	RB	O	O
reflect	VIZAMYL.xml:S1:584:7	reflect	VB	O	O
the	VIZAMYL.xml:S1:592:3	the	DT	O	O
rates	VIZAMYL.xml:S1:596:5	rate	NNS	O	O
observed	VIZAMYL.xml:S1:602:8	observ	VBD	O	O
in	VIZAMYL.xml:S1:611:2	in	IN	O	O
clinical	VIZAMYL.xml:S1:614:8	clinic	JJ	O	O
practice	VIZAMYL.xml:S1:623:8	practic	NN	O	O
.	VIZAMYL.xml:S1:631:1	.	.	O	O

In	VIZAMYL.xml:S1:637:2	In	IN	O	O
clinical	VIZAMYL.xml:S1:640:8	clinic	JJ	O	O
trials	VIZAMYL.xml:S1:649:6	trial	NNS	O	O
,	VIZAMYL.xml:S1:655:1	,	,	O	O
761	VIZAMYL.xml:S1:657:3	761	CD	O	O
adults	VIZAMYL.xml:S1:661:6	adult	NNS	O	O
(	VIZAMYL.xml:S1:668:1	(	(	O	O
367	VIZAMYL.xml:S1:669:3	367	CD	O	O
men	VIZAMYL.xml:S1:673:3	men	NNS	O	O
and	VIZAMYL.xml:S1:677:3	and	CC	O	O
394	VIZAMYL.xml:S1:681:3	394	CD	O	O
women	VIZAMYL.xml:S1:685:5	women	NNS	O	O
,	VIZAMYL.xml:S1:690:1	,	,	O	O
91%	VIZAMYL.xml:S1:692:3	91%	CD	O	O
Caucasian	VIZAMYL.xml:S1:696:9	caucasian	JJ	O	O
)	VIZAMYL.xml:S1:705:1	)	)	O	O
with	VIZAMYL.xml:S1:707:4	with	IN	O	O
a	VIZAMYL.xml:S1:712:1	a	DT	O	O
mean	VIZAMYL.xml:S1:714:4	mean	JJ	O	O
age	VIZAMYL.xml:S1:719:3	age	NN	O	O
of	VIZAMYL.xml:S1:723:2	of	IN	O	O
62	VIZAMYL.xml:S1:726:2	62	CD	O	O
years	VIZAMYL.xml:S1:729:5	year	NNS	O	O
(	VIZAMYL.xml:S1:735:1	(	(	O	O
range	VIZAMYL.xml:S1:736:5	rang	NN	O	O
18	VIZAMYL.xml:S1:742:2	18	CD	O	O
-	VIZAMYL.xml:S1:744:1	-	:	O	O
93	VIZAMYL.xml:S1:745:2	93	CD	O	O
years	VIZAMYL.xml:S1:748:5	year	NNS	O	O
)	VIZAMYL.xml:S1:753:1	)	)	O	O
received	VIZAMYL.xml:S1:755:8	receiv	VBD	O	O
Vizamyl	VIZAMYL.xml:S1:764:7	vizamyl	NNP	O	O
.	VIZAMYL.xml:S1:771:1	.	.	O	O

Most	VIZAMYL.xml:S1:773:4	most	JJS	O	O
subjects	VIZAMYL.xml:S1:778:8	subject	NNS	O	O
(	VIZAMYL.xml:S1:787:1	(	(	O	O
530	VIZAMYL.xml:S1:788:3	530	CD	O	O
,	VIZAMYL.xml:S1:791:1	,	,	O	O
70%	VIZAMYL.xml:S1:793:3	70%	CD	O	O
)	VIZAMYL.xml:S1:796:1	)	)	O	O
received	VIZAMYL.xml:S1:798:8	receiv	VBD	O	O
a	VIZAMYL.xml:S1:807:1	a	DT	O	O
dose	VIZAMYL.xml:S1:809:4	dose	NN	O	O
of	VIZAMYL.xml:S1:814:2	of	IN	O	O
185	VIZAMYL.xml:S1:817:3	185	CD	O	O
MBq	VIZAMYL.xml:S1:821:3	mbq	NNP	O	O
(	VIZAMYL.xml:S1:825:1	(	(	O	O
5	VIZAMYL.xml:S1:826:1	5	CD	O	O
mCi	VIZAMYL.xml:S1:828:3	mci	NN	O	O
)	VIZAMYL.xml:S1:831:1	)	)	O	O
.	VIZAMYL.xml:S1:832:1	.	.	O	O

One	VIZAMYL.xml:S1:838:3	one	CD	O	O
subject	VIZAMYL.xml:S1:842:7	subject	NN	O	O
out	VIZAMYL.xml:S1:850:3	out	IN	O	O
of	VIZAMYL.xml:S1:854:2	of	IN	O	O
761	VIZAMYL.xml:S1:857:3	761	CD	O	O
administered	VIZAMYL.xml:S1:861:12	administ	JJ	O	O
Vizamyl	VIZAMYL.xml:S1:874:7	vizamyl	NNP	O	O
experienced	VIZAMYL.xml:S1:882:11	experienc	VBD	O	O
a	VIZAMYL.xml:S1:894:1	a	DT	O	O
serious	VIZAMYL.xml:S1:896:7	seriou	JJ	O	O
hypersensitivity	VIZAMYL.xml:S1:904:16	hypersensit	NN	B-AdverseReaction	O
reaction	VIZAMYL.xml:S1:921:8	reaction	NN	I-AdverseReaction	O
with	VIZAMYL.xml:S1:930:4	with	IN	O	O
flushing	VIZAMYL.xml:S1:935:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	VIZAMYL.xml:S1:943:1	,	,	O	O
dyspnea	VIZAMYL.xml:S1:945:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
and	VIZAMYL.xml:S1:953:3	and	CC	O	O
chest	VIZAMYL.xml:S1:957:5	chest	NN	B-AdverseReaction	B-AdverseReaction
pressure	VIZAMYL.xml:S1:963:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
within	VIZAMYL.xml:S1:972:6	within	IN	O	O
minutes	VIZAMYL.xml:S1:979:7	minut	NNS	O	O
following	VIZAMYL.xml:S1:987:9	follow	VBG	O	O
Vizamyl	VIZAMYL.xml:S1:997:7	vizamyl	NNP	O	O
administration	VIZAMYL.xml:S1:1005:14	administr	NN	O	O
and	VIZAMYL.xml:S1:1020:3	and	CC	O	O
recovered	VIZAMYL.xml:S1:1024:9	recov	VBD	O	O
with	VIZAMYL.xml:S1:1034:4	with	IN	O	O
treatment	VIZAMYL.xml:S1:1039:9	treatment	NN	O	O
.	VIZAMYL.xml:S1:1048:1	.	.	O	O

Most	VIZAMYL.xml:S1:1054:4	most	JJS	O	O
adverse	VIZAMYL.xml:S1:1059:7	advers	JJ	O	O
reactions	VIZAMYL.xml:S1:1067:9	reaction	NNS	O	O
were	VIZAMYL.xml:S1:1077:4	were	VBD	O	O
mild	VIZAMYL.xml:S1:1082:4	mild	JJ	O	O
to	VIZAMYL.xml:S1:1087:2	to	TO	O	O
moderate	VIZAMYL.xml:S1:1090:8	moder	VB	O	O
in	VIZAMYL.xml:S1:1099:2	in	IN	O	O
intensity	VIZAMYL.xml:S1:1102:9	intens	NN	O	O
and	VIZAMYL.xml:S1:1112:3	and	CC	O	O
resolved	VIZAMYL.xml:S1:1116:8	resolv	VBD	O	O
spontaneously	VIZAMYL.xml:S1:1125:13	spontan	RB	O	O
.	VIZAMYL.xml:S1:1138:1	.	.	O	O

The	VIZAMYL.xml:S1:1140:3	the	DT	O	O
most	VIZAMYL.xml:S1:1144:4	most	RBS	O	O
commonly	VIZAMYL.xml:S1:1149:8	commonli	RB	O	O
reported	VIZAMYL.xml:S1:1158:8	report	VBD	O	O
adverse	VIZAMYL.xml:S1:1167:7	advers	JJ	O	O
reactions	VIZAMYL.xml:S1:1175:9	reaction	NNS	O	O
(	VIZAMYL.xml:S1:1185:1	(	(	O	O
occurring	VIZAMYL.xml:S1:1186:9	occur	VBG	O	O
in	VIZAMYL.xml:S1:1196:2	in	IN	O	O
at	VIZAMYL.xml:S1:1199:2	at	IN	O	O
least	VIZAMYL.xml:S1:1202:5	least	JJS	O	O
1%	VIZAMYL.xml:S1:1208:2	1%	CD	O	O
of	VIZAMYL.xml:S1:1211:2	of	IN	O	O
subjects	VIZAMYL.xml:S1:1214:8	subject	NNS	O	O
)	VIZAMYL.xml:S1:1222:1	)	)	O	O
in	VIZAMYL.xml:S1:1224:2	in	IN	O	O
Vizamyl	VIZAMYL.xml:S1:1227:7	vizamyl	NNP	O	O
-	VIZAMYL.xml:S1:1234:1	-	:	O	O
treated	VIZAMYL.xml:S1:1235:7	treat	JJ	O	O
subjects	VIZAMYL.xml:S1:1243:8	subject	NNS	O	O
are	VIZAMYL.xml:S1:1252:3	are	VBP	O	O
shown	VIZAMYL.xml:S1:1256:5	shown	VBN	O	O
in	VIZAMYL.xml:S1:1262:2	in	IN	O	O
Table	VIZAMYL.xml:S1:1265:5	tabl	JJ	O	O
2	VIZAMYL.xml:S1:1271:1	2	CD	O	O
.	VIZAMYL.xml:S1:1272:1	.	.	O	O

Table	VIZAMYL.xml:S1:1278:5	tabl	JJ	O	O
2	VIZAMYL.xml:S1:1284:1	2	CD	O	O
:	VIZAMYL.xml:S1:1285:1	:	:	O	O
Adverse	VIZAMYL.xml:S1:1287:7	advers	JJ	O	O
Reactions	VIZAMYL.xml:S1:1295:9	reaction	NNP	O	O
Reported	VIZAMYL.xml:S1:1305:8	report	NNP	O	O
in	VIZAMYL.xml:S1:1314:2	in	IN	O	O
Clinical	VIZAMYL.xml:S1:1317:8	clinic	NNP	O	O
Trials	VIZAMYL.xml:S1:1326:6	trial	NNP	O	O
of	VIZAMYL.xml:S1:1333:2	of	IN	O	O
Vizamyl	VIZAMYL.xml:S1:1336:7	vizamyl	NNP	O	O
(	VIZAMYL.xml:S1:1344:1	(	(	O	O
N	VIZAMYL.xml:S1:1345:1	N	NNP	O	O
761	VIZAMYL.xml:S1:1349:3	761	CD	O	O
subjects	VIZAMYL.xml:S1:1353:8	subject	NNS	O	O
)	VIZAMYL.xml:S1:1361:1	)	)	O	O

Adverse	VIZAMYL.xml:S1:1365:7	advers	JJ	O	O
Reaction	VIZAMYL.xml:S1:1373:8	reaction	NNP	O	O
N	VIZAMYL.xml:S1:1430:1	N	NNP	O	O
(	VIZAMYL.xml:S1:1432:1	(	(	O	O
percent	VIZAMYL.xml:S1:1433:7	percent	NN	O	O
of	VIZAMYL.xml:S1:1441:2	of	IN	O	O
patients	VIZAMYL.xml:S1:1444:8	patient	NNS	O	O
)	VIZAMYL.xml:S1:1452:1	)	)	O	O

Flushing	VIZAMYL.xml:S1:1475:8	flush	VBG	B-AdverseReaction	B-AdverseReaction

16	VIZAMYL.xml:S1:1548:2	16	CD	O	O
(	VIZAMYL.xml:S1:1551:1	(	(	O	O
2%	VIZAMYL.xml:S1:1552:2	2%	CD	O	O
)	VIZAMYL.xml:S1:1554:1	)	)	O	O

Increased	VIZAMYL.xml:S1:1582:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
blood	VIZAMYL.xml:S1:1592:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	VIZAMYL.xml:S1:1598:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
13	VIZAMYL.xml:S1:1655:2	13	CD	O	O
(	VIZAMYL.xml:S1:1658:1	(	(	O	O
2%	VIZAMYL.xml:S1:1659:2	2%	CD	O	O
)	VIZAMYL.xml:S1:1661:1	)	)	O	O

Headache	VIZAMYL.xml:S1:1689:8	headach	$	B-AdverseReaction	B-AdverseReaction
10	VIZAMYL.xml:S1:1762:2	10	CD	O	O
(	VIZAMYL.xml:S1:1765:1	(	(	O	O
1%	VIZAMYL.xml:S1:1766:2	1%	CD	O	O
)	VIZAMYL.xml:S1:1768:1	)	)	O	O

Nausea	VIZAMYL.xml:S1:1796:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
8	VIZAMYL.xml:S1:1870:1	8	CD	O	O
(	VIZAMYL.xml:S1:1872:1	(	(	O	O
1%	VIZAMYL.xml:S1:1873:2	1%	CD	O	O
)	VIZAMYL.xml:S1:1875:1	)	)	O	O

Dizziness	VIZAMYL.xml:S1:1903:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
8	VIZAMYL.xml:S1:1977:1	8	CD	O	O
(	VIZAMYL.xml:S1:1979:1	(	(	O	O
1%	VIZAMYL.xml:S1:1980:2	1%	CD	O	O
)	VIZAMYL.xml:S1:1982:1	)	)	O	O
5	VIZAMYL.xml:S2:4:1	5	CD	O	O
WARNINGS	VIZAMYL.xml:S2:6:8	warn	NNP	O	O
AND	VIZAMYL.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	VIZAMYL.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	VIZAMYL.xml:S2:37:7	excerpt	NN	O	O
:	VIZAMYL.xml:S2:44:1	:	:	O	O
Hypersensitivity	VIZAMYL.xml:S2:52:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	VIZAMYL.xml:S2:69:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
:	VIZAMYL.xml:S2:78:1	:	:	O	O
Ask	VIZAMYL.xml:S2:80:3	ask	NNP	O	O
patients	VIZAMYL.xml:S2:84:8	patient	NNS	O	O
about	VIZAMYL.xml:S2:93:5	about	IN	O	O
prior	VIZAMYL.xml:S2:99:5	prior	JJ	O	O
reactions	VIZAMYL.xml:S2:105:9	reaction	NNS	O	O
to	VIZAMYL.xml:S2:115:2	to	TO	O	O
Vizamyl	VIZAMYL.xml:S2:118:7	vizamyl	NNP	O	O
.	VIZAMYL.xml:S2:125:1	.	.	O	O

Observe	VIZAMYL.xml:S2:127:7	observ	NN	O	O
for	VIZAMYL.xml:S2:135:3	for	IN	O	O
hypersensitivity	VIZAMYL.xml:S2:139:16	hypersensit	NN	O	O
signs	VIZAMYL.xml:S2:156:5	sign	NNS	O	O
and	VIZAMYL.xml:S2:162:3	and	CC	O	O
symptoms	VIZAMYL.xml:S2:166:8	symptom	NNS	O	O
following	VIZAMYL.xml:S2:175:9	follow	VBG	O	O
Vizamyl	VIZAMYL.xml:S2:185:7	vizamyl	NNP	O	O
administration	VIZAMYL.xml:S2:193:14	administr	NN	O	O
.	VIZAMYL.xml:S2:207:1	.	.	O	O

Have	VIZAMYL.xml:S2:209:4	have	NNP	O	O
resuscitation	VIZAMYL.xml:S2:214:13	resuscit	NN	O	O
equipment	VIZAMYL.xml:S2:228:9	equip	NN	O	O
and	VIZAMYL.xml:S2:238:3	and	CC	O	O
trained	VIZAMYL.xml:S2:242:7	train	JJ	O	O
personnel	VIZAMYL.xml:S2:250:9	personnel	NNS	O	O
available	VIZAMYL.xml:S2:260:9	avail	JJ	O	O
at	VIZAMYL.xml:S2:270:2	at	IN	O	O
time	VIZAMYL.xml:S2:273:4	time	NN	O	O
of	VIZAMYL.xml:S2:278:2	of	IN	O	O
Vizamyl	VIZAMYL.xml:S2:281:7	vizamyl	NNP	O	O
administration	VIZAMYL.xml:S2:289:14	administr	NN	O	O
(	VIZAMYL.xml:S2:304:1	(	(	O	O
5.1	VIZAMYL.xml:S2:307:3	5.1	CD	O	O
)	VIZAMYL.xml:S2:312:1	)	)	O	O

Image	VIZAMYL.xml:S2:319:5	imag	NN	O	O
interpretation	VIZAMYL.xml:S2:325:14	interpret	NN	O	O
errors	VIZAMYL.xml:S2:340:6	error	NNS	O	O
(	VIZAMYL.xml:S2:347:1	(	(	O	O
especially	VIZAMYL.xml:S2:348:10	especi	RB	O	O
false	VIZAMYL.xml:S2:359:5	fals	JJ	O	O
positives	VIZAMYL.xml:S2:365:9	posit	NNS	O	O
)	VIZAMYL.xml:S2:374:1	)	)	O	O
have	VIZAMYL.xml:S2:376:4	have	VBP	O	O
been	VIZAMYL.xml:S2:381:4	been	VBN	O	O
observed	VIZAMYL.xml:S2:386:8	observ	VBN	O	O
(	VIZAMYL.xml:S2:395:1	(	(	O	O
5.2	VIZAMYL.xml:S2:398:3	5.2	CD	O	O
)	VIZAMYL.xml:S2:403:1	)	)	O	O

Radiation	VIZAMYL.xml:S2:410:9	radiat	NN	B-AdverseReaction	B-AdverseReaction
risk	VIZAMYL.xml:S2:420:4	risk	NN	I-AdverseReaction	I-AdverseReaction
:	VIZAMYL.xml:S2:424:1	:	:	O	O
Vizamyl	VIZAMYL.xml:S2:426:7	vizamyl	NNP	O	O
,	VIZAMYL.xml:S2:433:1	,	,	O	O
similar	VIZAMYL.xml:S2:435:7	similar	JJ	O	O
to	VIZAMYL.xml:S2:443:2	to	TO	O	O
all	VIZAMYL.xml:S2:446:3	all	DT	O	O
radiopharmaceuticals	VIZAMYL.xml:S2:450:20	radiopharmaceut	NNS	O	O
,	VIZAMYL.xml:S2:470:1	,	,	O	O
contributes	VIZAMYL.xml:S2:472:11	contribut	NNS	O	O
to	VIZAMYL.xml:S2:484:2	to	TO	O	O
a	VIZAMYL.xml:S2:487:1	a	DT	O	O
patient	VIZAMYL.xml:S2:489:7	patient	NN	O	O
's	VIZAMYL.xml:S2:496:2	's	POS	O	O
long	VIZAMYL.xml:S2:499:4	long	JJ	B-AdverseReaction	O
-	VIZAMYL.xml:S2:503:1	-	:	I-AdverseReaction	O
term	VIZAMYL.xml:S2:504:4	term	NN	I-AdverseReaction	O
cumulative	VIZAMYL.xml:S2:509:10	cumul	JJ	I-AdverseReaction	O
radiation	VIZAMYL.xml:S2:520:9	radiat	NN	I-AdverseReaction	O
exposure	VIZAMYL.xml:S2:530:8	exposur	NN	I-AdverseReaction	O
.	VIZAMYL.xml:S2:538:1	.	.	O	O

Ensure	VIZAMYL.xml:S2:540:6	ensur	NN	O	O
safe	VIZAMYL.xml:S2:547:4	safe	JJ	O	O
handling	VIZAMYL.xml:S2:552:8	handl	NN	O	O
to	VIZAMYL.xml:S2:561:2	to	TO	O	O
protect	VIZAMYL.xml:S2:564:7	protect	VB	O	O
patients	VIZAMYL.xml:S2:572:8	patient	NNS	O	O
and	VIZAMYL.xml:S2:581:3	and	CC	O	O
health	VIZAMYL.xml:S2:585:6	health	NN	O	O
care	VIZAMYL.xml:S2:592:4	care	NN	O	O
workers	VIZAMYL.xml:S2:597:7	worker	NNS	O	O
from	VIZAMYL.xml:S2:605:4	from	IN	O	O
unintentional	VIZAMYL.xml:S2:610:13	unintent	JJ	O	O
radiation	VIZAMYL.xml:S2:624:9	radiat	NN	O	O
exposure	VIZAMYL.xml:S2:634:8	exposur	NN	O	O
(	VIZAMYL.xml:S2:643:1	(	(	O	O
2.1	VIZAMYL.xml:S2:646:3	2.1	CD	O	O
,	VIZAMYL.xml:S2:651:1	,	,	O	O
5.3	VIZAMYL.xml:S2:654:3	5.3	CD	O	O
)	VIZAMYL.xml:S2:659:1	)	)	O	O

5.1	VIZAMYL.xml:S2:673:3	5.1	CD	O	O

Hypersensitivity	VIZAMYL.xml:S2:677:16	hypersensit	NN	O	O

Reactions	VIZAMYL.xml:S2:694:9	reaction	NNS	O	O

Hypersensitivity	VIZAMYL.xml:S2:709:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	VIZAMYL.xml:S2:726:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
such	VIZAMYL.xml:S2:736:4	such	JJ	O	O
as	VIZAMYL.xml:S2:741:2	as	IN	O	O
flushing	VIZAMYL.xml:S2:744:8	flush	NN	B-AdverseReaction	B-AdverseReaction
and	VIZAMYL.xml:S2:753:3	and	CC	O	O
dyspnea	VIZAMYL.xml:S2:757:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
have	VIZAMYL.xml:S2:765:4	have	VBP	O	O
been	VIZAMYL.xml:S2:770:4	been	VBN	O	O
observed	VIZAMYL.xml:S2:775:8	observ	VBN	O	O
within	VIZAMYL.xml:S2:784:6	within	IN	O	O
minutes	VIZAMYL.xml:S2:791:7	minut	NNS	O	O
following	VIZAMYL.xml:S2:799:9	follow	VBG	O	O
Vizamyl	VIZAMYL.xml:S2:809:7	vizamyl	NNP	O	O
administration	VIZAMYL.xml:S2:817:14	administr	NN	O	O
.	VIZAMYL.xml:S2:831:1	.	.	O	O

These	VIZAMYL.xml:S2:833:5	these	DT	O	O
reactions	VIZAMYL.xml:S2:839:9	reaction	NNS	O	O
may	VIZAMYL.xml:S2:849:3	may	MD	O	O
occur	VIZAMYL.xml:S2:853:5	occur	VB	O	O
in	VIZAMYL.xml:S2:859:2	in	IN	O	O
patients	VIZAMYL.xml:S2:862:8	patient	NNS	O	O
with	VIZAMYL.xml:S2:871:4	with	IN	O	O
no	VIZAMYL.xml:S2:876:2	no	DT	O	O
history	VIZAMYL.xml:S2:879:7	histori	NN	O	O
of	VIZAMYL.xml:S2:887:2	of	IN	O	O
prior	VIZAMYL.xml:S2:890:5	prior	JJ	O	O
exposure	VIZAMYL.xml:S2:896:8	exposur	NN	O	O
to	VIZAMYL.xml:S2:905:2	to	TO	O	O
Vizamyl	VIZAMYL.xml:S2:908:7	vizamyl	NNP	O	O
.	VIZAMYL.xml:S2:915:1	.	.	O	O

Before	VIZAMYL.xml:S2:921:6	befor	IN	O	O
administering	VIZAMYL.xml:S2:928:13	administ	VBG	O	O
Vizamyl	VIZAMYL.xml:S2:942:7	vizamyl	NNP	O	O
,	VIZAMYL.xml:S2:949:1	,	,	O	O
ask	VIZAMYL.xml:S2:951:3	ask	NN	O	O
patients	VIZAMYL.xml:S2:955:8	patient	NNS	O	O
about	VIZAMYL.xml:S2:964:5	about	IN	O	O
prior	VIZAMYL.xml:S2:970:5	prior	JJ	O	O
reactions	VIZAMYL.xml:S2:976:9	reaction	NNS	O	O
to	VIZAMYL.xml:S2:986:2	to	TO	O	O
drugs	VIZAMYL.xml:S2:989:5	drug	NNS	O	O
,	VIZAMYL.xml:S2:994:1	,	,	O	O
especially	VIZAMYL.xml:S2:996:10	especi	RB	O	O
those	VIZAMYL.xml:S2:1007:5	those	DT	O	O
containing	VIZAMYL.xml:S2:1013:10	contain	VBG	O	O
polysorbate	VIZAMYL.xml:S2:1024:11	polysorb	JJ	O	O
80	VIZAMYL.xml:S2:1036:2	80	CD	O	O
.	VIZAMYL.xml:S2:1038:1	.	.	O	O

Have	VIZAMYL.xml:S2:1044:4	have	NNP	O	O
resuscitation	VIZAMYL.xml:S2:1049:13	resuscit	NN	O	O
equipment	VIZAMYL.xml:S2:1063:9	equip	NN	O	O
and	VIZAMYL.xml:S2:1073:3	and	CC	O	O
trained	VIZAMYL.xml:S2:1077:7	train	JJ	O	O
personnel	VIZAMYL.xml:S2:1085:9	personnel	NNS	O	O
immediately	VIZAMYL.xml:S2:1095:11	immedi	RB	O	O
available	VIZAMYL.xml:S2:1107:9	avail	JJ	O	O
at	VIZAMYL.xml:S2:1117:2	at	IN	O	O
the	VIZAMYL.xml:S2:1120:3	the	DT	O	O
time	VIZAMYL.xml:S2:1124:4	time	NN	O	O
of	VIZAMYL.xml:S2:1129:2	of	IN	O	O
Vizamyl	VIZAMYL.xml:S2:1132:7	vizamyl	NNP	O	O
administration	VIZAMYL.xml:S2:1140:14	administr	NN	O	O
[	VIZAMYL.xml:S2:1155:1	[	NNP	O	O
see	VIZAMYL.xml:S2:1157:3	see	VBP	O	O
Contraindications	VIZAMYL.xml:S2:1162:17	contraind	NNP	O	O
(	VIZAMYL.xml:S2:1180:1	(	(	O	O
4	VIZAMYL.xml:S2:1181:1	4	CD	O	O
)	VIZAMYL.xml:S2:1182:1	)	)	O	O
]	VIZAMYL.xml:S2:1187:1	]	NN	O	O
.	VIZAMYL.xml:S2:1188:1	.	.	O	O

5.2	VIZAMYL.xml:S2:1197:3	5.2	CD	O	O
Risk	VIZAMYL.xml:S2:1201:4	risk	NN	O	O
for	VIZAMYL.xml:S2:1206:3	for	IN	O	O
Image	VIZAMYL.xml:S2:1210:5	imag	NNP	O	O
Misinterpretation	VIZAMYL.xml:S2:1216:17	misinterpret	NNP	O	O
and	VIZAMYL.xml:S2:1234:3	and	CC	O	O
Other	VIZAMYL.xml:S2:1238:5	other	JJ	O	O
Errors	VIZAMYL.xml:S2:1244:6	error	NNS	O	O

Errors	VIZAMYL.xml:S2:1256:6	error	NNS	O	O
may	VIZAMYL.xml:S2:1263:3	may	MD	O	O
occur	VIZAMYL.xml:S2:1267:5	occur	VB	O	O
while	VIZAMYL.xml:S2:1273:5	while	IN	O	O
using	VIZAMYL.xml:S2:1279:5	use	VBG	O	O
Vizamyl	VIZAMYL.xml:S2:1285:7	vizamyl	NNP	O	O
PET	VIZAMYL.xml:S2:1293:3	pet	NNP	O	O
images	VIZAMYL.xml:S2:1297:6	imag	NNS	O	O
to	VIZAMYL.xml:S2:1304:2	to	TO	O	O
estimate	VIZAMYL.xml:S2:1307:8	estim	VB	O	O
brain	VIZAMYL.xml:S2:1316:5	brain	NN	O	O
neuritic	VIZAMYL.xml:S2:1322:8	neurit	JJ	O	O
plaque	VIZAMYL.xml:S2:1331:6	plaqu	NN	O	O
density	VIZAMYL.xml:S2:1338:7	densiti	NN	O	O
[	VIZAMYL.xml:S2:1346:1	[	NNP	O	O
see	VIZAMYL.xml:S2:1348:3	see	VBP	O	O
Clinical	VIZAMYL.xml:S2:1353:8	clinic	JJ	O	O
Studies	VIZAMYL.xml:S2:1362:7	studi	NNP	O	O
(	VIZAMYL.xml:S2:1370:1	(	(	O	O
14	VIZAMYL.xml:S2:1371:2	14	CD	O	O
)	VIZAMYL.xml:S2:1373:1	)	)	O	O
]	VIZAMYL.xml:S2:1378:1	]	NN	O	O
.	VIZAMYL.xml:S2:1379:1	.	.	O	O

Image	VIZAMYL.xml:S2:1385:5	imag	NN	O	O
interpretation	VIZAMYL.xml:S2:1391:14	interpret	NN	O	O
is	VIZAMYL.xml:S2:1406:2	is	VBZ	O	O
performed	VIZAMYL.xml:S2:1409:9	perform	VBN	O	O
independently	VIZAMYL.xml:S2:1419:13	independ	RB	O	O
of	VIZAMYL.xml:S2:1433:2	of	IN	O	O
the	VIZAMYL.xml:S2:1436:3	the	DT	O	O
patient	VIZAMYL.xml:S2:1440:7	patient	NN	O	O
's	VIZAMYL.xml:S2:1447:2	's	POS	O	O
clinical	VIZAMYL.xml:S2:1450:8	clinic	JJ	O	O
information	VIZAMYL.xml:S2:1459:11	inform	NN	O	O
.	VIZAMYL.xml:S2:1470:1	.	.	O	O

The	VIZAMYL.xml:S2:1472:3	the	DT	O	O
use	VIZAMYL.xml:S2:1476:3	use	NN	O	O
of	VIZAMYL.xml:S2:1480:2	of	IN	O	O
clinical	VIZAMYL.xml:S2:1483:8	clinic	JJ	O	O
information	VIZAMYL.xml:S2:1492:11	inform	NN	O	O
in	VIZAMYL.xml:S2:1504:2	in	IN	O	O
the	VIZAMYL.xml:S2:1507:3	the	DT	O	O
interpretation	VIZAMYL.xml:S2:1511:14	interpret	NN	O	O
of	VIZAMYL.xml:S2:1526:2	of	IN	O	O
Vizamyl	VIZAMYL.xml:S2:1529:7	vizamyl	NNP	O	O
images	VIZAMYL.xml:S2:1537:6	imag	NNS	O	O
has	VIZAMYL.xml:S2:1544:3	ha	VBZ	O	O
not	VIZAMYL.xml:S2:1548:3	not	RB	O	O
been	VIZAMYL.xml:S2:1552:4	been	VBN	O	O
evaluated	VIZAMYL.xml:S2:1557:9	evalu	VBN	O	O
and	VIZAMYL.xml:S2:1567:3	and	CC	O	O
may	VIZAMYL.xml:S2:1571:3	may	MD	O	O
lead	VIZAMYL.xml:S2:1575:4	lead	VB	O	O
to	VIZAMYL.xml:S2:1580:2	to	TO	O	O
errors	VIZAMYL.xml:S2:1583:6	error	NNS	O	O
.	VIZAMYL.xml:S2:1589:1	.	.	O	O

Extensive	VIZAMYL.xml:S2:1591:9	extens	JJ	O	O
brain	VIZAMYL.xml:S2:1601:5	brain	NN	O	O
atrophy	VIZAMYL.xml:S2:1607:7	atrophi	NN	O	O
may	VIZAMYL.xml:S2:1615:3	may	MD	O	O
limit	VIZAMYL.xml:S2:1619:5	limit	VB	O	O
the	VIZAMYL.xml:S2:1625:3	the	DT	O	O
ability	VIZAMYL.xml:S2:1629:7	abil	NN	O	O
to	VIZAMYL.xml:S2:1637:2	to	TO	O	O
distinguish	VIZAMYL.xml:S2:1640:11	distinguish	VB	O	O
grey	VIZAMYL.xml:S2:1652:4	grey	NN	O	O
and	VIZAMYL.xml:S2:1657:3	and	CC	O	O
white	VIZAMYL.xml:S2:1661:5	white	JJ	O	O
matter	VIZAMYL.xml:S2:1667:6	matter	NN	O	O
on	VIZAMYL.xml:S2:1674:2	on	IN	O	O
a	VIZAMYL.xml:S2:1677:1	a	DT	O	O
Vizamyl	VIZAMYL.xml:S2:1679:7	vizamyl	NNP	O	O
scan	VIZAMYL.xml:S2:1687:4	scan	JJ	O	O
[	VIZAMYL.xml:S2:1692:1	[	NNP	O	O
see	VIZAMYL.xml:S2:1694:3	see	NN	O	O
Dosage	VIZAMYL.xml:S2:1699:6	dosag	NNP	O	O
and	VIZAMYL.xml:S2:1706:3	and	CC	O	O
Administration	VIZAMYL.xml:S2:1710:14	administr	NNP	O	O
(	VIZAMYL.xml:S2:1725:1	(	(	O	O
2.5	VIZAMYL.xml:S2:1726:3	2.5	CD	O	O
)	VIZAMYL.xml:S2:1729:1	)	)	O	O
]	VIZAMYL.xml:S2:1734:1	]	NN	O	O
.	VIZAMYL.xml:S2:1735:1	.	.	O	O

Motion	VIZAMYL.xml:S2:1737:6	motion	NNP	O	O
artifacts	VIZAMYL.xml:S2:1744:9	artifact	NNS	O	O
may	VIZAMYL.xml:S2:1754:3	may	MD	O	O
distort	VIZAMYL.xml:S2:1758:7	distort	VB	O	O
the	VIZAMYL.xml:S2:1766:3	the	DT	O	O
image	VIZAMYL.xml:S2:1770:5	imag	NN	O	O
[	VIZAMYL.xml:S2:1776:1	[	NNP	O	O
see	VIZAMYL.xml:S2:1778:3	see	VBP	O	O
Dosage	VIZAMYL.xml:S2:1783:6	dosag	NNP	O	O
and	VIZAMYL.xml:S2:1790:3	and	CC	O	O
Administration	VIZAMYL.xml:S2:1794:14	administr	NNP	O	O
(	VIZAMYL.xml:S2:1809:1	(	(	O	O
2.3	VIZAMYL.xml:S2:1810:3	2.3	CD	O	O
)	VIZAMYL.xml:S2:1813:1	)	)	O	O
]	VIZAMYL.xml:S2:1818:1	]	NN	O	O
.	VIZAMYL.xml:S2:1819:1	.	.	O	O

Vizamyl	VIZAMYL.xml:S2:1825:7	vizamyl	JJ	O	O
scan	VIZAMYL.xml:S2:1833:4	scan	JJ	O	O
results	VIZAMYL.xml:S2:1838:7	result	NNS	O	O
are	VIZAMYL.xml:S2:1846:3	are	VBP	O	O
indicative	VIZAMYL.xml:S2:1850:10	indic	JJ	O	O
of	VIZAMYL.xml:S2:1861:2	of	IN	O	O
the	VIZAMYL.xml:S2:1864:3	the	DT	O	O
brain	VIZAMYL.xml:S2:1868:5	brain	NN	O	O
neuritic	VIZAMYL.xml:S2:1874:8	neurit	JJ	O	O
amyloid	VIZAMYL.xml:S2:1883:7	amyloid	NN	O	O
plaque	VIZAMYL.xml:S2:1891:6	plaqu	NN	O	O
content	VIZAMYL.xml:S2:1898:7	content	NN	O	O
only	VIZAMYL.xml:S2:1906:4	onli	RB	O	O
at	VIZAMYL.xml:S2:1911:2	at	IN	O	O
the	VIZAMYL.xml:S2:1914:3	the	DT	O	O
time	VIZAMYL.xml:S2:1918:4	time	NN	O	O
of	VIZAMYL.xml:S2:1923:2	of	IN	O	O
image	VIZAMYL.xml:S2:1926:5	imag	NN	O	O
acquisition	VIZAMYL.xml:S2:1932:11	acquisit	NN	O	O
and	VIZAMYL.xml:S2:1944:3	and	CC	O	O
a	VIZAMYL.xml:S2:1948:1	a	DT	O	O
negative	VIZAMYL.xml:S2:1950:8	neg	JJ	O	O
scan	VIZAMYL.xml:S2:1959:4	scan	JJ	O	O
result	VIZAMYL.xml:S2:1964:6	result	NN	O	O
does	VIZAMYL.xml:S2:1971:4	doe	VBZ	O	O
not	VIZAMYL.xml:S2:1976:3	not	RB	O	O
preclude	VIZAMYL.xml:S2:1980:8	preclud	VB	O	O
the	VIZAMYL.xml:S2:1989:3	the	DT	O	O
development	VIZAMYL.xml:S2:1993:11	develop	NN	O	O
of	VIZAMYL.xml:S2:2005:2	of	IN	O	O
brain	VIZAMYL.xml:S2:2008:5	brain	NN	O	O
amyloid	VIZAMYL.xml:S2:2014:7	amyloid	NN	O	O
in	VIZAMYL.xml:S2:2022:2	in	IN	O	O
the	VIZAMYL.xml:S2:2025:3	the	DT	O	O
future	VIZAMYL.xml:S2:2029:6	futur	NN	O	O
.	VIZAMYL.xml:S2:2035:1	.	.	O	O

5.3	VIZAMYL.xml:S2:2044:3	5.3	CD	O	O
Radiation	VIZAMYL.xml:S2:2048:9	radiat	NNP	O	O
Risk	VIZAMYL.xml:S2:2058:4	risk	NN	O	O

Vizamyl	VIZAMYL.xml:S2:2068:7	vizamyl	NNP	O	O
,	VIZAMYL.xml:S2:2075:1	,	,	O	O
similar	VIZAMYL.xml:S2:2077:7	similar	JJ	O	O
to	VIZAMYL.xml:S2:2085:2	to	TO	O	O
other	VIZAMYL.xml:S2:2088:5	other	JJ	O	O
radiopharmaceuticals	VIZAMYL.xml:S2:2094:20	radiopharmaceut	NNS	O	O
,	VIZAMYL.xml:S2:2114:1	,	,	O	O
contributes	VIZAMYL.xml:S2:2116:11	contribut	NNS	O	O
to	VIZAMYL.xml:S2:2128:2	to	TO	O	O
a	VIZAMYL.xml:S2:2131:1	a	DT	O	O
patient	VIZAMYL.xml:S2:2133:7	patient	NN	O	O
's	VIZAMYL.xml:S2:2140:2	's	POS	O	O
overall	VIZAMYL.xml:S2:2143:7	overal	JJ	O	O
long	VIZAMYL.xml:S2:2151:4	long	JJ	B-AdverseReaction	O
-	VIZAMYL.xml:S2:2155:1	-	:	I-AdverseReaction	O
term	VIZAMYL.xml:S2:2156:4	term	NN	I-AdverseReaction	O
cumulative	VIZAMYL.xml:S2:2161:10	cumul	JJ	I-AdverseReaction	O
radiation	VIZAMYL.xml:S2:2172:9	radiat	NN	I-AdverseReaction	O
exposure	VIZAMYL.xml:S2:2182:8	exposur	NN	I-AdverseReaction	O
.	VIZAMYL.xml:S2:2190:1	.	.	O	O

Long	VIZAMYL.xml:S2:2192:4	long	NNP	B-AdverseReaction	O
-	VIZAMYL.xml:S2:2196:1	-	:	I-AdverseReaction	O
term	VIZAMYL.xml:S2:2197:4	term	NN	I-AdverseReaction	O
cumulative	VIZAMYL.xml:S2:2202:10	cumul	JJ	I-AdverseReaction	O
radiation	VIZAMYL.xml:S2:2213:9	radiat	NN	I-AdverseReaction	O
exposure	VIZAMYL.xml:S2:2223:8	exposur	NN	I-AdverseReaction	O
is	VIZAMYL.xml:S2:2232:2	is	VBZ	O	O
associated	VIZAMYL.xml:S2:2235:10	associ	VBN	O	O
with	VIZAMYL.xml:S2:2246:4	with	IN	O	O
an	VIZAMYL.xml:S2:2251:2	an	DT	O	O
increased	VIZAMYL.xml:S2:2254:9	increas	VBN	O	O
risk	VIZAMYL.xml:S2:2264:4	risk	NN	O	O
of	VIZAMYL.xml:S2:2269:2	of	IN	O	O
cancer	VIZAMYL.xml:S2:2272:6	cancer	NN	B-AdverseReaction	B-AdverseReaction
.	VIZAMYL.xml:S2:2278:1	.	.	O	O

Ensure	VIZAMYL.xml:S2:2280:6	ensur	NN	O	O
safe	VIZAMYL.xml:S2:2287:4	safe	JJ	O	O
handling	VIZAMYL.xml:S2:2292:8	handl	NN	O	O
to	VIZAMYL.xml:S2:2301:2	to	TO	O	O
protect	VIZAMYL.xml:S2:2304:7	protect	VB	O	O
patients	VIZAMYL.xml:S2:2312:8	patient	NNS	O	O
and	VIZAMYL.xml:S2:2321:3	and	CC	O	O
health	VIZAMYL.xml:S2:2325:6	health	NN	O	O
care	VIZAMYL.xml:S2:2332:4	care	NN	O	O
workers	VIZAMYL.xml:S2:2337:7	worker	NNS	O	O
from	VIZAMYL.xml:S2:2345:4	from	IN	O	O
unintentional	VIZAMYL.xml:S2:2350:13	unintent	JJ	O	O
radiation	VIZAMYL.xml:S2:2364:9	radiat	NN	O	O
exposure	VIZAMYL.xml:S2:2374:8	exposur	NN	O	O
[	VIZAMYL.xml:S2:2383:1	[	NNP	O	O
see	VIZAMYL.xml:S2:2385:3	see	VBP	O	O
Dosage	VIZAMYL.xml:S2:2390:6	dosag	NNP	O	O
and	VIZAMYL.xml:S2:2397:3	and	CC	O	O
Administration	VIZAMYL.xml:S2:2401:14	administr	NNP	O	O
(	VIZAMYL.xml:S2:2416:1	(	(	O	O
2.1	VIZAMYL.xml:S2:2417:3	2.1	CD	O	O
)	VIZAMYL.xml:S2:2420:1	)	)	O	O
]	VIZAMYL.xml:S2:2425:1	]	NN	O	O
.	VIZAMYL.xml:S2:2427:1	.	.	O	O
6	VORAXAZE.xml:S1:4:1	6	CD	O	O
ADVERSE	VORAXAZE.xml:S1:12:7	advers	JJ	O	O
REACTIONS	VORAXAZE.xml:S1:20:9	reaction	NN	O	O

Serious	VORAXAZE.xml:S1:33:7	seriou	JJ	O	O
allergic	VORAXAZE.xml:S1:41:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VORAXAZE.xml:S1:50:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	VORAXAZE.xml:S1:59:1	,	,	O	O
including	VORAXAZE.xml:S1:61:9	includ	VBG	O	O
anaphylactic	VORAXAZE.xml:S1:71:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VORAXAZE.xml:S1:84:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	VORAXAZE.xml:S1:93:1	,	,	O	O
may	VORAXAZE.xml:S1:95:3	may	MD	O	O
occur	VORAXAZE.xml:S1:99:5	occur	VB	O	O
.	VORAXAZE.xml:S1:104:1	.	.	O	O

The	VORAXAZE.xml:S1:106:3	the	DT	O	O
most	VORAXAZE.xml:S1:110:4	most	RBS	O	O
common	VORAXAZE.xml:S1:115:6	common	JJ	O	O
adverse	VORAXAZE.xml:S1:122:7	advers	JJ	O	O
reactions	VORAXAZE.xml:S1:130:9	reaction	NNS	O	O
(	VORAXAZE.xml:S1:140:1	(	(	O	O
incidence	VORAXAZE.xml:S1:141:9	incid	VB	O	O
1%	VORAXAZE.xml:S1:152:2	1%	CD	O	O
)	VORAXAZE.xml:S1:154:1	)	)	O	O
with	VORAXAZE.xml:S1:156:4	with	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:161:8	voraxaz	NNP	O	O
are	VORAXAZE.xml:S1:170:3	are	VBP	O	O
paraesthesias	VORAXAZE.xml:S1:174:13	paraesthesia	JJ	B-AdverseReaction	O
,	VORAXAZE.xml:S1:187:1	,	,	O	O
flushing	VORAXAZE.xml:S1:189:8	flush	JJ	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:197:1	,	,	O	O
nausea	VORAXAZE.xml:S1:199:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
and	VORAXAZE.xml:S1:206:3	and	CC	O	O
or	VORAXAZE.xml:S1:210:2	or	CC	O	O
vomiting	VORAXAZE.xml:S1:213:8	vomit	NN	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:221:1	,	,	O	O
hypotension	VORAXAZE.xml:S1:223:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:234:1	,	,	O	O
and	VORAXAZE.xml:S1:236:3	and	CC	O	O
headache	VORAXAZE.xml:S1:240:8	headach	NN	B-AdverseReaction	B-AdverseReaction
.	VORAXAZE.xml:S1:248:1	.	.	O	O

EXCERPT	VORAXAZE.xml:S1:256:7	excerpt	NN	O	O
:	VORAXAZE.xml:S1:263:1	:	:	O	O
In	VORAXAZE.xml:S1:267:2	In	IN	O	O
clinical	VORAXAZE.xml:S1:270:8	clinic	JJ	O	O
trials	VORAXAZE.xml:S1:279:6	trial	NNS	O	O
,	VORAXAZE.xml:S1:285:1	,	,	O	O
the	VORAXAZE.xml:S1:287:3	the	DT	O	O
most	VORAXAZE.xml:S1:291:4	most	RBS	O	O
common	VORAXAZE.xml:S1:296:6	common	JJ	O	O
related	VORAXAZE.xml:S1:303:7	relat	JJ	O	O
adverse	VORAXAZE.xml:S1:311:7	advers	JJ	O	O
events	VORAXAZE.xml:S1:319:6	event	NNS	O	O
(	VORAXAZE.xml:S1:326:1	(	(	O	O
occurring	VORAXAZE.xml:S1:327:9	occur	VBG	O	O
in	VORAXAZE.xml:S1:337:2	in	IN	O	O
1%	VORAXAZE.xml:S1:341:2	1%	CD	O	O
of	VORAXAZE.xml:S1:344:2	of	IN	O	O
patients	VORAXAZE.xml:S1:347:8	patient	NNS	O	O
)	VORAXAZE.xml:S1:355:1	)	)	O	O
were	VORAXAZE.xml:S1:357:4	were	VBD	O	O
paraesthesia	VORAXAZE.xml:S1:362:12	paraesthesia	JJ	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:374:1	,	,	O	O
flushing	VORAXAZE.xml:S1:376:8	flush	JJ	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:384:1	,	,	O	O
nausea	VORAXAZE.xml:S1:386:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
and	VORAXAZE.xml:S1:393:3	and	CC	O	O
or	VORAXAZE.xml:S1:397:2	or	CC	O	O
vomiting	VORAXAZE.xml:S1:400:8	vomit	NN	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:408:1	,	,	O	O
hypotension	VORAXAZE.xml:S1:410:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
and	VORAXAZE.xml:S1:422:3	and	CC	O	O
headache	VORAXAZE.xml:S1:426:8	headach	NN	B-AdverseReaction	B-AdverseReaction
.	VORAXAZE.xml:S1:434:1	.	.	O	O

(	VORAXAZE.xml:S1:436:1	(	(	O	O
6	VORAXAZE.xml:S1:439:1	6	CD	O	O
)	VORAXAZE.xml:S1:442:1	)	)	O	O

To	VORAXAZE.xml:S1:455:2	To	TO	O	O

report	VORAXAZE.xml:S1:458:6	report	NN	O	O
SUSPECTED	VORAXAZE.xml:S1:465:9	suspect	NNP	O	O
ADVERSE	VORAXAZE.xml:S1:475:7	advers	NNP	O	O
REACTIONS	VORAXAZE.xml:S1:483:9	reaction	NNP	O	O
,	VORAXAZE.xml:S1:492:1	,	,	O	O
call	VORAXAZE.xml:S1:494:4	call	VB	O	O
877	VORAXAZE.xml:S1:499:3	877	CD	O	O
-	VORAXAZE.xml:S1:502:1	-	:	O	O
377	VORAXAZE.xml:S1:503:3	377	CD	O	O
-	VORAXAZE.xml:S1:506:1	-	:	O	O
3784	VORAXAZE.xml:S1:507:4	3784	CD	O	O
or	VORAXAZE.xml:S1:512:2	or	CC	O	O
contact	VORAXAZE.xml:S1:515:7	contact	VB	O	O
FDA	VORAXAZE.xml:S1:523:3	fda	NNP	O	O
at	VORAXAZE.xml:S1:527:2	at	IN	O	O
1	VORAXAZE.xml:S1:530:1	1	CD	O	O
-	VORAXAZE.xml:S1:531:1	-	:	O	O
800	VORAXAZE.xml:S1:532:3	800	CD	O	O
-	VORAXAZE.xml:S1:535:1	-	:	O	O
FDA	VORAXAZE.xml:S1:536:3	fda	NNP	O	O
-	VORAXAZE.xml:S1:539:1	-	:	O	O
1088	VORAXAZE.xml:S1:540:4	1088	CD	O	O
or	VORAXAZE.xml:S1:545:2	or	CC	O	O
www	VORAXAZE.xml:S1:551:3	www	VB	O	O
.	VORAXAZE.xml:S1:554:1	.	.	O	O
fda	VORAXAZE.xml:S1:555:3	fda	NN	O	O
.	VORAXAZE.xml:S1:558:1	.	.	O	O
gov	VORAXAZE.xml:S1:559:3	gov	JJ	O	O
medwatch	VORAXAZE.xml:S1:563:8	medwatch	NN	O	O
.	VORAXAZE.xml:S1:575:1	.	.	O	O

6.1	VORAXAZE.xml:S1:587:3	6.1	CD	O	O

Clinical	VORAXAZE.xml:S1:595:8	clinic	JJ	O	O
Trials	VORAXAZE.xml:S1:604:6	trial	NNS	O	O
Experience	VORAXAZE.xml:S1:611:10	experi	NN	O	O

Because	VORAXAZE.xml:S1:625:7	becaus	IN	O	O
clinical	VORAXAZE.xml:S1:633:8	clinic	JJ	O	O
trials	VORAXAZE.xml:S1:642:6	trial	NNS	O	O
are	VORAXAZE.xml:S1:649:3	are	VBP	O	O
conducted	VORAXAZE.xml:S1:653:9	conduct	VBN	O	O
under	VORAXAZE.xml:S1:663:5	under	IN	O	O
controlled	VORAXAZE.xml:S1:669:10	control	VBN	O	O
but	VORAXAZE.xml:S1:680:3	but	CC	O	O
widely	VORAXAZE.xml:S1:684:6	wide	RB	O	O
varying	VORAXAZE.xml:S1:691:7	vari	JJ	O	O
conditions	VORAXAZE.xml:S1:699:10	condit	NNS	O	O
,	VORAXAZE.xml:S1:709:1	,	,	O	O
adverse	VORAXAZE.xml:S1:711:7	advers	JJ	O	O
reaction	VORAXAZE.xml:S1:719:8	reaction	NN	O	O
rates	VORAXAZE.xml:S1:728:5	rate	NNS	O	O
observed	VORAXAZE.xml:S1:734:8	observ	VBD	O	O
in	VORAXAZE.xml:S1:743:2	in	IN	O	O
clinical	VORAXAZE.xml:S1:746:8	clinic	JJ	O	O
trials	VORAXAZE.xml:S1:755:6	trial	NNS	O	O
of	VORAXAZE.xml:S1:762:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:765:8	voraxaz	NNP	O	O
cannot	VORAXAZE.xml:S1:774:6	cannot	NN	O	O
be	VORAXAZE.xml:S1:781:2	be	VB	O	O
directly	VORAXAZE.xml:S1:784:8	directli	RB	O	O
compared	VORAXAZE.xml:S1:793:8	compar	VBN	O	O
to	VORAXAZE.xml:S1:802:2	to	TO	O	O
rates	VORAXAZE.xml:S1:805:5	rate	NNS	O	O
in	VORAXAZE.xml:S1:811:2	in	IN	O	O
the	VORAXAZE.xml:S1:814:3	the	DT	O	O
clinical	VORAXAZE.xml:S1:818:8	clinic	JJ	O	O
trials	VORAXAZE.xml:S1:827:6	trial	NNS	O	O
of	VORAXAZE.xml:S1:834:2	of	IN	O	O
other	VORAXAZE.xml:S1:837:5	other	JJ	O	O
drugs	VORAXAZE.xml:S1:843:5	drug	NNS	O	O
and	VORAXAZE.xml:S1:849:3	and	CC	O	O
may	VORAXAZE.xml:S1:853:3	may	MD	O	O
not	VORAXAZE.xml:S1:857:3	not	RB	O	O
reflect	VORAXAZE.xml:S1:861:7	reflect	VB	O	O
the	VORAXAZE.xml:S1:869:3	the	DT	O	O
rates	VORAXAZE.xml:S1:873:5	rate	NNS	O	O
observed	VORAXAZE.xml:S1:879:8	observ	VBD	O	O
in	VORAXAZE.xml:S1:888:2	in	IN	O	O
practice	VORAXAZE.xml:S1:891:8	practic	NN	O	O
.	VORAXAZE.xml:S1:899:1	.	.	O	O

The	VORAXAZE.xml:S1:905:3	the	DT	O	O
evaluation	VORAXAZE.xml:S1:909:10	evalu	NN	O	O
of	VORAXAZE.xml:S1:920:2	of	IN	O	O
adverse	VORAXAZE.xml:S1:923:7	advers	JJ	O	O
reactions	VORAXAZE.xml:S1:931:9	reaction	NNS	O	O
in	VORAXAZE.xml:S1:941:2	in	IN	O	O
patients	VORAXAZE.xml:S1:944:8	patient	NNS	O	O
treated	VORAXAZE.xml:S1:953:7	treat	VBN	O	O
with	VORAXAZE.xml:S1:961:4	with	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:966:8	voraxaz	NNP	O	O
is	VORAXAZE.xml:S1:975:2	is	VBZ	O	O
confounded	VORAXAZE.xml:S1:978:10	confound	VBN	O	O
by	VORAXAZE.xml:S1:989:2	by	IN	O	O
the	VORAXAZE.xml:S1:992:3	the	DT	O	O
population	VORAXAZE.xml:S1:996:10	popul	NN	O	O
in	VORAXAZE.xml:S1:1007:2	in	IN	O	O
which	VORAXAZE.xml:S1:1010:5	which	WDT	O	O
it	VORAXAZE.xml:S1:1016:2	it	PRP	O	O
was	VORAXAZE.xml:S1:1019:3	wa	VBD	O	O
studied	VORAXAZE.xml:S1:1023:7	studi	VBN	O	O
,	VORAXAZE.xml:S1:1030:1	,	,	O	O
patients	VORAXAZE.xml:S1:1032:8	patient	NNS	O	O
with	VORAXAZE.xml:S1:1041:4	with	IN	O	O
toxic	VORAXAZE.xml:S1:1046:5	toxic	JJ	O	O
plasma	VORAXAZE.xml:S1:1052:6	plasma	NNS	O	O
methotrexate	VORAXAZE.xml:S1:1059:12	methotrex	NN	O	O
levels	VORAXAZE.xml:S1:1072:6	level	NNS	O	O
due	VORAXAZE.xml:S1:1079:3	due	JJ	O	O
to	VORAXAZE.xml:S1:1083:2	to	TO	O	O
impaired	VORAXAZE.xml:S1:1086:8	impair	JJ	O	O
renal	VORAXAZE.xml:S1:1095:5	renal	JJ	O	O
function	VORAXAZE.xml:S1:1101:8	function	NN	O	O
.	VORAXAZE.xml:S1:1109:1	.	.	O	O

Adverse	VORAXAZE.xml:S1:1111:7	advers	JJ	O	O
reactions	VORAXAZE.xml:S1:1119:9	reaction	NNS	O	O
related	VORAXAZE.xml:S1:1129:7	relat	VBN	O	O
to	VORAXAZE.xml:S1:1137:2	to	TO	O	O
toxic	VORAXAZE.xml:S1:1140:5	toxic	VB	O	B-AdverseReaction
methotrexate	VORAXAZE.xml:S1:1146:12	methotrex	NN	O	I-AdverseReaction
levels	VORAXAZE.xml:S1:1159:6	level	NNS	O	I-AdverseReaction
due	VORAXAZE.xml:S1:1166:3	due	JJ	O	O
to	VORAXAZE.xml:S1:1170:2	to	TO	O	O
prolonged	VORAXAZE.xml:S1:1173:9	prolong	JJ	O	O
methotrexate	VORAXAZE.xml:S1:1183:12	methotrex	JJ	O	O
clearance	VORAXAZE.xml:S1:1196:9	clearanc	NN	O	O
include	VORAXAZE.xml:S1:1206:7	includ	VBP	O	O
myelosuppression	VORAXAZE.xml:S1:1214:16	myelosuppress	NN	O	B-AdverseReaction
,	VORAXAZE.xml:S1:1230:1	,	,	O	O
mucositis	VORAXAZE.xml:S1:1232:9	mucos	NN	O	B-AdverseReaction
,	VORAXAZE.xml:S1:1241:1	,	,	O	O
acute	VORAXAZE.xml:S1:1243:5	acut	JJ	O	B-AdverseReaction
hepatitis	VORAXAZE.xml:S1:1249:9	hepat	NN	O	I-AdverseReaction
,	VORAXAZE.xml:S1:1258:1	,	,	O	O
and	VORAXAZE.xml:S1:1260:3	and	CC	O	O
renal	VORAXAZE.xml:S1:1264:5	renal	JJ	O	B-AdverseReaction
dysfunction	VORAXAZE.xml:S1:1270:11	dysfunct	NN	O	I-AdverseReaction
and	VORAXAZE.xml:S1:1282:3	and	CC	O	O
failure	VORAXAZE.xml:S1:1286:7	failur	NN	O	O
.	VORAXAZE.xml:S1:1293:1	.	.	O	O

The	VORAXAZE.xml:S1:1299:3	the	DT	O	O
safety	VORAXAZE.xml:S1:1303:6	safeti	NN	O	O
of	VORAXAZE.xml:S1:1310:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:1313:8	voraxaz	NNP	O	O
is	VORAXAZE.xml:S1:1322:2	is	VBZ	O	O
based	VORAXAZE.xml:S1:1325:5	base	VBN	O	O
on	VORAXAZE.xml:S1:1331:2	on	IN	O	O
data	VORAXAZE.xml:S1:1334:4	data	NNS	O	O
from	VORAXAZE.xml:S1:1339:4	from	IN	O	O
290	VORAXAZE.xml:S1:1344:3	290	CD	O	O
patients	VORAXAZE.xml:S1:1348:8	patient	NNS	O	O
who	VORAXAZE.xml:S1:1357:3	who	WP	O	O
were	VORAXAZE.xml:S1:1361:4	were	VBD	O	O
treated	VORAXAZE.xml:S1:1366:7	treat	VBN	O	O
in	VORAXAZE.xml:S1:1374:2	in	IN	O	O
2	VORAXAZE.xml:S1:1377:1	2	CD	O	O
single	VORAXAZE.xml:S1:1379:6	singl	JJ	O	O
-	VORAXAZE.xml:S1:1385:1	-	:	O	O
arm	VORAXAZE.xml:S1:1386:3	arm	NN	O	O
,	VORAXAZE.xml:S1:1389:1	,	,	O	O
open	VORAXAZE.xml:S1:1391:4	open	JJ	O	O
-	VORAXAZE.xml:S1:1395:1	-	:	O	O
label	VORAXAZE.xml:S1:1396:5	label	NN	O	O
,	VORAXAZE.xml:S1:1401:1	,	,	O	O
multicenter	VORAXAZE.xml:S1:1403:11	multicent	NN	O	O
trials	VORAXAZE.xml:S1:1415:6	trial	NNS	O	O
enrolling	VORAXAZE.xml:S1:1422:9	enrol	VBG	O	O
patients	VORAXAZE.xml:S1:1432:8	patient	NNS	O	O
who	VORAXAZE.xml:S1:1441:3	who	WP	O	O
had	VORAXAZE.xml:S1:1445:3	had	VBD	O	O
markedly	VORAXAZE.xml:S1:1449:8	markedli	RB	O	O
delayed	VORAXAZE.xml:S1:1458:7	delay	VBN	O	O
methotrexate	VORAXAZE.xml:S1:1466:12	methotrex	NN	O	O
clearance	VORAXAZE.xml:S1:1479:9	clearanc	NN	O	O
secondary	VORAXAZE.xml:S1:1489:9	secondari	JJ	O	O
to	VORAXAZE.xml:S1:1499:2	to	TO	O	O
renal	VORAXAZE.xml:S1:1502:5	renal	JJ	O	B-AdverseReaction
dysfunction	VORAXAZE.xml:S1:1508:11	dysfunct	NN	O	I-AdverseReaction
.	VORAXAZE.xml:S1:1519:1	.	.	O	O

Patients	VORAXAZE.xml:S1:1521:8	patient	NNS	O	O
with	VORAXAZE.xml:S1:1530:4	with	IN	O	O
osteosarcoma	VORAXAZE.xml:S1:1535:12	osteosarcoma	NNS	O	O
were	VORAXAZE.xml:S1:1548:4	were	VBD	O	O
eligible	VORAXAZE.xml:S1:1553:8	elig	JJ	O	O
for	VORAXAZE.xml:S1:1562:3	for	IN	O	O
these	VORAXAZE.xml:S1:1566:5	these	DT	O	O
studies	VORAXAZE.xml:S1:1572:7	studi	NNS	O	O
if	VORAXAZE.xml:S1:1580:2	if	IN	O	O
the	VORAXAZE.xml:S1:1583:3	the	DT	O	O
plasma	VORAXAZE.xml:S1:1587:6	plasma	NN	O	O
methotrexate	VORAXAZE.xml:S1:1594:12	methotrex	NN	O	O
concentration	VORAXAZE.xml:S1:1607:13	concentr	NN	O	O
was	VORAXAZE.xml:S1:1621:3	wa	VBD	O	O
greater	VORAXAZE.xml:S1:1625:7	greater	JJR	O	O
than	VORAXAZE.xml:S1:1633:4	than	IN	O	O
50	VORAXAZE.xml:S1:1638:2	50	CD	O	O
mumol	VORAXAZE.xml:S1:1641:5	mumol	JJ	O	O
L	VORAXAZE.xml:S1:1647:1	L	NNP	O	O
at	VORAXAZE.xml:S1:1649:2	at	IN	O	O
24	VORAXAZE.xml:S1:1652:2	24	CD	O	O
hours	VORAXAZE.xml:S1:1655:5	hour	NNS	O	O
,	VORAXAZE.xml:S1:1660:1	,	,	O	O
greater	VORAXAZE.xml:S1:1662:7	greater	JJR	O	O
that	VORAXAZE.xml:S1:1670:4	that	IN	O	O
5	VORAXAZE.xml:S1:1675:1	5	CD	O	O
mumol	VORAXAZE.xml:S1:1677:5	mumol	NNS	O	O
L	VORAXAZE.xml:S1:1683:1	L	NNP	O	O
at	VORAXAZE.xml:S1:1685:2	at	IN	O	O
48	VORAXAZE.xml:S1:1688:2	48	CD	O	O
hours	VORAXAZE.xml:S1:1691:5	hour	NNS	O	O
,	VORAXAZE.xml:S1:1696:1	,	,	O	O
or	VORAXAZE.xml:S1:1698:2	or	CC	O	O
greater	VORAXAZE.xml:S1:1701:7	greater	JJR	O	O
than	VORAXAZE.xml:S1:1709:4	than	IN	O	O
2	VORAXAZE.xml:S1:1714:1	2	CD	O	O
standard	VORAXAZE.xml:S1:1716:8	standard	JJ	O	O
deviations	VORAXAZE.xml:S1:1725:10	deviat	NNS	O	O
above	VORAXAZE.xml:S1:1736:5	abov	IN	O	O
the	VORAXAZE.xml:S1:1742:3	the	DT	O	O
mean	VORAXAZE.xml:S1:1746:4	mean	JJ	O	O
methotrexate	VORAXAZE.xml:S1:1751:12	methotrex	NN	O	O
elimination	VORAXAZE.xml:S1:1764:11	elimin	NN	O	O
curve	VORAXAZE.xml:S1:1776:5	curv	NN	O	O
at	VORAXAZE.xml:S1:1782:2	at	IN	O	O
least	VORAXAZE.xml:S1:1785:5	least	JJS	O	O
12	VORAXAZE.xml:S1:1791:2	12	CD	O	O
hours	VORAXAZE.xml:S1:1794:5	hour	NNS	O	O
after	VORAXAZE.xml:S1:1800:5	after	IN	O	O
methotrexate	VORAXAZE.xml:S1:1806:12	methotrex	JJ	O	O
administration	VORAXAZE.xml:S1:1819:14	administr	NN	O	O
and	VORAXAZE.xml:S1:1834:3	and	CC	O	O
there	VORAXAZE.xml:S1:1838:5	there	EX	O	O
was	VORAXAZE.xml:S1:1844:3	wa	VBD	O	O
a	VORAXAZE.xml:S1:1848:1	a	DT	O	O
2	VORAXAZE.xml:S1:1850:1	2	CD	O	O
-	VORAXAZE.xml:S1:1851:1	-	:	O	O
fold	VORAXAZE.xml:S1:1852:4	fold	NN	O	O
or	VORAXAZE.xml:S1:1857:2	or	CC	O	O
greater	VORAXAZE.xml:S1:1860:7	greater	JJR	O	O
increase	VORAXAZE.xml:S1:1868:8	increas	NN	O	B-AdverseReaction
in	VORAXAZE.xml:S1:1877:2	in	IN	O	I-AdverseReaction
serum	VORAXAZE.xml:S1:1880:5	serum	JJ	O	I-AdverseReaction
creatinine	VORAXAZE.xml:S1:1886:10	creatinin	NN	O	I-AdverseReaction
above	VORAXAZE.xml:S1:1897:5	abov	IN	O	O
baseline	VORAXAZE.xml:S1:1903:8	baselin	NN	O	O
.	VORAXAZE.xml:S1:1911:1	.	.	O	O

All	VORAXAZE.xml:S1:1913:3	all	DT	O	O
other	VORAXAZE.xml:S1:1917:5	other	JJ	O	O
patients	VORAXAZE.xml:S1:1923:8	patient	NNS	O	O
were	VORAXAZE.xml:S1:1932:4	were	VBD	O	O
eligible	VORAXAZE.xml:S1:1937:8	elig	JJ	O	O
for	VORAXAZE.xml:S1:1946:3	for	IN	O	O
these	VORAXAZE.xml:S1:1950:5	these	DT	O	O
studies	VORAXAZE.xml:S1:1956:7	studi	NNS	O	O
if	VORAXAZE.xml:S1:1964:2	if	IN	O	O
the	VORAXAZE.xml:S1:1967:3	the	DT	O	O
plasma	VORAXAZE.xml:S1:1971:6	plasma	NN	O	O
methotrexate	VORAXAZE.xml:S1:1978:12	methotrex	NN	O	O
level	VORAXAZE.xml:S1:1991:5	level	NN	O	O
was	VORAXAZE.xml:S1:1997:3	wa	VBD	O	O
greater	VORAXAZE.xml:S1:2001:7	greater	JJR	O	O
than	VORAXAZE.xml:S1:2009:4	than	IN	O	O
10	VORAXAZE.xml:S1:2014:2	10	CD	O	O
mumol	VORAXAZE.xml:S1:2017:5	mumol	JJ	O	O
L	VORAXAZE.xml:S1:2023:1	L	NNP	O	O
more	VORAXAZE.xml:S1:2025:4	more	JJR	O	O
than	VORAXAZE.xml:S1:2030:4	than	IN	O	O
42	VORAXAZE.xml:S1:2035:2	42	CD	O	O
hours	VORAXAZE.xml:S1:2038:5	hour	NNS	O	O
after	VORAXAZE.xml:S1:2044:5	after	IN	O	O
the	VORAXAZE.xml:S1:2050:3	the	DT	O	O
start	VORAXAZE.xml:S1:2054:5	start	NN	O	O
of	VORAXAZE.xml:S1:2060:2	of	IN	O	O
the	VORAXAZE.xml:S1:2063:3	the	DT	O	O
methotrexate	VORAXAZE.xml:S1:2067:12	methotrex	NN	O	O
or	VORAXAZE.xml:S1:2080:2	or	CC	O	O
the	VORAXAZE.xml:S1:2083:3	the	DT	O	O
plasma	VORAXAZE.xml:S1:2087:6	plasma	JJ	O	O
level	VORAXAZE.xml:S1:2094:5	level	NN	O	O
was	VORAXAZE.xml:S1:2100:3	wa	VBD	O	O
greater	VORAXAZE.xml:S1:2104:7	greater	JJR	O	O
than	VORAXAZE.xml:S1:2112:4	than	IN	O	O
2	VORAXAZE.xml:S1:2117:1	2	CD	O	O
standard	VORAXAZE.xml:S1:2119:8	standard	JJ	O	O
deviations	VORAXAZE.xml:S1:2128:10	deviat	NNS	O	O
above	VORAXAZE.xml:S1:2139:5	abov	IN	O	O
the	VORAXAZE.xml:S1:2145:3	the	DT	O	O
mean	VORAXAZE.xml:S1:2149:4	mean	JJ	O	O
methotrexate	VORAXAZE.xml:S1:2154:12	methotrex	NN	O	O
excretion	VORAXAZE.xml:S1:2167:9	excret	NN	O	O
curve	VORAXAZE.xml:S1:2177:5	curv	NN	O	O
at	VORAXAZE.xml:S1:2183:2	at	IN	O	O
least	VORAXAZE.xml:S1:2186:5	least	JJS	O	O
12	VORAXAZE.xml:S1:2192:2	12	CD	O	O
hours	VORAXAZE.xml:S1:2195:5	hour	NNS	O	O
following	VORAXAZE.xml:S1:2201:9	follow	VBG	O	O
methotrexate	VORAXAZE.xml:S1:2211:12	methotrex	NN	O	O
and	VORAXAZE.xml:S1:2224:3	and	CC	O	O
the	VORAXAZE.xml:S1:2228:3	the	DT	O	O
serum	VORAXAZE.xml:S1:2232:5	serum	NN	O	O
creatinine	VORAXAZE.xml:S1:2238:10	creatinin	NN	O	O
was	VORAXAZE.xml:S1:2249:3	wa	VBD	O	O
greater	VORAXAZE.xml:S1:2253:7	greater	JJR	O	O
than	VORAXAZE.xml:S1:2261:4	than	IN	O	O
1.5	VORAXAZE.xml:S1:2266:3	1.5	CD	O	O
times	VORAXAZE.xml:S1:2270:5	time	NNS	O	O
the	VORAXAZE.xml:S1:2276:3	the	DT	O	O
upper	VORAXAZE.xml:S1:2280:5	upper	JJ	O	O
limit	VORAXAZE.xml:S1:2286:5	limit	NN	O	O
of	VORAXAZE.xml:S1:2292:2	of	IN	O	O
normal	VORAXAZE.xml:S1:2295:6	normal	JJ	O	O
or	VORAXAZE.xml:S1:2302:2	or	CC	O	O
the	VORAXAZE.xml:S1:2305:3	the	DT	O	O
creatinine	VORAXAZE.xml:S1:2309:10	creatinin	JJ	O	O
clearance	VORAXAZE.xml:S1:2320:9	clearanc	NN	O	O
was	VORAXAZE.xml:S1:2330:3	wa	VBD	O	O
less	VORAXAZE.xml:S1:2334:4	less	JJR	O	O
than	VORAXAZE.xml:S1:2339:4	than	IN	O	O
60	VORAXAZE.xml:S1:2344:2	60	CD	O	O
mL	VORAXAZE.xml:S1:2347:2	mL	JJ	O	O
min	VORAXAZE.xml:S1:2350:3	min	NN	O	O
at	VORAXAZE.xml:S1:2354:2	at	IN	O	O
least	VORAXAZE.xml:S1:2357:5	least	JJS	O	O
12	VORAXAZE.xml:S1:2363:2	12	CD	O	O
hours	VORAXAZE.xml:S1:2366:5	hour	NNS	O	O
following	VORAXAZE.xml:S1:2372:9	follow	VBG	O	O
methotrexate	VORAXAZE.xml:S1:2382:12	methotrex	JJ	O	O
administration	VORAXAZE.xml:S1:2395:14	administr	NN	O	O
.	VORAXAZE.xml:S1:2409:1	.	.	O	O

Study	VORAXAZE.xml:S1:2415:5	studi	NNP	O	O
1	VORAXAZE.xml:S1:2421:1	1	CD	O	O
,	VORAXAZE.xml:S1:2422:1	,	,	O	O
conducted	VORAXAZE.xml:S1:2424:9	conduct	VBN	O	O
by	VORAXAZE.xml:S1:2434:2	by	IN	O	O
the	VORAXAZE.xml:S1:2437:3	the	DT	O	O
National	VORAXAZE.xml:S1:2441:8	nation	NNP	O	O
Cancer	VORAXAZE.xml:S1:2450:6	cancer	NNP	O	O
Institute	VORAXAZE.xml:S1:2457:9	institut	NNP	O	O
(	VORAXAZE.xml:S1:2467:1	(	(	O	O
NCI	VORAXAZE.xml:S1:2468:3	nci	NNP	O	O
)	VORAXAZE.xml:S1:2471:1	)	)	O	O
,	VORAXAZE.xml:S1:2472:1	,	,	O	O
enrolled	VORAXAZE.xml:S1:2474:8	enrol	VBD	O	O
184	VORAXAZE.xml:S1:2483:3	184	CD	O	O
patients	VORAXAZE.xml:S1:2487:8	patient	NNS	O	O
;	VORAXAZE.xml:S1:2495:1	;	:	O	O
safety	VORAXAZE.xml:S1:2497:6	safeti	NN	O	O
information	VORAXAZE.xml:S1:2504:11	inform	NN	O	O
is	VORAXAZE.xml:S1:2516:2	is	VBZ	O	O
available	VORAXAZE.xml:S1:2519:9	avail	JJ	O	O
for	VORAXAZE.xml:S1:2529:3	for	IN	O	O
149	VORAXAZE.xml:S1:2533:3	149	CD	O	O
patients	VORAXAZE.xml:S1:2537:8	patient	NNS	O	O
.	VORAXAZE.xml:S1:2545:1	.	.	O	O

VORAXAZE	VORAXAZE.xml:S1:2547:8	voraxaz	NNP	O	O
was	VORAXAZE.xml:S1:2556:3	wa	VBD	O	O
given	VORAXAZE.xml:S1:2560:5	given	VBN	O	O
at	VORAXAZE.xml:S1:2566:2	at	IN	O	O
a	VORAXAZE.xml:S1:2569:1	a	DT	O	O
dose	VORAXAZE.xml:S1:2571:4	dose	NN	O	O
of	VORAXAZE.xml:S1:2576:2	of	IN	O	O
50	VORAXAZE.xml:S1:2579:2	50	CD	O	O
Units	VORAXAZE.xml:S1:2582:5	unit	NNS	O	O
kg	VORAXAZE.xml:S1:2588:2	kg	VBD	O	O
as	VORAXAZE.xml:S1:2591:2	as	IN	O	O
an	VORAXAZE.xml:S1:2594:2	an	DT	O	O
intravenous	VORAXAZE.xml:S1:2597:11	intraven	JJ	O	O
injection	VORAXAZE.xml:S1:2609:9	inject	NN	O	O
over	VORAXAZE.xml:S1:2619:4	over	IN	O	O
5	VORAXAZE.xml:S1:2624:1	5	CD	O	O
minutes	VORAXAZE.xml:S1:2626:7	minut	NNS	O	O
.	VORAXAZE.xml:S1:2633:1	.	.	O	O

Patients	VORAXAZE.xml:S1:2635:8	patient	NNS	O	O
with	VORAXAZE.xml:S1:2644:4	with	IN	O	O
pre	VORAXAZE.xml:S1:2649:3	pre	JJ	O	O
-	VORAXAZE.xml:S1:2652:1	-	:	O	O
VORAXAZE	VORAXAZE.xml:S1:2653:8	voraxaz	NNP	O	O
methotrexate	VORAXAZE.xml:S1:2662:12	methotrex	VBP	O	O
concentrations	VORAXAZE.xml:S1:2675:14	concentr	NNS	O	O
100	VORAXAZE.xml:S1:2691:3	100	CD	O	O
mumol	VORAXAZE.xml:S1:2695:5	mumol	NNS	O	O
L	VORAXAZE.xml:S1:2701:1	L	NNP	O	O
were	VORAXAZE.xml:S1:2703:4	were	VBD	O	O
to	VORAXAZE.xml:S1:2708:2	to	TO	O	O
receive	VORAXAZE.xml:S1:2711:7	receiv	VB	O	O
a	VORAXAZE.xml:S1:2719:1	a	DT	O	O
second	VORAXAZE.xml:S1:2721:6	second	JJ	O	O
dose	VORAXAZE.xml:S1:2728:4	dose	NN	O	O
of	VORAXAZE.xml:S1:2733:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:2736:8	voraxaz	NNP	O	O
48	VORAXAZE.xml:S1:2745:2	48	CD	O	O
hours	VORAXAZE.xml:S1:2748:5	hour	NNS	O	O
after	VORAXAZE.xml:S1:2754:5	after	IN	O	O
the	VORAXAZE.xml:S1:2760:3	the	DT	O	O
first	VORAXAZE.xml:S1:2764:5	first	JJ	O	O
dose	VORAXAZE.xml:S1:2770:4	dose	NN	O	O
.	VORAXAZE.xml:S1:2774:1	.	.	O	O

The	VORAXAZE.xml:S1:2776:3	the	DT	O	O
protocol	VORAXAZE.xml:S1:2780:8	protocol	NN	O	O
specified	VORAXAZE.xml:S1:2789:9	specifi	VBD	O	O
that	VORAXAZE.xml:S1:2799:4	that	IN	O	O
patients	VORAXAZE.xml:S1:2804:8	patient	NNS	O	O
continue	VORAXAZE.xml:S1:2813:8	continu	VBP	O	O
receiving	VORAXAZE.xml:S1:2822:9	receiv	VBG	O	O
intravenous	VORAXAZE.xml:S1:2832:11	intraven	JJ	O	O
hydration	VORAXAZE.xml:S1:2844:9	hydrat	NN	O	O
,	VORAXAZE.xml:S1:2853:1	,	,	O	O
urinary	VORAXAZE.xml:S1:2855:7	urinari	JJ	O	B-AdverseReaction
alkalinization	VORAXAZE.xml:S1:2863:14	alkalin	NN	O	I-AdverseReaction
and	VORAXAZE.xml:S1:2878:3	and	CC	O	O
leucovorin	VORAXAZE.xml:S1:2882:10	leucovorin	NN	O	O
,	VORAXAZE.xml:S1:2892:1	,	,	O	O
and	VORAXAZE.xml:S1:2894:3	and	CC	O	O
that	VORAXAZE.xml:S1:2898:4	that	IN	O	O
leucovorin	VORAXAZE.xml:S1:2903:10	leucovorin	JJ	O	O
administration	VORAXAZE.xml:S1:2914:14	administr	NN	O	O
be	VORAXAZE.xml:S1:2929:2	be	VB	O	O
adjusted	VORAXAZE.xml:S1:2932:8	adjust	VBN	O	O
to	VORAXAZE.xml:S1:2941:2	to	TO	O	O
ensure	VORAXAZE.xml:S1:2944:6	ensur	VB	O	O
that	VORAXAZE.xml:S1:2951:4	that	IN	O	O
it	VORAXAZE.xml:S1:2956:2	it	PRP	O	O
was	VORAXAZE.xml:S1:2959:3	wa	VBD	O	O
not	VORAXAZE.xml:S1:2963:3	not	RB	O	O
administered	VORAXAZE.xml:S1:2967:12	administ	VBN	O	O
within	VORAXAZE.xml:S1:2980:6	within	IN	O	O
two	VORAXAZE.xml:S1:2987:3	two	CD	O	O
hours	VORAXAZE.xml:S1:2991:5	hour	NNS	O	O
before	VORAXAZE.xml:S1:2997:6	befor	IN	O	O
or	VORAXAZE.xml:S1:3004:2	or	CC	O	O
after	VORAXAZE.xml:S1:3007:5	after	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:3013:8	voraxaz	NNP	O	O
.	VORAXAZE.xml:S1:3021:1	.	.	O	O

In	VORAXAZE.xml:S1:3027:2	In	IN	O	O
Study	VORAXAZE.xml:S1:3030:5	studi	NNP	O	O
1	VORAXAZE.xml:S1:3036:1	1	CD	O	O
,	VORAXAZE.xml:S1:3037:1	,	,	O	O
VORAXAZE	VORAXAZE.xml:S1:3039:8	voraxaz	NNP	O	B-AdverseReaction
-	VORAXAZE.xml:S1:3047:1	-	:	O	I-AdverseReaction
related	VORAXAZE.xml:S1:3048:7	relat	JJ	O	I-AdverseReaction
adverse	VORAXAZE.xml:S1:3056:7	advers	JJ	O	I-AdverseReaction
reactions	VORAXAZE.xml:S1:3064:9	reaction	NNS	O	I-AdverseReaction
were	VORAXAZE.xml:S1:3074:4	were	VBD	O	O
collected	VORAXAZE.xml:S1:3079:9	collect	VBN	O	O
on	VORAXAZE.xml:S1:3089:2	on	IN	O	O
a	VORAXAZE.xml:S1:3092:1	a	DT	O	O
flow	VORAXAZE.xml:S1:3094:4	flow	JJ	O	O
sheet	VORAXAZE.xml:S1:3099:5	sheet	NN	O	O
with	VORAXAZE.xml:S1:3105:4	with	IN	O	O
a	VORAXAZE.xml:S1:3110:1	a	DT	O	O
daily	VORAXAZE.xml:S1:3112:5	daili	JJ	O	O
log	VORAXAZE.xml:S1:3118:3	log	NN	O	O
of	VORAXAZE.xml:S1:3122:2	of	IN	O	O
adverse	VORAXAZE.xml:S1:3125:7	advers	JJ	O	O
reactions	VORAXAZE.xml:S1:3133:9	reaction	NNS	O	O
characterized	VORAXAZE.xml:S1:3143:13	character	VBN	O	O
as	VORAXAZE.xml:S1:3157:2	as	IN	O	O
"	VORAXAZE.xml:S1:3160:1	"	JJ	O	O
glucarpidase	VORAXAZE.xml:S1:3161:12	glucarpidas	NN	O	O
toxicity	VORAXAZE.xml:S1:3174:8	toxic	NN	O	O
.	VORAXAZE.xml:S1:3182:1	.	.	O	O
"	VORAXAZE.xml:S1:3183:1	"	VB	O	O

Additional	VORAXAZE.xml:S1:3185:10	addit	NNP	O	O
safety	VORAXAZE.xml:S1:3196:6	safeti	NN	O	O
information	VORAXAZE.xml:S1:3203:11	inform	NN	O	O
was	VORAXAZE.xml:S1:3215:3	wa	VBD	O	O
collected	VORAXAZE.xml:S1:3219:9	collect	VBN	O	O
from	VORAXAZE.xml:S1:3229:4	from	IN	O	O
clinical	VORAXAZE.xml:S1:3234:8	clinic	JJ	O	O
records	VORAXAZE.xml:S1:3243:7	record	NNS	O	O
submitted	VORAXAZE.xml:S1:3251:9	submit	VBN	O	O
by	VORAXAZE.xml:S1:3261:2	by	IN	O	O
treating	VORAXAZE.xml:S1:3264:8	treat	VBG	O	O
physicians	VORAXAZE.xml:S1:3273:10	physician	NNS	O	O
.	VORAXAZE.xml:S1:3283:1	.	.	O	O

This	VORAXAZE.xml:S1:3285:4	thi	DT	O	O
information	VORAXAZE.xml:S1:3290:11	inform	NN	O	O
was	VORAXAZE.xml:S1:3302:3	wa	VBD	O	O
abstracted	VORAXAZE.xml:S1:3306:10	abstract	VBN	O	O
and	VORAXAZE.xml:S1:3317:3	and	CC	O	O
categorized	VORAXAZE.xml:S1:3321:11	categor	VBN	O	O
using	VORAXAZE.xml:S1:3333:5	use	VBG	O	O
the	VORAXAZE.xml:S1:3339:3	the	DT	O	O
National	VORAXAZE.xml:S1:3343:8	nation	NNP	O	O
Cancer	VORAXAZE.xml:S1:3352:6	cancer	NNP	O	O
Institute	VORAXAZE.xml:S1:3359:9	institut	NNP	O	O
(	VORAXAZE.xml:S1:3369:1	(	(	O	O
NCI	VORAXAZE.xml:S1:3370:3	nci	NNP	O	O
)	VORAXAZE.xml:S1:3373:1	)	)	O	O
"	VORAXAZE.xml:S1:3375:1	"	VBP	O	O
Common	VORAXAZE.xml:S1:3376:6	common	NNP	O	O
Terminology	VORAXAZE.xml:S1:3383:11	terminolog	NNP	O	O
Criteria	VORAXAZE.xml:S1:3395:8	criteria	NNP	O	O
for	VORAXAZE.xml:S1:3404:3	for	IN	O	O
Adverse	VORAXAZE.xml:S1:3408:7	advers	NNP	O	O
Events	VORAXAZE.xml:S1:3416:6	event	NNP	O	O
"	VORAXAZE.xml:S1:3422:1	"	NNP	O	O
(	VORAXAZE.xml:S1:3424:1	(	(	O	O
CTCAE	VORAXAZE.xml:S1:3425:5	ctcae	NNP	O	O
)	VORAXAZE.xml:S1:3430:1	)	)	O	O
version	VORAXAZE.xml:S1:3432:7	version	NN	O	O
3	VORAXAZE.xml:S1:3440:1	3	CD	O	O
scale	VORAXAZE.xml:S1:3442:5	scale	NN	O	O
.	VORAXAZE.xml:S1:3447:1	.	.	O	O

The	VORAXAZE.xml:S1:3453:3	the	DT	O	O
Study	VORAXAZE.xml:S1:3457:5	studi	NNP	O	O
1	VORAXAZE.xml:S1:3463:1	1	CD	O	O
population	VORAXAZE.xml:S1:3465:10	popul	NN	O	O
enrolled	VORAXAZE.xml:S1:3476:8	enrol	VBD	O	O
patients	VORAXAZE.xml:S1:3485:8	patient	NNS	O	O
with	VORAXAZE.xml:S1:3494:4	with	IN	O	O
a	VORAXAZE.xml:S1:3499:1	a	DT	O	O
median	VORAXAZE.xml:S1:3501:6	median	JJ	O	O
age	VORAXAZE.xml:S1:3508:3	age	NN	O	O
of	VORAXAZE.xml:S1:3512:2	of	IN	O	O
18	VORAXAZE.xml:S1:3515:2	18	CD	O	O
years	VORAXAZE.xml:S1:3518:5	year	NNS	O	O
(	VORAXAZE.xml:S1:3524:1	(	(	O	O
1	VORAXAZE.xml:S1:3525:1	1	CD	O	O
month	VORAXAZE.xml:S1:3527:5	month	NN	O	O
to	VORAXAZE.xml:S1:3533:2	to	TO	O	O
85	VORAXAZE.xml:S1:3536:2	85	CD	O	O
years	VORAXAZE.xml:S1:3539:5	year	NNS	O	O
)	VORAXAZE.xml:S1:3544:1	)	)	O	O
;	VORAXAZE.xml:S1:3545:1	;	:	O	O
63%	VORAXAZE.xml:S1:3547:3	63%	CD	O	O
were	VORAXAZE.xml:S1:3551:4	were	VBD	O	O
male	VORAXAZE.xml:S1:3556:4	male	NN	O	O
,	VORAXAZE.xml:S1:3560:1	,	,	O	O
and	VORAXAZE.xml:S1:3562:3	and	CC	O	O
the	VORAXAZE.xml:S1:3566:3	the	DT	O	O
underlying	VORAXAZE.xml:S1:3570:10	underli	JJ	O	O
malignancies	VORAXAZE.xml:S1:3581:12	malign	NNS	O	O
were	VORAXAZE.xml:S1:3594:4	were	VBD	O	O
osteosarcoma	VORAXAZE.xml:S1:3599:12	osteosarcoma	JJ	O	O
sarcomas	VORAXAZE.xml:S1:3612:8	sarcoma	NN	O	O
in	VORAXAZE.xml:S1:3621:2	in	IN	O	O
32%	VORAXAZE.xml:S1:3624:3	32%	CD	O	O
,	VORAXAZE.xml:S1:3627:1	,	,	O	O
and	VORAXAZE.xml:S1:3629:3	and	CC	O	O
leukemia	VORAXAZE.xml:S1:3633:8	leukemia	NN	O	O
or	VORAXAZE.xml:S1:3642:2	or	CC	O	O
lymphoma	VORAXAZE.xml:S1:3645:8	lymphoma	NN	O	O
in	VORAXAZE.xml:S1:3654:2	in	IN	O	O
63%	VORAXAZE.xml:S1:3657:3	63%	CD	O	O
of	VORAXAZE.xml:S1:3661:2	of	IN	O	O
patients	VORAXAZE.xml:S1:3664:8	patient	NNS	O	O
.	VORAXAZE.xml:S1:3672:1	.	.	O	O

One	VORAXAZE.xml:S1:3674:3	one	CD	O	O
(	VORAXAZE.xml:S1:3678:1	(	(	O	O
n	VORAXAZE.xml:S1:3679:1	n	IN	O	O
106	VORAXAZE.xml:S1:3681:3	106	CD	O	O
)	VORAXAZE.xml:S1:3684:1	)	)	O	O
or	VORAXAZE.xml:S1:3686:2	or	CC	O	O
2	VORAXAZE.xml:S1:3689:1	2	CD	O	O
(	VORAXAZE.xml:S1:3691:1	(	(	O	O
n	VORAXAZE.xml:S1:3692:1	n	JJ	O	O
30	VORAXAZE.xml:S1:3695:2	30	CD	O	O
)	VORAXAZE.xml:S1:3697:1	)	)	O	O
doses	VORAXAZE.xml:S1:3699:5	dose	NNS	O	O
of	VORAXAZE.xml:S1:3705:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:3708:8	voraxaz	NNP	O	O
were	VORAXAZE.xml:S1:3717:4	were	VBD	O	O
administered	VORAXAZE.xml:S1:3722:12	administ	VBN	O	O
intravenously	VORAXAZE.xml:S1:3735:13	intraven	RB	O	O
;	VORAXAZE.xml:S1:3748:1	;	:	O	O
the	VORAXAZE.xml:S1:3750:3	the	DT	O	O
number	VORAXAZE.xml:S1:3754:6	number	NN	O	O
of	VORAXAZE.xml:S1:3761:2	of	IN	O	O
doses	VORAXAZE.xml:S1:3764:5	dose	NNS	O	O
was	VORAXAZE.xml:S1:3770:3	wa	VBD	O	O
not	VORAXAZE.xml:S1:3774:3	not	RB	O	O
specified	VORAXAZE.xml:S1:3778:9	specifi	VBN	O	O
in	VORAXAZE.xml:S1:3788:2	in	IN	O	O
13	VORAXAZE.xml:S1:3791:2	13	CD	O	O
patients	VORAXAZE.xml:S1:3794:8	patient	NNS	O	O
.	VORAXAZE.xml:S1:3802:1	.	.	O	O

Doses	VORAXAZE.xml:S1:3804:5	dose	NNS	O	O
ranged	VORAXAZE.xml:S1:3810:6	rang	VBD	O	O
from	VORAXAZE.xml:S1:3817:4	from	IN	O	O
18	VORAXAZE.xml:S1:3822:2	18	CD	O	O
to	VORAXAZE.xml:S1:3825:2	to	TO	O	O
98	VORAXAZE.xml:S1:3828:2	98	CD	O	O
Units	VORAXAZE.xml:S1:3831:5	unit	NNS	O	O
kg	VORAXAZE.xml:S1:3837:2	kg	NNS	O	O
,	VORAXAZE.xml:S1:3839:1	,	,	O	O
with	VORAXAZE.xml:S1:3841:4	with	IN	O	O
a	VORAXAZE.xml:S1:3846:1	a	DT	O	O
median	VORAXAZE.xml:S1:3848:6	median	JJ	O	O
dose	VORAXAZE.xml:S1:3855:4	dose	NN	O	O
of	VORAXAZE.xml:S1:3860:2	of	IN	O	O
49	VORAXAZE.xml:S1:3863:2	49	CD	O	O
Units	VORAXAZE.xml:S1:3866:5	unit	NNS	O	O
kg	VORAXAZE.xml:S1:3872:2	kg	NNS	O	O
.	VORAXAZE.xml:S1:3874:1	.	.	O	O

Study	VORAXAZE.xml:S1:3880:5	studi	NNP	O	O
2	VORAXAZE.xml:S1:3886:1	2	CD	O	O
is	VORAXAZE.xml:S1:3888:2	is	VBZ	O	O
an	VORAXAZE.xml:S1:3891:2	an	DT	O	O
ongoing	VORAXAZE.xml:S1:3894:7	ongo	JJ	O	O
expanded	VORAXAZE.xml:S1:3902:8	expand	JJ	O	O
access	VORAXAZE.xml:S1:3911:6	access	NN	O	O
program	VORAXAZE.xml:S1:3918:7	program	NN	O	O
.	VORAXAZE.xml:S1:3925:1	.	.	O	O

At	VORAXAZE.xml:S1:3927:2	At	IN	O	O
the	VORAXAZE.xml:S1:3930:3	the	DT	O	O
time	VORAXAZE.xml:S1:3934:4	time	NN	O	O
of	VORAXAZE.xml:S1:3939:2	of	IN	O	O
data	VORAXAZE.xml:S1:3942:4	data	NNS	O	O
cut	VORAXAZE.xml:S1:3947:3	cut	VBN	O	O
-	VORAXAZE.xml:S1:3950:1	-	:	O	O
off	VORAXAZE.xml:S1:3951:3	off	RB	O	O
,	VORAXAZE.xml:S1:3954:1	,	,	O	O
243	VORAXAZE.xml:S1:3956:3	243	CD	O	O
patients	VORAXAZE.xml:S1:3960:8	patient	NNS	O	O
were	VORAXAZE.xml:S1:3969:4	were	VBD	O	O
enrolled	VORAXAZE.xml:S1:3974:8	enrol	VBN	O	O
and	VORAXAZE.xml:S1:3983:3	and	CC	O	O
safety	VORAXAZE.xml:S1:3987:6	safeti	NN	O	O
data	VORAXAZE.xml:S1:3994:4	data	NNS	O	O
was	VORAXAZE.xml:S1:3999:3	wa	VBD	O	O
available	VORAXAZE.xml:S1:4003:9	avail	JJ	O	O
for	VORAXAZE.xml:S1:4013:3	for	IN	O	O
141	VORAXAZE.xml:S1:4017:3	141	CD	O	O
patients	VORAXAZE.xml:S1:4021:8	patient	NNS	O	O
.	VORAXAZE.xml:S1:4029:1	.	.	O	O

VORAXAZE	VORAXAZE.xml:S1:4031:8	voraxaz	NNP	O	O
was	VORAXAZE.xml:S1:4040:3	wa	VBD	O	O
given	VORAXAZE.xml:S1:4044:5	given	VBN	O	O
at	VORAXAZE.xml:S1:4050:2	at	IN	O	O
a	VORAXAZE.xml:S1:4053:1	a	DT	O	O
dose	VORAXAZE.xml:S1:4055:4	dose	NN	O	O
of	VORAXAZE.xml:S1:4060:2	of	IN	O	O
50	VORAXAZE.xml:S1:4063:2	50	CD	O	O
Units	VORAXAZE.xml:S1:4066:5	unit	NNS	O	O
kg	VORAXAZE.xml:S1:4072:2	kg	VBD	O	O
as	VORAXAZE.xml:S1:4075:2	as	IN	O	O
an	VORAXAZE.xml:S1:4078:2	an	DT	O	O
intravenous	VORAXAZE.xml:S1:4081:11	intraven	JJ	O	O
injection	VORAXAZE.xml:S1:4093:9	inject	NN	O	O
over	VORAXAZE.xml:S1:4103:4	over	IN	O	O
5	VORAXAZE.xml:S1:4108:1	5	CD	O	O
minutes	VORAXAZE.xml:S1:4110:7	minut	NNS	O	O
.	VORAXAZE.xml:S1:4117:1	.	.	O	O

The	VORAXAZE.xml:S1:4119:3	the	DT	O	O
criterion	VORAXAZE.xml:S1:4123:9	criterion	NN	O	O
for	VORAXAZE.xml:S1:4133:3	for	IN	O	O
allowing	VORAXAZE.xml:S1:4137:8	allow	VBG	O	O
patients	VORAXAZE.xml:S1:4146:8	patient	NNS	O	O
to	VORAXAZE.xml:S1:4155:2	to	TO	O	O
receive	VORAXAZE.xml:S1:4158:7	receiv	VB	O	O
a	VORAXAZE.xml:S1:4166:1	a	DT	O	O
second	VORAXAZE.xml:S1:4168:6	second	JJ	O	O
glucarpidase	VORAXAZE.xml:S1:4175:12	glucarpidas	NN	O	O
dose	VORAXAZE.xml:S1:4188:4	dose	NN	O	O
was	VORAXAZE.xml:S1:4193:3	wa	VBD	O	O
not	VORAXAZE.xml:S1:4197:3	not	RB	O	O
specified	VORAXAZE.xml:S1:4201:9	specifi	VBN	O	O
in	VORAXAZE.xml:S1:4211:2	in	IN	O	O
the	VORAXAZE.xml:S1:4214:3	the	DT	O	O
protocol	VORAXAZE.xml:S1:4218:8	protocol	NN	O	O
.	VORAXAZE.xml:S1:4226:1	.	.	O	O

The	VORAXAZE.xml:S1:4228:3	the	DT	O	O
protocol	VORAXAZE.xml:S1:4232:8	protocol	NN	O	O
specified	VORAXAZE.xml:S1:4241:9	specifi	VBD	O	O
that	VORAXAZE.xml:S1:4251:4	that	IN	O	O
patients	VORAXAZE.xml:S1:4256:8	patient	NNS	O	O
continue	VORAXAZE.xml:S1:4265:8	continu	VBP	O	O
receiving	VORAXAZE.xml:S1:4274:9	receiv	VBG	O	O
intravenous	VORAXAZE.xml:S1:4284:11	intraven	JJ	O	O
hydration	VORAXAZE.xml:S1:4296:9	hydrat	NN	O	O
,	VORAXAZE.xml:S1:4305:1	,	,	O	O
urinary	VORAXAZE.xml:S1:4307:7	urinari	JJ	O	B-AdverseReaction
alkalinization	VORAXAZE.xml:S1:4315:14	alkalin	NN	O	I-AdverseReaction
and	VORAXAZE.xml:S1:4330:3	and	CC	O	O
leucovorin	VORAXAZE.xml:S1:4334:10	leucovorin	NN	O	O
,	VORAXAZE.xml:S1:4344:1	,	,	O	O
and	VORAXAZE.xml:S1:4346:3	and	CC	O	O
that	VORAXAZE.xml:S1:4350:4	that	IN	O	O
leucovorin	VORAXAZE.xml:S1:4355:10	leucovorin	JJ	O	O
administration	VORAXAZE.xml:S1:4366:14	administr	NN	O	O
be	VORAXAZE.xml:S1:4381:2	be	VB	O	O
adjusted	VORAXAZE.xml:S1:4384:8	adjust	VBN	O	O
to	VORAXAZE.xml:S1:4393:2	to	TO	O	O
ensure	VORAXAZE.xml:S1:4396:6	ensur	VB	O	O
that	VORAXAZE.xml:S1:4403:4	that	IN	O	O
it	VORAXAZE.xml:S1:4408:2	it	PRP	O	O
was	VORAXAZE.xml:S1:4411:3	wa	VBD	O	O
not	VORAXAZE.xml:S1:4415:3	not	RB	O	O
administered	VORAXAZE.xml:S1:4419:12	administ	VBN	O	O
within	VORAXAZE.xml:S1:4432:6	within	IN	O	O
two	VORAXAZE.xml:S1:4439:3	two	CD	O	O
hours	VORAXAZE.xml:S1:4443:5	hour	NNS	O	O
before	VORAXAZE.xml:S1:4449:6	befor	IN	O	O
or	VORAXAZE.xml:S1:4456:2	or	CC	O	O
after	VORAXAZE.xml:S1:4459:5	after	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:4465:8	voraxaz	NNP	O	O
.	VORAXAZE.xml:S1:4473:1	.	.	O	O

Study	VORAXAZE.xml:S1:4479:5	studi	NNP	O	O
2	VORAXAZE.xml:S1:4485:1	2	CD	O	O
enrolled	VORAXAZE.xml:S1:4487:8	enrol	VBD	O	O
patients	VORAXAZE.xml:S1:4496:8	patient	NNS	O	O
with	VORAXAZE.xml:S1:4505:4	with	IN	O	O
a	VORAXAZE.xml:S1:4510:1	a	DT	O	O
median	VORAXAZE.xml:S1:4512:6	median	JJ	O	O
age	VORAXAZE.xml:S1:4519:3	age	NN	O	O
of	VORAXAZE.xml:S1:4523:2	of	IN	O	O
17	VORAXAZE.xml:S1:4526:2	17	CD	O	O
years	VORAXAZE.xml:S1:4529:5	year	NNS	O	O
(	VORAXAZE.xml:S1:4535:1	(	(	O	O
6	VORAXAZE.xml:S1:4536:1	6	CD	O	O
months	VORAXAZE.xml:S1:4538:6	month	NNS	O	O
to	VORAXAZE.xml:S1:4545:2	to	TO	O	O
85	VORAXAZE.xml:S1:4548:2	85	CD	O	O
years	VORAXAZE.xml:S1:4551:5	year	NNS	O	O
)	VORAXAZE.xml:S1:4556:1	)	)	O	O
;	VORAXAZE.xml:S1:4557:1	;	:	O	O
64%	VORAXAZE.xml:S1:4559:3	64%	CD	O	O
were	VORAXAZE.xml:S1:4563:4	were	VBD	O	O
male	VORAXAZE.xml:S1:4568:4	male	NN	O	O
,	VORAXAZE.xml:S1:4572:1	,	,	O	O
and	VORAXAZE.xml:S1:4574:3	and	CC	O	O
the	VORAXAZE.xml:S1:4578:3	the	DT	O	O
underlying	VORAXAZE.xml:S1:4582:10	underli	JJ	O	O
malignancies	VORAXAZE.xml:S1:4593:12	malign	NNS	O	O
were	VORAXAZE.xml:S1:4606:4	were	VBD	O	O
osteogenic	VORAXAZE.xml:S1:4611:10	osteogen	JJ	O	O
sarcoma	VORAXAZE.xml:S1:4622:7	sarcoma	NN	O	O
in	VORAXAZE.xml:S1:4630:2	in	IN	O	O
32%	VORAXAZE.xml:S1:4633:3	32%	CD	O	O
,	VORAXAZE.xml:S1:4636:1	,	,	O	O
and	VORAXAZE.xml:S1:4638:3	and	CC	O	O
leukemia	VORAXAZE.xml:S1:4642:8	leukemia	NN	O	O
or	VORAXAZE.xml:S1:4651:2	or	CC	O	O
lymphoma	VORAXAZE.xml:S1:4654:8	lymphoma	NN	O	O
in	VORAXAZE.xml:S1:4663:2	in	IN	O	O
62%	VORAXAZE.xml:S1:4666:3	62%	CD	O	O
of	VORAXAZE.xml:S1:4670:2	of	IN	O	O
patients	VORAXAZE.xml:S1:4673:8	patient	NNS	O	O
.	VORAXAZE.xml:S1:4681:1	.	.	O	O

One	VORAXAZE.xml:S1:4683:3	one	CD	O	O
(	VORAXAZE.xml:S1:4687:1	(	(	O	O
n	VORAXAZE.xml:S1:4688:1	n	IN	O	O
122	VORAXAZE.xml:S1:4690:3	122	CD	O	O
)	VORAXAZE.xml:S1:4693:1	)	)	O	O
or	VORAXAZE.xml:S1:4695:2	or	CC	O	O
2	VORAXAZE.xml:S1:4698:1	2	CD	O	O
(	VORAXAZE.xml:S1:4700:1	(	(	O	O
n	VORAXAZE.xml:S1:4701:1	n	JJ	O	O
18	VORAXAZE.xml:S1:4704:2	18	CD	O	O
)	VORAXAZE.xml:S1:4706:1	)	)	O	O
doses	VORAXAZE.xml:S1:4708:5	dose	NNS	O	O
of	VORAXAZE.xml:S1:4714:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:4717:8	voraxaz	NNP	O	O
were	VORAXAZE.xml:S1:4726:4	were	VBD	O	O
administered	VORAXAZE.xml:S1:4731:12	administ	VBN	O	O
intravenously	VORAXAZE.xml:S1:4744:13	intraven	RB	O	O
;	VORAXAZE.xml:S1:4757:1	;	:	O	O
the	VORAXAZE.xml:S1:4759:3	the	DT	O	O
number	VORAXAZE.xml:S1:4763:6	number	NN	O	O
of	VORAXAZE.xml:S1:4770:2	of	IN	O	O
doses	VORAXAZE.xml:S1:4773:5	dose	NNS	O	O
was	VORAXAZE.xml:S1:4779:3	wa	VBD	O	O
not	VORAXAZE.xml:S1:4783:3	not	RB	O	O
specified	VORAXAZE.xml:S1:4787:9	specifi	VBN	O	O
for	VORAXAZE.xml:S1:4797:3	for	IN	O	O
1	VORAXAZE.xml:S1:4801:1	1	CD	O	O
patient	VORAXAZE.xml:S1:4803:7	patient	NN	O	O
.	VORAXAZE.xml:S1:4810:1	.	.	O	O

Doses	VORAXAZE.xml:S1:4812:5	dose	NNS	O	O
ranged	VORAXAZE.xml:S1:4818:6	rang	VBD	O	O
from	VORAXAZE.xml:S1:4825:4	from	IN	O	O
6	VORAXAZE.xml:S1:4830:1	6	CD	O	O
to	VORAXAZE.xml:S1:4832:2	to	TO	O	O
189	VORAXAZE.xml:S1:4835:3	189	CD	O	O
Units	VORAXAZE.xml:S1:4839:5	unit	NNS	O	O
kg	VORAXAZE.xml:S1:4845:2	kg	NNS	O	O
,	VORAXAZE.xml:S1:4847:1	,	,	O	O
with	VORAXAZE.xml:S1:4849:4	with	IN	O	O
a	VORAXAZE.xml:S1:4854:1	a	DT	O	O
median	VORAXAZE.xml:S1:4856:6	median	JJ	O	O
dose	VORAXAZE.xml:S1:4863:4	dose	NN	O	O
of	VORAXAZE.xml:S1:4868:2	of	IN	O	O
50	VORAXAZE.xml:S1:4871:2	50	CD	O	O
Units	VORAXAZE.xml:S1:4874:5	unit	NNS	O	O
kg	VORAXAZE.xml:S1:4880:2	kg	NNS	O	O
.	VORAXAZE.xml:S1:4882:1	.	.	O	O

In	VORAXAZE.xml:S1:4888:2	In	IN	O	O
Study	VORAXAZE.xml:S1:4891:5	studi	NNP	O	O
2	VORAXAZE.xml:S1:4897:1	2	CD	O	O
only	VORAXAZE.xml:S1:4899:4	onli	RB	O	O
VORAXAZE	VORAXAZE.xml:S1:4904:8	voraxaz	NNP	O	O
-	VORAXAZE.xml:S1:4912:1	-	:	O	O
related	VORAXAZE.xml:S1:4913:7	relat	JJ	O	O
adverse	VORAXAZE.xml:S1:4921:7	advers	JJ	O	O
reactions	VORAXAZE.xml:S1:4929:9	reaction	NNS	O	O
were	VORAXAZE.xml:S1:4939:4	were	VBD	O	O
collected	VORAXAZE.xml:S1:4944:9	collect	VBN	O	O
and	VORAXAZE.xml:S1:4954:3	and	CC	O	O
severity	VORAXAZE.xml:S1:4958:8	sever	NN	O	O
was	VORAXAZE.xml:S1:4967:3	wa	VBD	O	O
graded	VORAXAZE.xml:S1:4971:6	grade	VBN	O	O
according	VORAXAZE.xml:S1:4978:9	accord	VBG	O	O
to	VORAXAZE.xml:S1:4988:2	to	TO	O	O
NCI	VORAXAZE.xml:S1:4991:3	nci	NNP	O	O
CTCAE	VORAXAZE.xml:S1:4995:5	ctcae	NNP	O	O
version	VORAXAZE.xml:S1:5001:7	version	NN	O	O
3	VORAXAZE.xml:S1:5009:1	3	CD	O	O
.	VORAXAZE.xml:S1:5010:1	.	.	O	O

Among	VORAXAZE.xml:S1:5016:5	among	IN	O	O
the	VORAXAZE.xml:S1:5022:3	the	DT	O	O
290	VORAXAZE.xml:S1:5026:3	290	CD	O	O
patients	VORAXAZE.xml:S1:5030:8	patient	NNS	O	O
included	VORAXAZE.xml:S1:5039:8	includ	VBN	O	O
in	VORAXAZE.xml:S1:5048:2	in	IN	O	O
the	VORAXAZE.xml:S1:5051:3	the	DT	O	O
safety	VORAXAZE.xml:S1:5055:6	safeti	NN	O	O
evaluation	VORAXAZE.xml:S1:5062:10	evalu	NN	O	O
of	VORAXAZE.xml:S1:5073:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:5076:8	voraxaz	NNP	O	O
,	VORAXAZE.xml:S1:5084:1	,	,	O	O
there	VORAXAZE.xml:S1:5086:5	there	EX	O	O
were	VORAXAZE.xml:S1:5092:4	were	VBD	O	O
8	VORAXAZE.xml:S1:5097:1	8	CD	O	O
deaths	VORAXAZE.xml:S1:5099:6	death	NNS	B-AdverseReaction	B-AdverseReaction
within	VORAXAZE.xml:S1:5106:6	within	IN	O	O
30	VORAXAZE.xml:S1:5113:2	30	CD	O	O
days	VORAXAZE.xml:S1:5116:4	day	NNS	O	O
of	VORAXAZE.xml:S1:5121:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:5124:8	voraxaz	NNP	O	O
exposure	VORAXAZE.xml:S1:5133:8	exposur	NN	O	O
that	VORAXAZE.xml:S1:5142:4	that	WDT	O	O
were	VORAXAZE.xml:S1:5147:4	were	VBD	O	O
not	VORAXAZE.xml:S1:5152:3	not	RB	O	O
related	VORAXAZE.xml:S1:5156:7	relat	VBN	O	O
to	VORAXAZE.xml:S1:5164:2	to	TO	O	O
progressive	VORAXAZE.xml:S1:5167:11	progress	JJ	O	O
disease	VORAXAZE.xml:S1:5179:7	diseas	NN	O	O
.	VORAXAZE.xml:S1:5186:1	.	.	O	O

Twenty	VORAXAZE.xml:S1:5188:6	twenti	NNP	O	O
-	VORAXAZE.xml:S1:5194:1	-	:	O	O
one	VORAXAZE.xml:S1:5195:3	one	CD	O	O
of	VORAXAZE.xml:S1:5199:2	of	IN	O	O
290	VORAXAZE.xml:S1:5202:3	290	CD	O	O
patients	VORAXAZE.xml:S1:5206:8	patient	NNS	O	O
(	VORAXAZE.xml:S1:5215:1	(	(	O	O
7%	VORAXAZE.xml:S1:5216:2	7%	CD	O	O
)	VORAXAZE.xml:S1:5218:1	)	)	O	O
experienced	VORAXAZE.xml:S1:5220:11	experienc	VBD	O	O
adverse	VORAXAZE.xml:S1:5232:7	advers	JJ	O	O
reactions	VORAXAZE.xml:S1:5240:9	reaction	NNS	O	O
that	VORAXAZE.xml:S1:5250:4	that	WDT	O	O
were	VORAXAZE.xml:S1:5255:4	were	VBD	O	O
assessed	VORAXAZE.xml:S1:5260:8	assess	VBN	O	O
as	VORAXAZE.xml:S1:5269:2	as	RB	O	O
related	VORAXAZE.xml:S1:5272:7	relat	VBN	O	O
to	VORAXAZE.xml:S1:5280:2	to	TO	O	O
VORAXAZE	VORAXAZE.xml:S1:5283:8	voraxaz	NNP	O	O
.	VORAXAZE.xml:S1:5291:1	.	.	O	O

Most	VORAXAZE.xml:S1:5293:4	most	JJS	O	O
were	VORAXAZE.xml:S1:5298:4	were	VBD	O	O
Grade	VORAXAZE.xml:S1:5303:5	grade	NNP	O	O
1	VORAXAZE.xml:S1:5309:1	1	CD	O	O
or	VORAXAZE.xml:S1:5311:2	or	CC	O	O
2	VORAXAZE.xml:S1:5314:1	2	CD	O	O
events	VORAXAZE.xml:S1:5316:6	event	NNS	O	O
.	VORAXAZE.xml:S1:5322:1	.	.	O	O

One	VORAXAZE.xml:S1:5324:3	one	CD	O	O
patient	VORAXAZE.xml:S1:5328:7	patient	NN	O	O
experienced	VORAXAZE.xml:S1:5336:11	experienc	VBD	O	O
related	VORAXAZE.xml:S1:5348:7	relat	JJ	O	O
Grade	VORAXAZE.xml:S1:5356:5	grade	NNP	O	O
3	VORAXAZE.xml:S1:5362:1	3	CD	O	O
flushing	VORAXAZE.xml:S1:5364:8	flush	NN	B-AdverseReaction	O
.	VORAXAZE.xml:S1:5372:1	.	.	O	O

The	VORAXAZE.xml:S1:5374:3	the	DT	O	O
most	VORAXAZE.xml:S1:5378:4	most	RBS	O	O
common	VORAXAZE.xml:S1:5383:6	common	JJ	O	O
related	VORAXAZE.xml:S1:5390:7	relat	JJ	O	O
adverse	VORAXAZE.xml:S1:5398:7	advers	JJ	O	O
reactions	VORAXAZE.xml:S1:5406:9	reaction	NNS	O	O
that	VORAXAZE.xml:S1:5416:4	that	WDT	O	O
were	VORAXAZE.xml:S1:5421:4	were	VBD	O	O
not	VORAXAZE.xml:S1:5426:3	not	RB	O	O
hematologic	VORAXAZE.xml:S1:5430:11	hematolog	JJ	O	O
,	VORAXAZE.xml:S1:5441:1	,	,	O	O
hepatic	VORAXAZE.xml:S1:5443:7	hepat	JJ	O	O
or	VORAXAZE.xml:S1:5451:2	or	CC	O	O
renal	VORAXAZE.xml:S1:5454:5	renal	JJ	O	O
events	VORAXAZE.xml:S1:5460:6	event	NNS	O	O
were	VORAXAZE.xml:S1:5467:4	were	VBD	O	O
paresthesia	VORAXAZE.xml:S1:5472:11	paresthesia	RB	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:5483:1	,	,	O	O
flushing	VORAXAZE.xml:S1:5485:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:5493:1	,	,	O	O
and	VORAXAZE.xml:S1:5495:3	and	CC	O	O
nausea	VORAXAZE.xml:S1:5499:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
and	VORAXAZE.xml:S1:5506:3	and	CC	O	O
or	VORAXAZE.xml:S1:5510:2	or	CC	O	O
vomiting	VORAXAZE.xml:S1:5513:8	vomit	NN	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:5521:1	,	,	O	O
which	VORAXAZE.xml:S1:5523:5	which	WDT	O	O
each	VORAXAZE.xml:S1:5529:4	each	DT	O	O
occurred	VORAXAZE.xml:S1:5534:8	occur	VBD	O	O
in	VORAXAZE.xml:S1:5543:2	in	IN	O	O
2%	VORAXAZE.xml:S1:5546:2	2%	CD	O	O
of	VORAXAZE.xml:S1:5549:2	of	IN	O	O
patients	VORAXAZE.xml:S1:5552:8	patient	NNS	O	O
(	VORAXAZE.xml:S1:5561:1	(	(	O	O
Table	VORAXAZE.xml:S1:5562:5	tabl	JJ	O	O
1	VORAXAZE.xml:S1:5568:1	1	CD	O	O
)	VORAXAZE.xml:S1:5569:1	)	)	O	O
.	VORAXAZE.xml:S1:5570:1	.	.	O	O

Table	VORAXAZE.xml:S1:5576:5	tabl	JJ	O	O
1	VORAXAZE.xml:S1:5582:1	1	CD	O	O
:	VORAXAZE.xml:S1:5583:1	:	:	O	O
Per	VORAXAZE.xml:S1:5585:3	per	NNP	O	O
Patient	VORAXAZE.xml:S1:5589:7	patient	NNP	O	O
Incidence	VORAXAZE.xml:S1:5597:9	incid	NNP	O	O
of	VORAXAZE.xml:S1:5607:2	of	IN	O	O
Grade	VORAXAZE.xml:S1:5610:5	grade	NNP	O	O
1	VORAXAZE.xml:S1:5616:1	1	CD	O	O
and	VORAXAZE.xml:S1:5618:3	and	CC	O	O
2	VORAXAZE.xml:S1:5622:1	2	CD	O	O
Adverse	VORAXAZE.xml:S1:5624:7	advers	JJ	O	O
Reactions	VORAXAZE.xml:S1:5632:9	reaction	NNS	O	O
Assessed	VORAXAZE.xml:S1:5642:8	assess	VBD	O	O
as	VORAXAZE.xml:S1:5651:2	as	IN	O	O
Possibly	VORAXAZE.xml:S1:5654:8	possibl	NNP	O	O
,	VORAXAZE.xml:S1:5662:1	,	,	O	O
Probably	VORAXAZE.xml:S1:5664:8	probabl	NNP	O	O
,	VORAXAZE.xml:S1:5672:1	,	,	O	O
or	VORAXAZE.xml:S1:5674:2	or	CC	O	O
Definitely	VORAXAZE.xml:S1:5677:10	definit	RB	O	O
Related	VORAXAZE.xml:S1:5688:7	relat	VBN	O	O
to	VORAXAZE.xml:S1:5696:2	to	TO	O	O
VORAXAZE	VORAXAZE.xml:S1:5699:8	voraxaz	NNP	O	O
Excluding	VORAXAZE.xml:S1:5708:9	exclud	NNP	O	O
Hematologic	VORAXAZE.xml:S1:5718:11	hematolog	NNP	O	O
,	VORAXAZE.xml:S1:5729:1	,	,	O	O
Hepatic	VORAXAZE.xml:S1:5731:7	hepat	NNP	O	O
,	VORAXAZE.xml:S1:5738:1	,	,	O	O
or	VORAXAZE.xml:S1:5740:2	or	CC	O	O
Renal	VORAXAZE.xml:S1:5743:5	renal	JJ	O	O
Adverse	VORAXAZE.xml:S1:5749:7	advers	JJ	O	O
Reactions	VORAXAZE.xml:S1:5757:9	reaction	NNS	O	O

1	VORAXAZE.xml:S1:5771:1	1	CD	O	O
This	VORAXAZE.xml:S1:5774:4	thi	DT	O	O
incidence	VORAXAZE.xml:S1:5779:9	incid	NN	O	O
includes	VORAXAZE.xml:S1:5789:8	includ	VBZ	O	O
the	VORAXAZE.xml:S1:5798:3	the	DT	O	O
following	VORAXAZE.xml:S1:5802:9	follow	JJ	O	O
terms	VORAXAZE.xml:S1:5812:5	term	NNS	O	O
:	VORAXAZE.xml:S1:5817:1	:	:	O	O
flushing	VORAXAZE.xml:S1:5819:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	VORAXAZE.xml:S1:5827:1	,	,	O	O
feeling	VORAXAZE.xml:S1:5829:7	feel	VBG	B-AdverseReaction	B-AdverseReaction
hot	VORAXAZE.xml:S1:5837:3	hot	JJ	I-AdverseReaction	I-AdverseReaction
,	VORAXAZE.xml:S1:5840:1	,	,	O	O
burning	VORAXAZE.xml:S1:5842:7	burn	VBG	B-AdverseReaction	B-AdverseReaction
sensation	VORAXAZE.xml:S1:5850:9	sensat	NN	I-AdverseReaction	I-AdverseReaction
.	VORAXAZE.xml:S1:5859:1	.	.	O	O

2	VORAXAZE.xml:S1:5862:1	2	CD	O	O
One	VORAXAZE.xml:S1:5865:3	one	CD	O	O
of	VORAXAZE.xml:S1:5869:2	of	IN	O	O
these	VORAXAZE.xml:S1:5872:5	these	DT	O	O
reactions	VORAXAZE.xml:S1:5878:9	reaction	NNS	O	O
was	VORAXAZE.xml:S1:5888:3	wa	VBD	O	O
classified	VORAXAZE.xml:S1:5892:10	classifi	VBN	O	O
as	VORAXAZE.xml:S1:5903:2	as	IN	O	O
Grade	VORAXAZE.xml:S1:5906:5	grade	NNP	O	O
3	VORAXAZE.xml:S1:5912:1	3	CD	O	O
in	VORAXAZE.xml:S1:5914:2	in	IN	O	O
severity	VORAXAZE.xml:S1:5917:8	sever	NN	O	O
.	VORAXAZE.xml:S1:5925:1	.	.	O	O

Adverse	VORAXAZE.xml:S1:5936:7	advers	NN	O	O

Reaction	VORAXAZE.xml:S1:5944:8	reaction	NNP	O	O
N	VORAXAZE.xml:S1:5963:1	N	NNP	O	O
290	VORAXAZE.xml:S1:5966:3	290	CD	O	O
n	VORAXAZE.xml:S1:5969:1	n	NN	O	O
(	VORAXAZE.xml:S1:5971:1	(	(	O	O
)	VORAXAZE.xml:S1:5973:1	)	)	O	O

Paresthesias	VORAXAZE.xml:S1:5991:12	paresthesia	$	B-AdverseReaction	B-AdverseReaction
7	VORAXAZE.xml:S1:6018:1	7	CD	O	O
(	VORAXAZE.xml:S1:6020:1	(	(	O	O
2%	VORAXAZE.xml:S1:6021:2	2%	CD	O	O
)	VORAXAZE.xml:S1:6023:1	)	)	O	O

Flushing	VORAXAZE.xml:S1:6048:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
1	VORAXAZE.xml:S1:6058:1	1	CD	O	O
,	VORAXAZE.xml:S1:6059:1	,	,	O	O
2	VORAXAZE.xml:S1:6060:1	2	CD	O	O
5	VORAXAZE.xml:S1:6075:1	5	CD	O	O
(	VORAXAZE.xml:S1:6077:1	(	(	O	O
2%	VORAXAZE.xml:S1:6078:2	2%	CD	O	O
)	VORAXAZE.xml:S1:6080:1	)	)	O	O

Nausea	VORAXAZE.xml:S1:6105:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
Vomiting	VORAXAZE.xml:S1:6112:8	vomit	VBG	B-AdverseReaction	I-AdverseReaction
5	VORAXAZE.xml:S1:6132:1	5	CD	O	O
(	VORAXAZE.xml:S1:6134:1	(	(	O	O
2%	VORAXAZE.xml:S1:6135:2	2%	CD	O	O
)	VORAXAZE.xml:S1:6137:1	)	)	O	O

Headache	VORAXAZE.xml:S1:6162:8	headach	$	B-AdverseReaction	B-AdverseReaction
2	VORAXAZE.xml:S1:6189:1	2	CD	O	O
(	VORAXAZE.xml:S1:6191:1	(	(	O	O
1%	VORAXAZE.xml:S1:6192:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6194:1	)	)	O	O

Hypotension	VORAXAZE.xml:S1:6219:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
2	VORAXAZE.xml:S1:6246:1	2	CD	O	O
(	VORAXAZE.xml:S1:6248:1	(	(	O	O
1%	VORAXAZE.xml:S1:6249:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6251:1	)	)	O	O

Blurred	VORAXAZE.xml:S1:6276:7	blur	NNP	B-AdverseReaction	B-AdverseReaction
Vision	VORAXAZE.xml:S1:6284:6	vision	NNP	I-AdverseReaction	I-AdverseReaction
1	VORAXAZE.xml:S1:6303:1	1	CD	O	O
(	VORAXAZE.xml:S1:6305:1	(	(	O	O
1%	VORAXAZE.xml:S1:6307:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6309:1	)	)	O	O

Diarrhea	VORAXAZE.xml:S1:6333:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
1	VORAXAZE.xml:S1:6360:1	1	CD	O	O
(	VORAXAZE.xml:S1:6362:1	(	(	O	O
1%	VORAXAZE.xml:S1:6364:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6366:1	)	)	O	O

Hypersensitivity	VORAXAZE.xml:S1:6390:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
1	VORAXAZE.xml:S1:6417:1	1	CD	O	O
(	VORAXAZE.xml:S1:6419:1	(	(	O	O
1%	VORAXAZE.xml:S1:6421:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6423:1	)	)	O	O

Hypertension	VORAXAZE.xml:S1:6447:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
1	VORAXAZE.xml:S1:6474:1	1	CD	O	O
(	VORAXAZE.xml:S1:6476:1	(	(	O	O
1%	VORAXAZE.xml:S1:6478:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6480:1	)	)	O	O

Rash	VORAXAZE.xml:S1:6504:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
1	VORAXAZE.xml:S1:6531:1	1	CD	O	O
(	VORAXAZE.xml:S1:6533:1	(	(	O	O
1%	VORAXAZE.xml:S1:6535:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6537:1	)	)	O	O

Throat	VORAXAZE.xml:S1:6561:6	throat	NNP	B-AdverseReaction	B-AdverseReaction
irritation	VORAXAZE.xml:S1:6568:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
Throat	VORAXAZE.xml:S1:6579:6	throat	NNP	B-AdverseReaction	I-AdverseReaction
tightness	VORAXAZE.xml:S1:6586:9	tight	NN	I-AdverseReaction	I-AdverseReaction
1	VORAXAZE.xml:S1:6597:1	1	CD	O	O
(	VORAXAZE.xml:S1:6599:1	(	(	O	O
1%	VORAXAZE.xml:S1:6601:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6603:1	)	)	O	O

Tremor	VORAXAZE.xml:S1:6627:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
1	VORAXAZE.xml:S1:6654:1	1	CD	O	O
(	VORAXAZE.xml:S1:6656:1	(	(	O	O
1%	VORAXAZE.xml:S1:6658:2	1%	CD	O	O
)	VORAXAZE.xml:S1:6660:1	)	)	O	O

6.2	VORAXAZE.xml:S1:6691:3	6.2	CD	O	O
Immunogenicity	VORAXAZE.xml:S1:6699:14	immunogen	NN	O	O

As	VORAXAZE.xml:S1:6719:2	As	IN	O	O
with	VORAXAZE.xml:S1:6722:4	with	IN	O	O
all	VORAXAZE.xml:S1:6727:3	all	DT	O	O
therapeutic	VORAXAZE.xml:S1:6731:11	therapeut	JJ	O	O
proteins	VORAXAZE.xml:S1:6743:8	protein	NNS	O	O
,	VORAXAZE.xml:S1:6751:1	,	,	O	O
there	VORAXAZE.xml:S1:6753:5	there	EX	O	O
is	VORAXAZE.xml:S1:6759:2	is	VBZ	O	O
potential	VORAXAZE.xml:S1:6762:9	potenti	JJ	O	O
for	VORAXAZE.xml:S1:6772:3	for	IN	O	O
immunogenicity	VORAXAZE.xml:S1:6776:14	immunogen	NN	O	O
.	VORAXAZE.xml:S1:6790:1	.	.	O	O

In	VORAXAZE.xml:S1:6792:2	In	IN	O	O
clinical	VORAXAZE.xml:S1:6795:8	clinic	JJ	O	O
trials	VORAXAZE.xml:S1:6804:6	trial	NNS	O	O
,	VORAXAZE.xml:S1:6810:1	,	,	O	O
121	VORAXAZE.xml:S1:6812:3	121	CD	O	O
patients	VORAXAZE.xml:S1:6816:8	patient	NNS	O	O
who	VORAXAZE.xml:S1:6825:3	who	WP	O	O
received	VORAXAZE.xml:S1:6829:8	receiv	VBD	O	O
one	VORAXAZE.xml:S1:6838:3	one	CD	O	O
(	VORAXAZE.xml:S1:6842:1	(	(	O	O
n	VORAXAZE.xml:S1:6843:1	n	IN	O	O
99	VORAXAZE.xml:S1:6845:2	99	CD	O	O
)	VORAXAZE.xml:S1:6847:1	)	)	O	O
,	VORAXAZE.xml:S1:6848:1	,	,	O	O
two	VORAXAZE.xml:S1:6850:3	two	CD	O	O
(	VORAXAZE.xml:S1:6854:1	(	(	O	O
n	VORAXAZE.xml:S1:6855:1	n	IN	O	O
21	VORAXAZE.xml:S1:6857:2	21	CD	O	O
)	VORAXAZE.xml:S1:6859:1	)	)	O	O
,	VORAXAZE.xml:S1:6860:1	,	,	O	O
or	VORAXAZE.xml:S1:6862:2	or	CC	O	O
three	VORAXAZE.xml:S1:6865:5	three	CD	O	O
(	VORAXAZE.xml:S1:6871:1	(	(	O	O
n	VORAXAZE.xml:S1:6872:1	n	IN	O	O
1	VORAXAZE.xml:S1:6874:1	1	CD	O	O
)	VORAXAZE.xml:S1:6875:1	)	)	O	O
doses	VORAXAZE.xml:S1:6877:5	dose	NNS	O	O
of	VORAXAZE.xml:S1:6883:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:6886:8	voraxaz	NNP	O	O
were	VORAXAZE.xml:S1:6895:4	were	VBD	O	O
evaluated	VORAXAZE.xml:S1:6900:9	evalu	VBN	O	O
for	VORAXAZE.xml:S1:6910:3	for	IN	O	O
anti	VORAXAZE.xml:S1:6914:4	anti	JJ	O	O
-	VORAXAZE.xml:S1:6918:1	-	:	O	O
glucarpidase	VORAXAZE.xml:S1:6919:12	glucarpidas	NN	O	O
antibodies	VORAXAZE.xml:S1:6932:10	antibodi	NNS	O	O
.	VORAXAZE.xml:S1:6942:1	.	.	O	O

Twenty	VORAXAZE.xml:S1:6944:6	twenti	CD	O	O
-	VORAXAZE.xml:S1:6950:1	-	:	O	O
five	VORAXAZE.xml:S1:6951:4	five	CD	O	O
of	VORAXAZE.xml:S1:6956:2	of	IN	O	O
these	VORAXAZE.xml:S1:6959:5	these	DT	O	O
121	VORAXAZE.xml:S1:6965:3	121	CD	O	O
patients	VORAXAZE.xml:S1:6969:8	patient	NNS	O	O
(	VORAXAZE.xml:S1:6978:1	(	(	O	O
21%	VORAXAZE.xml:S1:6979:3	21%	CD	O	O
)	VORAXAZE.xml:S1:6982:1	)	)	O	O
had	VORAXAZE.xml:S1:6984:3	had	VBD	O	O
detectable	VORAXAZE.xml:S1:6988:10	detect	JJ	O	O
anti	VORAXAZE.xml:S1:6999:4	anti	JJ	O	O
-	VORAXAZE.xml:S1:7003:1	-	:	O	O
glucarpidase	VORAXAZE.xml:S1:7004:12	glucarpidas	NN	O	O
antibodies	VORAXAZE.xml:S1:7017:10	antibodi	NNS	O	O
following	VORAXAZE.xml:S1:7028:9	follow	VBG	O	O
VORAXAZE	VORAXAZE.xml:S1:7038:8	voraxaz	NNP	O	O
administration	VORAXAZE.xml:S1:7047:14	administr	NN	O	O
,	VORAXAZE.xml:S1:7061:1	,	,	O	O
of	VORAXAZE.xml:S1:7063:2	of	IN	O	O
which	VORAXAZE.xml:S1:7066:5	which	WDT	O	O
19	VORAXAZE.xml:S1:7072:2	19	CD	O	O
received	VORAXAZE.xml:S1:7075:8	receiv	VBD	O	O
a	VORAXAZE.xml:S1:7084:1	a	DT	O	O
single	VORAXAZE.xml:S1:7086:6	singl	JJ	O	O
dose	VORAXAZE.xml:S1:7093:4	dose	NN	O	O
of	VORAXAZE.xml:S1:7098:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:7101:8	voraxaz	NNP	O	O
and	VORAXAZE.xml:S1:7110:3	and	CC	O	O
6	VORAXAZE.xml:S1:7114:1	6	CD	O	O
received	VORAXAZE.xml:S1:7116:8	receiv	VBD	O	O
two	VORAXAZE.xml:S1:7125:3	two	CD	O	O
doses	VORAXAZE.xml:S1:7129:5	dose	NNS	O	O
of	VORAXAZE.xml:S1:7135:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:7138:8	voraxaz	NNP	O	O
.	VORAXAZE.xml:S1:7146:1	.	.	O	O

Antibody	VORAXAZE.xml:S1:7148:8	antibodi	NN	O	O
titers	VORAXAZE.xml:S1:7157:6	titer	NNS	O	O
were	VORAXAZE.xml:S1:7164:4	were	VBD	O	O
determined	VORAXAZE.xml:S1:7169:10	determin	VBN	O	O
using	VORAXAZE.xml:S1:7180:5	use	VBG	O	O
a	VORAXAZE.xml:S1:7186:1	a	DT	O	O
bridging	VORAXAZE.xml:S1:7188:8	bridg	NN	O	O
enzyme	VORAXAZE.xml:S1:7197:6	enzym	SYM	O	O
-	VORAXAZE.xml:S1:7203:1	-	:	O	O
linked	VORAXAZE.xml:S1:7204:6	link	VBN	O	O
immunosorbent	VORAXAZE.xml:S1:7211:13	immunosorb	JJ	O	O
assay	VORAXAZE.xml:S1:7225:5	assay	NN	O	O
(	VORAXAZE.xml:S1:7231:1	(	(	O	O
ELISA	VORAXAZE.xml:S1:7232:5	elisa	NNP	O	O
)	VORAXAZE.xml:S1:7237:1	)	)	O	O
for	VORAXAZE.xml:S1:7239:3	for	IN	O	O
anti	VORAXAZE.xml:S1:7243:4	anti	JJ	O	O
-	VORAXAZE.xml:S1:7247:1	-	:	O	O
glucarpidase	VORAXAZE.xml:S1:7248:12	glucarpidas	NN	O	O
antibodies	VORAXAZE.xml:S1:7261:10	antibodi	NNS	O	O
.	VORAXAZE.xml:S1:7271:1	.	.	O	O

Neutralizing	VORAXAZE.xml:S1:7281:12	neutral	VBG	O	O
antibodies	VORAXAZE.xml:S1:7294:10	antibodi	NNS	O	O
were	VORAXAZE.xml:S1:7305:4	were	VBD	O	O
detected	VORAXAZE.xml:S1:7310:8	detect	VBN	O	O
in	VORAXAZE.xml:S1:7319:2	in	IN	O	O
11	VORAXAZE.xml:S1:7322:2	11	CD	O	O
of	VORAXAZE.xml:S1:7325:2	of	IN	O	O
the	VORAXAZE.xml:S1:7328:3	the	DT	O	O
25	VORAXAZE.xml:S1:7332:2	25	CD	O	O
patients	VORAXAZE.xml:S1:7335:8	patient	NNS	O	O
who	VORAXAZE.xml:S1:7344:3	who	WP	O	O
tested	VORAXAZE.xml:S1:7348:6	test	VBD	O	O
positive	VORAXAZE.xml:S1:7355:8	posit	JJ	O	O
for	VORAXAZE.xml:S1:7364:3	for	IN	O	O
anti	VORAXAZE.xml:S1:7368:4	anti	JJ	O	O
-	VORAXAZE.xml:S1:7372:1	-	:	O	O
glucarpidase	VORAXAZE.xml:S1:7373:12	glucarpidas	NN	O	O
binding	VORAXAZE.xml:S1:7386:7	bind	NN	O	O
antibodies	VORAXAZE.xml:S1:7394:10	antibodi	NNS	O	O
.	VORAXAZE.xml:S1:7404:1	.	.	O	O

Eight	VORAXAZE.xml:S1:7406:5	eight	CD	O	O
of	VORAXAZE.xml:S1:7412:2	of	IN	O	O
these	VORAXAZE.xml:S1:7415:5	these	DT	O	O
11	VORAXAZE.xml:S1:7421:2	11	CD	O	O
patients	VORAXAZE.xml:S1:7424:8	patient	NNS	O	O
had	VORAXAZE.xml:S1:7433:3	had	VBD	O	O
received	VORAXAZE.xml:S1:7437:8	receiv	VBN	O	O
a	VORAXAZE.xml:S1:7446:1	a	DT	O	O
single	VORAXAZE.xml:S1:7448:6	singl	JJ	O	O
dose	VORAXAZE.xml:S1:7455:4	dose	NN	O	O
of	VORAXAZE.xml:S1:7460:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S1:7463:8	voraxaz	NNP	O	O
.	VORAXAZE.xml:S1:7471:1	.	.	O	O

However	VORAXAZE.xml:S1:7473:7	howev	RB	O	O
,	VORAXAZE.xml:S1:7480:1	,	,	O	O
the	VORAXAZE.xml:S1:7482:3	the	DT	O	O
development	VORAXAZE.xml:S1:7486:11	develop	NN	O	O
of	VORAXAZE.xml:S1:7498:2	of	IN	O	O
neutralizing	VORAXAZE.xml:S1:7501:12	neutral	VBG	O	O
antibodies	VORAXAZE.xml:S1:7514:10	antibodi	NNS	O	O
may	VORAXAZE.xml:S1:7525:3	may	MD	O	O
be	VORAXAZE.xml:S1:7529:2	be	VB	O	O
underreported	VORAXAZE.xml:S1:7532:13	underreport	VBN	O	O
due	VORAXAZE.xml:S1:7546:3	due	JJ	O	O
to	VORAXAZE.xml:S1:7550:2	to	TO	O	O
lack	VORAXAZE.xml:S1:7553:4	lack	VB	O	O
of	VORAXAZE.xml:S1:7558:2	of	IN	O	O
assay	VORAXAZE.xml:S1:7561:5	assay	JJ	O	O
sensitivity	VORAXAZE.xml:S1:7567:11	sensit	NN	O	O
.	VORAXAZE.xml:S1:7578:1	.	.	O	O

The	VORAXAZE.xml:S1:7588:3	the	DT	O	O
detection	VORAXAZE.xml:S1:7592:9	detect	NN	O	O
of	VORAXAZE.xml:S1:7602:2	of	IN	O	O
antibody	VORAXAZE.xml:S1:7605:8	antibodi	NN	O	O
formation	VORAXAZE.xml:S1:7614:9	format	NN	O	O
is	VORAXAZE.xml:S1:7624:2	is	VBZ	O	O
highly	VORAXAZE.xml:S1:7627:6	highli	RB	O	O
dependent	VORAXAZE.xml:S1:7634:9	depend	JJ	O	O
on	VORAXAZE.xml:S1:7644:2	on	IN	O	O
the	VORAXAZE.xml:S1:7647:3	the	DT	O	O
sensitivity	VORAXAZE.xml:S1:7651:11	sensit	NN	O	O
and	VORAXAZE.xml:S1:7663:3	and	CC	O	O
specificity	VORAXAZE.xml:S1:7667:11	specif	NN	O	O
of	VORAXAZE.xml:S1:7679:2	of	IN	O	O
the	VORAXAZE.xml:S1:7682:3	the	DT	O	O
assay	VORAXAZE.xml:S1:7686:5	assay	NN	O	O
.	VORAXAZE.xml:S1:7691:1	.	.	O	O

Additionally	VORAXAZE.xml:S1:7693:12	addit	RB	O	O
,	VORAXAZE.xml:S1:7705:1	,	,	O	O
the	VORAXAZE.xml:S1:7707:3	the	DT	O	O
observed	VORAXAZE.xml:S1:7711:8	observ	JJ	O	O
incidence	VORAXAZE.xml:S1:7720:9	incid	NN	O	O
of	VORAXAZE.xml:S1:7730:2	of	IN	O	O
antibody	VORAXAZE.xml:S1:7733:8	antibodi	NN	O	O
(	VORAXAZE.xml:S1:7742:1	(	(	O	O
including	VORAXAZE.xml:S1:7743:9	includ	VBG	O	O
neutralizing	VORAXAZE.xml:S1:7753:12	neutral	VBG	O	O
antibody	VORAXAZE.xml:S1:7766:8	antibodi	NN	O	O
)	VORAXAZE.xml:S1:7774:1	)	)	O	O
positivity	VORAXAZE.xml:S1:7776:10	posit	NN	O	O
in	VORAXAZE.xml:S1:7787:2	in	IN	O	O
an	VORAXAZE.xml:S1:7790:2	an	DT	O	O
assay	VORAXAZE.xml:S1:7793:5	assay	NN	O	O
may	VORAXAZE.xml:S1:7799:3	may	MD	O	O
be	VORAXAZE.xml:S1:7803:2	be	VB	O	O
influenced	VORAXAZE.xml:S1:7806:10	influenc	VBN	O	O
by	VORAXAZE.xml:S1:7817:2	by	IN	O	O
several	VORAXAZE.xml:S1:7820:7	sever	JJ	O	O
factors	VORAXAZE.xml:S1:7828:7	factor	NNS	O	O
,	VORAXAZE.xml:S1:7836:1	,	,	O	O
including	VORAXAZE.xml:S1:7838:9	includ	VBG	O	O
assay	VORAXAZE.xml:S1:7848:5	assay	JJ	O	O
methodology	VORAXAZE.xml:S1:7854:11	methodolog	NN	O	O
,	VORAXAZE.xml:S1:7865:1	,	,	O	O
sample	VORAXAZE.xml:S1:7867:6	sampl	NN	O	O
handling	VORAXAZE.xml:S1:7874:8	handl	NN	O	O
,	VORAXAZE.xml:S1:7882:1	,	,	O	O
timing	VORAXAZE.xml:S1:7884:6	time	NN	O	O
of	VORAXAZE.xml:S1:7891:2	of	IN	O	O
sample	VORAXAZE.xml:S1:7894:6	sampl	JJ	O	O
collection	VORAXAZE.xml:S1:7901:10	collect	NN	O	O
,	VORAXAZE.xml:S1:7911:1	,	,	O	O
concomitant	VORAXAZE.xml:S1:7913:11	concomit	JJ	O	O
medications	VORAXAZE.xml:S1:7925:11	medic	NNS	O	O
,	VORAXAZE.xml:S1:7936:1	,	,	O	O
and	VORAXAZE.xml:S1:7938:3	and	CC	O	O
underlying	VORAXAZE.xml:S1:7942:10	underli	JJ	O	O
disease	VORAXAZE.xml:S1:7953:7	diseas	NN	O	O
.	VORAXAZE.xml:S1:7960:1	.	.	O	O

For	VORAXAZE.xml:S1:7962:3	for	IN	O	O
these	VORAXAZE.xml:S1:7966:5	these	DT	O	O
reasons	VORAXAZE.xml:S1:7972:7	reason	NNS	O	O
,	VORAXAZE.xml:S1:7979:1	,	,	O	O
comparison	VORAXAZE.xml:S1:7981:10	comparison	NN	O	O
of	VORAXAZE.xml:S1:7992:2	of	IN	O	O
incidence	VORAXAZE.xml:S1:7995:9	incid	NN	O	O
of	VORAXAZE.xml:S1:8005:2	of	IN	O	O
antibodies	VORAXAZE.xml:S1:8008:10	antibodi	NNS	O	O
to	VORAXAZE.xml:S1:8019:2	to	TO	O	O
VORAXAZE	VORAXAZE.xml:S1:8022:8	voraxaz	VB	O	O
with	VORAXAZE.xml:S1:8031:4	with	IN	O	O
the	VORAXAZE.xml:S1:8036:3	the	DT	O	O
incidence	VORAXAZE.xml:S1:8040:9	incid	NN	O	O
of	VORAXAZE.xml:S1:8050:2	of	IN	O	O
antibodies	VORAXAZE.xml:S1:8053:10	antibodi	NNS	O	O
to	VORAXAZE.xml:S1:8064:2	to	TO	O	O
other	VORAXAZE.xml:S1:8067:5	other	JJ	O	O
products	VORAXAZE.xml:S1:8073:8	product	NNS	O	O
may	VORAXAZE.xml:S1:8082:3	may	MD	O	O
be	VORAXAZE.xml:S1:8086:2	be	VB	O	O
misleading	VORAXAZE.xml:S1:8089:10	mislead	VBG	O	O
.	VORAXAZE.xml:S1:8099:1	.	.	O	O
5	VORAXAZE.xml:S2:4:1	5	CD	O	O
WARNINGS	VORAXAZE.xml:S2:13:8	warn	NNP	O	O
AND	VORAXAZE.xml:S2:22:3	and	NNP	O	O
PRECAUTIONS	VORAXAZE.xml:S2:26:11	precaut	NNP	O	O

EXCERPT	VORAXAZE.xml:S2:44:7	excerpt	NN	O	O
:	VORAXAZE.xml:S2:51:1	:	:	O	O
Serious	VORAXAZE.xml:S2:59:7	seriou	JJ	O	O
allergic	VORAXAZE.xml:S2:67:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VORAXAZE.xml:S2:76:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	VORAXAZE.xml:S2:85:1	,	,	O	O
including	VORAXAZE.xml:S2:87:9	includ	VBG	O	O
anaphylactic	VORAXAZE.xml:S2:97:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VORAXAZE.xml:S2:110:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	VORAXAZE.xml:S2:119:1	,	,	O	O
may	VORAXAZE.xml:S2:121:3	may	MD	O	O
occur	VORAXAZE.xml:S2:125:5	occur	VB	O	O
.	VORAXAZE.xml:S2:130:1	.	.	O	O

(	VORAXAZE.xml:S2:132:1	(	(	O	O
5.1	VORAXAZE.xml:S2:135:3	5.1	CD	O	O
)	VORAXAZE.xml:S2:140:1	)	)	O	O

Measurement	VORAXAZE.xml:S2:147:11	measur	NN	O	O
of	VORAXAZE.xml:S2:159:2	of	IN	O	O
methotrexate	VORAXAZE.xml:S2:162:12	methotrex	NN	O	O
using	VORAXAZE.xml:S2:175:5	use	VBG	O	O
immunoassays	VORAXAZE.xml:S2:181:12	immunoassay	NNS	O	O
is	VORAXAZE.xml:S2:194:2	is	VBZ	O	O
unreliable	VORAXAZE.xml:S2:197:10	unreli	JJ	O	O
for	VORAXAZE.xml:S2:208:3	for	IN	O	O
samples	VORAXAZE.xml:S2:212:7	sampl	NNS	O	O
collected	VORAXAZE.xml:S2:220:9	collect	VBN	O	O
within	VORAXAZE.xml:S2:230:6	within	IN	O	O
48	VORAXAZE.xml:S2:237:2	48	CD	O	O
hours	VORAXAZE.xml:S2:240:5	hour	NNS	O	O
following	VORAXAZE.xml:S2:246:9	follow	VBG	O	O
VORAXAZE	VORAXAZE.xml:S2:256:8	voraxaz	NNP	O	O
administration	VORAXAZE.xml:S2:265:14	administr	NN	O	O
.	VORAXAZE.xml:S2:279:1	.	.	O	O

(	VORAXAZE.xml:S2:281:1	(	(	O	O
5.2	VORAXAZE.xml:S2:284:3	5.2	CD	O	O
)	VORAXAZE.xml:S2:289:1	)	)	O	O

Continue	VORAXAZE.xml:S2:296:8	continu	NNP	O	O
therapy	VORAXAZE.xml:S2:305:7	therapi	NN	O	O
with	VORAXAZE.xml:S2:313:4	with	IN	O	O
leucovorin	VORAXAZE.xml:S2:318:10	leucovorin	NN	O	O
until	VORAXAZE.xml:S2:329:5	until	IN	O	O
the	VORAXAZE.xml:S2:335:3	the	DT	O	O
methotrexate	VORAXAZE.xml:S2:339:12	methotrex	NN	O	O
concentration	VORAXAZE.xml:S2:352:13	concentr	NN	O	O
has	VORAXAZE.xml:S2:366:3	ha	VBZ	O	O
been	VORAXAZE.xml:S2:370:4	been	VBN	O	O
maintained	VORAXAZE.xml:S2:375:10	maintain	VBN	O	O
below	VORAXAZE.xml:S2:386:5	below	IN	O	O
the	VORAXAZE.xml:S2:392:3	the	DT	O	O
leucovorin	VORAXAZE.xml:S2:396:10	leucovorin	NN	O	O
treatment	VORAXAZE.xml:S2:407:9	treatment	NN	O	O
threshold	VORAXAZE.xml:S2:417:9	threshold	NN	O	O
for	VORAXAZE.xml:S2:427:3	for	IN	O	O
a	VORAXAZE.xml:S2:431:1	a	DT	O	O
minimum	VORAXAZE.xml:S2:433:7	minimum	NN	O	O
of	VORAXAZE.xml:S2:441:2	of	IN	O	O
3	VORAXAZE.xml:S2:444:1	3	CD	O	O
days	VORAXAZE.xml:S2:446:4	day	NNS	O	O
.	VORAXAZE.xml:S2:450:1	.	.	O	O

(	VORAXAZE.xml:S2:452:1	(	(	O	O
5.3	VORAXAZE.xml:S2:455:3	5.3	CD	O	O
)	VORAXAZE.xml:S2:460:1	)	)	O	O

Do	VORAXAZE.xml:S2:467:2	Do	NNP	O	O
not	VORAXAZE.xml:S2:470:3	not	RB	O	O
administer	VORAXAZE.xml:S2:474:10	administ	VB	O	O
leucovorin	VORAXAZE.xml:S2:485:10	leucovorin	NN	O	O
within	VORAXAZE.xml:S2:496:6	within	IN	O	O
2	VORAXAZE.xml:S2:503:1	2	CD	O	O
hours	VORAXAZE.xml:S2:505:5	hour	NNS	O	O
before	VORAXAZE.xml:S2:511:6	befor	IN	O	O
or	VORAXAZE.xml:S2:518:2	or	CC	O	O
after	VORAXAZE.xml:S2:521:5	after	IN	O	O
a	VORAXAZE.xml:S2:527:1	a	DT	O	O
dose	VORAXAZE.xml:S2:529:4	dose	NN	O	O
of	VORAXAZE.xml:S2:534:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:537:8	voraxaz	NNP	O	O
.	VORAXAZE.xml:S2:545:1	.	.	O	O

(	VORAXAZE.xml:S2:547:1	(	(	O	O
5.3	VORAXAZE.xml:S2:550:3	5.3	CD	O	O
)	VORAXAZE.xml:S2:555:1	)	)	O	O

For	VORAXAZE.xml:S2:562:3	for	IN	O	O
48	VORAXAZE.xml:S2:566:2	48	CD	O	O
hours	VORAXAZE.xml:S2:569:5	hour	NNS	O	O
after	VORAXAZE.xml:S2:575:5	after	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:581:8	voraxaz	NNP	O	O
administration	VORAXAZE.xml:S2:590:14	administr	NN	O	O
,	VORAXAZE.xml:S2:604:1	,	,	O	O
determine	VORAXAZE.xml:S2:606:9	determin	VB	O	O
the	VORAXAZE.xml:S2:616:3	the	DT	O	O
leucovorin	VORAXAZE.xml:S2:620:10	leucovorin	NN	O	O
dose	VORAXAZE.xml:S2:631:4	dose	NN	O	O
based	VORAXAZE.xml:S2:636:5	base	VBN	O	O
on	VORAXAZE.xml:S2:642:2	on	IN	O	O
the	VORAXAZE.xml:S2:645:3	the	DT	O	O
patient	VORAXAZE.xml:S2:649:7	patient	NN	O	O
's	VORAXAZE.xml:S2:656:2	's	POS	O	O
pre	VORAXAZE.xml:S2:659:3	pre	JJ	O	O
-	VORAXAZE.xml:S2:662:1	-	:	O	O
VORAXAZE	VORAXAZE.xml:S2:663:8	voraxaz	NNP	O	O
methotrexate	VORAXAZE.xml:S2:672:12	methotrex	NN	O	O
concentration	VORAXAZE.xml:S2:685:13	concentr	NN	O	O
.	VORAXAZE.xml:S2:698:1	.	.	O	O

(	VORAXAZE.xml:S2:700:1	(	(	O	O
5.3	VORAXAZE.xml:S2:703:3	5.3	CD	O	O
)	VORAXAZE.xml:S2:708:1	)	)	O	O

Continue	VORAXAZE.xml:S2:715:8	continu	NNP	O	O
hydration	VORAXAZE.xml:S2:724:9	hydrat	NN	O	O
and	VORAXAZE.xml:S2:734:3	and	CC	O	O
alkalinization	VORAXAZE.xml:S2:738:14	alkalin	NN	O	O
of	VORAXAZE.xml:S2:753:2	of	IN	O	O
the	VORAXAZE.xml:S2:756:3	the	DT	O	O
urine	VORAXAZE.xml:S2:760:5	urin	NN	O	O
as	VORAXAZE.xml:S2:766:2	as	IN	O	O
indicated	VORAXAZE.xml:S2:769:9	indic	JJ	O	O
.	VORAXAZE.xml:S2:778:1	.	.	O	O

(	VORAXAZE.xml:S2:780:1	(	(	O	O
5.3	VORAXAZE.xml:S2:783:3	5.3	CD	O	O
)	VORAXAZE.xml:S2:788:1	)	)	O	O

5.1	VORAXAZE.xml:S2:802:3	5.1	CD	O	O

Serious	VORAXAZE.xml:S2:810:7	seriou	JJ	O	O

Allergic	VORAXAZE.xml:S2:818:8	allerg	JJ	O	O
Reactions	VORAXAZE.xml:S2:827:9	reaction	NNS	O	O

Serious	VORAXAZE.xml:S2:842:7	seriou	JJ	O	O
allergic	VORAXAZE.xml:S2:850:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
reactions	VORAXAZE.xml:S2:859:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
occurred	VORAXAZE.xml:S2:869:8	occur	VBD	O	O
in	VORAXAZE.xml:S2:878:2	in	IN	O	O
less	VORAXAZE.xml:S2:881:4	less	JJR	O	O
than	VORAXAZE.xml:S2:886:4	than	IN	O	O
1%	VORAXAZE.xml:S2:891:2	1%	CD	O	O
of	VORAXAZE.xml:S2:894:2	of	IN	O	O
patients	VORAXAZE.xml:S2:897:8	patient	NNS	O	O
[	VORAXAZE.xml:S2:906:1	[	JJ	O	O
see	VORAXAZE.xml:S2:908:3	see	VBP	O	O
Adverse	VORAXAZE.xml:S2:912:7	advers	JJ	O	O
Reactions	VORAXAZE.xml:S2:920:9	reaction	NNP	O	O
(	VORAXAZE.xml:S2:930:1	(	(	O	O
6.1	VORAXAZE.xml:S2:933:3	6.1	CD	O	O
)	VORAXAZE.xml:S2:938:1	)	)	O	O
]	VORAXAZE.xml:S2:941:1	]	NN	O	O
.	VORAXAZE.xml:S2:942:1	.	.	O	O

5.2	VORAXAZE.xml:S2:951:3	5.2	CD	O	O
Monitoring	VORAXAZE.xml:S2:959:10	monitor	NNP	O	O
Methotrexate	VORAXAZE.xml:S2:970:12	methotrex	NNP	O	O
Concentration	VORAXAZE.xml:S2:983:13	concentr	NNP	O	O
Interference	VORAXAZE.xml:S2:997:12	interfer	NNP	O	O
with	VORAXAZE.xml:S2:1010:4	with	IN	O	O
Assay	VORAXAZE.xml:S2:1015:5	assay	NNP	O	O

Methotrexate	VORAXAZE.xml:S2:1026:12	methotrex	NNP	O	O
concentrations	VORAXAZE.xml:S2:1039:14	concentr	NNS	O	O
within	VORAXAZE.xml:S2:1054:6	within	IN	O	O
48	VORAXAZE.xml:S2:1061:2	48	CD	O	O
hours	VORAXAZE.xml:S2:1064:5	hour	NNS	O	O
following	VORAXAZE.xml:S2:1070:9	follow	VBG	O	O
administration	VORAXAZE.xml:S2:1080:14	administr	NN	O	O
of	VORAXAZE.xml:S2:1095:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:1098:8	voraxaz	NNP	O	O
can	VORAXAZE.xml:S2:1107:3	can	MD	O	O
only	VORAXAZE.xml:S2:1111:4	onli	RB	O	O
be	VORAXAZE.xml:S2:1116:2	be	VB	O	O
reliably	VORAXAZE.xml:S2:1119:8	reliabl	RB	O	O
measured	VORAXAZE.xml:S2:1128:8	measur	VBN	O	O
by	VORAXAZE.xml:S2:1137:2	by	IN	O	O
a	VORAXAZE.xml:S2:1140:1	a	DT	O	O
chromatographic	VORAXAZE.xml:S2:1142:15	chromatograph	JJ	O	O
method	VORAXAZE.xml:S2:1158:6	method	NN	O	O
.	VORAXAZE.xml:S2:1164:1	.	.	O	O

DAMPA	VORAXAZE.xml:S2:1166:5	dampa	NNP	O	O
(	VORAXAZE.xml:S2:1172:1	(	(	O	O
4	VORAXAZE.xml:S2:1173:1	4	CD	O	O
-	VORAXAZE.xml:S2:1174:1	-	:	O	O
deoxy	VORAXAZE.xml:S2:1175:5	deoxi	NN	O	O
-	VORAXAZE.xml:S2:1180:1	-	:	O	O
4	VORAXAZE.xml:S2:1181:1	4	CD	O	O
-	VORAXAZE.xml:S2:1182:1	-	:	O	O
amino	VORAXAZE.xml:S2:1183:5	amino	NN	O	O
-	VORAXAZE.xml:S2:1188:1	-	:	O	O
N	VORAXAZE.xml:S2:1189:1	N	CC	O	O
10	VORAXAZE.xml:S2:1192:2	10	CD	O	O
-	VORAXAZE.xml:S2:1196:1	-	:	O	O
methylpteroic	VORAXAZE.xml:S2:1197:13	methylptero	NN	O	O
acid	VORAXAZE.xml:S2:1211:4	acid	NN	O	O
)	VORAXAZE.xml:S2:1215:1	)	)	O	O
is	VORAXAZE.xml:S2:1217:2	is	VBZ	O	O
an	VORAXAZE.xml:S2:1220:2	an	DT	O	O
inactive	VORAXAZE.xml:S2:1223:8	inact	JJ	O	O
metabolite	VORAXAZE.xml:S2:1232:10	metabolit	NN	O	O
of	VORAXAZE.xml:S2:1243:2	of	IN	O	O
methotrexate	VORAXAZE.xml:S2:1246:12	methotrex	NN	O	O
resulting	VORAXAZE.xml:S2:1259:9	result	VBG	O	O
from	VORAXAZE.xml:S2:1269:4	from	IN	O	O
treatment	VORAXAZE.xml:S2:1274:9	treatment	NN	O	O
with	VORAXAZE.xml:S2:1284:4	with	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:1289:8	voraxaz	NNP	O	O
.	VORAXAZE.xml:S2:1297:1	.	.	O	O

DAMPA	VORAXAZE.xml:S2:1299:5	dampa	NNP	O	O
interferes	VORAXAZE.xml:S2:1305:10	interfer	VBZ	O	O
with	VORAXAZE.xml:S2:1316:4	with	IN	O	O
the	VORAXAZE.xml:S2:1321:3	the	DT	O	O
measurement	VORAXAZE.xml:S2:1325:11	measur	NN	O	O
of	VORAXAZE.xml:S2:1337:2	of	IN	O	O
methotrexate	VORAXAZE.xml:S2:1340:12	methotrex	NN	O	O
concentration	VORAXAZE.xml:S2:1353:13	concentr	NN	O	O
using	VORAXAZE.xml:S2:1367:5	use	VBG	O	O
immunoassays	VORAXAZE.xml:S2:1373:12	immunoassay	NNS	O	O
resulting	VORAXAZE.xml:S2:1386:9	result	VBG	O	O
in	VORAXAZE.xml:S2:1396:2	in	IN	O	O
an	VORAXAZE.xml:S2:1399:2	an	DT	O	O
erroneous	VORAXAZE.xml:S2:1402:9	erron	JJ	O	O
measurement	VORAXAZE.xml:S2:1412:11	measur	NN	O	O
which	VORAXAZE.xml:S2:1424:5	which	WDT	O	O
overestimates	VORAXAZE.xml:S2:1430:13	overestim	VBZ	O	O
the	VORAXAZE.xml:S2:1444:3	the	DT	O	O
methotrexate	VORAXAZE.xml:S2:1448:12	methotrex	NN	O	O
concentration	VORAXAZE.xml:S2:1461:13	concentr	NN	O	O
.	VORAXAZE.xml:S2:1474:1	.	.	O	O

Due	VORAXAZE.xml:S2:1476:3	due	JJ	O	O
to	VORAXAZE.xml:S2:1480:2	to	TO	O	O
the	VORAXAZE.xml:S2:1483:3	the	DT	O	O
long	VORAXAZE.xml:S2:1487:4	long	JJ	O	O
half	VORAXAZE.xml:S2:1492:4	half	NN	O	O
-	VORAXAZE.xml:S2:1496:1	-	:	O	O
life	VORAXAZE.xml:S2:1497:4	life	NN	O	O
of	VORAXAZE.xml:S2:1502:2	of	IN	O	O
DAMPA	VORAXAZE.xml:S2:1505:5	dampa	NNP	O	O
(	VORAXAZE.xml:S2:1511:1	(	(	O	O
t1	VORAXAZE.xml:S2:1512:2	t1	JJ	O	O
2	VORAXAZE.xml:S2:1515:1	2	CD	O	O
of	VORAXAZE.xml:S2:1516:2	of	IN	O	O
approximately	VORAXAZE.xml:S2:1519:13	approxim	RB	O	O
9	VORAXAZE.xml:S2:1533:1	9	CD	O	O
hours	VORAXAZE.xml:S2:1535:5	hour	NNS	O	O
)	VORAXAZE.xml:S2:1540:1	)	)	O	O
,	VORAXAZE.xml:S2:1541:1	,	,	O	O
measurement	VORAXAZE.xml:S2:1543:11	measur	NN	O	O
of	VORAXAZE.xml:S2:1555:2	of	IN	O	O
methotrexate	VORAXAZE.xml:S2:1558:12	methotrex	NN	O	O
using	VORAXAZE.xml:S2:1571:5	use	VBG	O	O
immunoassays	VORAXAZE.xml:S2:1577:12	immunoassay	NNS	O	O
is	VORAXAZE.xml:S2:1590:2	is	VBZ	O	O
unreliable	VORAXAZE.xml:S2:1593:10	unreli	JJ	O	O
for	VORAXAZE.xml:S2:1604:3	for	IN	O	O
samples	VORAXAZE.xml:S2:1608:7	sampl	NNS	O	O
collected	VORAXAZE.xml:S2:1616:9	collect	VBN	O	O
within	VORAXAZE.xml:S2:1626:6	within	IN	O	O
48	VORAXAZE.xml:S2:1633:2	48	CD	O	O
hours	VORAXAZE.xml:S2:1636:5	hour	NNS	O	O
following	VORAXAZE.xml:S2:1642:9	follow	VBG	O	O
VORAXAZE	VORAXAZE.xml:S2:1652:8	voraxaz	NNP	O	O
administration	VORAXAZE.xml:S2:1661:14	administr	NN	O	O
[	VORAXAZE.xml:S2:1676:1	[	NNP	O	O
see	VORAXAZE.xml:S2:1678:3	see	VBP	O	O
Clinical	VORAXAZE.xml:S2:1682:8	clinic	JJ	O	O
Pharmacology	VORAXAZE.xml:S2:1691:12	pharmacolog	NNP	O	O
(	VORAXAZE.xml:S2:1704:1	(	(	O	O
12.1	VORAXAZE.xml:S2:1707:4	12.1	CD	O	O
)	VORAXAZE.xml:S2:1713:1	)	)	O	O
]	VORAXAZE.xml:S2:1716:1	]	NN	O	O
.	VORAXAZE.xml:S2:1717:1	.	.	O	O

5.3	VORAXAZE.xml:S2:1726:3	5.3	CD	O	O
Continuation	VORAXAZE.xml:S2:1734:12	continu	NNP	O	O
and	VORAXAZE.xml:S2:1747:3	and	CC	O	O
Timing	VORAXAZE.xml:S2:1751:6	time	NNP	O	O
of	VORAXAZE.xml:S2:1758:2	of	IN	O	O
Leucovorin	VORAXAZE.xml:S2:1761:10	leucovorin	NNP	O	O
Rescue	VORAXAZE.xml:S2:1772:6	rescu	NNP	O	O

Continue	VORAXAZE.xml:S2:1784:8	continu	NNP	O	O
to	VORAXAZE.xml:S2:1793:2	to	TO	O	O
administer	VORAXAZE.xml:S2:1796:10	administ	VB	O	O
leucovorin	VORAXAZE.xml:S2:1807:10	leucovorin	NN	O	O
after	VORAXAZE.xml:S2:1818:5	after	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:1824:8	voraxaz	NNP	O	O
.	VORAXAZE.xml:S2:1832:1	.	.	O	O

Do	VORAXAZE.xml:S2:1834:2	Do	NNP	O	O
not	VORAXAZE.xml:S2:1837:3	not	RB	O	O
administer	VORAXAZE.xml:S2:1841:10	administ	VB	O	O
leucovorin	VORAXAZE.xml:S2:1853:10	leucovorin	NN	O	O
within	VORAXAZE.xml:S2:1864:6	within	IN	O	O
2	VORAXAZE.xml:S2:1871:1	2	CD	O	O
hours	VORAXAZE.xml:S2:1873:5	hour	NNS	O	O
before	VORAXAZE.xml:S2:1879:6	befor	IN	O	O
or	VORAXAZE.xml:S2:1886:2	or	CC	O	O
after	VORAXAZE.xml:S2:1889:5	after	IN	O	O
a	VORAXAZE.xml:S2:1895:1	a	DT	O	O
dose	VORAXAZE.xml:S2:1897:4	dose	NN	O	O
of	VORAXAZE.xml:S2:1902:2	of	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:1905:8	voraxaz	NNP	O	O
because	VORAXAZE.xml:S2:1914:7	becaus	IN	O	O
leucovorin	VORAXAZE.xml:S2:1922:10	leucovorin	NN	O	O
is	VORAXAZE.xml:S2:1933:2	is	VBZ	O	O
a	VORAXAZE.xml:S2:1936:1	a	DT	O	O
substrate	VORAXAZE.xml:S2:1938:9	substrat	NN	O	O
for	VORAXAZE.xml:S2:1948:3	for	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:1952:8	voraxaz	NNP	O	O
[	VORAXAZE.xml:S2:1961:1	[	NNP	O	O
see	VORAXAZE.xml:S2:1963:3	see	VBP	O	O
Drug	VORAXAZE.xml:S2:1967:4	drug	NNP	O	O
Interactions	VORAXAZE.xml:S2:1972:12	interact	NNP	O	O
(	VORAXAZE.xml:S2:1985:1	(	(	O	O
7.1	VORAXAZE.xml:S2:1988:3	7.1	CD	O	O
)	VORAXAZE.xml:S2:1993:1	)	)	O	O
]	VORAXAZE.xml:S2:1996:1	]	NN	O	O
.	VORAXAZE.xml:S2:1997:1	.	.	O	O

For	VORAXAZE.xml:S2:2003:3	for	IN	O	O
the	VORAXAZE.xml:S2:2007:3	the	DT	O	O
first	VORAXAZE.xml:S2:2011:5	first	JJ	O	O
48	VORAXAZE.xml:S2:2017:2	48	CD	O	O
hours	VORAXAZE.xml:S2:2020:5	hour	NNS	O	O
after	VORAXAZE.xml:S2:2026:5	after	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:2032:8	voraxaz	NNP	O	O
,	VORAXAZE.xml:S2:2040:1	,	,	O	O
administer	VORAXAZE.xml:S2:2042:10	administ	RB	O	O
the	VORAXAZE.xml:S2:2053:3	the	DT	O	O
same	VORAXAZE.xml:S2:2057:4	same	JJ	O	O
leucovorin	VORAXAZE.xml:S2:2062:10	leucovorin	NN	O	O
dose	VORAXAZE.xml:S2:2073:4	dose	NN	O	O
as	VORAXAZE.xml:S2:2078:2	as	IN	O	O
given	VORAXAZE.xml:S2:2081:5	given	VBN	O	O
prior	VORAXAZE.xml:S2:2087:5	prior	RB	O	O
to	VORAXAZE.xml:S2:2093:2	to	TO	O	O
VORAXAZE	VORAXAZE.xml:S2:2096:8	voraxaz	NNP	O	O
[	VORAXAZE.xml:S2:2105:1	[	NNP	O	O
see	VORAXAZE.xml:S2:2107:3	see	VBP	O	O
Warnings	VORAXAZE.xml:S2:2111:8	warn	NNP	O	O
and	VORAXAZE.xml:S2:2120:3	and	CC	O	O
Precautions	VORAXAZE.xml:S2:2124:11	precaut	NNP	O	O
(	VORAXAZE.xml:S2:2136:1	(	(	O	O
5.2	VORAXAZE.xml:S2:2139:3	5.2	CD	O	O
)	VORAXAZE.xml:S2:2144:1	)	)	O	O
]	VORAXAZE.xml:S2:2147:1	]	NN	O	O
.	VORAXAZE.xml:S2:2148:1	.	.	O	O

Beyond	VORAXAZE.xml:S2:2150:6	beyond	IN	O	O
48	VORAXAZE.xml:S2:2157:2	48	CD	O	O
hours	VORAXAZE.xml:S2:2160:5	hour	NNS	O	O
after	VORAXAZE.xml:S2:2166:5	after	IN	O	O
VORAXAZE	VORAXAZE.xml:S2:2172:8	voraxaz	NNP	O	O
,	VORAXAZE.xml:S2:2180:1	,	,	O	O
administer	VORAXAZE.xml:S2:2182:10	administ	NN	O	O
leucovorin	VORAXAZE.xml:S2:2193:10	leucovorin	NN	O	O
based	VORAXAZE.xml:S2:2204:5	base	VBN	O	O
on	VORAXAZE.xml:S2:2210:2	on	IN	O	O
the	VORAXAZE.xml:S2:2213:3	the	DT	O	O
measured	VORAXAZE.xml:S2:2217:8	measur	JJ	O	O
methotrexate	VORAXAZE.xml:S2:2226:12	methotrex	NN	O	O
concentration	VORAXAZE.xml:S2:2239:13	concentr	NN	O	O
.	VORAXAZE.xml:S2:2252:1	.	.	O	O

Do	VORAXAZE.xml:S2:2254:2	Do	NNP	O	O
not	VORAXAZE.xml:S2:2257:3	not	RB	O	O
discontinue	VORAXAZE.xml:S2:2261:11	discontinu	VB	O	O
therapy	VORAXAZE.xml:S2:2273:7	therapi	NN	O	O
with	VORAXAZE.xml:S2:2281:4	with	IN	O	O
leucovorin	VORAXAZE.xml:S2:2286:10	leucovorin	NNS	O	O
based	VORAXAZE.xml:S2:2297:5	base	VBN	O	O
on	VORAXAZE.xml:S2:2303:2	on	IN	O	O
the	VORAXAZE.xml:S2:2306:3	the	DT	O	O
determination	VORAXAZE.xml:S2:2310:13	determin	NN	O	O
of	VORAXAZE.xml:S2:2324:2	of	IN	O	O
a	VORAXAZE.xml:S2:2327:1	a	DT	O	O
single	VORAXAZE.xml:S2:2329:6	singl	JJ	O	O
methotrexate	VORAXAZE.xml:S2:2336:12	methotrex	NN	O	O
concentration	VORAXAZE.xml:S2:2349:13	concentr	NN	O	O
below	VORAXAZE.xml:S2:2363:5	below	IN	O	O
the	VORAXAZE.xml:S2:2369:3	the	DT	O	O
leucovorin	VORAXAZE.xml:S2:2373:10	leucovorin	NN	O	O
treatment	VORAXAZE.xml:S2:2384:9	treatment	NN	O	O
threshold	VORAXAZE.xml:S2:2394:9	threshold	NN	O	O
.	VORAXAZE.xml:S2:2403:1	.	.	O	O

Therapy	VORAXAZE.xml:S2:2405:7	therapi	NN	O	O
with	VORAXAZE.xml:S2:2413:4	with	IN	O	O
leucovorin	VORAXAZE.xml:S2:2418:10	leucovorin	NN	O	O
should	VORAXAZE.xml:S2:2429:6	should	MD	O	O
be	VORAXAZE.xml:S2:2436:2	be	VB	O	O
continued	VORAXAZE.xml:S2:2439:9	continu	VBN	O	O
until	VORAXAZE.xml:S2:2449:5	until	IN	O	O
the	VORAXAZE.xml:S2:2455:3	the	DT	O	O
methotrexate	VORAXAZE.xml:S2:2459:12	methotrex	NN	O	O
concentration	VORAXAZE.xml:S2:2472:13	concentr	NN	O	O
has	VORAXAZE.xml:S2:2486:3	ha	VBZ	O	O
been	VORAXAZE.xml:S2:2490:4	been	VBN	O	O
maintained	VORAXAZE.xml:S2:2495:10	maintain	VBN	O	O
below	VORAXAZE.xml:S2:2506:5	below	IN	O	O
the	VORAXAZE.xml:S2:2512:3	the	DT	O	O
leucovorin	VORAXAZE.xml:S2:2516:10	leucovorin	NN	O	O
treatment	VORAXAZE.xml:S2:2527:9	treatment	NN	O	O
threshold	VORAXAZE.xml:S2:2537:9	threshold	NN	O	O
for	VORAXAZE.xml:S2:2547:3	for	IN	O	O
a	VORAXAZE.xml:S2:2551:1	a	DT	O	O
minimum	VORAXAZE.xml:S2:2553:7	minimum	NN	O	O
of	VORAXAZE.xml:S2:2561:2	of	IN	O	O
3	VORAXAZE.xml:S2:2564:1	3	CD	O	O
days	VORAXAZE.xml:S2:2566:4	day	NNS	O	O
.	VORAXAZE.xml:S2:2570:1	.	.	O	O

Continue	VORAXAZE.xml:S2:2576:8	continu	NNP	O	O
hydration	VORAXAZE.xml:S2:2585:9	hydrat	NN	O	O
and	VORAXAZE.xml:S2:2595:3	and	CC	O	O
alkalinization	VORAXAZE.xml:S2:2599:14	alkalin	NN	O	O
of	VORAXAZE.xml:S2:2614:2	of	IN	O	O
the	VORAXAZE.xml:S2:2617:3	the	DT	O	O
urine	VORAXAZE.xml:S2:2621:5	urin	NN	O	O
as	VORAXAZE.xml:S2:2627:2	as	IN	O	O
indicated	VORAXAZE.xml:S2:2630:9	indic	JJ	O	O
.	VORAXAZE.xml:S2:2639:1	.	.	O	O
6	XALKORI.xml:S1:4:1	6	CD	O	O
ADVERSE	XALKORI.xml:S1:6:7	advers	JJ	O	O
REACTIONS	XALKORI.xml:S1:14:9	reaction	NN	O	O

The	XALKORI.xml:S1:27:3	the	DT	O	O
following	XALKORI.xml:S1:31:9	follow	JJ	O	O
adverse	XALKORI.xml:S1:41:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:49:9	reaction	NNS	O	O
are	XALKORI.xml:S1:59:3	are	VBP	O	O
discussed	XALKORI.xml:S1:63:9	discuss	VBN	O	O
in	XALKORI.xml:S1:73:2	in	IN	O	O
greater	XALKORI.xml:S1:76:7	greater	JJR	O	O
detail	XALKORI.xml:S1:84:6	detail	NN	O	O
in	XALKORI.xml:S1:91:2	in	IN	O	O
other	XALKORI.xml:S1:94:5	other	JJ	O	O
sections	XALKORI.xml:S1:100:8	section	NNS	O	O
of	XALKORI.xml:S1:109:2	of	IN	O	O
the	XALKORI.xml:S1:112:3	the	DT	O	O
labeling	XALKORI.xml:S1:116:8	label	NN	O	O
:	XALKORI.xml:S1:124:1	:	:	O	O

Hepatotoxicity	XALKORI.xml:S1:133:14	hepatotox	NNP	B-AdverseReaction	B-AdverseReaction
[	XALKORI.xml:S1:148:1	[	NNP	O	O
see	XALKORI.xml:S1:149:3	see	VBP	O	O
Warnings	XALKORI.xml:S1:154:8	warn	NNP	O	O
and	XALKORI.xml:S1:163:3	and	CC	O	O
Precautions	XALKORI.xml:S1:167:11	precaut	NNP	O	O
(	XALKORI.xml:S1:179:1	(	(	O	O
5.1	XALKORI.xml:S1:180:3	5.1	CD	O	O
)	XALKORI.xml:S1:183:1	)	)	O	O
]	XALKORI.xml:S1:186:1	]	NN	O	O

Interstitial	XALKORI.xml:S1:194:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
Lung	XALKORI.xml:S1:207:4	lung	NNP	I-AdverseReaction	I-AdverseReaction
Disease	XALKORI.xml:S1:212:7	diseas	NNP	I-AdverseReaction	I-AdverseReaction
Pneumonitis	XALKORI.xml:S1:220:11	pneumon	NNP	B-AdverseReaction	I-AdverseReaction
[	XALKORI.xml:S1:232:1	[	NNP	O	O
see	XALKORI.xml:S1:233:3	see	VBP	O	O
Warnings	XALKORI.xml:S1:238:8	warn	NNP	O	O
and	XALKORI.xml:S1:247:3	and	CC	O	O
Precautions	XALKORI.xml:S1:251:11	precaut	NNP	O	O
(	XALKORI.xml:S1:263:1	(	(	O	O
5.2	XALKORI.xml:S1:264:3	5.2	CD	O	O
)	XALKORI.xml:S1:267:1	)	)	O	O
]	XALKORI.xml:S1:270:1	]	NN	O	O

QT	XALKORI.xml:S1:278:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
Interval	XALKORI.xml:S1:281:8	interv	NNP	I-AdverseReaction	I-AdverseReaction
Prolongation	XALKORI.xml:S1:290:12	prolong	NNP	I-AdverseReaction	I-AdverseReaction
[	XALKORI.xml:S1:303:1	[	NNP	O	O
see	XALKORI.xml:S1:304:3	see	VBP	O	O
Warnings	XALKORI.xml:S1:309:8	warn	NNP	O	O
and	XALKORI.xml:S1:318:3	and	CC	O	O
Precautions	XALKORI.xml:S1:322:11	precaut	NNP	O	O
(	XALKORI.xml:S1:334:1	(	(	O	O
5.3	XALKORI.xml:S1:335:3	5.3	CD	O	O
)	XALKORI.xml:S1:338:1	)	)	O	O
]	XALKORI.xml:S1:341:1	]	NN	O	O

Bradycardia	XALKORI.xml:S1:349:11	bradycardia	NNP	B-AdverseReaction	B-AdverseReaction
[	XALKORI.xml:S1:361:1	[	NNP	O	O
see	XALKORI.xml:S1:362:3	see	VBP	O	O
Warnings	XALKORI.xml:S1:367:8	warn	NNP	O	O
and	XALKORI.xml:S1:376:3	and	CC	O	O
Precautions	XALKORI.xml:S1:380:11	precaut	NNP	O	O
(	XALKORI.xml:S1:392:1	(	(	O	O
5.4	XALKORI.xml:S1:393:3	5.4	CD	O	O
)	XALKORI.xml:S1:396:1	)	)	O	O
]	XALKORI.xml:S1:399:1	]	NN	O	O

Severe	XALKORI.xml:S1:407:6	sever	JJ	O	O
Visual	XALKORI.xml:S1:414:6	visual	NNP	B-AdverseReaction	O
Loss	XALKORI.xml:S1:421:4	loss	NNP	I-AdverseReaction	O
[	XALKORI.xml:S1:426:1	[	NNP	O	O
see	XALKORI.xml:S1:427:3	see	VBP	O	O
Warnings	XALKORI.xml:S1:432:8	warn	NNP	O	O
and	XALKORI.xml:S1:441:3	and	CC	O	O
Precautions	XALKORI.xml:S1:445:11	precaut	NNP	O	O
(	XALKORI.xml:S1:457:1	(	(	O	O
5.5	XALKORI.xml:S1:458:3	5.5	CD	O	O
)	XALKORI.xml:S1:461:1	)	)	O	O
]	XALKORI.xml:S1:464:1	]	NN	O	O

EXCERPT	XALKORI.xml:S1:474:7	excerpt	NN	O	O
:	XALKORI.xml:S1:481:1	:	:	O	O
The	XALKORI.xml:S1:485:3	the	DT	O	O
most	XALKORI.xml:S1:489:4	most	RBS	O	O
common	XALKORI.xml:S1:494:6	common	JJ	O	O
adverse	XALKORI.xml:S1:501:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:509:9	reaction	NNS	O	O
(	XALKORI.xml:S1:519:1	(	(	O	O
25%	XALKORI.xml:S1:522:3	25%	CD	O	O
)	XALKORI.xml:S1:525:1	)	)	O	O
are	XALKORI.xml:S1:527:3	are	VBP	O	O
vision	XALKORI.xml:S1:531:6	vision	NN	B-AdverseReaction	O
disorders	XALKORI.xml:S1:538:9	disord	NNS	I-AdverseReaction	O
,	XALKORI.xml:S1:547:1	,	,	O	O
diarrhea	XALKORI.xml:S1:549:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:557:1	,	,	O	O
nausea	XALKORI.xml:S1:559:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:565:1	,	,	O	O
vomiting	XALKORI.xml:S1:567:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:575:1	,	,	O	O
constipation	XALKORI.xml:S1:577:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:589:1	,	,	O	O
edema	XALKORI.xml:S1:591:5	edema	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:596:1	,	,	O	O
elevated	XALKORI.xml:S1:598:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
transaminases	XALKORI.xml:S1:607:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:620:1	,	,	O	O
upper	XALKORI.xml:S1:622:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XALKORI.xml:S1:628:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
infection	XALKORI.xml:S1:640:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:649:1	,	,	O	O
decreased	XALKORI.xml:S1:651:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	XALKORI.xml:S1:661:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:669:1	,	,	O	O
and	XALKORI.xml:S1:671:3	and	CC	O	O
dysgeusia	XALKORI.xml:S1:675:9	dysgeusia	NN	B-AdverseReaction	B-AdverseReaction
.	XALKORI.xml:S1:684:1	.	.	O	O

(	XALKORI.xml:S1:686:1	(	(	O	O
6	XALKORI.xml:S1:689:1	6	CD	O	O
)	XALKORI.xml:S1:692:1	)	)	O	O

To	XALKORI.xml:S1:700:2	To	TO	O	O

report	XALKORI.xml:S1:703:6	report	NN	O	O
SUSPECTED	XALKORI.xml:S1:710:9	suspect	NNP	O	O
ADVERSE	XALKORI.xml:S1:720:7	advers	NNP	O	O
REACTIONS	XALKORI.xml:S1:728:9	reaction	NNP	O	O
,	XALKORI.xml:S1:737:1	,	,	O	O
contact	XALKORI.xml:S1:739:7	contact	NN	O	O
Pfizer	XALKORI.xml:S1:747:6	pfizer	NNP	O	O
Inc	XALKORI.xml:S1:754:3	inc	NNP	O	O
.	XALKORI.xml:S1:757:1	.	.	O	O

at	XALKORI.xml:S1:759:2	at	IN	O	O
1	XALKORI.xml:S1:762:1	1	CD	O	O
-	XALKORI.xml:S1:763:1	-	:	O	O
800	XALKORI.xml:S1:764:3	800	CD	O	O
-	XALKORI.xml:S1:767:1	-	:	O	O
438	XALKORI.xml:S1:768:3	438	CD	O	O
-	XALKORI.xml:S1:771:1	-	:	O	O
1985	XALKORI.xml:S1:772:4	1985	CD	O	O
or	XALKORI.xml:S1:777:2	or	CC	O	O
FDA	XALKORI.xml:S1:780:3	fda	NNP	O	O
at	XALKORI.xml:S1:784:2	at	IN	O	O
1	XALKORI.xml:S1:787:1	1	CD	O	O
-	XALKORI.xml:S1:788:1	-	:	O	O
800	XALKORI.xml:S1:789:3	800	CD	O	O
-	XALKORI.xml:S1:792:1	-	:	O	O
FDA	XALKORI.xml:S1:793:3	fda	NNP	O	O
-	XALKORI.xml:S1:796:1	-	:	O	O
1088	XALKORI.xml:S1:797:4	1088	CD	O	O
or	XALKORI.xml:S1:802:2	or	CC	O	O
www	XALKORI.xml:S1:806:3	www	VB	O	O
.	XALKORI.xml:S1:809:1	.	.	O	O
fda	XALKORI.xml:S1:810:3	fda	NN	O	O
.	XALKORI.xml:S1:813:1	.	.	O	O
gov	XALKORI.xml:S1:814:3	gov	JJ	O	O
medwatch	XALKORI.xml:S1:818:8	medwatch	NN	O	O
.	XALKORI.xml:S1:828:1	.	.	O	O

6.1	XALKORI.xml:S1:840:3	6.1	CD	O	O

Clinical	XALKORI.xml:S1:844:8	clinic	JJ	O	O
Trials	XALKORI.xml:S1:853:6	trial	NNS	O	O
Experience	XALKORI.xml:S1:860:10	experi	NN	O	O

Because	XALKORI.xml:S1:874:7	becaus	IN	O	O
clinical	XALKORI.xml:S1:882:8	clinic	JJ	O	O
trials	XALKORI.xml:S1:891:6	trial	NNS	O	O
are	XALKORI.xml:S1:898:3	are	VBP	O	O
conducted	XALKORI.xml:S1:902:9	conduct	VBN	O	O
under	XALKORI.xml:S1:912:5	under	IN	O	O
widely	XALKORI.xml:S1:918:6	wide	RB	O	O
varying	XALKORI.xml:S1:925:7	vari	VBG	O	O
conditions	XALKORI.xml:S1:933:10	condit	NNS	O	O
,	XALKORI.xml:S1:943:1	,	,	O	O
adverse	XALKORI.xml:S1:945:7	advers	JJ	O	O
reaction	XALKORI.xml:S1:953:8	reaction	NN	O	O
rates	XALKORI.xml:S1:962:5	rate	NNS	O	O
observed	XALKORI.xml:S1:968:8	observ	VBD	O	O
in	XALKORI.xml:S1:977:2	in	IN	O	O
the	XALKORI.xml:S1:980:3	the	DT	O	O
clinical	XALKORI.xml:S1:984:8	clinic	JJ	O	O
trials	XALKORI.xml:S1:993:6	trial	NNS	O	O
of	XALKORI.xml:S1:1000:2	of	IN	O	O
a	XALKORI.xml:S1:1003:1	a	DT	O	O
drug	XALKORI.xml:S1:1005:4	drug	NN	O	O
cannot	XALKORI.xml:S1:1010:6	cannot	NN	O	O
be	XALKORI.xml:S1:1017:2	be	VB	O	O
directly	XALKORI.xml:S1:1020:8	directli	RB	O	O
compared	XALKORI.xml:S1:1029:8	compar	VBN	O	O
to	XALKORI.xml:S1:1038:2	to	TO	O	O
rates	XALKORI.xml:S1:1041:5	rate	NNS	O	O
in	XALKORI.xml:S1:1047:2	in	IN	O	O
the	XALKORI.xml:S1:1050:3	the	DT	O	O
clinical	XALKORI.xml:S1:1054:8	clinic	JJ	O	O
trials	XALKORI.xml:S1:1063:6	trial	NNS	O	O
of	XALKORI.xml:S1:1070:2	of	IN	O	O
another	XALKORI.xml:S1:1073:7	anoth	DT	O	O
drug	XALKORI.xml:S1:1081:4	drug	NN	O	O
and	XALKORI.xml:S1:1086:3	and	CC	O	O
may	XALKORI.xml:S1:1090:3	may	MD	O	O
not	XALKORI.xml:S1:1094:3	not	RB	O	O
reflect	XALKORI.xml:S1:1098:7	reflect	VB	O	O
the	XALKORI.xml:S1:1106:3	the	DT	O	O
rates	XALKORI.xml:S1:1110:5	rate	NNS	O	O
observed	XALKORI.xml:S1:1116:8	observ	VBD	O	O
in	XALKORI.xml:S1:1125:2	in	IN	O	O
clinical	XALKORI.xml:S1:1128:8	clinic	JJ	O	O
practice	XALKORI.xml:S1:1137:8	practic	NN	O	O
.	XALKORI.xml:S1:1145:1	.	.	O	O

The	XALKORI.xml:S1:1151:3	the	DT	O	O
safety	XALKORI.xml:S1:1155:6	safeti	NN	O	O
of	XALKORI.xml:S1:1162:2	of	IN	O	O
XALKORI	XALKORI.xml:S1:1165:7	xalkori	NNP	O	O
is	XALKORI.xml:S1:1173:2	is	VBZ	O	O
based	XALKORI.xml:S1:1176:5	base	VBN	O	O
primarily	XALKORI.xml:S1:1182:9	primarili	RB	O	O
on	XALKORI.xml:S1:1192:2	on	IN	O	O
343	XALKORI.xml:S1:1195:3	343	CD	O	O
patients	XALKORI.xml:S1:1199:8	patient	NNS	O	O
with	XALKORI.xml:S1:1208:4	with	IN	O	O
ALK	XALKORI.xml:S1:1213:3	alk	NNP	O	O
-	XALKORI.xml:S1:1216:1	-	:	O	O
positive	XALKORI.xml:S1:1217:8	posit	JJ	O	O
metastatic	XALKORI.xml:S1:1226:10	metastat	JJ	O	O
NSCLC	XALKORI.xml:S1:1237:5	nsclc	NNP	O	O
who	XALKORI.xml:S1:1243:3	who	WP	O	O
received	XALKORI.xml:S1:1247:8	receiv	VBD	O	O
XALKORI	XALKORI.xml:S1:1256:7	xalkori	NNP	O	O
250	XALKORI.xml:S1:1264:3	250	CD	O	O
mg	XALKORI.xml:S1:1268:2	mg	NN	O	O
twice	XALKORI.xml:S1:1271:5	twice	RB	O	O
daily	XALKORI.xml:S1:1277:5	daili	RB	O	O
in	XALKORI.xml:S1:1283:2	in	IN	O	O
two	XALKORI.xml:S1:1286:3	two	CD	O	O
open	XALKORI.xml:S1:1290:4	open	JJ	O	O
-	XALKORI.xml:S1:1294:1	-	:	O	O
label	XALKORI.xml:S1:1295:5	label	NN	O	O
,	XALKORI.xml:S1:1300:1	,	,	O	O
randomized	XALKORI.xml:S1:1302:10	random	VBN	O	O
,	XALKORI.xml:S1:1312:1	,	,	O	O
active	XALKORI.xml:S1:1314:6	activ	JJ	O	O
-	XALKORI.xml:S1:1320:1	-	:	O	O
controlled	XALKORI.xml:S1:1321:10	control	VBN	O	O
trials	XALKORI.xml:S1:1332:6	trial	NNS	O	O
(	XALKORI.xml:S1:1339:1	(	(	O	O
Studies	XALKORI.xml:S1:1340:7	studi	NNPS	O	O
1	XALKORI.xml:S1:1348:1	1	CD	O	O
and	XALKORI.xml:S1:1350:3	and	CC	O	O
2	XALKORI.xml:S1:1354:1	2	CD	O	O
)	XALKORI.xml:S1:1355:1	)	)	O	O
.	XALKORI.xml:S1:1356:1	.	.	O	O

This	XALKORI.xml:S1:1358:4	thi	DT	O	O
is	XALKORI.xml:S1:1363:2	is	VBZ	O	O
supplemented	XALKORI.xml:S1:1366:12	supplement	VBN	O	O
with	XALKORI.xml:S1:1379:4	with	IN	O	O
information	XALKORI.xml:S1:1384:11	inform	NN	O	O
on	XALKORI.xml:S1:1396:2	on	IN	O	O
adverse	XALKORI.xml:S1:1399:7	advers	JJ	O	O
drug	XALKORI.xml:S1:1407:4	drug	NN	O	O
reactions	XALKORI.xml:S1:1412:9	reaction	NNS	O	O
in	XALKORI.xml:S1:1422:2	in	IN	O	O
1326	XALKORI.xml:S1:1425:4	1326	CD	O	O
patients	XALKORI.xml:S1:1430:8	patient	NNS	O	O
with	XALKORI.xml:S1:1439:4	with	IN	O	O
ALK	XALKORI.xml:S1:1444:3	alk	NNP	O	O
-	XALKORI.xml:S1:1447:1	-	:	O	O
positive	XALKORI.xml:S1:1448:8	posit	JJ	O	O
metastatic	XALKORI.xml:S1:1457:10	metastat	JJ	O	O
NSCLC	XALKORI.xml:S1:1468:5	nsclc	NNP	O	O
who	XALKORI.xml:S1:1474:3	who	WP	O	O
received	XALKORI.xml:S1:1478:8	receiv	VBD	O	O
XALKORI	XALKORI.xml:S1:1487:7	xalkori	NNP	O	O
250	XALKORI.xml:S1:1495:3	250	CD	O	O
mg	XALKORI.xml:S1:1499:2	mg	NN	O	O
twice	XALKORI.xml:S1:1502:5	twice	RB	O	O
daily	XALKORI.xml:S1:1508:5	daili	RB	O	O
across	XALKORI.xml:S1:1514:6	across	IN	O	O
clinical	XALKORI.xml:S1:1521:8	clinic	JJ	O	O
trials	XALKORI.xml:S1:1530:6	trial	NNS	O	O
,	XALKORI.xml:S1:1536:1	,	,	O	O
for	XALKORI.xml:S1:1538:3	for	IN	O	O
a	XALKORI.xml:S1:1542:1	a	DT	O	O
total	XALKORI.xml:S1:1544:5	total	NN	O	O
of	XALKORI.xml:S1:1550:2	of	IN	O	O
1669	XALKORI.xml:S1:1553:4	1669	CD	O	O
patients	XALKORI.xml:S1:1558:8	patient	NNS	O	O
across	XALKORI.xml:S1:1567:6	across	IN	O	O
all	XALKORI.xml:S1:1574:3	all	DT	O	O
clinical	XALKORI.xml:S1:1578:8	clinic	JJ	O	O
studies	XALKORI.xml:S1:1587:7	studi	NNS	O	O
.	XALKORI.xml:S1:1594:1	.	.	O	O

The	XALKORI.xml:S1:1600:3	the	DT	O	O
most	XALKORI.xml:S1:1604:4	most	RBS	O	O
common	XALKORI.xml:S1:1609:6	common	JJ	O	O
adverse	XALKORI.xml:S1:1616:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:1624:9	reaction	NNS	O	O
(	XALKORI.xml:S1:1634:1	(	(	O	O
25%	XALKORI.xml:S1:1637:3	25%	CD	O	O
)	XALKORI.xml:S1:1640:1	)	)	O	O
of	XALKORI.xml:S1:1642:2	of	IN	O	O
XALKORI	XALKORI.xml:S1:1645:7	xalkori	NN	O	O
in	XALKORI.xml:S1:1653:2	in	IN	O	O
Studies	XALKORI.xml:S1:1656:7	studi	NNP	O	O
1	XALKORI.xml:S1:1664:1	1	CD	O	O
and	XALKORI.xml:S1:1666:3	and	CC	O	O
2	XALKORI.xml:S1:1670:1	2	CD	O	O
are	XALKORI.xml:S1:1672:3	are	VBP	O	O
vision	XALKORI.xml:S1:1676:6	vision	NN	B-AdverseReaction	O
disorders	XALKORI.xml:S1:1683:9	disord	NNS	I-AdverseReaction	O
,	XALKORI.xml:S1:1692:1	,	,	O	O
diarrhea	XALKORI.xml:S1:1694:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:1702:1	,	,	O	O
nausea	XALKORI.xml:S1:1704:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:1710:1	,	,	O	O
vomiting	XALKORI.xml:S1:1712:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:1720:1	,	,	O	O
constipation	XALKORI.xml:S1:1722:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:1734:1	,	,	O	O
edema	XALKORI.xml:S1:1736:5	edema	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:1741:1	,	,	O	O
elevated	XALKORI.xml:S1:1743:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
transaminases	XALKORI.xml:S1:1752:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:1765:1	,	,	O	O
upper	XALKORI.xml:S1:1767:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XALKORI.xml:S1:1773:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
infection	XALKORI.xml:S1:1785:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:1794:1	,	,	O	O
decreased	XALKORI.xml:S1:1796:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	XALKORI.xml:S1:1806:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:1814:1	,	,	O	O
and	XALKORI.xml:S1:1816:3	and	CC	O	O
dysgeusia	XALKORI.xml:S1:1820:9	dysgeusia	NN	B-AdverseReaction	B-AdverseReaction
.	XALKORI.xml:S1:1829:1	.	.	O	O

Previously	XALKORI.xml:S1:1839:10	previous	RB	O	O
Untreated	XALKORI.xml:S1:1850:9	untreat	VBN	O	O
ALK	XALKORI.xml:S1:1860:3	alk	NNP	O	O
-	XALKORI.xml:S1:1863:1	-	:	O	O
Positive	XALKORI.xml:S1:1864:8	posit	JJ	O	O
Metastatic	XALKORI.xml:S1:1873:10	metastat	NNP	O	O
NSCLC	XALKORI.xml:S1:1884:5	nsclc	NNP	O	O
-	XALKORI.xml:S1:1890:1	-	:	O	O
Study	XALKORI.xml:S1:1892:5	studi	NN	O	O
1	XALKORI.xml:S1:1898:1	1	CD	O	O

The	XALKORI.xml:S1:1906:3	the	DT	O	O
data	XALKORI.xml:S1:1910:4	data	NN	O	O
in	XALKORI.xml:S1:1915:2	in	IN	O	O
Table	XALKORI.xml:S1:1918:5	tabl	JJ	O	O
3	XALKORI.xml:S1:1924:1	3	CD	O	O
are	XALKORI.xml:S1:1926:3	are	VBP	O	O
derived	XALKORI.xml:S1:1930:7	deriv	VBN	O	O
from	XALKORI.xml:S1:1938:4	from	IN	O	O
340	XALKORI.xml:S1:1943:3	340	CD	O	O
patients	XALKORI.xml:S1:1947:8	patient	NNS	O	O
with	XALKORI.xml:S1:1956:4	with	IN	O	O
ALK	XALKORI.xml:S1:1961:3	alk	NNP	O	O
-	XALKORI.xml:S1:1964:1	-	:	O	O
positive	XALKORI.xml:S1:1965:8	posit	JJ	O	O
metastatic	XALKORI.xml:S1:1974:10	metastat	JJ	O	O
NSCLC	XALKORI.xml:S1:1985:5	nsclc	NNP	O	O
who	XALKORI.xml:S1:1991:3	who	WP	O	O
had	XALKORI.xml:S1:1995:3	had	VBD	O	O
not	XALKORI.xml:S1:1999:3	not	RB	O	O
received	XALKORI.xml:S1:2003:8	receiv	VBN	O	O
previous	XALKORI.xml:S1:2012:8	previou	JJ	O	O
systemic	XALKORI.xml:S1:2021:8	system	JJ	O	O
treatment	XALKORI.xml:S1:2030:9	treatment	NN	O	O
for	XALKORI.xml:S1:2040:3	for	IN	O	O
advanced	XALKORI.xml:S1:2044:8	advanc	JJ	O	O
disease	XALKORI.xml:S1:2053:7	diseas	NN	O	O
who	XALKORI.xml:S1:2061:3	who	WP	O	O
received	XALKORI.xml:S1:2065:8	receiv	VBD	O	O
treatment	XALKORI.xml:S1:2074:9	treatment	NN	O	O
in	XALKORI.xml:S1:2084:2	in	IN	O	O
a	XALKORI.xml:S1:2087:1	a	DT	O	O
randomized	XALKORI.xml:S1:2089:10	random	JJ	O	O
,	XALKORI.xml:S1:2099:1	,	,	O	O
multicenter	XALKORI.xml:S1:2101:11	multicent	NN	O	O
,	XALKORI.xml:S1:2112:1	,	,	O	O
open	XALKORI.xml:S1:2114:4	open	JJ	O	O
-	XALKORI.xml:S1:2118:1	-	:	O	O
label	XALKORI.xml:S1:2119:5	label	NN	O	O
,	XALKORI.xml:S1:2124:1	,	,	O	O
active	XALKORI.xml:S1:2126:6	activ	JJ	O	O
-	XALKORI.xml:S1:2132:1	-	:	O	O
controlled	XALKORI.xml:S1:2133:10	control	VBN	O	O
trial	XALKORI.xml:S1:2144:5	trial	NN	O	O
(	XALKORI.xml:S1:2150:1	(	(	O	O
Study	XALKORI.xml:S1:2151:5	studi	NNP	O	O
1	XALKORI.xml:S1:2157:1	1	CD	O	O
)	XALKORI.xml:S1:2158:1	)	)	O	O
.	XALKORI.xml:S1:2159:1	.	.	O	O

Patients	XALKORI.xml:S1:2161:8	patient	NNS	O	O
in	XALKORI.xml:S1:2170:2	in	IN	O	O
the	XALKORI.xml:S1:2173:3	the	DT	O	O
XALKORI	XALKORI.xml:S1:2177:7	xalkori	NNP	O	O
arm	XALKORI.xml:S1:2185:3	arm	NN	O	O
(	XALKORI.xml:S1:2189:1	(	(	O	O
n	XALKORI.xml:S1:2190:1	n	JJ	O	O
171	XALKORI.xml:S1:2192:3	171	CD	O	O
)	XALKORI.xml:S1:2195:1	)	)	O	O
received	XALKORI.xml:S1:2197:8	receiv	VBD	O	O
XALKORI	XALKORI.xml:S1:2206:7	xalkori	$	O	O
250	XALKORI.xml:S1:2214:3	250	CD	O	O
mg	XALKORI.xml:S1:2218:2	mg	NN	O	O
orally	XALKORI.xml:S1:2221:6	oral	RB	O	O
twice	XALKORI.xml:S1:2228:5	twice	JJ	O	O
daily	XALKORI.xml:S1:2234:5	daili	RB	O	O
until	XALKORI.xml:S1:2240:5	until	IN	O	O
documented	XALKORI.xml:S1:2246:10	document	JJ	O	O
disease	XALKORI.xml:S1:2257:7	diseas	NN	O	O
progression	XALKORI.xml:S1:2265:11	progress	NN	O	O
,	XALKORI.xml:S1:2276:1	,	,	O	O
intolerance	XALKORI.xml:S1:2278:11	intoler	NN	O	O
to	XALKORI.xml:S1:2290:2	to	TO	O	O
therapy	XALKORI.xml:S1:2293:7	therapi	VB	O	O
,	XALKORI.xml:S1:2300:1	,	,	O	O
or	XALKORI.xml:S1:2302:2	or	CC	O	O
the	XALKORI.xml:S1:2305:3	the	DT	O	O
investigator	XALKORI.xml:S1:2309:12	investig	NN	O	O
determined	XALKORI.xml:S1:2322:10	determin	VBD	O	O
that	XALKORI.xml:S1:2333:4	that	IN	O	O
the	XALKORI.xml:S1:2338:3	the	DT	O	O
patient	XALKORI.xml:S1:2342:7	patient	NN	O	O
was	XALKORI.xml:S1:2350:3	wa	VBD	O	O
no	XALKORI.xml:S1:2354:2	no	RB	O	O
longer	XALKORI.xml:S1:2357:6	longer	JJR	O	O
experiencing	XALKORI.xml:S1:2364:12	experienc	VBG	O	O
clinical	XALKORI.xml:S1:2377:8	clinic	JJ	O	O
benefit	XALKORI.xml:S1:2386:7	benefit	NN	O	O
.	XALKORI.xml:S1:2393:1	.	.	O	O

A	XALKORI.xml:S1:2395:1	A	DT	O	O
total	XALKORI.xml:S1:2397:5	total	NN	O	O
of	XALKORI.xml:S1:2403:2	of	IN	O	O
169	XALKORI.xml:S1:2406:3	169	CD	O	O
patients	XALKORI.xml:S1:2410:8	patient	NNS	O	O
in	XALKORI.xml:S1:2419:2	in	IN	O	O
the	XALKORI.xml:S1:2422:3	the	DT	O	O
chemotherapy	XALKORI.xml:S1:2426:12	chemotherapi	NN	O	O
arm	XALKORI.xml:S1:2439:3	arm	NN	O	O
received	XALKORI.xml:S1:2443:8	receiv	VBD	O	O
pemetrexed	XALKORI.xml:S1:2452:10	pemetrex	JJ	O	O
500	XALKORI.xml:S1:2463:3	500	CD	O	O
mg	XALKORI.xml:S1:2467:2	mg	NN	O	O
m	XALKORI.xml:S1:2470:1	m	NN	O	O
2	XALKORI.xml:S1:2473:1	2	CD	O	O
in	XALKORI.xml:S1:2476:2	in	IN	O	O
combination	XALKORI.xml:S1:2479:11	combin	NN	O	O
with	XALKORI.xml:S1:2491:4	with	IN	O	O
cisplatin	XALKORI.xml:S1:2496:9	cisplatin	JJ	O	O
75	XALKORI.xml:S1:2506:2	75	CD	O	O
mg	XALKORI.xml:S1:2509:2	mg	NN	O	O
m	XALKORI.xml:S1:2512:1	m	NN	O	O
2	XALKORI.xml:S1:2515:1	2	CD	O	O
(	XALKORI.xml:S1:2518:1	(	(	O	O
n	XALKORI.xml:S1:2519:1	n	JJ	O	O
91	XALKORI.xml:S1:2521:2	91	CD	O	O
)	XALKORI.xml:S1:2523:1	)	)	O	O
or	XALKORI.xml:S1:2525:2	or	CC	O	O
carboplatin	XALKORI.xml:S1:2528:11	carboplatin	NN	O	O
at	XALKORI.xml:S1:2540:2	at	IN	O	O
a	XALKORI.xml:S1:2543:1	a	DT	O	O
dose	XALKORI.xml:S1:2545:4	dose	NN	O	O
calculated	XALKORI.xml:S1:2550:10	calcul	VBN	O	O
to	XALKORI.xml:S1:2561:2	to	TO	O	O
produce	XALKORI.xml:S1:2564:7	produc	VB	O	O
an	XALKORI.xml:S1:2572:2	an	DT	O	O
area	XALKORI.xml:S1:2575:4	area	NN	O	O
under	XALKORI.xml:S1:2580:5	under	IN	O	O
the	XALKORI.xml:S1:2586:3	the	DT	O	O
concentration	XALKORI.xml:S1:2590:13	concentr	NN	O	O
-	XALKORI.xml:S1:2603:1	-	:	O	O
time	XALKORI.xml:S1:2604:4	time	NN	O	O
curve	XALKORI.xml:S1:2609:5	curv	NN	O	O
(	XALKORI.xml:S1:2615:1	(	(	O	O
AUC	XALKORI.xml:S1:2616:3	auc	NNP	O	O
)	XALKORI.xml:S1:2619:1	)	)	O	O
of	XALKORI.xml:S1:2621:2	of	IN	O	O
5	XALKORI.xml:S1:2624:1	5	CD	O	O
or	XALKORI.xml:S1:2626:2	or	CC	O	O
6	XALKORI.xml:S1:2629:1	6	CD	O	O
mg	XALKORI.xml:S1:2631:2	mg	NNS	O	O
?	XALKORI.xml:S1:2633:1	?	.	O	O
min	XALKORI.xml:S1:2634:3	min	NN	O	O
mL	XALKORI.xml:S1:2638:2	mL	NN	O	O
(	XALKORI.xml:S1:2641:1	(	(	O	O
n	XALKORI.xml:S1:2642:1	n	JJ	O	O
78	XALKORI.xml:S1:2644:2	78	CD	O	O
)	XALKORI.xml:S1:2646:1	)	)	O	O
.	XALKORI.xml:S1:2647:1	.	.	O	O

Chemotherapy	XALKORI.xml:S1:2649:12	chemotherapi	NNP	O	O
was	XALKORI.xml:S1:2662:3	wa	VBD	O	O
given	XALKORI.xml:S1:2666:5	given	VBN	O	O
by	XALKORI.xml:S1:2672:2	by	IN	O	O
intravenous	XALKORI.xml:S1:2675:11	intraven	JJ	O	O
infusion	XALKORI.xml:S1:2687:8	infus	NN	O	O
every	XALKORI.xml:S1:2696:5	everi	DT	O	O
3	XALKORI.xml:S1:2702:1	3	CD	O	O
weeks	XALKORI.xml:S1:2704:5	week	NNS	O	O
for	XALKORI.xml:S1:2710:3	for	IN	O	O
up	XALKORI.xml:S1:2714:2	up	IN	O	O
to	XALKORI.xml:S1:2717:2	to	TO	O	O
6	XALKORI.xml:S1:2720:1	6	CD	O	O
cycles	XALKORI.xml:S1:2722:6	cycl	NNS	O	O
,	XALKORI.xml:S1:2728:1	,	,	O	O
in	XALKORI.xml:S1:2730:2	in	IN	O	O
the	XALKORI.xml:S1:2733:3	the	DT	O	O
absence	XALKORI.xml:S1:2737:7	absenc	NN	O	O
of	XALKORI.xml:S1:2745:2	of	IN	O	O
dose	XALKORI.xml:S1:2748:4	dose	JJ	O	O
-	XALKORI.xml:S1:2752:1	-	:	O	O
limiting	XALKORI.xml:S1:2753:8	limit	VBG	O	O
chemotherapy	XALKORI.xml:S1:2762:12	chemotherapi	NN	O	O
-	XALKORI.xml:S1:2774:1	-	:	O	O
related	XALKORI.xml:S1:2775:7	relat	JJ	O	O
toxicities	XALKORI.xml:S1:2783:10	toxic	NNS	O	O
.	XALKORI.xml:S1:2793:1	.	.	O	O

After	XALKORI.xml:S1:2795:5	after	IN	O	O
6	XALKORI.xml:S1:2801:1	6	CD	O	O
cycles	XALKORI.xml:S1:2803:6	cycl	NNS	O	O
,	XALKORI.xml:S1:2809:1	,	,	O	O
patients	XALKORI.xml:S1:2811:8	patient	NNS	O	O
remained	XALKORI.xml:S1:2820:8	remain	VBD	O	O
on	XALKORI.xml:S1:2829:2	on	IN	O	O
study	XALKORI.xml:S1:2832:5	studi	NN	O	O
with	XALKORI.xml:S1:2838:4	with	IN	O	O
no	XALKORI.xml:S1:2843:2	no	DT	O	O
additional	XALKORI.xml:S1:2846:10	addit	JJ	O	O
anticancer	XALKORI.xml:S1:2857:10	anticanc	NN	O	O
treatment	XALKORI.xml:S1:2868:9	treatment	NN	O	O
,	XALKORI.xml:S1:2877:1	,	,	O	O
and	XALKORI.xml:S1:2879:3	and	CC	O	O
tumor	XALKORI.xml:S1:2883:5	tumor	NN	O	O
assessments	XALKORI.xml:S1:2889:11	assess	NNS	O	O
continued	XALKORI.xml:S1:2901:9	continu	VBD	O	O
until	XALKORI.xml:S1:2911:5	until	IN	O	O
documented	XALKORI.xml:S1:2917:10	document	JJ	O	O
disease	XALKORI.xml:S1:2928:7	diseas	NN	O	O
progression	XALKORI.xml:S1:2936:11	progress	NN	O	O
.	XALKORI.xml:S1:2947:1	.	.	O	O

The	XALKORI.xml:S1:2953:3	the	DT	O	O
median	XALKORI.xml:S1:2957:6	median	JJ	O	O
duration	XALKORI.xml:S1:2964:8	durat	NN	O	O
of	XALKORI.xml:S1:2973:2	of	IN	O	O
study	XALKORI.xml:S1:2976:5	studi	NN	O	O
treatment	XALKORI.xml:S1:2982:9	treatment	NN	O	O
was	XALKORI.xml:S1:2992:3	wa	VBD	O	O
10.9	XALKORI.xml:S1:2996:4	10.9	CD	O	O
months	XALKORI.xml:S1:3001:6	month	NNS	O	O
for	XALKORI.xml:S1:3008:3	for	IN	O	O
patients	XALKORI.xml:S1:3012:8	patient	NNS	O	O
in	XALKORI.xml:S1:3021:2	in	IN	O	O
the	XALKORI.xml:S1:3024:3	the	DT	O	O
XALKORI	XALKORI.xml:S1:3028:7	xalkori	NNP	O	O
arm	XALKORI.xml:S1:3036:3	arm	NN	O	O
and	XALKORI.xml:S1:3040:3	and	CC	O	O
4.1	XALKORI.xml:S1:3044:3	4.1	CD	O	O
months	XALKORI.xml:S1:3048:6	month	NNS	O	O
for	XALKORI.xml:S1:3055:3	for	IN	O	O
patients	XALKORI.xml:S1:3059:8	patient	NNS	O	O
in	XALKORI.xml:S1:3068:2	in	IN	O	O
the	XALKORI.xml:S1:3071:3	the	DT	O	O
chemotherapy	XALKORI.xml:S1:3075:12	chemotherapi	NN	O	O
arm	XALKORI.xml:S1:3088:3	arm	NN	O	O
.	XALKORI.xml:S1:3091:1	.	.	O	O

Median	XALKORI.xml:S1:3093:6	median	JJ	O	O
duration	XALKORI.xml:S1:3100:8	durat	NN	O	O
of	XALKORI.xml:S1:3109:2	of	IN	O	O
treatment	XALKORI.xml:S1:3112:9	treatment	NN	O	O
was	XALKORI.xml:S1:3122:3	wa	VBD	O	O
5.2	XALKORI.xml:S1:3126:3	5.2	CD	O	O
months	XALKORI.xml:S1:3130:6	month	NNS	O	O
for	XALKORI.xml:S1:3137:3	for	IN	O	O
patients	XALKORI.xml:S1:3141:8	patient	NNS	O	O
who	XALKORI.xml:S1:3150:3	who	WP	O	O
received	XALKORI.xml:S1:3154:8	receiv	VBD	O	O
XALKORI	XALKORI.xml:S1:3163:7	xalkori	NNP	O	O
after	XALKORI.xml:S1:3171:5	after	IN	O	O
cross	XALKORI.xml:S1:3177:5	cross	NN	O	O
over	XALKORI.xml:S1:3183:4	over	IN	O	O
from	XALKORI.xml:S1:3188:4	from	IN	O	O
chemotherapy	XALKORI.xml:S1:3193:12	chemotherapi	NN	O	O
.	XALKORI.xml:S1:3205:1	.	.	O	O

Across	XALKORI.xml:S1:3207:6	across	IN	O	O
the	XALKORI.xml:S1:3214:3	the	DT	O	O
340	XALKORI.xml:S1:3218:3	340	CD	O	O
patients	XALKORI.xml:S1:3222:8	patient	NNS	O	O
who	XALKORI.xml:S1:3231:3	who	WP	O	O
were	XALKORI.xml:S1:3235:4	were	VBD	O	O
treated	XALKORI.xml:S1:3240:7	treat	VBN	O	O
in	XALKORI.xml:S1:3248:2	in	IN	O	O
Study	XALKORI.xml:S1:3251:5	studi	NNP	O	O
1	XALKORI.xml:S1:3257:1	1	CD	O	O
,	XALKORI.xml:S1:3258:1	,	,	O	O
the	XALKORI.xml:S1:3260:3	the	DT	O	O
median	XALKORI.xml:S1:3264:6	median	JJ	O	O
age	XALKORI.xml:S1:3271:3	age	NN	O	O
was	XALKORI.xml:S1:3275:3	wa	VBD	O	O
53	XALKORI.xml:S1:3279:2	53	CD	O	O
years	XALKORI.xml:S1:3282:5	year	NNS	O	O
;	XALKORI.xml:S1:3287:1	;	:	O	O
16%	XALKORI.xml:S1:3289:3	16%	CD	O	O
of	XALKORI.xml:S1:3293:2	of	IN	O	O
patients	XALKORI.xml:S1:3296:8	patient	NNS	O	O
were	XALKORI.xml:S1:3305:4	were	VBD	O	O
older	XALKORI.xml:S1:3310:5	older	JJR	O	O
than	XALKORI.xml:S1:3316:4	than	IN	O	O
65	XALKORI.xml:S1:3321:2	65	CD	O	O
years	XALKORI.xml:S1:3324:5	year	NNS	O	O
.	XALKORI.xml:S1:3329:1	.	.	O	O

A	XALKORI.xml:S1:3331:1	A	DT	O	O
total	XALKORI.xml:S1:3333:5	total	NN	O	O
of	XALKORI.xml:S1:3339:2	of	IN	O	O
62%	XALKORI.xml:S1:3342:3	62%	CD	O	O
of	XALKORI.xml:S1:3346:2	of	IN	O	O
patients	XALKORI.xml:S1:3349:8	patient	NNS	O	O
were	XALKORI.xml:S1:3358:4	were	VBD	O	O
female	XALKORI.xml:S1:3363:6	femal	JJ	O	O
and	XALKORI.xml:S1:3370:3	and	CC	O	O
46%	XALKORI.xml:S1:3374:3	46%	CD	O	O
were	XALKORI.xml:S1:3378:4	were	VBD	O	O
Asian	XALKORI.xml:S1:3383:5	asian	JJ	O	O
.	XALKORI.xml:S1:3388:1	.	.	O	O

Serious	XALKORI.xml:S1:3394:7	seriou	JJ	O	O
adverse	XALKORI.xml:S1:3402:7	advers	JJ	O	O
events	XALKORI.xml:S1:3410:6	event	NNS	O	O
were	XALKORI.xml:S1:3417:4	were	VBD	O	O
reported	XALKORI.xml:S1:3422:8	report	VBN	O	O
in	XALKORI.xml:S1:3431:2	in	IN	O	O
58	XALKORI.xml:S1:3434:2	58	CD	O	O
patients	XALKORI.xml:S1:3437:8	patient	NNS	O	O
(	XALKORI.xml:S1:3446:1	(	(	O	O
34%	XALKORI.xml:S1:3447:3	34%	CD	O	O
)	XALKORI.xml:S1:3450:1	)	)	O	O
treated	XALKORI.xml:S1:3452:7	treat	VBN	O	O
with	XALKORI.xml:S1:3460:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:3465:7	xalkori	NNP	O	O
.	XALKORI.xml:S1:3472:1	.	.	O	O

The	XALKORI.xml:S1:3474:3	the	DT	O	O
most	XALKORI.xml:S1:3478:4	most	RBS	O	O
frequent	XALKORI.xml:S1:3483:8	frequent	JJ	O	O
serious	XALKORI.xml:S1:3492:7	seriou	JJ	O	O
adverse	XALKORI.xml:S1:3500:7	advers	JJ	O	O
events	XALKORI.xml:S1:3508:6	event	NNS	O	O
reported	XALKORI.xml:S1:3515:8	report	VBN	O	O
in	XALKORI.xml:S1:3524:2	in	IN	O	O
patients	XALKORI.xml:S1:3527:8	patient	NNS	O	O
treated	XALKORI.xml:S1:3536:7	treat	VBN	O	O
with	XALKORI.xml:S1:3544:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:3549:7	xalkori	NNP	O	O
were	XALKORI.xml:S1:3557:4	were	VBD	O	O
dyspnea	XALKORI.xml:S1:3562:7	dyspnea	NNS	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:3570:1	(	(	O	O
4.1%	XALKORI.xml:S1:3571:4	4.1%	CD	O	O
)	XALKORI.xml:S1:3575:1	)	)	O	O
and	XALKORI.xml:S1:3577:3	and	CC	O	O
pulmonary	XALKORI.xml:S1:3581:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
embolism	XALKORI.xml:S1:3591:8	embol	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:3600:1	(	(	O	O
2.9%	XALKORI.xml:S1:3601:4	2.9%	CD	O	O
)	XALKORI.xml:S1:3605:1	)	)	O	O
.	XALKORI.xml:S1:3606:1	.	.	O	O

Fatal	XALKORI.xml:S1:3608:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
adverse	XALKORI.xml:S1:3614:7	advers	JJ	O	O
events	XALKORI.xml:S1:3622:6	event	NNS	O	O
in	XALKORI.xml:S1:3629:2	in	IN	O	O
XALKORI	XALKORI.xml:S1:3632:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:3639:1	-	:	O	O
treated	XALKORI.xml:S1:3640:7	treat	VBD	O	O
patients	XALKORI.xml:S1:3648:8	patient	NNS	O	O
occurred	XALKORI.xml:S1:3657:8	occur	VBD	O	O
in	XALKORI.xml:S1:3666:2	in	IN	O	O
2.3%	XALKORI.xml:S1:3669:4	2.3%	CD	O	O
patients	XALKORI.xml:S1:3674:8	patient	NNS	O	O
,	XALKORI.xml:S1:3682:1	,	,	O	O
consisting	XALKORI.xml:S1:3684:10	consist	VBG	O	O
of	XALKORI.xml:S1:3695:2	of	IN	O	O
septic	XALKORI.xml:S1:3698:6	septic	JJ	B-AdverseReaction	B-AdverseReaction
shock	XALKORI.xml:S1:3705:5	shock	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:3710:1	,	,	O	O
acute	XALKORI.xml:S1:3712:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XALKORI.xml:S1:3718:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
failure	XALKORI.xml:S1:3730:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:3737:1	,	,	O	O
and	XALKORI.xml:S1:3739:3	and	CC	O	O
diabetic	XALKORI.xml:S1:3743:8	diabet	JJ	B-AdverseReaction	B-AdverseReaction
ketoacidosis	XALKORI.xml:S1:3752:12	ketoacidosi	NN	I-AdverseReaction	I-AdverseReaction
.	XALKORI.xml:S1:3764:1	.	.	O	O

Dose	XALKORI.xml:S1:3770:4	dose	NNP	O	O
reductions	XALKORI.xml:S1:3775:10	reduct	NNS	O	O
due	XALKORI.xml:S1:3786:3	due	JJ	O	O
to	XALKORI.xml:S1:3790:2	to	TO	O	O
adverse	XALKORI.xml:S1:3793:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:3801:9	reaction	NNS	O	O
were	XALKORI.xml:S1:3811:4	were	VBD	O	O
required	XALKORI.xml:S1:3816:8	requir	VBN	O	O
in	XALKORI.xml:S1:3825:2	in	IN	O	O
6.4%	XALKORI.xml:S1:3828:4	6.4%	CD	O	O
of	XALKORI.xml:S1:3833:2	of	IN	O	O
XALKORI	XALKORI.xml:S1:3836:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:3843:1	-	:	O	O
treated	XALKORI.xml:S1:3844:7	treat	VBD	O	O
patients	XALKORI.xml:S1:3852:8	patient	NNS	O	O
.	XALKORI.xml:S1:3860:1	.	.	O	O

The	XALKORI.xml:S1:3862:3	the	DT	O	O
most	XALKORI.xml:S1:3866:4	most	RBS	O	O
frequent	XALKORI.xml:S1:3871:8	frequent	JJ	O	O
adverse	XALKORI.xml:S1:3880:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:3888:9	reaction	NNS	O	O
that	XALKORI.xml:S1:3898:4	that	WDT	O	O
led	XALKORI.xml:S1:3903:3	led	VBD	O	O
to	XALKORI.xml:S1:3907:2	to	TO	O	O
dose	XALKORI.xml:S1:3910:4	dose	VB	O	O
reduction	XALKORI.xml:S1:3915:9	reduct	NN	O	O
in	XALKORI.xml:S1:3925:2	in	IN	O	O
these	XALKORI.xml:S1:3928:5	these	DT	O	O
patients	XALKORI.xml:S1:3934:8	patient	NNS	O	O
were	XALKORI.xml:S1:3943:4	were	VBD	O	O
nausea	XALKORI.xml:S1:3948:6	nausea	JJ	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:3955:1	(	(	O	O
1.8%	XALKORI.xml:S1:3956:4	1.8%	CD	O	O
)	XALKORI.xml:S1:3960:1	)	)	O	O
and	XALKORI.xml:S1:3962:3	and	CC	O	O
elevated	XALKORI.xml:S1:3966:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
transaminases	XALKORI.xml:S1:3975:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:3989:1	(	(	O	O
1.8%	XALKORI.xml:S1:3990:4	1.8%	CD	O	O
)	XALKORI.xml:S1:3994:1	)	)	O	O
.	XALKORI.xml:S1:3995:1	.	.	O	O

Permanent	XALKORI.xml:S1:4001:9	perman	JJ	O	O
discontinuation	XALKORI.xml:S1:4011:15	discontinu	NN	O	O
of	XALKORI.xml:S1:4027:2	of	IN	O	O
XALKORI	XALKORI.xml:S1:4030:7	xalkori	NNP	O	O
treatment	XALKORI.xml:S1:4038:9	treatment	NN	O	O
for	XALKORI.xml:S1:4048:3	for	IN	O	O
adverse	XALKORI.xml:S1:4052:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:4060:9	reaction	NNS	O	O
was	XALKORI.xml:S1:4070:3	wa	VBD	O	O
8.2%	XALKORI.xml:S1:4074:4	8.2%	CD	O	O
.	XALKORI.xml:S1:4078:1	.	.	O	O

The	XALKORI.xml:S1:4080:3	the	DT	O	O
most	XALKORI.xml:S1:4084:4	most	RBS	O	O
frequent	XALKORI.xml:S1:4089:8	frequent	JJ	O	O
adverse	XALKORI.xml:S1:4098:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:4106:9	reaction	NNS	O	O
that	XALKORI.xml:S1:4116:4	that	WDT	O	O
led	XALKORI.xml:S1:4121:3	led	VBD	O	O
to	XALKORI.xml:S1:4125:2	to	TO	O	O
permanent	XALKORI.xml:S1:4128:9	perman	JJ	O	O
discontinuation	XALKORI.xml:S1:4138:15	discontinu	NN	O	O
in	XALKORI.xml:S1:4154:2	in	IN	O	O
XALKORI	XALKORI.xml:S1:4157:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:4164:1	-	:	O	O
treated	XALKORI.xml:S1:4165:7	treat	VBD	O	O
patients	XALKORI.xml:S1:4173:8	patient	NNS	O	O
were	XALKORI.xml:S1:4182:4	were	VBD	O	O
elevated	XALKORI.xml:S1:4187:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
transaminases	XALKORI.xml:S1:4196:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:4210:1	(	(	O	O
1.2%	XALKORI.xml:S1:4211:4	1.2%	CD	O	O
)	XALKORI.xml:S1:4215:1	)	)	O	O
,	XALKORI.xml:S1:4216:1	,	,	O	O
hepatotoxicity	XALKORI.xml:S1:4218:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:4233:1	(	(	O	O
1.2%	XALKORI.xml:S1:4234:4	1.2%	CD	O	O
)	XALKORI.xml:S1:4238:1	)	)	O	O
,	XALKORI.xml:S1:4239:1	,	,	O	O
and	XALKORI.xml:S1:4241:3	and	CC	O	O
ILD	XALKORI.xml:S1:4245:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:4249:1	(	(	O	O
1.2%	XALKORI.xml:S1:4250:4	1.2%	CD	O	O
)	XALKORI.xml:S1:4254:1	)	)	O	O
.	XALKORI.xml:S1:4255:1	.	.	O	O

Tables	XALKORI.xml:S1:4261:6	tabl	NNS	O	O
3	XALKORI.xml:S1:4268:1	3	CD	O	O
and	XALKORI.xml:S1:4270:3	and	CC	O	O
4	XALKORI.xml:S1:4274:1	4	CD	O	O
summarize	XALKORI.xml:S1:4276:9	summar	JJ	O	O
common	XALKORI.xml:S1:4286:6	common	JJ	O	O
adverse	XALKORI.xml:S1:4293:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:4301:9	reaction	NNS	O	O
and	XALKORI.xml:S1:4311:3	and	CC	O	O
laboratory	XALKORI.xml:S1:4315:10	laboratori	NN	O	O
abnormalities	XALKORI.xml:S1:4326:13	abnorm	NNS	O	O
in	XALKORI.xml:S1:4340:2	in	IN	O	O
XALKORI	XALKORI.xml:S1:4343:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:4350:1	-	:	O	O
treated	XALKORI.xml:S1:4351:7	treat	VBD	O	O
patients	XALKORI.xml:S1:4359:8	patient	NNS	O	O
.	XALKORI.xml:S1:4367:1	.	.	O	O

Table	XALKORI.xml:S1:4373:5	tabl	JJ	O	O
3	XALKORI.xml:S1:4379:1	3	CD	O	O
.	XALKORI.xml:S1:4380:1	.	.	O	O

Adverse	XALKORI.xml:S1:4382:7	advers	JJ	O	O
Reactions	XALKORI.xml:S1:4390:9	reaction	NNP	O	O
Reported	XALKORI.xml:S1:4400:8	report	VBD	O	O
at	XALKORI.xml:S1:4409:2	at	IN	O	O
a	XALKORI.xml:S1:4412:1	a	DT	O	O
Higher	XALKORI.xml:S1:4414:6	higher	JJR	O	O
Incidence	XALKORI.xml:S1:4421:9	incid	NNP	O	O
(	XALKORI.xml:S1:4431:1	(	(	O	O
5%	XALKORI.xml:S1:4434:2	5%	CD	O	O
Higher	XALKORI.xml:S1:4437:6	higher	JJR	O	O
for	XALKORI.xml:S1:4444:3	for	IN	O	O
All	XALKORI.xml:S1:4448:3	all	DT	O	O
Grades	XALKORI.xml:S1:4452:6	grade	NNP	O	O
or	XALKORI.xml:S1:4459:2	or	CC	O	O
2%	XALKORI.xml:S1:4464:2	2%	CD	O	O
Higher	XALKORI.xml:S1:4467:6	higher	JJR	O	O
for	XALKORI.xml:S1:4474:3	for	IN	O	O
Grades	XALKORI.xml:S1:4478:6	grade	NNP	O	O
3	XALKORI.xml:S1:4485:1	3	CD	O	O
4	XALKORI.xml:S1:4487:1	4	CD	O	O
)	XALKORI.xml:S1:4488:1	)	)	O	O
with	XALKORI.xml:S1:4490:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:4495:7	xalkori	NNP	O	O
than	XALKORI.xml:S1:4503:4	than	IN	O	O
Chemotherapy	XALKORI.xml:S1:4508:12	chemotherapi	NNP	O	O
in	XALKORI.xml:S1:4521:2	in	IN	O	O
Study	XALKORI.xml:S1:4524:5	studi	NNP	O	O
1	XALKORI.xml:S1:4530:1	1	CD	O	O

Adverse	XALKORI.xml:S1:4534:7	advers	JJ	O	O
Reaction	XALKORI.xml:S1:4542:8	reaction	NNP	O	O
XALKORI	XALKORI.xml:S1:4576:7	xalkori	NNP	O	O
(	XALKORI.xml:S1:4583:1	(	(	O	O
N	XALKORI.xml:S1:4584:1	N	NNP	O	O
171	XALKORI.xml:S1:4586:3	171	CD	O	O
)	XALKORI.xml:S1:4589:1	)	)	O	O
Chemotherapy	XALKORI.xml:S1:4593:12	chemotherapi	NNP	O	O
(	XALKORI.xml:S1:4606:1	(	(	O	O
Pemetrexed	XALKORI.xml:S1:4607:10	pemetrex	NNP	O	O
Cisplatin	XALKORI.xml:S1:4618:9	cisplatin	NNP	O	O
or	XALKORI.xml:S1:4628:2	or	CC	O	O
Pemetrexed	XALKORI.xml:S1:4631:10	pemetrex	NNP	O	O
Carboplatin	XALKORI.xml:S1:4642:11	carboplatin	NNP	O	O
)(	XALKORI.xml:S1:4653:2	)(	NNP	O	O
N	XALKORI.xml:S1:4655:1	N	NNP	O	O
169	XALKORI.xml:S1:4657:3	169	CD	O	O
)	XALKORI.xml:S1:4660:1	)	)	O	O

All	XALKORI.xml:S1:4666:3	all	DT	O	O
Grades	XALKORI.xml:S1:4670:6	grade	NNP	O	O
(	XALKORI.xml:S1:4676:1	(	(	O	O
)	XALKORI.xml:S1:4678:1	)	)	O	O
Grade	XALKORI.xml:S1:4709:5	grade	VBD	O	O
3	XALKORI.xml:S1:4715:1	3	CD	O	O
4	XALKORI.xml:S1:4717:1	4	CD	O	O
(	XALKORI.xml:S1:4718:1	(	(	O	O
)	XALKORI.xml:S1:4720:1	)	)	O	O
All	XALKORI.xml:S1:4726:3	all	DT	O	O
Grades	XALKORI.xml:S1:4730:6	grade	NNP	O	O
(	XALKORI.xml:S1:4736:1	(	(	O	O
)	XALKORI.xml:S1:4738:1	)	)	O	O
Grade	XALKORI.xml:S1:4743:5	grade	VBD	O	O
3	XALKORI.xml:S1:4749:1	3	CD	O	O
4	XALKORI.xml:S1:4751:1	4	CD	O	O
(	XALKORI.xml:S1:4752:1	(	(	O	O
)	XALKORI.xml:S1:4754:1	)	)	O	O

Includes	XALKORI.xml:S1:4765:8	includ	NNS	O	O

cases	XALKORI.xml:S1:4774:5	case	NNS	O	O
reported	XALKORI.xml:S1:4780:8	report	VBD	O	O
within	XALKORI.xml:S1:4789:6	within	IN	O	O
the	XALKORI.xml:S1:4796:3	the	DT	O	O
clustered	XALKORI.xml:S1:4800:9	cluster	JJ	O	O
terms	XALKORI.xml:S1:4810:5	term	NNS	O	O
:	XALKORI.xml:S1:4815:1	:	:	O	O

Cardiac	XALKORI.xml:S1:4826:7	cardiac	NN	O	O

Disorders	XALKORI.xml:S1:4834:9	disord	NNS	O	O

Electrocardiogram	XALKORI.xml:S1:4939:17	electrocardiogram	NNP	B-AdverseReaction	B-AdverseReaction
QT	XALKORI.xml:S1:4957:2	QT	NNP	I-AdverseReaction	I-AdverseReaction
prolonged	XALKORI.xml:S1:4960:9	prolong	VBD	I-AdverseReaction	I-AdverseReaction
6	XALKORI.xml:S1:4986:1	6	CD	O	O
2	XALKORI.xml:S1:5003:1	2	CD	O	O
2	XALKORI.xml:S1:5020:1	2	CD	O	O
0	XALKORI.xml:S1:5037:1	0	CD	O	O

Bradycardia	XALKORI.xml:S1:5052:11	bradycardia	NNP	B-AdverseReaction	B-AdverseReaction
14	XALKORI.xml:S1:5098:2	14	CD	O	O
1	XALKORI.xml:S1:5116:1	1	CD	O	O
1	XALKORI.xml:S1:5133:1	1	CD	O	O
0	XALKORI.xml:S1:5150:1	0	CD	O	O

Eye	XALKORI.xml:S1:5165:3	eye	NN	O	O
Disorders	XALKORI.xml:S1:5169:9	disord	NNS	O	O

Vision	XALKORI.xml:S1:5278:6	vision	NNP	B-AdverseReaction	B-AdverseReaction
disorder	XALKORI.xml:S1:5285:8	disord	VBZ	I-AdverseReaction	I-AdverseReaction
71	XALKORI.xml:S1:5324:2	71	CD	O	O
1	XALKORI.xml:S1:5342:1	1	CD	O	O
10	XALKORI.xml:S1:5358:2	10	CD	O	O
0	XALKORI.xml:S1:5376:1	0	CD	O	O

Gastrointestinal	XALKORI.xml:S1:5391:16	gastrointestin	JJ	O	O
Disorders	XALKORI.xml:S1:5408:9	disord	NNS	O	O

Vomiting	XALKORI.xml:S1:5504:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
46	XALKORI.xml:S1:5550:2	46	CD	O	O
2	XALKORI.xml:S1:5568:1	2	CD	O	O
36	XALKORI.xml:S1:5584:2	36	CD	O	O
3	XALKORI.xml:S1:5602:1	3	CD	O	O

Diarrhea	XALKORI.xml:S1:5617:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
61	XALKORI.xml:S1:5663:2	61	CD	O	O
2	XALKORI.xml:S1:5681:1	2	CD	O	O
13	XALKORI.xml:S1:5697:2	13	CD	O	O
1	XALKORI.xml:S1:5715:1	1	CD	O	O

Constipation	XALKORI.xml:S1:5730:12	constip	NN	B-AdverseReaction	B-AdverseReaction
43	XALKORI.xml:S1:5776:2	43	CD	O	O
2	XALKORI.xml:S1:5794:1	2	CD	O	O
30	XALKORI.xml:S1:5810:2	30	CD	O	O
0	XALKORI.xml:S1:5828:1	0	CD	O	O

Dyspepsia	XALKORI.xml:S1:5843:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
14	XALKORI.xml:S1:5889:2	14	CD	O	O
0	XALKORI.xml:S1:5907:1	0	CD	O	O
2	XALKORI.xml:S1:5924:1	2	CD	O	O
0	XALKORI.xml:S1:5941:1	0	CD	O	O

Dysphagia	XALKORI.xml:S1:5956:9	dysphagia	NNP	B-AdverseReaction	B-AdverseReaction
10	XALKORI.xml:S1:6002:2	10	CD	O	O
1	XALKORI.xml:S1:6020:1	1	CD	O	O
2	XALKORI.xml:S1:6037:1	2	CD	O	O
1	XALKORI.xml:S1:6054:1	1	CD	O	O

Abdominal	XALKORI.xml:S1:6069:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	XALKORI.xml:S1:6079:4	pain	NN	I-AdverseReaction	I-AdverseReaction
26	XALKORI.xml:S1:6115:2	26	CD	O	O
0	XALKORI.xml:S1:6133:1	0	CD	O	O
12	XALKORI.xml:S1:6149:2	12	CD	O	O
0	XALKORI.xml:S1:6167:1	0	CD	O	O

General	XALKORI.xml:S1:6182:7	gener	NNP	O	O
Disorders	XALKORI.xml:S1:6190:9	disord	NNP	O	O
and	XALKORI.xml:S1:6200:3	and	CC	O	O
Administration	XALKORI.xml:S1:6204:14	administr	NNP	O	O
Site	XALKORI.xml:S1:6219:4	site	NNP	O	O
Conditions	XALKORI.xml:S1:6224:10	condit	NNS	O	O

Edema	XALKORI.xml:S1:6311:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
49	XALKORI.xml:S1:6357:2	49	CD	O	O
1	XALKORI.xml:S1:6375:1	1	CD	O	O
12	XALKORI.xml:S1:6391:2	12	CD	O	O
1	XALKORI.xml:S1:6409:1	1	CD	O	O

Pyrexia	XALKORI.xml:S1:6424:7	pyrexia	NNP	B-AdverseReaction	B-AdverseReaction
19	XALKORI.xml:S1:6470:2	19	CD	O	O
0	XALKORI.xml:S1:6488:1	0	CD	O	O
11	XALKORI.xml:S1:6504:2	11	CD	O	O
1	XALKORI.xml:S1:6522:1	1	CD	O	O

Infections	XALKORI.xml:S1:6537:10	infect	NNS	O	O
and	XALKORI.xml:S1:6548:3	and	CC	O	O
Infestations	XALKORI.xml:S1:6552:12	infest	NNS	O	O

Upper	XALKORI.xml:S1:6650:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	XALKORI.xml:S1:6656:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
infection	XALKORI.xml:S1:6668:9	infect	NN	I-AdverseReaction	I-AdverseReaction
32	XALKORI.xml:S1:6696:2	32	CD	O	O
0	XALKORI.xml:S1:6714:1	0	CD	O	O
12	XALKORI.xml:S1:6730:2	12	CD	O	O
1	XALKORI.xml:S1:6748:1	1	CD	O	O

Investigations	XALKORI.xml:S1:6763:14	investig	NNS	O	O

Weight	XALKORI.xml:S1:6876:6	weight	NNP	B-AdverseReaction	B-AdverseReaction
increased	XALKORI.xml:S1:6883:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
8	XALKORI.xml:S1:6923:1	8	CD	O	O
1	XALKORI.xml:S1:6940:1	1	CD	O	O
2	XALKORI.xml:S1:6957:1	2	CD	O	O
0	XALKORI.xml:S1:6974:1	0	CD	O	O

Musculoskeletal	XALKORI.xml:S1:6989:15	musculoskelet	NNP	O	O
and	XALKORI.xml:S1:7005:3	and	CC	O	O
Connective	XALKORI.xml:S1:7009:10	connect	NNP	O	O
Tissue	XALKORI.xml:S1:7020:6	tissu	NNP	O	O
Disorders	XALKORI.xml:S1:7027:9	disord	NNP	O	O

Pain	XALKORI.xml:S1:7113:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	XALKORI.xml:S1:7118:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	XALKORI.xml:S1:7121:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
16	XALKORI.xml:S1:7159:2	16	CD	O	O
0	XALKORI.xml:S1:7177:1	0	CD	O	O
7	XALKORI.xml:S1:7194:1	7	CD	O	O
0	XALKORI.xml:S1:7211:1	0	CD	O	O

Muscle	XALKORI.xml:S1:7226:6	muscl	NNP	B-AdverseReaction	B-AdverseReaction
spasm	XALKORI.xml:S1:7233:5	spasm	VBD	I-AdverseReaction	I-AdverseReaction
8	XALKORI.xml:S1:7273:1	8	CD	O	O
0	XALKORI.xml:S1:7290:1	0	CD	O	O
2	XALKORI.xml:S1:7307:1	2	CD	O	O
1	XALKORI.xml:S1:7324:1	1	CD	O	O

Nervous	XALKORI.xml:S1:7339:7	nervou	JJ	O	O
System	XALKORI.xml:S1:7347:6	system	NNP	O	O
Disorder	XALKORI.xml:S1:7354:8	disord	NNP	O	O

Dizziness	XALKORI.xml:S1:7452:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
18	XALKORI.xml:S1:7498:2	18	CD	O	O
0	XALKORI.xml:S1:7516:1	0	CD	O	O
10	XALKORI.xml:S1:7532:2	10	CD	O	O
1	XALKORI.xml:S1:7550:1	1	CD	O	O

Dysgeusia	XALKORI.xml:S1:7565:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
26	XALKORI.xml:S1:7611:2	26	CD	O	O
0	XALKORI.xml:S1:7629:1	0	CD	O	O
5	XALKORI.xml:S1:7646:1	5	CD	O	O
0	XALKORI.xml:S1:7663:1	0	CD	O	O

Headache	XALKORI.xml:S1:7678:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
22	XALKORI.xml:S1:7724:2	22	CD	O	O
1	XALKORI.xml:S1:7742:1	1	CD	O	O
15	XALKORI.xml:S1:7758:2	15	CD	O	O
0	XALKORI.xml:S1:7776:1	0	CD	O	O

Additional	XALKORI.xml:S1:7799:10	addit	JJ	O	O
adverse	XALKORI.xml:S1:7810:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:7818:9	reaction	NNS	O	O
occurring	XALKORI.xml:S1:7828:9	occur	VBG	O	O
at	XALKORI.xml:S1:7838:2	at	IN	O	O
an	XALKORI.xml:S1:7841:2	an	DT	O	O
overall	XALKORI.xml:S1:7844:7	overal	JJ	O	O
incidence	XALKORI.xml:S1:7852:9	incid	NN	O	O
between	XALKORI.xml:S1:7862:7	between	IN	O	O
1%	XALKORI.xml:S1:7870:2	1%	CD	O	O
and	XALKORI.xml:S1:7873:3	and	CC	O	O
60%	XALKORI.xml:S1:7877:3	60%	CD	O	O
in	XALKORI.xml:S1:7881:2	in	IN	O	O
patients	XALKORI.xml:S1:7884:8	patient	NNS	O	O
treated	XALKORI.xml:S1:7893:7	treat	VBN	O	O
with	XALKORI.xml:S1:7901:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:7906:7	xalkori	NNP	O	O
included	XALKORI.xml:S1:7914:8	includ	VBD	O	O
nausea	XALKORI.xml:S1:7923:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:7930:1	(	(	O	O
56%	XALKORI.xml:S1:7931:3	56%	CD	O	O
)	XALKORI.xml:S1:7934:1	)	)	O	O
,	XALKORI.xml:S1:7935:1	,	,	O	O
decreased	XALKORI.xml:S1:7937:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	XALKORI.xml:S1:7947:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:7956:1	(	(	O	O
30%	XALKORI.xml:S1:7957:3	30%	CD	O	O
)	XALKORI.xml:S1:7960:1	)	)	O	O
,	XALKORI.xml:S1:7961:1	,	,	O	O
fatigue	XALKORI.xml:S1:7963:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:7971:1	(	(	O	O
29%	XALKORI.xml:S1:7972:3	29%	CD	O	O
)	XALKORI.xml:S1:7975:1	)	)	O	O
,	XALKORI.xml:S1:7976:1	,	,	O	O
neuropathy	XALKORI.xml:S1:7978:10	neuropathi	JJ	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:7989:1	(	(	O	O
21%	XALKORI.xml:S1:7990:3	21%	CD	O	O
;	XALKORI.xml:S1:7993:1	;	:	O	O
which	XALKORI.xml:S1:7995:5	which	WDT	O	O
included	XALKORI.xml:S1:8001:8	includ	VBD	O	O
gait	XALKORI.xml:S1:8010:4	gait	NN	B-AdverseReaction	B-AdverseReaction
disturbance	XALKORI.xml:S1:8015:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:8026:1	,	,	O	O
hypoaesthesia	XALKORI.xml:S1:8028:13	hypoaesthesia	NN	B-AdverseReaction	O
,	XALKORI.xml:S1:8041:1	,	,	O	O
muscular	XALKORI.xml:S1:8043:8	muscular	JJ	B-AdverseReaction	B-AdverseReaction
weakness	XALKORI.xml:S1:8052:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:8060:1	,	,	O	O
neuralgia	XALKORI.xml:S1:8062:9	neuralgia	RB	B-AdverseReaction	O
,	XALKORI.xml:S1:8071:1	,	,	O	O
neuropathy	XALKORI.xml:S1:8073:10	neuropathi	JJ	B-AdverseReaction	B-AdverseReaction
peripheral	XALKORI.xml:S1:8084:10	peripher	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:8094:1	,	,	O	O
paraesthesia	XALKORI.xml:S1:8096:12	paraesthesia	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:8108:1	,	,	O	O
peripheral	XALKORI.xml:S1:8110:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
sensory	XALKORI.xml:S1:8121:7	sensori	NN	I-AdverseReaction	I-AdverseReaction
neuropathy	XALKORI.xml:S1:8129:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:8139:1	,	,	O	O
polyneuropathy	XALKORI.xml:S1:8141:14	polyneuropathi	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:8155:1	,	,	O	O
sensory	XALKORI.xml:S1:8157:7	sensori	JJ	B-AdverseReaction	B-AdverseReaction
disturbance	XALKORI.xml:S1:8165:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
)	XALKORI.xml:S1:8176:1	)	)	O	O
,	XALKORI.xml:S1:8177:1	,	,	O	O
rash	XALKORI.xml:S1:8179:4	rash	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:8184:1	(	(	O	O
11%	XALKORI.xml:S1:8185:3	11%	CD	O	O
)	XALKORI.xml:S1:8188:1	)	)	O	O
,	XALKORI.xml:S1:8189:1	,	,	O	O
renal	XALKORI.xml:S1:8191:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
cyst	XALKORI.xml:S1:8197:4	cyst	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:8202:1	(	(	O	O
5%	XALKORI.xml:S1:8203:2	5%	CD	O	O
)	XALKORI.xml:S1:8205:1	)	)	O	O
,	XALKORI.xml:S1:8206:1	,	,	O	O
ILD	XALKORI.xml:S1:8208:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:8212:1	(	(	O	O
1%	XALKORI.xml:S1:8213:2	1%	CD	O	O
;	XALKORI.xml:S1:8215:1	;	:	O	O
ILD	XALKORI.xml:S1:8217:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:8220:1	,	,	O	O
pneumonitis	XALKORI.xml:S1:8222:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
)	XALKORI.xml:S1:8233:1	)	)	O	O
,	XALKORI.xml:S1:8234:1	,	,	O	O
and	XALKORI.xml:S1:8236:3	and	CC	O	O
syncope	XALKORI.xml:S1:8240:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:8248:1	(	(	O	O
1%	XALKORI.xml:S1:8249:2	1%	CD	O	O
)	XALKORI.xml:S1:8251:1	)	)	O	O
.	XALKORI.xml:S1:8252:1	.	.	O	O

Table	XALKORI.xml:S1:8258:5	tabl	NN	O	O

4	XALKORI.xml:S1:8264:1	4	CD	O	O
.	XALKORI.xml:S1:8265:1	.	.	O	O

Summary	XALKORI.xml:S1:8267:7	summari	NNP	O	O
of	XALKORI.xml:S1:8275:2	of	IN	O	O
Treatment	XALKORI.xml:S1:8278:9	treatment	NNP	O	O
-	XALKORI.xml:S1:8287:1	-	:	O	O
Emergent	XALKORI.xml:S1:8288:8	emerg	JJ	O	O
Laboratory	XALKORI.xml:S1:8297:10	laboratori	NNP	O	O
Abnormalities	XALKORI.xml:S1:8308:13	abnorm	NNP	O	O
with	XALKORI.xml:S1:8322:4	with	IN	O	O
Grade	XALKORI.xml:S1:8327:5	grade	NNP	O	O
3	XALKORI.xml:S1:8333:1	3	CD	O	O
or	XALKORI.xml:S1:8335:2	or	CC	O	O
4	XALKORI.xml:S1:8338:1	4	CD	O	O
Incidence	XALKORI.xml:S1:8340:9	incid	NN	O	O
of	XALKORI.xml:S1:8350:2	of	IN	O	O
4%	XALKORI.xml:S1:8355:2	4%	CD	O	O
in	XALKORI.xml:S1:8358:2	in	IN	O	O
XALKORI	XALKORI.xml:S1:8361:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:8368:1	-	:	O	O
Treated	XALKORI.xml:S1:8369:7	treat	VBD	O	O
Patients	XALKORI.xml:S1:8377:8	patient	NNS	O	O
in	XALKORI.xml:S1:8386:2	in	IN	O	O
Study	XALKORI.xml:S1:8389:5	studi	NNP	O	O
1	XALKORI.xml:S1:8395:1	1	CD	O	O

Laboratory	XALKORI.xml:S1:8399:10	laboratori	NNP	O	O
Abnormality	XALKORI.xml:S1:8410:11	abnorm	NNP	O	O
XALKORI	XALKORI.xml:S1:8434:7	xalkori	NNP	O	O
Chemotherapy	XALKORI.xml:S1:8452:12	chemotherapi	NNP	O	O

Any	XALKORI.xml:S1:8472:3	ani	DT	O	O
Grade	XALKORI.xml:S1:8476:5	grade	NNP	O	O
(	XALKORI.xml:S1:8481:1	(	(	O	O
)	XALKORI.xml:S1:8483:1	)	)	O	O
Grade	XALKORI.xml:S1:8505:5	grade	VBD	O	O
3	XALKORI.xml:S1:8511:1	3	CD	O	O
4	XALKORI.xml:S1:8513:1	4	CD	O	O
(	XALKORI.xml:S1:8514:1	(	(	O	O
)	XALKORI.xml:S1:8516:1	)	)	O	O
Any	XALKORI.xml:S1:8525:3	ani	DT	O	O
Grade	XALKORI.xml:S1:8529:5	grade	NNP	O	O
(	XALKORI.xml:S1:8534:1	(	(	O	O
)	XALKORI.xml:S1:8536:1	)	)	O	O
Grade	XALKORI.xml:S1:8545:5	grade	VBD	O	O
3	XALKORI.xml:S1:8551:1	3	CD	O	O
4	XALKORI.xml:S1:8553:1	4	CD	O	O
(	XALKORI.xml:S1:8554:1	(	(	O	O
)	XALKORI.xml:S1:8556:1	)	)	O	O

Hematology	XALKORI.xml:S1:8570:10	hematolog	NN	O	O

Neutropenia	XALKORI.xml:S1:8683:11	neutropenia	NN	B-AdverseReaction	O

52	XALKORI.xml:S1:8719:2	52	CD	O	O
11	XALKORI.xml:S1:8739:2	11	CD	O	O
59	XALKORI.xml:S1:8759:2	59	CD	O	O
16	XALKORI.xml:S1:8779:2	16	CD	O	O

Lymphopenia	XALKORI.xml:S1:8796:11	lymphopenia	NNP	B-AdverseReaction	B-AdverseReaction
48	XALKORI.xml:S1:8832:2	48	CD	O	O
7	XALKORI.xml:S1:8852:1	7	CD	O	O
53	XALKORI.xml:S1:8872:2	53	CD	O	O
13	XALKORI.xml:S1:8892:2	13	CD	O	O

Chemistry	XALKORI.xml:S1:8909:9	chemistri	NN	O	O

ALT	XALKORI.xml:S1:9022:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
elevation	XALKORI.xml:S1:9026:9	elev	NN	I-AdverseReaction	I-AdverseReaction
79	XALKORI.xml:S1:9058:2	79	CD	O	O
15	XALKORI.xml:S1:9078:2	15	CD	O	O
33	XALKORI.xml:S1:9098:2	33	CD	O	O
2	XALKORI.xml:S1:9118:1	2	CD	O	O

AST	XALKORI.xml:S1:9135:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
elevation	XALKORI.xml:S1:9139:9	elev	NN	I-AdverseReaction	I-AdverseReaction
66	XALKORI.xml:S1:9171:2	66	CD	O	O
8	XALKORI.xml:S1:9191:1	8	CD	O	O
28	XALKORI.xml:S1:9211:2	28	CD	O	O
1	XALKORI.xml:S1:9231:1	1	CD	O	O

Hypophosphatemia	XALKORI.xml:S1:9248:16	hypophosphatemia	NNP	B-AdverseReaction	B-AdverseReaction
32	XALKORI.xml:S1:9284:2	32	CD	O	O
10	XALKORI.xml:S1:9304:2	10	CD	O	O
21	XALKORI.xml:S1:9324:2	21	CD	O	O
6	XALKORI.xml:S1:9344:1	6	CD	O	O

Previously	XALKORI.xml:S1:9373:10	previous	RB	O	O
Treated	XALKORI.xml:S1:9384:7	treat	VBN	O	O
ALK	XALKORI.xml:S1:9392:3	alk	NNP	O	O
-	XALKORI.xml:S1:9395:1	-	:	O	O
Positive	XALKORI.xml:S1:9396:8	posit	JJ	O	O
Metastatic	XALKORI.xml:S1:9405:10	metastat	NNP	O	O
NSCLC	XALKORI.xml:S1:9416:5	nsclc	NNP	O	O
-	XALKORI.xml:S1:9422:1	-	:	O	O
Study	XALKORI.xml:S1:9424:5	studi	NN	O	O
2	XALKORI.xml:S1:9430:1	2	CD	O	O

The	XALKORI.xml:S1:9438:3	the	DT	O	O

data	XALKORI.xml:S1:9442:4	data	NNS	O	O
in	XALKORI.xml:S1:9447:2	in	IN	O	O
Table	XALKORI.xml:S1:9450:5	tabl	JJ	O	O
5	XALKORI.xml:S1:9456:1	5	CD	O	O
are	XALKORI.xml:S1:9458:3	are	VBP	O	O
derived	XALKORI.xml:S1:9462:7	deriv	VBN	O	O
from	XALKORI.xml:S1:9470:4	from	IN	O	O
343	XALKORI.xml:S1:9475:3	343	CD	O	O
patients	XALKORI.xml:S1:9479:8	patient	NNS	O	O
with	XALKORI.xml:S1:9488:4	with	IN	O	O
ALK	XALKORI.xml:S1:9493:3	alk	NNP	O	O
-	XALKORI.xml:S1:9496:1	-	:	O	O
positive	XALKORI.xml:S1:9497:8	posit	JJ	O	O
metastatic	XALKORI.xml:S1:9506:10	metastat	JJ	O	O
NSCLC	XALKORI.xml:S1:9517:5	nsclc	NNP	O	O
enrolled	XALKORI.xml:S1:9523:8	enrol	VBD	O	O
in	XALKORI.xml:S1:9532:2	in	IN	O	O
a	XALKORI.xml:S1:9535:1	a	DT	O	O
randomized	XALKORI.xml:S1:9537:10	random	JJ	O	O
,	XALKORI.xml:S1:9547:1	,	,	O	O
multicenter	XALKORI.xml:S1:9549:11	multicent	NN	O	O
,	XALKORI.xml:S1:9560:1	,	,	O	O
active	XALKORI.xml:S1:9562:6	activ	JJ	O	O
-	XALKORI.xml:S1:9568:1	-	:	O	O
controlled	XALKORI.xml:S1:9569:10	control	VBN	O	O
,	XALKORI.xml:S1:9579:1	,	,	O	O
open	XALKORI.xml:S1:9581:4	open	JJ	O	O
-	XALKORI.xml:S1:9585:1	-	:	O	O
label	XALKORI.xml:S1:9586:5	label	NN	O	O
trial	XALKORI.xml:S1:9592:5	trial	NN	O	O
(	XALKORI.xml:S1:9598:1	(	(	O	O
Study	XALKORI.xml:S1:9599:5	studi	NNP	O	O
2	XALKORI.xml:S1:9605:1	2	CD	O	O
)	XALKORI.xml:S1:9606:1	)	)	O	O
.	XALKORI.xml:S1:9607:1	.	.	O	O

Patients	XALKORI.xml:S1:9609:8	patient	NNS	O	O
in	XALKORI.xml:S1:9618:2	in	IN	O	O
the	XALKORI.xml:S1:9621:3	the	DT	O	O
XALKORI	XALKORI.xml:S1:9625:7	xalkori	NNP	O	O
arm	XALKORI.xml:S1:9633:3	arm	NN	O	O
(	XALKORI.xml:S1:9637:1	(	(	O	O
n	XALKORI.xml:S1:9638:1	n	JJ	O	O
172	XALKORI.xml:S1:9640:3	172	CD	O	O
)	XALKORI.xml:S1:9643:1	)	)	O	O
received	XALKORI.xml:S1:9645:8	receiv	VBD	O	O
XALKORI	XALKORI.xml:S1:9654:7	xalkori	$	O	O
250	XALKORI.xml:S1:9662:3	250	CD	O	O
mg	XALKORI.xml:S1:9666:2	mg	NN	O	O
orally	XALKORI.xml:S1:9669:6	oral	RB	O	O
twice	XALKORI.xml:S1:9676:5	twice	JJ	O	O
daily	XALKORI.xml:S1:9682:5	daili	RB	O	O
until	XALKORI.xml:S1:9688:5	until	IN	O	O
documented	XALKORI.xml:S1:9694:10	document	JJ	O	O
disease	XALKORI.xml:S1:9705:7	diseas	NN	O	O
progression	XALKORI.xml:S1:9713:11	progress	NN	O	O
,	XALKORI.xml:S1:9724:1	,	,	O	O
intolerance	XALKORI.xml:S1:9726:11	intoler	NN	O	O
to	XALKORI.xml:S1:9738:2	to	TO	O	O
therapy	XALKORI.xml:S1:9741:7	therapi	VB	O	O
,	XALKORI.xml:S1:9748:1	,	,	O	O
or	XALKORI.xml:S1:9750:2	or	CC	O	O
the	XALKORI.xml:S1:9753:3	the	DT	O	O
investigator	XALKORI.xml:S1:9757:12	investig	NN	O	O
determined	XALKORI.xml:S1:9770:10	determin	VBD	O	O
that	XALKORI.xml:S1:9781:4	that	IN	O	O
the	XALKORI.xml:S1:9786:3	the	DT	O	O
patient	XALKORI.xml:S1:9790:7	patient	NN	O	O
was	XALKORI.xml:S1:9798:3	wa	VBD	O	O
no	XALKORI.xml:S1:9802:2	no	RB	O	O
longer	XALKORI.xml:S1:9805:6	longer	JJR	O	O
experiencing	XALKORI.xml:S1:9812:12	experienc	VBG	O	O
clinical	XALKORI.xml:S1:9825:8	clinic	JJ	O	O
benefit	XALKORI.xml:S1:9834:7	benefit	NN	O	O
.	XALKORI.xml:S1:9841:1	.	.	O	O

A	XALKORI.xml:S1:9843:1	A	DT	O	O
total	XALKORI.xml:S1:9845:5	total	NN	O	O
of	XALKORI.xml:S1:9851:2	of	IN	O	O
171	XALKORI.xml:S1:9854:3	171	CD	O	O
patients	XALKORI.xml:S1:9858:8	patient	NNS	O	O
in	XALKORI.xml:S1:9867:2	in	IN	O	O
the	XALKORI.xml:S1:9870:3	the	DT	O	O
chemotherapy	XALKORI.xml:S1:9874:12	chemotherapi	NN	O	O
arm	XALKORI.xml:S1:9887:3	arm	NN	O	O
received	XALKORI.xml:S1:9891:8	receiv	VBD	O	O
pemetrexed	XALKORI.xml:S1:9900:10	pemetrex	JJ	O	O
500	XALKORI.xml:S1:9911:3	500	CD	O	O
mg	XALKORI.xml:S1:9915:2	mg	NN	O	O
m	XALKORI.xml:S1:9918:1	m	NN	O	O
2	XALKORI.xml:S1:9921:1	2	CD	O	O
(	XALKORI.xml:S1:9924:1	(	(	O	O
n	XALKORI.xml:S1:9925:1	n	JJ	O	O
99	XALKORI.xml:S1:9927:2	99	CD	O	O
)	XALKORI.xml:S1:9929:1	)	)	O	O
or	XALKORI.xml:S1:9931:2	or	CC	O	O
docetaxel	XALKORI.xml:S1:9934:9	docetaxel	$	O	O
75	XALKORI.xml:S1:9944:2	75	CD	O	O
mg	XALKORI.xml:S1:9947:2	mg	NN	O	O
m	XALKORI.xml:S1:9950:1	m	NN	O	O
2	XALKORI.xml:S1:9953:1	2	CD	O	O
(	XALKORI.xml:S1:9956:1	(	(	O	O
n	XALKORI.xml:S1:9957:1	n	JJ	O	O
72	XALKORI.xml:S1:9959:2	72	CD	O	O
)	XALKORI.xml:S1:9961:1	)	)	O	O
by	XALKORI.xml:S1:9963:2	by	IN	O	O
intravenous	XALKORI.xml:S1:9966:11	intraven	JJ	O	O
infusion	XALKORI.xml:S1:9978:8	infus	NN	O	O
every	XALKORI.xml:S1:9987:5	everi	DT	O	O
three	XALKORI.xml:S1:9993:5	three	CD	O	O
weeks	XALKORI.xml:S1:9999:5	week	NNS	O	O
until	XALKORI.xml:S1:10005:5	until	IN	O	O
documented	XALKORI.xml:S1:10011:10	document	JJ	O	O
disease	XALKORI.xml:S1:10022:7	diseas	NN	O	O
progression	XALKORI.xml:S1:10030:11	progress	NN	O	O
,	XALKORI.xml:S1:10041:1	,	,	O	O
intolerance	XALKORI.xml:S1:10043:11	intoler	NN	O	O
to	XALKORI.xml:S1:10055:2	to	TO	O	O
therapy	XALKORI.xml:S1:10058:7	therapi	VB	O	O
,	XALKORI.xml:S1:10065:1	,	,	O	O
or	XALKORI.xml:S1:10067:2	or	CC	O	O
the	XALKORI.xml:S1:10070:3	the	DT	O	O
investigator	XALKORI.xml:S1:10074:12	investig	NN	O	O
determined	XALKORI.xml:S1:10087:10	determin	VBD	O	O
that	XALKORI.xml:S1:10098:4	that	IN	O	O
the	XALKORI.xml:S1:10103:3	the	DT	O	O
patient	XALKORI.xml:S1:10107:7	patient	NN	O	O
was	XALKORI.xml:S1:10115:3	wa	VBD	O	O
no	XALKORI.xml:S1:10119:2	no	RB	O	O
longer	XALKORI.xml:S1:10122:6	longer	JJR	O	O
experiencing	XALKORI.xml:S1:10129:12	experienc	VBG	O	O
clinical	XALKORI.xml:S1:10142:8	clinic	JJ	O	O
benefit	XALKORI.xml:S1:10151:7	benefit	NN	O	O
.	XALKORI.xml:S1:10158:1	.	.	O	O

Patients	XALKORI.xml:S1:10160:8	patient	NNS	O	O
in	XALKORI.xml:S1:10169:2	in	IN	O	O
the	XALKORI.xml:S1:10172:3	the	DT	O	O
chemotherapy	XALKORI.xml:S1:10176:12	chemotherapi	NN	O	O
arm	XALKORI.xml:S1:10189:3	arm	NN	O	O
received	XALKORI.xml:S1:10193:8	receiv	VBD	O	O
pemetrexed	XALKORI.xml:S1:10202:10	pemetrex	JJ	O	O
unless	XALKORI.xml:S1:10213:6	unless	IN	O	O
they	XALKORI.xml:S1:10220:4	they	PRP	O	O
had	XALKORI.xml:S1:10225:3	had	VBD	O	O
received	XALKORI.xml:S1:10229:8	receiv	VBN	O	O
pemetrexed	XALKORI.xml:S1:10238:10	pemetrex	VBN	O	O
as	XALKORI.xml:S1:10249:2	as	IN	O	O
part	XALKORI.xml:S1:10252:4	part	NN	O	O
of	XALKORI.xml:S1:10257:2	of	IN	O	O
first	XALKORI.xml:S1:10260:5	first	JJ	O	O
-	XALKORI.xml:S1:10265:1	-	:	O	O
line	XALKORI.xml:S1:10266:4	line	NN	O	O
or	XALKORI.xml:S1:10271:2	or	CC	O	O
maintenance	XALKORI.xml:S1:10274:11	mainten	NN	O	O
treatment	XALKORI.xml:S1:10286:9	treatment	NN	O	O
.	XALKORI.xml:S1:10295:1	.	.	O	O

The	XALKORI.xml:S1:10301:3	the	DT	O	O
median	XALKORI.xml:S1:10305:6	median	JJ	O	O
duration	XALKORI.xml:S1:10312:8	durat	NN	O	O
of	XALKORI.xml:S1:10321:2	of	IN	O	O
study	XALKORI.xml:S1:10324:5	studi	NN	O	O
treatment	XALKORI.xml:S1:10330:9	treatment	NN	O	O
was	XALKORI.xml:S1:10340:3	wa	VBD	O	O
7.1	XALKORI.xml:S1:10344:3	7.1	CD	O	O
months	XALKORI.xml:S1:10348:6	month	NNS	O	O
for	XALKORI.xml:S1:10355:3	for	IN	O	O
patients	XALKORI.xml:S1:10359:8	patient	NNS	O	O
who	XALKORI.xml:S1:10368:3	who	WP	O	O
received	XALKORI.xml:S1:10372:8	receiv	VBD	O	O
XALKORI	XALKORI.xml:S1:10381:7	xalkori	NNP	O	O
and	XALKORI.xml:S1:10389:3	and	CC	O	O
2.8	XALKORI.xml:S1:10393:3	2.8	CD	O	O
months	XALKORI.xml:S1:10397:6	month	NNS	O	O
for	XALKORI.xml:S1:10404:3	for	IN	O	O
patients	XALKORI.xml:S1:10408:8	patient	NNS	O	O
who	XALKORI.xml:S1:10417:3	who	WP	O	O
received	XALKORI.xml:S1:10421:8	receiv	VBD	O	O
chemotherapy	XALKORI.xml:S1:10430:12	chemotherapi	NN	O	O
.	XALKORI.xml:S1:10442:1	.	.	O	O

Across	XALKORI.xml:S1:10444:6	across	IN	O	O
the	XALKORI.xml:S1:10451:3	the	DT	O	O
347	XALKORI.xml:S1:10455:3	347	CD	O	O
patients	XALKORI.xml:S1:10459:8	patient	NNS	O	O
who	XALKORI.xml:S1:10468:3	who	WP	O	O
were	XALKORI.xml:S1:10472:4	were	VBD	O	O
randomized	XALKORI.xml:S1:10477:10	random	VBN	O	O
to	XALKORI.xml:S1:10488:2	to	TO	O	O
study	XALKORI.xml:S1:10491:5	studi	VB	O	O
treatment	XALKORI.xml:S1:10497:9	treatment	NN	O	O
(	XALKORI.xml:S1:10507:1	(	(	O	O
343	XALKORI.xml:S1:10508:3	343	CD	O	O
received	XALKORI.xml:S1:10512:8	receiv	VBN	O	O
at	XALKORI.xml:S1:10521:2	at	IN	O	O
least	XALKORI.xml:S1:10524:5	least	JJS	O	O
one	XALKORI.xml:S1:10530:3	one	CD	O	O
dose	XALKORI.xml:S1:10534:4	dose	NN	O	O
of	XALKORI.xml:S1:10539:2	of	IN	O	O
study	XALKORI.xml:S1:10542:5	studi	NN	O	O
treatment	XALKORI.xml:S1:10548:9	treatment	NN	O	O
)	XALKORI.xml:S1:10557:1	)	)	O	O
,	XALKORI.xml:S1:10558:1	,	,	O	O
the	XALKORI.xml:S1:10560:3	the	DT	O	O
median	XALKORI.xml:S1:10564:6	median	JJ	O	O
age	XALKORI.xml:S1:10571:3	age	NN	O	O
was	XALKORI.xml:S1:10575:3	wa	VBD	O	O
50	XALKORI.xml:S1:10579:2	50	CD	O	O
years	XALKORI.xml:S1:10582:5	year	NNS	O	O
;	XALKORI.xml:S1:10587:1	;	:	O	O
14%	XALKORI.xml:S1:10589:3	14%	CD	O	O
of	XALKORI.xml:S1:10593:2	of	IN	O	O
patients	XALKORI.xml:S1:10596:8	patient	NNS	O	O
were	XALKORI.xml:S1:10605:4	were	VBD	O	O
older	XALKORI.xml:S1:10610:5	older	JJR	O	O
than	XALKORI.xml:S1:10616:4	than	IN	O	O
65	XALKORI.xml:S1:10621:2	65	CD	O	O
years	XALKORI.xml:S1:10624:5	year	NNS	O	O
.	XALKORI.xml:S1:10629:1	.	.	O	O

A	XALKORI.xml:S1:10631:1	A	DT	O	O
total	XALKORI.xml:S1:10633:5	total	NN	O	O
of	XALKORI.xml:S1:10639:2	of	IN	O	O
56%	XALKORI.xml:S1:10642:3	56%	CD	O	O
of	XALKORI.xml:S1:10646:2	of	IN	O	O
patients	XALKORI.xml:S1:10649:8	patient	NNS	O	O
were	XALKORI.xml:S1:10658:4	were	VBD	O	O
female	XALKORI.xml:S1:10663:6	femal	JJ	O	O
and	XALKORI.xml:S1:10670:3	and	CC	O	O
45%	XALKORI.xml:S1:10674:3	45%	CD	O	O
of	XALKORI.xml:S1:10678:2	of	IN	O	O
patients	XALKORI.xml:S1:10681:8	patient	NNS	O	O
were	XALKORI.xml:S1:10690:4	were	VBD	O	O
Asian	XALKORI.xml:S1:10695:5	asian	JJ	O	O
.	XALKORI.xml:S1:10700:1	.	.	O	O

Serious	XALKORI.xml:S1:10706:7	seriou	JJ	O	O
adverse	XALKORI.xml:S1:10714:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:10722:9	reaction	NNS	O	O
were	XALKORI.xml:S1:10732:4	were	VBD	O	O
reported	XALKORI.xml:S1:10737:8	report	VBN	O	O
in	XALKORI.xml:S1:10746:2	in	IN	O	O
64	XALKORI.xml:S1:10749:2	64	CD	O	O
patients	XALKORI.xml:S1:10752:8	patient	NNS	O	O
(	XALKORI.xml:S1:10761:1	(	(	O	O
37.2%	XALKORI.xml:S1:10762:5	37.2%	CD	O	O
)	XALKORI.xml:S1:10767:1	)	)	O	O
treated	XALKORI.xml:S1:10769:7	treat	VBN	O	O
with	XALKORI.xml:S1:10777:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:10782:7	xalkori	NNP	O	O
and	XALKORI.xml:S1:10790:3	and	CC	O	O
40	XALKORI.xml:S1:10794:2	40	CD	O	O
patients	XALKORI.xml:S1:10797:8	patient	NNS	O	O
(	XALKORI.xml:S1:10806:1	(	(	O	O
23.4%	XALKORI.xml:S1:10807:5	23.4%	CD	O	O
)	XALKORI.xml:S1:10812:1	)	)	O	O
in	XALKORI.xml:S1:10814:2	in	IN	O	O
the	XALKORI.xml:S1:10817:3	the	DT	O	O
chemotherapy	XALKORI.xml:S1:10821:12	chemotherapi	NN	O	O
arm	XALKORI.xml:S1:10834:3	arm	NN	O	O
.	XALKORI.xml:S1:10837:1	.	.	O	O

The	XALKORI.xml:S1:10839:3	the	DT	O	O
most	XALKORI.xml:S1:10843:4	most	RBS	O	O
frequent	XALKORI.xml:S1:10848:8	frequent	JJ	O	O
serious	XALKORI.xml:S1:10857:7	seriou	JJ	O	O
adverse	XALKORI.xml:S1:10865:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:10873:9	reaction	NNS	O	O
reported	XALKORI.xml:S1:10883:8	report	VBN	O	O
in	XALKORI.xml:S1:10892:2	in	IN	O	O
patients	XALKORI.xml:S1:10895:8	patient	NNS	O	O
treated	XALKORI.xml:S1:10904:7	treat	VBN	O	O
with	XALKORI.xml:S1:10912:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:10917:7	xalkori	NNP	O	O
were	XALKORI.xml:S1:10925:4	were	VBD	O	O
pneumonia	XALKORI.xml:S1:10930:9	pneumonia	VBN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:10940:1	(	(	O	O
4.1%	XALKORI.xml:S1:10941:4	4.1%	CD	O	O
)	XALKORI.xml:S1:10945:1	)	)	O	O
,	XALKORI.xml:S1:10946:1	,	,	O	O
pulmonary	XALKORI.xml:S1:10948:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
embolism	XALKORI.xml:S1:10958:8	embol	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:10967:1	(	(	O	O
3.5%	XALKORI.xml:S1:10968:4	3.5%	CD	O	O
)	XALKORI.xml:S1:10972:1	)	)	O	O
,	XALKORI.xml:S1:10973:1	,	,	O	O
dyspnea	XALKORI.xml:S1:10975:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:10983:1	(	(	O	O
2.3%	XALKORI.xml:S1:10984:4	2.3%	CD	O	O
)	XALKORI.xml:S1:10988:1	)	)	O	O
,	XALKORI.xml:S1:10989:1	,	,	O	O
and	XALKORI.xml:S1:10991:3	and	CC	O	O
ILD	XALKORI.xml:S1:10995:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:10999:1	(	(	O	O
2.9%	XALKORI.xml:S1:11000:4	2.9%	CD	O	O
)	XALKORI.xml:S1:11004:1	)	)	O	O
.	XALKORI.xml:S1:11005:1	.	.	O	O

Fatal	XALKORI.xml:S1:11007:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
adverse	XALKORI.xml:S1:11013:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:11021:9	reaction	NNS	O	O
in	XALKORI.xml:S1:11031:2	in	IN	O	O
XALKORI	XALKORI.xml:S1:11034:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:11041:1	-	:	O	O
treated	XALKORI.xml:S1:11042:7	treat	VBD	O	O
patients	XALKORI.xml:S1:11050:8	patient	NNS	O	O
in	XALKORI.xml:S1:11059:2	in	IN	O	O
Study	XALKORI.xml:S1:11062:5	studi	NNP	O	O
2	XALKORI.xml:S1:11068:1	2	CD	O	O
occurred	XALKORI.xml:S1:11070:8	occur	VBD	O	O
in	XALKORI.xml:S1:11079:2	in	IN	O	O
9	XALKORI.xml:S1:11082:1	9	CD	O	O
(	XALKORI.xml:S1:11084:1	(	(	O	O
5%	XALKORI.xml:S1:11085:2	5%	CD	O	O
)	XALKORI.xml:S1:11087:1	)	)	O	O
patients	XALKORI.xml:S1:11089:8	patient	NNS	O	O
,	XALKORI.xml:S1:11097:1	,	,	O	O
consisting	XALKORI.xml:S1:11099:10	consist	VBG	O	O
of	XALKORI.xml:S1:11110:2	of	IN	O	O
:	XALKORI.xml:S1:11112:1	:	:	O	O
acute	XALKORI.xml:S1:11114:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XALKORI.xml:S1:11120:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
distress	XALKORI.xml:S1:11132:8	distress	NN	I-AdverseReaction	I-AdverseReaction
syndrome	XALKORI.xml:S1:11141:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:11149:1	,	,	O	O
arrhythmia	XALKORI.xml:S1:11151:10	arrhythmia	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:11161:1	,	,	O	O
dyspnea	XALKORI.xml:S1:11163:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:11170:1	,	,	O	O
pneumonia	XALKORI.xml:S1:11172:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:11181:1	,	,	O	O
pneumonitis	XALKORI.xml:S1:11183:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:11194:1	,	,	O	O
pulmonary	XALKORI.xml:S1:11196:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
embolism	XALKORI.xml:S1:11206:8	embol	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:11214:1	,	,	O	O
ILD	XALKORI.xml:S1:11216:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:11219:1	,	,	O	O
respiratory	XALKORI.xml:S1:11221:11	respiratori	JJ	B-AdverseReaction	B-AdverseReaction
failure	XALKORI.xml:S1:11233:7	failur	NN	I-AdverseReaction	I-AdverseReaction
and	XALKORI.xml:S1:11241:3	and	CC	O	O
sepsis	XALKORI.xml:S1:11245:6	sepsi	NN	B-AdverseReaction	B-AdverseReaction
.	XALKORI.xml:S1:11251:1	.	.	O	O

Dose	XALKORI.xml:S1:11257:4	dose	NNP	O	O
reductions	XALKORI.xml:S1:11262:10	reduct	NNS	O	O
due	XALKORI.xml:S1:11273:3	due	JJ	O	O
to	XALKORI.xml:S1:11277:2	to	TO	O	O
adverse	XALKORI.xml:S1:11280:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:11288:9	reaction	NNS	O	O
were	XALKORI.xml:S1:11298:4	were	VBD	O	O
required	XALKORI.xml:S1:11303:8	requir	VBN	O	O
in	XALKORI.xml:S1:11312:2	in	IN	O	O
16%	XALKORI.xml:S1:11315:3	16%	CD	O	O
of	XALKORI.xml:S1:11319:2	of	IN	O	O
XALKORI	XALKORI.xml:S1:11322:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:11329:1	-	:	O	O
treated	XALKORI.xml:S1:11330:7	treat	VBD	O	O
patients	XALKORI.xml:S1:11338:8	patient	NNS	O	O
.	XALKORI.xml:S1:11346:1	.	.	O	O

The	XALKORI.xml:S1:11348:3	the	DT	O	O
most	XALKORI.xml:S1:11352:4	most	RBS	O	O
frequent	XALKORI.xml:S1:11357:8	frequent	JJ	O	O
adverse	XALKORI.xml:S1:11366:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:11374:9	reaction	NNS	O	O
that	XALKORI.xml:S1:11384:4	that	WDT	O	O
led	XALKORI.xml:S1:11389:3	led	VBD	O	O
to	XALKORI.xml:S1:11393:2	to	TO	O	O
dose	XALKORI.xml:S1:11396:4	dose	VB	O	O
reduction	XALKORI.xml:S1:11401:9	reduct	NN	O	O
in	XALKORI.xml:S1:11411:2	in	IN	O	O
the	XALKORI.xml:S1:11414:3	the	DT	O	O
patients	XALKORI.xml:S1:11418:8	patient	NNS	O	O
treated	XALKORI.xml:S1:11427:7	treat	VBN	O	O
with	XALKORI.xml:S1:11435:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:11440:7	xalkori	NNP	O	O
were	XALKORI.xml:S1:11448:4	were	VBD	O	O
alanine	XALKORI.xml:S1:11453:7	alanin	JJ	B-AdverseReaction	O
aminotransferase	XALKORI.xml:S1:11461:16	aminotransferas	NN	I-AdverseReaction	O
(	XALKORI.xml:S1:11478:1	(	(	O	O
ALT	XALKORI.xml:S1:11479:3	alt	NNP	B-AdverseReaction	O
)	XALKORI.xml:S1:11482:1	)	)	O	O
elevation	XALKORI.xml:S1:11484:9	elev	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:11494:1	(	(	O	O
7.6%	XALKORI.xml:S1:11495:4	7.6%	CD	O	O
)	XALKORI.xml:S1:11499:1	)	)	O	O
including	XALKORI.xml:S1:11501:9	includ	VBG	O	O
some	XALKORI.xml:S1:11511:4	some	DT	O	O
patients	XALKORI.xml:S1:11516:8	patient	NNS	O	O
with	XALKORI.xml:S1:11525:4	with	IN	O	O
concurrent	XALKORI.xml:S1:11530:10	concurr	JJ	O	O
aspartate	XALKORI.xml:S1:11541:9	aspart	NN	B-AdverseReaction	O
aminotransferase	XALKORI.xml:S1:11551:16	aminotransferas	NN	I-AdverseReaction	O
(	XALKORI.xml:S1:11568:1	(	(	O	O
AST	XALKORI.xml:S1:11569:3	ast	NNP	B-AdverseReaction	O
)	XALKORI.xml:S1:11572:1	)	)	O	O
elevation	XALKORI.xml:S1:11574:9	elev	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:11583:1	,	,	O	O
QTc	XALKORI.xml:S1:11585:3	qtc	NNP	B-AdverseReaction	B-AdverseReaction
prolongation	XALKORI.xml:S1:11589:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:11602:1	(	(	O	O
2.9%	XALKORI.xml:S1:11603:4	2.9%	CD	O	O
)	XALKORI.xml:S1:11607:1	)	)	O	O
,	XALKORI.xml:S1:11608:1	,	,	O	O
and	XALKORI.xml:S1:11610:3	and	CC	O	O
neutropenia	XALKORI.xml:S1:11614:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:11626:1	(	(	O	O
2.3%	XALKORI.xml:S1:11627:4	2.3%	CD	O	O
)	XALKORI.xml:S1:11631:1	)	)	O	O
.	XALKORI.xml:S1:11632:1	.	.	O	O

XALKORI	XALKORI.xml:S1:11638:7	xalkori	NN	O	O
was	XALKORI.xml:S1:11646:3	wa	VBD	O	O
discontinued	XALKORI.xml:S1:11650:12	discontinu	VBN	O	O
for	XALKORI.xml:S1:11663:3	for	IN	O	O
adverse	XALKORI.xml:S1:11667:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:11675:9	reaction	NNS	O	O
in	XALKORI.xml:S1:11685:2	in	IN	O	O
15%	XALKORI.xml:S1:11688:3	15%	CD	O	O
of	XALKORI.xml:S1:11692:2	of	IN	O	O
patients	XALKORI.xml:S1:11695:8	patient	NNS	O	O
.	XALKORI.xml:S1:11703:1	.	.	O	O

The	XALKORI.xml:S1:11705:3	the	DT	O	O
most	XALKORI.xml:S1:11709:4	most	RBS	O	O
frequent	XALKORI.xml:S1:11714:8	frequent	JJ	O	O
adverse	XALKORI.xml:S1:11723:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:11731:9	reaction	NNS	O	O
that	XALKORI.xml:S1:11741:4	that	WDT	O	O
led	XALKORI.xml:S1:11746:3	led	VBD	O	O
to	XALKORI.xml:S1:11750:2	to	TO	O	O
discontinuation	XALKORI.xml:S1:11753:15	discontinu	NN	O	O
of	XALKORI.xml:S1:11769:2	of	IN	O	O
XALKORI	XALKORI.xml:S1:11772:7	xalkori	NNP	O	O
were	XALKORI.xml:S1:11780:4	were	VBD	O	O
ILD	XALKORI.xml:S1:11785:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:11789:1	(	(	O	O
1.7%	XALKORI.xml:S1:11790:4	1.7%	CD	O	O
)	XALKORI.xml:S1:11794:1	)	)	O	O
,	XALKORI.xml:S1:11795:1	,	,	O	O
ALT	XALKORI.xml:S1:11797:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
and	XALKORI.xml:S1:11801:3	and	CC	O	O
AST	XALKORI.xml:S1:11805:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
elevation	XALKORI.xml:S1:11809:9	elev	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:11819:1	(	(	O	O
1.2%	XALKORI.xml:S1:11820:4	1.2%	CD	O	O
)	XALKORI.xml:S1:11824:1	)	)	O	O
,	XALKORI.xml:S1:11825:1	,	,	O	O
dyspnea	XALKORI.xml:S1:11827:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:11835:1	(	(	O	O
1.2%	XALKORI.xml:S1:11836:4	1.2%	CD	O	O
)	XALKORI.xml:S1:11840:1	)	)	O	O
,	XALKORI.xml:S1:11841:1	,	,	O	O
and	XALKORI.xml:S1:11843:3	and	CC	O	O
pulmonary	XALKORI.xml:S1:11847:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
embolism	XALKORI.xml:S1:11857:8	embol	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:11866:1	(	(	O	O
1.2%	XALKORI.xml:S1:11867:4	1.2%	CD	O	O
)	XALKORI.xml:S1:11871:1	)	)	O	O
.	XALKORI.xml:S1:11872:1	.	.	O	O

Tables	XALKORI.xml:S1:11878:6	tabl	NNS	O	O
5	XALKORI.xml:S1:11885:1	5	CD	O	O
and	XALKORI.xml:S1:11887:3	and	CC	O	O
6	XALKORI.xml:S1:11891:1	6	CD	O	O
summarize	XALKORI.xml:S1:11893:9	summar	JJ	O	O
common	XALKORI.xml:S1:11903:6	common	JJ	O	O
adverse	XALKORI.xml:S1:11910:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:11918:9	reaction	NNS	O	O
and	XALKORI.xml:S1:11928:3	and	CC	O	O
laboratory	XALKORI.xml:S1:11932:10	laboratori	NN	O	O
abnormalities	XALKORI.xml:S1:11943:13	abnorm	NNS	O	O
in	XALKORI.xml:S1:11957:2	in	IN	O	O
XALKORI	XALKORI.xml:S1:11960:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:11967:1	-	:	O	O
treated	XALKORI.xml:S1:11968:7	treat	VBD	O	O
patients	XALKORI.xml:S1:11976:8	patient	NNS	O	O
.	XALKORI.xml:S1:11984:1	.	.	O	O

Table	XALKORI.xml:S1:11990:5	tabl	JJ	O	O
5	XALKORI.xml:S1:11996:1	5	CD	O	O
.	XALKORI.xml:S1:11997:1	.	.	O	O

Adverse	XALKORI.xml:S1:11999:7	advers	JJ	O	O
Reactions	XALKORI.xml:S1:12007:9	reaction	NNP	O	O
Reported	XALKORI.xml:S1:12017:8	report	VBD	O	O
at	XALKORI.xml:S1:12026:2	at	IN	O	O
a	XALKORI.xml:S1:12029:1	a	DT	O	O
Higher	XALKORI.xml:S1:12031:6	higher	JJR	O	O
Incidence	XALKORI.xml:S1:12038:9	incid	NNP	O	O
(	XALKORI.xml:S1:12048:1	(	(	O	O
5%	XALKORI.xml:S1:12051:2	5%	CD	O	O
Higher	XALKORI.xml:S1:12054:6	higher	JJR	O	O
for	XALKORI.xml:S1:12061:3	for	IN	O	O
All	XALKORI.xml:S1:12065:3	all	DT	O	O
Grades	XALKORI.xml:S1:12069:6	grade	NNP	O	O
or	XALKORI.xml:S1:12076:2	or	CC	O	O
2%	XALKORI.xml:S1:12081:2	2%	CD	O	O
Higher	XALKORI.xml:S1:12084:6	higher	JJR	O	O
for	XALKORI.xml:S1:12091:3	for	IN	O	O
Grades	XALKORI.xml:S1:12095:6	grade	NNP	O	O
3	XALKORI.xml:S1:12102:1	3	CD	O	O
4	XALKORI.xml:S1:12104:1	4	CD	O	O
)	XALKORI.xml:S1:12105:1	)	)	O	O
with	XALKORI.xml:S1:12107:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:12112:7	xalkori	NNP	O	O
than	XALKORI.xml:S1:12120:4	than	IN	O	O
Chemotherapy	XALKORI.xml:S1:12125:12	chemotherapi	NNP	O	O
in	XALKORI.xml:S1:12138:2	in	IN	O	O
Study	XALKORI.xml:S1:12141:5	studi	NNP	O	O
2	XALKORI.xml:S1:12147:1	2	CD	O	O

Adverse	XALKORI.xml:S1:12151:7	advers	JJ	O	O
Reaction	XALKORI.xml:S1:12159:8	reaction	NNP	O	O
XALKORI	XALKORI.xml:S1:12193:7	xalkori	NNP	O	O
(	XALKORI.xml:S1:12200:1	(	(	O	O
N	XALKORI.xml:S1:12201:1	N	NNP	O	O
172	XALKORI.xml:S1:12203:3	172	CD	O	O
)	XALKORI.xml:S1:12206:1	)	)	O	O
Chemotherapy	XALKORI.xml:S1:12210:12	chemotherapi	NNP	O	O
(	XALKORI.xml:S1:12223:1	(	(	O	O
Pemetrexed	XALKORI.xml:S1:12224:10	pemetrex	NNP	O	O
or	XALKORI.xml:S1:12235:2	or	CC	O	O
Docetaxel	XALKORI.xml:S1:12238:9	docetaxel	NNP	O	O
)(	XALKORI.xml:S1:12247:2	)(	NNP	O	O
N	XALKORI.xml:S1:12249:1	N	NNP	O	O
171	XALKORI.xml:S1:12251:3	171	CD	O	O
)	XALKORI.xml:S1:12254:1	)	)	O	O

All	XALKORI.xml:S1:12260:3	all	DT	O	O
Grades	XALKORI.xml:S1:12264:6	grade	NNP	O	O
(	XALKORI.xml:S1:12270:1	(	(	O	O
)	XALKORI.xml:S1:12272:1	)	)	O	O
Grade	XALKORI.xml:S1:12303:5	grade	VBD	O	O
3	XALKORI.xml:S1:12309:1	3	CD	O	O
4	XALKORI.xml:S1:12311:1	4	CD	O	O
(	XALKORI.xml:S1:12312:1	(	(	O	O
)	XALKORI.xml:S1:12314:1	)	)	O	O
All	XALKORI.xml:S1:12320:3	all	DT	O	O
Grades	XALKORI.xml:S1:12324:6	grade	NNP	O	O
(	XALKORI.xml:S1:12330:1	(	(	O	O
)	XALKORI.xml:S1:12332:1	)	)	O	O
Grade	XALKORI.xml:S1:12337:5	grade	VBD	O	O
3	XALKORI.xml:S1:12343:1	3	CD	O	O
4	XALKORI.xml:S1:12345:1	4	CD	O	O
(	XALKORI.xml:S1:12346:1	(	(	O	O
)	XALKORI.xml:S1:12348:1	)	)	O	O

Includes	XALKORI.xml:S1:12359:8	includ	NNS	O	O

cases	XALKORI.xml:S1:12368:5	case	NNS	O	O
reported	XALKORI.xml:S1:12374:8	report	VBD	O	O
within	XALKORI.xml:S1:12383:6	within	IN	O	O
the	XALKORI.xml:S1:12390:3	the	DT	O	O
clustered	XALKORI.xml:S1:12394:9	cluster	JJ	O	O
terms	XALKORI.xml:S1:12404:5	term	NNS	O	O
:	XALKORI.xml:S1:12409:1	:	:	O	O

Nervous	XALKORI.xml:S1:12420:7	nervou	JJ	O	O

System	XALKORI.xml:S1:12428:6	system	NN	O	O
Disorder	XALKORI.xml:S1:12435:8	disord	NNP	O	O

Dizziness	XALKORI.xml:S1:12533:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
22	XALKORI.xml:S1:12579:2	22	CD	O	O
1	XALKORI.xml:S1:12597:1	1	CD	O	O
8	XALKORI.xml:S1:12614:1	8	CD	O	O
0	XALKORI.xml:S1:12631:1	0	CD	O	O

Dysgeusia	XALKORI.xml:S1:12646:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
26	XALKORI.xml:S1:12692:2	26	CD	O	O
0	XALKORI.xml:S1:12710:1	0	CD	O	O
9	XALKORI.xml:S1:12727:1	9	CD	O	O
0	XALKORI.xml:S1:12744:1	0	CD	O	O

Syncope	XALKORI.xml:S1:12759:7	syncop	NNP	B-AdverseReaction	B-AdverseReaction
3	XALKORI.xml:S1:12806:1	3	CD	O	O
3	XALKORI.xml:S1:12823:1	3	CD	O	O
0	XALKORI.xml:S1:12840:1	0	CD	O	O
0	XALKORI.xml:S1:12857:1	0	CD	O	O

Eye	XALKORI.xml:S1:12872:3	eye	NN	O	O
Disorders	XALKORI.xml:S1:12876:9	disord	NNS	O	O

Vision	XALKORI.xml:S1:12985:6	vision	NNP	B-AdverseReaction	B-AdverseReaction
disorder	XALKORI.xml:S1:12992:8	disord	VBZ	I-AdverseReaction	I-AdverseReaction
60	XALKORI.xml:S1:13031:2	60	CD	O	O
0	XALKORI.xml:S1:13049:1	0	CD	O	O
9	XALKORI.xml:S1:13066:1	9	CD	O	O
0	XALKORI.xml:S1:13083:1	0	CD	O	O

Cardiac	XALKORI.xml:S1:13098:7	cardiac	JJ	O	O
Disorders	XALKORI.xml:S1:13106:9	disord	NNS	O	O

Electrocardiogram	XALKORI.xml:S1:13211:17	electrocardiogram	NNP	B-AdverseReaction	B-AdverseReaction
QT	XALKORI.xml:S1:13229:2	QT	NNP	I-AdverseReaction	I-AdverseReaction
prolonged	XALKORI.xml:S1:13232:9	prolong	VBD	I-AdverseReaction	I-AdverseReaction
5	XALKORI.xml:S1:13258:1	5	CD	O	O
3	XALKORI.xml:S1:13275:1	3	CD	O	O
0	XALKORI.xml:S1:13292:1	0	CD	O	O
0	XALKORI.xml:S1:13309:1	0	CD	O	O

Bradycardia	XALKORI.xml:S1:13324:11	bradycardia	NNP	B-AdverseReaction	B-AdverseReaction
5	XALKORI.xml:S1:13371:1	5	CD	O	O
0	XALKORI.xml:S1:13388:1	0	CD	O	O
0	XALKORI.xml:S1:13405:1	0	CD	O	O
0	XALKORI.xml:S1:13422:1	0	CD	O	O

Investigations	XALKORI.xml:S1:13437:14	investig	NNS	O	O

Weight	XALKORI.xml:S1:13550:6	weight	NNP	B-AdverseReaction	B-AdverseReaction
decreased	XALKORI.xml:S1:13557:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
10	XALKORI.xml:S1:13596:2	10	CD	O	O
1	XALKORI.xml:S1:13614:1	1	CD	O	O
4	XALKORI.xml:S1:13631:1	4	CD	O	O
0	XALKORI.xml:S1:13648:1	0	CD	O	O

Gastrointestinal	XALKORI.xml:S1:13663:16	gastrointestin	JJ	O	O
Disorders	XALKORI.xml:S1:13680:9	disord	NNS	O	O

Vomiting	XALKORI.xml:S1:13776:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
47	XALKORI.xml:S1:13822:2	47	CD	O	O
1	XALKORI.xml:S1:13840:1	1	CD	O	O
18	XALKORI.xml:S1:13856:2	18	CD	O	O
0	XALKORI.xml:S1:13874:1	0	CD	O	O

Nausea	XALKORI.xml:S1:13889:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
55	XALKORI.xml:S1:13935:2	55	CD	O	O
1	XALKORI.xml:S1:13953:1	1	CD	O	O
37	XALKORI.xml:S1:13969:2	37	CD	O	O
1	XALKORI.xml:S1:13987:1	1	CD	O	O

Diarrhea	XALKORI.xml:S1:14002:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
60	XALKORI.xml:S1:14048:2	60	CD	O	O
0	XALKORI.xml:S1:14066:1	0	CD	O	O
19	XALKORI.xml:S1:14082:2	19	CD	O	O
1	XALKORI.xml:S1:14100:1	1	CD	O	O

Constipation	XALKORI.xml:S1:14115:12	constip	NN	B-AdverseReaction	B-AdverseReaction
42	XALKORI.xml:S1:14161:2	42	CD	O	O
2	XALKORI.xml:S1:14179:1	2	CD	O	O
23	XALKORI.xml:S1:14195:2	23	CD	O	O
0	XALKORI.xml:S1:14213:1	0	CD	O	O

Dyspepsia	XALKORI.xml:S1:14228:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
8	XALKORI.xml:S1:14275:1	8	CD	O	O
0	XALKORI.xml:S1:14292:1	0	CD	O	O
3	XALKORI.xml:S1:14309:1	3	CD	O	O
0	XALKORI.xml:S1:14326:1	0	CD	O	O

Infections	XALKORI.xml:S1:14341:10	infect	NNS	O	O
and	XALKORI.xml:S1:14352:3	and	CC	O	O
Infestations	XALKORI.xml:S1:14356:12	infest	NNS	O	O

Upper	XALKORI.xml:S1:14454:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	XALKORI.xml:S1:14460:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
infection	XALKORI.xml:S1:14472:9	infect	NN	I-AdverseReaction	I-AdverseReaction
26	XALKORI.xml:S1:14500:2	26	CD	O	O
0	XALKORI.xml:S1:14518:1	0	CD	O	O
13	XALKORI.xml:S1:14534:2	13	CD	O	O
1	XALKORI.xml:S1:14552:1	1	CD	O	O

Respiratory	XALKORI.xml:S1:14567:11	respiratori	NNP	O	O
,	XALKORI.xml:S1:14578:1	,	,	O	O
Thoracic	XALKORI.xml:S1:14580:8	thorac	NNP	O	O
and	XALKORI.xml:S1:14589:3	and	CC	O	O
Mediastinal	XALKORI.xml:S1:14593:11	mediastin	NNP	O	O
Disorders	XALKORI.xml:S1:14605:9	disord	NNP	O	O

Pulmonary	XALKORI.xml:S1:14691:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
embolism	XALKORI.xml:S1:14701:8	embol	NN	I-AdverseReaction	I-AdverseReaction
6	XALKORI.xml:S1:14738:1	6	CD	O	O
5	XALKORI.xml:S1:14755:1	5	CD	O	O
2	XALKORI.xml:S1:14772:1	2	CD	O	O
2	XALKORI.xml:S1:14789:1	2	CD	O	O

General	XALKORI.xml:S1:14804:7	gener	NNP	O	O
Disorders	XALKORI.xml:S1:14812:9	disord	NNP	O	O
and	XALKORI.xml:S1:14822:3	and	CC	O	O
Administration	XALKORI.xml:S1:14826:14	administr	NNP	O	O
Site	XALKORI.xml:S1:14841:4	site	NNP	O	O
Conditions	XALKORI.xml:S1:14846:10	condit	NNS	O	O

Edema	XALKORI.xml:S1:14933:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
31	XALKORI.xml:S1:14979:2	31	CD	O	O
0	XALKORI.xml:S1:14997:1	0	CD	O	O
16	XALKORI.xml:S1:15013:2	16	CD	O	O
0	XALKORI.xml:S1:15031:1	0	CD	O	O

Additional	XALKORI.xml:S1:15054:10	addit	JJ	O	O
adverse	XALKORI.xml:S1:15065:7	advers	JJ	O	O
reactions	XALKORI.xml:S1:15073:9	reaction	NNS	O	O
occurring	XALKORI.xml:S1:15083:9	occur	VBG	O	O
at	XALKORI.xml:S1:15093:2	at	IN	O	O
an	XALKORI.xml:S1:15096:2	an	DT	O	O
overall	XALKORI.xml:S1:15099:7	overal	JJ	O	O
incidence	XALKORI.xml:S1:15107:9	incid	NN	O	O
between	XALKORI.xml:S1:15117:7	between	IN	O	O
1%	XALKORI.xml:S1:15125:2	1%	CD	O	O
and	XALKORI.xml:S1:15128:3	and	CC	O	O
30%	XALKORI.xml:S1:15132:3	30%	CD	O	O
in	XALKORI.xml:S1:15136:2	in	IN	O	O
patients	XALKORI.xml:S1:15139:8	patient	NNS	O	O
treated	XALKORI.xml:S1:15148:7	treat	VBN	O	O
with	XALKORI.xml:S1:15156:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:15161:7	xalkori	NNP	O	O
included	XALKORI.xml:S1:15169:8	includ	VBD	O	O
(	XALKORI.xml:S1:15178:1	(	(	O	O
)	XALKORI.xml:S1:15180:1	)	)	O	O
,	XALKORI.xml:S1:15181:1	,	,	O	O
fatigue	XALKORI.xml:S1:15183:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:15191:1	(	(	O	O
27%	XALKORI.xml:S1:15192:3	27%	CD	O	O
)	XALKORI.xml:S1:15195:1	)	)	O	O
,	XALKORI.xml:S1:15196:1	,	,	O	O
neuropathy	XALKORI.xml:S1:15198:10	neuropathi	JJ	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:15209:1	(	(	O	O
19%	XALKORI.xml:S1:15210:3	19%	CD	O	O
;	XALKORI.xml:S1:15213:1	;	:	O	O
dysesthesia	XALKORI.xml:S1:15215:11	dysesthesia	NN	B-AdverseReaction	O
,	XALKORI.xml:S1:15226:1	,	,	O	O
gait	XALKORI.xml:S1:15228:4	gait	NN	B-AdverseReaction	B-AdverseReaction
disturbance	XALKORI.xml:S1:15233:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:15244:1	,	,	O	O
hypoesthesia	XALKORI.xml:S1:15246:12	hypoesthesia	NN	B-AdverseReaction	O
,	XALKORI.xml:S1:15258:1	,	,	O	O
muscular	XALKORI.xml:S1:15260:8	muscular	JJ	B-AdverseReaction	B-AdverseReaction
weakness	XALKORI.xml:S1:15269:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:15277:1	,	,	O	O
neuralgia	XALKORI.xml:S1:15279:9	neuralgia	RB	B-AdverseReaction	O
,	XALKORI.xml:S1:15288:1	,	,	O	O
peripheral	XALKORI.xml:S1:15290:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
neuropathy	XALKORI.xml:S1:15301:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:15311:1	,	,	O	O
parasthesia	XALKORI.xml:S1:15313:11	parasthesia	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:15324:1	,	,	O	O
peripheral	XALKORI.xml:S1:15326:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
sensory	XALKORI.xml:S1:15337:7	sensori	NN	I-AdverseReaction	I-AdverseReaction
neuropathy	XALKORI.xml:S1:15345:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:15355:1	,	,	O	O
polyneuropathy	XALKORI.xml:S1:15357:14	polyneuropathi	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:15371:1	,	,	O	O
burning	XALKORI.xml:S1:15373:7	burn	VBG	B-AdverseReaction	B-AdverseReaction
sensation	XALKORI.xml:S1:15381:9	sensat	NN	I-AdverseReaction	I-AdverseReaction
in	XALKORI.xml:S1:15391:2	in	IN	I-AdverseReaction	O
skin	XALKORI.xml:S1:15394:4	skin	NN	I-AdverseReaction	O
)	XALKORI.xml:S1:15398:1	)	)	O	O
,	XALKORI.xml:S1:15399:1	,	,	O	O
rash	XALKORI.xml:S1:15401:4	rash	NN	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:15406:1	(	(	O	O
9%	XALKORI.xml:S1:15407:2	9%	CD	O	O
)	XALKORI.xml:S1:15409:1	)	)	O	O
,	XALKORI.xml:S1:15410:1	,	,	O	O
ILD	XALKORI.xml:S1:15412:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
(	XALKORI.xml:S1:15416:1	(	(	O	O
4%	XALKORI.xml:S1:15417:2	4%	CD	O	O
;	XALKORI.xml:S1:15419:1	;	:	O	O
acute	XALKORI.xml:S1:15421:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XALKORI.xml:S1:15427:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
distress	XALKORI.xml:S1:15439:8	distress	NN	I-AdverseReaction	I-AdverseReaction
syndrome	XALKORI.xml:S1:15448:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:15456:1	,	,	O	O
ILD	XALKORI.xml:S1:15458:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:15461:1	,	,	O	O
pneumonitis	XALKORI.xml:S1:15463:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
)	XALKORI.xml:S1:15474:1	)	)	O	O
,	XALKORI.xml:S1:15475:1	,	,	O	O
renal	XALKORI.xml:S1:15477:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
cyst	XALKORI.xml:S1:15483:4	cyst	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:15488:1	(	(	O	O
4%	XALKORI.xml:S1:15489:2	4%	CD	O	O
)	XALKORI.xml:S1:15491:1	)	)	O	O
,	XALKORI.xml:S1:15492:1	,	,	O	O
and	XALKORI.xml:S1:15494:3	and	CC	O	O
hepatic	XALKORI.xml:S1:15498:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
failure	XALKORI.xml:S1:15506:7	failur	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S1:15514:1	(	(	O	O
1%	XALKORI.xml:S1:15515:2	1%	CD	O	O
)	XALKORI.xml:S1:15517:1	)	)	O	O
.	XALKORI.xml:S1:15518:1	.	.	O	O

Table	XALKORI.xml:S1:15524:5	tabl	NN	O	O

6	XALKORI.xml:S1:15530:1	6	CD	O	O
.	XALKORI.xml:S1:15531:1	.	.	O	O

Summary	XALKORI.xml:S1:15533:7	summari	NNP	O	O
of	XALKORI.xml:S1:15541:2	of	IN	O	O
Treatment	XALKORI.xml:S1:15544:9	treatment	NNP	O	O
-	XALKORI.xml:S1:15553:1	-	:	O	O
Emergent	XALKORI.xml:S1:15554:8	emerg	JJ	O	O
Laboratory	XALKORI.xml:S1:15563:10	laboratori	NNP	O	O
Abnormalities	XALKORI.xml:S1:15574:13	abnorm	NNP	O	O
with	XALKORI.xml:S1:15588:4	with	IN	O	O
Grade	XALKORI.xml:S1:15593:5	grade	NNP	O	O
3	XALKORI.xml:S1:15599:1	3	CD	O	O
or	XALKORI.xml:S1:15601:2	or	CC	O	O
4	XALKORI.xml:S1:15604:1	4	CD	O	O
Incidence	XALKORI.xml:S1:15606:9	incid	NN	O	O
of	XALKORI.xml:S1:15616:2	of	IN	O	O
4%	XALKORI.xml:S1:15621:2	4%	CD	O	O
in	XALKORI.xml:S1:15624:2	in	IN	O	O
XALKORI	XALKORI.xml:S1:15627:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:15634:1	-	:	O	O
Treated	XALKORI.xml:S1:15635:7	treat	VBD	O	O
Patients	XALKORI.xml:S1:15643:8	patient	NNS	O	O
in	XALKORI.xml:S1:15652:2	in	IN	O	O
Study	XALKORI.xml:S1:15655:5	studi	NNP	O	O
2	XALKORI.xml:S1:15661:1	2	CD	O	O

Laboratory	XALKORI.xml:S1:15665:10	laboratori	NNP	O	O
Abnormality	XALKORI.xml:S1:15676:11	abnorm	NNP	O	O
XALKORI	XALKORI.xml:S1:15711:7	xalkori	NNP	O	O
Chemotherapy	XALKORI.xml:S1:15725:12	chemotherapi	NNP	O	O

Any	XALKORI.xml:S1:15744:3	ani	DT	O	O
Grade	XALKORI.xml:S1:15748:5	grade	NNP	O	O
(	XALKORI.xml:S1:15753:1	(	(	O	O
)	XALKORI.xml:S1:15755:1	)	)	O	O
Grade	XALKORI.xml:S1:15787:5	grade	VBD	O	O
3	XALKORI.xml:S1:15793:1	3	CD	O	O
4	XALKORI.xml:S1:15795:1	4	CD	O	O
(	XALKORI.xml:S1:15796:1	(	(	O	O
)	XALKORI.xml:S1:15798:1	)	)	O	O
Any	XALKORI.xml:S1:15804:3	ani	DT	O	O
Grade	XALKORI.xml:S1:15808:5	grade	NNP	O	O
(	XALKORI.xml:S1:15813:1	(	(	O	O
)	XALKORI.xml:S1:15815:1	)	)	O	O
Grade	XALKORI.xml:S1:15821:5	grade	VBD	O	O
3	XALKORI.xml:S1:15827:1	3	CD	O	O
4	XALKORI.xml:S1:15829:1	4	CD	O	O
(	XALKORI.xml:S1:15830:1	(	(	O	O
)	XALKORI.xml:S1:15832:1	)	)	O	O

Hematology	XALKORI.xml:S1:15845:10	hematolog	NN	O	O

Neutropenia	XALKORI.xml:S1:15958:11	neutropenia	NN	B-AdverseReaction	O

49	XALKORI.xml:S1:16004:2	49	CD	O	O
12	XALKORI.xml:S1:16021:2	12	CD	O	O
28	XALKORI.xml:S1:16038:2	28	CD	O	O
12	XALKORI.xml:S1:16055:2	12	CD	O	O

Lymphopenia	XALKORI.xml:S1:16071:11	lymphopenia	NNP	B-AdverseReaction	B-AdverseReaction
51	XALKORI.xml:S1:16117:2	51	CD	O	O
9	XALKORI.xml:S1:16135:1	9	CD	O	O
60	XALKORI.xml:S1:16151:2	60	CD	O	O
25	XALKORI.xml:S1:16168:2	25	CD	O	O

Chemistry	XALKORI.xml:S1:16184:9	chemistri	NN	O	O

ALT	XALKORI.xml:S1:16297:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
elevation	XALKORI.xml:S1:16301:9	elev	NN	I-AdverseReaction	I-AdverseReaction
76	XALKORI.xml:S1:16343:2	76	CD	O	O
17	XALKORI.xml:S1:16360:2	17	CD	O	O
38	XALKORI.xml:S1:16377:2	38	CD	O	O
4	XALKORI.xml:S1:16395:1	4	CD	O	O

AST	XALKORI.xml:S1:16410:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
elevation	XALKORI.xml:S1:16414:9	elev	NN	I-AdverseReaction	I-AdverseReaction
61	XALKORI.xml:S1:16456:2	61	CD	O	O
9	XALKORI.xml:S1:16474:1	9	CD	O	O
33	XALKORI.xml:S1:16490:2	33	CD	O	O
0	XALKORI.xml:S1:16508:1	0	CD	O	O

Hypokalemia	XALKORI.xml:S1:16523:11	hypokalemia	NNP	B-AdverseReaction	B-AdverseReaction
18	XALKORI.xml:S1:16569:2	18	CD	O	O
4	XALKORI.xml:S1:16587:1	4	CD	O	O
10	XALKORI.xml:S1:16603:2	10	CD	O	O
1	XALKORI.xml:S1:16621:1	1	CD	O	O

Hypophosphatemia	XALKORI.xml:S1:16636:16	hypophosphatemia	NNP	B-AdverseReaction	B-AdverseReaction
28	XALKORI.xml:S1:16682:2	28	CD	O	O
5	XALKORI.xml:S1:16700:1	5	CD	O	O
25	XALKORI.xml:S1:16716:2	25	CD	O	O
6	XALKORI.xml:S1:16734:1	6	CD	O	O

Description	XALKORI.xml:S1:16761:11	descript	NN	O	O
of	XALKORI.xml:S1:16773:2	of	IN	O	O
Selected	XALKORI.xml:S1:16776:8	select	NNP	O	O
Adverse	XALKORI.xml:S1:16785:7	advers	NNP	O	O
Drug	XALKORI.xml:S1:16793:4	drug	NNP	O	O
Reactions	XALKORI.xml:S1:16798:9	reaction	NNP	O	O

Vision	XALKORI.xml:S1:16818:6	vision	NN	O	O

disorders	XALKORI.xml:S1:16825:9	disord	NNS	O	O

Vision	XALKORI.xml:S1:16841:6	vision	NN	B-AdverseReaction	O
disorders	XALKORI.xml:S1:16848:9	disord	NNS	I-AdverseReaction	O
,	XALKORI.xml:S1:16857:1	,	,	O	O
most	XALKORI.xml:S1:16859:4	most	JJS	O	O
commonly	XALKORI.xml:S1:16864:8	commonli	RB	O	O
visual	XALKORI.xml:S1:16873:6	visual	JJ	B-AdverseReaction	O
impairment	XALKORI.xml:S1:16880:10	impair	NN	I-AdverseReaction	O
,	XALKORI.xml:S1:16890:1	,	,	O	O
photopsia	XALKORI.xml:S1:16892:9	photopsia	NN	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S1:16901:1	,	,	O	O
blurred	XALKORI.xml:S1:16903:7	blur	VBN	B-AdverseReaction	B-AdverseReaction
vision	XALKORI.xml:S1:16911:6	vision	NN	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:16917:1	,	,	O	O
or	XALKORI.xml:S1:16919:2	or	CC	O	O
vitreous	XALKORI.xml:S1:16922:8	vitreou	JJ	B-AdverseReaction	B-AdverseReaction
floaters	XALKORI.xml:S1:16931:8	floater	NNS	I-AdverseReaction	I-AdverseReaction
,	XALKORI.xml:S1:16939:1	,	,	O	O
occurred	XALKORI.xml:S1:16941:8	occur	VBD	O	O
in	XALKORI.xml:S1:16950:2	in	IN	O	O
1038	XALKORI.xml:S1:16953:4	1038	CD	O	O
(	XALKORI.xml:S1:16958:1	(	(	O	O
62%	XALKORI.xml:S1:16959:3	62%	CD	O	O
)	XALKORI.xml:S1:16962:1	)	)	O	O
of	XALKORI.xml:S1:16964:2	of	IN	O	O
1669	XALKORI.xml:S1:16967:4	1669	CD	O	O
patients	XALKORI.xml:S1:16972:8	patient	NNS	O	O
.	XALKORI.xml:S1:16980:1	.	.	O	O

The	XALKORI.xml:S1:16982:3	the	DT	O	O
majority	XALKORI.xml:S1:16986:8	major	NN	O	O
(	XALKORI.xml:S1:16995:1	(	(	O	O
95%	XALKORI.xml:S1:16996:3	95%	CD	O	O
)	XALKORI.xml:S1:16999:1	)	)	O	O
of	XALKORI.xml:S1:17001:2	of	IN	O	O
these	XALKORI.xml:S1:17004:5	these	DT	O	O
patients	XALKORI.xml:S1:17010:8	patient	NNS	O	O
had	XALKORI.xml:S1:17019:3	had	VBD	O	O
Grade	XALKORI.xml:S1:17023:5	grade	VBN	O	O
1	XALKORI.xml:S1:17029:1	1	CD	O	O
visual	XALKORI.xml:S1:17031:6	visual	JJ	B-AdverseReaction	O
adverse	XALKORI.xml:S1:17038:7	advers	JJ	I-AdverseReaction	O
reactions	XALKORI.xml:S1:17046:9	reaction	NNS	I-AdverseReaction	O
.	XALKORI.xml:S1:17055:1	.	.	O	O

There	XALKORI.xml:S1:17057:5	there	EX	O	O
were	XALKORI.xml:S1:17063:4	were	VBD	O	O
13	XALKORI.xml:S1:17068:2	13	CD	O	O
(	XALKORI.xml:S1:17071:1	(	(	O	O
0.8%	XALKORI.xml:S1:17072:4	0.8%	CD	O	O
)	XALKORI.xml:S1:17076:1	)	)	O	O
patients	XALKORI.xml:S1:17078:8	patient	NNS	O	O
with	XALKORI.xml:S1:17087:4	with	IN	O	O
Grade	XALKORI.xml:S1:17092:5	grade	NNP	O	O
3	XALKORI.xml:S1:17098:1	3	CD	O	O
and	XALKORI.xml:S1:17100:3	and	CC	O	O
4	XALKORI.xml:S1:17104:1	4	CD	O	O
(	XALKORI.xml:S1:17106:1	(	(	O	O
0.2%	XALKORI.xml:S1:17107:4	0.2%	CD	O	O
)	XALKORI.xml:S1:17111:1	)	)	O	O
patients	XALKORI.xml:S1:17113:8	patient	NNS	O	O
with	XALKORI.xml:S1:17122:4	with	IN	O	O
Grade	XALKORI.xml:S1:17127:5	grade	NNP	O	O
4	XALKORI.xml:S1:17133:1	4	CD	O	O
visual	XALKORI.xml:S1:17135:6	visual	JJ	B-AdverseReaction	B-AdverseReaction
impairment	XALKORI.xml:S1:17142:10	impair	NN	I-AdverseReaction	I-AdverseReaction
.	XALKORI.xml:S1:17152:1	.	.	O	O

Based	XALKORI.xml:S1:17158:5	base	VBN	O	O
on	XALKORI.xml:S1:17164:2	on	IN	O	O
the	XALKORI.xml:S1:17167:3	the	DT	O	O
Visual	XALKORI.xml:S1:17171:6	visual	NNP	O	O
Symptom	XALKORI.xml:S1:17178:7	symptom	NNP	O	O
Assessment	XALKORI.xml:S1:17186:10	assess	NNP	O	O
Questionnaire	XALKORI.xml:S1:17197:13	questionnair	NNP	O	O
(	XALKORI.xml:S1:17211:1	(	(	O	O
VSAQ	XALKORI.xml:S1:17212:4	vsaq	NNP	O	O
-	XALKORI.xml:S1:17216:1	-	:	O	O
ALK	XALKORI.xml:S1:17217:3	alk	NNP	O	O
)	XALKORI.xml:S1:17220:1	)	)	O	O
,	XALKORI.xml:S1:17221:1	,	,	O	O
patients	XALKORI.xml:S1:17223:8	patient	NNS	O	O
treated	XALKORI.xml:S1:17232:7	treat	VBD	O	O
with	XALKORI.xml:S1:17240:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:17245:7	xalkori	NNP	O	O
in	XALKORI.xml:S1:17253:2	in	IN	O	O
Studies	XALKORI.xml:S1:17256:7	studi	NNP	O	O
1	XALKORI.xml:S1:17264:1	1	CD	O	O
and	XALKORI.xml:S1:17266:3	and	CC	O	O
2	XALKORI.xml:S1:17270:1	2	CD	O	O
reported	XALKORI.xml:S1:17272:8	report	VBD	O	O
a	XALKORI.xml:S1:17281:1	a	DT	O	O
higher	XALKORI.xml:S1:17283:6	higher	JJR	O	O
incidence	XALKORI.xml:S1:17290:9	incid	NN	O	O
of	XALKORI.xml:S1:17300:2	of	IN	O	O
visual	XALKORI.xml:S1:17303:6	visual	JJ	B-AdverseReaction	O
disturbances	XALKORI.xml:S1:17310:12	disturb	NNS	I-AdverseReaction	O
compared	XALKORI.xml:S1:17323:8	compar	VBN	O	O
to	XALKORI.xml:S1:17332:2	to	TO	O	O
patients	XALKORI.xml:S1:17335:8	patient	NNS	O	O
treated	XALKORI.xml:S1:17344:7	treat	VBN	O	O
with	XALKORI.xml:S1:17352:4	with	IN	O	O
chemotherapy	XALKORI.xml:S1:17357:12	chemotherapi	NN	O	O
.	XALKORI.xml:S1:17369:1	.	.	O	O

The	XALKORI.xml:S1:17371:3	the	DT	O	O
onset	XALKORI.xml:S1:17375:5	onset	NN	O	O
of	XALKORI.xml:S1:17381:2	of	IN	O	O
vision	XALKORI.xml:S1:17384:6	vision	NN	B-AdverseReaction	O
disorder	XALKORI.xml:S1:17391:8	disord	NN	I-AdverseReaction	O
generally	XALKORI.xml:S1:17400:9	gener	RB	O	O
was	XALKORI.xml:S1:17410:3	wa	VBD	O	O
within	XALKORI.xml:S1:17414:6	within	IN	O	O
the	XALKORI.xml:S1:17421:3	the	DT	O	O
first	XALKORI.xml:S1:17425:5	first	JJ	O	O
week	XALKORI.xml:S1:17431:4	week	NN	O	O
of	XALKORI.xml:S1:17436:2	of	IN	O	O
drug	XALKORI.xml:S1:17439:4	drug	NN	O	O
administration	XALKORI.xml:S1:17444:14	administr	NN	O	O
.	XALKORI.xml:S1:17458:1	.	.	O	O

The	XALKORI.xml:S1:17460:3	the	DT	O	O
majority	XALKORI.xml:S1:17464:8	major	NN	O	O
of	XALKORI.xml:S1:17473:2	of	IN	O	O
patients	XALKORI.xml:S1:17476:8	patient	NNS	O	O
on	XALKORI.xml:S1:17485:2	on	IN	O	O
the	XALKORI.xml:S1:17488:3	the	DT	O	O
XALKORI	XALKORI.xml:S1:17492:7	xalkori	NN	O	O
arms	XALKORI.xml:S1:17500:4	arm	NNS	O	O
in	XALKORI.xml:S1:17505:2	in	IN	O	O
Studies	XALKORI.xml:S1:17508:7	studi	NNS	O	O
1	XALKORI.xml:S1:17516:1	1	CD	O	O
and	XALKORI.xml:S1:17518:3	and	CC	O	O
2	XALKORI.xml:S1:17522:1	2	CD	O	O
(	XALKORI.xml:S1:17524:1	(	(	O	O
50%	XALKORI.xml:S1:17526:3	50%	CD	O	O
)	XALKORI.xml:S1:17529:1	)	)	O	O
reported	XALKORI.xml:S1:17531:8	report	VBD	O	O
visual	XALKORI.xml:S1:17540:6	visual	JJ	B-AdverseReaction	B-AdverseReaction
disturbances	XALKORI.xml:S1:17547:12	disturb	NNS	I-AdverseReaction	I-AdverseReaction
which	XALKORI.xml:S1:17560:5	which	WDT	O	O
occurred	XALKORI.xml:S1:17566:8	occur	VBD	O	O
at	XALKORI.xml:S1:17575:2	at	IN	O	O
a	XALKORI.xml:S1:17578:1	a	DT	O	O
frequency	XALKORI.xml:S1:17580:9	frequenc	NN	O	O
of	XALKORI.xml:S1:17590:2	of	IN	O	O
4	XALKORI.xml:S1:17593:1	4	CD	O	O
-	XALKORI.xml:S1:17594:1	-	:	O	O
7	XALKORI.xml:S1:17595:1	7	CD	O	O
days	XALKORI.xml:S1:17597:4	day	NNS	O	O
each	XALKORI.xml:S1:17602:4	each	DT	O	O
week	XALKORI.xml:S1:17607:4	week	NN	O	O
,	XALKORI.xml:S1:17611:1	,	,	O	O
lasted	XALKORI.xml:S1:17613:6	last	VBD	O	O
up	XALKORI.xml:S1:17620:2	up	RB	O	O
to	XALKORI.xml:S1:17623:2	to	TO	O	O
1	XALKORI.xml:S1:17626:1	1	CD	O	O
minute	XALKORI.xml:S1:17628:6	minut	NN	O	O
,	XALKORI.xml:S1:17634:1	,	,	O	O
and	XALKORI.xml:S1:17636:3	and	CC	O	O
had	XALKORI.xml:S1:17640:3	had	VBD	O	O
mild	XALKORI.xml:S1:17644:4	mild	VBN	O	O
or	XALKORI.xml:S1:17649:2	or	CC	O	O
no	XALKORI.xml:S1:17652:2	no	DT	O	O
impact	XALKORI.xml:S1:17655:6	impact	NN	O	O
(	XALKORI.xml:S1:17662:1	(	(	O	O
scores	XALKORI.xml:S1:17663:6	score	VBZ	O	O
0	XALKORI.xml:S1:17670:1	0	CD	O	O
to	XALKORI.xml:S1:17672:2	to	TO	O	O
3	XALKORI.xml:S1:17675:1	3	CD	O	O
out	XALKORI.xml:S1:17677:3	out	IN	O	O
of	XALKORI.xml:S1:17681:2	of	IN	O	O
a	XALKORI.xml:S1:17684:1	a	DT	O	O
maximum	XALKORI.xml:S1:17686:7	maximum	JJ	O	O
score	XALKORI.xml:S1:17694:5	score	NN	O	O
of	XALKORI.xml:S1:17700:2	of	IN	O	O
10	XALKORI.xml:S1:17703:2	10	CD	O	O
)	XALKORI.xml:S1:17705:1	)	)	O	O
on	XALKORI.xml:S1:17707:2	on	IN	O	O
daily	XALKORI.xml:S1:17710:5	daili	JJ	O	O
activities	XALKORI.xml:S1:17716:10	activ	NNS	O	O
as	XALKORI.xml:S1:17727:2	as	IN	O	O
captured	XALKORI.xml:S1:17730:8	captur	VBN	O	O
in	XALKORI.xml:S1:17739:2	in	IN	O	O
the	XALKORI.xml:S1:17742:3	the	DT	O	O
VSAQ	XALKORI.xml:S1:17746:4	vsaq	NNP	O	O
-	XALKORI.xml:S1:17750:1	-	:	O	O
ALK	XALKORI.xml:S1:17751:3	alk	NNP	O	O
questionnaire	XALKORI.xml:S1:17755:13	questionnair	NN	O	O
.	XALKORI.xml:S1:17768:1	.	.	O	O

Neuropathy	XALKORI.xml:S1:17778:10	neuropathi	NN	O	O

Neuropathy	XALKORI.xml:S1:17795:10	neuropathi	NNP	B-AdverseReaction	O
,	XALKORI.xml:S1:17805:1	,	,	O	O
most	XALKORI.xml:S1:17807:4	most	JJS	O	O
commonly	XALKORI.xml:S1:17812:8	commonli	RB	O	O
sensory	XALKORI.xml:S1:17821:7	sensori	JJ	I-AdverseReaction	O
in	XALKORI.xml:S1:17829:2	in	IN	O	O
nature	XALKORI.xml:S1:17832:6	natur	NN	O	O
,	XALKORI.xml:S1:17838:1	,	,	O	O
occurred	XALKORI.xml:S1:17840:8	occur	VBD	O	O
in	XALKORI.xml:S1:17849:2	in	IN	O	O
419	XALKORI.xml:S1:17852:3	419	CD	O	O
(	XALKORI.xml:S1:17856:1	(	(	O	O
25%	XALKORI.xml:S1:17857:3	25%	CD	O	O
)	XALKORI.xml:S1:17860:1	)	)	O	O
of	XALKORI.xml:S1:17862:2	of	IN	O	O
1669	XALKORI.xml:S1:17865:4	1669	CD	O	O
patients	XALKORI.xml:S1:17870:8	patient	NNS	O	O
.	XALKORI.xml:S1:17878:1	.	.	O	O

Most	XALKORI.xml:S1:17880:4	most	JJS	O	O
events	XALKORI.xml:S1:17885:6	event	NNS	O	O
(	XALKORI.xml:S1:17892:1	(	(	O	O
95%	XALKORI.xml:S1:17893:3	95%	CD	O	O
)	XALKORI.xml:S1:17896:1	)	)	O	O
were	XALKORI.xml:S1:17898:4	were	VBD	O	O
Grade	XALKORI.xml:S1:17903:5	grade	VBN	O	O
1	XALKORI.xml:S1:17909:1	1	CD	O	O
or	XALKORI.xml:S1:17911:2	or	CC	O	O
Grade	XALKORI.xml:S1:17914:5	grade	VB	O	O
2	XALKORI.xml:S1:17920:1	2	CD	O	O
in	XALKORI.xml:S1:17922:2	in	IN	O	O
severity	XALKORI.xml:S1:17925:8	sever	NN	O	O
.	XALKORI.xml:S1:17933:1	.	.	O	O

Renal	XALKORI.xml:S1:17943:5	renal	JJ	O	O
Cysts	XALKORI.xml:S1:17949:5	cyst	NNS	O	O

Renal	XALKORI.xml:S1:17961:5	renal	JJ	B-AdverseReaction	O
cysts	XALKORI.xml:S1:17967:5	cyst	NNS	I-AdverseReaction	O
were	XALKORI.xml:S1:17973:4	were	VBD	O	O
experienced	XALKORI.xml:S1:17978:11	experienc	VBN	O	O
by	XALKORI.xml:S1:17990:2	by	IN	O	O
50	XALKORI.xml:S1:17993:2	50	CD	O	O
(	XALKORI.xml:S1:17996:1	(	(	O	O
3%	XALKORI.xml:S1:17997:2	3%	CD	O	O
)	XALKORI.xml:S1:17999:1	)	)	O	O
of	XALKORI.xml:S1:18001:2	of	IN	O	O
1669	XALKORI.xml:S1:18004:4	1669	CD	O	O
patients	XALKORI.xml:S1:18009:8	patient	NNS	O	O
.	XALKORI.xml:S1:18017:1	.	.	O	O

Renal	XALKORI.xml:S1:18019:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
cysts	XALKORI.xml:S1:18025:5	cyst	NNS	I-AdverseReaction	I-AdverseReaction
occurred	XALKORI.xml:S1:18031:8	occur	VBD	O	O
in	XALKORI.xml:S1:18040:2	in	IN	O	O
8	XALKORI.xml:S1:18043:1	8	CD	O	O
(	XALKORI.xml:S1:18045:1	(	(	O	O
5%	XALKORI.xml:S1:18046:2	5%	CD	O	O
)	XALKORI.xml:S1:18048:1	)	)	O	O
patients	XALKORI.xml:S1:18050:8	patient	NNS	O	O
treated	XALKORI.xml:S1:18059:7	treat	VBN	O	O
with	XALKORI.xml:S1:18067:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:18072:7	xalkori	NNP	O	O
and	XALKORI.xml:S1:18080:3	and	CC	O	O
1	XALKORI.xml:S1:18084:1	1	CD	O	O
(	XALKORI.xml:S1:18086:1	(	(	O	O
1%	XALKORI.xml:S1:18087:2	1%	CD	O	O
)	XALKORI.xml:S1:18089:1	)	)	O	O
patient	XALKORI.xml:S1:18091:7	patient	NN	O	O
treated	XALKORI.xml:S1:18099:7	treat	VBN	O	O
with	XALKORI.xml:S1:18107:4	with	IN	O	O
chemotherapy	XALKORI.xml:S1:18112:12	chemotherapi	NN	O	O
in	XALKORI.xml:S1:18125:2	in	IN	O	O
Study	XALKORI.xml:S1:18128:5	studi	NNP	O	O
1	XALKORI.xml:S1:18134:1	1	CD	O	O
.	XALKORI.xml:S1:18135:1	.	.	O	O

Renal	XALKORI.xml:S1:18137:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
cysts	XALKORI.xml:S1:18143:5	cyst	NNS	I-AdverseReaction	I-AdverseReaction
occurred	XALKORI.xml:S1:18149:8	occur	VBD	O	O
in	XALKORI.xml:S1:18158:2	in	IN	O	O
8	XALKORI.xml:S1:18161:1	8	CD	O	O
(	XALKORI.xml:S1:18163:1	(	(	O	O
5%	XALKORI.xml:S1:18164:2	5%	CD	O	O
)	XALKORI.xml:S1:18166:1	)	)	O	O
patients	XALKORI.xml:S1:18168:8	patient	NNS	O	O
treated	XALKORI.xml:S1:18177:7	treat	VBN	O	O
with	XALKORI.xml:S1:18185:4	with	IN	O	O
XALKORI	XALKORI.xml:S1:18190:7	xalkori	NNP	O	O
and	XALKORI.xml:S1:18198:3	and	CC	O	O
1	XALKORI.xml:S1:18202:1	1	CD	O	O
(	XALKORI.xml:S1:18204:1	(	(	O	O
1%	XALKORI.xml:S1:18205:2	1%	CD	O	O
)	XALKORI.xml:S1:18207:1	)	)	O	O
patient	XALKORI.xml:S1:18209:7	patient	NN	O	O
treated	XALKORI.xml:S1:18217:7	treat	VBN	O	O
with	XALKORI.xml:S1:18225:4	with	IN	O	O
chemotherapy	XALKORI.xml:S1:18230:12	chemotherapi	NN	O	O
in	XALKORI.xml:S1:18243:2	in	IN	O	O
Study	XALKORI.xml:S1:18246:5	studi	NNP	O	O
2	XALKORI.xml:S1:18252:1	2	CD	O	O
.	XALKORI.xml:S1:18253:1	.	.	O	O

The	XALKORI.xml:S1:18255:3	the	DT	O	O
majority	XALKORI.xml:S1:18259:8	major	NN	O	O
of	XALKORI.xml:S1:18268:2	of	IN	O	O
renal	XALKORI.xml:S1:18271:5	renal	JJ	B-AdverseReaction	O
cysts	XALKORI.xml:S1:18277:5	cyst	NNS	I-AdverseReaction	O
in	XALKORI.xml:S1:18283:2	in	IN	O	O
XALKORI	XALKORI.xml:S1:18286:7	xalkori	NNP	O	O
-	XALKORI.xml:S1:18293:1	-	:	O	O
treated	XALKORI.xml:S1:18294:7	treat	VBD	O	O
patients	XALKORI.xml:S1:18302:8	patient	NNS	O	O
were	XALKORI.xml:S1:18311:4	were	VBD	O	O
complex	XALKORI.xml:S1:18316:7	complex	JJ	I-AdverseReaction	O
.	XALKORI.xml:S1:18323:1	.	.	O	O

Local	XALKORI.xml:S1:18325:5	local	JJ	B-AdverseReaction	O
cystic	XALKORI.xml:S1:18331:6	cystic	JJ	I-AdverseReaction	O
invasion	XALKORI.xml:S1:18338:8	invas	NN	I-AdverseReaction	O
beyond	XALKORI.xml:S1:18347:6	beyond	IN	I-AdverseReaction	O
the	XALKORI.xml:S1:18354:3	the	DT	I-AdverseReaction	O
kidney	XALKORI.xml:S1:18358:6	kidney	NN	I-AdverseReaction	O
occurred	XALKORI.xml:S1:18365:8	occur	VBD	O	O
,	XALKORI.xml:S1:18373:1	,	,	O	O
in	XALKORI.xml:S1:18375:2	in	IN	O	O
some	XALKORI.xml:S1:18378:4	some	DT	O	O
cases	XALKORI.xml:S1:18383:5	case	NNS	O	O
with	XALKORI.xml:S1:18389:4	with	IN	O	O
imaging	XALKORI.xml:S1:18394:7	imag	VBG	O	O
characteristics	XALKORI.xml:S1:18402:15	characterist	NNS	O	O
suggestive	XALKORI.xml:S1:18418:10	suggest	JJ	O	O
of	XALKORI.xml:S1:18429:2	of	IN	O	O
abscess	XALKORI.xml:S1:18432:7	abscess	JJ	B-AdverseReaction	O
formation	XALKORI.xml:S1:18440:9	format	NN	O	O
.	XALKORI.xml:S1:18449:1	.	.	O	O

However	XALKORI.xml:S1:18451:7	howev	RB	O	O
,	XALKORI.xml:S1:18458:1	,	,	O	O
across	XALKORI.xml:S1:18460:6	across	IN	O	O
clinical	XALKORI.xml:S1:18467:8	clinic	JJ	O	O
trials	XALKORI.xml:S1:18476:6	trial	NNS	O	O
no	XALKORI.xml:S1:18483:2	no	DT	O	O
renal	XALKORI.xml:S1:18486:5	renal	JJ	B-AdverseReaction	O
abscesses	XALKORI.xml:S1:18492:9	abscess	NNS	I-AdverseReaction	O
were	XALKORI.xml:S1:18502:4	were	VBD	O	O
confirmed	XALKORI.xml:S1:18507:9	confirm	VBN	O	O
by	XALKORI.xml:S1:18517:2	by	IN	O	O
microbiology	XALKORI.xml:S1:18520:12	microbiolog	NN	O	O
tests	XALKORI.xml:S1:18533:5	test	NNS	O	O
.	XALKORI.xml:S1:18538:1	.	.	O	O
5	XALKORI.xml:S2:4:1	5	CD	O	O
WARNINGS	XALKORI.xml:S2:6:8	warn	NNP	O	O
AND	XALKORI.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	XALKORI.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	XALKORI.xml:S2:37:7	excerpt	NN	O	O
:	XALKORI.xml:S2:44:1	:	:	O	O
Hepatotoxicity	XALKORI.xml:S2:52:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
:	XALKORI.xml:S2:66:1	:	:	O	O
Fatal	XALKORI.xml:S2:68:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
hepatotoxicity	XALKORI.xml:S2:74:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
occurred	XALKORI.xml:S2:89:8	occur	VBD	O	O
in	XALKORI.xml:S2:98:2	in	IN	O	O
0.1%	XALKORI.xml:S2:101:4	0.1%	CD	O	O
of	XALKORI.xml:S2:106:2	of	IN	O	O
patients	XALKORI.xml:S2:109:8	patient	NNS	O	O
.	XALKORI.xml:S2:117:1	.	.	O	O

Monitor	XALKORI.xml:S2:119:7	monitor	NN	O	O
with	XALKORI.xml:S2:127:4	with	IN	O	O
periodic	XALKORI.xml:S2:132:8	period	JJ	O	O
liver	XALKORI.xml:S2:141:5	liver	NN	O	O
testing	XALKORI.xml:S2:147:7	test	NN	O	O
.	XALKORI.xml:S2:154:1	.	.	O	O

Temporarily	XALKORI.xml:S2:156:11	temporarili	RB	O	O
suspend	XALKORI.xml:S2:168:7	suspend	VB	O	O
,	XALKORI.xml:S2:175:1	,	,	O	O
dose	XALKORI.xml:S2:177:4	dose	VB	O	O
reduce	XALKORI.xml:S2:182:6	reduc	VB	O	O
,	XALKORI.xml:S2:188:1	,	,	O	O
or	XALKORI.xml:S2:190:2	or	CC	O	O
permanently	XALKORI.xml:S2:193:11	perman	RB	O	O
discontinue	XALKORI.xml:S2:205:11	discontinu	JJ	O	O
XALKORI	XALKORI.xml:S2:217:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:224:1	.	.	O	O

(	XALKORI.xml:S2:226:1	(	(	O	O
5.1	XALKORI.xml:S2:229:3	5.1	CD	O	O
)	XALKORI.xml:S2:234:1	)	)	O	O

Interstitial	XALKORI.xml:S2:241:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
Lung	XALKORI.xml:S2:254:4	lung	NNP	I-AdverseReaction	I-AdverseReaction
Disease	XALKORI.xml:S2:259:7	diseas	NNP	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S2:267:1	(	(	O	O
ILD	XALKORI.xml:S2:268:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
)	XALKORI.xml:S2:271:1	)	)	O	O
Pneumonitis	XALKORI.xml:S2:273:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
:	XALKORI.xml:S2:284:1	:	:	O	O
Occurred	XALKORI.xml:S2:286:8	occur	VBN	O	O
in	XALKORI.xml:S2:295:2	in	IN	O	O
2.9%	XALKORI.xml:S2:298:4	2.9%	CD	O	O
of	XALKORI.xml:S2:303:2	of	IN	O	O
patients	XALKORI.xml:S2:306:8	patient	NNS	O	O
.	XALKORI.xml:S2:314:1	.	.	O	O

Permanently	XALKORI.xml:S2:316:11	perman	RB	O	O
discontinue	XALKORI.xml:S2:328:11	discontinu	NN	O	O
in	XALKORI.xml:S2:340:2	in	IN	O	O
patients	XALKORI.xml:S2:343:8	patient	NNS	O	O
with	XALKORI.xml:S2:352:4	with	IN	O	O
ILD	XALKORI.xml:S2:357:3	ild	NNP	O	O
pneumonitis	XALKORI.xml:S2:361:11	pneumon	NN	O	O
.	XALKORI.xml:S2:372:1	.	.	O	O

(	XALKORI.xml:S2:374:1	(	(	O	O
5.2	XALKORI.xml:S2:377:3	5.2	CD	O	O
)	XALKORI.xml:S2:382:1	)	)	O	O

QT	XALKORI.xml:S2:389:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
Interval	XALKORI.xml:S2:392:8	interv	NNP	I-AdverseReaction	I-AdverseReaction
Prolongation	XALKORI.xml:S2:401:12	prolong	NNP	I-AdverseReaction	I-AdverseReaction
:	XALKORI.xml:S2:413:1	:	:	O	O
Occurred	XALKORI.xml:S2:415:8	occur	VBD	O	O
in	XALKORI.xml:S2:424:2	in	IN	O	O
2.1%	XALKORI.xml:S2:427:4	2.1%	CD	O	O
of	XALKORI.xml:S2:432:2	of	IN	O	O
patients	XALKORI.xml:S2:435:8	patient	NNS	O	O
.	XALKORI.xml:S2:443:1	.	.	O	O

Monitor	XALKORI.xml:S2:445:7	monitor	NN	O	O
with	XALKORI.xml:S2:453:4	with	IN	O	O
electrocardiograms	XALKORI.xml:S2:458:18	electrocardiogram	NNS	O	O
and	XALKORI.xml:S2:477:3	and	CC	O	O
electrolytes	XALKORI.xml:S2:481:12	electrolyt	NNS	O	O
in	XALKORI.xml:S2:494:2	in	IN	O	O
patients	XALKORI.xml:S2:497:8	patient	NNS	O	O
who	XALKORI.xml:S2:506:3	who	WP	O	O
have	XALKORI.xml:S2:510:4	have	VBP	O	O
a	XALKORI.xml:S2:515:1	a	DT	O	O
history	XALKORI.xml:S2:517:7	histori	NN	O	O
of	XALKORI.xml:S2:525:2	of	IN	O	O
or	XALKORI.xml:S2:528:2	or	CC	O	O
predisposition	XALKORI.xml:S2:531:14	predisposit	NN	O	O
for	XALKORI.xml:S2:546:3	for	IN	O	O
QTc	XALKORI.xml:S2:550:3	qtc	NNP	O	O
prolongation	XALKORI.xml:S2:554:12	prolong	NN	O	O
,	XALKORI.xml:S2:566:1	,	,	O	O
or	XALKORI.xml:S2:568:2	or	CC	O	O
who	XALKORI.xml:S2:571:3	who	WP	O	O
are	XALKORI.xml:S2:575:3	are	VBP	O	O
taking	XALKORI.xml:S2:579:6	take	VBG	O	O
medications	XALKORI.xml:S2:586:11	medic	NNS	O	O
that	XALKORI.xml:S2:598:4	that	WDT	O	O
prolong	XALKORI.xml:S2:603:7	prolong	VBP	O	O
QT	XALKORI.xml:S2:611:2	QT	NNP	O	O
.	XALKORI.xml:S2:613:1	.	.	O	O

Temporarily	XALKORI.xml:S2:615:11	temporarili	RB	O	O
suspend	XALKORI.xml:S2:627:7	suspend	VB	O	O
,	XALKORI.xml:S2:634:1	,	,	O	O
dose	XALKORI.xml:S2:636:4	dose	VB	O	O
reduce	XALKORI.xml:S2:641:6	reduc	VB	O	O
,	XALKORI.xml:S2:647:1	,	,	O	O
or	XALKORI.xml:S2:649:2	or	CC	O	O
permanently	XALKORI.xml:S2:652:11	perman	RB	O	O
discontinue	XALKORI.xml:S2:664:11	discontinu	JJ	O	O
XALKORI	XALKORI.xml:S2:676:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:683:1	.	.	O	O

(	XALKORI.xml:S2:685:1	(	(	O	O
5.3	XALKORI.xml:S2:688:3	5.3	CD	O	O
)	XALKORI.xml:S2:693:1	)	)	O	O

Bradycardia	XALKORI.xml:S2:700:11	bradycardia	NNP	B-AdverseReaction	O
:	XALKORI.xml:S2:711:1	:	:	O	O
XALKORI	XALKORI.xml:S2:713:7	xalkori	NN	O	O
can	XALKORI.xml:S2:721:3	can	MD	O	O
cause	XALKORI.xml:S2:725:5	caus	VB	O	O
bradycardia	XALKORI.xml:S2:731:11	bradycardia	NN	B-AdverseReaction	B-AdverseReaction
.	XALKORI.xml:S2:742:1	.	.	O	O

Monitor	XALKORI.xml:S2:744:7	monitor	NNP	O	O
heart	XALKORI.xml:S2:752:5	heart	NN	O	O
rate	XALKORI.xml:S2:758:4	rate	NN	O	O
and	XALKORI.xml:S2:763:3	and	CC	O	O
blood	XALKORI.xml:S2:767:5	blood	NN	O	O
pressure	XALKORI.xml:S2:773:8	pressur	NN	O	O
regularly	XALKORI.xml:S2:782:9	regularli	RB	O	O
.	XALKORI.xml:S2:791:1	.	.	O	O

Temporarily	XALKORI.xml:S2:793:11	temporarili	RB	O	O
suspend	XALKORI.xml:S2:805:7	suspend	VB	O	O
,	XALKORI.xml:S2:812:1	,	,	O	O
dose	XALKORI.xml:S2:814:4	dose	VB	O	O
reduce	XALKORI.xml:S2:819:6	reduc	VB	O	O
,	XALKORI.xml:S2:825:1	,	,	O	O
or	XALKORI.xml:S2:827:2	or	CC	O	O
permanently	XALKORI.xml:S2:830:11	perman	RB	O	O
discontinue	XALKORI.xml:S2:842:11	discontinu	JJ	O	O
XALKORI	XALKORI.xml:S2:854:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:861:1	.	.	O	O

(	XALKORI.xml:S2:863:1	(	(	O	O
5.4	XALKORI.xml:S2:866:3	5.4	CD	O	O
)	XALKORI.xml:S2:871:1	)	)	O	O

Severe	XALKORI.xml:S2:878:6	sever	JJ	O	O
Visual	XALKORI.xml:S2:885:6	visual	JJ	B-AdverseReaction	B-AdverseReaction
Loss	XALKORI.xml:S2:892:4	loss	NN	I-AdverseReaction	I-AdverseReaction
:	XALKORI.xml:S2:896:1	:	:	O	O
Reported	XALKORI.xml:S2:898:8	report	VBN	O	O
in	XALKORI.xml:S2:907:2	in	IN	O	O
0.2%	XALKORI.xml:S2:910:4	0.2%	CD	O	O
of	XALKORI.xml:S2:915:2	of	IN	O	O
patients	XALKORI.xml:S2:918:8	patient	NNS	O	O
.	XALKORI.xml:S2:926:1	.	.	O	O

Discontinue	XALKORI.xml:S2:928:11	discontinu	NNP	O	O
XALKORI	XALKORI.xml:S2:940:7	xalkori	NNP	O	O
in	XALKORI.xml:S2:948:2	in	IN	O	O
patients	XALKORI.xml:S2:951:8	patient	NNS	O	O
with	XALKORI.xml:S2:960:4	with	IN	O	O
severe	XALKORI.xml:S2:965:6	sever	JJ	O	O
visual	XALKORI.xml:S2:972:6	visual	JJ	O	O
loss	XALKORI.xml:S2:979:4	loss	NN	O	O
.	XALKORI.xml:S2:983:1	.	.	O	O

Perform	XALKORI.xml:S2:985:7	perform	VB	O	O
an	XALKORI.xml:S2:993:2	an	DT	O	O
ophthalmological	XALKORI.xml:S2:996:16	ophthalmolog	JJ	O	O
evaluation	XALKORI.xml:S2:1013:10	evalu	NN	O	O
.	XALKORI.xml:S2:1023:1	.	.	O	O

(	XALKORI.xml:S2:1025:1	(	(	O	O
5.5	XALKORI.xml:S2:1028:3	5.5	CD	O	O
)	XALKORI.xml:S2:1033:1	)	)	O	O

Embryofetal	XALKORI.xml:S2:1040:11	embryofet	JJ	B-AdverseReaction	B-AdverseReaction
Toxicity	XALKORI.xml:S2:1052:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
:	XALKORI.xml:S2:1060:1	:	:	O	O
Can	XALKORI.xml:S2:1062:3	can	MD	O	O
cause	XALKORI.xml:S2:1066:5	caus	VB	O	O
fetal	XALKORI.xml:S2:1072:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	XALKORI.xml:S2:1078:4	harm	NN	I-AdverseReaction	I-AdverseReaction
.	XALKORI.xml:S2:1082:1	.	.	O	O

Advise	XALKORI.xml:S2:1084:6	advis	NNP	O	O
females	XALKORI.xml:S2:1091:7	femal	NNS	O	O
of	XALKORI.xml:S2:1099:2	of	IN	O	O
reproductive	XALKORI.xml:S2:1102:12	reproduct	JJ	O	O
potential	XALKORI.xml:S2:1115:9	potenti	NN	O	O
of	XALKORI.xml:S2:1125:2	of	IN	O	O
the	XALKORI.xml:S2:1128:3	the	DT	O	O
potential	XALKORI.xml:S2:1132:9	potenti	JJ	O	O
risk	XALKORI.xml:S2:1142:4	risk	NN	O	O
to	XALKORI.xml:S2:1147:2	to	TO	O	O
a	XALKORI.xml:S2:1150:1	a	DT	O	O
fetus	XALKORI.xml:S2:1152:5	fetu	NN	O	O
and	XALKORI.xml:S2:1158:3	and	CC	O	O
use	XALKORI.xml:S2:1162:3	use	NN	O	O
of	XALKORI.xml:S2:1166:2	of	IN	O	O
effective	XALKORI.xml:S2:1169:9	effect	JJ	O	O
contraception	XALKORI.xml:S2:1179:13	contracept	NN	O	O
.	XALKORI.xml:S2:1192:1	.	.	O	O

(	XALKORI.xml:S2:1194:1	(	(	O	O
5.6	XALKORI.xml:S2:1197:3	5.6	CD	O	O
,	XALKORI.xml:S2:1202:1	,	,	O	O
8.1	XALKORI.xml:S2:1205:3	8.1	CD	O	O
,	XALKORI.xml:S2:1210:1	,	,	O	O
8.3	XALKORI.xml:S2:1213:3	8.3	CD	O	O
)	XALKORI.xml:S2:1218:1	)	)	O	O

5.1	XALKORI.xml:S2:1232:3	5.1	CD	O	O

Hepatotoxicity	XALKORI.xml:S2:1236:14	hepatotox	NN	O	O

Drug	XALKORI.xml:S2:1257:4	drug	NN	O	O

-	XALKORI.xml:S2:1261:1	-	:	O	O
induced	XALKORI.xml:S2:1262:7	induc	VBN	O	O
hepatotoxicity	XALKORI.xml:S2:1270:14	hepatotox	NN	B-AdverseReaction	O
with	XALKORI.xml:S2:1285:4	with	IN	O	O
fatal	XALKORI.xml:S2:1290:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
outcome	XALKORI.xml:S2:1296:7	outcom	NN	O	O
occurred	XALKORI.xml:S2:1304:8	occur	VBD	O	O
in	XALKORI.xml:S2:1313:2	in	IN	O	O
2	XALKORI.xml:S2:1316:1	2	CD	O	O
(	XALKORI.xml:S2:1318:1	(	(	O	O
0.1%	XALKORI.xml:S2:1319:4	0.1%	CD	O	O
)	XALKORI.xml:S2:1323:1	)	)	O	O
of	XALKORI.xml:S2:1325:2	of	IN	O	O
the	XALKORI.xml:S2:1328:3	the	DT	O	O
1669	XALKORI.xml:S2:1332:4	1669	CD	O	O
patients	XALKORI.xml:S2:1337:8	patient	NNS	O	O
treated	XALKORI.xml:S2:1346:7	treat	VBN	O	O
with	XALKORI.xml:S2:1354:4	with	IN	O	O
XALKORI	XALKORI.xml:S2:1359:7	xalkori	NNP	O	O
across	XALKORI.xml:S2:1367:6	across	IN	O	O
clinical	XALKORI.xml:S2:1374:8	clinic	JJ	O	O
trials	XALKORI.xml:S2:1383:6	trial	NNS	O	O
in	XALKORI.xml:S2:1390:2	in	IN	O	O
patients	XALKORI.xml:S2:1393:8	patient	NNS	O	O
with	XALKORI.xml:S2:1402:4	with	IN	O	O
NSCLC	XALKORI.xml:S2:1407:5	nsclc	NNP	O	O
.	XALKORI.xml:S2:1412:1	.	.	O	O

Concurrent	XALKORI.xml:S2:1414:10	concurr	JJ	O	O
elevations	XALKORI.xml:S2:1425:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	XALKORI.xml:S2:1436:2	in	IN	I-AdverseReaction	I-AdverseReaction
alanine	XALKORI.xml:S2:1439:7	alanin	JJ	I-AdverseReaction	I-AdverseReaction
aminotransferase	XALKORI.xml:S2:1447:16	aminotransferas	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S2:1464:1	(	(	O	O
ALT	XALKORI.xml:S2:1465:3	alt	NNP	I-AdverseReaction	O
)	XALKORI.xml:S2:1468:1	)	)	O	O
or	XALKORI.xml:S2:1470:2	or	CC	O	O
aspartate	XALKORI.xml:S2:1473:9	aspart	JJ	I-AdverseReaction	O
aminotransferase	XALKORI.xml:S2:1483:16	aminotransferas	NN	I-AdverseReaction	O
(	XALKORI.xml:S2:1500:1	(	(	O	O
AST	XALKORI.xml:S2:1501:3	ast	NNP	I-AdverseReaction	O
)	XALKORI.xml:S2:1504:1	)	)	O	O
greater	XALKORI.xml:S2:1506:7	greater	JJR	O	O
than	XALKORI.xml:S2:1514:4	than	IN	O	O
or	XALKORI.xml:S2:1519:2	or	CC	O	O
equal	XALKORI.xml:S2:1522:5	equal	JJ	O	O
to	XALKORI.xml:S2:1528:2	to	TO	O	O
three	XALKORI.xml:S2:1531:5	three	CD	O	O
times	XALKORI.xml:S2:1537:5	time	NNS	O	O
the	XALKORI.xml:S2:1543:3	the	DT	O	O
upper	XALKORI.xml:S2:1547:5	upper	JJ	O	O
limit	XALKORI.xml:S2:1553:5	limit	NN	O	O
of	XALKORI.xml:S2:1559:2	of	IN	O	O
normal	XALKORI.xml:S2:1562:6	normal	JJ	O	O
(	XALKORI.xml:S2:1569:1	(	(	O	O
ULN	XALKORI.xml:S2:1570:3	uln	NNP	O	O
)	XALKORI.xml:S2:1573:1	)	)	O	O
and	XALKORI.xml:S2:1575:3	and	CC	O	O
total	XALKORI.xml:S2:1579:5	total	JJ	B-AdverseReaction	B-AdverseReaction
bilirubin	XALKORI.xml:S2:1585:9	bilirubin	NN	I-AdverseReaction	I-AdverseReaction
greater	XALKORI.xml:S2:1595:7	greater	JJR	O	O
than	XALKORI.xml:S2:1603:4	than	IN	O	O
or	XALKORI.xml:S2:1608:2	or	CC	O	O
equal	XALKORI.xml:S2:1611:5	equal	JJ	O	O
to	XALKORI.xml:S2:1617:2	to	TO	O	O
two	XALKORI.xml:S2:1620:3	two	CD	I-AdverseReaction	O
times	XALKORI.xml:S2:1624:5	time	NNS	I-AdverseReaction	O
the	XALKORI.xml:S2:1630:3	the	DT	I-AdverseReaction	O
ULN	XALKORI.xml:S2:1634:3	uln	NNP	I-AdverseReaction	O
,	XALKORI.xml:S2:1637:1	,	,	O	O
with	XALKORI.xml:S2:1639:4	with	IN	O	O
normal	XALKORI.xml:S2:1644:6	normal	JJ	O	O
alkaline	XALKORI.xml:S2:1651:8	alkalin	JJ	O	O
phosphatase	XALKORI.xml:S2:1660:11	phosphatas	NN	O	O
,	XALKORI.xml:S2:1671:1	,	,	O	O
occurred	XALKORI.xml:S2:1673:8	occur	VBD	O	O
in	XALKORI.xml:S2:1682:2	in	IN	O	O
10	XALKORI.xml:S2:1685:2	10	CD	O	O
patients	XALKORI.xml:S2:1688:8	patient	NNS	O	O
(	XALKORI.xml:S2:1697:1	(	(	O	O
0.6%	XALKORI.xml:S2:1698:4	0.6%	CD	O	O
)	XALKORI.xml:S2:1702:1	)	)	O	O
treated	XALKORI.xml:S2:1704:7	treat	VBN	O	O
with	XALKORI.xml:S2:1712:4	with	IN	O	O
XALKORI	XALKORI.xml:S2:1717:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:1724:1	.	.	O	O

Additionally	XALKORI.xml:S2:1726:12	addit	RB	O	O
,	XALKORI.xml:S2:1738:1	,	,	O	O
elevations	XALKORI.xml:S2:1740:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	XALKORI.xml:S2:1751:2	in	IN	I-AdverseReaction	I-AdverseReaction
ALT	XALKORI.xml:S2:1754:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
or	XALKORI.xml:S2:1758:2	or	CC	O	O
AST	XALKORI.xml:S2:1761:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
greater	XALKORI.xml:S2:1765:7	greater	JJR	O	O
than	XALKORI.xml:S2:1773:4	than	IN	O	O
five	XALKORI.xml:S2:1778:4	five	CD	O	O
times	XALKORI.xml:S2:1783:5	time	NNS	O	O
the	XALKORI.xml:S2:1789:3	the	DT	O	O
ULN	XALKORI.xml:S2:1793:3	uln	NNP	O	O
occurred	XALKORI.xml:S2:1797:8	occur	VBD	O	O
in	XALKORI.xml:S2:1806:2	in	IN	O	O
184	XALKORI.xml:S2:1809:3	184	CD	O	O
(	XALKORI.xml:S2:1813:1	(	(	O	O
11%	XALKORI.xml:S2:1814:3	11%	CD	O	O
)	XALKORI.xml:S2:1817:1	)	)	O	O
and	XALKORI.xml:S2:1819:3	and	CC	O	O
93	XALKORI.xml:S2:1823:2	93	CD	O	O
(	XALKORI.xml:S2:1826:1	(	(	O	O
5.7%	XALKORI.xml:S2:1827:4	5.7%	CD	O	O
)	XALKORI.xml:S2:1831:1	)	)	O	O
patients	XALKORI.xml:S2:1833:8	patient	NNS	O	O
,	XALKORI.xml:S2:1841:1	,	,	O	O
respectively	XALKORI.xml:S2:1843:12	respect	RB	O	O
.	XALKORI.xml:S2:1855:1	.	.	O	O

Seventeen	XALKORI.xml:S2:1857:9	seventeen	JJ	O	O
patients	XALKORI.xml:S2:1867:8	patient	NNS	O	O
(	XALKORI.xml:S2:1876:1	(	(	O	O
1.0%	XALKORI.xml:S2:1877:4	1.0%	CD	O	O
)	XALKORI.xml:S2:1881:1	)	)	O	O
required	XALKORI.xml:S2:1883:8	requir	VBN	O	O
permanent	XALKORI.xml:S2:1892:9	perman	JJ	O	O
discontinuation	XALKORI.xml:S2:1902:15	discontinu	NN	O	O
due	XALKORI.xml:S2:1918:3	due	JJ	O	O
to	XALKORI.xml:S2:1922:2	to	TO	O	O
elevated	XALKORI.xml:S2:1925:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
transaminases	XALKORI.xml:S2:1934:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
.	XALKORI.xml:S2:1947:1	.	.	O	O

Transaminase	XALKORI.xml:S2:1949:12	transaminas	NN	B-AdverseReaction	O
elevations	XALKORI.xml:S2:1962:10	elev	NNS	I-AdverseReaction	B-AdverseReaction
generally	XALKORI.xml:S2:1973:9	gener	RB	O	I-AdverseReaction
occurred	XALKORI.xml:S2:1983:8	occur	VBD	O	O
within	XALKORI.xml:S2:1992:6	within	IN	O	O
the	XALKORI.xml:S2:1999:3	the	DT	O	O
first	XALKORI.xml:S2:2003:5	first	JJ	O	O
2	XALKORI.xml:S2:2009:1	2	CD	O	O
months	XALKORI.xml:S2:2011:6	month	NNS	O	O
of	XALKORI.xml:S2:2018:2	of	IN	O	O
treatment	XALKORI.xml:S2:2021:9	treatment	NN	O	O
.	XALKORI.xml:S2:2030:1	.	.	O	O

Monitor	XALKORI.xml:S2:2038:7	monitor	NN	O	O
with	XALKORI.xml:S2:2046:4	with	IN	O	O
liver	XALKORI.xml:S2:2051:5	liver	JJ	O	O
function	XALKORI.xml:S2:2057:8	function	NN	O	O
tests	XALKORI.xml:S2:2066:5	test	NNS	O	O
including	XALKORI.xml:S2:2072:9	includ	VBG	O	O
ALT	XALKORI.xml:S2:2082:3	alt	NNP	O	I-AdverseReaction
and	XALKORI.xml:S2:2086:3	and	CC	O	O
total	XALKORI.xml:S2:2090:5	total	JJ	O	O
bilirubin	XALKORI.xml:S2:2096:9	bilirubin	NN	O	O
every	XALKORI.xml:S2:2106:5	everi	DT	O	O
2	XALKORI.xml:S2:2112:1	2	CD	O	O
weeks	XALKORI.xml:S2:2114:5	week	NNS	O	O
during	XALKORI.xml:S2:2120:6	dure	IN	O	O
the	XALKORI.xml:S2:2127:3	the	DT	O	O
first	XALKORI.xml:S2:2131:5	first	JJ	O	O
2	XALKORI.xml:S2:2137:1	2	CD	O	O
months	XALKORI.xml:S2:2139:6	month	NNS	O	O
of	XALKORI.xml:S2:2146:2	of	IN	O	O
treatment	XALKORI.xml:S2:2149:9	treatment	NN	O	O
,	XALKORI.xml:S2:2158:1	,	,	O	O
then	XALKORI.xml:S2:2160:4	then	RB	O	O
once	XALKORI.xml:S2:2165:4	onc	RB	O	O
a	XALKORI.xml:S2:2170:1	a	DT	O	O
month	XALKORI.xml:S2:2172:5	month	NN	O	O
and	XALKORI.xml:S2:2178:3	and	CC	O	O
as	XALKORI.xml:S2:2182:2	as	IN	O	O
clinically	XALKORI.xml:S2:2185:10	clinic	RB	O	O
indicated	XALKORI.xml:S2:2196:9	indic	VBN	O	O
,	XALKORI.xml:S2:2205:1	,	,	O	O
with	XALKORI.xml:S2:2207:4	with	IN	O	O
more	XALKORI.xml:S2:2212:4	more	RBR	O	O
frequent	XALKORI.xml:S2:2217:8	frequent	JJ	O	O
repeat	XALKORI.xml:S2:2226:6	repeat	NN	O	O
testing	XALKORI.xml:S2:2233:7	test	VBG	O	O
for	XALKORI.xml:S2:2241:3	for	IN	O	O
increased	XALKORI.xml:S2:2245:9	increas	VBN	O	B-AdverseReaction
liver	XALKORI.xml:S2:2255:5	liver	NN	O	I-AdverseReaction
transaminases	XALKORI.xml:S2:2261:13	transaminas	NNS	O	I-AdverseReaction
,	XALKORI.xml:S2:2274:1	,	,	O	O
alkaline	XALKORI.xml:S2:2276:8	alkalin	JJ	O	O
phosphatase	XALKORI.xml:S2:2285:11	phosphatas	NN	O	O
,	XALKORI.xml:S2:2296:1	,	,	O	O
or	XALKORI.xml:S2:2298:2	or	CC	O	O
total	XALKORI.xml:S2:2301:5	total	JJ	O	O
bilirubin	XALKORI.xml:S2:2307:9	bilirubin	NN	O	O
in	XALKORI.xml:S2:2317:2	in	IN	O	O
patients	XALKORI.xml:S2:2320:8	patient	NNS	O	O
who	XALKORI.xml:S2:2329:3	who	WP	O	O
develop	XALKORI.xml:S2:2333:7	develop	VBP	O	O
transaminase	XALKORI.xml:S2:2341:12	transaminas	JJ	O	O
elevations	XALKORI.xml:S2:2354:10	elev	NNS	O	O
.	XALKORI.xml:S2:2364:1	.	.	O	O

Temporarily	XALKORI.xml:S2:2366:11	temporarili	RB	O	O
suspend	XALKORI.xml:S2:2378:7	suspend	VB	O	O
,	XALKORI.xml:S2:2385:1	,	,	O	O
dose	XALKORI.xml:S2:2387:4	dose	VB	O	O
reduce	XALKORI.xml:S2:2392:6	reduc	VB	O	O
,	XALKORI.xml:S2:2398:1	,	,	O	O
or	XALKORI.xml:S2:2400:2	or	CC	O	O
permanently	XALKORI.xml:S2:2403:11	perman	RB	O	O
discontinue	XALKORI.xml:S2:2415:11	discontinu	JJ	O	O
XALKORI	XALKORI.xml:S2:2427:7	xalkori	NNP	O	O
as	XALKORI.xml:S2:2435:2	as	IN	O	O
described	XALKORI.xml:S2:2438:9	describ	VBN	O	O
in	XALKORI.xml:S2:2448:2	in	IN	O	O
Table	XALKORI.xml:S2:2451:5	tabl	JJ	O	O
2	XALKORI.xml:S2:2457:1	2	CD	O	O
[	XALKORI.xml:S2:2459:1	[	NN	O	O
see	XALKORI.xml:S2:2460:3	see	NN	O	O
Dosage	XALKORI.xml:S2:2465:6	dosag	NNP	O	O
and	XALKORI.xml:S2:2472:3	and	CC	O	O
Administration	XALKORI.xml:S2:2476:14	administr	NNP	O	O
(	XALKORI.xml:S2:2491:1	(	(	O	O
2.3	XALKORI.xml:S2:2492:3	2.3	CD	O	O
)	XALKORI.xml:S2:2495:1	)	)	O	O
and	XALKORI.xml:S2:2498:3	and	CC	O	O
Adverse	XALKORI.xml:S2:2503:7	advers	JJ	O	O
Reactions	XALKORI.xml:S2:2511:9	reaction	NNP	O	O
(	XALKORI.xml:S2:2521:1	(	(	O	O
6	XALKORI.xml:S2:2522:1	6	CD	O	O
)	XALKORI.xml:S2:2523:1	)	)	O	O
]	XALKORI.xml:S2:2526:1	]	NN	O	O
.	XALKORI.xml:S2:2529:1	.	.	O	O

5.2	XALKORI.xml:S2:2538:3	5.2	CD	O	O
Interstitial	XALKORI.xml:S2:2542:12	interstiti	JJ	O	O
Lung	XALKORI.xml:S2:2555:4	lung	NNP	O	O
Disease	XALKORI.xml:S2:2560:7	diseas	NNP	O	O
(	XALKORI.xml:S2:2568:1	(	(	O	O
Pneumonitis	XALKORI.xml:S2:2569:11	pneumon	NNP	O	O
)	XALKORI.xml:S2:2580:1	)	)	O	O

Severe	XALKORI.xml:S2:2588:6	sever	NNP	O	O
,	XALKORI.xml:S2:2594:1	,	,	O	O
life	XALKORI.xml:S2:2596:4	life	NN	O	O
-	XALKORI.xml:S2:2600:1	-	:	O	O
threatening	XALKORI.xml:S2:2601:11	threaten	NN	O	O
,	XALKORI.xml:S2:2612:1	,	,	O	O
or	XALKORI.xml:S2:2614:2	or	CC	O	O
fatal	XALKORI.xml:S2:2617:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
interstitial	XALKORI.xml:S2:2623:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
lung	XALKORI.xml:S2:2636:4	lung	NN	I-AdverseReaction	I-AdverseReaction
disease	XALKORI.xml:S2:2641:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
(	XALKORI.xml:S2:2649:1	(	(	O	O
ILD	XALKORI.xml:S2:2650:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
)	XALKORI.xml:S2:2653:1	)	)	O	O
pneumonitis	XALKORI.xml:S2:2655:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
can	XALKORI.xml:S2:2667:3	can	MD	O	O
occur	XALKORI.xml:S2:2671:5	occur	VB	O	O
in	XALKORI.xml:S2:2677:2	in	IN	O	O
patients	XALKORI.xml:S2:2680:8	patient	NNS	O	O
treated	XALKORI.xml:S2:2689:7	treat	VBN	O	O
with	XALKORI.xml:S2:2697:4	with	IN	O	O
XALKORI	XALKORI.xml:S2:2702:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:2709:1	.	.	O	O

Across	XALKORI.xml:S2:2711:6	across	IN	O	O
clinical	XALKORI.xml:S2:2718:8	clinic	JJ	O	O
trials	XALKORI.xml:S2:2727:6	trial	NNS	O	O
(	XALKORI.xml:S2:2734:1	(	(	O	O
n	XALKORI.xml:S2:2735:1	n	JJ	O	O
1669	XALKORI.xml:S2:2737:4	1669	CD	O	O
)	XALKORI.xml:S2:2741:1	)	)	O	O
,	XALKORI.xml:S2:2742:1	,	,	O	O
49	XALKORI.xml:S2:2744:2	49	CD	O	O
XALKORI	XALKORI.xml:S2:2747:7	xalkori	SYM	O	O
-	XALKORI.xml:S2:2754:1	-	:	O	O
treated	XALKORI.xml:S2:2755:7	treat	VBN	O	O
patients	XALKORI.xml:S2:2763:8	patient	NNS	O	O
(	XALKORI.xml:S2:2772:1	(	(	O	O
2.9%	XALKORI.xml:S2:2773:4	2.9%	CD	O	O
)	XALKORI.xml:S2:2777:1	)	)	O	O
had	XALKORI.xml:S2:2779:3	had	VBD	O	O
ILD	XALKORI.xml:S2:2783:3	ild	NNP	B-AdverseReaction	O
of	XALKORI.xml:S2:2787:2	of	IN	O	O
any	XALKORI.xml:S2:2790:3	ani	DT	O	O
grade	XALKORI.xml:S2:2794:5	grade	NN	O	O
,	XALKORI.xml:S2:2799:1	,	,	O	O
18	XALKORI.xml:S2:2801:2	18	CD	O	O
patients	XALKORI.xml:S2:2804:8	patient	NNS	O	O
(	XALKORI.xml:S2:2813:1	(	(	O	O
1.1%	XALKORI.xml:S2:2814:4	1.1%	CD	O	O
)	XALKORI.xml:S2:2818:1	)	)	O	O
had	XALKORI.xml:S2:2820:3	had	VBD	O	O
Grade	XALKORI.xml:S2:2824:5	grade	VBN	O	O
3	XALKORI.xml:S2:2830:1	3	CD	O	O
or	XALKORI.xml:S2:2832:2	or	CC	O	O
4	XALKORI.xml:S2:2835:1	4	CD	O	O
ILD	XALKORI.xml:S2:2837:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
,	XALKORI.xml:S2:2840:1	,	,	O	O
and	XALKORI.xml:S2:2842:3	and	CC	O	O
8	XALKORI.xml:S2:2846:1	8	CD	O	O
patients	XALKORI.xml:S2:2848:8	patient	NNS	O	O
(	XALKORI.xml:S2:2857:1	(	(	O	O
0.5%	XALKORI.xml:S2:2858:4	0.5%	CD	O	O
)	XALKORI.xml:S2:2862:1	)	)	O	O
had	XALKORI.xml:S2:2864:3	had	VBD	O	O
fatal	XALKORI.xml:S2:2868:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
ILD	XALKORI.xml:S2:2874:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
.	XALKORI.xml:S2:2877:1	.	.	O	O

These	XALKORI.xml:S2:2879:5	these	DT	O	O
cases	XALKORI.xml:S2:2885:5	case	NNS	O	O
generally	XALKORI.xml:S2:2891:9	gener	RB	O	O
occurred	XALKORI.xml:S2:2901:8	occur	VBD	O	O
within	XALKORI.xml:S2:2910:6	within	IN	O	O
3	XALKORI.xml:S2:2917:1	3	CD	O	O
months	XALKORI.xml:S2:2919:6	month	NNS	O	O
after	XALKORI.xml:S2:2926:5	after	IN	O	O
the	XALKORI.xml:S2:2932:3	the	DT	O	O
initiation	XALKORI.xml:S2:2936:10	initi	NN	O	O
of	XALKORI.xml:S2:2947:2	of	IN	O	O
XALKORI	XALKORI.xml:S2:2950:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:2957:1	.	.	O	O

Monitor	XALKORI.xml:S2:2965:7	monitor	NN	O	O
patients	XALKORI.xml:S2:2973:8	patient	NNS	O	O
for	XALKORI.xml:S2:2982:3	for	IN	O	O
pulmonary	XALKORI.xml:S2:2986:9	pulmonari	JJ	O	O
symptoms	XALKORI.xml:S2:2996:8	symptom	NNS	O	O
indicative	XALKORI.xml:S2:3005:10	indic	JJ	O	O
of	XALKORI.xml:S2:3016:2	of	IN	O	O
ILD	XALKORI.xml:S2:3019:3	ild	NNP	O	B-AdverseReaction
pneumonitis	XALKORI.xml:S2:3023:11	pneumon	NN	O	I-AdverseReaction
.	XALKORI.xml:S2:3034:1	.	.	O	O

Exclude	XALKORI.xml:S2:3036:7	exclud	NNP	O	O
other	XALKORI.xml:S2:3044:5	other	JJ	O	O
potential	XALKORI.xml:S2:3050:9	potenti	JJ	O	O
causes	XALKORI.xml:S2:3060:6	caus	NNS	O	O
of	XALKORI.xml:S2:3067:2	of	IN	O	O
ILD	XALKORI.xml:S2:3070:3	ild	NNP	O	B-AdverseReaction
pneumonitis	XALKORI.xml:S2:3074:11	pneumon	NN	O	I-AdverseReaction
,	XALKORI.xml:S2:3085:1	,	,	O	O
and	XALKORI.xml:S2:3087:3	and	CC	O	O
permanently	XALKORI.xml:S2:3091:11	perman	RB	O	O
discontinue	XALKORI.xml:S2:3103:11	discontinu	VB	O	O
XALKORI	XALKORI.xml:S2:3115:7	xalkori	NNP	O	O
in	XALKORI.xml:S2:3123:2	in	IN	O	O
patients	XALKORI.xml:S2:3126:8	patient	NNS	O	O
diagnosed	XALKORI.xml:S2:3135:9	diagnos	VBN	O	O
with	XALKORI.xml:S2:3145:4	with	IN	O	O
drug	XALKORI.xml:S2:3150:4	drug	NN	O	O
-	XALKORI.xml:S2:3154:1	-	:	O	O
related	XALKORI.xml:S2:3155:7	relat	VBN	O	O
ILD	XALKORI.xml:S2:3163:3	ild	NNP	O	B-AdverseReaction
pneumonitis	XALKORI.xml:S2:3167:11	pneumon	NN	O	B-AdverseReaction
[	XALKORI.xml:S2:3179:1	[	NNP	O	O
see	XALKORI.xml:S2:3180:3	see	VBP	O	O
Dosage	XALKORI.xml:S2:3185:6	dosag	NNP	O	O
and	XALKORI.xml:S2:3192:3	and	CC	O	O
Administration	XALKORI.xml:S2:3196:14	administr	NNP	O	O
(	XALKORI.xml:S2:3211:1	(	(	O	O
2.3	XALKORI.xml:S2:3212:3	2.3	CD	O	O
)	XALKORI.xml:S2:3215:1	)	)	O	O
and	XALKORI.xml:S2:3218:3	and	CC	O	O
Adverse	XALKORI.xml:S2:3223:7	advers	JJ	O	O
Reactions	XALKORI.xml:S2:3231:9	reaction	NNP	O	O
(	XALKORI.xml:S2:3241:1	(	(	O	O
6	XALKORI.xml:S2:3242:1	6	CD	O	O
)	XALKORI.xml:S2:3243:1	)	)	O	O
]	XALKORI.xml:S2:3246:1	]	NN	O	O
.	XALKORI.xml:S2:3249:1	.	.	O	O

5.3	XALKORI.xml:S2:3258:3	5.3	CD	O	O
QT	XALKORI.xml:S2:3262:2	QT	NNP	O	O
Interval	XALKORI.xml:S2:3265:8	interv	NNP	O	O
Prolongation	XALKORI.xml:S2:3274:12	prolong	NNP	O	O

QTc	XALKORI.xml:S2:3293:3	qtc	NNP	B-AdverseReaction	B-AdverseReaction
prolongation	XALKORI.xml:S2:3297:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
can	XALKORI.xml:S2:3310:3	can	MD	O	O
occur	XALKORI.xml:S2:3314:5	occur	VB	O	O
in	XALKORI.xml:S2:3320:2	in	IN	O	O
patients	XALKORI.xml:S2:3323:8	patient	NNS	O	O
treated	XALKORI.xml:S2:3332:7	treat	VBN	O	O
with	XALKORI.xml:S2:3340:4	with	IN	O	O
XALKORI	XALKORI.xml:S2:3345:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:3352:1	.	.	O	O

Across	XALKORI.xml:S2:3354:6	across	IN	O	O
clinical	XALKORI.xml:S2:3361:8	clinic	JJ	O	O
trials	XALKORI.xml:S2:3370:6	trial	NNS	O	O
,	XALKORI.xml:S2:3376:1	,	,	O	O
32	XALKORI.xml:S2:3378:2	32	CD	O	O
of	XALKORI.xml:S2:3381:2	of	IN	O	O
1560	XALKORI.xml:S2:3384:4	1560	CD	O	O
patients	XALKORI.xml:S2:3389:8	patient	NNS	O	O
(	XALKORI.xml:S2:3398:1	(	(	O	O
2.1%	XALKORI.xml:S2:3399:4	2.1%	CD	O	O
)	XALKORI.xml:S2:3403:1	)	)	O	O
had	XALKORI.xml:S2:3405:3	had	VBD	O	O
QTcF	XALKORI.xml:S2:3409:4	qtcf	NNP	B-AdverseReaction	O
(	XALKORI.xml:S2:3414:1	(	(	O	O
corrected	XALKORI.xml:S2:3415:9	correct	VBN	O	O
QT	XALKORI.xml:S2:3425:2	QT	NNP	O	O
by	XALKORI.xml:S2:3428:2	by	IN	O	O
the	XALKORI.xml:S2:3431:3	the	DT	O	O
Fridericia	XALKORI.xml:S2:3435:10	fridericia	NNP	O	O
method	XALKORI.xml:S2:3446:6	method	NN	O	O
)	XALKORI.xml:S2:3452:1	)	)	O	O
greater	XALKORI.xml:S2:3454:7	greater	JJR	I-AdverseReaction	O
than	XALKORI.xml:S2:3462:4	than	IN	I-AdverseReaction	O
or	XALKORI.xml:S2:3467:2	or	CC	I-AdverseReaction	O
equal	XALKORI.xml:S2:3470:5	equal	JJ	I-AdverseReaction	O
to	XALKORI.xml:S2:3476:2	to	TO	I-AdverseReaction	O
500	XALKORI.xml:S2:3479:3	500	CD	I-AdverseReaction	O
ms	XALKORI.xml:S2:3483:2	ms	NNS	I-AdverseReaction	O
and	XALKORI.xml:S2:3486:3	and	CC	O	O
76	XALKORI.xml:S2:3490:2	76	CD	O	O
of	XALKORI.xml:S2:3493:2	of	IN	O	O
1520	XALKORI.xml:S2:3496:4	1520	CD	O	O
patients	XALKORI.xml:S2:3501:8	patient	NNS	O	O
(	XALKORI.xml:S2:3510:1	(	(	O	O
5.0%	XALKORI.xml:S2:3511:4	5.0%	CD	O	O
)	XALKORI.xml:S2:3515:1	)	)	O	O
had	XALKORI.xml:S2:3517:3	had	VBD	O	O
an	XALKORI.xml:S2:3521:2	an	DT	O	O
increase	XALKORI.xml:S2:3524:8	increas	NN	B-AdverseReaction	B-AdverseReaction
from	XALKORI.xml:S2:3533:4	from	IN	O	O
baseline	XALKORI.xml:S2:3538:8	baselin	JJ	O	O
QTcF	XALKORI.xml:S2:3547:4	qtcf	NNP	I-AdverseReaction	O
greater	XALKORI.xml:S2:3552:7	greater	JJR	O	O
than	XALKORI.xml:S2:3560:4	than	IN	O	O
or	XALKORI.xml:S2:3565:2	or	CC	O	O
equal	XALKORI.xml:S2:3568:5	equal	JJ	O	O
to	XALKORI.xml:S2:3574:2	to	TO	O	O
60	XALKORI.xml:S2:3577:2	60	CD	O	O
ms	XALKORI.xml:S2:3580:2	ms	NNS	O	O
by	XALKORI.xml:S2:3583:2	by	IN	O	O
automated	XALKORI.xml:S2:3586:9	autom	JJ	O	O
machine	XALKORI.xml:S2:3596:7	machin	NN	O	O
-	XALKORI.xml:S2:3603:1	-	:	O	O
read	XALKORI.xml:S2:3604:4	read	JJ	O	O
evaluation	XALKORI.xml:S2:3609:10	evalu	NN	O	O
of	XALKORI.xml:S2:3620:2	of	IN	O	O
ECG	XALKORI.xml:S2:3623:3	ecg	NNP	O	O
.	XALKORI.xml:S2:3626:1	.	.	O	O

Avoid	XALKORI.xml:S2:3634:5	avoid	NNP	O	O
use	XALKORI.xml:S2:3640:3	use	NN	O	O
of	XALKORI.xml:S2:3644:2	of	IN	O	O
XALKORI	XALKORI.xml:S2:3647:7	xalkori	NN	O	O
in	XALKORI.xml:S2:3655:2	in	IN	O	O
patients	XALKORI.xml:S2:3658:8	patient	NNS	O	O
with	XALKORI.xml:S2:3667:4	with	IN	O	O
congenital	XALKORI.xml:S2:3672:10	congenit	JJ	O	O
long	XALKORI.xml:S2:3683:4	long	JJ	O	O
QT	XALKORI.xml:S2:3688:2	QT	NNP	O	O
syndrome	XALKORI.xml:S2:3691:8	syndrom	NN	O	O
.	XALKORI.xml:S2:3699:1	.	.	O	O

Consider	XALKORI.xml:S2:3701:8	consid	VB	O	O
periodic	XALKORI.xml:S2:3710:8	period	JJ	O	O
monitoring	XALKORI.xml:S2:3719:10	monitor	NN	O	O
with	XALKORI.xml:S2:3730:4	with	IN	O	O
electrocardiograms	XALKORI.xml:S2:3735:18	electrocardiogram	NNS	O	O
(	XALKORI.xml:S2:3754:1	(	(	O	O
ECGs	XALKORI.xml:S2:3755:4	ecg	NNP	O	O
)	XALKORI.xml:S2:3759:1	)	)	O	O
and	XALKORI.xml:S2:3761:3	and	CC	O	O
electrolytes	XALKORI.xml:S2:3765:12	electrolyt	VBZ	O	O
in	XALKORI.xml:S2:3778:2	in	IN	O	O
patients	XALKORI.xml:S2:3781:8	patient	NNS	O	O
with	XALKORI.xml:S2:3790:4	with	IN	O	O
congestive	XALKORI.xml:S2:3795:10	congest	JJ	O	O
heart	XALKORI.xml:S2:3806:5	heart	NN	O	O
failure	XALKORI.xml:S2:3812:7	failur	NN	O	O
,	XALKORI.xml:S2:3819:1	,	,	O	O
bradyarrhythmias	XALKORI.xml:S2:3821:16	bradyarrhythmia	NN	O	B-AdverseReaction
,	XALKORI.xml:S2:3837:1	,	,	O	O
electrolyte	XALKORI.xml:S2:3839:11	electrolyt	JJ	O	O
abnormalities	XALKORI.xml:S2:3851:13	abnorm	NNS	O	O
,	XALKORI.xml:S2:3864:1	,	,	O	O
or	XALKORI.xml:S2:3866:2	or	CC	O	O
who	XALKORI.xml:S2:3869:3	who	WP	O	O
are	XALKORI.xml:S2:3873:3	are	VBP	O	O
taking	XALKORI.xml:S2:3877:6	take	VBG	O	O
medications	XALKORI.xml:S2:3884:11	medic	NNS	O	O
that	XALKORI.xml:S2:3896:4	that	WDT	O	O
are	XALKORI.xml:S2:3901:3	are	VBP	O	O
known	XALKORI.xml:S2:3905:5	known	VBN	O	O
to	XALKORI.xml:S2:3911:2	to	TO	O	O
prolong	XALKORI.xml:S2:3914:7	prolong	VB	O	O
the	XALKORI.xml:S2:3922:3	the	DT	O	O
QT	XALKORI.xml:S2:3926:2	QT	NNP	O	O
interval	XALKORI.xml:S2:3929:8	interv	NN	O	O
.	XALKORI.xml:S2:3937:1	.	.	O	O

Permanently	XALKORI.xml:S2:3939:11	perman	RB	O	O
discontinue	XALKORI.xml:S2:3951:11	discontinu	JJ	O	O
XALKORI	XALKORI.xml:S2:3963:7	xalkori	NNP	O	O
in	XALKORI.xml:S2:3971:2	in	IN	O	O
patients	XALKORI.xml:S2:3974:8	patient	NNS	O	O
who	XALKORI.xml:S2:3983:3	who	WP	O	O
develop	XALKORI.xml:S2:3987:7	develop	VBP	O	O
QTc	XALKORI.xml:S2:3995:3	qtc	NNP	O	O
greater	XALKORI.xml:S2:3999:7	greater	JJR	O	O
than	XALKORI.xml:S2:4007:4	than	IN	O	O
500	XALKORI.xml:S2:4012:3	500	CD	O	O
ms	XALKORI.xml:S2:4016:2	ms	NN	O	O
or	XALKORI.xml:S2:4019:2	or	CC	O	O
greater	XALKORI.xml:S2:4022:7	greater	JJR	O	O
than	XALKORI.xml:S2:4030:4	than	IN	O	O
or	XALKORI.xml:S2:4035:2	or	CC	O	O
equal	XALKORI.xml:S2:4038:5	equal	JJ	O	O
to	XALKORI.xml:S2:4044:2	to	TO	O	O
60	XALKORI.xml:S2:4047:2	60	CD	O	O
ms	XALKORI.xml:S2:4050:2	ms	NNS	O	O
change	XALKORI.xml:S2:4053:6	chang	VBP	O	O
from	XALKORI.xml:S2:4060:4	from	IN	O	O
baseline	XALKORI.xml:S2:4065:8	baselin	NN	O	O
with	XALKORI.xml:S2:4074:4	with	IN	O	O
Torsade	XALKORI.xml:S2:4079:7	torsad	NNP	O	O
de	XALKORI.xml:S2:4087:2	de	FW	O	O
pointes	XALKORI.xml:S2:4090:7	point	VBZ	O	O
or	XALKORI.xml:S2:4098:2	or	CC	O	O
polymorphic	XALKORI.xml:S2:4101:11	polymorph	JJ	O	O
ventricular	XALKORI.xml:S2:4113:11	ventricular	JJ	O	O
tachycardia	XALKORI.xml:S2:4125:11	tachycardia	NN	O	O
or	XALKORI.xml:S2:4137:2	or	CC	O	O
signs	XALKORI.xml:S2:4140:5	sign	NNS	O	O
symptoms	XALKORI.xml:S2:4146:8	symptom	NNS	O	O
of	XALKORI.xml:S2:4155:2	of	IN	O	O
serious	XALKORI.xml:S2:4158:7	seriou	JJ	O	O
arrhythmia	XALKORI.xml:S2:4166:10	arrhythmia	NN	O	O
.	XALKORI.xml:S2:4176:1	.	.	O	O

Withhold	XALKORI.xml:S2:4178:8	withhold	NNP	O	O
XALKORI	XALKORI.xml:S2:4187:7	xalkori	NNP	O	O
in	XALKORI.xml:S2:4195:2	in	IN	O	O
patients	XALKORI.xml:S2:4198:8	patient	NNS	O	O
who	XALKORI.xml:S2:4207:3	who	WP	O	O
develop	XALKORI.xml:S2:4211:7	develop	VBP	O	O
QTc	XALKORI.xml:S2:4219:3	qtc	NNP	O	O
greater	XALKORI.xml:S2:4223:7	greater	JJR	O	O
than	XALKORI.xml:S2:4231:4	than	IN	O	O
500	XALKORI.xml:S2:4236:3	500	CD	O	O
ms	XALKORI.xml:S2:4240:2	ms	NN	O	O
on	XALKORI.xml:S2:4243:2	on	IN	O	O
at	XALKORI.xml:S2:4246:2	at	IN	O	O
least	XALKORI.xml:S2:4249:5	least	JJS	O	O
2	XALKORI.xml:S2:4255:1	2	CD	O	O
separate	XALKORI.xml:S2:4257:8	separ	JJ	O	O
ECGs	XALKORI.xml:S2:4266:4	ecg	NNP	O	O
until	XALKORI.xml:S2:4271:5	until	IN	O	O
recovery	XALKORI.xml:S2:4277:8	recoveri	NN	O	O
to	XALKORI.xml:S2:4286:2	to	TO	O	O
a	XALKORI.xml:S2:4289:1	a	DT	O	O
QTc	XALKORI.xml:S2:4291:3	qtc	NNP	O	O
less	XALKORI.xml:S2:4295:4	less	JJR	O	O
than	XALKORI.xml:S2:4300:4	than	IN	O	O
or	XALKORI.xml:S2:4305:2	or	CC	O	O
equal	XALKORI.xml:S2:4308:5	equal	JJ	O	O
to	XALKORI.xml:S2:4314:2	to	TO	O	O
480	XALKORI.xml:S2:4317:3	480	CD	O	O
ms	XALKORI.xml:S2:4321:2	ms	NNS	O	O
,	XALKORI.xml:S2:4323:1	,	,	O	O
then	XALKORI.xml:S2:4325:4	then	RB	O	O
resume	XALKORI.xml:S2:4330:6	resum	VB	O	O
XALKORI	XALKORI.xml:S2:4337:7	xalkori	NNP	O	O
at	XALKORI.xml:S2:4345:2	at	IN	O	O
a	XALKORI.xml:S2:4348:1	a	DT	O	O
reduced	XALKORI.xml:S2:4350:7	reduc	JJ	O	O
dose	XALKORI.xml:S2:4358:4	dose	NN	O	O
as	XALKORI.xml:S2:4363:2	as	IN	O	O
described	XALKORI.xml:S2:4366:9	describ	VBN	O	O
in	XALKORI.xml:S2:4376:2	in	IN	O	O
Table	XALKORI.xml:S2:4379:5	tabl	JJ	O	O
2	XALKORI.xml:S2:4385:1	2	CD	O	O
[	XALKORI.xml:S2:4387:1	[	NN	O	O
see	XALKORI.xml:S2:4388:3	see	NN	O	O
Dosage	XALKORI.xml:S2:4393:6	dosag	NNP	O	O
and	XALKORI.xml:S2:4400:3	and	CC	O	O
Administration	XALKORI.xml:S2:4404:14	administr	NNP	O	O
(	XALKORI.xml:S2:4419:1	(	(	O	O
2.3	XALKORI.xml:S2:4420:3	2.3	CD	O	O
)	XALKORI.xml:S2:4423:1	)	)	O	O
and	XALKORI.xml:S2:4428:3	and	CC	O	O
Clinical	XALKORI.xml:S2:4434:8	clinic	JJ	O	O
Pharmacology	XALKORI.xml:S2:4443:12	pharmacolog	NNP	O	O
(	XALKORI.xml:S2:4456:1	(	(	O	O
12.2	XALKORI.xml:S2:4457:4	12.2	CD	O	O
)	XALKORI.xml:S2:4461:1	)	)	O	O
]	XALKORI.xml:S2:4464:1	]	NN	O	O
.	XALKORI.xml:S2:4467:1	.	.	O	O

5.4	XALKORI.xml:S2:4476:3	5.4	CD	O	O
Bradycardia	XALKORI.xml:S2:4480:11	bradycardia	NNP	O	O

Symptomatic	XALKORI.xml:S2:4498:11	symptomat	JJ	B-AdverseReaction	B-AdverseReaction
bradycardia	XALKORI.xml:S2:4510:11	bradycardia	NN	I-AdverseReaction	I-AdverseReaction
can	XALKORI.xml:S2:4522:3	can	MD	O	O
occur	XALKORI.xml:S2:4526:5	occur	VB	O	O
in	XALKORI.xml:S2:4532:2	in	IN	O	O
patients	XALKORI.xml:S2:4535:8	patient	NNS	O	O
receiving	XALKORI.xml:S2:4544:9	receiv	VBG	O	O
XALKORI	XALKORI.xml:S2:4554:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:4561:1	.	.	O	O

Across	XALKORI.xml:S2:4563:6	across	IN	O	O
clinical	XALKORI.xml:S2:4570:8	clinic	JJ	O	O
trials	XALKORI.xml:S2:4579:6	trial	NNS	O	O
,	XALKORI.xml:S2:4585:1	,	,	O	O
bradycardia	XALKORI.xml:S2:4587:11	bradycardia	NN	B-AdverseReaction	B-AdverseReaction
occurred	XALKORI.xml:S2:4599:8	occur	VBD	O	O
in	XALKORI.xml:S2:4608:2	in	IN	O	O
205	XALKORI.xml:S2:4611:3	205	CD	O	O
(	XALKORI.xml:S2:4615:1	(	(	O	O
12.3%	XALKORI.xml:S2:4616:5	12.3%	CD	O	O
)	XALKORI.xml:S2:4621:1	)	)	O	O
of	XALKORI.xml:S2:4623:2	of	IN	O	O
1669	XALKORI.xml:S2:4626:4	1669	CD	O	O
patients	XALKORI.xml:S2:4631:8	patient	NNS	O	O
treated	XALKORI.xml:S2:4640:7	treat	VBN	O	O
with	XALKORI.xml:S2:4648:4	with	IN	O	O
XALKORI	XALKORI.xml:S2:4653:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:4660:1	.	.	O	O

A	XALKORI.xml:S2:4662:1	A	DT	O	O
total	XALKORI.xml:S2:4664:5	total	NN	O	O
of	XALKORI.xml:S2:4670:2	of	IN	O	O
242	XALKORI.xml:S2:4673:3	242	CD	O	O
(	XALKORI.xml:S2:4677:1	(	(	O	O
14.9%	XALKORI.xml:S2:4678:5	14.9%	CD	O	O
)	XALKORI.xml:S2:4683:1	)	)	O	O
patients	XALKORI.xml:S2:4685:8	patient	NNS	O	O
had	XALKORI.xml:S2:4694:3	had	VBD	O	O
a	XALKORI.xml:S2:4698:1	a	DT	O	O
heart	XALKORI.xml:S2:4700:5	heart	NN	B-AdverseReaction	O
rate	XALKORI.xml:S2:4706:4	rate	NN	I-AdverseReaction	O
less	XALKORI.xml:S2:4711:4	less	JJR	I-AdverseReaction	O
than	XALKORI.xml:S2:4716:4	than	IN	I-AdverseReaction	O
50	XALKORI.xml:S2:4721:2	50	CD	I-AdverseReaction	O
beats	XALKORI.xml:S2:4724:5	beat	NNS	I-AdverseReaction	O
per	XALKORI.xml:S2:4730:3	per	IN	I-AdverseReaction	O
minute	XALKORI.xml:S2:4734:6	minut	NN	I-AdverseReaction	O
.	XALKORI.xml:S2:4740:1	.	.	O	O

In	XALKORI.xml:S2:4742:2	In	IN	O	O
Studies	XALKORI.xml:S2:4745:7	studi	NNP	O	O
1	XALKORI.xml:S2:4753:1	1	CD	O	O
and	XALKORI.xml:S2:4755:3	and	CC	O	O
2	XALKORI.xml:S2:4759:1	2	CD	O	O
,	XALKORI.xml:S2:4760:1	,	,	O	O
Grade	XALKORI.xml:S2:4762:5	grade	VBD	O	O
3	XALKORI.xml:S2:4768:1	3	CD	O	O
syncope	XALKORI.xml:S2:4770:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
occurred	XALKORI.xml:S2:4778:8	occur	VBD	O	O
in	XALKORI.xml:S2:4787:2	in	IN	O	O
2.0%	XALKORI.xml:S2:4790:4	2.0%	CD	O	O
of	XALKORI.xml:S2:4795:2	of	IN	O	O
XALKORI	XALKORI.xml:S2:4798:7	xalkori	NNP	O	O
-	XALKORI.xml:S2:4805:1	-	:	O	O
treated	XALKORI.xml:S2:4806:7	treat	VBD	O	O
patients	XALKORI.xml:S2:4814:8	patient	NNS	O	O
and	XALKORI.xml:S2:4823:3	and	CC	O	O
in	XALKORI.xml:S2:4827:2	in	IN	O	O
0.6%	XALKORI.xml:S2:4830:4	0.6%	CD	O	O
of	XALKORI.xml:S2:4835:2	of	IN	O	O
the	XALKORI.xml:S2:4838:3	the	DT	O	O
chemotherapy	XALKORI.xml:S2:4842:12	chemotherapi	NN	O	O
-	XALKORI.xml:S2:4854:1	-	:	O	O
treated	XALKORI.xml:S2:4855:7	treat	JJ	O	O
patients	XALKORI.xml:S2:4863:8	patient	NNS	O	O
.	XALKORI.xml:S2:4871:1	.	.	O	O

Avoid	XALKORI.xml:S2:4879:5	avoid	NNP	O	O
using	XALKORI.xml:S2:4885:5	use	VBG	O	O
XALKORI	XALKORI.xml:S2:4891:7	xalkori	NNP	O	O
in	XALKORI.xml:S2:4899:2	in	IN	O	O
combination	XALKORI.xml:S2:4902:11	combin	NN	O	O
with	XALKORI.xml:S2:4914:4	with	IN	O	O
other	XALKORI.xml:S2:4919:5	other	JJ	O	O
agents	XALKORI.xml:S2:4925:6	agent	NNS	O	O
known	XALKORI.xml:S2:4932:5	known	VBN	O	O
to	XALKORI.xml:S2:4938:2	to	TO	O	O
cause	XALKORI.xml:S2:4941:5	caus	VB	O	O
bradycardia	XALKORI.xml:S2:4947:11	bradycardia	NN	O	O
(	XALKORI.xml:S2:4959:1	(	(	O	O
e	XALKORI.xml:S2:4960:1	e	NN	O	O
.	XALKORI.xml:S2:4961:1	.	.	O	O
g	XALKORI.xml:S2:4962:1	g	NN	O	O
.	XALKORI.xml:S2:4963:1	.	.	O	O
,	XALKORI.xml:S2:4964:1	,	,	O	O
beta	XALKORI.xml:S2:4966:4	beta	SYM	O	O
-	XALKORI.xml:S2:4970:1	-	:	O	O
blockers	XALKORI.xml:S2:4971:8	blocker	NNS	O	O
,	XALKORI.xml:S2:4979:1	,	,	O	O
non	XALKORI.xml:S2:4981:3	non	SYM	O	O
-	XALKORI.xml:S2:4984:1	-	:	O	O
dihydropyridine	XALKORI.xml:S2:4985:15	dihydropyridin	NN	O	O
calcium	XALKORI.xml:S2:5001:7	calcium	NN	O	O
channel	XALKORI.xml:S2:5009:7	channel	NN	O	O
blockers	XALKORI.xml:S2:5017:8	blocker	NNS	O	O
,	XALKORI.xml:S2:5025:1	,	,	O	O
clonidine	XALKORI.xml:S2:5027:9	clonidin	NN	O	O
and	XALKORI.xml:S2:5037:3	and	CC	O	O
digoxin	XALKORI.xml:S2:5041:7	digoxin	NN	O	O
)	XALKORI.xml:S2:5048:1	)	)	O	O
to	XALKORI.xml:S2:5050:2	to	TO	O	O
the	XALKORI.xml:S2:5053:3	the	DT	O	O
extent	XALKORI.xml:S2:5057:6	extent	NN	O	O
possible	XALKORI.xml:S2:5064:8	possibl	JJ	O	O
.	XALKORI.xml:S2:5072:1	.	.	O	O

Monitor	XALKORI.xml:S2:5074:7	monitor	NNP	O	O
heart	XALKORI.xml:S2:5082:5	heart	NN	O	O
rate	XALKORI.xml:S2:5088:4	rate	NN	O	O
and	XALKORI.xml:S2:5093:3	and	CC	O	O
blood	XALKORI.xml:S2:5097:5	blood	NN	O	O
pressure	XALKORI.xml:S2:5103:8	pressur	NN	O	O
regularly	XALKORI.xml:S2:5112:9	regularli	RB	O	O
.	XALKORI.xml:S2:5121:1	.	.	O	O

In	XALKORI.xml:S2:5123:2	In	IN	O	O
cases	XALKORI.xml:S2:5126:5	case	NNS	O	O
of	XALKORI.xml:S2:5132:2	of	IN	O	O
symptomatic	XALKORI.xml:S2:5135:11	symptomat	JJ	O	O
bradycardia	XALKORI.xml:S2:5147:11	bradycardia	NN	O	O
that	XALKORI.xml:S2:5159:4	that	WDT	O	O
is	XALKORI.xml:S2:5164:2	is	VBZ	O	O
not	XALKORI.xml:S2:5167:3	not	RB	O	O
life	XALKORI.xml:S2:5171:4	life	NN	O	O
-	XALKORI.xml:S2:5175:1	-	:	O	O
threatening	XALKORI.xml:S2:5176:11	threaten	NN	O	O
,	XALKORI.xml:S2:5187:1	,	,	O	O
hold	XALKORI.xml:S2:5189:4	hold	VBP	O	O
XALKORI	XALKORI.xml:S2:5194:7	xalkori	NNP	O	O
until	XALKORI.xml:S2:5202:5	until	IN	O	O
recovery	XALKORI.xml:S2:5208:8	recoveri	NN	O	O
to	XALKORI.xml:S2:5217:2	to	TO	O	O
asymptomatic	XALKORI.xml:S2:5220:12	asymptomat	JJ	O	O
bradycardia	XALKORI.xml:S2:5233:11	bradycardia	NN	O	O
or	XALKORI.xml:S2:5245:2	or	CC	O	O
to	XALKORI.xml:S2:5248:2	to	TO	O	O
a	XALKORI.xml:S2:5251:1	a	DT	O	O
heart	XALKORI.xml:S2:5253:5	heart	NN	O	O
rate	XALKORI.xml:S2:5259:4	rate	NN	O	O
of	XALKORI.xml:S2:5264:2	of	IN	O	O
60	XALKORI.xml:S2:5267:2	60	CD	O	O
bpm	XALKORI.xml:S2:5270:3	bpm	NN	O	O
or	XALKORI.xml:S2:5274:2	or	CC	O	O
above	XALKORI.xml:S2:5277:5	abov	IN	O	O
,	XALKORI.xml:S2:5282:1	,	,	O	O
re	XALKORI.xml:S2:5284:2	re	VB	O	O
-	XALKORI.xml:S2:5286:1	-	:	O	O
evaluate	XALKORI.xml:S2:5287:8	evalu	VB	O	O
the	XALKORI.xml:S2:5296:3	the	DT	O	O
use	XALKORI.xml:S2:5300:3	use	NN	O	O
of	XALKORI.xml:S2:5304:2	of	IN	O	O
concomitant	XALKORI.xml:S2:5307:11	concomit	JJ	O	O
medications	XALKORI.xml:S2:5319:11	medic	NNS	O	O
,	XALKORI.xml:S2:5330:1	,	,	O	O
and	XALKORI.xml:S2:5332:3	and	CC	O	O
adjust	XALKORI.xml:S2:5336:6	adjust	VBP	O	O
the	XALKORI.xml:S2:5343:3	the	DT	O	O
dose	XALKORI.xml:S2:5347:4	dose	NN	O	O
of	XALKORI.xml:S2:5352:2	of	IN	O	O
XALKORI	XALKORI.xml:S2:5355:7	xalkori	NNP	O	O
.	XALKORI.xml:S2:5362:1	.	.	O	O

Permanently	XALKORI.xml:S2:5364:11	perman	RB	O	O
discontinue	XALKORI.xml:S2:5376:11	discontinu	NN	O	O
for	XALKORI.xml:S2:5388:3	for	IN	O	O
life	XALKORI.xml:S2:5392:4	life	NN	O	O
-	XALKORI.xml:S2:5396:1	-	:	O	O
threatening	XALKORI.xml:S2:5397:11	threaten	JJ	O	O
bradycardia	XALKORI.xml:S2:5409:11	bradycardia	NN	O	O
due	XALKORI.xml:S2:5421:3	due	JJ	O	O
to	XALKORI.xml:S2:5425:2	to	TO	O	O
XALKORI	XALKORI.xml:S2:5428:7	xalkori	NNP	O	O
;	XALKORI.xml:S2:5435:1	;	:	O	O
however	XALKORI.xml:S2:5437:7	howev	RB	O	O
,	XALKORI.xml:S2:5444:1	,	,	O	O
if	XALKORI.xml:S2:5446:2	if	IN	O	O
associated	XALKORI.xml:S2:5449:10	associ	VBN	O	O
with	XALKORI.xml:S2:5460:4	with	IN	O	O
concomitant	XALKORI.xml:S2:5465:11	concomit	JJ	O	O
medications	XALKORI.xml:S2:5477:11	medic	NNS	O	O
known	XALKORI.xml:S2:5489:5	known	VBN	O	O
to	XALKORI.xml:S2:5495:2	to	TO	O	O
cause	XALKORI.xml:S2:5498:5	caus	VB	O	O
bradycardia	XALKORI.xml:S2:5504:11	bradycardia	NN	O	O
or	XALKORI.xml:S2:5516:2	or	CC	O	O
hypotension	XALKORI.xml:S2:5519:11	hypotens	NN	O	B-AdverseReaction
,	XALKORI.xml:S2:5530:1	,	,	O	O
hold	XALKORI.xml:S2:5532:4	hold	VBP	O	O
XALKORI	XALKORI.xml:S2:5537:7	xalkori	NNP	O	O
until	XALKORI.xml:S2:5545:5	until	IN	O	O
recovery	XALKORI.xml:S2:5551:8	recoveri	NN	O	O
to	XALKORI.xml:S2:5560:2	to	TO	O	O
asymptomatic	XALKORI.xml:S2:5563:12	asymptomat	JJ	O	O
bradycardia	XALKORI.xml:S2:5576:11	bradycardia	NN	O	O
or	XALKORI.xml:S2:5588:2	or	CC	O	O
to	XALKORI.xml:S2:5591:2	to	TO	O	O
a	XALKORI.xml:S2:5594:1	a	DT	O	O
heart	XALKORI.xml:S2:5596:5	heart	NN	O	O
rate	XALKORI.xml:S2:5602:4	rate	NN	O	O
of	XALKORI.xml:S2:5607:2	of	IN	O	O
60	XALKORI.xml:S2:5610:2	60	CD	O	O
bpm	XALKORI.xml:S2:5613:3	bpm	NN	O	O
or	XALKORI.xml:S2:5617:2	or	CC	O	O
above	XALKORI.xml:S2:5620:5	abov	NN	O	O
,	XALKORI.xml:S2:5625:1	,	,	O	O
and	XALKORI.xml:S2:5627:3	and	CC	O	O
if	XALKORI.xml:S2:5631:2	if	IN	O	O
concomitant	XALKORI.xml:S2:5634:11	concomit	JJ	O	O
medications	XALKORI.xml:S2:5646:11	medic	NNS	O	O
can	XALKORI.xml:S2:5658:3	can	MD	O	O
be	XALKORI.xml:S2:5662:2	be	VB	O	O
adjusted	XALKORI.xml:S2:5665:8	adjust	VBN	O	O
or	XALKORI.xml:S2:5674:2	or	CC	O	O
discontinued	XALKORI.xml:S2:5677:12	discontinu	VBN	O	O
,	XALKORI.xml:S2:5689:1	,	,	O	O
restart	XALKORI.xml:S2:5691:7	restart	VB	O	O
XALKORI	XALKORI.xml:S2:5699:7	xalkori	NNP	O	O
at	XALKORI.xml:S2:5707:2	at	IN	O	O
250	XALKORI.xml:S2:5710:3	250	CD	O	O
mg	XALKORI.xml:S2:5714:2	mg	NNS	O	O
once	XALKORI.xml:S2:5717:4	onc	RB	O	O
daily	XALKORI.xml:S2:5722:5	daili	JJ	O	O
with	XALKORI.xml:S2:5728:4	with	IN	O	O
frequent	XALKORI.xml:S2:5733:8	frequent	JJ	O	O
monitoring	XALKORI.xml:S2:5742:10	monitor	NN	O	O
[	XALKORI.xml:S2:5753:1	[	NNP	O	O
see	XALKORI.xml:S2:5754:3	see	VBP	O	O
Dosage	XALKORI.xml:S2:5759:6	dosag	NNP	O	O
and	XALKORI.xml:S2:5766:3	and	CC	O	O
Administration	XALKORI.xml:S2:5770:14	administr	NNP	O	O
(	XALKORI.xml:S2:5785:1	(	(	O	O
2.3	XALKORI.xml:S2:5786:3	2.3	CD	O	O
)	XALKORI.xml:S2:5789:1	)	)	O	O
and	XALKORI.xml:S2:5792:3	and	CC	O	O
Adverse	XALKORI.xml:S2:5797:7	advers	JJ	O	O
Reactions	XALKORI.xml:S2:5805:9	reaction	NNP	O	O
(	XALKORI.xml:S2:5815:1	(	(	O	O
6	XALKORI.xml:S2:5816:1	6	CD	O	O
)	XALKORI.xml:S2:5817:1	)	)	O	O
]	XALKORI.xml:S2:5820:1	]	NN	O	O
.	XALKORI.xml:S2:5823:1	.	.	O	O

5.5	XALKORI.xml:S2:5832:3	5.5	CD	O	O
Severe	XALKORI.xml:S2:5836:6	sever	JJ	O	O
Visual	XALKORI.xml:S2:5843:6	visual	NNP	O	O
Loss	XALKORI.xml:S2:5850:4	loss	NNP	O	O

Across	XALKORI.xml:S2:5861:6	across	IN	O	O
all	XALKORI.xml:S2:5868:3	all	DT	O	O
clinical	XALKORI.xml:S2:5872:8	clinic	JJ	O	O
trials	XALKORI.xml:S2:5881:6	trial	NNS	O	O
,	XALKORI.xml:S2:5887:1	,	,	O	O
the	XALKORI.xml:S2:5889:3	the	DT	O	O
incidence	XALKORI.xml:S2:5893:9	incid	NN	O	O
of	XALKORI.xml:S2:5903:2	of	IN	O	O
Grade	XALKORI.xml:S2:5906:5	grade	NNP	O	O
4	XALKORI.xml:S2:5912:1	4	CD	O	O
visual	XALKORI.xml:S2:5914:6	visual	JJ	B-AdverseReaction	B-AdverseReaction
field	XALKORI.xml:S2:5921:5	field	NN	I-AdverseReaction	I-AdverseReaction
defect	XALKORI.xml:S2:5927:6	defect	NN	I-AdverseReaction	I-AdverseReaction
with	XALKORI.xml:S2:5934:4	with	IN	O	I-AdverseReaction
vision	XALKORI.xml:S2:5939:6	vision	NN	B-AdverseReaction	I-AdverseReaction
loss	XALKORI.xml:S2:5946:4	loss	NN	I-AdverseReaction	I-AdverseReaction
was	XALKORI.xml:S2:5951:3	wa	VBD	O	O
0.2%	XALKORI.xml:S2:5955:4	0.2%	CD	O	O
(	XALKORI.xml:S2:5960:1	(	(	O	O
4	XALKORI.xml:S2:5961:1	4	CD	O	O
1669	XALKORI.xml:S2:5963:4	1669	CD	O	O
)	XALKORI.xml:S2:5967:1	)	)	O	O
.	XALKORI.xml:S2:5968:1	.	.	O	O

Optic	XALKORI.xml:S2:5970:5	optic	JJ	B-AdverseReaction	B-AdverseReaction
atrophy	XALKORI.xml:S2:5976:7	atrophi	NN	I-AdverseReaction	I-AdverseReaction
and	XALKORI.xml:S2:5984:3	and	CC	O	O
optic	XALKORI.xml:S2:5988:5	optic	JJ	B-AdverseReaction	B-AdverseReaction
nerve	XALKORI.xml:S2:5994:5	nerv	NN	I-AdverseReaction	I-AdverseReaction
disorder	XALKORI.xml:S2:6000:8	disord	NN	I-AdverseReaction	I-AdverseReaction
have	XALKORI.xml:S2:6009:4	have	VBP	O	O
been	XALKORI.xml:S2:6014:4	been	VBN	O	O
reported	XALKORI.xml:S2:6019:8	report	VBN	O	O
as	XALKORI.xml:S2:6028:2	as	IN	O	O
potential	XALKORI.xml:S2:6031:9	potenti	JJ	O	O
causes	XALKORI.xml:S2:6041:6	caus	NNS	O	O
of	XALKORI.xml:S2:6048:2	of	IN	O	O
vision	XALKORI.xml:S2:6051:6	vision	NN	B-AdverseReaction	O
loss	XALKORI.xml:S2:6058:4	loss	NN	I-AdverseReaction	O
.	XALKORI.xml:S2:6062:1	.	.	O	O

Discontinue	XALKORI.xml:S2:6071:11	discontinu	NNP	O	O
XALKORI	XALKORI.xml:S2:6083:7	xalkori	NNP	O	O
in	XALKORI.xml:S2:6091:2	in	IN	O	O
patients	XALKORI.xml:S2:6094:8	patient	NNS	O	O
with	XALKORI.xml:S2:6103:4	with	IN	O	O
new	XALKORI.xml:S2:6108:3	new	JJ	O	O
onset	XALKORI.xml:S2:6112:5	onset	NN	O	O
of	XALKORI.xml:S2:6118:2	of	IN	O	O
severe	XALKORI.xml:S2:6121:6	sever	JJ	O	O
visual	XALKORI.xml:S2:6128:6	visual	JJ	O	O
loss	XALKORI.xml:S2:6135:4	loss	NN	O	O
(	XALKORI.xml:S2:6140:1	(	(	O	O
best	XALKORI.xml:S2:6141:4	best	JJS	O	O
corrected	XALKORI.xml:S2:6146:9	correct	VBN	O	O
vision	XALKORI.xml:S2:6156:6	vision	NN	O	O
less	XALKORI.xml:S2:6163:4	less	JJR	O	O
than	XALKORI.xml:S2:6168:4	than	IN	O	O
20	XALKORI.xml:S2:6173:2	20	CD	O	O
200	XALKORI.xml:S2:6176:3	200	CD	O	O
in	XALKORI.xml:S2:6180:2	in	IN	O	O
one	XALKORI.xml:S2:6183:3	one	CD	O	O
or	XALKORI.xml:S2:6187:2	or	CC	O	O
both	XALKORI.xml:S2:6190:4	both	DT	O	O
eyes	XALKORI.xml:S2:6195:4	eye	NNS	O	O
)	XALKORI.xml:S2:6199:1	)	)	O	O
.	XALKORI.xml:S2:6200:1	.	.	O	O

Perform	XALKORI.xml:S2:6202:7	perform	VB	O	O
an	XALKORI.xml:S2:6210:2	an	DT	O	O
ophthalmological	XALKORI.xml:S2:6213:16	ophthalmolog	JJ	O	O
evaluation	XALKORI.xml:S2:6230:10	evalu	NN	O	O
consisting	XALKORI.xml:S2:6241:10	consist	NN	O	O
of	XALKORI.xml:S2:6252:2	of	IN	O	O
best	XALKORI.xml:S2:6255:4	best	RB	O	O
corrected	XALKORI.xml:S2:6260:9	correct	VBN	O	O
visual	XALKORI.xml:S2:6270:6	visual	JJ	O	B-AdverseReaction
acuity	XALKORI.xml:S2:6277:6	acuiti	NN	O	I-AdverseReaction
,	XALKORI.xml:S2:6283:1	,	,	O	O
retinal	XALKORI.xml:S2:6285:7	retin	JJ	O	B-AdverseReaction
photographs	XALKORI.xml:S2:6293:11	photograph	NN	O	I-AdverseReaction
,	XALKORI.xml:S2:6304:1	,	,	O	O
visual	XALKORI.xml:S2:6306:6	visual	JJ	O	B-AdverseReaction
fields	XALKORI.xml:S2:6313:6	field	NNS	O	I-AdverseReaction
,	XALKORI.xml:S2:6319:1	,	,	O	O
optical	XALKORI.xml:S2:6321:7	optic	JJ	O	B-AdverseReaction
coherence	XALKORI.xml:S2:6329:9	coher	NN	O	I-AdverseReaction
tomography	XALKORI.xml:S2:6339:10	tomographi	NN	O	I-AdverseReaction
(	XALKORI.xml:S2:6350:1	(	(	O	O
OCT	XALKORI.xml:S2:6351:3	oct	NNP	O	O
)	XALKORI.xml:S2:6354:1	)	)	O	O
and	XALKORI.xml:S2:6356:3	and	CC	O	O
other	XALKORI.xml:S2:6360:5	other	JJ	O	O
evaluations	XALKORI.xml:S2:6366:11	evalu	NNS	O	O
as	XALKORI.xml:S2:6378:2	as	IN	O	O
appropriate	XALKORI.xml:S2:6381:11	appropri	NN	O	O
for	XALKORI.xml:S2:6393:3	for	IN	O	O
new	XALKORI.xml:S2:6397:3	new	JJ	O	O
onset	XALKORI.xml:S2:6401:5	onset	NN	O	O
of	XALKORI.xml:S2:6407:2	of	IN	O	O
severe	XALKORI.xml:S2:6410:6	sever	JJ	O	O
visual	XALKORI.xml:S2:6417:6	visual	JJ	O	O
loss	XALKORI.xml:S2:6424:4	loss	NN	O	O
.	XALKORI.xml:S2:6428:1	.	.	O	O

There	XALKORI.xml:S2:6430:5	there	EX	O	O
is	XALKORI.xml:S2:6436:2	is	VBZ	O	O
insufficient	XALKORI.xml:S2:6439:12	insuffici	JJ	O	O
information	XALKORI.xml:S2:6452:11	inform	NN	O	O
to	XALKORI.xml:S2:6464:2	to	TO	O	O
characterize	XALKORI.xml:S2:6467:12	character	VB	O	O
the	XALKORI.xml:S2:6480:3	the	DT	O	O
risks	XALKORI.xml:S2:6484:5	risk	NNS	O	O
of	XALKORI.xml:S2:6490:2	of	IN	O	O
resumption	XALKORI.xml:S2:6493:10	resumpt	NN	O	O
of	XALKORI.xml:S2:6504:2	of	IN	O	O
XALKORI	XALKORI.xml:S2:6507:7	xalkori	NNP	O	O
in	XALKORI.xml:S2:6515:2	in	IN	O	O
patients	XALKORI.xml:S2:6518:8	patient	NNS	O	O
with	XALKORI.xml:S2:6527:4	with	IN	O	O
a	XALKORI.xml:S2:6532:1	a	DT	O	O
severe	XALKORI.xml:S2:6534:6	sever	JJ	O	O
visual	XALKORI.xml:S2:6541:6	visual	JJ	O	O
loss	XALKORI.xml:S2:6548:4	loss	NN	O	O
;	XALKORI.xml:S2:6552:1	;	:	O	O
a	XALKORI.xml:S2:6554:1	a	DT	O	O
decision	XALKORI.xml:S2:6556:8	decis	NN	O	O
to	XALKORI.xml:S2:6565:2	to	TO	O	O
resume	XALKORI.xml:S2:6568:6	resum	VB	O	O
XALKORI	XALKORI.xml:S2:6575:7	xalkori	NNP	O	O
should	XALKORI.xml:S2:6583:6	should	MD	O	O
consider	XALKORI.xml:S2:6590:8	consid	VB	O	O
the	XALKORI.xml:S2:6599:3	the	DT	O	O
potential	XALKORI.xml:S2:6603:9	potenti	JJ	O	O
benefits	XALKORI.xml:S2:6613:8	benefit	NNS	O	O
to	XALKORI.xml:S2:6622:2	to	TO	O	O
the	XALKORI.xml:S2:6625:3	the	DT	O	O
patient	XALKORI.xml:S2:6629:7	patient	NN	O	O
.	XALKORI.xml:S2:6636:1	.	.	O	O

5.6	XALKORI.xml:S2:6647:3	5.6	CD	O	O
Embryofetal	XALKORI.xml:S2:6651:11	embryofet	JJ	O	O
Toxicity	XALKORI.xml:S2:6663:8	toxic	NN	O	O

Based	XALKORI.xml:S2:6678:5	base	VBN	O	O
on	XALKORI.xml:S2:6684:2	on	IN	O	O
its	XALKORI.xml:S2:6687:3	it	PRP$	O	O
mechanism	XALKORI.xml:S2:6691:9	mechan	NN	O	O
of	XALKORI.xml:S2:6701:2	of	IN	O	O
action	XALKORI.xml:S2:6704:6	action	NN	O	O
,	XALKORI.xml:S2:6710:1	,	,	O	O
XALKORI	XALKORI.xml:S2:6712:7	xalkori	NNP	O	O
can	XALKORI.xml:S2:6720:3	can	MD	O	O
cause	XALKORI.xml:S2:6724:5	caus	VB	O	O
fetal	XALKORI.xml:S2:6730:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	XALKORI.xml:S2:6736:4	harm	NN	I-AdverseReaction	I-AdverseReaction
when	XALKORI.xml:S2:6741:4	when	WRB	O	O
administered	XALKORI.xml:S2:6746:12	administ	VBN	O	O
to	XALKORI.xml:S2:6759:2	to	TO	O	O
a	XALKORI.xml:S2:6762:1	a	DT	O	O
pregnant	XALKORI.xml:S2:6764:8	pregnant	JJ	O	O
woman	XALKORI.xml:S2:6773:5	woman	NN	O	O
.	XALKORI.xml:S2:6778:1	.	.	O	O

In	XALKORI.xml:S2:6780:2	In	IN	O	O
animal	XALKORI.xml:S2:6783:6	anim	JJ	O	O
reproduction	XALKORI.xml:S2:6790:12	reproduct	NN	O	O
studies	XALKORI.xml:S2:6803:7	studi	NNS	O	O
,	XALKORI.xml:S2:6810:1	,	,	O	O
oral	XALKORI.xml:S2:6812:4	oral	JJ	O	O
administration	XALKORI.xml:S2:6817:14	administr	NN	O	O
of	XALKORI.xml:S2:6832:2	of	IN	O	O
crizotinib	XALKORI.xml:S2:6835:10	crizotinib	NN	O	O
in	XALKORI.xml:S2:6846:2	in	IN	O	O
pregnant	XALKORI.xml:S2:6849:8	pregnant	JJ	O	O
rats	XALKORI.xml:S2:6858:4	rat	NNS	O	O
during	XALKORI.xml:S2:6863:6	dure	IN	O	O
organogenesis	XALKORI.xml:S2:6870:13	organogenesi	NN	O	O
at	XALKORI.xml:S2:6884:2	at	IN	O	O
exposures	XALKORI.xml:S2:6887:9	exposur	NNS	O	O
similar	XALKORI.xml:S2:6897:7	similar	JJ	O	O
to	XALKORI.xml:S2:6905:2	to	TO	O	O
those	XALKORI.xml:S2:6908:5	those	DT	O	O
observed	XALKORI.xml:S2:6914:8	observ	VBN	O	O
with	XALKORI.xml:S2:6923:4	with	IN	O	O
the	XALKORI.xml:S2:6928:3	the	DT	O	O
maximum	XALKORI.xml:S2:6932:7	maximum	NN	O	O
recommended	XALKORI.xml:S2:6940:11	recommend	VBD	O	O
human	XALKORI.xml:S2:6952:5	human	JJ	O	O
dose	XALKORI.xml:S2:6958:4	dose	NN	O	O
resulted	XALKORI.xml:S2:6963:8	result	VBD	O	O
in	XALKORI.xml:S2:6972:2	in	IN	O	O
embryotoxicity	XALKORI.xml:S2:6975:14	embryotox	NN	B-AdverseReaction	B-AdverseReaction
and	XALKORI.xml:S2:6990:3	and	CC	O	O
fetotoxicity	XALKORI.xml:S2:6994:12	fetotox	NN	B-AdverseReaction	B-AdverseReaction
.	XALKORI.xml:S2:7006:1	.	.	O	O

Advise	XALKORI.xml:S2:7008:6	advis	NNP	O	O
pregnant	XALKORI.xml:S2:7015:8	pregnant	JJ	O	O
women	XALKORI.xml:S2:7024:5	women	NNS	O	O
of	XALKORI.xml:S2:7030:2	of	IN	O	O
the	XALKORI.xml:S2:7033:3	the	DT	O	O
potential	XALKORI.xml:S2:7037:9	potenti	JJ	O	O
risk	XALKORI.xml:S2:7047:4	risk	NN	O	O
to	XALKORI.xml:S2:7052:2	to	TO	O	O
a	XALKORI.xml:S2:7055:1	a	DT	O	O
fetus	XALKORI.xml:S2:7057:5	fetu	NN	O	O
.	XALKORI.xml:S2:7062:1	.	.	O	O

Advise	XALKORI.xml:S2:7064:6	advis	NNP	O	O
females	XALKORI.xml:S2:7071:7	femal	NNS	O	O
of	XALKORI.xml:S2:7079:2	of	IN	O	O
reproductive	XALKORI.xml:S2:7082:12	reproduct	JJ	O	O
potential	XALKORI.xml:S2:7095:9	potenti	NN	O	O
to	XALKORI.xml:S2:7105:2	to	TO	O	O
use	XALKORI.xml:S2:7108:3	use	VB	O	O
effective	XALKORI.xml:S2:7112:9	effect	JJ	O	O
contraception	XALKORI.xml:S2:7122:13	contracept	NN	O	O
during	XALKORI.xml:S2:7136:6	dure	IN	O	O
treatment	XALKORI.xml:S2:7143:9	treatment	NN	O	O
with	XALKORI.xml:S2:7153:4	with	IN	O	O
XALKORI	XALKORI.xml:S2:7158:7	xalkori	NNP	O	O
and	XALKORI.xml:S2:7166:3	and	CC	O	O
for	XALKORI.xml:S2:7170:3	for	IN	O	O
at	XALKORI.xml:S2:7174:2	at	IN	O	O
least	XALKORI.xml:S2:7177:5	least	JJS	O	O
45	XALKORI.xml:S2:7183:2	45	CD	O	O
days	XALKORI.xml:S2:7186:4	day	NNS	O	O
following	XALKORI.xml:S2:7191:9	follow	VBG	O	O
the	XALKORI.xml:S2:7201:3	the	DT	O	O
final	XALKORI.xml:S2:7205:5	final	JJ	O	O
dose	XALKORI.xml:S2:7211:4	dose	NN	O	O
[	XALKORI.xml:S2:7216:1	[	NNP	O	O
see	XALKORI.xml:S2:7217:3	see	NN	O	O
Use	XALKORI.xml:S2:7222:3	use	NNP	O	O
in	XALKORI.xml:S2:7226:2	in	IN	O	O
Specific	XALKORI.xml:S2:7229:8	specif	NNP	O	O
Populations	XALKORI.xml:S2:7238:11	popul	NNP	O	O
(	XALKORI.xml:S2:7250:1	(	(	O	O
8.1	XALKORI.xml:S2:7251:3	8.1	CD	O	O
,	XALKORI.xml:S2:7256:1	,	,	O	O
8.3	XALKORI.xml:S2:7259:3	8.3	CD	O	O
)	XALKORI.xml:S2:7262:1	)	)	O	O
]	XALKORI.xml:S2:7265:1	]	NN	O	O
.	XALKORI.xml:S2:7268:1	.	.	O	O
6	XEOMIN.xml:S1:4:1	6	CD	O	O
ADVERSE	XEOMIN.xml:S1:6:7	advers	JJ	O	O
REACTIONS	XEOMIN.xml:S1:14:9	reaction	NN	O	O

The	XEOMIN.xml:S1:27:3	the	DT	O	O
following	XEOMIN.xml:S1:31:9	follow	JJ	O	O
adverse	XEOMIN.xml:S1:41:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:49:9	reaction	NNS	O	O
to	XEOMIN.xml:S1:59:2	to	TO	O	O
XEOMIN	XEOMIN.xml:S1:62:6	xeomin	NNS	O	O
are	XEOMIN.xml:S1:69:3	are	VBP	O	O
discussed	XEOMIN.xml:S1:73:9	discuss	VBN	O	O
in	XEOMIN.xml:S1:83:2	in	IN	O	O
greater	XEOMIN.xml:S1:86:7	greater	JJR	O	O
detail	XEOMIN.xml:S1:94:6	detail	NN	O	O
in	XEOMIN.xml:S1:101:2	in	IN	O	O
other	XEOMIN.xml:S1:104:5	other	JJ	O	O
sections	XEOMIN.xml:S1:110:8	section	NNS	O	O
of	XEOMIN.xml:S1:119:2	of	IN	O	O
the	XEOMIN.xml:S1:122:3	the	DT	O	O
labeling	XEOMIN.xml:S1:126:8	label	NN	O	O
:	XEOMIN.xml:S1:134:1	:	:	O	O

Hypersensitivity	XEOMIN.xml:S1:143:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
[	XEOMIN.xml:S1:160:1	[	NNP	O	O
see	XEOMIN.xml:S1:162:3	see	VBP	O	O
Contraindications	XEOMIN.xml:S1:167:17	contraind	NNP	O	O
(	XEOMIN.xml:S1:185:1	(	(	O	O
4	XEOMIN.xml:S1:186:1	4	CD	O	O
)	XEOMIN.xml:S1:187:1	)	)	O	O
and	XEOMIN.xml:S1:190:3	and	CC	O	O
Warnings	XEOMIN.xml:S1:195:8	warn	NNP	O	O
and	XEOMIN.xml:S1:204:3	and	CC	O	O
Precautions	XEOMIN.xml:S1:208:11	precaut	NNP	O	O
(	XEOMIN.xml:S1:220:1	(	(	O	O
5.3	XEOMIN.xml:S1:221:3	5.3	CD	O	O
)	XEOMIN.xml:S1:224:1	)	)	O	O
]	XEOMIN.xml:S1:227:1	]	NN	O	O

Dysphagia	XEOMIN.xml:S1:235:9	dysphagia	NNP	B-AdverseReaction	B-AdverseReaction
and	XEOMIN.xml:S1:245:3	and	CC	O	O
Breathing	XEOMIN.xml:S1:249:9	breath	NNP	B-AdverseReaction	O
Difficulties	XEOMIN.xml:S1:259:12	difficulti	NNP	I-AdverseReaction	O
in	XEOMIN.xml:S1:272:2	in	IN	O	O
Treatment	XEOMIN.xml:S1:275:9	treatment	NNP	O	O
of	XEOMIN.xml:S1:285:2	of	IN	O	O
cervical	XEOMIN.xml:S1:288:8	cervic	JJ	O	O
dystonia	XEOMIN.xml:S1:297:8	dystonia	NN	O	O
[	XEOMIN.xml:S1:306:1	[	NNP	O	O
see	XEOMIN.xml:S1:308:3	see	VBP	O	O
Warnings	XEOMIN.xml:S1:313:8	warn	NNP	O	O
and	XEOMIN.xml:S1:322:3	and	CC	O	O
Precautions	XEOMIN.xml:S1:326:11	precaut	NNP	O	O
(	XEOMIN.xml:S1:338:1	(	(	O	O
5.4	XEOMIN.xml:S1:339:3	5.4	CD	O	O
)	XEOMIN.xml:S1:342:1	)	)	O	O
]	XEOMIN.xml:S1:346:1	]	NN	O	O

Spread	XEOMIN.xml:S1:353:6	spread	NN	B-AdverseReaction	B-AdverseReaction
of	XEOMIN.xml:S1:360:2	of	IN	I-AdverseReaction	I-AdverseReaction
Effects	XEOMIN.xml:S1:363:7	effect	NNS	I-AdverseReaction	I-AdverseReaction
from	XEOMIN.xml:S1:371:4	from	IN	I-AdverseReaction	I-AdverseReaction
Toxin	XEOMIN.xml:S1:376:5	toxin	NNP	I-AdverseReaction	I-AdverseReaction
[	XEOMIN.xml:S1:382:1	[	NNP	O	O
see	XEOMIN.xml:S1:383:3	see	VBP	O	O
Warnings	XEOMIN.xml:S1:388:8	warn	NNP	O	O
and	XEOMIN.xml:S1:397:3	and	CC	O	O
Precautions	XEOMIN.xml:S1:401:11	precaut	NNP	O	O
(	XEOMIN.xml:S1:413:1	(	(	O	O
5.1	XEOMIN.xml:S1:414:3	5.1	CD	O	O
)	XEOMIN.xml:S1:417:1	)	)	O	O
]	XEOMIN.xml:S1:420:1	]	NN	O	O

EXCERPT	XEOMIN.xml:S1:430:7	excerpt	NN	O	O
:	XEOMIN.xml:S1:437:1	:	:	O	O
Cervical	XEOMIN.xml:S1:443:8	cervic	JJ	O	O
Dystonia	XEOMIN.xml:S1:452:8	dystonia	NNP	O	O
:	XEOMIN.xml:S1:460:1	:	:	O	O
The	XEOMIN.xml:S1:463:3	the	DT	O	O
most	XEOMIN.xml:S1:467:4	most	RBS	O	O
commonly	XEOMIN.xml:S1:472:8	commonli	RB	O	O
observed	XEOMIN.xml:S1:481:8	observ	JJ	O	O
adverse	XEOMIN.xml:S1:490:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:498:9	reaction	NNS	O	O
(	XEOMIN.xml:S1:508:1	(	(	O	O
5%	XEOMIN.xml:S1:511:2	5%	CD	O	O
of	XEOMIN.xml:S1:514:2	of	IN	O	O
patients	XEOMIN.xml:S1:517:8	patient	NNS	O	O
and	XEOMIN.xml:S1:526:3	and	CC	O	O
placebo	XEOMIN.xml:S1:532:7	placebo	NN	O	O
)	XEOMIN.xml:S1:539:1	)	)	O	O
are	XEOMIN.xml:S1:541:3	are	VBP	O	O
dysphagia	XEOMIN.xml:S1:545:9	dysphagia	JJ	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:554:1	,	,	O	O
neck	XEOMIN.xml:S1:556:4	neck	RB	B-AdverseReaction	B-AdverseReaction
pain	XEOMIN.xml:S1:561:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:565:1	,	,	O	O
muscle	XEOMIN.xml:S1:567:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
weakness	XEOMIN.xml:S1:574:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:582:1	,	,	O	O
injection	XEOMIN.xml:S1:584:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:594:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XEOMIN.xml:S1:599:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:603:1	,	,	O	O
and	XEOMIN.xml:S1:605:3	and	CC	O	O
musculoskeletal	XEOMIN.xml:S1:609:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	XEOMIN.xml:S1:625:4	pain	NN	I-AdverseReaction	I-AdverseReaction
(	XEOMIN.xml:S1:630:1	(	(	O	O
6.1	XEOMIN.xml:S1:633:3	6.1	CD	O	O
)	XEOMIN.xml:S1:638:1	)	)	O	O
.	XEOMIN.xml:S1:639:1	.	.	O	O

Blepharospasm	XEOMIN.xml:S1:647:13	blepharospasm	NN	O	O

:	XEOMIN.xml:S1:660:1	:	:	O	O
The	XEOMIN.xml:S1:663:3	the	DT	O	O
most	XEOMIN.xml:S1:667:4	most	RBS	O	O
commonly	XEOMIN.xml:S1:672:8	commonli	RB	O	O
observed	XEOMIN.xml:S1:681:8	observ	JJ	O	O
adverse	XEOMIN.xml:S1:690:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:698:9	reaction	NNS	O	O
(	XEOMIN.xml:S1:708:1	(	(	O	O
5%	XEOMIN.xml:S1:711:2	5%	CD	O	O
of	XEOMIN.xml:S1:714:2	of	IN	O	O
patients	XEOMIN.xml:S1:717:8	patient	NNS	O	O
and	XEOMIN.xml:S1:726:3	and	CC	O	O
placebo	XEOMIN.xml:S1:732:7	placebo	NN	O	O
)	XEOMIN.xml:S1:739:1	)	)	O	O
are	XEOMIN.xml:S1:741:3	are	VBP	O	O
eyelid	XEOMIN.xml:S1:745:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
ptosis	XEOMIN.xml:S1:752:6	ptosi	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:758:1	,	,	O	O
dry	XEOMIN.xml:S1:760:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
eye	XEOMIN.xml:S1:764:3	eye	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:767:1	,	,	O	O
dry	XEOMIN.xml:S1:769:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	XEOMIN.xml:S1:773:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:778:1	,	,	O	O
diarrhea	XEOMIN.xml:S1:780:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:788:1	,	,	O	O
headache	XEOMIN.xml:S1:790:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:798:1	,	,	O	O
visual	XEOMIN.xml:S1:800:6	visual	JJ	B-AdverseReaction	B-AdverseReaction
impairment	XEOMIN.xml:S1:807:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:817:1	,	,	O	O
dyspnea	XEOMIN.xml:S1:819:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:826:1	,	,	O	O
nasopharyngitis	XEOMIN.xml:S1:828:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:843:1	,	,	O	O
and	XEOMIN.xml:S1:845:3	and	CC	O	O
respiratory	XEOMIN.xml:S1:849:11	respiratori	JJ	B-AdverseReaction	B-AdverseReaction
tract	XEOMIN.xml:S1:861:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	XEOMIN.xml:S1:867:9	infect	NN	I-AdverseReaction	I-AdverseReaction
(	XEOMIN.xml:S1:877:1	(	(	O	O
6.1	XEOMIN.xml:S1:880:3	6.1	CD	O	O
)	XEOMIN.xml:S1:885:1	)	)	O	O
.	XEOMIN.xml:S1:886:1	.	.	O	O

Glabellar	XEOMIN.xml:S1:894:9	glabellar	JJ	O	O
Lines	XEOMIN.xml:S1:904:5	line	NNS	O	O
:	XEOMIN.xml:S1:909:1	:	:	O	O
The	XEOMIN.xml:S1:912:3	the	DT	O	O
most	XEOMIN.xml:S1:916:4	most	RBS	O	O
commonly	XEOMIN.xml:S1:921:8	commonli	RB	O	O
observed	XEOMIN.xml:S1:930:8	observ	JJ	O	O
adverse	XEOMIN.xml:S1:939:7	advers	JJ	O	O
reaction	XEOMIN.xml:S1:947:8	reaction	NN	O	O
(	XEOMIN.xml:S1:956:1	(	(	O	O
1%	XEOMIN.xml:S1:958:2	1%	CD	O	O
of	XEOMIN.xml:S1:961:2	of	IN	O	O
patients	XEOMIN.xml:S1:964:8	patient	NNS	O	O
and	XEOMIN.xml:S1:973:3	and	CC	O	O
placebo	XEOMIN.xml:S1:979:7	placebo	NN	O	O
)	XEOMIN.xml:S1:986:1	)	)	O	O
is	XEOMIN.xml:S1:988:2	is	VBZ	O	O
headache	XEOMIN.xml:S1:991:8	headach	JJ	B-AdverseReaction	B-AdverseReaction
(	XEOMIN.xml:S1:1000:1	(	(	O	O
6.1	XEOMIN.xml:S1:1003:3	6.1	CD	O	O
)	XEOMIN.xml:S1:1008:1	)	)	O	O
.	XEOMIN.xml:S1:1009:1	.	.	O	O

To	XEOMIN.xml:S1:1017:2	To	TO	O	O
report	XEOMIN.xml:S1:1020:6	report	VB	O	O
SUSPECTED	XEOMIN.xml:S1:1027:9	suspect	NNP	O	O
ADVERSE	XEOMIN.xml:S1:1037:7	advers	NNP	O	O
REACTIONS	XEOMIN.xml:S1:1045:9	reaction	NNP	O	O
,	XEOMIN.xml:S1:1054:1	,	,	O	O
contact	XEOMIN.xml:S1:1056:7	contact	NN	O	O
Merz	XEOMIN.xml:S1:1064:4	merz	NNP	O	O
Pharmaceuticals	XEOMIN.xml:S1:1069:15	pharmaceut	NNP	O	O
,	XEOMIN.xml:S1:1084:1	,	,	O	O
LLC	XEOMIN.xml:S1:1086:3	llc	NNP	O	O
at	XEOMIN.xml:S1:1090:2	at	IN	O	O
888	XEOMIN.xml:S1:1093:3	888	CD	O	O
-	XEOMIN.xml:S1:1096:1	-	:	O	O
493	XEOMIN.xml:S1:1097:3	493	CD	O	O
-	XEOMIN.xml:S1:1100:1	-	:	O	O
6646	XEOMIN.xml:S1:1101:4	6646	CD	O	O
or	XEOMIN.xml:S1:1106:2	or	CC	O	O
FDA	XEOMIN.xml:S1:1109:3	fda	NNP	O	O
at	XEOMIN.xml:S1:1113:2	at	IN	O	O
1	XEOMIN.xml:S1:1116:1	1	CD	O	O
-	XEOMIN.xml:S1:1117:1	-	:	O	O
800	XEOMIN.xml:S1:1118:3	800	CD	O	O
-	XEOMIN.xml:S1:1121:1	-	:	O	O
FDA	XEOMIN.xml:S1:1122:3	fda	NNP	O	O
-	XEOMIN.xml:S1:1125:1	-	:	O	O
1088	XEOMIN.xml:S1:1126:4	1088	CD	O	O
or	XEOMIN.xml:S1:1131:2	or	CC	O	O
www	XEOMIN.xml:S1:1135:3	www	VB	O	O
.	XEOMIN.xml:S1:1138:1	.	.	O	O
fda	XEOMIN.xml:S1:1139:3	fda	NN	O	O
.	XEOMIN.xml:S1:1142:1	.	.	O	O
gov	XEOMIN.xml:S1:1143:3	gov	JJ	O	O
medwatch	XEOMIN.xml:S1:1147:8	medwatch	NN	O	O
.	XEOMIN.xml:S1:1155:1	.	.	O	O

6.1	XEOMIN.xml:S1:1169:3	6.1	CD	O	O

Clinical	XEOMIN.xml:S1:1173:8	clinic	JJ	O	O
Trials	XEOMIN.xml:S1:1182:6	trial	NNS	O	O
Experience	XEOMIN.xml:S1:1189:10	experi	NN	O	O

Because	XEOMIN.xml:S1:1203:7	becaus	IN	O	O
clinical	XEOMIN.xml:S1:1211:8	clinic	JJ	O	O
trials	XEOMIN.xml:S1:1220:6	trial	NNS	O	O
are	XEOMIN.xml:S1:1227:3	are	VBP	O	O
conducted	XEOMIN.xml:S1:1231:9	conduct	VBN	O	O
under	XEOMIN.xml:S1:1241:5	under	IN	O	O
widely	XEOMIN.xml:S1:1247:6	wide	RB	O	O
varying	XEOMIN.xml:S1:1254:7	vari	VBG	O	O
conditions	XEOMIN.xml:S1:1262:10	condit	NNS	O	O
,	XEOMIN.xml:S1:1272:1	,	,	O	O
adverse	XEOMIN.xml:S1:1274:7	advers	JJ	O	O
reaction	XEOMIN.xml:S1:1282:8	reaction	NN	O	O
rates	XEOMIN.xml:S1:1291:5	rate	NNS	O	O
observed	XEOMIN.xml:S1:1297:8	observ	VBD	O	O
in	XEOMIN.xml:S1:1306:2	in	IN	O	O
the	XEOMIN.xml:S1:1309:3	the	DT	O	O
clinical	XEOMIN.xml:S1:1313:8	clinic	JJ	O	O
trials	XEOMIN.xml:S1:1322:6	trial	NNS	O	O
of	XEOMIN.xml:S1:1329:2	of	IN	O	O
a	XEOMIN.xml:S1:1332:1	a	DT	O	O
drug	XEOMIN.xml:S1:1334:4	drug	NN	O	O
cannot	XEOMIN.xml:S1:1339:6	cannot	NN	O	O
be	XEOMIN.xml:S1:1346:2	be	VB	O	O
directly	XEOMIN.xml:S1:1349:8	directli	RB	O	O
compared	XEOMIN.xml:S1:1358:8	compar	VBN	O	O
to	XEOMIN.xml:S1:1367:2	to	TO	O	O
rates	XEOMIN.xml:S1:1370:5	rate	NNS	O	O
in	XEOMIN.xml:S1:1376:2	in	IN	O	O
the	XEOMIN.xml:S1:1379:3	the	DT	O	O
clinical	XEOMIN.xml:S1:1383:8	clinic	JJ	O	O
trials	XEOMIN.xml:S1:1392:6	trial	NNS	O	O
of	XEOMIN.xml:S1:1399:2	of	IN	O	O
another	XEOMIN.xml:S1:1402:7	anoth	DT	O	O
drug	XEOMIN.xml:S1:1410:4	drug	NN	O	O
,	XEOMIN.xml:S1:1414:1	,	,	O	O
and	XEOMIN.xml:S1:1416:3	and	CC	O	O
may	XEOMIN.xml:S1:1420:3	may	MD	O	O
not	XEOMIN.xml:S1:1424:3	not	RB	O	O
reflect	XEOMIN.xml:S1:1428:7	reflect	VB	O	O
the	XEOMIN.xml:S1:1436:3	the	DT	O	O
rates	XEOMIN.xml:S1:1440:5	rate	NNS	O	O
observed	XEOMIN.xml:S1:1446:8	observ	VBD	O	O
in	XEOMIN.xml:S1:1455:2	in	IN	O	O
practice	XEOMIN.xml:S1:1458:8	practic	NN	O	O
.	XEOMIN.xml:S1:1466:1	.	.	O	O

Cervical	XEOMIN.xml:S1:1476:8	cervic	JJ	O	O
Dystonia	XEOMIN.xml:S1:1485:8	dystonia	NNP	O	O

The	XEOMIN.xml:S1:1500:3	the	DT	O	O
data	XEOMIN.xml:S1:1504:4	data	NNS	O	O
described	XEOMIN.xml:S1:1509:9	describ	VBD	O	O
below	XEOMIN.xml:S1:1519:5	below	IN	O	O
reflect	XEOMIN.xml:S1:1525:7	reflect	NN	O	O
exposure	XEOMIN.xml:S1:1533:8	exposur	NN	O	O
to	XEOMIN.xml:S1:1542:2	to	TO	O	O
a	XEOMIN.xml:S1:1545:1	a	DT	O	O
single	XEOMIN.xml:S1:1547:6	singl	JJ	O	O
intramuscular	XEOMIN.xml:S1:1554:13	intramuscular	NN	O	O
dose	XEOMIN.xml:S1:1568:4	dose	NN	O	O
of	XEOMIN.xml:S1:1573:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S1:1576:6	xeomin	NNP	O	O
in	XEOMIN.xml:S1:1583:2	in	IN	O	O
a	XEOMIN.xml:S1:1586:1	a	DT	O	O
placebo	XEOMIN.xml:S1:1588:7	placebo	NN	O	O
-	XEOMIN.xml:S1:1595:1	-	:	O	O
controlled	XEOMIN.xml:S1:1596:10	control	VBN	O	O
,	XEOMIN.xml:S1:1606:1	,	,	O	O
Phase	XEOMIN.xml:S1:1608:5	phase	NNP	O	O
3	XEOMIN.xml:S1:1614:1	3	CD	O	O
trial	XEOMIN.xml:S1:1616:5	trial	NN	O	O
in	XEOMIN.xml:S1:1622:2	in	IN	O	O
patients	XEOMIN.xml:S1:1625:8	patient	NNS	O	O
with	XEOMIN.xml:S1:1634:4	with	IN	O	O
cervical	XEOMIN.xml:S1:1639:8	cervic	JJ	O	O
dystonia	XEOMIN.xml:S1:1648:8	dystonia	NN	O	O
[	XEOMIN.xml:S1:1657:1	[	NNP	O	O
see	XEOMIN.xml:S1:1660:3	see	VBP	O	O
Clinical	XEOMIN.xml:S1:1665:8	clinic	JJ	O	O
Studies	XEOMIN.xml:S1:1674:7	studi	NNP	O	O
(	XEOMIN.xml:S1:1682:1	(	(	O	O
14.1	XEOMIN.xml:S1:1683:4	14.1	CD	O	O
)	XEOMIN.xml:S1:1687:1	)	)	O	O
]	XEOMIN.xml:S1:1692:1	]	NN	O	O
.	XEOMIN.xml:S1:1693:1	.	.	O	O

In	XEOMIN.xml:S1:1695:2	In	IN	O	O
this	XEOMIN.xml:S1:1698:4	thi	DT	O	O
study	XEOMIN.xml:S1:1703:5	studi	NN	O	O
,	XEOMIN.xml:S1:1708:1	,	,	O	O
159	XEOMIN.xml:S1:1710:3	159	CD	O	O
patients	XEOMIN.xml:S1:1714:8	patient	NNS	O	O
received	XEOMIN.xml:S1:1723:8	receiv	VBN	O	O
XEOMIN	XEOMIN.xml:S1:1732:6	xeomin	NNP	O	O
(	XEOMIN.xml:S1:1739:1	(	(	O	O
78	XEOMIN.xml:S1:1740:2	78	CD	O	O
were	XEOMIN.xml:S1:1743:4	were	VBD	O	O
randomized	XEOMIN.xml:S1:1748:10	random	VBN	O	O
to	XEOMIN.xml:S1:1759:2	to	TO	O	O
receive	XEOMIN.xml:S1:1762:7	receiv	VB	O	O
a	XEOMIN.xml:S1:1770:1	a	DT	O	O
total	XEOMIN.xml:S1:1772:5	total	JJ	O	O
dose	XEOMIN.xml:S1:1778:4	dose	NN	O	O
of	XEOMIN.xml:S1:1783:2	of	IN	O	O
120	XEOMIN.xml:S1:1786:3	120	CD	O	O
Units	XEOMIN.xml:S1:1790:5	unit	NNS	O	O
,	XEOMIN.xml:S1:1795:1	,	,	O	O
and	XEOMIN.xml:S1:1797:3	and	CC	O	O
81	XEOMIN.xml:S1:1801:2	81	CD	O	O
were	XEOMIN.xml:S1:1804:4	were	VBD	O	O
randomized	XEOMIN.xml:S1:1809:10	random	VBN	O	O
to	XEOMIN.xml:S1:1820:2	to	TO	O	O
receive	XEOMIN.xml:S1:1823:7	receiv	VB	O	O
a	XEOMIN.xml:S1:1831:1	a	DT	O	O
total	XEOMIN.xml:S1:1833:5	total	JJ	O	O
dose	XEOMIN.xml:S1:1839:4	dose	NN	O	O
of	XEOMIN.xml:S1:1844:2	of	IN	O	O
240	XEOMIN.xml:S1:1847:3	240	CD	O	O
Units	XEOMIN.xml:S1:1851:5	unit	NNS	O	O
)	XEOMIN.xml:S1:1856:1	)	)	O	O
.	XEOMIN.xml:S1:1857:1	.	.	O	O

XEOMIN	XEOMIN.xml:S1:1859:6	xeomin	SYM	O	O
-	XEOMIN.xml:S1:1865:1	-	:	O	O
treated	XEOMIN.xml:S1:1866:7	treat	JJ	O	O
patients	XEOMIN.xml:S1:1874:8	patient	NNS	O	O
were	XEOMIN.xml:S1:1883:4	were	VBD	O	O
18	XEOMIN.xml:S1:1888:2	18	CD	O	O
to	XEOMIN.xml:S1:1891:2	to	TO	O	O
79	XEOMIN.xml:S1:1894:2	79	CD	O	O
years	XEOMIN.xml:S1:1897:5	year	NNS	O	O
old	XEOMIN.xml:S1:1903:3	old	JJ	O	O
(	XEOMIN.xml:S1:1907:1	(	(	O	O
mean	XEOMIN.xml:S1:1908:4	mean	JJ	O	O
53	XEOMIN.xml:S1:1913:2	53	CD	O	O
years	XEOMIN.xml:S1:1916:5	year	NNS	O	O
)	XEOMIN.xml:S1:1921:1	)	)	O	O
,	XEOMIN.xml:S1:1922:1	,	,	O	O
and	XEOMIN.xml:S1:1924:3	and	CC	O	O
were	XEOMIN.xml:S1:1928:4	were	VBD	O	O
predominantly	XEOMIN.xml:S1:1933:13	predominantli	RB	O	O
female	XEOMIN.xml:S1:1947:6	femal	JJ	O	O
(	XEOMIN.xml:S1:1954:1	(	(	O	O
66%	XEOMIN.xml:S1:1955:3	66%	CD	O	O
)	XEOMIN.xml:S1:1958:1	)	)	O	O
and	XEOMIN.xml:S1:1960:3	and	CC	O	O
Caucasian	XEOMIN.xml:S1:1964:9	caucasian	NNP	O	O
(	XEOMIN.xml:S1:1974:1	(	(	O	O
91%	XEOMIN.xml:S1:1975:3	91%	CD	O	O
)	XEOMIN.xml:S1:1978:1	)	)	O	O
.	XEOMIN.xml:S1:1979:1	.	.	O	O

At	XEOMIN.xml:S1:1981:2	At	IN	O	O
study	XEOMIN.xml:S1:1984:5	studi	NN	O	O
baseline	XEOMIN.xml:S1:1990:8	baselin	NN	O	O
,	XEOMIN.xml:S1:1998:1	,	,	O	O
approximately	XEOMIN.xml:S1:2000:13	approxim	RB	O	O
25%	XEOMIN.xml:S1:2014:3	25%	CD	O	O
had	XEOMIN.xml:S1:2018:3	had	VBD	O	O
mild	XEOMIN.xml:S1:2022:4	mild	VBN	O	O
,	XEOMIN.xml:S1:2026:1	,	,	O	O
50%	XEOMIN.xml:S1:2028:3	50%	CD	O	O
had	XEOMIN.xml:S1:2032:3	had	VBD	O	O
moderate	XEOMIN.xml:S1:2036:8	moder	NN	O	O
,	XEOMIN.xml:S1:2044:1	,	,	O	O
and	XEOMIN.xml:S1:2046:3	and	CC	O	O
25%	XEOMIN.xml:S1:2050:3	25%	CD	O	O
had	XEOMIN.xml:S1:2054:3	had	VBD	O	O
severe	XEOMIN.xml:S1:2058:6	sever	JJ	O	O
cervical	XEOMIN.xml:S1:2065:8	cervic	JJ	O	O
dystonia	XEOMIN.xml:S1:2074:8	dystonia	NN	O	O
.	XEOMIN.xml:S1:2082:1	.	.	O	O

Approximately	XEOMIN.xml:S1:2084:13	approxim	RB	O	O
61%	XEOMIN.xml:S1:2098:3	61%	CD	O	O
of	XEOMIN.xml:S1:2102:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S1:2105:6	xeomin	NNP	O	O
-	XEOMIN.xml:S1:2111:1	-	:	O	O
treated	XEOMIN.xml:S1:2112:7	treat	VBD	O	O
patients	XEOMIN.xml:S1:2120:8	patient	NNS	O	O
had	XEOMIN.xml:S1:2129:3	had	VBD	O	O
previously	XEOMIN.xml:S1:2133:10	previous	RB	O	O
received	XEOMIN.xml:S1:2144:8	receiv	VBN	O	O
another	XEOMIN.xml:S1:2153:7	anoth	DT	O	O
botulinum	XEOMIN.xml:S1:2161:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S1:2171:5	toxin	NN	O	O
type	XEOMIN.xml:S1:2177:4	type	NN	O	O
A	XEOMIN.xml:S1:2182:1	A	DT	O	O
product	XEOMIN.xml:S1:2184:7	product	NN	O	O
.	XEOMIN.xml:S1:2191:1	.	.	O	O

Common	XEOMIN.xml:S1:2193:6	common	JJ	O	O
adverse	XEOMIN.xml:S1:2200:7	advers	JJ	O	O
events	XEOMIN.xml:S1:2208:6	event	NNS	O	O
(	XEOMIN.xml:S1:2215:1	(	(	O	O
5%	XEOMIN.xml:S1:2218:2	5%	CD	O	O
in	XEOMIN.xml:S1:2221:2	in	IN	O	O
any	XEOMIN.xml:S1:2224:3	ani	DT	O	O
XEOMIN	XEOMIN.xml:S1:2228:6	xeomin	NNP	O	O
treatment	XEOMIN.xml:S1:2235:9	treatment	NN	O	O
group	XEOMIN.xml:S1:2245:5	group	NN	O	O
)	XEOMIN.xml:S1:2250:1	)	)	O	O
observed	XEOMIN.xml:S1:2252:8	observ	VBD	O	O
in	XEOMIN.xml:S1:2261:2	in	IN	O	O
patients	XEOMIN.xml:S1:2264:8	patient	NNS	O	O
who	XEOMIN.xml:S1:2273:3	who	WP	O	O
received	XEOMIN.xml:S1:2277:8	receiv	VBD	O	O
XEOMIN	XEOMIN.xml:S1:2286:6	xeomin	NNP	O	O
(	XEOMIN.xml:S1:2293:1	(	(	O	O
120	XEOMIN.xml:S1:2294:3	120	CD	O	O
Units	XEOMIN.xml:S1:2298:5	unit	NNS	O	O
or	XEOMIN.xml:S1:2304:2	or	CC	O	O
240	XEOMIN.xml:S1:2307:3	240	CD	O	O
Units	XEOMIN.xml:S1:2311:5	unit	NNS	O	O
)	XEOMIN.xml:S1:2316:1	)	)	O	O
included	XEOMIN.xml:S1:2318:8	includ	VBD	O	O
dysphagia	XEOMIN.xml:S1:2327:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:2336:1	,	,	O	O
neck	XEOMIN.xml:S1:2338:4	neck	NN	B-AdverseReaction	B-AdverseReaction
pain	XEOMIN.xml:S1:2343:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:2347:1	,	,	O	O
muscle	XEOMIN.xml:S1:2349:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
weakness	XEOMIN.xml:S1:2356:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:2364:1	,	,	O	O
injection	XEOMIN.xml:S1:2366:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:2376:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XEOMIN.xml:S1:2381:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:2385:1	,	,	O	O
and	XEOMIN.xml:S1:2387:3	and	CC	O	O
musculoskeletal	XEOMIN.xml:S1:2391:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	XEOMIN.xml:S1:2407:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S1:2411:1	.	.	O	O

Table	XEOMIN.xml:S1:2417:5	tabl	JJ	O	O
2	XEOMIN.xml:S1:2423:1	2	CD	O	O
:	XEOMIN.xml:S1:2424:1	:	:	O	O
Most	XEOMIN.xml:S1:2426:4	most	JJS	O	O
Common	XEOMIN.xml:S1:2431:6	common	JJ	O	O
TEAEs	XEOMIN.xml:S1:2438:5	teae	NNP	O	O
(	XEOMIN.xml:S1:2444:1	(	(	O	O
5%	XEOMIN.xml:S1:2447:2	5%	CD	O	O
)	XEOMIN.xml:S1:2449:1	)	)	O	O
and	XEOMIN.xml:S1:2451:3	and	CC	O	O
Greater	XEOMIN.xml:S1:2455:7	greater	NNP	O	O
than	XEOMIN.xml:S1:2463:4	than	IN	O	O
Placebo	XEOMIN.xml:S1:2468:7	placebo	NNP	O	O
:	XEOMIN.xml:S1:2475:1	:	:	O	O
Double	XEOMIN.xml:S1:2477:6	doubl	JJ	O	O
-	XEOMIN.xml:S1:2483:1	-	:	O	O
Blind	XEOMIN.xml:S1:2484:5	blind	IN	O	O
Phase	XEOMIN.xml:S1:2490:5	phase	NNP	O	O
of	XEOMIN.xml:S1:2496:2	of	IN	O	O
Clinical	XEOMIN.xml:S1:2499:8	clinic	NNP	O	O
Trial	XEOMIN.xml:S1:2508:5	trial	NNP	O	O

Double	XEOMIN.xml:S1:2552:6	doubl	NNP	O	O
-	XEOMIN.xml:S1:2558:1	-	:	O	O
Blind	XEOMIN.xml:S1:2559:5	blind	NNP	O	O
Phase	XEOMIN.xml:S1:2565:5	phase	NNP	O	O

System	XEOMIN.xml:S1:2579:6	system	NNP	O	O
Organ	XEOMIN.xml:S1:2586:5	organ	NNP	O	O
ClassPreferred	XEOMIN.xml:S1:2592:14	classpref	NNP	O	O
Term	XEOMIN.xml:S1:2607:4	term	NNP	O	O
XEOMIN	XEOMIN.xml:S1:2615:6	xeomin	NNP	O	O
120	XEOMIN.xml:S1:2622:3	120	CD	O	O
Units	XEOMIN.xml:S1:2626:5	unit	NNP	O	O
(	XEOMIN.xml:S1:2631:1	(	(	O	O
N	XEOMIN.xml:S1:2632:1	N	NNP	O	O
77	XEOMIN.xml:S1:2634:2	77	CD	O	O
)	XEOMIN.xml:S1:2636:1	)	)	O	O
XEOMIN	XEOMIN.xml:S1:2639:6	xeomin	$	O	O
240	XEOMIN.xml:S1:2646:3	240	CD	O	O
Units	XEOMIN.xml:S1:2650:5	unit	NNP	O	O
(	XEOMIN.xml:S1:2655:1	(	(	O	O
N	XEOMIN.xml:S1:2656:1	N	NNP	O	O
82	XEOMIN.xml:S1:2658:2	82	CD	O	O
)	XEOMIN.xml:S1:2660:1	)	)	O	O
Placebo	XEOMIN.xml:S1:2663:7	placebo	NNP	O	O
(	XEOMIN.xml:S1:2670:1	(	(	O	O
N	XEOMIN.xml:S1:2671:1	N	NNP	O	O
74	XEOMIN.xml:S1:2673:2	74	CD	O	O
)	XEOMIN.xml:S1:2675:1	)	)	O	O

Any	XEOMIN.xml:S1:2693:3	ani	DT	O	O

TEAEs	XEOMIN.xml:S1:2697:5	teae	NNP	O	B-AdverseReaction
57%	XEOMIN.xml:S1:2729:3	57%	CD	O	O
55%	XEOMIN.xml:S1:2753:3	55%	CD	O	O
42%	XEOMIN.xml:S1:2777:3	42%	CD	O	O

Musculoskeletal	XEOMIN.xml:S1:2804:15	musculoskelet	NNP	O	O
and	XEOMIN.xml:S1:2820:3	and	CC	O	O
connective	XEOMIN.xml:S1:2824:10	connect	JJ	O	O
tissue	XEOMIN.xml:S1:2835:6	tissu	NN	O	O
disorders	XEOMIN.xml:S1:2842:9	disord	NNS	O	O
23%	XEOMIN.xml:S1:2853:3	23%	CD	O	O
32%	XEOMIN.xml:S1:2877:3	32%	CD	O	O
11%	XEOMIN.xml:S1:2901:3	11%	CD	O	O

Neck	XEOMIN.xml:S1:2930:4	neck	NNP	B-AdverseReaction	B-AdverseReaction
pain	XEOMIN.xml:S1:2935:4	pain	VBP	I-AdverseReaction	I-AdverseReaction
7%	XEOMIN.xml:S1:2964:2	7%	CD	O	O
15%	XEOMIN.xml:S1:2988:3	15%	CD	O	O
4%	XEOMIN.xml:S1:3012:2	4%	CD	O	O

Muscular	XEOMIN.xml:S1:3041:8	muscular	JJ	B-AdverseReaction	B-AdverseReaction
weakness	XEOMIN.xml:S1:3050:8	weak	NN	I-AdverseReaction	I-AdverseReaction
7%	XEOMIN.xml:S1:3075:2	7%	CD	O	O
11%	XEOMIN.xml:S1:3099:3	11%	CD	O	O
1%	XEOMIN.xml:S1:3123:2	1%	CD	O	O

Musculoskeletal	XEOMIN.xml:S1:3152:15	musculoskelet	NNP	B-AdverseReaction	B-AdverseReaction
pain	XEOMIN.xml:S1:3168:4	pain	NN	I-AdverseReaction	I-AdverseReaction
7%	XEOMIN.xml:S1:3186:2	7%	CD	O	O
4%	XEOMIN.xml:S1:3210:2	4%	CD	O	O
1%	XEOMIN.xml:S1:3234:2	1%	CD	O	O

Gastrointestinal	XEOMIN.xml:S1:3261:16	gastrointestin	NNP	O	B-AdverseReaction
disorders	XEOMIN.xml:S1:3278:9	disord	NNS	O	I-AdverseReaction
18%	XEOMIN.xml:S1:3297:3	18%	CD	O	O
24%	XEOMIN.xml:S1:3321:3	24%	CD	O	O
4%	XEOMIN.xml:S1:3345:2	4%	CD	O	O

Dysphagia	XEOMIN.xml:S1:3374:9	dysphagia	NNP	B-AdverseReaction	B-AdverseReaction
13%	XEOMIN.xml:S1:3408:3	13%	CD	O	O
18%	XEOMIN.xml:S1:3432:3	18%	CD	O	O
3%	XEOMIN.xml:S1:3456:2	3%	CD	O	O

Nervous	XEOMIN.xml:S1:3483:7	nervou	JJ	O	O
system	XEOMIN.xml:S1:3491:6	system	NN	O	O
disorders	XEOMIN.xml:S1:3498:9	disord	NNS	O	O
16%	XEOMIN.xml:S1:3519:3	16%	CD	O	O
17%	XEOMIN.xml:S1:3543:3	17%	CD	O	O
7%	XEOMIN.xml:S1:3567:2	7%	CD	O	O

General	XEOMIN.xml:S1:3594:7	gener	NNP	O	O
disorders	XEOMIN.xml:S1:3602:9	disord	NNS	O	O
and	XEOMIN.xml:S1:3612:3	and	CC	O	O
administration	XEOMIN.xml:S1:3616:14	administr	NN	O	O
site	XEOMIN.xml:S1:3631:4	site	NN	O	O
conditions	XEOMIN.xml:S1:3636:10	condit	NNS	O	O
16%	XEOMIN.xml:S1:3648:3	16%	CD	O	O
11%	XEOMIN.xml:S1:3672:3	11%	CD	O	O
11%	XEOMIN.xml:S1:3696:3	11%	CD	O	O

Injection	XEOMIN.xml:S1:3725:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:3735:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XEOMIN.xml:S1:3740:4	pain	NN	I-AdverseReaction	I-AdverseReaction
9%	XEOMIN.xml:S1:3759:2	9%	CD	O	O
4%	XEOMIN.xml:S1:3783:2	4%	CD	O	O
7%	XEOMIN.xml:S1:3807:2	7%	CD	O	O

Infections	XEOMIN.xml:S1:3834:10	infect	NNS	O	O
and	XEOMIN.xml:S1:3845:3	and	CC	O	O
infestations	XEOMIN.xml:S1:3849:12	infest	NNS	O	O
14%	XEOMIN.xml:S1:3870:3	14%	CD	O	O
13%	XEOMIN.xml:S1:3894:3	13%	CD	O	O
11%	XEOMIN.xml:S1:3918:3	11%	CD	O	O

Respiratory	XEOMIN.xml:S1:3945:11	respiratori	NNP	O	O
,	XEOMIN.xml:S1:3956:1	,	,	O	O
thoracic	XEOMIN.xml:S1:3958:8	thorac	NN	O	O
and	XEOMIN.xml:S1:3967:3	and	CC	O	O
mediastinal	XEOMIN.xml:S1:3971:11	mediastin	JJ	O	O
disorders	XEOMIN.xml:S1:3983:9	disord	NNS	O	O
13%	XEOMIN.xml:S1:3994:3	13%	CD	O	O
10%	XEOMIN.xml:S1:4018:3	10%	CD	O	O
3%	XEOMIN.xml:S1:4042:2	3%	CD	O	O

Blepharospasm	XEOMIN.xml:S1:4082:13	blepharospasm	NN	O	O

In	XEOMIN.xml:S1:4102:2	In	IN	O	O

the	XEOMIN.xml:S1:4105:3	the	DT	O	O
placebo	XEOMIN.xml:S1:4109:7	placebo	NN	O	O
-	XEOMIN.xml:S1:4116:1	-	:	O	O
controlled	XEOMIN.xml:S1:4117:10	control	VBN	O	O
Phase	XEOMIN.xml:S1:4128:5	phase	NNP	O	O
3	XEOMIN.xml:S1:4134:1	3	CD	O	O
trial	XEOMIN.xml:S1:4136:5	trial	NN	O	O
in	XEOMIN.xml:S1:4142:2	in	IN	O	O
patients	XEOMIN.xml:S1:4145:8	patient	NNS	O	O
with	XEOMIN.xml:S1:4154:4	with	IN	O	O
blepharospasm	XEOMIN.xml:S1:4159:13	blepharospasm	NN	B-AdverseReaction	O
previously	XEOMIN.xml:S1:4173:10	previous	RB	O	O
treated	XEOMIN.xml:S1:4184:7	treat	VBN	O	O
with	XEOMIN.xml:S1:4192:4	with	IN	O	O
onabotulinumtoxinA	XEOMIN.xml:S1:4197:18	onabotulinumtoxina	NN	O	O
(	XEOMIN.xml:S1:4216:1	(	(	O	O
Botox	XEOMIN.xml:S1:4217:5	botox	NNP	O	O
)	XEOMIN.xml:S1:4222:1	)	)	O	O
[	XEOMIN.xml:S1:4225:1	[	VBD	O	O
see	XEOMIN.xml:S1:4226:3	see	VB	O	O
Clinical	XEOMIN.xml:S1:4231:8	clinic	JJ	O	O
Studies	XEOMIN.xml:S1:4240:7	studi	NNP	O	O
(	XEOMIN.xml:S1:4248:1	(	(	O	O
14.2	XEOMIN.xml:S1:4249:4	14.2	CD	O	O
)	XEOMIN.xml:S1:4253:1	)	)	O	O
]	XEOMIN.xml:S1:4256:1	]	NN	O	O
,	XEOMIN.xml:S1:4259:1	,	,	O	O
74	XEOMIN.xml:S1:4261:2	74	CD	O	O
patients	XEOMIN.xml:S1:4264:8	patient	NNS	O	O
received	XEOMIN.xml:S1:4273:8	receiv	VBD	O	O
XEOMIN	XEOMIN.xml:S1:4282:6	xeomin	NNP	O	O
at	XEOMIN.xml:S1:4289:2	at	IN	O	O
a	XEOMIN.xml:S1:4292:1	a	DT	O	O
mean	XEOMIN.xml:S1:4294:4	mean	JJ	O	O
dose	XEOMIN.xml:S1:4299:4	dose	NN	O	O
of	XEOMIN.xml:S1:4304:2	of	IN	O	O
approximately	XEOMIN.xml:S1:4307:13	approxim	RB	O	O
33	XEOMIN.xml:S1:4321:2	33	CD	O	O
Units	XEOMIN.xml:S1:4324:5	unit	NNS	O	O
per	XEOMIN.xml:S1:4330:3	per	IN	O	O
eye	XEOMIN.xml:S1:4334:3	eye	NN	O	O
(	XEOMIN.xml:S1:4338:1	(	(	O	O
minimum	XEOMIN.xml:S1:4339:7	minimum	JJ	O	O
10	XEOMIN.xml:S1:4347:2	10	CD	O	O
Units	XEOMIN.xml:S1:4350:5	unit	NNS	O	O
,	XEOMIN.xml:S1:4355:1	,	,	O	O
maximum	XEOMIN.xml:S1:4357:7	maximum	JJ	O	O
50	XEOMIN.xml:S1:4365:2	50	CD	O	O
Units	XEOMIN.xml:S1:4368:5	unit	NNS	O	O
)	XEOMIN.xml:S1:4373:1	)	)	O	O
.	XEOMIN.xml:S1:4374:1	.	.	O	O

XEOMIN	XEOMIN.xml:S1:4376:6	xeomin	SYM	O	O
-	XEOMIN.xml:S1:4382:1	-	:	O	O
treated	XEOMIN.xml:S1:4383:7	treat	JJ	O	O
patients	XEOMIN.xml:S1:4391:8	patient	NNS	O	O
were	XEOMIN.xml:S1:4400:4	were	VBD	O	O
22	XEOMIN.xml:S1:4405:2	22	CD	O	O
to	XEOMIN.xml:S1:4408:2	to	TO	O	O
79	XEOMIN.xml:S1:4411:2	79	CD	O	O
years	XEOMIN.xml:S1:4414:5	year	NNS	O	O
of	XEOMIN.xml:S1:4420:2	of	IN	O	O
age	XEOMIN.xml:S1:4423:3	age	NN	O	O
(	XEOMIN.xml:S1:4427:1	(	(	O	O
mean	XEOMIN.xml:S1:4428:4	mean	JJ	O	O
62	XEOMIN.xml:S1:4433:2	62	CD	O	O
years	XEOMIN.xml:S1:4436:5	year	NNS	O	O
)	XEOMIN.xml:S1:4441:1	)	)	O	O
,	XEOMIN.xml:S1:4442:1	,	,	O	O
predominantly	XEOMIN.xml:S1:4444:13	predominantli	RB	O	O
female	XEOMIN.xml:S1:4458:6	femal	JJ	O	O
(	XEOMIN.xml:S1:4465:1	(	(	O	O
65%	XEOMIN.xml:S1:4466:3	65%	CD	O	O
)	XEOMIN.xml:S1:4469:1	)	)	O	O
,	XEOMIN.xml:S1:4470:1	,	,	O	O
Caucasian	XEOMIN.xml:S1:4472:9	caucasian	NNP	O	O
(	XEOMIN.xml:S1:4482:1	(	(	O	O
79%	XEOMIN.xml:S1:4483:3	79%	CD	O	O
)	XEOMIN.xml:S1:4486:1	)	)	O	O
,	XEOMIN.xml:S1:4487:1	,	,	O	O
and	XEOMIN.xml:S1:4489:3	and	CC	O	O
had	XEOMIN.xml:S1:4493:3	had	VBD	O	O
a	XEOMIN.xml:S1:4497:1	a	DT	O	O
mean	XEOMIN.xml:S1:4499:4	mean	JJ	O	O
time	XEOMIN.xml:S1:4504:4	time	NN	O	O
since	XEOMIN.xml:S1:4509:5	sinc	IN	O	O
diagnosis	XEOMIN.xml:S1:4515:9	diagnosi	NN	O	O
of	XEOMIN.xml:S1:4525:2	of	IN	O	O
approximately	XEOMIN.xml:S1:4528:13	approxim	RB	O	O
5	XEOMIN.xml:S1:4542:1	5	CD	O	O
years	XEOMIN.xml:S1:4544:5	year	NNS	O	O
.	XEOMIN.xml:S1:4549:1	.	.	O	O

The	XEOMIN.xml:S1:4555:3	the	DT	O	O
adverse	XEOMIN.xml:S1:4559:7	advers	JJ	O	O
events	XEOMIN.xml:S1:4567:6	event	NNS	O	O
occurring	XEOMIN.xml:S1:4574:9	occur	VBG	O	O
in	XEOMIN.xml:S1:4584:2	in	IN	O	O
5%	XEOMIN.xml:S1:4589:2	5%	CD	O	O
of	XEOMIN.xml:S1:4592:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S1:4595:6	xeomin	NNP	O	O
-	XEOMIN.xml:S1:4601:1	-	:	O	O
treated	XEOMIN.xml:S1:4602:7	treat	VBD	O	O
patients	XEOMIN.xml:S1:4610:8	patient	NNS	O	O
and	XEOMIN.xml:S1:4619:3	and	CC	O	O
greater	XEOMIN.xml:S1:4623:7	greater	JJR	O	O
than	XEOMIN.xml:S1:4631:4	than	IN	O	O
placebo	XEOMIN.xml:S1:4636:7	placebo	NN	O	O
in	XEOMIN.xml:S1:4644:2	in	IN	O	O
the	XEOMIN.xml:S1:4647:3	the	DT	O	O
Phase	XEOMIN.xml:S1:4651:5	phase	NNP	O	O
3	XEOMIN.xml:S1:4657:1	3	CD	O	O
study	XEOMIN.xml:S1:4659:5	studi	NN	O	O
were	XEOMIN.xml:S1:4665:4	were	VBD	O	O
eyelid	XEOMIN.xml:S1:4670:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
ptosis	XEOMIN.xml:S1:4677:6	ptosi	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:4683:1	,	,	O	O
dry	XEOMIN.xml:S1:4685:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
eye	XEOMIN.xml:S1:4689:3	eye	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:4692:1	,	,	O	O
dry	XEOMIN.xml:S1:4694:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	XEOMIN.xml:S1:4698:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:4703:1	,	,	O	O
diarrhea	XEOMIN.xml:S1:4705:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:4713:1	,	,	O	O
headache	XEOMIN.xml:S1:4715:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:4723:1	,	,	O	O
visual	XEOMIN.xml:S1:4725:6	visual	JJ	B-AdverseReaction	B-AdverseReaction
impairment	XEOMIN.xml:S1:4732:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:4742:1	,	,	O	O
dyspnea	XEOMIN.xml:S1:4744:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:4751:1	,	,	O	O
nasopharyngitis	XEOMIN.xml:S1:4753:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:4768:1	,	,	O	O
and	XEOMIN.xml:S1:4770:3	and	CC	O	O
respiratory	XEOMIN.xml:S1:4774:11	respiratori	JJ	B-AdverseReaction	B-AdverseReaction
tract	XEOMIN.xml:S1:4786:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	XEOMIN.xml:S1:4792:9	infect	NN	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S1:4801:1	.	.	O	O

No	XEOMIN.xml:S1:4803:2	No	DT	O	O
serious	XEOMIN.xml:S1:4806:7	seriou	JJ	O	O
adverse	XEOMIN.xml:S1:4814:7	advers	JJ	O	O
events	XEOMIN.xml:S1:4822:6	event	NNS	O	O
occurred	XEOMIN.xml:S1:4829:8	occur	VBD	O	O
in	XEOMIN.xml:S1:4838:2	in	IN	O	O
patients	XEOMIN.xml:S1:4841:8	patient	NNS	O	O
who	XEOMIN.xml:S1:4850:3	who	WP	O	O
received	XEOMIN.xml:S1:4854:8	receiv	VBD	O	O
XEOMIN	XEOMIN.xml:S1:4863:6	xeomin	NNP	O	O
;	XEOMIN.xml:S1:4869:1	;	:	O	O
one	XEOMIN.xml:S1:4871:3	one	CD	O	O
placebo	XEOMIN.xml:S1:4875:7	placebo	NN	O	O
-	XEOMIN.xml:S1:4882:1	-	:	O	O
treated	XEOMIN.xml:S1:4883:7	treat	VBN	O	O
patient	XEOMIN.xml:S1:4891:7	patient	NN	O	O
experienced	XEOMIN.xml:S1:4899:11	experienc	VBD	O	O
a	XEOMIN.xml:S1:4911:1	a	DT	O	O
serious	XEOMIN.xml:S1:4913:7	seriou	JJ	O	O
adverse	XEOMIN.xml:S1:4921:7	advers	JJ	O	O
event	XEOMIN.xml:S1:4929:5	event	NN	O	O
(	XEOMIN.xml:S1:4935:1	(	(	O	O
dyspnea	XEOMIN.xml:S1:4936:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
)	XEOMIN.xml:S1:4943:1	)	)	O	O
.	XEOMIN.xml:S1:4944:1	.	.	O	O

Table	XEOMIN.xml:S1:4950:5	tabl	JJ	O	O
3	XEOMIN.xml:S1:4956:1	3	CD	O	O
:	XEOMIN.xml:S1:4957:1	:	:	O	O
Most	XEOMIN.xml:S1:4959:4	most	JJS	O	O
Common	XEOMIN.xml:S1:4964:6	common	JJ	O	O
TEAEs	XEOMIN.xml:S1:4971:5	teae	NNP	O	O
(	XEOMIN.xml:S1:4977:1	(	(	O	O
5%	XEOMIN.xml:S1:4980:2	5%	CD	O	O
)	XEOMIN.xml:S1:4982:1	)	)	O	O
and	XEOMIN.xml:S1:4984:3	and	CC	O	O
Greater	XEOMIN.xml:S1:4988:7	greater	NNP	O	O
than	XEOMIN.xml:S1:4996:4	than	IN	O	O
Placebo	XEOMIN.xml:S1:5001:7	placebo	NNP	O	O
:	XEOMIN.xml:S1:5008:1	:	:	O	O
Double	XEOMIN.xml:S1:5010:6	doubl	JJ	O	O
-	XEOMIN.xml:S1:5016:1	-	:	O	O
Blind	XEOMIN.xml:S1:5017:5	blind	IN	O	O
Phase	XEOMIN.xml:S1:5023:5	phase	NNP	O	O
of	XEOMIN.xml:S1:5029:2	of	IN	O	O
Clinical	XEOMIN.xml:S1:5032:8	clinic	NNP	O	O
Trial	XEOMIN.xml:S1:5041:5	trial	NNP	O	O

Double	XEOMIN.xml:S1:5104:6	doubl	NNP	O	O
-	XEOMIN.xml:S1:5110:1	-	:	O	O
Blind	XEOMIN.xml:S1:5111:5	blind	NNP	O	O
Phase	XEOMIN.xml:S1:5117:5	phase	NNP	O	O

System	XEOMIN.xml:S1:5131:6	system	NNP	O	O
Organ	XEOMIN.xml:S1:5138:5	organ	NNP	O	O
Class	XEOMIN.xml:S1:5144:5	class	NNP	O	O
Preferred	XEOMIN.xml:S1:5151:9	prefer	NNP	O	O
Term	XEOMIN.xml:S1:5161:4	term	NNP	O	O
XEOMIN	XEOMIN.xml:S1:5189:6	xeomin	NNP	O	O
(	XEOMIN.xml:S1:5195:1	(	(	O	O
N	XEOMIN.xml:S1:5196:1	N	NNP	O	O
74	XEOMIN.xml:S1:5198:2	74	CD	O	O
)	XEOMIN.xml:S1:5200:1	)	)	O	O
Placebo	XEOMIN.xml:S1:5216:7	placebo	NNP	O	O
(	XEOMIN.xml:S1:5223:1	(	(	O	O
N	XEOMIN.xml:S1:5224:1	N	NNP	O	O
34	XEOMIN.xml:S1:5226:2	34	CD	O	O
)	XEOMIN.xml:S1:5228:1	)	)	O	O

Subjects	XEOMIN.xml:S1:5243:8	subject	NNS	O	O

with	XEOMIN.xml:S1:5252:4	with	IN	O	O
TEAEs	XEOMIN.xml:S1:5257:5	teae	NNP	O	O
70%	XEOMIN.xml:S1:5306:3	70%	CD	O	O
62%	XEOMIN.xml:S1:5333:3	62%	CD	O	O

Eye	XEOMIN.xml:S1:5352:3	eye	NNP	O	B-AdverseReaction
disorders	XEOMIN.xml:S1:5356:9	disord	NNS	O	I-AdverseReaction
38%	XEOMIN.xml:S1:5415:3	38%	CD	O	O
21%	XEOMIN.xml:S1:5442:3	21%	CD	O	O

Eyelid	XEOMIN.xml:S1:5463:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
ptosis	XEOMIN.xml:S1:5470:6	ptosi	NN	I-AdverseReaction	I-AdverseReaction
19%	XEOMIN.xml:S1:5524:3	19%	CD	O	O
9%	XEOMIN.xml:S1:5551:2	9%	CD	O	O

Dry	XEOMIN.xml:S1:5572:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
eye	XEOMIN.xml:S1:5576:3	eye	NN	I-AdverseReaction	I-AdverseReaction
16%	XEOMIN.xml:S1:5633:3	16%	CD	O	O
12%	XEOMIN.xml:S1:5660:3	12%	CD	O	O

Visual	XEOMIN.xml:S1:5681:6	visual	JJ	B-AdverseReaction	B-AdverseReaction
impairment	XEOMIN.xml:S1:5688:10	impair	NN	I-AdverseReaction	I-AdverseReaction
12%	XEOMIN.xml:S1:5742:3	12%	CD	O	O
6%	XEOMIN.xml:S1:5769:2	6%	CD	O	O

Gastrointestinal	XEOMIN.xml:S1:5788:16	gastrointestin	NNP	O	B-AdverseReaction
disorders	XEOMIN.xml:S1:5805:9	disord	NNS	O	I-AdverseReaction
30%	XEOMIN.xml:S1:5851:3	30%	CD	O	O
15%	XEOMIN.xml:S1:5878:3	15%	CD	O	O

Dry	XEOMIN.xml:S1:5899:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
mouth	XEOMIN.xml:S1:5903:5	mouth	VBD	I-AdverseReaction	I-AdverseReaction
16%	XEOMIN.xml:S1:5960:3	16%	CD	O	O
3%	XEOMIN.xml:S1:5987:2	3%	CD	O	O

Diarrhoea	XEOMIN.xml:S1:6008:9	diarrhoea	NNP	B-AdverseReaction	O
8%	XEOMIN.xml:S1:6069:2	8%	CD	O	O
-	XEOMIN.xml:S1:6097:1	-	:	O	O

Infections	XEOMIN.xml:S1:6115:10	infect	NNS	O	O
and	XEOMIN.xml:S1:6126:3	and	CC	O	O
infestations	XEOMIN.xml:S1:6130:12	infest	NNS	O	O
20%	XEOMIN.xml:S1:6178:3	20%	CD	O	O
15%	XEOMIN.xml:S1:6205:3	15%	CD	O	O

Nasopharyngitis	XEOMIN.xml:S1:6226:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
5%	XEOMIN.xml:S1:6287:2	5%	CD	O	O
3%	XEOMIN.xml:S1:6314:2	3%	CD	O	O

Respiratory	XEOMIN.xml:S1:6333:11	respiratori	NNP	B-AdverseReaction	B-AdverseReaction
tract	XEOMIN.xml:S1:6345:5	tract	JJ	I-AdverseReaction	I-AdverseReaction
infection	XEOMIN.xml:S1:6351:9	infect	NN	I-AdverseReaction	I-AdverseReaction
5%	XEOMIN.xml:S1:6396:2	5%	CD	O	O
3%	XEOMIN.xml:S1:6423:2	3%	CD	O	O

Nervous	XEOMIN.xml:S1:6442:7	nervou	JJ	O	O
system	XEOMIN.xml:S1:6450:6	system	NN	O	O
disorders	XEOMIN.xml:S1:6457:9	disord	NNS	O	O
14%	XEOMIN.xml:S1:6505:3	14%	CD	O	O
9%	XEOMIN.xml:S1:6532:2	9%	CD	O	O

Headache	XEOMIN.xml:S1:6553:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
7%	XEOMIN.xml:S1:6614:2	7%	CD	O	O
3%	XEOMIN.xml:S1:6641:2	3%	CD	O	O

General	XEOMIN.xml:S1:6660:7	gener	NNP	O	O
disorders	XEOMIN.xml:S1:6668:9	disord	NNS	O	O
and	XEOMIN.xml:S1:6678:3	and	CC	O	O
administration	XEOMIN.xml:S1:6682:14	administr	NN	O	O
site	XEOMIN.xml:S1:6697:4	site	NN	O	O
conditions	XEOMIN.xml:S1:6702:10	condit	NNS	O	O
11%	XEOMIN.xml:S1:6725:3	11%	CD	O	O
9%	XEOMIN.xml:S1:6752:2	9%	CD	O	O

Respiratory	XEOMIN.xml:S1:6771:11	respiratori	NNP	O	O
,	XEOMIN.xml:S1:6782:1	,	,	O	O
thoracic	XEOMIN.xml:S1:6784:8	thorac	NN	O	O
and	XEOMIN.xml:S1:6793:3	and	CC	O	O
mediastinal	XEOMIN.xml:S1:6797:11	mediastin	JJ	O	B-AdverseReaction
disorders	XEOMIN.xml:S1:6809:9	disord	NNS	O	I-AdverseReaction
11%	XEOMIN.xml:S1:6834:3	11%	CD	O	O
3%	XEOMIN.xml:S1:6861:2	3%	CD	O	O

Dyspnoea	XEOMIN.xml:S1:6882:8	dyspnoea	NNP	B-AdverseReaction	B-AdverseReaction
5%	XEOMIN.xml:S1:6943:2	5%	CD	O	O
3%	XEOMIN.xml:S1:6970:2	3%	CD	O	O

Glabellar	XEOMIN.xml:S1:7001:9	glabellar	JJ	O	O
Lines	XEOMIN.xml:S1:7011:5	line	NNS	O	O

In	XEOMIN.xml:S1:7023:2	In	IN	O	O

three	XEOMIN.xml:S1:7026:5	three	CD	O	O
placebo	XEOMIN.xml:S1:7032:7	placebo	SYM	O	O
-	XEOMIN.xml:S1:7039:1	-	:	O	O
controlled	XEOMIN.xml:S1:7040:10	control	VBN	O	O
trials	XEOMIN.xml:S1:7051:6	trial	NNS	O	O
in	XEOMIN.xml:S1:7058:2	in	IN	O	O
803	XEOMIN.xml:S1:7061:3	803	CD	O	O
subjects	XEOMIN.xml:S1:7065:8	subject	NNS	O	O
with	XEOMIN.xml:S1:7074:4	with	IN	O	O
glabellar	XEOMIN.xml:S1:7079:9	glabellar	JJ	O	O
lines	XEOMIN.xml:S1:7089:5	line	NNS	O	O
,	XEOMIN.xml:S1:7094:1	,	,	O	O
535	XEOMIN.xml:S1:7096:3	535	CD	O	O
subjects	XEOMIN.xml:S1:7100:8	subject	NNS	O	O
received	XEOMIN.xml:S1:7109:8	receiv	VBD	O	O
a	XEOMIN.xml:S1:7118:1	a	DT	O	O
single	XEOMIN.xml:S1:7120:6	singl	JJ	O	O
dose	XEOMIN.xml:S1:7127:4	dose	NN	O	O
of	XEOMIN.xml:S1:7132:2	of	IN	O	O
20	XEOMIN.xml:S1:7135:2	20	CD	O	O
Units	XEOMIN.xml:S1:7138:5	unit	NNS	O	O
XEOMIN	XEOMIN.xml:S1:7144:6	xeomin	NNP	O	O
and	XEOMIN.xml:S1:7151:3	and	CC	O	O
268	XEOMIN.xml:S1:7155:3	268	CD	O	O
subjects	XEOMIN.xml:S1:7159:8	subject	NNS	O	O
received	XEOMIN.xml:S1:7168:8	receiv	VBN	O	O
placebo	XEOMIN.xml:S1:7177:7	placebo	NN	O	O
.	XEOMIN.xml:S1:7184:1	.	.	O	O

XEOMIN	XEOMIN.xml:S1:7186:6	xeomin	RB	O	O
treated	XEOMIN.xml:S1:7193:7	treat	VBN	O	O
subjects	XEOMIN.xml:S1:7201:8	subject	NNS	O	O
were	XEOMIN.xml:S1:7210:4	were	VBD	O	O
24	XEOMIN.xml:S1:7215:2	24	CD	O	O
to	XEOMIN.xml:S1:7218:2	to	TO	O	O
74	XEOMIN.xml:S1:7221:2	74	CD	O	O
years	XEOMIN.xml:S1:7224:5	year	NNS	O	O
old	XEOMIN.xml:S1:7230:3	old	JJ	O	O
,	XEOMIN.xml:S1:7233:1	,	,	O	O
and	XEOMIN.xml:S1:7235:3	and	CC	O	O
were	XEOMIN.xml:S1:7239:4	were	VBD	O	O
predominantly	XEOMIN.xml:S1:7244:13	predominantli	RB	O	O
female	XEOMIN.xml:S1:7258:6	femal	JJ	O	O
(	XEOMIN.xml:S1:7265:1	(	(	O	O
88%	XEOMIN.xml:S1:7266:3	88%	CD	O	O
)	XEOMIN.xml:S1:7269:1	)	)	O	O
.	XEOMIN.xml:S1:7270:1	.	.	O	O

The	XEOMIN.xml:S1:7272:3	the	DT	O	O
most	XEOMIN.xml:S1:7276:4	most	RBS	O	O
frequent	XEOMIN.xml:S1:7281:8	frequent	JJ	O	O
adverse	XEOMIN.xml:S1:7290:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:7298:9	reaction	NNS	O	O
in	XEOMIN.xml:S1:7308:2	in	IN	O	O
XEOMIN	XEOMIN.xml:S1:7311:6	xeomin	NNP	O	O
treated	XEOMIN.xml:S1:7318:7	treat	VBD	O	O
subjects	XEOMIN.xml:S1:7326:8	subject	NNS	O	O
were	XEOMIN.xml:S1:7335:4	were	VBD	O	O
:	XEOMIN.xml:S1:7339:1	:	:	O	O
headache	XEOMIN.xml:S1:7341:8	headach	NN	B-AdverseReaction	B-AdverseReaction
29	XEOMIN.xml:S1:7350:2	29	CD	O	O
(	XEOMIN.xml:S1:7353:1	(	(	O	O
5.4%	XEOMIN.xml:S1:7354:4	5.4%	CD	O	O
)	XEOMIN.xml:S1:7358:1	)	)	O	O
,	XEOMIN.xml:S1:7359:1	,	,	O	O
facial	XEOMIN.xml:S1:7361:6	facial	JJ	B-AdverseReaction	B-AdverseReaction
paresis	XEOMIN.xml:S1:7368:7	paresi	NN	I-AdverseReaction	I-AdverseReaction
4	XEOMIN.xml:S1:7376:1	4	CD	O	O
(	XEOMIN.xml:S1:7378:1	(	(	O	O
0.7%	XEOMIN.xml:S1:7379:4	0.7%	CD	O	O
)	XEOMIN.xml:S1:7383:1	)	)	O	O
,	XEOMIN.xml:S1:7384:1	,	,	O	O
injection	XEOMIN.xml:S1:7386:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:7396:4	site	NN	I-AdverseReaction	I-AdverseReaction
hematoma	XEOMIN.xml:S1:7401:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
3	XEOMIN.xml:S1:7410:1	3	CD	O	O
(	XEOMIN.xml:S1:7412:1	(	(	O	O
0.6%	XEOMIN.xml:S1:7413:4	0.6%	CD	O	O
)	XEOMIN.xml:S1:7417:1	)	)	O	O
and	XEOMIN.xml:S1:7419:3	and	CC	O	O
eyelid	XEOMIN.xml:S1:7423:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
edema	XEOMIN.xml:S1:7430:5	edema	NN	I-AdverseReaction	I-AdverseReaction
2	XEOMIN.xml:S1:7436:1	2	CD	O	O
(	XEOMIN.xml:S1:7438:1	(	(	O	O
0.4%	XEOMIN.xml:S1:7439:4	0.4%	CD	O	O
)	XEOMIN.xml:S1:7443:1	)	)	O	O
.	XEOMIN.xml:S1:7444:1	.	.	O	O

Four	XEOMIN.xml:S1:7446:4	four	CD	O	O
serious	XEOMIN.xml:S1:7451:7	seriou	JJ	O	O
adverse	XEOMIN.xml:S1:7459:7	advers	JJ	O	O
events	XEOMIN.xml:S1:7467:6	event	NNS	O	O
occurred	XEOMIN.xml:S1:7474:8	occur	VBD	O	O
in	XEOMIN.xml:S1:7483:2	in	IN	O	O
two	XEOMIN.xml:S1:7486:3	two	CD	O	O
placebo	XEOMIN.xml:S1:7490:7	placebo	NN	O	O
-	XEOMIN.xml:S1:7497:1	-	:	O	O
treated	XEOMIN.xml:S1:7498:7	treat	JJ	O	O
subjects	XEOMIN.xml:S1:7506:8	subject	NNS	O	O
.	XEOMIN.xml:S1:7514:1	.	.	O	O

Six	XEOMIN.xml:S1:7516:3	six	NNP	O	O
XEOMIN	XEOMIN.xml:S1:7520:6	xeomin	NNP	O	O
treated	XEOMIN.xml:S1:7527:7	treat	VBD	O	O
subjects	XEOMIN.xml:S1:7535:8	subject	NNS	O	O
experienced	XEOMIN.xml:S1:7544:11	experienc	VBD	O	O
six	XEOMIN.xml:S1:7556:3	six	CD	O	O
serious	XEOMIN.xml:S1:7560:7	seriou	JJ	O	O
adverse	XEOMIN.xml:S1:7568:7	advers	JJ	O	O
events	XEOMIN.xml:S1:7576:6	event	NNS	O	O
.	XEOMIN.xml:S1:7582:1	.	.	O	O

All	XEOMIN.xml:S1:7584:3	all	DT	O	O
serious	XEOMIN.xml:S1:7588:7	seriou	JJ	O	O
adverse	XEOMIN.xml:S1:7596:7	advers	JJ	O	O
events	XEOMIN.xml:S1:7604:6	event	NNS	O	O
were	XEOMIN.xml:S1:7611:4	were	VBD	O	O
assessed	XEOMIN.xml:S1:7616:8	assess	VBN	O	O
as	XEOMIN.xml:S1:7625:2	as	RB	O	O
unrelated	XEOMIN.xml:S1:7628:9	unrel	JJ	O	O
to	XEOMIN.xml:S1:7638:2	to	TO	O	O
study	XEOMIN.xml:S1:7641:5	studi	VB	O	O
drug	XEOMIN.xml:S1:7647:4	drug	NN	O	O
.	XEOMIN.xml:S1:7651:1	.	.	O	O

The	XEOMIN.xml:S1:7657:3	the	DT	O	O
adverse	XEOMIN.xml:S1:7661:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:7669:9	reaction	NNS	O	O
below	XEOMIN.xml:S1:7679:5	below	IN	O	O
reflect	XEOMIN.xml:S1:7685:7	reflect	NN	O	O
exposure	XEOMIN.xml:S1:7693:8	exposur	NN	O	O
to	XEOMIN.xml:S1:7702:2	to	TO	O	O
XEOMIN	XEOMIN.xml:S1:7705:6	xeomin	VB	O	O
with	XEOMIN.xml:S1:7712:4	with	IN	O	O
glabellar	XEOMIN.xml:S1:7717:9	glabellar	JJ	O	O
lines	XEOMIN.xml:S1:7727:5	line	NNS	O	O
in	XEOMIN.xml:S1:7733:2	in	IN	O	O
placebo	XEOMIN.xml:S1:7736:7	placebo	NN	O	O
-	XEOMIN.xml:S1:7743:1	-	:	O	O
controlled	XEOMIN.xml:S1:7744:10	control	VBN	O	O
studies	XEOMIN.xml:S1:7755:7	studi	NNS	O	O
.	XEOMIN.xml:S1:7762:1	.	.	O	O

Adverse	XEOMIN.xml:S1:7764:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:7772:9	reaction	NNS	O	O
are	XEOMIN.xml:S1:7782:3	are	VBP	O	O
adverse	XEOMIN.xml:S1:7786:7	advers	JJ	O	O
events	XEOMIN.xml:S1:7794:6	event	NNS	O	O
in	XEOMIN.xml:S1:7801:2	in	IN	O	O
which	XEOMIN.xml:S1:7804:5	which	WDT	O	O
there	XEOMIN.xml:S1:7810:5	there	EX	O	O
is	XEOMIN.xml:S1:7816:2	is	VBZ	O	O
some	XEOMIN.xml:S1:7819:4	some	DT	O	O
basis	XEOMIN.xml:S1:7824:5	basi	NN	O	O
to	XEOMIN.xml:S1:7830:2	to	TO	O	O
believe	XEOMIN.xml:S1:7833:7	believ	VB	O	O
there	XEOMIN.xml:S1:7841:5	there	EX	O	O
is	XEOMIN.xml:S1:7847:2	is	VBZ	O	O
a	XEOMIN.xml:S1:7850:1	a	DT	O	O
causal	XEOMIN.xml:S1:7852:6	causal	NN	O	O
relationship	XEOMIN.xml:S1:7859:12	relationship	NN	O	O
between	XEOMIN.xml:S1:7872:7	between	IN	O	O
the	XEOMIN.xml:S1:7880:3	the	DT	O	O
drug	XEOMIN.xml:S1:7884:4	drug	NN	O	O
and	XEOMIN.xml:S1:7889:3	and	CC	O	O
the	XEOMIN.xml:S1:7893:3	the	DT	O	O
occurrence	XEOMIN.xml:S1:7897:10	occurr	NN	O	O
of	XEOMIN.xml:S1:7908:2	of	IN	O	O
the	XEOMIN.xml:S1:7911:3	the	DT	O	O
adverse	XEOMIN.xml:S1:7915:7	advers	JJ	O	O
event	XEOMIN.xml:S1:7923:5	event	NN	O	O
.	XEOMIN.xml:S1:7928:1	.	.	O	O

Because	XEOMIN.xml:S1:7934:7	becaus	IN	O	O
clinical	XEOMIN.xml:S1:7942:8	clinic	JJ	O	O
trials	XEOMIN.xml:S1:7951:6	trial	NNS	O	O
are	XEOMIN.xml:S1:7958:3	are	VBP	O	O
conducted	XEOMIN.xml:S1:7962:9	conduct	VBN	O	O
under	XEOMIN.xml:S1:7972:5	under	IN	O	O
widely	XEOMIN.xml:S1:7978:6	wide	RB	O	O
varying	XEOMIN.xml:S1:7985:7	vari	VBG	O	O
conditions	XEOMIN.xml:S1:7993:10	condit	NNS	O	O
,	XEOMIN.xml:S1:8003:1	,	,	O	O
adverse	XEOMIN.xml:S1:8005:7	advers	JJ	O	O
reaction	XEOMIN.xml:S1:8013:8	reaction	NN	O	O
rates	XEOMIN.xml:S1:8022:5	rate	NNS	O	O
observed	XEOMIN.xml:S1:8028:8	observ	VBD	O	O
in	XEOMIN.xml:S1:8037:2	in	IN	O	O
the	XEOMIN.xml:S1:8040:3	the	DT	O	O
clinical	XEOMIN.xml:S1:8044:8	clinic	JJ	O	O
trials	XEOMIN.xml:S1:8053:6	trial	NNS	O	O
of	XEOMIN.xml:S1:8060:2	of	IN	O	O
a	XEOMIN.xml:S1:8063:1	a	DT	O	O
drug	XEOMIN.xml:S1:8065:4	drug	NN	O	O
cannot	XEOMIN.xml:S1:8070:6	cannot	NN	O	O
be	XEOMIN.xml:S1:8077:2	be	VB	O	O
directly	XEOMIN.xml:S1:8080:8	directli	RB	O	O
compared	XEOMIN.xml:S1:8089:8	compar	VBN	O	O
to	XEOMIN.xml:S1:8098:2	to	TO	O	O
rates	XEOMIN.xml:S1:8101:5	rate	NNS	O	O
in	XEOMIN.xml:S1:8107:2	in	IN	O	O
the	XEOMIN.xml:S1:8110:3	the	DT	O	O
clinical	XEOMIN.xml:S1:8114:8	clinic	JJ	O	O
trials	XEOMIN.xml:S1:8123:6	trial	NNS	O	O
of	XEOMIN.xml:S1:8130:2	of	IN	O	O
another	XEOMIN.xml:S1:8133:7	anoth	DT	O	O
drug	XEOMIN.xml:S1:8141:4	drug	NN	O	O
and	XEOMIN.xml:S1:8146:3	and	CC	O	O
may	XEOMIN.xml:S1:8150:3	may	MD	O	O
not	XEOMIN.xml:S1:8154:3	not	RB	O	O
reflect	XEOMIN.xml:S1:8158:7	reflect	VB	O	O
the	XEOMIN.xml:S1:8166:3	the	DT	O	O
rates	XEOMIN.xml:S1:8170:5	rate	NNS	O	O
observed	XEOMIN.xml:S1:8176:8	observ	VBD	O	O
in	XEOMIN.xml:S1:8185:2	in	IN	O	O
practice	XEOMIN.xml:S1:8188:8	practic	NN	O	O
.	XEOMIN.xml:S1:8196:1	.	.	O	O

Table	XEOMIN.xml:S1:8202:5	tabl	JJ	O	O
4	XEOMIN.xml:S1:8208:1	4	CD	O	O
:	XEOMIN.xml:S1:8209:1	:	:	O	O
Adverse	XEOMIN.xml:S1:8211:7	advers	JJ	O	O
Reactions	XEOMIN.xml:S1:8219:9	reaction	NNS	O	O
in	XEOMIN.xml:S1:8229:2	in	IN	O	O
Placebo	XEOMIN.xml:S1:8232:7	placebo	NNP	O	O
-	XEOMIN.xml:S1:8239:1	-	:	O	O
Controlled	XEOMIN.xml:S1:8240:10	control	VBD	O	O
Trials	XEOMIN.xml:S1:8251:6	trial	NNS	O	O

Adverse	XEOMIN.xml:S1:8270:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:8278:9	reaction	NNS	O	O
XEOMIN	XEOMIN.xml:S1:8307:6	xeomin	VBP	O	O
(	XEOMIN.xml:S1:8313:1	(	(	O	O
N	XEOMIN.xml:S1:8314:1	N	NNP	O	O
535	XEOMIN.xml:S1:8316:3	535	CD	O	O
)	XEOMIN.xml:S1:8319:1	)	)	O	O
(	XEOMIN.xml:S1:8321:1	(	(	O	O
)	XEOMIN.xml:S1:8323:1	)	)	O	O
Placebo	XEOMIN.xml:S1:8339:7	placebo	NNP	O	O
(	XEOMIN.xml:S1:8346:1	(	(	O	O
N	XEOMIN.xml:S1:8347:1	N	NNP	O	O
268	XEOMIN.xml:S1:8349:3	268	CD	O	O
)	XEOMIN.xml:S1:8352:1	)	)	O	O
(	XEOMIN.xml:S1:8354:1	(	(	O	O
)	XEOMIN.xml:S1:8356:1	)	)	O	O

Nervous	XEOMIN.xml:S1:8379:7	nervou	JJ	O	O

system	XEOMIN.xml:S1:8387:6	system	NN	O	O
disorders	XEOMIN.xml:S1:8394:9	disord	NNS	O	O
33	XEOMIN.xml:S1:8423:2	33	CD	O	O
(	XEOMIN.xml:S1:8426:1	(	(	O	O
6.1	XEOMIN.xml:S1:8427:3	6.1	CD	O	O
)	XEOMIN.xml:S1:8430:1	)	)	O	O
6	XEOMIN.xml:S1:8457:1	6	CD	O	O
(	XEOMIN.xml:S1:8459:1	(	(	O	O
2.2	XEOMIN.xml:S1:8460:3	2.2	CD	O	O
)	XEOMIN.xml:S1:8463:1	)	)	O	O

Headache	XEOMIN.xml:S1:8493:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
1	XEOMIN.xml:S1:8503:1	1	CD	O	O
29	XEOMIN.xml:S1:8532:2	29	CD	O	O
(	XEOMIN.xml:S1:8535:1	(	(	O	O
5.4	XEOMIN.xml:S1:8536:3	5.4	CD	O	O
)	XEOMIN.xml:S1:8539:1	)	)	O	O
6	XEOMIN.xml:S1:8566:1	6	CD	O	O
(	XEOMIN.xml:S1:8568:1	(	(	O	O
2.2	XEOMIN.xml:S1:8569:3	2.2	CD	O	O
)	XEOMIN.xml:S1:8572:1	)	)	O	O

Facial	XEOMIN.xml:S1:8595:6	facial	JJ	B-AdverseReaction	O
paresis	XEOMIN.xml:S1:8602:7	paresi	NN	I-AdverseReaction	O
(	XEOMIN.xml:S1:8610:1	(	(	O	O
brow	XEOMIN.xml:S1:8611:4	brow	JJ	B-AdverseReaction	O
ptosis	XEOMIN.xml:S1:8616:6	ptosi	NN	I-AdverseReaction	O
)	XEOMIN.xml:S1:8622:1	)	)	O	O
4	XEOMIN.xml:S1:8642:1	4	CD	O	O
(	XEOMIN.xml:S1:8644:1	(	(	O	O
0.7	XEOMIN.xml:S1:8645:3	0.7	CD	O	O
)	XEOMIN.xml:S1:8648:1	)	)	O	O
0	XEOMIN.xml:S1:8678:1	0	CD	O	O

General	XEOMIN.xml:S1:8701:7	gener	NNP	O	O
disorders	XEOMIN.xml:S1:8709:9	disord	NNS	O	O
and	XEOMIN.xml:S1:8719:3	and	CC	O	O
administration	XEOMIN.xml:S1:8723:14	administr	NN	O	O
site	XEOMIN.xml:S1:8738:4	site	NN	O	O
conditions	XEOMIN.xml:S1:8743:10	condit	NNS	O	O
5	XEOMIN.xml:S1:8769:1	5	CD	O	O
(	XEOMIN.xml:S1:8771:1	(	(	O	O
0.9	XEOMIN.xml:S1:8772:3	0.9	CD	O	O
)	XEOMIN.xml:S1:8775:1	)	)	O	O
2	XEOMIN.xml:S1:8802:1	2	CD	O	O
(	XEOMIN.xml:S1:8804:1	(	(	O	O
0.7	XEOMIN.xml:S1:8805:3	0.7	CD	O	O
)	XEOMIN.xml:S1:8808:1	)	)	O	O

Injection	XEOMIN.xml:S1:8833:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:8843:4	site	NN	I-AdverseReaction	I-AdverseReaction
hematoma	XEOMIN.xml:S1:8848:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
3	XEOMIN.xml:S1:8878:1	3	CD	O	O
(	XEOMIN.xml:S1:8880:1	(	(	O	O
0.6	XEOMIN.xml:S1:8881:3	0.6	CD	O	O
)	XEOMIN.xml:S1:8884:1	)	)	O	O
0	XEOMIN.xml:S1:8914:1	0	CD	O	O

Injection	XEOMIN.xml:S1:8944:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:8954:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XEOMIN.xml:S1:8959:4	pain	NN	I-AdverseReaction	I-AdverseReaction
1	XEOMIN.xml:S1:8987:1	1	CD	O	O
(	XEOMIN.xml:S1:8989:1	(	(	O	O
0.2	XEOMIN.xml:S1:8990:3	0.2	CD	O	O
)	XEOMIN.xml:S1:8993:1	)	)	O	O
0	XEOMIN.xml:S1:9023:1	0	CD	O	O

Facial	XEOMIN.xml:S1:9057:6	facial	NNP	B-AdverseReaction	B-AdverseReaction
pain	XEOMIN.xml:S1:9064:4	pain	NN	I-AdverseReaction	I-AdverseReaction
1	XEOMIN.xml:S1:9096:1	1	CD	O	O
(	XEOMIN.xml:S1:9098:1	(	(	O	O
0.2	XEOMIN.xml:S1:9099:3	0.2	CD	O	O
)	XEOMIN.xml:S1:9102:1	)	)	O	O
0	XEOMIN.xml:S1:9132:1	0	CD	O	O

Injection	XEOMIN.xml:S1:9160:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:9170:4	site	NN	I-AdverseReaction	I-AdverseReaction
swelling	XEOMIN.xml:S1:9175:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
0	XEOMIN.xml:S1:9208:1	0	CD	O	O
1	XEOMIN.xml:S1:9238:1	1	CD	O	O
(	XEOMIN.xml:S1:9240:1	(	(	O	O
0.4	XEOMIN.xml:S1:9241:3	0.4	CD	O	O
)	XEOMIN.xml:S1:9244:1	)	)	O	O

Sensation	XEOMIN.xml:S1:9270:9	sensat	NN	B-AdverseReaction	B-AdverseReaction
of	XEOMIN.xml:S1:9280:2	of	IN	I-AdverseReaction	I-AdverseReaction
pressure	XEOMIN.xml:S1:9283:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
0	XEOMIN.xml:S1:9317:1	0	CD	O	O
1	XEOMIN.xml:S1:9347:1	1	CD	O	O
(	XEOMIN.xml:S1:9349:1	(	(	O	O
0.4	XEOMIN.xml:S1:9350:3	0.4	CD	O	O
)	XEOMIN.xml:S1:9353:1	)	)	O	O

Eye	XEOMIN.xml:S1:9383:3	eye	NNP	O	B-AdverseReaction
disorders	XEOMIN.xml:S1:9387:9	disord	NNS	O	I-AdverseReaction
5	XEOMIN.xml:S1:9423:1	5	CD	O	O
(	XEOMIN.xml:S1:9425:1	(	(	O	O
0.9	XEOMIN.xml:S1:9426:3	0.9	CD	O	O
)	XEOMIN.xml:S1:9429:1	)	)	O	O
0	XEOMIN.xml:S1:9459:1	0	CD	O	O

Eyelid	XEOMIN.xml:S1:9493:6	eyelid	NNP	B-AdverseReaction	B-AdverseReaction
edema	XEOMIN.xml:S1:9500:5	edema	NN	I-AdverseReaction	I-AdverseReaction
2	XEOMIN.xml:S1:9532:1	2	CD	O	O
(	XEOMIN.xml:S1:9534:1	(	(	O	O
0.4	XEOMIN.xml:S1:9535:3	0.4	CD	O	O
)	XEOMIN.xml:S1:9538:1	)	)	O	O
0	XEOMIN.xml:S1:9568:1	0	CD	O	O

Blepharospasm	XEOMIN.xml:S1:9601:13	blepharospasm	NNP	B-AdverseReaction	B-AdverseReaction
1	XEOMIN.xml:S1:9641:1	1	CD	O	O
(	XEOMIN.xml:S1:9643:1	(	(	O	O
0.2	XEOMIN.xml:S1:9644:3	0.2	CD	O	O
)	XEOMIN.xml:S1:9647:1	)	)	O	O
0	XEOMIN.xml:S1:9677:1	0	CD	O	O

Eye	XEOMIN.xml:S1:9711:3	eye	NNP	B-AdverseReaction	B-AdverseReaction
disorder	XEOMIN.xml:S1:9715:8	disord	NN	I-AdverseReaction	I-AdverseReaction
1	XEOMIN.xml:S1:9750:1	1	CD	O	O
(	XEOMIN.xml:S1:9751:1	(	(	O	O
0.2	XEOMIN.xml:S1:9752:3	0.2	CD	O	O
)	XEOMIN.xml:S1:9755:1	)	)	O	O
0	XEOMIN.xml:S1:9786:1	0	CD	O	O

Eyelid	XEOMIN.xml:S1:9819:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
ptosis	XEOMIN.xml:S1:9826:6	ptosi	NN	I-AdverseReaction	I-AdverseReaction
1	XEOMIN.xml:S1:9859:1	1	CD	O	O
(	XEOMIN.xml:S1:9860:1	(	(	O	O
0.2	XEOMIN.xml:S1:9861:3	0.2	CD	O	O
)	XEOMIN.xml:S1:9864:1	)	)	O	O
0	XEOMIN.xml:S1:9895:1	0	CD	O	O

In	XEOMIN.xml:S1:9924:2	In	IN	O	O
open	XEOMIN.xml:S1:9927:4	open	JJ	O	O
label	XEOMIN.xml:S1:9932:5	label	NN	O	O
,	XEOMIN.xml:S1:9937:1	,	,	O	O
multiple	XEOMIN.xml:S1:9939:8	multipl	JJ	O	O
dose	XEOMIN.xml:S1:9948:4	dose	NN	O	O
trials	XEOMIN.xml:S1:9953:6	trial	NNS	O	O
,	XEOMIN.xml:S1:9959:1	,	,	O	O
adverse	XEOMIN.xml:S1:9961:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:9969:9	reaction	NNS	O	O
were	XEOMIN.xml:S1:9979:4	were	VBD	O	O
reported	XEOMIN.xml:S1:9984:8	report	VBN	O	O
for	XEOMIN.xml:S1:9993:3	for	IN	O	O
105	XEOMIN.xml:S1:9997:3	105	CD	O	O
of	XEOMIN.xml:S1:10001:2	of	IN	O	O
the	XEOMIN.xml:S1:10004:3	the	DT	O	O
800	XEOMIN.xml:S1:10008:3	800	CD	O	O
subjects	XEOMIN.xml:S1:10012:8	subject	NNS	O	O
(	XEOMIN.xml:S1:10021:1	(	(	O	O
13.1%	XEOMIN.xml:S1:10022:5	13.1%	CD	O	O
)	XEOMIN.xml:S1:10027:1	)	)	O	O
.	XEOMIN.xml:S1:10028:1	.	.	O	O

Headache	XEOMIN.xml:S1:10030:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
was	XEOMIN.xml:S1:10039:3	wa	VBD	O	O
the	XEOMIN.xml:S1:10043:3	the	DT	O	O
most	XEOMIN.xml:S1:10047:4	most	RBS	O	O
common	XEOMIN.xml:S1:10052:6	common	JJ	O	O
adverse	XEOMIN.xml:S1:10059:7	advers	JJ	O	O
reaction	XEOMIN.xml:S1:10067:8	reaction	NN	O	O
,	XEOMIN.xml:S1:10075:1	,	,	O	O
reported	XEOMIN.xml:S1:10077:8	report	VBD	O	O
for	XEOMIN.xml:S1:10086:3	for	IN	O	O
57	XEOMIN.xml:S1:10090:2	57	CD	O	O
subjects	XEOMIN.xml:S1:10093:8	subject	NNS	O	O
(	XEOMIN.xml:S1:10102:1	(	(	O	O
7.1%	XEOMIN.xml:S1:10103:4	7.1%	CD	O	O
)	XEOMIN.xml:S1:10107:1	)	)	O	O
,	XEOMIN.xml:S1:10108:1	,	,	O	O
followed	XEOMIN.xml:S1:10110:8	follow	VBN	O	O
by	XEOMIN.xml:S1:10119:2	by	IN	O	O
injection	XEOMIN.xml:S1:10122:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:10132:4	site	NN	I-AdverseReaction	I-AdverseReaction
hematoma	XEOMIN.xml:S1:10137:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
in	XEOMIN.xml:S1:10146:2	in	IN	O	O
8	XEOMIN.xml:S1:10149:1	8	CD	O	O
subjects	XEOMIN.xml:S1:10151:8	subject	NNS	O	O
(	XEOMIN.xml:S1:10160:1	(	(	O	O
1.0%	XEOMIN.xml:S1:10161:4	1.0%	CD	O	O
)	XEOMIN.xml:S1:10165:1	)	)	O	O
.	XEOMIN.xml:S1:10166:1	.	.	O	O

Adverse	XEOMIN.xml:S1:10168:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:10176:9	reaction	NNS	O	O
reported	XEOMIN.xml:S1:10186:8	report	VBN	O	O
in	XEOMIN.xml:S1:10195:2	in	IN	O	O
less	XEOMIN.xml:S1:10198:4	less	JJR	O	O
than	XEOMIN.xml:S1:10203:4	than	IN	O	O
1%	XEOMIN.xml:S1:10208:2	1%	CD	O	O
of	XEOMIN.xml:S1:10211:2	of	IN	O	O
subjects	XEOMIN.xml:S1:10214:8	subject	NNS	O	O
were	XEOMIN.xml:S1:10223:4	were	VBD	O	O
:	XEOMIN.xml:S1:10227:1	:	:	O	O
facial	XEOMIN.xml:S1:10229:6	facial	JJ	B-AdverseReaction	B-AdverseReaction
paresis	XEOMIN.xml:S1:10236:7	paresi	NN	I-AdverseReaction	I-AdverseReaction
(	XEOMIN.xml:S1:10244:1	(	(	O	O
brow	XEOMIN.xml:S1:10245:4	brow	JJ	B-AdverseReaction	O
ptosis	XEOMIN.xml:S1:10250:6	ptosi	NN	I-AdverseReaction	O
)	XEOMIN.xml:S1:10256:1	)	)	O	O
,	XEOMIN.xml:S1:10257:1	,	,	O	O
muscle	XEOMIN.xml:S1:10259:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
disorder	XEOMIN.xml:S1:10266:8	disord	NN	I-AdverseReaction	I-AdverseReaction
(	XEOMIN.xml:S1:10275:1	(	(	O	O
elevation	XEOMIN.xml:S1:10276:9	elev	NN	B-AdverseReaction	B-AdverseReaction
of	XEOMIN.xml:S1:10286:2	of	IN	I-AdverseReaction	I-AdverseReaction
eyebrow	XEOMIN.xml:S1:10289:7	eyebrow	NN	I-AdverseReaction	I-AdverseReaction
)	XEOMIN.xml:S1:10296:1	)	)	O	O
,	XEOMIN.xml:S1:10297:1	,	,	O	O
injection	XEOMIN.xml:S1:10299:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:10309:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XEOMIN.xml:S1:10314:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:10318:1	,	,	O	O
and	XEOMIN.xml:S1:10320:3	and	CC	O	O
eyelid	XEOMIN.xml:S1:10324:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
edema	XEOMIN.xml:S1:10331:5	edema	NN	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S1:10336:1	.	.	O	O

6.2	XEOMIN.xml:S1:10344:3	6.2	CD	O	O

Immunogenicity	XEOMIN.xml:S1:10348:14	immunogen	NN	O	O

As	XEOMIN.xml:S1:10366:2	As	IN	O	O
with	XEOMIN.xml:S1:10369:4	with	IN	O	O
all	XEOMIN.xml:S1:10374:3	all	DT	O	O
therapeutic	XEOMIN.xml:S1:10378:11	therapeut	JJ	O	O
proteins	XEOMIN.xml:S1:10390:8	protein	NNS	O	O
,	XEOMIN.xml:S1:10398:1	,	,	O	O
there	XEOMIN.xml:S1:10400:5	there	EX	O	O
is	XEOMIN.xml:S1:10406:2	is	VBZ	O	O
a	XEOMIN.xml:S1:10409:1	a	DT	O	O
potential	XEOMIN.xml:S1:10411:9	potenti	JJ	O	O
for	XEOMIN.xml:S1:10421:3	for	IN	O	O
immunogenicity	XEOMIN.xml:S1:10425:14	immunogen	NN	O	O
.	XEOMIN.xml:S1:10439:1	.	.	O	O

The	XEOMIN.xml:S1:10445:3	the	DT	O	O
incidence	XEOMIN.xml:S1:10449:9	incid	NN	O	O
of	XEOMIN.xml:S1:10459:2	of	IN	O	O
antibody	XEOMIN.xml:S1:10462:8	antibodi	NN	O	O
formation	XEOMIN.xml:S1:10471:9	format	NN	O	O
is	XEOMIN.xml:S1:10481:2	is	VBZ	O	O
highly	XEOMIN.xml:S1:10484:6	highli	RB	O	O
dependent	XEOMIN.xml:S1:10491:9	depend	JJ	O	O
on	XEOMIN.xml:S1:10501:2	on	IN	O	O
the	XEOMIN.xml:S1:10504:3	the	DT	O	O
sensitivity	XEOMIN.xml:S1:10508:11	sensit	NN	O	O
and	XEOMIN.xml:S1:10520:3	and	CC	O	O
specificity	XEOMIN.xml:S1:10524:11	specif	NN	O	O
of	XEOMIN.xml:S1:10536:2	of	IN	O	O
the	XEOMIN.xml:S1:10539:3	the	DT	O	O
assay	XEOMIN.xml:S1:10543:5	assay	NN	O	O
.	XEOMIN.xml:S1:10548:1	.	.	O	O

In	XEOMIN.xml:S1:10550:2	In	IN	O	O
addition	XEOMIN.xml:S1:10553:8	addit	NN	O	O
,	XEOMIN.xml:S1:10561:1	,	,	O	O
the	XEOMIN.xml:S1:10563:3	the	DT	O	O
observed	XEOMIN.xml:S1:10567:8	observ	JJ	O	O
incidence	XEOMIN.xml:S1:10576:9	incid	NN	O	O
of	XEOMIN.xml:S1:10586:2	of	IN	O	O
antibody	XEOMIN.xml:S1:10589:8	antibodi	NN	O	O
positivity	XEOMIN.xml:S1:10598:10	posit	NN	O	O
in	XEOMIN.xml:S1:10609:2	in	IN	O	O
an	XEOMIN.xml:S1:10612:2	an	DT	O	O
assay	XEOMIN.xml:S1:10615:5	assay	NN	O	O
may	XEOMIN.xml:S1:10621:3	may	MD	O	O
be	XEOMIN.xml:S1:10625:2	be	VB	O	O
influenced	XEOMIN.xml:S1:10628:10	influenc	VBN	O	O
by	XEOMIN.xml:S1:10639:2	by	IN	O	O
several	XEOMIN.xml:S1:10642:7	sever	JJ	O	O
factors	XEOMIN.xml:S1:10650:7	factor	NNS	O	O
including	XEOMIN.xml:S1:10658:9	includ	VBG	O	O
assay	XEOMIN.xml:S1:10668:5	assay	JJ	O	O
methodology	XEOMIN.xml:S1:10674:11	methodolog	NN	O	O
,	XEOMIN.xml:S1:10685:1	,	,	O	O
sample	XEOMIN.xml:S1:10687:6	sampl	NN	O	O
handling	XEOMIN.xml:S1:10694:8	handl	NN	O	O
,	XEOMIN.xml:S1:10702:1	,	,	O	O
timing	XEOMIN.xml:S1:10704:6	time	NN	O	O
of	XEOMIN.xml:S1:10711:2	of	IN	O	O
sample	XEOMIN.xml:S1:10714:6	sampl	JJ	O	O
collection	XEOMIN.xml:S1:10721:10	collect	NN	O	O
,	XEOMIN.xml:S1:10731:1	,	,	O	O
concomitant	XEOMIN.xml:S1:10733:11	concomit	JJ	O	O
medications	XEOMIN.xml:S1:10745:11	medic	NNS	O	O
,	XEOMIN.xml:S1:10756:1	,	,	O	O
and	XEOMIN.xml:S1:10758:3	and	CC	O	O
underlying	XEOMIN.xml:S1:10762:10	underli	JJ	O	O
disease	XEOMIN.xml:S1:10773:7	diseas	NN	O	O
.	XEOMIN.xml:S1:10780:1	.	.	O	O

For	XEOMIN.xml:S1:10782:3	for	IN	O	O
these	XEOMIN.xml:S1:10786:5	these	DT	O	O
reasons	XEOMIN.xml:S1:10792:7	reason	NNS	O	O
,	XEOMIN.xml:S1:10799:1	,	,	O	O
comparison	XEOMIN.xml:S1:10801:10	comparison	NN	O	O
of	XEOMIN.xml:S1:10812:2	of	IN	O	O
the	XEOMIN.xml:S1:10815:3	the	DT	O	O
incidence	XEOMIN.xml:S1:10819:9	incid	NN	O	O
of	XEOMIN.xml:S1:10829:2	of	IN	O	O
antibodies	XEOMIN.xml:S1:10832:10	antibodi	NNS	O	O
across	XEOMIN.xml:S1:10843:6	across	IN	O	O
products	XEOMIN.xml:S1:10850:8	product	NNS	O	O
in	XEOMIN.xml:S1:10859:2	in	IN	O	O
this	XEOMIN.xml:S1:10862:4	thi	DT	O	O
class	XEOMIN.xml:S1:10867:5	class	NN	O	O
may	XEOMIN.xml:S1:10873:3	may	MD	O	O
be	XEOMIN.xml:S1:10877:2	be	VB	O	O
misleading	XEOMIN.xml:S1:10880:10	mislead	VBG	O	O
.	XEOMIN.xml:S1:10890:1	.	.	O	O

6.3	XEOMIN.xml:S1:10898:3	6.3	CD	O	O
Postmarketing	XEOMIN.xml:S1:10902:13	postmarket	VBG	O	O
Experience	XEOMIN.xml:S1:10916:10	experi	NN	O	O

The	XEOMIN.xml:S1:10930:3	the	DT	O	O
following	XEOMIN.xml:S1:10934:9	follow	JJ	O	O
adverse	XEOMIN.xml:S1:10944:7	advers	JJ	O	O
reactions	XEOMIN.xml:S1:10952:9	reaction	NNS	O	O
have	XEOMIN.xml:S1:10962:4	have	VBP	O	O
been	XEOMIN.xml:S1:10967:4	been	VBN	O	O
reported	XEOMIN.xml:S1:10972:8	report	VBN	O	O
during	XEOMIN.xml:S1:10981:6	dure	IN	O	O
post	XEOMIN.xml:S1:10988:4	post	NN	O	O
-	XEOMIN.xml:S1:10992:1	-	:	O	O
approval	XEOMIN.xml:S1:10993:8	approv	NN	O	O
use	XEOMIN.xml:S1:11002:3	use	NN	O	O
with	XEOMIN.xml:S1:11006:4	with	IN	O	O
XEOMIN	XEOMIN.xml:S1:11011:6	xeomin	NNP	O	O
.	XEOMIN.xml:S1:11017:1	.	.	O	O

Because	XEOMIN.xml:S1:11019:7	becaus	IN	O	O
these	XEOMIN.xml:S1:11027:5	these	DT	O	O
reactions	XEOMIN.xml:S1:11033:9	reaction	NNS	O	O
are	XEOMIN.xml:S1:11043:3	are	VBP	O	O
reported	XEOMIN.xml:S1:11047:8	report	VBN	O	O
voluntarily	XEOMIN.xml:S1:11056:11	voluntarili	RB	O	O
from	XEOMIN.xml:S1:11068:4	from	IN	O	O
a	XEOMIN.xml:S1:11073:1	a	DT	O	O
population	XEOMIN.xml:S1:11075:10	popul	NN	O	O
of	XEOMIN.xml:S1:11086:2	of	IN	O	O
uncertain	XEOMIN.xml:S1:11089:9	uncertain	JJ	O	O
size	XEOMIN.xml:S1:11099:4	size	NN	O	O
,	XEOMIN.xml:S1:11103:1	,	,	O	O
it	XEOMIN.xml:S1:11105:2	it	PRP	O	O
is	XEOMIN.xml:S1:11108:2	is	VBZ	O	O
not	XEOMIN.xml:S1:11111:3	not	RB	O	O
always	XEOMIN.xml:S1:11115:6	alway	RB	O	O
possible	XEOMIN.xml:S1:11122:8	possibl	JJ	O	O
to	XEOMIN.xml:S1:11131:2	to	TO	O	O
reliably	XEOMIN.xml:S1:11134:8	reliabl	VB	O	O
estimate	XEOMIN.xml:S1:11143:8	estim	VB	O	O
their	XEOMIN.xml:S1:11152:5	their	PRP$	O	O
frequency	XEOMIN.xml:S1:11158:9	frequenc	NN	O	O
or	XEOMIN.xml:S1:11168:2	or	CC	O	O
establish	XEOMIN.xml:S1:11171:9	establish	VB	O	O
a	XEOMIN.xml:S1:11181:1	a	DT	O	O
causal	XEOMIN.xml:S1:11183:6	causal	NN	O	O
relationship	XEOMIN.xml:S1:11190:12	relationship	NN	O	O
to	XEOMIN.xml:S1:11203:2	to	TO	O	O
drug	XEOMIN.xml:S1:11206:4	drug	NN	O	O
exposure	XEOMIN.xml:S1:11211:8	exposur	NN	O	O
:	XEOMIN.xml:S1:11219:1	:	:	O	O
eye	XEOMIN.xml:S1:11221:3	eye	NN	B-AdverseReaction	B-AdverseReaction
swelling	XEOMIN.xml:S1:11225:8	swell	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11233:1	,	,	O	O
eyelid	XEOMIN.xml:S1:11235:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
edema	XEOMIN.xml:S1:11242:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11247:1	,	,	O	O
dysphagia	XEOMIN.xml:S1:11249:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:11258:1	,	,	O	O
nausea	XEOMIN.xml:S1:11260:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:11266:1	,	,	O	O
flu	XEOMIN.xml:S1:11268:3	flu	SYM	B-AdverseReaction	B-AdverseReaction
-	XEOMIN.xml:S1:11271:1	-	:	I-AdverseReaction	I-AdverseReaction
like	XEOMIN.xml:S1:11272:4	like	IN	I-AdverseReaction	I-AdverseReaction
symptoms	XEOMIN.xml:S1:11277:8	symptom	NNS	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11285:1	,	,	O	O
injection	XEOMIN.xml:S1:11287:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:11297:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XEOMIN.xml:S1:11302:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11306:1	,	,	O	O
injection	XEOMIN.xml:S1:11308:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XEOMIN.xml:S1:11318:4	site	NN	I-AdverseReaction	I-AdverseReaction
reaction	XEOMIN.xml:S1:11323:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11331:1	,	,	O	O
allergic	XEOMIN.xml:S1:11333:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
dermatitis	XEOMIN.xml:S1:11342:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11352:1	,	,	O	O
localized	XEOMIN.xml:S1:11354:9	local	VBN	B-AdverseReaction	O
allergic	XEOMIN.xml:S1:11364:8	allerg	JJ	I-AdverseReaction	B-AdverseReaction
reactions	XEOMIN.xml:S1:11373:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
like	XEOMIN.xml:S1:11383:4	like	IN	O	I-AdverseReaction
swelling	XEOMIN.xml:S1:11388:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11396:1	,	,	O	O
edema	XEOMIN.xml:S1:11398:5	edema	NN	I-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:11403:1	,	,	O	O
erythema	XEOMIN.xml:S1:11405:8	erythema	NN	I-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:11413:1	,	,	O	O
pruritus	XEOMIN.xml:S1:11415:8	pruritu	NN	I-AdverseReaction	B-AdverseReaction
or	XEOMIN.xml:S1:11424:2	or	CC	O	O
rash	XEOMIN.xml:S1:11427:4	rash	NN	I-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:11431:1	,	,	O	O
herpes	XEOMIN.xml:S1:11433:6	herp	NNS	B-AdverseReaction	B-AdverseReaction
zoster	XEOMIN.xml:S1:11440:6	zoster	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11446:1	,	,	O	O
muscular	XEOMIN.xml:S1:11448:8	muscular	JJ	B-AdverseReaction	B-AdverseReaction
weakness	XEOMIN.xml:S1:11457:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11465:1	,	,	O	O
muscle	XEOMIN.xml:S1:11467:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
spasm	XEOMIN.xml:S1:11474:5	spasm	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S1:11479:1	,	,	O	O
dysarthria	XEOMIN.xml:S1:11481:10	dysarthria	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S1:11491:1	,	,	O	O
myalgia	XEOMIN.xml:S1:11493:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction
and	XEOMIN.xml:S1:11501:3	and	CC	O	O
hypersensitivity	XEOMIN.xml:S1:11505:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
.	XEOMIN.xml:S1:11521:1	.	.	O	O
\n\n	XEOMIN.xml:S2:0:2	\n\n	VB	O	O
BOXED	XEOMIN.xml:S2:6:5	box	NNP	O	O
WARNING	XEOMIN.xml:S2:12:7	warn	NNP	O	O
:	XEOMIN.xml:S2:19:1	:	:	O	O
WARNING	XEOMIN.xml:S2:21:7	warn	NN	O	O
:	XEOMIN.xml:S2:28:1	:	:	O	O
DISTANT	XEOMIN.xml:S2:30:7	distant	NNP	B-AdverseReaction	B-AdverseReaction
SPREAD	XEOMIN.xml:S2:38:6	spread	NNP	I-AdverseReaction	I-AdverseReaction
OF	XEOMIN.xml:S2:45:2	OF	NNP	I-AdverseReaction	I-AdverseReaction
TOXIN	XEOMIN.xml:S2:48:5	toxin	NNP	I-AdverseReaction	I-AdverseReaction
EFFECT	XEOMIN.xml:S2:54:6	effect	NNP	I-AdverseReaction	I-AdverseReaction
\n\n	XEOMIN.xml:S2:60:2	\n\n	NNP	O	O
WARNING	XEOMIN.xml:S2:66:7	warn	NN	O	O
:	XEOMIN.xml:S2:73:1	:	:	O	O
DISTANT	XEOMIN.xml:S2:75:7	distant	NNP	B-AdverseReaction	B-AdverseReaction
SPREAD	XEOMIN.xml:S2:83:6	spread	NNP	I-AdverseReaction	I-AdverseReaction
OF	XEOMIN.xml:S2:90:2	OF	NNP	I-AdverseReaction	I-AdverseReaction
TOXIN	XEOMIN.xml:S2:93:5	toxin	NNP	I-AdverseReaction	I-AdverseReaction
EFFECT	XEOMIN.xml:S2:99:6	effect	NNP	I-AdverseReaction	I-AdverseReaction
\n\n	XEOMIN.xml:S2:107:2	\n\n	NNP	O	O
Postmarketing	XEOMIN.xml:S2:113:13	postmarket	NNP	O	O
reports	XEOMIN.xml:S2:127:7	report	NNS	O	O
indicate	XEOMIN.xml:S2:135:8	indic	VBP	O	O
that	XEOMIN.xml:S2:144:4	that	IN	O	O
the	XEOMIN.xml:S2:149:3	the	DT	O	O
effects	XEOMIN.xml:S2:153:7	effect	NNS	O	O
of	XEOMIN.xml:S2:161:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S2:164:6	xeomin	NNP	O	O
and	XEOMIN.xml:S2:171:3	and	CC	O	O
all	XEOMIN.xml:S2:175:3	all	DT	O	O
botulinum	XEOMIN.xml:S2:179:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S2:189:5	toxin	NN	O	O
products	XEOMIN.xml:S2:195:8	product	NNS	O	O
may	XEOMIN.xml:S2:204:3	may	MD	O	O
spread	XEOMIN.xml:S2:208:6	spread	VB	B-AdverseReaction	B-AdverseReaction
from	XEOMIN.xml:S2:215:4	from	IN	I-AdverseReaction	O
the	XEOMIN.xml:S2:220:3	the	DT	I-AdverseReaction	O
area	XEOMIN.xml:S2:224:4	area	NN	I-AdverseReaction	O
of	XEOMIN.xml:S2:229:2	of	IN	I-AdverseReaction	O
injection	XEOMIN.xml:S2:232:9	inject	NN	I-AdverseReaction	O
to	XEOMIN.xml:S2:242:2	to	TO	O	O
produce	XEOMIN.xml:S2:245:7	produc	VB	O	O
symptoms	XEOMIN.xml:S2:253:8	symptom	NNS	O	O
consistent	XEOMIN.xml:S2:262:10	consist	JJ	O	O
with	XEOMIN.xml:S2:273:4	with	IN	O	O
botulinum	XEOMIN.xml:S2:278:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S2:288:5	toxin	NN	B-AdverseReaction	I-AdverseReaction
effects	XEOMIN.xml:S2:294:7	effect	NNS	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S2:301:1	.	.	O	O

These	XEOMIN.xml:S2:303:5	these	DT	O	O
may	XEOMIN.xml:S2:309:3	may	MD	O	O
include	XEOMIN.xml:S2:313:7	includ	VB	O	O
asthenia	XEOMIN.xml:S2:321:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S2:329:1	,	,	O	O
generalized	XEOMIN.xml:S2:331:11	gener	VBN	B-AdverseReaction	B-AdverseReaction
muscle	XEOMIN.xml:S2:343:6	muscl	NN	I-AdverseReaction	I-AdverseReaction
weakness	XEOMIN.xml:S2:350:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S2:358:1	,	,	O	O
diplopia	XEOMIN.xml:S2:360:8	diplopia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S2:368:1	,	,	O	O
blurred	XEOMIN.xml:S2:370:7	blur	VBN	B-AdverseReaction	B-AdverseReaction
vision	XEOMIN.xml:S2:378:6	vision	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S2:384:1	,	,	O	O
ptosis	XEOMIN.xml:S2:386:6	ptosi	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S2:392:1	,	,	O	O
dysphagia	XEOMIN.xml:S2:394:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S2:403:1	,	,	O	O
dysphonia	XEOMIN.xml:S2:405:9	dysphonia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S2:414:1	,	,	O	O
dysarthria	XEOMIN.xml:S2:416:10	dysarthria	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S2:426:1	,	,	O	O
urinary	XEOMIN.xml:S2:428:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
incontinence	XEOMIN.xml:S2:436:12	incontin	NN	I-AdverseReaction	I-AdverseReaction
and	XEOMIN.xml:S2:449:3	and	CC	O	O
breathing	XEOMIN.xml:S2:453:9	breath	NN	B-AdverseReaction	B-AdverseReaction
difficulties	XEOMIN.xml:S2:463:12	difficulti	NNS	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S2:475:1	.	.	O	O

These	XEOMIN.xml:S2:477:5	these	DT	O	O
symptoms	XEOMIN.xml:S2:483:8	symptom	NNS	O	O
have	XEOMIN.xml:S2:492:4	have	VBP	O	O
been	XEOMIN.xml:S2:497:4	been	VBN	O	O
reported	XEOMIN.xml:S2:502:8	report	VBN	O	O
hours	XEOMIN.xml:S2:511:5	hour	NNS	O	O
to	XEOMIN.xml:S2:517:2	to	TO	O	O
weeks	XEOMIN.xml:S2:520:5	week	NNS	O	O
after	XEOMIN.xml:S2:526:5	after	IN	O	O
injection	XEOMIN.xml:S2:532:9	inject	NN	O	O
.	XEOMIN.xml:S2:541:1	.	.	O	O

Swallowing	XEOMIN.xml:S2:543:10	swallow	VBG	B-AdverseReaction	B-AdverseReaction
and	XEOMIN.xml:S2:554:3	and	CC	O	O
breathing	XEOMIN.xml:S2:558:9	breath	VBG	B-AdverseReaction	B-AdverseReaction
difficulties	XEOMIN.xml:S2:568:12	difficulti	NNS	I-AdverseReaction	I-AdverseReaction
can	XEOMIN.xml:S2:581:3	can	MD	O	O
be	XEOMIN.xml:S2:585:2	be	VB	O	O
life	XEOMIN.xml:S2:588:4	life	NN	O	O
threatening	XEOMIN.xml:S2:593:11	threaten	VBG	O	O
and	XEOMIN.xml:S2:605:3	and	CC	O	O
there	XEOMIN.xml:S2:609:5	there	EX	O	O
have	XEOMIN.xml:S2:615:4	have	VBP	O	O
been	XEOMIN.xml:S2:620:4	been	VBN	O	O
reports	XEOMIN.xml:S2:625:7	report	NNS	O	O
of	XEOMIN.xml:S2:633:2	of	IN	O	O
death	XEOMIN.xml:S2:636:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	XEOMIN.xml:S2:641:1	.	.	O	O

The	XEOMIN.xml:S2:643:3	the	DT	O	O
risk	XEOMIN.xml:S2:647:4	risk	NN	O	O
of	XEOMIN.xml:S2:652:2	of	IN	O	O
symptoms	XEOMIN.xml:S2:655:8	symptom	NNS	O	O
is	XEOMIN.xml:S2:664:2	is	VBZ	O	O
probably	XEOMIN.xml:S2:667:8	probabl	RB	O	O
greatest	XEOMIN.xml:S2:676:8	greatest	JJS	O	O
in	XEOMIN.xml:S2:685:2	in	IN	O	O
children	XEOMIN.xml:S2:688:8	children	NNS	O	O
treated	XEOMIN.xml:S2:697:7	treat	VBN	O	O
for	XEOMIN.xml:S2:705:3	for	IN	O	O
spasticity	XEOMIN.xml:S2:709:10	spastic	NN	O	O
but	XEOMIN.xml:S2:720:3	but	CC	O	O
symptoms	XEOMIN.xml:S2:724:8	symptom	NNS	O	O
can	XEOMIN.xml:S2:733:3	can	MD	O	O
also	XEOMIN.xml:S2:737:4	also	RB	O	O
occur	XEOMIN.xml:S2:742:5	occur	VB	O	O
in	XEOMIN.xml:S2:748:2	in	IN	O	O
adults	XEOMIN.xml:S2:751:6	adult	NNS	O	O
treated	XEOMIN.xml:S2:758:7	treat	VBN	O	O
for	XEOMIN.xml:S2:766:3	for	IN	O	O
spasticity	XEOMIN.xml:S2:770:10	spastic	NN	O	O
and	XEOMIN.xml:S2:781:3	and	CC	O	O
other	XEOMIN.xml:S2:785:5	other	JJ	O	O
conditions	XEOMIN.xml:S2:791:10	condit	NNS	O	O
,	XEOMIN.xml:S2:801:1	,	,	O	O
particularly	XEOMIN.xml:S2:803:12	particularli	RB	O	O
in	XEOMIN.xml:S2:816:2	in	IN	O	O
those	XEOMIN.xml:S2:819:5	those	DT	O	O
patients	XEOMIN.xml:S2:825:8	patient	NNS	O	O
who	XEOMIN.xml:S2:834:3	who	WP	O	O
have	XEOMIN.xml:S2:838:4	have	VBP	O	O
underlying	XEOMIN.xml:S2:843:10	underli	JJ	O	O
conditions	XEOMIN.xml:S2:854:10	condit	NNS	O	O
that	XEOMIN.xml:S2:865:4	that	WDT	O	O
would	XEOMIN.xml:S2:870:5	would	MD	O	O
predispose	XEOMIN.xml:S2:876:10	predispos	VB	O	O
them	XEOMIN.xml:S2:887:4	them	PRP	O	O
to	XEOMIN.xml:S2:892:2	to	TO	O	O
these	XEOMIN.xml:S2:895:5	these	DT	O	O
symptoms	XEOMIN.xml:S2:901:8	symptom	NNS	O	O
.	XEOMIN.xml:S2:909:1	.	.	O	O

In	XEOMIN.xml:S2:911:2	In	IN	O	O
unapproved	XEOMIN.xml:S2:914:10	unapprov	JJ	O	O
uses	XEOMIN.xml:S2:925:4	use	NNS	O	O
,	XEOMIN.xml:S2:929:1	,	,	O	O
including	XEOMIN.xml:S2:931:9	includ	VBG	O	O
spasticity	XEOMIN.xml:S2:941:10	spastic	NN	O	O
in	XEOMIN.xml:S2:952:2	in	IN	O	O
children	XEOMIN.xml:S2:955:8	children	NNS	O	O
and	XEOMIN.xml:S2:964:3	and	CC	O	O
adults	XEOMIN.xml:S2:968:6	adult	NNS	O	O
,	XEOMIN.xml:S2:974:1	,	,	O	O
and	XEOMIN.xml:S2:976:3	and	CC	O	O
in	XEOMIN.xml:S2:980:2	in	IN	O	O
approved	XEOMIN.xml:S2:983:8	approv	JJ	O	O
indications	XEOMIN.xml:S2:992:11	indic	NNS	O	O
,	XEOMIN.xml:S2:1003:1	,	,	O	O
cases	XEOMIN.xml:S2:1005:5	case	NNS	O	O
of	XEOMIN.xml:S2:1011:2	of	IN	O	O
spread	XEOMIN.xml:S2:1014:6	spread	NN	B-AdverseReaction	O
of	XEOMIN.xml:S2:1021:2	of	IN	I-AdverseReaction	O
effect	XEOMIN.xml:S2:1024:6	effect	NN	I-AdverseReaction	O
have	XEOMIN.xml:S2:1031:4	have	VBP	O	O
been	XEOMIN.xml:S2:1036:4	been	VBN	O	O
reported	XEOMIN.xml:S2:1041:8	report	VBN	O	O
at	XEOMIN.xml:S2:1050:2	at	IN	O	O
doses	XEOMIN.xml:S2:1053:5	dose	NNS	O	O
comparable	XEOMIN.xml:S2:1059:10	compar	JJ	O	O
to	XEOMIN.xml:S2:1070:2	to	TO	O	O
those	XEOMIN.xml:S2:1073:5	those	DT	O	O
used	XEOMIN.xml:S2:1079:4	use	VBN	O	O
to	XEOMIN.xml:S2:1084:2	to	TO	O	O
treat	XEOMIN.xml:S2:1087:5	treat	VB	O	O
cervical	XEOMIN.xml:S2:1093:8	cervic	JJ	O	O
dystonia	XEOMIN.xml:S2:1102:8	dystonia	NN	O	O
and	XEOMIN.xml:S2:1111:3	and	CC	O	O
at	XEOMIN.xml:S2:1115:2	at	IN	O	O
lower	XEOMIN.xml:S2:1118:5	lower	JJR	O	O
doses	XEOMIN.xml:S2:1124:5	dose	NNS	O	O
[	XEOMIN.xml:S2:1134:1	[	VBP	O	O
see	XEOMIN.xml:S2:1135:3	see	VBP	O	O
Warnings	XEOMIN.xml:S2:1141:8	warn	NNS	O	O
and	XEOMIN.xml:S2:1150:3	and	CC	O	O
Precautions	XEOMIN.xml:S2:1154:11	precaut	NNP	O	O
(	XEOMIN.xml:S2:1166:1	(	(	O	O
5.1	XEOMIN.xml:S2:1167:3	5.1	CD	O	O
)	XEOMIN.xml:S2:1170:1	)	)	O	O
]	XEOMIN.xml:S2:1173:1	]	NN	O	O
.	XEOMIN.xml:S2:1178:1	.	.	O	O

EXCERPT	XEOMIN.xml:S2:1188:7	excerpt	NN	O	O
:	XEOMIN.xml:S2:1195:1	:	:	O	O
WARNING	XEOMIN.xml:S2:1201:7	warn	NN	O	O
:	XEOMIN.xml:S2:1208:1	:	:	O	O
DISTANT	XEOMIN.xml:S2:1210:7	distant	NNP	B-AdverseReaction	B-AdverseReaction
SPREAD	XEOMIN.xml:S2:1218:6	spread	NNP	I-AdverseReaction	I-AdverseReaction
OF	XEOMIN.xml:S2:1225:2	OF	NNP	I-AdverseReaction	I-AdverseReaction
TOXIN	XEOMIN.xml:S2:1228:5	toxin	NNP	I-AdverseReaction	I-AdverseReaction
EFFECT	XEOMIN.xml:S2:1234:6	effect	NNP	I-AdverseReaction	I-AdverseReaction
\n\n\n\n	XEOMIN.xml:S2:1242:4	\n\n\n\n	NNP	O	O
See	XEOMIN.xml:S2:1247:3	see	NNP	O	O
full	XEOMIN.xml:S2:1251:4	full	JJ	O	O
prescribing	XEOMIN.xml:S2:1256:11	prescrib	VBG	O	O
information	XEOMIN.xml:S2:1268:11	inform	NN	O	O
for	XEOMIN.xml:S2:1280:3	for	IN	O	O
complete	XEOMIN.xml:S2:1284:8	complet	JJ	O	O
boxed	XEOMIN.xml:S2:1295:5	box	JJ	O	O
warning	XEOMIN.xml:S2:1301:7	warn	NN	O	O
.	XEOMIN.xml:S2:1310:1	.	.	O	O

The	XEOMIN.xml:S2:1312:3	the	DT	O	O
effects	XEOMIN.xml:S2:1316:7	effect	NNS	O	O
of	XEOMIN.xml:S2:1324:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S2:1329:6	xeomin	NNP	O	O
and	XEOMIN.xml:S2:1338:3	and	CC	O	O
all	XEOMIN.xml:S2:1342:3	all	DT	O	O
botulinum	XEOMIN.xml:S2:1346:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S2:1356:5	toxin	NN	O	O
products	XEOMIN.xml:S2:1362:8	product	NNS	O	O
may	XEOMIN.xml:S2:1371:3	may	MD	O	O
spread	XEOMIN.xml:S2:1375:6	spread	VB	B-AdverseReaction	B-AdverseReaction
from	XEOMIN.xml:S2:1382:4	from	IN	I-AdverseReaction	O
the	XEOMIN.xml:S2:1387:3	the	DT	I-AdverseReaction	O
area	XEOMIN.xml:S2:1391:4	area	NN	I-AdverseReaction	O
of	XEOMIN.xml:S2:1396:2	of	IN	I-AdverseReaction	O
injection	XEOMIN.xml:S2:1399:9	inject	NN	I-AdverseReaction	O
to	XEOMIN.xml:S2:1409:2	to	TO	O	O
produce	XEOMIN.xml:S2:1412:7	produc	VB	O	O
symptoms	XEOMIN.xml:S2:1420:8	symptom	NNS	O	O
consistent	XEOMIN.xml:S2:1429:10	consist	JJ	O	O
with	XEOMIN.xml:S2:1440:4	with	IN	O	O
botulinum	XEOMIN.xml:S2:1445:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S2:1455:5	toxin	NN	B-AdverseReaction	I-AdverseReaction
effects	XEOMIN.xml:S2:1461:7	effect	NNS	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S2:1468:1	.	.	O	O

These	XEOMIN.xml:S2:1470:5	these	DT	O	O
symptoms	XEOMIN.xml:S2:1476:8	symptom	NNS	O	O
have	XEOMIN.xml:S2:1485:4	have	VBP	O	O
been	XEOMIN.xml:S2:1490:4	been	VBN	O	O
reported	XEOMIN.xml:S2:1495:8	report	VBN	O	O
hours	XEOMIN.xml:S2:1504:5	hour	NNS	O	O
to	XEOMIN.xml:S2:1510:2	to	TO	O	O
weeks	XEOMIN.xml:S2:1513:5	week	NNS	O	O
after	XEOMIN.xml:S2:1519:5	after	IN	O	O
injection	XEOMIN.xml:S2:1525:9	inject	NN	O	O
.	XEOMIN.xml:S2:1534:1	.	.	O	O

Swallowing	XEOMIN.xml:S2:1536:10	swallow	VBG	B-AdverseReaction	B-AdverseReaction
and	XEOMIN.xml:S2:1547:3	and	CC	O	O
breathing	XEOMIN.xml:S2:1551:9	breath	VBG	B-AdverseReaction	B-AdverseReaction
difficulties	XEOMIN.xml:S2:1561:12	difficulti	NNS	I-AdverseReaction	I-AdverseReaction
can	XEOMIN.xml:S2:1574:3	can	MD	O	O
be	XEOMIN.xml:S2:1578:2	be	VB	O	O
life	XEOMIN.xml:S2:1581:4	life	NN	O	O
threatening	XEOMIN.xml:S2:1586:11	threaten	VBG	O	O
and	XEOMIN.xml:S2:1598:3	and	CC	O	O
there	XEOMIN.xml:S2:1602:5	there	EX	O	O
have	XEOMIN.xml:S2:1608:4	have	VBP	O	O
been	XEOMIN.xml:S2:1613:4	been	VBN	O	O
reports	XEOMIN.xml:S2:1618:7	report	NNS	O	O
of	XEOMIN.xml:S2:1626:2	of	IN	O	O
death	XEOMIN.xml:S2:1629:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	XEOMIN.xml:S2:1634:1	.	.	O	O

The	XEOMIN.xml:S2:1636:3	the	DT	O	O
risk	XEOMIN.xml:S2:1640:4	risk	NN	O	O
of	XEOMIN.xml:S2:1645:2	of	IN	O	O
symptoms	XEOMIN.xml:S2:1648:8	symptom	NNS	O	O
is	XEOMIN.xml:S2:1657:2	is	VBZ	O	O
probably	XEOMIN.xml:S2:1660:8	probabl	RB	O	O
greatest	XEOMIN.xml:S2:1669:8	greatest	JJS	O	O
in	XEOMIN.xml:S2:1678:2	in	IN	O	O
children	XEOMIN.xml:S2:1681:8	children	NNS	O	O
treated	XEOMIN.xml:S2:1690:7	treat	VBN	O	O
for	XEOMIN.xml:S2:1698:3	for	IN	O	O
spasticity	XEOMIN.xml:S2:1702:10	spastic	NN	O	O
but	XEOMIN.xml:S2:1713:3	but	CC	O	O
symptoms	XEOMIN.xml:S2:1717:8	symptom	NNS	O	O
can	XEOMIN.xml:S2:1726:3	can	MD	O	O
also	XEOMIN.xml:S2:1730:4	also	RB	O	O
occur	XEOMIN.xml:S2:1735:5	occur	VB	O	O
in	XEOMIN.xml:S2:1741:2	in	IN	O	O
adults	XEOMIN.xml:S2:1744:6	adult	NNS	O	O
,	XEOMIN.xml:S2:1750:1	,	,	O	O
particularly	XEOMIN.xml:S2:1752:12	particularli	RB	O	O
in	XEOMIN.xml:S2:1765:2	in	IN	O	O
those	XEOMIN.xml:S2:1768:5	those	DT	O	O
patients	XEOMIN.xml:S2:1774:8	patient	NNS	O	O
who	XEOMIN.xml:S2:1783:3	who	WP	O	O
have	XEOMIN.xml:S2:1787:4	have	VBP	O	O
underlying	XEOMIN.xml:S2:1792:10	underli	JJ	O	O
conditions	XEOMIN.xml:S2:1803:10	condit	NNS	O	O
that	XEOMIN.xml:S2:1814:4	that	WDT	O	O
would	XEOMIN.xml:S2:1819:5	would	MD	O	O
predispose	XEOMIN.xml:S2:1825:10	predispos	VB	O	O
them	XEOMIN.xml:S2:1836:4	them	PRP	O	O
to	XEOMIN.xml:S2:1841:2	to	TO	O	O
these	XEOMIN.xml:S2:1844:5	these	DT	O	O
symptoms	XEOMIN.xml:S2:1850:8	symptom	NNS	O	O
.	XEOMIN.xml:S2:1858:1	.	.	O	O

(	XEOMIN.xml:S2:1860:1	(	(	O	O
5.1	XEOMIN.xml:S2:1863:3	5.1	CD	O	O
)\n	XEOMIN.xml:S2:1868:2	)\n	RB	O	O
5	XEOMIN.xml:S3:4:1	5	CD	O	O
WARNINGS	XEOMIN.xml:S3:6:8	warn	NNP	O	O
AND	XEOMIN.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	XEOMIN.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	XEOMIN.xml:S3:36:7	excerpt	NN	O	O
:	XEOMIN.xml:S3:43:1	:	:	O	O
For	XEOMIN.xml:S3:48:3	for	IN	O	O
All	XEOMIN.xml:S3:52:3	all	DT	O	O
Indications	XEOMIN.xml:S3:56:11	indic	NNS	O	O
:	XEOMIN.xml:S3:67:1	:	:	O	O

The	XEOMIN.xml:S3:78:3	the	DT	O	O
potency	XEOMIN.xml:S3:82:7	potenc	NN	O	O
Units	XEOMIN.xml:S3:90:5	unit	NNP	O	O
of	XEOMIN.xml:S3:96:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S3:99:6	xeomin	NNP	O	O
are	XEOMIN.xml:S3:106:3	are	VBP	O	O
not	XEOMIN.xml:S3:110:3	not	RB	O	O
interchangeable	XEOMIN.xml:S3:114:15	interchang	JJ	O	O
with	XEOMIN.xml:S3:130:4	with	IN	O	O
other	XEOMIN.xml:S3:135:5	other	JJ	O	O
preparations	XEOMIN.xml:S3:141:12	prepar	NNS	O	O
of	XEOMIN.xml:S3:154:2	of	IN	O	O
botulinum	XEOMIN.xml:S3:157:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:167:5	toxin	NN	O	O
products	XEOMIN.xml:S3:173:8	product	NNS	O	O
.	XEOMIN.xml:S3:181:1	.	.	O	O

Therefore	XEOMIN.xml:S3:183:9	therefor	RB	O	O
,	XEOMIN.xml:S3:192:1	,	,	O	O
Units	XEOMIN.xml:S3:194:5	unit	NNS	O	O
of	XEOMIN.xml:S3:200:2	of	IN	O	O
biological	XEOMIN.xml:S3:203:10	biolog	JJ	O	O
activity	XEOMIN.xml:S3:214:8	activ	NN	O	O
of	XEOMIN.xml:S3:223:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S3:226:6	xeomin	NNP	O	O
cannot	XEOMIN.xml:S3:233:6	cannot	NN	O	O
be	XEOMIN.xml:S3:240:2	be	VB	O	O
compared	XEOMIN.xml:S3:243:8	compar	VBN	O	O
to	XEOMIN.xml:S3:252:2	to	TO	O	O
or	XEOMIN.xml:S3:255:2	or	CC	O	O
converted	XEOMIN.xml:S3:258:9	convert	VBN	O	O
into	XEOMIN.xml:S3:268:4	into	IN	O	O
Units	XEOMIN.xml:S3:273:5	unit	NNS	O	O
of	XEOMIN.xml:S3:279:2	of	IN	O	O
any	XEOMIN.xml:S3:282:3	ani	DT	O	O
other	XEOMIN.xml:S3:286:5	other	JJ	O	O
botulinum	XEOMIN.xml:S3:292:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:302:5	toxin	NN	O	O
products	XEOMIN.xml:S3:308:8	product	NNS	O	O
(	XEOMIN.xml:S3:317:1	(	(	O	O
5.2	XEOMIN.xml:S3:320:3	5.2	CD	O	O
)	XEOMIN.xml:S3:325:1	)	)	O	O
.	XEOMIN.xml:S3:326:1	.	.	O	O

Immediate	XEOMIN.xml:S3:333:9	immedi	NNP	O	O
medical	XEOMIN.xml:S3:343:7	medic	JJ	O	O
attention	XEOMIN.xml:S3:351:9	attent	NN	O	O
may	XEOMIN.xml:S3:361:3	may	MD	O	O
be	XEOMIN.xml:S3:365:2	be	VB	O	O
required	XEOMIN.xml:S3:368:8	requir	VBN	O	O
in	XEOMIN.xml:S3:377:2	in	IN	O	O
cases	XEOMIN.xml:S3:380:5	case	NNS	O	O
of	XEOMIN.xml:S3:386:2	of	IN	O	O
respiratory	XEOMIN.xml:S3:389:11	respiratori	NN	O	B-AdverseReaction
,	XEOMIN.xml:S3:400:1	,	,	O	O
speech	XEOMIN.xml:S3:402:6	speech	NN	O	B-AdverseReaction
or	XEOMIN.xml:S3:409:2	or	CC	O	O
swallowing	XEOMIN.xml:S3:412:10	swallow	VBG	O	B-AdverseReaction
difficulties	XEOMIN.xml:S3:423:12	difficulti	NNS	O	I-AdverseReaction
(	XEOMIN.xml:S3:436:1	(	(	O	O
5.1	XEOMIN.xml:S3:439:3	5.1	CD	O	O
,	XEOMIN.xml:S3:444:1	,	,	O	O
5.4	XEOMIN.xml:S3:447:3	5.4	CD	O	O
)	XEOMIN.xml:S3:452:1	)	)	O	O
.	XEOMIN.xml:S3:453:1	.	.	O	O

Use	XEOMIN.xml:S3:460:3	use	NN	O	O
with	XEOMIN.xml:S3:464:4	with	IN	O	O
caution	XEOMIN.xml:S3:469:7	caution	NN	O	O
in	XEOMIN.xml:S3:477:2	in	IN	O	O
patients	XEOMIN.xml:S3:480:8	patient	NNS	O	O
with	XEOMIN.xml:S3:489:4	with	IN	O	O
compromised	XEOMIN.xml:S3:494:11	compromis	JJ	O	O
respiratory	XEOMIN.xml:S3:506:11	respiratori	NN	O	O
function	XEOMIN.xml:S3:518:8	function	NN	O	O
or	XEOMIN.xml:S3:527:2	or	CC	O	O
dysphagia	XEOMIN.xml:S3:530:9	dysphagia	NN	O	O
(	XEOMIN.xml:S3:540:1	(	(	O	O
5.4	XEOMIN.xml:S3:543:3	5.4	CD	O	O
)	XEOMIN.xml:S3:548:1	)	)	O	O
.	XEOMIN.xml:S3:549:1	.	.	O	O

Concomitant	XEOMIN.xml:S3:556:11	concomit	NNP	O	O
neuromuscular	XEOMIN.xml:S3:568:13	neuromuscular	JJ	O	O
disorders	XEOMIN.xml:S3:582:9	disord	NNS	O	O
may	XEOMIN.xml:S3:592:3	may	MD	O	O
exacerbate	XEOMIN.xml:S3:596:10	exacerb	VB	O	O
clinical	XEOMIN.xml:S3:607:8	clinic	JJ	O	O
effects	XEOMIN.xml:S3:616:7	effect	NNS	O	O
of	XEOMIN.xml:S3:624:2	of	IN	O	O
treatment	XEOMIN.xml:S3:627:9	treatment	NN	O	O
(	XEOMIN.xml:S3:637:1	(	(	O	O
5.5	XEOMIN.xml:S3:640:3	5.5	CD	O	O
)	XEOMIN.xml:S3:645:1	)	)	O	O
.	XEOMIN.xml:S3:646:1	.	.	O	O

Cervical	XEOMIN.xml:S3:654:8	cervic	JJ	O	O
Dystonia	XEOMIN.xml:S3:663:8	dystonia	NNP	O	O
(	XEOMIN.xml:S3:672:1	(	(	O	O
5.4	XEOMIN.xml:S3:675:3	5.4	CD	O	O
)	XEOMIN.xml:S3:680:1	)	)	O	O
:	XEOMIN.xml:S3:681:1	:	:	O	O

Patients	XEOMIN.xml:S3:692:8	patient	NNS	O	O

with	XEOMIN.xml:S3:701:4	with	IN	O	O
smaller	XEOMIN.xml:S3:706:7	smaller	JJR	O	O
neck	XEOMIN.xml:S3:714:4	neck	NN	O	O
muscle	XEOMIN.xml:S3:719:6	muscl	NN	O	O
mass	XEOMIN.xml:S3:726:4	mass	NN	O	O
and	XEOMIN.xml:S3:731:3	and	CC	O	O
patients	XEOMIN.xml:S3:735:8	patient	NNS	O	O
who	XEOMIN.xml:S3:744:3	who	WP	O	O
require	XEOMIN.xml:S3:748:7	requir	VBP	O	O
bilateral	XEOMIN.xml:S3:756:9	bilater	JJ	O	O
injections	XEOMIN.xml:S3:766:10	inject	NNS	O	O
into	XEOMIN.xml:S3:777:4	into	IN	O	O
the	XEOMIN.xml:S3:782:3	the	DT	O	O
sternocleidomastoid	XEOMIN.xml:S3:786:19	sternocleidomastoid	JJ	O	O
muscles	XEOMIN.xml:S3:806:7	muscl	NNS	O	O
are	XEOMIN.xml:S3:814:3	are	VBP	O	O
at	XEOMIN.xml:S3:818:2	at	IN	O	O
greater	XEOMIN.xml:S3:821:7	greater	JJR	O	O
risk	XEOMIN.xml:S3:829:4	risk	NN	O	O
of	XEOMIN.xml:S3:834:2	of	IN	O	O
dysphagia	XEOMIN.xml:S3:837:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
.	XEOMIN.xml:S3:846:1	.	.	O	O

Limiting	XEOMIN.xml:S3:853:8	limit	VBG	O	O
the	XEOMIN.xml:S3:862:3	the	DT	O	O
dose	XEOMIN.xml:S3:866:4	dose	NN	O	O
injected	XEOMIN.xml:S3:871:8	inject	VBD	O	O
into	XEOMIN.xml:S3:880:4	into	IN	O	O
the	XEOMIN.xml:S3:885:3	the	DT	O	O
sternocleidomastoid	XEOMIN.xml:S3:889:19	sternocleidomastoid	JJ	O	O
muscle	XEOMIN.xml:S3:909:6	muscl	NN	O	O
may	XEOMIN.xml:S3:916:3	may	MD	O	O
decrease	XEOMIN.xml:S3:920:8	decreas	VB	O	O
the	XEOMIN.xml:S3:929:3	the	DT	O	O
occurrence	XEOMIN.xml:S3:933:10	occurr	NN	O	O
of	XEOMIN.xml:S3:944:2	of	IN	O	O
dysphagia	XEOMIN.xml:S3:947:9	dysphagia	NN	O	B-AdverseReaction
.	XEOMIN.xml:S3:956:1	.	.	O	O

Blepharospasm	XEOMIN.xml:S3:964:13	blepharospasm	NNP	O	O
(	XEOMIN.xml:S3:978:1	(	(	O	O
5.6	XEOMIN.xml:S3:981:3	5.6	CD	O	O
)	XEOMIN.xml:S3:986:1	)	)	O	O
:	XEOMIN.xml:S3:987:1	:	:	O	O

Corneal	XEOMIN.xml:S3:998:7	corneal	NN	B-AdverseReaction	O

exposure	XEOMIN.xml:S3:1006:8	exposur	NN	I-AdverseReaction	O
and	XEOMIN.xml:S3:1015:3	and	CC	O	O
ulceration	XEOMIN.xml:S3:1019:10	ulcer	NN	I-AdverseReaction	O

Injection	XEOMIN.xml:S3:1035:9	inject	NN	O	O
of	XEOMIN.xml:S3:1045:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S3:1048:6	xeomin	NNP	O	O
into	XEOMIN.xml:S3:1055:4	into	IN	O	O
the	XEOMIN.xml:S3:1060:3	the	DT	O	O
orbicularis	XEOMIN.xml:S3:1064:11	orbiculari	JJ	O	O
oculi	XEOMIN.xml:S3:1076:5	oculi	JJ	O	O
muscle	XEOMIN.xml:S3:1082:6	muscl	NN	O	O
may	XEOMIN.xml:S3:1089:3	may	MD	O	O
lead	XEOMIN.xml:S3:1093:4	lead	VB	O	O
to	XEOMIN.xml:S3:1098:2	to	TO	O	O
reduced	XEOMIN.xml:S3:1101:7	reduc	VB	B-AdverseReaction	O
blinking	XEOMIN.xml:S3:1109:8	blink	NN	I-AdverseReaction	O
and	XEOMIN.xml:S3:1118:3	and	CC	O	O
corneal	XEOMIN.xml:S3:1122:7	corneal	NN	B-AdverseReaction	O
exposure	XEOMIN.xml:S3:1130:8	exposur	NN	I-AdverseReaction	O
with	XEOMIN.xml:S3:1139:4	with	IN	O	O
possible	XEOMIN.xml:S3:1144:8	possibl	JJ	O	O
ulceration	XEOMIN.xml:S3:1153:10	ulcer	NN	I-AdverseReaction	O
or	XEOMIN.xml:S3:1164:2	or	CC	O	O
perforation	XEOMIN.xml:S3:1167:11	perfor	NN	I-AdverseReaction	O
.	XEOMIN.xml:S3:1178:1	.	.	O	O

Lower	XEOMIN.xml:S3:1185:5	lower	JJR	O	O
lid	XEOMIN.xml:S3:1191:3	lid	JJ	O	O
injections	XEOMIN.xml:S3:1195:10	inject	NNS	O	O
should	XEOMIN.xml:S3:1206:6	should	MD	O	O
not	XEOMIN.xml:S3:1213:3	not	RB	O	O
be	XEOMIN.xml:S3:1217:2	be	VB	O	O
repeated	XEOMIN.xml:S3:1220:8	repeat	VBN	O	O
if	XEOMIN.xml:S3:1229:2	if	IN	O	O
diplopia	XEOMIN.xml:S3:1232:8	diplopia	NNS	O	O
occurred	XEOMIN.xml:S3:1241:8	occur	VBD	O	O
with	XEOMIN.xml:S3:1250:4	with	IN	O	O
previous	XEOMIN.xml:S3:1255:8	previou	JJ	O	O
botulinum	XEOMIN.xml:S3:1264:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:1274:5	toxin	NN	O	O
injections	XEOMIN.xml:S3:1280:10	inject	NNS	O	O
.	XEOMIN.xml:S3:1290:1	.	.	O	O

Glabellar	XEOMIN.xml:S3:1298:9	glabellar	JJ	O	O
Lines	XEOMIN.xml:S3:1308:5	line	NNP	O	O
(	XEOMIN.xml:S3:1314:1	(	(	O	O
5.7	XEOMIN.xml:S3:1317:3	5.7	CD	O	O
)	XEOMIN.xml:S3:1322:1	)	)	O	O
:	XEOMIN.xml:S3:1323:1	:	:	O	O

Risk	XEOMIN.xml:S3:1334:4	risk	NN	O	O

of	XEOMIN.xml:S3:1339:2	of	IN	O	O
ptosis	XEOMIN.xml:S3:1342:6	ptosi	NN	B-AdverseReaction	O
(	XEOMIN.xml:S3:1349:1	(	(	O	O
5.7	XEOMIN.xml:S3:1352:3	5.7	CD	O	O
)	XEOMIN.xml:S3:1357:1	)	)	O	O
.	XEOMIN.xml:S3:1358:1	.	.	O	O

5.1	XEOMIN.xml:S3:1372:3	5.1	CD	O	O

Spread	XEOMIN.xml:S3:1376:6	spread	NN	O	O

of	XEOMIN.xml:S3:1383:2	of	IN	O	O
Toxin	XEOMIN.xml:S3:1386:5	toxin	NNP	O	O
Effect	XEOMIN.xml:S3:1392:6	effect	NNP	O	O

Postmarketing	XEOMIN.xml:S3:1404:13	postmarket	VBG	O	O
safety	XEOMIN.xml:S3:1418:6	safeti	NN	O	O
data	XEOMIN.xml:S3:1425:4	data	NNS	O	O
from	XEOMIN.xml:S3:1430:4	from	IN	O	O
XEOMIN	XEOMIN.xml:S3:1435:6	xeomin	NNP	O	O
and	XEOMIN.xml:S3:1442:3	and	CC	O	O
other	XEOMIN.xml:S3:1446:5	other	JJ	O	O
approved	XEOMIN.xml:S3:1452:8	approv	VBD	O	O
botulinum	XEOMIN.xml:S3:1461:9	botulinum	JJ	O	O
toxins	XEOMIN.xml:S3:1471:6	toxin	NNS	O	O
suggest	XEOMIN.xml:S3:1478:7	suggest	VBP	O	O
that	XEOMIN.xml:S3:1486:4	that	IN	O	O
botulinum	XEOMIN.xml:S3:1491:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:1501:5	toxin	NN	B-AdverseReaction	B-AdverseReaction
effects	XEOMIN.xml:S3:1507:7	effect	NNS	I-AdverseReaction	I-AdverseReaction
may	XEOMIN.xml:S3:1515:3	may	MD	O	O
,	XEOMIN.xml:S3:1518:1	,	,	O	O
in	XEOMIN.xml:S3:1520:2	in	IN	O	O
some	XEOMIN.xml:S3:1523:4	some	DT	O	O
cases	XEOMIN.xml:S3:1528:5	case	NNS	O	O
,	XEOMIN.xml:S3:1533:1	,	,	O	O
be	XEOMIN.xml:S3:1535:2	be	VB	O	O
observed	XEOMIN.xml:S3:1538:8	observ	VBN	O	O
beyond	XEOMIN.xml:S3:1547:6	beyond	IN	I-AdverseReaction	I-AdverseReaction
the	XEOMIN.xml:S3:1554:3	the	DT	I-AdverseReaction	I-AdverseReaction
site	XEOMIN.xml:S3:1558:4	site	NN	I-AdverseReaction	I-AdverseReaction
of	XEOMIN.xml:S3:1563:2	of	IN	I-AdverseReaction	I-AdverseReaction
local	XEOMIN.xml:S3:1566:5	local	JJ	I-AdverseReaction	I-AdverseReaction
injection	XEOMIN.xml:S3:1572:9	inject	NN	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S3:1581:1	.	.	O	O

The	XEOMIN.xml:S3:1583:3	the	DT	O	O
symptoms	XEOMIN.xml:S3:1587:8	symptom	NNS	O	O
are	XEOMIN.xml:S3:1596:3	are	VBP	O	O
consistent	XEOMIN.xml:S3:1600:10	consist	JJ	O	O
with	XEOMIN.xml:S3:1611:4	with	IN	O	O
the	XEOMIN.xml:S3:1616:3	the	DT	O	O
mechanism	XEOMIN.xml:S3:1620:9	mechan	NN	O	O
of	XEOMIN.xml:S3:1630:2	of	IN	O	O
action	XEOMIN.xml:S3:1633:6	action	NN	O	O
of	XEOMIN.xml:S3:1640:2	of	IN	O	O
botulinum	XEOMIN.xml:S3:1643:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:1653:5	toxin	NN	O	O
and	XEOMIN.xml:S3:1659:3	and	CC	O	O
may	XEOMIN.xml:S3:1663:3	may	MD	O	O
include	XEOMIN.xml:S3:1667:7	includ	VB	O	O
asthenia	XEOMIN.xml:S3:1675:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S3:1683:1	,	,	O	O
generalized	XEOMIN.xml:S3:1685:11	gener	VBN	B-AdverseReaction	B-AdverseReaction
muscle	XEOMIN.xml:S3:1697:6	muscl	NN	I-AdverseReaction	I-AdverseReaction
weakness	XEOMIN.xml:S3:1704:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S3:1712:1	,	,	O	O
diplopia	XEOMIN.xml:S3:1714:8	diplopia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S3:1722:1	,	,	O	O
blurred	XEOMIN.xml:S3:1724:7	blur	VBN	B-AdverseReaction	B-AdverseReaction
vision	XEOMIN.xml:S3:1732:6	vision	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S3:1738:1	,	,	O	O
ptosis	XEOMIN.xml:S3:1740:6	ptosi	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S3:1746:1	,	,	O	O
dysphagia	XEOMIN.xml:S3:1748:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S3:1757:1	,	,	O	O
dysphonia	XEOMIN.xml:S3:1759:9	dysphonia	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S3:1768:1	,	,	O	O
dysarthria	XEOMIN.xml:S3:1770:10	dysarthria	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S3:1780:1	,	,	O	O
urinary	XEOMIN.xml:S3:1782:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
incontinence	XEOMIN.xml:S3:1790:12	incontin	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S3:1802:1	,	,	O	O
and	XEOMIN.xml:S3:1804:3	and	CC	O	O
breathing	XEOMIN.xml:S3:1808:9	breath	VBG	B-AdverseReaction	B-AdverseReaction
difficulties	XEOMIN.xml:S3:1818:12	difficulti	NNS	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S3:1830:1	.	.	O	O

These	XEOMIN.xml:S3:1832:5	these	DT	O	O
symptoms	XEOMIN.xml:S3:1838:8	symptom	NNS	O	O
have	XEOMIN.xml:S3:1847:4	have	VBP	O	O
been	XEOMIN.xml:S3:1852:4	been	VBN	O	O
reported	XEOMIN.xml:S3:1857:8	report	VBN	O	O
hours	XEOMIN.xml:S3:1866:5	hour	NNS	O	O
to	XEOMIN.xml:S3:1872:2	to	TO	O	O
weeks	XEOMIN.xml:S3:1875:5	week	NNS	O	O
after	XEOMIN.xml:S3:1881:5	after	IN	O	O
injection	XEOMIN.xml:S3:1887:9	inject	NN	O	O
.	XEOMIN.xml:S3:1896:1	.	.	O	O

Swallowing	XEOMIN.xml:S3:1898:10	swallow	VBG	B-AdverseReaction	B-AdverseReaction
and	XEOMIN.xml:S3:1909:3	and	CC	O	O
breathing	XEOMIN.xml:S3:1913:9	breath	VBG	B-AdverseReaction	B-AdverseReaction
difficulties	XEOMIN.xml:S3:1923:12	difficulti	NNS	I-AdverseReaction	I-AdverseReaction
can	XEOMIN.xml:S3:1936:3	can	MD	O	O
be	XEOMIN.xml:S3:1940:2	be	VB	O	O
life	XEOMIN.xml:S3:1943:4	life	NN	O	O
threatening	XEOMIN.xml:S3:1948:11	threaten	VBG	O	O
and	XEOMIN.xml:S3:1960:3	and	CC	O	O
there	XEOMIN.xml:S3:1964:5	there	EX	O	O
have	XEOMIN.xml:S3:1970:4	have	VBP	O	O
been	XEOMIN.xml:S3:1975:4	been	VBN	O	O
reports	XEOMIN.xml:S3:1980:7	report	NNS	O	O
of	XEOMIN.xml:S3:1988:2	of	IN	O	O
death	XEOMIN.xml:S3:1991:5	death	NN	B-AdverseReaction	B-AdverseReaction
related	XEOMIN.xml:S3:1997:7	relat	VBN	O	O
to	XEOMIN.xml:S3:2005:2	to	TO	O	I-AdverseReaction
the	XEOMIN.xml:S3:2008:3	the	DT	O	I-AdverseReaction
spread	XEOMIN.xml:S3:2012:6	spread	NN	B-AdverseReaction	I-AdverseReaction
of	XEOMIN.xml:S3:2019:2	of	IN	I-AdverseReaction	I-AdverseReaction
toxin	XEOMIN.xml:S3:2022:5	toxin	NN	I-AdverseReaction	I-AdverseReaction
effects	XEOMIN.xml:S3:2028:7	effect	NNS	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S3:2035:1	.	.	O	O

The	XEOMIN.xml:S3:2037:3	the	DT	O	O
risk	XEOMIN.xml:S3:2041:4	risk	NN	O	O
of	XEOMIN.xml:S3:2046:2	of	IN	O	O
symptoms	XEOMIN.xml:S3:2049:8	symptom	NNS	O	O
is	XEOMIN.xml:S3:2058:2	is	VBZ	O	O
probably	XEOMIN.xml:S3:2061:8	probabl	RB	O	O
greatest	XEOMIN.xml:S3:2070:8	greatest	JJS	O	O
in	XEOMIN.xml:S3:2079:2	in	IN	O	O
children	XEOMIN.xml:S3:2082:8	children	NNS	O	O
treated	XEOMIN.xml:S3:2091:7	treat	VBN	O	O
for	XEOMIN.xml:S3:2099:3	for	IN	O	O
spasticity	XEOMIN.xml:S3:2103:10	spastic	NN	O	O
but	XEOMIN.xml:S3:2114:3	but	CC	O	O
symptoms	XEOMIN.xml:S3:2118:8	symptom	NNS	O	O
can	XEOMIN.xml:S3:2127:3	can	MD	O	O
occur	XEOMIN.xml:S3:2131:5	occur	VB	O	O
in	XEOMIN.xml:S3:2137:2	in	IN	O	O
adults	XEOMIN.xml:S3:2140:6	adult	NNS	O	O
treated	XEOMIN.xml:S3:2147:7	treat	VBN	O	O
for	XEOMIN.xml:S3:2155:3	for	IN	O	O
spasticity	XEOMIN.xml:S3:2159:10	spastic	NN	O	O
and	XEOMIN.xml:S3:2170:3	and	CC	O	O
other	XEOMIN.xml:S3:2174:5	other	JJ	O	O
conditions	XEOMIN.xml:S3:2180:10	condit	NNS	O	O
,	XEOMIN.xml:S3:2190:1	,	,	O	O
and	XEOMIN.xml:S3:2192:3	and	CC	O	O
particularly	XEOMIN.xml:S3:2196:12	particularli	RB	O	O
in	XEOMIN.xml:S3:2209:2	in	IN	O	O
those	XEOMIN.xml:S3:2212:5	those	DT	O	O
patients	XEOMIN.xml:S3:2218:8	patient	NNS	O	O
who	XEOMIN.xml:S3:2227:3	who	WP	O	O
have	XEOMIN.xml:S3:2231:4	have	VBP	O	O
underlying	XEOMIN.xml:S3:2236:10	underli	JJ	O	O
conditions	XEOMIN.xml:S3:2247:10	condit	NNS	O	O
that	XEOMIN.xml:S3:2258:4	that	WDT	O	O
would	XEOMIN.xml:S3:2263:5	would	MD	O	O
predispose	XEOMIN.xml:S3:2269:10	predispos	VB	O	O
them	XEOMIN.xml:S3:2280:4	them	PRP	O	O
to	XEOMIN.xml:S3:2285:2	to	TO	O	O
these	XEOMIN.xml:S3:2288:5	these	DT	O	O
symptoms	XEOMIN.xml:S3:2294:8	symptom	NNS	O	O
.	XEOMIN.xml:S3:2302:1	.	.	O	O

In	XEOMIN.xml:S3:2304:2	In	IN	O	O
unapproved	XEOMIN.xml:S3:2307:10	unapprov	JJ	O	O
uses	XEOMIN.xml:S3:2318:4	use	NNS	O	O
,	XEOMIN.xml:S3:2322:1	,	,	O	O
including	XEOMIN.xml:S3:2324:9	includ	VBG	O	O
spasticity	XEOMIN.xml:S3:2334:10	spastic	NN	O	O
in	XEOMIN.xml:S3:2345:2	in	IN	O	O
children	XEOMIN.xml:S3:2348:8	children	NNS	O	O
and	XEOMIN.xml:S3:2357:3	and	CC	O	O
adults	XEOMIN.xml:S3:2361:6	adult	NNS	O	O
,	XEOMIN.xml:S3:2367:1	,	,	O	O
and	XEOMIN.xml:S3:2369:3	and	CC	O	O
in	XEOMIN.xml:S3:2373:2	in	IN	O	O
approved	XEOMIN.xml:S3:2376:8	approv	JJ	O	O
indications	XEOMIN.xml:S3:2385:11	indic	NNS	O	O
,	XEOMIN.xml:S3:2396:1	,	,	O	O
symptoms	XEOMIN.xml:S3:2398:8	symptom	NNS	O	O
consistent	XEOMIN.xml:S3:2407:10	consist	VBP	O	O
with	XEOMIN.xml:S3:2418:4	with	IN	O	O
spread	XEOMIN.xml:S3:2423:6	spread	NN	B-AdverseReaction	B-AdverseReaction
of	XEOMIN.xml:S3:2430:2	of	IN	I-AdverseReaction	I-AdverseReaction
toxin	XEOMIN.xml:S3:2433:5	toxin	NN	I-AdverseReaction	I-AdverseReaction
effect	XEOMIN.xml:S3:2439:6	effect	NN	I-AdverseReaction	I-AdverseReaction
have	XEOMIN.xml:S3:2446:4	have	VBP	O	O
been	XEOMIN.xml:S3:2451:4	been	VBN	O	O
reported	XEOMIN.xml:S3:2456:8	report	VBN	O	O
at	XEOMIN.xml:S3:2465:2	at	IN	O	O
doses	XEOMIN.xml:S3:2468:5	dose	NNS	O	O
comparable	XEOMIN.xml:S3:2474:10	compar	JJ	O	O
to	XEOMIN.xml:S3:2485:2	to	TO	O	O
or	XEOMIN.xml:S3:2488:2	or	CC	O	O
lower	XEOMIN.xml:S3:2491:5	lower	JJR	O	O
than	XEOMIN.xml:S3:2497:4	than	IN	O	O
doses	XEOMIN.xml:S3:2502:5	dose	NNS	O	O
used	XEOMIN.xml:S3:2508:4	use	VBN	O	O
to	XEOMIN.xml:S3:2513:2	to	TO	O	O
treat	XEOMIN.xml:S3:2516:5	treat	VB	O	O
cervical	XEOMIN.xml:S3:2522:8	cervic	JJ	O	O
dystonia	XEOMIN.xml:S3:2531:8	dystonia	NN	O	O
.	XEOMIN.xml:S3:2539:1	.	.	O	O

Patients	XEOMIN.xml:S3:2545:8	patient	NNS	O	O
or	XEOMIN.xml:S3:2554:2	or	CC	O	O
caregivers	XEOMIN.xml:S3:2557:10	caregiv	NNS	O	O
should	XEOMIN.xml:S3:2568:6	should	MD	O	O
be	XEOMIN.xml:S3:2575:2	be	VB	O	O
advised	XEOMIN.xml:S3:2578:7	advis	VBN	O	O
to	XEOMIN.xml:S3:2586:2	to	TO	O	O
seek	XEOMIN.xml:S3:2589:4	seek	VB	O	O
immediate	XEOMIN.xml:S3:2594:9	immedi	JJ	O	O
medical	XEOMIN.xml:S3:2604:7	medic	JJ	O	O
care	XEOMIN.xml:S3:2612:4	care	NN	O	O
if	XEOMIN.xml:S3:2617:2	if	IN	O	O
swallowing	XEOMIN.xml:S3:2620:10	swallow	NN	O	O
,	XEOMIN.xml:S3:2630:1	,	,	O	O
speech	XEOMIN.xml:S3:2632:6	speech	NN	O	O
,	XEOMIN.xml:S3:2638:1	,	,	O	O
or	XEOMIN.xml:S3:2640:2	or	CC	O	O
respiratory	XEOMIN.xml:S3:2643:11	respiratori	NN	O	O
disorders	XEOMIN.xml:S3:2655:9	disord	NNS	O	O
occur	XEOMIN.xml:S3:2665:5	occur	VBP	O	O
.	XEOMIN.xml:S3:2670:1	.	.	O	O

5.2	XEOMIN.xml:S3:2679:3	5.2	CD	O	O
Lack	XEOMIN.xml:S3:2683:4	lack	NNP	O	O
of	XEOMIN.xml:S3:2688:2	of	IN	O	O
Interchangeability	XEOMIN.xml:S3:2691:18	interchang	NNP	O	O
between	XEOMIN.xml:S3:2710:7	between	IN	O	O
Botulinum	XEOMIN.xml:S3:2718:9	botulinum	NNP	O	O
Toxin	XEOMIN.xml:S3:2728:5	toxin	NNP	O	O
Products	XEOMIN.xml:S3:2734:8	product	NNS	O	O

The	XEOMIN.xml:S3:2748:3	the	DT	O	O
potency	XEOMIN.xml:S3:2752:7	potenc	NN	O	O
Units	XEOMIN.xml:S3:2760:5	unit	NNP	O	O
of	XEOMIN.xml:S3:2766:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S3:2769:6	xeomin	NNP	O	O
are	XEOMIN.xml:S3:2776:3	are	VBP	O	O
specific	XEOMIN.xml:S3:2780:8	specif	JJ	O	O
to	XEOMIN.xml:S3:2789:2	to	TO	O	O
the	XEOMIN.xml:S3:2792:3	the	DT	O	O
preparation	XEOMIN.xml:S3:2796:11	prepar	NN	O	O
and	XEOMIN.xml:S3:2808:3	and	CC	O	O
assay	XEOMIN.xml:S3:2812:5	assay	VB	O	O
method	XEOMIN.xml:S3:2818:6	method	NN	O	O
utilized	XEOMIN.xml:S3:2825:8	util	JJ	O	O
.	XEOMIN.xml:S3:2833:1	.	.	O	O

They	XEOMIN.xml:S3:2835:4	they	PRP	O	O
are	XEOMIN.xml:S3:2840:3	are	VBP	O	O
not	XEOMIN.xml:S3:2844:3	not	RB	O	O
interchangeable	XEOMIN.xml:S3:2848:15	interchang	JJ	O	O
with	XEOMIN.xml:S3:2864:4	with	IN	O	O
the	XEOMIN.xml:S3:2869:3	the	DT	O	O
other	XEOMIN.xml:S3:2873:5	other	JJ	O	O
preparations	XEOMIN.xml:S3:2879:12	prepar	NNS	O	O
of	XEOMIN.xml:S3:2892:2	of	IN	O	O
botulinum	XEOMIN.xml:S3:2895:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:2905:5	toxin	NN	O	O
products	XEOMIN.xml:S3:2911:8	product	NNS	O	O
and	XEOMIN.xml:S3:2920:3	and	CC	O	O
,	XEOMIN.xml:S3:2923:1	,	,	O	O
therefore	XEOMIN.xml:S3:2925:9	therefor	RB	O	O
,	XEOMIN.xml:S3:2934:1	,	,	O	O
Units	XEOMIN.xml:S3:2936:5	unit	NNS	O	O
of	XEOMIN.xml:S3:2942:2	of	IN	O	O
biological	XEOMIN.xml:S3:2945:10	biolog	JJ	O	O
activity	XEOMIN.xml:S3:2956:8	activ	NN	O	O
of	XEOMIN.xml:S3:2965:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S3:2968:6	xeomin	NNP	O	O
cannot	XEOMIN.xml:S3:2975:6	cannot	NN	O	O
be	XEOMIN.xml:S3:2982:2	be	VB	O	O
compared	XEOMIN.xml:S3:2985:8	compar	VBN	O	O
to	XEOMIN.xml:S3:2994:2	to	TO	O	O
or	XEOMIN.xml:S3:2997:2	or	CC	O	O
converted	XEOMIN.xml:S3:3000:9	convert	VBN	O	O
into	XEOMIN.xml:S3:3010:4	into	IN	O	O
Units	XEOMIN.xml:S3:3015:5	unit	NNS	O	O
of	XEOMIN.xml:S3:3021:2	of	IN	O	O
any	XEOMIN.xml:S3:3024:3	ani	DT	O	O
other	XEOMIN.xml:S3:3028:5	other	JJ	O	O
botulinum	XEOMIN.xml:S3:3034:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:3044:5	toxin	NN	O	O
products	XEOMIN.xml:S3:3050:8	product	NNS	O	O
assessed	XEOMIN.xml:S3:3059:8	assess	VBN	O	O
with	XEOMIN.xml:S3:3068:4	with	IN	O	O
any	XEOMIN.xml:S3:3073:3	ani	DT	O	O
other	XEOMIN.xml:S3:3077:5	other	JJ	O	O
specific	XEOMIN.xml:S3:3083:8	specif	JJ	O	O
assay	XEOMIN.xml:S3:3092:5	assay	VBP	O	O
method	XEOMIN.xml:S3:3098:6	method	JJ	O	O
[	XEOMIN.xml:S3:3105:1	[	NNP	O	O
see	XEOMIN.xml:S3:3106:3	see	NN	O	O
Description	XEOMIN.xml:S3:3111:11	descript	NNP	O	O
(	XEOMIN.xml:S3:3123:1	(	(	O	O
11	XEOMIN.xml:S3:3124:2	11	CD	O	O
)	XEOMIN.xml:S3:3126:1	)	)	O	O
]	XEOMIN.xml:S3:3129:1	]	NN	O	O
.	XEOMIN.xml:S3:3132:1	.	.	O	O

5.3	XEOMIN.xml:S3:3141:3	5.3	CD	O	O
Hypersensitivity	XEOMIN.xml:S3:3145:16	hypersensit	NNP	O	O
Reactions	XEOMIN.xml:S3:3162:9	reaction	NNP	O	O

Hypersensitivity	XEOMIN.xml:S3:3177:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	XEOMIN.xml:S3:3194:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
have	XEOMIN.xml:S3:3204:4	have	VBP	O	O
been	XEOMIN.xml:S3:3209:4	been	VBN	O	O
reported	XEOMIN.xml:S3:3214:8	report	VBN	O	O
with	XEOMIN.xml:S3:3223:4	with	IN	O	O
botulinum	XEOMIN.xml:S3:3228:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:3238:5	toxin	NN	O	O
products	XEOMIN.xml:S3:3244:8	product	NNS	O	O
(	XEOMIN.xml:S3:3253:1	(	(	O	O
anaphylaxis	XEOMIN.xml:S3:3254:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S3:3265:1	,	,	O	O
serum	XEOMIN.xml:S3:3267:5	serum	NN	B-AdverseReaction	B-AdverseReaction
sickness	XEOMIN.xml:S3:3273:8	sick	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S3:3281:1	,	,	O	O
urticaria	XEOMIN.xml:S3:3283:9	urticaria	JJ	B-AdverseReaction	B-AdverseReaction
,	XEOMIN.xml:S3:3292:1	,	,	O	O
soft	XEOMIN.xml:S3:3294:4	soft	JJ	B-AdverseReaction	B-AdverseReaction
tissue	XEOMIN.xml:S3:3299:6	tissu	NN	I-AdverseReaction	I-AdverseReaction
edema	XEOMIN.xml:S3:3306:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S3:3311:1	,	,	O	O
and	XEOMIN.xml:S3:3313:3	and	CC	O	O
dyspnea	XEOMIN.xml:S3:3317:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
)	XEOMIN.xml:S3:3324:1	)	)	O	O
.	XEOMIN.xml:S3:3325:1	.	.	O	O

If	XEOMIN.xml:S3:3327:2	If	IN	O	O
serious	XEOMIN.xml:S3:3330:7	seriou	JJ	O	O
and	XEOMIN.xml:S3:3338:3	and	CC	O	O
or	XEOMIN.xml:S3:3342:2	or	CC	O	O
immediate	XEOMIN.xml:S3:3345:9	immedi	JJ	O	O
hypersensitivity	XEOMIN.xml:S3:3355:16	hypersensit	NN	O	O
reactions	XEOMIN.xml:S3:3372:9	reaction	NNS	O	O
occur	XEOMIN.xml:S3:3382:5	occur	VBP	O	O
further	XEOMIN.xml:S3:3388:7	further	JJ	O	O
injection	XEOMIN.xml:S3:3396:9	inject	NN	O	O
of	XEOMIN.xml:S3:3406:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S3:3409:6	xeomin	NNP	O	O
should	XEOMIN.xml:S3:3416:6	should	MD	O	O
be	XEOMIN.xml:S3:3423:2	be	VB	O	O
discontinued	XEOMIN.xml:S3:3426:12	discontinu	VBN	O	O
and	XEOMIN.xml:S3:3439:3	and	CC	O	O
appropriate	XEOMIN.xml:S3:3443:11	appropri	JJ	O	O
medical	XEOMIN.xml:S3:3455:7	medic	JJ	O	O
therapy	XEOMIN.xml:S3:3463:7	therapi	NN	O	O
immediately	XEOMIN.xml:S3:3471:11	immedi	RB	O	O
instituted	XEOMIN.xml:S3:3483:10	institut	VBD	O	O
.	XEOMIN.xml:S3:3493:1	.	.	O	O

5.4	XEOMIN.xml:S3:3502:3	5.4	CD	O	O
Dysphagia	XEOMIN.xml:S3:3506:9	dysphagia	NNP	O	O
and	XEOMIN.xml:S3:3516:3	and	CC	O	O
Breathing	XEOMIN.xml:S3:3520:9	breath	NNP	O	O
Difficulties	XEOMIN.xml:S3:3530:12	difficulti	NNP	O	O
in	XEOMIN.xml:S3:3543:2	in	IN	O	O
Treatment	XEOMIN.xml:S3:3546:9	treatment	NNP	O	O
of	XEOMIN.xml:S3:3556:2	of	IN	O	O
Cervical	XEOMIN.xml:S3:3559:8	cervic	NNP	O	O
Dystonia	XEOMIN.xml:S3:3568:8	dystonia	NNP	O	O

Treatment	XEOMIN.xml:S3:3582:9	treatment	NN	O	O
with	XEOMIN.xml:S3:3592:4	with	IN	O	O
XEOMIN	XEOMIN.xml:S3:3597:6	xeomin	NNP	O	O
and	XEOMIN.xml:S3:3604:3	and	CC	O	O
other	XEOMIN.xml:S3:3608:5	other	JJ	O	O
botulinum	XEOMIN.xml:S3:3614:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:3624:5	toxin	NN	O	O
products	XEOMIN.xml:S3:3630:8	product	NNS	O	O
can	XEOMIN.xml:S3:3639:3	can	MD	O	O
result	XEOMIN.xml:S3:3643:6	result	VB	O	O
in	XEOMIN.xml:S3:3650:2	in	IN	O	O
swallowing	XEOMIN.xml:S3:3653:10	swallow	NN	B-AdverseReaction	B-AdverseReaction
or	XEOMIN.xml:S3:3664:2	or	CC	O	O
breathing	XEOMIN.xml:S3:3667:9	breath	NN	B-AdverseReaction	B-AdverseReaction
difficulties	XEOMIN.xml:S3:3677:12	difficulti	NNS	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S3:3689:1	.	.	O	O

Patients	XEOMIN.xml:S3:3691:8	patient	NNS	O	O
with	XEOMIN.xml:S3:3700:4	with	IN	O	O
pre	XEOMIN.xml:S3:3705:3	pre	JJ	O	O
-	XEOMIN.xml:S3:3708:1	-	:	O	O
existing	XEOMIN.xml:S3:3709:8	exist	VBG	O	O
swallowing	XEOMIN.xml:S3:3718:10	swallow	NN	O	O
or	XEOMIN.xml:S3:3729:2	or	CC	O	O
breathing	XEOMIN.xml:S3:3732:9	breath	VBG	O	O
difficulties	XEOMIN.xml:S3:3742:12	difficulti	NNS	O	O
may	XEOMIN.xml:S3:3755:3	may	MD	O	O
be	XEOMIN.xml:S3:3759:2	be	VB	O	O
more	XEOMIN.xml:S3:3762:4	more	RBR	O	O
susceptible	XEOMIN.xml:S3:3767:11	suscept	JJ	O	O
to	XEOMIN.xml:S3:3779:2	to	TO	O	O
these	XEOMIN.xml:S3:3782:5	these	DT	O	O
complications	XEOMIN.xml:S3:3788:13	complic	NNS	O	O
.	XEOMIN.xml:S3:3801:1	.	.	O	O

In	XEOMIN.xml:S3:3803:2	In	IN	O	O
most	XEOMIN.xml:S3:3806:4	most	JJS	O	O
cases	XEOMIN.xml:S3:3811:5	case	NNS	O	O
,	XEOMIN.xml:S3:3816:1	,	,	O	O
this	XEOMIN.xml:S3:3818:4	thi	DT	O	O
is	XEOMIN.xml:S3:3823:2	is	VBZ	O	O
a	XEOMIN.xml:S3:3826:1	a	DT	O	O
consequence	XEOMIN.xml:S3:3828:11	consequ	NN	O	O
of	XEOMIN.xml:S3:3840:2	of	IN	O	O
weakening	XEOMIN.xml:S3:3843:9	weaken	NN	O	O
of	XEOMIN.xml:S3:3853:2	of	IN	O	O
muscles	XEOMIN.xml:S3:3856:7	muscl	NNS	O	O
in	XEOMIN.xml:S3:3864:2	in	IN	O	O
the	XEOMIN.xml:S3:3867:3	the	DT	O	O
area	XEOMIN.xml:S3:3871:4	area	NN	O	O
of	XEOMIN.xml:S3:3876:2	of	IN	O	O
injection	XEOMIN.xml:S3:3879:9	inject	NN	O	O
that	XEOMIN.xml:S3:3889:4	that	WDT	O	O
are	XEOMIN.xml:S3:3894:3	are	VBP	O	O
involved	XEOMIN.xml:S3:3898:8	involv	VBN	O	O
in	XEOMIN.xml:S3:3907:2	in	IN	O	O
breathing	XEOMIN.xml:S3:3910:9	breath	VBG	O	O
or	XEOMIN.xml:S3:3920:2	or	CC	O	O
swallowing	XEOMIN.xml:S3:3923:10	swallow	VBG	O	O
.	XEOMIN.xml:S3:3933:1	.	.	O	O

When	XEOMIN.xml:S3:3935:4	when	WRB	O	O
distant	XEOMIN.xml:S3:3940:7	distant	JJ	O	O
effects	XEOMIN.xml:S3:3948:7	effect	NNS	O	O
occur	XEOMIN.xml:S3:3956:5	occur	VBP	O	O
,	XEOMIN.xml:S3:3961:1	,	,	O	O
additional	XEOMIN.xml:S3:3963:10	addit	JJ	O	O
respiratory	XEOMIN.xml:S3:3974:11	respiratori	NN	O	O
muscles	XEOMIN.xml:S3:3986:7	muscl	NNS	O	O
may	XEOMIN.xml:S3:3994:3	may	MD	O	O
be	XEOMIN.xml:S3:3998:2	be	VB	O	O
involved	XEOMIN.xml:S3:4001:8	involv	VBN	O	O
[	XEOMIN.xml:S3:4010:1	[	NNP	O	O
See	XEOMIN.xml:S3:4011:3	see	NNP	O	O
Warnings	XEOMIN.xml:S3:4016:8	warn	NNP	O	O
and	XEOMIN.xml:S3:4025:3	and	CC	O	O
Precautions	XEOMIN.xml:S3:4029:11	precaut	NNP	O	O
(	XEOMIN.xml:S3:4041:1	(	(	O	O
5.1	XEOMIN.xml:S3:4042:3	5.1	CD	O	O
)	XEOMIN.xml:S3:4045:1	)	)	O	O
]	XEOMIN.xml:S3:4048:1	]	NN	O	O
.	XEOMIN.xml:S3:4051:1	.	.	O	O

Deaths	XEOMIN.xml:S3:4057:6	death	NNS	B-AdverseReaction	B-AdverseReaction
as	XEOMIN.xml:S3:4064:2	as	IN	O	O
a	XEOMIN.xml:S3:4067:1	a	DT	O	O
complication	XEOMIN.xml:S3:4069:12	complic	NN	O	O
of	XEOMIN.xml:S3:4082:2	of	IN	O	O
severe	XEOMIN.xml:S3:4085:6	sever	JJ	O	O
dysphagia	XEOMIN.xml:S3:4092:9	dysphagia	NNS	B-AdverseReaction	B-AdverseReaction
have	XEOMIN.xml:S3:4102:4	have	VBP	O	O
been	XEOMIN.xml:S3:4107:4	been	VBN	O	O
reported	XEOMIN.xml:S3:4112:8	report	VBN	O	O
after	XEOMIN.xml:S3:4121:5	after	IN	O	O
treatment	XEOMIN.xml:S3:4127:9	treatment	NN	O	O
with	XEOMIN.xml:S3:4137:4	with	IN	O	O
botulinum	XEOMIN.xml:S3:4142:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:4152:5	toxin	NN	O	O
.	XEOMIN.xml:S3:4157:1	.	.	O	O

Dysphagia	XEOMIN.xml:S3:4159:9	dysphagia	NNP	B-AdverseReaction	B-AdverseReaction
may	XEOMIN.xml:S3:4169:3	may	MD	O	O
persist	XEOMIN.xml:S3:4173:7	persist	VB	O	O
for	XEOMIN.xml:S3:4181:3	for	IN	O	O
several	XEOMIN.xml:S3:4185:7	sever	JJ	O	O
months	XEOMIN.xml:S3:4193:6	month	NNS	O	O
,	XEOMIN.xml:S3:4199:1	,	,	O	O
and	XEOMIN.xml:S3:4201:3	and	CC	O	O
require	XEOMIN.xml:S3:4205:7	requir	VBP	O	O
use	XEOMIN.xml:S3:4213:3	use	NN	O	O
of	XEOMIN.xml:S3:4217:2	of	IN	O	O
a	XEOMIN.xml:S3:4220:1	a	DT	O	O
feeding	XEOMIN.xml:S3:4222:7	feed	NN	O	O
tube	XEOMIN.xml:S3:4230:4	tube	NN	O	O
to	XEOMIN.xml:S3:4235:2	to	TO	O	O
maintain	XEOMIN.xml:S3:4238:8	maintain	VB	O	O
adequate	XEOMIN.xml:S3:4247:8	adequ	JJ	O	O
nutrition	XEOMIN.xml:S3:4256:9	nutrit	NN	O	O
and	XEOMIN.xml:S3:4266:3	and	CC	O	O
hydration	XEOMIN.xml:S3:4270:9	hydrat	NN	O	O
.	XEOMIN.xml:S3:4279:1	.	.	O	O

Aspiration	XEOMIN.xml:S3:4281:10	aspir	NN	B-AdverseReaction	B-AdverseReaction
may	XEOMIN.xml:S3:4292:3	may	MD	O	O
result	XEOMIN.xml:S3:4296:6	result	VB	O	O
from	XEOMIN.xml:S3:4303:4	from	IN	O	O
severe	XEOMIN.xml:S3:4308:6	sever	JJ	O	O
dysphagia	XEOMIN.xml:S3:4315:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
and	XEOMIN.xml:S3:4325:3	and	CC	O	O
is	XEOMIN.xml:S3:4329:2	is	VBZ	O	O
a	XEOMIN.xml:S3:4332:1	a	DT	O	O
particular	XEOMIN.xml:S3:4334:10	particular	JJ	O	O
risk	XEOMIN.xml:S3:4345:4	risk	NN	O	O
when	XEOMIN.xml:S3:4350:4	when	WRB	O	O
treating	XEOMIN.xml:S3:4355:8	treat	VBG	O	O
patients	XEOMIN.xml:S3:4364:8	patient	NNS	O	O
in	XEOMIN.xml:S3:4373:2	in	IN	O	O
whom	XEOMIN.xml:S3:4376:4	whom	WP	O	O
swallowing	XEOMIN.xml:S3:4381:10	swallow	VBG	O	O
or	XEOMIN.xml:S3:4392:2	or	CC	O	O
respiratory	XEOMIN.xml:S3:4395:11	respiratori	JJ	O	O
function	XEOMIN.xml:S3:4407:8	function	NN	O	O
is	XEOMIN.xml:S3:4416:2	is	VBZ	O	O
already	XEOMIN.xml:S3:4419:7	alreadi	RB	O	O
compromised	XEOMIN.xml:S3:4427:11	compromis	VBN	O	O
.	XEOMIN.xml:S3:4438:1	.	.	O	O

Treatment	XEOMIN.xml:S3:4444:9	treatment	NN	O	O
of	XEOMIN.xml:S3:4454:2	of	IN	O	O
cervical	XEOMIN.xml:S3:4457:8	cervic	JJ	O	O
dystonia	XEOMIN.xml:S3:4466:8	dystonia	NN	O	O
with	XEOMIN.xml:S3:4475:4	with	IN	O	O
botulinum	XEOMIN.xml:S3:4480:9	botulinum	NN	O	O
toxins	XEOMIN.xml:S3:4490:6	toxin	NNS	O	O
may	XEOMIN.xml:S3:4497:3	may	MD	O	O
weaken	XEOMIN.xml:S3:4501:6	weaken	VB	B-AdverseReaction	B-AdverseReaction
neck	XEOMIN.xml:S3:4508:4	neck	NN	I-AdverseReaction	I-AdverseReaction
muscles	XEOMIN.xml:S3:4513:7	muscl	NNS	I-AdverseReaction	I-AdverseReaction
that	XEOMIN.xml:S3:4521:4	that	WDT	O	O
serve	XEOMIN.xml:S3:4526:5	serv	VBP	O	O
as	XEOMIN.xml:S3:4532:2	as	IN	O	O
accessory	XEOMIN.xml:S3:4535:9	accessori	JJ	O	O
muscles	XEOMIN.xml:S3:4545:7	muscl	NNS	O	O
of	XEOMIN.xml:S3:4553:2	of	IN	O	O
ventilation	XEOMIN.xml:S3:4556:11	ventil	NN	O	O
.	XEOMIN.xml:S3:4567:1	.	.	O	O

This	XEOMIN.xml:S3:4569:4	thi	DT	O	O
may	XEOMIN.xml:S3:4574:3	may	MD	O	O
result	XEOMIN.xml:S3:4578:6	result	VB	O	O
in	XEOMIN.xml:S3:4585:2	in	IN	O	O
critical	XEOMIN.xml:S3:4588:8	critic	JJ	O	B-AdverseReaction
loss	XEOMIN.xml:S3:4597:4	loss	NN	B-AdverseReaction	I-AdverseReaction
of	XEOMIN.xml:S3:4602:2	of	IN	I-AdverseReaction	I-AdverseReaction
breathing	XEOMIN.xml:S3:4605:9	breath	VBG	I-AdverseReaction	I-AdverseReaction
capacity	XEOMIN.xml:S3:4615:8	capac	NN	I-AdverseReaction	I-AdverseReaction
in	XEOMIN.xml:S3:4624:2	in	IN	O	O
patients	XEOMIN.xml:S3:4627:8	patient	NNS	O	O
with	XEOMIN.xml:S3:4636:4	with	IN	O	O
respiratory	XEOMIN.xml:S3:4641:11	respiratori	JJ	O	O
disorders	XEOMIN.xml:S3:4653:9	disord	NNS	O	O
who	XEOMIN.xml:S3:4663:3	who	WP	O	O
may	XEOMIN.xml:S3:4667:3	may	MD	O	O
have	XEOMIN.xml:S3:4671:4	have	VB	O	O
become	XEOMIN.xml:S3:4676:6	becom	VBN	O	O
dependent	XEOMIN.xml:S3:4683:9	depend	JJ	O	O
upon	XEOMIN.xml:S3:4693:4	upon	IN	O	O
these	XEOMIN.xml:S3:4698:5	these	DT	O	O
accessory	XEOMIN.xml:S3:4704:9	accessori	JJ	O	O
muscles	XEOMIN.xml:S3:4714:7	muscl	NNS	O	O
.	XEOMIN.xml:S3:4721:1	.	.	O	O

There	XEOMIN.xml:S3:4723:5	there	EX	O	O
have	XEOMIN.xml:S3:4729:4	have	VBP	O	O
been	XEOMIN.xml:S3:4734:4	been	VBN	O	O
post	XEOMIN.xml:S3:4739:4	post	VBN	O	O
-	XEOMIN.xml:S3:4743:1	-	:	O	O
marketing	XEOMIN.xml:S3:4744:9	market	NN	O	O
reports	XEOMIN.xml:S3:4754:7	report	NNS	O	O
of	XEOMIN.xml:S3:4762:2	of	IN	O	O
serious	XEOMIN.xml:S3:4765:7	seriou	JJ	O	O
breathing	XEOMIN.xml:S3:4773:9	breath	VBG	B-AdverseReaction	B-AdverseReaction
difficulties	XEOMIN.xml:S3:4783:12	difficulti	NNS	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S3:4795:1	,	,	O	O
including	XEOMIN.xml:S3:4797:9	includ	VBG	O	O
respiratory	XEOMIN.xml:S3:4807:11	respiratori	JJ	B-AdverseReaction	B-AdverseReaction
failure	XEOMIN.xml:S3:4819:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S3:4826:1	,	,	O	O
in	XEOMIN.xml:S3:4828:2	in	IN	O	O
patients	XEOMIN.xml:S3:4831:8	patient	NNS	O	O
with	XEOMIN.xml:S3:4840:4	with	IN	O	O
cervical	XEOMIN.xml:S3:4845:8	cervic	JJ	O	O
dystonia	XEOMIN.xml:S3:4854:8	dystonia	NN	O	O
treated	XEOMIN.xml:S3:4863:7	treat	VBN	O	O
with	XEOMIN.xml:S3:4871:4	with	IN	O	O
botulinum	XEOMIN.xml:S3:4876:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:4886:5	toxin	NN	O	O
products	XEOMIN.xml:S3:4892:8	product	NNS	O	O
.	XEOMIN.xml:S3:4900:1	.	.	O	O

Patients	XEOMIN.xml:S3:4906:8	patient	NNS	O	O
with	XEOMIN.xml:S3:4915:4	with	IN	O	O
smaller	XEOMIN.xml:S3:4920:7	smaller	JJR	O	O
neck	XEOMIN.xml:S3:4928:4	neck	NN	O	O
muscle	XEOMIN.xml:S3:4933:6	muscl	NN	O	O
mass	XEOMIN.xml:S3:4940:4	mass	NN	O	O
and	XEOMIN.xml:S3:4945:3	and	CC	O	O
patients	XEOMIN.xml:S3:4949:8	patient	NNS	O	O
who	XEOMIN.xml:S3:4958:3	who	WP	O	O
require	XEOMIN.xml:S3:4962:7	requir	VBP	O	O
bilateral	XEOMIN.xml:S3:4970:9	bilater	JJ	O	O
injections	XEOMIN.xml:S3:4980:10	inject	NNS	O	O
into	XEOMIN.xml:S3:4991:4	into	IN	O	O
the	XEOMIN.xml:S3:4996:3	the	DT	O	O
sternocleidomastoid	XEOMIN.xml:S3:5000:19	sternocleidomastoid	NN	O	O
muscles	XEOMIN.xml:S3:5020:7	muscl	NNS	O	O
have	XEOMIN.xml:S3:5028:4	have	VBP	O	O
been	XEOMIN.xml:S3:5033:4	been	VBN	O	O
reported	XEOMIN.xml:S3:5038:8	report	VBN	O	O
to	XEOMIN.xml:S3:5047:2	to	TO	O	O
be	XEOMIN.xml:S3:5050:2	be	VB	O	O
at	XEOMIN.xml:S3:5053:2	at	IN	O	O
greater	XEOMIN.xml:S3:5056:7	greater	JJR	O	O
risk	XEOMIN.xml:S3:5064:4	risk	NN	O	O
of	XEOMIN.xml:S3:5069:2	of	IN	O	O
dysphagia	XEOMIN.xml:S3:5072:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
.	XEOMIN.xml:S3:5081:1	.	.	O	O

In	XEOMIN.xml:S3:5083:2	In	IN	O	O
general	XEOMIN.xml:S3:5086:7	gener	JJ	O	O
,	XEOMIN.xml:S3:5093:1	,	,	O	O
limiting	XEOMIN.xml:S3:5095:8	limit	VBG	O	O
the	XEOMIN.xml:S3:5104:3	the	DT	O	O
dose	XEOMIN.xml:S3:5108:4	dose	NN	O	O
injected	XEOMIN.xml:S3:5113:8	inject	VBD	O	O
into	XEOMIN.xml:S3:5122:4	into	IN	O	O
the	XEOMIN.xml:S3:5127:3	the	DT	O	O
sternocleidomastoid	XEOMIN.xml:S3:5131:19	sternocleidomastoid	JJ	O	O
muscle	XEOMIN.xml:S3:5151:6	muscl	NN	O	O
may	XEOMIN.xml:S3:5158:3	may	MD	O	O
decrease	XEOMIN.xml:S3:5162:8	decreas	VB	O	O
the	XEOMIN.xml:S3:5171:3	the	DT	O	O
occurrence	XEOMIN.xml:S3:5175:10	occurr	NN	O	O
of	XEOMIN.xml:S3:5186:2	of	IN	O	O
dysphagia	XEOMIN.xml:S3:5189:9	dysphagia	NN	O	B-AdverseReaction
.	XEOMIN.xml:S3:5198:1	.	.	O	O

Patients	XEOMIN.xml:S3:5204:8	patient	NNS	O	O
treated	XEOMIN.xml:S3:5213:7	treat	VBN	O	O
with	XEOMIN.xml:S3:5221:4	with	IN	O	O
botulinum	XEOMIN.xml:S3:5226:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:5236:5	toxin	NN	O	O
may	XEOMIN.xml:S3:5242:3	may	MD	O	O
require	XEOMIN.xml:S3:5246:7	requir	VB	O	O
immediate	XEOMIN.xml:S3:5254:9	immedi	JJ	O	O
medical	XEOMIN.xml:S3:5264:7	medic	JJ	O	O
attention	XEOMIN.xml:S3:5272:9	attent	NN	O	O
should	XEOMIN.xml:S3:5282:6	should	MD	O	O
they	XEOMIN.xml:S3:5289:4	they	PRP	O	O
develop	XEOMIN.xml:S3:5294:7	develop	VB	O	O
problems	XEOMIN.xml:S3:5302:8	problem	NNS	O	O
with	XEOMIN.xml:S3:5311:4	with	IN	O	O
swallowing	XEOMIN.xml:S3:5316:10	swallow	NN	O	O
,	XEOMIN.xml:S3:5326:1	,	,	O	O
speech	XEOMIN.xml:S3:5328:6	speech	NN	O	O
or	XEOMIN.xml:S3:5335:2	or	CC	O	O
respiratory	XEOMIN.xml:S3:5338:11	respiratori	NN	O	O
disorders	XEOMIN.xml:S3:5350:9	disord	NNS	O	O
.	XEOMIN.xml:S3:5359:1	.	.	O	O

These	XEOMIN.xml:S3:5361:5	these	DT	O	O
reactions	XEOMIN.xml:S3:5367:9	reaction	NNS	O	O
can	XEOMIN.xml:S3:5377:3	can	MD	O	O
occur	XEOMIN.xml:S3:5381:5	occur	VB	O	O
within	XEOMIN.xml:S3:5387:6	within	IN	O	O
hours	XEOMIN.xml:S3:5394:5	hour	NNS	O	O
to	XEOMIN.xml:S3:5400:2	to	TO	O	O
weeks	XEOMIN.xml:S3:5403:5	week	NNS	O	O
after	XEOMIN.xml:S3:5409:5	after	IN	O	O
injection	XEOMIN.xml:S3:5415:9	inject	NN	O	O
with	XEOMIN.xml:S3:5425:4	with	IN	O	O
botulinum	XEOMIN.xml:S3:5430:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:5440:5	toxin	NN	O	O
[	XEOMIN.xml:S3:5446:1	[	NNP	O	O
See	XEOMIN.xml:S3:5447:3	see	NNP	O	O
Warnings	XEOMIN.xml:S3:5452:8	warn	NNP	O	O
and	XEOMIN.xml:S3:5461:3	and	CC	O	O
Precautions	XEOMIN.xml:S3:5465:11	precaut	NNP	O	O
(	XEOMIN.xml:S3:5477:1	(	(	O	O
5.1	XEOMIN.xml:S3:5478:3	5.1	CD	O	O
)	XEOMIN.xml:S3:5481:1	)	)	O	O
and	XEOMIN.xml:S3:5484:3	and	CC	O	O
Adverse	XEOMIN.xml:S3:5489:7	advers	JJ	O	O
Reactions	XEOMIN.xml:S3:5497:9	reaction	NNP	O	O
(	XEOMIN.xml:S3:5507:1	(	(	O	O
6.1	XEOMIN.xml:S3:5508:3	6.1	CD	O	O
)	XEOMIN.xml:S3:5511:1	)	)	O	O
]	XEOMIN.xml:S3:5514:1	]	NN	O	O
.	XEOMIN.xml:S3:5517:1	.	.	O	O

5.5	XEOMIN.xml:S3:5526:3	5.5	CD	O	O
Pre	XEOMIN.xml:S3:5530:3	pre	NNP	O	O
-	XEOMIN.xml:S3:5533:1	-	:	O	O
existing	XEOMIN.xml:S3:5534:8	exist	VBG	O	O
Neuromuscular	XEOMIN.xml:S3:5543:13	neuromuscular	JJ	O	O
Disorders	XEOMIN.xml:S3:5557:9	disord	NNS	O	O
and	XEOMIN.xml:S3:5567:3	and	CC	O	O
other	XEOMIN.xml:S3:5571:5	other	JJ	O	O
Special	XEOMIN.xml:S3:5577:7	special	JJ	O	O
Populations	XEOMIN.xml:S3:5585:11	popul	NNS	O	O

Individuals	XEOMIN.xml:S3:5602:11	individu	NNS	O	O
with	XEOMIN.xml:S3:5614:4	with	IN	O	O
peripheral	XEOMIN.xml:S3:5619:10	peripher	JJ	O	O
motor	XEOMIN.xml:S3:5630:5	motor	NN	O	O
neuropathic	XEOMIN.xml:S3:5636:11	neuropath	JJ	O	O
diseases	XEOMIN.xml:S3:5648:8	diseas	NNS	O	O
,	XEOMIN.xml:S3:5656:1	,	,	O	O
amyotrophic	XEOMIN.xml:S3:5658:11	amyotroph	JJ	O	O
lateral	XEOMIN.xml:S3:5670:7	later	JJ	O	O
sclerosis	XEOMIN.xml:S3:5678:9	sclerosi	NN	O	O
,	XEOMIN.xml:S3:5687:1	,	,	O	O
or	XEOMIN.xml:S3:5689:2	or	CC	O	O
neuromuscular	XEOMIN.xml:S3:5692:13	neuromuscular	JJ	O	O
junctional	XEOMIN.xml:S3:5706:10	junction	NN	O	O
disorders	XEOMIN.xml:S3:5717:9	disord	NNS	O	O
(	XEOMIN.xml:S3:5727:1	(	(	O	O
e	XEOMIN.xml:S3:5728:1	e	NN	O	O
.	XEOMIN.xml:S3:5729:1	.	.	O	O
g	XEOMIN.xml:S3:5730:1	g	NN	O	O
.	XEOMIN.xml:S3:5731:1	.	.	O	O
,	XEOMIN.xml:S3:5732:1	,	,	O	O
myasthenia	XEOMIN.xml:S3:5734:10	myasthenia	JJ	O	O
gravis	XEOMIN.xml:S3:5745:6	gravi	NN	O	O
or	XEOMIN.xml:S3:5752:2	or	CC	O	O
Lambert	XEOMIN.xml:S3:5755:7	lambert	NNP	O	O
-	XEOMIN.xml:S3:5762:1	-	:	O	O
Eaton	XEOMIN.xml:S3:5763:5	eaton	NNP	O	O
syndrome	XEOMIN.xml:S3:5769:8	syndrom	NN	O	O
)	XEOMIN.xml:S3:5777:1	)	)	O	O
should	XEOMIN.xml:S3:5779:6	should	MD	O	O
be	XEOMIN.xml:S3:5786:2	be	VB	O	O
monitored	XEOMIN.xml:S3:5789:9	monitor	VBN	O	O
particularly	XEOMIN.xml:S3:5799:12	particularli	RB	O	O
closely	XEOMIN.xml:S3:5812:7	close	RB	O	O
when	XEOMIN.xml:S3:5820:4	when	WRB	O	O
given	XEOMIN.xml:S3:5825:5	given	VBN	O	O
botulinum	XEOMIN.xml:S3:5831:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:5841:5	toxin	NN	O	O
.	XEOMIN.xml:S3:5846:1	.	.	O	O

Patients	XEOMIN.xml:S3:5848:8	patient	NNS	O	O
with	XEOMIN.xml:S3:5857:4	with	IN	O	O
neuromuscular	XEOMIN.xml:S3:5862:13	neuromuscular	JJ	O	O
disorders	XEOMIN.xml:S3:5876:9	disord	NNS	O	O
may	XEOMIN.xml:S3:5886:3	may	MD	O	O
be	XEOMIN.xml:S3:5890:2	be	VB	O	O
at	XEOMIN.xml:S3:5893:2	at	IN	O	O
increased	XEOMIN.xml:S3:5896:9	increas	JJ	O	O
risk	XEOMIN.xml:S3:5906:4	risk	NN	O	O
of	XEOMIN.xml:S3:5911:2	of	IN	O	O
clinically	XEOMIN.xml:S3:5914:10	clinic	RB	O	O
significant	XEOMIN.xml:S3:5925:11	signific	JJ	O	O
effects	XEOMIN.xml:S3:5937:7	effect	NNS	O	O
including	XEOMIN.xml:S3:5945:9	includ	VBG	O	O
severe	XEOMIN.xml:S3:5955:6	sever	JJ	O	O
dysphagia	XEOMIN.xml:S3:5962:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
and	XEOMIN.xml:S3:5972:3	and	CC	O	O
respiratory	XEOMIN.xml:S3:5976:11	respiratori	JJ	B-AdverseReaction	B-AdverseReaction
compromise	XEOMIN.xml:S3:5988:10	compromis	NN	I-AdverseReaction	I-AdverseReaction
from	XEOMIN.xml:S3:5999:4	from	IN	O	O
typical	XEOMIN.xml:S3:6004:7	typic	JJ	O	O
doses	XEOMIN.xml:S3:6012:5	dose	NNS	O	O
of	XEOMIN.xml:S3:6018:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S3:6021:6	xeomin	NNP	O	O
[	XEOMIN.xml:S3:6028:1	[	NNP	O	O
See	XEOMIN.xml:S3:6029:3	see	NNP	O	O
Adverse	XEOMIN.xml:S3:6034:7	advers	NNP	O	O
Reactions	XEOMIN.xml:S3:6042:9	reaction	NNP	O	O
(	XEOMIN.xml:S3:6052:1	(	(	O	O
6.1	XEOMIN.xml:S3:6053:3	6.1	CD	O	O
)	XEOMIN.xml:S3:6056:1	)	)	O	O
]	XEOMIN.xml:S3:6059:1	]	NN	O	O
.	XEOMIN.xml:S3:6062:1	.	.	O	O

5.6	XEOMIN.xml:S3:6071:3	5.6	CD	O	O
Corneal	XEOMIN.xml:S3:6075:7	corneal	NNP	O	O
Exposure	XEOMIN.xml:S3:6083:8	exposur	NNP	O	O
,	XEOMIN.xml:S3:6091:1	,	,	O	O
Corneal	XEOMIN.xml:S3:6093:7	corneal	NNP	O	O
Ulceration	XEOMIN.xml:S3:6101:10	ulcer	NNP	O	O
,	XEOMIN.xml:S3:6111:1	,	,	O	O
and	XEOMIN.xml:S3:6113:3	and	CC	O	O
Ectropion	XEOMIN.xml:S3:6117:9	ectropion	NNP	O	O
in	XEOMIN.xml:S3:6127:2	in	IN	O	O
Patients	XEOMIN.xml:S3:6130:8	patient	NNP	O	O
Treated	XEOMIN.xml:S3:6139:7	treat	NNP	O	O
with	XEOMIN.xml:S3:6147:4	with	IN	O	O
XEOMIN	XEOMIN.xml:S3:6152:6	xeomin	NNP	O	O
for	XEOMIN.xml:S3:6159:3	for	IN	O	O
Blepharospasm	XEOMIN.xml:S3:6163:13	blepharospasm	NNP	O	O

Reduced	XEOMIN.xml:S3:6182:7	reduc	VBN	B-AdverseReaction	O
blinking	XEOMIN.xml:S3:6190:8	blink	NN	I-AdverseReaction	O
from	XEOMIN.xml:S3:6199:4	from	IN	O	O
injection	XEOMIN.xml:S3:6204:9	inject	NN	O	O
of	XEOMIN.xml:S3:6214:2	of	IN	O	O
botulinum	XEOMIN.xml:S3:6217:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:6227:5	toxin	NN	O	O
products	XEOMIN.xml:S3:6233:8	product	NNS	O	O
in	XEOMIN.xml:S3:6242:2	in	IN	O	O
the	XEOMIN.xml:S3:6245:3	the	DT	O	O
orbicularis	XEOMIN.xml:S3:6249:11	orbiculari	JJ	O	O
muscle	XEOMIN.xml:S3:6261:6	muscl	NN	O	O
can	XEOMIN.xml:S3:6268:3	can	MD	O	O
lead	XEOMIN.xml:S3:6272:4	lead	VB	O	O
to	XEOMIN.xml:S3:6277:2	to	TO	O	O
corneal	XEOMIN.xml:S3:6280:7	corneal	VB	B-AdverseReaction	O
exposure	XEOMIN.xml:S3:6288:8	exposur	NN	I-AdverseReaction	O
,	XEOMIN.xml:S3:6296:1	,	,	O	O
persistent	XEOMIN.xml:S3:6298:10	persist	JJ	I-AdverseReaction	O
epithelial	XEOMIN.xml:S3:6309:10	epitheli	JJ	I-AdverseReaction	O
defect	XEOMIN.xml:S3:6320:6	defect	NN	I-AdverseReaction	O
and	XEOMIN.xml:S3:6327:3	and	CC	O	O
corneal	XEOMIN.xml:S3:6331:7	corneal	JJ	B-AdverseReaction	B-AdverseReaction
ulceration	XEOMIN.xml:S3:6339:10	ulcer	NN	I-AdverseReaction	I-AdverseReaction
,	XEOMIN.xml:S3:6349:1	,	,	O	O
especially	XEOMIN.xml:S3:6351:10	especi	RB	O	O
in	XEOMIN.xml:S3:6362:2	in	IN	O	O
patients	XEOMIN.xml:S3:6365:8	patient	NNS	O	O
with	XEOMIN.xml:S3:6374:4	with	IN	O	O
VII	XEOMIN.xml:S3:6379:3	vii	NNP	O	O
nerve	XEOMIN.xml:S3:6383:5	nerv	NN	O	O
disorders	XEOMIN.xml:S3:6389:9	disord	NNS	O	O
.	XEOMIN.xml:S3:6398:1	.	.	O	O

Careful	XEOMIN.xml:S3:6400:7	care	JJ	O	O
testing	XEOMIN.xml:S3:6408:7	test	NN	O	O
of	XEOMIN.xml:S3:6416:2	of	IN	O	O
corneal	XEOMIN.xml:S3:6419:7	corneal	JJ	O	O
sensation	XEOMIN.xml:S3:6427:9	sensat	NN	O	O
in	XEOMIN.xml:S3:6437:2	in	IN	O	O
eyes	XEOMIN.xml:S3:6440:4	eye	NNS	O	O
previously	XEOMIN.xml:S3:6445:10	previous	RB	O	O
operated	XEOMIN.xml:S3:6456:8	oper	VBD	O	O
upon	XEOMIN.xml:S3:6465:4	upon	NN	O	O
,	XEOMIN.xml:S3:6469:1	,	,	O	O
avoidance	XEOMIN.xml:S3:6471:9	avoid	NN	O	O
of	XEOMIN.xml:S3:6481:2	of	IN	O	O
injection	XEOMIN.xml:S3:6484:9	inject	NN	O	O
into	XEOMIN.xml:S3:6494:4	into	IN	O	O
the	XEOMIN.xml:S3:6499:3	the	DT	O	O
lower	XEOMIN.xml:S3:6503:5	lower	JJR	O	O
lid	XEOMIN.xml:S3:6509:3	lid	JJ	O	O
area	XEOMIN.xml:S3:6513:4	area	NN	O	O
to	XEOMIN.xml:S3:6518:2	to	TO	O	O
avoid	XEOMIN.xml:S3:6521:5	avoid	VB	O	O
ectropion	XEOMIN.xml:S3:6527:9	ectropion	NN	O	O
,	XEOMIN.xml:S3:6536:1	,	,	O	O
and	XEOMIN.xml:S3:6538:3	and	CC	O	O
vigorous	XEOMIN.xml:S3:6542:8	vigor	JJ	O	O
treatment	XEOMIN.xml:S3:6551:9	treatment	NN	O	O
of	XEOMIN.xml:S3:6561:2	of	IN	O	O
any	XEOMIN.xml:S3:6564:3	ani	DT	O	O
epithelial	XEOMIN.xml:S3:6568:10	epitheli	JJ	O	O
defect	XEOMIN.xml:S3:6579:6	defect	NN	O	O
should	XEOMIN.xml:S3:6586:6	should	MD	O	O
be	XEOMIN.xml:S3:6593:2	be	VB	O	O
employed	XEOMIN.xml:S3:6596:8	employ	VBN	O	O
.	XEOMIN.xml:S3:6604:1	.	.	O	O

This	XEOMIN.xml:S3:6606:4	thi	DT	O	O
may	XEOMIN.xml:S3:6611:3	may	MD	O	O
require	XEOMIN.xml:S3:6615:7	requir	VB	O	O
protective	XEOMIN.xml:S3:6623:10	protect	JJ	O	O
drops	XEOMIN.xml:S3:6634:5	drop	NNS	O	O
,	XEOMIN.xml:S3:6639:1	,	,	O	O
ointment	XEOMIN.xml:S3:6641:8	ointment	NN	O	O
,	XEOMIN.xml:S3:6649:1	,	,	O	O
therapeutic	XEOMIN.xml:S3:6651:11	therapeut	JJ	O	O
soft	XEOMIN.xml:S3:6663:4	soft	JJ	O	O
contact	XEOMIN.xml:S3:6668:7	contact	NN	O	O
lenses	XEOMIN.xml:S3:6676:6	lens	NNS	O	O
,	XEOMIN.xml:S3:6682:1	,	,	O	O
or	XEOMIN.xml:S3:6684:2	or	CC	O	O
closure	XEOMIN.xml:S3:6687:7	closur	NN	O	B-AdverseReaction
of	XEOMIN.xml:S3:6695:2	of	IN	O	I-AdverseReaction
the	XEOMIN.xml:S3:6698:3	the	DT	O	I-AdverseReaction
eye	XEOMIN.xml:S3:6702:3	eye	NN	O	I-AdverseReaction
by	XEOMIN.xml:S3:6706:2	by	IN	O	O
patching	XEOMIN.xml:S3:6709:8	patch	VBG	O	O
or	XEOMIN.xml:S3:6718:2	or	CC	O	O
other	XEOMIN.xml:S3:6721:5	other	JJ	O	O
means	XEOMIN.xml:S3:6727:5	mean	NNS	O	O
.	XEOMIN.xml:S3:6732:1	.	.	O	O

Because	XEOMIN.xml:S3:6734:7	becaus	IN	O	O
of	XEOMIN.xml:S3:6742:2	of	IN	O	O
its	XEOMIN.xml:S3:6745:3	it	PRP$	O	O
anticholinergic	XEOMIN.xml:S3:6749:15	anticholinerg	JJ	O	O
effects	XEOMIN.xml:S3:6765:7	effect	NNS	O	O
,	XEOMIN.xml:S3:6772:1	,	,	O	O
XEOMIN	XEOMIN.xml:S3:6774:6	xeomin	NNP	O	O
should	XEOMIN.xml:S3:6781:6	should	MD	O	O
be	XEOMIN.xml:S3:6788:2	be	VB	O	O
used	XEOMIN.xml:S3:6791:4	use	VBN	O	O
with	XEOMIN.xml:S3:6796:4	with	IN	O	O
caution	XEOMIN.xml:S3:6801:7	caution	NN	O	O
in	XEOMIN.xml:S3:6809:2	in	IN	O	O
patients	XEOMIN.xml:S3:6812:8	patient	NNS	O	O
at	XEOMIN.xml:S3:6821:2	at	IN	O	O
risk	XEOMIN.xml:S3:6824:4	risk	NN	O	O
of	XEOMIN.xml:S3:6829:2	of	IN	O	O
developing	XEOMIN.xml:S3:6832:10	develop	VBG	O	O
narrow	XEOMIN.xml:S3:6843:6	narrow	JJ	O	O
angle	XEOMIN.xml:S3:6850:5	angl	NN	O	O
glaucoma	XEOMIN.xml:S3:6856:8	glaucoma	NN	O	O
.	XEOMIN.xml:S3:6864:1	.	.	O	O

To	XEOMIN.xml:S3:6866:2	To	TO	O	O
prevent	XEOMIN.xml:S3:6869:7	prevent	VB	O	O
ectropion	XEOMIN.xml:S3:6877:9	ectropion	NN	O	O
,	XEOMIN.xml:S3:6886:1	,	,	O	O
botulinum	XEOMIN.xml:S3:6888:9	botulinum	NN	O	O
toxin	XEOMIN.xml:S3:6898:5	toxin	NN	O	O
products	XEOMIN.xml:S3:6904:8	product	NNS	O	O
should	XEOMIN.xml:S3:6913:6	should	MD	O	O
not	XEOMIN.xml:S3:6920:3	not	RB	O	O
be	XEOMIN.xml:S3:6924:2	be	VB	O	O
injected	XEOMIN.xml:S3:6927:8	inject	VBN	O	O
into	XEOMIN.xml:S3:6936:4	into	IN	O	O
the	XEOMIN.xml:S3:6941:3	the	DT	O	O
medial	XEOMIN.xml:S3:6945:6	medial	JJ	O	O
lower	XEOMIN.xml:S3:6952:5	lower	JJR	O	O
eyelid	XEOMIN.xml:S3:6958:6	eyelid	JJ	O	O
area	XEOMIN.xml:S3:6965:4	area	NN	O	O
.	XEOMIN.xml:S3:6969:1	.	.	O	O

Ecchymosis	XEOMIN.xml:S3:6975:10	ecchymosi	NNP	O	O
easily	XEOMIN.xml:S3:6986:6	easili	RB	O	O
occurs	XEOMIN.xml:S3:6993:6	occur	VBZ	O	O
in	XEOMIN.xml:S3:7000:2	in	IN	O	O
the	XEOMIN.xml:S3:7003:3	the	DT	O	O
soft	XEOMIN.xml:S3:7007:4	soft	JJ	O	O
tissues	XEOMIN.xml:S3:7012:7	tissu	NNS	O	O
of	XEOMIN.xml:S3:7020:2	of	IN	O	O
the	XEOMIN.xml:S3:7023:3	the	DT	O	O
eyelid	XEOMIN.xml:S3:7027:6	eyelid	NN	O	O
.	XEOMIN.xml:S3:7033:1	.	.	O	O

Immediate	XEOMIN.xml:S3:7035:9	immedi	NNP	O	B-AdverseReaction
gentle	XEOMIN.xml:S3:7045:6	gentl	JJ	O	I-AdverseReaction
pressure	XEOMIN.xml:S3:7052:8	pressur	NN	O	I-AdverseReaction
at	XEOMIN.xml:S3:7061:2	at	IN	O	I-AdverseReaction
the	XEOMIN.xml:S3:7064:3	the	DT	O	I-AdverseReaction
injection	XEOMIN.xml:S3:7068:9	inject	NN	O	I-AdverseReaction
site	XEOMIN.xml:S3:7078:4	site	NN	O	I-AdverseReaction
can	XEOMIN.xml:S3:7083:3	can	MD	O	O
limit	XEOMIN.xml:S3:7087:5	limit	VB	O	O
that	XEOMIN.xml:S3:7093:4	that	DT	O	O
risk	XEOMIN.xml:S3:7098:4	risk	NN	O	O
.	XEOMIN.xml:S3:7102:1	.	.	O	O

5.7	XEOMIN.xml:S3:7111:3	5.7	CD	O	O
Risk	XEOMIN.xml:S3:7115:4	risk	NN	O	O
of	XEOMIN.xml:S3:7120:2	of	IN	O	O
Ptosis	XEOMIN.xml:S3:7123:6	ptosi	NNP	O	O
in	XEOMIN.xml:S3:7130:2	in	IN	O	O
Patients	XEOMIN.xml:S3:7133:8	patient	NNP	O	O
Treated	XEOMIN.xml:S3:7142:7	treat	NNP	O	O
with	XEOMIN.xml:S3:7150:4	with	IN	O	O
XEOMIN	XEOMIN.xml:S3:7155:6	xeomin	NNP	O	O
for	XEOMIN.xml:S3:7162:3	for	IN	O	O
Glabellar	XEOMIN.xml:S3:7166:9	glabellar	NNP	O	O
Lines	XEOMIN.xml:S3:7176:5	line	NNS	O	O

Do	XEOMIN.xml:S3:7187:2	Do	NNP	O	O
not	XEOMIN.xml:S3:7190:3	not	RB	O	O
exceed	XEOMIN.xml:S3:7194:6	exceed	VB	O	O
the	XEOMIN.xml:S3:7201:3	the	DT	O	O
recommended	XEOMIN.xml:S3:7205:11	recommend	JJ	O	O
dosage	XEOMIN.xml:S3:7217:6	dosag	NN	O	O
and	XEOMIN.xml:S3:7224:3	and	CC	O	O
frequency	XEOMIN.xml:S3:7228:9	frequenc	NN	O	O
of	XEOMIN.xml:S3:7238:2	of	IN	O	O
administration	XEOMIN.xml:S3:7241:14	administr	NN	O	O
of	XEOMIN.xml:S3:7256:2	of	IN	O	O
XEOMIN	XEOMIN.xml:S3:7259:6	xeomin	NNP	O	O
.	XEOMIN.xml:S3:7265:1	.	.	O	O

In	XEOMIN.xml:S3:7271:2	In	IN	O	O
order	XEOMIN.xml:S3:7274:5	order	NN	O	O
to	XEOMIN.xml:S3:7280:2	to	TO	O	O
reduce	XEOMIN.xml:S3:7283:6	reduc	VB	O	O
the	XEOMIN.xml:S3:7290:3	the	DT	O	O
complication	XEOMIN.xml:S3:7294:12	complic	NN	O	O
of	XEOMIN.xml:S3:7307:2	of	IN	O	O
ptosis	XEOMIN.xml:S3:7310:6	ptosi	NN	O	O
the	XEOMIN.xml:S3:7317:3	the	DT	O	O
following	XEOMIN.xml:S3:7321:9	follow	JJ	O	O
steps	XEOMIN.xml:S3:7331:5	step	NNS	O	O
should	XEOMIN.xml:S3:7337:6	should	MD	O	O
be	XEOMIN.xml:S3:7344:2	be	VB	O	O
taken	XEOMIN.xml:S3:7347:5	taken	VBN	O	O
:	XEOMIN.xml:S3:7352:1	:	:	O	O

Avoid	XEOMIN.xml:S3:7361:5	avoid	NNP	O	O
injection	XEOMIN.xml:S3:7367:9	inject	NN	O	O
near	XEOMIN.xml:S3:7377:4	near	IN	O	O
the	XEOMIN.xml:S3:7382:3	the	DT	O	O
levator	XEOMIN.xml:S3:7386:7	levat	NN	O	O
palpebrae	XEOMIN.xml:S3:7394:9	palpebra	NN	O	O
superioris	XEOMIN.xml:S3:7404:10	superiori	NN	O	O
,	XEOMIN.xml:S3:7414:1	,	,	O	O
particularly	XEOMIN.xml:S3:7416:12	particularli	RB	O	O
in	XEOMIN.xml:S3:7429:2	in	IN	O	O
patients	XEOMIN.xml:S3:7432:8	patient	NNS	O	O
with	XEOMIN.xml:S3:7441:4	with	IN	O	O
larger	XEOMIN.xml:S3:7446:6	larger	JJR	O	O
brow	XEOMIN.xml:S3:7453:4	brow	NN	O	O
depressor	XEOMIN.xml:S3:7458:9	depressor	NN	O	O
complexes	XEOMIN.xml:S3:7468:9	complex	NNS	O	O
.	XEOMIN.xml:S3:7477:1	.	.	O	O

Corrugator	XEOMIN.xml:S3:7484:10	corrug	NNP	O	O
injections	XEOMIN.xml:S3:7495:10	inject	NNS	O	O
should	XEOMIN.xml:S3:7506:6	should	MD	O	O
be	XEOMIN.xml:S3:7513:2	be	VB	O	O
placed	XEOMIN.xml:S3:7516:6	place	VBN	O	O
at	XEOMIN.xml:S3:7523:2	at	IN	O	O
least	XEOMIN.xml:S3:7526:5	least	JJS	O	O
1	XEOMIN.xml:S3:7532:1	1	CD	O	O
cm	XEOMIN.xml:S3:7534:2	cm	NNS	O	O
above	XEOMIN.xml:S3:7537:5	abov	IN	O	O
the	XEOMIN.xml:S3:7543:3	the	DT	O	O
bony	XEOMIN.xml:S3:7547:4	boni	NN	O	O
supraorbital	XEOMIN.xml:S3:7552:12	supraorbit	JJ	O	O
ridge	XEOMIN.xml:S3:7565:5	ridg	NN	O	O
.	XEOMIN.xml:S3:7570:1	.	.	O	O

5.8	XEOMIN.xml:S3:7580:3	5.8	CD	O	O
Human	XEOMIN.xml:S3:7584:5	human	NNP	O	O
Albumin	XEOMIN.xml:S3:7590:7	albumin	NNP	O	O
and	XEOMIN.xml:S3:7598:3	and	CC	O	O
Transmission	XEOMIN.xml:S3:7602:12	transmiss	NNP	O	O
of	XEOMIN.xml:S3:7615:2	of	IN	O	O
Viral	XEOMIN.xml:S3:7618:5	viral	NNP	O	O
Diseases	XEOMIN.xml:S3:7624:8	diseas	NNP	O	O

This	XEOMIN.xml:S3:7638:4	thi	DT	O	O

product	XEOMIN.xml:S3:7643:7	product	NN	O	O
contains	XEOMIN.xml:S3:7651:8	contain	VBZ	O	O
albumin	XEOMIN.xml:S3:7660:7	albumin	JJ	O	O
,	XEOMIN.xml:S3:7667:1	,	,	O	O
a	XEOMIN.xml:S3:7669:1	a	DT	O	O
derivative	XEOMIN.xml:S3:7671:10	deriv	NN	O	O
of	XEOMIN.xml:S3:7682:2	of	IN	O	O
human	XEOMIN.xml:S3:7685:5	human	JJ	O	O
blood	XEOMIN.xml:S3:7691:5	blood	NN	O	O
.	XEOMIN.xml:S3:7696:1	.	.	O	O

Based	XEOMIN.xml:S3:7698:5	base	VBN	O	O
on	XEOMIN.xml:S3:7704:2	on	IN	O	O
effective	XEOMIN.xml:S3:7707:9	effect	JJ	O	O
donor	XEOMIN.xml:S3:7717:5	donor	NN	O	O
screening	XEOMIN.xml:S3:7723:9	screen	NN	O	O
and	XEOMIN.xml:S3:7733:3	and	CC	O	O
product	XEOMIN.xml:S3:7737:7	product	NN	O	O
manufacturing	XEOMIN.xml:S3:7745:13	manufactur	NN	O	O
processes	XEOMIN.xml:S3:7759:9	process	VBZ	O	O
,	XEOMIN.xml:S3:7768:1	,	,	O	O
it	XEOMIN.xml:S3:7770:2	it	PRP	O	O
carries	XEOMIN.xml:S3:7773:7	carri	VBZ	O	O
an	XEOMIN.xml:S3:7781:2	an	DT	O	O
extremely	XEOMIN.xml:S3:7784:9	extrem	RB	O	O
remote	XEOMIN.xml:S3:7794:6	remot	JJ	O	O
risk	XEOMIN.xml:S3:7801:4	risk	NN	O	O
for	XEOMIN.xml:S3:7806:3	for	IN	O	O
transmission	XEOMIN.xml:S3:7810:12	transmiss	NN	B-AdverseReaction	O
of	XEOMIN.xml:S3:7823:2	of	IN	I-AdverseReaction	O
viral	XEOMIN.xml:S3:7826:5	viral	JJ	I-AdverseReaction	B-AdverseReaction
diseases	XEOMIN.xml:S3:7832:8	diseas	NNS	I-AdverseReaction	I-AdverseReaction
.	XEOMIN.xml:S3:7840:1	.	.	O	O

A	XEOMIN.xml:S3:7842:1	A	DT	O	O
theoretical	XEOMIN.xml:S3:7844:11	theoret	JJ	O	O
risk	XEOMIN.xml:S3:7856:4	risk	NN	O	O
for	XEOMIN.xml:S3:7861:3	for	IN	O	O
transmission	XEOMIN.xml:S3:7865:12	transmiss	NN	O	O
of	XEOMIN.xml:S3:7878:2	of	IN	O	O
Creutzfeldt	XEOMIN.xml:S3:7881:11	creutzfeldt	NNP	B-AdverseReaction	B-AdverseReaction
-	XEOMIN.xml:S3:7892:1	-	:	I-AdverseReaction	I-AdverseReaction
Jakob	XEOMIN.xml:S3:7893:5	jakob	NNP	I-AdverseReaction	I-AdverseReaction
disease	XEOMIN.xml:S3:7899:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
(	XEOMIN.xml:S3:7907:1	(	(	O	O
CJD	XEOMIN.xml:S3:7908:3	cjd	NNP	B-AdverseReaction	B-AdverseReaction
)	XEOMIN.xml:S3:7911:1	)	)	O	O
is	XEOMIN.xml:S3:7913:2	is	VBZ	O	O
also	XEOMIN.xml:S3:7916:4	also	RB	O	O
considered	XEOMIN.xml:S3:7921:10	consid	VBN	O	O
extremely	XEOMIN.xml:S3:7932:9	extrem	RB	O	O
remote	XEOMIN.xml:S3:7942:6	remot	JJ	O	O
.	XEOMIN.xml:S3:7948:1	.	.	O	O

No	XEOMIN.xml:S3:7950:2	No	DT	O	O
cases	XEOMIN.xml:S3:7953:5	case	NNS	O	O
of	XEOMIN.xml:S3:7959:2	of	IN	O	O
transmission	XEOMIN.xml:S3:7962:12	transmiss	NN	O	O
of	XEOMIN.xml:S3:7975:2	of	IN	O	O
viral	XEOMIN.xml:S3:7978:5	viral	JJ	O	B-AdverseReaction
diseases	XEOMIN.xml:S3:7984:8	diseas	NNS	O	I-AdverseReaction
or	XEOMIN.xml:S3:7993:2	or	CC	O	O
CJD	XEOMIN.xml:S3:7996:3	cjd	NNP	O	B-AdverseReaction
have	XEOMIN.xml:S3:8000:4	have	VBP	O	O
ever	XEOMIN.xml:S3:8005:4	ever	RB	O	O
been	XEOMIN.xml:S3:8010:4	been	VBN	O	O
reported	XEOMIN.xml:S3:8015:8	report	VBN	O	O
for	XEOMIN.xml:S3:8024:3	for	IN	O	O
albumin	XEOMIN.xml:S3:8028:7	albumin	NN	O	O
.	XEOMIN.xml:S3:8035:1	.	.	O	O
6	XIAFLEX.xml:S1:4:1	6	CD	O	O
ADVERSE	XIAFLEX.xml:S1:6:7	advers	JJ	O	O
REACTIONS	XIAFLEX.xml:S1:14:9	reaction	NN	O	O

The	XIAFLEX.xml:S1:27:3	the	DT	O	O
following	XIAFLEX.xml:S1:31:9	follow	VBG	O	O
serious	XIAFLEX.xml:S1:41:7	seriou	JJ	O	O
adverse	XIAFLEX.xml:S1:49:7	advers	JJ	O	O
reactions	XIAFLEX.xml:S1:57:9	reaction	NNS	O	O
in	XIAFLEX.xml:S1:67:2	in	IN	O	O
patients	XIAFLEX.xml:S1:70:8	patient	NNS	O	O
with	XIAFLEX.xml:S1:79:4	with	IN	O	O
Dupuytren	XIAFLEX.xml:S1:84:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:93:2	's	POS	O	O
contracture	XIAFLEX.xml:S1:96:11	contractur	NN	O	O
are	XIAFLEX.xml:S1:108:3	are	VBP	O	O
discussed	XIAFLEX.xml:S1:112:9	discuss	VBN	O	O
in	XIAFLEX.xml:S1:122:2	in	IN	O	O
greater	XIAFLEX.xml:S1:125:7	greater	JJR	O	O
detail	XIAFLEX.xml:S1:133:6	detail	NN	O	O
elsewhere	XIAFLEX.xml:S1:140:9	elsewher	RB	O	O
in	XIAFLEX.xml:S1:150:2	in	IN	O	O
the	XIAFLEX.xml:S1:153:3	the	DT	O	O
labeling	XIAFLEX.xml:S1:157:8	label	NN	O	O
:	XIAFLEX.xml:S1:165:1	:	:	O	O

Tendon	XIAFLEX.xml:S1:174:6	tendon	NNP	B-AdverseReaction	O
ruptures	XIAFLEX.xml:S1:181:8	ruptur	NNS	I-AdverseReaction	O
or	XIAFLEX.xml:S1:190:2	or	CC	O	O
other	XIAFLEX.xml:S1:193:5	other	JJ	O	O
serious	XIAFLEX.xml:S1:199:7	seriou	JJ	O	O
injury	XIAFLEX.xml:S1:207:6	injuri	NN	B-AdverseReaction	O
to	XIAFLEX.xml:S1:214:2	to	TO	I-AdverseReaction	O
the	XIAFLEX.xml:S1:217:3	the	DT	I-AdverseReaction	O
injected	XIAFLEX.xml:S1:221:8	inject	JJ	I-AdverseReaction	O
extremity	XIAFLEX.xml:S1:230:9	extrem	NN	I-AdverseReaction	O
[	XIAFLEX.xml:S1:242:1	[	NNP	O	O
see	XIAFLEX.xml:S1:243:3	see	VBP	O	O
Warnings	XIAFLEX.xml:S1:247:8	warn	NNP	O	O
and	XIAFLEX.xml:S1:256:3	and	CC	O	O
Precautions	XIAFLEX.xml:S1:260:11	precaut	NNP	O	O
(	XIAFLEX.xml:S1:272:1	(	(	O	O
5.1	XIAFLEX.xml:S1:273:3	5.1	CD	O	O
)]	XIAFLEX.xml:S1:276:2	)]	NN	O	O

The	XIAFLEX.xml:S1:287:3	the	DT	O	O
following	XIAFLEX.xml:S1:291:9	follow	VBG	O	O
serious	XIAFLEX.xml:S1:301:7	seriou	JJ	O	O
adverse	XIAFLEX.xml:S1:309:7	advers	JJ	O	O
reactions	XIAFLEX.xml:S1:317:9	reaction	NNS	O	O
in	XIAFLEX.xml:S1:327:2	in	IN	O	O
patients	XIAFLEX.xml:S1:330:8	patient	NNS	O	O
with	XIAFLEX.xml:S1:339:4	with	IN	O	O
Peyronie	XIAFLEX.xml:S1:344:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:352:2	's	POS	O	O
disease	XIAFLEX.xml:S1:355:7	diseas	NN	O	O
are	XIAFLEX.xml:S1:363:3	are	VBP	O	O
discussed	XIAFLEX.xml:S1:367:9	discuss	VBN	O	O
in	XIAFLEX.xml:S1:377:2	in	IN	O	O
greater	XIAFLEX.xml:S1:380:7	greater	JJR	O	O
detail	XIAFLEX.xml:S1:388:6	detail	NN	O	O
elsewhere	XIAFLEX.xml:S1:395:9	elsewher	RB	O	O
in	XIAFLEX.xml:S1:405:2	in	IN	O	O
the	XIAFLEX.xml:S1:408:3	the	DT	O	O
labeling	XIAFLEX.xml:S1:412:8	label	NN	O	O
:	XIAFLEX.xml:S1:420:1	:	:	O	O

Corporal	XIAFLEX.xml:S1:429:8	corpor	JJ	B-AdverseReaction	O

rupture	XIAFLEX.xml:S1:438:7	ruptur	NN	I-AdverseReaction	O
(	XIAFLEX.xml:S1:446:1	(	(	O	O
penile	XIAFLEX.xml:S1:447:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
fracture	XIAFLEX.xml:S1:454:8	fractur	NN	I-AdverseReaction	I-AdverseReaction
)	XIAFLEX.xml:S1:462:1	)	)	O	O
and	XIAFLEX.xml:S1:464:3	and	CC	O	O
severe	XIAFLEX.xml:S1:468:6	sever	JJ	O	O
penile	XIAFLEX.xml:S1:475:6	penil	NN	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:482:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
[	XIAFLEX.xml:S1:493:1	[	NNP	O	O
see	XIAFLEX.xml:S1:494:3	see	VBP	O	O
Warnings	XIAFLEX.xml:S1:498:8	warn	NNP	O	O
and	XIAFLEX.xml:S1:507:3	and	CC	O	O
Precautions	XIAFLEX.xml:S1:511:11	precaut	NNP	O	O
(	XIAFLEX.xml:S1:523:1	(	(	O	O
5.2	XIAFLEX.xml:S1:524:3	5.2	CD	O	O
)]	XIAFLEX.xml:S1:527:2	)]	NN	O	O

In	XIAFLEX.xml:S1:538:2	In	IN	O	O
other	XIAFLEX.xml:S1:541:5	other	JJ	O	O
XIAFLEX	XIAFLEX.xml:S1:547:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:554:1	-	:	O	O
treated	XIAFLEX.xml:S1:555:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:563:8	patient	NNS	O	O
,	XIAFLEX.xml:S1:571:1	,	,	O	O
a	XIAFLEX.xml:S1:573:1	a	DT	O	O
combination	XIAFLEX.xml:S1:575:11	combin	NN	O	O
of	XIAFLEX.xml:S1:587:2	of	IN	O	O
penile	XIAFLEX.xml:S1:590:6	penil	JJ	B-AdverseReaction	O
ecchymoses	XIAFLEX.xml:S1:597:10	ecchymos	NNS	I-AdverseReaction	O
or	XIAFLEX.xml:S1:608:2	or	CC	O	O
hematoma	XIAFLEX.xml:S1:611:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:619:1	,	,	O	O
sudden	XIAFLEX.xml:S1:621:6	sudden	JJ	O	B-AdverseReaction
penile	XIAFLEX.xml:S1:628:6	penil	NN	B-AdverseReaction	I-AdverseReaction
detumescence	XIAFLEX.xml:S1:635:12	detumesc	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:647:1	,	,	O	O
and	XIAFLEX.xml:S1:649:3	and	CC	O	O
or	XIAFLEX.xml:S1:653:2	or	CC	O	O
a	XIAFLEX.xml:S1:656:1	a	DT	O	O
penile	XIAFLEX.xml:S1:658:6	penil	JJ	B-AdverseReaction	O
"	XIAFLEX.xml:S1:665:1	"	NN	I-AdverseReaction	O
popping	XIAFLEX.xml:S1:666:7	pop	VBG	I-AdverseReaction	O
"	XIAFLEX.xml:S1:673:1	"	JJ	I-AdverseReaction	O
sound	XIAFLEX.xml:S1:675:5	sound	NN	I-AdverseReaction	O
or	XIAFLEX.xml:S1:681:2	or	CC	O	O
sensation	XIAFLEX.xml:S1:684:9	sensat	NN	I-AdverseReaction	B-AdverseReaction
was	XIAFLEX.xml:S1:694:3	wa	VBD	O	O
reported	XIAFLEX.xml:S1:698:8	report	VBN	O	O
,	XIAFLEX.xml:S1:706:1	,	,	O	O
and	XIAFLEX.xml:S1:708:3	and	CC	O	O
in	XIAFLEX.xml:S1:712:2	in	IN	O	O
these	XIAFLEX.xml:S1:715:5	these	DT	O	O
cases	XIAFLEX.xml:S1:721:5	case	NNS	O	O
,	XIAFLEX.xml:S1:726:1	,	,	O	O
a	XIAFLEX.xml:S1:728:1	a	DT	O	O
diagnosis	XIAFLEX.xml:S1:730:9	diagnosi	NN	O	O
of	XIAFLEX.xml:S1:740:2	of	IN	O	O
corporal	XIAFLEX.xml:S1:743:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S1:752:7	ruptur	NN	I-AdverseReaction	O
cannot	XIAFLEX.xml:S1:760:6	cannot	NN	O	O
be	XIAFLEX.xml:S1:767:2	be	VB	O	O
excluded	XIAFLEX.xml:S1:770:8	exclud	VBN	O	O
[	XIAFLEX.xml:S1:781:1	[	NNP	O	O
see	XIAFLEX.xml:S1:782:3	see	VBP	O	O
Warnings	XIAFLEX.xml:S1:786:8	warn	NNP	O	O
and	XIAFLEX.xml:S1:795:3	and	CC	O	O
Precautions	XIAFLEX.xml:S1:799:11	precaut	NNP	O	O
(	XIAFLEX.xml:S1:811:1	(	(	O	O
5.2	XIAFLEX.xml:S1:812:3	5.2	CD	O	O
)]	XIAFLEX.xml:S1:815:2	)]	NN	O	O

EXCERPT	XIAFLEX.xml:S1:828:7	excerpt	NN	O	O
:	XIAFLEX.xml:S1:835:1	:	:	O	O
Dupuytren	XIAFLEX.xml:S1:841:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:850:2	's	POS	O	O
Contracture	XIAFLEX.xml:S1:853:11	contractur	NNP	O	O
(	XIAFLEX.xml:S1:865:1	(	(	O	O
6.1	XIAFLEX.xml:S1:868:3	6.1	CD	O	O
)	XIAFLEX.xml:S1:873:1	)	)	O	O

The	XIAFLEX.xml:S1:881:3	the	DT	O	O

most	XIAFLEX.xml:S1:885:4	most	RBS	O	O
common	XIAFLEX.xml:S1:890:6	common	JJ	O	O
adverse	XIAFLEX.xml:S1:897:7	advers	JJ	O	O
reactions	XIAFLEX.xml:S1:905:9	reaction	NNS	O	O
reported	XIAFLEX.xml:S1:915:8	report	VBN	O	O
in	XIAFLEX.xml:S1:924:2	in	IN	O	O
25%	XIAFLEX.xml:S1:930:3	25%	CD	O	O
of	XIAFLEX.xml:S1:934:2	of	IN	O	O
patients	XIAFLEX.xml:S1:937:8	patient	NNS	O	O
treated	XIAFLEX.xml:S1:946:7	treat	VBN	O	O
with	XIAFLEX.xml:S1:954:4	with	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:959:7	xiaflex	NNP	O	O
and	XIAFLEX.xml:S1:967:3	and	CC	O	O
at	XIAFLEX.xml:S1:971:2	at	IN	O	O
an	XIAFLEX.xml:S1:974:2	an	DT	O	O
incidence	XIAFLEX.xml:S1:977:9	incid	NN	O	O
greater	XIAFLEX.xml:S1:987:7	greater	JJR	O	O
than	XIAFLEX.xml:S1:995:4	than	IN	O	O
placebo	XIAFLEX.xml:S1:1000:7	placebo	NN	O	O
were	XIAFLEX.xml:S1:1008:4	were	VBD	O	O
edema	XIAFLEX.xml:S1:1013:5	edema	JJ	B-AdverseReaction	B-AdverseReaction
peripheral	XIAFLEX.xml:S1:1019:10	peripher	JJ	I-AdverseReaction	I-AdverseReaction
(	XIAFLEX.xml:S1:1030:1	(	(	O	O
e	XIAFLEX.xml:S1:1031:1	e	NN	O	O
.	XIAFLEX.xml:S1:1032:1	.	.	O	O
g	XIAFLEX.xml:S1:1033:1	g	NN	O	O
.	XIAFLEX.xml:S1:1034:1	.	.	O	O
,	XIAFLEX.xml:S1:1035:1	,	,	O	O
swelling	XIAFLEX.xml:S1:1037:8	swell	VBG	B-AdverseReaction	O
of	XIAFLEX.xml:S1:1046:2	of	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S1:1049:3	the	DT	I-AdverseReaction	O
injected	XIAFLEX.xml:S1:1053:8	inject	JJ	I-AdverseReaction	O
hand	XIAFLEX.xml:S1:1062:4	hand	NN	I-AdverseReaction	O
)	XIAFLEX.xml:S1:1066:1	)	)	O	O
,	XIAFLEX.xml:S1:1067:1	,	,	O	O
contusion	XIAFLEX.xml:S1:1069:9	contus	NN	B-AdverseReaction	B-AdverseReaction
,	XIAFLEX.xml:S1:1078:1	,	,	O	O
injection	XIAFLEX.xml:S1:1080:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:1090:4	site	NN	I-AdverseReaction	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:1095:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:1105:1	,	,	O	O
injection	XIAFLEX.xml:S1:1107:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:1117:4	site	NN	I-AdverseReaction	I-AdverseReaction
reaction	XIAFLEX.xml:S1:1122:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:1130:1	,	,	O	O
and	XIAFLEX.xml:S1:1132:3	and	CC	O	O
pain	XIAFLEX.xml:S1:1136:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	XIAFLEX.xml:S1:1141:2	in	IN	I-AdverseReaction	I-AdverseReaction
the	XIAFLEX.xml:S1:1144:3	the	DT	I-AdverseReaction	I-AdverseReaction
injected	XIAFLEX.xml:S1:1148:8	inject	JJ	I-AdverseReaction	I-AdverseReaction
extremity	XIAFLEX.xml:S1:1157:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
.	XIAFLEX.xml:S1:1166:1	.	.	O	O

Peyronie	XIAFLEX.xml:S1:1174:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:1182:2	's	POS	O	O
Disease	XIAFLEX.xml:S1:1185:7	diseas	NNP	O	O
(	XIAFLEX.xml:S1:1193:1	(	(	O	O
6.2	XIAFLEX.xml:S1:1196:3	6.2	CD	O	O
)	XIAFLEX.xml:S1:1201:1	)	)	O	O

The	XIAFLEX.xml:S1:1209:3	the	DT	O	O
most	XIAFLEX.xml:S1:1213:4	most	RBS	O	O
frequently	XIAFLEX.xml:S1:1218:10	frequent	RB	O	O
reported	XIAFLEX.xml:S1:1229:8	report	VBD	O	O
adverse	XIAFLEX.xml:S1:1238:7	advers	JJ	O	O
drug	XIAFLEX.xml:S1:1246:4	drug	NN	O	O
reactions	XIAFLEX.xml:S1:1251:9	reaction	NNS	O	O
reported	XIAFLEX.xml:S1:1261:8	report	VBD	O	O
with	XIAFLEX.xml:S1:1270:4	with	IN	O	O
25%	XIAFLEX.xml:S1:1278:3	25%	CD	O	O
of	XIAFLEX.xml:S1:1282:2	of	IN	O	O
patients	XIAFLEX.xml:S1:1285:8	patient	NNS	O	O
treated	XIAFLEX.xml:S1:1294:7	treat	VBN	O	O
with	XIAFLEX.xml:S1:1302:4	with	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:1307:7	xiaflex	NNP	O	O
and	XIAFLEX.xml:S1:1315:3	and	CC	O	O
at	XIAFLEX.xml:S1:1319:2	at	IN	O	O
an	XIAFLEX.xml:S1:1322:2	an	DT	O	O
incidence	XIAFLEX.xml:S1:1325:9	incid	NN	O	O
greater	XIAFLEX.xml:S1:1335:7	greater	JJR	O	O
than	XIAFLEX.xml:S1:1343:4	than	IN	O	O
placebo	XIAFLEX.xml:S1:1348:7	placebo	NN	O	O
were	XIAFLEX.xml:S1:1356:4	were	VBD	O	O
penile	XIAFLEX.xml:S1:1361:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:1368:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:1376:1	,	,	O	O
penile	XIAFLEX.xml:S1:1378:6	penil	IN	B-AdverseReaction	I-AdverseReaction
swelling	XIAFLEX.xml:S1:1385:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
and	XIAFLEX.xml:S1:1394:3	and	CC	O	O
penile	XIAFLEX.xml:S1:1398:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
pain	XIAFLEX.xml:S1:1405:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	XIAFLEX.xml:S1:1409:1	.	.	O	O

To	XIAFLEX.xml:S1:1417:2	To	TO	O	O
report	XIAFLEX.xml:S1:1420:6	report	VB	O	O
SUSPECTED	XIAFLEX.xml:S1:1427:9	suspect	NNP	O	O
ADVERSE	XIAFLEX.xml:S1:1437:7	advers	NNP	O	O
REACTIONS	XIAFLEX.xml:S1:1445:9	reaction	NNP	O	O
,	XIAFLEX.xml:S1:1454:1	,	,	O	O
contact	XIAFLEX.xml:S1:1456:7	contact	NN	O	O
Auxilium	XIAFLEX.xml:S1:1464:8	auxilium	NNP	O	O
Pharmaceuticals	XIAFLEX.xml:S1:1473:15	pharmaceut	NNP	O	O
,	XIAFLEX.xml:S1:1488:1	,	,	O	O
Inc	XIAFLEX.xml:S1:1490:3	inc	NNP	O	O
.	XIAFLEX.xml:S1:1493:1	.	.	O	O

at	XIAFLEX.xml:S1:1495:2	at	IN	O	O
1	XIAFLEX.xml:S1:1498:1	1	CD	O	O
-	XIAFLEX.xml:S1:1499:1	-	:	O	O
877	XIAFLEX.xml:S1:1500:3	877	CD	O	O
-	XIAFLEX.xml:S1:1503:1	-	:	O	O
663	XIAFLEX.xml:S1:1504:3	663	CD	O	O
-	XIAFLEX.xml:S1:1507:1	-	:	O	O
0412	XIAFLEX.xml:S1:1508:4	0412	CD	O	O
or	XIAFLEX.xml:S1:1513:2	or	CC	O	O
FDA	XIAFLEX.xml:S1:1516:3	fda	NNP	O	O
at	XIAFLEX.xml:S1:1520:2	at	IN	O	O
1	XIAFLEX.xml:S1:1523:1	1	CD	O	O
-	XIAFLEX.xml:S1:1524:1	-	:	O	O
800	XIAFLEX.xml:S1:1525:3	800	CD	O	O
-	XIAFLEX.xml:S1:1528:1	-	:	O	O
FDA	XIAFLEX.xml:S1:1529:3	fda	NNP	O	O
-	XIAFLEX.xml:S1:1532:1	-	:	O	O
1088	XIAFLEX.xml:S1:1533:4	1088	CD	O	O
or	XIAFLEX.xml:S1:1538:2	or	CC	O	O
www	XIAFLEX.xml:S1:1542:3	www	VB	O	O
.	XIAFLEX.xml:S1:1545:1	.	.	O	O
fda	XIAFLEX.xml:S1:1546:3	fda	NN	O	O
.	XIAFLEX.xml:S1:1549:1	.	.	O	O
gov	XIAFLEX.xml:S1:1550:3	gov	JJ	O	O
medwatch	XIAFLEX.xml:S1:1554:8	medwatch	NN	O	O
.	XIAFLEX.xml:S1:1562:1	.	.	O	O

6.1	XIAFLEX.xml:S1:1576:3	6.1	CD	O	O

Clinical	XIAFLEX.xml:S1:1580:8	clinic	JJ	O	O
Studies	XIAFLEX.xml:S1:1589:7	studi	NNS	O	O
Experience	XIAFLEX.xml:S1:1597:10	experi	NNP	O	O
in	XIAFLEX.xml:S1:1608:2	in	IN	O	O
Patients	XIAFLEX.xml:S1:1611:8	patient	NNP	O	O
with	XIAFLEX.xml:S1:1620:4	with	IN	O	O
Dupuytren	XIAFLEX.xml:S1:1625:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:1634:2	's	POS	O	O
Contracture	XIAFLEX.xml:S1:1637:11	contractur	NN	O	O

Because	XIAFLEX.xml:S1:1652:7	becaus	IN	O	O
clinical	XIAFLEX.xml:S1:1660:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:1669:7	studi	NNS	O	O
are	XIAFLEX.xml:S1:1677:3	are	VBP	O	O
conducted	XIAFLEX.xml:S1:1681:9	conduct	VBN	O	O
under	XIAFLEX.xml:S1:1691:5	under	IN	O	O
widely	XIAFLEX.xml:S1:1697:6	wide	RB	O	O
varying	XIAFLEX.xml:S1:1704:7	vari	VBG	O	O
conditions	XIAFLEX.xml:S1:1712:10	condit	NNS	O	O
,	XIAFLEX.xml:S1:1722:1	,	,	O	O
adverse	XIAFLEX.xml:S1:1724:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:1732:8	reaction	NN	O	O
rates	XIAFLEX.xml:S1:1741:5	rate	NNS	O	O
observed	XIAFLEX.xml:S1:1747:8	observ	VBD	O	O
in	XIAFLEX.xml:S1:1756:2	in	IN	O	O
the	XIAFLEX.xml:S1:1759:3	the	DT	O	O
clinical	XIAFLEX.xml:S1:1763:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:1772:7	studi	NNS	O	O
of	XIAFLEX.xml:S1:1780:2	of	IN	O	O
a	XIAFLEX.xml:S1:1783:1	a	DT	O	O
drug	XIAFLEX.xml:S1:1785:4	drug	NN	O	O
cannot	XIAFLEX.xml:S1:1790:6	cannot	NN	O	O
be	XIAFLEX.xml:S1:1797:2	be	VB	O	O
directly	XIAFLEX.xml:S1:1800:8	directli	RB	O	O
compared	XIAFLEX.xml:S1:1809:8	compar	VBN	O	O
to	XIAFLEX.xml:S1:1818:2	to	TO	O	O
rates	XIAFLEX.xml:S1:1821:5	rate	NNS	O	O
in	XIAFLEX.xml:S1:1827:2	in	IN	O	O
the	XIAFLEX.xml:S1:1830:3	the	DT	O	O
clinical	XIAFLEX.xml:S1:1834:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:1843:7	studi	NNS	O	O
of	XIAFLEX.xml:S1:1851:2	of	IN	O	O
another	XIAFLEX.xml:S1:1854:7	anoth	DT	O	O
drug	XIAFLEX.xml:S1:1862:4	drug	NN	O	O
and	XIAFLEX.xml:S1:1867:3	and	CC	O	O
may	XIAFLEX.xml:S1:1871:3	may	MD	O	O
not	XIAFLEX.xml:S1:1875:3	not	RB	O	O
reflect	XIAFLEX.xml:S1:1879:7	reflect	VB	O	O
the	XIAFLEX.xml:S1:1887:3	the	DT	O	O
rates	XIAFLEX.xml:S1:1891:5	rate	NNS	O	O
observed	XIAFLEX.xml:S1:1897:8	observ	VBD	O	O
in	XIAFLEX.xml:S1:1906:2	in	IN	O	O
practice	XIAFLEX.xml:S1:1909:8	practic	NN	O	O
.	XIAFLEX.xml:S1:1917:1	.	.	O	O

Out	XIAFLEX.xml:S1:1923:3	out	IN	O	O
of	XIAFLEX.xml:S1:1927:2	of	IN	O	O
1082	XIAFLEX.xml:S1:1930:4	1082	CD	O	O
patients	XIAFLEX.xml:S1:1935:8	patient	NNS	O	O
who	XIAFLEX.xml:S1:1944:3	who	WP	O	O
received	XIAFLEX.xml:S1:1948:8	receiv	VBD	O	O
0.58	XIAFLEX.xml:S1:1957:4	0.58	CD	O	O
mg	XIAFLEX.xml:S1:1962:2	mg	NN	O	O
of	XIAFLEX.xml:S1:1965:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:1968:7	xiaflex	NNP	O	O
in	XIAFLEX.xml:S1:1976:2	in	IN	O	O
the	XIAFLEX.xml:S1:1979:3	the	DT	O	O
controlled	XIAFLEX.xml:S1:1983:10	control	VBN	O	O
and	XIAFLEX.xml:S1:1994:3	and	CC	O	O
uncontrolled	XIAFLEX.xml:S1:1998:12	uncontrol	JJ	O	O
portions	XIAFLEX.xml:S1:2011:8	portion	NNS	O	O
of	XIAFLEX.xml:S1:2020:2	of	IN	O	O
the	XIAFLEX.xml:S1:2023:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S1:2027:7	xiaflex	NNP	O	O
studies	XIAFLEX.xml:S1:2035:7	studi	NNS	O	O
(	XIAFLEX.xml:S1:2043:1	(	(	O	O
2630	XIAFLEX.xml:S1:2044:4	2630	CD	O	O
XIAFLEX	XIAFLEX.xml:S1:2049:7	xiaflex	NNP	O	O
injections	XIAFLEX.xml:S1:2057:10	inject	NNS	O	O
)	XIAFLEX.xml:S1:2067:1	)	)	O	O
,	XIAFLEX.xml:S1:2068:1	,	,	O	O
3	XIAFLEX.xml:S1:2070:1	3	CD	O	O
(	XIAFLEX.xml:S1:2072:1	(	(	O	O
0.3%	XIAFLEX.xml:S1:2073:4	0.3%	CD	O	O
)	XIAFLEX.xml:S1:2077:1	)	)	O	O
patients	XIAFLEX.xml:S1:2079:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:2088:3	had	VBD	O	O
a	XIAFLEX.xml:S1:2092:1	a	DT	O	O
flexor	XIAFLEX.xml:S1:2094:6	flexor	JJ	B-AdverseReaction	O
tendon	XIAFLEX.xml:S1:2101:6	tendon	JJ	I-AdverseReaction	O
rupture	XIAFLEX.xml:S1:2108:7	ruptur	NN	I-AdverseReaction	O
of	XIAFLEX.xml:S1:2116:2	of	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S1:2119:3	the	DT	I-AdverseReaction	O
treated	XIAFLEX.xml:S1:2123:7	treat	JJ	O	O
finger	XIAFLEX.xml:S1:2131:6	finger	NN	I-AdverseReaction	O
within	XIAFLEX.xml:S1:2138:6	within	IN	O	O
7	XIAFLEX.xml:S1:2145:1	7	CD	O	O
days	XIAFLEX.xml:S1:2147:4	day	NNS	O	O
of	XIAFLEX.xml:S1:2152:2	of	IN	O	O
the	XIAFLEX.xml:S1:2155:3	the	DT	O	O
injection	XIAFLEX.xml:S1:2159:9	inject	NN	O	O
.	XIAFLEX.xml:S1:2168:1	.	.	O	O

The	XIAFLEX.xml:S1:2174:3	the	DT	O	O
data	XIAFLEX.xml:S1:2178:4	data	NNS	O	O
described	XIAFLEX.xml:S1:2183:9	describ	VBN	O	O
below	XIAFLEX.xml:S1:2193:5	below	IN	O	O
are	XIAFLEX.xml:S1:2199:3	are	VBP	O	O
based	XIAFLEX.xml:S1:2203:5	base	VBN	O	O
on	XIAFLEX.xml:S1:2209:2	on	IN	O	O
two	XIAFLEX.xml:S1:2212:3	two	CD	O	O
pooled	XIAFLEX.xml:S1:2216:6	pool	JJ	O	O
randomized	XIAFLEX.xml:S1:2223:10	random	VBN	O	O
,	XIAFLEX.xml:S1:2233:1	,	,	O	O
double	XIAFLEX.xml:S1:2235:6	doubl	JJ	O	O
-	XIAFLEX.xml:S1:2241:1	-	:	O	O
blind	XIAFLEX.xml:S1:2242:5	blind	NN	O	O
,	XIAFLEX.xml:S1:2247:1	,	,	O	O
placebo	XIAFLEX.xml:S1:2249:7	placebo	SYM	O	O
-	XIAFLEX.xml:S1:2256:1	-	:	O	O
controlled	XIAFLEX.xml:S1:2257:10	control	VBN	O	O
trials	XIAFLEX.xml:S1:2268:6	trial	NNS	O	O
through	XIAFLEX.xml:S1:2275:7	through	IN	O	O
Day	XIAFLEX.xml:S1:2283:3	day	NNP	O	O
90	XIAFLEX.xml:S1:2287:2	90	CD	O	O
in	XIAFLEX.xml:S1:2290:2	in	IN	O	O
patients	XIAFLEX.xml:S1:2293:8	patient	NNS	O	O
with	XIAFLEX.xml:S1:2302:4	with	IN	O	O
Dupuytren	XIAFLEX.xml:S1:2307:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:2316:2	's	POS	O	O
contracture	XIAFLEX.xml:S1:2319:11	contractur	NN	O	O
(	XIAFLEX.xml:S1:2331:1	(	(	O	O
Studies	XIAFLEX.xml:S1:2332:7	studi	NNPS	O	O
1	XIAFLEX.xml:S1:2340:1	1	CD	O	O
and	XIAFLEX.xml:S1:2342:3	and	CC	O	O
2	XIAFLEX.xml:S1:2346:1	2	CD	O	O
)	XIAFLEX.xml:S1:2347:1	)	)	O	O
.	XIAFLEX.xml:S1:2348:1	.	.	O	O

In	XIAFLEX.xml:S1:2350:2	In	IN	O	O
these	XIAFLEX.xml:S1:2353:5	these	DT	O	O
trials	XIAFLEX.xml:S1:2359:6	trial	NNS	O	O
,	XIAFLEX.xml:S1:2365:1	,	,	O	O
patients	XIAFLEX.xml:S1:2367:8	patient	NNS	O	O
were	XIAFLEX.xml:S1:2376:4	were	VBD	O	O
treated	XIAFLEX.xml:S1:2381:7	treat	VBN	O	O
with	XIAFLEX.xml:S1:2389:4	with	IN	O	O
up	XIAFLEX.xml:S1:2394:2	up	IN	O	O
to	XIAFLEX.xml:S1:2397:2	to	TO	O	O
3	XIAFLEX.xml:S1:2400:1	3	CD	O	O
injections	XIAFLEX.xml:S1:2402:10	inject	NNS	O	O
of	XIAFLEX.xml:S1:2413:2	of	IN	O	O
0.58	XIAFLEX.xml:S1:2416:4	0.58	CD	O	O
mg	XIAFLEX.xml:S1:2421:2	mg	NN	O	O
of	XIAFLEX.xml:S1:2424:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:2427:7	xiaflex	NNP	O	O
or	XIAFLEX.xml:S1:2435:2	or	CC	O	O
placebo	XIAFLEX.xml:S1:2438:7	placebo	NN	O	O
with	XIAFLEX.xml:S1:2446:4	with	IN	O	O
approximately	XIAFLEX.xml:S1:2451:13	approxim	RB	O	O
4	XIAFLEX.xml:S1:2465:1	4	CD	O	O
-	XIAFLEX.xml:S1:2466:1	-	:	O	O
week	XIAFLEX.xml:S1:2467:4	week	NN	O	O
intervals	XIAFLEX.xml:S1:2472:9	interv	NNS	O	O
between	XIAFLEX.xml:S1:2482:7	between	IN	O	O
injections	XIAFLEX.xml:S1:2490:10	inject	NNS	O	O
and	XIAFLEX.xml:S1:2501:3	and	CC	O	O
the	XIAFLEX.xml:S1:2505:3	the	DT	O	O
patients	XIAFLEX.xml:S1:2509:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:2518:3	had	VBD	O	O
finger	XIAFLEX.xml:S1:2522:6	finger	VBN	O	O
extension	XIAFLEX.xml:S1:2529:9	extens	NN	O	O
procedures	XIAFLEX.xml:S1:2539:10	procedur	VBZ	O	O
the	XIAFLEX.xml:S1:2550:3	the	DT	O	O
day	XIAFLEX.xml:S1:2554:3	day	NN	O	O
after	XIAFLEX.xml:S1:2558:5	after	IN	O	O
injection	XIAFLEX.xml:S1:2564:9	inject	NN	O	O
,	XIAFLEX.xml:S1:2573:1	,	,	O	O
if	XIAFLEX.xml:S1:2575:2	if	IN	O	O
needed	XIAFLEX.xml:S1:2578:6	need	VBN	O	O
,	XIAFLEX.xml:S1:2584:1	,	,	O	O
to	XIAFLEX.xml:S1:2586:2	to	TO	O	O
facilitate	XIAFLEX.xml:S1:2589:10	facilit	VB	O	O
disruption	XIAFLEX.xml:S1:2600:10	disrupt	NN	O	O
of	XIAFLEX.xml:S1:2611:2	of	IN	O	O
the	XIAFLEX.xml:S1:2614:3	the	DT	O	O
cord	XIAFLEX.xml:S1:2618:4	cord	NN	O	O
[	XIAFLEX.xml:S1:2626:1	[	NNP	O	O
see	XIAFLEX.xml:S1:2627:3	see	VBP	O	O
Clinical	XIAFLEX.xml:S1:2631:8	clinic	JJ	O	O
Studies	XIAFLEX.xml:S1:2640:7	studi	NNP	O	O
(	XIAFLEX.xml:S1:2648:1	(	(	O	O
14	XIAFLEX.xml:S1:2649:2	14	CD	O	O
)]	XIAFLEX.xml:S1:2651:2	)]	NN	O	O
.	XIAFLEX.xml:S1:2657:1	.	.	O	O

These	XIAFLEX.xml:S1:2659:5	these	DT	O	O
trials	XIAFLEX.xml:S1:2665:6	trial	NNS	O	O
were	XIAFLEX.xml:S1:2672:4	were	VBD	O	O
comprised	XIAFLEX.xml:S1:2677:9	compris	VBN	O	O
of	XIAFLEX.xml:S1:2687:2	of	IN	O	O
374	XIAFLEX.xml:S1:2690:3	374	CD	O	O
patients	XIAFLEX.xml:S1:2694:8	patient	NNS	O	O
of	XIAFLEX.xml:S1:2703:2	of	IN	O	O
whom	XIAFLEX.xml:S1:2706:4	whom	WP	O	O
249	XIAFLEX.xml:S1:2711:3	249	CD	O	O
and	XIAFLEX.xml:S1:2715:3	and	CC	O	O
125	XIAFLEX.xml:S1:2719:3	125	CD	O	O
received	XIAFLEX.xml:S1:2723:8	receiv	VBD	O	O
0.58	XIAFLEX.xml:S1:2732:4	0.58	CD	O	O
mg	XIAFLEX.xml:S1:2737:2	mg	NN	O	O
of	XIAFLEX.xml:S1:2740:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:2743:7	xiaflex	NNP	O	O
and	XIAFLEX.xml:S1:2751:3	and	CC	O	O
placebo	XIAFLEX.xml:S1:2755:7	placebo	NN	O	O
,	XIAFLEX.xml:S1:2762:1	,	,	O	O
respectively	XIAFLEX.xml:S1:2764:12	respect	RB	O	O
.	XIAFLEX.xml:S1:2776:1	.	.	O	O

The	XIAFLEX.xml:S1:2778:3	the	DT	O	O
mean	XIAFLEX.xml:S1:2782:4	mean	JJ	O	O
age	XIAFLEX.xml:S1:2787:3	age	NN	O	O
was	XIAFLEX.xml:S1:2791:3	wa	VBD	O	O
63	XIAFLEX.xml:S1:2795:2	63	CD	O	O
years	XIAFLEX.xml:S1:2798:5	year	NNS	O	O
,	XIAFLEX.xml:S1:2803:1	,	,	O	O
80%	XIAFLEX.xml:S1:2805:3	80%	CD	O	O
were	XIAFLEX.xml:S1:2809:4	were	VBD	O	O
male	XIAFLEX.xml:S1:2814:4	male	JJ	O	O
and	XIAFLEX.xml:S1:2819:3	and	CC	O	O
20%	XIAFLEX.xml:S1:2823:3	20%	CD	O	O
were	XIAFLEX.xml:S1:2827:4	were	VBD	O	O
female	XIAFLEX.xml:S1:2832:6	femal	JJ	O	O
,	XIAFLEX.xml:S1:2838:1	,	,	O	O
and	XIAFLEX.xml:S1:2840:3	and	CC	O	O
100%	XIAFLEX.xml:S1:2844:4	100%	CD	O	O
were	XIAFLEX.xml:S1:2849:4	were	VBD	O	O
white	XIAFLEX.xml:S1:2854:5	white	JJ	O	O
.	XIAFLEX.xml:S1:2859:1	.	.	O	O

In	XIAFLEX.xml:S1:2865:2	In	IN	O	O
the	XIAFLEX.xml:S1:2868:3	the	DT	O	O
placebo	XIAFLEX.xml:S1:2872:7	placebo	NN	O	O
-	XIAFLEX.xml:S1:2879:1	-	:	O	O
controlled	XIAFLEX.xml:S1:2880:10	control	JJ	O	O
portions	XIAFLEX.xml:S1:2891:8	portion	NNS	O	O
of	XIAFLEX.xml:S1:2900:2	of	IN	O	O
Studies	XIAFLEX.xml:S1:2903:7	studi	NNS	O	O
1	XIAFLEX.xml:S1:2911:1	1	CD	O	O
and	XIAFLEX.xml:S1:2913:3	and	CC	O	O
2	XIAFLEX.xml:S1:2917:1	2	CD	O	O
through	XIAFLEX.xml:S1:2919:7	through	IN	O	O
Day	XIAFLEX.xml:S1:2927:3	day	NNP	O	O
90	XIAFLEX.xml:S1:2931:2	90	CD	O	O
,	XIAFLEX.xml:S1:2933:1	,	,	O	O
98%	XIAFLEX.xml:S1:2935:3	98%	CD	O	O
and	XIAFLEX.xml:S1:2939:3	and	CC	O	O
51%	XIAFLEX.xml:S1:2943:3	51%	CD	O	O
of	XIAFLEX.xml:S1:2947:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:2950:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:2957:1	-	:	O	O
treated	XIAFLEX.xml:S1:2958:7	treat	VBD	O	O
and	XIAFLEX.xml:S1:2966:3	and	CC	O	O
placebo	XIAFLEX.xml:S1:2970:7	placebo	SYM	O	O
-	XIAFLEX.xml:S1:2977:1	-	:	O	O
treated	XIAFLEX.xml:S1:2978:7	treat	JJ	O	O
patients	XIAFLEX.xml:S1:2986:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:2995:3	had	VBD	O	O
an	XIAFLEX.xml:S1:2999:2	an	DT	O	O
adverse	XIAFLEX.xml:S1:3002:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:3010:8	reaction	NN	O	O
after	XIAFLEX.xml:S1:3019:5	after	IN	O	O
up	XIAFLEX.xml:S1:3025:2	up	IN	O	O
to	XIAFLEX.xml:S1:3028:2	to	TO	O	O
3	XIAFLEX.xml:S1:3031:1	3	CD	O	O
injections	XIAFLEX.xml:S1:3033:10	inject	NNS	O	O
,	XIAFLEX.xml:S1:3043:1	,	,	O	O
respectively	XIAFLEX.xml:S1:3045:12	respect	RB	O	O
.	XIAFLEX.xml:S1:3057:1	.	.	O	O

Over	XIAFLEX.xml:S1:3059:4	over	IN	O	O
95%	XIAFLEX.xml:S1:3064:3	95%	CD	O	O
of	XIAFLEX.xml:S1:3068:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:3071:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:3078:1	-	:	O	O
treated	XIAFLEX.xml:S1:3079:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:3087:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:3096:3	had	VBD	O	O
an	XIAFLEX.xml:S1:3100:2	an	DT	O	O
adverse	XIAFLEX.xml:S1:3103:7	advers	JJ	B-AdverseReaction	O
reaction	XIAFLEX.xml:S1:3111:8	reaction	NN	I-AdverseReaction	O
of	XIAFLEX.xml:S1:3120:2	of	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S1:3123:3	the	DT	I-AdverseReaction	O
injected	XIAFLEX.xml:S1:3127:8	inject	JJ	I-AdverseReaction	O
extremity	XIAFLEX.xml:S1:3136:9	extrem	NN	I-AdverseReaction	O
after	XIAFLEX.xml:S1:3146:5	after	IN	O	O
up	XIAFLEX.xml:S1:3152:2	up	IN	O	O
to	XIAFLEX.xml:S1:3155:2	to	TO	O	O
3	XIAFLEX.xml:S1:3158:1	3	CD	O	O
injections	XIAFLEX.xml:S1:3160:10	inject	NNS	O	O
.	XIAFLEX.xml:S1:3170:1	.	.	O	O

Approximately	XIAFLEX.xml:S1:3172:13	approxim	RB	O	O
81%	XIAFLEX.xml:S1:3186:3	81%	CD	O	O
of	XIAFLEX.xml:S1:3190:2	of	IN	O	O
these	XIAFLEX.xml:S1:3193:5	these	DT	O	O
local	XIAFLEX.xml:S1:3199:5	local	JJ	O	O
reactions	XIAFLEX.xml:S1:3205:9	reaction	NNS	O	O
resolved	XIAFLEX.xml:S1:3215:8	resolv	VBD	O	O
without	XIAFLEX.xml:S1:3224:7	without	IN	O	O
intervention	XIAFLEX.xml:S1:3232:12	intervent	NN	O	O
within	XIAFLEX.xml:S1:3245:6	within	IN	O	O
4	XIAFLEX.xml:S1:3252:1	4	CD	O	O
weeks	XIAFLEX.xml:S1:3254:5	week	NNS	O	O
of	XIAFLEX.xml:S1:3260:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:3263:7	xiaflex	NNP	O	O
injections	XIAFLEX.xml:S1:3271:10	inject	NNS	O	O
.	XIAFLEX.xml:S1:3281:1	.	.	O	O

The	XIAFLEX.xml:S1:3283:3	the	DT	O	O
adverse	XIAFLEX.xml:S1:3287:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:3295:8	reaction	NN	O	O
profile	XIAFLEX.xml:S1:3304:7	profil	NN	O	O
was	XIAFLEX.xml:S1:3312:3	wa	VBD	O	O
similar	XIAFLEX.xml:S1:3316:7	similar	JJ	O	O
for	XIAFLEX.xml:S1:3324:3	for	IN	O	O
each	XIAFLEX.xml:S1:3328:4	each	DT	O	O
injection	XIAFLEX.xml:S1:3333:9	inject	NN	O	O
,	XIAFLEX.xml:S1:3342:1	,	,	O	O
regardless	XIAFLEX.xml:S1:3344:10	regardless	RB	O	O
of	XIAFLEX.xml:S1:3355:2	of	IN	O	O
the	XIAFLEX.xml:S1:3358:3	the	DT	O	O
number	XIAFLEX.xml:S1:3362:6	number	NN	O	O
of	XIAFLEX.xml:S1:3369:2	of	IN	O	O
injections	XIAFLEX.xml:S1:3372:10	inject	NNS	O	O
administered	XIAFLEX.xml:S1:3383:12	administ	VBN	O	O
.	XIAFLEX.xml:S1:3395:1	.	.	O	O

However	XIAFLEX.xml:S1:3397:7	howev	RB	O	O
,	XIAFLEX.xml:S1:3404:1	,	,	O	O
the	XIAFLEX.xml:S1:3406:3	the	DT	O	O
incidence	XIAFLEX.xml:S1:3410:9	incid	NN	O	O
of	XIAFLEX.xml:S1:3420:2	of	IN	O	O
pruritus	XIAFLEX.xml:S1:3423:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
increased	XIAFLEX.xml:S1:3432:9	increas	VBN	O	O
with	XIAFLEX.xml:S1:3442:4	with	IN	O	O
more	XIAFLEX.xml:S1:3447:4	more	RBR	O	O
injections	XIAFLEX.xml:S1:3452:10	inject	NNS	O	O
[	XIAFLEX.xml:S1:3466:1	[	VBP	O	O
see	XIAFLEX.xml:S1:3467:3	see	VBP	O	O
Warnings	XIAFLEX.xml:S1:3471:8	warn	NNS	O	O
and	XIAFLEX.xml:S1:3480:3	and	CC	O	O
Precautions	XIAFLEX.xml:S1:3484:11	precaut	NNP	O	O
(	XIAFLEX.xml:S1:3496:1	(	(	O	O
5.4	XIAFLEX.xml:S1:3497:3	5.4	CD	O	O
)]	XIAFLEX.xml:S1:3500:2	)]	NN	O	O
.	XIAFLEX.xml:S1:3502:1	.	.	O	O

The	XIAFLEX.xml:S1:3512:3	the	DT	O	O
most	XIAFLEX.xml:S1:3516:4	most	RBS	O	O
frequently	XIAFLEX.xml:S1:3521:10	frequent	RB	O	O
reported	XIAFLEX.xml:S1:3532:8	report	VBD	O	O
adverse	XIAFLEX.xml:S1:3541:7	advers	JJ	O	O
drug	XIAFLEX.xml:S1:3549:4	drug	NN	O	O
reactions	XIAFLEX.xml:S1:3554:9	reaction	NNS	O	O
(	XIAFLEX.xml:S1:3564:1	(	(	O	O
25%	XIAFLEX.xml:S1:3568:3	25%	CD	O	O
)	XIAFLEX.xml:S1:3571:1	)	)	O	O
in	XIAFLEX.xml:S1:3573:2	in	IN	O	O
the	XIAFLEX.xml:S1:3576:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S1:3580:7	xiaflex	NNP	O	O
clinical	XIAFLEX.xml:S1:3588:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S1:3597:6	trial	NNS	O	O
in	XIAFLEX.xml:S1:3604:2	in	IN	O	O
patients	XIAFLEX.xml:S1:3607:8	patient	NNS	O	O
with	XIAFLEX.xml:S1:3616:4	with	IN	O	O
Dupuytren	XIAFLEX.xml:S1:3621:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:3630:2	's	POS	O	O
contracture	XIAFLEX.xml:S1:3633:11	contractur	NN	O	O
included	XIAFLEX.xml:S1:3645:8	includ	VBD	O	O
edema	XIAFLEX.xml:S1:3654:5	edema	JJ	B-AdverseReaction	B-AdverseReaction
peripheral	XIAFLEX.xml:S1:3660:10	peripher	NN	I-AdverseReaction	I-AdverseReaction
(	XIAFLEX.xml:S1:3671:1	(	(	O	O
mostly	XIAFLEX.xml:S1:3672:6	mostli	RB	O	O
swelling	XIAFLEX.xml:S1:3679:8	swell	VBG	B-AdverseReaction	O
of	XIAFLEX.xml:S1:3688:2	of	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S1:3691:3	the	DT	I-AdverseReaction	O
injected	XIAFLEX.xml:S1:3695:8	inject	JJ	I-AdverseReaction	O
hand	XIAFLEX.xml:S1:3704:4	hand	NN	I-AdverseReaction	O
)	XIAFLEX.xml:S1:3708:1	)	)	O	O
,	XIAFLEX.xml:S1:3709:1	,	,	O	O
contusion	XIAFLEX.xml:S1:3711:9	contus	NN	B-AdverseReaction	B-AdverseReaction
,	XIAFLEX.xml:S1:3720:1	,	,	O	O
injection	XIAFLEX.xml:S1:3722:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:3732:4	site	NN	I-AdverseReaction	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:3737:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:3747:1	,	,	O	O
injection	XIAFLEX.xml:S1:3749:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:3759:4	site	NN	I-AdverseReaction	I-AdverseReaction
reaction	XIAFLEX.xml:S1:3764:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:3772:1	,	,	O	O
and	XIAFLEX.xml:S1:3774:3	and	CC	O	O
pain	XIAFLEX.xml:S1:3778:4	pain	NN	B-AdverseReaction	O
in	XIAFLEX.xml:S1:3783:2	in	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S1:3786:3	the	DT	I-AdverseReaction	O
treated	XIAFLEX.xml:S1:3790:7	treat	JJ	I-AdverseReaction	O
extremity	XIAFLEX.xml:S1:3798:9	extrem	NN	I-AdverseReaction	O
.	XIAFLEX.xml:S1:3807:1	.	.	O	O

Table	XIAFLEX.xml:S1:3809:5	tabl	JJ	O	O
3	XIAFLEX.xml:S1:3815:1	3	CD	O	O
shows	XIAFLEX.xml:S1:3817:5	show	VBZ	O	O
the	XIAFLEX.xml:S1:3823:3	the	DT	O	O
incidence	XIAFLEX.xml:S1:3827:9	incid	NN	O	O
of	XIAFLEX.xml:S1:3837:2	of	IN	O	O
adverse	XIAFLEX.xml:S1:3840:7	advers	JJ	O	O
reactions	XIAFLEX.xml:S1:3848:9	reaction	NNS	O	O
that	XIAFLEX.xml:S1:3858:4	that	WDT	O	O
were	XIAFLEX.xml:S1:3863:4	were	VBD	O	O
reported	XIAFLEX.xml:S1:3868:8	report	VBN	O	O
in	XIAFLEX.xml:S1:3877:2	in	IN	O	O
greater	XIAFLEX.xml:S1:3880:7	greater	JJR	O	O
than	XIAFLEX.xml:S1:3888:4	than	IN	O	O
or	XIAFLEX.xml:S1:3893:2	or	CC	O	O
equal	XIAFLEX.xml:S1:3896:5	equal	JJ	O	O
to	XIAFLEX.xml:S1:3902:2	to	TO	O	O
5%	XIAFLEX.xml:S1:3905:2	5%	CD	O	O
of	XIAFLEX.xml:S1:3908:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:3911:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:3918:1	-	:	O	O
treated	XIAFLEX.xml:S1:3919:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:3927:8	patient	NNS	O	O
and	XIAFLEX.xml:S1:3936:3	and	CC	O	O
at	XIAFLEX.xml:S1:3940:2	at	IN	O	O
a	XIAFLEX.xml:S1:3943:1	a	DT	O	O
frequency	XIAFLEX.xml:S1:3945:9	frequenc	NN	O	O
greater	XIAFLEX.xml:S1:3955:7	greater	JJR	O	O
than	XIAFLEX.xml:S1:3963:4	than	IN	O	O
placebo	XIAFLEX.xml:S1:3968:7	placebo	SYM	O	O
-	XIAFLEX.xml:S1:3975:1	-	:	O	O
treated	XIAFLEX.xml:S1:3976:7	treat	VBN	O	O
patients	XIAFLEX.xml:S1:3984:8	patient	NNS	O	O
after	XIAFLEX.xml:S1:3993:5	after	IN	O	O
up	XIAFLEX.xml:S1:3999:2	up	IN	O	O
to	XIAFLEX.xml:S1:4002:2	to	TO	O	O
3	XIAFLEX.xml:S1:4005:1	3	CD	O	O
injections	XIAFLEX.xml:S1:4007:10	inject	NNS	O	O
in	XIAFLEX.xml:S1:4018:2	in	IN	O	O
the	XIAFLEX.xml:S1:4021:3	the	DT	O	O
pooled	XIAFLEX.xml:S1:4025:6	pool	JJ	O	O
placebo	XIAFLEX.xml:S1:4032:7	placebo	NN	O	O
-	XIAFLEX.xml:S1:4039:1	-	:	O	O
controlled	XIAFLEX.xml:S1:4040:10	control	VBN	O	O
trials	XIAFLEX.xml:S1:4051:6	trial	NNS	O	O
through	XIAFLEX.xml:S1:4058:7	through	IN	O	O
Day	XIAFLEX.xml:S1:4066:3	day	NNP	O	O
90	XIAFLEX.xml:S1:4070:2	90	CD	O	O
(	XIAFLEX.xml:S1:4073:1	(	(	O	O
Studies	XIAFLEX.xml:S1:4074:7	studi	NNPS	O	O
1	XIAFLEX.xml:S1:4082:1	1	CD	O	O
and	XIAFLEX.xml:S1:4084:3	and	CC	O	O
2	XIAFLEX.xml:S1:4088:1	2	CD	O	O
)	XIAFLEX.xml:S1:4089:1	)	)	O	O
.	XIAFLEX.xml:S1:4090:1	.	.	O	O

Table	XIAFLEX.xml:S1:4096:5	tabl	JJ	O	O
3	XIAFLEX.xml:S1:4102:1	3	CD	O	O
.	XIAFLEX.xml:S1:4103:1	.	.	O	O

Adverse	XIAFLEX.xml:S1:4105:7	advers	JJ	O	O
Reactions	XIAFLEX.xml:S1:4113:9	reaction	NNP	O	O
Occurring	XIAFLEX.xml:S1:4123:9	occur	NNP	O	O
in	XIAFLEX.xml:S1:4133:2	in	IN	O	O
5%	XIAFLEX.xml:S1:4139:2	5%	CD	O	O
of	XIAFLEX.xml:S1:4142:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:4145:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:4152:1	-	:	O	O
Treated	XIAFLEX.xml:S1:4153:7	treat	VBD	O	O
Patients	XIAFLEX.xml:S1:4161:8	patient	NNS	O	O
with	XIAFLEX.xml:S1:4170:4	with	IN	O	O
Dupuytren	XIAFLEX.xml:S1:4175:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:4184:2	's	POS	O	O
Contracture	XIAFLEX.xml:S1:4187:11	contractur	NN	O	O
and	XIAFLEX.xml:S1:4199:3	and	CC	O	O
at	XIAFLEX.xml:S1:4203:2	at	IN	O	O
a	XIAFLEX.xml:S1:4206:1	a	DT	O	O
Greater	XIAFLEX.xml:S1:4208:7	greater	NNP	O	O
Incidence	XIAFLEX.xml:S1:4216:9	incid	NNP	O	O
than	XIAFLEX.xml:S1:4226:4	than	IN	O	O
Placebo	XIAFLEX.xml:S1:4231:7	placebo	NNP	O	O
in	XIAFLEX.xml:S1:4239:2	in	IN	O	O
the	XIAFLEX.xml:S1:4242:3	the	DT	O	O
Placebo	XIAFLEX.xml:S1:4246:7	placebo	NNP	O	O
-	XIAFLEX.xml:S1:4253:1	-	:	O	O
Controlled	XIAFLEX.xml:S1:4254:10	control	VBD	O	O
Trials	XIAFLEX.xml:S1:4265:6	trial	NNS	O	O
Through	XIAFLEX.xml:S1:4272:7	through	IN	O	O
Day	XIAFLEX.xml:S1:4280:3	day	NNP	O	O
90	XIAFLEX.xml:S1:4284:2	90	CD	O	O
After	XIAFLEX.xml:S1:4287:5	after	IN	O	O
Up	XIAFLEX.xml:S1:4293:2	Up	NNP	O	O
to	XIAFLEX.xml:S1:4296:2	to	TO	O	O
3	XIAFLEX.xml:S1:4299:1	3	CD	O	O
Injections	XIAFLEX.xml:S1:4301:10	inject	NNS	O	O

a	XIAFLEX.xml:S1:4317:1	a	DT	O	O
Most	XIAFLEX.xml:S1:4320:4	most	NNP	O	O
of	XIAFLEX.xml:S1:4325:2	of	IN	O	O
these	XIAFLEX.xml:S1:4328:5	these	DT	O	O
events	XIAFLEX.xml:S1:4334:6	event	NNS	O	O
were	XIAFLEX.xml:S1:4341:4	were	VBD	O	O
swelling	XIAFLEX.xml:S1:4346:8	swell	VBG	B-AdverseReaction	B-AdverseReaction
of	XIAFLEX.xml:S1:4355:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	XIAFLEX.xml:S1:4358:3	the	DT	I-AdverseReaction	I-AdverseReaction
injected	XIAFLEX.xml:S1:4362:8	inject	JJ	I-AdverseReaction	I-AdverseReaction
hand	XIAFLEX.xml:S1:4371:4	hand	NN	I-AdverseReaction	I-AdverseReaction
.	XIAFLEX.xml:S1:4375:1	.	.	O	O

b	XIAFLEX.xml:S1:4384:1	b	NN	O	O
Includes	XIAFLEX.xml:S1:4387:8	includ	VBZ	O	O
the	XIAFLEX.xml:S1:4396:3	the	DT	O	O
terms	XIAFLEX.xml:S1:4400:5	term	NNS	O	O
:	XIAFLEX.xml:S1:4405:1	:	:	O	O
contusion	XIAFLEX.xml:S1:4407:9	contus	NN	B-AdverseReaction	B-AdverseReaction
(	XIAFLEX.xml:S1:4417:1	(	(	O	O
any	XIAFLEX.xml:S1:4418:3	ani	DT	O	O
body	XIAFLEX.xml:S1:4422:4	bodi	NN	O	O
system	XIAFLEX.xml:S1:4427:6	system	NN	O	O
)	XIAFLEX.xml:S1:4433:1	)	)	O	O
and	XIAFLEX.xml:S1:4435:3	and	CC	O	O
ecchymosis	XIAFLEX.xml:S1:4439:10	ecchymosi	NN	B-AdverseReaction	O

c	XIAFLEX.xml:S1:4457:1	c	SYM	O	O
Includes	XIAFLEX.xml:S1:4460:8	includ	VBZ	O	O
the	XIAFLEX.xml:S1:4469:3	the	DT	O	O
terms	XIAFLEX.xml:S1:4473:5	term	NNS	O	O
:	XIAFLEX.xml:S1:4478:1	:	:	O	O
injection	XIAFLEX.xml:S1:4480:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4490:4	site	NN	I-AdverseReaction	I-AdverseReaction
reaction	XIAFLEX.xml:S1:4495:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:4503:1	,	,	O	O
injection	XIAFLEX.xml:S1:4505:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4515:4	site	NN	I-AdverseReaction	I-AdverseReaction
erythema	XIAFLEX.xml:S1:4520:8	erythema	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:4528:1	,	,	O	O
injection	XIAFLEX.xml:S1:4530:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4540:4	site	NN	I-AdverseReaction	I-AdverseReaction
inflammation	XIAFLEX.xml:S1:4545:12	inflamm	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:4557:1	,	,	O	O
injection	XIAFLEX.xml:S1:4559:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4569:4	site	NN	I-AdverseReaction	I-AdverseReaction
irritation	XIAFLEX.xml:S1:4574:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:4584:1	,	,	O	O
injection	XIAFLEX.xml:S1:4586:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4596:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XIAFLEX.xml:S1:4601:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:4605:1	,	,	O	O
and	XIAFLEX.xml:S1:4607:3	and	CC	O	O
injection	XIAFLEX.xml:S1:4611:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4621:4	site	NN	I-AdverseReaction	I-AdverseReaction
warmth	XIAFLEX.xml:S1:4626:6	warmth	NN	I-AdverseReaction	I-AdverseReaction

d	XIAFLEX.xml:S1:4640:1	d	NN	O	O
Includes	XIAFLEX.xml:S1:4643:8	includ	VBZ	O	O
the	XIAFLEX.xml:S1:4652:3	the	DT	O	O
terms	XIAFLEX.xml:S1:4656:5	term	NNS	O	O
:	XIAFLEX.xml:S1:4661:1	:	:	O	O
injection	XIAFLEX.xml:S1:4663:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4673:4	site	NN	I-AdverseReaction	I-AdverseReaction
swelling	XIAFLEX.xml:S1:4678:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
and	XIAFLEX.xml:S1:4687:3	and	CC	O	O
injection	XIAFLEX.xml:S1:4691:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4701:4	site	NN	I-AdverseReaction	I-AdverseReaction
edema	XIAFLEX.xml:S1:4706:5	edema	NN	I-AdverseReaction	I-AdverseReaction

e	XIAFLEX.xml:S1:4719:1	e	NN	O	O
Includes	XIAFLEX.xml:S1:4722:8	includ	VBZ	O	O
the	XIAFLEX.xml:S1:4731:3	the	DT	O	O
terms	XIAFLEX.xml:S1:4735:5	term	NNS	O	O
:	XIAFLEX.xml:S1:4740:1	:	:	O	O
pruritus	XIAFLEX.xml:S1:4742:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
and	XIAFLEX.xml:S1:4751:3	and	CC	O	O
injection	XIAFLEX.xml:S1:4755:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:4765:4	site	NN	I-AdverseReaction	I-AdverseReaction
pruritus	XIAFLEX.xml:S1:4770:8	pruritu	NN	I-AdverseReaction	I-AdverseReaction

f	XIAFLEX.xml:S1:4786:1	f	NN	O	O
Includes	XIAFLEX.xml:S1:4789:8	includ	VBZ	O	O
the	XIAFLEX.xml:S1:4798:3	the	DT	O	O
terms	XIAFLEX.xml:S1:4802:5	term	NNS	O	O
:	XIAFLEX.xml:S1:4807:1	:	:	O	O
lymphadenopathy	XIAFLEX.xml:S1:4809:15	lymphadenopathi	NN	B-AdverseReaction	B-AdverseReaction
and	XIAFLEX.xml:S1:4825:3	and	CC	O	O
axillary	XIAFLEX.xml:S1:4829:8	axillari	JJ	B-AdverseReaction	O
mass	XIAFLEX.xml:S1:4838:4	mass	NN	I-AdverseReaction	O

Adverse	XIAFLEX.xml:S1:4853:7	advers	NN	O	O

Reaction	XIAFLEX.xml:S1:4861:8	reaction	NNP	O	O
XIAFLEXN	XIAFLEX.xml:S1:4876:8	xiaflexn	NNP	O	O
249	XIAFLEX.xml:S1:4885:3	249	CD	O	O
PlaceboN	XIAFLEX.xml:S1:4895:8	placebon	NNP	O	O
125	XIAFLEX.xml:S1:4904:3	125	CD	O	O

All	XIAFLEX.xml:S1:4915:3	all	DT	O	O
Adverse	XIAFLEX.xml:S1:4919:7	advers	NNP	O	O
Reactions	XIAFLEX.xml:S1:4927:9	reaction	NNP	O	O
98%	XIAFLEX.xml:S1:4939:3	98%	CD	O	O
51%	XIAFLEX.xml:S1:4945:3	51%	CD	O	O

Edema	XIAFLEX.xml:S1:4954:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
Peripheral	XIAFLEX.xml:S1:4960:10	peripher	NNP	I-AdverseReaction	I-AdverseReaction
a	XIAFLEX.xml:S1:4972:1	a	DT	O	O
73%	XIAFLEX.xml:S1:4978:3	73%	CD	O	O
5%	XIAFLEX.xml:S1:4984:2	5%	CD	O	O

Contusion	XIAFLEX.xml:S1:4992:9	contus	NN	B-AdverseReaction	B-AdverseReaction
b	XIAFLEX.xml:S1:5003:1	b	VBD	O	O
70%	XIAFLEX.xml:S1:5009:3	70%	CD	O	O
3%	XIAFLEX.xml:S1:5015:2	3%	CD	O	O

Injection	XIAFLEX.xml:S1:5023:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
Site	XIAFLEX.xml:S1:5033:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Hemorrhage	XIAFLEX.xml:S1:5038:10	hemorrhag	NNP	I-AdverseReaction	I-AdverseReaction
38%	XIAFLEX.xml:S1:5051:3	38%	CD	O	O
3%	XIAFLEX.xml:S1:5057:2	3%	CD	O	O

Injection	XIAFLEX.xml:S1:5065:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
Site	XIAFLEX.xml:S1:5075:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Reaction	XIAFLEX.xml:S1:5080:8	reaction	NNP	I-AdverseReaction	I-AdverseReaction
c	XIAFLEX.xml:S1:5090:1	c	VBD	O	O
35%	XIAFLEX.xml:S1:5096:3	35%	CD	O	O
6%	XIAFLEX.xml:S1:5102:2	6%	CD	O	O

Pain	XIAFLEX.xml:S1:5110:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	XIAFLEX.xml:S1:5115:2	in	IN	I-AdverseReaction	I-AdverseReaction
Extremity	XIAFLEX.xml:S1:5118:9	extrem	NNP	I-AdverseReaction	I-AdverseReaction
35%	XIAFLEX.xml:S1:5130:3	35%	CD	O	O
4%	XIAFLEX.xml:S1:5136:2	4%	CD	O	O

Tenderness	XIAFLEX.xml:S1:5144:10	tender	RB	B-AdverseReaction	O
24%	XIAFLEX.xml:S1:5157:3	24%	CD	O	O
0%	XIAFLEX.xml:S1:5163:2	0%	CD	O	O

Injection	XIAFLEX.xml:S1:5171:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
Site	XIAFLEX.xml:S1:5181:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Swelling	XIAFLEX.xml:S1:5186:8	swell	NNP	I-AdverseReaction	I-AdverseReaction
d	XIAFLEX.xml:S1:5196:1	d	VBD	O	O
24%	XIAFLEX.xml:S1:5202:3	24%	CD	O	O
6%	XIAFLEX.xml:S1:5208:2	6%	CD	O	O

Pruritus	XIAFLEX.xml:S1:5216:8	pruritu	NNP	B-AdverseReaction	B-AdverseReaction
e	XIAFLEX.xml:S1:5226:1	e	VBD	O	O
15%	XIAFLEX.xml:S1:5232:3	15%	CD	O	O
1%	XIAFLEX.xml:S1:5238:2	1%	CD	O	O

Lymphadenopathy	XIAFLEX.xml:S1:5246:15	lymphadenopathi	NNP	B-AdverseReaction	B-AdverseReaction
f	XIAFLEX.xml:S1:5263:1	f	VBD	O	I-AdverseReaction
13%	XIAFLEX.xml:S1:5269:3	13%	CD	O	O
0%	XIAFLEX.xml:S1:5275:2	0%	CD	O	O

Skin	XIAFLEX.xml:S1:5283:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
Laceration	XIAFLEX.xml:S1:5288:10	lacer	NNP	I-AdverseReaction	I-AdverseReaction
9%	XIAFLEX.xml:S1:5301:2	9%	CD	O	O
0%	XIAFLEX.xml:S1:5306:2	0%	CD	O	O

Lymph	XIAFLEX.xml:S1:5314:5	lymph	NNP	B-AdverseReaction	B-AdverseReaction
Node	XIAFLEX.xml:S1:5320:4	node	NNP	I-AdverseReaction	I-AdverseReaction
Pain	XIAFLEX.xml:S1:5325:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
8%	XIAFLEX.xml:S1:5332:2	8%	CD	O	O
0%	XIAFLEX.xml:S1:5337:2	0%	CD	O	O

Erythema	XIAFLEX.xml:S1:5345:8	erythema	NNP	B-AdverseReaction	B-AdverseReaction
6%	XIAFLEX.xml:S1:5356:2	6%	CD	O	O
0%	XIAFLEX.xml:S1:5361:2	0%	CD	O	O

Axillary	XIAFLEX.xml:S1:5369:8	axillari	NNP	B-AdverseReaction	B-AdverseReaction
Pain	XIAFLEX.xml:S1:5378:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
6%	XIAFLEX.xml:S1:5385:2	6%	CD	O	O
0%	XIAFLEX.xml:S1:5390:2	0%	CD	O	O

Some	XIAFLEX.xml:S1:5405:4	some	DT	O	O
patients	XIAFLEX.xml:S1:5410:8	patient	NNS	O	O
developed	XIAFLEX.xml:S1:5419:9	develop	VBD	O	O
vasovagal	XIAFLEX.xml:S1:5429:9	vasovag	JJ	B-AdverseReaction	O
syncope	XIAFLEX.xml:S1:5439:7	syncop	NN	I-AdverseReaction	O
after	XIAFLEX.xml:S1:5447:5	after	IN	O	O
finger	XIAFLEX.xml:S1:5453:6	finger	JJR	O	O
extension	XIAFLEX.xml:S1:5460:9	extens	NN	O	O
procedures	XIAFLEX.xml:S1:5470:10	procedur	NNS	O	O
.	XIAFLEX.xml:S1:5480:1	.	.	O	O

The	XIAFLEX.xml:S1:5486:3	the	DT	O	O

safety	XIAFLEX.xml:S1:5490:6	safeti	NN	O	O
of	XIAFLEX.xml:S1:5497:2	of	IN	O	O
two	XIAFLEX.xml:S1:5500:3	two	CD	O	O
concurrent	XIAFLEX.xml:S1:5504:10	concurr	JJ	O	O
injections	XIAFLEX.xml:S1:5515:10	inject	NNS	O	O
of	XIAFLEX.xml:S1:5526:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:5529:7	xiaflex	NNP	O	O
0.58	XIAFLEX.xml:S1:5537:4	0.58	CD	O	O
mg	XIAFLEX.xml:S1:5542:2	mg	NN	O	O
into	XIAFLEX.xml:S1:5545:4	into	IN	O	O
Dupuytren	XIAFLEX.xml:S1:5550:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:5559:2	's	POS	O	O
cords	XIAFLEX.xml:S1:5562:5	cord	NNS	O	O
in	XIAFLEX.xml:S1:5568:2	in	IN	O	O
the	XIAFLEX.xml:S1:5571:3	the	DT	O	O
same	XIAFLEX.xml:S1:5575:4	same	JJ	O	O
hand	XIAFLEX.xml:S1:5580:4	hand	NN	O	O
was	XIAFLEX.xml:S1:5585:3	wa	VBD	O	O
evaluated	XIAFLEX.xml:S1:5589:9	evalu	VBN	O	O
in	XIAFLEX.xml:S1:5599:2	in	IN	O	O
a	XIAFLEX.xml:S1:5602:1	a	DT	O	O
historically	XIAFLEX.xml:S1:5604:12	histor	RB	O	O
-	XIAFLEX.xml:S1:5616:1	-	:	O	O
controlled	XIAFLEX.xml:S1:5617:10	control	VBN	O	O
,	XIAFLEX.xml:S1:5627:1	,	,	O	O
open	XIAFLEX.xml:S1:5629:4	open	JJ	O	O
-	XIAFLEX.xml:S1:5633:1	-	:	O	O
label	XIAFLEX.xml:S1:5634:5	label	NN	O	O
multi	XIAFLEX.xml:S1:5640:5	multi	SYM	O	O
-	XIAFLEX.xml:S1:5645:1	-	:	O	O
center	XIAFLEX.xml:S1:5646:6	center	NN	O	O
trial	XIAFLEX.xml:S1:5653:5	trial	NN	O	O
in	XIAFLEX.xml:S1:5659:2	in	IN	O	O
715	XIAFLEX.xml:S1:5662:3	715	CD	O	O
adult	XIAFLEX.xml:S1:5666:5	adult	NN	O	O
subjects	XIAFLEX.xml:S1:5672:8	subject	NNS	O	O
with	XIAFLEX.xml:S1:5681:4	with	IN	O	O
Dupuytren	XIAFLEX.xml:S1:5686:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:5695:2	's	POS	O	O
contracture	XIAFLEX.xml:S1:5698:11	contractur	NN	O	O
(	XIAFLEX.xml:S1:5710:1	(	(	O	O
Study	XIAFLEX.xml:S1:5711:5	studi	NNP	O	O
3	XIAFLEX.xml:S1:5717:1	3	CD	O	O
)	XIAFLEX.xml:S1:5718:1	)	)	O	O
.	XIAFLEX.xml:S1:5719:1	.	.	O	O

In	XIAFLEX.xml:S1:5721:2	In	IN	O	O
Study	XIAFLEX.xml:S1:5724:5	studi	NNP	O	O
3	XIAFLEX.xml:S1:5730:1	3	CD	O	O
,	XIAFLEX.xml:S1:5731:1	,	,	O	O
finger	XIAFLEX.xml:S1:5733:6	finger	JJR	O	O
extension	XIAFLEX.xml:S1:5740:9	extens	NN	O	O
procedures	XIAFLEX.xml:S1:5750:10	procedur	NNS	O	O
were	XIAFLEX.xml:S1:5761:4	were	VBD	O	O
performed	XIAFLEX.xml:S1:5766:9	perform	VBN	O	O
approximately	XIAFLEX.xml:S1:5776:13	approxim	RB	O	O
24	XIAFLEX.xml:S1:5790:2	24	CD	O	O
to	XIAFLEX.xml:S1:5793:2	to	TO	O	O
72	XIAFLEX.xml:S1:5796:2	72	CD	O	O
hours	XIAFLEX.xml:S1:5799:5	hour	NNS	O	O
after	XIAFLEX.xml:S1:5805:5	after	IN	O	O
injection	XIAFLEX.xml:S1:5811:9	inject	NN	O	O
.	XIAFLEX.xml:S1:5820:1	.	.	O	O

The	XIAFLEX.xml:S1:5822:3	the	DT	O	O
patient	XIAFLEX.xml:S1:5826:7	patient	NN	O	O
demographics	XIAFLEX.xml:S1:5834:12	demograph	NNS	O	O
were	XIAFLEX.xml:S1:5847:4	were	VBD	O	O
similar	XIAFLEX.xml:S1:5852:7	similar	JJ	O	O
to	XIAFLEX.xml:S1:5860:2	to	TO	O	O
Studies	XIAFLEX.xml:S1:5863:7	studi	VB	O	O
1	XIAFLEX.xml:S1:5871:1	1	CD	O	O
and	XIAFLEX.xml:S1:5873:3	and	CC	O	O
2	XIAFLEX.xml:S1:5877:1	2	CD	O	O
.	XIAFLEX.xml:S1:5878:1	.	.	O	O

Out	XIAFLEX.xml:S1:5884:3	out	IN	O	O
of	XIAFLEX.xml:S1:5888:2	of	IN	O	O
715	XIAFLEX.xml:S1:5891:3	715	CD	O	O
patients	XIAFLEX.xml:S1:5895:8	patient	NNS	O	O
who	XIAFLEX.xml:S1:5904:3	who	WP	O	O
received	XIAFLEX.xml:S1:5908:8	receiv	VBD	O	O
two	XIAFLEX.xml:S1:5917:3	two	CD	O	O
concurrent	XIAFLEX.xml:S1:5921:10	concurr	JJ	O	O
injections	XIAFLEX.xml:S1:5932:10	inject	NNS	O	O
of	XIAFLEX.xml:S1:5943:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:5946:7	xiaflex	NNP	O	O
0.58	XIAFLEX.xml:S1:5954:4	0.58	CD	O	O
mg	XIAFLEX.xml:S1:5959:2	mg	NN	O	O
in	XIAFLEX.xml:S1:5962:2	in	IN	O	O
the	XIAFLEX.xml:S1:5965:3	the	DT	O	O
same	XIAFLEX.xml:S1:5969:4	same	JJ	O	O
hand	XIAFLEX.xml:S1:5974:4	hand	NN	O	O
(	XIAFLEX.xml:S1:5979:1	(	(	O	O
1450	XIAFLEX.xml:S1:5980:4	1450	CD	O	O
XIAFLEX	XIAFLEX.xml:S1:5985:7	xiaflex	NNP	O	O
injections	XIAFLEX.xml:S1:5993:10	inject	NNS	O	O
)	XIAFLEX.xml:S1:6003:1	)	)	O	O
in	XIAFLEX.xml:S1:6005:2	in	IN	O	O
Study	XIAFLEX.xml:S1:6008:5	studi	NNP	O	O
3	XIAFLEX.xml:S1:6014:1	3	CD	O	O
,	XIAFLEX.xml:S1:6015:1	,	,	O	O
one	XIAFLEX.xml:S1:6017:3	one	CD	O	O
(	XIAFLEX.xml:S1:6021:1	(	(	O	O
0.1%	XIAFLEX.xml:S1:6022:4	0.1%	CD	O	O
)	XIAFLEX.xml:S1:6026:1	)	)	O	O
patient	XIAFLEX.xml:S1:6028:7	patient	NN	O	O
experienced	XIAFLEX.xml:S1:6036:11	experienc	VBD	O	O
a	XIAFLEX.xml:S1:6048:1	a	DT	O	O
tendon	XIAFLEX.xml:S1:6050:6	tendon	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S1:6057:7	ruptur	NN	I-AdverseReaction	O
of	XIAFLEX.xml:S1:6065:2	of	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S1:6068:3	the	DT	I-AdverseReaction	O
treated	XIAFLEX.xml:S1:6072:7	treat	JJ	O	O
finger	XIAFLEX.xml:S1:6080:6	finger	NN	I-AdverseReaction	O
within	XIAFLEX.xml:S1:6087:6	within	IN	O	O
3	XIAFLEX.xml:S1:6094:1	3	CD	O	O
days	XIAFLEX.xml:S1:6096:4	day	NNS	O	O
of	XIAFLEX.xml:S1:6101:2	of	IN	O	O
the	XIAFLEX.xml:S1:6104:3	the	DT	O	O
injection	XIAFLEX.xml:S1:6108:9	inject	NN	O	O
.	XIAFLEX.xml:S1:6117:1	.	.	O	O

Table	XIAFLEX.xml:S1:6123:5	tabl	JJ	O	O
4	XIAFLEX.xml:S1:6129:1	4	CD	O	O
shows	XIAFLEX.xml:S1:6131:5	show	VBZ	O	O
the	XIAFLEX.xml:S1:6137:3	the	DT	O	O
incidence	XIAFLEX.xml:S1:6141:9	incid	NN	O	O
of	XIAFLEX.xml:S1:6151:2	of	IN	O	O
adverse	XIAFLEX.xml:S1:6154:7	advers	JJ	O	O
reactions	XIAFLEX.xml:S1:6162:9	reaction	NNS	O	O
that	XIAFLEX.xml:S1:6172:4	that	WDT	O	O
were	XIAFLEX.xml:S1:6177:4	were	VBD	O	O
reported	XIAFLEX.xml:S1:6182:8	report	VBN	O	O
in	XIAFLEX.xml:S1:6191:2	in	IN	O	O
greater	XIAFLEX.xml:S1:6194:7	greater	JJR	O	O
than	XIAFLEX.xml:S1:6202:4	than	IN	O	O
or	XIAFLEX.xml:S1:6207:2	or	CC	O	O
equal	XIAFLEX.xml:S1:6210:5	equal	JJ	O	O
to	XIAFLEX.xml:S1:6216:2	to	TO	O	O
5%	XIAFLEX.xml:S1:6219:2	5%	CD	O	O
of	XIAFLEX.xml:S1:6222:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:6225:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:6232:1	-	:	O	O
treated	XIAFLEX.xml:S1:6233:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:6241:8	patient	NNS	O	O
after	XIAFLEX.xml:S1:6250:5	after	IN	O	O
two	XIAFLEX.xml:S1:6256:3	two	CD	O	O
concurrent	XIAFLEX.xml:S1:6260:10	concurr	JJ	O	O
injections	XIAFLEX.xml:S1:6271:10	inject	NNS	O	O
of	XIAFLEX.xml:S1:6282:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:6285:7	xiaflex	NN	O	O
in	XIAFLEX.xml:S1:6293:2	in	IN	O	O
the	XIAFLEX.xml:S1:6296:3	the	DT	O	O
same	XIAFLEX.xml:S1:6300:4	same	JJ	O	O
hand	XIAFLEX.xml:S1:6305:4	hand	NN	O	O
through	XIAFLEX.xml:S1:6310:7	through	IN	O	O
Day	XIAFLEX.xml:S1:6318:3	day	NNP	O	O
60	XIAFLEX.xml:S1:6322:2	60	CD	O	O
in	XIAFLEX.xml:S1:6325:2	in	IN	O	O
Study	XIAFLEX.xml:S1:6328:5	studi	NNP	O	O
3	XIAFLEX.xml:S1:6334:1	3	CD	O	O
.	XIAFLEX.xml:S1:6335:1	.	.	O	O

Table	XIAFLEX.xml:S1:6341:5	tabl	JJ	O	O
4	XIAFLEX.xml:S1:6347:1	4	CD	O	O
.	XIAFLEX.xml:S1:6348:1	.	.	O	O

Adverse	XIAFLEX.xml:S1:6350:7	advers	JJ	O	O
Reactions	XIAFLEX.xml:S1:6358:9	reaction	NNP	O	O
Occurring	XIAFLEX.xml:S1:6368:9	occur	NNP	O	O
in	XIAFLEX.xml:S1:6378:2	in	IN	O	O
5.0%	XIAFLEX.xml:S1:6383:4	5.0%	CD	O	O
of	XIAFLEX.xml:S1:6388:2	of	IN	O	O
Subjects	XIAFLEX.xml:S1:6391:8	subject	NNS	O	O
Who	XIAFLEX.xml:S1:6400:3	who	NNP	O	O
Received	XIAFLEX.xml:S1:6404:8	receiv	VBD	O	O
Two	XIAFLEX.xml:S1:6413:3	two	CD	O	O
Concurrent	XIAFLEX.xml:S1:6417:10	concurr	NNP	O	O
Injections	XIAFLEX.xml:S1:6428:10	inject	NNS	O	O
of	XIAFLEX.xml:S1:6439:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:6442:7	xiaflex	NNP	O	O
in	XIAFLEX.xml:S1:6450:2	in	IN	O	O
Study	XIAFLEX.xml:S1:6453:5	studi	NNP	O	O
3	XIAFLEX.xml:S1:6459:1	3	CD	O	O

Adverse	XIAFLEX.xml:S1:6465:7	advers	JJ	O	O
Reaction	XIAFLEX.xml:S1:6473:8	reaction	NNP	O	O
XIAFLEXN	XIAFLEX.xml:S1:6537:8	xiaflexn	NNP	O	O
715	XIAFLEX.xml:S1:6546:3	715	CD	O	O

Subjects	XIAFLEX.xml:S1:6570:8	subject	NNS	O	O
with	XIAFLEX.xml:S1:6579:4	with	IN	O	O
1	XIAFLEX.xml:S1:6586:1	1	CD	O	O
adverse	XIAFLEX.xml:S1:6588:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:6596:8	reaction	NN	O	O
95%	XIAFLEX.xml:S1:6642:3	95%	CD	O	O

Edema	XIAFLEX.xml:S1:6677:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
peripheral	XIAFLEX.xml:S1:6683:10	peripher	JJ	I-AdverseReaction	I-AdverseReaction
77%	XIAFLEX.xml:S1:6749:3	77%	CD	O	O

Contusion	XIAFLEX.xml:S1:6784:9	contus	NN	B-AdverseReaction	B-AdverseReaction
59%	XIAFLEX.xml:S1:6856:3	59%	CD	O	O

Pain	XIAFLEX.xml:S1:6891:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	XIAFLEX.xml:S1:6896:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	XIAFLEX.xml:S1:6899:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
51%	XIAFLEX.xml:S1:6963:3	51%	CD	O	O

Laceration	XIAFLEX.xml:S1:6998:10	lacer	NN	B-AdverseReaction	O
22%	XIAFLEX.xml:S1:7070:3	22%	CD	O	O

Pruritus	XIAFLEX.xml:S1:7105:8	pruritu	NNP	B-AdverseReaction	B-AdverseReaction
15%	XIAFLEX.xml:S1:7177:3	15%	CD	O	O

Injection	XIAFLEX.xml:S1:7212:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:7222:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XIAFLEX.xml:S1:7227:4	pain	NN	I-AdverseReaction	I-AdverseReaction
14%	XIAFLEX.xml:S1:7284:3	14%	CD	O	O

Lymphadenopathy	XIAFLEX.xml:S1:7319:15	lymphadenopathi	JJ	B-AdverseReaction	B-AdverseReaction
13%	XIAFLEX.xml:S1:7391:3	13%	CD	O	O

Blood	XIAFLEX.xml:S1:7426:5	blood	NNP	B-AdverseReaction	O
blister	XIAFLEX.xml:S1:7432:7	blister	NN	I-AdverseReaction	O
12%	XIAFLEX.xml:S1:7498:3	12%	CD	O	O

Injection	XIAFLEX.xml:S1:7533:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:7543:4	site	NN	I-AdverseReaction	I-AdverseReaction
hematoma	XIAFLEX.xml:S1:7548:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
8%	XIAFLEX.xml:S1:7605:2	8%	CD	O	O

Axillary	XIAFLEX.xml:S1:7640:8	axillari	NNP	B-AdverseReaction	B-AdverseReaction
pain	XIAFLEX.xml:S1:7649:4	pain	NN	I-AdverseReaction	I-AdverseReaction
7%	XIAFLEX.xml:S1:7712:2	7%	CD	O	O

Injection	XIAFLEX.xml:S1:7747:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:7757:4	site	NN	I-AdverseReaction	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:7762:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
6%	XIAFLEX.xml:S1:7819:2	6%	CD	O	O

Injection	XIAFLEX.xml:S1:7854:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:7864:4	site	NN	I-AdverseReaction	I-AdverseReaction
swelling	XIAFLEX.xml:S1:7869:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
5%	XIAFLEX.xml:S1:7926:2	5%	CD	O	O

Ecchymosis	XIAFLEX.xml:S1:7961:10	ecchymosi	NN	B-AdverseReaction	O
5%	XIAFLEX.xml:S1:8033:2	5%	CD	O	O

Safety	XIAFLEX.xml:S1:8077:6	safeti	NN	O	O
of	XIAFLEX.xml:S1:8084:2	of	IN	O	O
Retreatment	XIAFLEX.xml:S1:8087:11	retreat	NNP	O	O
of	XIAFLEX.xml:S1:8099:2	of	IN	O	O
Recurrent	XIAFLEX.xml:S1:8102:9	recurr	NNP	O	O
Contractures	XIAFLEX.xml:S1:8112:12	contractur	NNP	O	O

An	XIAFLEX.xml:S1:8131:2	An	DT	O	O

observational	XIAFLEX.xml:S1:8134:13	observ	JJ	O	O
,	XIAFLEX.xml:S1:8147:1	,	,	O	O
open	XIAFLEX.xml:S1:8149:4	open	JJ	O	O
label	XIAFLEX.xml:S1:8154:5	label	NN	O	O
study	XIAFLEX.xml:S1:8160:5	studi	NN	O	O
was	XIAFLEX.xml:S1:8166:3	wa	VBD	O	O
conducted	XIAFLEX.xml:S1:8170:9	conduct	VBN	O	O
in	XIAFLEX.xml:S1:8180:2	in	IN	O	O
subjects	XIAFLEX.xml:S1:8183:8	subject	NNS	O	O
who	XIAFLEX.xml:S1:8192:3	who	WP	O	O
had	XIAFLEX.xml:S1:8196:3	had	VBD	O	O
participated	XIAFLEX.xml:S1:8200:12	particip	VBN	O	O
in	XIAFLEX.xml:S1:8213:2	in	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:8216:7	xiaflex	NNP	O	O
clinical	XIAFLEX.xml:S1:8224:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S1:8233:6	trial	NNS	O	O
for	XIAFLEX.xml:S1:8240:3	for	IN	O	O
Dupuytren	XIAFLEX.xml:S1:8244:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:8253:2	's	POS	O	O
contracture	XIAFLEX.xml:S1:8256:11	contractur	NN	O	O
(	XIAFLEX.xml:S1:8268:1	(	(	O	O
Study	XIAFLEX.xml:S1:8269:5	studi	NNP	O	O
4	XIAFLEX.xml:S1:8275:1	4	CD	O	O
)	XIAFLEX.xml:S1:8276:1	)	)	O	O
.	XIAFLEX.xml:S1:8277:1	.	.	O	O

A	XIAFLEX.xml:S1:8280:1	A	DT	O	O
subset	XIAFLEX.xml:S1:8282:6	subset	NN	O	O
of	XIAFLEX.xml:S1:8289:2	of	IN	O	O
patients	XIAFLEX.xml:S1:8292:8	patient	NNS	O	O
who	XIAFLEX.xml:S1:8301:3	who	WP	O	O
had	XIAFLEX.xml:S1:8305:3	had	VBD	O	O
recurrence	XIAFLEX.xml:S1:8309:10	recurr	NN	O	O
of	XIAFLEX.xml:S1:8320:2	of	IN	O	O
contracture	XIAFLEX.xml:S1:8323:11	contractur	NN	O	O
in	XIAFLEX.xml:S1:8335:2	in	IN	O	O
a	XIAFLEX.xml:S1:8338:1	a	DT	O	O
joint	XIAFLEX.xml:S1:8340:5	joint	JJ	O	O
that	XIAFLEX.xml:S1:8346:4	that	WDT	O	O
was	XIAFLEX.xml:S1:8351:3	wa	VBD	O	O
previously	XIAFLEX.xml:S1:8355:10	previous	RB	O	O
successfully	XIAFLEX.xml:S1:8366:12	success	RB	O	O
treated	XIAFLEX.xml:S1:8379:7	treat	VBN	O	O
with	XIAFLEX.xml:S1:8387:4	with	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:8392:7	xiaflex	NNP	O	O
in	XIAFLEX.xml:S1:8400:2	in	IN	O	O
Study	XIAFLEX.xml:S1:8403:5	studi	NNP	O	O
4	XIAFLEX.xml:S1:8409:1	4	CD	O	O
were	XIAFLEX.xml:S1:8411:4	were	VBD	O	O
retreated	XIAFLEX.xml:S1:8416:9	retreat	VBN	O	O
(	XIAFLEX.xml:S1:8426:1	(	(	O	O
Study	XIAFLEX.xml:S1:8427:5	studi	NNP	O	O
5	XIAFLEX.xml:S1:8433:1	5	CD	O	O
)	XIAFLEX.xml:S1:8434:1	)	)	O	O
.	XIAFLEX.xml:S1:8435:1	.	.	O	O

No	XIAFLEX.xml:S1:8438:2	No	DT	O	O
new	XIAFLEX.xml:S1:8441:3	new	JJ	O	O
safety	XIAFLEX.xml:S1:8445:6	safeti	NN	O	O
signals	XIAFLEX.xml:S1:8452:7	signal	NNS	O	O
were	XIAFLEX.xml:S1:8460:4	were	VBD	O	O
identified	XIAFLEX.xml:S1:8465:10	identifi	VBN	O	O
among	XIAFLEX.xml:S1:8476:5	among	IN	O	O
subjects	XIAFLEX.xml:S1:8482:8	subject	NNS	O	O
who	XIAFLEX.xml:S1:8491:3	who	WP	O	O
were	XIAFLEX.xml:S1:8495:4	were	VBD	O	O
retreated	XIAFLEX.xml:S1:8500:9	retreat	VBN	O	O
with	XIAFLEX.xml:S1:8510:4	with	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:8515:7	xiaflex	NNP	O	O
.	XIAFLEX.xml:S1:8522:1	.	.	O	O

6.2	XIAFLEX.xml:S1:8530:3	6.2	CD	O	O
Clinical	XIAFLEX.xml:S1:8534:8	clinic	JJ	O	O
Studies	XIAFLEX.xml:S1:8543:7	studi	NNS	O	O
Experience	XIAFLEX.xml:S1:8551:10	experi	NNP	O	O
in	XIAFLEX.xml:S1:8562:2	in	IN	O	O
Patients	XIAFLEX.xml:S1:8565:8	patient	NNP	O	O
with	XIAFLEX.xml:S1:8574:4	with	IN	O	O
Peyronie	XIAFLEX.xml:S1:8579:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:8587:2	's	POS	O	O
Disease	XIAFLEX.xml:S1:8590:7	diseas	NNP	O	O

Because	XIAFLEX.xml:S1:8601:7	becaus	IN	O	O
clinical	XIAFLEX.xml:S1:8609:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:8618:7	studi	NNS	O	O
are	XIAFLEX.xml:S1:8626:3	are	VBP	O	O
conducted	XIAFLEX.xml:S1:8630:9	conduct	VBN	O	O
under	XIAFLEX.xml:S1:8640:5	under	IN	O	O
widely	XIAFLEX.xml:S1:8646:6	wide	RB	O	O
varying	XIAFLEX.xml:S1:8653:7	vari	VBG	O	O
conditions	XIAFLEX.xml:S1:8661:10	condit	NNS	O	O
,	XIAFLEX.xml:S1:8671:1	,	,	O	O
adverse	XIAFLEX.xml:S1:8673:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:8681:8	reaction	NN	O	O
rates	XIAFLEX.xml:S1:8690:5	rate	NNS	O	O
observed	XIAFLEX.xml:S1:8696:8	observ	VBD	O	O
in	XIAFLEX.xml:S1:8705:2	in	IN	O	O
the	XIAFLEX.xml:S1:8708:3	the	DT	O	O
clinical	XIAFLEX.xml:S1:8712:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:8721:7	studi	NNS	O	O
of	XIAFLEX.xml:S1:8729:2	of	IN	O	O
a	XIAFLEX.xml:S1:8732:1	a	DT	O	O
drug	XIAFLEX.xml:S1:8734:4	drug	NN	O	O
cannot	XIAFLEX.xml:S1:8739:6	cannot	NN	O	O
be	XIAFLEX.xml:S1:8746:2	be	VB	O	O
directly	XIAFLEX.xml:S1:8749:8	directli	RB	O	O
compared	XIAFLEX.xml:S1:8758:8	compar	VBN	O	O
to	XIAFLEX.xml:S1:8767:2	to	TO	O	O
rates	XIAFLEX.xml:S1:8770:5	rate	NNS	O	O
in	XIAFLEX.xml:S1:8776:2	in	IN	O	O
the	XIAFLEX.xml:S1:8779:3	the	DT	O	O
clinical	XIAFLEX.xml:S1:8783:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:8792:7	studi	NNS	O	O
of	XIAFLEX.xml:S1:8800:2	of	IN	O	O
another	XIAFLEX.xml:S1:8803:7	anoth	DT	O	O
drug	XIAFLEX.xml:S1:8811:4	drug	NN	O	O
and	XIAFLEX.xml:S1:8816:3	and	CC	O	O
may	XIAFLEX.xml:S1:8820:3	may	MD	O	O
not	XIAFLEX.xml:S1:8824:3	not	RB	O	O
reflect	XIAFLEX.xml:S1:8828:7	reflect	VB	O	O
the	XIAFLEX.xml:S1:8836:3	the	DT	O	O
rates	XIAFLEX.xml:S1:8840:5	rate	NNS	O	O
observed	XIAFLEX.xml:S1:8846:8	observ	VBD	O	O
in	XIAFLEX.xml:S1:8855:2	in	IN	O	O
practice	XIAFLEX.xml:S1:8858:8	practic	NN	O	O
.	XIAFLEX.xml:S1:8866:1	.	.	O	O

In	XIAFLEX.xml:S1:8872:2	In	IN	O	O
the	XIAFLEX.xml:S1:8875:3	the	DT	O	O
controlled	XIAFLEX.xml:S1:8879:10	control	VBN	O	O
and	XIAFLEX.xml:S1:8890:3	and	CC	O	O
uncontrolled	XIAFLEX.xml:S1:8894:12	uncontrol	JJ	O	O
clinical	XIAFLEX.xml:S1:8907:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:8916:7	studi	NNS	O	O
of	XIAFLEX.xml:S1:8924:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:8927:7	xiaflex	NNP	O	O
in	XIAFLEX.xml:S1:8935:2	in	IN	O	O
Peyronie	XIAFLEX.xml:S1:8938:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:8946:2	's	POS	O	O
disease	XIAFLEX.xml:S1:8949:7	diseas	NN	O	O
,	XIAFLEX.xml:S1:8956:1	,	,	O	O
1044	XIAFLEX.xml:S1:8958:4	1044	CD	O	O
patients	XIAFLEX.xml:S1:8963:8	patient	NNS	O	O
received	XIAFLEX.xml:S1:8972:8	receiv	VBD	O	O
a	XIAFLEX.xml:S1:8981:1	a	DT	O	O
total	XIAFLEX.xml:S1:8983:5	total	NN	O	O
of	XIAFLEX.xml:S1:8989:2	of	IN	O	O
7466	XIAFLEX.xml:S1:8992:4	7466	CD	O	O
XIAFLEX	XIAFLEX.xml:S1:8997:7	xiaflex	NNP	O	O
injections	XIAFLEX.xml:S1:9005:10	inject	NNS	O	O
.	XIAFLEX.xml:S1:9015:1	.	.	O	O

Corporal	XIAFLEX.xml:S1:9023:8	corpor	JJ	O	O
Rupture	XIAFLEX.xml:S1:9032:7	ruptur	NNP	O	O
and	XIAFLEX.xml:S1:9040:3	and	CC	O	O
Other	XIAFLEX.xml:S1:9044:5	other	JJ	O	O
Serious	XIAFLEX.xml:S1:9050:7	seriou	NNP	O	O
Penile	XIAFLEX.xml:S1:9058:6	penil	NNP	O	O
Injury	XIAFLEX.xml:S1:9065:6	injuri	NNP	O	O

Corporal	XIAFLEX.xml:S1:9081:8	corpor	JJ	B-AdverseReaction	B-AdverseReaction
rupture	XIAFLEX.xml:S1:9090:7	ruptur	NN	I-AdverseReaction	I-AdverseReaction
was	XIAFLEX.xml:S1:9098:3	wa	VBD	O	O
reported	XIAFLEX.xml:S1:9102:8	report	VBN	O	O
as	XIAFLEX.xml:S1:9111:2	as	IN	O	O
an	XIAFLEX.xml:S1:9114:2	an	DT	O	O
adverse	XIAFLEX.xml:S1:9117:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:9125:8	reaction	NN	O	O
after	XIAFLEX.xml:S1:9134:5	after	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:9140:7	xiaflex	JJ	O	O
injections	XIAFLEX.xml:S1:9148:10	inject	NNS	O	O
in	XIAFLEX.xml:S1:9159:2	in	IN	O	O
5	XIAFLEX.xml:S1:9162:1	5	CD	O	O
of	XIAFLEX.xml:S1:9164:2	of	IN	O	O
1044	XIAFLEX.xml:S1:9167:4	1044	CD	O	O
(	XIAFLEX.xml:S1:9172:1	(	(	O	O
0.5%	XIAFLEX.xml:S1:9173:4	0.5%	CD	O	O
)	XIAFLEX.xml:S1:9177:1	)	)	O	O
XIAFLEX	XIAFLEX.xml:S1:9179:7	xiaflex	NN	O	O
treated	XIAFLEX.xml:S1:9187:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:9195:8	patient	NNS	O	O
.	XIAFLEX.xml:S1:9203:1	.	.	O	O

In	XIAFLEX.xml:S1:9210:2	In	IN	O	O
other	XIAFLEX.xml:S1:9213:5	other	JJ	O	O
XIAFLEX	XIAFLEX.xml:S1:9219:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:9226:1	-	:	O	O
treated	XIAFLEX.xml:S1:9227:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:9235:8	patient	NNS	O	O
(	XIAFLEX.xml:S1:9244:1	(	(	O	O
9	XIAFLEX.xml:S1:9245:1	9	CD	O	O
of	XIAFLEX.xml:S1:9247:2	of	IN	O	O
1044	XIAFLEX.xml:S1:9250:4	1044	CD	O	O
;	XIAFLEX.xml:S1:9254:1	;	:	O	O
0.9%	XIAFLEX.xml:S1:9256:4	0.9%	CD	O	O
)	XIAFLEX.xml:S1:9260:1	)	)	O	O
,	XIAFLEX.xml:S1:9261:1	,	,	O	O
a	XIAFLEX.xml:S1:9263:1	a	DT	O	O
combination	XIAFLEX.xml:S1:9265:11	combin	NN	O	O
of	XIAFLEX.xml:S1:9277:2	of	IN	O	O
penile	XIAFLEX.xml:S1:9280:6	penil	JJ	B-AdverseReaction	O
ecchymoses	XIAFLEX.xml:S1:9287:10	ecchymos	NNS	I-AdverseReaction	O
or	XIAFLEX.xml:S1:9298:2	or	CC	O	O
hematoma	XIAFLEX.xml:S1:9301:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:9309:1	,	,	O	O
sudden	XIAFLEX.xml:S1:9311:6	sudden	JJ	O	B-AdverseReaction
penile	XIAFLEX.xml:S1:9318:6	penil	NN	B-AdverseReaction	I-AdverseReaction
detumescence	XIAFLEX.xml:S1:9325:12	detumesc	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:9337:1	,	,	O	O
and	XIAFLEX.xml:S1:9339:3	and	CC	O	O
or	XIAFLEX.xml:S1:9343:2	or	CC	O	O
a	XIAFLEX.xml:S1:9346:1	a	DT	O	O
penile	XIAFLEX.xml:S1:9348:6	penil	JJ	B-AdverseReaction	O
"	XIAFLEX.xml:S1:9355:1	"	NN	I-AdverseReaction	O
popping	XIAFLEX.xml:S1:9356:7	pop	VBG	I-AdverseReaction	O
"	XIAFLEX.xml:S1:9363:1	"	JJ	I-AdverseReaction	O
sound	XIAFLEX.xml:S1:9365:5	sound	NN	I-AdverseReaction	O
or	XIAFLEX.xml:S1:9371:2	or	CC	O	O
sensation	XIAFLEX.xml:S1:9374:9	sensat	NN	I-AdverseReaction	B-AdverseReaction
was	XIAFLEX.xml:S1:9384:3	wa	VBD	O	O
reported	XIAFLEX.xml:S1:9388:8	report	VBN	O	O
,	XIAFLEX.xml:S1:9396:1	,	,	O	O
and	XIAFLEX.xml:S1:9398:3	and	CC	O	O
in	XIAFLEX.xml:S1:9402:2	in	IN	O	O
these	XIAFLEX.xml:S1:9405:5	these	DT	O	O
cases	XIAFLEX.xml:S1:9411:5	case	NNS	O	O
,	XIAFLEX.xml:S1:9416:1	,	,	O	O
a	XIAFLEX.xml:S1:9418:1	a	DT	O	O
diagnosis	XIAFLEX.xml:S1:9420:9	diagnosi	NN	O	O
of	XIAFLEX.xml:S1:9430:2	of	IN	O	O
corporal	XIAFLEX.xml:S1:9433:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S1:9442:7	ruptur	NN	I-AdverseReaction	O
cannot	XIAFLEX.xml:S1:9450:6	cannot	NN	O	O
be	XIAFLEX.xml:S1:9457:2	be	VB	O	O
excluded	XIAFLEX.xml:S1:9460:8	exclud	VBN	O	O
.	XIAFLEX.xml:S1:9468:1	.	.	O	O

These	XIAFLEX.xml:S1:9470:5	these	DT	O	O
patients	XIAFLEX.xml:S1:9476:8	patient	NNS	O	O
were	XIAFLEX.xml:S1:9485:4	were	VBD	O	O
managed	XIAFLEX.xml:S1:9490:7	manag	VBN	O	O
without	XIAFLEX.xml:S1:9498:7	without	IN	O	O
surgical	XIAFLEX.xml:S1:9506:8	surgic	JJ	O	O
intervention	XIAFLEX.xml:S1:9515:12	intervent	NN	O	O
,	XIAFLEX.xml:S1:9527:1	,	,	O	O
but	XIAFLEX.xml:S1:9529:3	but	CC	O	O
the	XIAFLEX.xml:S1:9533:3	the	DT	O	O
long	XIAFLEX.xml:S1:9537:4	long	JJ	O	O
-	XIAFLEX.xml:S1:9541:1	-	:	O	O
term	XIAFLEX.xml:S1:9542:4	term	NN	O	O
consequences	XIAFLEX.xml:S1:9547:12	consequ	NNS	O	O
are	XIAFLEX.xml:S1:9560:3	are	VBP	O	O
unknown	XIAFLEX.xml:S1:9564:7	unknown	JJ	O	O
.	XIAFLEX.xml:S1:9571:1	.	.	O	O

Severe	XIAFLEX.xml:S1:9578:6	sever	NNP	O	O
penile	XIAFLEX.xml:S1:9585:6	penil	NN	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:9592:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
was	XIAFLEX.xml:S1:9601:3	wa	VBD	O	O
also	XIAFLEX.xml:S1:9605:4	also	RB	O	O
reported	XIAFLEX.xml:S1:9610:8	report	VBN	O	O
as	XIAFLEX.xml:S1:9619:2	as	IN	O	O
an	XIAFLEX.xml:S1:9622:2	an	DT	O	O
adverse	XIAFLEX.xml:S1:9625:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:9633:8	reaction	NN	O	O
in	XIAFLEX.xml:S1:9642:2	in	IN	O	O
39	XIAFLEX.xml:S1:9645:2	39	CD	O	O
of	XIAFLEX.xml:S1:9648:2	of	IN	O	O
1044	XIAFLEX.xml:S1:9651:4	1044	CD	O	O
patients	XIAFLEX.xml:S1:9656:8	patient	NNS	O	O
(	XIAFLEX.xml:S1:9665:1	(	(	O	O
3.7%	XIAFLEX.xml:S1:9666:4	3.7%	CD	O	O
)	XIAFLEX.xml:S1:9670:1	)	)	O	O
in	XIAFLEX.xml:S1:9672:2	in	IN	O	O
the	XIAFLEX.xml:S1:9675:3	the	DT	O	O
controlled	XIAFLEX.xml:S1:9679:10	control	VBN	O	O
and	XIAFLEX.xml:S1:9690:3	and	CC	O	O
uncontrolled	XIAFLEX.xml:S1:9694:12	uncontrol	JJ	O	O
clinical	XIAFLEX.xml:S1:9707:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S1:9716:6	trial	NNS	O	O
in	XIAFLEX.xml:S1:9723:2	in	IN	O	O
Peyronie	XIAFLEX.xml:S1:9726:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:9734:2	's	POS	O	O
disease	XIAFLEX.xml:S1:9737:7	diseas	NN	O	O
[	XIAFLEX.xml:S1:9747:1	[	NNP	O	O
see	XIAFLEX.xml:S1:9748:3	see	VBP	O	O
Adverse	XIAFLEX.xml:S1:9752:7	advers	JJ	O	O
Reactions	XIAFLEX.xml:S1:9760:9	reaction	NNP	O	O
(	XIAFLEX.xml:S1:9770:1	(	(	O	O
6	XIAFLEX.xml:S1:9771:1	6	CD	O	O
)]	XIAFLEX.xml:S1:9772:2	)]	NN	O	O
.	XIAFLEX.xml:S1:9774:1	.	.	O	O

The	XIAFLEX.xml:S1:9784:3	the	DT	O	O
data	XIAFLEX.xml:S1:9788:4	data	NNS	O	O
described	XIAFLEX.xml:S1:9793:9	describ	VBN	O	O
below	XIAFLEX.xml:S1:9803:5	below	IN	O	O
are	XIAFLEX.xml:S1:9809:3	are	VBP	O	O
based	XIAFLEX.xml:S1:9813:5	base	VBN	O	O
on	XIAFLEX.xml:S1:9819:2	on	IN	O	O
two	XIAFLEX.xml:S1:9822:3	two	CD	O	O
identical	XIAFLEX.xml:S1:9826:9	ident	JJ	O	O
,	XIAFLEX.xml:S1:9835:1	,	,	O	O
pooled	XIAFLEX.xml:S1:9837:6	pool	VBD	O	O
,	XIAFLEX.xml:S1:9843:1	,	,	O	O
randomized	XIAFLEX.xml:S1:9845:10	random	VBN	O	O
,	XIAFLEX.xml:S1:9855:1	,	,	O	O
double	XIAFLEX.xml:S1:9857:6	doubl	JJ	O	O
-	XIAFLEX.xml:S1:9863:1	-	:	O	O
blind	XIAFLEX.xml:S1:9864:5	blind	NN	O	O
,	XIAFLEX.xml:S1:9869:1	,	,	O	O
placebo	XIAFLEX.xml:S1:9871:7	placebo	SYM	O	O
-	XIAFLEX.xml:S1:9878:1	-	:	O	O
controlled	XIAFLEX.xml:S1:9879:10	control	VBN	O	O
,	XIAFLEX.xml:S1:9889:1	,	,	O	O
multi	XIAFLEX.xml:S1:9891:5	multi	SYM	O	O
-	XIAFLEX.xml:S1:9896:1	-	:	O	O
center	XIAFLEX.xml:S1:9897:6	center	NN	O	O
trials	XIAFLEX.xml:S1:9904:6	trial	NNS	O	O
through	XIAFLEX.xml:S1:9911:7	through	IN	O	O
Day	XIAFLEX.xml:S1:9919:3	day	NNP	O	O
365	XIAFLEX.xml:S1:9923:3	365	CD	O	O
in	XIAFLEX.xml:S1:9927:2	in	IN	O	O
patients	XIAFLEX.xml:S1:9930:8	patient	NNS	O	O
with	XIAFLEX.xml:S1:9939:4	with	IN	O	O
Peyronie	XIAFLEX.xml:S1:9944:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:9952:2	's	POS	O	O
disease	XIAFLEX.xml:S1:9955:7	diseas	NN	O	O
(	XIAFLEX.xml:S1:9963:1	(	(	O	O
Studies	XIAFLEX.xml:S1:9964:7	studi	NNPS	O	O
1	XIAFLEX.xml:S1:9972:1	1	CD	O	O
and	XIAFLEX.xml:S1:9974:3	and	CC	O	O
2	XIAFLEX.xml:S1:9978:1	2	CD	O	O
)	XIAFLEX.xml:S1:9979:1	)	)	O	O
.	XIAFLEX.xml:S1:9980:1	.	.	O	O

These	XIAFLEX.xml:S1:9982:5	these	DT	O	O
trials	XIAFLEX.xml:S1:9988:6	trial	NNS	O	O
included	XIAFLEX.xml:S1:9995:8	includ	VBD	O	O
832	XIAFLEX.xml:S1:10004:3	832	CD	O	O
patients	XIAFLEX.xml:S1:10008:8	patient	NNS	O	O
of	XIAFLEX.xml:S1:10017:2	of	IN	O	O
whom	XIAFLEX.xml:S1:10020:4	whom	WP	O	O
551	XIAFLEX.xml:S1:10025:3	551	CD	O	O
and	XIAFLEX.xml:S1:10029:3	and	CC	O	O
281	XIAFLEX.xml:S1:10033:3	281	CD	O	O
received	XIAFLEX.xml:S1:10037:8	receiv	VBN	O	O
XIAFLEX	XIAFLEX.xml:S1:10046:7	xiaflex	NN	O	O
and	XIAFLEX.xml:S1:10054:3	and	CC	O	O
placebo	XIAFLEX.xml:S1:10058:7	placebo	NN	O	O
,	XIAFLEX.xml:S1:10065:1	,	,	O	O
respectively	XIAFLEX.xml:S1:10067:12	respect	RB	O	O
.	XIAFLEX.xml:S1:10079:1	.	.	O	O

In	XIAFLEX.xml:S1:10081:2	In	IN	O	O
these	XIAFLEX.xml:S1:10084:5	these	DT	O	O
trials	XIAFLEX.xml:S1:10090:6	trial	NNS	O	O
,	XIAFLEX.xml:S1:10096:1	,	,	O	O
patients	XIAFLEX.xml:S1:10098:8	patient	NNS	O	O
were	XIAFLEX.xml:S1:10107:4	were	VBD	O	O
given	XIAFLEX.xml:S1:10112:5	given	VBN	O	O
up	XIAFLEX.xml:S1:10118:2	up	RP	O	O
to	XIAFLEX.xml:S1:10121:2	to	TO	O	O
4	XIAFLEX.xml:S1:10124:1	4	CD	O	O
treatment	XIAFLEX.xml:S1:10126:9	treatment	NN	O	O
cycles	XIAFLEX.xml:S1:10136:6	cycl	NNS	O	O
of	XIAFLEX.xml:S1:10143:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:10146:7	xiaflex	NNP	O	O
or	XIAFLEX.xml:S1:10154:2	or	CC	O	O
placebo	XIAFLEX.xml:S1:10157:7	placebo	NN	O	O
.	XIAFLEX.xml:S1:10164:1	.	.	O	O

In	XIAFLEX.xml:S1:10166:2	In	IN	O	O
each	XIAFLEX.xml:S1:10169:4	each	DT	O	O
cycle	XIAFLEX.xml:S1:10174:5	cycl	NN	O	O
,	XIAFLEX.xml:S1:10179:1	,	,	O	O
two	XIAFLEX.xml:S1:10181:3	two	CD	O	O
injections	XIAFLEX.xml:S1:10185:10	inject	NNS	O	O
of	XIAFLEX.xml:S1:10196:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:10199:7	xiaflex	NNP	O	O
or	XIAFLEX.xml:S1:10207:2	or	CC	O	O
two	XIAFLEX.xml:S1:10210:3	two	CD	O	O
injections	XIAFLEX.xml:S1:10214:10	inject	NNS	O	O
of	XIAFLEX.xml:S1:10225:2	of	IN	O	O
placebo	XIAFLEX.xml:S1:10228:7	placebo	NN	O	O
were	XIAFLEX.xml:S1:10236:4	were	VBD	O	O
administered	XIAFLEX.xml:S1:10241:12	administ	VBN	O	O
1	XIAFLEX.xml:S1:10254:1	1	CD	O	O
to	XIAFLEX.xml:S1:10256:2	to	TO	O	O
3	XIAFLEX.xml:S1:10259:1	3	CD	O	O
days	XIAFLEX.xml:S1:10261:4	day	NNS	O	O
apart	XIAFLEX.xml:S1:10266:5	apart	RB	O	O
.	XIAFLEX.xml:S1:10271:1	.	.	O	O

A	XIAFLEX.xml:S1:10273:1	A	DT	O	O
penile	XIAFLEX.xml:S1:10275:6	penil	NN	O	O
modeling	XIAFLEX.xml:S1:10282:8	model	VBG	O	O
procedure	XIAFLEX.xml:S1:10291:9	procedur	NN	O	O
was	XIAFLEX.xml:S1:10301:3	wa	VBD	O	O
performed	XIAFLEX.xml:S1:10305:9	perform	VBN	O	O
at	XIAFLEX.xml:S1:10315:2	at	IN	O	O
the	XIAFLEX.xml:S1:10318:3	the	DT	O	O
study	XIAFLEX.xml:S1:10322:5	studi	NN	O	O
site	XIAFLEX.xml:S1:10328:4	site	NN	O	O
on	XIAFLEX.xml:S1:10333:2	on	IN	O	O
patients	XIAFLEX.xml:S1:10336:8	patient	NNS	O	O
1	XIAFLEX.xml:S1:10345:1	1	CD	O	O
to	XIAFLEX.xml:S1:10347:2	to	TO	O	O
3	XIAFLEX.xml:S1:10350:1	3	CD	O	O
days	XIAFLEX.xml:S1:10352:4	day	NNS	O	O
after	XIAFLEX.xml:S1:10357:5	after	IN	O	O
the	XIAFLEX.xml:S1:10363:3	the	DT	O	O
second	XIAFLEX.xml:S1:10367:6	second	JJ	O	O
injection	XIAFLEX.xml:S1:10374:9	inject	NN	O	O
of	XIAFLEX.xml:S1:10384:2	of	IN	O	O
the	XIAFLEX.xml:S1:10387:3	the	DT	O	O
cycle	XIAFLEX.xml:S1:10391:5	cycl	NN	O	O
.	XIAFLEX.xml:S1:10396:1	.	.	O	O

The	XIAFLEX.xml:S1:10398:3	the	DT	O	O
treatment	XIAFLEX.xml:S1:10402:9	treatment	NN	O	O
cycle	XIAFLEX.xml:S1:10412:5	cycl	NN	O	O
was	XIAFLEX.xml:S1:10418:3	wa	VBD	O	O
repeated	XIAFLEX.xml:S1:10422:8	repeat	VBN	O	O
at	XIAFLEX.xml:S1:10431:2	at	IN	O	O
approximately	XIAFLEX.xml:S1:10434:13	approxim	RB	O	O
6	XIAFLEX.xml:S1:10448:1	6	CD	O	O
-	XIAFLEX.xml:S1:10449:1	-	:	O	O
week	XIAFLEX.xml:S1:10450:4	week	NN	O	O
intervals	XIAFLEX.xml:S1:10455:9	interv	NNS	O	O
up	XIAFLEX.xml:S1:10465:2	up	RB	O	O
to	XIAFLEX.xml:S1:10468:2	to	TO	O	O
three	XIAFLEX.xml:S1:10471:5	three	CD	O	O
additional	XIAFLEX.xml:S1:10477:10	addit	JJ	O	O
times	XIAFLEX.xml:S1:10488:5	time	NNS	O	O
,	XIAFLEX.xml:S1:10493:1	,	,	O	O
for	XIAFLEX.xml:S1:10495:3	for	IN	O	O
a	XIAFLEX.xml:S1:10499:1	a	DT	O	O
maximum	XIAFLEX.xml:S1:10501:7	maximum	NN	O	O
of	XIAFLEX.xml:S1:10509:2	of	IN	O	O
8	XIAFLEX.xml:S1:10512:1	8	CD	O	O
total	XIAFLEX.xml:S1:10514:5	total	JJ	O	O
injection	XIAFLEX.xml:S1:10520:9	inject	NN	O	O
procedures	XIAFLEX.xml:S1:10530:10	procedur	NNS	O	O
and	XIAFLEX.xml:S1:10541:3	and	CC	O	O
4	XIAFLEX.xml:S1:10545:1	4	CD	O	O
total	XIAFLEX.xml:S1:10547:5	total	JJ	O	B-AdverseReaction
modeling	XIAFLEX.xml:S1:10553:8	model	NN	O	I-AdverseReaction
procedures	XIAFLEX.xml:S1:10562:10	procedur	NNS	O	I-AdverseReaction
[	XIAFLEX.xml:S1:10576:1	[	VBP	O	O
see	XIAFLEX.xml:S1:10577:3	see	VB	O	O
Clinical	XIAFLEX.xml:S1:10581:8	clinic	JJ	O	O
Studies	XIAFLEX.xml:S1:10590:7	studi	NNP	O	O
(	XIAFLEX.xml:S1:10598:1	(	(	O	O
14.2	XIAFLEX.xml:S1:10599:4	14.2	CD	O	O
)]	XIAFLEX.xml:S1:10603:2	)]	NN	O	O
.	XIAFLEX.xml:S1:10605:1	.	.	O	O

The	XIAFLEX.xml:S1:10615:3	the	DT	O	O

majority	XIAFLEX.xml:S1:10619:8	major	NN	O	O
of	XIAFLEX.xml:S1:10628:2	of	IN	O	O
Peyronie	XIAFLEX.xml:S1:10631:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:10639:2	's	POS	O	O
patients	XIAFLEX.xml:S1:10642:8	patient	NNS	O	O
experienced	XIAFLEX.xml:S1:10651:11	experienc	VBD	O	O
at	XIAFLEX.xml:S1:10663:2	at	IN	O	O
least	XIAFLEX.xml:S1:10666:5	least	JJS	O	O
one	XIAFLEX.xml:S1:10672:3	one	CD	O	O
adverse	XIAFLEX.xml:S1:10676:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:10684:8	reaction	NN	O	O
(	XIAFLEX.xml:S1:10693:1	(	(	O	O
92%	XIAFLEX.xml:S1:10694:3	92%	CD	O	O
XIAFLEX	XIAFLEX.xml:S1:10698:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:10705:1	-	:	O	O
treated	XIAFLEX.xml:S1:10706:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:10714:8	patient	NNS	O	O
,	XIAFLEX.xml:S1:10722:1	,	,	O	O
61%	XIAFLEX.xml:S1:10724:3	61%	CD	O	O
placebo	XIAFLEX.xml:S1:10728:7	placebo	NN	O	O
-	XIAFLEX.xml:S1:10735:1	-	:	O	O
treated	XIAFLEX.xml:S1:10736:7	treat	VBN	O	O
)	XIAFLEX.xml:S1:10743:1	)	)	O	O
.	XIAFLEX.xml:S1:10744:1	.	.	O	O

Most	XIAFLEX.xml:S1:10746:4	most	JJS	O	O
adverse	XIAFLEX.xml:S1:10751:7	advers	JJ	B-AdverseReaction	O
reactions	XIAFLEX.xml:S1:10759:9	reaction	NNS	I-AdverseReaction	O
were	XIAFLEX.xml:S1:10769:4	were	VBD	O	O
local	XIAFLEX.xml:S1:10774:5	local	JJ	O	B-AdverseReaction
events	XIAFLEX.xml:S1:10780:6	event	NNS	O	I-AdverseReaction
of	XIAFLEX.xml:S1:10787:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	XIAFLEX.xml:S1:10790:3	the	DT	I-AdverseReaction	I-AdverseReaction
penis	XIAFLEX.xml:S1:10794:5	peni	NN	I-AdverseReaction	I-AdverseReaction
and	XIAFLEX.xml:S1:10800:3	and	CC	O	O
groin	XIAFLEX.xml:S1:10804:5	groin	NN	I-AdverseReaction	O
and	XIAFLEX.xml:S1:10810:3	and	CC	O	O
the	XIAFLEX.xml:S1:10814:3	the	DT	O	O
majority	XIAFLEX.xml:S1:10818:8	major	NN	O	O
of	XIAFLEX.xml:S1:10827:2	of	IN	O	O
these	XIAFLEX.xml:S1:10830:5	these	DT	O	O
events	XIAFLEX.xml:S1:10836:6	event	NNS	O	O
were	XIAFLEX.xml:S1:10843:4	were	VBD	O	O
of	XIAFLEX.xml:S1:10848:2	of	IN	O	O
mild	XIAFLEX.xml:S1:10851:4	mild	NN	O	O
or	XIAFLEX.xml:S1:10856:2	or	CC	O	O
moderate	XIAFLEX.xml:S1:10859:8	moder	JJ	O	O
severity	XIAFLEX.xml:S1:10868:8	sever	NN	O	O
,	XIAFLEX.xml:S1:10876:1	,	,	O	O
and	XIAFLEX.xml:S1:10878:3	and	CC	O	O
most	XIAFLEX.xml:S1:10882:4	most	JJS	O	O
(	XIAFLEX.xml:S1:10887:1	(	(	O	O
79%	XIAFLEX.xml:S1:10888:3	79%	CD	O	O
)	XIAFLEX.xml:S1:10891:1	)	)	O	O
resolved	XIAFLEX.xml:S1:10893:8	resolv	VBD	O	O
within	XIAFLEX.xml:S1:10902:6	within	IN	O	O
14	XIAFLEX.xml:S1:10909:2	14	CD	O	O
days	XIAFLEX.xml:S1:10912:4	day	NNS	O	O
of	XIAFLEX.xml:S1:10917:2	of	IN	O	O
the	XIAFLEX.xml:S1:10920:3	the	DT	O	O
injection	XIAFLEX.xml:S1:10924:9	inject	NN	O	O
.	XIAFLEX.xml:S1:10933:1	.	.	O	O

The	XIAFLEX.xml:S1:10935:3	the	DT	O	O
adverse	XIAFLEX.xml:S1:10939:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S1:10947:8	reaction	NN	O	O
profile	XIAFLEX.xml:S1:10956:7	profil	NN	O	O
was	XIAFLEX.xml:S1:10964:3	wa	VBD	O	O
similar	XIAFLEX.xml:S1:10968:7	similar	JJ	O	O
after	XIAFLEX.xml:S1:10976:5	after	IN	O	O
each	XIAFLEX.xml:S1:10982:4	each	DT	O	O
injection	XIAFLEX.xml:S1:10987:9	inject	NN	O	O
,	XIAFLEX.xml:S1:10996:1	,	,	O	O
regardless	XIAFLEX.xml:S1:10998:10	regardless	RB	O	O
of	XIAFLEX.xml:S1:11009:2	of	IN	O	O
the	XIAFLEX.xml:S1:11012:3	the	DT	O	O
number	XIAFLEX.xml:S1:11016:6	number	NN	O	O
of	XIAFLEX.xml:S1:11023:2	of	IN	O	O
injections	XIAFLEX.xml:S1:11026:10	inject	NNS	O	O
administered	XIAFLEX.xml:S1:11037:12	administ	VBN	O	O
.	XIAFLEX.xml:S1:11049:1	.	.	O	O

The	XIAFLEX.xml:S1:11055:3	the	DT	O	O
most	XIAFLEX.xml:S1:11059:4	most	RBS	O	O
frequently	XIAFLEX.xml:S1:11064:10	frequent	RB	O	O
reported	XIAFLEX.xml:S1:11075:8	report	VBD	O	O
adverse	XIAFLEX.xml:S1:11084:7	advers	JJ	O	O
drug	XIAFLEX.xml:S1:11092:4	drug	NN	O	O
reactions	XIAFLEX.xml:S1:11097:9	reaction	NNS	O	O
(	XIAFLEX.xml:S1:11107:1	(	(	O	O
25%	XIAFLEX.xml:S1:11111:3	25%	CD	O	O
)	XIAFLEX.xml:S1:11114:1	)	)	O	O
in	XIAFLEX.xml:S1:11116:2	in	IN	O	O
the	XIAFLEX.xml:S1:11119:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S1:11123:7	xiaflex	NNP	O	O
clinical	XIAFLEX.xml:S1:11131:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S1:11140:6	trial	NNS	O	O
in	XIAFLEX.xml:S1:11147:2	in	IN	O	O
patients	XIAFLEX.xml:S1:11150:8	patient	NNS	O	O
with	XIAFLEX.xml:S1:11159:4	with	IN	O	O
Peyronie	XIAFLEX.xml:S1:11164:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:11172:2	's	POS	O	O
disease	XIAFLEX.xml:S1:11175:7	diseas	NN	O	I-AdverseReaction
were	XIAFLEX.xml:S1:11183:4	were	VBD	O	O
penile	XIAFLEX.xml:S1:11188:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:11195:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:11203:1	,	,	O	O
penile	XIAFLEX.xml:S1:11205:6	penil	IN	B-AdverseReaction	O
swelling	XIAFLEX.xml:S1:11212:8	swell	VBG	I-AdverseReaction	O
,	XIAFLEX.xml:S1:11220:1	,	,	O	O
and	XIAFLEX.xml:S1:11222:3	and	CC	O	O
penile	XIAFLEX.xml:S1:11226:6	penil	RB	B-AdverseReaction	B-AdverseReaction
pain	XIAFLEX.xml:S1:11233:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	XIAFLEX.xml:S1:11237:1	.	.	O	O

Table	XIAFLEX.xml:S1:11239:5	tabl	JJ	O	O
5	XIAFLEX.xml:S1:11245:1	5	CD	O	O
shows	XIAFLEX.xml:S1:11247:5	show	VBZ	O	O
the	XIAFLEX.xml:S1:11253:3	the	DT	O	O
incidence	XIAFLEX.xml:S1:11257:9	incid	NN	O	O
of	XIAFLEX.xml:S1:11267:2	of	IN	O	O
adverse	XIAFLEX.xml:S1:11270:7	advers	JJ	O	O
reactions	XIAFLEX.xml:S1:11278:9	reaction	NNS	O	O
that	XIAFLEX.xml:S1:11288:4	that	WDT	O	O
were	XIAFLEX.xml:S1:11293:4	were	VBD	O	O
reported	XIAFLEX.xml:S1:11298:8	report	VBN	O	O
in	XIAFLEX.xml:S1:11307:2	in	IN	O	O
greater	XIAFLEX.xml:S1:11310:7	greater	JJR	O	O
than	XIAFLEX.xml:S1:11318:4	than	IN	O	O
or	XIAFLEX.xml:S1:11323:2	or	CC	O	O
equal	XIAFLEX.xml:S1:11326:5	equal	JJ	O	O
to	XIAFLEX.xml:S1:11332:2	to	TO	O	O
1%	XIAFLEX.xml:S1:11335:2	1%	CD	O	O
of	XIAFLEX.xml:S1:11338:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:11341:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:11348:1	-	:	O	O
treated	XIAFLEX.xml:S1:11349:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:11357:8	patient	NNS	O	O
and	XIAFLEX.xml:S1:11366:3	and	CC	O	O
at	XIAFLEX.xml:S1:11370:2	at	IN	O	O
a	XIAFLEX.xml:S1:11373:1	a	DT	O	O
frequency	XIAFLEX.xml:S1:11375:9	frequenc	NN	O	O
greater	XIAFLEX.xml:S1:11385:7	greater	JJR	O	O
than	XIAFLEX.xml:S1:11393:4	than	IN	O	O
placebo	XIAFLEX.xml:S1:11398:7	placebo	SYM	O	O
-	XIAFLEX.xml:S1:11405:1	-	:	O	O
treated	XIAFLEX.xml:S1:11406:7	treat	VBN	O	O
patients	XIAFLEX.xml:S1:11414:8	patient	NNS	O	O
after	XIAFLEX.xml:S1:11423:5	after	IN	O	O
up	XIAFLEX.xml:S1:11429:2	up	IN	O	O
to	XIAFLEX.xml:S1:11432:2	to	TO	O	O
8	XIAFLEX.xml:S1:11435:1	8	CD	O	O
injections	XIAFLEX.xml:S1:11437:10	inject	NNS	O	O
in	XIAFLEX.xml:S1:11448:2	in	IN	O	O
the	XIAFLEX.xml:S1:11451:3	the	DT	O	O
pooled	XIAFLEX.xml:S1:11455:6	pool	JJ	O	O
placebo	XIAFLEX.xml:S1:11462:7	placebo	NN	O	O
-	XIAFLEX.xml:S1:11469:1	-	:	O	O
controlled	XIAFLEX.xml:S1:11470:10	control	VBN	O	O
trials	XIAFLEX.xml:S1:11481:6	trial	NNS	O	O
through	XIAFLEX.xml:S1:11488:7	through	IN	O	O
Day	XIAFLEX.xml:S1:11496:3	day	NNP	O	O
365	XIAFLEX.xml:S1:11500:3	365	CD	O	O
.	XIAFLEX.xml:S1:11503:1	.	.	O	O

Table	XIAFLEX.xml:S1:11509:5	tabl	JJ	O	O
5	XIAFLEX.xml:S1:11515:1	5	CD	O	O
.	XIAFLEX.xml:S1:11516:1	.	.	O	O

Adverse	XIAFLEX.xml:S1:11518:7	advers	JJ	O	O
Reactions	XIAFLEX.xml:S1:11526:9	reaction	NNP	O	O
Occurring	XIAFLEX.xml:S1:11536:9	occur	NNP	O	O
in	XIAFLEX.xml:S1:11546:2	in	IN	O	O
1%	XIAFLEX.xml:S1:11552:2	1%	CD	O	O
of	XIAFLEX.xml:S1:11555:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:11558:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:11565:1	-	:	O	O
Treated	XIAFLEX.xml:S1:11566:7	treat	VBD	O	O
Patients	XIAFLEX.xml:S1:11574:8	patient	NNS	O	O
with	XIAFLEX.xml:S1:11583:4	with	IN	O	O
Peyronie	XIAFLEX.xml:S1:11588:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:11596:2	's	POS	O	O
disease	XIAFLEX.xml:S1:11599:7	diseas	NN	O	O
and	XIAFLEX.xml:S1:11607:3	and	CC	O	O
at	XIAFLEX.xml:S1:11611:2	at	IN	O	O
a	XIAFLEX.xml:S1:11614:1	a	DT	O	O
Greater	XIAFLEX.xml:S1:11616:7	greater	NNP	O	O
Incidence	XIAFLEX.xml:S1:11624:9	incid	NNP	O	O
than	XIAFLEX.xml:S1:11634:4	than	IN	O	O
Placebo	XIAFLEX.xml:S1:11639:7	placebo	NNP	O	O
After	XIAFLEX.xml:S1:11647:5	after	IN	O	O
Up	XIAFLEX.xml:S1:11653:2	Up	NNP	O	O
to	XIAFLEX.xml:S1:11656:2	to	TO	O	O
Four	XIAFLEX.xml:S1:11659:4	four	CD	O	O
Treatment	XIAFLEX.xml:S1:11664:9	treatment	NN	O	O
Cycles	XIAFLEX.xml:S1:11674:6	cycl	NNP	O	O
in	XIAFLEX.xml:S1:11681:2	in	IN	O	O
Studies	XIAFLEX.xml:S1:11684:7	studi	NNP	O	O
1	XIAFLEX.xml:S1:11692:1	1	CD	O	O
and	XIAFLEX.xml:S1:11694:3	and	CC	O	O
2	XIAFLEX.xml:S1:11698:1	2	CD	O	O
Combined	XIAFLEX.xml:S1:11700:8	combin	VBD	O	O

a	XIAFLEX.xml:S1:11714:1	a	DT	O	O
Includes	XIAFLEX.xml:S1:11717:8	includ	NNS	O	O
:	XIAFLEX.xml:S1:11725:1	:	:	O	O
injection	XIAFLEX.xml:S1:11727:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:11737:4	site	NN	I-AdverseReaction	I-AdverseReaction
hematoma	XIAFLEX.xml:S1:11742:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
and	XIAFLEX.xml:S1:11751:3	and	CC	O	O
penile	XIAFLEX.xml:S1:11755:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:11762:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
were	XIAFLEX.xml:S1:11771:4	were	VBD	O	O
reported	XIAFLEX.xml:S1:11776:8	report	VBN	O	O
with	XIAFLEX.xml:S1:11785:4	with	IN	O	O
the	XIAFLEX.xml:S1:11790:3	the	DT	O	O
verbatim	XIAFLEX.xml:S1:11794:8	verbatim	JJ	O	O
term	XIAFLEX.xml:S1:11803:4	term	NN	O	O
of	XIAFLEX.xml:S1:11808:2	of	IN	O	O
penile	XIAFLEX.xml:S1:11811:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
bruising	XIAFLEX.xml:S1:11818:8	bruis	NN	I-AdverseReaction	I-AdverseReaction
or	XIAFLEX.xml:S1:11827:2	or	CC	O	O
injection	XIAFLEX.xml:S1:11830:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:11840:4	site	NN	I-AdverseReaction	I-AdverseReaction
bruising	XIAFLEX.xml:S1:11845:8	bruis	NN	I-AdverseReaction	I-AdverseReaction
in	XIAFLEX.xml:S1:11854:2	in	IN	O	O
87%	XIAFLEX.xml:S1:11857:3	87%	CD	O	O
of	XIAFLEX.xml:S1:11861:2	of	IN	O	O
subjects	XIAFLEX.xml:S1:11864:8	subject	NNS	O	O
.	XIAFLEX.xml:S1:11872:1	.	.	O	O

b	XIAFLEX.xml:S1:11881:1	b	NN	O	O
Includes	XIAFLEX.xml:S1:11884:8	includ	NNS	O	O
:	XIAFLEX.xml:S1:11892:1	:	:	O	O
injection	XIAFLEX.xml:S1:11894:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:11904:4	site	NN	I-AdverseReaction	I-AdverseReaction
swelling	XIAFLEX.xml:S1:11909:8	swell	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:11917:1	,	,	O	O
penile	XIAFLEX.xml:S1:11919:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
edema	XIAFLEX.xml:S1:11926:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:11931:1	,	,	O	O
penile	XIAFLEX.xml:S1:11933:6	penil	IN	B-AdverseReaction	I-AdverseReaction
swelling	XIAFLEX.xml:S1:11940:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:11948:1	,	,	O	O
local	XIAFLEX.xml:S1:11950:5	local	JJ	B-AdverseReaction	B-AdverseReaction
swelling	XIAFLEX.xml:S1:11956:8	swell	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:11964:1	,	,	O	O
scrotal	XIAFLEX.xml:S1:11966:7	scrotal	JJ	B-AdverseReaction	B-AdverseReaction
swelling	XIAFLEX.xml:S1:11974:8	swell	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:11982:1	,	,	O	O
and	XIAFLEX.xml:S1:11984:3	and	CC	O	O
injection	XIAFLEX.xml:S1:11988:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:11998:4	site	NN	I-AdverseReaction	I-AdverseReaction
edema	XIAFLEX.xml:S1:12003:5	edema	NN	I-AdverseReaction	I-AdverseReaction
.	XIAFLEX.xml:S1:12008:1	.	.	O	O

c	XIAFLEX.xml:S1:12017:1	c	SYM	O	O
Includes	XIAFLEX.xml:S1:12020:8	includ	NNS	O	O
:	XIAFLEX.xml:S1:12028:1	:	:	O	O
injection	XIAFLEX.xml:S1:12030:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:12040:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	XIAFLEX.xml:S1:12045:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:12049:1	,	,	O	O
penile	XIAFLEX.xml:S1:12051:6	penil	NN	B-AdverseReaction	B-AdverseReaction
pain	XIAFLEX.xml:S1:12058:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:12062:1	,	,	O	O
and	XIAFLEX.xml:S1:12064:3	and	CC	O	O
injection	XIAFLEX.xml:S1:12068:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:12078:4	site	NN	I-AdverseReaction	I-AdverseReaction
discomfort	XIAFLEX.xml:S1:12083:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
.	XIAFLEX.xml:S1:12093:1	.	.	O	O

d	XIAFLEX.xml:S1:12102:1	d	NN	O	O
Includes	XIAFLEX.xml:S1:12105:8	includ	NNS	O	O
:	XIAFLEX.xml:S1:12113:1	:	:	O	O
contusion	XIAFLEX.xml:S1:12115:9	contus	NN	B-AdverseReaction	O
,	XIAFLEX.xml:S1:12124:1	,	,	O	O
ecchymoses	XIAFLEX.xml:S1:12126:10	ecchymos	VBZ	B-AdverseReaction	O
,	XIAFLEX.xml:S1:12136:1	,	,	O	O
penile	XIAFLEX.xml:S1:12138:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:12145:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:12155:1	,	,	O	O
and	XIAFLEX.xml:S1:12157:3	and	CC	O	O
injection	XIAFLEX.xml:S1:12161:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:12171:4	site	NN	I-AdverseReaction	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:12176:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
.	XIAFLEX.xml:S1:12186:1	.	.	O	O

Adverse	XIAFLEX.xml:S1:12198:7	advers	NN	O	O

Reaction	XIAFLEX.xml:S1:12206:8	reaction	NNP	O	O
XIAFLEXN	XIAFLEX.xml:S1:12240:8	xiaflexn	NNP	O	O
551	XIAFLEX.xml:S1:12249:3	551	CD	O	O
PlaceboN	XIAFLEX.xml:S1:12262:8	placebon	NNP	O	O
281	XIAFLEX.xml:S1:12271:3	281	CD	O	O

All	XIAFLEX.xml:S1:12305:3	all	DT	O	O
Adverse	XIAFLEX.xml:S1:12309:7	advers	NNP	O	O
Reactions	XIAFLEX.xml:S1:12317:9	reaction	NNP	O	O
84.2%	XIAFLEX.xml:S1:12347:5	84.2%	CD	O	O
36.3%	XIAFLEX.xml:S1:12369:5	36.3%	CD	O	O

Penile	XIAFLEX.xml:S1:12414:6	penil	NNP	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:12421:8	hematoma	VBD	I-AdverseReaction	I-AdverseReaction
a	XIAFLEX.xml:S1:12431:1	a	DT	O	O
65.5%	XIAFLEX.xml:S1:12456:5	65.5%	CD	O	O
19.2%	XIAFLEX.xml:S1:12478:5	19.2%	CD	O	O

Penile	XIAFLEX.xml:S1:12523:6	penil	NNP	B-AdverseReaction	B-AdverseReaction
swelling	XIAFLEX.xml:S1:12530:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
b	XIAFLEX.xml:S1:12540:1	b	NN	O	I-AdverseReaction
55.0%	XIAFLEX.xml:S1:12565:5	55.0%	CD	O	O
3.2%	XIAFLEX.xml:S1:12587:4	3.2%	CD	O	O

Penile	XIAFLEX.xml:S1:12632:6	penil	NNP	B-AdverseReaction	B-AdverseReaction
pain	XIAFLEX.xml:S1:12639:4	pain	NN	I-AdverseReaction	I-AdverseReaction
c	XIAFLEX.xml:S1:12645:1	c	VBD	O	O
45.4%	XIAFLEX.xml:S1:12674:5	45.4%	CD	O	O
9.3%	XIAFLEX.xml:S1:12696:4	9.3%	CD	O	O

Penile	XIAFLEX.xml:S1:12741:6	penil	NNP	B-AdverseReaction	O
ecchymoses	XIAFLEX.xml:S1:12748:10	ecchymos	VBZ	I-AdverseReaction	O
d	XIAFLEX.xml:S1:12760:1	d	VBP	O	O
14.5%	XIAFLEX.xml:S1:12783:5	14.5%	CD	O	O
6.8%	XIAFLEX.xml:S1:12805:4	6.8%	CD	O	O

Blood	XIAFLEX.xml:S1:12850:5	blood	NNP	B-AdverseReaction	B-AdverseReaction
blister	XIAFLEX.xml:S1:12856:7	blister	NN	I-AdverseReaction	I-AdverseReaction
4.5%	XIAFLEX.xml:S1:12892:4	4.5%	CD	O	O
0	XIAFLEX.xml:S1:12914:1	0	CD	O	O

Penile	XIAFLEX.xml:S1:12959:6	penil	NNP	B-AdverseReaction	B-AdverseReaction
blister	XIAFLEX.xml:S1:12966:7	blister	NN	I-AdverseReaction	I-AdverseReaction
3.3%	XIAFLEX.xml:S1:13001:4	3.3%	CD	O	O
0	XIAFLEX.xml:S1:13023:1	0	CD	O	O

Pruritus	XIAFLEX.xml:S1:13068:8	pruritu	NNP	B-AdverseReaction	B-AdverseReaction
genital	XIAFLEX.xml:S1:13077:7	genit	JJ	I-AdverseReaction	I-AdverseReaction
3.1%	XIAFLEX.xml:S1:13110:4	3.1%	CD	O	O
0	XIAFLEX.xml:S1:13132:1	0	CD	O	O

Painful	XIAFLEX.xml:S1:13177:7	pain	JJ	B-AdverseReaction	B-AdverseReaction
erection	XIAFLEX.xml:S1:13185:8	erect	NN	I-AdverseReaction	I-AdverseReaction
2.9%	XIAFLEX.xml:S1:13219:4	2.9%	CD	O	O
0	XIAFLEX.xml:S1:13241:1	0	CD	O	O

Erectile	XIAFLEX.xml:S1:13286:8	erectil	NNP	B-AdverseReaction	B-AdverseReaction
dysfunction	XIAFLEX.xml:S1:13295:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
1.8%	XIAFLEX.xml:S1:13328:4	1.8%	CD	O	O
0.4%	XIAFLEX.xml:S1:13350:4	0.4%	CD	O	O

Skin	XIAFLEX.xml:S1:13395:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
discoloration	XIAFLEX.xml:S1:13400:13	discolor	NN	I-AdverseReaction	I-AdverseReaction
1.8%	XIAFLEX.xml:S1:13437:4	1.8%	CD	O	O
0	XIAFLEX.xml:S1:13459:1	0	CD	O	O

Procedural	XIAFLEX.xml:S1:13504:10	procedur	NNP	B-AdverseReaction	B-AdverseReaction
pain	XIAFLEX.xml:S1:13515:4	pain	NN	I-AdverseReaction	I-AdverseReaction
1.6%	XIAFLEX.xml:S1:13546:4	1.6%	CD	O	O
0.7%	XIAFLEX.xml:S1:13568:4	0.7%	CD	O	O

Injection	XIAFLEX.xml:S1:13613:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:13623:4	site	NN	I-AdverseReaction	I-AdverseReaction
vesicles	XIAFLEX.xml:S1:13628:8	vesicl	NNS	I-AdverseReaction	I-AdverseReaction
1.3%	XIAFLEX.xml:S1:13655:4	1.3%	CD	O	O
0	XIAFLEX.xml:S1:13677:1	0	CD	O	O

Localized	XIAFLEX.xml:S1:13722:9	local	VBN	B-AdverseReaction	B-AdverseReaction
edema	XIAFLEX.xml:S1:13732:5	edema	RB	I-AdverseReaction	I-AdverseReaction
1.3%	XIAFLEX.xml:S1:13764:4	1.3%	CD	O	O
0	XIAFLEX.xml:S1:13786:1	0	CD	O	O

Dyspareunia	XIAFLEX.xml:S1:13831:11	dyspareunia	NNP	B-AdverseReaction	B-AdverseReaction
1.1%	XIAFLEX.xml:S1:13873:4	1.1%	CD	O	O
0	XIAFLEX.xml:S1:13895:1	0	CD	O	O

Injection	XIAFLEX.xml:S1:13940:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:13950:4	site	NN	I-AdverseReaction	I-AdverseReaction
pruritus	XIAFLEX.xml:S1:13955:8	pruritu	NN	I-AdverseReaction	I-AdverseReaction
1.1%	XIAFLEX.xml:S1:13982:4	1.1%	CD	O	O
0	XIAFLEX.xml:S1:14004:1	0	CD	O	O

Nodule	XIAFLEX.xml:S1:14049:6	nodul	NNP	B-AdverseReaction	B-AdverseReaction
1.1%	XIAFLEX.xml:S1:14091:4	1.1%	CD	O	O
0	XIAFLEX.xml:S1:14113:1	0	CD	O	O

Suprapubic	XIAFLEX.xml:S1:14158:10	suprapub	NNP	B-AdverseReaction	B-AdverseReaction
pain	XIAFLEX.xml:S1:14169:4	pain	VBP	I-AdverseReaction	I-AdverseReaction
1.1%	XIAFLEX.xml:S1:14200:4	1.1%	CD	O	O
0	XIAFLEX.xml:S1:14222:1	0	CD	O	O

Severe	XIAFLEX.xml:S1:14274:6	sever	NNP	O	O
penile	XIAFLEX.xml:S1:14281:6	penil	NN	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:14288:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
or	XIAFLEX.xml:S1:14297:2	or	CC	O	O
severe	XIAFLEX.xml:S1:14300:6	sever	JJ	O	O
injection	XIAFLEX.xml:S1:14307:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S1:14317:4	site	NN	I-AdverseReaction	I-AdverseReaction
hematoma	XIAFLEX.xml:S1:14322:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
were	XIAFLEX.xml:S1:14331:4	were	VBD	O	O
reported	XIAFLEX.xml:S1:14336:8	report	VBN	O	O
in	XIAFLEX.xml:S1:14345:2	in	IN	O	O
33	XIAFLEX.xml:S1:14348:2	33	CD	O	O
551	XIAFLEX.xml:S1:14351:3	551	CD	O	O
(	XIAFLEX.xml:S1:14355:1	(	(	O	O
6.0%	XIAFLEX.xml:S1:14356:4	6.0%	CD	O	O
)	XIAFLEX.xml:S1:14360:1	)	)	O	O
of	XIAFLEX.xml:S1:14362:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:14365:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:14372:1	-	:	O	O
treated	XIAFLEX.xml:S1:14373:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:14381:8	patient	NNS	O	O
and	XIAFLEX.xml:S1:14390:3	and	CC	O	O
0	XIAFLEX.xml:S1:14394:1	0	CD	O	O
281	XIAFLEX.xml:S1:14396:3	281	CD	O	O
(	XIAFLEX.xml:S1:14400:1	(	(	O	O
0%	XIAFLEX.xml:S1:14401:2	0%	CD	O	O
)	XIAFLEX.xml:S1:14403:1	)	)	O	O
of	XIAFLEX.xml:S1:14405:2	of	IN	O	O
placebo	XIAFLEX.xml:S1:14408:7	placebo	NN	O	O
-	XIAFLEX.xml:S1:14415:1	-	:	O	O
treated	XIAFLEX.xml:S1:14416:7	treat	JJ	O	O
patients	XIAFLEX.xml:S1:14424:8	patient	NNS	O	O
,	XIAFLEX.xml:S1:14432:1	,	,	O	O
in	XIAFLEX.xml:S1:14434:2	in	IN	O	O
Studies	XIAFLEX.xml:S1:14437:7	studi	NNP	O	O
1	XIAFLEX.xml:S1:14445:1	1	CD	O	O
and	XIAFLEX.xml:S1:14447:3	and	CC	O	O
2	XIAFLEX.xml:S1:14451:1	2	CD	O	O
combined	XIAFLEX.xml:S1:14453:8	combin	VBN	O	O
.	XIAFLEX.xml:S1:14461:1	.	.	O	O

Reports	XIAFLEX.xml:S1:14471:7	report	NNS	O	O

of	XIAFLEX.xml:S1:14479:2	of	IN	O	O
penile	XIAFLEX.xml:S1:14482:6	penil	JJ	O	O
"	XIAFLEX.xml:S1:14489:1	"	NNP	O	O
popping	XIAFLEX.xml:S1:14490:7	pop	VBG	O	O
"	XIAFLEX.xml:S1:14497:1	"	JJ	O	O
sounds	XIAFLEX.xml:S1:14499:6	sound	NNS	O	O
or	XIAFLEX.xml:S1:14506:2	or	CC	O	O
sensations	XIAFLEX.xml:S1:14509:10	sensat	NNS	O	O
A	XIAFLEX.xml:S1:14523:1	A	VBP	O	O
popping	XIAFLEX.xml:S1:14525:7	pop	VBG	B-AdverseReaction	O
noise	XIAFLEX.xml:S1:14533:5	nois	NN	I-AdverseReaction	O
or	XIAFLEX.xml:S1:14539:2	or	CC	O	O
popping	XIAFLEX.xml:S1:14542:7	pop	VBG	B-AdverseReaction	O
sensation	XIAFLEX.xml:S1:14550:9	sensat	NN	I-AdverseReaction	O
in	XIAFLEX.xml:S1:14560:2	in	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S1:14563:3	the	DT	I-AdverseReaction	O
penis	XIAFLEX.xml:S1:14567:5	peni	NN	I-AdverseReaction	O
,	XIAFLEX.xml:S1:14572:1	,	,	O	O
sometimes	XIAFLEX.xml:S1:14574:9	sometim	RB	O	O
described	XIAFLEX.xml:S1:14584:9	describ	VBN	O	O
as	XIAFLEX.xml:S1:14594:2	as	IN	O	O
"	XIAFLEX.xml:S1:14597:1	"	JJ	O	O
snapping	XIAFLEX.xml:S1:14598:8	snap	VBG	I-AdverseReaction	O
"	XIAFLEX.xml:S1:14606:1	"	NN	O	O
or	XIAFLEX.xml:S1:14608:2	or	CC	O	O
"	XIAFLEX.xml:S1:14611:1	"	VB	O	O
cracking	XIAFLEX.xml:S1:14612:8	crack	VBG	I-AdverseReaction	O
"	XIAFLEX.xml:S1:14620:1	"	NNP	O	O
,	XIAFLEX.xml:S1:14621:1	,	,	O	O
and	XIAFLEX.xml:S1:14623:3	and	CC	O	O
sometimes	XIAFLEX.xml:S1:14627:9	sometim	RB	O	O
accompanied	XIAFLEX.xml:S1:14637:11	accompani	VBN	O	O
by	XIAFLEX.xml:S1:14649:2	by	IN	O	O
detumescence	XIAFLEX.xml:S1:14652:12	detumesc	NN	B-AdverseReaction	O
,	XIAFLEX.xml:S1:14664:1	,	,	O	O
hematoma	XIAFLEX.xml:S1:14666:8	hematoma	NN	B-AdverseReaction	B-AdverseReaction
and	XIAFLEX.xml:S1:14675:3	and	CC	O	O
or	XIAFLEX.xml:S1:14679:2	or	CC	O	O
pain	XIAFLEX.xml:S1:14682:4	pain	NN	B-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S1:14686:1	,	,	O	O
were	XIAFLEX.xml:S1:14688:4	were	VBD	O	O
reported	XIAFLEX.xml:S1:14693:8	report	VBN	O	O
in	XIAFLEX.xml:S1:14702:2	in	IN	O	O
73	XIAFLEX.xml:S1:14705:2	73	CD	O	O
551	XIAFLEX.xml:S1:14708:3	551	CD	O	O
(	XIAFLEX.xml:S1:14712:1	(	(	O	O
13.2%	XIAFLEX.xml:S1:14713:5	13.2%	CD	O	O
)	XIAFLEX.xml:S1:14718:1	)	)	O	O
XIAFLEX	XIAFLEX.xml:S1:14720:7	xiaflex	SYM	O	O
-	XIAFLEX.xml:S1:14727:1	-	:	O	O
treated	XIAFLEX.xml:S1:14728:7	treat	JJ	O	O
patients	XIAFLEX.xml:S1:14736:8	patient	NNS	O	O
and	XIAFLEX.xml:S1:14745:3	and	CC	O	O
1	XIAFLEX.xml:S1:14749:1	1	CD	O	O
281	XIAFLEX.xml:S1:14751:3	281	CD	O	O
(	XIAFLEX.xml:S1:14755:1	(	(	O	O
0.3%	XIAFLEX.xml:S1:14756:4	0.3%	CD	O	O
)	XIAFLEX.xml:S1:14760:1	)	)	O	O
placebo	XIAFLEX.xml:S1:14762:7	placebo	NN	O	O
-	XIAFLEX.xml:S1:14769:1	-	:	O	O
treated	XIAFLEX.xml:S1:14770:7	treat	JJ	O	O
patients	XIAFLEX.xml:S1:14778:8	patient	NNS	O	O
.	XIAFLEX.xml:S1:14786:1	.	.	O	O

There	XIAFLEX.xml:S1:14792:5	there	EX	O	O
were	XIAFLEX.xml:S1:14798:4	were	VBD	O	O
no	XIAFLEX.xml:S1:14803:2	no	DT	O	O
clinically	XIAFLEX.xml:S1:14806:10	clinic	RB	O	O
meaningful	XIAFLEX.xml:S1:14817:10	meaning	JJ	O	O
differences	XIAFLEX.xml:S1:14828:11	differ	NNS	O	O
in	XIAFLEX.xml:S1:14840:2	in	IN	O	O
the	XIAFLEX.xml:S1:14843:3	the	DT	O	O
incidence	XIAFLEX.xml:S1:14847:9	incid	NN	O	O
of	XIAFLEX.xml:S1:14857:2	of	IN	O	O
adverse	XIAFLEX.xml:S1:14860:7	advers	JJ	O	O
events	XIAFLEX.xml:S1:14868:6	event	NNS	O	O
following	XIAFLEX.xml:S1:14875:9	follow	VBG	O	O
treatment	XIAFLEX.xml:S1:14885:9	treatment	NN	O	O
with	XIAFLEX.xml:S1:14895:4	with	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:14900:7	xiaflex	NNP	O	O
based	XIAFLEX.xml:S1:14908:5	base	VBN	O	O
on	XIAFLEX.xml:S1:14914:2	on	IN	O	O
the	XIAFLEX.xml:S1:14917:3	the	DT	O	O
severity	XIAFLEX.xml:S1:14921:8	sever	NN	O	O
of	XIAFLEX.xml:S1:14930:2	of	IN	O	O
baseline	XIAFLEX.xml:S1:14933:8	baselin	NN	O	O
erectile	XIAFLEX.xml:S1:14942:8	erectil	JJ	O	O
dysfunction	XIAFLEX.xml:S1:14951:11	dysfunct	NN	O	O
or	XIAFLEX.xml:S1:14963:2	or	CC	O	O
concomitant	XIAFLEX.xml:S1:14966:11	concomit	JJ	O	O
phosphodiesterase	XIAFLEX.xml:S1:14978:17	phosphodiesteras	NN	O	O
type	XIAFLEX.xml:S1:14996:4	type	NN	O	O
5	XIAFLEX.xml:S1:15001:1	5	CD	O	O
(	XIAFLEX.xml:S1:15003:1	(	(	O	O
PDE5	XIAFLEX.xml:S1:15004:4	pde5	NNP	O	O
)	XIAFLEX.xml:S1:15008:1	)	)	O	O
inhibitor	XIAFLEX.xml:S1:15010:9	inhibitor	NN	O	O
use	XIAFLEX.xml:S1:15020:3	use	NN	O	O
.	XIAFLEX.xml:S1:15023:1	.	.	O	O

XIAFLEX	XIAFLEX.xml:S1:15029:7	xiaflex	NN	O	O
was	XIAFLEX.xml:S1:15037:3	wa	VBD	O	O
not	XIAFLEX.xml:S1:15041:3	not	RB	O	O
associated	XIAFLEX.xml:S1:15045:10	associ	VBN	O	O
with	XIAFLEX.xml:S1:15056:4	with	IN	O	O
shortening	XIAFLEX.xml:S1:15061:10	shorten	NN	B-AdverseReaction	O
of	XIAFLEX.xml:S1:15072:2	of	IN	I-AdverseReaction	O
penile	XIAFLEX.xml:S1:15075:6	penil	JJ	I-AdverseReaction	O
length	XIAFLEX.xml:S1:15082:6	length	NN	I-AdverseReaction	O
in	XIAFLEX.xml:S1:15089:2	in	IN	O	O
clinical	XIAFLEX.xml:S1:15092:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S1:15101:6	trial	NNS	O	O
in	XIAFLEX.xml:S1:15108:2	in	IN	O	O
the	XIAFLEX.xml:S1:15111:3	the	DT	O	O
treatment	XIAFLEX.xml:S1:15115:9	treatment	NN	O	O
of	XIAFLEX.xml:S1:15125:2	of	IN	O	O
Peyronie	XIAFLEX.xml:S1:15128:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:15136:2	's	POS	O	O
disease	XIAFLEX.xml:S1:15139:7	diseas	NN	O	O
.	XIAFLEX.xml:S1:15146:1	.	.	O	O

6.3	XIAFLEX.xml:S1:15154:3	6.3	CD	O	O
Immunogenicity	XIAFLEX.xml:S1:15158:14	immunogen	NN	O	O

During	XIAFLEX.xml:S1:15176:6	dure	IN	O	O
clinical	XIAFLEX.xml:S1:15183:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:15192:7	studi	NNS	O	O
in	XIAFLEX.xml:S1:15200:2	in	IN	O	O
Dupuytren	XIAFLEX.xml:S1:15203:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:15212:2	's	POS	O	O
contracture	XIAFLEX.xml:S1:15215:11	contractur	NN	O	O
and	XIAFLEX.xml:S1:15227:3	and	CC	O	O
Peyronie	XIAFLEX.xml:S1:15231:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:15239:2	's	POS	O	O
disease	XIAFLEX.xml:S1:15242:7	diseas	NN	O	O
,	XIAFLEX.xml:S1:15249:1	,	,	O	O
patients	XIAFLEX.xml:S1:15251:8	patient	NNS	O	O
were	XIAFLEX.xml:S1:15260:4	were	VBD	O	O
tested	XIAFLEX.xml:S1:15265:6	test	VBN	O	O
at	XIAFLEX.xml:S1:15272:2	at	IN	O	O
multiple	XIAFLEX.xml:S1:15275:8	multipl	JJ	O	O
time	XIAFLEX.xml:S1:15284:4	time	NN	O	O
points	XIAFLEX.xml:S1:15289:6	point	NNS	O	O
for	XIAFLEX.xml:S1:15296:3	for	IN	O	O
antibodies	XIAFLEX.xml:S1:15300:10	antibodi	NNS	O	O
to	XIAFLEX.xml:S1:15311:2	to	TO	O	O
the	XIAFLEX.xml:S1:15314:3	the	DT	O	O
protein	XIAFLEX.xml:S1:15318:7	protein	NN	O	O
components	XIAFLEX.xml:S1:15326:10	compon	NNS	O	O
of	XIAFLEX.xml:S1:15337:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:15340:7	xiaflex	NNP	O	O
(	XIAFLEX.xml:S1:15348:1	(	(	O	O
AUX	XIAFLEX.xml:S1:15349:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15352:1	-	:	O	O
I	XIAFLEX.xml:S1:15353:1	I	PRP	O	O
and	XIAFLEX.xml:S1:15355:3	and	CC	O	O
AUX	XIAFLEX.xml:S1:15359:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15362:1	-	:	O	O
II	XIAFLEX.xml:S1:15363:2	II	NN	O	O
)	XIAFLEX.xml:S1:15365:1	)	)	O	O
.	XIAFLEX.xml:S1:15366:1	.	.	O	O

In	XIAFLEX.xml:S1:15372:2	In	IN	O	O
the	XIAFLEX.xml:S1:15375:3	the	DT	O	O
Dupuytren	XIAFLEX.xml:S1:15379:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S1:15388:2	's	POS	O	O
contracture	XIAFLEX.xml:S1:15391:11	contractur	NN	O	O
clinical	XIAFLEX.xml:S1:15403:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:15412:7	studi	NNS	O	O
(	XIAFLEX.xml:S1:15420:1	(	(	O	O
Studies	XIAFLEX.xml:S1:15421:7	studi	NNPS	O	O
1	XIAFLEX.xml:S1:15429:1	1	CD	O	O
and	XIAFLEX.xml:S1:15431:3	and	CC	O	O
2	XIAFLEX.xml:S1:15435:1	2	CD	O	O
)	XIAFLEX.xml:S1:15436:1	)	)	O	O
,	XIAFLEX.xml:S1:15437:1	,	,	O	O
at	XIAFLEX.xml:S1:15439:2	at	IN	O	O
30	XIAFLEX.xml:S1:15442:2	30	CD	O	O
days	XIAFLEX.xml:S1:15445:4	day	NNS	O	O
post	XIAFLEX.xml:S1:15450:4	post	VBD	O	O
the	XIAFLEX.xml:S1:15455:3	the	DT	O	O
first	XIAFLEX.xml:S1:15459:5	first	JJ	O	O
injection	XIAFLEX.xml:S1:15465:9	inject	NN	O	O
of	XIAFLEX.xml:S1:15475:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:15478:7	xiaflex	$	O	O
0.58	XIAFLEX.xml:S1:15486:4	0.58	CD	O	O
mg	XIAFLEX.xml:S1:15491:2	mg	NN	O	O
,	XIAFLEX.xml:S1:15493:1	,	,	O	O
92%	XIAFLEX.xml:S1:15495:3	92%	CD	O	O
of	XIAFLEX.xml:S1:15499:2	of	IN	O	O
patients	XIAFLEX.xml:S1:15502:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:15511:3	had	VBD	O	O
antibodies	XIAFLEX.xml:S1:15515:10	antibodi	NNS	O	O
against	XIAFLEX.xml:S1:15526:7	against	IN	O	O
AUX	XIAFLEX.xml:S1:15534:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15537:1	-	:	O	O
I	XIAFLEX.xml:S1:15538:1	I	PRP	O	O
detected	XIAFLEX.xml:S1:15540:8	detect	VBD	O	O
and	XIAFLEX.xml:S1:15549:3	and	CC	O	O
86%	XIAFLEX.xml:S1:15553:3	86%	CD	O	O
of	XIAFLEX.xml:S1:15557:2	of	IN	O	O
patients	XIAFLEX.xml:S1:15560:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:15569:3	had	VBD	O	O
antibodies	XIAFLEX.xml:S1:15573:10	antibodi	NNS	O	O
against	XIAFLEX.xml:S1:15584:7	against	IN	O	O
AUX	XIAFLEX.xml:S1:15592:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15595:1	-	:	O	O
II	XIAFLEX.xml:S1:15596:2	II	NNP	O	O
detected	XIAFLEX.xml:S1:15599:8	detect	VBD	O	O
.	XIAFLEX.xml:S1:15607:1	.	.	O	O

After	XIAFLEX.xml:S1:15609:5	after	IN	O	O
the	XIAFLEX.xml:S1:15615:3	the	DT	O	O
fourth	XIAFLEX.xml:S1:15619:6	fourth	JJ	O	O
injection	XIAFLEX.xml:S1:15626:9	inject	NN	O	O
of	XIAFLEX.xml:S1:15636:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:15639:7	xiaflex	NNP	O	O
,	XIAFLEX.xml:S1:15646:1	,	,	O	O
every	XIAFLEX.xml:S1:15648:5	everi	DT	O	O
XIAFLEX	XIAFLEX.xml:S1:15654:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:15661:1	-	:	O	O
treated	XIAFLEX.xml:S1:15662:7	treat	VBD	O	O
patient	XIAFLEX.xml:S1:15670:7	patient	JJ	O	O
developed	XIAFLEX.xml:S1:15678:9	develop	JJ	O	O
high	XIAFLEX.xml:S1:15688:4	high	JJ	O	O
titers	XIAFLEX.xml:S1:15693:6	titer	NNS	O	O
of	XIAFLEX.xml:S1:15700:2	of	IN	O	O
antibodies	XIAFLEX.xml:S1:15703:10	antibodi	NNS	O	O
to	XIAFLEX.xml:S1:15714:2	to	TO	O	O
both	XIAFLEX.xml:S1:15717:4	both	DT	O	O
AUX	XIAFLEX.xml:S1:15722:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15725:1	-	:	O	O
I	XIAFLEX.xml:S1:15726:1	I	PRP	O	O
and	XIAFLEX.xml:S1:15728:3	and	CC	O	O
AUX	XIAFLEX.xml:S1:15732:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15735:1	-	:	O	O
II	XIAFLEX.xml:S1:15736:2	II	NNP	O	O
.	XIAFLEX.xml:S1:15738:1	.	.	O	O

After	XIAFLEX.xml:S1:15741:5	after	IN	O	O
five	XIAFLEX.xml:S1:15747:4	five	CD	O	O
years	XIAFLEX.xml:S1:15752:5	year	NNS	O	O
more	XIAFLEX.xml:S1:15758:4	more	JJR	O	O
than	XIAFLEX.xml:S1:15763:4	than	IN	O	O
90	XIAFLEX.xml:S1:15768:2	90	CD	O	O
percent	XIAFLEX.xml:S1:15771:7	percent	NN	O	O
of	XIAFLEX.xml:S1:15779:2	of	IN	O	O
patients	XIAFLEX.xml:S1:15782:8	patient	NNS	O	O
remained	XIAFLEX.xml:S1:15791:8	remain	VBD	O	O
seropositive	XIAFLEX.xml:S1:15800:12	seroposit	JJ	O	O
for	XIAFLEX.xml:S1:15813:3	for	IN	O	O
anti	XIAFLEX.xml:S1:15817:4	anti	JJ	O	O
-	XIAFLEX.xml:S1:15821:1	-	:	O	O
AUX	XIAFLEX.xml:S1:15822:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15825:1	-	:	O	O
I	XIAFLEX.xml:S1:15826:1	I	PRP	O	O
and	XIAFLEX.xml:S1:15828:3	and	CC	O	O
anti	XIAFLEX.xml:S1:15832:4	anti	VB	O	O
-	XIAFLEX.xml:S1:15836:1	-	:	O	O
AUX	XIAFLEX.xml:S1:15837:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15840:1	-	:	O	O
II	XIAFLEX.xml:S1:15841:2	II	NNP	O	O
antibody	XIAFLEX.xml:S1:15844:8	antibodi	NN	O	O
(	XIAFLEX.xml:S1:15853:1	(	(	O	O
Study	XIAFLEX.xml:S1:15854:5	studi	NNP	O	O
4	XIAFLEX.xml:S1:15860:1	4	CD	O	O
)	XIAFLEX.xml:S1:15861:1	)	)	O	O
.	XIAFLEX.xml:S1:15862:1	.	.	O	O

Neutralizing	XIAFLEX.xml:S1:15865:12	neutral	VBG	O	O
antibodies	XIAFLEX.xml:S1:15878:10	antibodi	NNS	O	O
were	XIAFLEX.xml:S1:15889:4	were	VBD	O	O
assayed	XIAFLEX.xml:S1:15894:7	assay	VBN	O	O
for	XIAFLEX.xml:S1:15902:3	for	IN	O	O
all	XIAFLEX.xml:S1:15906:3	all	DT	O	O
patients	XIAFLEX.xml:S1:15910:8	patient	NNS	O	O
(	XIAFLEX.xml:S1:15919:1	(	(	O	O
204	XIAFLEX.xml:S1:15920:3	204	CD	O	O
)	XIAFLEX.xml:S1:15923:1	)	)	O	O
in	XIAFLEX.xml:S1:15925:2	in	IN	O	O
Study	XIAFLEX.xml:S1:15928:5	studi	NNP	O	O
1	XIAFLEX.xml:S1:15934:1	1	CD	O	O
.	XIAFLEX.xml:S1:15935:1	.	.	O	O

Neutralizing	XIAFLEX.xml:S1:15937:12	neutral	VBG	O	O
antibodies	XIAFLEX.xml:S1:15950:10	antibodi	NNS	O	O
to	XIAFLEX.xml:S1:15961:2	to	TO	O	O
AUX	XIAFLEX.xml:S1:15964:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15967:1	-	:	O	O
I	XIAFLEX.xml:S1:15968:1	I	PRP	O	O
or	XIAFLEX.xml:S1:15970:2	or	CC	O	O
AUX	XIAFLEX.xml:S1:15973:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:15976:1	-	:	O	O
II	XIAFLEX.xml:S1:15977:2	II	NN	O	O
,	XIAFLEX.xml:S1:15979:1	,	,	O	O
were	XIAFLEX.xml:S1:15981:4	were	VBD	O	O
detected	XIAFLEX.xml:S1:15986:8	detect	VBN	O	O
in	XIAFLEX.xml:S1:15995:2	in	IN	O	O
10%	XIAFLEX.xml:S1:15998:3	10%	CD	O	O
and	XIAFLEX.xml:S1:16002:3	and	CC	O	O
21%	XIAFLEX.xml:S1:16006:3	21%	CD	O	O
,	XIAFLEX.xml:S1:16009:1	,	,	O	O
respectively	XIAFLEX.xml:S1:16011:12	respect	RB	O	O
,	XIAFLEX.xml:S1:16023:1	,	,	O	O
of	XIAFLEX.xml:S1:16025:2	of	IN	O	O
patients	XIAFLEX.xml:S1:16028:8	patient	NNS	O	O
treated	XIAFLEX.xml:S1:16037:7	treat	VBN	O	O
with	XIAFLEX.xml:S1:16045:4	with	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:16050:7	xiaflex	NNP	O	O
.	XIAFLEX.xml:S1:16057:1	.	.	O	O

Among	XIAFLEX.xml:S1:16059:5	among	IN	O	O
patients	XIAFLEX.xml:S1:16065:8	patient	NNS	O	O
in	XIAFLEX.xml:S1:16074:2	in	IN	O	O
Study	XIAFLEX.xml:S1:16077:5	studi	NNP	O	O
3	XIAFLEX.xml:S1:16083:1	3	CD	O	O
who	XIAFLEX.xml:S1:16085:3	who	WP	O	O
reported	XIAFLEX.xml:S1:16089:8	report	VBD	O	O
no	XIAFLEX.xml:S1:16098:2	no	DT	O	O
prior	XIAFLEX.xml:S1:16101:5	prior	JJ	O	O
exposure	XIAFLEX.xml:S1:16107:8	exposur	NN	O	O
to	XIAFLEX.xml:S1:16116:2	to	TO	O	O
XIAFLEX	XIAFLEX.xml:S1:16119:7	xiaflex	NNP	O	O
,	XIAFLEX.xml:S1:16126:1	,	,	O	O
97%	XIAFLEX.xml:S1:16128:3	97%	CD	O	O
of	XIAFLEX.xml:S1:16132:2	of	IN	O	O
patients	XIAFLEX.xml:S1:16135:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:16144:3	had	VBD	O	O
antibodies	XIAFLEX.xml:S1:16148:10	antibodi	NNS	O	O
against	XIAFLEX.xml:S1:16159:7	against	IN	O	O
AUX	XIAFLEX.xml:S1:16167:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:16170:1	-	:	O	O
I	XIAFLEX.xml:S1:16171:1	I	PRP	O	O
and	XIAFLEX.xml:S1:16173:3	and	CC	O	O
AUX	XIAFLEX.xml:S1:16177:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:16180:1	-	:	O	O
II	XIAFLEX.xml:S1:16181:2	II	NN	O	O
after	XIAFLEX.xml:S1:16184:5	after	IN	O	O
two	XIAFLEX.xml:S1:16190:3	two	CD	O	O
concurrent	XIAFLEX.xml:S1:16194:10	concurr	JJ	O	O
doses	XIAFLEX.xml:S1:16205:5	dose	NNS	O	O
of	XIAFLEX.xml:S1:16211:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:16214:7	xiaflex	NNP	O	O
0.58	XIAFLEX.xml:S1:16222:4	0.58	CD	O	O
mg	XIAFLEX.xml:S1:16227:2	mg	NN	O	O
(	XIAFLEX.xml:S1:16230:1	(	(	O	O
total	XIAFLEX.xml:S1:16231:5	total	JJ	O	O
dose	XIAFLEX.xml:S1:16237:4	dose	NN	O	O
of	XIAFLEX.xml:S1:16242:2	of	IN	O	O
1.16	XIAFLEX.xml:S1:16245:4	1.16	CD	O	O
mg	XIAFLEX.xml:S1:16250:2	mg	NN	O	O
)	XIAFLEX.xml:S1:16252:1	)	)	O	O
in	XIAFLEX.xml:S1:16254:2	in	IN	O	O
the	XIAFLEX.xml:S1:16257:3	the	DT	O	O
same	XIAFLEX.xml:S1:16261:4	same	JJ	O	O
hand	XIAFLEX.xml:S1:16266:4	hand	NN	O	O
.	XIAFLEX.xml:S1:16270:1	.	.	O	O

In	XIAFLEX.xml:S1:16273:2	In	IN	O	O
Study	XIAFLEX.xml:S1:16276:5	studi	NNP	O	O
5	XIAFLEX.xml:S1:16282:1	5	CD	O	O
,	XIAFLEX.xml:S1:16283:1	,	,	O	O
treatment	XIAFLEX.xml:S1:16285:9	treatment	NN	O	O
of	XIAFLEX.xml:S1:16295:2	of	IN	O	O
recurrent	XIAFLEX.xml:S1:16298:9	recurr	NN	O	O
contractures	XIAFLEX.xml:S1:16308:12	contractur	NNS	O	O
with	XIAFLEX.xml:S1:16321:4	with	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:16326:7	xiaflex	NNP	O	O
resulted	XIAFLEX.xml:S1:16334:8	result	VBD	O	O
in	XIAFLEX.xml:S1:16343:2	in	IN	O	O
similar	XIAFLEX.xml:S1:16346:7	similar	JJ	O	O
immunogenicity	XIAFLEX.xml:S1:16354:14	immunogen	NN	O	O
results	XIAFLEX.xml:S1:16369:7	result	NNS	O	O
as	XIAFLEX.xml:S1:16377:2	as	IN	O	O
seen	XIAFLEX.xml:S1:16380:4	seen	VBN	O	O
in	XIAFLEX.xml:S1:16385:2	in	IN	O	O
Studies	XIAFLEX.xml:S1:16388:7	studi	NNP	O	O
1	XIAFLEX.xml:S1:16396:1	1	CD	O	O
and	XIAFLEX.xml:S1:16398:3	and	CC	O	O
2	XIAFLEX.xml:S1:16402:1	2	CD	O	O
.	XIAFLEX.xml:S1:16403:1	.	.	O	O

In	XIAFLEX.xml:S1:16409:2	In	IN	O	O
the	XIAFLEX.xml:S1:16412:3	the	DT	O	O
Peyronie	XIAFLEX.xml:S1:16416:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S1:16424:2	's	POS	O	O
disease	XIAFLEX.xml:S1:16427:7	diseas	NN	O	O
clinical	XIAFLEX.xml:S1:16435:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S1:16444:7	studi	NNS	O	O
,	XIAFLEX.xml:S1:16451:1	,	,	O	O
at	XIAFLEX.xml:S1:16453:2	at	IN	O	O
6	XIAFLEX.xml:S1:16456:1	6	CD	O	O
weeks	XIAFLEX.xml:S1:16458:5	week	NNS	O	O
after	XIAFLEX.xml:S1:16464:5	after	IN	O	O
the	XIAFLEX.xml:S1:16470:3	the	DT	O	O
first	XIAFLEX.xml:S1:16474:5	first	JJ	O	O
treatment	XIAFLEX.xml:S1:16480:9	treatment	NN	O	O
cycle	XIAFLEX.xml:S1:16490:5	cycl	NN	O	O
of	XIAFLEX.xml:S1:16496:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:16499:7	xiaflex	$	O	O
0.58	XIAFLEX.xml:S1:16507:4	0.58	CD	O	O
mg	XIAFLEX.xml:S1:16512:2	mg	NN	O	O
,	XIAFLEX.xml:S1:16514:1	,	,	O	O
approximately	XIAFLEX.xml:S1:16516:13	approxim	RB	O	O
75%	XIAFLEX.xml:S1:16530:3	75%	CD	O	O
of	XIAFLEX.xml:S1:16534:2	of	IN	O	O
patients	XIAFLEX.xml:S1:16537:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:16546:3	had	VBD	O	O
antibodies	XIAFLEX.xml:S1:16550:10	antibodi	NNS	O	O
against	XIAFLEX.xml:S1:16561:7	against	IN	O	O
AUX	XIAFLEX.xml:S1:16569:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:16572:1	-	:	O	O
I	XIAFLEX.xml:S1:16573:1	I	PRP	O	O
and	XIAFLEX.xml:S1:16575:3	and	CC	O	O
approximately	XIAFLEX.xml:S1:16579:13	approxim	RB	O	O
55%	XIAFLEX.xml:S1:16593:3	55%	CD	O	O
of	XIAFLEX.xml:S1:16597:2	of	IN	O	O
patients	XIAFLEX.xml:S1:16600:8	patient	NNS	O	O
had	XIAFLEX.xml:S1:16609:3	had	VBD	O	O
antibodies	XIAFLEX.xml:S1:16613:10	antibodi	NNS	O	O
against	XIAFLEX.xml:S1:16624:7	against	IN	O	O
AUX	XIAFLEX.xml:S1:16632:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:16635:1	-	:	O	O
II	XIAFLEX.xml:S1:16636:2	II	NNP	O	O
.	XIAFLEX.xml:S1:16638:1	.	.	O	O

Six	XIAFLEX.xml:S1:16640:3	six	NNP	O	O
weeks	XIAFLEX.xml:S1:16644:5	week	NNS	O	O
after	XIAFLEX.xml:S1:16650:5	after	IN	O	O
the	XIAFLEX.xml:S1:16656:3	the	DT	O	O
eighth	XIAFLEX.xml:S1:16660:6	eighth	JJ	O	O
injection	XIAFLEX.xml:S1:16667:9	inject	NN	O	O
(	XIAFLEX.xml:S1:16677:1	(	(	O	O
fourth	XIAFLEX.xml:S1:16678:6	fourth	JJ	O	O
treatment	XIAFLEX.xml:S1:16685:9	treatment	NN	O	O
cycle	XIAFLEX.xml:S1:16695:5	cycl	NN	O	O
)	XIAFLEX.xml:S1:16700:1	)	)	O	O
of	XIAFLEX.xml:S1:16702:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:16705:7	xiaflex	NNP	O	O
,	XIAFLEX.xml:S1:16712:1	,	,	O	O
99%	XIAFLEX.xml:S1:16715:3	99%	CD	O	O
of	XIAFLEX.xml:S1:16719:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:16722:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S1:16729:1	-	:	O	O
treated	XIAFLEX.xml:S1:16730:7	treat	VBD	O	O
patients	XIAFLEX.xml:S1:16738:8	patient	NNS	O	O
developed	XIAFLEX.xml:S1:16747:9	develop	JJ	O	O
high	XIAFLEX.xml:S1:16757:4	high	JJ	O	O
titers	XIAFLEX.xml:S1:16762:6	titer	NNS	O	O
of	XIAFLEX.xml:S1:16769:2	of	IN	O	O
antibodies	XIAFLEX.xml:S1:16772:10	antibodi	NNS	O	O
to	XIAFLEX.xml:S1:16783:2	to	TO	O	O
both	XIAFLEX.xml:S1:16786:4	both	DT	O	O
AUX	XIAFLEX.xml:S1:16791:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:16794:1	-	:	O	O
I	XIAFLEX.xml:S1:16795:1	I	PRP	O	O
and	XIAFLEX.xml:S1:16797:3	and	CC	O	O
AUX	XIAFLEX.xml:S1:16801:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:16804:1	-	:	O	O
II	XIAFLEX.xml:S1:16805:2	II	NNP	O	O
.	XIAFLEX.xml:S1:16807:1	.	.	O	O

Neutralizing	XIAFLEX.xml:S1:16809:12	neutral	VBG	O	O
antibodies	XIAFLEX.xml:S1:16822:10	antibodi	NNS	O	O
were	XIAFLEX.xml:S1:16833:4	were	VBD	O	O
assayed	XIAFLEX.xml:S1:16838:7	assay	VBN	O	O
for	XIAFLEX.xml:S1:16846:3	for	IN	O	O
a	XIAFLEX.xml:S1:16850:1	a	DT	O	O
subset	XIAFLEX.xml:S1:16852:6	subset	NN	O	O
of	XIAFLEX.xml:S1:16859:2	of	IN	O	O
70	XIAFLEX.xml:S1:16862:2	70	CD	O	O
samples	XIAFLEX.xml:S1:16865:7	sampl	NNS	O	O
selected	XIAFLEX.xml:S1:16873:8	select	VBN	O	O
to	XIAFLEX.xml:S1:16882:2	to	TO	O	O
be	XIAFLEX.xml:S1:16885:2	be	VB	O	O
representative	XIAFLEX.xml:S1:16888:14	repres	JJ	O	O
of	XIAFLEX.xml:S1:16903:2	of	IN	O	O
high	XIAFLEX.xml:S1:16906:4	high	JJ	O	O
and	XIAFLEX.xml:S1:16911:3	and	CC	O	O
low	XIAFLEX.xml:S1:16915:3	low	JJ	O	B-AdverseReaction
titer	XIAFLEX.xml:S1:16919:5	titer	NN	O	I-AdverseReaction
binding	XIAFLEX.xml:S1:16925:7	bind	VBG	O	O
antibody	XIAFLEX.xml:S1:16933:8	antibodi	NN	O	O
responses	XIAFLEX.xml:S1:16942:9	respons	NNS	O	O
at	XIAFLEX.xml:S1:16952:2	at	IN	O	O
week	XIAFLEX.xml:S1:16955:4	week	NN	O	O
12	XIAFLEX.xml:S1:16960:2	12	CD	O	O
of	XIAFLEX.xml:S1:16963:2	of	IN	O	O
treatment	XIAFLEX.xml:S1:16966:9	treatment	NN	O	O
.	XIAFLEX.xml:S1:16975:1	.	.	O	O

For	XIAFLEX.xml:S1:16977:3	for	IN	O	O
each	XIAFLEX.xml:S1:16981:4	each	DT	O	O
subject	XIAFLEX.xml:S1:16986:7	subject	NN	O	O
in	XIAFLEX.xml:S1:16994:2	in	IN	O	O
whom	XIAFLEX.xml:S1:16997:4	whom	WP	O	O
a	XIAFLEX.xml:S1:17002:1	a	DT	O	O
Week	XIAFLEX.xml:S1:17004:4	week	JJ	O	O
12	XIAFLEX.xml:S1:17009:2	12	CD	O	O
sample	XIAFLEX.xml:S1:17012:6	sampl	NN	O	O
was	XIAFLEX.xml:S1:17019:3	wa	VBD	O	O
selected	XIAFLEX.xml:S1:17023:8	select	VBN	O	O
,	XIAFLEX.xml:S1:17031:1	,	,	O	O
the	XIAFLEX.xml:S1:17033:3	the	DT	O	O
corresponding	XIAFLEX.xml:S1:17037:13	correspond	JJ	O	O
Week	XIAFLEX.xml:S1:17051:4	week	NNP	O	O
6	XIAFLEX.xml:S1:17056:1	6	CD	O	O
,	XIAFLEX.xml:S1:17057:1	,	,	O	O
18	XIAFLEX.xml:S1:17059:2	18	CD	O	O
,	XIAFLEX.xml:S1:17061:1	,	,	O	O
24	XIAFLEX.xml:S1:17063:2	24	CD	O	O
,	XIAFLEX.xml:S1:17065:1	,	,	O	O
and	XIAFLEX.xml:S1:17067:3	and	CC	O	O
52	XIAFLEX.xml:S1:17071:2	52	CD	O	O
samples	XIAFLEX.xml:S1:17074:7	sampl	NNS	O	O
were	XIAFLEX.xml:S1:17082:4	were	VBD	O	O
assayed	XIAFLEX.xml:S1:17087:7	assay	VBN	O	O
if	XIAFLEX.xml:S1:17095:2	if	IN	O	O
they	XIAFLEX.xml:S1:17098:4	they	PRP	O	O
were	XIAFLEX.xml:S1:17103:4	were	VBD	O	O
also	XIAFLEX.xml:S1:17108:4	also	RB	O	O
binding	XIAFLEX.xml:S1:17113:7	bind	VBG	O	O
antibody	XIAFLEX.xml:S1:17121:8	antibodi	NN	O	O
positive	XIAFLEX.xml:S1:17130:8	posit	JJ	O	O
.	XIAFLEX.xml:S1:17138:1	.	.	O	O

Neutralizing	XIAFLEX.xml:S1:17140:12	neutral	VBG	O	O
antibodies	XIAFLEX.xml:S1:17153:10	antibodi	NNS	O	O
to	XIAFLEX.xml:S1:17164:2	to	TO	O	O
AUX	XIAFLEX.xml:S1:17167:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:17170:1	-	:	O	O
I	XIAFLEX.xml:S1:17171:1	I	PRP	O	O
or	XIAFLEX.xml:S1:17173:2	or	CC	O	O
AUX	XIAFLEX.xml:S1:17176:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:17179:1	-	:	O	O
II	XIAFLEX.xml:S1:17180:2	II	NN	O	O
,	XIAFLEX.xml:S1:17182:1	,	,	O	O
were	XIAFLEX.xml:S1:17184:4	were	VBD	O	O
detected	XIAFLEX.xml:S1:17189:8	detect	VBN	O	O
in	XIAFLEX.xml:S1:17198:2	in	IN	O	O
60%	XIAFLEX.xml:S1:17201:3	60%	CD	O	O
and	XIAFLEX.xml:S1:17205:3	and	CC	O	O
51.8%	XIAFLEX.xml:S1:17209:5	51.8%	CD	O	O
,	XIAFLEX.xml:S1:17214:1	,	,	O	O
respectively	XIAFLEX.xml:S1:17216:12	respect	RB	O	O
,	XIAFLEX.xml:S1:17228:1	,	,	O	O
of	XIAFLEX.xml:S1:17230:2	of	IN	O	O
patients	XIAFLEX.xml:S1:17233:8	patient	NNS	O	O
tested	XIAFLEX.xml:S1:17242:6	test	VBN	O	O
.	XIAFLEX.xml:S1:17248:1	.	.	O	O

In	XIAFLEX.xml:S1:17254:2	In	IN	O	O
patients	XIAFLEX.xml:S1:17257:8	patient	NNS	O	O
treated	XIAFLEX.xml:S1:17266:7	treat	VBN	O	O
for	XIAFLEX.xml:S1:17274:3	for	IN	O	O
these	XIAFLEX.xml:S1:17278:5	these	DT	O	O
two	XIAFLEX.xml:S1:17284:3	two	CD	O	O
indications	XIAFLEX.xml:S1:17288:11	indic	NNS	O	O
,	XIAFLEX.xml:S1:17299:1	,	,	O	O
there	XIAFLEX.xml:S1:17301:5	there	EX	O	O
was	XIAFLEX.xml:S1:17307:3	wa	VBD	O	O
no	XIAFLEX.xml:S1:17311:2	no	DT	O	O
apparent	XIAFLEX.xml:S1:17314:8	appar	JJ	O	O
correlation	XIAFLEX.xml:S1:17323:11	correl	NN	O	O
of	XIAFLEX.xml:S1:17335:2	of	IN	O	O
antibody	XIAFLEX.xml:S1:17338:8	antibodi	NN	O	O
frequency	XIAFLEX.xml:S1:17347:9	frequenc	NN	O	O
,	XIAFLEX.xml:S1:17356:1	,	,	O	O
antibody	XIAFLEX.xml:S1:17358:8	antibodi	NN	O	O
titers	XIAFLEX.xml:S1:17367:6	titer	NNS	O	O
,	XIAFLEX.xml:S1:17373:1	,	,	O	O
or	XIAFLEX.xml:S1:17375:2	or	CC	O	O
neutralizing	XIAFLEX.xml:S1:17378:12	neutral	VBG	O	O
status	XIAFLEX.xml:S1:17391:6	statu	NN	O	O
to	XIAFLEX.xml:S1:17398:2	to	TO	O	O
clinical	XIAFLEX.xml:S1:17401:8	clinic	JJ	O	O
response	XIAFLEX.xml:S1:17410:8	respons	NN	O	O
or	XIAFLEX.xml:S1:17419:2	or	CC	O	O
adverse	XIAFLEX.xml:S1:17422:7	advers	JJ	O	O
reactions	XIAFLEX.xml:S1:17430:9	reaction	NNS	O	O
.	XIAFLEX.xml:S1:17439:1	.	.	O	O

Since	XIAFLEX.xml:S1:17445:5	sinc	IN	O	O
the	XIAFLEX.xml:S1:17451:3	the	DT	O	O
protein	XIAFLEX.xml:S1:17455:7	protein	NN	O	O
components	XIAFLEX.xml:S1:17463:10	compon	NNS	O	O
in	XIAFLEX.xml:S1:17474:2	in	IN	O	O
XIAFLEX	XIAFLEX.xml:S1:17477:7	xiaflex	NNP	O	O
(	XIAFLEX.xml:S1:17485:1	(	(	O	O
AUX	XIAFLEX.xml:S1:17486:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:17489:1	-	:	O	O
I	XIAFLEX.xml:S1:17490:1	I	PRP	O	O
and	XIAFLEX.xml:S1:17492:3	and	CC	O	O
AUX	XIAFLEX.xml:S1:17496:3	aux	NNP	O	O
-	XIAFLEX.xml:S1:17499:1	-	:	O	O
II	XIAFLEX.xml:S1:17500:2	II	NN	O	O
)	XIAFLEX.xml:S1:17502:1	)	)	O	O
have	XIAFLEX.xml:S1:17504:4	have	VBP	O	O
some	XIAFLEX.xml:S1:17509:4	some	DT	O	O
sequence	XIAFLEX.xml:S1:17514:8	sequenc	NN	O	O
homology	XIAFLEX.xml:S1:17523:8	homolog	NN	O	O
with	XIAFLEX.xml:S1:17532:4	with	IN	O	O
human	XIAFLEX.xml:S1:17537:5	human	JJ	O	O
matrix	XIAFLEX.xml:S1:17543:6	matrix	NN	O	O
metalloproteinases	XIAFLEX.xml:S1:17550:18	metalloproteinas	NNS	O	O
(	XIAFLEX.xml:S1:17569:1	(	(	O	O
MMPs	XIAFLEX.xml:S1:17570:4	mmp	NNP	O	O
)	XIAFLEX.xml:S1:17574:1	)	)	O	O
,	XIAFLEX.xml:S1:17575:1	,	,	O	O
anti	XIAFLEX.xml:S1:17577:4	anti	JJ	O	O
-	XIAFLEX.xml:S1:17581:1	-	:	O	O
product	XIAFLEX.xml:S1:17582:7	product	NN	O	O
antibodies	XIAFLEX.xml:S1:17590:10	antibodi	NNS	O	O
could	XIAFLEX.xml:S1:17601:5	could	MD	O	O
theoretically	XIAFLEX.xml:S1:17607:13	theoret	RB	O	O
interfere	XIAFLEX.xml:S1:17621:9	interfer	VB	O	O
with	XIAFLEX.xml:S1:17631:4	with	IN	O	O
human	XIAFLEX.xml:S1:17636:5	human	JJ	O	O
MMPs	XIAFLEX.xml:S1:17642:4	mmp	NNP	O	O
.	XIAFLEX.xml:S1:17646:1	.	.	O	O

In	XIAFLEX.xml:S1:17648:2	In	IN	O	O
vitro	XIAFLEX.xml:S1:17651:5	vitro	JJ	O	O
studies	XIAFLEX.xml:S1:17657:7	studi	NNS	O	O
showed	XIAFLEX.xml:S1:17665:6	show	VBD	O	O
no	XIAFLEX.xml:S1:17672:2	no	DT	O	O
evidence	XIAFLEX.xml:S1:17675:8	evid	NN	O	O
of	XIAFLEX.xml:S1:17684:2	of	IN	O	O
cross	XIAFLEX.xml:S1:17687:5	cross	NN	O	O
-	XIAFLEX.xml:S1:17692:1	-	:	O	O
reactivity	XIAFLEX.xml:S1:17693:10	reactiv	NN	O	O
between	XIAFLEX.xml:S1:17704:7	between	IN	O	O
anti	XIAFLEX.xml:S1:17712:4	anti	JJ	O	O
-	XIAFLEX.xml:S1:17716:1	-	:	O	O
drug	XIAFLEX.xml:S1:17717:4	drug	NN	O	O
-	XIAFLEX.xml:S1:17721:1	-	:	O	O
antibody	XIAFLEX.xml:S1:17722:8	antibodi	NN	O	O
positive	XIAFLEX.xml:S1:17731:8	posit	JJ	O	O
patient	XIAFLEX.xml:S1:17740:7	patient	NN	O	O
sera	XIAFLEX.xml:S1:17748:4	sera	NN	O	O
and	XIAFLEX.xml:S1:17753:3	and	CC	O	O
a	XIAFLEX.xml:S1:17757:1	a	DT	O	O
series	XIAFLEX.xml:S1:17759:6	seri	NN	O	O
of	XIAFLEX.xml:S1:17766:2	of	IN	O	O
relevant	XIAFLEX.xml:S1:17769:8	relev	JJ	O	O
MMPs	XIAFLEX.xml:S1:17778:4	mmp	NNP	O	O
.	XIAFLEX.xml:S1:17782:1	.	.	O	O

In	XIAFLEX.xml:S1:17784:2	In	IN	O	O
addition	XIAFLEX.xml:S1:17787:8	addit	NN	O	O
,	XIAFLEX.xml:S1:17795:1	,	,	O	O
no	XIAFLEX.xml:S1:17797:2	no	DT	O	O
clinical	XIAFLEX.xml:S1:17800:8	clinic	JJ	O	O
safety	XIAFLEX.xml:S1:17809:6	safeti	NN	O	O
concerns	XIAFLEX.xml:S1:17816:8	concern	NNS	O	O
related	XIAFLEX.xml:S1:17825:7	relat	VBN	O	O
to	XIAFLEX.xml:S1:17833:2	to	TO	O	O
the	XIAFLEX.xml:S1:17836:3	the	DT	O	O
inhibition	XIAFLEX.xml:S1:17840:10	inhibit	NN	O	O
of	XIAFLEX.xml:S1:17851:2	of	IN	O	O
endogenous	XIAFLEX.xml:S1:17854:10	endogen	JJ	O	O
MMPs	XIAFLEX.xml:S1:17865:4	mmp	NNP	O	O
have	XIAFLEX.xml:S1:17870:4	have	VBP	O	O
been	XIAFLEX.xml:S1:17875:4	been	VBN	O	O
observed	XIAFLEX.xml:S1:17880:8	observ	VBN	O	O
.	XIAFLEX.xml:S1:17888:1	.	.	O	O

Immunogenicity	XIAFLEX.xml:S1:17894:14	immunogen	NNP	O	O
assay	XIAFLEX.xml:S1:17909:5	assay	VBP	O	O
results	XIAFLEX.xml:S1:17915:7	result	NNS	O	O
are	XIAFLEX.xml:S1:17923:3	are	VBP	O	O
highly	XIAFLEX.xml:S1:17927:6	highli	RB	O	O
dependent	XIAFLEX.xml:S1:17934:9	depend	JJ	O	O
on	XIAFLEX.xml:S1:17944:2	on	IN	O	O
the	XIAFLEX.xml:S1:17947:3	the	DT	O	O
sensitivity	XIAFLEX.xml:S1:17951:11	sensit	NN	O	O
and	XIAFLEX.xml:S1:17963:3	and	CC	O	O
specificity	XIAFLEX.xml:S1:17967:11	specif	NN	O	O
of	XIAFLEX.xml:S1:17979:2	of	IN	O	O
the	XIAFLEX.xml:S1:17982:3	the	DT	O	O
assay	XIAFLEX.xml:S1:17986:5	assay	NN	O	O
used	XIAFLEX.xml:S1:17992:4	use	VBN	O	O
in	XIAFLEX.xml:S1:17997:2	in	IN	O	O
detection	XIAFLEX.xml:S1:18000:9	detect	NN	O	O
and	XIAFLEX.xml:S1:18010:3	and	CC	O	O
may	XIAFLEX.xml:S1:18014:3	may	MD	O	O
be	XIAFLEX.xml:S1:18018:2	be	VB	O	O
influenced	XIAFLEX.xml:S1:18021:10	influenc	VBN	O	O
by	XIAFLEX.xml:S1:18032:2	by	IN	O	O
several	XIAFLEX.xml:S1:18035:7	sever	JJ	O	O
factors	XIAFLEX.xml:S1:18043:7	factor	NNS	O	O
,	XIAFLEX.xml:S1:18050:1	,	,	O	O
including	XIAFLEX.xml:S1:18052:9	includ	VBG	O	O
sample	XIAFLEX.xml:S1:18062:6	sampl	NN	O	O
handling	XIAFLEX.xml:S1:18069:8	handl	NN	O	O
,	XIAFLEX.xml:S1:18077:1	,	,	O	O
timing	XIAFLEX.xml:S1:18079:6	time	NN	O	O
of	XIAFLEX.xml:S1:18086:2	of	IN	O	O
sample	XIAFLEX.xml:S1:18089:6	sampl	JJ	O	O
collection	XIAFLEX.xml:S1:18096:10	collect	NN	O	O
,	XIAFLEX.xml:S1:18106:1	,	,	O	O
concomitant	XIAFLEX.xml:S1:18108:11	concomit	JJ	O	O
medications	XIAFLEX.xml:S1:18120:11	medic	NNS	O	O
,	XIAFLEX.xml:S1:18131:1	,	,	O	O
and	XIAFLEX.xml:S1:18133:3	and	CC	O	O
underlying	XIAFLEX.xml:S1:18137:10	underli	JJ	O	O
disease	XIAFLEX.xml:S1:18148:7	diseas	NN	O	O
.	XIAFLEX.xml:S1:18155:1	.	.	O	O

For	XIAFLEX.xml:S1:18157:3	for	IN	O	O
these	XIAFLEX.xml:S1:18161:5	these	DT	O	O
reasons	XIAFLEX.xml:S1:18167:7	reason	NNS	O	O
,	XIAFLEX.xml:S1:18174:1	,	,	O	O
comparison	XIAFLEX.xml:S1:18176:10	comparison	NN	O	O
of	XIAFLEX.xml:S1:18187:2	of	IN	O	O
incidence	XIAFLEX.xml:S1:18190:9	incid	NN	O	O
of	XIAFLEX.xml:S1:18200:2	of	IN	O	O
antibodies	XIAFLEX.xml:S1:18203:10	antibodi	NNS	O	O
to	XIAFLEX.xml:S1:18214:2	to	TO	O	O
collagenase	XIAFLEX.xml:S1:18217:11	collagenas	VB	O	O
clostridium	XIAFLEX.xml:S1:18229:11	clostridium	NN	O	O
histolyticum	XIAFLEX.xml:S1:18241:12	histolyticum	NN	O	O
with	XIAFLEX.xml:S1:18254:4	with	IN	O	O
the	XIAFLEX.xml:S1:18259:3	the	DT	O	O
incidence	XIAFLEX.xml:S1:18263:9	incid	NN	O	O
of	XIAFLEX.xml:S1:18273:2	of	IN	O	O
antibodies	XIAFLEX.xml:S1:18276:10	antibodi	NNS	O	O
to	XIAFLEX.xml:S1:18287:2	to	TO	O	O
other	XIAFLEX.xml:S1:18290:5	other	JJ	O	O
products	XIAFLEX.xml:S1:18296:8	product	NNS	O	O
may	XIAFLEX.xml:S1:18305:3	may	MD	O	O
be	XIAFLEX.xml:S1:18309:2	be	VB	O	O
misleading	XIAFLEX.xml:S1:18312:10	mislead	VBG	O	O
.	XIAFLEX.xml:S1:18322:1	.	.	O	O
\n\n	XIAFLEX.xml:S2:0:2	\n\n	VB	O	O
BOXED	XIAFLEX.xml:S2:6:5	box	NNP	O	O
WARNING	XIAFLEX.xml:S2:12:7	warn	NNP	O	O
:	XIAFLEX.xml:S2:19:1	:	:	O	O
WARNING	XIAFLEX.xml:S2:21:7	warn	NN	O	O
:	XIAFLEX.xml:S2:28:1	:	:	O	O
\n\n\n\n	XIAFLEX.xml:S2:30:4	\n\n\n\n	JJ	O	O
CORPORAL	XIAFLEX.xml:S2:34:8	corpor	NNP	B-AdverseReaction	O
RUPTURE	XIAFLEX.xml:S2:43:7	ruptur	NNP	I-AdverseReaction	O
(	XIAFLEX.xml:S2:51:1	(	(	O	O
PENILE	XIAFLEX.xml:S2:52:6	penil	NNP	B-AdverseReaction	O
FRACTURE	XIAFLEX.xml:S2:59:8	fractur	NNP	I-AdverseReaction	O
)	XIAFLEX.xml:S2:67:1	)	)	O	O
OR	XIAFLEX.xml:S2:69:2	OR	NNP	O	O
\n\n	XIAFLEX.xml:S2:71:2	\n\n	VBZ	O	O
OTHER	XIAFLEX.xml:S2:73:5	other	NNP	O	O
SERIOUS	XIAFLEX.xml:S2:79:7	seriou	NNP	O	O
PENILE	XIAFLEX.xml:S2:87:6	penil	NNP	B-AdverseReaction	O
INJURY	XIAFLEX.xml:S2:94:6	injuri	NNP	I-AdverseReaction	O
IN	XIAFLEX.xml:S2:101:2	IN	NNP	O	O
THE	XIAFLEX.xml:S2:104:3	the	NNP	O	O
TREATMENT	XIAFLEX.xml:S2:108:9	treatment	NNP	O	O
OF	XIAFLEX.xml:S2:118:2	OF	NNP	O	O
PEYRONIE	XIAFLEX.xml:S2:121:8	peyroni	NNP	O	O
S	XIAFLEX.xml:S2:130:1	S	NNP	O	O
DISEASE	XIAFLEX.xml:S2:132:7	diseas	NNP	O	O
\n\n	XIAFLEX.xml:S2:139:2	\n\n	NNP	O	O
WARNING	XIAFLEX.xml:S2:143:7	warn	NN	O	O
:	XIAFLEX.xml:S2:150:1	:	:	O	O
\n\n\n\n	XIAFLEX.xml:S2:152:4	\n\n\n\n	JJ	O	O
CORPORAL	XIAFLEX.xml:S2:156:8	corpor	NNP	B-AdverseReaction	O
RUPTURE	XIAFLEX.xml:S2:165:7	ruptur	NNP	I-AdverseReaction	O
(	XIAFLEX.xml:S2:173:1	(	(	O	O
PENILE	XIAFLEX.xml:S2:174:6	penil	NNP	B-AdverseReaction	O
FRACTURE	XIAFLEX.xml:S2:181:8	fractur	NNP	I-AdverseReaction	O
)	XIAFLEX.xml:S2:189:1	)	)	O	O
OR	XIAFLEX.xml:S2:191:2	OR	NNP	O	O
\n\n	XIAFLEX.xml:S2:193:2	\n\n	VBZ	O	O
OTHER	XIAFLEX.xml:S2:195:5	other	NNP	O	O
SERIOUS	XIAFLEX.xml:S2:201:7	seriou	NNP	O	O
PENILE	XIAFLEX.xml:S2:209:6	penil	NNP	B-AdverseReaction	O
INJURY	XIAFLEX.xml:S2:216:6	injuri	NNP	I-AdverseReaction	O
IN	XIAFLEX.xml:S2:223:2	IN	NNP	O	O
THE	XIAFLEX.xml:S2:226:3	the	NNP	O	O
TREATMENT	XIAFLEX.xml:S2:230:9	treatment	NNP	O	O
OF	XIAFLEX.xml:S2:240:2	OF	NNP	O	O
PEYRONIE	XIAFLEX.xml:S2:243:8	peyroni	NNP	O	O
S	XIAFLEX.xml:S2:252:1	S	NNP	O	O
DISEASE	XIAFLEX.xml:S2:254:7	diseas	NNP	O	O
\n\n	XIAFLEX.xml:S2:261:2	\n\n	NNP	O	O
Corporal	XIAFLEX.xml:S2:265:8	corpor	NNP	B-AdverseReaction	O
rupture	XIAFLEX.xml:S2:274:7	ruptur	NN	I-AdverseReaction	O
(	XIAFLEX.xml:S2:282:1	(	(	O	O
penile	XIAFLEX.xml:S2:283:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
fracture	XIAFLEX.xml:S2:290:8	fractur	NN	I-AdverseReaction	I-AdverseReaction
)	XIAFLEX.xml:S2:298:1	)	)	O	O
was	XIAFLEX.xml:S2:300:3	wa	VBD	O	O
reported	XIAFLEX.xml:S2:304:8	report	VBN	O	O
as	XIAFLEX.xml:S2:313:2	as	IN	O	O
an	XIAFLEX.xml:S2:316:2	an	DT	O	O
adverse	XIAFLEX.xml:S2:319:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S2:327:8	reaction	NN	O	O
in	XIAFLEX.xml:S2:336:2	in	IN	O	O
5	XIAFLEX.xml:S2:339:1	5	CD	O	O
of	XIAFLEX.xml:S2:341:2	of	IN	O	O
1044	XIAFLEX.xml:S2:344:4	1044	CD	O	O
(	XIAFLEX.xml:S2:349:1	(	(	O	O
0.5%	XIAFLEX.xml:S2:350:4	0.5%	CD	O	O
)	XIAFLEX.xml:S2:354:1	)	)	O	O
XIAFLEX	XIAFLEX.xml:S2:356:7	xiaflex	SYM	O	O
-	XIAFLEX.xml:S2:363:1	-	:	O	O
treated	XIAFLEX.xml:S2:364:7	treat	JJ	O	O
patients	XIAFLEX.xml:S2:372:8	patient	NNS	O	O
in	XIAFLEX.xml:S2:381:2	in	IN	O	O
clinical	XIAFLEX.xml:S2:384:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S2:393:7	studi	NNS	O	O
.	XIAFLEX.xml:S2:400:1	.	.	O	O

In	XIAFLEX.xml:S2:402:2	In	IN	O	O
other	XIAFLEX.xml:S2:405:5	other	JJ	O	O
XIAFLEX	XIAFLEX.xml:S2:411:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S2:418:1	-	:	O	O
treated	XIAFLEX.xml:S2:419:7	treat	VBD	O	O
patients	XIAFLEX.xml:S2:427:8	patient	NNS	O	O
(	XIAFLEX.xml:S2:436:1	(	(	O	O
9	XIAFLEX.xml:S2:437:1	9	CD	O	O
of	XIAFLEX.xml:S2:439:2	of	IN	O	O
1044	XIAFLEX.xml:S2:442:4	1044	CD	O	O
;	XIAFLEX.xml:S2:446:1	;	:	O	O
0.9%	XIAFLEX.xml:S2:448:4	0.9%	CD	O	O
)	XIAFLEX.xml:S2:452:1	)	)	O	O
,	XIAFLEX.xml:S2:453:1	,	,	O	O
a	XIAFLEX.xml:S2:455:1	a	DT	O	O
combination	XIAFLEX.xml:S2:457:11	combin	NN	O	O
of	XIAFLEX.xml:S2:469:2	of	IN	O	O
penile	XIAFLEX.xml:S2:472:6	penil	JJ	B-AdverseReaction	O
ecchymoses	XIAFLEX.xml:S2:479:10	ecchymos	NNS	I-AdverseReaction	O
or	XIAFLEX.xml:S2:490:2	or	CC	O	O
hematoma	XIAFLEX.xml:S2:493:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S2:501:1	,	,	O	O
sudden	XIAFLEX.xml:S2:503:6	sudden	JJ	O	B-AdverseReaction
penile	XIAFLEX.xml:S2:510:6	penil	NN	B-AdverseReaction	I-AdverseReaction
detumescence	XIAFLEX.xml:S2:517:12	detumesc	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S2:529:1	,	,	O	O
and	XIAFLEX.xml:S2:531:3	and	CC	O	O
or	XIAFLEX.xml:S2:535:2	or	CC	O	O
a	XIAFLEX.xml:S2:538:1	a	DT	O	O
penile	XIAFLEX.xml:S2:540:6	penil	JJ	B-AdverseReaction	O
"	XIAFLEX.xml:S2:547:1	"	NN	I-AdverseReaction	O
popping	XIAFLEX.xml:S2:548:7	pop	VBG	I-AdverseReaction	O
"	XIAFLEX.xml:S2:555:1	"	JJ	I-AdverseReaction	O
sound	XIAFLEX.xml:S2:557:5	sound	NN	I-AdverseReaction	O
or	XIAFLEX.xml:S2:563:2	or	CC	O	O
sensation	XIAFLEX.xml:S2:566:9	sensat	NN	I-AdverseReaction	B-AdverseReaction
was	XIAFLEX.xml:S2:576:3	wa	VBD	O	O
reported	XIAFLEX.xml:S2:580:8	report	VBN	O	O
,	XIAFLEX.xml:S2:588:1	,	,	O	O
and	XIAFLEX.xml:S2:590:3	and	CC	O	O
in	XIAFLEX.xml:S2:594:2	in	IN	O	O
these	XIAFLEX.xml:S2:597:5	these	DT	O	O
cases	XIAFLEX.xml:S2:603:5	case	NNS	O	O
,	XIAFLEX.xml:S2:608:1	,	,	O	O
a	XIAFLEX.xml:S2:610:1	a	DT	O	O
diagnosis	XIAFLEX.xml:S2:612:9	diagnosi	NN	O	O
of	XIAFLEX.xml:S2:622:2	of	IN	O	O
corporal	XIAFLEX.xml:S2:625:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S2:634:7	ruptur	NN	I-AdverseReaction	O
cannot	XIAFLEX.xml:S2:642:6	cannot	NN	O	O
be	XIAFLEX.xml:S2:649:2	be	VB	O	O
excluded	XIAFLEX.xml:S2:652:8	exclud	VBN	O	O
.	XIAFLEX.xml:S2:660:1	.	.	O	O

Severe	XIAFLEX.xml:S2:662:6	sever	NNP	O	O
penile	XIAFLEX.xml:S2:669:6	penil	NN	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S2:676:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
was	XIAFLEX.xml:S2:685:3	wa	VBD	O	O
also	XIAFLEX.xml:S2:689:4	also	RB	O	O
reported	XIAFLEX.xml:S2:694:8	report	VBN	O	O
as	XIAFLEX.xml:S2:703:2	as	IN	O	O
an	XIAFLEX.xml:S2:706:2	an	DT	O	O
adverse	XIAFLEX.xml:S2:709:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S2:717:8	reaction	NN	O	O
in	XIAFLEX.xml:S2:726:2	in	IN	O	O
39	XIAFLEX.xml:S2:729:2	39	CD	O	O
of	XIAFLEX.xml:S2:732:2	of	IN	O	O
1044	XIAFLEX.xml:S2:735:4	1044	CD	O	O
(	XIAFLEX.xml:S2:740:1	(	(	O	O
3.7%	XIAFLEX.xml:S2:741:4	3.7%	CD	O	O
)	XIAFLEX.xml:S2:745:1	)	)	O	O
XIAFLEX	XIAFLEX.xml:S2:747:7	xiaflex	SYM	O	O
-	XIAFLEX.xml:S2:754:1	-	:	O	O
treated	XIAFLEX.xml:S2:755:7	treat	JJ	O	O
patients	XIAFLEX.xml:S2:763:8	patient	NNS	O	O
[	XIAFLEX.xml:S2:774:1	[	JJ	O	O
see	XIAFLEX.xml:S2:775:3	see	VBP	O	O
Warnings	XIAFLEX.xml:S2:779:8	warn	NNS	O	O
and	XIAFLEX.xml:S2:788:3	and	CC	O	O
Precautions	XIAFLEX.xml:S2:792:11	precaut	NNP	O	O
(	XIAFLEX.xml:S2:804:1	(	(	O	O
5.2	XIAFLEX.xml:S2:805:3	5.2	CD	O	O
)]	XIAFLEX.xml:S2:808:2	)]	NN	O	O
.	XIAFLEX.xml:S2:812:1	.	.	O	O

Signs	XIAFLEX.xml:S2:818:5	sign	NNS	O	O
or	XIAFLEX.xml:S2:824:2	or	CC	O	O
symptoms	XIAFLEX.xml:S2:827:8	symptom	NNS	O	O
that	XIAFLEX.xml:S2:836:4	that	WDT	O	O
may	XIAFLEX.xml:S2:841:3	may	MD	O	O
reflect	XIAFLEX.xml:S2:845:7	reflect	VB	O	O
serious	XIAFLEX.xml:S2:853:7	seriou	JJ	O	O
penile	XIAFLEX.xml:S2:861:6	penil	JJ	O	O
injury	XIAFLEX.xml:S2:868:6	injuri	NN	O	O
should	XIAFLEX.xml:S2:875:6	should	MD	O	O
be	XIAFLEX.xml:S2:882:2	be	VB	O	O
promptly	XIAFLEX.xml:S2:885:8	promptli	RB	O	O
evaluated	XIAFLEX.xml:S2:894:9	evalu	VBN	O	O
to	XIAFLEX.xml:S2:904:2	to	TO	O	O
assess	XIAFLEX.xml:S2:907:6	assess	VB	O	O
for	XIAFLEX.xml:S2:914:3	for	IN	O	O
corporal	XIAFLEX.xml:S2:918:8	corpor	JJ	O	O
rupture	XIAFLEX.xml:S2:927:7	ruptur	NN	O	O
or	XIAFLEX.xml:S2:935:2	or	CC	O	O
severe	XIAFLEX.xml:S2:938:6	sever	JJ	O	O
penile	XIAFLEX.xml:S2:945:6	penil	NN	O	O
hematoma	XIAFLEX.xml:S2:952:8	hematoma	NN	O	O
which	XIAFLEX.xml:S2:961:5	which	WDT	O	O
may	XIAFLEX.xml:S2:967:3	may	MD	O	O
require	XIAFLEX.xml:S2:971:7	requir	VB	O	O
surgical	XIAFLEX.xml:S2:979:8	surgic	JJ	O	O
intervention	XIAFLEX.xml:S2:988:12	intervent	NN	O	O
[	XIAFLEX.xml:S2:1003:1	[	NNP	O	O
see	XIAFLEX.xml:S2:1004:3	see	VBP	O	O
Warnings	XIAFLEX.xml:S2:1008:8	warn	NNP	O	O
and	XIAFLEX.xml:S2:1017:3	and	CC	O	O
Precautions	XIAFLEX.xml:S2:1021:11	precaut	NNP	O	O
(	XIAFLEX.xml:S2:1033:1	(	(	O	O
5.2	XIAFLEX.xml:S2:1034:3	5.2	CD	O	O
)]	XIAFLEX.xml:S2:1037:2	)]	NN	O	O
.	XIAFLEX.xml:S2:1041:1	.	.	O	O

Because	XIAFLEX.xml:S2:1047:7	becaus	IN	O	O
of	XIAFLEX.xml:S2:1055:2	of	IN	O	O
the	XIAFLEX.xml:S2:1058:3	the	DT	O	O
risks	XIAFLEX.xml:S2:1062:5	risk	NNS	O	O
of	XIAFLEX.xml:S2:1068:2	of	IN	O	O
corporal	XIAFLEX.xml:S2:1071:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S2:1080:7	ruptur	NN	I-AdverseReaction	O
or	XIAFLEX.xml:S2:1088:2	or	CC	O	O
other	XIAFLEX.xml:S2:1091:5	other	JJ	O	O
serious	XIAFLEX.xml:S2:1097:7	seriou	JJ	O	O
penile	XIAFLEX.xml:S2:1105:6	penil	JJ	B-AdverseReaction	O
injury	XIAFLEX.xml:S2:1112:6	injuri	NN	I-AdverseReaction	O
,	XIAFLEX.xml:S2:1118:1	,	,	O	O
XIAFLEX	XIAFLEX.xml:S2:1120:7	xiaflex	NNP	O	O
is	XIAFLEX.xml:S2:1128:2	is	VBZ	O	O
available	XIAFLEX.xml:S2:1131:9	avail	JJ	O	O
for	XIAFLEX.xml:S2:1141:3	for	IN	O	O
the	XIAFLEX.xml:S2:1145:3	the	DT	O	O
treatment	XIAFLEX.xml:S2:1149:9	treatment	NN	O	O
of	XIAFLEX.xml:S2:1159:2	of	IN	O	O
Peyronie	XIAFLEX.xml:S2:1162:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S2:1170:2	's	POS	O	O
disease	XIAFLEX.xml:S2:1173:7	diseas	NN	O	O
only	XIAFLEX.xml:S2:1181:4	onli	RB	O	O
through	XIAFLEX.xml:S2:1186:7	through	IN	O	O
a	XIAFLEX.xml:S2:1194:1	a	DT	O	O
restricted	XIAFLEX.xml:S2:1196:10	restrict	VBN	O	O
program	XIAFLEX.xml:S2:1207:7	program	NN	O	O
under	XIAFLEX.xml:S2:1215:5	under	IN	O	O
a	XIAFLEX.xml:S2:1221:1	a	DT	O	O
Risk	XIAFLEX.xml:S2:1223:4	risk	NNP	O	O
Evaluation	XIAFLEX.xml:S2:1228:10	evalu	NNP	O	O
and	XIAFLEX.xml:S2:1239:3	and	CC	O	O
Mitigation	XIAFLEX.xml:S2:1243:10	mitig	NNP	O	O
Strategy	XIAFLEX.xml:S2:1254:8	strategi	NNP	O	O
(	XIAFLEX.xml:S2:1263:1	(	(	O	O
REMS	XIAFLEX.xml:S2:1264:4	rem	NNP	O	O
)	XIAFLEX.xml:S2:1268:1	)	)	O	O
called	XIAFLEX.xml:S2:1270:6	call	VBD	O	O
the	XIAFLEX.xml:S2:1277:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S2:1281:7	xiaflex	NNP	O	O
REMS	XIAFLEX.xml:S2:1289:4	rem	NNP	O	O
Program	XIAFLEX.xml:S2:1294:7	program	NNP	O	O
[	XIAFLEX.xml:S2:1304:1	[	NNP	O	O
see	XIAFLEX.xml:S2:1305:3	see	VBP	O	O
Warnings	XIAFLEX.xml:S2:1309:8	warn	NNP	O	O
and	XIAFLEX.xml:S2:1318:3	and	CC	O	O
Precautions	XIAFLEX.xml:S2:1322:11	precaut	NNP	O	O
(	XIAFLEX.xml:S2:1334:1	(	(	O	O
5.3	XIAFLEX.xml:S2:1335:3	5.3	CD	O	O
)]	XIAFLEX.xml:S2:1338:2	)]	NN	O	O
.	XIAFLEX.xml:S2:1342:1	.	.	O	O

EXCERPT	XIAFLEX.xml:S2:1350:7	excerpt	NN	O	O
:	XIAFLEX.xml:S2:1357:1	:	:	O	O
WARNING	XIAFLEX.xml:S2:1361:7	warn	NN	O	O
:	XIAFLEX.xml:S2:1368:1	:	:	O	O
CORPORAL	XIAFLEX.xml:S2:1370:8	corpor	JJ	B-AdverseReaction	O
RUPTURE	XIAFLEX.xml:S2:1379:7	ruptur	NNP	I-AdverseReaction	O
(	XIAFLEX.xml:S2:1387:1	(	(	O	O
PENILE	XIAFLEX.xml:S2:1388:6	penil	NNP	B-AdverseReaction	O
FRACTURE	XIAFLEX.xml:S2:1395:8	fractur	NNP	I-AdverseReaction	O
)	XIAFLEX.xml:S2:1403:1	)	)	O	O
OR	XIAFLEX.xml:S2:1405:2	OR	NNP	O	O
OTHER	XIAFLEX.xml:S2:1408:5	other	NNP	O	O
SERIOUS	XIAFLEX.xml:S2:1414:7	seriou	NNP	O	O
PENILE	XIAFLEX.xml:S2:1422:6	penil	NNP	B-AdverseReaction	O
INJURY	XIAFLEX.xml:S2:1429:6	injuri	NNP	I-AdverseReaction	O
IN	XIAFLEX.xml:S2:1436:2	IN	NNP	O	O
THE	XIAFLEX.xml:S2:1439:3	the	NNP	O	O
TREATMENT	XIAFLEX.xml:S2:1443:9	treatment	NNP	O	O
OF	XIAFLEX.xml:S2:1453:2	OF	NNP	O	O
PEYRONIE	XIAFLEX.xml:S2:1456:8	peyroni	NNP	O	O
S	XIAFLEX.xml:S2:1465:1	S	NNP	O	O
DISEASE	XIAFLEX.xml:S2:1467:7	diseas	NNP	O	O
\n\n\n\n	XIAFLEX.xml:S2:1474:4	\n\n\n\n	NNP	O	O
See	XIAFLEX.xml:S2:1481:3	see	NNP	O	O
full	XIAFLEX.xml:S2:1485:4	full	JJ	O	O
prescribing	XIAFLEX.xml:S2:1490:11	prescrib	VBG	O	O
information	XIAFLEX.xml:S2:1502:11	inform	NN	O	O
for	XIAFLEX.xml:S2:1514:3	for	IN	O	O
complete	XIAFLEX.xml:S2:1518:8	complet	JJ	O	O
boxed	XIAFLEX.xml:S2:1529:5	box	JJ	O	O
warning	XIAFLEX.xml:S2:1535:7	warn	NN	O	O
\n\n\n\n	XIAFLEX.xml:S2:1546:4	\n\n\n\n	JJ	O	O
Corporal	XIAFLEX.xml:S2:1554:8	corpor	NNP	B-AdverseReaction	O
rupture	XIAFLEX.xml:S2:1563:7	ruptur	NN	I-AdverseReaction	O
(	XIAFLEX.xml:S2:1571:1	(	(	O	O
penile	XIAFLEX.xml:S2:1572:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
fracture	XIAFLEX.xml:S2:1579:8	fractur	NN	I-AdverseReaction	I-AdverseReaction
)	XIAFLEX.xml:S2:1587:1	)	)	O	O
was	XIAFLEX.xml:S2:1589:3	wa	VBD	O	O
reported	XIAFLEX.xml:S2:1593:8	report	VBN	O	O
as	XIAFLEX.xml:S2:1602:2	as	IN	O	O
an	XIAFLEX.xml:S2:1605:2	an	DT	O	O
adverse	XIAFLEX.xml:S2:1608:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S2:1616:8	reaction	NN	O	O
in	XIAFLEX.xml:S2:1625:2	in	IN	O	O
5	XIAFLEX.xml:S2:1628:1	5	CD	O	O
of	XIAFLEX.xml:S2:1630:2	of	IN	O	O
1044	XIAFLEX.xml:S2:1633:4	1044	CD	O	O
(	XIAFLEX.xml:S2:1638:1	(	(	O	O
0.5%	XIAFLEX.xml:S2:1639:4	0.5%	CD	O	O
)	XIAFLEX.xml:S2:1643:1	)	)	O	O
XIAFLEX	XIAFLEX.xml:S2:1645:7	xiaflex	SYM	O	O
-	XIAFLEX.xml:S2:1652:1	-	:	O	O
treated	XIAFLEX.xml:S2:1653:7	treat	JJ	O	O
patients	XIAFLEX.xml:S2:1661:8	patient	NNS	O	O
in	XIAFLEX.xml:S2:1670:2	in	IN	O	O
clinical	XIAFLEX.xml:S2:1673:8	clinic	JJ	O	O
studies	XIAFLEX.xml:S2:1682:7	studi	NNS	O	O
.	XIAFLEX.xml:S2:1689:1	.	.	O	O

In	XIAFLEX.xml:S2:1691:2	In	IN	O	O
other	XIAFLEX.xml:S2:1694:5	other	JJ	O	O
XIAFLEX	XIAFLEX.xml:S2:1700:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S2:1707:1	-	:	O	O
treated	XIAFLEX.xml:S2:1708:7	treat	VBD	O	O
patients	XIAFLEX.xml:S2:1716:8	patient	NNS	O	O
(	XIAFLEX.xml:S2:1725:1	(	(	O	O
9	XIAFLEX.xml:S2:1726:1	9	CD	O	O
of	XIAFLEX.xml:S2:1728:2	of	IN	O	O
1044	XIAFLEX.xml:S2:1731:4	1044	CD	O	O
;	XIAFLEX.xml:S2:1735:1	;	:	O	O
0.9%	XIAFLEX.xml:S2:1737:4	0.9%	CD	O	O
)	XIAFLEX.xml:S2:1741:1	)	)	O	O
,	XIAFLEX.xml:S2:1742:1	,	,	O	O
a	XIAFLEX.xml:S2:1744:1	a	DT	O	O
diagnosis	XIAFLEX.xml:S2:1746:9	diagnosi	NN	O	O
of	XIAFLEX.xml:S2:1756:2	of	IN	O	O
corporal	XIAFLEX.xml:S2:1759:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S2:1768:7	ruptur	NN	I-AdverseReaction	O
cannot	XIAFLEX.xml:S2:1776:6	cannot	NN	O	O
be	XIAFLEX.xml:S2:1783:2	be	VB	O	O
excluded	XIAFLEX.xml:S2:1786:8	exclud	VBN	O	O
.	XIAFLEX.xml:S2:1794:1	.	.	O	O

Severe	XIAFLEX.xml:S2:1796:6	sever	NNP	O	O
penile	XIAFLEX.xml:S2:1803:6	penil	NN	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S2:1810:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
was	XIAFLEX.xml:S2:1819:3	wa	VBD	O	O
also	XIAFLEX.xml:S2:1823:4	also	RB	O	O
reported	XIAFLEX.xml:S2:1828:8	report	VBN	O	O
as	XIAFLEX.xml:S2:1837:2	as	IN	O	O
an	XIAFLEX.xml:S2:1840:2	an	DT	O	O
adverse	XIAFLEX.xml:S2:1843:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S2:1851:8	reaction	NN	O	O
in	XIAFLEX.xml:S2:1860:2	in	IN	O	O
39	XIAFLEX.xml:S2:1863:2	39	CD	O	O
of	XIAFLEX.xml:S2:1866:2	of	IN	O	O
1044	XIAFLEX.xml:S2:1869:4	1044	CD	O	O
(	XIAFLEX.xml:S2:1874:1	(	(	O	O
3.7%	XIAFLEX.xml:S2:1875:4	3.7%	CD	O	O
)	XIAFLEX.xml:S2:1879:1	)	)	O	O
XIAFLEX	XIAFLEX.xml:S2:1881:7	xiaflex	SYM	O	O
-	XIAFLEX.xml:S2:1888:1	-	:	O	O
treated	XIAFLEX.xml:S2:1889:7	treat	VBN	O	O
patients	XIAFLEX.xml:S2:1897:8	patient	NNS	O	O
(	XIAFLEX.xml:S2:1906:1	(	(	O	O
5.2	XIAFLEX.xml:S2:1907:3	5.2	CD	O	O
)	XIAFLEX.xml:S2:1910:1	)	)	O	O
.	XIAFLEX.xml:S2:1911:1	.	.	O	O

XIAFLEX	XIAFLEX.xml:S2:1918:7	xiaflex	NN	O	O
is	XIAFLEX.xml:S2:1926:2	is	VBZ	O	O
available	XIAFLEX.xml:S2:1929:9	avail	JJ	O	O
for	XIAFLEX.xml:S2:1939:3	for	IN	O	O
the	XIAFLEX.xml:S2:1943:3	the	DT	O	O
treatment	XIAFLEX.xml:S2:1947:9	treatment	NN	O	O
of	XIAFLEX.xml:S2:1957:2	of	IN	O	O
Peyronie	XIAFLEX.xml:S2:1960:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S2:1968:2	's	POS	O	O
disease	XIAFLEX.xml:S2:1971:7	diseas	NN	O	O
only	XIAFLEX.xml:S2:1979:4	onli	RB	O	O
through	XIAFLEX.xml:S2:1984:7	through	IN	O	O
a	XIAFLEX.xml:S2:1992:1	a	DT	O	O
restricted	XIAFLEX.xml:S2:1994:10	restrict	VBN	O	O
program	XIAFLEX.xml:S2:2005:7	program	NN	O	O
called	XIAFLEX.xml:S2:2013:6	call	VBN	O	O
the	XIAFLEX.xml:S2:2020:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S2:2024:7	xiaflex	NNP	O	O
REMS	XIAFLEX.xml:S2:2032:4	rem	NNP	O	O
Program	XIAFLEX.xml:S2:2037:7	program	NNP	O	O
(	XIAFLEX.xml:S2:2045:1	(	(	O	O
5.3	XIAFLEX.xml:S2:2046:3	5.3	CD	O	O
)	XIAFLEX.xml:S2:2049:1	)	)	O	O
.	XIAFLEX.xml:S2:2050:1	.	.	O	O
\n	XIAFLEX.xml:S2:2052:1	\n	$	O	O
5	XIAFLEX.xml:S3:4:1	5	CD	O	O
WARNINGS	XIAFLEX.xml:S3:6:8	warn	NNP	O	O
AND	XIAFLEX.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	XIAFLEX.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	XIAFLEX.xml:S3:37:7	excerpt	NN	O	O
:	XIAFLEX.xml:S3:44:1	:	:	O	O
Tendon	XIAFLEX.xml:S3:52:6	tendon	JJ	B-AdverseReaction	B-AdverseReaction
rupture	XIAFLEX.xml:S3:59:7	ruptur	NN	I-AdverseReaction	I-AdverseReaction
or	XIAFLEX.xml:S3:67:2	or	CC	O	O
serious	XIAFLEX.xml:S3:70:7	seriou	JJ	O	O
injury	XIAFLEX.xml:S3:78:6	injuri	NN	B-AdverseReaction	O
to	XIAFLEX.xml:S3:85:2	to	TO	I-AdverseReaction	O
the	XIAFLEX.xml:S3:88:3	the	DT	I-AdverseReaction	O
injected	XIAFLEX.xml:S3:92:8	inject	JJ	I-AdverseReaction	O
finger	XIAFLEX.xml:S3:101:6	finger	NN	I-AdverseReaction	O
hand	XIAFLEX.xml:S3:108:4	hand	NN	I-AdverseReaction	O
:	XIAFLEX.xml:S3:112:1	:	:	O	O
Avoid	XIAFLEX.xml:S3:114:5	avoid	NNP	O	O
injecting	XIAFLEX.xml:S3:120:9	inject	VBG	O	O
XIAFLEX	XIAFLEX.xml:S3:130:7	xiaflex	NNP	O	O
into	XIAFLEX.xml:S3:138:4	into	IN	O	O
tendons	XIAFLEX.xml:S3:143:7	tendon	NNS	O	O
,	XIAFLEX.xml:S3:150:1	,	,	O	O
nerves	XIAFLEX.xml:S3:152:6	nerv	NNS	O	O
,	XIAFLEX.xml:S3:158:1	,	,	O	O
blood	XIAFLEX.xml:S3:160:5	blood	NN	O	O
vessels	XIAFLEX.xml:S3:166:7	vessel	NNS	O	O
,	XIAFLEX.xml:S3:173:1	,	,	O	O
or	XIAFLEX.xml:S3:175:2	or	CC	O	O
other	XIAFLEX.xml:S3:178:5	other	JJ	O	O
collagen	XIAFLEX.xml:S3:184:8	collagen	NN	O	O
-	XIAFLEX.xml:S3:192:1	-	:	O	O
containing	XIAFLEX.xml:S3:193:10	contain	NN	O	O
structure	XIAFLEX.xml:S3:204:9	structur	NN	O	O
of	XIAFLEX.xml:S3:214:2	of	IN	O	O
the	XIAFLEX.xml:S3:217:3	the	DT	O	O
hand	XIAFLEX.xml:S3:221:4	hand	NN	O	O
.	XIAFLEX.xml:S3:225:1	.	.	O	O

Injection	XIAFLEX.xml:S3:227:9	inject	NN	O	O
into	XIAFLEX.xml:S3:237:4	into	IN	O	O
these	XIAFLEX.xml:S3:242:5	these	DT	O	O
structures	XIAFLEX.xml:S3:248:10	structur	NNS	O	O
may	XIAFLEX.xml:S3:259:3	may	MD	O	O
result	XIAFLEX.xml:S3:263:6	result	VB	O	O
in	XIAFLEX.xml:S3:270:2	in	IN	O	O
possible	XIAFLEX.xml:S3:273:8	possibl	JJ	O	O
permanent	XIAFLEX.xml:S3:282:9	perman	JJ	O	O
injury	XIAFLEX.xml:S3:292:6	injuri	NN	O	O
,	XIAFLEX.xml:S3:298:1	,	,	O	O
such	XIAFLEX.xml:S3:300:4	such	JJ	O	O
as	XIAFLEX.xml:S3:305:2	as	IN	O	O
tendon	XIAFLEX.xml:S3:308:6	tendon	JJ	O	O
rupture	XIAFLEX.xml:S3:315:7	ruptur	NN	O	O
or	XIAFLEX.xml:S3:323:2	or	CC	O	O
ligament	XIAFLEX.xml:S3:326:8	ligament	JJ	O	O
damage	XIAFLEX.xml:S3:335:6	damag	NN	O	O
,	XIAFLEX.xml:S3:341:1	,	,	O	O
or	XIAFLEX.xml:S3:343:2	or	CC	O	O
skin	XIAFLEX.xml:S3:346:4	skin	JJ	O	O
laceration	XIAFLEX.xml:S3:351:10	lacer	NN	O	O
.	XIAFLEX.xml:S3:361:1	.	.	O	O

(	XIAFLEX.xml:S3:363:1	(	(	O	O
5.1	XIAFLEX.xml:S3:366:3	5.1	CD	O	O
)	XIAFLEX.xml:S3:371:1	)	)	O	O

Corporal	XIAFLEX.xml:S3:378:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S3:387:7	ruptur	NN	I-AdverseReaction	O
(	XIAFLEX.xml:S3:395:1	(	(	O	O
penile	XIAFLEX.xml:S3:396:6	penil	JJ	B-AdverseReaction	O
fracture	XIAFLEX.xml:S3:403:8	fractur	NN	I-AdverseReaction	O
)	XIAFLEX.xml:S3:411:1	)	)	O	O
or	XIAFLEX.xml:S3:413:2	or	CC	O	O
other	XIAFLEX.xml:S3:416:5	other	JJ	O	O
serious	XIAFLEX.xml:S3:422:7	seriou	JJ	O	O
injury	XIAFLEX.xml:S3:430:6	injuri	NN	B-AdverseReaction	O
to	XIAFLEX.xml:S3:437:2	to	TO	I-AdverseReaction	O
the	XIAFLEX.xml:S3:440:3	the	DT	I-AdverseReaction	O
penis	XIAFLEX.xml:S3:444:5	peni	NN	I-AdverseReaction	O
:	XIAFLEX.xml:S3:449:1	:	:	O	O
Avoid	XIAFLEX.xml:S3:451:5	avoid	JJ	O	O
injecting	XIAFLEX.xml:S3:457:9	inject	VBG	O	O
into	XIAFLEX.xml:S3:467:4	into	IN	O	O
the	XIAFLEX.xml:S3:472:3	the	DT	O	O
urethra	XIAFLEX.xml:S3:476:7	urethra	NN	O	O
,	XIAFLEX.xml:S3:483:1	,	,	O	O
nerves	XIAFLEX.xml:S3:485:6	nerv	NNS	O	O
,	XIAFLEX.xml:S3:491:1	,	,	O	O
blood	XIAFLEX.xml:S3:493:5	blood	NN	O	O
vessels	XIAFLEX.xml:S3:499:7	vessel	NNS	O	O
,	XIAFLEX.xml:S3:506:1	,	,	O	O
corpora	XIAFLEX.xml:S3:508:7	corpora	NNS	O	O
cavernosa	XIAFLEX.xml:S3:516:9	cavernosa	VBP	O	O
or	XIAFLEX.xml:S3:526:2	or	CC	O	O
other	XIAFLEX.xml:S3:529:5	other	JJ	O	O
collagen	XIAFLEX.xml:S3:535:8	collagen	NN	O	O
-	XIAFLEX.xml:S3:543:1	-	:	O	O
containing	XIAFLEX.xml:S3:544:10	contain	VBG	O	O
structures	XIAFLEX.xml:S3:555:10	structur	NNS	O	O
of	XIAFLEX.xml:S3:566:2	of	IN	O	O
the	XIAFLEX.xml:S3:569:3	the	DT	O	O
penis	XIAFLEX.xml:S3:573:5	peni	NN	O	O
.	XIAFLEX.xml:S3:578:1	.	.	O	O

Injection	XIAFLEX.xml:S3:580:9	inject	NN	O	O
into	XIAFLEX.xml:S3:590:4	into	IN	O	O
these	XIAFLEX.xml:S3:595:5	these	DT	O	O
structures	XIAFLEX.xml:S3:601:10	structur	NNS	O	O
may	XIAFLEX.xml:S3:612:3	may	MD	O	O
result	XIAFLEX.xml:S3:616:6	result	VB	O	O
in	XIAFLEX.xml:S3:623:2	in	IN	O	O
possible	XIAFLEX.xml:S3:626:8	possibl	JJ	O	O
permanent	XIAFLEX.xml:S3:635:9	perman	JJ	B-AdverseReaction	O
injury	XIAFLEX.xml:S3:645:6	injuri	NN	I-AdverseReaction	O
such	XIAFLEX.xml:S3:652:4	such	JJ	O	O
as	XIAFLEX.xml:S3:657:2	as	IN	O	O
corporal	XIAFLEX.xml:S3:660:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S3:669:7	ruptur	NN	I-AdverseReaction	O
(	XIAFLEX.xml:S3:677:1	(	(	O	O
penile	XIAFLEX.xml:S3:678:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
fracture	XIAFLEX.xml:S3:685:8	fractur	NN	I-AdverseReaction	I-AdverseReaction
)	XIAFLEX.xml:S3:693:1	)	)	O	O
.	XIAFLEX.xml:S3:694:1	.	.	O	O

(	XIAFLEX.xml:S3:696:1	(	(	O	O
5.2	XIAFLEX.xml:S3:699:3	5.2	CD	O	O
)	XIAFLEX.xml:S3:704:1	)	)	O	O

Hypersensitivity	XIAFLEX.xml:S3:711:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	XIAFLEX.xml:S3:728:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S3:737:1	,	,	O	O
including	XIAFLEX.xml:S3:739:9	includ	VBG	O	O
anaphylaxis	XIAFLEX.xml:S3:749:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
:	XIAFLEX.xml:S3:760:1	:	:	O	O
Healthcare	XIAFLEX.xml:S3:762:10	healthcar	JJ	O	O
providers	XIAFLEX.xml:S3:773:9	provid	NNS	O	O
should	XIAFLEX.xml:S3:783:6	should	MD	O	O
be	XIAFLEX.xml:S3:790:2	be	VB	O	O
prepared	XIAFLEX.xml:S3:793:8	prepar	VBN	O	O
to	XIAFLEX.xml:S3:802:2	to	TO	O	O
address	XIAFLEX.xml:S3:805:7	address	VB	O	O
hypersensitivity	XIAFLEX.xml:S3:813:16	hypersensit	NN	O	B-AdverseReaction
reactions	XIAFLEX.xml:S3:830:9	reaction	NNS	O	I-AdverseReaction
,	XIAFLEX.xml:S3:839:1	,	,	O	O
including	XIAFLEX.xml:S3:841:9	includ	VBG	O	O
anaphylaxis	XIAFLEX.xml:S3:851:11	anaphylaxi	NN	O	B-AdverseReaction
,	XIAFLEX.xml:S3:862:1	,	,	O	O
following	XIAFLEX.xml:S3:864:9	follow	VBG	O	O
XIAFLEX	XIAFLEX.xml:S3:874:7	xiaflex	JJ	O	O
injections	XIAFLEX.xml:S3:882:10	inject	NNS	O	O
.	XIAFLEX.xml:S3:892:1	.	.	O	O

(	XIAFLEX.xml:S3:894:1	(	(	O	O
5.4	XIAFLEX.xml:S3:897:3	5.4	CD	O	O
)	XIAFLEX.xml:S3:902:1	)	)	O	O

Patients	XIAFLEX.xml:S3:909:8	patient	NNS	O	O
with	XIAFLEX.xml:S3:918:4	with	IN	O	O
abnormal	XIAFLEX.xml:S3:923:8	abnorm	JJ	O	O
coagulation	XIAFLEX.xml:S3:932:11	coagul	NN	O	O
:	XIAFLEX.xml:S3:943:1	:	:	O	O
Use	XIAFLEX.xml:S3:945:3	use	NN	O	O
with	XIAFLEX.xml:S3:949:4	with	IN	O	O
caution	XIAFLEX.xml:S3:954:7	caution	NN	O	O
,	XIAFLEX.xml:S3:961:1	,	,	O	O
including	XIAFLEX.xml:S3:963:9	includ	VBG	O	O
in	XIAFLEX.xml:S3:973:2	in	IN	O	O
patients	XIAFLEX.xml:S3:976:8	patient	NNS	O	O
who	XIAFLEX.xml:S3:985:3	who	WP	O	O
have	XIAFLEX.xml:S3:989:4	have	VBP	O	O
received	XIAFLEX.xml:S3:994:8	receiv	VBN	O	O
anticoagulant	XIAFLEX.xml:S3:1003:13	anticoagul	JJ	O	O
medications	XIAFLEX.xml:S3:1017:11	medic	NNS	O	O
other	XIAFLEX.xml:S3:1029:5	other	JJ	O	O
than	XIAFLEX.xml:S3:1035:4	than	IN	O	O
low	XIAFLEX.xml:S3:1040:3	low	JJ	O	O
-	XIAFLEX.xml:S3:1043:1	-	:	O	O
dose	XIAFLEX.xml:S3:1044:4	dose	NN	O	O
aspirin	XIAFLEX.xml:S3:1049:7	aspirin	NN	O	O
within	XIAFLEX.xml:S3:1057:6	within	IN	O	O
7	XIAFLEX.xml:S3:1064:1	7	CD	O	O
days	XIAFLEX.xml:S3:1066:4	day	NNS	O	O
of	XIAFLEX.xml:S3:1071:2	of	IN	O	O
the	XIAFLEX.xml:S3:1074:3	the	DT	O	O
injection	XIAFLEX.xml:S3:1078:9	inject	NN	O	O
.	XIAFLEX.xml:S3:1087:1	.	.	O	O

(	XIAFLEX.xml:S3:1089:1	(	(	O	O
5.5	XIAFLEX.xml:S3:1092:3	5.5	CD	O	O
)	XIAFLEX.xml:S3:1097:1	)	)	O	O

5.1	XIAFLEX.xml:S3:1111:3	5.1	CD	O	O

Tendon	XIAFLEX.xml:S3:1115:6	tendon	NN	O	O

Rupture	XIAFLEX.xml:S3:1122:7	ruptur	NN	O	O
or	XIAFLEX.xml:S3:1130:2	or	CC	O	O
Other	XIAFLEX.xml:S3:1133:5	other	JJ	O	O
Serious	XIAFLEX.xml:S3:1139:7	seriou	JJ	O	O
Injury	XIAFLEX.xml:S3:1147:6	injuri	NNP	O	O
to	XIAFLEX.xml:S3:1154:2	to	TO	O	O
the	XIAFLEX.xml:S3:1157:3	the	DT	O	O
Injected	XIAFLEX.xml:S3:1161:8	inject	NNP	O	O
Finger	XIAFLEX.xml:S3:1170:6	finger	NNP	O	O
Hand	XIAFLEX.xml:S3:1177:4	hand	NNP	O	O
in	XIAFLEX.xml:S3:1182:2	in	IN	O	O
the	XIAFLEX.xml:S3:1185:3	the	DT	O	O
Treatment	XIAFLEX.xml:S3:1189:9	treatment	NNP	O	O
of	XIAFLEX.xml:S3:1199:2	of	IN	O	O
Dupuytren	XIAFLEX.xml:S3:1202:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S3:1211:2	's	POS	O	O
Contracture	XIAFLEX.xml:S3:1214:11	contractur	NN	O	O

In	XIAFLEX.xml:S3:1231:2	In	IN	O	O
the	XIAFLEX.xml:S3:1234:3	the	DT	O	O
controlled	XIAFLEX.xml:S3:1238:10	control	VBN	O	O
and	XIAFLEX.xml:S3:1249:3	and	CC	O	O
uncontrolled	XIAFLEX.xml:S3:1253:12	uncontrol	JJ	O	O
portions	XIAFLEX.xml:S3:1266:8	portion	NNS	O	O
of	XIAFLEX.xml:S3:1275:2	of	IN	O	O
clinical	XIAFLEX.xml:S3:1278:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S3:1287:6	trial	NNS	O	O
in	XIAFLEX.xml:S3:1294:2	in	IN	O	O
Dupuytren	XIAFLEX.xml:S3:1297:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S3:1306:2	's	POS	O	O
contracture	XIAFLEX.xml:S3:1309:11	contractur	NN	O	O
,	XIAFLEX.xml:S3:1320:1	,	,	O	O
flexor	XIAFLEX.xml:S3:1322:6	flexor	JJ	B-AdverseReaction	B-AdverseReaction
tendon	XIAFLEX.xml:S3:1329:6	tendon	NN	I-AdverseReaction	I-AdverseReaction
ruptures	XIAFLEX.xml:S3:1336:8	ruptur	NNS	I-AdverseReaction	I-AdverseReaction
occurred	XIAFLEX.xml:S3:1345:8	occur	VBD	O	O
after	XIAFLEX.xml:S3:1354:5	after	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:1360:7	xiaflex	NNP	O	O
injection	XIAFLEX.xml:S3:1368:9	inject	NN	O	O
[	XIAFLEX.xml:S3:1380:1	[	NNP	O	O
see	XIAFLEX.xml:S3:1381:3	see	VBP	O	O
Adverse	XIAFLEX.xml:S3:1385:7	advers	JJ	O	O
Reactions	XIAFLEX.xml:S3:1393:9	reaction	NNP	O	O
(	XIAFLEX.xml:S3:1403:1	(	(	O	O
6.1	XIAFLEX.xml:S3:1404:3	6.1	CD	O	O
)]	XIAFLEX.xml:S3:1407:2	)]	NN	O	O
.	XIAFLEX.xml:S3:1413:1	.	.	O	O

Injection	XIAFLEX.xml:S3:1415:9	inject	NN	O	O
of	XIAFLEX.xml:S3:1425:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:1428:7	xiaflex	NNP	O	O
into	XIAFLEX.xml:S3:1436:4	into	IN	O	O
collagen	XIAFLEX.xml:S3:1441:8	collagen	NN	B-AdverseReaction	O
-	XIAFLEX.xml:S3:1449:1	-	:	I-AdverseReaction	O
containing	XIAFLEX.xml:S3:1450:10	contain	VBG	I-AdverseReaction	O
structures	XIAFLEX.xml:S3:1461:10	structur	NNS	I-AdverseReaction	O
such	XIAFLEX.xml:S3:1472:4	such	JJ	O	O
as	XIAFLEX.xml:S3:1477:2	as	IN	O	O
tendons	XIAFLEX.xml:S3:1480:7	tendon	NNS	B-AdverseReaction	O
or	XIAFLEX.xml:S3:1488:2	or	CC	O	O
ligaments	XIAFLEX.xml:S3:1491:9	ligament	NNS	B-AdverseReaction	O
of	XIAFLEX.xml:S3:1501:2	of	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S3:1504:3	the	DT	I-AdverseReaction	O
hand	XIAFLEX.xml:S3:1508:4	hand	NN	I-AdverseReaction	O
may	XIAFLEX.xml:S3:1513:3	may	MD	O	O
result	XIAFLEX.xml:S3:1517:6	result	VB	O	O
in	XIAFLEX.xml:S3:1524:2	in	IN	O	O
damage	XIAFLEX.xml:S3:1527:6	damag	NN	I-AdverseReaction	O
to	XIAFLEX.xml:S3:1534:2	to	TO	O	O
those	XIAFLEX.xml:S3:1537:5	those	DT	O	O
structures	XIAFLEX.xml:S3:1543:10	structur	NNS	O	O
and	XIAFLEX.xml:S3:1554:3	and	CC	O	O
possible	XIAFLEX.xml:S3:1558:8	possibl	JJ	O	O
permanent	XIAFLEX.xml:S3:1567:9	perman	JJ	B-AdverseReaction	O
injury	XIAFLEX.xml:S3:1577:6	injuri	NN	I-AdverseReaction	O
such	XIAFLEX.xml:S3:1584:4	such	JJ	O	O
as	XIAFLEX.xml:S3:1589:2	as	IN	O	O
tendon	XIAFLEX.xml:S3:1592:6	tendon	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S3:1599:7	ruptur	NN	I-AdverseReaction	O
or	XIAFLEX.xml:S3:1607:2	or	CC	O	O
ligament	XIAFLEX.xml:S3:1610:8	ligament	JJ	B-AdverseReaction	O
damage	XIAFLEX.xml:S3:1619:6	damag	NN	I-AdverseReaction	O
.	XIAFLEX.xml:S3:1625:1	.	.	O	O

Therefore	XIAFLEX.xml:S3:1627:9	therefor	RB	O	O
,	XIAFLEX.xml:S3:1636:1	,	,	O	O
XIAFLEX	XIAFLEX.xml:S3:1638:7	xiaflex	NNP	O	O
should	XIAFLEX.xml:S3:1646:6	should	MD	O	O
be	XIAFLEX.xml:S3:1653:2	be	VB	O	O
injected	XIAFLEX.xml:S3:1656:8	inject	VBN	O	O
only	XIAFLEX.xml:S3:1665:4	onli	RB	O	O
into	XIAFLEX.xml:S3:1670:4	into	IN	O	O
the	XIAFLEX.xml:S3:1675:3	the	DT	O	O
collagen	XIAFLEX.xml:S3:1679:8	collagen	NN	O	O
cord	XIAFLEX.xml:S3:1688:4	cord	NN	O	O
with	XIAFLEX.xml:S3:1693:4	with	IN	O	O
a	XIAFLEX.xml:S3:1698:1	a	DT	O	O
MP	XIAFLEX.xml:S3:1700:2	MP	NNP	O	O
or	XIAFLEX.xml:S3:1703:2	or	CC	O	O
PIP	XIAFLEX.xml:S3:1706:3	pip	NNP	O	O
joint	XIAFLEX.xml:S3:1710:5	joint	JJ	O	O
contracture	XIAFLEX.xml:S3:1716:11	contractur	NN	O	O
,	XIAFLEX.xml:S3:1727:1	,	,	O	O
and	XIAFLEX.xml:S3:1729:3	and	CC	O	O
care	XIAFLEX.xml:S3:1733:4	care	NN	O	O
should	XIAFLEX.xml:S3:1738:6	should	MD	O	O
be	XIAFLEX.xml:S3:1745:2	be	VB	O	O
taken	XIAFLEX.xml:S3:1748:5	taken	VBN	O	O
to	XIAFLEX.xml:S3:1754:2	to	TO	O	O
avoid	XIAFLEX.xml:S3:1757:5	avoid	VB	O	O
injecting	XIAFLEX.xml:S3:1763:9	inject	VBG	O	O
into	XIAFLEX.xml:S3:1773:4	into	IN	O	O
tendons	XIAFLEX.xml:S3:1778:7	tendon	NNS	O	O
,	XIAFLEX.xml:S3:1785:1	,	,	O	O
nerves	XIAFLEX.xml:S3:1787:6	nerv	NNS	O	O
,	XIAFLEX.xml:S3:1793:1	,	,	O	O
blood	XIAFLEX.xml:S3:1795:5	blood	NN	O	O
vessels	XIAFLEX.xml:S3:1801:7	vessel	NNS	O	O
,	XIAFLEX.xml:S3:1808:1	,	,	O	O
or	XIAFLEX.xml:S3:1810:2	or	CC	O	O
other	XIAFLEX.xml:S3:1813:5	other	JJ	O	O
collagen	XIAFLEX.xml:S3:1819:8	collagen	NN	O	O
-	XIAFLEX.xml:S3:1827:1	-	:	O	O
containing	XIAFLEX.xml:S3:1828:10	contain	VBG	O	O
structures	XIAFLEX.xml:S3:1839:10	structur	NNS	O	O
of	XIAFLEX.xml:S3:1850:2	of	IN	O	O
the	XIAFLEX.xml:S3:1853:3	the	DT	O	O
hand	XIAFLEX.xml:S3:1857:4	hand	NN	O	O
.	XIAFLEX.xml:S3:1861:1	.	.	O	O

When	XIAFLEX.xml:S3:1863:4	when	WRB	O	O
injecting	XIAFLEX.xml:S3:1868:9	inject	VBG	O	O
a	XIAFLEX.xml:S3:1878:1	a	DT	O	O
cord	XIAFLEX.xml:S3:1880:4	cord	NN	O	O
affecting	XIAFLEX.xml:S3:1885:9	affect	VBG	O	O
a	XIAFLEX.xml:S3:1895:1	a	DT	O	O
PIP	XIAFLEX.xml:S3:1897:3	pip	NNP	O	O
joint	XIAFLEX.xml:S3:1901:5	joint	NN	O	O
of	XIAFLEX.xml:S3:1907:2	of	IN	O	O
the	XIAFLEX.xml:S3:1910:3	the	DT	O	O
fifth	XIAFLEX.xml:S3:1914:5	fifth	JJ	O	O
finger	XIAFLEX.xml:S3:1920:6	finger	NN	O	O
,	XIAFLEX.xml:S3:1926:1	,	,	O	O
the	XIAFLEX.xml:S3:1928:3	the	DT	O	O
needle	XIAFLEX.xml:S3:1932:6	needl	JJ	O	O
insertion	XIAFLEX.xml:S3:1939:9	insert	NN	O	O
should	XIAFLEX.xml:S3:1949:6	should	MD	O	O
not	XIAFLEX.xml:S3:1956:3	not	RB	O	O
be	XIAFLEX.xml:S3:1960:2	be	VB	O	O
more	XIAFLEX.xml:S3:1963:4	more	JJR	O	O
than	XIAFLEX.xml:S3:1968:4	than	IN	O	O
2	XIAFLEX.xml:S3:1973:1	2	CD	O	O
to	XIAFLEX.xml:S3:1975:2	to	TO	O	O
3	XIAFLEX.xml:S3:1978:1	3	CD	O	O
mm	XIAFLEX.xml:S3:1980:2	mm	NNS	O	O
in	XIAFLEX.xml:S3:1983:2	in	IN	O	O
depth	XIAFLEX.xml:S3:1986:5	depth	NN	O	O
and	XIAFLEX.xml:S3:1992:3	and	CC	O	O
avoid	XIAFLEX.xml:S3:1996:5	avoid	VB	O	O
injecting	XIAFLEX.xml:S3:2002:9	inject	VBG	O	O
more	XIAFLEX.xml:S3:2012:4	more	JJR	O	O
than	XIAFLEX.xml:S3:2017:4	than	IN	O	O
4	XIAFLEX.xml:S3:2022:1	4	CD	O	O
mm	XIAFLEX.xml:S3:2024:2	mm	JJ	O	O
distal	XIAFLEX.xml:S3:2027:6	distal	NN	O	O
to	XIAFLEX.xml:S3:2034:2	to	TO	O	O
the	XIAFLEX.xml:S3:2037:3	the	DT	O	O
palmar	XIAFLEX.xml:S3:2041:6	palmar	NN	O	O
digital	XIAFLEX.xml:S3:2048:7	digit	JJ	O	O
crease	XIAFLEX.xml:S3:2056:6	creas	NN	O	O
[	XIAFLEX.xml:S3:2065:1	[	NNP	O	O
see	XIAFLEX.xml:S3:2066:3	see	VBP	O	O
Dosage	XIAFLEX.xml:S3:2070:6	dosag	NNP	O	O
and	XIAFLEX.xml:S3:2077:3	and	CC	O	O
Administration	XIAFLEX.xml:S3:2081:14	administr	NNP	O	O
(	XIAFLEX.xml:S3:2096:1	(	(	O	O
2.1	XIAFLEX.xml:S3:2097:3	2.1	CD	O	O
)]	XIAFLEX.xml:S3:2100:2	)]	NN	O	O
.	XIAFLEX.xml:S3:2106:1	.	.	O	O

Other	XIAFLEX.xml:S3:2113:5	other	JJ	O	O
XIAFLEX	XIAFLEX.xml:S3:2119:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S3:2126:1	-	:	O	O
associated	XIAFLEX.xml:S3:2127:10	associ	VBN	O	O
serious	XIAFLEX.xml:S3:2138:7	seriou	JJ	O	O
local	XIAFLEX.xml:S3:2146:5	local	JJ	O	B-AdverseReaction
adverse	XIAFLEX.xml:S3:2152:7	advers	JJ	O	I-AdverseReaction
reactions	XIAFLEX.xml:S3:2160:9	reaction	NNS	O	I-AdverseReaction
included	XIAFLEX.xml:S3:2170:8	includ	VBD	O	O
pulley	XIAFLEX.xml:S3:2179:6	pulley	JJ	B-AdverseReaction	B-AdverseReaction
rupture	XIAFLEX.xml:S3:2186:7	ruptur	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S3:2193:1	,	,	O	O
ligament	XIAFLEX.xml:S3:2195:8	ligament	JJ	B-AdverseReaction	B-AdverseReaction
injury	XIAFLEX.xml:S3:2204:6	injuri	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S3:2210:1	,	,	O	O
complex	XIAFLEX.xml:S3:2212:7	complex	JJ	B-AdverseReaction	B-AdverseReaction
regional	XIAFLEX.xml:S3:2220:8	region	JJ	I-AdverseReaction	I-AdverseReaction
pain	XIAFLEX.xml:S3:2229:4	pain	NN	I-AdverseReaction	I-AdverseReaction
syndrome	XIAFLEX.xml:S3:2234:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
(	XIAFLEX.xml:S3:2243:1	(	(	O	O
CRPS	XIAFLEX.xml:S3:2244:4	crp	NNP	B-AdverseReaction	O
)	XIAFLEX.xml:S3:2248:1	)	)	O	O
,	XIAFLEX.xml:S3:2249:1	,	,	O	O
sensory	XIAFLEX.xml:S3:2251:7	sensori	JJ	B-AdverseReaction	O
abnormality	XIAFLEX.xml:S3:2259:11	abnorm	NN	I-AdverseReaction	O
of	XIAFLEX.xml:S3:2271:2	of	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S3:2274:3	the	DT	I-AdverseReaction	O
hand	XIAFLEX.xml:S3:2278:4	hand	NN	I-AdverseReaction	O
,	XIAFLEX.xml:S3:2282:1	,	,	O	O
and	XIAFLEX.xml:S3:2284:3	and	CC	O	O
skin	XIAFLEX.xml:S3:2288:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
laceration	XIAFLEX.xml:S3:2293:10	lacer	NN	I-AdverseReaction	I-AdverseReaction
(	XIAFLEX.xml:S3:2304:1	(	(	O	O
tear	XIAFLEX.xml:S3:2305:4	tear	JJ	I-AdverseReaction	O
)	XIAFLEX.xml:S3:2309:1	)	)	O	O
.	XIAFLEX.xml:S3:2310:1	.	.	O	O

In	XIAFLEX.xml:S3:2312:2	In	IN	O	O
a	XIAFLEX.xml:S3:2315:1	a	DT	O	O
historically	XIAFLEX.xml:S3:2317:12	histor	RB	O	O
controlled	XIAFLEX.xml:S3:2330:10	control	VBN	O	O
post	XIAFLEX.xml:S3:2341:4	post	NN	O	O
-	XIAFLEX.xml:S3:2345:1	-	:	O	O
marketing	XIAFLEX.xml:S3:2346:9	market	NN	O	O
trial	XIAFLEX.xml:S3:2356:5	trial	NN	O	O
,	XIAFLEX.xml:S3:2361:1	,	,	O	O
the	XIAFLEX.xml:S3:2363:3	the	DT	O	O
incidence	XIAFLEX.xml:S3:2367:9	incid	NN	O	O
of	XIAFLEX.xml:S3:2377:2	of	IN	O	O
skin	XIAFLEX.xml:S3:2380:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
laceration	XIAFLEX.xml:S3:2385:10	lacer	NN	I-AdverseReaction	I-AdverseReaction
(	XIAFLEX.xml:S3:2396:1	(	(	O	O
22%	XIAFLEX.xml:S3:2397:3	22%	CD	O	O
)	XIAFLEX.xml:S3:2400:1	)	)	O	O
was	XIAFLEX.xml:S3:2402:3	wa	VBD	O	O
higher	XIAFLEX.xml:S3:2406:6	higher	JJR	O	O
for	XIAFLEX.xml:S3:2413:3	for	IN	O	O
subjects	XIAFLEX.xml:S3:2417:8	subject	NNS	O	O
treated	XIAFLEX.xml:S3:2426:7	treat	VBN	O	O
with	XIAFLEX.xml:S3:2434:4	with	IN	O	O
two	XIAFLEX.xml:S3:2439:3	two	CD	O	O
concurrent	XIAFLEX.xml:S3:2443:10	concurr	JJ	O	O
injections	XIAFLEX.xml:S3:2454:10	inject	NNS	O	O
of	XIAFLEX.xml:S3:2465:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:2468:7	xiaflex	NNP	O	O
compared	XIAFLEX.xml:S3:2476:8	compar	VBN	O	O
with	XIAFLEX.xml:S3:2485:4	with	IN	O	O
subjects	XIAFLEX.xml:S3:2490:8	subject	NNS	O	O
treated	XIAFLEX.xml:S3:2499:7	treat	VBN	O	O
with	XIAFLEX.xml:S3:2507:4	with	IN	O	O
up	XIAFLEX.xml:S3:2512:2	up	IN	O	O
to	XIAFLEX.xml:S3:2515:2	to	TO	O	O
three	XIAFLEX.xml:S3:2518:5	three	CD	O	O
single	XIAFLEX.xml:S3:2524:6	singl	JJ	O	O
injections	XIAFLEX.xml:S3:2531:10	inject	NNS	O	O
in	XIAFLEX.xml:S3:2542:2	in	IN	O	O
the	XIAFLEX.xml:S3:2545:3	the	DT	O	O
placebo	XIAFLEX.xml:S3:2549:7	placebo	NN	O	O
-	XIAFLEX.xml:S3:2556:1	-	:	O	O
controlled	XIAFLEX.xml:S3:2557:10	control	VBN	O	O
premarketing	XIAFLEX.xml:S3:2568:12	premarket	NN	O	O
trials	XIAFLEX.xml:S3:2581:6	trial	NNS	O	O
(	XIAFLEX.xml:S3:2588:1	(	(	O	O
9%	XIAFLEX.xml:S3:2589:2	9%	CD	O	O
)	XIAFLEX.xml:S3:2591:1	)	)	O	O
.	XIAFLEX.xml:S3:2592:1	.	.	O	O

Cases	XIAFLEX.xml:S3:2594:5	case	NNS	O	O
of	XIAFLEX.xml:S3:2600:2	of	IN	O	O
skin	XIAFLEX.xml:S3:2603:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
laceration	XIAFLEX.xml:S3:2608:10	lacer	NN	I-AdverseReaction	I-AdverseReaction
requiring	XIAFLEX.xml:S3:2619:9	requir	VBG	O	O
skin	XIAFLEX.xml:S3:2629:4	skin	NN	O	O
graft	XIAFLEX.xml:S3:2634:5	graft	NN	O	O
after	XIAFLEX.xml:S3:2640:5	after	IN	O	O
finger	XIAFLEX.xml:S3:2646:6	finger	JJR	O	O
extension	XIAFLEX.xml:S3:2653:9	extens	NN	O	O
procedures	XIAFLEX.xml:S3:2663:10	procedur	NNS	O	O
have	XIAFLEX.xml:S3:2674:4	have	VBP	O	O
been	XIAFLEX.xml:S3:2679:4	been	VBN	O	O
reported	XIAFLEX.xml:S3:2684:8	report	VBN	O	O
post	XIAFLEX.xml:S3:2693:4	post	NN	O	O
-	XIAFLEX.xml:S3:2697:1	-	:	O	O
marketing	XIAFLEX.xml:S3:2698:9	market	NN	O	O
.	XIAFLEX.xml:S3:2707:1	.	.	O	O

Signs	XIAFLEX.xml:S3:2709:5	sign	NNS	O	O
or	XIAFLEX.xml:S3:2715:2	or	CC	O	O
symptoms	XIAFLEX.xml:S3:2718:8	symptom	NNS	O	O
that	XIAFLEX.xml:S3:2727:4	that	WDT	O	O
may	XIAFLEX.xml:S3:2732:3	may	MD	O	O
reflect	XIAFLEX.xml:S3:2736:7	reflect	VB	O	O
serious	XIAFLEX.xml:S3:2744:7	seriou	JJ	O	O
injury	XIAFLEX.xml:S3:2752:6	injuri	NN	O	O
to	XIAFLEX.xml:S3:2759:2	to	TO	O	O
the	XIAFLEX.xml:S3:2762:3	the	DT	O	O
injected	XIAFLEX.xml:S3:2766:8	inject	JJ	O	O
finger	XIAFLEX.xml:S3:2775:6	finger	NN	O	O
hand	XIAFLEX.xml:S3:2782:4	hand	NN	O	O
should	XIAFLEX.xml:S3:2787:6	should	MD	O	O
be	XIAFLEX.xml:S3:2794:2	be	VB	O	O
promptly	XIAFLEX.xml:S3:2797:8	promptli	RB	O	O
evaluated	XIAFLEX.xml:S3:2806:9	evalu	VBN	O	O
because	XIAFLEX.xml:S3:2816:7	becaus	RB	O	O
surgical	XIAFLEX.xml:S3:2824:8	surgic	JJ	O	O
intervention	XIAFLEX.xml:S3:2833:12	intervent	NN	O	O
may	XIAFLEX.xml:S3:2846:3	may	MD	O	O
be	XIAFLEX.xml:S3:2850:2	be	VB	O	O
required	XIAFLEX.xml:S3:2853:8	requir	VBN	O	O
.	XIAFLEX.xml:S3:2861:1	.	.	O	O

5.2	XIAFLEX.xml:S3:2872:3	5.2	CD	O	O
Corporal	XIAFLEX.xml:S3:2876:8	corpor	JJ	O	O
Rupture	XIAFLEX.xml:S3:2885:7	ruptur	NNP	O	O
(	XIAFLEX.xml:S3:2893:1	(	(	O	O
Penile	XIAFLEX.xml:S3:2894:6	penil	NNP	O	O
Fracture	XIAFLEX.xml:S3:2901:8	fractur	NNP	O	O
)	XIAFLEX.xml:S3:2909:1	)	)	O	O
or	XIAFLEX.xml:S3:2911:2	or	CC	O	O
Other	XIAFLEX.xml:S3:2914:5	other	JJ	O	O
Serious	XIAFLEX.xml:S3:2920:7	seriou	JJ	O	O
Injury	XIAFLEX.xml:S3:2928:6	injuri	NNP	O	O
to	XIAFLEX.xml:S3:2935:2	to	TO	O	O
the	XIAFLEX.xml:S3:2938:3	the	DT	O	O
Penis	XIAFLEX.xml:S3:2942:5	peni	NNP	O	O
in	XIAFLEX.xml:S3:2948:2	in	IN	O	O
the	XIAFLEX.xml:S3:2951:3	the	DT	O	O
Treatment	XIAFLEX.xml:S3:2955:9	treatment	NNP	O	O
of	XIAFLEX.xml:S3:2965:2	of	IN	O	O
Peyronie	XIAFLEX.xml:S3:2968:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S3:2976:2	's	POS	O	O
Disease	XIAFLEX.xml:S3:2979:7	diseas	NNP	O	O

Corporal	XIAFLEX.xml:S3:2992:8	corpor	JJ	B-AdverseReaction	B-AdverseReaction
rupture	XIAFLEX.xml:S3:3001:7	ruptur	NN	I-AdverseReaction	I-AdverseReaction
was	XIAFLEX.xml:S3:3009:3	wa	VBD	O	O
reported	XIAFLEX.xml:S3:3013:8	report	VBN	O	O
as	XIAFLEX.xml:S3:3022:2	as	IN	O	O
an	XIAFLEX.xml:S3:3025:2	an	DT	O	O
adverse	XIAFLEX.xml:S3:3028:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S3:3036:8	reaction	NN	O	O
after	XIAFLEX.xml:S3:3045:5	after	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:3051:7	xiaflex	JJ	O	O
injections	XIAFLEX.xml:S3:3059:10	inject	NNS	O	O
in	XIAFLEX.xml:S3:3070:2	in	IN	O	O
5	XIAFLEX.xml:S3:3073:1	5	CD	O	O
of	XIAFLEX.xml:S3:3075:2	of	IN	O	O
1044	XIAFLEX.xml:S3:3078:4	1044	CD	O	O
(	XIAFLEX.xml:S3:3083:1	(	(	O	O
0.5%	XIAFLEX.xml:S3:3084:4	0.5%	CD	O	O
)	XIAFLEX.xml:S3:3088:1	)	)	O	O
XIAFLEX	XIAFLEX.xml:S3:3090:7	xiaflex	NN	O	O
treated	XIAFLEX.xml:S3:3098:7	treat	VBD	O	O
patients	XIAFLEX.xml:S3:3106:8	patient	NNS	O	O
in	XIAFLEX.xml:S3:3115:2	in	IN	O	O
the	XIAFLEX.xml:S3:3118:3	the	DT	O	O
controlled	XIAFLEX.xml:S3:3122:10	control	VBN	O	O
and	XIAFLEX.xml:S3:3133:3	and	CC	O	O
uncontrolled	XIAFLEX.xml:S3:3137:12	uncontrol	JJ	O	O
clinical	XIAFLEX.xml:S3:3150:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S3:3159:6	trial	NNS	O	O
in	XIAFLEX.xml:S3:3166:2	in	IN	O	O
Peyronie	XIAFLEX.xml:S3:3169:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S3:3177:2	's	POS	O	O
disease	XIAFLEX.xml:S3:3180:7	diseas	NN	O	O
.	XIAFLEX.xml:S3:3187:1	.	.	O	O

In	XIAFLEX.xml:S3:3193:2	In	IN	O	O
other	XIAFLEX.xml:S3:3196:5	other	JJ	O	O
XIAFLEX	XIAFLEX.xml:S3:3202:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S3:3209:1	-	:	O	O
treated	XIAFLEX.xml:S3:3210:7	treat	VBD	O	O
patients	XIAFLEX.xml:S3:3218:8	patient	NNS	O	O
(	XIAFLEX.xml:S3:3227:1	(	(	O	O
9	XIAFLEX.xml:S3:3228:1	9	CD	O	O
of	XIAFLEX.xml:S3:3230:2	of	IN	O	O
1044	XIAFLEX.xml:S3:3233:4	1044	CD	O	O
;	XIAFLEX.xml:S3:3237:1	;	:	O	O
0.9%	XIAFLEX.xml:S3:3239:4	0.9%	CD	O	O
)	XIAFLEX.xml:S3:3243:1	)	)	O	O
,	XIAFLEX.xml:S3:3244:1	,	,	O	O
a	XIAFLEX.xml:S3:3246:1	a	DT	O	O
combination	XIAFLEX.xml:S3:3248:11	combin	NN	O	O
of	XIAFLEX.xml:S3:3260:2	of	IN	O	O
penile	XIAFLEX.xml:S3:3263:6	penil	JJ	B-AdverseReaction	O
ecchymoses	XIAFLEX.xml:S3:3270:10	ecchymos	NNS	I-AdverseReaction	O
or	XIAFLEX.xml:S3:3281:2	or	CC	O	O
hematoma	XIAFLEX.xml:S3:3284:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S3:3292:1	,	,	O	O
sudden	XIAFLEX.xml:S3:3294:6	sudden	JJ	O	B-AdverseReaction
penile	XIAFLEX.xml:S3:3301:6	penil	NN	B-AdverseReaction	I-AdverseReaction
detumescence	XIAFLEX.xml:S3:3308:12	detumesc	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S3:3320:1	,	,	O	O
and	XIAFLEX.xml:S3:3322:3	and	CC	O	O
or	XIAFLEX.xml:S3:3326:2	or	CC	O	O
a	XIAFLEX.xml:S3:3329:1	a	DT	O	O
penile	XIAFLEX.xml:S3:3331:6	penil	JJ	B-AdverseReaction	O
"	XIAFLEX.xml:S3:3338:1	"	NN	I-AdverseReaction	O
popping	XIAFLEX.xml:S3:3339:7	pop	VBG	I-AdverseReaction	O
"	XIAFLEX.xml:S3:3346:1	"	JJ	I-AdverseReaction	O
sound	XIAFLEX.xml:S3:3348:5	sound	NN	I-AdverseReaction	O
or	XIAFLEX.xml:S3:3354:2	or	CC	O	O
sensation	XIAFLEX.xml:S3:3357:9	sensat	NN	I-AdverseReaction	B-AdverseReaction
was	XIAFLEX.xml:S3:3367:3	wa	VBD	O	O
reported	XIAFLEX.xml:S3:3371:8	report	VBN	O	O
,	XIAFLEX.xml:S3:3379:1	,	,	O	O
and	XIAFLEX.xml:S3:3381:3	and	CC	O	O
in	XIAFLEX.xml:S3:3385:2	in	IN	O	O
these	XIAFLEX.xml:S3:3388:5	these	DT	O	O
cases	XIAFLEX.xml:S3:3394:5	case	NNS	O	O
,	XIAFLEX.xml:S3:3399:1	,	,	O	O
a	XIAFLEX.xml:S3:3401:1	a	DT	O	O
diagnosis	XIAFLEX.xml:S3:3403:9	diagnosi	NN	O	O
of	XIAFLEX.xml:S3:3413:2	of	IN	O	O
corporal	XIAFLEX.xml:S3:3416:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S3:3425:7	ruptur	NN	I-AdverseReaction	O
can	XIAFLEX.xml:S3:3433:3	can	MD	O	O
not	XIAFLEX.xml:S3:3437:3	not	RB	O	O
be	XIAFLEX.xml:S3:3441:2	be	VB	O	O
excluded	XIAFLEX.xml:S3:3444:8	exclud	VBN	O	O
.	XIAFLEX.xml:S3:3452:1	.	.	O	O

These	XIAFLEX.xml:S3:3454:5	these	DT	O	O
patients	XIAFLEX.xml:S3:3460:8	patient	NNS	O	O
were	XIAFLEX.xml:S3:3469:4	were	VBD	O	O
managed	XIAFLEX.xml:S3:3474:7	manag	VBN	O	O
without	XIAFLEX.xml:S3:3482:7	without	IN	O	O
surgical	XIAFLEX.xml:S3:3490:8	surgic	JJ	O	O
intervention	XIAFLEX.xml:S3:3499:12	intervent	NN	O	O
,	XIAFLEX.xml:S3:3511:1	,	,	O	O
but	XIAFLEX.xml:S3:3513:3	but	CC	O	O
the	XIAFLEX.xml:S3:3517:3	the	DT	O	O
long	XIAFLEX.xml:S3:3521:4	long	JJ	O	O
-	XIAFLEX.xml:S3:3525:1	-	:	O	O
term	XIAFLEX.xml:S3:3526:4	term	NN	O	O
consequences	XIAFLEX.xml:S3:3531:12	consequ	NNS	O	O
are	XIAFLEX.xml:S3:3544:3	are	VBP	O	O
unknown	XIAFLEX.xml:S3:3548:7	unknown	JJ	O	O
.	XIAFLEX.xml:S3:3555:1	.	.	O	O

Severe	XIAFLEX.xml:S3:3561:6	sever	NNP	O	O
penile	XIAFLEX.xml:S3:3568:6	penil	NN	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S3:3575:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
was	XIAFLEX.xml:S3:3584:3	wa	VBD	O	O
also	XIAFLEX.xml:S3:3588:4	also	RB	O	O
reported	XIAFLEX.xml:S3:3593:8	report	VBN	O	O
as	XIAFLEX.xml:S3:3602:2	as	IN	O	O
an	XIAFLEX.xml:S3:3605:2	an	DT	O	O
adverse	XIAFLEX.xml:S3:3608:7	advers	JJ	O	O
reaction	XIAFLEX.xml:S3:3616:8	reaction	NN	O	O
in	XIAFLEX.xml:S3:3625:2	in	IN	O	O
39	XIAFLEX.xml:S3:3628:2	39	CD	O	O
of	XIAFLEX.xml:S3:3631:2	of	IN	O	O
1044	XIAFLEX.xml:S3:3634:4	1044	CD	O	O
patients	XIAFLEX.xml:S3:3639:8	patient	NNS	O	O
(	XIAFLEX.xml:S3:3648:1	(	(	O	O
3.7%	XIAFLEX.xml:S3:3649:4	3.7%	CD	O	O
)	XIAFLEX.xml:S3:3653:1	)	)	O	O
in	XIAFLEX.xml:S3:3655:2	in	IN	O	O
the	XIAFLEX.xml:S3:3658:3	the	DT	O	O
controlled	XIAFLEX.xml:S3:3662:10	control	VBN	O	O
and	XIAFLEX.xml:S3:3673:3	and	CC	O	O
uncontrolled	XIAFLEX.xml:S3:3677:12	uncontrol	JJ	O	O
clinical	XIAFLEX.xml:S3:3690:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S3:3699:6	trial	NNS	O	O
in	XIAFLEX.xml:S3:3706:2	in	IN	O	O
Peyronie	XIAFLEX.xml:S3:3709:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S3:3717:2	's	POS	O	O
disease	XIAFLEX.xml:S3:3720:7	diseas	NN	O	O
[	XIAFLEX.xml:S3:3728:1	[	NNP	O	O
see	XIAFLEX.xml:S3:3730:3	see	VBP	O	O
Adverse	XIAFLEX.xml:S3:3734:7	advers	JJ	O	O
Reactions	XIAFLEX.xml:S3:3742:9	reaction	NNP	O	O
(	XIAFLEX.xml:S3:3752:1	(	(	O	O
6	XIAFLEX.xml:S3:3755:1	6	CD	O	O
)	XIAFLEX.xml:S3:3758:1	)	)	O	O
]	XIAFLEX.xml:S3:3761:1	]	NN	O	O
.	XIAFLEX.xml:S3:3762:1	.	.	O	O

Signs	XIAFLEX.xml:S3:3768:5	sign	NNS	O	O
or	XIAFLEX.xml:S3:3774:2	or	CC	O	O
symptoms	XIAFLEX.xml:S3:3777:8	symptom	NNS	O	O
that	XIAFLEX.xml:S3:3786:4	that	WDT	O	O
may	XIAFLEX.xml:S3:3791:3	may	MD	O	O
reflect	XIAFLEX.xml:S3:3795:7	reflect	VB	O	O
serious	XIAFLEX.xml:S3:3803:7	seriou	JJ	O	O
injury	XIAFLEX.xml:S3:3811:6	injuri	NN	O	O
to	XIAFLEX.xml:S3:3818:2	to	TO	O	O
the	XIAFLEX.xml:S3:3821:3	the	DT	O	O
penis	XIAFLEX.xml:S3:3825:5	peni	NN	O	O
should	XIAFLEX.xml:S3:3831:6	should	MD	O	O
be	XIAFLEX.xml:S3:3838:2	be	VB	O	O
promptly	XIAFLEX.xml:S3:3841:8	promptli	RB	O	O
evaluated	XIAFLEX.xml:S3:3850:9	evalu	VBN	O	O
in	XIAFLEX.xml:S3:3860:2	in	IN	O	O
order	XIAFLEX.xml:S3:3863:5	order	NN	O	O
to	XIAFLEX.xml:S3:3869:2	to	TO	O	O
assess	XIAFLEX.xml:S3:3872:6	assess	VB	O	O
for	XIAFLEX.xml:S3:3879:3	for	IN	O	O
corporal	XIAFLEX.xml:S3:3883:8	corpor	JJ	O	O
rupture	XIAFLEX.xml:S3:3892:7	ruptur	NN	O	O
or	XIAFLEX.xml:S3:3900:2	or	CC	O	O
severe	XIAFLEX.xml:S3:3903:6	sever	JJ	O	O
penile	XIAFLEX.xml:S3:3910:6	penil	NN	O	B-AdverseReaction
hematoma	XIAFLEX.xml:S3:3917:8	hematoma	NN	O	I-AdverseReaction
,	XIAFLEX.xml:S3:3925:1	,	,	O	O
which	XIAFLEX.xml:S3:3927:5	which	WDT	O	O
may	XIAFLEX.xml:S3:3933:3	may	MD	O	O
require	XIAFLEX.xml:S3:3937:7	requir	VB	O	O
surgical	XIAFLEX.xml:S3:3945:8	surgic	JJ	O	O
intervention	XIAFLEX.xml:S3:3954:12	intervent	NN	O	O
.	XIAFLEX.xml:S3:3966:1	.	.	O	O

Injection	XIAFLEX.xml:S3:3972:9	inject	NN	O	O
of	XIAFLEX.xml:S3:3982:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:3985:7	xiaflex	NNP	O	O
into	XIAFLEX.xml:S3:3993:4	into	IN	O	O
collagen	XIAFLEX.xml:S3:3998:8	collagen	NN	B-AdverseReaction	O
-	XIAFLEX.xml:S3:4006:1	-	:	I-AdverseReaction	O
containing	XIAFLEX.xml:S3:4007:10	contain	VBG	I-AdverseReaction	O
structures	XIAFLEX.xml:S3:4018:10	structur	NNS	I-AdverseReaction	O
such	XIAFLEX.xml:S3:4029:4	such	JJ	O	O
as	XIAFLEX.xml:S3:4034:2	as	IN	O	O
the	XIAFLEX.xml:S3:4037:3	the	DT	O	O
corpora	XIAFLEX.xml:S3:4041:7	corpora	NN	B-AdverseReaction	O
cavernosa	XIAFLEX.xml:S3:4049:9	cavernosa	NN	I-AdverseReaction	O
of	XIAFLEX.xml:S3:4059:2	of	IN	I-AdverseReaction	O
the	XIAFLEX.xml:S3:4062:3	the	DT	I-AdverseReaction	O
penis	XIAFLEX.xml:S3:4066:5	peni	NN	I-AdverseReaction	O
may	XIAFLEX.xml:S3:4072:3	may	MD	O	O
result	XIAFLEX.xml:S3:4076:6	result	VB	O	O
in	XIAFLEX.xml:S3:4083:2	in	IN	O	O
damage	XIAFLEX.xml:S3:4086:6	damag	NN	I-AdverseReaction	O
to	XIAFLEX.xml:S3:4093:2	to	TO	O	O
those	XIAFLEX.xml:S3:4096:5	those	DT	O	O
structures	XIAFLEX.xml:S3:4102:10	structur	NNS	O	O
and	XIAFLEX.xml:S3:4113:3	and	CC	O	O
possible	XIAFLEX.xml:S3:4117:8	possibl	JJ	O	O
injury	XIAFLEX.xml:S3:4126:6	injuri	NN	O	O
such	XIAFLEX.xml:S3:4133:4	such	JJ	O	O
as	XIAFLEX.xml:S3:4138:2	as	IN	O	O
corporal	XIAFLEX.xml:S3:4141:8	corpor	JJ	B-AdverseReaction	O
rupture	XIAFLEX.xml:S3:4150:7	ruptur	NN	I-AdverseReaction	O
(	XIAFLEX.xml:S3:4158:1	(	(	O	O
penile	XIAFLEX.xml:S3:4159:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
fracture	XIAFLEX.xml:S3:4166:8	fractur	NN	I-AdverseReaction	I-AdverseReaction
)	XIAFLEX.xml:S3:4174:1	)	)	O	O
.	XIAFLEX.xml:S3:4175:1	.	.	O	O

Therefore	XIAFLEX.xml:S3:4177:9	therefor	RB	O	O
,	XIAFLEX.xml:S3:4186:1	,	,	O	O
XIAFLEX	XIAFLEX.xml:S3:4188:7	xiaflex	NNP	O	O
should	XIAFLEX.xml:S3:4196:6	should	MD	O	O
be	XIAFLEX.xml:S3:4203:2	be	VB	O	O
injected	XIAFLEX.xml:S3:4206:8	inject	VBN	O	O
only	XIAFLEX.xml:S3:4215:4	onli	RB	O	O
into	XIAFLEX.xml:S3:4220:4	into	IN	O	O
the	XIAFLEX.xml:S3:4225:3	the	DT	O	O
Peyronie	XIAFLEX.xml:S3:4229:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S3:4237:2	's	POS	O	O
plaque	XIAFLEX.xml:S3:4240:6	plaqu	NN	O	O
and	XIAFLEX.xml:S3:4247:3	and	CC	O	O
care	XIAFLEX.xml:S3:4251:4	care	NN	O	O
should	XIAFLEX.xml:S3:4256:6	should	MD	O	O
be	XIAFLEX.xml:S3:4263:2	be	VB	O	O
taken	XIAFLEX.xml:S3:4266:5	taken	VBN	O	O
to	XIAFLEX.xml:S3:4272:2	to	TO	O	O
avoid	XIAFLEX.xml:S3:4275:5	avoid	VB	O	O
injecting	XIAFLEX.xml:S3:4281:9	inject	VBG	O	O
into	XIAFLEX.xml:S3:4291:4	into	IN	O	O
the	XIAFLEX.xml:S3:4296:3	the	DT	O	O
urethra	XIAFLEX.xml:S3:4300:7	urethra	NN	O	O
,	XIAFLEX.xml:S3:4307:1	,	,	O	O
nerves	XIAFLEX.xml:S3:4309:6	nerv	NNS	O	O
,	XIAFLEX.xml:S3:4315:1	,	,	O	O
blood	XIAFLEX.xml:S3:4317:5	blood	NN	O	O
vessels	XIAFLEX.xml:S3:4323:7	vessel	NNS	O	O
,	XIAFLEX.xml:S3:4330:1	,	,	O	O
corpora	XIAFLEX.xml:S3:4332:7	corpora	NNS	O	O
cavernosa	XIAFLEX.xml:S3:4340:9	cavernosa	VBP	O	O
or	XIAFLEX.xml:S3:4350:2	or	CC	O	O
other	XIAFLEX.xml:S3:4353:5	other	JJ	O	O
collagen	XIAFLEX.xml:S3:4359:8	collagen	NN	O	O
-	XIAFLEX.xml:S3:4367:1	-	:	O	O
containing	XIAFLEX.xml:S3:4368:10	contain	VBG	O	O
structures	XIAFLEX.xml:S3:4379:10	structur	NNS	O	O
of	XIAFLEX.xml:S3:4390:2	of	IN	O	O
the	XIAFLEX.xml:S3:4393:3	the	DT	O	O
penis	XIAFLEX.xml:S3:4397:5	peni	NN	O	O
.	XIAFLEX.xml:S3:4402:1	.	.	O	O

5.3	XIAFLEX.xml:S3:4411:3	5.3	CD	O	O
XIAFLEX	XIAFLEX.xml:S3:4415:7	xiaflex	JJ	O	O
REMS	XIAFLEX.xml:S3:4423:4	rem	NNP	O	O
Program	XIAFLEX.xml:S3:4428:7	program	NNP	O	O

Because	XIAFLEX.xml:S3:4441:7	becaus	IN	O	O
of	XIAFLEX.xml:S3:4449:2	of	IN	O	O
the	XIAFLEX.xml:S3:4452:3	the	DT	O	O
risks	XIAFLEX.xml:S3:4456:5	risk	NNS	O	O
of	XIAFLEX.xml:S3:4462:2	of	IN	O	O
corporal	XIAFLEX.xml:S3:4465:8	corpor	JJ	O	O
rupture	XIAFLEX.xml:S3:4474:7	ruptur	NN	O	O
(	XIAFLEX.xml:S3:4482:1	(	(	O	O
penile	XIAFLEX.xml:S3:4483:6	penil	JJ	O	O
fracture	XIAFLEX.xml:S3:4490:8	fractur	NN	O	O
)	XIAFLEX.xml:S3:4498:1	)	)	O	O
or	XIAFLEX.xml:S3:4500:2	or	CC	O	O
other	XIAFLEX.xml:S3:4503:5	other	JJ	O	O
serious	XIAFLEX.xml:S3:4509:7	seriou	JJ	O	O
penile	XIAFLEX.xml:S3:4517:6	penil	JJ	O	O
injury	XIAFLEX.xml:S3:4524:6	injuri	NN	O	O
in	XIAFLEX.xml:S3:4531:2	in	IN	O	O
the	XIAFLEX.xml:S3:4534:3	the	DT	O	O
treatment	XIAFLEX.xml:S3:4538:9	treatment	NN	O	O
of	XIAFLEX.xml:S3:4548:2	of	IN	O	O
Peyronie	XIAFLEX.xml:S3:4551:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S3:4559:2	's	POS	O	O
disease	XIAFLEX.xml:S3:4562:7	diseas	NN	O	O
,	XIAFLEX.xml:S3:4569:1	,	,	O	O
XIAFLEX	XIAFLEX.xml:S3:4571:7	xiaflex	NNP	O	O
is	XIAFLEX.xml:S3:4579:2	is	VBZ	O	O
available	XIAFLEX.xml:S3:4582:9	avail	JJ	O	O
only	XIAFLEX.xml:S3:4592:4	onli	RB	O	O
through	XIAFLEX.xml:S3:4597:7	through	IN	O	O
the	XIAFLEX.xml:S3:4605:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S3:4609:7	xiaflex	NNP	O	O
REMS	XIAFLEX.xml:S3:4617:4	rem	NNP	O	O
Program	XIAFLEX.xml:S3:4622:7	program	NNP	O	O
[	XIAFLEX.xml:S3:4635:1	[	NNP	O	O
see	XIAFLEX.xml:S3:4636:3	see	VBP	O	O
Warnings	XIAFLEX.xml:S3:4640:8	warn	NNP	O	O
and	XIAFLEX.xml:S3:4649:3	and	CC	O	O
Precautions	XIAFLEX.xml:S3:4653:11	precaut	NNP	O	O
(	XIAFLEX.xml:S3:4665:1	(	(	O	O
5.2	XIAFLEX.xml:S3:4666:3	5.2	CD	O	O
)]	XIAFLEX.xml:S3:4669:2	)]	NN	O	O
.	XIAFLEX.xml:S3:4673:1	.	.	O	O

Required	XIAFLEX.xml:S3:4681:8	requir	JJ	O	O
components	XIAFLEX.xml:S3:4690:10	compon	NNS	O	O
of	XIAFLEX.xml:S3:4701:2	of	IN	O	O
the	XIAFLEX.xml:S3:4704:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S3:4708:7	xiaflex	NNP	O	O
REMS	XIAFLEX.xml:S3:4716:4	rem	NNP	O	O
Program	XIAFLEX.xml:S3:4721:7	program	NNP	O	O
include	XIAFLEX.xml:S3:4730:7	includ	VBP	O	O
the	XIAFLEX.xml:S3:4738:3	the	DT	O	O
following	XIAFLEX.xml:S3:4742:9	follow	NN	O	O
:	XIAFLEX.xml:S3:4751:1	:	:	O	O

Prescribers	XIAFLEX.xml:S3:4760:11	prescrib	NNS	O	O
must	XIAFLEX.xml:S3:4772:4	must	MD	O	O
be	XIAFLEX.xml:S3:4777:2	be	VB	O	O
certified	XIAFLEX.xml:S3:4780:9	certifi	VBN	O	O
with	XIAFLEX.xml:S3:4790:4	with	IN	O	O
the	XIAFLEX.xml:S3:4795:3	the	DT	O	O
program	XIAFLEX.xml:S3:4799:7	program	NN	O	O
by	XIAFLEX.xml:S3:4807:2	by	IN	O	O
enrolling	XIAFLEX.xml:S3:4810:9	enrol	VBG	O	O
and	XIAFLEX.xml:S3:4820:3	and	CC	O	O
completing	XIAFLEX.xml:S3:4824:10	complet	VBG	O	O
training	XIAFLEX.xml:S3:4835:8	train	NN	O	O
in	XIAFLEX.xml:S3:4844:2	in	IN	O	O
the	XIAFLEX.xml:S3:4847:3	the	DT	O	O
administration	XIAFLEX.xml:S3:4851:14	administr	NN	O	O
of	XIAFLEX.xml:S3:4866:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:4869:7	xiaflex	NNP	O	O
treatment	XIAFLEX.xml:S3:4877:9	treatment	NN	O	O
for	XIAFLEX.xml:S3:4887:3	for	IN	O	O
Peyronie	XIAFLEX.xml:S3:4891:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S3:4899:2	's	POS	O	O
disease	XIAFLEX.xml:S3:4902:7	diseas	NN	O	O
.	XIAFLEX.xml:S3:4909:1	.	.	O	O

Healthcare	XIAFLEX.xml:S3:4916:10	healthcar	NNP	O	O
sites	XIAFLEX.xml:S3:4927:5	site	VBZ	O	O
must	XIAFLEX.xml:S3:4933:4	must	MD	O	O
be	XIAFLEX.xml:S3:4938:2	be	VB	O	O
certified	XIAFLEX.xml:S3:4941:9	certifi	VBN	O	O
with	XIAFLEX.xml:S3:4951:4	with	IN	O	O
the	XIAFLEX.xml:S3:4956:3	the	DT	O	O
program	XIAFLEX.xml:S3:4960:7	program	NN	O	O
and	XIAFLEX.xml:S3:4968:3	and	CC	O	O
ensure	XIAFLEX.xml:S3:4972:6	ensur	VB	O	O
that	XIAFLEX.xml:S3:4979:4	that	DT	O	O
XIAFLEX	XIAFLEX.xml:S3:4984:7	xiaflex	NN	O	O
is	XIAFLEX.xml:S3:4992:2	is	VBZ	O	O
only	XIAFLEX.xml:S3:4995:4	onli	RB	O	O
dispensed	XIAFLEX.xml:S3:5000:9	dispens	VBN	O	O
for	XIAFLEX.xml:S3:5010:3	for	IN	O	O
use	XIAFLEX.xml:S3:5014:3	use	NN	O	O
by	XIAFLEX.xml:S3:5018:2	by	IN	O	O
certified	XIAFLEX.xml:S3:5021:9	certifi	JJ	O	O
prescribers	XIAFLEX.xml:S3:5031:11	prescrib	NNS	O	O
.	XIAFLEX.xml:S3:5042:1	.	.	O	O

Further	XIAFLEX.xml:S3:5049:7	further	JJ	O	O
information	XIAFLEX.xml:S3:5057:11	inform	NN	O	O
is	XIAFLEX.xml:S3:5069:2	is	VBZ	O	O
available	XIAFLEX.xml:S3:5072:9	avail	JJ	O	O
at	XIAFLEX.xml:S3:5082:2	at	IN	O	O
www	XIAFLEX.xml:S3:5085:3	www	NN	O	O
.	XIAFLEX.xml:S3:5088:1	.	.	O	O
XIAFLEXREMS	XIAFLEX.xml:S3:5089:11	xiaflexrem	NNP	O	O
.	XIAFLEX.xml:S3:5100:1	.	.	O	O
com	XIAFLEX.xml:S3:5101:3	com	NN	O	O
or	XIAFLEX.xml:S3:5105:2	or	CC	O	O
1	XIAFLEX.xml:S3:5108:1	1	CD	O	O
-	XIAFLEX.xml:S3:5109:1	-	:	O	O
877	XIAFLEX.xml:S3:5110:3	877	CD	O	O
-	XIAFLEX.xml:S3:5113:1	-	:	O	O
313	XIAFLEX.xml:S3:5114:3	313	CD	O	O
-	XIAFLEX.xml:S3:5117:1	-	:	O	O
1235	XIAFLEX.xml:S3:5118:4	1235	CD	O	O
.	XIAFLEX.xml:S3:5122:1	.	.	O	O

5.4	XIAFLEX.xml:S3:5131:3	5.4	CD	O	O

Hypersensitivity	XIAFLEX.xml:S3:5135:16	hypersensit	NNP	O	B-AdverseReaction
Reactions	XIAFLEX.xml:S3:5152:9	reaction	NNP	O	I-AdverseReaction
,	XIAFLEX.xml:S3:5161:1	,	,	O	O
Including	XIAFLEX.xml:S3:5163:9	includ	NNP	O	O
Anaphylaxis	XIAFLEX.xml:S3:5173:11	anaphylaxi	NNP	O	O

In	XIAFLEX.xml:S3:5190:2	In	IN	O	O
the	XIAFLEX.xml:S3:5193:3	the	DT	O	O
controlled	XIAFLEX.xml:S3:5197:10	control	JJ	O	O
portions	XIAFLEX.xml:S3:5208:8	portion	NNS	O	O
of	XIAFLEX.xml:S3:5217:2	of	IN	O	O
the	XIAFLEX.xml:S3:5220:3	the	DT	O	O
clinical	XIAFLEX.xml:S3:5224:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S3:5233:6	trial	NNS	O	O
in	XIAFLEX.xml:S3:5240:2	in	IN	O	O
Dupuytren	XIAFLEX.xml:S3:5243:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S3:5252:2	's	POS	O	O
contracture	XIAFLEX.xml:S3:5255:11	contractur	NN	O	O
(	XIAFLEX.xml:S3:5267:1	(	(	O	O
Studies	XIAFLEX.xml:S3:5268:7	studi	NNPS	O	O
1	XIAFLEX.xml:S3:5276:1	1	CD	O	O
and	XIAFLEX.xml:S3:5278:3	and	CC	O	O
2	XIAFLEX.xml:S3:5282:1	2	CD	O	O
)	XIAFLEX.xml:S3:5283:1	)	)	O	O
,	XIAFLEX.xml:S3:5284:1	,	,	O	O
a	XIAFLEX.xml:S3:5286:1	a	DT	O	O
greater	XIAFLEX.xml:S3:5288:7	greater	JJR	O	O
proportion	XIAFLEX.xml:S3:5296:10	proport	NN	O	O
of	XIAFLEX.xml:S3:5307:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:5310:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S3:5317:1	-	:	O	O
treated	XIAFLEX.xml:S3:5318:7	treat	VBD	O	O
patients	XIAFLEX.xml:S3:5326:8	patient	NNS	O	O
(	XIAFLEX.xml:S3:5335:1	(	(	O	O
15%	XIAFLEX.xml:S3:5336:3	15%	CD	O	O
)	XIAFLEX.xml:S3:5339:1	)	)	O	O
compared	XIAFLEX.xml:S3:5341:8	compar	VBN	O	O
to	XIAFLEX.xml:S3:5350:2	to	TO	O	O
placebo	XIAFLEX.xml:S3:5353:7	placebo	VB	O	O
-	XIAFLEX.xml:S3:5360:1	-	:	O	O
treated	XIAFLEX.xml:S3:5361:7	treat	VBN	O	O
patients	XIAFLEX.xml:S3:5369:8	patient	NNS	O	O
(	XIAFLEX.xml:S3:5378:1	(	(	O	O
1%	XIAFLEX.xml:S3:5379:2	1%	CD	O	O
)	XIAFLEX.xml:S3:5381:1	)	)	O	O
had	XIAFLEX.xml:S3:5383:3	had	VBD	O	O
mild	XIAFLEX.xml:S3:5387:4	mild	VBN	O	O
allergic	XIAFLEX.xml:S3:5392:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
reactions	XIAFLEX.xml:S3:5401:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	XIAFLEX.xml:S3:5411:1	(	(	O	O
pruritus	XIAFLEX.xml:S3:5412:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
)	XIAFLEX.xml:S3:5420:1	)	)	O	O
after	XIAFLEX.xml:S3:5422:5	after	IN	O	O
up	XIAFLEX.xml:S3:5428:2	up	IN	O	O
to	XIAFLEX.xml:S3:5431:2	to	TO	O	O
3	XIAFLEX.xml:S3:5434:1	3	CD	O	O
injections	XIAFLEX.xml:S3:5436:10	inject	NNS	O	O
.	XIAFLEX.xml:S3:5446:1	.	.	O	O

The	XIAFLEX.xml:S3:5448:3	the	DT	O	O
incidence	XIAFLEX.xml:S3:5452:9	incid	NN	O	O
of	XIAFLEX.xml:S3:5462:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:5465:7	xiaflex	NNP	O	B-AdverseReaction
-	XIAFLEX.xml:S3:5472:1	-	:	O	I-AdverseReaction
associated	XIAFLEX.xml:S3:5473:10	associ	JJ	O	I-AdverseReaction
pruritus	XIAFLEX.xml:S3:5484:8	pruritu	NN	B-AdverseReaction	I-AdverseReaction
increased	XIAFLEX.xml:S3:5493:9	increas	VBD	O	I-AdverseReaction
after	XIAFLEX.xml:S3:5503:5	after	IN	O	O
more	XIAFLEX.xml:S3:5509:4	more	RBR	O	O
XIAFLEX	XIAFLEX.xml:S3:5514:7	xiaflex	JJ	O	O
injections	XIAFLEX.xml:S3:5522:10	inject	NNS	O	O
in	XIAFLEX.xml:S3:5533:2	in	IN	O	O
patients	XIAFLEX.xml:S3:5536:8	patient	NNS	O	O
with	XIAFLEX.xml:S3:5545:4	with	IN	O	O
Dupuytren	XIAFLEX.xml:S3:5550:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S3:5559:2	's	POS	O	O
contracture	XIAFLEX.xml:S3:5562:11	contractur	NN	O	O
.	XIAFLEX.xml:S3:5573:1	.	.	O	O

In	XIAFLEX.xml:S3:5580:2	In	IN	O	O
the	XIAFLEX.xml:S3:5583:3	the	DT	O	O
double	XIAFLEX.xml:S3:5587:6	doubl	JJ	O	O
-	XIAFLEX.xml:S3:5593:1	-	:	O	O
blind	XIAFLEX.xml:S3:5594:5	blind	NN	O	O
,	XIAFLEX.xml:S3:5599:1	,	,	O	O
placebo	XIAFLEX.xml:S3:5601:7	placebo	SYM	O	O
-	XIAFLEX.xml:S3:5608:1	-	:	O	O
controlled	XIAFLEX.xml:S3:5609:10	control	JJ	O	O
portions	XIAFLEX.xml:S3:5620:8	portion	NNS	O	O
of	XIAFLEX.xml:S3:5629:2	of	IN	O	O
the	XIAFLEX.xml:S3:5632:3	the	DT	O	O
clinical	XIAFLEX.xml:S3:5636:8	clinic	JJ	O	O
trials	XIAFLEX.xml:S3:5645:6	trial	NNS	O	O
in	XIAFLEX.xml:S3:5652:2	in	IN	O	O
Peyronie	XIAFLEX.xml:S3:5655:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S3:5663:2	's	POS	O	O
disease	XIAFLEX.xml:S3:5666:7	diseas	NN	O	O
(	XIAFLEX.xml:S3:5674:1	(	(	O	O
Studies	XIAFLEX.xml:S3:5675:7	studi	NNPS	O	O
1	XIAFLEX.xml:S3:5683:1	1	CD	O	O
and	XIAFLEX.xml:S3:5685:3	and	CC	O	O
2	XIAFLEX.xml:S3:5689:1	2	CD	O	O
)	XIAFLEX.xml:S3:5690:1	)	)	O	O
,	XIAFLEX.xml:S3:5691:1	,	,	O	O
a	XIAFLEX.xml:S3:5693:1	a	DT	O	O
greater	XIAFLEX.xml:S3:5695:7	greater	JJR	O	O
proportion	XIAFLEX.xml:S3:5703:10	proport	NN	O	O
of	XIAFLEX.xml:S3:5714:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:5717:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S3:5724:1	-	:	O	O
treated	XIAFLEX.xml:S3:5725:7	treat	VBD	O	O
patients	XIAFLEX.xml:S3:5733:8	patient	NNS	O	O
(	XIAFLEX.xml:S3:5742:1	(	(	O	O
4%	XIAFLEX.xml:S3:5743:2	4%	CD	O	O
)	XIAFLEX.xml:S3:5745:1	)	)	O	O
compared	XIAFLEX.xml:S3:5747:8	compar	VBN	O	O
to	XIAFLEX.xml:S3:5756:2	to	TO	O	O
placebo	XIAFLEX.xml:S3:5759:7	placebo	VB	O	O
-	XIAFLEX.xml:S3:5766:1	-	:	O	O
treated	XIAFLEX.xml:S3:5767:7	treat	VBN	O	O
patients	XIAFLEX.xml:S3:5775:8	patient	NNS	O	O
(	XIAFLEX.xml:S3:5784:1	(	(	O	O
1%	XIAFLEX.xml:S3:5785:2	1%	CD	O	O
)	XIAFLEX.xml:S3:5787:1	)	)	O	O
had	XIAFLEX.xml:S3:5789:3	had	VBD	O	O
localized	XIAFLEX.xml:S3:5793:9	local	VBN	B-AdverseReaction	O
pruritus	XIAFLEX.xml:S3:5803:8	pruritu	NN	I-AdverseReaction	O
after	XIAFLEX.xml:S3:5812:5	after	IN	O	O
up	XIAFLEX.xml:S3:5818:2	up	IN	O	O
to	XIAFLEX.xml:S3:5821:2	to	TO	O	O
4	XIAFLEX.xml:S3:5824:1	4	CD	O	O
treatment	XIAFLEX.xml:S3:5826:9	treatment	NN	O	O
cycles	XIAFLEX.xml:S3:5836:6	cycl	NNS	O	O
(	XIAFLEX.xml:S3:5843:1	(	(	O	O
involving	XIAFLEX.xml:S3:5844:9	involv	VBG	O	O
up	XIAFLEX.xml:S3:5854:2	up	RB	O	O
to	XIAFLEX.xml:S3:5857:2	to	TO	O	O
8	XIAFLEX.xml:S3:5860:1	8	CD	O	O
XIAFLEX	XIAFLEX.xml:S3:5862:7	xiaflex	NNP	O	O
injection	XIAFLEX.xml:S3:5870:9	inject	NN	O	O
procedures	XIAFLEX.xml:S3:5880:10	procedur	NNS	O	O
)	XIAFLEX.xml:S3:5890:1	)	)	O	O
.	XIAFLEX.xml:S3:5891:1	.	.	O	O

The	XIAFLEX.xml:S3:5893:3	the	DT	O	O
incidence	XIAFLEX.xml:S3:5897:9	incid	NN	O	O
of	XIAFLEX.xml:S3:5907:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:5910:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S3:5917:1	-	:	O	O
associated	XIAFLEX.xml:S3:5918:10	associ	VBD	O	O
pruritus	XIAFLEX.xml:S3:5929:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
was	XIAFLEX.xml:S3:5938:3	wa	VBD	O	O
similar	XIAFLEX.xml:S3:5942:7	similar	JJ	O	O
after	XIAFLEX.xml:S3:5950:5	after	IN	O	O
each	XIAFLEX.xml:S3:5956:4	each	DT	O	O
injection	XIAFLEX.xml:S3:5961:9	inject	NN	O	O
regardless	XIAFLEX.xml:S3:5971:10	regardless	RB	O	O
of	XIAFLEX.xml:S3:5982:2	of	IN	O	O
the	XIAFLEX.xml:S3:5985:3	the	DT	O	O
number	XIAFLEX.xml:S3:5989:6	number	NN	O	O
of	XIAFLEX.xml:S3:5996:2	of	IN	O	O
injections	XIAFLEX.xml:S3:5999:10	inject	NNS	O	O
administered	XIAFLEX.xml:S3:6010:12	administ	VBN	O	O
.	XIAFLEX.xml:S3:6022:1	.	.	O	O

Because	XIAFLEX.xml:S3:6031:7	becaus	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:6039:7	xiaflex	NNP	O	O
contains	XIAFLEX.xml:S3:6047:8	contain	VBZ	O	O
foreign	XIAFLEX.xml:S3:6056:7	foreign	JJ	O	O
proteins	XIAFLEX.xml:S3:6064:8	protein	NNS	O	O
,	XIAFLEX.xml:S3:6072:1	,	,	O	O
severe	XIAFLEX.xml:S3:6074:6	sever	JJ	O	O
allergic	XIAFLEX.xml:S3:6081:8	allerg	JJ	B-AdverseReaction	O
reactions	XIAFLEX.xml:S3:6090:9	reaction	NNS	I-AdverseReaction	O
to	XIAFLEX.xml:S3:6100:2	to	TO	O	O
XIAFLEX	XIAFLEX.xml:S3:6103:7	xiaflex	VB	O	O
can	XIAFLEX.xml:S3:6111:3	can	MD	O	O
occur	XIAFLEX.xml:S3:6115:5	occur	VB	O	O
.	XIAFLEX.xml:S3:6120:1	.	.	O	O

Anaphylaxis	XIAFLEX.xml:S3:6122:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
was	XIAFLEX.xml:S3:6134:3	wa	VBD	O	O
reported	XIAFLEX.xml:S3:6138:8	report	VBN	O	O
in	XIAFLEX.xml:S3:6147:2	in	IN	O	O
a	XIAFLEX.xml:S3:6150:1	a	DT	O	O
post	XIAFLEX.xml:S3:6152:4	post	NN	O	O
-	XIAFLEX.xml:S3:6156:1	-	:	O	O
marketing	XIAFLEX.xml:S3:6157:9	market	NN	O	O
clinical	XIAFLEX.xml:S3:6167:8	clinic	JJ	O	O
trial	XIAFLEX.xml:S3:6176:5	trial	NN	O	O
(	XIAFLEX.xml:S3:6182:1	(	(	O	O
Study	XIAFLEX.xml:S3:6183:5	studi	NNP	O	O
3	XIAFLEX.xml:S3:6189:1	3	CD	O	O
)	XIAFLEX.xml:S3:6190:1	)	)	O	O
in	XIAFLEX.xml:S3:6192:2	in	IN	O	O
one	XIAFLEX.xml:S3:6195:3	one	CD	O	O
patient	XIAFLEX.xml:S3:6199:7	patient	NN	O	O
who	XIAFLEX.xml:S3:6207:3	who	WP	O	O
had	XIAFLEX.xml:S3:6211:3	had	VBD	O	O
previous	XIAFLEX.xml:S3:6215:8	previou	JJ	O	O
exposure	XIAFLEX.xml:S3:6224:8	exposur	NN	O	O
to	XIAFLEX.xml:S3:6233:2	to	TO	O	O
XIAFLEX	XIAFLEX.xml:S3:6236:7	xiaflex	VB	O	O
for	XIAFLEX.xml:S3:6244:3	for	IN	O	O
the	XIAFLEX.xml:S3:6248:3	the	DT	O	O
treatment	XIAFLEX.xml:S3:6252:9	treatment	NN	O	O
of	XIAFLEX.xml:S3:6262:2	of	IN	O	O
Dupuytren	XIAFLEX.xml:S3:6265:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S3:6274:2	's	POS	O	O
contracture	XIAFLEX.xml:S3:6277:11	contractur	NN	O	O
.	XIAFLEX.xml:S3:6288:1	.	.	O	O

Some	XIAFLEX.xml:S3:6290:4	some	DT	O	O
patients	XIAFLEX.xml:S3:6295:8	patient	NNS	O	O
with	XIAFLEX.xml:S3:6304:4	with	IN	O	O
Dupuytren	XIAFLEX.xml:S3:6309:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S3:6318:2	's	POS	O	O
contracture	XIAFLEX.xml:S3:6321:11	contractur	NN	O	O
developed	XIAFLEX.xml:S3:6333:9	develop	VBD	O	O
IgE	XIAFLEX.xml:S3:6343:3	ige	NNP	O	O
-	XIAFLEX.xml:S3:6346:1	-	:	O	O
anti	XIAFLEX.xml:S3:6347:4	anti	JJ	O	O
-	XIAFLEX.xml:S3:6351:1	-	:	O	O
drug	XIAFLEX.xml:S3:6352:4	drug	NN	O	O
antibodies	XIAFLEX.xml:S3:6357:10	antibodi	NNS	O	O
in	XIAFLEX.xml:S3:6368:2	in	IN	O	O
greater	XIAFLEX.xml:S3:6371:7	greater	JJR	O	O
proportions	XIAFLEX.xml:S3:6379:11	proport	NNS	O	O
and	XIAFLEX.xml:S3:6391:3	and	CC	O	O
higher	XIAFLEX.xml:S3:6395:6	higher	JJR	O	O
titers	XIAFLEX.xml:S3:6402:6	titer	NNS	O	O
with	XIAFLEX.xml:S3:6409:4	with	IN	O	O
successive	XIAFLEX.xml:S3:6414:10	success	JJ	O	O
XIAFLEX	XIAFLEX.xml:S3:6425:7	xiaflex	NN	O	O
injections	XIAFLEX.xml:S3:6433:10	inject	NNS	O	O
.	XIAFLEX.xml:S3:6443:1	.	.	O	O

Healthcare	XIAFLEX.xml:S3:6445:10	healthcar	NNP	O	O
providers	XIAFLEX.xml:S3:6456:9	provid	NNS	O	O
should	XIAFLEX.xml:S3:6466:6	should	MD	O	O
be	XIAFLEX.xml:S3:6473:2	be	VB	O	O
prepared	XIAFLEX.xml:S3:6476:8	prepar	VBN	O	O
to	XIAFLEX.xml:S3:6485:2	to	TO	O	O
address	XIAFLEX.xml:S3:6488:7	address	VB	O	O
severe	XIAFLEX.xml:S3:6496:6	sever	JJ	O	O
allergic	XIAFLEX.xml:S3:6503:8	allerg	JJ	O	B-AdverseReaction
reactions	XIAFLEX.xml:S3:6512:9	reaction	NNS	O	I-AdverseReaction
following	XIAFLEX.xml:S3:6522:9	follow	VBG	O	O
XIAFLEX	XIAFLEX.xml:S3:6532:7	xiaflex	JJ	O	O
injections	XIAFLEX.xml:S3:6540:10	inject	NNS	O	O
.	XIAFLEX.xml:S3:6550:1	.	.	O	O

5.5	XIAFLEX.xml:S3:6561:3	5.5	CD	O	O
Risk	XIAFLEX.xml:S3:6565:4	risk	NN	O	O
of	XIAFLEX.xml:S3:6570:2	of	IN	O	O
bleeding	XIAFLEX.xml:S3:6573:8	bleed	VBG	O	O
in	XIAFLEX.xml:S3:6582:2	in	IN	O	O
Patients	XIAFLEX.xml:S3:6585:8	patient	NNS	O	O
with	XIAFLEX.xml:S3:6594:4	with	IN	O	O
Abnormal	XIAFLEX.xml:S3:6599:8	abnorm	NNP	O	O
Coagulation	XIAFLEX.xml:S3:6608:11	coagul	NNP	O	O

In	XIAFLEX.xml:S3:6625:2	In	IN	O	O
the	XIAFLEX.xml:S3:6628:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S3:6632:7	xiaflex	NN	O	O
trials	XIAFLEX.xml:S3:6640:6	trial	NNS	O	O
in	XIAFLEX.xml:S3:6647:2	in	IN	O	O
Dupuytren	XIAFLEX.xml:S3:6650:9	dupuytren	NNP	O	O
's	XIAFLEX.xml:S3:6659:2	's	POS	O	O
contracture	XIAFLEX.xml:S3:6662:11	contractur	NN	O	O
(	XIAFLEX.xml:S3:6674:1	(	(	O	O
Studies	XIAFLEX.xml:S3:6675:7	studi	NNPS	O	O
1	XIAFLEX.xml:S3:6683:1	1	CD	O	O
and	XIAFLEX.xml:S3:6685:3	and	CC	O	O
2	XIAFLEX.xml:S3:6689:1	2	CD	O	O
)	XIAFLEX.xml:S3:6690:1	)	)	O	O
,	XIAFLEX.xml:S3:6691:1	,	,	O	O
70%	XIAFLEX.xml:S3:6693:3	70%	CD	O	O
and	XIAFLEX.xml:S3:6697:3	and	CC	O	O
38%	XIAFLEX.xml:S3:6701:3	38%	CD	O	O
of	XIAFLEX.xml:S3:6705:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:6708:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S3:6715:1	-	:	O	O
treated	XIAFLEX.xml:S3:6716:7	treat	VBD	O	O
patients	XIAFLEX.xml:S3:6724:8	patient	NNS	O	O
developed	XIAFLEX.xml:S3:6733:9	develop	VBD	O	O
an	XIAFLEX.xml:S3:6743:2	an	DT	O	O
ecchymosis	XIAFLEX.xml:S3:6746:10	ecchymosi	NN	B-AdverseReaction	O
contusion	XIAFLEX.xml:S3:6757:9	contus	NN	B-AdverseReaction	O
or	XIAFLEX.xml:S3:6767:2	or	CC	O	O
an	XIAFLEX.xml:S3:6770:2	an	DT	O	O
injection	XIAFLEX.xml:S3:6773:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	XIAFLEX.xml:S3:6783:4	site	NN	I-AdverseReaction	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S3:6788:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S3:6798:1	,	,	O	O
respectively	XIAFLEX.xml:S3:6800:12	respect	RB	O	O
(	XIAFLEX.xml:S3:6813:1	(	(	O	O
see	XIAFLEX.xml:S3:6814:3	see	VB	O	O
Table	XIAFLEX.xml:S3:6818:5	tabl	NNP	O	O
3	XIAFLEX.xml:S3:6824:1	3	CD	O	O
)	XIAFLEX.xml:S3:6825:1	)	)	O	O
.	XIAFLEX.xml:S3:6826:1	.	.	O	O

In	XIAFLEX.xml:S3:6828:2	In	IN	O	O
the	XIAFLEX.xml:S3:6831:3	the	DT	O	O
XIAFLEX	XIAFLEX.xml:S3:6835:7	xiaflex	NNP	O	O
controlled	XIAFLEX.xml:S3:6843:10	control	VBD	O	O
trials	XIAFLEX.xml:S3:6854:6	trial	NNS	O	O
in	XIAFLEX.xml:S3:6861:2	in	IN	O	O
Peyronie	XIAFLEX.xml:S3:6864:8	peyroni	NNP	O	O
's	XIAFLEX.xml:S3:6872:2	's	POS	O	O
disease	XIAFLEX.xml:S3:6875:7	diseas	NN	O	O
(	XIAFLEX.xml:S3:6883:1	(	(	O	O
Studies	XIAFLEX.xml:S3:6884:7	studi	NNPS	O	O
1	XIAFLEX.xml:S3:6892:1	1	CD	O	O
and	XIAFLEX.xml:S3:6894:3	and	CC	O	O
2	XIAFLEX.xml:S3:6898:1	2	CD	O	O
)	XIAFLEX.xml:S3:6899:1	)	)	O	O
,	XIAFLEX.xml:S3:6900:1	,	,	O	O
65.5%	XIAFLEX.xml:S3:6902:5	65.5%	CD	O	O
of	XIAFLEX.xml:S3:6908:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:6911:7	xiaflex	NNP	O	O
-	XIAFLEX.xml:S3:6918:1	-	:	O	O
treated	XIAFLEX.xml:S3:6919:7	treat	VBD	O	O
patients	XIAFLEX.xml:S3:6927:8	patient	NNS	O	O
developed	XIAFLEX.xml:S3:6936:9	develop	VBN	O	O
penile	XIAFLEX.xml:S3:6946:6	penil	JJ	B-AdverseReaction	B-AdverseReaction
hematoma	XIAFLEX.xml:S3:6953:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
,	XIAFLEX.xml:S3:6961:1	,	,	O	O
and	XIAFLEX.xml:S3:6963:3	and	CC	O	O
14.5%	XIAFLEX.xml:S3:6967:5	14.5%	CD	O	O
developed	XIAFLEX.xml:S3:6973:9	develop	VBD	O	O
penile	XIAFLEX.xml:S3:6983:6	penil	JJ	B-AdverseReaction	O
ecchymosis	XIAFLEX.xml:S3:6990:10	ecchymosi	NN	I-AdverseReaction	O
(	XIAFLEX.xml:S3:7001:1	(	(	O	O
see	XIAFLEX.xml:S3:7002:3	see	VB	O	O
Table	XIAFLEX.xml:S3:7006:5	tabl	NNP	O	O
4	XIAFLEX.xml:S3:7012:1	4	CD	O	O
)	XIAFLEX.xml:S3:7013:1	)	)	O	O
.	XIAFLEX.xml:S3:7014:1	.	.	O	O

Patients	XIAFLEX.xml:S3:7016:8	patient	NNS	O	O
with	XIAFLEX.xml:S3:7025:4	with	IN	O	O
abnormal	XIAFLEX.xml:S3:7030:8	abnorm	JJ	O	O
coagulation	XIAFLEX.xml:S3:7039:11	coagul	NN	O	O
(	XIAFLEX.xml:S3:7051:1	(	(	O	O
except	XIAFLEX.xml:S3:7052:6	except	IN	O	O
for	XIAFLEX.xml:S3:7059:3	for	IN	O	O
patients	XIAFLEX.xml:S3:7063:8	patient	NNS	O	O
taking	XIAFLEX.xml:S3:7072:6	take	VBG	O	O
low	XIAFLEX.xml:S3:7079:3	low	JJ	O	O
-	XIAFLEX.xml:S3:7082:1	-	:	O	O
dose	XIAFLEX.xml:S3:7083:4	dose	NN	O	O
aspirin	XIAFLEX.xml:S3:7088:7	aspirin	NN	O	O
,	XIAFLEX.xml:S3:7095:1	,	,	O	O
e	XIAFLEX.xml:S3:7097:1	e	NN	O	O
.	XIAFLEX.xml:S3:7098:1	.	.	O	O
g	XIAFLEX.xml:S3:7099:1	g	NN	O	O
.	XIAFLEX.xml:S3:7100:1	.	.	O	O
,	XIAFLEX.xml:S3:7101:1	,	,	O	O
up	XIAFLEX.xml:S3:7103:2	up	RB	O	O
to	XIAFLEX.xml:S3:7106:2	to	TO	O	O
150	XIAFLEX.xml:S3:7109:3	150	CD	O	O
mg	XIAFLEX.xml:S3:7113:2	mg	NNS	O	O
per	XIAFLEX.xml:S3:7116:3	per	IN	O	O
day	XIAFLEX.xml:S3:7120:3	day	NN	O	O
)	XIAFLEX.xml:S3:7123:1	)	)	O	O
were	XIAFLEX.xml:S3:7125:4	were	VBD	O	O
excluded	XIAFLEX.xml:S3:7130:8	exclud	VBN	O	O
from	XIAFLEX.xml:S3:7139:4	from	IN	O	O
participating	XIAFLEX.xml:S3:7144:13	particip	VBG	O	O
in	XIAFLEX.xml:S3:7158:2	in	IN	O	O
these	XIAFLEX.xml:S3:7161:5	these	DT	O	O
studies	XIAFLEX.xml:S3:7167:7	studi	NNS	O	O
.	XIAFLEX.xml:S3:7174:1	.	.	O	O

Therefore	XIAFLEX.xml:S3:7180:9	therefor	RB	O	O
,	XIAFLEX.xml:S3:7189:1	,	,	O	O
the	XIAFLEX.xml:S3:7191:3	the	DT	O	O
efficacy	XIAFLEX.xml:S3:7195:8	efficaci	NN	O	O
and	XIAFLEX.xml:S3:7204:3	and	CC	O	O
safety	XIAFLEX.xml:S3:7208:6	safeti	NN	O	O
of	XIAFLEX.xml:S3:7215:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:7218:7	xiaflex	NNP	O	O
in	XIAFLEX.xml:S3:7226:2	in	IN	O	O
patients	XIAFLEX.xml:S3:7229:8	patient	NNS	O	O
receiving	XIAFLEX.xml:S3:7238:9	receiv	VBG	O	O
anticoagulant	XIAFLEX.xml:S3:7248:13	anticoagul	JJ	O	O
medications	XIAFLEX.xml:S3:7262:11	medic	NNS	O	O
(	XIAFLEX.xml:S3:7274:1	(	(	O	O
other	XIAFLEX.xml:S3:7275:5	other	JJ	O	O
than	XIAFLEX.xml:S3:7281:4	than	IN	O	O
low	XIAFLEX.xml:S3:7286:3	low	JJ	O	O
-	XIAFLEX.xml:S3:7289:1	-	:	O	O
dose	XIAFLEX.xml:S3:7290:4	dose	NN	O	O
aspirin	XIAFLEX.xml:S3:7295:7	aspirin	NN	O	O
,	XIAFLEX.xml:S3:7302:1	,	,	O	O
e	XIAFLEX.xml:S3:7304:1	e	NN	O	O
.	XIAFLEX.xml:S3:7305:1	.	.	O	O
g	XIAFLEX.xml:S3:7306:1	g	NN	O	O
.	XIAFLEX.xml:S3:7307:1	.	.	O	O
,	XIAFLEX.xml:S3:7308:1	,	,	O	O
up	XIAFLEX.xml:S3:7310:2	up	RB	O	O
to	XIAFLEX.xml:S3:7313:2	to	TO	O	O
150	XIAFLEX.xml:S3:7316:3	150	CD	O	O
mg	XIAFLEX.xml:S3:7320:2	mg	NNS	O	O
per	XIAFLEX.xml:S3:7323:3	per	IN	O	O
day	XIAFLEX.xml:S3:7327:3	day	NN	O	O
)	XIAFLEX.xml:S3:7330:1	)	)	O	O
within	XIAFLEX.xml:S3:7332:6	within	IN	O	O
7	XIAFLEX.xml:S3:7339:1	7	CD	O	O
days	XIAFLEX.xml:S3:7341:4	day	NNS	O	O
prior	XIAFLEX.xml:S3:7346:5	prior	RB	O	O
to	XIAFLEX.xml:S3:7352:2	to	TO	O	O
XIAFLEX	XIAFLEX.xml:S3:7355:7	xiaflex	NNP	O	O
administration	XIAFLEX.xml:S3:7363:14	administr	NN	O	O
is	XIAFLEX.xml:S3:7378:2	is	VBZ	O	O
not	XIAFLEX.xml:S3:7381:3	not	RB	O	O
known	XIAFLEX.xml:S3:7385:5	known	VBN	O	O
.	XIAFLEX.xml:S3:7390:1	.	.	O	O

In	XIAFLEX.xml:S3:7392:2	In	IN	O	O
addition	XIAFLEX.xml:S3:7395:8	addit	NN	O	O
,	XIAFLEX.xml:S3:7403:1	,	,	O	O
it	XIAFLEX.xml:S3:7405:2	it	PRP	O	O
is	XIAFLEX.xml:S3:7408:2	is	VBZ	O	O
recommended	XIAFLEX.xml:S3:7411:11	recommend	VBN	O	O
to	XIAFLEX.xml:S3:7423:2	to	TO	O	O
avoid	XIAFLEX.xml:S3:7426:5	avoid	VB	O	O
use	XIAFLEX.xml:S3:7432:3	use	NN	O	O
of	XIAFLEX.xml:S3:7436:2	of	IN	O	O
XIAFLEX	XIAFLEX.xml:S3:7439:7	xiaflex	NN	O	O
in	XIAFLEX.xml:S3:7447:2	in	IN	O	O
patients	XIAFLEX.xml:S3:7450:8	patient	NNS	O	O
with	XIAFLEX.xml:S3:7459:4	with	IN	O	O
coagulation	XIAFLEX.xml:S3:7464:11	coagul	NN	O	O
disorders	XIAFLEX.xml:S3:7476:9	disord	NNS	O	O
,	XIAFLEX.xml:S3:7485:1	,	,	O	O
including	XIAFLEX.xml:S3:7487:9	includ	VBG	O	O
patients	XIAFLEX.xml:S3:7497:8	patient	NNS	O	O
receiving	XIAFLEX.xml:S3:7506:9	receiv	VBG	O	O
concomitant	XIAFLEX.xml:S3:7516:11	concomit	JJ	O	O
anticoagulants	XIAFLEX.xml:S3:7528:14	anticoagul	NNS	O	O
(	XIAFLEX.xml:S3:7543:1	(	(	O	O
except	XIAFLEX.xml:S3:7544:6	except	IN	O	O
for	XIAFLEX.xml:S3:7551:3	for	IN	O	O
low	XIAFLEX.xml:S3:7555:3	low	JJ	O	O
-	XIAFLEX.xml:S3:7558:1	-	:	O	O
dose	XIAFLEX.xml:S3:7559:4	dose	NN	O	O
aspirin	XIAFLEX.xml:S3:7564:7	aspirin	NN	O	O
)	XIAFLEX.xml:S3:7571:1	)	)	O	O
.	XIAFLEX.xml:S3:7572:1	.	.	O	O
6	XTANDI.xml:S1:4:1	6	CD	O	O
ADVERSE	XTANDI.xml:S1:6:7	advers	JJ	O	O
REACTIONS	XTANDI.xml:S1:14:9	reaction	NN	O	O

The	XTANDI.xml:S1:27:3	the	DT	O	O
following	XTANDI.xml:S1:31:9	follow	NN	O	O
is	XTANDI.xml:S1:41:2	is	VBZ	O	O
discussed	XTANDI.xml:S1:44:9	discuss	VBN	O	O
in	XTANDI.xml:S1:54:2	in	IN	O	O
more	XTANDI.xml:S1:57:4	more	JJR	O	O
detail	XTANDI.xml:S1:62:6	detail	NN	O	O
in	XTANDI.xml:S1:69:2	in	IN	O	O
other	XTANDI.xml:S1:72:5	other	JJ	O	O
sections	XTANDI.xml:S1:78:8	section	NNS	O	O
of	XTANDI.xml:S1:87:2	of	IN	O	O
the	XTANDI.xml:S1:90:3	the	DT	O	O
labeling	XTANDI.xml:S1:94:8	label	NN	O	O
:	XTANDI.xml:S1:102:1	:	:	O	O

Seizure	XTANDI.xml:S1:113:7	seizur	NN	B-AdverseReaction	B-AdverseReaction
[	XTANDI.xml:S1:121:1	[	NNP	O	O
see	XTANDI.xml:S1:122:3	see	VBP	O	O
Warnings	XTANDI.xml:S1:127:8	warn	NNP	O	O
and	XTANDI.xml:S1:136:3	and	CC	O	O
Precautions	XTANDI.xml:S1:140:11	precaut	NNP	O	O
(	XTANDI.xml:S1:153:1	(	(	O	O
5.1	XTANDI.xml:S1:156:3	5.1	CD	O	O
)]	XTANDI.xml:S1:161:2	)]	NN	O	O

EXCERPT	XTANDI.xml:S1:172:7	excerpt	NN	O	O
:	XTANDI.xml:S1:179:1	:	:	O	O
The	XTANDI.xml:S1:183:3	the	DT	O	O
most	XTANDI.xml:S1:187:4	most	RBS	O	O
common	XTANDI.xml:S1:192:6	common	JJ	O	O
adverse	XTANDI.xml:S1:199:7	advers	JJ	O	O
reactions	XTANDI.xml:S1:207:9	reaction	NNS	O	O
(	XTANDI.xml:S1:217:1	(	(	O	O
10%	XTANDI.xml:S1:221:3	10%	CD	O	O
)	XTANDI.xml:S1:224:1	)	)	O	O
are	XTANDI.xml:S1:226:3	are	VBP	O	O
asthenia	XTANDI.xml:S1:230:8	asthenia	JJ	B-AdverseReaction	B-AdverseReaction
fatigue	XTANDI.xml:S1:239:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:246:1	,	,	O	O
back	XTANDI.xml:S1:248:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	XTANDI.xml:S1:253:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:257:1	,	,	O	O
decreased	XTANDI.xml:S1:259:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	XTANDI.xml:S1:269:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:277:1	,	,	O	O
constipation	XTANDI.xml:S1:279:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:291:1	,	,	O	O
arthralgia	XTANDI.xml:S1:293:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:303:1	,	,	O	O
diarrhea	XTANDI.xml:S1:305:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:313:1	,	,	O	O
hot	XTANDI.xml:S1:315:3	hot	JJ	B-AdverseReaction	B-AdverseReaction
flush	XTANDI.xml:S1:319:5	flush	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:324:1	,	,	O	O
upper	XTANDI.xml:S1:326:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XTANDI.xml:S1:332:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	XTANDI.xml:S1:344:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	XTANDI.xml:S1:350:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:359:1	,	,	O	O
peripheral	XTANDI.xml:S1:361:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	XTANDI.xml:S1:372:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:377:1	,	,	O	O
dyspnea	XTANDI.xml:S1:379:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:386:1	,	,	O	O
musculoskeletal	XTANDI.xml:S1:388:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	XTANDI.xml:S1:404:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:408:1	,	,	O	O
weight	XTANDI.xml:S1:410:6	weight	NN	B-AdverseReaction	B-AdverseReaction
decreased	XTANDI.xml:S1:417:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:426:1	,	,	O	O
headache	XTANDI.xml:S1:428:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:436:1	,	,	O	O
hypertension	XTANDI.xml:S1:438:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:450:1	,	,	O	O
and	XTANDI.xml:S1:452:3	and	CC	O	O
dizziness	XTANDI.xml:S1:456:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
vertigo	XTANDI.xml:S1:466:7	vertigo	NN	B-AdverseReaction	I-AdverseReaction
.	XTANDI.xml:S1:473:1	.	.	O	O

(	XTANDI.xml:S1:475:1	(	(	O	O
6.1	XTANDI.xml:S1:478:3	6.1	CD	O	O
)	XTANDI.xml:S1:483:1	)	)	O	O

To	XTANDI.xml:S1:491:2	To	TO	O	O

report	XTANDI.xml:S1:494:6	report	NN	O	O
SUSPECTED	XTANDI.xml:S1:501:9	suspect	NNP	O	O
ADVERSE	XTANDI.xml:S1:511:7	advers	NNP	O	O
REACTIONS	XTANDI.xml:S1:519:9	reaction	NNP	O	O
,	XTANDI.xml:S1:528:1	,	,	O	O
contact	XTANDI.xml:S1:530:7	contact	NN	O	O
Astellas	XTANDI.xml:S1:538:8	astella	NNP	O	O
Pharma	XTANDI.xml:S1:547:6	pharma	NNP	O	O
US	XTANDI.xml:S1:554:2	US	NNP	O	O
,	XTANDI.xml:S1:556:1	,	,	O	O
Inc	XTANDI.xml:S1:558:3	inc	NNP	O	O
.	XTANDI.xml:S1:561:1	.	.	O	O

at	XTANDI.xml:S1:563:2	at	IN	O	O
1	XTANDI.xml:S1:566:1	1	CD	O	O
-	XTANDI.xml:S1:567:1	-	:	O	O
800	XTANDI.xml:S1:568:3	800	CD	O	O
-	XTANDI.xml:S1:571:1	-	:	O	O
727	XTANDI.xml:S1:572:3	727	CD	O	O
-	XTANDI.xml:S1:575:1	-	:	O	O
7003	XTANDI.xml:S1:576:4	7003	CD	O	O
or	XTANDI.xml:S1:581:2	or	CC	O	O
FDA	XTANDI.xml:S1:584:3	fda	NNP	O	O
at	XTANDI.xml:S1:588:2	at	IN	O	O
1	XTANDI.xml:S1:591:1	1	CD	O	O
-	XTANDI.xml:S1:592:1	-	:	O	O
800	XTANDI.xml:S1:593:3	800	CD	O	O
-	XTANDI.xml:S1:596:1	-	:	O	O
FDA	XTANDI.xml:S1:597:3	fda	NNP	O	O
-	XTANDI.xml:S1:600:1	-	:	O	O
1088	XTANDI.xml:S1:601:4	1088	CD	O	O
or	XTANDI.xml:S1:606:2	or	CC	O	O
www	XTANDI.xml:S1:612:3	www	VB	O	O
.	XTANDI.xml:S1:615:1	.	.	O	O
fda	XTANDI.xml:S1:616:3	fda	NN	O	O
.	XTANDI.xml:S1:619:1	.	.	O	O
gov	XTANDI.xml:S1:620:3	gov	JJ	O	O
medwatch	XTANDI.xml:S1:624:8	medwatch	NN	O	O
.	XTANDI.xml:S1:636:1	.	.	O	O

6.1	XTANDI.xml:S1:648:3	6.1	CD	O	O

Clinical	XTANDI.xml:S1:652:8	clinic	JJ	O	O
Trial	XTANDI.xml:S1:661:5	trial	NNP	O	O
Experience	XTANDI.xml:S1:667:10	experi	NN	O	O

Because	XTANDI.xml:S1:681:7	becaus	IN	O	O
clinical	XTANDI.xml:S1:689:8	clinic	JJ	O	O
trials	XTANDI.xml:S1:698:6	trial	NNS	O	O
are	XTANDI.xml:S1:705:3	are	VBP	O	O
conducted	XTANDI.xml:S1:709:9	conduct	VBN	O	O
under	XTANDI.xml:S1:719:5	under	IN	O	O
widely	XTANDI.xml:S1:725:6	wide	RB	O	O
varying	XTANDI.xml:S1:732:7	vari	VBG	O	O
conditions	XTANDI.xml:S1:740:10	condit	NNS	O	O
,	XTANDI.xml:S1:750:1	,	,	O	O
adverse	XTANDI.xml:S1:752:7	advers	JJ	O	O
reaction	XTANDI.xml:S1:760:8	reaction	NN	O	O
rates	XTANDI.xml:S1:769:5	rate	NNS	O	O
observed	XTANDI.xml:S1:775:8	observ	VBD	O	O
in	XTANDI.xml:S1:784:2	in	IN	O	O
the	XTANDI.xml:S1:787:3	the	DT	O	O
clinical	XTANDI.xml:S1:791:8	clinic	JJ	O	O
trials	XTANDI.xml:S1:800:6	trial	NNS	O	O
of	XTANDI.xml:S1:807:2	of	IN	O	O
a	XTANDI.xml:S1:810:1	a	DT	O	O
drug	XTANDI.xml:S1:812:4	drug	NN	O	O
cannot	XTANDI.xml:S1:817:6	cannot	NN	O	O
be	XTANDI.xml:S1:824:2	be	VB	O	O
directly	XTANDI.xml:S1:827:8	directli	RB	O	O
compared	XTANDI.xml:S1:836:8	compar	VBN	O	O
to	XTANDI.xml:S1:845:2	to	TO	O	O
rates	XTANDI.xml:S1:848:5	rate	NNS	O	O
in	XTANDI.xml:S1:854:2	in	IN	O	O
the	XTANDI.xml:S1:857:3	the	DT	O	O
clinical	XTANDI.xml:S1:861:8	clinic	JJ	O	O
trials	XTANDI.xml:S1:870:6	trial	NNS	O	O
of	XTANDI.xml:S1:877:2	of	IN	O	O
another	XTANDI.xml:S1:880:7	anoth	DT	O	O
drug	XTANDI.xml:S1:888:4	drug	NN	O	O
and	XTANDI.xml:S1:893:3	and	CC	O	O
may	XTANDI.xml:S1:897:3	may	MD	O	O
not	XTANDI.xml:S1:901:3	not	RB	O	O
reflect	XTANDI.xml:S1:905:7	reflect	VB	O	O
the	XTANDI.xml:S1:913:3	the	DT	O	O
rates	XTANDI.xml:S1:917:5	rate	NNS	O	O
observed	XTANDI.xml:S1:923:8	observ	VBD	O	O
in	XTANDI.xml:S1:932:2	in	IN	O	O
practice	XTANDI.xml:S1:935:8	practic	NN	O	O
.	XTANDI.xml:S1:943:1	.	.	O	O

Two	XTANDI.xml:S1:949:3	two	CD	O	O
randomized	XTANDI.xml:S1:953:10	random	JJ	O	O
clinical	XTANDI.xml:S1:964:8	clinic	JJ	O	O
trials	XTANDI.xml:S1:973:6	trial	NNS	O	O
enrolled	XTANDI.xml:S1:980:8	enrol	VBD	O	O
patients	XTANDI.xml:S1:989:8	patient	NNS	O	O
with	XTANDI.xml:S1:998:4	with	IN	O	O
metastatic	XTANDI.xml:S1:1003:10	metastat	JJ	O	O
prostate	XTANDI.xml:S1:1014:8	prostat	NN	O	O
cancer	XTANDI.xml:S1:1023:6	cancer	NN	O	O
that	XTANDI.xml:S1:1030:4	that	WDT	O	O
has	XTANDI.xml:S1:1035:3	ha	VBZ	O	O
progressed	XTANDI.xml:S1:1039:10	progress	VBN	O	O
on	XTANDI.xml:S1:1050:2	on	IN	O	O
androgen	XTANDI.xml:S1:1053:8	androgen	NN	O	O
deprivation	XTANDI.xml:S1:1062:11	depriv	NN	O	O
therapy	XTANDI.xml:S1:1074:7	therapi	NN	O	O
(	XTANDI.xml:S1:1082:1	(	(	O	O
GnRH	XTANDI.xml:S1:1083:4	gnrh	NNP	O	O
therapy	XTANDI.xml:S1:1088:7	therapi	NN	O	O
or	XTANDI.xml:S1:1096:2	or	CC	O	O
bilateral	XTANDI.xml:S1:1099:9	bilater	JJ	O	O
orchiectomy	XTANDI.xml:S1:1109:11	orchiectomi	NN	O	O
)	XTANDI.xml:S1:1120:1	)	)	O	O
,	XTANDI.xml:S1:1121:1	,	,	O	O
a	XTANDI.xml:S1:1123:1	a	DT	O	O
disease	XTANDI.xml:S1:1125:7	diseas	NN	O	O
setting	XTANDI.xml:S1:1133:7	set	VBG	O	O
that	XTANDI.xml:S1:1141:4	that	WDT	O	O
is	XTANDI.xml:S1:1146:2	is	VBZ	O	O
also	XTANDI.xml:S1:1149:4	also	RB	O	O
defined	XTANDI.xml:S1:1154:7	defin	VBN	O	O
as	XTANDI.xml:S1:1162:2	as	IN	O	O
metastatic	XTANDI.xml:S1:1165:10	metastat	JJ	O	O
CRPC	XTANDI.xml:S1:1176:4	crpc	NNP	O	O
.	XTANDI.xml:S1:1180:1	.	.	O	O

In	XTANDI.xml:S1:1182:2	In	IN	O	O
both	XTANDI.xml:S1:1185:4	both	DT	O	O
studies	XTANDI.xml:S1:1190:7	studi	NNS	O	O
,	XTANDI.xml:S1:1197:1	,	,	O	O
patients	XTANDI.xml:S1:1199:8	patient	NNS	O	O
received	XTANDI.xml:S1:1208:8	receiv	VBD	O	O
XTANDI	XTANDI.xml:S1:1217:6	xtandi	JJ	O	O
160	XTANDI.xml:S1:1224:3	160	CD	O	O
mg	XTANDI.xml:S1:1228:2	mg	NN	O	O
orally	XTANDI.xml:S1:1231:6	oral	RB	O	O
once	XTANDI.xml:S1:1238:4	onc	RB	O	O
daily	XTANDI.xml:S1:1243:5	daili	JJ	O	O
in	XTANDI.xml:S1:1249:2	in	IN	O	O
the	XTANDI.xml:S1:1252:3	the	DT	O	O
active	XTANDI.xml:S1:1256:6	activ	JJ	O	O
treatment	XTANDI.xml:S1:1263:9	treatment	NN	O	O
arm	XTANDI.xml:S1:1273:3	arm	NN	O	O
or	XTANDI.xml:S1:1277:2	or	CC	O	O
placebo	XTANDI.xml:S1:1280:7	placebo	NN	O	O
in	XTANDI.xml:S1:1288:2	in	IN	O	O
the	XTANDI.xml:S1:1291:3	the	DT	O	O
control	XTANDI.xml:S1:1295:7	control	NN	O	O
arm	XTANDI.xml:S1:1303:3	arm	NN	O	O
.	XTANDI.xml:S1:1306:1	.	.	O	O

All	XTANDI.xml:S1:1308:3	all	DT	O	O
patients	XTANDI.xml:S1:1312:8	patient	NNS	O	O
continued	XTANDI.xml:S1:1321:9	continu	VBD	O	O
androgen	XTANDI.xml:S1:1331:8	androgen	JJ	O	O
deprivation	XTANDI.xml:S1:1340:11	depriv	NN	O	O
therapy	XTANDI.xml:S1:1352:7	therapi	NN	O	O
.	XTANDI.xml:S1:1359:1	.	.	O	O

Patients	XTANDI.xml:S1:1361:8	patient	NNS	O	O
were	XTANDI.xml:S1:1370:4	were	VBD	O	O
allowed	XTANDI.xml:S1:1375:7	allow	VBN	O	O
,	XTANDI.xml:S1:1382:1	,	,	O	O
but	XTANDI.xml:S1:1384:3	but	CC	O	O
not	XTANDI.xml:S1:1388:3	not	RB	O	O
required	XTANDI.xml:S1:1392:8	requir	VBN	O	O
,	XTANDI.xml:S1:1400:1	,	,	O	O
to	XTANDI.xml:S1:1402:2	to	TO	O	O
take	XTANDI.xml:S1:1405:4	take	VB	O	O
glucocorticoids	XTANDI.xml:S1:1410:15	glucocorticoid	NNS	O	O
.	XTANDI.xml:S1:1425:1	.	.	O	O

The	XTANDI.xml:S1:1431:3	the	DT	O	O
most	XTANDI.xml:S1:1435:4	most	RBS	O	O
common	XTANDI.xml:S1:1440:6	common	JJ	O	O
adverse	XTANDI.xml:S1:1447:7	advers	JJ	O	O
reactions	XTANDI.xml:S1:1455:9	reaction	NNS	O	O
(	XTANDI.xml:S1:1465:1	(	(	O	O
10%	XTANDI.xml:S1:1469:3	10%	CD	O	O
)	XTANDI.xml:S1:1472:1	)	)	O	O
that	XTANDI.xml:S1:1474:4	that	WDT	O	O
occurred	XTANDI.xml:S1:1479:8	occur	VBD	O	O
more	XTANDI.xml:S1:1488:4	more	JJR	O	O
commonly	XTANDI.xml:S1:1493:8	commonli	RB	O	O
(	XTANDI.xml:S1:1502:1	(	(	O	O
2%	XTANDI.xml:S1:1506:2	2%	CD	O	O
over	XTANDI.xml:S1:1509:4	over	IN	O	O
placebo	XTANDI.xml:S1:1514:7	placebo	NN	O	O
)	XTANDI.xml:S1:1521:1	)	)	O	O
in	XTANDI.xml:S1:1523:2	in	IN	O	O
the	XTANDI.xml:S1:1526:3	the	DT	O	O
XTANDI	XTANDI.xml:S1:1530:6	xtandi	NNP	O	O
-	XTANDI.xml:S1:1536:1	-	:	O	O
treated	XTANDI.xml:S1:1537:7	treat	VBD	O	O
patients	XTANDI.xml:S1:1545:8	patient	NNS	O	O
from	XTANDI.xml:S1:1554:4	from	IN	O	O
the	XTANDI.xml:S1:1559:3	the	DT	O	O
two	XTANDI.xml:S1:1563:3	two	CD	O	O
randomized	XTANDI.xml:S1:1567:10	random	VBD	O	O
clinical	XTANDI.xml:S1:1578:8	clinic	JJ	O	O
trials	XTANDI.xml:S1:1587:6	trial	NNS	O	O
were	XTANDI.xml:S1:1594:4	were	VBD	O	O
asthenia	XTANDI.xml:S1:1599:8	asthenia	JJ	B-AdverseReaction	B-AdverseReaction
fatigue	XTANDI.xml:S1:1608:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:1615:1	,	,	O	O
back	XTANDI.xml:S1:1617:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	XTANDI.xml:S1:1622:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:1626:1	,	,	O	O
decreased	XTANDI.xml:S1:1628:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	XTANDI.xml:S1:1638:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:1646:1	,	,	O	O
constipation	XTANDI.xml:S1:1648:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:1660:1	,	,	O	O
arthralgia	XTANDI.xml:S1:1662:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:1672:1	,	,	O	O
diarrhea	XTANDI.xml:S1:1674:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:1682:1	,	,	O	O
hot	XTANDI.xml:S1:1684:3	hot	JJ	B-AdverseReaction	B-AdverseReaction
flush	XTANDI.xml:S1:1688:5	flush	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:1693:1	,	,	O	O
upper	XTANDI.xml:S1:1695:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XTANDI.xml:S1:1701:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	XTANDI.xml:S1:1713:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	XTANDI.xml:S1:1719:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:1728:1	,	,	O	O
peripheral	XTANDI.xml:S1:1730:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	XTANDI.xml:S1:1741:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:1746:1	,	,	O	O
dyspnea	XTANDI.xml:S1:1748:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:1755:1	,	,	O	O
musculoskeletal	XTANDI.xml:S1:1757:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	XTANDI.xml:S1:1773:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:1777:1	,	,	O	O
weight	XTANDI.xml:S1:1779:6	weight	NN	B-AdverseReaction	B-AdverseReaction
decreased	XTANDI.xml:S1:1786:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:1795:1	,	,	O	O
headache	XTANDI.xml:S1:1797:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:1805:1	,	,	O	O
hypertension	XTANDI.xml:S1:1807:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:1819:1	,	,	O	O
and	XTANDI.xml:S1:1821:3	and	CC	O	O
dizziness	XTANDI.xml:S1:1825:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
vertigo	XTANDI.xml:S1:1835:7	vertigo	NN	B-AdverseReaction	I-AdverseReaction
.	XTANDI.xml:S1:1842:1	.	.	O	O

Study	XTANDI.xml:S1:1850:5	studi	NN	O	O
1	XTANDI.xml:S1:1856:1	1	CD	O	O
:	XTANDI.xml:S1:1857:1	:	:	O	O
Metastatic	XTANDI.xml:S1:1859:10	metastat	JJ	O	O
Castration	XTANDI.xml:S1:1870:10	castrat	NNP	O	O
-	XTANDI.xml:S1:1880:1	-	:	O	O
Resistant	XTANDI.xml:S1:1881:9	resist	JJ	O	O
Prostate	XTANDI.xml:S1:1891:8	prostat	NNP	O	O
Cancer	XTANDI.xml:S1:1900:6	cancer	NNP	O	O
Following	XTANDI.xml:S1:1907:9	follow	NNP	O	O
Chemotherapy	XTANDI.xml:S1:1917:12	chemotherapi	NNP	O	O
Study	XTANDI.xml:S1:1931:5	studi	NNP	O	O
1	XTANDI.xml:S1:1937:1	1	CD	O	O
enrolled	XTANDI.xml:S1:1939:8	enrol	VBD	O	O
1199	XTANDI.xml:S1:1948:4	1199	CD	O	O
patients	XTANDI.xml:S1:1953:8	patient	NNS	O	O
with	XTANDI.xml:S1:1962:4	with	IN	O	O
metastatic	XTANDI.xml:S1:1967:10	metastat	JJ	O	O
CRPC	XTANDI.xml:S1:1978:4	crpc	NNP	O	O
who	XTANDI.xml:S1:1983:3	who	WP	O	O
had	XTANDI.xml:S1:1987:3	had	VBD	O	O
previously	XTANDI.xml:S1:1991:10	previous	RB	O	O
received	XTANDI.xml:S1:2002:8	receiv	VBN	O	O
docetaxel	XTANDI.xml:S1:2011:9	docetaxel	NN	O	O
.	XTANDI.xml:S1:2020:1	.	.	O	O

The	XTANDI.xml:S1:2022:3	the	DT	O	O
median	XTANDI.xml:S1:2026:6	median	JJ	O	O
duration	XTANDI.xml:S1:2033:8	durat	NN	O	O
of	XTANDI.xml:S1:2042:2	of	IN	O	O
treatment	XTANDI.xml:S1:2045:9	treatment	NN	O	O
was	XTANDI.xml:S1:2055:3	wa	VBD	O	O
8.3	XTANDI.xml:S1:2059:3	8.3	CD	O	O
months	XTANDI.xml:S1:2063:6	month	NNS	O	O
with	XTANDI.xml:S1:2070:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:2075:6	xtandi	NNP	O	O
and	XTANDI.xml:S1:2082:3	and	CC	O	O
3.0	XTANDI.xml:S1:2086:3	3.0	CD	O	O
months	XTANDI.xml:S1:2090:6	month	NNS	O	O
with	XTANDI.xml:S1:2097:4	with	IN	O	O
placebo	XTANDI.xml:S1:2102:7	placebo	NN	O	O
.	XTANDI.xml:S1:2109:1	.	.	O	O

During	XTANDI.xml:S1:2111:6	dure	IN	O	O
the	XTANDI.xml:S1:2118:3	the	DT	O	O
trial	XTANDI.xml:S1:2122:5	trial	NN	O	O
,	XTANDI.xml:S1:2127:1	,	,	O	O
48%	XTANDI.xml:S1:2129:3	48%	CD	O	O
of	XTANDI.xml:S1:2133:2	of	IN	O	O
patients	XTANDI.xml:S1:2136:8	patient	NNS	O	O
on	XTANDI.xml:S1:2145:2	on	IN	O	O
the	XTANDI.xml:S1:2148:3	the	DT	O	O
XTANDI	XTANDI.xml:S1:2152:6	xtandi	NNP	O	O
arm	XTANDI.xml:S1:2159:3	arm	NN	O	O
and	XTANDI.xml:S1:2163:3	and	CC	O	O
46%	XTANDI.xml:S1:2167:3	46%	CD	O	O
of	XTANDI.xml:S1:2171:2	of	IN	O	O
patients	XTANDI.xml:S1:2174:8	patient	NNS	O	O
on	XTANDI.xml:S1:2183:2	on	IN	O	O
the	XTANDI.xml:S1:2186:3	the	DT	O	O
placebo	XTANDI.xml:S1:2190:7	placebo	NN	O	O
arm	XTANDI.xml:S1:2198:3	arm	NN	O	O
received	XTANDI.xml:S1:2202:8	receiv	VBD	O	O
glucocorticoids	XTANDI.xml:S1:2211:15	glucocorticoid	NNS	O	O
.	XTANDI.xml:S1:2226:1	.	.	O	O

Grade	XTANDI.xml:S1:2232:5	grade	VB	O	O
3	XTANDI.xml:S1:2238:1	3	CD	O	O
and	XTANDI.xml:S1:2240:3	and	CC	O	O
higher	XTANDI.xml:S1:2244:6	higher	JJR	O	O
adverse	XTANDI.xml:S1:2251:7	advers	JJ	O	O
reactions	XTANDI.xml:S1:2259:9	reaction	NNS	O	O
were	XTANDI.xml:S1:2269:4	were	VBD	O	O
reported	XTANDI.xml:S1:2274:8	report	VBN	O	O
among	XTANDI.xml:S1:2283:5	among	IN	O	O
47%	XTANDI.xml:S1:2289:3	47%	CD	O	O
of	XTANDI.xml:S1:2293:2	of	IN	O	O
XTANDI	XTANDI.xml:S1:2296:6	xtandi	NNP	O	O
-	XTANDI.xml:S1:2302:1	-	:	O	O
treated	XTANDI.xml:S1:2303:7	treat	VBD	O	O
patients	XTANDI.xml:S1:2311:8	patient	NNS	O	O
and	XTANDI.xml:S1:2320:3	and	CC	O	O
53%	XTANDI.xml:S1:2324:3	53%	CD	O	O
of	XTANDI.xml:S1:2328:2	of	IN	O	O
placebo	XTANDI.xml:S1:2331:7	placebo	NN	O	O
-	XTANDI.xml:S1:2338:1	-	:	O	O
treated	XTANDI.xml:S1:2339:7	treat	JJ	O	O
patients	XTANDI.xml:S1:2347:8	patient	NNS	O	O
.	XTANDI.xml:S1:2355:1	.	.	O	O

Discontinuations	XTANDI.xml:S1:2357:16	discontinu	NNS	O	O
due	XTANDI.xml:S1:2374:3	due	JJ	O	O
to	XTANDI.xml:S1:2378:2	to	TO	O	O
adverse	XTANDI.xml:S1:2381:7	advers	JJ	O	O
events	XTANDI.xml:S1:2389:6	event	NNS	O	O
were	XTANDI.xml:S1:2396:4	were	VBD	O	O
reported	XTANDI.xml:S1:2401:8	report	VBN	O	O
for	XTANDI.xml:S1:2410:3	for	IN	O	O
16%	XTANDI.xml:S1:2414:3	16%	CD	O	O
of	XTANDI.xml:S1:2418:2	of	IN	O	O
XTANDI	XTANDI.xml:S1:2421:6	xtandi	NNP	O	O
-	XTANDI.xml:S1:2427:1	-	:	O	O
treated	XTANDI.xml:S1:2428:7	treat	VBD	O	O
patients	XTANDI.xml:S1:2436:8	patient	NNS	O	O
and	XTANDI.xml:S1:2445:3	and	CC	O	O
18%	XTANDI.xml:S1:2449:3	18%	CD	O	O
of	XTANDI.xml:S1:2453:2	of	IN	O	O
placebo	XTANDI.xml:S1:2456:7	placebo	NN	O	O
-	XTANDI.xml:S1:2463:1	-	:	O	O
treated	XTANDI.xml:S1:2464:7	treat	JJ	O	O
patients	XTANDI.xml:S1:2472:8	patient	NNS	O	O
.	XTANDI.xml:S1:2480:1	.	.	O	O

The	XTANDI.xml:S1:2482:3	the	DT	O	O
most	XTANDI.xml:S1:2486:4	most	RBS	O	O
common	XTANDI.xml:S1:2491:6	common	JJ	O	O
adverse	XTANDI.xml:S1:2498:7	advers	JJ	O	O
reaction	XTANDI.xml:S1:2506:8	reaction	NN	O	O
leading	XTANDI.xml:S1:2515:7	lead	VBG	O	O
to	XTANDI.xml:S1:2523:2	to	TO	O	O
treatment	XTANDI.xml:S1:2526:9	treatment	NN	O	O
discontinuation	XTANDI.xml:S1:2536:15	discontinu	NN	O	O
was	XTANDI.xml:S1:2552:3	wa	VBD	O	O
seizure	XTANDI.xml:S1:2556:7	seizur	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:2563:1	,	,	O	O
which	XTANDI.xml:S1:2565:5	which	WDT	O	O
occurred	XTANDI.xml:S1:2571:8	occur	VBD	O	O
in	XTANDI.xml:S1:2580:2	in	IN	O	O
0.9%	XTANDI.xml:S1:2583:4	0.9%	CD	O	O
of	XTANDI.xml:S1:2588:2	of	IN	O	O
the	XTANDI.xml:S1:2591:3	the	DT	O	O
XTANDI	XTANDI.xml:S1:2595:6	xtandi	NNP	O	O
-	XTANDI.xml:S1:2601:1	-	:	O	O
treated	XTANDI.xml:S1:2602:7	treat	VBD	O	O
patients	XTANDI.xml:S1:2610:8	patient	NNS	O	O
compared	XTANDI.xml:S1:2619:8	compar	VBN	O	O
to	XTANDI.xml:S1:2628:2	to	TO	O	O
none	XTANDI.xml:S1:2631:4	none	NN	O	O
(	XTANDI.xml:S1:2636:1	(	(	O	O
0%	XTANDI.xml:S1:2637:2	0%	CD	O	O
)	XTANDI.xml:S1:2639:1	)	)	O	O
of	XTANDI.xml:S1:2641:2	of	IN	O	O
the	XTANDI.xml:S1:2644:3	the	DT	O	O
placebo	XTANDI.xml:S1:2648:7	placebo	NN	O	O
-	XTANDI.xml:S1:2655:1	-	:	O	O
treated	XTANDI.xml:S1:2656:7	treat	JJ	O	O
patients	XTANDI.xml:S1:2664:8	patient	NNS	O	O
.	XTANDI.xml:S1:2672:1	.	.	O	O

Table	XTANDI.xml:S1:2675:5	tabl	JJ	O	O
1	XTANDI.xml:S1:2681:1	1	CD	O	O
shows	XTANDI.xml:S1:2684:5	show	NNS	O	O
adverse	XTANDI.xml:S1:2690:7	advers	JJ	O	O
reactions	XTANDI.xml:S1:2698:9	reaction	NNS	O	O
reported	XTANDI.xml:S1:2708:8	report	VBN	O	O
in	XTANDI.xml:S1:2717:2	in	IN	O	O
Study	XTANDI.xml:S1:2720:5	studi	NNP	O	O
1	XTANDI.xml:S1:2726:1	1	CD	O	O
that	XTANDI.xml:S1:2728:4	that	WDT	O	O
occurred	XTANDI.xml:S1:2733:8	occur	VBD	O	O
at	XTANDI.xml:S1:2742:2	at	IN	O	O
a	XTANDI.xml:S1:2745:1	a	DT	O	O
2%	XTANDI.xml:S1:2750:2	2%	CD	O	O
higher	XTANDI.xml:S1:2753:6	higher	JJR	O	O
frequency	XTANDI.xml:S1:2760:9	frequenc	NN	O	O
in	XTANDI.xml:S1:2770:2	in	IN	O	O
the	XTANDI.xml:S1:2773:3	the	DT	O	O
XTANDI	XTANDI.xml:S1:2777:6	xtandi	NNP	O	O
arm	XTANDI.xml:S1:2784:3	arm	NN	O	O
compared	XTANDI.xml:S1:2788:8	compar	VBN	O	O
to	XTANDI.xml:S1:2797:2	to	TO	O	O
the	XTANDI.xml:S1:2800:3	the	DT	O	O
placebo	XTANDI.xml:S1:2804:7	placebo	NN	O	O
arm	XTANDI.xml:S1:2812:3	arm	NN	O	O
.	XTANDI.xml:S1:2815:1	.	.	O	O

Table	XTANDI.xml:S1:2821:5	tabl	JJ	O	O
1	XTANDI.xml:S1:2827:1	1	CD	O	O
.	XTANDI.xml:S1:2828:1	.	.	O	O

Adverse	XTANDI.xml:S1:2830:7	advers	JJ	O	O
Reactions	XTANDI.xml:S1:2838:9	reaction	NNP	O	O
in	XTANDI.xml:S1:2848:2	in	IN	O	O
Study	XTANDI.xml:S1:2851:5	studi	NNP	O	O
1	XTANDI.xml:S1:2857:1	1	CD	O	O

XTANDI	XTANDI.xml:S1:2894:6	xtandi	NNP	O	O
N	XTANDI.xml:S1:2902:1	N	NNP	O	O
800	XTANDI.xml:S1:2906:3	800	CD	O	O
Placebo	XTANDI.xml:S1:2913:7	placebo	NNP	O	O
N	XTANDI.xml:S1:2922:1	N	NNP	O	O
399	XTANDI.xml:S1:2926:3	399	CD	O	O

Grade	XTANDI.xml:S1:2936:5	grade	$	O	O
1	XTANDI.xml:S1:2942:1	1	CD	O	O
-	XTANDI.xml:S1:2943:1	-	:	O	O
4	XTANDI.xml:S1:2944:1	4	CD	O	O
a	XTANDI.xml:S1:2945:1	a	DT	O	O
(	XTANDI.xml:S1:2948:1	(	(	O	O
)	XTANDI.xml:S1:2950:1	)	)	O	O
Grade	XTANDI.xml:S1:2968:5	grade	VBD	O	O
3	XTANDI.xml:S1:2974:1	3	CD	O	O
-	XTANDI.xml:S1:2975:1	-	:	O	O
4	XTANDI.xml:S1:2976:1	4	CD	O	O
(	XTANDI.xml:S1:2979:1	(	(	O	O
)	XTANDI.xml:S1:2981:1	)	)	O	O
Grade	XTANDI.xml:S1:2987:5	grade	VBD	O	O
1	XTANDI.xml:S1:2993:1	1	CD	O	O
-	XTANDI.xml:S1:2994:1	-	:	O	O
4	XTANDI.xml:S1:2995:1	4	CD	O	O
(	XTANDI.xml:S1:2998:1	(	(	O	O
)	XTANDI.xml:S1:3000:1	)	)	O	O
Grade	XTANDI.xml:S1:3006:5	grade	VBD	O	O
3	XTANDI.xml:S1:3012:1	3	CD	O	O
-	XTANDI.xml:S1:3013:1	-	:	O	O
4	XTANDI.xml:S1:3014:1	4	CD	O	O
(	XTANDI.xml:S1:3017:1	(	(	O	O
)	XTANDI.xml:S1:3019:1	)	)	O	O

General	XTANDI.xml:S1:3028:7	gener	NNP	O	O
Disorders	XTANDI.xml:S1:3036:9	disord	NNP	O	O

Asthenic	XTANDI.xml:S1:3067:8	asthen	NNP	B-AdverseReaction	B-AdverseReaction
Conditionsb	XTANDI.xml:S1:3076:11	conditionsb	NNP	I-AdverseReaction	I-AdverseReaction
50.6	XTANDI.xml:S1:3095:4	50.6	CD	O	O
9.0	XTANDI.xml:S1:3114:3	9.0	CD	O	O
44.4	XTANDI.xml:S1:3133:4	44.4	CD	O	O
9.3	XTANDI.xml:S1:3152:3	9.3	CD	O	O

Peripheral	XTANDI.xml:S1:3178:10	peripher	NNP	B-AdverseReaction	B-AdverseReaction
Edema	XTANDI.xml:S1:3189:5	edema	NNP	I-AdverseReaction	I-AdverseReaction
15.4	XTANDI.xml:S1:3206:4	15.4	CD	O	O
1.0	XTANDI.xml:S1:3225:3	1.0	CD	O	O
13.3	XTANDI.xml:S1:3244:4	13.3	CD	O	O
0.8	XTANDI.xml:S1:3263:3	0.8	CD	O	O

Musculoskeletal	XTANDI.xml:S1:3285:15	musculoskelet	NNP	O	O
And	XTANDI.xml:S1:3301:3	and	CC	O	O
Connective	XTANDI.xml:S1:3305:10	connect	NNP	O	O
Tissue	XTANDI.xml:S1:3316:6	tissu	NNP	O	O
Disorders	XTANDI.xml:S1:3323:9	disord	NNP	O	O

Back	XTANDI.xml:S1:3343:4	back	RB	B-AdverseReaction	B-AdverseReaction
Pain	XTANDI.xml:S1:3348:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
26.4	XTANDI.xml:S1:3371:4	26.4	CD	O	O
5.3	XTANDI.xml:S1:3390:3	5.3	CD	O	O
24.3	XTANDI.xml:S1:3409:4	24.3	CD	O	O
4.0	XTANDI.xml:S1:3428:3	4.0	CD	O	O

Arthralgia	XTANDI.xml:S1:3454:10	arthralgia	NNP	B-AdverseReaction	B-AdverseReaction
20.5	XTANDI.xml:S1:3482:4	20.5	CD	O	O
2.5	XTANDI.xml:S1:3501:3	2.5	CD	O	O
17.3	XTANDI.xml:S1:3520:4	17.3	CD	O	O
1.8	XTANDI.xml:S1:3539:3	1.8	CD	O	O

Musculoskeletal	XTANDI.xml:S1:3565:15	musculoskelet	NNP	B-AdverseReaction	B-AdverseReaction
Pain	XTANDI.xml:S1:3581:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
15.0	XTANDI.xml:S1:3593:4	15.0	CD	O	O
1.3	XTANDI.xml:S1:3612:3	1.3	CD	O	O
11.5	XTANDI.xml:S1:3631:4	11.5	CD	O	O
0.3	XTANDI.xml:S1:3650:3	0.3	CD	O	O

Muscular	XTANDI.xml:S1:3676:8	muscular	JJ	B-AdverseReaction	B-AdverseReaction
Weakness	XTANDI.xml:S1:3685:8	weak	NNP	I-AdverseReaction	I-AdverseReaction
9.8	XTANDI.xml:S1:3704:3	9.8	CD	O	O
1.5	XTANDI.xml:S1:3723:3	1.5	CD	O	O
6.8	XTANDI.xml:S1:3742:3	6.8	CD	O	O
1.8	XTANDI.xml:S1:3761:3	1.8	CD	O	O

Musculoskeletal	XTANDI.xml:S1:3787:15	musculoskelet	NNP	B-AdverseReaction	B-AdverseReaction
Stiffness	XTANDI.xml:S1:3803:9	stiff	NNP	I-AdverseReaction	I-AdverseReaction
2.6	XTANDI.xml:S1:3816:3	2.6	CD	O	O
0.3	XTANDI.xml:S1:3835:3	0.3	CD	O	O
0.3	XTANDI.xml:S1:3854:3	0.3	CD	O	O
0.0	XTANDI.xml:S1:3873:3	0.0	CD	O	O

Gastrointestinal	XTANDI.xml:S1:3895:16	gastrointestin	JJ	O	O
Disorders	XTANDI.xml:S1:3912:9	disord	NNS	O	O

Diarrhea	XTANDI.xml:S1:3934:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
21.8	XTANDI.xml:S1:3962:4	21.8	CD	O	O
1.1	XTANDI.xml:S1:3981:3	1.1	CD	O	O
17.5	XTANDI.xml:S1:4000:4	17.5	CD	O	O
0.3	XTANDI.xml:S1:4019:3	0.3	CD	O	O

Vascular	XTANDI.xml:S1:4041:8	vascular	JJ	O	O
Disorders	XTANDI.xml:S1:4050:9	disord	NNS	O	O

Hot	XTANDI.xml:S1:4080:3	hot	NNP	B-AdverseReaction	B-AdverseReaction
Flush	XTANDI.xml:S1:4084:5	flush	NNP	I-AdverseReaction	I-AdverseReaction
20.3	XTANDI.xml:S1:4108:4	20.3	CD	O	O
0.0	XTANDI.xml:S1:4127:3	0.0	CD	O	O
10.3	XTANDI.xml:S1:4146:4	10.3	CD	O	O
0.0	XTANDI.xml:S1:4165:3	0.0	CD	O	O

Hypertension	XTANDI.xml:S1:4191:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
6.4	XTANDI.xml:S1:4219:3	6.4	CD	O	O
2.1	XTANDI.xml:S1:4238:3	2.1	CD	O	O
2.8	XTANDI.xml:S1:4257:3	2.8	CD	O	O
1.3	XTANDI.xml:S1:4276:3	1.3	CD	O	O

Nervous	XTANDI.xml:S1:4298:7	nervou	JJ	O	O
System	XTANDI.xml:S1:4306:6	system	NNP	O	O
Disorders	XTANDI.xml:S1:4313:9	disord	NNP	O	O

Headache	XTANDI.xml:S1:4337:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
12.1	XTANDI.xml:S1:4365:4	12.1	CD	O	O
0.9	XTANDI.xml:S1:4384:3	0.9	CD	O	O
5.5	XTANDI.xml:S1:4403:3	5.5	CD	O	O
0.0	XTANDI.xml:S1:4422:3	0.0	CD	O	O

Dizzinessc	XTANDI.xml:S1:4448:10	dizzinessc	NNP	B-AdverseReaction	B-AdverseReaction
9.5	XTANDI.xml:S1:4476:3	9.5	CD	O	O
0.5	XTANDI.xml:S1:4495:3	0.5	CD	O	O
7.5	XTANDI.xml:S1:4514:3	7.5	CD	O	O
0.5	XTANDI.xml:S1:4533:3	0.5	CD	O	O

Spinal	XTANDI.xml:S1:4559:6	spinal	NNP	B-AdverseReaction	O
Cord	XTANDI.xml:S1:4566:4	cord	NNP	I-AdverseReaction	O
Compression	XTANDI.xml:S1:4571:11	compress	NNP	I-AdverseReaction	O
and	XTANDI.xml:S1:4587:3	and	CC	O	O
Cauda	XTANDI.xml:S1:4591:5	cauda	NNP	B-AdverseReaction	B-AdverseReaction
Equina	XTANDI.xml:S1:4597:6	equina	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	XTANDI.xml:S1:4604:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
7.4	XTANDI.xml:S1:4616:3	7.4	CD	O	O
6.6	XTANDI.xml:S1:4635:3	6.6	CD	O	O
4.5	XTANDI.xml:S1:4654:3	4.5	CD	O	O
3.8	XTANDI.xml:S1:4673:3	3.8	CD	O	O

Paresthesia	XTANDI.xml:S1:4699:11	paresthesia	NNP	B-AdverseReaction	B-AdverseReaction
6.6	XTANDI.xml:S1:4727:3	6.6	CD	O	O
0.0	XTANDI.xml:S1:4746:3	0.0	CD	O	O
4.5	XTANDI.xml:S1:4765:3	4.5	CD	O	O
0.0	XTANDI.xml:S1:4784:3	0.0	CD	O	O

Mental	XTANDI.xml:S1:4810:6	mental	JJ	B-AdverseReaction	B-AdverseReaction
Impairment	XTANDI.xml:S1:4817:10	impair	NNP	I-AdverseReaction	I-AdverseReaction
Disordersd	XTANDI.xml:S1:4828:10	disordersd	NNP	I-AdverseReaction	I-AdverseReaction
4.3	XTANDI.xml:S1:4842:3	4.3	CD	O	O
0.3	XTANDI.xml:S1:4861:3	0.3	CD	O	O
1.8	XTANDI.xml:S1:4880:3	1.8	CD	O	O
0.0	XTANDI.xml:S1:4899:3	0.0	CD	O	O

Hypoesthesia	XTANDI.xml:S1:4925:12	hypoesthesia	$	B-AdverseReaction	B-AdverseReaction
4.0	XTANDI.xml:S1:4953:3	4.0	CD	O	O
0.3	XTANDI.xml:S1:4972:3	0.3	CD	O	O
1.8	XTANDI.xml:S1:4991:3	1.8	CD	O	O
0.0	XTANDI.xml:S1:5010:3	0.0	CD	O	O

Infections	XTANDI.xml:S1:5032:10	infect	NNS	O	O
And	XTANDI.xml:S1:5043:3	and	CC	O	O
Infestations	XTANDI.xml:S1:5047:12	infest	NNS	O	O

Upper	XTANDI.xml:S1:5071:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
Respiratory	XTANDI.xml:S1:5077:11	respiratori	NNP	I-AdverseReaction	I-AdverseReaction
Tract	XTANDI.xml:S1:5089:5	tract	NNP	I-AdverseReaction	I-AdverseReaction
Infectione	XTANDI.xml:S1:5099:10	infection	NNP	I-AdverseReaction	I-AdverseReaction
10.9	XTANDI.xml:S1:5113:4	10.9	CD	O	O
0.0	XTANDI.xml:S1:5132:3	0.0	CD	O	O
6.5	XTANDI.xml:S1:5151:3	6.5	CD	O	O
0.3	XTANDI.xml:S1:5170:3	0.3	CD	O	O

Lower	XTANDI.xml:S1:5196:5	lower	JJR	B-AdverseReaction	O
Respiratory	XTANDI.xml:S1:5202:11	respiratori	NNP	I-AdverseReaction	O
Tract	XTANDI.xml:S1:5214:5	tract	NNP	I-AdverseReaction	O
And	XTANDI.xml:S1:5220:3	and	CC	O	O
Lung	XTANDI.xml:S1:5228:4	lung	NNP	B-AdverseReaction	O
Infectionf	XTANDI.xml:S1:5233:10	infectionf	NNP	I-AdverseReaction	O
8.5	XTANDI.xml:S1:5247:3	8.5	CD	O	O
2.4	XTANDI.xml:S1:5266:3	2.4	CD	O	O
4.8	XTANDI.xml:S1:5285:3	4.8	CD	O	O
1.3	XTANDI.xml:S1:5304:3	1.3	CD	O	O

Psychiatric	XTANDI.xml:S1:5326:11	psychiatr	JJ	O	O
Disorders	XTANDI.xml:S1:5338:9	disord	NNS	O	O

Insomnia	XTANDI.xml:S1:5365:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
8.8	XTANDI.xml:S1:5393:3	8.8	CD	O	O
0.0	XTANDI.xml:S1:5412:3	0.0	CD	O	O
6.0	XTANDI.xml:S1:5431:3	6.0	CD	O	O
0.5	XTANDI.xml:S1:5450:3	0.5	CD	O	O

Anxiety	XTANDI.xml:S1:5476:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
6.5	XTANDI.xml:S1:5504:3	6.5	CD	O	O
0.3	XTANDI.xml:S1:5523:3	0.3	CD	O	O
4.0	XTANDI.xml:S1:5542:3	4.0	CD	O	O
0.0	XTANDI.xml:S1:5561:3	0.0	CD	O	O

Renal	XTANDI.xml:S1:5583:5	renal	NNP	O	O
And	XTANDI.xml:S1:5589:3	and	CC	O	O
Urinary	XTANDI.xml:S1:5593:7	urinari	NNP	O	O
Disorders	XTANDI.xml:S1:5601:9	disord	NNS	O	O

Hematuria	XTANDI.xml:S1:5622:9	hematuria	NNP	B-AdverseReaction	B-AdverseReaction
6.9	XTANDI.xml:S1:5650:3	6.9	CD	O	O
1.8	XTANDI.xml:S1:5669:3	1.8	CD	O	O
4.5	XTANDI.xml:S1:5688:3	4.5	CD	O	O
1.0	XTANDI.xml:S1:5707:3	1.0	CD	O	O

Pollakiuria	XTANDI.xml:S1:5733:11	pollakiuria	NNP	B-AdverseReaction	B-AdverseReaction
4.8	XTANDI.xml:S1:5761:3	4.8	CD	O	O
0.0	XTANDI.xml:S1:5780:3	0.0	CD	O	O
2.5	XTANDI.xml:S1:5799:3	2.5	CD	O	O
0.0	XTANDI.xml:S1:5818:3	0.0	CD	O	O

Injury	XTANDI.xml:S1:5840:6	injuri	NNP	O	O
,	XTANDI.xml:S1:5846:1	,	,	O	O
Poisoning	XTANDI.xml:S1:5848:9	poison	NNP	O	O
And	XTANDI.xml:S1:5858:3	and	CC	O	O
Procedural	XTANDI.xml:S1:5862:10	procedur	NNP	O	O
Complications	XTANDI.xml:S1:5873:13	complic	NNP	O	O

Fall	XTANDI.xml:S1:5897:4	fall	NN	B-AdverseReaction	B-AdverseReaction
4.6	XTANDI.xml:S1:5925:3	4.6	CD	O	O
0.3	XTANDI.xml:S1:5944:3	0.3	CD	O	O
1.3	XTANDI.xml:S1:5963:3	1.3	CD	O	O
0.0	XTANDI.xml:S1:5982:3	0.0	CD	O	O

Non	XTANDI.xml:S1:6008:3	non	NNP	B-AdverseReaction	B-AdverseReaction
-	XTANDI.xml:S1:6011:1	-	:	I-AdverseReaction	I-AdverseReaction
pathologic	XTANDI.xml:S1:6012:10	patholog	NN	I-AdverseReaction	I-AdverseReaction
Fractures	XTANDI.xml:S1:6023:9	fractur	VBZ	I-AdverseReaction	I-AdverseReaction
4.0	XTANDI.xml:S1:6036:3	4.0	CD	O	O
1.4	XTANDI.xml:S1:6055:3	1.4	CD	O	O
0.8	XTANDI.xml:S1:6074:3	0.8	CD	O	O
0.3	XTANDI.xml:S1:6093:3	0.3	CD	O	O

Skin	XTANDI.xml:S1:6115:4	skin	NNP	O	O
And	XTANDI.xml:S1:6120:3	and	CC	O	O
Subcutaneous	XTANDI.xml:S1:6124:12	subcutan	NNP	O	O
Tissue	XTANDI.xml:S1:6137:6	tissu	NNP	O	O
Disorders	XTANDI.xml:S1:6144:9	disord	NNP	O	O

Pruritus	XTANDI.xml:S1:6164:8	pruritu	NNP	B-AdverseReaction	B-AdverseReaction
3.8	XTANDI.xml:S1:6192:3	3.8	CD	O	O
0.0	XTANDI.xml:S1:6211:3	0.0	CD	O	O
1.3	XTANDI.xml:S1:6230:3	1.3	CD	O	O
0.0	XTANDI.xml:S1:6249:3	0.0	CD	O	O

Dry	XTANDI.xml:S1:6275:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
Skin	XTANDI.xml:S1:6279:4	skin	NNP	I-AdverseReaction	I-AdverseReaction
3.5	XTANDI.xml:S1:6303:3	3.5	CD	O	O
0.0	XTANDI.xml:S1:6322:3	0.0	CD	O	O
1.3	XTANDI.xml:S1:6341:3	1.3	CD	O	O
0.0	XTANDI.xml:S1:6360:3	0.0	CD	O	O

Respiratory	XTANDI.xml:S1:6382:11	respiratori	NN	O	O
Disorders	XTANDI.xml:S1:6394:9	disord	NNS	O	O

Epistaxis	XTANDI.xml:S1:6421:9	epistaxi	NNP	B-AdverseReaction	B-AdverseReaction
3.3	XTANDI.xml:S1:6449:3	3.3	CD	O	O
0.1	XTANDI.xml:S1:6468:3	0.1	CD	O	O
1.3	XTANDI.xml:S1:6487:3	1.3	CD	O	O
0.3	XTANDI.xml:S1:6506:3	0.3	CD	O	O

a	XTANDI.xml:S1:6528:1	a	DT	O	O
CTCAE	XTANDI.xml:S1:6533:5	ctcae	NNP	O	O
v4b	XTANDI.xml:S1:6539:3	v4b	NN	O	O
Includes	XTANDI.xml:S1:6546:8	includ	NNP	O	O
asthenia	XTANDI.xml:S1:6555:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
and	XTANDI.xml:S1:6564:3	and	CC	O	O
fatigue	XTANDI.xml:S1:6568:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
.	XTANDI.xml:S1:6575:1	.	.	O	O
c	XTANDI.xml:S1:6576:1	c	VB	O	O
Includes	XTANDI.xml:S1:6581:8	includ	NNP	O	O
dizziness	XTANDI.xml:S1:6590:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
and	XTANDI.xml:S1:6600:3	and	CC	O	O
vertigo	XTANDI.xml:S1:6604:7	vertigo	NN	B-AdverseReaction	B-AdverseReaction
.	XTANDI.xml:S1:6611:1	.	.	O	O
d	XTANDI.xml:S1:6612:1	d	NN	O	O
Includes	XTANDI.xml:S1:6617:8	includ	NNP	O	O
amnesia	XTANDI.xml:S1:6626:7	amnesia	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:6633:1	,	,	O	O
memory	XTANDI.xml:S1:6635:6	memori	NN	B-AdverseReaction	B-AdverseReaction
impairment	XTANDI.xml:S1:6642:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:6652:1	,	,	O	O
cognitive	XTANDI.xml:S1:6654:9	cognit	JJ	B-AdverseReaction	B-AdverseReaction
disorder	XTANDI.xml:S1:6664:8	disord	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:6672:1	,	,	O	O
and	XTANDI.xml:S1:6674:3	and	CC	O	O
disturbance	XTANDI.xml:S1:6678:11	disturb	NN	B-AdverseReaction	B-AdverseReaction
in	XTANDI.xml:S1:6690:2	in	IN	I-AdverseReaction	I-AdverseReaction
attention	XTANDI.xml:S1:6693:9	attent	NN	I-AdverseReaction	I-AdverseReaction
.	XTANDI.xml:S1:6702:1	.	.	O	O
e	XTANDI.xml:S1:6703:1	e	NN	O	O
Includes	XTANDI.xml:S1:6708:8	includ	NNP	O	O
nasopharyngitis	XTANDI.xml:S1:6717:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:6732:1	,	,	O	O
upper	XTANDI.xml:S1:6734:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XTANDI.xml:S1:6740:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	XTANDI.xml:S1:6752:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	XTANDI.xml:S1:6758:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:6767:1	,	,	O	O
sinusitis	XTANDI.xml:S1:6769:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:6778:1	,	,	O	O
rhinitis	XTANDI.xml:S1:6780:8	rhiniti	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:6788:1	,	,	O	O
pharyngitis	XTANDI.xml:S1:6790:11	pharyng	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:6801:1	,	,	O	O
and	XTANDI.xml:S1:6803:3	and	CC	O	O
laryngitis	XTANDI.xml:S1:6807:10	laryng	NN	B-AdverseReaction	B-AdverseReaction
.	XTANDI.xml:S1:6817:1	.	.	O	O
f	XTANDI.xml:S1:6818:1	f	NN	O	O
Includes	XTANDI.xml:S1:6823:8	includ	NNP	O	O
pneumonia	XTANDI.xml:S1:6832:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:6841:1	,	,	O	O
lower	XTANDI.xml:S1:6843:5	lower	JJR	B-AdverseReaction	B-AdverseReaction
respiratory	XTANDI.xml:S1:6849:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	XTANDI.xml:S1:6861:5	tract	JJ	I-AdverseReaction	I-AdverseReaction
infection	XTANDI.xml:S1:6867:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:6876:1	,	,	O	O
bronchitis	XTANDI.xml:S1:6878:10	bronchiti	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:6888:1	,	,	O	O
and	XTANDI.xml:S1:6890:3	and	CC	O	O
lung	XTANDI.xml:S1:6894:4	lung	NN	B-AdverseReaction	O
infection	XTANDI.xml:S1:6899:9	infect	NN	I-AdverseReaction	O
.	XTANDI.xml:S1:6908:1	.	.	O	O

Study	XTANDI.xml:S1:6927:5	studi	NN	O	O
2	XTANDI.xml:S1:6933:1	2	CD	O	O
:	XTANDI.xml:S1:6934:1	:	:	O	O
Chemotherapy	XTANDI.xml:S1:6936:12	chemotherapi	NNP	O	O
-	XTANDI.xml:S1:6948:1	-	:	O	O
naive	XTANDI.xml:S1:6949:5	naiv	JJ	O	O
Metastatic	XTANDI.xml:S1:6955:10	metastat	NNP	O	O
Castration	XTANDI.xml:S1:6966:10	castrat	NNP	O	O
-	XTANDI.xml:S1:6976:1	-	:	O	O
Resistant	XTANDI.xml:S1:6977:9	resist	JJ	O	O
Prostate	XTANDI.xml:S1:6987:8	prostat	NNP	O	O
Cancer	XTANDI.xml:S1:6996:6	cancer	NNP	O	O
Study	XTANDI.xml:S1:7004:5	studi	NNP	O	O
2	XTANDI.xml:S1:7010:1	2	CD	O	O
enrolled	XTANDI.xml:S1:7012:8	enrol	VBD	O	O
1717	XTANDI.xml:S1:7021:4	1717	CD	O	O
patients	XTANDI.xml:S1:7026:8	patient	NNS	O	O
with	XTANDI.xml:S1:7035:4	with	IN	O	O
metastatic	XTANDI.xml:S1:7040:10	metastat	JJ	O	O
CRPC	XTANDI.xml:S1:7051:4	crpc	NNP	O	O
who	XTANDI.xml:S1:7056:3	who	WP	O	O
had	XTANDI.xml:S1:7060:3	had	VBD	O	O
not	XTANDI.xml:S1:7064:3	not	RB	O	O
received	XTANDI.xml:S1:7068:8	receiv	VBN	O	O
prior	XTANDI.xml:S1:7077:5	prior	RB	O	O
cytotoxic	XTANDI.xml:S1:7083:9	cytotox	JJ	O	O
chemotherapy	XTANDI.xml:S1:7093:12	chemotherapi	NN	O	O
,	XTANDI.xml:S1:7105:1	,	,	O	O
of	XTANDI.xml:S1:7107:2	of	IN	O	O
whom	XTANDI.xml:S1:7110:4	whom	WP	O	O
1715	XTANDI.xml:S1:7115:4	1715	CD	O	O
received	XTANDI.xml:S1:7120:8	receiv	VBD	O	O
at	XTANDI.xml:S1:7129:2	at	IN	O	O
least	XTANDI.xml:S1:7132:5	least	JJS	O	O
one	XTANDI.xml:S1:7138:3	one	CD	O	O
dose	XTANDI.xml:S1:7142:4	dose	NN	O	O
of	XTANDI.xml:S1:7147:2	of	IN	O	O
study	XTANDI.xml:S1:7150:5	studi	JJ	O	O
drug	XTANDI.xml:S1:7156:4	drug	NN	O	O
.	XTANDI.xml:S1:7160:1	.	.	O	O

The	XTANDI.xml:S1:7162:3	the	DT	O	O
median	XTANDI.xml:S1:7166:6	median	JJ	O	O
duration	XTANDI.xml:S1:7173:8	durat	NN	O	O
of	XTANDI.xml:S1:7182:2	of	IN	O	O
treatment	XTANDI.xml:S1:7185:9	treatment	NN	O	O
was	XTANDI.xml:S1:7195:3	wa	VBD	O	O
17.5	XTANDI.xml:S1:7199:4	17.5	CD	O	O
months	XTANDI.xml:S1:7204:6	month	NNS	O	O
with	XTANDI.xml:S1:7211:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:7216:6	xtandi	NNP	O	O
and	XTANDI.xml:S1:7223:3	and	CC	O	O
4.6	XTANDI.xml:S1:7227:3	4.6	CD	O	O
months	XTANDI.xml:S1:7231:6	month	NNS	O	O
with	XTANDI.xml:S1:7238:4	with	IN	O	O
placebo	XTANDI.xml:S1:7243:7	placebo	NN	O	O
.	XTANDI.xml:S1:7250:1	.	.	O	O

Grade	XTANDI.xml:S1:7252:5	grade	$	O	O
3	XTANDI.xml:S1:7258:1	3	CD	O	O
-	XTANDI.xml:S1:7259:1	-	:	O	O
4	XTANDI.xml:S1:7260:1	4	CD	O	O
adverse	XTANDI.xml:S1:7262:7	advers	JJ	O	O
reactions	XTANDI.xml:S1:7270:9	reaction	NNS	O	O
were	XTANDI.xml:S1:7280:4	were	VBD	O	O
reported	XTANDI.xml:S1:7285:8	report	VBN	O	O
in	XTANDI.xml:S1:7294:2	in	IN	O	O
44%	XTANDI.xml:S1:7297:3	44%	CD	O	O
of	XTANDI.xml:S1:7301:2	of	IN	O	O
XTANDI	XTANDI.xml:S1:7304:6	xtandi	NNP	O	O
-	XTANDI.xml:S1:7310:1	-	:	O	O
treated	XTANDI.xml:S1:7311:7	treat	VBD	O	O
patients	XTANDI.xml:S1:7319:8	patient	NNS	O	O
and	XTANDI.xml:S1:7328:3	and	CC	O	O
37%	XTANDI.xml:S1:7332:3	37%	CD	O	O
of	XTANDI.xml:S1:7336:2	of	IN	O	O
placebo	XTANDI.xml:S1:7339:7	placebo	NN	O	O
-	XTANDI.xml:S1:7346:1	-	:	O	O
treated	XTANDI.xml:S1:7347:7	treat	JJ	O	O
patients	XTANDI.xml:S1:7355:8	patient	NNS	O	O
.	XTANDI.xml:S1:7363:1	.	.	O	O

Discontinuations	XTANDI.xml:S1:7365:16	discontinu	NNS	O	O
due	XTANDI.xml:S1:7382:3	due	JJ	O	O
to	XTANDI.xml:S1:7386:2	to	TO	O	O
adverse	XTANDI.xml:S1:7389:7	advers	JJ	O	O
events	XTANDI.xml:S1:7397:6	event	NNS	O	O
were	XTANDI.xml:S1:7404:4	were	VBD	O	O
reported	XTANDI.xml:S1:7409:8	report	VBN	O	O
for	XTANDI.xml:S1:7418:3	for	IN	O	O
6%	XTANDI.xml:S1:7422:2	6%	CD	O	O
of	XTANDI.xml:S1:7425:2	of	IN	O	O
XTANDI	XTANDI.xml:S1:7428:6	xtandi	NNP	O	O
-	XTANDI.xml:S1:7434:1	-	:	O	O
treated	XTANDI.xml:S1:7435:7	treat	VBD	O	O
patients	XTANDI.xml:S1:7443:8	patient	NNS	O	O
and	XTANDI.xml:S1:7452:3	and	CC	O	O
6%	XTANDI.xml:S1:7456:2	6%	CD	O	O
of	XTANDI.xml:S1:7459:2	of	IN	O	O
placebo	XTANDI.xml:S1:7462:7	placebo	NN	O	O
-	XTANDI.xml:S1:7469:1	-	:	O	O
treated	XTANDI.xml:S1:7470:7	treat	JJ	O	O
patients	XTANDI.xml:S1:7478:8	patient	NNS	O	O
.	XTANDI.xml:S1:7486:1	.	.	O	O

The	XTANDI.xml:S1:7488:3	the	DT	O	O
most	XTANDI.xml:S1:7492:4	most	RBS	O	O
common	XTANDI.xml:S1:7497:6	common	JJ	O	O
adverse	XTANDI.xml:S1:7504:7	advers	JJ	O	O
reaction	XTANDI.xml:S1:7512:8	reaction	NN	O	O
leading	XTANDI.xml:S1:7521:7	lead	VBG	O	O
to	XTANDI.xml:S1:7529:2	to	TO	O	O
treatment	XTANDI.xml:S1:7532:9	treatment	NN	O	O
discontinuation	XTANDI.xml:S1:7542:15	discontinu	NN	O	O
was	XTANDI.xml:S1:7558:3	wa	VBD	O	O
fatigue	XTANDI.xml:S1:7562:7	fatigu	JJ	B-AdverseReaction	B-AdverseReaction
asthenia	XTANDI.xml:S1:7570:8	asthenia	NN	B-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:7578:1	,	,	O	O
which	XTANDI.xml:S1:7580:5	which	WDT	O	O
occurred	XTANDI.xml:S1:7586:8	occur	VBD	O	O
in	XTANDI.xml:S1:7595:2	in	IN	O	O
1%	XTANDI.xml:S1:7598:2	1%	CD	O	O
of	XTANDI.xml:S1:7601:2	of	IN	O	O
patients	XTANDI.xml:S1:7604:8	patient	NNS	O	O
on	XTANDI.xml:S1:7613:2	on	IN	O	O
each	XTANDI.xml:S1:7616:4	each	DT	O	O
treatment	XTANDI.xml:S1:7621:9	treatment	NN	O	O
arm	XTANDI.xml:S1:7631:3	arm	NN	O	O
.	XTANDI.xml:S1:7634:1	.	.	O	O

Table	XTANDI.xml:S1:7637:5	tabl	JJ	O	O
2	XTANDI.xml:S1:7643:1	2	CD	O	O
includes	XTANDI.xml:S1:7646:8	includ	VBZ	O	O
adverse	XTANDI.xml:S1:7655:7	advers	JJ	O	O
reactions	XTANDI.xml:S1:7663:9	reaction	NNS	O	O
reported	XTANDI.xml:S1:7673:8	report	VBN	O	O
in	XTANDI.xml:S1:7682:2	in	IN	O	O
Study	XTANDI.xml:S1:7685:5	studi	NNP	O	O
2	XTANDI.xml:S1:7691:1	2	CD	O	O
that	XTANDI.xml:S1:7693:4	that	WDT	O	O
occurred	XTANDI.xml:S1:7698:8	occur	VBD	O	O
at	XTANDI.xml:S1:7707:2	at	IN	O	O
a	XTANDI.xml:S1:7710:1	a	DT	O	O
2%	XTANDI.xml:S1:7715:2	2%	CD	O	O
higher	XTANDI.xml:S1:7718:6	higher	JJR	O	O
frequency	XTANDI.xml:S1:7725:9	frequenc	NN	O	O
in	XTANDI.xml:S1:7735:2	in	IN	O	O
the	XTANDI.xml:S1:7738:3	the	DT	O	O
XTANDI	XTANDI.xml:S1:7742:6	xtandi	NNP	O	O
arm	XTANDI.xml:S1:7749:3	arm	NN	O	O
compared	XTANDI.xml:S1:7753:8	compar	VBN	O	O
to	XTANDI.xml:S1:7762:2	to	TO	O	O
the	XTANDI.xml:S1:7765:3	the	DT	O	O
placebo	XTANDI.xml:S1:7769:7	placebo	NN	O	O
arm	XTANDI.xml:S1:7777:3	arm	NN	O	O
.	XTANDI.xml:S1:7780:1	.	.	O	O

Table	XTANDI.xml:S1:7786:5	tabl	NN	O	O

2	XTANDI.xml:S1:7792:1	2	CD	O	O
.	XTANDI.xml:S1:7793:1	.	.	O	O

Adverse	XTANDI.xml:S1:7795:7	advers	JJ	O	O
Reactions	XTANDI.xml:S1:7803:9	reaction	NNP	O	O
in	XTANDI.xml:S1:7813:2	in	IN	O	O
Study	XTANDI.xml:S1:7816:5	studi	NNP	O	O
2	XTANDI.xml:S1:7822:1	2	CD	O	O

XTANDI	XTANDI.xml:S1:7861:6	xtandi	NNP	O	O
N	XTANDI.xml:S1:7871:1	N	NNP	O	O
871	XTANDI.xml:S1:7875:3	871	CD	O	O
Placebo	XTANDI.xml:S1:7884:7	placebo	NNP	O	O
N	XTANDI.xml:S1:7895:1	N	NNP	O	O
844	XTANDI.xml:S1:7899:3	844	CD	O	O

Grade	XTANDI.xml:S1:7911:5	grade	$	O	O
1	XTANDI.xml:S1:7917:1	1	CD	O	O
-	XTANDI.xml:S1:7918:1	-	:	O	O
4	XTANDI.xml:S1:7919:1	4	CD	O	O
a	XTANDI.xml:S1:7922:1	a	DT	O	O
(	XTANDI.xml:S1:7929:1	(	(	O	O
)	XTANDI.xml:S1:7931:1	)	)	O	O
Grade	XTANDI.xml:S1:7944:5	grade	VBD	O	O
3	XTANDI.xml:S1:7950:1	3	CD	O	O
-	XTANDI.xml:S1:7951:1	-	:	O	O
4	XTANDI.xml:S1:7952:1	4	CD	O	O
(	XTANDI.xml:S1:7957:1	(	(	O	O
)	XTANDI.xml:S1:7959:1	)	)	O	O
Grade	XTANDI.xml:S1:7966:5	grade	VBD	O	O
1	XTANDI.xml:S1:7972:1	1	CD	O	O
-	XTANDI.xml:S1:7973:1	-	:	O	O
4	XTANDI.xml:S1:7974:1	4	CD	O	O
(	XTANDI.xml:S1:7979:1	(	(	O	O
)	XTANDI.xml:S1:7981:1	)	)	O	O
Grade	XTANDI.xml:S1:7988:5	grade	VBD	O	O
3	XTANDI.xml:S1:7994:1	3	CD	O	O
-	XTANDI.xml:S1:7995:1	-	:	O	O
4	XTANDI.xml:S1:7996:1	4	CD	O	O
(	XTANDI.xml:S1:8001:1	(	(	O	O
)	XTANDI.xml:S1:8003:1	)	)	O	O

General	XTANDI.xml:S1:8015:7	gener	NNP	O	O

Disorders	XTANDI.xml:S1:8023:9	disord	NNS	O	O

Asthenic	XTANDI.xml:S1:8055:8	asthen	NNP	B-AdverseReaction	B-AdverseReaction
Conditionsb	XTANDI.xml:S1:8064:11	conditionsb	NNP	I-AdverseReaction	I-AdverseReaction
46.9	XTANDI.xml:S1:8084:4	46.9	CD	O	O
3.4	XTANDI.xml:S1:8103:3	3.4	CD	O	O
33.0	XTANDI.xml:S1:8122:4	33.0	CD	O	O
2.8	XTANDI.xml:S1:8141:3	2.8	CD	O	O

Peripheral	XTANDI.xml:S1:8167:10	peripher	NNP	B-AdverseReaction	B-AdverseReaction
Edema	XTANDI.xml:S1:8178:5	edema	NNP	I-AdverseReaction	I-AdverseReaction
11.5	XTANDI.xml:S1:8196:4	11.5	CD	O	O
0.2	XTANDI.xml:S1:8215:3	0.2	CD	O	O
8.2	XTANDI.xml:S1:8234:3	8.2	CD	O	O
0.4	XTANDI.xml:S1:8253:3	0.4	CD	O	O

Musculoskeletal	XTANDI.xml:S1:8275:15	musculoskelet	NNP	O	O
And	XTANDI.xml:S1:8291:3	and	CC	O	O
Connective	XTANDI.xml:S1:8295:10	connect	NNP	O	O
Tissue	XTANDI.xml:S1:8306:6	tissu	NNP	O	O
Disorders	XTANDI.xml:S1:8313:9	disord	NNP	O	O

Back	XTANDI.xml:S1:8333:4	back	RB	B-AdverseReaction	B-AdverseReaction
Pain	XTANDI.xml:S1:8338:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
28.6	XTANDI.xml:S1:8362:4	28.6	CD	O	O
2.5	XTANDI.xml:S1:8381:3	2.5	CD	O	O
22.4	XTANDI.xml:S1:8400:4	22.4	CD	O	O
3.0	XTANDI.xml:S1:8419:3	3.0	CD	O	O

Arthralgia	XTANDI.xml:S1:8445:10	arthralgia	NNP	B-AdverseReaction	B-AdverseReaction
21.4	XTANDI.xml:S1:8474:4	21.4	CD	O	O
1.6	XTANDI.xml:S1:8493:3	1.6	CD	O	O
16.1	XTANDI.xml:S1:8512:4	16.1	CD	O	O
1.1	XTANDI.xml:S1:8531:3	1.1	CD	O	O

Gastrointestinal	XTANDI.xml:S1:8553:16	gastrointestin	JJ	O	O
Disorders	XTANDI.xml:S1:8570:9	disord	NNS	O	O

Constipation	XTANDI.xml:S1:8593:12	constip	NN	B-AdverseReaction	B-AdverseReaction
23.2	XTANDI.xml:S1:8622:4	23.2	CD	O	O
0.7	XTANDI.xml:S1:8641:3	0.7	CD	O	O
17.3	XTANDI.xml:S1:8660:4	17.3	CD	O	O
0.4	XTANDI.xml:S1:8679:3	0.4	CD	O	O

Diarrhea	XTANDI.xml:S1:8705:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
16.8	XTANDI.xml:S1:8734:4	16.8	CD	O	O
0.3	XTANDI.xml:S1:8753:3	0.3	CD	O	O
14.3	XTANDI.xml:S1:8772:4	14.3	CD	O	O
0.4	XTANDI.xml:S1:8791:3	0.4	CD	O	O

Vascular	XTANDI.xml:S1:8813:8	vascular	JJ	O	O
Disorders	XTANDI.xml:S1:8822:9	disord	NNS	O	O

Hot	XTANDI.xml:S1:8853:3	hot	NNP	B-AdverseReaction	B-AdverseReaction
Flush	XTANDI.xml:S1:8857:5	flush	NNP	I-AdverseReaction	I-AdverseReaction
18.0	XTANDI.xml:S1:8882:4	18.0	CD	O	O
0.1	XTANDI.xml:S1:8901:3	0.1	CD	O	O
7.8	XTANDI.xml:S1:8920:3	7.8	CD	O	O
0.0	XTANDI.xml:S1:8939:3	0.0	CD	O	O

Hypertension	XTANDI.xml:S1:8965:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
14.2	XTANDI.xml:S1:8994:4	14.2	CD	O	O
7.2	XTANDI.xml:S1:9013:3	7.2	CD	O	O
4.1	XTANDI.xml:S1:9032:3	4.1	CD	O	O
2.3	XTANDI.xml:S1:9051:3	2.3	CD	O	O

Nervous	XTANDI.xml:S1:9073:7	nervou	JJ	O	O
System	XTANDI.xml:S1:9081:6	system	NNP	O	O
Disorders	XTANDI.xml:S1:9088:9	disord	NNP	O	O

Dizzinessc	XTANDI.xml:S1:9113:10	dizzinessc	NNP	B-AdverseReaction	B-AdverseReaction
11.3	XTANDI.xml:S1:9142:4	11.3	CD	O	O
0.3	XTANDI.xml:S1:9161:3	0.3	CD	O	O
7.1	XTANDI.xml:S1:9180:3	7.1	CD	O	O
0.0	XTANDI.xml:S1:9199:3	0.0	CD	O	O

Headache	XTANDI.xml:S1:9225:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
11.0	XTANDI.xml:S1:9254:4	11.0	CD	O	O
0.2	XTANDI.xml:S1:9273:3	0.2	CD	O	O
7.0	XTANDI.xml:S1:9292:3	7.0	CD	O	O
0.4	XTANDI.xml:S1:9311:3	0.4	CD	O	O

Dysgeusia	XTANDI.xml:S1:9337:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
7.6	XTANDI.xml:S1:9366:3	7.6	CD	O	O
0.1	XTANDI.xml:S1:9385:3	0.1	CD	O	O
3.7	XTANDI.xml:S1:9404:3	3.7	CD	O	O
0.0	XTANDI.xml:S1:9423:3	0.0	CD	O	O

Mental	XTANDI.xml:S1:9449:6	mental	JJ	B-AdverseReaction	B-AdverseReaction
Impairment	XTANDI.xml:S1:9456:10	impair	NNP	I-AdverseReaction	I-AdverseReaction
Disordersd	XTANDI.xml:S1:9467:10	disordersd	NNP	I-AdverseReaction	I-AdverseReaction
5.7	XTANDI.xml:S1:9481:3	5.7	CD	O	O
0.0	XTANDI.xml:S1:9500:3	0.0	CD	O	O
1.3	XTANDI.xml:S1:9519:3	1.3	CD	O	O
0.1	XTANDI.xml:S1:9538:3	0.1	CD	O	O

Restless	XTANDI.xml:S1:9564:8	restless	NNP	B-AdverseReaction	B-AdverseReaction
Legs	XTANDI.xml:S1:9573:4	leg	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	XTANDI.xml:S1:9578:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
2.1	XTANDI.xml:S1:9593:3	2.1	CD	O	O
0.1	XTANDI.xml:S1:9612:3	0.1	CD	O	O
0.4	XTANDI.xml:S1:9631:3	0.4	CD	O	O
0.0	XTANDI.xml:S1:9650:3	0.0	CD	O	O

Respiratory	XTANDI.xml:S1:9672:11	respiratori	NN	O	O
Disorders	XTANDI.xml:S1:9684:9	disord	NNS	O	O

Dyspneae	XTANDI.xml:S1:9712:8	dyspnea	NNP	B-AdverseReaction	B-AdverseReaction
11.0	XTANDI.xml:S1:9741:4	11.0	CD	O	O
0.6	XTANDI.xml:S1:9760:3	0.6	CD	O	O
8.5	XTANDI.xml:S1:9779:3	8.5	CD	O	O
0.6	XTANDI.xml:S1:9798:3	0.6	CD	O	O

Infections	XTANDI.xml:S1:9820:10	infect	NNS	O	O
And	XTANDI.xml:S1:9831:3	and	CC	O	O
Infestations	XTANDI.xml:S1:9835:12	infest	NNS	O	O

Upper	XTANDI.xml:S1:9860:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
Respiratory	XTANDI.xml:S1:9866:11	respiratori	NNP	I-AdverseReaction	I-AdverseReaction
Tract	XTANDI.xml:S1:9878:5	tract	NNP	I-AdverseReaction	I-AdverseReaction
Infectionf	XTANDI.xml:S1:9888:10	infectionf	NNP	I-AdverseReaction	I-AdverseReaction
16.4	XTANDI.xml:S1:9902:4	16.4	CD	O	O
0.0	XTANDI.xml:S1:9921:3	0.0	CD	O	O
10.5	XTANDI.xml:S1:9940:4	10.5	CD	O	O
0.0	XTANDI.xml:S1:9959:3	0.0	CD	O	O

Lower	XTANDI.xml:S1:9985:5	lower	JJR	B-AdverseReaction	O
Respiratory	XTANDI.xml:S1:9991:11	respiratori	NNP	I-AdverseReaction	O
Tract	XTANDI.xml:S1:10003:5	tract	NNP	I-AdverseReaction	O
And	XTANDI.xml:S1:10009:3	and	CC	O	O
Lung	XTANDI.xml:S1:10017:4	lung	NNP	B-AdverseReaction	O
Infectiong	XTANDI.xml:S1:10022:10	infectiong	NNP	I-AdverseReaction	O
7.9	XTANDI.xml:S1:10036:3	7.9	CD	O	O
1.5	XTANDI.xml:S1:10055:3	1.5	CD	O	O
4.7	XTANDI.xml:S1:10074:3	4.7	CD	O	O
1.1	XTANDI.xml:S1:10093:3	1.1	CD	O	O

Psychiatric	XTANDI.xml:S1:10115:11	psychiatr	JJ	O	O
Disorders	XTANDI.xml:S1:10127:9	disord	NNS	O	O

Insomnia	XTANDI.xml:S1:10155:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
8.2	XTANDI.xml:S1:10184:3	8.2	CD	O	O
0.1	XTANDI.xml:S1:10203:3	0.1	CD	O	O
5.7	XTANDI.xml:S1:10222:3	5.7	CD	O	O
0.0	XTANDI.xml:S1:10241:3	0.0	CD	O	O

Renal	XTANDI.xml:S1:10263:5	renal	NNP	O	O
And	XTANDI.xml:S1:10269:3	and	CC	O	O
Urinary	XTANDI.xml:S1:10273:7	urinari	NNP	O	O
Disorders	XTANDI.xml:S1:10281:9	disord	NNS	O	O

Hematuria	XTANDI.xml:S1:10303:9	hematuria	NNP	B-AdverseReaction	B-AdverseReaction
8.8	XTANDI.xml:S1:10332:3	8.8	CD	O	O
1.3	XTANDI.xml:S1:10351:3	1.3	CD	O	O
5.8	XTANDI.xml:S1:10370:3	5.8	CD	O	O
1.3	XTANDI.xml:S1:10389:3	1.3	CD	O	O

Injury	XTANDI.xml:S1:10411:6	injuri	NNP	O	O
,	XTANDI.xml:S1:10417:1	,	,	O	O
Poisoning	XTANDI.xml:S1:10419:9	poison	NNP	O	O
And	XTANDI.xml:S1:10429:3	and	CC	O	O
Procedural	XTANDI.xml:S1:10433:10	procedur	NNP	O	O
Complications	XTANDI.xml:S1:10444:13	complic	NNP	O	O

Fall	XTANDI.xml:S1:10468:4	fall	NN	B-AdverseReaction	B-AdverseReaction
12.7	XTANDI.xml:S1:10497:4	12.7	CD	O	O
1.6	XTANDI.xml:S1:10516:3	1.6	CD	O	O
5.3	XTANDI.xml:S1:10535:3	5.3	CD	O	O
0.7	XTANDI.xml:S1:10554:3	0.7	CD	O	O

Non	XTANDI.xml:S1:10580:3	non	NNP	B-AdverseReaction	B-AdverseReaction
-	XTANDI.xml:S1:10583:1	-	:	I-AdverseReaction	I-AdverseReaction
Pathological	XTANDI.xml:S1:10584:12	patholog	JJ	I-AdverseReaction	I-AdverseReaction
Fracture	XTANDI.xml:S1:10597:8	fractur	NN	I-AdverseReaction	I-AdverseReaction
8.8	XTANDI.xml:S1:10609:3	8.8	CD	O	O
2.1	XTANDI.xml:S1:10628:3	2.1	CD	O	O
3.0	XTANDI.xml:S1:10647:3	3.0	CD	O	O
1.1	XTANDI.xml:S1:10666:3	1.1	CD	O	O

Metabolism	XTANDI.xml:S1:10688:10	metabol	NN	O	O
and	XTANDI.xml:S1:10699:3	and	CC	O	O
Nutrition	XTANDI.xml:S1:10703:9	nutrit	NN	O	O
Disorders	XTANDI.xml:S1:10713:9	disord	NNS	O	O

Decreased	XTANDI.xml:S1:10733:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
Appetite	XTANDI.xml:S1:10743:8	appetit	NNP	I-AdverseReaction	I-AdverseReaction
18.9	XTANDI.xml:S1:10762:4	18.9	CD	O	O
0.3	XTANDI.xml:S1:10781:3	0.3	CD	O	O
16.4	XTANDI.xml:S1:10800:4	16.4	CD	O	O
0.7	XTANDI.xml:S1:10819:3	0.7	CD	O	O

Investigations	XTANDI.xml:S1:10841:14	investig	NNS	O	O

Weight	XTANDI.xml:S1:10881:6	weight	NNP	B-AdverseReaction	B-AdverseReaction
Decreased	XTANDI.xml:S1:10888:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
12.4	XTANDI.xml:S1:10910:4	12.4	CD	O	O
0.8	XTANDI.xml:S1:10929:3	0.8	CD	O	O
8.5	XTANDI.xml:S1:10948:3	8.5	CD	O	O
0.2	XTANDI.xml:S1:10967:3	0.2	CD	O	O

Reproductive	XTANDI.xml:S1:10989:12	reproduct	JJ	O	O
System	XTANDI.xml:S1:11002:6	system	NNP	O	O
and	XTANDI.xml:S1:11009:3	and	CC	O	O
Breast	XTANDI.xml:S1:11013:6	breast	NNP	O	O
disorders	XTANDI.xml:S1:11020:9	disord	NNS	O	O

Gynecomastia	XTANDI.xml:S1:11040:12	gynecomastia	NNP	B-AdverseReaction	B-AdverseReaction
3.4	XTANDI.xml:S1:11069:3	3.4	CD	O	O
0.0	XTANDI.xml:S1:11088:3	0.0	CD	O	O
1.4	XTANDI.xml:S1:11107:3	1.4	CD	O	O
0.0	XTANDI.xml:S1:11126:3	0.0	CD	O	O

a	XTANDI.xml:S1:11148:1	a	DT	O	O
CTCAE	XTANDI.xml:S1:11153:5	ctcae	NNP	O	O
v4b	XTANDI.xml:S1:11159:3	v4b	NN	O	O
Includes	XTANDI.xml:S1:11166:8	includ	NNP	O	O
asthenia	XTANDI.xml:S1:11175:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
and	XTANDI.xml:S1:11184:3	and	CC	O	O
fatigue	XTANDI.xml:S1:11188:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
.	XTANDI.xml:S1:11195:1	.	.	O	O
c	XTANDI.xml:S1:11196:1	c	VB	O	O
Includes	XTANDI.xml:S1:11201:8	includ	NNP	O	O
dizziness	XTANDI.xml:S1:11210:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
and	XTANDI.xml:S1:11220:3	and	CC	O	O
vertigo	XTANDI.xml:S1:11224:7	vertigo	NN	B-AdverseReaction	B-AdverseReaction
.	XTANDI.xml:S1:11231:1	.	.	O	O
d	XTANDI.xml:S1:11232:1	d	NN	O	O
Includes	XTANDI.xml:S1:11237:8	includ	NNP	O	O
amnesia	XTANDI.xml:S1:11246:7	amnesia	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:11253:1	,	,	O	O
memory	XTANDI.xml:S1:11255:6	memori	NN	B-AdverseReaction	B-AdverseReaction
impairment	XTANDI.xml:S1:11262:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:11272:1	,	,	O	O
cognitive	XTANDI.xml:S1:11274:9	cognit	JJ	B-AdverseReaction	B-AdverseReaction
disorder	XTANDI.xml:S1:11284:8	disord	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:11292:1	,	,	O	O
and	XTANDI.xml:S1:11294:3	and	CC	O	O
disturbance	XTANDI.xml:S1:11298:11	disturb	NN	B-AdverseReaction	B-AdverseReaction
in	XTANDI.xml:S1:11310:2	in	IN	I-AdverseReaction	I-AdverseReaction
attention	XTANDI.xml:S1:11313:9	attent	NN	I-AdverseReaction	I-AdverseReaction
.	XTANDI.xml:S1:11322:1	.	.	O	O
e	XTANDI.xml:S1:11323:1	e	NN	O	O
Includes	XTANDI.xml:S1:11328:8	includ	NNP	O	O
dyspnea	XTANDI.xml:S1:11337:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:11344:1	,	,	O	O
exertional	XTANDI.xml:S1:11346:10	exert	JJ	B-AdverseReaction	B-AdverseReaction
dyspnea	XTANDI.xml:S1:11357:7	dyspnea	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:11364:1	,	,	O	O
and	XTANDI.xml:S1:11366:3	and	CC	O	O
dyspnea	XTANDI.xml:S1:11370:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
at	XTANDI.xml:S1:11378:2	at	IN	I-AdverseReaction	O
rest	XTANDI.xml:S1:11381:4	rest	NN	I-AdverseReaction	O
.	XTANDI.xml:S1:11385:1	.	.	O	O
f	XTANDI.xml:S1:11386:1	f	VB	O	O
Includes	XTANDI.xml:S1:11391:8	includ	NNP	O	O
nasopharyngitis	XTANDI.xml:S1:11400:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:11415:1	,	,	O	O
upper	XTANDI.xml:S1:11417:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	XTANDI.xml:S1:11423:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	XTANDI.xml:S1:11435:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	XTANDI.xml:S1:11441:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:11450:1	,	,	O	O
sinusitis	XTANDI.xml:S1:11452:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:11461:1	,	,	O	O
rhinitis	XTANDI.xml:S1:11463:8	rhiniti	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:11471:1	,	,	O	O
pharyngitis	XTANDI.xml:S1:11473:11	pharyng	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:11484:1	,	,	O	O
and	XTANDI.xml:S1:11486:3	and	CC	O	O
laryngitis	XTANDI.xml:S1:11490:10	laryng	NN	B-AdverseReaction	O
.	XTANDI.xml:S1:11500:1	.	.	O	O
g	XTANDI.xml:S1:11501:1	g	NN	O	O
Includes	XTANDI.xml:S1:11506:8	includ	NNP	O	O
pneumonia	XTANDI.xml:S1:11515:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:11524:1	,	,	O	O
lower	XTANDI.xml:S1:11526:5	lower	JJR	B-AdverseReaction	B-AdverseReaction
respiratory	XTANDI.xml:S1:11532:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	XTANDI.xml:S1:11544:5	tract	JJ	I-AdverseReaction	I-AdverseReaction
infection	XTANDI.xml:S1:11550:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:11559:1	,	,	O	O
bronchitis	XTANDI.xml:S1:11561:10	bronchiti	NN	B-AdverseReaction	B-AdverseReaction
,	XTANDI.xml:S1:11571:1	,	,	O	O
and	XTANDI.xml:S1:11573:3	and	CC	O	O
lung	XTANDI.xml:S1:11577:4	lung	NN	B-AdverseReaction	O
infection	XTANDI.xml:S1:11582:9	infect	NN	I-AdverseReaction	O
.	XTANDI.xml:S1:11591:1	.	.	O	O

Laboratory	XTANDI.xml:S1:11610:10	laboratori	NN	O	O
Abnormalities	XTANDI.xml:S1:11621:13	abnorm	NNS	O	O
In	XTANDI.xml:S1:11636:2	In	IN	O	O
the	XTANDI.xml:S1:11639:3	the	DT	O	O
two	XTANDI.xml:S1:11643:3	two	CD	O	O
randomized	XTANDI.xml:S1:11647:10	random	VBD	O	O
clinical	XTANDI.xml:S1:11658:8	clinic	JJ	O	O
trials	XTANDI.xml:S1:11667:6	trial	NNS	O	O
,	XTANDI.xml:S1:11673:1	,	,	O	O
Grade	XTANDI.xml:S1:11675:5	grade	NNP	O	O
1	XTANDI.xml:S1:11681:1	1	CD	O	O
-	XTANDI.xml:S1:11682:1	-	:	O	O
4	XTANDI.xml:S1:11683:1	4	CD	O	O
neutropenia	XTANDI.xml:S1:11685:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
occurred	XTANDI.xml:S1:11697:8	occur	VBD	O	O
in	XTANDI.xml:S1:11706:2	in	IN	O	O
15%	XTANDI.xml:S1:11709:3	15%	CD	O	O
of	XTANDI.xml:S1:11713:2	of	IN	O	O
patients	XTANDI.xml:S1:11716:8	patient	NNS	O	O
treated	XTANDI.xml:S1:11725:7	treat	VBN	O	O
with	XTANDI.xml:S1:11733:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:11738:6	xtandi	NNP	O	O
(	XTANDI.xml:S1:11745:1	(	(	O	O
1%	XTANDI.xml:S1:11746:2	1%	CD	O	O
Grade	XTANDI.xml:S1:11749:5	grade	NNP	O	O
3	XTANDI.xml:S1:11755:1	3	CD	O	O
-	XTANDI.xml:S1:11756:1	-	:	O	O
4	XTANDI.xml:S1:11757:1	4	CD	O	O
)	XTANDI.xml:S1:11758:1	)	)	O	O
and	XTANDI.xml:S1:11760:3	and	CC	O	O
in	XTANDI.xml:S1:11764:2	in	IN	O	O
6%	XTANDI.xml:S1:11767:2	6%	CD	O	O
of	XTANDI.xml:S1:11770:2	of	IN	O	O
patients	XTANDI.xml:S1:11773:8	patient	NNS	O	O
treated	XTANDI.xml:S1:11782:7	treat	VBN	O	O
with	XTANDI.xml:S1:11790:4	with	IN	O	O
placebo	XTANDI.xml:S1:11795:7	placebo	NN	O	O
(	XTANDI.xml:S1:11803:1	(	(	O	O
0.5%	XTANDI.xml:S1:11804:4	0.5%	CD	O	O
Grade	XTANDI.xml:S1:11809:5	grade	NNP	O	O
3	XTANDI.xml:S1:11815:1	3	CD	O	O
-	XTANDI.xml:S1:11816:1	-	:	O	O
4	XTANDI.xml:S1:11817:1	4	CD	O	O
)	XTANDI.xml:S1:11818:1	)	)	O	O
.	XTANDI.xml:S1:11819:1	.	.	O	O

The	XTANDI.xml:S1:11821:3	the	DT	O	O
incidence	XTANDI.xml:S1:11825:9	incid	NN	O	O
of	XTANDI.xml:S1:11835:2	of	IN	O	O
Grade	XTANDI.xml:S1:11838:5	grade	NNP	O	O
1	XTANDI.xml:S1:11844:1	1	CD	O	O
-	XTANDI.xml:S1:11845:1	-	:	O	O
4	XTANDI.xml:S1:11846:1	4	CD	O	O
thrombocytopenia	XTANDI.xml:S1:11848:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
was	XTANDI.xml:S1:11865:3	wa	VBD	O	O
6%	XTANDI.xml:S1:11869:2	6%	CD	O	O
of	XTANDI.xml:S1:11872:2	of	IN	O	O
patients	XTANDI.xml:S1:11875:8	patient	NNS	O	O
treated	XTANDI.xml:S1:11884:7	treat	VBN	O	O
with	XTANDI.xml:S1:11892:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:11897:6	xtandi	NNP	O	O
(	XTANDI.xml:S1:11904:1	(	(	O	O
0.3%	XTANDI.xml:S1:11905:4	0.3%	CD	O	O
Grade	XTANDI.xml:S1:11910:5	grade	NNP	O	O
3	XTANDI.xml:S1:11916:1	3	CD	O	O
-	XTANDI.xml:S1:11917:1	-	:	O	O
4	XTANDI.xml:S1:11918:1	4	CD	O	O
)	XTANDI.xml:S1:11919:1	)	)	O	O
and	XTANDI.xml:S1:11921:3	and	CC	O	O
5%	XTANDI.xml:S1:11925:2	5%	CD	O	O
of	XTANDI.xml:S1:11928:2	of	IN	O	O
patients	XTANDI.xml:S1:11931:8	patient	NNS	O	O
treated	XTANDI.xml:S1:11940:7	treat	VBN	O	O
with	XTANDI.xml:S1:11948:4	with	IN	O	O
placebo	XTANDI.xml:S1:11953:7	placebo	NN	O	O
(	XTANDI.xml:S1:11961:1	(	(	O	O
0.5%	XTANDI.xml:S1:11962:4	0.5%	CD	O	O
Grade	XTANDI.xml:S1:11967:5	grade	NNP	O	O
3	XTANDI.xml:S1:11973:1	3	CD	O	O
-	XTANDI.xml:S1:11974:1	-	:	O	O
4	XTANDI.xml:S1:11975:1	4	CD	O	O
)	XTANDI.xml:S1:11976:1	)	)	O	O
.	XTANDI.xml:S1:11977:1	.	.	O	O

Grade	XTANDI.xml:S1:11979:5	grade	$	O	O
1	XTANDI.xml:S1:11985:1	1	CD	O	O
-	XTANDI.xml:S1:11986:1	-	:	O	O
4	XTANDI.xml:S1:11987:1	4	CD	O	O
elevations	XTANDI.xml:S1:11989:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	XTANDI.xml:S1:12000:2	in	IN	I-AdverseReaction	I-AdverseReaction
ALT	XTANDI.xml:S1:12003:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
occurred	XTANDI.xml:S1:12007:8	occur	VBD	O	O
in	XTANDI.xml:S1:12016:2	in	IN	O	O
10%	XTANDI.xml:S1:12019:3	10%	CD	O	O
of	XTANDI.xml:S1:12023:2	of	IN	O	O
patients	XTANDI.xml:S1:12026:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12035:7	treat	VBN	O	O
with	XTANDI.xml:S1:12043:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:12048:6	xtandi	NNP	O	O
(	XTANDI.xml:S1:12055:1	(	(	O	O
0.2%	XTANDI.xml:S1:12056:4	0.2%	CD	O	O
Grade	XTANDI.xml:S1:12061:5	grade	NNP	O	O
3	XTANDI.xml:S1:12067:1	3	CD	O	O
-	XTANDI.xml:S1:12068:1	-	:	O	O
4	XTANDI.xml:S1:12069:1	4	CD	O	O
)	XTANDI.xml:S1:12070:1	)	)	O	O
and	XTANDI.xml:S1:12072:3	and	CC	O	O
16%	XTANDI.xml:S1:12076:3	16%	CD	O	O
of	XTANDI.xml:S1:12080:2	of	IN	O	O
patients	XTANDI.xml:S1:12083:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12092:7	treat	VBN	O	O
with	XTANDI.xml:S1:12100:4	with	IN	O	O
placebo	XTANDI.xml:S1:12105:7	placebo	NN	O	O
(	XTANDI.xml:S1:12113:1	(	(	O	O
0.2%	XTANDI.xml:S1:12114:4	0.2%	CD	O	O
Grade	XTANDI.xml:S1:12119:5	grade	NNP	O	O
3	XTANDI.xml:S1:12125:1	3	CD	O	O
-	XTANDI.xml:S1:12126:1	-	:	O	O
4	XTANDI.xml:S1:12127:1	4	CD	O	O
)	XTANDI.xml:S1:12128:1	)	)	O	O
.	XTANDI.xml:S1:12129:1	.	.	O	O

Grade	XTANDI.xml:S1:12131:5	grade	$	O	O
1	XTANDI.xml:S1:12137:1	1	CD	O	O
-	XTANDI.xml:S1:12138:1	-	:	O	O
4	XTANDI.xml:S1:12139:1	4	CD	O	O
elevations	XTANDI.xml:S1:12141:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	XTANDI.xml:S1:12152:2	in	IN	I-AdverseReaction	I-AdverseReaction
bilirubin	XTANDI.xml:S1:12155:9	bilirubin	NN	I-AdverseReaction	I-AdverseReaction
occurred	XTANDI.xml:S1:12165:8	occur	VBD	O	O
in	XTANDI.xml:S1:12174:2	in	IN	O	O
3%	XTANDI.xml:S1:12177:2	3%	CD	O	O
of	XTANDI.xml:S1:12180:2	of	IN	O	O
patients	XTANDI.xml:S1:12183:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12192:7	treat	VBN	O	O
with	XTANDI.xml:S1:12200:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:12205:6	xtandi	NNP	O	O
(	XTANDI.xml:S1:12212:1	(	(	O	O
0.1%	XTANDI.xml:S1:12213:4	0.1%	CD	O	O
Grade	XTANDI.xml:S1:12218:5	grade	NNP	O	O
3	XTANDI.xml:S1:12224:1	3	CD	O	O
-	XTANDI.xml:S1:12225:1	-	:	O	O
4	XTANDI.xml:S1:12226:1	4	CD	O	O
)	XTANDI.xml:S1:12227:1	)	)	O	O
and	XTANDI.xml:S1:12229:3	and	CC	O	O
2%	XTANDI.xml:S1:12233:2	2%	CD	O	O
of	XTANDI.xml:S1:12236:2	of	IN	O	O
patients	XTANDI.xml:S1:12239:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12248:7	treat	VBN	O	O
with	XTANDI.xml:S1:12256:4	with	IN	O	O
placebo	XTANDI.xml:S1:12261:7	placebo	NN	O	O
(	XTANDI.xml:S1:12269:1	(	(	O	O
no	XTANDI.xml:S1:12270:2	no	DT	O	O
Grade	XTANDI.xml:S1:12273:5	grade	NNP	O	O
3	XTANDI.xml:S1:12279:1	3	CD	O	O
-	XTANDI.xml:S1:12280:1	-	:	O	O
4	XTANDI.xml:S1:12281:1	4	CD	O	O
)	XTANDI.xml:S1:12282:1	)	)	O	O
.	XTANDI.xml:S1:12283:1	.	.	O	O

Infections	XTANDI.xml:S1:12291:10	infect	NNS	O	O

In	XTANDI.xml:S1:12303:2	In	IN	O	O
Study	XTANDI.xml:S1:12306:5	studi	NNP	O	O
1	XTANDI.xml:S1:12312:1	1	CD	O	O
,	XTANDI.xml:S1:12313:1	,	,	O	O
1%	XTANDI.xml:S1:12315:2	1%	CD	O	O
of	XTANDI.xml:S1:12318:2	of	IN	O	O
patients	XTANDI.xml:S1:12321:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12330:7	treat	VBN	O	O
with	XTANDI.xml:S1:12338:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:12343:6	xtandi	NNP	O	O
compared	XTANDI.xml:S1:12350:8	compar	VBN	O	O
to	XTANDI.xml:S1:12359:2	to	TO	O	O
0.3%	XTANDI.xml:S1:12362:4	0.3%	CD	O	O
of	XTANDI.xml:S1:12367:2	of	IN	O	O
patients	XTANDI.xml:S1:12370:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12379:7	treat	VBN	O	O
with	XTANDI.xml:S1:12387:4	with	IN	O	O
placebo	XTANDI.xml:S1:12392:7	placebo	NN	O	O
died	XTANDI.xml:S1:12400:4	die	VBN	B-AdverseReaction	B-AdverseReaction
from	XTANDI.xml:S1:12405:4	from	IN	O	I-AdverseReaction
infections	XTANDI.xml:S1:12410:10	infect	NNS	B-AdverseReaction	I-AdverseReaction
or	XTANDI.xml:S1:12421:2	or	CC	O	O
sepsis	XTANDI.xml:S1:12424:6	sepsi	NN	B-AdverseReaction	O
.	XTANDI.xml:S1:12430:1	.	.	O	O

In	XTANDI.xml:S1:12432:2	In	IN	O	O
Study	XTANDI.xml:S1:12435:5	studi	NNP	O	O
2	XTANDI.xml:S1:12441:1	2	CD	O	O
,	XTANDI.xml:S1:12442:1	,	,	O	O
1	XTANDI.xml:S1:12444:1	1	CD	O	O
patient	XTANDI.xml:S1:12446:7	patient	NN	O	O
in	XTANDI.xml:S1:12454:2	in	IN	O	O
each	XTANDI.xml:S1:12457:4	each	DT	O	O
treatment	XTANDI.xml:S1:12462:9	treatment	NN	O	O
group	XTANDI.xml:S1:12472:5	group	NN	O	O
(	XTANDI.xml:S1:12478:1	(	(	O	O
0.1%	XTANDI.xml:S1:12479:4	0.1%	CD	O	O
)	XTANDI.xml:S1:12483:1	)	)	O	O
had	XTANDI.xml:S1:12485:3	had	VBD	O	O
an	XTANDI.xml:S1:12489:2	an	DT	O	O
infection	XTANDI.xml:S1:12492:9	infect	NN	B-AdverseReaction	O
resulting	XTANDI.xml:S1:12502:9	result	VBG	O	O
in	XTANDI.xml:S1:12512:2	in	IN	O	O
death	XTANDI.xml:S1:12515:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	XTANDI.xml:S1:12520:1	.	.	O	O

Falls	XTANDI.xml:S1:12528:5	fall	NNS	O	O
and	XTANDI.xml:S1:12534:3	and	CC	O	O
Fall	XTANDI.xml:S1:12538:4	fall	NNP	O	B-AdverseReaction
-	XTANDI.xml:S1:12542:1	-	:	O	I-AdverseReaction
related	XTANDI.xml:S1:12543:7	relat	JJ	O	I-AdverseReaction
Injuries	XTANDI.xml:S1:12551:8	injuri	NNS	O	I-AdverseReaction
In	XTANDI.xml:S1:12561:2	In	IN	O	O
the	XTANDI.xml:S1:12564:3	the	DT	O	O
two	XTANDI.xml:S1:12568:3	two	CD	O	O
randomized	XTANDI.xml:S1:12572:10	random	VBD	O	O
clinical	XTANDI.xml:S1:12583:8	clinic	JJ	O	O
trials	XTANDI.xml:S1:12592:6	trial	NNS	O	O
,	XTANDI.xml:S1:12598:1	,	,	O	O
falls	XTANDI.xml:S1:12600:5	fall	VBZ	B-AdverseReaction	O
including	XTANDI.xml:S1:12606:9	includ	VBG	O	O
fall	XTANDI.xml:S1:12616:4	fall	VB	B-AdverseReaction	B-AdverseReaction
-	XTANDI.xml:S1:12620:1	-	:	I-AdverseReaction	I-AdverseReaction
related	XTANDI.xml:S1:12621:7	relat	JJ	I-AdverseReaction	I-AdverseReaction
injuries	XTANDI.xml:S1:12629:8	injuri	NNS	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:12637:1	,	,	O	O
occurred	XTANDI.xml:S1:12639:8	occur	VBD	O	O
in	XTANDI.xml:S1:12648:2	in	IN	O	O
9%	XTANDI.xml:S1:12651:2	9%	CD	O	O
of	XTANDI.xml:S1:12654:2	of	IN	O	O
patients	XTANDI.xml:S1:12657:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12666:7	treat	VBN	O	O
with	XTANDI.xml:S1:12674:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:12679:6	xtandi	NNP	O	O
compared	XTANDI.xml:S1:12686:8	compar	VBN	O	O
to	XTANDI.xml:S1:12695:2	to	TO	O	O
4%	XTANDI.xml:S1:12698:2	4%	CD	O	O
of	XTANDI.xml:S1:12701:2	of	IN	O	O
patients	XTANDI.xml:S1:12704:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12713:7	treat	VBN	O	O
with	XTANDI.xml:S1:12721:4	with	IN	O	O
placebo	XTANDI.xml:S1:12726:7	placebo	NN	O	O
.	XTANDI.xml:S1:12733:1	.	.	O	O

Falls	XTANDI.xml:S1:12735:5	fall	NNS	B-AdverseReaction	B-AdverseReaction
were	XTANDI.xml:S1:12741:4	were	VBD	O	O
not	XTANDI.xml:S1:12746:3	not	RB	O	O
associated	XTANDI.xml:S1:12750:10	associ	VBN	O	O
with	XTANDI.xml:S1:12761:4	with	IN	O	O
loss	XTANDI.xml:S1:12766:4	loss	NN	B-AdverseReaction	O
of	XTANDI.xml:S1:12771:2	of	IN	I-AdverseReaction	O
consciousness	XTANDI.xml:S1:12774:13	conscious	NN	I-AdverseReaction	O
or	XTANDI.xml:S1:12788:2	or	CC	O	O
seizure	XTANDI.xml:S1:12791:7	seizur	NN	B-AdverseReaction	O
.	XTANDI.xml:S1:12798:1	.	.	O	O

Fall	XTANDI.xml:S1:12800:4	fall	NNP	B-AdverseReaction	B-AdverseReaction
-	XTANDI.xml:S1:12804:1	-	:	I-AdverseReaction	I-AdverseReaction
related	XTANDI.xml:S1:12805:7	relat	JJ	I-AdverseReaction	I-AdverseReaction
injuries	XTANDI.xml:S1:12813:8	injuri	NNS	I-AdverseReaction	I-AdverseReaction
were	XTANDI.xml:S1:12822:4	were	VBD	O	O
more	XTANDI.xml:S1:12827:4	more	RBR	O	O
severe	XTANDI.xml:S1:12832:6	sever	JJ	O	O
in	XTANDI.xml:S1:12839:2	in	IN	O	O
patients	XTANDI.xml:S1:12842:8	patient	NNS	O	O
treated	XTANDI.xml:S1:12851:7	treat	VBN	O	O
with	XTANDI.xml:S1:12859:4	with	IN	O	O
XTANDI	XTANDI.xml:S1:12864:6	xtandi	NNP	O	O
and	XTANDI.xml:S1:12871:3	and	CC	O	O
included	XTANDI.xml:S1:12875:8	includ	VBD	O	O
non	XTANDI.xml:S1:12884:3	non	SYM	B-AdverseReaction	B-AdverseReaction
-	XTANDI.xml:S1:12887:1	-	:	I-AdverseReaction	I-AdverseReaction
pathologic	XTANDI.xml:S1:12888:10	patholog	NN	I-AdverseReaction	I-AdverseReaction
fractures	XTANDI.xml:S1:12899:9	fractur	NNS	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:12908:1	,	,	O	O
joint	XTANDI.xml:S1:12910:5	joint	JJ	B-AdverseReaction	B-AdverseReaction
injuries	XTANDI.xml:S1:12916:8	injuri	NNS	I-AdverseReaction	I-AdverseReaction
,	XTANDI.xml:S1:12924:1	,	,	O	O
and	XTANDI.xml:S1:12926:3	and	CC	O	O
hematomas	XTANDI.xml:S1:12930:9	hematoma	NN	B-AdverseReaction	B-AdverseReaction
.	XTANDI.xml:S1:12939:1	.	.	O	O

Hypertension	XTANDI.xml:S1:12947:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
In	XTANDI.xml:S1:12961:2	In	IN	O	O
the	XTANDI.xml:S1:12964:3	the	DT	O	O
two	XTANDI.xml:S1:12968:3	two	CD	O	O
randomized	XTANDI.xml:S1:12972:10	random	JJ	O	O
trials	XTANDI.xml:S1:12983:6	trial	NNS	O	O
,	XTANDI.xml:S1:12989:1	,	,	O	O
hypertension	XTANDI.xml:S1:12991:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
was	XTANDI.xml:S1:13004:3	wa	VBD	O	O
reported	XTANDI.xml:S1:13008:8	report	VBN	O	O
in	XTANDI.xml:S1:13017:2	in	IN	O	O
11%	XTANDI.xml:S1:13020:3	11%	CD	O	O
of	XTANDI.xml:S1:13024:2	of	IN	O	O
patients	XTANDI.xml:S1:13027:8	patient	NNS	O	O
receiving	XTANDI.xml:S1:13036:9	receiv	VBG	O	O
XTANDI	XTANDI.xml:S1:13046:6	xtandi	NNP	O	O
and	XTANDI.xml:S1:13053:3	and	CC	O	O
4%	XTANDI.xml:S1:13057:2	4%	CD	O	O
of	XTANDI.xml:S1:13060:2	of	IN	O	O
patients	XTANDI.xml:S1:13063:8	patient	NNS	O	O
receiving	XTANDI.xml:S1:13072:9	receiv	VBG	O	O
placebo	XTANDI.xml:S1:13082:7	placebo	NN	O	O
.	XTANDI.xml:S1:13089:1	.	.	O	O

No	XTANDI.xml:S1:13091:2	No	DT	O	O
patients	XTANDI.xml:S1:13094:8	patient	NNS	O	O
experienced	XTANDI.xml:S1:13103:11	experienc	VBD	O	O
hypertensive	XTANDI.xml:S1:13115:12	hypertens	JJ	B-AdverseReaction	B-AdverseReaction
crisis	XTANDI.xml:S1:13128:6	crisi	NN	I-AdverseReaction	I-AdverseReaction
.	XTANDI.xml:S1:13134:1	.	.	O	O

Medical	XTANDI.xml:S1:13136:7	medic	JJ	O	O
history	XTANDI.xml:S1:13144:7	histori	NN	O	O
of	XTANDI.xml:S1:13152:2	of	IN	O	O
hypertension	XTANDI.xml:S1:13155:12	hypertens	NN	O	O
was	XTANDI.xml:S1:13168:3	wa	VBD	O	O
balanced	XTANDI.xml:S1:13172:8	balanc	VBN	O	O
between	XTANDI.xml:S1:13181:7	between	IN	O	O
arms	XTANDI.xml:S1:13189:4	arm	NNS	O	O
.	XTANDI.xml:S1:13193:1	.	.	O	O

Hypertension	XTANDI.xml:S1:13195:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
led	XTANDI.xml:S1:13208:3	led	VBD	O	O
to	XTANDI.xml:S1:13212:2	to	TO	O	O
study	XTANDI.xml:S1:13215:5	studi	VB	O	O
discontinuation	XTANDI.xml:S1:13221:15	discontinu	NN	O	O
in	XTANDI.xml:S1:13237:2	in	IN	O	O
1%	XTANDI.xml:S1:13242:2	1%	CD	O	O
of	XTANDI.xml:S1:13245:2	of	IN	O	O
patients	XTANDI.xml:S1:13248:8	patient	NNS	O	O
in	XTANDI.xml:S1:13257:2	in	IN	O	O
each	XTANDI.xml:S1:13260:4	each	DT	O	O
arm	XTANDI.xml:S1:13265:3	arm	NN	O	O
.	XTANDI.xml:S1:13268:1	.	.	O	O
5	XTANDI.xml:S2:4:1	5	CD	O	O
WARNINGS	XTANDI.xml:S2:6:8	warn	NNP	O	O
AND	XTANDI.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	XTANDI.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	XTANDI.xml:S2:36:7	excerpt	NN	O	O
:	XTANDI.xml:S2:43:1	:	:	O	O
Seizure	XTANDI.xml:S2:47:7	seizur	NN	B-AdverseReaction	B-AdverseReaction
occurred	XTANDI.xml:S2:55:8	occur	VBD	O	O
in	XTANDI.xml:S2:64:2	in	IN	O	O
0.9%	XTANDI.xml:S2:67:4	0.9%	CD	O	O
of	XTANDI.xml:S2:72:2	of	IN	O	O
patients	XTANDI.xml:S2:75:8	patient	NNS	O	O
receiving	XTANDI.xml:S2:84:9	receiv	VBG	O	O
XTANDI	XTANDI.xml:S2:94:6	xtandi	NN	O	O
who	XTANDI.xml:S2:101:3	who	WP	O	O
previously	XTANDI.xml:S2:105:10	previous	RB	O	O
received	XTANDI.xml:S2:116:8	receiv	VBD	O	O
docetaxel	XTANDI.xml:S2:125:9	docetaxel	NN	O	O
and	XTANDI.xml:S2:135:3	and	CC	O	O
in	XTANDI.xml:S2:139:2	in	IN	O	O
0.1%	XTANDI.xml:S2:142:4	0.1%	CD	O	O
of	XTANDI.xml:S2:147:2	of	IN	O	O
patients	XTANDI.xml:S2:150:8	patient	NNS	O	O
who	XTANDI.xml:S2:159:3	who	WP	O	O
were	XTANDI.xml:S2:163:4	were	VBD	O	O
chemotherapy	XTANDI.xml:S2:168:12	chemotherapi	JJ	O	O
-	XTANDI.xml:S2:180:1	-	:	O	O
naive	XTANDI.xml:S2:181:5	naiv	NN	O	O
.	XTANDI.xml:S2:186:1	.	.	O	O

There	XTANDI.xml:S2:188:5	there	EX	O	O
is	XTANDI.xml:S2:194:2	is	VBZ	O	O
no	XTANDI.xml:S2:197:2	no	DT	O	O
clinical	XTANDI.xml:S2:200:8	clinic	JJ	O	O
trial	XTANDI.xml:S2:209:5	trial	NN	O	O
experience	XTANDI.xml:S2:215:10	experi	NN	O	O
with	XTANDI.xml:S2:226:4	with	IN	O	O
XTANDI	XTANDI.xml:S2:231:6	xtandi	NNP	O	O
in	XTANDI.xml:S2:238:2	in	IN	O	O
patients	XTANDI.xml:S2:241:8	patient	NNS	O	O
who	XTANDI.xml:S2:250:3	who	WP	O	O
have	XTANDI.xml:S2:254:4	have	VBP	O	O
had	XTANDI.xml:S2:259:3	had	VBD	O	O
a	XTANDI.xml:S2:263:1	a	DT	O	O
seizure	XTANDI.xml:S2:265:7	seizur	NN	O	O
.	XTANDI.xml:S2:272:1	.	.	O	O

Permanently	XTANDI.xml:S2:274:11	perman	RB	O	O
discontinue	XTANDI.xml:S2:286:11	discontinu	JJ	O	O
XTANDI	XTANDI.xml:S2:298:6	xtandi	NNP	O	O
in	XTANDI.xml:S2:305:2	in	IN	O	O
patients	XTANDI.xml:S2:308:8	patient	NNS	O	O
who	XTANDI.xml:S2:317:3	who	WP	O	O
develop	XTANDI.xml:S2:321:7	develop	VBP	O	O
a	XTANDI.xml:S2:329:1	a	DT	O	O
seizure	XTANDI.xml:S2:331:7	seizur	NN	O	O
during	XTANDI.xml:S2:339:6	dure	IN	O	O
treatment	XTANDI.xml:S2:346:9	treatment	NN	O	O
.	XTANDI.xml:S2:355:1	.	.	O	O

(	XTANDI.xml:S2:357:1	(	(	O	O
5.1	XTANDI.xml:S2:360:3	5.1	CD	O	O
)	XTANDI.xml:S2:365:1	)	)	O	O

5.1	XTANDI.xml:S2:378:3	5.1	CD	O	O

Seizure	XTANDI.xml:S2:382:7	seizur	NN	O	O

In	XTANDI.xml:S2:396:2	In	IN	O	O
Study	XTANDI.xml:S2:399:5	studi	NNP	O	O
1	XTANDI.xml:S2:405:1	1	CD	O	O
,	XTANDI.xml:S2:406:1	,	,	O	O
which	XTANDI.xml:S2:408:5	which	WDT	O	O
enrolled	XTANDI.xml:S2:414:8	enrol	VBD	O	O
patients	XTANDI.xml:S2:423:8	patient	NNS	O	O
who	XTANDI.xml:S2:432:3	who	WP	O	O
previously	XTANDI.xml:S2:436:10	previous	RB	O	O
received	XTANDI.xml:S2:447:8	receiv	VBD	O	O
docetaxel	XTANDI.xml:S2:456:9	docetaxel	NN	O	O
,	XTANDI.xml:S2:465:1	,	,	O	O
7	XTANDI.xml:S2:467:1	7	CD	O	O
of	XTANDI.xml:S2:469:2	of	IN	O	O
800	XTANDI.xml:S2:472:3	800	CD	O	O
(	XTANDI.xml:S2:476:1	(	(	O	O
0.9%	XTANDI.xml:S2:477:4	0.9%	CD	O	O
)	XTANDI.xml:S2:481:1	)	)	O	O
patients	XTANDI.xml:S2:483:8	patient	NNS	O	O
treated	XTANDI.xml:S2:492:7	treat	VBN	O	O
with	XTANDI.xml:S2:500:4	with	IN	O	O
XTANDI	XTANDI.xml:S2:505:6	xtandi	NNP	O	O
experienced	XTANDI.xml:S2:512:11	experienc	VBD	O	O
a	XTANDI.xml:S2:524:1	a	DT	O	O
seizure	XTANDI.xml:S2:526:7	seizur	NN	B-AdverseReaction	O
and	XTANDI.xml:S2:534:3	and	CC	O	O
no	XTANDI.xml:S2:538:2	no	DT	O	O
patients	XTANDI.xml:S2:541:8	patient	NNS	O	O
treated	XTANDI.xml:S2:550:7	treat	VBN	O	O
with	XTANDI.xml:S2:558:4	with	IN	O	O
placebo	XTANDI.xml:S2:563:7	placebo	NN	O	O
experienced	XTANDI.xml:S2:571:11	experienc	VBD	O	O
a	XTANDI.xml:S2:583:1	a	DT	O	O
seizure	XTANDI.xml:S2:585:7	seizur	NN	B-AdverseReaction	O
.	XTANDI.xml:S2:592:1	.	.	O	O

Seizure	XTANDI.xml:S2:594:7	seizur	NN	B-AdverseReaction	B-AdverseReaction
occurred	XTANDI.xml:S2:602:8	occur	VBD	O	O
from	XTANDI.xml:S2:611:4	from	IN	O	O
31	XTANDI.xml:S2:616:2	31	CD	O	O
to	XTANDI.xml:S2:619:2	to	TO	O	O
603	XTANDI.xml:S2:622:3	603	CD	O	O
days	XTANDI.xml:S2:626:4	day	NNS	O	O
after	XTANDI.xml:S2:631:5	after	IN	O	O
initiation	XTANDI.xml:S2:637:10	initi	NN	O	O
of	XTANDI.xml:S2:648:2	of	IN	O	O
XTANDI	XTANDI.xml:S2:651:6	xtandi	NNP	O	O
.	XTANDI.xml:S2:657:1	.	.	O	O

In	XTANDI.xml:S2:659:2	In	IN	O	O
Study	XTANDI.xml:S2:662:5	studi	NNP	O	O
2	XTANDI.xml:S2:668:1	2	CD	O	O
,	XTANDI.xml:S2:669:1	,	,	O	O
1	XTANDI.xml:S2:671:1	1	CD	O	O
of	XTANDI.xml:S2:673:2	of	IN	O	O
871	XTANDI.xml:S2:676:3	871	CD	O	O
(	XTANDI.xml:S2:680:1	(	(	O	O
0.1%	XTANDI.xml:S2:681:4	0.1%	CD	O	O
)	XTANDI.xml:S2:685:1	)	)	O	O
chemotherapy	XTANDI.xml:S2:687:12	chemotherapi	NN	O	O
-	XTANDI.xml:S2:699:1	-	:	O	O
naive	XTANDI.xml:S2:700:5	naiv	JJ	O	O
patients	XTANDI.xml:S2:706:8	patient	NNS	O	O
treated	XTANDI.xml:S2:715:7	treat	VBN	O	O
with	XTANDI.xml:S2:723:4	with	IN	O	O
XTANDI	XTANDI.xml:S2:728:6	xtandi	NNP	O	O
and	XTANDI.xml:S2:735:3	and	CC	O	O
1	XTANDI.xml:S2:739:1	1	CD	O	O
of	XTANDI.xml:S2:741:2	of	IN	O	O
844	XTANDI.xml:S2:744:3	844	CD	O	O
(	XTANDI.xml:S2:748:1	(	(	O	O
0.1%	XTANDI.xml:S2:749:4	0.1%	CD	O	O
)	XTANDI.xml:S2:753:1	)	)	O	O
patients	XTANDI.xml:S2:755:8	patient	NNS	O	O
treated	XTANDI.xml:S2:764:7	treat	VBN	O	O
with	XTANDI.xml:S2:772:4	with	IN	O	O
placebo	XTANDI.xml:S2:777:7	placebo	NN	O	O
experienced	XTANDI.xml:S2:785:11	experienc	VBD	O	O
a	XTANDI.xml:S2:797:1	a	DT	O	O
seizure	XTANDI.xml:S2:799:7	seizur	NN	B-AdverseReaction	O
.	XTANDI.xml:S2:806:1	.	.	O	O

Patients	XTANDI.xml:S2:808:8	patient	NNS	O	O
experiencing	XTANDI.xml:S2:817:12	experienc	VBG	O	O
seizure	XTANDI.xml:S2:830:7	seizur	NN	B-AdverseReaction	O
were	XTANDI.xml:S2:838:4	were	VBD	O	O
permanently	XTANDI.xml:S2:843:11	perman	RB	O	O
discontinued	XTANDI.xml:S2:855:12	discontinu	VBN	O	O
from	XTANDI.xml:S2:868:4	from	IN	O	O
therapy	XTANDI.xml:S2:873:7	therapi	NN	O	O
and	XTANDI.xml:S2:881:3	and	CC	O	O
all	XTANDI.xml:S2:885:3	all	DT	O	O
seizure	XTANDI.xml:S2:889:7	seizur	NN	O	O
events	XTANDI.xml:S2:897:6	event	NNS	O	O
resolved	XTANDI.xml:S2:904:8	resolv	VBD	O	O
.	XTANDI.xml:S2:912:1	.	.	O	O

There	XTANDI.xml:S2:914:5	there	EX	O	O
is	XTANDI.xml:S2:920:2	is	VBZ	O	O
no	XTANDI.xml:S2:923:2	no	DT	O	O
clinical	XTANDI.xml:S2:926:8	clinic	JJ	O	O
trial	XTANDI.xml:S2:935:5	trial	NN	O	O
experience	XTANDI.xml:S2:941:10	experi	NN	O	O
re	XTANDI.xml:S2:952:2	re	NN	O	O
-	XTANDI.xml:S2:954:1	-	:	O	O
administering	XTANDI.xml:S2:955:13	administ	VBG	O	O
XTANDI	XTANDI.xml:S2:969:6	xtandi	NN	O	O
to	XTANDI.xml:S2:976:2	to	TO	O	O
patients	XTANDI.xml:S2:979:8	patient	NNS	O	O
who	XTANDI.xml:S2:988:3	who	WP	O	O
experienced	XTANDI.xml:S2:992:11	experienc	VBD	O	O
seizure	XTANDI.xml:S2:1004:7	seizur	NN	O	O
.	XTANDI.xml:S2:1011:1	.	.	O	O

Limited	XTANDI.xml:S2:1020:7	limit	JJ	O	O
safety	XTANDI.xml:S2:1028:6	safeti	NN	O	O
data	XTANDI.xml:S2:1035:4	data	NNS	O	O
are	XTANDI.xml:S2:1040:3	are	VBP	O	O
available	XTANDI.xml:S2:1044:9	avail	JJ	O	O
in	XTANDI.xml:S2:1054:2	in	IN	O	O
patients	XTANDI.xml:S2:1057:8	patient	NNS	O	O
with	XTANDI.xml:S2:1066:4	with	IN	O	O
predisposing	XTANDI.xml:S2:1071:12	predispos	JJ	O	O
factors	XTANDI.xml:S2:1084:7	factor	NNS	O	O
for	XTANDI.xml:S2:1092:3	for	IN	O	O
seizure	XTANDI.xml:S2:1096:7	seizur	NN	O	O
because	XTANDI.xml:S2:1104:7	becaus	IN	O	O
these	XTANDI.xml:S2:1112:5	these	DT	O	O
patients	XTANDI.xml:S2:1118:8	patient	NNS	O	O
were	XTANDI.xml:S2:1127:4	were	VBD	O	O
generally	XTANDI.xml:S2:1132:9	gener	RB	O	O
excluded	XTANDI.xml:S2:1142:8	exclud	VBN	O	O
from	XTANDI.xml:S2:1151:4	from	IN	O	O
the	XTANDI.xml:S2:1156:3	the	DT	O	O
trials	XTANDI.xml:S2:1160:6	trial	NNS	O	O
.	XTANDI.xml:S2:1166:1	.	.	O	O

These	XTANDI.xml:S2:1168:5	these	DT	O	O
exclusion	XTANDI.xml:S2:1174:9	exclus	NN	O	O
criteria	XTANDI.xml:S2:1184:8	criteria	NNS	O	O
included	XTANDI.xml:S2:1193:8	includ	VBD	O	O
a	XTANDI.xml:S2:1202:1	a	DT	O	O
history	XTANDI.xml:S2:1204:7	histori	NN	O	O
of	XTANDI.xml:S2:1212:2	of	IN	O	O
seizure	XTANDI.xml:S2:1215:7	seizur	NN	O	O
,	XTANDI.xml:S2:1222:1	,	,	O	O
underlying	XTANDI.xml:S2:1224:10	underli	VBG	O	O
brain	XTANDI.xml:S2:1235:5	brain	NN	O	O
injury	XTANDI.xml:S2:1241:6	injuri	NN	O	O
with	XTANDI.xml:S2:1248:4	with	IN	O	O
loss	XTANDI.xml:S2:1253:4	loss	NN	O	O
of	XTANDI.xml:S2:1258:2	of	IN	O	O
consciousness	XTANDI.xml:S2:1261:13	conscious	NN	O	O
,	XTANDI.xml:S2:1274:1	,	,	O	O
transient	XTANDI.xml:S2:1276:9	transient	JJ	O	B-AdverseReaction
ischemic	XTANDI.xml:S2:1286:8	ischem	JJ	O	I-AdverseReaction
attack	XTANDI.xml:S2:1295:6	attack	NN	O	I-AdverseReaction
within	XTANDI.xml:S2:1302:6	within	IN	O	O
the	XTANDI.xml:S2:1309:3	the	DT	O	O
past	XTANDI.xml:S2:1313:4	past	JJ	O	O
12	XTANDI.xml:S2:1318:2	12	CD	O	O
months	XTANDI.xml:S2:1321:6	month	NNS	O	O
,	XTANDI.xml:S2:1327:1	,	,	O	O
cerebral	XTANDI.xml:S2:1329:8	cerebr	JJ	O	O
vascular	XTANDI.xml:S2:1338:8	vascular	JJ	O	O
accident	XTANDI.xml:S2:1347:8	accid	NN	O	O
,	XTANDI.xml:S2:1355:1	,	,	O	O
brain	XTANDI.xml:S2:1357:5	brain	NN	O	O
metastases	XTANDI.xml:S2:1363:10	metastas	NNS	O	O
,	XTANDI.xml:S2:1373:1	,	,	O	O
and	XTANDI.xml:S2:1375:3	and	CC	O	O
brain	XTANDI.xml:S2:1379:5	brain	NN	O	O
arteriovenous	XTANDI.xml:S2:1385:13	arterioven	JJ	O	O
malformation	XTANDI.xml:S2:1399:12	malform	NN	O	O
.	XTANDI.xml:S2:1411:1	.	.	O	O

Study	XTANDI.xml:S2:1413:5	studi	NNP	O	O
1	XTANDI.xml:S2:1419:1	1	CD	O	O
excluded	XTANDI.xml:S2:1421:8	exclud	VBD	O	O
the	XTANDI.xml:S2:1430:3	the	DT	O	O
use	XTANDI.xml:S2:1434:3	use	NN	O	O
of	XTANDI.xml:S2:1438:2	of	IN	O	O
concomitant	XTANDI.xml:S2:1441:11	concomit	JJ	O	O
medications	XTANDI.xml:S2:1453:11	medic	NNS	O	O
that	XTANDI.xml:S2:1465:4	that	WDT	O	O
may	XTANDI.xml:S2:1470:3	may	MD	O	O
lower	XTANDI.xml:S2:1474:5	lower	VB	O	O
the	XTANDI.xml:S2:1480:3	the	DT	O	O
seizure	XTANDI.xml:S2:1484:7	seizur	NN	O	O
threshold	XTANDI.xml:S2:1492:9	threshold	NN	O	O
,	XTANDI.xml:S2:1501:1	,	,	O	O
whereas	XTANDI.xml:S2:1503:7	wherea	WP	O	O
Study	XTANDI.xml:S2:1511:5	studi	NNP	O	O
2	XTANDI.xml:S2:1517:1	2	CD	O	O
permitted	XTANDI.xml:S2:1519:9	permit	VBD	O	O
the	XTANDI.xml:S2:1529:3	the	DT	O	O
use	XTANDI.xml:S2:1533:3	use	NN	O	O
of	XTANDI.xml:S2:1537:2	of	IN	O	O
these	XTANDI.xml:S2:1540:5	these	DT	O	O
medications	XTANDI.xml:S2:1546:11	medic	NNS	O	O
.	XTANDI.xml:S2:1557:1	.	.	O	O

Because	XTANDI.xml:S2:1566:7	becaus	IN	O	O
of	XTANDI.xml:S2:1574:2	of	IN	O	O
the	XTANDI.xml:S2:1577:3	the	DT	O	O
risk	XTANDI.xml:S2:1581:4	risk	NN	O	O
of	XTANDI.xml:S2:1586:2	of	IN	O	O
seizure	XTANDI.xml:S2:1589:7	seizur	NN	O	O
associated	XTANDI.xml:S2:1597:10	associ	VBN	O	O
with	XTANDI.xml:S2:1608:4	with	IN	O	O
XTANDI	XTANDI.xml:S2:1613:6	xtandi	NNP	O	O
use	XTANDI.xml:S2:1620:3	use	NN	O	O
,	XTANDI.xml:S2:1623:1	,	,	O	O
patients	XTANDI.xml:S2:1625:8	patient	NNS	O	O
should	XTANDI.xml:S2:1634:6	should	MD	O	O
be	XTANDI.xml:S2:1641:2	be	VB	O	O
advised	XTANDI.xml:S2:1644:7	advis	VBN	O	O
of	XTANDI.xml:S2:1652:2	of	IN	O	O
the	XTANDI.xml:S2:1655:3	the	DT	O	O
risk	XTANDI.xml:S2:1659:4	risk	NN	O	O
of	XTANDI.xml:S2:1664:2	of	IN	O	O
engaging	XTANDI.xml:S2:1667:8	engag	VBG	O	O
in	XTANDI.xml:S2:1676:2	in	IN	O	O
any	XTANDI.xml:S2:1679:3	ani	DT	O	O
activity	XTANDI.xml:S2:1683:8	activ	NN	O	O
where	XTANDI.xml:S2:1692:5	where	WRB	O	O
sudden	XTANDI.xml:S2:1698:6	sudden	JJ	O	O
loss	XTANDI.xml:S2:1705:4	loss	NN	O	O
of	XTANDI.xml:S2:1710:2	of	IN	O	O
consciousness	XTANDI.xml:S2:1713:13	conscious	NN	O	O
could	XTANDI.xml:S2:1727:5	could	MD	O	O
cause	XTANDI.xml:S2:1733:5	caus	VB	O	O
serious	XTANDI.xml:S2:1739:7	seriou	JJ	O	O
harm	XTANDI.xml:S2:1747:4	harm	NN	O	O
to	XTANDI.xml:S2:1752:2	to	TO	O	O
themselves	XTANDI.xml:S2:1755:10	themselv	PRP	O	O
or	XTANDI.xml:S2:1766:2	or	CC	O	O
others	XTANDI.xml:S2:1769:6	other	NNS	O	O
.	XTANDI.xml:S2:1775:1	.	.	O	O

Permanently	XTANDI.xml:S2:1777:11	perman	RB	O	O
discontinue	XTANDI.xml:S2:1789:11	discontinu	JJ	O	O
XTANDI	XTANDI.xml:S2:1801:6	xtandi	NNP	O	O
in	XTANDI.xml:S2:1808:2	in	IN	O	O
patients	XTANDI.xml:S2:1811:8	patient	NNS	O	O
who	XTANDI.xml:S2:1820:3	who	WP	O	O
develop	XTANDI.xml:S2:1824:7	develop	VBP	O	O
a	XTANDI.xml:S2:1832:1	a	DT	O	O
seizure	XTANDI.xml:S2:1834:7	seizur	NN	O	O
during	XTANDI.xml:S2:1842:6	dure	IN	O	O
treatment	XTANDI.xml:S2:1849:9	treatment	NN	O	O
.	XTANDI.xml:S2:1858:1	.	.	O	O
6	YERVOY.xml:S1:4:1	6	CD	O	O
ADVERSE	YERVOY.xml:S1:9:7	advers	JJ	O	O
REACTIONS	YERVOY.xml:S1:17:9	reaction	NN	O	O

The	YERVOY.xml:S1:30:3	the	DT	O	O
following	YERVOY.xml:S1:34:9	follow	JJ	O	O
adverse	YERVOY.xml:S1:44:7	advers	JJ	O	O
reactions	YERVOY.xml:S1:52:9	reaction	NNS	O	O
are	YERVOY.xml:S1:62:3	are	VBP	O	O
discussed	YERVOY.xml:S1:66:9	discuss	VBN	O	O
in	YERVOY.xml:S1:76:2	in	IN	O	O
greater	YERVOY.xml:S1:79:7	greater	JJR	O	O
detail	YERVOY.xml:S1:87:6	detail	NN	O	O
in	YERVOY.xml:S1:94:2	in	IN	O	O
other	YERVOY.xml:S1:97:5	other	JJ	O	O
sections	YERVOY.xml:S1:103:8	section	NNS	O	O
of	YERVOY.xml:S1:112:2	of	IN	O	O
the	YERVOY.xml:S1:115:3	the	DT	O	O
labeling	YERVOY.xml:S1:119:8	label	NN	O	O
.	YERVOY.xml:S1:127:1	.	.	O	O

?	YERVOY.xml:S1:136:1	?	.	O	O

Immune	YERVOY.xml:S1:139:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S1:145:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S1:146:8	mediat	VBD	I-AdverseReaction	I-AdverseReaction
enterocolitis	YERVOY.xml:S1:155:13	enterocol	JJ	I-AdverseReaction	I-AdverseReaction
[	YERVOY.xml:S1:169:1	[	NNP	O	O
see	YERVOY.xml:S1:170:3	see	VBP	O	O
Warnings	YERVOY.xml:S1:175:8	warn	NNP	O	O
and	YERVOY.xml:S1:184:3	and	CC	O	O
Precautions	YERVOY.xml:S1:188:11	precaut	NNP	O	O
(	YERVOY.xml:S1:200:1	(	(	O	O
5.1	YERVOY.xml:S1:201:3	5.1	CD	O	O
)	YERVOY.xml:S1:204:1	)	)	O	O
]	YERVOY.xml:S1:207:1	]	NN	O	O
.	YERVOY.xml:S1:209:1	.	.	O	O

?	YERVOY.xml:S1:216:1	?	.	O	O

Immune	YERVOY.xml:S1:219:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S1:225:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S1:226:8	mediat	VBD	I-AdverseReaction	I-AdverseReaction
hepatitis	YERVOY.xml:S1:235:9	hepat	NN	I-AdverseReaction	I-AdverseReaction
[	YERVOY.xml:S1:245:1	[	NNP	O	O
see	YERVOY.xml:S1:246:3	see	VBP	O	O
Warnings	YERVOY.xml:S1:251:8	warn	NNP	O	O
and	YERVOY.xml:S1:260:3	and	CC	O	O
Precautions	YERVOY.xml:S1:264:11	precaut	NNP	O	O
(	YERVOY.xml:S1:276:1	(	(	O	O
5.2	YERVOY.xml:S1:277:3	5.2	CD	O	O
)	YERVOY.xml:S1:280:1	)	)	O	O
]	YERVOY.xml:S1:283:1	]	NN	O	O
.	YERVOY.xml:S1:285:1	.	.	O	O

?	YERVOY.xml:S1:292:1	?	.	O	O

Immune	YERVOY.xml:S1:295:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S1:301:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S1:302:8	mediat	VBD	I-AdverseReaction	I-AdverseReaction
dermatitis	YERVOY.xml:S1:311:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
[	YERVOY.xml:S1:322:1	[	NNP	O	O
see	YERVOY.xml:S1:323:3	see	VBP	O	O
Warnings	YERVOY.xml:S1:328:8	warn	NNP	O	O
and	YERVOY.xml:S1:337:3	and	CC	O	O
Precautions	YERVOY.xml:S1:341:11	precaut	NNP	O	O
(	YERVOY.xml:S1:353:1	(	(	O	O
5.3	YERVOY.xml:S1:354:3	5.3	CD	O	O
)	YERVOY.xml:S1:357:1	)	)	O	O
]	YERVOY.xml:S1:360:1	]	NN	O	O
.	YERVOY.xml:S1:362:1	.	.	O	O

?	YERVOY.xml:S1:369:1	?	.	O	O

Immune	YERVOY.xml:S1:372:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S1:378:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S1:379:8	mediat	VBD	I-AdverseReaction	I-AdverseReaction
neuropathies	YERVOY.xml:S1:388:12	neuropathi	NNS	I-AdverseReaction	I-AdverseReaction
[	YERVOY.xml:S1:401:1	[	NNP	O	O
see	YERVOY.xml:S1:402:3	see	VBP	O	O
Warnings	YERVOY.xml:S1:407:8	warn	NNP	O	O
and	YERVOY.xml:S1:416:3	and	CC	O	O
Precautions	YERVOY.xml:S1:420:11	precaut	NNP	O	O
(	YERVOY.xml:S1:432:1	(	(	O	O
5.4	YERVOY.xml:S1:433:3	5.4	CD	O	O
)	YERVOY.xml:S1:436:1	)	)	O	O
]	YERVOY.xml:S1:439:1	]	NN	O	O
.	YERVOY.xml:S1:441:1	.	.	O	O

?	YERVOY.xml:S1:448:1	?	.	O	O

Immune	YERVOY.xml:S1:451:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S1:457:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S1:458:8	mediat	VBD	I-AdverseReaction	I-AdverseReaction
endocrinopathies	YERVOY.xml:S1:467:16	endocrinopathi	NNS	I-AdverseReaction	I-AdverseReaction
[	YERVOY.xml:S1:484:1	[	NNP	O	O
see	YERVOY.xml:S1:485:3	see	VBP	O	O
Warnings	YERVOY.xml:S1:490:8	warn	NNP	O	O
and	YERVOY.xml:S1:499:3	and	CC	O	O
Precautions	YERVOY.xml:S1:503:11	precaut	NNP	O	O
(	YERVOY.xml:S1:515:1	(	(	O	O
5.5	YERVOY.xml:S1:516:3	5.5	CD	O	O
)	YERVOY.xml:S1:519:1	)	)	O	O
]	YERVOY.xml:S1:522:1	]	NN	O	O
.	YERVOY.xml:S1:524:1	.	.	O	O

?	YERVOY.xml:S1:531:1	?	.	O	O

Other	YERVOY.xml:S1:534:5	other	JJ	O	O
immune	YERVOY.xml:S1:540:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S1:546:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S1:547:8	mediat	JJ	I-AdverseReaction	O
adverse	YERVOY.xml:S1:556:7	advers	JJ	I-AdverseReaction	O
reactions	YERVOY.xml:S1:564:9	reaction	NNS	I-AdverseReaction	O
,	YERVOY.xml:S1:573:1	,	,	O	O
including	YERVOY.xml:S1:575:9	includ	VBG	O	O
ocular	YERVOY.xml:S1:585:6	ocular	JJ	B-AdverseReaction	B-AdverseReaction
manifestations	YERVOY.xml:S1:592:14	manifest	NNS	I-AdverseReaction	I-AdverseReaction
[	YERVOY.xml:S1:607:1	[	VBP	O	O
see	YERVOY.xml:S1:608:3	see	VBP	O	O
Warnings	YERVOY.xml:S1:613:8	warn	NNS	O	O
and	YERVOY.xml:S1:622:3	and	CC	O	O
Precautions	YERVOY.xml:S1:626:11	precaut	NNP	O	O
(	YERVOY.xml:S1:638:1	(	(	O	O
5.6	YERVOY.xml:S1:639:3	5.6	CD	O	O
)	YERVOY.xml:S1:642:1	)	)	O	O
]	YERVOY.xml:S1:645:1	]	NN	O	O
.	YERVOY.xml:S1:647:1	.	.	O	O

EXCERPT	YERVOY.xml:S1:656:7	excerpt	NNS	O	O
:	YERVOY.xml:S1:663:1	:	:	O	O
Most	YERVOY.xml:S1:667:4	most	JJS	O	O
common	YERVOY.xml:S1:672:6	common	JJ	O	O
adverse	YERVOY.xml:S1:679:7	advers	JJ	O	O
reactions	YERVOY.xml:S1:687:9	reaction	NNS	O	O
(	YERVOY.xml:S1:697:1	(	(	O	O
5%	YERVOY.xml:S1:700:2	5%	CD	O	O
)	YERVOY.xml:S1:702:1	)	)	O	O
are	YERVOY.xml:S1:704:3	are	VBP	O	O
fatigue	YERVOY.xml:S1:708:7	fatigu	JJ	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:715:1	,	,	O	O
diarrhea	YERVOY.xml:S1:717:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:725:1	,	,	O	O
pruritus	YERVOY.xml:S1:727:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:735:1	,	,	O	O
rash	YERVOY.xml:S1:737:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:741:1	,	,	O	O
and	YERVOY.xml:S1:743:3	and	CC	O	O
colitis	YERVOY.xml:S1:747:7	coliti	NN	B-AdverseReaction	B-AdverseReaction
.	YERVOY.xml:S1:754:1	.	.	O	O

(	YERVOY.xml:S1:757:1	(	(	O	O
6.1	YERVOY.xml:S1:758:3	6.1	CD	O	O
)	YERVOY.xml:S1:761:1	)	)	O	O

To	YERVOY.xml:S1:771:2	To	TO	O	O

report	YERVOY.xml:S1:774:6	report	NN	O	O
SUSPECTED	YERVOY.xml:S1:781:9	suspect	NNP	O	O
ADVERSE	YERVOY.xml:S1:791:7	advers	NNP	O	O
REACTIONS	YERVOY.xml:S1:799:9	reaction	NNP	O	O
,	YERVOY.xml:S1:808:1	,	,	O	O
contact	YERVOY.xml:S1:810:7	contact	NN	O	O
Bristol	YERVOY.xml:S1:818:7	bristol	NNP	O	O
-	YERVOY.xml:S1:825:1	-	:	O	O
Myers	YERVOY.xml:S1:826:5	myer	NNS	O	O
Squibb	YERVOY.xml:S1:832:6	squibb	VBP	O	O
at	YERVOY.xml:S1:839:2	at	IN	O	O
1	YERVOY.xml:S1:842:1	1	CD	O	O
-	YERVOY.xml:S1:843:1	-	:	O	O
800	YERVOY.xml:S1:844:3	800	CD	O	O
-	YERVOY.xml:S1:847:1	-	:	O	O
721	YERVOY.xml:S1:848:3	721	CD	O	O
-	YERVOY.xml:S1:851:1	-	:	O	O
5072	YERVOY.xml:S1:852:4	5072	CD	O	O
or	YERVOY.xml:S1:857:2	or	CC	O	O
FDA	YERVOY.xml:S1:860:3	fda	NNP	O	O
at	YERVOY.xml:S1:864:2	at	IN	O	O
1	YERVOY.xml:S1:867:1	1	CD	O	O
-	YERVOY.xml:S1:868:1	-	:	O	O
800	YERVOY.xml:S1:869:3	800	CD	O	O
-	YERVOY.xml:S1:872:1	-	:	O	O
FDA	YERVOY.xml:S1:873:3	fda	NNP	O	O
-	YERVOY.xml:S1:876:1	-	:	O	O
1088	YERVOY.xml:S1:877:4	1088	CD	O	O
or	YERVOY.xml:S1:882:2	or	CC	O	O
www	YERVOY.xml:S1:886:3	www	VB	O	O
.	YERVOY.xml:S1:889:1	.	.	O	O
fda	YERVOY.xml:S1:890:3	fda	NN	O	O
.	YERVOY.xml:S1:893:1	.	.	O	O
gov	YERVOY.xml:S1:894:3	gov	JJ	O	O
medwatch	YERVOY.xml:S1:898:8	medwatch	NN	O	O
.	YERVOY.xml:S1:908:1	.	.	O	O

6.1	YERVOY.xml:S1:920:3	6.1	CD	O	O

Clinical	YERVOY.xml:S1:926:8	clinic	JJ	O	O
Trials	YERVOY.xml:S1:935:6	trial	NNS	O	O
Experience	YERVOY.xml:S1:942:10	experi	NN	O	O

Because	YERVOY.xml:S1:956:7	becaus	IN	O	O
clinical	YERVOY.xml:S1:964:8	clinic	JJ	O	O
trials	YERVOY.xml:S1:973:6	trial	NNS	O	O
are	YERVOY.xml:S1:980:3	are	VBP	O	O
conducted	YERVOY.xml:S1:984:9	conduct	VBN	O	O
under	YERVOY.xml:S1:994:5	under	IN	O	O
widely	YERVOY.xml:S1:1000:6	wide	RB	O	O
varying	YERVOY.xml:S1:1007:7	vari	VBG	O	O
conditions	YERVOY.xml:S1:1015:10	condit	NNS	O	O
,	YERVOY.xml:S1:1025:1	,	,	O	O
the	YERVOY.xml:S1:1027:3	the	DT	O	O
adverse	YERVOY.xml:S1:1031:7	advers	JJ	O	O
reaction	YERVOY.xml:S1:1039:8	reaction	NN	O	O
rates	YERVOY.xml:S1:1048:5	rate	NNS	O	O
observed	YERVOY.xml:S1:1054:8	observ	VBD	O	O
cannot	YERVOY.xml:S1:1063:6	cannot	JJ	O	O
be	YERVOY.xml:S1:1070:2	be	VB	O	O
directly	YERVOY.xml:S1:1073:8	directli	RB	O	O
compared	YERVOY.xml:S1:1082:8	compar	VBN	O	O
with	YERVOY.xml:S1:1091:4	with	IN	O	O
rates	YERVOY.xml:S1:1096:5	rate	NNS	O	O
in	YERVOY.xml:S1:1102:2	in	IN	O	O
other	YERVOY.xml:S1:1105:5	other	JJ	O	O
clinical	YERVOY.xml:S1:1111:8	clinic	JJ	O	O
trials	YERVOY.xml:S1:1120:6	trial	NNS	O	O
or	YERVOY.xml:S1:1127:2	or	CC	O	O
experience	YERVOY.xml:S1:1130:10	experi	NN	O	O
with	YERVOY.xml:S1:1141:4	with	IN	O	O
therapeutics	YERVOY.xml:S1:1146:12	therapeut	NNS	O	O
in	YERVOY.xml:S1:1159:2	in	IN	O	O
the	YERVOY.xml:S1:1162:3	the	DT	O	O
same	YERVOY.xml:S1:1166:4	same	JJ	O	O
class	YERVOY.xml:S1:1171:5	class	NN	O	O
and	YERVOY.xml:S1:1177:3	and	CC	O	O
may	YERVOY.xml:S1:1181:3	may	MD	O	O
not	YERVOY.xml:S1:1185:3	not	RB	O	O
reflect	YERVOY.xml:S1:1189:7	reflect	VB	O	O
the	YERVOY.xml:S1:1197:3	the	DT	O	O
rates	YERVOY.xml:S1:1201:5	rate	NNS	O	O
observed	YERVOY.xml:S1:1207:8	observ	VBD	O	O
in	YERVOY.xml:S1:1216:2	in	IN	O	O
clinical	YERVOY.xml:S1:1219:8	clinic	JJ	O	O
practice	YERVOY.xml:S1:1228:8	practic	NN	O	O
.	YERVOY.xml:S1:1236:1	.	.	O	O

The	YERVOY.xml:S1:1242:3	the	DT	O	O
clinical	YERVOY.xml:S1:1246:8	clinic	JJ	O	O
development	YERVOY.xml:S1:1255:11	develop	NN	O	O
program	YERVOY.xml:S1:1267:7	program	NN	O	O
excluded	YERVOY.xml:S1:1275:8	exclud	VBD	O	O
patients	YERVOY.xml:S1:1284:8	patient	NNS	O	O
with	YERVOY.xml:S1:1293:4	with	IN	O	O
active	YERVOY.xml:S1:1298:6	activ	JJ	O	O
autoimmune	YERVOY.xml:S1:1305:10	autoimmun	JJ	O	O
disease	YERVOY.xml:S1:1316:7	diseas	NN	O	O
or	YERVOY.xml:S1:1324:2	or	CC	O	O
those	YERVOY.xml:S1:1327:5	those	DT	O	O
receiving	YERVOY.xml:S1:1333:9	receiv	VBG	O	O
systemic	YERVOY.xml:S1:1343:8	system	JJ	O	O
immunosuppression	YERVOY.xml:S1:1352:17	immunosuppress	NN	O	O
for	YERVOY.xml:S1:1370:3	for	IN	O	O
organ	YERVOY.xml:S1:1374:5	organ	JJ	O	O
transplantation	YERVOY.xml:S1:1380:15	transplant	NN	O	O
.	YERVOY.xml:S1:1395:1	.	.	O	O

Exposure	YERVOY.xml:S1:1397:8	exposur	NN	O	O
to	YERVOY.xml:S1:1406:2	to	TO	O	O
YERVOY	YERVOY.xml:S1:1409:6	yervoy	VB	O	O
3	YERVOY.xml:S1:1416:1	3	CD	O	O
mg	YERVOY.xml:S1:1418:2	mg	NNS	O	O
kg	YERVOY.xml:S1:1421:2	kg	NN	O	O
for	YERVOY.xml:S1:1424:3	for	IN	O	O
4	YERVOY.xml:S1:1428:1	4	CD	O	O
doses	YERVOY.xml:S1:1430:5	dose	NNS	O	O
given	YERVOY.xml:S1:1436:5	given	VBN	O	O
by	YERVOY.xml:S1:1442:2	by	IN	O	O
intravenous	YERVOY.xml:S1:1445:11	intraven	JJ	O	O
infusion	YERVOY.xml:S1:1457:8	infus	NN	O	O
in	YERVOY.xml:S1:1466:2	in	IN	O	O
previously	YERVOY.xml:S1:1469:10	previous	RB	O	O
treated	YERVOY.xml:S1:1480:7	treat	VBN	O	O
patients	YERVOY.xml:S1:1488:8	patient	NNS	O	O
with	YERVOY.xml:S1:1497:4	with	IN	O	O
unresectable	YERVOY.xml:S1:1502:12	unresect	JJ	O	O
or	YERVOY.xml:S1:1515:2	or	CC	O	O
metastatic	YERVOY.xml:S1:1518:10	metastat	JJ	O	O
melanoma	YERVOY.xml:S1:1529:8	melanoma	NN	O	O
was	YERVOY.xml:S1:1538:3	wa	VBD	O	O
assessed	YERVOY.xml:S1:1542:8	assess	VBN	O	O
in	YERVOY.xml:S1:1551:2	in	IN	O	O
a	YERVOY.xml:S1:1554:1	a	DT	O	O
randomized	YERVOY.xml:S1:1556:10	random	JJ	O	O
,	YERVOY.xml:S1:1566:1	,	,	O	O
double	YERVOY.xml:S1:1568:6	doubl	JJ	O	O
-	YERVOY.xml:S1:1574:1	-	:	O	O
blind	YERVOY.xml:S1:1575:5	blind	VB	O	O
clinical	YERVOY.xml:S1:1581:8	clinic	JJ	O	O
study	YERVOY.xml:S1:1590:5	studi	NN	O	O
(	YERVOY.xml:S1:1596:1	(	(	O	O
Study	YERVOY.xml:S1:1597:5	studi	NNP	O	O
1	YERVOY.xml:S1:1603:1	1	CD	O	O
)	YERVOY.xml:S1:1604:1	)	)	O	O
.	YERVOY.xml:S1:1605:1	.	.	O	O

[	YERVOY.xml:S1:1608:1	[	NNS	O	O
See	YERVOY.xml:S1:1609:3	see	NNP	O	O
Clinical	YERVOY.xml:S1:1614:8	clinic	JJ	O	O
Studies	YERVOY.xml:S1:1623:7	studi	NNP	O	O
(	YERVOY.xml:S1:1631:1	(	(	O	O
14	YERVOY.xml:S1:1632:2	14	CD	O	O
)	YERVOY.xml:S1:1634:1	)	)	O	O
.	YERVOY.xml:S1:1637:1	.	.	O	O
]	YERVOY.xml:S1:1638:1	]	NN	O	O

One	YERVOY.xml:S1:1641:3	one	CD	O	O
hundred	YERVOY.xml:S1:1645:7	hundr	VBD	O	O
thirty	YERVOY.xml:S1:1653:6	thirti	SYM	O	O
-	YERVOY.xml:S1:1659:1	-	:	O	O
one	YERVOY.xml:S1:1660:3	one	CD	O	O
patients	YERVOY.xml:S1:1664:8	patient	NNS	O	O
(	YERVOY.xml:S1:1673:1	(	(	O	O
median	YERVOY.xml:S1:1674:6	median	JJ	O	O
age	YERVOY.xml:S1:1681:3	age	NN	O	O
57	YERVOY.xml:S1:1685:2	57	CD	O	O
years	YERVOY.xml:S1:1688:5	year	NNS	O	O
,	YERVOY.xml:S1:1693:1	,	,	O	O
60%	YERVOY.xml:S1:1695:3	60%	CD	O	O
male	YERVOY.xml:S1:1699:4	male	NN	O	O
)	YERVOY.xml:S1:1703:1	)	)	O	O
received	YERVOY.xml:S1:1705:8	receiv	VBD	O	O
YERVOY	YERVOY.xml:S1:1714:6	yervoy	NNP	O	O
as	YERVOY.xml:S1:1721:2	as	IN	O	O
a	YERVOY.xml:S1:1724:1	a	DT	O	O
single	YERVOY.xml:S1:1726:6	singl	JJ	O	O
agent	YERVOY.xml:S1:1733:5	agent	NN	O	O
,	YERVOY.xml:S1:1738:1	,	,	O	O
380	YERVOY.xml:S1:1740:3	380	CD	O	O
patients	YERVOY.xml:S1:1744:8	patient	NNS	O	O
(	YERVOY.xml:S1:1753:1	(	(	O	O
median	YERVOY.xml:S1:1754:6	median	JJ	O	O
age	YERVOY.xml:S1:1761:3	age	NN	O	O
56	YERVOY.xml:S1:1765:2	56	CD	O	O
years	YERVOY.xml:S1:1768:5	year	NNS	O	O
,	YERVOY.xml:S1:1773:1	,	,	O	O
61%	YERVOY.xml:S1:1775:3	61%	CD	O	O
male	YERVOY.xml:S1:1779:4	male	NN	O	O
)	YERVOY.xml:S1:1783:1	)	)	O	O
received	YERVOY.xml:S1:1785:8	receiv	VBD	O	O
YERVOY	YERVOY.xml:S1:1794:6	yervoy	NNP	O	O
with	YERVOY.xml:S1:1801:4	with	IN	O	O
an	YERVOY.xml:S1:1806:2	an	DT	O	O
investigational	YERVOY.xml:S1:1809:15	investig	JJ	O	O
gp100	YERVOY.xml:S1:1825:5	gp100	NN	O	O
peptide	YERVOY.xml:S1:1831:7	peptid	NN	O	O
vaccine	YERVOY.xml:S1:1839:7	vaccin	NN	O	O
(	YERVOY.xml:S1:1847:1	(	(	O	O
gp100	YERVOY.xml:S1:1848:5	gp100	NN	O	O
)	YERVOY.xml:S1:1853:1	)	)	O	O
,	YERVOY.xml:S1:1854:1	,	,	O	O
and	YERVOY.xml:S1:1856:3	and	CC	O	O
132	YERVOY.xml:S1:1860:3	132	CD	O	O
patients	YERVOY.xml:S1:1864:8	patient	NNS	O	O
(	YERVOY.xml:S1:1873:1	(	(	O	O
median	YERVOY.xml:S1:1874:6	median	JJ	O	O
age	YERVOY.xml:S1:1881:3	age	NN	O	O
57	YERVOY.xml:S1:1885:2	57	CD	O	O
years	YERVOY.xml:S1:1888:5	year	NNS	O	O
,	YERVOY.xml:S1:1893:1	,	,	O	O
54%	YERVOY.xml:S1:1895:3	54%	CD	O	O
male	YERVOY.xml:S1:1899:4	male	NN	O	O
)	YERVOY.xml:S1:1903:1	)	)	O	O
received	YERVOY.xml:S1:1905:8	receiv	VBD	O	O
gp100	YERVOY.xml:S1:1914:5	gp100	JJ	O	O
peptide	YERVOY.xml:S1:1920:7	peptid	JJ	O	O
vaccine	YERVOY.xml:S1:1928:7	vaccin	NN	O	O
alone	YERVOY.xml:S1:1936:5	alon	RB	O	O
.	YERVOY.xml:S1:1941:1	.	.	O	O

Patients	YERVOY.xml:S1:1943:8	patient	NNS	O	O
in	YERVOY.xml:S1:1952:2	in	IN	O	O
the	YERVOY.xml:S1:1955:3	the	DT	O	O
study	YERVOY.xml:S1:1959:5	studi	NN	O	O
received	YERVOY.xml:S1:1965:8	receiv	VBD	O	O
a	YERVOY.xml:S1:1974:1	a	DT	O	O
median	YERVOY.xml:S1:1976:6	median	NN	O	O
of	YERVOY.xml:S1:1983:2	of	IN	O	O
4	YERVOY.xml:S1:1986:1	4	CD	O	O
doses	YERVOY.xml:S1:1988:5	dose	NNS	O	O
(	YERVOY.xml:S1:1994:1	(	(	O	O
range	YERVOY.xml:S1:1995:5	rang	NN	O	O
:	YERVOY.xml:S1:2000:1	:	:	O	O
1	YERVOY.xml:S1:2002:1	1	CD	O	O
-	YERVOY.xml:S1:2003:1	-	:	O	O
4	YERVOY.xml:S1:2004:1	4	CD	O	O
doses	YERVOY.xml:S1:2006:5	dose	NNS	O	O
)	YERVOY.xml:S1:2011:1	)	)	O	O
.	YERVOY.xml:S1:2012:1	.	.	O	O

YERVOY	YERVOY.xml:S1:2014:6	yervoy	NN	O	O
was	YERVOY.xml:S1:2021:3	wa	VBD	O	O
discontinued	YERVOY.xml:S1:2025:12	discontinu	VBN	O	O
for	YERVOY.xml:S1:2038:3	for	IN	O	O
adverse	YERVOY.xml:S1:2042:7	advers	JJ	O	O
reactions	YERVOY.xml:S1:2050:9	reaction	NNS	O	O
in	YERVOY.xml:S1:2060:2	in	IN	O	O
10%	YERVOY.xml:S1:2063:3	10%	CD	O	O
of	YERVOY.xml:S1:2067:2	of	IN	O	O
patients	YERVOY.xml:S1:2070:8	patient	NNS	O	O
.	YERVOY.xml:S1:2078:1	.	.	O	O

The	YERVOY.xml:S1:2084:3	the	DT	O	O
most	YERVOY.xml:S1:2088:4	most	RBS	O	O
common	YERVOY.xml:S1:2093:6	common	JJ	O	O
adverse	YERVOY.xml:S1:2100:7	advers	JJ	O	O
reactions	YERVOY.xml:S1:2108:9	reaction	NNS	O	O
(	YERVOY.xml:S1:2118:1	(	(	O	O
5%	YERVOY.xml:S1:2121:2	5%	CD	O	O
)	YERVOY.xml:S1:2123:1	)	)	O	O
in	YERVOY.xml:S1:2125:2	in	IN	O	O
patients	YERVOY.xml:S1:2128:8	patient	NNS	O	O
who	YERVOY.xml:S1:2137:3	who	WP	O	O
received	YERVOY.xml:S1:2141:8	receiv	VBD	O	O
YERVOY	YERVOY.xml:S1:2150:6	yervoy	NNP	O	O
at	YERVOY.xml:S1:2157:2	at	IN	O	O
3	YERVOY.xml:S1:2160:1	3	CD	O	O
mg	YERVOY.xml:S1:2162:2	mg	NNS	O	O
kg	YERVOY.xml:S1:2165:2	kg	NNS	O	O
were	YERVOY.xml:S1:2168:4	were	VBD	O	O
fatigue	YERVOY.xml:S1:2173:7	fatigu	JJ	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:2180:1	,	,	O	O
diarrhea	YERVOY.xml:S1:2182:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:2190:1	,	,	O	O
pruritus	YERVOY.xml:S1:2192:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:2200:1	,	,	O	O
rash	YERVOY.xml:S1:2202:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:2206:1	,	,	O	O
and	YERVOY.xml:S1:2208:3	and	CC	O	O
colitis	YERVOY.xml:S1:2212:7	coliti	NN	B-AdverseReaction	B-AdverseReaction
.	YERVOY.xml:S1:2219:1	.	.	O	O

Table	YERVOY.xml:S1:2225:5	tabl	JJ	O	O
1	YERVOY.xml:S1:2231:1	1	CD	O	O
presents	YERVOY.xml:S1:2233:8	present	NNS	O	O
selected	YERVOY.xml:S1:2242:8	select	VBN	O	O
adverse	YERVOY.xml:S1:2251:7	advers	JJ	O	O
reactions	YERVOY.xml:S1:2259:9	reaction	NNS	O	O
from	YERVOY.xml:S1:2269:4	from	IN	O	O
Study	YERVOY.xml:S1:2274:5	studi	NNP	O	O
1	YERVOY.xml:S1:2280:1	1	CD	O	O
,	YERVOY.xml:S1:2281:1	,	,	O	O
which	YERVOY.xml:S1:2283:5	which	WDT	O	O
occurred	YERVOY.xml:S1:2289:8	occur	VBD	O	O
in	YERVOY.xml:S1:2298:2	in	IN	O	O
at	YERVOY.xml:S1:2301:2	at	IN	O	O
least	YERVOY.xml:S1:2304:5	least	JJS	O	O
5%	YERVOY.xml:S1:2310:2	5%	CD	O	O
of	YERVOY.xml:S1:2313:2	of	IN	O	O
patients	YERVOY.xml:S1:2316:8	patient	NNS	O	O
in	YERVOY.xml:S1:2325:2	in	IN	O	O
the	YERVOY.xml:S1:2328:3	the	DT	O	O
YERVOY	YERVOY.xml:S1:2332:6	yervoy	NNP	O	O
-	YERVOY.xml:S1:2338:1	-	:	O	O
containing	YERVOY.xml:S1:2339:10	contain	NN	O	O
arms	YERVOY.xml:S1:2350:4	arm	NNS	O	O
and	YERVOY.xml:S1:2355:3	and	CC	O	O
with	YERVOY.xml:S1:2359:4	with	IN	O	O
at	YERVOY.xml:S1:2364:2	at	IN	O	O
least	YERVOY.xml:S1:2367:5	least	JJS	O	O
5%	YERVOY.xml:S1:2373:2	5%	CD	O	O
increased	YERVOY.xml:S1:2376:9	increas	VBD	O	O
incidence	YERVOY.xml:S1:2386:9	incid	NN	O	O
over	YERVOY.xml:S1:2396:4	over	IN	O	O
the	YERVOY.xml:S1:2401:3	the	DT	O	O
control	YERVOY.xml:S1:2405:7	control	NN	O	O
gp100	YERVOY.xml:S1:2413:5	gp100	NN	O	O
arm	YERVOY.xml:S1:2419:3	arm	NN	O	O
for	YERVOY.xml:S1:2423:3	for	IN	O	O
all	YERVOY.xml:S1:2427:3	all	DT	O	O
-	YERVOY.xml:S1:2430:1	-	:	O	O
grade	YERVOY.xml:S1:2431:5	grade	NN	O	O
events	YERVOY.xml:S1:2437:6	event	NNS	O	O
and	YERVOY.xml:S1:2444:3	and	CC	O	O
at	YERVOY.xml:S1:2448:2	at	IN	O	O
least	YERVOY.xml:S1:2451:5	least	JJS	O	O
1%	YERVOY.xml:S1:2457:2	1%	CD	O	O
incidence	YERVOY.xml:S1:2460:9	incid	NN	O	O
over	YERVOY.xml:S1:2470:4	over	IN	O	O
the	YERVOY.xml:S1:2475:3	the	DT	O	O
control	YERVOY.xml:S1:2479:7	control	NN	O	O
group	YERVOY.xml:S1:2487:5	group	NN	O	O
for	YERVOY.xml:S1:2493:3	for	IN	O	O
Grade	YERVOY.xml:S1:2497:5	grade	NNP	O	O
3	YERVOY.xml:S1:2503:1	3	CD	O	O
-	YERVOY.xml:S1:2504:1	-	:	O	O
5	YERVOY.xml:S1:2505:1	5	CD	O	O
events	YERVOY.xml:S1:2507:6	event	NNS	O	O
.	YERVOY.xml:S1:2513:1	.	.	O	O

Table	YERVOY.xml:S1:2519:5	tabl	JJ	O	O
1	YERVOY.xml:S1:2525:1	1	CD	O	O
:	YERVOY.xml:S1:2526:1	:	:	O	O
Selected	YERVOY.xml:S1:2532:8	select	VBN	O	O
Adverse	YERVOY.xml:S1:2541:7	advers	NNP	O	O
Reactions	YERVOY.xml:S1:2549:9	reaction	NNP	O	O
in	YERVOY.xml:S1:2559:2	in	IN	O	O
Study	YERVOY.xml:S1:2562:5	studi	NNP	O	O
1	YERVOY.xml:S1:2568:1	1	CD	O	O

a	YERVOY.xml:S1:2574:1	a	DT	O	O
Incidences	YERVOY.xml:S1:2580:10	incid	NNP	O	O
presented	YERVOY.xml:S1:2591:9	present	VBN	O	O
in	YERVOY.xml:S1:2601:2	in	IN	O	O
this	YERVOY.xml:S1:2604:4	thi	DT	O	O
table	YERVOY.xml:S1:2609:5	tabl	NN	O	O
are	YERVOY.xml:S1:2615:3	are	VBP	O	O
based	YERVOY.xml:S1:2619:5	base	VBN	O	O
on	YERVOY.xml:S1:2625:2	on	IN	O	O
reports	YERVOY.xml:S1:2628:7	report	NNS	O	O
of	YERVOY.xml:S1:2636:2	of	IN	O	O
adverse	YERVOY.xml:S1:2639:7	advers	JJ	O	O
events	YERVOY.xml:S1:2647:6	event	NNS	O	O
regardless	YERVOY.xml:S1:2654:10	regardless	NN	O	O
of	YERVOY.xml:S1:2665:2	of	IN	O	O
causality	YERVOY.xml:S1:2668:9	causal	NN	O	O
.	YERVOY.xml:S1:2677:1	.	.	O	O

Percentage	YERVOY.xml:S1:2723:10	percentag	NN	O	O

(	YERVOY.xml:S1:2734:1	(	(	O	O
)	YERVOY.xml:S1:2736:1	)	)	O	O
of	YERVOY.xml:S1:2738:2	of	IN	O	O
Patientsa	YERVOY.xml:S1:2741:9	patientsa	NNP	O	O

YERVOY3	YERVOY.xml:S1:2793:7	yervoy3	NNP	O	O
mg	YERVOY.xml:S1:2801:2	mg	VBD	O	O
kgn	YERVOY.xml:S1:2804:3	kgn	$	O	O
131	YERVOY.xml:S1:2808:3	131	CD	O	O
YERVOY3	YERVOY.xml:S1:2815:7	yervoy3	NNP	O	O
mg	YERVOY.xml:S1:2823:2	mg	NN	O	O
kg	YERVOY.xml:S1:2826:2	kg	NN	O	O
gp100n	YERVOY.xml:S1:2829:6	gp100n	VBD	O	O
380	YERVOY.xml:S1:2836:3	380	CD	O	O
gp100n	YERVOY.xml:S1:2843:6	gp100n	NN	O	O
132	YERVOY.xml:S1:2850:3	132	CD	O	O

System	YERVOY.xml:S1:2860:6	system	NNP	O	O
Organ	YERVOY.xml:S1:2867:5	organ	NNP	O	O
Class	YERVOY.xml:S1:2873:5	class	NNP	O	O
Preferred	YERVOY.xml:S1:2879:9	prefer	NNP	O	O
Term	YERVOY.xml:S1:2889:4	term	NNP	O	O
AnyGrade	YERVOY.xml:S1:2897:8	anygrad	NNP	O	O
Grade3	YERVOY.xml:S1:2910:6	grade3	NNP	O	O
-	YERVOY.xml:S1:2916:1	-	:	O	O
5	YERVOY.xml:S1:2917:1	5	CD	O	O
AnyGrade	YERVOY.xml:S1:2923:8	anygrad	NNP	O	O
Grade3	YERVOY.xml:S1:2936:6	grade3	NNP	O	O
-	YERVOY.xml:S1:2942:1	-	:	O	O
5	YERVOY.xml:S1:2943:1	5	CD	O	O
AnyGrade	YERVOY.xml:S1:2949:8	anygrad	NNP	O	O
Grade3	YERVOY.xml:S1:2962:6	grade3	NNP	O	O
-	YERVOY.xml:S1:2968:1	-	:	O	O
5	YERVOY.xml:S1:2969:1	5	CD	O	O

Gastrointestinal	YERVOY.xml:S1:2978:16	gastrointestin	JJ	O	O
Disorders	YERVOY.xml:S1:2995:9	disord	NNS	O	O

Diarrhea	YERVOY.xml:S1:3034:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
32	YERVOY.xml:S1:3066:2	32	CD	O	O
5	YERVOY.xml:S1:3079:1	5	CD	O	O
37	YERVOY.xml:S1:3092:2	37	CD	O	O
4	YERVOY.xml:S1:3105:1	4	CD	O	O
20	YERVOY.xml:S1:3118:2	20	CD	O	O
1	YERVOY.xml:S1:3131:1	1	CD	O	O

Colitis	YERVOY.xml:S1:3151:7	coliti	NN	B-AdverseReaction	B-AdverseReaction
8	YERVOY.xml:S1:3183:1	8	CD	O	O
5	YERVOY.xml:S1:3196:1	5	CD	O	O
5	YERVOY.xml:S1:3209:1	5	CD	O	O
3	YERVOY.xml:S1:3222:1	3	CD	O	O
2	YERVOY.xml:S1:3235:1	2	CD	O	O
0	YERVOY.xml:S1:3248:1	0	CD	O	O

Skin	YERVOY.xml:S1:3264:4	skin	NNP	O	O
and	YERVOY.xml:S1:3269:3	and	CC	O	O
Subcutaneous	YERVOY.xml:S1:3273:12	subcutan	NNP	O	O
Tissue	YERVOY.xml:S1:3286:6	tissu	NNP	O	O
Disorders	YERVOY.xml:S1:3293:9	disord	NNP	O	O

Pruritus	YERVOY.xml:S1:3326:8	pruritu	NNP	B-AdverseReaction	B-AdverseReaction
31	YERVOY.xml:S1:3358:2	31	CD	O	O
0	YERVOY.xml:S1:3371:1	0	CD	O	O
21	YERVOY.xml:S1:3384:2	21	CD	O	O
1	YERVOY.xml:S1:3398:1	1	CD	O	O
11	YERVOY.xml:S1:3410:2	11	CD	O	O
0	YERVOY.xml:S1:3423:1	0	CD	O	O

Rash	YERVOY.xml:S1:3443:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
29	YERVOY.xml:S1:3475:2	29	CD	O	O
2	YERVOY.xml:S1:3488:1	2	CD	O	O
25	YERVOY.xml:S1:3501:2	25	CD	O	O
2	YERVOY.xml:S1:3514:1	2	CD	O	O
8	YERVOY.xml:S1:3527:1	8	CD	O	O
0	YERVOY.xml:S1:3540:1	0	CD	O	O

General	YERVOY.xml:S1:3556:7	gener	NNP	O	O
Disorders	YERVOY.xml:S1:3564:9	disord	NNP	O	O
and	YERVOY.xml:S1:3574:3	and	CC	O	O
Administration	YERVOY.xml:S1:3578:14	administr	NNP	O	O
Site	YERVOY.xml:S1:3593:4	site	NNP	O	O
Conditions	YERVOY.xml:S1:3598:10	condit	NNS	O	O

Fatigue	YERVOY.xml:S1:3632:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
41	YERVOY.xml:S1:3664:2	41	CD	O	O
7	YERVOY.xml:S1:3677:1	7	CD	O	O
34	YERVOY.xml:S1:3690:2	34	CD	O	O
5	YERVOY.xml:S1:3703:1	5	CD	O	O
31	YERVOY.xml:S1:3716:2	31	CD	O	O
3	YERVOY.xml:S1:3729:1	3	CD	O	O

Table	YERVOY.xml:S1:3756:5	tabl	JJ	O	O
2	YERVOY.xml:S1:3762:1	2	CD	O	O
presents	YERVOY.xml:S1:3764:8	present	VBZ	O	O
the	YERVOY.xml:S1:3773:3	the	DT	O	O
per	YERVOY.xml:S1:3777:3	per	IN	O	O
-	YERVOY.xml:S1:3780:1	-	:	O	O
patient	YERVOY.xml:S1:3781:7	patient	NN	O	O
incidence	YERVOY.xml:S1:3789:9	incid	NN	O	O
of	YERVOY.xml:S1:3799:2	of	IN	O	O
severe	YERVOY.xml:S1:3802:6	sever	JJ	O	O
,	YERVOY.xml:S1:3808:1	,	,	O	O
life	YERVOY.xml:S1:3810:4	life	NN	O	O
-	YERVOY.xml:S1:3814:1	-	:	O	O
threatening	YERVOY.xml:S1:3815:11	threaten	NN	O	O
,	YERVOY.xml:S1:3826:1	,	,	O	O
or	YERVOY.xml:S1:3828:2	or	CC	O	O
fatal	YERVOY.xml:S1:3831:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
immune	YERVOY.xml:S1:3837:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S1:3843:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S1:3844:8	mediat	JJ	I-AdverseReaction	O
adverse	YERVOY.xml:S1:3853:7	advers	JJ	I-AdverseReaction	O
reactions	YERVOY.xml:S1:3861:9	reaction	NNS	I-AdverseReaction	O
from	YERVOY.xml:S1:3871:4	from	IN	O	O
Study	YERVOY.xml:S1:3876:5	studi	NNP	O	O
1	YERVOY.xml:S1:3882:1	1	CD	O	O
.	YERVOY.xml:S1:3883:1	.	.	O	O

Table	YERVOY.xml:S1:3889:5	tabl	NN	O	O

2	YERVOY.xml:S1:3895:1	2	CD	O	O
:	YERVOY.xml:S1:3896:1	:	:	O	O
Severe	YERVOY.xml:S1:3902:6	sever	JJ	O	O
to	YERVOY.xml:S1:3909:2	to	TO	O	O
Fatal	YERVOY.xml:S1:3912:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
Immune	YERVOY.xml:S1:3918:6	immun	NNP	B-AdverseReaction	O
-	YERVOY.xml:S1:3924:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S1:3925:8	mediat	VBD	I-AdverseReaction	O
Adverse	YERVOY.xml:S1:3934:7	advers	JJ	I-AdverseReaction	O
Reactions	YERVOY.xml:S1:3942:9	reaction	NNP	I-AdverseReaction	O
in	YERVOY.xml:S1:3952:2	in	IN	O	O
Study	YERVOY.xml:S1:3955:5	studi	NNP	O	O
1	YERVOY.xml:S1:3961:1	1	CD	O	O

a	YERVOY.xml:S1:3967:1	a	DT	O	O
Including	YERVOY.xml:S1:3973:9	includ	NNP	O	O
fatal	YERVOY.xml:S1:3983:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
outcome	YERVOY.xml:S1:3989:7	outcom	NN	O	O
.	YERVOY.xml:S1:3996:1	.	.	O	O

b	YERVOY.xml:S1:3999:1	b	NN	O	O
Including	YERVOY.xml:S1:4005:9	includ	NNP	O	O
intestinal	YERVOY.xml:S1:4015:10	intestin	JJ	B-AdverseReaction	B-AdverseReaction
perforation	YERVOY.xml:S1:4026:11	perfor	NN	I-AdverseReaction	I-AdverseReaction
.	YERVOY.xml:S1:4037:1	.	.	O	O

c	YERVOY.xml:S1:4040:1	c	NNS	O	O
Underlying	YERVOY.xml:S1:4046:10	underli	VBG	O	O
etiology	YERVOY.xml:S1:4057:8	etiolog	NN	O	O
not	YERVOY.xml:S1:4066:3	not	RB	O	O
established	YERVOY.xml:S1:4070:11	establish	VBN	O	O
.	YERVOY.xml:S1:4081:1	.	.	O	O

Percentage	YERVOY.xml:S1:4133:10	percentag	NN	O	O

(	YERVOY.xml:S1:4144:1	(	(	O	O
)	YERVOY.xml:S1:4146:1	)	)	O	O
of	YERVOY.xml:S1:4148:2	of	IN	O	O
Patients	YERVOY.xml:S1:4151:8	patient	NNS	O	O

YERVOY3	YERVOY.xml:S1:4210:7	yervoy3	NNP	O	O
mg	YERVOY.xml:S1:4218:2	mg	VBD	O	O
kgn	YERVOY.xml:S1:4221:3	kgn	$	O	O
131	YERVOY.xml:S1:4225:3	131	CD	O	O
YERVOY3	YERVOY.xml:S1:4242:7	yervoy3	NNP	O	O
mg	YERVOY.xml:S1:4250:2	mg	NN	O	O
kg	YERVOY.xml:S1:4253:2	kg	NN	O	O
gp100n	YERVOY.xml:S1:4256:6	gp100n	VBD	O	O
380	YERVOY.xml:S1:4263:3	380	CD	O	O

Any	YERVOY.xml:S1:4277:3	ani	DT	O	O
Immune	YERVOY.xml:S1:4281:6	immun	NNP	O	O
-	YERVOY.xml:S1:4287:1	-	:	O	O
mediated	YERVOY.xml:S1:4288:8	mediat	VBD	O	O
Adverse	YERVOY.xml:S1:4297:7	advers	JJ	O	O
Reaction	YERVOY.xml:S1:4305:8	reaction	NNP	O	O
15	YERVOY.xml:S1:4319:2	15	CD	O	O
12	YERVOY.xml:S1:4351:2	12	CD	O	O

Enterocolitisa	YERVOY.xml:S1:4386:14	enterocolitisa	NNP	B-AdverseReaction	O
,	YERVOY.xml:S1:4400:1	,	,	O	O
b	YERVOY.xml:S1:4401:1	b	VBD	O	O
7	YERVOY.xml:S1:4428:1	7	CD	O	O
7	YERVOY.xml:S1:4460:1	7	CD	O	O

Hepatotoxicitya	YERVOY.xml:S1:4495:15	hepatotoxicitya	NNP	B-AdverseReaction	B-AdverseReaction
1	YERVOY.xml:S1:4537:1	1	CD	O	O
2	YERVOY.xml:S1:4569:1	2	CD	O	O

Dermatitisa	YERVOY.xml:S1:4604:11	dermatitisa	NNP	B-AdverseReaction	B-AdverseReaction
2	YERVOY.xml:S1:4646:1	2	CD	O	O
3	YERVOY.xml:S1:4678:1	3	CD	O	O

Neuropathya	YERVOY.xml:S1:4713:11	neuropathya	NNP	B-AdverseReaction	B-AdverseReaction
1	YERVOY.xml:S1:4755:1	1	CD	O	O
1	YERVOY.xml:S1:4788:1	1	CD	O	O

Endocrinopathy	YERVOY.xml:S1:4822:14	endocrinopathi	JJ	B-AdverseReaction	O
4	YERVOY.xml:S1:4864:1	4	CD	O	O
1	YERVOY.xml:S1:4896:1	1	CD	O	O

Hypopituitarism	YERVOY.xml:S1:4935:15	hypopituitar	NNP	B-AdverseReaction	B-AdverseReaction
4	YERVOY.xml:S1:4973:1	4	CD	O	O
1	YERVOY.xml:S1:5005:1	1	CD	O	O

Adrenal	YERVOY.xml:S1:5044:7	adren	NNP	B-AdverseReaction	B-AdverseReaction
insufficiency	YERVOY.xml:S1:5052:13	insuffici	NN	I-AdverseReaction	I-AdverseReaction
0	YERVOY.xml:S1:5082:1	0	CD	O	O
1	YERVOY.xml:S1:5114:1	1	CD	O	O

Other	YERVOY.xml:S1:5149:5	other	JJ	O	O

Pneumonitis	YERVOY.xml:S1:5262:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
0	YERVOY.xml:S1:5300:1	0	CD	O	O
1	YERVOY.xml:S1:5333:1	1	CD	O	O

Meningitis	YERVOY.xml:S1:5371:10	mening	NNP	B-AdverseReaction	B-AdverseReaction
0	YERVOY.xml:S1:5409:1	0	CD	O	O
1	YERVOY.xml:S1:5442:1	1	CD	O	O

Nephritis	YERVOY.xml:S1:5480:9	nephriti	RB	B-AdverseReaction	B-AdverseReaction
1	YERVOY.xml:S1:5518:1	1	CD	O	O
0	YERVOY.xml:S1:5550:1	0	CD	O	O

Eosinophiliac	YERVOY.xml:S1:5589:13	eosinophiliac	NNP	B-AdverseReaction	B-AdverseReaction
1	YERVOY.xml:S1:5627:1	1	CD	O	O
0	YERVOY.xml:S1:5659:1	0	CD	O	O

Pericarditisa	YERVOY.xml:S1:5698:13	pericarditisa	NNP	B-AdverseReaction	O
,	YERVOY.xml:S1:5711:1	,	,	O	O
c	YERVOY.xml:S1:5712:1	c	VBD	O	O
0	YERVOY.xml:S1:5736:1	0	CD	O	O
1	YERVOY.xml:S1:5769:1	1	CD	O	O

Across	YERVOY.xml:S1:5810:6	across	IN	O	O
clinical	YERVOY.xml:S1:5817:8	clinic	JJ	O	O
studies	YERVOY.xml:S1:5826:7	studi	NNS	O	O
that	YERVOY.xml:S1:5834:4	that	WDT	O	O
utilized	YERVOY.xml:S1:5839:8	util	VBD	O	O
YERVOY	YERVOY.xml:S1:5848:6	yervoy	NNP	O	O
doses	YERVOY.xml:S1:5855:5	dose	NNS	O	O
ranging	YERVOY.xml:S1:5861:7	rang	VBG	O	O
from	YERVOY.xml:S1:5869:4	from	IN	O	O
0.3	YERVOY.xml:S1:5874:3	0.3	CD	O	O
to	YERVOY.xml:S1:5878:2	to	TO	O	O
10	YERVOY.xml:S1:5881:2	10	CD	O	O
mg	YERVOY.xml:S1:5884:2	mg	NN	O	O
kg	YERVOY.xml:S1:5887:2	kg	NN	O	O
,	YERVOY.xml:S1:5889:1	,	,	O	O
the	YERVOY.xml:S1:5891:3	the	DT	O	O
following	YERVOY.xml:S1:5895:9	follow	JJ	O	O
adverse	YERVOY.xml:S1:5905:7	advers	JJ	O	O
reactions	YERVOY.xml:S1:5913:9	reaction	NNS	O	O
were	YERVOY.xml:S1:5923:4	were	VBD	O	O
also	YERVOY.xml:S1:5928:4	also	RB	O	O
reported	YERVOY.xml:S1:5933:8	report	VBN	O	O
(	YERVOY.xml:S1:5942:1	(	(	O	O
incidence	YERVOY.xml:S1:5943:9	incid	NN	O	O
less	YERVOY.xml:S1:5953:4	less	JJR	O	O
than	YERVOY.xml:S1:5958:4	than	IN	O	O
1%	YERVOY.xml:S1:5963:2	1%	CD	O	O
unless	YERVOY.xml:S1:5966:6	unless	IN	O	O
otherwise	YERVOY.xml:S1:5973:9	otherwis	RB	O	O
noted	YERVOY.xml:S1:5983:5	note	VBN	O	O
)	YERVOY.xml:S1:5988:1	)	)	O	O
:	YERVOY.xml:S1:5989:1	:	:	O	O
urticaria	YERVOY.xml:S1:5991:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
(	YERVOY.xml:S1:6001:1	(	(	O	O
2%	YERVOY.xml:S1:6002:2	2%	CD	O	O
)	YERVOY.xml:S1:6004:1	)	)	O	O
,	YERVOY.xml:S1:6005:1	,	,	O	O
large	YERVOY.xml:S1:6007:5	larg	JJ	B-AdverseReaction	B-AdverseReaction
intestinal	YERVOY.xml:S1:6013:10	intestin	JJ	I-AdverseReaction	I-AdverseReaction
ulcer	YERVOY.xml:S1:6024:5	ulcer	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S1:6029:1	,	,	O	O
esophagitis	YERVOY.xml:S1:6031:11	esophag	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S1:6042:1	,	,	O	O
acute	YERVOY.xml:S1:6044:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	YERVOY.xml:S1:6050:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
distress	YERVOY.xml:S1:6062:8	distress	NN	I-AdverseReaction	I-AdverseReaction
syndrome	YERVOY.xml:S1:6071:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S1:6079:1	,	,	O	O
renal	YERVOY.xml:S1:6081:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	YERVOY.xml:S1:6087:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S1:6094:1	,	,	O	O
and	YERVOY.xml:S1:6096:3	and	CC	O	O
infusion	YERVOY.xml:S1:6100:8	infus	NN	B-AdverseReaction	B-AdverseReaction
reaction	YERVOY.xml:S1:6109:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
.	YERVOY.xml:S1:6117:1	.	.	O	O

Based	YERVOY.xml:S1:6123:5	base	VBN	O	O

on	YERVOY.xml:S1:6129:2	on	IN	O	O
the	YERVOY.xml:S1:6132:3	the	DT	O	O
experience	YERVOY.xml:S1:6136:10	experi	NN	O	O
in	YERVOY.xml:S1:6147:2	in	IN	O	O
the	YERVOY.xml:S1:6150:3	the	DT	O	O
entire	YERVOY.xml:S1:6154:6	entir	JJ	O	O
clinical	YERVOY.xml:S1:6161:8	clinic	JJ	O	O
program	YERVOY.xml:S1:6170:7	program	NN	O	O
for	YERVOY.xml:S1:6178:3	for	IN	O	O
melanoma	YERVOY.xml:S1:6182:8	melanoma	NN	O	O
,	YERVOY.xml:S1:6190:1	,	,	O	O
the	YERVOY.xml:S1:6192:3	the	DT	O	O
incidence	YERVOY.xml:S1:6196:9	incid	NN	O	O
and	YERVOY.xml:S1:6206:3	and	CC	O	O
severity	YERVOY.xml:S1:6210:8	sever	NN	O	O
of	YERVOY.xml:S1:6219:2	of	IN	O	O
enterocolitis	YERVOY.xml:S1:6222:13	enterocol	NN	B-AdverseReaction	O
and	YERVOY.xml:S1:6236:3	and	CC	O	O
hepatitis	YERVOY.xml:S1:6240:9	hepat	NN	B-AdverseReaction	B-AdverseReaction
appear	YERVOY.xml:S1:6250:6	appear	VBP	O	O
to	YERVOY.xml:S1:6257:2	to	TO	O	O
be	YERVOY.xml:S1:6260:2	be	VB	O	O
dose	YERVOY.xml:S1:6263:4	dose	JJ	O	O
dependent	YERVOY.xml:S1:6268:9	depend	NN	O	O
.	YERVOY.xml:S1:6277:1	.	.	O	O

6.2	YERVOY.xml:S1:6285:3	6.2	CD	O	O
Postmarketing	YERVOY.xml:S1:6291:13	postmarket	VBG	O	O
Experience	YERVOY.xml:S1:6305:10	experi	NN	O	O

The	YERVOY.xml:S1:6319:3	the	DT	O	O
following	YERVOY.xml:S1:6323:9	follow	JJ	O	O
adverse	YERVOY.xml:S1:6333:7	advers	JJ	O	O
reactions	YERVOY.xml:S1:6341:9	reaction	NNS	O	O
have	YERVOY.xml:S1:6351:4	have	VBP	O	O
been	YERVOY.xml:S1:6356:4	been	VBN	O	O
identified	YERVOY.xml:S1:6361:10	identifi	VBN	O	O
during	YERVOY.xml:S1:6372:6	dure	IN	O	O
postapproval	YERVOY.xml:S1:6379:12	postapprov	JJ	O	O
use	YERVOY.xml:S1:6392:3	use	NN	O	O
of	YERVOY.xml:S1:6396:2	of	IN	O	O
YERVOY	YERVOY.xml:S1:6399:6	yervoy	NNP	O	O
.	YERVOY.xml:S1:6405:1	.	.	O	O

Because	YERVOY.xml:S1:6407:7	becaus	IN	O	O
these	YERVOY.xml:S1:6415:5	these	DT	O	O
reactions	YERVOY.xml:S1:6421:9	reaction	NNS	O	O
are	YERVOY.xml:S1:6431:3	are	VBP	O	O
reported	YERVOY.xml:S1:6435:8	report	VBN	O	O
voluntarily	YERVOY.xml:S1:6444:11	voluntarili	RB	O	O
from	YERVOY.xml:S1:6456:4	from	IN	O	O
a	YERVOY.xml:S1:6461:1	a	DT	O	O
population	YERVOY.xml:S1:6463:10	popul	NN	O	O
of	YERVOY.xml:S1:6474:2	of	IN	O	O
uncertain	YERVOY.xml:S1:6477:9	uncertain	JJ	O	O
size	YERVOY.xml:S1:6487:4	size	NN	O	O
,	YERVOY.xml:S1:6491:1	,	,	O	O
it	YERVOY.xml:S1:6493:2	it	PRP	O	O
is	YERVOY.xml:S1:6496:2	is	VBZ	O	O
not	YERVOY.xml:S1:6499:3	not	RB	O	O
always	YERVOY.xml:S1:6503:6	alway	RB	O	O
possible	YERVOY.xml:S1:6510:8	possibl	JJ	O	O
to	YERVOY.xml:S1:6519:2	to	TO	O	O
reliably	YERVOY.xml:S1:6522:8	reliabl	VB	O	O
estimate	YERVOY.xml:S1:6531:8	estim	VB	O	O
their	YERVOY.xml:S1:6540:5	their	PRP$	O	O
frequency	YERVOY.xml:S1:6546:9	frequenc	NN	O	O
or	YERVOY.xml:S1:6556:2	or	CC	O	O
establish	YERVOY.xml:S1:6559:9	establish	VB	O	O
a	YERVOY.xml:S1:6569:1	a	DT	O	O
causal	YERVOY.xml:S1:6571:6	causal	NN	O	O
relationship	YERVOY.xml:S1:6578:12	relationship	NN	O	O
to	YERVOY.xml:S1:6591:2	to	TO	O	O
drug	YERVOY.xml:S1:6594:4	drug	NN	O	O
exposure	YERVOY.xml:S1:6599:8	exposur	NN	O	O
.	YERVOY.xml:S1:6607:1	.	.	O	O

Skin	YERVOY.xml:S1:6615:4	skin	NNP	O	O
and	YERVOY.xml:S1:6620:3	and	CC	O	O
Subcutaneous	YERVOY.xml:S1:6624:12	subcutan	NNP	O	O
Tissue	YERVOY.xml:S1:6637:6	tissu	NNP	O	O
Disorders	YERVOY.xml:S1:6644:9	disord	NNP	O	O
:	YERVOY.xml:S1:6653:1	:	:	O	O
Drug	YERVOY.xml:S1:6656:4	drug	NNP	B-AdverseReaction	B-AdverseReaction
reaction	YERVOY.xml:S1:6661:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
with	YERVOY.xml:S1:6670:4	with	IN	I-AdverseReaction	I-AdverseReaction
eosinophilia	YERVOY.xml:S1:6675:12	eosinophilia	NNS	I-AdverseReaction	I-AdverseReaction
and	YERVOY.xml:S1:6688:3	and	CC	I-AdverseReaction	I-AdverseReaction
systemic	YERVOY.xml:S1:6692:8	system	JJ	I-AdverseReaction	I-AdverseReaction
symptoms	YERVOY.xml:S1:6701:8	symptom	NNS	I-AdverseReaction	I-AdverseReaction
(	YERVOY.xml:S1:6710:1	(	(	O	O
DRESS	YERVOY.xml:S1:6711:5	dress	NNP	B-AdverseReaction	B-AdverseReaction
syndrome	YERVOY.xml:S1:6717:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
)	YERVOY.xml:S1:6725:1	)	)	O	O

6.3	YERVOY.xml:S1:6733:3	6.3	CD	O	O
Immunogenicity	YERVOY.xml:S1:6739:14	immunogen	NN	O	O

In	YERVOY.xml:S1:6757:2	In	IN	O	O
clinical	YERVOY.xml:S1:6760:8	clinic	JJ	O	O
studies	YERVOY.xml:S1:6769:7	studi	NNS	O	O
,	YERVOY.xml:S1:6776:1	,	,	O	O
1.1%	YERVOY.xml:S1:6778:4	1.1%	CD	O	O
of	YERVOY.xml:S1:6783:2	of	IN	O	O
1024	YERVOY.xml:S1:6786:4	1024	CD	O	O
evaluable	YERVOY.xml:S1:6791:9	evalu	JJ	O	O
patients	YERVOY.xml:S1:6801:8	patient	NNS	O	O
tested	YERVOY.xml:S1:6810:6	test	VBD	O	O
positive	YERVOY.xml:S1:6817:8	posit	JJ	O	O
for	YERVOY.xml:S1:6826:3	for	IN	O	O
binding	YERVOY.xml:S1:6830:7	bind	VBG	O	O
antibodies	YERVOY.xml:S1:6838:10	antibodi	NNS	O	O
against	YERVOY.xml:S1:6849:7	against	IN	O	O
ipilimumab	YERVOY.xml:S1:6857:10	ipilimumab	NN	O	O
in	YERVOY.xml:S1:6868:2	in	IN	O	O
an	YERVOY.xml:S1:6871:2	an	DT	O	O
electrochemiluminescent	YERVOY.xml:S1:6874:23	electrochemiluminesc	NN	O	O
(	YERVOY.xml:S1:6898:1	(	(	O	O
ECL	YERVOY.xml:S1:6899:3	ecl	NNP	O	O
)	YERVOY.xml:S1:6902:1	)	)	O	O
based	YERVOY.xml:S1:6904:5	base	VBN	O	O
assay	YERVOY.xml:S1:6910:5	assay	NN	O	O
.	YERVOY.xml:S1:6915:1	.	.	O	O

This	YERVOY.xml:S1:6917:4	thi	DT	O	O
assay	YERVOY.xml:S1:6922:5	assay	NN	O	O
has	YERVOY.xml:S1:6928:3	ha	VBZ	O	O
substantial	YERVOY.xml:S1:6932:11	substanti	JJ	O	O
limitations	YERVOY.xml:S1:6944:11	limit	NNS	O	O
in	YERVOY.xml:S1:6956:2	in	IN	O	O
detecting	YERVOY.xml:S1:6959:9	detect	VBG	O	O
anti	YERVOY.xml:S1:6969:4	anti	JJ	O	O
-	YERVOY.xml:S1:6973:1	-	:	O	O
ipilimumab	YERVOY.xml:S1:6974:10	ipilimumab	NN	O	O
antibodies	YERVOY.xml:S1:6985:10	antibodi	NNS	O	O
in	YERVOY.xml:S1:6996:2	in	IN	O	O
the	YERVOY.xml:S1:6999:3	the	DT	O	O
presence	YERVOY.xml:S1:7003:8	presenc	NN	O	O
of	YERVOY.xml:S1:7012:2	of	IN	O	O
ipilimumab	YERVOY.xml:S1:7015:10	ipilimumab	NN	O	O
.	YERVOY.xml:S1:7025:1	.	.	O	O

Infusion	YERVOY.xml:S1:7027:8	infus	NNP	B-AdverseReaction	O
-	YERVOY.xml:S1:7035:1	-	:	I-AdverseReaction	O
related	YERVOY.xml:S1:7036:7	relat	VBD	I-AdverseReaction	O
or	YERVOY.xml:S1:7044:2	or	CC	O	O
peri	YERVOY.xml:S1:7047:4	peri	JJ	B-AdverseReaction	O
-	YERVOY.xml:S1:7051:1	-	:	I-AdverseReaction	O
infusional	YERVOY.xml:S1:7052:10	infusion	JJ	I-AdverseReaction	O
reactions	YERVOY.xml:S1:7063:9	reaction	NNS	I-AdverseReaction	O
consistent	YERVOY.xml:S1:7073:10	consist	VBP	O	O
with	YERVOY.xml:S1:7084:4	with	IN	O	O
hypersensitivity	YERVOY.xml:S1:7089:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
or	YERVOY.xml:S1:7106:2	or	CC	O	O
anaphylaxis	YERVOY.xml:S1:7109:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
were	YERVOY.xml:S1:7121:4	were	VBD	O	O
not	YERVOY.xml:S1:7126:3	not	RB	O	O
reported	YERVOY.xml:S1:7130:8	report	VBN	O	O
in	YERVOY.xml:S1:7139:2	in	IN	O	O
these	YERVOY.xml:S1:7142:5	these	DT	O	O
11	YERVOY.xml:S1:7148:2	11	CD	O	O
patients	YERVOY.xml:S1:7151:8	patient	NNS	O	O
nor	YERVOY.xml:S1:7160:3	nor	CC	O	O
were	YERVOY.xml:S1:7164:4	were	VBD	O	O
neutralizing	YERVOY.xml:S1:7169:12	neutral	VBG	O	O
antibodies	YERVOY.xml:S1:7182:10	antibodi	NNS	O	O
against	YERVOY.xml:S1:7193:7	against	IN	O	O
ipilimumab	YERVOY.xml:S1:7201:10	ipilimumab	NN	O	O
detected	YERVOY.xml:S1:7212:8	detect	VBN	O	O
.	YERVOY.xml:S1:7220:1	.	.	O	O

Because	YERVOY.xml:S1:7226:7	becaus	IN	O	O
trough	YERVOY.xml:S1:7234:6	trough	JJ	O	O
levels	YERVOY.xml:S1:7241:6	level	NNS	O	O
of	YERVOY.xml:S1:7248:2	of	IN	O	O
ipilimumab	YERVOY.xml:S1:7251:10	ipilimumab	NN	O	O
interfere	YERVOY.xml:S1:7262:9	interfer	NN	O	O
with	YERVOY.xml:S1:7272:4	with	IN	O	O
the	YERVOY.xml:S1:7277:3	the	DT	O	O
ECL	YERVOY.xml:S1:7281:3	ecl	NNP	O	O
assay	YERVOY.xml:S1:7285:5	assay	NN	O	O
results	YERVOY.xml:S1:7291:7	result	NNS	O	O
,	YERVOY.xml:S1:7298:1	,	,	O	O
a	YERVOY.xml:S1:7300:1	a	DT	O	O
subset	YERVOY.xml:S1:7302:6	subset	NN	O	O
analysis	YERVOY.xml:S1:7309:8	analysi	NN	O	O
was	YERVOY.xml:S1:7318:3	wa	VBD	O	O
performed	YERVOY.xml:S1:7322:9	perform	VBN	O	O
in	YERVOY.xml:S1:7332:2	in	IN	O	O
the	YERVOY.xml:S1:7335:3	the	DT	O	O
dose	YERVOY.xml:S1:7339:4	dose	JJ	O	O
cohort	YERVOY.xml:S1:7344:6	cohort	NN	O	O
with	YERVOY.xml:S1:7351:4	with	IN	O	O
the	YERVOY.xml:S1:7356:3	the	DT	O	O
lowest	YERVOY.xml:S1:7360:6	lowest	JJS	O	O
trough	YERVOY.xml:S1:7367:6	trough	NN	O	O
levels	YERVOY.xml:S1:7374:6	level	NNS	O	O
.	YERVOY.xml:S1:7380:1	.	.	O	O

In	YERVOY.xml:S1:7382:2	In	IN	O	O
this	YERVOY.xml:S1:7385:4	thi	DT	O	O
analysis	YERVOY.xml:S1:7390:8	analysi	NN	O	O
,	YERVOY.xml:S1:7398:1	,	,	O	O
6.9%	YERVOY.xml:S1:7400:4	6.9%	CD	O	O
of	YERVOY.xml:S1:7405:2	of	IN	O	O
58	YERVOY.xml:S1:7408:2	58	CD	O	O
evaluable	YERVOY.xml:S1:7411:9	evalu	JJ	O	O
patients	YERVOY.xml:S1:7421:8	patient	NNS	O	O
,	YERVOY.xml:S1:7429:1	,	,	O	O
who	YERVOY.xml:S1:7431:3	who	WP	O	O
were	YERVOY.xml:S1:7435:4	were	VBD	O	O
treated	YERVOY.xml:S1:7440:7	treat	VBN	O	O
with	YERVOY.xml:S1:7448:4	with	IN	O	O
0.3	YERVOY.xml:S1:7453:3	0.3	CD	O	O
mg	YERVOY.xml:S1:7457:2	mg	NNS	O	O
kg	YERVOY.xml:S1:7460:2	kg	VBD	O	O
dose	YERVOY.xml:S1:7463:4	dose	RB	O	O
,	YERVOY.xml:S1:7467:1	,	,	O	O
tested	YERVOY.xml:S1:7469:6	test	VBD	O	O
positive	YERVOY.xml:S1:7476:8	posit	JJ	O	O
for	YERVOY.xml:S1:7485:3	for	IN	O	O
binding	YERVOY.xml:S1:7489:7	bind	VBG	O	O
antibodies	YERVOY.xml:S1:7497:10	antibodi	NNS	O	O
against	YERVOY.xml:S1:7508:7	against	IN	O	O
ipilimumab	YERVOY.xml:S1:7516:10	ipilimumab	NN	O	O
.	YERVOY.xml:S1:7526:1	.	.	O	O

Immunogenicity	YERVOY.xml:S1:7532:14	immunogen	NNP	O	O
assay	YERVOY.xml:S1:7547:5	assay	VBP	O	O
results	YERVOY.xml:S1:7553:7	result	NNS	O	O
are	YERVOY.xml:S1:7561:3	are	VBP	O	O
highly	YERVOY.xml:S1:7565:6	highli	RB	O	O
dependent	YERVOY.xml:S1:7572:9	depend	JJ	O	O
on	YERVOY.xml:S1:7582:2	on	IN	O	O
several	YERVOY.xml:S1:7585:7	sever	JJ	O	O
factors	YERVOY.xml:S1:7593:7	factor	NNS	O	O
including	YERVOY.xml:S1:7601:9	includ	VBG	O	O
assay	YERVOY.xml:S1:7611:5	assay	JJ	O	O
sensitivity	YERVOY.xml:S1:7617:11	sensit	NN	O	O
and	YERVOY.xml:S1:7629:3	and	CC	O	O
specificity	YERVOY.xml:S1:7633:11	specif	NN	O	O
,	YERVOY.xml:S1:7644:1	,	,	O	O
assay	YERVOY.xml:S1:7646:5	assay	VBP	O	O
methodology	YERVOY.xml:S1:7652:11	methodolog	NN	O	O
,	YERVOY.xml:S1:7663:1	,	,	O	O
sample	YERVOY.xml:S1:7665:6	sampl	NN	O	O
handling	YERVOY.xml:S1:7672:8	handl	NN	O	O
,	YERVOY.xml:S1:7680:1	,	,	O	O
timing	YERVOY.xml:S1:7682:6	time	NN	O	O
of	YERVOY.xml:S1:7689:2	of	IN	O	O
sample	YERVOY.xml:S1:7692:6	sampl	JJ	O	O
collection	YERVOY.xml:S1:7699:10	collect	NN	O	O
,	YERVOY.xml:S1:7709:1	,	,	O	O
concomitant	YERVOY.xml:S1:7711:11	concomit	JJ	O	O
medications	YERVOY.xml:S1:7723:11	medic	NNS	O	O
,	YERVOY.xml:S1:7734:1	,	,	O	O
and	YERVOY.xml:S1:7736:3	and	CC	O	O
underlying	YERVOY.xml:S1:7740:10	underli	JJ	O	O
disease	YERVOY.xml:S1:7751:7	diseas	NN	O	O
.	YERVOY.xml:S1:7758:1	.	.	O	O

For	YERVOY.xml:S1:7760:3	for	IN	O	O
these	YERVOY.xml:S1:7764:5	these	DT	O	O
reasons	YERVOY.xml:S1:7770:7	reason	NNS	O	O
,	YERVOY.xml:S1:7777:1	,	,	O	O
comparison	YERVOY.xml:S1:7779:10	comparison	NN	O	O
of	YERVOY.xml:S1:7790:2	of	IN	O	O
incidence	YERVOY.xml:S1:7793:9	incid	NN	O	O
of	YERVOY.xml:S1:7803:2	of	IN	O	O
antibodies	YERVOY.xml:S1:7806:10	antibodi	NNS	O	O
to	YERVOY.xml:S1:7817:2	to	TO	O	O
YERVOY	YERVOY.xml:S1:7820:6	yervoy	VB	O	O
with	YERVOY.xml:S1:7827:4	with	IN	O	O
the	YERVOY.xml:S1:7832:3	the	DT	O	O
incidences	YERVOY.xml:S1:7836:10	incid	NNS	O	O
of	YERVOY.xml:S1:7847:2	of	IN	O	O
antibodies	YERVOY.xml:S1:7850:10	antibodi	NNS	O	O
to	YERVOY.xml:S1:7861:2	to	TO	O	O
other	YERVOY.xml:S1:7864:5	other	JJ	O	O
products	YERVOY.xml:S1:7870:8	product	NNS	O	O
may	YERVOY.xml:S1:7879:3	may	MD	O	O
be	YERVOY.xml:S1:7883:2	be	VB	O	O
misleading	YERVOY.xml:S1:7886:10	mislead	VBG	O	O
.	YERVOY.xml:S1:7896:1	.	.	O	O
\n\n	YERVOY.xml:S2:0:2	\n\n	VB	O	O
BOXED	YERVOY.xml:S2:6:5	box	NNP	O	O
WARNING	YERVOY.xml:S2:12:7	warn	NNP	O	O
:	YERVOY.xml:S2:19:1	:	:	O	O
WARNING	YERVOY.xml:S2:21:7	warn	NN	O	O
:	YERVOY.xml:S2:28:1	:	:	O	O
IMMUNE	YERVOY.xml:S2:30:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S2:36:1	-	:	I-AdverseReaction	I-AdverseReaction
MEDIATED	YERVOY.xml:S2:37:8	mediat	NNP	I-AdverseReaction	I-AdverseReaction
ADVERSE	YERVOY.xml:S2:46:7	advers	NNP	I-AdverseReaction	I-AdverseReaction
REACTIONS	YERVOY.xml:S2:54:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
\n\n	YERVOY.xml:S2:63:2	\n\n	VBP	O	O
WARNING	YERVOY.xml:S2:67:7	warn	NN	O	O
:	YERVOY.xml:S2:74:1	:	:	O	O
IMMUNE	YERVOY.xml:S2:76:6	immun	NNP	B-AdverseReaction	O
-	YERVOY.xml:S2:82:1	-	:	I-AdverseReaction	O
MEDIATED	YERVOY.xml:S2:83:8	mediat	NNP	I-AdverseReaction	O
ADVERSE	YERVOY.xml:S2:92:7	advers	NNP	I-AdverseReaction	O
REACTIONS	YERVOY.xml:S2:100:9	reaction	NNP	I-AdverseReaction	O
\n\n	YERVOY.xml:S2:109:2	\n\n	NNP	O	O
YERVOY	YERVOY.xml:S2:115:6	yervoy	NNP	O	O
can	YERVOY.xml:S2:122:3	can	MD	O	O
result	YERVOY.xml:S2:126:6	result	VB	O	O
in	YERVOY.xml:S2:133:2	in	IN	O	O
severe	YERVOY.xml:S2:136:6	sever	JJ	O	O
and	YERVOY.xml:S2:143:3	and	CC	O	O
fatal	YERVOY.xml:S2:147:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
immune	YERVOY.xml:S2:153:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S2:159:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S2:160:8	mediat	JJ	I-AdverseReaction	I-AdverseReaction
adverse	YERVOY.xml:S2:169:7	advers	JJ	I-AdverseReaction	I-AdverseReaction
reactions	YERVOY.xml:S2:177:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
due	YERVOY.xml:S2:187:3	due	JJ	O	O
to	YERVOY.xml:S2:191:2	to	TO	O	O
T	YERVOY.xml:S2:194:1	T	NNP	O	O
-	YERVOY.xml:S2:195:1	-	:	O	O
cell	YERVOY.xml:S2:196:4	cell	NN	O	O
activation	YERVOY.xml:S2:201:10	activ	NN	O	O
and	YERVOY.xml:S2:212:3	and	CC	O	O
proliferation	YERVOY.xml:S2:216:13	prolifer	NN	O	O
.	YERVOY.xml:S2:229:1	.	.	O	O

These	YERVOY.xml:S2:231:5	these	DT	O	O
immune	YERVOY.xml:S2:237:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S2:243:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S2:244:8	mediat	VBN	I-AdverseReaction	O
reactions	YERVOY.xml:S2:253:9	reaction	NNS	I-AdverseReaction	O
may	YERVOY.xml:S2:263:3	may	MD	O	O
involve	YERVOY.xml:S2:267:7	involv	VB	O	O
any	YERVOY.xml:S2:275:3	ani	DT	O	O
organ	YERVOY.xml:S2:279:5	organ	JJ	O	O
system	YERVOY.xml:S2:285:6	system	NN	O	O
;	YERVOY.xml:S2:291:1	;	:	O	O
however	YERVOY.xml:S2:293:7	howev	RB	O	O
,	YERVOY.xml:S2:300:1	,	,	O	O
the	YERVOY.xml:S2:302:3	the	DT	O	O
most	YERVOY.xml:S2:306:4	most	RBS	O	O
common	YERVOY.xml:S2:311:6	common	JJ	O	O
severe	YERVOY.xml:S2:318:6	sever	JJ	O	O
immune	YERVOY.xml:S2:325:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S2:331:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S2:332:8	mediat	JJ	I-AdverseReaction	O
adverse	YERVOY.xml:S2:341:7	advers	JJ	I-AdverseReaction	O
reactions	YERVOY.xml:S2:349:9	reaction	NNS	I-AdverseReaction	O
are	YERVOY.xml:S2:359:3	are	VBP	O	O
enterocolitis	YERVOY.xml:S2:363:13	enterocol	RB	B-AdverseReaction	O
,	YERVOY.xml:S2:376:1	,	,	O	O
hepatitis	YERVOY.xml:S2:378:9	hepat	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S2:387:1	,	,	O	O
dermatitis	YERVOY.xml:S2:389:10	dermat	NN	B-AdverseReaction	B-AdverseReaction
(	YERVOY.xml:S2:400:1	(	(	O	O
including	YERVOY.xml:S2:401:9	includ	VBG	O	O
toxic	YERVOY.xml:S2:411:5	toxic	NN	B-AdverseReaction	O
epidermal	YERVOY.xml:S2:417:9	epiderm	JJ	I-AdverseReaction	O
necrolysis	YERVOY.xml:S2:427:10	necrolysi	NN	I-AdverseReaction	O
)	YERVOY.xml:S2:437:1	)	)	O	O
,	YERVOY.xml:S2:438:1	,	,	O	O
neuropathy	YERVOY.xml:S2:440:10	neuropathi	JJ	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S2:450:1	,	,	O	O
and	YERVOY.xml:S2:452:3	and	CC	O	O
endocrinopathy	YERVOY.xml:S2:456:14	endocrinopathi	NN	B-AdverseReaction	O
.	YERVOY.xml:S2:470:1	.	.	O	O

The	YERVOY.xml:S2:472:3	the	DT	O	O
majority	YERVOY.xml:S2:476:8	major	NN	O	O
of	YERVOY.xml:S2:485:2	of	IN	O	O
these	YERVOY.xml:S2:488:5	these	DT	O	O
immune	YERVOY.xml:S2:494:6	immun	JJ	O	O
-	YERVOY.xml:S2:500:1	-	:	O	O
mediated	YERVOY.xml:S2:501:8	mediat	VBN	O	O
reactions	YERVOY.xml:S2:510:9	reaction	NNS	O	O
initially	YERVOY.xml:S2:520:9	initi	RB	O	O
manifested	YERVOY.xml:S2:530:10	manifest	VBD	O	O
during	YERVOY.xml:S2:541:6	dure	IN	O	O
treatment	YERVOY.xml:S2:548:9	treatment	NN	O	O
;	YERVOY.xml:S2:557:1	;	:	O	O
however	YERVOY.xml:S2:559:7	howev	RB	O	O
,	YERVOY.xml:S2:566:1	,	,	O	O
a	YERVOY.xml:S2:568:1	a	DT	O	O
minority	YERVOY.xml:S2:570:8	minor	NN	O	O
occurred	YERVOY.xml:S2:579:8	occur	VBD	O	O
weeks	YERVOY.xml:S2:588:5	week	NNS	O	O
to	YERVOY.xml:S2:594:2	to	TO	O	O
months	YERVOY.xml:S2:597:6	month	NNS	O	O
after	YERVOY.xml:S2:604:5	after	IN	O	O
discontinuation	YERVOY.xml:S2:610:15	discontinu	NN	O	O
of	YERVOY.xml:S2:626:2	of	IN	O	O
YERVOY	YERVOY.xml:S2:629:6	yervoy	NNP	O	O
.	YERVOY.xml:S2:635:1	.	.	O	O

Permanently	YERVOY.xml:S2:645:11	perman	RB	O	O
discontinue	YERVOY.xml:S2:657:11	discontinu	JJ	O	O
YERVOY	YERVOY.xml:S2:669:6	yervoy	NNP	O	O
and	YERVOY.xml:S2:676:3	and	CC	O	O
initiate	YERVOY.xml:S2:680:8	initi	VB	O	O
systemic	YERVOY.xml:S2:689:8	system	JJ	O	O
high	YERVOY.xml:S2:698:4	high	JJ	O	O
-	YERVOY.xml:S2:702:1	-	:	O	O
dose	YERVOY.xml:S2:703:4	dose	JJ	O	O
corticosteroid	YERVOY.xml:S2:708:14	corticosteroid	JJ	O	O
therapy	YERVOY.xml:S2:723:7	therapi	NN	O	O
for	YERVOY.xml:S2:731:3	for	IN	O	O
severe	YERVOY.xml:S2:735:6	sever	JJ	O	O
immune	YERVOY.xml:S2:742:6	immun	JJ	O	O
-	YERVOY.xml:S2:748:1	-	:	O	O
mediated	YERVOY.xml:S2:749:8	mediat	VBN	O	O
reactions	YERVOY.xml:S2:758:9	reaction	NNS	O	O
.	YERVOY.xml:S2:767:1	.	.	O	O

[	YERVOY.xml:S2:771:1	[	NNS	O	O
See	YERVOY.xml:S2:772:3	see	NNP	O	O
Dosage	YERVOY.xml:S2:778:6	dosag	NNP	O	O
and	YERVOY.xml:S2:785:3	and	CC	O	O
Administration	YERVOY.xml:S2:789:14	administr	NNP	O	O
(	YERVOY.xml:S2:804:1	(	(	O	O
2.2	YERVOY.xml:S2:805:3	2.2	CD	O	O
)	YERVOY.xml:S2:808:1	)	)	O	O
.	YERVOY.xml:S2:811:1	.	.	O	O
]	YERVOY.xml:S2:812:1	]	NN	O	O

Assess	YERVOY.xml:S2:824:6	assess	NN	O	O
patients	YERVOY.xml:S2:831:8	patient	NNS	O	O
for	YERVOY.xml:S2:840:3	for	IN	O	O
signs	YERVOY.xml:S2:844:5	sign	NNS	O	O
and	YERVOY.xml:S2:850:3	and	CC	O	O
symptoms	YERVOY.xml:S2:854:8	symptom	NNS	O	O
of	YERVOY.xml:S2:863:2	of	IN	O	O
enterocolitis	YERVOY.xml:S2:866:13	enterocol	NN	O	O
,	YERVOY.xml:S2:879:1	,	,	O	O
dermatitis	YERVOY.xml:S2:881:10	dermat	NN	O	B-AdverseReaction
,	YERVOY.xml:S2:891:1	,	,	O	O
neuropathy	YERVOY.xml:S2:893:10	neuropathi	JJ	O	B-AdverseReaction
,	YERVOY.xml:S2:903:1	,	,	O	O
and	YERVOY.xml:S2:905:3	and	CC	O	O
endocrinopathy	YERVOY.xml:S2:909:14	endocrinopathi	JJ	O	O
and	YERVOY.xml:S2:924:3	and	CC	O	O
evaluate	YERVOY.xml:S2:928:8	evalu	JJ	O	O
clinical	YERVOY.xml:S2:937:8	clinic	JJ	O	O
chemistries	YERVOY.xml:S2:946:11	chemistri	NNS	O	O
including	YERVOY.xml:S2:958:9	includ	VBG	O	O
liver	YERVOY.xml:S2:968:5	liver	JJ	O	O
function	YERVOY.xml:S2:974:8	function	NN	O	O
tests	YERVOY.xml:S2:983:5	test	NNS	O	O
and	YERVOY.xml:S2:989:3	and	CC	O	O
thyroid	YERVOY.xml:S2:993:7	thyroid	JJ	O	O
function	YERVOY.xml:S2:1001:8	function	NN	O	O
tests	YERVOY.xml:S2:1010:5	test	NNS	O	O
at	YERVOY.xml:S2:1016:2	at	IN	O	O
baseline	YERVOY.xml:S2:1019:8	baselin	NN	O	O
and	YERVOY.xml:S2:1028:3	and	CC	O	O
before	YERVOY.xml:S2:1032:6	befor	IN	O	O
each	YERVOY.xml:S2:1039:4	each	DT	O	O
dose	YERVOY.xml:S2:1044:4	dose	NN	O	O
.	YERVOY.xml:S2:1048:1	.	.	O	O

[	YERVOY.xml:S2:1052:1	[	NNS	O	O
See	YERVOY.xml:S2:1053:3	see	NNP	O	O
Warnings	YERVOY.xml:S2:1059:8	warn	NNP	O	O
and	YERVOY.xml:S2:1068:3	and	CC	O	O
Precautions	YERVOY.xml:S2:1072:11	precaut	NNP	O	O
(	YERVOY.xml:S2:1084:1	(	(	O	O
5.1	YERVOY.xml:S2:1085:3	5.1	CD	O	O
,	YERVOY.xml:S2:1090:1	,	,	O	O
5.2	YERVOY.xml:S2:1094:3	5.2	CD	O	O
,	YERVOY.xml:S2:1099:1	,	,	O	O
5.3	YERVOY.xml:S2:1103:3	5.3	CD	O	O
,	YERVOY.xml:S2:1108:1	,	,	O	O
5.4	YERVOY.xml:S2:1112:3	5.4	CD	O	O
,	YERVOY.xml:S2:1117:1	,	,	O	O
5.5	YERVOY.xml:S2:1121:3	5.5	CD	O	O
)	YERVOY.xml:S2:1124:1	)	)	O	O
.	YERVOY.xml:S2:1127:1	.	.	O	O
]	YERVOY.xml:S2:1128:1	]	NN	O	O

EXCERPT	YERVOY.xml:S2:1140:7	excerpt	NN	O	O
:	YERVOY.xml:S2:1147:1	:	:	O	O
WARNING	YERVOY.xml:S2:1151:7	warn	NN	O	O
:	YERVOY.xml:S2:1158:1	:	:	O	O
IMMUNE	YERVOY.xml:S2:1160:6	immun	NNP	B-AdverseReaction	O
-	YERVOY.xml:S2:1166:1	-	:	I-AdverseReaction	O
MEDIATED	YERVOY.xml:S2:1167:8	mediat	NNP	I-AdverseReaction	O
ADVERSE	YERVOY.xml:S2:1176:7	advers	NNP	I-AdverseReaction	O
REACTIONS	YERVOY.xml:S2:1184:9	reaction	NNP	I-AdverseReaction	O
\n\n\n\n	YERVOY.xml:S2:1193:4	\n\n\n\n	NNP	O	O
See	YERVOY.xml:S2:1200:3	see	NNP	O	O
full	YERVOY.xml:S2:1204:4	full	JJ	O	O
prescribing	YERVOY.xml:S2:1209:11	prescrib	VBG	O	O
information	YERVOY.xml:S2:1221:11	inform	NN	O	O
for	YERVOY.xml:S2:1233:3	for	IN	O	O
complete	YERVOY.xml:S2:1237:8	complet	JJ	O	O
boxed	YERVOY.xml:S2:1246:5	box	JJ	O	O
warning	YERVOY.xml:S2:1252:7	warn	NN	O	O
.	YERVOY.xml:S2:1259:1	.	.	O	O

YERVOY	YERVOY.xml:S2:1269:6	yervoy	NN	O	O
can	YERVOY.xml:S2:1276:3	can	MD	O	O
result	YERVOY.xml:S2:1280:6	result	VB	O	O
in	YERVOY.xml:S2:1287:2	in	IN	O	O
severe	YERVOY.xml:S2:1290:6	sever	JJ	O	O
and	YERVOY.xml:S2:1297:3	and	CC	O	O
fatal	YERVOY.xml:S2:1301:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
immune	YERVOY.xml:S2:1307:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S2:1313:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S2:1314:8	mediat	JJ	I-AdverseReaction	I-AdverseReaction
adverse	YERVOY.xml:S2:1323:7	advers	JJ	I-AdverseReaction	I-AdverseReaction
reactions	YERVOY.xml:S2:1331:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
due	YERVOY.xml:S2:1341:3	due	JJ	O	O
to	YERVOY.xml:S2:1345:2	to	TO	O	O
T	YERVOY.xml:S2:1348:1	T	NNP	O	O
-	YERVOY.xml:S2:1349:1	-	:	O	O
cell	YERVOY.xml:S2:1350:4	cell	NN	O	O
activation	YERVOY.xml:S2:1355:10	activ	NN	O	O
and	YERVOY.xml:S2:1366:3	and	CC	O	O
proliferation	YERVOY.xml:S2:1370:13	prolifer	NN	O	O
.	YERVOY.xml:S2:1383:1	.	.	O	O

These	YERVOY.xml:S2:1385:5	these	DT	O	O
immune	YERVOY.xml:S2:1391:6	immun	JJ	O	O
-	YERVOY.xml:S2:1397:1	-	:	O	O
mediated	YERVOY.xml:S2:1398:8	mediat	VBN	O	O
reactions	YERVOY.xml:S2:1407:9	reaction	NNS	O	O
may	YERVOY.xml:S2:1417:3	may	MD	O	O
involve	YERVOY.xml:S2:1421:7	involv	VB	O	O
any	YERVOY.xml:S2:1429:3	ani	DT	O	O
organ	YERVOY.xml:S2:1433:5	organ	JJ	O	O
system	YERVOY.xml:S2:1439:6	system	NN	O	O
;	YERVOY.xml:S2:1445:1	;	:	O	O
however	YERVOY.xml:S2:1447:7	howev	RB	O	O
,	YERVOY.xml:S2:1454:1	,	,	O	O
the	YERVOY.xml:S2:1456:3	the	DT	O	O
most	YERVOY.xml:S2:1460:4	most	RBS	O	O
common	YERVOY.xml:S2:1465:6	common	JJ	O	O
severe	YERVOY.xml:S2:1472:6	sever	JJ	O	O
immune	YERVOY.xml:S2:1479:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S2:1485:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S2:1486:8	mediat	JJ	I-AdverseReaction	O
adverse	YERVOY.xml:S2:1495:7	advers	JJ	I-AdverseReaction	O
reactions	YERVOY.xml:S2:1503:9	reaction	NNS	I-AdverseReaction	O
are	YERVOY.xml:S2:1513:3	are	VBP	O	O
enterocolitis	YERVOY.xml:S2:1517:13	enterocol	RB	B-AdverseReaction	O
,	YERVOY.xml:S2:1530:1	,	,	O	O
hepatitis	YERVOY.xml:S2:1532:9	hepat	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S2:1541:1	,	,	O	O
dermatitis	YERVOY.xml:S2:1543:10	dermat	NN	B-AdverseReaction	B-AdverseReaction
(	YERVOY.xml:S2:1554:1	(	(	O	O
including	YERVOY.xml:S2:1555:9	includ	VBG	O	O
toxic	YERVOY.xml:S2:1565:5	toxic	NN	B-AdverseReaction	O
epidermal	YERVOY.xml:S2:1571:9	epiderm	JJ	I-AdverseReaction	O
necrolysis	YERVOY.xml:S2:1581:10	necrolysi	NN	I-AdverseReaction	O
)	YERVOY.xml:S2:1591:1	)	)	O	O
,	YERVOY.xml:S2:1592:1	,	,	O	O
neuropathy	YERVOY.xml:S2:1594:10	neuropathi	JJ	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S2:1604:1	,	,	O	O
and	YERVOY.xml:S2:1606:3	and	CC	O	O
endocrinopathy	YERVOY.xml:S2:1610:14	endocrinopathi	NN	B-AdverseReaction	O
.	YERVOY.xml:S2:1624:1	.	.	O	O

The	YERVOY.xml:S2:1626:3	the	DT	O	O
majority	YERVOY.xml:S2:1630:8	major	NN	O	O
of	YERVOY.xml:S2:1639:2	of	IN	O	O
these	YERVOY.xml:S2:1642:5	these	DT	O	O
immune	YERVOY.xml:S2:1648:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S2:1654:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S2:1655:8	mediat	VBN	I-AdverseReaction	O
reactions	YERVOY.xml:S2:1664:9	reaction	NNS	I-AdverseReaction	O
initially	YERVOY.xml:S2:1674:9	initi	RB	O	O
manifested	YERVOY.xml:S2:1684:10	manifest	VBD	O	O
during	YERVOY.xml:S2:1695:6	dure	IN	O	O
treatment	YERVOY.xml:S2:1702:9	treatment	NN	O	O
;	YERVOY.xml:S2:1711:1	;	:	O	O
however	YERVOY.xml:S2:1713:7	howev	RB	O	O
,	YERVOY.xml:S2:1720:1	,	,	O	O
a	YERVOY.xml:S2:1722:1	a	DT	O	O
minority	YERVOY.xml:S2:1724:8	minor	NN	O	O
occurred	YERVOY.xml:S2:1733:8	occur	VBD	O	O
weeks	YERVOY.xml:S2:1742:5	week	NNS	O	O
to	YERVOY.xml:S2:1748:2	to	TO	O	O
months	YERVOY.xml:S2:1751:6	month	NNS	O	O
after	YERVOY.xml:S2:1758:5	after	IN	O	O
discontinuation	YERVOY.xml:S2:1764:15	discontinu	NN	O	O
of	YERVOY.xml:S2:1780:2	of	IN	O	O
YERVOY	YERVOY.xml:S2:1783:6	yervoy	NNP	O	O
.	YERVOY.xml:S2:1789:1	.	.	O	O

Permanently	YERVOY.xml:S2:1799:11	perman	RB	O	O
discontinue	YERVOY.xml:S2:1811:11	discontinu	JJ	O	O
YERVOY	YERVOY.xml:S2:1823:6	yervoy	NNP	O	O
and	YERVOY.xml:S2:1830:3	and	CC	O	O
initiate	YERVOY.xml:S2:1834:8	initi	VB	O	O
systemic	YERVOY.xml:S2:1843:8	system	JJ	O	O
high	YERVOY.xml:S2:1852:4	high	JJ	O	O
-	YERVOY.xml:S2:1856:1	-	:	O	O
dose	YERVOY.xml:S2:1857:4	dose	JJ	O	O
corticosteroid	YERVOY.xml:S2:1862:14	corticosteroid	JJ	O	O
therapy	YERVOY.xml:S2:1877:7	therapi	NN	O	O
for	YERVOY.xml:S2:1885:3	for	IN	O	O
severe	YERVOY.xml:S2:1889:6	sever	JJ	O	O
immune	YERVOY.xml:S2:1896:6	immun	JJ	O	O
-	YERVOY.xml:S2:1902:1	-	:	O	O
mediated	YERVOY.xml:S2:1903:8	mediat	VBN	O	O
reactions	YERVOY.xml:S2:1912:9	reaction	NNS	O	O
.	YERVOY.xml:S2:1921:1	.	.	O	O

(	YERVOY.xml:S2:1925:1	(	(	O	O
2.2	YERVOY.xml:S2:1926:3	2.2	CD	O	O
)	YERVOY.xml:S2:1929:1	)	)	O	O
\n\n\n\n	YERVOY.xml:S2:1934:4	\n\n\n\n	NN	O	O
Assess	YERVOY.xml:S2:1941:6	assess	NNP	O	O
patients	YERVOY.xml:S2:1948:8	patient	NNS	O	O
for	YERVOY.xml:S2:1957:3	for	IN	O	O
signs	YERVOY.xml:S2:1961:5	sign	NNS	O	O
and	YERVOY.xml:S2:1967:3	and	CC	O	O
symptoms	YERVOY.xml:S2:1971:8	symptom	NNS	O	O
of	YERVOY.xml:S2:1980:2	of	IN	O	O
enterocolitis	YERVOY.xml:S2:1983:13	enterocol	NN	O	O
,	YERVOY.xml:S2:1996:1	,	,	O	O
dermatitis	YERVOY.xml:S2:1998:10	dermat	NN	O	B-AdverseReaction
,	YERVOY.xml:S2:2008:1	,	,	O	O
neuropathy	YERVOY.xml:S2:2010:10	neuropathi	JJ	O	B-AdverseReaction
,	YERVOY.xml:S2:2020:1	,	,	O	O
and	YERVOY.xml:S2:2022:3	and	CC	O	O
endocrinopathy	YERVOY.xml:S2:2026:14	endocrinopathi	JJ	O	O
and	YERVOY.xml:S2:2041:3	and	CC	O	O
evaluate	YERVOY.xml:S2:2045:8	evalu	JJ	O	O
clinical	YERVOY.xml:S2:2054:8	clinic	JJ	O	O
chemistries	YERVOY.xml:S2:2063:11	chemistri	NNS	O	O
including	YERVOY.xml:S2:2075:9	includ	VBG	O	O
liver	YERVOY.xml:S2:2085:5	liver	JJ	O	O
function	YERVOY.xml:S2:2091:8	function	NN	O	O
tests	YERVOY.xml:S2:2100:5	test	NNS	O	O
and	YERVOY.xml:S2:2106:3	and	CC	O	O
thyroid	YERVOY.xml:S2:2110:7	thyroid	JJ	O	O
function	YERVOY.xml:S2:2118:8	function	NN	O	O
tests	YERVOY.xml:S2:2127:5	test	NNS	O	O
at	YERVOY.xml:S2:2133:2	at	IN	O	O
baseline	YERVOY.xml:S2:2136:8	baselin	NN	O	O
and	YERVOY.xml:S2:2145:3	and	CC	O	O
before	YERVOY.xml:S2:2149:6	befor	IN	O	O
each	YERVOY.xml:S2:2156:4	each	DT	O	O
dose	YERVOY.xml:S2:2161:4	dose	NN	O	O
.	YERVOY.xml:S2:2165:1	.	.	O	O

(	YERVOY.xml:S2:2169:1	(	(	O	O
5.1	YERVOY.xml:S2:2170:3	5.1	CD	O	O
,	YERVOY.xml:S2:2175:1	,	,	O	O
5.2	YERVOY.xml:S2:2179:3	5.2	CD	O	O
,	YERVOY.xml:S2:2184:1	,	,	O	O
5.3	YERVOY.xml:S2:2188:3	5.3	CD	O	O
,	YERVOY.xml:S2:2193:1	,	,	O	O
5.4	YERVOY.xml:S2:2197:3	5.4	CD	O	O
,	YERVOY.xml:S2:2202:1	,	,	O	O
5.5	YERVOY.xml:S2:2206:3	5.5	CD	O	O
)	YERVOY.xml:S2:2209:1	)	)	O	O
\n	YERVOY.xml:S2:2214:1	\n	VBD	O	O
5	YERVOY.xml:S3:4:1	5	CD	O	O
WARNINGS	YERVOY.xml:S3:9:8	warn	NNP	O	O
AND	YERVOY.xml:S3:18:3	and	NNP	O	O
PRECAUTIONS	YERVOY.xml:S3:22:11	precaut	NNP	O	O

YERVOY	YERVOY.xml:S3:39:6	yervoy	NN	O	O
can	YERVOY.xml:S3:46:3	can	MD	O	O
result	YERVOY.xml:S3:50:6	result	VB	O	O
in	YERVOY.xml:S3:57:2	in	IN	O	O
severe	YERVOY.xml:S3:60:6	sever	JJ	O	O
and	YERVOY.xml:S3:67:3	and	CC	O	O
fatal	YERVOY.xml:S3:71:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
immune	YERVOY.xml:S3:77:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:83:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S3:84:8	mediat	VBN	I-AdverseReaction	I-AdverseReaction
reactions	YERVOY.xml:S3:93:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
due	YERVOY.xml:S3:103:3	due	JJ	O	O
to	YERVOY.xml:S3:107:2	to	TO	O	O
T	YERVOY.xml:S3:110:1	T	NNP	O	O
-	YERVOY.xml:S3:111:1	-	:	O	O
cell	YERVOY.xml:S3:112:4	cell	NN	O	O
activation	YERVOY.xml:S3:117:10	activ	NN	O	O
and	YERVOY.xml:S3:128:3	and	CC	O	O
proliferation	YERVOY.xml:S3:132:13	prolifer	NN	O	O
.	YERVOY.xml:S3:145:1	.	.	O	O

[	YERVOY.xml:S3:147:1	[	NNS	O	O
See	YERVOY.xml:S3:148:3	see	NNP	O	O
Boxed	YERVOY.xml:S3:153:5	box	NNP	O	O
Warning	YERVOY.xml:S3:159:7	warn	NNP	O	O
.	YERVOY.xml:S3:168:1	.	.	O	O
]	YERVOY.xml:S3:169:1	]	NN	O	O

EXCERPT	YERVOY.xml:S3:179:7	excerpt	NN	O	O
:	YERVOY.xml:S3:186:1	:	:	O	O
Immune	YERVOY.xml:S3:190:6	immun	NNP	B-AdverseReaction	O
-	YERVOY.xml:S3:196:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S3:197:8	mediat	VBD	I-AdverseReaction	O
adverse	YERVOY.xml:S3:206:7	advers	JJ	I-AdverseReaction	O
reactions	YERVOY.xml:S3:214:9	reaction	NNS	I-AdverseReaction	O
:	YERVOY.xml:S3:223:1	:	:	O	O
Permanently	YERVOY.xml:S3:225:11	perman	RB	O	O
discontinue	YERVOY.xml:S3:237:11	discontinu	VBP	O	O
for	YERVOY.xml:S3:249:3	for	IN	O	O
severe	YERVOY.xml:S3:253:6	sever	JJ	O	O
reactions	YERVOY.xml:S3:260:9	reaction	NNS	O	O
.	YERVOY.xml:S3:269:1	.	.	O	O

Withhold	YERVOY.xml:S3:271:8	withhold	NNP	O	O
dose	YERVOY.xml:S3:280:4	dose	NN	O	O
for	YERVOY.xml:S3:285:3	for	IN	O	O
moderate	YERVOY.xml:S3:289:8	moder	JJ	O	O
immune	YERVOY.xml:S3:298:6	immun	JJ	O	O
-	YERVOY.xml:S3:304:1	-	:	O	O
mediated	YERVOY.xml:S3:305:8	mediat	JJ	O	O
adverse	YERVOY.xml:S3:314:7	advers	JJ	O	O
reactions	YERVOY.xml:S3:322:9	reaction	NNS	O	O
until	YERVOY.xml:S3:332:5	until	IN	O	O
return	YERVOY.xml:S3:338:6	return	NN	O	O
to	YERVOY.xml:S3:345:2	to	TO	O	O
baseline	YERVOY.xml:S3:348:8	baselin	VB	O	O
,	YERVOY.xml:S3:356:1	,	,	O	O
improvement	YERVOY.xml:S3:358:11	improv	NN	O	O
to	YERVOY.xml:S3:370:2	to	TO	O	O
mild	YERVOY.xml:S3:373:4	mild	VB	O	O
severity	YERVOY.xml:S3:378:8	sever	NN	O	O
,	YERVOY.xml:S3:386:1	,	,	O	O
or	YERVOY.xml:S3:388:2	or	CC	O	O
complete	YERVOY.xml:S3:391:8	complet	JJ	O	O
resolution	YERVOY.xml:S3:400:10	resolut	NN	O	O
,	YERVOY.xml:S3:410:1	,	,	O	O
and	YERVOY.xml:S3:412:3	and	CC	O	O
patient	YERVOY.xml:S3:416:7	patient	NN	O	O
is	YERVOY.xml:S3:424:2	is	VBZ	O	O
receiving	YERVOY.xml:S3:427:9	receiv	VBG	O	O
less	YERVOY.xml:S3:437:4	less	JJR	O	O
than	YERVOY.xml:S3:442:4	than	IN	O	O
7.5	YERVOY.xml:S3:447:3	7.5	CD	O	O
mg	YERVOY.xml:S3:451:2	mg	JJ	O	O
prednisone	YERVOY.xml:S3:454:10	prednison	NN	O	O
or	YERVOY.xml:S3:465:2	or	CC	O	O
equivalent	YERVOY.xml:S3:468:10	equival	JJ	O	O
per	YERVOY.xml:S3:479:3	per	IN	O	O
day	YERVOY.xml:S3:483:3	day	NN	O	O
.	YERVOY.xml:S3:486:1	.	.	O	O

Administer	YERVOY.xml:S3:488:10	administ	NNP	O	O
systemic	YERVOY.xml:S3:499:8	system	JJ	O	O
high	YERVOY.xml:S3:508:4	high	JJ	O	O
-	YERVOY.xml:S3:512:1	-	:	O	O
dose	YERVOY.xml:S3:513:4	dose	JJ	O	O
corticosteroids	YERVOY.xml:S3:518:15	corticosteroid	NNS	O	O
for	YERVOY.xml:S3:534:3	for	IN	O	O
severe	YERVOY.xml:S3:538:6	sever	JJ	O	O
,	YERVOY.xml:S3:544:1	,	,	O	O
persistent	YERVOY.xml:S3:546:10	persist	JJ	O	O
,	YERVOY.xml:S3:556:1	,	,	O	O
or	YERVOY.xml:S3:558:2	or	CC	O	O
recurring	YERVOY.xml:S3:561:9	recur	VBG	O	O
immune	YERVOY.xml:S3:571:6	immun	JJ	O	O
-	YERVOY.xml:S3:577:1	-	:	O	O
mediated	YERVOY.xml:S3:578:8	mediat	VBN	O	O
reactions	YERVOY.xml:S3:587:9	reaction	NNS	O	O
.	YERVOY.xml:S3:596:1	.	.	O	O

(	YERVOY.xml:S3:599:1	(	(	O	O
5.1	YERVOY.xml:S3:600:3	5.1	CD	O	O
,	YERVOY.xml:S3:605:1	,	,	O	O
5.2	YERVOY.xml:S3:608:3	5.2	CD	O	O
,	YERVOY.xml:S3:613:1	,	,	O	O
5.3	YERVOY.xml:S3:616:3	5.3	CD	O	O
,	YERVOY.xml:S3:621:1	,	,	O	O
5.4	YERVOY.xml:S3:624:3	5.4	CD	O	O
,	YERVOY.xml:S3:629:1	,	,	O	O
5.5	YERVOY.xml:S3:632:3	5.5	CD	O	O
)	YERVOY.xml:S3:635:1	)	)	O	O

?	YERVOY.xml:S3:646:1	?	.	O	O

Immune	YERVOY.xml:S3:649:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:655:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S3:656:8	mediat	VBD	I-AdverseReaction	I-AdverseReaction
hepatitis	YERVOY.xml:S3:665:9	hepat	NN	I-AdverseReaction	I-AdverseReaction
:	YERVOY.xml:S3:674:1	:	:	O	O
Evaluate	YERVOY.xml:S3:676:8	evalu	NNP	O	O
liver	YERVOY.xml:S3:685:5	liver	NN	O	O
function	YERVOY.xml:S3:691:8	function	NN	O	O
tests	YERVOY.xml:S3:700:5	test	NNS	O	O
before	YERVOY.xml:S3:706:6	befor	IN	O	O
each	YERVOY.xml:S3:713:4	each	DT	O	O
dose	YERVOY.xml:S3:718:4	dose	NN	O	O
of	YERVOY.xml:S3:723:2	of	IN	O	O
YERVOY	YERVOY.xml:S3:726:6	yervoy	NNP	O	O
.	YERVOY.xml:S3:732:1	.	.	O	O

(	YERVOY.xml:S3:735:1	(	(	O	O
5.2	YERVOY.xml:S3:736:3	5.2	CD	O	O
)	YERVOY.xml:S3:739:1	)	)	O	O

?	YERVOY.xml:S3:748:1	?	.	O	O

Immune	YERVOY.xml:S3:751:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:757:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S3:758:8	mediat	JJ	I-AdverseReaction	I-AdverseReaction
endocrinopathies	YERVOY.xml:S3:767:16	endocrinopathi	NNS	I-AdverseReaction	I-AdverseReaction
:	YERVOY.xml:S3:783:1	:	:	O	O
Monitor	YERVOY.xml:S3:785:7	monitor	NNP	O	O
thyroid	YERVOY.xml:S3:793:7	thyroid	JJ	O	O
function	YERVOY.xml:S3:801:8	function	NN	O	O
tests	YERVOY.xml:S3:810:5	test	NNS	O	O
and	YERVOY.xml:S3:816:3	and	CC	O	O
clinical	YERVOY.xml:S3:820:8	clinic	JJ	O	O
chemistries	YERVOY.xml:S3:829:11	chemistri	NNS	O	O
prior	YERVOY.xml:S3:841:5	prior	RB	O	O
to	YERVOY.xml:S3:847:2	to	TO	O	O
each	YERVOY.xml:S3:850:4	each	DT	O	O
dose	YERVOY.xml:S3:855:4	dose	NN	O	O
.	YERVOY.xml:S3:859:1	.	.	O	O

Evaluate	YERVOY.xml:S3:861:8	evalu	NN	O	O
at	YERVOY.xml:S3:870:2	at	IN	O	O
each	YERVOY.xml:S3:873:4	each	DT	O	O
visit	YERVOY.xml:S3:878:5	visit	NN	O	O
for	YERVOY.xml:S3:884:3	for	IN	O	O
signs	YERVOY.xml:S3:888:5	sign	NNS	O	O
and	YERVOY.xml:S3:894:3	and	CC	O	O
symptoms	YERVOY.xml:S3:898:8	symptom	NNS	O	O
of	YERVOY.xml:S3:907:2	of	IN	O	O
endocrinopathy	YERVOY.xml:S3:910:14	endocrinopathi	NN	O	O
.	YERVOY.xml:S3:924:1	.	.	O	O

Institute	YERVOY.xml:S3:926:9	institut	NNP	O	O
hormone	YERVOY.xml:S3:936:7	hormon	NN	O	O
replacement	YERVOY.xml:S3:944:11	replac	NN	O	O
therapy	YERVOY.xml:S3:956:7	therapi	NN	O	O
as	YERVOY.xml:S3:964:2	as	IN	O	O
needed	YERVOY.xml:S3:967:6	need	VBN	O	O
.	YERVOY.xml:S3:973:1	.	.	O	O

(	YERVOY.xml:S3:976:1	(	(	O	O
5.5	YERVOY.xml:S3:977:3	5.5	CD	O	O
)	YERVOY.xml:S3:980:1	)	)	O	O

5.1	YERVOY.xml:S3:996:3	5.1	CD	O	O

Immune	YERVOY.xml:S3:1002:6	immun	NN	O	O

-	YERVOY.xml:S3:1008:1	-	:	O	O
mediated	YERVOY.xml:S3:1009:8	mediat	VBD	O	O
Enterocolitis	YERVOY.xml:S3:1018:13	enterocol	NN	O	O

In	YERVOY.xml:S3:1037:2	In	IN	O	O
Study	YERVOY.xml:S3:1040:5	studi	NNP	O	O
1	YERVOY.xml:S3:1046:1	1	CD	O	O
,	YERVOY.xml:S3:1047:1	,	,	O	O
severe	YERVOY.xml:S3:1049:6	sever	RB	O	O
,	YERVOY.xml:S3:1055:1	,	,	O	O
life	YERVOY.xml:S3:1057:4	life	NN	O	O
-	YERVOY.xml:S3:1061:1	-	:	O	O
threatening	YERVOY.xml:S3:1062:11	threaten	NN	O	O
,	YERVOY.xml:S3:1073:1	,	,	O	O
or	YERVOY.xml:S3:1075:2	or	CC	O	O
fatal	YERVOY.xml:S3:1078:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
(	YERVOY.xml:S3:1084:1	(	(	O	O
diarrhea	YERVOY.xml:S3:1085:8	diarrhea	NN	B-AdverseReaction	O
of	YERVOY.xml:S3:1094:2	of	IN	O	O
7	YERVOY.xml:S3:1097:1	7	CD	O	O
or	YERVOY.xml:S3:1099:2	or	CC	O	O
more	YERVOY.xml:S3:1102:4	more	JJR	O	O
stools	YERVOY.xml:S3:1107:6	stool	NNS	O	O
above	YERVOY.xml:S3:1114:5	abov	IN	O	O
baseline	YERVOY.xml:S3:1120:8	baselin	NN	O	O
,	YERVOY.xml:S3:1128:1	,	,	O	O
fever	YERVOY.xml:S3:1130:5	fever	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:1135:1	,	,	O	O
ileus	YERVOY.xml:S3:1137:5	ileu	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:1142:1	,	,	O	O
peritoneal	YERVOY.xml:S3:1144:10	periton	JJ	B-AdverseReaction	B-AdverseReaction
signs	YERVOY.xml:S3:1155:5	sign	NNS	I-AdverseReaction	I-AdverseReaction
;	YERVOY.xml:S3:1160:1	;	:	O	O
Grade	YERVOY.xml:S3:1162:5	grade	NNP	O	O
3	YERVOY.xml:S3:1168:1	3	CD	O	O
-	YERVOY.xml:S3:1169:1	-	:	O	O
5	YERVOY.xml:S3:1170:1	5	CD	O	O
)	YERVOY.xml:S3:1171:1	)	)	O	O
immune	YERVOY.xml:S3:1173:6	immun	NN	B-AdverseReaction	O
-	YERVOY.xml:S3:1179:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S3:1180:8	mediat	VBN	I-AdverseReaction	O
enterocolitis	YERVOY.xml:S3:1189:13	enterocol	NN	I-AdverseReaction	O
occurred	YERVOY.xml:S3:1203:8	occur	VBD	O	O
in	YERVOY.xml:S3:1212:2	in	IN	O	O
34	YERVOY.xml:S3:1215:2	34	CD	O	O
(	YERVOY.xml:S3:1218:1	(	(	O	O
7%	YERVOY.xml:S3:1219:2	7%	CD	O	O
)	YERVOY.xml:S3:1221:1	)	)	O	O
YERVOY	YERVOY.xml:S3:1223:6	yervoy	SYM	O	O
-	YERVOY.xml:S3:1229:1	-	:	O	O
treated	YERVOY.xml:S3:1230:7	treat	JJ	O	O
patients	YERVOY.xml:S3:1238:8	patient	NNS	O	O
,	YERVOY.xml:S3:1246:1	,	,	O	O
and	YERVOY.xml:S3:1248:3	and	CC	O	O
moderate	YERVOY.xml:S3:1252:8	moder	JJ	O	O
(	YERVOY.xml:S3:1261:1	(	(	O	O
diarrhea	YERVOY.xml:S3:1262:8	diarrhea	NN	B-AdverseReaction	O
with	YERVOY.xml:S3:1271:4	with	IN	O	O
up	YERVOY.xml:S3:1276:2	up	IN	O	O
to	YERVOY.xml:S3:1279:2	to	TO	O	O
6	YERVOY.xml:S3:1282:1	6	CD	O	O
stools	YERVOY.xml:S3:1284:6	stool	NNS	O	O
above	YERVOY.xml:S3:1291:5	abov	IN	O	O
baseline	YERVOY.xml:S3:1297:8	baselin	NN	O	O
,	YERVOY.xml:S3:1305:1	,	,	O	O
abdominal	YERVOY.xml:S3:1307:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	YERVOY.xml:S3:1317:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:1321:1	,	,	O	O
mucus	YERVOY.xml:S3:1323:5	mucu	NN	B-AdverseReaction	O
or	YERVOY.xml:S3:1329:2	or	CC	O	O
blood	YERVOY.xml:S3:1332:5	blood	NN	B-AdverseReaction	O
in	YERVOY.xml:S3:1338:2	in	IN	I-AdverseReaction	O
stool	YERVOY.xml:S3:1341:5	stool	NN	I-AdverseReaction	O
;	YERVOY.xml:S3:1346:1	;	:	O	O
Grade	YERVOY.xml:S3:1348:5	grade	NNP	O	O
2	YERVOY.xml:S3:1354:1	2	CD	O	O
)	YERVOY.xml:S3:1355:1	)	)	O	O
enterocolitis	YERVOY.xml:S3:1357:13	enterocol	NN	B-AdverseReaction	O
occurred	YERVOY.xml:S3:1371:8	occur	VBD	O	O
in	YERVOY.xml:S3:1380:2	in	IN	O	O
28	YERVOY.xml:S3:1383:2	28	CD	O	O
(	YERVOY.xml:S3:1386:1	(	(	O	O
5%	YERVOY.xml:S3:1387:2	5%	CD	O	O
)	YERVOY.xml:S3:1389:1	)	)	O	O
YERVOY	YERVOY.xml:S3:1391:6	yervoy	SYM	O	O
-	YERVOY.xml:S3:1397:1	-	:	O	O
treated	YERVOY.xml:S3:1398:7	treat	JJ	O	O
patients	YERVOY.xml:S3:1406:8	patient	NNS	O	O
.	YERVOY.xml:S3:1414:1	.	.	O	O

Across	YERVOY.xml:S3:1416:6	across	IN	O	O
all	YERVOY.xml:S3:1423:3	all	DT	O	O
YERVOY	YERVOY.xml:S3:1427:6	yervoy	NNP	O	O
-	YERVOY.xml:S3:1433:1	-	:	O	O
treated	YERVOY.xml:S3:1434:7	treat	VBD	O	O
patients	YERVOY.xml:S3:1442:8	patient	NNS	O	O
(	YERVOY.xml:S3:1451:1	(	(	O	O
n	YERVOY.xml:S3:1452:1	n	JJ	O	O
511	YERVOY.xml:S3:1454:3	511	CD	O	O
)	YERVOY.xml:S3:1457:1	)	)	O	O
,	YERVOY.xml:S3:1458:1	,	,	O	O
5	YERVOY.xml:S3:1460:1	5	CD	O	O
(	YERVOY.xml:S3:1462:1	(	(	O	O
1%	YERVOY.xml:S3:1463:2	1%	CD	O	O
)	YERVOY.xml:S3:1465:1	)	)	O	O
patients	YERVOY.xml:S3:1467:8	patient	NNS	O	O
developed	YERVOY.xml:S3:1476:9	develop	VBD	O	O
intestinal	YERVOY.xml:S3:1486:10	intestin	JJ	B-AdverseReaction	B-AdverseReaction
perforation	YERVOY.xml:S3:1497:11	perfor	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:1508:1	,	,	O	O
4	YERVOY.xml:S3:1510:1	4	CD	O	O
(	YERVOY.xml:S3:1512:1	(	(	O	O
0.8%	YERVOY.xml:S3:1513:4	0.8%	CD	O	O
)	YERVOY.xml:S3:1517:1	)	)	O	O
patients	YERVOY.xml:S3:1519:8	patient	NNS	O	O
died	YERVOY.xml:S3:1528:4	die	VBD	B-AdverseReaction	B-AdverseReaction
as	YERVOY.xml:S3:1533:2	as	IN	O	O
a	YERVOY.xml:S3:1536:1	a	DT	O	O
result	YERVOY.xml:S3:1538:6	result	NN	O	O
of	YERVOY.xml:S3:1545:2	of	IN	O	O
complications	YERVOY.xml:S3:1548:13	complic	NNS	O	O
,	YERVOY.xml:S3:1561:1	,	,	O	O
and	YERVOY.xml:S3:1563:3	and	CC	O	O
26	YERVOY.xml:S3:1567:2	26	CD	O	O
(	YERVOY.xml:S3:1570:1	(	(	O	O
5%	YERVOY.xml:S3:1571:2	5%	CD	O	O
)	YERVOY.xml:S3:1573:1	)	)	O	O
patients	YERVOY.xml:S3:1575:8	patient	NNS	O	O
were	YERVOY.xml:S3:1584:4	were	VBD	O	O
hospitalized	YERVOY.xml:S3:1589:12	hospit	VBN	O	O
for	YERVOY.xml:S3:1602:3	for	IN	O	O
severe	YERVOY.xml:S3:1606:6	sever	JJ	O	O
enterocolitis	YERVOY.xml:S3:1613:13	enterocol	NN	B-AdverseReaction	O
.	YERVOY.xml:S3:1626:1	.	.	O	O

The	YERVOY.xml:S3:1632:3	the	DT	O	O
median	YERVOY.xml:S3:1636:6	median	JJ	O	O
time	YERVOY.xml:S3:1643:4	time	NN	O	O
to	YERVOY.xml:S3:1648:2	to	TO	O	O
onset	YERVOY.xml:S3:1651:5	onset	VB	O	O
was	YERVOY.xml:S3:1657:3	wa	VBD	O	O
7.4	YERVOY.xml:S3:1661:3	7.4	CD	O	O
weeks	YERVOY.xml:S3:1665:5	week	NNS	O	O
(	YERVOY.xml:S3:1671:1	(	(	O	O
range	YERVOY.xml:S3:1672:5	rang	NN	O	O
:	YERVOY.xml:S3:1677:1	:	:	O	O
1.6	YERVOY.xml:S3:1679:3	1.6	CD	O	O
-	YERVOY.xml:S3:1682:1	-	:	O	O
13.4	YERVOY.xml:S3:1683:4	13.4	CD	O	O
)	YERVOY.xml:S3:1687:1	)	)	O	O
and	YERVOY.xml:S3:1689:3	and	CC	O	O
6.3	YERVOY.xml:S3:1693:3	6.3	CD	O	O
weeks	YERVOY.xml:S3:1697:5	week	NNS	O	O
(	YERVOY.xml:S3:1703:1	(	(	O	O
range	YERVOY.xml:S3:1704:5	rang	NN	O	O
:	YERVOY.xml:S3:1709:1	:	:	O	O
0.3	YERVOY.xml:S3:1711:3	0.3	CD	O	O
-	YERVOY.xml:S3:1714:1	-	:	O	O
18.9	YERVOY.xml:S3:1715:4	18.9	CD	O	O
)	YERVOY.xml:S3:1719:1	)	)	O	O
after	YERVOY.xml:S3:1721:5	after	IN	O	O
the	YERVOY.xml:S3:1727:3	the	DT	O	O
initiation	YERVOY.xml:S3:1731:10	initi	NN	O	O
of	YERVOY.xml:S3:1742:2	of	IN	O	O
YERVOY	YERVOY.xml:S3:1745:6	yervoy	NNP	O	O
for	YERVOY.xml:S3:1752:3	for	IN	O	O
patients	YERVOY.xml:S3:1756:8	patient	NNS	O	O
with	YERVOY.xml:S3:1765:4	with	IN	O	O
Grade	YERVOY.xml:S3:1770:5	grade	NNP	O	O
3	YERVOY.xml:S3:1776:1	3	CD	O	O
-	YERVOY.xml:S3:1777:1	-	:	O	O
5	YERVOY.xml:S3:1778:1	5	CD	O	O
enterocolitis	YERVOY.xml:S3:1780:13	enterocol	NN	B-AdverseReaction	O
and	YERVOY.xml:S3:1794:3	and	CC	O	O
with	YERVOY.xml:S3:1798:4	with	IN	O	O
Grade	YERVOY.xml:S3:1803:5	grade	NNP	O	O
2	YERVOY.xml:S3:1809:1	2	CD	O	O
enterocolitis	YERVOY.xml:S3:1811:13	enterocol	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:1824:1	,	,	O	O
respectively	YERVOY.xml:S3:1826:12	respect	RB	O	O
.	YERVOY.xml:S3:1838:1	.	.	O	O

Twenty	YERVOY.xml:S3:1844:6	twenti	NNP	O	O
-	YERVOY.xml:S3:1850:1	-	:	O	O
nine	YERVOY.xml:S3:1851:4	nine	CD	O	O
patients	YERVOY.xml:S3:1856:8	patient	NNS	O	O
(	YERVOY.xml:S3:1865:1	(	(	O	O
85%	YERVOY.xml:S3:1866:3	85%	CD	O	O
)	YERVOY.xml:S3:1869:1	)	)	O	O
with	YERVOY.xml:S3:1871:4	with	IN	O	O
Grade	YERVOY.xml:S3:1876:5	grade	NNP	O	O
3	YERVOY.xml:S3:1882:1	3	CD	O	O
-	YERVOY.xml:S3:1883:1	-	:	O	O
5	YERVOY.xml:S3:1884:1	5	CD	O	O
enterocolitis	YERVOY.xml:S3:1886:13	enterocol	NN	B-AdverseReaction	O
were	YERVOY.xml:S3:1900:4	were	VBD	O	O
treated	YERVOY.xml:S3:1905:7	treat	VBN	O	O
with	YERVOY.xml:S3:1913:4	with	IN	O	O
high	YERVOY.xml:S3:1918:4	high	JJ	O	O
-	YERVOY.xml:S3:1922:1	-	:	O	O
dose	YERVOY.xml:S3:1923:4	dose	NN	O	O
(	YERVOY.xml:S3:1928:1	(	(	O	O
40	YERVOY.xml:S3:1931:2	40	CD	O	O
mg	YERVOY.xml:S3:1934:2	mg	RB	O	O
prednisone	YERVOY.xml:S3:1937:10	prednison	JJ	O	O
equivalent	YERVOY.xml:S3:1948:10	equival	JJ	O	O
per	YERVOY.xml:S3:1959:3	per	IN	O	O
day	YERVOY.xml:S3:1963:3	day	NN	O	O
)	YERVOY.xml:S3:1966:1	)	)	O	O
corticosteroids	YERVOY.xml:S3:1968:15	corticosteroid	NNS	O	O
,	YERVOY.xml:S3:1983:1	,	,	O	O
with	YERVOY.xml:S3:1985:4	with	IN	O	O
a	YERVOY.xml:S3:1990:1	a	DT	O	O
median	YERVOY.xml:S3:1992:6	median	JJ	O	O
dose	YERVOY.xml:S3:1999:4	dose	NN	O	O
of	YERVOY.xml:S3:2004:2	of	IN	O	O
80	YERVOY.xml:S3:2007:2	80	CD	O	O
mg	YERVOY.xml:S3:2010:2	mg	JJ	O	O
day	YERVOY.xml:S3:2013:3	day	NN	O	O
of	YERVOY.xml:S3:2017:2	of	IN	O	O
prednisone	YERVOY.xml:S3:2020:10	prednison	NN	O	O
or	YERVOY.xml:S3:2031:2	or	CC	O	O
equivalent	YERVOY.xml:S3:2034:10	equival	NN	O	O
;	YERVOY.xml:S3:2044:1	;	:	O	O
the	YERVOY.xml:S3:2046:3	the	DT	O	O
median	YERVOY.xml:S3:2050:6	median	JJ	O	O
duration	YERVOY.xml:S3:2057:8	durat	NN	O	O
of	YERVOY.xml:S3:2066:2	of	IN	O	O
treatment	YERVOY.xml:S3:2069:9	treatment	NN	O	O
was	YERVOY.xml:S3:2079:3	wa	VBD	O	O
2.3	YERVOY.xml:S3:2083:3	2.3	CD	O	O
weeks	YERVOY.xml:S3:2087:5	week	NNS	O	O
(	YERVOY.xml:S3:2093:1	(	(	O	O
ranging	YERVOY.xml:S3:2094:7	rang	VBG	O	O
up	YERVOY.xml:S3:2102:2	up	RB	O	O
to	YERVOY.xml:S3:2105:2	to	TO	O	O
13.9	YERVOY.xml:S3:2108:4	13.9	CD	O	O
weeks	YERVOY.xml:S3:2113:5	week	NNS	O	O
)	YERVOY.xml:S3:2118:1	)	)	O	O
followed	YERVOY.xml:S3:2120:8	follow	VBN	O	O
by	YERVOY.xml:S3:2129:2	by	IN	O	O
corticosteroid	YERVOY.xml:S3:2132:14	corticosteroid	JJ	O	O
taper	YERVOY.xml:S3:2147:5	taper	NN	O	O
.	YERVOY.xml:S3:2152:1	.	.	O	O

Of	YERVOY.xml:S3:2154:2	Of	IN	O	O
the	YERVOY.xml:S3:2157:3	the	DT	O	O
28	YERVOY.xml:S3:2161:2	28	CD	O	O
patients	YERVOY.xml:S3:2164:8	patient	NNS	O	O
with	YERVOY.xml:S3:2173:4	with	IN	O	O
moderate	YERVOY.xml:S3:2178:8	moder	JJ	O	O
enterocolitis	YERVOY.xml:S3:2187:13	enterocol	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:2200:1	,	,	O	O
46%	YERVOY.xml:S3:2202:3	46%	CD	O	O
were	YERVOY.xml:S3:2206:4	were	VBD	O	O
not	YERVOY.xml:S3:2211:3	not	RB	O	O
treated	YERVOY.xml:S3:2215:7	treat	VBN	O	O
with	YERVOY.xml:S3:2223:4	with	IN	O	O
systemic	YERVOY.xml:S3:2228:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:2237:15	corticosteroid	NNS	O	O
,	YERVOY.xml:S3:2252:1	,	,	O	O
29%	YERVOY.xml:S3:2254:3	29%	CD	O	O
were	YERVOY.xml:S3:2258:4	were	VBD	O	O
treated	YERVOY.xml:S3:2263:7	treat	VBN	O	O
with	YERVOY.xml:S3:2271:4	with	IN	O	O
40	YERVOY.xml:S3:2277:2	40	CD	O	O
mg	YERVOY.xml:S3:2280:2	mg	NNS	O	O
prednisone	YERVOY.xml:S3:2283:10	prednison	NN	O	O
or	YERVOY.xml:S3:2294:2	or	CC	O	O
equivalent	YERVOY.xml:S3:2297:10	equival	JJ	O	O
per	YERVOY.xml:S3:2308:3	per	IN	O	O
day	YERVOY.xml:S3:2312:3	day	NN	O	O
for	YERVOY.xml:S3:2316:3	for	IN	O	O
a	YERVOY.xml:S3:2320:1	a	DT	O	O
median	YERVOY.xml:S3:2322:6	median	JJ	O	O
duration	YERVOY.xml:S3:2329:8	durat	NN	O	O
of	YERVOY.xml:S3:2338:2	of	IN	O	O
5.1	YERVOY.xml:S3:2341:3	5.1	CD	O	O
weeks	YERVOY.xml:S3:2345:5	week	NNS	O	O
,	YERVOY.xml:S3:2350:1	,	,	O	O
and	YERVOY.xml:S3:2352:3	and	CC	O	O
25%	YERVOY.xml:S3:2356:3	25%	CD	O	O
were	YERVOY.xml:S3:2360:4	were	VBD	O	O
treated	YERVOY.xml:S3:2365:7	treat	VBN	O	O
with	YERVOY.xml:S3:2373:4	with	IN	O	O
high	YERVOY.xml:S3:2378:4	high	JJ	O	O
-	YERVOY.xml:S3:2382:1	-	:	O	O
dose	YERVOY.xml:S3:2383:4	dose	JJ	O	O
corticosteroids	YERVOY.xml:S3:2388:15	corticosteroid	NNS	O	O
for	YERVOY.xml:S3:2404:3	for	IN	O	O
a	YERVOY.xml:S3:2408:1	a	DT	O	O
median	YERVOY.xml:S3:2410:6	median	JJ	O	O
duration	YERVOY.xml:S3:2417:8	durat	NN	O	O
of	YERVOY.xml:S3:2426:2	of	IN	O	O
10	YERVOY.xml:S3:2429:2	10	CD	O	O
days	YERVOY.xml:S3:2432:4	day	NNS	O	O
prior	YERVOY.xml:S3:2437:5	prior	RB	O	O
to	YERVOY.xml:S3:2443:2	to	TO	O	O
corticosteroid	YERVOY.xml:S3:2446:14	corticosteroid	VB	O	O
taper	YERVOY.xml:S3:2461:5	taper	NN	O	O
.	YERVOY.xml:S3:2466:1	.	.	O	O

Infliximab	YERVOY.xml:S3:2468:10	infliximab	NNP	O	O
was	YERVOY.xml:S3:2479:3	wa	VBD	O	O
administered	YERVOY.xml:S3:2483:12	administ	VBN	O	O
to	YERVOY.xml:S3:2496:2	to	TO	O	O
5	YERVOY.xml:S3:2499:1	5	CD	O	O
of	YERVOY.xml:S3:2501:2	of	IN	O	O
the	YERVOY.xml:S3:2504:3	the	DT	O	O
62	YERVOY.xml:S3:2508:2	62	CD	O	O
patients	YERVOY.xml:S3:2511:8	patient	NNS	O	O
(	YERVOY.xml:S3:2520:1	(	(	O	O
8%	YERVOY.xml:S3:2521:2	8%	CD	O	O
)	YERVOY.xml:S3:2523:1	)	)	O	O
with	YERVOY.xml:S3:2525:4	with	IN	O	O
moderate	YERVOY.xml:S3:2530:8	moder	JJ	O	O
,	YERVOY.xml:S3:2538:1	,	,	O	O
severe	YERVOY.xml:S3:2540:6	sever	JJ	O	O
,	YERVOY.xml:S3:2546:1	,	,	O	O
or	YERVOY.xml:S3:2548:2	or	CC	O	O
life	YERVOY.xml:S3:2551:4	life	NN	O	O
-	YERVOY.xml:S3:2555:1	-	:	O	O
threatening	YERVOY.xml:S3:2556:11	threaten	VBG	O	O
immune	YERVOY.xml:S3:2568:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S3:2574:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S3:2575:8	mediat	VBN	I-AdverseReaction	O
enterocolitis	YERVOY.xml:S3:2584:13	enterocol	NN	I-AdverseReaction	O
following	YERVOY.xml:S3:2598:9	follow	VBG	O	O
inadequate	YERVOY.xml:S3:2608:10	inadequ	JJ	O	O
response	YERVOY.xml:S3:2619:8	respons	NN	O	O
to	YERVOY.xml:S3:2628:2	to	TO	O	O
corticosteroids	YERVOY.xml:S3:2631:15	corticosteroid	NNS	O	O
.	YERVOY.xml:S3:2646:1	.	.	O	O

Of	YERVOY.xml:S3:2652:2	Of	IN	O	O
the	YERVOY.xml:S3:2655:3	the	DT	O	O
34	YERVOY.xml:S3:2659:2	34	CD	O	O
patients	YERVOY.xml:S3:2662:8	patient	NNS	O	O
with	YERVOY.xml:S3:2671:4	with	IN	O	O
Grade	YERVOY.xml:S3:2676:5	grade	NNP	O	O
3	YERVOY.xml:S3:2682:1	3	CD	O	O
-	YERVOY.xml:S3:2683:1	-	:	O	O
5	YERVOY.xml:S3:2684:1	5	CD	O	O
enterocolitis	YERVOY.xml:S3:2686:13	enterocol	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:2699:1	,	,	O	O
74%	YERVOY.xml:S3:2701:3	74%	CD	O	O
experienced	YERVOY.xml:S3:2705:11	experienc	VBD	O	O
complete	YERVOY.xml:S3:2717:8	complet	JJ	O	B-AdverseReaction
resolution	YERVOY.xml:S3:2726:10	resolut	NN	O	I-AdverseReaction
,	YERVOY.xml:S3:2736:1	,	,	O	O
3%	YERVOY.xml:S3:2738:2	3%	CD	O	O
experienced	YERVOY.xml:S3:2741:11	experienc	VBD	O	O
improvement	YERVOY.xml:S3:2753:11	improv	NN	O	O
to	YERVOY.xml:S3:2765:2	to	TO	O	O
Grade	YERVOY.xml:S3:2768:5	grade	VB	O	O
2	YERVOY.xml:S3:2774:1	2	CD	O	O
severity	YERVOY.xml:S3:2776:8	sever	NN	O	O
,	YERVOY.xml:S3:2784:1	,	,	O	O
and	YERVOY.xml:S3:2786:3	and	CC	O	O
24%	YERVOY.xml:S3:2790:3	24%	CD	O	O
did	YERVOY.xml:S3:2794:3	did	VBD	O	O
not	YERVOY.xml:S3:2798:3	not	RB	O	O
improve	YERVOY.xml:S3:2802:7	improv	VB	O	O
.	YERVOY.xml:S3:2809:1	.	.	O	O

Among	YERVOY.xml:S3:2811:5	among	IN	O	O
the	YERVOY.xml:S3:2817:3	the	DT	O	O
28	YERVOY.xml:S3:2821:2	28	CD	O	O
patients	YERVOY.xml:S3:2824:8	patient	NNS	O	O
with	YERVOY.xml:S3:2833:4	with	IN	O	O
Grade	YERVOY.xml:S3:2838:5	grade	NNP	O	O
2	YERVOY.xml:S3:2844:1	2	CD	O	O
enterocolitis	YERVOY.xml:S3:2846:13	enterocol	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:2859:1	,	,	O	O
79%	YERVOY.xml:S3:2861:3	79%	CD	O	O
experienced	YERVOY.xml:S3:2865:11	experienc	VBD	O	O
complete	YERVOY.xml:S3:2877:8	complet	JJ	O	B-AdverseReaction
resolution	YERVOY.xml:S3:2886:10	resolut	NN	O	I-AdverseReaction
,	YERVOY.xml:S3:2896:1	,	,	O	O
11%	YERVOY.xml:S3:2898:3	11%	CD	O	O
improved	YERVOY.xml:S3:2902:8	improv	VBN	O	O
,	YERVOY.xml:S3:2910:1	,	,	O	O
and	YERVOY.xml:S3:2912:3	and	CC	O	O
11%	YERVOY.xml:S3:2916:3	11%	CD	O	O
did	YERVOY.xml:S3:2920:3	did	VBD	O	O
not	YERVOY.xml:S3:2924:3	not	RB	O	O
improve	YERVOY.xml:S3:2928:7	improv	VB	O	O
.	YERVOY.xml:S3:2935:1	.	.	O	O

Monitor	YERVOY.xml:S3:2941:7	monitor	NN	O	O
patients	YERVOY.xml:S3:2949:8	patient	NNS	O	O
for	YERVOY.xml:S3:2958:3	for	IN	O	O
signs	YERVOY.xml:S3:2962:5	sign	NNS	O	O
and	YERVOY.xml:S3:2968:3	and	CC	O	O
symptoms	YERVOY.xml:S3:2972:8	symptom	NNS	O	O
of	YERVOY.xml:S3:2981:2	of	IN	O	O
enterocolitis	YERVOY.xml:S3:2984:13	enterocol	NN	O	O
(	YERVOY.xml:S3:2998:1	(	(	O	O
such	YERVOY.xml:S3:2999:4	such	JJ	O	O
as	YERVOY.xml:S3:3004:2	as	IN	O	O
diarrhea	YERVOY.xml:S3:3007:8	diarrhea	NN	O	B-AdverseReaction
,	YERVOY.xml:S3:3015:1	,	,	O	O
abdominal	YERVOY.xml:S3:3017:9	abdomin	JJ	O	B-AdverseReaction
pain	YERVOY.xml:S3:3027:4	pain	NN	O	I-AdverseReaction
,	YERVOY.xml:S3:3031:1	,	,	O	O
mucus	YERVOY.xml:S3:3033:5	mucu	NN	O	O
or	YERVOY.xml:S3:3039:2	or	CC	O	O
blood	YERVOY.xml:S3:3042:5	blood	NN	O	O
in	YERVOY.xml:S3:3048:2	in	IN	O	O
stool	YERVOY.xml:S3:3051:5	stool	NN	O	O
,	YERVOY.xml:S3:3056:1	,	,	O	O
with	YERVOY.xml:S3:3058:4	with	IN	O	O
or	YERVOY.xml:S3:3063:2	or	CC	O	O
without	YERVOY.xml:S3:3066:7	without	IN	O	O
fever	YERVOY.xml:S3:3074:5	fever	NN	O	O
)	YERVOY.xml:S3:3079:1	)	)	O	O
and	YERVOY.xml:S3:3081:3	and	CC	O	O
of	YERVOY.xml:S3:3085:2	of	IN	O	O
bowel	YERVOY.xml:S3:3088:5	bowel	NN	O	B-AdverseReaction
perforation	YERVOY.xml:S3:3094:11	perfor	NN	O	I-AdverseReaction
(	YERVOY.xml:S3:3106:1	(	(	O	O
such	YERVOY.xml:S3:3107:4	such	JJ	O	O
as	YERVOY.xml:S3:3112:2	as	IN	O	O
peritoneal	YERVOY.xml:S3:3115:10	periton	JJ	O	O
signs	YERVOY.xml:S3:3126:5	sign	NNS	O	O
and	YERVOY.xml:S3:3132:3	and	CC	O	O
ileus	YERVOY.xml:S3:3136:5	ileu	NN	O	O
)	YERVOY.xml:S3:3141:1	)	)	O	O
.	YERVOY.xml:S3:3142:1	.	.	O	O

In	YERVOY.xml:S3:3144:2	In	IN	O	O
symptomatic	YERVOY.xml:S3:3147:11	symptomat	JJ	O	O
patients	YERVOY.xml:S3:3159:8	patient	NNS	O	O
,	YERVOY.xml:S3:3167:1	,	,	O	O
rule	YERVOY.xml:S3:3169:4	rule	NN	O	O
out	YERVOY.xml:S3:3174:3	out	IN	O	O
infectious	YERVOY.xml:S3:3178:10	infecti	JJ	O	O
etiologies	YERVOY.xml:S3:3189:10	etiolog	NNS	O	O
and	YERVOY.xml:S3:3200:3	and	CC	O	O
consider	YERVOY.xml:S3:3204:8	consid	VB	O	O
endoscopic	YERVOY.xml:S3:3213:10	endoscop	JJ	O	O
evaluation	YERVOY.xml:S3:3224:10	evalu	NN	O	O
for	YERVOY.xml:S3:3235:3	for	IN	O	O
persistent	YERVOY.xml:S3:3239:10	persist	NN	O	O
or	YERVOY.xml:S3:3250:2	or	CC	O	O
severe	YERVOY.xml:S3:3253:6	sever	JJ	O	O
symptoms	YERVOY.xml:S3:3260:8	symptom	NNS	O	O
.	YERVOY.xml:S3:3268:1	.	.	O	O

Permanently	YERVOY.xml:S3:3274:11	perman	RB	O	O
discontinue	YERVOY.xml:S3:3286:11	discontinu	JJ	O	O
YERVOY	YERVOY.xml:S3:3298:6	yervoy	NNP	O	O
in	YERVOY.xml:S3:3305:2	in	IN	O	O
patients	YERVOY.xml:S3:3308:8	patient	NNS	O	O
with	YERVOY.xml:S3:3317:4	with	IN	O	O
severe	YERVOY.xml:S3:3322:6	sever	JJ	O	O
enterocolitis	YERVOY.xml:S3:3329:13	enterocol	NN	O	O
and	YERVOY.xml:S3:3343:3	and	CC	O	O
initiate	YERVOY.xml:S3:3347:8	initi	VB	O	O
systemic	YERVOY.xml:S3:3356:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:3365:15	corticosteroid	NNS	O	O
at	YERVOY.xml:S3:3381:2	at	IN	O	O
a	YERVOY.xml:S3:3384:1	a	DT	O	O
dose	YERVOY.xml:S3:3386:4	dose	NN	O	O
of	YERVOY.xml:S3:3391:2	of	IN	O	O
1	YERVOY.xml:S3:3394:1	1	CD	O	O
to	YERVOY.xml:S3:3396:2	to	TO	O	O
2	YERVOY.xml:S3:3399:1	2	CD	O	O
mg	YERVOY.xml:S3:3401:2	mg	NNS	O	O
kg	YERVOY.xml:S3:3404:2	kg	JJ	O	O
day	YERVOY.xml:S3:3407:3	day	NN	O	O
of	YERVOY.xml:S3:3411:2	of	IN	O	O
prednisone	YERVOY.xml:S3:3414:10	prednison	NN	O	O
or	YERVOY.xml:S3:3425:2	or	CC	O	O
equivalent	YERVOY.xml:S3:3428:10	equival	NN	O	O
.	YERVOY.xml:S3:3438:1	.	.	O	O

Upon	YERVOY.xml:S3:3440:4	upon	IN	O	O
improvement	YERVOY.xml:S3:3445:11	improv	NN	O	O
to	YERVOY.xml:S3:3457:2	to	TO	O	O
Grade	YERVOY.xml:S3:3460:5	grade	VB	O	O
1	YERVOY.xml:S3:3466:1	1	CD	O	O
or	YERVOY.xml:S3:3468:2	or	CC	O	O
less	YERVOY.xml:S3:3471:4	less	JJR	O	O
,	YERVOY.xml:S3:3475:1	,	,	O	O
initiate	YERVOY.xml:S3:3477:8	initi	JJ	O	O
corticosteroid	YERVOY.xml:S3:3486:14	corticosteroid	NN	O	O
taper	YERVOY.xml:S3:3501:5	taper	NN	O	O
and	YERVOY.xml:S3:3507:3	and	CC	O	O
continue	YERVOY.xml:S3:3511:8	continu	VB	O	O
to	YERVOY.xml:S3:3520:2	to	TO	O	O
taper	YERVOY.xml:S3:3523:5	taper	VB	O	O
over	YERVOY.xml:S3:3529:4	over	RP	O	O
at	YERVOY.xml:S3:3534:2	at	IN	O	O
least	YERVOY.xml:S3:3537:5	least	JJS	O	O
1	YERVOY.xml:S3:3543:1	1	CD	O	O
month	YERVOY.xml:S3:3545:5	month	NN	O	O
.	YERVOY.xml:S3:3550:1	.	.	O	O

In	YERVOY.xml:S3:3552:2	In	IN	O	O
clinical	YERVOY.xml:S3:3555:8	clinic	JJ	O	O
trials	YERVOY.xml:S3:3564:6	trial	NNS	O	O
,	YERVOY.xml:S3:3570:1	,	,	O	O
rapid	YERVOY.xml:S3:3572:5	rapid	JJ	O	O
corticosteroid	YERVOY.xml:S3:3578:14	corticosteroid	NN	O	O
tapering	YERVOY.xml:S3:3593:8	taper	VBG	O	O
resulted	YERVOY.xml:S3:3602:8	result	VBN	O	O
in	YERVOY.xml:S3:3611:2	in	IN	O	O
recurrence	YERVOY.xml:S3:3614:10	recurr	NN	O	O
or	YERVOY.xml:S3:3625:2	or	CC	O	O
worsening	YERVOY.xml:S3:3628:9	worsen	VBG	O	O
symptoms	YERVOY.xml:S3:3638:8	symptom	NNS	O	O
of	YERVOY.xml:S3:3647:2	of	IN	O	O
enterocolitis	YERVOY.xml:S3:3650:13	enterocol	NN	O	O
in	YERVOY.xml:S3:3664:2	in	IN	O	O
some	YERVOY.xml:S3:3667:4	some	DT	O	O
patients	YERVOY.xml:S3:3672:8	patient	NNS	O	O
.	YERVOY.xml:S3:3680:1	.	.	O	O

Withhold	YERVOY.xml:S3:3686:8	withhold	NNP	O	O
YERVOY	YERVOY.xml:S3:3695:6	yervoy	NNP	O	O
dosing	YERVOY.xml:S3:3702:6	dose	VBG	O	O
for	YERVOY.xml:S3:3709:3	for	IN	O	O
moderate	YERVOY.xml:S3:3713:8	moder	JJ	O	O
enterocolitis	YERVOY.xml:S3:3722:13	enterocol	NN	O	O
;	YERVOY.xml:S3:3735:1	;	:	O	O
administer	YERVOY.xml:S3:3737:10	administ	CC	O	O
anti	YERVOY.xml:S3:3748:4	anti	SYM	O	O
-	YERVOY.xml:S3:3752:1	-	:	O	O
diarrheal	YERVOY.xml:S3:3753:9	diarrheal	NN	O	O
treatment	YERVOY.xml:S3:3763:9	treatment	NN	O	O
and	YERVOY.xml:S3:3773:3	and	CC	O	O
,	YERVOY.xml:S3:3776:1	,	,	O	O
if	YERVOY.xml:S3:3778:2	if	IN	O	O
persistent	YERVOY.xml:S3:3781:10	persist	JJ	O	O
for	YERVOY.xml:S3:3792:3	for	IN	O	O
more	YERVOY.xml:S3:3796:4	more	JJR	O	O
than	YERVOY.xml:S3:3801:4	than	IN	O	O
1	YERVOY.xml:S3:3806:1	1	CD	O	O
week	YERVOY.xml:S3:3808:4	week	NN	O	O
,	YERVOY.xml:S3:3812:1	,	,	O	O
initiate	YERVOY.xml:S3:3814:8	initi	VBP	O	O
systemic	YERVOY.xml:S3:3823:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:3832:15	corticosteroid	NNS	O	O
at	YERVOY.xml:S3:3848:2	at	IN	O	O
a	YERVOY.xml:S3:3851:1	a	DT	O	O
dose	YERVOY.xml:S3:3853:4	dose	NN	O	O
of	YERVOY.xml:S3:3858:2	of	IN	O	O
0.5	YERVOY.xml:S3:3861:3	0.5	CD	O	O
mg	YERVOY.xml:S3:3865:2	mg	NNS	O	O
kg	YERVOY.xml:S3:3868:2	kg	JJ	O	O
day	YERVOY.xml:S3:3871:3	day	NN	O	O
prednisone	YERVOY.xml:S3:3875:10	prednison	NN	O	O
or	YERVOY.xml:S3:3886:2	or	CC	O	O
equivalent	YERVOY.xml:S3:3889:10	equival	NN	O	O
.	YERVOY.xml:S3:3899:1	.	.	O	O

[	YERVOY.xml:S3:3901:1	[	NNS	O	O
See	YERVOY.xml:S3:3902:3	see	NNP	O	O
Dosage	YERVOY.xml:S3:3907:6	dosag	NNP	O	O
and	YERVOY.xml:S3:3914:3	and	CC	O	O
Administration	YERVOY.xml:S3:3918:14	administr	NNP	O	O
(	YERVOY.xml:S3:3933:1	(	(	O	O
2.2	YERVOY.xml:S3:3934:3	2.2	CD	O	O
)	YERVOY.xml:S3:3937:1	)	)	O	O
.	YERVOY.xml:S3:3940:1	.	.	O	O
]	YERVOY.xml:S3:3941:1	]	NN	O	O

5.2	YERVOY.xml:S3:3952:3	5.2	CD	O	O
Immune	YERVOY.xml:S3:3958:6	immun	NNP	O	O
-	YERVOY.xml:S3:3964:1	-	:	O	O
mediated	YERVOY.xml:S3:3965:8	mediat	VBD	O	O
Hepatitis	YERVOY.xml:S3:3974:9	hepat	NNP	O	O

In	YERVOY.xml:S3:3989:2	In	IN	O	O
Study	YERVOY.xml:S3:3992:5	studi	NNP	O	O
1	YERVOY.xml:S3:3998:1	1	CD	O	O
,	YERVOY.xml:S3:3999:1	,	,	O	O
severe	YERVOY.xml:S3:4001:6	sever	RB	O	O
,	YERVOY.xml:S3:4007:1	,	,	O	O
life	YERVOY.xml:S3:4009:4	life	NN	O	O
-	YERVOY.xml:S3:4013:1	-	:	O	O
threatening	YERVOY.xml:S3:4014:11	threaten	NN	O	O
,	YERVOY.xml:S3:4025:1	,	,	O	O
or	YERVOY.xml:S3:4027:2	or	CC	O	O
fatal	YERVOY.xml:S3:4030:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
hepatotoxicity	YERVOY.xml:S3:4036:14	hepatotox	NN	B-AdverseReaction	O
(	YERVOY.xml:S3:4051:1	(	(	O	O
AST	YERVOY.xml:S3:4052:3	ast	NNP	B-AdverseReaction	O
or	YERVOY.xml:S3:4056:2	or	CC	O	O
ALT	YERVOY.xml:S3:4059:3	alt	NNP	B-AdverseReaction	I-AdverseReaction
elevations	YERVOY.xml:S3:4063:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
of	YERVOY.xml:S3:4074:2	of	IN	O	O
more	YERVOY.xml:S3:4077:4	more	JJR	O	O
than	YERVOY.xml:S3:4082:4	than	IN	O	O
5	YERVOY.xml:S3:4087:1	5	CD	O	O
times	YERVOY.xml:S3:4089:5	time	NNS	O	O
the	YERVOY.xml:S3:4095:3	the	DT	O	O
upper	YERVOY.xml:S3:4099:5	upper	JJ	O	O
limit	YERVOY.xml:S3:4105:5	limit	NN	O	O
of	YERVOY.xml:S3:4111:2	of	IN	O	O
normal	YERVOY.xml:S3:4114:6	normal	JJ	O	O
or	YERVOY.xml:S3:4121:2	or	CC	O	O
total	YERVOY.xml:S3:4124:5	total	JJ	B-AdverseReaction	O
bilirubin	YERVOY.xml:S3:4130:9	bilirubin	JJ	I-AdverseReaction	O
elevations	YERVOY.xml:S3:4140:10	elev	NNS	I-AdverseReaction	O
more	YERVOY.xml:S3:4151:4	more	JJR	O	O
than	YERVOY.xml:S3:4156:4	than	IN	O	O
3	YERVOY.xml:S3:4161:1	3	CD	O	O
times	YERVOY.xml:S3:4163:5	time	NNS	O	O
the	YERVOY.xml:S3:4169:3	the	DT	O	O
upper	YERVOY.xml:S3:4173:5	upper	JJ	O	O
limit	YERVOY.xml:S3:4179:5	limit	NN	O	O
of	YERVOY.xml:S3:4185:2	of	IN	O	O
normal	YERVOY.xml:S3:4188:6	normal	JJ	O	O
;	YERVOY.xml:S3:4194:1	;	:	O	O
Grade	YERVOY.xml:S3:4196:5	grade	NNP	O	O
3	YERVOY.xml:S3:4202:1	3	CD	O	O
-	YERVOY.xml:S3:4203:1	-	:	O	O
5	YERVOY.xml:S3:4204:1	5	CD	O	O
)	YERVOY.xml:S3:4205:1	)	)	O	O
occurred	YERVOY.xml:S3:4207:8	occur	VBD	O	O
in	YERVOY.xml:S3:4216:2	in	IN	O	O
8	YERVOY.xml:S3:4219:1	8	CD	O	O
(	YERVOY.xml:S3:4221:1	(	(	O	O
2%	YERVOY.xml:S3:4222:2	2%	CD	O	O
)	YERVOY.xml:S3:4224:1	)	)	O	O
YERVOY	YERVOY.xml:S3:4226:6	yervoy	SYM	O	O
-	YERVOY.xml:S3:4232:1	-	:	O	O
treated	YERVOY.xml:S3:4233:7	treat	JJ	O	O
patients	YERVOY.xml:S3:4241:8	patient	NNS	O	O
,	YERVOY.xml:S3:4249:1	,	,	O	O
with	YERVOY.xml:S3:4251:4	with	IN	O	O
fatal	YERVOY.xml:S3:4256:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
hepatic	YERVOY.xml:S3:4262:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
failure	YERVOY.xml:S3:4270:7	failur	NN	I-AdverseReaction	I-AdverseReaction
in	YERVOY.xml:S3:4278:2	in	IN	O	O
0.2%	YERVOY.xml:S3:4281:4	0.2%	CD	O	O
and	YERVOY.xml:S3:4286:3	and	CC	O	O
hospitalization	YERVOY.xml:S3:4290:15	hospit	NN	O	O
in	YERVOY.xml:S3:4306:2	in	IN	O	O
0.4%	YERVOY.xml:S3:4309:4	0.4%	CD	O	O
of	YERVOY.xml:S3:4314:2	of	IN	O	O
YERVOY	YERVOY.xml:S3:4317:6	yervoy	NNP	O	O
-	YERVOY.xml:S3:4323:1	-	:	O	O
treated	YERVOY.xml:S3:4324:7	treat	VBD	O	O
patients	YERVOY.xml:S3:4332:8	patient	NNS	O	O
.	YERVOY.xml:S3:4340:1	.	.	O	O

An	YERVOY.xml:S3:4342:2	An	DT	O	O
additional	YERVOY.xml:S3:4345:10	addit	JJ	O	O
13	YERVOY.xml:S3:4356:2	13	CD	O	O
(	YERVOY.xml:S3:4359:1	(	(	O	O
2.5%	YERVOY.xml:S3:4360:4	2.5%	CD	O	O
)	YERVOY.xml:S3:4364:1	)	)	O	O
patients	YERVOY.xml:S3:4366:8	patient	NNS	O	O
experienced	YERVOY.xml:S3:4375:11	experienc	JJ	O	O
moderate	YERVOY.xml:S3:4387:8	moder	JJ	O	O
hepatotoxicity	YERVOY.xml:S3:4396:14	hepatotox	NN	B-AdverseReaction	O
manifested	YERVOY.xml:S3:4411:10	manifest	VBN	O	O
by	YERVOY.xml:S3:4422:2	by	IN	O	O
liver	YERVOY.xml:S3:4425:5	liver	NN	B-AdverseReaction	O
function	YERVOY.xml:S3:4431:8	function	NN	I-AdverseReaction	O
test	YERVOY.xml:S3:4440:4	test	NN	I-AdverseReaction	O
abnormalities	YERVOY.xml:S3:4445:13	abnorm	NNS	I-AdverseReaction	O
(	YERVOY.xml:S3:4459:1	(	(	O	O
AST	YERVOY.xml:S3:4460:3	ast	NNP	B-AdverseReaction	O
or	YERVOY.xml:S3:4464:2	or	CC	O	O
ALT	YERVOY.xml:S3:4467:3	alt	NNP	B-AdverseReaction	I-AdverseReaction
elevations	YERVOY.xml:S3:4471:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
of	YERVOY.xml:S3:4482:2	of	IN	O	O
more	YERVOY.xml:S3:4485:4	more	JJR	O	O
than	YERVOY.xml:S3:4490:4	than	IN	O	O
2.5	YERVOY.xml:S3:4495:3	2.5	CD	O	O
times	YERVOY.xml:S3:4499:5	time	NNS	O	O
but	YERVOY.xml:S3:4505:3	but	CC	O	O
not	YERVOY.xml:S3:4509:3	not	RB	O	O
more	YERVOY.xml:S3:4513:4	more	JJR	O	O
than	YERVOY.xml:S3:4518:4	than	IN	O	O
5	YERVOY.xml:S3:4523:1	5	CD	O	O
times	YERVOY.xml:S3:4525:5	time	NNS	O	O
the	YERVOY.xml:S3:4531:3	the	DT	O	O
upper	YERVOY.xml:S3:4535:5	upper	JJ	O	O
limit	YERVOY.xml:S3:4541:5	limit	NN	O	O
of	YERVOY.xml:S3:4547:2	of	IN	O	O
normal	YERVOY.xml:S3:4550:6	normal	JJ	O	O
or	YERVOY.xml:S3:4557:2	or	CC	O	O
total	YERVOY.xml:S3:4560:5	total	JJ	B-AdverseReaction	O
bilirubin	YERVOY.xml:S3:4566:9	bilirubin	JJ	I-AdverseReaction	O
elevation	YERVOY.xml:S3:4576:9	elev	NN	I-AdverseReaction	O
of	YERVOY.xml:S3:4586:2	of	IN	O	O
more	YERVOY.xml:S3:4589:4	more	JJR	O	O
than	YERVOY.xml:S3:4594:4	than	IN	O	O
1.5	YERVOY.xml:S3:4599:3	1.5	CD	O	O
times	YERVOY.xml:S3:4603:5	time	NNS	O	O
but	YERVOY.xml:S3:4609:3	but	CC	O	O
not	YERVOY.xml:S3:4613:3	not	RB	O	O
more	YERVOY.xml:S3:4617:4	more	JJR	O	O
than	YERVOY.xml:S3:4622:4	than	IN	O	O
3	YERVOY.xml:S3:4627:1	3	CD	O	O
times	YERVOY.xml:S3:4629:5	time	NNS	O	O
the	YERVOY.xml:S3:4635:3	the	DT	O	O
upper	YERVOY.xml:S3:4639:5	upper	JJ	O	O
limit	YERVOY.xml:S3:4645:5	limit	NN	O	O
of	YERVOY.xml:S3:4651:2	of	IN	O	O
normal	YERVOY.xml:S3:4654:6	normal	JJ	O	O
;	YERVOY.xml:S3:4660:1	;	:	O	O
Grade	YERVOY.xml:S3:4662:5	grade	NNP	O	O
2	YERVOY.xml:S3:4668:1	2	CD	O	O
)	YERVOY.xml:S3:4669:1	)	)	O	O
.	YERVOY.xml:S3:4670:1	.	.	O	O

The	YERVOY.xml:S3:4672:3	the	DT	O	O
underlying	YERVOY.xml:S3:4676:10	underli	VBG	O	O
pathology	YERVOY.xml:S3:4687:9	patholog	NN	O	O
was	YERVOY.xml:S3:4697:3	wa	VBD	O	O
not	YERVOY.xml:S3:4701:3	not	RB	O	O
ascertained	YERVOY.xml:S3:4705:11	ascertain	VBN	O	O
in	YERVOY.xml:S3:4717:2	in	IN	O	O
all	YERVOY.xml:S3:4720:3	all	DT	O	O
patients	YERVOY.xml:S3:4724:8	patient	NNS	O	O
but	YERVOY.xml:S3:4733:3	but	CC	O	O
in	YERVOY.xml:S3:4737:2	in	IN	O	O
some	YERVOY.xml:S3:4740:4	some	DT	O	O
instances	YERVOY.xml:S3:4745:9	instanc	NNS	O	O
included	YERVOY.xml:S3:4755:8	includ	VBD	O	O
immune	YERVOY.xml:S3:4764:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:4770:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S3:4771:8	mediat	VBN	I-AdverseReaction	I-AdverseReaction
hepatitis	YERVOY.xml:S3:4780:9	hepat	NN	I-AdverseReaction	I-AdverseReaction
.	YERVOY.xml:S3:4789:1	.	.	O	O

There	YERVOY.xml:S3:4791:5	there	EX	O	O
were	YERVOY.xml:S3:4797:4	were	VBD	O	O
insufficient	YERVOY.xml:S3:4802:12	insuffici	JJ	O	O
numbers	YERVOY.xml:S3:4815:7	number	NNS	O	O
of	YERVOY.xml:S3:4823:2	of	IN	O	O
patients	YERVOY.xml:S3:4826:8	patient	NNS	O	O
with	YERVOY.xml:S3:4835:4	with	IN	O	O
biopsy	YERVOY.xml:S3:4840:6	biopsi	JJ	O	O
-	YERVOY.xml:S3:4846:1	-	:	O	O
proven	YERVOY.xml:S3:4847:6	proven	RB	O	O
hepatitis	YERVOY.xml:S3:4854:9	hepat	NN	O	O
to	YERVOY.xml:S3:4864:2	to	TO	O	O
characterize	YERVOY.xml:S3:4867:12	character	VB	O	O
the	YERVOY.xml:S3:4880:3	the	DT	O	O
clinical	YERVOY.xml:S3:4884:8	clinic	JJ	O	O
course	YERVOY.xml:S3:4893:6	cours	NN	O	O
of	YERVOY.xml:S3:4900:2	of	IN	O	O
this	YERVOY.xml:S3:4903:4	thi	DT	O	O
event	YERVOY.xml:S3:4908:5	event	NN	O	O
.	YERVOY.xml:S3:4913:1	.	.	O	O

Monitor	YERVOY.xml:S3:4919:7	monitor	NNP	O	O
liver	YERVOY.xml:S3:4927:5	liver	JJ	O	O
function	YERVOY.xml:S3:4933:8	function	NN	O	O
tests	YERVOY.xml:S3:4942:5	test	NNS	O	O
(	YERVOY.xml:S3:4948:1	(	(	O	O
hepatic	YERVOY.xml:S3:4949:7	hepat	JJ	O	O
transaminase	YERVOY.xml:S3:4957:12	transaminas	NN	O	O
and	YERVOY.xml:S3:4970:3	and	CC	O	O
bilirubin	YERVOY.xml:S3:4974:9	bilirubin	NN	O	O
levels	YERVOY.xml:S3:4984:6	level	NNS	O	O
)	YERVOY.xml:S3:4990:1	)	)	O	O
and	YERVOY.xml:S3:4992:3	and	CC	O	O
assess	YERVOY.xml:S3:4996:6	assess	JJ	O	O
patients	YERVOY.xml:S3:5003:8	patient	NNS	O	O
for	YERVOY.xml:S3:5012:3	for	IN	O	O
signs	YERVOY.xml:S3:5016:5	sign	NNS	O	O
and	YERVOY.xml:S3:5022:3	and	CC	O	O
symptoms	YERVOY.xml:S3:5026:8	symptom	NNS	O	O
of	YERVOY.xml:S3:5035:2	of	IN	O	O
hepatotoxicity	YERVOY.xml:S3:5038:14	hepatotox	NN	O	O
before	YERVOY.xml:S3:5053:6	befor	IN	O	O
each	YERVOY.xml:S3:5060:4	each	DT	O	O
dose	YERVOY.xml:S3:5065:4	dose	NN	O	O
of	YERVOY.xml:S3:5070:2	of	IN	O	O
YERVOY	YERVOY.xml:S3:5073:6	yervoy	NNP	O	O
.	YERVOY.xml:S3:5079:1	.	.	O	O

In	YERVOY.xml:S3:5081:2	In	IN	O	O
patients	YERVOY.xml:S3:5084:8	patient	NNS	O	O
with	YERVOY.xml:S3:5093:4	with	IN	O	O
hepatotoxicity	YERVOY.xml:S3:5098:14	hepatotox	NN	O	O
,	YERVOY.xml:S3:5112:1	,	,	O	O
rule	YERVOY.xml:S3:5114:4	rule	NN	O	O
out	YERVOY.xml:S3:5119:3	out	RB	O	O
infectious	YERVOY.xml:S3:5123:10	infecti	JJ	O	O
or	YERVOY.xml:S3:5134:2	or	CC	O	O
malignant	YERVOY.xml:S3:5137:9	malign	JJ	O	O
causes	YERVOY.xml:S3:5147:6	caus	NNS	O	O
and	YERVOY.xml:S3:5154:3	and	CC	O	O
increase	YERVOY.xml:S3:5158:8	increas	VB	O	O
frequency	YERVOY.xml:S3:5167:9	frequenc	NN	O	O
of	YERVOY.xml:S3:5177:2	of	IN	O	O
liver	YERVOY.xml:S3:5180:5	liver	NN	O	O
function	YERVOY.xml:S3:5186:8	function	NN	O	O
test	YERVOY.xml:S3:5195:4	test	NN	O	O
monitoring	YERVOY.xml:S3:5200:10	monitor	NN	O	O
until	YERVOY.xml:S3:5211:5	until	IN	O	O
resolution	YERVOY.xml:S3:5217:10	resolut	NN	O	O
.	YERVOY.xml:S3:5227:1	.	.	O	O

Permanently	YERVOY.xml:S3:5233:11	perman	RB	O	O
discontinue	YERVOY.xml:S3:5245:11	discontinu	JJ	O	O
YERVOY	YERVOY.xml:S3:5257:6	yervoy	NNP	O	O
in	YERVOY.xml:S3:5264:2	in	IN	O	O
patients	YERVOY.xml:S3:5267:8	patient	NNS	O	O
with	YERVOY.xml:S3:5276:4	with	IN	O	O
Grade	YERVOY.xml:S3:5281:5	grade	NNP	O	O
3	YERVOY.xml:S3:5287:1	3	CD	O	O
-	YERVOY.xml:S3:5288:1	-	:	O	O
5	YERVOY.xml:S3:5289:1	5	CD	O	O
hepatotoxicity	YERVOY.xml:S3:5291:14	hepatotox	NN	O	O
and	YERVOY.xml:S3:5306:3	and	CC	O	O
administer	YERVOY.xml:S3:5310:10	administ	NN	O	O
systemic	YERVOY.xml:S3:5321:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:5330:15	corticosteroid	NNS	O	O
at	YERVOY.xml:S3:5346:2	at	IN	O	O
a	YERVOY.xml:S3:5349:1	a	DT	O	O
dose	YERVOY.xml:S3:5351:4	dose	NN	O	O
of	YERVOY.xml:S3:5356:2	of	IN	O	O
1	YERVOY.xml:S3:5359:1	1	CD	O	O
to	YERVOY.xml:S3:5361:2	to	TO	O	O
2	YERVOY.xml:S3:5364:1	2	CD	O	O
mg	YERVOY.xml:S3:5366:2	mg	NNS	O	O
kg	YERVOY.xml:S3:5369:2	kg	JJ	O	O
day	YERVOY.xml:S3:5372:3	day	NN	O	O
of	YERVOY.xml:S3:5376:2	of	IN	O	O
prednisone	YERVOY.xml:S3:5379:10	prednison	NN	O	O
or	YERVOY.xml:S3:5390:2	or	CC	O	O
equivalent	YERVOY.xml:S3:5393:10	equival	NN	O	O
.	YERVOY.xml:S3:5403:1	.	.	O	O

When	YERVOY.xml:S3:5405:4	when	WRB	O	O
liver	YERVOY.xml:S3:5410:5	liver	NN	O	O
function	YERVOY.xml:S3:5416:8	function	NN	O	O
tests	YERVOY.xml:S3:5425:5	test	NNS	O	O
show	YERVOY.xml:S3:5431:4	show	VBP	O	O
sustained	YERVOY.xml:S3:5436:9	sustain	JJ	O	O
improvement	YERVOY.xml:S3:5446:11	improv	NN	O	O
or	YERVOY.xml:S3:5458:2	or	CC	O	O
return	YERVOY.xml:S3:5461:6	return	NN	O	O
to	YERVOY.xml:S3:5468:2	to	TO	O	O
baseline	YERVOY.xml:S3:5471:8	baselin	VB	O	O
,	YERVOY.xml:S3:5479:1	,	,	O	O
initiate	YERVOY.xml:S3:5481:8	initi	VB	O	O
corticosteroid	YERVOY.xml:S3:5490:14	corticosteroid	NN	O	O
tapering	YERVOY.xml:S3:5505:8	taper	NN	O	O
and	YERVOY.xml:S3:5514:3	and	CC	O	O
continue	YERVOY.xml:S3:5518:8	continu	VB	O	O
to	YERVOY.xml:S3:5527:2	to	TO	O	O
taper	YERVOY.xml:S3:5530:5	taper	VB	O	O
over	YERVOY.xml:S3:5536:4	over	IN	O	O
1	YERVOY.xml:S3:5541:1	1	CD	O	O
month	YERVOY.xml:S3:5543:5	month	NN	O	O
.	YERVOY.xml:S3:5548:1	.	.	O	O

Across	YERVOY.xml:S3:5550:6	across	IN	O	O
the	YERVOY.xml:S3:5557:3	the	DT	O	O
clinical	YERVOY.xml:S3:5561:8	clinic	JJ	O	O
development	YERVOY.xml:S3:5570:11	develop	NN	O	O
program	YERVOY.xml:S3:5582:7	program	NN	O	O
for	YERVOY.xml:S3:5590:3	for	IN	O	O
YERVOY	YERVOY.xml:S3:5594:6	yervoy	NNP	O	O
,	YERVOY.xml:S3:5600:1	,	,	O	O
mycophenolate	YERVOY.xml:S3:5602:13	mycophenol	NN	O	O
treatment	YERVOY.xml:S3:5616:9	treatment	NN	O	O
has	YERVOY.xml:S3:5626:3	ha	VBZ	O	O
been	YERVOY.xml:S3:5630:4	been	VBN	O	O
administered	YERVOY.xml:S3:5635:12	administ	VBN	O	O
in	YERVOY.xml:S3:5648:2	in	IN	O	O
patients	YERVOY.xml:S3:5651:8	patient	NNS	O	O
who	YERVOY.xml:S3:5660:3	who	WP	O	O
have	YERVOY.xml:S3:5664:4	have	VBP	O	O
persistent	YERVOY.xml:S3:5669:10	persist	VBN	O	O
severe	YERVOY.xml:S3:5680:6	sever	JJ	O	O
hepatitis	YERVOY.xml:S3:5687:9	hepat	NN	O	O
despite	YERVOY.xml:S3:5697:7	despit	IN	O	O
high	YERVOY.xml:S3:5705:4	high	JJ	O	O
-	YERVOY.xml:S3:5709:1	-	:	O	O
dose	YERVOY.xml:S3:5710:4	dose	JJ	O	O
corticosteroids	YERVOY.xml:S3:5715:15	corticosteroid	NNS	O	O
.	YERVOY.xml:S3:5730:1	.	.	O	O

Withhold	YERVOY.xml:S3:5732:8	withhold	NNP	O	O
YERVOY	YERVOY.xml:S3:5741:6	yervoy	NNP	O	O
in	YERVOY.xml:S3:5748:2	in	IN	O	O
patients	YERVOY.xml:S3:5751:8	patient	NNS	O	O
with	YERVOY.xml:S3:5760:4	with	IN	O	O
Grade	YERVOY.xml:S3:5765:5	grade	NNP	O	O
2	YERVOY.xml:S3:5771:1	2	CD	O	O
hepatotoxicity	YERVOY.xml:S3:5773:14	hepatotox	NN	O	O
.	YERVOY.xml:S3:5787:1	.	.	O	O

[	YERVOY.xml:S3:5789:1	[	NNS	O	O
See	YERVOY.xml:S3:5790:3	see	NNP	O	O
Dosage	YERVOY.xml:S3:5795:6	dosag	NNP	O	O
and	YERVOY.xml:S3:5802:3	and	CC	O	O
Administration	YERVOY.xml:S3:5806:14	administr	NNP	O	O
(	YERVOY.xml:S3:5821:1	(	(	O	O
2.2	YERVOY.xml:S3:5822:3	2.2	CD	O	O
)	YERVOY.xml:S3:5825:1	)	)	O	O
.	YERVOY.xml:S3:5828:1	.	.	O	O
]	YERVOY.xml:S3:5829:1	]	NN	O	O

Concurrent	YERVOY.xml:S3:5840:10	concurr	JJ	O	O
Administration	YERVOY.xml:S3:5851:14	administr	NNP	O	O
with	YERVOY.xml:S3:5866:4	with	IN	O	O
Vemurafenib	YERVOY.xml:S3:5871:11	vemurafenib	NNP	O	O

In	YERVOY.xml:S3:5888:2	In	IN	O	O
a	YERVOY.xml:S3:5891:1	a	DT	O	O
dose	YERVOY.xml:S3:5893:4	dose	JJ	O	O
-	YERVOY.xml:S3:5897:1	-	:	O	O
finding	YERVOY.xml:S3:5898:7	find	VBG	O	O
trial	YERVOY.xml:S3:5906:5	trial	NN	O	O
,	YERVOY.xml:S3:5911:1	,	,	O	O
Grade	YERVOY.xml:S3:5913:5	grade	VBD	O	O
3	YERVOY.xml:S3:5919:1	3	CD	O	O
increases	YERVOY.xml:S3:5921:9	increas	NNS	B-AdverseReaction	O
in	YERVOY.xml:S3:5931:2	in	IN	I-AdverseReaction	O
transaminases	YERVOY.xml:S3:5934:13	transaminas	NNS	I-AdverseReaction	O
with	YERVOY.xml:S3:5948:4	with	IN	O	O
or	YERVOY.xml:S3:5953:2	or	CC	O	O
without	YERVOY.xml:S3:5956:7	without	IN	O	O
concomitant	YERVOY.xml:S3:5964:11	concomit	JJ	O	O
increases	YERVOY.xml:S3:5976:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	YERVOY.xml:S3:5986:2	in	IN	I-AdverseReaction	I-AdverseReaction
total	YERVOY.xml:S3:5989:5	total	JJ	I-AdverseReaction	I-AdverseReaction
bilirubin	YERVOY.xml:S3:5995:9	bilirubin	NN	I-AdverseReaction	I-AdverseReaction
occurred	YERVOY.xml:S3:6005:8	occur	VBD	O	O
in	YERVOY.xml:S3:6014:2	in	IN	O	O
6	YERVOY.xml:S3:6017:1	6	CD	O	O
of	YERVOY.xml:S3:6019:2	of	IN	O	O
10	YERVOY.xml:S3:6022:2	10	CD	O	O
patients	YERVOY.xml:S3:6025:8	patient	NNS	O	O
who	YERVOY.xml:S3:6034:3	who	WP	O	O
received	YERVOY.xml:S3:6038:8	receiv	VBD	O	O
concurrent	YERVOY.xml:S3:6047:10	concurr	JJ	O	O
YERVOY	YERVOY.xml:S3:6058:6	yervoy	NNP	O	O
(	YERVOY.xml:S3:6065:1	(	(	O	O
3	YERVOY.xml:S3:6066:1	3	CD	O	O
mg	YERVOY.xml:S3:6068:2	mg	RB	O	O
kg	YERVOY.xml:S3:6071:2	kg	NN	O	O
)	YERVOY.xml:S3:6073:1	)	)	O	O
and	YERVOY.xml:S3:6075:3	and	CC	O	O
vemurafenib	YERVOY.xml:S3:6079:11	vemurafenib	NN	O	O
(	YERVOY.xml:S3:6091:1	(	(	O	O
960	YERVOY.xml:S3:6092:3	960	CD	O	O
mg	YERVOY.xml:S3:6096:2	mg	NN	O	O
BID	YERVOY.xml:S3:6099:3	bid	NNP	O	O
or	YERVOY.xml:S3:6103:2	or	CC	O	O
720	YERVOY.xml:S3:6106:3	720	CD	O	O
mg	YERVOY.xml:S3:6110:2	mg	NNS	O	O
BID	YERVOY.xml:S3:6113:3	bid	NNP	O	O
)	YERVOY.xml:S3:6116:1	)	)	O	O
.	YERVOY.xml:S3:6117:1	.	.	O	O

5.3	YERVOY.xml:S3:6126:3	5.3	CD	O	O
Immune	YERVOY.xml:S3:6132:6	immun	NNP	O	O
-	YERVOY.xml:S3:6138:1	-	:	O	O
mediated	YERVOY.xml:S3:6139:8	mediat	VBD	O	O
Dermatitis	YERVOY.xml:S3:6148:10	dermat	NNP	O	O

In	YERVOY.xml:S3:6164:2	In	IN	O	O
Study	YERVOY.xml:S3:6167:5	studi	NNP	O	O
1	YERVOY.xml:S3:6173:1	1	CD	O	O
,	YERVOY.xml:S3:6174:1	,	,	O	O
severe	YERVOY.xml:S3:6176:6	sever	RB	O	O
,	YERVOY.xml:S3:6182:1	,	,	O	O
life	YERVOY.xml:S3:6184:4	life	NN	O	O
-	YERVOY.xml:S3:6188:1	-	:	O	O
threatening	YERVOY.xml:S3:6189:11	threaten	NN	O	O
,	YERVOY.xml:S3:6200:1	,	,	O	O
or	YERVOY.xml:S3:6202:2	or	CC	O	O
fatal	YERVOY.xml:S3:6205:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
immune	YERVOY.xml:S3:6211:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:6217:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S3:6218:8	mediat	VBN	I-AdverseReaction	I-AdverseReaction
dermatitis	YERVOY.xml:S3:6227:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
(	YERVOY.xml:S3:6238:1	(	(	O	O
eg	YERVOY.xml:S3:6239:2	eg	JJ	O	O
,	YERVOY.xml:S3:6241:1	,	,	O	O
Stevens	YERVOY.xml:S3:6243:7	steven	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:6250:1	-	:	I-AdverseReaction	I-AdverseReaction
Johnson	YERVOY.xml:S3:6251:7	johnson	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	YERVOY.xml:S3:6259:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:6267:1	,	,	O	O
toxic	YERVOY.xml:S3:6269:5	toxic	JJ	B-AdverseReaction	B-AdverseReaction
epidermal	YERVOY.xml:S3:6275:9	epiderm	JJ	I-AdverseReaction	I-AdverseReaction
necrolysis	YERVOY.xml:S3:6285:10	necrolysi	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:6295:1	,	,	O	O
or	YERVOY.xml:S3:6297:2	or	CC	O	O
rash	YERVOY.xml:S3:6300:4	rash	NN	B-AdverseReaction	B-AdverseReaction
complicated	YERVOY.xml:S3:6305:11	complic	VBN	O	O
by	YERVOY.xml:S3:6317:2	by	IN	O	O
full	YERVOY.xml:S3:6320:4	full	JJ	O	O
thickness	YERVOY.xml:S3:6325:9	thick	NN	O	O
dermal	YERVOY.xml:S3:6335:6	dermal	JJ	B-AdverseReaction	O
ulceration	YERVOY.xml:S3:6342:10	ulcer	NN	I-AdverseReaction	O
,	YERVOY.xml:S3:6352:1	,	,	O	O
or	YERVOY.xml:S3:6354:2	or	CC	O	O
necrotic	YERVOY.xml:S3:6357:8	necrot	JJ	I-AdverseReaction	O
,	YERVOY.xml:S3:6365:1	,	,	O	O
bullous	YERVOY.xml:S3:6367:7	bullou	JJ	I-AdverseReaction	O
,	YERVOY.xml:S3:6374:1	,	,	O	O
or	YERVOY.xml:S3:6376:2	or	CC	O	O
hemorrhagic	YERVOY.xml:S3:6379:11	hemorrhag	JJ	I-AdverseReaction	O
manifestations	YERVOY.xml:S3:6391:14	manifest	NNS	I-AdverseReaction	O
;	YERVOY.xml:S3:6405:1	;	:	O	O
Grade	YERVOY.xml:S3:6407:5	grade	NNP	O	O
3	YERVOY.xml:S3:6413:1	3	CD	O	O
-	YERVOY.xml:S3:6414:1	-	:	O	O
5	YERVOY.xml:S3:6415:1	5	CD	O	O
)	YERVOY.xml:S3:6416:1	)	)	O	O
occurred	YERVOY.xml:S3:6418:8	occur	VBD	O	O
in	YERVOY.xml:S3:6427:2	in	IN	O	O
13	YERVOY.xml:S3:6430:2	13	CD	O	O
(	YERVOY.xml:S3:6433:1	(	(	O	O
2.5%	YERVOY.xml:S3:6434:4	2.5%	CD	O	O
)	YERVOY.xml:S3:6438:1	)	)	O	O
YERVOY	YERVOY.xml:S3:6440:6	yervoy	SYM	O	O
-	YERVOY.xml:S3:6446:1	-	:	O	O
treated	YERVOY.xml:S3:6447:7	treat	JJ	O	O
patients	YERVOY.xml:S3:6455:8	patient	NNS	O	O
.	YERVOY.xml:S3:6463:1	.	.	O	O

One	YERVOY.xml:S3:6465:3	one	CD	O	O
(	YERVOY.xml:S3:6469:1	(	(	O	O
0.2%	YERVOY.xml:S3:6470:4	0.2%	CD	O	O
)	YERVOY.xml:S3:6474:1	)	)	O	O
patient	YERVOY.xml:S3:6476:7	patient	NN	O	O
died	YERVOY.xml:S3:6484:4	die	VBD	B-AdverseReaction	O
as	YERVOY.xml:S3:6489:2	as	IN	O	O
a	YERVOY.xml:S3:6492:1	a	DT	O	O
result	YERVOY.xml:S3:6494:6	result	NN	O	O
of	YERVOY.xml:S3:6501:2	of	IN	O	O
toxic	YERVOY.xml:S3:6504:5	toxic	NN	B-AdverseReaction	O
epidermal	YERVOY.xml:S3:6510:9	epiderm	JJ	I-AdverseReaction	O
necrolysis	YERVOY.xml:S3:6520:10	necrolysi	NN	I-AdverseReaction	O
and	YERVOY.xml:S3:6531:3	and	CC	O	O
one	YERVOY.xml:S3:6535:3	one	CD	O	O
additional	YERVOY.xml:S3:6539:10	addit	JJ	O	O
patient	YERVOY.xml:S3:6550:7	patient	NN	O	O
required	YERVOY.xml:S3:6558:8	requir	VBN	O	O
hospitalization	YERVOY.xml:S3:6567:15	hospit	NN	O	O
for	YERVOY.xml:S3:6583:3	for	IN	O	O
severe	YERVOY.xml:S3:6587:6	sever	JJ	O	O
dermatitis	YERVOY.xml:S3:6594:10	dermat	NN	B-AdverseReaction	O
.	YERVOY.xml:S3:6604:1	.	.	O	O

There	YERVOY.xml:S3:6606:5	there	EX	O	O
were	YERVOY.xml:S3:6612:4	were	VBD	O	O
63	YERVOY.xml:S3:6617:2	63	CD	O	O
(	YERVOY.xml:S3:6620:1	(	(	O	O
12%	YERVOY.xml:S3:6621:3	12%	CD	O	O
)	YERVOY.xml:S3:6624:1	)	)	O	O
patients	YERVOY.xml:S3:6626:8	patient	NNS	O	O
with	YERVOY.xml:S3:6635:4	with	IN	O	O
moderate	YERVOY.xml:S3:6640:8	moder	JJ	O	O
(	YERVOY.xml:S3:6649:1	(	(	O	O
Grade	YERVOY.xml:S3:6650:5	grade	NNP	O	O
2	YERVOY.xml:S3:6656:1	2	CD	O	O
)	YERVOY.xml:S3:6657:1	)	)	O	O
dermatitis	YERVOY.xml:S3:6659:10	dermat	NN	B-AdverseReaction	O
.	YERVOY.xml:S3:6669:1	.	.	O	O

The	YERVOY.xml:S3:6675:3	the	DT	O	O
median	YERVOY.xml:S3:6679:6	median	JJ	O	O
time	YERVOY.xml:S3:6686:4	time	NN	O	O
to	YERVOY.xml:S3:6691:2	to	TO	O	O
onset	YERVOY.xml:S3:6694:5	onset	VB	O	O
of	YERVOY.xml:S3:6700:2	of	IN	O	O
moderate	YERVOY.xml:S3:6703:8	moder	JJ	O	O
,	YERVOY.xml:S3:6711:1	,	,	O	O
severe	YERVOY.xml:S3:6713:6	sever	JJ	O	O
,	YERVOY.xml:S3:6719:1	,	,	O	O
or	YERVOY.xml:S3:6721:2	or	CC	O	O
life	YERVOY.xml:S3:6724:4	life	NN	O	O
-	YERVOY.xml:S3:6728:1	-	:	O	O
threatening	YERVOY.xml:S3:6729:11	threaten	VBG	O	O
immune	YERVOY.xml:S3:6741:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:6747:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S3:6748:8	mediat	VBD	I-AdverseReaction	I-AdverseReaction
dermatitis	YERVOY.xml:S3:6757:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
was	YERVOY.xml:S3:6768:3	wa	VBD	O	O
3.1	YERVOY.xml:S3:6772:3	3.1	CD	O	O
weeks	YERVOY.xml:S3:6776:5	week	NNS	O	O
and	YERVOY.xml:S3:6782:3	and	CC	O	O
ranged	YERVOY.xml:S3:6786:6	rang	VBD	O	O
up	YERVOY.xml:S3:6793:2	up	RB	O	O
to	YERVOY.xml:S3:6796:2	to	TO	O	O
17.3	YERVOY.xml:S3:6799:4	17.3	CD	O	O
weeks	YERVOY.xml:S3:6804:5	week	NNS	O	O
from	YERVOY.xml:S3:6810:4	from	IN	O	O
the	YERVOY.xml:S3:6815:3	the	DT	O	O
initiation	YERVOY.xml:S3:6819:10	initi	NN	O	O
of	YERVOY.xml:S3:6830:2	of	IN	O	O
YERVOY	YERVOY.xml:S3:6833:6	yervoy	NNP	O	O
.	YERVOY.xml:S3:6839:1	.	.	O	O

Seven	YERVOY.xml:S3:6845:5	seven	NNP	O	O
(	YERVOY.xml:S3:6851:1	(	(	O	O
54%	YERVOY.xml:S3:6852:3	54%	CD	O	O
)	YERVOY.xml:S3:6855:1	)	)	O	O
YERVOY	YERVOY.xml:S3:6857:6	yervoy	SYM	O	O
-	YERVOY.xml:S3:6863:1	-	:	O	O
treated	YERVOY.xml:S3:6864:7	treat	JJ	O	O
patients	YERVOY.xml:S3:6872:8	patient	NNS	O	O
with	YERVOY.xml:S3:6881:4	with	IN	O	O
severe	YERVOY.xml:S3:6886:6	sever	JJ	O	O
dermatitis	YERVOY.xml:S3:6893:10	dermat	NN	B-AdverseReaction	O
received	YERVOY.xml:S3:6904:8	receiv	VBD	O	O
high	YERVOY.xml:S3:6913:4	high	JJ	O	O
-	YERVOY.xml:S3:6917:1	-	:	O	O
dose	YERVOY.xml:S3:6918:4	dose	JJ	O	O
corticosteroids	YERVOY.xml:S3:6923:15	corticosteroid	NNS	O	O
(	YERVOY.xml:S3:6939:1	(	(	O	O
median	YERVOY.xml:S3:6940:6	median	JJ	O	O
dose	YERVOY.xml:S3:6947:4	dose	NN	O	O
60	YERVOY.xml:S3:6952:2	60	CD	O	O
mg	YERVOY.xml:S3:6955:2	mg	NN	O	O
prednisone	YERVOY.xml:S3:6958:10	prednison	NN	O	O
day	YERVOY.xml:S3:6969:3	day	NN	O	O
or	YERVOY.xml:S3:6973:2	or	CC	O	O
equivalent	YERVOY.xml:S3:6976:10	equival	NN	O	O
)	YERVOY.xml:S3:6986:1	)	)	O	O
for	YERVOY.xml:S3:6988:3	for	IN	O	O
up	YERVOY.xml:S3:6992:2	up	IN	O	O
to	YERVOY.xml:S3:6995:2	to	TO	O	O
14.9	YERVOY.xml:S3:6998:4	14.9	CD	O	O
weeks	YERVOY.xml:S3:7003:5	week	NNS	O	O
followed	YERVOY.xml:S3:7009:8	follow	VBN	O	O
by	YERVOY.xml:S3:7018:2	by	IN	O	O
corticosteroid	YERVOY.xml:S3:7021:14	corticosteroid	JJ	O	O
taper	YERVOY.xml:S3:7036:5	taper	NN	O	O
.	YERVOY.xml:S3:7041:1	.	.	O	O

Of	YERVOY.xml:S3:7043:2	Of	IN	O	O
these	YERVOY.xml:S3:7046:5	these	DT	O	O
7	YERVOY.xml:S3:7052:1	7	CD	O	O
patients	YERVOY.xml:S3:7054:8	patient	NNS	O	O
,	YERVOY.xml:S3:7062:1	,	,	O	O
6	YERVOY.xml:S3:7064:1	6	CD	O	O
had	YERVOY.xml:S3:7066:3	had	VBD	O	O
complete	YERVOY.xml:S3:7070:8	complet	JJ	O	O
resolution	YERVOY.xml:S3:7079:10	resolut	NN	O	O
;	YERVOY.xml:S3:7089:1	;	:	O	O
time	YERVOY.xml:S3:7091:4	time	NN	O	O
to	YERVOY.xml:S3:7096:2	to	TO	O	O
resolution	YERVOY.xml:S3:7099:10	resolut	NN	O	O
ranged	YERVOY.xml:S3:7110:6	rang	VBD	O	O
up	YERVOY.xml:S3:7117:2	up	RB	O	O
to	YERVOY.xml:S3:7120:2	to	TO	O	O
15.6	YERVOY.xml:S3:7123:4	15.6	CD	O	O
weeks	YERVOY.xml:S3:7128:5	week	NNS	O	O
.	YERVOY.xml:S3:7133:1	.	.	O	O

Of	YERVOY.xml:S3:7139:2	Of	IN	O	O
the	YERVOY.xml:S3:7142:3	the	DT	O	O
63	YERVOY.xml:S3:7146:2	63	CD	O	O
patients	YERVOY.xml:S3:7149:8	patient	NNS	O	O
with	YERVOY.xml:S3:7158:4	with	IN	O	O
moderate	YERVOY.xml:S3:7163:8	moder	JJ	O	O
dermatitis	YERVOY.xml:S3:7172:10	dermat	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:7182:1	,	,	O	O
25	YERVOY.xml:S3:7184:2	25	CD	O	O
(	YERVOY.xml:S3:7187:1	(	(	O	O
40%	YERVOY.xml:S3:7188:3	40%	CD	O	O
)	YERVOY.xml:S3:7191:1	)	)	O	O
were	YERVOY.xml:S3:7193:4	were	VBD	O	O
treated	YERVOY.xml:S3:7198:7	treat	VBN	O	O
with	YERVOY.xml:S3:7206:4	with	IN	O	O
systemic	YERVOY.xml:S3:7211:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:7220:15	corticosteroid	NNS	O	O
(	YERVOY.xml:S3:7236:1	(	(	O	O
median	YERVOY.xml:S3:7237:6	median	NN	O	O
of	YERVOY.xml:S3:7244:2	of	IN	O	O
60	YERVOY.xml:S3:7247:2	60	CD	O	O
mg	YERVOY.xml:S3:7250:2	mg	JJ	O	O
day	YERVOY.xml:S3:7253:3	day	NN	O	O
of	YERVOY.xml:S3:7257:2	of	IN	O	O
prednisone	YERVOY.xml:S3:7260:10	prednison	NN	O	O
or	YERVOY.xml:S3:7271:2	or	CC	O	O
equivalent	YERVOY.xml:S3:7274:10	equival	NN	O	O
)	YERVOY.xml:S3:7284:1	)	)	O	O
for	YERVOY.xml:S3:7286:3	for	IN	O	O
a	YERVOY.xml:S3:7290:1	a	DT	O	O
median	YERVOY.xml:S3:7292:6	median	NN	O	O
of	YERVOY.xml:S3:7299:2	of	IN	O	O
2.1	YERVOY.xml:S3:7302:3	2.1	CD	O	O
weeks	YERVOY.xml:S3:7306:5	week	NNS	O	O
,	YERVOY.xml:S3:7311:1	,	,	O	O
7	YERVOY.xml:S3:7313:1	7	CD	O	O
(	YERVOY.xml:S3:7315:1	(	(	O	O
11%	YERVOY.xml:S3:7316:3	11%	CD	O	O
)	YERVOY.xml:S3:7319:1	)	)	O	O
were	YERVOY.xml:S3:7321:4	were	VBD	O	O
treated	YERVOY.xml:S3:7326:7	treat	VBN	O	O
with	YERVOY.xml:S3:7334:4	with	IN	O	O
only	YERVOY.xml:S3:7339:4	onli	RB	O	O
topical	YERVOY.xml:S3:7344:7	topic	JJ	O	O
corticosteroids	YERVOY.xml:S3:7352:15	corticosteroid	NNS	O	O
,	YERVOY.xml:S3:7367:1	,	,	O	O
and	YERVOY.xml:S3:7369:3	and	CC	O	O
31	YERVOY.xml:S3:7373:2	31	CD	O	O
(	YERVOY.xml:S3:7376:1	(	(	O	O
49%	YERVOY.xml:S3:7377:3	49%	CD	O	O
)	YERVOY.xml:S3:7380:1	)	)	O	O
did	YERVOY.xml:S3:7382:3	did	VBD	O	O
not	YERVOY.xml:S3:7386:3	not	RB	O	O
receive	YERVOY.xml:S3:7390:7	receiv	VB	O	O
systemic	YERVOY.xml:S3:7398:8	system	NN	O	O
or	YERVOY.xml:S3:7407:2	or	CC	O	O
topical	YERVOY.xml:S3:7410:7	topic	JJ	O	O
corticosteroids	YERVOY.xml:S3:7418:15	corticosteroid	NNS	O	O
.	YERVOY.xml:S3:7433:1	.	.	O	O

Forty	YERVOY.xml:S3:7435:5	forti	NNP	O	O
-	YERVOY.xml:S3:7440:1	-	:	O	O
four	YERVOY.xml:S3:7441:4	four	CD	O	O
(	YERVOY.xml:S3:7446:1	(	(	O	O
70%	YERVOY.xml:S3:7447:3	70%	CD	O	O
)	YERVOY.xml:S3:7450:1	)	)	O	O
patients	YERVOY.xml:S3:7452:8	patient	NNS	O	O
with	YERVOY.xml:S3:7461:4	with	IN	O	O
moderate	YERVOY.xml:S3:7466:8	moder	JJ	O	O
dermatitis	YERVOY.xml:S3:7475:10	dermat	NN	B-AdverseReaction	O
were	YERVOY.xml:S3:7486:4	were	VBD	O	O
reported	YERVOY.xml:S3:7491:8	report	VBN	O	O
to	YERVOY.xml:S3:7500:2	to	TO	O	O
have	YERVOY.xml:S3:7503:4	have	VB	O	O
complete	YERVOY.xml:S3:7508:8	complet	JJ	O	O
resolution	YERVOY.xml:S3:7517:10	resolut	NN	O	O
,	YERVOY.xml:S3:7527:1	,	,	O	O
7	YERVOY.xml:S3:7529:1	7	CD	O	O
(	YERVOY.xml:S3:7531:1	(	(	O	O
11%	YERVOY.xml:S3:7532:3	11%	CD	O	O
)	YERVOY.xml:S3:7535:1	)	)	O	O
improved	YERVOY.xml:S3:7537:8	improv	VBN	O	O
to	YERVOY.xml:S3:7546:2	to	TO	O	O
mild	YERVOY.xml:S3:7549:4	mild	VB	O	O
(	YERVOY.xml:S3:7554:1	(	(	O	O
Grade	YERVOY.xml:S3:7555:5	grade	NNP	O	O
1	YERVOY.xml:S3:7561:1	1	CD	O	O
)	YERVOY.xml:S3:7562:1	)	)	O	O
severity	YERVOY.xml:S3:7564:8	sever	NN	O	O
,	YERVOY.xml:S3:7572:1	,	,	O	O
and	YERVOY.xml:S3:7574:3	and	CC	O	O
12	YERVOY.xml:S3:7578:2	12	CD	O	O
(	YERVOY.xml:S3:7581:1	(	(	O	O
19%	YERVOY.xml:S3:7582:3	19%	CD	O	O
)	YERVOY.xml:S3:7585:1	)	)	O	O
had	YERVOY.xml:S3:7587:3	had	VBD	O	O
no	YERVOY.xml:S3:7591:2	no	DT	O	O
reported	YERVOY.xml:S3:7594:8	report	VBN	O	O
improvement	YERVOY.xml:S3:7603:11	improv	NN	O	O
.	YERVOY.xml:S3:7614:1	.	.	O	O

Monitor	YERVOY.xml:S3:7620:7	monitor	NN	O	O
patients	YERVOY.xml:S3:7628:8	patient	NNS	O	O
for	YERVOY.xml:S3:7637:3	for	IN	O	O
signs	YERVOY.xml:S3:7641:5	sign	NNS	O	O
and	YERVOY.xml:S3:7647:3	and	CC	O	O
symptoms	YERVOY.xml:S3:7651:8	symptom	NNS	O	O
of	YERVOY.xml:S3:7660:2	of	IN	O	O
dermatitis	YERVOY.xml:S3:7663:10	dermat	NN	O	O
such	YERVOY.xml:S3:7674:4	such	JJ	O	O
as	YERVOY.xml:S3:7679:2	as	IN	O	O
rash	YERVOY.xml:S3:7682:4	rash	NN	O	B-AdverseReaction
and	YERVOY.xml:S3:7687:3	and	CC	O	O
pruritus	YERVOY.xml:S3:7691:8	pruritu	NN	O	B-AdverseReaction
.	YERVOY.xml:S3:7699:1	.	.	O	O

Unless	YERVOY.xml:S3:7701:6	unless	IN	O	O
an	YERVOY.xml:S3:7708:2	an	DT	O	O
alternate	YERVOY.xml:S3:7711:9	altern	NN	O	O
etiology	YERVOY.xml:S3:7721:8	etiolog	NN	O	O
has	YERVOY.xml:S3:7730:3	ha	VBZ	O	O
been	YERVOY.xml:S3:7734:4	been	VBN	O	O
identified	YERVOY.xml:S3:7739:10	identifi	VBN	O	O
,	YERVOY.xml:S3:7749:1	,	,	O	O
signs	YERVOY.xml:S3:7751:5	sign	NNS	O	O
or	YERVOY.xml:S3:7757:2	or	CC	O	O
symptoms	YERVOY.xml:S3:7760:8	symptom	NNS	O	O
of	YERVOY.xml:S3:7769:2	of	IN	O	O
dermatitis	YERVOY.xml:S3:7772:10	dermat	NN	O	O
should	YERVOY.xml:S3:7783:6	should	MD	O	O
be	YERVOY.xml:S3:7790:2	be	VB	O	O
considered	YERVOY.xml:S3:7793:10	consid	VBN	O	O
immune	YERVOY.xml:S3:7804:6	immun	JJ	O	O
-	YERVOY.xml:S3:7810:1	-	:	O	O
mediated	YERVOY.xml:S3:7811:8	mediat	VBN	O	O
.	YERVOY.xml:S3:7819:1	.	.	O	O

Permanently	YERVOY.xml:S3:7825:11	perman	RB	O	O
discontinue	YERVOY.xml:S3:7837:11	discontinu	JJ	O	O
YERVOY	YERVOY.xml:S3:7849:6	yervoy	NNP	O	O
in	YERVOY.xml:S3:7856:2	in	IN	O	O
patients	YERVOY.xml:S3:7859:8	patient	NNS	O	O
with	YERVOY.xml:S3:7868:4	with	IN	O	O
Stevens	YERVOY.xml:S3:7873:7	steven	NNP	O	O
-	YERVOY.xml:S3:7880:1	-	:	O	O
Johnson	YERVOY.xml:S3:7881:7	johnson	NNP	O	O
syndrome	YERVOY.xml:S3:7889:8	syndrom	NN	O	O
,	YERVOY.xml:S3:7897:1	,	,	O	O
toxic	YERVOY.xml:S3:7899:5	toxic	JJ	O	B-AdverseReaction
epidermal	YERVOY.xml:S3:7905:9	epiderm	JJ	O	I-AdverseReaction
necrolysis	YERVOY.xml:S3:7915:10	necrolysi	NN	O	I-AdverseReaction
,	YERVOY.xml:S3:7925:1	,	,	O	O
or	YERVOY.xml:S3:7927:2	or	CC	O	O
rash	YERVOY.xml:S3:7930:4	rash	NN	O	B-AdverseReaction
complicated	YERVOY.xml:S3:7935:11	complic	VBN	O	O
by	YERVOY.xml:S3:7947:2	by	IN	O	O
full	YERVOY.xml:S3:7950:4	full	JJ	O	O
thickness	YERVOY.xml:S3:7955:9	thick	NN	O	O
dermal	YERVOY.xml:S3:7965:6	dermal	JJ	O	O
ulceration	YERVOY.xml:S3:7972:10	ulcer	NN	O	O
,	YERVOY.xml:S3:7982:1	,	,	O	O
or	YERVOY.xml:S3:7984:2	or	CC	O	O
necrotic	YERVOY.xml:S3:7987:8	necrot	JJ	O	O
,	YERVOY.xml:S3:7995:1	,	,	O	O
bullous	YERVOY.xml:S3:7997:7	bullou	JJ	O	O
,	YERVOY.xml:S3:8004:1	,	,	O	O
or	YERVOY.xml:S3:8006:2	or	CC	O	O
hemorrhagic	YERVOY.xml:S3:8009:11	hemorrhag	JJ	O	O
manifestations	YERVOY.xml:S3:8021:14	manifest	NNS	O	O
.	YERVOY.xml:S3:8035:1	.	.	O	O

Administer	YERVOY.xml:S3:8037:10	administ	NNP	O	O
systemic	YERVOY.xml:S3:8048:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:8057:15	corticosteroid	NNS	O	O
at	YERVOY.xml:S3:8073:2	at	IN	O	O
a	YERVOY.xml:S3:8076:1	a	DT	O	O
dose	YERVOY.xml:S3:8078:4	dose	NN	O	O
of	YERVOY.xml:S3:8083:2	of	IN	O	O
1	YERVOY.xml:S3:8086:1	1	CD	O	O
to	YERVOY.xml:S3:8088:2	to	TO	O	O
2	YERVOY.xml:S3:8091:1	2	CD	O	O
mg	YERVOY.xml:S3:8093:2	mg	NNS	O	O
kg	YERVOY.xml:S3:8096:2	kg	JJ	O	O
day	YERVOY.xml:S3:8099:3	day	NN	O	O
of	YERVOY.xml:S3:8103:2	of	IN	O	O
prednisone	YERVOY.xml:S3:8106:10	prednison	NN	O	O
or	YERVOY.xml:S3:8117:2	or	CC	O	O
equivalent	YERVOY.xml:S3:8120:10	equival	NN	O	O
.	YERVOY.xml:S3:8130:1	.	.	O	O

When	YERVOY.xml:S3:8132:4	when	WRB	O	O
dermatitis	YERVOY.xml:S3:8137:10	dermat	NN	O	O
is	YERVOY.xml:S3:8148:2	is	VBZ	O	O
controlled	YERVOY.xml:S3:8151:10	control	VBN	O	O
,	YERVOY.xml:S3:8161:1	,	,	O	O
corticosteroid	YERVOY.xml:S3:8163:14	corticosteroid	JJ	O	O
tapering	YERVOY.xml:S3:8178:8	taper	NN	O	O
should	YERVOY.xml:S3:8187:6	should	MD	O	O
occur	YERVOY.xml:S3:8194:5	occur	VB	O	O
over	YERVOY.xml:S3:8200:4	over	IN	O	O
a	YERVOY.xml:S3:8205:1	a	DT	O	O
period	YERVOY.xml:S3:8207:6	period	NN	O	O
of	YERVOY.xml:S3:8214:2	of	IN	O	O
at	YERVOY.xml:S3:8217:2	at	IN	O	O
least	YERVOY.xml:S3:8220:5	least	JJS	O	O
1	YERVOY.xml:S3:8226:1	1	CD	O	O
month	YERVOY.xml:S3:8228:5	month	NN	O	O
.	YERVOY.xml:S3:8233:1	.	.	O	O

Withhold	YERVOY.xml:S3:8235:8	withhold	NNP	O	O
YERVOY	YERVOY.xml:S3:8244:6	yervoy	NNP	O	O
dosing	YERVOY.xml:S3:8251:6	dose	VBG	O	O
in	YERVOY.xml:S3:8258:2	in	IN	O	O
patients	YERVOY.xml:S3:8261:8	patient	NNS	O	O
with	YERVOY.xml:S3:8270:4	with	IN	O	O
moderate	YERVOY.xml:S3:8275:8	moder	JJ	O	O
to	YERVOY.xml:S3:8284:2	to	TO	O	O
severe	YERVOY.xml:S3:8287:6	sever	VB	O	O
signs	YERVOY.xml:S3:8294:5	sign	NNS	O	O
and	YERVOY.xml:S3:8300:3	and	CC	O	O
symptoms	YERVOY.xml:S3:8304:8	symptom	NNS	O	O
.	YERVOY.xml:S3:8312:1	.	.	O	O

[	YERVOY.xml:S3:8314:1	[	NNS	O	O
See	YERVOY.xml:S3:8315:3	see	NNP	O	O
Dosage	YERVOY.xml:S3:8320:6	dosag	NNP	O	O
and	YERVOY.xml:S3:8327:3	and	CC	O	O
Administration	YERVOY.xml:S3:8331:14	administr	NNP	O	O
(	YERVOY.xml:S3:8346:1	(	(	O	O
2.2	YERVOY.xml:S3:8347:3	2.2	CD	O	O
)	YERVOY.xml:S3:8350:1	)	)	O	O
.	YERVOY.xml:S3:8353:1	.	.	O	O
]	YERVOY.xml:S3:8354:1	]	NN	O	O

For	YERVOY.xml:S3:8362:3	for	IN	O	O
mild	YERVOY.xml:S3:8366:4	mild	NN	O	O
to	YERVOY.xml:S3:8371:2	to	TO	O	O
moderate	YERVOY.xml:S3:8374:8	moder	VB	O	O
dermatitis	YERVOY.xml:S3:8383:10	dermat	NN	O	O
,	YERVOY.xml:S3:8393:1	,	,	O	O
such	YERVOY.xml:S3:8395:4	such	JJ	O	O
as	YERVOY.xml:S3:8400:2	as	IN	O	O
localized	YERVOY.xml:S3:8403:9	local	JJ	O	B-AdverseReaction
rash	YERVOY.xml:S3:8413:4	rash	NN	O	I-AdverseReaction
and	YERVOY.xml:S3:8418:3	and	CC	O	O
pruritus	YERVOY.xml:S3:8422:8	pruritu	NN	O	B-AdverseReaction
,	YERVOY.xml:S3:8430:1	,	,	O	O
treat	YERVOY.xml:S3:8432:5	treat	NN	O	O
symptomatically	YERVOY.xml:S3:8438:15	symptomat	RB	O	O
.	YERVOY.xml:S3:8453:1	.	.	O	O

Administer	YERVOY.xml:S3:8455:10	administ	NNP	O	O
topical	YERVOY.xml:S3:8466:7	topic	JJ	O	O
or	YERVOY.xml:S3:8474:2	or	CC	O	O
systemic	YERVOY.xml:S3:8477:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:8486:15	corticosteroid	NNS	O	O
if	YERVOY.xml:S3:8502:2	if	IN	O	O
there	YERVOY.xml:S3:8505:5	there	EX	O	O
is	YERVOY.xml:S3:8511:2	is	VBZ	O	O
no	YERVOY.xml:S3:8514:2	no	DT	O	O
improvement	YERVOY.xml:S3:8517:11	improv	NN	O	O
of	YERVOY.xml:S3:8529:2	of	IN	O	O
symptoms	YERVOY.xml:S3:8532:8	symptom	NNS	O	O
within	YERVOY.xml:S3:8541:6	within	IN	O	O
1	YERVOY.xml:S3:8548:1	1	CD	O	O
week	YERVOY.xml:S3:8550:4	week	NN	O	O
.	YERVOY.xml:S3:8554:1	.	.	O	O

5.4	YERVOY.xml:S3:8563:3	5.4	CD	O	O
Immune	YERVOY.xml:S3:8569:6	immun	NNP	O	O
-	YERVOY.xml:S3:8575:1	-	:	O	O
mediated	YERVOY.xml:S3:8576:8	mediat	VBD	O	O
Neuropathies	YERVOY.xml:S3:8585:12	neuropathi	NNS	O	O

In	YERVOY.xml:S3:8603:2	In	IN	O	O
Study	YERVOY.xml:S3:8606:5	studi	NNP	O	O
1	YERVOY.xml:S3:8612:1	1	CD	O	O
,	YERVOY.xml:S3:8613:1	,	,	O	O
1	YERVOY.xml:S3:8615:1	1	CD	O	O
case	YERVOY.xml:S3:8617:4	case	NN	O	O
of	YERVOY.xml:S3:8622:2	of	IN	O	O
fatal	YERVOY.xml:S3:8625:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
Guillain	YERVOY.xml:S3:8631:8	guillain	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:8639:1	-	:	I-AdverseReaction	I-AdverseReaction
Barre	YERVOY.xml:S3:8640:5	barr	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	YERVOY.xml:S3:8646:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
and	YERVOY.xml:S3:8655:3	and	CC	O	O
1	YERVOY.xml:S3:8659:1	1	CD	O	O
case	YERVOY.xml:S3:8661:4	case	NN	O	O
of	YERVOY.xml:S3:8666:2	of	IN	O	O
severe	YERVOY.xml:S3:8669:6	sever	JJ	O	O
(	YERVOY.xml:S3:8676:1	(	(	O	O
Grade	YERVOY.xml:S3:8677:5	grade	NNP	O	O
3	YERVOY.xml:S3:8683:1	3	CD	O	O
)	YERVOY.xml:S3:8684:1	)	)	O	O
peripheral	YERVOY.xml:S3:8686:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
motor	YERVOY.xml:S3:8697:5	motor	NN	I-AdverseReaction	I-AdverseReaction
neuropathy	YERVOY.xml:S3:8703:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
were	YERVOY.xml:S3:8714:4	were	VBD	O	O
reported	YERVOY.xml:S3:8719:8	report	VBN	O	O
.	YERVOY.xml:S3:8727:1	.	.	O	O

Across	YERVOY.xml:S3:8729:6	across	IN	O	O
the	YERVOY.xml:S3:8736:3	the	DT	O	O
clinical	YERVOY.xml:S3:8740:8	clinic	JJ	O	O
development	YERVOY.xml:S3:8749:11	develop	NN	O	O
program	YERVOY.xml:S3:8761:7	program	NN	O	O
of	YERVOY.xml:S3:8769:2	of	IN	O	O
YERVOY	YERVOY.xml:S3:8772:6	yervoy	NNP	O	O
,	YERVOY.xml:S3:8778:1	,	,	O	O
myasthenia	YERVOY.xml:S3:8780:10	myasthenia	NN	B-AdverseReaction	O
gravis	YERVOY.xml:S3:8791:6	gravi	NN	I-AdverseReaction	O
and	YERVOY.xml:S3:8798:3	and	CC	O	O
additional	YERVOY.xml:S3:8802:10	addit	JJ	O	O
cases	YERVOY.xml:S3:8813:5	case	NNS	O	O
of	YERVOY.xml:S3:8819:2	of	IN	O	O
Guillain	YERVOY.xml:S3:8822:8	guillain	NNP	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:8830:1	-	:	I-AdverseReaction	I-AdverseReaction
Barre	YERVOY.xml:S3:8831:5	barr	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	YERVOY.xml:S3:8837:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
have	YERVOY.xml:S3:8846:4	have	VBP	O	O
been	YERVOY.xml:S3:8851:4	been	VBN	O	O
reported	YERVOY.xml:S3:8856:8	report	VBN	O	O
.	YERVOY.xml:S3:8864:1	.	.	O	O

Monitor	YERVOY.xml:S3:8870:7	monitor	NNP	O	O
for	YERVOY.xml:S3:8878:3	for	IN	O	O
symptoms	YERVOY.xml:S3:8882:8	symptom	NNS	O	O
of	YERVOY.xml:S3:8891:2	of	IN	O	O
motor	YERVOY.xml:S3:8894:5	motor	NN	O	O
or	YERVOY.xml:S3:8900:2	or	CC	O	O
sensory	YERVOY.xml:S3:8903:7	sensori	JJ	O	O
neuropathy	YERVOY.xml:S3:8911:10	neuropathi	JJ	O	O
such	YERVOY.xml:S3:8922:4	such	JJ	O	O
as	YERVOY.xml:S3:8927:2	as	IN	O	O
unilateral	YERVOY.xml:S3:8930:10	unilater	JJ	O	O
or	YERVOY.xml:S3:8941:2	or	CC	O	O
bilateral	YERVOY.xml:S3:8944:9	bilater	JJ	O	O
weakness	YERVOY.xml:S3:8954:8	weak	NN	O	O
,	YERVOY.xml:S3:8962:1	,	,	O	O
sensory	YERVOY.xml:S3:8964:7	sensori	JJ	O	O
alterations	YERVOY.xml:S3:8972:11	alter	NNS	O	O
,	YERVOY.xml:S3:8983:1	,	,	O	O
or	YERVOY.xml:S3:8985:2	or	CC	O	O
paresthesia	YERVOY.xml:S3:8988:11	paresthesia	NN	O	O
.	YERVOY.xml:S3:8999:1	.	.	O	O

Permanently	YERVOY.xml:S3:9001:11	perman	RB	O	O
discontinue	YERVOY.xml:S3:9013:11	discontinu	JJ	O	O
YERVOY	YERVOY.xml:S3:9025:6	yervoy	NNP	O	O
in	YERVOY.xml:S3:9032:2	in	IN	O	O
patients	YERVOY.xml:S3:9035:8	patient	NNS	O	O
with	YERVOY.xml:S3:9044:4	with	IN	O	O
severe	YERVOY.xml:S3:9049:6	sever	JJ	O	O
neuropathy	YERVOY.xml:S3:9056:10	neuropathi	NN	O	O
(	YERVOY.xml:S3:9067:1	(	(	O	O
interfering	YERVOY.xml:S3:9068:11	interf	VBG	O	O
with	YERVOY.xml:S3:9080:4	with	IN	O	O
daily	YERVOY.xml:S3:9085:5	daili	JJ	O	O
activities	YERVOY.xml:S3:9091:10	activ	NNS	O	O
)	YERVOY.xml:S3:9101:1	)	)	O	O
such	YERVOY.xml:S3:9103:4	such	JJ	O	O
as	YERVOY.xml:S3:9108:2	as	IN	O	O
Guillain	YERVOY.xml:S3:9111:8	guillain	NNP	O	O
-	YERVOY.xml:S3:9119:1	-	:	O	O
Barre	YERVOY.xml:S3:9120:5	barr	NNP	O	O
-	YERVOY.xml:S3:9125:1	-	:	O	O
like	YERVOY.xml:S3:9126:4	like	IN	O	O
syndromes	YERVOY.xml:S3:9131:9	syndrom	NNS	O	O
.	YERVOY.xml:S3:9140:1	.	.	O	O

Institute	YERVOY.xml:S3:9142:9	institut	NNP	O	O
medical	YERVOY.xml:S3:9152:7	medic	JJ	O	O
intervention	YERVOY.xml:S3:9160:12	intervent	NN	O	O
as	YERVOY.xml:S3:9173:2	as	IN	O	O
appropriate	YERVOY.xml:S3:9176:11	appropri	NN	O	O
for	YERVOY.xml:S3:9188:3	for	IN	O	O
management	YERVOY.xml:S3:9192:10	manag	NN	O	O
of	YERVOY.xml:S3:9203:2	of	IN	O	O
severe	YERVOY.xml:S3:9206:6	sever	JJ	O	O
neuropathy	YERVOY.xml:S3:9213:10	neuropathi	NN	O	O
.	YERVOY.xml:S3:9223:1	.	.	O	O

Consider	YERVOY.xml:S3:9225:8	consid	VB	O	O
initiation	YERVOY.xml:S3:9234:10	initi	NN	O	O
of	YERVOY.xml:S3:9245:2	of	IN	O	O
systemic	YERVOY.xml:S3:9248:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:9257:15	corticosteroid	NNS	O	O
at	YERVOY.xml:S3:9273:2	at	IN	O	O
a	YERVOY.xml:S3:9276:1	a	DT	O	O
dose	YERVOY.xml:S3:9278:4	dose	NN	O	O
of	YERVOY.xml:S3:9283:2	of	IN	O	O
1	YERVOY.xml:S3:9286:1	1	CD	O	O
to	YERVOY.xml:S3:9288:2	to	TO	O	O
2	YERVOY.xml:S3:9291:1	2	CD	O	O
mg	YERVOY.xml:S3:9293:2	mg	NNS	O	O
kg	YERVOY.xml:S3:9296:2	kg	JJ	O	O
day	YERVOY.xml:S3:9299:3	day	NN	O	O
prednisone	YERVOY.xml:S3:9303:10	prednison	NN	O	O
or	YERVOY.xml:S3:9314:2	or	CC	O	O
equivalent	YERVOY.xml:S3:9317:10	equival	NN	O	O
for	YERVOY.xml:S3:9328:3	for	IN	O	O
severe	YERVOY.xml:S3:9332:6	sever	JJ	O	O
neuropathies	YERVOY.xml:S3:9339:12	neuropathi	NNS	O	O
.	YERVOY.xml:S3:9351:1	.	.	O	O

Withhold	YERVOY.xml:S3:9353:8	withhold	NNP	O	O
YERVOY	YERVOY.xml:S3:9362:6	yervoy	NNP	O	O
dosing	YERVOY.xml:S3:9369:6	dose	VBG	O	O
in	YERVOY.xml:S3:9376:2	in	IN	O	O
patients	YERVOY.xml:S3:9379:8	patient	NNS	O	O
with	YERVOY.xml:S3:9388:4	with	IN	O	O
moderate	YERVOY.xml:S3:9393:8	moder	JJ	O	O
neuropathy	YERVOY.xml:S3:9402:10	neuropathi	NNS	O	O
(	YERVOY.xml:S3:9413:1	(	(	O	O
not	YERVOY.xml:S3:9414:3	not	RB	O	O
interfering	YERVOY.xml:S3:9418:11	interf	VBG	O	O
with	YERVOY.xml:S3:9430:4	with	IN	O	O
daily	YERVOY.xml:S3:9435:5	daili	JJ	O	O
activities	YERVOY.xml:S3:9441:10	activ	NNS	O	O
)	YERVOY.xml:S3:9451:1	)	)	O	O
.	YERVOY.xml:S3:9452:1	.	.	O	O

[	YERVOY.xml:S3:9454:1	[	NNS	O	O
See	YERVOY.xml:S3:9455:3	see	NNP	O	O
Dosage	YERVOY.xml:S3:9460:6	dosag	NNP	O	O
and	YERVOY.xml:S3:9467:3	and	CC	O	O
Administration	YERVOY.xml:S3:9471:14	administr	NNP	O	O
(	YERVOY.xml:S3:9486:1	(	(	O	O
2.2	YERVOY.xml:S3:9487:3	2.2	CD	O	O
)	YERVOY.xml:S3:9490:1	)	)	O	O
.	YERVOY.xml:S3:9493:1	.	.	O	O
]	YERVOY.xml:S3:9494:1	]	NN	O	O

5.5	YERVOY.xml:S3:9505:3	5.5	CD	O	O
Immune	YERVOY.xml:S3:9511:6	immun	NNP	O	O
-	YERVOY.xml:S3:9517:1	-	:	O	O
mediated	YERVOY.xml:S3:9518:8	mediat	VBD	O	O
Endocrinopathies	YERVOY.xml:S3:9527:16	endocrinopathi	NNS	O	O

In	YERVOY.xml:S3:9549:2	In	IN	O	O
Study	YERVOY.xml:S3:9552:5	studi	NNP	O	O
1	YERVOY.xml:S3:9558:1	1	CD	O	O
,	YERVOY.xml:S3:9559:1	,	,	O	O
severe	YERVOY.xml:S3:9561:6	sever	FW	O	O
to	YERVOY.xml:S3:9568:2	to	TO	O	O
life	YERVOY.xml:S3:9571:4	life	NN	O	O
-	YERVOY.xml:S3:9575:1	-	:	O	O
threatening	YERVOY.xml:S3:9576:11	threaten	VBG	O	O
immune	YERVOY.xml:S3:9588:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S3:9594:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S3:9595:8	mediat	VBN	I-AdverseReaction	O
endocrinopathies	YERVOY.xml:S3:9604:16	endocrinopathi	NNS	I-AdverseReaction	O
(	YERVOY.xml:S3:9621:1	(	(	O	O
requiring	YERVOY.xml:S3:9622:9	requir	VBG	O	O
hospitalization	YERVOY.xml:S3:9632:15	hospit	NN	O	O
,	YERVOY.xml:S3:9647:1	,	,	O	O
urgent	YERVOY.xml:S3:9649:6	urgent	JJ	O	O
medical	YERVOY.xml:S3:9656:7	medic	JJ	O	O
intervention	YERVOY.xml:S3:9664:12	intervent	NN	O	O
,	YERVOY.xml:S3:9676:1	,	,	O	O
or	YERVOY.xml:S3:9678:2	or	CC	O	O
interfering	YERVOY.xml:S3:9681:11	interf	VBG	O	O
with	YERVOY.xml:S3:9693:4	with	IN	O	O
activities	YERVOY.xml:S3:9698:10	activ	NNS	O	O
of	YERVOY.xml:S3:9709:2	of	IN	O	O
daily	YERVOY.xml:S3:9712:5	daili	JJ	O	O
living	YERVOY.xml:S3:9718:6	live	NN	O	O
;	YERVOY.xml:S3:9724:1	;	:	O	O
Grade	YERVOY.xml:S3:9726:5	grade	NNP	O	O
3	YERVOY.xml:S3:9732:1	3	CD	O	O
-	YERVOY.xml:S3:9733:1	-	:	O	O
4	YERVOY.xml:S3:9734:1	4	CD	O	O
)	YERVOY.xml:S3:9735:1	)	)	O	O
occurred	YERVOY.xml:S3:9737:8	occur	VBD	O	O
in	YERVOY.xml:S3:9746:2	in	IN	O	O
9	YERVOY.xml:S3:9749:1	9	CD	O	O
(	YERVOY.xml:S3:9751:1	(	(	O	O
1.8%	YERVOY.xml:S3:9752:4	1.8%	CD	O	O
)	YERVOY.xml:S3:9756:1	)	)	O	O
YERVOY	YERVOY.xml:S3:9758:6	yervoy	SYM	O	O
-	YERVOY.xml:S3:9764:1	-	:	O	O
treated	YERVOY.xml:S3:9765:7	treat	JJ	O	O
patients	YERVOY.xml:S3:9773:8	patient	NNS	O	O
.	YERVOY.xml:S3:9781:1	.	.	O	O

All	YERVOY.xml:S3:9783:3	all	DT	O	O
9	YERVOY.xml:S3:9787:1	9	CD	O	O
patients	YERVOY.xml:S3:9789:8	patient	NNS	O	O
had	YERVOY.xml:S3:9798:3	had	VBD	O	O
hypopituitarism	YERVOY.xml:S3:9802:15	hypopituitar	NN	B-AdverseReaction	O
and	YERVOY.xml:S3:9818:3	and	CC	O	O
some	YERVOY.xml:S3:9822:4	some	DT	O	O
had	YERVOY.xml:S3:9827:3	had	VBD	O	O
additional	YERVOY.xml:S3:9831:10	addit	JJ	O	O
concomitant	YERVOY.xml:S3:9842:11	concomit	NN	O	O
endocrinopathies	YERVOY.xml:S3:9854:16	endocrinopathi	NNS	B-AdverseReaction	O
such	YERVOY.xml:S3:9871:4	such	JJ	O	O
as	YERVOY.xml:S3:9876:2	as	IN	O	O
adrenal	YERVOY.xml:S3:9879:7	adren	JJ	B-AdverseReaction	O
insufficiency	YERVOY.xml:S3:9887:13	insuffici	NN	I-AdverseReaction	O
,	YERVOY.xml:S3:9900:1	,	,	O	O
hypogonadism	YERVOY.xml:S3:9902:12	hypogonad	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:9914:1	,	,	O	O
and	YERVOY.xml:S3:9916:3	and	CC	O	O
hypothyroidism	YERVOY.xml:S3:9920:14	hypothyroid	NN	B-AdverseReaction	B-AdverseReaction
.	YERVOY.xml:S3:9934:1	.	.	O	O

Six	YERVOY.xml:S3:9936:3	six	CD	O	O
of	YERVOY.xml:S3:9940:2	of	IN	O	O
the	YERVOY.xml:S3:9943:3	the	DT	O	O
9	YERVOY.xml:S3:9947:1	9	CD	O	O
patients	YERVOY.xml:S3:9949:8	patient	NNS	O	O
were	YERVOY.xml:S3:9958:4	were	VBD	O	O
hospitalized	YERVOY.xml:S3:9963:12	hospit	VBN	O	O
for	YERVOY.xml:S3:9976:3	for	IN	O	O
severe	YERVOY.xml:S3:9980:6	sever	JJ	O	O
endocrinopathies	YERVOY.xml:S3:9987:16	endocrinopathi	NNS	B-AdverseReaction	O
.	YERVOY.xml:S3:10003:1	.	.	O	O

Moderate	YERVOY.xml:S3:10005:8	moder	NNP	O	O
endocrinopathy	YERVOY.xml:S3:10014:14	endocrinopathi	NN	B-AdverseReaction	O
(	YERVOY.xml:S3:10029:1	(	(	O	O
requiring	YERVOY.xml:S3:10030:9	requir	VBG	O	O
hormone	YERVOY.xml:S3:10040:7	hormon	NN	O	O
replacement	YERVOY.xml:S3:10048:11	replac	NN	O	O
or	YERVOY.xml:S3:10060:2	or	CC	O	O
medical	YERVOY.xml:S3:10063:7	medic	JJ	O	O
intervention	YERVOY.xml:S3:10071:12	intervent	NN	O	O
;	YERVOY.xml:S3:10083:1	;	:	O	O
Grade	YERVOY.xml:S3:10085:5	grade	NNP	O	O
2	YERVOY.xml:S3:10091:1	2	CD	O	O
)	YERVOY.xml:S3:10092:1	)	)	O	O
occurred	YERVOY.xml:S3:10094:8	occur	VBD	O	O
in	YERVOY.xml:S3:10103:2	in	IN	O	O
12	YERVOY.xml:S3:10106:2	12	CD	O	O
(	YERVOY.xml:S3:10109:1	(	(	O	O
2.3%	YERVOY.xml:S3:10110:4	2.3%	CD	O	O
)	YERVOY.xml:S3:10114:1	)	)	O	O
patients	YERVOY.xml:S3:10116:8	patient	NNS	O	O
and	YERVOY.xml:S3:10125:3	and	CC	O	O
consisted	YERVOY.xml:S3:10129:9	consist	VBN	O	O
of	YERVOY.xml:S3:10139:2	of	IN	O	O
hypothyroidism	YERVOY.xml:S3:10142:14	hypothyroid	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:10156:1	,	,	O	O
adrenal	YERVOY.xml:S3:10158:7	adren	JJ	B-AdverseReaction	B-AdverseReaction
insufficiency	YERVOY.xml:S3:10166:13	insuffici	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:10179:1	,	,	O	O
hypopituitarism	YERVOY.xml:S3:10181:15	hypopituitar	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:10196:1	,	,	O	O
and	YERVOY.xml:S3:10198:3	and	CC	O	O
1	YERVOY.xml:S3:10202:1	1	CD	O	O
case	YERVOY.xml:S3:10204:4	case	NN	O	O
each	YERVOY.xml:S3:10209:4	each	DT	O	O
of	YERVOY.xml:S3:10214:2	of	IN	O	O
hyperthyroidism	YERVOY.xml:S3:10217:15	hyperthyroid	NN	B-AdverseReaction	O
and	YERVOY.xml:S3:10233:3	and	CC	O	O
Cushing	YERVOY.xml:S3:10237:7	cush	NNP	B-AdverseReaction	B-AdverseReaction
's	YERVOY.xml:S3:10244:2	's	POS	I-AdverseReaction	I-AdverseReaction
syndrome	YERVOY.xml:S3:10247:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
.	YERVOY.xml:S3:10255:1	.	.	O	O

The	YERVOY.xml:S3:10257:3	the	DT	O	O
median	YERVOY.xml:S3:10261:6	median	JJ	O	O
time	YERVOY.xml:S3:10268:4	time	NN	O	O
to	YERVOY.xml:S3:10273:2	to	TO	O	O
onset	YERVOY.xml:S3:10276:5	onset	VB	O	O
of	YERVOY.xml:S3:10282:2	of	IN	O	O
moderate	YERVOY.xml:S3:10285:8	moder	JJ	O	O
to	YERVOY.xml:S3:10294:2	to	TO	O	O
severe	YERVOY.xml:S3:10297:6	sever	VB	O	O
immune	YERVOY.xml:S3:10304:6	immun	JJ	B-AdverseReaction	B-AdverseReaction
-	YERVOY.xml:S3:10310:1	-	:	I-AdverseReaction	I-AdverseReaction
mediated	YERVOY.xml:S3:10311:8	mediat	VBD	I-AdverseReaction	I-AdverseReaction
endocrinopathy	YERVOY.xml:S3:10320:14	endocrinopathi	NN	I-AdverseReaction	I-AdverseReaction
was	YERVOY.xml:S3:10335:3	wa	VBD	O	O
11	YERVOY.xml:S3:10339:2	11	CD	O	O
weeks	YERVOY.xml:S3:10342:5	week	NNS	O	O
and	YERVOY.xml:S3:10348:3	and	CC	O	O
ranged	YERVOY.xml:S3:10352:6	rang	VBD	O	O
up	YERVOY.xml:S3:10359:2	up	RB	O	O
to	YERVOY.xml:S3:10362:2	to	TO	O	O
19.3	YERVOY.xml:S3:10365:4	19.3	CD	O	O
weeks	YERVOY.xml:S3:10370:5	week	NNS	O	O
after	YERVOY.xml:S3:10376:5	after	IN	O	O
the	YERVOY.xml:S3:10382:3	the	DT	O	O
initiation	YERVOY.xml:S3:10386:10	initi	NN	O	O
of	YERVOY.xml:S3:10397:2	of	IN	O	O
YERVOY	YERVOY.xml:S3:10400:6	yervoy	NNP	O	O
.	YERVOY.xml:S3:10406:1	.	.	O	O

Of	YERVOY.xml:S3:10412:2	Of	IN	O	O
the	YERVOY.xml:S3:10415:3	the	DT	O	O
21	YERVOY.xml:S3:10419:2	21	CD	O	O
patients	YERVOY.xml:S3:10422:8	patient	NNS	O	O
with	YERVOY.xml:S3:10431:4	with	IN	O	O
moderate	YERVOY.xml:S3:10436:8	moder	JJ	O	O
to	YERVOY.xml:S3:10445:2	to	TO	O	O
life	YERVOY.xml:S3:10448:4	life	NN	O	O
-	YERVOY.xml:S3:10452:1	-	:	O	O
threatening	YERVOY.xml:S3:10453:11	threaten	NN	O	O
endocrinopathy	YERVOY.xml:S3:10465:14	endocrinopathi	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:10479:1	,	,	O	O
17	YERVOY.xml:S3:10481:2	17	CD	O	O
patients	YERVOY.xml:S3:10484:8	patient	NNS	O	O
required	YERVOY.xml:S3:10493:8	requir	VBN	O	O
long	YERVOY.xml:S3:10502:4	long	RB	O	O
-	YERVOY.xml:S3:10506:1	-	:	O	O
term	YERVOY.xml:S3:10507:4	term	NN	O	O
hormone	YERVOY.xml:S3:10512:7	hormon	NN	O	O
replacement	YERVOY.xml:S3:10520:11	replac	NN	O	O
therapy	YERVOY.xml:S3:10532:7	therapi	NN	O	O
including	YERVOY.xml:S3:10540:9	includ	VBG	O	O
,	YERVOY.xml:S3:10549:1	,	,	O	O
most	YERVOY.xml:S3:10551:4	most	JJS	O	O
commonly	YERVOY.xml:S3:10556:8	commonli	RB	O	O
,	YERVOY.xml:S3:10564:1	,	,	O	O
adrenal	YERVOY.xml:S3:10566:7	adren	JJ	O	O
hormones	YERVOY.xml:S3:10574:8	hormon	NNS	O	O
(	YERVOY.xml:S3:10583:1	(	(	O	O
n	YERVOY.xml:S3:10584:1	n	JJ	O	O
10	YERVOY.xml:S3:10586:2	10	CD	O	O
)	YERVOY.xml:S3:10588:1	)	)	O	O
and	YERVOY.xml:S3:10590:3	and	CC	O	O
thyroid	YERVOY.xml:S3:10594:7	thyroid	JJ	O	O
hormones	YERVOY.xml:S3:10602:8	hormon	NNS	O	O
(	YERVOY.xml:S3:10611:1	(	(	O	O
n	YERVOY.xml:S3:10612:1	n	JJ	O	O
13	YERVOY.xml:S3:10614:2	13	CD	O	O
)	YERVOY.xml:S3:10616:1	)	)	O	O
.	YERVOY.xml:S3:10617:1	.	.	O	O

Monitor	YERVOY.xml:S3:10623:7	monitor	NN	O	O
patients	YERVOY.xml:S3:10631:8	patient	NNS	O	O
for	YERVOY.xml:S3:10640:3	for	IN	O	O
clinical	YERVOY.xml:S3:10644:8	clinic	JJ	O	O
signs	YERVOY.xml:S3:10653:5	sign	NNS	O	O
and	YERVOY.xml:S3:10659:3	and	CC	O	O
symptoms	YERVOY.xml:S3:10663:8	symptom	NNS	O	O
of	YERVOY.xml:S3:10672:2	of	IN	O	O
hypophysitis	YERVOY.xml:S3:10675:12	hypophys	NN	O	O
,	YERVOY.xml:S3:10687:1	,	,	O	O
adrenal	YERVOY.xml:S3:10689:7	adren	JJ	O	B-AdverseReaction
insufficiency	YERVOY.xml:S3:10697:13	insuffici	NN	O	I-AdverseReaction
(	YERVOY.xml:S3:10711:1	(	(	O	O
including	YERVOY.xml:S3:10712:9	includ	VBG	O	O
adrenal	YERVOY.xml:S3:10722:7	adren	JJ	O	B-AdverseReaction
crisis	YERVOY.xml:S3:10730:6	crisi	NN	O	I-AdverseReaction
)	YERVOY.xml:S3:10736:1	)	)	O	O
,	YERVOY.xml:S3:10737:1	,	,	O	O
and	YERVOY.xml:S3:10739:3	and	CC	O	O
hyper	YERVOY.xml:S3:10743:5	hyper	SYM	O	O
-	YERVOY.xml:S3:10748:1	-	:	O	O
or	YERVOY.xml:S3:10750:2	or	CC	O	O
hypothyroidism	YERVOY.xml:S3:10753:14	hypothyroid	NN	O	B-AdverseReaction
.	YERVOY.xml:S3:10767:1	.	.	O	O

Patients	YERVOY.xml:S3:10769:8	patient	NNS	O	O
may	YERVOY.xml:S3:10778:3	may	MD	O	O
present	YERVOY.xml:S3:10782:7	present	VB	O	O
with	YERVOY.xml:S3:10790:4	with	IN	O	O
fatigue	YERVOY.xml:S3:10795:7	fatigu	NN	O	O
,	YERVOY.xml:S3:10802:1	,	,	O	O
headache	YERVOY.xml:S3:10804:8	headach	NN	O	B-AdverseReaction
,	YERVOY.xml:S3:10812:1	,	,	O	O
mental	YERVOY.xml:S3:10814:6	mental	JJ	O	B-AdverseReaction
status	YERVOY.xml:S3:10821:6	statu	NN	O	I-AdverseReaction
changes	YERVOY.xml:S3:10828:7	chang	NNS	O	I-AdverseReaction
,	YERVOY.xml:S3:10835:1	,	,	O	O
abdominal	YERVOY.xml:S3:10837:9	abdomin	JJ	O	B-AdverseReaction
pain	YERVOY.xml:S3:10847:4	pain	NN	O	I-AdverseReaction
,	YERVOY.xml:S3:10851:1	,	,	O	O
unusual	YERVOY.xml:S3:10853:7	unusu	JJ	O	B-AdverseReaction
bowel	YERVOY.xml:S3:10861:5	bowel	NN	O	I-AdverseReaction
habits	YERVOY.xml:S3:10867:6	habit	NNS	O	I-AdverseReaction
,	YERVOY.xml:S3:10873:1	,	,	O	O
and	YERVOY.xml:S3:10875:3	and	CC	O	O
hypotension	YERVOY.xml:S3:10879:11	hypotens	NN	O	B-AdverseReaction
,	YERVOY.xml:S3:10890:1	,	,	O	O
or	YERVOY.xml:S3:10892:2	or	CC	O	O
nonspecific	YERVOY.xml:S3:10895:11	nonspecif	NN	O	O
symptoms	YERVOY.xml:S3:10907:8	symptom	NNS	O	O
which	YERVOY.xml:S3:10916:5	which	WDT	O	O
may	YERVOY.xml:S3:10922:3	may	MD	O	O
resemble	YERVOY.xml:S3:10926:8	resembl	VB	O	O
other	YERVOY.xml:S3:10935:5	other	JJ	O	O
causes	YERVOY.xml:S3:10941:6	caus	NNS	O	O
such	YERVOY.xml:S3:10948:4	such	JJ	O	O
as	YERVOY.xml:S3:10953:2	as	IN	O	O
brain	YERVOY.xml:S3:10956:5	brain	NN	O	O
metastasis	YERVOY.xml:S3:10962:10	metastasi	NN	O	O
or	YERVOY.xml:S3:10973:2	or	CC	O	O
underlying	YERVOY.xml:S3:10976:10	underli	JJ	O	O
disease	YERVOY.xml:S3:10987:7	diseas	NN	O	O
.	YERVOY.xml:S3:10994:1	.	.	O	O

Unless	YERVOY.xml:S3:10996:6	unless	IN	O	O
an	YERVOY.xml:S3:11003:2	an	DT	O	O
alternate	YERVOY.xml:S3:11006:9	altern	NN	O	O
etiology	YERVOY.xml:S3:11016:8	etiolog	NN	O	O
has	YERVOY.xml:S3:11025:3	ha	VBZ	O	O
been	YERVOY.xml:S3:11029:4	been	VBN	O	O
identified	YERVOY.xml:S3:11034:10	identifi	VBN	O	O
,	YERVOY.xml:S3:11044:1	,	,	O	O
signs	YERVOY.xml:S3:11046:5	sign	NNS	O	O
or	YERVOY.xml:S3:11052:2	or	CC	O	O
symptoms	YERVOY.xml:S3:11055:8	symptom	NNS	O	O
of	YERVOY.xml:S3:11064:2	of	IN	O	O
endocrinopathies	YERVOY.xml:S3:11067:16	endocrinopathi	NNS	O	O
should	YERVOY.xml:S3:11084:6	should	MD	O	O
be	YERVOY.xml:S3:11091:2	be	VB	O	O
considered	YERVOY.xml:S3:11094:10	consid	VBN	O	O
immune	YERVOY.xml:S3:11105:6	immun	JJ	O	O
-	YERVOY.xml:S3:11111:1	-	:	O	O
mediated	YERVOY.xml:S3:11112:8	mediat	VBN	O	O
.	YERVOY.xml:S3:11120:1	.	.	O	O

Monitor	YERVOY.xml:S3:11126:7	monitor	NNP	O	O
thyroid	YERVOY.xml:S3:11134:7	thyroid	JJ	O	O
function	YERVOY.xml:S3:11142:8	function	NN	O	O
tests	YERVOY.xml:S3:11151:5	test	NNS	O	O
and	YERVOY.xml:S3:11157:3	and	CC	O	O
clinical	YERVOY.xml:S3:11161:8	clinic	JJ	O	O
chemistries	YERVOY.xml:S3:11170:11	chemistri	NNS	O	O
at	YERVOY.xml:S3:11182:2	at	IN	O	O
the	YERVOY.xml:S3:11185:3	the	DT	O	O
start	YERVOY.xml:S3:11189:5	start	NN	O	O
of	YERVOY.xml:S3:11195:2	of	IN	O	O
treatment	YERVOY.xml:S3:11198:9	treatment	NN	O	O
,	YERVOY.xml:S3:11207:1	,	,	O	O
before	YERVOY.xml:S3:11209:6	befor	IN	O	O
each	YERVOY.xml:S3:11216:4	each	DT	O	O
dose	YERVOY.xml:S3:11221:4	dose	NN	O	O
,	YERVOY.xml:S3:11225:1	,	,	O	O
and	YERVOY.xml:S3:11227:3	and	CC	O	O
as	YERVOY.xml:S3:11231:2	as	IN	O	O
clinically	YERVOY.xml:S3:11234:10	clinic	RB	O	O
indicated	YERVOY.xml:S3:11245:9	indic	VBN	O	O
based	YERVOY.xml:S3:11255:5	base	VBN	O	O
on	YERVOY.xml:S3:11261:2	on	IN	O	O
symptoms	YERVOY.xml:S3:11264:8	symptom	NNS	O	O
.	YERVOY.xml:S3:11272:1	.	.	O	O

In	YERVOY.xml:S3:11274:2	In	IN	O	O
a	YERVOY.xml:S3:11277:1	a	DT	O	O
limited	YERVOY.xml:S3:11279:7	limit	JJ	O	O
number	YERVOY.xml:S3:11287:6	number	NN	O	O
of	YERVOY.xml:S3:11294:2	of	IN	O	O
patients	YERVOY.xml:S3:11297:8	patient	NNS	O	O
,	YERVOY.xml:S3:11305:1	,	,	O	O
hypophysitis	YERVOY.xml:S3:11307:12	hypophys	NN	B-AdverseReaction	O
was	YERVOY.xml:S3:11320:3	wa	VBD	O	O
diagnosed	YERVOY.xml:S3:11324:9	diagnos	VBN	O	O
by	YERVOY.xml:S3:11334:2	by	IN	O	O
imaging	YERVOY.xml:S3:11337:7	imag	VBG	O	O
studies	YERVOY.xml:S3:11345:7	studi	NNS	O	O
through	YERVOY.xml:S3:11353:7	through	IN	O	O
enlargement	YERVOY.xml:S3:11361:11	enlarg	NN	O	O
of	YERVOY.xml:S3:11373:2	of	IN	O	O
the	YERVOY.xml:S3:11376:3	the	DT	O	O
pituitary	YERVOY.xml:S3:11380:9	pituitari	JJ	O	O
gland	YERVOY.xml:S3:11390:5	gland	NN	O	O
.	YERVOY.xml:S3:11395:1	.	.	O	O

Withhold	YERVOY.xml:S3:11401:8	withhold	NNP	O	O
YERVOY	YERVOY.xml:S3:11410:6	yervoy	NNP	O	O
dosing	YERVOY.xml:S3:11417:6	dose	VBG	O	O
in	YERVOY.xml:S3:11424:2	in	IN	O	O
symptomatic	YERVOY.xml:S3:11427:11	symptomat	JJ	O	O
patients	YERVOY.xml:S3:11439:8	patient	NNS	O	O
.	YERVOY.xml:S3:11447:1	.	.	O	O

Initiate	YERVOY.xml:S3:11449:8	initi	NNP	O	O
systemic	YERVOY.xml:S3:11458:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:11467:15	corticosteroid	NNS	O	O
at	YERVOY.xml:S3:11483:2	at	IN	O	O
a	YERVOY.xml:S3:11486:1	a	DT	O	O
dose	YERVOY.xml:S3:11488:4	dose	NN	O	O
of	YERVOY.xml:S3:11493:2	of	IN	O	O
1	YERVOY.xml:S3:11496:1	1	CD	O	O
to	YERVOY.xml:S3:11498:2	to	TO	O	O
2	YERVOY.xml:S3:11501:1	2	CD	O	O
mg	YERVOY.xml:S3:11503:2	mg	NNS	O	O
kg	YERVOY.xml:S3:11506:2	kg	JJ	O	O
day	YERVOY.xml:S3:11509:3	day	NN	O	O
of	YERVOY.xml:S3:11513:2	of	IN	O	O
prednisone	YERVOY.xml:S3:11516:10	prednison	NN	O	O
or	YERVOY.xml:S3:11527:2	or	CC	O	O
equivalent	YERVOY.xml:S3:11530:10	equival	NN	O	O
,	YERVOY.xml:S3:11540:1	,	,	O	O
and	YERVOY.xml:S3:11542:3	and	CC	O	O
initiate	YERVOY.xml:S3:11546:8	initi	VB	O	O
appropriate	YERVOY.xml:S3:11555:11	appropri	JJ	O	O
hormone	YERVOY.xml:S3:11567:7	hormon	NN	O	O
replacement	YERVOY.xml:S3:11575:11	replac	NN	O	O
therapy	YERVOY.xml:S3:11587:7	therapi	NN	O	O
.	YERVOY.xml:S3:11594:1	.	.	O	O

[	YERVOY.xml:S3:11596:1	[	NNS	O	O
See	YERVOY.xml:S3:11597:3	see	NNP	O	O
Dosage	YERVOY.xml:S3:11602:6	dosag	NNP	O	O
and	YERVOY.xml:S3:11609:3	and	CC	O	O
Administration	YERVOY.xml:S3:11613:14	administr	NNP	O	O
(	YERVOY.xml:S3:11628:1	(	(	O	O
2.2	YERVOY.xml:S3:11629:3	2.2	CD	O	O
)	YERVOY.xml:S3:11632:1	)	)	O	O
.	YERVOY.xml:S3:11635:1	.	.	O	O
]	YERVOY.xml:S3:11636:1	]	NN	O	O

5.6	YERVOY.xml:S3:11647:3	5.6	CD	O	O
Other	YERVOY.xml:S3:11653:5	other	JJ	O	O
Immune	YERVOY.xml:S3:11659:6	immun	NNP	O	O
-	YERVOY.xml:S3:11665:1	-	:	O	O
mediated	YERVOY.xml:S3:11666:8	mediat	VBD	O	O
Adverse	YERVOY.xml:S3:11675:7	advers	JJ	O	O
Reactions	YERVOY.xml:S3:11683:9	reaction	NNP	O	O
,	YERVOY.xml:S3:11692:1	,	,	O	O
Including	YERVOY.xml:S3:11694:9	includ	NNP	O	O
Ocular	YERVOY.xml:S3:11704:6	ocular	NNP	O	O
Manifestations	YERVOY.xml:S3:11711:14	manifest	NNP	O	O

The	YERVOY.xml:S3:11731:3	the	DT	O	O
following	YERVOY.xml:S3:11735:9	follow	VBG	O	O
clinically	YERVOY.xml:S3:11745:10	clinic	RB	O	O
significant	YERVOY.xml:S3:11756:11	signific	JJ	O	O
immune	YERVOY.xml:S3:11768:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S3:11774:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S3:11775:8	mediat	JJ	I-AdverseReaction	O
adverse	YERVOY.xml:S3:11784:7	advers	JJ	I-AdverseReaction	O
reactions	YERVOY.xml:S3:11792:9	reaction	NNS	I-AdverseReaction	O
were	YERVOY.xml:S3:11802:4	were	VBD	O	O
seen	YERVOY.xml:S3:11807:4	seen	VBN	O	O
in	YERVOY.xml:S3:11812:2	in	IN	O	O
less	YERVOY.xml:S3:11815:4	less	JJR	O	O
than	YERVOY.xml:S3:11820:4	than	IN	O	O
1%	YERVOY.xml:S3:11825:2	1%	CD	O	O
of	YERVOY.xml:S3:11828:2	of	IN	O	O
YERVOY	YERVOY.xml:S3:11831:6	yervoy	NNP	O	O
-	YERVOY.xml:S3:11837:1	-	:	O	O
treated	YERVOY.xml:S3:11838:7	treat	VBD	O	O
patients	YERVOY.xml:S3:11846:8	patient	NNS	O	O
in	YERVOY.xml:S3:11855:2	in	IN	O	O
Study	YERVOY.xml:S3:11858:5	studi	NNP	O	O
1	YERVOY.xml:S3:11864:1	1	CD	O	O
:	YERVOY.xml:S3:11865:1	:	:	O	O
nephritis	YERVOY.xml:S3:11867:9	nephriti	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:11876:1	,	,	O	O
pneumonitis	YERVOY.xml:S3:11878:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:11889:1	,	,	O	O
meningitis	YERVOY.xml:S3:11891:10	mening	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:11901:1	,	,	O	O
pericarditis	YERVOY.xml:S3:11903:12	pericard	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:11915:1	,	,	O	O
uveitis	YERVOY.xml:S3:11917:7	uveiti	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:11924:1	,	,	O	O
iritis	YERVOY.xml:S3:11926:6	iriti	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:11932:1	,	,	O	O
and	YERVOY.xml:S3:11934:3	and	CC	O	O
hemolytic	YERVOY.xml:S3:11938:9	hemolyt	JJ	B-AdverseReaction	B-AdverseReaction
anemia	YERVOY.xml:S3:11948:6	anemia	NN	I-AdverseReaction	I-AdverseReaction
.	YERVOY.xml:S3:11954:1	.	.	O	O

Across	YERVOY.xml:S3:11960:6	across	IN	O	O
the	YERVOY.xml:S3:11967:3	the	DT	O	O
clinical	YERVOY.xml:S3:11971:8	clinic	JJ	O	O
development	YERVOY.xml:S3:11980:11	develop	NN	O	O
program	YERVOY.xml:S3:11992:7	program	NN	O	O
for	YERVOY.xml:S3:12000:3	for	IN	O	O
YERVOY	YERVOY.xml:S3:12004:6	yervoy	NNP	O	O
,	YERVOY.xml:S3:12010:1	,	,	O	O
the	YERVOY.xml:S3:12012:3	the	DT	O	O
following	YERVOY.xml:S3:12016:9	follow	VBG	O	O
likely	YERVOY.xml:S3:12026:6	like	JJ	O	O
immune	YERVOY.xml:S3:12033:6	immun	JJ	B-AdverseReaction	O
-	YERVOY.xml:S3:12039:1	-	:	I-AdverseReaction	O
mediated	YERVOY.xml:S3:12040:8	mediat	JJ	I-AdverseReaction	O
adverse	YERVOY.xml:S3:12049:7	advers	JJ	I-AdverseReaction	O
reactions	YERVOY.xml:S3:12057:9	reaction	NNS	I-AdverseReaction	O
were	YERVOY.xml:S3:12067:4	were	VBD	O	O
also	YERVOY.xml:S3:12072:4	also	RB	O	O
reported	YERVOY.xml:S3:12077:8	report	VBN	O	O
with	YERVOY.xml:S3:12086:4	with	IN	O	O
less	YERVOY.xml:S3:12091:4	less	JJR	O	O
than	YERVOY.xml:S3:12096:4	than	IN	O	O
1%	YERVOY.xml:S3:12101:2	1%	CD	O	O
incidence	YERVOY.xml:S3:12104:9	incid	NN	O	O
:	YERVOY.xml:S3:12113:1	:	:	O	O
myocarditis	YERVOY.xml:S3:12115:11	myocard	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12126:1	,	,	O	O
angiopathy	YERVOY.xml:S3:12128:10	angiopathi	JJ	B-AdverseReaction	O
,	YERVOY.xml:S3:12138:1	,	,	O	O
temporal	YERVOY.xml:S3:12140:8	tempor	JJ	B-AdverseReaction	B-AdverseReaction
arteritis	YERVOY.xml:S3:12149:9	arter	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:12158:1	,	,	O	O
vasculitis	YERVOY.xml:S3:12160:10	vascul	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12170:1	,	,	O	O
polymyalgia	YERVOY.xml:S3:12172:11	polymyalgia	NN	B-AdverseReaction	B-AdverseReaction
rheumatica	YERVOY.xml:S3:12184:10	rheumatica	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:12194:1	,	,	O	O
conjunctivitis	YERVOY.xml:S3:12196:14	conjunct	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12210:1	,	,	O	O
blepharitis	YERVOY.xml:S3:12212:11	blephar	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:12223:1	,	,	O	O
episcleritis	YERVOY.xml:S3:12225:12	episcler	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12237:1	,	,	O	O
scleritis	YERVOY.xml:S3:12239:9	scleriti	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12248:1	,	,	O	O
leukocytoclastic	YERVOY.xml:S3:12250:16	leukocytoclast	JJ	B-AdverseReaction	B-AdverseReaction
vasculitis	YERVOY.xml:S3:12267:10	vascul	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:12277:1	,	,	O	O
erythema	YERVOY.xml:S3:12279:8	erythema	JJ	B-AdverseReaction	B-AdverseReaction
multiforme	YERVOY.xml:S3:12288:10	multiform	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:12298:1	,	,	O	O
psoriasis	YERVOY.xml:S3:12300:9	psoriasi	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12309:1	,	,	O	O
pancreatitis	YERVOY.xml:S3:12311:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12323:1	,	,	O	O
arthritis	YERVOY.xml:S3:12325:9	arthriti	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12334:1	,	,	O	O
autoimmune	YERVOY.xml:S3:12336:10	autoimmun	JJ	B-AdverseReaction	B-AdverseReaction
thyroiditis	YERVOY.xml:S3:12347:11	thyroid	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:12358:1	,	,	O	O
sarcoidosis	YERVOY.xml:S3:12360:11	sarcoidosi	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12371:1	,	,	O	O
neurosensory	YERVOY.xml:S3:12373:12	neurosensori	JJ	B-AdverseReaction	B-AdverseReaction
hypoacusis	YERVOY.xml:S3:12386:10	hypoacusi	NN	I-AdverseReaction	I-AdverseReaction
,	YERVOY.xml:S3:12396:1	,	,	O	O
autoimmune	YERVOY.xml:S3:12398:10	autoimmun	JJ	B-AdverseReaction	B-AdverseReaction
central	YERVOY.xml:S3:12409:7	central	JJ	I-AdverseReaction	I-AdverseReaction
neuropathy	YERVOY.xml:S3:12417:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
(	YERVOY.xml:S3:12428:1	(	(	O	O
encephalitis	YERVOY.xml:S3:12429:12	enceph	NN	B-AdverseReaction	O
)	YERVOY.xml:S3:12441:1	)	)	O	O
,	YERVOY.xml:S3:12442:1	,	,	O	O
myositis	YERVOY.xml:S3:12444:8	myositi	NN	B-AdverseReaction	B-AdverseReaction
,	YERVOY.xml:S3:12452:1	,	,	O	O
polymyositis	YERVOY.xml:S3:12454:12	polymyos	NN	B-AdverseReaction	O
,	YERVOY.xml:S3:12466:1	,	,	O	O
and	YERVOY.xml:S3:12468:3	and	CC	O	O
ocular	YERVOY.xml:S3:12472:6	ocular	JJ	B-AdverseReaction	B-AdverseReaction
myositis	YERVOY.xml:S3:12479:8	myositi	NN	I-AdverseReaction	I-AdverseReaction
.	YERVOY.xml:S3:12487:1	.	.	O	O

Permanently	YERVOY.xml:S3:12493:11	perman	RB	O	O
discontinue	YERVOY.xml:S3:12505:11	discontinu	VBZ	O	O
YERVOY	YERVOY.xml:S3:12517:6	yervoy	NNP	O	O
for	YERVOY.xml:S3:12524:3	for	IN	O	O
clinically	YERVOY.xml:S3:12528:10	clinic	RB	O	O
significant	YERVOY.xml:S3:12539:11	signific	JJ	O	O
or	YERVOY.xml:S3:12551:2	or	CC	O	O
severe	YERVOY.xml:S3:12554:6	sever	JJ	O	O
immune	YERVOY.xml:S3:12561:6	immun	JJ	O	O
-	YERVOY.xml:S3:12567:1	-	:	O	O
mediated	YERVOY.xml:S3:12568:8	mediat	JJ	O	O
adverse	YERVOY.xml:S3:12577:7	advers	JJ	O	O
reactions	YERVOY.xml:S3:12585:9	reaction	NNS	O	O
.	YERVOY.xml:S3:12594:1	.	.	O	O

Initiate	YERVOY.xml:S3:12596:8	initi	NNP	O	O
systemic	YERVOY.xml:S3:12605:8	system	JJ	O	O
corticosteroids	YERVOY.xml:S3:12614:15	corticosteroid	NNS	O	O
at	YERVOY.xml:S3:12630:2	at	IN	O	O
a	YERVOY.xml:S3:12633:1	a	DT	O	O
dose	YERVOY.xml:S3:12635:4	dose	NN	O	O
of	YERVOY.xml:S3:12640:2	of	IN	O	O
1	YERVOY.xml:S3:12643:1	1	CD	O	O
to	YERVOY.xml:S3:12645:2	to	TO	O	O
2	YERVOY.xml:S3:12648:1	2	CD	O	O
mg	YERVOY.xml:S3:12650:2	mg	NNS	O	O
kg	YERVOY.xml:S3:12653:2	kg	JJ	O	O
day	YERVOY.xml:S3:12656:3	day	NN	O	O
prednisone	YERVOY.xml:S3:12660:10	prednison	NN	O	O
or	YERVOY.xml:S3:12671:2	or	CC	O	O
equivalent	YERVOY.xml:S3:12674:10	equival	NN	O	O
for	YERVOY.xml:S3:12685:3	for	IN	O	O
severe	YERVOY.xml:S3:12689:6	sever	JJ	O	O
immune	YERVOY.xml:S3:12696:6	immun	JJ	O	O
-	YERVOY.xml:S3:12702:1	-	:	O	O
mediated	YERVOY.xml:S3:12703:8	mediat	JJ	O	O
adverse	YERVOY.xml:S3:12712:7	advers	JJ	O	O
reactions	YERVOY.xml:S3:12720:9	reaction	NNS	O	O
.	YERVOY.xml:S3:12729:1	.	.	O	O

Administer	YERVOY.xml:S3:12735:10	administ	NNP	O	O
corticosteroid	YERVOY.xml:S3:12746:14	corticosteroid	NN	O	O
eye	YERVOY.xml:S3:12761:3	eye	NN	O	O
drops	YERVOY.xml:S3:12765:5	drop	NNS	O	O
to	YERVOY.xml:S3:12771:2	to	TO	O	O
patients	YERVOY.xml:S3:12774:8	patient	NNS	O	O
who	YERVOY.xml:S3:12783:3	who	WP	O	O
develop	YERVOY.xml:S3:12787:7	develop	VBP	O	O
uveitis	YERVOY.xml:S3:12795:7	uveiti	NN	O	O
,	YERVOY.xml:S3:12802:1	,	,	O	O
iritis	YERVOY.xml:S3:12804:6	iriti	NN	O	O
,	YERVOY.xml:S3:12810:1	,	,	O	O
or	YERVOY.xml:S3:12812:2	or	CC	O	O
episcleritis	YERVOY.xml:S3:12815:12	episcler	NN	O	O
.	YERVOY.xml:S3:12827:1	.	.	O	O

Permanently	YERVOY.xml:S3:12829:11	perman	RB	O	O
discontinue	YERVOY.xml:S3:12841:11	discontinu	VBZ	O	O
YERVOY	YERVOY.xml:S3:12853:6	yervoy	NNP	O	O
for	YERVOY.xml:S3:12860:3	for	IN	O	O
immune	YERVOY.xml:S3:12864:6	immun	JJ	O	O
-	YERVOY.xml:S3:12870:1	-	:	O	O
mediated	YERVOY.xml:S3:12871:8	mediat	VBN	O	O
ocular	YERVOY.xml:S3:12880:6	ocular	JJ	O	O
disease	YERVOY.xml:S3:12887:7	diseas	NN	O	O
that	YERVOY.xml:S3:12895:4	that	WDT	O	O
is	YERVOY.xml:S3:12900:2	is	VBZ	O	O
unresponsive	YERVOY.xml:S3:12903:12	unrespons	JJ	O	O
to	YERVOY.xml:S3:12916:2	to	TO	O	O
local	YERVOY.xml:S3:12919:5	local	JJ	O	O
immunosuppressive	YERVOY.xml:S3:12925:17	immunosuppress	JJ	O	O
therapy	YERVOY.xml:S3:12943:7	therapi	NN	O	O
.	YERVOY.xml:S3:12950:1	.	.	O	O

[	YERVOY.xml:S3:12952:1	[	NNS	O	O
See	YERVOY.xml:S3:12953:3	see	NNP	O	O
Dosage	YERVOY.xml:S3:12958:6	dosag	NNP	O	O
and	YERVOY.xml:S3:12965:3	and	CC	O	O
Administration	YERVOY.xml:S3:12969:14	administr	NNP	O	O
(	YERVOY.xml:S3:12984:1	(	(	O	O
2.2	YERVOY.xml:S3:12985:3	2.2	CD	O	O
)	YERVOY.xml:S3:12988:1	)	)	O	O
.	YERVOY.xml:S3:12991:1	.	.	O	O
]	YERVOY.xml:S3:12992:1	]	$	O	O
6	ZERBAXA.xml:S1:4:1	6	CD	O	O
ADVERSE	ZERBAXA.xml:S1:6:7	advers	NNP	O	O
REACTIONS	ZERBAXA.xml:S1:14:9	reaction	NNP	O	O

The	ZERBAXA.xml:S1:27:3	the	DT	O	O
following	ZERBAXA.xml:S1:31:9	follow	VBG	O	O
serious	ZERBAXA.xml:S1:41:7	seriou	JJ	O	O
reactions	ZERBAXA.xml:S1:49:9	reaction	NNS	O	O
are	ZERBAXA.xml:S1:59:3	are	VBP	O	O
described	ZERBAXA.xml:S1:63:9	describ	VBN	O	O
in	ZERBAXA.xml:S1:73:2	in	IN	O	O
greater	ZERBAXA.xml:S1:76:7	greater	JJR	O	O
detail	ZERBAXA.xml:S1:84:6	detail	NN	O	O
in	ZERBAXA.xml:S1:91:2	in	IN	O	O
the	ZERBAXA.xml:S1:94:3	the	DT	O	O
Warnings	ZERBAXA.xml:S1:98:8	warn	NNP	O	O
and	ZERBAXA.xml:S1:107:3	and	CC	O	O
Precautions	ZERBAXA.xml:S1:111:11	precaut	NNPS	O	O
section	ZERBAXA.xml:S1:123:7	section	NN	O	O
:	ZERBAXA.xml:S1:130:1	:	:	O	O

Hypersensitivity	ZERBAXA.xml:S1:139:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	ZERBAXA.xml:S1:156:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
[	ZERBAXA.xml:S1:166:1	[	VBP	O	O
see	ZERBAXA.xml:S1:167:3	see	VBP	O	O
Warnings	ZERBAXA.xml:S1:172:8	warn	NNS	O	O
and	ZERBAXA.xml:S1:181:3	and	CC	O	O
Precautions	ZERBAXA.xml:S1:185:11	precaut	NNP	O	O
(	ZERBAXA.xml:S1:197:1	(	(	O	O
5.2	ZERBAXA.xml:S1:198:3	5.2	CD	O	O
)	ZERBAXA.xml:S1:201:1	)	)	O	O
]	ZERBAXA.xml:S1:204:1	]	NN	O	O

Clostridium	ZERBAXA.xml:S1:213:11	clostridium	NN	B-AdverseReaction	B-AdverseReaction
difficile	ZERBAXA.xml:S1:225:9	difficil	NN	I-AdverseReaction	I-AdverseReaction
-	ZERBAXA.xml:S1:235:1	-	:	I-AdverseReaction	I-AdverseReaction
associated	ZERBAXA.xml:S1:236:10	associ	VBN	I-AdverseReaction	I-AdverseReaction
diarrhea	ZERBAXA.xml:S1:247:8	diarrhea	JJ	I-AdverseReaction	I-AdverseReaction
[	ZERBAXA.xml:S1:256:1	[	NNP	O	O
see	ZERBAXA.xml:S1:257:3	see	VBP	O	O
Warnings	ZERBAXA.xml:S1:262:8	warn	NNP	O	O
and	ZERBAXA.xml:S1:271:3	and	CC	O	O
Precautions	ZERBAXA.xml:S1:275:11	precaut	NNP	O	O
(	ZERBAXA.xml:S1:287:1	(	(	O	O
5.3	ZERBAXA.xml:S1:288:3	5.3	CD	O	O
)	ZERBAXA.xml:S1:291:1	)	)	O	O
]	ZERBAXA.xml:S1:294:1	]	NN	O	O

EXCERPT	ZERBAXA.xml:S1:304:7	excerpt	NN	O	O
:	ZERBAXA.xml:S1:311:1	:	:	O	O
The	ZERBAXA.xml:S1:315:3	the	DT	O	O
most	ZERBAXA.xml:S1:319:4	most	RBS	O	O
common	ZERBAXA.xml:S1:324:6	common	JJ	O	O
adverse	ZERBAXA.xml:S1:331:7	advers	JJ	O	O
reactions	ZERBAXA.xml:S1:339:9	reaction	NNS	O	O
(	ZERBAXA.xml:S1:349:1	(	(	O	O
5%	ZERBAXA.xml:S1:352:2	5%	CD	O	O
in	ZERBAXA.xml:S1:355:2	in	IN	O	O
either	ZERBAXA.xml:S1:358:6	either	DT	O	O
indication	ZERBAXA.xml:S1:365:10	indic	NN	O	O
)	ZERBAXA.xml:S1:375:1	)	)	O	O
are	ZERBAXA.xml:S1:377:3	are	VBP	O	O
nausea	ZERBAXA.xml:S1:381:6	nausea	JJ	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:387:1	,	,	O	O
diarrhea	ZERBAXA.xml:S1:389:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:397:1	,	,	O	O
headache	ZERBAXA.xml:S1:399:8	headach	NN	B-AdverseReaction	B-AdverseReaction
and	ZERBAXA.xml:S1:408:3	and	CC	O	O
pyrexia	ZERBAXA.xml:S1:412:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
.	ZERBAXA.xml:S1:419:1	.	.	O	O

(	ZERBAXA.xml:S1:421:1	(	(	O	O
6.1	ZERBAXA.xml:S1:424:3	6.1	CD	O	O
)	ZERBAXA.xml:S1:429:1	)	)	O	O
To	ZERBAXA.xml:S1:432:2	To	TO	O	O
report	ZERBAXA.xml:S1:435:6	report	VB	O	O
SUSPECTED	ZERBAXA.xml:S1:442:9	suspect	NNP	O	O
ADVERSE	ZERBAXA.xml:S1:452:7	advers	NNP	O	O
REACTIONS	ZERBAXA.xml:S1:460:9	reaction	NNP	O	O
,	ZERBAXA.xml:S1:469:1	,	,	O	O
contact	ZERBAXA.xml:S1:471:7	contact	NN	O	O
Merck	ZERBAXA.xml:S1:479:5	merck	NNP	O	O
Sharp	ZERBAXA.xml:S1:485:5	sharp	NNP	O	O
Dohme	ZERBAXA.xml:S1:493:5	dohm	NNP	O	O
Corp	ZERBAXA.xml:S1:499:4	corp	NNP	O	O
.	ZERBAXA.xml:S1:503:1	.	.	O	O
,	ZERBAXA.xml:S1:504:1	,	,	O	O
a	ZERBAXA.xml:S1:506:1	a	DT	O	O
subsidiary	ZERBAXA.xml:S1:508:10	subsidiari	NN	O	O
of	ZERBAXA.xml:S1:519:2	of	IN	O	O
Merck	ZERBAXA.xml:S1:522:5	merck	NNP	O	O
Co	ZERBAXA.xml:S1:530:2	Co	NNP	O	O
.	ZERBAXA.xml:S1:532:1	.	.	O	O
,	ZERBAXA.xml:S1:533:1	,	,	O	O
Inc	ZERBAXA.xml:S1:535:3	inc	NNP	O	O
.	ZERBAXA.xml:S1:538:1	.	.	O	O
,	ZERBAXA.xml:S1:539:1	,	,	O	O
at	ZERBAXA.xml:S1:541:2	at	IN	O	O
1	ZERBAXA.xml:S1:544:1	1	CD	O	O
-	ZERBAXA.xml:S1:545:1	-	:	O	O
877	ZERBAXA.xml:S1:546:3	877	CD	O	O
-	ZERBAXA.xml:S1:549:1	-	:	O	O
888	ZERBAXA.xml:S1:550:3	888	CD	O	O
-	ZERBAXA.xml:S1:553:1	-	:	O	O
4231	ZERBAXA.xml:S1:554:4	4231	CD	O	O
or	ZERBAXA.xml:S1:559:2	or	CC	O	O
FDA	ZERBAXA.xml:S1:562:3	fda	NNP	O	O
at	ZERBAXA.xml:S1:566:2	at	IN	O	O
1	ZERBAXA.xml:S1:569:1	1	CD	O	O
-	ZERBAXA.xml:S1:570:1	-	:	O	O
800	ZERBAXA.xml:S1:571:3	800	CD	O	O
-	ZERBAXA.xml:S1:574:1	-	:	O	O
FDA	ZERBAXA.xml:S1:575:3	fda	NNP	O	O
-	ZERBAXA.xml:S1:578:1	-	:	O	O
1088	ZERBAXA.xml:S1:579:4	1088	CD	O	O
or	ZERBAXA.xml:S1:584:2	or	CC	O	O
www	ZERBAXA.xml:S1:587:3	www	VB	O	O
.	ZERBAXA.xml:S1:590:1	.	.	O	O
fda	ZERBAXA.xml:S1:591:3	fda	NN	O	O
.	ZERBAXA.xml:S1:594:1	.	.	O	O
gov	ZERBAXA.xml:S1:595:3	gov	JJ	O	O
medwatch	ZERBAXA.xml:S1:599:8	medwatch	NN	O	O
.	ZERBAXA.xml:S1:607:1	.	.	O	O

6.1	ZERBAXA.xml:S1:619:3	6.1	CD	O	O

Clinical	ZERBAXA.xml:S1:623:8	clinic	JJ	O	O

Trial	ZERBAXA.xml:S1:632:5	trial	JJ	O	O
Experience	ZERBAXA.xml:S1:638:10	experi	NN	O	O

Because	ZERBAXA.xml:S1:652:7	becaus	IN	O	O
clinical	ZERBAXA.xml:S1:660:8	clinic	JJ	O	O
trials	ZERBAXA.xml:S1:669:6	trial	NNS	O	O
are	ZERBAXA.xml:S1:676:3	are	VBP	O	O
conducted	ZERBAXA.xml:S1:680:9	conduct	VBN	O	O
under	ZERBAXA.xml:S1:690:5	under	IN	O	O
widely	ZERBAXA.xml:S1:696:6	wide	RB	O	O
varying	ZERBAXA.xml:S1:703:7	vari	VBG	O	O
conditions	ZERBAXA.xml:S1:711:10	condit	NNS	O	O
,	ZERBAXA.xml:S1:721:1	,	,	O	O
adverse	ZERBAXA.xml:S1:723:7	advers	JJ	O	O
reaction	ZERBAXA.xml:S1:731:8	reaction	NN	O	O
rates	ZERBAXA.xml:S1:740:5	rate	NNS	O	O
observed	ZERBAXA.xml:S1:746:8	observ	VBD	O	O
in	ZERBAXA.xml:S1:755:2	in	IN	O	O
the	ZERBAXA.xml:S1:758:3	the	DT	O	O
clinical	ZERBAXA.xml:S1:762:8	clinic	JJ	O	O
trials	ZERBAXA.xml:S1:771:6	trial	NNS	O	O
of	ZERBAXA.xml:S1:778:2	of	IN	O	O
a	ZERBAXA.xml:S1:781:1	a	DT	O	O
drug	ZERBAXA.xml:S1:783:4	drug	NN	O	O
cannot	ZERBAXA.xml:S1:788:6	cannot	NN	O	O
be	ZERBAXA.xml:S1:795:2	be	VB	O	O
directly	ZERBAXA.xml:S1:798:8	directli	RB	O	O
compared	ZERBAXA.xml:S1:807:8	compar	VBN	O	O
to	ZERBAXA.xml:S1:816:2	to	TO	O	O
rates	ZERBAXA.xml:S1:819:5	rate	NNS	O	O
in	ZERBAXA.xml:S1:825:2	in	IN	O	O
the	ZERBAXA.xml:S1:828:3	the	DT	O	O
clinical	ZERBAXA.xml:S1:832:8	clinic	JJ	O	O
trials	ZERBAXA.xml:S1:841:6	trial	NNS	O	O
of	ZERBAXA.xml:S1:848:2	of	IN	O	O
another	ZERBAXA.xml:S1:851:7	anoth	DT	O	O
drug	ZERBAXA.xml:S1:859:4	drug	NN	O	O
and	ZERBAXA.xml:S1:864:3	and	CC	O	O
also	ZERBAXA.xml:S1:868:4	also	RB	O	O
may	ZERBAXA.xml:S1:873:3	may	MD	O	O
not	ZERBAXA.xml:S1:877:3	not	RB	O	O
reflect	ZERBAXA.xml:S1:881:7	reflect	VB	O	O
rates	ZERBAXA.xml:S1:889:5	rate	NNS	O	O
observed	ZERBAXA.xml:S1:895:8	observ	VBN	O	O
in	ZERBAXA.xml:S1:904:2	in	IN	O	O
practice	ZERBAXA.xml:S1:907:8	practic	NN	O	O
.	ZERBAXA.xml:S1:915:1	.	.	O	O

ZERBAXA	ZERBAXA.xml:S1:921:7	zerbaxa	NNP	O	O
was	ZERBAXA.xml:S1:929:3	wa	VBD	O	O
evaluated	ZERBAXA.xml:S1:933:9	evalu	VBN	O	O
in	ZERBAXA.xml:S1:943:2	in	IN	O	O
Phase	ZERBAXA.xml:S1:946:5	phase	NNP	O	O
3	ZERBAXA.xml:S1:952:1	3	CD	O	O
comparator	ZERBAXA.xml:S1:954:10	compar	NN	O	O
-	ZERBAXA.xml:S1:964:1	-	:	O	O
controlled	ZERBAXA.xml:S1:965:10	control	VBN	O	O
clinical	ZERBAXA.xml:S1:976:8	clinic	JJ	O	O
trials	ZERBAXA.xml:S1:985:6	trial	NNS	O	O
of	ZERBAXA.xml:S1:992:2	of	IN	O	O
cIAI	ZERBAXA.xml:S1:995:4	ciai	NN	O	O
and	ZERBAXA.xml:S1:1000:3	and	CC	O	O
cUTI	ZERBAXA.xml:S1:1004:4	cuti	NN	O	B-AdverseReaction
,	ZERBAXA.xml:S1:1008:1	,	,	O	O
which	ZERBAXA.xml:S1:1010:5	which	WDT	O	O
included	ZERBAXA.xml:S1:1016:8	includ	VBD	O	O
a	ZERBAXA.xml:S1:1025:1	a	DT	O	O
total	ZERBAXA.xml:S1:1027:5	total	NN	O	O
of	ZERBAXA.xml:S1:1033:2	of	IN	O	O
1015	ZERBAXA.xml:S1:1036:4	1015	CD	O	O
patients	ZERBAXA.xml:S1:1041:8	patient	NNS	O	O
treated	ZERBAXA.xml:S1:1050:7	treat	VBN	O	O
with	ZERBAXA.xml:S1:1058:4	with	IN	O	O
ZERBAXA	ZERBAXA.xml:S1:1063:7	zerbaxa	NNP	O	O
and	ZERBAXA.xml:S1:1071:3	and	CC	O	O
1032	ZERBAXA.xml:S1:1075:4	1032	CD	O	O
patients	ZERBAXA.xml:S1:1080:8	patient	NNS	O	O
treated	ZERBAXA.xml:S1:1089:7	treat	VBN	O	O
with	ZERBAXA.xml:S1:1097:4	with	IN	O	O
comparator	ZERBAXA.xml:S1:1102:10	compar	NN	O	O
(	ZERBAXA.xml:S1:1113:1	(	(	O	O
levofloxacin	ZERBAXA.xml:S1:1114:12	levofloxacin	JJ	O	O
750	ZERBAXA.xml:S1:1127:3	750	CD	O	O
mg	ZERBAXA.xml:S1:1131:2	mg	JJ	O	O
daily	ZERBAXA.xml:S1:1134:5	daili	RB	O	O
in	ZERBAXA.xml:S1:1140:2	in	IN	O	O
cUTI	ZERBAXA.xml:S1:1143:4	cuti	NN	O	O
or	ZERBAXA.xml:S1:1148:2	or	CC	O	O
meropenem	ZERBAXA.xml:S1:1151:9	meropenem	VB	O	O
1	ZERBAXA.xml:S1:1161:1	1	CD	O	O
g	ZERBAXA.xml:S1:1163:1	g	NN	O	O
every	ZERBAXA.xml:S1:1165:5	everi	DT	O	O
8	ZERBAXA.xml:S1:1171:1	8	CD	O	O
hours	ZERBAXA.xml:S1:1173:5	hour	NNS	O	O
in	ZERBAXA.xml:S1:1179:2	in	IN	O	O
cIAI	ZERBAXA.xml:S1:1182:4	ciai	NN	O	O
)	ZERBAXA.xml:S1:1186:1	)	)	O	O
for	ZERBAXA.xml:S1:1188:3	for	IN	O	O
up	ZERBAXA.xml:S1:1192:2	up	IN	O	O
to	ZERBAXA.xml:S1:1195:2	to	TO	O	O
14	ZERBAXA.xml:S1:1198:2	14	CD	O	O
days	ZERBAXA.xml:S1:1201:4	day	NNS	O	O
.	ZERBAXA.xml:S1:1205:1	.	.	O	O

The	ZERBAXA.xml:S1:1207:3	the	DT	O	O
mean	ZERBAXA.xml:S1:1211:4	mean	JJ	O	O
age	ZERBAXA.xml:S1:1216:3	age	NN	O	O
of	ZERBAXA.xml:S1:1220:2	of	IN	O	O
treated	ZERBAXA.xml:S1:1223:7	treat	JJ	O	O
patients	ZERBAXA.xml:S1:1231:8	patient	NNS	O	O
was	ZERBAXA.xml:S1:1240:3	wa	VBD	O	O
48	ZERBAXA.xml:S1:1244:2	48	CD	O	O
to	ZERBAXA.xml:S1:1247:2	to	TO	O	O
50	ZERBAXA.xml:S1:1250:2	50	CD	O	O
years	ZERBAXA.xml:S1:1253:5	year	NNS	O	O
(	ZERBAXA.xml:S1:1259:1	(	(	O	O
range	ZERBAXA.xml:S1:1260:5	rang	VB	O	O
18	ZERBAXA.xml:S1:1266:2	18	CD	O	O
to	ZERBAXA.xml:S1:1269:2	to	TO	O	O
92	ZERBAXA.xml:S1:1272:2	92	CD	O	O
years	ZERBAXA.xml:S1:1275:5	year	NNS	O	O
)	ZERBAXA.xml:S1:1280:1	)	)	O	O
,	ZERBAXA.xml:S1:1281:1	,	,	O	O
across	ZERBAXA.xml:S1:1283:6	across	IN	O	O
treatment	ZERBAXA.xml:S1:1290:9	treatment	NN	O	O
arms	ZERBAXA.xml:S1:1300:4	arm	NNS	O	O
and	ZERBAXA.xml:S1:1305:3	and	CC	O	O
indications	ZERBAXA.xml:S1:1309:11	indic	NNS	O	O
.	ZERBAXA.xml:S1:1320:1	.	.	O	O

In	ZERBAXA.xml:S1:1322:2	In	IN	O	O
both	ZERBAXA.xml:S1:1325:4	both	DT	O	O
indications	ZERBAXA.xml:S1:1330:11	indic	NNS	O	O
,	ZERBAXA.xml:S1:1341:1	,	,	O	O
about	ZERBAXA.xml:S1:1343:5	about	IN	O	O
25%	ZERBAXA.xml:S1:1349:3	25%	CD	O	O
of	ZERBAXA.xml:S1:1353:2	of	IN	O	O
the	ZERBAXA.xml:S1:1356:3	the	DT	O	O
subjects	ZERBAXA.xml:S1:1360:8	subject	NNS	O	O
were	ZERBAXA.xml:S1:1369:4	were	VBD	O	O
65	ZERBAXA.xml:S1:1374:2	65	CD	O	O
years	ZERBAXA.xml:S1:1377:5	year	NNS	O	O
of	ZERBAXA.xml:S1:1383:2	of	IN	O	O
age	ZERBAXA.xml:S1:1386:3	age	NN	O	O
or	ZERBAXA.xml:S1:1390:2	or	CC	O	O
older	ZERBAXA.xml:S1:1393:5	older	JJR	O	O
.	ZERBAXA.xml:S1:1398:1	.	.	O	O

Most	ZERBAXA.xml:S1:1400:4	most	JJS	O	O
patients	ZERBAXA.xml:S1:1405:8	patient	NNS	O	O
(	ZERBAXA.xml:S1:1414:1	(	(	O	O
75%	ZERBAXA.xml:S1:1415:3	75%	CD	O	O
)	ZERBAXA.xml:S1:1418:1	)	)	O	O
enrolled	ZERBAXA.xml:S1:1420:8	enrol	VBN	O	O
in	ZERBAXA.xml:S1:1429:2	in	IN	O	O
the	ZERBAXA.xml:S1:1432:3	the	DT	O	O
cUTI	ZERBAXA.xml:S1:1436:4	cuti	JJ	O	O
trial	ZERBAXA.xml:S1:1441:5	trial	NN	O	O
were	ZERBAXA.xml:S1:1447:4	were	VBD	O	O
female	ZERBAXA.xml:S1:1452:6	femal	JJ	O	O
,	ZERBAXA.xml:S1:1458:1	,	,	O	O
and	ZERBAXA.xml:S1:1460:3	and	CC	O	O
most	ZERBAXA.xml:S1:1464:4	most	JJS	O	O
patients	ZERBAXA.xml:S1:1469:8	patient	NNS	O	O
(	ZERBAXA.xml:S1:1478:1	(	(	O	O
58%	ZERBAXA.xml:S1:1479:3	58%	CD	O	O
)	ZERBAXA.xml:S1:1482:1	)	)	O	O
enrolled	ZERBAXA.xml:S1:1484:8	enrol	VBN	O	O
in	ZERBAXA.xml:S1:1493:2	in	IN	O	O
the	ZERBAXA.xml:S1:1496:3	the	DT	O	O
cIAI	ZERBAXA.xml:S1:1500:4	ciai	JJ	O	O
trial	ZERBAXA.xml:S1:1505:5	trial	NN	O	O
were	ZERBAXA.xml:S1:1511:4	were	VBD	O	O
male	ZERBAXA.xml:S1:1516:4	male	JJ	O	O
.	ZERBAXA.xml:S1:1520:1	.	.	O	O

Most	ZERBAXA.xml:S1:1522:4	most	JJS	O	O
patients	ZERBAXA.xml:S1:1527:8	patient	NNS	O	O
(	ZERBAXA.xml:S1:1536:1	(	(	O	O
70%	ZERBAXA.xml:S1:1538:3	70%	CD	O	O
)	ZERBAXA.xml:S1:1541:1	)	)	O	O
in	ZERBAXA.xml:S1:1543:2	in	IN	O	O
both	ZERBAXA.xml:S1:1546:4	both	DT	O	O
trials	ZERBAXA.xml:S1:1551:6	trial	NNS	O	O
were	ZERBAXA.xml:S1:1558:4	were	VBD	O	O
enrolled	ZERBAXA.xml:S1:1563:8	enrol	VBN	O	O
in	ZERBAXA.xml:S1:1572:2	in	IN	O	O
Eastern	ZERBAXA.xml:S1:1575:7	eastern	NNP	O	O
Europe	ZERBAXA.xml:S1:1583:6	europ	NNP	O	O
and	ZERBAXA.xml:S1:1590:3	and	CC	O	O
were	ZERBAXA.xml:S1:1594:4	were	VBD	O	O
White	ZERBAXA.xml:S1:1599:5	white	NNP	O	O
.	ZERBAXA.xml:S1:1604:1	.	.	O	O

The	ZERBAXA.xml:S1:1610:3	the	DT	O	O
most	ZERBAXA.xml:S1:1614:4	most	RBS	O	O
common	ZERBAXA.xml:S1:1619:6	common	JJ	O	O
adverse	ZERBAXA.xml:S1:1626:7	advers	JJ	O	O
reactions	ZERBAXA.xml:S1:1634:9	reaction	NNS	O	O
(	ZERBAXA.xml:S1:1644:1	(	(	O	O
5%	ZERBAXA.xml:S1:1645:2	5%	CD	O	O
or	ZERBAXA.xml:S1:1648:2	or	CC	O	O
greater	ZERBAXA.xml:S1:1651:7	greater	JJR	O	O
in	ZERBAXA.xml:S1:1659:2	in	IN	O	O
either	ZERBAXA.xml:S1:1662:6	either	DT	O	O
indication	ZERBAXA.xml:S1:1669:10	indic	NN	O	O
)	ZERBAXA.xml:S1:1679:1	)	)	O	O
occurring	ZERBAXA.xml:S1:1681:9	occur	VBG	O	O
in	ZERBAXA.xml:S1:1691:2	in	IN	O	O
patients	ZERBAXA.xml:S1:1694:8	patient	NNS	O	O
receiving	ZERBAXA.xml:S1:1703:9	receiv	VBG	O	O
ZERBAXA	ZERBAXA.xml:S1:1713:7	zerbaxa	NNP	O	O
were	ZERBAXA.xml:S1:1721:4	were	VBD	O	O
nausea	ZERBAXA.xml:S1:1726:6	nausea	RB	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:1732:1	,	,	O	O
diarrhea	ZERBAXA.xml:S1:1734:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:1742:1	,	,	O	O
headache	ZERBAXA.xml:S1:1744:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:1752:1	,	,	O	O
and	ZERBAXA.xml:S1:1754:3	and	CC	O	O
pyrexia	ZERBAXA.xml:S1:1758:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
.	ZERBAXA.xml:S1:1765:1	.	.	O	O

Table	ZERBAXA.xml:S1:1767:5	tabl	JJ	O	O
5	ZERBAXA.xml:S1:1773:1	5	CD	O	O
lists	ZERBAXA.xml:S1:1775:5	list	NNS	O	O
adverse	ZERBAXA.xml:S1:1781:7	advers	JJ	O	O
reactions	ZERBAXA.xml:S1:1789:9	reaction	NNS	O	O
occurring	ZERBAXA.xml:S1:1799:9	occur	VBG	O	O
in	ZERBAXA.xml:S1:1809:2	in	IN	O	O
1%	ZERBAXA.xml:S1:1812:2	1%	CD	O	O
or	ZERBAXA.xml:S1:1815:2	or	CC	O	O
greater	ZERBAXA.xml:S1:1818:7	greater	JJR	O	O
of	ZERBAXA.xml:S1:1826:2	of	IN	O	O
patients	ZERBAXA.xml:S1:1829:8	patient	NNS	O	O
receiving	ZERBAXA.xml:S1:1838:9	receiv	VBG	O	O
ZERBAXA	ZERBAXA.xml:S1:1848:7	zerbaxa	NNP	O	O
in	ZERBAXA.xml:S1:1856:2	in	IN	O	O
Phase	ZERBAXA.xml:S1:1859:5	phase	NNP	O	O
3	ZERBAXA.xml:S1:1865:1	3	CD	O	O
clinical	ZERBAXA.xml:S1:1867:8	clinic	JJ	O	O
trials	ZERBAXA.xml:S1:1876:6	trial	NNS	O	O
.	ZERBAXA.xml:S1:1882:1	.	.	O	O

Table	ZERBAXA.xml:S1:1888:5	tabl	JJ	O	O
5	ZERBAXA.xml:S1:1894:1	5	CD	O	O
:	ZERBAXA.xml:S1:1895:1	:	:	O	O
Adverse	ZERBAXA.xml:S1:1897:7	advers	JJ	O	O
Reactions	ZERBAXA.xml:S1:1905:9	reaction	NNS	O	O
Occurring	ZERBAXA.xml:S1:1915:9	occur	VBG	O	O
in	ZERBAXA.xml:S1:1925:2	in	IN	O	O
1%	ZERBAXA.xml:S1:1928:2	1%	CD	O	O
or	ZERBAXA.xml:S1:1931:2	or	CC	O	O
Greater	ZERBAXA.xml:S1:1934:7	greater	NNP	O	O
of	ZERBAXA.xml:S1:1942:2	of	IN	O	O
Patients	ZERBAXA.xml:S1:1945:8	patient	NNPS	O	O
Receiving	ZERBAXA.xml:S1:1954:9	receiv	VBG	O	O
ZERBAXA	ZERBAXA.xml:S1:1964:7	zerbaxa	NNP	O	O
in	ZERBAXA.xml:S1:1972:2	in	IN	O	O
Phase	ZERBAXA.xml:S1:1975:5	phase	NNP	O	O
3	ZERBAXA.xml:S1:1981:1	3	CD	O	O
Clinical	ZERBAXA.xml:S1:1983:8	clinic	NNP	O	O
Trials	ZERBAXA.xml:S1:1992:6	trial	NNS	O	O

Preferred	ZERBAXA.xml:S1:2001:9	prefer	JJ	O	O
Term	ZERBAXA.xml:S1:2011:4	term	NNP	O	O
Complicated	ZERBAXA.xml:S1:2023:11	complic	NNP	O	O
Intra	ZERBAXA.xml:S1:2035:5	intra	NNP	O	O
-	ZERBAXA.xml:S1:2040:1	-	:	O	O
abdominal	ZERBAXA.xml:S1:2041:9	abdomin	JJ	O	O
Infections	ZERBAXA.xml:S1:2051:10	infect	NNS	O	O
Complicated	ZERBAXA.xml:S1:2063:11	complic	VBD	O	O
Urinary	ZERBAXA.xml:S1:2075:7	urinari	NNP	O	B-AdverseReaction
Tract	ZERBAXA.xml:S1:2083:5	tract	NNP	O	I-AdverseReaction
Infections	ZERBAXA.xml:S1:2089:10	infect	NNP	O	I-AdverseReaction
,	ZERBAXA.xml:S1:2099:1	,	,	O	O
Including	ZERBAXA.xml:S1:2101:9	includ	NNP	O	O
Pyelonephritis	ZERBAXA.xml:S1:2111:14	pyelonephr	NNP	O	O

ZERBAXA	ZERBAXA.xml:S1:2130:7	zerbaxa	NNP	O	O
(	ZERBAXA.xml:S1:2137:1	(	(	O	O
N	ZERBAXA.xml:S1:2138:1	N	NNP	O	O
482	ZERBAXA.xml:S1:2140:3	482	CD	O	O
)	ZERBAXA.xml:S1:2143:1	)	)	O	O
Meropenem	ZERBAXA.xml:S1:2154:9	meropenem	NNP	O	O
(	ZERBAXA.xml:S1:2163:1	(	(	O	O
N	ZERBAXA.xml:S1:2164:1	N	NNP	O	O
497	ZERBAXA.xml:S1:2166:3	497	CD	O	O
)	ZERBAXA.xml:S1:2169:1	)	)	O	O
ZERBAXA	ZERBAXA.xml:S1:2177:7	zerbaxa	NNP	O	O
(	ZERBAXA.xml:S1:2184:1	(	(	O	O
N	ZERBAXA.xml:S1:2185:1	N	NNP	O	O
533	ZERBAXA.xml:S1:2187:3	533	CD	O	O
)	ZERBAXA.xml:S1:2190:1	)	)	O	O
Levofloxacin	ZERBAXA.xml:S1:2196:12	levofloxacin	NNP	O	O
(	ZERBAXA.xml:S1:2208:1	(	(	O	O
N	ZERBAXA.xml:S1:2209:1	N	NNP	O	O
535	ZERBAXA.xml:S1:2211:3	535	CD	O	O
)	ZERBAXA.xml:S1:2214:1	)	)	O	O

Nausea	ZERBAXA.xml:S1:2224:6	nausea	NN	B-AdverseReaction	B-AdverseReaction

38	ZERBAXA.xml:S1:2252:2	38	CD	O	O
(	ZERBAXA.xml:S1:2255:1	(	(	O	O
7.9	ZERBAXA.xml:S1:2256:3	7.9	CD	O	O
)	ZERBAXA.xml:S1:2259:1	)	)	O	O
29	ZERBAXA.xml:S1:2274:2	29	CD	O	O
(	ZERBAXA.xml:S1:2277:1	(	(	O	O
5.8	ZERBAXA.xml:S1:2278:3	5.8	CD	O	O
)	ZERBAXA.xml:S1:2281:1	)	)	O	O
15	ZERBAXA.xml:S1:2296:2	15	CD	O	O
(	ZERBAXA.xml:S1:2299:1	(	(	O	O
2.8	ZERBAXA.xml:S1:2300:3	2.8	CD	O	O
)	ZERBAXA.xml:S1:2303:1	)	)	O	O
9	ZERBAXA.xml:S1:2318:1	9	CD	O	O
(	ZERBAXA.xml:S1:2320:1	(	(	O	O
1.7	ZERBAXA.xml:S1:2321:3	1.7	CD	O	O
)	ZERBAXA.xml:S1:2324:1	)	)	O	O

Headache	ZERBAXA.xml:S1:2337:8	headach	$	B-AdverseReaction	B-AdverseReaction
12	ZERBAXA.xml:S1:2365:2	12	CD	O	O
(	ZERBAXA.xml:S1:2368:1	(	(	O	O
2.5	ZERBAXA.xml:S1:2369:3	2.5	CD	O	O
)	ZERBAXA.xml:S1:2372:1	)	)	O	O
9	ZERBAXA.xml:S1:2387:1	9	CD	O	O
(	ZERBAXA.xml:S1:2389:1	(	(	O	O
1.8	ZERBAXA.xml:S1:2390:3	1.8	CD	O	O
)	ZERBAXA.xml:S1:2393:1	)	)	O	O
31	ZERBAXA.xml:S1:2409:2	31	CD	O	O
(	ZERBAXA.xml:S1:2412:1	(	(	O	O
5.8	ZERBAXA.xml:S1:2413:3	5.8	CD	O	O
)	ZERBAXA.xml:S1:2416:1	)	)	O	O
26	ZERBAXA.xml:S1:2431:2	26	CD	O	O
(	ZERBAXA.xml:S1:2434:1	(	(	O	O
4.9	ZERBAXA.xml:S1:2435:3	4.9	CD	O	O
)	ZERBAXA.xml:S1:2438:1	)	)	O	O

Diarrhea	ZERBAXA.xml:S1:2450:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
30	ZERBAXA.xml:S1:2478:2	30	CD	O	O
(	ZERBAXA.xml:S1:2481:1	(	(	O	O
6.2	ZERBAXA.xml:S1:2482:3	6.2	CD	O	O
)	ZERBAXA.xml:S1:2485:1	)	)	O	O
25	ZERBAXA.xml:S1:2501:2	25	CD	O	O
(	ZERBAXA.xml:S1:2504:1	(	(	O	O
5	ZERBAXA.xml:S1:2505:1	5	CD	O	O
)	ZERBAXA.xml:S1:2506:1	)	)	O	O
10	ZERBAXA.xml:S1:2522:2	10	CD	O	O
(	ZERBAXA.xml:S1:2525:1	(	(	O	O
1.9	ZERBAXA.xml:S1:2526:3	1.9	CD	O	O
)	ZERBAXA.xml:S1:2529:1	)	)	O	O
23	ZERBAXA.xml:S1:2544:2	23	CD	O	O
(	ZERBAXA.xml:S1:2547:1	(	(	O	O
4.3	ZERBAXA.xml:S1:2548:3	4.3	CD	O	O
)	ZERBAXA.xml:S1:2551:1	)	)	O	O

Pyrexia	ZERBAXA.xml:S1:2563:7	pyrexia	$	B-AdverseReaction	B-AdverseReaction
27	ZERBAXA.xml:S1:2591:2	27	CD	O	O
(	ZERBAXA.xml:S1:2594:1	(	(	O	O
5.6	ZERBAXA.xml:S1:2595:3	5.6	CD	O	O
)	ZERBAXA.xml:S1:2598:1	)	)	O	O
20	ZERBAXA.xml:S1:2614:2	20	CD	O	O
(	ZERBAXA.xml:S1:2617:1	(	(	O	O
4	ZERBAXA.xml:S1:2618:1	4	CD	O	O
)	ZERBAXA.xml:S1:2619:1	)	)	O	O
9	ZERBAXA.xml:S1:2635:1	9	CD	O	O
(	ZERBAXA.xml:S1:2637:1	(	(	O	O
1.7	ZERBAXA.xml:S1:2638:3	1.7	CD	O	O
)	ZERBAXA.xml:S1:2641:1	)	)	O	O
5	ZERBAXA.xml:S1:2657:1	5	CD	O	O
(	ZERBAXA.xml:S1:2659:1	(	(	O	O
0.9	ZERBAXA.xml:S1:2660:3	0.9	CD	O	O
)	ZERBAXA.xml:S1:2663:1	)	)	O	O

Constipation	ZERBAXA.xml:S1:2676:12	constip	NN	B-AdverseReaction	B-AdverseReaction
9	ZERBAXA.xml:S1:2704:1	9	CD	O	O
(	ZERBAXA.xml:S1:2706:1	(	(	O	O
1.9	ZERBAXA.xml:S1:2707:3	1.9	CD	O	O
)	ZERBAXA.xml:S1:2710:1	)	)	O	O
6	ZERBAXA.xml:S1:2726:1	6	CD	O	O
(	ZERBAXA.xml:S1:2728:1	(	(	O	O
1.2	ZERBAXA.xml:S1:2729:3	1.2	CD	O	O
)	ZERBAXA.xml:S1:2732:1	)	)	O	O
21	ZERBAXA.xml:S1:2748:2	21	CD	O	O
(	ZERBAXA.xml:S1:2751:1	(	(	O	O
3.9	ZERBAXA.xml:S1:2752:3	3.9	CD	O	O
)	ZERBAXA.xml:S1:2755:1	)	)	O	O
17	ZERBAXA.xml:S1:2770:2	17	CD	O	O
(	ZERBAXA.xml:S1:2773:1	(	(	O	O
3.2	ZERBAXA.xml:S1:2774:3	3.2	CD	O	O
)	ZERBAXA.xml:S1:2777:1	)	)	O	O

Insomnia	ZERBAXA.xml:S1:2789:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
17	ZERBAXA.xml:S1:2817:2	17	CD	O	O
(	ZERBAXA.xml:S1:2820:1	(	(	O	O
3.5	ZERBAXA.xml:S1:2821:3	3.5	CD	O	O
)	ZERBAXA.xml:S1:2824:1	)	)	O	O
11	ZERBAXA.xml:S1:2839:2	11	CD	O	O
(	ZERBAXA.xml:S1:2842:1	(	(	O	O
2.2	ZERBAXA.xml:S1:2843:3	2.2	CD	O	O
)	ZERBAXA.xml:S1:2846:1	)	)	O	O
7	ZERBAXA.xml:S1:2861:1	7	CD	O	O
(	ZERBAXA.xml:S1:2863:1	(	(	O	O
1.3	ZERBAXA.xml:S1:2864:3	1.3	CD	O	O
)	ZERBAXA.xml:S1:2867:1	)	)	O	O
14	ZERBAXA.xml:S1:2883:2	14	CD	O	O
(	ZERBAXA.xml:S1:2886:1	(	(	O	O
2.6	ZERBAXA.xml:S1:2887:3	2.6	CD	O	O
)	ZERBAXA.xml:S1:2890:1	)	)	O	O

Vomiting	ZERBAXA.xml:S1:2902:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
16	ZERBAXA.xml:S1:2930:2	16	CD	O	O
(	ZERBAXA.xml:S1:2933:1	(	(	O	O
3.3	ZERBAXA.xml:S1:2934:3	3.3	CD	O	O
)	ZERBAXA.xml:S1:2937:1	)	)	O	O
20	ZERBAXA.xml:S1:2953:2	20	CD	O	O
(	ZERBAXA.xml:S1:2956:1	(	(	O	O
4	ZERBAXA.xml:S1:2957:1	4	CD	O	O
)	ZERBAXA.xml:S1:2958:1	)	)	O	O
6	ZERBAXA.xml:S1:2974:1	6	CD	O	O
(	ZERBAXA.xml:S1:2976:1	(	(	O	O
1.1	ZERBAXA.xml:S1:2977:3	1.1	CD	O	O
)	ZERBAXA.xml:S1:2980:1	)	)	O	O
6	ZERBAXA.xml:S1:2996:1	6	CD	O	O
(	ZERBAXA.xml:S1:2998:1	(	(	O	O
1.1	ZERBAXA.xml:S1:2999:3	1.1	CD	O	O
)	ZERBAXA.xml:S1:3002:1	)	)	O	O

Hypokalemia	ZERBAXA.xml:S1:3015:11	hypokalemia	$	B-AdverseReaction	B-AdverseReaction
16	ZERBAXA.xml:S1:3043:2	16	CD	O	O
(	ZERBAXA.xml:S1:3046:1	(	(	O	O
3.3	ZERBAXA.xml:S1:3047:3	3.3	CD	O	O
)	ZERBAXA.xml:S1:3050:1	)	)	O	O
10	ZERBAXA.xml:S1:3066:2	10	CD	O	O
(	ZERBAXA.xml:S1:3069:1	(	(	O	O
2	ZERBAXA.xml:S1:3070:1	2	CD	O	O
)	ZERBAXA.xml:S1:3071:1	)	)	O	O
4	ZERBAXA.xml:S1:3087:1	4	CD	O	O
(	ZERBAXA.xml:S1:3089:1	(	(	O	O
0.8	ZERBAXA.xml:S1:3090:3	0.8	CD	O	O
)	ZERBAXA.xml:S1:3093:1	)	)	O	O
2	ZERBAXA.xml:S1:3109:1	2	CD	O	O
(	ZERBAXA.xml:S1:3111:1	(	(	O	O
0.4	ZERBAXA.xml:S1:3112:3	0.4	CD	O	O
)	ZERBAXA.xml:S1:3115:1	)	)	O	O

ALT	ZERBAXA.xml:S1:3128:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZERBAXA.xml:S1:3132:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
7	ZERBAXA.xml:S1:3156:1	7	CD	O	O
(	ZERBAXA.xml:S1:3158:1	(	(	O	O
1.5	ZERBAXA.xml:S1:3159:3	1.5	CD	O	O
)	ZERBAXA.xml:S1:3162:1	)	)	O	O
5	ZERBAXA.xml:S1:3179:1	5	CD	O	O
(	ZERBAXA.xml:S1:3181:1	(	(	O	O
1	ZERBAXA.xml:S1:3182:1	1	CD	O	O
)	ZERBAXA.xml:S1:3183:1	)	)	O	O
9	ZERBAXA.xml:S1:3200:1	9	CD	O	O
(	ZERBAXA.xml:S1:3202:1	(	(	O	O
1.7	ZERBAXA.xml:S1:3203:3	1.7	CD	O	O
)	ZERBAXA.xml:S1:3206:1	)	)	O	O
5	ZERBAXA.xml:S1:3222:1	5	CD	O	O
(	ZERBAXA.xml:S1:3224:1	(	(	O	O
0.9	ZERBAXA.xml:S1:3225:3	0.9	CD	O	O
)	ZERBAXA.xml:S1:3228:1	)	)	O	O

AST	ZERBAXA.xml:S1:3241:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZERBAXA.xml:S1:3245:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
5	ZERBAXA.xml:S1:3270:1	5	CD	O	O
(	ZERBAXA.xml:S1:3272:1	(	(	O	O
1	ZERBAXA.xml:S1:3273:1	1	CD	O	O
)	ZERBAXA.xml:S1:3274:1	)	)	O	O
3	ZERBAXA.xml:S1:3291:1	3	CD	O	O
(	ZERBAXA.xml:S1:3293:1	(	(	O	O
0.6	ZERBAXA.xml:S1:3294:3	0.6	CD	O	O
)	ZERBAXA.xml:S1:3297:1	)	)	O	O
9	ZERBAXA.xml:S1:3313:1	9	CD	O	O
(	ZERBAXA.xml:S1:3315:1	(	(	O	O
1.7	ZERBAXA.xml:S1:3316:3	1.7	CD	O	O
)	ZERBAXA.xml:S1:3319:1	)	)	O	O
5	ZERBAXA.xml:S1:3335:1	5	CD	O	O
(	ZERBAXA.xml:S1:3337:1	(	(	O	O
0.9	ZERBAXA.xml:S1:3338:3	0.9	CD	O	O
)	ZERBAXA.xml:S1:3341:1	)	)	O	O

Anemia	ZERBAXA.xml:S1:3354:6	anemia	$	B-AdverseReaction	B-AdverseReaction
7	ZERBAXA.xml:S1:3382:1	7	CD	O	O
(	ZERBAXA.xml:S1:3384:1	(	(	O	O
1.5	ZERBAXA.xml:S1:3385:3	1.5	CD	O	O
)	ZERBAXA.xml:S1:3388:1	)	)	O	O
5	ZERBAXA.xml:S1:3405:1	5	CD	O	O
(	ZERBAXA.xml:S1:3407:1	(	(	O	O
1	ZERBAXA.xml:S1:3408:1	1	CD	O	O
)	ZERBAXA.xml:S1:3409:1	)	)	O	O
2	ZERBAXA.xml:S1:3426:1	2	CD	O	O
(	ZERBAXA.xml:S1:3428:1	(	(	O	O
0.4	ZERBAXA.xml:S1:3429:3	0.4	CD	O	O
)	ZERBAXA.xml:S1:3432:1	)	)	O	O
5	ZERBAXA.xml:S1:3448:1	5	CD	O	O
(	ZERBAXA.xml:S1:3450:1	(	(	O	O
0.9	ZERBAXA.xml:S1:3451:3	0.9	CD	O	O
)	ZERBAXA.xml:S1:3454:1	)	)	O	O

Thrombocytosis	ZERBAXA.xml:S1:3467:14	thrombocytosi	NN	B-AdverseReaction	B-AdverseReaction
9	ZERBAXA.xml:S1:3495:1	9	CD	O	O
(	ZERBAXA.xml:S1:3497:1	(	(	O	O
1.9	ZERBAXA.xml:S1:3498:3	1.9	CD	O	O
)	ZERBAXA.xml:S1:3501:1	)	)	O	O
5	ZERBAXA.xml:S1:3518:1	5	CD	O	O
(	ZERBAXA.xml:S1:3520:1	(	(	O	O
1	ZERBAXA.xml:S1:3521:1	1	CD	O	O
)	ZERBAXA.xml:S1:3522:1	)	)	O	O
2	ZERBAXA.xml:S1:3539:1	2	CD	O	O
(	ZERBAXA.xml:S1:3541:1	(	(	O	O
0.4	ZERBAXA.xml:S1:3542:3	0.4	CD	O	O
)	ZERBAXA.xml:S1:3545:1	)	)	O	O
2	ZERBAXA.xml:S1:3561:1	2	CD	O	O
(	ZERBAXA.xml:S1:3563:1	(	(	O	O
0.4	ZERBAXA.xml:S1:3564:3	0.4	CD	O	O
)	ZERBAXA.xml:S1:3567:1	)	)	O	O

Abdominal	ZERBAXA.xml:S1:3580:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	ZERBAXA.xml:S1:3590:4	pain	NN	I-AdverseReaction	I-AdverseReaction
6	ZERBAXA.xml:S1:3608:1	6	CD	O	O
(	ZERBAXA.xml:S1:3610:1	(	(	O	O
1.2	ZERBAXA.xml:S1:3611:3	1.2	CD	O	O
)	ZERBAXA.xml:S1:3614:1	)	)	O	O
2	ZERBAXA.xml:S1:3630:1	2	CD	O	O
(	ZERBAXA.xml:S1:3632:1	(	(	O	O
0.4	ZERBAXA.xml:S1:3633:3	0.4	CD	O	O
)	ZERBAXA.xml:S1:3636:1	)	)	O	O
4	ZERBAXA.xml:S1:3652:1	4	CD	O	O
(	ZERBAXA.xml:S1:3654:1	(	(	O	O
0.8	ZERBAXA.xml:S1:3655:3	0.8	CD	O	O
)	ZERBAXA.xml:S1:3658:1	)	)	O	O
2	ZERBAXA.xml:S1:3674:1	2	CD	O	O
(	ZERBAXA.xml:S1:3676:1	(	(	O	O
0.4	ZERBAXA.xml:S1:3677:3	0.4	CD	O	O
)	ZERBAXA.xml:S1:3680:1	)	)	O	O

Anxiety	ZERBAXA.xml:S1:3693:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
9	ZERBAXA.xml:S1:3721:1	9	CD	O	O
(	ZERBAXA.xml:S1:3723:1	(	(	O	O
1.9	ZERBAXA.xml:S1:3724:3	1.9	CD	O	O
)	ZERBAXA.xml:S1:3727:1	)	)	O	O
7	ZERBAXA.xml:S1:3743:1	7	CD	O	O
(	ZERBAXA.xml:S1:3745:1	(	(	O	O
1.4	ZERBAXA.xml:S1:3746:3	1.4	CD	O	O
)	ZERBAXA.xml:S1:3749:1	)	)	O	O
1	ZERBAXA.xml:S1:3765:1	1	CD	O	O
(	ZERBAXA.xml:S1:3767:1	(	(	O	O
0.2	ZERBAXA.xml:S1:3768:3	0.2	CD	O	O
)	ZERBAXA.xml:S1:3771:1	)	)	O	O
4	ZERBAXA.xml:S1:3787:1	4	CD	O	O
(	ZERBAXA.xml:S1:3789:1	(	(	O	O
0.7	ZERBAXA.xml:S1:3790:3	0.7	CD	O	O
)	ZERBAXA.xml:S1:3793:1	)	)	O	O

Dizziness	ZERBAXA.xml:S1:3806:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
4	ZERBAXA.xml:S1:3834:1	4	CD	O	O
(	ZERBAXA.xml:S1:3836:1	(	(	O	O
0.8	ZERBAXA.xml:S1:3837:3	0.8	CD	O	O
)	ZERBAXA.xml:S1:3840:1	)	)	O	O
5	ZERBAXA.xml:S1:3857:1	5	CD	O	O
(	ZERBAXA.xml:S1:3859:1	(	(	O	O
1	ZERBAXA.xml:S1:3860:1	1	CD	O	O
)	ZERBAXA.xml:S1:3861:1	)	)	O	O
6	ZERBAXA.xml:S1:3878:1	6	CD	O	O
(	ZERBAXA.xml:S1:3880:1	(	(	O	O
1.1	ZERBAXA.xml:S1:3881:3	1.1	CD	O	O
)	ZERBAXA.xml:S1:3884:1	)	)	O	O
1	ZERBAXA.xml:S1:3900:1	1	CD	O	O
(	ZERBAXA.xml:S1:3902:1	(	(	O	O
0.2	ZERBAXA.xml:S1:3903:3	0.2	CD	O	O
)	ZERBAXA.xml:S1:3906:1	)	)	O	O

Hypotension	ZERBAXA.xml:S1:3919:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
8	ZERBAXA.xml:S1:3947:1	8	CD	O	O
(	ZERBAXA.xml:S1:3949:1	(	(	O	O
1.7	ZERBAXA.xml:S1:3950:3	1.7	CD	O	O
)	ZERBAXA.xml:S1:3953:1	)	)	O	O
4	ZERBAXA.xml:S1:3969:1	4	CD	O	O
(	ZERBAXA.xml:S1:3971:1	(	(	O	O
0.8	ZERBAXA.xml:S1:3972:3	0.8	CD	O	O
)	ZERBAXA.xml:S1:3975:1	)	)	O	O
2	ZERBAXA.xml:S1:3991:1	2	CD	O	O
(	ZERBAXA.xml:S1:3993:1	(	(	O	O
0.4	ZERBAXA.xml:S1:3994:3	0.4	CD	O	O
)	ZERBAXA.xml:S1:3997:1	)	)	O	O
1	ZERBAXA.xml:S1:4013:1	1	CD	O	O
(	ZERBAXA.xml:S1:4015:1	(	(	O	O
0.2	ZERBAXA.xml:S1:4016:3	0.2	CD	O	O
)	ZERBAXA.xml:S1:4019:1	)	)	O	O

Atrial	ZERBAXA.xml:S1:4032:6	atrial	JJ	B-AdverseReaction	B-AdverseReaction
fibrillation	ZERBAXA.xml:S1:4039:12	fibril	NN	I-AdverseReaction	I-AdverseReaction
6	ZERBAXA.xml:S1:4060:1	6	CD	O	O
(	ZERBAXA.xml:S1:4062:1	(	(	O	O
1.2	ZERBAXA.xml:S1:4063:3	1.2	CD	O	O
)	ZERBAXA.xml:S1:4066:1	)	)	O	O
3	ZERBAXA.xml:S1:4082:1	3	CD	O	O
(	ZERBAXA.xml:S1:4084:1	(	(	O	O
0.6	ZERBAXA.xml:S1:4085:3	0.6	CD	O	O
)	ZERBAXA.xml:S1:4088:1	)	)	O	O
1	ZERBAXA.xml:S1:4104:1	1	CD	O	O
(	ZERBAXA.xml:S1:4106:1	(	(	O	O
0.2	ZERBAXA.xml:S1:4107:3	0.2	CD	O	O
)	ZERBAXA.xml:S1:4110:1	)	)	O	O
0	ZERBAXA.xml:S1:4129:1	0	CD	O	O

Rash	ZERBAXA.xml:S1:4145:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
8	ZERBAXA.xml:S1:4173:1	8	CD	O	O
(	ZERBAXA.xml:S1:4175:1	(	(	O	O
1.7	ZERBAXA.xml:S1:4176:3	1.7	CD	O	O
)	ZERBAXA.xml:S1:4179:1	)	)	O	O
7	ZERBAXA.xml:S1:4195:1	7	CD	O	O
(	ZERBAXA.xml:S1:4197:1	(	(	O	O
1.4	ZERBAXA.xml:S1:4198:3	1.4	CD	O	O
)	ZERBAXA.xml:S1:4201:1	)	)	O	O
5	ZERBAXA.xml:S1:4217:1	5	CD	O	O
(	ZERBAXA.xml:S1:4219:1	(	(	O	O
0.9	ZERBAXA.xml:S1:4220:3	0.9	CD	O	O
)	ZERBAXA.xml:S1:4223:1	)	)	O	O
2	ZERBAXA.xml:S1:4239:1	2	CD	O	O
(	ZERBAXA.xml:S1:4241:1	(	(	O	O
0.4	ZERBAXA.xml:S1:4242:3	0.4	CD	O	O
)	ZERBAXA.xml:S1:4245:1	)	)	O	O

Treatment	ZERBAXA.xml:S1:4268:9	treatment	JJ	O	O
discontinuation	ZERBAXA.xml:S1:4278:15	discontinu	NN	O	O
due	ZERBAXA.xml:S1:4294:3	due	JJ	O	O
to	ZERBAXA.xml:S1:4298:2	to	TO	O	O
adverse	ZERBAXA.xml:S1:4301:7	advers	JJ	O	O
events	ZERBAXA.xml:S1:4309:6	event	NNS	O	O
occurred	ZERBAXA.xml:S1:4316:8	occur	VBD	O	O
in	ZERBAXA.xml:S1:4325:2	in	IN	O	O
2.0%	ZERBAXA.xml:S1:4328:4	2.0%	CD	O	O
(	ZERBAXA.xml:S1:4333:1	(	(	O	O
20	ZERBAXA.xml:S1:4334:2	20	CD	O	O
1015	ZERBAXA.xml:S1:4337:4	1015	CD	O	O
)	ZERBAXA.xml:S1:4341:1	)	)	O	O
of	ZERBAXA.xml:S1:4343:2	of	IN	O	O
patients	ZERBAXA.xml:S1:4346:8	patient	NNS	O	O
receiving	ZERBAXA.xml:S1:4355:9	receiv	VBG	O	O
ZERBAXA	ZERBAXA.xml:S1:4365:7	zerbaxa	NNP	O	O
and	ZERBAXA.xml:S1:4373:3	and	CC	O	O
1.9%	ZERBAXA.xml:S1:4377:4	1.9%	CD	O	O
(	ZERBAXA.xml:S1:4382:1	(	(	O	O
20	ZERBAXA.xml:S1:4383:2	20	CD	O	O
1032	ZERBAXA.xml:S1:4386:4	1032	CD	O	O
)	ZERBAXA.xml:S1:4390:1	)	)	O	O
of	ZERBAXA.xml:S1:4392:2	of	IN	O	O
patients	ZERBAXA.xml:S1:4395:8	patient	NNS	O	O
receiving	ZERBAXA.xml:S1:4404:9	receiv	VBG	O	O
comparator	ZERBAXA.xml:S1:4414:10	compar	NN	O	O
drugs	ZERBAXA.xml:S1:4425:5	drug	NNS	O	O
.	ZERBAXA.xml:S1:4430:1	.	.	O	O

Renal	ZERBAXA.xml:S1:4432:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
impairment	ZERBAXA.xml:S1:4438:10	impair	NN	I-AdverseReaction	I-AdverseReaction
(	ZERBAXA.xml:S1:4449:1	(	(	O	O
including	ZERBAXA.xml:S1:4450:9	includ	VBG	O	O
the	ZERBAXA.xml:S1:4460:3	the	DT	O	O
terms	ZERBAXA.xml:S1:4464:5	term	NNS	O	O
renal	ZERBAXA.xml:S1:4470:5	renal	JJ	B-AdverseReaction	O
impairment	ZERBAXA.xml:S1:4476:10	impair	NN	I-AdverseReaction	O
,	ZERBAXA.xml:S1:4486:1	,	,	O	O
renal	ZERBAXA.xml:S1:4488:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZERBAXA.xml:S1:4494:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	ZERBAXA.xml:S1:4501:1	,	,	O	O
and	ZERBAXA.xml:S1:4503:3	and	CC	O	O
renal	ZERBAXA.xml:S1:4507:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZERBAXA.xml:S1:4513:7	failur	NN	I-AdverseReaction	I-AdverseReaction
acute	ZERBAXA.xml:S1:4521:5	acut	NN	I-AdverseReaction	I-AdverseReaction
)	ZERBAXA.xml:S1:4526:1	)	)	O	O
led	ZERBAXA.xml:S1:4528:3	led	VBD	O	O
to	ZERBAXA.xml:S1:4532:2	to	TO	O	O
discontinuation	ZERBAXA.xml:S1:4535:15	discontinu	NN	O	O
of	ZERBAXA.xml:S1:4551:2	of	IN	O	O
treatment	ZERBAXA.xml:S1:4554:9	treatment	NN	O	O
in	ZERBAXA.xml:S1:4564:2	in	IN	O	O
5	ZERBAXA.xml:S1:4567:1	5	CD	O	O
1015	ZERBAXA.xml:S1:4569:4	1015	CD	O	O
(	ZERBAXA.xml:S1:4574:1	(	(	O	O
0.5%	ZERBAXA.xml:S1:4575:4	0.5%	CD	O	O
)	ZERBAXA.xml:S1:4579:1	)	)	O	O
subjects	ZERBAXA.xml:S1:4581:8	subject	NNS	O	O
receiving	ZERBAXA.xml:S1:4590:9	receiv	VBG	O	O
ZERBAXA	ZERBAXA.xml:S1:4600:7	zerbaxa	NNP	O	O
and	ZERBAXA.xml:S1:4608:3	and	CC	O	O
none	ZERBAXA.xml:S1:4612:4	none	NN	O	O
in	ZERBAXA.xml:S1:4617:2	in	IN	O	O
the	ZERBAXA.xml:S1:4620:3	the	DT	O	O
comparator	ZERBAXA.xml:S1:4624:10	compar	NN	O	O
arms	ZERBAXA.xml:S1:4635:4	arm	NNS	O	O
.	ZERBAXA.xml:S1:4639:1	.	.	O	O

Increased	ZERBAXA.xml:S1:4649:9	increas	VBN	O	O

Mortality	ZERBAXA.xml:S1:4659:9	mortal	NN	O	O

In	ZERBAXA.xml:S1:4675:2	In	IN	O	O
the	ZERBAXA.xml:S1:4678:3	the	DT	O	O
cIAI	ZERBAXA.xml:S1:4682:4	ciai	NN	O	O
trials	ZERBAXA.xml:S1:4687:6	trial	NNS	O	O
(	ZERBAXA.xml:S1:4694:1	(	(	O	O
Phase	ZERBAXA.xml:S1:4695:5	phase	NNP	O	O
2	ZERBAXA.xml:S1:4701:1	2	CD	O	O
and	ZERBAXA.xml:S1:4703:3	and	CC	O	O
3	ZERBAXA.xml:S1:4707:1	3	CD	O	O
)	ZERBAXA.xml:S1:4708:1	)	)	O	O
,	ZERBAXA.xml:S1:4709:1	,	,	O	O
death	ZERBAXA.xml:S1:4711:5	death	NN	B-AdverseReaction	B-AdverseReaction
occurred	ZERBAXA.xml:S1:4717:8	occur	VBD	O	O
in	ZERBAXA.xml:S1:4726:2	in	IN	O	O
2.5%	ZERBAXA.xml:S1:4729:4	2.5%	CD	O	O
(	ZERBAXA.xml:S1:4734:1	(	(	O	O
14	ZERBAXA.xml:S1:4735:2	14	CD	O	O
564	ZERBAXA.xml:S1:4738:3	564	CD	O	O
)	ZERBAXA.xml:S1:4741:1	)	)	O	O
of	ZERBAXA.xml:S1:4743:2	of	IN	O	O
patients	ZERBAXA.xml:S1:4746:8	patient	NNS	O	O
receiving	ZERBAXA.xml:S1:4755:9	receiv	VBG	O	O
ZERBAXA	ZERBAXA.xml:S1:4765:7	zerbaxa	NNP	O	O
and	ZERBAXA.xml:S1:4773:3	and	CC	O	O
in	ZERBAXA.xml:S1:4777:2	in	IN	O	O
1.5%	ZERBAXA.xml:S1:4780:4	1.5%	CD	O	O
(	ZERBAXA.xml:S1:4785:1	(	(	O	O
8	ZERBAXA.xml:S1:4786:1	8	CD	O	O
536	ZERBAXA.xml:S1:4788:3	536	CD	O	O
)	ZERBAXA.xml:S1:4791:1	)	)	O	O
of	ZERBAXA.xml:S1:4793:2	of	IN	O	O
patients	ZERBAXA.xml:S1:4796:8	patient	NNS	O	O
receiving	ZERBAXA.xml:S1:4805:9	receiv	VBG	O	O
meropenem	ZERBAXA.xml:S1:4815:9	meropenem	NN	O	O
.	ZERBAXA.xml:S1:4824:1	.	.	O	O

The	ZERBAXA.xml:S1:4826:3	the	DT	O	O
causes	ZERBAXA.xml:S1:4830:6	caus	NNS	O	O
of	ZERBAXA.xml:S1:4837:2	of	IN	O	O
death	ZERBAXA.xml:S1:4840:5	death	NN	B-AdverseReaction	B-AdverseReaction
varied	ZERBAXA.xml:S1:4846:6	vari	VBN	O	O
and	ZERBAXA.xml:S1:4853:3	and	CC	O	O
included	ZERBAXA.xml:S1:4857:8	includ	VBN	O	O
worsening	ZERBAXA.xml:S1:4866:9	worsen	NN	B-AdverseReaction	O
and	ZERBAXA.xml:S1:4876:3	and	CC	O	O
or	ZERBAXA.xml:S1:4880:2	or	CC	O	O
complications	ZERBAXA.xml:S1:4883:13	complic	NNS	B-AdverseReaction	O
of	ZERBAXA.xml:S1:4897:2	of	IN	I-AdverseReaction	O
infection	ZERBAXA.xml:S1:4900:9	infect	NN	I-AdverseReaction	O
,	ZERBAXA.xml:S1:4909:1	,	,	O	O
surgery	ZERBAXA.xml:S1:4911:7	surgeri	NN	O	O
and	ZERBAXA.xml:S1:4919:3	and	CC	O	O
underlying	ZERBAXA.xml:S1:4923:10	underli	JJ	O	O
conditions	ZERBAXA.xml:S1:4934:10	condit	NNS	O	O
.	ZERBAXA.xml:S1:4944:1	.	.	O	O

Less	ZERBAXA.xml:S1:4954:4	less	NNP	O	O
Common	ZERBAXA.xml:S1:4959:6	common	NNP	O	O
Adverse	ZERBAXA.xml:S1:4966:7	advers	NNP	O	O
Reactions	ZERBAXA.xml:S1:4974:9	reaction	NNP	O	O

The	ZERBAXA.xml:S1:4990:3	the	DT	O	O
following	ZERBAXA.xml:S1:4994:9	follow	JJ	O	O
selected	ZERBAXA.xml:S1:5004:8	select	JJ	O	O
adverse	ZERBAXA.xml:S1:5013:7	advers	JJ	O	O
reactions	ZERBAXA.xml:S1:5021:9	reaction	NNS	O	O
were	ZERBAXA.xml:S1:5031:4	were	VBD	O	O
reported	ZERBAXA.xml:S1:5036:8	report	VBN	O	O
in	ZERBAXA.xml:S1:5045:2	in	IN	O	O
ZERBAXA	ZERBAXA.xml:S1:5048:7	zerbaxa	NNP	O	O
-	ZERBAXA.xml:S1:5055:1	-	:	O	O
treated	ZERBAXA.xml:S1:5056:7	treat	JJ	O	O
subjects	ZERBAXA.xml:S1:5064:8	subject	NNS	O	O
at	ZERBAXA.xml:S1:5073:2	at	IN	O	O
a	ZERBAXA.xml:S1:5076:1	a	DT	O	O
rate	ZERBAXA.xml:S1:5078:4	rate	NN	O	O
of	ZERBAXA.xml:S1:5083:2	of	IN	O	O
less	ZERBAXA.xml:S1:5086:4	less	JJR	O	O
than	ZERBAXA.xml:S1:5091:4	than	IN	O	O
1%	ZERBAXA.xml:S1:5096:2	1%	CD	O	O
:	ZERBAXA.xml:S1:5098:1	:	:	O	O

Cardiac	ZERBAXA.xml:S1:5111:7	cardiac	JJ	O	O
disorders	ZERBAXA.xml:S1:5119:9	disord	NNS	O	O
:	ZERBAXA.xml:S1:5128:1	:	:	O	O
tachycardia	ZERBAXA.xml:S1:5130:11	tachycardia	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5141:1	,	,	O	O
angina	ZERBAXA.xml:S1:5143:6	angina	VBP	B-AdverseReaction	B-AdverseReaction
pectoris	ZERBAXA.xml:S1:5150:8	pectori	NN	I-AdverseReaction	I-AdverseReaction

Gastrointestinal	ZERBAXA.xml:S1:5168:16	gastrointestin	JJ	O	O
disorders	ZERBAXA.xml:S1:5185:9	disord	NNS	O	O
:	ZERBAXA.xml:S1:5194:1	:	:	O	O
ileus	ZERBAXA.xml:S1:5196:5	ileu	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5201:1	,	,	O	O
gastritis	ZERBAXA.xml:S1:5203:9	gastriti	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5212:1	,	,	O	O
abdominal	ZERBAXA.xml:S1:5214:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
distension	ZERBAXA.xml:S1:5224:10	distens	NN	I-AdverseReaction	I-AdverseReaction
,	ZERBAXA.xml:S1:5234:1	,	,	O	O
dyspepsia	ZERBAXA.xml:S1:5236:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5245:1	,	,	O	O
flatulence	ZERBAXA.xml:S1:5247:10	flatul	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5257:1	,	,	O	O
ileus	ZERBAXA.xml:S1:5259:5	ileu	JJ	B-AdverseReaction	O
paralytic	ZERBAXA.xml:S1:5265:9	paralyt	NN	I-AdverseReaction	O

General	ZERBAXA.xml:S1:5284:7	gener	NNP	O	O
disorders	ZERBAXA.xml:S1:5292:9	disord	NNS	O	O
and	ZERBAXA.xml:S1:5302:3	and	CC	O	O
administration	ZERBAXA.xml:S1:5306:14	administr	NN	O	O
site	ZERBAXA.xml:S1:5321:4	site	NN	O	O
conditions	ZERBAXA.xml:S1:5326:10	condit	NNS	O	O
:	ZERBAXA.xml:S1:5336:1	:	:	O	O
infusion	ZERBAXA.xml:S1:5338:8	infus	NN	B-AdverseReaction	O
site	ZERBAXA.xml:S1:5347:4	site	NN	I-AdverseReaction	O
reactions	ZERBAXA.xml:S1:5352:9	reaction	NNS	I-AdverseReaction	O

Infections	ZERBAXA.xml:S1:5371:10	infect	NNS	O	O
and	ZERBAXA.xml:S1:5382:3	and	CC	O	O
infestations	ZERBAXA.xml:S1:5386:12	infest	NNS	O	O
:	ZERBAXA.xml:S1:5398:1	:	:	O	O
candidiasis	ZERBAXA.xml:S1:5400:11	candidiasi	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5411:1	,	,	O	O
oropharyngeal	ZERBAXA.xml:S1:5413:13	oropharyng	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5426:1	,	,	O	O
fungal	ZERBAXA.xml:S1:5428:6	fungal	JJ	B-AdverseReaction	B-AdverseReaction
urinary	ZERBAXA.xml:S1:5435:7	urinari	JJ	I-AdverseReaction	I-AdverseReaction
tract	ZERBAXA.xml:S1:5443:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ZERBAXA.xml:S1:5449:9	infect	NN	I-AdverseReaction	I-AdverseReaction

Investigations	ZERBAXA.xml:S1:5468:14	investig	NNS	O	O
:	ZERBAXA.xml:S1:5482:1	:	:	O	O
increased	ZERBAXA.xml:S1:5484:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
serum	ZERBAXA.xml:S1:5494:5	serum	NN	I-AdverseReaction	I-AdverseReaction
gamma	ZERBAXA.xml:S1:5500:5	gamma	NN	I-AdverseReaction	I-AdverseReaction
-	ZERBAXA.xml:S1:5505:1	-	:	I-AdverseReaction	I-AdverseReaction
glutamyl	ZERBAXA.xml:S1:5506:8	glutamyl	NN	I-AdverseReaction	I-AdverseReaction
transpeptidase	ZERBAXA.xml:S1:5515:14	transpeptidas	NN	I-AdverseReaction	I-AdverseReaction
(	ZERBAXA.xml:S1:5530:1	(	(	O	O
GGT	ZERBAXA.xml:S1:5531:3	ggt	NNP	O	O
)	ZERBAXA.xml:S1:5534:1	)	)	O	O
,	ZERBAXA.xml:S1:5535:1	,	,	O	O
increased	ZERBAXA.xml:S1:5537:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
serum	ZERBAXA.xml:S1:5547:5	serum	JJ	I-AdverseReaction	I-AdverseReaction
alkaline	ZERBAXA.xml:S1:5553:8	alkalin	NN	I-AdverseReaction	I-AdverseReaction
phosphatase	ZERBAXA.xml:S1:5562:11	phosphatas	NN	I-AdverseReaction	I-AdverseReaction
,	ZERBAXA.xml:S1:5573:1	,	,	O	O
positive	ZERBAXA.xml:S1:5575:8	posit	JJ	B-AdverseReaction	O
Coombs	ZERBAXA.xml:S1:5584:6	coomb	NNP	I-AdverseReaction	O
test	ZERBAXA.xml:S1:5591:4	test	NN	I-AdverseReaction	O

Metabolism	ZERBAXA.xml:S1:5605:10	metabol	NN	O	O
and	ZERBAXA.xml:S1:5616:3	and	CC	O	O
nutrition	ZERBAXA.xml:S1:5620:9	nutrit	NN	O	O
disorders	ZERBAXA.xml:S1:5630:9	disord	NNS	O	O
:	ZERBAXA.xml:S1:5639:1	:	:	O	O
hyperglycemia	ZERBAXA.xml:S1:5641:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5654:1	,	,	O	O
hypomagnesemia	ZERBAXA.xml:S1:5656:14	hypomagnesemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZERBAXA.xml:S1:5670:1	,	,	O	O
hypophosphatemia	ZERBAXA.xml:S1:5672:16	hypophosphatemia	NN	B-AdverseReaction	B-AdverseReaction

Nervous	ZERBAXA.xml:S1:5698:7	nervou	JJ	O	O
system	ZERBAXA.xml:S1:5706:6	system	NN	O	O
disorders	ZERBAXA.xml:S1:5713:9	disord	NNS	O	O
:	ZERBAXA.xml:S1:5722:1	:	:	O	O
ischemic	ZERBAXA.xml:S1:5724:8	ischem	JJ	B-AdverseReaction	B-AdverseReaction
stroke	ZERBAXA.xml:S1:5733:6	stroke	NN	I-AdverseReaction	I-AdverseReaction

Renal	ZERBAXA.xml:S1:5749:5	renal	NNP	O	O
and	ZERBAXA.xml:S1:5755:3	and	CC	O	O
urinary	ZERBAXA.xml:S1:5759:7	urinari	JJ	O	O
system	ZERBAXA.xml:S1:5767:6	system	NN	O	O
:	ZERBAXA.xml:S1:5773:1	:	:	O	O
renal	ZERBAXA.xml:S1:5775:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
impairment	ZERBAXA.xml:S1:5781:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	ZERBAXA.xml:S1:5791:1	,	,	O	O
renal	ZERBAXA.xml:S1:5793:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZERBAXA.xml:S1:5799:7	failur	NN	I-AdverseReaction	I-AdverseReaction

Respiratory	ZERBAXA.xml:S1:5816:11	respiratori	NNP	O	O
,	ZERBAXA.xml:S1:5827:1	,	,	O	O
thoracic	ZERBAXA.xml:S1:5829:8	thorac	NN	O	O
and	ZERBAXA.xml:S1:5838:3	and	CC	O	O
mediastinal	ZERBAXA.xml:S1:5842:11	mediastin	JJ	O	O
disorders	ZERBAXA.xml:S1:5854:9	disord	NNS	O	O
:	ZERBAXA.xml:S1:5863:1	:	:	O	O
dyspnea	ZERBAXA.xml:S1:5865:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction

Skin	ZERBAXA.xml:S1:5882:4	skin	NNP	O	O
and	ZERBAXA.xml:S1:5887:3	and	CC	O	O
subcutaneous	ZERBAXA.xml:S1:5891:12	subcutan	JJ	O	O
tissue	ZERBAXA.xml:S1:5904:6	tissu	NN	O	O
disorders	ZERBAXA.xml:S1:5911:9	disord	NNS	O	O
:	ZERBAXA.xml:S1:5920:1	:	:	O	O
urticaria	ZERBAXA.xml:S1:5922:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction

Vascular	ZERBAXA.xml:S1:5941:8	vascular	JJ	O	O
disorders	ZERBAXA.xml:S1:5950:9	disord	NNS	O	O
:	ZERBAXA.xml:S1:5959:1	:	:	O	O
venous	ZERBAXA.xml:S1:5961:6	venou	JJ	B-AdverseReaction	B-AdverseReaction
thrombosis	ZERBAXA.xml:S1:5968:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction
5	ZERBAXA.xml:S2:4:1	5	CD	O	O
WARNINGS	ZERBAXA.xml:S2:6:8	warn	NNP	O	O
AND	ZERBAXA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	ZERBAXA.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	ZERBAXA.xml:S2:37:7	excerpt	NN	O	O
:	ZERBAXA.xml:S2:44:1	:	:	O	O
Decreased	ZERBAXA.xml:S2:52:9	decreas	VBN	O	B-AdverseReaction
efficacy	ZERBAXA.xml:S2:62:8	efficaci	NN	O	I-AdverseReaction
in	ZERBAXA.xml:S2:71:2	in	IN	O	O
patients	ZERBAXA.xml:S2:74:8	patient	NNS	O	O
with	ZERBAXA.xml:S2:83:4	with	IN	O	O
baseline	ZERBAXA.xml:S2:88:8	baselin	JJ	O	O
CrCl	ZERBAXA.xml:S2:97:4	crcl	NNP	O	O
of	ZERBAXA.xml:S2:102:2	of	IN	O	O
30	ZERBAXA.xml:S2:105:2	30	CD	O	O
to	ZERBAXA.xml:S2:108:2	to	TO	O	O
50	ZERBAXA.xml:S2:113:2	50	CD	O	O
mL	ZERBAXA.xml:S2:116:2	mL	NNS	O	O
min	ZERBAXA.xml:S2:119:3	min	NN	O	O
.	ZERBAXA.xml:S2:122:1	.	.	O	O

Monitor	ZERBAXA.xml:S2:124:7	monitor	NNP	O	O
CrCl	ZERBAXA.xml:S2:132:4	crcl	NNP	O	O
at	ZERBAXA.xml:S2:137:2	at	IN	O	O
least	ZERBAXA.xml:S2:140:5	least	JJS	O	O
daily	ZERBAXA.xml:S2:146:5	daili	JJ	O	O
in	ZERBAXA.xml:S2:152:2	in	IN	O	O
patients	ZERBAXA.xml:S2:155:8	patient	NNS	O	O
with	ZERBAXA.xml:S2:164:4	with	IN	O	O
changing	ZERBAXA.xml:S2:169:8	chang	VBG	O	O
renal	ZERBAXA.xml:S2:178:5	renal	JJ	O	O
function	ZERBAXA.xml:S2:184:8	function	NN	O	O
and	ZERBAXA.xml:S2:193:3	and	CC	O	O
adjust	ZERBAXA.xml:S2:197:6	adjust	VBP	O	O
the	ZERBAXA.xml:S2:204:3	the	DT	O	O
dose	ZERBAXA.xml:S2:208:4	dose	NN	O	O
of	ZERBAXA.xml:S2:213:2	of	IN	O	O
ZERBAXA	ZERBAXA.xml:S2:216:7	zerbaxa	NNP	O	O
accordingly	ZERBAXA.xml:S2:224:11	accordingli	RB	O	O
.	ZERBAXA.xml:S2:235:1	.	.	O	O

(	ZERBAXA.xml:S2:237:1	(	(	O	O
5.1	ZERBAXA.xml:S2:240:3	5.1	CD	O	O
)	ZERBAXA.xml:S2:245:1	)	)	O	O

Serious	ZERBAXA.xml:S2:252:7	seriou	JJ	O	O
hypersensitivity	ZERBAXA.xml:S2:260:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
(	ZERBAXA.xml:S2:277:1	(	(	O	O
anaphylactic	ZERBAXA.xml:S2:278:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
)	ZERBAXA.xml:S2:290:1	)	)	O	O
reactions	ZERBAXA.xml:S2:292:9	reaction	NNS	I-AdverseReaction	O
have	ZERBAXA.xml:S2:302:4	have	VBP	O	O
been	ZERBAXA.xml:S2:307:4	been	VBN	O	O
reported	ZERBAXA.xml:S2:312:8	report	VBN	O	O
with	ZERBAXA.xml:S2:321:4	with	IN	O	O
beta	ZERBAXA.xml:S2:326:4	beta	NN	O	O
-	ZERBAXA.xml:S2:330:1	-	:	O	O
lactam	ZERBAXA.xml:S2:331:6	lactam	JJ	O	O
antibacterial	ZERBAXA.xml:S2:338:13	antibacteri	JJ	O	O
drugs	ZERBAXA.xml:S2:352:5	drug	NNS	O	O
.	ZERBAXA.xml:S2:357:1	.	.	O	O

Exercise	ZERBAXA.xml:S2:359:8	exercis	NN	O	O
caution	ZERBAXA.xml:S2:368:7	caution	NN	O	O
in	ZERBAXA.xml:S2:376:2	in	IN	O	O
patients	ZERBAXA.xml:S2:379:8	patient	NNS	O	O
with	ZERBAXA.xml:S2:388:4	with	IN	O	O
known	ZERBAXA.xml:S2:393:5	known	JJ	O	O
hypersensitivity	ZERBAXA.xml:S2:399:16	hypersensit	NN	O	O
to	ZERBAXA.xml:S2:416:2	to	TO	O	O
beta	ZERBAXA.xml:S2:419:4	beta	VB	O	O
-	ZERBAXA.xml:S2:423:1	-	:	O	O
lactam	ZERBAXA.xml:S2:424:6	lactam	NN	O	O
antibacterial	ZERBAXA.xml:S2:431:13	antibacteri	JJ	O	O
drugs	ZERBAXA.xml:S2:445:5	drug	NNS	O	O
.	ZERBAXA.xml:S2:450:1	.	.	O	O

(	ZERBAXA.xml:S2:452:1	(	(	O	O
5.2	ZERBAXA.xml:S2:455:3	5.2	CD	O	O
)	ZERBAXA.xml:S2:460:1	)	)	O	O

Clostridium	ZERBAXA.xml:S2:468:11	clostridium	NN	B-AdverseReaction	B-AdverseReaction
difficile	ZERBAXA.xml:S2:480:9	difficil	NN	I-AdverseReaction	I-AdverseReaction
-	ZERBAXA.xml:S2:490:1	-	:	I-AdverseReaction	I-AdverseReaction
associated	ZERBAXA.xml:S2:491:10	associ	VBN	I-AdverseReaction	I-AdverseReaction
diarrhea	ZERBAXA.xml:S2:502:8	diarrhea	NN	I-AdverseReaction	I-AdverseReaction
(	ZERBAXA.xml:S2:511:1	(	(	O	O
CDAD	ZERBAXA.xml:S2:512:4	cdad	NNP	B-AdverseReaction	B-AdverseReaction
)	ZERBAXA.xml:S2:516:1	)	)	O	O
has	ZERBAXA.xml:S2:518:3	ha	VBZ	O	O
been	ZERBAXA.xml:S2:522:4	been	VBN	O	O
reported	ZERBAXA.xml:S2:527:8	report	VBN	O	O
with	ZERBAXA.xml:S2:536:4	with	IN	O	O
nearly	ZERBAXA.xml:S2:541:6	nearli	RB	O	O
all	ZERBAXA.xml:S2:548:3	all	DT	O	O
systemic	ZERBAXA.xml:S2:552:8	system	JJ	O	O
antibacterial	ZERBAXA.xml:S2:561:13	antibacteri	JJ	O	O
agents	ZERBAXA.xml:S2:575:6	agent	NNS	O	O
,	ZERBAXA.xml:S2:581:1	,	,	O	O
including	ZERBAXA.xml:S2:583:9	includ	VBG	O	O
ZERBAXA	ZERBAXA.xml:S2:593:7	zerbaxa	NNP	O	O
.	ZERBAXA.xml:S2:600:1	.	.	O	O

Evaluate	ZERBAXA.xml:S2:602:8	evalu	VB	O	O
if	ZERBAXA.xml:S2:611:2	if	IN	O	O
diarrhea	ZERBAXA.xml:S2:614:8	diarrhea	JJ	O	O
occurs	ZERBAXA.xml:S2:623:6	occur	NNS	O	O
.	ZERBAXA.xml:S2:629:1	.	.	O	O

(	ZERBAXA.xml:S2:631:1	(	(	O	O
5.3	ZERBAXA.xml:S2:634:3	5.3	CD	O	O
)	ZERBAXA.xml:S2:639:1	)	)	O	O

5.1	ZERBAXA.xml:S2:653:3	5.1	CD	O	O

Decreased	ZERBAXA.xml:S2:657:9	decreas	VBN	O	O

Efficacy	ZERBAXA.xml:S2:667:8	efficaci	NN	O	O
in	ZERBAXA.xml:S2:676:2	in	IN	O	O
Patients	ZERBAXA.xml:S2:679:8	patient	NNS	O	O
with	ZERBAXA.xml:S2:688:4	with	IN	O	O
Baseline	ZERBAXA.xml:S2:693:8	baselin	NNP	O	O
Creatinine	ZERBAXA.xml:S2:702:10	creatinin	NNP	O	O
Clearance	ZERBAXA.xml:S2:713:9	clearanc	NNP	O	O
of	ZERBAXA.xml:S2:723:2	of	IN	O	O
30	ZERBAXA.xml:S2:726:2	30	CD	O	O
to	ZERBAXA.xml:S2:729:2	to	TO	O	O
50	ZERBAXA.xml:S2:734:2	50	CD	O	O
mL	ZERBAXA.xml:S2:737:2	mL	NNS	O	O
min	ZERBAXA.xml:S2:740:3	min	NN	O	O

In	ZERBAXA.xml:S2:749:2	In	IN	O	O
a	ZERBAXA.xml:S2:752:1	a	DT	O	O
subgroup	ZERBAXA.xml:S2:754:8	subgroup	JJ	O	O
analysis	ZERBAXA.xml:S2:763:8	analysi	NN	O	O
of	ZERBAXA.xml:S2:772:2	of	IN	O	O
a	ZERBAXA.xml:S2:775:1	a	DT	O	O
Phase	ZERBAXA.xml:S2:777:5	phase	NNP	O	O
3	ZERBAXA.xml:S2:783:1	3	CD	O	O
cIAI	ZERBAXA.xml:S2:785:4	ciai	NN	O	O
trial	ZERBAXA.xml:S2:790:5	trial	NN	O	O
,	ZERBAXA.xml:S2:795:1	,	,	O	O
clinical	ZERBAXA.xml:S2:797:8	clinic	JJ	O	O
cure	ZERBAXA.xml:S2:806:4	cure	NN	O	O
rates	ZERBAXA.xml:S2:811:5	rate	NNS	O	O
were	ZERBAXA.xml:S2:817:4	were	VBD	O	O
lower	ZERBAXA.xml:S2:822:5	lower	JJR	O	O
in	ZERBAXA.xml:S2:828:2	in	IN	O	O
patients	ZERBAXA.xml:S2:831:8	patient	NNS	O	O
with	ZERBAXA.xml:S2:840:4	with	IN	O	O
baseline	ZERBAXA.xml:S2:845:8	baselin	JJ	O	O
creatinine	ZERBAXA.xml:S2:854:10	creatinin	NN	O	O
clearance	ZERBAXA.xml:S2:865:9	clearanc	NN	O	O
(	ZERBAXA.xml:S2:875:1	(	(	O	O
CrCl	ZERBAXA.xml:S2:876:4	crcl	NNP	O	O
)	ZERBAXA.xml:S2:880:1	)	)	O	O
of	ZERBAXA.xml:S2:882:2	of	IN	O	O
30	ZERBAXA.xml:S2:885:2	30	CD	O	O
to	ZERBAXA.xml:S2:888:2	to	TO	O	O
50	ZERBAXA.xml:S2:893:2	50	CD	O	O
mL	ZERBAXA.xml:S2:896:2	mL	NNS	O	O
min	ZERBAXA.xml:S2:899:3	min	RB	O	O
compared	ZERBAXA.xml:S2:903:8	compar	VBN	O	O
to	ZERBAXA.xml:S2:912:2	to	TO	O	O
those	ZERBAXA.xml:S2:915:5	those	DT	O	O
with	ZERBAXA.xml:S2:921:4	with	IN	O	O
CrCl	ZERBAXA.xml:S2:926:4	crcl	NNP	O	O
50	ZERBAXA.xml:S2:933:2	50	CD	O	O
mL	ZERBAXA.xml:S2:936:2	mL	NN	O	O
min	ZERBAXA.xml:S2:939:3	min	NN	O	O
(	ZERBAXA.xml:S2:943:1	(	(	O	O
Table	ZERBAXA.xml:S2:944:5	tabl	JJ	O	O
4	ZERBAXA.xml:S2:950:1	4	CD	O	O
)	ZERBAXA.xml:S2:951:1	)	)	O	O
.	ZERBAXA.xml:S2:952:1	.	.	O	O

The	ZERBAXA.xml:S2:954:3	the	DT	O	O
reduction	ZERBAXA.xml:S2:958:9	reduct	NN	O	O
in	ZERBAXA.xml:S2:968:2	in	IN	O	O
clinical	ZERBAXA.xml:S2:971:8	clinic	JJ	O	O
cure	ZERBAXA.xml:S2:980:4	cure	NN	O	O
rates	ZERBAXA.xml:S2:985:5	rate	NNS	O	O
was	ZERBAXA.xml:S2:991:3	wa	VBD	O	O
more	ZERBAXA.xml:S2:995:4	more	RBR	O	O
marked	ZERBAXA.xml:S2:1000:6	mark	JJ	O	O
in	ZERBAXA.xml:S2:1007:2	in	IN	O	O
the	ZERBAXA.xml:S2:1010:3	the	DT	O	O
ZERBAXA	ZERBAXA.xml:S2:1014:7	zerbaxa	NNP	O	O
plus	ZERBAXA.xml:S2:1022:4	plu	CC	O	O
metronidazole	ZERBAXA.xml:S2:1027:13	metronidazol	JJ	O	O
arm	ZERBAXA.xml:S2:1041:3	arm	NN	O	O
compared	ZERBAXA.xml:S2:1045:8	compar	VBN	O	O
to	ZERBAXA.xml:S2:1054:2	to	TO	O	O
the	ZERBAXA.xml:S2:1057:3	the	DT	O	O
meropenem	ZERBAXA.xml:S2:1061:9	meropenem	NN	O	O
arm	ZERBAXA.xml:S2:1071:3	arm	NN	O	O
.	ZERBAXA.xml:S2:1074:1	.	.	O	O

A	ZERBAXA.xml:S2:1076:1	A	DT	O	O
similar	ZERBAXA.xml:S2:1078:7	similar	JJ	O	O
trend	ZERBAXA.xml:S2:1086:5	trend	NN	O	O
was	ZERBAXA.xml:S2:1092:3	wa	VBD	O	O
also	ZERBAXA.xml:S2:1096:4	also	RB	O	O
seen	ZERBAXA.xml:S2:1101:4	seen	VBN	O	O
in	ZERBAXA.xml:S2:1106:2	in	IN	O	O
the	ZERBAXA.xml:S2:1109:3	the	DT	O	O
cUTI	ZERBAXA.xml:S2:1113:4	cuti	JJ	O	O
trial	ZERBAXA.xml:S2:1118:5	trial	NN	O	O
.	ZERBAXA.xml:S2:1123:1	.	.	O	O

Monitor	ZERBAXA.xml:S2:1125:7	monitor	NNP	O	O
CrCl	ZERBAXA.xml:S2:1133:4	crcl	NNP	O	O
at	ZERBAXA.xml:S2:1138:2	at	IN	O	O
least	ZERBAXA.xml:S2:1141:5	least	JJS	O	O
daily	ZERBAXA.xml:S2:1147:5	daili	JJ	O	O
in	ZERBAXA.xml:S2:1153:2	in	IN	O	O
patients	ZERBAXA.xml:S2:1156:8	patient	NNS	O	O
with	ZERBAXA.xml:S2:1165:4	with	IN	O	O
changing	ZERBAXA.xml:S2:1170:8	chang	VBG	O	O
renal	ZERBAXA.xml:S2:1179:5	renal	JJ	O	O
function	ZERBAXA.xml:S2:1185:8	function	NN	O	O
and	ZERBAXA.xml:S2:1194:3	and	CC	O	O
adjust	ZERBAXA.xml:S2:1198:6	adjust	VBP	O	O
the	ZERBAXA.xml:S2:1205:3	the	DT	O	O
dosage	ZERBAXA.xml:S2:1209:6	dosag	NN	O	O
of	ZERBAXA.xml:S2:1216:2	of	IN	O	O
ZERBAXA	ZERBAXA.xml:S2:1219:7	zerbaxa	NNP	O	O
accordingly	ZERBAXA.xml:S2:1227:11	accordingli	RB	O	O
[	ZERBAXA.xml:S2:1239:1	[	VBD	O	O
see	ZERBAXA.xml:S2:1240:3	see	JJ	O	O
Dosage	ZERBAXA.xml:S2:1245:6	dosag	NNP	O	O
and	ZERBAXA.xml:S2:1252:3	and	CC	O	O
Administration	ZERBAXA.xml:S2:1256:14	administr	NNP	O	O
(	ZERBAXA.xml:S2:1271:1	(	(	O	O
2.2	ZERBAXA.xml:S2:1272:3	2.2	CD	O	O
)	ZERBAXA.xml:S2:1275:1	)	)	O	O
]	ZERBAXA.xml:S2:1278:1	]	NN	O	O
.	ZERBAXA.xml:S2:1281:1	.	.	O	O

Table	ZERBAXA.xml:S2:1287:5	tabl	JJ	O	O
4	ZERBAXA.xml:S2:1293:1	4	CD	O	O
:	ZERBAXA.xml:S2:1294:1	:	:	O	O
Clinical	ZERBAXA.xml:S2:1296:8	clinic	JJ	O	O
Cure	ZERBAXA.xml:S2:1305:4	cure	NN	O	O
Rates	ZERBAXA.xml:S2:1310:5	rate	VBZ	O	O
in	ZERBAXA.xml:S2:1316:2	in	IN	O	O
a	ZERBAXA.xml:S2:1319:1	a	DT	O	O
Phase	ZERBAXA.xml:S2:1321:5	phase	NNP	O	O
3	ZERBAXA.xml:S2:1327:1	3	CD	O	O
Trial	ZERBAXA.xml:S2:1329:5	trial	NNP	O	O
of	ZERBAXA.xml:S2:1335:2	of	IN	O	O
cIAI	ZERBAXA.xml:S2:1338:4	ciai	NN	O	O
by	ZERBAXA.xml:S2:1343:2	by	IN	O	O
Baseline	ZERBAXA.xml:S2:1346:8	baselin	NNP	O	O
Renal	ZERBAXA.xml:S2:1355:5	renal	NNP	O	O
Function	ZERBAXA.xml:S2:1361:8	function	NNP	O	O
(	ZERBAXA.xml:S2:1370:1	(	(	O	O
MITT	ZERBAXA.xml:S2:1371:4	mitt	NNP	O	O
Population	ZERBAXA.xml:S2:1376:10	popul	NNP	O	O
)	ZERBAXA.xml:S2:1386:1	)	)	O	O

Baseline	ZERBAXA.xml:S2:1390:8	baselin	NNP	O	O
Renal	ZERBAXA.xml:S2:1399:5	renal	NNP	O	O
Function	ZERBAXA.xml:S2:1405:8	function	NNP	O	O
ZERBAXA	ZERBAXA.xml:S2:1426:7	zerbaxa	NNP	O	O
plus	ZERBAXA.xml:S2:1434:4	plu	CC	O	O
metronidazolen	ZERBAXA.xml:S2:1439:14	metronidazolen	VBN	O	O
N	ZERBAXA.xml:S2:1454:1	N	NNP	O	O
(	ZERBAXA.xml:S2:1456:1	(	(	O	O
)	ZERBAXA.xml:S2:1458:1	)	)	O	O
Meropenemn	ZERBAXA.xml:S2:1469:10	meropenemn	NNP	O	O
N	ZERBAXA.xml:S2:1480:1	N	NNP	O	O
(	ZERBAXA.xml:S2:1482:1	(	(	O	O
)	ZERBAXA.xml:S2:1484:1	)	)	O	O

Normal	ZERBAXA.xml:S2:1502:6	normal	JJ	O	O

mild	ZERBAXA.xml:S2:1509:4	mild	JJ	O	O
impairment	ZERBAXA.xml:S2:1514:10	impair	NN	O	O
(	ZERBAXA.xml:S2:1524:1	(	(	O	O
CrCl	ZERBAXA.xml:S2:1525:4	crcl	NNP	O	O
50	ZERBAXA.xml:S2:1532:2	50	CD	O	O
mL	ZERBAXA.xml:S2:1535:2	mL	NNP	O	O
min	ZERBAXA.xml:S2:1538:3	min	NN	O	O
)	ZERBAXA.xml:S2:1541:1	)	)	O	O
312	ZERBAXA.xml:S2:1553:3	312	CD	O	O
366	ZERBAXA.xml:S2:1557:3	366	CD	O	O
(	ZERBAXA.xml:S2:1561:1	(	(	O	O
85.2	ZERBAXA.xml:S2:1562:4	85.2	CD	O	O
)	ZERBAXA.xml:S2:1566:1	)	)	O	O
355	ZERBAXA.xml:S2:1588:3	355	CD	O	O
404	ZERBAXA.xml:S2:1592:3	404	CD	O	O
(	ZERBAXA.xml:S2:1596:1	(	(	O	O
87.9	ZERBAXA.xml:S2:1597:4	87.9	CD	O	O
)	ZERBAXA.xml:S2:1601:1	)	)	O	O

Moderate	ZERBAXA.xml:S2:1617:8	moder	JJ	O	O
impairment	ZERBAXA.xml:S2:1626:10	impair	NN	O	O
(	ZERBAXA.xml:S2:1636:1	(	(	O	O
CrCl	ZERBAXA.xml:S2:1637:4	crcl	NNP	O	O
30	ZERBAXA.xml:S2:1642:2	30	CD	O	O
to	ZERBAXA.xml:S2:1645:2	to	TO	O	O
50	ZERBAXA.xml:S2:1650:2	50	CD	O	O
mL	ZERBAXA.xml:S2:1653:2	mL	NNS	O	O
min	ZERBAXA.xml:S2:1656:3	min	NN	O	O
)	ZERBAXA.xml:S2:1659:1	)	)	O	O
11	ZERBAXA.xml:S2:1672:2	11	CD	O	O
23	ZERBAXA.xml:S2:1675:2	23	CD	O	O
(	ZERBAXA.xml:S2:1678:1	(	(	O	O
47.8	ZERBAXA.xml:S2:1679:4	47.8	CD	O	O
)	ZERBAXA.xml:S2:1683:1	)	)	O	O
9	ZERBAXA.xml:S2:1708:1	9	CD	O	O
13	ZERBAXA.xml:S2:1710:2	13	CD	O	O
(	ZERBAXA.xml:S2:1713:1	(	(	O	O
69.2	ZERBAXA.xml:S2:1714:4	69.2	CD	O	O
)	ZERBAXA.xml:S2:1718:1	)	)	O	O

5.2	ZERBAXA.xml:S2:1746:3	5.2	CD	O	O
Hypersensitivity	ZERBAXA.xml:S2:1750:16	hypersensit	NNP	O	O
Reactions	ZERBAXA.xml:S2:1767:9	reaction	NNP	O	O

Serious	ZERBAXA.xml:S2:1782:7	seriou	JJ	O	O

and	ZERBAXA.xml:S2:1790:3	and	CC	O	O
occasionally	ZERBAXA.xml:S2:1794:12	occasion	RB	O	O
fatal	ZERBAXA.xml:S2:1807:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
hypersensitivity	ZERBAXA.xml:S2:1813:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
(	ZERBAXA.xml:S2:1830:1	(	(	O	O
anaphylactic	ZERBAXA.xml:S2:1831:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
)	ZERBAXA.xml:S2:1843:1	)	)	O	O
reactions	ZERBAXA.xml:S2:1845:9	reaction	NNS	I-AdverseReaction	O
have	ZERBAXA.xml:S2:1855:4	have	VBP	O	O
been	ZERBAXA.xml:S2:1860:4	been	VBN	O	O
reported	ZERBAXA.xml:S2:1865:8	report	VBN	O	O
in	ZERBAXA.xml:S2:1874:2	in	IN	O	O
patients	ZERBAXA.xml:S2:1877:8	patient	NNS	O	O
receiving	ZERBAXA.xml:S2:1886:9	receiv	VBG	O	O
beta	ZERBAXA.xml:S2:1896:4	beta	SYM	O	O
-	ZERBAXA.xml:S2:1900:1	-	:	O	O
lactam	ZERBAXA.xml:S2:1901:6	lactam	JJ	O	O
antibacterial	ZERBAXA.xml:S2:1908:13	antibacteri	JJ	O	O
drugs	ZERBAXA.xml:S2:1922:5	drug	NNS	O	O
.	ZERBAXA.xml:S2:1927:1	.	.	O	O

Before	ZERBAXA.xml:S2:1933:6	befor	IN	O	O
initiating	ZERBAXA.xml:S2:1940:10	initi	VBG	O	O
therapy	ZERBAXA.xml:S2:1951:7	therapi	NN	O	O
with	ZERBAXA.xml:S2:1959:4	with	IN	O	O
ZERBAXA	ZERBAXA.xml:S2:1964:7	zerbaxa	NNP	O	O
,	ZERBAXA.xml:S2:1971:1	,	,	O	O
make	ZERBAXA.xml:S2:1973:4	make	VBP	O	O
careful	ZERBAXA.xml:S2:1978:7	care	JJ	O	O
inquiry	ZERBAXA.xml:S2:1986:7	inquiri	NN	O	O
about	ZERBAXA.xml:S2:1994:5	about	IN	O	O
previous	ZERBAXA.xml:S2:2000:8	previou	JJ	O	O
hypersensitivity	ZERBAXA.xml:S2:2009:16	hypersensit	NN	O	O
reactions	ZERBAXA.xml:S2:2026:9	reaction	NNS	O	O
to	ZERBAXA.xml:S2:2036:2	to	TO	O	O
other	ZERBAXA.xml:S2:2039:5	other	JJ	O	O
cephalosporins	ZERBAXA.xml:S2:2045:14	cephalosporin	NNS	O	O
,	ZERBAXA.xml:S2:2059:1	,	,	O	O
penicillins	ZERBAXA.xml:S2:2061:11	penicillin	NNS	O	O
,	ZERBAXA.xml:S2:2072:1	,	,	O	O
or	ZERBAXA.xml:S2:2074:2	or	CC	O	O
other	ZERBAXA.xml:S2:2077:5	other	JJ	O	O
beta	ZERBAXA.xml:S2:2083:4	beta	NN	O	O
-	ZERBAXA.xml:S2:2087:1	-	:	O	O
lactams	ZERBAXA.xml:S2:2088:7	lactam	NN	O	O
.	ZERBAXA.xml:S2:2095:1	.	.	O	O

If	ZERBAXA.xml:S2:2097:2	If	IN	O	O
this	ZERBAXA.xml:S2:2100:4	thi	DT	O	O
product	ZERBAXA.xml:S2:2105:7	product	NN	O	O
is	ZERBAXA.xml:S2:2113:2	is	VBZ	O	O
to	ZERBAXA.xml:S2:2116:2	to	TO	O	O
be	ZERBAXA.xml:S2:2119:2	be	VB	O	O
given	ZERBAXA.xml:S2:2122:5	given	VBN	O	O
to	ZERBAXA.xml:S2:2128:2	to	TO	O	O
a	ZERBAXA.xml:S2:2131:1	a	DT	O	O
patient	ZERBAXA.xml:S2:2133:7	patient	NN	O	O
with	ZERBAXA.xml:S2:2141:4	with	IN	O	O
a	ZERBAXA.xml:S2:2146:1	a	DT	O	O
cephalosporin	ZERBAXA.xml:S2:2148:13	cephalosporin	NN	O	O
,	ZERBAXA.xml:S2:2161:1	,	,	O	O
penicillin	ZERBAXA.xml:S2:2163:10	penicillin	NN	O	O
,	ZERBAXA.xml:S2:2173:1	,	,	O	O
or	ZERBAXA.xml:S2:2175:2	or	CC	O	O
other	ZERBAXA.xml:S2:2178:5	other	JJ	O	O
beta	ZERBAXA.xml:S2:2184:4	beta	NN	O	O
-	ZERBAXA.xml:S2:2188:1	-	:	O	O
lactam	ZERBAXA.xml:S2:2189:6	lactam	NN	O	O
allergy	ZERBAXA.xml:S2:2196:7	allergi	NN	O	O
,	ZERBAXA.xml:S2:2203:1	,	,	O	O
exercise	ZERBAXA.xml:S2:2205:8	exercis	NN	O	O
caution	ZERBAXA.xml:S2:2214:7	caution	NN	O	O
because	ZERBAXA.xml:S2:2222:7	becaus	IN	O	O
cross	ZERBAXA.xml:S2:2230:5	cross	NN	O	O
sensitivity	ZERBAXA.xml:S2:2236:11	sensit	NN	O	O
has	ZERBAXA.xml:S2:2248:3	ha	VBZ	O	O
been	ZERBAXA.xml:S2:2252:4	been	VBN	O	O
established	ZERBAXA.xml:S2:2257:11	establish	VBN	O	O
.	ZERBAXA.xml:S2:2268:1	.	.	O	O

If	ZERBAXA.xml:S2:2270:2	If	IN	O	O
an	ZERBAXA.xml:S2:2273:2	an	DT	O	O
anaphylactic	ZERBAXA.xml:S2:2276:12	anaphylact	JJ	O	O
reaction	ZERBAXA.xml:S2:2289:8	reaction	NN	O	O
to	ZERBAXA.xml:S2:2298:2	to	TO	O	O
ZERBAXA	ZERBAXA.xml:S2:2301:7	zerbaxa	NNP	O	O
occurs	ZERBAXA.xml:S2:2309:6	occur	NNS	O	O
,	ZERBAXA.xml:S2:2315:1	,	,	O	O
discontinue	ZERBAXA.xml:S2:2317:11	discontinu	VBP	O	O
the	ZERBAXA.xml:S2:2329:3	the	DT	O	O
drug	ZERBAXA.xml:S2:2333:4	drug	NN	O	O
and	ZERBAXA.xml:S2:2338:3	and	CC	O	O
institute	ZERBAXA.xml:S2:2342:9	institut	NN	O	O
appropriate	ZERBAXA.xml:S2:2352:11	appropri	JJ	O	O
therapy	ZERBAXA.xml:S2:2364:7	therapi	NN	O	O
.	ZERBAXA.xml:S2:2371:1	.	.	O	O

5.3	ZERBAXA.xml:S2:2380:3	5.3	CD	O	O
Clostridium	ZERBAXA.xml:S2:2384:11	clostridium	NNP	O	O
difficile	ZERBAXA.xml:S2:2396:9	difficil	NN	O	O
-	ZERBAXA.xml:S2:2407:1	-	:	O	O
associated	ZERBAXA.xml:S2:2408:10	associ	VBN	O	O
Diarrhea	ZERBAXA.xml:S2:2419:8	diarrhea	NNP	O	O

Clostridium	ZERBAXA.xml:S2:2434:11	clostridium	NN	B-AdverseReaction	B-AdverseReaction
difficile	ZERBAXA.xml:S2:2446:9	difficil	NN	I-AdverseReaction	I-AdverseReaction
-	ZERBAXA.xml:S2:2457:1	-	:	I-AdverseReaction	I-AdverseReaction
associated	ZERBAXA.xml:S2:2458:10	associ	VBN	I-AdverseReaction	I-AdverseReaction
diarrhea	ZERBAXA.xml:S2:2469:8	diarrhea	NN	I-AdverseReaction	I-AdverseReaction
(	ZERBAXA.xml:S2:2478:1	(	(	O	O
CDAD	ZERBAXA.xml:S2:2479:4	cdad	NNP	B-AdverseReaction	B-AdverseReaction
)	ZERBAXA.xml:S2:2483:1	)	)	O	O
has	ZERBAXA.xml:S2:2485:3	ha	VBZ	O	O
been	ZERBAXA.xml:S2:2489:4	been	VBN	O	O
reported	ZERBAXA.xml:S2:2494:8	report	VBN	O	O
for	ZERBAXA.xml:S2:2503:3	for	IN	O	O
nearly	ZERBAXA.xml:S2:2507:6	nearli	RB	O	O
all	ZERBAXA.xml:S2:2514:3	all	DT	O	O
systemic	ZERBAXA.xml:S2:2518:8	system	JJ	O	O
antibacterial	ZERBAXA.xml:S2:2527:13	antibacteri	JJ	O	O
agents	ZERBAXA.xml:S2:2541:6	agent	NNS	O	O
,	ZERBAXA.xml:S2:2547:1	,	,	O	O
including	ZERBAXA.xml:S2:2549:9	includ	VBG	O	O
ZERBAXA	ZERBAXA.xml:S2:2559:7	zerbaxa	NNP	O	O
,	ZERBAXA.xml:S2:2566:1	,	,	O	O
and	ZERBAXA.xml:S2:2568:3	and	CC	O	O
may	ZERBAXA.xml:S2:2572:3	may	MD	O	O
range	ZERBAXA.xml:S2:2576:5	rang	VB	O	O
in	ZERBAXA.xml:S2:2582:2	in	IN	O	O
severity	ZERBAXA.xml:S2:2585:8	sever	NN	O	O
from	ZERBAXA.xml:S2:2594:4	from	IN	O	O
mild	ZERBAXA.xml:S2:2599:4	mild	JJ	O	O
diarrhea	ZERBAXA.xml:S2:2604:8	diarrhea	NN	B-AdverseReaction	O
to	ZERBAXA.xml:S2:2613:2	to	TO	O	O
fatal	ZERBAXA.xml:S2:2616:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
colitis	ZERBAXA.xml:S2:2622:7	coliti	NN	B-AdverseReaction	B-AdverseReaction
.	ZERBAXA.xml:S2:2629:1	.	.	O	O

Treatment	ZERBAXA.xml:S2:2631:9	treatment	NN	O	O
with	ZERBAXA.xml:S2:2641:4	with	IN	O	O
antibacterial	ZERBAXA.xml:S2:2646:13	antibacteri	JJ	O	O
agents	ZERBAXA.xml:S2:2660:6	agent	NNS	O	O
alters	ZERBAXA.xml:S2:2667:6	alter	VBZ	O	O
the	ZERBAXA.xml:S2:2674:3	the	DT	O	O
normal	ZERBAXA.xml:S2:2678:6	normal	JJ	O	O
flora	ZERBAXA.xml:S2:2685:5	flora	NN	O	O
of	ZERBAXA.xml:S2:2691:2	of	IN	O	O
the	ZERBAXA.xml:S2:2694:3	the	DT	O	O
colon	ZERBAXA.xml:S2:2698:5	colon	NN	O	O
and	ZERBAXA.xml:S2:2704:3	and	CC	O	O
may	ZERBAXA.xml:S2:2708:3	may	MD	O	O
permit	ZERBAXA.xml:S2:2712:6	permit	VB	O	O
overgrowth	ZERBAXA.xml:S2:2719:10	overgrowth	NN	O	O
of	ZERBAXA.xml:S2:2730:2	of	IN	O	O
C	ZERBAXA.xml:S2:2733:1	C	NNP	O	O
.	ZERBAXA.xml:S2:2736:1	.	.	O	O

difficile	ZERBAXA.xml:S2:2738:9	difficil	NN	O	O
.	ZERBAXA.xml:S2:2749:1	.	.	O	O

C.	ZERBAXA.xml:S2:2756:2	C.	NNP	O	O
difficile	ZERBAXA.xml:S2:2759:9	difficil	NN	O	O
produces	ZERBAXA.xml:S2:2770:8	produc	VBZ	O	O
toxins	ZERBAXA.xml:S2:2779:6	toxin	VBZ	O	O
A	ZERBAXA.xml:S2:2786:1	A	NNP	O	O
and	ZERBAXA.xml:S2:2788:3	and	CC	O	O
B	ZERBAXA.xml:S2:2792:1	B	NNP	O	O
which	ZERBAXA.xml:S2:2794:5	which	WDT	O	O
contribute	ZERBAXA.xml:S2:2800:10	contribut	VBP	O	O
to	ZERBAXA.xml:S2:2811:2	to	TO	O	O
the	ZERBAXA.xml:S2:2814:3	the	DT	O	O
development	ZERBAXA.xml:S2:2818:11	develop	NN	O	O
of	ZERBAXA.xml:S2:2830:2	of	IN	O	O
CDAD	ZERBAXA.xml:S2:2833:4	cdad	NNP	O	O
.	ZERBAXA.xml:S2:2837:1	.	.	O	O

CDAD	ZERBAXA.xml:S2:2839:4	cdad	NNP	O	O
must	ZERBAXA.xml:S2:2844:4	must	MD	O	O
be	ZERBAXA.xml:S2:2849:2	be	VB	O	O
considered	ZERBAXA.xml:S2:2852:10	consid	VBN	O	O
in	ZERBAXA.xml:S2:2863:2	in	IN	O	O
all	ZERBAXA.xml:S2:2866:3	all	DT	O	O
patients	ZERBAXA.xml:S2:2870:8	patient	NNS	O	O
who	ZERBAXA.xml:S2:2879:3	who	WP	O	O
present	ZERBAXA.xml:S2:2883:7	present	VBP	O	O
with	ZERBAXA.xml:S2:2891:4	with	IN	O	O
diarrhea	ZERBAXA.xml:S2:2896:8	diarrhea	NN	O	O
following	ZERBAXA.xml:S2:2905:9	follow	VBG	O	O
antibacterial	ZERBAXA.xml:S2:2915:13	antibacteri	JJ	O	O
use	ZERBAXA.xml:S2:2929:3	use	NN	O	O
.	ZERBAXA.xml:S2:2932:1	.	.	O	O

Careful	ZERBAXA.xml:S2:2934:7	care	JJ	O	O
medical	ZERBAXA.xml:S2:2942:7	medic	JJ	O	O
history	ZERBAXA.xml:S2:2950:7	histori	NN	O	O
is	ZERBAXA.xml:S2:2958:2	is	VBZ	O	O
necessary	ZERBAXA.xml:S2:2961:9	necessari	JJ	O	O
because	ZERBAXA.xml:S2:2971:7	becaus	IN	O	O
CDAD	ZERBAXA.xml:S2:2979:4	cdad	NNP	O	O
has	ZERBAXA.xml:S2:2984:3	ha	VBZ	O	O
been	ZERBAXA.xml:S2:2988:4	been	VBN	O	O
reported	ZERBAXA.xml:S2:2993:8	report	VBN	O	O
to	ZERBAXA.xml:S2:3002:2	to	TO	O	O
occur	ZERBAXA.xml:S2:3005:5	occur	VB	O	O
more	ZERBAXA.xml:S2:3011:4	more	JJR	O	O
than	ZERBAXA.xml:S2:3016:4	than	IN	O	O
2	ZERBAXA.xml:S2:3021:1	2	CD	O	O
months	ZERBAXA.xml:S2:3023:6	month	NNS	O	O
after	ZERBAXA.xml:S2:3030:5	after	IN	O	O
the	ZERBAXA.xml:S2:3036:3	the	DT	O	O
administration	ZERBAXA.xml:S2:3040:14	administr	NN	O	O
of	ZERBAXA.xml:S2:3055:2	of	IN	O	O
antibacterial	ZERBAXA.xml:S2:3058:13	antibacteri	JJ	O	O
agents	ZERBAXA.xml:S2:3072:6	agent	NNS	O	O
.	ZERBAXA.xml:S2:3078:1	.	.	O	O

If	ZERBAXA.xml:S2:3084:2	If	IN	O	O
CDAD	ZERBAXA.xml:S2:3087:4	cdad	NNP	O	O
is	ZERBAXA.xml:S2:3092:2	is	VBZ	O	O
confirmed	ZERBAXA.xml:S2:3095:9	confirm	VBN	O	O
,	ZERBAXA.xml:S2:3104:1	,	,	O	O
discontinue	ZERBAXA.xml:S2:3106:11	discontinu	NN	O	O
antibacterials	ZERBAXA.xml:S2:3118:14	antibacteri	NNS	O	O
not	ZERBAXA.xml:S2:3133:3	not	RB	O	O
directed	ZERBAXA.xml:S2:3137:8	direct	VBN	O	O
against	ZERBAXA.xml:S2:3146:7	against	IN	O	O
C.	ZERBAXA.xml:S2:3154:2	C.	NNP	O	O
difficile	ZERBAXA.xml:S2:3157:9	difficil	NN	O	O
,	ZERBAXA.xml:S2:3168:1	,	,	O	O
if	ZERBAXA.xml:S2:3170:2	if	IN	O	O
possible	ZERBAXA.xml:S2:3173:8	possibl	JJ	O	O
.	ZERBAXA.xml:S2:3181:1	.	.	O	O

Manage	ZERBAXA.xml:S2:3183:6	manag	NN	O	O
fluid	ZERBAXA.xml:S2:3190:5	fluid	NN	O	O
and	ZERBAXA.xml:S2:3196:3	and	CC	O	O
electrolyte	ZERBAXA.xml:S2:3200:11	electrolyt	NN	O	O
levels	ZERBAXA.xml:S2:3212:6	level	NNS	O	O
as	ZERBAXA.xml:S2:3219:2	as	IN	O	O
appropriate	ZERBAXA.xml:S2:3222:11	appropri	NN	O	O
,	ZERBAXA.xml:S2:3233:1	,	,	O	O
supplement	ZERBAXA.xml:S2:3235:10	supplement	JJ	O	O
protein	ZERBAXA.xml:S2:3246:7	protein	NN	O	O
intake	ZERBAXA.xml:S2:3254:6	intak	NN	O	O
,	ZERBAXA.xml:S2:3260:1	,	,	O	O
monitor	ZERBAXA.xml:S2:3262:7	monitor	VBP	O	O
antibacterial	ZERBAXA.xml:S2:3270:13	antibacteri	JJ	O	O
treatment	ZERBAXA.xml:S2:3284:9	treatment	NN	O	O
of	ZERBAXA.xml:S2:3294:2	of	IN	O	O
C.	ZERBAXA.xml:S2:3297:2	C.	NNP	O	O
difficile	ZERBAXA.xml:S2:3300:9	difficil	NN	O	O
,	ZERBAXA.xml:S2:3311:1	,	,	O	O
and	ZERBAXA.xml:S2:3313:3	and	CC	O	O
institute	ZERBAXA.xml:S2:3317:9	institut	VB	O	O
surgical	ZERBAXA.xml:S2:3327:8	surgic	JJ	O	O
evaluation	ZERBAXA.xml:S2:3336:10	evalu	NN	O	O
as	ZERBAXA.xml:S2:3347:2	as	IN	O	O
clinically	ZERBAXA.xml:S2:3350:10	clinic	RB	O	O
indicated	ZERBAXA.xml:S2:3361:9	indic	VBN	O	O
.	ZERBAXA.xml:S2:3370:1	.	.	O	O

5.4	ZERBAXA.xml:S2:3379:3	5.4	CD	O	O
Development	ZERBAXA.xml:S2:3383:11	develop	NNP	O	O
of	ZERBAXA.xml:S2:3395:2	of	IN	O	O
Drug	ZERBAXA.xml:S2:3398:4	drug	NNP	O	O
-	ZERBAXA.xml:S2:3402:1	-	:	O	O
Resistant	ZERBAXA.xml:S2:3403:9	resist	JJ	O	O
Bacteria	ZERBAXA.xml:S2:3413:8	bacteria	NNS	O	O

Prescribing	ZERBAXA.xml:S2:3427:11	prescrib	VBG	O	O
ZERBAXA	ZERBAXA.xml:S2:3439:7	zerbaxa	NNP	O	O
in	ZERBAXA.xml:S2:3447:2	in	IN	O	O
the	ZERBAXA.xml:S2:3450:3	the	DT	O	O
absence	ZERBAXA.xml:S2:3454:7	absenc	NN	O	O
of	ZERBAXA.xml:S2:3462:2	of	IN	O	O
a	ZERBAXA.xml:S2:3465:1	a	DT	O	O
proven	ZERBAXA.xml:S2:3467:6	proven	NN	O	O
or	ZERBAXA.xml:S2:3474:2	or	CC	O	O
strongly	ZERBAXA.xml:S2:3477:8	strongli	RB	O	O
suspected	ZERBAXA.xml:S2:3486:9	suspect	VBN	O	O
bacterial	ZERBAXA.xml:S2:3496:9	bacteri	JJ	O	O
infection	ZERBAXA.xml:S2:3506:9	infect	NN	O	O
is	ZERBAXA.xml:S2:3516:2	is	VBZ	O	O
unlikely	ZERBAXA.xml:S2:3519:8	unlik	JJ	O	O
to	ZERBAXA.xml:S2:3528:2	to	TO	O	O
provide	ZERBAXA.xml:S2:3531:7	provid	VB	O	O
benefit	ZERBAXA.xml:S2:3539:7	benefit	NN	O	O
to	ZERBAXA.xml:S2:3547:2	to	TO	O	O
the	ZERBAXA.xml:S2:3550:3	the	DT	O	O
patient	ZERBAXA.xml:S2:3554:7	patient	NN	O	O
and	ZERBAXA.xml:S2:3562:3	and	CC	O	O
risks	ZERBAXA.xml:S2:3566:5	risk	VB	O	O
the	ZERBAXA.xml:S2:3572:3	the	DT	O	O
development	ZERBAXA.xml:S2:3576:11	develop	NN	O	O
of	ZERBAXA.xml:S2:3588:2	of	IN	O	O
drug	ZERBAXA.xml:S2:3591:4	drug	NN	O	O
-	ZERBAXA.xml:S2:3595:1	-	:	O	O
resistant	ZERBAXA.xml:S2:3596:9	resist	JJ	O	O
bacteria	ZERBAXA.xml:S2:3606:8	bacteria	NNS	O	O
.	ZERBAXA.xml:S2:3614:1	.	.	O	O
6	ZYDELIG.xml:S1:4:1	6	CD	O	O
ADVERSE	ZYDELIG.xml:S1:6:7	advers	JJ	O	O
REACTIONS	ZYDELIG.xml:S1:14:9	reaction	NN	O	O

The	ZYDELIG.xml:S1:27:3	the	DT	O	O
following	ZYDELIG.xml:S1:31:9	follow	VBG	O	O
serious	ZYDELIG.xml:S1:41:7	seriou	JJ	O	O
adverse	ZYDELIG.xml:S1:49:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:57:9	reaction	NNS	O	O
have	ZYDELIG.xml:S1:67:4	have	VBP	O	O
been	ZYDELIG.xml:S1:72:4	been	VBN	O	O
associated	ZYDELIG.xml:S1:77:10	associ	VBN	O	O
with	ZYDELIG.xml:S1:88:4	with	IN	O	O
Zydelig	ZYDELIG.xml:S1:93:7	zydelig	NNP	O	O
in	ZYDELIG.xml:S1:101:2	in	IN	O	O
clinical	ZYDELIG.xml:S1:104:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S1:113:6	trial	NNS	O	O
and	ZYDELIG.xml:S1:120:3	and	CC	O	O
are	ZYDELIG.xml:S1:124:3	are	VBP	O	O
discussed	ZYDELIG.xml:S1:128:9	discuss	VBN	O	O
in	ZYDELIG.xml:S1:138:2	in	IN	O	O
greater	ZYDELIG.xml:S1:141:7	greater	JJR	O	O
detail	ZYDELIG.xml:S1:149:6	detail	NN	O	O
in	ZYDELIG.xml:S1:156:2	in	IN	O	O
other	ZYDELIG.xml:S1:159:5	other	JJ	O	O
sections	ZYDELIG.xml:S1:165:8	section	NNS	O	O
of	ZYDELIG.xml:S1:174:2	of	IN	O	O
the	ZYDELIG.xml:S1:177:3	the	DT	O	O
prescribing	ZYDELIG.xml:S1:181:11	prescrib	NN	O	O
information	ZYDELIG.xml:S1:193:11	inform	NN	O	O
.	ZYDELIG.xml:S1:204:1	.	.	O	O

Hepatotoxicity	ZYDELIG.xml:S1:213:14	hepatotox	NNP	B-AdverseReaction	B-AdverseReaction
[	ZYDELIG.xml:S1:228:1	[	NNP	O	O
see	ZYDELIG.xml:S1:229:3	see	VBP	O	O
Warnings	ZYDELIG.xml:S1:234:8	warn	NNP	O	O
and	ZYDELIG.xml:S1:243:3	and	CC	O	O
Precautions	ZYDELIG.xml:S1:247:11	precaut	NNP	O	O
(	ZYDELIG.xml:S1:259:1	(	(	O	O
5.1	ZYDELIG.xml:S1:260:3	5.1	CD	O	O
)	ZYDELIG.xml:S1:263:1	)	)	O	O
]	ZYDELIG.xml:S1:266:1	]	NN	O	O

Severe	ZYDELIG.xml:S1:274:6	sever	JJ	O	O
Diarrhea	ZYDELIG.xml:S1:281:8	diarrhea	NNP	B-AdverseReaction	O
or	ZYDELIG.xml:S1:290:2	or	CC	O	O
Colitis	ZYDELIG.xml:S1:293:7	coliti	NNP	B-AdverseReaction	O
[	ZYDELIG.xml:S1:301:1	[	NNP	O	O
see	ZYDELIG.xml:S1:302:3	see	VBP	O	O
Warnings	ZYDELIG.xml:S1:307:8	warn	NNP	O	O
and	ZYDELIG.xml:S1:316:3	and	CC	O	O
Precautions	ZYDELIG.xml:S1:320:11	precaut	NNP	O	O
(	ZYDELIG.xml:S1:332:1	(	(	O	O
5.2	ZYDELIG.xml:S1:333:3	5.2	CD	O	O
)	ZYDELIG.xml:S1:336:1	)	)	O	O
]	ZYDELIG.xml:S1:339:1	]	NN	O	O

Pneumonitis	ZYDELIG.xml:S1:347:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
[	ZYDELIG.xml:S1:359:1	[	NNP	O	O
see	ZYDELIG.xml:S1:360:3	see	VBP	O	O
Warnings	ZYDELIG.xml:S1:365:8	warn	NNP	O	O
and	ZYDELIG.xml:S1:374:3	and	CC	O	O
Precautions	ZYDELIG.xml:S1:378:11	precaut	NNP	O	O
(	ZYDELIG.xml:S1:390:1	(	(	O	O
5.3	ZYDELIG.xml:S1:391:3	5.3	CD	O	O
)	ZYDELIG.xml:S1:394:1	)	)	O	O
]	ZYDELIG.xml:S1:397:1	]	NN	O	O

Intestinal	ZYDELIG.xml:S1:405:10	intestin	JJ	B-AdverseReaction	B-AdverseReaction
Perforation	ZYDELIG.xml:S1:416:11	perfor	NNP	I-AdverseReaction	I-AdverseReaction
[	ZYDELIG.xml:S1:428:1	[	NNP	O	O
see	ZYDELIG.xml:S1:429:3	see	VBP	O	O
Warnings	ZYDELIG.xml:S1:434:8	warn	NNP	O	O
and	ZYDELIG.xml:S1:443:3	and	CC	O	O
Precautions	ZYDELIG.xml:S1:447:11	precaut	NNP	O	O
(	ZYDELIG.xml:S1:459:1	(	(	O	O
5.4	ZYDELIG.xml:S1:460:3	5.4	CD	O	O
)	ZYDELIG.xml:S1:463:1	)	)	O	O
]	ZYDELIG.xml:S1:466:1	]	NN	O	O

Severe	ZYDELIG.xml:S1:474:6	sever	NNP	O	O
Cutaneous	ZYDELIG.xml:S1:481:9	cutan	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	ZYDELIG.xml:S1:491:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	ZYDELIG.xml:S1:501:1	[	NNP	O	O
see	ZYDELIG.xml:S1:502:3	see	VBP	O	O
Warnings	ZYDELIG.xml:S1:507:8	warn	NNP	O	O
and	ZYDELIG.xml:S1:516:3	and	CC	O	O
Precautions	ZYDELIG.xml:S1:520:11	precaut	NNP	O	O
(	ZYDELIG.xml:S1:532:1	(	(	O	O
5.5	ZYDELIG.xml:S1:533:3	5.5	CD	O	O
)	ZYDELIG.xml:S1:536:1	)	)	O	O
]	ZYDELIG.xml:S1:539:1	]	NN	O	O

Anaphylaxis	ZYDELIG.xml:S1:547:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
[	ZYDELIG.xml:S1:559:1	[	NNP	O	O
see	ZYDELIG.xml:S1:560:3	see	VBP	O	O
Warnings	ZYDELIG.xml:S1:565:8	warn	NNP	O	O
and	ZYDELIG.xml:S1:574:3	and	CC	O	O
Precautions	ZYDELIG.xml:S1:578:11	precaut	NNP	O	O
(	ZYDELIG.xml:S1:590:1	(	(	O	O
5.6	ZYDELIG.xml:S1:591:3	5.6	CD	O	O
)	ZYDELIG.xml:S1:594:1	)	)	O	O
]	ZYDELIG.xml:S1:597:1	]	NN	O	O

Neutropenia	ZYDELIG.xml:S1:605:11	neutropenia	NNP	B-AdverseReaction	B-AdverseReaction
[	ZYDELIG.xml:S1:617:1	[	NNP	O	O
see	ZYDELIG.xml:S1:618:3	see	VBP	O	O
Warnings	ZYDELIG.xml:S1:623:8	warn	NNP	O	O
and	ZYDELIG.xml:S1:632:3	and	CC	O	O
Precautions	ZYDELIG.xml:S1:636:11	precaut	NNP	O	O
(	ZYDELIG.xml:S1:648:1	(	(	O	O
5.7	ZYDELIG.xml:S1:649:3	5.7	CD	O	O
)	ZYDELIG.xml:S1:652:1	)	)	O	O
]	ZYDELIG.xml:S1:655:1	]	NN	O	O

EXCERPT	ZYDELIG.xml:S1:665:7	excerpt	NN	O	O
:	ZYDELIG.xml:S1:672:1	:	:	O	O
The	ZYDELIG.xml:S1:676:3	the	DT	O	O
most	ZYDELIG.xml:S1:680:4	most	RBS	O	O
common	ZYDELIG.xml:S1:685:6	common	JJ	O	O
adverse	ZYDELIG.xml:S1:692:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:700:9	reaction	NNS	O	O
(	ZYDELIG.xml:S1:710:1	(	(	O	O
incidence	ZYDELIG.xml:S1:711:9	incid	VB	O	O
20%	ZYDELIG.xml:S1:723:3	20%	CD	O	O
)	ZYDELIG.xml:S1:726:1	)	)	O	O
are	ZYDELIG.xml:S1:728:3	are	VBP	O	O
diarrhea	ZYDELIG.xml:S1:732:8	diarrhea	JJ	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:740:1	,	,	O	O
pyrexia	ZYDELIG.xml:S1:742:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:749:1	,	,	O	O
fatigue	ZYDELIG.xml:S1:751:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:758:1	,	,	O	O
nausea	ZYDELIG.xml:S1:760:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:766:1	,	,	O	O
cough	ZYDELIG.xml:S1:768:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:773:1	,	,	O	O
pneumonia	ZYDELIG.xml:S1:775:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:784:1	,	,	O	O
abdominal	ZYDELIG.xml:S1:786:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ZYDELIG.xml:S1:796:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S1:800:1	,	,	O	O
chills	ZYDELIG.xml:S1:802:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:808:1	,	,	O	O
and	ZYDELIG.xml:S1:810:3	and	CC	O	O
rash	ZYDELIG.xml:S1:814:4	rash	NN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:819:1	(	(	O	O
6.1	ZYDELIG.xml:S1:822:3	6.1	CD	O	O
)	ZYDELIG.xml:S1:827:1	)	)	O	O
.	ZYDELIG.xml:S1:828:1	.	.	O	O

The	ZYDELIG.xml:S1:834:3	the	DT	O	O

most	ZYDELIG.xml:S1:838:4	most	RBS	O	O
common	ZYDELIG.xml:S1:843:6	common	JJ	O	O
laboratory	ZYDELIG.xml:S1:850:10	laboratori	NN	O	O
abnormalities	ZYDELIG.xml:S1:861:13	abnorm	NNS	O	O
(	ZYDELIG.xml:S1:875:1	(	(	O	O
incidence	ZYDELIG.xml:S1:876:9	incid	VB	O	O
30%	ZYDELIG.xml:S1:888:3	30%	CD	O	O
)	ZYDELIG.xml:S1:891:1	)	)	O	O
are	ZYDELIG.xml:S1:893:3	are	VBP	O	O
neutropenia	ZYDELIG.xml:S1:897:11	neutropenia	JJ	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:908:1	,	,	O	O
hypertriglyceridemia	ZYDELIG.xml:S1:910:20	hypertriglyceridemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:930:1	,	,	O	O
hyperglycemia	ZYDELIG.xml:S1:932:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S1:945:1	,	,	O	O
ALT	ZYDELIG.xml:S1:947:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
elevations	ZYDELIG.xml:S1:951:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S1:961:1	,	,	O	O
and	ZYDELIG.xml:S1:963:3	and	CC	O	O
AST	ZYDELIG.xml:S1:967:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
elevations	ZYDELIG.xml:S1:971:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
(	ZYDELIG.xml:S1:982:1	(	(	O	O
6.1	ZYDELIG.xml:S1:985:3	6.1	CD	O	O
)	ZYDELIG.xml:S1:990:1	)	)	O	O
.	ZYDELIG.xml:S1:991:1	.	.	O	O

To	ZYDELIG.xml:S1:999:2	To	TO	O	O
report	ZYDELIG.xml:S1:1002:6	report	VB	O	O
SUSPECTED	ZYDELIG.xml:S1:1009:9	suspect	NNP	O	O
ADVERSE	ZYDELIG.xml:S1:1019:7	advers	NNP	O	O
REACTIONS	ZYDELIG.xml:S1:1027:9	reaction	NNP	O	O
,	ZYDELIG.xml:S1:1036:1	,	,	O	O
contact	ZYDELIG.xml:S1:1038:7	contact	NN	O	O
Gilead	ZYDELIG.xml:S1:1046:6	gilead	NNP	O	O
Sciences	ZYDELIG.xml:S1:1053:8	scienc	NNPS	O	O
,	ZYDELIG.xml:S1:1061:1	,	,	O	O
Inc	ZYDELIG.xml:S1:1063:3	inc	NNP	O	O
.	ZYDELIG.xml:S1:1066:1	.	.	O	O

at	ZYDELIG.xml:S1:1068:2	at	IN	O	O
1	ZYDELIG.xml:S1:1071:1	1	CD	O	O
-	ZYDELIG.xml:S1:1072:1	-	:	O	O
800	ZYDELIG.xml:S1:1073:3	800	CD	O	O
-	ZYDELIG.xml:S1:1076:1	-	:	O	O
GILEAD	ZYDELIG.xml:S1:1077:6	gilead	NNP	O	O
-	ZYDELIG.xml:S1:1083:1	-	:	O	O
5	ZYDELIG.xml:S1:1084:1	5	CD	O	O
or	ZYDELIG.xml:S1:1086:2	or	CC	O	O
FDA	ZYDELIG.xml:S1:1089:3	fda	NNP	O	O
at	ZYDELIG.xml:S1:1093:2	at	IN	O	O
1	ZYDELIG.xml:S1:1096:1	1	CD	O	O
-	ZYDELIG.xml:S1:1097:1	-	:	O	O
800	ZYDELIG.xml:S1:1098:3	800	CD	O	O
-	ZYDELIG.xml:S1:1101:1	-	:	O	O
FDA	ZYDELIG.xml:S1:1102:3	fda	NNP	O	O
-	ZYDELIG.xml:S1:1105:1	-	:	O	O
1088	ZYDELIG.xml:S1:1106:4	1088	CD	O	O
or	ZYDELIG.xml:S1:1111:2	or	CC	O	O
www	ZYDELIG.xml:S1:1114:3	www	VB	O	O
.	ZYDELIG.xml:S1:1117:1	.	.	O	O
fda	ZYDELIG.xml:S1:1118:3	fda	NN	O	O
.	ZYDELIG.xml:S1:1121:1	.	.	O	O
gov	ZYDELIG.xml:S1:1122:3	gov	NN	O	O
medwatch	ZYDELIG.xml:S1:1126:8	medwatch	NN	O	O

6.1	ZYDELIG.xml:S1:1145:3	6.1	CD	O	O

Clinical	ZYDELIG.xml:S1:1149:8	clinic	JJ	O	O
Trial	ZYDELIG.xml:S1:1158:5	trial	NNP	O	O
Experience	ZYDELIG.xml:S1:1164:10	experi	NN	O	O

Because	ZYDELIG.xml:S1:1178:7	becaus	IN	O	O
clinical	ZYDELIG.xml:S1:1186:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S1:1195:6	trial	NNS	O	O
are	ZYDELIG.xml:S1:1202:3	are	VBP	O	O
conducted	ZYDELIG.xml:S1:1206:9	conduct	VBN	O	O
under	ZYDELIG.xml:S1:1216:5	under	IN	O	O
widely	ZYDELIG.xml:S1:1222:6	wide	RB	O	O
varying	ZYDELIG.xml:S1:1229:7	vari	VBG	O	O
conditions	ZYDELIG.xml:S1:1237:10	condit	NNS	O	O
,	ZYDELIG.xml:S1:1247:1	,	,	O	O
adverse	ZYDELIG.xml:S1:1249:7	advers	JJ	O	O
reaction	ZYDELIG.xml:S1:1257:8	reaction	NN	O	O
rates	ZYDELIG.xml:S1:1266:5	rate	NNS	O	O
observed	ZYDELIG.xml:S1:1272:8	observ	VBD	O	O
in	ZYDELIG.xml:S1:1281:2	in	IN	O	O
the	ZYDELIG.xml:S1:1284:3	the	DT	O	O
clinical	ZYDELIG.xml:S1:1288:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S1:1297:6	trial	NNS	O	O
of	ZYDELIG.xml:S1:1304:2	of	IN	O	O
a	ZYDELIG.xml:S1:1307:1	a	DT	O	O
drug	ZYDELIG.xml:S1:1309:4	drug	NN	O	O
cannot	ZYDELIG.xml:S1:1314:6	cannot	NN	O	O
be	ZYDELIG.xml:S1:1321:2	be	VB	O	O
directly	ZYDELIG.xml:S1:1324:8	directli	RB	O	O
compared	ZYDELIG.xml:S1:1333:8	compar	VBN	O	O
to	ZYDELIG.xml:S1:1342:2	to	TO	O	O
rates	ZYDELIG.xml:S1:1345:5	rate	NNS	O	O
in	ZYDELIG.xml:S1:1351:2	in	IN	O	O
the	ZYDELIG.xml:S1:1354:3	the	DT	O	O
clinical	ZYDELIG.xml:S1:1358:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S1:1367:6	trial	NNS	O	O
of	ZYDELIG.xml:S1:1374:2	of	IN	O	O
another	ZYDELIG.xml:S1:1377:7	anoth	DT	O	O
drug	ZYDELIG.xml:S1:1385:4	drug	NN	O	O
and	ZYDELIG.xml:S1:1390:3	and	CC	O	O
may	ZYDELIG.xml:S1:1394:3	may	MD	O	O
not	ZYDELIG.xml:S1:1398:3	not	RB	O	O
reflect	ZYDELIG.xml:S1:1402:7	reflect	VB	O	O
the	ZYDELIG.xml:S1:1410:3	the	DT	O	O
rates	ZYDELIG.xml:S1:1414:5	rate	NNS	O	O
observed	ZYDELIG.xml:S1:1420:8	observ	VBD	O	O
in	ZYDELIG.xml:S1:1429:2	in	IN	O	O
practice	ZYDELIG.xml:S1:1432:8	practic	NN	O	O
.	ZYDELIG.xml:S1:1440:1	.	.	O	O

Summary	ZYDELIG.xml:S1:1452:7	summari	NNP	O	O
of	ZYDELIG.xml:S1:1460:2	of	IN	O	O
Clinical	ZYDELIG.xml:S1:1463:8	clinic	NNP	O	O
Trials	ZYDELIG.xml:S1:1472:6	trial	NNP	O	O
in	ZYDELIG.xml:S1:1479:2	in	IN	O	O
Chronic	ZYDELIG.xml:S1:1482:7	chronic	NNP	O	O
Lymphocytic	ZYDELIG.xml:S1:1490:11	lymphocyt	NNP	O	O
Leukemia	ZYDELIG.xml:S1:1502:8	leukemia	NNP	O	O

The	ZYDELIG.xml:S1:1519:3	the	DT	O	O
safety	ZYDELIG.xml:S1:1523:6	safeti	NN	O	O
data	ZYDELIG.xml:S1:1530:4	data	NNS	O	O
reflect	ZYDELIG.xml:S1:1535:7	reflect	VBP	O	O
subject	ZYDELIG.xml:S1:1543:7	subject	JJ	O	O
exposure	ZYDELIG.xml:S1:1551:8	exposur	NN	O	O
to	ZYDELIG.xml:S1:1560:2	to	TO	O	O
Zydelig	ZYDELIG.xml:S1:1563:7	zydelig	NNP	O	O
from	ZYDELIG.xml:S1:1571:4	from	IN	O	O
Study	ZYDELIG.xml:S1:1576:5	studi	NNP	O	O
1	ZYDELIG.xml:S1:1582:1	1	CD	O	O
,	ZYDELIG.xml:S1:1583:1	,	,	O	O
in	ZYDELIG.xml:S1:1585:2	in	IN	O	O
which	ZYDELIG.xml:S1:1588:5	which	WDT	O	O
218	ZYDELIG.xml:S1:1594:3	218	CD	O	O
subjects	ZYDELIG.xml:S1:1598:8	subject	NNS	O	O
with	ZYDELIG.xml:S1:1607:4	with	IN	O	O
relapsed	ZYDELIG.xml:S1:1612:8	relaps	JJ	O	O
CLL	ZYDELIG.xml:S1:1621:3	cll	NNP	O	O
received	ZYDELIG.xml:S1:1625:8	receiv	VBD	O	O
up	ZYDELIG.xml:S1:1634:2	up	RB	O	O
to	ZYDELIG.xml:S1:1637:2	to	TO	O	O
8	ZYDELIG.xml:S1:1640:1	8	CD	O	O
doses	ZYDELIG.xml:S1:1642:5	dose	NNS	O	O
of	ZYDELIG.xml:S1:1648:2	of	IN	O	O
rituximab	ZYDELIG.xml:S1:1651:9	rituximab	NN	O	O
with	ZYDELIG.xml:S1:1661:4	with	IN	O	O
or	ZYDELIG.xml:S1:1666:2	or	CC	O	O
without	ZYDELIG.xml:S1:1669:7	without	IN	O	O
Zydelig	ZYDELIG.xml:S1:1677:7	zydelig	NNP	O	O
150	ZYDELIG.xml:S1:1685:3	150	CD	O	O
mg	ZYDELIG.xml:S1:1689:2	mg	NN	O	O
twice	ZYDELIG.xml:S1:1692:5	twice	RB	O	O
daily	ZYDELIG.xml:S1:1698:5	daili	RB	O	O
.	ZYDELIG.xml:S1:1703:1	.	.	O	O

The	ZYDELIG.xml:S1:1705:3	the	DT	O	O
median	ZYDELIG.xml:S1:1709:6	median	JJ	O	O
duration	ZYDELIG.xml:S1:1716:8	durat	NN	O	O
of	ZYDELIG.xml:S1:1725:2	of	IN	O	O
exposure	ZYDELIG.xml:S1:1728:8	exposur	NN	O	O
to	ZYDELIG.xml:S1:1737:2	to	TO	O	O
Zydelig	ZYDELIG.xml:S1:1740:7	zydelig	NNP	O	O
was	ZYDELIG.xml:S1:1748:3	wa	VBD	O	O
5	ZYDELIG.xml:S1:1752:1	5	CD	O	O
months	ZYDELIG.xml:S1:1754:6	month	NNS	O	O
.	ZYDELIG.xml:S1:1760:1	.	.	O	O

Serious	ZYDELIG.xml:S1:1766:7	seriou	JJ	O	O
adverse	ZYDELIG.xml:S1:1774:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:1782:9	reaction	NNS	O	O
were	ZYDELIG.xml:S1:1792:4	were	VBD	O	O
reported	ZYDELIG.xml:S1:1797:8	report	VBN	O	O
in	ZYDELIG.xml:S1:1806:2	in	IN	O	O
54	ZYDELIG.xml:S1:1809:2	54	CD	O	O
(	ZYDELIG.xml:S1:1812:1	(	(	O	O
49%	ZYDELIG.xml:S1:1813:3	49%	CD	O	O
)	ZYDELIG.xml:S1:1816:1	)	)	O	O
subjects	ZYDELIG.xml:S1:1818:8	subject	NNS	O	O
treated	ZYDELIG.xml:S1:1827:7	treat	VBN	O	O
with	ZYDELIG.xml:S1:1835:4	with	IN	O	O
Zydelig	ZYDELIG.xml:S1:1840:7	zydelig	NNP	O	O
rituximab	ZYDELIG.xml:S1:1850:9	rituximab	NN	O	O
.	ZYDELIG.xml:S1:1859:1	.	.	O	O

The	ZYDELIG.xml:S1:1861:3	the	DT	O	O
most	ZYDELIG.xml:S1:1865:4	most	RBS	O	O
frequent	ZYDELIG.xml:S1:1870:8	frequent	JJ	O	O
(	ZYDELIG.xml:S1:1879:1	(	(	O	O
2%	ZYDELIG.xml:S1:1882:2	2%	CD	O	O
)	ZYDELIG.xml:S1:1884:1	)	)	O	O
serious	ZYDELIG.xml:S1:1886:7	seriou	JJ	O	O
adverse	ZYDELIG.xml:S1:1894:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:1902:9	reaction	NNS	O	O
reported	ZYDELIG.xml:S1:1912:8	report	VBD	O	O
for	ZYDELIG.xml:S1:1921:3	for	IN	O	O
subjects	ZYDELIG.xml:S1:1925:8	subject	NNS	O	O
treated	ZYDELIG.xml:S1:1934:7	treat	VBN	O	O
with	ZYDELIG.xml:S1:1942:4	with	IN	O	O
Zydelig	ZYDELIG.xml:S1:1947:7	zydelig	NNP	O	O
were	ZYDELIG.xml:S1:1955:4	were	VBD	O	O
pneumonia	ZYDELIG.xml:S1:1960:9	pneumonia	VBN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:1970:1	(	(	O	O
17%	ZYDELIG.xml:S1:1971:3	17%	CD	O	O
)	ZYDELIG.xml:S1:1974:1	)	)	O	O
,	ZYDELIG.xml:S1:1975:1	,	,	O	O
pyrexia	ZYDELIG.xml:S1:1977:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:1985:1	(	(	O	O
9%	ZYDELIG.xml:S1:1986:2	9%	CD	O	O
)	ZYDELIG.xml:S1:1988:1	)	)	O	O
,	ZYDELIG.xml:S1:1989:1	,	,	O	O
sepsis	ZYDELIG.xml:S1:1991:6	sepsi	NN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:1998:1	(	(	O	O
8%	ZYDELIG.xml:S1:1999:2	8%	CD	O	O
)	ZYDELIG.xml:S1:2001:1	)	)	O	O
,	ZYDELIG.xml:S1:2002:1	,	,	O	O
febrile	ZYDELIG.xml:S1:2004:7	febril	JJ	B-AdverseReaction	B-AdverseReaction
neutropenia	ZYDELIG.xml:S1:2012:11	neutropenia	NN	I-AdverseReaction	I-AdverseReaction
(	ZYDELIG.xml:S1:2024:1	(	(	O	O
5%	ZYDELIG.xml:S1:2025:2	5%	CD	O	O
)	ZYDELIG.xml:S1:2027:1	)	)	O	O
and	ZYDELIG.xml:S1:2029:3	and	CC	O	O
diarrhea	ZYDELIG.xml:S1:2033:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:2042:1	(	(	O	O
5%	ZYDELIG.xml:S1:2043:2	5%	CD	O	O
)	ZYDELIG.xml:S1:2045:1	)	)	O	O
.	ZYDELIG.xml:S1:2046:1	.	.	O	O

Adverse	ZYDELIG.xml:S1:2048:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:2056:9	reaction	NNS	O	O
that	ZYDELIG.xml:S1:2066:4	that	WDT	O	O
led	ZYDELIG.xml:S1:2071:3	led	VBD	O	O
to	ZYDELIG.xml:S1:2075:2	to	TO	O	O
discontinuation	ZYDELIG.xml:S1:2078:15	discontinu	NN	O	O
of	ZYDELIG.xml:S1:2094:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S1:2097:7	zydelig	NNP	O	O
occurred	ZYDELIG.xml:S1:2105:8	occur	VBD	O	O
in	ZYDELIG.xml:S1:2114:2	in	IN	O	O
11	ZYDELIG.xml:S1:2117:2	11	CD	O	O
(	ZYDELIG.xml:S1:2120:1	(	(	O	O
10%	ZYDELIG.xml:S1:2121:3	10%	CD	O	O
)	ZYDELIG.xml:S1:2124:1	)	)	O	O
subjects	ZYDELIG.xml:S1:2126:8	subject	NNS	O	O
.	ZYDELIG.xml:S1:2134:1	.	.	O	O

The	ZYDELIG.xml:S1:2136:3	the	DT	O	O
most	ZYDELIG.xml:S1:2140:4	most	RBS	O	O
common	ZYDELIG.xml:S1:2145:6	common	JJ	O	O
adverse	ZYDELIG.xml:S1:2152:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:2160:9	reaction	NNS	O	O
that	ZYDELIG.xml:S1:2170:4	that	WDT	O	O
led	ZYDELIG.xml:S1:2175:3	led	VBD	O	O
to	ZYDELIG.xml:S1:2179:2	to	TO	O	O
treatment	ZYDELIG.xml:S1:2182:9	treatment	NN	O	O
discontinuations	ZYDELIG.xml:S1:2192:16	discontinu	NNS	O	O
were	ZYDELIG.xml:S1:2209:4	were	VBD	O	O
hepatotoxicity	ZYDELIG.xml:S1:2214:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S1:2229:3	and	CC	O	O
diarrhea	ZYDELIG.xml:S1:2233:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
colitis	ZYDELIG.xml:S1:2242:7	coliti	NN	B-AdverseReaction	I-AdverseReaction
.	ZYDELIG.xml:S1:2249:1	.	.	O	O

Thirty	ZYDELIG.xml:S1:2255:6	thirti	NNP	O	O
-	ZYDELIG.xml:S1:2261:1	-	:	O	O
nine	ZYDELIG.xml:S1:2262:4	nine	CD	O	O
subjects	ZYDELIG.xml:S1:2267:8	subject	NNS	O	O
(	ZYDELIG.xml:S1:2276:1	(	(	O	O
35%	ZYDELIG.xml:S1:2277:3	35%	CD	O	O
)	ZYDELIG.xml:S1:2280:1	)	)	O	O
had	ZYDELIG.xml:S1:2282:3	had	VBD	O	O
dose	ZYDELIG.xml:S1:2286:4	dose	JJ	O	O
interruptions	ZYDELIG.xml:S1:2291:13	interrupt	NNS	O	O
and	ZYDELIG.xml:S1:2305:3	and	CC	O	O
sixteen	ZYDELIG.xml:S1:2309:7	sixteen	JJ	O	O
subjects	ZYDELIG.xml:S1:2317:8	subject	NNS	O	O
(	ZYDELIG.xml:S1:2326:1	(	(	O	O
15%	ZYDELIG.xml:S1:2327:3	15%	CD	O	O
)	ZYDELIG.xml:S1:2330:1	)	)	O	O
had	ZYDELIG.xml:S1:2332:3	had	VBD	O	O
dose	ZYDELIG.xml:S1:2336:4	dose	JJ	O	O
reductions	ZYDELIG.xml:S1:2341:10	reduct	NNS	O	O
due	ZYDELIG.xml:S1:2352:3	due	JJ	O	O
to	ZYDELIG.xml:S1:2356:2	to	TO	O	O
adverse	ZYDELIG.xml:S1:2359:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:2367:9	reaction	NNS	O	O
or	ZYDELIG.xml:S1:2377:2	or	CC	O	O
laboratory	ZYDELIG.xml:S1:2380:10	laboratori	NN	O	O
abnormalities	ZYDELIG.xml:S1:2391:13	abnorm	NNS	O	O
.	ZYDELIG.xml:S1:2404:1	.	.	O	O

The	ZYDELIG.xml:S1:2406:3	the	DT	O	O
most	ZYDELIG.xml:S1:2410:4	most	RBS	O	O
common	ZYDELIG.xml:S1:2415:6	common	JJ	O	O
reasons	ZYDELIG.xml:S1:2422:7	reason	NNS	O	O
for	ZYDELIG.xml:S1:2430:3	for	IN	O	O
dose	ZYDELIG.xml:S1:2434:4	dose	JJ	O	O
reductions	ZYDELIG.xml:S1:2439:10	reduct	NNS	O	O
were	ZYDELIG.xml:S1:2450:4	were	VBD	O	O
elevated	ZYDELIG.xml:S1:2455:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
transaminases	ZYDELIG.xml:S1:2464:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S1:2477:1	,	,	O	O
diarrhea	ZYDELIG.xml:S1:2479:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
or	ZYDELIG.xml:S1:2488:2	or	CC	O	O
colitis	ZYDELIG.xml:S1:2491:7	coliti	NN	B-AdverseReaction	O
,	ZYDELIG.xml:S1:2498:1	,	,	O	O
and	ZYDELIG.xml:S1:2500:3	and	CC	O	O
rash	ZYDELIG.xml:S1:2504:4	rash	NN	B-AdverseReaction	B-AdverseReaction
.	ZYDELIG.xml:S1:2508:1	.	.	O	O

Table	ZYDELIG.xml:S1:2514:5	tabl	JJ	O	O
2	ZYDELIG.xml:S1:2520:1	2	CD	O	O
and	ZYDELIG.xml:S1:2522:3	and	CC	O	O
Table	ZYDELIG.xml:S1:2526:5	tabl	JJ	O	O
3	ZYDELIG.xml:S1:2532:1	3	CD	O	O
summarize	ZYDELIG.xml:S1:2534:9	summar	JJ	O	O
common	ZYDELIG.xml:S1:2544:6	common	JJ	O	O
adverse	ZYDELIG.xml:S1:2551:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:2559:9	reaction	NNS	O	O
and	ZYDELIG.xml:S1:2569:3	and	CC	O	O
laboratory	ZYDELIG.xml:S1:2573:10	laboratori	NN	O	O
abnormalities	ZYDELIG.xml:S1:2584:13	abnorm	NNS	O	O
reported	ZYDELIG.xml:S1:2598:8	report	VBN	O	O
for	ZYDELIG.xml:S1:2607:3	for	IN	O	O
Zydelig	ZYDELIG.xml:S1:2611:7	zydelig	NNP	O	O
rituximab	ZYDELIG.xml:S1:2621:9	rituximab	NN	O	O
and	ZYDELIG.xml:S1:2631:3	and	CC	O	O
placebo	ZYDELIG.xml:S1:2635:7	placebo	NN	O	O
rituximab	ZYDELIG.xml:S1:2645:9	rituximab	NN	O	O
arms	ZYDELIG.xml:S1:2655:4	arm	NNS	O	O
.	ZYDELIG.xml:S1:2659:1	.	.	O	O

Table	ZYDELIG.xml:S1:2665:5	tabl	JJ	O	O
2	ZYDELIG.xml:S1:2671:1	2	CD	O	O
Adverse	ZYDELIG.xml:S1:2673:7	advers	JJ	O	O
Reactions	ZYDELIG.xml:S1:2681:9	reaction	NNP	O	O
Reported	ZYDELIG.xml:S1:2691:8	report	VBD	O	O
in	ZYDELIG.xml:S1:2700:2	in	IN	O	O
5%	ZYDELIG.xml:S1:2705:2	5%	CD	O	O
of	ZYDELIG.xml:S1:2708:2	of	IN	O	O
CLL	ZYDELIG.xml:S1:2711:3	cll	NNP	O	O
Patients	ZYDELIG.xml:S1:2715:8	patient	NNPS	O	O
and	ZYDELIG.xml:S1:2724:3	and	CC	O	O
Occurred	ZYDELIG.xml:S1:2728:8	occur	VBD	O	O
at	ZYDELIG.xml:S1:2737:2	at	IN	O	O
2%	ZYDELIG.xml:S1:2742:2	2%	CD	O	O
Higher	ZYDELIG.xml:S1:2745:6	higher	JJR	O	O
Incidence	ZYDELIG.xml:S1:2752:9	incid	NN	O	O
in	ZYDELIG.xml:S1:2762:2	in	IN	O	O
Subjects	ZYDELIG.xml:S1:2765:8	subject	NNP	O	O
Receiving	ZYDELIG.xml:S1:2774:9	receiv	NNP	O	O
Zydelig	ZYDELIG.xml:S1:2784:7	zydelig	NNP	O	O

Zydelig	ZYDELIG.xml:S1:2836:7	zydelig	NNP	O	O
RN	ZYDELIG.xml:S1:2846:2	RN	NNP	O	O
110	ZYDELIG.xml:S1:2849:3	110	CD	O	O
(	ZYDELIG.xml:S1:2853:1	(	(	O	O
)	ZYDELIG.xml:S1:2855:1	)	)	O	O
Placebo	ZYDELIG.xml:S1:2858:7	placebo	NNP	O	O
RN	ZYDELIG.xml:S1:2868:2	RN	NNP	O	O
108	ZYDELIG.xml:S1:2871:3	108	CD	O	O
(	ZYDELIG.xml:S1:2875:1	(	(	O	O
)	ZYDELIG.xml:S1:2877:1	)	)	O	O

Adverse	ZYDELIG.xml:S1:2883:7	advers	JJ	O	O
Reaction	ZYDELIG.xml:S1:2891:8	reaction	NNP	O	O
Any	ZYDELIG.xml:S1:2925:3	ani	NNP	O	O
Grade	ZYDELIG.xml:S1:2929:5	grade	NNP	O	O
Grade	ZYDELIG.xml:S1:2942:5	grade	NNP	O	O
3	ZYDELIG.xml:S1:2950:1	3	CD	O	O
Any	ZYDELIG.xml:S1:2959:3	ani	NNP	O	O
Grade	ZYDELIG.xml:S1:2963:5	grade	NNP	O	O
Grade	ZYDELIG.xml:S1:2976:5	grade	NNP	O	O
3	ZYDELIG.xml:S1:2984:1	3	CD	O	O

R	ZYDELIG.xml:S1:2999:1	R	NN	O	O

:	ZYDELIG.xml:S1:3000:1	:	:	O	O
rituximab	ZYDELIG.xml:S1:3002:9	rituximab	NN	O	O

Gastrointestinal	ZYDELIG.xml:S1:3047:16	gastrointestin	JJ	O	O

disorders	ZYDELIG.xml:S1:3064:9	disord	NNS	O	O

nausea	ZYDELIG.xml:S1:3094:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
28	ZYDELIG.xml:S1:3134:2	28	CD	O	O
(	ZYDELIG.xml:S1:3137:1	(	(	O	O
25	ZYDELIG.xml:S1:3138:2	25	CD	O	O
)	ZYDELIG.xml:S1:3140:1	)	)	O	O
0	ZYDELIG.xml:S1:3151:1	0	CD	O	O
23	ZYDELIG.xml:S1:3168:2	23	CD	O	O
(	ZYDELIG.xml:S1:3171:1	(	(	O	O
21	ZYDELIG.xml:S1:3172:2	21	CD	O	O
)	ZYDELIG.xml:S1:3174:1	)	)	O	O
0	ZYDELIG.xml:S1:3185:1	0	CD	O	O

vomiting	ZYDELIG.xml:S1:3207:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
14	ZYDELIG.xml:S1:3247:2	14	CD	O	O
(	ZYDELIG.xml:S1:3250:1	(	(	O	O
13	ZYDELIG.xml:S1:3251:2	13	CD	O	O
)	ZYDELIG.xml:S1:3253:1	)	)	O	O
0	ZYDELIG.xml:S1:3264:1	0	CD	O	O
9	ZYDELIG.xml:S1:3281:1	9	CD	O	O
(	ZYDELIG.xml:S1:3283:1	(	(	O	O
8	ZYDELIG.xml:S1:3284:1	8	CD	O	O
)	ZYDELIG.xml:S1:3285:1	)	)	O	O
0	ZYDELIG.xml:S1:3298:1	0	CD	O	O

diarrhea	ZYDELIG.xml:S1:3320:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
23	ZYDELIG.xml:S1:3360:2	23	CD	O	O
(	ZYDELIG.xml:S1:3363:1	(	(	O	O
21	ZYDELIG.xml:S1:3364:2	21	CD	O	O
)	ZYDELIG.xml:S1:3366:1	)	)	O	O
6	ZYDELIG.xml:S1:3377:1	6	CD	O	O
(	ZYDELIG.xml:S1:3379:1	(	(	O	O
5	ZYDELIG.xml:S1:3380:1	5	CD	O	O
)	ZYDELIG.xml:S1:3381:1	)	)	O	O
17	ZYDELIG.xml:S1:3394:2	17	CD	O	O
(	ZYDELIG.xml:S1:3397:1	(	(	O	O
16	ZYDELIG.xml:S1:3398:2	16	CD	O	O
)	ZYDELIG.xml:S1:3400:1	)	)	O	O
0	ZYDELIG.xml:S1:3411:1	0	CD	O	O

gastroesophageal	ZYDELIG.xml:S1:3433:16	gastroesophag	NN	B-AdverseReaction	B-AdverseReaction
reflux	ZYDELIG.xml:S1:3450:6	reflux	NN	I-AdverseReaction	I-AdverseReaction
disease	ZYDELIG.xml:S1:3457:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
7	ZYDELIG.xml:S1:3473:1	7	CD	O	O
(	ZYDELIG.xml:S1:3475:1	(	(	O	O
6	ZYDELIG.xml:S1:3476:1	6	CD	O	O
)	ZYDELIG.xml:S1:3477:1	)	)	O	O
0	ZYDELIG.xml:S1:3490:1	0	CD	O	O
1	ZYDELIG.xml:S1:3507:1	1	CD	O	O
(	ZYDELIG.xml:S1:3509:1	(	(	O	O
1	ZYDELIG.xml:S1:3510:1	1	CD	O	O
)	ZYDELIG.xml:S1:3511:1	)	)	O	O
0	ZYDELIG.xml:S1:3524:1	0	CD	O	O

stomatitis	ZYDELIG.xml:S1:3546:10	stomat	NN	B-AdverseReaction	B-AdverseReaction
7	ZYDELIG.xml:S1:3586:1	7	CD	O	O
(	ZYDELIG.xml:S1:3588:1	(	(	O	O
6	ZYDELIG.xml:S1:3589:1	6	CD	O	O
)	ZYDELIG.xml:S1:3590:1	)	)	O	O
2	ZYDELIG.xml:S1:3603:1	2	CD	O	O
(	ZYDELIG.xml:S1:3605:1	(	(	O	O
2	ZYDELIG.xml:S1:3606:1	2	CD	O	O
)	ZYDELIG.xml:S1:3607:1	)	)	O	O
2	ZYDELIG.xml:S1:3620:1	2	CD	O	O
(	ZYDELIG.xml:S1:3622:1	(	(	O	O
2	ZYDELIG.xml:S1:3623:1	2	CD	O	O
)	ZYDELIG.xml:S1:3624:1	)	)	O	O
0	ZYDELIG.xml:S1:3637:1	0	CD	O	O

Nervous	ZYDELIG.xml:S1:3657:7	nervou	JJ	O	O
system	ZYDELIG.xml:S1:3665:6	system	NN	O	O
disorders	ZYDELIG.xml:S1:3672:9	disord	NNS	O	O

headache	ZYDELIG.xml:S1:3704:8	headach	NN	B-AdverseReaction	B-AdverseReaction
11	ZYDELIG.xml:S1:3744:2	11	CD	O	O
(	ZYDELIG.xml:S1:3747:1	(	(	O	O
10	ZYDELIG.xml:S1:3748:2	10	CD	O	O
)	ZYDELIG.xml:S1:3750:1	)	)	O	O
1	ZYDELIG.xml:S1:3761:1	1	CD	O	O
(	ZYDELIG.xml:S1:3763:1	(	(	O	O
1	ZYDELIG.xml:S1:3764:1	1	CD	O	O
)	ZYDELIG.xml:S1:3765:1	)	)	O	O
5	ZYDELIG.xml:S1:3778:1	5	CD	O	O
(	ZYDELIG.xml:S1:3780:1	(	(	O	O
5	ZYDELIG.xml:S1:3781:1	5	CD	O	O
)	ZYDELIG.xml:S1:3782:1	)	)	O	O
0	ZYDELIG.xml:S1:3795:1	0	CD	O	O

General	ZYDELIG.xml:S1:3815:7	gener	NNP	O	O
disorders	ZYDELIG.xml:S1:3823:9	disord	NNS	O	O
and	ZYDELIG.xml:S1:3833:3	and	CC	O	O
administration	ZYDELIG.xml:S1:3837:14	administr	NN	O	O
site	ZYDELIG.xml:S1:3852:4	site	NN	O	O
conditions	ZYDELIG.xml:S1:3857:10	condit	NNS	O	O

pyrexia	ZYDELIG.xml:S1:3874:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
38	ZYDELIG.xml:S1:3914:2	38	CD	O	O
(	ZYDELIG.xml:S1:3917:1	(	(	O	O
35	ZYDELIG.xml:S1:3918:2	35	CD	O	O
)	ZYDELIG.xml:S1:3920:1	)	)	O	O
3	ZYDELIG.xml:S1:3931:1	3	CD	O	O
(	ZYDELIG.xml:S1:3933:1	(	(	O	O
3	ZYDELIG.xml:S1:3934:1	3	CD	O	O
)	ZYDELIG.xml:S1:3935:1	)	)	O	O
18	ZYDELIG.xml:S1:3948:2	18	CD	O	O
(	ZYDELIG.xml:S1:3951:1	(	(	O	O
17	ZYDELIG.xml:S1:3952:2	17	CD	O	O
)	ZYDELIG.xml:S1:3954:1	)	)	O	O
1	ZYDELIG.xml:S1:3965:1	1	CD	O	O
(	ZYDELIG.xml:S1:3967:1	(	(	O	O
1	ZYDELIG.xml:S1:3968:1	1	CD	O	O
)	ZYDELIG.xml:S1:3969:1	)	)	O	O

chills	ZYDELIG.xml:S1:3987:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
23	ZYDELIG.xml:S1:4027:2	23	CD	O	O
(	ZYDELIG.xml:S1:4030:1	(	(	O	O
21	ZYDELIG.xml:S1:4031:2	21	CD	O	O
)	ZYDELIG.xml:S1:4033:1	)	)	O	O
2	ZYDELIG.xml:S1:4044:1	2	CD	O	O
(	ZYDELIG.xml:S1:4046:1	(	(	O	O
2	ZYDELIG.xml:S1:4047:1	2	CD	O	O
)	ZYDELIG.xml:S1:4048:1	)	)	O	O
17	ZYDELIG.xml:S1:4061:2	17	CD	O	O
(	ZYDELIG.xml:S1:4064:1	(	(	O	O
16	ZYDELIG.xml:S1:4065:2	16	CD	O	O
)	ZYDELIG.xml:S1:4067:1	)	)	O	O
0	ZYDELIG.xml:S1:4078:1	0	CD	O	O

pain	ZYDELIG.xml:S1:4100:4	pain	NN	B-AdverseReaction	B-AdverseReaction
8	ZYDELIG.xml:S1:4140:1	8	CD	O	O
(	ZYDELIG.xml:S1:4142:1	(	(	O	O
7	ZYDELIG.xml:S1:4143:1	7	CD	O	O
)	ZYDELIG.xml:S1:4144:1	)	)	O	O
0	ZYDELIG.xml:S1:4157:1	0	CD	O	O
2	ZYDELIG.xml:S1:4174:1	2	CD	O	O
(	ZYDELIG.xml:S1:4176:1	(	(	O	O
2	ZYDELIG.xml:S1:4177:1	2	CD	O	O
)	ZYDELIG.xml:S1:4178:1	)	)	O	O
0	ZYDELIG.xml:S1:4191:1	0	CD	O	O

Skin	ZYDELIG.xml:S1:4211:4	skin	NNP	O	O
and	ZYDELIG.xml:S1:4216:3	and	CC	O	O
subcutaneous	ZYDELIG.xml:S1:4220:12	subcutan	JJ	O	O
tissue	ZYDELIG.xml:S1:4233:6	tissu	NN	O	O
disorders	ZYDELIG.xml:S1:4240:9	disord	NNS	O	O

rash	ZYDELIG.xml:S1:4258:4	rash	NN	B-AdverseReaction	B-AdverseReaction
20	ZYDELIG.xml:S1:4298:2	20	CD	O	O
(	ZYDELIG.xml:S1:4301:1	(	(	O	O
18	ZYDELIG.xml:S1:4302:2	18	CD	O	O
)	ZYDELIG.xml:S1:4304:1	)	)	O	O
4	ZYDELIG.xml:S1:4315:1	4	CD	O	O
(	ZYDELIG.xml:S1:4317:1	(	(	O	O
4	ZYDELIG.xml:S1:4318:1	4	CD	O	O
)	ZYDELIG.xml:S1:4319:1	)	)	O	O
7	ZYDELIG.xml:S1:4332:1	7	CD	O	O
(	ZYDELIG.xml:S1:4334:1	(	(	O	O
6	ZYDELIG.xml:S1:4335:1	6	CD	O	O
)	ZYDELIG.xml:S1:4336:1	)	)	O	O
1	ZYDELIG.xml:S1:4349:1	1	CD	O	O
(	ZYDELIG.xml:S1:4351:1	(	(	O	O
1	ZYDELIG.xml:S1:4352:1	1	CD	O	O
)	ZYDELIG.xml:S1:4353:1	)	)	O	O

Respiratory	ZYDELIG.xml:S1:4369:11	respiratori	NNP	O	O
,	ZYDELIG.xml:S1:4380:1	,	,	O	O
thoracic	ZYDELIG.xml:S1:4382:8	thorac	NN	O	O
,	ZYDELIG.xml:S1:4390:1	,	,	O	O
and	ZYDELIG.xml:S1:4392:3	and	CC	O	O
mediastinal	ZYDELIG.xml:S1:4396:11	mediastin	JJ	O	O
disorders	ZYDELIG.xml:S1:4408:9	disord	NNS	O	O

pneumonia	ZYDELIG.xml:S1:4424:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
25	ZYDELIG.xml:S1:4464:2	25	CD	O	O
(	ZYDELIG.xml:S1:4467:1	(	(	O	O
23	ZYDELIG.xml:S1:4468:2	23	CD	O	O
)	ZYDELIG.xml:S1:4470:1	)	)	O	O
18	ZYDELIG.xml:S1:4481:2	18	CD	O	O
(	ZYDELIG.xml:S1:4484:1	(	(	O	O
16	ZYDELIG.xml:S1:4485:2	16	CD	O	O
)	ZYDELIG.xml:S1:4487:1	)	)	O	O
19	ZYDELIG.xml:S1:4498:2	19	CD	O	O
(	ZYDELIG.xml:S1:4501:1	(	(	O	O
18	ZYDELIG.xml:S1:4502:2	18	CD	O	O
)	ZYDELIG.xml:S1:4504:1	)	)	O	O
14	ZYDELIG.xml:S1:4515:2	14	CD	O	O
(	ZYDELIG.xml:S1:4518:1	(	(	O	O
13	ZYDELIG.xml:S1:4519:2	13	CD	O	O
)	ZYDELIG.xml:S1:4521:1	)	)	O	O

nasal	ZYDELIG.xml:S1:4537:5	nasal	JJ	B-AdverseReaction	B-AdverseReaction
congestion	ZYDELIG.xml:S1:4543:10	congest	NN	I-AdverseReaction	I-AdverseReaction
6	ZYDELIG.xml:S1:4577:1	6	CD	O	O
(	ZYDELIG.xml:S1:4579:1	(	(	O	O
5	ZYDELIG.xml:S1:4580:1	5	CD	O	O
)	ZYDELIG.xml:S1:4581:1	)	)	O	O
0	ZYDELIG.xml:S1:4594:1	0	CD	O	O
2	ZYDELIG.xml:S1:4611:1	2	CD	O	O
(	ZYDELIG.xml:S1:4613:1	(	(	O	O
2	ZYDELIG.xml:S1:4614:1	2	CD	O	O
)	ZYDELIG.xml:S1:4615:1	)	)	O	O
0	ZYDELIG.xml:S1:4628:1	0	CD	O	O

Infections	ZYDELIG.xml:S1:4648:10	infect	NNS	O	O
and	ZYDELIG.xml:S1:4659:3	and	CC	O	O
infestations	ZYDELIG.xml:S1:4663:12	infest	NNS	O	O

sepsis	ZYDELIG.xml:S1:4695:6	sepsi	NN	B-AdverseReaction	B-AdverseReaction
9	ZYDELIG.xml:S1:4735:1	9	CD	O	O
(	ZYDELIG.xml:S1:4737:1	(	(	O	O
8	ZYDELIG.xml:S1:4738:1	8	CD	O	O
)	ZYDELIG.xml:S1:4739:1	)	)	O	O
8	ZYDELIG.xml:S1:4752:1	8	CD	O	O
(	ZYDELIG.xml:S1:4754:1	(	(	O	O
7	ZYDELIG.xml:S1:4755:1	7	CD	O	O
)	ZYDELIG.xml:S1:4756:1	)	)	O	O
4	ZYDELIG.xml:S1:4769:1	4	CD	O	O
(	ZYDELIG.xml:S1:4771:1	(	(	O	O
4	ZYDELIG.xml:S1:4772:1	4	CD	O	O
)	ZYDELIG.xml:S1:4773:1	)	)	O	O
4	ZYDELIG.xml:S1:4786:1	4	CD	O	O
(	ZYDELIG.xml:S1:4788:1	(	(	O	O
4	ZYDELIG.xml:S1:4789:1	4	CD	O	O
)	ZYDELIG.xml:S1:4790:1	)	)	O	O

bronchitis	ZYDELIG.xml:S1:4808:10	bronchiti	NN	B-AdverseReaction	B-AdverseReaction
7	ZYDELIG.xml:S1:4848:1	7	CD	O	O
(	ZYDELIG.xml:S1:4850:1	(	(	O	O
6	ZYDELIG.xml:S1:4851:1	6	CD	O	O
)	ZYDELIG.xml:S1:4852:1	)	)	O	O
1	ZYDELIG.xml:S1:4865:1	1	CD	O	O
(	ZYDELIG.xml:S1:4867:1	(	(	O	O
1	ZYDELIG.xml:S1:4868:1	1	CD	O	O
)	ZYDELIG.xml:S1:4869:1	)	)	O	O
3	ZYDELIG.xml:S1:4882:1	3	CD	O	O
(	ZYDELIG.xml:S1:4884:1	(	(	O	O
3	ZYDELIG.xml:S1:4885:1	3	CD	O	O
)	ZYDELIG.xml:S1:4886:1	)	)	O	O
1	ZYDELIG.xml:S1:4899:1	1	CD	O	O
(	ZYDELIG.xml:S1:4901:1	(	(	O	O
1	ZYDELIG.xml:S1:4902:1	1	CD	O	O
)	ZYDELIG.xml:S1:4903:1	)	)	O	O

sinusitis	ZYDELIG.xml:S1:4921:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
9	ZYDELIG.xml:S1:4961:1	9	CD	O	O
(	ZYDELIG.xml:S1:4963:1	(	(	O	O
8	ZYDELIG.xml:S1:4964:1	8	CD	O	O
)	ZYDELIG.xml:S1:4965:1	)	)	O	O
0	ZYDELIG.xml:S1:4978:1	0	CD	O	O
4	ZYDELIG.xml:S1:4995:1	4	CD	O	O
(	ZYDELIG.xml:S1:4997:1	(	(	O	O
4	ZYDELIG.xml:S1:4998:1	4	CD	O	O
)	ZYDELIG.xml:S1:4999:1	)	)	O	O
0	ZYDELIG.xml:S1:5012:1	0	CD	O	O

urinary	ZYDELIG.xml:S1:5034:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	ZYDELIG.xml:S1:5042:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ZYDELIG.xml:S1:5048:9	infect	NN	I-AdverseReaction	I-AdverseReaction
6	ZYDELIG.xml:S1:5074:1	6	CD	O	O
(	ZYDELIG.xml:S1:5076:1	(	(	O	O
5	ZYDELIG.xml:S1:5077:1	5	CD	O	O
)	ZYDELIG.xml:S1:5078:1	)	)	O	O
0	ZYDELIG.xml:S1:5091:1	0	CD	O	O
3	ZYDELIG.xml:S1:5108:1	3	CD	O	O
(	ZYDELIG.xml:S1:5110:1	(	(	O	O
3	ZYDELIG.xml:S1:5111:1	3	CD	O	O
)	ZYDELIG.xml:S1:5112:1	)	)	O	O
2	ZYDELIG.xml:S1:5125:1	2	CD	O	O
(	ZYDELIG.xml:S1:5127:1	(	(	O	O
2	ZYDELIG.xml:S1:5128:1	2	CD	O	O
)	ZYDELIG.xml:S1:5129:1	)	)	O	O

Musculoskeletal	ZYDELIG.xml:S1:5145:15	musculoskelet	NNP	O	O
and	ZYDELIG.xml:S1:5161:3	and	CC	O	O
connective	ZYDELIG.xml:S1:5165:10	connect	JJ	O	O
tissue	ZYDELIG.xml:S1:5176:6	tissu	NN	O	O
disorders	ZYDELIG.xml:S1:5183:9	disord	NNS	O	O

arthralgia	ZYDELIG.xml:S1:5199:10	arthralgia	RB	B-AdverseReaction	B-AdverseReaction
8	ZYDELIG.xml:S1:5239:1	8	CD	O	O
(	ZYDELIG.xml:S1:5241:1	(	(	O	O
7	ZYDELIG.xml:S1:5242:1	7	CD	O	O
)	ZYDELIG.xml:S1:5243:1	)	)	O	O
1	ZYDELIG.xml:S1:5256:1	1	CD	O	O
(	ZYDELIG.xml:S1:5258:1	(	(	O	O
1	ZYDELIG.xml:S1:5259:1	1	CD	O	O
)	ZYDELIG.xml:S1:5260:1	)	)	O	O
4	ZYDELIG.xml:S1:5273:1	4	CD	O	O
(	ZYDELIG.xml:S1:5275:1	(	(	O	O
4	ZYDELIG.xml:S1:5276:1	4	CD	O	O
)	ZYDELIG.xml:S1:5277:1	)	)	O	O
1	ZYDELIG.xml:S1:5290:1	1	CD	O	O
(	ZYDELIG.xml:S1:5292:1	(	(	O	O
1	ZYDELIG.xml:S1:5293:1	1	CD	O	O
)	ZYDELIG.xml:S1:5294:1	)	)	O	O

Table	ZYDELIG.xml:S1:5319:5	tabl	JJ	O	O
3	ZYDELIG.xml:S1:5325:1	3	CD	O	O
Treatment	ZYDELIG.xml:S1:5327:9	treatment	NNP	O	O
-	ZYDELIG.xml:S1:5336:1	-	:	O	O
emergent	ZYDELIG.xml:S1:5337:8	emerg	NN	O	O
Laboratory	ZYDELIG.xml:S1:5346:10	laboratori	NN	O	O
Abnormalities	ZYDELIG.xml:S1:5357:13	abnorm	NNP	O	O
Reported	ZYDELIG.xml:S1:5371:8	report	NNP	O	O
in	ZYDELIG.xml:S1:5380:2	in	IN	O	O
10%	ZYDELIG.xml:S1:5385:3	10%	CD	O	O
of	ZYDELIG.xml:S1:5389:2	of	IN	O	O
CLL	ZYDELIG.xml:S1:5392:3	cll	NNP	O	O
Patients	ZYDELIG.xml:S1:5396:8	patient	NNPS	O	O
Occurring	ZYDELIG.xml:S1:5405:9	occur	VBG	O	O
at	ZYDELIG.xml:S1:5415:2	at	IN	O	O
a	ZYDELIG.xml:S1:5418:1	a	DT	O	O
5%	ZYDELIG.xml:S1:5422:2	5%	CD	O	O
Higher	ZYDELIG.xml:S1:5425:6	higher	JJR	O	O
Incidence	ZYDELIG.xml:S1:5432:9	incid	NN	O	O
in	ZYDELIG.xml:S1:5442:2	in	IN	O	O
Subjects	ZYDELIG.xml:S1:5445:8	subject	NNP	O	O
Receiving	ZYDELIG.xml:S1:5454:9	receiv	NNP	O	O
Zydelig	ZYDELIG.xml:S1:5464:7	zydelig	NNP	O	O

Zydelig	ZYDELIG.xml:S1:5516:7	zydelig	NNP	O	O
RN	ZYDELIG.xml:S1:5526:2	RN	NNP	O	O
110	ZYDELIG.xml:S1:5529:3	110	CD	O	O
(	ZYDELIG.xml:S1:5533:1	(	(	O	O
)	ZYDELIG.xml:S1:5535:1	)	)	O	O
Placebo	ZYDELIG.xml:S1:5538:7	placebo	NNP	O	O
RN	ZYDELIG.xml:S1:5548:2	RN	NNP	O	O
108	ZYDELIG.xml:S1:5551:3	108	CD	O	O
(	ZYDELIG.xml:S1:5555:1	(	(	O	O
)	ZYDELIG.xml:S1:5557:1	)	)	O	O

Laboratory	ZYDELIG.xml:S1:5563:10	laboratori	NNP	O	O
Parameter	ZYDELIG.xml:S1:5574:9	paramet	NNP	O	O
Any	ZYDELIG.xml:S1:5605:3	ani	NNP	O	O
Grade	ZYDELIG.xml:S1:5609:5	grade	NNP	O	O
Grade	ZYDELIG.xml:S1:5622:5	grade	NNP	O	O
3	ZYDELIG.xml:S1:5628:1	3	CD	O	O
-	ZYDELIG.xml:S1:5629:1	-	:	O	O
4	ZYDELIG.xml:S1:5630:1	4	CD	O	O
Any	ZYDELIG.xml:S1:5639:3	ani	NNP	O	O
Grade	ZYDELIG.xml:S1:5643:5	grade	NNP	O	O
Grade	ZYDELIG.xml:S1:5656:5	grade	NNP	O	O
3	ZYDELIG.xml:S1:5662:1	3	CD	O	O
-	ZYDELIG.xml:S1:5663:1	-	:	O	O
4	ZYDELIG.xml:S1:5664:1	4	CD	O	O

Grades	ZYDELIG.xml:S1:5679:6	grade	NNS	O	O

were	ZYDELIG.xml:S1:5686:4	were	VBD	O	O
obtained	ZYDELIG.xml:S1:5691:8	obtain	VBN	O	O
per	ZYDELIG.xml:S1:5700:3	per	IN	O	O
CTCAE	ZYDELIG.xml:S1:5704:5	ctcae	NNP	O	O
version	ZYDELIG.xml:S1:5710:7	version	NN	O	O
4.03	ZYDELIG.xml:S1:5718:4	4.03	CD	O	O
.	ZYDELIG.xml:S1:5722:1	.	.	O	O
R	ZYDELIG.xml:S1:5723:1	R	NN	O	O
:	ZYDELIG.xml:S1:5724:1	:	:	O	O
rituximab	ZYDELIG.xml:S1:5726:9	rituximab	NN	O	O

Hematology	ZYDELIG.xml:S1:5743:10	hematolog	NN	O	O

abnormalities	ZYDELIG.xml:S1:5754:13	abnorm	NNS	O	O

neutrophil	ZYDELIG.xml:S1:5790:10	neutrophil	JJ	B-AdverseReaction	B-AdverseReaction
count	ZYDELIG.xml:S1:5801:5	count	NN	I-AdverseReaction	I-AdverseReaction
decreased	ZYDELIG.xml:S1:5807:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
66	ZYDELIG.xml:S1:5830:2	66	CD	O	O
(	ZYDELIG.xml:S1:5833:1	(	(	O	O
60	ZYDELIG.xml:S1:5834:2	60	CD	O	O
)	ZYDELIG.xml:S1:5836:1	)	)	O	O
41	ZYDELIG.xml:S1:5847:2	41	CD	O	O
(	ZYDELIG.xml:S1:5850:1	(	(	O	O
37	ZYDELIG.xml:S1:5851:2	37	CD	O	O
)	ZYDELIG.xml:S1:5853:1	)	)	O	O
55	ZYDELIG.xml:S1:5864:2	55	CD	O	O
(	ZYDELIG.xml:S1:5867:1	(	(	O	O
51	ZYDELIG.xml:S1:5868:2	51	CD	O	O
)	ZYDELIG.xml:S1:5870:1	)	)	O	O
29	ZYDELIG.xml:S1:5881:2	29	CD	O	O
(	ZYDELIG.xml:S1:5884:1	(	(	O	O
27	ZYDELIG.xml:S1:5885:2	27	CD	O	O
)	ZYDELIG.xml:S1:5887:1	)	)	O	O

lymphocyte	ZYDELIG.xml:S1:5903:10	lymphocyt	NN	B-AdverseReaction	B-AdverseReaction
count	ZYDELIG.xml:S1:5914:5	count	NN	I-AdverseReaction	I-AdverseReaction
decreased	ZYDELIG.xml:S1:5920:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
22	ZYDELIG.xml:S1:5943:2	22	CD	O	O
(	ZYDELIG.xml:S1:5946:1	(	(	O	O
20	ZYDELIG.xml:S1:5947:2	20	CD	O	O
)	ZYDELIG.xml:S1:5949:1	)	)	O	O
10	ZYDELIG.xml:S1:5960:2	10	CD	O	O
(	ZYDELIG.xml:S1:5963:1	(	(	O	O
9	ZYDELIG.xml:S1:5964:1	9	CD	O	O
)	ZYDELIG.xml:S1:5965:1	)	)	O	O
13	ZYDELIG.xml:S1:5977:2	13	CD	O	O
(	ZYDELIG.xml:S1:5980:1	(	(	O	O
12	ZYDELIG.xml:S1:5981:2	12	CD	O	O
)	ZYDELIG.xml:S1:5983:1	)	)	O	O
4	ZYDELIG.xml:S1:5994:1	4	CD	O	O
(	ZYDELIG.xml:S1:5996:1	(	(	O	O
4	ZYDELIG.xml:S1:5997:1	4	CD	O	O
)	ZYDELIG.xml:S1:5998:1	)	)	O	O

lymphocyte	ZYDELIG.xml:S1:6016:10	lymphocyt	JJ	B-AdverseReaction	B-AdverseReaction
count	ZYDELIG.xml:S1:6027:5	count	NN	I-AdverseReaction	I-AdverseReaction
increased	ZYDELIG.xml:S1:6033:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
27	ZYDELIG.xml:S1:6056:2	27	CD	O	O
(	ZYDELIG.xml:S1:6059:1	(	(	O	O
25	ZYDELIG.xml:S1:6060:2	25	CD	O	O
)	ZYDELIG.xml:S1:6062:1	)	)	O	O
20	ZYDELIG.xml:S1:6073:2	20	CD	O	O
(	ZYDELIG.xml:S1:6076:1	(	(	O	O
18	ZYDELIG.xml:S1:6077:2	18	CD	O	O
)	ZYDELIG.xml:S1:6079:1	)	)	O	O
10	ZYDELIG.xml:S1:6090:2	10	CD	O	O
(	ZYDELIG.xml:S1:6093:1	(	(	O	O
9	ZYDELIG.xml:S1:6094:1	9	CD	O	O
)	ZYDELIG.xml:S1:6095:1	)	)	O	O
5	ZYDELIG.xml:S1:6107:1	5	CD	O	O
(	ZYDELIG.xml:S1:6109:1	(	(	O	O
5	ZYDELIG.xml:S1:6110:1	5	CD	O	O
)	ZYDELIG.xml:S1:6111:1	)	)	O	O

Serum	ZYDELIG.xml:S1:6127:5	serum	NNP	O	O
chemistry	ZYDELIG.xml:S1:6133:9	chemistri	NN	O	O
abnormalities	ZYDELIG.xml:S1:6143:13	abnorm	NNS	O	O

ALT	ZYDELIG.xml:S1:6174:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZYDELIG.xml:S1:6178:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
38	ZYDELIG.xml:S1:6214:2	38	CD	O	O
(	ZYDELIG.xml:S1:6217:1	(	(	O	O
35	ZYDELIG.xml:S1:6218:2	35	CD	O	O
)	ZYDELIG.xml:S1:6220:1	)	)	O	O
9	ZYDELIG.xml:S1:6231:1	9	CD	O	O
(	ZYDELIG.xml:S1:6233:1	(	(	O	O
8	ZYDELIG.xml:S1:6234:1	8	CD	O	O
)	ZYDELIG.xml:S1:6235:1	)	)	O	O
11	ZYDELIG.xml:S1:6248:2	11	CD	O	O
(	ZYDELIG.xml:S1:6251:1	(	(	O	O
10	ZYDELIG.xml:S1:6252:2	10	CD	O	O
)	ZYDELIG.xml:S1:6254:1	)	)	O	O
1	ZYDELIG.xml:S1:6265:1	1	CD	O	O
(	ZYDELIG.xml:S1:6267:1	(	(	O	O
1	ZYDELIG.xml:S1:6268:1	1	CD	O	O
)	ZYDELIG.xml:S1:6269:1	)	)	O	O

AST	ZYDELIG.xml:S1:6287:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZYDELIG.xml:S1:6291:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
27	ZYDELIG.xml:S1:6327:2	27	CD	O	O
(	ZYDELIG.xml:S1:6330:1	(	(	O	O
25	ZYDELIG.xml:S1:6331:2	25	CD	O	O
)	ZYDELIG.xml:S1:6333:1	)	)	O	O
6	ZYDELIG.xml:S1:6344:1	6	CD	O	O
(	ZYDELIG.xml:S1:6346:1	(	(	O	O
5	ZYDELIG.xml:S1:6347:1	5	CD	O	O
)	ZYDELIG.xml:S1:6348:1	)	)	O	O
15	ZYDELIG.xml:S1:6361:2	15	CD	O	O
(	ZYDELIG.xml:S1:6364:1	(	(	O	O
14	ZYDELIG.xml:S1:6365:2	14	CD	O	O
)	ZYDELIG.xml:S1:6367:1	)	)	O	O
0	ZYDELIG.xml:S1:6378:1	0	CD	O	O

GGT	ZYDELIG.xml:S1:6400:3	ggt	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZYDELIG.xml:S1:6404:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
29	ZYDELIG.xml:S1:6440:2	29	CD	O	O
(	ZYDELIG.xml:S1:6443:1	(	(	O	O
26	ZYDELIG.xml:S1:6444:2	26	CD	O	O
)	ZYDELIG.xml:S1:6446:1	)	)	O	O
2	ZYDELIG.xml:S1:6457:1	2	CD	O	O
(	ZYDELIG.xml:S1:6459:1	(	(	O	O
2	ZYDELIG.xml:S1:6460:1	2	CD	O	O
)	ZYDELIG.xml:S1:6461:1	)	)	O	O
15	ZYDELIG.xml:S1:6474:2	15	CD	O	O
(	ZYDELIG.xml:S1:6477:1	(	(	O	O
14	ZYDELIG.xml:S1:6478:2	14	CD	O	O
)	ZYDELIG.xml:S1:6480:1	)	)	O	O
3	ZYDELIG.xml:S1:6491:1	3	CD	O	O
(	ZYDELIG.xml:S1:6493:1	(	(	O	O
3	ZYDELIG.xml:S1:6494:1	3	CD	O	O
)	ZYDELIG.xml:S1:6495:1	)	)	O	O

triglycerides	ZYDELIG.xml:S1:6513:13	triglycerid	NNS	O	O
(	ZYDELIG.xml:S1:6527:1	(	(	O	O
hypertriglyceridemia	ZYDELIG.xml:S1:6528:20	hypertriglyceridemia	NN	B-AdverseReaction	O
)	ZYDELIG.xml:S1:6548:1	)	)	O	O
62	ZYDELIG.xml:S1:6553:2	62	CD	O	O
(	ZYDELIG.xml:S1:6556:1	(	(	O	O
56	ZYDELIG.xml:S1:6557:2	56	CD	O	O
)	ZYDELIG.xml:S1:6559:1	)	)	O	O
3	ZYDELIG.xml:S1:6570:1	3	CD	O	O
(	ZYDELIG.xml:S1:6572:1	(	(	O	O
3	ZYDELIG.xml:S1:6573:1	3	CD	O	O
)	ZYDELIG.xml:S1:6574:1	)	)	O	O
37	ZYDELIG.xml:S1:6587:2	37	CD	O	O
(	ZYDELIG.xml:S1:6590:1	(	(	O	O
34	ZYDELIG.xml:S1:6591:2	34	CD	O	O
)	ZYDELIG.xml:S1:6593:1	)	)	O	O
0	ZYDELIG.xml:S1:6604:1	0	CD	O	O

hyperglycemia	ZYDELIG.xml:S1:6626:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
59	ZYDELIG.xml:S1:6666:2	59	CD	O	O
(	ZYDELIG.xml:S1:6669:1	(	(	O	O
54	ZYDELIG.xml:S1:6670:2	54	CD	O	O
)	ZYDELIG.xml:S1:6672:1	)	)	O	O
8	ZYDELIG.xml:S1:6683:1	8	CD	O	O
(	ZYDELIG.xml:S1:6685:1	(	(	O	O
7	ZYDELIG.xml:S1:6686:1	7	CD	O	O
)	ZYDELIG.xml:S1:6687:1	)	)	O	O
50	ZYDELIG.xml:S1:6700:2	50	CD	O	O
(	ZYDELIG.xml:S1:6703:1	(	(	O	O
46	ZYDELIG.xml:S1:6704:2	46	CD	O	O
)	ZYDELIG.xml:S1:6706:1	)	)	O	O
2	ZYDELIG.xml:S1:6717:1	2	CD	O	O
(	ZYDELIG.xml:S1:6719:1	(	(	O	O
2	ZYDELIG.xml:S1:6720:1	2	CD	O	O
)	ZYDELIG.xml:S1:6721:1	)	)	O	O

hypoglycemia	ZYDELIG.xml:S1:6739:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
12	ZYDELIG.xml:S1:6779:2	12	CD	O	O
(	ZYDELIG.xml:S1:6782:1	(	(	O	O
11	ZYDELIG.xml:S1:6783:2	11	CD	O	O
)	ZYDELIG.xml:S1:6785:1	)	)	O	O
0	ZYDELIG.xml:S1:6796:1	0	CD	O	O
5	ZYDELIG.xml:S1:6813:1	5	CD	O	O
(	ZYDELIG.xml:S1:6815:1	(	(	O	O
5	ZYDELIG.xml:S1:6816:1	5	CD	O	O
)	ZYDELIG.xml:S1:6817:1	)	)	O	O
0	ZYDELIG.xml:S1:6830:1	0	CD	O	O

hyponatremia	ZYDELIG.xml:S1:6852:12	hyponatremia	NN	B-AdverseReaction	B-AdverseReaction
22	ZYDELIG.xml:S1:6892:2	22	CD	O	O
(	ZYDELIG.xml:S1:6895:1	(	(	O	O
20	ZYDELIG.xml:S1:6896:2	20	CD	O	O
)	ZYDELIG.xml:S1:6898:1	)	)	O	O
2	ZYDELIG.xml:S1:6909:1	2	CD	O	O
(	ZYDELIG.xml:S1:6911:1	(	(	O	O
2	ZYDELIG.xml:S1:6912:1	2	CD	O	O
)	ZYDELIG.xml:S1:6913:1	)	)	O	O
16	ZYDELIG.xml:S1:6926:2	16	CD	O	O
(	ZYDELIG.xml:S1:6929:1	(	(	O	O
15	ZYDELIG.xml:S1:6930:2	15	CD	O	O
)	ZYDELIG.xml:S1:6932:1	)	)	O	O
7	ZYDELIG.xml:S1:6943:1	7	CD	O	O
(	ZYDELIG.xml:S1:6945:1	(	(	O	O
6	ZYDELIG.xml:S1:6946:1	6	CD	O	O
)	ZYDELIG.xml:S1:6947:1	)	)	O	O

Summary	ZYDELIG.xml:S1:6979:7	summari	NNP	O	O
of	ZYDELIG.xml:S1:6987:2	of	IN	O	O
Clinical	ZYDELIG.xml:S1:6990:8	clinic	NNP	O	O
Trials	ZYDELIG.xml:S1:6999:6	trial	NNP	O	O
in	ZYDELIG.xml:S1:7006:2	in	IN	O	O
Indolent	ZYDELIG.xml:S1:7009:8	indol	NNP	O	O
Non	ZYDELIG.xml:S1:7018:3	non	NNP	O	O
-	ZYDELIG.xml:S1:7021:1	-	:	O	O
Hodgkin	ZYDELIG.xml:S1:7022:7	hodgkin	NNP	O	O
Lymphoma	ZYDELIG.xml:S1:7030:8	lymphoma	NNP	O	O

The	ZYDELIG.xml:S1:7047:3	the	DT	O	O

safety	ZYDELIG.xml:S1:7051:6	safeti	NN	O	O
data	ZYDELIG.xml:S1:7058:4	data	NNS	O	O
reflect	ZYDELIG.xml:S1:7063:7	reflect	VBP	O	O
exposure	ZYDELIG.xml:S1:7071:8	exposur	NN	O	O
to	ZYDELIG.xml:S1:7080:2	to	TO	O	O
Zydelig	ZYDELIG.xml:S1:7083:7	zydelig	NNP	O	O
in	ZYDELIG.xml:S1:7091:2	in	IN	O	O
146	ZYDELIG.xml:S1:7094:3	146	CD	O	O
adults	ZYDELIG.xml:S1:7098:6	adult	NNS	O	O
with	ZYDELIG.xml:S1:7105:4	with	IN	O	O
indolent	ZYDELIG.xml:S1:7110:8	indol	NN	O	O
non	ZYDELIG.xml:S1:7119:3	non	SYM	O	O
-	ZYDELIG.xml:S1:7122:1	-	:	O	O
Hodgkin	ZYDELIG.xml:S1:7123:7	hodgkin	NNP	O	O
lymphoma	ZYDELIG.xml:S1:7131:8	lymphoma	NN	O	O
treated	ZYDELIG.xml:S1:7140:7	treat	VBD	O	O
with	ZYDELIG.xml:S1:7148:4	with	IN	O	O
Zydelig	ZYDELIG.xml:S1:7153:7	zydelig	NNP	O	O
150	ZYDELIG.xml:S1:7161:3	150	CD	O	O
mg	ZYDELIG.xml:S1:7165:2	mg	NN	O	O
twice	ZYDELIG.xml:S1:7168:5	twice	RB	O	O
daily	ZYDELIG.xml:S1:7174:5	daili	RB	O	O
in	ZYDELIG.xml:S1:7180:2	in	IN	O	O
clinical	ZYDELIG.xml:S1:7183:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S1:7192:6	trial	NNS	O	O
.	ZYDELIG.xml:S1:7198:1	.	.	O	O

The	ZYDELIG.xml:S1:7200:3	the	DT	O	O
median	ZYDELIG.xml:S1:7204:6	median	JJ	O	O
duration	ZYDELIG.xml:S1:7211:8	durat	NN	O	O
of	ZYDELIG.xml:S1:7220:2	of	IN	O	O
exposure	ZYDELIG.xml:S1:7223:8	exposur	NN	O	O
was	ZYDELIG.xml:S1:7232:3	wa	VBD	O	O
6.1	ZYDELIG.xml:S1:7236:3	6.1	CD	O	O
months	ZYDELIG.xml:S1:7240:6	month	NNS	O	O
(	ZYDELIG.xml:S1:7247:1	(	(	O	O
range	ZYDELIG.xml:S1:7248:5	rang	VB	O	O
0.3	ZYDELIG.xml:S1:7254:3	0.3	CD	O	O
to	ZYDELIG.xml:S1:7258:2	to	TO	O	O
26.4	ZYDELIG.xml:S1:7261:4	26.4	CD	O	O
months	ZYDELIG.xml:S1:7266:6	month	NNS	O	O
)	ZYDELIG.xml:S1:7272:1	)	)	O	O
.	ZYDELIG.xml:S1:7273:1	.	.	O	O

Serious	ZYDELIG.xml:S1:7279:7	seriou	JJ	O	O
adverse	ZYDELIG.xml:S1:7287:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:7295:9	reaction	NNS	O	O
were	ZYDELIG.xml:S1:7305:4	were	VBD	O	O
reported	ZYDELIG.xml:S1:7310:8	report	VBN	O	O
in	ZYDELIG.xml:S1:7319:2	in	IN	O	O
73	ZYDELIG.xml:S1:7322:2	73	CD	O	O
(	ZYDELIG.xml:S1:7325:1	(	(	O	O
50%	ZYDELIG.xml:S1:7326:3	50%	CD	O	O
)	ZYDELIG.xml:S1:7329:1	)	)	O	O
subjects	ZYDELIG.xml:S1:7331:8	subject	NNS	O	O
.	ZYDELIG.xml:S1:7339:1	.	.	O	O

The	ZYDELIG.xml:S1:7341:3	the	DT	O	O
most	ZYDELIG.xml:S1:7345:4	most	RBS	O	O
frequent	ZYDELIG.xml:S1:7350:8	frequent	JJ	O	O
serious	ZYDELIG.xml:S1:7359:7	seriou	JJ	O	O
adverse	ZYDELIG.xml:S1:7367:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:7375:9	reaction	NNS	O	O
that	ZYDELIG.xml:S1:7385:4	that	WDT	O	O
occurred	ZYDELIG.xml:S1:7390:8	occur	VBD	O	O
were	ZYDELIG.xml:S1:7399:4	were	VBD	O	O
pneumonia	ZYDELIG.xml:S1:7404:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:7414:1	(	(	O	O
15%	ZYDELIG.xml:S1:7415:3	15%	CD	O	O
)	ZYDELIG.xml:S1:7418:1	)	)	O	O
,	ZYDELIG.xml:S1:7419:1	,	,	O	O
diarrhea	ZYDELIG.xml:S1:7421:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:7430:1	(	(	O	O
11%	ZYDELIG.xml:S1:7431:3	11%	CD	O	O
)	ZYDELIG.xml:S1:7434:1	)	)	O	O
,	ZYDELIG.xml:S1:7435:1	,	,	O	O
and	ZYDELIG.xml:S1:7437:3	and	CC	O	O
pyrexia	ZYDELIG.xml:S1:7441:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:7449:1	(	(	O	O
9%	ZYDELIG.xml:S1:7450:2	9%	CD	O	O
)	ZYDELIG.xml:S1:7452:1	)	)	O	O
.	ZYDELIG.xml:S1:7453:1	.	.	O	O

Adverse	ZYDELIG.xml:S1:7459:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:7467:9	reaction	NNS	O	O
resulted	ZYDELIG.xml:S1:7477:8	result	VBD	O	O
in	ZYDELIG.xml:S1:7486:2	in	IN	O	O
interruption	ZYDELIG.xml:S1:7489:12	interrupt	NN	O	O
or	ZYDELIG.xml:S1:7502:2	or	CC	O	O
discontinuation	ZYDELIG.xml:S1:7505:15	discontinu	NN	O	O
for	ZYDELIG.xml:S1:7521:3	for	IN	O	O
78	ZYDELIG.xml:S1:7525:2	78	CD	O	O
(	ZYDELIG.xml:S1:7528:1	(	(	O	O
53%	ZYDELIG.xml:S1:7529:3	53%	CD	O	O
)	ZYDELIG.xml:S1:7532:1	)	)	O	O
subjects	ZYDELIG.xml:S1:7534:8	subject	NNS	O	O
.	ZYDELIG.xml:S1:7542:1	.	.	O	O

The	ZYDELIG.xml:S1:7544:3	the	DT	O	O
most	ZYDELIG.xml:S1:7548:4	most	RBS	O	O
common	ZYDELIG.xml:S1:7553:6	common	JJ	O	O
reasons	ZYDELIG.xml:S1:7560:7	reason	NNS	O	O
for	ZYDELIG.xml:S1:7568:3	for	IN	O	O
interruption	ZYDELIG.xml:S1:7572:12	interrupt	NN	O	O
or	ZYDELIG.xml:S1:7585:2	or	CC	O	O
discontinuations	ZYDELIG.xml:S1:7588:16	discontinu	NNS	O	O
were	ZYDELIG.xml:S1:7605:4	were	VBD	O	O
diarrhea	ZYDELIG.xml:S1:7610:8	diarrhea	JJ	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:7619:1	(	(	O	O
11%	ZYDELIG.xml:S1:7620:3	11%	CD	O	O
)	ZYDELIG.xml:S1:7623:1	)	)	O	O
,	ZYDELIG.xml:S1:7624:1	,	,	O	O
pneumonia	ZYDELIG.xml:S1:7626:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
(	ZYDELIG.xml:S1:7636:1	(	(	O	O
11%	ZYDELIG.xml:S1:7637:3	11%	CD	O	O
)	ZYDELIG.xml:S1:7640:1	)	)	O	O
,	ZYDELIG.xml:S1:7641:1	,	,	O	O
and	ZYDELIG.xml:S1:7643:3	and	CC	O	O
elevated	ZYDELIG.xml:S1:7647:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
transaminases	ZYDELIG.xml:S1:7656:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
(	ZYDELIG.xml:S1:7670:1	(	(	O	O
10%	ZYDELIG.xml:S1:7671:3	10%	CD	O	O
)	ZYDELIG.xml:S1:7674:1	)	)	O	O
.	ZYDELIG.xml:S1:7675:1	.	.	O	O

Table	ZYDELIG.xml:S1:7681:5	tabl	JJ	O	O
4	ZYDELIG.xml:S1:7687:1	4	CD	O	O
provides	ZYDELIG.xml:S1:7689:8	provid	VBZ	O	O
the	ZYDELIG.xml:S1:7698:3	the	DT	O	O
adverse	ZYDELIG.xml:S1:7702:7	advers	JJ	O	O
reactions	ZYDELIG.xml:S1:7710:9	reaction	NNS	O	O
occurring	ZYDELIG.xml:S1:7720:9	occur	VBG	O	O
in	ZYDELIG.xml:S1:7730:2	in	IN	O	O
at	ZYDELIG.xml:S1:7733:2	at	IN	O	O
least	ZYDELIG.xml:S1:7736:5	least	JJS	O	O
10%	ZYDELIG.xml:S1:7742:3	10%	CD	O	O
of	ZYDELIG.xml:S1:7746:2	of	IN	O	O
subjects	ZYDELIG.xml:S1:7749:8	subject	NNS	O	O
receiving	ZYDELIG.xml:S1:7758:9	receiv	VBG	O	O
Zydelig	ZYDELIG.xml:S1:7768:7	zydelig	NNP	O	O
monotherapy	ZYDELIG.xml:S1:7776:11	monotherapi	NN	O	O
,	ZYDELIG.xml:S1:7787:1	,	,	O	O
and	ZYDELIG.xml:S1:7789:3	and	CC	O	O
Table	ZYDELIG.xml:S1:7793:5	tabl	JJ	O	O
5	ZYDELIG.xml:S1:7799:1	5	CD	O	O
provides	ZYDELIG.xml:S1:7801:8	provid	VBZ	O	O
the	ZYDELIG.xml:S1:7810:3	the	DT	O	O
treatment	ZYDELIG.xml:S1:7814:9	treatment	NN	O	O
-	ZYDELIG.xml:S1:7823:1	-	:	O	O
emergent	ZYDELIG.xml:S1:7824:8	emerg	JJ	O	O
laboratory	ZYDELIG.xml:S1:7833:10	laboratori	NN	O	O
abnormalities	ZYDELIG.xml:S1:7844:13	abnorm	NNS	O	O
.	ZYDELIG.xml:S1:7857:1	.	.	O	O

Table	ZYDELIG.xml:S1:7863:5	tabl	JJ	O	O
4	ZYDELIG.xml:S1:7869:1	4	CD	O	O
Adverse	ZYDELIG.xml:S1:7871:7	advers	JJ	O	O
Reactions	ZYDELIG.xml:S1:7879:9	reaction	NNP	O	O
(	ZYDELIG.xml:S1:7889:1	(	(	O	O
10%	ZYDELIG.xml:S1:7893:3	10%	CD	O	O
of	ZYDELIG.xml:S1:7897:2	of	IN	O	O
Subjects	ZYDELIG.xml:S1:7900:8	subject	NNS	O	O
)	ZYDELIG.xml:S1:7908:1	)	)	O	O
in	ZYDELIG.xml:S1:7910:2	in	IN	O	O
Patients	ZYDELIG.xml:S1:7913:8	patient	NNS	O	O
with	ZYDELIG.xml:S1:7922:4	with	IN	O	O
Indolent	ZYDELIG.xml:S1:7927:8	indol	NNP	O	O
non	ZYDELIG.xml:S1:7936:3	non	SYM	O	O
-	ZYDELIG.xml:S1:7939:1	-	:	O	O
Hodgkin	ZYDELIG.xml:S1:7940:7	hodgkin	NNP	O	O
Lymphoma	ZYDELIG.xml:S1:7948:8	lymphoma	NNP	O	O
Treated	ZYDELIG.xml:S1:7957:7	treat	NNP	O	O
with	ZYDELIG.xml:S1:7965:4	with	IN	O	O
Zydelig	ZYDELIG.xml:S1:7970:7	zydelig	NNP	O	O
150	ZYDELIG.xml:S1:7978:3	150	CD	O	O
mg	ZYDELIG.xml:S1:7982:2	mg	NN	O	O
BID	ZYDELIG.xml:S1:7985:3	bid	NN	O	O

Zydelig	ZYDELIG.xml:S1:8043:7	zydelig	NNP	O	O
MonotherapyN	ZYDELIG.xml:S1:8051:12	monotherapyn	NNP	O	O
146	ZYDELIG.xml:S1:8064:3	146	CD	O	O
(	ZYDELIG.xml:S1:8068:1	(	(	O	O
)	ZYDELIG.xml:S1:8070:1	)	)	O	O

Adverse	ZYDELIG.xml:S1:8076:7	advers	JJ	O	O
Reaction	ZYDELIG.xml:S1:8084:8	reaction	NNP	O	O
Any	ZYDELIG.xml:S1:8128:3	ani	NNP	O	O
Grade	ZYDELIG.xml:S1:8132:5	grade	NNP	O	O
Grade	ZYDELIG.xml:S1:8155:5	grade	NNP	O	O
3	ZYDELIG.xml:S1:8163:1	3	CD	O	O

Gastrointestinal	ZYDELIG.xml:S1:8188:16	gastrointestin	JJ	O	O

disorders	ZYDELIG.xml:S1:8205:9	disord	NNS	O	O

diarrhea	ZYDELIG.xml:S1:8245:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
68	ZYDELIG.xml:S1:8295:2	68	CD	O	O
(	ZYDELIG.xml:S1:8298:1	(	(	O	O
47	ZYDELIG.xml:S1:8299:2	47	CD	O	O
)	ZYDELIG.xml:S1:8301:1	)	)	O	O
20	ZYDELIG.xml:S1:8322:2	20	CD	O	O
(	ZYDELIG.xml:S1:8325:1	(	(	O	O
14	ZYDELIG.xml:S1:8326:2	14	CD	O	O
)	ZYDELIG.xml:S1:8328:1	)	)	O	O

nausea	ZYDELIG.xml:S1:8354:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
42	ZYDELIG.xml:S1:8404:2	42	CD	O	O
(	ZYDELIG.xml:S1:8407:1	(	(	O	O
29	ZYDELIG.xml:S1:8408:2	29	CD	O	O
)	ZYDELIG.xml:S1:8410:1	)	)	O	O
2	ZYDELIG.xml:S1:8431:1	2	CD	O	O
(	ZYDELIG.xml:S1:8433:1	(	(	O	O
1	ZYDELIG.xml:S1:8434:1	1	CD	O	O
)	ZYDELIG.xml:S1:8435:1	)	)	O	O

abdominal	ZYDELIG.xml:S1:8463:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ZYDELIG.xml:S1:8473:4	pain	NN	I-AdverseReaction	I-AdverseReaction
38	ZYDELIG.xml:S1:8513:2	38	CD	O	O
(	ZYDELIG.xml:S1:8516:1	(	(	O	O
26	ZYDELIG.xml:S1:8517:2	26	CD	O	O
)	ZYDELIG.xml:S1:8519:1	)	)	O	O
3	ZYDELIG.xml:S1:8540:1	3	CD	O	O
(	ZYDELIG.xml:S1:8542:1	(	(	O	O
2	ZYDELIG.xml:S1:8543:1	2	CD	O	O
)	ZYDELIG.xml:S1:8544:1	)	)	O	O

vomiting	ZYDELIG.xml:S1:8572:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
22	ZYDELIG.xml:S1:8622:2	22	CD	O	O
(	ZYDELIG.xml:S1:8625:1	(	(	O	O
15	ZYDELIG.xml:S1:8626:2	15	CD	O	O
)	ZYDELIG.xml:S1:8628:1	)	)	O	O
2	ZYDELIG.xml:S1:8649:1	2	CD	O	O
(	ZYDELIG.xml:S1:8651:1	(	(	O	O
1	ZYDELIG.xml:S1:8652:1	1	CD	O	O
)	ZYDELIG.xml:S1:8653:1	)	)	O	O

General	ZYDELIG.xml:S1:8679:7	gener	NNP	O	O
disorders	ZYDELIG.xml:S1:8687:9	disord	NNS	O	O
and	ZYDELIG.xml:S1:8697:3	and	CC	O	O
administration	ZYDELIG.xml:S1:8701:14	administr	NN	O	O
site	ZYDELIG.xml:S1:8716:4	site	NN	O	O
conditions	ZYDELIG.xml:S1:8721:10	condit	NNS	O	O

fatigue	ZYDELIG.xml:S1:8738:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
44	ZYDELIG.xml:S1:8788:2	44	CD	O	O
(	ZYDELIG.xml:S1:8791:1	(	(	O	O
30	ZYDELIG.xml:S1:8792:2	30	CD	O	O
)	ZYDELIG.xml:S1:8794:1	)	)	O	O
2	ZYDELIG.xml:S1:8815:1	2	CD	O	O
(	ZYDELIG.xml:S1:8817:1	(	(	O	O
1	ZYDELIG.xml:S1:8818:1	1	CD	O	O
)	ZYDELIG.xml:S1:8819:1	)	)	O	O

pyrexia	ZYDELIG.xml:S1:8847:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
41	ZYDELIG.xml:S1:8897:2	41	CD	O	O
(	ZYDELIG.xml:S1:8900:1	(	(	O	O
28	ZYDELIG.xml:S1:8901:2	28	CD	O	O
)	ZYDELIG.xml:S1:8903:1	)	)	O	O
3	ZYDELIG.xml:S1:8924:1	3	CD	O	O
(	ZYDELIG.xml:S1:8926:1	(	(	O	O
2	ZYDELIG.xml:S1:8927:1	2	CD	O	O
)	ZYDELIG.xml:S1:8928:1	)	)	O	O

asthenia	ZYDELIG.xml:S1:8956:8	asthenia	RB	B-AdverseReaction	B-AdverseReaction
17	ZYDELIG.xml:S1:9006:2	17	CD	O	O
(	ZYDELIG.xml:S1:9009:1	(	(	O	O
12	ZYDELIG.xml:S1:9010:2	12	CD	O	O
)	ZYDELIG.xml:S1:9012:1	)	)	O	O
3	ZYDELIG.xml:S1:9033:1	3	CD	O	O
(	ZYDELIG.xml:S1:9035:1	(	(	O	O
2	ZYDELIG.xml:S1:9036:1	2	CD	O	O
)	ZYDELIG.xml:S1:9037:1	)	)	O	O

peripheral	ZYDELIG.xml:S1:9065:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	ZYDELIG.xml:S1:9076:5	edema	NN	I-AdverseReaction	I-AdverseReaction
15	ZYDELIG.xml:S1:9115:2	15	CD	O	O
(	ZYDELIG.xml:S1:9118:1	(	(	O	O
10	ZYDELIG.xml:S1:9119:2	10	CD	O	O
)	ZYDELIG.xml:S1:9121:1	)	)	O	O
3	ZYDELIG.xml:S1:9142:1	3	CD	O	O
(	ZYDELIG.xml:S1:9144:1	(	(	O	O
2	ZYDELIG.xml:S1:9145:1	2	CD	O	O
)	ZYDELIG.xml:S1:9146:1	)	)	O	O

Infections	ZYDELIG.xml:S1:9172:10	infect	NNS	O	O
and	ZYDELIG.xml:S1:9183:3	and	CC	O	O
infestations	ZYDELIG.xml:S1:9187:12	infest	NNS	O	O

upper	ZYDELIG.xml:S1:9229:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	ZYDELIG.xml:S1:9235:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	ZYDELIG.xml:S1:9247:5	tract	JJ	I-AdverseReaction	I-AdverseReaction
infection	ZYDELIG.xml:S1:9253:9	infect	NN	I-AdverseReaction	I-AdverseReaction
18	ZYDELIG.xml:S1:9279:2	18	CD	O	O
(	ZYDELIG.xml:S1:9282:1	(	(	O	O
12	ZYDELIG.xml:S1:9283:2	12	CD	O	O
)	ZYDELIG.xml:S1:9285:1	)	)	O	O
0	ZYDELIG.xml:S1:9306:1	0	CD	O	O

Respiratory	ZYDELIG.xml:S1:9336:11	respiratori	NNP	O	O
,	ZYDELIG.xml:S1:9347:1	,	,	O	O
thoracic	ZYDELIG.xml:S1:9349:8	thorac	NN	O	O
,	ZYDELIG.xml:S1:9357:1	,	,	O	O
and	ZYDELIG.xml:S1:9359:3	and	CC	O	O
mediastinal	ZYDELIG.xml:S1:9363:11	mediastin	JJ	O	O
disorders	ZYDELIG.xml:S1:9375:9	disord	NNS	O	O

pneumonia	ZYDELIG.xml:S1:9393:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
37	ZYDELIG.xml:S1:9443:2	37	CD	O	O
(	ZYDELIG.xml:S1:9446:1	(	(	O	O
25	ZYDELIG.xml:S1:9447:2	25	CD	O	O
)	ZYDELIG.xml:S1:9449:1	)	)	O	O
23	ZYDELIG.xml:S1:9470:2	23	CD	O	O
(	ZYDELIG.xml:S1:9473:1	(	(	O	O
16	ZYDELIG.xml:S1:9474:2	16	CD	O	O
)	ZYDELIG.xml:S1:9476:1	)	)	O	O

cough	ZYDELIG.xml:S1:9502:5	cough	NN	B-AdverseReaction	B-AdverseReaction
42	ZYDELIG.xml:S1:9552:2	42	CD	O	O
(	ZYDELIG.xml:S1:9555:1	(	(	O	O
29	ZYDELIG.xml:S1:9556:2	29	CD	O	O
)	ZYDELIG.xml:S1:9558:1	)	)	O	O
1	ZYDELIG.xml:S1:9579:1	1	CD	O	O
(	ZYDELIG.xml:S1:9581:1	(	(	O	O
1	ZYDELIG.xml:S1:9582:1	1	CD	O	O
)	ZYDELIG.xml:S1:9583:1	)	)	O	O

dyspnea	ZYDELIG.xml:S1:9611:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
25	ZYDELIG.xml:S1:9661:2	25	CD	O	O
(	ZYDELIG.xml:S1:9664:1	(	(	O	O
17	ZYDELIG.xml:S1:9665:2	17	CD	O	O
)	ZYDELIG.xml:S1:9667:1	)	)	O	O
6	ZYDELIG.xml:S1:9688:1	6	CD	O	O
(	ZYDELIG.xml:S1:9690:1	(	(	O	O
4	ZYDELIG.xml:S1:9691:1	4	CD	O	O
)	ZYDELIG.xml:S1:9692:1	)	)	O	O

Skin	ZYDELIG.xml:S1:9718:4	skin	NNP	O	O
and	ZYDELIG.xml:S1:9723:3	and	CC	O	O
subcutaneous	ZYDELIG.xml:S1:9727:12	subcutan	JJ	O	O
disorders	ZYDELIG.xml:S1:9740:9	disord	NNS	O	O

rash	ZYDELIG.xml:S1:9775:4	rash	NN	B-AdverseReaction	B-AdverseReaction
31	ZYDELIG.xml:S1:9825:2	31	CD	O	O
(	ZYDELIG.xml:S1:9828:1	(	(	O	O
21	ZYDELIG.xml:S1:9829:2	21	CD	O	O
)	ZYDELIG.xml:S1:9831:1	)	)	O	O
4	ZYDELIG.xml:S1:9852:1	4	CD	O	O
(	ZYDELIG.xml:S1:9854:1	(	(	O	O
3	ZYDELIG.xml:S1:9855:1	3	CD	O	O
)	ZYDELIG.xml:S1:9856:1	)	)	O	O

night	ZYDELIG.xml:S1:9884:5	night	NN	B-AdverseReaction	B-AdverseReaction
sweats	ZYDELIG.xml:S1:9890:6	sweat	NNS	I-AdverseReaction	I-AdverseReaction
18	ZYDELIG.xml:S1:9934:2	18	CD	O	O
(	ZYDELIG.xml:S1:9937:1	(	(	O	O
12	ZYDELIG.xml:S1:9938:2	12	CD	O	O
)	ZYDELIG.xml:S1:9940:1	)	)	O	O
0	ZYDELIG.xml:S1:9961:1	0	CD	O	O

Nervous	ZYDELIG.xml:S1:9991:7	nervou	JJ	O	O
system	ZYDELIG.xml:S1:9999:6	system	NN	O	O
disorders	ZYDELIG.xml:S1:10006:9	disord	NNS	O	O

headache	ZYDELIG.xml:S1:10048:8	headach	NN	B-AdverseReaction	B-AdverseReaction
16	ZYDELIG.xml:S1:10098:2	16	CD	O	O
(	ZYDELIG.xml:S1:10101:1	(	(	O	O
11	ZYDELIG.xml:S1:10102:2	11	CD	O	O
)	ZYDELIG.xml:S1:10104:1	)	)	O	O
1	ZYDELIG.xml:S1:10125:1	1	CD	O	O
(	ZYDELIG.xml:S1:10127:1	(	(	O	O
1	ZYDELIG.xml:S1:10128:1	1	CD	O	O
)	ZYDELIG.xml:S1:10129:1	)	)	O	O

Metabolism	ZYDELIG.xml:S1:10155:10	metabol	NN	O	O
and	ZYDELIG.xml:S1:10166:3	and	CC	O	O
nutrition	ZYDELIG.xml:S1:10170:9	nutrit	NN	O	O
disorders	ZYDELIG.xml:S1:10180:9	disord	NNS	O	O

decreased	ZYDELIG.xml:S1:10212:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	ZYDELIG.xml:S1:10222:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
24	ZYDELIG.xml:S1:10262:2	24	CD	O	O
(	ZYDELIG.xml:S1:10265:1	(	(	O	O
16	ZYDELIG.xml:S1:10266:2	16	CD	O	O
)	ZYDELIG.xml:S1:10268:1	)	)	O	O
1	ZYDELIG.xml:S1:10289:1	1	CD	O	O
(	ZYDELIG.xml:S1:10291:1	(	(	O	O
1	ZYDELIG.xml:S1:10292:1	1	CD	O	O
)	ZYDELIG.xml:S1:10293:1	)	)	O	O

Psychiatric	ZYDELIG.xml:S1:10319:11	psychiatr	JJ	O	O
disorders	ZYDELIG.xml:S1:10331:9	disord	NNS	O	O

insomnia	ZYDELIG.xml:S1:10376:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
17	ZYDELIG.xml:S1:10426:2	17	CD	O	O
(	ZYDELIG.xml:S1:10429:1	(	(	O	O
12	ZYDELIG.xml:S1:10430:2	12	CD	O	O
)	ZYDELIG.xml:S1:10432:1	)	)	O	O
0	ZYDELIG.xml:S1:10453:1	0	CD	O	O

Table	ZYDELIG.xml:S1:10490:5	tabl	JJ	O	O
5	ZYDELIG.xml:S1:10496:1	5	CD	O	O
Treatment	ZYDELIG.xml:S1:10498:9	treatment	NNP	O	O
-	ZYDELIG.xml:S1:10507:1	-	:	O	O
emergent	ZYDELIG.xml:S1:10508:8	emerg	NN	O	O
Laboratory	ZYDELIG.xml:S1:10517:10	laboratori	NNP	O	O
Abnormalities	ZYDELIG.xml:S1:10528:13	abnorm	NNP	O	O
in	ZYDELIG.xml:S1:10542:2	in	IN	O	O
Patients	ZYDELIG.xml:S1:10545:8	patient	NNP	O	O
with	ZYDELIG.xml:S1:10554:4	with	IN	O	O
Indolent	ZYDELIG.xml:S1:10559:8	indol	NNP	O	O
non	ZYDELIG.xml:S1:10568:3	non	SYM	O	O
-	ZYDELIG.xml:S1:10571:1	-	:	O	O
Hodgkin	ZYDELIG.xml:S1:10572:7	hodgkin	NNP	O	O
Lymphoma	ZYDELIG.xml:S1:10580:8	lymphoma	NNP	O	O
Treated	ZYDELIG.xml:S1:10589:7	treat	NNP	O	O
with	ZYDELIG.xml:S1:10597:4	with	IN	O	O
Zydelig	ZYDELIG.xml:S1:10602:7	zydelig	NNP	O	O
150	ZYDELIG.xml:S1:10610:3	150	CD	O	O
mg	ZYDELIG.xml:S1:10614:2	mg	NN	O	O
BID	ZYDELIG.xml:S1:10617:3	bid	NN	O	O

Zydelig	ZYDELIG.xml:S1:10674:7	zydelig	NNP	O	O
MonotherapyN	ZYDELIG.xml:S1:10682:12	monotherapyn	NNP	O	O
146	ZYDELIG.xml:S1:10695:3	146	CD	O	O
(	ZYDELIG.xml:S1:10699:1	(	(	O	O
)	ZYDELIG.xml:S1:10701:1	)	)	O	O

Laboratory	ZYDELIG.xml:S1:10707:10	laboratori	NNP	O	O
Abnormality	ZYDELIG.xml:S1:10718:11	abnorm	NNP	O	O
Any	ZYDELIG.xml:S1:10758:3	ani	NNP	O	O
Grade	ZYDELIG.xml:S1:10762:5	grade	NNP	O	O
Grade	ZYDELIG.xml:S1:10777:5	grade	NNP	O	O
3	ZYDELIG.xml:S1:10783:1	3	CD	O	O
Grade	ZYDELIG.xml:S1:10796:5	grade	NNP	O	O
4	ZYDELIG.xml:S1:10802:1	4	CD	O	O

Grades	ZYDELIG.xml:S1:10821:6	grade	NNS	O	O

were	ZYDELIG.xml:S1:10828:4	were	VBD	O	O
obtained	ZYDELIG.xml:S1:10833:8	obtain	VBN	O	O
per	ZYDELIG.xml:S1:10842:3	per	IN	O	O
CTCAE	ZYDELIG.xml:S1:10846:5	ctcae	NNP	O	O
version	ZYDELIG.xml:S1:10852:7	version	NN	O	O
4.03	ZYDELIG.xml:S1:10860:4	4.03	CD	O	O
.	ZYDELIG.xml:S1:10864:1	.	.	O	O

Serum	ZYDELIG.xml:S1:10878:5	serum	NN	O	O

chemistry	ZYDELIG.xml:S1:10884:9	chemistri	NN	O	O
abnormalities	ZYDELIG.xml:S1:10894:13	abnorm	NNS	O	O

ALT	ZYDELIG.xml:S1:10991:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZYDELIG.xml:S1:10995:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
73	ZYDELIG.xml:S1:11040:2	73	CD	O	O
(	ZYDELIG.xml:S1:11043:1	(	(	O	O
50	ZYDELIG.xml:S1:11044:2	50	CD	O	O
)	ZYDELIG.xml:S1:11046:1	)	)	O	O
20	ZYDELIG.xml:S1:11059:2	20	CD	O	O
(	ZYDELIG.xml:S1:11062:1	(	(	O	O
14	ZYDELIG.xml:S1:11063:2	14	CD	O	O
)	ZYDELIG.xml:S1:11065:1	)	)	O	O
7	ZYDELIG.xml:S1:11078:1	7	CD	O	O
(	ZYDELIG.xml:S1:11080:1	(	(	O	O
5	ZYDELIG.xml:S1:11081:1	5	CD	O	O
)	ZYDELIG.xml:S1:11082:1	)	)	O	O

AST	ZYDELIG.xml:S1:11102:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZYDELIG.xml:S1:11106:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
60	ZYDELIG.xml:S1:11151:2	60	CD	O	O
(	ZYDELIG.xml:S1:11154:1	(	(	O	O
41	ZYDELIG.xml:S1:11155:2	41	CD	O	O
)	ZYDELIG.xml:S1:11157:1	)	)	O	O
12	ZYDELIG.xml:S1:11170:2	12	CD	O	O
(	ZYDELIG.xml:S1:11173:1	(	(	O	O
8	ZYDELIG.xml:S1:11174:1	8	CD	O	O
)	ZYDELIG.xml:S1:11175:1	)	)	O	O
6	ZYDELIG.xml:S1:11189:1	6	CD	O	O
(	ZYDELIG.xml:S1:11191:1	(	(	O	O
4	ZYDELIG.xml:S1:11192:1	4	CD	O	O
)	ZYDELIG.xml:S1:11193:1	)	)	O	O

Hematology	ZYDELIG.xml:S1:11211:10	hematolog	NNP	O	O
abnormalities	ZYDELIG.xml:S1:11222:13	abnorm	NNS	O	O

neutrophils	ZYDELIG.xml:S1:11267:11	neutrophil	NNS	B-AdverseReaction	B-AdverseReaction
decreased	ZYDELIG.xml:S1:11279:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
78	ZYDELIG.xml:S1:11316:2	78	CD	O	O
(	ZYDELIG.xml:S1:11319:1	(	(	O	O
53	ZYDELIG.xml:S1:11320:2	53	CD	O	O
)	ZYDELIG.xml:S1:11322:1	)	)	O	O
20	ZYDELIG.xml:S1:11335:2	20	CD	O	O
(	ZYDELIG.xml:S1:11338:1	(	(	O	O
14	ZYDELIG.xml:S1:11339:2	14	CD	O	O
)	ZYDELIG.xml:S1:11341:1	)	)	O	O
16	ZYDELIG.xml:S1:11354:2	16	CD	O	O
(	ZYDELIG.xml:S1:11357:1	(	(	O	O
11	ZYDELIG.xml:S1:11358:2	11	CD	O	O
)	ZYDELIG.xml:S1:11360:1	)	)	O	O

hemoglobin	ZYDELIG.xml:S1:11378:10	hemoglobin	NN	B-AdverseReaction	B-AdverseReaction
decreased	ZYDELIG.xml:S1:11389:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
41	ZYDELIG.xml:S1:11427:2	41	CD	O	O
(	ZYDELIG.xml:S1:11430:1	(	(	O	O
28	ZYDELIG.xml:S1:11431:2	28	CD	O	O
)	ZYDELIG.xml:S1:11433:1	)	)	O	O
3	ZYDELIG.xml:S1:11446:1	3	CD	O	O
(	ZYDELIG.xml:S1:11448:1	(	(	O	O
2	ZYDELIG.xml:S1:11449:1	2	CD	O	O
)	ZYDELIG.xml:S1:11450:1	)	)	O	O
0	ZYDELIG.xml:S1:11465:1	0	CD	O	O

platelets	ZYDELIG.xml:S1:11489:9	platelet	NNS	B-AdverseReaction	B-AdverseReaction
decreased	ZYDELIG.xml:S1:11499:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
38	ZYDELIG.xml:S1:11538:2	38	CD	O	O
(	ZYDELIG.xml:S1:11541:1	(	(	O	O
26	ZYDELIG.xml:S1:11542:2	26	CD	O	O
)	ZYDELIG.xml:S1:11544:1	)	)	O	O
4	ZYDELIG.xml:S1:11557:1	4	CD	O	O
(	ZYDELIG.xml:S1:11559:1	(	(	O	O
3	ZYDELIG.xml:S1:11560:1	3	CD	O	O
)	ZYDELIG.xml:S1:11561:1	)	)	O	O
5	ZYDELIG.xml:S1:11576:1	5	CD	O	O
(	ZYDELIG.xml:S1:11578:1	(	(	O	O
3	ZYDELIG.xml:S1:11579:1	3	CD	O	O
)	ZYDELIG.xml:S1:11580:1	)	)	O	O
\n\n	ZYDELIG.xml:S2:0:2	\n\n	NN	O	O
BOXED	ZYDELIG.xml:S2:6:5	box	NNP	O	O
WARNING	ZYDELIG.xml:S2:12:7	warn	NN	O	O
:	ZYDELIG.xml:S2:19:1	:	:	O	O
WARNING	ZYDELIG.xml:S2:21:7	warn	NN	O	O
:	ZYDELIG.xml:S2:28:1	:	:	O	O
FATAL	ZYDELIG.xml:S2:30:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
AND	ZYDELIG.xml:S2:36:3	and	NNP	O	O
SERIOUS	ZYDELIG.xml:S2:40:7	seriou	NNP	O	O
TOXICITIES	ZYDELIG.xml:S2:48:10	toxic	NNP	B-AdverseReaction	O
:	ZYDELIG.xml:S2:58:1	:	:	O	O
HEPATIC	ZYDELIG.xml:S2:60:7	hepat	NNP	I-AdverseReaction	O
,	ZYDELIG.xml:S2:67:1	,	,	O	O
SEVERE	ZYDELIG.xml:S2:69:6	sever	NNP	O	O
DIARRHEA	ZYDELIG.xml:S2:76:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:84:1	,	,	O	O
COLITIS	ZYDELIG.xml:S2:86:7	coliti	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:93:1	,	,	O	O
PNEUMONITIS	ZYDELIG.xml:S2:95:11	pneumon	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:106:1	,	,	O	O
and	ZYDELIG.xml:S2:108:3	and	CC	O	O
INTESTINAL	ZYDELIG.xml:S2:113:10	intestin	NNP	B-AdverseReaction	B-AdverseReaction
PERFORATION	ZYDELIG.xml:S2:124:11	perfor	NNP	I-AdverseReaction	I-AdverseReaction
\n\n	ZYDELIG.xml:S2:135:2	\n\n	NNP	O	O
WARNING	ZYDELIG.xml:S2:139:7	warn	NN	O	O
:	ZYDELIG.xml:S2:146:1	:	:	O	O
FATAL	ZYDELIG.xml:S2:148:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
AND	ZYDELIG.xml:S2:154:3	and	NNP	O	O
SERIOUS	ZYDELIG.xml:S2:158:7	seriou	NNP	O	O
TOXICITIES	ZYDELIG.xml:S2:166:10	toxic	NNP	B-AdverseReaction	O
:	ZYDELIG.xml:S2:176:1	:	:	O	O
HEPATIC	ZYDELIG.xml:S2:178:7	hepat	NNP	I-AdverseReaction	O
,	ZYDELIG.xml:S2:185:1	,	,	O	O
SEVERE	ZYDELIG.xml:S2:187:6	sever	NNP	O	O
DIARRHEA	ZYDELIG.xml:S2:194:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:202:1	,	,	O	O
COLITIS	ZYDELIG.xml:S2:204:7	coliti	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:211:1	,	,	O	O
PNEUMONITIS	ZYDELIG.xml:S2:213:11	pneumon	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:224:1	,	,	O	O
and	ZYDELIG.xml:S2:226:3	and	CC	O	O
INTESTINAL	ZYDELIG.xml:S2:231:10	intestin	NNP	B-AdverseReaction	B-AdverseReaction
PERFORATION	ZYDELIG.xml:S2:242:11	perfor	NNP	I-AdverseReaction	I-AdverseReaction
\n\n	ZYDELIG.xml:S2:253:2	\n\n	NNP	O	O
Fatal	ZYDELIG.xml:S2:262:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S2:268:3	and	CC	O	O
or	ZYDELIG.xml:S2:272:2	or	CC	O	O
serious	ZYDELIG.xml:S2:275:7	seriou	JJ	O	O
hepatotoxicity	ZYDELIG.xml:S2:283:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
occurred	ZYDELIG.xml:S2:298:8	occur	VBD	O	O
in	ZYDELIG.xml:S2:307:2	in	IN	O	O
14%	ZYDELIG.xml:S2:310:3	14%	CD	O	O
of	ZYDELIG.xml:S2:314:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S2:317:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S2:324:1	-	:	O	O
treated	ZYDELIG.xml:S2:325:7	treat	VBD	O	O
patients	ZYDELIG.xml:S2:333:8	patient	NNS	O	O
.	ZYDELIG.xml:S2:341:1	.	.	O	O

Monitor	ZYDELIG.xml:S2:343:7	monitor	NNP	O	O
hepatic	ZYDELIG.xml:S2:351:7	hepat	JJ	O	O
function	ZYDELIG.xml:S2:359:8	function	NN	O	O
prior	ZYDELIG.xml:S2:368:5	prior	RB	O	O
to	ZYDELIG.xml:S2:374:2	to	TO	O	O
and	ZYDELIG.xml:S2:377:3	and	CC	O	O
during	ZYDELIG.xml:S2:381:6	dure	IN	O	O
treatment	ZYDELIG.xml:S2:388:9	treatment	NN	O	O
.	ZYDELIG.xml:S2:397:1	.	.	O	O

Interrupt	ZYDELIG.xml:S2:399:9	interrupt	NNP	O	O
and	ZYDELIG.xml:S2:409:3	and	CC	O	O
then	ZYDELIG.xml:S2:413:4	then	RB	O	O
reduce	ZYDELIG.xml:S2:418:6	reduc	VB	O	O
or	ZYDELIG.xml:S2:425:2	or	CC	O	O
discontinue	ZYDELIG.xml:S2:428:11	discontinu	VB	O	O
Zydelig	ZYDELIG.xml:S2:440:7	zydelig	NNP	O	O
as	ZYDELIG.xml:S2:448:2	as	IN	O	O
recommended	ZYDELIG.xml:S2:451:11	recommend	JJ	O	O
[	ZYDELIG.xml:S2:463:1	[	NN	O	O
see	ZYDELIG.xml:S2:464:3	see	VBP	O	O
Dosage	ZYDELIG.xml:S2:468:6	dosag	NNP	O	O
and	ZYDELIG.xml:S2:475:3	and	CC	O	O
Administration	ZYDELIG.xml:S2:479:14	administr	NNP	O	O
(	ZYDELIG.xml:S2:494:1	(	(	O	O
2.2	ZYDELIG.xml:S2:495:3	2.2	CD	O	O
)	ZYDELIG.xml:S2:498:1	)	)	O	O
,	ZYDELIG.xml:S2:499:1	,	,	O	O
Warnings	ZYDELIG.xml:S2:501:8	warn	NNP	O	O
and	ZYDELIG.xml:S2:510:3	and	CC	O	O
Precautions	ZYDELIG.xml:S2:514:11	precaut	NNP	O	O
(	ZYDELIG.xml:S2:526:1	(	(	O	O
5.1	ZYDELIG.xml:S2:527:3	5.1	CD	O	O
)]	ZYDELIG.xml:S2:530:2	)]	NN	O	O
.	ZYDELIG.xml:S2:532:1	.	.	O	O

Fatal	ZYDELIG.xml:S2:539:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S2:545:3	and	CC	O	O
or	ZYDELIG.xml:S2:549:2	or	CC	O	O
serious	ZYDELIG.xml:S2:552:7	seriou	JJ	O	O
and	ZYDELIG.xml:S2:560:3	and	CC	O	O
severe	ZYDELIG.xml:S2:564:6	sever	JJ	O	O
diarrhea	ZYDELIG.xml:S2:571:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
or	ZYDELIG.xml:S2:580:2	or	CC	O	O
colitis	ZYDELIG.xml:S2:583:7	coliti	NN	B-AdverseReaction	B-AdverseReaction
occurred	ZYDELIG.xml:S2:591:8	occur	VBD	O	O
in	ZYDELIG.xml:S2:600:2	in	IN	O	O
14%	ZYDELIG.xml:S2:603:3	14%	CD	O	O
of	ZYDELIG.xml:S2:607:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S2:610:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S2:617:1	-	:	O	O
treated	ZYDELIG.xml:S2:618:7	treat	VBD	O	O
patients	ZYDELIG.xml:S2:626:8	patient	NNS	O	O
.	ZYDELIG.xml:S2:634:1	.	.	O	O

Monitor	ZYDELIG.xml:S2:636:7	monitor	NN	O	O
for	ZYDELIG.xml:S2:644:3	for	IN	O	O
the	ZYDELIG.xml:S2:648:3	the	DT	O	O
development	ZYDELIG.xml:S2:652:11	develop	NN	O	O
of	ZYDELIG.xml:S2:664:2	of	IN	O	O
severe	ZYDELIG.xml:S2:667:6	sever	JJ	O	O
diarrhea	ZYDELIG.xml:S2:674:8	diarrhea	NN	O	O
or	ZYDELIG.xml:S2:683:2	or	CC	O	O
colitis	ZYDELIG.xml:S2:686:7	coliti	NN	O	O
.	ZYDELIG.xml:S2:693:1	.	.	O	O

Interrupt	ZYDELIG.xml:S2:695:9	interrupt	NNP	O	O
and	ZYDELIG.xml:S2:705:3	and	CC	O	O
then	ZYDELIG.xml:S2:709:4	then	RB	O	O
reduce	ZYDELIG.xml:S2:714:6	reduc	VB	O	O
or	ZYDELIG.xml:S2:721:2	or	CC	O	O
discontinue	ZYDELIG.xml:S2:724:11	discontinu	VB	O	O
Zydelig	ZYDELIG.xml:S2:736:7	zydelig	NNP	O	O
as	ZYDELIG.xml:S2:744:2	as	IN	O	O
recommended	ZYDELIG.xml:S2:747:11	recommend	JJ	O	O
[	ZYDELIG.xml:S2:759:1	[	NN	O	O
see	ZYDELIG.xml:S2:760:3	see	VBP	O	O
Dosage	ZYDELIG.xml:S2:764:6	dosag	NNP	O	O
and	ZYDELIG.xml:S2:771:3	and	CC	O	O
Administration	ZYDELIG.xml:S2:775:14	administr	NNP	O	O
(	ZYDELIG.xml:S2:790:1	(	(	O	O
2.2	ZYDELIG.xml:S2:791:3	2.2	CD	O	O
)	ZYDELIG.xml:S2:794:1	)	)	O	O
,	ZYDELIG.xml:S2:795:1	,	,	O	O
Warnings	ZYDELIG.xml:S2:797:8	warn	NNP	O	O
and	ZYDELIG.xml:S2:806:3	and	CC	O	O
Precautions	ZYDELIG.xml:S2:810:11	precaut	NNP	O	O
(	ZYDELIG.xml:S2:822:1	(	(	O	O
5.2	ZYDELIG.xml:S2:823:3	5.2	CD	O	O
)]	ZYDELIG.xml:S2:826:2	)]	NN	O	O
.	ZYDELIG.xml:S2:828:1	.	.	O	O

Fatal	ZYDELIG.xml:S2:835:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S2:841:3	and	CC	O	O
serious	ZYDELIG.xml:S2:845:7	seriou	JJ	O	O
pneumonitis	ZYDELIG.xml:S2:853:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
can	ZYDELIG.xml:S2:865:3	can	MD	O	O
occur	ZYDELIG.xml:S2:869:5	occur	VB	O	O
in	ZYDELIG.xml:S2:875:2	in	IN	O	O
Zydelig	ZYDELIG.xml:S2:878:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S2:885:1	-	:	O	O
treated	ZYDELIG.xml:S2:886:7	treat	VBD	O	O
patients	ZYDELIG.xml:S2:894:8	patient	NNS	O	O
.	ZYDELIG.xml:S2:902:1	.	.	O	O

Monitor	ZYDELIG.xml:S2:904:7	monitor	NNP	O	O
for	ZYDELIG.xml:S2:912:3	for	IN	O	O
pulmonary	ZYDELIG.xml:S2:916:9	pulmonari	JJ	O	O
symptoms	ZYDELIG.xml:S2:926:8	symptom	NNS	O	O
and	ZYDELIG.xml:S2:935:3	and	CC	O	O
bilateral	ZYDELIG.xml:S2:939:9	bilater	JJ	O	O
interstitial	ZYDELIG.xml:S2:949:12	interstiti	JJ	O	O
infiltrates	ZYDELIG.xml:S2:962:11	infiltr	NNS	O	O
.	ZYDELIG.xml:S2:973:1	.	.	O	O

Interrupt	ZYDELIG.xml:S2:975:9	interrupt	NNP	O	O
or	ZYDELIG.xml:S2:985:2	or	CC	O	O
discontinue	ZYDELIG.xml:S2:988:11	discontinu	VB	O	O
Zydelig	ZYDELIG.xml:S2:1000:7	zydelig	NNP	O	O
as	ZYDELIG.xml:S2:1008:2	as	IN	O	O
recommended	ZYDELIG.xml:S2:1011:11	recommend	JJ	O	O
[	ZYDELIG.xml:S2:1023:1	[	NN	O	O
see	ZYDELIG.xml:S2:1024:3	see	VBP	O	O
Dosage	ZYDELIG.xml:S2:1028:6	dosag	NNP	O	O
and	ZYDELIG.xml:S2:1035:3	and	CC	O	O
Administration	ZYDELIG.xml:S2:1039:14	administr	NNP	O	O
(	ZYDELIG.xml:S2:1054:1	(	(	O	O
2.2	ZYDELIG.xml:S2:1055:3	2.2	CD	O	O
)	ZYDELIG.xml:S2:1058:1	)	)	O	O
,	ZYDELIG.xml:S2:1059:1	,	,	O	O
Warnings	ZYDELIG.xml:S2:1061:8	warn	NNP	O	O
and	ZYDELIG.xml:S2:1070:3	and	CC	O	O
Precautions	ZYDELIG.xml:S2:1074:11	precaut	NNP	O	O
(	ZYDELIG.xml:S2:1086:1	(	(	O	O
5.3	ZYDELIG.xml:S2:1087:3	5.3	CD	O	O
)]	ZYDELIG.xml:S2:1090:2	)]	NN	O	O
.	ZYDELIG.xml:S2:1092:1	.	.	O	O

Fatal	ZYDELIG.xml:S2:1099:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S2:1105:3	and	CC	O	O
serious	ZYDELIG.xml:S2:1109:7	seriou	JJ	O	O
intestinal	ZYDELIG.xml:S2:1117:10	intestin	JJ	B-AdverseReaction	B-AdverseReaction
perforation	ZYDELIG.xml:S2:1128:11	perfor	NN	I-AdverseReaction	I-AdverseReaction
can	ZYDELIG.xml:S2:1140:3	can	MD	O	O
occur	ZYDELIG.xml:S2:1144:5	occur	VB	O	O
in	ZYDELIG.xml:S2:1150:2	in	IN	O	O
Zydelig	ZYDELIG.xml:S2:1153:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S2:1160:1	-	:	O	O
treated	ZYDELIG.xml:S2:1161:7	treat	VBD	O	O
patients	ZYDELIG.xml:S2:1169:8	patient	NNS	O	O
across	ZYDELIG.xml:S2:1178:6	across	IN	O	O
clinical	ZYDELIG.xml:S2:1185:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S2:1194:6	trial	NNS	O	O
.	ZYDELIG.xml:S2:1200:1	.	.	O	O

Discontinue	ZYDELIG.xml:S2:1202:11	discontinu	NNP	O	O
Zydelig	ZYDELIG.xml:S2:1214:7	zydelig	NNP	O	O
for	ZYDELIG.xml:S2:1222:3	for	IN	O	O
intestinal	ZYDELIG.xml:S2:1226:10	intestin	JJ	O	O
perforation	ZYDELIG.xml:S2:1237:11	perfor	NN	O	O
[	ZYDELIG.xml:S2:1249:1	[	NNP	O	O
see	ZYDELIG.xml:S2:1250:3	see	VBP	O	O
Warnings	ZYDELIG.xml:S2:1254:8	warn	NNP	O	O
and	ZYDELIG.xml:S2:1263:3	and	CC	O	O
Precautions	ZYDELIG.xml:S2:1267:11	precaut	NNP	O	O
(	ZYDELIG.xml:S2:1279:1	(	(	O	O
5.4	ZYDELIG.xml:S2:1280:3	5.4	CD	O	O
)]	ZYDELIG.xml:S2:1283:2	)]	NN	O	O
.	ZYDELIG.xml:S2:1285:1	.	.	O	O

EXCERPT	ZYDELIG.xml:S2:1294:7	excerpt	NN	O	O
:	ZYDELIG.xml:S2:1301:1	:	:	O	O
WARNING	ZYDELIG.xml:S2:1305:7	warn	NN	O	O
:	ZYDELIG.xml:S2:1312:1	:	:	O	O
FATAL	ZYDELIG.xml:S2:1314:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
AND	ZYDELIG.xml:S2:1320:3	and	NNP	O	O
SERIOUS	ZYDELIG.xml:S2:1324:7	seriou	NNP	O	O
TOXICITIES	ZYDELIG.xml:S2:1332:10	toxic	NNP	B-AdverseReaction	O
:	ZYDELIG.xml:S2:1342:1	:	:	O	O
HEPATIC	ZYDELIG.xml:S2:1344:7	hepat	NNP	I-AdverseReaction	O
,	ZYDELIG.xml:S2:1351:1	,	,	O	O
SEVERE	ZYDELIG.xml:S2:1353:6	sever	NNP	O	O
DIARRHEA	ZYDELIG.xml:S2:1360:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:1368:1	,	,	O	O
COLITIS	ZYDELIG.xml:S2:1370:7	coliti	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:1377:1	,	,	O	O
PNEUMONITIS	ZYDELIG.xml:S2:1379:11	pneumon	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S2:1390:1	,	,	O	O
and	ZYDELIG.xml:S2:1392:3	and	CC	O	O
INTESTINAL	ZYDELIG.xml:S2:1396:10	intestin	NNP	B-AdverseReaction	O
PERFORATION	ZYDELIG.xml:S2:1407:11	perfor	NNP	I-AdverseReaction	O
\n	ZYDELIG.xml:S2:1418:1	\n	NNP	O	O
\n\n	ZYDELIG.xml:S2:1420:2	\n\n	NNP	O	O
See	ZYDELIG.xml:S2:1427:3	see	NNP	O	O
full	ZYDELIG.xml:S2:1431:4	full	JJ	O	O
prescribing	ZYDELIG.xml:S2:1436:11	prescrib	VBG	O	O
information	ZYDELIG.xml:S2:1448:11	inform	NN	O	O
for	ZYDELIG.xml:S2:1460:3	for	IN	O	O
complete	ZYDELIG.xml:S2:1464:8	complet	JJ	O	O
boxed	ZYDELIG.xml:S2:1473:5	box	JJ	O	O
warning	ZYDELIG.xml:S2:1479:7	warn	NN	O	O
.	ZYDELIG.xml:S2:1486:1	.	.	O	O

Fatal	ZYDELIG.xml:S2:1499:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S2:1505:3	and	CC	O	O
or	ZYDELIG.xml:S2:1509:2	or	CC	O	O
serious	ZYDELIG.xml:S2:1512:7	seriou	JJ	O	O
hepatotoxicity	ZYDELIG.xml:S2:1520:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
occurred	ZYDELIG.xml:S2:1535:8	occur	VBD	O	O
in	ZYDELIG.xml:S2:1544:2	in	IN	O	O
14%	ZYDELIG.xml:S2:1547:3	14%	CD	O	O
of	ZYDELIG.xml:S2:1551:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S2:1554:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S2:1561:1	-	:	O	O
treated	ZYDELIG.xml:S2:1562:7	treat	VBD	O	O
patients	ZYDELIG.xml:S2:1570:8	patient	NNS	O	O
.	ZYDELIG.xml:S2:1578:1	.	.	O	O

Monitor	ZYDELIG.xml:S2:1580:7	monitor	NNP	O	O
hepatic	ZYDELIG.xml:S2:1588:7	hepat	JJ	O	O
function	ZYDELIG.xml:S2:1596:8	function	NN	O	O
prior	ZYDELIG.xml:S2:1605:5	prior	RB	O	O
to	ZYDELIG.xml:S2:1611:2	to	TO	O	O
and	ZYDELIG.xml:S2:1614:3	and	CC	O	O
during	ZYDELIG.xml:S2:1618:6	dure	IN	O	O
treatment	ZYDELIG.xml:S2:1625:9	treatment	NN	O	O
.	ZYDELIG.xml:S2:1634:1	.	.	O	O

Interrupt	ZYDELIG.xml:S2:1636:9	interrupt	NNP	O	O
and	ZYDELIG.xml:S2:1646:3	and	CC	O	O
then	ZYDELIG.xml:S2:1650:4	then	RB	O	O
reduce	ZYDELIG.xml:S2:1655:6	reduc	VB	O	O
or	ZYDELIG.xml:S2:1662:2	or	CC	O	O
discontinue	ZYDELIG.xml:S2:1665:11	discontinu	VB	O	O
Zydelig	ZYDELIG.xml:S2:1677:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S2:1684:1	.	.	O	O

(	ZYDELIG.xml:S2:1686:1	(	(	O	O
5.1	ZYDELIG.xml:S2:1688:3	5.1	CD	O	O
)	ZYDELIG.xml:S2:1691:1	)	)	O	O
\n	ZYDELIG.xml:S2:1693:1	\n	FW	O	O
Fatal	ZYDELIG.xml:S2:1698:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S2:1704:3	and	CC	O	O
or	ZYDELIG.xml:S2:1708:2	or	CC	O	O
serious	ZYDELIG.xml:S2:1711:7	seriou	JJ	O	O
and	ZYDELIG.xml:S2:1719:3	and	CC	O	O
severe	ZYDELIG.xml:S2:1723:6	sever	JJ	O	O
diarrhea	ZYDELIG.xml:S2:1730:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
or	ZYDELIG.xml:S2:1739:2	or	CC	O	O
colitis	ZYDELIG.xml:S2:1742:7	coliti	NN	B-AdverseReaction	B-AdverseReaction
occurred	ZYDELIG.xml:S2:1750:8	occur	VBD	O	O
in	ZYDELIG.xml:S2:1759:2	in	IN	O	O
14%	ZYDELIG.xml:S2:1762:3	14%	CD	O	O
of	ZYDELIG.xml:S2:1766:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S2:1769:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S2:1776:1	-	:	O	O
treated	ZYDELIG.xml:S2:1777:7	treat	VBD	O	O
patients	ZYDELIG.xml:S2:1785:8	patient	NNS	O	O
.	ZYDELIG.xml:S2:1793:1	.	.	O	O

Monitor	ZYDELIG.xml:S2:1795:7	monitor	NN	O	O
for	ZYDELIG.xml:S2:1803:3	for	IN	O	O
the	ZYDELIG.xml:S2:1807:3	the	DT	O	O
development	ZYDELIG.xml:S2:1811:11	develop	NN	O	O
of	ZYDELIG.xml:S2:1823:2	of	IN	O	O
severe	ZYDELIG.xml:S2:1826:6	sever	JJ	O	O
diarrhea	ZYDELIG.xml:S2:1833:8	diarrhea	NN	O	O
or	ZYDELIG.xml:S2:1842:2	or	CC	O	O
colitis	ZYDELIG.xml:S2:1845:7	coliti	NN	O	O
.	ZYDELIG.xml:S2:1852:1	.	.	O	O

Interrupt	ZYDELIG.xml:S2:1854:9	interrupt	NNP	O	O
and	ZYDELIG.xml:S2:1864:3	and	CC	O	O
then	ZYDELIG.xml:S2:1868:4	then	RB	O	O
reduce	ZYDELIG.xml:S2:1873:6	reduc	VB	O	O
or	ZYDELIG.xml:S2:1880:2	or	CC	O	O
discontinue	ZYDELIG.xml:S2:1883:11	discontinu	VB	O	O
Zydelig	ZYDELIG.xml:S2:1895:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S2:1902:1	.	.	O	O

(	ZYDELIG.xml:S2:1904:1	(	(	O	O
5.2	ZYDELIG.xml:S2:1906:3	5.2	CD	O	O
)	ZYDELIG.xml:S2:1909:1	)	)	O	O
\n	ZYDELIG.xml:S2:1911:1	\n	FW	O	O
Fatal	ZYDELIG.xml:S2:1916:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S2:1922:3	and	CC	O	O
serious	ZYDELIG.xml:S2:1926:7	seriou	JJ	O	O
pneumonitis	ZYDELIG.xml:S2:1934:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
can	ZYDELIG.xml:S2:1946:3	can	MD	O	O
occur	ZYDELIG.xml:S2:1950:5	occur	VB	O	O
in	ZYDELIG.xml:S2:1956:2	in	IN	O	O
Zydelig	ZYDELIG.xml:S2:1959:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S2:1966:1	-	:	O	O
treated	ZYDELIG.xml:S2:1967:7	treat	VBD	O	O
patients	ZYDELIG.xml:S2:1975:8	patient	NNS	O	O
.	ZYDELIG.xml:S2:1983:1	.	.	O	O

Monitor	ZYDELIG.xml:S2:1985:7	monitor	NNP	O	O
for	ZYDELIG.xml:S2:1993:3	for	IN	O	O
pulmonary	ZYDELIG.xml:S2:1997:9	pulmonari	JJ	O	O
symptoms	ZYDELIG.xml:S2:2007:8	symptom	NNS	O	O
and	ZYDELIG.xml:S2:2016:3	and	CC	O	O
bilateral	ZYDELIG.xml:S2:2020:9	bilater	JJ	O	O
interstitial	ZYDELIG.xml:S2:2030:12	interstiti	JJ	O	O
infiltrates	ZYDELIG.xml:S2:2043:11	infiltr	NNS	O	O
.	ZYDELIG.xml:S2:2054:1	.	.	O	O

Interrupt	ZYDELIG.xml:S2:2056:9	interrupt	NNP	O	O
or	ZYDELIG.xml:S2:2066:2	or	CC	O	O
discontinue	ZYDELIG.xml:S2:2069:11	discontinu	VB	O	O
Zydelig	ZYDELIG.xml:S2:2081:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S2:2088:1	.	.	O	O

(	ZYDELIG.xml:S2:2090:1	(	(	O	O
5.3	ZYDELIG.xml:S2:2092:3	5.3	CD	O	O
)	ZYDELIG.xml:S2:2095:1	)	)	O	O
\n	ZYDELIG.xml:S2:2097:1	\n	FW	O	O
Fatal	ZYDELIG.xml:S2:2102:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S2:2108:3	and	CC	O	O
serious	ZYDELIG.xml:S2:2112:7	seriou	JJ	O	O
intestinal	ZYDELIG.xml:S2:2120:10	intestin	JJ	B-AdverseReaction	B-AdverseReaction
perforation	ZYDELIG.xml:S2:2131:11	perfor	NN	I-AdverseReaction	I-AdverseReaction
can	ZYDELIG.xml:S2:2143:3	can	MD	O	O
occur	ZYDELIG.xml:S2:2147:5	occur	VB	O	O
in	ZYDELIG.xml:S2:2153:2	in	IN	O	O
Zydelig	ZYDELIG.xml:S2:2156:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S2:2163:1	-	:	O	O
treated	ZYDELIG.xml:S2:2164:7	treat	VBD	O	O
patients	ZYDELIG.xml:S2:2172:8	patient	NNS	O	O
across	ZYDELIG.xml:S2:2181:6	across	IN	O	O
clinical	ZYDELIG.xml:S2:2188:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S2:2197:6	trial	NNS	O	O
.	ZYDELIG.xml:S2:2203:1	.	.	O	O

Discontinue	ZYDELIG.xml:S2:2205:11	discontinu	NNP	O	O
Zydelig	ZYDELIG.xml:S2:2217:7	zydelig	NNP	O	O
if	ZYDELIG.xml:S2:2225:2	if	IN	O	O
intestinal	ZYDELIG.xml:S2:2228:10	intestin	JJ	O	O
perforation	ZYDELIG.xml:S2:2239:11	perfor	NN	O	O
is	ZYDELIG.xml:S2:2251:2	is	VBZ	O	O
suspected	ZYDELIG.xml:S2:2254:9	suspect	VBN	O	O
.	ZYDELIG.xml:S2:2263:1	.	.	O	O

(	ZYDELIG.xml:S2:2265:1	(	(	O	O
5.4	ZYDELIG.xml:S2:2267:3	5.4	CD	O	O
)	ZYDELIG.xml:S2:2270:1	)	)	O	O
\n	ZYDELIG.xml:S2:2272:1	\n	VBD	O	O
5	ZYDELIG.xml:S3:4:1	5	CD	O	O
WARNINGS	ZYDELIG.xml:S3:6:8	warn	NNP	O	O
AND	ZYDELIG.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	ZYDELIG.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	ZYDELIG.xml:S3:37:7	excerpt	NN	O	O
:	ZYDELIG.xml:S3:44:1	:	:	O	O
Severe	ZYDELIG.xml:S3:52:6	sever	NNP	O	O
cutaneous	ZYDELIG.xml:S3:59:9	cutan	JJ	B-AdverseReaction	B-AdverseReaction
reactions	ZYDELIG.xml:S3:69:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
:	ZYDELIG.xml:S3:78:1	:	:	O	O
Monitor	ZYDELIG.xml:S3:80:7	monitor	NN	O	O
patients	ZYDELIG.xml:S3:88:8	patient	NNS	O	O
for	ZYDELIG.xml:S3:97:3	for	IN	O	O
the	ZYDELIG.xml:S3:101:3	the	DT	O	O
development	ZYDELIG.xml:S3:105:11	develop	NN	O	O
of	ZYDELIG.xml:S3:117:2	of	IN	O	O
severe	ZYDELIG.xml:S3:120:6	sever	JJ	O	O
cutaneous	ZYDELIG.xml:S3:127:9	cutan	JJ	O	B-AdverseReaction
reactions	ZYDELIG.xml:S3:137:9	reaction	NNS	O	I-AdverseReaction
and	ZYDELIG.xml:S3:147:3	and	CC	O	O
discontinue	ZYDELIG.xml:S3:151:11	discontinu	NN	O	O
Zydelig	ZYDELIG.xml:S3:163:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S3:170:1	.	.	O	O

(	ZYDELIG.xml:S3:172:1	(	(	O	O
5.5	ZYDELIG.xml:S3:175:3	5.5	CD	O	O
)	ZYDELIG.xml:S3:180:1	)	)	O	O

Anaphylaxis	ZYDELIG.xml:S3:187:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
:	ZYDELIG.xml:S3:198:1	:	:	O	O
Monitor	ZYDELIG.xml:S3:200:7	monitor	NN	O	O
patients	ZYDELIG.xml:S3:208:8	patient	NNS	O	O
for	ZYDELIG.xml:S3:217:3	for	IN	O	O
anaphylaxis	ZYDELIG.xml:S3:221:11	anaphylaxi	NN	O	O
and	ZYDELIG.xml:S3:233:3	and	CC	O	O
discontinue	ZYDELIG.xml:S3:237:11	discontinu	NN	O	O
Zydelig	ZYDELIG.xml:S3:249:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S3:256:1	.	.	O	O

(	ZYDELIG.xml:S3:258:1	(	(	O	O
5.6	ZYDELIG.xml:S3:261:3	5.6	CD	O	O
)	ZYDELIG.xml:S3:266:1	)	)	O	O

Neutropenia	ZYDELIG.xml:S3:273:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
:	ZYDELIG.xml:S3:284:1	:	:	O	O
monitor	ZYDELIG.xml:S3:286:7	monitor	NN	O	O
blood	ZYDELIG.xml:S3:294:5	blood	NN	O	O
counts	ZYDELIG.xml:S3:300:6	count	NNS	O	O
.	ZYDELIG.xml:S3:306:1	.	.	O	O

(	ZYDELIG.xml:S3:308:1	(	(	O	O
5.7	ZYDELIG.xml:S3:311:3	5.7	CD	O	O
)	ZYDELIG.xml:S3:316:1	)	)	O	O

Embryo	ZYDELIG.xml:S3:323:6	embryo	NNP	B-AdverseReaction	B-AdverseReaction
-	ZYDELIG.xml:S3:329:1	-	:	I-AdverseReaction	I-AdverseReaction
fetal	ZYDELIG.xml:S3:330:5	fetal	JJ	I-AdverseReaction	I-AdverseReaction
toxicity	ZYDELIG.xml:S3:336:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
:	ZYDELIG.xml:S3:344:1	:	:	O	O
may	ZYDELIG.xml:S3:346:3	may	MD	O	O
cause	ZYDELIG.xml:S3:350:5	caus	VB	O	O
fetal	ZYDELIG.xml:S3:356:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	ZYDELIG.xml:S3:362:4	harm	NN	I-AdverseReaction	I-AdverseReaction
.	ZYDELIG.xml:S3:366:1	.	.	O	O

Advise	ZYDELIG.xml:S3:368:6	advis	NNP	O	O
women	ZYDELIG.xml:S3:375:5	women	NNS	O	O
of	ZYDELIG.xml:S3:381:2	of	IN	O	O
potential	ZYDELIG.xml:S3:384:9	potenti	JJ	O	O
risk	ZYDELIG.xml:S3:394:4	risk	NN	O	O
to	ZYDELIG.xml:S3:399:2	to	TO	O	O
a	ZYDELIG.xml:S3:402:1	a	DT	O	O
fetus	ZYDELIG.xml:S3:404:5	fetu	NN	O	O
and	ZYDELIG.xml:S3:410:3	and	CC	O	O
to	ZYDELIG.xml:S3:414:2	to	TO	O	O
avoid	ZYDELIG.xml:S3:417:5	avoid	VB	O	O
pregnancy	ZYDELIG.xml:S3:423:9	pregnanc	NN	O	O
while	ZYDELIG.xml:S3:433:5	while	IN	O	O
taking	ZYDELIG.xml:S3:439:6	take	VBG	O	O
Zydelig	ZYDELIG.xml:S3:446:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S3:453:1	.	.	O	O

(	ZYDELIG.xml:S3:455:1	(	(	O	O
5.8	ZYDELIG.xml:S3:458:3	5.8	CD	O	O
)	ZYDELIG.xml:S3:463:1	)	)	O	O

5.1	ZYDELIG.xml:S3:477:3	5.1	CD	O	O

Hepatotoxicity	ZYDELIG.xml:S3:481:14	hepatotox	NN	O	O

Fatal	ZYDELIG.xml:S3:501:5	fatal	NN	B-AdverseReaction	B-AdverseReaction

and	ZYDELIG.xml:S3:507:3	and	CC	O	O
or	ZYDELIG.xml:S3:511:2	or	CC	O	O
serious	ZYDELIG.xml:S3:514:7	seriou	JJ	O	O
hepatotoxicity	ZYDELIG.xml:S3:522:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
occurred	ZYDELIG.xml:S3:537:8	occur	VBD	O	O
in	ZYDELIG.xml:S3:546:2	in	IN	O	O
14%	ZYDELIG.xml:S3:549:3	14%	CD	O	O
of	ZYDELIG.xml:S3:553:2	of	IN	O	O
patients	ZYDELIG.xml:S3:556:8	patient	NNS	O	O
treated	ZYDELIG.xml:S3:565:7	treat	VBN	O	O
with	ZYDELIG.xml:S3:573:4	with	IN	O	O
Zydelig	ZYDELIG.xml:S3:578:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S3:585:1	.	.	O	O

Elevations	ZYDELIG.xml:S3:587:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	ZYDELIG.xml:S3:598:2	in	IN	I-AdverseReaction	I-AdverseReaction
ALT	ZYDELIG.xml:S3:601:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
or	ZYDELIG.xml:S3:605:2	or	CC	O	O
AST	ZYDELIG.xml:S3:608:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
greater	ZYDELIG.xml:S3:612:7	greater	JJR	O	O
than	ZYDELIG.xml:S3:620:4	than	IN	O	O
5	ZYDELIG.xml:S3:625:1	5	CD	O	O
times	ZYDELIG.xml:S3:627:5	time	NNS	O	O
the	ZYDELIG.xml:S3:633:3	the	DT	O	O
upper	ZYDELIG.xml:S3:637:5	upper	JJ	O	O
limit	ZYDELIG.xml:S3:643:5	limit	NN	O	O
of	ZYDELIG.xml:S3:649:2	of	IN	O	O
normal	ZYDELIG.xml:S3:652:6	normal	JJ	O	O
have	ZYDELIG.xml:S3:659:4	have	VBP	O	O
occurred	ZYDELIG.xml:S3:664:8	occur	VBN	O	O
[	ZYDELIG.xml:S3:673:1	[	NNP	O	O
see	ZYDELIG.xml:S3:674:3	see	VBP	O	O
Adverse	ZYDELIG.xml:S3:679:7	advers	JJ	O	O
Reactions	ZYDELIG.xml:S3:687:9	reaction	NNP	O	O
(	ZYDELIG.xml:S3:697:1	(	(	O	O
6.1	ZYDELIG.xml:S3:698:3	6.1	CD	O	O
)	ZYDELIG.xml:S3:701:1	)	)	O	O
]	ZYDELIG.xml:S3:704:1	]	NN	O	O
.	ZYDELIG.xml:S3:705:1	.	.	O	O

These	ZYDELIG.xml:S3:708:5	these	DT	O	O
findings	ZYDELIG.xml:S3:714:8	find	NNS	O	O
were	ZYDELIG.xml:S3:723:4	were	VBD	O	O
generally	ZYDELIG.xml:S3:728:9	gener	RB	O	O
observed	ZYDELIG.xml:S3:738:8	observ	VBN	O	O
within	ZYDELIG.xml:S3:747:6	within	IN	O	O
the	ZYDELIG.xml:S3:754:3	the	DT	O	O
first	ZYDELIG.xml:S3:758:5	first	JJ	O	O
12	ZYDELIG.xml:S3:764:2	12	CD	O	O
weeks	ZYDELIG.xml:S3:767:5	week	NNS	O	O
of	ZYDELIG.xml:S3:773:2	of	IN	O	O
treatment	ZYDELIG.xml:S3:776:9	treatment	NN	O	O
and	ZYDELIG.xml:S3:786:3	and	CC	O	O
were	ZYDELIG.xml:S3:790:4	were	VBD	O	O
reversible	ZYDELIG.xml:S3:795:10	revers	JJ	O	O
with	ZYDELIG.xml:S3:806:4	with	IN	O	O
dose	ZYDELIG.xml:S3:811:4	dose	JJ	O	O
interruption	ZYDELIG.xml:S3:816:12	interrupt	NN	O	O
.	ZYDELIG.xml:S3:828:1	.	.	O	O

After	ZYDELIG.xml:S3:830:5	after	IN	O	O
resumption	ZYDELIG.xml:S3:836:10	resumpt	NN	O	O
of	ZYDELIG.xml:S3:847:2	of	IN	O	O
treatment	ZYDELIG.xml:S3:850:9	treatment	NN	O	O
at	ZYDELIG.xml:S3:860:2	at	IN	O	O
a	ZYDELIG.xml:S3:863:1	a	DT	O	O
lower	ZYDELIG.xml:S3:865:5	lower	JJR	O	O
dose	ZYDELIG.xml:S3:871:4	dose	NN	O	O
,	ZYDELIG.xml:S3:875:1	,	,	O	O
26%	ZYDELIG.xml:S3:877:3	26%	CD	O	O
of	ZYDELIG.xml:S3:881:2	of	IN	O	O
patients	ZYDELIG.xml:S3:884:8	patient	NNS	O	O
had	ZYDELIG.xml:S3:893:3	had	VBD	O	O
recurrence	ZYDELIG.xml:S3:897:10	recurr	NN	B-AdverseReaction	O
of	ZYDELIG.xml:S3:908:2	of	IN	O	O
ALT	ZYDELIG.xml:S3:911:3	alt	NNP	I-AdverseReaction	O
and	ZYDELIG.xml:S3:915:3	and	CC	O	O
AST	ZYDELIG.xml:S3:919:3	ast	NNP	I-AdverseReaction	B-AdverseReaction
elevations	ZYDELIG.xml:S3:923:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
.	ZYDELIG.xml:S3:933:1	.	.	O	O

Discontinue	ZYDELIG.xml:S3:935:11	discontinu	NNP	O	O
Zydelig	ZYDELIG.xml:S3:947:7	zydelig	NNP	O	O
for	ZYDELIG.xml:S3:955:3	for	IN	O	O
recurrent	ZYDELIG.xml:S3:959:9	recurr	JJ	O	O
hepatotoxicity	ZYDELIG.xml:S3:969:14	hepatotox	NN	O	O
.	ZYDELIG.xml:S3:983:1	.	.	O	O

Avoid	ZYDELIG.xml:S3:989:5	avoid	NNP	O	O
concurrent	ZYDELIG.xml:S3:995:10	concurr	NN	O	O
use	ZYDELIG.xml:S3:1006:3	use	NN	O	O
of	ZYDELIG.xml:S3:1010:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S3:1013:7	zydelig	NNP	O	O
with	ZYDELIG.xml:S3:1021:4	with	IN	O	O
other	ZYDELIG.xml:S3:1026:5	other	JJ	O	O
drugs	ZYDELIG.xml:S3:1032:5	drug	NNS	O	O
that	ZYDELIG.xml:S3:1038:4	that	WDT	O	O
may	ZYDELIG.xml:S3:1043:3	may	MD	O	O
cause	ZYDELIG.xml:S3:1047:5	caus	VB	O	O
liver	ZYDELIG.xml:S3:1053:5	liver	NN	O	B-AdverseReaction
toxicity	ZYDELIG.xml:S3:1059:8	toxic	NN	O	I-AdverseReaction
.	ZYDELIG.xml:S3:1067:1	.	.	O	O

Monitor	ZYDELIG.xml:S3:1073:7	monitor	NNP	O	O
ALT	ZYDELIG.xml:S3:1081:3	alt	NNP	O	O
and	ZYDELIG.xml:S3:1085:3	and	CC	O	O
AST	ZYDELIG.xml:S3:1089:3	ast	NNP	O	I-AdverseReaction
in	ZYDELIG.xml:S3:1093:2	in	IN	O	O
all	ZYDELIG.xml:S3:1096:3	all	DT	O	O
patients	ZYDELIG.xml:S3:1100:8	patient	NNS	O	O
every	ZYDELIG.xml:S3:1109:5	everi	DT	O	O
2	ZYDELIG.xml:S3:1115:1	2	CD	O	O
weeks	ZYDELIG.xml:S3:1117:5	week	NNS	O	O
for	ZYDELIG.xml:S3:1123:3	for	IN	O	O
the	ZYDELIG.xml:S3:1127:3	the	DT	O	O
first	ZYDELIG.xml:S3:1131:5	first	JJ	O	O
3	ZYDELIG.xml:S3:1137:1	3	CD	O	O
months	ZYDELIG.xml:S3:1139:6	month	NNS	O	O
of	ZYDELIG.xml:S3:1146:2	of	IN	O	O
treatment	ZYDELIG.xml:S3:1149:9	treatment	NN	O	O
,	ZYDELIG.xml:S3:1158:1	,	,	O	O
every	ZYDELIG.xml:S3:1160:5	everi	DT	O	O
4	ZYDELIG.xml:S3:1166:1	4	CD	O	O
weeks	ZYDELIG.xml:S3:1168:5	week	NNS	O	O
for	ZYDELIG.xml:S3:1174:3	for	IN	O	O
the	ZYDELIG.xml:S3:1178:3	the	DT	O	O
next	ZYDELIG.xml:S3:1182:4	next	JJ	O	O
3	ZYDELIG.xml:S3:1187:1	3	CD	O	O
months	ZYDELIG.xml:S3:1189:6	month	NNS	O	O
,	ZYDELIG.xml:S3:1195:1	,	,	O	O
then	ZYDELIG.xml:S3:1197:4	then	RB	O	O
every	ZYDELIG.xml:S3:1202:5	everi	DT	O	O
1	ZYDELIG.xml:S3:1208:1	1	CD	O	O
to	ZYDELIG.xml:S3:1210:2	to	TO	O	O
3	ZYDELIG.xml:S3:1213:1	3	CD	O	O
months	ZYDELIG.xml:S3:1215:6	month	NNS	O	O
thereafter	ZYDELIG.xml:S3:1222:10	thereaft	RB	O	O
.	ZYDELIG.xml:S3:1232:1	.	.	O	O

Monitor	ZYDELIG.xml:S3:1234:7	monitor	NNP	O	O
weekly	ZYDELIG.xml:S3:1242:6	weekli	JJ	O	O
for	ZYDELIG.xml:S3:1249:3	for	IN	O	O
liver	ZYDELIG.xml:S3:1253:5	liver	JJ	O	O
toxicity	ZYDELIG.xml:S3:1259:8	toxic	NN	O	O
if	ZYDELIG.xml:S3:1268:2	if	IN	O	O
the	ZYDELIG.xml:S3:1271:3	the	DT	O	O
ALT	ZYDELIG.xml:S3:1275:3	alt	NNP	O	O
or	ZYDELIG.xml:S3:1279:2	or	CC	O	O
AST	ZYDELIG.xml:S3:1282:3	ast	NNP	O	O
rises	ZYDELIG.xml:S3:1286:5	rise	NNS	O	O
above	ZYDELIG.xml:S3:1292:5	abov	IN	O	O
3	ZYDELIG.xml:S3:1298:1	3	CD	O	O
times	ZYDELIG.xml:S3:1300:5	time	NNS	O	O
the	ZYDELIG.xml:S3:1306:3	the	DT	O	O
upper	ZYDELIG.xml:S3:1310:5	upper	JJ	O	O
limit	ZYDELIG.xml:S3:1316:5	limit	NN	O	O
of	ZYDELIG.xml:S3:1322:2	of	IN	O	O
normal	ZYDELIG.xml:S3:1325:6	normal	JJ	O	O
until	ZYDELIG.xml:S3:1332:5	until	IN	O	O
resolved	ZYDELIG.xml:S3:1338:8	resolv	VBN	O	O
.	ZYDELIG.xml:S3:1346:1	.	.	O	O

Withhold	ZYDELIG.xml:S3:1348:8	withhold	NNP	O	O
Zydelig	ZYDELIG.xml:S3:1357:7	zydelig	NNP	O	O
if	ZYDELIG.xml:S3:1365:2	if	IN	O	O
the	ZYDELIG.xml:S3:1368:3	the	DT	O	O
ALT	ZYDELIG.xml:S3:1372:3	alt	NNP	O	O
or	ZYDELIG.xml:S3:1376:2	or	CC	O	O
AST	ZYDELIG.xml:S3:1379:3	ast	NNP	O	O
is	ZYDELIG.xml:S3:1383:2	is	VBZ	O	O
greater	ZYDELIG.xml:S3:1386:7	greater	JJR	O	O
than	ZYDELIG.xml:S3:1394:4	than	IN	O	O
5	ZYDELIG.xml:S3:1399:1	5	CD	O	O
times	ZYDELIG.xml:S3:1401:5	time	NNS	O	O
the	ZYDELIG.xml:S3:1407:3	the	DT	O	O
upper	ZYDELIG.xml:S3:1411:5	upper	JJ	O	O
limit	ZYDELIG.xml:S3:1417:5	limit	NN	O	O
of	ZYDELIG.xml:S3:1423:2	of	IN	O	O
normal	ZYDELIG.xml:S3:1426:6	normal	JJ	O	O
,	ZYDELIG.xml:S3:1432:1	,	,	O	O
and	ZYDELIG.xml:S3:1434:3	and	CC	O	O
continue	ZYDELIG.xml:S3:1438:8	continu	VB	O	O
to	ZYDELIG.xml:S3:1447:2	to	TO	O	O
monitor	ZYDELIG.xml:S3:1450:7	monitor	VB	O	O
AST	ZYDELIG.xml:S3:1458:3	ast	NNP	O	O
,	ZYDELIG.xml:S3:1461:1	,	,	O	O
ALT	ZYDELIG.xml:S3:1463:3	alt	NNP	O	I-AdverseReaction
and	ZYDELIG.xml:S3:1467:3	and	CC	O	O
total	ZYDELIG.xml:S3:1471:5	total	JJ	O	O
bilirubin	ZYDELIG.xml:S3:1477:9	bilirubin	JJ	O	O
weekly	ZYDELIG.xml:S3:1487:6	weekli	JJ	O	O
until	ZYDELIG.xml:S3:1494:5	until	IN	O	O
the	ZYDELIG.xml:S3:1500:3	the	DT	O	O
abnormality	ZYDELIG.xml:S3:1504:11	abnorm	NN	O	O
is	ZYDELIG.xml:S3:1516:2	is	VBZ	O	O
resolved	ZYDELIG.xml:S3:1519:8	resolv	VBN	O	O
[	ZYDELIG.xml:S3:1528:1	[	JJ	O	O
see	ZYDELIG.xml:S3:1529:3	see	NN	O	O
Dosage	ZYDELIG.xml:S3:1534:6	dosag	NNP	O	O
and	ZYDELIG.xml:S3:1541:3	and	CC	O	O
Administration	ZYDELIG.xml:S3:1545:14	administr	NNP	O	O
(	ZYDELIG.xml:S3:1560:1	(	(	O	O
2.2	ZYDELIG.xml:S3:1561:3	2.2	CD	O	O
)	ZYDELIG.xml:S3:1564:1	)	)	O	O
]	ZYDELIG.xml:S3:1567:1	]	NN	O	O
.	ZYDELIG.xml:S3:1568:1	.	.	O	O

5.2	ZYDELIG.xml:S3:1579:3	5.2	CD	O	O
Severe	ZYDELIG.xml:S3:1583:6	sever	NNP	O	O
Diarrhea	ZYDELIG.xml:S3:1590:8	diarrhea	NNP	O	O
or	ZYDELIG.xml:S3:1599:2	or	CC	O	O
Colitis	ZYDELIG.xml:S3:1602:7	coliti	NNP	O	O

Severe	ZYDELIG.xml:S3:1615:6	sever	JJ	O	O
diarrhea	ZYDELIG.xml:S3:1622:8	diarrhea	NN	B-AdverseReaction	O
or	ZYDELIG.xml:S3:1631:2	or	CC	O	O
colitis	ZYDELIG.xml:S3:1634:7	coliti	NN	B-AdverseReaction	O
(	ZYDELIG.xml:S3:1642:1	(	(	O	O
Grade	ZYDELIG.xml:S3:1643:5	grade	NNP	O	O
3	ZYDELIG.xml:S3:1649:1	3	CD	O	O
or	ZYDELIG.xml:S3:1651:2	or	CC	O	O
higher	ZYDELIG.xml:S3:1654:6	higher	JJR	O	O
)	ZYDELIG.xml:S3:1660:1	)	)	O	O
occurred	ZYDELIG.xml:S3:1662:8	occur	VBD	O	O
in	ZYDELIG.xml:S3:1671:2	in	IN	O	O
14%	ZYDELIG.xml:S3:1674:3	14%	CD	O	O
of	ZYDELIG.xml:S3:1678:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S3:1681:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S3:1688:1	-	:	O	O
treated	ZYDELIG.xml:S3:1689:7	treat	VBD	O	O
patients	ZYDELIG.xml:S3:1697:8	patient	NNS	O	O
across	ZYDELIG.xml:S3:1706:6	across	IN	O	O
clinical	ZYDELIG.xml:S3:1713:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S3:1722:6	trial	NNS	O	O
[	ZYDELIG.xml:S3:1729:1	[	VBP	O	O
see	ZYDELIG.xml:S3:1730:3	see	VB	O	O
Adverse	ZYDELIG.xml:S3:1735:7	advers	JJ	O	O
Reactions	ZYDELIG.xml:S3:1743:9	reaction	NNP	O	O
(	ZYDELIG.xml:S3:1753:1	(	(	O	O
6.1	ZYDELIG.xml:S3:1754:3	6.1	CD	O	O
)	ZYDELIG.xml:S3:1757:1	)	)	O	O
]	ZYDELIG.xml:S3:1760:1	]	NN	O	O
.	ZYDELIG.xml:S3:1761:1	.	.	O	O

Diarrhea	ZYDELIG.xml:S3:1764:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
can	ZYDELIG.xml:S3:1773:3	can	MD	O	O
occur	ZYDELIG.xml:S3:1777:5	occur	VB	O	O
at	ZYDELIG.xml:S3:1783:2	at	IN	O	O
any	ZYDELIG.xml:S3:1786:3	ani	DT	O	O
time	ZYDELIG.xml:S3:1790:4	time	NN	O	O
.	ZYDELIG.xml:S3:1794:1	.	.	O	O

Avoid	ZYDELIG.xml:S3:1796:5	avoid	NNP	O	O
concurrent	ZYDELIG.xml:S3:1802:10	concurr	NN	O	O
use	ZYDELIG.xml:S3:1813:3	use	NN	O	O
of	ZYDELIG.xml:S3:1817:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S3:1820:7	zydelig	NNP	O	O
and	ZYDELIG.xml:S3:1828:3	and	CC	O	O
other	ZYDELIG.xml:S3:1832:5	other	JJ	O	O
drugs	ZYDELIG.xml:S3:1838:5	drug	NNS	O	O
that	ZYDELIG.xml:S3:1844:4	that	WDT	O	O
cause	ZYDELIG.xml:S3:1849:5	caus	VBP	O	O
diarrhea	ZYDELIG.xml:S3:1855:8	diarrhea	NN	O	B-AdverseReaction
.	ZYDELIG.xml:S3:1863:1	.	.	O	O

Diarrhea	ZYDELIG.xml:S3:1865:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
due	ZYDELIG.xml:S3:1874:3	due	JJ	O	O
to	ZYDELIG.xml:S3:1878:2	to	TO	O	O
Zydelig	ZYDELIG.xml:S3:1881:7	zydelig	NNP	O	O
responds	ZYDELIG.xml:S3:1889:8	respond	VBZ	O	O
poorly	ZYDELIG.xml:S3:1898:6	poorli	RB	O	O
to	ZYDELIG.xml:S3:1905:2	to	TO	O	O
antimotility	ZYDELIG.xml:S3:1908:12	antimotil	NN	O	O
agents	ZYDELIG.xml:S3:1921:6	agent	NNS	O	O
.	ZYDELIG.xml:S3:1927:1	.	.	O	O

Median	ZYDELIG.xml:S3:1929:6	median	JJ	O	O
time	ZYDELIG.xml:S3:1936:4	time	NN	O	O
to	ZYDELIG.xml:S3:1941:2	to	TO	O	O
resolution	ZYDELIG.xml:S3:1944:10	resolut	VB	O	O
ranged	ZYDELIG.xml:S3:1955:6	rang	VBN	O	O
between	ZYDELIG.xml:S3:1962:7	between	IN	O	O
1	ZYDELIG.xml:S3:1970:1	1	CD	O	O
week	ZYDELIG.xml:S3:1972:4	week	NN	O	O
and	ZYDELIG.xml:S3:1977:3	and	CC	O	O
1	ZYDELIG.xml:S3:1981:1	1	CD	O	O
month	ZYDELIG.xml:S3:1983:5	month	NN	O	O
across	ZYDELIG.xml:S3:1989:6	across	IN	O	O
trials	ZYDELIG.xml:S3:1996:6	trial	NNS	O	O
,	ZYDELIG.xml:S3:2002:1	,	,	O	O
following	ZYDELIG.xml:S3:2004:9	follow	VBG	O	O
interruption	ZYDELIG.xml:S3:2014:12	interrupt	NN	O	O
of	ZYDELIG.xml:S3:2027:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S3:2030:7	zydelig	NNP	O	O
therapy	ZYDELIG.xml:S3:2038:7	therapi	NN	O	O
and	ZYDELIG.xml:S3:2046:3	and	CC	O	O
in	ZYDELIG.xml:S3:2050:2	in	IN	O	O
some	ZYDELIG.xml:S3:2053:4	some	DT	O	O
instances	ZYDELIG.xml:S3:2058:9	instanc	NNS	O	O
,	ZYDELIG.xml:S3:2067:1	,	,	O	O
use	ZYDELIG.xml:S3:2069:3	use	NN	O	O
of	ZYDELIG.xml:S3:2073:2	of	IN	O	O
corticosteroids	ZYDELIG.xml:S3:2076:15	corticosteroid	NNS	O	O
[	ZYDELIG.xml:S3:2092:1	[	NNP	O	O
see	ZYDELIG.xml:S3:2093:3	see	VBP	O	O
Dosage	ZYDELIG.xml:S3:2098:6	dosag	NNP	O	O
and	ZYDELIG.xml:S3:2105:3	and	CC	O	O
Administration	ZYDELIG.xml:S3:2109:14	administr	NNP	O	O
(	ZYDELIG.xml:S3:2124:1	(	(	O	O
2.2	ZYDELIG.xml:S3:2125:3	2.2	CD	O	O
)	ZYDELIG.xml:S3:2128:1	)	)	O	O
]	ZYDELIG.xml:S3:2131:1	]	NN	O	O
.	ZYDELIG.xml:S3:2132:1	.	.	O	O

5.3	ZYDELIG.xml:S3:2143:3	5.3	CD	O	O
Pneumonitis	ZYDELIG.xml:S3:2147:11	pneumon	NN	O	O

Fatal	ZYDELIG.xml:S3:2164:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S3:2170:3	and	CC	O	O
serious	ZYDELIG.xml:S3:2174:7	seriou	JJ	O	O
pneumonitis	ZYDELIG.xml:S3:2182:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
occurred	ZYDELIG.xml:S3:2194:8	occur	VBD	O	O
in	ZYDELIG.xml:S3:2203:2	in	IN	O	O
patients	ZYDELIG.xml:S3:2206:8	patient	NNS	O	O
treated	ZYDELIG.xml:S3:2215:7	treat	VBN	O	O
with	ZYDELIG.xml:S3:2223:4	with	IN	O	O
Zydelig	ZYDELIG.xml:S3:2228:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S3:2235:1	.	.	O	O

Patients	ZYDELIG.xml:S3:2237:8	patient	NNS	O	O
taking	ZYDELIG.xml:S3:2246:6	take	VBG	O	O
Zydelig	ZYDELIG.xml:S3:2253:7	zydelig	NNP	O	O
who	ZYDELIG.xml:S3:2261:3	who	WP	O	O
present	ZYDELIG.xml:S3:2265:7	present	VBP	O	O
with	ZYDELIG.xml:S3:2273:4	with	IN	O	O
pulmonary	ZYDELIG.xml:S3:2278:9	pulmonari	JJ	O	O
symptoms	ZYDELIG.xml:S3:2288:8	symptom	NNS	O	O
such	ZYDELIG.xml:S3:2297:4	such	JJ	O	O
as	ZYDELIG.xml:S3:2302:2	as	IN	O	O
cough	ZYDELIG.xml:S3:2305:5	cough	NN	O	B-AdverseReaction
,	ZYDELIG.xml:S3:2310:1	,	,	O	O
dyspnea	ZYDELIG.xml:S3:2312:7	dyspnea	NN	O	B-AdverseReaction
,	ZYDELIG.xml:S3:2319:1	,	,	O	O
hypoxia	ZYDELIG.xml:S3:2321:7	hypoxia	NN	O	B-AdverseReaction
,	ZYDELIG.xml:S3:2328:1	,	,	O	O
interstitial	ZYDELIG.xml:S3:2330:12	interstiti	JJ	O	O
infiltrates	ZYDELIG.xml:S3:2343:11	infiltr	NNS	O	O
on	ZYDELIG.xml:S3:2355:2	on	IN	O	O
a	ZYDELIG.xml:S3:2358:1	a	DT	O	O
radiologic	ZYDELIG.xml:S3:2360:10	radiolog	JJ	O	O
exam	ZYDELIG.xml:S3:2371:4	exam	NN	O	O
,	ZYDELIG.xml:S3:2375:1	,	,	O	O
or	ZYDELIG.xml:S3:2377:2	or	CC	O	O
a	ZYDELIG.xml:S3:2380:1	a	DT	O	O
decline	ZYDELIG.xml:S3:2382:7	declin	NN	O	O
by	ZYDELIG.xml:S3:2390:2	by	IN	O	O
more	ZYDELIG.xml:S3:2393:4	more	JJR	O	O
than	ZYDELIG.xml:S3:2398:4	than	IN	O	O
5%	ZYDELIG.xml:S3:2403:2	5%	CD	O	O
in	ZYDELIG.xml:S3:2406:2	in	IN	O	O
oxygen	ZYDELIG.xml:S3:2409:6	oxygen	NN	O	O
saturation	ZYDELIG.xml:S3:2416:10	satur	NN	O	O
should	ZYDELIG.xml:S3:2427:6	should	MD	O	O
be	ZYDELIG.xml:S3:2434:2	be	VB	O	O
evaluated	ZYDELIG.xml:S3:2437:9	evalu	VBN	O	O
for	ZYDELIG.xml:S3:2447:3	for	IN	O	O
pneumonitis	ZYDELIG.xml:S3:2451:11	pneumon	NN	O	O
.	ZYDELIG.xml:S3:2462:1	.	.	O	O

If	ZYDELIG.xml:S3:2464:2	If	IN	O	O
pneumonitis	ZYDELIG.xml:S3:2467:11	pneumon	NN	O	O
is	ZYDELIG.xml:S3:2479:2	is	VBZ	O	O
suspected	ZYDELIG.xml:S3:2482:9	suspect	VBN	O	O
,	ZYDELIG.xml:S3:2491:1	,	,	O	O
interrupt	ZYDELIG.xml:S3:2493:9	interrupt	JJ	O	O
Zydelig	ZYDELIG.xml:S3:2503:7	zydelig	NNP	O	O
until	ZYDELIG.xml:S3:2511:5	until	IN	O	O
the	ZYDELIG.xml:S3:2517:3	the	DT	O	O
etiology	ZYDELIG.xml:S3:2521:8	etiolog	NN	O	O
of	ZYDELIG.xml:S3:2530:2	of	IN	O	O
the	ZYDELIG.xml:S3:2533:3	the	DT	O	O
pulmonary	ZYDELIG.xml:S3:2537:9	pulmonari	NN	O	O
symptoms	ZYDELIG.xml:S3:2547:8	symptom	NNS	O	O
has	ZYDELIG.xml:S3:2556:3	ha	VBZ	O	O
been	ZYDELIG.xml:S3:2560:4	been	VBN	O	O
determined	ZYDELIG.xml:S3:2565:10	determin	VBN	O	O
.	ZYDELIG.xml:S3:2575:1	.	.	O	O

Patients	ZYDELIG.xml:S3:2577:8	patient	NNS	O	O
with	ZYDELIG.xml:S3:2586:4	with	IN	O	O
pneumonitis	ZYDELIG.xml:S3:2591:11	pneumon	NN	O	O
thought	ZYDELIG.xml:S3:2603:7	thought	VBN	O	O
to	ZYDELIG.xml:S3:2611:2	to	TO	O	O
be	ZYDELIG.xml:S3:2614:2	be	VB	O	O
caused	ZYDELIG.xml:S3:2617:6	caus	VBN	O	O
by	ZYDELIG.xml:S3:2624:2	by	IN	O	O
Zydelig	ZYDELIG.xml:S3:2627:7	zydelig	NNP	O	O
have	ZYDELIG.xml:S3:2635:4	have	VBP	O	O
been	ZYDELIG.xml:S3:2640:4	been	VBN	O	O
treated	ZYDELIG.xml:S3:2645:7	treat	VBN	O	O
with	ZYDELIG.xml:S3:2653:4	with	IN	O	O
discontinuation	ZYDELIG.xml:S3:2658:15	discontinu	NN	O	O
of	ZYDELIG.xml:S3:2674:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S3:2677:7	zydelig	NNP	O	O
and	ZYDELIG.xml:S3:2685:3	and	CC	O	O
administration	ZYDELIG.xml:S3:2689:14	administr	NN	O	O
of	ZYDELIG.xml:S3:2704:2	of	IN	O	O
corticosteroids	ZYDELIG.xml:S3:2707:15	corticosteroid	NNS	O	O
.	ZYDELIG.xml:S3:2722:1	.	.	O	O

5.4	ZYDELIG.xml:S3:2731:3	5.4	CD	O	O
Intestinal	ZYDELIG.xml:S3:2735:10	intestin	JJ	O	O
Perforation	ZYDELIG.xml:S3:2746:11	perfor	NN	O	O

Fatal	ZYDELIG.xml:S3:2763:5	fatal	NNP	B-AdverseReaction	B-AdverseReaction
and	ZYDELIG.xml:S3:2769:3	and	CC	O	O
serious	ZYDELIG.xml:S3:2773:7	seriou	JJ	O	O
intestinal	ZYDELIG.xml:S3:2781:10	intestin	JJ	B-AdverseReaction	B-AdverseReaction
perforation	ZYDELIG.xml:S3:2792:11	perfor	NN	I-AdverseReaction	I-AdverseReaction
occurred	ZYDELIG.xml:S3:2804:8	occur	VBD	O	O
in	ZYDELIG.xml:S3:2813:2	in	IN	O	O
Zydelig	ZYDELIG.xml:S3:2816:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S3:2823:1	-	:	O	O
treated	ZYDELIG.xml:S3:2824:7	treat	VBD	O	O
patients	ZYDELIG.xml:S3:2832:8	patient	NNS	O	O
.	ZYDELIG.xml:S3:2840:1	.	.	O	O

At	ZYDELIG.xml:S3:2842:2	At	IN	O	O
the	ZYDELIG.xml:S3:2845:3	the	DT	O	O
time	ZYDELIG.xml:S3:2849:4	time	NN	O	O
of	ZYDELIG.xml:S3:2854:2	of	IN	O	O
perforation	ZYDELIG.xml:S3:2857:11	perfor	NN	O	O
,	ZYDELIG.xml:S3:2868:1	,	,	O	O
some	ZYDELIG.xml:S3:2870:4	some	DT	O	O
patients	ZYDELIG.xml:S3:2875:8	patient	NNS	O	O
had	ZYDELIG.xml:S3:2884:3	had	VBD	O	O
moderate	ZYDELIG.xml:S3:2888:8	moder	JJ	O	O
to	ZYDELIG.xml:S3:2897:2	to	TO	O	O
severe	ZYDELIG.xml:S3:2900:6	sever	VB	O	O
diarrhea	ZYDELIG.xml:S3:2907:8	diarrhea	NN	B-AdverseReaction	O
.	ZYDELIG.xml:S3:2915:1	.	.	O	O

Advise	ZYDELIG.xml:S3:2917:6	advis	NN	O	O
patients	ZYDELIG.xml:S3:2924:8	patient	NNS	O	O
to	ZYDELIG.xml:S3:2933:2	to	TO	O	O
promptly	ZYDELIG.xml:S3:2936:8	promptli	VB	O	O
report	ZYDELIG.xml:S3:2945:6	report	VB	O	O
any	ZYDELIG.xml:S3:2952:3	ani	DT	O	O
new	ZYDELIG.xml:S3:2956:3	new	JJ	O	O
or	ZYDELIG.xml:S3:2960:2	or	CC	O	O
worsening	ZYDELIG.xml:S3:2963:9	worsen	JJ	O	B-AdverseReaction
abdominal	ZYDELIG.xml:S3:2973:9	abdomin	JJ	O	I-AdverseReaction
pain	ZYDELIG.xml:S3:2983:4	pain	NN	O	I-AdverseReaction
,	ZYDELIG.xml:S3:2987:1	,	,	O	O
chills	ZYDELIG.xml:S3:2989:6	chill	NNS	O	B-AdverseReaction
,	ZYDELIG.xml:S3:2995:1	,	,	O	O
fever	ZYDELIG.xml:S3:2997:5	fever	NN	O	B-AdverseReaction
,	ZYDELIG.xml:S3:3002:1	,	,	O	O
nausea	ZYDELIG.xml:S3:3004:6	nausea	NN	O	B-AdverseReaction
,	ZYDELIG.xml:S3:3010:1	,	,	O	O
or	ZYDELIG.xml:S3:3012:2	or	CC	O	O
vomiting	ZYDELIG.xml:S3:3015:8	vomit	NN	O	B-AdverseReaction
.	ZYDELIG.xml:S3:3023:1	.	.	O	O

Discontinue	ZYDELIG.xml:S3:3025:11	discontinu	NNP	O	O
Zydelig	ZYDELIG.xml:S3:3037:7	zydelig	NNP	O	O
permanently	ZYDELIG.xml:S3:3045:11	perman	RB	O	O
in	ZYDELIG.xml:S3:3057:2	in	IN	O	O
patients	ZYDELIG.xml:S3:3060:8	patient	NNS	O	O
who	ZYDELIG.xml:S3:3069:3	who	WP	O	O
experience	ZYDELIG.xml:S3:3073:10	experi	VBP	O	O
intestinal	ZYDELIG.xml:S3:3084:10	intestin	JJ	O	O
perforation	ZYDELIG.xml:S3:3095:11	perfor	NN	O	O
.	ZYDELIG.xml:S3:3106:1	.	.	O	O

5.5	ZYDELIG.xml:S3:3115:3	5.5	CD	O	O
Severe	ZYDELIG.xml:S3:3119:6	sever	NNP	O	O
Cutaneous	ZYDELIG.xml:S3:3126:9	cutan	NNP	O	O
Reactions	ZYDELIG.xml:S3:3136:9	reaction	NNS	O	O

One	ZYDELIG.xml:S3:3151:3	one	CD	O	O
case	ZYDELIG.xml:S3:3155:4	case	NN	O	O
of	ZYDELIG.xml:S3:3160:2	of	IN	O	O
toxic	ZYDELIG.xml:S3:3163:5	toxic	NN	B-AdverseReaction	O
epidermal	ZYDELIG.xml:S3:3169:9	epiderm	JJ	I-AdverseReaction	O
necrolysis	ZYDELIG.xml:S3:3179:10	necrolysi	NN	I-AdverseReaction	O
(	ZYDELIG.xml:S3:3190:1	(	(	O	O
TEN	ZYDELIG.xml:S3:3191:3	ten	NNP	B-AdverseReaction	B-AdverseReaction
)	ZYDELIG.xml:S3:3194:1	)	)	O	O
occurred	ZYDELIG.xml:S3:3196:8	occur	VBD	O	O
in	ZYDELIG.xml:S3:3205:2	in	IN	O	O
a	ZYDELIG.xml:S3:3208:1	a	DT	O	O
study	ZYDELIG.xml:S3:3210:5	studi	NN	O	O
of	ZYDELIG.xml:S3:3216:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S3:3219:7	zydelig	NNP	O	O
in	ZYDELIG.xml:S3:3227:2	in	IN	O	O
combination	ZYDELIG.xml:S3:3230:11	combin	NN	O	O
with	ZYDELIG.xml:S3:3242:4	with	IN	O	O
rituximab	ZYDELIG.xml:S3:3247:9	rituximab	NN	O	O
and	ZYDELIG.xml:S3:3257:3	and	CC	O	O
bendamustine	ZYDELIG.xml:S3:3261:12	bendamustin	NN	O	O
.	ZYDELIG.xml:S3:3273:1	.	.	O	O

Other	ZYDELIG.xml:S3:3275:5	other	JJ	O	O
severe	ZYDELIG.xml:S3:3281:6	sever	JJ	O	O
or	ZYDELIG.xml:S3:3288:2	or	CC	O	O
life	ZYDELIG.xml:S3:3291:4	life	NN	O	O
-	ZYDELIG.xml:S3:3295:1	-	:	O	O
threatening	ZYDELIG.xml:S3:3296:11	threaten	NN	O	O
(	ZYDELIG.xml:S3:3308:1	(	(	O	O
Grade	ZYDELIG.xml:S3:3309:5	grade	NNP	O	O
3	ZYDELIG.xml:S3:3317:1	3	CD	O	O
)	ZYDELIG.xml:S3:3318:1	)	)	O	O
cutaneous	ZYDELIG.xml:S3:3320:9	cutan	JJ	B-AdverseReaction	O
reactions	ZYDELIG.xml:S3:3330:9	reaction	NNS	I-AdverseReaction	O
,	ZYDELIG.xml:S3:3339:1	,	,	O	O
including	ZYDELIG.xml:S3:3341:9	includ	VBG	O	O
dermatitis	ZYDELIG.xml:S3:3351:10	dermat	NN	B-AdverseReaction	B-AdverseReaction
exfoliative	ZYDELIG.xml:S3:3362:11	exfoli	NN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3373:1	,	,	O	O
rash	ZYDELIG.xml:S3:3375:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S3:3379:1	,	,	O	O
rash	ZYDELIG.xml:S3:3381:4	rash	VBP	B-AdverseReaction	B-AdverseReaction
erythematous	ZYDELIG.xml:S3:3386:12	erythemat	JJ	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3398:1	,	,	O	O
rash	ZYDELIG.xml:S3:3400:4	rash	JJ	B-AdverseReaction	B-AdverseReaction
generalized	ZYDELIG.xml:S3:3405:11	gener	VBN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3416:1	,	,	O	O
rash	ZYDELIG.xml:S3:3418:4	rash	VB	B-AdverseReaction	B-AdverseReaction
macular	ZYDELIG.xml:S3:3423:7	macular	NN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3430:1	,	,	O	O
rash	ZYDELIG.xml:S3:3432:4	rash	NN	B-AdverseReaction	B-AdverseReaction
maculo	ZYDELIG.xml:S3:3437:6	maculo	SYM	I-AdverseReaction	I-AdverseReaction
-	ZYDELIG.xml:S3:3443:1	-	:	I-AdverseReaction	I-AdverseReaction
papular	ZYDELIG.xml:S3:3444:7	papular	NN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3451:1	,	,	O	O
rash	ZYDELIG.xml:S3:3453:4	rash	NN	B-AdverseReaction	B-AdverseReaction
papular	ZYDELIG.xml:S3:3458:7	papular	NN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3465:1	,	,	O	O
rash	ZYDELIG.xml:S3:3467:4	rash	NN	B-AdverseReaction	B-AdverseReaction
pruritic	ZYDELIG.xml:S3:3472:8	prurit	NN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3480:1	,	,	O	O
exfoliative	ZYDELIG.xml:S3:3482:11	exfoli	JJ	B-AdverseReaction	B-AdverseReaction
rash	ZYDELIG.xml:S3:3494:4	rash	NN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3498:1	,	,	O	O
and	ZYDELIG.xml:S3:3500:3	and	CC	O	O
skin	ZYDELIG.xml:S3:3504:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
disorder	ZYDELIG.xml:S3:3509:8	disord	NN	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3517:1	,	,	O	O
have	ZYDELIG.xml:S3:3519:4	have	VBP	O	O
been	ZYDELIG.xml:S3:3524:4	been	VBN	O	O
reported	ZYDELIG.xml:S3:3529:8	report	VBN	O	O
in	ZYDELIG.xml:S3:3538:2	in	IN	O	O
Zydelig	ZYDELIG.xml:S3:3541:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S3:3548:1	-	:	O	O
treated	ZYDELIG.xml:S3:3549:7	treat	VBD	O	O
patients	ZYDELIG.xml:S3:3557:8	patient	NNS	O	O
.	ZYDELIG.xml:S3:3565:1	.	.	O	O

Monitor	ZYDELIG.xml:S3:3567:7	monitor	NN	O	O
patients	ZYDELIG.xml:S3:3575:8	patient	NNS	O	O
for	ZYDELIG.xml:S3:3584:3	for	IN	O	O
the	ZYDELIG.xml:S3:3588:3	the	DT	O	O
development	ZYDELIG.xml:S3:3592:11	develop	NN	O	O
of	ZYDELIG.xml:S3:3604:2	of	IN	O	O
severe	ZYDELIG.xml:S3:3607:6	sever	JJ	O	O
cutaneous	ZYDELIG.xml:S3:3614:9	cutan	JJ	O	B-AdverseReaction
reactions	ZYDELIG.xml:S3:3624:9	reaction	NNS	O	I-AdverseReaction
and	ZYDELIG.xml:S3:3634:3	and	CC	O	O
discontinue	ZYDELIG.xml:S3:3638:11	discontinu	NN	O	O
Zydelig	ZYDELIG.xml:S3:3650:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S3:3657:1	.	.	O	O

5.6	ZYDELIG.xml:S3:3666:3	5.6	CD	O	O
Anaphylaxis	ZYDELIG.xml:S3:3670:11	anaphylaxi	NNP	O	O

Serious	ZYDELIG.xml:S3:3687:7	seriou	JJ	O	O
allergic	ZYDELIG.xml:S3:3695:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
reactions	ZYDELIG.xml:S3:3704:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	ZYDELIG.xml:S3:3713:1	,	,	O	O
including	ZYDELIG.xml:S3:3715:9	includ	VBG	O	O
anaphylaxis	ZYDELIG.xml:S3:3725:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
,	ZYDELIG.xml:S3:3736:1	,	,	O	O
have	ZYDELIG.xml:S3:3738:4	have	VBP	O	O
been	ZYDELIG.xml:S3:3743:4	been	VBN	O	O
reported	ZYDELIG.xml:S3:3748:8	report	VBN	O	O
in	ZYDELIG.xml:S3:3757:2	in	IN	O	O
patients	ZYDELIG.xml:S3:3760:8	patient	NNS	O	O
on	ZYDELIG.xml:S3:3769:2	on	IN	O	O
Zydelig	ZYDELIG.xml:S3:3772:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S3:3779:1	.	.	O	O

In	ZYDELIG.xml:S3:3781:2	In	IN	O	O
patients	ZYDELIG.xml:S3:3784:8	patient	NNS	O	O
who	ZYDELIG.xml:S3:3793:3	who	WP	O	O
develop	ZYDELIG.xml:S3:3797:7	develop	VBP	O	O
serious	ZYDELIG.xml:S3:3805:7	seriou	JJ	O	O
allergic	ZYDELIG.xml:S3:3813:8	allerg	JJ	O	B-AdverseReaction
reactions	ZYDELIG.xml:S3:3822:9	reaction	NNS	O	I-AdverseReaction
,	ZYDELIG.xml:S3:3831:1	,	,	O	O
discontinue	ZYDELIG.xml:S3:3833:11	discontinu	VBP	O	O
Zydelig	ZYDELIG.xml:S3:3845:7	zydelig	NNP	O	O
permanently	ZYDELIG.xml:S3:3853:11	perman	RB	O	O
and	ZYDELIG.xml:S3:3865:3	and	CC	O	O
institute	ZYDELIG.xml:S3:3869:9	institut	VB	O	O
appropriate	ZYDELIG.xml:S3:3879:11	appropri	JJ	O	O
supportive	ZYDELIG.xml:S3:3891:10	support	JJ	O	O
measures	ZYDELIG.xml:S3:3902:8	measur	NNS	O	O
.	ZYDELIG.xml:S3:3910:1	.	.	O	O

5.7	ZYDELIG.xml:S3:3919:3	5.7	CD	O	O
Neutropenia	ZYDELIG.xml:S3:3923:11	neutropenia	NNP	O	O

Treatment	ZYDELIG.xml:S3:3940:9	treatment	NNP	O	O
-	ZYDELIG.xml:S3:3949:1	-	:	O	O
emergent	ZYDELIG.xml:S3:3950:8	emerg	NN	O	O
Grade	ZYDELIG.xml:S3:3959:5	grade	VBD	O	O
3	ZYDELIG.xml:S3:3965:1	3	CD	O	O
or	ZYDELIG.xml:S3:3967:2	or	CC	O	O
4	ZYDELIG.xml:S3:3970:1	4	CD	O	O
neutropenia	ZYDELIG.xml:S3:3972:11	neutropenia	NNS	B-AdverseReaction	B-AdverseReaction
occurred	ZYDELIG.xml:S3:3984:8	occur	VBD	O	O
in	ZYDELIG.xml:S3:3993:2	in	IN	O	O
31%	ZYDELIG.xml:S3:3996:3	31%	CD	O	O
of	ZYDELIG.xml:S3:4000:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S3:4003:7	zydelig	NNP	O	O
-	ZYDELIG.xml:S3:4010:1	-	:	O	O
treated	ZYDELIG.xml:S3:4011:7	treat	VBD	O	O
patients	ZYDELIG.xml:S3:4019:8	patient	NNS	O	O
across	ZYDELIG.xml:S3:4028:6	across	IN	O	O
clinical	ZYDELIG.xml:S3:4035:8	clinic	JJ	O	O
trials	ZYDELIG.xml:S3:4044:6	trial	NNS	O	O
[	ZYDELIG.xml:S3:4051:1	[	VBP	O	O
see	ZYDELIG.xml:S3:4052:3	see	VB	O	O
Adverse	ZYDELIG.xml:S3:4057:7	advers	JJ	O	O
Reactions	ZYDELIG.xml:S3:4065:9	reaction	NNP	O	O
(	ZYDELIG.xml:S3:4075:1	(	(	O	O
6.1	ZYDELIG.xml:S3:4076:3	6.1	CD	O	O
)	ZYDELIG.xml:S3:4079:1	)	)	O	O
]	ZYDELIG.xml:S3:4082:1	]	NN	O	O
.	ZYDELIG.xml:S3:4083:1	.	.	O	O

Monitor	ZYDELIG.xml:S3:4086:7	monitor	NNP	O	O
blood	ZYDELIG.xml:S3:4094:5	blood	NN	O	O
counts	ZYDELIG.xml:S3:4100:6	count	NNS	O	O
at	ZYDELIG.xml:S3:4107:2	at	IN	O	O
least	ZYDELIG.xml:S3:4110:5	least	JJS	O	O
every	ZYDELIG.xml:S3:4116:5	everi	DT	O	O
two	ZYDELIG.xml:S3:4122:3	two	CD	O	O
weeks	ZYDELIG.xml:S3:4126:5	week	NNS	O	O
for	ZYDELIG.xml:S3:4132:3	for	IN	O	O
the	ZYDELIG.xml:S3:4136:3	the	DT	O	O
first	ZYDELIG.xml:S3:4140:5	first	JJ	O	O
3	ZYDELIG.xml:S3:4146:1	3	CD	O	O
months	ZYDELIG.xml:S3:4148:6	month	NNS	O	O
of	ZYDELIG.xml:S3:4155:2	of	IN	O	O
therapy	ZYDELIG.xml:S3:4158:7	therapi	NN	O	O
,	ZYDELIG.xml:S3:4165:1	,	,	O	O
and	ZYDELIG.xml:S3:4167:3	and	CC	O	O
at	ZYDELIG.xml:S3:4171:2	at	IN	O	O
least	ZYDELIG.xml:S3:4174:5	least	JJS	O	O
weekly	ZYDELIG.xml:S3:4180:6	weekli	JJ	O	O
in	ZYDELIG.xml:S3:4187:2	in	IN	O	O
patients	ZYDELIG.xml:S3:4190:8	patient	NNS	O	O
while	ZYDELIG.xml:S3:4199:5	while	IN	O	O
neutrophil	ZYDELIG.xml:S3:4205:10	neutrophil	JJ	O	O
counts	ZYDELIG.xml:S3:4216:6	count	NNS	O	O
are	ZYDELIG.xml:S3:4223:3	are	VBP	O	O
less	ZYDELIG.xml:S3:4227:4	less	JJR	O	O
than	ZYDELIG.xml:S3:4232:4	than	IN	O	O
1.0	ZYDELIG.xml:S3:4237:3	1.0	CD	O	O
Gi	ZYDELIG.xml:S3:4241:2	Gi	NNP	O	O
L	ZYDELIG.xml:S3:4244:1	L	NNP	O	O
[	ZYDELIG.xml:S3:4246:1	[	NNP	O	O
see	ZYDELIG.xml:S3:4247:3	see	VBP	O	O
Dosage	ZYDELIG.xml:S3:4252:6	dosag	NNP	O	O
and	ZYDELIG.xml:S3:4259:3	and	CC	O	O
Administration	ZYDELIG.xml:S3:4263:14	administr	NNP	O	O
(	ZYDELIG.xml:S3:4278:1	(	(	O	O
2.2	ZYDELIG.xml:S3:4279:3	2.2	CD	O	O
)	ZYDELIG.xml:S3:4282:1	)	)	O	O
]	ZYDELIG.xml:S3:4285:1	]	NN	O	O
.	ZYDELIG.xml:S3:4286:1	.	.	O	O

5.8	ZYDELIG.xml:S3:4297:3	5.8	CD	O	O
Embryo	ZYDELIG.xml:S3:4301:6	embryo	NNP	O	O
-	ZYDELIG.xml:S3:4307:1	-	:	O	O
fetal	ZYDELIG.xml:S3:4308:5	fetal	JJ	O	O
Toxicity	ZYDELIG.xml:S3:4314:8	toxic	NN	O	O

Based	ZYDELIG.xml:S3:4328:5	base	VBN	O	O
on	ZYDELIG.xml:S3:4334:2	on	IN	O	O
findings	ZYDELIG.xml:S3:4337:8	find	NNS	O	O
in	ZYDELIG.xml:S3:4346:2	in	IN	O	O
animals	ZYDELIG.xml:S3:4349:7	anim	NNS	O	O
,	ZYDELIG.xml:S3:4356:1	,	,	O	O
Zydelig	ZYDELIG.xml:S3:4358:7	zydelig	NNP	O	O
may	ZYDELIG.xml:S3:4366:3	may	MD	O	O
cause	ZYDELIG.xml:S3:4370:5	caus	VB	O	O
fetal	ZYDELIG.xml:S3:4376:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	ZYDELIG.xml:S3:4382:4	harm	NN	I-AdverseReaction	I-AdverseReaction
when	ZYDELIG.xml:S3:4387:4	when	WRB	O	O
administered	ZYDELIG.xml:S3:4392:12	administ	VBN	O	O
to	ZYDELIG.xml:S3:4405:2	to	TO	O	O
a	ZYDELIG.xml:S3:4408:1	a	DT	O	O
pregnant	ZYDELIG.xml:S3:4410:8	pregnant	JJ	O	O
woman	ZYDELIG.xml:S3:4419:5	woman	NN	O	O
.	ZYDELIG.xml:S3:4424:1	.	.	O	O

Idelalisib	ZYDELIG.xml:S3:4426:10	idelalisib	NNP	O	O
is	ZYDELIG.xml:S3:4437:2	is	VBZ	O	O
teratogenic	ZYDELIG.xml:S3:4440:11	teratogen	JJ	B-AdverseReaction	B-AdverseReaction
in	ZYDELIG.xml:S3:4452:2	in	IN	O	O
rats	ZYDELIG.xml:S3:4455:4	rat	NNS	O	O
,	ZYDELIG.xml:S3:4459:1	,	,	O	O
at	ZYDELIG.xml:S3:4461:2	at	IN	O	O
systemic	ZYDELIG.xml:S3:4464:8	system	JJ	O	O
exposures	ZYDELIG.xml:S3:4473:9	exposur	NNS	O	O
12	ZYDELIG.xml:S3:4483:2	12	CD	O	O
times	ZYDELIG.xml:S3:4486:5	time	NNS	O	O
those	ZYDELIG.xml:S3:4492:5	those	DT	O	O
reported	ZYDELIG.xml:S3:4498:8	report	VBN	O	O
in	ZYDELIG.xml:S3:4507:2	in	IN	O	O
patients	ZYDELIG.xml:S3:4510:8	patient	NNS	O	O
at	ZYDELIG.xml:S3:4519:2	at	IN	O	O
the	ZYDELIG.xml:S3:4522:3	the	DT	O	O
recommended	ZYDELIG.xml:S3:4526:11	recommend	JJ	O	O
dose	ZYDELIG.xml:S3:4538:4	dose	NN	O	O
of	ZYDELIG.xml:S3:4543:2	of	IN	O	O
150	ZYDELIG.xml:S3:4546:3	150	CD	O	O
mg	ZYDELIG.xml:S3:4550:2	mg	JJ	O	O
twice	ZYDELIG.xml:S3:4553:5	twice	RB	O	O
daily	ZYDELIG.xml:S3:4559:5	daili	RB	O	O
.	ZYDELIG.xml:S3:4564:1	.	.	O	O

If	ZYDELIG.xml:S3:4566:2	If	IN	O	O
this	ZYDELIG.xml:S3:4569:4	thi	DT	O	O
drug	ZYDELIG.xml:S3:4574:4	drug	NN	O	O
is	ZYDELIG.xml:S3:4579:2	is	VBZ	O	O
used	ZYDELIG.xml:S3:4582:4	use	VBN	O	O
during	ZYDELIG.xml:S3:4587:6	dure	IN	O	O
pregnancy	ZYDELIG.xml:S3:4594:9	pregnanc	NN	O	O
,	ZYDELIG.xml:S3:4603:1	,	,	O	O
or	ZYDELIG.xml:S3:4605:2	or	CC	O	O
if	ZYDELIG.xml:S3:4608:2	if	IN	O	O
the	ZYDELIG.xml:S3:4611:3	the	DT	O	O
patient	ZYDELIG.xml:S3:4615:7	patient	NN	O	O
becomes	ZYDELIG.xml:S3:4623:7	becom	VBZ	O	O
pregnant	ZYDELIG.xml:S3:4631:8	pregnant	JJ	O	O
while	ZYDELIG.xml:S3:4640:5	while	IN	O	O
taking	ZYDELIG.xml:S3:4646:6	take	VBG	O	O
this	ZYDELIG.xml:S3:4653:4	thi	DT	O	O
drug	ZYDELIG.xml:S3:4658:4	drug	NN	O	O
,	ZYDELIG.xml:S3:4662:1	,	,	O	O
the	ZYDELIG.xml:S3:4664:3	the	DT	O	O
patient	ZYDELIG.xml:S3:4668:7	patient	NN	O	O
should	ZYDELIG.xml:S3:4676:6	should	MD	O	O
be	ZYDELIG.xml:S3:4683:2	be	VB	O	O
apprised	ZYDELIG.xml:S3:4686:8	appris	VBN	O	O
of	ZYDELIG.xml:S3:4695:2	of	IN	O	O
the	ZYDELIG.xml:S3:4698:3	the	DT	O	O
potential	ZYDELIG.xml:S3:4702:9	potenti	JJ	O	O
hazard	ZYDELIG.xml:S3:4712:6	hazard	NN	O	O
to	ZYDELIG.xml:S3:4719:2	to	TO	O	O
a	ZYDELIG.xml:S3:4722:1	a	DT	O	O
fetus	ZYDELIG.xml:S3:4724:5	fetu	NN	O	O
[	ZYDELIG.xml:S3:4730:1	[	NNP	O	O
see	ZYDELIG.xml:S3:4731:3	see	NN	O	O
Use	ZYDELIG.xml:S3:4736:3	use	NNP	O	O
in	ZYDELIG.xml:S3:4740:2	in	IN	O	O
Specific	ZYDELIG.xml:S3:4743:8	specif	NNP	O	O
Populations	ZYDELIG.xml:S3:4752:11	popul	NNP	O	O
(	ZYDELIG.xml:S3:4764:1	(	(	O	O
8.1	ZYDELIG.xml:S3:4765:3	8.1	CD	O	O
)	ZYDELIG.xml:S3:4768:1	)	)	O	O
]	ZYDELIG.xml:S3:4771:1	]	NN	O	O
.	ZYDELIG.xml:S3:4772:1	.	.	O	O

Advise	ZYDELIG.xml:S3:4780:6	advis	NNP	O	O
females	ZYDELIG.xml:S3:4787:7	femal	NNS	O	O
of	ZYDELIG.xml:S3:4795:2	of	IN	O	O
reproductive	ZYDELIG.xml:S3:4798:12	reproduct	JJ	O	O
potential	ZYDELIG.xml:S3:4811:9	potenti	NN	O	O
to	ZYDELIG.xml:S3:4821:2	to	TO	O	O
avoid	ZYDELIG.xml:S3:4824:5	avoid	VB	O	O
becoming	ZYDELIG.xml:S3:4830:8	becom	VBG	O	O
pregnant	ZYDELIG.xml:S3:4839:8	pregnant	JJ	O	O
while	ZYDELIG.xml:S3:4848:5	while	IN	O	O
taking	ZYDELIG.xml:S3:4854:6	take	VBG	O	O
Zydelig	ZYDELIG.xml:S3:4861:7	zydelig	NNP	O	O
.	ZYDELIG.xml:S3:4868:1	.	.	O	O

If	ZYDELIG.xml:S3:4870:2	If	IN	O	O
contraceptive	ZYDELIG.xml:S3:4873:13	contracept	JJ	O	O
methods	ZYDELIG.xml:S3:4887:7	method	NNS	O	O
are	ZYDELIG.xml:S3:4895:3	are	VBP	O	O
being	ZYDELIG.xml:S3:4899:5	be	VBG	O	O
considered	ZYDELIG.xml:S3:4905:10	consid	VBN	O	O
,	ZYDELIG.xml:S3:4915:1	,	,	O	O
use	ZYDELIG.xml:S3:4917:3	use	VBP	O	O
effective	ZYDELIG.xml:S3:4921:9	effect	JJ	O	O
contraception	ZYDELIG.xml:S3:4931:13	contracept	NN	O	O
during	ZYDELIG.xml:S3:4945:6	dure	IN	O	O
treatment	ZYDELIG.xml:S3:4952:9	treatment	NN	O	O
,	ZYDELIG.xml:S3:4961:1	,	,	O	O
and	ZYDELIG.xml:S3:4963:3	and	CC	O	O
for	ZYDELIG.xml:S3:4967:3	for	IN	O	O
at	ZYDELIG.xml:S3:4971:2	at	IN	O	O
least	ZYDELIG.xml:S3:4974:5	least	JJS	O	O
1	ZYDELIG.xml:S3:4980:1	1	CD	O	O
month	ZYDELIG.xml:S3:4982:5	month	NN	O	O
after	ZYDELIG.xml:S3:4988:5	after	IN	O	O
the	ZYDELIG.xml:S3:4994:3	the	DT	O	O
last	ZYDELIG.xml:S3:4998:4	last	JJ	O	O
dose	ZYDELIG.xml:S3:5003:4	dose	NN	O	O
of	ZYDELIG.xml:S3:5008:2	of	IN	O	O
Zydelig	ZYDELIG.xml:S3:5011:7	zydelig	NNP	O	O
[	ZYDELIG.xml:S3:5019:1	[	NNP	O	O
see	ZYDELIG.xml:S3:5020:3	see	VBP	O	O
Use	ZYDELIG.xml:S3:5025:3	use	NNP	O	O
in	ZYDELIG.xml:S3:5029:2	in	IN	O	O
Specific	ZYDELIG.xml:S3:5032:8	specif	NNP	O	O
Populations	ZYDELIG.xml:S3:5041:11	popul	NNP	O	O
(	ZYDELIG.xml:S3:5053:1	(	(	O	O
8.6	ZYDELIG.xml:S3:5054:3	8.6	CD	O	O
)	ZYDELIG.xml:S3:5057:1	)	)	O	O
]	ZYDELIG.xml:S3:5060:1	]	NN	O	O
.	ZYDELIG.xml:S3:5061:1	.	.	O	O
6	ZYKADIA.xml:S1:6:1	6	CD	O	O
ADVERSE	ZYKADIA.xml:S1:12:7	advers	JJ	O	O
REACTIONS	ZYKADIA.xml:S1:20:9	reaction	NN	O	O

The	ZYKADIA.xml:S1:35:3	the	DT	O	O
following	ZYKADIA.xml:S1:39:9	follow	JJ	O	O
adverse	ZYKADIA.xml:S1:49:7	advers	JJ	O	O
reactions	ZYKADIA.xml:S1:57:9	reaction	NNS	O	O
are	ZYKADIA.xml:S1:67:3	are	VBP	O	O
discussed	ZYKADIA.xml:S1:71:9	discuss	VBN	O	O
in	ZYKADIA.xml:S1:81:2	in	IN	O	O
greater	ZYKADIA.xml:S1:84:7	greater	JJR	O	O
detail	ZYKADIA.xml:S1:92:6	detail	NN	O	O
in	ZYKADIA.xml:S1:99:2	in	IN	O	O
other	ZYKADIA.xml:S1:102:5	other	JJ	O	O
sections	ZYKADIA.xml:S1:108:8	section	NNS	O	O
of	ZYKADIA.xml:S1:117:2	of	IN	O	O
the	ZYKADIA.xml:S1:120:3	the	DT	O	O
labeling	ZYKADIA.xml:S1:124:8	label	NN	O	O
:	ZYKADIA.xml:S1:132:1	:	:	O	O

Severe	ZYKADIA.xml:S1:141:6	sever	NNP	O	O
or	ZYKADIA.xml:S1:148:2	or	CC	O	O
Persistent	ZYKADIA.xml:S1:151:10	persist	NNP	O	O
Gastrointestinal	ZYKADIA.xml:S1:162:16	gastrointestin	NNP	B-AdverseReaction	O
Toxicity	ZYKADIA.xml:S1:179:8	toxic	NNP	I-AdverseReaction	O
[	ZYKADIA.xml:S1:188:1	[	NNP	O	O
see	ZYKADIA.xml:S1:189:3	see	VBP	O	O
Warnings	ZYKADIA.xml:S1:193:8	warn	NNP	O	O
and	ZYKADIA.xml:S1:202:3	and	CC	O	O
Precautions	ZYKADIA.xml:S1:206:11	precaut	NNP	O	O
(	ZYKADIA.xml:S1:218:1	(	(	O	O
5.1	ZYKADIA.xml:S1:219:3	5.1	CD	O	O
)]	ZYKADIA.xml:S1:222:2	)]	NN	O	O

Hepatotoxicity	ZYKADIA.xml:S1:231:14	hepatotox	NNP	B-AdverseReaction	B-AdverseReaction
[	ZYKADIA.xml:S1:246:1	[	NNP	O	O
see	ZYKADIA.xml:S1:247:3	see	VBP	O	O
Warnings	ZYKADIA.xml:S1:251:8	warn	NNP	O	O
and	ZYKADIA.xml:S1:260:3	and	CC	O	O
Precautions	ZYKADIA.xml:S1:264:11	precaut	NNP	O	O
(	ZYKADIA.xml:S1:276:1	(	(	O	O
5.2	ZYKADIA.xml:S1:277:3	5.2	CD	O	O
)]	ZYKADIA.xml:S1:280:2	)]	NN	O	O

Interstitial	ZYKADIA.xml:S1:289:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
Lung	ZYKADIA.xml:S1:302:4	lung	NNP	I-AdverseReaction	I-AdverseReaction
Disease	ZYKADIA.xml:S1:307:7	diseas	NNP	I-AdverseReaction	I-AdverseReaction
Pneumonitis	ZYKADIA.xml:S1:315:11	pneumon	NNP	B-AdverseReaction	I-AdverseReaction
[	ZYKADIA.xml:S1:327:1	[	NNP	O	O
see	ZYKADIA.xml:S1:328:3	see	VBP	O	O
Warnings	ZYKADIA.xml:S1:332:8	warn	NNP	O	O
and	ZYKADIA.xml:S1:341:3	and	CC	O	O
Precautions	ZYKADIA.xml:S1:345:11	precaut	NNP	O	O
(	ZYKADIA.xml:S1:357:1	(	(	O	O
5.3	ZYKADIA.xml:S1:358:3	5.3	CD	O	O
)]	ZYKADIA.xml:S1:361:2	)]	NN	O	O

QT	ZYKADIA.xml:S1:370:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
Interval	ZYKADIA.xml:S1:373:8	interv	NNP	I-AdverseReaction	I-AdverseReaction
Prolongation	ZYKADIA.xml:S1:382:12	prolong	NNP	I-AdverseReaction	I-AdverseReaction
[	ZYKADIA.xml:S1:395:1	[	NNP	O	O
see	ZYKADIA.xml:S1:396:3	see	VBP	O	O
Warnings	ZYKADIA.xml:S1:400:8	warn	NNP	O	O
and	ZYKADIA.xml:S1:409:3	and	CC	O	O
Precautions	ZYKADIA.xml:S1:413:11	precaut	NNP	O	O
(	ZYKADIA.xml:S1:425:1	(	(	O	O
5.4	ZYKADIA.xml:S1:426:3	5.4	CD	O	O
)	ZYKADIA.xml:S1:429:1	)	)	O	O
and	ZYKADIA.xml:S1:431:3	and	CC	O	O
Clinical	ZYKADIA.xml:S1:435:8	clinic	JJ	O	O
Pharmacology	ZYKADIA.xml:S1:444:12	pharmacolog	NNP	O	O
(	ZYKADIA.xml:S1:457:1	(	(	O	O
12.2	ZYKADIA.xml:S1:458:4	12.2	CD	O	O
)]	ZYKADIA.xml:S1:462:2	)]	NN	O	O

Hyperglycemia	ZYKADIA.xml:S1:471:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
[	ZYKADIA.xml:S1:485:1	[	NNP	O	O
see	ZYKADIA.xml:S1:486:3	see	VBP	O	O
Warnings	ZYKADIA.xml:S1:490:8	warn	NNP	O	O
and	ZYKADIA.xml:S1:499:3	and	CC	O	O
Precautions	ZYKADIA.xml:S1:503:11	precaut	NNP	O	O
(	ZYKADIA.xml:S1:515:1	(	(	O	O
5.5	ZYKADIA.xml:S1:516:3	5.5	CD	O	O
)]	ZYKADIA.xml:S1:519:2	)]	NN	O	O

Bradycardia	ZYKADIA.xml:S1:528:11	bradycardia	NNP	B-AdverseReaction	B-AdverseReaction
[	ZYKADIA.xml:S1:540:1	[	NNP	O	O
see	ZYKADIA.xml:S1:541:3	see	VBP	O	O
Warnings	ZYKADIA.xml:S1:545:8	warn	NNP	O	O
and	ZYKADIA.xml:S1:554:3	and	CC	O	O
Precautions	ZYKADIA.xml:S1:558:11	precaut	NNP	O	O
(	ZYKADIA.xml:S1:570:1	(	(	O	O
5.6	ZYKADIA.xml:S1:571:3	5.6	CD	O	O
)	ZYKADIA.xml:S1:574:1	)	)	O	O
and	ZYKADIA.xml:S1:576:3	and	CC	O	O
Clinical	ZYKADIA.xml:S1:580:8	clinic	JJ	O	O
Pharmacology	ZYKADIA.xml:S1:589:12	pharmacolog	NNP	O	O
(	ZYKADIA.xml:S1:602:1	(	(	O	O
12.2	ZYKADIA.xml:S1:603:4	12.2	CD	O	O
)]	ZYKADIA.xml:S1:607:2	)]	NN	O	O

Pancreatitis	ZYKADIA.xml:S1:616:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
[	ZYKADIA.xml:S1:629:1	[	NNP	O	O
see	ZYKADIA.xml:S1:630:3	see	VBP	O	O
Warnings	ZYKADIA.xml:S1:634:8	warn	NNP	O	O
and	ZYKADIA.xml:S1:643:3	and	CC	O	O
Precautions	ZYKADIA.xml:S1:647:11	precaut	NNP	O	O
(	ZYKADIA.xml:S1:659:1	(	(	O	O
5.7	ZYKADIA.xml:S1:660:3	5.7	CD	O	O
)]	ZYKADIA.xml:S1:663:2	)]	NN	O	O

EXCERPT	ZYKADIA.xml:S1:674:7	excerpt	NN	O	O
:	ZYKADIA.xml:S1:681:1	:	:	O	O
The	ZYKADIA.xml:S1:685:3	the	DT	O	O
most	ZYKADIA.xml:S1:689:4	most	RBS	O	O
common	ZYKADIA.xml:S1:694:6	common	JJ	O	O
adverse	ZYKADIA.xml:S1:701:7	advers	JJ	O	O
reactions	ZYKADIA.xml:S1:709:9	reaction	NNS	O	O
(	ZYKADIA.xml:S1:719:1	(	(	O	O
incidence	ZYKADIA.xml:S1:720:9	incid	NN	O	O
of	ZYKADIA.xml:S1:730:2	of	IN	O	O
at	ZYKADIA.xml:S1:733:2	at	IN	O	O
least	ZYKADIA.xml:S1:736:5	least	JJS	O	O
25%	ZYKADIA.xml:S1:742:3	25%	CD	O	O
)	ZYKADIA.xml:S1:745:1	)	)	O	O
are	ZYKADIA.xml:S1:747:3	are	VBP	O	O
diarrhea	ZYKADIA.xml:S1:751:8	diarrhea	JJ	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:759:1	,	,	O	O
nausea	ZYKADIA.xml:S1:761:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:767:1	,	,	O	O
elevated	ZYKADIA.xml:S1:769:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
transaminases	ZYKADIA.xml:S1:778:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:791:1	,	,	O	O
vomiting	ZYKADIA.xml:S1:793:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:801:1	,	,	O	O
abdominal	ZYKADIA.xml:S1:803:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ZYKADIA.xml:S1:813:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:817:1	,	,	O	O
fatigue	ZYKADIA.xml:S1:819:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:826:1	,	,	O	O
decreased	ZYKADIA.xml:S1:828:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	ZYKADIA.xml:S1:838:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:846:1	,	,	O	O
and	ZYKADIA.xml:S1:848:3	and	CC	O	O
constipation	ZYKADIA.xml:S1:852:12	constip	NN	B-AdverseReaction	B-AdverseReaction
.	ZYKADIA.xml:S1:864:1	.	.	O	O

(	ZYKADIA.xml:S1:866:1	(	(	O	O
6	ZYKADIA.xml:S1:869:1	6	CD	O	O
)	ZYKADIA.xml:S1:872:1	)	)	O	O

To	ZYKADIA.xml:S1:880:2	To	TO	O	O

report	ZYKADIA.xml:S1:883:6	report	NN	O	O
SUSPECTED	ZYKADIA.xml:S1:890:9	suspect	NNP	O	O
ADVERSE	ZYKADIA.xml:S1:900:7	advers	NNP	O	O
REACTIONS	ZYKADIA.xml:S1:908:9	reaction	NNP	O	O
,	ZYKADIA.xml:S1:917:1	,	,	O	O
contact	ZYKADIA.xml:S1:919:7	contact	NN	O	O
Novartis	ZYKADIA.xml:S1:927:8	novarti	NNP	O	O
Pharmaceuticals	ZYKADIA.xml:S1:936:15	pharmaceut	NNP	O	O
Corporation	ZYKADIA.xml:S1:952:11	corpor	NNP	O	O
at	ZYKADIA.xml:S1:964:2	at	IN	O	O
1	ZYKADIA.xml:S1:967:1	1	CD	O	O
-	ZYKADIA.xml:S1:968:1	-	:	O	O
888	ZYKADIA.xml:S1:969:3	888	CD	O	O
-	ZYKADIA.xml:S1:972:1	-	:	O	O
669	ZYKADIA.xml:S1:973:3	669	CD	O	O
-	ZYKADIA.xml:S1:976:1	-	:	O	O
6682	ZYKADIA.xml:S1:977:4	6682	CD	O	O
or	ZYKADIA.xml:S1:982:2	or	CC	O	O
FDA	ZYKADIA.xml:S1:985:3	fda	NNP	O	O
at	ZYKADIA.xml:S1:989:2	at	IN	O	O
1	ZYKADIA.xml:S1:992:1	1	CD	O	O
-	ZYKADIA.xml:S1:993:1	-	:	O	O
800	ZYKADIA.xml:S1:994:3	800	CD	O	O
-	ZYKADIA.xml:S1:997:1	-	:	O	O
FDA	ZYKADIA.xml:S1:998:3	fda	NNP	O	O
-	ZYKADIA.xml:S1:1001:1	-	:	O	O
1088	ZYKADIA.xml:S1:1002:4	1088	CD	O	O
or	ZYKADIA.xml:S1:1007:2	or	CC	O	O
www	ZYKADIA.xml:S1:1011:3	www	VB	O	O
.	ZYKADIA.xml:S1:1014:1	.	.	O	O
fda	ZYKADIA.xml:S1:1015:3	fda	NN	O	O
.	ZYKADIA.xml:S1:1018:1	.	.	O	O
gov	ZYKADIA.xml:S1:1019:3	gov	JJ	O	O
medwatch	ZYKADIA.xml:S1:1023:8	medwatch	NN	O	O
.	ZYKADIA.xml:S1:1033:1	.	.	O	O

6.1	ZYKADIA.xml:S1:1045:3	6.1	CD	O	O

Clinical	ZYKADIA.xml:S1:1053:8	clinic	JJ	O	O
Trials	ZYKADIA.xml:S1:1062:6	trial	NNS	O	O
Experience	ZYKADIA.xml:S1:1069:10	experi	NN	O	O

Because	ZYKADIA.xml:S1:1083:7	becaus	IN	O	O
clinical	ZYKADIA.xml:S1:1091:8	clinic	JJ	O	O
trials	ZYKADIA.xml:S1:1100:6	trial	NNS	O	O
are	ZYKADIA.xml:S1:1107:3	are	VBP	O	O
conducted	ZYKADIA.xml:S1:1111:9	conduct	VBN	O	O
under	ZYKADIA.xml:S1:1121:5	under	IN	O	O
widely	ZYKADIA.xml:S1:1127:6	wide	RB	O	O
varying	ZYKADIA.xml:S1:1134:7	vari	VBG	O	O
conditions	ZYKADIA.xml:S1:1142:10	condit	NNS	O	O
,	ZYKADIA.xml:S1:1152:1	,	,	O	O
adverse	ZYKADIA.xml:S1:1154:7	advers	JJ	O	O
reaction	ZYKADIA.xml:S1:1162:8	reaction	NN	O	O
rates	ZYKADIA.xml:S1:1171:5	rate	NNS	O	O
observed	ZYKADIA.xml:S1:1177:8	observ	VBD	O	O
in	ZYKADIA.xml:S1:1186:2	in	IN	O	O
the	ZYKADIA.xml:S1:1189:3	the	DT	O	O
clinical	ZYKADIA.xml:S1:1193:8	clinic	JJ	O	O
trials	ZYKADIA.xml:S1:1202:6	trial	NNS	O	O
of	ZYKADIA.xml:S1:1209:2	of	IN	O	O
a	ZYKADIA.xml:S1:1212:1	a	DT	O	O
drug	ZYKADIA.xml:S1:1214:4	drug	NN	O	O
cannot	ZYKADIA.xml:S1:1219:6	cannot	NN	O	O
be	ZYKADIA.xml:S1:1226:2	be	VB	O	O
directly	ZYKADIA.xml:S1:1229:8	directli	RB	O	O
compared	ZYKADIA.xml:S1:1238:8	compar	VBN	O	O
to	ZYKADIA.xml:S1:1247:2	to	TO	O	O
rates	ZYKADIA.xml:S1:1250:5	rate	NNS	O	O
in	ZYKADIA.xml:S1:1256:2	in	IN	O	O
the	ZYKADIA.xml:S1:1259:3	the	DT	O	O
clinical	ZYKADIA.xml:S1:1263:8	clinic	JJ	O	O
trials	ZYKADIA.xml:S1:1272:6	trial	NNS	O	O
of	ZYKADIA.xml:S1:1279:2	of	IN	O	O
another	ZYKADIA.xml:S1:1282:7	anoth	DT	O	O
drug	ZYKADIA.xml:S1:1290:4	drug	NN	O	O
and	ZYKADIA.xml:S1:1295:3	and	CC	O	O
may	ZYKADIA.xml:S1:1299:3	may	MD	O	O
not	ZYKADIA.xml:S1:1303:3	not	RB	O	O
reflect	ZYKADIA.xml:S1:1307:7	reflect	VB	O	O
the	ZYKADIA.xml:S1:1315:3	the	DT	O	O
rates	ZYKADIA.xml:S1:1319:5	rate	NNS	O	O
observed	ZYKADIA.xml:S1:1325:8	observ	VBD	O	O
in	ZYKADIA.xml:S1:1334:2	in	IN	O	O
practice	ZYKADIA.xml:S1:1337:8	practic	NN	O	O
.	ZYKADIA.xml:S1:1345:1	.	.	O	O

The	ZYKADIA.xml:S1:1351:3	the	DT	O	O
safety	ZYKADIA.xml:S1:1355:6	safeti	NN	O	O
evaluation	ZYKADIA.xml:S1:1362:10	evalu	NN	O	O
of	ZYKADIA.xml:S1:1373:2	of	IN	O	O
ZYKADIA	ZYKADIA.xml:S1:1376:7	zykadia	NNP	O	O
is	ZYKADIA.xml:S1:1384:2	is	VBZ	O	O
based	ZYKADIA.xml:S1:1387:5	base	VBN	O	O
on	ZYKADIA.xml:S1:1393:2	on	IN	O	O
255	ZYKADIA.xml:S1:1396:3	255	CD	O	O
ALK	ZYKADIA.xml:S1:1400:3	alk	NNP	O	O
-	ZYKADIA.xml:S1:1403:1	-	:	O	O
positive	ZYKADIA.xml:S1:1404:8	posit	JJ	O	O
patients	ZYKADIA.xml:S1:1413:8	patient	NNS	O	O
in	ZYKADIA.xml:S1:1422:2	in	IN	O	O
Study	ZYKADIA.xml:S1:1425:5	studi	NNP	O	O
1	ZYKADIA.xml:S1:1431:1	1	CD	O	O
(	ZYKADIA.xml:S1:1433:1	(	(	O	O
246	ZYKADIA.xml:S1:1434:3	246	CD	O	O
patients	ZYKADIA.xml:S1:1438:8	patient	NNS	O	O
with	ZYKADIA.xml:S1:1447:4	with	IN	O	O
NSCLC	ZYKADIA.xml:S1:1452:5	nsclc	NNP	O	O
and	ZYKADIA.xml:S1:1458:3	and	CC	O	O
9	ZYKADIA.xml:S1:1462:1	9	CD	O	O
patients	ZYKADIA.xml:S1:1464:8	patient	NNS	O	O
with	ZYKADIA.xml:S1:1473:4	with	IN	O	O
other	ZYKADIA.xml:S1:1478:5	other	JJ	O	O
cancers	ZYKADIA.xml:S1:1484:7	cancer	NNS	O	O
who	ZYKADIA.xml:S1:1492:3	who	WP	O	O
received	ZYKADIA.xml:S1:1496:8	receiv	VBD	O	O
ZYKADIA	ZYKADIA.xml:S1:1505:7	zykadia	NNP	O	O
at	ZYKADIA.xml:S1:1513:2	at	IN	O	O
a	ZYKADIA.xml:S1:1516:1	a	DT	O	O
dose	ZYKADIA.xml:S1:1518:4	dose	NN	O	O
of	ZYKADIA.xml:S1:1523:2	of	IN	O	O
750	ZYKADIA.xml:S1:1526:3	750	CD	O	O
mg	ZYKADIA.xml:S1:1530:2	mg	NNS	O	O
daily	ZYKADIA.xml:S1:1533:5	daili	RB	O	O
)	ZYKADIA.xml:S1:1538:1	)	)	O	O
.	ZYKADIA.xml:S1:1539:1	.	.	O	O

The	ZYKADIA.xml:S1:1541:3	the	DT	O	O
median	ZYKADIA.xml:S1:1545:6	median	JJ	O	O
duration	ZYKADIA.xml:S1:1552:8	durat	NN	O	O
of	ZYKADIA.xml:S1:1561:2	of	IN	O	O
exposure	ZYKADIA.xml:S1:1564:8	exposur	NN	O	O
to	ZYKADIA.xml:S1:1573:2	to	TO	O	O
ZYKADIA	ZYKADIA.xml:S1:1576:7	zykadia	NNP	O	O
was	ZYKADIA.xml:S1:1584:3	wa	VBD	O	O
6	ZYKADIA.xml:S1:1588:1	6	CD	O	O
months	ZYKADIA.xml:S1:1590:6	month	NNS	O	O
.	ZYKADIA.xml:S1:1596:1	.	.	O	O

The	ZYKADIA.xml:S1:1598:3	the	DT	O	O
study	ZYKADIA.xml:S1:1602:5	studi	NN	O	O
population	ZYKADIA.xml:S1:1608:10	popul	NN	O	O
characteristics	ZYKADIA.xml:S1:1619:15	characterist	NNS	O	O
were	ZYKADIA.xml:S1:1635:4	were	VBD	O	O
:	ZYKADIA.xml:S1:1639:1	:	:	O	O
median	ZYKADIA.xml:S1:1641:6	median	JJ	O	O
age	ZYKADIA.xml:S1:1648:3	age	NN	O	O
53	ZYKADIA.xml:S1:1652:2	53	CD	O	O
years	ZYKADIA.xml:S1:1655:5	year	NNS	O	O
,	ZYKADIA.xml:S1:1660:1	,	,	O	O
age	ZYKADIA.xml:S1:1662:3	age	NN	O	O
less	ZYKADIA.xml:S1:1666:4	less	JJR	O	O
than	ZYKADIA.xml:S1:1671:4	than	IN	O	O
65	ZYKADIA.xml:S1:1676:2	65	CD	O	O
(	ZYKADIA.xml:S1:1679:1	(	(	O	O
84%	ZYKADIA.xml:S1:1680:3	84%	CD	O	O
)	ZYKADIA.xml:S1:1683:1	)	)	O	O
,	ZYKADIA.xml:S1:1684:1	,	,	O	O
female	ZYKADIA.xml:S1:1686:6	femal	JJ	O	O
(	ZYKADIA.xml:S1:1693:1	(	(	O	O
53%	ZYKADIA.xml:S1:1694:3	53%	CD	O	O
)	ZYKADIA.xml:S1:1697:1	)	)	O	O
,	ZYKADIA.xml:S1:1698:1	,	,	O	O
Caucasian	ZYKADIA.xml:S1:1700:9	caucasian	NNP	O	O
(	ZYKADIA.xml:S1:1710:1	(	(	O	O
63%	ZYKADIA.xml:S1:1711:3	63%	CD	O	O
)	ZYKADIA.xml:S1:1714:1	)	)	O	O
,	ZYKADIA.xml:S1:1715:1	,	,	O	O
Asian	ZYKADIA.xml:S1:1717:5	asian	NNP	O	O
(	ZYKADIA.xml:S1:1723:1	(	(	O	O
34%	ZYKADIA.xml:S1:1724:3	34%	CD	O	O
)	ZYKADIA.xml:S1:1727:1	)	)	O	O
,	ZYKADIA.xml:S1:1728:1	,	,	O	O
NSCLC	ZYKADIA.xml:S1:1730:5	nsclc	NNP	O	B-AdverseReaction
adenocarcinoma	ZYKADIA.xml:S1:1736:14	adenocarcinoma	VBZ	O	I-AdverseReaction
histology	ZYKADIA.xml:S1:1751:9	histolog	NN	O	I-AdverseReaction
(	ZYKADIA.xml:S1:1761:1	(	(	O	O
90%	ZYKADIA.xml:S1:1762:3	90%	CD	O	O
)	ZYKADIA.xml:S1:1765:1	)	)	O	O
,	ZYKADIA.xml:S1:1766:1	,	,	O	O
never	ZYKADIA.xml:S1:1768:5	never	RB	O	O
or	ZYKADIA.xml:S1:1774:2	or	CC	O	O
former	ZYKADIA.xml:S1:1777:6	former	JJ	O	O
smoker	ZYKADIA.xml:S1:1784:6	smoker	NN	O	O
(	ZYKADIA.xml:S1:1791:1	(	(	O	O
97%	ZYKADIA.xml:S1:1792:3	97%	CD	O	O
)	ZYKADIA.xml:S1:1795:1	)	)	O	O
,	ZYKADIA.xml:S1:1796:1	,	,	O	O
ECOG	ZYKADIA.xml:S1:1798:4	ecog	NNP	O	O
PS	ZYKADIA.xml:S1:1803:2	PS	NNP	O	O
0	ZYKADIA.xml:S1:1806:1	0	CD	O	O
or	ZYKADIA.xml:S1:1808:2	or	CC	O	O
1	ZYKADIA.xml:S1:1811:1	1	CD	O	O
(	ZYKADIA.xml:S1:1813:1	(	(	O	O
89%	ZYKADIA.xml:S1:1814:3	89%	CD	O	O
)	ZYKADIA.xml:S1:1817:1	)	)	O	O
,	ZYKADIA.xml:S1:1818:1	,	,	O	O
brain	ZYKADIA.xml:S1:1820:5	brain	NN	O	O
metastasis	ZYKADIA.xml:S1:1826:10	metastasi	NN	O	O
(	ZYKADIA.xml:S1:1837:1	(	(	O	O
49%	ZYKADIA.xml:S1:1838:3	49%	CD	O	O
)	ZYKADIA.xml:S1:1841:1	)	)	O	O
,	ZYKADIA.xml:S1:1842:1	,	,	O	O
and	ZYKADIA.xml:S1:1844:3	and	CC	O	O
number	ZYKADIA.xml:S1:1848:6	number	NN	O	O
of	ZYKADIA.xml:S1:1855:2	of	IN	O	O
prior	ZYKADIA.xml:S1:1858:5	prior	JJ	O	O
therapies	ZYKADIA.xml:S1:1864:9	therapi	NNS	O	O
2	ZYKADIA.xml:S1:1874:1	2	CD	O	O
or	ZYKADIA.xml:S1:1876:2	or	CC	O	O
more	ZYKADIA.xml:S1:1879:4	more	JJR	O	O
(	ZYKADIA.xml:S1:1884:1	(	(	O	O
67%	ZYKADIA.xml:S1:1885:3	67%	CD	O	O
)	ZYKADIA.xml:S1:1888:1	)	)	O	O
.	ZYKADIA.xml:S1:1889:1	.	.	O	O

Dose	ZYKADIA.xml:S1:1895:4	dose	NNP	O	O
reductions	ZYKADIA.xml:S1:1900:10	reduct	NNS	O	O
due	ZYKADIA.xml:S1:1911:3	due	JJ	O	O
to	ZYKADIA.xml:S1:1915:2	to	TO	O	O
adverse	ZYKADIA.xml:S1:1918:7	advers	JJ	O	O
reactions	ZYKADIA.xml:S1:1926:9	reaction	NNS	O	O
occurred	ZYKADIA.xml:S1:1936:8	occur	VBD	O	O
in	ZYKADIA.xml:S1:1945:2	in	IN	O	O
59%	ZYKADIA.xml:S1:1948:3	59%	CD	O	O
of	ZYKADIA.xml:S1:1952:2	of	IN	O	O
patients	ZYKADIA.xml:S1:1955:8	patient	NNS	O	O
treated	ZYKADIA.xml:S1:1964:7	treat	VBN	O	O
with	ZYKADIA.xml:S1:1972:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S1:1977:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S1:1984:1	.	.	O	O

The	ZYKADIA.xml:S1:1986:3	the	DT	O	O
most	ZYKADIA.xml:S1:1990:4	most	RBS	O	O
frequent	ZYKADIA.xml:S1:1995:8	frequent	JJ	O	O
adverse	ZYKADIA.xml:S1:2004:7	advers	JJ	O	O
reactions	ZYKADIA.xml:S1:2012:9	reaction	NNS	O	O
,	ZYKADIA.xml:S1:2021:1	,	,	O	O
reported	ZYKADIA.xml:S1:2023:8	report	VBD	O	O
in	ZYKADIA.xml:S1:2032:2	in	IN	O	O
at	ZYKADIA.xml:S1:2035:2	at	IN	O	O
least	ZYKADIA.xml:S1:2038:5	least	JJS	O	O
10%	ZYKADIA.xml:S1:2044:3	10%	CD	O	O
of	ZYKADIA.xml:S1:2048:2	of	IN	O	O
patients	ZYKADIA.xml:S1:2051:8	patient	NNS	O	O
,	ZYKADIA.xml:S1:2059:1	,	,	O	O
that	ZYKADIA.xml:S1:2061:4	that	WDT	O	O
led	ZYKADIA.xml:S1:2066:3	led	VBD	O	O
to	ZYKADIA.xml:S1:2070:2	to	TO	O	O
dose	ZYKADIA.xml:S1:2073:4	dose	VB	O	O
reductions	ZYKADIA.xml:S1:2078:10	reduct	NNS	O	O
or	ZYKADIA.xml:S1:2089:2	or	CC	O	O
interruptions	ZYKADIA.xml:S1:2092:13	interrupt	NNS	O	O
were	ZYKADIA.xml:S1:2106:4	were	VBD	O	O
:	ZYKADIA.xml:S1:2110:1	:	:	O	O
increased	ZYKADIA.xml:S1:2112:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
ALT	ZYKADIA.xml:S1:2122:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S1:2126:1	(	(	O	O
29%	ZYKADIA.xml:S1:2127:3	29%	CD	O	O
)	ZYKADIA.xml:S1:2130:1	)	)	O	O
,	ZYKADIA.xml:S1:2131:1	,	,	O	O
nausea	ZYKADIA.xml:S1:2133:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
(	ZYKADIA.xml:S1:2140:1	(	(	O	O
20%	ZYKADIA.xml:S1:2141:3	20%	CD	O	O
)	ZYKADIA.xml:S1:2144:1	)	)	O	O
,	ZYKADIA.xml:S1:2145:1	,	,	O	O
increased	ZYKADIA.xml:S1:2147:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
AST	ZYKADIA.xml:S1:2157:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S1:2161:1	(	(	O	O
16%	ZYKADIA.xml:S1:2162:3	16%	CD	O	O
)	ZYKADIA.xml:S1:2165:1	)	)	O	O
,	ZYKADIA.xml:S1:2166:1	,	,	O	O
diarrhea	ZYKADIA.xml:S1:2168:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
(	ZYKADIA.xml:S1:2177:1	(	(	O	O
16%	ZYKADIA.xml:S1:2178:3	16%	CD	O	O
)	ZYKADIA.xml:S1:2181:1	)	)	O	O
,	ZYKADIA.xml:S1:2182:1	,	,	O	O
and	ZYKADIA.xml:S1:2184:3	and	CC	O	O
vomiting	ZYKADIA.xml:S1:2188:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
(	ZYKADIA.xml:S1:2197:1	(	(	O	O
16%	ZYKADIA.xml:S1:2198:3	16%	CD	O	O
)	ZYKADIA.xml:S1:2201:1	)	)	O	O
.	ZYKADIA.xml:S1:2202:1	.	.	O	O

Serious	ZYKADIA.xml:S1:2204:7	seriou	JJ	O	O
adverse	ZYKADIA.xml:S1:2212:7	advers	JJ	O	O
drug	ZYKADIA.xml:S1:2220:4	drug	NN	O	O
reactions	ZYKADIA.xml:S1:2225:9	reaction	NNS	O	O
reported	ZYKADIA.xml:S1:2235:8	report	VBN	O	O
in	ZYKADIA.xml:S1:2244:2	in	IN	O	O
2%	ZYKADIA.xml:S1:2247:2	2%	CD	O	O
or	ZYKADIA.xml:S1:2250:2	or	CC	O	O
more	ZYKADIA.xml:S1:2253:4	more	JJR	O	O
of	ZYKADIA.xml:S1:2258:2	of	IN	O	O
patients	ZYKADIA.xml:S1:2261:8	patient	NNS	O	O
in	ZYKADIA.xml:S1:2270:2	in	IN	O	O
Study	ZYKADIA.xml:S1:2273:5	studi	NNP	O	O
1	ZYKADIA.xml:S1:2279:1	1	CD	O	O
were	ZYKADIA.xml:S1:2281:4	were	VBD	O	O
convulsion	ZYKADIA.xml:S1:2286:10	convuls	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:2296:1	,	,	O	O
pneumonia	ZYKADIA.xml:S1:2298:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:2307:1	,	,	O	O
ILD	ZYKADIA.xml:S1:2309:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S1:2313:11	pneumon	NN	B-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:2324:1	,	,	O	O
dyspnea	ZYKADIA.xml:S1:2326:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:2333:1	,	,	O	O
dehydration	ZYKADIA.xml:S1:2335:11	dehydr	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:2346:1	,	,	O	O
hyperglycemia	ZYKADIA.xml:S1:2348:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:2361:1	,	,	O	O
and	ZYKADIA.xml:S1:2363:3	and	CC	O	O
nausea	ZYKADIA.xml:S1:2367:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
.	ZYKADIA.xml:S1:2373:1	.	.	O	O

Fatal	ZYKADIA.xml:S1:2375:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
adverse	ZYKADIA.xml:S1:2381:7	advers	JJ	O	O
reactions	ZYKADIA.xml:S1:2389:9	reaction	NNS	O	O
in	ZYKADIA.xml:S1:2399:2	in	IN	O	O
patients	ZYKADIA.xml:S1:2402:8	patient	NNS	O	O
treated	ZYKADIA.xml:S1:2411:7	treat	VBN	O	O
with	ZYKADIA.xml:S1:2419:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S1:2424:7	zykadia	NNP	O	O
occurred	ZYKADIA.xml:S1:2432:8	occur	VBD	O	O
in	ZYKADIA.xml:S1:2441:2	in	IN	O	O
5%	ZYKADIA.xml:S1:2444:2	5%	CD	O	O
of	ZYKADIA.xml:S1:2447:2	of	IN	O	O
patients	ZYKADIA.xml:S1:2450:8	patient	NNS	O	O
,	ZYKADIA.xml:S1:2458:1	,	,	O	O
consisting	ZYKADIA.xml:S1:2460:10	consist	VBG	O	O
of	ZYKADIA.xml:S1:2471:2	of	IN	O	O
:	ZYKADIA.xml:S1:2473:1	:	:	O	O
pneumonia	ZYKADIA.xml:S1:2475:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
(	ZYKADIA.xml:S1:2485:1	(	(	O	O
4	ZYKADIA.xml:S1:2486:1	4	CD	O	O
patients	ZYKADIA.xml:S1:2488:8	patient	NNS	O	O
)	ZYKADIA.xml:S1:2496:1	)	)	O	O
,	ZYKADIA.xml:S1:2497:1	,	,	O	O
respiratory	ZYKADIA.xml:S1:2499:11	respiratori	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZYKADIA.xml:S1:2511:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:2518:1	,	,	O	O
ILD	ZYKADIA.xml:S1:2520:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S1:2524:11	pneumon	NN	B-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:2535:1	,	,	O	O
pneumothorax	ZYKADIA.xml:S1:2537:12	pneumothorax	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:2549:1	,	,	O	O
gastric	ZYKADIA.xml:S1:2551:7	gastric	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	ZYKADIA.xml:S1:2559:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:2569:1	,	,	O	O
general	ZYKADIA.xml:S1:2571:7	gener	JJ	B-AdverseReaction	B-AdverseReaction
physical	ZYKADIA.xml:S1:2579:8	physic	JJ	I-AdverseReaction	I-AdverseReaction
health	ZYKADIA.xml:S1:2588:6	health	NN	I-AdverseReaction	I-AdverseReaction
deterioration	ZYKADIA.xml:S1:2595:13	deterior	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:2608:1	,	,	O	O
pulmonary	ZYKADIA.xml:S1:2610:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
tuberculosis	ZYKADIA.xml:S1:2620:12	tuberculosi	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:2632:1	,	,	O	O
cardiac	ZYKADIA.xml:S1:2634:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
tamponade	ZYKADIA.xml:S1:2642:9	tamponad	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:2651:1	,	,	O	O
and	ZYKADIA.xml:S1:2653:3	and	CC	O	O
sepsis	ZYKADIA.xml:S1:2657:6	sepsi	NN	B-AdverseReaction	B-AdverseReaction
(	ZYKADIA.xml:S1:2664:1	(	(	O	O
1	ZYKADIA.xml:S1:2665:1	1	CD	O	O
patient	ZYKADIA.xml:S1:2667:7	patient	NN	O	O
each	ZYKADIA.xml:S1:2675:4	each	DT	O	O
)	ZYKADIA.xml:S1:2679:1	)	)	O	O
.	ZYKADIA.xml:S1:2680:1	.	.	O	O

Discontinuation	ZYKADIA.xml:S1:2682:15	discontinu	NN	O	O
of	ZYKADIA.xml:S1:2698:2	of	IN	O	O
therapy	ZYKADIA.xml:S1:2701:7	therapi	NN	O	O
due	ZYKADIA.xml:S1:2709:3	due	JJ	O	O
to	ZYKADIA.xml:S1:2713:2	to	TO	O	O
adverse	ZYKADIA.xml:S1:2716:7	advers	JJ	O	O
reactions	ZYKADIA.xml:S1:2724:9	reaction	NNS	O	O
occurred	ZYKADIA.xml:S1:2734:8	occur	VBD	O	O
in	ZYKADIA.xml:S1:2743:2	in	IN	O	O
10%	ZYKADIA.xml:S1:2746:3	10%	CD	O	O
of	ZYKADIA.xml:S1:2750:2	of	IN	O	O
patients	ZYKADIA.xml:S1:2753:8	patient	NNS	O	O
treated	ZYKADIA.xml:S1:2762:7	treat	VBN	O	O
with	ZYKADIA.xml:S1:2770:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S1:2775:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S1:2782:1	.	.	O	O

The	ZYKADIA.xml:S1:2784:3	the	DT	O	O
most	ZYKADIA.xml:S1:2788:4	most	RBS	O	O
frequent	ZYKADIA.xml:S1:2793:8	frequent	JJ	O	O
adverse	ZYKADIA.xml:S1:2802:7	advers	JJ	O	O
drug	ZYKADIA.xml:S1:2810:4	drug	NN	O	O
reactions	ZYKADIA.xml:S1:2815:9	reaction	NNS	O	O
that	ZYKADIA.xml:S1:2825:4	that	WDT	O	O
led	ZYKADIA.xml:S1:2830:3	led	VBD	O	O
to	ZYKADIA.xml:S1:2834:2	to	TO	O	O
discontinuation	ZYKADIA.xml:S1:2837:15	discontinu	NN	O	O
in	ZYKADIA.xml:S1:2853:2	in	IN	O	O
1%	ZYKADIA.xml:S1:2856:2	1%	CD	O	O
or	ZYKADIA.xml:S1:2859:2	or	CC	O	O
more	ZYKADIA.xml:S1:2862:4	more	JJR	O	O
of	ZYKADIA.xml:S1:2867:2	of	IN	O	O
patients	ZYKADIA.xml:S1:2870:8	patient	NNS	O	O
in	ZYKADIA.xml:S1:2879:2	in	IN	O	O
Study	ZYKADIA.xml:S1:2882:5	studi	NNP	O	O
1	ZYKADIA.xml:S1:2888:1	1	CD	O	O
were	ZYKADIA.xml:S1:2890:4	were	VBD	O	O
pneumonia	ZYKADIA.xml:S1:2895:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:2904:1	,	,	O	O
ILD	ZYKADIA.xml:S1:2906:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S1:2910:11	pneumon	NN	B-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:2921:1	,	,	O	O
and	ZYKADIA.xml:S1:2923:3	and	CC	O	O
decreased	ZYKADIA.xml:S1:2927:9	decreas	VBD	B-AdverseReaction	B-AdverseReaction
appetite	ZYKADIA.xml:S1:2937:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
.	ZYKADIA.xml:S1:2945:1	.	.	O	O

Tables	ZYKADIA.xml:S1:2951:6	tabl	NNS	O	O
2	ZYKADIA.xml:S1:2958:1	2	CD	O	O
and	ZYKADIA.xml:S1:2960:3	and	CC	O	O
3	ZYKADIA.xml:S1:2964:1	3	CD	O	O
summarize	ZYKADIA.xml:S1:2966:9	summar	VBP	O	O
the	ZYKADIA.xml:S1:2976:3	the	DT	O	O
common	ZYKADIA.xml:S1:2980:6	common	JJ	O	O
adverse	ZYKADIA.xml:S1:2987:7	advers	JJ	O	O
reactions	ZYKADIA.xml:S1:2995:9	reaction	NNS	O	O
and	ZYKADIA.xml:S1:3005:3	and	CC	O	O
laboratory	ZYKADIA.xml:S1:3009:10	laboratori	NN	O	O
abnormalities	ZYKADIA.xml:S1:3020:13	abnorm	NNS	O	O
observed	ZYKADIA.xml:S1:3034:8	observ	VBN	O	O
in	ZYKADIA.xml:S1:3043:2	in	IN	O	O
ZYKADIA	ZYKADIA.xml:S1:3046:7	zykadia	NNP	O	O
-	ZYKADIA.xml:S1:3053:1	-	:	O	O
treated	ZYKADIA.xml:S1:3054:7	treat	VBD	O	O
patients	ZYKADIA.xml:S1:3062:8	patient	NNS	O	O
.	ZYKADIA.xml:S1:3070:1	.	.	O	O

Table	ZYKADIA.xml:S1:3076:5	tabl	JJ	O	O
2	ZYKADIA.xml:S1:3082:1	2	CD	O	O
:	ZYKADIA.xml:S1:3083:1	:	:	O	O
Adverse	ZYKADIA.xml:S1:3085:7	advers	JJ	O	O
Reactions	ZYKADIA.xml:S1:3093:9	reaction	NNP	O	O
(	ZYKADIA.xml:S1:3103:1	(	(	O	O
10%	ZYKADIA.xml:S1:3105:3	10%	CD	O	O
for	ZYKADIA.xml:S1:3109:3	for	IN	O	O
All	ZYKADIA.xml:S1:3113:3	all	DT	O	O
NCI	ZYKADIA.xml:S1:3117:3	nci	NNP	O	O
CTCAE	ZYKADIA.xml:S1:3121:5	ctcae	NNP	O	O
Grades	ZYKADIA.xml:S1:3128:6	grade	NNP	O	O
or	ZYKADIA.xml:S1:3135:2	or	CC	O	O
2%	ZYKADIA.xml:S1:3140:2	2%	CD	O	O
for	ZYKADIA.xml:S1:3143:3	for	IN	O	O
Grades	ZYKADIA.xml:S1:3147:6	grade	NNP	O	O
3	ZYKADIA.xml:S1:3154:1	3	CD	O	O
-	ZYKADIA.xml:S1:3155:1	-	:	O	O
4	ZYKADIA.xml:S1:3156:1	4	CD	O	O
)	ZYKADIA.xml:S1:3157:1	)	)	O	O
in	ZYKADIA.xml:S1:3159:2	in	IN	O	O
ALK	ZYKADIA.xml:S1:3162:3	alk	NNP	O	O
-	ZYKADIA.xml:S1:3165:1	-	:	O	O
Positive	ZYKADIA.xml:S1:3166:8	posit	JJ	O	O
Patients	ZYKADIA.xml:S1:3175:8	patient	NNS	O	O
Treated	ZYKADIA.xml:S1:3184:7	treat	VBN	O	O
with	ZYKADIA.xml:S1:3192:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S1:3197:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S1:3205:2	in	IN	O	O
Study	ZYKADIA.xml:S1:3208:5	studi	NNP	O	O
1	ZYKADIA.xml:S1:3214:1	1	CD	O	O

National	ZYKADIA.xml:S1:3219:8	nation	NNP	O	O
Cancer	ZYKADIA.xml:S1:3228:6	cancer	NNP	O	O
Institute	ZYKADIA.xml:S1:3235:9	institut	NNP	O	O
Common	ZYKADIA.xml:S1:3245:6	common	NNP	O	O
Terminology	ZYKADIA.xml:S1:3252:11	terminolog	NNP	O	O
Criteria	ZYKADIA.xml:S1:3264:8	criteria	NNP	O	O
for	ZYKADIA.xml:S1:3273:3	for	IN	O	O
Adverse	ZYKADIA.xml:S1:3277:7	advers	NNP	O	O
Events	ZYKADIA.xml:S1:3285:6	event	NNP	O	O
(	ZYKADIA.xml:S1:3292:1	(	(	O	O
version	ZYKADIA.xml:S1:3293:7	version	NN	O	O
4.03	ZYKADIA.xml:S1:3301:4	4.03	CD	O	O
)	ZYKADIA.xml:S1:3305:1	)	)	O	O
a	ZYKADIA.xml:S1:3308:1	a	DT	O	O
Abdominal	ZYKADIA.xml:S1:3311:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ZYKADIA.xml:S1:3321:4	pain	NN	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S1:3326:1	(	(	O	O
abdominal	ZYKADIA.xml:S1:3327:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ZYKADIA.xml:S1:3337:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:3341:1	,	,	O	O
upper	ZYKADIA.xml:S1:3343:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
abdominal	ZYKADIA.xml:S1:3349:9	abdomin	JJ	I-AdverseReaction	I-AdverseReaction
pain	ZYKADIA.xml:S1:3359:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:3363:1	,	,	O	O
abdominal	ZYKADIA.xml:S1:3365:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	ZYKADIA.xml:S1:3375:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:3385:1	,	,	O	O
epigastric	ZYKADIA.xml:S1:3387:10	epigastr	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	ZYKADIA.xml:S1:3398:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
)	ZYKADIA.xml:S1:3408:1	)	)	O	O
b	ZYKADIA.xml:S1:3411:1	b	NN	O	O
Esophageal	ZYKADIA.xml:S1:3414:10	esophag	NNP	B-AdverseReaction	O
disorder	ZYKADIA.xml:S1:3425:8	disord	NN	I-AdverseReaction	O
(	ZYKADIA.xml:S1:3434:1	(	(	O	O
dyspepsia	ZYKADIA.xml:S1:3435:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:3444:1	,	,	O	O
gastroesophageal	ZYKADIA.xml:S1:3446:16	gastroesophag	JJ	B-AdverseReaction	B-AdverseReaction
reflux	ZYKADIA.xml:S1:3463:6	reflux	NN	I-AdverseReaction	I-AdverseReaction
disease	ZYKADIA.xml:S1:3470:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:3477:1	,	,	O	O
dysphagia	ZYKADIA.xml:S1:3479:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
)	ZYKADIA.xml:S1:3488:1	)	)	O	O
c	ZYKADIA.xml:S1:3491:1	c	NN	O	O
Fatigue	ZYKADIA.xml:S1:3494:7	fatigu	NNP	B-AdverseReaction	O
(	ZYKADIA.xml:S1:3502:1	(	(	O	O
fatigue	ZYKADIA.xml:S1:3503:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:3510:1	,	,	O	O
asthenia	ZYKADIA.xml:S1:3512:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
)	ZYKADIA.xml:S1:3520:1	)	)	O	O
d	ZYKADIA.xml:S1:3523:1	d	NN	O	O
Rash	ZYKADIA.xml:S1:3526:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
(	ZYKADIA.xml:S1:3531:1	(	(	O	O
rash	ZYKADIA.xml:S1:3532:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:3536:1	,	,	O	O
maculopapular	ZYKADIA.xml:S1:3538:13	maculopapular	JJ	B-AdverseReaction	B-AdverseReaction
rash	ZYKADIA.xml:S1:3552:4	rash	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:3556:1	,	,	O	O
acneiform	ZYKADIA.xml:S1:3558:9	acneiform	VB	B-AdverseReaction	B-AdverseReaction
dermatitis	ZYKADIA.xml:S1:3568:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
)	ZYKADIA.xml:S1:3578:1	)	)	O	O

ZYKADIAN	ZYKADIA.xml:S1:3606:8	zykadian	NN	O	O

255	ZYKADIA.xml:S1:3615:3	255	CD	O	O

All	ZYKADIA.xml:S1:3644:3	all	DT	O	O
Grades	ZYKADIA.xml:S1:3648:6	grade	NNP	O	O
Grade	ZYKADIA.xml:S1:3661:5	grade	NNP	O	O
3	ZYKADIA.xml:S1:3667:1	3	CD	O	O
-	ZYKADIA.xml:S1:3668:1	-	:	O	O
4	ZYKADIA.xml:S1:3669:1	4	CD	O	O

Gastrointestinal	ZYKADIA.xml:S1:3735:16	gastrointestin	JJ	O	O

disorders	ZYKADIA.xml:S1:3752:9	disord	NNS	O	O

Diarrhea	ZYKADIA.xml:S1:3806:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
86	ZYKADIA.xml:S1:3819:2	86	CD	O	O
6	ZYKADIA.xml:S1:3836:1	6	CD	O	O

Nausea	ZYKADIA.xml:S1:3860:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
80	ZYKADIA.xml:S1:3873:2	80	CD	O	O
4	ZYKADIA.xml:S1:3890:1	4	CD	O	O

Vomiting	ZYKADIA.xml:S1:3914:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
60	ZYKADIA.xml:S1:3927:2	60	CD	O	O
4	ZYKADIA.xml:S1:3944:1	4	CD	O	O

Abdominal	ZYKADIA.xml:S1:3968:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	ZYKADIA.xml:S1:3978:4	pain	NN	I-AdverseReaction	I-AdverseReaction
a	ZYKADIA.xml:S1:3984:1	a	DT	O	O
54	ZYKADIA.xml:S1:3989:2	54	CD	O	O
2	ZYKADIA.xml:S1:4006:1	2	CD	O	O

Constipation	ZYKADIA.xml:S1:4030:12	constip	NN	B-AdverseReaction	B-AdverseReaction
29	ZYKADIA.xml:S1:4044:2	29	CD	O	O
0	ZYKADIA.xml:S1:4061:1	0	CD	O	O

Esophageal	ZYKADIA.xml:S1:4085:10	esophag	NNP	B-AdverseReaction	B-AdverseReaction
disorder	ZYKADIA.xml:S1:4096:8	disord	NN	I-AdverseReaction	I-AdverseReaction
b	ZYKADIA.xml:S1:4106:1	b	VBD	O	O
16	ZYKADIA.xml:S1:4111:2	16	CD	O	O
1	ZYKADIA.xml:S1:4128:1	1	CD	O	O

General	ZYKADIA.xml:S1:4150:7	gener	NNP	O	O
disorders	ZYKADIA.xml:S1:4158:9	disord	NNS	O	O
and	ZYKADIA.xml:S1:4168:3	and	CC	O	O
administration	ZYKADIA.xml:S1:4172:14	administr	NN	O	O
site	ZYKADIA.xml:S1:4187:4	site	NN	O	O
conditions	ZYKADIA.xml:S1:4192:10	condit	NNS	O	O

Fatigue	ZYKADIA.xml:S1:4247:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
c	ZYKADIA.xml:S1:4256:1	c	VBD	O	O
52	ZYKADIA.xml:S1:4261:2	52	CD	O	O
5	ZYKADIA.xml:S1:4278:1	5	CD	O	O

Metabolism	ZYKADIA.xml:S1:4300:10	metabol	NN	O	O
and	ZYKADIA.xml:S1:4311:3	and	CC	O	O
nutrition	ZYKADIA.xml:S1:4315:9	nutrit	NN	O	O
disorders	ZYKADIA.xml:S1:4325:9	disord	NNS	O	O

Decreased	ZYKADIA.xml:S1:4379:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	ZYKADIA.xml:S1:4389:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
34	ZYKADIA.xml:S1:4399:2	34	CD	O	O
1	ZYKADIA.xml:S1:4416:1	1	CD	O	O

Skin	ZYKADIA.xml:S1:4438:4	skin	NNP	O	O
and	ZYKADIA.xml:S1:4443:3	and	CC	O	O
subcutaneous	ZYKADIA.xml:S1:4447:12	subcutan	JJ	O	O
tissue	ZYKADIA.xml:S1:4460:6	tissu	NN	O	O
disorders	ZYKADIA.xml:S1:4467:9	disord	NNS	O	O

Rash	ZYKADIA.xml:S1:4521:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
d	ZYKADIA.xml:S1:4527:1	d	VBD	O	O
16	ZYKADIA.xml:S1:4534:2	16	CD	O	O
0	ZYKADIA.xml:S1:4551:1	0	CD	O	O

Respiratory	ZYKADIA.xml:S1:4573:11	respiratori	NNP	O	O
,	ZYKADIA.xml:S1:4584:1	,	,	O	O
thoracic	ZYKADIA.xml:S1:4586:8	thorac	NN	O	O
and	ZYKADIA.xml:S1:4595:3	and	CC	O	O
mediastinal	ZYKADIA.xml:S1:4599:11	mediastin	JJ	O	O
disorders	ZYKADIA.xml:S1:4611:9	disord	NNS	O	O

Interstitial	ZYKADIA.xml:S1:4665:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
lung	ZYKADIA.xml:S1:4678:4	lung	NN	I-AdverseReaction	I-AdverseReaction
disease	ZYKADIA.xml:S1:4683:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
pneumonitis	ZYKADIA.xml:S1:4691:11	pneumon	VBD	B-AdverseReaction	O
4	ZYKADIA.xml:S1:4704:1	4	CD	O	O
3	ZYKADIA.xml:S1:4721:1	3	CD	O	O

Additional	ZYKADIA.xml:S1:4749:10	addit	NNP	O	O
clinically	ZYKADIA.xml:S1:4760:10	clinic	RB	O	O
significant	ZYKADIA.xml:S1:4771:11	signific	JJ	O	O
adverse	ZYKADIA.xml:S1:4783:7	advers	JJ	O	O
reactions	ZYKADIA.xml:S1:4791:9	reaction	NNS	O	O
occurring	ZYKADIA.xml:S1:4801:9	occur	VBG	O	O
in	ZYKADIA.xml:S1:4811:2	in	IN	O	O
2%	ZYKADIA.xml:S1:4814:2	2%	CD	O	O
or	ZYKADIA.xml:S1:4817:2	or	CC	O	O
more	ZYKADIA.xml:S1:4820:4	more	JJR	O	O
of	ZYKADIA.xml:S1:4825:2	of	IN	O	O
patients	ZYKADIA.xml:S1:4828:8	patient	NNS	O	O
treated	ZYKADIA.xml:S1:4837:7	treat	VBN	O	O
with	ZYKADIA.xml:S1:4845:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S1:4850:7	zykadia	NNP	O	O
included	ZYKADIA.xml:S1:4858:8	includ	VBD	O	O
neuropathy	ZYKADIA.xml:S1:4867:10	neuropathi	JJ	B-AdverseReaction	B-AdverseReaction
(	ZYKADIA.xml:S1:4878:1	(	(	O	O
17%	ZYKADIA.xml:S1:4879:3	17%	CD	O	O
;	ZYKADIA.xml:S1:4882:1	;	:	O	O
comprised	ZYKADIA.xml:S1:4884:9	compris	VBN	O	O
of	ZYKADIA.xml:S1:4894:2	of	IN	O	O
paresthesia	ZYKADIA.xml:S1:4897:11	paresthesia	NN	B-AdverseReaction	O
,	ZYKADIA.xml:S1:4908:1	,	,	O	O
muscular	ZYKADIA.xml:S1:4910:8	muscular	JJ	B-AdverseReaction	B-AdverseReaction
weakness	ZYKADIA.xml:S1:4919:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:4927:1	,	,	O	O
gait	ZYKADIA.xml:S1:4929:4	gait	NN	B-AdverseReaction	B-AdverseReaction
disturbance	ZYKADIA.xml:S1:4934:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:4945:1	,	,	O	O
peripheral	ZYKADIA.xml:S1:4947:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
neuropathy	ZYKADIA.xml:S1:4958:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:4968:1	,	,	O	O
hypoesthesia	ZYKADIA.xml:S1:4970:12	hypoesthesia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:4982:1	,	,	O	O
peripheral	ZYKADIA.xml:S1:4984:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
sensory	ZYKADIA.xml:S1:4995:7	sensori	NN	I-AdverseReaction	I-AdverseReaction
neuropathy	ZYKADIA.xml:S1:5003:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:5013:1	,	,	O	O
dysesthesia	ZYKADIA.xml:S1:5015:11	dysesthesia	NN	B-AdverseReaction	O
,	ZYKADIA.xml:S1:5026:1	,	,	O	O
neuralgia	ZYKADIA.xml:S1:5028:9	neuralgia	RB	B-AdverseReaction	O
,	ZYKADIA.xml:S1:5037:1	,	,	O	O
peripheral	ZYKADIA.xml:S1:5039:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
motor	ZYKADIA.xml:S1:5050:5	motor	NN	I-AdverseReaction	I-AdverseReaction
neuropathy	ZYKADIA.xml:S1:5056:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:5066:1	,	,	O	O
hypotonia	ZYKADIA.xml:S1:5068:9	hypotonia	NN	B-AdverseReaction	O
,	ZYKADIA.xml:S1:5077:1	,	,	O	O
or	ZYKADIA.xml:S1:5079:2	or	CC	O	O
polyneuropathy	ZYKADIA.xml:S1:5082:14	polyneuropathi	NN	B-AdverseReaction	O
)	ZYKADIA.xml:S1:5096:1	)	)	O	O
,	ZYKADIA.xml:S1:5097:1	,	,	O	O
vision	ZYKADIA.xml:S1:5099:6	vision	NN	B-AdverseReaction	B-AdverseReaction
disorder	ZYKADIA.xml:S1:5106:8	disord	NN	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S1:5115:1	(	(	O	O
9%	ZYKADIA.xml:S1:5116:2	9%	CD	O	O
;	ZYKADIA.xml:S1:5118:1	;	:	O	O
comprised	ZYKADIA.xml:S1:5120:9	compris	VBN	O	O
of	ZYKADIA.xml:S1:5130:2	of	IN	O	O
vision	ZYKADIA.xml:S1:5133:6	vision	NN	B-AdverseReaction	B-AdverseReaction
impairment	ZYKADIA.xml:S1:5140:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:5150:1	,	,	O	O
blurred	ZYKADIA.xml:S1:5152:7	blur	VBN	B-AdverseReaction	B-AdverseReaction
vision	ZYKADIA.xml:S1:5160:6	vision	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:5166:1	,	,	O	O
photopsia	ZYKADIA.xml:S1:5168:9	photopsia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S1:5177:1	,	,	O	O
accommodation	ZYKADIA.xml:S1:5179:13	accommod	NN	B-AdverseReaction	B-AdverseReaction
disorder	ZYKADIA.xml:S1:5193:8	disord	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S1:5201:1	,	,	O	O
presbyopia	ZYKADIA.xml:S1:5203:10	presbyopia	NN	B-AdverseReaction	O
,	ZYKADIA.xml:S1:5213:1	,	,	O	O
or	ZYKADIA.xml:S1:5215:2	or	CC	O	O
reduced	ZYKADIA.xml:S1:5218:7	reduc	VBN	B-AdverseReaction	B-AdverseReaction
visual	ZYKADIA.xml:S1:5226:6	visual	JJ	I-AdverseReaction	I-AdverseReaction
acuity	ZYKADIA.xml:S1:5233:6	acuiti	NN	I-AdverseReaction	I-AdverseReaction
)	ZYKADIA.xml:S1:5239:1	)	)	O	O
,	ZYKADIA.xml:S1:5240:1	,	,	O	O
prolonged	ZYKADIA.xml:S1:5242:9	prolong	VBD	B-AdverseReaction	B-AdverseReaction
QT	ZYKADIA.xml:S1:5252:2	QT	NNP	I-AdverseReaction	I-AdverseReaction
interval	ZYKADIA.xml:S1:5255:8	interv	NN	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S1:5264:1	(	(	O	O
4%	ZYKADIA.xml:S1:5265:2	4%	CD	O	O
)	ZYKADIA.xml:S1:5267:1	)	)	O	O
,	ZYKADIA.xml:S1:5268:1	,	,	O	O
and	ZYKADIA.xml:S1:5270:3	and	CC	O	O
bradycardia	ZYKADIA.xml:S1:5274:11	bradycardia	NN	B-AdverseReaction	B-AdverseReaction
(	ZYKADIA.xml:S1:5286:1	(	(	O	O
3%	ZYKADIA.xml:S1:5287:2	3%	CD	O	O
)	ZYKADIA.xml:S1:5289:1	)	)	O	O
.	ZYKADIA.xml:S1:5290:1	.	.	O	O

Table	ZYKADIA.xml:S1:5296:5	tabl	NN	O	O

3	ZYKADIA.xml:S1:5302:1	3	CD	O	O
:	ZYKADIA.xml:S1:5303:1	:	:	O	O
Key	ZYKADIA.xml:S1:5305:3	key	NNP	O	O
Laboratory	ZYKADIA.xml:S1:5309:10	laboratori	NNP	O	O
Abnormalities	ZYKADIA.xml:S1:5320:13	abnorm	NNP	O	O
Occurring	ZYKADIA.xml:S1:5334:9	occur	NNP	O	O
in	ZYKADIA.xml:S1:5344:2	in	IN	O	O
10%	ZYKADIA.xml:S1:5348:3	10%	CD	O	O
(	ZYKADIA.xml:S1:5352:1	(	(	O	O
All	ZYKADIA.xml:S1:5353:3	all	DT	O	O
NCI	ZYKADIA.xml:S1:5357:3	nci	NNP	O	O
CTCAE	ZYKADIA.xml:S1:5361:5	ctcae	NNP	O	O
Grades	ZYKADIA.xml:S1:5367:6	grade	NNP	O	O
)	ZYKADIA.xml:S1:5373:1	)	)	O	O
of	ZYKADIA.xml:S1:5375:2	of	IN	O	O
ALK	ZYKADIA.xml:S1:5378:3	alk	NNP	O	O
-	ZYKADIA.xml:S1:5381:1	-	:	O	O
Positive	ZYKADIA.xml:S1:5382:8	posit	JJ	O	O
Patients	ZYKADIA.xml:S1:5391:8	patient	NNS	O	O
Treated	ZYKADIA.xml:S1:5400:7	treat	VBN	O	O
with	ZYKADIA.xml:S1:5408:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S1:5413:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S1:5421:2	in	IN	O	O
Study	ZYKADIA.xml:S1:5424:5	studi	NNP	O	O
1	ZYKADIA.xml:S1:5430:1	1	CD	O	O

ZYKADIAN	ZYKADIA.xml:S1:5453:8	zykadian	$	O	B-AdverseReaction
255	ZYKADIA.xml:S1:5462:3	255	CD	O	O

All	ZYKADIA.xml:S1:5491:3	all	DT	O	O
Grades	ZYKADIA.xml:S1:5495:6	grade	NNP	O	O
Grade	ZYKADIA.xml:S1:5508:5	grade	NNP	O	O
3	ZYKADIA.xml:S1:5514:1	3	CD	O	O
-	ZYKADIA.xml:S1:5515:1	-	:	O	O
4	ZYKADIA.xml:S1:5516:1	4	CD	O	O

Hemoglobin	ZYKADIA.xml:S1:5584:10	hemoglobin	NN	B-AdverseReaction	B-AdverseReaction

decreased	ZYKADIA.xml:S1:5595:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
84	ZYKADIA.xml:S1:5606:2	84	CD	O	O
5	ZYKADIA.xml:S1:5623:1	5	CD	O	O

Alanine	ZYKADIA.xml:S1:5647:7	alanin	NNP	B-AdverseReaction	B-AdverseReaction
transaminase	ZYKADIA.xml:S1:5655:12	transaminas	NN	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S1:5668:1	(	(	O	O
ALT	ZYKADIA.xml:S1:5669:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
)	ZYKADIA.xml:S1:5672:1	)	)	O	O
increased	ZYKADIA.xml:S1:5674:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
80	ZYKADIA.xml:S1:5685:2	80	CD	O	O
27	ZYKADIA.xml:S1:5702:2	27	CD	O	O

Aspartate	ZYKADIA.xml:S1:5726:9	aspart	NNP	B-AdverseReaction	B-AdverseReaction
transaminase	ZYKADIA.xml:S1:5736:12	transaminas	NN	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S1:5749:1	(	(	O	O
AST	ZYKADIA.xml:S1:5750:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
)	ZYKADIA.xml:S1:5753:1	)	)	O	O
increased	ZYKADIA.xml:S1:5755:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
75	ZYKADIA.xml:S1:5766:2	75	CD	O	O
13	ZYKADIA.xml:S1:5783:2	13	CD	O	O

Creatinine	ZYKADIA.xml:S1:5807:10	creatinin	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZYKADIA.xml:S1:5818:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
58	ZYKADIA.xml:S1:5829:2	58	CD	O	O
2	ZYKADIA.xml:S1:5846:1	2	CD	O	O

Glucose	ZYKADIA.xml:S1:5870:7	glucos	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZYKADIA.xml:S1:5878:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
49	ZYKADIA.xml:S1:5889:2	49	CD	O	O
13	ZYKADIA.xml:S1:5906:2	13	CD	O	O

Phosphate	ZYKADIA.xml:S1:5930:9	phosphat	NNP	B-AdverseReaction	B-AdverseReaction
decreased	ZYKADIA.xml:S1:5940:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
36	ZYKADIA.xml:S1:5951:2	36	CD	O	O
7	ZYKADIA.xml:S1:5968:1	7	CD	O	O

Lipase	ZYKADIA.xml:S1:5992:6	lipas	NNP	B-AdverseReaction	B-AdverseReaction
increased	ZYKADIA.xml:S1:5999:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
28	ZYKADIA.xml:S1:6010:2	28	CD	O	O
10	ZYKADIA.xml:S1:6027:2	10	CD	O	O

Bilirubin	ZYKADIA.xml:S1:6051:9	bilirubin	NNP	B-AdverseReaction	O
(	ZYKADIA.xml:S1:6061:1	(	(	O	O
total	ZYKADIA.xml:S1:6062:5	total	JJ	I-AdverseReaction	O
)	ZYKADIA.xml:S1:6067:1	)	)	O	O
increased	ZYKADIA.xml:S1:6069:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
15	ZYKADIA.xml:S1:6080:2	15	CD	O	O
1	ZYKADIA.xml:S1:6097:1	1	CD	O	O
5	ZYKADIA.xml:S2:4:1	5	CD	O	O
WARNINGS	ZYKADIA.xml:S2:10:8	warn	NNP	O	O
AND	ZYKADIA.xml:S2:19:3	and	NNP	O	O
PRECAUTIONS	ZYKADIA.xml:S2:23:11	precaut	NNP	O	O

EXCERPT	ZYKADIA.xml:S2:41:7	excerpt	NN	O	O
:	ZYKADIA.xml:S2:48:1	:	:	O	O
Severe	ZYKADIA.xml:S2:57:6	sever	JJ	O	O
or	ZYKADIA.xml:S2:64:2	or	CC	O	O
Persistent	ZYKADIA.xml:S2:67:10	persist	JJ	O	O
Gastrointestinal	ZYKADIA.xml:S2:78:16	gastrointestin	JJ	O	O
Toxicity	ZYKADIA.xml:S2:95:8	toxic	NN	O	O
:	ZYKADIA.xml:S2:104:1	:	:	O	O
Dose	ZYKADIA.xml:S2:106:4	dose	JJ	O	O
modification	ZYKADIA.xml:S2:111:12	modif	NN	O	O
due	ZYKADIA.xml:S2:124:3	due	JJ	O	O
to	ZYKADIA.xml:S2:128:2	to	TO	O	O
diarrhea	ZYKADIA.xml:S2:131:8	diarrhea	VB	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:139:1	,	,	O	O
nausea	ZYKADIA.xml:S2:141:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:147:1	,	,	O	O
vomiting	ZYKADIA.xml:S2:149:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
or	ZYKADIA.xml:S2:158:2	or	CC	O	O
abdominal	ZYKADIA.xml:S2:161:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ZYKADIA.xml:S2:171:4	pain	NN	I-AdverseReaction	I-AdverseReaction
occurred	ZYKADIA.xml:S2:176:8	occur	VBD	O	O
in	ZYKADIA.xml:S2:185:2	in	IN	O	O
38%	ZYKADIA.xml:S2:188:3	38%	CD	O	O
of	ZYKADIA.xml:S2:192:2	of	IN	O	O
patients	ZYKADIA.xml:S2:195:8	patient	NNS	O	O
.	ZYKADIA.xml:S2:203:1	.	.	O	O

Withhold	ZYKADIA.xml:S2:205:8	withhold	VB	O	O
if	ZYKADIA.xml:S2:214:2	if	IN	O	O
not	ZYKADIA.xml:S2:217:3	not	RB	O	O
responsive	ZYKADIA.xml:S2:221:10	respons	JJ	O	O
to	ZYKADIA.xml:S2:232:2	to	TO	O	O
anti	ZYKADIA.xml:S2:235:4	anti	VB	O	O
-	ZYKADIA.xml:S2:239:1	-	:	O	O
emetics	ZYKADIA.xml:S2:240:7	emet	NNS	O	O
or	ZYKADIA.xml:S2:248:2	or	CC	O	O
anti	ZYKADIA.xml:S2:251:4	anti	VB	O	O
-	ZYKADIA.xml:S2:255:1	-	:	O	O
diarrheals	ZYKADIA.xml:S2:256:10	diarrheal	NNS	O	O
,	ZYKADIA.xml:S2:266:1	,	,	O	O
then	ZYKADIA.xml:S2:268:4	then	RB	O	O
dose	ZYKADIA.xml:S2:273:4	dose	VB	O	O
reduce	ZYKADIA.xml:S2:278:6	reduc	VB	O	O
ZYKADIA	ZYKADIA.xml:S2:285:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:292:1	.	.	O	O

(	ZYKADIA.xml:S2:294:1	(	(	O	O
2.2	ZYKADIA.xml:S2:297:3	2.2	CD	O	O
,	ZYKADIA.xml:S2:302:1	,	,	O	O
5.1	ZYKADIA.xml:S2:305:3	5.1	CD	O	O
)	ZYKADIA.xml:S2:310:1	)	)	O	O

Hepatotoxicity	ZYKADIA.xml:S2:318:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
:	ZYKADIA.xml:S2:333:1	:	:	O	O
ZYKADIA	ZYKADIA.xml:S2:335:7	zykadia	NNP	O	O
can	ZYKADIA.xml:S2:343:3	can	MD	O	O
cause	ZYKADIA.xml:S2:347:5	caus	VB	O	O
hepatotoxicity	ZYKADIA.xml:S2:353:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
.	ZYKADIA.xml:S2:367:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:369:7	monitor	NNP	O	O
liver	ZYKADIA.xml:S2:377:5	liver	JJ	O	O
laboratory	ZYKADIA.xml:S2:383:10	laboratori	NN	O	O
tests	ZYKADIA.xml:S2:394:5	test	NNS	O	O
at	ZYKADIA.xml:S2:400:2	at	IN	O	O
least	ZYKADIA.xml:S2:403:5	least	JJS	O	O
monthly	ZYKADIA.xml:S2:409:7	monthli	JJ	O	O
.	ZYKADIA.xml:S2:416:1	.	.	O	O

Withhold	ZYKADIA.xml:S2:418:8	withhold	NNP	O	O
then	ZYKADIA.xml:S2:427:4	then	RB	O	O
dose	ZYKADIA.xml:S2:432:4	dose	VBD	O	O
reduce	ZYKADIA.xml:S2:437:6	reduc	VB	O	O
,	ZYKADIA.xml:S2:443:1	,	,	O	O
or	ZYKADIA.xml:S2:445:2	or	CC	O	O
permanently	ZYKADIA.xml:S2:448:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:460:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:472:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:479:1	.	.	O	O

(	ZYKADIA.xml:S2:481:1	(	(	O	O
2.2	ZYKADIA.xml:S2:484:3	2.2	CD	O	O
,	ZYKADIA.xml:S2:489:1	,	,	O	O
5.2	ZYKADIA.xml:S2:492:3	5.2	CD	O	O
)	ZYKADIA.xml:S2:497:1	)	)	O	O

Interstitial	ZYKADIA.xml:S2:505:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
Lung	ZYKADIA.xml:S2:518:4	lung	NNP	I-AdverseReaction	I-AdverseReaction
Disease	ZYKADIA.xml:S2:523:7	diseas	NNP	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S2:531:1	(	(	O	O
ILD	ZYKADIA.xml:S2:532:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
)	ZYKADIA.xml:S2:535:1	)	)	O	O
Pneumonitis	ZYKADIA.xml:S2:537:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
:	ZYKADIA.xml:S2:549:1	:	:	O	O
Occurred	ZYKADIA.xml:S2:551:8	occur	VBN	O	O
in	ZYKADIA.xml:S2:560:2	in	IN	O	O
4%	ZYKADIA.xml:S2:563:2	4%	CD	O	O
of	ZYKADIA.xml:S2:566:2	of	IN	O	O
patients	ZYKADIA.xml:S2:569:8	patient	NNS	O	O
.	ZYKADIA.xml:S2:577:1	.	.	O	O

Permanently	ZYKADIA.xml:S2:579:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:591:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:603:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:611:2	in	IN	O	O
patients	ZYKADIA.xml:S2:614:8	patient	NNS	O	O
diagnosed	ZYKADIA.xml:S2:623:9	diagnos	VBN	O	O
with	ZYKADIA.xml:S2:633:4	with	IN	O	O
treatment	ZYKADIA.xml:S2:638:9	treatment	NN	O	O
-	ZYKADIA.xml:S2:647:1	-	:	O	O
related	ZYKADIA.xml:S2:648:7	relat	JJ	O	O
ILD	ZYKADIA.xml:S2:656:3	ild	NNP	O	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S2:660:11	pneumon	NN	O	I-AdverseReaction
.	ZYKADIA.xml:S2:671:1	.	.	O	O

(	ZYKADIA.xml:S2:673:1	(	(	O	O
2.2	ZYKADIA.xml:S2:676:3	2.2	CD	O	O
,	ZYKADIA.xml:S2:681:1	,	,	O	O
5.3	ZYKADIA.xml:S2:684:3	5.3	CD	O	O
)	ZYKADIA.xml:S2:689:1	)	)	O	O

QT	ZYKADIA.xml:S2:697:2	QT	NNP	B-AdverseReaction	O
Interval	ZYKADIA.xml:S2:700:8	interv	NNP	I-AdverseReaction	O
Prolongation	ZYKADIA.xml:S2:709:12	prolong	NNP	I-AdverseReaction	O
:	ZYKADIA.xml:S2:722:1	:	:	O	O
ZYKADIA	ZYKADIA.xml:S2:724:7	zykadia	NN	O	O
can	ZYKADIA.xml:S2:732:3	can	MD	O	O
cause	ZYKADIA.xml:S2:736:5	caus	VB	O	O
QTc	ZYKADIA.xml:S2:742:3	qtc	NNP	B-AdverseReaction	B-AdverseReaction
interval	ZYKADIA.xml:S2:746:8	interv	JJ	I-AdverseReaction	I-AdverseReaction
prolongation	ZYKADIA.xml:S2:755:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
.	ZYKADIA.xml:S2:767:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:769:7	monitor	NNP	O	O
electrocardiograms	ZYKADIA.xml:S2:777:18	electrocardiogram	NNS	O	O
and	ZYKADIA.xml:S2:796:3	and	CC	O	O
electrolytes	ZYKADIA.xml:S2:800:12	electrolyt	NNS	O	O
in	ZYKADIA.xml:S2:813:2	in	IN	O	O
patients	ZYKADIA.xml:S2:816:8	patient	NNS	O	O
with	ZYKADIA.xml:S2:825:4	with	IN	O	O
congestive	ZYKADIA.xml:S2:830:10	congest	JJ	O	O
heart	ZYKADIA.xml:S2:841:5	heart	NN	O	O
failure	ZYKADIA.xml:S2:847:7	failur	NN	O	O
,	ZYKADIA.xml:S2:854:1	,	,	O	O
bradyarrhythmias	ZYKADIA.xml:S2:856:16	bradyarrhythmia	NN	O	B-AdverseReaction
,	ZYKADIA.xml:S2:872:1	,	,	O	O
electrolyte	ZYKADIA.xml:S2:874:11	electrolyt	JJ	O	O
abnormalities	ZYKADIA.xml:S2:886:13	abnorm	NNS	O	O
,	ZYKADIA.xml:S2:899:1	,	,	O	O
or	ZYKADIA.xml:S2:901:2	or	CC	O	O
those	ZYKADIA.xml:S2:904:5	those	DT	O	O
who	ZYKADIA.xml:S2:910:3	who	WP	O	O
are	ZYKADIA.xml:S2:914:3	are	VBP	O	O
taking	ZYKADIA.xml:S2:918:6	take	VBG	O	O
medications	ZYKADIA.xml:S2:925:11	medic	NNS	O	O
that	ZYKADIA.xml:S2:937:4	that	WDT	O	O
are	ZYKADIA.xml:S2:942:3	are	VBP	O	O
known	ZYKADIA.xml:S2:946:5	known	VBN	O	O
to	ZYKADIA.xml:S2:952:2	to	TO	O	O
prolong	ZYKADIA.xml:S2:955:7	prolong	VB	O	O
the	ZYKADIA.xml:S2:963:3	the	DT	O	O
QTc	ZYKADIA.xml:S2:967:3	qtc	NNP	O	O
interval	ZYKADIA.xml:S2:971:8	interv	NN	O	O
.	ZYKADIA.xml:S2:979:1	.	.	O	O

Withhold	ZYKADIA.xml:S2:981:8	withhold	NNP	O	O
then	ZYKADIA.xml:S2:990:4	then	RB	O	O
dose	ZYKADIA.xml:S2:995:4	dose	VBD	O	O
reduce	ZYKADIA.xml:S2:1000:6	reduc	VB	O	O
,	ZYKADIA.xml:S2:1006:1	,	,	O	O
or	ZYKADIA.xml:S2:1008:2	or	CC	O	O
permanently	ZYKADIA.xml:S2:1011:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:1023:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:1035:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:1042:1	.	.	O	O

(	ZYKADIA.xml:S2:1044:1	(	(	O	O
2.2	ZYKADIA.xml:S2:1047:3	2.2	CD	O	O
,	ZYKADIA.xml:S2:1052:1	,	,	O	O
5.4	ZYKADIA.xml:S2:1055:3	5.4	CD	O	O
)	ZYKADIA.xml:S2:1060:1	)	)	O	O

Hyperglycemia	ZYKADIA.xml:S2:1068:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
:	ZYKADIA.xml:S2:1082:1	:	:	O	O
ZYKADIA	ZYKADIA.xml:S2:1084:7	zykadia	NNP	O	O
can	ZYKADIA.xml:S2:1092:3	can	MD	O	O
cause	ZYKADIA.xml:S2:1096:5	caus	VB	O	O
hyperglycemia	ZYKADIA.xml:S2:1102:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
.	ZYKADIA.xml:S2:1115:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:1117:7	monitor	NNP	O	O
fasting	ZYKADIA.xml:S2:1125:7	fast	VBG	O	O
glucose	ZYKADIA.xml:S2:1133:7	glucos	RB	O	O
prior	ZYKADIA.xml:S2:1141:5	prior	JJ	O	O
to	ZYKADIA.xml:S2:1147:2	to	TO	O	O
treatment	ZYKADIA.xml:S2:1150:9	treatment	NN	O	O
and	ZYKADIA.xml:S2:1160:3	and	CC	O	O
periodically	ZYKADIA.xml:S2:1164:12	period	RB	O	O
thereafter	ZYKADIA.xml:S2:1177:10	thereaft	RB	O	O
as	ZYKADIA.xml:S2:1188:2	as	IN	O	O
clinically	ZYKADIA.xml:S2:1191:10	clinic	RB	O	O
indicated	ZYKADIA.xml:S2:1202:9	indic	VBN	O	O
.	ZYKADIA.xml:S2:1211:1	.	.	O	O

Initiate	ZYKADIA.xml:S2:1213:8	initi	NNP	O	O
or	ZYKADIA.xml:S2:1222:2	or	CC	O	O
optimize	ZYKADIA.xml:S2:1225:8	optim	VB	O	O
anti	ZYKADIA.xml:S2:1234:4	anti	JJ	O	O
-	ZYKADIA.xml:S2:1238:1	-	:	O	O
hyperglycemic	ZYKADIA.xml:S2:1239:13	hyperglycem	JJ	O	O
medications	ZYKADIA.xml:S2:1253:11	medic	NNS	O	O
as	ZYKADIA.xml:S2:1265:2	as	IN	O	O
indicated	ZYKADIA.xml:S2:1268:9	indic	JJ	O	O
.	ZYKADIA.xml:S2:1277:1	.	.	O	O

Withhold	ZYKADIA.xml:S2:1279:8	withhold	NNP	O	O
then	ZYKADIA.xml:S2:1288:4	then	RB	O	O
dose	ZYKADIA.xml:S2:1293:4	dose	VBD	O	O
reduce	ZYKADIA.xml:S2:1298:6	reduc	VB	O	O
,	ZYKADIA.xml:S2:1304:1	,	,	O	O
or	ZYKADIA.xml:S2:1306:2	or	CC	O	O
permanently	ZYKADIA.xml:S2:1309:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:1321:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:1333:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:1340:1	.	.	O	O

(	ZYKADIA.xml:S2:1342:1	(	(	O	O
2.2	ZYKADIA.xml:S2:1345:3	2.2	CD	O	O
,	ZYKADIA.xml:S2:1350:1	,	,	O	O
5.5	ZYKADIA.xml:S2:1353:3	5.5	CD	O	O
)	ZYKADIA.xml:S2:1358:1	)	)	O	O

Bradycardia	ZYKADIA.xml:S2:1366:11	bradycardia	NNP	B-AdverseReaction	O
:	ZYKADIA.xml:S2:1378:1	:	:	O	O
ZYKADIA	ZYKADIA.xml:S2:1380:7	zykadia	NN	O	O
can	ZYKADIA.xml:S2:1388:3	can	MD	O	O
cause	ZYKADIA.xml:S2:1392:5	caus	VB	O	O
bradycardia	ZYKADIA.xml:S2:1398:11	bradycardia	NN	B-AdverseReaction	B-AdverseReaction
.	ZYKADIA.xml:S2:1409:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:1411:7	monitor	NNP	O	O
heart	ZYKADIA.xml:S2:1419:5	heart	NN	O	O
rate	ZYKADIA.xml:S2:1425:4	rate	NN	O	O
and	ZYKADIA.xml:S2:1430:3	and	CC	O	O
blood	ZYKADIA.xml:S2:1434:5	blood	NN	O	O
pressure	ZYKADIA.xml:S2:1440:8	pressur	NN	O	O
regularly	ZYKADIA.xml:S2:1449:9	regularli	RB	O	O
.	ZYKADIA.xml:S2:1458:1	.	.	O	O

Withhold	ZYKADIA.xml:S2:1460:8	withhold	NNP	O	O
then	ZYKADIA.xml:S2:1469:4	then	RB	O	O
dose	ZYKADIA.xml:S2:1474:4	dose	VBD	O	O
reduce	ZYKADIA.xml:S2:1479:6	reduc	VB	O	O
,	ZYKADIA.xml:S2:1485:1	,	,	O	O
or	ZYKADIA.xml:S2:1487:2	or	CC	O	O
permanently	ZYKADIA.xml:S2:1490:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:1502:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:1514:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:1521:1	.	.	O	O

(	ZYKADIA.xml:S2:1523:1	(	(	O	O
2.2	ZYKADIA.xml:S2:1526:3	2.2	CD	O	O
,	ZYKADIA.xml:S2:1531:1	,	,	O	O
5.6	ZYKADIA.xml:S2:1534:3	5.6	CD	O	O
)	ZYKADIA.xml:S2:1539:1	)	)	O	O

Pancreatitis	ZYKADIA.xml:S2:1547:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
:	ZYKADIA.xml:S2:1560:1	:	:	O	O
Elevations	ZYKADIA.xml:S2:1562:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
of	ZYKADIA.xml:S2:1573:2	of	IN	I-AdverseReaction	I-AdverseReaction
lipase	ZYKADIA.xml:S2:1576:6	lipas	NN	I-AdverseReaction	I-AdverseReaction
and	ZYKADIA.xml:S2:1583:3	and	CC	O	O
or	ZYKADIA.xml:S2:1587:2	or	CC	O	O
amylase	ZYKADIA.xml:S2:1590:7	amylas	NN	I-AdverseReaction	O
and	ZYKADIA.xml:S2:1598:3	and	CC	O	O
pancreatitis	ZYKADIA.xml:S2:1602:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
can	ZYKADIA.xml:S2:1615:3	can	MD	O	O
occur	ZYKADIA.xml:S2:1619:5	occur	VB	O	O
.	ZYKADIA.xml:S2:1624:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:1626:7	monitor	NNP	O	O
lipase	ZYKADIA.xml:S2:1634:6	lipas	NN	O	O
and	ZYKADIA.xml:S2:1641:3	and	CC	O	O
amylase	ZYKADIA.xml:S2:1645:7	amylas	NN	O	O
prior	ZYKADIA.xml:S2:1653:5	prior	RB	O	O
to	ZYKADIA.xml:S2:1659:2	to	TO	O	O
treatment	ZYKADIA.xml:S2:1662:9	treatment	NN	O	O
and	ZYKADIA.xml:S2:1672:3	and	CC	O	O
periodically	ZYKADIA.xml:S2:1676:12	period	RB	O	O
thereafter	ZYKADIA.xml:S2:1689:10	thereaft	RB	O	O
as	ZYKADIA.xml:S2:1700:2	as	IN	O	O
clinically	ZYKADIA.xml:S2:1703:10	clinic	RB	O	O
indicated	ZYKADIA.xml:S2:1714:9	indic	VBN	O	O
.	ZYKADIA.xml:S2:1723:1	.	.	O	O

(	ZYKADIA.xml:S2:1725:1	(	(	O	O
2.2	ZYKADIA.xml:S2:1728:3	2.2	CD	O	O
,	ZYKADIA.xml:S2:1733:1	,	,	O	O
5.7	ZYKADIA.xml:S2:1736:3	5.7	CD	O	O
)	ZYKADIA.xml:S2:1741:1	)	)	O	O

Embryofetal	ZYKADIA.xml:S2:1749:11	embryofet	JJ	B-AdverseReaction	B-AdverseReaction
Toxicity	ZYKADIA.xml:S2:1761:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
:	ZYKADIA.xml:S2:1770:1	:	:	O	O
ZYKADIA	ZYKADIA.xml:S2:1772:7	zykadia	NNP	O	O
may	ZYKADIA.xml:S2:1780:3	may	MD	O	O
cause	ZYKADIA.xml:S2:1784:5	caus	VB	O	O
fetal	ZYKADIA.xml:S2:1790:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	ZYKADIA.xml:S2:1796:4	harm	NN	I-AdverseReaction	I-AdverseReaction
.	ZYKADIA.xml:S2:1800:1	.	.	O	O

Advise	ZYKADIA.xml:S2:1802:6	advis	NNP	O	O
females	ZYKADIA.xml:S2:1809:7	femal	NNS	O	O
of	ZYKADIA.xml:S2:1817:2	of	IN	O	O
reproductive	ZYKADIA.xml:S2:1820:12	reproduct	JJ	O	O
potential	ZYKADIA.xml:S2:1833:9	potenti	NN	O	O
of	ZYKADIA.xml:S2:1843:2	of	IN	O	O
the	ZYKADIA.xml:S2:1846:3	the	DT	O	O
potential	ZYKADIA.xml:S2:1850:9	potenti	JJ	O	O
risk	ZYKADIA.xml:S2:1860:4	risk	NN	O	O
to	ZYKADIA.xml:S2:1865:2	to	TO	O	O
a	ZYKADIA.xml:S2:1868:1	a	DT	O	O
fetus	ZYKADIA.xml:S2:1870:5	fetu	NN	O	O
.	ZYKADIA.xml:S2:1875:1	.	.	O	O

(	ZYKADIA.xml:S2:1877:1	(	(	O	O
5.8	ZYKADIA.xml:S2:1880:3	5.8	CD	O	O
,	ZYKADIA.xml:S2:1885:1	,	,	O	O
8.1	ZYKADIA.xml:S2:1888:3	8.1	CD	O	O
,	ZYKADIA.xml:S2:1893:1	,	,	O	O
8.7	ZYKADIA.xml:S2:1896:3	8.7	CD	O	O
)	ZYKADIA.xml:S2:1901:1	)	)	O	O

5.1	ZYKADIA.xml:S2:1915:3	5.1	CD	O	O

Severe	ZYKADIA.xml:S2:1923:6	sever	JJ	O	O

or	ZYKADIA.xml:S2:1930:2	or	CC	O	O
Persistent	ZYKADIA.xml:S2:1933:10	persist	NNP	O	O
Gastrointestinal	ZYKADIA.xml:S2:1944:16	gastrointestin	NNP	O	O
Toxicity	ZYKADIA.xml:S2:1961:8	toxic	NNP	O	O

Diarrhea	ZYKADIA.xml:S2:1975:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:1983:1	,	,	O	O
nausea	ZYKADIA.xml:S2:1985:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:1991:1	,	,	O	O
vomiting	ZYKADIA.xml:S2:1993:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:2001:1	,	,	O	O
or	ZYKADIA.xml:S2:2003:2	or	CC	O	O
abdominal	ZYKADIA.xml:S2:2006:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ZYKADIA.xml:S2:2016:4	pain	NN	I-AdverseReaction	I-AdverseReaction
occurred	ZYKADIA.xml:S2:2021:8	occur	VBD	O	O
in	ZYKADIA.xml:S2:2030:2	in	IN	O	O
96%	ZYKADIA.xml:S2:2033:3	96%	CD	O	O
of	ZYKADIA.xml:S2:2037:2	of	IN	O	O
255	ZYKADIA.xml:S2:2040:3	255	CD	O	O
patients	ZYKADIA.xml:S2:2044:8	patient	NNS	O	O
including	ZYKADIA.xml:S2:2053:9	includ	VBG	O	O
severe	ZYKADIA.xml:S2:2063:6	sever	JJ	O	O
cases	ZYKADIA.xml:S2:2070:5	case	NNS	O	O
in	ZYKADIA.xml:S2:2076:2	in	IN	O	O
14%	ZYKADIA.xml:S2:2079:3	14%	CD	O	O
of	ZYKADIA.xml:S2:2083:2	of	IN	O	O
patients	ZYKADIA.xml:S2:2086:8	patient	NNS	O	O
treated	ZYKADIA.xml:S2:2095:7	treat	VBN	O	O
with	ZYKADIA.xml:S2:2103:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:2108:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:2116:2	in	IN	O	O
Study	ZYKADIA.xml:S2:2119:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:2125:1	1	CD	O	O
.	ZYKADIA.xml:S2:2126:1	.	.	O	O

Dose	ZYKADIA.xml:S2:2128:4	dose	NNP	O	O
modification	ZYKADIA.xml:S2:2133:12	modif	NN	O	O
due	ZYKADIA.xml:S2:2146:3	due	JJ	O	O
to	ZYKADIA.xml:S2:2150:2	to	TO	O	O
diarrhea	ZYKADIA.xml:S2:2153:8	diarrhea	VB	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:2161:1	,	,	O	O
nausea	ZYKADIA.xml:S2:2163:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:2169:1	,	,	O	O
vomiting	ZYKADIA.xml:S2:2171:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:2179:1	,	,	O	O
or	ZYKADIA.xml:S2:2181:2	or	CC	O	O
abdominal	ZYKADIA.xml:S2:2184:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	ZYKADIA.xml:S2:2194:4	pain	NN	I-AdverseReaction	I-AdverseReaction
occurred	ZYKADIA.xml:S2:2199:8	occur	VBD	O	O
in	ZYKADIA.xml:S2:2208:2	in	IN	O	O
38%	ZYKADIA.xml:S2:2211:3	38%	CD	O	O
of	ZYKADIA.xml:S2:2215:2	of	IN	O	O
patients	ZYKADIA.xml:S2:2218:8	patient	NNS	O	O
.	ZYKADIA.xml:S2:2226:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:2232:7	monitor	NNP	O	O
and	ZYKADIA.xml:S2:2240:3	and	CC	O	O
manage	ZYKADIA.xml:S2:2244:6	manag	NN	O	O
patients	ZYKADIA.xml:S2:2251:8	patient	NNS	O	O
using	ZYKADIA.xml:S2:2260:5	use	VBG	O	O
standards	ZYKADIA.xml:S2:2266:9	standard	NNS	O	O
of	ZYKADIA.xml:S2:2276:2	of	IN	O	O
care	ZYKADIA.xml:S2:2279:4	care	NN	O	O
,	ZYKADIA.xml:S2:2283:1	,	,	O	O
including	ZYKADIA.xml:S2:2285:9	includ	VBG	O	O
anti	ZYKADIA.xml:S2:2295:4	anti	SYM	O	O
-	ZYKADIA.xml:S2:2299:1	-	:	O	O
diarrheals	ZYKADIA.xml:S2:2300:10	diarrheal	NNS	O	O
,	ZYKADIA.xml:S2:2310:1	,	,	O	O
anti	ZYKADIA.xml:S2:2312:4	anti	SYM	O	O
-	ZYKADIA.xml:S2:2316:1	-	:	O	O
emetics	ZYKADIA.xml:S2:2317:7	emet	NNS	O	O
,	ZYKADIA.xml:S2:2324:1	,	,	O	O
or	ZYKADIA.xml:S2:2326:2	or	CC	O	O
fluid	ZYKADIA.xml:S2:2329:5	fluid	JJ	O	O
replacement	ZYKADIA.xml:S2:2335:11	replac	NN	O	O
,	ZYKADIA.xml:S2:2346:1	,	,	O	O
as	ZYKADIA.xml:S2:2348:2	as	IN	O	O
indicated	ZYKADIA.xml:S2:2351:9	indic	VBN	O	O
.	ZYKADIA.xml:S2:2360:1	.	.	O	O

Based	ZYKADIA.xml:S2:2362:5	base	VBN	O	O
on	ZYKADIA.xml:S2:2368:2	on	IN	O	O
the	ZYKADIA.xml:S2:2371:3	the	DT	O	O
severity	ZYKADIA.xml:S2:2375:8	sever	NN	O	O
of	ZYKADIA.xml:S2:2384:2	of	IN	O	O
the	ZYKADIA.xml:S2:2387:3	the	DT	O	O
adverse	ZYKADIA.xml:S2:2391:7	advers	JJ	O	O
drug	ZYKADIA.xml:S2:2399:4	drug	NN	O	O
reaction	ZYKADIA.xml:S2:2404:8	reaction	NN	O	O
,	ZYKADIA.xml:S2:2412:1	,	,	O	O
withhold	ZYKADIA.xml:S2:2414:8	withhold	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:2423:7	zykadia	NNP	O	O
with	ZYKADIA.xml:S2:2431:4	with	IN	O	O
resumption	ZYKADIA.xml:S2:2436:10	resumpt	NN	O	O
at	ZYKADIA.xml:S2:2447:2	at	IN	O	O
a	ZYKADIA.xml:S2:2450:1	a	DT	O	O
reduced	ZYKADIA.xml:S2:2452:7	reduc	JJ	O	O
dose	ZYKADIA.xml:S2:2460:4	dose	NN	O	O
as	ZYKADIA.xml:S2:2465:2	as	IN	O	O
described	ZYKADIA.xml:S2:2468:9	describ	VBN	O	O
in	ZYKADIA.xml:S2:2478:2	in	IN	O	O
Table	ZYKADIA.xml:S2:2481:5	tabl	JJ	O	O
1	ZYKADIA.xml:S2:2487:1	1	CD	O	O
[	ZYKADIA.xml:S2:2489:1	[	NN	O	O
see	ZYKADIA.xml:S2:2490:3	see	NN	O	O
Dosage	ZYKADIA.xml:S2:2494:6	dosag	NNP	O	O
and	ZYKADIA.xml:S2:2501:3	and	CC	O	O
Administration	ZYKADIA.xml:S2:2505:14	administr	NNP	O	O
(	ZYKADIA.xml:S2:2520:1	(	(	O	O
2.2	ZYKADIA.xml:S2:2521:3	2.2	CD	O	O
)	ZYKADIA.xml:S2:2524:1	)	)	O	O
and	ZYKADIA.xml:S2:2526:3	and	CC	O	O
Adverse	ZYKADIA.xml:S2:2530:7	advers	JJ	O	O
Reactions	ZYKADIA.xml:S2:2538:9	reaction	NNP	O	O
(	ZYKADIA.xml:S2:2548:1	(	(	O	O
6	ZYKADIA.xml:S2:2549:1	6	CD	O	O
)]	ZYKADIA.xml:S2:2550:2	)]	NN	O	O
.	ZYKADIA.xml:S2:2554:1	.	.	O	O

5.2	ZYKADIA.xml:S2:2563:3	5.2	CD	O	O
Hepatotoxicity	ZYKADIA.xml:S2:2571:14	hepatotox	NN	O	O

Drug	ZYKADIA.xml:S2:2592:4	drug	NNP	O	B-AdverseReaction
-	ZYKADIA.xml:S2:2596:1	-	:	O	I-AdverseReaction
induced	ZYKADIA.xml:S2:2597:7	induc	JJ	O	I-AdverseReaction
hepatotoxicity	ZYKADIA.xml:S2:2605:14	hepatotox	NN	B-AdverseReaction	I-AdverseReaction
occurred	ZYKADIA.xml:S2:2620:8	occur	VBD	O	O
in	ZYKADIA.xml:S2:2629:2	in	IN	O	O
patients	ZYKADIA.xml:S2:2632:8	patient	NNS	O	O
treated	ZYKADIA.xml:S2:2641:7	treat	VBN	O	O
with	ZYKADIA.xml:S2:2649:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:2654:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:2661:1	.	.	O	O

Elevations	ZYKADIA.xml:S2:2663:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	ZYKADIA.xml:S2:2674:2	in	IN	I-AdverseReaction	I-AdverseReaction
alanine	ZYKADIA.xml:S2:2677:7	alanin	JJ	I-AdverseReaction	I-AdverseReaction
aminotransferase	ZYKADIA.xml:S2:2685:16	aminotransferas	NN	I-AdverseReaction	I-AdverseReaction
(	ZYKADIA.xml:S2:2702:1	(	(	O	O
ALT	ZYKADIA.xml:S2:2703:3	alt	NNP	O	O
)	ZYKADIA.xml:S2:2706:1	)	)	O	O
greater	ZYKADIA.xml:S2:2708:7	greater	JJR	O	O
than	ZYKADIA.xml:S2:2716:4	than	IN	O	O
5	ZYKADIA.xml:S2:2721:1	5	CD	O	O
times	ZYKADIA.xml:S2:2723:5	time	NNS	O	O
the	ZYKADIA.xml:S2:2729:3	the	DT	O	O
upper	ZYKADIA.xml:S2:2733:5	upper	JJ	O	O
limit	ZYKADIA.xml:S2:2739:5	limit	NN	O	O
of	ZYKADIA.xml:S2:2745:2	of	IN	O	O
normal	ZYKADIA.xml:S2:2748:6	normal	JJ	O	O
(	ZYKADIA.xml:S2:2755:1	(	(	O	O
ULN	ZYKADIA.xml:S2:2756:3	uln	NNP	O	O
)	ZYKADIA.xml:S2:2759:1	)	)	O	O
occurred	ZYKADIA.xml:S2:2761:8	occur	VBD	O	O
in	ZYKADIA.xml:S2:2770:2	in	IN	O	O
27%	ZYKADIA.xml:S2:2773:3	27%	CD	O	O
of	ZYKADIA.xml:S2:2777:2	of	IN	O	O
255	ZYKADIA.xml:S2:2780:3	255	CD	O	O
patients	ZYKADIA.xml:S2:2784:8	patient	NNS	O	O
in	ZYKADIA.xml:S2:2793:2	in	IN	O	O
Study	ZYKADIA.xml:S2:2796:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:2802:1	1	CD	O	O
.	ZYKADIA.xml:S2:2803:1	.	.	O	O

One	ZYKADIA.xml:S2:2805:3	one	CD	O	O
patient	ZYKADIA.xml:S2:2809:7	patient	NN	O	O
(	ZYKADIA.xml:S2:2817:1	(	(	O	O
0.4%	ZYKADIA.xml:S2:2818:4	0.4%	CD	O	O
)	ZYKADIA.xml:S2:2822:1	)	)	O	O
required	ZYKADIA.xml:S2:2824:8	requir	VBN	O	O
permanent	ZYKADIA.xml:S2:2833:9	perman	JJ	O	O
discontinuation	ZYKADIA.xml:S2:2843:15	discontinu	NN	O	O
due	ZYKADIA.xml:S2:2859:3	due	JJ	O	O
to	ZYKADIA.xml:S2:2863:2	to	TO	O	O
elevated	ZYKADIA.xml:S2:2866:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
transaminases	ZYKADIA.xml:S2:2875:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S2:2888:1	,	,	O	O
and	ZYKADIA.xml:S2:2890:3	and	CC	O	O
jaundice	ZYKADIA.xml:S2:2894:8	jaundic	NN	B-AdverseReaction	O
.	ZYKADIA.xml:S2:2902:1	.	.	O	O

Concurrent	ZYKADIA.xml:S2:2904:10	concurr	JJ	O	O
elevations	ZYKADIA.xml:S2:2915:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	ZYKADIA.xml:S2:2926:2	in	IN	I-AdverseReaction	I-AdverseReaction
ALT	ZYKADIA.xml:S2:2929:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
greater	ZYKADIA.xml:S2:2933:7	greater	JJR	O	O
than	ZYKADIA.xml:S2:2941:4	than	IN	O	O
3	ZYKADIA.xml:S2:2946:1	3	CD	O	O
times	ZYKADIA.xml:S2:2948:5	time	NNS	O	O
the	ZYKADIA.xml:S2:2954:3	the	DT	O	O
ULN	ZYKADIA.xml:S2:2958:3	uln	NNP	O	O
and	ZYKADIA.xml:S2:2962:3	and	CC	O	O
total	ZYKADIA.xml:S2:2966:5	total	JJ	B-AdverseReaction	B-AdverseReaction
bilirubin	ZYKADIA.xml:S2:2972:9	bilirubin	NN	I-AdverseReaction	I-AdverseReaction
greater	ZYKADIA.xml:S2:2982:7	greater	JJR	O	O
than	ZYKADIA.xml:S2:2990:4	than	IN	O	O
2	ZYKADIA.xml:S2:2995:1	2	CD	I-AdverseReaction	O
times	ZYKADIA.xml:S2:2997:5	time	NNS	I-AdverseReaction	O
the	ZYKADIA.xml:S2:3003:3	the	DT	I-AdverseReaction	O
ULN	ZYKADIA.xml:S2:3007:3	uln	NNP	I-AdverseReaction	O
,	ZYKADIA.xml:S2:3010:1	,	,	O	O
with	ZYKADIA.xml:S2:3012:4	with	IN	O	O
normal	ZYKADIA.xml:S2:3017:6	normal	JJ	O	O
alkaline	ZYKADIA.xml:S2:3024:8	alkalin	JJ	O	O
phosphatase	ZYKADIA.xml:S2:3033:11	phosphatas	NN	O	O
,	ZYKADIA.xml:S2:3044:1	,	,	O	O
occurred	ZYKADIA.xml:S2:3046:8	occur	VBD	O	O
in	ZYKADIA.xml:S2:3055:2	in	IN	O	O
less	ZYKADIA.xml:S2:3058:4	less	JJR	O	O
than	ZYKADIA.xml:S2:3063:4	than	IN	O	O
1%	ZYKADIA.xml:S2:3068:2	1%	CD	O	O
of	ZYKADIA.xml:S2:3071:2	of	IN	O	O
patients	ZYKADIA.xml:S2:3074:8	patient	NNS	O	O
in	ZYKADIA.xml:S2:3083:2	in	IN	O	O
clinical	ZYKADIA.xml:S2:3086:8	clinic	JJ	O	O
studies	ZYKADIA.xml:S2:3095:7	studi	NNS	O	O
.	ZYKADIA.xml:S2:3102:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:3110:7	monitor	NN	O	O
with	ZYKADIA.xml:S2:3118:4	with	IN	O	O
liver	ZYKADIA.xml:S2:3123:5	liver	JJ	O	O
laboratory	ZYKADIA.xml:S2:3129:10	laboratori	NN	O	O
tests	ZYKADIA.xml:S2:3140:5	test	NNS	O	O
including	ZYKADIA.xml:S2:3146:9	includ	VBG	O	O
ALT	ZYKADIA.xml:S2:3156:3	alt	NNP	O	I-AdverseReaction
,	ZYKADIA.xml:S2:3159:1	,	,	O	O
aspartate	ZYKADIA.xml:S2:3161:9	aspart	JJ	O	O
aminotransferase	ZYKADIA.xml:S2:3171:16	aminotransferas	NN	O	O
(	ZYKADIA.xml:S2:3188:1	(	(	O	O
AST	ZYKADIA.xml:S2:3189:3	ast	NNP	O	O
)	ZYKADIA.xml:S2:3192:1	)	)	O	O
,	ZYKADIA.xml:S2:3193:1	,	,	O	O
and	ZYKADIA.xml:S2:3195:3	and	CC	O	O
total	ZYKADIA.xml:S2:3199:5	total	JJ	O	O
bilirubin	ZYKADIA.xml:S2:3205:9	bilirubin	NN	O	O
once	ZYKADIA.xml:S2:3215:4	onc	RB	O	O
a	ZYKADIA.xml:S2:3220:1	a	DT	O	O
month	ZYKADIA.xml:S2:3222:5	month	NN	O	O
and	ZYKADIA.xml:S2:3228:3	and	CC	O	O
as	ZYKADIA.xml:S2:3232:2	as	IN	O	O
clinically	ZYKADIA.xml:S2:3235:10	clinic	RB	O	O
indicated	ZYKADIA.xml:S2:3246:9	indic	VBN	O	O
,	ZYKADIA.xml:S2:3255:1	,	,	O	O
with	ZYKADIA.xml:S2:3257:4	with	IN	O	O
more	ZYKADIA.xml:S2:3262:4	more	RBR	O	O
frequent	ZYKADIA.xml:S2:3267:8	frequent	JJ	O	O
testing	ZYKADIA.xml:S2:3276:7	test	NN	O	O
in	ZYKADIA.xml:S2:3284:2	in	IN	O	O
patients	ZYKADIA.xml:S2:3287:8	patient	NNS	O	O
who	ZYKADIA.xml:S2:3296:3	who	WP	O	O
develop	ZYKADIA.xml:S2:3300:7	develop	VBP	O	O
transaminase	ZYKADIA.xml:S2:3308:12	transaminas	JJ	O	O
elevations	ZYKADIA.xml:S2:3321:10	elev	NNS	O	O
.	ZYKADIA.xml:S2:3331:1	.	.	O	O

Based	ZYKADIA.xml:S2:3333:5	base	VBN	O	O
on	ZYKADIA.xml:S2:3339:2	on	IN	O	O
the	ZYKADIA.xml:S2:3342:3	the	DT	O	O
severity	ZYKADIA.xml:S2:3346:8	sever	NN	O	O
of	ZYKADIA.xml:S2:3355:2	of	IN	O	O
the	ZYKADIA.xml:S2:3358:3	the	DT	O	O
adverse	ZYKADIA.xml:S2:3362:7	advers	JJ	O	O
drug	ZYKADIA.xml:S2:3370:4	drug	NN	O	O
reaction	ZYKADIA.xml:S2:3375:8	reaction	NN	O	O
,	ZYKADIA.xml:S2:3383:1	,	,	O	O
withhold	ZYKADIA.xml:S2:3385:8	withhold	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:3394:7	zykadia	NNP	O	O
with	ZYKADIA.xml:S2:3402:4	with	IN	O	O
resumption	ZYKADIA.xml:S2:3407:10	resumpt	NN	O	O
at	ZYKADIA.xml:S2:3418:2	at	IN	O	O
a	ZYKADIA.xml:S2:3421:1	a	DT	O	O
reduced	ZYKADIA.xml:S2:3423:7	reduc	JJ	O	O
dose	ZYKADIA.xml:S2:3431:4	dose	NN	O	O
,	ZYKADIA.xml:S2:3435:1	,	,	O	O
or	ZYKADIA.xml:S2:3437:2	or	CC	O	O
permanently	ZYKADIA.xml:S2:3440:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:3452:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:3464:7	zykadia	NNP	O	O
as	ZYKADIA.xml:S2:3472:2	as	IN	O	O
described	ZYKADIA.xml:S2:3475:9	describ	VBN	O	O
in	ZYKADIA.xml:S2:3485:2	in	IN	O	O
Table	ZYKADIA.xml:S2:3488:5	tabl	JJ	O	O
1	ZYKADIA.xml:S2:3494:1	1	CD	O	O
[	ZYKADIA.xml:S2:3496:1	[	NN	O	O
see	ZYKADIA.xml:S2:3497:3	see	NN	O	O
Dosage	ZYKADIA.xml:S2:3501:6	dosag	NNP	O	O
and	ZYKADIA.xml:S2:3508:3	and	CC	O	O
Administration	ZYKADIA.xml:S2:3512:14	administr	NNP	O	O
(	ZYKADIA.xml:S2:3527:1	(	(	O	O
2.2	ZYKADIA.xml:S2:3528:3	2.2	CD	O	O
)	ZYKADIA.xml:S2:3531:1	)	)	O	O
and	ZYKADIA.xml:S2:3533:3	and	CC	O	O
Adverse	ZYKADIA.xml:S2:3537:7	advers	JJ	O	O
Reactions	ZYKADIA.xml:S2:3545:9	reaction	NNP	O	O
(	ZYKADIA.xml:S2:3555:1	(	(	O	O
6	ZYKADIA.xml:S2:3556:1	6	CD	O	O
)]	ZYKADIA.xml:S2:3557:2	)]	NN	O	O
.	ZYKADIA.xml:S2:3561:1	.	.	O	O

5.3	ZYKADIA.xml:S2:3570:3	5.3	CD	O	O
Interstitial	ZYKADIA.xml:S2:3578:12	interstiti	JJ	O	O
Lung	ZYKADIA.xml:S2:3591:4	lung	NNP	O	O
Disease	ZYKADIA.xml:S2:3596:7	diseas	NNP	O	O
(	ZYKADIA.xml:S2:3604:1	(	(	O	O
ILD	ZYKADIA.xml:S2:3605:3	ild	NNP	O	B-AdverseReaction
)	ZYKADIA.xml:S2:3608:1	)	)	O	O
Pneumonitis	ZYKADIA.xml:S2:3610:11	pneumon	NN	O	O

Severe	ZYKADIA.xml:S2:3627:6	sever	NNP	O	O
,	ZYKADIA.xml:S2:3633:1	,	,	O	O
life	ZYKADIA.xml:S2:3635:4	life	NN	O	O
-	ZYKADIA.xml:S2:3639:1	-	:	O	O
threatening	ZYKADIA.xml:S2:3640:11	threaten	NN	O	O
,	ZYKADIA.xml:S2:3651:1	,	,	O	O
or	ZYKADIA.xml:S2:3653:2	or	CC	O	O
fatal	ZYKADIA.xml:S2:3656:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
ILD	ZYKADIA.xml:S2:3662:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S2:3666:11	pneumon	NN	B-AdverseReaction	I-AdverseReaction
can	ZYKADIA.xml:S2:3678:3	can	MD	O	O
occur	ZYKADIA.xml:S2:3682:5	occur	VB	O	O
in	ZYKADIA.xml:S2:3688:2	in	IN	O	O
patients	ZYKADIA.xml:S2:3691:8	patient	NNS	O	O
treated	ZYKADIA.xml:S2:3700:7	treat	VBN	O	O
with	ZYKADIA.xml:S2:3708:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:3713:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:3720:1	.	.	O	O

In	ZYKADIA.xml:S2:3722:2	In	IN	O	O
Study	ZYKADIA.xml:S2:3725:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:3731:1	1	CD	O	O
,	ZYKADIA.xml:S2:3732:1	,	,	O	O
pneumonitis	ZYKADIA.xml:S2:3734:11	pneumon	NN	B-AdverseReaction	B-AdverseReaction
was	ZYKADIA.xml:S2:3746:3	wa	VBD	O	O
reported	ZYKADIA.xml:S2:3750:8	report	VBN	O	O
in	ZYKADIA.xml:S2:3759:2	in	IN	O	O
4%	ZYKADIA.xml:S2:3762:2	4%	CD	O	O
of	ZYKADIA.xml:S2:3765:2	of	IN	O	O
255	ZYKADIA.xml:S2:3768:3	255	CD	O	O
patients	ZYKADIA.xml:S2:3772:8	patient	NNS	O	O
treated	ZYKADIA.xml:S2:3781:7	treat	VBN	O	O
with	ZYKADIA.xml:S2:3789:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:3794:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:3801:1	.	.	O	O

CTCAE	ZYKADIA.xml:S2:3803:5	ctcae	NNP	O	O
Grade	ZYKADIA.xml:S2:3809:5	grade	NNP	O	O
3	ZYKADIA.xml:S2:3815:1	3	CD	O	O
or	ZYKADIA.xml:S2:3817:2	or	CC	O	O
4	ZYKADIA.xml:S2:3820:1	4	CD	O	O
ILD	ZYKADIA.xml:S2:3822:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S2:3826:11	pneumon	NN	B-AdverseReaction	I-AdverseReaction
was	ZYKADIA.xml:S2:3838:3	wa	VBD	O	O
reported	ZYKADIA.xml:S2:3842:8	report	VBN	O	O
in	ZYKADIA.xml:S2:3851:2	in	IN	O	O
3%	ZYKADIA.xml:S2:3854:2	3%	CD	O	O
of	ZYKADIA.xml:S2:3857:2	of	IN	O	O
patients	ZYKADIA.xml:S2:3860:8	patient	NNS	O	O
,	ZYKADIA.xml:S2:3868:1	,	,	O	O
and	ZYKADIA.xml:S2:3870:3	and	CC	O	O
fatal	ZYKADIA.xml:S2:3874:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
ILD	ZYKADIA.xml:S2:3880:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S2:3884:11	pneumon	NN	B-AdverseReaction	I-AdverseReaction
was	ZYKADIA.xml:S2:3896:3	wa	VBD	O	O
reported	ZYKADIA.xml:S2:3900:8	report	VBN	O	O
in	ZYKADIA.xml:S2:3909:2	in	IN	O	O
1	ZYKADIA.xml:S2:3912:1	1	CD	O	O
patient	ZYKADIA.xml:S2:3914:7	patient	NN	O	O
(	ZYKADIA.xml:S2:3922:1	(	(	O	O
0.4%	ZYKADIA.xml:S2:3923:4	0.4%	CD	O	O
)	ZYKADIA.xml:S2:3927:1	)	)	O	O
in	ZYKADIA.xml:S2:3929:2	in	IN	O	O
Study	ZYKADIA.xml:S2:3932:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:3938:1	1	CD	O	O
.	ZYKADIA.xml:S2:3939:1	.	.	O	O

One	ZYKADIA.xml:S2:3941:3	one	CD	O	O
percent	ZYKADIA.xml:S2:3945:7	percent	NN	O	O
(	ZYKADIA.xml:S2:3953:1	(	(	O	O
1%	ZYKADIA.xml:S2:3954:2	1%	CD	O	O
)	ZYKADIA.xml:S2:3956:1	)	)	O	O
of	ZYKADIA.xml:S2:3958:2	of	IN	O	O
patients	ZYKADIA.xml:S2:3961:8	patient	NNS	O	O
discontinued	ZYKADIA.xml:S2:3970:12	discontinu	VBN	O	O
ZYKADIA	ZYKADIA.xml:S2:3983:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:3991:2	in	IN	O	O
Study	ZYKADIA.xml:S2:3994:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:4000:1	1	CD	O	O
due	ZYKADIA.xml:S2:4002:3	due	JJ	O	O
to	ZYKADIA.xml:S2:4006:2	to	TO	O	O
ILD	ZYKADIA.xml:S2:4009:3	ild	NNP	B-AdverseReaction	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S2:4013:11	pneumon	NN	B-AdverseReaction	I-AdverseReaction
.	ZYKADIA.xml:S2:4024:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:4030:7	monitor	NN	O	O
patients	ZYKADIA.xml:S2:4038:8	patient	NNS	O	O
for	ZYKADIA.xml:S2:4047:3	for	IN	O	O
pulmonary	ZYKADIA.xml:S2:4051:9	pulmonari	JJ	O	O
symptoms	ZYKADIA.xml:S2:4061:8	symptom	NNS	O	O
indicative	ZYKADIA.xml:S2:4070:10	indic	JJ	O	O
of	ZYKADIA.xml:S2:4081:2	of	IN	O	O
ILD	ZYKADIA.xml:S2:4084:3	ild	NNP	O	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S2:4088:11	pneumon	NN	O	I-AdverseReaction
.	ZYKADIA.xml:S2:4099:1	.	.	O	O

Exclude	ZYKADIA.xml:S2:4101:7	exclud	NNP	O	O
other	ZYKADIA.xml:S2:4109:5	other	JJ	O	O
potential	ZYKADIA.xml:S2:4115:9	potenti	JJ	O	O
causes	ZYKADIA.xml:S2:4125:6	caus	NNS	O	O
of	ZYKADIA.xml:S2:4132:2	of	IN	O	O
ILD	ZYKADIA.xml:S2:4135:3	ild	NNP	O	B-AdverseReaction
pneumonitis	ZYKADIA.xml:S2:4139:11	pneumon	NN	O	I-AdverseReaction
,	ZYKADIA.xml:S2:4150:1	,	,	O	O
and	ZYKADIA.xml:S2:4152:3	and	CC	O	O
permanently	ZYKADIA.xml:S2:4156:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:4168:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:4180:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:4188:2	in	IN	O	O
patients	ZYKADIA.xml:S2:4191:8	patient	NNS	O	O
diagnosed	ZYKADIA.xml:S2:4200:9	diagnos	VBN	O	O
with	ZYKADIA.xml:S2:4210:4	with	IN	O	O
treatment	ZYKADIA.xml:S2:4215:9	treatment	NN	O	O
-	ZYKADIA.xml:S2:4224:1	-	:	O	O
related	ZYKADIA.xml:S2:4225:7	relat	JJ	O	O
ILD	ZYKADIA.xml:S2:4233:3	ild	NNP	O	O
pneumonitis	ZYKADIA.xml:S2:4237:11	pneumon	NN	O	B-AdverseReaction
[	ZYKADIA.xml:S2:4249:1	[	NNP	O	O
see	ZYKADIA.xml:S2:4250:3	see	VBP	O	O
Dosage	ZYKADIA.xml:S2:4254:6	dosag	NNP	O	O
and	ZYKADIA.xml:S2:4261:3	and	CC	O	O
Administration	ZYKADIA.xml:S2:4265:14	administr	NNP	O	O
(	ZYKADIA.xml:S2:4280:1	(	(	O	O
2.2	ZYKADIA.xml:S2:4281:3	2.2	CD	O	O
)	ZYKADIA.xml:S2:4284:1	)	)	O	O
and	ZYKADIA.xml:S2:4286:3	and	CC	O	O
Adverse	ZYKADIA.xml:S2:4290:7	advers	JJ	O	O
Reactions	ZYKADIA.xml:S2:4298:9	reaction	NNP	O	O
(	ZYKADIA.xml:S2:4308:1	(	(	O	O
6	ZYKADIA.xml:S2:4309:1	6	CD	O	O
)]	ZYKADIA.xml:S2:4310:2	)]	NN	O	O
.	ZYKADIA.xml:S2:4314:1	.	.	O	O

5.4	ZYKADIA.xml:S2:4323:3	5.4	CD	O	O
QT	ZYKADIA.xml:S2:4331:2	QT	NNP	O	O
Interval	ZYKADIA.xml:S2:4334:8	interv	NNP	O	O
Prolongation	ZYKADIA.xml:S2:4343:12	prolong	NNP	O	O

QTc	ZYKADIA.xml:S2:4362:3	qtc	NNP	B-AdverseReaction	B-AdverseReaction
interval	ZYKADIA.xml:S2:4366:8	interv	JJ	I-AdverseReaction	I-AdverseReaction
prolongation	ZYKADIA.xml:S2:4375:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S2:4387:1	,	,	O	O
which	ZYKADIA.xml:S2:4389:5	which	WDT	O	O
may	ZYKADIA.xml:S2:4395:3	may	MD	O	O
lead	ZYKADIA.xml:S2:4399:4	lead	VB	O	O
to	ZYKADIA.xml:S2:4404:2	to	TO	O	O
an	ZYKADIA.xml:S2:4407:2	an	DT	O	O
increased	ZYKADIA.xml:S2:4410:9	increas	VBN	O	O
risk	ZYKADIA.xml:S2:4420:4	risk	NN	O	O
for	ZYKADIA.xml:S2:4425:3	for	IN	O	O
ventricular	ZYKADIA.xml:S2:4429:11	ventricular	JJ	B-AdverseReaction	O
tachyarrhythmias	ZYKADIA.xml:S2:4441:16	tachyarrhythmia	NN	I-AdverseReaction	O
(	ZYKADIA.xml:S2:4458:1	(	(	O	O
e	ZYKADIA.xml:S2:4459:1	e	NN	O	O
.	ZYKADIA.xml:S2:4460:1	.	.	O	O
g	ZYKADIA.xml:S2:4461:1	g	NN	O	O
.	ZYKADIA.xml:S2:4462:1	.	.	O	O
,	ZYKADIA.xml:S2:4463:1	,	,	O	O
Torsade	ZYKADIA.xml:S2:4465:7	torsad	NNP	B-AdverseReaction	O
de	ZYKADIA.xml:S2:4473:2	de	FW	I-AdverseReaction	O
pointes	ZYKADIA.xml:S2:4476:7	point	NNS	I-AdverseReaction	O
)	ZYKADIA.xml:S2:4483:1	)	)	O	O
or	ZYKADIA.xml:S2:4485:2	or	CC	O	O
sudden	ZYKADIA.xml:S2:4488:6	sudden	JJ	B-AdverseReaction	O
death	ZYKADIA.xml:S2:4495:5	death	NN	I-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:4500:1	,	,	O	O
occurred	ZYKADIA.xml:S2:4502:8	occur	VBD	O	O
in	ZYKADIA.xml:S2:4511:2	in	IN	O	O
patients	ZYKADIA.xml:S2:4514:8	patient	NNS	O	O
treated	ZYKADIA.xml:S2:4523:7	treat	VBN	O	O
with	ZYKADIA.xml:S2:4531:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:4536:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:4544:2	in	IN	O	O
clinical	ZYKADIA.xml:S2:4547:8	clinic	JJ	O	O
trials	ZYKADIA.xml:S2:4556:6	trial	NNS	O	O
.	ZYKADIA.xml:S2:4562:1	.	.	O	O

Three	ZYKADIA.xml:S2:4564:5	three	CD	O	O
percent	ZYKADIA.xml:S2:4570:7	percent	NN	O	O
(	ZYKADIA.xml:S2:4578:1	(	(	O	O
3%	ZYKADIA.xml:S2:4579:2	3%	CD	O	O
)	ZYKADIA.xml:S2:4581:1	)	)	O	O
of	ZYKADIA.xml:S2:4583:2	of	IN	O	O
255	ZYKADIA.xml:S2:4586:3	255	CD	O	O
patients	ZYKADIA.xml:S2:4590:8	patient	NNS	O	O
experienced	ZYKADIA.xml:S2:4599:11	experienc	VBD	O	O
a	ZYKADIA.xml:S2:4611:1	a	DT	O	O
QTc	ZYKADIA.xml:S2:4613:3	qtc	NNP	B-AdverseReaction	B-AdverseReaction
interval	ZYKADIA.xml:S2:4617:8	interv	JJ	I-AdverseReaction	I-AdverseReaction
increase	ZYKADIA.xml:S2:4626:8	increas	NN	I-AdverseReaction	I-AdverseReaction
over	ZYKADIA.xml:S2:4635:4	over	IN	O	O
baseline	ZYKADIA.xml:S2:4640:8	baselin	NN	O	O
greater	ZYKADIA.xml:S2:4649:7	greater	JJR	O	O
than	ZYKADIA.xml:S2:4657:4	than	IN	O	O
60	ZYKADIA.xml:S2:4662:2	60	CD	O	O
msec	ZYKADIA.xml:S2:4665:4	msec	NN	O	O
in	ZYKADIA.xml:S2:4670:2	in	IN	O	O
Study	ZYKADIA.xml:S2:4673:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:4679:1	1	CD	O	O
.	ZYKADIA.xml:S2:4680:1	.	.	O	O

Across	ZYKADIA.xml:S2:4682:6	across	IN	O	O
the	ZYKADIA.xml:S2:4689:3	the	DT	O	O
development	ZYKADIA.xml:S2:4693:11	develop	NN	O	O
program	ZYKADIA.xml:S2:4705:7	program	NN	O	O
of	ZYKADIA.xml:S2:4713:2	of	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:4716:7	zykadia	NNP	O	O
,	ZYKADIA.xml:S2:4723:1	,	,	O	O
one	ZYKADIA.xml:S2:4725:3	one	CD	O	O
of	ZYKADIA.xml:S2:4729:2	of	IN	O	O
304	ZYKADIA.xml:S2:4732:3	304	CD	O	O
patients	ZYKADIA.xml:S2:4736:8	patient	NNS	O	O
(	ZYKADIA.xml:S2:4745:1	(	(	O	O
less	ZYKADIA.xml:S2:4746:4	less	JJR	O	O
than	ZYKADIA.xml:S2:4751:4	than	IN	O	O
1%	ZYKADIA.xml:S2:4756:2	1%	CD	O	O
)	ZYKADIA.xml:S2:4758:1	)	)	O	O
treated	ZYKADIA.xml:S2:4760:7	treat	VBN	O	O
with	ZYKADIA.xml:S2:4768:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:4773:7	zykadia	NNP	O	O
doses	ZYKADIA.xml:S2:4781:5	dose	NNS	O	O
ranging	ZYKADIA.xml:S2:4787:7	rang	VBG	O	O
from	ZYKADIA.xml:S2:4795:4	from	IN	O	O
50	ZYKADIA.xml:S2:4800:2	50	CD	O	O
to	ZYKADIA.xml:S2:4803:2	to	TO	O	O
750	ZYKADIA.xml:S2:4806:3	750	CD	O	O
mg	ZYKADIA.xml:S2:4810:2	mg	NN	O	O
was	ZYKADIA.xml:S2:4813:3	wa	VBD	O	O
found	ZYKADIA.xml:S2:4817:5	found	VBN	O	O
to	ZYKADIA.xml:S2:4823:2	to	TO	O	O
have	ZYKADIA.xml:S2:4826:4	have	VB	O	O
a	ZYKADIA.xml:S2:4831:1	a	DT	O	O
QTc	ZYKADIA.xml:S2:4833:3	qtc	NNP	B-AdverseReaction	O
greater	ZYKADIA.xml:S2:4837:7	greater	JJR	I-AdverseReaction	O
than	ZYKADIA.xml:S2:4845:4	than	IN	I-AdverseReaction	O
500	ZYKADIA.xml:S2:4850:3	500	CD	I-AdverseReaction	O
msec	ZYKADIA.xml:S2:4854:4	msec	NNS	I-AdverseReaction	O
and	ZYKADIA.xml:S2:4859:3	and	CC	O	O
3%	ZYKADIA.xml:S2:4863:2	3%	CD	O	O
of	ZYKADIA.xml:S2:4866:2	of	IN	O	O
patients	ZYKADIA.xml:S2:4869:8	patient	NNS	O	O
had	ZYKADIA.xml:S2:4878:3	had	VBD	O	O
an	ZYKADIA.xml:S2:4882:2	an	DT	O	O
increase	ZYKADIA.xml:S2:4885:8	increas	NN	B-AdverseReaction	B-AdverseReaction
from	ZYKADIA.xml:S2:4894:4	from	IN	I-AdverseReaction	O
baseline	ZYKADIA.xml:S2:4899:8	baselin	JJ	I-AdverseReaction	O
QTc	ZYKADIA.xml:S2:4908:3	qtc	NNP	I-AdverseReaction	O
greater	ZYKADIA.xml:S2:4912:7	greater	JJR	O	O
than	ZYKADIA.xml:S2:4920:4	than	IN	O	O
60	ZYKADIA.xml:S2:4925:2	60	CD	O	O
msec	ZYKADIA.xml:S2:4928:4	msec	NN	O	O
.	ZYKADIA.xml:S2:4932:1	.	.	O	O

A	ZYKADIA.xml:S2:4934:1	A	DT	O	O
pharmacokinetic	ZYKADIA.xml:S2:4936:15	pharmacokinet	JJ	O	O
analysis	ZYKADIA.xml:S2:4952:8	analysi	NN	O	O
suggested	ZYKADIA.xml:S2:4961:9	suggest	VBD	O	O
that	ZYKADIA.xml:S2:4971:4	that	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:4976:7	zykadia	NNP	O	O
causes	ZYKADIA.xml:S2:4984:6	caus	VBZ	O	O
concentration	ZYKADIA.xml:S2:4991:13	concentr	NN	O	O
-	ZYKADIA.xml:S2:5004:1	-	:	O	O
dependent	ZYKADIA.xml:S2:5005:9	depend	NN	O	O
increases	ZYKADIA.xml:S2:5015:9	increas	NNS	B-AdverseReaction	O
in	ZYKADIA.xml:S2:5025:2	in	IN	I-AdverseReaction	O
the	ZYKADIA.xml:S2:5028:3	the	DT	I-AdverseReaction	O
QTc	ZYKADIA.xml:S2:5032:3	qtc	NNP	I-AdverseReaction	O
interval	ZYKADIA.xml:S2:5036:8	interv	NN	I-AdverseReaction	O
.	ZYKADIA.xml:S2:5044:1	.	.	O	O

When	ZYKADIA.xml:S2:5052:4	when	WRB	O	O
possible	ZYKADIA.xml:S2:5057:8	possibl	JJ	O	O
,	ZYKADIA.xml:S2:5065:1	,	,	O	O
avoid	ZYKADIA.xml:S2:5067:5	avoid	JJ	O	O
use	ZYKADIA.xml:S2:5073:3	use	NN	O	O
of	ZYKADIA.xml:S2:5077:2	of	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:5080:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:5088:2	in	IN	O	O
patients	ZYKADIA.xml:S2:5091:8	patient	NNS	O	O
with	ZYKADIA.xml:S2:5100:4	with	IN	O	O
congenital	ZYKADIA.xml:S2:5105:10	congenit	JJ	O	O
long	ZYKADIA.xml:S2:5116:4	long	JJ	O	O
QT	ZYKADIA.xml:S2:5121:2	QT	NNP	O	O
syndrome	ZYKADIA.xml:S2:5124:8	syndrom	NN	O	O
.	ZYKADIA.xml:S2:5132:1	.	.	O	O

Conduct	ZYKADIA.xml:S2:5134:7	conduct	NNP	O	O
periodic	ZYKADIA.xml:S2:5142:8	period	JJ	O	O
monitoring	ZYKADIA.xml:S2:5151:10	monitor	NN	O	O
with	ZYKADIA.xml:S2:5162:4	with	IN	O	O
electrocardiograms	ZYKADIA.xml:S2:5167:18	electrocardiogram	NNS	O	O
(	ZYKADIA.xml:S2:5186:1	(	(	O	O
ECGs	ZYKADIA.xml:S2:5187:4	ecg	NNP	O	O
)	ZYKADIA.xml:S2:5191:1	)	)	O	O
and	ZYKADIA.xml:S2:5193:3	and	CC	O	O
electrolytes	ZYKADIA.xml:S2:5197:12	electrolyt	VBZ	O	O
in	ZYKADIA.xml:S2:5210:2	in	IN	O	O
patients	ZYKADIA.xml:S2:5213:8	patient	NNS	O	O
with	ZYKADIA.xml:S2:5222:4	with	IN	O	O
congestive	ZYKADIA.xml:S2:5227:10	congest	JJ	O	O
heart	ZYKADIA.xml:S2:5238:5	heart	NN	O	O
failure	ZYKADIA.xml:S2:5244:7	failur	NN	O	O
,	ZYKADIA.xml:S2:5251:1	,	,	O	O
bradyarrhythmias	ZYKADIA.xml:S2:5253:16	bradyarrhythmia	NN	O	B-AdverseReaction
,	ZYKADIA.xml:S2:5269:1	,	,	O	O
electrolyte	ZYKADIA.xml:S2:5271:11	electrolyt	JJ	O	O
abnormalities	ZYKADIA.xml:S2:5283:13	abnorm	NNS	O	O
,	ZYKADIA.xml:S2:5296:1	,	,	O	O
or	ZYKADIA.xml:S2:5298:2	or	CC	O	O
those	ZYKADIA.xml:S2:5301:5	those	DT	O	O
who	ZYKADIA.xml:S2:5307:3	who	WP	O	O
are	ZYKADIA.xml:S2:5311:3	are	VBP	O	O
taking	ZYKADIA.xml:S2:5315:6	take	VBG	O	O
medications	ZYKADIA.xml:S2:5322:11	medic	NNS	O	O
that	ZYKADIA.xml:S2:5334:4	that	WDT	O	O
are	ZYKADIA.xml:S2:5339:3	are	VBP	O	O
known	ZYKADIA.xml:S2:5343:5	known	VBN	O	O
to	ZYKADIA.xml:S2:5349:2	to	TO	O	O
prolong	ZYKADIA.xml:S2:5352:7	prolong	VB	O	O
the	ZYKADIA.xml:S2:5360:3	the	DT	O	O
QTc	ZYKADIA.xml:S2:5364:3	qtc	NNP	O	O
interval	ZYKADIA.xml:S2:5368:8	interv	NN	O	O
.	ZYKADIA.xml:S2:5376:1	.	.	O	O

Withhold	ZYKADIA.xml:S2:5378:8	withhold	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:5387:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:5395:2	in	IN	O	O
patients	ZYKADIA.xml:S2:5398:8	patient	NNS	O	O
who	ZYKADIA.xml:S2:5407:3	who	WP	O	O
develop	ZYKADIA.xml:S2:5411:7	develop	VBP	O	O
a	ZYKADIA.xml:S2:5419:1	a	DT	O	O
QTc	ZYKADIA.xml:S2:5421:3	qtc	NNP	O	O
interval	ZYKADIA.xml:S2:5425:8	interv	NN	O	O
greater	ZYKADIA.xml:S2:5434:7	greater	JJR	O	O
than	ZYKADIA.xml:S2:5442:4	than	IN	O	O
500	ZYKADIA.xml:S2:5447:3	500	CD	O	O
msec	ZYKADIA.xml:S2:5451:4	msec	NN	O	O
on	ZYKADIA.xml:S2:5456:2	on	IN	O	O
at	ZYKADIA.xml:S2:5459:2	at	IN	O	O
least	ZYKADIA.xml:S2:5462:5	least	JJS	O	O
2	ZYKADIA.xml:S2:5468:1	2	CD	O	O
separate	ZYKADIA.xml:S2:5470:8	separ	JJ	O	O
ECGs	ZYKADIA.xml:S2:5479:4	ecg	NNP	O	O
until	ZYKADIA.xml:S2:5484:5	until	IN	O	O
the	ZYKADIA.xml:S2:5490:3	the	DT	O	O
QTc	ZYKADIA.xml:S2:5494:3	qtc	NNP	O	O
interval	ZYKADIA.xml:S2:5498:8	interv	NN	O	O
is	ZYKADIA.xml:S2:5507:2	is	VBZ	O	O
less	ZYKADIA.xml:S2:5510:4	less	JJR	O	O
than	ZYKADIA.xml:S2:5515:4	than	IN	O	O
481	ZYKADIA.xml:S2:5520:3	481	CD	O	O
msec	ZYKADIA.xml:S2:5524:4	msec	NN	O	O
or	ZYKADIA.xml:S2:5529:2	or	CC	O	O
recovery	ZYKADIA.xml:S2:5532:8	recoveri	NN	O	O
to	ZYKADIA.xml:S2:5541:2	to	TO	O	O
baseline	ZYKADIA.xml:S2:5544:8	baselin	VB	O	O
if	ZYKADIA.xml:S2:5553:2	if	IN	O	O
the	ZYKADIA.xml:S2:5556:3	the	DT	O	O
QTc	ZYKADIA.xml:S2:5560:3	qtc	NNP	O	O
interval	ZYKADIA.xml:S2:5564:8	interv	NN	O	O
is	ZYKADIA.xml:S2:5573:2	is	VBZ	O	O
greater	ZYKADIA.xml:S2:5576:7	greater	JJR	O	O
than	ZYKADIA.xml:S2:5584:4	than	IN	O	O
or	ZYKADIA.xml:S2:5589:2	or	CC	O	O
equal	ZYKADIA.xml:S2:5592:5	equal	JJ	O	O
to	ZYKADIA.xml:S2:5598:2	to	TO	O	O
481	ZYKADIA.xml:S2:5601:3	481	CD	O	O
msec	ZYKADIA.xml:S2:5605:4	msec	NNS	O	O
,	ZYKADIA.xml:S2:5609:1	,	,	O	O
then	ZYKADIA.xml:S2:5611:4	then	RB	O	O
resume	ZYKADIA.xml:S2:5616:6	resum	VB	O	O
ZYKADIA	ZYKADIA.xml:S2:5623:7	zykadia	NNP	O	O
at	ZYKADIA.xml:S2:5631:2	at	IN	O	O
a	ZYKADIA.xml:S2:5634:1	a	DT	O	O
reduced	ZYKADIA.xml:S2:5636:7	reduc	JJ	O	O
dose	ZYKADIA.xml:S2:5644:4	dose	NN	O	O
as	ZYKADIA.xml:S2:5649:2	as	IN	O	O
described	ZYKADIA.xml:S2:5652:9	describ	VBN	O	O
in	ZYKADIA.xml:S2:5662:2	in	IN	O	O
Table	ZYKADIA.xml:S2:5665:5	tabl	JJ	O	O
1	ZYKADIA.xml:S2:5671:1	1	CD	O	O
.	ZYKADIA.xml:S2:5672:1	.	.	O	O

Permanently	ZYKADIA.xml:S2:5674:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:5686:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:5698:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:5706:2	in	IN	O	O
patients	ZYKADIA.xml:S2:5709:8	patient	NNS	O	O
who	ZYKADIA.xml:S2:5718:3	who	WP	O	O
develop	ZYKADIA.xml:S2:5722:7	develop	VBP	O	O
QTc	ZYKADIA.xml:S2:5730:3	qtc	NNP	O	O
interval	ZYKADIA.xml:S2:5734:8	interv	JJ	O	O
prolongation	ZYKADIA.xml:S2:5743:12	prolong	NN	O	O
in	ZYKADIA.xml:S2:5756:2	in	IN	O	O
combination	ZYKADIA.xml:S2:5759:11	combin	NN	O	O
with	ZYKADIA.xml:S2:5771:4	with	IN	O	O
Torsade	ZYKADIA.xml:S2:5776:7	torsad	NNP	O	O
de	ZYKADIA.xml:S2:5784:2	de	FW	O	O
pointes	ZYKADIA.xml:S2:5787:7	point	VBZ	O	O
or	ZYKADIA.xml:S2:5795:2	or	CC	O	O
polymorphic	ZYKADIA.xml:S2:5798:11	polymorph	JJ	O	O
ventricular	ZYKADIA.xml:S2:5810:11	ventricular	JJ	O	O
tachycardia	ZYKADIA.xml:S2:5822:11	tachycardia	NN	O	O
or	ZYKADIA.xml:S2:5834:2	or	CC	O	O
signs	ZYKADIA.xml:S2:5837:5	sign	NNS	O	O
symptoms	ZYKADIA.xml:S2:5843:8	symptom	NNS	O	O
of	ZYKADIA.xml:S2:5852:2	of	IN	O	O
serious	ZYKADIA.xml:S2:5855:7	seriou	JJ	O	O
arrhythmia	ZYKADIA.xml:S2:5863:10	arrhythmia	NN	O	O
[	ZYKADIA.xml:S2:5874:1	[	NNP	O	O
see	ZYKADIA.xml:S2:5875:3	see	VBP	O	O
Dosage	ZYKADIA.xml:S2:5879:6	dosag	NNP	O	O
and	ZYKADIA.xml:S2:5886:3	and	CC	O	O
Administration	ZYKADIA.xml:S2:5890:14	administr	NNP	O	O
(	ZYKADIA.xml:S2:5905:1	(	(	O	O
2.2	ZYKADIA.xml:S2:5906:3	2.2	CD	O	O
)	ZYKADIA.xml:S2:5909:1	)	)	O	O
and	ZYKADIA.xml:S2:5911:3	and	CC	O	O
Clinical	ZYKADIA.xml:S2:5915:8	clinic	JJ	O	O
Pharmacology	ZYKADIA.xml:S2:5924:12	pharmacolog	NNP	O	O
(	ZYKADIA.xml:S2:5937:1	(	(	O	O
12.2	ZYKADIA.xml:S2:5938:4	12.2	CD	O	O
)]	ZYKADIA.xml:S2:5942:2	)]	NN	O	O
.	ZYKADIA.xml:S2:5946:1	.	.	O	O

5.5	ZYKADIA.xml:S2:5955:3	5.5	CD	O	O
Hyperglycemia	ZYKADIA.xml:S2:5963:13	hyperglycemia	NN	O	O

Hyperglycemia	ZYKADIA.xml:S2:5982:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
can	ZYKADIA.xml:S2:5996:3	can	MD	O	O
occur	ZYKADIA.xml:S2:6000:5	occur	VB	O	O
in	ZYKADIA.xml:S2:6006:2	in	IN	O	O
patients	ZYKADIA.xml:S2:6009:8	patient	NNS	O	O
receiving	ZYKADIA.xml:S2:6018:9	receiv	VBG	O	O
ZYKADIA	ZYKADIA.xml:S2:6028:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:6035:1	.	.	O	O

In	ZYKADIA.xml:S2:6037:2	In	IN	O	O
Study	ZYKADIA.xml:S2:6040:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:6046:1	1	CD	O	O
,	ZYKADIA.xml:S2:6047:1	,	,	O	O
CTCAE	ZYKADIA.xml:S2:6049:5	ctcae	NNP	O	O
Grade	ZYKADIA.xml:S2:6055:5	grade	NNP	O	O
3	ZYKADIA.xml:S2:6061:1	3	CD	O	O
-	ZYKADIA.xml:S2:6062:1	-	:	O	O
4	ZYKADIA.xml:S2:6063:1	4	CD	O	O
hyperglycemia	ZYKADIA.xml:S2:6065:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:6078:1	,	,	O	O
based	ZYKADIA.xml:S2:6080:5	base	VBN	O	O
on	ZYKADIA.xml:S2:6086:2	on	IN	O	O
laboratory	ZYKADIA.xml:S2:6089:10	laboratori	NN	O	O
values	ZYKADIA.xml:S2:6100:6	valu	NNS	O	O
,	ZYKADIA.xml:S2:6106:1	,	,	O	O
occurred	ZYKADIA.xml:S2:6108:8	occur	VBD	O	O
in	ZYKADIA.xml:S2:6117:2	in	IN	O	O
13%	ZYKADIA.xml:S2:6120:3	13%	CD	O	O
of	ZYKADIA.xml:S2:6124:2	of	IN	O	O
255	ZYKADIA.xml:S2:6127:3	255	CD	O	O
patients	ZYKADIA.xml:S2:6131:8	patient	NNS	O	O
.	ZYKADIA.xml:S2:6139:1	.	.	O	O

There	ZYKADIA.xml:S2:6141:5	there	EX	O	O
was	ZYKADIA.xml:S2:6147:3	wa	VBD	O	O
a	ZYKADIA.xml:S2:6151:1	a	DT	O	O
6	ZYKADIA.xml:S2:6153:1	6	CD	O	O
-	ZYKADIA.xml:S2:6154:1	-	:	O	O
fold	ZYKADIA.xml:S2:6155:4	fold	JJ	O	O
increase	ZYKADIA.xml:S2:6160:8	increas	NN	O	O
in	ZYKADIA.xml:S2:6169:2	in	IN	O	O
the	ZYKADIA.xml:S2:6172:3	the	DT	O	O
risk	ZYKADIA.xml:S2:6176:4	risk	NN	O	O
of	ZYKADIA.xml:S2:6181:2	of	IN	O	O
CTCAE	ZYKADIA.xml:S2:6184:5	ctcae	NNP	O	O
Grade	ZYKADIA.xml:S2:6190:5	grade	NNP	O	O
3	ZYKADIA.xml:S2:6196:1	3	CD	O	O
-	ZYKADIA.xml:S2:6197:1	-	:	O	O
4	ZYKADIA.xml:S2:6198:1	4	CD	O	O
hyperglycemia	ZYKADIA.xml:S2:6200:13	hyperglycemia	NN	B-AdverseReaction	O
in	ZYKADIA.xml:S2:6214:2	in	IN	O	O
patients	ZYKADIA.xml:S2:6217:8	patient	NNS	O	O
with	ZYKADIA.xml:S2:6226:4	with	IN	O	O
diabetes	ZYKADIA.xml:S2:6231:8	diabet	NNS	O	O
or	ZYKADIA.xml:S2:6240:2	or	CC	O	O
glucose	ZYKADIA.xml:S2:6243:7	glucos	JJ	O	O
intolerance	ZYKADIA.xml:S2:6251:11	intoler	NN	O	O
and	ZYKADIA.xml:S2:6263:3	and	CC	O	O
a	ZYKADIA.xml:S2:6267:1	a	DT	O	O
2	ZYKADIA.xml:S2:6269:1	2	CD	O	O
-	ZYKADIA.xml:S2:6270:1	-	:	O	O
fold	ZYKADIA.xml:S2:6271:4	fold	JJ	O	O
increase	ZYKADIA.xml:S2:6276:8	increas	NN	O	O
in	ZYKADIA.xml:S2:6285:2	in	IN	O	O
patients	ZYKADIA.xml:S2:6288:8	patient	NNS	O	O
taking	ZYKADIA.xml:S2:6297:6	take	VBG	O	O
corticosteroids	ZYKADIA.xml:S2:6304:15	corticosteroid	NNS	O	O
.	ZYKADIA.xml:S2:6319:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:6326:7	monitor	NNP	O	O
fasting	ZYKADIA.xml:S2:6334:7	fast	VBG	O	O
serum	ZYKADIA.xml:S2:6342:5	serum	NN	O	O
glucose	ZYKADIA.xml:S2:6348:7	glucos	JJ	O	O
prior	ZYKADIA.xml:S2:6356:5	prior	RB	O	O
to	ZYKADIA.xml:S2:6362:2	to	TO	O	O
the	ZYKADIA.xml:S2:6365:3	the	DT	O	O
start	ZYKADIA.xml:S2:6369:5	start	NN	O	O
of	ZYKADIA.xml:S2:6375:2	of	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:6378:7	zykadia	NNP	O	O
treatment	ZYKADIA.xml:S2:6386:9	treatment	NN	O	O
and	ZYKADIA.xml:S2:6396:3	and	CC	O	O
periodically	ZYKADIA.xml:S2:6400:12	period	RB	O	O
thereafter	ZYKADIA.xml:S2:6413:10	thereaft	RB	O	O
as	ZYKADIA.xml:S2:6424:2	as	IN	O	O
clinically	ZYKADIA.xml:S2:6427:10	clinic	RB	O	O
indicated	ZYKADIA.xml:S2:6438:9	indic	VBN	O	O
.	ZYKADIA.xml:S2:6447:1	.	.	O	O

Initiate	ZYKADIA.xml:S2:6449:8	initi	NNP	O	O
or	ZYKADIA.xml:S2:6458:2	or	CC	O	O
optimize	ZYKADIA.xml:S2:6461:8	optim	VB	O	O
anti	ZYKADIA.xml:S2:6470:4	anti	JJ	O	O
-	ZYKADIA.xml:S2:6474:1	-	:	O	O
hyperglycemic	ZYKADIA.xml:S2:6475:13	hyperglycem	JJ	O	O
medications	ZYKADIA.xml:S2:6489:11	medic	NNS	O	O
as	ZYKADIA.xml:S2:6501:2	as	IN	O	O
indicated	ZYKADIA.xml:S2:6504:9	indic	JJ	O	O
.	ZYKADIA.xml:S2:6513:1	.	.	O	O

Based	ZYKADIA.xml:S2:6515:5	base	VBN	O	O
on	ZYKADIA.xml:S2:6521:2	on	IN	O	O
the	ZYKADIA.xml:S2:6524:3	the	DT	O	O
severity	ZYKADIA.xml:S2:6528:8	sever	NN	O	O
of	ZYKADIA.xml:S2:6537:2	of	IN	O	O
the	ZYKADIA.xml:S2:6540:3	the	DT	O	O
adverse	ZYKADIA.xml:S2:6544:7	advers	JJ	O	O
drug	ZYKADIA.xml:S2:6552:4	drug	NN	O	O
reaction	ZYKADIA.xml:S2:6557:8	reaction	NN	O	O
,	ZYKADIA.xml:S2:6565:1	,	,	O	O
withhold	ZYKADIA.xml:S2:6567:8	withhold	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:6576:7	zykadia	NNP	O	O
until	ZYKADIA.xml:S2:6584:5	until	IN	O	O
hyperglycemia	ZYKADIA.xml:S2:6590:13	hyperglycemia	NN	O	O
is	ZYKADIA.xml:S2:6604:2	is	VBZ	O	O
adequately	ZYKADIA.xml:S2:6607:10	adequ	RB	O	O
controlled	ZYKADIA.xml:S2:6618:10	control	VBN	O	O
,	ZYKADIA.xml:S2:6628:1	,	,	O	O
then	ZYKADIA.xml:S2:6630:4	then	RB	O	O
resume	ZYKADIA.xml:S2:6635:6	resum	VB	O	O
ZYKADIA	ZYKADIA.xml:S2:6642:7	zykadia	NNP	O	O
at	ZYKADIA.xml:S2:6650:2	at	IN	O	O
a	ZYKADIA.xml:S2:6653:1	a	DT	O	O
reduced	ZYKADIA.xml:S2:6655:7	reduc	JJ	O	O
dose	ZYKADIA.xml:S2:6663:4	dose	NN	O	O
as	ZYKADIA.xml:S2:6668:2	as	IN	O	O
described	ZYKADIA.xml:S2:6671:9	describ	VBN	O	O
in	ZYKADIA.xml:S2:6681:2	in	IN	O	O
Table	ZYKADIA.xml:S2:6684:5	tabl	JJ	O	O
1	ZYKADIA.xml:S2:6690:1	1	CD	O	O
.	ZYKADIA.xml:S2:6691:1	.	.	O	O

If	ZYKADIA.xml:S2:6693:2	If	IN	O	O
adequate	ZYKADIA.xml:S2:6696:8	adequ	JJ	O	O
hyperglycemic	ZYKADIA.xml:S2:6705:13	hyperglycem	NNS	O	O
control	ZYKADIA.xml:S2:6719:7	control	NN	O	O
cannot	ZYKADIA.xml:S2:6727:6	cannot	NN	O	O
be	ZYKADIA.xml:S2:6734:2	be	VB	O	O
achieved	ZYKADIA.xml:S2:6737:8	achiev	VBN	O	O
with	ZYKADIA.xml:S2:6746:4	with	IN	O	O
optimal	ZYKADIA.xml:S2:6751:7	optim	JJ	O	O
medical	ZYKADIA.xml:S2:6759:7	medic	JJ	O	O
management	ZYKADIA.xml:S2:6767:10	manag	NN	O	O
,	ZYKADIA.xml:S2:6777:1	,	,	O	O
permanently	ZYKADIA.xml:S2:6779:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:6791:11	discontinu	VBP	O	O
ZYKADIA	ZYKADIA.xml:S2:6803:7	zykadia	NNP	O	O
[	ZYKADIA.xml:S2:6811:1	[	NNP	O	O
see	ZYKADIA.xml:S2:6812:3	see	VBP	O	O
Dosage	ZYKADIA.xml:S2:6816:6	dosag	NNP	O	O
and	ZYKADIA.xml:S2:6823:3	and	CC	O	O
Administration	ZYKADIA.xml:S2:6827:14	administr	NNP	O	O
(	ZYKADIA.xml:S2:6842:1	(	(	O	O
2.2	ZYKADIA.xml:S2:6843:3	2.2	CD	O	O
)	ZYKADIA.xml:S2:6846:1	)	)	O	O
and	ZYKADIA.xml:S2:6848:3	and	CC	O	O
Adverse	ZYKADIA.xml:S2:6852:7	advers	JJ	O	O
Reactions	ZYKADIA.xml:S2:6860:9	reaction	NNP	O	O
(	ZYKADIA.xml:S2:6870:1	(	(	O	O
6	ZYKADIA.xml:S2:6871:1	6	CD	O	O
)]	ZYKADIA.xml:S2:6872:2	)]	NN	O	O
.	ZYKADIA.xml:S2:6876:1	.	.	O	O

5.6	ZYKADIA.xml:S2:6887:3	5.6	CD	O	O
Bradycardia	ZYKADIA.xml:S2:6895:11	bradycardia	NNP	O	O

Bradycardia	ZYKADIA.xml:S2:6912:11	bradycardia	NNP	B-AdverseReaction	B-AdverseReaction
can	ZYKADIA.xml:S2:6924:3	can	MD	O	O
occur	ZYKADIA.xml:S2:6928:5	occur	VB	O	O
in	ZYKADIA.xml:S2:6934:2	in	IN	O	O
patients	ZYKADIA.xml:S2:6937:8	patient	NNS	O	O
receiving	ZYKADIA.xml:S2:6946:9	receiv	VBG	O	O
ZYKADIA	ZYKADIA.xml:S2:6956:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:6963:1	.	.	O	O

In	ZYKADIA.xml:S2:6965:2	In	IN	O	O
Study	ZYKADIA.xml:S2:6968:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:6974:1	1	CD	O	O
,	ZYKADIA.xml:S2:6975:1	,	,	O	O
sinus	ZYKADIA.xml:S2:6977:5	sinu	NN	B-AdverseReaction	B-AdverseReaction
bradycardia	ZYKADIA.xml:S2:6983:11	bradycardia	NN	I-AdverseReaction	I-AdverseReaction
,	ZYKADIA.xml:S2:6994:1	,	,	O	O
defined	ZYKADIA.xml:S2:6996:7	defin	VBD	O	O
as	ZYKADIA.xml:S2:7004:2	as	IN	O	O
a	ZYKADIA.xml:S2:7007:1	a	DT	O	O
heart	ZYKADIA.xml:S2:7009:5	heart	NN	B-AdverseReaction	O
rate	ZYKADIA.xml:S2:7015:4	rate	NN	I-AdverseReaction	O
of	ZYKADIA.xml:S2:7020:2	of	IN	I-AdverseReaction	O
less	ZYKADIA.xml:S2:7023:4	less	JJR	I-AdverseReaction	O
than	ZYKADIA.xml:S2:7028:4	than	IN	I-AdverseReaction	O
50	ZYKADIA.xml:S2:7033:2	50	CD	I-AdverseReaction	O
beats	ZYKADIA.xml:S2:7036:5	beat	NNS	I-AdverseReaction	O
per	ZYKADIA.xml:S2:7042:3	per	IN	I-AdverseReaction	O
minute	ZYKADIA.xml:S2:7046:6	minut	NN	I-AdverseReaction	O
,	ZYKADIA.xml:S2:7052:1	,	,	O	O
was	ZYKADIA.xml:S2:7054:3	wa	VBD	O	O
noted	ZYKADIA.xml:S2:7058:5	note	VBN	O	O
as	ZYKADIA.xml:S2:7064:2	as	IN	O	O
a	ZYKADIA.xml:S2:7067:1	a	DT	O	O
new	ZYKADIA.xml:S2:7069:3	new	JJ	O	O
finding	ZYKADIA.xml:S2:7073:7	find	NN	O	O
in	ZYKADIA.xml:S2:7081:2	in	IN	O	O
1%	ZYKADIA.xml:S2:7084:2	1%	CD	O	O
of	ZYKADIA.xml:S2:7087:2	of	IN	O	O
255	ZYKADIA.xml:S2:7090:3	255	CD	O	O
patients	ZYKADIA.xml:S2:7094:8	patient	NNS	O	O
.	ZYKADIA.xml:S2:7102:1	.	.	O	O

Bradycardia	ZYKADIA.xml:S2:7104:11	bradycardia	NNP	B-AdverseReaction	B-AdverseReaction
was	ZYKADIA.xml:S2:7116:3	wa	VBD	O	O
reported	ZYKADIA.xml:S2:7120:8	report	VBN	O	O
as	ZYKADIA.xml:S2:7129:2	as	IN	O	O
an	ZYKADIA.xml:S2:7132:2	an	DT	O	O
adverse	ZYKADIA.xml:S2:7135:7	advers	JJ	O	O
drug	ZYKADIA.xml:S2:7143:4	drug	NN	O	O
reaction	ZYKADIA.xml:S2:7148:8	reaction	NN	O	O
in	ZYKADIA.xml:S2:7157:2	in	IN	O	O
3%	ZYKADIA.xml:S2:7160:2	3%	CD	O	O
of	ZYKADIA.xml:S2:7163:2	of	IN	O	O
patients	ZYKADIA.xml:S2:7166:8	patient	NNS	O	O
in	ZYKADIA.xml:S2:7175:2	in	IN	O	O
Study	ZYKADIA.xml:S2:7178:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:7184:1	1	CD	O	O
.	ZYKADIA.xml:S2:7185:1	.	.	O	O

Avoid	ZYKADIA.xml:S2:7191:5	avoid	NNP	O	O
using	ZYKADIA.xml:S2:7197:5	use	VBG	O	O
ZYKADIA	ZYKADIA.xml:S2:7203:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:7211:2	in	IN	O	O
combination	ZYKADIA.xml:S2:7214:11	combin	NN	O	O
with	ZYKADIA.xml:S2:7226:4	with	IN	O	O
other	ZYKADIA.xml:S2:7231:5	other	JJ	O	O
agents	ZYKADIA.xml:S2:7237:6	agent	NNS	O	O
known	ZYKADIA.xml:S2:7244:5	known	VBN	O	O
to	ZYKADIA.xml:S2:7250:2	to	TO	O	O
cause	ZYKADIA.xml:S2:7253:5	caus	VB	O	O
bradycardia	ZYKADIA.xml:S2:7259:11	bradycardia	NN	O	O
(	ZYKADIA.xml:S2:7271:1	(	(	O	O
e	ZYKADIA.xml:S2:7272:1	e	NN	O	O
.	ZYKADIA.xml:S2:7273:1	.	.	O	O
g	ZYKADIA.xml:S2:7274:1	g	NN	O	O
.	ZYKADIA.xml:S2:7275:1	.	.	O	O
,	ZYKADIA.xml:S2:7276:1	,	,	O	O
beta	ZYKADIA.xml:S2:7278:4	beta	SYM	O	O
-	ZYKADIA.xml:S2:7282:1	-	:	O	O
blockers	ZYKADIA.xml:S2:7283:8	blocker	NNS	O	O
,	ZYKADIA.xml:S2:7291:1	,	,	O	O
non	ZYKADIA.xml:S2:7293:3	non	SYM	O	O
-	ZYKADIA.xml:S2:7296:1	-	:	O	O
dihydropyridine	ZYKADIA.xml:S2:7297:15	dihydropyridin	NN	O	O
calcium	ZYKADIA.xml:S2:7313:7	calcium	NN	O	O
channel	ZYKADIA.xml:S2:7321:7	channel	NN	O	O
blockers	ZYKADIA.xml:S2:7329:8	blocker	NNS	O	O
,	ZYKADIA.xml:S2:7337:1	,	,	O	O
clonidine	ZYKADIA.xml:S2:7339:9	clonidin	NN	O	O
,	ZYKADIA.xml:S2:7348:1	,	,	O	O
and	ZYKADIA.xml:S2:7350:3	and	CC	O	O
digoxin	ZYKADIA.xml:S2:7354:7	digoxin	NN	O	O
)	ZYKADIA.xml:S2:7361:1	)	)	O	O
to	ZYKADIA.xml:S2:7363:2	to	TO	O	O
the	ZYKADIA.xml:S2:7366:3	the	DT	O	O
extent	ZYKADIA.xml:S2:7370:6	extent	NN	O	O
possible	ZYKADIA.xml:S2:7377:8	possibl	JJ	O	O
.	ZYKADIA.xml:S2:7385:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:7387:7	monitor	NNP	O	O
heart	ZYKADIA.xml:S2:7395:5	heart	NN	O	O
rate	ZYKADIA.xml:S2:7401:4	rate	NN	O	O
and	ZYKADIA.xml:S2:7406:3	and	CC	O	O
blood	ZYKADIA.xml:S2:7410:5	blood	NN	O	O
pressure	ZYKADIA.xml:S2:7416:8	pressur	NN	O	O
regularly	ZYKADIA.xml:S2:7425:9	regularli	RB	O	O
.	ZYKADIA.xml:S2:7434:1	.	.	O	O

In	ZYKADIA.xml:S2:7436:2	In	IN	O	O
cases	ZYKADIA.xml:S2:7439:5	case	NNS	O	O
of	ZYKADIA.xml:S2:7445:2	of	IN	O	O
symptomatic	ZYKADIA.xml:S2:7448:11	symptomat	JJ	O	O
bradycardia	ZYKADIA.xml:S2:7460:11	bradycardia	NN	O	O
that	ZYKADIA.xml:S2:7472:4	that	WDT	O	O
is	ZYKADIA.xml:S2:7477:2	is	VBZ	O	O
not	ZYKADIA.xml:S2:7480:3	not	RB	O	O
life	ZYKADIA.xml:S2:7484:4	life	NN	O	O
-	ZYKADIA.xml:S2:7488:1	-	:	O	O
threatening	ZYKADIA.xml:S2:7489:11	threaten	NN	O	O
,	ZYKADIA.xml:S2:7500:1	,	,	O	O
withhold	ZYKADIA.xml:S2:7502:8	withhold	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:7511:7	zykadia	NNP	O	O
until	ZYKADIA.xml:S2:7519:5	until	IN	O	O
recovery	ZYKADIA.xml:S2:7525:8	recoveri	NN	O	O
to	ZYKADIA.xml:S2:7534:2	to	TO	O	O
asymptomatic	ZYKADIA.xml:S2:7537:12	asymptomat	JJ	O	O
bradycardia	ZYKADIA.xml:S2:7550:11	bradycardia	NN	O	O
or	ZYKADIA.xml:S2:7562:2	or	CC	O	O
to	ZYKADIA.xml:S2:7565:2	to	TO	O	O
a	ZYKADIA.xml:S2:7568:1	a	DT	O	O
heart	ZYKADIA.xml:S2:7570:5	heart	NN	O	O
rate	ZYKADIA.xml:S2:7576:4	rate	NN	O	O
of	ZYKADIA.xml:S2:7581:2	of	IN	O	O
60	ZYKADIA.xml:S2:7584:2	60	CD	O	O
bpm	ZYKADIA.xml:S2:7587:3	bpm	NN	O	O
or	ZYKADIA.xml:S2:7591:2	or	CC	O	O
above	ZYKADIA.xml:S2:7594:5	abov	IN	O	O
,	ZYKADIA.xml:S2:7599:1	,	,	O	O
evaluate	ZYKADIA.xml:S2:7601:8	evalu	VB	O	O
the	ZYKADIA.xml:S2:7610:3	the	DT	O	O
use	ZYKADIA.xml:S2:7614:3	use	NN	O	O
of	ZYKADIA.xml:S2:7618:2	of	IN	O	O
concomitant	ZYKADIA.xml:S2:7621:11	concomit	JJ	O	O
medications	ZYKADIA.xml:S2:7633:11	medic	NNS	O	O
,	ZYKADIA.xml:S2:7644:1	,	,	O	O
and	ZYKADIA.xml:S2:7646:3	and	CC	O	O
adjust	ZYKADIA.xml:S2:7650:6	adjust	VBP	O	O
the	ZYKADIA.xml:S2:7657:3	the	DT	O	O
dose	ZYKADIA.xml:S2:7661:4	dose	NN	O	O
of	ZYKADIA.xml:S2:7666:2	of	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:7669:7	zykadia	NNP	O	O
.	ZYKADIA.xml:S2:7676:1	.	.	O	O

Permanently	ZYKADIA.xml:S2:7678:11	perman	RB	O	O
discontinue	ZYKADIA.xml:S2:7690:11	discontinu	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:7702:7	zykadia	NNP	O	O
for	ZYKADIA.xml:S2:7710:3	for	IN	O	O
life	ZYKADIA.xml:S2:7714:4	life	NN	O	O
-	ZYKADIA.xml:S2:7718:1	-	:	O	O
threatening	ZYKADIA.xml:S2:7719:11	threaten	JJ	O	O
bradycardia	ZYKADIA.xml:S2:7731:11	bradycardia	NN	O	O
if	ZYKADIA.xml:S2:7743:2	if	IN	O	O
no	ZYKADIA.xml:S2:7746:2	no	DT	O	O
contributing	ZYKADIA.xml:S2:7749:12	contribut	VBG	O	O
concomitant	ZYKADIA.xml:S2:7762:11	concomit	JJ	O	O
medication	ZYKADIA.xml:S2:7774:10	medic	NN	O	O
is	ZYKADIA.xml:S2:7785:2	is	VBZ	O	O
identified	ZYKADIA.xml:S2:7788:10	identifi	VBN	O	O
;	ZYKADIA.xml:S2:7798:1	;	:	O	O
however	ZYKADIA.xml:S2:7800:7	howev	RB	O	O
,	ZYKADIA.xml:S2:7807:1	,	,	O	O
if	ZYKADIA.xml:S2:7809:2	if	IN	O	O
associated	ZYKADIA.xml:S2:7812:10	associ	VBN	O	O
with	ZYKADIA.xml:S2:7823:4	with	IN	O	O
a	ZYKADIA.xml:S2:7828:1	a	DT	O	O
concomitant	ZYKADIA.xml:S2:7830:11	concomit	JJ	O	O
medication	ZYKADIA.xml:S2:7842:10	medic	NN	O	O
known	ZYKADIA.xml:S2:7853:5	known	VBN	O	O
to	ZYKADIA.xml:S2:7859:2	to	TO	O	O
cause	ZYKADIA.xml:S2:7862:5	caus	VB	O	O
bradycardia	ZYKADIA.xml:S2:7868:11	bradycardia	NN	O	O
or	ZYKADIA.xml:S2:7880:2	or	CC	O	O
hypotension	ZYKADIA.xml:S2:7883:11	hypotens	NN	O	O
,	ZYKADIA.xml:S2:7894:1	,	,	O	O
withhold	ZYKADIA.xml:S2:7896:8	withhold	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:7905:7	zykadia	NNP	O	O
until	ZYKADIA.xml:S2:7913:5	until	IN	O	O
recovery	ZYKADIA.xml:S2:7919:8	recoveri	NN	O	O
to	ZYKADIA.xml:S2:7928:2	to	TO	O	O
asymptomatic	ZYKADIA.xml:S2:7931:12	asymptomat	JJ	O	O
bradycardia	ZYKADIA.xml:S2:7944:11	bradycardia	NN	O	O
or	ZYKADIA.xml:S2:7956:2	or	CC	O	O
to	ZYKADIA.xml:S2:7959:2	to	TO	O	O
a	ZYKADIA.xml:S2:7962:1	a	DT	O	O
heart	ZYKADIA.xml:S2:7964:5	heart	NN	O	O
rate	ZYKADIA.xml:S2:7970:4	rate	NN	O	O
of	ZYKADIA.xml:S2:7975:2	of	IN	O	O
60	ZYKADIA.xml:S2:7978:2	60	CD	O	O
bpm	ZYKADIA.xml:S2:7981:3	bpm	NN	O	O
or	ZYKADIA.xml:S2:7985:2	or	CC	O	O
above	ZYKADIA.xml:S2:7988:5	abov	NN	O	O
,	ZYKADIA.xml:S2:7993:1	,	,	O	O
and	ZYKADIA.xml:S2:7995:3	and	CC	O	O
if	ZYKADIA.xml:S2:7999:2	if	IN	O	O
the	ZYKADIA.xml:S2:8002:3	the	DT	O	O
concomitant	ZYKADIA.xml:S2:8006:11	concomit	JJ	O	O
medication	ZYKADIA.xml:S2:8018:10	medic	NN	O	O
can	ZYKADIA.xml:S2:8029:3	can	MD	O	O
be	ZYKADIA.xml:S2:8033:2	be	VB	O	O
adjusted	ZYKADIA.xml:S2:8036:8	adjust	VBN	O	O
or	ZYKADIA.xml:S2:8045:2	or	CC	O	O
discontinued	ZYKADIA.xml:S2:8048:12	discontinu	VBN	O	O
,	ZYKADIA.xml:S2:8060:1	,	,	O	O
resume	ZYKADIA.xml:S2:8062:6	resum	VB	O	O
ZYKADIA	ZYKADIA.xml:S2:8069:7	zykadia	NNP	O	O
at	ZYKADIA.xml:S2:8077:2	at	IN	O	O
a	ZYKADIA.xml:S2:8080:1	a	DT	O	O
reduced	ZYKADIA.xml:S2:8082:7	reduc	JJ	O	O
dose	ZYKADIA.xml:S2:8090:4	dose	NN	O	O
as	ZYKADIA.xml:S2:8095:2	as	IN	O	O
described	ZYKADIA.xml:S2:8098:9	describ	VBN	O	O
in	ZYKADIA.xml:S2:8108:2	in	IN	O	O
Table	ZYKADIA.xml:S2:8111:5	tabl	JJ	O	O
1	ZYKADIA.xml:S2:8117:1	1	CD	O	O
upon	ZYKADIA.xml:S2:8119:4	upon	JJ	O	O
recovery	ZYKADIA.xml:S2:8124:8	recoveri	NN	O	O
to	ZYKADIA.xml:S2:8133:2	to	TO	O	O
asymptomatic	ZYKADIA.xml:S2:8136:12	asymptomat	JJ	O	O
bradycardia	ZYKADIA.xml:S2:8149:11	bradycardia	NN	O	O
or	ZYKADIA.xml:S2:8161:2	or	CC	O	O
to	ZYKADIA.xml:S2:8164:2	to	TO	O	O
a	ZYKADIA.xml:S2:8167:1	a	DT	O	O
heart	ZYKADIA.xml:S2:8169:5	heart	NN	O	O
rate	ZYKADIA.xml:S2:8175:4	rate	NN	O	O
of	ZYKADIA.xml:S2:8180:2	of	IN	O	O
60	ZYKADIA.xml:S2:8183:2	60	CD	O	O
bpm	ZYKADIA.xml:S2:8186:3	bpm	NN	O	O
or	ZYKADIA.xml:S2:8190:2	or	CC	O	O
above	ZYKADIA.xml:S2:8193:5	abov	IN	O	O
,	ZYKADIA.xml:S2:8198:1	,	,	O	O
with	ZYKADIA.xml:S2:8200:4	with	IN	O	O
frequent	ZYKADIA.xml:S2:8205:8	frequent	JJ	O	O
monitoring	ZYKADIA.xml:S2:8214:10	monitor	NN	O	O
[	ZYKADIA.xml:S2:8225:1	[	NNP	O	O
see	ZYKADIA.xml:S2:8226:3	see	VBP	O	O
Dosage	ZYKADIA.xml:S2:8230:6	dosag	NNP	O	O
and	ZYKADIA.xml:S2:8237:3	and	CC	O	O
Administration	ZYKADIA.xml:S2:8241:14	administr	NNP	O	O
(	ZYKADIA.xml:S2:8256:1	(	(	O	O
2.2	ZYKADIA.xml:S2:8257:3	2.2	CD	O	O
)	ZYKADIA.xml:S2:8260:1	)	)	O	O
and	ZYKADIA.xml:S2:8262:3	and	CC	O	O
Adverse	ZYKADIA.xml:S2:8266:7	advers	JJ	O	O
Reactions	ZYKADIA.xml:S2:8274:9	reaction	NNP	O	O
(	ZYKADIA.xml:S2:8284:1	(	(	O	O
6	ZYKADIA.xml:S2:8285:1	6	CD	O	O
)]	ZYKADIA.xml:S2:8286:2	)]	NN	O	O
.	ZYKADIA.xml:S2:8290:1	.	.	O	O

5.7	ZYKADIA.xml:S2:8299:3	5.7	CD	O	O
Pancreatitis	ZYKADIA.xml:S2:8307:12	pancreat	NN	O	O

Pancreatitis	ZYKADIA.xml:S2:8326:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:8338:1	,	,	O	O
including	ZYKADIA.xml:S2:8340:9	includ	VBG	O	O
one	ZYKADIA.xml:S2:8350:3	one	CD	O	O
fatality	ZYKADIA.xml:S2:8354:8	fatal	NN	B-AdverseReaction	B-AdverseReaction
,	ZYKADIA.xml:S2:8362:1	,	,	O	O
has	ZYKADIA.xml:S2:8364:3	ha	VBZ	O	O
been	ZYKADIA.xml:S2:8368:4	been	VBN	O	O
reported	ZYKADIA.xml:S2:8373:8	report	VBN	O	O
in	ZYKADIA.xml:S2:8382:2	in	IN	O	O
less	ZYKADIA.xml:S2:8385:4	less	JJR	O	O
than	ZYKADIA.xml:S2:8390:4	than	IN	O	O
1%	ZYKADIA.xml:S2:8395:2	1%	CD	O	O
of	ZYKADIA.xml:S2:8398:2	of	IN	O	O
patients	ZYKADIA.xml:S2:8401:8	patient	NNS	O	O
receiving	ZYKADIA.xml:S2:8410:9	receiv	VBG	O	O
ZYKADIA	ZYKADIA.xml:S2:8420:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:8428:2	in	IN	O	O
clinical	ZYKADIA.xml:S2:8431:8	clinic	JJ	O	O
trials	ZYKADIA.xml:S2:8440:6	trial	NNS	O	O
.	ZYKADIA.xml:S2:8446:1	.	.	O	O

CTCAE	ZYKADIA.xml:S2:8448:5	ctcae	NNP	O	O
Grade	ZYKADIA.xml:S2:8454:5	grade	NNP	O	O
3	ZYKADIA.xml:S2:8460:1	3	CD	O	O
-	ZYKADIA.xml:S2:8461:1	-	:	O	O
4	ZYKADIA.xml:S2:8462:1	4	CD	O	O
elevations	ZYKADIA.xml:S2:8464:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
of	ZYKADIA.xml:S2:8475:2	of	IN	I-AdverseReaction	I-AdverseReaction
lipase	ZYKADIA.xml:S2:8478:6	lipas	NN	I-AdverseReaction	I-AdverseReaction
and	ZYKADIA.xml:S2:8485:3	and	CC	O	O
or	ZYKADIA.xml:S2:8489:2	or	CC	O	O
amylase	ZYKADIA.xml:S2:8492:7	amylas	VB	I-AdverseReaction	O
occurred	ZYKADIA.xml:S2:8500:8	occur	VBN	O	O
in	ZYKADIA.xml:S2:8509:2	in	IN	O	O
15%	ZYKADIA.xml:S2:8512:3	15%	CD	O	O
of	ZYKADIA.xml:S2:8516:2	of	IN	O	O
patients	ZYKADIA.xml:S2:8519:8	patient	NNS	O	O
receiving	ZYKADIA.xml:S2:8528:9	receiv	VBG	O	O
ZYKADIA	ZYKADIA.xml:S2:8538:7	zykadia	NNP	O	O
in	ZYKADIA.xml:S2:8546:2	in	IN	O	O
Study	ZYKADIA.xml:S2:8549:5	studi	NNP	O	O
1	ZYKADIA.xml:S2:8555:1	1	CD	O	O
.	ZYKADIA.xml:S2:8556:1	.	.	O	O

Monitor	ZYKADIA.xml:S2:8558:7	monitor	NNP	O	O
lipase	ZYKADIA.xml:S2:8566:6	lipas	NN	O	O
and	ZYKADIA.xml:S2:8573:3	and	CC	O	O
amylase	ZYKADIA.xml:S2:8577:7	amylas	NN	O	O
prior	ZYKADIA.xml:S2:8585:5	prior	RB	O	O
to	ZYKADIA.xml:S2:8591:2	to	TO	O	O
the	ZYKADIA.xml:S2:8594:3	the	DT	O	O
start	ZYKADIA.xml:S2:8598:5	start	NN	O	O
of	ZYKADIA.xml:S2:8604:2	of	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:8607:7	zykadia	NNP	O	O
treatment	ZYKADIA.xml:S2:8615:9	treatment	NN	O	O
and	ZYKADIA.xml:S2:8625:3	and	CC	O	O
periodically	ZYKADIA.xml:S2:8629:12	period	RB	O	O
thereafter	ZYKADIA.xml:S2:8642:10	thereaft	RB	O	O
as	ZYKADIA.xml:S2:8653:2	as	IN	O	O
clinically	ZYKADIA.xml:S2:8656:10	clinic	RB	O	O
indicated	ZYKADIA.xml:S2:8667:9	indic	VBN	O	O
.	ZYKADIA.xml:S2:8676:1	.	.	O	O

Based	ZYKADIA.xml:S2:8678:5	base	VBN	O	O
on	ZYKADIA.xml:S2:8684:2	on	IN	O	O
the	ZYKADIA.xml:S2:8687:3	the	DT	O	O
severity	ZYKADIA.xml:S2:8691:8	sever	NN	O	O
of	ZYKADIA.xml:S2:8700:2	of	IN	O	O
the	ZYKADIA.xml:S2:8703:3	the	DT	O	O
laboratory	ZYKADIA.xml:S2:8707:10	laboratori	NN	O	O
abnormalities	ZYKADIA.xml:S2:8718:13	abnorm	NNS	O	O
,	ZYKADIA.xml:S2:8731:1	,	,	O	O
withhold	ZYKADIA.xml:S2:8733:8	withhold	JJ	O	O
ZYKADIA	ZYKADIA.xml:S2:8742:7	zykadia	NNP	O	O
with	ZYKADIA.xml:S2:8750:4	with	IN	O	O
resumption	ZYKADIA.xml:S2:8755:10	resumpt	NN	O	O
at	ZYKADIA.xml:S2:8766:2	at	IN	O	O
a	ZYKADIA.xml:S2:8769:1	a	DT	O	O
reduced	ZYKADIA.xml:S2:8771:7	reduc	JJ	O	O
dose	ZYKADIA.xml:S2:8779:4	dose	NN	O	O
as	ZYKADIA.xml:S2:8784:2	as	IN	O	O
described	ZYKADIA.xml:S2:8787:9	describ	VBN	O	O
in	ZYKADIA.xml:S2:8797:2	in	IN	O	O
Table	ZYKADIA.xml:S2:8800:5	tabl	JJ	O	O
1	ZYKADIA.xml:S2:8806:1	1	CD	O	O
[	ZYKADIA.xml:S2:8808:1	[	NN	O	O
see	ZYKADIA.xml:S2:8809:3	see	NN	O	O
Dosage	ZYKADIA.xml:S2:8813:6	dosag	NNP	O	O
and	ZYKADIA.xml:S2:8820:3	and	CC	O	O
Administration	ZYKADIA.xml:S2:8824:14	administr	NNP	O	O
(	ZYKADIA.xml:S2:8839:1	(	(	O	O
2.2	ZYKADIA.xml:S2:8840:3	2.2	CD	O	O
)	ZYKADIA.xml:S2:8843:1	)	)	O	O
and	ZYKADIA.xml:S2:8845:3	and	CC	O	O
Adverse	ZYKADIA.xml:S2:8849:7	advers	JJ	O	O
Reactions	ZYKADIA.xml:S2:8857:9	reaction	NNP	O	O
(	ZYKADIA.xml:S2:8867:1	(	(	O	O
6	ZYKADIA.xml:S2:8868:1	6	CD	O	O
)]	ZYKADIA.xml:S2:8869:2	)]	NN	O	O
.	ZYKADIA.xml:S2:8873:1	.	.	O	O

5.8	ZYKADIA.xml:S2:8884:3	5.8	CD	O	O
Embryofetal	ZYKADIA.xml:S2:8892:11	embryofet	JJ	O	O
Toxicity	ZYKADIA.xml:S2:8904:8	toxic	NN	O	O

Based	ZYKADIA.xml:S2:8918:5	base	VBN	O	O
on	ZYKADIA.xml:S2:8924:2	on	IN	O	O
its	ZYKADIA.xml:S2:8927:3	it	PRP$	O	O
mechanism	ZYKADIA.xml:S2:8931:9	mechan	NN	O	O
of	ZYKADIA.xml:S2:8941:2	of	IN	O	O
action	ZYKADIA.xml:S2:8944:6	action	NN	O	O
,	ZYKADIA.xml:S2:8950:1	,	,	O	O
ZYKADIA	ZYKADIA.xml:S2:8952:7	zykadia	NNP	O	O
may	ZYKADIA.xml:S2:8960:3	may	MD	O	O
cause	ZYKADIA.xml:S2:8964:5	caus	VB	O	O
fetal	ZYKADIA.xml:S2:8970:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	ZYKADIA.xml:S2:8976:4	harm	NN	I-AdverseReaction	I-AdverseReaction
when	ZYKADIA.xml:S2:8981:4	when	WRB	O	O
administered	ZYKADIA.xml:S2:8986:12	administ	VBN	O	O
to	ZYKADIA.xml:S2:8999:2	to	TO	O	O
a	ZYKADIA.xml:S2:9002:1	a	DT	O	O
pregnant	ZYKADIA.xml:S2:9004:8	pregnant	JJ	O	O
woman	ZYKADIA.xml:S2:9013:5	woman	NN	O	O
.	ZYKADIA.xml:S2:9018:1	.	.	O	O

In	ZYKADIA.xml:S2:9020:2	In	IN	O	O
animal	ZYKADIA.xml:S2:9023:6	anim	JJ	O	O
studies	ZYKADIA.xml:S2:9030:7	studi	NNS	O	O
,	ZYKADIA.xml:S2:9037:1	,	,	O	O
administration	ZYKADIA.xml:S2:9039:14	administr	NN	O	O
of	ZYKADIA.xml:S2:9054:2	of	IN	O	O
ceritinib	ZYKADIA.xml:S2:9057:9	ceritinib	NN	O	O
to	ZYKADIA.xml:S2:9067:2	to	TO	O	O
rats	ZYKADIA.xml:S2:9070:4	rat	NNS	O	O
and	ZYKADIA.xml:S2:9075:3	and	CC	O	O
rabbits	ZYKADIA.xml:S2:9079:7	rabbit	NNS	O	O
during	ZYKADIA.xml:S2:9087:6	dure	IN	O	O
organogenesis	ZYKADIA.xml:S2:9094:13	organogenesi	NN	O	O
at	ZYKADIA.xml:S2:9108:2	at	IN	O	O
maternal	ZYKADIA.xml:S2:9111:8	matern	JJ	O	O
plasma	ZYKADIA.xml:S2:9120:6	plasma	NN	O	O
exposures	ZYKADIA.xml:S2:9127:9	exposur	NNS	O	O
below	ZYKADIA.xml:S2:9137:5	below	IN	O	O
the	ZYKADIA.xml:S2:9143:3	the	DT	O	O
recommended	ZYKADIA.xml:S2:9147:11	recommend	JJ	O	O
human	ZYKADIA.xml:S2:9159:5	human	JJ	O	O
dose	ZYKADIA.xml:S2:9165:4	dose	NN	O	O
of	ZYKADIA.xml:S2:9170:2	of	IN	O	O
750	ZYKADIA.xml:S2:9173:3	750	CD	O	O
mg	ZYKADIA.xml:S2:9177:2	mg	JJ	O	O
daily	ZYKADIA.xml:S2:9180:5	daili	RB	O	O
caused	ZYKADIA.xml:S2:9186:6	caus	VBN	O	O
increases	ZYKADIA.xml:S2:9193:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	ZYKADIA.xml:S2:9203:2	in	IN	I-AdverseReaction	I-AdverseReaction
skeletal	ZYKADIA.xml:S2:9206:8	skelet	JJ	I-AdverseReaction	I-AdverseReaction
anomalies	ZYKADIA.xml:S2:9215:9	anomali	NNS	I-AdverseReaction	I-AdverseReaction
in	ZYKADIA.xml:S2:9225:2	in	IN	O	O
rats	ZYKADIA.xml:S2:9228:4	rat	NNS	O	O
and	ZYKADIA.xml:S2:9233:3	and	CC	O	O
rabbits	ZYKADIA.xml:S2:9237:7	rabbit	NNS	O	O
.	ZYKADIA.xml:S2:9244:1	.	.	O	O

Apprise	ZYKADIA.xml:S2:9246:7	appris	NNP	O	O
women	ZYKADIA.xml:S2:9254:5	women	NNS	O	O
of	ZYKADIA.xml:S2:9260:2	of	IN	O	O
reproductive	ZYKADIA.xml:S2:9263:12	reproduct	JJ	O	O
potential	ZYKADIA.xml:S2:9276:9	potenti	NN	O	O
of	ZYKADIA.xml:S2:9286:2	of	IN	O	O
the	ZYKADIA.xml:S2:9289:3	the	DT	O	O
potential	ZYKADIA.xml:S2:9293:9	potenti	JJ	O	O
hazard	ZYKADIA.xml:S2:9303:6	hazard	NN	O	O
to	ZYKADIA.xml:S2:9310:2	to	TO	O	O
a	ZYKADIA.xml:S2:9313:1	a	DT	O	O
fetus	ZYKADIA.xml:S2:9315:5	fetu	NN	O	O
[	ZYKADIA.xml:S2:9321:1	[	NNP	O	O
see	ZYKADIA.xml:S2:9322:3	see	NN	O	O
Use	ZYKADIA.xml:S2:9326:3	use	NNP	O	O
in	ZYKADIA.xml:S2:9330:2	in	IN	O	O
Specific	ZYKADIA.xml:S2:9333:8	specif	NNP	O	O
Populations	ZYKADIA.xml:S2:9342:11	popul	NNP	O	O
(	ZYKADIA.xml:S2:9354:1	(	(	O	O
8.1	ZYKADIA.xml:S2:9355:3	8.1	CD	O	O
)]	ZYKADIA.xml:S2:9358:2	)]	NN	O	O
.	ZYKADIA.xml:S2:9362:1	.	.	O	O

Advise	ZYKADIA.xml:S2:9364:6	advis	NNP	O	O
females	ZYKADIA.xml:S2:9371:7	femal	NNS	O	O
of	ZYKADIA.xml:S2:9379:2	of	IN	O	O
reproductive	ZYKADIA.xml:S2:9382:12	reproduct	JJ	O	O
potential	ZYKADIA.xml:S2:9395:9	potenti	NN	O	O
to	ZYKADIA.xml:S2:9405:2	to	TO	O	O
use	ZYKADIA.xml:S2:9408:3	use	VB	O	O
effective	ZYKADIA.xml:S2:9412:9	effect	JJ	O	O
contraception	ZYKADIA.xml:S2:9422:13	contracept	NN	O	O
during	ZYKADIA.xml:S2:9436:6	dure	IN	O	O
treatment	ZYKADIA.xml:S2:9443:9	treatment	NN	O	O
with	ZYKADIA.xml:S2:9453:4	with	IN	O	O
ZYKADIA	ZYKADIA.xml:S2:9458:7	zykadia	NNP	O	O
and	ZYKADIA.xml:S2:9466:3	and	CC	O	O
for	ZYKADIA.xml:S2:9470:3	for	IN	O	O
at	ZYKADIA.xml:S2:9474:2	at	IN	O	O
least	ZYKADIA.xml:S2:9477:5	least	JJS	O	O
2	ZYKADIA.xml:S2:9483:1	2	CD	O	O
weeks	ZYKADIA.xml:S2:9485:5	week	NNS	O	O
following	ZYKADIA.xml:S2:9491:9	follow	VBG	O	O
completion	ZYKADIA.xml:S2:9501:10	complet	NN	O	O
of	ZYKADIA.xml:S2:9512:2	of	IN	O	O
therapy	ZYKADIA.xml:S2:9515:7	therapi	NN	O	O
[	ZYKADIA.xml:S2:9523:1	[	NNP	O	O
see	ZYKADIA.xml:S2:9524:3	see	NN	O	O
Use	ZYKADIA.xml:S2:9528:3	use	NNP	O	O
in	ZYKADIA.xml:S2:9532:2	in	IN	O	O
Specific	ZYKADIA.xml:S2:9535:8	specif	NNP	O	O
Populations	ZYKADIA.xml:S2:9544:11	popul	NNP	O	O
(	ZYKADIA.xml:S2:9556:1	(	(	O	O
8.7	ZYKADIA.xml:S2:9557:3	8.7	CD	O	O
)]	ZYKADIA.xml:S2:9560:2	)]	NN	O	O
.	ZYKADIA.xml:S2:9564:1	.	.	O	O
6	ZYTIGA.xml:S1:4:1	6	CD	O	O
ADVERSE	ZYTIGA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	ZYTIGA.xml:S1:14:9	reaction	NN	O	O

The	ZYTIGA.xml:S1:27:3	the	DT	O	O
following	ZYTIGA.xml:S1:31:9	follow	NN	O	O
are	ZYTIGA.xml:S1:41:3	are	VBP	O	O
discussed	ZYTIGA.xml:S1:45:9	discuss	VBN	O	O
in	ZYTIGA.xml:S1:55:2	in	IN	O	O
more	ZYTIGA.xml:S1:58:4	more	JJR	O	O
detail	ZYTIGA.xml:S1:63:6	detail	NN	O	O
in	ZYTIGA.xml:S1:70:2	in	IN	O	O
other	ZYTIGA.xml:S1:73:5	other	JJ	O	O
sections	ZYTIGA.xml:S1:79:8	section	NNS	O	O
of	ZYTIGA.xml:S1:88:2	of	IN	O	O
the	ZYTIGA.xml:S1:91:3	the	DT	O	O
labeling	ZYTIGA.xml:S1:95:8	label	NN	O	O
:	ZYTIGA.xml:S1:103:1	:	:	O	O

Hypertension	ZYTIGA.xml:S1:112:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:124:1	,	,	O	O
Hypokalemia	ZYTIGA.xml:S1:126:11	hypokalemia	NNP	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:137:1	,	,	O	O
and	ZYTIGA.xml:S1:139:3	and	CC	O	O
Fluid	ZYTIGA.xml:S1:143:5	fluid	NNP	B-AdverseReaction	B-AdverseReaction
Retention	ZYTIGA.xml:S1:149:9	retent	NNP	I-AdverseReaction	I-AdverseReaction
due	ZYTIGA.xml:S1:159:3	due	JJ	O	O
to	ZYTIGA.xml:S1:163:2	to	TO	O	O
Mineralocorticoid	ZYTIGA.xml:S1:166:17	mineralocorticoid	NNP	B-AdverseReaction	O
Excess	ZYTIGA.xml:S1:184:6	excess	NNP	I-AdverseReaction	O
[	ZYTIGA.xml:S1:191:1	[	NNP	O	O
seeWarnings	ZYTIGA.xml:S1:192:11	seewarn	NNS	O	O
and	ZYTIGA.xml:S1:204:3	and	CC	O	O
Precautions	ZYTIGA.xml:S1:208:11	precaut	NNP	O	O
(	ZYTIGA.xml:S1:220:1	(	(	O	O
5.1	ZYTIGA.xml:S1:221:3	5.1	CD	O	O
)]	ZYTIGA.xml:S1:224:2	)]	NN	O	O
.	ZYTIGA.xml:S1:227:1	.	.	O	O

Adrenocortical	ZYTIGA.xml:S1:234:14	adrenocort	JJ	B-AdverseReaction	O
Insufficiency	ZYTIGA.xml:S1:249:13	insuffici	NNP	I-AdverseReaction	O
[	ZYTIGA.xml:S1:263:1	[	NNP	O	O
seeWarnings	ZYTIGA.xml:S1:264:11	seewarn	NNS	O	O
and	ZYTIGA.xml:S1:276:3	and	CC	O	O
Precautions	ZYTIGA.xml:S1:280:11	precaut	NNP	O	O
(	ZYTIGA.xml:S1:292:1	(	(	O	O
5.2	ZYTIGA.xml:S1:293:3	5.2	CD	O	O
)]	ZYTIGA.xml:S1:296:2	)]	NN	O	O
.	ZYTIGA.xml:S1:299:1	.	.	O	O

Hepatotoxicity	ZYTIGA.xml:S1:306:14	hepatotox	NNP	B-AdverseReaction	B-AdverseReaction
[	ZYTIGA.xml:S1:321:1	[	NNP	O	O
seeWarnings	ZYTIGA.xml:S1:322:11	seewarn	NNS	O	O
and	ZYTIGA.xml:S1:334:3	and	CC	O	O
Precautions	ZYTIGA.xml:S1:338:11	precaut	NNP	O	O
(	ZYTIGA.xml:S1:350:1	(	(	O	O
5.3	ZYTIGA.xml:S1:351:3	5.3	CD	O	O
)]	ZYTIGA.xml:S1:354:2	)]	NN	O	O
.	ZYTIGA.xml:S1:357:1	.	.	O	O

EXCERPT	ZYTIGA.xml:S1:366:7	excerpt	NN	O	O
:	ZYTIGA.xml:S1:373:1	:	:	O	O
The	ZYTIGA.xml:S1:377:3	the	DT	O	O
most	ZYTIGA.xml:S1:381:4	most	RBS	O	O
common	ZYTIGA.xml:S1:386:6	common	JJ	O	O
adverse	ZYTIGA.xml:S1:393:7	advers	JJ	O	O
reactions	ZYTIGA.xml:S1:401:9	reaction	NNS	O	O
(	ZYTIGA.xml:S1:411:1	(	(	O	O
10%	ZYTIGA.xml:S1:414:3	10%	CD	O	O
)	ZYTIGA.xml:S1:417:1	)	)	O	O
are	ZYTIGA.xml:S1:419:3	are	VBP	O	O
fatigue	ZYTIGA.xml:S1:423:7	fatigu	JJ	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:430:1	,	,	O	O
joint	ZYTIGA.xml:S1:432:5	joint	JJ	B-AdverseReaction	B-AdverseReaction
swelling	ZYTIGA.xml:S1:438:8	swell	NN	I-AdverseReaction	I-AdverseReaction
or	ZYTIGA.xml:S1:447:2	or	CC	O	O
discomfort	ZYTIGA.xml:S1:450:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	ZYTIGA.xml:S1:460:1	,	,	O	O
edema	ZYTIGA.xml:S1:462:5	edema	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:467:1	,	,	O	O
hot	ZYTIGA.xml:S1:469:3	hot	JJ	B-AdverseReaction	B-AdverseReaction
flush	ZYTIGA.xml:S1:473:5	flush	NN	I-AdverseReaction	I-AdverseReaction
,	ZYTIGA.xml:S1:478:1	,	,	O	O
diarrhea	ZYTIGA.xml:S1:480:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:488:1	,	,	O	O
vomiting	ZYTIGA.xml:S1:490:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:498:1	,	,	O	O
cough	ZYTIGA.xml:S1:500:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:505:1	,	,	O	O
hypertension	ZYTIGA.xml:S1:507:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:519:1	,	,	O	O
dyspnea	ZYTIGA.xml:S1:521:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:528:1	,	,	O	O
urinary	ZYTIGA.xml:S1:530:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	ZYTIGA.xml:S1:538:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ZYTIGA.xml:S1:544:9	infect	NN	I-AdverseReaction	I-AdverseReaction
and	ZYTIGA.xml:S1:554:3	and	CC	O	O
contusion	ZYTIGA.xml:S1:558:9	contus	NN	B-AdverseReaction	B-AdverseReaction
.	ZYTIGA.xml:S1:567:1	.	.	O	O

The	ZYTIGA.xml:S1:573:3	the	DT	O	O

most	ZYTIGA.xml:S1:577:4	most	RBS	O	O
common	ZYTIGA.xml:S1:582:6	common	JJ	O	O
laboratory	ZYTIGA.xml:S1:589:10	laboratori	NN	O	O
abnormalities	ZYTIGA.xml:S1:600:13	abnorm	NNS	O	O
(	ZYTIGA.xml:S1:614:1	(	(	O	O
20%	ZYTIGA.xml:S1:616:3	20%	CD	O	O
)	ZYTIGA.xml:S1:619:1	)	)	O	O
are	ZYTIGA.xml:S1:621:3	are	VBP	O	O
anemia	ZYTIGA.xml:S1:625:6	anemia	JJ	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:631:1	,	,	O	O
elevated	ZYTIGA.xml:S1:633:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
alkaline	ZYTIGA.xml:S1:642:8	alkalin	NN	I-AdverseReaction	I-AdverseReaction
phosphatase	ZYTIGA.xml:S1:651:11	phosphatas	NN	I-AdverseReaction	I-AdverseReaction
,	ZYTIGA.xml:S1:662:1	,	,	O	O
hypertriglyceridemia	ZYTIGA.xml:S1:664:20	hypertriglyceridemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:684:1	,	,	O	O
lymphopenia	ZYTIGA.xml:S1:686:11	lymphopenia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:697:1	,	,	O	O
hypercholesterolemia	ZYTIGA.xml:S1:699:20	hypercholesterolemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:719:1	,	,	O	O
hyperglycemia	ZYTIGA.xml:S1:721:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:734:1	,	,	O	O
elevated	ZYTIGA.xml:S1:736:8	elev	VBD	B-AdverseReaction	B-AdverseReaction
AST	ZYTIGA.xml:S1:745:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
,	ZYTIGA.xml:S1:748:1	,	,	O	O
hypophosphatemia	ZYTIGA.xml:S1:750:16	hypophosphatemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:766:1	,	,	O	O
elevated	ZYTIGA.xml:S1:768:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
ALT	ZYTIGA.xml:S1:777:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
and	ZYTIGA.xml:S1:781:3	and	CC	O	O
hypokalemia	ZYTIGA.xml:S1:785:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
.	ZYTIGA.xml:S1:796:1	.	.	O	O

(	ZYTIGA.xml:S1:798:1	(	(	O	O
6	ZYTIGA.xml:S1:799:1	6	CD	O	O
)	ZYTIGA.xml:S1:800:1	)	)	O	O
To	ZYTIGA.xml:S1:803:2	To	TO	O	O
report	ZYTIGA.xml:S1:806:6	report	VB	O	O
SUSPECTED	ZYTIGA.xml:S1:813:9	suspect	NNP	O	O
ADVERSE	ZYTIGA.xml:S1:823:7	advers	NNP	O	O
REACTIONS	ZYTIGA.xml:S1:831:9	reaction	NNP	O	O
,	ZYTIGA.xml:S1:840:1	,	,	O	O
contact	ZYTIGA.xml:S1:842:7	contact	NN	O	O
Janssen	ZYTIGA.xml:S1:850:7	janssen	NNP	O	O
Biotech	ZYTIGA.xml:S1:858:7	biotech	NNP	O	O
,	ZYTIGA.xml:S1:865:1	,	,	O	O
Inc	ZYTIGA.xml:S1:867:3	inc	NNP	O	O
.	ZYTIGA.xml:S1:870:1	.	.	O	O

at	ZYTIGA.xml:S1:872:2	at	IN	O	O
1	ZYTIGA.xml:S1:875:1	1	CD	O	O
-	ZYTIGA.xml:S1:876:1	-	:	O	O
800	ZYTIGA.xml:S1:877:3	800	CD	O	O
-	ZYTIGA.xml:S1:880:1	-	:	O	O
526	ZYTIGA.xml:S1:881:3	526	CD	O	O
-	ZYTIGA.xml:S1:884:1	-	:	O	O
7736	ZYTIGA.xml:S1:885:4	7736	CD	O	O
(	ZYTIGA.xml:S1:890:1	(	(	O	O
1	ZYTIGA.xml:S1:891:1	1	CD	O	O
-	ZYTIGA.xml:S1:892:1	-	:	O	O
800	ZYTIGA.xml:S1:893:3	800	CD	O	O
-	ZYTIGA.xml:S1:896:1	-	:	O	O
JANSSEN	ZYTIGA.xml:S1:897:7	janssen	NN	O	O
)	ZYTIGA.xml:S1:904:1	)	)	O	O
or	ZYTIGA.xml:S1:906:2	or	CC	O	O
FDA	ZYTIGA.xml:S1:909:3	fda	NNP	O	O
at	ZYTIGA.xml:S1:913:2	at	IN	O	O
1	ZYTIGA.xml:S1:916:1	1	CD	O	O
-	ZYTIGA.xml:S1:917:1	-	:	O	O
800	ZYTIGA.xml:S1:918:3	800	CD	O	O
-	ZYTIGA.xml:S1:921:1	-	:	O	O
FDA	ZYTIGA.xml:S1:922:3	fda	NNP	O	O
-	ZYTIGA.xml:S1:925:1	-	:	O	O
1088	ZYTIGA.xml:S1:926:4	1088	CD	O	O
or	ZYTIGA.xml:S1:931:2	or	CC	O	O
www	ZYTIGA.xml:S1:935:3	www	VB	O	O
.	ZYTIGA.xml:S1:938:1	.	.	O	O
fda	ZYTIGA.xml:S1:939:3	fda	NN	O	O
.	ZYTIGA.xml:S1:942:1	.	.	O	O
gov	ZYTIGA.xml:S1:943:3	gov	JJ	O	O
medwatch	ZYTIGA.xml:S1:947:8	medwatch	NN	O	O
.	ZYTIGA.xml:S1:955:1	.	.	O	O

6.1	ZYTIGA.xml:S1:969:3	6.1	CD	O	O

Clinical	ZYTIGA.xml:S1:973:8	clinic	JJ	O	O
Trial	ZYTIGA.xml:S1:982:5	trial	NNP	O	O
Experience	ZYTIGA.xml:S1:988:10	experi	NN	O	O

Because	ZYTIGA.xml:S1:1002:7	becaus	IN	O	O
clinical	ZYTIGA.xml:S1:1010:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S1:1019:6	trial	NNS	O	O
are	ZYTIGA.xml:S1:1026:3	are	VBP	O	O
conducted	ZYTIGA.xml:S1:1030:9	conduct	VBN	O	O
under	ZYTIGA.xml:S1:1040:5	under	IN	O	O
widely	ZYTIGA.xml:S1:1046:6	wide	RB	O	O
varying	ZYTIGA.xml:S1:1053:7	vari	VBG	O	O
conditions	ZYTIGA.xml:S1:1061:10	condit	NNS	O	O
,	ZYTIGA.xml:S1:1071:1	,	,	O	O
adverse	ZYTIGA.xml:S1:1073:7	advers	JJ	O	O
reaction	ZYTIGA.xml:S1:1081:8	reaction	NN	O	O
rates	ZYTIGA.xml:S1:1090:5	rate	NNS	O	O
observed	ZYTIGA.xml:S1:1096:8	observ	VBD	O	O
in	ZYTIGA.xml:S1:1105:2	in	IN	O	O
the	ZYTIGA.xml:S1:1108:3	the	DT	O	O
clinical	ZYTIGA.xml:S1:1112:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S1:1121:6	trial	NNS	O	O
of	ZYTIGA.xml:S1:1128:2	of	IN	O	O
a	ZYTIGA.xml:S1:1131:1	a	DT	O	O
drug	ZYTIGA.xml:S1:1133:4	drug	NN	O	O
cannot	ZYTIGA.xml:S1:1138:6	cannot	NN	O	O
be	ZYTIGA.xml:S1:1145:2	be	VB	O	O
directly	ZYTIGA.xml:S1:1148:8	directli	RB	O	O
compared	ZYTIGA.xml:S1:1157:8	compar	VBN	O	O
to	ZYTIGA.xml:S1:1166:2	to	TO	O	O
rates	ZYTIGA.xml:S1:1169:5	rate	NNS	O	O
in	ZYTIGA.xml:S1:1175:2	in	IN	O	O
the	ZYTIGA.xml:S1:1178:3	the	DT	O	O
clinical	ZYTIGA.xml:S1:1182:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S1:1191:6	trial	NNS	O	O
of	ZYTIGA.xml:S1:1198:2	of	IN	O	O
another	ZYTIGA.xml:S1:1201:7	anoth	DT	O	O
drug	ZYTIGA.xml:S1:1209:4	drug	NN	O	O
and	ZYTIGA.xml:S1:1214:3	and	CC	O	O
may	ZYTIGA.xml:S1:1218:3	may	MD	O	O
not	ZYTIGA.xml:S1:1222:3	not	RB	O	O
reflect	ZYTIGA.xml:S1:1226:7	reflect	VB	O	O
the	ZYTIGA.xml:S1:1234:3	the	DT	O	O
rates	ZYTIGA.xml:S1:1238:5	rate	NNS	O	O
observed	ZYTIGA.xml:S1:1244:8	observ	VBD	O	O
in	ZYTIGA.xml:S1:1253:2	in	IN	O	O
clinical	ZYTIGA.xml:S1:1256:8	clinic	JJ	O	O
practice	ZYTIGA.xml:S1:1265:8	practic	NN	O	O
.	ZYTIGA.xml:S1:1273:1	.	.	O	O

Two	ZYTIGA.xml:S1:1279:3	two	CD	O	O
randomized	ZYTIGA.xml:S1:1283:10	random	JJ	O	O
placebo	ZYTIGA.xml:S1:1294:7	placebo	NN	O	O
-	ZYTIGA.xml:S1:1301:1	-	:	O	O
controlled	ZYTIGA.xml:S1:1302:10	control	VBN	O	O
,	ZYTIGA.xml:S1:1312:1	,	,	O	O
multicenter	ZYTIGA.xml:S1:1314:11	multicent	RBR	O	O
clinical	ZYTIGA.xml:S1:1326:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S1:1335:6	trial	NNS	O	O
enrolled	ZYTIGA.xml:S1:1342:8	enrol	VBD	O	O
patients	ZYTIGA.xml:S1:1351:8	patient	NNS	O	O
who	ZYTIGA.xml:S1:1360:3	who	WP	O	O
had	ZYTIGA.xml:S1:1364:3	had	VBD	O	O
metastatic	ZYTIGA.xml:S1:1368:10	metastat	JJ	O	O
castration	ZYTIGA.xml:S1:1379:10	castrat	NN	O	O
-	ZYTIGA.xml:S1:1389:1	-	:	O	O
resistant	ZYTIGA.xml:S1:1390:9	resist	JJ	O	O
prostate	ZYTIGA.xml:S1:1400:8	prostat	NN	O	O
cancer	ZYTIGA.xml:S1:1409:6	cancer	NN	O	O
who	ZYTIGA.xml:S1:1416:3	who	WP	O	O
were	ZYTIGA.xml:S1:1420:4	were	VBD	O	O
using	ZYTIGA.xml:S1:1425:5	use	VBG	O	O
a	ZYTIGA.xml:S1:1431:1	a	DT	O	O
gonadotropin	ZYTIGA.xml:S1:1433:12	gonadotropin	NN	O	O
-	ZYTIGA.xml:S1:1445:1	-	:	O	O
releasing	ZYTIGA.xml:S1:1446:9	releas	VBG	O	O
hormone	ZYTIGA.xml:S1:1456:7	hormon	NN	O	O
(	ZYTIGA.xml:S1:1464:1	(	(	O	O
GnRH	ZYTIGA.xml:S1:1465:4	gnrh	NNP	O	O
)	ZYTIGA.xml:S1:1469:1	)	)	O	O
agonist	ZYTIGA.xml:S1:1471:7	agonist	NN	O	O
or	ZYTIGA.xml:S1:1479:2	or	CC	O	O
were	ZYTIGA.xml:S1:1482:4	were	VBD	O	O
previously	ZYTIGA.xml:S1:1487:10	previous	RB	O	O
treated	ZYTIGA.xml:S1:1498:7	treat	VBN	O	O
with	ZYTIGA.xml:S1:1506:4	with	IN	O	O
orchiectomy	ZYTIGA.xml:S1:1511:11	orchiectomi	NN	O	O
.	ZYTIGA.xml:S1:1522:1	.	.	O	O

In	ZYTIGA.xml:S1:1524:2	In	IN	O	O
both	ZYTIGA.xml:S1:1527:4	both	DT	O	O
Study	ZYTIGA.xml:S1:1532:5	studi	NNP	O	O
1	ZYTIGA.xml:S1:1538:1	1	CD	O	O
and	ZYTIGA.xml:S1:1540:3	and	CC	O	O
Study	ZYTIGA.xml:S1:1544:5	studi	NNP	O	O
2	ZYTIGA.xml:S1:1550:1	2	CD	O	O
ZYTIGA	ZYTIGA.xml:S1:1552:6	zytiga	NNP	O	O
was	ZYTIGA.xml:S1:1559:3	wa	VBD	O	O
administered	ZYTIGA.xml:S1:1563:12	administ	VBN	O	O
at	ZYTIGA.xml:S1:1576:2	at	IN	O	O
a	ZYTIGA.xml:S1:1579:1	a	DT	O	O
dose	ZYTIGA.xml:S1:1581:4	dose	NN	O	O
of	ZYTIGA.xml:S1:1586:2	of	IN	O	O
1	ZYTIGA.xml:S1:1589:1	1	CD	O	O
,	ZYTIGA.xml:S1:1590:1	,	,	O	O
000	ZYTIGA.xml:S1:1591:3	000	CD	O	O
mg	ZYTIGA.xml:S1:1595:2	mg	JJ	O	O
daily	ZYTIGA.xml:S1:1598:5	daili	RB	O	O
in	ZYTIGA.xml:S1:1604:2	in	IN	O	O
combination	ZYTIGA.xml:S1:1607:11	combin	NN	O	O
with	ZYTIGA.xml:S1:1619:4	with	IN	O	O
prednisone	ZYTIGA.xml:S1:1624:10	prednison	NN	O	O
5	ZYTIGA.xml:S1:1635:1	5	CD	O	O
mg	ZYTIGA.xml:S1:1637:2	mg	NN	O	O
twice	ZYTIGA.xml:S1:1640:5	twice	RB	O	O
daily	ZYTIGA.xml:S1:1646:5	daili	RB	O	O
in	ZYTIGA.xml:S1:1652:2	in	IN	O	O
the	ZYTIGA.xml:S1:1655:3	the	DT	O	O
active	ZYTIGA.xml:S1:1659:6	activ	JJ	O	O
treatment	ZYTIGA.xml:S1:1666:9	treatment	NN	O	O
arms	ZYTIGA.xml:S1:1676:4	arm	NNS	O	O
.	ZYTIGA.xml:S1:1680:1	.	.	O	O

Placebo	ZYTIGA.xml:S1:1682:7	placebo	NNP	O	O
plus	ZYTIGA.xml:S1:1690:4	plu	CC	O	O
prednisone	ZYTIGA.xml:S1:1695:10	prednison	NN	O	O
5	ZYTIGA.xml:S1:1706:1	5	CD	O	O
mg	ZYTIGA.xml:S1:1708:2	mg	NN	O	O
twice	ZYTIGA.xml:S1:1711:5	twice	RB	O	O
daily	ZYTIGA.xml:S1:1717:5	daili	RB	O	O
was	ZYTIGA.xml:S1:1723:3	wa	VBD	O	O
given	ZYTIGA.xml:S1:1727:5	given	VBN	O	O
to	ZYTIGA.xml:S1:1733:2	to	TO	O	O
control	ZYTIGA.xml:S1:1736:7	control	VB	O	O
patients	ZYTIGA.xml:S1:1744:8	patient	NNS	O	O
.	ZYTIGA.xml:S1:1752:1	.	.	O	O

The	ZYTIGA.xml:S1:1758:3	the	DT	O	O
most	ZYTIGA.xml:S1:1762:4	most	RBS	O	O
common	ZYTIGA.xml:S1:1767:6	common	JJ	O	O
adverse	ZYTIGA.xml:S1:1774:7	advers	JJ	O	O
drug	ZYTIGA.xml:S1:1782:4	drug	NN	O	O
reactions	ZYTIGA.xml:S1:1787:9	reaction	NNS	O	O
(	ZYTIGA.xml:S1:1797:1	(	(	O	O
10%	ZYTIGA.xml:S1:1800:3	10%	CD	O	O
)	ZYTIGA.xml:S1:1803:1	)	)	O	O
reported	ZYTIGA.xml:S1:1805:8	report	VBN	O	O
in	ZYTIGA.xml:S1:1814:2	in	IN	O	O
the	ZYTIGA.xml:S1:1817:3	the	DT	O	O
two	ZYTIGA.xml:S1:1821:3	two	CD	O	O
randomized	ZYTIGA.xml:S1:1825:10	random	VBD	O	O
clinical	ZYTIGA.xml:S1:1836:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S1:1845:6	trial	NNS	O	O
that	ZYTIGA.xml:S1:1852:4	that	WDT	O	O
occurred	ZYTIGA.xml:S1:1857:8	occur	VBD	O	O
more	ZYTIGA.xml:S1:1866:4	more	JJR	O	O
commonly	ZYTIGA.xml:S1:1871:8	commonli	RB	O	O
(	ZYTIGA.xml:S1:1880:1	(	(	O	O
2%	ZYTIGA.xml:S1:1882:2	2%	CD	O	O
)	ZYTIGA.xml:S1:1884:1	)	)	O	O
in	ZYTIGA.xml:S1:1886:2	in	IN	O	O
the	ZYTIGA.xml:S1:1889:3	the	DT	O	O
abiraterone	ZYTIGA.xml:S1:1893:11	abirateron	NN	O	O
acetate	ZYTIGA.xml:S1:1905:7	acet	NN	O	O
arm	ZYTIGA.xml:S1:1913:3	arm	NN	O	O
were	ZYTIGA.xml:S1:1917:4	were	VBD	O	O
fatigue	ZYTIGA.xml:S1:1922:7	fatigu	JJ	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:1929:1	,	,	O	O
joint	ZYTIGA.xml:S1:1931:5	joint	JJ	B-AdverseReaction	B-AdverseReaction
swelling	ZYTIGA.xml:S1:1937:8	swell	NN	I-AdverseReaction	I-AdverseReaction
or	ZYTIGA.xml:S1:1946:2	or	CC	O	O
discomfort	ZYTIGA.xml:S1:1949:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	ZYTIGA.xml:S1:1959:1	,	,	O	O
edema	ZYTIGA.xml:S1:1961:5	edema	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:1966:1	,	,	O	O
hot	ZYTIGA.xml:S1:1968:3	hot	JJ	B-AdverseReaction	B-AdverseReaction
flush	ZYTIGA.xml:S1:1972:5	flush	NN	I-AdverseReaction	I-AdverseReaction
,	ZYTIGA.xml:S1:1977:1	,	,	O	O
diarrhea	ZYTIGA.xml:S1:1979:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:1987:1	,	,	O	O
vomiting	ZYTIGA.xml:S1:1989:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:1997:1	,	,	O	O
cough	ZYTIGA.xml:S1:1999:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2004:1	,	,	O	O
hypertension	ZYTIGA.xml:S1:2006:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2018:1	,	,	O	O
dyspnea	ZYTIGA.xml:S1:2020:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2027:1	,	,	O	O
urinary	ZYTIGA.xml:S1:2029:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	ZYTIGA.xml:S1:2037:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ZYTIGA.xml:S1:2043:9	infect	NN	I-AdverseReaction	I-AdverseReaction
and	ZYTIGA.xml:S1:2053:3	and	CC	O	O
contusion	ZYTIGA.xml:S1:2057:9	contus	NN	B-AdverseReaction	B-AdverseReaction
.	ZYTIGA.xml:S1:2066:1	.	.	O	O

The	ZYTIGA.xml:S1:2072:3	the	DT	O	O
most	ZYTIGA.xml:S1:2076:4	most	RBS	O	O
common	ZYTIGA.xml:S1:2081:6	common	JJ	O	O
laboratory	ZYTIGA.xml:S1:2088:10	laboratori	NN	O	O
abnormalities	ZYTIGA.xml:S1:2099:13	abnorm	NNS	O	O
(	ZYTIGA.xml:S1:2113:1	(	(	O	O
20%	ZYTIGA.xml:S1:2115:3	20%	CD	O	O
)	ZYTIGA.xml:S1:2118:1	)	)	O	O
reported	ZYTIGA.xml:S1:2120:8	report	VBN	O	O
in	ZYTIGA.xml:S1:2129:2	in	IN	O	O
the	ZYTIGA.xml:S1:2132:3	the	DT	O	O
two	ZYTIGA.xml:S1:2136:3	two	CD	O	O
randomized	ZYTIGA.xml:S1:2140:10	random	VBD	O	O
clinical	ZYTIGA.xml:S1:2151:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S1:2160:6	trial	NNS	O	O
that	ZYTIGA.xml:S1:2167:4	that	WDT	O	O
occurred	ZYTIGA.xml:S1:2172:8	occur	VBD	O	O
more	ZYTIGA.xml:S1:2181:4	more	JJR	O	O
commonly	ZYTIGA.xml:S1:2186:8	commonli	RB	O	O
(	ZYTIGA.xml:S1:2195:1	(	(	O	O
2%	ZYTIGA.xml:S1:2198:2	2%	CD	O	O
)	ZYTIGA.xml:S1:2200:1	)	)	O	O
in	ZYTIGA.xml:S1:2202:2	in	IN	O	O
the	ZYTIGA.xml:S1:2205:3	the	DT	O	O
abiraterone	ZYTIGA.xml:S1:2209:11	abirateron	NN	O	O
acetate	ZYTIGA.xml:S1:2221:7	acet	NN	O	O
arm	ZYTIGA.xml:S1:2229:3	arm	NN	O	O
were	ZYTIGA.xml:S1:2233:4	were	VBD	O	O
anemia	ZYTIGA.xml:S1:2238:6	anemia	RB	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2244:1	,	,	O	O
elevated	ZYTIGA.xml:S1:2246:8	elev	VBD	B-AdverseReaction	B-AdverseReaction
alkaline	ZYTIGA.xml:S1:2255:8	alkalin	JJ	I-AdverseReaction	I-AdverseReaction
phosphatase	ZYTIGA.xml:S1:2264:11	phosphatas	NN	I-AdverseReaction	I-AdverseReaction
,	ZYTIGA.xml:S1:2275:1	,	,	O	O
hypertriglyceridemia	ZYTIGA.xml:S1:2277:20	hypertriglyceridemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2297:1	,	,	O	O
lymphopenia	ZYTIGA.xml:S1:2299:11	lymphopenia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2310:1	,	,	O	O
hypercholesterolemia	ZYTIGA.xml:S1:2312:20	hypercholesterolemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2332:1	,	,	O	O
hyperglycemia	ZYTIGA.xml:S1:2334:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2347:1	,	,	O	O
elevated	ZYTIGA.xml:S1:2349:8	elev	VBD	B-AdverseReaction	B-AdverseReaction
AST	ZYTIGA.xml:S1:2358:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
,	ZYTIGA.xml:S1:2361:1	,	,	O	O
hypophosphatemia	ZYTIGA.xml:S1:2363:16	hypophosphatemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:2379:1	,	,	O	O
elevated	ZYTIGA.xml:S1:2381:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
ALT	ZYTIGA.xml:S1:2390:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
and	ZYTIGA.xml:S1:2394:3	and	CC	O	O
hypokalemia	ZYTIGA.xml:S1:2398:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
.	ZYTIGA.xml:S1:2409:1	.	.	O	O

Study	ZYTIGA.xml:S1:2419:5	studi	NN	O	O
1	ZYTIGA.xml:S1:2425:1	1	CD	O	O
:	ZYTIGA.xml:S1:2426:1	:	:	O	O
Metastatic	ZYTIGA.xml:S1:2428:10	metastat	JJ	O	O
CRPC	ZYTIGA.xml:S1:2439:4	crpc	NNP	O	O
Following	ZYTIGA.xml:S1:2444:9	follow	NNP	O	O
Chemotherapy	ZYTIGA.xml:S1:2454:12	chemotherapi	NNP	O	O

Study	ZYTIGA.xml:S1:2473:5	studi	NNP	O	O
1	ZYTIGA.xml:S1:2479:1	1	CD	O	O
enrolled	ZYTIGA.xml:S1:2481:8	enrol	VBD	O	O
1195	ZYTIGA.xml:S1:2490:4	1195	CD	O	O
patients	ZYTIGA.xml:S1:2495:8	patient	NNS	O	O
with	ZYTIGA.xml:S1:2504:4	with	IN	O	O
metastatic	ZYTIGA.xml:S1:2509:10	metastat	JJ	O	O
CRPC	ZYTIGA.xml:S1:2520:4	crpc	NNP	O	O
who	ZYTIGA.xml:S1:2525:3	who	WP	O	O
had	ZYTIGA.xml:S1:2529:3	had	VBD	O	O
received	ZYTIGA.xml:S1:2533:8	receiv	VBN	O	O
prior	ZYTIGA.xml:S1:2542:5	prior	RB	O	O
docetaxel	ZYTIGA.xml:S1:2548:9	docetaxel	JJ	O	O
chemotherapy	ZYTIGA.xml:S1:2558:12	chemotherapi	NN	O	O
.	ZYTIGA.xml:S1:2570:1	.	.	O	O

Patients	ZYTIGA.xml:S1:2572:8	patient	NNS	O	O
were	ZYTIGA.xml:S1:2581:4	were	VBD	O	O
not	ZYTIGA.xml:S1:2586:3	not	RB	O	O
eligible	ZYTIGA.xml:S1:2590:8	elig	JJ	O	O
if	ZYTIGA.xml:S1:2599:2	if	IN	O	O
AST	ZYTIGA.xml:S1:2602:3	ast	NNP	O	O
and	ZYTIGA.xml:S1:2606:3	and	CC	O	O
or	ZYTIGA.xml:S1:2610:2	or	CC	O	O
ALT	ZYTIGA.xml:S1:2613:3	alt	NNP	O	O
2.5	ZYTIGA.xml:S1:2619:3	2.5	CD	O	O
ULN	ZYTIGA.xml:S1:2624:3	uln	NNP	O	O
in	ZYTIGA.xml:S1:2628:2	in	IN	O	O
the	ZYTIGA.xml:S1:2631:3	the	DT	O	O
absence	ZYTIGA.xml:S1:2635:7	absenc	NN	O	O
of	ZYTIGA.xml:S1:2643:2	of	IN	O	O
liver	ZYTIGA.xml:S1:2646:5	liver	NN	O	O
metastases	ZYTIGA.xml:S1:2652:10	metastas	NNS	O	O
.	ZYTIGA.xml:S1:2662:1	.	.	O	O

Patients	ZYTIGA.xml:S1:2664:8	patient	NNS	O	O
with	ZYTIGA.xml:S1:2673:4	with	IN	O	O
liver	ZYTIGA.xml:S1:2678:5	liver	JJ	O	O
metastases	ZYTIGA.xml:S1:2684:10	metastas	NNS	O	O
were	ZYTIGA.xml:S1:2695:4	were	VBD	O	O
excluded	ZYTIGA.xml:S1:2700:8	exclud	VBN	O	O
if	ZYTIGA.xml:S1:2709:2	if	IN	O	O
AST	ZYTIGA.xml:S1:2712:3	ast	NNP	O	O
and	ZYTIGA.xml:S1:2716:3	and	CC	O	O
or	ZYTIGA.xml:S1:2720:2	or	CC	O	O
ALT	ZYTIGA.xml:S1:2723:3	alt	NNP	O	O
5	ZYTIGA.xml:S1:2728:1	5	CD	O	O
ULN	ZYTIGA.xml:S1:2731:3	uln	NNP	O	O
.	ZYTIGA.xml:S1:2734:1	.	.	O	O

Table	ZYTIGA.xml:S1:2740:5	tabl	JJ	O	O
1	ZYTIGA.xml:S1:2746:1	1	CD	O	O
shows	ZYTIGA.xml:S1:2748:5	show	NNS	O	O
adverse	ZYTIGA.xml:S1:2754:7	advers	JJ	O	O
reactions	ZYTIGA.xml:S1:2762:9	reaction	NNS	O	O
on	ZYTIGA.xml:S1:2772:2	on	IN	O	O
the	ZYTIGA.xml:S1:2775:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:2779:6	zytiga	NNP	O	O
arm	ZYTIGA.xml:S1:2786:3	arm	NN	O	O
in	ZYTIGA.xml:S1:2790:2	in	IN	O	O
Study	ZYTIGA.xml:S1:2793:5	studi	NNP	O	O
1	ZYTIGA.xml:S1:2799:1	1	CD	O	O
that	ZYTIGA.xml:S1:2801:4	that	WDT	O	O
occurred	ZYTIGA.xml:S1:2806:8	occur	VBD	O	O
with	ZYTIGA.xml:S1:2815:4	with	IN	O	O
a	ZYTIGA.xml:S1:2820:1	a	DT	O	O
2%	ZYTIGA.xml:S1:2824:2	2%	CD	O	O
absolute	ZYTIGA.xml:S1:2827:8	absolut	JJ	O	O
increase	ZYTIGA.xml:S1:2836:8	increas	NN	O	O
in	ZYTIGA.xml:S1:2845:2	in	IN	O	O
frequency	ZYTIGA.xml:S1:2848:9	frequenc	NN	O	O
compared	ZYTIGA.xml:S1:2858:8	compar	VBN	O	O
to	ZYTIGA.xml:S1:2867:2	to	TO	O	O
placebo	ZYTIGA.xml:S1:2870:7	placebo	VB	O	O
or	ZYTIGA.xml:S1:2878:2	or	CC	O	O
were	ZYTIGA.xml:S1:2881:4	were	VBD	O	O
events	ZYTIGA.xml:S1:2886:6	event	NNS	O	O
of	ZYTIGA.xml:S1:2893:2	of	IN	O	O
special	ZYTIGA.xml:S1:2896:7	special	JJ	O	O
interest	ZYTIGA.xml:S1:2904:8	interest	NN	O	O
.	ZYTIGA.xml:S1:2912:1	.	.	O	O

The	ZYTIGA.xml:S1:2914:3	the	DT	O	O
median	ZYTIGA.xml:S1:2918:6	median	JJ	O	O
duration	ZYTIGA.xml:S1:2925:8	durat	NN	O	O
of	ZYTIGA.xml:S1:2934:2	of	IN	O	O
treatment	ZYTIGA.xml:S1:2937:9	treatment	NN	O	O
with	ZYTIGA.xml:S1:2947:4	with	IN	O	O
ZYTIGA	ZYTIGA.xml:S1:2952:6	zytiga	NNP	O	O
was	ZYTIGA.xml:S1:2959:3	wa	VBD	O	O
8	ZYTIGA.xml:S1:2963:1	8	CD	O	O
months	ZYTIGA.xml:S1:2965:6	month	NNS	O	O
.	ZYTIGA.xml:S1:2971:1	.	.	O	O

Table	ZYTIGA.xml:S1:2977:5	tabl	JJ	O	O
1	ZYTIGA.xml:S1:2983:1	1	CD	O	O
:	ZYTIGA.xml:S1:2984:1	:	:	O	O
Adverse	ZYTIGA.xml:S1:2986:7	advers	JJ	O	O
Reactions	ZYTIGA.xml:S1:2994:9	reaction	NNS	O	O
due	ZYTIGA.xml:S1:3004:3	due	JJ	O	O
to	ZYTIGA.xml:S1:3008:2	to	TO	O	O
ZYTIGA	ZYTIGA.xml:S1:3011:6	zytiga	NNP	O	O
in	ZYTIGA.xml:S1:3018:2	in	IN	O	O
Study	ZYTIGA.xml:S1:3021:5	studi	NNP	O	O
1	ZYTIGA.xml:S1:3027:1	1	CD	O	O

ZYTIGA	ZYTIGA.xml:S1:3073:6	zytiga	NNP	O	O
with	ZYTIGA.xml:S1:3080:4	with	IN	O	O
Prednisone	ZYTIGA.xml:S1:3085:10	prednison	NNP	O	O
(	ZYTIGA.xml:S1:3095:1	(	(	O	O
N	ZYTIGA.xml:S1:3096:1	N	NNP	O	O
791	ZYTIGA.xml:S1:3098:3	791	CD	O	O
)	ZYTIGA.xml:S1:3101:1	)	)	O	O
Placebo	ZYTIGA.xml:S1:3104:7	placebo	NN	O	O
with	ZYTIGA.xml:S1:3112:4	with	IN	O	O
Prednisone	ZYTIGA.xml:S1:3117:10	prednison	NNP	O	O
(	ZYTIGA.xml:S1:3127:1	(	(	O	O
N	ZYTIGA.xml:S1:3128:1	N	NNP	O	O
394	ZYTIGA.xml:S1:3130:3	394	CD	O	O
)	ZYTIGA.xml:S1:3133:1	)	)	O	O

System	ZYTIGA.xml:S1:3139:6	system	NNP	O	O
Organ	ZYTIGA.xml:S1:3146:5	organ	NNP	O	O
Class	ZYTIGA.xml:S1:3152:5	class	NNP	O	O
Adverse	ZYTIGA.xml:S1:3159:7	advers	NNP	O	O
reaction	ZYTIGA.xml:S1:3167:8	reaction	NN	O	O
All	ZYTIGA.xml:S1:3183:3	all	NNP	O	O
Grades	ZYTIGA.xml:S1:3187:6	grade	NNP	O	O
Grade	ZYTIGA.xml:S1:3200:5	grade	NNP	O	O
3	ZYTIGA.xml:S1:3206:1	3	CD	O	O
-	ZYTIGA.xml:S1:3207:1	-	:	O	O
4%	ZYTIGA.xml:S1:3208:2	4%	CD	O	O
All	ZYTIGA.xml:S1:3217:3	all	DT	O	O
Grades	ZYTIGA.xml:S1:3221:6	grade	NNP	O	O
Grade	ZYTIGA.xml:S1:3234:5	grade	NNP	O	O
3	ZYTIGA.xml:S1:3240:1	3	CD	O	O
-	ZYTIGA.xml:S1:3241:1	-	:	O	O
4%	ZYTIGA.xml:S1:3242:2	4%	CD	O	O

Musculoskeletal	ZYTIGA.xml:S1:3257:15	musculoskelet	NN	O	O

and	ZYTIGA.xml:S1:3273:3	and	CC	O	O
connective	ZYTIGA.xml:S1:3277:10	connect	JJ	O	O
tissue	ZYTIGA.xml:S1:3288:6	tissu	NN	O	O
disorders	ZYTIGA.xml:S1:3295:9	disord	NNS	O	O

Joint	ZYTIGA.xml:S1:3381:5	joint	JJ	B-AdverseReaction	B-AdverseReaction
swelling	ZYTIGA.xml:S1:3387:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
discomfort	ZYTIGA.xml:S1:3396:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
29.5	ZYTIGA.xml:S1:3426:4	29.5	CD	O	O
4.2	ZYTIGA.xml:S1:3444:3	4.2	CD	O	O
23.4	ZYTIGA.xml:S1:3460:4	23.4	CD	O	O
4.1	ZYTIGA.xml:S1:3478:3	4.1	CD	O	O

Muscle	ZYTIGA.xml:S1:3494:6	muscl	NNP	B-AdverseReaction	B-AdverseReaction
discomfort	ZYTIGA.xml:S1:3501:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
26.2	ZYTIGA.xml:S1:3539:4	26.2	CD	O	O
3.0	ZYTIGA.xml:S1:3557:3	3.0	CD	O	O
23.1	ZYTIGA.xml:S1:3573:4	23.1	CD	O	O
2.3	ZYTIGA.xml:S1:3591:3	2.3	CD	O	O

General	ZYTIGA.xml:S1:3607:7	gener	NNP	O	O
disorders	ZYTIGA.xml:S1:3615:9	disord	NNS	O	O

Edema	ZYTIGA.xml:S1:3720:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
26.7	ZYTIGA.xml:S1:3765:4	26.7	CD	O	O
1.9	ZYTIGA.xml:S1:3783:3	1.9	CD	O	O
18.3	ZYTIGA.xml:S1:3799:4	18.3	CD	O	O
0.8	ZYTIGA.xml:S1:3817:3	0.8	CD	O	O

Vascular	ZYTIGA.xml:S1:3833:8	vascular	JJ	O	O
disorders	ZYTIGA.xml:S1:3842:9	disord	NNS	O	O

Hot	ZYTIGA.xml:S1:3946:3	hot	NNP	B-AdverseReaction	B-AdverseReaction
flush	ZYTIGA.xml:S1:3950:5	flush	VBD	I-AdverseReaction	I-AdverseReaction
19.0	ZYTIGA.xml:S1:3991:4	19.0	CD	O	O
0.3	ZYTIGA.xml:S1:4009:3	0.3	CD	O	O
16.8	ZYTIGA.xml:S1:4025:4	16.8	CD	O	O
0.3	ZYTIGA.xml:S1:4043:3	0.3	CD	O	O

Hypertension	ZYTIGA.xml:S1:4059:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
8.5	ZYTIGA.xml:S1:4105:3	8.5	CD	O	O
1.3	ZYTIGA.xml:S1:4122:3	1.3	CD	O	O
6.9	ZYTIGA.xml:S1:4139:3	6.9	CD	O	O
0.3	ZYTIGA.xml:S1:4156:3	0.3	CD	O	O

Gastrointestinal	ZYTIGA.xml:S1:4172:16	gastrointestin	JJ	O	O
disorders	ZYTIGA.xml:S1:4189:9	disord	NNS	O	O

Diarrhea	ZYTIGA.xml:S1:4285:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
17.6	ZYTIGA.xml:S1:4330:4	17.6	CD	O	O
0.6	ZYTIGA.xml:S1:4348:3	0.6	CD	O	O
13.5	ZYTIGA.xml:S1:4364:4	13.5	CD	O	O
1.3	ZYTIGA.xml:S1:4382:3	1.3	CD	O	O

Dyspepsia	ZYTIGA.xml:S1:4398:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
6.1	ZYTIGA.xml:S1:4444:3	6.1	CD	O	O
0	ZYTIGA.xml:S1:4462:1	0	CD	O	O
3.3	ZYTIGA.xml:S1:4478:3	3.3	CD	O	O
0	ZYTIGA.xml:S1:4496:1	0	CD	O	O

Infections	ZYTIGA.xml:S1:4511:10	infect	NNS	O	O
and	ZYTIGA.xml:S1:4522:3	and	CC	O	O
infestations	ZYTIGA.xml:S1:4526:12	infest	NNS	O	O

Urinary	ZYTIGA.xml:S1:4624:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	ZYTIGA.xml:S1:4632:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ZYTIGA.xml:S1:4638:9	infect	NN	I-AdverseReaction	I-AdverseReaction
11.5	ZYTIGA.xml:S1:4669:4	11.5	CD	O	O
2.1	ZYTIGA.xml:S1:4687:3	2.1	CD	O	O
7.1	ZYTIGA.xml:S1:4704:3	7.1	CD	O	O
0.5	ZYTIGA.xml:S1:4721:3	0.5	CD	O	O

Upper	ZYTIGA.xml:S1:4737:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	ZYTIGA.xml:S1:4743:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	ZYTIGA.xml:S1:4755:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ZYTIGA.xml:S1:4761:9	infect	NN	I-AdverseReaction	I-AdverseReaction
5.4	ZYTIGA.xml:S1:4783:3	5.4	CD	O	O
0	ZYTIGA.xml:S1:4801:1	0	CD	O	O
2.5	ZYTIGA.xml:S1:4817:3	2.5	CD	O	O
0	ZYTIGA.xml:S1:4835:1	0	CD	O	O

Respiratory	ZYTIGA.xml:S1:4850:11	respiratori	NNP	O	O
,	ZYTIGA.xml:S1:4861:1	,	,	O	O
thoracic	ZYTIGA.xml:S1:4863:8	thorac	NN	O	O
and	ZYTIGA.xml:S1:4872:3	and	CC	O	O
mediastinal	ZYTIGA.xml:S1:4876:11	mediastin	JJ	O	O
disorders	ZYTIGA.xml:S1:4888:9	disord	NNS	O	O

Cough	ZYTIGA.xml:S1:4974:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
10.6	ZYTIGA.xml:S1:5019:4	10.6	CD	O	O
0	ZYTIGA.xml:S1:5038:1	0	CD	O	O
7.6	ZYTIGA.xml:S1:5054:3	7.6	CD	O	O
0	ZYTIGA.xml:S1:5072:1	0	CD	O	O

Renal	ZYTIGA.xml:S1:5087:5	renal	NNP	O	O
and	ZYTIGA.xml:S1:5093:3	and	CC	O	O
urinary	ZYTIGA.xml:S1:5097:7	urinari	JJ	O	O
disorders	ZYTIGA.xml:S1:5105:9	disord	NNS	O	O

Urinary	ZYTIGA.xml:S1:5200:7	urinari	JJ	B-AdverseReaction	O
frequency	ZYTIGA.xml:S1:5208:9	frequenc	NN	I-AdverseReaction	O
7.2	ZYTIGA.xml:S1:5246:3	7.2	CD	O	O
0.3	ZYTIGA.xml:S1:5263:3	0.3	CD	O	O
5.1	ZYTIGA.xml:S1:5280:3	5.1	CD	O	O
0.3	ZYTIGA.xml:S1:5297:3	0.3	CD	O	O

Nocturia	ZYTIGA.xml:S1:5313:8	nocturia	NNP	B-AdverseReaction	B-AdverseReaction
6.2	ZYTIGA.xml:S1:5359:3	6.2	CD	O	O
0	ZYTIGA.xml:S1:5377:1	0	CD	O	O
4.1	ZYTIGA.xml:S1:5393:3	4.1	CD	O	O
0	ZYTIGA.xml:S1:5411:1	0	CD	O	O

Injury	ZYTIGA.xml:S1:5426:6	injuri	NNP	O	O
,	ZYTIGA.xml:S1:5432:1	,	,	O	O
poisoning	ZYTIGA.xml:S1:5434:9	poison	NN	O	O
and	ZYTIGA.xml:S1:5444:3	and	CC	O	O
procedural	ZYTIGA.xml:S1:5448:10	procedur	JJ	O	O
complications	ZYTIGA.xml:S1:5459:13	complic	NNS	O	O

Fractures	ZYTIGA.xml:S1:5549:9	fractur	NNS	B-AdverseReaction	B-AdverseReaction
5.9	ZYTIGA.xml:S1:5595:3	5.9	CD	O	O
1.4	ZYTIGA.xml:S1:5612:3	1.4	CD	O	O
2.3	ZYTIGA.xml:S1:5629:3	2.3	CD	O	O
0	ZYTIGA.xml:S1:5647:1	0	CD	O	O

Cardiac	ZYTIGA.xml:S1:5662:7	cardiac	JJ	O	O
disorders	ZYTIGA.xml:S1:5670:9	disord	NNS	O	O

Arrhythmia	ZYTIGA.xml:S1:5775:10	arrhythmia	NNP	B-AdverseReaction	B-AdverseReaction
7.2	ZYTIGA.xml:S1:5821:3	7.2	CD	O	O
1.1	ZYTIGA.xml:S1:5838:3	1.1	CD	O	O
4.6	ZYTIGA.xml:S1:5855:3	4.6	CD	O	O
1.0	ZYTIGA.xml:S1:5872:3	1.0	CD	O	O

Chest	ZYTIGA.xml:S1:5888:5	chest	NNP	B-AdverseReaction	B-AdverseReaction
pain	ZYTIGA.xml:S1:5894:4	pain	NN	I-AdverseReaction	I-AdverseReaction
or	ZYTIGA.xml:S1:5899:2	or	CC	O	O
chest	ZYTIGA.xml:S1:5902:5	chest	VB	B-AdverseReaction	B-AdverseReaction
discomfort	ZYTIGA.xml:S1:5908:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
3.8	ZYTIGA.xml:S1:5934:3	3.8	CD	O	O
0.5	ZYTIGA.xml:S1:5951:3	0.5	CD	O	O
2.8	ZYTIGA.xml:S1:5968:3	2.8	CD	O	O
0	ZYTIGA.xml:S1:5986:1	0	CD	O	O

Cardiac	ZYTIGA.xml:S1:6001:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZYTIGA.xml:S1:6009:7	failur	NN	I-AdverseReaction	I-AdverseReaction
2.3	ZYTIGA.xml:S1:6047:3	2.3	CD	O	O
1.9	ZYTIGA.xml:S1:6064:3	1.9	CD	O	O
1.0	ZYTIGA.xml:S1:6081:3	1.0	CD	O	O
0.3	ZYTIGA.xml:S1:6098:3	0.3	CD	O	O

Table	ZYTIGA.xml:S1:6122:5	tabl	JJ	O	O
2	ZYTIGA.xml:S1:6128:1	2	CD	O	O
shows	ZYTIGA.xml:S1:6130:5	show	NNS	O	O
laboratory	ZYTIGA.xml:S1:6136:10	laboratori	JJ	O	O
abnormalities	ZYTIGA.xml:S1:6147:13	abnorm	NNS	O	O
of	ZYTIGA.xml:S1:6161:2	of	IN	O	O
interest	ZYTIGA.xml:S1:6164:8	interest	NN	O	O
from	ZYTIGA.xml:S1:6173:4	from	IN	O	O
Study	ZYTIGA.xml:S1:6178:5	studi	NNP	O	O
1	ZYTIGA.xml:S1:6184:1	1	CD	O	O
.	ZYTIGA.xml:S1:6185:1	.	.	O	O

Grade	ZYTIGA.xml:S1:6187:5	grade	$	O	O
3	ZYTIGA.xml:S1:6193:1	3	CD	O	O
-	ZYTIGA.xml:S1:6194:1	-	:	O	O
4	ZYTIGA.xml:S1:6195:1	4	CD	O	O
low	ZYTIGA.xml:S1:6197:3	low	JJ	B-AdverseReaction	B-AdverseReaction
serum	ZYTIGA.xml:S1:6201:5	serum	NN	I-AdverseReaction	I-AdverseReaction
phosphorus	ZYTIGA.xml:S1:6207:10	phosphoru	NN	I-AdverseReaction	I-AdverseReaction
(	ZYTIGA.xml:S1:6218:1	(	(	O	O
7%	ZYTIGA.xml:S1:6219:2	7%	CD	O	O
)	ZYTIGA.xml:S1:6221:1	)	)	O	O
and	ZYTIGA.xml:S1:6223:3	and	CC	O	O
low	ZYTIGA.xml:S1:6227:3	low	JJ	B-AdverseReaction	B-AdverseReaction
potassium	ZYTIGA.xml:S1:6231:9	potassium	NN	I-AdverseReaction	I-AdverseReaction
(	ZYTIGA.xml:S1:6241:1	(	(	O	O
5%	ZYTIGA.xml:S1:6242:2	5%	CD	O	O
)	ZYTIGA.xml:S1:6244:1	)	)	O	O
occurred	ZYTIGA.xml:S1:6246:8	occur	VBD	O	O
at	ZYTIGA.xml:S1:6255:2	at	IN	O	O
a	ZYTIGA.xml:S1:6258:1	a	DT	O	O
greater	ZYTIGA.xml:S1:6260:7	greater	JJR	O	O
than	ZYTIGA.xml:S1:6268:4	than	IN	O	O
or	ZYTIGA.xml:S1:6273:2	or	CC	O	O
equal	ZYTIGA.xml:S1:6276:5	equal	JJ	O	O
to	ZYTIGA.xml:S1:6282:2	to	TO	O	O
5%	ZYTIGA.xml:S1:6285:2	5%	CD	O	O
rate	ZYTIGA.xml:S1:6288:4	rate	NN	O	O
in	ZYTIGA.xml:S1:6293:2	in	IN	O	O
the	ZYTIGA.xml:S1:6296:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:6300:6	zytiga	NNP	O	O
arm	ZYTIGA.xml:S1:6307:3	arm	NN	O	O
.	ZYTIGA.xml:S1:6310:1	.	.	O	O

Table	ZYTIGA.xml:S1:6316:5	tabl	NN	O	O

2	ZYTIGA.xml:S1:6322:1	2	CD	O	O
:	ZYTIGA.xml:S1:6323:1	:	:	O	O
Laboratory	ZYTIGA.xml:S1:6325:10	laboratori	JJ	O	O
Abnormalities	ZYTIGA.xml:S1:6336:13	abnorm	NNS	O	O
of	ZYTIGA.xml:S1:6350:2	of	IN	O	O
Interest	ZYTIGA.xml:S1:6353:8	interest	NNP	O	O
in	ZYTIGA.xml:S1:6362:2	in	IN	O	O
Study	ZYTIGA.xml:S1:6365:5	studi	NNP	O	O
1	ZYTIGA.xml:S1:6371:1	1	CD	O	O

Abiraterone	ZYTIGA.xml:S1:6417:11	abirateron	NNP	O	O
(	ZYTIGA.xml:S1:6429:1	(	(	O	O
N	ZYTIGA.xml:S1:6430:1	N	NNP	O	O
791	ZYTIGA.xml:S1:6432:3	791	CD	O	O
)	ZYTIGA.xml:S1:6435:1	)	)	O	O
Placebo	ZYTIGA.xml:S1:6438:7	placebo	NNP	O	O
(	ZYTIGA.xml:S1:6446:1	(	(	O	O
N	ZYTIGA.xml:S1:6447:1	N	NNP	O	O
394	ZYTIGA.xml:S1:6449:3	394	CD	O	O
)	ZYTIGA.xml:S1:6452:1	)	)	O	O

Laboratory	ZYTIGA.xml:S1:6458:10	laboratori	NNP	O	O
Abnormality	ZYTIGA.xml:S1:6469:11	abnorm	NNP	O	O
All	ZYTIGA.xml:S1:6500:3	all	NNP	O	O
Grades	ZYTIGA.xml:S1:6504:6	grade	NNP	O	O
(	ZYTIGA.xml:S1:6511:1	(	(	O	O
)	ZYTIGA.xml:S1:6513:1	)	)	O	O
Grade	ZYTIGA.xml:S1:6518:5	grade	VBD	O	O
3	ZYTIGA.xml:S1:6524:1	3	CD	O	O
-	ZYTIGA.xml:S1:6525:1	-	:	O	O
4	ZYTIGA.xml:S1:6526:1	4	CD	O	O
(	ZYTIGA.xml:S1:6528:1	(	(	O	O
)	ZYTIGA.xml:S1:6530:1	)	)	O	O
All	ZYTIGA.xml:S1:6534:3	all	DT	O	O
Grades	ZYTIGA.xml:S1:6538:6	grade	NNP	O	O
(	ZYTIGA.xml:S1:6545:1	(	(	O	O
)	ZYTIGA.xml:S1:6547:1	)	)	O	O
Grade	ZYTIGA.xml:S1:6552:5	grade	VBD	O	O
3	ZYTIGA.xml:S1:6558:1	3	CD	O	O
-	ZYTIGA.xml:S1:6559:1	-	:	O	O
4	ZYTIGA.xml:S1:6560:1	4	CD	O	O
(	ZYTIGA.xml:S1:6562:1	(	(	O	O
)	ZYTIGA.xml:S1:6564:1	)	)	O	O

Hypertriglyceridemia	ZYTIGA.xml:S1:6574:20	hypertriglyceridemia	NN	B-AdverseReaction	O

62.5	ZYTIGA.xml:S1:6621:4	62.5	CD	O	O
0.4	ZYTIGA.xml:S1:6639:3	0.4	CD	O	O
53.0	ZYTIGA.xml:S1:6655:4	53.0	CD	O	O
0	ZYTIGA.xml:S1:6674:1	0	CD	O	O

High	ZYTIGA.xml:S1:6687:4	high	JJ	B-AdverseReaction	B-AdverseReaction
AST	ZYTIGA.xml:S1:6692:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
30.6	ZYTIGA.xml:S1:6734:4	30.6	CD	O	O
2.1	ZYTIGA.xml:S1:6752:3	2.1	CD	O	O
36.3	ZYTIGA.xml:S1:6768:4	36.3	CD	O	O
1.5	ZYTIGA.xml:S1:6786:3	1.5	CD	O	O

Hypokalemia	ZYTIGA.xml:S1:6800:11	hypokalemia	NNP	B-AdverseReaction	B-AdverseReaction
28.3	ZYTIGA.xml:S1:6847:4	28.3	CD	O	O
5.3	ZYTIGA.xml:S1:6865:3	5.3	CD	O	O
19.8	ZYTIGA.xml:S1:6881:4	19.8	CD	O	O
1.0	ZYTIGA.xml:S1:6899:3	1.0	CD	O	O

Hypophosphatemia	ZYTIGA.xml:S1:6913:16	hypophosphatemia	NNP	B-AdverseReaction	B-AdverseReaction
23.8	ZYTIGA.xml:S1:6960:4	23.8	CD	O	O
7.2	ZYTIGA.xml:S1:6978:3	7.2	CD	O	O
15.7	ZYTIGA.xml:S1:6994:4	15.7	CD	O	O
5.8	ZYTIGA.xml:S1:7012:3	5.8	CD	O	O

High	ZYTIGA.xml:S1:7026:4	high	JJ	B-AdverseReaction	B-AdverseReaction
ALT	ZYTIGA.xml:S1:7031:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
11.1	ZYTIGA.xml:S1:7073:4	11.1	CD	O	O
1.4	ZYTIGA.xml:S1:7091:3	1.4	CD	O	O
10.4	ZYTIGA.xml:S1:7107:4	10.4	CD	O	O
0.8	ZYTIGA.xml:S1:7125:3	0.8	CD	O	O

High	ZYTIGA.xml:S1:7139:4	high	JJ	B-AdverseReaction	B-AdverseReaction
Total	ZYTIGA.xml:S1:7144:5	total	NNP	I-AdverseReaction	I-AdverseReaction
Bilirubin	ZYTIGA.xml:S1:7150:9	bilirubin	NNP	I-AdverseReaction	I-AdverseReaction
6.6	ZYTIGA.xml:S1:7187:3	6.6	CD	O	O
0.1	ZYTIGA.xml:S1:7204:3	0.1	CD	O	O
4.6	ZYTIGA.xml:S1:7221:3	4.6	CD	O	O
0	ZYTIGA.xml:S1:7239:1	0	CD	O	O

Study	ZYTIGA.xml:S1:7266:5	studi	NN	O	O
2	ZYTIGA.xml:S1:7272:1	2	CD	O	O
:	ZYTIGA.xml:S1:7273:1	:	:	O	O
Metastatic	ZYTIGA.xml:S1:7275:10	metastat	JJ	O	O
CRPC	ZYTIGA.xml:S1:7286:4	crpc	NNP	O	O
Prior	ZYTIGA.xml:S1:7291:5	prior	NNP	O	O
to	ZYTIGA.xml:S1:7297:2	to	TO	O	O
Chemotherapy	ZYTIGA.xml:S1:7300:12	chemotherapi	VB	O	O

Study	ZYTIGA.xml:S1:7319:5	studi	NN	O	O

2	ZYTIGA.xml:S1:7325:1	2	CD	O	O
enrolled	ZYTIGA.xml:S1:7327:8	enrol	JJ	O	O
1088	ZYTIGA.xml:S1:7336:4	1088	CD	O	O
patients	ZYTIGA.xml:S1:7341:8	patient	NNS	O	O
with	ZYTIGA.xml:S1:7350:4	with	IN	O	O
metastatic	ZYTIGA.xml:S1:7355:10	metastat	JJ	O	O
CRPC	ZYTIGA.xml:S1:7366:4	crpc	NNP	O	O
who	ZYTIGA.xml:S1:7371:3	who	WP	O	O
had	ZYTIGA.xml:S1:7375:3	had	VBD	O	O
not	ZYTIGA.xml:S1:7379:3	not	RB	O	O
received	ZYTIGA.xml:S1:7383:8	receiv	VBN	O	O
prior	ZYTIGA.xml:S1:7392:5	prior	RB	O	O
cytotoxic	ZYTIGA.xml:S1:7398:9	cytotox	JJ	O	O
chemotherapy	ZYTIGA.xml:S1:7408:12	chemotherapi	NN	O	O
.	ZYTIGA.xml:S1:7420:1	.	.	O	O

Patients	ZYTIGA.xml:S1:7422:8	patient	NNS	O	O
were	ZYTIGA.xml:S1:7431:4	were	VBD	O	O
ineligible	ZYTIGA.xml:S1:7436:10	inelig	JJ	O	O
if	ZYTIGA.xml:S1:7447:2	if	IN	O	O
AST	ZYTIGA.xml:S1:7450:3	ast	NNP	O	O
and	ZYTIGA.xml:S1:7454:3	and	CC	O	O
or	ZYTIGA.xml:S1:7458:2	or	CC	O	O
ALT	ZYTIGA.xml:S1:7461:3	alt	NNP	O	O
2.5	ZYTIGA.xml:S1:7467:3	2.5	CD	O	O
ULN	ZYTIGA.xml:S1:7472:3	uln	NNP	O	O
and	ZYTIGA.xml:S1:7476:3	and	CC	O	O
patients	ZYTIGA.xml:S1:7480:8	patient	NNS	O	O
were	ZYTIGA.xml:S1:7489:4	were	VBD	O	O
excluded	ZYTIGA.xml:S1:7494:8	exclud	VBN	O	O
if	ZYTIGA.xml:S1:7503:2	if	IN	O	O
they	ZYTIGA.xml:S1:7506:4	they	PRP	O	O
had	ZYTIGA.xml:S1:7511:3	had	VBD	O	O
liver	ZYTIGA.xml:S1:7515:5	liver	NN	O	O
metastases	ZYTIGA.xml:S1:7521:10	metastas	NNS	O	O
.	ZYTIGA.xml:S1:7531:1	.	.	O	O

Table	ZYTIGA.xml:S1:7537:5	tabl	JJ	O	O
3	ZYTIGA.xml:S1:7543:1	3	CD	O	O
shows	ZYTIGA.xml:S1:7545:5	show	NNS	O	O
adverse	ZYTIGA.xml:S1:7551:7	advers	JJ	O	O
reactions	ZYTIGA.xml:S1:7559:9	reaction	NNS	O	O
on	ZYTIGA.xml:S1:7569:2	on	IN	O	O
the	ZYTIGA.xml:S1:7572:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:7576:6	zytiga	NNP	O	O
arm	ZYTIGA.xml:S1:7583:3	arm	NN	O	O
in	ZYTIGA.xml:S1:7587:2	in	IN	O	O
Study	ZYTIGA.xml:S1:7590:5	studi	NNP	O	O
2	ZYTIGA.xml:S1:7596:1	2	CD	O	O
that	ZYTIGA.xml:S1:7598:4	that	WDT	O	O
occurred	ZYTIGA.xml:S1:7603:8	occur	VBD	O	O
with	ZYTIGA.xml:S1:7612:4	with	IN	O	O
a	ZYTIGA.xml:S1:7617:1	a	DT	O	O
2%	ZYTIGA.xml:S1:7621:2	2%	CD	O	O
absolute	ZYTIGA.xml:S1:7624:8	absolut	JJ	O	O
increase	ZYTIGA.xml:S1:7633:8	increas	NN	O	O
in	ZYTIGA.xml:S1:7642:2	in	IN	O	O
frequency	ZYTIGA.xml:S1:7645:9	frequenc	NN	O	O
compared	ZYTIGA.xml:S1:7655:8	compar	VBN	O	O
to	ZYTIGA.xml:S1:7664:2	to	TO	O	O
placebo	ZYTIGA.xml:S1:7667:7	placebo	VB	O	O
.	ZYTIGA.xml:S1:7674:1	.	.	O	O

The	ZYTIGA.xml:S1:7676:3	the	DT	O	O
median	ZYTIGA.xml:S1:7680:6	median	JJ	O	O
duration	ZYTIGA.xml:S1:7687:8	durat	NN	O	O
of	ZYTIGA.xml:S1:7696:2	of	IN	O	O
treatment	ZYTIGA.xml:S1:7699:9	treatment	NN	O	O
with	ZYTIGA.xml:S1:7709:4	with	IN	O	O
ZYTIGA	ZYTIGA.xml:S1:7714:6	zytiga	NNP	O	O
was	ZYTIGA.xml:S1:7721:3	wa	VBD	O	O
13.8	ZYTIGA.xml:S1:7725:4	13.8	CD	O	O
months	ZYTIGA.xml:S1:7730:6	month	NNS	O	O
.	ZYTIGA.xml:S1:7736:1	.	.	O	O

Table	ZYTIGA.xml:S1:7742:5	tabl	JJ	O	O
3	ZYTIGA.xml:S1:7748:1	3	CD	O	O
:	ZYTIGA.xml:S1:7749:1	:	:	O	O
Adverse	ZYTIGA.xml:S1:7751:7	advers	JJ	O	O
Reactions	ZYTIGA.xml:S1:7759:9	reaction	NNS	O	O
in	ZYTIGA.xml:S1:7769:2	in	IN	O	O
5%	ZYTIGA.xml:S1:7774:2	5%	CD	O	O
of	ZYTIGA.xml:S1:7777:2	of	IN	O	O
Patients	ZYTIGA.xml:S1:7780:8	patient	NNS	O	O
on	ZYTIGA.xml:S1:7789:2	on	IN	O	O
the	ZYTIGA.xml:S1:7792:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:7796:6	zytiga	NNP	O	O
Arm	ZYTIGA.xml:S1:7803:3	arm	NNP	O	O
in	ZYTIGA.xml:S1:7807:2	in	IN	O	O
Study	ZYTIGA.xml:S1:7810:5	studi	NNP	O	O
2	ZYTIGA.xml:S1:7816:1	2	CD	O	O

ZYTIGA	ZYTIGA.xml:S1:7862:6	zytiga	NNP	O	O
with	ZYTIGA.xml:S1:7869:4	with	IN	O	O
Prednisone	ZYTIGA.xml:S1:7874:10	prednison	NNP	O	O
(	ZYTIGA.xml:S1:7885:1	(	(	O	O
N	ZYTIGA.xml:S1:7886:1	N	NNP	O	O
542	ZYTIGA.xml:S1:7888:3	542	CD	O	O
)	ZYTIGA.xml:S1:7891:1	)	)	O	O
Placebo	ZYTIGA.xml:S1:7894:7	placebo	NN	O	O
with	ZYTIGA.xml:S1:7902:4	with	IN	O	O
Prednisone	ZYTIGA.xml:S1:7907:10	prednison	NNP	O	O
(	ZYTIGA.xml:S1:7918:1	(	(	O	O
N	ZYTIGA.xml:S1:7919:1	N	NNP	O	O
540	ZYTIGA.xml:S1:7921:3	540	CD	O	O
)	ZYTIGA.xml:S1:7924:1	)	)	O	O

System	ZYTIGA.xml:S1:7930:6	system	NNP	O	O
Organ	ZYTIGA.xml:S1:7937:5	organ	NNP	O	O
Class	ZYTIGA.xml:S1:7943:5	class	NNP	O	O
Adverse	ZYTIGA.xml:S1:7950:7	advers	NNP	O	O
reaction	ZYTIGA.xml:S1:7958:8	reaction	NN	O	O
All	ZYTIGA.xml:S1:7974:3	all	NNP	O	O
Grades	ZYTIGA.xml:S1:7978:6	grade	NNP	O	O
Grade	ZYTIGA.xml:S1:7991:5	grade	NNP	O	O
3	ZYTIGA.xml:S1:7997:1	3	CD	O	O
-	ZYTIGA.xml:S1:7998:1	-	:	O	O
4%	ZYTIGA.xml:S1:7999:2	4%	CD	O	O
All	ZYTIGA.xml:S1:8008:3	all	DT	O	O
Grades	ZYTIGA.xml:S1:8012:6	grade	NNP	O	O
Grade	ZYTIGA.xml:S1:8025:5	grade	NNP	O	O
3	ZYTIGA.xml:S1:8031:1	3	CD	O	O
-	ZYTIGA.xml:S1:8032:1	-	:	O	O
4%	ZYTIGA.xml:S1:8033:2	4%	CD	O	O

General	ZYTIGA.xml:S1:8048:7	gener	NNP	O	O

disorders	ZYTIGA.xml:S1:8056:9	disord	NNS	O	O

Fatigue	ZYTIGA.xml:S1:8161:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
39.1	ZYTIGA.xml:S1:8206:4	39.1	CD	O	O
2.2	ZYTIGA.xml:S1:8224:3	2.2	CD	O	O
34.3	ZYTIGA.xml:S1:8240:4	34.3	CD	O	O
1.7	ZYTIGA.xml:S1:8258:3	1.7	CD	O	O

Edema	ZYTIGA.xml:S1:8274:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
25.1	ZYTIGA.xml:S1:8319:4	25.1	CD	O	O
0.4	ZYTIGA.xml:S1:8337:3	0.4	CD	O	O
20.7	ZYTIGA.xml:S1:8353:4	20.7	CD	O	O
1.1	ZYTIGA.xml:S1:8371:3	1.1	CD	O	O

Pyrexia	ZYTIGA.xml:S1:8387:7	pyrexia	NNP	B-AdverseReaction	B-AdverseReaction
8.7	ZYTIGA.xml:S1:8433:3	8.7	CD	O	O
0.6	ZYTIGA.xml:S1:8450:3	0.6	CD	O	O
5.9	ZYTIGA.xml:S1:8467:3	5.9	CD	O	O
0.2	ZYTIGA.xml:S1:8484:3	0.2	CD	O	O

Musculoskeletal	ZYTIGA.xml:S1:8500:15	musculoskelet	NNP	O	O
and	ZYTIGA.xml:S1:8516:3	and	CC	O	O
connective	ZYTIGA.xml:S1:8520:10	connect	JJ	O	O
tissue	ZYTIGA.xml:S1:8531:6	tissu	NN	O	O
disorders	ZYTIGA.xml:S1:8538:9	disord	NNS	O	O

Joint	ZYTIGA.xml:S1:8624:5	joint	JJ	B-AdverseReaction	B-AdverseReaction
swelling	ZYTIGA.xml:S1:8630:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
discomfort	ZYTIGA.xml:S1:8639:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
30.3	ZYTIGA.xml:S1:8669:4	30.3	CD	O	O
2.0	ZYTIGA.xml:S1:8687:3	2.0	CD	O	O
25.2	ZYTIGA.xml:S1:8703:4	25.2	CD	O	O
2.0	ZYTIGA.xml:S1:8721:3	2.0	CD	O	O

Groin	ZYTIGA.xml:S1:8737:5	groin	NNP	B-AdverseReaction	B-AdverseReaction
pain	ZYTIGA.xml:S1:8743:4	pain	VBP	I-AdverseReaction	I-AdverseReaction
6.6	ZYTIGA.xml:S1:8783:3	6.6	CD	O	O
0.4	ZYTIGA.xml:S1:8800:3	0.4	CD	O	O
4.1	ZYTIGA.xml:S1:8817:3	4.1	CD	O	O
0.7	ZYTIGA.xml:S1:8834:3	0.7	CD	O	O

Gastrointestinal	ZYTIGA.xml:S1:8850:16	gastrointestin	JJ	O	O
disorders	ZYTIGA.xml:S1:8867:9	disord	NNS	O	O

Constipation	ZYTIGA.xml:S1:8963:12	constip	NN	B-AdverseReaction	B-AdverseReaction
23.1	ZYTIGA.xml:S1:9008:4	23.1	CD	O	O
0.4	ZYTIGA.xml:S1:9026:3	0.4	CD	O	O
19.1	ZYTIGA.xml:S1:9042:4	19.1	CD	O	O
0.6	ZYTIGA.xml:S1:9060:3	0.6	CD	O	O

Diarrhea	ZYTIGA.xml:S1:9076:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
21.6	ZYTIGA.xml:S1:9121:4	21.6	CD	O	O
0.9	ZYTIGA.xml:S1:9139:3	0.9	CD	O	O
17.8	ZYTIGA.xml:S1:9155:4	17.8	CD	O	O
0.9	ZYTIGA.xml:S1:9173:3	0.9	CD	O	O

Dyspepsia	ZYTIGA.xml:S1:9189:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
11.1	ZYTIGA.xml:S1:9234:4	11.1	CD	O	O
0.0	ZYTIGA.xml:S1:9252:3	0.0	CD	O	O
5.0	ZYTIGA.xml:S1:9269:3	5.0	CD	O	O
0.2	ZYTIGA.xml:S1:9286:3	0.2	CD	O	O

Vascular	ZYTIGA.xml:S1:9302:8	vascular	JJ	O	O
disorders	ZYTIGA.xml:S1:9311:9	disord	NNS	O	O

Hot	ZYTIGA.xml:S1:9415:3	hot	NNP	B-AdverseReaction	B-AdverseReaction
flush	ZYTIGA.xml:S1:9419:5	flush	VBD	I-AdverseReaction	I-AdverseReaction
22.3	ZYTIGA.xml:S1:9460:4	22.3	CD	O	O
0.2	ZYTIGA.xml:S1:9478:3	0.2	CD	O	O
18.1	ZYTIGA.xml:S1:9494:4	18.1	CD	O	O
0.0	ZYTIGA.xml:S1:9512:3	0.0	CD	O	O

Hypertension	ZYTIGA.xml:S1:9528:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
21.6	ZYTIGA.xml:S1:9573:4	21.6	CD	O	O
3.9	ZYTIGA.xml:S1:9591:3	3.9	CD	O	O
13.1	ZYTIGA.xml:S1:9607:4	13.1	CD	O	O
3.0	ZYTIGA.xml:S1:9625:3	3.0	CD	O	O

Respiratory	ZYTIGA.xml:S1:9641:11	respiratori	NNP	O	O
,	ZYTIGA.xml:S1:9652:1	,	,	O	O
thoracic	ZYTIGA.xml:S1:9654:8	thorac	NN	O	O
and	ZYTIGA.xml:S1:9663:3	and	CC	O	O
mediastinal	ZYTIGA.xml:S1:9667:11	mediastin	JJ	O	O
disorders	ZYTIGA.xml:S1:9679:9	disord	NNS	O	O

Cough	ZYTIGA.xml:S1:9765:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
17.3	ZYTIGA.xml:S1:9810:4	17.3	CD	O	O
0.0	ZYTIGA.xml:S1:9828:3	0.0	CD	O	O
13.5	ZYTIGA.xml:S1:9844:4	13.5	CD	O	O
0.2	ZYTIGA.xml:S1:9862:3	0.2	CD	O	O

Dyspnea	ZYTIGA.xml:S1:9878:7	dyspnea	NNP	B-AdverseReaction	B-AdverseReaction
11.8	ZYTIGA.xml:S1:9923:4	11.8	CD	O	O
2.4	ZYTIGA.xml:S1:9941:3	2.4	CD	O	O
9.6	ZYTIGA.xml:S1:9958:3	9.6	CD	O	O
0.9	ZYTIGA.xml:S1:9975:3	0.9	CD	O	O

Psychiatric	ZYTIGA.xml:S1:9991:11	psychiatr	JJ	O	O
disorders	ZYTIGA.xml:S1:10003:9	disord	NNS	O	O

Insomnia	ZYTIGA.xml:S1:10104:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
13.5	ZYTIGA.xml:S1:10149:4	13.5	CD	O	O
0.2	ZYTIGA.xml:S1:10167:3	0.2	CD	O	O
11.3	ZYTIGA.xml:S1:10183:4	11.3	CD	O	O
0.0	ZYTIGA.xml:S1:10201:3	0.0	CD	O	O

Injury	ZYTIGA.xml:S1:10217:6	injuri	NNP	O	O
,	ZYTIGA.xml:S1:10223:1	,	,	O	O
poisoning	ZYTIGA.xml:S1:10225:9	poison	NN	O	O
and	ZYTIGA.xml:S1:10235:3	and	CC	O	O
procedural	ZYTIGA.xml:S1:10239:10	procedur	JJ	O	O
complications	ZYTIGA.xml:S1:10250:13	complic	NNS	O	O

Contusion	ZYTIGA.xml:S1:10340:9	contus	NN	B-AdverseReaction	B-AdverseReaction
13.3	ZYTIGA.xml:S1:10385:4	13.3	CD	O	O
0.0	ZYTIGA.xml:S1:10403:3	0.0	CD	O	O
9.1	ZYTIGA.xml:S1:10420:3	9.1	CD	O	O
0.0	ZYTIGA.xml:S1:10437:3	0.0	CD	O	O

Falls	ZYTIGA.xml:S1:10453:5	fall	NNP	B-AdverseReaction	B-AdverseReaction
5.9	ZYTIGA.xml:S1:10499:3	5.9	CD	O	O
0.0	ZYTIGA.xml:S1:10516:3	0.0	CD	O	O
3.3	ZYTIGA.xml:S1:10533:3	3.3	CD	O	O
0.0	ZYTIGA.xml:S1:10550:3	0.0	CD	O	O

Infections	ZYTIGA.xml:S1:10566:10	infect	NNS	O	O
and	ZYTIGA.xml:S1:10577:3	and	CC	O	O
infestations	ZYTIGA.xml:S1:10581:12	infest	NNS	O	O

Upper	ZYTIGA.xml:S1:10679:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	ZYTIGA.xml:S1:10685:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	ZYTIGA.xml:S1:10697:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ZYTIGA.xml:S1:10703:9	infect	NN	I-AdverseReaction	I-AdverseReaction
12.7	ZYTIGA.xml:S1:10724:4	12.7	CD	O	O
0.0	ZYTIGA.xml:S1:10742:3	0.0	CD	O	O
8.0	ZYTIGA.xml:S1:10759:3	8.0	CD	O	O
0.0	ZYTIGA.xml:S1:10776:3	0.0	CD	O	O

Nasopharyngitis	ZYTIGA.xml:S1:10792:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
10.7	ZYTIGA.xml:S1:10837:4	10.7	CD	O	O
0.0	ZYTIGA.xml:S1:10855:3	0.0	CD	O	O
8.1	ZYTIGA.xml:S1:10872:3	8.1	CD	O	O
0.0	ZYTIGA.xml:S1:10889:3	0.0	CD	O	O

Renal	ZYTIGA.xml:S1:10905:5	renal	NNP	O	O
and	ZYTIGA.xml:S1:10911:3	and	CC	O	O
urinary	ZYTIGA.xml:S1:10915:7	urinari	JJ	O	O
disorders	ZYTIGA.xml:S1:10923:9	disord	NNS	O	O

Hematuria	ZYTIGA.xml:S1:11018:9	hematuria	NNP	B-AdverseReaction	B-AdverseReaction
10.3	ZYTIGA.xml:S1:11063:4	10.3	CD	O	O
1.3	ZYTIGA.xml:S1:11081:3	1.3	CD	O	O
5.6	ZYTIGA.xml:S1:11098:3	5.6	CD	O	O
0.6	ZYTIGA.xml:S1:11115:3	0.6	CD	O	O

Skin	ZYTIGA.xml:S1:11131:4	skin	NNP	O	O
and	ZYTIGA.xml:S1:11136:3	and	CC	O	O
subcutaneous	ZYTIGA.xml:S1:11140:12	subcutan	JJ	O	O
tissue	ZYTIGA.xml:S1:11153:6	tissu	NN	O	O
disorders	ZYTIGA.xml:S1:11160:9	disord	NNS	O	O

Rash	ZYTIGA.xml:S1:11246:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
8.1	ZYTIGA.xml:S1:11292:3	8.1	CD	O	O
0.0	ZYTIGA.xml:S1:11309:3	0.0	CD	O	O
3.7	ZYTIGA.xml:S1:11326:3	3.7	CD	O	O
0.0	ZYTIGA.xml:S1:11343:3	0.0	CD	O	O

Table	ZYTIGA.xml:S1:11367:5	tabl	JJ	O	O
4	ZYTIGA.xml:S1:11373:1	4	CD	O	O
shows	ZYTIGA.xml:S1:11375:5	show	NNS	O	O
laboratory	ZYTIGA.xml:S1:11381:10	laboratori	NN	O	O
abnormalities	ZYTIGA.xml:S1:11392:13	abnorm	NNS	O	O
that	ZYTIGA.xml:S1:11406:4	that	WDT	O	O
occurred	ZYTIGA.xml:S1:11411:8	occur	VBD	O	O
in	ZYTIGA.xml:S1:11420:2	in	IN	O	O
greater	ZYTIGA.xml:S1:11423:7	greater	JJR	O	O
than	ZYTIGA.xml:S1:11431:4	than	IN	O	O
15%	ZYTIGA.xml:S1:11436:3	15%	CD	O	O
of	ZYTIGA.xml:S1:11440:2	of	IN	O	O
patients	ZYTIGA.xml:S1:11443:8	patient	NNS	O	O
,	ZYTIGA.xml:S1:11451:1	,	,	O	O
and	ZYTIGA.xml:S1:11453:3	and	CC	O	O
more	ZYTIGA.xml:S1:11457:4	more	RBR	O	O
frequently	ZYTIGA.xml:S1:11462:10	frequent	RB	O	O
(	ZYTIGA.xml:S1:11473:1	(	(	O	O
5%	ZYTIGA.xml:S1:11475:2	5%	CD	O	O
)	ZYTIGA.xml:S1:11477:1	)	)	O	O
in	ZYTIGA.xml:S1:11479:2	in	IN	O	O
the	ZYTIGA.xml:S1:11482:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:11486:6	zytiga	NNP	O	O
arm	ZYTIGA.xml:S1:11493:3	arm	NN	O	O
compared	ZYTIGA.xml:S1:11497:8	compar	VBN	O	O
to	ZYTIGA.xml:S1:11506:2	to	TO	O	O
placebo	ZYTIGA.xml:S1:11509:7	placebo	VB	O	O
in	ZYTIGA.xml:S1:11517:2	in	IN	O	O
Study	ZYTIGA.xml:S1:11520:5	studi	NNP	O	O
2	ZYTIGA.xml:S1:11526:1	2	CD	O	O
.	ZYTIGA.xml:S1:11527:1	.	.	O	O

Grade	ZYTIGA.xml:S1:11529:5	grade	$	O	O
3	ZYTIGA.xml:S1:11535:1	3	CD	O	O
-	ZYTIGA.xml:S1:11536:1	-	:	O	O
4	ZYTIGA.xml:S1:11537:1	4	CD	O	O
lymphopenia	ZYTIGA.xml:S1:11539:11	lymphopenia	NN	B-AdverseReaction	B-AdverseReaction
(	ZYTIGA.xml:S1:11551:1	(	(	O	O
9%	ZYTIGA.xml:S1:11552:2	9%	CD	O	O
)	ZYTIGA.xml:S1:11554:1	)	)	O	O
,	ZYTIGA.xml:S1:11555:1	,	,	O	O
hyperglycemia	ZYTIGA.xml:S1:11557:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
(	ZYTIGA.xml:S1:11571:1	(	(	O	O
7%	ZYTIGA.xml:S1:11572:2	7%	CD	O	O
)	ZYTIGA.xml:S1:11574:1	)	)	O	O
and	ZYTIGA.xml:S1:11576:3	and	CC	O	O
high	ZYTIGA.xml:S1:11580:4	high	JJ	B-AdverseReaction	B-AdverseReaction
alanine	ZYTIGA.xml:S1:11585:7	alanin	NN	I-AdverseReaction	I-AdverseReaction
aminotransferase	ZYTIGA.xml:S1:11593:16	aminotransferas	NN	I-AdverseReaction	I-AdverseReaction
(	ZYTIGA.xml:S1:11610:1	(	(	O	O
6%	ZYTIGA.xml:S1:11611:2	6%	CD	O	O
)	ZYTIGA.xml:S1:11613:1	)	)	O	O
occurred	ZYTIGA.xml:S1:11615:8	occur	VBD	O	O
at	ZYTIGA.xml:S1:11624:2	at	IN	O	O
a	ZYTIGA.xml:S1:11627:1	a	DT	O	O
greater	ZYTIGA.xml:S1:11629:7	greater	JJR	O	O
than	ZYTIGA.xml:S1:11637:4	than	IN	O	O
5%	ZYTIGA.xml:S1:11642:2	5%	CD	O	O
rate	ZYTIGA.xml:S1:11645:4	rate	NN	O	O
in	ZYTIGA.xml:S1:11650:2	in	IN	O	O
the	ZYTIGA.xml:S1:11653:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:11657:6	zytiga	NNP	O	O
arm	ZYTIGA.xml:S1:11664:3	arm	NN	O	O
.	ZYTIGA.xml:S1:11667:1	.	.	O	O

Table	ZYTIGA.xml:S1:11673:5	tabl	NN	O	O

4	ZYTIGA.xml:S1:11679:1	4	CD	O	O
:	ZYTIGA.xml:S1:11680:1	:	:	O	O
Laboratory	ZYTIGA.xml:S1:11682:10	laboratori	NN	O	O
Abnormalities	ZYTIGA.xml:S1:11693:13	abnorm	NNS	O	O
in	ZYTIGA.xml:S1:11707:2	in	IN	O	O
15%	ZYTIGA.xml:S1:11711:3	15%	CD	O	O
of	ZYTIGA.xml:S1:11715:2	of	IN	O	O
Patients	ZYTIGA.xml:S1:11718:8	patient	NNS	O	O
in	ZYTIGA.xml:S1:11727:2	in	IN	O	O
the	ZYTIGA.xml:S1:11730:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:11734:6	zytiga	NNP	O	O
Arm	ZYTIGA.xml:S1:11741:3	arm	NNP	O	O
of	ZYTIGA.xml:S1:11745:2	of	IN	O	O
Study	ZYTIGA.xml:S1:11748:5	studi	NNP	O	O
2	ZYTIGA.xml:S1:11754:1	2	CD	O	O

Abiraterone	ZYTIGA.xml:S1:11800:11	abirateron	NNP	O	O
(	ZYTIGA.xml:S1:11812:1	(	(	O	O
N	ZYTIGA.xml:S1:11813:1	N	NNP	O	O
542	ZYTIGA.xml:S1:11815:3	542	CD	O	O
)	ZYTIGA.xml:S1:11818:1	)	)	O	O
Placebo	ZYTIGA.xml:S1:11821:7	placebo	NNP	O	O
(	ZYTIGA.xml:S1:11829:1	(	(	O	O
N	ZYTIGA.xml:S1:11830:1	N	NNP	O	O
540	ZYTIGA.xml:S1:11832:3	540	CD	O	O
)	ZYTIGA.xml:S1:11835:1	)	)	O	O

Laboratory	ZYTIGA.xml:S1:11841:10	laboratori	NNP	O	O
Abnormality	ZYTIGA.xml:S1:11852:11	abnorm	NNP	O	O
Grade	ZYTIGA.xml:S1:11885:5	grade	NNP	O	O
1	ZYTIGA.xml:S1:11891:1	1	CD	O	O
-	ZYTIGA.xml:S1:11892:1	-	:	O	O
4%	ZYTIGA.xml:S1:11893:2	4%	CD	O	O
Grade	ZYTIGA.xml:S1:11902:5	grade	NNP	O	O
3	ZYTIGA.xml:S1:11908:1	3	CD	O	O
-	ZYTIGA.xml:S1:11909:1	-	:	O	O
4%	ZYTIGA.xml:S1:11910:2	4%	CD	O	O
Grade	ZYTIGA.xml:S1:11919:5	grade	NNP	O	O
1	ZYTIGA.xml:S1:11925:1	1	CD	O	O
-	ZYTIGA.xml:S1:11926:1	-	:	O	O
4%	ZYTIGA.xml:S1:11927:2	4%	CD	O	O
Grade	ZYTIGA.xml:S1:11936:5	grade	NNP	O	O
3	ZYTIGA.xml:S1:11942:1	3	CD	O	O
-	ZYTIGA.xml:S1:11943:1	-	:	O	O
4%	ZYTIGA.xml:S1:11944:2	4%	CD	O	O

Hematology	ZYTIGA.xml:S1:11957:10	hematolog	NN	O	O

Lymphopenia	ZYTIGA.xml:S1:12072:11	lymphopenia	NNP	B-AdverseReaction	O

38.2	ZYTIGA.xml:S1:12117:4	38.2	CD	O	O
8.7	ZYTIGA.xml:S1:12135:3	8.7	CD	O	O
31.7	ZYTIGA.xml:S1:12151:4	31.7	CD	O	O
7.4	ZYTIGA.xml:S1:12169:3	7.4	CD	O	O

Chemistry	ZYTIGA.xml:S1:12183:9	chemistri	NN	O	O

Hyperglycemia	ZYTIGA.xml:S1:12298:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
56.6	ZYTIGA.xml:S1:12343:4	56.6	CD	O	O
6.5	ZYTIGA.xml:S1:12361:3	6.5	CD	O	O
50.9	ZYTIGA.xml:S1:12377:4	50.9	CD	O	O
5.2	ZYTIGA.xml:S1:12395:3	5.2	CD	O	O

High	ZYTIGA.xml:S1:12411:4	high	JJ	B-AdverseReaction	B-AdverseReaction
ALT	ZYTIGA.xml:S1:12416:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
41.9	ZYTIGA.xml:S1:12456:4	41.9	CD	O	O
6.1	ZYTIGA.xml:S1:12474:3	6.1	CD	O	O
29.1	ZYTIGA.xml:S1:12490:4	29.1	CD	O	O
0.7	ZYTIGA.xml:S1:12508:3	0.7	CD	O	O

High	ZYTIGA.xml:S1:12524:4	high	JJ	B-AdverseReaction	B-AdverseReaction
AST	ZYTIGA.xml:S1:12529:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
37.3	ZYTIGA.xml:S1:12569:4	37.3	CD	O	O
3.1	ZYTIGA.xml:S1:12587:3	3.1	CD	O	O
28.7	ZYTIGA.xml:S1:12603:4	28.7	CD	O	O
1.1	ZYTIGA.xml:S1:12621:3	1.1	CD	O	O

Hypernatremia	ZYTIGA.xml:S1:12637:13	hypernatremia	NNP	B-AdverseReaction	B-AdverseReaction
32.8	ZYTIGA.xml:S1:12682:4	32.8	CD	O	O
0.4	ZYTIGA.xml:S1:12700:3	0.4	CD	O	O
25.0	ZYTIGA.xml:S1:12716:4	25.0	CD	O	O
0.2	ZYTIGA.xml:S1:12734:3	0.2	CD	O	O

Hypokalemia	ZYTIGA.xml:S1:12750:11	hypokalemia	NNP	B-AdverseReaction	B-AdverseReaction
17.2	ZYTIGA.xml:S1:12795:4	17.2	CD	O	O
2.8	ZYTIGA.xml:S1:12813:3	2.8	CD	O	O
10.2	ZYTIGA.xml:S1:12829:4	10.2	CD	O	O
1.7	ZYTIGA.xml:S1:12847:3	1.7	CD	O	O

Cardiovascular	ZYTIGA.xml:S1:12875:14	cardiovascular	JJ	O	O
Adverse	ZYTIGA.xml:S1:12890:7	advers	JJ	O	O
Reactions	ZYTIGA.xml:S1:12898:9	reaction	NNS	O	O
:	ZYTIGA.xml:S1:12907:1	:	:	O	O

In	ZYTIGA.xml:S1:12915:2	In	IN	O	O

the	ZYTIGA.xml:S1:12918:3	the	DT	O	O
combined	ZYTIGA.xml:S1:12922:8	combin	VBN	O	O
data	ZYTIGA.xml:S1:12931:4	data	NNS	O	O
for	ZYTIGA.xml:S1:12936:3	for	IN	O	O
studies	ZYTIGA.xml:S1:12940:7	studi	NNS	O	O
1	ZYTIGA.xml:S1:12948:1	1	CD	O	O
and	ZYTIGA.xml:S1:12950:3	and	CC	O	O
2	ZYTIGA.xml:S1:12954:1	2	CD	O	O
,	ZYTIGA.xml:S1:12955:1	,	,	O	O
cardiac	ZYTIGA.xml:S1:12957:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZYTIGA.xml:S1:12965:7	failur	NN	I-AdverseReaction	I-AdverseReaction
occurred	ZYTIGA.xml:S1:12973:8	occur	VBD	O	O
more	ZYTIGA.xml:S1:12982:4	more	JJR	O	O
commonly	ZYTIGA.xml:S1:12987:8	commonli	RB	O	O
in	ZYTIGA.xml:S1:12996:2	in	IN	O	O
patients	ZYTIGA.xml:S1:12999:8	patient	NNS	O	O
treated	ZYTIGA.xml:S1:13008:7	treat	VBN	O	O
with	ZYTIGA.xml:S1:13016:4	with	IN	O	O
ZYTIGA	ZYTIGA.xml:S1:13021:6	zytiga	NNP	O	O
compared	ZYTIGA.xml:S1:13028:8	compar	VBN	O	O
to	ZYTIGA.xml:S1:13037:2	to	TO	O	O
patients	ZYTIGA.xml:S1:13040:8	patient	NNS	O	O
on	ZYTIGA.xml:S1:13049:2	on	IN	O	O
the	ZYTIGA.xml:S1:13052:3	the	DT	O	O
placebo	ZYTIGA.xml:S1:13056:7	placebo	NN	O	O
arm	ZYTIGA.xml:S1:13064:3	arm	NN	O	O
(	ZYTIGA.xml:S1:13068:1	(	(	O	O
2.1%	ZYTIGA.xml:S1:13069:4	2.1%	CD	O	O
versus	ZYTIGA.xml:S1:13074:6	versu	IN	O	O
0.7%	ZYTIGA.xml:S1:13081:4	0.7%	CD	O	O
)	ZYTIGA.xml:S1:13085:1	)	)	O	O
.	ZYTIGA.xml:S1:13086:1	.	.	O	O

Grade	ZYTIGA.xml:S1:13088:5	grade	$	O	O
3	ZYTIGA.xml:S1:13094:1	3	CD	O	O
-	ZYTIGA.xml:S1:13095:1	-	:	O	O
4	ZYTIGA.xml:S1:13096:1	4	CD	O	O
cardiac	ZYTIGA.xml:S1:13098:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZYTIGA.xml:S1:13106:7	failur	NN	I-AdverseReaction	I-AdverseReaction
occurred	ZYTIGA.xml:S1:13114:8	occur	VBD	O	O
in	ZYTIGA.xml:S1:13123:2	in	IN	O	O
1.6%	ZYTIGA.xml:S1:13126:4	1.6%	CD	O	O
of	ZYTIGA.xml:S1:13131:2	of	IN	O	O
patients	ZYTIGA.xml:S1:13134:8	patient	NNS	O	O
taking	ZYTIGA.xml:S1:13143:6	take	VBG	O	O
ZYTIGA	ZYTIGA.xml:S1:13150:6	zytiga	NNP	O	O
and	ZYTIGA.xml:S1:13157:3	and	CC	O	O
led	ZYTIGA.xml:S1:13161:3	led	VBD	O	O
to	ZYTIGA.xml:S1:13165:2	to	TO	O	O
5	ZYTIGA.xml:S1:13168:1	5	CD	O	O
treatment	ZYTIGA.xml:S1:13170:9	treatment	NN	O	O
discontinuations	ZYTIGA.xml:S1:13180:16	discontinu	NNS	O	O
and	ZYTIGA.xml:S1:13197:3	and	CC	O	O
2	ZYTIGA.xml:S1:13201:1	2	CD	O	O
deaths	ZYTIGA.xml:S1:13203:6	death	NNS	B-AdverseReaction	B-AdverseReaction
.	ZYTIGA.xml:S1:13209:1	.	.	O	O

Grade	ZYTIGA.xml:S1:13211:5	grade	$	O	O
3	ZYTIGA.xml:S1:13217:1	3	CD	O	O
-	ZYTIGA.xml:S1:13218:1	-	:	O	O
4	ZYTIGA.xml:S1:13219:1	4	CD	O	O
cardiac	ZYTIGA.xml:S1:13221:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZYTIGA.xml:S1:13229:7	failur	NN	I-AdverseReaction	I-AdverseReaction
occurred	ZYTIGA.xml:S1:13237:8	occur	VBD	O	O
in	ZYTIGA.xml:S1:13246:2	in	IN	O	O
0.2%	ZYTIGA.xml:S1:13249:4	0.2%	CD	O	O
of	ZYTIGA.xml:S1:13254:2	of	IN	O	O
patients	ZYTIGA.xml:S1:13257:8	patient	NNS	O	O
taking	ZYTIGA.xml:S1:13266:6	take	VBG	O	O
placebo	ZYTIGA.xml:S1:13273:7	placebo	NN	O	O
.	ZYTIGA.xml:S1:13280:1	.	.	O	O

There	ZYTIGA.xml:S1:13282:5	there	EX	O	O
were	ZYTIGA.xml:S1:13288:4	were	VBD	O	O
no	ZYTIGA.xml:S1:13293:2	no	DT	O	O
treatment	ZYTIGA.xml:S1:13296:9	treatment	NN	O	O
discontinuations	ZYTIGA.xml:S1:13306:16	discontinu	NNS	O	O
and	ZYTIGA.xml:S1:13323:3	and	CC	O	O
one	ZYTIGA.xml:S1:13327:3	one	CD	O	O
death	ZYTIGA.xml:S1:13331:5	death	NN	B-AdverseReaction	B-AdverseReaction
due	ZYTIGA.xml:S1:13337:3	due	JJ	O	O
to	ZYTIGA.xml:S1:13341:2	to	TO	O	O
cardiac	ZYTIGA.xml:S1:13344:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
failure	ZYTIGA.xml:S1:13352:7	failur	NN	I-AdverseReaction	I-AdverseReaction
in	ZYTIGA.xml:S1:13360:2	in	IN	O	O
the	ZYTIGA.xml:S1:13363:3	the	DT	O	O
placebo	ZYTIGA.xml:S1:13367:7	placebo	NN	O	O
group	ZYTIGA.xml:S1:13375:5	group	NN	O	O
.	ZYTIGA.xml:S1:13380:1	.	.	O	O

In	ZYTIGA.xml:S1:13386:2	In	IN	O	O
Study	ZYTIGA.xml:S1:13389:5	studi	NNP	O	O
1	ZYTIGA.xml:S1:13395:1	1	CD	O	O
and	ZYTIGA.xml:S1:13397:3	and	CC	O	O
2	ZYTIGA.xml:S1:13401:1	2	CD	O	O
,	ZYTIGA.xml:S1:13402:1	,	,	O	O
the	ZYTIGA.xml:S1:13404:3	the	DT	O	O
majority	ZYTIGA.xml:S1:13408:8	major	NN	O	O
of	ZYTIGA.xml:S1:13417:2	of	IN	O	O
arrhythmias	ZYTIGA.xml:S1:13420:11	arrhythmia	NNS	B-AdverseReaction	O
were	ZYTIGA.xml:S1:13432:4	were	VBD	O	O
grade	ZYTIGA.xml:S1:13437:5	grade	JJ	O	O
1	ZYTIGA.xml:S1:13443:1	1	CD	O	O
or	ZYTIGA.xml:S1:13445:2	or	CC	O	O
2	ZYTIGA.xml:S1:13448:1	2	CD	O	O
.	ZYTIGA.xml:S1:13449:1	.	.	O	O

There	ZYTIGA.xml:S1:13451:5	there	EX	O	O
was	ZYTIGA.xml:S1:13457:3	wa	VBD	O	O
one	ZYTIGA.xml:S1:13461:3	one	CD	O	O
death	ZYTIGA.xml:S1:13465:5	death	NN	B-AdverseReaction	B-AdverseReaction
associated	ZYTIGA.xml:S1:13471:10	associ	VBN	O	O
with	ZYTIGA.xml:S1:13482:4	with	IN	O	O
arrhythmia	ZYTIGA.xml:S1:13487:10	arrhythmia	NN	B-AdverseReaction	O
and	ZYTIGA.xml:S1:13498:3	and	CC	O	O
one	ZYTIGA.xml:S1:13502:3	one	CD	O	O
patient	ZYTIGA.xml:S1:13506:7	patient	NN	O	O
with	ZYTIGA.xml:S1:13514:4	with	IN	O	O
sudden	ZYTIGA.xml:S1:13519:6	sudden	JJ	B-AdverseReaction	O
death	ZYTIGA.xml:S1:13526:5	death	NN	I-AdverseReaction	O
in	ZYTIGA.xml:S1:13532:2	in	IN	O	O
the	ZYTIGA.xml:S1:13535:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:13539:6	zytiga	NNP	O	O
arms	ZYTIGA.xml:S1:13546:4	arm	NNS	O	O
and	ZYTIGA.xml:S1:13551:3	and	CC	O	O
no	ZYTIGA.xml:S1:13555:2	no	DT	O	O
deaths	ZYTIGA.xml:S1:13558:6	death	NNS	B-AdverseReaction	B-AdverseReaction
in	ZYTIGA.xml:S1:13565:2	in	IN	O	O
the	ZYTIGA.xml:S1:13568:3	the	DT	O	O
placebo	ZYTIGA.xml:S1:13572:7	placebo	NN	O	O
arms	ZYTIGA.xml:S1:13580:4	arm	NNS	O	O
.	ZYTIGA.xml:S1:13584:1	.	.	O	O

There	ZYTIGA.xml:S1:13586:5	there	EX	O	O
were	ZYTIGA.xml:S1:13592:4	were	VBD	O	O
7	ZYTIGA.xml:S1:13597:1	7	CD	O	O
(	ZYTIGA.xml:S1:13599:1	(	(	O	O
0.5%	ZYTIGA.xml:S1:13600:4	0.5%	CD	O	O
)	ZYTIGA.xml:S1:13604:1	)	)	O	O
deaths	ZYTIGA.xml:S1:13606:6	death	NNS	B-AdverseReaction	B-AdverseReaction
due	ZYTIGA.xml:S1:13613:3	due	JJ	O	O
to	ZYTIGA.xml:S1:13617:2	to	TO	O	O
cardiorespiratory	ZYTIGA.xml:S1:13620:17	cardiorespiratori	JJ	B-AdverseReaction	B-AdverseReaction
arrest	ZYTIGA.xml:S1:13638:6	arrest	NN	I-AdverseReaction	I-AdverseReaction
in	ZYTIGA.xml:S1:13645:2	in	IN	O	O
the	ZYTIGA.xml:S1:13648:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:13652:6	zytiga	NNP	O	O
arms	ZYTIGA.xml:S1:13659:4	arm	NNS	O	O
and	ZYTIGA.xml:S1:13664:3	and	CC	O	O
3	ZYTIGA.xml:S1:13668:1	3	CD	O	O
(	ZYTIGA.xml:S1:13670:1	(	(	O	O
0.3%	ZYTIGA.xml:S1:13671:4	0.3%	CD	O	O
)	ZYTIGA.xml:S1:13675:1	)	)	O	O
deaths	ZYTIGA.xml:S1:13677:6	death	NNS	B-AdverseReaction	B-AdverseReaction
in	ZYTIGA.xml:S1:13684:2	in	IN	O	O
the	ZYTIGA.xml:S1:13687:3	the	DT	O	O
placebo	ZYTIGA.xml:S1:13691:7	placebo	NN	O	O
arms	ZYTIGA.xml:S1:13699:4	arm	NNS	O	O
.	ZYTIGA.xml:S1:13703:1	.	.	O	O

Myocardial	ZYTIGA.xml:S1:13705:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
ischemia	ZYTIGA.xml:S1:13716:8	ischemia	NN	I-AdverseReaction	I-AdverseReaction
or	ZYTIGA.xml:S1:13725:2	or	CC	O	O
myocardial	ZYTIGA.xml:S1:13728:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
infarction	ZYTIGA.xml:S1:13739:10	infarct	NN	I-AdverseReaction	I-AdverseReaction
led	ZYTIGA.xml:S1:13750:3	led	VBD	O	O
to	ZYTIGA.xml:S1:13754:2	to	TO	O	O
death	ZYTIGA.xml:S1:13757:5	death	NN	B-AdverseReaction	B-AdverseReaction
in	ZYTIGA.xml:S1:13763:2	in	IN	O	O
3	ZYTIGA.xml:S1:13766:1	3	CD	O	O
patients	ZYTIGA.xml:S1:13768:8	patient	NNS	O	O
in	ZYTIGA.xml:S1:13777:2	in	IN	O	O
the	ZYTIGA.xml:S1:13780:3	the	DT	O	O
placebo	ZYTIGA.xml:S1:13784:7	placebo	NN	O	O
arms	ZYTIGA.xml:S1:13792:4	arm	NNS	O	O
and	ZYTIGA.xml:S1:13797:3	and	CC	O	O
2	ZYTIGA.xml:S1:13801:1	2	CD	O	O
deaths	ZYTIGA.xml:S1:13803:6	death	NNS	B-AdverseReaction	B-AdverseReaction
in	ZYTIGA.xml:S1:13810:2	in	IN	O	O
the	ZYTIGA.xml:S1:13813:3	the	DT	O	O
ZYTIGA	ZYTIGA.xml:S1:13817:6	zytiga	NNP	O	O
arms	ZYTIGA.xml:S1:13824:4	arm	NNS	O	O
.	ZYTIGA.xml:S1:13828:1	.	.	O	O

6.2	ZYTIGA.xml:S1:13836:3	6.2	CD	O	O
Post	ZYTIGA.xml:S1:13840:4	post	NNP	O	O
Marketing	ZYTIGA.xml:S1:13845:9	market	NNP	O	O
Experience	ZYTIGA.xml:S1:13855:10	experi	NN	O	O

The	ZYTIGA.xml:S1:13869:3	the	DT	O	O
following	ZYTIGA.xml:S1:13873:9	follow	JJ	O	O
additional	ZYTIGA.xml:S1:13883:10	addit	JJ	O	O
adverse	ZYTIGA.xml:S1:13894:7	advers	JJ	O	O
reactions	ZYTIGA.xml:S1:13902:9	reaction	NNS	O	O
have	ZYTIGA.xml:S1:13912:4	have	VBP	O	O
been	ZYTIGA.xml:S1:13917:4	been	VBN	O	O
identified	ZYTIGA.xml:S1:13922:10	identifi	VBN	O	O
during	ZYTIGA.xml:S1:13933:6	dure	IN	O	O
post	ZYTIGA.xml:S1:13940:4	post	NN	O	O
approval	ZYTIGA.xml:S1:13945:8	approv	NN	O	O
use	ZYTIGA.xml:S1:13954:3	use	NN	O	O
of	ZYTIGA.xml:S1:13958:2	of	IN	O	O
ZYTIGA	ZYTIGA.xml:S1:13961:6	zytiga	NNP	O	O
.	ZYTIGA.xml:S1:13967:1	.	.	O	O

Because	ZYTIGA.xml:S1:13969:7	becaus	IN	O	O
these	ZYTIGA.xml:S1:13977:5	these	DT	O	O
reactions	ZYTIGA.xml:S1:13983:9	reaction	NNS	O	O
are	ZYTIGA.xml:S1:13993:3	are	VBP	O	O
reported	ZYTIGA.xml:S1:13997:8	report	VBN	O	O
voluntarily	ZYTIGA.xml:S1:14006:11	voluntarili	RB	O	O
from	ZYTIGA.xml:S1:14018:4	from	IN	O	O
a	ZYTIGA.xml:S1:14023:1	a	DT	O	O
population	ZYTIGA.xml:S1:14025:10	popul	NN	O	O
of	ZYTIGA.xml:S1:14036:2	of	IN	O	O
uncertain	ZYTIGA.xml:S1:14039:9	uncertain	JJ	O	O
size	ZYTIGA.xml:S1:14049:4	size	NN	O	O
,	ZYTIGA.xml:S1:14053:1	,	,	O	O
it	ZYTIGA.xml:S1:14055:2	it	PRP	O	O
is	ZYTIGA.xml:S1:14058:2	is	VBZ	O	O
not	ZYTIGA.xml:S1:14061:3	not	RB	O	O
always	ZYTIGA.xml:S1:14065:6	alway	RB	O	O
possible	ZYTIGA.xml:S1:14072:8	possibl	JJ	O	O
to	ZYTIGA.xml:S1:14081:2	to	TO	O	O
reliably	ZYTIGA.xml:S1:14084:8	reliabl	VB	O	O
estimate	ZYTIGA.xml:S1:14093:8	estim	VB	O	O
their	ZYTIGA.xml:S1:14102:5	their	PRP$	O	O
frequency	ZYTIGA.xml:S1:14108:9	frequenc	NN	O	O
or	ZYTIGA.xml:S1:14118:2	or	CC	O	O
establish	ZYTIGA.xml:S1:14121:9	establish	VB	O	O
a	ZYTIGA.xml:S1:14131:1	a	DT	O	O
causal	ZYTIGA.xml:S1:14133:6	causal	NN	O	O
relationship	ZYTIGA.xml:S1:14140:12	relationship	NN	O	O
to	ZYTIGA.xml:S1:14153:2	to	TO	O	O
drug	ZYTIGA.xml:S1:14156:4	drug	NN	O	O
exposure	ZYTIGA.xml:S1:14161:8	exposur	NN	O	O
.	ZYTIGA.xml:S1:14169:1	.	.	O	O

Respiratory	ZYTIGA.xml:S1:14177:11	respiratori	NNP	O	O
,	ZYTIGA.xml:S1:14188:1	,	,	O	O
Thoracic	ZYTIGA.xml:S1:14190:8	thorac	NNP	O	O
and	ZYTIGA.xml:S1:14199:3	and	CC	O	O
Mediastinal	ZYTIGA.xml:S1:14203:11	mediastin	NNP	O	O
Disorders	ZYTIGA.xml:S1:14215:9	disord	NNS	O	O
:	ZYTIGA.xml:S1:14224:1	:	:	O	O
non	ZYTIGA.xml:S1:14227:3	non	SYM	B-AdverseReaction	B-AdverseReaction
-	ZYTIGA.xml:S1:14230:1	-	:	I-AdverseReaction	I-AdverseReaction
infectious	ZYTIGA.xml:S1:14231:10	infecti	JJ	I-AdverseReaction	I-AdverseReaction
pneumonitis	ZYTIGA.xml:S1:14242:11	pneumon	NN	I-AdverseReaction	I-AdverseReaction
.	ZYTIGA.xml:S1:14253:1	.	.	O	O

Musculoskeletal	ZYTIGA.xml:S1:14261:15	musculoskelet	NNP	O	O
and	ZYTIGA.xml:S1:14277:3	and	CC	O	O
Connective	ZYTIGA.xml:S1:14281:10	connect	NNP	O	O
Tissue	ZYTIGA.xml:S1:14292:6	tissu	NNP	O	O
Disorders	ZYTIGA.xml:S1:14299:9	disord	NNP	O	O
:	ZYTIGA.xml:S1:14310:1	:	:	O	O
myopathy	ZYTIGA.xml:S1:14312:8	myopathi	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S1:14320:1	,	,	O	O
including	ZYTIGA.xml:S1:14322:9	includ	VBG	O	O
rhabdomyolysis	ZYTIGA.xml:S1:14332:14	rhabdomyolysi	NN	B-AdverseReaction	B-AdverseReaction
.	ZYTIGA.xml:S1:14346:1	.	.	O	O
5	ZYTIGA.xml:S2:4:1	5	CD	O	O
WARNINGS	ZYTIGA.xml:S2:6:8	warn	NNP	O	O
AND	ZYTIGA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	ZYTIGA.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	ZYTIGA.xml:S2:35:7	excerpt	NN	O	O
:	ZYTIGA.xml:S2:42:1	:	:	O	O
Mineralocorticoid	ZYTIGA.xml:S2:50:17	mineralocorticoid	JJ	B-AdverseReaction	B-AdverseReaction
excess	ZYTIGA.xml:S2:68:6	excess	NN	I-AdverseReaction	I-AdverseReaction
:	ZYTIGA.xml:S2:74:1	:	:	O	O
Use	ZYTIGA.xml:S2:76:3	use	NNP	O	O
ZYTIGA	ZYTIGA.xml:S2:80:6	zytiga	NNP	O	O
with	ZYTIGA.xml:S2:87:4	with	IN	O	O
caution	ZYTIGA.xml:S2:92:7	caution	NN	O	O
in	ZYTIGA.xml:S2:100:2	in	IN	O	O
patients	ZYTIGA.xml:S2:103:8	patient	NNS	O	O
with	ZYTIGA.xml:S2:112:4	with	IN	O	O
a	ZYTIGA.xml:S2:117:1	a	DT	O	O
history	ZYTIGA.xml:S2:119:7	histori	NN	O	O
of	ZYTIGA.xml:S2:127:2	of	IN	O	O
cardiovascular	ZYTIGA.xml:S2:130:14	cardiovascular	JJ	O	O
disease	ZYTIGA.xml:S2:145:7	diseas	NN	O	O
.	ZYTIGA.xml:S2:152:1	.	.	O	O

The	ZYTIGA.xml:S2:154:3	the	DT	O	O
safety	ZYTIGA.xml:S2:158:6	safeti	NN	O	O
of	ZYTIGA.xml:S2:165:2	of	IN	O	O
ZYTIGA	ZYTIGA.xml:S2:168:6	zytiga	NNP	O	O
in	ZYTIGA.xml:S2:175:2	in	IN	O	O
patients	ZYTIGA.xml:S2:178:8	patient	NNS	O	O
with	ZYTIGA.xml:S2:187:4	with	IN	O	O
LVEF	ZYTIGA.xml:S2:192:4	lvef	NNP	O	O
50%	ZYTIGA.xml:S2:199:3	50%	CD	O	O
or	ZYTIGA.xml:S2:203:2	or	CC	O	O
NYHA	ZYTIGA.xml:S2:206:4	nyha	NNP	O	O
Class	ZYTIGA.xml:S2:211:5	class	NNP	O	O
III	ZYTIGA.xml:S2:217:3	iii	NNP	O	O
or	ZYTIGA.xml:S2:221:2	or	CC	O	O
IV	ZYTIGA.xml:S2:224:2	IV	NNP	O	O
heart	ZYTIGA.xml:S2:227:5	heart	NN	O	O
failure	ZYTIGA.xml:S2:233:7	failur	NN	O	O
in	ZYTIGA.xml:S2:241:2	in	IN	O	O
Study	ZYTIGA.xml:S2:244:5	studi	NNP	O	O
1	ZYTIGA.xml:S2:250:1	1	CD	O	O
or	ZYTIGA.xml:S2:252:2	or	CC	O	O
LVEF	ZYTIGA.xml:S2:255:4	lvef	NNP	O	O
50%	ZYTIGA.xml:S2:262:3	50%	CD	O	O
or	ZYTIGA.xml:S2:266:2	or	CC	O	O
NYHA	ZYTIGA.xml:S2:269:4	nyha	NNP	O	O
Class	ZYTIGA.xml:S2:274:5	class	NNP	O	O
II	ZYTIGA.xml:S2:280:2	II	NNP	O	O
to	ZYTIGA.xml:S2:283:2	to	TO	O	O
IV	ZYTIGA.xml:S2:286:2	IV	NNP	O	O
heart	ZYTIGA.xml:S2:289:5	heart	NN	O	O
failure	ZYTIGA.xml:S2:295:7	failur	NN	O	O
in	ZYTIGA.xml:S2:303:2	in	IN	O	O
Study	ZYTIGA.xml:S2:306:5	studi	NNP	O	O
2	ZYTIGA.xml:S2:312:1	2	CD	O	O
was	ZYTIGA.xml:S2:314:3	wa	VBD	O	O
not	ZYTIGA.xml:S2:318:3	not	RB	O	O
established	ZYTIGA.xml:S2:322:11	establish	VBN	O	O
.	ZYTIGA.xml:S2:333:1	.	.	O	O

Control	ZYTIGA.xml:S2:335:7	control	NNP	O	O
hypertension	ZYTIGA.xml:S2:343:12	hypertens	NN	O	O
and	ZYTIGA.xml:S2:356:3	and	CC	O	O
correct	ZYTIGA.xml:S2:360:7	correct	JJ	O	O
hypokalemia	ZYTIGA.xml:S2:368:11	hypokalemia	NN	O	O
before	ZYTIGA.xml:S2:380:6	befor	IN	O	O
treatment	ZYTIGA.xml:S2:387:9	treatment	NN	O	O
.	ZYTIGA.xml:S2:396:1	.	.	O	O

Monitor	ZYTIGA.xml:S2:398:7	monitor	NNP	O	O
blood	ZYTIGA.xml:S2:406:5	blood	NN	O	O
pressure	ZYTIGA.xml:S2:412:8	pressur	NN	O	O
,	ZYTIGA.xml:S2:420:1	,	,	O	O
serum	ZYTIGA.xml:S2:422:5	serum	JJ	O	O
potassium	ZYTIGA.xml:S2:428:9	potassium	NN	O	O
and	ZYTIGA.xml:S2:438:3	and	CC	O	O
symptoms	ZYTIGA.xml:S2:442:8	symptom	NNS	O	O
of	ZYTIGA.xml:S2:451:2	of	IN	O	O
fluid	ZYTIGA.xml:S2:454:5	fluid	JJ	O	O
retention	ZYTIGA.xml:S2:460:9	retent	NN	O	O
at	ZYTIGA.xml:S2:470:2	at	IN	O	O
least	ZYTIGA.xml:S2:473:5	least	JJS	O	O
monthly	ZYTIGA.xml:S2:479:7	monthli	JJ	O	O
.	ZYTIGA.xml:S2:486:1	.	.	O	O

(	ZYTIGA.xml:S2:488:1	(	(	O	O
5.1	ZYTIGA.xml:S2:489:3	5.1	CD	O	O
)	ZYTIGA.xml:S2:492:1	)	)	O	O

Adrenocortical	ZYTIGA.xml:S2:499:14	adrenocort	JJ	B-AdverseReaction	B-AdverseReaction
insufficiency	ZYTIGA.xml:S2:514:13	insuffici	NN	I-AdverseReaction	I-AdverseReaction
:	ZYTIGA.xml:S2:527:1	:	:	O	O
Monitor	ZYTIGA.xml:S2:529:7	monitor	NN	O	O
for	ZYTIGA.xml:S2:537:3	for	IN	O	O
symptoms	ZYTIGA.xml:S2:541:8	symptom	NNS	O	O
and	ZYTIGA.xml:S2:550:3	and	CC	O	O
signs	ZYTIGA.xml:S2:554:5	sign	NNS	O	O
of	ZYTIGA.xml:S2:560:2	of	IN	O	O
adrenocortical	ZYTIGA.xml:S2:563:14	adrenocort	JJ	O	O
insufficiency	ZYTIGA.xml:S2:578:13	insuffici	NN	O	O
.	ZYTIGA.xml:S2:591:1	.	.	O	O

Increased	ZYTIGA.xml:S2:593:9	increas	VBN	O	O
dosage	ZYTIGA.xml:S2:603:6	dosag	NN	O	O
of	ZYTIGA.xml:S2:610:2	of	IN	O	O
corticosteroids	ZYTIGA.xml:S2:613:15	corticosteroid	NNS	O	O
may	ZYTIGA.xml:S2:629:3	may	MD	O	O
be	ZYTIGA.xml:S2:633:2	be	VB	O	O
indicated	ZYTIGA.xml:S2:636:9	indic	VBN	O	O
before	ZYTIGA.xml:S2:646:6	befor	IN	O	O
,	ZYTIGA.xml:S2:652:1	,	,	O	O
during	ZYTIGA.xml:S2:654:6	dure	IN	O	O
and	ZYTIGA.xml:S2:661:3	and	CC	O	O
after	ZYTIGA.xml:S2:665:5	after	IN	O	O
stressful	ZYTIGA.xml:S2:671:9	stress	JJ	O	O
situations	ZYTIGA.xml:S2:681:10	situat	NNS	O	O
.	ZYTIGA.xml:S2:691:1	.	.	O	O

(	ZYTIGA.xml:S2:693:1	(	(	O	O
5.2	ZYTIGA.xml:S2:694:3	5.2	CD	O	O
)	ZYTIGA.xml:S2:697:1	)	)	O	O

Hepatotoxicity	ZYTIGA.xml:S2:704:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
:	ZYTIGA.xml:S2:718:1	:	:	O	O
Increases	ZYTIGA.xml:S2:720:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	ZYTIGA.xml:S2:730:2	in	IN	I-AdverseReaction	I-AdverseReaction
liver	ZYTIGA.xml:S2:733:5	liver	NN	I-AdverseReaction	I-AdverseReaction
enzymes	ZYTIGA.xml:S2:739:7	enzym	NNS	I-AdverseReaction	I-AdverseReaction
have	ZYTIGA.xml:S2:747:4	have	VBP	O	O
led	ZYTIGA.xml:S2:752:3	led	VBN	O	O
to	ZYTIGA.xml:S2:756:2	to	TO	O	O
drug	ZYTIGA.xml:S2:759:4	drug	NN	O	O
interruption	ZYTIGA.xml:S2:764:12	interrupt	NN	O	O
,	ZYTIGA.xml:S2:776:1	,	,	O	O
dose	ZYTIGA.xml:S2:778:4	dose	JJ	O	O
modification	ZYTIGA.xml:S2:783:12	modif	NN	O	O
and	ZYTIGA.xml:S2:796:3	and	CC	O	O
or	ZYTIGA.xml:S2:800:2	or	CC	O	O
discontinuation	ZYTIGA.xml:S2:803:15	discontinu	NN	O	O
.	ZYTIGA.xml:S2:818:1	.	.	O	O

Monitor	ZYTIGA.xml:S2:820:7	monitor	NNP	O	O
liver	ZYTIGA.xml:S2:828:5	liver	CC	O	O
function	ZYTIGA.xml:S2:834:8	function	NN	O	O
and	ZYTIGA.xml:S2:843:3	and	CC	O	O
modify	ZYTIGA.xml:S2:847:6	modifi	NN	O	O
,	ZYTIGA.xml:S2:853:1	,	,	O	O
interrupt	ZYTIGA.xml:S2:855:9	interrupt	NN	O	O
,	ZYTIGA.xml:S2:864:1	,	,	O	O
or	ZYTIGA.xml:S2:866:2	or	CC	O	O
discontinue	ZYTIGA.xml:S2:869:11	discontinu	VB	O	O
ZYTIGA	ZYTIGA.xml:S2:881:6	zytiga	NNP	O	O
dosing	ZYTIGA.xml:S2:888:6	dose	VBG	O	O
as	ZYTIGA.xml:S2:895:2	as	RB	O	O
recommended	ZYTIGA.xml:S2:898:11	recommend	VBN	O	O
.	ZYTIGA.xml:S2:909:1	.	.	O	O

(	ZYTIGA.xml:S2:911:1	(	(	O	O
5.3	ZYTIGA.xml:S2:912:3	5.3	CD	O	O
)	ZYTIGA.xml:S2:915:1	)	)	O	O

5.1	ZYTIGA.xml:S2:926:3	5.1	CD	O	O

Hypertension	ZYTIGA.xml:S2:930:12	hypertens	NN	O	B-AdverseReaction
,	ZYTIGA.xml:S2:942:1	,	,	O	O
Hypokalemia	ZYTIGA.xml:S2:944:11	hypokalemia	NNP	O	B-AdverseReaction
and	ZYTIGA.xml:S2:956:3	and	CC	O	O
Fluid	ZYTIGA.xml:S2:960:5	fluid	NNP	O	B-AdverseReaction
Retention	ZYTIGA.xml:S2:966:9	retent	NNP	O	I-AdverseReaction
Due	ZYTIGA.xml:S2:976:3	due	NNP	O	O
to	ZYTIGA.xml:S2:980:2	to	TO	O	O
Mineralocorticoid	ZYTIGA.xml:S2:983:17	mineralocorticoid	NNP	O	O
Excess	ZYTIGA.xml:S2:1001:6	excess	NNP	O	O

ZYTIGA	ZYTIGA.xml:S2:1011:6	zytiga	NNP	O	O
may	ZYTIGA.xml:S2:1018:3	may	MD	O	O
cause	ZYTIGA.xml:S2:1022:5	caus	VB	O	O
hypertension	ZYTIGA.xml:S2:1028:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S2:1040:1	,	,	O	O
hypokalemia	ZYTIGA.xml:S2:1042:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
,	ZYTIGA.xml:S2:1053:1	,	,	O	O
and	ZYTIGA.xml:S2:1055:3	and	CC	O	O
fluid	ZYTIGA.xml:S2:1059:5	fluid	JJ	B-AdverseReaction	B-AdverseReaction
retention	ZYTIGA.xml:S2:1065:9	retent	NN	I-AdverseReaction	I-AdverseReaction
as	ZYTIGA.xml:S2:1075:2	as	IN	O	O
a	ZYTIGA.xml:S2:1078:1	a	DT	O	O
consequence	ZYTIGA.xml:S2:1080:11	consequ	NN	O	O
of	ZYTIGA.xml:S2:1092:2	of	IN	O	O
increased	ZYTIGA.xml:S2:1095:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
mineralocorticoid	ZYTIGA.xml:S2:1105:17	mineralocorticoid	NN	I-AdverseReaction	I-AdverseReaction
levels	ZYTIGA.xml:S2:1123:6	level	NNS	I-AdverseReaction	I-AdverseReaction
resulting	ZYTIGA.xml:S2:1130:9	result	VBG	O	O
from	ZYTIGA.xml:S2:1140:4	from	IN	O	O
CYP17	ZYTIGA.xml:S2:1145:5	cyp17	NNP	O	O
inhibition	ZYTIGA.xml:S2:1151:10	inhibit	NN	O	O
[	ZYTIGA.xml:S2:1163:1	[	NNP	O	O
seeClinical	ZYTIGA.xml:S2:1164:11	seeclin	JJ	O	O
Pharmacology	ZYTIGA.xml:S2:1176:12	pharmacolog	NNP	O	O
(	ZYTIGA.xml:S2:1189:1	(	(	O	O
12.1	ZYTIGA.xml:S2:1190:4	12.1	CD	O	O
)]	ZYTIGA.xml:S2:1194:2	)]	NN	O	O
.	ZYTIGA.xml:S2:1198:1	.	.	O	O

In	ZYTIGA.xml:S2:1200:2	In	IN	O	O
the	ZYTIGA.xml:S2:1203:3	the	DT	O	O
two	ZYTIGA.xml:S2:1207:3	two	CD	O	O
randomized	ZYTIGA.xml:S2:1211:10	random	VBD	O	O
clinical	ZYTIGA.xml:S2:1222:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S2:1231:6	trial	NNS	O	O
,	ZYTIGA.xml:S2:1237:1	,	,	O	O
grade	ZYTIGA.xml:S2:1239:5	grade	VBD	O	O
3	ZYTIGA.xml:S2:1245:1	3	CD	O	O
to	ZYTIGA.xml:S2:1247:2	to	TO	O	O
4	ZYTIGA.xml:S2:1250:1	4	CD	O	O
hypertension	ZYTIGA.xml:S2:1252:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
occurred	ZYTIGA.xml:S2:1265:8	occur	VBD	O	O
in	ZYTIGA.xml:S2:1274:2	in	IN	O	O
2%	ZYTIGA.xml:S2:1277:2	2%	CD	O	O
of	ZYTIGA.xml:S2:1280:2	of	IN	O	O
patients	ZYTIGA.xml:S2:1283:8	patient	NNS	O	O
,	ZYTIGA.xml:S2:1291:1	,	,	O	O
grade	ZYTIGA.xml:S2:1293:5	grade	VBD	O	O
3	ZYTIGA.xml:S2:1299:1	3	CD	O	O
to	ZYTIGA.xml:S2:1301:2	to	TO	O	O
4	ZYTIGA.xml:S2:1304:1	4	CD	O	O
hypokalemia	ZYTIGA.xml:S2:1306:11	hypokalemia	NN	B-AdverseReaction	O
in	ZYTIGA.xml:S2:1318:2	in	IN	O	O
4%	ZYTIGA.xml:S2:1321:2	4%	CD	O	O
of	ZYTIGA.xml:S2:1324:2	of	IN	O	O
patients	ZYTIGA.xml:S2:1327:8	patient	NNS	O	O
,	ZYTIGA.xml:S2:1335:1	,	,	O	O
and	ZYTIGA.xml:S2:1337:3	and	CC	O	O
grade	ZYTIGA.xml:S2:1341:5	grade	VBD	O	O
3	ZYTIGA.xml:S2:1347:1	3	CD	O	O
to	ZYTIGA.xml:S2:1349:2	to	TO	O	O
4	ZYTIGA.xml:S2:1352:1	4	CD	O	O
edema	ZYTIGA.xml:S2:1354:5	edema	NN	B-AdverseReaction	O
in	ZYTIGA.xml:S2:1360:2	in	IN	O	O
1%	ZYTIGA.xml:S2:1363:2	1%	CD	O	O
of	ZYTIGA.xml:S2:1366:2	of	IN	O	O
patients	ZYTIGA.xml:S2:1369:8	patient	NNS	O	O
treated	ZYTIGA.xml:S2:1378:7	treat	VBN	O	O
with	ZYTIGA.xml:S2:1386:4	with	IN	O	O
ZYTIGA	ZYTIGA.xml:S2:1391:6	zytiga	NNP	O	O
[	ZYTIGA.xml:S2:1399:1	[	NNP	O	O
seeAdverse	ZYTIGA.xml:S2:1400:10	seeadvers	NN	O	O
Reactions	ZYTIGA.xml:S2:1411:9	reaction	NNP	O	O
(	ZYTIGA.xml:S2:1421:1	(	(	O	O
6	ZYTIGA.xml:S2:1422:1	6	CD	O	O
)]	ZYTIGA.xml:S2:1423:2	)]	NN	O	O
.	ZYTIGA.xml:S2:1427:1	.	.	O	O

Co	ZYTIGA.xml:S2:1433:2	Co	NNP	O	O
-	ZYTIGA.xml:S2:1435:1	-	:	O	O
administration	ZYTIGA.xml:S2:1436:14	administr	NN	O	O
of	ZYTIGA.xml:S2:1451:2	of	IN	O	O
a	ZYTIGA.xml:S2:1454:1	a	DT	O	O
corticosteroid	ZYTIGA.xml:S2:1456:14	corticosteroid	JJ	O	O
suppresses	ZYTIGA.xml:S2:1471:10	suppress	NNS	O	O
adrenocorticotropic	ZYTIGA.xml:S2:1482:19	adrenocorticotrop	VBP	O	O
hormone	ZYTIGA.xml:S2:1502:7	hormon	NN	O	O
(	ZYTIGA.xml:S2:1510:1	(	(	O	O
ACTH	ZYTIGA.xml:S2:1511:4	acth	NNP	O	O
)	ZYTIGA.xml:S2:1515:1	)	)	O	O
drive	ZYTIGA.xml:S2:1517:5	drive	NN	O	O
,	ZYTIGA.xml:S2:1522:1	,	,	O	O
resulting	ZYTIGA.xml:S2:1524:9	result	VBG	O	O
in	ZYTIGA.xml:S2:1534:2	in	IN	O	O
a	ZYTIGA.xml:S2:1537:1	a	DT	O	O
reduction	ZYTIGA.xml:S2:1539:9	reduct	NN	O	O
in	ZYTIGA.xml:S2:1549:2	in	IN	O	O
the	ZYTIGA.xml:S2:1552:3	the	DT	O	O
incidence	ZYTIGA.xml:S2:1556:9	incid	NN	O	O
and	ZYTIGA.xml:S2:1566:3	and	CC	O	O
severity	ZYTIGA.xml:S2:1570:8	sever	NN	O	O
of	ZYTIGA.xml:S2:1579:2	of	IN	O	O
these	ZYTIGA.xml:S2:1582:5	these	DT	O	O
adverse	ZYTIGA.xml:S2:1588:7	advers	JJ	O	O
reactions	ZYTIGA.xml:S2:1596:9	reaction	NNS	O	O
.	ZYTIGA.xml:S2:1605:1	.	.	O	O

Use	ZYTIGA.xml:S2:1607:3	use	NNP	O	O
caution	ZYTIGA.xml:S2:1611:7	caution	NN	O	O
when	ZYTIGA.xml:S2:1619:4	when	WRB	O	O
treating	ZYTIGA.xml:S2:1624:8	treat	VBG	O	O
patients	ZYTIGA.xml:S2:1633:8	patient	NNS	O	O
whose	ZYTIGA.xml:S2:1642:5	whose	WP$	O	O
underlying	ZYTIGA.xml:S2:1648:10	underli	JJ	O	O
medical	ZYTIGA.xml:S2:1659:7	medic	JJ	O	O
conditions	ZYTIGA.xml:S2:1667:10	condit	NNS	O	O
might	ZYTIGA.xml:S2:1678:5	might	MD	O	O
be	ZYTIGA.xml:S2:1684:2	be	VB	O	O
compromised	ZYTIGA.xml:S2:1687:11	compromis	VBN	O	O
by	ZYTIGA.xml:S2:1699:2	by	IN	O	O
increases	ZYTIGA.xml:S2:1702:9	increas	NNS	O	B-AdverseReaction
in	ZYTIGA.xml:S2:1712:2	in	IN	O	I-AdverseReaction
blood	ZYTIGA.xml:S2:1715:5	blood	NN	O	I-AdverseReaction
pressure	ZYTIGA.xml:S2:1721:8	pressur	NN	O	I-AdverseReaction
,	ZYTIGA.xml:S2:1729:1	,	,	O	O
hypokalemia	ZYTIGA.xml:S2:1731:11	hypokalemia	NN	O	B-AdverseReaction
or	ZYTIGA.xml:S2:1743:2	or	CC	O	O
fluid	ZYTIGA.xml:S2:1746:5	fluid	NN	O	B-AdverseReaction
retention	ZYTIGA.xml:S2:1752:9	retent	NN	O	I-AdverseReaction
,	ZYTIGA.xml:S2:1761:1	,	,	O	O
e	ZYTIGA.xml:S2:1763:1	e	NN	O	O
.	ZYTIGA.xml:S2:1764:1	.	.	O	O
g	ZYTIGA.xml:S2:1765:1	g	NN	O	O
.	ZYTIGA.xml:S2:1766:1	.	.	O	O
,	ZYTIGA.xml:S2:1767:1	,	,	O	O
those	ZYTIGA.xml:S2:1769:5	those	DT	O	O
with	ZYTIGA.xml:S2:1775:4	with	IN	O	O
heart	ZYTIGA.xml:S2:1780:5	heart	NN	O	O
failure	ZYTIGA.xml:S2:1786:7	failur	NN	O	O
,	ZYTIGA.xml:S2:1793:1	,	,	O	O
recent	ZYTIGA.xml:S2:1795:6	recent	JJ	O	O
myocardial	ZYTIGA.xml:S2:1802:10	myocardi	JJ	O	O
infarction	ZYTIGA.xml:S2:1813:10	infarct	NN	O	O
or	ZYTIGA.xml:S2:1824:2	or	CC	O	O
ventricular	ZYTIGA.xml:S2:1827:11	ventricular	JJ	O	O
arrhythmia	ZYTIGA.xml:S2:1839:10	arrhythmia	NN	O	O
.	ZYTIGA.xml:S2:1849:1	.	.	O	O

Use	ZYTIGA.xml:S2:1851:3	use	NNP	O	O
ZYTIGA	ZYTIGA.xml:S2:1855:6	zytiga	NNP	O	O
with	ZYTIGA.xml:S2:1862:4	with	IN	O	O
caution	ZYTIGA.xml:S2:1867:7	caution	NN	O	O
in	ZYTIGA.xml:S2:1875:2	in	IN	O	O
patients	ZYTIGA.xml:S2:1878:8	patient	NNS	O	O
with	ZYTIGA.xml:S2:1887:4	with	IN	O	O
a	ZYTIGA.xml:S2:1892:1	a	DT	O	O
history	ZYTIGA.xml:S2:1894:7	histori	NN	O	O
of	ZYTIGA.xml:S2:1902:2	of	IN	O	O
cardiovascular	ZYTIGA.xml:S2:1905:14	cardiovascular	JJ	O	O
disease	ZYTIGA.xml:S2:1920:7	diseas	NN	O	O
.	ZYTIGA.xml:S2:1927:1	.	.	O	O

The	ZYTIGA.xml:S2:1929:3	the	DT	O	O
safety	ZYTIGA.xml:S2:1933:6	safeti	NN	O	O
of	ZYTIGA.xml:S2:1940:2	of	IN	O	O
ZYTIGA	ZYTIGA.xml:S2:1943:6	zytiga	NNP	O	O
in	ZYTIGA.xml:S2:1950:2	in	IN	O	O
patients	ZYTIGA.xml:S2:1953:8	patient	NNS	O	O
with	ZYTIGA.xml:S2:1962:4	with	IN	O	O
left	ZYTIGA.xml:S2:1967:4	left	JJ	O	O
ventricular	ZYTIGA.xml:S2:1972:11	ventricular	JJ	O	O
ejection	ZYTIGA.xml:S2:1984:8	eject	NN	O	O
fraction	ZYTIGA.xml:S2:1993:8	fraction	NN	O	O
50%	ZYTIGA.xml:S2:2003:3	50%	CD	O	O
or	ZYTIGA.xml:S2:2007:2	or	CC	O	O
New	ZYTIGA.xml:S2:2010:3	new	NNP	O	O
York	ZYTIGA.xml:S2:2014:4	york	NNP	O	O
Heart	ZYTIGA.xml:S2:2019:5	heart	NNP	O	O
Association	ZYTIGA.xml:S2:2025:11	associ	NNP	O	O
(	ZYTIGA.xml:S2:2037:1	(	(	O	O
NYHA	ZYTIGA.xml:S2:2038:4	nyha	NNP	O	O
)	ZYTIGA.xml:S2:2042:1	)	)	O	O
Class	ZYTIGA.xml:S2:2044:5	class	NNP	O	O
III	ZYTIGA.xml:S2:2050:3	iii	NNP	O	O
or	ZYTIGA.xml:S2:2054:2	or	CC	O	O
IV	ZYTIGA.xml:S2:2057:2	IV	NNP	O	O
heart	ZYTIGA.xml:S2:2060:5	heart	NN	O	O
failure	ZYTIGA.xml:S2:2066:7	failur	NN	O	O
(	ZYTIGA.xml:S2:2074:1	(	(	O	O
in	ZYTIGA.xml:S2:2075:2	in	IN	O	O
Study	ZYTIGA.xml:S2:2078:5	studi	NNP	O	O
1	ZYTIGA.xml:S2:2084:1	1	CD	O	O
)	ZYTIGA.xml:S2:2085:1	)	)	O	O
or	ZYTIGA.xml:S2:2087:2	or	CC	O	O
NYHA	ZYTIGA.xml:S2:2090:4	nyha	NNP	O	O
Class	ZYTIGA.xml:S2:2095:5	class	NNP	O	O
II	ZYTIGA.xml:S2:2101:2	II	NNP	O	O
to	ZYTIGA.xml:S2:2104:2	to	TO	O	O
IV	ZYTIGA.xml:S2:2107:2	IV	NNP	O	B-AdverseReaction
heart	ZYTIGA.xml:S2:2110:5	heart	NN	O	I-AdverseReaction
failure	ZYTIGA.xml:S2:2116:7	failur	NN	O	I-AdverseReaction
(	ZYTIGA.xml:S2:2124:1	(	(	O	O
in	ZYTIGA.xml:S2:2125:2	in	IN	O	O
Study	ZYTIGA.xml:S2:2128:5	studi	NNP	O	O
2	ZYTIGA.xml:S2:2134:1	2	CD	O	O
)	ZYTIGA.xml:S2:2135:1	)	)	O	O
was	ZYTIGA.xml:S2:2137:3	wa	VBD	O	O
not	ZYTIGA.xml:S2:2141:3	not	RB	O	O
established	ZYTIGA.xml:S2:2145:11	establish	VBN	O	O
because	ZYTIGA.xml:S2:2157:7	becaus	IN	O	O
these	ZYTIGA.xml:S2:2165:5	these	DT	O	O
patients	ZYTIGA.xml:S2:2171:8	patient	NNS	O	O
were	ZYTIGA.xml:S2:2180:4	were	VBD	O	O
excluded	ZYTIGA.xml:S2:2185:8	exclud	VBN	O	O
from	ZYTIGA.xml:S2:2194:4	from	IN	O	O
these	ZYTIGA.xml:S2:2199:5	these	DT	O	O
randomized	ZYTIGA.xml:S2:2205:10	random	VBN	O	O
clinical	ZYTIGA.xml:S2:2216:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S2:2225:6	trial	NNS	O	O
[	ZYTIGA.xml:S2:2233:1	[	VBP	O	O
seeClinical	ZYTIGA.xml:S2:2234:11	seeclin	JJ	O	O
Studies	ZYTIGA.xml:S2:2246:7	studi	NNP	O	O
(	ZYTIGA.xml:S2:2254:1	(	(	O	O
14	ZYTIGA.xml:S2:2255:2	14	CD	O	O
)]	ZYTIGA.xml:S2:2257:2	)]	NN	O	O
.	ZYTIGA.xml:S2:2261:1	.	.	O	O

Monitor	ZYTIGA.xml:S2:2263:7	monitor	NN	O	O
patients	ZYTIGA.xml:S2:2271:8	patient	NNS	O	O
for	ZYTIGA.xml:S2:2280:3	for	IN	O	O
hypertension	ZYTIGA.xml:S2:2284:12	hypertens	NN	O	O
,	ZYTIGA.xml:S2:2296:1	,	,	O	O
hypokalemia	ZYTIGA.xml:S2:2298:11	hypokalemia	NN	O	B-AdverseReaction
,	ZYTIGA.xml:S2:2309:1	,	,	O	O
and	ZYTIGA.xml:S2:2311:3	and	CC	O	O
fluid	ZYTIGA.xml:S2:2315:5	fluid	JJ	O	B-AdverseReaction
retention	ZYTIGA.xml:S2:2321:9	retent	NN	O	I-AdverseReaction
at	ZYTIGA.xml:S2:2331:2	at	IN	O	O
least	ZYTIGA.xml:S2:2334:5	least	JJS	O	O
once	ZYTIGA.xml:S2:2340:4	onc	RB	O	O
a	ZYTIGA.xml:S2:2345:1	a	DT	O	O
month	ZYTIGA.xml:S2:2347:5	month	NN	O	O
.	ZYTIGA.xml:S2:2352:1	.	.	O	O

Control	ZYTIGA.xml:S2:2354:7	control	NNP	O	O
hypertension	ZYTIGA.xml:S2:2362:12	hypertens	NN	O	O
and	ZYTIGA.xml:S2:2375:3	and	CC	O	O
correct	ZYTIGA.xml:S2:2379:7	correct	JJ	O	O
hypokalemia	ZYTIGA.xml:S2:2387:11	hypokalemia	NN	O	O
before	ZYTIGA.xml:S2:2399:6	befor	IN	O	O
and	ZYTIGA.xml:S2:2406:3	and	CC	O	O
during	ZYTIGA.xml:S2:2410:6	dure	IN	O	O
treatment	ZYTIGA.xml:S2:2417:9	treatment	NN	O	O
with	ZYTIGA.xml:S2:2427:4	with	IN	O	O
ZYTIGA	ZYTIGA.xml:S2:2432:6	zytiga	NNP	O	O
.	ZYTIGA.xml:S2:2438:1	.	.	O	O

5.2	ZYTIGA.xml:S2:2446:3	5.2	CD	O	O
Adrenocortical	ZYTIGA.xml:S2:2450:14	adrenocort	JJ	O	O
Insufficiency	ZYTIGA.xml:S2:2465:13	insuffici	NN	O	O

Adrenal	ZYTIGA.xml:S2:2482:7	adren	JJ	B-AdverseReaction	O
insufficiency	ZYTIGA.xml:S2:2490:13	insuffici	NN	I-AdverseReaction	O
occurred	ZYTIGA.xml:S2:2504:8	occur	VBD	O	O
in	ZYTIGA.xml:S2:2513:2	in	IN	O	O
the	ZYTIGA.xml:S2:2516:3	the	DT	O	O
two	ZYTIGA.xml:S2:2520:3	two	CD	O	O
randomized	ZYTIGA.xml:S2:2524:10	random	VBD	O	O
clinical	ZYTIGA.xml:S2:2535:8	clinic	JJ	O	O
studies	ZYTIGA.xml:S2:2544:7	studi	NNS	O	O
in	ZYTIGA.xml:S2:2552:2	in	IN	O	O
0.5%	ZYTIGA.xml:S2:2555:4	0.5%	CD	O	O
of	ZYTIGA.xml:S2:2560:2	of	IN	O	O
patients	ZYTIGA.xml:S2:2563:8	patient	NNS	O	O
taking	ZYTIGA.xml:S2:2572:6	take	VBG	O	O
ZYTIGA	ZYTIGA.xml:S2:2579:6	zytiga	NNP	O	O
and	ZYTIGA.xml:S2:2586:3	and	CC	O	O
in	ZYTIGA.xml:S2:2590:2	in	IN	O	O
0.2%	ZYTIGA.xml:S2:2593:4	0.2%	CD	O	O
of	ZYTIGA.xml:S2:2598:2	of	IN	O	O
patients	ZYTIGA.xml:S2:2601:8	patient	NNS	O	O
taking	ZYTIGA.xml:S2:2610:6	take	VBG	O	O
placebo	ZYTIGA.xml:S2:2617:7	placebo	NN	O	O
.	ZYTIGA.xml:S2:2624:1	.	.	O	O

Adrenocortical	ZYTIGA.xml:S2:2626:14	adrenocort	JJ	B-AdverseReaction	B-AdverseReaction
insufficiency	ZYTIGA.xml:S2:2641:13	insuffici	NN	I-AdverseReaction	I-AdverseReaction
was	ZYTIGA.xml:S2:2655:3	wa	VBD	O	O
reported	ZYTIGA.xml:S2:2659:8	report	VBN	O	O
in	ZYTIGA.xml:S2:2668:2	in	IN	O	O
patients	ZYTIGA.xml:S2:2671:8	patient	NNS	O	O
receiving	ZYTIGA.xml:S2:2680:9	receiv	VBG	O	O
ZYTIGA	ZYTIGA.xml:S2:2690:6	zytiga	NNP	O	O
in	ZYTIGA.xml:S2:2697:2	in	IN	O	O
combination	ZYTIGA.xml:S2:2700:11	combin	NN	O	O
with	ZYTIGA.xml:S2:2712:4	with	IN	O	O
prednisone	ZYTIGA.xml:S2:2717:10	prednison	NN	O	O
,	ZYTIGA.xml:S2:2727:1	,	,	O	O
following	ZYTIGA.xml:S2:2729:9	follow	VBG	O	O
interruption	ZYTIGA.xml:S2:2739:12	interrupt	NN	O	O
of	ZYTIGA.xml:S2:2752:2	of	IN	O	O
daily	ZYTIGA.xml:S2:2755:5	daili	JJ	O	O
steroids	ZYTIGA.xml:S2:2761:8	steroid	NNS	O	O
and	ZYTIGA.xml:S2:2770:3	and	CC	O	O
or	ZYTIGA.xml:S2:2774:2	or	CC	O	O
with	ZYTIGA.xml:S2:2777:4	with	IN	O	O
concurrent	ZYTIGA.xml:S2:2782:10	concurr	JJ	O	O
infection	ZYTIGA.xml:S2:2793:9	infect	NN	O	O
or	ZYTIGA.xml:S2:2803:2	or	CC	O	O
stress	ZYTIGA.xml:S2:2806:6	stress	NN	O	O
.	ZYTIGA.xml:S2:2812:1	.	.	O	O

Use	ZYTIGA.xml:S2:2814:3	use	NNP	O	O
caution	ZYTIGA.xml:S2:2818:7	caution	NN	O	O
and	ZYTIGA.xml:S2:2826:3	and	CC	O	O
monitor	ZYTIGA.xml:S2:2830:7	monitor	NN	O	O
for	ZYTIGA.xml:S2:2838:3	for	IN	O	O
symptoms	ZYTIGA.xml:S2:2842:8	symptom	NNS	O	O
and	ZYTIGA.xml:S2:2851:3	and	CC	O	O
signs	ZYTIGA.xml:S2:2855:5	sign	NNS	O	O
of	ZYTIGA.xml:S2:2861:2	of	IN	O	O
adrenocortical	ZYTIGA.xml:S2:2864:14	adrenocort	JJ	O	O
insufficiency	ZYTIGA.xml:S2:2879:13	insuffici	NN	O	O
,	ZYTIGA.xml:S2:2892:1	,	,	O	O
particularly	ZYTIGA.xml:S2:2894:12	particularli	RB	O	O
if	ZYTIGA.xml:S2:2907:2	if	IN	O	O
patients	ZYTIGA.xml:S2:2910:8	patient	NNS	O	O
are	ZYTIGA.xml:S2:2919:3	are	VBP	O	O
withdrawn	ZYTIGA.xml:S2:2923:9	withdrawn	VBN	O	O
from	ZYTIGA.xml:S2:2933:4	from	IN	O	O
prednisone	ZYTIGA.xml:S2:2938:10	prednison	NN	O	O
,	ZYTIGA.xml:S2:2948:1	,	,	O	O
have	ZYTIGA.xml:S2:2950:4	have	VBP	O	O
prednisone	ZYTIGA.xml:S2:2955:10	prednison	VBN	O	O
dose	ZYTIGA.xml:S2:2966:4	dose	JJ	O	O
reductions	ZYTIGA.xml:S2:2971:10	reduct	NNS	O	O
,	ZYTIGA.xml:S2:2981:1	,	,	O	O
or	ZYTIGA.xml:S2:2983:2	or	CC	O	O
experience	ZYTIGA.xml:S2:2986:10	experi	VB	O	O
unusual	ZYTIGA.xml:S2:2997:7	unusu	JJ	O	O
stress	ZYTIGA.xml:S2:3005:6	stress	NN	O	O
.	ZYTIGA.xml:S2:3011:1	.	.	O	O

Symptoms	ZYTIGA.xml:S2:3013:8	symptom	NNS	O	O
and	ZYTIGA.xml:S2:3022:3	and	CC	O	O
signs	ZYTIGA.xml:S2:3026:5	sign	NNS	O	O
of	ZYTIGA.xml:S2:3032:2	of	IN	O	O
adrenocortical	ZYTIGA.xml:S2:3035:14	adrenocort	JJ	B-AdverseReaction	O
insufficiency	ZYTIGA.xml:S2:3050:13	insuffici	NN	I-AdverseReaction	O
may	ZYTIGA.xml:S2:3064:3	may	MD	O	O
be	ZYTIGA.xml:S2:3068:2	be	VB	O	O
masked	ZYTIGA.xml:S2:3071:6	mask	VBN	O	O
by	ZYTIGA.xml:S2:3078:2	by	IN	O	O
adverse	ZYTIGA.xml:S2:3081:7	advers	JJ	O	O
reactions	ZYTIGA.xml:S2:3089:9	reaction	NNS	O	O
associated	ZYTIGA.xml:S2:3099:10	associ	VBN	O	O
with	ZYTIGA.xml:S2:3110:4	with	IN	O	O
mineralocorticoid	ZYTIGA.xml:S2:3115:17	mineralocorticoid	NN	B-AdverseReaction	O
excess	ZYTIGA.xml:S2:3133:6	excess	NN	I-AdverseReaction	O
seen	ZYTIGA.xml:S2:3140:4	seen	VBN	O	O
in	ZYTIGA.xml:S2:3145:2	in	IN	O	O
patients	ZYTIGA.xml:S2:3148:8	patient	NNS	O	O
treated	ZYTIGA.xml:S2:3157:7	treat	VBN	O	O
with	ZYTIGA.xml:S2:3165:4	with	IN	O	O
ZYTIGA	ZYTIGA.xml:S2:3170:6	zytiga	NNP	O	O
.	ZYTIGA.xml:S2:3176:1	.	.	O	O

If	ZYTIGA.xml:S2:3178:2	If	IN	O	O
clinically	ZYTIGA.xml:S2:3181:10	clinic	RB	O	O
indicated	ZYTIGA.xml:S2:3192:9	indic	VBN	O	O
,	ZYTIGA.xml:S2:3201:1	,	,	O	O
perform	ZYTIGA.xml:S2:3203:7	perform	VB	O	O
appropriate	ZYTIGA.xml:S2:3211:11	appropri	JJ	O	O
tests	ZYTIGA.xml:S2:3223:5	test	NNS	O	O
to	ZYTIGA.xml:S2:3229:2	to	TO	O	O
confirm	ZYTIGA.xml:S2:3232:7	confirm	VB	O	O
the	ZYTIGA.xml:S2:3240:3	the	DT	O	O
diagnosis	ZYTIGA.xml:S2:3244:9	diagnosi	NN	O	O
of	ZYTIGA.xml:S2:3254:2	of	IN	O	O
adrenocortical	ZYTIGA.xml:S2:3257:14	adrenocort	JJ	O	O
insufficiency	ZYTIGA.xml:S2:3272:13	insuffici	NN	O	O
.	ZYTIGA.xml:S2:3285:1	.	.	O	O

Increased	ZYTIGA.xml:S2:3287:9	increas	VBN	O	O
dosage	ZYTIGA.xml:S2:3297:6	dosag	NN	O	O
of	ZYTIGA.xml:S2:3304:2	of	IN	O	O
corticosteroids	ZYTIGA.xml:S2:3307:15	corticosteroid	NNS	O	O
may	ZYTIGA.xml:S2:3323:3	may	MD	O	O
be	ZYTIGA.xml:S2:3327:2	be	VB	O	O
indicated	ZYTIGA.xml:S2:3330:9	indic	VBN	O	O
before	ZYTIGA.xml:S2:3340:6	befor	IN	O	O
,	ZYTIGA.xml:S2:3346:1	,	,	O	O
during	ZYTIGA.xml:S2:3348:6	dure	IN	O	O
and	ZYTIGA.xml:S2:3355:3	and	CC	O	O
after	ZYTIGA.xml:S2:3359:5	after	IN	O	O
stressful	ZYTIGA.xml:S2:3365:9	stress	JJ	O	O
situations	ZYTIGA.xml:S2:3375:10	situat	NNS	O	O
[	ZYTIGA.xml:S2:3387:1	[	VBP	O	O
seeWarnings	ZYTIGA.xml:S2:3388:11	seewarn	NNS	O	O
and	ZYTIGA.xml:S2:3400:3	and	CC	O	O
Precautions	ZYTIGA.xml:S2:3404:11	precaut	NNP	O	O
(	ZYTIGA.xml:S2:3416:1	(	(	O	O
5.1	ZYTIGA.xml:S2:3417:3	5.1	CD	O	O
)]	ZYTIGA.xml:S2:3420:2	)]	NN	O	O
.	ZYTIGA.xml:S2:3422:1	.	.	O	O

5.3	ZYTIGA.xml:S2:3432:3	5.3	CD	O	O
Hepatotoxicity	ZYTIGA.xml:S2:3436:14	hepatotox	NN	O	O

In	ZYTIGA.xml:S2:3454:2	In	IN	O	O
the	ZYTIGA.xml:S2:3457:3	the	DT	O	O
two	ZYTIGA.xml:S2:3461:3	two	CD	O	O
randomized	ZYTIGA.xml:S2:3465:10	random	VBD	O	O
clinical	ZYTIGA.xml:S2:3476:8	clinic	JJ	O	O
trials	ZYTIGA.xml:S2:3485:6	trial	NNS	O	O
,	ZYTIGA.xml:S2:3491:1	,	,	O	O
grade	ZYTIGA.xml:S2:3493:5	grade	VBD	O	O
3	ZYTIGA.xml:S2:3499:1	3	CD	O	O
or	ZYTIGA.xml:S2:3501:2	or	CC	O	O
4	ZYTIGA.xml:S2:3504:1	4	CD	O	O
ALT	ZYTIGA.xml:S2:3506:3	alt	NNPS	B-AdverseReaction	O
or	ZYTIGA.xml:S2:3510:2	or	CC	O	O
AST	ZYTIGA.xml:S2:3513:3	ast	NNP	B-AdverseReaction	O
increases	ZYTIGA.xml:S2:3517:9	increas	NNS	I-AdverseReaction	O
(	ZYTIGA.xml:S2:3527:1	(	(	O	O
at	ZYTIGA.xml:S2:3528:2	at	IN	O	O
least	ZYTIGA.xml:S2:3531:5	least	JJS	O	O
5	ZYTIGA.xml:S2:3537:1	5	CD	O	O
ULN	ZYTIGA.xml:S2:3540:3	uln	NNP	O	O
)	ZYTIGA.xml:S2:3543:1	)	)	O	O
were	ZYTIGA.xml:S2:3545:4	were	VBD	O	O
reported	ZYTIGA.xml:S2:3550:8	report	VBN	O	O
in	ZYTIGA.xml:S2:3559:2	in	IN	O	O
4%	ZYTIGA.xml:S2:3562:2	4%	CD	O	O
of	ZYTIGA.xml:S2:3565:2	of	IN	O	O
patients	ZYTIGA.xml:S2:3568:8	patient	NNS	O	O
who	ZYTIGA.xml:S2:3577:3	who	WP	O	O
received	ZYTIGA.xml:S2:3581:8	receiv	VBD	O	O
ZYTIGA	ZYTIGA.xml:S2:3590:6	zytiga	NNP	O	O
,	ZYTIGA.xml:S2:3596:1	,	,	O	O
typically	ZYTIGA.xml:S2:3598:9	typic	RB	O	O
during	ZYTIGA.xml:S2:3608:6	dure	IN	O	O
the	ZYTIGA.xml:S2:3615:3	the	DT	O	O
first	ZYTIGA.xml:S2:3619:5	first	JJ	O	O
3	ZYTIGA.xml:S2:3625:1	3	CD	O	O
months	ZYTIGA.xml:S2:3627:6	month	NNS	O	O
after	ZYTIGA.xml:S2:3634:5	after	IN	O	O
starting	ZYTIGA.xml:S2:3640:8	start	VBG	O	O
treatment	ZYTIGA.xml:S2:3649:9	treatment	NN	O	O
.	ZYTIGA.xml:S2:3658:1	.	.	O	O

Patients	ZYTIGA.xml:S2:3660:8	patient	NNS	O	O
whose	ZYTIGA.xml:S2:3669:5	whose	WP$	O	O
baseline	ZYTIGA.xml:S2:3675:8	baselin	JJ	O	O
ALT	ZYTIGA.xml:S2:3684:3	alt	NNP	O	O
or	ZYTIGA.xml:S2:3688:2	or	CC	O	O
AST	ZYTIGA.xml:S2:3691:3	ast	NNP	O	O
were	ZYTIGA.xml:S2:3695:4	were	VBD	O	O
elevated	ZYTIGA.xml:S2:3700:8	elev	VBN	O	O
were	ZYTIGA.xml:S2:3709:4	were	VBD	O	O
more	ZYTIGA.xml:S2:3714:4	more	RBR	O	O
likely	ZYTIGA.xml:S2:3719:6	like	JJ	O	O
to	ZYTIGA.xml:S2:3726:2	to	TO	O	O
experience	ZYTIGA.xml:S2:3729:10	experi	VB	O	O
liver	ZYTIGA.xml:S2:3740:5	liver	RB	B-AdverseReaction	O
test	ZYTIGA.xml:S2:3746:4	test	NN	I-AdverseReaction	O
elevation	ZYTIGA.xml:S2:3751:9	elev	NN	I-AdverseReaction	O
than	ZYTIGA.xml:S2:3761:4	than	IN	O	O
those	ZYTIGA.xml:S2:3766:5	those	DT	O	O
beginning	ZYTIGA.xml:S2:3772:9	begin	VBG	O	O
with	ZYTIGA.xml:S2:3782:4	with	IN	O	O
normal	ZYTIGA.xml:S2:3787:6	normal	JJ	O	O
values	ZYTIGA.xml:S2:3794:6	valu	NNS	O	O
.	ZYTIGA.xml:S2:3800:1	.	.	O	O

Treatment	ZYTIGA.xml:S2:3802:9	treatment	JJ	O	O
discontinuation	ZYTIGA.xml:S2:3812:15	discontinu	NN	O	O
due	ZYTIGA.xml:S2:3828:3	due	JJ	O	O
to	ZYTIGA.xml:S2:3832:2	to	TO	O	O
liver	ZYTIGA.xml:S2:3835:5	liver	VB	B-AdverseReaction	B-AdverseReaction
enzyme	ZYTIGA.xml:S2:3841:6	enzym	NN	I-AdverseReaction	I-AdverseReaction
increases	ZYTIGA.xml:S2:3848:9	increas	NNS	I-AdverseReaction	I-AdverseReaction
occurred	ZYTIGA.xml:S2:3858:8	occur	VBD	O	O
in	ZYTIGA.xml:S2:3867:2	in	IN	O	O
1%	ZYTIGA.xml:S2:3870:2	1%	CD	O	O
of	ZYTIGA.xml:S2:3873:2	of	IN	O	O
patients	ZYTIGA.xml:S2:3876:8	patient	NNS	O	O
taking	ZYTIGA.xml:S2:3885:6	take	VBG	O	O
ZYTIGA	ZYTIGA.xml:S2:3892:6	zytiga	NNP	O	O
.	ZYTIGA.xml:S2:3898:1	.	.	O	O

No	ZYTIGA.xml:S2:3900:2	No	DT	O	O
deaths	ZYTIGA.xml:S2:3903:6	death	NNS	B-AdverseReaction	B-AdverseReaction
clearly	ZYTIGA.xml:S2:3910:7	clearli	RB	O	O
related	ZYTIGA.xml:S2:3918:7	relat	VBN	O	O
to	ZYTIGA.xml:S2:3926:2	to	TO	O	O
ZYTIGA	ZYTIGA.xml:S2:3929:6	zytiga	NNP	O	B-AdverseReaction
were	ZYTIGA.xml:S2:3936:4	were	VBD	O	O
reported	ZYTIGA.xml:S2:3941:8	report	VBN	O	O
due	ZYTIGA.xml:S2:3950:3	due	JJ	O	O
to	ZYTIGA.xml:S2:3954:2	to	TO	O	O
hepatotoxicity	ZYTIGA.xml:S2:3957:14	hepatotox	JJ	B-AdverseReaction	B-AdverseReaction
events	ZYTIGA.xml:S2:3972:6	event	NNS	O	I-AdverseReaction
.	ZYTIGA.xml:S2:3978:1	.	.	O	O

Measure	ZYTIGA.xml:S2:3984:7	measur	NN	O	B-AdverseReaction
serum	ZYTIGA.xml:S2:3992:5	serum	NN	O	I-AdverseReaction
transaminases	ZYTIGA.xml:S2:3998:13	transaminas	NNS	O	I-AdverseReaction
(	ZYTIGA.xml:S2:4012:1	(	(	O	O
ALT	ZYTIGA.xml:S2:4013:3	alt	NNP	O	I-AdverseReaction
and	ZYTIGA.xml:S2:4017:3	and	CC	O	O
AST	ZYTIGA.xml:S2:4021:3	ast	NNP	O	I-AdverseReaction
)	ZYTIGA.xml:S2:4024:1	)	)	O	O
and	ZYTIGA.xml:S2:4026:3	and	CC	O	O
bilirubin	ZYTIGA.xml:S2:4030:9	bilirubin	NN	O	O
levels	ZYTIGA.xml:S2:4040:6	level	NNS	O	O
prior	ZYTIGA.xml:S2:4047:5	prior	RB	O	O
to	ZYTIGA.xml:S2:4053:2	to	TO	O	O
starting	ZYTIGA.xml:S2:4056:8	start	VBG	O	O
treatment	ZYTIGA.xml:S2:4065:9	treatment	NN	O	O
with	ZYTIGA.xml:S2:4075:4	with	IN	O	O
ZYTIGA	ZYTIGA.xml:S2:4080:6	zytiga	NNP	O	O
,	ZYTIGA.xml:S2:4086:1	,	,	O	O
every	ZYTIGA.xml:S2:4088:5	everi	DT	O	O
two	ZYTIGA.xml:S2:4094:3	two	CD	O	O
weeks	ZYTIGA.xml:S2:4098:5	week	NNS	O	O
for	ZYTIGA.xml:S2:4104:3	for	IN	O	O
the	ZYTIGA.xml:S2:4108:3	the	DT	O	O
first	ZYTIGA.xml:S2:4112:5	first	JJ	O	O
three	ZYTIGA.xml:S2:4118:5	three	CD	O	O
months	ZYTIGA.xml:S2:4124:6	month	NNS	O	O
of	ZYTIGA.xml:S2:4131:2	of	IN	O	O
treatment	ZYTIGA.xml:S2:4134:9	treatment	NN	O	O
and	ZYTIGA.xml:S2:4144:3	and	CC	O	O
monthly	ZYTIGA.xml:S2:4148:7	monthli	JJ	O	O
thereafter	ZYTIGA.xml:S2:4156:10	thereaft	NN	O	O
.	ZYTIGA.xml:S2:4166:1	.	.	O	O

In	ZYTIGA.xml:S2:4168:2	In	IN	O	O
patients	ZYTIGA.xml:S2:4171:8	patient	NNS	O	O
with	ZYTIGA.xml:S2:4180:4	with	IN	O	O
baseline	ZYTIGA.xml:S2:4185:8	baselin	JJ	O	O
moderate	ZYTIGA.xml:S2:4194:8	moder	JJ	O	O
hepatic	ZYTIGA.xml:S2:4203:7	hepat	JJ	O	O
impairment	ZYTIGA.xml:S2:4211:10	impair	NN	O	O
receiving	ZYTIGA.xml:S2:4222:9	receiv	VBG	O	O
a	ZYTIGA.xml:S2:4232:1	a	DT	O	O
reduced	ZYTIGA.xml:S2:4234:7	reduc	VBN	O	O
ZYTIGA	ZYTIGA.xml:S2:4242:6	zytiga	NNP	O	O
dose	ZYTIGA.xml:S2:4249:4	dose	NN	O	O
of	ZYTIGA.xml:S2:4254:2	of	IN	O	O
250	ZYTIGA.xml:S2:4257:3	250	CD	O	O
mg	ZYTIGA.xml:S2:4261:2	mg	NN	O	O
,	ZYTIGA.xml:S2:4263:1	,	,	O	O
measure	ZYTIGA.xml:S2:4265:7	measur	NN	O	B-AdverseReaction
ALT	ZYTIGA.xml:S2:4273:3	alt	NNP	O	I-AdverseReaction
,	ZYTIGA.xml:S2:4276:1	,	,	O	O
AST	ZYTIGA.xml:S2:4278:3	ast	NNP	O	I-AdverseReaction
,	ZYTIGA.xml:S2:4281:1	,	,	O	O
and	ZYTIGA.xml:S2:4283:3	and	CC	O	O
bilirubin	ZYTIGA.xml:S2:4287:9	bilirubin	RB	O	O
prior	ZYTIGA.xml:S2:4297:5	prior	RB	O	O
to	ZYTIGA.xml:S2:4303:2	to	TO	O	O
the	ZYTIGA.xml:S2:4306:3	the	DT	O	O
start	ZYTIGA.xml:S2:4310:5	start	NN	O	O
of	ZYTIGA.xml:S2:4316:2	of	IN	O	O
treatment	ZYTIGA.xml:S2:4319:9	treatment	NN	O	O
,	ZYTIGA.xml:S2:4328:1	,	,	O	O
every	ZYTIGA.xml:S2:4330:5	everi	DT	O	O
week	ZYTIGA.xml:S2:4336:4	week	NN	O	O
for	ZYTIGA.xml:S2:4341:3	for	IN	O	O
the	ZYTIGA.xml:S2:4345:3	the	DT	O	O
first	ZYTIGA.xml:S2:4349:5	first	JJ	O	O
month	ZYTIGA.xml:S2:4355:5	month	NN	O	O
,	ZYTIGA.xml:S2:4360:1	,	,	O	O
every	ZYTIGA.xml:S2:4362:5	everi	DT	O	O
two	ZYTIGA.xml:S2:4368:3	two	CD	O	O
weeks	ZYTIGA.xml:S2:4372:5	week	NNS	O	O
for	ZYTIGA.xml:S2:4378:3	for	IN	O	O
the	ZYTIGA.xml:S2:4382:3	the	DT	O	O
following	ZYTIGA.xml:S2:4386:9	follow	JJ	O	O
two	ZYTIGA.xml:S2:4396:3	two	CD	O	O
months	ZYTIGA.xml:S2:4400:6	month	NNS	O	O
of	ZYTIGA.xml:S2:4407:2	of	IN	O	O
treatment	ZYTIGA.xml:S2:4410:9	treatment	NN	O	O
and	ZYTIGA.xml:S2:4420:3	and	CC	O	O
monthly	ZYTIGA.xml:S2:4424:7	monthli	JJ	O	O
thereafter	ZYTIGA.xml:S2:4432:10	thereaft	NN	O	O
.	ZYTIGA.xml:S2:4442:1	.	.	O	O

Promptly	ZYTIGA.xml:S2:4444:8	promptli	RB	O	O
measure	ZYTIGA.xml:S2:4453:7	measur	NN	O	O
serum	ZYTIGA.xml:S2:4461:5	serum	JJ	O	O
total	ZYTIGA.xml:S2:4467:5	total	JJ	O	O
bilirubin	ZYTIGA.xml:S2:4473:9	bilirubin	NN	O	O
,	ZYTIGA.xml:S2:4482:1	,	,	O	O
AST	ZYTIGA.xml:S2:4484:3	ast	NNP	O	I-AdverseReaction
,	ZYTIGA.xml:S2:4487:1	,	,	O	O
and	ZYTIGA.xml:S2:4489:3	and	CC	O	O
ALT	ZYTIGA.xml:S2:4493:3	alt	NNP	O	O
if	ZYTIGA.xml:S2:4497:2	if	IN	O	O
clinical	ZYTIGA.xml:S2:4500:8	clinic	JJ	O	O
symptoms	ZYTIGA.xml:S2:4509:8	symptom	NNS	O	O
or	ZYTIGA.xml:S2:4518:2	or	CC	O	O
signs	ZYTIGA.xml:S2:4521:5	sign	NNS	O	O
suggestive	ZYTIGA.xml:S2:4527:10	suggest	CD	O	O
of	ZYTIGA.xml:S2:4538:2	of	IN	O	O
hepatotoxicity	ZYTIGA.xml:S2:4541:14	hepatotox	NN	O	O
develop	ZYTIGA.xml:S2:4556:7	develop	NN	O	O
.	ZYTIGA.xml:S2:4563:1	.	.	O	O

Elevations	ZYTIGA.xml:S2:4565:10	elev	NNS	O	B-AdverseReaction
of	ZYTIGA.xml:S2:4576:2	of	IN	O	I-AdverseReaction
AST	ZYTIGA.xml:S2:4579:3	ast	NNP	O	I-AdverseReaction
,	ZYTIGA.xml:S2:4582:1	,	,	O	O
ALT	ZYTIGA.xml:S2:4584:3	alt	NNP	O	I-AdverseReaction
,	ZYTIGA.xml:S2:4587:1	,	,	O	O
or	ZYTIGA.xml:S2:4589:2	or	CC	O	O
bilirubin	ZYTIGA.xml:S2:4592:9	bilirubin	NN	O	O
from	ZYTIGA.xml:S2:4602:4	from	IN	O	O
the	ZYTIGA.xml:S2:4607:3	the	DT	O	O
patient	ZYTIGA.xml:S2:4611:7	patient	NN	O	O
's	ZYTIGA.xml:S2:4618:2	's	POS	O	O
baseline	ZYTIGA.xml:S2:4621:8	baselin	NN	O	O
should	ZYTIGA.xml:S2:4630:6	should	MD	O	O
prompt	ZYTIGA.xml:S2:4637:6	prompt	VB	O	O
more	ZYTIGA.xml:S2:4644:4	more	RBR	O	O
frequent	ZYTIGA.xml:S2:4649:8	frequent	JJ	O	O
monitoring	ZYTIGA.xml:S2:4658:10	monitor	NN	O	O
.	ZYTIGA.xml:S2:4668:1	.	.	O	O

If	ZYTIGA.xml:S2:4670:2	If	IN	O	O
at	ZYTIGA.xml:S2:4673:2	at	IN	O	O
any	ZYTIGA.xml:S2:4676:3	ani	DT	O	O
time	ZYTIGA.xml:S2:4680:4	time	NN	O	O
AST	ZYTIGA.xml:S2:4685:3	ast	NNP	O	O
or	ZYTIGA.xml:S2:4689:2	or	CC	O	O
ALT	ZYTIGA.xml:S2:4692:3	alt	NNP	O	I-AdverseReaction
rise	ZYTIGA.xml:S2:4696:4	rise	VBP	O	O
above	ZYTIGA.xml:S2:4701:5	abov	RB	O	O
five	ZYTIGA.xml:S2:4707:4	five	CD	O	O
times	ZYTIGA.xml:S2:4712:5	time	NNS	O	O
the	ZYTIGA.xml:S2:4718:3	the	DT	O	O
ULN	ZYTIGA.xml:S2:4722:3	uln	NNP	O	O
,	ZYTIGA.xml:S2:4725:1	,	,	O	O
or	ZYTIGA.xml:S2:4727:2	or	CC	O	O
the	ZYTIGA.xml:S2:4730:3	the	DT	O	O
bilirubin	ZYTIGA.xml:S2:4734:9	bilirubin	NN	O	O
rises	ZYTIGA.xml:S2:4744:5	rise	VBZ	O	O
above	ZYTIGA.xml:S2:4750:5	abov	IN	O	O
three	ZYTIGA.xml:S2:4756:5	three	CD	O	O
times	ZYTIGA.xml:S2:4762:5	time	NNS	O	O
the	ZYTIGA.xml:S2:4768:3	the	DT	O	O
ULN	ZYTIGA.xml:S2:4772:3	uln	NNP	O	O
,	ZYTIGA.xml:S2:4775:1	,	,	O	O
interrupt	ZYTIGA.xml:S2:4777:9	interrupt	JJ	O	O
ZYTIGA	ZYTIGA.xml:S2:4787:6	zytiga	NNP	O	O
treatment	ZYTIGA.xml:S2:4794:9	treatment	NN	O	O
and	ZYTIGA.xml:S2:4804:3	and	CC	O	O
closely	ZYTIGA.xml:S2:4808:7	close	RB	O	O
monitor	ZYTIGA.xml:S2:4816:7	monitor	VB	O	O
liver	ZYTIGA.xml:S2:4824:5	liver	JJ	O	O
function	ZYTIGA.xml:S2:4830:8	function	NN	O	O
.	ZYTIGA.xml:S2:4838:1	.	.	O	O

Re	ZYTIGA.xml:S2:4844:2	Re	NNP	O	O
-	ZYTIGA.xml:S2:4846:1	-	:	O	O
treatment	ZYTIGA.xml:S2:4847:9	treatment	NN	O	O
with	ZYTIGA.xml:S2:4857:4	with	IN	O	O
ZYTIGA	ZYTIGA.xml:S2:4862:6	zytiga	NNP	O	O
at	ZYTIGA.xml:S2:4869:2	at	IN	O	O
a	ZYTIGA.xml:S2:4872:1	a	DT	O	O
reduced	ZYTIGA.xml:S2:4874:7	reduc	JJ	O	O
dose	ZYTIGA.xml:S2:4882:4	dose	JJ	O	O
level	ZYTIGA.xml:S2:4887:5	level	NN	O	O
may	ZYTIGA.xml:S2:4893:3	may	MD	O	O
take	ZYTIGA.xml:S2:4897:4	take	VB	O	O
place	ZYTIGA.xml:S2:4902:5	place	NN	O	O
only	ZYTIGA.xml:S2:4908:4	onli	RB	O	O
after	ZYTIGA.xml:S2:4913:5	after	IN	O	O
return	ZYTIGA.xml:S2:4919:6	return	NN	O	O
of	ZYTIGA.xml:S2:4926:2	of	IN	O	O
liver	ZYTIGA.xml:S2:4929:5	liver	JJ	O	O
function	ZYTIGA.xml:S2:4935:8	function	NN	O	O
tests	ZYTIGA.xml:S2:4944:5	test	NNS	O	O
to	ZYTIGA.xml:S2:4950:2	to	TO	O	O
the	ZYTIGA.xml:S2:4953:3	the	DT	O	O
patient	ZYTIGA.xml:S2:4957:7	patient	NN	O	O
's	ZYTIGA.xml:S2:4964:2	's	POS	O	O
baseline	ZYTIGA.xml:S2:4967:8	baselin	NN	O	O
or	ZYTIGA.xml:S2:4976:2	or	CC	O	O
to	ZYTIGA.xml:S2:4979:2	to	TO	O	O
AST	ZYTIGA.xml:S2:4982:3	ast	NNP	O	O
and	ZYTIGA.xml:S2:4986:3	and	CC	O	O
ALT	ZYTIGA.xml:S2:4990:3	alt	NNP	O	I-AdverseReaction
less	ZYTIGA.xml:S2:4994:4	less	JJR	O	O
than	ZYTIGA.xml:S2:4999:4	than	IN	O	O
or	ZYTIGA.xml:S2:5004:2	or	CC	O	O
equal	ZYTIGA.xml:S2:5007:5	equal	JJ	O	O
to	ZYTIGA.xml:S2:5013:2	to	TO	O	O
2.5	ZYTIGA.xml:S2:5016:3	2.5	CD	O	O
ULN	ZYTIGA.xml:S2:5021:3	uln	NNP	O	O
and	ZYTIGA.xml:S2:5025:3	and	CC	O	O
total	ZYTIGA.xml:S2:5029:5	total	JJ	O	O
bilirubin	ZYTIGA.xml:S2:5035:9	bilirubin	NN	O	O
less	ZYTIGA.xml:S2:5045:4	less	JJR	O	O
than	ZYTIGA.xml:S2:5050:4	than	IN	O	O
or	ZYTIGA.xml:S2:5055:2	or	CC	O	O
equal	ZYTIGA.xml:S2:5058:5	equal	JJ	O	O
to	ZYTIGA.xml:S2:5064:2	to	TO	O	O
1.5	ZYTIGA.xml:S2:5067:3	1.5	CD	O	O
ULN	ZYTIGA.xml:S2:5072:3	uln	NNP	O	O
[	ZYTIGA.xml:S2:5077:1	[	NNP	O	O
seeDosage	ZYTIGA.xml:S2:5078:9	seedosag	NN	O	O
and	ZYTIGA.xml:S2:5088:3	and	CC	O	O
Administration	ZYTIGA.xml:S2:5092:14	administr	NNP	O	O
(	ZYTIGA.xml:S2:5107:1	(	(	O	O
2.2	ZYTIGA.xml:S2:5108:3	2.2	CD	O	O
)]	ZYTIGA.xml:S2:5111:2	)]	NN	O	O
.	ZYTIGA.xml:S2:5113:1	.	.	O	O

The	ZYTIGA.xml:S2:5121:3	the	DT	O	O
safety	ZYTIGA.xml:S2:5125:6	safeti	NN	O	O
of	ZYTIGA.xml:S2:5132:2	of	IN	O	O
ZYTIGA	ZYTIGA.xml:S2:5135:6	zytiga	NNP	O	O
re	ZYTIGA.xml:S2:5142:2	re	FW	O	O
-	ZYTIGA.xml:S2:5144:1	-	:	O	O
treatment	ZYTIGA.xml:S2:5145:9	treatment	NN	O	O
of	ZYTIGA.xml:S2:5155:2	of	IN	O	O
patients	ZYTIGA.xml:S2:5158:8	patient	NNS	O	O
who	ZYTIGA.xml:S2:5167:3	who	WP	O	O
develop	ZYTIGA.xml:S2:5171:7	develop	VBP	O	O
AST	ZYTIGA.xml:S2:5179:3	ast	NNP	O	I-AdverseReaction
or	ZYTIGA.xml:S2:5183:2	or	CC	O	O
ALT	ZYTIGA.xml:S2:5186:3	alt	NNP	O	I-AdverseReaction
greater	ZYTIGA.xml:S2:5190:7	greater	JJR	O	O
than	ZYTIGA.xml:S2:5198:4	than	IN	O	O
or	ZYTIGA.xml:S2:5203:2	or	CC	O	O
equal	ZYTIGA.xml:S2:5206:5	equal	JJ	O	O
to	ZYTIGA.xml:S2:5212:2	to	TO	O	O
20	ZYTIGA.xml:S2:5215:2	20	CD	O	O
ULN	ZYTIGA.xml:S2:5219:3	uln	NNP	O	O
and	ZYTIGA.xml:S2:5223:3	and	CC	O	O
or	ZYTIGA.xml:S2:5227:2	or	CC	O	O
bilirubin	ZYTIGA.xml:S2:5230:9	bilirubin	VB	O	O
greater	ZYTIGA.xml:S2:5240:7	greater	JJR	O	O
than	ZYTIGA.xml:S2:5248:4	than	IN	O	O
or	ZYTIGA.xml:S2:5253:2	or	CC	O	O
equal	ZYTIGA.xml:S2:5256:5	equal	JJ	O	O
to	ZYTIGA.xml:S2:5262:2	to	TO	O	O
10	ZYTIGA.xml:S2:5265:2	10	CD	O	O
ULN	ZYTIGA.xml:S2:5269:3	uln	NNP	O	O
is	ZYTIGA.xml:S2:5273:2	is	VBZ	O	O
unknown	ZYTIGA.xml:S2:5276:7	unknown	JJ	O	O
.	ZYTIGA.xml:S2:5283:1	.	.	O	O

